

1000628280-25-00374810-K HEALTHPEAK PROPERTIES, INC. 2025020420250204163433163437163437 0 0001628280-25-003748 10-K 185 20241231 20250204 20250204 HEALTHPEAK
PROPERTIES, INC. 0000765880 6798 330091377 MD 1231 10-K 34-001-08895 25588837 4600 SOUTH SYRACUSE STREET SUITE 500 DENVER CO 80237 949-407-0700 4600 SOUTH
SYRACUSE STREET SUITE 500 DENVER CO 80237 HP, INC. 20070911 HEALTH CARE PROPERTY INVESTORS INC 19920703 10-K 1 peak-20241231.htm 10-K peak-

202412310000765880false2024FYhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftMemberhttp://fasb.org/us-
gaap/2024#SecuredOvernightFinancingRateSoftMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftMemberhttp://fasb.org/us-
gaap/2024#SecuredOvernightFinancingRateSoftMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftMemberhttp://fasb.org/us-
gaap/2024#SecuredOvernightFinancingRateSoftMemberP1Y1PY3Yiso4217-USDXbriI-sharesiso4217-USDXbriI-sharesxbrLI:purepeak:propertypeak:joint_venturepeak:leasepeak:squareFeetutr:sql

-01-012024-12-3100007658802024-06-3000007658802025-01-3100007658802024-12-3100007658802023-12-3100007658802023-01-012023-12-3100007658802022-01-012022-12-
310000765880us-gaap:CommonStockMember2021-12-310000765880us-gaap:AdditionalPaidInCapitalMember2021-12-310000765880us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000765880us-
gaap:ParentMember2021-12-310000765880us-gaap:NoncontrollingInterestMember2021-12-3100007658802021-12-310000765880us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-01-012022-12-310000765880us-gaap:ParentMember2022-01-012022-12-310000765880us-
gaap:NoncontrollingInterestMember2022-01-012022-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000765880us-
gaap:CommonStockMember2022-01-012022-12-310000765880us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000765880us-gaap:CommonStockMember2022-12-
310000765880us-gaap:AdditionalPaidInCapitalMember2022-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-12-310000765880us-
gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000765880us-gaap:ParentMember2022-12-310000765880us-gaap:NoncontrollingInterestMember2022-12-
3100007658802022-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-01-012023-12-310000765880us-gaap:ParentMember2023-01-012023-12-
310000765880us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000765880us-
gaap:CommonStockMember2023-01-012023-12-310000765880us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000765880us-gaap:CommonStockMember2023-12-
310000765880us-gaap:AdditionalPaidInCapitalMember2023-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-12-310000765880us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000765880us-gaap:ParentMember2023-12-310000765880us-gaap:NoncontrollingInterestMember2023-12-310000765880us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-01-012024-12-310000765880us-gaap:ParentMember2024-01-012024-12-310000765880us-
gaap:NoncontrollingInterestMember2024-01-012024-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000765880us-
gaap:CommonStockMember2024-01-012024-12-310000765880us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000765880us-gaap:CommonStockMember2024-12-
310000765880us-gaap:AdditionalPaidInCapitalMember2024-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-12-310000765880us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000765880us-gaap:ParentMember2024-12-310000765880us-gaap:NoncontrollingInterestMember2024-12-310000765880us-
gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESAActMember2024-01-012024-12-310000765880us-
gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESAActMember2023-01-012023-12-310000765880us-
gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESAActMember2022-01-012022-12-310000765880us-
gaap:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESAActMember2024-01-012024-12-310000765880us-
gaap:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESAActMember2023-01-012023-12-310000765880us-
gaap:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESAActMember2022-01-012022-12-310000765880us-
gaap:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESAActMember2024-01-012024-12-310000765880us-
gaap:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESAActMember2023-01-012023-12-310000765880us-
gaap:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESAActMember2022-01-012022-12-310000765880us-
gaap:GovernmentAssistanceCARESAActMember2024-01-012024-12-310000765880us-gaap:BuildingAndBuildingImprovementsMember2024-12-310000765880us-
gaap:HealthpeakOPMember2023-02-100000765880peak:HealthpeakOPMember-us-gaap:NoncontrollingInterestMember2023-02-102023-02-
100000765880peak:PhysiciansRealtyTrustMember2024-03-012024-03-010000765880peak:PhysiciansRealtyTrustMemberpeak:OutpatientMedicalBuildingsMember2024-03-012024-03-
010000765880peak:PhysiciansRealtyTrustMember2024-03-010000765880peak:PhysiciansRealtyTrustMemberpeak:RestrictedSharesMember2024-03-012024-03-
010000765880peak:PhysiciansRealtyTrustMember-us-gaap:CommonStockMember2024-03-012024-03-010000765880peak:PhysiciansRealtyTrustMembersr:ScenarioPreviouslyReportedMember2024-03-
010000765880peak:PhysiciansRealtyTrustMembersrt.RestatementAdjustmentMember2024-03-010000765880peak:PhysiciansRealtyTrustMembersrt.ScenarioPreviouslyReportedMember2024-
03-012024-03-010000765880peak:PhysiciansRealtyTrustMembersrt.RestatementAdjustmentMember2024-03-012024-03-
010000765880peak:PhysiciansRealtyTrustMembersrt.MinimumMember2024-03-012024-03-010000765880peak:PhysiciansRealtyTrustMembersrt.MaximumMember2024-03-012024-03-
010000765880peak:PhysiciansRealtyTrustMember2024-01-012024-12-310000765880peak:PhysiciansRealtyTrustMemberpeak:FeesPaidToInvestmentBanksAndAdvisorsMember2024-01-
012024-12-310000765880peak:PhysiciansRealtyTrustMemberpeak:SuccessBasedPaymentsRelatedToServiceProvidersMember2024-01-012024-12-
310000765880peak:PhysiciansRealtyTrustMemberpeak:SeveranceExpenseDueToDualTriggerSeveranceArrangementsMember2024-01-012024-12-
310000765880peak:PhysiciansRealtyTrustMemberpeak:PostCombinationExpenseAcceleratedVestingOfAcquireeEquityAwardsMember2024-01-012024-12-
310000765880peak:PhysiciansRealtyTrustMemberpeak:LegalAccountingTaxAndOtherCostsMember2024-01-012024-12-
310000765880peak:PhysiciansRealtyTrustMemberpeak:SeveranceExpenseRelatedToEliminationOfCertainPositionsMember2024-01-012024-12-
310000765880peak:PhysiciansRealtyTrustMemberpeak:LegalAccountingTaxAndOtherCostsMember2023-01-012023-12-310000765880peak:PhysiciansRealtyTrustMember2023-01-012023-12-
310000765880str:M.Apeak:LabMember2023-01-012023-01-310000765880peak:HCPVenturesIVLLCMember2023-04-300000765880peak:HCPVenturesIVLLCMember2023-04-012023-04-
300000765880str:P.Apeak:LabMember2022-01-012022-01-310000765880str:C.HCApeak:LabMember2022-01-012022-01-310000765880str:T.Xpeak:MedialOfficeMember2022

310000765880peak:OtherMemberpeak:SecuredOvernightFinancingRateSOFROvernightIndexSwapRateLastSixMonthsMemberpeak:SecuredMortgageLoansMember2022-12-310000765880peak:CCRCJVINvestmentMemberpeak:BrookdaleMTCAMemberpeak:OtherNonReportingSegmentMember2024-12-310000765880peak:CCRCJVINvestmentMemberpeak:BrookdaleMTCAMemberpeak:OtherNonReportingSegmentMember2023-12-310000765880us-gaap:PerformingFinancingReceivableMemberus-gaap:MortgageReceivablesMember2024-12-310000765880peak:WatchListFinancingReceivableMemberus-gaap:MortgageReceivablesMember2024-12-310000765880peak:WorkoutFinancingReceivableMemberus-gaap:MortgageReceivablesMember2024-12-310000765880us-gaap:MortgageReceivablesMember2024-12-310000765880peak:CurrentPeriodGrossWriteOffsMemberus-gaap:MortgageReceivablesMember2024-12-310000765880peak:CurrentPeriodRecoveriesMemberus-gaap:MortgageReceivablesMember2024-12-310000765880peak:CurrentPeriodNetWriteOffsMemberus-gaap:MortgageReceivablesMember2024-12-310000765880us-gaap:PerformingFinancingReceivableMemberpeak:MezzanineLoansMember2024-12-310000765880peak:MezzanineLoansMember2024-12-310000765880peak:WatchListFinancingReceivableMemberpeak:MezzanineLoansMember2024-12-310000765880peak:MezzanineLoansMember2024-12-310000765880peak:CurrentPeriodGrossWriteOffsMemberpeak:MezzanineLoansMember2024-12-310000765880peak:CurrentPeriodRecoveriesMemberpeak:MezzanineLoansMember2024-12-310000765880peak:CurrentPeriodNetWriteOffsMemberpeak:MezzanineLoansMember2024-12-310000765880us-gaap:PerformingFinancingReceivableMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:WatchListFinancingReceivableMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:WorkoutFinancingReceivableMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:CurrentPeriodGrossWriteOffsMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:CurrentPeriodRecoveriesMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:CurrentPeriodNetWriteOffsMemberpeak:CCRCResidentLoansMember2024-12-310000765880peak:SecuredMortgageLoansMember2022-12-310000765880peak:MezzanineLoansAndOtherMember2022-12-310000765880peak:SecuredMortgageLoansMember2024-01-012024-12-310000765880peak:MezzanineLoansAndOtherMember2023-01-012023-12-310000765880peak:SecuredMortgageLoansMember2023-01-012023-12-280000765880peak:MezzanineLoansAndOtherMember2023-01-012023-12-310000765880peak:MezzanineLoansAndOtherMember2024-12-310000765880peak:SouthSanFranciscoJVsMemberpeak:LabBuildingsMember2024-12-310000765880peak:SouthSanFranciscoJVsMemberpeak:LabBuildingsMember2023-12-310000765880peak:SWFSHJVMemberpeak:OtherNonReportingSegmentMember2024-12-310000765880peak:SWFSHJVMemberpeak:OtherNonReportingSegmentMember2023-12-310000765880peak:CallanRidgeJointVentureMemberpeak:LabBuildingsMember2024-12-310000765880peak:CallanRidgeJointVentureMemberpeak:LabBuildingsMember2023-12-310000765880peak:PMAKJVMemberpeak:OutpatientMedicalMember2024-12-310000765880peak:PMAKJVMemberpeak:OutpatientMedicalMember2023-12-310000765880peak:LabJVMemberpeak:LabBuildingsMember2024-12-310000765880peak:LabJVMemberpeak:LabBuildingsMember2023-12-310000765880peak:NeedhamLandParcelJVMemberpeak:LabBuildingsMember2024-12-310000765880peak:NeedhamLandParcelJVMemberpeak:LabBuildingsMember2023-12-310000765880peak:DavisJVMemberpeak:OutpatientMedicalMember2024-12-310000765880peak:DavisJVMemberpeak:OutpatientMedicalMember2023-12-310000765880peak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember2024-12-310000765880peak:MedicalOfficeJVsMembersrt:MinimumMemberpeak:OutpatientMedicalMember2024-12-310000765880peak:MedicalOfficeJVsMembersrt:MaximumMemberpeak:OutpatientMedicalMember2024-12-310000765880peak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember2023-12-310000765880peak:MedicalOfficeJVsMember2024-12-310000765880peak:HCPVenturesIVLLCMember2024-12-310000765880peak:SuburbanPropertiesLLCMember2024-12-310000765880peak:HCPVenturesIVLLCMember2023-04-012023-04-280000765880peak:MedicalOfficeJVsMember2023-04-300000765880peak:HCPVenturesIVLLCMember2023-04-012023-04-280000765880peak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LabMember2022-08-010000765880peak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LabMember2022-08-012022-08-010000765880peak:CallanRidgeJointVentureMemberpeak:CallanRidgeJointVentureMemberpeak:LabMember2024-01-310000765880peak:CallanRidgeJointVentureMemberpeak:LabMember2024-01-310000765880peak:CallanRidgeJointVentureMemberpeak:CallanRidgeJointVentureMemberpeak:LabMember2024-01-012024-01-012024-01-012024-03-010000765880srt:OtherPropertyMember2023-01-012023-12-310000765880peak:OperatingLeasesIncomeStatementLeaseRevenueMember2024-12-310000765880peak:DepreciationDepletionandAmortizationNonproductionMember2024-12-310000765880peak:OutpatientMedicalMember2024-12-310000765880peak:OutpatientMedicalMember2023-12-310000765880peak:CCRCMember2024-12-310000765880peak:CCRCMember2023-12-310000765880peak:OtherNonReportingSegmentMember2024-12-310000765880peak:OtherNonReportingSegmentMember2023-12-310000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember2024-03-010000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-010000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember2024-03-012024-03-010000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMembersrt:MinimumMember2024-03-012024-03-010000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMembersrt:MaximumMember2024-03-012024-03-010000765880peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember2024-01-012024-12-310000765880peak:SeniorUnsecuredTermLoanMember2024-03-010000765880peak:SeniorUnsecuredNotesDue2027Member2024-03-010000765880peak:SeniorUnsecuredNotesDue2028Member2024-03-010000765880peak:SeniorUnsecuredNotesDue2031Member2024-03-010000765880peak:MortgageDebtMember2024-03-010000765880peak:MortgageDebtMemberpeak:OutpatientMedicalBuildingsMember2024-03-010000765880peak:MortgageDebtMember2024-03-012024-03-010000765880peak:MortgageDebtMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-010000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-05-230000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-09-300000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-09-012021-09-300000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-012024-12-310000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-12-310000765880peak:VariableRateComponentOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-12-310000765880us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000765880peak:TermLoanAgreementMember2022-08-222022-08-220000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesMemberus-gaap:LineOfCreditMember2022-08-220000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesMemberus-gaap:LineOfCreditMember2022-08-222022-08-220000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesMemberus-gaap:LineOfCreditMember2022-10-310000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesOneMemberus-gaap:LineOfCreditMember2022-08-220000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesTwoMemberus-gaap:LineOfCreditMember2022-08-220000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesTwoMemberus-gaap:LineOfCreditMember2022-08-222022-08-220000765880peak:TermLoanAgreementMemberpeak:A2027TermLoanFacilitiesMemberus-gaap:LineOfCreditMember2024-01-012024-12-310000765880us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-08-210000765880peak:TermLoanAgreementMemberus-gaap:InterestRateSwapMember2024-12-310000765880peak:TermLoanAgreementMember2024-02-290000765880peak:TermLoanAgreementMember2024-03-010000765880peak:UnsecuredTermLoanMember2024-03-010000765880peak:UnsecuredTermLoanMember2024-03-012024-03-010000765880peak:UnsecuredTermLoanMember2022-08-222022-08-220000765880peak:A2029TermLoanMemberpeak:UnsecuredTermLoanMember2024-01-012024-12-310000765880peak:TermLoanAgreementMember2024-12-310000765880peak:TermLoanAgreementMember2023-12-310000765880peak:TermLoanAgreementMemberpeak:TermLoanFacilitiesMember2024-12-310000765880peak:CommercialPaperProgramMember2023-12-310000765880peak:CommercialPaperProgramMember2024-12-310000765880peak:CommercialPaperProgramMember2024-01-012024-12-310000765880peak:CommercialPaperProgramMember2022-01-012022-12-310000765880peak:CommercialPaperProgramMember2023-01-012023-12-310000765880us-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:UnsecuredDebtMember2023-12-310000765880us-gaap:UnsecuredDebtMember2024-03-010000765880peak:SeniorUnsecuredNotes525Memberus-gaap:UnsecuredDebtMember2023-01-170000765880peak:SeniorUnsecuredNotes525Memberus-gaap:UnsecuredDebtMember2023-05-100000765880peak:SeniorUnsecuredNotes340Memberus-gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember2025-02-040000765880us-gaap:SecuredDebtMember2024-12-310000765880us-gaap:SecuredDebtMember2023-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember2024-12-310000765880us-gaap:SecuredDebtMemberpeak:CCRCMember2024-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember2023-12-310000765880us-gaap:SecuredDebtMemberpeak:CCRCMember2023-12-310000765880us-gaap:SecuredDebtMember2024-01-012024-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember2024-01-012024-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember2024-12-310000765880us-gaap:SecuredDebtMemberpeak:CCRCMember2023-12-310000765880us-gaap:SecuredDebtMemberpeak:CCRCMember2023-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember2024-12-310000765880us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-300000765880us-gaap:LineOfCreditMember2024-12-310000765880us-gaap:CommercialPaperMember2024-12-310000765880us-gaap:LoansPayableMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SecuredDebtMember2024-12-310000765880us-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:UnsecuredDebtMember2024-12-310000765880peak:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:UnsecuredDebtMember2024-12-310000765880peak:DebtInstrumentRedemptionPeriodThereafterMemberus-gaap:UnsecuredDebtMember2024-12-310000765880peak:DebtInstrumentRedemptionPeriodThereafterMemberus-gaap:SecuredDebtMember2024-12-310000765880srt:MinimumMemberus-gaap:UnsecuredDebtMember2024-12-310000765880srt:MaximumMemberus-gaap:UnsecuredDebtMember2024-12-310000765880us-gaap:UnsecuredDebtMember2024-01-012024-12-310000765880srt:MinimumMemberus-gaap:SecuredDebtMember2024-12-310000765880srt:MaximumMemberus-gaap:SecuredDebtMember2024-01-012024-12-310000765880us-gaap:IndemnificationGuaranteeMember2024-12-310000765880us-gaap:IndemnificationGuaranteeMemberus-gaap:SubsequentEventMember2025-01-310000765880peak:LifeScienceJVsMemberpeak:LabMember2024-12-310000765880peak:DevelopmentCommitmentsMember2024-12-310000765880peak:LeaseandothercommitmentMember2024-12-310000765880us-gaap:LetterOfCreditMember2024-12-310000765880us-gaap:LetterOfCreditMembersrt:ScenarioForecastMember2025-01-012025-12-310000765880us-gaap:LetterOfCreditMembersrt:ScenarioForecastMember2026-01-012026-12-310000765880us-gaap:SubsequentEventMember2025-02-032025-02-030000765880us-gaap:SubsequentEventMember2025-02-022025-02-020000765880us-gaap:CommonStockMember2024-03-012024-03-010000765880peak:AtTheMarketProgramMember2024-01-012024-12-310000765880peak:AtTheMarketProgramMembersrt:MinimumMember2024-01-012024-12-310000765880peak:AtTheMarketProgramMembersrt:MaximumMember2024-01-012024-12-310000765880peak:A2023AtTheMarketProgramMember2024-01-012024-12-310000765880peak:AtTheMarketProgramMember2021-01-012021-12-310000765880peak:AtTheMarketProgramMember2022-12-012022-12-310000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2024-01-012024-12-310000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2023-01-012023-12-310000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2022-01-012022-12-3100007658802022-08-010000765880peak:A2022ShareRepurchaseProgramMember2022-01-012022-12-310000765880peak:A2022ShareRepurchaseProgramMember2024-01-012024-12-310000765880peak:A2024ShareRepurchaseProgramMember2024-01-012024-12-310000765880us-gaap:CommonStockMember2024-01-012024-12-310000765880us-gaap:CommonStockMember2023-01-012023-12-310000765880us-gaap:CommonStockMember2022-01-012022-12-3100007658802022-04-300000765880peak:HealthpeakOPMemberus-gaap:NoncontrollingInterestMember2024-01-012024-12-310000765880peak:DownREITMember2024-01-012024-12-310000765880peak:DownREITMember2023-01-012023-12-310000765880peak:DownREITMember2022-01-012022-12-310000765880peak:StockBasedCompensation2014IncentivePlanMember2023-04-230000765880peak:StockBasedCompensation2006IncentivePlanMember2023-04-230000765880peak:StockBasedCompensation2021IncentivePlanMember2023-04-230000765880peak:StockBasedCompensation2023IncentivePlanMember2024-12-310000765880us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-12-310000765880us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-12-310000765880peak:MarketBasedRestrictedStockUnitsMember2024-01-012024-12-310000765880peak:MarketBasedRestrictedStockUnitsMembersrt:MinimumMember2024-01-012024-12-310000765880peak:MarketBasedRestrictedStockUnitsMembersrt:MaximumMember2024-01-012024-12-310000765880peak:MarketBasedRestrictedStockUnitsMember2023-01-012023-12-310000765880peak:MarketBasedRestrictedStockUnitsMember2022-01-012022-12-310000765880peak:TimeBasedRestrictedStockUnitsMember2022-01-012022-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000765880peak:LTIPUnitsMembersrt:MinimumMember2024-01-012024-12-

00000765880us-gaap:LTIUnitsMember2024-01-012024-12-310000765880us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000765880us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000765880us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000765880us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000765880us-gaap:GeneralAndAdministrativeExpenseMember2022-10-012022-12-310000765880us-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-01-012024-12-310000765880us-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-01-012023-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember2024-01-012024-12-310000765880us-gaap:OperatingSegmentsMemberpeak:LabMember2024-01-012024-12-310000765880us-gaap:OperatingSegmentsMemberpeak:CCRCMember2024-01-012024-12-310000765880us-gaap:OperatingSegmentsMember2024-01-012024-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember2023-01-012023-12-310000765880us-gaap:OperatingSegmentsMemberpeak:LabMember2023-01-012023-12-310000765880us-gaap:OperatingSegmentsMemberpeak:CCRCMember2023-01-012023-12-310000765880us-gaap:OperatingSegmentsMember2023-01-012023-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember2022-01-012022-12-310000765880us-gaap:OperatingSegmentsMemberpeak:LabMember2022-01-012022-12-310000765880us-gaap:OperatingSegmentsMemberpeak:CCRCMember2022-01-012022-12-310000765880us-gaap:OperatingSegmentsMember2022-01-012022-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OtherNonReportingSegmentMember2024-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember2023-12-310000765880us-gaap:OperatingSegmentsMemberpeak:OtherNonReportingSegmentMember2022-12-310000765880us-gaap:DownREITMember2024-01-012024-12-310000765880us-gaap:DownREITMember2023-01-012023-12-310000765880us-gaap:DownREITMember2022-01-012022-12-310000765880us-gaap:TaxableRealEstateInvestmentSubsidiariesMember2024-01-012024-12-310000765880us-gaap:TaxableRealEstateInvestmentSubsidiariesMember2023-01-012023-12-310000765880us-gaap:TaxableRealEstateInvestmentSubsidiariesMember2022-01-012022-12-310000765880us-gaap:CallanRidgeJointVentureMember2024-01-012024-12-310000765880us-gaap:SouthSanFranciscoJVsMember2024-01-012024-12-310000765880us-gaap:SouthSanFranciscoJVsMember2022-01-012022-12-310000765880us-gaap:CallanRidgeJointVentureMember2024-01-012024-12-310000765880us-gaap:CallanRidgeJointVentureMember2023-01-012023-12-310000765880us-gaap:CallanRidgeJointVentureMember2022-01-012022-12-310000765880us-gaap:SegmentDiscontinuedOperationsMember2024-01-012024-12-310000765880us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-12-310000765880us-gaap:SegmentDiscontinuedOperationsMember2022-01-012022-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-310000765880us-gaap:CommercialMortgageBackedSecuritiesMember2024-12-310000765880us-gaap:PropTechMember2024-01-012024-12-310000765880us-gaap:NeedhamLandParcelJVMemberpeak:LabMember2021-12-012021-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-310000765880us-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryDebtInvestmentMember2024-12-310000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember2024-12-310000765880us-gaap:VenturesVLLCMember2024-01-012024-12-310000765880us-gaap:MorganStanleyRealEstateInvestmentJVMember2024-01-012024-12-310000765880us-gaap:DownreitPartnershipsMember2024-12-310000765880us-gaap:DownreitPartnershipsMember2023-12-310000765880us-gaap:LifeScienceJVsMember2023-01-012023-12-310000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2022-01-012022-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2022-01-012022-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:AssetsTotalMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310000765880us-gaap:GeographicConcentrationRiskMember-us-gaap:SalesRevenueNetMember-us-gaap:SegmentContinuingOperationsMember2022-01-012022-12-310000765880us-gaap:CustomerConcentrationRiskMemberpeak:OutpatientMedicalMemberpeak:LargestTenantMemberpeak:HCAHealthcareIncMember-us-gaap:SalesRevenueNetMember2024-01-012024-12-310000765880us-gaap:CustomerConcentrationRiskMemberpeak:OutpatientMedicalMemberpeak:LargestTenantMemberpeak:CommonSpiritMember-us-gaap:SalesRevenueNetMember2024-01-012024-12-310000765880us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310000765880us-gaap:FairValueInputsLevel2Member-us-gaap:EstimateOffFairValueFairValueDisclosureMember2024-12-310000765880us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000765880us-gaap:FairValueInputsLevel2Member-us-gaap:EstimateOffFairValueFairValueDisclosureMember2023-12-310000765880us-gaap:InterestRateSwapMember-us-gaap:InterestRateSwapMember-us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000765880us-gaap:FairValueInputsLevel2Member-us-gaap:InterestRateSwapMember-us-gaap:EstimateOffFairValueFairValueDisclosureMember2023-12-310000765880us-gaap:FairValueInputsLevel1Member-us-gaap:EstimateOffFairValueFairValueDisclosureMember2023-12-310000765880us-gaap:InterestRateSwapMember-us-gaap:DesignatedAsHedgingInstrumentMemberpeak:MortgageDebtMember2022-04-300000765880us-gaap:InterestRateSwapMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2023-02-280000765880us-gaap:InterestRateSwapMember-us-gaap:DesignatedAsHedgingInstrumentMember2024-01-310000765880us-gaap:InterestRateSwap499PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000765880us-gaap:InterestRateSwap499PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000765880us-gaap:InterestRateSwap454PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000765880us-gaap:InterestRateSwap454PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000765880us-gaap:InterestRateSwap260PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000765880us-gaap:InterestRateSwap260PayRateMember-us-gaap:CashFlowHedgingMember-us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000765

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

2024, have been incorporated by reference into PartÂ III of this Report.Table of ContentsHealthpeak Properties, Inc.Form 10-KFor the Fiscal Year Ended DecemberÂ 31, 2024 Table of ContentsCautionaryÂ LanguageÂ RegardingÂ Forward-LookingÂ Statements1Risk Factors Summary1Important Information Regarding Our Disclosure to Investors3Part 14Item 1.1.Business4Item 1A.1.Risk Factors14Item 1B.Unresolved Staff Comments38Item 1C.Cybersecurity38Item 2.1.Properties39Item 3.Legal Proceedings42Item 4.Mine Safety Disclosures42Part 1143Item 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity43Item 6. [Reserved]46Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations46Item 7A.Quantitative and Qualitative Disclosures About Market Risk65Item 8.Financial Statements and Supplementary Data67Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure142Item 9A.Controls and Procedures142Item 9B.Other Information144Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections144Part III145Item 10.Directors, Executive Officers and Corporate Governance145Item 11.Executive Compensation145Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters145Item 13.Certain Relationships and Related Transactions, and Director Independence145Item 14.Principal Accountant Fees and Services145Part IV146Item 15.Exhibits and Financial Statement Schedules146Item 16.Form 10-K Summary151Signatures152Table of ContentsAll references in this report to "Healthpeak," "the Company," "we," "our," "ourselves," "our company" mean Healthpeak Properties, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to "Healthpeak Properties, Inc." mean the parent company without its subsidiaries.Cautionary Language Regarding Forward-Looking StatementsStatements in this Annual Report on Form 10-K that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). A Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could cause actual results, including our future financial condition and results of operations, to differ materially from those expressed or implied by any forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below under "Risk Factors Summary" and in "Item 1A, Risk Factors" in this report. Forward-looking statements are based on certain assumptions and analysis made in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate under the circumstances. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Annual Report, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.Risk Factors SummaryInvestors should consider the risks and uncertainties described below that may affect our business and future financial performance. These and other risks and uncertainties are more fully described in "Item 1A, Risk Factors" in this report. Additional risks not presently known to us or that we currently deem immaterial may also affect us. If any of these risks occur, our business, financial condition or results of operations could be materially and adversely affected. As more fully set forth under "Item 1A, Risk Factors" in this report, principal risks and uncertainties that may affect our business, financial condition, or results of operations include: "macroeconomic trends that may increase construction, labor, and other operating costs;" "changes within the life science industry, and significant regulation, funding requirements, and uncertainty faced by our lab tenants;" "factors adversely affecting our tenants' operators' or borrowers' ability to meet their financial and other contractual obligations to us;" "the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers;" "our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors;" "the illiquidity of real estate investments;" "our ability to identify and secure new or replacement tenants and operators;" "our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion;" "the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable;" "our ability to develop, maintain, or expand hospital and health system client relationships;" "operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as "RIDEA");" "Table of Contents" "economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments;" "uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses;" "our use of joint ventures may limit our returns on and our flexibility with jointly owned investments;" "our use of rent escalators or contingent rent provisions in our leases;" "competition for suitable healthcare properties to grow our investment portfolio;" "our ability to exercise rights on collateral securing our real estate-related loans;" "any requirement that we recognize reserves, allowances, credit losses, or impairment charges;" "investment of substantial resources and time in transactions that are not consummated;" "our ability to successfully integrate or operate acquisitions and/or internalize property management;" "the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs;" "environmental compliance costs and liabilities associated with our real estate investments;" "environmental, social, and governance ("corporate impact") and sustainability commitments and requirements, as well as stakeholder expectations;" "epidemics, pandemics, or other infectious diseases, including the coronavirus disease ("COVID-19"), and health and safety measures intended to reduce their spread;" "human capital risks, including the loss or limited availability of our key personnel;" "our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology;" "the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors;" "volatility, disruption, or uncertainty in the financial markets;" "increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities;" "cash available for distribution to stockholders and our ability to make dividend distributions at expected levels;" "the availability of external capital on acceptable terms or at all;" "an increase in our level of indebtedness;" "covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants;" "volatility in the market price and trading volume of our common stock;" "adverse changes in our credit ratings;" "the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements;" "required regulatory approvals to transfer our senior housing properties;" "compliance with the Americans with Disabilities Act and fire, safety, and other regulations;" "laws or regulations prohibiting eviction of our tenants;" "the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, and legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services;" "our participation in the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") Provider Relief Fund and other COVID-related stimulus and relief programs;" "changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate;" "Table of Contents" "our ability to successfully integrate our operations with Physicians Realty Trust and realize the anticipated synergies of the Merger (as defined below) and benefits of property management internalization;" "our ability to maintain our qualification as a real estate investment trust ("REIT");" "our taxable REIT subsidiaries being subject to corporate level tax;" "tax imposed on any net income from "prohibited transactions;" "changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions;" "calculating non-REIT tax earnings and profits distributions;" "tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels;" "ownership limits in our charter that restrict ownership in our stock, and provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of the stockholders;" "conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC ("Healthpeak OP") common units;" "provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; and" "our status as a holding company of Healthpeak OP.Important Information Regarding Our Disclosure to InvestorsWe may use our website (www.healthpeak.com) and our LinkedIn account (https://www.linkedin.com/company/healthpeak) to communicate with our investors and disclose company information. The information disclosed through these channels may be considered to be material, so investors should monitor them in addition to our press releases, SEC filings, and public conference calls and webcasts. The contents of our website or social media channels referenced herein are not incorporated by reference into this Annual Report on Form 10-K.3Table of ContentsPART ITEM 1.Â A BusinessGeneral OverviewHealthpeak Properties, Inc. is a Standard & Poor's ("S&P") 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States ("U.S."). Our company was originally founded in 1985. In 2023, we completed our corporate reorganization (the "Reorganization") into an umbrella partnership REIT ("UPREIT"). We hold substantially all of our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S.We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and continuing care retirement community ("CCRC") real estate. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Under the CCRC segment, our properties are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our "SWF SH JV") and (ii) loans receivable. These non-reportable segments have been presented on a combined basis herein.The MergerOn March 1, 2024 (the "Closing Date"), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the "Merger Agreement"), by and among us, DOC DR Holdco, LLC, one of our wholly owned subsidiaries (the "DOC DR Holdco"), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (the "DOC DR OP Sub"), Physicians Realty Trust, Physicians Realty L.P. (the "Physicians Partnership"), Physicians Realty Trust merged with and into DOC DR Holdco (the "Company Merger"), with DOC DR Holdco surviving as our wholly owned subsidiary (the "Company Surviving Entity"); (i) immediately following the effectiveness of the Company Merger, we contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the "Contribution"); and (ii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the "Partnership Merger" and, together with the Company Merger, the "Merger"), with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP. Subsequent to the Closing Date, the "Combined Company" means Healthpeak and its subsidiaries.On the Closing Date, each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) were converted into the right to receive 0.674 (the "Exchange Ratio") shares of our common stock, and each outstanding common unit of the Physicians Partnership was converted into common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.As a result of the Merger, we acquired 299 outpatient medical buildings. See Note 3 to the Consolidated Financial Statements for additional information.At December 31, 2024, our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in 697 properties: (i) Outpatient medical "524 properties; (ii) Lab "139 properties; (iii) CCRC "15 properties; and (iv) Other non-reportable "19 properties. The following table summarizes information for our reportable segments for the year ended December 31, 2024 (dollars in thousands):SegmentAdjusted NOI by Reportable Segment(1)Outpatient medical\$748,730Â Lab590,606Â CCRC136,104Â (1)Our Adjusted NOI for our reportable segments, which we also refer to as Total Portfolio Adjusted NOI for our reportable segments, includes results of operations from disposed properties through the disposition date. See Note 16 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by reportable segment to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. See our Segment Analysis below for additional information.For a description of our significant activities during 2024, see "Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations" "Company Highlights" in this report.4Table of ContentsBusiness StrategyOur strategy is to own, operate, and develop high-quality real estate focused on healthcare discovery and delivery. We manage our real estate portfolio for the long-term to maximize risk-adjusted returns and support the growth of our dividends. Our strategy consists of four core elements: (i)Our real estate: Our portfolio consists of high-quality properties in desirable locations. Our portfolio is focused on outpatient medical and lab buildings, favorable sectors that benefit from the universal desire for improved health. We have built scale and fostered deep industry relationships, two unique factors that provide us with a competitive advantage.(ii)Our financials: We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest rate volatility and refinancing risk.(iii)Our partnerships: We work with leading pharmaceutical, biotechnology, and medical device companies, as well as healthcare delivery systems, specialty physician groups, and other healthcare service providers, to meet their real estate needs. We provide high-quality property management services to encourage tenants to renew, expand, and relocate into our properties, which drives increased occupancy, rental rates, and property values.(iv)Our platform: We have a people-first culture that we believe attracts, develops, and retains top talent. We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.Internal Growth StrategiesWe believe our real estate portfolio holds the potential for increased future cash flows as it is well-maintained and in desirable locations. Our strategy for maximizing the benefits from these opportunities is to: (i) work with new or existing tenants to address their space and capital needs and (ii) provide high-quality property management services in order to motivate tenants to renew, expand, or relocate into our properties. We expect to continue our internal growth as a result of our ability to: "Build and maintain long-term leasing and management relationships with quality tenants. In choosing locations for our properties, we focus on the physical environment, adjacency to established businesses (e.g., hospital systems or life science submarkets) and educational centers, proximity to sources of business growth, and other local demographic factors." "Replace tenants at the best available market terms and lowest possible transaction costs. We believe we are well-positioned to attract new tenants and achieve attractive rental rates and operating cash flow as a result of the location, design, and maintenance of our properties, together with our reputation for high-quality building services, responsiveness to tenants, and our ability to offer space alternatives within our portfolio." "Extend and modify terms of existing leases prior to expiration. We selectively structure lease extensions, early renewals, or modifications, which reduce the cost associated with lease downtime, while securing the tenancy and relationship of our high-quality tenants on a long-term basis.Investment StrategiesThe discovery and delivery of healthcare services requires real estate and, as a result, tenants depend on our real estate, in part, to maintain and grow their businesses. We believe the healthcare real estate market provides investment opportunities due to the: (i) compelling long-term demographics driving the demand for healthcare services; (ii) specialized nature of healthcare real estate investing; and (iii) ongoing consolidation of the fragmented healthcare real estate sector.While we emphasize healthcare real estate ownership, we may also provide real estate secured financing to, or invest in equity or debt securities of, healthcare operators or other entities engaged in healthcare real estate ownership. We may also acquire all or substantially all of the securities or assets of other REITs, operating companies, or similar entities where such investments would be consistent with our investment strategies. We may co-invest alongside institutional or development investors through partnerships or limited liability companies.5Table of ContentsWe monitor our investments based on the percentage of our total assets that may be invested in any one property type, investment vehicle, or geographic location, the number of properties that may be leased to a single tenant or operator, or loans that may be made to a single borrower. In allocating capital, we target opportunities with the most attractive risk/reward profile for our portfolio as a whole. We may take additional measures to mitigate risk, including diversifying our investments (by sector, geography, and tenant), structuring transactions as master leases, requiring tenant or operator insurance and indemnifications, and/or obtaining credit enhancements in the form of guarantees, letters of credit, or security deposits. We believe we are well-positioned to achieve external growth through acquisitions, development, and redevelopment. Other factors that contribute to our competitive position include: "our reputation gained through decades of successful operations and the strength of our existing portfolio of properties;" "our relationships with leading pharmaceutical and biotechnology tenants, healthcare operators and systems, investment banks and other market intermediaries, corporations, private equity firms, not-for-profit organizations, and companies seeking to monetize existing assets or develop new facilities;" "our

relationships with institutional buyers and sellers of high-quality healthcare real estate;â€¢our track record and reputation for executing acquisitions responsively and efficiently, which provides confidence to domestic and foreign institutions and private investors who seek to sell healthcare real estate in our market areas;â€¢our relationships with nationally recognized financial institutions that provide capital to the healthcare and real estate industries; andâ€¢our control of land sites held for future development.Financing StrategiesOur REIT qualification requires us to distribute at least 90% of our REIT taxable income (excluding net capital gains); therefore, we do not retain a significant amount of earnings. As a result, we regularly access the public equity and debt markets to raise the funds necessary to finance acquisitions and debt investments, develop and redevelop properties, and refinance maturing debt.Â¢We may finance acquisitions and other investments in a variety of ways, including:â€¢cash flow from operations;â€¢sale or exchange of ownership interests in properties or other investments;â€¢borrowings under our credit facility or commercial paper program;â€¢issuance of additional debt, including unsecured notes, term loans, and mortgage debt; and/orâ€¢issuance of common stock or preferred stock or its equivalent.We maintain a disciplined investment-grade balance sheet by actively managing our debt to equity levels and maintaining access to multiple sources of liquidity. Our debt obligations are primarily long-term fixed rate with staggered maturities. We finance our investments based on our evaluation of available sources of funding. For short-term purposes, we may utilize our revolving line of credit facility or commercial paper program, arrange for other short-term borrowings from banks or other sources, or issue equity securities pursuant to our at-the-market equity offering program. We arrange for longer-term financing by offering debt and equity, placing mortgage debt, and obtaining capital from institutional lenders and joint venture partners.In addition, capital recycling through dispositions and redeployment through acquisitions, developments, and redevelopments is an important facet of our investment and financing strategies. We routinely have multiple transactions involving both individual properties and portfolios under consideration that are in varying stages of evaluation, underwriting, negotiation, and due diligence review, some of which, if consummated or completed, may have a material effect on our liquidity, results of operations, and financial condition.6Table of ContentsSegmentsOutpatient MedicalOur outpatient medical segment includes outpatient medical buildings and hospitals. Outpatient medical buildings typically contain physiciansâ€™ offices and examination rooms, and may also include pharmacies, hospital ancillary service space, and outpatient services such as diagnostic centers, rehabilitation clinics, and day-surgery operating rooms. While these facilities have certain similarities to commercial office buildings, they require additional plumbing, electrical, and mechanical systems to accommodate multiple exam rooms that may require sinks in every room and specialized equipment such as x-ray machines and MRIs. Outpatient medical buildings are often built to accommodate higher structural loads for such specialized equipment and may contain vaults or other unique construction. Our outpatient medical buildings are typically multi-tenant properties leased to healthcare providers (hospitals and physician practices), with approximately 78% of our outpatient medical buildings located on or adjacent to hospital campuses and 96% affiliated with hospital systems as of December 31, 2024 (based on total square feet). Occasionally, we invest in outpatient medical buildings located on hospital campuses subject to ground leases. At December 31, 2024, approximately 76% of our outpatient medical buildings were triple-net leased (based on leased square feet) with the remaining leased under gross or modified gross leases.The following table provides information about our most significant outpatient medical tenant concentration for the year ended December 31, 2024:TenantPercentage ofSegment RevenuesPercentage ofTotal RevenuesHCA Healthcare, Inc. (HCA)15% 7% A CommonSpirit Health6% 3% Â¢During the year ended December 31, 2024, we had various other outpatient medical tenants that each represented 1% or less of total revenues. Our outpatient medical segment also includes nine hospitals. Services provided by our tenants and operators in hospitals are paid for by private sources, third-party payors (e.g., Â¢ insurance and HMOs), or through Medicare and Medicaid programs. Our hospital property types include acute care, long-term acute care, and specialty and rehabilitation hospitals. All of our hospitals are triple-net leased.LabOur lab properties, which contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. While these properties have certain characteristics similar to commercial office buildings, they generally accommodate heavier floor loads and contain more advanced electrical, mechanical, heating, ventilating, and air conditioning systems. The facilities generally have specialty equipment including emergency generators, fume hoods, lab bench tops, and related amenities. In addition to improvements funded by us as the landlord, many of our lab tenants make significant investments to improve their leased space to accommodate biology, chemistry, or medical device research initiatives.Lab properties are primarily configured in business park or campus settings and include multiple buildings. The business park and campus settings allow us the opportunity to provide flexible, contiguous/adjacent expansion to accommodate the growth of existing tenants. Our properties are located in well-established geographical markets known for scientific research and drug discovery, including San Francisco (53%) and San Diego (17%), California, and Boston, Massachusetts (28%) (based on total square feet). At December 31, 2024, 88% of our lab properties were triple-net leased (based on leased square feet).During the year ended December 31, 2024, we had various lab tenants that each represented 1% or less of total revenues. Continuing care retirement community, or CCRCCCRCs are retirement communities that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus. Our CCRCs are owned through RIDEA structures, which is permitted by the Housing and Economic Recovery Act of 2008, and includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007. The services provided by our third-party manager-operators under a RIDEA structure at our properties are primarily paid for by the residents directly or through private insurance and are less reliant on government reimbursement programs such as Medicare and Medicaid.7Table of ContentsA RIDEA structure allows us, through a taxable REIT subsidiary (â€¢TRSâ€¢), to receive cash flow from the operations of a healthcare facility in compliance with REIT tax requirements. The criteria for operating a healthcare facility through a RIDEA structure require us to lease the facility to an affiliate TRS and for such affiliate TRS to engage an independent qualifying management company (also known as an eligible independent contractor or third-party operator) to manage and operate the day-to-day business of the facility in exchange for a management fee. As a result, under a RIDEA structure, we are required to rely on a third-party operator to hire and train all facility employees, enter into third-party contracts for the benefit of the facility, including resident/patient agreements, comply with laws, including healthcare laws, and provide resident care. We are substantially limited in our ability to control or influence day-to-day operations under a RIDEA structure, and thus rely on the third-party operator to manage and operate the business. Through our TRS entities, we bear all operational risks and liabilities associated with the operation of these properties, with limited exceptions, such as a third-party operatorâ€™s gross negligence or willful misconduct. These operational risks and liabilities include those relating to any employment matters of our operator, compliance with healthcare and other laws, liabilities relating to personal injury-tort matters, resident-patient quality of care claims, and any governmental reimbursement matters, even though we have limited ability to control or influence our third-party operatorsâ€™ management of these risks. The management agreements we have in RIDEA structures related to CCRCs have original terms ranging from 10 to 15 years, with mutual renewal options. There are base management fees and incentive management fees payable to our third-party operators if operating results of the RIDEA properties exceed pre-established thresholds. Conversely, there are also provisions in the management agreements that reduce management fees payable to our third-party operators if operating results do not meet certain pre-established thresholds.CCRCs are different from other housing and care options for seniors because they typically provide written agreements or long-term contracts between residents and the communities (frequently lasting the term of the residentâ€™s lifetime), which offer a continuum of housing, services, and healthcare on one campus or site. CCRCs are appealing as they allow residents to â€¢age in placeâ€¢ and typically the individual is independent and in relatively good health upon entry. As third-party operators manage our RIDEA properties in exchange for the receipt of a management fee, we are not directly exposed to the credit risk of these operators in the same manner or to the same extent as a triple-net tenant.Other non-reportable segmentAt December 31, 2024, we had the following investments in our other non-reportable segments: (i) our unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets (which we refer to as our SWF SH JV) and (ii) loans receivable. The properties in our SWF SH JV are owned through RIDEA structures and include independent living facilities and assisted living facilities, which cater to different segments of the elderly population based upon their personal needs. These facilities are often in apartment-like buildings with private residences ranging from single rooms to large apartments.CompetitionInvesting in real estate serving the healthcare industry is highly competitive. We face competition from other REITs, investment companies, pension funds, private equity investors, sovereign funds, healthcare operators, lenders, developers, and other institutional investors, some of whom may have greater flexibility (e.g., non-REIT competitors), greater resources, and lower costs of capital than we do. Increased competition and resulting capitalization rate compression, as well as the impacts of inflation and higher interest rates, make it more challenging for us to identify and successfully capitalize on opportunities that meet our objectives. Our ability to compete may also be impacted by global, national, and local economic trends, availability of investment alternatives, availability and cost of capital, construction and renovation costs, existing laws and regulations, new legislation, and population trends.Income from our investments depends on our tenantsâ€™ and operatorsâ€™ ability to compete with other companies on multiple levels, including: (i) the quality of care provided, (ii) reputation, (iii) success of product or drug development, (iv) price, (v) the range of services offered, (vi) the physical appearance of a property, (vii) alternatives for healthcare delivery, (viii) the supply of competing properties, (ix) physicians, (x) staff, (xi) referral sources, (xii) location, (xiii) the size and demographics of the population in surrounding areas, and (xiv) the financial condition of our tenants and operators. For a discussion of the risks associated with competitive conditions affecting our business, see â€¢Item 1A, Risk Factorsâ€¢ in this report.8Table of ContentsGovernment Regulation, Licensing, and EnforcementOverviewOur healthcare facility operators (which include our TRS entities when we use a RIDEA structure) and tenants are subject to extensive and complex federal, state, and local healthcare laws and regulations relating to quality of care, licensure and certificate of need, resident rights (including abuse and neglect), consumer protection, government reimbursement, fraud and abuse practices, and similar laws governing the operation of healthcare facilities. We expect the healthcare industry, in general, will continue to face increased regulation and pressure in the areas of fraud, waste and abuse, cost control, healthcare management, and provision of services, among others. Federal, state, and local officials are increasingly focusing their efforts on enforcement of these laws and regulations. In addition, our operators are subject to a variety of laws, regulations, and executive orders, including those relating to operatorsâ€™ response to Covid and other infectious diseases, which can vary based on the provider type and jurisdiction, complicating compliance efforts. These regulations are wide ranging and can subject our tenants and operators to civil, criminal, and administrative sanctions, including enhanced or additional penalties, sanctions, and other adverse actions that may arise under new regulations adopted in response to Covid. Affected tenants and operators may find it increasingly difficult to comply with this complex and evolving regulatory environment because of a relative lack of guidance in many areas as certain of our healthcare properties are subject to oversight from several government agencies, and the laws may vary from one jurisdiction to another. Changes in laws, regulations, reimbursement enforcement activity, and regulatory non-compliance by our tenants and operators can all have a significant effect on their operations and financial condition, which in turn may adversely impact us, as detailed below and set forth under â€¢Item 1A, Risk Factorsâ€¢ in this report.The following is a discussion of certain laws and regulations generally applicable to our operators, and in certain cases, to us.Fraud and Abuse EnforcementThere are various extremely complex U.S. federal and state laws and regulations governing healthcare providersâ€™ referrals, relationships and arrangements and prohibiting fraudulent and abusive practices by such providers. These laws include: (i) U.S. federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid, or other U.S. federal or state false healthcare programs; (ii) U.S. federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid anti-kickback statute, which prohibit or restrict the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services; (iii) U.S. federal and state physician self-referral laws (commonly referred to as the â€¢Stark Lawâ€¢), which, subject to certain exceptions, generally prohibit referrals of specifically designated health services by physicians to entities with which the physician or an immediate family member has a financial relationship; and (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare services and which authorizes the U.S. Department of Health and Human Services to impose monetary penalties for certain fraudulent acts. Violations of U.S. healthcare fraud and abuse laws carry civil, criminal, and administrative sanctions, including punitive sanctions, monetary penalties, imprisonment, denial of Medicare and Medicaid reimbursement, payment suspensions, and potential exclusion from Medicare, Medicaid, or other federal or state healthcare programs. These laws are enforced by a variety of federal, state, and local agencies and in the U.S. can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or â€¢whistleblowerâ€¢ actions, in which individuals have tremendous financial gain in bringing a whistleblower claim as federal and state false claim acts provide that individuals receive between 15% and 30% of the money recouped. Additionally, violations of false claims acts can result in treble damages. Our tenants and operators that participate in government reimbursement programs are subject to these laws and may become the subject of governmental enforcement actions or whistleblower actions if they fail to comply with applicable laws. Additionally, the licensed operators of our U.S. long-term care facilities that participate in government reimbursement programs are required to have compliance and ethics programs that meet the requirements of federal laws and regulations relating to the Social Security Act. Where we have used a RIDEA structure, we are dependent on management companies to fulfill our compliance obligations, and we have developed a program to periodically monitor compliance with such obligations. Investigation by a federal or state governmental body for violation of fraud and abuse laws or imposition of any of these penalties upon one of our operators could jeopardize that operatorâ€™s business, reputation, and ability to operate.9Table of ContentsLaws and Regulations Governing Privacy and SecurityThere are various U.S. federal and state privacy laws and regulations, including the privacy and security rules contained in the Health Insurance Portability and Accountability Act of 1996 (commonly referred to as â€¢HIPAAâ€¢), that provide for the privacy and security of personal health information. An increasing focus of the U. S. Federal Trade Commissionâ€™s (â€¢FTCâ€¢) consumer protection regulation is the impact of technological change on protection of consumer privacy. The FTC, as well as state attorneys general, have taken enforcement action against companies that do not abide by their representations to consumers regarding electronic security and privacy. To the extent we or our affiliated operating entities are a covered entity or business associate under HIPAA and the Health Information Technology for Economic and Clinical Health Act (the â€¢HITECH Actâ€¢), compliance with those requirements require us to, among other things, conduct a risk analysis, implement a risk management plan, implement policies and procedures, and conduct employee training. In most cases, we are dependent on our tenants and management companies to fulfill our compliance obligations, and we have developed a program to periodically monitor compliance with such obligations. Because of the far reaching nature of these laws, there can be no assurance we would not be required to alter one or more of our systems and data security procedures to be in compliance with these laws. Our failure to protect health information could subject us to civil or criminal liability and adverse publicity, and could harm our business and impair our ability to attract new customers and residents. We may be required to notify individuals, as well as government agencies and the media, if we experience a data breach.Further, as reliance on technology has increased, so have the risks posed to those systems. Parties that provide us with services essential to our operations must continuously monitor and develop their networks and information technology to prevent, detect, address, and mitigate the risk of unauthorized access, misuse, computer viruses, and social engineering, such as phishing. Our tenants and management companies are continuously working, including with the aid of third-party service providers, to install new, and to upgrade existing, network and information technology systems, to create processes for risk assessment, testing, prioritization, remediation, risk acceptance, and reporting, and to provide awareness training around phishing, malware, and other cyber risks to ensure that our partners that provide us with services essential to our operations are protected against cyber risks and security breaches and that we are also therefore so protected. However, these upgrades, processes, new technology, and training may not be sufficient to protect us from all risks. Even the most well protected information, networks, systems, and facilities remain potentially vulnerable because the techniques and technologies used in attempted attacks and intrusions evolve and generally are not recognized until launched against a target. In some cases, attempted attacks and intrusions are designed not to be detected and, in fact, may not be detected.ReimbursementSources of revenue for some of our tenants and operators include, among others, governmental healthcare programs, such as the federal Medicare programs and state Medicaid programs, and non-governmental third-party payors, such as insurance carriers and HMOs. Our tenants and operators who participate in governmental healthcare programs are subject to government reviews, audits, and investigations to verify compliance with these programs and applicable laws and regulations. As federal and state governments focus on healthcare reform initiatives, and as the federal government and many states face significant current and future budget deficits, efforts to reduce costs by these payors will likely continue, which may result in reduced or slower growth in reimbursement for certain services provided by some of our tenants and operators. Governmental healthcare programs are highly regulated and are subject to frequent and substantial legislative, regulatory, and interpretive changes, which could adversely affect reimbursement rates and the method and timing of payment under these programs. Additionally, new and evolving payor and provider programs in the U.S., including Medicare Advantage, Dual Eligible, Accountable Care Organizations, Post-Acute Care Payment Models, SNF Value-Based Purchasing

Programs, and Bundled Payments could adversely impact our tenants’ and operators’ liquidity, financial condition, or results of operations. Effective January 16, 2024, Medicare and Medicaid nursing facilities are required to disclose new data about the facility’s ownership, management, and the owners of real property lessors upon initial enrollment and revalidation. In addition, the nursing facilities are required to timely report any changes, including in connection with any change of ownership. The Centers for Medicare and Medicaid Services (‘CMS’) defines the new disclosable parties to include members of the facility’s governing body, persons, or entities who are an officer, director, member, partner, trustee, or managing employee of the facility, persons, or entities that exercise operational, financial, or managerial control, lease or sublease real property to the facility, own a direct or indirect interest of five percent or greater of the real property, or provide management or administrative services to the facility. Additionally, facilities are required to disclose whether any entity on the enrollment form is a private equity company or REIT. CMS makes the information publicly available. This new disclosure requirement involves reporting extensive information and may complicate our healthcare facility operators’ efforts to comply with Medicare and Medicaid requirements. Failure to comply with the new disclosure requirements could negatively affect our healthcare facility operators’ participation in Medicare and state Medicaid programs.

Table of Contents Healthcare Licensure and Certificate of Need Certain healthcare facilities in our portfolio are subject to extensive national, federal, state, and local licensure, certification, and inspection laws and regulations. A healthcare facility’s failure to comply with these laws and regulations could result in a revocation, suspension, restriction, or non-renewal of the facility’s license and loss of a certificate of need, which could adversely affect the facility’s operations and ability to bill for items and services provided at the facility. In addition, various licenses and permits are required to handle controlled substances (including narcotics), operate pharmacies, handle radioactive materials, and operate equipment. Many states in the U.S. require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion, or closure of certain healthcare facilities. The approval process related to state certificate of need laws may impact the ability of some of our tenants and operators to expand or change their businesses. Changes in these laws and regulations could negatively affect the ability of our tenants to make lease payments to us. In some states, healthcare facilities are subject to various state certificate of need (‘CON’) laws requiring governmental approval prior to the development or expansion of healthcare facilities and services. State CON laws often materially impact the ability of competitors to enter into the marketplace of our facilities and the repeal of CON laws could allow competitors to freely operate in previously closed markets.

Product Approvals While our lab tenants include some well-established companies, other tenants are less established and, in some cases, may not yet have a product approved by the Food and Drug Administration, or other regulatory authorities, for commercial sale. Creating a new pharmaceutical product or medical device requires substantial investments of time and capital, in part because of the extensive regulation of the healthcare industry. It also entails considerable risk of failure in demonstrating that the product is safe and effective and in gaining regulatory approval and market acceptance.

Entrance Fee Communities Our CCRCs are operated as entrance fee communities. Generally, an entrance fee is an upfront fee or consideration paid by a resident, a portion of which may be refundable, in exchange for some form of long-term benefit, typically consisting of a right to receive certain personal or health care services. In certain states (including the ones in which we operate) entrance fee communities are subject to significant state regulatory oversight, including, for example, oversight of each facility’s financial condition, establishment and monitoring of reserve requirements and other financial restrictions, the right of residents to cancel their contracts within a specified period of time, the right of residents to receive a refund of their entrance fees, lien rights in favor of the residents, restrictions on change of ownership, and similar matters. Americans with Disabilities Act (‘ADA’) Our properties must comply with the ADA and any similar state or local laws to the extent that such properties are ‘public accommodations’ as defined in those statutes. The ADA may require removal of barriers to access by persons with disabilities in certain public areas of our properties where such removal is readily achievable. To date, we have not received any notices of noncompliance with the ADA that have caused us to incur substantial capital expenditures to address ADA concerns. Should barriers to access by persons with disabilities be discovered at any of our properties, we may be directly or indirectly responsible for additional costs that may be required to make facilities ADA-compliant. Noncompliance with the ADA could result in the imposition of fines or an award of damages to private litigants. The obligation to make readily achievable accommodations pursuant to the ADA is an ongoing one, and we continue to assess our properties and make modifications as appropriate in this respect.

Environmental Matters A wide variety of federal, state, and local environmental and occupational health and safety laws and regulations affect healthcare facility operations. These complex federal and state statutes, and their enforcement, involve a myriad of regulations, many of which involve strict liability on the part of the potential offender. Some of these federal and state statutes may directly impact us. Under various federal, state, and local environmental laws, ordinances, and regulations, an owner of real property or a secured lender, such as us, may be liable for the costs of removal or remediation of hazardous or toxic substances at, under or disposed of in connection with such property, as well as other potential costs relating to hazardous or toxic substances (including government fines and damages for injuries to persons and adjacent property). The cost of any required remediation, removal, fines, personal or property damages, and any related liability therefore could exceed or impair the value of the property and/or the assets. In addition, the presence of such substances, or the failure to properly dispose of or remediate such substances, may adversely affect the value of such property and the owner’s ability to sell or rent such property or to borrow using such property as collateral, which, in turn, could reduce our earnings. For a description of the risks associated with environmental matters, see ‘Item 1A, Risk Factors’ in this report.

Table of Contents Insurance We obtain various types of insurance to mitigate the impact of property, business interruption, liability, flood, windstorm, earthquake, fire, environmental, and terrorism-related losses. We attempt to obtain appropriate policy terms, conditions, limits, and deductibles considering the relative risk of loss, the cost of such coverage, and current industry practice. There are, however, certain types of extraordinary losses, such as those due to acts of war or other events, that may be either uninsurable or not economically insurable. In addition, we have a large number of properties that are exposed to earthquake, flood, and windstorm occurrences, which carry higher deductibles. We maintain property insurance for all of our properties. Tenants under triple-net leases are required to provide primary property, business interruption, and liability insurance. We maintain separate general and professional liability insurance for our CCRCs and the senior housing facilities owned by our SWF SH JV. Additionally, our corporate general liability insurance program also extends coverage for all of our properties beyond the aforementioned. We periodically review whether we or our RIDEA operators will bear responsibility for maintaining the required insurance coverage for the applicable CCRCs and senior housing facilities owned by our SWF SH JV, but the costs of such insurance are facility expenses paid from the revenues of those properties, regardless of who maintains the insurance. We also maintain directors and officers liability insurance, which provides protection for claims against our directors and officers arising from their responsibilities as directors and officers. Such insurance also extends to us in certain situations.

Sustainability and Corporate Impact We believe that corporate impact initiatives are a vital part of corporate responsibility, which supports our primary goal of increasing stockholder value through profitable growth. We continue to advance our commitment to sustainability, with a focus on achieving goals in each of the corporate impact dimensions. Our Board of Directors oversees corporate impact matters, with the Nominating and Corporate Governance Committee overseeing sustainability and corporate governance matters, the Audit Committee overseeing risk management, and the Compensation and Human Capital Committee overseeing human capital management. We use an integrated approach to corporate impact throughout our business to identify risks and opportunities, capture efficiencies and cost savings, and report on the issues most relevant to stakeholders.

Environment: Our environmental management programs strive to make our buildings more sustainable and capture cost efficiencies that ultimately benefit our investors, employees, tenants, business partners, and other stakeholders, while reducing our carbon footprint and providing a positive impact on the communities in which we operate. We regularly assess the risks and financial impacts to our business posed by climate change, including transition risks, physical climate risks, potential business disruption, and regulatory requirements, and work with our property managers, operators, and tenants to implement projects to mitigate these risks and impacts. For a description of the risks associated with climate risk matters, see ‘Item 1A, Risk Factors’ in this report.

Social: See ‘Human Capital Matters’ below.

Governance: Our transparent corporate governance initiatives incorporate sustainability as a critical component in achieving our business objectives and properly managing risks. Our recent corporate impact highlights include: ‘Reported a reduction of 2.1% in Scope 1 and Scope 2 greenhouse gas emissions (‘GHG’) in 2023 compared to 2022 on a like-for-like comparative basis (as defined below)’ ‘Obtained 6 new LEED certifications, 19 new ENERGY STAR certifications, and 150 ENERGY STAR recertifications in 2024’ ‘Named an ENERGY STAR Partner of the Year for Sustained Excellence in 2024, marking our fourth time receiving the Partner of the Year award and first time being recognized for Sustained Excellence’ ‘Received a Green Star rating from the Global Real Estate Sustainability Benchmark (‘GRESB’) for the thirteenth consecutive year, recognizing leading sustainability performance in our sector’ ‘Named to Newsweek’s ‘America’s Most Responsible Companies list for the third consecutive year’ ‘Named a constituent in the FTSE4Good Index for the thirteenth consecutive year’ ‘Named a constituent in the S&P Global Dow Jones Sustainability World Index for the fifth time and S&P Global North America Dow Jones Sustainability Index for the twelfth consecutive year’ ‘Named to the S&P Global Sustainability Yearbook for the ninth consecutive year’

Table of Contents Under our ‘like-for-like’ methodology, direct and indirect GHG emissions are compared on a year-over-year rolling basis using Scope 1 and Scope 2 GHG emissions for the properties that we have owned for two full consecutive calendar years, excluding non-stabilized developments and redevelopments in each year of the calculation. Base data utilized in the calculation of Scope 1 and Scope 2 GHG emissions is obtained from third-party invoices or estimates. For additional information regarding our corporate impact initiatives, methodologies, and approach to climate change, please visit our website at www.healthpeak.com/corporate-impact.

Human Capital Matters Our employees represent our greatest asset, and as of December 31, 2024, we had 387 full-time employees. Our Board of Directors, through its Compensation and Human Capital Committee, retains oversight of human capital management, including corporate culture, diversity, inclusion, talent acquisition, retention, employee satisfaction, engagement, and succession planning. We report on human capital matters at each regularly scheduled Board of Directors meeting and periodically throughout the year. The most significant human capital measures or objectives that we focus on in managing our business and our related human capital initiatives include the following:

- ‘Workforce Diversity: We believe we are a stronger organization when our workforce represents a diversity of ideas and experiences. We value and embrace such diversity in our employee recruiting, hiring, and development practices. Our workforce was made up of 59% female employees and 35% racially or ethnically diverse employees as of December 31, 2024.’
- ‘Inclusion and Belonging: We promote a work environment that emphasizes respect, fairness, inclusion, and dignity. We are committed to providing equal opportunity and fair treatment to all individuals based on merit, without discrimination based on race, color, religion, national origin, citizenship, marital status, gender (including pregnancy), gender identity, gender expression, sexual orientation, age, disability, veteran status, or other characteristics protected by law. We do not tolerate discrimination or harassment. All employees are required to attend a biennial training on unconscious bias.’
- ‘Engagement: High employee engagement and satisfaction are both critical to attracting and retaining top talent and benefit our business in many ways. We conduct a regular employee engagement survey through an independent third party, measuring our progress on important employee issues and identifying opportunities for growth and improvement.’
- ‘Training and Development: We conduct at least annual employee training on our Code of Business Conduct and Ethics, as well as annual training on harassment prevention or unconscious bias. We also provide training and development to all employees, focusing on career development, professional development, and REIT essentials.’
- ‘Compensation and Benefits: We aim to ensure merit-based, equitable compensation practices to attract, retain, and recognize talent. We provide competitive compensation and benefit packages to our employees.’
- ‘Health, Safety, and Wellness: The health, safety, and wellness of our employees are vital to our success. We are committed to protecting the well-being and safety of employees through special training and other measures. We maintain a hybrid work model, which we believe maximizes company-wide productivity, and provide employees with resources, including virtual tools and ergonomic equipment, to maximize work-from-home efficiency.’

Community Partnership: Our Social Responsibility Committee is responsible for oversight of our charitable and volunteer activities. We partner with organizations that share our desire to support research, education, and other activities related to healthcare. For additional information on human capital matters, please see our most recent proxy statement or corporate impact report, each of which is available on our website at www.healthpeak.com.

Available Information Our website address is www.healthpeak.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available on our website, free of charge, as soon as reasonably practicable after we electronically file such materials with the SEC, including us, to the SEC. Additionally, the SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us, at www.sec.gov. References to our website throughout this Annual Report on Form 10-K are provided for convenience only and the content on our website does not constitute a part of this Annual Report on Form 10-K.

Table of Contents **Item 1A – Risk Factors** The section below discusses the risk factors that may materially adversely affect our business, results of operations, and financial condition. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business. As set forth below, we believe that the risks we face generally fall into the following categories:

- ‘risks related to our business and operations;’
- ‘risks related to our capital structure and market conditions;’
- ‘risks related to the regulatory environment;’
- ‘risks relating to integration and property management internalization following our Merger with Physicians Realty Trust;’
- ‘risks related to tax, including REIT-related risks, and related to our jurisdiction of incorporation and our structure as an UPREIT.’

Risks Related to Our Business and Operations We may be negatively impacted by macroeconomic trends that may increase construction, labor, and other operating costs for us and our tenants, operators, and borrowers. In recent periods, many of our costs, including labor costs, construction costs, utilities, and other operating and administrative costs, have been adversely affected by macroeconomic trends, including inflation, price volatility, declines in economic growth rates, and changes in unemployment. These macroeconomic trends have been exacerbated by higher interest rates, supply chain disruptions, geopolitical conflicts, federal government deficits, responses to the Covid pandemic, and other international and domestic events impacting the macroeconomic environment. If any of these adverse macroeconomic trends continue or recur in the future, our business and results of operations may be negatively impacted. Interest rates rose substantially in 2022 and 2023. U.S. government policies implemented to address inflation, including actions by the Federal Reserve System’s Federal Open Market Committee (the ‘FOMC’) to increase short-term interest rates, resulted in increases in interest rates in the credit markets and other impacts on the macroeconomic environment. Interest rates may continue to remain elevated above historical levels for the foreseeable future or rise again. The FOMC may maintain a higher federal funds rate for a longer period of time, or may determine to raise the federal funds rate again, either of which would likely lead to higher short-term interest rates and the possibility of lower asset values, slowing economic growth and increasing the possibility of a recession. Historically higher interest rates have caused, and may in the future cause, unfavorable financing terms and increased interest costs for variable rate debt and new debt. Further, actions by the FOMC to decrease short-term interest rates could lead to inflationary pressures. We may not be able to offset additional costs caused by inflation, higher interest rates, or other macroeconomic trends by passing them through, or increasing the rates we charge, to tenants and residents. These increased costs may hinder our ability to execute on accretive acquisitions or otherwise adversely affect our business, results of operations, and financial condition. Increased interest rates could also negatively impact consumer spending and our tenants’, operators’, and borrowers’ businesses and future demand for our properties. Furthermore, rising labor costs and personnel shortages may adversely impact us or our tenants, operators, and borrowers. Competitive pressures may require that we or our tenants, operators, or borrowers enhance pay and benefits packages to compete effectively for such personnel. To the extent we or our tenants, operators, or borrowers cannot hire a sufficient number of qualified personnel, we or they may need to utilize high-cost alternatives to meet labor needs, including contract and overtime labor, or our business may operate below capacity, which may affect our ability to effectively manage risk and pursue potential revenue and growth opportunities. Additionally, changing technologies, political and regulatory conditions, and cultural trends could negatively impact future demand for our properties, which could have a material adverse effect on our business, results of operations, and financial condition.

Table of Contents **Life science industry changes** could have a material adverse effect on our business, results of operations, and financial condition. If economic, financial, regulatory, or industry conditions adversely affect the life science industry, we may be unable to lease or re-lease our lab properties in a timely manner or at profitable rates or with favorable terms. In addition, because lab property infrastructure improvements are typically significantly more costly than improvements to other property types due to their highly specialized nature, and lab tenants typically require greater lease square footage relative to outpatient medical tenants, repositioning efforts would have a disproportionate adverse effect on our lab segment performance. Further, our lab investments could face decreased demand from biotech and life science companies relative to supply, and life science industry consolidation could reduce the rentable square footage requirements of our client tenants and prospective client tenants, which may adversely impact our revenues from lease payments. Finally, our lab investments could also be adversely affected if the life science industry migrates from the U.S. to other countries or to areas outside of our primary lab markets in the greater South San Francisco, San Diego, and Boston areas. Our

lab tenants face significant regulation, funding requirements, and uncertainty. Our lab tenants face substantial requirements for, and risks related to, the research, development, clinical testing, manufacture, and commercialization of their products and technologies, including: significant funding requirements, including for rent payments due to us; federal, state, and foreign regulatory approvals that may be costly or difficult to obtain, may take several years and be subject to delay, may not be obtained at all, require validation through clinical trials that may face delays or difficulties, or ultimately be unsuccessful; product and technology efficacy risks; acceptance risks among doctors and patients; significant regulatory and liability risks, including the possible later discovery of safety concerns and other defects and potential loss of approvals, competition from new products, and the expiration of patent protection; new and emerging laws aimed at the life science/biotechnology industry, increasing regulatory requirements and compliance costs, as well as healthcare reforms and reimbursement policies of government or private healthcare payors, including price controls for prescription drug prices; intellectual property and technology risks under patent, copyright, and trade secret laws; and economic conditions potentially restricting growth opportunities. Our lab tenants' ability to raise capital depends on the actual or perceived viability of their products and technologies, their financial and operating condition and outlook, and the overall financial, banking, and economic environment. If venture capital firms, private investors, the public markets, companies in the life science industry, the government, or other sources of funding are difficult to obtain or unavailable to support our tenants' activities, including as a result of general economic conditions or adverse market conditions that negatively impact our tenants' ability to raise capital, our tenants' business would be adversely affected or could fail. If our lab tenants' businesses are adversely affected, they may fail to make their rent payments to us, which could have a material adverse effect on our business, results of operations, and financial condition. Decreases in our tenants' operators' revenues, or increases in their expenses, or other factors adversely affecting their ability to borrow money, could affect their ability to meet their financial and other contractual obligations to us. Occupancy levels at, and rental income from, our outpatient medical and senior housing properties depend on our ability and the ability of our tenants, operators, and borrowers to compete with respect to (i) the quality of care provided, (ii) reputation, (iii) price, (iv) the range of services offered, (v) the physical appearance of a property, (vi) family preference, (vii) referral sources, and (viii) location. In addition, our outpatient medical and senior housing tenants, operators, and borrowers compete with certain companies that have superior resources and attributes and/or provide similar healthcare services or alternatives such as home health agencies, telemedicine, life care at home, community-based service programs, retirement communities, and convalescent centers. There have been, and there are expected to continue to be, advances and changes in technology, payment models, healthcare delivery models, regulation, and consumer behavior, preferences, and perception that could reduce demand for on-site activities provided at our properties. If our tenants, operators, or borrowers are unable to adapt to long-term changes in demand, their financial condition could be materially impacted and our business, financial condition, and results of operations could be adversely affected.

15 Table of Contents Furthermore, these tenants, operators, and borrowers face a competitive labor market. A shortage of care givers or other trained personnel, union activities (including strikes, labor slowdowns, or contract negotiations), wage laws, or general inflationary pressures on wages may require our tenants, operators, and borrowers to enhance pay and benefits packages, or to use more expensive contract personnel, and they may be unable to offset these added costs by increasing the rates charged to residents or patients. An inability to attract and retain qualified personnel, including personnel possessing the expertise needed to operate in the life science, outpatient medical, and senior housing sectors, could negatively impact the ability of our tenants, operators, and borrowers to meet their obligations to us. Our tenants, operators, and borrowers could also be adversely impacted by a bank failure or other event affecting financial institutions, including through disruptions in access to bank deposits or borrowing capacity, including access to letters of credit from certain of our tenants relating to lease obligations, and any resulting adverse effects to our tenants' operators' or borrowers' liquidity or financial performance could affect their ability to meet their financial and other contractual obligations to us. Although we generally have the right under specified circumstances to terminate a lease, evict a tenant or terminate an operator, demand immediate repayment of outstanding loan amounts or other obligations to us, or draw on a letter of credit, we may be unable to enforce these rights or we may determine not to do so if we believe that doing so would be more detrimental than alternative approaches. If widespread default or nonpayment of outstanding obligations from our tenants, operators, or borrowers occurs at a time when terminating our agreements with them and replacing them would be difficult or impossible, we could elect instead to amend our agreements on materially less favorable terms to us. The failure of our tenants, operators, or borrowers to meet their financial and other contractual obligations to us could have a material adverse effect on our business, results of operations, and financial condition. We may be negatively impacted by the insolvency or bankruptcy of, or the inability to obtain funding by, one or more of our major tenants, operators, or borrowers. A downturn in our tenants' operators' or borrowers' businesses has led, and could in the future lead, to voluntary or involuntary bankruptcy or similar insolvency proceedings, including assignment for the benefit of creditors, liquidation, or winding-up. Bankruptcy and insolvency laws afford certain rights to a defaulting tenant, operator, or borrower that has filed for bankruptcy or reorganization that has, and in the future may, render certain of our remedies unenforceable or, at the least, delay our ability to pursue such remedies and realize any related recoveries. A debtor has the right to assume, or to assume and assign to a third party, or to reject its executory contracts and unexpired leases in a bankruptcy proceeding. We have been subject to rejection of our leases in the past and may experience such rejection in the future. When a debtor rejects its leases with us, obligations under such rejected leases cease. The claim against the rejecting debtor for remaining rental payments due under the lease is an unsecured claim limited by the statutory cap set forth in the U.S. Bankruptcy Code. This statutory cap may be substantially less than the remaining rent actually owed under the lease. In addition, a debtor may also assert in bankruptcy proceedings that certain leases should be re-characterized as financing agreements, which could result in our being deemed a lender instead of a landlord. A lender's rights and remedies, as compared to a landlord's, generally are materially less favorable, and our rights as a lender may be subject to lower priority for payment under the U.S. Bankruptcy Code. Furthermore, the automatic stay provisions of the U.S. Bankruptcy Code preclude us from enforcing our remedies unless we first obtain relief from the court having jurisdiction over the bankruptcy case. This effectively limits or delays our ability to collect unpaid rent or interest payments, and we may ultimately not receive any payment at all. In addition, we have been, and may again be, required to fund certain expenses and obligations (e.g., real estate taxes, insurance, debt costs, and maintenance expenses) to preserve the value of our properties, avoid the imposition of liens on our properties, or transition our properties to a new tenant or operator. If we are unable to transition affected properties, they would likely experience prolonged operational disruption, leading to lower occupancy rates and further depressed revenues. Publicity about the operator's financial condition and insolvency proceeds may also negatively impact their and our reputations, decreasing customer demand and revenues. Any or all of these risks could have a material adverse effect on our revenues, results of operations, and cash flows. These risks could be magnified where we lease multiple properties to a single operator under a master lease, as an operator failure or default under a master lease would expose us to these risks across multiple properties.

16 Table of Contents We depend on real estate investments, particularly in the healthcare property sector, making us more vulnerable to a downturn or slowdown in that specific sector than if we were investing across multiple sectors. We concentrate our investments in the healthcare property sector. A downturn or slowdown in this sector would have a greater adverse impact on our business than if we had investments across multiple sectors, and could negatively impact the ability of our tenants, operators, and borrowers to meet their obligations to us, as well as their ability to maintain historical rental and occupancy rates, which could have a material adverse effect on our business, results of operations, and financial condition. In addition, such downturns could have a material adverse effect on the value of our properties and our ability to sell properties at prices or on terms acceptable or favorable to us. The illiquidity of our real estate investments may prevent us from timely responding to economic or investment performance changes. Our real estate investments can be relatively illiquid due to: (i) restrictions on our ability to sell properties under applicable REIT tax laws, (ii) other tax-related considerations, (iii) regulatory hurdles, and (iv) market conditions. As a result, we may be unable to recognize full value for any property that we seek to sell. Our inability to timely respond to economic or investment performance changes could have a material adverse effect on our business, results of operations, and financial condition. Identifying and securing new or replacement tenants or operators can be time consuming and costly. Healthcare properties can be highly customized, and the improvements generally required to conform a property to healthcare use are costly, sometimes tenant-specific, and may be subject to regulatory requirements. A new or replacement tenant or operator may require different features in a property, depending on that tenant's or operator's particular business. In addition, infrastructure improvements for outpatient medical and lab properties typically are significantly more expensive than improvements to other property types due to the highly specialized nature of the properties, and with respect to lab properties, the greater lease square footage often required by lab tenants. Therefore, we may incur substantial expenditures to modify a lab property and experience delays before we are able to secure a new or replacement tenant or operator or to accommodate multiple tenants or operators, which may have a material adverse effect on our business, results of operations, and financial condition. In addition, we may fail to identify suitable replacements or enter into leases, management agreements, or other arrangements with new tenants or operators on a timely basis or on terms as favorable to us as our current leases, if at all. We also may be required to fund certain expenses and obligations, such as real estate taxes, debt costs, insurance costs, and maintenance expenses, to preserve the value of, and avoid the imposition of liens on, our properties while they are being repositioned. In addition, we may incur certain obligations and liabilities, including obligations to indemnify the replacement tenant or operator. Identifying and securing new or replacement tenants or operators can be time consuming and costly, which could have a material adverse effect on our business, results of operations, and financial condition. Property development, redevelopment, and tenant improvement risks can render a project less profitable or unprofitable and delay or prevent its undertaking or completion. Our property development, redevelopment, and tenant improvement projects could be canceled, abandoned, delayed or, if completed, fail to perform in accordance with expectations due to, among other things: the inability to obtain financing on favorable terms or at all, or the lack of liquidity we deem necessary or appropriate for the project; legal and regulatory hurdles, including moratoriums on development and redevelopment activities, net zero or carbon neutrality requirements, or other building and energy performance requirements; the failure to obtain, or costs associated with obtaining, necessary zoning, entitlements, and permits; cost increases; and other factors over which we have limited or no control, including: (i) changes in market and economic conditions; (ii) natural disasters and other catastrophic events or physical climate risks, such as wildfires, earthquakes, and wind storms; (iii) pandemics or other health crises; (iv) labor conditions, including a labor shortage or work stoppage; (v) shortages of construction materials; (vi) environmental conditions; or (vii) civil unrest and acts of war or terrorism. Project costs may materially exceed original estimates due to, among other things: higher interest rates; increased costs for materials, transportation, environmental remediation, labor, or other inputs, including those caused by a shortage of construction materials or labor; negligent construction or construction defects; 17 Table of Contents damage, vandalism, or accidents; and increased operating costs, including insurance premiums, utilities, real estate taxes, and costs of complying with changes in government regulations or increases in tariffs. Delays in project completion also delay the commencement of related rental payments, including increases in rental payments following tenant improvement projects, and may provide tenants the right to terminate leases or cause us to incur additional costs, including through rent abatement. Demand for a project may decrease prior to a project's completion, and resulting lease-up rates, rental rates, lease commencement dates, and occupancy levels may fail to meet expectations. Tenants that have pre-leased at a project may file for bankruptcy or become insolvent, or elect to terminate their lease prior to delivery if they are acquired or for other reasons. Finally, a project may have defects that we do not discover through the inspection processes, including latent defects not discovered until after we put a property in service. The foregoing risks could result in not achieving anticipated returns on investment and could have a material adverse effect on our business, results of operations, and financial condition. The hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems could fail to remain competitive or financially viable, which could adversely impact their ability to attract physicians and physician groups to our outpatient medical buildings and our other properties that serve the healthcare industry. The viability of hospitals depends on factors such as: (i) the quality and mix of healthcare services provided, (ii) competition for patients and physicians, (iii) demographic trends in the surrounding community, (iv) market position, (v) growth potential, and (vi) changes to the reimbursement system, as well as the ability of the affiliated healthcare systems to provide economies of scale and access to capital. In addition, hospitals could be negatively affected by widespread cancellations of elective procedures due to health and safety measures or otherwise. If a hospital whose campus is located near one of our outpatient medical buildings is unable to meet its financial obligations, and if an affiliated healthcare system is unable to support that hospital or goes bankrupt, the hospital may be unable to successfully compete or could be forced to close, relocate, or be sold to another provider, which could adversely impact its ability to attract physicians and other healthcare-related users. In addition, hospitals can also be adversely affected by increasing legal and regulatory scrutiny and hurdles, including requirements for hospitals to be able to engage in certain transactions or change owners or operators, which could impact the financial viability of the hospitals. Because we rely on our proximity to, and affiliations with, these hospitals to create tenant demand for space in our outpatient medical buildings, their inability to remain competitive or financially viable, or to attract physicians and physician groups, could adversely affect our outpatient medical building operations and have a material adverse effect on us. We may be unable to develop, maintain, or expand hospital and health system client relationships. We invest significant time in developing, maintaining, and expanding relationships with both new and existing hospital and health system clients. If we fail to maintain these relationships, including through a lack of responsiveness, failure to adapt to the current market, or employment of individuals with inadequate experience, our reputation and relationships will be harmed and we may lose business to competitors, which could have a material adverse effect on us. We assume operational risks with respect to our senior housing properties managed in RIDEA structures that could have a material adverse effect on our business, results of operations, and financial condition. Although the RIDEA structure gives us certain oversight approval rights (e.g., budgets and material contracts) and the right to review operational and financial reporting information, our operators are ultimately in control of the day-to-day business of the property. As a result, we have limited rights to direct or influence the business or operations of our CCRCs and in the properties owned by our SWF SH JV, all of which are under RIDEA structures, and we depend on our operators to operate these properties in a manner that complies with applicable law, minimizes legal risk, and maximizes the value of our investment. Under a RIDEA structure, our TRS is ultimately responsible for all operational risks and other liabilities of the properties, other than those arising out of certain actions by our operator, such as gross negligence or willful misconduct. Operational risks include, and our resulting revenues therefore depend on, among other things: (i) occupancy rates; (ii) the entrance fees and rental rates charged to residents; (iii) the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, to the extent applicable, including changes to reimbursement rates; (iv) our operators' reputations and ability to attract and retain residents; (v) general economic conditions and market factors that impact seniors, including general inflationary pressures; (vi) competition from other senior housing providers; (vii) compliance with federal, state, local, and industry-regulated licensure, certification and inspection laws, regulations and standards; (viii) litigation involving our properties or residents/patients; (ix) the availability and cost of general and professional liability insurance coverage or increases in insurance policy deductibles; and (x) the ability to control operating expenses.

18 Table of Contents Operators of our CCRCs and the SWF SH JV properties primarily depend on private sources for their revenues and the ability of their patients and residents to pay fees. Costs associated with independent and assisted living services are not generally reimbursable under governmental reimbursement programs such as Medicare and Medicaid. Accordingly, our operators of these properties depend on attracting seniors with appropriate levels of income and assets, which may be affected by many factors, including: (i) prevailing economic and market trends, including general inflationary pressures; (ii) consumer confidence; (iii) demographics; (iv) property condition and safety; (v) public perception about such properties; (vi) social and environmental factors; and (vii) changes in consumer preferences (such as favoring home health services instead of residing in a senior housing community). In addition, epidemics, pandemics, and severe flu seasons or any other widespread illness could result in early move-outs or delayed move-ins during quarantine periods or during periods when actual or perceived risks of such illnesses are heightened, and have reduced, and could continue to reduce, our operators' revenues. If our operators fail to effectively conduct operations on our behalf, or to maintain and improve our properties, it could adversely affect our business reputation as the owner of the properties, as well as the business reputation of our operators and their ability to attract and retain patients and residents in our properties, which could have a material adverse effect on our and our operators' business, results of operations, and financial condition. Economic conditions, natural disasters, weather, and other events or conditions that negatively affect geographic areas where we have concentrated investments could have a material adverse effect on our business, results of operations, and financial condition. We are subject to increased exposure to adverse conditions affecting the geographies in which our properties are located, including: (i) downturns in local economies or increases in unemployment rates; (ii) changes in local real estate conditions, including increases in real estate taxes and property insurance premiums; (iii) increased competition; (iv) decreased demand; (v) changes in political administrations, or federal, state, and local legislation, including changes affecting business or property taxes; (vi) local climate events and natural disasters and other catastrophic events, such as pandemics, earthquakes,

hurricanes, windstorms, flooding, wildfires, and mudslides and other physical climate risks, including water stress and heat stress; and (vii) failures of regional banks. These risks could significantly disrupt our businesses in the region, harm our ability to compete effectively, result in increased costs or construction delays, and divert management attention, any or all of which could have a material adverse effect on our business, results of operations, and financial condition. In addition, significant climate changes in areas where we own property could result in extreme weather and changes in precipitation, temperature, and other weather patterns, all of which could result in physical damage to or a decrease in demand for properties located in these areas or affected by these conditions or delays in construction. Moreover, an increase in volatility and difficulty predicting adverse weather events, such as freeze events in warmer climates in recent years, as well as increased hurricane intensity, may result in additional losses. Intensifying natural disasters resulting from climate change and extreme weather events, coupled with macroeconomic factors, have directly affected the availability of insurance, premiums, deductibles, and capacity that insurers are willing to underwrite. As a result, we may determine to self-insure more of our exposures, absorb more below deductible losses, and look for alternative means of risk transfer in order to avoid spiraling insurance costs. These events also have indirect effects on our business by increasing the costs of energy, maintenance, and snow removal at our properties. If changes in the climate have material effects, such as property destruction, or occur for extended periods, this could have a material adverse effect on business, results of operations, and financial condition. Uninsured or underinsured losses could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses. A large number of our properties are located in areas exposed to earthquakes, hurricanes, windstorms, flooding, water stress, heat stress, and other common natural disasters and physical climate risks. In particular, (i) a significant portion of our lab development projects and approximately 67% of our lab portfolio (based on gross asset value as of December 31, 2024) was concentrated in California, which is known to be subject to earthquakes, wildfires, and other natural disasters, and (ii) approximately 68% of our CCRC portfolio (based on gross asset value as of December 31, 2024) was concentrated in Florida, which is known to be subject to hurricanes. While we maintain insurance coverage for earthquakes, fires, hurricanes, windstorms, floods, and other natural disasters and physical climate risks, we may be unable to purchase the limits and terms we desire on a commercially reasonable basis due to increased insurance costs or the unavailability of insurance for certain exposures in other regions. We maintain additional earthquake insurance for our properties that are located in the vicinity of active earthquake zones in amounts and with deductibles we believe are commercially reasonable. Because of our significant concentration in the seismically active regions of South San Francisco, California, and San Diego, California, an earthquake in these areas could damage a significant portion of our lab portfolio. Similarly, a hurricane in Florida could damage a significant portion of our CCRC portfolio. As a result, aggregate deductible amounts may be material, and our insurance coverage may be materially insufficient to cover our losses. Furthermore, there are certain exposures for which we do not purchase insurance because we do not believe it is economically feasible to do so or there is no viable insurance market.

19 Table of Contents If one of our properties experiences a loss that is uninsured or that exceeds policy coverage limits, we could lose our investment in the damaged property as well as the anticipated future cash flows from such property. If the damaged property is subject to recourse indebtedness, we could continue to be liable for the indebtedness even if the property is irreparably damaged. In addition, even if damage to our properties is covered by insurance, a disruption of business caused by a casualty event may result in loss of revenues for us. Any business interruption insurance may not fully compensate the lender or us for such loss of revenue. Our insurance coverage does not include damages as a result of a pandemic (such as Covid), including business interruption, loss of revenue or earnings, or any related effects (e.g., increased costs related to personal protective equipment, sanitization/sterilization of surfaces and equipment, and additional staffing). Insurance coverage for pandemics is not generally available; if it does become available again, it may not be on commercially reasonable terms and we may be unable to receive insurance proceeds that would compensate us fully for our liabilities, costs, and expenses in the event of a pandemic. Our CCRC and senior housing operators also face various forms of class-action lawsuits from time to time, such as wage and hour and consumer rights actions, which generally are not covered by insurance. These class actions could result in significant defense costs, as well as settlements or verdicts that materially decrease anticipated revenues from a property and can result in the loss of a portion or all of our invested capital. We may also incur significant out-of-pocket costs associated with legal proceedings or other claims from residents and patients at our properties. Any of the foregoing risks could have a material adverse effect on our business, results of operations, and financial condition. In addition, the rise in outsized jury verdicts and/or intensifying natural disasters could threaten policy limits and/or sublimits, which may result in the exhaustion of available insurance coverage for the remainder of the policy year. These events could also have a material adverse effect on our business, results of operations, and financial condition. Our use of joint ventures may limit our returns on and our flexibility with jointly owned investments. From time to time, we develop, acquire, and/or recapitalize properties in joint ventures with other persons or entities when circumstances warrant the use of these structures. Our participation in joint ventures is subject to risks that may not be present with other methods of ownership, including:

- our joint venture partners could have investment and financing goals that are inconsistent with our objectives, including the timing, terms, and strategies for any investments, and what levels of debt to incur or carry;
- because we lack sole decision-making authority, we could experience impasses or disputes relating to certain decisions, including those related to budget approvals, entitlements, construction and development, acquisitions, sales of assets, debt financing, execution of lease agreements, and vendor approvals, which could result in delayed decisions and missed opportunities and could require us to expend additional resources on litigation or arbitration to resolve;
- our joint venture partners may have competing interests that create conflicts of interest in our markets;
- our ability to transfer our interest in a joint venture to a third party may be restricted;
- the market for our interest may be limited and/or valued lower than fair market value;
- our joint venture partners may be structured differently than us for tax purposes, and this could create conflicts of interest and risks to our REIT status or could restrict the ways in which we are able to exit investments;
- our joint venture partners might become insolvent, fail to fund their share of required capital contributions or fail to fulfill their obligations as a joint venture partner, which may require us to infuse our own capital into the venture on behalf of the partner despite other competing uses for such capital;
- our joint venture agreements may contain anti-competitive restrictions that impact certain of our non-joint venture assets and require us to manage the non-joint venture assets in a manner we otherwise would not;
- our joint venture agreements may in certain circumstances grant our partners a right of first refusal to acquire certain of our non-joint venture assets;
- our joint venture agreements may give our partners management rights that allow them to make operational or other decisions with which we disagree or that we would manage differently;
- and
- our joint venture agreements may impose limitations or caps on the property management fees that we otherwise would have been entitled to receive if the underlying property were wholly owned. In addition, in some instances, our joint venture partner will have the right to cause us to sell our interest, or acquire their interest, at a time when we otherwise would not have initiated such a transaction. Our ability to acquire our partner's interest will be limited if we lack sufficient capital resources. This could require us to sell our interest in the joint venture when we might otherwise prefer to retain it. Any of the foregoing risks could have a material adverse effect on our business, results of operations, and financial condition.

20 Table of Contents Rent escalators or contingent rent provisions in our leases could hinder our profitability and growth. We derive a significant portion of our revenues from leasing properties pursuant to leases that generally provide for fixed rental rates, subject to annual escalations. If inflation exceeds our annual escalations, as it often recently has, our growth and profitability may be limited. Under certain leases, a portion of the tenant's rental payment to us is based on the property's revenues (i.e., contingent rent). If a tenant's revenue at a rental property with contingent rent declines, our rental revenues would decrease. Additionally, some of our leases provide that annual rent is modified based on changes in the Consumer Price Index or other thresholds (i.e., contingent rent escalators). If the Consumer Price Index does not increase or other applicable thresholds are not met, rental rates may not increase as anticipated or at all, which could hinder our profitability and growth. Furthermore, if economic conditions result in significant increases in the Consumer Price Index, but the escalations under our leases with contingent rent escalators are capped or the increase in the Consumer Price Index exceeds our tenants' ability to pay, our growth and profitability also may be limited. Competition may make it difficult to identify and purchase, or develop, suitable healthcare properties to grow our investment portfolio, to finance acquisitions on favorable terms, or to retain or attract tenants and operators. We face significant competition from other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders, developers, and other institutional investors, some of whom may have greater resources and lower costs of capital than we do. Increased competition and resulting capitalization rate compression make it more challenging for us to identify and successfully capitalize on opportunities that meet our business goals and could improve the bargaining power of property owners seeking to sell, thereby impeding our investment, acquisition, and development activities. Similarly, our properties face competition for tenants and operators from other properties in the same market, which may affect our ability to attract and retain tenants and operators, or may reduce the rents we are able to charge. The failure to capitalize on our development pipeline, identify and purchase a sufficient quantity of healthcare properties at favorable prices, finance acquisitions on commercially favorable terms, or attract and retain profitable tenants could have a material adverse effect on our business, results of operations, and financial condition. We may be unable to successfully exercise rights on the collateral securing our real estate-related loans and, even if we are successful in exercising those rights, we may be unable to successfully operate, occupy, or reposition the underlying real estate. If a borrower defaults under one of our real estate related loans, we may look to exercise our rights under the loan, including acquiring title to the collateral via deed in lieu of foreclosure, foreclosure, statutory or judicial foreclosure, or commencing collection litigation. In some cases, because our collateral consists of the equity interests in an entity that directly or indirectly owns the applicable real property or interests in other operating properties, we may not have full recourse with respect to assets of that entity, or that entity may have incurred unexpected liabilities, either of which would preclude us from fully recovering our investment. Borrowers and guarantors may contest enforcement of foreclosure or other remedies, seek bankruptcy protection against our exercise of enforcement or other remedies, and/or bring claims for lender liability in response to actions to enforce borrower obligations. Because many of the properties securing our mortgage loans are licensed senior housing health care facilities, we would also need to navigate and comply with various healthcare regulatory matters in a variety of states in connection with any foreclosure effort. Enforcement or collections-related costs, high loan-to-value ratios, healthcare regulatory issues or consents, or declines in the value of the property, may prevent us from realizing an amount equal to our loan balance upon enforcement or conclusion of litigation, and we may be required to record a valuation allowance for such losses. Even if we are able to successfully exercise our rights on the collateral securing our real estate-related loans, we may acquire properties for which we may be unable to expeditiously secure tenants or operators, if at all, or that are burdened with healthcare regulatory compliance issues that need to be addressed, or we may acquire equity interests that we are unable to immediately resell or otherwise liquidate due to limitations under the securities laws, either of which would adversely affect our ability to fully recover our investment. We may also determine that substantial improvements or repairs to the property are necessary in order to maximize the property's investment potential. Alternatively, we may determine to sell a distressed loan for less than full value, in which event we may incur a loss on the investment.

21 Table of Contents We may be required to recognize reserves, allowances, credit losses, or impairment charges. Declines in the value of our properties or other assets or loan collateral, financial deterioration of our tenants, borrowers, or other obligors, or other factors may result in the recognition of reserves, allowances, credit losses, or impairment charges. Our determination of such reserves, allowances, or credit losses relies on estimates regarding the fair value of any loan collateral, which is a complex and subjective process. In addition, we evaluate our assets for impairments based on various triggers, including market conditions, our current intentions with respect to holding or disposing of the assets and the expected future undiscounted cash flows from the assets. Impairments, reserves, allowances, and credit losses are based on estimates and assumptions that are inherently uncertain, may increase or decrease in the future, and may not represent or reflect the ultimate value of, or loss that we ultimately realize with respect to, the relevant assets. Any such impairment, reserve, allowance, or credit loss, or any change in any of the foregoing, could have an adverse impact on our results of operations and financial condition. We may invest substantial resources and time in transactions that are not consummated. We regularly review potential transactions in order to maximize stockholder value. Our review process may require significant management attention, and a potential transaction could be abandoned or rejected by us or the other parties involved after we expend significant resources and time. We may not be able to successfully integrate or operate acquisitions and/or internalize property management, or may incur unanticipated liabilities. Successful integration of acquired companies and/or internalization of the property management function, as applicable, depends primarily on our ability to consolidate operations, systems, procedures, properties, and personnel, and to eliminate redundancies and reduce costs. We may encounter difficulties in these integrations and property management internalizations. Potential difficulties associated with acquisitions and property management internalizations include: (i) our ability to effectively monitor and manage our expanded portfolio of properties; (ii) the loss of key employees; (iii) the disruption of our ongoing business or that of the acquired entity; (iv) possible inconsistencies in standards, controls, procedures, and policies; and (v) the assumption of unexpected liabilities and claims, including:- liabilities relating to the cleanup or remediation of undisclosed environmental conditions;
- unasserted claims of vendors, residents, patients, or other persons dealing with the seller;
- liabilities, claims, and litigation, whether or not incurred in the ordinary course of business, relating to periods prior to the acquisition;
- claims for indemnification by general partners, directors, officers, and others indemnified by the seller;
- claims for return of government reimbursement payments; and
- liabilities for taxes relating to periods prior to the acquisition. In addition, acquired companies and their properties may fail to perform as expected, including with respect to estimated cost savings. Inaccurate assumptions regarding future rental or occupancy rates could result in overly optimistic estimates of future revenues. Similarly, we may underestimate future operating expenses or the costs necessary to bring properties up to standards established for their intended use or for property improvements. If we have difficulties with any of these areas, or if we later discover additional liabilities or experience unforeseen costs relating to our acquired companies or property management internalization, we may not achieve the anticipated economic benefits from our acquisitions or property management internalization, and this may have a material adverse effect on our business, results of operations, and financial condition. For additional information on risks related to integration following the Merger, see "Risks Relating to Integration following our Merger with Physicians Realty Trust" below.

22 Table of Contents We may be affected by unfavorable resolution of litigation or disputes and rising liability and insurance costs as a result thereof or other market factors. Our tenants, operators, property managers, employees, and borrowers are from time to time parties to litigation, including, for example, disputes regarding the quality of care at healthcare properties or the operations of the properties. The effect of litigation may materially increase the costs incurred by our tenants, operators, property managers, and borrowers, including costs to monitor and report quality of care compliance. In addition, the cost of professional liability, medical malpractice, property, business interruption, general liability, and insurance policies can be significant and may increase or not be available at a reasonable cost or at all. Cost increases could cause our tenants and borrowers to be unable to make their lease or mortgage payments or fail to purchase the appropriate liability and malpractice insurance, or cause our borrowers to be unable to meet their obligations to us, potentially decreasing our revenues and increasing our collection and litigation costs. Cost increases could also lead our operators and property managers to increase the fees they charge, which could have a material adverse effect on our business, results of operations, and financial condition. Furthermore, with respect to our CCRC properties and the properties in our SWF SH JV, all of which are operated in RIDEA structures, we generally directly bear the costs of any such increases in litigation, monitoring, reporting, and insurance due to our direct exposure to the cash flows of such properties. We are responsible for these claims, litigation, and liabilities, with limited indemnification rights against our operators, which are typically based on the gross negligence or willful misconduct by the operator. Although our leases provide us with certain information rights with respect to our tenants, one or more of our tenants may be or become party to pending litigation or investigation of which we are unaware or in which we do not have a right to participate or evaluate. In such cases, we would be unable to determine the potential impact of such litigation or investigation on our tenants or our business or results. Moreover, negative publicity of any of our operators', property managers', or tenants' litigation, other legal proceedings or investigations may also negatively impact their and our reputation, resulting in lower customer demand and revenues, which could have a material adverse effect on our financial condition, results of operations, and cash flows. We may also be named as defendants in lawsuits arising out of our alleged actions or the alleged actions of our tenants, operators, or property managers for which such tenants, operators, or property managers may have agreed to indemnify us. Unfavorable resolution of any such litigation, including an outsized jury verdict, or negative publicity as a result of such litigation could have a material adverse effect on our business, results of operations, and financial condition. Regardless of the outcome, litigation or other legal proceedings may result in substantial costs, disruption of our normal business operations, and the diversion of management attention. We may be unable to prevail in, or achieve a favorable settlement of, any pending or future legal action against us. Even when a tenant or operator is obligated to indemnify us for liability incurred as a result of a lawsuit pursuant to the terms of its agreement with us, the tenant may fail to satisfy those obligations and, in such event, we would have to incur the costs that should have been covered by the tenant, operator, or property manager and to determine whether to expend additional resources to seek the contractually owed indemnity from that tenant, operator, or property

manager, including potentially through litigation or arbitration. In some instances, we may decide not to enforce our indemnification rights if we believe that enforcement of such rights would be more detrimental to our business than alternative approaches. Regardless, such an event would divert management attention and may result in a disruption to our normal business operations, any or all of which could have an adverse effect on our business, results of operations, and financial condition. Environmental compliance costs and liabilities associated with our real estate-related investments may be substantial and may materially impair the value of those investments. Federal, state and local laws, ordinances, and regulations may require us, as a current or previous owner of real estate, to investigate, monitor, and/or clean up certain hazardous or toxic substances released at a property. We may be held liable to a governmental entity or to third parties for injury or property damage and for investigation and cleanup costs incurred in connection with the contamination. The costs of cleanup and remediation could be substantial. In addition, some environmental laws create a lien on the contaminated site in favor of the government for damages and the costs it incurs in connection with the contamination, and/or impose fines and penalties on the property owner with respect to such contamination.

23Table of ContentsAlthough we currently carry environmental insurance on our properties in an amount that we believe is commercially reasonable and generally require our tenants and operators to indemnify us for environmental liabilities they cause, such liabilities could exceed the amount of our insurance, the financial ability of the tenant or operator to indemnify us, or the value of the contaminated property. As the owner of a site, we may also be held liable to third parties for damages and injuries resulting from environmental contamination emanating from the site. We may also experience environmental costs and liabilities arising from conditions not known to us or disrupted during development. The cost of defending against these claims, complying with environmental regulatory requirements, conducting remediation of any contaminated property, or paying personal injury or other claims or fines could be substantial and could have a material adverse effect on our business, results of operations, and financial condition. In addition, the presence of contamination or the failure to remediate contamination may materially adversely affect our ability to use, develop, sell, or lease the property or to borrow using the property as collateral. Corporate impact and sustainability commitments and requirements, as well as stakeholder expectations, may impose additional costs and expose us to new risks. Investors, tenants, business partners and other stakeholders, as well as regulators and other groups, are increasingly focusing on our corporate impact and sustainability commitments and performance. Some investors may use corporate impact factors to guide their investment strategies and, in some cases, may choose not to invest in us if our corporate impact commitment and performance do not satisfy their criteria. Similarly, some business partners or tenants may use corporate impact factors to guide their business decisions and choose not to do business with us if they believe our corporate impact or sustainability policies are inadequate. Third-party providers of corporate impact ratings have increased in number, resulting in varied and, in some cases, inconsistent standards. In addition, the criteria by which companies’ corporate impact and sustainability practices are assessed are evolving, which could result in greater expectations for us to undertake costly initiatives to satisfy such new criteria. At the same time, diverging views on corporate impact may emerge from regulators and stakeholders, potentially resulting in increased scrutiny of our corporate impact practices and political or reputational risk. We have established corporate goals to reduce greenhouse gas emissions, energy, water and waste in our operations, and various regions in which we own properties are establishing building performance standards. Our reputation may be adversely affected if we do not meet our announced goals or these external standards. In addition, metrics and quantitative data we disclose related to our corporate impact and sustainability commitments are based on and verified in accordance with standards that are different from U.S. generally accepted accounting principles. Such data and metrics may be subject to measurement uncertainties resulting from limitations inherent in the nature and the methods used for determining such data. The selection of different but acceptable measurement techniques can result in materially different measurements. If we fail to satisfy the expectations of investors, tenants, business partners or other stakeholders, or our announced goals and other initiatives are not executed as planned or there are changes in the measurement techniques (including any changes in estimates or assumptions underlying the measurements) or in the standards referenced for the measurement of data, our reputation and financial results could be adversely affected, and our revenues, results of operations and ability to grow our business may be negatively impacted. In addition, we may incur significant costs in attempting to comply with corporate impact policies or third-party expectations or demands.

In addition, changes in federal, state, and local legislation and regulation relating to climate change, net zero or carbon neutrality requirements, and building and energy performance standards could require (i) increased capital expenditures to improve the energy efficiency or resiliency of our existing properties and increase the costs of new developments and (ii) increased compliance costs for us and our tenants, in each case without a corresponding increase in revenue. In addition, our reputation may be adversely affected if we do not meet stakeholder expectations to mitigate climate risk in a transition to a low-carbon economy. We may be impacted by epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread. Epidemics, pandemics, or other infectious diseases, including future outbreaks of Covid and its variants, as well as both future widespread and localized outbreaks of infectious diseases and other health concerns, and the health and safety measures taken to reduce the spread or lessen the impact, could cause a material disruption to our industry or deteriorate the economy as a whole. The impacts of such events could be severe and far-reaching, and may impact our operations in several ways, including: (i) tenants could experience deteriorating financial condition and be unable or unwilling to pay rent on time and in full; (ii) we may have to restructure tenants’ obligations and may not be able to do so on terms that are favorable to us; (iii) inquiries and tours at our properties could decrease; (iv) move-ins, new tenanting efforts, and re-letting efforts could slow or stop altogether; (v) move-outs and potential early termination of leases thereunder could increase; (vi) operating expenses, including the costs of certain essential services or supplies, including payments to third-party contractors, service providers, and employees essential to ensure continuity in our building operations, may increase; (vii) procedures normally conducted on our properties may be disrupted, adversely affecting the economic viability of our tenants; and (viii) costs of development, including expenditures for materials utilized in construction and labor essential to complete existing developments in progress, may increase substantially.

24Table of ContentsHuman capital risks, including the loss or limited availability of our key personnel, could disrupt or impair our operations. We face elevated labor costs and increased competition for talent. Insufficient employee development, inadequate succession planning or an inability to successfully maintain a hybrid work model could negatively impact our business and operations. We also depend on the efforts of our executive officers for the success of our business. Although they are covered by our Executive Severance Plan and Executive Change in Control Severance Plan, which provide many of the benefits typically found in executive employment agreements, none of our executive officers have employment agreements with us. The loss or limited availability of the services of any of our executive officers, or our inability to recruit and retain qualified personnel, could, at least temporarily, disrupt, or impair our operations. We rely on information technology in our operations, and any material failure, inadequacy, interruption, or security failure of that technology could harm our business. We rely on information technology networks, enterprise applications, and other information systems to process, transmit, and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, to maintain personal identifying information and tenant and lease data, and to operate building management systems. We utilize software and cloud-based technology from third-party service providers, on whom our information systems depend. We rely on commercially available systems, software, tools, and monitoring to provide security for the processing, transmission, and storage of confidential employee, tenant and customer data, including individually identifiable information relating to financial accounts, as well as building access, security, and operations. Although we have taken steps to protect the security of our information systems, with multiple layers of controls around the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems’ improper functioning or damage, or the improper access of systems or disclosure of personally identifiable information such as in the event of cyber-attacks or other cybersecurity incidents. Our third-party service providers may also experience unexpected power losses, computer system failures, or data network disruptions, negatively impacting the systems or solutions we depend on. If our third-party providers face a security incident or other interruptions, or if there is a flaw or failed software update in the third-party software used in our systems, our information systems may become disabled or inaccessible. This could limit access to our data and business information, potentially causing significant disruptions to our operations. Furthermore, because our operators as well as other third-party service providers with whom we and they do business (including vendors, software creators and cloud solution and cybersecurity providers) also rely on the Internet, information technology networks, enterprise applications, systems, and software, some of our data may be vulnerable to cybersecurity incidents or cybersecurity threats involving our operators and third parties with whom we or they do business. We do not control the cybersecurity systems and protocols put in place by our operators or other third parties, and such parties may have limited indemnification obligations to us, which could cause us to be negatively impacted as a result. Cybersecurity incidents and cybersecurity threats affecting our or our operators’ or other third party providers’ information systems, including those caused by physical or electronic break-ins, computer viruses, malware, worms, attacks by hackers or foreign governments, ransomware attacks, disruptions from unauthorized access and tampering, including through social engineering such as phishing or vishing attacks, coordinated denial-of-service attacks, and similar breaches, could result in, among other things: (i) system disruptions; (ii) shutdowns; (iii) unauthorized access to or disclosure of confidential information, including as a result of impersonation of authorized users or manipulated communications; (iv) misappropriation of our or our business partners’ proprietary or confidential information; (v) breach of our legal, regulatory, or contractual obligations; (vi) inability to access or rely upon critical business records or systems; or (vii) other delays in our operations. In some cases, it may be difficult to anticipate or immediately detect such cybersecurity threats and cybersecurity incidents and the damage they cause. The risk of cybersecurity incidents and cybersecurity threats has generally increased as the number, intensity, and sophistication of attacks and intrusions affecting companies generally have increased, and we have seen a significant increase in cyber phishing attacks. The risk of security breaches has also increased under our hybrid work model. We may be required to expend significant financial resources to detect, protect against or remediate such cybersecurity incidents or cybersecurity threats. In addition, our technology infrastructure and information systems are vulnerable to damage or interruption from natural disasters, power loss, and telecommunications failures. Any failure to adequately train employees or to maintain proper function, security, and availability of our and our operators’ information systems and the data maintained in those systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties, harm our business relationships, or increase our security and insurance costs, which could have a material adverse effect on our business, financial condition, and results of operations.

25Table of ContentsOur tenants and borrowers may also from time to time experience cybersecurity incidents or cybersecurity threats that compromise, damage or disrupt their information systems or result in the loss or misuse of confidential information, intellectual property or sensitive or personal information. Any resulting financial impact to our tenants or borrowers, including liability claims or regulatory penalties, increased security and insurance costs as well as business impacts resulting from any damage to their reputation or harm to their business relationships, could negatively impact the ability of our tenants and borrowers to meet their financial and other contractual obligations to us, which could have a material adverse effect on our business, financial condition and results of operations. The use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors presents risks and challenges that may adversely impact our business and operating results or the business and operating results of our tenants and vendors or may adversely impact the requirements and demand for properties. We may use generative artificial intelligence and/or machine learning (collectively, “AI”) tools in our operations. If our peers use AI tools to optimize operations and we fail to utilize AI tools in a comparable manner, we may be competitively disadvantaged. However, while AI tools may facilitate optimization and operational efficiencies, they also have the potential for inaccuracy, bias, infringement or misappropriation of intellectual property, and risks related to data privacy and cybersecurity. The use of AI tools may introduce errors or inadequacies that are not easily detectable, including deficiencies, inaccuracies, or biases in the data used for AI training, or in the content, analyses, or recommendations generated by AI applications. The results of such errors or inadequacies may adversely affect our business, financial condition, and results of operations. The legal requirements relating to AI continue to evolve and remain uncertain, including how legal developments could impact our business and ability to enforce our proprietary rights or protect against infringement of those rights. Cybersecurity threat actors may utilize AI tools to automate and enhance cybersecurity attacks against us. We utilize software and platforms designed to detect such cybersecurity threats, including AI-based tools, but these threats could become more sophisticated and harder to detect and counteract, which may pose significant risks to our data security and systems. Such cybersecurity attacks, if successful, could lead to data breaches, loss of confidential or sensitive information, and financial or reputational harm. The integration of AI tools in the healthcare industry may present significant opportunities and risks, including for our tenants. For example, in the life science industry, AI predictive models have the potential to be utilized broadly across various stages of drug development. Physicians in our outpatient medical portfolio may use AI tools to run comprehensive diagnostic tests. However, the adoption of AI tools also introduces a complex risk landscape for our tenants, similar to those risks described above. Moreover, the adoption of AI tools by our tenants may lead to infrastructure requirements that our buildings currently do not accommodate, such as increased power needs for high-performance computing. Infrastructure upgrades may require significant capital expenditures and could potentially impact the environmental footprint of our building operations. Our vendors may use AI tools in their products or services without our knowledge, and the providers of these tools may not meet the evolving regulatory or industry standards for privacy and data protection. Consequently, this may inhibit our or our vendors’ ability to uphold an appropriate level of service and data privacy. If we, our vendors, or other third parties with which we conduct business experience an actual or perceived breach of privacy or security incident due to the use of AI, we may be adversely impacted, lose valuable intellectual property or confidential information, and incur harm to our reputation and the public perception of the effectiveness of our security measures. In addition, investors, analysts, and other market participants may use AI tools to process, summarize or interpret our financial information or other data about us. The use of AI tools in financial and market analysis may introduce risks similar to those described above, including an inaccurate interpretation of our financial or operational performance or market trends or conditions, which in turn could result in inaccurate conclusions or investment recommendations.

26Table of ContentsRisks Related to Our Capital Structure and Market ConditionsVolatility, disruption, or uncertainty in the financial markets may impair our ability to raise capital, obtain new financing or refinance existing obligations, and fund acquisition and development activities. Increased or prolonged market disruption, volatility, or uncertainty could have a material adverse effect on our ability to raise capital, obtain new financing or refinance our existing obligations as they mature, and fund acquisition and development activities. Our lenders and other financial institutions could also require us to agree to more restrictive covenants, grant liens on our assets as collateral, and/or accept other terms that are not commercially beneficial to us in order to obtain financing. One or more of our lenders under our credit facility could refuse or fail to fund their financing commitment to us as a result of lender liquidity and/or viability challenges, which financing commitments we may not be able to replace on favorable terms, or at all. In addition, the failure of a bank, or events involving limited liquidity, defaults, non-performance or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, or concerns or rumors about such events, could lead to disruptions in access to our bank deposits, our inability to access our bank deposits in excess of the Federal Deposit Insurance Corporation (FDIC) limits, or otherwise adversely impact our liquidity and financial performance, and our tenants, operators, and borrowers could be similarly adversely affected. Market volatility could also lead to significant uncertainty in the valuation of our investments and those of our joint ventures, which may result in a substantial decrease in the value of our properties and those of our joint ventures. As a result, we may be unable to recover the carrying amount of such investments and the associated goodwill, if any, which may require us to recognize impairment charges in earnings. Increased borrowing costs could materially adversely impact our ability to refinance existing debt, sell properties, and conduct investment activities. We currently have and may incur additional debt obligations that have variable interest rates and related payments that vary with the movement of certain indices. During inflationary periods, interest rates have historically increased. For example, actions taken by the FOMC in response to recent inflationary conditions led to rising interest rates, which may continue to remain at elevated levels for the foreseeable future. Elevated interest rates result in increased interest costs for our variable rate debt and our new debt, which adversely affects our cost of capital and makes the financing of any acquisition and development activity more costly. In addition, elevated interest rates have lowered, and could continue to lower, the amount third parties are willing to pay for our properties, thereby negatively impacting our ability to reposition our portfolio promptly in response to changes in economic or other conditions. Higher borrowing costs could limit our ability to refinance existing debt when it matures, or cause us to pay higher interest rates upon refinancing and increased interest expense on refinanced indebtedness. We manage a portion of our exposure to interest rate risk by accessing debt with staggered maturities and through the use of derivative instruments, primarily interest rate cap and swap agreements. These agreements involve risk, including that counterparties may fail to honor their obligations under these arrangements, that these arrangements may not be effective in reducing our exposure to interest rate changes, that the amount of income we earn from hedging transactions may be limited by federal tax provisions governing REITs, and that these arrangements may cause us to incur higher debt service costs than would otherwise be the case. Failure to hedge effectively against interest rate risk could adversely affect our results of operations and financial

condition. Additionally, higher borrowing costs and attendant negative impacts on our business can reduce the amount investors are willing to pay for our common stock. Because REIT stocks are often perceived as high-yield investments, investors may perceive less relative benefit to owning REIT stocks as borrowing costs increase. Cash available for distribution to stockholders may be insufficient to make dividend distributions at expected levels and are made at the discretion of our Board of Directors. Decreases in cash available for distributions may result in us being unable to make dividend distributions at expected levels. Our failure to make distributions commensurate with market expectations would likely result in a decrease in the market price of our common stock. Further, all distributions are made at the discretion of our Board of Directors in accordance with Maryland law and depend on: (i) our earnings; (ii) our financial condition; (iii) debt and equity capital available to us; (iv) our expectations for future capital requirements and operating performance; (v) covenants in our financial or other contractual arrangements, including those in our credit facility agreement; (vi) maintenance of our REIT qualification; and (vii) other factors as our Board of Directors may deem relevant from time to time.

Table of Contents

§ 1. Access to external capital is unavailable on acceptable terms or at all, it could have a material adverse effect on our ability to meet commitments as they become due or make investments necessary to grow our business. We periodically rely on external sources of capital (including debt and equity financing) to fulfill our capital requirements. The availability of external capital sources is affected by several factors, some of which we have little or no control over, including: § 2. general availability of capital, including our ability to raise capital on acceptable terms, higher interest rates, and increased borrowing costs; § 3. the market price of the shares of our equity securities and the credit ratings of our debt and any preferred securities we may issue; § 4. the market's perception of our growth potential and our current and potential future earnings and cash distributions; § 5. our degree of financial leverage and operational flexibility; § 6. the financial integrity of our lenders, which might impair their ability to meet their commitments to us or their willingness to make additional loans to us, and our inability to replace the financing commitment of any such lender on favorable terms, or at all; § 7. bank failures or other events affecting financial institutions, which could adversely affect our or our tenants' liquidity and financial performance; § 8. the stability of the market value of our properties; § 9. the financial performance and general market perception of our tenants and operators; § 10. changes in the credit ratings on U.S. government debt securities or default or delay in payment by the U.S. of its obligations; § 11. issues facing the healthcare industry, including healthcare reform and changes in government reimbursement policies; and § 12. the performance of the national and global economies generally, including any economic downturn and volatility in the financial markets.

If access to capital is unavailable on acceptable terms or at all, it could have a material adverse impact on our ability to fund operations, repay or refinance our debt obligations, fund dividend payments, acquire properties, and make the investments in development and redevelopment activities, as well as capital expenditures, needed to grow our business. Our level of indebtedness may increase and materially adversely affect our future operations. Our outstanding indebtedness as of December 31, 2024 was approximately \$8.7A billion. We may incur additional indebtedness, which may be substantial. Any significant additional indebtedness would likely negatively affect the credit ratings of our debt and require us to dedicate a growing portion of our cash flow to interest and principal payments. Greater demands on our cash resources may reduce funds available to us to pay dividends, conduct development activities, make capital expenditures and acquisitions, or carry out other aspects of our business strategy. Increased indebtedness can also make us more vulnerable to general adverse economic and industry conditions and create competitive disadvantages for us compared to other companies with comparatively lower debt levels. Increased future debt service obligations may limit our operational flexibility, including our ability to finance or refinance our properties, contribute properties to joint ventures, or sell properties as needed. In addition, any changes to benchmark rates, or uncertainty as to the nature of such potential changes, may increase the cost of our variable rate debt or cost of funds, adversely affect the trading market for our securities, have an unpredictable impact on the financial markets or otherwise affect our financial condition and results of operations. Covenants in our debt instruments limit our operational flexibility, and breaches of these covenants could result in adverse actions by our creditors. The terms of our current secured and unsecured debt instruments require us to comply with a number of customary financial and other covenants, such as maintaining leverage ratios, minimum tangible net worth requirements, REIT status, and certain levels of debt service coverage. Our ability to incur additional debt and to conduct business in general is subject to compliance with these covenants, which limits our operational flexibility. For example, mortgages on our properties contain customary covenants such as those that limit or restrict our ability, without the consent of the lender, to further encumber or sell the applicable properties, or to replace the applicable tenant or operator. Breaches of certain covenants may result in defaults under the mortgages on our properties and cross-defaults under certain of our other indebtedness, even if we satisfy our payment obligations to the respective obligee. Covenants that limit our operational flexibility, as well as defaults resulting from the breach of any of these covenants, could have a material adverse effect on our business, results of operations, and financial condition.

Table of Contents

The market price and trading volume of our common stock may be volatile. The market price of our common stock has been, and may in the future be, highly volatile and subject to wide fluctuations. In addition, the trading volume in our common stock may fluctuate and cause significant price variations to occur. The stock market has experienced extreme price and volume fluctuations that have affected the market price of many companies in industries similar or related to ours and that have been unrelated to these companies' operating performances. If the market price of our common stock declines significantly, you may be unable to resell your shares at a gain. We cannot assure you that the market price of our common stock will not fluctuate or decline significantly in the future. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our common stock include: § 1. actual or anticipated variations in our quarterly operating results, guidance, or distributions; § 2. changes in market valuations of similar companies; § 3. adverse market reaction to any increased indebtedness we may incur in the future; § 4. issuance of additional equity securities; § 5. actions by institutional stockholders; § 6. the publication of research reports and articles (or false or misleading information) about us, our tenants, the real estate industry, or the industries in which our tenants operate; § 7. speculation in the press or investment research community and investor sentiment regarding commercial real estate generally, our industry sectors or other real estate sectors, the industries in which our tenants operate, and the regions in which our properties are located; § 8. short selling of our common stock or related derivative securities; and § 9. general market and economic conditions. Adverse changes in our credit ratings could impair our ability to obtain additional debt and equity financing on favorable terms. Our credit ratings affect the amount and type of capital, as well as the terms of any financing we may obtain. The credit ratings of our senior unsecured debt are based on, among other things, our operating performance, liquidity and leverage ratios, geographic and tenant concentration, and pending or future changes in the regulatory framework applicable to our operators and our industry. If we are unable to maintain our current credit ratings, we would likely incur higher borrowing costs, which would make it more difficult or expensive to obtain additional financing or refinance existing obligations and commitments. An adverse change in our outlook may ultimately lead to a downgrade in our credit ratings, which would trigger additional borrowing costs or other potentially negative consequences under our current credit facilities and debt instruments. Also, if our credit ratings are downgraded, or general market conditions were to ascribe higher risk to our ratings, our industry, or us, our access to capital and the cost of any future debt financing will be further negatively impacted. In addition, the terms of future debt agreements could include more restrictive covenants, or require incremental collateral, which may further restrict our business operations or be unavailable due to our covenant restrictions then in effect. There is no guarantee that debt or equity financings will be available in the future to fund future acquisitions, developments, or general operating expenses, or that such financing will be available on terms consistent with our historical agreements or expectations.

Table of Contents

Risks

Tenants, operators, and borrowers that fail to comply with federal, state, local, and international laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements, may cease to operate or be unable to meet their financial and other contractual obligations to us. Our tenants, operators, and borrowers across our segments are subject to or impacted by extensive, frequently changing federal, state, and local laws and regulations. See § 1. Business's Government Regulation, Licensing and Enforcement. Healthcare Licensure and Certificate of Need for a discussion of certain of these laws and regulations. Unannounced surveys, inspections, or audits occur frequently, including following a regulator's receipt of a complaint about a facility, and these surveys, inspections, and audits can result in deficiencies and further adverse action. Our tenants', operators', or borrowers' failure to comply with any of the laws, regulations, or requirements applicable to them could result in: (i) loss of accreditation; (ii) denial of reimbursement; (iii) imposition of fines and civil monetary penalties; (iv) suspension or decertification from government healthcare programs; (v) civil liability; and (vi) in certain instances, suspension, or denial of admissions, criminal penalties, loss of license, or closure of the property and/or the incurrence of considerable costs arising from an investigation or regulatory action, which may have an adverse effect on properties that we own and lease to a third party tenant in our outpatient medical and lab segments, that we own and operate through a RIDEA structure in our CCRC segment or our SWF SH JV, or on which we hold a mortgage, and therefore may materially adversely impact us. Furthermore, we are required under RIDEA to rely on our operators to oversee and direct these aspects of the properties' operations to ensure compliance with applicable laws and regulations. If one or more of our healthcare properties fails to comply with applicable laws and regulations, our TRS would be responsible (except in limited circumstances, such as the gross negligence or willful misconduct of our operators, where we would have a contractual claim against them), which could subject our TRS to penalties including loss or suspension of licenses, certification or accreditation, exclusion from government healthcare programs (i.e., Medicare, Medicaid), administrative sanctions, and civil monetary penalties. Some states also reserve the right to sanction affiliates of a licensee when they take administrative action against the licensee, and require a licensee to report all healthcare-related administrative actions that have been brought against any of the licensee's affiliates, even in other states. Additionally, when we receive individually identifiable health information relating to residents of our healthcare properties, we are subject to federal and state data privacy and security laws and rules, and could be subject to liability in the event of an audit, complaint, cybersecurity incident, or data breach. Furthermore, our TRS has exposure to professional liability claims that could arise out of resident claims, such as quality of care, and the associated litigation costs. Required regulatory approvals can delay or prohibit transfers of our senior housing properties. Transfers of senior housing properties, including in connection with the foreclosure of a real-estate secured loan, to successor owners or operators are typically subject to regulatory approvals or ratifications, including change of ownership approvals for licensure and Medicare / Medicaid (if applicable) that are not required for transfers of other types of commercial operations and other types of real estate. Federal and state authorities have become increasingly focused on the review and potential regulation of healthcare transactions for impacts on costs, access to care, and quality, which could involve lengthy review and approval periods, enhanced disclosure obligations, impact analysis, public notices, and hearings. Such regulation could adversely impact the time and cost of completing transactions and, in certain circumstances, affect the feasibility of pursuing or completing such transactions. The sale of, or replacement of any operator at, our senior housing facilities, or the foreclosure of a loan secured by senior housing real estate, could be delayed by the regulatory approval process of any federal, state, or local government agency necessary for the transfer of the property or the replacement of the operator licensed to manage the property, during which time the property may experience performance declines. We may also elect to use an interim licensing structure to facilitate such transfers, which structure expedites the transfer by allowing a third party to operate under our license until the required regulatory approvals are obtained, but could subject us to fines or penalties if the third party fails to comply with applicable laws and regulations and fails to indemnify us for such fines or penalties pursuant to the terms of its agreement with us. Compliance with the Americans with Disabilities Act and fire, safety, and other regulations may require us to make expenditures that adversely affect our cash flows. Our properties must comply with applicable ADA and any similar state and local laws. These laws may require removal of barriers to access by persons with disabilities in public areas of our properties. Noncompliance could result in the incurrence of additional costs associated with bringing the properties into compliance, the imposition of fines or an award of damages to private litigants in individual lawsuits or as part of a class action. We could also be required to expend funds to comply with the provisions of the ADA and similar state and local laws on behalf of tenants, which could adversely affect our results of operations and financial condition.

Table of Contents

In addition, we are required to operate our properties in compliance with fire and safety regulations, building codes and other land use regulations. New and revised regulations and codes may be adopted by governmental agencies and bodies and become applicable to our properties. For example, new safety laws for senior housing properties were adopted following the particularly damaging 2018 hurricane season. Compliance could require substantial capital expenditures, both for significant upgrades and for tenant relocations that may be necessary depending on the scope and duration of upgrades, and may restrict our ability to renovate our properties. These expenditures and restrictions could have a material adverse effect on our financial condition and cash flows. Laws or regulations prohibiting eviction of our tenants, even on a temporary basis, could have a material adverse effect on our revenues if our tenants fail to make their contractual rent payments to us. Various federal, state, and local governments previously enacted, and may again enact, laws, regulations, and moratoriums or take other actions that could limit our ability to evict tenants until such laws, regulations, or moratoriums are reversed or lifted. In particular, several state and local governments implemented eviction moratoriums as a result of the Covid pandemic that applied to both residential and commercial tenants. Although these moratoriums have generally terminated or expired, federal, state, and local governments could enact moratoriums under similar circumstances in the future. While we generally have arrangements and other agreements that give us the right under specified circumstances to terminate a lease or evict a tenant for nonpayment of contractual rent, such laws, regulations, and moratoriums may restrict our ability to begin eviction proceedings even where no rent or only partial rent is being paid. Further, under current laws and regulations, eviction proceedings for delinquent tenants are already costly and time-consuming, and, if there are existing backlogs or backlogs develop in courts due to higher than normal eviction proceedings, we may incur significant costs and it may take a significant amount of time to ultimately evict any tenant who is not meeting their contractual rent obligations. If we are restricted, delayed, or prohibited from evicting tenants for failing to make contractual rent payments, it may have a material adverse effect on our business, results of operations, and financial condition. The requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid may adversely affect our tenants', operators', and borrowers' ability to meet their financial and other contractual obligations to us. Certain of our tenants, operators, and borrowers, as well as our owned assets in the CCRC segment and SWF SH JV, are affected, directly or indirectly, by a complex set of federal, state, and local laws and regulations pertaining to governmental reimbursement programs. These laws and regulations are subject to frequent and substantial changes that are sometimes applied retroactively. See § 1. Business's Government Regulation, Licensing and Enforcement. For example, to the extent that our tenants, operators, or borrowers, or assets owned in our CCRC segment or through the SWF SH JV, receive a significant portion of their revenues from governmental payors, primarily Medicare and Medicaid, they are generally subject to, among other things: § 1. statutory and regulatory changes, including changes that impact state reimbursement programs, particularly Medicaid reimbursement and managed care payments; § 2. minimum staffing levels and other staffing and quality requirements; § 3. retroactive rate adjustments and recoupment efforts; § 4. recovery of program overpayments or set-offs; § 5. federal, state, and local litigation and enforcement actions, including those relating to Covid and the failure to satisfy the terms and conditions of financial relief; § 6. administrative proceedings; § 7. policy interpretations; § 8. payment or other delays by fiscal intermediaries or carriers; § 9. government funding restrictions (at a program level or with respect to specific properties); § 10. reduced reimbursement rates under managed care contracts; § 11. changes in reimbursement rates, methods, or timing under governmental reimbursement programs, including changes that impact state reimbursement programs, particularly Medicaid reimbursement and managed care payments; § 12. pre- and post-payment reviews and audits by governmental authorities, which could result in recoupments, denials or delay of payments; § 13. interruption or delays in payments due to any ongoing governmental investigations and audits at such properties or due to a partial or total federal or state government shutdown for a prolonged period of time; and § 14. Table of Contents reputational harm of publicly disclosed enforcement actions, audits, or investigations related to billing and reimbursements. We are unable to predict future changes to or interpretations of, or the intensity of enforcement efforts with respect to, these laws and regulations, including those that pertain to the Medicare and Medicaid programs. The failure to comply with the extensive laws, regulations, and other requirements applicable to their business and the operation of our properties could result in, among other challenges: (i) becoming ineligible to receive reimbursement from governmental reimbursement programs or being compelled to repay amounts received, including under the CARES Act; (ii) becoming subject to prepayment reviews or claims for overpayments; (iii) bans on admissions of new patients or residents; (iv) civil or criminal penalties; and (v) significant operational changes, including requirements to increase staffing or the scope of care given to residents. These laws and regulations are enforced by a variety of federal, state, and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or whistleblower actions. Any changes in the regulatory framework or the intensity or extent of governmental or private enforcement actions could have a material adverse effect on our tenants, operators, borrowers, and/or assets. The status of the Patient Protection and Affordable Care Act, along with the Health Care and Education Reconciliation Act of 2010 (collectively, the Affordable Care Act) and related regulations may be subject to change, and other health reform measures could be implemented as a result of political, legislative, regulatory, and

administrative developments and judicial proceedings, including those with far reaching implications and effecting fundamental changes in the healthcare system. Federal and state authorities may continue to implement new or modified reimbursement methodologies that may negatively impact health care property operations. There can be no assurance that adequate reimbursements will be available for services provided by our operators and tenants. Additionally, the patient driven payment model utilized by the Centers for Medicare and Medicaid Services to calculate reimbursement rates for patients in skilled nursing properties (which is among the unit types in our CCRCs) could result in decreases in payments to our operators and tenants or increase our operators' and tenants' costs. We cannot make any assessment as to the ultimate timing or the effect that any future changes may have on our tenants', operators', and borrowers' costs of doing business, or the cost of doing business for or the assets owned in our CCRC segment or through the SFW SH JV, and on the amount of reimbursement by government and other third-party payors. Any significant limits on the scope of services reimbursed, reductions in reimbursement rates and fees, or increases in provider or similar types of taxes, could materially adversely affect their ability to meet their financial and contractual obligations to us. We could be negatively impacted by legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services or other legislative or regulatory changes affecting REITs or the industries in which we operate. Congressional consideration of legislation pertaining to the federal debt ceiling, the Affordable Care Act, tax reform, and entitlement programs, including reimbursement rates for physicians, could have a material adverse effect on our tenants', operators', and borrowers' liquidity, financial condition, or results of operations. In particular, reduced funding for entitlement programs such as Medicare and Medicaid would result in increased costs and fees for programs such as Medicare Advantage Plans and additional reductions in reimbursements to providers. Amendments to the Affordable Care Act in whole or in part and decisions by the Centers for Medicare and Medicaid Services could impact the delivery of services and benefits under Medicare, Medicaid, or Medicare Advantage Plans and could affect our tenants and operators and the manner in which they are reimbursed by such programs. Any shutdown of the federal government that delays or disrupts payments or any other material adverse effect on payments to our tenants, operators, or borrowers could adversely affect their ability to satisfy their obligations to us and could have a material adverse effect on us. In addition, changes in federal, state, or local laws affecting the healthcare or life sciences industries, particularly that apply to REITs, or changes in the scope, interpretation, or enforcement of the related regulatory frameworks could adversely affect us or our tenants, operators, or borrowers. Our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs could subject us or our operators to disruptive government and financial audits, enforcement actions, and recovery activity. Under the CARES Act and subsequent Covid relief legislation, Congress allocated more than \$178 billion to eligible health care providers through the Public Health and Social Services Emergency Fund (the "Provider Relief Fund" or "PRRF"). The U.S. Department of Health and Human Services ("HHS") distributed PRRF awards through various general and targeted distributions. We and our senior housing operators (including operators of senior housing facilities that we have subsequently disposed of) received relief funds through several distributions. Table of Contents PRRF funds are intended to reimburse eligible providers for unreimbursed health care-related expenses and lost revenues attributable to Covid and must be used only to prevent, prepare for, or respond to Covid. PRRF funds received under certain targeted distributions are further limited to specific uses. Additionally, the PRRF program imposes certain distribution-specific eligibility criteria and requires recipients to comply with various terms and conditions. PRRF program terms and conditions include limitations and requirements governing use of PRRF funds, implementation of controls, retention of records, audit and reporting to governmental authorities, and other PRRF program requirements, the interpretation of which may change over time. Failure to comply with program requirements may result in payment recovery or other enforcement actions. We also may be subject to or incur costs related to PRRF compliance activities, as well as government oversight and enforcement, including post-payment recovery and recoupment and government investigations, audits, enforcement activity, and penalties. Our current and former operators may similarly be impacted. Differences in operators' PRRF policies and protocols may adversely impact availability of data and financial audits. Changes in federal, state, or local laws or regulations may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate. Changes in federal, state, or local laws or regulations, including changes limiting REIT investment in the healthcare sector, reducing healthcare-related tax benefits for REITs, or requiring additional approvals for healthcare entities to transact with REITs, could have a material adverse effect on our ability to participate in the ownership of or invest in healthcare providers and healthcare real estate. Legislation potentially impacting REIT ownership and investment in the healthcare sector has recently been introduced or is under discussion at the federal and state level. Such legislation or similar laws or regulations, if enacted, could have a material adverse impact on our business. Risks Relating to Integration and Property Management Internalization Following the Merger We may be unable to fully integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies of the Merger and benefits of property management internalization or do so within the anticipated time frame. We have benefited from, and expect to continue to benefit from, the synergies from our Merger with Physicians Realty Trust as a result of (i) the elimination of duplicative costs associated with supporting an additional public company platform, (ii) internalization of the property management function, and (iii) leveraging state-of-the-art technology and systems. However, we continue to devote significant management attention and resources to integrating the operations of the Company and Physicians Realty Trust and internalizing the property management function. Potential difficulties we may encounter in the ongoing integration process include the following: the inability to successfully combine the operations of the Company and Physicians Realty Trust, including the integration of employees, customer records and maintaining cybersecurity protections, in a manner that permits us to achieve the cost savings anticipated from the Merger, which would result in the anticipated benefits of the Merger not being realized in the time frame currently anticipated or at all; the inability to dispose of assets or operations that we desire to dispose of; the complexities associated with managing the combined businesses out of different locations and integrating personnel from the two companies; the failure to retain key employees of either of the two companies; potential disruptions and performance shortfalls due to the failure to successfully internalize the property management function; potential unknown liabilities and unforeseen increased expenses, delays, or regulatory conditions associated with the Merger; and performance shortfalls as a result of the diversion of management's attention caused by integrating the companies' operations. For all these reasons, it is possible that the integration and property management internalization process could result in the distraction of management, the disruption of our ongoing business, or inconsistencies in our operations, services, standards, controls, procedures, and policies, any of which could adversely affect our ability to maintain relationships with tenants, property managers, and employees or to achieve the anticipated synergies and other benefits of the Merger, or could otherwise adversely affect our business and financial results. Table of Contents Risks Related to Tax, Including REIT-Related Risks, and Related to Our Jurisdiction of Incorporation and Our Structure as an UPREIT Loss of our tax status as a REIT would substantially reduce our available funds and would have materially adverse consequences for us and the value of our common stock. Qualification as a REIT involves the application of numerous highly technical and complex provisions of the Internal Revenue Code of 1986, as amended (the "Code"), for which there are limited judicial and administrative interpretations, as well as the determination of various factual matters and circumstances not entirely within our control. We intend to continue to operate in a manner that enables us to qualify as a REIT. However, our qualification and taxation as a REIT depend upon our ability to meet the various qualification tests imposed under the Code, through actual annual operating results, asset diversification, distribution levels, and diversity of stock ownership. For example, to qualify as a REIT, at least 95% of our gross income in any year must be derived from qualifying sources, and we must make distributions to our stockholders aggregating annually to at least 90% of our REIT taxable income, excluding net capital gains. Rents we receive from a TRS in a RIDEA structure are treated as qualifying rents from real property for REIT tax purposes only if (i) they are paid pursuant to a lease of a qualified healthcare property and (ii) the operator qualifies as an eligible independent contractor, as each term is defined in the Code. If either of these requirements is not satisfied, then the rents we receive from the TRS will not be qualifying rents and we may not satisfy the REIT gross income requirements. Furthermore, new legislation, regulations, administrative interpretations, or court decisions could change the tax laws or interpretations of the tax laws regarding qualification as a REIT, or the federal income tax consequences of that qualification, in a manner that is materially adverse to our stockholders. Accordingly, we cannot assure you that we have operated or will continue to operate in a manner so as to qualify or remain qualified as a REIT. If we lose our REIT status, we will face serious tax consequences that will substantially reduce the funds available to make payments of principal and interest on the debt securities we issue and to make distributions to stockholders. If we fail to qualify as a REIT, we will not be allowed a deduction for distributions to stockholders in computing our taxable income; we will be subject to corporate-level income tax on our taxable income at regular corporate rates; we will be subject to increased state and local income taxes; and unless we are entitled to relief under relevant statutory provisions, we will be disqualified from taxation as a REIT for the four taxable years following the year during which we fail to qualify as a REIT. As a result of all these factors, our failure to qualify as a REIT could also impair our ability to expand our business and raise capital and could materially adversely affect the value of our common stock. Our taxable REIT subsidiaries (TRSs) may be subject to corporate level tax. Certain of our subsidiaries have elected or will elect with us to be treated as TRSs. Other than some activities relating to lodging and health care facilities, a TRS may generally engage in any business, including the provision of customary or non-customary services to tenants of its parent REIT that the parent REIT could not provide directly. TRSs are taxed as regular C corporations, and are thus generally required to pay regular corporate income tax, and potentially the alternative minimum tax, on their earnings. Any taxes paid by our TRSs will reduce the amounts that our TRSs could otherwise distribute to us. Furthermore, new legislation, regulations, administrative interpretations, or court decisions could change the tax laws or interpretations of the tax laws regarding our ability to continue to use one or more TRSs or other structures or arrangements in such a manner that could be materially adverse to us. The tax imposed on any net income from prohibited transactions may limit our ability to engage in transactions which would be treated as sales for federal income tax purposes. We will be required to pay a 100% tax on any net income from prohibited transactions. Prohibited transactions are, in general, sales or other taxable dispositions of property, other than foreclosure property, held as inventory or primarily for sale to customers in the ordinary course of business. A sale will not be considered a prohibited transaction, however, if it meets certain safe harbor requirements. Although we do not intend to hold any properties that would be characterized as held for sale to customers in the ordinary course of our business (other than through a TRS), such characterization is a factual determination and no guarantee can be given that the U.S. Internal Revenue Service (the "IRS") would agree with our characterization of our properties or that we will always be able to take advantage of available safe harbors. Table of Contents Further changes to U.S. federal income tax laws could materially and adversely affect us and our stockholders. The present federal income tax treatment of REITs and various transactional structures that we utilize may be modified, possibly with retroactive effect, by legislative, judicial, or administrative action at any time, which could affect the federal income tax treatment of an investment in us. The federal income tax rules dealing with U.S. federal income taxation and REITs are constantly under review by persons involved in the legislative process, the IRS, and the U.S. Treasury Department, which results in statutory changes as well as revisions to regulations and interpretations. We cannot predict how changes in the tax laws might affect our investors or us. Revisions in federal tax laws and interpretations thereof could significantly and negatively affect our ability to qualify as a REIT, as well as the tax considerations relevant to an investment in us, or could cause us to change our investments and commitments. Potential deferred and contingent tax liabilities from corporate acquisitions could limit or delay future property sales. If, during the five-year period beginning on the date we acquire certain assets or companies in certain tax deferred transactions, we recognize a gain on the disposition of any property acquired, then, to the extent of the excess of (i) the fair market value of such property as of the acquisition date, over (ii) our adjusted income tax basis in such property as of that date, we will be required to pay a corporate-level federal income tax on this gain at the highest regular corporate rate. These potential tax effects could limit or delay future property sales. In addition, the IRS may assert liabilities against us for income taxes of certain entities we acquire for taxable years prior to the time that we acquire such entities, in which case we will owe these taxes plus interest and penalties, if any. There are uncertainties relating to the calculation of non-REIT tax earnings and profits ("E&P") in certain acquisitions, which may require us to distribute E&P. In order to remain qualified as a REIT, we are required to distribute to our stockholders all of the accumulated non-REIT E&P of certain C corporations that we acquire, prior to the close of the first taxable year in which the acquisition occurs. Failure to make such E&P distributions could result in our disqualification as a REIT. The determination of the amount to be distributed in such E&P distributions is a complex factual and legal determination. We may have less than complete information at the time we undertake our analysis, or we may interpret the applicable law differently from the IRS. We currently believe that we have satisfied the requirements relating to such E&P distributions. There are, however, substantial uncertainties relating to the determination of E&P, including the possibility that the IRS could successfully assert that the taxable income of the companies acquired should be increased, which could increase our non-REIT E&P. Thus, we might fail to satisfy the requirement that we distribute all of our non-REIT E&P by the close of the first taxable year in which the acquisition occurs. Although there are procedures available to cure a failure to distribute all of our E&P, we cannot now determine whether we will be able to take advantage of these procedures or the economic impact on us of doing so. Tax protection agreements may limit our ability to sell or otherwise dispose of certain properties and may require us to maintain certain debt levels that otherwise would not be required to operate our business. We acquired in the past and in the future may acquire properties or portfolios of properties through tax deferred contribution transactions in exchange for units in our DownREITs or Healthpeak OP. In connection with these transactions, our DownREITs have entered and, with Healthpeak OP, may in the future enter into tax protection agreements that enable contributing partners to defer the recognition of taxable gain resulting from the sale or other disposition of the contributed properties. Tax protection agreements may make it economically prohibitive to sell any properties that are subject to such agreements even though it may otherwise be in our stockholders' best interests to do so. In addition, under these agreements, we may be required to maintain a minimum level of indebtedness throughout the term of the agreements regardless of whether such debt levels are otherwise required to operate our business. Physicians Realty Trust and the Physicians Partnership has also entered into similar tax protection arrangements with certain third parties and, as a result of the Merger, we inherited the obligations under such arrangements. Our charter contains ownership limits with respect to our common stock and other classes of capital stock. Our charter contains restrictions on the ownership and transfer of our common stock and preferred stock that are intended to assist us in preserving our qualification as a REIT. Under our charter, subject to certain exceptions, no person or entity may own, actually or constructively, more than 9.8% (by value or by number of shares, whichever is more restrictive) of the outstanding shares of our common stock or any class or series of our preferred stock. Additionally, our charter has a 9.9% ownership limitation on the direct or indirect ownership of our voting shares, which may include common stock or other classes of capital stock. Our Board of Directors, in its sole discretion, may exempt a proposed transferee from either ownership limit. The ownership limits may delay, defer or prevent a transaction or a change of control that might involve a premium price for our common stock or might otherwise be in the best interests of our stockholders. Table of Contents We are subject to certain provisions of Maryland law and our charter relating to business combinations that may prevent a transaction that may otherwise be in the interest of our stockholders. We are subject to the Maryland Business Combination Act (the "MBCA"), which provides that unless exempted, a Maryland corporation may not engage in certain business combinations with an "interested stockholder" or an affiliate of an interested stockholder for five years after the most recent date on which the interested stockholder became an interested stockholder, and thereafter unless specified criteria are met. In addition to the restrictions on business combinations contained in the MBCA, our charter also requires that, except in certain circumstances, "business combinations" with a "related person" must be approved by the affirmative vote of the holders of at least 90% of our outstanding voting stock. These restrictions on business combinations may delay, defer, or prevent a change of control or other transaction even if such transaction involves a premium price for our common stock or our stockholders believe that such transaction is otherwise in their best interests. Conflicts of interest may exist or could arise in the future between the interests of our stockholders and the interests of holders of Healthpeak OP common units, which may impede business decisions that could benefit our stockholders. Conflicts of interest may exist or could arise in the future as a result of the relationships between us and our affiliates, on the one hand, and Healthpeak OP or any member thereof, on the other. Our directors and officers have duties to our company under Maryland law in connection with their management of our company. At the same time, we, as the managing member of Healthpeak OP, have certain fiduciary duties and obligations to Healthpeak OP and its members under Maryland law and the operating agreement of Healthpeak OP in connection with the management of Healthpeak OP. Our fiduciary duties and obligations as the managing member of Healthpeak OP may come into conflict with the duties of our directors and officers to our company. Under Maryland law, a managing member of a Maryland limited liability company has fiduciary duties of loyalty and care to the limited liability company and its members and must discharge its duties and exercise its rights as managing member under the operating agreement or Maryland law consistent with the obligation of good faith and fair dealing. The operating agreement provides that, to the maximum extent permitted under the Maryland Limited Liability Company Act, the only duties that the managing member owes to Healthpeak OP, any member, or any other person, fiduciary or otherwise, are to perform its contractual obligations as expressly set forth in the operating agreement

[illegible]

holders. On February 3, 2025, our Board of Directors declared a quarterly common stock cash dividend of \$0.305 per share, reflecting an increase from \$0.30 to \$0.305 per share. The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025. Table of Contents Issuer Purchases of Equity Securities The following table sets forth information with respect to purchases of our common stock made by or on our behalf during the three months ended December 31, 2024. Period Covered Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) October 1-31, 2024 \$500,000.000A November 1-30, 2024 \$500,000.000A December 1-31, 2024 \$500,000.000A (1) On July 24, 2024, our Board of Directors approved the 2024 Share Repurchase Program under which we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of \$500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. As of December 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program. Therefore, at December 31, 2024, \$500A million of the Company's common stock remained available for repurchase under the 2024 Share Repurchase Program. 44 Table of Contents Performance Graph The graph and table below compare the cumulative total return of Healthpeak, the S&P 500 Index, and the Equity REIT Index of Nareit, from January 1, 2020 to December 31, 2024. Total cumulative return is based on a \$100 investment in Healthpeak common stock and in each of the indices at the close of trading on December 31, 2019 and assumes quarterly reinvestment of dividends before consideration of income taxes. Stockholder returns over the indicated periods should not be considered indicative of future stock prices or stockholder returns. COMPARISON OF FIVE-YEAR CUMULATIVE TOTAL RETURN AMONG S&P 500, EQUITY REITS AND HEALTHPEAK PROPERTIES, INC. RATE OF RETURN TREND COMPARISON JANUARY 1, 2020 = DECEMBER 31, 2024 (JANUARY 1, 2020 = \$100) Performance Graph Total Stockholder Return December 31, 2020 2021 2022 2023 2024 FTSE Nareit Equity REIT Index 94.88A \$134.06A \$100.62A \$112.04A \$117.56A S&P 500 118.39A 152.34A 124.73A 157.48A 196.85A Healthpeak Properties, Inc. 92.33A 114.25A 82.83A 69.24A 75.37A 45 Table of Contents ITEM 6 A A A A A Management's Discussion and Analysis of Financial Condition and Results of Operations The information set forth in this Item 7 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations. This section generally discusses the results of our operations for the year ended December 31, 2024 compared to the year ended December 31, 2023. For a discussion of the year ended December 31, 2023 compared to the year ended December 31, 2022, please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 9, 2024. The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in Item 1A, Risk Factors. See also Cautionary Language Regarding Forward-Looking Statements preceding Part I. The following discussion and analysis should be read in conjunction with our accompanying, consolidated financial statements and the notes thereto. We will discuss and provide our analysis in the following order: Market Trends and Uncertainties Company Highlights Dividends Results of Operations Liquidity and Capital Resources Non-GAAP Financial Measures Reconciliations Critical Accounting Estimates Recent Accounting Pronouncements Market Trends and Uncertainties Our operating results have been and will continue to be impacted by global and national economic and market conditions generally and by the local economic conditions where our properties are located. Increased interest rates, ongoing geopolitical tensions, and volatility in public and private equity and fixed income markets have led to increased costs and limitations on the availability of capital. In addition, increased interest rates have and could continue to adversely impact our borrowing costs, the fair value of our fixed rate instruments, transaction volume, and real estate values generally, including our real estate. To the extent our tenants and/or operators have also experienced increased costs, liquidity constraints, and financing difficulties due to the foregoing macroeconomic and market conditions, they may be unable or unwilling to make payments or perform their obligations when due. We have also been affected by increased costs relating to tenant improvements and construction, which, together with higher costs of capital, have adversely affected, and in the future may adversely affect, the expected yields on our development and redevelopment projects. While there have been signs that cost pressures are moderating, there can be no assurance that this will continue to be the case. We continuously monitor the effects of domestic and global events on our operations and financial position, and on the operations and financial position of our tenants, operators, and borrowers, to enable us to remain responsive and adaptable to the dynamic changes in our operating environment. These events include but are not limited to inflation; interest rates; challenges in the financial markets; and changes in the U.S. political administration, which could affect healthcare policy, labor supply, procurement and construction costs, and economic conditions, among other things. See Item 1A, Risk Factors in this report for additional discussion of the risks posed by macroeconomic conditions, as well as the uncertainties we and our tenants, operators, and borrowers may face as a result. 46 Table of Contents Company Highlights On March 1, 2024, we completed the Merger with Physicians Realty Trust, which resulted in the acquisition of 299 outpatient medical buildings. Real Estate Transactions In January 2024, we sold a 65% interest in two lab buildings in San Diego, California (the Callan Ridge JV) to a third-party for net proceeds of \$128 million. In April 2024, we exercised our option to buy out four redeemable noncontrolling interests, made aggregate cash payments for the total redemption value of \$53A million to the related noncontrolling interest holders, and acquired the redeemable noncontrolling interests associated with these entities. During the year ended December 31, 2024, we sold: (i) a portfolio of 61 outpatient medical buildings for \$697A million and provided the buyer with a mortgage loan secured by the real estate sold for \$419A million, (ii) 14 outpatient medical buildings for \$220A million, (iii) a portfolio of seven lab buildings for \$180A million, and (iv) a portfolio comprised of a land parcel and various vacant buildings on certain of our CCRC campuses for \$12 million. Development and Redevelopment Activities During the year ended December 31, 2024, the following projects were placed in service: (i) a portion of two lab development projects with total project costs of \$83 million, (ii) two outpatient medical development projects with total project costs of \$62 million, (iii) one outpatient medical development project held in a consolidated joint venture of which our share of total project costs was \$22 million, (iv) one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was \$15 million, (v) one lab redevelopment project with total project costs of \$14 million, (vi) a portion of one lab redevelopment project with total project costs of \$13 million, and (vii) a portion of one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was \$9 million. Financing Activities In March 2024, we executed a \$750A million five year unsecured term loan (the 2029 Term Loan) as an incremental facility under the term loan agreement. In January 2024, we entered into forward-starting interest rate swap instruments on the 2029 Term Loan which are designated as cash flow hedges and establish a blended fixed effective interest rate of 4.66%. During the year ended December 31, 2024, we repurchased 10.5A million shares of our common stock under our 2022 Share Repurchase Program (as defined below) at a weighted average price of \$17.98 per share for a total of \$188A million. In February 2025, we repaid \$348A million aggregate principal amount of 3.40% senior unsecured notes at maturity. Other Activities During the year ended December 31, 2024, we refinanced one of our existing seller financing loans receivable, extended the maturity date to August 2027, and received aggregate partial principal repayments of \$74 million. During the year ended December 31, 2024, we executed an early lease renewal for approximately 2A million square feet leased by CommonSpirit Health, which is subject to a master agreement, which extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%. In January 2025, we received full repayment of: (i) the \$48A million outstanding balance of one of our seller financing loans receivable and (ii) the \$15A million outstanding balance of one secured loan with an original maturity of July 2027. Dividends Quarterly common stock cash dividends paid during 2024 aggregated to \$1.20 per share. On February 3, 2025, our Board of Directors declared a quarterly common stock cash dividend of \$0.305 per share, reflecting an increase from \$0.30 to \$0.305 per share. The dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025. 47 Table of Contents Results of Operations We evaluate our business and allocate resources among our operating segments: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in our unconsolidated SWF SH JV, and (v) loans receivable. Our operating segments are aggregated into the following reportable segments: (i) outpatient medical, (ii) lab, and (iii) CCRC. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Our CCRCs are operated through RIDEA structures. The SWF SH JV and loans receivable are non-reportable segments that have been presented on a combined basis herein. We evaluate performance based upon property adjusted net operating income (Adjusted NOI) or Cash NOI in each segment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 to the Consolidated Financial Statements. Non-GAAP Financial Measures Adjusted NOI Adjusted NOI is a non-U.S. generally accepted accounting principles (GAAP) supplemental financial measure used to evaluate the operating performance of real estate. Adjusted NOI represents real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 16 to the Consolidated Financial Statements. Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus our share of Adjusted NOI from unconsolidated joint ventures (calculated by applying our actual ownership percentage for the period), less noncontrolling interests' share of Adjusted NOI from consolidated joint ventures (calculated by applying our actual ownership percentage for the period). We utilize our share of Adjusted NOI in assessing our performance as we have various joint ventures that contribute to our performance. Our share of Adjusted NOI should not be considered a substitute for, and should only be considered together with and as a supplement to, our financial information presented in accordance with GAAP. Adjusted NOI is oftentimes referred to as Cash NOI. Management believes Adjusted NOI is an important supplemental measure because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presents them on an unlevered basis. We use Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Merger-Combined Same-Store (Merger-Combined SS) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to Adjusted NOI. Adjusted NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, our definition of Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating Adjusted NOI. As described in Note 16 to the Consolidated Financial Statements, our chief operating decision maker (CODM) evaluates the performance of our operating segments based on Adjusted NOI. Our operating segments are aggregated into reportable segments for which we disclose Total Portfolio Adjusted NOI for our reportable segments. For further information, including information reconciling our Adjusted NOI for reportable segments to our income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures, refer to Note 16 to the Consolidated Financial Statements. Operating expenses generally relate to leased outpatient medical and lab buildings, as well as CCRC facilities. We generally recover all or a portion of our leased outpatient medical and lab property expenses through tenant recoveries, which are recognized within rental and related revenues. Merger-Combined Same-Store Adjusted NOI Merger-Combined Same-Store Adjusted NOI includes legacy Physicians Realty Trust properties that met the same-store criteria as if they were owned by the Company for the full analysis period. This information allows our investors, analysts, and us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Adjusted NOI (see Adjusted NOI definition above for further discussion regarding our use of pro-rata share information and its limitations). Merger-Combined Same-Store Adjusted NOI excludes government grant income under the CARES Act, amortization of deferred revenue from tenant-funded improvements, and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. 48 Table of Contents Properties are included in Merger-Combined Same-Store once they are fully operating for the entirety of the comparative periods presented. A property is removed from Merger-Combined Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, or a significant tenant relocates from a Merger-Combined Same-Store property to a Merger-Combined non Same-Store property and that change results in a corresponding increase in revenue. We do not report Merger-Combined Same-Store metrics for our other non-reportable segments. Management believes that continued reporting of the same-store portfolio for only pre-merger Healthpeak Properties, Inc. offers minimal value to investors who are seeking to understand the operating performance and growth potential of the Combined Company. The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust (which financial statements have been audited or, in the case of interim periods, reviewed) and other detailed information about each property, such as the acquisition date. Based on this available information, the Company was able to consistently apply its same-store definition across the combined portfolio. As a result of the Merger, approximately 97% of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment for the year ended December 31, 2024. For a reconciliation of Merger-Combined Same-Store to total portfolio Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below. Nareit FFO. Funds from Operations (FFO), as defined by the National Association of Real Estate Investment Trusts (Nareit), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share

Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction and merger-related items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (â€œFFO as Adjustedâ€). These adjustments are net of tax, when applicable, and are reflective of our share of our joint 49Table of Contentsventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See â€œNareit FFOâ€ above for further disclosures regarding our use of pro rata share information and its limitations. Transaction and merger-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that â€œmanagement of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.â€ We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to FFO as Adjusted and other relevant disclosure, refer to â€œNon-GAAP Financial Measures Reconciliationsâ€ below. Adjusted FFO (â€œAFFOâ€). AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) stock-based compensation amortization expense, (ii) amortization of deferred financing costs and debt discounts (premiums), (iii) straight-line rents, (iv) deferred income taxes, (v) amortization of above (below) market lease intangibles, net, (vi) non-refundable entrance fees collected in excess of (less than) the related amortization, and (vii) other AFFO adjustments, which include: (a) lease incentive amortization (reduction of straight-line rents), (b) actuarial reserves for insurance claims that have been incurred but not reported, and (c) amortization of deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, AFFO is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements (â€œAFFO capital expendituresâ€). All adjustments are reflective of our pro rata share of both our consolidated and unconsolidated joint ventures (reported in â€œother AFFO adjustmentsâ€). We reflect our share of AFFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our AFFO to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See â€œNareit FFOâ€ above for further disclosures regarding our use of pro rata share information and its limitations. We believe AFFO is an alternative run-rate performance measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. AFFO does not represent cash generated from operating activities determined in accordance with GAAP and is not indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, and (iv) restructuring and severance-related charges. Furthermore, AFFO is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. Other REITs or real estate companies may use different methodologies for calculating AFFO, and accordingly, our AFFO may not be comparable to those reported by other REITs. Management believes AFFO provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT, and by presenting AFFO, we are assisting these parties in their evaluation. AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP and should only be considered together with and as a supplement to our financial information prepared in accordance with GAAP. For a reconciliation of net income (loss) to AFFO and other relevant disclosures, refer to â€œNon-GAAP Financial Measures Reconciliationsâ€ below. 50Table of ContentsComparison of the Year Ended December 31, 2024 to the Year Ended December 31, 2023 OverviewThe following table summarizes results for the years ended December 31, 2024 and 2023(1) (in thousands):Year Ended December 31, 20242023ChangeNet income (loss) applicable to common shares\$242,384\$ 304,284\$ (61,900)Nareit FFO1,092,730\$ 985,180\$ 107,550AFFO as Adjusted1,231,868\$ 978,306\$ 253,562AFFO1,140,665\$ 884,230\$ 256,435

(1)For the reconciliation of non-GAAP financial measures, see â€œNon-GAAP Financial Measures Reconciliationsâ€ below. Net income (loss) applicable to common shares decreased primarily as a result of the following: â€œcan increase in depreciation, primarily as a result of: (i) assets acquired as part of the Merger and (ii) development and redevelopment projects placed in service during 2023 and 2024; â€œcan increase in transaction and merger-related costs, primarily as a result of costs incurred in connection with the Merger; â€œcan increase in interest expense, primarily as a result of: (i) debt assumed as part of the Merger, including \$1.25 billion aggregate principal amount of senior unsecured notes, \$400 million aggregate principal amount of senior unsecured term loans assumed as part of the Merger (the â€œ2028 Term Loanâ€), and \$128 million aggregate principal amount of mortgage debt and (ii) borrowings under the 2029 Term Loan, which closed in March 2024; â€œcan increase in impairments and loan loss reserves (recoveries), net, primarily as a result of: (i) impairment charges associated with an asset impaired under the held for sale model and (ii) an increase in loan loss reserves recognized on secured loans and mezzanine loans receivable acquired as part of the Merger; â€œcan increase in casualty-related losses from Hurricane Milton during the fourth quarter of 2024; and â€œcan increase in income tax expense primarily as a result of an income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024. The decrease in net income (loss) applicable to common shares was partially offset by: â€œcan increase in Adjusted NOI generated from our lab and outpatient medical segments related to: (i) assets acquired as part of the Merger, (ii) development and redevelopment projects placed in service during 2023 and 2024, and (iii) new leasing activity during 2023 and 2024 (including the impact to straight-line rents); â€œcan increase in gain on sales of depreciable real estate sales during 2024 as compared to 2023; â€œcan gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024; and â€œcan increase in interest income related to mezzanine and secured loans receivable acquired as part of the Merger and seller financing provided in connection with the disposition of 61 outpatient medical buildings in 2024. Nareit FFO increased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO: â€œdepreciation and amortization expense; â€œgain on sales of depreciable real estate; â€œgain upon change of control; â€œimpairments of depreciable real estate; and â€œtaxes associated with real estate dispositions. 51Table of ContentsAFFO as Adjusted increased primarily as a result of the aforementioned events impacting Nareit FFO, except the following, which are excluded from FFO as Adjusted: â€œtransaction and merger-related items; â€œcasualty-related losses; and â€œloan loss reserves (recoveries). AFFO increased primarily as a result of higher cash collections of non-refundable entrance fees at our CCRCs, and the aforementioned events impacting FFO as Adjusted, except for the impact of straight-line rents and amortization of deferred financing costs, deferred income taxes, and debt discounts (premiums) on amounts recognized in connection with the Merger, which are excluded from AFFO, partially offset by higher AFFO capital expenditures during the period. Segment AnalysisThe following tables provide selected operating information for our Merger-Combined Same-Store and total property portfolio for each of our reportable segments. For the year ended December 31, 2024, our Merger-Combined Same-Store consists of 625 properties representing properties fully operating on or prior to January 1, 2023 and that remained in operation through December 31, 2024. Legacy Physicians Realty Trust properties that met the definition of Merger-Combined Same-Store are included in both periods presented as if they were owned by the Company for the full analysis period. See â€œNon-GAAP Financial Measuresâ€ above for additional information. Our total property portfolio consisted of 697 and 477 properties at December 31, 2024 and 2023, respectively. 52Table of ContentsOutpatient MedicalThe following table summarizes results at and for the years ended December 31, 2024 and 2023 (dollars and square feet in thousands, except per square foot data):Merger-Combined SS(1)Total Portfolio(2)Year Ended December 31,Year Ended December 31,20242023Change20242023ChangeRental and related revenues\$1,197,264\$1,138,437\$58,827\$1,205,748\$753,479\$452,265\$1Healthpeakâ€™s share of unconsolidated joint venture total revenues26,092\$24,012,014,0413,033\$1,008\$1Noncontrolling interestsâ€™ share of consolidated joint venture total revenues(36,083)\$(35,365)\$(718)\$(37,643)\$(35,073)\$(2,570)Operating expenses(395,079)\$(382,748)\$(12,331)\$(405,993)\$(263,132)\$(142,861)Healthpeakâ€™s share of unconsolidated joint venture operating expenses(10,007)\$(8,986)\$(1,021)\$(9,034)\$(1,189)\$(7,845)Noncontrolling interestsâ€™ share of consolidated joint venture operating expenses(10,071)10,149(78)10,582,921661\$1 Adjustments to NOI(3)\$(37,396)\$(14,468)\$(22,928)\$(38,967)\$(14,314) (24,653)Adjusted NOI\$754,862\$731,110\$23,752\$748,730\$52,725\$296,005\$1Pre-Merger legacy Physicians Realty Trust Adjusted NOI(4)\$61,398\$309,000\$247,602\$Less: Merger-Combined Non-SS Adjusted NOI(5)\$266(30,615)\$(24,651)Merger-Combined SS Adjusted NOI\$754,862\$731,110\$23,752\$Adjusted NOI 1% change3.2A %Property count(5)506\$506\$524\$297\$A End of period occupancy(6)92.3A %92.4A %92.2A %90.7A %Average occupancy(6)92.3A %92.2A %90.1A %Average occupied square feet33,407\$33,320\$35,726\$21,531\$A Average annual total revenues per occupied square foot(7)\$36\$35\$36\$35\$A Average annual base rent per occupied square foot(8)\$28\$27\$29\$29\$A (1)Merger-Combined Same-Store includes legacy Physicians Realty Trust properties that met the definition of Merger-Combined Same-Store as if they were owned by the Company for the full analysis period. Refer to â€œNon-GAAP Financial Measuresâ€ above for the definition of Merger-Combined Same-Store. (2)Total Portfolio includes results of operations from disposed properties through the disposition date. 2024 Total Portfolio includes results of operations for legacy Healthpeak prior to the Closing Date and results of operations for the Combined Company after the Closing Date. (3)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 16 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to â€œNon-GAAP Financial Measuresâ€ above for the definition of Adjusted NOI. (4)Represents Adjusted NOI for legacy Physicians Realty Trust properties prior to the Closing Date. (5)From our 2023 presentation of Same-Store, we added: (i) 290 properties acquired as part of the Merger, (ii) 8 stabilized developments placed in service, (iii) 5 stabilized redevelopments placed in service, and (iv) 4 stabilized acquisitions, and we removed: (i) 72 assets that were sold and (ii) 1 asset that was classified as held for sale. (6)Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale. (7)Average annual total revenues does not include non-cash revenue adjustments (i.e., A straight-line rents, amortization of market lease intangibles, and deferred revenues). (8)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., A straight-line rents, amortization of market lease intangibles, and deferred revenues). Merger-Combined Same-Store Adjusted NOI increased primarily as a result of the following: â€œmark-to-market lease renewals; â€œhigher average occupancy; and â€œannual rent escalations; partially offset by â€œhigher operating expenses, net of savings from our internalization of property management. Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Merger-Combined Same-Store and the following Merger-Combined Non-Same-Store impacts: â€œAdjusted NOI from the outpatient medical buildings acquired as part of the Merger in 2024; â€œincreased occupancy in former redevelopment and development properties that have been placed into service; partially offset by â€œbusiness interruption proceeds received in 2023 related to a demolished asset; and â€œdecreased Adjusted NOI from our 2023 and 2024 dispositions. 53Table of ContentsLabThe following table summarizes results at and for the years ended December 31, 2024 and 2023 (dollars and square feet in thousands, except per square foot data):Merger-Combined SSTotal Portfolio(1)Year Ended December 31,Year Ended December 31,20242023Change20242023ChangeRental and related revenues\$671,796\$644,775\$27,021\$881,452\$878,326\$3,126\$1Healthpeakâ€™s share of unconsolidated joint venture total revenues\$3,229\$3,347(118)19\$7339,924\$809\$1Noncontrolling interestsâ€™ share of consolidated joint venture total revenues\$â€“(â€“(196)619)423\$1 Operating expenses(184,839)\$(176,142)\$(8,697)\$(239,620)\$(229,630)\$(9,990)Healthpeakâ€™s share of unconsolidated joint venture operating expenses(1,800)\$(1,878)78(6,366)\$(4,092)\$(2,274)Noncontrolling interestsâ€™ share of consolidated joint venture operating expenses\$â€“(â€“(52156)104)Adjustments to NOI(2)\$(31,101)\$(34,665)3,564(64,449)\$(36,524)\$(27,925)Adjusted NOI\$457,285\$435,437\$21,848\$Adjusted NOI 1% change5.0A %Property count(3)104\$104\$139\$146\$A End of period occupancy(4)97.6A %97.4A %96.9A %Average occupancy(4)97.7A %98.2A %96.0A %97.8A %Average occupied square feet7,194\$7,759\$9,665\$10,524\$A Average annual total revenues per occupied square foot(5)\$84\$79\$87\$81\$A Average annual base rent per occupied square foot(6)\$61\$59\$66\$63\$A (1)Total Portfolio includes results of operations from disposed properties through the disposition date. (2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 16 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to â€œNon-GAAP Financial Measuresâ€ above for the definition of Adjusted NOI. (3)From our 2023 presentation of Same-Store, we added: (i) 6 stabilized developments placed in service, (ii) 2 stabilized redevelopments placed in service, and (iii) 2 buildings that previously experienced a significant tenant relocation, and we removed: (i) 15 buildings that were placed into redevelopment and (ii) 7 assets that were sold. (4)Refer to â€œNon-GAAP Financial Measuresâ€ above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale. (5)Average annual total revenues does not include non-cash revenue adjustments (i.e., A straight-line rents, amortization of market lease intangibles, and deferred revenues). (6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues). Merger-Combined Same-Store Adjusted NOI increased primarily as a result of the following: â€œannual rent escalations; partially offset by â€œhigher operating expenses, net of savings from our internalization of property management; and â€œlower average occupancy. Total Portfolio Adjusted NOI decreased primarily as a result of the aforementioned impacts to Merger-Combined Same-Store and the following Merger-Combined Non-Same-Store impacts: â€œdecreased Adjusted NOI from our 2023 and 2024 dispositions; and â€œdecreased Adjusted NOI from buildings placed into development and redevelopment in 2023 and 2024. 54Table of ContentsContinuing Care Retirement CommunityThe following table summarizes results at and for the years ended December 31, 2024 and 2023 (dollars in thousands, except per unit data):Merger-Combined SSTotal PortfolioYear Ended December 31,Year Ended December 31,20242023Change20242023ChangeResident fees and services\$567,261\$562,769\$40,492\$568,475\$527,411\$41,058\$A Government grant income(1)\$â€“(â€“(184)184)Operating expenses(426,922)\$(411,539)\$(15,383)\$(429,248)\$(413,472) (15,776)Adjusted NOI to NOI(2)\$(3,122)\$(1,618)\$(1,504)\$(3,123)\$(1,618)1,505)Adjusted NOI\$137,217\$113,612\$23,605\$136,104\$112,511\$23,593\$15 (less): Merger-Combined Non-SS adjustments1,131,101\$12,168\$Merger-Combined SS Adjusted NOI\$137,217\$113,612\$23,605\$Adjusted NOI 1% change20.8A %Property count(3)15\$15\$15\$15\$A Average occupancy(4)85.4A %83.8A %85.4A %83.9A %Average occupied units(5)6,029\$5,962\$5,960\$A Average annual rent per occupied

units\$94,089Ä \$88,503Ä \$94,103Ä \$88,524Ä (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations.(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 16 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to Non-GAAP Financial Measures above for the definition of Adjusted NOI.(3)From our 2023 presentation of Same-Store, no properties were added or removed.(4)Refer to Non-GAAP Financial Measures above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.(5)Represents average occupied units as reported by the operators for the twelve-month period.Merger-Combined Same-Store Adjusted NOI and Total Portfolio Adjusted NOI increased primarily as a result of the following:Increased rates for resident fees; andhigher occupancy; partially offset byhigher costs of compensation and property management, food, and other operating expenses.55Table of ContentsOther Income and Expense ItemsThe following table summarizes the results of our other income and expense items for the years ended December 31, 2024 and 2023 (in thousands):Year Ended December 31,20242023ChangeInterest income and other\$44,778Ä \$21,781Ä \$22,997Ä Interest expense280,430Ä 200,331Ä 80,099Ä Depreciation and amortization1,057,205Ä 749,904Ä 307,304Ä General and administrative97,162Ä 95,132Ä 2,030Ä Transaction and merger-related costs132,685Ä 17,515Ä 115,170Ä Impairments and loan loss reserves (recoveries), net22,978Ä (5,601)Ä 28,579Ä Gain (loss) on sales of real estate, net178,695Ä 86,463Ä 92,232Ä Other income (expense), net59,345Ä 6,808Ä 52,537Ä Income tax benefit (expense)(4,350)9,617Ä (13,967)Equity income (loss) from unconsolidated joint ventures(1,515)10,204Ä (11,719)Noncontrolling interests share in continuing operations(24,161)(28,748)4,587Ä Interest income and otherInterest income and other increased for the year endedÄ DecemberÄ 31, 2024Ä primarily as a result of: (i) mezzanine and secured loans receivable acquired as part of the Merger and (ii) seller financing provided in connection with the disposition of 61 outpatient medical buildings during 2024, partially offset by principal repayments on loans receivable in 2023 and 2024.Interest expenseInterest expense increased for the year ended December 31, 2024 primarily as a result of: (i) debt assumed as part of the Merger, including \$1.25 billion aggregate principal amount of senior unsecured notes, \$400 million aggregate principal amount of the 2028 Term Loan, and \$128 million aggregate principal amount of mortgage debt, (ii) borrowings under the 2029 Term Loan, which closed in March 2024, and (iii) senior unsecured notes issued in January and May 2023, partially offset by lower borrowings on the commercial paper program.Depreciation and amortizationDepreciation and amortization expense increased for the year ended December 31, 2024 primarily as a result of: (i) assets acquired as part of the Merger and (ii) development and redevelopment projects placed in service during 2023 and 2024, partially offset by: (i) assets placed into development and redevelopment in 2023 and 2024 and (ii) dispositions of real estate in 2023 and 2024.General and administrativeGeneral and administrative expenses increased for the year ended December 31, 2024 primarily as a result of increased compensation, travel, information technology, and other costs incurred as a result of a higher headcount, partially offset by merger-related synergies and lower corporate office rent expense.Transaction and merger-related costsTransaction and merger-related costs increased for the year ended December 31, 2024 primarily as a result of advisory, legal, accounting, tax, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust that were incurred in connection with the Merger, partially offset by: (i) merger-related costs incurred during the year ended December 31, 2023 and (ii) expenses incurred in connection with our reorganization to an UPREIT structure in 2023.Impairments and loan loss reserves (recoveries), netImpairments and loan loss reserves (recoveries), net increased for the year ended December 31, 2024 primarily as a result of: (i) impairment charges associated with an asset impaired under the held for sale model and (ii) an increase in loan loss reserves under the current expected credit losses model, which is primarily due to reserves recognized on secured loans and mezzanine loans receivable acquired as part of the Merger.56Table of ContentsGain (loss) on sales of real estate, netGain on sales of real estate, net increased during the year ended December 31, 2024 primarily as a result of the \$179Ä million gain on sales from: (i) a portfolio of 61 outpatient medical buildings sold for proceeds of \$697Ä million, (ii) 14 outpatient medical buildings sold for proceeds of \$220Ä million, (iii) a portfolio of seven lab buildings sold for proceeds of \$180Ä million, and (vi) a portfolio comprised of a land parcel and various vacant buildings on certain of the CompanyÄs CCRC campuses sold for proceeds of \$12 million, which were sold during the year ended December 31, 2024, as compared to the \$81Ä million gain on sales from: (i) two lab buildings in Durham, North Carolina sold for proceeds of \$113Ä million and (ii) two outpatient medical buildings sold for proceeds of \$32Ä million, which were sold during the year ended December 31, 2023. Refer to Note 5 to the Consolidated Financial Statements for additional information regarding dispositions of real estate and the associated gain (loss) on sales recognized.Other income (expense), netOther income increased for the year ended December 31, 2024 primarily due to a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024, partially offset by casualty-related losses from Hurricane Milton during the fourth quarter of 2024.Income tax benefit (expense)Income tax expense increased for the year ended December 31, 2024 primarily as a result of: (i) income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024 and (ii) an increase in operating income associated with our CCRCs, partially offset by the tax impact of casualty-related losses from Hurricane Milton.Equity income (loss) from unconsolidated joint venturesEquity income from unconsolidated joint ventures decreased for the year ended December 31, 2024 primarily as a result of losses on unconsolidated joint ventures acquired as part of the Merger, partially offset by increased income from the South San Francisco JVs.Noncontrolling interests share in continuing operationsNoncontrolling interests share in continuing operations decreased for the year ended December 31, 2024 primarily as a result of a gain on sale of an outpatient medical building in a consolidated joint venture in the first quarter of 2023, partially offset by increased income from consolidated joint ventures acquired as part of the Merger.Liquidity and Capital ResourcesWe anticipate that our cash flows from operations, available cash balances, and cash from our various financing activities will be adequate for the next 12 months and for the foreseeable future for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements; and (iii) satisfying funding of distributions to our stockholders and non-controlling interest members. Distributions are made using a combination of cash flows from operations, funds available under our bank line of credit (the Revolving Facility) and commercial paper program, proceeds from the sale of properties, and other sources of cash available to us.In addition to funding the activities above, our principal liquidity needs for the next 12 months are to:fund capital expenditures, including tenant improvements and leasing costs; andfund future acquisition, transactional, and development and redevelopment activities.Our longer term liquidity needs include the items listed above as well as meeting debt service requirements.We anticipate satisfying these future needs using one or more of the following:cash flows from operations; sale of, or exchange of ownership interests in, properties or other investments;borrowings under our Revolving Facility and commercial paper program;issuance of additional debt, including unsecured notes, term loans, and mortgage debt; and/orissuance of common or preferred stock or its equivalent, including sales of common stock under the ATM Program (as defined below).57Table of ContentsOur ability to access the capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. Our 2029 Term Loan, our two senior unsecured delayed draw term loans with an aggregate principal amount of \$500Ä million (the 2027 Term Loans), our 2028 Term Loan, and our Revolving Facility accrue interest at the Secured Overnight Financing Rate (SOFR) plus a margin that depends on the credit ratings of our senior unsecured long-term debt. We also pay a facility fee on the entire commitment under our Revolving Facility that depends upon our credit ratings. As of January 31, 2025, we had long-term credit ratings of Baa1 from MoodyÄs and BBB+ from S&P Global, and short-term credit ratings of P-2 from MoodyÄs and A-2 from S&P Global.A downgrade in credit ratings by MoodyÄs or S&P Global may have a negative impact on (i) the interest rates of our Revolving Facility, 2027 Term Loans, 2028 Term Loan, and 2029 Term Loan, (ii) facility fees for our Revolving Facility, and (iii) the pricing of notes issued under our commercial paper program and senior unsecured notes. While a downgrade in our credit ratings would adversely impact our cost of borrowing, we believe we would continue to have access to the unsecured debt markets, and we could also seek to enter into one or more secured debt financings, issue additional securities, including under our ATM Program, or dispose of certain assets to fund future operating costs, capital expenditures, or acquisitions, although no assurances can be made in this regard. Refer to Market Trends and Uncertainties above for a more comprehensive discussion of the potential impact of economic and market conditions on our business.Material Cash RequirementsOur material cash requirements include the below contractual and other obligations.Debt. As of December 31, 2024, we had total debt of \$8.7 billion, including notes outstanding under our commercial paper program, senior unsecured notes, term loans, and mortgage debt. Of our total debt, the total amount payable within twelve months is comprised of \$800 million of senior unsecured notes and \$7 million of mortgage debt. Commercial paper borrowings are backstopped by the availability under our Revolving Facility. As such, we calculate the weighted average remaining term of our commercial paper borrowings using the maturity date of our Revolving Facility. Future interest payments associated with borrowings under our senior unsecured notes, term loans, and mortgage debt total \$1.5 billion, \$304 million of which are payable within twelve months. Future interest payments associated with commercial paper borrowings payable within the next twelve months total \$7 million, assuming no change in interest rates and borrowings remain outstanding for the next twelve months. Development and redevelopment commitments. Our development and redevelopment commitments represent construction and other commitments for development and redevelopment projects in progress and includes certain allowances for Company-owned tenant improvements that we have provided as a lessor. As of December 31, 2024, we had \$199 million of development and redevelopment commitments, all of which we expect to spend within the next twelve months.Lease and other contractual commitments. Our lease and other contractual commitments represent our commitments, as lessor, under signed leases and contracts for operating properties and include allowances for Company-owned tenant improvements and leasing commissions. These commitments exclude allowances for Company-owned tenant improvements related to developments and redevelopments in progress for which we have executed an agreement with a general contractor to complete the tenant improvements, which are recognized as development and redevelopment commitments and are discussed further above. As of December 31, 2024, we had total lease and other contractual commitments of \$85 million, \$83 million of which we expect to spend within the next twelve months. Construction loan commitments. As of December 31, 2024, we are obligated to provide additional loans up to \$85 million to fund outpatient medical capital expenditure projects, which extend through 2028. As a result of the repayment of a secured loan in January 2025, this remaining commitment was reduced to \$67Ä million. See Note 8 to the Consolidated Financial Statements for additional information.Ground and other operating lease commitments. Our ground and other operating lease commitments represent our commitments as lessee under signed operating leases. As of December 31, 2024, we had total ground and other operating lease commitments of \$834 million, \$22 million of which are payable within twelve months. See Note 7 to the Consolidated Financial Statements for additional information.Redeemable noncontrolling interests. As of December 31, 2024, we have one redeemable noncontrolling interest and the redemption value of our redeemable noncontrolling interest was \$3 million. Our noncontrolling interest holder has the ability to put their equity interest to us beginning in September 2025. The put option is subject to changes in redemption value in the event that the underlying property generates specified returns for us and meets certain promote thresholds pursuant to the respective agreement. See Note 13 to the Consolidated Financial Statements for additional information.58Table of ContentsDistribution and Dividend Requirements. Our dividend policy on our common stock is to distribute a percentage of our cash flow to ensure that we meet the dividend requirements of the Code, relative to maintaining our REIT status, while still allowing us to retain cash to fund capital improvements and other investment activities. Under the Code, REITs may be subject to certain federal income and excise taxes on undistributed taxable income. We paid quarterly common stock cash dividends of \$0.30 per share in 2024. In February 2025, our Board of Directors declared an increase in the quarterly common stock cash dividend, from \$0.30 to \$0.305 per share. Our future common stock cash dividends, if and as declared, may vary and will be determined by the Board based upon the circumstances prevailing at the time, including our financial condition. Off-Balance Sheet Arrangements We own interests in certain unconsolidated joint ventures as described in Note 9 to the Consolidated Financial Statements. Four of these joint ventures have aggregate mortgage debt of \$845 million, of which our share is \$187 million. Except in limited circumstances, our risk of loss is limited to our investment in the applicable joint venture. Additionally, as of December 31, 2024, we had 15 outstanding letter of credit obligations totaling \$12 million expiring in 2025 and one outstanding letter of credit obligation of \$100 thousand expiring in 2026. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.InflationA significant portion of our revenues are derived from leases that generally provide for fixed rental rates, subject to annual escalations. A period of high inflation could result in increases in the Consumer Price Index in excess of our fixed annual escalations. Certain of our leases provide that annual rent is modified based on changes in the Consumer Price Index or other thresholds. Most of our outpatient medical leases require the tenant to pay a share of property operating costs such as real estate taxes, insurance, and utilities. Substantially all of our lab leases require the tenant or operator to pay all of the property operating costs or reimburse us for all such costs. Labor costs, costs of construction materials, interest, utilities, and other operating costs may increase during periods of inflation. Inflationary increases in expenses will generally be offset, in whole or in part, by the tenant expense reimbursements and contractual rent increases described above. Cash Flow SummaryThe following summary discussion of our cash flows is based on the Consolidated Statements of Cash Flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below. The following table sets forth changes in cash flows (in thousands):Year Ended December 31,20242023ChangeNet cash provided by (used in) operating activities\$1,070,497Ä \$956,242Ä \$114,255Ä Net cash provided by (used in) investing activities(113,799)(576,754)462,955Ä Net cash provided by (used in) financing activities(941,416)(337,299)(604,117)Operating Cash FlowsOur cash flows from operations are dependent upon the occupancy levels of our buildings, rental rates on leases, our tenantsÄ performance on their lease obligations, the level of operating expenses, and other factors. Our net cash provided by operating activities increased \$114 million for the year ended December 31, 2024 compared to the year ended December 31, 2023 primarily as a result of:Ä (i) an increase in Adjusted NOI from properties acquired as part of the Merger, (ii) developments and redevelopments placed in service during 2023 and 2024, (iii) annual rent increases, and (iv) new leasing and renewal activity. The increase in net cash provided by operating activities was partially offset by: (i) an increase in merger-related costs and (ii) an increase in cash paid for interest.59Table of ContentsInvesting Cash FlowsOur cash flows from investing activities are generally used to fund acquisitions, developments, and redevelopments of real estate, net of proceeds received from sales of real estate, and repayments on loans receivable. Our net cash used in investing activities decreased \$463 million for the year ended December 31, 2024 compared to the year ended December 31, 2023 primarily as a result of the following: (i) an increase in proceeds from sales of real estate, (ii) a reduction in cash used for development and redevelopment of real estate, (iii) proceeds received from the Callan Ridge JV transaction, (iv) a reduction in investments in unconsolidated joint ventures, and (v) a reduction in cash used for acquisitions of real estate. The decrease in cash used in investing activities was partially offset by: (i) cash paid in connection with the Merger, (ii) a decrease in proceeds from principal repayments on loans receivable and marketable debt securities, (iii) an increase in fundings of loans receivable, and (iv) a decrease in proceeds received from insurance recoveries.Financing Cash FlowsOur cash flows from financing activities are generally impacted by issuances and/or repurchases of equity, borrowings and repayments under our bank line of credit and commercial paper program, senior unsecured notes, term loans, and mortgage debt, net of dividends paid to common shareholders. Our net cash used in financing activities increased \$604 million for the year ended December 31, 2024 compared to the year ended December 31, 2023 primarily as a result of the following: (i) higher net repayments under the commercial paper program, (ii) repurchases of common stock under our 2022 Share Repurchase Program, (iii) an increase in dividends paid on common stock, (iv) cash used to buy out four redeemable noncontrolling interests in April 2024, and (v) an increase in payments for deferred financing costs. The increase in cash used in financing activities was partially offset by lower repayments of mortgage debt.Discontinued OperationsOperating, investing, and financing cash flows in our Consolidated Statements of Cash Flows are reported inclusive of both cash flows from continuing operations and cash flows from discontinued operations. Certain significant cash flows from discontinued operations are disclosed in Note 18 to the Consolidated Financial Statements.DebtIn December 2024, we amended our Revolving Facility to extend the maturity date to January 2029, which may be further extended pursuant to two six-month extension options, subject to certain customary conditions.On March 1, 2024, concurrently with the consummation of the Merger, we assumed the following debt instruments: (i) \$1.25Ä billion aggregate principal of senior unsecured notes, (ii) the \$400Ä million 2028 Term Loan, and (iii) \$128Ä million aggregate principal of mortgage debt. Additionally, on March 1, 2024, concurrently with the consummation of the Merger, we executed the \$750Ä million 2029 Term Loan, which is an incremental facility under our existing term loan agreement. In January 2024, we entered into forward-starting interest rate swap instruments that are designated as cash flow hedges that effectively established a fixed interest rate for the 2029 Term Loan at a blended effective interest rate of 4.66%. Additionally, on March 1, 2024, in connection with the consummation of the Merger, we acquired: (i) three interest rate swap instruments that are

designated as cash flow hedges that effectively establish a fixed interest rate for the 2028 Term Loan in a blended effective interest rate of 4.44% and (ii) one interest rate swap instrument on \$36A million of variable rate mortgage debt that was designated as a cash flow hedge prior to the maturity of the interest rate swap instrument in October 2024. See Note 11 to the Consolidated Financial Statements for additional information about our outstanding debt. Approximately 97% and 90% of our consolidated debt was fixed rate debt as of DecemberA 31, 2024 and 2023, respectively. At DecemberA 31, 2024, our fixed rate debt and variable rate debt had weighted average effective interest rates of 4.04% and 5.56%, respectively. At DecemberA 31, 2023, our fixed rate debt and variable rate debt had weighted average effective interest rates of 3.70% and 5.72%, respectively. As of DecemberA 31, 2024, we had the following swapped to fixed rates through interest rate swap instruments: (i) the \$750A million 2029 Term Loan, (ii) the \$500 million 2027 Term Loans, (iii) the \$400 million 2028 Term Loan, and (iv) \$142A million of variable rate mortgage debt. These interest rate swap instruments are designated as cash flow hedges. For purposes of classification of the amounts above, variable rate debt with a derivative financial instrument designated as a cash flow hedge is reported as fixed rate debt due to us having effectively established a fixed interest rate for the underlying debt instrument. For a more detailed discussion of our interest rate risk, see [Accounting 7A](#), Quantitative and Qualitative Disclosures About Market Risk, below.

[Table of Contents](#)
[Supplemental Guarantor Information](#)

Healthpeak OP has issued the senior unsecured notes issued by Healthpeak prior to the consummation of the Merger as described in Note 11 to the Consolidated Financial Statements. The obligations of Healthpeak OP to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, DOC DR Holdco, and DOC DR OP Sub. Additionally, DOC DR OP Sub is the issuer, as successor to the Physicians Partnership upon the Merger, of the senior unsecured notes issued by the Physicians Partnership prior to, and assumed by Healthpeak as part of, the Merger as described in Note 11 to the Consolidated Financial Statements. The obligations of DOC DR OP Sub to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, Healthpeak OP, and DOC DR Holdco. Subsidiary issuers of obligations guaranteed by the parent are not required to provide separate financial statements, provided that the parent guarantee is [effective](#) and unconditional, the subsidiary obligor is a consolidated subsidiary of the parent company, the guaranteed security is debt or debt-like, and consolidated financial statements of the parent company have been filed. Accordingly, separate consolidated financial statements of Healthpeak OP, DOC DR Holdco, and DOC DR OP Sub have not been presented. As permitted under Rule 13-01 of Regulation S-X, we have excluded the summarized financial information for the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP because the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP have no material assets, liabilities, or operations other than the debt financing activities described in the first paragraph of Note 11 to the Consolidated Financial Statements and their investments in non-guarantor subsidiaries, and management believes such summarized financial information would be repetitive and would not provide incremental value to investors. Equity At DecemberA 31, 2024, we had 699 million shares of common stock outstanding, equity totaled \$9.1 billion, and our equity securities had a market value of \$14.5 billion. The Merger Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) automatically converted into the right to receive 0.674 shares of our common stock. Based on the number of outstanding Physicians Realty Trust common shares as of the Closing Date, we issued 162A million shares of our common stock. Refer to Note 3 to the Consolidated Financial Statements for additional information regarding the Merger. At The Market Program In February 2023, in connection with the Reorganization, we terminated our previous at-the-market equity offering program and established a new at-the-market equity offering program (the [ATM Program](#)) that allows for the sale of shares of common stock having an aggregate gross sales price of up to \$1.5 billion. The ATM Program was amended in March 2024 to contemplate the sale of the remaining shares of common stock pursuant to the Company's Registration Statement on Form S-3 filed with the SEC on February 8, 2024. In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements (each, an [ATM forward contract](#)) with sales agents for the sale of our shares of common stock under our ATM Program. During the year ended DecemberA 31, 2024, we did not issue any shares of our common stock under any ATM Program. At DecemberA 31, 2024, \$1.5 billion of our common stock remained available for sale under the ATM Program. Actual future sales of our common stock will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock, and our capital needs. We have no obligation to sell any shares under our ATM Program. See Note 13 to the Consolidated Financial Statements for additional information about our ATM Program.

[Table of Contents](#)
[Noncontrolling Interests](#)
[Healthpeak OP](#)

Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, certain of our employees ([OP Unitholders](#)) have been issued noncontrolling, non-managing member units in Healthpeak OP ([OP Units](#)). During the three months ended March 31, 2024, OP Unitholders were issued approximately 2A million OP Units. When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of our common stock, at our option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of our common stock or cash equal to the fair value of a share of common stock at the time of redemption. We classify the OP Units in permanent equity because we may elect, in our sole discretion, to issue shares of our common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. As of DecemberA 31, 2024, there were approximately 3A million OP Units outstanding, 76A thousand of which had met the criteria for redemption. DownREITs. During the year ended DecemberA 31, 2024, in connection with the Merger, Physicians Partnership merged with and into DOC DR OP Sub with DOC DR OP Sub surviving as the Partnership Surviving Entity. As of DecemberA 31, 2024, approximately 6A million DownREIT units in the Partnership Surviving Entity were outstanding (6A million shares of Healthpeak common stock are issuable upon conversion). Refer to Note 3 to the Consolidated Financial Statements for additional information regarding the Merger. At DecemberA 31, 2024, non-managing members held an aggregate of approximately 11 million units in eight limited liability companies for which we hold controlling interests and/or are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications). At DecemberA 31, 2024, the outstanding DownREIT units were convertible into approximately 14A million shares of our common stock. Share Repurchase Programs On August 1, 2022, our Board of Directors approved a share repurchase program under which we could acquire shares of our common stock in the open market up to an aggregate purchase price of \$500A million (the [2022 Share Repurchase Program](#)). Purchases of common stock under the 2022 Share Repurchase Program could be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. Through July 24, 2024, we repurchased 10.5A million shares of our common stock under the 2022 Share Repurchase Program at a weighted average price of \$17.98 per share for a total of \$188A million. On July 24, 2024, our Board of Directors approved a new share repurchase program (the [2024 Share Repurchase Program](#)) to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Program, no further share repurchases may be made pursuant to the 2022 Share Repurchase Program. Under the 2024 Share Repurchase Program, we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of \$500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. As of DecemberA 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program. Therefore, at DecemberA 31, 2024, \$500A million of the Company's common stock remained available for repurchase under the 2024 Share Repurchase Program. Shelf Registration On February 8, 2024, the Company and Healthpeak OP jointly filed a prospectus with the SEC as part of a registration statement on Form S-3, using an automatic shelf registration process. This shelf registration statement expires on February 8, 2027 and at or prior to such time, we expect to file a new shelf registration statement. Under the [shelf](#) process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include future offerings of: (i) the Company's common stock, preferred stock, depositary shares, warrants, debt securities, and guarantees by the Company of debt securities issued by Healthpeak OP and/or by the Company's existing and future subsidiaries, and (ii) Healthpeak OP's debt securities and guarantees by Healthpeak OP of debt securities issued by the Company and/or by Healthpeak OP's existing and future subsidiaries.

[Table of Contents](#)
[Non-GAAP Financial Measures](#)
[Reconciliations](#)

The following is a reconciliation from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Net FFO, FFO as Adjusted, and AFFO (in thousands):

Year Ended December 31, 2024	2023	2022				
Net income (loss) applicable to common shares	\$242,384	\$304,284	\$497,792			
Real estate related depreciation and amortization	1,057,205	749,901	710,569			
Healthpeak's share of real estate related depreciation and amortization	(18,328)	(18,654)	(19,201)			
Loss (gain) on sales of depreciable real estate, net	(178,695)	(86,463)	(10,422)			
Healthpeak's share of loss (gain) on sales of depreciable real estate, net	(11,546)	12A	Loss (gain) upon change of control, net	(177,548)	(234)	(31,438)
Taxes associated with real estate dispositions	(219,633)	A	29A			
Impairments (recoveries) of depreciable real estate, net	13,118	A	A			
Nareit FFO applicable to common shares	1,092,730	985,180	895,166			
Distributions on dilutive convertible units and other	16,211	9,394	9,407			
Diluted Nareit FFO applicable to common shares	\$1,108,941	\$994,574	\$904,573			
Impact of adjustments to Nareit FFO: Transaction and merger-related items	(3)	\$115,105	\$13,835			
Other impairments (recoveries) and other losses (gains), net	(419,381)	(3,850)	3,829			
Restructuring and severance-related charges	(5)	A	1,368			
3A Casualty-related charges (recoveries), net	(625,848)	(4,033)	4,401			
Recognition (reversal) of valuation allowance on deferred tax assets	(7)	(11,196)	(14,194)			
A Total adjustments	\$139,138	\$6,874	\$45,767			
FFO as Adjusted applicable to common shares	\$1,231,868	\$978,306	\$940,933			
Distributions on dilutive convertible units and other	16,061	9,402	9,326			
Diluted FFO as Adjusted applicable to common shares	\$1,247,929	\$987,708	\$950,259			
FFO as Adjusted applicable to common shares	\$1,231,868	\$978,306	\$940,933			
Stock-based compensation amortization expense	15,543	14,480	16,537			
Amortization of deferred financing costs and debt discounts (premiums)	28,974	11,916	10,881			
Straight-line rents	(8)	(41,276)	(14,387)			
AFFO capital expenditures	(115,784)	(113,596)	(108,510)			
CCRC entrance fees	(9)	53,697	43,453			
22,095A Deferred income taxes	6,176	(81				

our best estimates based on our evaluation of the specific characteristics of each tenant’s lease. Factors considered include estimates of carrying costs during hypothetical expected lease-up periods, market conditions, and costs to execute similar leases. Our assumptions affect the amount of future revenue and/or depreciation and amortization expense that we will recognize over the remaining useful life for the acquired in-place leases. Our fair value estimates for loans receivable and debt consider market-based information, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active (markets with few transactions), inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs). Our fair value estimates for joint ventures consider ownership interests, subordination characteristics, redemption values, discounts for lack of control (as applicable), and hypothetical liquidation waterfalls.

Impairment of Long-Lived AssetsWe assess the carrying value of our real estate assets and related intangibles (real estate assets) when events or changes in circumstances indicate that the carrying value may not be recoverable. Recoverability of real estate assets is measured by comparing the carrying amount of the real estate assets to the respective estimated future undiscounted cash flows. The expected future undiscounted cash flows reflect external market factors, and based on the specific facts and circumstances, may be probability-weighted to reflect multiple possible cash-flow scenarios, including selling the assets at various points in the future. Additionally, the estimated future undiscounted cash flows are calculated utilizing the lowest level of identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. In order to review our real estate assets for recoverability, we make assumptions regarding external market conditions (including capitalization rates and growth rates), forecasted cash flows and sales prices, and our intent with respect to holding or disposing of the asset. If our analysis indicates that the carrying value of the real estate assets is not recoverable on an undiscounted cash flow basis, we recognize an impairment charge for the amount by which the carrying value exceeds the fair value of the real estate assets. Determining the fair value of real estate assets, including assets classified as held for sale, involves significant judgment and generally utilizes market capitalization rates, comparable market transactions, estimated per unit or per square foot prices, negotiations with prospective buyers, and forecasted cash flows (primarily lease revenue rates, expense rates, and growth rates). Our ability to accurately predict future operating results and resulting cash flows, and estimate fair values, impacts the timing and recognition of impairments. While we believe our assumptions are reasonable, changes in these assumptions may have a material impact on our consolidated financial statements.

Recent Accounting PronouncementsSee Note 2 to the Consolidated Financial Statements for the impact of new accounting standards.

ITEM 7A. A Quantitative and Qualitative Disclosures About Market RiskWe are exposed to various market risks, primarily from the potential loss arising from adverse changes in interest rates. We use derivative and other financial instruments in the normal course of business to mitigate interest rate risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note 22 to the Consolidated Financial Statements). To illustrate the effect of movements in the interest rate markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves of our derivative portfolio in order to determine the change in fair value. At December 31, 2024, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to \$53A million.

Table of ContentsInterest Rate RiskAt December 31, 2024, our exposure to interest rate risk was primarily on our variable rate debt. At December 31, 2024, we had the following swapped to fixed rates through interest rate swap instruments: (i) the \$750A million 2029 Term Loan, (ii) the \$500 million 2027 Term Loans, (iii) the \$400 million 2028 Term Loan, and (iv) \$142A million of variable rate mortgage debt. The interest rate swap instruments are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable rate debt to fixed interest rates. At December 31, 2024, both the fair value and carrying value of the interest rate swap instruments were \$35A million. Our remaining variable rate debt at December 31, 2024 was comprised of borrowings under our commercial paper program and certain of our mortgage debt. Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. Interest rate changes will affect the fair value of our fixed rate instruments. At December 31, 2024, a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately \$241 million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately \$259 million. Additionally, at December 31, 2024, a one percentage point increase or decrease in interest rates would change the fair value of our fixed rate loans receivable by approximately \$15 million. These changes would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point increase in the interest rates related to our variable rate debt, and assuming no other changes in the outstanding balance at December 31, 2024, our annual interest expense would increase by approximately \$3 million. Lastly, assuming a one percentage point decrease in the interest rates related to our variable rate loans receivable, and assuming no other changes in the outstanding balance at December 31, 2024, our annual interest income would decrease by approximately \$1 million.

Table of ContentsITEM 8. A A Financial Statements and Supplementary DataHealthpeak Properties, Inc. Index to the Consolidated Financial StatementsReport of Independent Registered Public Accounting Firm (PCAOB ID No. 34)68Consolidated Balance SheetsDecember 31, 2024 and 202370Consolidated Statements of OperationsDecember 31, 2024, 2023, and 202271Consolidated Statements of Comprehensive Income (Loss)December 31, 2024, 2023, and 202272Consolidated Statements of Equity and Redeemable Noncontrolling InterestsDecember 31, 2024, 2023, and 202273Consolidated Statements of Cash FlowsDecember 31, 2024, 2023, and 202273Consolidated Statements of Cash FlowsDecember 31, 2024, 2023, and 202275Notes to the Consolidated Financial Statements7667Table of ContentsREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMTo the stockholders and the Board of Directors of Healthpeak Properties, Inc. Opinion on the Financial StatementsWe have audited the accompanying Consolidated Balance Sheets of Healthpeak Properties, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related Consolidated Statements of Operations, Comprehensive Income (Loss), Equity and Redeemable Noncontrolling Interests, and Cash Flows, for each of the three years in the period ended December 31, 2024, and the related Notes and the schedules listed in the Index at Item 15 (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 4, 2025, expressed an unqualified opinion on the Company’s internal control over financial reporting. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit MattersThe critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Impairments – Real Estate Refer to Notes 2 and 6 to the financial statements.

Critical Audit Matter Description The Company’s evaluation of impairment of real estate involves an assessment of the carrying value of real estate assets and related intangibles (real estate assets) when events or changes in circumstances indicate that the carrying value may not be recoverable. Auditing the Company’s process to evaluate real estate assets for impairment was complex due to the subjectivity in determining whether impairment indicators were present. Additionally, for real estate assets where indicators of impairment were determined to be present, the determination of the future undiscounted cash flows involved significant judgment. In particular, the undiscounted cash flows were forecasted based on significant assumptions such as lease-up periods, lease revenue rates, operating expenses, and revenue and expense growth rates, and included judgments around the intended hold period and terminal capitalization rates. Given the Company’s evaluation of impairment indicators, forecasted cash flows, and sales prices of a long-lived asset requires management to make significant estimates and assumptions related to market capitalization rates, market prices per unit, and/or forecasted cash flows, performing audit procedures required a high degree of auditor judgment and an increased extent of effort.

Table of ContentsHow the Critical Audit Matter Was Addressed in the AuditOur audit procedures related to real estate asset impairment included the following, among others: We tested the effectiveness of controls over impairment of real estate assets, including those over identifying impairment indicators, and the determination of forecasted undiscounted cash flows and sales prices for real estate assets. We performed an independent search for impairment indicators through the evaluation of several factors including an analysis of industry and market data and trends in financial performance. For real estate assets where indicators of impairment were determined to be present, we subjected a sample of undiscounted cash flow models to testing by (1) evaluating the source information and assumptions used by management, (2) testing the mathematical accuracy of the undiscounted cash flow models, and (3) evaluating management’s intended hold period.

Business Combination – Physicians Realty Trust Merger Valuation Refer to Notes 2 and 3 to the financial statements.

Critical Audit Matter Description The Company completed the acquisition of Physicians Realty Trust on March 1, 2024 for total consideration of \$3.0A billion. The Company accounted for this acquisition as a business combination. Accordingly, the purchase price was allocated to the assets acquired, liabilities assumed, and noncontrolling interests based on their relative fair values, including approximately \$3.7A billion of consolidated real estate, \$891A million in related intangible assets, and \$150A million in related intangible liabilities. The fair value determination of the real estate assets acquired and liabilities assumed required management to make significant estimates related to assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates. Given the fair value determination of assets acquired and liabilities assumed requires management to make significant estimates and assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates, performing audit procedures to evaluate the reasonableness of these assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists. How the Critical Audit Matter Was Addressed in the AuditOur audit procedures related to the fair value of real estate assets acquired and liabilities assumed included the following, among others: We tested the effectiveness of controls over the purchase price allocation, including management’s controls over the identification of real estate assets, and the valuation methodology for estimating the fair value of real estate assets acquired and liabilities assumed. With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) relevant market data, and (3) assumptions used in the valuation of land, buildings, and related intangible assets and liabilities, including testing the mathematical accuracy of the calculations, and comparing management’s assumptions to independently validated data sources used by market participants. We assessed the accuracy and completeness of the underlying data used in the valuation of land, buildings, and related intangible assets and liabilities including in-place lease agreements, square footage, and historical operating data./

DELOITTE & TOUCHE LLPCosta Mesa, CaliforniaFebruary 4, 2025We have served as the Company’s auditor since 2010.

Table of ContentsHealthpeak Properties, Inc. CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share data)December 31, 20242023ASSETSReal estate:Buildings and improvements\$16,115,283A \$13,329,464A Development costs and construction in progress\$880,393A \$643,217A Land and improvements\$2,918,758A \$2,647,633A Accumulated depreciation and amortization\$(4,083,030) \$(3,591,951)Net real estate\$15,831,404A \$13,028,363A Loans receivable, net of reserves of \$10,499 and \$2,830,717\$1,190A \$218,450A Investments in and advances to unconsolidated joint ventures\$936,814A \$782,853A Accounts receivable, net of allowance of \$2,243 and \$2,282,76,810A \$55,820A Cash and cash equivalents\$19,818A \$17,635A Restricted cash\$64,487A \$1,388A Intangible assets, net\$17,254A \$314,156A Assets held for sale, net\$7,840A \$117,986A Right-of-use assets, net\$424,173A \$204,155A Other assets, net\$942,465A \$772,044A Total assets\$19,938,255A \$15,698,850A LIABILITIES AND EQUITYBank line of credit and commercial papers\$150,000A \$720,000A Term loans\$1,646,043A \$496,824A Senior unsecured notes\$563,256A \$540,378A Mortgage debt\$356,750A \$256,097A Intangible liabilities, net\$191,884A \$127,380A Liabilities related to assets held for sale, net\$A \$729A Lease liability\$307,220A \$206,743A Accounts payable, accrued liabilities, and other liabilities\$725,342A \$657,196A Deferred revenue\$940,136A \$905,633A Total liabilities\$10,880,631A \$7,773,980A Commitments and contingencies (Note 12)Redeemable noncontrolling interests\$2,610A \$48,828A Common stock, \$1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 699,485,139 and 547,156,311 shares issued and outstanding\$699,485A \$547,156A Additional paid-in capital\$12,847,252A \$10,405,780A Cumulative dividends in excess of earnings\$(5,174,279) \$(4,621,861)Accumulated other comprehensive income (loss)\$28,818A \$19,371A Total stockholders’ equity\$8,401,276A \$6,350,446A Joint venture partners\$15,821A \$10,998A Non-managing member unitholders\$37,917A \$214,598A Total noncontrolling interests\$653,738A \$525,596A Total equity\$9,055,014A \$6,876,042A Total liabilities and equity\$19,938,255A \$15,698,850A See accompanying Notes to the Consolidated Financial Statements.

Table of ContentsHealthpeak Properties, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Year Ended December 31, 202420232022Revenues:Rental and related revenues\$2,087,196A \$1,631,805A \$1,541,775A Resident fees and services\$68,475A \$527,417A \$494,935A Interest income and other\$44,778A \$21,781A \$23,300A Income from direct financing leases\$A \$A \$A Total revenues\$2,700,449A \$2,181,003A \$2,061,178A Costs and expenses:Interest expense\$280,430A \$200,331A \$172,944A Depreciation and amortization\$1,057,205A \$749,901A \$710,569A Operating\$1,074,861A \$902,060A \$862,991A General and administrative\$97,162A \$95,132A \$131,033A Transaction and merger-related costs\$132,685A \$17,151A \$4,853A Impairments and loan loss reserves (recoveries), net\$22,978A \$(5,601) \$7,004A Total costs and expenses\$2,665,321A \$1,959,338A \$1,889,394A Other income (expense):A A A Gain (loss) on sales of real estate, net\$178,695A \$86,463A \$9,078A Other income (expense), net\$59,345A \$6,808A \$326,268A Total other income (expense), net\$238,040A \$93,271A \$335,346A Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures\$273,168A \$314,936A \$507,130A Income tax benefit (expense) \$(4,350) \$9,617A \$4,425A Equity income (loss) from unconsolidated joint ventures\$(1,515) \$10,204A \$1,985A Income (loss) from continuing operations\$267,303A \$334,757A \$513,540A Income (loss) from discontinued operations\$A \$A \$A A 2,884A Net income (loss)\$267,303A \$334,757A \$516,424A Noncontrolling interests’ share in continuing operations\$(24,161) \$(28,748) \$(15,975)Net income (loss) attributable to Healthpeak Properties, Inc.\$243,142A \$306,009A \$500,449A Participating securities’ share in earnings\$(758) \$(1,725) \$(2,657)Net income (loss) applicable to common shares\$242,384A \$304,284A \$497,792A Basic earnings (loss) per common share:Continuing operations\$0.36A \$0.56A \$0.92A Discontinued operations\$A \$A \$A A 0.00A Net income (loss) applicable to common shares\$0.36A \$0.56A \$0.92A Diluted earnings (loss) per common share:Continuing operations\$0.36A \$0.56A \$0.92A Discontinued operations\$A \$A \$A A 0.00A Net income (loss) applicable to common shares\$0.36A \$0.56A \$0.92A Weighted average shares outstanding:Basic\$675,680A \$547,006A \$538,809A Diluted\$676,233A \$547,275A \$539,147A See accompanying Notes to the Consolidated Financial Statements.

Table of ContentsHealthpeak Properties, Inc. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (In thousands)Year Ended December 31, 202420232022Net income (loss)\$267,303A \$334,757A \$516,424A Other comprehensive income (loss):Net unrealized gains (losses) on derivatives\$9,462A \$(8,900) \$30,145A Change in Supplemental Executive Retirement Plan obligation and other\$(15) \$137A \$1,136A Total other comprehensive income (loss)\$9,447A \$(8,763) \$31,281A Total comprehensive income (loss)\$276,750A \$325,994A \$547,705A Total comprehensive (income) loss attributable to noncontrolling interests’ share in continuing operations\$(24,161) \$(28,748) \$(15,975)Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.\$252,589A \$297,246A \$531,730A See accompanying Notes to the Consolidated

[illegible]

classified as held-for-investment based on management's intent and ability to hold the loans for the foreseeable future or to maturity. Loans held-for-investment are carried at amortized cost and reduced by a valuation allowance for estimated credit losses, as necessary. When collectibility of the future payments is reasonably assured, the Company utilizes the interest method on a loan-by-loan basis to recognize interest income on its loans, which includes the amortization of discounts and premiums as well as loan fees paid and received. Management Fee Income

The Company provides various services to certain of its unconsolidated joint ventures in exchange for fees and reimbursement. These services are considered related party transactions under ASC 850, Related Party Disclosures. Management fee income is recognized in interest income and other on the Consolidated Statements of Operations. Gain (Loss) on Sales of Real Estate, Net

The Company recognizes a gain (loss) on sale of real estate when the criteria for an asset to be derecognized are met, which include when: (i) a contract exists, (ii) the buyer obtains control of the asset, and (iii) it is probable that the Company will receive substantially all of the consideration to which it is entitled. These criteria are generally satisfied at the time of sale.

Table of Contents

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) to provide financial aid to individuals, businesses, and state and local governments. During the years ended December 31, 2023 and 2022, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenues during the coronavirus pandemic. Grant income is recognized to the extent that qualifying expenses and lost revenues exceed grants received and the Company will comply with all conditions attached to the grant. As of December 31, 2024, the amount of qualifying expenditures and lost revenues exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture. The following table summarizes information related to government grant income received and recognized by the Company (in thousands):

Year Ended December 31, 2024	2023	2022
Government grant income recorded in other income (expense), net	\$184.4	\$6,765.4
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	\$229.4	\$78.4

Government grant income recorded in income (loss) from discontinued operations \$217.4 | Total government grants received | \$413.4 | \$7,860.4 || Credit Losses | The Company evaluates the liquidity and creditworthiness of its occupants, operators, and borrowers on a monthly and quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company's evaluation considers payment history and current credit status, industry conditions, current economic conditions, forecasted economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends. The determination of loan losses also considers concentration of credit risk associated with the senior housing and outpatient medical industries to which its loans receivable relate. The Company's occupants, operators, and borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the lease or debt service coverages in its assessment of internal ratings that it uses as a primary credit quality indicator. Lease and debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rate, reimbursement trends, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures. The Company evaluates, on a monthly basis or immediately upon a significant change in circumstance, its occupants', operators', and borrowers' ability to service their obligations with the Company. In connection with the Company's quarterly review process or upon the occurrence of a significant event, loans receivable and DFLs (collectively, "finance receivables"), are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Finance receivables that are deemed Performing meet all present contractual obligations, and collection and timing, of all amounts owed is reasonably assured. Watch List finance receivables are defined as finance receivables that do not meet the definition of Performing or Workout. Workout finance receivables are defined as finance receivables in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the tenant, operator, or borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment. |

Table of Contents

Finance receivables are placed on nonaccrual status when management determines that the collectibility of contractual amounts is not reasonably assured (the asset will have an internal rating of either Watch List or Workout). Further, the Company performs a credit analysis to support the tenant's, operator's, borrower's, and/or guarantor's repayment capacity and the underlying collateral values. The Company uses the cash basis method of accounting for finance receivables placed on nonaccrual status unless one of the following conditions exist whereby it utilizes the cost recovery method of accounting if: (i) the Company determines that it is probable that it will only recover the recorded investment in the finance receivable, net of associated allowances or charge-offs (if any), or (ii) the Company cannot reasonably estimate the amount of an impaired finance receivable. For cash basis method of accounting, the Company applies payments received, excluding principal paydowns, to interest income so long as that amount does not exceed the amount that would have been earned under the original contractual terms. For cost recovery method of accounting, any payment received is applied to reduce the recorded investment. Generally, the Company returns a finance receivable to accrual status when all delinquent payments become current under the terms of the loan or lease agreements and collectibility of the remaining contractual loan or lease payments is reasonably assured. At inception of a finance receivable, the Company recognizes an allowance for credit losses expected to be incurred over the life of the instrument. The model utilized by the Company to determine such losses emphasizes historical experience and future market expectations to determine a loss to be recognized at inception. However, the model is applied on an individual basis and relies on counter-party specific information to ensure the most accurate estimate is recognized. The Company also performs a quarterly review process (or upon the occurrence of a significant event) to evaluate its borrowers' creditworthiness and liquidity to determine the amount of credit losses to recognize during the period. If a finance receivable is deemed partially or wholly uncollectible, the uncollectible balance is deducted from the allowance in the period in which such determination is made. Credit loss expenses and recoveries are recorded in impairments and loan loss reserves (recoveries), net. Real Estate

The Company's real estate acquisitions are generally classified as asset acquisitions for which the Company records identifiable assets acquired, liabilities assumed, and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill is recognized, third party transaction costs are capitalized and any associated contingent consideration is generally recorded when the amount of consideration is reasonably estimable and probable of being paid. The Company assesses fair value based on available market information, such as capitalization and discount rates, comparable sale transactions, and relevant per square foot or unit cost information. A real estate asset's fair value may be determined utilizing cash flow projections that incorporate such market information. Estimates of future cash flows are based on a number of factors including historical operating results, known and anticipated trends, as well as market and economic conditions. The fair value of tangible assets of an acquired property is based on the value of the property as if it is vacant. The Company recognizes acquired above and below market leases at their relative fair value (for asset acquisitions) using discount rates which reflect the risks associated with the leases acquired. The fair value is based on the present value of the difference between (i) the contractual amounts paid pursuant to each in-place lease and (ii) management's estimate of fair market lease rates for each in-place lease, measured over a period equal to the remaining term of the lease for above market leases and the initial term plus the extended term for any leases with renewal options that are reasonably certain to be exercised. Other intangible assets acquired include amounts for in-place lease values that are based on an evaluation of the specific characteristics of each property and the acquired tenant lease(s). Factors considered include estimates of carrying costs during hypothetical expected lease-up periods, market conditions, and costs to execute similar leases. In estimating carrying costs, the Company includes estimates of lost rents at market rates during the hypothetical expected lease-up periods, which are dependent on local market conditions and expected trends. In estimating costs to execute similar leases, the Company considers leasing commissions, legal, and other related costs. Certain of the Company's acquisitions involve the assumption of contract liabilities. The Company typically estimates the fair value of contract liabilities by applying a reasonable profit margin to the total discounted estimated future costs associated with servicing the contract. A variety of market and contract-specific conditions are considered when making assumptions that impact the estimated fair value of the contract liability.

Table of Contents

The Company capitalizes direct construction and development costs, including predevelopment costs, interest, property taxes, insurance, and other costs directly related and essential to the development or construction of a real estate asset. The Company capitalizes construction and development costs while substantive activities are ongoing to prepare an asset for its intended use. During the holding or development period, certain real estate assets generate incidental income that is not associated with the future profit or return from the intended use of the property. Such income is recognized as a reduction of the associated project costs. The Company considers a construction project as substantially complete and held available for occupancy upon the completion of Company-owned tenant improvements, but no later than one year from cessation of significant construction activity. Costs incurred after a project is substantially complete and ready for its intended use, or after development activities have ceased, are expensed as incurred. For redevelopment of existing operating properties, the Company capitalizes the cost for the construction and improvement incurred in connection with the redevelopment. Costs previously capitalized related to abandoned developments/redevelopments are charged to earnings. Expenditures for repairs and maintenance are expensed as incurred. The Company considers costs incurred in conjunction with re-leasing properties, including tenant improvements and lease commissions, to represent the acquisition of productive assets and such costs are reflected as investing activities in the Company's Consolidated Statements of Cash Flows. Initial direct costs incurred in connection with successful property leasing are capitalized as deferred leasing costs and classified as investing activities in the Consolidated Statements of Cash Flows. Initial direct costs include only those costs that are incremental to the arrangement and would not have been incurred if the lease had not been obtained. Initial direct costs consist of leasing commissions paid to employees and external third party brokers and lease incentives. Initial direct costs are included in other assets, net in the Consolidated Balance Sheets. At December 31, 2024 and 2023, the balance of net initial direct costs were \$204.4 million and \$172.4 million, respectively. Initial direct costs are amortized in depreciation and amortization in the Consolidated Statements of Operations using the straight-line method over the lease term. The Company computes depreciation on properties using the straight-line method over the asset's estimated useful lives. These useful lives are reassessed following changes in the remaining period that the asset is expected to be held and used, and depreciation is discontinued when a property meets the criteria to be classified as held for sale. Buildings and improvements are depreciated over useful lives ranging up to 50 years. Above and below market lease intangibles are amortized to revenue over the remaining noncancellable lease terms and renewal periods that are reasonably certain to be exercised, if any. In-place lease intangibles are amortized to expense over the remaining noncancellable lease term and renewal periods that are reasonably certain to be exercised, if any. Business Combinations

For the Company's real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The fair values are determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant. Other Assets, Net

Other assets, net consist primarily of straight-line rent receivable (as discussed above), initial direct costs (as discussed above), deferred income taxes (see Note 17), goodwill (see Note 10), corporate assets (see Note 7), derivative assets (see Note 22), other equity investments (as discussed below and see Note 19), and prepaid expenses. Other Equity Investments

The Company has certain investments recognized in accordance with ASC 321, Investments in Equity Securities, within other assets, net on the Consolidated Balance Sheets. These investments do not have readily determinable fair values and the practical expedient to estimate fair value using net asset value per share has not been elected. Accordingly, the investments are measured at cost, less any impairments, and are adjusted for any observable price changes, with such changes included in earnings. An observable price results from an orderly transaction for an identical or similar investment of the same issuer, which is observed by an investor without expending undue cost and effort. Observable price changes may result from equity transactions of the same issuer, including subsequent equity offerings. To determine whether transactions are indicative of an observable price change, the Company evaluates, among other factors, whether the transactions have similar rights and obligations, which include voting rights, distribution rights and preferences, and conversion features.

Table of Contents

Lessee Accounting

For leases greater than 12 months for which the Company is the lessee, such as ground leases and corporate office leases, the Company recognizes a right-of-use asset and related lease liability on the Consolidated Balance Sheets at inception of the lease. The lease liability is calculated as the sum of: (i) the present value of minimum lease payments at lease commencement (discounted using the Company's secured incremental borrowing rate) and (ii) the present value of amounts probable of being paid under any residual value guarantees. Certain of the Company's lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if they are considered reasonably certain of exercise. The right-of-use asset is calculated as the lease liability, adjusted for the following: (i) any lease payments made to the lessor at or before the commencement date, minus any lease incentives received and (ii) any initial direct costs incurred by the Company. Lease expense related to corporate assets is included in general and administrative expenses and lease expense related to ground leases is included within operating expenses in the Company's Consolidated Statements of Operations. For leases with a noncancellable lease term of 12 months or less for which the Company is the lessee, the Company recognizes expenses on a straight-line basis and does not recognize such leases on the Consolidated Balance Sheets. Impairment of Long-Lived Assets and Goodwill

The Company assesses the carrying value of real estate assets and related intangibles (other real assets) when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company tests its real estate assets for impairment by comparing the sum of the expected future undiscounted cash flows to the carrying value of the real estate assets. The expected future undiscounted cash flows reflect external market factors and the expected use and eventual disposition of the asset, and based on the specific facts and circumstances, may be probability-weighted to reflect multiple possible cash-flow scenarios, including selling the assets at various points in the future. Further, the analysis considers the impact, if any, of master lease agreements on cash flows, which are calculated utilizing the lowest level of identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. If the carrying value exceeds the expected future undiscounted cash flows, an impairment loss will be recognized to the extent that the carrying value of the real estate assets exceeds their fair value. Determining the fair value of real estate assets, including assets classified as held-for-sale, involves significant judgment and generally utilizes market capitalization rates, comparable market transactions, estimated per unit or per square foot prices, negotiations with prospective buyers, and forecasted cash flows (primarily lease revenue rates, expense rates, and growth rates). When testing goodwill for impairment, if the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company recognizes an impairment loss for the amount by which the carrying value, including goodwill, exceeds the reporting unit's fair value. Assets Held for Sale and Discontinued Operations

The Company classifies a real estate property as held for sale when: (i) management has approved the disposal, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposal plan will significantly change or be withdrawn. If a real estate property is classified as held for sale, it is reported at the lower of its carrying value or fair value less costs to sell and no longer depreciated. The Company classifies a loan receivable as held for sale when management no longer has the intent and ability to hold the loan receivable for the foreseeable future or until maturity. If a loan receivable is classified as held for sale, it is reported at the lower of amortized cost or fair value. A discontinued operation represents: (i) a component of the Company or group of components that has been disposed of or is classified as held for sale in a single transaction and represents a strategic shift that has or will have a major effect on the Company's operations and financial results or (ii) an acquired business that is classified as held for sale on the date of acquisition. Examples of a strategic shift may include disposing of: (i) a separate major line of business, (ii) a separate major geographic area of operations, or (iii) other major parts of the Company. Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 5 for further information.

Table of Contents

Investments in Unconsolidated Joint Ventures

Investments in entities the Company does not consolidate, but over which the Company has the ability to exercise significant influence over operating and financial policies, are reported under the equity method of accounting. Under the equity method of accounting, the Company's share of the investee's earnings or losses is included in equity income (loss) from unconsolidated joint ventures within

the Company’s Consolidated Statements of Operations. The initial carrying value of investments in unconsolidated joint ventures is based on the amount paid to purchase the joint venture interest, the fair value of assets contributed to the joint venture, or the fair value of the assets prior to the sale of interests in the joint venture. To the extent that the Company’s cost basis is different from the basis reflected at the joint venture level, the basis difference is generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of equity in earnings of the joint venture. If an equity method investment shows indicators of impairment, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the equity method investment to its carrying value. When the Company determines a decline in fair value below carrying value of an investment in an unconsolidated joint venture is other-than-temporary, an impairment is recorded. The Company recognizes gains on the sale of interests in joint ventures to the extent the economic substance of the transaction is a sale. The Company’s fair values of its equity method investments are determined based on discounted cash flow models that include all estimated cash inflows and outflows over a specified holding period and, where applicable, any estimated debt premiums or discounts. Capitalization rates, discount rates, and credit spreads utilized in these valuation models are based on assumptions that the Company believes to be within a reasonable range of current market rates for the respective investments. Stock-Based Compensation Compensation expense for share-based awards granted to employees with graded vesting schedules is generally recognized on a straight-line basis over the vesting period. Forfeitures of share-based awards are recognized as they occur. Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash on hand and short-term investments with original maturities of three months or less when purchased. Restricted cash primarily consists of amounts held by mortgage lenders to provide for: (i) real estate tax expenditures, (ii) tenant improvements, and (iii) capital expenditures, as well as security deposits and net proceeds from property sales that were executed as tax-deferred dispositions. The Company maintains its cash and cash equivalents at financial institutions insured by the Federal Deposit Insurance Corporation (the FDIC) up to \$250,000 per institution. As the account balances at each institution periodically exceed the FDIC insurance coverage, there is a concentration of credit risk related to amounts in excess of such coverage. Derivatives and Hedging During its normal course of business, the Company uses certain types of derivative instruments for the purpose of managing interest rate risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives that are required to be bifurcated, as assets or liabilities to the Consolidated Balance Sheets at fair value. Changes in fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in other income (expense), net. For derivative instruments designated in qualifying cash flow hedging relationships, changes in fair value related to the effective portion of the derivative instruments are recognized in accumulated other comprehensive income (loss), whereas changes in fair value related to the ineffective portion would be recognized in earnings. If it is determined that a derivative instrument ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, the Company discontinues its cash flow hedge accounting prospectively and records the appropriate adjustment to earnings based on the current fair value of the derivative instrument. 83Table of Contents Income Taxes Healthpeak Properties, Inc. has elected REIT status and believes it has always operated so as to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, as amended (the Code). Accordingly, Healthpeak Properties, Inc. will generally not be subject to U.S. federal income tax, provided that it continues to qualify as a REIT and makes distributions to stockholders equal to or in excess of its taxable income. In addition, the Company has formed several consolidated subsidiaries that have elected REIT status. Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are each subject to the REIT qualification requirements under the Code. If any REIT fails to qualify as a REIT in any taxable year, it will be subject to federal income taxes at regular corporate rates and may be ineligible to qualify as a REIT for four subsequent tax years. Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are subject to state and local income taxes in some jurisdictions. In certain circumstances each REIT may also be subject to federal excise taxes on undistributed income. In addition, certain activities that the Company undertakes may be conducted by entities that have elected to be treated as taxable REIT subsidiaries (TRSs). TRSs are subject to federal, state, and local income taxes. The Company recognizes tax penalties relating to unrecognized tax benefits as additional income tax expense. Interest relating to unrecognized tax benefits is recognized as interest expense. The Company is required to evaluate its deferred tax assets for realizability and recognize a valuation allowance, which is recorded against its deferred tax assets, if it is more likely than not that the deferred tax assets will not be realized. The Company considers all available evidence in its determination of whether a valuation allowance for deferred tax assets is required. Advertising Costs All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was \$9A million, \$8A million, and \$8A million, respectively. Capital Raising Issuance Costs Costs incurred in connection with the issuance of common shares are recorded as a reduction of additional paid-in capital. Debt issuance costs related to debt instruments, excluding line of credit arrangements and commercial paper, are deferred, recorded as a reduction of the related debt liability, and amortized to interest expense over the remaining term of the related debt liability utilizing the effective interest method. Debt issuance costs related to line of credit arrangements and commercial paper are deferred, included in other assets, and amortized to interest expense on a straight-line basis over the remaining term of the related line of credit arrangement. Commercial paper are unsecured short-term debt securities with varying maturities. A line of credit serves as a liquidity backdrop for repayment of commercial paper borrowings. Penalties incurred to extinguish debt and any remaining unamortized debt issuance costs, discounts, and premiums are recognized as income or expense in the Consolidated Statements of Operations at the time of extinguishment. Segment Reporting The Company’s reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. Noncontrolling Interests Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Net income (loss) attributable to a noncontrolling interest is included in net income (loss) on the Consolidated Statements of Operations and, upon a gain or loss of control, the interest purchased or sold, and any interest retained, is recorded at fair value with any gain or loss recognized in earnings. The Company accounts for purchases or sales of equity interests that do not result in a change in control as equity transactions. Redeemable Noncontrolling Interests Certain of the Company’s noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time. Each put option is payable in cash and subject to increases in redemption value in the event that the underlying property generates specified returns and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period. 84Table of Contents Healthpeak OP Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, certain employees of the Company (the OP Unitholders) were issued noncontrolling, non-managing member units in Healthpeak OP (the OP Units). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. DownREITs The Company consolidates non-managing member limited liability companies (the DownREITs) because it exercises control, and the noncontrolling interests in these entities are carried at cost. The non-managing member limited liability company (the LLC) units (the DownREIT units) are exchangeable for an amount of cash approximating the then-current market value of shares of the Company’s common stock or, at the Company’s option, shares of the Company’s common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company’s common stock, the carrying amount of the DownREIT units is reclassified to stockholders’ equity. Fair Value Measurement The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: Level 1 quoted prices for identical instruments in active markets; Level 2 quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and Level 3 fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities that are required to be measured at fair value. When available, the Company utilizes quoted market prices to determine fair value and classifies such items in Level 1. In instances where a market price is available, but the instrument is in an inactive or over-the-counter market, the Company consistently applies the dealer (market maker) pricing estimate and classifies the asset or liability in Level 2. If quoted market prices or inputs are not available, fair value measurements are based on valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads, and/or market capitalization rates. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, the asset or liability could be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques used by the Company include discounted cash flow models. The Company also considers its counterparty’s and own credit risk for derivative instruments and other liabilities measured at fair value. The Company has elected the mid-market pricing expedient when determining fair value. Earnings per Share Basic earnings per common share is computed by dividing net income (loss) applicable to common shares by the weighted average number of shares of common stock outstanding during the period. The Company accounts for unvested share-based payment awards that contain non-forfeitable dividend rights or dividend equivalents (whether paid or unpaid) as participating securities, which are included in the computation of earnings per share pursuant to the two-class method. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units. 85Table of Contents Recent Accounting Pronouncements Adopted Segment Reporting. In November 2023, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (the ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (the ASU 2023-07), to improve reportable segment disclosure requirements so that investors can better understand an entity’s overall performance and assess potential future cash flows. The amendments in ASU 2023-07 include, but are not limited to: (i) disclosure of, on an annual basis, significant segment expenses that are regularly provided to the chief operating decision maker (the CODM) and included within each reported measure of segment profit or loss; (ii) disclosure of, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition (the other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss); (iii) disclosure of, on an interim basis, all currently required annual disclosures about a reportable segment’s profit (loss) and assets; (iv) clarification that if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, an entity may report one or more of those additional measures of segment profit; and (v) disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. During the year ended December 31, 2024, the amendments in ASU 2023-07 were adopted retrospectively and did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows. Not Yet Adopted Income Taxes. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (the ASU 2023-09), to provide disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation (using both percentages and reporting currency amounts) of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is evaluating the impact ASU 2023-09 will have on its disclosures. Expense Disaggregation. In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (the ASU 2024-03), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact these ASUs will have on its disclosures. 86Table of Contents NOTE 3. The Merger On March 1, 2024 (the Closing Date), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the Merger Agreement), by and among the Company, DOC DR Holdco, LLC, a wholly owned subsidiary of the Company (the DOC DR Holdco), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (the DOC DR OP Sub), Physicians Realty Trust, and Physicians Realty L.P. (the Physicians Partnership): (i) Physicians Realty Trust merged with and into DOC DR Holdco (the Company Merger), with DOC DR Holdco surviving as a wholly owned subsidiary of the Company (the Company Surviving Entity); (ii) immediately following the effectiveness of the Company Merger, the Company contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the Contribution); and (iii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the Partnership Merger) and, together with the Company Merger, the Merger, with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP (the Partnership Surviving Entity). Subsequent to the Closing Date, the Combined Company means the Company and its subsidiaries. On the Closing Date and in connection with the Merger, (i) each outstanding common share of beneficial interest of Physicians Realty Trust (the Physicians Realty Trust common shares) (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) was automatically converted into the right to receive 0.674 (the Exchange Ratio) shares of the Company’s common stock, and (ii) each outstanding common unit of the Physicians Partnership was converted into common units in the Partnership Surviving Entity equal to the Exchange Ratio. As a result of the Merger, the Company acquired 299 outpatient medical buildings. The primary reason for the Merger was to expand the Company’s size, scale, and diversification, in order to further enhance the Company’s competitive advantages and accelerate investment activities. The Merger was accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, which requires, among other things, the assets acquired and the liabilities assumed to be recognized at their acquisition date fair value. For accounting purposes, the Company was treated as the accounting acquirer of Physicians Realty Trust. The Company was considered to be the accounting acquirer primarily because: (i) the Company is the entity that transferred consideration to consummate the Merger; (ii) the Company’s stockholders as a group retained the largest portion of the voting rights of the Combined Company and have the ability to elect, appoint, or remove a majority of the members of the Combined Company’s board of directors; and (iii) its senior management constitutes the majority of management of the Combined Company. 87Table of Contents The consideration transferred on the Closing Date is as follows (in thousands, except per share data): March 1, 2024 Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged (1) 240,699 Exchange Ratio 0.674 Shares of Healthpeak common stock issued 162,231 Closing price of Healthpeak common stock on March 1, 2024 (2) \$17.10A fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and

RSUs\$2,774,147\$ Less: Fair value of share consideration attributable to the post-combination period(3)(16,223)Physicians Realty Trust revolving credit facility termination(4)\$175,411 Settlement of Physicians Realty Trust\$™'s transaction costs23,913\$ Payments made in connection with share settlement(5)11,315\$ Cash consideration\$210,639\$ Consideration transferred\$2,968,563\$ (1)Includes 241\$ million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares; (ii) 1\$ million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (â€œPSUsâ€) (reflected at the maximum level of performance); and (iii) 300\$ thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (â€œRSUsâ€).(2)The fair value of Healthpeak common stock issued to former holders of Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs was based on the per share closing price of Healthpeak common stock on March 1, 2024.(3)Represents the fair value of unvested Physicians Realty Trust restricted shares, PSUs, and RSUs attributable to post-combination services that were converted into Healthpeak common stock on the Closing Date in accordance with the Merger Agreement. Although no future service after the Closing Date is required, the value attributable to post-combination services reflected the incremental fair value provided to the Physicians Realty Trust equity award holders and the accelerated vesting of such awards at the Closing Date in accordance with the Merger Agreement. This amount was recognized as transaction and merger-related costs on the Consolidated Statements of Operations.(4)Represents the Companyâ€™'s cash repayment of all outstanding balances under Physicians Realty Trustâ€™'s revolving credit facility on the Closing Date in connection with the related termination.(5)Includes cash settlement of: (i) tax liability related to holdback elections made under the pre-existing terms and conditions of Physicians Realty Trustâ€™'s equity programs and (ii) fractional share consideration.Purchase Price AllocationFor the Companyâ€™'s real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests were based on information that was available at the Closing Date. The fair values were determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant.88Table of ContentsThe following table summarizes the estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests at the Closing Date (in thousands):Preliminary Amounts Recognized on the Closing DateMeasurement Period AdjustmentsAmounts Recognized on the Closing Date (As Adjusted)ASSETS\$ Real estate:\$ Buildings and improvements\$3,199,884\$ (\$6,889)\$3,192,995\$ Development costs and construction in progress68,171\$ â€”\$ 68,171\$ Land and improvements435,353\$ â€”\$ 435,353\$ Real estate\$3,703,408\$ (6,889)\$3,696,519\$ Loans receivable118,908\$ â€”\$ 118,908\$ Investments in and advances to unconsolidated joint ventures58,636\$ â€”\$ 58,636\$ Accounts receivable, net(1)9,536\$ (254)9,282\$ Cash and cash equivalents30,417\$ â€”\$ 30,417\$ Restricted cash1,007\$ â€”\$ 1,007\$ Intangible assets(2)890,827\$ â€”\$ 890,827\$ Right-of-use asset191,415\$ (113)191,302\$ Other assets44,691\$ (668)44,023\$ Total assets\$5,048,845\$ (9,724)\$5,040,921\$ LIABILITIES AND EQUITY\$ Term loans\$402,320\$ â€”\$ 402,320\$ Senior unsecured notes1,139,760\$ â€”\$ 1,139,760\$ Mortgage debt127,176\$ â€”\$ 127,176\$ Intangible liabilities(3)149,875\$ â€”\$ 149,875\$ Lease liability\$97,160\$ (113)97,047\$ Accounts payable, accrued liabilities, and other liabilities72,864\$ (2,976)69,888\$ Total liabilities\$1,989,155\$ (3,089)\$1,986,066\$ Redeemable noncontrolling interests1,536\$ 1,573\$ 3,109\$ Joint venture partners(4)20,109\$ (3,043)17,066\$ Non-managing member unitholders(5)116,618\$ â€”\$ 116,618\$ Total noncontrolling interests\$136,727\$ (3,043)\$133,684\$ Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests\$2,921,427\$ (\$3,365)\$2,918,062\$ Goodwill147,136\$ 3,365\$ 50,501\$ Total purchase price\$2,968,563\$ â€”\$ 2,968,563\$ (1)Includes \$14\$ million of gross contractual accounts receivable.(2)The intangible assets acquired had a weighted average amortization period of 6 years (see Note 10).(3)The intangible liabilities acquired had a weighted average amortization period of 9 years (see Note 10).(4)Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7% to 99.7% on the Closing Date.(5)In connection with the Merger, Physicians Partnership merged with and into DOC DR OP Sub with DOC DR OP Sub surviving as the Partnership Surviving Entity. The Company controls the Partnership Surviving Entity via its ownership of its managing member, and the Partnership Surviving Entity is consolidated by the Company.The measurement period adjustments recorded through December 31, 2024 are final and were primarily the result of additional information obtained during the measurement period by the Company related to certain assets acquired and liabilities assumed and updated valuations of noncontrolling interests, resulting in an increase to goodwill of \$3\$ million. 89Table of ContentsBased on the final purchase price allocation of fair value, approximately \$51\$ million has been allocated to goodwill. The recognized goodwill is attributable to expected synergies, cost savings, acquired workforce, and potential economies of scale benefits from outpatient medical property management and tenant and vendor relationships following the closing of the Merger. None of the goodwill recognized is expected to be deductible for tax purposes.Merger-Related CostsDuring the year ended December 31, 2024, the Company incurred approximately \$129\$ million of merger-related costs, which primarily related to advisory, legal, accounting, tax, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust. Included in this amount is: (i) \$38\$ million of fees paid to investment banks and advisors to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters, inclusive of \$21\$ million of success-based fees incurred upon consummation of the Merger, (ii) \$26\$ million of severance expense due to certain Physicians Realty Trust dual-trigger severance arrangements that are required to be recognized as post-combination expense in accordance with ASC 805, (iii) \$16\$ million of post-combination stock compensation expense for the accelerated vesting of Physicians Realty Trust equity awards pursuant to the terms of the Merger Agreement, based on the fair value of Healthpeak common stock issued to holders of Physicians Realty Trust equity awards, (iv) \$35\$ million of legal, accounting, tax, and other costs, and (v) \$13\$ million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately \$11\$ million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations.Unaudited Pro Forma Financial InformationThe Consolidated Statements of Operations for the year ended December 31, 2024 include \$473\$ million of revenues and \$6\$ million of net loss applicable to common shares associated with the results of operations of legacy Physicians Realty Trust from the Closing Date to December 31, 2024.The following unaudited pro forma information presents a summary of the results of operations for the Combined Company, as if the Merger had been consummated on January 1, 2023 (in thousands). The following unaudited pro forma financial information is not necessarily indicative of the results of operations had the acquisition been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the unaudited pro forma financial information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.\$ Year EndedDecember 31, 20242023Total revenues\$2,765,670\$ 2,771,468\$ Net income (loss) applicable to common shares353,347\$ 24,630\$ The unaudited pro forma financial information above includes nonrecurring significant adjustments made to account for certain costs incurred as if the Merger had been completed on January 1, 2023. Transaction and merger-related costs of \$129\$ million that were incurred during the year ended December 31, 2024, were excluded from the unaudited pro forma financial information for the year ended December 31, 2024, but included for the year ended December 31, 2023. The year ended December 31, 2023 also includes \$11\$ million of transaction and merger-related costs that were recognized during the year then ended.NOTE 4. Real Estate Investments2024 Real Estate Investment AcquisitionsThe MergerAs a result of the Merger, the Company acquired 299 outpatient medical buildings (see Note 3).2023 Real Estate Investment Acquisitions60 Loomis Land ParcelIn January 2023, the Company acquired a lab land parcel in Cambridge, Massachusetts for \$9\$ million.90Table of ContentsWylie Outpatient Medical BuildingIn April 2023, the Company acquired the remaining 80% interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for \$4\$ million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of \$0.2\$ million, which is recorded in other income (expense), net during the year ended December 31, 2023.2022 Real Estate Investment Acquisitions 67 Smith Placeln January 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for \$72\$ million.Vista Sorrento Phase IIIn January 2022, the Company closed a lab acquisition in San Diego, California for \$24\$ million.Webster Outpatient Medical PortfolioIn March 2022, the Company acquired a portfolio of two outpatient medical buildings in Houston, Texas for \$43\$ million. Northwest Medical Plazaln May 2022, the Company acquired one outpatient medical building in Bentonville, Arkansas for \$26\$ million.Concord Avenue Land ParcelIn December 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for \$18\$ million.Development ActivitiesConstruction, Tenant, and Other Capital ImprovementsThe following table summarizes the Companyâ€™'s expenditures for construction, tenant improvements, and other capital improvements for its consolidated property investments, excluding expenditures related to properties classified as discontinued operations (in thousands): \$ Year Ended December 31, Segment202420232022Outpatient medical\$356,273\$ 236,135\$ 237,761\$ Lab313,749\$ 428,961\$ 658,542\$ CCRC66,741\$ 109,465\$ 65,691\$ 736,763\$ 774,561\$ 961,994\$ NOTE 5. \$ \$ \$ Dispositions of Real Estate and Discontinued Operations2024 Dispositions of Real EstateDuring the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for \$674\$ million and provided the buyer with a mortgage loan secured by the real estate sold for \$405\$ million (see Note 8), (ii) 14 outpatient medical buildings for \$220\$ million, (iii) a portfolio of seven lab buildings for \$180\$ million, (iv) a portfolio of two outpatient medical buildings for \$23\$ million and provided the buyer with a mortgage loan secured by the real estate sold for \$14\$ million (see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Companyâ€™'s CCRC campuses for \$12\$ million, resulting in total net gain on sales of \$179\$ million.2023 Dispositions of Real EstateDuring the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for \$113\$ million and two outpatient medical buildings for \$32\$ million, resulting in total gain on sales of \$81\$ million.2022 Dispositions of Real EstateDuring the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for \$14\$ million and five outpatient medical buildings and one outpatient medical land parcel for \$36\$ million, resulting in total gain on sales of \$15\$ million.91Table of ContentsHeld for Sale and Discontinued OperationsAs of December 31, 2024, one outpatient medical building was classified as held for sale, with a carrying value of \$8\$ million, primarily comprised of net real estate assets. As of December 31, 2024, liabilities related to the asset held for sale were zero. As of December 31, 2023, two lab buildings and one outpatient medical building were classified as held for sale, with a carrying value of \$118\$ million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were \$1\$ million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65% interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein. The Company has successfully completed the disposition of its senior housing triple-net and SHOP properties.At each of December 31, 2024 and 2023, the total assets and total liabilities classified as discontinued operations were zero. The results of discontinued operations during the years ended December 31, 2024, 2023, and 2022 are presented below (in thousands) and are included in the consolidated results of operations for the years ended December 31, 2024, 2023, and 2022.\$ Year Ended December 31, 202420232022Revenues:Resident fees and services\$â€”\$ 3\$ 4\$ 7,489\$ Total revenues\$â€”\$ 3\$ 4\$ 7,489\$ Costs and expenses:Operating\$â€”\$ 6\$ 4\$ 6,452\$ Total costs and expenses\$â€”\$ 6\$ 4\$ 6,452\$ Other income (expense):Gain (loss) on sales of real estate, net\$â€”\$ 1\$ 1,344\$ Other income (expense), net\$â€”\$ 1\$ 169\$ Total other income (expense), net\$â€”\$ 1\$ 1,513\$ Other income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures\$â€”\$ 2\$ 2,550\$ Income tax benefit (expense)\$â€”\$ 2\$ 270\$ Equity income (loss) from unconsolidated joint ventures\$â€”\$ 6\$ 4\$ Income (loss) from discontinued operations\$â€”\$ 3\$ 2\$ 2,884\$ NOTE 6. \$ \$ \$ Impairments of Real EstateImpairment ChargesDuring the year ended December 31, 2024, the Company recognized an impairment charge of \$13\$ million, which is reported in impairments and loan loss reserves (recoveries), net, on the Consolidated Statements of Operations related to one outpatient medical building that met the held for sale criteria. Upon classifying the asset as held for sale, the Company recognized an impairment charge to write down the buildingâ€™'s carrying value of \$21\$ million to its fair value, less estimated costs to sell, of \$8\$ million. The fair value of the impaired asset was based on the forecasted sales price which is considered to be a Level 3 measurement within the fair value hierarchy. The Companyâ€™'s fair value estimates primarily relied on a market approach, which utilized comparable market transactions and negotiations with prospective buyers.During the years ended December 31, 2023 and 2022, the Company did not recognize any impairment charges.92Table of ContentsCasualty-Related ChargesDuring the years ended December 31, 2024, 2023, and 2022, the Company recognized \$30\$ million, \$(3)\$ million, and \$6\$ million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to damages as a result of Hurricane Milton, partially offset by recoveries from proceeds received for water damage at an outpatient medical building during the year then ended. During the year ended December 31, 2023, such recoveries were primarily attributable to proceeds received for water damage at an outpatient medical building. During the year ended December 31, 2022, such charges were primarily attributable to damages as a result of Hurricane Ian. Casualty-related charges are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. Also during the years ended December 31, 2024, 2023, and 2022, the Company collected business interruption proceeds of \$0.7\$ million, \$44\$ million, and \$3\$ million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations.Other LossesDuring the year ended December 31, 2022, the Company recognized \$14\$ million of expenses within other income (expense), net on the Consolidated Statements of Operations for tenant relocation and other costs associated with the demolition of an outpatient medical building.See Note 8 for information related to the Companyâ€™'s reserve for loan losses.NOTE 7. \$ \$ \$ LeasesLease IncomeThe following table summarizes the Companyâ€™'s lease income (in thousands): \$ Year Ended December 31, 202420232022Fixed income from operating leases\$1,530,493\$ 1,236,502\$ 1,182,463\$ Variable income from operating leases\$556,703\$ 395,303\$ 359,312\$ Interest income from direct financing leases\$â€”\$ 1,168\$ 1,168\$ Direct Financing Leases 2022 Direct Financing Lease SaleDuring the first quarter of 2022, the Company sold its remaining hospital under a DFL for \$68\$ million and recognized a gain on sale of \$23\$ million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL.Operating LeasesFuture Minimum RentsThe following table summarizes future minimum lease payments to be received from tenants under non-cancelable operating leases as of December 31, 2024 (in thousands):YearAmount2025\$1,427,402\$ 20261,339,275\$ 20271,246,068\$ 20281,138,062\$ 20291,003,394\$ Thereafter3,681,731\$ 9,835,932\$ 93Table of ContentsTenant Purchase OptionsCertain leases contain purchase options whereby the tenant may elect to acquire the underlying real estate. Annualized base rent from leases subject to purchase options, summarized by the year the purchase options are exercisable are as follows (dollars in thousands):YearAnnualizedBase\$ Rent(1)Number\$oProperties2025\$16,109\$ 12\$ 202619,071\$ 8\$ 20278,415\$ 4\$ 202816,209\$ 5\$ 20296,053\$ 7\$ Thereafter22,364\$ 9\$ 88,221\$ 45\$ _____ the most recent monthâ€™'s base rent including additional rent floors annualized for 12 months. Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., \$ straight-line rents, amortization of market lease intangibles, and deferred revenues).Lease CostsThe following tables provide information regarding the Companyâ€™'s leases to which it is the lessee, such as corporate offices and ground leases, excluding lease costs related to discontinued operations (dollars in thousands):Year Ended December 31,Lease Expense Information:202420232022Total lease expense\$2,768\$ 17,010\$ 16,689\$ Weighted Average Lease Term and Discount Rate:December 31,2024December 31,2023Weighted average remaining lease term (years):Operating leases(1)4851\$ Weighted average discount rate:Operating leases4.79\$ 4.23\$ % (1)As of December 31, 2024 and 2023, the weighted average remaining lease term including the Companyâ€™'s options to extend its operating leases was 66 years and 67 years, respectively.The following table summarizes future minimum lease payments under non-cancelable ground and other operating leases included in the Companyâ€™'s lease liability as of December 31, 2024 (in thousands):YearAmount2025\$21,514\$ 202618,423\$ 202718,434\$ 202818,489\$ 202918,687\$ Thereafter738,666\$ Undiscounted minimum lease payments included in the lease liability834,213\$ Less: imputed interest(526,993)\$ Present value of lease liability\$307,220\$ 94Table of ContentsDepreciation ExpenseWhile the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes.

were in the Ventures IV unconsolidated joint venture for \$4.4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. At December 31, 2024 and 2023, the aggregate unamortized basis difference of the Company's investments in unconsolidated joint ventures of \$424 million and \$494 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint ventures and capitalized interest related to the redevelopment activities at the South San Francisco JVs. The differences are amortized over the remaining useful lives of the related assets and are included in equity income (loss) from unconsolidated joint ventures. 100Table of ContentsSouth San Francisco JVs On August 1, 2022, the Company sold a 30% interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (the "SWF Partner") for cash of \$126.4 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70% investment in the South San Francisco joint ventures (the "South San Francisco JVs") at fair value, and accounting for its investment using the equity method. The fair values of the Company's retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of \$311.1 million, which is recorded in other income (expense), net. The Company is entitled to a preferred return, a promote, and certain fees in exchange for development and asset management services provided to the South San Francisco JVs when certain conditions are met. Callan Ridge JV In January 2024, the Company sold a 65% interest in two lab buildings in San Diego, California (the "Callan Ridge JV") to a third-party (the "JV Partner") for net proceeds of \$128.4 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35% investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company's retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of \$78.4 million, which is recorded in other income (expense), net. 10.0 A A A Intangibles Intangible assets primarily consist of lease-up intangibles and above market lease intangibles. The following table summarizes the Company's intangible lease assets (dollars in thousands):

	December 31, 2024	December 31, 2023
Gross intangible lease assets	\$1,468,985	\$739,228
Accumulated depreciation and amortization	(2,651,731)	(425,072)
Intangible assets, net	\$817,254	\$314,156

Weighted average remaining amortization period in years: 5.5 (2024) and 5.2 (2023)

(1) As of December 31, 2024 and 2023, includes \$1.424 billion and \$725.4 million, respectively, of gross lease-up intangibles and \$45.4 million and \$14.4 million, respectively, of gross above market lease intangibles. (2) As of December 31, 2024 and 2023, includes \$640.4 million and \$418.4 million, respectively, of accumulated depreciation and amortization on lease-up intangibles and \$12.4 million and \$7.4 million, respectively, of accumulated depreciation and amortization on above market lease intangibles. Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company's intangible lease liabilities (dollars in thousands):

	December 31, 2024	December 31, 2023
Gross intangible lease liabilities	\$351,602	\$228,105
Accumulated depreciation and amortization	(159,718)	(100,725)
Intangible liabilities, net	\$191,884	\$127,380

Weighted average remaining amortization period in years: 9.7 (2024) and 10.1 (2023)

Table of Contents The following table sets forth amortization related to intangible assets, net and intangible liabilities, net (in thousands):

	Year Ended December 31, 2024	Year Ended December 31, 2023
Depreciation and amortization expense related to amortization of lease-up intangibles	\$273,146	\$102,249
Rental and related revenues related to amortization of net below market lease liabilities	\$62,894	\$27,012
On the Closing Date of the Merger, the Company acquired intangible assets of \$891.1 million, inclusive of \$852.4 million of lease-up intangibles and \$39.4 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of \$150 million (see Note 3). The intangible assets and liabilities acquired had a weighted average amortization period at acquisition of 6 years and 9 years, respectively. During the year ended December 31, 2023, in conjunction with the Company's acquisition of real estate, the Company acquired \$0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years. The following table summarizes the estimated annual amortization for each of the five succeeding fiscal years and thereafter (in thousands):		
Rental and Related Revenues	\$256,925	\$262,629
Depreciation and	\$171,520	\$272,304
Amortization	\$253,618	\$256,925

On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of \$51.1 million, which was allocated to the Company's outpatient medical segment (see Note 3). Goodwill is included in other assets, net on the Consolidated Balance Sheets. At December 31, 2024 and 2023, goodwill was allocated to the Company's segment assets as follows (in thousands):

	December 31, 2024	December 31, 2023
Outpatient medical	\$64,680	\$14,178
Other non-reportable	\$1,851.1	\$68,529

During the years ended December 31, 2024, 2023, and 2022, the fair value of the assets within each of the Company's reporting units was greater than the respective carrying value of the assets and related goodwill, and as a result, no impairment charges were recognized. 11.0 A A A Debt Healthpeak OP, the Company's consolidated operating subsidiary, is the borrower under, and the Company, DOC DR Holdco, and DOC DR OP Sub are the guarantors of, the Revolving Facility, 2027 Term Loans, 2029 Term Loan, Commercial Paper Program (each as defined below), and senior unsecured notes issued by the Company prior to the Merger. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan (as defined below) and senior unsecured notes issued by the Physicians Partnership prior to, and assumed by the Company as part of, the Merger. Guarantees of senior unsecured notes are full and unconditional and applicable to existing and future senior unsecured notes. 10.2 Table of Contents The Merger On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of \$400.1 million (the "2028 Term Loan") that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as borrower, and the other parties thereto. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan. In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub's credit ratings as of December 31, 2024, the 2028 Term Loan had a blended fixed effective interest rate of 4.44%, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments. Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85% to 1.65% for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company's credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was 1.00%. Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership's \$1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) \$400.1 million aggregate principal amount of 4.30% senior unsecured notes due 2027, (ii) \$350.1 million aggregate principal amount of 3.95% senior unsecured notes due 2028, and (iii) \$500.1 million aggregate principal amount of 2.63% senior unsecured notes due 2031. On the Closing Date, the Company capitalized \$1.1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP's previously issued senior unsecured notes, as further described below. Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed \$128.4 million aggregate principal of mortgage debt (see Note 3), which was secured by five outpatient medical buildings, with an aggregate carrying value of \$259.4 million as of March 1, 2024. Of this \$128.4 million, \$59.4 million was fixed rate debt with a weighted average contractual interest rate of 3.77% and maturities ranging from November 2024 through December 2026 and \$69.4 million was variable rate debt with a weighted average contractual interest rate of 7.25% and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of \$0.5 million on the \$128.4 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one related interest rate swap instrument with a notional amount of \$36.4 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024. 10.3 Table of Contents Bank Line of Credit and Term Loans Revolving Facility On May 23, 2019, the Company executed a \$2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the "Revolving Facility") to increase total revolving commitments from \$2.5 billion to \$3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP's obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company's senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company's credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was 0.88% and the facility fee was 0.15%. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to \$750.1 million, subject to securing additional commitments. At each of December 31, 2024 and 2023, the Company had no balance outstanding under the Revolving Facility. Term Loan Agreement On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the "Term Loan Agreement") that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to \$500.1 million (the "2027 Term Loans"). The 2027 Term Loans were available to be drawn from time to time during a 180-day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the \$500.1 million under the 2027 Term Loans in October 2022. \$250.1 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other \$250.1 million of the 2027 Term Loans has a stated maturity of five years with no option to extend. Loans outstanding under the 2027 Term Loans accrue interest at Term SOFR plus a margin that depends on the credit ratings of the Company's senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01% based on the Company's achievement of specified sustainability-linked metrics. Based on the Company's credit ratings as of December 31, 2024, and inclusive of achievement of a sustainability-linked metric and an adjustment related to SOFR transition, the margin on the 2027 Term Loans was 0.94%. In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges

requires maintenance of the assets in good condition, includes conditions to obtain lender consent to enter into or terminate material leases, requires insurance on the assets, requires payment of real estate taxes, restricts transfer of the encumbered assets and repayment of the loan, and prohibits additional liens. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.105Table of ContentsDuring the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of \$27.4 million, \$90 million, and \$5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the \$27.4 million of aggregate principal payments of mortgage debt for the year ended December 31, 2024 was a \$23.4 million full principal repayment of mortgage debt secured by one outpatient medical building acquired as part of the Merger that matured in November 2024. Included in the \$90.4 million of aggregate principal repayments of mortgage debt for the year ended December 31, 2023 was an \$85.4 million full principal repayment of mortgage debt secured by one CCRC that matured in December 2023. The Company has \$142.4 million of mortgage debt secured by a portfolio of 13 outpatient medical buildings that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026. In February 2023, the agreements associated with this variable rate mortgage debt were amended to change the interest rate benchmarks from LIBOR to SOFR, effective March 2023. Concurrently, the Company modified the related interest rate swap instruments to reflect the change in the interest rate benchmarks from LIBOR to SOFR (see Note 22). The variable rate mortgage debt associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument. Debt MaturitiesThe following table summarizes the Company's stated debt maturities and scheduled principal repayments at December 31, 2024 (dollars in thousands): Senior Unsecured Notes (3) Mortgage Debt (4) Year Bank Line of Credit (1) Commercial Paper (1) (2) Term Loans Amount Interest Rate (5) Amount Interest Rate (5) Total 2025 \$ 4.0 \$ 4.0 \$ 800,000 3.92% \$ 7,432.4 6.28% \$ 807,432.4 2026 \$ 4.0 \$ 4.0 \$ 650,000 3.40% \$ 344,999.4 5.13% \$ 994,999.4 2027 \$ 4.0 \$ 4.0 \$ 500,000 850,000 3.23 (discounts), and debt issuance costs, net \$ 13,395.7 (136,744) 702.4 (139,999) \$ 150,000 1,646,043.4 \$ 6,563,256.4 \$ 356,750.4 \$ 8,716,049.4 (1) As of December 31, 2024, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were \$18.4 million, which are recorded in other assets, net on the Consolidated Balance Sheets. (2) Commercial Paper Program borrowings are backstopped by the availability under the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility. (3) Effective interest rates on the senior unsecured notes range from 1.54% to 6.87% with a weighted average effective interest rate of 3.96% and a weighted average maturity of approximately 5 years. (4) Effective interest rates on the mortgage debt range from 3.44% to 8.50% with a weighted average effective interest rate of 5.16% and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt. (5) Represents the weighted-average effective interest rate as of the end of the applicable period, including amortization of debt premiums (discounts) and debt issuance costs. NOTE 12.4.1 Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company's business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's financial condition, results of operations, or cash flows. The Company's policy is to expense legal costs as they are incurred. 106 Table of Contents DownREITs and Other Partnerships In connection with the formation of DownREITs, members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code (the "make-whole payments"). These make-whole payments include a tax gross-up provision. As of December 31, 2024, the Company had indemnification agreements on a total of 41 properties within its DownREITs. In January 2025, indemnification agreements on 13 properties expired. Additionally, the Company owns a 49% interest in the Lab JV (see Note 9). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the contribution to the joint venture. Commitments The following table summarizes the Company's material commitments, excluding obligations as the lessee under operating leases (see Note 7), commitments to fund additional loans for outpatient medical capital expenditure projects (see Note 8), debt service obligations (see Note 11), and potential future obligations related to redeemable noncontrolling interests (see Note 13) at December 31, 2024 (in thousands): Amount Development and redevelopment commitments (1) \$ 199,139.4 Lease and other contractual commitments (2) 84,654.4 Letters of credit (3) 11,929.4 \$ 295,722.4 (1) Represents construction and other commitments as of December 31, 2024 for developments and redevelopments in progress and includes allowances for Company-owned tenant improvements that the Company has provided as a lessor. (2) Represents the Company's commitments, as lessor, under signed leases and contracts for operating properties as of December 31, 2024 and includes allowances for Company-owned tenant improvements and leasing commissions. Excludes allowances for Company-owned tenant improvements related to developments and redevelopments in progress for which the Company has executed an agreement with a general contractor to complete the tenant improvements (recognized in the "Development and redevelopment commitments" line). (3) Represents 15 outstanding letter of credit obligations expiring in 2025 and one outstanding letter of credit obligation expiring in 2026. Environmental Costs Various environmental laws govern certain aspects of the ongoing management and operation of our facilities, including those related to presence of asbestos-containing materials. The presence of, or the failure to manage and/or remediate, such materials may adversely affect the occupancy and performance of the Company's facilities. The Company monitors its properties for the presence of such hazardous or toxic substances and is not aware of any environmental liability with respect to the properties that would have a material adverse effect on the Company's business, financial condition, or results of operations. The Company carries environmental insurance and believes that the policy terms, conditions, limitations, and deductibles are adequate and appropriate under the circumstances, given the relative risk of loss, the cost of such coverage, and current industry practice. General Uninsured Losses The Company obtains various types of insurance to mitigate the impact of property, business interruption, liability, workers' compensation, flood, windstorm, earthquake, environmental, cyber, and terrorism related losses. The Company attempts to obtain appropriate policy terms, conditions, limits, and deductibles considering the relative risk of loss, the cost of such coverage, and current industry practice. There are, however, certain types of extraordinary losses, such as those due to acts of war or other events that may be either uninsurable or not economically insurable. In addition, the Company has a large number of properties that are exposed to earthquake, flood, and windstorm occurrences for which the related insurances carry high deductibles and have limits. 107 Table of Contents NOTE 13.4.1 Equity and Redeemable Noncontrolling Interests Dividends On February 3, 2025, the Company's Board of Directors declared a quarterly common stock cash dividend of \$0.305 per share, reflecting an increase from \$0.30 to \$0.305 per share. The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025. During each of the years ended December 31, 2024, 2023, and 2022, the Company declared and paid a common stock cash dividend of \$1.20. Issuance of Common Stock in Connection with the Merger Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) automatically converted into the right to receive 0.674 shares of the Company's common stock. Based on the number of outstanding Physicians Realty Trust common shares as of the Closing Date, the Company issued 162.4 million shares of common stock. Refer to Note 3 for additional information regarding the Merger. At-The Market Equity Offering Program In February 2023, in connection with the Reorganization, the Company terminated the previous at-the-market equity offering program (as amended from time to time, the "2020 ATM Program") and established a new at-the-market equity offering program (the "2023 ATM Program" and, together with the 2020 ATM Program, the "ATM Programs"). The 2023 ATM Program was amended in March 2024 to contemplate the sale of the remaining shares of common stock pursuant to the Company's Registration Statement on Form S-3 filed with the SEC on February 8, 2024. The ATM Programs allow for the sale of shares of common stock having an aggregate gross sales price of up to \$1.5 billion (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an "ATM forward contract"). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract becomes effective, but defer receiving the proceeds from the sale of shares until a later date. ATM forward contracts generally have a one- to two-year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company's election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers' stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract. At December 31, 2024, 1.5 billion of the Company's common stock remained available for sale under the 2023 ATM Program. ATM Forward Contracts During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of \$35.25 per share, after commissions. In December 2022, the Company settled all 9.1 million shares previously outstanding under ATM forward contracts at a weighted average net price of \$34.01 per share, after commissions, resulting in net proceeds of \$308 million. During the years ended December 31, 2024, 2023, and 2022 the Company did not utilize the forward provisions under the ATM Programs. ATM Direct Issuances During each of the years ended December 31, 2024, 2023, and 2022, there were no direct issuances of shares of common stock under the ATM Programs. 108 Table of Contents Share Repurchase Programs On August 1, 2022, the Company's Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of \$500.4 million (the "2022 Share Repurchase Program"). Purchases of common stock under the 2022 Share Repurchase Program could be exercised at the Company's discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. Under Maryland General Corporation Law, outstanding shares of common stock acquired by a corporation become authorized but unissued shares, which may be re-issued. During the year ended December 31, 2022, the Company repurchased 2.1 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of \$27.16 per share for a total of \$56.4 million. During the year ended December 31, 2023, there were no repurchases under the 2022 Share Repurchase Program. During the year ended December 31, 2024, the Company repurchased 10.5 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of \$17.98 per share for a total of \$188.4 million. On July 24, 2024, the Company's Board of Directors approved a new share repurchase program (the "2024 Share Repurchase Program") to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Program, no further share repurchases may be made pursuant to the 2022 Share Repurchase Program. Under the 2024 Share Repurchase Program, the Company may acquire shares of its common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of \$500.4 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at the Company's discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. As of December 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program. Therefore, at December 31, 2024, \$500.4 million of the Company's common stock remained available for repurchase under the 2024 Share Repurchase Program. Other Common Stock Activities The following table summarizes the Company's other common stock activities (in thousands): Year Ended December 31, 2024 2023 2022 Dividend reinvestment and stock purchase plan \$ 57.4 \$ 70.4 \$ 59.4 Conversion of DownREIT units 256.4 72.4 27.4 Vesting of restricted stock units 377.4 613.4 820.4 Repurchase of common stock 10,592.4 241.4 2,418.4 Accumulated Other Comprehensive Income (Loss) The following table summarizes the Company's accumulated other comprehensive income (loss) (in thousands): A December 31, 2024 2023 Unrealized gains (losses) on derivatives, net \$ 30,707.4 \$ 21,245.4 Supplemental Executive Retirement Plan minimum liability (1,889) (1,874) Total accumulated other comprehensive income (loss) \$ 28,818.4 \$ 19,371.4 The Company has a defined benefit pension plan, known as the Supplemental Executive Retirement Plan, with one plan participant, a former Chief Executive Officer (the "CEO") of the Company who departed in 2003. Changes to the Supplemental Executive Retirement Plan minimum liability are reflected in other comprehensive income (loss). 109 Table of Contents Noncontrolling Interests Redeemable Noncontrolling Interests Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company's noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time (the "Option Requirements"). Each put option is payable in cash and subject to changes in redemption value in the event that the underlying property generates specified returns for the Company and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period. In addition to the rights of the redeemable noncontrolling interest holders, once the Option Requirements have been met, the Company has the ability to buy out the interests of the noncontrolling interest holders. The values of the redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date. On March 1, 2024, concurrently with the consummation of the Merger, the Company assumed one redeemable noncontrolling interest, which had not yet met the conditions for redemption as of December 31, 2024. This interest will become redeemable in September 2025. In April 2024, the Company exercised its option to buy out four redeemable noncontrolling interests that met the criteria for redemption. Accordingly, during the year ended December 31, 2024, the Company made aggregate cash payments for the total redemption value of \$53.4 million to the related noncontrolling interest holders and acquired the redeemable noncontrolling interests associated with the entities. Healthpeak OP Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, OP Unitholders were issued approximately 2.4 million OP Units during the year ended December 31, 2023, all of which were LTIP Units (as defined in Note 15). During the year ended December 31, 2024, OP Unitholders were issued approximately 2.4 million OP Units, all of which were LTIP Units. When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company's common stock, at the Company's option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company's common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. As of December 31, 2024, there were approximately 3.4 million OP Units outstanding and 76.4 thousand had met the criteria for redemption. As of December 31, 2023, there were approximately 2.4 million OP Units outstanding, none of which had met the criteria for redemption. DownREITs The non-managing member units of the Company's DownREITs are exchangeable for an amount of cash approximating the then-current market value of shares of the Company's common stock or, at the Company's option, shares of the Company's common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company's common stock, the carrying amount of the DownREIT units is reclassified to stockholders' equity. At December 31, 2024, there were approximately 11.4 million DownREIT units (1.4 million shares of Healthpeak common stock are issuable upon conversion) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At December 31, 2024, the carrying value of the 11.4 million DownREIT units was \$310.4 million. At December 31, 2023, there were approximately 5.4 million DownREIT units (7.4 million shares of Healthpeak common stock are issuable upon conversion) outstanding in seven DownREIT LLCs, for all of which the

Company acts as the managing member. At December 31, 2023, the carrying value of the 5Â million DownREIT units was \$199Â million.NOTE 14.Â Â Â Earnings Per Common ShareBasic income (loss) per common share (âââââ) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method, common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Companyâs basic income (loss) per share are included in diluted income (loss) per share during the periods presented.Certain restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.110Table of ContentsThe Company considers the potential dilution resulting from forward agreements under its ATM Programs to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. Refer to Note 13 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented. The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):Year Ended December 31,202420232022Numerator - BasicIncome (loss) from continuing operations\$267,303Â \$334,757Â \$513,540Â Noncontrolling interestsâ share in continuing operations(24,161)(28,748) (15,975)Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.243,142Â 306,009Â 497,565Â Less: Participating securitiesâ share in continuing operations(758) (1,725)(2,657)Income (loss) from continuing operations applicable to common shares242,384Â 304,284Â 494,908Â Income (loss) from discontinued operationsâÂ Â âÂ 2,884Â Net income (loss) applicable to common shares\$242,384Â \$304,284Â \$497,792Â Numerator - DilutiveNet income (loss) applicable to common shares\$242,384Â \$304,284Â \$497,792Â Add: distributions on dilutive convertible units and other107Â Â Â Â Â Dilutive net income (loss) available to common shares\$242,491Â \$304,284Â \$497,792Â DenominatorBasic weighted average shares outstanding675,680Â 547,006Â 538,809Â Dilutive potential common shares - equity awards(1)148Â 269Â 338Â Dilutive potential common shares - OP Units(2)405Â Â Â Â Diluted weighted average common shares676,233Â 547,275Â 539,147Â Basic earnings (loss) per common shareContinuing operations\$0.36Â \$0.56Â \$0.92Â Discontinued operationsâÂ Â Â 0.00Â Net income (loss) applicable to common shares\$0.36Â \$0.56Â \$0.92Â Diluted earnings (loss) per common shareContinuing operations\$0.36Â \$0.56Â \$0.92Â Discontinued operationsâÂ Â Â 0.00Â Net income (loss) applicable to common shares\$0.36Â \$0.56Â \$0.92Â (1)For all periods presented, represents the dilutive impact of 1Â million outstanding equity awards (restricted stock units and stock options).(2)For the year ended December 31, 2024, represents the dilutive impact of 3Â million outstanding OP Units. For the years ended December 31, 2024, 2023, and 2022, all 14Â million, 7Â million, and 7Â million shares issuable upon conversion of DownREIT units, respectively, were not included because they were anti-dilutive. For the years ended December 31, 2024 and 2023, forward equity sales agreements had no dilutive impact as no shares were outstanding under ATM forward contracts during the year. For the year ended December 31, 2022, all shares that were settled during the year then ended were anti-dilutive. 11Table of ContentsNOTE 15.Â Â Â Â Compensation PlansStock-Based CompensationOn May 11, 2006, the Companyâs stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the â2006 Planâ). On May 1, 2014, the Companyâs stockholders approved the 2014 Performance Incentive Plan, which was amended and restated in 2019 and further amended in 2023 (the â2014 Planâ). Following the adoption of the 2014 Plan, no new awards were issued under the 2006 Plan. On April 27, 2023, the Companyâs stockholders approved the 2023 Performance Plan (the â2023 Planâ and collectively with the 2006 Plan and the 2014 Plan, the âPlansâ). Following the adoption of the 2023 Plan, no new awards may be issued under the 2014 Plan.Â The Plans provide for the granting of stock-based compensation to officers, employees, and directors, including stock options, restricted stock, restricted stock units, and with respect to the 2014 and 2023 Plans, profits interests in Healthpeak OP (âLTP Unitsâ). The maximum number of shares reserved for awards under the 2023 Plan is 31Â million shares, and, as of December 31, 2024, 28Â million of the reserved shares under the 2023 Plan are available for future awards, of which 19Â million shares may be issued as restricted stock, restricted stock units, or LTP Units.Restricted Stock UnitsUnder the Plans, time-based restricted stock units and market-based restricted stock units (collectively, âRestricted Stock Unitsâ) are granted subject to certain restrictions. Conditions of vesting are determined at the time of grant. Restrictions on certain awards generally lapse, as provided in the Plans or in the applicable award agreement, upon retirement, a change in control, or other specified events. The fair market value of Restricted Stock Units is expensed over the period of vesting. Time-based restricted stock units, which vest based solely upon passage of time, generally vest on a graded schedule over a period of one to five years. The fair value of time-based restricted stock units is determined based on the closing market price of the Companyâs shares on the grant date. Market-based restricted stock units, which vest dependent upon attainment of total shareholder return (âTSRâ) performance that equal or exceed threshold levels as measured against certain peer and industry benchmarks, generally vest in their entirety at the end of a three-year performance period. The number of shares that ultimately vest based on performance can vary from 0% to 200% of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, respectively: (i) expected term of 3 years, 3 years, and 3 years (equal to the remaining performance period at the grant date), (ii) historical volatility of 26.0%, 33.0%, and 38.9%, (iii) dividend yield of 5.2%, 4.4%, and 3.5%, (iv) risk-free rate of 4.5%, 4.4%, and 1.8%, and (v) post-vesting restrictions discount of 10.0%, 10.0%, and 5.8%. The total grant date fair value of time-based restricted stock units and market-based restricted stock units granted during the years ended December 31, 2024, 2023, and 2022 was \$11Â million, \$9Â million, and \$27Â million, respectively. The total fair value (at vesting) of time-based restricted stock units and market-based restricted stock units that vested during the years ended December 31, 2024, 2023, and 2022 was \$7Â million, \$16Â million, and \$27Â million, respectively. Upon vesting of Restricted Stock Units, the participant is required to pay the related tax withholding obligation, as applicable. The Company reduces the number of common stock shares delivered to pay the employee tax withholding obligation. The value of the shares withheld is dependent on the closing market price of the Companyâs common stock on the trading date prior to the relevant transaction occurring. During the years ended December 31, 2024, 2023, and 2022, the Company withheld 123,000, 241,000, and 356,000 shares, respectively, to offset tax withholding obligations with respect to the vesting of the Restricted Stock Units.LTIP UnitsDuring each of the years ended December 31, 2024 and 2023, approximately 2Â million LTIP Units were issued to officers of the Company. These awards are designed to qualify as âprofits interestsâ in Healthpeak OP for federal income tax purposes. Such interests are initially not economically equivalent in value to a share of common stock until reaching one-for-one parity with the Companyâs common stock, subject to any vesting conditions applicable to the award. When certain conditions are met, LTIP Units are converted to common units, which may then be redeemed for cash or shares of the Companyâs common stock, at the Companyâs option as managing member of Healthpeak OP (see also Note 13).112Table of ContentsUnder the Plans, time-based LTIP Units and market-based LTIP Units (collectively, âLTIP Unitsâ), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of three to six years. The fair value of the time-based LTIP Units is determined based on the closing market price of the Companyâs shares on the grant date less a discount for post-vesting restrictions, liquidity risk, and uncertainty of the time-based LTIP Units reaching parity. The market-based LTIP Units are granted at the maximum potential payout, inclusive of expected distributions during the performance period. Market-based LTIP Units, which vest dependent upon attainment of various levels of TSR performance that equal or exceed threshold levels as measured against certain peer and industry benchmarks, generally vest in their entirety at the end of a three-year performance period. The number of market-based LTIP Units that ultimately vest can vary from 0% to 200% of target depending on the level of achievement of the performance criteria, and any difference from the original grant are forfeited. The fair value of market-based LTIP Units granted during the years ended December 31, 2024 and 2023 is determined based on the Monte Carlo valuation model using the same assumptions as market-based restricted stock units described above less a discount for post-vesting restrictions, liquidity risk, and uncertainty of the market-based LTIP Units reaching parity with the value of the Companyâs common stock and the vesting terms of the awards. The total grant date fair value of LTIP Units granted during the years ended December 31, 2024 and 2023 was \$13Â million and \$29Â million. The total fair value (at vesting) of LTIP Units that vested during the years ended December 31, 2024 and 2023 was \$3Â million and \$2Â million. Dividends and DistributionsHolders of time-based restricted stock units and time-based LTIP Units are generally entitled to receive dividends and distributions, respectively, equal to the amount that would be paid on an equivalent number of shares of common stock. Market-based restricted stock units receive cumulative cash dividends upon vesting for the entirety of the performance period based on the level of achievement of the performance criteria. The market-based LTIP Units receive cash distributions equal to 10% of the quarterly dividends paid on the Companyâs common stock during the performance period. Based on the level of achievement of the performance criteria at the end of the performance period, the market-based LTIP Units receive distributions in the form of additional LTIP Units for amounts ultimately vested during the performance period, less cash distributions already paid.Stock OptionsThere have been no grants of stock options since 2014. Stock options outstanding and exercisable were zero at December 31, 2024 and 0.2Â million at December 31, 2023. There were no stock options exercised under the Plans for the years ended December 31, 2024, 2023, and 2022. No compensation cost related to stock options was incurred during the years ended December 31, 2024, 2023, and 2022.The following table summarizes Restricted Stock Unit and LTIP Unit activity for the year ended December 31, 2024 (units in thousands):Restricted Stock UnitsLTIP UnitsÂ Number of UnitsWeightedAverageGrantÂ DateFairÂ ValueNumber of UnitsWeightedAverageGrantÂ DateFairÂ ValueUnvested at January 1, 2024879Â \$29.91Â 1,894Â \$14.26Â Granted597Â 17,691,511Â 8,751,511Â Vested(377)27,888(199)17,434 Forfeited(224)27,200(304)12,700 Unvested at December 31, 2024875Â 29,910Â 2,902Â 10,880 Total stock-based compensation cost was \$20 million, \$19 million, and \$32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included \$10Â million of severance-related charges resulting from a decrease in the requisite service period of restricted stock units associated with the Company's former CEO, as further described below. Of the total stock-based compensation cost, \$4Â million was capitalized as part of real estate for each of the years ended December 31, 2024, 2023, and 2022. As of December 31, 2024, there was \$22 million of future expenses related to unvested stock-based compensation arrangements granted under the Companyâs incentive plans, which is expected to be recognized over a weighted average period of 1.6 years associated with future employee service. Compensation cost recognized for all Restricted Stock Units and LTIP Units is net of actual forfeitures.113Table of ContentsDeparture of ExecutivesOn October 6, 2022, the Company and Thomas M. Herzog mutually agreed that Mr. Herzog would step down from his position as CEO and from the board of directors of the Company, effective immediately. On November 1, 2022, the Company and Troy E. McHenry mutually agreed that Mr. McHenry would step down from his position as Chief Legal Officer and General Counsel, effective immediately. During the fourth quarter of 2022, the Company recognized total severance-related charges of \$33Â million in general and administrative expenses on the Consolidated Statements of Operations, \$10Â million of which related to a decrease in the requisite service period of Restricted Stock Units as discussed above. These Restricted Stock Units continue to vest in accordance with the original terms of the grants. As of December 31, 2024 and 2023, \$4Â million and \$8Â million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets.NOTE 16.Â Â Â A Segment DisclosuresThe Companyâs operating segments, based on how its CODM, the President and Chief Executive Officer, evaluates the business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in an unconsolidated joint venture that owns 19 senior housing assets (the âSWF SH JVâ), and (v) loans receivable. The Companyâs reportable segments, as determined in accordance with ASC 280, Segment Reporting, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. The SWF SH JV and loans receivable are non-reportable segments that have been presented on a combined basis within the Notes to the Consolidated Financial Statements herein. The accounting policies of the segments are the same as those described in the Companyâs Summary of Significant Accounting Policies (see Note 2).The CODM evaluates performance based on property Adjusted NOI. Adjusted NOI is used to evaluate performance because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. Adjusted NOI represents real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claimsÂ that have been incurred but not reported, and the impact of deferred community fee income and expense. Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus the Companyâs share of Adjusted NOI from unconsolidated joint ventures (calculated by applying the Companyâs actual ownership percentage for the period), less noncontrolling interestsâ share of Adjusted NOI from consolidated joint ventures (calculated by applying the Companyâs actual ownership percentage for the period). Management utilizes its share of Adjusted NOI in assessing its performance as the Company has various joint ventures that contribute to its performance. Segment assets consist of real estate assets, intangible assets, and right-of-use assets. Non-segment assets consist of assets in the Companyâs other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, other assets, and real estate assets held for sale. Reportable segment asset information is not provided to the CODM as the CODM does not use segment asset information to evaluate the business and allocate resources.114Table of ContentsThe following tables summarize information for the reportable segments for the year ended December 31, 2024 (in thousands):Outpatient MedicalLabCCRCTotalTotal revenues\$1,205,744Â \$881,452Â \$568,475Â \$2,655,671Â Healthpeakâs share of unconsolidated joint venture total revenues\$24,041Â 19,733Â Â Â 43,774Â Noncontrolling interestsâ share of consolidated joint venture total revenues(37,643)(196)âÂ (37,839)Operating expenses(1)405,993(239,620)(429,248)(1,074,861)Healthpeakâs share of unconsolidated joint venture operating expenses(9,034)(6,366)âÂ (15,400)Noncontrolling interestsâ share of consolidated joint venture operating expenses10,582 52Â Â Â 10,634Â Adjustments to NOI(2)(38,967)(64,449)(3,123)(106,539)Adjusted NOI for reportable segments\$748,730Â \$590,606Â \$136,104Â \$1,475,440Â Plus: Adjustments to NOI(2)106,539Â Interest income and other44,778Â Interest expense(280,430)Depreciation and amortization(1,057,205)General and administrative(97,162)Transaction and merger-related costs(132,685)Impairments and loan loss reserves, net(22,978)Gain (loss) on sales of real estate, net178,695Â Other income (expense), net59,345Â Less: Healthpeakâs share of unconsolidated joint venture Adjusted NOI(28,374)Plus: Noncontrolling interestsâ share of consolidated joint venture Adjusted NOI27,205Â Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures\$773,168Â (1)See reconciliation of significant expense categories below.(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claimsÂ that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Companyâs share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interestsâ share of income (loss) generated by consolidated joint ventures. The following table summarizes the Companyâs significant expense categories by reportable segment for the year ended December 31, 2024 (in thousands): Outpatient MedicalLabCCRCCompensation and property management\$56,066Â \$33,058Â \$277,686Â Food&Â Â Â 26,513Â Real estate taxes95,286Â 78,488Â 15,472Â Repairs and maintenance61,409Â 30,555Â 18,373Â Utilities69,690Â 50,793Â 22,309Â Other segment items(1)123,542Â 46,726Â 68,895Â Operating expenses\$405,993Â \$239,620Â \$429,248Â (1)Other segment items for each segment include:âOutpatient medical and lab â (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.âCCRC â (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense. 115Table of ContentsThe following tables summarize information for the reportable segments for the year ended December 31, 2023 (in thousands):Outpatient MedicalLabCCRCTotalTotal revenues\$753,479Â \$878,326Â \$527,417Â \$2,159,222Â Government grant income(1)âÂ Â Â 184Â 184Â Healthpeakâs share of unconsolidated joint venture total revenues\$3,033,924Â Â 12,957Â Noncontrolling interestsâ share of consolidated joint venture total revenues(35,073)(619)âÂ (35,692)Operating expenses(2)(263,132)(229,630)(413,472)(906,234)Healthpeakâs share of unconsolidated joint venture operating expenses(1,189) (4,092)âÂ (5,281)Noncontrolling interestsâ share of consolidated joint venture operating expenses9,921 156Â Â 10,077Â Adjustments to NOI(3)(14,314)(36,524)(1,618) (52,456)Adjusted NOI for reportable segments\$452,725Â \$617,541Â \$112,511Â \$1,182,777Â Plus: Adjustments to NOI(3)52,456Â Interest income and other21,781Â Interest expense(200,331)Depreciation and amortization(749,901)Corporate non-segment operating expenses4,174Â General and administrative(95,132)Transaction and merger-related

costs(17,515)Impairments and loan loss reserves, net5,601Â Gain (loss) on sales of real estate, net86,463Â Other income (expense), net6,808Â Less: Government grant income(184)Less: Healthpeakâ€™s share of unconsolidated joint venture Adjusted NOI(7,676)Plus: Noncontrolling interestsâ€™ share of consolidated joint venture Adjusted NOI25,615Â Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures\$314,936Â (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).(2)See reconciliation of significant expense categories below.(3)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claimsÂ that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Companyâ€™s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interestsâ€™ share of income (loss) generated by consolidated joint ventures.The following table summarizes the Companyâ€™s significant expense categories by reportable segment for the year ended DecemberÂ 31, 2023 (in thousands): Outpatient MedicalLabCCRCCompensation and property management\$29,752Â \$18,096Â \$260,624Â Foodâ€™Â \$Â 25,076Â Real estate taxes59,255Â 77,690Â 15,851Â Repairs and maintenance38,277Â 30,554Â 17,295Â Utilities43,348Â 45,490Â 22,787Â Other segment items(1)92,500Â 57,800Â 71,839Â Operating expenses\$263,132Â \$229,630Â \$413,472Â (1)Other segment items for each segment include:â€™Outpatient medical and lab â€™ (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.â€™CCRC â€™ (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense. 116Table of ContentsThe following table summarizes information for the reportable segments for the year ended DecemberÂ 31, 2022 (in thousands):Outpatient MedicalLabCCRCTotalTotal revenues\$725,370Â \$817,573Â \$494,935Â 2,037,878Â Government grant income(1)â€™Â \$Â 6,765Â 6,765Â Healthpeakâ€™s share of unconsolidated joint venture total revenues2,999Â 9,921Â â€™Â \$Â 12,920Â Healthpeakâ€™s share of unconsolidated joint venture government grant incomeâ€™Â \$Â 380Â 380Â Noncontrolling interestsâ€™ share of consolidated joint venture total revenues(35,717)(268)â€™Â \$ (35,985)Operating expenses(2)(253,309) (209,143)(400,539)(862,991)Healthpeakâ€™s share of unconsolidated joint venture operating expenses(1,178)(2,883)â€™Â \$ (4,061)Noncontrolling interestsâ€™ share of consolidated joint venture operating expenses(10,317Â 87Â \$Â 10,404Â Adjustments to NOI(3)(5,513)(62,754)2,300Â (75,967)Adjusted NOI for reportable segments\$432,969Â \$552,533Â \$103,841Â \$1,089,343Â Plus: Adjustments to NOI(3)(75,967Â Interest income and other23,300Â Interest expense(172,944)Depreciation and amortization(710,569)General and administrative(131,033)Transaction and merger-related costs(4,853)Impairments and loan loss reserves, net(7,004)Gain (loss) on sales of real estate, net9,078Â Other income (expense), net326,268Â Less: Government grant income(6,765)Less: Healthpeakâ€™s share of unconsolidated joint venture Adjusted NOI(9,239)Plus: Noncontrolling interestsâ€™ share of consolidated joint venture Adjusted NOI25,581Â Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures\$507,130Â (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).(2)See reconciliation of significant expense categories below.(3)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claimsÂ that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Companyâ€™s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interestsâ€™ share of income (loss) generated by consolidated joint ventures.The following table summarizes the Companyâ€™s significant expense categories by reportable segment for the year ended DecemberÂ 31, 2022 (in thousands): Outpatient MedicalLabCCRCCompensation and property management\$27,807Â \$16,817Â \$251,804Â Foodâ€™Â \$Â 23,641Â Real estate taxes59,992Â 75,459Â 14,090Â Repairs and maintenance36,439Â 26,884Â 16,522Â Utilities43,329Â 41,087Â 21,219Â Other segment items(1)85,742Â 48,896Â 73,263Â Operating expenses\$253,309Â \$209,143Â \$400,539Â (1)Other segment items for each segment include:â€™Outpatient medical and lab â€™ (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.â€™CCRC â€™ (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense. 117Table of ContentsThe following table summarizes the Companyâ€™s revenues by reportable segment (in thousands):Â December 31,Segment202420232022Outpatient medicals1,205,744Â \$753,479Â \$725,370Â Lab881,452Â 878,326Â 817,573Â CCRC568,475Â 527,417Â 494,935Â Total revenues for reportable segments2,655,671Â 2,159,222Â 2,037,878Â Interest income and other44,778Â 21,781Â 23,300Â Total revenues\$2,700,449Â \$2,181,003Â \$2,061,178Â At DecemberÂ 31, 2024, goodwill of \$69Â million was allocated to the Companyâ€™s segment assets as follows: (i) \$65Â million for outpatient medical, (ii) \$2Â million for CCRC, and (iii) \$2Â million for other non-reportable. At DecemberÂ 31, 2023, goodwill of \$18Â million was allocated to the Companyâ€™s segment assets as follows: (i) \$14Â million for outpatient medical, (ii) \$2Â million for CCRC, and (iii) \$2Â million for other non-reportable.NOTE 17. Â Â Â Â Â Income TaxesThe Company has elected to be taxed as a REIT under the applicable provisions of the Code beginning with the year ended December 31, 1985. The Company has also elected for certain of its subsidiaries to be treated as TRSs (the â€™TRS entitiesâ€™), which are subject to federal and state income taxes. All entities other than the TRS entities are collectively referred to as the â€™REITsâ€™ within this Note 17. Certain REIT entities are also subject to state and local income taxes.Distributions with respect to the Companyâ€™s common stock can be characterized for federal income tax purposes as ordinary dividends, capital gains, nondividend distributions, or a combination thereof.The following table shows the characterization of the Companyâ€™s annual common stock distributions per share:Year Ended December 31,202420232022Ordinary dividends(1)\$0.720440Â \$0.909692Â \$0.872948Â Capital gains(2)(3)0.295060Â 0.116992Â 0.183208Â Nondividend distributions0.184500Â 0.173316Â 0.143844Â \$1.200000Â \$1.200000Â \$1.200000Â (1)For the year ended December 31, 2024, the amount includes \$0.882312 of ordinary dividends qualified as business income for purposes of Code Section 199A and \$0.027380 of qualified dividend income for purposes of Code Section 1(h)(11). For the year ended December 31, 2022, all \$0.872948 of ordinary dividends qualified as business income for purposes of Code Section 199A. (2)For the years ended DecemberÂ 31, 2024, 2023, and 2022, the amount includes \$0.215960, \$0.036256, and \$0.017760, respectively, of unrecaptured Code Section 1250 gain. Pursuant to Treasury Regulation Section 1.1061-6(c), the Company is disclosing additional information related to the capital gain dividends for purposes of Section 1061 of the Code. Code Section 1061 is generally applicable to direct and indirect holders of â€™applicable partnership interests.â€™ For the years ended December 31, 2024 and 2023, the â€™One Year Amountsâ€™ and â€™Three Year Amountsâ€™ are each zero, since all capital gains relate to Code Section 1231 gains. For the year ended December 31, 2022, the â€™One Year Amountsâ€™ and â€™Three Year Amountsâ€™ are each 89.6708% of the total capital gain distributions and the remaining capital gain distributions are attributable to Code Section 1231 gains, which are not subject to Code Section 1061. (3)For the years ended DecemberÂ 31, 2024, 2023, and 2022, 100%, 100%, and 10.3292%, respectively, of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.The Companyâ€™s pretax income (loss) from continuing operations for the years ended DecemberÂ 31, 2024, 2023, and 2022 was \$272Â million, \$325Â million, and \$509Â million, respectively, of which \$217Â million, \$318Â million, and \$527Â million was attributable to the REIT entities for the years then ended. The TRS entities subject to tax reported income (losses) before income taxes from continuing operations of \$55 million, \$7 million, and \$(18) million for the years ended DecemberÂ 31, 2024, 2023, and 2022, respectively.118Table of ContentsThe total income tax benefit (expense) from continuing operations consists of the following components (in thousands):Year Ended December 31,202420232022CurrentFederal\$(2,389)\$ (1,663)\$(632)State(3,654)(3,325)(689)Total currents\$(6,043)\$(4,988)\$(1,321)DeferredFederal\$(3,429)\$11,682Â \$3,157Â State5,122Â 2,923Â 2,589Â Total deferred\$1,693Â \$14,605Â \$5,746Â Total income tax benefit (expense) from continuing operations\$(4,350)\$9,617Â \$4,425Â The Companyâ€™s income tax benefit from discontinued operations was zero, zero, and \$0.3Â million for the years ended DecemberÂ 31, 2024, 2023, and 2022, respectively (see Note 5).The following table reconciles income tax benefit (expense) from continuing operations at statutory rates to actual income tax benefit (expense) recorded (in thousands):Year Ended December 31,202420232022Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax\$(11,601)\$(1,404)\$(3,698) State income tax benefit (expense), net of federal tax (1,389)(1,035)911Â Gross receipts and margin taxes(1,774)(1,647)(956)Return to provision adjustments(287)(901)260Â Change in valuation allowance for deferred tax assets(10,698)13,797Â 194Â Change in tax status of TRSÂ (4)(682)Total income tax benefit (expense) from continuing operations\$(4,350)\$9,617Â \$4,425Â 119Table of ContentsDeferred income taxes reflect the net effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table summarizes the significant components of the Companyâ€™s deferred tax assets and liabilities from continuing operations (in thousands):December 31,202420232022Deferred tax assets:Deferred revenues103,470Â \$103,530Â \$102,504Â Net operating loss carryforward50,041Â 54,136Â 62,280Â Expense accruals11,787Â 12,324Â 12,399Â Real estate195Â 850Â 150Â Other 49Â 58Â 689Â Total deferred tax assets165,542Â 170,898Â 178,022Â Valuation allowance(2,306)(13,004)(26,098)Deferred tax assets, net of valuation allowance\$163,236Â \$157,894Â \$151,924Â Deferred tax liabilities:Real estate\$47,268Â \$43,488Â \$52,266Â Other876Â 818Â 674Â Deferred tax liabilities\$48,144Â \$44,306Â \$52,940Â Net deferred tax assets\$115,092Â \$113,588Â \$98,984Â Net deferred tax assets are included in other assets, net on the Consolidated Balance Sheets.The Company records a valuation allowance against deferred tax assets in certain jurisdictions when it is not more likely than not that it can realize the related deferred tax assets. The deferred tax asset valuation allowance is adequate to reduce the total deferred tax assets to an amount that the Company estimates will â€™more-likely-than-notâ€™ be realized.As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (â€™NOLsâ€™) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primarily NOL carryforwards) would be realized. During the year ended December 31, 2023, this conclusion was based on estimates of future taxable income for certain TRS entities in connection with the Callan Ridge JV transaction (see also Notes 5 and 9). Accordingly, the Company reversed a portion of the deferred tax asset valuation allowance and recognized an income tax benefit of \$14Â million during the year ended December 31, 2023. During the year ended DecemberÂ 31, 2024, the Company recognized an income tax expense of \$12Â million in conjunction with the closing of the Callan Ridge JV transaction. Additionally, during the year ended DecemberÂ 31, 2024, the Company completed a merger of certain TRS entities and as a result, reversed a portion of the deferred tax asset valuation allowance and recognized an income tax benefit of \$11Â million. As of DecemberÂ 31, 2024, 2023, and 2022, the Company had a deferred tax asset valuation allowance of \$2Â million, \$13Â million, and \$26Â million, respectively. At DecemberÂ 31, 2024, the Company had a NOL carryforward of \$193 million related to the TRS entities. If unused, \$2 million will begin to expire in 2035. The remainder, totaling \$191 million, may be carried forward indefinitely.The following table summarizes the Companyâ€™s unrecognized tax benefits (in thousands):December 31,202420232022Total unrecognized tax benefits at January 1\$â€™Â \$â€™Â \$469Â Gross amount of decreases for prior yearsâ€™ tax positionsâ€™Â \$Â 469)Total unrecognized tax benefits at December 31\$â€™Â \$â€™Â \$â€™Â For the years ended DecemberÂ 31, 2024, 2023, and 2022 the Company had no unrecognized tax benefits.The Company files numerous U.S. federal, state, and local income and franchise tax returns. With a few exceptions, the Company is no longer subject to U.S. federal, state, or local tax examinations by taxing authorities for years prior to 2021.120Table of Contents NOTE 18.Â Â Â Â Â Supplemental Cash Flow InformationThe following table provides supplemental cash flow information (in thousands):Year Ended December 31,202420232022Supplemental cash flow information:Interest paid, net of capitalized interests\$249,471Â \$188,213Â \$162,115Â Income taxes paid (refunded)7,862Â 1,923Â (1,903)Capitalized interest69,256Â 56,849Â 41,046Â Cash paid for amounts included in the measurement of lease liability for operating leases21,277Â 21,488Â 12,594Â Supplemental schedule of non-cash investing and financing activities:Increase in ROU asset in exchange for new lease liability related to operating leases15,457Â 9,454Â 9,454Â Accrued construction costs136,767Â 105,572Â 178,626Â Net noncash impact from the consolidation of property previously held in an unconsolidated joint ventureâ€™Â 993Â â€™Â Retained investment in connection with South San Francisco JVs transaction (see Note 9)â€™Â \$Â 293,265Â Retained investment in connection with Callan Ridge JV (see Note 9)69,255Â â€™Â Non-cash assets and liabilities assumed in connection with the Merger (see Note 3),926,141Â â€™Â \$Â Seller financing provided on disposition of real estate assets (see Note 8)418,389Â â€™Â \$Â Operating, investing, and financing cash flows in the Consolidated Statements of Cash Flows are reported inclusive of both cash flows from continuing operations and cash flows from discontinued operations. The following table summarizes certain cash flow information related to discontinued operations (in thousands):Year Ended December 31,202420232022Leasing costs, tenant improvements, and recurring capital expenditures\$â€™Â \$â€™Â \$21Â Development, redevelopment, and other major improvements of real estateâ€™Â \$Â 18Â Depreciation and amortization of real estate, in-place lease, and other intangiblesâ€™Â \$Â â€™Â The following table summarizes cash, cash equivalents, and restricted cash (in thousands):Year Ended December 31, 202420232022202420232022Continuing operationsDiscontinued operationsTotalBeginning of year:Cash and cash equivalents\$117,635Â \$72,032Â \$158,287Â \$â€™Â \$â€™Â \$7,707Â \$117,635Â \$72,032Â \$165,994Â Restricted cash51,388Â 54,802Â 53,454Â â€™Â \$Â â€™Â \$51,388Â 54,802Â 53,454Â Cash, cash equivalents, and restricted cash\$169,023Â \$126,834Â \$211,741Â \$â€™Â \$â€™Â \$7,707Â \$169,023Â \$126,834Â \$219,448Â End of year:Cash and cash equivalents\$119,818Â \$117,635Â \$72,032Â \$â€™Â \$â€™Â \$119,818Â \$117,635Â \$72,032Â Restricted cash\$64,487Â 51,388Â 54,802Â â€™Â \$Â â€™Â \$64,487Â 51,388Â 54,802Â Cash, cash equivalents, and restricted cash\$184,305Â \$169,023Â \$126,834Â \$â€™Â \$â€™Â \$184,305Â \$169,023Â \$126,834Â 121Table of ContentsNOTE 19.Â Â Â Â Â Variable Interest EntitiesOperating SubsidiaryHealthpeak OP is the Companyâ€™s operating subsidiary and a limited liability company that has governing provisions that are the functional equivalent of a limited partnership. The Company holds a membership interest in Healthpeak OP, acts as the managing member of Healthpeak OP, and exercises full responsibility, discretion, and control over the day-to-day management of Healthpeak OP. Because the noncontrolling interests in Healthpeak OP do not have substantive liquidation rights, substantive kick-out rights without cause, or substantive participating rights, the Company has determined that Healthpeak OP is a VIE. The Company, as managing member, has the power to direct the core activities of Healthpeak OP that most significantly affect Healthpeak OPâ€™s performance, and through its interest in Healthpeak OP, has both the right to receive benefits from and the obligation to absorb losses of Healthpeak OP. Accordingly, the Company is the primary beneficiary of Healthpeak OP and consolidates Healthpeak OP. As the Company conducts its business and holds its assets and liabilities through Healthpeak OP, the total consolidated assets and liabilities, income (losses), and cash flows of Healthpeak OP represent substantially all of the total consolidated assets and liabilities, including the consolidated and unconsolidated entities discussed in this Note 19, income (losses), and cash flows of the Company.Unconsolidated Variable Interest EntitiesAt DecemberÂ 31, 2024, the Company had investments in (i) two unconsolidated VIE joint ventures and (ii) the PropTech Investment, an unconsolidated VIE investment in a limited partnership. At DecemberÂ 31, 2023, the Company had investments in two unconsolidated VIE joint ventures. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Companyâ€™s equity interest in the unconsolidated joint ventures (the LLC Investment and Needham Land Parcel JV discussed below) and the PropTech Investment, it has no formal involvement in these VIEs beyond its investments.LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC (â€™LLC Investmentâ€™) that has been identified as a VIE. The Companyâ€™s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of three hospitals as well as senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).PropTech Investment. During the year ended DecemberÂ 31, 2024, the Company made an initial investment of \$1Â million in a property technology (â€™PropTechâ€™) fund that makes venture capital investments in early-stage real estate and construction-related companies (the â€™PropTech Investmentâ€™). The Company has an aggregate commitment of \$10Â million, or approximately 5% of total fund commitments, which is expected to be funded over the next five years. The PropTech Investment has been identified as a VIE. The Companyâ€™s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner and given its rights and ownership percentage, the Company has virtually no influence or control. The assets and liabilities of the entity primarily consist of investments in certain PropTech real estate and construction companies. All future investments will be funded with capital contributions from the Company and other limited partners in accordance with their respective commitments. Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a lab development joint venture in Needham, Massachusetts for \$13Â million. Current equity at risk is not sufficient to finance the joint ventureâ€™s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets

SpringCoAc"À 690A 8,338A 367A 690A 8,705A 9,395A (6,267)19901989882Colorado SpringsCoAc"À 12,933A 8,913A À 21,846A 21,846A (11,516)200720061199DenverCoAc"À 493A 7,897A 1,642A 604A 9,428A 10,032A (4,874)19932006808EnglewoodCoAc"À À 8,61 of ContentsEncumbrances at December 31, 2024Initial Cost to CompanyCosts Capitalized Subsequent to Acquisition(3)Gross Amount at Which Carried As of December 31, 2024Accumulated Depreciation(5)Year Constructed(6)Year AcquiredCityStateLand and improvements(1)BuildingsA and Improvements(2)Land and improvementsBuildingsA and ImprovementsTotal(4)2658Highlands RanchCoAc"À 1,637A 10,063A 95A 1,732A 10,063A 11,795A (2,730)20125017C00001JohnstownCoAc"À 1,254A 5,646A À 1,254A 5,646A 6,900A (271)20132024812LittletonCoAc"À À 4,56 TreeCoAc"À À À 21,731A À 21,731A 21,731A (10,737)200420203666Lone TreeCoAc"À À À 23,274A 3,959A 17A 27,216A 27,233A (13,399)200320062233Lone TreeCoAc"À À À 6,734A 34,699A À 41,433A 41,433A (1,919)201520143000Lone TreeCoAc"À 4,393A 31,643A 10,249A 4,552A 41,733A 46,285A (5,919)2020202021510ThorntonCoAc"À 236A 10,206A 14,228A 455A 24,215A 24,670A (9,530)200120212002CO0004ThorntonCoAc LakeFLAc"À 921A 7,403A 81A 921A 7,484A 8,405A (217)20112024603Lake WorthFLAc"À 1,507A 2,894A 537A 1,507A 3,431A 4,938A (1,609)19972006612MargateFLAc"À 1,553A 6,898A 4,180A 1,553A 11,078A 12,631A (5,692)19942006613MiamiFLAc"À 4,392A 11,841A ParkFLAc"À À À 18,302A À 18,302A 18,302A (2,649)20222019563OrlandoFLAc"À 2,144A 5,136A 13,014A 12,830A 7,464A 20,294A (6,902)19852003FL0025OrlandoFLAc"À 1,905A 16, CharlotteFLAc"À 2,244A 6,801A 285A 2,244A 7,086A 9,330A (357)200620242579Punta GordaFLAc"À À 9,379A 4,99A À 9,518A 9,518A (2,250)200620162833St. PetersburgFLAc"À À 13,754A 12,662A À 24,261A 26,416A (10,982)199520192006FL0022StuartFLAc"À 869A 4,396A 100A 869A 4,596A 5,465A (176)20132024FL0026StuartFLAc"À 2,882 ChapelFLAc"À 313A 29,074A 44A 313A 29,118A 29,431A (1,083)20201947FL0034YuleeFLAc"À 793A 7,994A À 793A 7,994A 8,787A (406)20202024887AtlantaGAAc"À 4,300A 13,690A (1,800) HeightsILAc"À 877A 3,011A 9,651A 2,821A 3,187A 12,296A 15,483A (1,998)1975201920132021702BolingbrookILLAc"À À 21,237A 4,108A À 25,345A 25,345A (4,203)20082020LL0002Bolingbrook ParkILAc"À 5,872A 2,767A 11,495A 1,981A 2,767A 13,476A 16,243A (1,728)200820213005LockportILAc"À 3,106A 22,645A À 3,106A 22,645A 25,751A (3,102)201020211065MarionILAc"À 99A of ContentsEncumbrances at December 31, 2024Initial Cost to CompanyCosts Capitalized Subsequent to Acquisition(3)Gross Amount at Which Carried As of December 31, 2024Accumulated Depreciation(5)Year Constructed(6)Year AcquiredCityStateLand and improvements(1)BuildingsA and Improvements(2)Land and improvementsBuildingsA and ImprovementsTotal(4)IL0005Palos HillsILAc"À 2,324A 5,087A 319A 2,324A 5,406A 7,730A (181)19852024IL0001SandwichILAc"À 116A 10,126A À 116A 10,126A 10,242A (369)20072024ILN0003BloomingtonINAc"À 622A 3,4 CityKSAc"À 440A 2,173A 389A 441A 2,461A 3,002A (842)20062021112Overland ParkKSAc"À 2,316A 10,681A 312A 2,316A 10,993A 13,249A (8,428)198919882043Overland ParkKSAc"À 7,668A 1,425A À 9,093A 9,093A (2,765)200920123062Overland ParkKSAc"À 872A 11,813A 8A 992A 11,701A 12,693A (3,121)20072019483WichitaKSAc"À 530A 3,341A 820A 605A 4,086A 4,691A (1,831)200020013018WichitaKSAc"À 3,946A 39,795A À 3,9 CityMDAc"À 1,115A 3,206A 2,758A 1,357A 5,722A 7,079A (2,734)19882006MD0002LanhamMDAc"À 227A 17,283A 43A 227A 17,326A 17,553A (584)200920241052TowsonMDAc"À À 14,233A CityMIac"À 705A 15,282A 15A 705A 15,297A 16,002A (695)20162024MI0006Grand BlancMIac"À 671A 12,097A 22A 671A 12,119A 12,790A (675)20062024MI0011Grosse PointeMIac"À 138A 12,400A À 138A 12,400A 12,538A (481)20162024MI0012PetoskeyMIac"À 236A 17,990A 166A 236A 18,156A 18,392A (870)19932024MI0013Rochester HillsMIac"À 1,100A 20,278A À 1,100A 20,278A 21,378A (993)20111024MI0014Sterling HeightsMIac"À 310A 28,116A 84A 310A 28,200A 28,510A (1,005)20092024MI0008Traverse CityMIac"À 1,709A 18,502A 99A 1,709A 18,601A 20,310A (1,045)20042024MI00A8Traverse CityMIac"À 255A 1,854A À 255A 1,854A 2,109A (108)2004202431Table of ContentsEncumbrances at December 31, 2024Initial Cost to CompanyCosts Capitalized Subsequent to Acquisition(3)Gross Amount at Which Carried As of December 31, 2024Accumulated Depreciation(5)Year Constructed(6)Year AcquiredCityStateLand and improvements(1)BuildingsA and Improvements(2)Land and improvementsBuildingsA and ImprovementsTotal(4)MN0018Apple ValleyMNAc"À 2,541A 8,011A À 2,541A 8,011A 10,552A (494)197420243002BurnsvilleMNN7,763A 2,801A 17,779A 1,151A 2,861A 18,870A 21,731A (4,793)198820213003BurnsvilleMNN5,176A RapidsMNAc"À 1,032A 4,568A À 1,032A 4,568A 5,600A (256)20072024MNN003CrystalMNAc"À 1,852A 7,888A 36A 1,852A 7,924A 9,776A (358)20122024MNN001EdinaMNAc"À 377A 7,984A ElmoMNAc"À 1,939A 5,435A À 1,939A 5,435A 3,74A (356)20152024MNN013Little FallsMNAc"À 75A 5,980A À 75A 5,980A 6,055A (317)19902024MNN014Little FallsMNAc"À 580A 1,618A À 580A 1,618A 2,198A (122)19992024MNN015Little FallsMNAc"À 59A 4,932A 3A 59A 4,935A 4,994A (277)19952024MNN012MaplewoodMNAc"À 716A 2,031A À 716A 2,031A 2,747A (119)20162024MNN019MaplewoodMNAc"À 4,884A 38,366A HeightsMNAc"À 2,028A 12,993A À 2,028A 12,993A 15,021A (603)201230242703ColumbiaMoAc"À 4,141A 21,364A (13,850A 4,141A 6,514A 10,655A (2,828)19972020MO0002Creve CoeurMoAc"À 1,622A 7,209A 287A 1,622A 7,496A 9,118A (365)19892024MO0001FentonMoAc"À 1,457A 3,589A À 1,457A 3,589A 5,046A (250)199920242023IndependenceMoAc"À À 48, CityMoAc"À 312A 23,251A 719A 312A 23,970A 24,282A (884)201520242866Kansas CityMoAc"À À 13,903A 13,903A À À 2024286

À CA æ"À 2,603Å 11,051Å 3,587Å 2,766Å 14,475Å 17,241Å (7,299)19972004679Å San Diego À CA æ"À 5,269Å 23,566Å 23,990Å 5,669Å 47,156Å 52,825Å (20,424)19972004837Å San Diego À CA æ"À 4,630Å 2,028Å 3,302Å 4,630Å 5,330Å 9,960Å (2,648)19882012006838Å San Diego À CA æ"À 2,040Å 903Å 3,354Å 2,040Å 4,257Å 6,297Å (1,439)1988/20122006839Å San Diego À CA æ"À 3,940Å 3,184Å 2,995Å 4,036Å 6,083Å 10,119Å (2,847)19872006840Å San Diego À CA æ"À 5,690Å 4,579Å 1,486Å 5,830Å 5,925Å 11,755Å (2,789)198720061418Å San Diego À CA æ"À 11,700Å 31,243Å 59,338Å 11,700Å 90,581Å 102,281Å (21,029)20220071419Å San Diego À CA æ"À 2,324Å æ"À 33,175Å 32,324Å æ"À 33,175Å 35,499Å (4,422)20220071420Å San Diego À CA æ"À 4,200Å æ"À 41,225Å 4,200Å 41,225Å 45,425Å (3,755)20220071421Å San Diego À CA æ"À 7,000Å 33,779Å æ"À 7,000Å 33,779Å 40,779Å (14,708)200020071422Å San Diego À CA æ"À 7,179Å 3,687Å 2,081Å 7,179Å 5,768Å 12,947Å (3,687)æ"20071423Å San Diego À CA æ"À 8,400Å 33,144Å 34,028Å 8,400Å 67,172Å 75,572Å (24,422)2002/202020071947Å San Diego À CA æ"À 2,581Å 10,534Å 4,497Å 2,581Å 15,031Å 17,612Å (8,664)200020111948Å San Diego À CA æ"À 5,879Å 25,305Å 8,311Å 5,879Å 33,616Å 39,495Å (14,802)200120112197Å San Diego À CA æ"À 7,621Å 3,913Å 7,590Å 7,621Å 11,503Å 19,124Å (7,733)1984200072476Å San Diego À CA æ"À 7,661Å 9,918Å 18,298Å 7,661Å 28,216Å 35,877Å (4,442)2000/200220162477Å San Diego À CA æ"À 9,207Å 14,613Å 8,481Å 9,207Å 23,094Å 32,301Å (6,775)2000/200120162478Å San Diego À CA æ"À 6,000Å æ"À 120,761Å 6,000Å 120,761Å 126,761Å æ"À æ"20162617Å San Diego À CA æ"À 2,734Å 5,195Å 9,363Å 2,734Å 14,558Å 17,292Å (4,106)1991/202020172618Å San Diego À CA æ"À 4,100Å 12,395Å 22,843Å 4,100Å 35,238Å 39,338Å (14,493)1991/202020172622Å San Diego À CA æ"À 17,201Å æ"À 17,201Å 17,201Å 17,201Å (2,091)202020042872Å San Diego À CA æ"À 4,120Å 38,351Å 1,044Å 10,120Å 39,395Å 49,515Å (9,481)199520182873Å San Diego À CA æ"À 6,052Å 14,122Å 1,445Å 6,052Å 15,567Å 21,619Å (2,941)199720183069Å San Diego À CA æ"À 7,054Å 7,794Å 24,081Å 6,954Å 31,975Å 38,929Å (4,467)2007/202120193110Å San Diego À CA æ"À 19,120Å æ"À 9,373Å 20,587Å 7,906Å 28,493Å (14)æ"20213111Å San Diego À CA æ"À 24,729Å æ"À 2,141Å 24,830Å 2,040Å 26,870Å (18)æ"2023153Å San Diego À CA æ"À 1,215Å æ"À 15Å 1,217Å 13Å 1,230Å æ"À æ"20231410Å South San Francisco À CA æ"À 4,900Å 18,100Å 12,327Å 4,900Å 30,427Å 35,327Å (16,142)2000/201920071411Å South San Francisco À CA æ"À 8,000Å 27,700Å 33,196Å 8,000Å 60,896Å 68,896Å (21,778)2003/201920071412Å South San Francisco À CA æ"À 10,100Å 22,521Å 10,501Å 10,100Å 33,022Å 43,122Å (14,123)199920071413Å South San Francisco À CA æ"À 8,000Å 28,299Å 8,603Å 8,000Å 36,902Å 44,902Å (19,128)200020071430Å South San Francisco À CA æ"À 10,700Å 23,621Å 27,995Å 10,733Å 51,583Å 62,316Å (16,385)1998/201920071431Å South San Francisco À CA æ"À 7,000Å 15,500Å 10,711Å 7,022Å 26,189Å 33,211Å (10,767)200120071435Å South San Francisco À CA æ"À 13,800Å 42,500Å 26,593Å 13,800Å 69,093Å 82,893Å (24,860)2008/201020071436Å South San Francisco À CA æ"À 14,500Å 45,300Å 42,147Å 14,500Å 87,447Å 101,947Å (26,760)202420071437Å South San Francisco À CA æ"À 9,400Å 24,800Å 36,750Å 9,400Å 61,550Å 70,950Å (24,113)2008/201020071439Å South San Francisco À CA æ"À 11,900Å 68,848Å 13,735Å 11,900Å 82,583Å 94,483Å (29,994)20032007136Table of ContentsEncumbrances at December 31, 2024Initial cost to CompanyCosts Capitalized Subsequent to Acquisition(3)Gross Amount at Which Carried As of December 31, 2024Accumulated Depreciation(5)Year Constructed(6)Year AcquiredCityStateLand and improvements(1)Buildings and Improvements(2)Land and improvementsBuildings and ImprovementsTotal(4)1440Å South San Francisco À CA æ"À 10,000Å 57,954Å 15,024Å 10,000Å 72,978Å 82,978Å (24,006)200320071441Å South San Francisco À CA æ"À 9,300Å 43,549Å 22,619Å 9,300Å 66,168Å 75,468Å (16,875)200320071442Å South San Francisco À CA æ"À 11,000Å 47,289Å 42,668Å 11,000Å 89,957Å 100,957Å (26,528)202320071443Å South San Francisco À CA æ"À 13,200Å 60,932Å 3,283Å 13,200Å 64,215Å 77,415Å (26,657)200720071444Å South San Francisco À CA æ"À 10,500Å 33,776Å 13,824Å 10,500Å 47,600Å 58,100Å (14,058)202420071445Å South San Francisco À CA æ"À 10,600Å 34,083Å 46Å 10,600Å 34,129Å 44,729Å (14,848)200320071458Å South San Francisco À CA æ"À 10,900Å 20,900Å 6,924Å 10,900Å 27,824Å 38,724Å (10,664)200520071459Å South San Francisco À CA æ"À 9,800Å 394Å 157,274Å 9,800Å 157,668Å 167,468Å (11,273)202320071462Å South San Francisco À CA æ"À 7,117Å 600Å 5,280Å 7,117Å 5,880Å 12,997Å (1,956)1984/201220071463Å South San Francisco À CA æ"À 10,381Å 2,300Å 17,197Å 10,381Å 19,497Å 29,878Å (6,763)1979/201220071464Å South San Francisco À CA æ"À 7,403Å 700Å 9,060Å 7,403Å 9,760Å 17,163Å (3,302)1965/201220071468Å South San Francisco À CA æ"À 10,100Å 24,010Å 11,565Å 10,100Å 35,578Å 45,678Å (16,168)200620071480Å South San Francisco À CA æ"À 32,210Å 3,110Å 160,550Å 32,210Å 163,660Å 195,870Å (7,004)202320071528Å South San Francisco À CA æ"À æ"À 188,739Å æ"À 188,739Å 188,739Å (275)æ"20071559Å South San Francisco À CA æ"À 5,666Å 5,773Å 9,965Å 5,666Å 5,972Å 11,638Å (5,923)196820071560Å South San Francisco À CA æ"À 1,204Å 1,293Å 2,683Å 1,204Å 3,976Å 5,180Å (3,267)196620071983Å South San Francisco À CA æ"À 8,648Å æ"À 90,582Å 8,648Å 90,582Å 99,230Å (31,738)201620111984Å South San Francisco À CA æ"À 7,844Å æ"À 90,761Å 7,844Å 90,761Å 98,605Å (34,910)201720111985Å South San Francisco À CA æ"À 6,708Å æ"À 122,716Å 6,708Å 122,716Å 129,424Å (38,270)201720111986Å South San Francisco À CA æ"À 6,708Å æ"À 120,758Å 6,708Å 120,758Å 127,466Å (38,078)201820111987Å South San Francisco À CA æ"À 8,544Å æ"À 100,777Å 8,544Å 100,777Å 109,321Å (28,885)201920111988Å South San Francisco À CA æ"À 10,120Å æ"À 119,625Å 10,120Å 119,625Å 129,745Å (35,906)201920111989Å South San Francisco À CA æ"À 9,169Å æ"À 100,395Å 9,169Å 100,395Å 109,564Å (23,088)202020112553Å South San Francisco À CA æ"À 2,897Å 8,691Å 4,478Å 2,897Å 13,169Å 16,066Å (5,172)198820152554Å South San Francisco À CA æ"À 995Å 2,754Å 2,332Å 995Å 5,086Å 6,081Å (1,757)198820152555Å South San Francisco À CA æ"À 2,202Å 10,776Å 2,527Å 2,202Å 13,303Å 15,505Å (3,917)198820152556Å South San Francisco À CA æ"À 2,962Å 15,108Å 1,557Å 2,962Å 16,665Å 19,627Å (4,704)198820152557Å South San Francisco À CA æ"À 2,453Å 13,063Å 3,842Å 2,453Å 16,905Å 19,358Å (6,725)198820152558Å South San Francisco À CA æ"À 1,163Å 5,925Å 315Å 1,163Å 6,240Å 7,403Å (1,626)198820152624Å South San Francisco À CA æ"À 25,502Å 42,910Å 14,832Å 25,502Å 57,742Å 83,244Å (14,353)200120172870Å South San Francisco À CA æ"À 23,297Å 41,797Å 28,804Å 23,330Å 70,568Å 93,898Å (21,151)1996/201920182871Å South San Francisco À CA æ"À 20,293Å 41,262Å 22,121Å 20,333Å 63,343Å 83,676Å (23,373)1999/201920183100Å South San Francisco À CA æ"À 14,245Å æ"À 15,095Å 14,245Å 15,095Å 29,340Å æ"À æ"20213101Å South San Francisco À CA æ"À 61,208Å æ"À 29,603Å 61,208Å 29,603Å 90,811Å æ"À æ"20213102Å South San Francisco À CA æ"À 43,885Å æ"À 6,359Å 43,885Å 6,359Å 50,244Å æ"À æ"20213123Å South San Francisco À CA æ"À æ"À 6,456Å æ"À 6,456Å æ"À æ"20073154Å South San Francisco CAæ"À æ"À æ"À 56,590Å æ"À 56,590Å 56,590Å (307)æ"æ"2705Å Cambridge À MA æ"À 24,371Å 128,498Å 197Å 24,371Å 128,695Å 153,066Å (17,582)201120202706Å Cambridge À MA æ"À 15,473Å 149,051Å 850Å 15,473Å 149,901Å 165,374Å (22,324)201920202707Å Cambridge À MA æ"À 25,549Å 229,547Å 8,597Å 25,549Å 138,144Å 263,693Å (33,377)201920202708Å Cambridge À MA æ"À æ"À 17,751Å 539Å æ"À 18,290Å 18,290Å (1,902)201020202709Å Cambridge À MA æ"À æ"À 15,451Å 29Å æ"À 15,480Å 15,480Å (1,579)201920202928Å Cambridge À MA æ"À 44,215Å 24,120Å 3,154Å 44,215Å 27,274Å 71,489Å (5,108)198420192929Å Cambridge À MA æ"À 20,516Å æ"À 159,436Å 20,516Å 159,436Å 179,952Å (15,859)202220193074Å Cambridge À MA æ"À 78,762Å 252,153Å 14,635Å 78,762Å 266,788Å 345,550Å (41,328)201820193106Å Cambridge À MA æ"À 20,644Å 2,982Å 621Å 20,644Å 3,603Å 24,247Å (340)195020213107Å Cambridge À MA æ"À 19,009Å 12,327Å 1,875Å 19,009Å 14,202Å 33,211Å (1,202)197320213108Å Cambridge À MA æ"À 123,074Å 7,513Å 8Å 123,074Å 7,521Å 130,595Å (969)196520213109Å Cambridge À MA æ"À 5,903Å æ"À 637Å 5,903Å 637Å 6,540Å æ"À æ"20213112Å Cambridge À MA æ"À 23,402Å 47,623Å 1,385Å 23,402Å 49,008Å 72,410Å (5,706)198520213113Å Cambridge À MA æ"À 32,244Å æ"À 8,417Å 36,119Å 4,542Å 40,661Å æ"À æ"20213114Å Cambridge À MA æ"À 22,969Å æ"À (1,179)22,969Å (1,179)21,790Å æ"À æ"20213115Å Cambridge À MA æ"À 66,786Å æ"À 2,536Å 66,786Å 2,536Å 69,322Å æ"À æ"20213116Å Cambridge À MA æ"À 17,413Å æ"À 17,413Å 17,413Å æ"À æ"20213119Å Cambridge À MA æ"À æ"À 29,667Å æ"À 29,667Å 29,667Å (2,984)202120213120Å Cambridge À MA æ"À 18,063Å æ"À 1,417Å 18,063Å 1,417Å 19,480Å æ"À æ"20213122Å Cambridge À MA æ"À 25,247Å æ"À 3,293Å 25,247Å 3,293Å 28,540Å æ"À æ"20213136Å Cambridge À MA æ"À 4,118Å æ"À (161)4,119Å (162)3,957Å æ"À æ"20213137Å Cambridge À MA æ"À 41,327Å æ"À 4,680Å 41,327Å 4,680Å 46,007Å æ"À æ"20213141Å Cambridge À MA æ"À 72,466Å æ"À 9,303Å 72,768Å 9,001Å 81,769Å æ"À æ"20223148Å Cambridge À MA æ"À 2,277Å æ"À 67Å 2,290Å 54Å 2,344Å æ"À æ"20223149Å Cambridge À MA æ"À 5,690Å æ"À 625Å 5,746Å 569Å 6,315Å æ"À æ"20223150Å Cambridge À MA æ"À 1,651Å æ"À 360Å 1,559Å 352Å 2,011Å æ"À æ"20223151Å Cambridge À MA æ"À 8,532Å æ"À 904Å 8,583Å 853Å 9,436Å æ"À æ"20223152Å Cambridge À MA æ"À 9,892Å æ"À 1,525Å 10,507Å 910Å 11,417Å æ"À æ"2023MA5394Å Cambridge À MA æ"À 4,441Å æ"À 113Å 4,441Å 113Å 4,554Å æ"À æ"20242630Å Lexington À MA æ"À 16,411Å 49,682Å (2,284)12,967Å 50,842Å 63,809Å (12,431)199920172631Å Lexington À MA æ"À 7,759Å 142,081Å 30,473Å 6,978Å 173,335Å 180,313Å (34,532)2010/202320172632Å Lexington À MA æ"À æ"À 21,390Å 126,772Å æ"À 148,162Å 148,162Å (25,261)202120183070Å Lexington À MA æ"À 14,013Å 17,083Å (269)14,013Å 16,814Å 30,827Å (3,110)1974/201220193071Å Lexington À MA æ"À 14,930Å 16,677Å (121)14,930Å 16,566Å 31,486Å (2,782)1970/201220193072Å Lexington À MA æ"À 34,598Å 43,023Å (288)34,598Å 42,744Å 77,342Å (9,256)1967/201320193073Å Lexington À MA æ"À 37,050Å 44,647Å 144Å 37,050Å 44,791Å 81,841Å (9,883)201720193093Å Waltham À MA æ"À 47,792Å 275,556Å 26,887Å 47,790Å 302,445Å 350,235Å (49,524)201820209999Å Denton à TX æ"À 100Å æ"À 100Å æ"À 100Å æ"À 2016464Å Salt Lake City À UT æ"À 630Å 6,921Å 2,563Å 630Å 9,484Å 10,114Å (6,260)19962001465Å Salt Lake City À UT æ"À 125Å 6,368Å 68Å 125Å 6,436Å 6,561Å (3,415)19992001466Å Salt Lake City À UT æ"À æ"À 14,614Å (1,401)æ"À 13,213Å 13,213Å (5,702)200220011593Å Salt Lake City À UT æ"À æ"À 23,998Å 250Å æ"À 24,248Å 24,248Å (10,516)20102010Å À S æ"À \$1,874,225Å \$3,195,605Å \$3,742,955Å \$1,877,701Å \$6,935,084Å \$8,812,785Å \$(1,644,660)À 137Table of ContentsEncumbrances at December 31, 2024Initial cost to CompanyCosts Capitalized Subsequent to Acquisition(3)Gross Amount at Which Carried As of December 31, 2024Accumulated Depreciation(5)Year Constructed(6)Year AcquiredCityStateLand and improvements(1)Buildings and Improvements(2)Land and improvementsBuildings and ImprovementsTotal(4)Continuing care retirement community3089Å Birmingham à AL \$æ"À \$6,193Å \$32,146Å \$7,845Å \$6,670Å \$39,514Å \$46,184Å \$(9,716)199120203090Å Bradenton à FL æ"À 5,216Å 88,090Å 29,437Å 6,037Å 116,706Å 122,743Å (27,956)198520202997Å Clearwater à FL 64,402Å 6,680Å 132,521Å 23,978Å 7,317Å 155,862Å 163,179Å (27,404)199120203086Å Jacksonville à FL æ"À 19,660Å 167,860Å 27,057Å 21,211Å 193,366Å 214,577Å (38,594)198920202996Å Leesburg à FL æ"À 8,941Å 65,698Å 20,758Å 9,817Å 85,580Å 95,397Å (19,236)199020202995Å Port Charlotte à FL æ"À 5,344Å 159,612Å 21,429Å 7,102Å 179,283Å 186,385Å (30,007)198720202998Å Seminole à FL 41,845Å 14,080Å 77,485Å 14,823Å 15,047Å 91,341Å 106,388Å (14,930)199020203085Å Seminole à FL æ"À 13,038Å 116,819Å 11,766Å 13,834Å 127,789Å 141,623Å (28,051)198820203092Å Sun City Center à FL æ"À 25,254Å 175,535Å 25,544Å 26,918Å 199,415Å 226,333Å (46,179)199220203087Å The Villages à FL æ"À 6,311Å 113,061Å 19,819Å 6,707Å 132,484Å 139,191Å (26,539)200920203084Å Holland à MI æ"À 1,572Å 88,960Å 13,297Å 2,134Å 101,695Å 103,829Å (19,395)199120202991Å Coatesville à PA æ"À 12,949Å 126,243Å 22,116Å 13,616Å 147,692Å 161,308Å (26,697)198820203080Å Haverford à PA æ"À 16,461Å 108,816Å 32,212Å 16,461Å 141,028Å 157,489Å (57,476)198920063088Å Spring à TX æ"À 3,210Å 30,085Å 13,679Å 3,544Å 43,430Å 46,974Å (7,776)200820203081Å Fort Belvoir À VA æ"À 11,594Å 99,528Å 22,394Å 11,594Å 121,922Å 133,516Å (55,893)19902006106,247Å \$156,503Å \$1,582,459Å \$36,154Å \$168,009Å \$1,877,107Å \$2,045,116Å \$(435,849)Å Total real estate assets held for saleæ"À (4,141)(20,364)13,844Å (4,141)(6,520)(10,661)2,821Å Total, excluding held for sale\$356,750Å \$2,887,257Å \$11,334,757Å \$5,692,420Å \$2,918,758Å \$16,995,676Å \$19,914,434Å \$(4,083,030) (1)Assets with no initial land costs to the Company represent land that the Company leases from a third party (i.e., ground leases).(2)Assets with no initial buildings and improvements costs to the Company represent development projects in process or completed.(3)Includes adjustments for impairments, disposals, casualty events, and costs capitalized subsequent to acquisition, net of incidental income, if applicable. See Note 6 for information regarding impairment charges recognized during the year ended December 31, 2024.(4)As of December 31, 2024, the aggregate gross cost of property included above for federal income tax purposes was approximately \$21Å billion.(5)Buildings and improvements are depreciated over useful lives ranging up to 50 years.(6)Year of original construction/year of last major renovation, if applicable.138Table of ContentsA summary of activity for real estate and accumulated depreciation is as follows (in thousands): Year ended December 31,202420232022Real estate:Balances at beginning of year\$16,620,314Å \$16,211,621Å \$15,506,658Å Real estate assets acquired in connection with the Merger\$3,696,519Å æ"À æ"À Acquisition of real estate and development and improvements\$668,803Å \$74,225Å 1,102,593Å Sales and/or transfers to assets held for sale(909,629)(137,731)(82,350)Deconsolidation of real estateæ"À æ"À (189,605)Impairments(13,118)æ"À æ"À Other(1)(148,455)(207,801)(125,675)Balances at end of year\$19,914,434Å \$16,620,314Å \$16,211,621Å Accumulated depreciation:Balances at beginning of year\$3,591,951Å \$3,188,138Å \$2,839,229Å Depreciation expense\$749,376Å 609,461Å 575,125Å Sales and/or transfers to assets held for sale(132,604)(12,711)(30,428)Deconsolidation of real estateæ"À æ"À (89,766)Other(1)(125,693)(192,937)(106,022)Balances at end of year\$5,483,083Å \$3,591,951Å \$3,188,138Å (1)Primarily represents real estate and accumulated depreciation related to fully depreciated assets and reductions to net real estate due to casualty events.139Table of ContentsSchedule IV: Mortgage Loans on Real Estate(in thousands)LocationSegmentInterest RateFixed / VariableMaturity DatePeriodic Payment TermsPrior LiensFace Amount of MortgagesCarrying Amount of MortgagesPrincipal Amount Subject to Delinquent Principal or InterestFirst mortgages relating to 61 properties: MultipleOther6.00Å %Fixed17/19/2026(1)Interest only\$æ"À \$418,389Å \$399,209Å \$æ"À First mortgages relating to 5 properties: MultipleOtherGreater of 9.00 or 4.00 + (SOFR + 10 bps)Variable81/2027Interest onlyæ"À 58,090Å \$7,177Å æ"À First mortgages relating to 10 properties: MultipleOtherGreater of 12.00 or 7.00 + (SOFR + 11 bps)Variable1/21/2025(2)Interest onlyæ"À 48,000Å 47,911Å æ"À Construction loan relating to one property: ArizonaOther7.47Å %Fixed26/6/2027(3)(4)æ"À 25,654Å 23,528Å æ"À Other construction loans each individually less than 3% of total carrying amount: Various(5)Other7.57 to 7.84%Fixed 12/31/2026 to 7/19/2027(4)æ"À 21,238Å 20,135Å æ"À First mortgages relating to one property: AlabamaOther10.00Å %Fixed1/12/2025(6)(4)æ"À 35,350Å 34,592Å æ"À Other first mortgages each individually less than 3% of total carrying amount: Various(7)Other7.00 to 10.00% Fixed6/30/2025 to 12/20/2028(8)(9)æ"À 31,761Å 30,232Å æ"À \$æ"À \$638,482Å \$612,784Å æ"À (1)This loan includes options to extend the maturity date to July 19, 2028.(2)In January 2025, the Company received full repayment of the outstanding balance of this secured loan (see Note 8 to the Consolidated Financial Statements for additional information).(3)This loan includes an option to extend the maturity date to May 5, 2028.(4)A portion of interest is due monthly with remaining interest added to the outstanding principal balance.(5)Includes various construction loans each related to one property in Arizona and Texas. In January 2025, the Company received full repayment of the \$15Å million

outstanding balance of a construction loan in Texas (see Note 8 to the Consolidated Financial Statements for additional information).)(6)In January 2025, the maturity date of this loan was extended to July 12, 2025.(7)Includes various first mortgages each related to one property in Arizona, Florida, Georgia, Texas, and Wisconsin.(8)This loan includes an option to extend the maturity date to December 20, 2029. (9)Includes both (i) loans that are interest only or (ii) loans in which a portion of interest is due monthly with remaining interest added to the outstanding principal balance.140Table of ContentsA Year Ended December 31, 202420232022Reconciliation of mortgage loansBalance at beginning of year\$175,717A \$341,749A \$390,291A Additions:New mortgage loans486,667A \$A \$A \$A Draws and additions to existing mortgage loans30,745A 11,602A 5,525A Total additions517,412A 11,602A 5,525A Deductions:Principal repayments(77,643)(183,084)(47,591)Recoveries (reserves) for loan losses(1)(2,702)5,450A (6,476)Total deductions(80,345)(177,634)(54,067)Balance at end of year\$612,784A \$175,717A \$341,749A (1)Excludes reserves and recoveries for expected loan losses associated with unfunded loan commitments which are included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets. 141Table of ContentsITEM 9. A A A Changes in and Disagreements with Accountants on Accounting and Financial DisclosureNone.ITEM 9A. A A A Controls and ProceduresDisclosureControls and Procedures. A We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rulesA and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.As required by RulesA 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of DecemberA 31, 2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of DecemberA 31, 2024.Managementâ€™s Annual Report on Internal Control over Financial Reporting. A Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act RulesA 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Controlâ€™Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Controlâ€™Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of DecemberA 31, 2024.The effectiveness of our internal control over financial reporting as of DecemberA 31, 2024 has been audited by Deloitte& ToucheA LLP, the independent registered public accounting firm that audited the financial statements included in this Annual Report on Form 10-K, as stated in their report, which is included herein.Changes in Internal Control Over Financial Reporting. A There were no changes in our internal control over financial reporting (as such term is defined in RulesA 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended DecemberA 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.142Table of ContentsREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMTTo the stockholders and the Board of Directors of Healthpeak Properties, Inc. Opinion on Internal Control over Financial Reporting We have audited the internal control over financial reporting of Healthpeak Properties, Inc. and subsidiaries (the â€œCompanyâ€) as of December 31, 2024, based on criteria established in Internal Control â€ Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (â€œCOSOâ€). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control â€ Integrated Framework (2013) issued by COSO. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2024, of the Company and our report dated February 4, 2025, expressed an unqualified opinion on those financial statements.Basis for Opinion The Companyâ€™s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Managementâ€™s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Companyâ€™s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control over Financial Reporting A companyâ€™s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companyâ€™s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companyâ€™s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate./s/ DELOITTE & TOUCHEA LLPCosta Mesa, CaliforniaFebruaryA 4, 2025143Table of ContentsITEM 9B. A A A Other InformationInsider Trading ArrangementsDuring the three months ended DecemberA 31, 2024, none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.ITEM 9C. A A A Disclosure Regarding Foreign Jurisdictions that Prevent InspectionsNot applicable.144Table of ContentsPART IIITEM 10. A A A Directors, Executive Officers and Corporate GovernanceExcept as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended DecemberA 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.We have adopted a Code of Business Conduct and Ethics that applies to all of our directors and employees, including our principal executive officer, principal financial officer, principal accounting officer, and controller. We have also adopted a Vendor Code of Business Conduct and Ethics applicable to our vendors and business partners. Current copies of our Code of Business Conduct and Ethics and Vendor Code of Business Conduct and Ethics are posted on our website at www.healthpeak.com/corporate-impact/governance. In addition, waivers from, and amendments to, our Code of Business Conduct and Ethics that apply to our directors and executive officers, including our principal executive officer, principal financial officer, principal accounting officer, or persons performing similar functions, will be timely posted in the Investors section of our website at www.healthpeak.com.ITEM 11. A A A Executive CompensationThe information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended DecemberA 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.ITEM 12. A A A Security Ownership of Certain Beneficial Owners and Management and Related Stockholder MattersThe information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended DecemberA 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.ITEM 13. A A A Certain Relationships and Related Transactions, and Director IndependenceThe information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended DecemberA 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.ITEM 14. A A A Principal Accountant Fees and ServicesThe information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended DecemberA 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.145Table of ContentsPART IVITEM 15. A A A Exhibits and Financial Statement Schedules(a) 1. A A Financial StatementsThe following Consolidated Financial Statements are included in Part II, Item 8, Financial Statements and Supplementary Data of this Annual Report on Form 10-K.Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)Consolidated Balance Sheets - DecemberA 31, 2024 and 2023Consolidated Statements of Operations - for the years ended DecemberA 31, 2024, 2023, and 2022Consolidated Statements of Comprehensive Income (Loss) - for the years ended DecemberA 31, 2024, 2023, and 2022Consolidated Statements of Equity and Redeemable Noncontrolling Interests - for the years ended DecemberA 31, 2024, 2023, and 2022Consolidated Statements of Cash Flows - for the years ended DecemberA 31, 2024, 2023, and 2022Notes to the Consolidated Financial Statements(a) 2. A A Financial Statement SchedulesThe following Consolidated Financial Statement Schedules are included in Part II, Item 8, Financial Statements and Supplementary Data of this Annual Report on Form 10-K.ScheduleA II: Valuation and Qualifying AccountsScheduleA III: Real Estate and Accumulated DepreciationSchedule IV: Mortgage Loans on Real Estate(a) 3. A A A ExhibitsExhibitIncorporated by reference hereinNumberDescriptionFormDate Filed2.1+Agreement and Plan of Merger, dated February 7, 2023, by and among Healthpeak Properties, Inc., New Healthpeak, Inc. and Healthpeak Merger Sub, Inc.Current Report on Form 8-K12BFebruary 10, 20232.2+Agreement and Plan of Merger, dated as of October 29, 2023, by and among Healthpeak Properties, Inc., DOC DR Holdco, LLC (formerly Alpine Sub, LLC), DOC DR, LLC (formerly Alpine OP Sub, LLC), Physicians Realty Trust and Physicians Realty L.P.Current Report on Form 8-KOctober 30, 20233.1Articles of Amendment and Restatement of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023.Current Report on Form 8-K12BFebruary 10, 20233.2Articles of Amendment of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023.Current Report on Form 8-K12BFebruary 10, 20233.3Articles of Amendment of Healthpeak Properties, Inc., effective February 29, 2024.Current Report on Form 8-KMarch 1, 20243.4Amended and Restated Bylaws of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.), dated February 10, 2023.Current Report on Form 8-K12BFebruary 10, 20233.5Amendment to the Bylaws of Healthpeak Properties, Inc., effective March 1, 2024.Current Report on Form 8-KMarch 1, 20244.1Indenture, dated as of September 1, 1993, between Healthpeak and The Bank of New York, as trustee.Registration Statement on Form Sâ€™3/A(Registration No. 333-86654)May 21, 2002146Table of Contents4.1.1First Supplemental Indenture dated as of January 24, 2011, to the Indenture, dated as of September 1, 1993, by and between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8â€™KJanuary 24, 20114.1.2Second Supplemental Indenture, dated as of February 10, 2023, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-K12BFebruary 10, 20234.1.3Third Supplemental Indenture, dated as of March 1, 2024, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, DOC DR Holdco, LLC, as guarantor, DOR DR, LLC, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KMarch 1, 20244.2Amended and Restated Indenture, dated as of February 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (amending and restating the Indenture, dated November 21, 2012, between Healthpeak and the trustee).Registration Statement on Form S-3ASR(Registration No. 333â€™269718)February 13, 20234.2.1Fifth Supplemental Indenture, dated January 21, 2015, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on FormA 8â€™KJanuary 21, 20154.2.2Sixth Supplemental Indenture, dated May 20, 2015, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on FormA 8â€™KMay 20, 20154.2.3Eighth Supplemental Indenture dated July 5, 2019, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on FormA 8â€™KJuly 5, 20194.2.4Ninth Supplemental Indenture dated November 19, 2019, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on FormA 8â€™KNovember 21, 20194.2.5Tenth Supplemental Indenture, dated June 23, 2020, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KJune 23, 20204.2.6Eleventh Supplemental Indenture, dated July 12, 2021, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KJuly 12, 20214.2.7Twelfth Supplemental Indenture, dated November 24, 2021, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KNovember 24, 20214.2.8Thirteenth Supplemental Indenture, dated January 17, 2023, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KJanuary 17, 20234.2.9Fourteenth Supplemental Indenture, dated as of February 10, 2023, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-K12BFebruary 10, 20234.2.10Fifteenth Supplemental Indenture, dated as of May 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Report on Form 8-KMay 10, 20234.2.11Sixteenth Supplemental Indenture, dated as of March 1, 2024, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, DOC DR Holdco, LLC, as guarantor, DOC DR, LLC, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.Current Form on Form 8-KMarch 1, 2024147Table of Contents4.3Senior Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee.Registration Statement on Form S-3 ASR (File No. 333-276954)February 8, 20244.3.1First Supplemental Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 4.300% Senior Notes due 2027.Registration Statement on Form S-3 ASR (File No. 333-276954)February 8, 20244.3.2Second Supplemental Indenture, dated as of December 1, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 3.950% Senior Notes due 2028.Registration Statement on Form S-3 ASR (File No. 333-276954)February 8, 20244.3.3Third Supplemental Indenture, dated as of October 13, 2021, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 2.625% Senior Notes due 2031.Registration Statement on Form S-3 ASR (File No. 333-276954)February 8, 20244.3.4Fourth Supplemental Indenture, dated as of March 1, 2024, among DOC DR, LLC, as issuer, DOC DR Holdco, LLC, as guarantor, Healthpeak Properties, Inc., as guarantor, Healthpeak OP, LLC, as guarantor, and U.S. Bank Trust Company, National Association, as trustee, including the form of guarantee.Current Report on Form 8-KMarch 1, 20244.4Form of 6.750% Senior Notes due 2041.Current Report on Form 8-KJanuary 24, 20114.5Form of 3.400% Senior Notes due 2025.Current Report on Form 8-KJanuary 21, 20154.6Form of 4.000% Senior Notes due 2025.Current Report on Form 8-KMay 20, 20154.7Form of 3.250% Senior Notes due 2026. Current Report on Form 8-KJuly 5, 20194.8Form of 3.500% Senior Notes due 2029. Current Report on Form 8-KJuly 5, 20194.9Form of 3.000% Senior Notes due 2030.Current Report on Form 8-KNovember 21, 20194.10Form of 2.875% Senior Notes due 2031.Current Report on Form 8-KJune 23, 20204.11Form of 1.350% Senior Notes due 2027.Current Report on Form 8-KJuly 12, 20214.12Form of 2.125% Senior Notes due 2028.Current Report on Form 8-KNovember 24, 20214.13Form of 5.250% Senior Notes due 2032.Current Report on Form 8-KJanuary 17, 20234.14Form of 5.250% Senior Notes due 2032, including the form of Notation of Guarantee.Current Report on Form 8-KMay 10, 20234.15â€ Description of Healthpeak Capital Stock.10.1Operating Agreement of Healthpeak OP, LLC, dated as of February 10, 2023.Current Report on Form 8-K12BFebruary 10, 202310.2Omnibus Assignment, Assumption and Amendment, dated February 7, 2023 by and between Healthpeak OP, LLC (formerly Healthpeak Properties, Inc.) and Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.).Current Report on Form 8-K12BFebruary 10, 202310.3Third Amended and Restated Credit Agreement, dated as of December 9, 2024, by and among Healthpeak OP, as borrower, Healthpeak, DOC Holdco and DOC DR, as guarantors, the lenders referred to therein, and Bank of America, N.A., as administrative agent.Current Report on Form 8-KDecember 9, 202410.4Third Amended and Restated Credit Agreement, dated as of September 24, 2021, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent.Current Report on Form 8-KMarch 1, 202410.4.1First Amendment to the Third Amended and Restated Credit Agreement, dated as of March 31, 2023, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent.Current Report on Form 8-KMarch 1, 2024148Table of Contents10.4.2Second Amendment to Third Amendment to Third Amended and Restated Credit Agreement, dated as of May 24, 2023, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders

party thereto and KeyBank National Association, as administrative agent.Current Report on Form 8-KMarch 1, 202410.4.3Consent and Third Amendment to Third Amended and Restated Credit Agreement, dated as of February 21, 2024, by and among DOC DR, LLC, DOC DR Holdco, LLC, Healthpeak Properties, Inc., Healthpeak OP, LLC, the lenders party thereto, and KeyBank National Association, as administrative agent.Current Report on Form 8-KMarch 1, 202410.4.4Fourth Amendment to Third Amended and Restated Credit Agreement, dated as of December 9, 2024, by and among DOC DR, as borrower, Healthpeak, Healthpeak OP and DOC Holdco, as guarantors, the lenders referred to therein, and KeyBank National Association, as administrative agent.Current Report on Form 8-KDecember 9, 202410.5Term Loan Agreement, dated as of August 22, 2022, by and among Healthpeak, as borrower, the lenders referred to therein, and Bank of America, N.A., as administrative agent.Current Report on Form 8-KAugust 22, 202210.5.1Consent and Amendment No. 1 to Term Loan Agreement, dated as of February 10, 2023, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., the lenders listed therein and Bank of America, N.A., as administrative agent.Current Report on Form 8-K12BFebruary 10, 202310.5.2Consent and Amendment No. 2 and Joinder to Term Loan Agreement, dated as of March 1, 2024, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., DOC DR Holdco, LLC, DOC DR, LLC, the lenders party thereto and Bank of America, N.A., as administrative agent.Quarterly Report on Form 10-QApril 26, 202410.5.3Amendment No. 3 to Term Loan Agreement, dated as of December 9, 2024, by and among Healthpeak OP, as borrower, Healthpeak, DOC Holdco and DOC DR, as guarantors, the lenders referred to therein, and Bank of America, N.A., as administrative agent.Current Report on Form 8-KDecember 9, 202410.6At-the-Market Equity Offering Sales Agreement, dated February 17, 2023, among Healthpeak Properties, Inc., Healthpeak OP, LLC, and the sales agents, forward sellers and forward purchasers referred to therein.Current Report on Form 8-KFebruary 17, 202310.6.1Amendment No. 1 to At-the-Market Equity Offering Sales Agreement, dated March 11, 2024, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward Purchasers.Current Report on Form 8-KMarch 11, 202410.6.2Amendment No. 2 to At-the-Market Equity Offering Sales Agreement, dated May 3, 2024, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward Purchasers.Quarterly Report on Form 10-QJuly 26, 202410.7*Second Amended and Restated Director Deferred Compensation Plan.Quarterly Report on Form 10a6QNovember 3, 200910.8*Non-Employee Directors Stock-for-Fees Program.Quarterly Report on Form 10-QAugust 5, 201410.9*Executive Severance Plan (as amended and restated as of April 27, 2023).Quarterly Report on Form 10-QApril 28, 202310.10*Executive Change in Control Severance Plan (as amended and restated as of April 27, 2023).Quarterly Report on Form 10-QApril 28, 2023149Table of Contents10.11*Amended and Restated Healthpeak Properties, Inc. 2014 Performance Incentive Plan, as amended through October 24, 2019.Anual Report on Form 10-KFebruary 13, 202010.11.1*First Amendment to Amended and Restated Healthpeak Properties, Inc. 2014 Performance Incentive Plan.Current Report on Form 8-K12BFebruary 10, 202310.11.2*Form of 2014 Performance Incentive Plan NEO Retentive LTIP RSU Agreement (adopted 2018).Quarterly Report on Form 10-QMay 3, 201810.11.3*Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based Restricted Stock Unit Agreement (adopted 2022).Quarterly Report on Form 10-QMay 4, 202210.11.4*Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Agreement (adopted 2023).Quarterly Report on Form 10-QApril 28, 202310.11.5*Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based LTIP Unit Agreement (adopted 2023).Quarterly Report on Form 10-QApril 28, 202310.11.6*Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).Quarterly Report on Form 10-QApril 28, 202310.11.7*Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).Quarterly Report on Form 10-QApril 28, 202310.11.8*Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Award Agreement (adopted 2023, for converted awards).Quarterly Report on Form 10-QApril 28, 202310.11.9*Form of 2014 Performance Incentive Plan Non-NEO LTIP Unit Award Agreement (adopted 2023, for converted awards).Quarterly Report on Form 10-QApril 28, 202310.12*Healthpeak Properties, Inc. 2023 Performance Incentive Plan.Current Report on Form 8-KApril 27, 202310.12.1*Form of 2023 Performance Incentive Plan Non-NEO Restricted Stock Unit Award Agreement (adopted 2023).Quarterly Report on Form 10-QApril 28, 202310.12.2*Form of 2023 Performance Incentive Plan Non-Employee Director Restricted Stock Unit Award Agreement (adopted 2023).Quarterly Report on Form 10-QApril 28, 202310.12.3*Form of 2023 Performance Incentive Plan Retentive Restricted Stock Unit Agreement (adopted in 2024).Quarterly Report on Form 10-QApril 26, 202410.12.4*Form of 2023 Performance Incentive Plan Retentive LTIP Unit Agreement (adopted in 2024).Quarterly Report on Form 10-QApril 26, 202410.12.5*Form of 2023 Performance Incentive Plan 3-Year Performance-Based Restricted Stock Unit Agreement (adopted in 2024).Quarterly Report on Form 10-QApril 26, 202410.12.6*Form of 2023 Performance Incentive Plan 3-Year Performance-Based LTIP Unit Agreement (adopted in 2024).Quarterly Report on Form 10-QApril 26, 202410.12.7*Form of 2023 Performance Incentive Plan Non-NEO OP Unit Award Agreement (adopted 2025, for converted awards).10.13*Form of Directors and Officers Indemnification Agreement.Anual Report on Form 10a6K, as amendedFebruary 12, 200810.14Amended and Restated Dividend Reinvestment and Stock Purchase Plan.Registration Statement on Form S 6S 3(Registration No. A 333a6 49746)November 13, 200010.15Offer Letter, dated February 29, 2024, from Healthpeak Properties, LLC to John T. Thomas.Quarterly Report on Form 10-QApril 26, 202419.1a Insider Trading Policy.21.1a Subsidiaries of the Company.22.1a List of Issuers of Guaranteed Securities.150Table of Contents23.1a Consent of Independent Registered Public Accounting Firma Deloitte & Touche LLP.31.1a Certification by Scott M. Brinker, Healthpeak's Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a6 14(a).31.2a Certification by Peter A. Scott, Healthpeak's Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a6 14(a).32.1a Certification by Scott M. Brinker, Healthpeak's Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a6 14(b) and 18 U.S.C. Section 1350.32.2a Certification by Peter A. Scott, Healthpeak's Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a6 14(b) and 18 U.S.C. Section 1350.97.1Policy Regarding the Recoupment of Certain Compensation Payments.Anual Report on Form 10-KFebruary 9, 2024101.INSa XBRL Instance Document a the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCHa XBRL Taxonomy Extension Schema Document.101.CALa XBRL Taxonomy Extension Calculation Linkbase Document.101.DEFa XBRL Taxonomy Extension Definition Linkbase Document.101.LABa XBRL Taxonomy Extension Label Linkbase Document.101.PREa XBRL Taxonomy Extension Presentation Linkbase Document.104Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101).

+ A A A Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). * A A A Management Contract or Compensatory Plan or Arrangement. a A A A Filed herewith. a A A A Furnished herewith. ITEM 16. A A A Form 10-K SummaryNone.151Table of ContentsSIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Dated: February 4, 2025Healthpeak Properties, Inc./s/ SCOTT M. BRINKERScott M. Brinker,President and Chief Executive Officer(Principal Executive Officer)Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.SignatureTitleDate/s/ SCOTT M. BRINKERPresident and Chief Executive Officer, DirectorFebruary 4, 2025Scott M. Brinker(Principal Executive Officer)/s/ PETER A. SCOTTChief Financial OfficerFebruary 4, 2025Peter A. Scott(Principal Financial Officer)/s/ SHAWN G. JOHNSTONExecutive Vice President and Chief Accounting OfficerFebruary 4, 2025Shawn G. Johnston(Principal Accounting Officer)/s/ KATHERINE M. SANDSTROMChair of the BoardFebruary 4, 2025Katherine M. Sandstrom/s/ JOHN T. THOMASVice Chair of the BoardFebruary 4, 2025John T. Thomas/s/ BRIAN G. CARTWRIGHTDirectorFebruary 4, 2025Brian G. Cartwright/s/ JAMES B. CONNORDirectorFebruary 4, 2025James B. Connor/s/ R. KENT GRIFFIN, Jr.DirectorFebruary 4, 2025R. Kent Griffin, Jr./s/ PAMELA J. KESSLERDirectorFebruary 4, 2025Pamela J. Kessler/s/ SARA G. LEWISDirectorFebruary 4, 2025Sara G. Lewis/s/ AVA E. LIAS-BOOKERDirectorFebruary 4, 2025Ava E. Lias-Booker/s/ TOMMY G. THOMPSONDirectorFebruary 4, 2025Tommy G. Thompson/s/ RICHARD A. WEISSDirectorFebruary 4, 2025Richard A. Weiss152 EX-4.15 2 ex41512312024.htm EX-4.15 DocumentEXHIBIT 4.15DESCRIPTION OF CAPITAL STOCK OF HEALTHPEAK PROPERTIES, INC.References to aew, a acausa and acaoura in this section refer to Healthpeak Properties, Inc.The following description summarizes the material provisions of the common stock and preferred stock we may offer, as well as certain provisions of Maryland law and of our charter, as amended, which we refer to as our charter, and our amended and restated bylaws, as amended, which we refer to as our bylaws. These descriptions are not complete and are subject to, and qualified in their entirety by reference to, our charter and our bylaws and applicable provisions of the Maryland General Corporation Law. For a complete description, we refer you to the Maryland General Corporation Law, our charter and our bylaws. Copies of our charter and bylaws are included as exhibits to our Annual Report on Form 10-KA for the fiscal year ended December 31, 2024.Our authorized capital stock consists of 1,500,000,000 shares of common stock, par value \$1.00A per share, and 50,000,000 shares of preferred stock, par value \$1.00 per share.Common StockAs of December 31, 2024, there were 699,485,139 shares of common stock outstanding. All shares of common stock participate equally in dividends payable to holders of common stock, when, and as if authorized by our board and declared by us, and in net assets available for distribution to holders of common stock on liquidation, dissolution, or winding up. Each outstanding share of common stock entitles the holder to one vote on all matters submitted to a vote of our stockholders. Holders of common stock do not have cumulative voting rights in the election of directors.All issued and outstanding shares of common stock are validly issued, fully paid and nonassessable. Holders of common stock do not have preference, conversion, exchange or preemptive rights. The common stock is listed on the New York Stock Exchange (NYSE Symbol: DOC).Preferred StockAs of December 31, 2024, we had no shares of preferred stock outstanding. Under our charter, our board is authorized without further stockholder action to establish and issue, from time to time, up to 50,000,000 shares of our preferred stock, in one or more series. Our board may grant the holders of preferred stock of any series preferences, powers and rights a voting or otherwise a senior to those of holders of shares of our common stock. Our board can authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of delaying or preventing a change of control transaction that might involve a premium price for holders of shares of our common stock or otherwise be in their best interest. All shares of preferred stock will, when issued in exchange for the consideration therefor, be fully paid and nonassessable and will have no preemptive rights. The Maryland General Corporation Law and our charter require our board to determine the terms and conditions of any series of preferred stock, including: a the number of shares constituting such series and the distinctive designation thereof; a the voting rights, if any, of such series; a the rate of dividends payable on such series, the time or times when dividends will be payable, the preference to, or any relation to, the payment of dividends to any other class or series of stock and whether the dividends will be cumulative or noncumulative; a whether there shall be a sinking or similar fund for the purchase of shares of such series and, if so, the terms and provisions that shall govern such fund;677897.4a the rights of the holders of shares of such series upon our liquidation, dissolution or winding up; a the rights, if any, of holders of shares of such series to convert such shares into, or to exchange such shares for, shares of any other class or series of our stock or any other securities, the price or prices or rate or rates of exchange, with such adjustments as shall be provided, at which such shares shall be convertible or exchangeable, whether such rights of conversion or exchange shall be exercisable at the option of the holder of the shares or upon the happening of a specified event and any other terms or conditions of such conversion or exchange; a if the shares are redeemable, the prices at which, and the terms and conditions on which, the shares of such series may be redeemed; and a any other preferences, powers and relative participating, optional or other special rights and qualifications, limitations or restrictions of shares of such series.Transfer and Ownership Restrictions Relating to Our Common StockOur charter contains restrictions on the ownership and transfer of our common stock that are intended to assist us in complying with the requirements to continue to qualify as a real estate investment trust, or REIT.Subject to limited exceptions, no person or entity may own, or be deemed to own by virtue of the applicable constructive ownership provisions of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, more than 9.8% (by number or value of shares, whichever is more restrictive) of the outstanding shares of our common stock. Our board may, but is in no event required to, waive the applicable ownership limit with respect to a particular stockholder if it determines that such ownership will not jeopardize our status as a REIT and our board otherwise decides such action would be in our best interests.These charter provisions further prohibit: a any person from actually or constructively owning shares of our stock that would result in our being a closely held a under Section 856(h) of the Internal Revenue Code or otherwise cause us to fail to qualify as a real estate investment trust (including but not limited to ownership that would result in us owning, actually or constructively, an interest in a tenant as described in Section 856(d)(2)(B) of the Internal Revenue Code) if the income derived by us, either directly or indirectly, from such tenant would cause us to fail to satisfy any of the gross income requirements of Section 856(c) of the Internal Revenue Code); and a any person from transferring shares of our capital stock if such transfer would result in shares of our stock being beneficially owned by fewer than 100 persons (determined without reference to any rules of attribution).Any person who acquires or attempts or intends to acquire actual or constructive ownership of shares of our stock that will or may violate any of these restrictions on ownership and transfer is required to give notice immediately to us and provide us with such other information as we may request in order to determine the effect of the transfer on our qualification as a REIT. Under our charter, if any purported transfer of our stock or any other event would otherwise result in any person violating the applicable ownership limit or such other limit as permitted by our board, then any such purported transfer is void and of no force or effect with respect to the purported transferee as to that number of shares of our stock in excess of the ownership limit or such other limit, and the transferee will acquire no right or interest in such excess shares. Any excess shares described above are transferred automatically, by operation of law, to a trust, the beneficiary of which is a qualified a charitable organization selected by us. Such automatic transfer will be deemed to be effective as of the close of business on the business day prior to the date of such violative transfer. Within 20A days of receiving notice from us of the transfer of shares to the trust, the trustee of the trust is required to sell the excess shares to a person or entity who could own the shares without violating the applicable ownership limit, or such other limit as permitted by our board, and distribute to the prohibited transferee an amount equal to the lesser of the price paid by the prohibited transferee for the excess shares or the sales proceeds received by the trust for the excess shares. Any proceeds in excess of the amount distributable to the prohibited transferee are distributed to the beneficiary of the trust. Prior to a sale of any such excess shares by the trust, the trustee is entitled to receive, in trust for the beneficiary, all dividends and other distributions paid by us with respect to such excess shares, and also is entitled to exercise all voting rights with respect to such excess shares.Subject to Maryland law, effective as of the date that such shares have been transferred to the trust, the trustee will have the authority, at the trustee's sole discretion: a to rescind as void any vote cast by a prohibited transferee prior to the discovery by us that the shares have been transferred to the trust; ora to recast such vote in accordance with the desires of the trustee acting for the benefit of the beneficiary of the trust.However, if we have already taken irreversible corporate action, then the trustee will not have the authority to rescind and recast such vote. Any dividend or other distribution paid to the prohibited transferee, prior to the discovery by us that such shares had been automatically transferred to a trust as described above, are required to be repaid to the trustee upon demand for distribution to the beneficiary of the trust. In the event that the transfer to the trust as described above is not automatically effective, for any reason, to prevent violation of the ownership limit or such other limit as permitted by our board, then our charter provides that the transfer of the excess shares is void ab initio.In addition, shares of common stock held in the trust shall be deemed to have been offered for sale to us, or our designee, at a price per share equal to the lesser of: a the price per share in the transaction that resulted in such transfer to the trust or, if the event that resulted in the transfer to the trust did not involve a purchase of such shares at market price, the market price on the day of such event; and a the market price on the date we, or our designee, accepted the offer.We will have the right to accept the offer until the trustee has sold the shares of stock held in the trust. Upon a sale to us, the interest of the beneficiary in the shares sold will terminate and the trustee will distribute the net proceeds of the sale to the prohibited transferee.If any purported transfer of shares of common stock would cause us to be beneficially owned by fewer than 100 persons, such transfer will be null and void ab initio in its entirety and the intended transferee will acquire no rights to the stock.All certificates representing shares of common stock bear a legend referring to the restrictions described above. The foregoing ownership limitations could delay, deter or prevent a transaction or a change in control of us that might involve a premium price for the common stock or otherwise be in the best interest of our stockholders.In addition, if our board shall, at any time and in good faith, be of the opinion that direct or indirect ownership of at least 9.9% of the voting shares of capital stock has or may become concentrated in the hands of one beneficial owner, it shall have the power: a by lot or other means deemed equitable by it to call for the purchase from any stockholder of a number of voting shares sufficient, in the opinion of our board, to maintain or bring the direct or indirect ownership of voting shares of capital stock of the beneficial owner to a level of no more than 9.9% of our outstanding voting shares; and a to refuse to transfer or issue voting shares of capital stock to any person whose acquisition of such voting shares would, in the opinion of the board, result in the direct or indirect ownership by that person of more than 9.9% of the outstanding voting shares of our capital stock.If our board fails to grant an exemption from this 9.9% ownership limitation, then the transfer of shares, options, warrants, or other securities convertible into voting shares that would create a beneficial owner of more than 9.9% of the outstanding voting shares shall be deemed void ab initio, and the intended transferee shall be deemed never to have had an interest in the transferred securities. The purchase price for any voting shares of capital stock so redeemed shall be equal to the fair market value of the shares reflected in the closing sales price for the

shares, if then listed on a national securities exchange, or the average of the closing sales prices for the shares if then listed on more than one national securities exchange, or if the shares are not then listed on a national securities exchange, the latest bid quotation for the shares if then traded over-the-counter, on the last business day immediately preceding the day on which we send notices of such acquisitions, or, if no such closing sales prices or quotations are available, then the purchase price shall be equal to the net asset value of such stock as determined by the board in accordance with the provisions of applicable law. From and after the date fixed for purchase by the board, the holder of any shares so called for purchase shall cease to be entitled to distributions, voting rights and other benefits with respect to such shares, except the right to payment of the purchase price for the shares. Business Combination Provisions Our charter requires that, except in some circumstances, any business combinations between us and a beneficial holder, together with its affiliates and associates, of 10% or more of our outstanding voting stock and any affiliate or associate of such holder, which we refer to as a Related Person, be approved by the affirmative vote of at least 90% of our outstanding voting shares. A business combination is defined in our charter as any merger or consolidation with or into a Related Person; any sale, lease, exchange, transfer or other disposition, including without limitation a mortgage or any other security device, of all or any Substantial Part (as defined below) of our assets, including any voting securities of a subsidiary, to a Related Person; any merger or consolidation of a Related Person with or into us; any sale, lease, exchange, transfer or other disposition of all or any Substantial Part of the assets of a Related Person to us; the issuance of any of our securities, other than by way of pro rata distribution to all stockholders, to a Related Person; and any agreement, contract or other arrangement providing for any of the transactions described above. The term Substantial Part means more than 10% of the book value of our total assets as of the end of our most recent fiscal year ending prior to the time the determination is being made. In addition to the restrictions on business combinations contained in our charter, Maryland law also contains restrictions on business combinations. See Certain Provisions of Maryland Law and Healthpeak Properties, Inc.'s Charter and Bylaws Business Combinations below. The foregoing provisions may have the effect of discouraging unilateral tender offers or other takeover proposals which stockholders might deem to be in their interests or in which they might receive a substantial premium. Our board's authority to issue and establish the terms of currently authorized preferred stock, without stockholder approval, may also have the effect of discouraging takeover attempts. See Preferred Stock above. The foregoing provisions could also have the effect of insulating current management against the possibility of removal and could, by possibly reducing temporary fluctuations in market price caused by accumulations of shares of our common stock, deprive stockholders of opportunities to sell at a temporarily higher market price. Our board believes, however, that inclusion of the business combination provisions in our charter may help assure fair treatment of our stockholders and preserve our assets. Transfer and Ownership Restrictions Relating to Our Preferred Stock Our charter may contain restrictions on the ownership and transfer of preferred stock that are intended to assist us in complying with the requirements to maintain our qualification as a REIT. Subject to limited exceptions, unless otherwise provided for in the terms of a particular series of preferred stock, no person or entity may own, or be deemed to own by virtue of the applicable constructive ownership provisions of the Internal Revenue Code, more than 9.8% (by number or value of shares, whichever is more restrictive) of the outstanding shares of such series of preferred stock. Our board may, but in no event will be required to, waive the applicable ownership limit with respect to a particular stockholder if it determines that such ownership will not jeopardize our qualification as a REIT and our board otherwise decides such action would be in our best interests. The mechanics for the ownership limits on our preferred stock will be similar to the mechanics related to our common stock, as described in Transfer and Ownership Restrictions Relating to Our Common Stock above, unless otherwise provided in the terms of a particular series of preferred stock. Certain Provisions of Maryland Law and of Healthpeak Properties, Inc.'s Charter and Bylaws Election of Directors Our bylaws provide that our board may establish, increase or decrease the number of directors, provided that the number thereof shall never be less than three nor more than thirteen. Our bylaws also provide for the election of directors, in uncontested elections, by a majority of the votes cast. In contested elections, the election of directors shall be by a plurality of the votes cast. Holders of common stock have no right to cumulative voting for the election of directors. Consequently, at each annual meeting of stockholders, the holders of a majority of the outstanding shares of our common stock can elect all of our directors. A vacancy resulting from an increase in the number of directors may be filled by a majority vote of the entire board or by the affirmative vote of the holders of a majority of our shares then entitled to vote at an election of directors. Other vacancies may be filled by the vote of a majority of the remaining directors. Removal of Directors Our charter provides that a director of ours may be removed by the affirmative vote of the holders of two-thirds of the outstanding shares of our voting stock or by a unanimous vote of all other directors. Our stockholders may elect a successor to fill any vacancy which results from the removal of a director. Business Combinations Under Maryland law, any business combinations between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include a merger, consolidation, share exchange, or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as: any person who beneficially owns ten percent or more of the voting power of the corporation's shares; or any affiliate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of ten percent or more of the voting power of the then outstanding voting stock of the corporation. After the five-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the board of the corporation and approved by the affirmative vote of at least 80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or which are held by an affiliate or associate of the interested stockholder. These super-majority vote requirements do not apply if the corporation's common stockholders receive a minimum price, as defined under Maryland law, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares. None of these provisions of Maryland law will apply, however, to business combinations that are approved or exempted by the board of the corporation prior to the time that the interested stockholder becomes an interested stockholder. In addition to the restrictions on business combinations provided under Maryland law, our charter also contains restrictions on business combinations. See Business Combination Provisions above. Control Share Acquisitions Maryland law provides that holders of any control shares of a Maryland corporation acquired in a control share acquisition have no voting rights with respect to the control shares except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter. Shares of stock owned by the acquiror, by officers or by directors who are employees of the corporation are excluded from shares entitled to vote on the matter. Any control shares are voting shares of stock which, if aggregated with all other shares of stock owned by the acquiror or shares of stock for which the acquiror is able to exercise or direct the exercise of voting power except solely by virtue of a revocable proxy, would entitle the acquiror to exercise voting power in electing directors within one of the following ranges of voting power: one-tenth or more but less than one-third; one-third or more but less than a majority; or a majority or more of all voting power. Control shares do not include shares the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval. Except as otherwise specified in the statute, a control share acquisition means the acquisition of control shares. Once a person who has made or proposes to make a control share acquisition has undertaken to pay expenses and satisfied other conditions, the person may compel the board to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. If no request for a meeting is made, the corporation may itself present the question at any stockholders meeting. If voting rights are not approved at the meeting or if the acquiring person does not deliver an acquiring person statement as required by the statute, then the corporation may be able to redeem any or all of the control shares for fair value, except for control shares for which voting rights previously have been approved. The right of the corporation to redeem control shares is subject to certain conditions and limitations. Fair value is determined without regard to the absence of voting rights for control shares, as of the date of the last control share acquisition by the acquiror or of any meeting of stockholders at which the voting rights of control shares are considered and not approved. If voting rights for control shares are approved at a stockholders meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights. The fair value of the shares as determined for purposes of these appraisal rights may not be less than the highest price per share paid by the acquiror in the control share acquisition. Some of the limitations and restrictions otherwise applicable to the exercise of dissenters' rights do not apply in the context of a control share acquisition. The control share acquisition statute does not apply to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction or to acquisitions approved or exempted by the charter or bylaws of the corporation. Our bylaws contain a provision exempting acquisitions of shares of our stock from the control share acquisition statute. However, our board may amend our bylaws in the future to repeal or modify this exemption, in which case any control shares of our company acquired in a control share acquisition will be subject to the control share acquisition statute. Unsolicited Takeovers Under Maryland law, a Maryland corporation with a class of equity securities registered under the Securities Exchange Act of 1934, or the Exchange Act, and at least three independent directors may elect to be subject to certain statutory provisions relating to unsolicited takeovers which, among other things, would automatically classify the board into three classes with staggered terms of three years each and vest in the board the exclusive right to determine the number of directors and the exclusive right, by the affirmative vote of a majority of the remaining directors, to fill vacancies on the board, even if the remaining directors do not constitute a quorum. These statutory provisions relating to unsolicited takeovers also provide that any director elected to fill a vacancy shall hold office for the remainder of the full term of the class of directors in which the vacancy occurred, rather than the next annual meeting of directors as would otherwise be the case, and until his successor is elected and qualified. Our board of directors has adopted a resolution prohibiting us from electing to be subject to the provisions of the unsolicited takeover statute relating to the classification of the board unless such election is first approved by our stockholders by the affirmative vote of a majority of all the votes entitled to be cast on the matter. An election to be subject to any or all of the other foregoing statutory provisions may be made in our charter or bylaws, or by resolution of our board without stockholder approval. Any such statutory provision to which we elect to be subject will apply even if other provisions of Maryland law or our charter or bylaws provide to the contrary. Neither our charter nor our bylaws provides that we are subject to any of the foregoing statutory provisions relating to unsolicited takeovers. However, our board could adopt a resolution, without stockholder approval, to elect to become subject to some or all of these statutory provisions except the statutory provisions relating to the classification of the board. If we made an election, upon stockholder approval of such election, to be subject to the statutory provisions relating to the classification of the board and our board were divided into three classes with staggered terms of office of three years each, the classification and staggered terms of office of our directors would make it more difficult for a third party to gain control of our board since at least two annual meetings of stockholders, instead of one, generally would be required to effect a change in the majority of our board. Amendments to the Charter Provisions of our charter on business combinations, the number of directors and certain ownership restrictions may be amended only if approved by our board and by our stockholders by the affirmative vote of two-thirds of all of the votes entitled to be cast by our stockholders on the matter. Other amendments to our charter require approval by our board and approval by our stockholders by the affirmative vote of a majority of all the votes entitled to be cast by our stockholders on the matter. Amendment to the Bylaws Provisions of our bylaws on the number of directors, in certain circumstances, and the vote required to amend the bylaws may be amended only by unanimous vote of the board or by the affirmative vote of not less than 90% of all of the votes entitled to be cast by our stockholders on the matter. Other amendments to our bylaws require the affirmative vote of a majority of the entire board or the affirmative vote of a majority of all of the votes entitled to be cast by our stockholders on the matter. Dissolution of Healthpeak Properties, Inc. Our dissolution must be approved by our board by a majority vote of the entire board and by our stockholders by the affirmative vote of a majority of all the votes entitled to be cast by our stockholders on the matter. Advance Notice of Director Nominations and New Business; Procedures of Special Meetings Requested by Stockholders Our bylaws provide that nominations of persons for election to the board and the proposal of business to be considered by stockholders at the annual or special meeting of stockholders may be made only: pursuant to our notice of the meeting; by or at the direction of the board; or by a stockholder who was a stockholder at the time the notice of meeting was given and is entitled to vote at the meeting and who has complied with the advance notice procedures, including the minimum time period, described in the bylaws. Our bylaws also provide that only the business specified in our notice of meeting may be brought before a special meeting of stockholders. Our bylaws provide that our stockholders have the right to call a special meeting only upon the written request of the stockholders holding in the aggregate not less than 50% of the outstanding shares entitled to vote on the business proposed to be transacted at such meeting. Proxy Access Our bylaws permit any stockholder or group of up to 25 stockholders (counting as one stockholder, for purposes of the aggregation limit, any two or more funds that are part of the same qualifying fund group, as such term is defined in our bylaws) who have maintained continuous qualifying ownership of 3% or more of our outstanding common stock for at least the previous three years to include up to a specified number of director nominees in our proxy materials for an annual meeting of stockholders. If a group of stockholders is aggregating its shareholdings in order to meet the 3% ownership requirement, the ownership of the group will be determined by aggregating the lowest number of shares continuously owned by each member during the three-year holding period. A nominating stockholder is considered to own only the shares for which the stockholder possesses the full voting and investment rights and the full economic interest (including the opportunity for profit and risk of loss). Under this provision, borrowed or hedged shares do not count as owned shares. Furthermore, to the extent not otherwise excluded pursuant to this definition of ownership, a nominating stockholder's short position as defined in Rule 14e-4 under the Exchange Act is deducted from the shares otherwise owned. Loaned shares are counted toward the ownership requirement, provided that certain recall requirements described in our bylaws are met. The maximum number of stockholder nominees permitted under the proxy access provisions of our bylaws shall not exceed the greater of (i) a two or (ii) a 20% of the directors in office as of the last day a notice of nomination may be timely received. If the 20% calculation does not result in a whole number, the maximum number of stockholder nominees is the closest whole number below 20%. If one or more vacancies occurs for any reason after the nomination deadline and our board decides to reduce the size of our board in connection therewith, the 20% calculation will be applied to the reduced size of the board, with the potential result that a stockholder nominee may be disqualified. Stockholder-nominated candidates whose nomination is withdrawn or whom the board determines to include in our proxy materials as board-nominated candidates will be counted against the 20% maximum. In addition, any director in office as of the nomination deadline who was included in our proxy materials as a stockholder nominee for either of the two preceding annual meetings and whom our board decides to renominate for election to the board also will be counted against the 20% maximum. Notice of a nomination pursuant to the proxy access provisions of our bylaws must be received no earlier than 150 days and no later than 120 days before the anniversary of the date that we distributed our proxy statement for the previous year's annual meeting of stockholders. The proxy access provisions of our bylaws require certain disclosure, representations and agreements to be provided or made by nominating stockholders and contain certain other procedural provisions. A stockholder nominee will not be eligible for inclusion in our proxy materials (i) if any stockholder has nominated a person pursuant to the advance notice provision of our bylaws; (ii) if the nominee would not be independent; (iii) if the nominee's election would cause us to violate our bylaws, our charter or any applicable listing standards, laws, rules or regulations; (iv) if the nominee is or has been an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, within the past three years; or (v) if the nominee or the stockholder who nominated him or her has provided false and misleading information to us or otherwise breached any of its or their obligations, representations or agreements under the proxy access provisions of our bylaws. Stockholder nominees who are included in our proxy materials but subsequently withdraw from or become ineligible or unavailable for election at the meeting or do not receive at least 10% of the votes cast in the election will be ineligible for nomination under the proxy access provisions of our bylaws for the next two annual meetings. A nomination made under the proxy access provisions of our bylaws will be disregarded at the annual meeting under certain circumstances described in our bylaws. Anti-Takeover Effect of Provisions of Maryland Law and of Our Charter and Bylaws The provisions in our charter on removal of directors and business combinations, the business combinations and control share acquisition provisions of Maryland law, the unsolicited takeover provisions of Maryland law (if we elect to become subject to such provisions) and the provisions of our bylaws relating to advance notice, proxy access and stockholder-requested special meetings may delay, deter or prevent a change of control or other transaction in which holders of some, or a majority, of the common stock might receive a premium for their common stock over the then prevailing market price or which such holders might believe to be otherwise in their best interests. Limitation of Liability and Indemnification Maryland law permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages. However, a Maryland corporation may not limit liability resulting from actual receipt of an improper benefit or profit in money, property or services. Also, liability resulting from active and deliberate dishonesty may not be eliminated if a final judgment establishes that the dishonesty is material to the cause of action. Our charter contains a provision which limits the liability of directors and officers for

money damages to the maximum extent permitted by Maryland law. This provision does not limit our right or that of our stockholders to obtain equitable relief, such as an injunction or rescission. Our bylaws obligate us, to the maximum extent permitted by Maryland law, to indemnify and, without requiring a preliminary determination as to the ultimate entitlement to indemnification, to pay or reimburse reasonable expenses before final disposition of a proceeding to: (a) any present or former director or officer who is made a party to the proceeding by reason of his service in that capacity; or (b) any individual who, while one of our directors or officers and at our request, serves or has served another corporation, partnership, joint venture, trust, employee benefit plan or any other enterprise as a director, officer, partner or trustee of such corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise and who is made a party to the proceeding by reason of his service in that capacity. The bylaws authorize us, with the approval of our board, to provide indemnification and advancement of expenses to our agents and employees. Unless limited by a corporation's charter, Maryland law requires a corporation to indemnify a director or officer who has been successful, on the merits or otherwise, in the defense of any proceeding to which he is made a party by reason of his service in that capacity, or in the defense of any claim, issue or matter in the proceeding. Our charter does not alter this requirement. Maryland law permits a corporation to indemnify its present and former directors and officers, among others, against: (a) judgments; (b) penalties; (c) fines; (d) settlements; and (e) reasonable expenses actually incurred by them in connection with any proceeding to which they may be made a party by reason of their service in those or other capacities. Maryland law does not permit a corporation to indemnify its present and former directors and officers if it is established that (a) the act or omission of the director or officer was material to the matter giving rise to the proceeding and was committed in bad faith or was the result of active and deliberate dishonesty; (b) the director or officer actually received an improper personal benefit in money, property or services; or (c) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. Under Maryland law, a Maryland corporation generally may not indemnify for an adverse judgment in a suit by or in the right of the corporation. Also, a Maryland corporation generally may not indemnify for a judgment of liability on the basis that personal benefit was improperly received. In either of these cases, a Maryland corporation may indemnify for expenses only if a court so orders. Maryland law permits a corporation to advance reasonable expenses to a director or officer. First, however, the corporation must receive a written affirmation by the director or officer of his good faith belief that he has met the standard of conduct necessary for indemnification by the corporation. The corporation must also receive a written undertaking, either by the director or officer or on his behalf, to repay the amount paid or reimbursed by the corporation if it shall ultimately be determined that the standard of conduct was not met. The termination of any proceeding by conviction, or upon a plea of nolo contendere or its equivalent, or an entry of any order of probation prior to judgment, creates a rebuttable presumption that the director or officer did not meet the requisite standard of conduct required for indemnification to be permitted. It is the position of the Securities and Exchange Commission that indemnification of directors and officers for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, is against public policy and is unenforceable pursuant to Section 14 of the Securities Act. Transfer Agent The registrar and transfer agent for our common stock is Equiniti Trust Company, LLC. EX-10.12.7 3 ex1012712312024.htm EX-10.12.7 Document Exhibit 10.12.7 HEALTHPEAK PROPERTIES, INC. 2023 PERFORMANCE INCENTIVE PLANNON-NEO OP UNIT AWARD AGREEMENT THIS NON-NEO OP UNIT AWARD AGREEMENT (this "Agreement") is effective as of [] (the "Award Date"). WHEREAS, a Maryland corporation (the "Corporation"), Healthpeak OP, LLC (the "Partnership"), and [] (the "Participant"). WITNESSETH WHEREAS, the Corporation maintains the Healthpeak Properties, Inc. 2023 Performance Incentive Plan, as amended and/or restated from time to time (the "Plan"); WHEREAS, pursuant to that certain Non-NEO Restricted Stock Unit Award Agreement, dated as of [] (the "Original Award Date"), Old Healthpeak (as defined below) previously granted to the Participant an award of [] restricted stock units under the Plan (the "RSU Award"); WHEREAS, pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the entity known as Healthpeak Properties, Inc. prior to the Merger (the "Old Healthpeak"), New Healthpeak, Inc. and Healthpeak Merger Sub, Inc. (the "Merger Sub"), Merger Sub merged with and into Old Healthpeak, with Old Healthpeak being the surviving entity and becoming a subsidiary of New Healthpeak, Inc. (the "Merger"); WHEREAS, following the Merger, New Healthpeak, Inc. changed its name to Healthpeak Properties, Inc. and Old Healthpeak converted to a Maryland limited liability company named Healthpeak OP, LLC; WHEREAS, effective as of the effective time of the Merger, the RSU Award was automatically converted into a restricted stock unit award with respect to the same number of shares of common stock of the Corporation and subject to the same terms and conditions, including vesting terms, as the RSU Award immediately prior to the effective time of the Merger; WHEREAS, as of the date hereof, [] restricted stock units remained outstanding under the RSU Award; WHEREAS, the Participant elected to cancel and replace the RSU Award with an award of profits interest units (the "OP Units", which are "LTIP Units" as defined in the Plan); and WHEREAS, the Corporation, the Partnership and the Participant desire to enter into this Agreement to set forth the terms of the award of OP Units resulting from the cancellation and replacement of the RSU Award. NOW THEREFORE, in consideration of services rendered and to be rendered by the Participant to or for the benefit of the Partnership, and the mutual promises made herein and the mutual benefits to be derived therefrom, the parties agree as follows: 1. Defined Terms. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Plan or the Partnership Agreement, as applicable. 2. Grant. (a) Subject to the terms of this Agreement, the Partnership hereby grants to the Participant an award (the "Award") of [] OP Units. The Partnership and the Participant acknowledge and agree that the OP Units are hereby issued to the Participant for the performance of services to or for the benefit of the Partnership in his or her capacity as a Member or in anticipation of the Participant becoming a Member. Upon receipt of the Award, the Participant shall, automatically and without further action on his or her part, be deemed to be a party to, signatory of and bound by the Partnership Agreement. At the request of the Partnership, the Participant shall execute the Partnership Agreement or a joinder or counterpart signature page thereto. The Participant acknowledges that the Partnership may from time to time issue or cancel (or otherwise modify) OP Units in accordance with the terms of the Partnership Agreement. The OP Units shall have the rights, voting powers, restrictions, limitations as to distributions, qualifications and terms and conditions of redemption and conversion set forth in this Agreement, the Plan and in the Partnership Agreement, and any rules adopted by the Administrator, as such rules are in effect from time to time. The parties acknowledge and agree that the OP Units are being granted subject to the cancellation of, and as a replacement for, the RSU Award, and the Participant acknowledges, agrees and consents to such cancellation and replacement as set forth herein. The Participant further agrees that, as of the Effective Date, the RSU Award and the restricted stock units subject thereto shall be cancelled and of no further force or effect, and the Participant shall have no further right, title or interest in the RSU Award, such restricted stock units or any shares of stock issuable thereunder. (b) As a condition to the grant of the Award and the Participant's right to receive and retain the OP Units, (i) concurrent with or prior to the execution of this Agreement, the Participant shall execute and deliver to the Company a Non-Referral Source Certification substantially in the form attached hereto as Exhibit AA (a "Certification") and (ii) the Participant's representations and warranties set forth therein shall be true and correct in all respects as of the date thereof. In the event that the Participant has previously delivered a true and correct Certification to the Company, the provisions of this Section 2(b) shall not apply and the Participant shall not be required to execute and deliver an additional Certification in connection with the grant of the Award. 3. Vesting. Subject to Section 8 below, the Award shall vest and become nonforfeitable with respect to 100% of the total number of the OP Units issued hereby on the third anniversary of the Original Award Date. 4. Continuation of Employment. Except as otherwise expressly provided in Section 8, the vesting schedule requires continued employment or service through each applicable vesting date, as provided in Section 3, as a condition to the vesting of the applicable installment of the Award and the rights and benefits under this Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Participant to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or service as provided in Section 8 below or under the Plan. Nothing contained in this Agreement or the Plan constitutes an employment or service commitment by the Corporation or any of its Subsidiaries, affects the Participant's status as an employee at will who is subject to termination without cause, confers upon the Participant any right to remain employed by or in service to the Corporation or any of its Subsidiaries, interferes in any way with the right of the Corporation or any of its Subsidiaries at any time to terminate such employment or services, or affects the right of the Corporation or any of its Subsidiaries to increase or decrease the Participant's other compensation or benefits. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Participant without his or her consent thereto. 5. Restrictions on Transfer. (a) The Award and the OP Units are subject to the restrictions on transfer of Membership Units (including, without limitation, OP Units) set forth in Article 11 of the Partnership Agreement. Any permitted transferee of the Award or OP Units shall take such Award or OP Units subject to the terms of the Plan, this Agreement, and the Partnership Agreement. Any such permitted transferee must, upon the request of the Partnership, agree to be bound by the Plan, the Partnership Agreement, and this Agreement, and shall execute the same on request, and must agree to such other waivers, limitations, and restrictions as the Partnership or the Corporation may reasonably require. Any Transfer of the Award or OP Units which is not made in compliance with the Plan, the Partnership Agreement and this Agreement shall be null and void and of no effect. (b) Without the consent of the Administrator (which it may give or withhold in its sole discretion), the Participant shall not transfer any unvested OP Units or any portion of the Award attributable to such unvested OP Units (or any securities into which such unvested OP Units are converted or exchanged), other than by will or pursuant to the laws of descent and distribution (the "Transfer Restrictions"); provided, however, that the Transfer Restrictions shall not apply to any Transfer of unvested OP Units or of the Award to the Partnership or the Corporation. (c) As to any vested OP Units, the Participant agrees that the Participant will not transfer such OP Units (or any Common Units or shares of Common Stock in respect of which such OP Units have been exchanged) prior to the date that is one (1) year after the date such OP Units became vested in accordance with the terms of the Award (for example, if 100 Common Units or shares of Common Stock were acquired in respect of 100 OP Units that became vested on a particular date, such one-year period would commence as of such vesting date as to those 100 Common Units or shares); provided, however, that the restrictions set forth in this Section 5(c) shall (i) not apply to any Units or shares sold by the Participant to satisfy any tax liability arising in connection with the exchange or disposition of the OP Units, (ii) not apply to any transfer made without consideration (or for only nominal consideration) to a family member (as such term is defined in the SEC General Instructions to a Registration Statement on Form S-8) of the Participant solely for purposes of estate or tax planning, and provided the transfer restrictions on such Units or shares continue in effect after any such transfer, and (iii) lapse upon the Participant's death or Total Disability or as otherwise provided by the Corporation. The Corporation may provide for any Units or shares of Common Stock acquired with respect to the Award and issued in book-entry form to include notations regarding the restrictions on transfer imposed under this Section 5(c) (or, as to any such Common Units or shares issued in certificate form, provide for such certificates to bear appropriate legends regarding such transfer restrictions). 6. Execution and Return of Documents and Certificates. At the Corporation's or the Partnership's request, the Participant hereby agrees to promptly execute, deliver and return to the Partnership any and all documents or certificates that the Corporation or the Partnership deems necessary or desirable to effectuate the cancellation and forfeiture of the unvested OP Units and the portion of the Award attributable to the unvested OP Units, or to effectuate the transfer or surrender of such unvested OP Units and portion of the Award to the Partnership. 7. Covenants, Representations and Warranties. The Participant hereby represents, warrants, covenants, acknowledges and agrees on behalf of the Participant and his or her spouse, if applicable, that: (a) Investment. The Participant is holding the Award and the OP Units for the Participant's own account and not for the account of any other Person. The Participant is holding the Award and the OP Units for investment and not with a view to distribution or resale thereof except, in compliance with applicable laws regulating securities. (b) Relation to the Partnership. The Participant is presently an employee of, or consultant to, the Partnership, or is otherwise providing services to or for the benefit of the Partnership, and in such capacity has become personally familiar with the business of the Partnership. (c) Access to Information. The Participant has had the opportunity to ask questions of, and to receive answers from, the Partnership with respect to the terms and conditions of the transactions contemplated hereby and with respect to the business, affairs, financial conditions and results of operations of the Partnership. (d) Registration. The Participant understands that the OP Units have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and the OP Units cannot be transferred by the Participant unless such transfer is registered under the Securities Act or an exemption from such registration is available. The Partnership has made no agreements, covenants or undertakings whatsoever to register the transfer of the OP Units under the Securities Act. The Partnership has made no representations, warranties or covenants whatsoever as to whether any exemption from the Securities Act, including, without limitation, any exemption for limited sales in routine brokers' transactions pursuant to Rule 144 of the Securities Act, will be available. (e) Public Trading. None of the Partnership's securities are presently publicly traded, and the Partnership has made no representations, covenants or agreements as to whether there will be a public market for any of its securities. (f) Tax Advice. The Partnership has made no warranties or representations to the Participant with respect to the income tax consequences of the transactions contemplated by this Agreement (including, without limitation, with respect to the decision of whether to make an election under Section 83(b) of the Code and with respect to the grant of the OP Units), and the Participant is in no manner relying on the Partnership or its representatives for an assessment of such tax consequences. The Participant hereby recognizes that the Internal Revenue Service has proposed regulations under Sections 83 and 704 of the Code that may affect the proper treatment of the OP Units for federal income tax purposes. In the event that those proposed regulations are finalized, the Participant hereby agrees to cooperate with the Partnership in amending this Agreement and the Partnership Agreement, and to take such other action as may be required, to conform to such regulations. The Participant is advised to consult with his or her own tax advisor with respect to the tax consequences of owning and disposing of the OP Units with respect to the cancellation and replacement of the RSU Award. 8. Effect of Termination of Employment or Services. If the Participant ceases to be employed by or ceases to provide services to the Corporation or a Subsidiary (the date of such termination of employment or service is referred to as the Participant's "Severance Date"), the Participant's OP Units shall be cancelled and forfeited to the extent such units have not become vested pursuant to Section 3 hereof upon the Severance Date regardless of the reason for the termination of the Participant's employment or services; provided, however, that if the Participant's employment is terminated as a result of the Participant's death, Total Disability (as defined below) or Retirement (as defined below), the Participant's OP Units, to the extent such units are not then vested, shall become fully vested as of the Severance Date. If any unvested OP Units are forfeited hereunder, such OP Units shall automatically be cancelled as of the applicable Severance Date without payment of any consideration by the Corporation and without any other action by the Company, the Partnership, the Participant, or the Participant's beneficiary or personal representative, as the case may be. For purposes of the Award, "Total Disability" means a permanent and total disability (within the meaning of Section 22(e) (3) of the Code or as otherwise determined by the Administrator). For purposes of the Award, "Retirement" means, that, as of the date of termination of the Participant's employment or services, the Participant (1) has attained age 65 and completed at least five (5) full years of service as an employee of the Corporation and its Subsidiaries and/or a member of the Board, or (2) has attained age 60 and completed at least fifteen (15) full years of service as an employee of the Corporation and its Subsidiaries and/or a member of the Board. Notwithstanding the foregoing, the Participant shall be entitled to any accelerated vesting with respect to the OP Units in connection with the Participant's severance provided for in the circumstances in, and subject to, the express terms of any written employment agreement entered into between the Participant and Corporation or any of its Subsidiaries and that is in effect on the Severance Date. 9. Adjustments Upon Specified Events; Change in Control Event. (a) Adjustments. To the extent applicable, the Award shall be subject to adjustment by the Administrator in accordance with Section 7.1 of the Plan. (b) Change in Control Event. Upon the occurrence of an event contemplated by Section 7.2 or 7.3 of the Plan and notwithstanding any provision of Section 7.2 and 7.3 of the Plan or any employment agreement to the contrary, the Award (to the extent outstanding at the time of such event) shall continue in effect in accordance with its terms following such event (subject to adjustment in connection with such event pursuant to Section 7.1 of the Plan); provided, however, that the Administrator shall determine, in its sole discretion, whether the vesting of the OP Units will accelerate in connection with such event and the extent of any such accelerated vesting. 10. Taxes. The Partnership and the Participant intend that (i) the OP Units be treated as a profits interest as defined in Internal Revenue Service Revenue Procedure 93-27, as clarified by Revenue Procedure 2001-43, (ii) the issuance and vesting of the OP Units shall not be taxable events to the Partnership or the Participant as provided in such revenue procedure, and (iii) the Partnership Agreement, the Plan and this Agreement be interpreted consistently with such intent. In furtherance of such intent, effective immediately prior to the issuance of the OP Units, the Partnership may revalue all Partnership assets to their respective gross fair market values, and make the resulting adjustments to the Capital Accounts (as defined in the Partnership Agreement) of the Members, in each case as set forth in the Partnership Agreement. The Corporation, the Partnership or any Subsidiary may withhold from the Participant's wages, or require the Participant to pay to such entity, any applicable withholding or employment taxes resulting from the issuance of the Award hereunder, from the vesting or lapse of any restrictions imposed on the Award, or from the ownership or disposition of the OP Units. 11. Capital

Account. The Participant shall make no contribution of capital to the Partnership in connection with the Award and, as a result, the Participant's Capital Account balance in the Partnership immediately after his or her receipt of the OP Units shall be equal to zero, unless the Participant was a Member of the Partnership prior to such issuance, in which case the Participant's Capital Account balance shall not be increased as a result of his or her receipt of the OP Units.12.Redemption Rights. Notwithstanding anything to the contrary in the Partnership Agreement, Membership Units which are acquired upon the conversion of the OP Units shall not, without the consent of the Partnership (which may be given or withheld in its sole discretion), be redeemed pursuant to Section 15.1 of the Partnership Agreement within two (2) years following the date of the issuance of such OP Units.13.Section 83(b) Election. The Participant covenants that the Participant shall make a timely election under Section 83(b) of the Code (and any comparable election in the state of the Participant's residence) with respect to the OP Units covered by the Award, and the Partnership hereby consents to the making of such election(s). In connection with such election, the Participant and the Participant's spouse, if applicable, shall promptly provide a copy of such election to the Partnership. Instructions for completing an election under Section 83(b) of the Code and a form of election under Section 83(b) of the Code are attached hereto as Exhibit B. The Participant represents that the Participant has consulted any tax advisor(s) that the Participant deems advisable in connection with the filing of an election under Section 83(b) of the Code and similar state tax provisions. The Participant acknowledges that it is the Participant's sole responsibility and not the Corporation's to timely file an election under Section 83(b) of the Code (and any comparable state election), even if the Participant requests that the Corporation or any representative of the Corporation make such filing on the Participant's behalf. The Participant should consult his or her tax advisor to determine if there is a comparable election to file in the state of his or her residence. 14.Ownership Information. The Participant hereby covenants that so long as the Participant holds any OP Units, at the request of the Partnership, the Participant shall disclose to the Partnership in writing such information relating to the Participant's ownership of the OP Units as the Partnership reasonably believes to be necessary or desirable to ascertain in order to comply with the Code or the requirements of any other appropriate taxing authority.15.Remedies. The Participant shall be liable to the Partnership for all costs and damages, including incidental and consequential damages, resulting from a disposition of the Award or the OP Units which is in violation of the provisions of this Agreement. Without limiting the generality of the foregoing, the Participant agrees that the Partnership shall be entitled to obtain specific performance of the obligations of the Participant under this Agreement and immediate injunctive relief in the event any action or proceeding is brought in equity to enforce the same. The Participant will not urge as a defense that there is an adequate remedy at law.16.Restrictive Legends. Certificates evidencing the OP Units, to the extent such certificates are issued, may bear such restrictive legends as the Partnership and/or the Partnership's counsel may deem necessary or advisable under applicable law or pursuant to this Agreement, including, without limitation, the following legends or any legends similar thereto:17.The securities represented hereby have not been registered under the Securities Act of 1933, as amended (the "Securities Act"). Any transfer of such securities will be invalid unless a Registration Statement under the Securities Act is in effect as to such transfer or in the opinion of counsel for Healthpeak OP, LLC (the "Partnership") such registration is unnecessary in order for such transfer to comply with the Securities Act.18.The securities represented hereby are subject to forfeiture, transferability and other restrictions as set forth in (i) a written agreement with the Partnership, (ii) the Healthpeak Properties, Inc. 2023 Performance Incentive Plan, and (iii) the Operating Agreement of Healthpeak OP, LLC, in each case, as has been and as may in the future be amended (or amended and restated) from time to time, and such securities may not be sold or otherwise transferred except pursuant to the provisions of such documents.17.Notices. Any notice to be given under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Participant at the Participant's last address reflected on the Corporation's payroll records. Any notice shall be delivered in person or shall be enclosed in a properly sealed envelope, addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government. Any such notice shall be given only when received, but if the Participant is no longer an Eligible Person, shall be deemed to have been duly given five (5) business days after the date mailed in accordance with the foregoing provisions of this Section 17.18.Plan and Partnership Agreement. The Award and all rights of the Participant under this Agreement are subject to the terms and conditions of the provisions of the Plan and the Partnership Agreement, each of which is incorporated herein by reference. The Participant agrees to be bound by the terms of the Plan, this Agreement and the Partnership Agreement. The Participant acknowledges having read and understanding the Plan, the Prospectus for the Plan, this Agreement and the Partnership Agreement. Unless otherwise expressly provided in other sections of this Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not (and shall not be deemed to) create any rights in the Participant unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof. 19.Entire Agreement. This Agreement, the Plan and the Partnership Agreement together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this Agreement may be amended pursuant to Section 8.6 of the Plan and/or the applicable provisions of the Partnership Agreement. Any such amendment must be in writing and signed by the Corporation (and, if applicable, the Partnership). Except to the extent provided in the Partnership Agreement, any such amendment that materially and adversely affects the Participant's rights under this Agreement requires the consent of the Participant in order to be effective with respect to the Award. The Corporation or the Partnership may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Participant hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof. The Participant acknowledges receipt of a copy of this Agreement, the Plan, the Prospectus for the Plan and the Partnership Agreement.20.Counterparts. This Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 21.Section Headings. The section headings of this Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.22.Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles thereunder.23.Construction. It is intended that the terms of the Award will not result in the imposition of any tax liability pursuant to Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent.24.Clawback Policy. The OP Units are subject to the terms of the Corporation's recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of the OP Units or any Common Units or shares of Common Stock or other cash or property received with respect to the OP Units (including any value received from a disposition thereof).25.Survival of Representations and Warranties. The representations, warranties and covenants contained in Section 7 hereof shall survive the later of the date of execution and delivery of this Agreement or the issuance of the Award.26.Fractional Units. For purposes of this Agreement, any fractional OP Units that vest or become entitled to distributions pursuant to the Partnership Agreement will be rounded as determined by the Corporation or the Partnership; provided, however, that in no event shall such rounding cause the aggregate number of OP Units that vest or become entitled to such distributions to exceed the total number of OP Units set forth in Section 2 of this Agreement. THE PARTICIPANT'S ACCEPTANCE OF THE AWARD THROUGH THE ELECTRONIC STOCK PLAN AWARD RECORDKEEPING SYSTEM MAINTAINED BY THE CORPORATION OR ITS DESIGNEE CONSTITUTES THE PARTICIPANT'S AGREEMENT TO THE TERMS AND CONDITIONS HEREOF, AND THAT THE AWARD IS GRANTED UNDER AND GOVERNED BY THE TERMS AND CONDITIONS OF THE PLAN AND THIS AGREEMENT. *A A A *A A A *The remainder of this page is intentionally left blank. EX-19.1 4 ex1912312024.htm EX-19.1 DocumentInsider Trading PolicyAmended and Restated: January 30, 2025TABLE OF CONTENTSPAGEI. OVERVIEW1A. Introduction1B. Applicability1C. Exceptions and Waivers1D. Questions2II. INSIDER TRADING PENALTIES2III. POLICIES AND PROCEDURES3A. Policy Prohibitions and Restrictions31. Awareness of Material Non-Public Information32. Transactions Involving a Purchase or Sale43. Tipping44. Financial Investments in Certain Public REITs45. Speculative Trading and Short Sales5A. Publicly Traded Options5b. Short Sales66. Anti-Hedging Policy67. Anti-Pledging Policy and Margin Accounts68. Gifts69. General Policy Exceptions7a. Net Exercises, Vestings and DRIP7b. Stock-for-Fees Program8B. Unauthorized Disclosure81. Use or Disclosure of Material Non-Public Information is Prohibited82. Third Party Inquiries8C. Material Non-Public Information81. Material Information82. Non-Public Information10D. Trading Window and Procedures101. Overview102. Trading Window113. Mandatory Pre-Approval Procedures12Appendix A 6 " Rule 10b5-1 Trading PlansA-11.OVERVIEWA.A A A IntroductionFederal and state laws prohibit the purchase or sale of securities by persons who have material information about a company that is not generally known or available to the public. These laws also prohibit persons with such material non-public information from disclosing it to others who may trade on the basis of the information.To promote compliance with federal and state securities laws (collectively "insider trading laws") and to protect Healthpeak Properties, Inc., together with its subsidiaries (collectively, "Healthpeak" or the "Company") and you from serious liabilities and penalties that can result from violations of these laws, we have adopted this Insider Trading Policy (this "Policy") regarding trading in securities by our directors, officers and employees. The Company may also determine that other persons are subject to this Policy, such as consultants who have access to material non-public information.B.A A A ApplicabilityThis Policy applies to you and (1) anyone that lives in your household, (2) any family members who do not live in your household but whose transactions in Healthpeak securities and companies with which Healthpeak does business are subject to your influence or control, (3) any corporations, partnerships or other business entities controlled or managed by you, it being understood that references to individuals covered by this Policy herein also include such entities and (4) any trusts for which you are the trustee or have a beneficial pecuniary interest (each and collectively, "Restricted Affiliates"). You are responsible for making sure that each of your Restricted Affiliates complies with this Policy. This Policy only provides guidelines and you are still ultimately responsible for ensuring that you and your Restricted Affiliates do not violate insider trading laws or this Policy.C.A A A Exceptions and WaiversA.A A Any exceptions and waivers to this Policy may only be granted by our General Counsel or the Board of Directors, as appropriate. Additionally, your ownership of, and transactions in, Healthpeak securities are subject to all applicable Healthpeak policies, including, but not limited to, the Code of Business Conduct and Ethics (the "Code of Conduct"), Section 16 Policy, Policy Regarding the Recoupment of Certain Compensation Payments (the "Clawback Policy"), Stock Ownership Guidelines and the Employee Handbook.D.A A A QuestionsIf you have any questions about this Policy or its application to a particular transaction, you should contact the General Counsel before you engage in such transaction.II.INSIDER TRADING PENALTIESThe penalties for violating insider trading laws and this Policy are severe. For example, if you violate federal insider trading laws, you may have to: (a) pay civil fines of up to three times the profit gained or loss avoided by such violation; (b) pay criminal fines of up to \$5 million per violation; and (c) serve a jail sentence of up to 20 years per violation.A violation of insider trading laws or this Policy also poses significant risks to Healthpeak. As a result of your insider trading violations, Healthpeak could also be subject to: (a) paying three times the profit gained or loss avoided by such violation; (b) paying a substantial additional civil fine; and (c) facing potential criminal fines of up to \$25 million. Healthpeak could be forced to disclose material non-public information, which could damage our competitive position, jeopardize important or strategic plans and threaten or eliminate strategic business opportunities, such as mergers and acquisitions or capital market financings. The Securities and Exchange Commission ("SEC"), the New York Stock Exchange , the Financial Industry Regulatory Authority ("FINRA"), as well as other federal and state regulators, are very effective at detecting and prosecuting insider trading cases. The SEC and FINRA routinely examine pre-announcement trading activity in the stock of companies that announce a significant transaction. The SEC has successfully prosecuted cases against employees trading through foreign accounts, trading by family members and friends and trading involving only a small number of shares. The size of the transaction or the amount of profit received does not have to be large to result in civil or criminal prosecution. Therefore, it is important that you understand the breadth of activities that constitute illegal insider trading.You must carefully read this Policy and follow its directives at all times. Failure to adhere to insider trading laws or this Policy or provide certification of the matters contained herein may result in immediate disciplinary measures, including termination of your employment or service with Healthpeak.If you become aware of a possible insider trading violation, you should immediately report the potential violation to the General Counsel.III. POLICIES AND PROCEDURES A.Policy Prohibitions and Restrictions This Policy prohibits (1) trading (i.e., purchasing or selling securities as described in Section III(A)(2) below) when you are aware of material non-public information, (2) tipping (as defined in Section III(A)(3) below), and (3) engaging in speculative trading or short sales as described in Section III(A)(5) below. This Policy also includes additional restrictions on certain other transactions in Healthpeak's securities or the securities of any publicly-traded real estate investment trust ("REIT"), as further described below in this Section III(A). These restrictions apply to all of Healthpeak's directors, officers and employees, as well as any consultants or other persons subject to this Policy. Additionally, these restrictions apply to your Restricted Affiliates because the SEC and prosecutors may presume that trading by Restricted Affiliates is based on information you supplied and these authorities may treat any such trades as if you had executed the trades yourself. These restrictions will continue to apply to you and your Restricted Affiliates after the termination of your employment or service with Healthpeak for so long as you are aware of material non-public information about Healthpeak or any other company obtained during your employment or service with Healthpeak. There are no exceptions to this Policy, except as expressly provided herein. The insider trading laws do not recognize any mitigating circumstances. Accordingly, transactions that you believe may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) or small transactions are not exempted from this Policy. 1.Awareness of Material Non-Public InformationYou or any Restricted Affiliate may not, directly or indirectly through family members or other persons or entities, purchase or sell stock or other securities of Healthpeak when in possession of material non-public information relating to Healthpeak or its securities, except in the circumstances expressly permitted by this Policy. Additionally, if, in the course of working for Healthpeak, you learn of material non-public information about a company with which Healthpeak does business or proposes to do business, including any tenant, operator or supplier, or with whom Healthpeak proposes to engage in an acquisition or other transaction, neither you nor any of your Restricted Affiliates may, directly or indirectly through family members or other persons or entities, purchase or sell securities of that company until the information becomes public or is no longer material.2.Transactions Involving a Purchase or Sale a.Purchase and Sale a.Purchase and Sale are defined broadly for purposes of the insider trading laws. "Purchase" includes the actual purchase of a security and any contract to purchase or otherwise acquire a security for value, and "Sale" includes the actual sale of a security and any contract to sell or otherwise dispose of a security for value. These definitions extend to a broad range of transactions including, without limitation:a.conventional cash-for-stock transactions;b.broker-assisted cashless exercises of stock options;c.engaging in short sales and other hedging transactions;d.placing "stop-loss" or "limit" orders;e.sales of Healthpeak's securities obtained through exercises of employee stock options or vestings, or payments of other equity awards granted by Healthpeak;f.pledging or margining securities; andg.purchases and sales of derivative securities (e.g., options, warrants, convertible securities, stock appreciation rights or any similar security with a value derived from the value of an equity security), including exchange traded options and other convertible securities.3.Tipping You or any Restricted Affiliate may not disclose to anyone, including without limitation family members, friends, business associates, investors and co-workers (except as may be required by the co-worker's job position), any material non-public information about Healthpeak and its securities or any other company and its securities that you learned in the course of your employment or service with Healthpeak. This includes refraining from making purchase, sell or hold recommendations to anyone about Healthpeak or any other company while you are aware of material non-public information. This practice is commonly known as "tipping," and violates insider trading laws, and can result in the same civil and criminal penalties that apply if you or any of your Restricted Affiliates engaged in insider trading directly.4.Financial Investments in Certain Public REITsWhile not restricted to Trading Windows (as defined below) applicable to Healthpeak securities, you must obtain pre-approval from the General Counsel prior to trading, directly or indirectly through any Restricted Affiliate, in the securities of the publicly-traded REITs listed on Appendix B attached hereto (each, a "Covered REIT"): provided, however, that such pre-approval shall not be required to: a.participate in any ordinary course compensatory stock or equity plans of any Covered REIT or make purchases in the securities of such Covered REIT if you or any Restricted Affiliate is employed by, or a member of the board of directors of, such Covered REIT; b.invest in a mutual fund or exchange-traded fund that holds securities of a Covered REIT; orc.retain any existing investments in a Covered REIT as of July 27, 2017 (i.e., you will only be required to seek approval to add to or dispose of these holdings).In conducting investment activities, whether or not permitted under this Policy, you and any Restricted Affiliate must adhere to this Policy and to all applicable insider trading and other laws. 5.Speculative Trading and Short SalesYou are encouraged to consider a purchase of Healthpeak's securities as a long-term investment, and through ownership of our securities, to develop an alignment of interest with the performance and prospects of Healthpeak. Consistent with this philosophy, you and your Restricted Affiliates are subject to the following additional prohibitions relating to speculative trading transactions involving Healthpeak's securities:a.Publicly Traded Options. Given the relatively short term of publicly-traded options, any purchase or sale of such options of Healthpeak's securities by you or any

of your Restricted Affiliates may create the appearance of trading based on material non-public information and focus attention on short-term performance at the expense of Healthpeak’s™ long-term objectives. Accordingly, transactions in put options, call options or other derivative securities, on an exchange or in any other market, are strictly prohibited. b.Short Sales. Short sales of Healthpeak’s™ securities (generally, the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller lacks confidence in Healthpeak’s™ prospects. Additionally, short sales may reduce a seller’s™ incentive to seek to improve Healthpeak’s™ performance. For these reasons, engaging in short sales of Healthpeak’s™ securities, which are illegal for Section 16 officers and directors, is strictly prohibited.6.Anti-Hedging Policy Certain forms of hedging or monetization transactions allow a person to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions may allow the person to continue to own the covered securities, but without the full risks and rewards of ownership. When this type of situation occurs, the person may no longer have the same objectives as Healthpeak’s™ other shareholders. For this reason, officers, directors, employees, any consultants or other persons subject to this Policy, and their respective Restricted Affiliates, are strictly prohibited from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Healthpeak securities. 7.Anti-Pledging Policy and Margin Accounts Securities held in a margin account may be sold by the broker without the customer’s™ consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material non-public information or otherwise is not permitted to trade in Healthpeak securities, you and your Restricted Affiliates are strictly prohibited from margining Healthpeak securities in an account or pledging Healthpeak securities as collateral for a loan. 8.GiftsBona fide gifts (including transfers to a trust for no consideration or other payment) or charitable contributions of securities may in certain circumstances be considered a “sale” under insider trading laws and are therefore subject to limitations under this Policy.A For example, any gift or charitable contribution of Healthpeak’s™ securities by you or your Restricted Affiliates may only be made at a time when you (and your Restricted Affiliates, if applicable) are not aware of material non-public information, and all gift transactions must be pre-approved by the General Counsel in accordance with Section III(D)(3) below.Â Under certain limited circumstances, you and your Restricted Affiliates may be permitted to gift or make charitable contributions of Healthpeak’s™ securities when the Trading Window is closed, provided, (i) you provide confirmation to the General Counsel that you (and your Restricted Affiliates, if applicable) are not aware of material non-public information, (ii) you provide details of the proposed gift or charitable contribution (e.g., amount of shares, proposed transaction date and recipient information, etc.), (iii) such gift or charitable contribution is pre-approved by the General Counsel, or the General Counsel’s™ designee, before the proposed transaction occurs, and (iv) such pre-approval is not revoked by the General Counsel, or the General Counsel’s™ designee, (in writing) prior to the consummation of the transaction.9.General Policy Exceptionsa.Net Exercises, Vestings and DRIPThe trading restrictions in this Policy do not include (i)Â the exercise of Healthpeak stock options if no shares are to be sold or if there is a “net exercise” (as defined below), (ii)Â the vesting of Healthpeak stock options or restricted stock units and awards, (iii) the crediting of dividend equivalents by Healthpeak on outstanding restricted stock units in accordance with the terms of the applicable award agreement, (iv) the payment by Healthpeak of vested restricted stock units and awards, or (v)Â the reacquisition or withholding of Healthpeak’s™ securities by Healthpeak (as opposed to a sale on the open market) to satisfy a tax withholding obligation upon the vesting of restricted stock units and awards where the “reacquisition or withholding of the securities is provided for and is in accordance with the terms of the applicable award. A “net exercise” (which is not restricted by this Policy) is the use of the underlying shares to pay the exercise price and/or tax withholding obligations in connection with the exercise of an option (i.e., no shares are sold on the open market), whereas a broker-assisted cashless exercise involves the broker selling some or all of the shares underlying the option on the open market and must be structured to satisfy this Policy.This Policy also does not apply to “purchases” of Healthpeak’s™ securities under Healthpeak’s™ Dividend Reinvestment and Stock Purchase Plan (the “DRIP”) resulting from reinvestment of dividends paid on Healthpeak’s™ securities under a standing election. However, this Policy does apply in connection with (i) the initial election to participate in the DRIP or any election to modify the level of participation under the DRIP, (ii) voluntary purchases of Healthpeak’s™ securities resulting from additional contributions to the DRIP, and (iii) the sale of any Healthpeak stock purchased under the DRIP. b.Stock-for-Fees ProgramThe trading restrictions in this Policy do not apply to purchases of Company stock in the Non-Employee Director Stock-For-Fees Program (the “Stock-For-Fees Program”) resulting from an election by a non-employee director to receive Company stock in lieu of cash payment of any director fees. The trading restrictions do apply, however, to (i) the election to participate in the Stock-For-Fees Program for any enrollment period, (ii) changes in elections, and (iii) sales of Company stock purchased under the Stock-For-Fees Program.B.Unauthorized Disclosure1.Use or Disclosure of Material Non-Public Information is ProhibitedAll persons subject to this Policy must maintain the confidentiality of Healthpeak information for competitive, security and other business reasons, as well as to comply with securities laws. All information you obtain about Healthpeak or its business plans is potentially non-public information until we publicly disclose it. You should treat this information as confidential and proprietary to Healthpeak and not disclose it to anyone, such as Restricted Affiliates, other relatives, or business or social acquaintances.Security laws, as well as our Code of Conduct, govern the timing and nature of our disclosure of material information to the public. Violation of these laws could result in substantial liability for you, Healthpeak and our management. For this reason, we permit only specifically designated representatives of Healthpeak, or “Company Spokespersons,” as identified in our Code of Conduct, to discuss Healthpeak matters with the news media, securities analysts, investment advisors and investors.2.Third Party InquiriesIf you receive any inquiries about Healthpeak from third parties, such as securities or industry analysts or members of the financial or business media, you should direct them to Healthpeak’s™ Chief Executive Officer, General Counsel, Chief Financial Officer or Investor Relations Officer as set forth in our Code of Conduct.C.Material Non-Public Information1.Material InformationInformation is generally considered material if there is a likelihood that a reasonable person would consider it important in making an investment decision to purchase, sell or hold securities. Material information includes either positive or negative information that could reasonably affect the price of a security.Although the materiality of information may vary depending on the circumstances, please note that such information will be scrutinized by federal, state and other governmental investigators with the benefit of evaluating the situation with hindsight. Consequently, you should avoid any appearance of impropriety, and you should carefully review the particular facts of each situation. When in doubt, you should always assume the information is material and not engage in any transaction involving that company. The following types of information about a company are likely to be considered material: a.earnings, revenues, expenses, dividends, funds from operations, funds available for distribution, liquidity and other non-public financial information;b.financial projections, including affirmations of prior earnings guidance and whether a company will or will not meet earnings expectations;c.unexpected financial results and unexpected events affecting such results;d.mergers, acquisitions, tender offers, joint ventures, divestitures or other changes in assets or the business;e.bank borrowings or financing transactions, including proposed financings, refinancing or capital market transactions and actual or potential liquidity issues;f.events regarding a company’s™ securities (including, without limitation, defaults on debt securities, redemptions of securities, repurchase plans, changes in dividends or dividend policy, stock splits, changes in rights of security holders, and public or private sales of additional securities);g.changes in credit ratings and actual or potential defaults;h.major environmental incidents;i.changes in or curtailment of operations or of significant facilities;j.developments regarding joint venture partners, borrowers, tenants, operators, lenders or acquisition/investment targets (including the entry into, amendment or loss of an important contract or other arrangement with any of the foregoing);k.information concerning changes in senior management, key personnel or the composition of the Board of Directors, including information concerning the business and personal lives of the foregoing;l.changes in compensation policies;m.a change of the independent registered public accounting firm or a notification that a company may no longer rely on a report from its independent registered public accounting firm;n.threatened or pending material litigation, and developments in ongoing material litigation and other contingencies;o.regulatory proceedings and governmental investigations; p.bankruptcy, corporate restructuring or receivership; andq.significant cybersecurity incidents, data breaches or similar events.The aforementioned list of information likely to be considered material is not exhaustive and depending upon the circumstances, other information not included may be considered material. In short, if a reasonable person would consider the information relevant in making an investment decision, you should assume it is material and treat it as such. Therefore, even if you would not consider the information relevant in making an investment decision, but believe that a third party might consider it as such, you should assume it is material. It is important to remember that both positive and negative information may be considered material information. 2.Non-Public InformationNon-public information is information that is not generally known or available to the public. We consider information to be available to the public only when (a) it has been released to the public through appropriate channels (e.g., press release, filing with the SEC, communicated by the media for broad public access or a widely disseminated statement from a Company Spokesperson); and (b) enough time has elapsed to permit the market to absorb the information.Generally, information regarding relatively routine matters, such as earnings results will be considered adequately disseminated and absorbed by the market after one (1) full trading day has elapsed following its public release. When non-routine matters, such as a prospective major acquisition or disposition are announced, Healthpeak may determine that additional time is required for the information to be absorbed by the market.D.Trading Window and Procedures1.OverviewAll persons subject to this Policy must comply with the restrictions detailed below with respect to transactions in Healthpeak’s™ securities by them or their Restricted Affiliates. Specifically, you and your Restricted Affiliates may only purchase or sell Healthpeak’s™ securities if (1) you are not aware of material non-public information, (2) the purchase or sale has been approved under Healthpeak’s™ Mandatory Pre-Approval Procedures detailed below, andÂ (3) the purchase or sale occurs within the Trading Window. In addition, as a reminder, gifts of Healthpeak securities are subject to the requirements of Section III(A)(8) of this Policy.Notwithstanding the foregoing, short-term trading of Healthpeak securities may be distracting and may promote a disproportionate focus on Healthpeak’s™ short-term performance instead of long-term business objectives. Accordingly, if you or your Restricted Affiliates make any open-market trades during a Trading Window, the trading person is not permitted to make any “opposite way” trades in the open market for the remainder of that Trading Window and throughout the subsequent Trading Window. An “opposite way” trade is a sale if you previously purchased stock, or a purchase if you previously sold stock. This Policy applies to all of Healthpeak’s™ securities held by you or your Restricted Affiliates, including any Healthpeak securities held in an account on your behalf by Healthpeak’s™ designated broker who administers our performance incentive plans, or any other third party brokerage accounts.2.Trading WindowYou and your Restricted Affiliates may only purchase or sell Healthpeak’s™ securities during a designated period each quarter (the “Trading Window”). The Trading Window is generally a six (6) week period each quarter, although it is typically shorter during the first quarter of each year. The Trading Window begins one (1) full trading day after Healthpeak’s™ public announcement of its annual or quarterly earnings and generally ends on the earlier of (i)Â six (6) weeks after such date, or (ii)Â two (2) weeks before the beginning of the next quarter. Notwithstanding the foregoing, we will provide you with explicit instructions on when the Trading Window is scheduled to open and when it is scheduled to close.If the Trading Window is open and you are aware of material non-public information about Healthpeak, you and your Restricted Affiliates may not trade in Healthpeak’s™ securities. Further, please be advised that all pending purchase and sale orders regarding Healthpeak’s™ securities that could be executed while the Trading Window is open must be cancelled or executed before the Trading Window closes. This includes any outstanding “stop-loss” or “limit” orders requested during an open Trading Window that have not been fulfilled before the Trading Window closes, unless such orders were entered into pursuant to the procedures described in RuleÂ 10b5-1 Trading Plans, attached hereto as Appendix A. Appendix A discusses situations where, even if the Trading Window is closed, you may purchase or sell Healthpeak’s™ securities pursuant to an approved RuleÂ 10b5-1 Trading Plan. Healthpeak may occasionally close the Trading Window early or entirely due to material non-public information developments. In such event, the General Counsel may notify certain individuals or all persons subject to this Policy that they are prohibited from engaging in any purchase or sale of Healthpeak’s™ securities, and such individuals should not disclose to others the fact that the Trading Window has been closed. 3.Mandatory Pre-Approval Procedures Healthpeak requires each employee, officer and director who desires to engage (or have a Restricted Affiliate engage) in a transaction involving Healthpeak’s™ securities (including any option exercise, stock purchase, stock sale, gift, loan, pledge, hedge, contribution to a trust, or any other transfer or acquisition), to request approval of such transaction from the General Counsel, or his or her designee, in advance of the proposed transaction. If the General Counsel desires to engage (or have a Restricted Affiliate engage) in a transaction requiring pre-approval or approval under this Policy, the General Counsel must obtain approval of such transaction from the President or Chief Executive Officer, or that person’s™ designee, in advance of the proposed transaction. All references to approval by the General Counsel below in this section shall be deemed to also refer to any applicable approval by the General Counsel’s™ designee from time to time or by the President or Chief Executive Officer, or that person’s™ designee, in the case of any transaction by the General Counsel. Notwithstanding the foregoing, an employee, officer or director is not required to request approval in accordance with the foregoing paragraph prior to a transaction involving Healthpeak’s™ securities made pursuant to an existing Rule 10b5-1 Trading Plan, provided that the Rule 10b5-1 Trading Plan is approved by the General Counsel before it is adopted. (See Appendix A for additional information on obtaining approval to enter into a Rule 10b5-1 Trading Plan.) An approval request should include all relevant information concerning the proposed transaction (e.g., amount of shares or options, proposed transaction date, etc.) and how best to be contacted with questions. The General Counsel may decide to withhold approval for a proposed transaction for various reasons, including, without limitation, the following examples:a.the employee, officer, or director may possess material non-public information;b.the Trading Window is not open;c.the purchase or sale by an officer or director does not comply with RuleÂ 144 of the Securities Act of 1933, as amended, and other legal requirements;d.the proposed transaction could result in adverse publicity or have a material adverse impact on trading in Healthpeak’s™ securities or Healthpeak;e.the purchase or sale could result in liability to an officer or director under the short-swing trading rules of SectionÂ 16(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or violate the short-term trading restriction in Section III(D)(1) of this Policy; orf.other relevant considerations cause the purchase or sale to be inappropriate.Please be aware that if the approval of a proposed purchase or sale is withheld by the General Counsel, the decision cannot be “overruled” by any member of management. In the event of a disagreement regarding a proposed purchase or sale, the General Counsel may be required to report the proposed purchase or sale to the Audit Committee of the Board of Directors. The General Counsel and the Audit Committee may obtain the advice of outside legal counsel with respect to a pre-approval request. An employee, officer, or director (or his or her Restricted Affiliate, if applicable) may not in any event engage in the proposed purchase or sale until a request has been pre-approved by the General Counsel or his or her designee in writing.Notwithstanding the General Counsel’s™ approval of a trade, each person subject to this Policy remains responsible for determining if he or she is aware of material non-public information and any action by Healthpeak, the General Counsel or any other employee or director pursuant to this Policy does not constitute legal advice or insulate him or her from liability under insider trading laws. Additionally, even if a trade has been approved by the General Counsel, such trade may not be executed if (a)Â the employee, officer or director (or Restricted Affiliates or others subject to this Policy) becomes aware of material non-public information concerning Healthpeak, (b)Â the General Counsel subsequently revokes the approval, or (c)Â the Trading Window is subsequently closed. If a purchase or sale is not completed within the Trading Window or other approved time period (or if the General Counsel revokes the approval), the purchase or sale must be resubmitted for approval to the General Counsel before it may be executed. If a proposed purchase or sale is not approved, the requesting person is prohibited from initiating any transaction in Healthpeak’s™ securities and should not inform anyone within or outside of Healthpeak of such prohibition.“A A A A A A A A A A”The remainder of this page is intentionally left blank.JAPPENDIX ARULE 10b5-1 TRADING PLANI.INTRODUCTIONRuleÂ 10b5-1 adopted by the SEC provides an affirmative defense to insider trading that is available to a person making a purchase or sale of securities who demonstrates that the purchase or sale was effected pursuant to a pre-arranged “trading plan” that meets certain conditions. Notwithstanding the other provisions of this Policy, you may purchase or sell Healthpeak’s™ securities regardless of whether you may be aware of material non-public information at the time of trading, provided that the purchase or sale is made pursuant to a plan (the “10b5-1 Trading Plan”) which is validly established in compliance with the provisions of Rule 10b5-1 and satisfies the following criteria:A.the 10b5-1 Trading Plan (including any modifications or terminations thereof) must be entered into only during an open Trading Window and at a time when you are not aware of material non-public information about Healthpeak or its securities;B.the 10b5-1 Trading Plan must be a written plan or binding contract (i.e., the plan may not consist of an oral arrangement or order to purchase or sell Healthpeak’s™ securities in the future) that does not allow you to exercise any subsequent influence over how, when or whether to effect the trade;C.the 10b5-1 Trading Plan must specify the amount, price and date of trades, or include a written formula, algorithm or computer program for trading determinations; D.the 10b5-1 Trading Plan must be entered into in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 and you

must act in good faith with respect to the 10b5-1 Trading Plan; E.the 10b5-1 Trading Plan (including any modifications or terminations thereof) must comply with the other requirements in this Appendix A and be pre-approved in advance by the General Counsel or the General Counselâ€™s designee (provided that, for a 10b5-1 Trading Plan of the General Counsel, such pre-approval must be provided by the President or Chief Executive Officer, or that personâ€™s designee, and all references to approval by the General Counsel below in this Appendix A shall be deemed to also refer to any applicable approval by the General Counselâ€™s designee or A-1by the President or Chief Executive, or that personâ€™s designee, in the case of a 10b5-1 Trading Plan of the General Counsel); andF.you must not alter or deviate from the terms of the 10b5-1 Trading Plan or enter into or alter a corresponding or hedging transaction or position with respect to the securities to be purchased or sold pursuant to such plan.II.DESCRPTION OF A QUALIFIED RULE 10b5-1 TRADING PLAN 10b5-1 Trading Plan (including any modifications or terminations thereof) must comply with all other applicable disclosure and other requirements under federal and state securities laws. As a condition to obtaining pre-approval of a 10b5-1 Trading Plan, the Rule 10b5-1 Trading Plan (and any modifications or terminations thereof) shall comply with and include the following safeguards with such additional conditions that Healthpeak may require:A.the 10b5-1 Trading Plan shall include a written representation from you that you are not aware of any material non-public information about Healthpeak or its securities at the time the 10b5-1 Trading Plan is established and that you are adopting (or modifying) the 10b5-1 Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1. In the event the General Counsel determines that there is material non-public information that has not been publicly disclosed at the time you wish to enter into a 10b5-1 Trading Plan (or to modify a previously adopted 10b5-1 Trading Plan), the General Counsel may delay approval of the 10b5-1 Trading Plan until the information has been publicly disclosed;B.the 10b5-1 Trading Plan must provide that the first trade will not occur until the later of (i) ninety (90) days after the adoption (or modification) of the 10b5-1 Trading Plan or (ii) two (2) business days following the disclosure of Healthpeak's financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the 10b5-1 Trading Plan was adopted (or modified) but, in any event, a maximum of 120 days after adoption (or modification) of the 10b5-1 Trading Plan (such period in which trades may not occur, the â€œCooling-Off Periodâ€); C.the 10b5-1 Trading Plan must provide for a minimum term of six (6) months and a maximum term of one (1) year, unless a shorter or longer term is approved by the General Counsel;D.no more than one (1) 10b5-1 Trading Plan shall be in effect at any time with respect to open market purchases or sales of Healthpeakâ€™s securities beneficially owned by you, except that, during the term of a 10b5-1 Trading Plan, you mayA.21.enter into a new 10b5-1 Trading Plan if such later-commencing 10b5-1 Trading Plan complies with Rule 10b5-1 and the additional requirements in this Appendix A and trading under such 10b5-1 Trading Plan is not authorized to commence until after all trades under the earlier-commencing 10b5-1 Trading Plan are completed or expired without execution; provided, however, that if the earlier-commencing 10b5-1 Trading Plan is terminated before its originally scheduled completion date, then the Cooling-Off Period for the later-commencing plan shall run from the date of such termination (and not from the date the later-commencing plan was adopted); and 2.enter into another contract, instruction, or plan providing only for the sale of such securities as are necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory award, such as restricted stock or restricted stock units, and provided that you do not exercise control over the timing of such sales (a â€œSell-to-Cover Planâ€). E.other than Sell-to-Cover Plans, no more than one (1) 10b5-1 Trading Plan providing for the open-market purchase or sale of Healthpeak securities in a single transaction may be in adopted within any twelve (12) month period;F.the 10b5-1 Trading Plan must contain procedures to ensure prompt compliance with (1) any reporting requirements under Section 16 of the Exchange Act, (2) SEC Rule 144 relating to any sales under the 10b5-1 Trading Plan, and (3) any suspension of trading or other restrictions that are imposed on transactions under an approved Rule 10b5-1 Trading Plan, including pursuant to customary lock-up commitments associated with underwritten public offerings of Healthpeakâ€™s securities; provided, however, that any 10b5-1 Trading Plan may permit the sale of up to 50,000 shares of our common stock by an officer or director (or such other amount as agreed to by Healthpeak for all of its senior officers) during any lock-up period to which such officer or director may become subject in connection with an underwritten public offering by Healthpeak; G.because a 10b5-1 Trading Plan must be entered into and acted on in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 or 10b5-1, a 10b5-1 Trading Plan should be adopted with the intention that it will not be amended or modified frequently, since changes to a 10b5-1 Trading Plan may raise issues as to an individualâ€™s good faith. For this reason, although modifications to or early termination of a 10b5-1 Trading Plan are not prohibited, the General Counsel will A-3approve modifications or early terminations only in limited and exceptional circumstances and subject to the following additional requirements: 1.any modification of a 10b5-1 Trading Plan may not occur more than once in any twelve-month period;2.any modification of a 10b5-1 Trading Plan must satisfy all of the requirements of Rule 10b5-1 and this Appendix A that apply to the adoption of a new 10b5-1 Trading Plan; and3.a 10b5-1 Trading Plan cannot be adopted if you have terminated a previous 10b5-1 Trading Plan prior to the end of its original term within the prior three (3) months.For purposes of the foregoing, a modification of a 10b5-1 Trading Plan includes any change to the amount, price, or timing of the purchase or sale of securities under such plan, but shall not include the substitution of the broker executing trades thereunder as long as such modified plan does not change the price, amount of securities to be purchased or sold or dates on which such purchases or sales are to be executed.Trades effected pursuant to a 10b5-1 Trading Plan will not require further pre-approval at the time of the trade if the 10b5-1 Trading Plan complies with the requirements set forth above. Any employee, officer or director who effects a transaction pursuant to a 10b5-1 Trading Plan (or his or her broker) must, however, report specific transaction details to the General Counsel no later than the same day on which the transaction occurred (e.g., amount of securities, date and price of any purchase or sale). It is important to note that the review and approval of the terms of the 10b5-1 Trading Plan by the General Counsel will not constitute sufficient notice of the transaction by you. In pre-approving the implementation, modification or termination of a Rule 10b5-1 Trading Plan, the General Counsel shall not be responsible for determining whether such plan is in compliance with the provisions of RuleA 10b5-1. Compliance with Rule 10b5-1 is solely your responsibility and we recommend that you consult with your legal and financial advisors regarding compliance with securities laws.*A A A A A A A A *The remainder of this page is intentionally left blank.JA-4 EX-21.1 5 ex21112312024.htm EX-21.1 DocumentEXHIBIT 21.1Healthpeak Properties, Inc.SubsidiariesAs of February 1, 2025EntityNameJurisdiction of Organization or Formation100 Discovery Park DE, LLCDelaware101 CPD LLCDelaware1040-1050 Waltham Street Lender, LLCDelaware3020-3030 Callan Road JV, L.L.C.Delaware3020-3030 Callan Road Mezz, L.L.C.Delaware3020-3030 Callan Road Owner, L.L.C.Delaware3020-3030 Callan Road TRS, L.L.C.Delaware424 Summit Property, LLCDelaware4902 Headquarters Point Investor, LLCDelaware557 Highland, LLCDelaware700 Broadway MOB, LLCDelaware87 CPD LLCDelawareAHP of Nevada, LLCDelawareAHP of Washington, Inc.WashingtonAnnapolis Assisted Living, LLCMarylandARC Richmond Place Real Estate Holdings, LLCDelawareArlington Heights MOB, LLCDelawareAurora HCP, LLCDelawareAurora MOB, LLCDelawareBayside Acquisition, LLCDelawareBayside Area Development, LLCDelawareBentonville Medical Offices, LLCDelawareBolingbrook MOB, LLCDelawareBrandon MOB, LLCDelawareBrandywine GP, LLCDelawareBrentwood MOB Owners LLCDelawareBrentwood MOB, LLCDelawareBritannia Biotech Gateway Limited PartnershipDelawareBritannia Gateway II Limited PartnershipDelawareBritannia Hacienda II Limited PartnershipDelawareBritannia Hacienda VIII LLCDelawareBritannia PG TRS, LLCDelawareBritannia Pointe Grand Limited PartnershipDelawareBuford Drive MOB I, LLCGeorgiaBurnsville 303 MOB, LLC DelawareBurnsville 305 MOB, LLCDelawareCambridge Nashville Medical Center, L.P.TennesseeCAN Real Estate, LLCIndianaCardinal Westerville II LLCOhioCCRC â€” Freedom Fairways Golf Course, LLCDelawareCCRC â€” Freedom Pointe at the Villages, LLCDelawareCCRC â€” Lake Port Square, LLCDelawareEntityNameJurisdiction of Organization or FormationCCRC â€” Regency Oaks, LLCDelawareCCRC â€” South Port Square, LLCDelawareCCRC 2019 OpCo TRS, LLCDelawareCCRC HoldCo â€” Holland, LLCDelawareCCRC OpCo â€” Bradenton, LLCDelawareCCRC OpCo â€” Cypress Village, LLCDelawareCCRC OpCo â€” Foxwood Springs, LLCDelawareCCRC OpCo â€” Freedom Square, LLCDelawareCCRC OpCo â€” Galleria Woods, LLCDelawareCCRC OpCo â€” Gleanloch Farms, LLCDelawareCCRC OpCo ~ Hillside, LLCDelawareCCRC OpCo â€” Holland, LLCDelawareCCRC OpCo â€” Robin Run, LLCDelawareCCRC OpCo â€” Sun City Center, LLCDelawareCCRC OpCo Ventures II, LLCDelawareCCRC OpCo Ventures, LLCDelawareCCRC PropCo â€” Bradenton, LLCDelawareCCRC PropCo â€” Brandywine MC, LLCDelawareCCRC PropCo â€” Cypress Village, LLCDelawareCCRC PropCo â€” Foxwood Springs, LLCDelawareCCRC PropCo â€” Freedom Plaza, LLCDelawareCCRC PropCo â€” Freedom Square, LLCDelawareCCRC PropCo â€” Galleria Woods, LLCDelawareCCRC PropCo â€” Gleanloch Farms, LLCDelawareCCRC PropCo ~ Hillside, LLCDelawareCCRC PropCo â€” Holland, LLCDelawareCCRC PropCo â€” Homewood Residence, LLCDelawareCCRC PropCo â€” Lady Lake, LLCDelawareCCRC PropCo â€” Robin Run, LLCDelawareCCRC PropCo Ventures II, LLCDelawareCCRC PropCo Ventures, LLCDelawareCCRC-Brandywine, LLCDelawareCDP Residential Holdings, LLCDelawareCEI Drive MOB, LLCOhioCentennial MOB, LLCDelawareCharles Pavilion Holding, LLCDelawareCherry Hill MOB, LLCDelawareChino Hills TRS, LLC DelawareCOG Real Estate Partners II, LLCOhioColumbia MOB, LLCDelawareCP MOB I and II, LLCDelawareCrescent City Surgical Centre Facility, L.L.CLouisianaCrystal Medical Building, LLCMinnesotaCullman POB II, LLCDelawareCullman POB Partners I, LLCDelawareEntityNameJurisdiction of Organization or FormationCypress Garden Homes, LLCDelawareDell Medical Building LLCMinnesotaDesert Cove MOB, LLCArizonaDOC DR Holdco, LLCMarylandDOC DR, LLCMarylandDOC Fund 1, LLCDelawareDOC-1 City Avenue MOB, LLCWisconsinDOC-1 St. Vincent Circle MOB, LLCWisconsinDOC-100 East Liberty Street MOB, LLCWisconsinDOC-100 Pilot Medical Drive MOB, LLCWisconsinDOC-1003 Reserve Boulevard MOB, LLCWisconsinDOC-10401 Spotsylvania Avenue MOB, LLCWisconsinDOC-105 West Stone Drive MOB, LLCWisconsinDOC-1050 SE Monterey Road MOB, LLCWisconsinDOC-10740 Palm River Rd MOB, LLCDelawareDOC-10800 Panama City Beach Parkway MOB, LLCWisconsinDOC-10815 West McDowell Road MOB, LLCWisconsinDOC-11045 Lansing Circle MOB, LLCWisconsinDOC-1105 West Frank Avenue MOB, LLCWisconsinDOC-1108 1st Street SE MOB, LLCWisconsinDOC-1110 West Peachtree Street NW MOB, LLCWisconsinDOC-11109 South 84th Street MOB, LLCWisconsinDOC-1111 West Frank Avenue MOB, LLCWisconsinDOC-1124 East McKellips Road MOB, LLCWisconsinDOC-11311 Bridgeport Way MOB, LLCWisconsinDOC-1155 SE Monterey Road ASC, LLCWisconsinDOC-118 Women's Center Lane MOB, LLCWisconsinDOC-1200 N State St MOB, LLCDelawareDOC-1203 Smizer Mill Road MOB, LLCWisconsinDOC-1212 East Main Street MOB, LLCWisconsinDOC-1213 15th Avenue W MOB, LLCWisconsinDOC-12600 Sorrento Road MOB, LLCWisconsinDOC-12601 Sorrento Road MOB, LLCWisconsinDOC-12635 West Bluemound Road MOB, LLCWisconsinDOC-12809 West Dodge Road MOB, LLCWisconsinDOC-1299 Industrial Drive MOB, LLCWisconsinDOC-1301 Barbara Jordan Boulevard MOB, LLCWisconsinDOC-1301 West Frank Avenue MOB, LLCWisconsinDOC-1310 East Main Avenue MOB, LLCWisconsinDOC-1315 Barbara Jordan Boulevard, LLCWisconsinDOC-1320 Broadcasting Road MOB, LLCWisconsinDOC-13555 West McDowell Road MOB, LLCWisconsinDOC-13950 Brandywine Road MOB, LLCWisconsinDOC-1400 Education Way MOB, LLCWisconsinDOC-1400 George Dieter Drive MOB, LLCWisconsinEntityNameJurisdiction of Organization or FormationDOC-1451 Harrodsburg Road MOB, LLCWisconsinDOC-1455 Higdon Ferry Road MOB, LLCWisconsinDOC-14655 Galaxie Avenue MOB, LLCWisconsinDOC-14688 Everton Avenue MOB, LLCWisconsinDOC-15255 Max Leggett Pkwy MOB, LLCDelawareDOC-1555 South Blvd East MOB, LLCDelawareDOC-1561 Ulster Avenue MOB, LLCDelawareDOC-1609 Hospital Parkway MOB, LLCWisconsinDOC-16221 St. Vincent Way MOB, LLCWisconsinDOC-1624 North McKenzie Street MOB, LLCWisconsinDOC-1624 South I Street MOB, LLCWisconsinDOC-1662 Higdon Ferry Road MOB, LLCWisconsinDOC-16815 E Jefferson Ave MOB, LLCDelawareDOC-16838 East Palisades Boulevard MOBs, LLCWisconsinDOC-16940 Lakeside Hills Plaza MOB, LLCWisconsinDOC-170 Taylor Station Road MOB, LLCWisconsinDOC-17030 Lakeside Hills Plaza MOB, LLCWisconsinDOC-1708 South Yakima Street MOB, LLCWisconsinDOC-1710 North Randall Road MOB, LLCWisconsinDOC-17198 St. Lukeâ€™s Way MOB, LLCWisconsinDOC-1755 Currie Drive MOB, LLCWisconsinDOC-1802 South Yakima Street MOB, LLCWisconsinDOC-1900 Bluegrass Avenue MOB, LLCWisconsinDOC-1903 West Hebron Lane MOB, LLCWisconsinDOC-1905 West Hebron Lane MOB, LLCWisconsinDOC-19900 Haggerty Road MOB, LLCWisconsinDOC-2 Hospital Plaza MOB, LLCDelawareDOC-200 Heart Center Lane MOB, LLCWisconsinDOC-2000 Lewis Turner Boulevard MOB, LLCWisconsinDOC-2001 Beam Avenue MOB, LLCWisconsinDOC-201 North Mountain Road MOB, LLCWisconsinDOC-2027 Lebanon Church Road MOB, LLCWisconsinDOC-2030 Stringtown Road MOB, LLCOhioDOC-207 Stonebridge Boulevard ASC, LLCWisconsinDOC-20745 North Scottsdale Road MOB, LLCWisconsinDOC-21 Laurel Avenue MOB, LLCWisconsinDOC-2101 Charlotte St MOB, LLCDelawareDOC-2101 Northside Drive MOB, LLCWisconsinDOC-2105 East Enterprise Avenue MOB, LLCWisconsinDOC-2111 Landmark Circle MOB, LLCWisconsinDOC-2116 West Faidley Avenue MOB, LLCWisconsinDOC-21st Century Sarasota, LLCWisconsinDOC-2213 Decatur Highway ASC, LLCWisconsinDOC-2215 East Villa Maria MOB, LLCWisconsinDOC-225 Abraham Flexner Way MOB, LLCWisconsinEntityNameJurisdiction of Organization or FormationDOC-225 Crosslake Drive MOB, LLCWisconsinDOC-2255 East Mossy Oaks Drive MOB, LLCWisconsinDOC-2315 Myrtle St MOB, LLCDelawareDOC-240 Grandview Avenue MOB, LLCWisconsinDOC-2401 Northampton Street MOB, LLCWisconsinDOC-2405 North Columbus Street MOB, LLCWisconsinDOC-2412 Cumming Street MOB, LLCWisconsinDOC-2420 South State Street MOB, LLCWisconsinDOC-2422 20th Street SW MOB, LLCWisconsinDOC-250 East Liberty Street MOB, LLCWisconsinDOC-250 Fame Avenue MOB, LLCWisconsinDOC-250 Riverchase Parkway East OMF, LLCWisconsinDOC-250 West 96th Street MOB, LLCWisconsinDOC-2500 Sunset Drive NW MOB, LLCWisconsinDOC-2501 Citico Avenue MOB, LLCWisconsinDOC-251 Breezeway St MOB, LLCDelawareDOC-2511 Terra Crossing Boulevard MOB, LLCWisconsinDOC-2590 Healing Way MOB, LLCWisconsinDOC-2600 Scripture Street MOB, LLCWisconsinDOC-2605 East Creeks Edge Drive MOB, LLCWisconsinDOC-2625 Market Place MOB, LLCWisconsinDOC-2633 Napoleon Avenue MOB, LLCWisconsinDOC-2660 10th Avenue South MOB, LLCWisconsinDOC-2700 East 29th Street MOB, LLCWisconsinDOC-2900 Curve Crest MOB, LLCWisconsinDOC-2945 Hazelwood Street MOB, LLCWisconsinDOC-2947 Rodeo Park Drive East MOB, LLCWisconsinDOC-300 Lake Drive East MOB, LLCWisconsinDOC-309 Renaissance, LLCWisconsinDOC-310 North 9th Street MOB, LLCWisconsinDOC-3100 Lee Trevino Drive MOB, LLCWisconsinDOC-3100 Plaza Properties Boulevard MOB, LLCWisconsinDOC-3101 Summit View Drive MOB, LLCWisconsinDOC-32 Northeast Drive MOB, LLCWisconsinDOC-3200 West 33rd Street MOB, LLCWisconsinDOC-3219 Central Avenue MOB, LLCWisconsinDOC-3311 North 44th Street MOBs, LLCWisconsinDOC-3316 West 66th Street MOB, LLCWisconsinDOC-33300 North 32nd Avenue MOB, LLCWisconsinDOC-3400 West 66th Street MOB, LLCWisconsinDOC-3410 North St. MOB, LLCWisconsinDOC-34509 9th Avenue South MOB, LLCWisconsinDOC-350 Peak One Drive MOB, LLCWisconsinDOC-3510 Old Washington Road MOB, LLCWisconsinDOC-3601 CCI Drive MOB, LLCWisconsinEntityNameJurisdiction of Organization or FormationDOC-3602 Kyoto Gardens Drive MOB, LLCWisconsinDOC-3641-3731 Ridge Mill Drive MOB, LLCWisconsinDOC-3699 Epworth Road MOB, LLCWisconsinDOC-3730 Plaza Way MOB, LLCWisconsinDOC-376 Tolland Turnpike MOB, LLCWisconsinDOC-3815 East Bell Road MOB, LLCWisconsinDOC-3833 Coon Rapids Boulevard NW MOB, LLCWisconsinDOC-3855 Pleasant Hill Road MOB, LLCWisconsinDOC-3920 Dutchmans Lane MOB, LLCWisconsinDOC-3925 North Gateway Drive MOB, LLCWisconsinDOC-3980 Colonnade Parkway MOB Investors, LLCWisconsinDOC-3980 Colonnade Parkway MOB, LLCWisconsinDOC-4 Columbus Ave MOB, LLCDelawareDOC-4000 Medical Center Drive MOB, LLCWisconsinDOC-401 East Gold Coast Road MOB, LLCWisconsinDOC-4075 East 128th Avenue MOB, LLCWisconsinDOC-4100 Park Forest MOB (Unit 4), LLCMichiganDOC-4100 Park Forest MOB, LLCMichiganDOC-411 North Section Street MOB, LLCWisconsinDOC-4352 North Josey Lane MOB, LLCWisconsinDOC-4397 Ronald Reagan Boulevard ASC, LLCWisconsinDOC-440 New Britain Avenue MOB, LLCWisconsinDOC-4402 Churchman Avenue MOB, LLCWisconsinDOC-4419 North Highway 7 MOB, LLCWisconsinDOC-44344 Dequindre Rd MOB, LLCDelawareDOC-4500 Churchman Avenue MOB, LLCWisconsinDOC-4518 Union Deposit MOB, LLCWisconsinDOC-4520 Union Deposit MOB, LLCWisconsinDOC-465 N. Cleveland Avenue MOB, LLCWisconsinDOC-4780 North Josey Lane MOB, LLCWisconsinDOC-4809 Ambassador Caffery Pkwy MOB, LLCDelawareDOC-484 County Line Rd West MOB, LLCWisconsinDOC-4921 Long Prairie Road MOB, LLCWisconsinDOC-4951 Long Prairie Road MOB, LLCWisconsinDOC-500 Medical Center Boulevard MOB, LLCWisconsinDOC-500 S. Henderson Street MOB, LLCWisconsinDOC-5000 Long Prairie Road MOB, LLCWisconsinDOC-5040 Forest Drive MOB, LLCWisconsinDOC-5100 West Taft Road MOB, LLCWisconsinDOC-5101 North Davis Highway MOB, LLCWisconsinDOC-5146 Preston Avenue ASC, LLCWisconsinDOC-515 West Middle Turnpike MOB, LLCWisconsinDOC-5150 North Davis Highway MOB, LLCWisconsinDOC-5401 South Congress Avenue MOB, LLCWisconsinDOC-560 North Cleveland Avenue MOB, LLCWisconsinEntityNameJurisdiction of Organization or FormationDOC-560 W Mitchell St MOB, LLCDelawareDOC-5757 Harper Drive NE MOB, LLCWisconsinDOC-600 Health Park Boulevard MOB, LLCWisconsinDOC-6010 Bay Parkway MOB, LLCDelawareDOC-6220 West Bell Road ASC, LLCWisconsinDOC-631 Professional Drive MOB, LLCWisconsinDOC-633 Emerson Road MOB, LLCWisconsinDOC-6401 Kimball Drive MOB, LLCWisconsinDOC-669 South McKenzie Street MOB, LLCWisconsinDOC-67 Prospect Avenue MOB, LLCWisconsinDOC-6734 Route 9 MOB, LLCWisconsinDOC-6829 North 72nd Street MOB, LLCWisconsinDOC-7242 East Osborn Road MOB, LLCWisconsinDOC-725 Glenwood Drive MOB, LLCWisconsinDOC-7277 Smithâ€™s Mill Road MOB, LLCWisconsinDOC-7308 Bridgeport Way W MOB, LLCWisconsinDOC-7330 North 99th Avenue MOB, LLCWisconsinDOC-7340 West College Drive MOB, LLCWisconsinDOC-7440 South 91st Street MOB, LLCWisconsinDOC-7710 Mercy Road MOB, LLCWisconsinDOC-808 3rd Street SE MOB, LLCWisconsinDOC-8096 Twin Beech Road MOB, LLCWisconsinDOC-810 East Rosser Avenue MOB, LLCWisconsinDOC-811 2nd Street SE MOB, LLCWisconsinDOC-8116 Good Luck Road MOB, LLCWisconsinDOC-850 Enterprise Pkwy MOB, LLCDelawareDOC-8515 Eagle Point Boulevard MOB, LLCWisconsinDOC-9 Centre Drive MOB, LLCWisconsinDOC-908 North Howard MOB, LLCWisconsinDOC-9085 Southern Street MOB, LLCWisconsinDOC-9118 Bluebonnet Centre Boulevard MOB, LLCWisconsinDOC-9160 Carothers Parkway MOB, LLCWisconsinDOC-9250 North 3rd Street MOB, LLCWisconsinDOC-9726 Touchton Road MOB, LLCWisconsinDOC-9999 Kenworthy

Street MOB, LLCWisconsinDOC-Baylor Mansfield ASC, LLCWisconsinDOC-Buford Drive MOB I Investors, LLCDelawareDOC-Buford Drive MOB I, LLCWisconsinDOC-Carmel MOB, LLCWisconsinDOC-CCP MOBs, LLCNew YorkDOC-CCSC Crescent City Land, LLCWisconsinDOC-CCSC Crescent City Surgical Centre, LLCWisconsinDOC-CHI Rockwall Holding, LLCWisconsinDOC-Cons Columbus MOB, LLCWisconsinDOC-CRMC Carlisle, MOB LLCWisconsinEntity NameJurisdiction of Organization or FormationDOC-Deauville Boulevard MOBs, LLCWisconsinDOC-Desert Cove MOB, LLCWisconsinDOC-DG 610 MOB, LLCWisconsinDOC-DG Holding, LLCWisconsinDOC-DG Lakeville MOB, LLCWisconsinDOC-DG MAPLE GROVE MOB, LLCWisconsinDOC-DG MOB Fund Holding, LLCWisconsinDOC-DG MOB Funding, LLCWisconsinDOC-DG Xchange MOB, LLCWisconsinDOC-DSF Roswell Riverwalk, LLCWisconsinDOC-DUNWOODY MEDICAL CAMPUS, LLCWisconsinDOC-FSH El Paso Medical Center Partners, LLCWisconsinDOC-FSH El Paso Medical Center, LLCWisconsinDOC-FSH San Antonio Hospital, LLCWisconsinDOC-FSH San Antonio MOB, LLCWisconsinDOC-Great Falls Holding, LLCWisconsinDOC-Grenada MOB, LLCWisconsinDOC-Greymark HQ OKC MOB, LLCWisconsinDOC-Griffin Road MOB, LLCWisconsinDOC-Harrodsburg Road MOBs, LLCWisconsinDOC-Indiana 7 MOB, LLCWisconsinDOC-Indiana American MOBs, LLCWisconsinDOC-Katy Medical MOBs, LLCWisconsinDOC-Landmark Holding 7, LLCDelawareDOC-Landmark TRS 7, LLCDelawareDOC-LM Elizabeth MOB, LLCWisconsinDOC-Medcore Eden Hill, LLCDelawareDOC-MedCore Realty HSP, LLCWisconsinDOC-Medical Quarters MOB TRS, LLCDelawareDOC-Medical Quarters MOB, LLCDelawareDOC-Medical Village at Maitland, LLCWisconsinDOC-Middletown Medical MOBs, LLCWisconsinDOC-Middletown Medical MOBs II, LLCDelawareDOC-MP Holding, LLCWisconsinDOC-MPC Port Worth MOB, LLCWisconsinDOC-MSM Greenwood MOBs, LLCWisconsinDOC-MSMOC Jackson MOB, LLCWisconsinDOC-Nashville MOB, LLCWisconsinDOC-Noblesville OMF, LLCWisconsinDOC-Oaks Lady Lake MOB, LLCWisconsinDOC-PDMC Atlanta, LLCWisconsinDOC-Pensacola Summit ASC, LLCWisconsinDOC-Pima Center Pkwy OMF LLCWisconsinDOC-Pinnacle Harrisburg MOBs, LLCWisconsinDOC-PMAK MOB Holding, LLCWisconsinEntity NameJurisdiction of Organization or FormationDOC-Premier Landmark MOBs, LLCWisconsinDOC-Renaissance Oshkosh MOB, LLCWisconsinDOC-SBO MOB, LLCWisconsinDOC-Scottsdale IRF, LLCWisconsinDOC-Shell Ridge Plaza MOB, LLCWisconsinDOC-SIM Monroe ASC, LLCWisconsinDOC-Summit Bloomington MOB, LLCWisconsinDOC-TL Sidell MOB, LLCWisconsinDOC-Unity Lafayette MOBs, LLCWisconsinDOC-West Roosevelt Street OMF, LLCWisconsinDOC-Yulee Holding Company, LLCDelawareDR California III Holdings, LLCDelawareDR California IV Holdings, LLCDelawareDSTS, LLCFloridaDurant MOB Manager LLCDelawareDurant MOB Owner LLCDelawareEagle Point Medical Building LLCMinnesotaEastwind MOB, LLCOhioEdina Medical Investment Partners L.L.C.MinnesotaEncino MOB, LLCDelawareEvansville MOB Owners Limited PartnershipDelawareFAEC 35 CPD, LLCDelawareFAEC Holdings (Abbey), LLCDelawareFAEC Holdings (Biddeford), LLCDelawareFAEC Holdings (Concord East Epsom Dover), LLCDelawareFAEC Holdings (Concord Horseshoe Commercial), LLCDelawareFAEC Holdings (Concord North Foundry), LLCDelawareFAEC Holdings (EP), LLCDelawareFAEC Holdings (Highlands Ranch), LLCDelawareFAEC Holdings (LA), LLCDelawareFAEC Holdings (Ortho Ashton), LLCDelawareFAEC Holdings (Ortho Shallotte), LLCDelawareFAEC Holdings (Ortho Shipyard), LLCDelawareFAEC Holdings (Riverwalk), LLCDelawareFAEC Holdings (Rockwall), LLCDelawareFAEC Holdings (Sidell), LLCDelawareFAEC-Kingwood Medical, LLCDelawareFaulkner Hinton/Suburban I, LLCKentuckyFaulkner Hinton/Suburban III, LLCKentuckyFDG-Vintage Park II Property, LLCDelawareFDG-Vintage Park II, LLCDelawareFoxwood Springs Garden Homes, LLCDelawareFrisco Centennial MOB I, LLCDelawareFrisco Centennial MOB II, LLCDelawareFSP-Deer Park, LLCDelawareEntity NameJurisdiction of Organization or FormationFSP-Waldwick Holding, LLCDelawareFSP-Waldwick Property, LLCDelawareGRSH IRF, LPTexasHacienda Stoneridge II, IncorporatedDelawareHartwell Innovation Campus, LLCDelawareHartwell Member, LLCDelawareHartwell TRS, LLCDelawareHayden Campus LLCDelawareHayden Campus TRS LLCDelawareHayward Point Eden I Limited PartnershipDelawareHazelwood Medical Building, LLCMinnesotaHC-3320 Live Oak Street BHF, LLCWisconsinHC-5788 Eckhert Road BHF, LLCWisconsinHCP - AM/Colorado, LLCDelawareHCP - AM/Florida, LLCDelawareHCP - AM/Illinois, LLCDelawareHCP - AM/Tennessee, LLCDelawareHCP - AM/Texas, LLCDelawareHCP 101 Cambridgepark Drive Member, LLCDelawareHCP 1101 Madison MOB, LLCDelawareHCP 3535 Market Street GP, LLCDelawareHCP 3535 Market Street, LPDelawareHCP 600 Broadway MOB, LLCDelawareHCP 833 Chestnut, LLCDelawareHCP Acquisitions, LLCDelawareHCP Albuquerque NM OpCo, LLCDelawareHCP Altamonte Springs, LLCDelawareHCP Arlington VA OpCo, LLCDelawareHCP Arnold MOB, LLCDelawareHCP Asia Investments, LLCDelawareHCP Atrium MOB LLCDelawareHCP Aur1 California A Pack, LLCDelawareHCP Beaumont TX OpCo, LLCDelawareHCP Beckett Lake, LLCDelawareHCP Bellevue VA OpCo, LLCDelawareHCP Bethesda MD OpCo, LLCDelawareHCP Beverly Hills CA OpCo, LLCDelawareHCP Biotech Gateway IncorporatedDelawareHCP Birmingham Portfolio, LLCDelawareHCP Boca Raton FL OpCo, LLCDelawareHCP Boynton Beach FL OpCo, LLCDelawareHCP Boynton Beach, LLCDelawareHCP Briargate MOB, LLCDelawareHCP Brofin Holdings, LLCDelawareHCP Brofin Properties, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP Brooklyn NY OpCo, LLCDelawareHCP BTC, LLCDelawareHCP Buford GA OpCo, LLCDelawareHCP Callan Road, LLCDelawareHCP Cambridgepark Drive Member LLCDelawareHCP Canton GA OpCo, LLCDelawareHCP Carrollwood, LLCDelawareHCP Cherry Hill NJ OpCo, LLCDelawareHCP Chino Hills, L.P.DelawareHCP Cincinnati OH OpCo, LLCDelawareHCP Clearlake OpCo, LLCDelawareHCP Clearwater, LLCDelawareHCP Coconut Creek FL OpCo, LLCDelawareHCP Columbia MD OpCo, LLCDelawareHCP Coosa MOB, LLCDelawareHCP Cresskill NJ OpCo, LLCDelawareHCP CRS1 2801 Denton TX GP, LLCDelawareHCP CRS1 2801 Denton TX, LPDelawareHCP CRS1 Delphis Lead Lender, LPDelawareHCP CRS2 Cleveland OH GP, LLCDelawareHCP CRS2 Cleveland OH, LPDelawareHCP CRS2 Fresno CA GP, LLCDelawareHCP CRS2 Fresno CA, LPDelawareHCP CRS2 GP, LLCDelawareHCP CRS2 Keller - Wylie TX, LLCDelawareHCP CRS2 Ogden UT GP, LLCDelawareHCP CRS2 Ogden UT, LPDelawareHCP CRS2 Plano TX GP, LLCDelawareHCP CRS2 Plano TX, LPDelawareHCP CRS2, LPDelawareHCP CTE, L.P.DelawareHCP Cy-Fair, LLCDelawareHCP Cypress TX MOB, LLCDelawareHCP DAS Acquisition, LLCDelawareHCP DAS Brentwood CA GP, LLCDelawareHCP DAS Cypress TX GP, LLCDelawareHCP DAS Cypress TX, LPDelawareHCP DAS Evansville IN GP, LLCDelawareHCP DAS GP, LLCDelawareHCP DAS Jackson II MS GP, LLCDelawareHCP DAS Lancaster TX GP, LLCDelawareHCP DAS Lender GP, LLCDelawareHCP DAS Lender, LPDelawareHCP DAS Lexington KY GP, LLCDelawareHCP DAS Marion IL GP, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP DAS Nassau Bay TX GP, LLCDelawareHCP DAS Parker CO GP, LLCDelawareHCP DAS Pearlton TX GP, LLCDelawareHCP DAS Pearlton TX, LPDelawareHCP DAS Pipeline I, LLCDelawareHCP DAS Scottsdale AZ GP, LLCDelawareHCP DAS Texarkana TX GP, LLCDelawareHCP DAS Towson MD GP, LLCDelawareHCP DAS Towson MD, LPDelawareHCP DAS, LPDelawareHCP Dayton OH OpCo, LLCDelawareHCP Delray Beach FL OpCo, LLCDelawareHCP Delray Beach, LLCDelawareHCP Des Peres MO OpCo, LLCDelawareHCP DR California II, LLCDelawareHCP DR California III HoldCo, LLCDelawareHCP DR California III, LLCDelawareHCP DR California, LLCDelawareHCP DR MCD, LLCDelawareHCP DSL Bradenton FL OpCo, LLCDelawareHCP DSL Fort Myers FL OpCo, LLCDelawareHCP DSL Fort Myers IL FL OpCo, LLCDelawareHCP DSL Melbourne FL OpCo, LLCDelawareHCP DSL Naples FL OpCo, LLCDelawareHCP DSL Palm Beach Gardens FL OpCo, LLCDelawareHCP DSL PropCo Castle Hills, LLCDelawareHCP DSL PropCo Palm Beach Gardens, LLCDelawareHCP DSL PropCo Fort Myers, LLCDelawareHCP DSL PropCo Melbourne, LLCDelawareHCP DSL PropCo Naples, LLCDelawareHCP DSL PropCo Palm Beach Gardens, LLCDelawareHCP DSL PropCo Sarasota Bay, LLCDelawareHCP DSL PropCo Sugarloaf, LLCDelawareHCP DSL PropCo Tampa Palms, LLCDelawareHCP DSL Suwanee GA OpCo, LLCDelawareHCP DSL Tampa FL OpCo, LLCDelawareHCP DSL TRS, LLCDelawareHCP Dunwoody GA OpCo, LLCDelawareHCP Eastgate LLCDelawareHCP Eby1 Davenport IA, LPDelawareHCP Eby1 GP, LLCDelawareHCP Eby1 Illinois GP, LLCDelawareHCP Eby1 Illinois, LPDelawareHCP Eby1 Iowa GP, LLCDelawareHCP Eby1 Marion IA, LPDelawareEntity NameJurisdiction of Organization or FormationHCP Eby1, LPDelawareHCP Eby2 Portage MI, LLCDelawareHCP Eden Manager, LLCDelawareHCP Eden1 Gainesville FL, LLCDelawareHCP Eden1 Jacksonville FL, LLCDelawareHCP Eden1 Tallahassee FL, LLCDelawareHCP Eden2 A Pack, LLCDelawareHCP Eden2 B Pack, LLCDelawareHCP Eden2 GP, LLCDelawareHCP Eden2 North Carolina GP, LLCDelawareHCP Eden2 North Carolina, LPDelawareHCP Eden2, LPDelawareHCP Edmonds WA OpCo, LLCDelawareHCP Emfin Properties, LLCDelawareHCP Emmons Ave NY OpCo, LLCDelawareHCP EMOH, LLCDelawareHCP ESL Fairborn OH OpCo, LLCDelawareHCP ESL Fairborn OH, LLCDelawareHCP ESL Fort Harrison IN OpCo, LLCDelawareHCP ESL Indiana, LLCDelawareHCP ESL Madison WI OpCo, LLCDelawareHCP ESL Portland OR OpCo, LLCDelawareHCP ESL West Lafayette IN OpCo, LLCDelawareHCP Estates USA Inc.DelawareHCP ETE, L.P.DelawareHCP Fallbrook TX OpCo, LLCDelawareHCP Falls Church VA OpCo, LLCDelawareHCP Fannin Medical Investors, LLCDelawareHCP Farmington Hills MI OpCo, LLCDelawareHCP Florham Park NJ OpCo, LLCDelawareHCP Forbes, LLCDelawareHCP Fortuna OpCo, LLCDelawareHCP Frederick MD OpCo, LLCDelawareHCP Friendswood, LLCDelawareHCP Fund Management, LLCDelawareHCP Fund, L.P.DelawareHCP FW TX OpCo, LLCDelawareHCP Gen Lender, LLCDelawareHCP Glastonbury CT OpCo, LLCDelawareHCP GP/Colorado, LLCDelawareHCP Gray Street MOB, LLCDelawareHCP Greensboro NC OpCo, LLCDelawareHCP Greenville SC MOB 1, LLCDelawareHCP Greenville SC MOB 2, LLCDelawareHCP Hazel Creek, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP HB2 Carrington-Cherry Hills, LLCDelawareHCP HB2 Emerald Bay Manor, LLCDelawareHCP HB2 Greenwich - East-West Bay - Olympia Fields, LLCDelawareHCP HB2 Heritage Palmeras, LLCDelawareHCP HB2 Herons Run, LLCDelawareHCP HB2 Manor - Pointe Newport Place, LLCDelawareHCP HB2 North Bay Manor, LLCDelawareHCP HB2 Park at Golf Mill, LLCDelawareHCP HB2 Pinecrest Place, LLCDelawareHCP HB2 Prosperity Oaks, LLCDelawareHCP HB2 Sakonnet Bay Manor, LLCDelawareHCP HB2 South Bay Manor, LLCDelawareHCP HB2 Waterside Retirement Estates, LLCDelawareHCP HB3 Spring Shadows Place, LLCDelawareHCP HB3 Willowbrook, LLCDelawareHCP Hyde Park TRS, LLCDelawareHCP Insurance TRS, LLCDelawareHCP Irvine CA OpCo, LLCDelawareHCP Irving, LLCDelawareHCP Jackson Central Investors, LLCDelawareHCP Jacksonville, LLCDelawareHCP Jona Dr VA OpCo, LLCDelawareHCP Kenmore WA OpCo, LLCDelawareHCP Kingwood Medical MOB, LLCDelawareHCP Kirkland, LLCDelawareHCP Lake Granbury Investors, LLCDelawareHCP Lakeview MOB, LLCDelawareHCP Lancaster MOB, LLCDelawareHCP Lantana FL OpCo, LLCDelawareHCP Leesburg VA OpCo, LLCDelawareHCP Lewisville TX OpCo, LLCDelawareHCP Life Science Assets TRS, LLCDelawareHCP Life Science Development, LLCDelawareHCP Life Science REIT, Inc.MarylandHCP Life Services TRS, LLCDelawareHCP Life Science, LLCDelawareHCP Lilburn GA OpCo, LLCDelawareHCP Louisville KY OpCo, LLCDelawareHCP LS Brisbane, LLCDelawareHCP LS Carlsbad, LLCDelawareHCP LS Poway I, LLCDelawareHCP LS Poway II, LLCDelawareHCP LS Poway III, LLCDelawareHCP LS Redwood City, LLCDelawareHCP LSE Property Manager, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP MA1 GP, LLCDelawareHCP MA1, LPDelawareHCP MA2 California, LPDelawareHCP MA2 GP Holding, LLCDelawareHCP MA2 Massachusetts, LPDelawareHCP MA2 Ohio, LPDelawareHCP MA2 Oklahoma, LPDelawareHCP MA2, LPDelawareHCP MA3 A Pack GP, LLCDelawareHCP MA3 A Pack, LPDelawareHCP MA3 California, LPDelawareHCP MA3 GP Holding, LLCDelawareHCP MA3 Pennsylvania, LPDelawareHCP MA3 South Carolina, LPDelawareHCP MA3 Virginia, LPDelawareHCP MA3 Washington, LPDelawareHCP MA3, LPDelawareHCP MA4 Cleveland OH, LPDelawareHCP MA4 Columbia MD, LPDelawareHCP MA4 GP Dayton OH, LPDelawareHCP MA4 Dayton OH, LPDelawareHCP MA4 Dunwoody GA, LPDelawareHCP MA4 GP Cleveland OH, LLCDelawareHCP MA4 GP Columbia MD, LLCDelawareHCP MA4 GP Dayton OH, LLCDelawareHCP MA4 GP Dunwoody GA, LLCDelawareHCP MA4 GP Florham Park NJ, LLCDelawareHCP MA4 GP Florida Holding, LLCDelawareHCP MA4 GP Greensboro NC, LLCDelawareHCP MA4 GP Kansas City KS, LLCDelawareHCP MA4 GP Northville MI, LLCDelawareHCP MA4 GP Omaha NE, LLCDelawareHCP MA4 GP Rockville MD, LLCDelawareHCP MA4 GP St. Charles IL, LLCDelawareHCP MA4 GP West Orange NJ, LLCDelawareHCP MA4 GP Wheaton IL, LLCDelawareHCP MA4 GP, LLCDelawareHCP MA4 Greensboro NC, LPDelawareHCP MA4 Kansas City KS, LPDelawareHCP MA4 Northville MI, LPDelawareHCP MA4 Omaha NE, LPDelawareHCP MA4 Rockville MD, LPDelawareHCP MA4 St. Charles IL, LPDelawareHCP MA4 Tampa FL, LPDelawareHCP MA4 Wheaton IL, LPDelawareHCP MA4, LPDelawareEntity NameJurisdiction of Organization or FormationHCP Madison NJ OpCo, LLCDelawareHCP Manahawkin NJ OpCo, LLCDelawareHCP MCD TRS, LLCDelawareHCP Medical Office Buildings I, LLCDelawareHCP Medical Office Buildings II, LLCDelawareHCP Medical Office Buildings, LLCDelawareHCP Medical Office Portfolio, LLCDelawareHCP Mercer Island WA OpCo, LLCDelawareHCP Milton Medical Equity Investors, LLCDelawareHCP MOB Centerpoint LLCDelawareHCP MOB Evanston LLCDelawareHCP MOB Jordan Valley II LLCDelawareHCP MOB Jordan Valley LLCDelawareHCP MOB K.C. Imaging LLCDelawareHCP MOB Life Center LLCDelawareHCP MOB Lone Peak LLCDelawareHCP MOB Member, LLCDelawareHCP MOB Mesquite LLCDelawareHCP MOB Miami, LLCDelawareHCP MOB Property Manager, LLCDelawareHCP MOB Scottsdale LLCDelawareHCP MOB Texas, LLCDelawareHCP Monterrey Holdings, LLCDelawareHCP Monterrey, LLCDelawareHCP Mooresville NC OpCo, LLCDelawareHCP MOP 1110 Irving TX, LPDelawareHCP MOP 1411 Aurora CO GP, LLCDelawareHCP MOP 1411 Aurora CO, LPDelawareHCP MOP 1421 Aurora CO GP, LPDelawareHCP MOP 1421 Aurora CO, LPDelawareHCP MOP 7200 Irving TX, LPDelawareHCP MOP A Pack GP, LLCDelawareHCP MOP California, LPDelawareHCP MOP Columbia MD GP, LLCDelawareHCP MOP Columbia MD, LPDelawareHCP MOP Denver CO GP, LLCDelawareHCP MOP Denver CO, LPDelawareHCP MOP Fairfax VA, LPDelawareHCP MOP GP, GP, LLCDelawareHCP MOP Houston TX, LLCDelawareHCP MOP Member, LLCDelawareHCP MOP, LPDelawareHCP Mount Vernon IL OpCo, LLCDelawareHCP Mount Vernon IL, LLCDelawareHCP NE Retail, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP NE Tower, LLCDelawareHCP Oak Park, LLCDelawareHCP Ocoee, LLCDelawareHCP Ogden MOB, LLCDelawareHCP Omaha NE OpCo, LLCDelawareHCP Orange NJ OpCo, LLCDelawareHCP Otay Ranch TRS, LLCDelawareHCP Oviedo, LLCDelawareHCP Owasso MOB, LLCDelawareHCP Oyster Point III LLCDelawareHCP Palm Springs OpCo, LLCDelawareHCP Partners, LPDelawareHCP PC1 Brentwood TN, LLCDelawareHCP PC1 Buckhead GA, LLCDelawareHCP PC1 Friendship Heights MD, LLCDelawareHCP PC1 Naples FL, LLCDelawareHCP PC1 New Jersey, LLCDelawareHCP PC1 North Carolina, LLCDelawareHCP PC1 Stamford CT, LLCDelawareHCP PC1 Venice FL, LLCDelawareHCP PC2, LLCDelawareHCP Pearlton TX MOB, LLCDelawareHCP Periferico 4338 Holdings, LLCDelawareHCP Periferico 4338, LLCDelawareHCP Pinellas Park, LLCDelawareHCP Pleasant, LLCDelawareHCP Plymouth MA OpCo, LLCDelawareHCP Plymouth Township MI OpCo, LLCDelawareHCP Point Eden IncorporatedDelawareHCP Port Orange FL OpCo, LLCDelawareHCP Port Orange, LLCDelawareHCP Prairie Village KS OpCo, LLCDelawareHCP Raleigh NC OpCo, LLCDelawareHCP Remington Oaks MOB, L.P.DelawareHCP Richmond Heights MO OpCo, LLCDelawareHCP RP1-VB, LLCDelawareHCP RSF Portfolio GP, LLCTexasHCP RSF Portfolio, LLCDelawareHCP Saddle River NJ OpCo, LLCDelawareHCP San Antonio TX MOB, LLCDelawareHCP Santa Rosa CA OpCo, LLCDelawareHCP Senior Housing Properties, LLCDelawareHCP S-H 2014 Member, LLCDelawareHCP S-H 2015 OpCo TRS, LLCDelawareHCP S-H ASL OpCo, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP S-H CA OpCo, LLCDelawareHCP SH California, LLCDelawareHCP S-H DSL OpCo HoldCo, LLCDelawareHCP SH Eldorado Heights, LLCDelawareHCP SH ELP1 Properties, LLCDelawareHCP SH ELP2 Properties, LLCDelawareHCP SH ELP3 Properties, LLCDelawareHCP S-H ESL OpCo, LLCDelawareHCP S-H FM OpCo, LLCDelawareHCP S-H Hermiston Terrace, LLCDelawareHCP SH Lassen House, LLCDelawareHCP S-H LCS OpCo, LLCDelawareHCP SH Mountain Laurel, LLCDelawareHCP SH Mountain View, LLCDelawareHCP S-H MRE/HCP OpCo Member, LLCDelawareHCP S-H MRE/HCP PropCo Member, LLCDelawareHCP S-H OpCo TRS, LLCDelawareHCP SH River Road, LLCDelawareHCP SH River Valley Landing, LLCDelawareHCP SH Sellwood Landing, LLCDelawareHCP S-H SHC OpCo, LLCDelawareHCP S-H Sunrise OpCo HoldCo, LLCDelawareHCP SH Windfield Village, LLCDelawareHCP Shore, LLCDelawareHCP Shorehaven MI OpCo, LLCDelawareHCP SLB Florida, LLCDelawareHCP South Buford GA OpCo, LLCDelawareHCP Southwest MOB, LLCDelawareHCP Springs MOB Louisville, LLCDelawareHCP Springtree, LLCDelawareHCP SSF, LLCDelawareHCP St Charles IL OpCo, LLCDelawareHCP St. Augustine, LLCDelawareHCP ST1 Colorado GP, LLCDelawareHCP ST1 Colorado, LPDelawareHCP Sterling VA OpCo, LLCDelawareHCP Stone Oak MOB, L.P.DelawareHCP Sun1 Beverly Hills CA, LLCDelawareHCP Sun1 Edmonds WA, LLCDelawareHCP Sun1 GP, LLCDelawareHCP Sun1 Lilburn GA, LLCDelawareHCP Sun1, LPDelawareHCP Sun2 Des Peres MO, LLCDelawareHCP Sun2 Richmond Heights MO, LLCDelawareHCP Sun2 Wilmette IL, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP Sunrise FL OpCo, LLCDelawareHCP Tampa FL MOB, LLCDelawareHCP Tampa FL OpCo, LLCDelawareHCP Tesson, LLCDelawareHCP Torrey Pines LLCDelawareHCP Torreyana, LLCDelawareHCP Torrington CT OpCo, LLCDelawareHCP TPSP, LLCDelawareHCP TRS LF Lender, LLCDelawareHCP UK Investments Holdings, LLCDelawareHCP UK Lender, LPDelawareHCP University Center East LLCDelawareHCP University Center West LLCDelawareHCP Ventures II Member, LLCDelawareHCP Ventures II Partner, LLCDelawareHCP Ventures II TRS, LLCDelawareHCP Ventures III, LLCDelawareHCP Ventures IV Member, LLCDelawareHCP Ventures IV, LLCDelawareHCP Ventures V Member, LLCDelawareHCP Ventures V TRS, LLCDelawareHCP Ventures V, LLCDelawareHCP Ventures VII, LLCDelawareHCP Ventures VIII, LLCDelawareHCP Veranda, LLCDelawareHCP Vintage Park II TRS, LLCDelawareHCP Voorhees Township NJ OpCo, LLCDelawareHCP VPI Sorrento II, LLCDelawareHCP Waldwick TRS, LLCDelawareHCP Wekiwa Springs, LLCDelawareHCP Westgate1 Auburn Hills MI, LLCDelawareHCP Westgate1 Sterling Heights MI, LLCDelawareHCP Westlake OH OpCo, LLCDelawareHCP Westminster MD OpCo, LLCDelawareHCP Wheaton IL OpCo, LLCDelawareHCP Wilmette IL OpCo, LLCDelawareHCP Wilson Blvd VA OpCo, LLCDelawareHCP Woodbridge, LLCDelawareHCP Woodlands TX MOB, LLCDelawareHCP Woodside TX OpCo, LLCDelawareHCP Youngstown OH OpCo, LLCDelawareHCP Yreka OpCo, LLCDelawareHCP/LFREP Carmichael Owner, LLCDelawareEntity NameJurisdiction of Organization or FormationHCP/LFREP Durham Lab, LLCDelawareHCP/LFREP Durham, LLCDelawareHCP/LFREP Ventures I, LLCDelawareHCP/LFREP Ventures II, LLCDelawareHCP/LS 2011 REIT LLCDelawareHCP/Colorado Springs Limited PartnershipDelawareHCP/Kansas Limited PartnershipDelawareHCP/Little Rock Limited PartnershipDelawareHCP/San Antonio Limited PartnershipDelawareHCP/Sorrento, LLCDelawareHCP/Stansbury, LLCDelawareHCP/Tennessee, LLCDelawareHCP/Utah II, LLCDelawareHCP/Utah, LLCDelawareHCP/Wesley,

LLCDelawareHCP-Pointe Grand, IncorporatedDelawareHCP-Torrey Pines I, Inc.DelawareHCP-Torrey Pines Science Center, Inc.DelawareHealthCo Properties, LLCDelawareHealth Care Investors III(California)Healthpeak - GP(National LLCDelawareHealthpeak (HI), LLCDelawareHealthpeak Crosswood II, LLCDelawareHealthpeak Crosswood, LLCDelawareHealthpeak CRS1 Delphis Lead Lender Partner 1, LLCDelawareHealthpeak CRS1 Delphis Lead Lender Partner 2, LLCDelawareHealthpeak Fund I, LLCDelawareHealthpeak Life Science Properties, Inc.DelawareHealthpeak LLCDelawareHealthpeak Louisville, LLCDelawareHealthpeak Medical Office Properties, LLCDelawareHealthpeak MOB (DE), LLCDelawareHealthpeak Mortgage LLCDelawareHealthpeak OP, LLCMarylandHealthpeak Partners GP, LLCDelawareHealthpeak Properties TRS, LLCDelawareHealthpeak Properties, Inc.MarylandHealthpeak Properties, LLCDelawareHealthpeak Senior Housing Properties LLCDelawareHealthpeak S-H 2015 Member, LLCDelawareHealthpeak SU TRS LLCDelawareHealthpeak TRS, LLCDelawareJackson HCP, LLCDelawareEntity NameJurisdiction of Organization or FormationJackson II MOB Owners LLCDelawareLake Seminole Square, LLC DelawareLakeview Regional MOB, LLCDelawareLansdowne MOB, LLCDelawareLASDK Limited PartnershipDelawareLaurel Terrace MOB, LLCDelawareLee's Summit MOB, LLCDelawareLexington Equity Investors, Ltd.FloridaLexington MOB Partners, Ltd.FloridaLockport Crossings MOB, LLCDelawareLS 100 CDP Member, LLCDelawareLS 200 CDP, LLCDelawareLS 400/500 CDP, LLCDelawareLS 725 Concord, LLCDelawareLS 75 Hayden TRS, LLCDelawareLS 75 Hayden, LLCDelawareLS Alewife I, LLCDelawareLS Alewife II, LLCDelawareLS Alewife III, LLCDelawareLS Alewife IV, LLCDelawareLS Alewife V, LLCDelawareLS Alewife VI, LLCDelawareLS Alewife VII, LLCDelawareLS Alewife VIII, LLCDelawareLS Alewife X, LLCDelawareLS Alewife X, LLCDelawareLS Lusk Land, LLCDelawareLS MA Holdco, LLCDelawareLS MA Services TRS, LLCDelawareLS Needham Holdco TRS, LLCDelawareLS Needham Member, LLCDelawareLS The Post, LLCDelawareLS Vista Sorrento I, LLCDelawareLS Vista Sorrento II, LLCDelawareMarion Medical Equity Investors LLCDelawareMarion Medical Investors, L.P.IllinoisMarion MOB Partners, L.P.IllinoisMCD Clodus Fields, LLCDelawareMcDowell Mountain Medical Investors, Ltd.FloridaMcKinney HCP GP, LLCDelawareMcKinney HCP, L.P.DelawareMcKinney MOB III, LLCDelawareMcKinney MOB, LLCDelawareEntity NameJurisdiction of Organization or FormationMeadowdome, LLCMarylandMedcap HCPI Development, LLCDelawareMedCap Holding II, LLCDelawareMedCap Holding III, LLCDelawareMedCap Holding IV, LLCDelawareMedCap Properties I, LLCDelawareMedcap Properties II, LLCDelawareMedcap Properties, LLCDelawareMedcore Realty Eden Hill, LLCDelawareMedical Office Buildings of Alaska, LLCDelawareMedical Office Buildings of California Goodsam, LLCDelawareMedical Office Buildings of California, LLCDelawareMedical Office Buildings of Colorado II, LLCDelawareMedical Office Buildings of Colorado III, LLCDelawareMedical Office Buildings of Colorado, LLCDelawareMedical Office Buildings of Florida, LLCDelawareMedical Office Buildings of Nevada, LLCDelawareMedical Office Buildings of Nevada-Southern Hills, LLCDelawareMedical Office Buildings of Osceola, LLCDelawareMedical Office Buildings of Plano, L.P.DelawareMedical Office Buildings of Plantation, LLCDelawareMedical Office Buildings of Reston, LLCDelawareMedical Office Buildings of Tennessee, LLCDelawareMedical Office Buildings of Texas City, L.P.DelawareMedical Office Buildings of Texas, L.P.DelawareMedical Office Buildings of Utah, LLCDelawareMeridan Fund, LLCDelawareMeridian Care Group MOB, LLCDelawareMichigan Road MOB, LLCDelawareMission Springs AL, LLCDelawareMMB Medical Partners LLCDelawareMOB 1 of California, LLCDelawareMOB 10 of Florida, LLCDelawareMOB 101 of Texas, L.P.DelawareMOB 103 of Texas, L.P.DelawareMOB 105 of Texas, L.P.DelawareMOB 11 of Florida, LLCDelawareMOB 111 of Texas, L.P.DelawareMOB 122 of Texas, L.P.DelawareMOB 124 of Texas, L.P.DelawareMOB 13 of Florida, LLCDelawareMOB 132 of Alaska, LLCDelawareMOB 135 of Florida, LLCDelawareEntity NameJurisdiction of Organization or FormationMOB 139 of Texas, L.P.DelawareMOB 14 of Florida, LLCDelawareMOB 147 of Tennessee, LLCDelawareMOB 17 of Florida, LLCDelawareMOB 2 of Florida, LLCDelawareMOB 3 of Florida, LLCDelawareMOB 46 of Nevada, LLCDelawareMOB 47 of Nevada, LLCDelawareMOB 48/49 of Nevada, LLCDelawareMOB 50 of Nevada, LLCDelawareMOB 59 of Tennessee, LLCDelawareMOB 65 of Tennessee, LLCDelawareMOB 66 of Tennessee, LLCDelawareMOB 68 of Tennessee, LLCDelawareMOB 69 of Tennessee, LLCDelawareMOB 70 of Tennessee, LLCDelawareMOB 71 of Tennessee, LLCDelawareMOB 72 of Tennessee, LLCDelawareMOB 74 of Tennessee, LLCDelawareMOB 75 of Tennessee, LLCDelawareMOB 77 of Texas, L.P.DelawareMOB 82/85/86 of Texas, L.P.DelawareMOB 83 of Texas, L.P.DelawareMOB 87 of Texas, L.P.DelawareMOB 88 of Texas, L.P.DelawareMOB 90 of Texas, L.P.DelawareMOB 93 of Texas, L.P.DelawareMOB 97 of Texas, L.P.DelawareMOB Colonial Building, LLCDelawareMOB GP Las Colinas II, LLCDelawareMOB Las Colinas II, L.P.DelawareMOB of Denver 1, LLCDelawareMOB of Denver 2, LLCDelawareMOB of Denver 3, LLCDelawareMOB of Denver 4, LLCDelawareMOB of Denver 5, LLCDelawareMOB of Denver 6, LLCDelawareMOB of Denver 7, LLCDelawareMOB Sky Ridge 1 of Colorado, LLCDelawareMOB Special Member, Inc.DelawareMOB Texas City 1 of Texas, L.P.DelawareMOB/Bay-1 of Florida, LLCDelawareMOB/GP 101 of Texas, LLCDelawareEntity NameJurisdiction of Organization or FormationMOB/GP 103 of Texas, LLCDelawareMOB/GP 105 of Texas, LLCDelawareMOB/GP 111 of Texas, LLCDelawareMOB/GP 122 of Texas, LLCDelawareMOB/GP 124 of Texas, LLCDelawareMOB/GP 139 of Texas, LLCDelawareMOB/GP 77 of Texas, LLCDelawareMOB/GP 82/85/86 of Texas, LLCDelawareMOB/GP 83 of Texas, LLCDelawareMOB/GP 87 of Texas, LLCDelawareMOB/GP 88 of Texas, LLCDelawareMOB/GP 90 of Texas, LLCDelawareMOB/GP 93 of Texas, LLCDelawareMOB/GP 97 of Texas, LLCDelawareMOB/GP of Plano, LLCDelawareMOB/GP of Texas City, LLCDelawareMOB/GP of Texas, LLCDelawareMOB/GP Texas City 1 of Texas, LLCDelawareMOB/GP-West Houston, LLCDelawareMOB/LP of Plano, LLCDelawareMOB/LP of Texas City, LLCDelawareMOB/LP of Texas, LLCDelawareMOB/LP Texas Holding, LLCDelawareMOB-West Houston, L.P.DelawareMooresville MOB, LLCDelawareMorristown MOB I, LLCDelawareMorristown MOB II, LLCDelawareMorristown MOB III, LLCDelawareMorristown MOB IV, LLCDelawareMP IV DOC Brooklyn MOB, LLCDelawareMTKA II MP LLCDelawareNeedham Developers, LLCDelawareNNGS Development, LLCFloridaNWSC MOB, LLCDelawareOak Hill MOB, LLCDelawareOcean Acquisition 1, LLCMarylandOcean Acquisition 2, LLCFloridaOcean Acquisition 3, LLCDelawareOcean TRS, LLCDelawareOld Henry Healthcare I, LLCKentuckyOmaha MOB Investors LLCFloridaOmaha MOB Manager LLCDelawareOmaha MOB Owners LLCDelawareEntity NameJurisdiction of Organization or FormationOp Lab Property Manager, LLCDelawareOrange Park MOB, LLCDelawareOverland Park MOB, LLCDelawarePace MOB, LLCAlabamaPacific Acquisitions 2019, LLCDelawareParker MOB Owners LLCDelawarePG 1169 Harbor, LLCDelawarePG II 230 East Grand, LLCDelawarePG III 250 East Grand, LLCDelawarePG Interim JV, LLCDelawarePG IV 256 East Grand, LLCDelawarePG JV I, LLCDelawarePG JV II, LLCDelawarePG JV V, LLCDelawarePG JV VI, LLCDelawarePG JV VIII, LLCDelawarePG REIT I, LLCDelawarePG REIT II, LLCDelawarePG REIT V, LLCDelawarePG REIT VI, LLCDelawarePG REIT VIII, LLCDelawarePG TRS, LLC DelawarePG V 260 East Grand, LLCDelawarePG VI 270 East Grand, LLCDelawarePG VII 280 East Grand, LLCDelawarePG VIII 170 Harbor Way, LLCDelawarePG VIII 210-220 East Grand, LLCDelawarePG VIII 240 East Grand, LLCDelawarePikesville Assisted Living, LLCMarylandPinnacle at RidgeGate MOB, LLCDelawareProfessional Center II MOB, LLCDelawareRaulerson MOB, LLCDelawareRemington Development Partners, LLCIllinoisResearch MOB, LLCDelawareRiver Oaks MOB Owners LLCDelawareRobin Run Garden Homes, LLCDelawareSandwich Development Partners, LLCIllinoisSanta Rosa 1 PropCo LLCDelawareSavage Medical Building, LLCMinnesotaSavannah MOB II, LLCDelawareSavannah MOB, LLCDelawareScripture MOB, LLCDelawareS-H 2014 OpCo TRS, Inc.DelawareEntity NameJurisdiction of Organization or FormationSH 2019 OpCo HoldCo I, LLCDelawareSH 2019 OpCo HoldCo II, LLCDelawareSH 2019 OpCo HoldCo III, LLC DelawareSH 2019 OpCo TRS I, LLC DelawareSH 2019 OpCo TRS II, LLC DelawareSH 2019 REIT I, LLCDelawareSH 2019 REIT II, LLCDelawareSH 2019 REIT III, LLCDelawareSH 2019 Ventures, LLCDelawareSH CSU OpCo HoldCo, LLCDelawareSH DR California IV HoldCo, LLCDelawareSH DR California IV, LLCDelawareSH DR V HoldCo, LLCDelawareSH DR V, LLCDelawareS-H DSL Investor, LLCDelawareSH DSL OpCo HoldCo, LLCDelawareS-H HCP/DSL Member, LLCDelawareS-H HCP/DSL Ventures, LLCDelawareS-H HCP/LCB OpCo Member, LLCDelawareS-H HCP/LCB OpCo Ventures, LLCDelawareS-H HCP/LCB PropCo Member, LLCDelawareS-H HCP/LCB PropCo Ventures, LLCDelawareS-H HCP/LCB Properties, LLCDelawareS-H Mid-Atlantic Master Tenant, LLCDelawareS-H Mid-Atlantic OpCo - Ellicott City, LLCDelawareS-H Mid-Atlantic OpCo - Friendship, LLCDelawareS-H Mid-Atlantic OpCo - Laurel, LLCDelawareS-H Mid-Atlantic OpCo - Leesburg, LLCDelawareS-H Mid-Atlantic OpCo - Satyr Hill, LLCDelawareS-H Mid-Atlantic OpCo - Spotsylvania, LLCDelawareS-H Mid-Atlantic PropCo - St. Charles, LLCDelawareS-H Mid-Atlantic PropCo - Leesburg, LLCDelawareS-H Mid-Atlantic PropCo - Ellicott City, LLCDelawareS-H Mid-Atlantic PropCo - Friendship, LLCDelawareS-H Mid-Atlantic PropCo - Laurel, LLCDelawareS-H Mid-Atlantic PropCo - Leesburg, LLCDelawareS-H Mid-Atlantic PropCo - Satyr Hill, LLCDelawareS-H Mid-Atlantic PropCo - Spotsylvania, LLCDelawareS-H Mid-Atlantic PropCo - St. Charles, LLCDelawareS-H Mid-Atlantic PropCo, LLCDelawareS-H MRE/HCP PropCo Ventures II LLCDelawareSH Northridge CA OpCo, LLCDelawareEntity NameJurisdiction of Organization or FormationSH OpCo Abilene, LLCDelawareSH OpCo Burleson, LLCDelawareS-H OpCo Carrington Pointe, LLCDelawareS-H OpCo Cherry Hills, LLCDelawareSH OpCo Chesapeake Place, LLCDelawareSH OpCo Chino Hills, LLCDelawareS-H OpCo Clear Lake, LLCDelawareSH OpCo Concord, LLCDelawareS-H OpCo Copperfield Village, LLCDelawareSH OpCo Crescent Point, LLCDelawareSH OpCo Crosswood Oaks, LLCDelawareS-H OpCo East Bay Manor, LLCDelawareSH OpCo Escondido Hills, LLCDelawareSH OpCo Fair Oaks, LLCDelawareS-H OpCo First Colony, LLCDelawareS-H OpCo Galleria, LLCDelawareS-H OpCo Germantown, LLCDelawareSH OpCo Good Place, LLCDelawareS-H OpCo Greenwich Bay Manor, LLCDelawareS-H OpCo Heritage Palmeras, LLCDelawareS-H OpCo Herons Run, LLCDelawareSH OpCo Huntington Beach, LLCDelawareS-H OpCo Manor at Newport Place, LLCDelawareSH OpCo Mariner Point, LLCDelawareSH OpCo Meadow Lakes, LLCDelawareSH OpCo Montecito, LLCDelawareSH OpCo Olney, LLCDelawareS-H OpCo Olympia Fields, LLCDelawareS-H OpCo Park at Golf Mill, LLCDelawareS-H OpCo Park at Vernon Hills, LLCDelawareS-H OpCo Pecan Park, LLCDelawareS-H OpCo Pinescrest Place, LLCDelawareS-H OpCo Pointe at Newport Place, LLCDelawareS-H OpCo Prosperity Oaks, LLCDelawareSH OpCo Roseville, LLCDelawareSH OpCo San Jose, LLCDelawareSH OpCo Santa Clarita, LLCDelawareS-H OpCo Spring Shadows Place, LLCDelawareS-H OpCo Terrace Memorial City, LLCDelawareS-H OpCo Terrace West, LLCDelawareSH OpCo Tesson Heights, LLCDelawareSH OpCo The Fairfax, LLCDelawareSH OpCo The Quadrangle, LLCDelawareEntity NameJurisdiction of Organization or FormationS-H OpCo Twenty-one TRS, LLCDelawareSH OpCo Valencia, LLCDelawareSH OpCo Veranda Club, LLCDelawareS-H OpCo Victoria, LLCDelawareS-H OpCo Vintage Park AL, LLCDelawareSH OpCo Vintage Park II, LLCDelawareS-H OpCo Waterside Retirement Estates, LLCDelawareSH OpCo Waxahachie, LLCDelawareS-H OpCo West Bay Manor, LLCDelawareSH OpCo Whittier, LLCDelawareS-H OpCo Willowbrook, LLCDelawareS-H OSL OpCo HoldCo, LLCDelawareS-H Otay Ranch OpCo Ventures, LLCDelawareS-H Otay Ranch OpCo, LLCDelawareS-H Otay Ranch PropCo Ventures, LLCDelawareSH PropCo Clear Lake, LLCDelawareSH PropCo First Colony, LLCDelawareSH PropCo Galleria, LLCDelawareSH PropCo Germantown, LLCDelawareSH PropCo Olney II, LLCDelawareSH PropCo Olney, LLCDelawareSH PropCo Park at Vernon Hills, LLCDelawareSH PropCo Pecan Park, LLCDelawareSH PropCo Terrace Memorial City, LLCDelawareSH PropCo Terrace West, LLCDelawareSH PropCo Vintage Park AL, LLCDelawareS-H Santa Rosa OpCo LLCDelawareS-H Thirty-Five MOB Properties, LLCDelawareS-H Thirty-Five OpCo - Altamonte Springs, LLCDelawareS-H Thirty-Five OpCo - Amber Park, LLCDelawareS-H Thirty-Five OpCo - Arvada Meridian, LLCDelawareS-H Thirty-Five OpCo - Bella Vita, LLCDelawareS-H Thirty-Five OpCo - Boulder Meridian, LLCDelawareS-H Thirty-Five OpCo - Clearwater, LLCDelawareS-H Thirty-Five OpCo - Englewood Meridian, LLCDelawareS-H Thirty-Five OpCo - Gayton Terrace, LLCDelawareS-H Thirty-Five OpCo - Graham, LLCDelawareS-H Thirty-Five OpCo - Grand Prairie, LLCDelawareS-H Thirty-Five OpCo - Lake Orienta, LLCDelawareS-H Thirty-Five OpCo - Lake Worth, LLCDelawareS-H Thirty-Five OpCo - Lakewood Meridian, LLCDelawareS-H Thirty-Five OpCo - Lowry, LLCDelawareS-H Thirty-Five OpCo - Lutz, LLCDelawareEntity NameJurisdiction of Organization or FormationS-H Thirty-Five OpCo - North Richland Hills, LLCDelawareS-H Thirty-Five OpCo - Operator, LLCDelawareS-H Thirty-Five OpCo - Orange City, LLCDelawareS-H Thirty-Five OpCo - Parkview, LLCDelawareS-H Thirty-Five OpCo - Pocasset, LLCDelawareS-H Thirty-Five OpCo - Port St. Lucie, LLCDelawareS-H Thirty-Five OpCo - Round Rock, LLCDelawareS-H Thirty-Five OpCo - San Antonio, LLCDelawareS-H Thirty-Five OpCo - San Marcos, LLCDelawareS-H Thirty-Five OpCo - Sarasota LLCDelawareS-H Thirty-Five OpCo - Tamarac Acquisition, LLCDelawareS-H Thirty-Five OpCo - Tamarac, LLCDelawareS-H Thirty-Five OpCo - Temple Meridian, LLCDelawareS-H Thirty-Five OpCo - Treemont, LLCDelawareS-H Thirty-Five OpCo - Vero Beach, LLCDelawareS-H Thirty-Five OpCo - Waterford, LLCDelawareS-H Thirty-Five OpCo - Westland Meridian, LLCDelawareS-H Thirty-Five OpCo - Wichita Falls, LLCDelawareS-H Thirty-Five OpCo - Willowwood, LLCDelawareS-H Thirty-Five OpCo Ventures, LLCDelawareS-H Thirty-Five PropCo - Altamonte Springs, LLCDelawareS-H Thirty-Five PropCo - Amber Park, LLCDelawareS-H Thirty-Five PropCo - Arvada Meridian, LLCDelawareS-H Thirty-Five PropCo - Bella Vita, LLCDelawareS-H Thirty-Five PropCo - Boulder Meridian, LLCDelawareS-H Thirty-Five PropCo - Englewood Meridian, LLCDelawareS-H Thirty-Five PropCo - Gayton Terrace, LLCDelawareS-H Thirty-Five PropCo - Graham, LLCWashingtonS-H Thirty-Five PropCo - Grand Prairie, LLCWashingtonS-H Thirty-Five PropCo - Ground Tenant, LLCDelawareS-H Thirty-Five PropCo - Lake Worth, LLCDelawareS-H Thirty-Five PropCo - Lakewood Meridian, LLCDelawareS-H Thirty-Five PropCo - Lowry, LLCDelawareS-H Thirty-Five PropCo - Lutz, LLCDelawareS-H Thirty-Five PropCo - North Richland Hills 1, LLCWashingtonS-H Thirty-Five PropCo - North Richland Hills 2, LLCWashingtonS-H Thirty-Five PropCo - Orange City, LLCFloridaS-H Thirty-Five PropCo - Parkview, LLCDelawareS-H Thirty-Five PropCo - Pocasset, LLCDelawareS-H Thirty-Five PropCo - Port St. Lucie, LLCDelawareS-H Thirty-Five PropCo - Round Rock, LLCWashingtonS-H Thirty-Five PropCo - San Antonio, LLCWashingtonS-H Thirty-Five PropCo - San Marcos, LLCWashingtonEntity NameJurisdiction of Organization or FormationS-H Thirty-Five PropCo - Sarasota, LLCFloridaS-H Thirty-Five PropCo - Tamarac Acquisition, LLCDelawareS-H Thirty-Five PropCo - Tamarac, LLCDelawareS-H Thirty-Five PropCo - Temple Meridian, LLCDelawareS-H Thirty-Five PropCo - Treemont, LLCDelawareS-H Thirty-Five PropCo - Trowbridge, LLCDelawareS-H Thirty-Five PropCo - Vero Beach, LLCWashingtonS-H Thirty-Five PropCo - Waterford, LLCDelawareS-H Thirty-Five PropCo - Westland Meridian, LLCDelawareS-H Thirty-Five PropCo - Wichita Falls, LLCWashingtonS-H Thirty-Five PropCo - Willowwood, LLCDelawareS-H Thirty-Five PropCo - Woodside Village, LLCDelawareS-H Thirty-Five PropCo - Wyndham Lakes, LLCDelawareS-H Thirty-Five PropCo Ventures, LLCDelawareS-H Thirty-Five Properties, LLCDelawareS-H Twenty-One OpCo Ventures, LLCDelawareS-H Twenty-One PropCo Ventures, LLCDelawareS-H Twenty-One Properties, LLCDelawareS-H Watertown Square OpCo, LLCDelawareSHAC, LLCAlabamaShavano Park HCP, LLCDelawareSHG Dunwoody, LLCNorth CarolinaSouthern Point LLCDelawareSt. Francis MOB, LLCDelawareSTV Carmel MOB, LLCDelawareSTV Fishers MOB, LLCDelawareSuburban Connector, LLCKentuckySuburban Properties LLCKentuckyTampa HCP, LLCDelawareTBICI-LS 100 CDP, LLCDelawareTCO Burnsville MOB, LLCDelawareTexarkana Medical Equity Investors LLCDelawareTexas HCP AL, L.P.DelawareTexas HCP Holding, L.P.DelawareTexas HCP Medical Office Buildings, L.P.DelawareTexas Healthpeak G.P., LLCDelawareTexas Healthpeak Medical G.P., LLCDelawareTexas Healthpeak, LLCDelawareTL MOB, LLCDelawareTorrey Pines Science Center Limited PartnershipDelawareTownship Women's Center MOB, LLCDelawareTPSC IV, LLCDelawareTPSC IX, LLCDelawareEntity NameJurisdiction of Organization or FormationTPSC VI LLCDelawareVH Medical Partners LLCDelawareVictoria HCP, LLCDelawareVintage Park II Member, LLCDelawareWatkins MOB I, LLCDelawareWatkins MOB II, LLCDelawareWebster MOB I, LLCDelawareWebster MOB II, LLCDelawareWebster MOB III, LLCDelawareWest Hills MOB, LLCDelawareWestminster HCP, LLCDelawareWestridge Insurance Company, Inc.HawaiiWestside MOB, LLCDelawareWHOT MOB, LLCDelawareWichita MOB, LLCDelawareZangmeister Center LLCDelawareZiegler-Arizona 23, LLCWisconsinZiegler-El Paso 8 Limited PartnershipWisconsinZiegler-Illinois 12, LLCWisconsinZiegler-Illinois 18, LLCWisconsinZiegler-Maine 15, LLCWisconsinZiegler-Tennessee 14, LLCWisconsinZiegler-Texas 8, LLCWisconsinZiegler-Wisconsin 16, LLCWisconsinZiegler-Wisconsin 24, LLCWisconsin EX-22.1 6 ex22112312024.htm EX-22.1 DocumentEXHIBIT 22.1List of Issuers of Guaranteed SecuritiesAs of February 4, 2025SecuritiesIssuerGuarantors4.000% Senior Notes due 2025,3.250% Senior Notes due 2026,1.350% Senior Notes due 2027,2.125% Senior Notes due 2028,3.500% Senior Notes due 2029,3.000% Senior Notes due 2030,2.875% Senior Notes due 2031,5.250% Senior Notes due 2032, and6.750% Senior Notes due 2041Healthpeak OP, LLCHealthpeak Properties, Inc.,DOC DR Holdco, LLC, andDOC DR, LLC4.300% Senior Notes due 2027,3.950% Senior Notes due 2028, and2.625% Senior Notes due 2031DOC DR, LLCHealthpeak Properties, Inc.,Healthpeak OP, LLC, andDOC DR Holdco, LLC EX-23.1 7 ex23112312024.htm EX-23.1 DocumentEXHIBIT 23.1Consent of Independent Registered Public Accounting FirmWe consent to the incorporation by reference in the following Registration Statements of our reports dated February 4, 2025, relating to the financial statements of Healthpeak Properties, Inc. and the effectiveness of Healthpeak Properties, Inc.â€™s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2024.We consent to the incorporation by reference in the following Registration Statements:â€œForm S-3ASR, File No. 333-276954 and No. 333-276954-01, related to the unlimited shelf registration of common stock, preferred stock, depository shares, warrants, debt securities and guarantees of Healthpeak Properties, Inc. and debt securities and guarantees of Healthpeak OP, LLC;â€œForm S-8, File No. 333-271514, related to the Healthpeak Properties, Inc. 2023 Performance Incentive Plan; andâ€œForm S-8 POS, File No. 333-195735, related to securities to be offered to employees under the Healthpeak Properties, Inc. 2014 Performance Incentive Plan, as amended and restated./s/ DLOITTE & LUTCH LLPCosta Mesa, CaliforniaFebruary4, 2025 EX-31.1 8 ex31112312024.htm EX-31.1 DocumentEXHIBIT A 31.1A CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERÂ I, Scott M. Brinker, certify that:Â 1. I have reviewed this annual report on FormÂ 10-K of Healthpeak Properties,Â Inc.Â for the period endedÂ DecemberÂ 31, 2024;Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4. The registrantâ€™s other certifying officer

and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 4 A Date: February 4, 2025/s/ SCOTT M. BRINKER A Scott M. Brinker A President and Chief Executive Officer A (Principal Executive Officer) EX-31.2 9 ex31212312024.htm EX-31.2 Document EXHIBIT A 31.2A CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER A I, Peter A. Scott, certify that: A 1. I have reviewed this annual report on Form 10-K of Healthpeak Properties, A Inc. A for the period ended December A 31, 2024; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A (a) A Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A (b) A Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A (c) A Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A (d) A Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and A 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): A (a) A All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and A (b) A Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A 4 A Date: February 4, 2025/s/ PETER A. SCOTTA Peter A. Scott A Chief Financial Officer A (Principal Financial Officer) EX-32.1 10 ex32112312024.htm EX-32.1 Document EXHIBIT A 32.1A CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER A Pursuant to 18 U.S.C. A 1350, as created by Section A 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, A Inc., a Maryland corporation (the "Company"), hereby certifies, to his knowledge, that: A (i) A the accompanying annual report on Form 10-K of the Company for the period ended December A 31, 2024 (the "Report") fully complies with the requirements of Section A 13(a) A or Section A 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and A (ii) A the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A A Date: February 4, 2025/s/ SCOTT M. BRINKER A Scott M. Brinker A President and Chief Executive Officer A (Principal Executive Officer) A signed original of this written statement required by Section A 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference. EX-32.2 11 ex32212312024.htm EX-32.2 Document EXHIBIT A 32.2A CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER A Pursuant to 18 U.S.C. A 1350, as created by Section A 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, A Inc., a Maryland corporation (the "Company"), hereby certifies, to his knowledge, that: A (i) A the accompanying annual report on Form 10-K of the Company for the period ended December A 31, 2024 (the "Report") fully complies with the requirements of Section A 13(a) A or Section A 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and A (ii) A the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A A Date: February 4, 2025/s/ PETER A. SCOTTA Peter A. Scott A Chief Financial Officer A (Principal Financial Officer) A signed original of this written statement required by Section A 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference. EX-101.SCH 12 peak-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link: presentationLink link: calculationLink link: definitionLink 9952151 - Statement - CONSOLIDATED BALANCE SHEETS link: presentationLink link: calculationLink link: definitionLink 9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link: presentationLink link: calculationLink link: definitionLink 9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link: presentationLink link: calculationLink link: definitionLink 9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS link: presentationLink link: calculationLink link: definitionLink 9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link: presentationLink link: calculationLink link: definitionLink 9952158 - Disclosure - Business link: presentationLink link: calculationLink link: definitionLink 9952159 - Disclosure - Summary of Significant Accounting Policies link: presentationLink link: calculationLink link: definitionLink 9952160 - Disclosure - The Merger link: presentationLink link: calculationLink link: definitionLink 9952161 - Disclosure - Real Estate Investments link: presentationLink link: calculationLink link: definitionLink 9952162 - Disclosure - Dispositions of Real Estate and Discontinued Operations link: presentationLink link: calculationLink link: definitionLink 9952163 - Disclosure - Impairments of Real Estate link: presentationLink link: calculationLink link: definitionLink 9952164 - Disclosure - Leases link: presentationLink link: calculationLink link: definitionLink 9952165 - Disclosure - Loans Receivable link: presentationLink link: calculationLink link: definitionLink 9952166 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures link: presentationLink link: calculationLink link: definitionLink 9952167 - Disclosure - Intangibles link: presentationLink link: calculationLink link: definitionLink 9952168 - Disclosure - Debt link: presentationLink link: calculationLink link: definitionLink 9952169 - Disclosure - Commitments and Contingencies link: presentationLink link: calculationLink link: definitionLink 9952170 - Disclosure - Equity and Redeemable Noncontrolling Interests link: presentationLink link: calculationLink link: definitionLink 9952171 - Disclosure - Earnings Per Common Share link: presentationLink link: calculationLink link: definitionLink 9952172 - Disclosure - Compensation Plans link: presentationLink link: calculationLink link: definitionLink 9952173 - Disclosure - Segment Disclosures link: presentationLink link: calculationLink link: definitionLink 9952174 - Disclosure - Income Taxes link: presentationLink link: calculationLink link: definitionLink 9952175 - Disclosure - Supplemental Cash Flow Information link: presentationLink link: calculationLink link: definitionLink 9952176 - Disclosure - Variable Interest Entities link: presentationLink link: calculationLink link: definitionLink 9952177 - Disclosure - Concentration of Credit Risk link: presentationLink link: calculationLink link: definitionLink 9952178 - Disclosure - Fair Value Measurements link: presentationLink link: calculationLink link: definitionLink 9952179 - Disclosure - Derivative Financial Instruments link: presentationLink link: calculationLink link: definitionLink 9952180 - Disclosure - Accounts Payable, Accrued Liabilities, and Other Liabilities link: presentationLink link: calculationLink link: definitionLink 9952181 - Disclosure - Deferred Revenue link: presentationLink link: calculationLink link: definitionLink 9952182 - Disclosure - Schedule II: Valuation and Qualifying Accounts link: presentationLink link: calculationLink link: definitionLink 9952183 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation link: presentationLink link: calculationLink link: definitionLink 9952184 - Disclosure - Schedule IV: Mortgage Loans on Real Estate link: presentationLink link: calculationLink link: definitionLink 9955511 - Disclosure - Summary of Significant Accounting Policies (Policies) link: presentationLink link: calculationLink link: definitionLink 9955512 - Disclosure - Summary of Significant Accounting Policies (Tables) link: presentationLink link: calculationLink link: definitionLink 9955513 - Disclosure - The Merger (Tables) link: presentationLink link: calculationLink link: definitionLink 9955514 - Disclosure - Real Estate Investments (Tables) link: presentationLink link: calculationLink link: definitionLink 9955515 - Disclosure - Dispositions of Real Estate and Discontinued Operations (Tables) link: presentationLink link: calculationLink link: definitionLink 9955516 - Disclosure - Leases (Tables) link: presentationLink link: calculationLink link: definitionLink 9955517 - Disclosure - Loans Receivable (Tables) link: presentationLink link: calculationLink link: definitionLink 9955518 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures (Tables) link: presentationLink link: calculationLink link: definitionLink 9955519 - Disclosure - Intangibles (Tables) link: presentationLink link: calculationLink link: definitionLink 9955520 - Disclosure - Debt (Tables) link: presentationLink link: calculationLink link: definitionLink 9955521 - Disclosure - Commitments and Contingencies (Tables) link: presentationLink link: calculationLink link: definitionLink 9955522 - Disclosure - Equity and Redeemable Noncontrolling Interests (Tables) link: presentationLink link: calculationLink link: definitionLink 9955523 - Disclosure - Earnings Per Common Share (Tables) link: presentationLink link: calculationLink link: definitionLink 9955524 - Disclosure - Compensation Plans (Tables) link: presentationLink link: calculationLink link: definitionLink 9955525 - Disclosure - Segment Disclosures (Tables) link: presentationLink link: calculationLink link: definitionLink 9955526 - Disclosure - Income Taxes (Tables) link: presentationLink link: calculationLink link: definitionLink 9955527 - Disclosure - Supplemental Cash Flow Information (Tables) link: presentationLink link: calculationLink link: definitionLink 9955528 - Disclosure - Variable Interest Entities (Tables) link: presentationLink link: calculationLink link: definitionLink 9955529 - Disclosure - Concentration of Credit Risk (Tables) link: presentationLink link: calculationLink link: definitionLink 9955530 - Disclosure - Fair Value Measurements (Tables) link: presentationLink link: calculationLink link: definitionLink 9955531 - Disclosure - Derivative Financial Instruments (Tables) link: presentationLink link: calculationLink link: definitionLink 9955532 - Disclosure - Accounts Payable, Accrued Liabilities, and Other Liabilities (Tables) link: presentationLink link: calculationLink link: definitionLink 9955533 - Disclosure - Deferred Revenue (Tables) link: presentationLink link: calculationLink link: definitionLink 9955534 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9955535 - Disclosure - Summary of Significant Accounting Policies - Schedule of Government Grant Receivables Cares Act (Details) link: presentationLink link: calculationLink link: definitionLink 9955536 - Disclosure - The Merger - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9955537 - Disclosure - The Merger - Schedule of Consideration Transferred (Details) link: presentationLink link: calculationLink link: definitionLink 9955538 - Disclosure - The Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) link: presentationLink link: calculationLink link: definitionLink 9955539 - Disclosure - The Merger - Schedule of Proforma Financial Information (Details) link: presentationLink link: calculationLink link: definitionLink 9955540 - Disclosure - Real Estate Investments - 2024 Real Estate Investment Acquisitions (Details) link: presentationLink link: calculationLink link: definitionLink 9955541 - Disclosure - Real Estate Investments - 2023 Real Estate Investment Acquisitions (Details) link: presentationLink link: calculationLink link: definitionLink 9955542 - Disclosure - Real Estate Investments - 2022 Real Estate Investment Acquisitions (Details) link: presentationLink link: calculationLink link: definitionLink 9955543 - Disclosure - Real Estate Investments - Construction, Tenant, and Other Capital Improvements (Details) link: presentationLink link: calculationLink link: definitionLink 9955544 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2024 Dispositions of Real Estate (Details) link: presentationLink link: calculationLink link: definitionLink 9955545 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2023 Dispositions of Real Estate (Details) link: presentationLink link: calculationLink link: definitionLink 9955546 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2022 Dispositions of Real Estate (Details) link: presentationLink link: calculationLink link: definitionLink 9955547 - Disclosure - Dispositions of Real Estate and Discontinued Operations - Held for Sale and Discontinued Operations (Details) link: presentationLink link: calculationLink link: definitionLink 9955548 - Disclosure - Dispositions of Real Estate and Discontinued Operations - Schedule of Results of Discontinued Operations (Details) link: presentationLink link: calculationLink link: definitionLink 9955549 - Disclosure - Impairments of Real Estate (Details) link: presentationLink link: calculationLink link: definitionLink 9955550 - Disclosure - Leases - Lease Income (Details) link: presentationLink link: calculationLink link: definitionLink 9955551 - Disclosure - Leases - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9955552 - Disclosure - Leases - Future Minimum Rents (Details) link: presentationLink link: calculationLink link: definitionLink 9955553 - Disclosure - Leases - Tenant Purchase Options (Details) link: presentationLink link: calculationLink link: definitionLink 9955554 - Disclosure - Leases - Lease Costs (Details) link: presentationLink link: calculationLink link: definitionLink 9955555 - Disclosure - Leases - Future Lease Obligations (Details) link: presentationLink link: calculationLink link: definitionLink 9955555 - Disclosure - Leases - Future Lease Obligations (Details) link: presentationLink link: calculationLink link: definitionLink 9955556 - Disclosure - Leases - Depreciation Expense (Details) link: presentationLink link: calculationLink link: definitionLink 9955557 - Disclosure - Leases - Denver Office Relocation (Details) link: presentationLink link: calculationLink link: definitionLink 9955558 - Disclosure - Leases - Tenant Updates (Details) link: presentationLink link: calculationLink link: definitionLink 9955559 - Disclosure - Loans Receivable - Schedule of Loans Receivable (Details) link: presentationLink link: calculationLink link: definitionLink 9955560 - Disclosure - Loans Receivable - The Merger (Details) link: presentationLink link: calculationLink link: definitionLink 9955561 - Disclosure - Loans Receivable - Sunrise Senior Housing Portfolio Seller Financing and Other Seller Financing (Details) link: presentationLink link: calculationLink link: definitionLink 9955562 - Disclosure - Loans Receivable - Outpatient Medical Seller Financing (Details) link: presentationLink link: calculationLink link: definitionLink 9955563 - Disclosure - Loans Receivable - 2025 Loans Receivable Transactions (Details) link: presentationLink link: calculationLink link: definitionLink 9955564 - Disclosure - Loans Receivable - 2024 Loans Receivable Transactions (Details) link: presentationLink link: calculationLink link: definitionLink 9955565 - Disclosure - Loans Receivable - 2023 Loans Receivable Transactions (Details) link: presentationLink link: calculationLink link: definitionLink 9955566 - Disclosure - Loans Receivable - 2022 Loans Receivable Transactions (Details) link: presentationLink link: calculationLink link: definitionLink 9955567 - Disclosure - Loans Receivable - CCRC Resident Loans (Details) link: presentationLink link: calculationLink link: definitionLink 9955568 - Disclosure - Loans Receivable - Schedule of Loans Receivable by Origination Year (Details) link: presentationLink link: calculationLink link: definitionLink 9955569 - Disclosure - Loans Receivable - Loan Losses (Details) link: presentationLink link: calculationLink link: definitionLink 9955570 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures - Schedule of Equity Method Investments (Details) link: presentationLink link: calculationLink link: definitionLink 9955571 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9955572 - Disclosure - Intangibles - Schedule of Intangibles Lease Assets (Details) link: presentationLink link: calculationLink link: definitionLink 9955573 - Disclosure - Intangibles - Schedule of Intangible Lease Liabilities (Details) link: presentationLink link: calculationLink link: definitionLink 9955574 - Disclosure - Intangibles - Amortization of Deferred Leasing Costs and Acquisition Related Intangibles (Details)

[illegible]

Amount Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Other assets, net Other Assets TX0008 Mansfield, TX TX0008 Mansfield, TX [Member] TX0008 Mansfield, TX 421 San Diego, CA 421 San Diego, CA [Member] Liabilities related to assets held for sale, net Real Estate Liabilities Associated with Assets Held for Development and Sale FL0025 Orlando, FL FL0025 Orlando, FL [Member] FL0025 Orlando, FL Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Nonrefundable entrance fees Nonrefundable Entrance Fees Nonrefundable Entrance Fees Government grant income recorded in other income (expense), net Other Nonoperating Income (Expense) [Member] 3152 Cambridge, MA 3152 Cambridge, MA [Member] 3152 Cambridge, MA Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months [Member] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months Numerator - Basic Net Income (Loss) Available to Common Stockholders, Basic [Abstract] 3214 Savannah, GA 3214 Savannah, GA [Member] Total deferred tax assets Deferred Tax Assets, Gross Maximum period available for occupancy from cessation of significant construction activity Maximum Period Available for Occupancy after Cessation of Significant Construction This element represents the period for occupancy, upon the completion of tenant improvements, after the cessation of significant construction activity. Dilutive potential common shares - OP Units (in shares) Incremental Common Shares Attributable To Dilutive Effect Of OP Units Outstanding Incremental Common Shares Attributable To Dilutive Effect Of OP Units Outstanding 469 Kaysville, UT 469 Kaysville, UT [Member] Total revenues Disposal Group, Including Discontinued Operation, Revenue 1553 Hayward, CA 1553 Hayward, CA [Member] TX0026 Bedford, TX TX0026 Bedford, TX [Member] TX0026 Bedford, TX Concentration Risk Type [Domain] Concentration Risk Type [Domain] 354 Salt Lake City, UT 354 Salt Lake City, UT [Member] Other deferred revenue Other Deferred Revenue Other Deferred Revenue 2928 Cambridge, MA 2928 Cambridge, MA [Member] Acquired Properties SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired Number of properties with first mortgages Number Of Properties With First Mortgages Number Of Properties With First Mortgages Sale of Stock [Domain] Sale of Stock [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Transaction and merger-related costs Transaction and merger-related costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Closing price of Healthpeak common stock on March 1, 2024 (in dollars per share) Business Acquisition, Share Price ASSETS Assets [Abstract] Accrued construction costs Construction Payable Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax 2862 Myrtle Beach, SC 2862 Myrtle Beach, SC [Member] Document Type Document Type Interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Derivative Contract [Domain] Derivative Contract [Domain] 2846 Greenville, SC 2846 Greenville, SC [Member] Cash, cash equivalents, and restricted cash, beginning of year Cash, cash equivalents, and restricted cash, end of year Cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Earnings (loss) of acquiree since acquisition date, actual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual 833 Pace, FL 833 Pace, FL [Member] MN0010 Hugo, MN MN0010 Hugo, MN [Member] MN0010 Hugo, MN 1403 Hayward, CA 1403 Hayward, CA [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Shares withheld to offset tax withholding obligations (in shares) Share-Based Compensation By Share-Based Payment Award, Shares Withheld to Offset Tax Withholding Obligations Represents the number of shares withheld by the reporting entity to offset tax withholding obligations of participants. CCRC JV Investment CCRC JV Investment [Member] Information related to the unconsolidated joint venture formed by the Company and Brookdale, under a RIDEA structure, to own and operate CCRC campuses. Intangible assets, net Finite-Lived Intangible Assets, Net 1319 Dallas, TX 1319 Dallas, TX [Member] Total lease expense Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Impaired Long-Lived Assets Held and Used [Line Items] Impaired Long-Lived Assets Held and Used [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount 2032 Independence, MO 2032 Independence, MO [Member] Investment, Name [Axis] Investment, Name [Axis] Section 1231, capital distribution percentage Income Tax, Section 1231 Gain (Loss), Total Capital Distribution Percentage Income Tax, Section 1231 Gain (Loss), Total Capital Distribution Percentage Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Total current Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] IN0002 Carmel, IN IN0002 Carmel, IN [Member] IN0002 Carmel, IN Term Loan Facilities One Term Loan Facilities One [Member] Term Loan Facilities One TN0010 Chattanooga, TN TN0010 Chattanooga, TN [Member] TN0010 Chattanooga, TN Other Property Other Property [Member] 2720 Nashville, TN 2720 Nashville, TN [Member] NY0013 Rhinebeck, NY NY0013 Rhinebeck, NY [Member] NY0013 Rhinebeck, NY Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Participating securitiesâ€™ share in earnings Less: Participating securitiesâ€™ share in continuing operations Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other Deferred Tax Liabilities, Other 3107 Cambridge, MA 3107 Cambridge, MA [Member] Total fair values (at vesting) of restricted stock and restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Indemnification Agreement Indemnification Agreement [Member] 1317 Dallas, TX 1317 Dallas, TX [Member] 2573 Florence, SC 2573 Florence, SC [Member] Interest Rate Swap, 3.61% Pay Rate Interest Rate Swap, 3.61% Pay Rate [Member] Interest Rate Swap, 3.61% Pay Rate 0126 Sherwood, AR 0126 Sherwood, AR [Member] Resident fees and services Revenue from Contract with Customer, Excluding Assessed Tax 1068 Omaha, NE 1068 Omaha, NE [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Proceeds from loan originations Proceeds from Loan Originations Number of real estate properties impaired Number Of Real Estate Properties Impaired Number Of Real Estate Properties Impaired Term Loan Agreement Term Loan Agreement [Member] Term Loan Agreement Total deductions SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Decrease SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Decrease 2849 Greer, SC 2849 Greer, SC [Member] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] 785 Seattle, WA 785 Seattle, WA [Member] Planned MOB Demolition, Tenant Relocation And Other Costs Planned MOB Demolition, Tenant Relocation And Other Costs [Member] Planned MOB Demolition, Tenant Relocation And Other Costs SWF SH JV SWF SH JV [Member] SWF SH JV Noncontrolling Interest [Table] Noncontrolling Interest [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] 2612 Allen, TX 2612 Allen, TX [Member] 2024 Scottsdale, AZ 2024 Scottsdale, AZ [Member] 1316 Dallas, TX 1316 Dallas, TX [Member] Number of DownREIT LLCs (in entities) Number of Down REIT LLCs This element represents the number of DownREIT LLCs for which the entity is the managing member. Real estate Deferred Tax Asset, Real Estate Deferred Tax Asset, Real Estate Loans receivable, interest rate Loans Receivable, Interest Rate, Stated Percentage Loans Receivable, Interest Rate, Stated Percentage 2865 Brentwood, TN 2865 Brentwood, TN [Member] 636 Nashville, TN 636 Nashville, TN [Member] Total grant date fair value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Value 1420 San Diego, CA 1420 San Diego, CA [Member] Workout loans Workout Financing Receivable [Member] Workout Financing Receivable [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] 2021 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2038 Evanston, WY 2038 Evanston, WY [Member] 3010 Springfield, OR 3010 Springfield, OR [Member] 2543 Houston, TX 2543 Houston, TX [Member] Cash, cash equivalents, and restricted cash Disposal Group, Including Discontinued Operations, Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Disposal Group, Including Discontinued Operations, Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Loans Receivable: Loans receivable Accounts, Notes, Loans and Financing Receivable [Line Items] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Interest Rate Swap, 4.54% Pay Rate Interest Rate Swap, 4.54% Pay Rate [Member] Interest Rate Swap, 4.54% Pay Rate 3012 Morristown, NJ 3012 Morristown, NJ [Member] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Restatement Determination Date Restatement Determination Date Concentration Risk [Table] Concentration Risk [Table] Number of stock options shares outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Impaired Long-Lived Asset, Held and Used [Table] Impaired Long-Lived Asset, Held and Used [Table] 624 Hendersonville, TN 624 Hendersonville, TN [Member] 583 Fort Worth, TX 583 Fort Worth, TX [Member] Weighted-average maturity Debt Instrument, Weighted Average Maturity This element represents weighted average maturity of debt. Expense on other Other Nonrecurring Expense Discontinued Operations Discontinued Operations [Member] Costs and expenses: Costs and Expenses [Abstract] 3111 San Diego, CA 3111 San Diego, CA [Member] Distributions to noncontrolling interests Temporary Equity, Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Temporary Equity, Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Borrowings under bank line of credit and commercial paper Proceeds from Lines of Credit Depreciation and amortization of real estate, in-place lease, and other intangibles Other Depreciation and Amortization AL0012 Birmingham, AL AL0012 Birmingham, AL [Member] AL0012 Birmingham, AL Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share 2028 Debt Instrument, Redemption, Period Four [Member] Impairments and loan loss reserves (recoveries), net Impairments And Allowance For Credit Loss Reserves (Recoveries), Net Impairments And Allowance For Credit Loss Reserves (Recoveries), Net Exchange ratio Business Combination, Exchange Ratio Business Combination, Exchange Ratio AR0008 Hot Springs, AR AR0008 Hot Springs, AR [Member] AR0008 Hot Springs, AR Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] TX0005 San Antonio, TX TX0005 San Antonio, TX [Member] TX0005 San Antonio, TX 2028 Lessor, Operating Lease, Payment to be Received, Year Four Equity income (loss) from unconsolidated joint ventures Income (Loss) from Equity Method Investments 1946 Louisville, KY 1946 Louisville, KY [Member] LLC Investment and PropTech Investment Variable Interest Entity Not Primary Beneficiary Debt Investment [Member] Represents a debt investment with a party that has been identified as a Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 673 Plantation, FL 673 Plantation, FL [Member] Secured Mortgage Loans 1 Secured Mortgage Loans 1 [Member] Secured Mortgage Loans 1 NE0010 Kearney, NE NE0010 Kearney, NE [Member] NE0010 Kearney, NE MN0006 Minnetonka, MN MN0006 Minnetonka, MN [Member] MN0006 Minnetonka, MN Senior Unsecured Notes Due 2028 Senior Unsecured Notes Due 2028 [Member] Senior Unsecured Notes Due 2028 SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Common stock, unit redemption share amount Common Stock, Unit Redemption Share Amount Common Stock, Unit Redemption Share Amount Qualified dividend income for purposes of Code Section 1(h)(1) (in dollars per share) Qualified Dividend Income, Code Section 1(h)(1) Qualified Dividend Income, Code Section 1(h)(1) Local Phone Number Local Phone Number Schedule of Capital Improvements Schedule of Capital Improvements [Table Text Block] Tabular disclosure of the amounts of funding, during the period, for construction, tenant and other capital improvements by segment. 2028 Scottsdale, AZ 2028 Scottsdale, AZ [Member] Unamortized discount Receivable with Imputed Interest, Discount 3119 Cambridge, MA 3119 Cambridge, MA [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] 738 Louisville, KY 738 Louisville, KY [Member] Investments in unconsolidated joint ventures Payments to Acquire Interest in Subsidiaries and Affiliates Operating expenses Operating expenses Operating Expenses Equity Method Investment [Table] Equity Method Investment [Table] FL0032 Jacksonville, FL FL0032 Jacksonville, FL [Member] FL0032 Jacksonville, FL 3151 Cambridge, MA 3151 Cambridge, MA [Member] Schedule of Estimated Aggregate Amortization of Intangible Assets and Liabilities for Each of the Five Succeeding Fiscal Years and Thereafter Schedule of Expected Amortization of Intangible Assets and Intangible Liabilities [Table Text Block] Tabular disclosure of the estimated aggregate amortization expense expected to be recorded in succeeding fiscal years for intangible assets and liabilities. Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Shares of Healthpeak common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Loan receivable, period of extensions Loan Receivable, Period Of Extension Loan Receivable, Period Of Extension Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] PA0014 Erie, PA PA0014 Erie, PA [Member] PA0014 Erie, PA Debt Disclosure [Abstract] Debt Disclosure [Abstract] 2699 Indianapolis, IN 2699 Indianapolis, IN [Member] Impairment of Long-Lived Assets and Goodwill Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Number of properties sold Number Of Properties To Be Sold Number Of Properties To Be Sold NE0011 Kearney, NE NE0011 Kearney, NE [Member] NE0011 Kearney, NE Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] 2025 Debt Instrument, Redemption, Period One [Member] Acquisition of real estate and development and improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Developments And Improvements The total amount of real estate investments acquired through acquisition, the amount of real estate developed, and the improvements made to real estate investments during the period. Number of facilities owned by unconsolidated joint venture Number Of Facilities Owned By Unconsolidated Joint Venture Number Of Facilities Owned By Unconsolidated Joint Venture Accelerated cost Share-Based Payment Arrangement, Accelerated Cost Entity Central Index Key Entity Central Index Key Other segment items Segment Reporting, Other Segment Item, Amount Current period net write-offs Current Period Net Write-Offs [Member] Current Period Net Write-Offs General and Administrative Expense General and Administrative Expense [Member] WI0002 Shawano, WI WI0002 Shawano, WI [Member] WI0002 Shawano, WI Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] 813 Littleton, CO 813 Littleton, CO [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 1421 San Diego, CA 1421 San Diego, CA [Member] Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] PA0002 Carlisle, PA PA0002 Carlisle, PA [Member] PA0002 Carlisle, PA 2658 Highlands Ranch, CO 2658 Highlands Ranch, CO [Member] Real estate: Real Estate Investment Property, Net [Abstract] 1418 San Diego, CA 1418 San Diego, CA [Member] Secured Overnight Financing Rate (SOFR), First Two Years Secured Overnight Financing Rate (SOFR), First Two Years [Member] Secured Overnight Financing Rate (SOFR), First Two Years 3141 Cambridge, MA 3141 Cambridge, MA [Member] Interest payment Debt Instrument, Periodic Payment, Interest Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Loans receivable, net Loans Receivable, Fair Value Disclosure Number of extensions (in renewal options) Debt Instrument, Number Of Extensions Debt Instrument, Number Of Extensions 2962 Orange Park, FL 2962 Orange Park, FL [Member] Discontinued operations Cash, Including Discontinued Operations [Abstract] Senior Unsecured Notes Unsecured Debt [Member] 674 Plantation, FL 674 Plantation, FL [Member] 674 Plantation, FL Real estate assets acquired in connection with the Merger SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Assets Acquired SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Assets Acquired unrecognized tax benefits Total unrecognized tax benefits at January 1 Total unrecognized tax benefits at December 31 Unrecognized Tax Benefits Total comprehensive (income) loss attributable to noncontrolling interestsâ€™ share in continuing operations Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest City Area Code City Area Code Auditor Location Auditor Location 3122 Cambridge, MA 3122 Cambridge, MA [Member] Other Other [Member] Represents the information pertaining to the Other [member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] 887 Atlanta, GA 887 Atlanta, GA [Member] 2997 Clearwater, FL 2997 Clearwater, FL [Member] 840 San Diego, CA 840 San Diego, CA [Member] 816 San Antonio, TX 816 San Antonio, TX [Member] 739 Louisville, KY 739 Louisville, KY [Member] Option indexed to issuers equity, term Option Indexed To Issuers Equity, Term Option Indexed To Issuers Equity, Term SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] 2202 Miami, FL 2022 Miami, FL [Member] Weighted Average GrantÂ Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] 2023 Incentive Plan Stock Based

Compensation, 2023 Incentive Plan [Member] Stock Based Compensation, 2023 Incentive Plan Other income (expense), net Disposal Group, Including Discontinued Operation, Other Income Term Loan Facilities Two Term Loan Facilities Two [Member] Term Loan Facilities Two 1501 Redwood City, CA 1501 Redwood City, CA [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] 1500 Redwood City, CA 1500 Redwood City, CA [Member] NY0014 Brooklyn, NY NY0014 Brooklyn, NY 834 Pensacola, FL 834 Pensacola, FL [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] 1504 Redwood City, CA 1504 Redwood City, CA [Member] TX0010 El Paso, TX TX0010 El Paso, TX [Member] TX0010 El Paso, TX 2029 Term Loan 2029 Term Loan [Member] 2029 Term Loan Class of Stock [Domain] Class of Stock [Domain] Forward sales agreements that have been settled (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements, Settled Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements, Settled 3153 San Diego, CA 3153 San Diego, CA [Member] 3153 San Diego, CA MI0014 Sterling Heights, MI MI0014 Sterling Heights, MI [Member] MI0014 Sterling Heights, MI 2477 San Diego, CA 2477 San Diego, CA [Member] 2026 Long Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount TN0002 Jackson, TN TN0002 Jackson, TN [Member] TN0002 Jackson, TN Equity Awards Adjustments Equity Awards Adjustments [Member] Underlying Securities Award Underlying Securities Amount Payments for deferred financing costs Payment for Debt Extinguishment or Debt Prepayment Cost 837 San Diego, CA 837 San Diego, CA [Member] Amendment Flag Amendment Flag 811 Englewood, CO 811 Englewood, CO [Member] Government grant income recorded in equity income (loss) from unconsolidated joint ventures Equity Income (Loss) From Unconsolidated Joint Ventures [Member] Equity Income (Loss) From Unconsolidated Joint Ventures [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] 2027 Term Loan Facilities 2027 Term Loan Facilities [Member] 2027 Term Loan Facilities Increase (Decrease) in Redeemable Noncontrolling Interests Increase (Decrease) in Temporary Equity [Roll Forward] Deconsolidation of real estate SEC Schedule III, Real Estate Accumulated Depreciation, Deconsolidation SEC Schedule III, Real Estate Accumulated Depreciation, Deconsolidation 1485 Brisbane, CA 1485 Brisbane, CA [Member] Thereafter Leases with Purchase Option Future Minimum Annualized Base Rent Receivable Thereafter Future annualized base rental payments receivable after the five years of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount Debt Instrument, Face Amount HCA Healthcare, Inc HCA Healthcare, Inc [Member] HCA Healthcare, Inc Entity Address, Postal Zip Code Entity Address, Postal Zip Code 1445 South San Francisco, CA 1445 South San Francisco, CA [Member] Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share KY0007 Louisville, KY KY0007 Louisville, KY [Member] KY0007 Louisville, KY Intangible liabilities, net Off-Market Lease, Unfavorable Cash paid in connection with the Merger, net Cash, Cash Equivalents, And Restricted Cash Paid As Part Of Mergers Cash, Cash Equivalents, And Restricted Cash Paid As Part Of Mergers Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Leases Lessor, Operating Leases [Text Block] Building and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements 3015 Midlothian, VA 3015 Midlothian, VA [Member] Number of hospitals Number Of Hospitals 815 San Antonio, TX 815 San Antonio, TX [Member] Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3112 Cambridge, MA 3112 Cambridge, MA [Member] Market Based Restricted Stock Units Market Based Restricted Stock Units [Member] Market Based Restricted Stock Units Other Equity Investments Equity Securities without Readily Determinable Fair Value [Policy Text Block] Largest Tenant Largest Tenant [Member] Largest Tenant Common Spirit Common Spirit [Member] Common Spirit Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Depreciation and amortization Depreciation and amortization Depreciation and amortization of real estate, in-place lease, and other intangibles Depreciation, Depletion and Amortization, Nonproduction Buildings& Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Building and Improvements, Amount Total Leases with Purchase Option Number of Properties Number of properties for which future annualized rental payments are receivable for the five years following the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Government Assistance Axis [Domain] Government Assistance Axis [Domain] Government Assistance Axis [Domain] 2655 Wilmington, NC 2655 Wilmington, NC [Member] Other Deferred Tax Assets, Tax Deferred Expense, Other Non-managing member unitholders Noncontrolling Interest in Preferred Unit Holders 1044 Houston, TX 1044 Houston, TX [Member] 2839 Cypress, TX 2839 Cypress, TX [Member] PMAK JV PMAK JV [Member] PMAK JV GA0031 Dunwoody, GA GA0031 Dunwoody, CA [Member] GA0031 Dunwoody, GA Net income (loss) applicable to common shares Net Income (Loss) Available to Common Stockholders, Basic Stock, Class of Stock [Table] Stock, Class of Stock [Table] Accounts payable, accrued liabilities, and other liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Liabilities, And Other Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Liabilities, And Other Liabilities Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Operating Cost of Goods and Services Sold Advertising Cost Advertising Cost [Policy Text Block] MO0002 Creve Coeur, MO MO0002 Creve Coeur, MO [Member] MO0002 Creve Coeur, MO FL0003 Venice, FL FL0003 Venice, FL [Member] FL0003 Venice, FL Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and contingencies (Note 12) Commitments and Contingencies Schedule of Reconciliation of Income Tax Expense at Statutory Rates to the Actual Income Tax Expense Recorded Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net noncash impact from the consolidation of property previously held in an unconsolidated joint venture Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) WI0004 Tacoma, WA WI0004 Tacoma, WA [Member] WI0004 Tacoma, WA Debt instrument, covenant net worth, minimum Debt Instrument, Covenant Net Worth, Minimum The required Minimum Consolidated Tangible Net Worth contained in the debt covenants. Business Nature of Operations [Text Block] Gross above market lease intangibles Above Market Lease Intangible Assets, Gross Above Market Lease Intangible Assets, Gross 2863 Lee's Summit, MO 2863 Lee's Summit, MO [Member] Debt Instrument [Axis] Debt Instrument [Axis] 2027 Scottsdale, AZ 2027 Scottsdale, AZ [Member] Trading Arrangement: Trading Arrangement [Axis] Summary of the Carrying Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number 2851 Travelers Rest, SC 2851 Travelers Rest, SC [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Total Noncontrolling Interests Noncontrolling Interest [Member] Entity Address, Address Line One Entity Address, Address Line One 1410 South San Francisco, CA 1410 South San Francisco, CA [Member] Federal Current Federal Tax Expense (Benefit) Entity Address, Address Line Two Entity Address, Address Line Two Common dividends Dividends, Common Stock Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Gross amount of decreases for prior yearsâ€™ tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 1945 Louisville, KY 1945 Louisville, KY [Member] Loans receivable, term Loans Receivable, Term Loans Receivable, Term Summary of financial instruments Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 2024 Share Repurchase Program 2024 Share Repurchase Program [Member] 2024 Share Repurchase Program PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount KY0008 Louisville, KY KY0008 Louisville, KY [Member] KY0008 Louisville, KY Aggregate carrying value before impairment Real Estate Investment Property, Aggregate Carrying Value Before Impairment Real Estate Investment Property, Aggregate Carrying Value Before Impairment Adjustment to Compensation: Adjustment to Compensation [Axis] Maximum loss exposure and carrying amount Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount 2656 Wilmington, NC 2656 Wilmington, NC [Member] 2871 South San Francisco, CA 2871 South San Francisco, CA [Member] 1057 Newburgh, IN 1057 Newburgh, IN [Member] 2982 Fort Worth, TX 2982 Fort Worth, TX [Member] 2621 Cedar Park, TX 2621 Cedar Park, TX [Member] Total equity Balance Balance Equity, Including Portion Attributable to Noncontrolling Interest 1592 Bountiful, UT 1592 Bountiful, UT [Member] 781 Seattle, WA 781 Seattle, WA [Member] Davis JV Davis JV [Member] Davis JV GA0025 Lawrenceville, GA GA0025 Lawrenceville, GA [Member] GA0025 Lawrenceville, GA 3150 Cambridge, MA 3150 Cambridge, MA [Member] 625 Nashville, TN 625 Nashville, TN [Member] Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Entity Filer Category Entity Filer Category 1556 Hayward, CA 1556 Hayward, CA [Member] 2037 Mesquite, NV 2037 Mesquite, NV [Member] 612 Margate, FL 612 Margate, FL [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] 3062 Overland Park, KS 3062 Overland Park, KS [Member] Nondividend distributions (in dollars per share) Real Estate Investment Trust, Distribution, Tax Status, Return of Capital, Per Unit Proceeds from sales/principal repayments on loans receivable and marketable debt securities Proceeds from Principal Repayment, Loan and Lease, Held-for-Investment Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Variable Interest Entity Variable Interest Entity, Primary Beneficiary [Member] Fair value Interest Rate Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value Income taxes paid (refunded) Income Taxes Paid, Net 2546 Houston, TX 2546 Houston, TX [Member] 2229 La Jolla, CA 2229 La Jolla, CA [Member] Other Commitments [Line Items] Other Commitments [Line Items] Redeemable noncontrolling interests Redeemable Noncontrolling Interest, Equity, Carrying Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount 1444 South San Francisco, CA 1444 South San Francisco, CA [Member] Buildings and improvements Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Building And Building Improvements Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Building And Building Improvements 565 San Jose, CA 565 San Jose, CA [Member] 2198 Webster, TX 2198 Webster, TX [Member] 3113 Cambridge, MA 3113 Cambridge, MA [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three 808 Englewood, CO 808 Englewood, CO [Member] Senior Unsecured Notes Due 2027 Senior Unsecured Notes Due 2027 [Member] Senior Unsecured Notes Due 2027 Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Leases Lessee, Operating Leases [Text Block] Dividend Reinvestment and Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Maximum number of shares available for future awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2029 Debt Instrument, Redemption, Period Five [Member] Intangibles [Abstract] Intangibles [Abstract] Intangibles [Abstract] Entity Tax Identification Number Entity Tax Identification Number Mortgage debt Mortgage debt Secured Debt Loans Receivable Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Denominator Earnings Per Share Reconciliation [Abstract] Mortgage Receivable Secured loans Mortgage Receivable [Member] Plan Name [Axis] Plan Name [Axis] WA0001 Lakewood, WA WA0001 Lakewood, WA [Member] WA0001 Lakewood, WA Development and redevelopment commitments Development Commitments [Member] Represents construction and other commitments for developments in progress, Equity Components [Axis] Equity Components [Axis] 3217 Brandon, FL 3217 Brandon, FL [Member] 3217 Brandon, FL 3023 Covington, LA 3023 Covington, LA [Member] AZ0010 Scottsdale, AZ AZ0010 Scottsdale, AZ [Member] AZ0010 Scottsdale, AZ FL0022 Stuart, FL FL0022 Stuart, FL [Member] FL0022 Stuart, FL Net income (loss) applicable to common shares Business Acquisition, Pro Forma Net Income (Loss) 3024 Webster, TX 3024 Webster, TX [Member] Notional amount Notional Amount Derivative Asset, Notional Amount Leasing costs, tenant improvements, and recurring capital expenditures Leasing costs, tenant improvements, and recurring capital expenditures Payments for Leasing Costs, Commissions, and Tenant Improvements PA0007 Harrisburg, PA PA0007 Harrisburg, PA [Member] PA0007 Harrisburg, PA Total costs and expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of Deferred Revenue Schedule of Deferred Revenue [Table Text Block] Schedule of Deferred Revenue Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Diluted earnings (loss) per common share: Diluted earnings (loss) per common share Earnings Per Share, Diluted [Abstract] Financing Receivable, Credit Quality Indicator [Line Items] Financing Receivable, Credit Quality Indicator [Line Items] Geographical [Axis] Geographical [Axis] 1480 South San Francisco, CA 1480 South San Francisco, CA [Member] 1067 Milton, FL 1067 Milton, FL [Member] MS0003 Jackson, MS MS0003 Jackson, MS [Member] MS0003 Jackson, MS Net deferred tax assets Deferred Tax Assets, Net Gross receipts and margin taxes Effective Income Tax Rate Reconciliation, Gross Receipts and Margin Taxes Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gross receipts and margin taxes. Repurchase of common stock Stock Repurchased During Period, Value Subsidiary or Equity Method Investee, Sale of Stock [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] 2875 Brisbane, CA 2875 Brisbane, CA [Member] 810 Englewood, CO 810 Englewood, CO [Member] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] 2866 Kansas City, MO 2866 Kansas City, MO [Member] 2866 Kansas City, MO 1549 Hayward, CA 1549 Hayward, CA [Member] 1041 Brentwood, CA 1041 Brentwood, CA [Member] 1059 Jackson, MS 1059 Jackson, MS [Member] Weighted-average interest rate (as a percent) Debt, Weighted Average Interest Rate Payments to acquire equity investments Payments To Acquire Equity Investments Payments To Acquire Equity Investments Lease-up intangibles Finite-Lived Intangible Liabilities, Lease Finite-Lived Intangible Liabilities, Lease Total other income (expense), net Disposal Group Including Discontinued Operation Nonoperating Income Expense Disposal Group Including Discontinued Operation Nonoperating Income Expense Acquisitions of real estate Payments to Acquire Other Real Estate Impairment of real estate Impairment of Real Estate Consolidation Items [Axis] Consolidation Items [Axis] Fair Value Measurement Fair Value of Financial Instruments, Policy [Policy Text Block] Income (loss) from continuing operations attributable to Healthpeak Properties, Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Senior Housing Operating Portfolio Senior Housing Operating Portfolio [Member] Represent senior housing operating portfolio. Noncontrolling interests acquired as part of the Merger Temporary Equity, Noncontrolling Interest, Increase From Business Combination Temporary Equity, Noncontrolling Interest, Increase From Business Combination 1499 Redwood City, CA 1499 Redwood City, CA [Member] Vested, Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Accumulated depreciation and amortization Accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Senior Unsecured Notes 5.25% Senior Unsecured Notes 5.25% [Member] Senior Unsecured Notes 5.25% 1510 Redwood City, CA 1510 Redwood City, CA [Member] Financing Receivable, Credit Quality Indicator [Table] Financing Receivable, Credit Quality Indicator [Table] Principal Amount Subject to Delinquent Principal or Interest SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Principal Amount of Delinquent Loans 300 Minneapolis, MN 300 Minneapolis, MN [Member] Unvested restricted stock and performance restricted stock units activity Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Difference between carrying amount and underlying equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Short-term debt Short-Term Debt Construction loans on real estate interest multiple due 2027 Construction Loans On Real Estate Interest Multiple, Due 2027 One [Member] Construction Loans On Real Estate Interest Multiple, Due 2027 One Lab JV Lab JV [Member] Lab JV Real estate taxes Real Estate Taxes and Insurance Time Based Restricted Stock Units Time Based Restricted Stock Units [Member] Time Based Restricted Stock Units Government grant income Government Grant Income From CARES Act Government Grant Income From CARES Act 430 Houston, TX 430 Houston, TX [Member] Number of tenants Number Of Tenants Number Of Tenants Dilutive potential common shares - OP Units (in shares) Incremental Common Shares Attributable To Dilutive Effect Of OP Units Incremental Common Shares Attributable To Dilutive Effect Of OP Units Common stock, shares issued (in shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] IN0018 Lafayette, IN IN0018 Lafayette, IN [Member] IN0018 Lafayette, IN IN0015 Lafayette, IN IN0015 Lafayette, IN [Member] IN0015 Lafayette, IN Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Interest Rate Swap, 3.57% Pay Rate Interest Rate Swap, 3.57% Pay Rate [Member] Interest Rate Swap, 3.57% Pay Rate Thereafter Debt Instrument Redemption Period Thereafter [Member] Represents the period after the last period separately disclosed of debt redemption features under terms of the debt agreement. 1505 Redwood City, CA 1505 Redwood City, CA [Member] IN0006 Bloomington, IN IN0006 Bloomington, IN [Member] IN0006 Bloomington, IN 1506 Redwood City, CA 1506 Redwood City, CA [Member] Accumulated depreciation related to corporate assets Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] 2554 South San Francisco, CA 2554 South San Francisco, CA [Member] Accounts receivable, net of allowance of \$,243 and \$,282 Accounts

recharge, net Accounts Receivable, after Allowance for Credit Loss MN0003 Crystal, MN MN0003 Crystal, MN [Member] MN0003 Crystal, MN 1196 Aurora, CO 1196 Aurora, CO [Member] Purchase of noncontrolling interests Temporary Equity, Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Temporary Equity, Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 3070 Lexington, MA 3070 Lexington, MA [Member] Statement of Financial Position Location, Activity, Accrual [Axis] Statement of Financial Position Location, Activity, Accrual [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] 2833 St. Petersburg, FL 2833 St. Petersburg, FL [Member] Loans receivable, conversion of basis spread on variable rate Loans Receivable, Conversion Of Basis Spread On Variable Rate Loans Receivable, Conversion Of Basis Spread On Variable Rate Mortgage debt Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Mortgage Debt Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Mortgage Debt SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract] MI0018 Apple Valley, MI MI0018 Apple Valley, MI [Member] MI0018 Apple Valley, MI Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Schedule of Government Grant Receivables Cares Act Schedule Of Government Grant Receivables CARES Act [Table Text Block] Schedule Of Government Grant Receivables CARES Act Total deferred Deferred Income Tax Expense (Benefit) Schedule of Proforma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] 569 McKinney, TX 569 McKinney, TX [Member] KY0006 Louisville, KY KY0006 Louisville, KY [Member] KY0006 Louisville, KY Interest income from direct financing leases Direct Financing Lease, Interest Income 2027 Leases with Purchase Option Future Minimum Annualized Base Rent Receivable in Three Years Future annualized base rental payments receivable within third year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Impairments and loan loss reserves (recoveries), net Asset Impairment Charges Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Equity investment, percentage of total fund commitments (Equity Investment, Aggregate Cost Equity Investment, Aggregate Cost Capital Raising Issuance Costs Capital Raising Issuance Costs [Policy Text Block] Disclosure of accounting policy for costs incurred in connection with raising capital. Thereafter Long-Term Debt, Maturity, after Year Five Financing receivable, gross Total Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss FL0034 Yulee, FL FL0034 Yulee, FL [Member] FL0034 Yulee, FL SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] 2705 Cambridge, MA 2705 Cambridge, MA [Member] Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Document Annual Report Document Annual Report 2544 Houston, TX 2544 Houston, TX [Member] 626 Nashville, TN 626 Nashville, TN [Member] 1464 South San Francisco, CA 1464 South San Francisco, CA [Member] TX0026 Bryan, TX TX0026 Bryan, TX [Member] TX0026 Bryan, TX Secured Overnight Financing Rate (SOFR), Last Eighteen Months Secured Overnight Financing Rate (SOFR), Last Eighteen Months [Member] Secured Overnight Financing Rate (SOFR), Last Eighteen Months Ordinary dividends (in dollars per share) Real Estate Investment Trust, Distribution, Tax Status, Ordinary Income, Per Unit Outstanding equity awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Awards Incremental Common Shares Attributable to Dilutive Effect of Equity Awards Deferred revenue Contract with Customer, Liability 448 Renton, WA 448 Renton, WA [Member] TX0028 Dallas, TX TX0028 Dallas, TX [Member] TX0028 Dallas, TX Movement in Valuation Allowances and Reserves SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Term Loan Facilities Term Loan Facilities [Member] Term Loan Facilities 573 Arlington, TX 573 Arlington, TX [Member] 2041 Salt Lake City, UT 2041 Salt Lake City, UT [Member] Bearing variable interest rate (as a percent) Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate The Merger Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date 2542 Houston, TX 2542 Houston, TX [Member] Balance at Beginning of Year Balance at End of Year SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 566 Salt Lake City, UT 566 Salt Lake City, UT [Member] 1197 Aurora, CO 1197 Aurora, CO [Member] Secured loans Secured Mortgage Loans Secured Mortgage Loans [Member] Secured Mortgage Loans Issuance of OP units (in units) Units Issued During Period, New Issues Units Issued During Period, New Issues Held-for-sale Discontinued Operations, Held-for-Sale [Member] Adjustments to NOI Non Cash Adjustments To Net Operating Income From Continuing Operations Represents straight-line rents, DFL accretion, amortization of market lease intangibles and lease termination fees. Revision of Prior Period [Axis] Revision of Prior Period [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Schedule of Loans Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] 2551 The Woodlands, TX 2551 Woodlands, TX [Member] KY0004 Louisville, KY KY0004 Louisville, KY [Member] KY0004 Louisville, KY 3081 Fort Belvoir, VA 3081 Fort Belvoir, VA [Member] PA0012 West Easton, PA PA0012 West Easton, PA [Member] PA0012 West Easton, PA Class of Stock [Line Items] Class of Stock [Line Items] Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Postvesting restrictions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions Class of Stock [Axis] Class of Stock [Axis] IN0025 Newburgh, IN IN0025 Newburgh, IN [Member] IN0025 Newburgh, IN 1484 Brisbane, CA 1484 Brisbane, CA [Member] Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Arizona, Florida, Georgia, Texas, and Wisconsin Arizona, Florida, Georgia, Texas, and Wisconsin [Member] Arizona, Florida, Georgia, Texas, and Wisconsin NJ0001 Monroe Township, NJ NJ0001 Monroe Township, NJ [Member] NJ0001 Monroe Township, NJ 2837 San Antonio, TX 2837 San Antonio, TX [Member] Stock-based compensation amortization expense Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] 3089 Birmingham, AL 3089 Birmingham, AL [Member] 2025 Leases with Purchase Option Number of Properties Next Twelve Months Number of properties for which future annualized rental payments are receivable within one year of the balance sheet date, on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage 662 Las Vegas, NV 662 Las Vegas, NV [Member] Total other income (expense), net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule II: Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] 671 Kissimmee, FL 671 Kissimmee, FL [Member] Summary of the Company's Internal Ratings for Loans Receivable on Net of Reserves for Loan Losses Financing Receivable Credit Quality Indicators [Table Text Block] Variable Rate [Domain] Variable Rate [Domain] Change in valuation allowance for deferred tax assets Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Payments for loans receivable Payments For Loans Receivable Payments For Loans Receivable Total liabilities and equity Liabilities and Equity MN0008 Coon Rapids, MN MN0008 Coon Rapids, MN [Member] MN0008 Coon Rapids, MN 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] 3148 Cambridge, MA 3148 Cambridge, MA [Member] GA0028 Atlanta, GA GA0028 Atlanta, GA [Member] GA0028 Atlanta, GA Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Restricted Stock Unit and LTIP Unit activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Accumulated Depreciation Balances at beginning of year Balances at end of year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation Buildings and improvements Investment Building and Building Improvements Increase in ROU asset in exchange for new lease liability related to operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3088 Spring, TX 3088 Spring, TX [Member] 3088 Spring, TX Underlying Security Market Price Change Underlying Security Market Price Change, Percent Building and Building Improvements Building and Building Improvements [Member] 1554 Hayward, CA 1554 Hayward, CA [Member] 1404 Hayward, CA 1404 Hayward, CA [Member] 562 Hermitage, TN 562 Hermitage, TN [Member] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Termination fees Termination Fees Termination Fees Liabilities related to assets held for sale, net Disposal Group, Including Discontinued Operation, Liabilities 1948 San Diego, CA 1948 San Diego, CA [Member] 2239 Louisville, KY 2239 Louisville, KY [Member] Statement [Line Items] Statement [Line Items] Less: Fair value of preliminary share consideration attributable to the post-combination period Business Combination, Consideration Transferred, Attributable To Post-Combination Period Business Combination, Consideration Transferred, Attributable To Post-Combination Period 1314 Dallas, TX 1314 Dallas, TX [Member] Number of redeemable noncontrolling interest with redemption conditions Number Of Redeemable Noncontrolling Interest With Redemption Conditions Number Of Redeemable Noncontrolling Interest With Redemption Conditions TX0013 Katy, TX TX0013 Katy, TX [Member] TX0013 Katy, TX 466 Salt Lake City, UT 466 Salt Lake City, UT [Member] Intangible liabilities Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Intangible Liabilities, Net Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Intangible Liabilities, Net Consideration transferred Total purchase price Business Combination, Consideration Transferred IN0010 Greenwood, IN IN0010 Greenwood, IN [Member] IN0010 Greenwood, IN 882 Colorado Springs, CO 882 Colorado Springs, CO [Member] Derivatives and Hedging Derivatives, Policy [Policy Text Block] Number of properties acquired Number Of Properties Acquired Number Of Properties Acquired 1507 Redwood City, CA 1507 Redwood City, CA [Member] GA0027 Lawrenceville, GA GA0027 Lawrenceville, GA [Member] GA0027 Lawrenceville, GA Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Fixed interest rate Pay Rate Derivative, Fixed Interest Rate Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date AR005 Hot Springs, AR AR0005 Hot Springs, AR [Member] AR0005 Hot Springs, AR Non-cash interest income Noncash or Part Noncash, Interest Income Noncash or Part Noncash, Interest Income Real estate Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment Property, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment Property, Net Adjustments to redemption value of redeemable noncontrolling interests Temporary Equity, Adjustments Of Permanent Equity To Temporary Equity Temporary Equity, Adjustments Of Permanent Equity To Temporary Equity 3001 Leesburg, VA 3001 Leesburg, VA [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Leases Lessor, Direct Financing Leases [Text Block] 435 Atlantis, FL 435 Atlantis, FL [Member] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] 1425 La Jolla, CA 1425 La Jolla, CA [Member] Exercise Price Award Exercise Price 2707 Cambridge, MA 2707 Cambridge, MA [Member] Interest expense Interest Expense, Other Schedule of Significant Components of the Company's Deferred Tax Asset and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] 806 Fort Worth, TX 806 Fort Worth, TX [Member] 1593 Salt Lake City, UT 1593 Salt Lake City, UT [Member] IN0012 Greenwood, IN IN0012 Greenwood, IN [Member] IN0012 Greenwood, IN Arrangement Duration Trading Arrangement Duration AR0007 Hot Springs, AR AR0007 Hot Springs, AR [Member] AR0007 Hot Springs, AR CT0001 Plainville, CT CT0001 Plainville, CT [Member] CT0001 Plainville, CT Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] 2026 Leases with Purchase Option Number of Properties in Two Years Number of properties for which future annualized rental payments are receivable within second year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share 2991 Coatesville, PA 2991 Coatesville, PA [Member] Government grant income Government Grant Income Government Grant Income 2022 Share Repurchase Program 2022 Share Repurchase Program [Member] 2022 Share Repurchase Program Name of Property [Axis] Name of Property [Axis] 1550 Hayward, CA 1550 Hayward, CA [Member] Real Estate and Accumulated Depreciation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] Total additions SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Increase SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Increase Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] TN0007 Chattanooga, TN TN0007 Chattanooga, TN [Member] TN0007 Chattanooga, TN 1947 San Diego, CA 1947 San Diego, CA [Member] WI0005 Tacoma, WA WI0005 Tacoma, WA [Member] WI0005 Tacoma, WA AR0006 Hot Springs, AR AR0006 Hot Springs, AR [Member] AR0006 Hot Springs, AR Sales and/or transfers to assets held for sale SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other income (expense), net Other Nonoperating Income (Expense) 1401 Hayward, CA 1401 Hayward, CA [Member] Loans receivable, net of reserves of \$10,499 and \$2,830 Loans receivable, net Loans receivable, net Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) 1426 La Jolla, CA 1426 La Jolla, CA [Member] CA0005 Walnut Creek, CA CA0005 Walnut Creek, CA [Member] CA0005 Walnut Creek, CA LA0004 Lafayette, LA LA0004 Lafayette, LA [Member] LA0004 Lafayette, LA MN0014 Little Falls, MN MN0014 Little Falls, MN [Member] MN0014 Little Falls, MN Accrued interest Interest Payable Aggregate amount remaining ATM Equity Offering Program Aggregate Amount Remaining ATM Equity Offering Program Aggregate Amount Remaining 1987 South San Francisco, CA 1987 South San Francisco, CA [Member] AZ0015 Phoenix, AZ AZ0015 Phoenix, AZ [Member] AZ0015 Phoenix, AZ Other Operating Segment [Member] Other Operating Segment [Member] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] 3072 Lexington, MA 3072 Lexington, MA [Member] 559 Hermitage, TN 559 Hermitage, TN [Member] 1424 La Jolla, CA 1424 La Jolla, CA [Member] 127 Colorado Springs, CO 127 Colorado Springs, CO [Member] 572 Reston, VA 572 Reston, VA [Member] Construction loan commitments Construction Loan Commitments [Member] Represents commitments to finance development projects and related working capital financings. SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward] SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward] Intangible assets, weighted average amortization, useful life Intangible Assets, Weighted Average Amortization, Useful Life Intangible Assets, Weighted Average Amortization, Useful Life 1984 South San Francisco, CA 1984 South San Francisco, CA [Member] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Conversion of DownREIT units to common stock (in shares) Conversion of DownREIT units (in shares) Stock Issued During Period, Shares, Conversion of Units Common stock issuable (in shares) Common Stock, Convertible, Shares Issuable Common Stock, Convertible, Shares Issuable Loss (gain) on sales of real estate, net Gain (Loss) on Sale of Investments 817 Owasso, OK 817 Owasso, OK [Member] IN0004 Bloomington, IN IN0004 Bloomington, IN [Member] IN0004 Bloomington, IN Utilities Utilities Operating Expense Change in Supplemental Executive Retirement Plan obligation and other Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 1402 Hayward, CA 1402 Hayward, CA [Member] Federal Deferred Federal Income Tax Expense (Benefit) 2238 Louisville, KY 2238 Louisville, KY [Member] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Cash and cash equivalents Cash and Cash Equivalents, Including Discontinued Operations, Total Cash and Cash Equivalents, Including Discontinued Operations, Total Issuance of common stock, net (in shares) Stock Issued During Period, Shares, New Issues 582 Dallas, TX 582 Dallas, TX [Member] Senior unsecured notes Senior unsecured notes Unsecured Debt Proceeds from the collection of loans receivable Proceeds from Collection of Loans Receivable Statement of Financial Position Location, Activity, Accrual [Domain] Statement of Financial Position Location, Activity, Accrual [Domain] KY0010 Louisville, KY KY0010 Louisville, KY [Member] KY0010 Louisville, KY 1459 South San Francisco, CA 1459 South San Francisco, CA [Member] 3022 Seattle, WA 3022 Seattle, WA [Member] TN0001 Kingsport, TN TN0001 Kingsport, TN [Member] TN0001 Kingsport, TN During May 2026 to May 2027 Mortgage During May 2026 to May 2027 [Member] Mortgage During May 2026 to May 2027 3021 Frisco, TX 3021 Frisco, TX [Member] Variable Interest Entities [Abstract] Variable Interest Entities [Abstract] Variable Interest Entities [Abstract] Equity Component [Domain] Equity Component [Domain] 735 Louisville, KY 735 Louisville, KY [Member] AZ0002 Avondale, AZ AZ0002 Avondale, AZ [Member] AZ0002 Avondale, AZ 2237 Louisville, KY 2237 Louisville, KY [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company CT0002 Plainville, CT CT0002 Plainville, CT [Member] CT0002 Plainville, CT 661 Las Vegas, NV 661 Las Vegas, NV [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Operating lease, percentage of annual lease escalations Operating Lease, Percentage Of Annual Lease Escalations Operating Lease, Percentage Of Annual Lease Escalations 1552 Hayward, CA 1552 Hayward, CA [Member] 576 Conroe, TX 576 Conroe, TX [Member] Accounts payable, accrued liabilities, and other liabilities Accounts payable, accrued liabilities, and other liabilities Accounts payable and Accrued Liabilities 2034 West Jordan, UT 2034 West Jordan, UT [Member] PA0011 Wyomissing, PA PA0011 Wyomissing, PA [Member] PA0011 Wyomissing, PA Counterparty Name [Axis] Counterparty Name [Axis] 1411 South San Francisco, CA 1411 South San Francisco, CA [Member] Consolidation Items [Domain] Consolidation Items [Domain] Interest paid, net of capitalized interest Interest Paid, Excluding Capitalized Interest, Operating

Activities 3102 South San Francisco, CA 3102 South San Francisco CA [Member] Funding for construction, tenant and other capital improvements Payments to Acquire Productive Assets Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] MN0011 Stillwater, MN MN0011 Stillwater, MN [Member] MN0011 Stillwater, MN Revision of Prior Period [Domain] Revision of Prior Period [Domain] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Loans receivable, extension fee Loans Receivable, Extension Fee Loans Receivable, Extension Fee Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] CO0004 Thornton, CO CO0004 Thornton, CO [Member] CO0004 Thornton, CO Issuance of OP units criteria redemption (in units) Units Issued During Period, New Issues, Criteria Redemption Units Issued During Period, New Issues, Criteria Redemption Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other Assets, Net Other Assets, Net [Policy Text Block] Other Assets, Net 351 Washington Terrace, UT 351 Washington Terrace, UT [Member] PropTech PropTech [Member] PropTech Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer South San Francisco JVs South San Francisco JVs [Member] South San Francisco JVs 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four MN0019 Maplewood, MN MN0019 Maplewood, MN [Member] MN0019 Maplewood, MN FL 00026 Stuart, FL [Member] FL0026 Stuart, FL IN0005 Bloomington, IN IN0005 Bloomington, IN [Member] IN0005 Bloomington, IN 2028 Term Loan 2028 Term Loan [Member] 2028 Term Loan Investments in loans receivable and other Payments To Acquire Loans Receivable And Other Payments To Acquire Loans Receivable And Other Amortization of nonrefundable entrance fee Amortization Of Nonrefundable Entrance Fee Amortization Of Nonrefundable Entrance Fee Weighted average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Resident fees and services Disposal Group Including Discontinued Operation Resident Fees And Services Disposal Group Including Discontinued Operation Resident Fees And Services Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities 467 Salt Lake City, UT 467 Salt Lake City, UT [Member] MN0015 Little Falls, MN MN0015 Little Falls, MN [Member] MN0015 Little Falls, MN 2025 Leases with Purchase Option Future Minimum Annualized Base Rent Receivable Next Twelve Months Future annualized base rental payments receivable within one year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Cash proceeds Proceeds from Real Estate and Real Estate Joint Ventures Other accounts payable and accrued liabilities Other Accounts Payable and Accrued Liabilities Initial direct costs Initial Direct Costs, Net Initial Direct Costs, Net Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] AZ0007 Phoenix, AZ AZ0007 Phoenix, AZ [Member] AZ0007 Phoenix, AZ 631 Nashville, TN 631 Nashville, TN [Member] Issuance of common stock, net Stock Issued During Period, Value, New Issues Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] CCRC resident loans CCRC Resident Loans [Member] CCRC Resident Loans Shares issued as part of the Merger Stock Issued During Period, Value, Acquisitions 3092 Sun City Center, FL 3092 Sun City Center, FL [Member] 1430 South San Francisco, CA 1430 South San Francisco, CA [Member] Variable Rate Component One Variable Rate Component One [Member] Variable Rate Component One Arizona And Texas Arizona And Texas [Member] Arizona And Texas TX0A22 Flower Mound, TX TX0A22 Flower Mound, TX [Member] TX0A22 Flower Mound, TX Concentration Risk [Line Items] Concentration Risk [Line Items] State income tax benefit (expense), net of federal tax Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Cumulative dividends in excess of earnings Accumulated Distributions in Excess of Net Income Real Estate Investments Real Estate Disclosure [Text Block] Cash paid for amounts included in the measurement of lease liability for operating leases Operating Lease, Payments 638 Anchorage, AK 638 Anchorage, AK [Member] Number of unconsolidated joint ventures Number of Unconsolidated Joint Venture Represents number of unconsolidated joint ventures between entity and an institutional capital partner. Lab Buildings Lab Buildings [Member] Properties that are part of continuing operations, and which are classified as life science. 659 Los Gatos, CA 659 Los Gatos, CA [Member] Corporate non-segment operating expenses. Corporate Non-Segment Operating Expenses Corporate Non-Segment Operating Expenses Ownership [Domain] Ownership [Domain] Rental and related revenues related to amortization of net below market lease liabilities Amortization of Below Market Lease Intangibles Net Additional Revenue This element represents the additional revenue from amortization of net below market lease intangibles. Sorrento Therapeutics, Inc. Sorrento Therapeutics, Inc. [Member] Sorrento Therapeutics, Inc. Share Repurchase Program [Axis] Share Repurchase Program [Axis] Previously Reported Previously Reported [Member] 598 Sugar Land, TX 598 Sugar Land, TX [Member] Volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate TX32429 Webster, TX TX32429 Webster, TX [Member] TX3249 Webster, TX Face Amount of Mortgages SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages Prepayment of rent Payments for Rent Operating Disposal Group, Including Discontinued Operation, Operating Expense Retained investments in connection with joint ventures Noncash or Part Noncash, Retained Investments In Connection With Joint Ventures Noncash or Part Noncash, Retained Investments In Connection With Joint Ventures Business Combinations Business Combinations Policy [Policy Text Block] Investments in and Advances to Unconsolidated Joint Ventures Equity Method Investments and Joint Ventures Disclosure [Text Block] Loss (gain) upon change of control, net Gain (Loss) From Change Of Control Gain (Loss) From Change Of Control 1038 Fresno, CA 1038 Fresno, CA [Member] Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Mezzanine loans Mezzanine Loans [Member] Mezzanine Loans Operating Activities [Domain] Operating Activities [Domain] Land and improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land ME0001 Brunswick, ML ME0001 Brunswick, ML [Member] ME0001 Brunswick, ML Entity Address, City or Town Entity Address, City or Town LTIP Units LTIP Units [Member] LTIP Units Dispositions of Real Estate and Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Distributions in excess of earnings from unconsolidated joint ventures Distributions in Excess of Earnings from Unconsolidated Joint Ventures The cash inflow from unconsolidated joint ventures in which the entity does not have sufficient US GAAP earnings (accumulated or in the current period) to distribute funds to partners, thereby constituting a return of investment. Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Schedule of Intangible Lease Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Senior Unsecured Notes Due 2031 Senior Unsecured Notes Due 2031 [Member] Senior Unsecured Notes Due 2031 GA0024 Atlanta, GA GA0024 Atlanta, GA [Member] GA0024 Atlanta, GA Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Stock repurchase program, total value Treasury Stock, Value, Acquired, Cost Method Severance costs Severance Costs NE0002 Omaha, NE NE0002 Omaha, NE [Member] NE0002 Omaha, NE Net discount on mortgage debt Premiums, (discounts), and debt issuance costs, net Debt Instrument, Unamortized Discount (Premium), Net 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Undiscounted minimum lease payments included in the lease liability Lessee, Operating Lease, Liability, to be Paid 1427 La Jolla, CA 1427 La Jolla, CA [Member] 1551 Hayward, CA 1551 Hayward, CA [Member] 3115 Cambridge, MA 3115 Cambridge, MA [Member] 596 N Richland Hills, TX 596 North Richland Hills, TX [Member] KY0001 Louisville, KY KY0001 Louisville, KY [Member] KY0001 Louisville, KY 2040 Mesa, AZ 2040 Mesa, AZ [Member] Insider Trading Arrangements [Line Items] 590 Irving, TX 590 Irving, TX [Member] 434 Atlantis, FL 434 Atlantis, FL [Member] Noncontrolling interestsâ€™ share of consolidated joint venture operating expenses Operating Expenses From Joint Venture Attributable To Noncontrolling Interest Operating Expenses From Joint Venture Attributable To Noncontrolling Interest Financial Instrument Performance Status [Axis] Financial Instrument Performance Status [Axis] TRS Taxable Real Estate Investment Subsidiaries [Member] Represents information pertaining to the Company's certain subsidiaries which are treated as taxable Real Estate Investment Trust subsidiaries ("TRS" or "TRS entities). 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three 2964 Okeechobee, FL 2964 Okeechobee, FL [Member] Depreciation and amortization expense related to amortization of lease-up intangibles Amortization of Lease Up and Non Compete Agreement Intangibles Additional Expense This element represents the additional expense from amortization of lease-up and non-compete agreement intangibles. Capital expenditure funding, amount committed Capital Expenditure Funding, Amount Committed Capital Expenditure Funding, Amount Committed 2620 Fort Worth, TX 2620 Fort Worth, TX [Member] Sunrise Senior Housing Portfolio Sunrise Senior Housing Portfolio [Member] Sunrise Senior Housing Portfolio Document Transition Report Document Transition Report 143 Lufkin, TX 143 Lufkin, TX [Member] Severance Expense Related to Elimination of Certain Positions Severance Expense Related To Elimination Of Certain Positions [Member] Severance Expense Related To Elimination Of Certain Positions Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Joint venture partners Noncontrolling Interest in Joint Ventures MD0002 Lanham, MD MD0002 Lanham, MD [Member] MD0002 Lanham, MD Customer [Domain] Customer [Domain] 2579 Punta Gorda, FL 2579 Punta Gorda, FL [Member] Interest expense related to fees and amortization of debt issuance costs Amortization of Debt Issuance Costs TX0031 Rockwall, TX TX0031 Rockwall, TX [Member] TX0031 Rockwall, TX 628 Nashville, TN 628 Nashville, TN [Member] 520 Chandler, AZ 520 Chandler, AZ [Member] 2036 West Jordan, UT 2036 West Jordan, UT [Member] 3025 Webster, TX 3025 Webster, TX [Member] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Investments in and advances to unconsolidated joint ventures Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures TX0033 Denton, TX TX0033 Denton, TX [Member] TX0033 Denton, TX W10005 Brookfield, WI W10005 Brookfield, WI [Member] W10005 Brookfield, WI Net operating loss carryforwards subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Letter of credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name 3216 McKinney, TX 3216 McKinney, TX [Member] 3216 McKinney, TX Income (loss) from continuing operations applicable to common shares Net Income Loss Continuing Operations Available To Common Stockholders Basic Net Income Loss Continuing Operations Available To Common Stockholders Basic 1441 South San Francisco, CA 1441 South San Francisco, CA [Member] AR0001 Little Rock, AR AR0001 Little Rock, AR [Member] AR0001 Little Rock, AR 2965 Aurora, CO 2965 Aurora, CO [Member] 2965 Aurora, CO Merger-related post-combination stock compensation expense Noncash Merger Related Costs Estimated aggregate amortization of Intangible Assets Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Senior Unsecured Notes 3.40% Senior Unsecured Notes 3.40% [Member] Senior Unsecured Notes 3.40% Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Cover [Abstract] Cover [Abstract] Healthpeakâ€™s share of unconsolidated joint venture government grant income Real Estate Revenues From Joint Venture Government Grant Income Real Estate Revenues From Joint Venture Government Grant Income 1513 Redwood City, CA 1513 Redwood City, CA [Member] Depreciation and amortization of lease-up intangibles Lease-Up Intangible Assets, Accumulated Depreciation And Amortization Lease-Up Intangible Assets, Accumulated Depreciation And Amortization 579 Conroe, TX 579 Conroe, TX [Member] Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest IL0005 Palos Heights, IL IL0005 Palos Heights, IL [Member] IL0005 Palos Heights, IL 1385 Seattle, WA 1385 Seattle, WA [Member] 510 Thornton, CO 510 Thornton, CO [Member] Common dividends, per share (in dollars per share) Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared 564 San Jose, CA 564 San Jose, CA [Member] 2026 Lessor, Operating Lease, Payment to be Received, Year Two 1078 Flowood, MS 1078 Flowood, MS [Member] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Area of square feet with early termination right Operating Lease, Area Of Square Feet With Early Termination Right Operating Lease, Area Of Square Feet With Early Termination Right Unrealized gains (losses) on derivatives, net AOI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Earnings per Share Earnings Per Share, Policy [Policy Text Block] 601 Corpus Christi, TX 601 Corpus Christi, TX [Member] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Income (loss) from continuing operations Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Hedging Relationship [Domain] Hedging Relationship [Domain] 355 Salt Lake City, UT 355 Salt Lake City, UT [Member] Proceeds received from options exercised Proceeds from Stock Options Exercised AZ00021 Glendale, AZ AZ0001 Glendale, AZ [Member] AZ0001 Glendale, AZ Award Timing Disclosures [Line Items] PA0004 Carlisle, PA PA0004 Carlisle, PA [Member] PA0004 Carlisle, PA Segment Reporting Segment Reporting, Policy [Policy Text Block] Plan Name [Domain] Plan Name [Domain] 627 Nashville, TN 627 Nashville, TN [Member] 3004 Highland Park, IL 3004 Highland Park, IL [Member] Proceeds from sale of lease receivables Proceeds from Sale of Lease Receivables Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents CA0003 Walnut Creek, CA CA0003 Walnut Creek, CA [Member] CA0003 Walnut Creek, CA Deferred Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Receivable Type [Axis] Receivable Type [Axis] 839 San Diego, CA 839 San Diego, CA [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] 1462 South San Francisco, CA 1462 South San Francisco, CA [Member] WA0006 Gig Harbor, WA WA0006 Gig Harbor, WA [Member] WA0006 Gig Harbor, WA KY0012 Lexington, KY KY0012 Lexington, KY [Member] KY0012 Lexington, KY Mortgage Debt Secured Debt [Member] Senior unsecured notes Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Senior Unsecured Notes Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Senior Unsecured Notes 663 Las Vegas, NV 663 Las Vegas, NV [Member] Outpatient Medical Buildings Outpatient Medical Buildings [Member] Properties that are part of continuing operations, and which are classified as medical office. TX0020 Lufkin, TX TX0020 Lufkin, TX [Member] TX0020 Lufkin, TX Mortgage loan on real estate, multiple due 2025 to 2028 Mortgage Loans On Real Estate Interest Multiple, Due 2025 To 2028 [Member] Mortgage Loans On Real Estate Interest Multiple, Due 2025 To 2028 1199 Denver, CO [Member] Number of redeemable noncontrolling interest Number Of Redeemable Noncontrolling Interest Number Of Redeemable Noncontrolling Interest Straight-line rents Straight line rent Straight Line Rent Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] 1555 Hayward, CA 1555 Hayward, CA [Member] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Insider Trading Policies and Procedures [Line Items] Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] CO0005 Englewood, CO CO0005 Englewood, CO [Member] CO0005 Englewood, CO Use of Estimates Use of Estimates, Policy [Policy Text Block] IN0022 Indianapolis, IN IN0022 Indianapolis, IN [Member] IN0022 Indianapolis, IN 578 Conroe, TX 578 Conroe, TX [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Disposal Group Classification [Axis] Disposal Group Classification [Axis] Entity Small Business Entity Small Business Accounts Payable, Accrued Liabilities, and Other Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] 357 Orem, UT 357 Orem, UT [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Capital expenditure funding, amount funded Capital Expenditure Funding, Amount Funded Capital Expenditure Funding, Amount Funded 2545 Houston, TX 2545 Houston, TX [Member] Audit Information [Abstract] Audit Information NumberA of Properties Leases with Purchase Option Future Minimum Annualized Payments Receivable Number of Properties [Abstract] Leases with Purchase Option Future Minimum Annualized Payments Receivable Number of Properties [Abstract] 3090 Bradenton, FL 3090 Bradenton, FL [Member] IN0020 Carmel, IN IN0020 Carmel, IN [Member] IN0020 Carmel, IN 2619 Fort Worth, TX 2619 Fort Worth, TX [Member] AL0003 Fairhope, AL AL0003 Fairhope, AL [Member] AL0003 Fairhope, AL Allowance for accounts receivable Accounts Receivable, Allowance for Credit Loss TX0023 Carrollton, TX TX0023 Carrollton, TX [Member] TX0023 Carrollton, TX Schedule of Common Stock Distributions Schedule Of Dividends And Distributions [Table Text Block] Schedule Of Dividends And Distributions [Table Text Block] Downreit Partnerships Downreit Partnerships [Member] Represents a joint venture, DownREIT Partnerships. Common Stock Options Share-Based Payment Arrangement, Option [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total comprehensive income (loss) attributable to Healthpeak Properties, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Repayments under bank line of credit and commercial paper Repayments of Lines of Credit 3005 Lockport, IL 3005 Lockport, IL [Member] 3005 Lockport, IL Award Type [Axis] Award Type [Axis] Interest Rate Swap, 2.54% Pay Rate Interest Rate Swap, 2.54% Pay Rate [Member] Interest Rate Swap, 2.54% Pay Rate 1437 South San Francisco, CA 1437 South San Francisco, CA [Member] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Repayments of debt Repayments of Debt ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities IN0013 Bloomington, IN IN0013 Bloomington, IN [Member] IN0013 Bloomington, IN Total noncontrolling interests Equity, Attributable to Noncontrolling Interest Schedule of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Percentage of performance metrics during performance period Percentage Of Performance Metrics During The Performance Period Represents information pertaining to the percentage of performance metrics for the performance period which is multiplied to the number of units granted to the participant. Continuing Operations Continuing Operations [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share TX0022 Flower Mound, TX TX0022 Flower Mound, TX [Member] TX0022 Flower Mound, TX

Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] 113 Glendale, AZ 113 Glendale, AZ [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] 2617 San Diego, CA 2617 San Diego, CA [Member] 2617 San Diego, CA [Member] 577 Conroe, TX 577 Conroe, TX [Member] Additions Valuation Allowances and Reserves Additions [Abstract] b7d34adf-2bf5-147d-53d6-c162579b23d2 2014 Incentive Plan Stock Based Compensation, 2014 Incentive Plan [Member] Information pertaining to 2014 Performance Incentive Plan. IL0002 Bolingbrook, IL IL0002 Bolingbrook, IL [Member] IL0002 Bolingbrook, IL Term loans Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Term Loans Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Term Loans Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Term Loans Net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards 1483 Brisbane, CA 1483 Brisbane, CA [Member] Interest Rate SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate Refundable entrance fees Refundable Entrance Fees, Current and Noncurrent Refundable Entrance Fees, Current and Noncurrent Subsequent Event [Line Items] Subsequent Event [Line Items] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table] 1508 Redwood City, CA 1508 Redwood City, CA [Member] 1509 Redwood City, CA 1509 Redwood City, CA [Member] Corporate assets Property, Plant and Equipment, Gross WI0004 Milwaukee, WI WI0004 Milwaukee, WI [Member] WI0004 Milwaukee, WI 2709 Cambridge, MA 2709 Cambridge, MA [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] During June 2024 to June 2025 Mortgage During June 2024 To June 2025 [Member] Mortgage During June 2024 To June 2025 KY0005 Louisville, KY KY0005 Louisville, KY [Member] KY0005 Louisville, KY Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Capital expenditure funding, cost of capital, percent committed Capital Expenditure Funding, Cost Of Capital, Percent Committed Capital Expenditure Funding, Cost Of Capital, Percent Committed MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Mortgage loan on real estate, multiple due 2025 Mortgage Loans On Real Estate Interest Multiple, Due 2025 One [Member] Mortgage Loans On Real Estate Interest Multiple, Due 2025 One 1436 South San Francisco, CA 1436 South San Francisco, CA [Member] Total stockholdersâ€™ equity Equity, Attributable to Parent Net real estate Real Estate Investment Property, Net 2611 Allen, TX 2611 Allen, TX [Member] CA0004 Walnut Creek, CA CA0004 Walnut Creek, CA [Member] CA0004 Walnut Creek, CA 729 Albuquerque, NM 729 Albuquerque, NM [Member] 2024 Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Schedule of Goodwill Schedule of Goodwill [Table Text Block] Gain (loss) on sales of real estate, net Gains (Losses) on Sales of Investment Real Estate 2700 Zionsville, IN 2700 Zionsville, IN [Member] AR0004 Hot Springs Village, AR AR0004 Hot Springs Village, AR [Member] AR0004 Hot Springs Village, AR Maximum number of shares reserved for awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 2874 Brisbane, CA 2874 Brisbane, CA [Member] 2557 South San Francisco, CA 2557 South San Francisco, CA [Member] 2028 Long-Term Debt, Maturity, Year Four Dilutive potential common shares - equity awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Interest Rate Swap, 3.60% Pay Rate Interest Rate Swap, 3.60% Pay Rate [Member] Interest Rate Swap, 3.60% Pay Rate 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Depreciation and Amortization Depreciation, Depletion and Amortization [Member] Depreciation, Depletion and Amortization, Nonproduction [Member] NY0009 Hudson, NY NY0009 Hudson, NY [Member] NY0009 Hudson, NY Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate New mortgage loans SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan 2035 Draper, UT 2035 Draper, UT [Member] NE0004 Omaha, NE NE0004 Omaha, NE [Member] NE0004 Omaha, NE Debt instrument, facility fee (as a percent) Line of Credit Facility, Commitment Fee Percentage 2549 Houston, TX 2549 Houston, TX [Member] 2027 Debt Instrument, Redemption, Period Three [Member] Schedule of Information for the Reportable Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Other income (expense): Other Income and Expenses [Abstract] MI000A8 Traverse City, MI MI000A8 Traverse City, MI [Member] MI000A8 Traverse City, MI Debt instrument, collateral, healthcare facilities carrying value Debt Instrument, Collateral Healthcare Facilities, Carrying Value Carrying amount of healthcare facilities which are secured by mortgage debt. 571 Las Vegas, NV 571 Las Vegas, NV [Member] Debt instrument, periodic payment, principal Debt Instrument, Periodic Payment, Principal Debt instrument, covenant debt to assets (as a percent) Debt Instrument, Covenant Debt to Assets The limit of the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value contained in the debt covenants. Subsequent Event [Table] Subsequent Event [Table] Restricted cash Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash Maximum Maximum [Member] TX0021 Lufkin, TX TX0021 Lufkin, TX [Member] TX0021 Lufkin, TX IN0017 Lafayette, IN IN0017 Lafayette, IN [Member] IN0017 Lafayette, IN 1440 South San Francisco, CA 1440 South San Francisco, CA [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 1207 Irving, TX 1207 Irving, TX [Member] 3020 Frisco, TX 3020 Frisco, TX [Member] MO0001 Eenton, MO MO0001 Eenton, MO [Member] MO0001 Eenton, MO 2834 Louisville, KY 2834 Louisville, KY [Member] FL0004 Englewood, FL FL0004 Englewood, FL [Member] FL0004 Englewood, FL Other SEC Schedule, 12-28, Real Estate Companies, Accumulated Depreciation Other Distributions to and purchase of noncontrolling interests Payments to Noncontrolling Interests Schedule of Intangible Lease Liabilities Schedule of Finite Lived Intangible Liabilities by Major Class [Table Text Block] Tabular disclosure of liabilities, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. 1463 South San Francisco, CA 1463 South San Francisco, CA [Member] Name Outstanding Recovery, Individual Name AL0011 Huntsville, AL AL0011 Huntsville, AL [Member] AL0011 Huntsville, AL 1983 South San Francisco, CA 1983 South San Francisco, CA [Member] Summary of Dispositions of Real Estate and Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] 1405 Hayward, CA 1405 Hayward, CA [Member] Goodwill, impairment loss Goodwill, Impairment Loss Conversion of DownREIT units to common stock Stock Issued During Period, Value, Conversion of Units 3084 Holland, MI 3084 Holland, MI [Member] Award Timing Predetermined Award Timing Predetermined [Flag] 3093 Waltham, MA 3093 Waltham, MA [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] AZ0005 Phoenix, AZ AZ0005 Phoenix, AZ [Member] AZ0005 Phoenix, AZ Business Interruption Loss [Domain] Business Interruption Loss [Domain] Forecast Forecast [Member] Net income (loss) applicable to common shares (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Income (loss) from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Domestic 737 Louisville, KY 737 Louisville, KY [Member] 3215 Wylie, TX 3215 Wylie, TX [Member] 3215 Wylie, TX Ownership [Axis] Ownership [Axis] 603 Lake Worth, FL 603 Lake Worth, FL [Member] Carrying Amount of Mortgages Balance at beginning of year Balance at end of year SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Customer [Axis] Customer [Axis] 2848 Greer, SC 2848 Greer, SC [Member] Liabilities related to assets held for sale, net Liabilities Related To Assets Held For Sale, Net Liabilities Related To Assets Held For Sale, Net 2027 Lessor, Operating Lease, Payment to be Received, Year Three Non-managing member unitholders Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Preferred Unit Holders Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Preferred Unit Holders 1528 South San Francisco, CA 1528 South San Francisco, CA [Member] 1528 South San Francisco, CA Income tax benefit (expense) Income tax expense (benefit) Total income tax benefit (expense) from continuing operations Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] 678 San Diego, CA 678 San Diego, CA [Member] Derivative amount Derivative, Notional Amount Interest rate instruments Derivative Asset 9999 Denton, TX 9999 Denton, TX [Member] 3120 Cambridge, MA 3120 Cambridge, MA [Member] Two Outpatient Medical Buildings Two Outpatient Medical Buildings [Member] Two Outpatient Medical Buildings Bearing fixed interest rate (as a percent) Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Percentage of segment revenues Operating Lease, Income As Percent Of Revenues Operating Lease, Income As Percent Of Revenues Add: distributions on dilutive convertible units and other Dilutive Securities, Effect on Basic Earnings Per Share Schedule of Tenant Purchase Options Schedule of Tenant Purchase Options [Table Text Block] Schedule of Tenant Purchase Options [Table Text Block] total unrecognized compensation cost, period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 809 Englewood, CO 809 Englewood, CO [Member] 2033 Sandy, UT 2033 Sandy, UT [Member] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Interest expense Interest expense Interest Expense, Operating and Nonoperating Real estate acquisitions [Line Items] Business Acquisition [Line Items] Investments in Unconsolidated Joint Ventures Equity Method Investments [Policy Text Block] Weighted average remaining amortization period in years Acquired Finite-Lived Intangible Liabilities, Weighted Average Useful Life Acquired Finite-Lived Intangible Liabilities, Weighted Average Useful Life All Adjustments to Compensation All Adjustments to Compensation [Member] Schedule of Company Owned Interests in Entities, Accounted Under Equity Method Equity Method Investments [Table Text Block] Additional paid-in capital Additional Paid in Capital WI0006 Appleton, WI WI0006 Appleton, WI [Member] WI0006 Appleton, WI 700 Irving, TX 700 Irving, TX [Member] 2854 Greenville, SC 2854 Greenville, SC [Member] MS0002 Jackson, MS MS0002 Jackson, MS [Member] MS0002 Jackson, MS Scenario [Domain] Scenario [Domain] Rental and related revenues Operating Lease, Lease Income Name of Property [Domain] Name of Property [Domain] CT0002 Manchester, CT CT0002 Manchester, CT [Member] CT0002 Manchester, CT Total Lessor, Operating Lease, Payment to be Received Redeemable noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest, Equity, Carrying Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest, Equity, Carrying Amount 1423 San Diego CA 1423 San Diego, CA [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Prior Liens SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Prior Lien, Amount MN0016 Lake Elmo, MN MN0016 Lake Elmo, MN [Member] MN0016 Lake Elmo, MN TX0006 San Antonio, TX TX0006 San Antonio, TX [Member] TX0006 San Antonio, TX 2028 Leases with Purchase Option Future Minimum Annualized Base Rent Receivable in Four Years Future annualized base rental payments receivable within four year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. 633 Nashville, TN 633 Nashville, TN [Member] AZ0012 Mesa, AZ AZ0012 Mesa, AZ [Member] AZ0012 Mesa, AZ Financial Instruments [Domain] Financial Instruments [Domain] Unvested at the beginning of the period, Weighted Average Grant Date Fair Value (in dollars per share) Unvested at the end of the period, Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Number of properties, indemnification agreement Contribution Of Property, Number Of Properties Contribution Of Property, Number Of Properties Unsecured Term Loan [Member] Unsecured Term Loan Schedule IV: Mortgage Loans on Real Estate SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Text Block] TX0002 El Paso, TX TX0002 El Paso, TX [Member] TX0002 El Paso, TX Fair Value Estimate of Fair Value Measurement [Member] Amounts Charged Against Operations, net SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] 3154 South San Francisco, CA 3154 South San Francisco, CA [Member] 3154 South San Francisco, CA Schedule III: Real Estate and Accumulated Depreciation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block] Right-of-use asset, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] VA0002 Hampton, VA VA0002 Hampton, VA [Member] VA0002 Hampton, VA 561 Hermitage, TN 561 Hermitage, TN [Member] AL0010 Birmingham, AL AL0010 Birmingham, AL [Member] AL0010 Birmingham, AL Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Payments to acquire equity method investments Payments to acquire equity method investment Payments to Acquire Equity Method Investments 1054 Durant, OK 1054 Durant, OK [Member] California CALIFORNIA 691 Las Vegas, NV 691 Las Vegas, NV [Member] 2043 Overland Park, KS 2043 Overland Park, KS [Member] Earnings Per Common Share Earnings Per Share [Text Block] 3142 Brisbane, CA 3142 Brisbane CA [Member] Subsequent Event Subsequent Event [Member] Restricted cash Restricted Cash and Cash Equivalents, Current Net unrealized gains (losses) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Granted, Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Gain on investments Gain (Loss) on Investments GA0030 Buford, GA GA0030 Buford, GA [Member] GA0030 Buford, GA 2696 Scottsdale, AZ 2696 Scottsdale, AZ [Member] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Land and improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Land, Amount DownREIT units outstanding (in shares) Down REIT Units Outstanding The number of DownREIT units outstanding. Thereafter Leases with Purchase Option Number of Properties Thereafter Number of properties for which future annualized rental payments are receivable after the fifth year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Gross lease-up intangibles Lease-Up Intangible Assets, Gross Lease-Up Intangible Assets, Gross 2558 South San Francisco, CA 2558 South San Francisco, CA [Member] Accumulated depreciation and amortization Finite Lived Intangible Liabilities Accumulated Amortization Accumulated amount of amortization of liabilities, excluding financial liabilities, lacking physical substance with a finite life. Qualified business income for purpose of Code Section 199A (in dollars per share) Qualified Business Income, Code Section 199A Qualified Business Income, Code Section 199A PEO PEO [Member] Percentage of carrying amount Percentage Of Carrying Amount Percentage Of Carrying Amount Real Estate [Line Items] Real Estate [Line Items] Length of debt instrument extension period Debt Instrument, Period Of Extension Represents the length of the debt instrument extension period. 563 Orlando, FL 563 Orlando, FL [Member] Arizona ARIZONA Name Trading Arrangement, Individual Name Schedule of Amortization of Deferred Lease Costs and Acquisition Related Intangibles Schedule Of Finite-lived Intangible Assets And Below Market Lease Amortization Expense [Table Text Block] Schedule Of Finite-lived Intangible Assets And Below Market Lease Amortization Expense [Table Text Block] 2630 Lexington, MA 2630 Lexington, MA [Member] ARKANSAS ARKANSAS Severance Expense Due to Dual-Trigger Severance Arrangements Severance Expense Due To Dual-Trigger Severance Arrangements [Member] Severance Expense Due To Dual-Trigger Severance Arrangements 2555 South San Francisco, CA 2555 South San Francisco, CA [Member] Alabama ALABAMA 440 West Hills, CA 440 West Hills, CA [Member] 3139 Brisbane, CA 3139 Brisbane, CA [Member] 679 San Diego CA 679 San Diego, CA [Member] Schedule of Concentration of Credit Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] 2575 Florence, SC 2575 Florence, SC [Member] 1064 Lexington, KY 1064 Lexington, KY [Member] Performing loans Performing Financial Instruments [Member] TX0029 Midland, TX TX0029 Midland, TX [Member] TX0029 Midland, TX 570 Lone Tree, CO 570 Lone Tree, CO [Member] Depreciation and amortization of above market lease intangibles Above Market Lease Intangible Assets, Accumulated Depreciation And Amortization Above Market Lease Intangible Assets, Accumulated Depreciation And Amortization Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Debt instrument, period after closing Debt Instrument, Draw Time Period After Closing Debt Instrument, Draw Time Period After Closing Right-of-use asset Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset, Net Gain (loss) on sales of real estate, net Disposal Group, Including Discontinued Operation, Gross Profit (Loss) LIABILITIES And EQUITY Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Valuation allowance Deferred Tax Assets, Valuation Allowance TX0032 Ft. Worth, TX TX0032 Ft. Worth, TX [Member] TX0032 Ft. Worth, TX Impairments SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve, Amount MI0012 Petoskey, MI MI0012 Petoskey, MI [Member] MI0012 Petoskey, MI Draws and additions to existing mortgage loans SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Other Addition Provision for expected loan losses on funded loans receivable Financing Receivable, Excluding Accrued Interest, Credit Loss Expense (Reversal) 782 Seattle, WA 782 Seattle, WA [Member] 2020 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year MO0003 Kansas City, MO MO0003 Kansas City, MO [Member] MO0003 Kansas City, MO Residency agreement term, minimum Residency Agreement Term, Minimum Represents the minimum period specified under the residency agreement. Changes in: Increase (Decrease) in Operating Capital [Abstract] 2026 Scottsdale, AZ 2026 Scottsdale, AZ [Member] 2578 Naples, FL 2578 Naples, FL [Member] Section 897, capital distribution percentage Income Tax, Section 897 Gain (Loss) Percentage Income Tax, Section 897 Gain (Loss) Percentage 1511 Redwood City, CA 1511 Redwood City, CA [Member] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] 144 Longview, TX 144 Longview, TX [Member] Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged (in shares) Business Combination, Shares To Be Exchanged Business Combination, Shares To Be

Exchanged Common Stock Common Stock [Member] 1949 La Jolla, CA 1949 La Jolla, CA [Member] 3109 Cambridge, MA 3109 Cambridge, MA [Member] NE0012 Kearney, NE NE0012 Lincoln, NE [Member] NE0012 Lincoln, NE CA0002 Walnut Creek, CA CA0002 Walnut Creek, CA [Member] CA0002 Walnut Creek, CA Forgone Recovery due to Expense of Enforcement, Amount 602 Atlantis, FL 602 Atlantis, FL [Member] Gain on sale of direct financing lease Gain (Loss) on Sale of Financing Receivable Bank Line of Credit Line of Credit [Member] MN0017 Edina, MN MN0017 Edina, MN [Member] MN0017 Edina, MN Segment Reporting [Abstract] Segment Reporting [Abstract] Forward rate per share (in dollars per share) Forward Contract Indexed to Issuer's Equity, Forward Rate Per Share Scenario [Axis] Scenario [Axis] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] 2632 Lexington, MA 2632 Lexington, MA [Member] 2632 Lexington, MA Number of loans Number Of Loans Number Of Loans Number of properties classified as held for sale Properties Held for Sale, Number The number of properties held for sale at the reporting date. Discontinued Operations and Disposal Groups [Abstract] 3018 Wichita, KS 3018 Wichita, KS [Member] Corporate Segment Corporate Segment [Member] MN0002 Savage, MN MN0002 Savage, MN [Member] MN0002 Savage, MN Equity and Redeemable Noncontrolling Interests Equity [Text Block] Segment Disclosures Segment Reporting Disclosure [Text Block] MI0013 Rochester Hills, MI MI0013 Rochester Hills, MI [Member] MI0013 Rochester Hills, MI, MI 2025 Scottsdale, AZ 2025 Scottsdale, AZ [Member] Measurement Basis [Axis] Measurement Basis [Axis] 664 Las Vegas, NV 664 Las Vegas, NV [Member] Title Trading Arrangement, Individual Title Interest Rate Swap, 3.59% Pay Rate, One Interest Rate Swap, 3.59% Pay Rate, One [Member] Interest Rate Swap, 3.59% Pay Rate, One 1512 Redwood City, CA 1512 Redwood City, CA [Member] Consolidated Entities [Axis] Consolidated Entities [Axis] Healthpeakâ€™s share of unconsolidated joint venture operating expenses Operating Expenses From Joint Venture Attributable To Parent Net Operating Expenses From Joint Venture Attributable To Parent Net 1439 South San Francisco, CA 1439 South San Francisco, CA [Member] 353 Salt Lake City, UT 353 Salt Lake City, UT [Member] Geographic Concentration Risk Geographic Concentration Risk [Member] 2029 Leases With Purchase Option Number Of Properties In Five Years Leases With Purchase Option Future Minimum Annualized Payments Receivable Number Of Properties In Five Years Income tax benefit (expense) Discontinued Operation, Tax Effect of Discontinued Operation Development costs and construction in progress Development costs and construction in progress Development in Process Disposal Group Classification [Domain] Disposal Group Classification [Domain] Land and improvements Land and Land Improvements Real estate: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward] 2570 Limerick, PA 2570 Limerick, PA [Member] Equity investment, aggregate cost Equity Investment, Percentage Of Total Fund Commitments Equity Investment, Percentage Of Total Fund Commitments Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt Proceeds from Bank Debt Repurchase of common stock Payments for Repurchase of Common Stock 783 Seattle, WA 783 Seattle, WA [Member] 610 Kissimmee, FL 610 Kissimmee, FL [Member] MSREI MOB JV Morgan Stanley Real Estate Investment JV [Member] Morgan Stanley Real Estate Investment JV [Member] Florida FLORIDA 456 Layton, UT 456 Layton, UT [Member] IN0007 Bloomington, IN IN0007 Bloomington, IN [Member] IN0007 Bloomington, IN Noncontrolling interestâ€™ share in continuing operations Noncontrolling interestâ€™ share in continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Principal repayments received Proceeds from Collection of Finance Receivables 2840 Kingwood, TX 2840 Kingwood, TX [Member] Proceeds from insurance recovery Proceeds from Insurance Settlement, Investing Activities Proceeds from the South San Francisco JVs transaction, net Proceeds From Divestitures Of Interest In Joint Venture2 Proceeds From Divestitures Of Interest In Joint Venture2 3086 Jacksonville, FL 3086 Jacksonville, FL [Member] Net income (loss) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Schedule of Senior Unsecured Notes Schedule of Debt [Table Text Block] General and administrative General and administrative General and Administrative Expense Deferred income tax expense (benefit) Deferred Income Taxes and Tax Credits MD0001 Waldorf, MD MD0001 Waldorf, MD [Member] MD0001 Waldorf, MD Lease liability Operating Lease, Liability AL0005 Foley, AL AL0005 Foley, AL [Member] AL0005 Foley, AL Variable rate Loans Receivable, Basis Spread on Variable Rate Watch list loans Watch List Financing Receivable [Member] Represents a financing receivable that is being monitored closely in order to spot irregularities. Carrying Value Reported Value Measurement [Member] Sales and/or transfers to assets held for sale SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Cost of Investment in Real Estate Sold 2963 Brooksville, FL 2963 Brooksville, FL [Member] Financial Instrument Performance Status [Domain] Financial Instrument Performance Status [Domain] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] 2650 Biddeford, ME 2650 Biddeford, ME [Member] 2650 Biddeford, ME [Member] Debt Debt Disclosure [Text Block] Massachusetts MASSACHUSETTS Credit Losses Financing Receivable [Policy Text Block] TX0030 Pasadena, TX TX0030 Pasadena, TX [Member] Advertising expense Advertising Expense Interest rate swap instruments Interest Rate Swap [Member] 3008 West Hills, CA 3008 West Hills, CA [Member] 3008 West Hills, CA, FL0031 Wesley Chapel, FL FL0031 Wesley Chapel, FL [Member] FL0031 Wesley Chapel, FL Land and improvements Land Intangible liabilities acquired Finite-Lived Intangible Liabilities Acquired Finite-Lived Intangible Liabilities Acquired GA0010 Atlanta, GA GA0010 Atlanta, GA [Member] GA0010 Atlanta, GA Other SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Other Maximum borrowing capacity Debt Instrument, Maximum Borrowing Capacity Debt Instrument, Maximum Borrowing Capacity Receivable with imputed interest Receivable with Imputed Interest, Net Amount Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] 3121 Cambridge, MA 3121 Cambridge, MA [Member] Auditor Name Auditor Name 1442 South San Francisco, CA 1442 South San Francisco, CA [Member] Current period recoveries Current Period Recoveries [Member] Current Period Recoveries Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt Repayments of Bank Debt IN0016 Lafayette, IN IN0016 Lafayette, IN [Member] IN0016 Lafayette, IN Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Accrued construction costs Construction in Progress Expenditures Incurred but Not yet Paid Depreciation expense SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense Fair Value Measurement [Domain] Fair Value Measurement [Domain] AZ0003 Goodyear, AZ AZ0003 Goodyear, AZ [Member] AZ0003 Goodyear, AZ Proceeds from sales of real estate, net Proceeds from Sale, Real Estate, Held-for-Investment 2966 Houston, TX 2966 Houston, TX [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Class of Financing Receivable [Axis] Class of Financing Receivable [Axis] Deferred revenue Deferred Tax Assets, Deferred Income KY0009 Louisville, KY KY0009 Louisville, KY [Member] KY0009 Louisville, KY Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] 2234 Philadelphia, PA 2234 Philadelphia, PA [Member] TN0008 Spring Hill, TN TN0008 Spring Hill, TN [Member] TN0008 Spring Hill, TN Interest Rate Swap, 3.56% Pay Rate Interest Rate Swap, 3.56% Pay Rate [Member] Interest Rate Swap, 3.56% Pay Rate 2648 Concord, NH 2648 Concord, NH [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount MI0006 Grand Blanc, MI MI0006 Grand Blanc, MI [Member] MI0006 Grand Blanc, MI Termination Date Trading Arrangement Termination Date Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two MN0001 Edina, MN MN0001 Edina, MN [Member] MN0001 Edina, MN 2025 Long-Term Debt, Maturity, Year One ASSETS Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Number of Leases Number Of Leases Number Of Leases Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Net income (loss) attributable to Healthpeak Properties, Inc. Net Income (Loss) Net Income (Loss) Attributable to Parent Variable Interest Entities Variable Interest Entities [Text Block] The entire disclosure for variable interest entities, including description of the terms of arrangements and categorized by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. 2022 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Impairments and loan loss reserves, net Impairments And Allowance For Credit Loss Reserves Impairments And Allowance For Credit Loss Reserves 3009 Burnsville, MN 3009 Burnsville, MN [Member] Restricted cash Restricted Cash and Cash Equivalents, Including Discontinued Operations, Total Restricted Cash and Cash Equivalents, Including Discontinued Operations, Total Income Statement [Abstract] Income Statement [Abstract] 2552 The Woodlands, TX 2552 Woodlands, TX [Member] Name Forgone Recovery, Individual Name Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Noncontrolling Interests Noncontrolling Interests [Policy Text Block] Disclosure of accounting policy for noncontrolling interests. 1458 South San Francisco, CA 1458 South San Francisco, CA [Member] Other non-cash items Other Noncash Income (Expense) Rental Revenues And Resident Fees And Services Rental Revenues And Resident Fees And Services [Member] Rental Revenues And Resident Fees And Services Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Intangible liabilities, weighted average amortization, useful life Intangible Liabilities, Weighted Average Amortization, Useful Life Intangible Liabilities, Weighted Average Amortization, Useful Life Schedule of Company's Other Common Stock Activities Schedule of Stock by Class [Table Text Block] 2023 At-The-Market Program 2023 At-The-Market Program [Member] 2023 At-The-Market Program Gain (loss) on deconsolidation Deconsolidation, Gain (Loss), Amount Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share 2835 Pearland, TX 2835 Pearland, TX [Member] PA0006 Camp Hill, PA PA0006 Camp Hill, PA [Member] PA0006 Camp Hill, PA 3006 Arlington Heights, IL 3006 Arlington Heights, IL [Member] Cumulative Dividends In Excess Of Earnings Accumulated Distributions in Excess of Net Income [Member] Casualty-Related Losses Casualty-Related Losses [Member] Casualty-Related Losses 465 Salt Lake City, UT 465 Salt Lake City, UT [Member] Medical Office JVs Medical Office JVs [Member] Medical Office JVs [Member] MN0007 Minnetonka, MN MN0007 Minnetonka, MN [Member] MN0007 Minnetonka, MN 3016 Midlothian, VA 3016 Midlothian, VA [Member] Interest Rate Swap, 4.99% Pay Rate Interest Rate Swap, 4.99% Pay Rate [Member] Interest Rate Swap, 4.99% Pay Rate Real estate: Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment Property, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Real Estate Investment Property, Net Accumulated other comprehensive income (loss) Total accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Restricted cash Restricted Cash and Cash Equivalents Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] 3137 Cambridge, MA 3137 Cambridge, MA [Member] 2647 Concord, NH 2647 Concord, NH [Member] Basic (in shares) Basic weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Return to provision adjustments Effective Income Tax Rate Reconciliation, Return to Provision Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments. 352 Washington Terrace, UT 352 Washington Terrace, UT [Member] 2719 Marion, IL 2719 Marion, IL [Member] Term loan Loans Payable to Bank, Noncurrent Amortization of deferred financing costs and debt discounts (premiums) Amortization of Debt Issuance Costs and Discounts Real Estate [Table] Real Estate [Table] Name Awards Close in Time to MNPI Disclosures, Individual Name Percentage of Total Company Revenues Revenue Benchmark [Member] Gross contractual account receivables Business Combination, Acquired Receivables, Gross Contractual Amount 2998 Seminole, FL 2998 Seminole, FL [Member] 2631 Lexington, MA 2631 Lexington, MA [Member] AZ0011 Scottsdale, AZ AZ0011 Scottsdale, AZ [Member] AZ0011 Scottsdale, AZ Balance (in shares) Balance (in shares) Shares, Issued Schedule of Future Minimum Lease Payments Due Under Operating Leases Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Straight line rent receivable, net of allowances Straight Line Rent Receivable, Net Of Allowances Straight Line Rent Receivable, Net Of Allowances Compensation and property management Compensation And Property Management Compensation And Property Management 604 Englewood, FL 604 Englewood, FL [Member] Food Food Expense Food Expense Schedule of Other Lease Information Lease, Cost [Table Text Block] KY0002 Shepherdsville, KY KY0002 Shepherdsville, KY [Member] KY0002 Shepherdsville, KY 3087 The Villages, FL 3087 The Villages, FL [Member] Real Estate Real Estate, Policy [Policy Text Block] 3108 Cambridge, MA 3108 Cambridge, MA [Member] Encumbrances as of Year end SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances 2006 Incentive Plan Stock Based Compensation, 2006 Incentive Plan [Member] Represents 2006 Performance Incentive Plan approved by stockholders on May 11, 2006. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Redemption value Redeemable Noncontrolling Interest, Equity, Redemption Value All Trading Arrangements All Trading Arrangements [Member] Schedule of Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock-based awards, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Schedule of Consolidated Assets and Liabilities of Variable Interest Entities Schedule Of Variable Interest Entities Included In The Balance Sheet [Table Text Block] Tabular disclosure of the VIE's total asset and liabilities included in the consolidated balance sheet. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Schedule of Company's Lease Income, Excluding Discontinued Operation Direct Financing Lease, Lease Income [Table Text Block] Allowance Accounts SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Allowance Accounts Allowance Accounts [Member] This element represents the allowance accounts including the allowance for doubtful accounts, straight-line rent reserves, and allowances for loan and direct financing lease losses. Fourteen Outpatient Medical Buildings Fourteen Outpatient Medical Buildings [Member] Fourteen Outpatient Medical Buildings AR0002 Little Rock, AR AR0002 Little Rock, AR [Member] AR0002 Little Rock, AR Equity method investments Equity method investments Equity Method Investments Dispositions of 2023 Dispositions Of 2023 [Member] Dispositions Of 2023 Pay vs Performance Disclosure [Line Items] AZ00A7 Phoenix, AZ AZ00A7 Phoenix, AZ [Member] AZ00A7 Phoenix, AZ Derivative [Table] Derivative [Table] 1560 South San Francisco, CA 1560 South San Francisco, CA [Member] 2873 San Diego, CA 2873 San Diego, CA [Member] Texas TEXAS SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] 483 Wichita, KS 483 Wichita, KS [Member] Other Performance Measure, Amount Other Performance Measure, Amount 2039 Kansas City, KS 2039 Kansas City, KS [Member] 634 Nashville, TN 634 Nashville, TN [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Capital gains (in dollars per share) Real Estate Investment Trust, Distribution, Tax Status, Capital Gain, Per Unit 1422 San Diego, CA 1422 San Diego, CA [Member] Loans receivable, floor rate percentage Loans Receivable, Floor Rate Loans Receivable, Floor Rate AL0006 Birmingham, AL AL0006 Birmingham, AL [Member] AL0006 Birmingham, AL Callan Ridge JV Callan Ridge Joint Venture [Member] Callan Ridge Joint Venture Cash Flow Hedging Cash Flow Hedging [Member] Purchase of noncontrolling interest Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests WA0010 Lakewood, WA WA0010 Lakewood, WA [Member] WA0010 Lakewood, WA Term Loans Loans Payable [Member] Issuance of common stock and exercise of options, net of offering costs Proceeds from Issuance or Sale of Equity 2841 Greenville, SC 2841 Greenville, SC [Member] 3026 Bentonville, AR 3026 Bentonville, AR [Member] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Common stock repurchased (in shares) Treasury Stock, Shares, Acquired 2864 Washington Terrace, UT 2864 Washington Terrace, UT [Member] Plus: Adjustments to NOI Reconciliation Of Operating Profit Loss From Segments To Consolidated Non Cash Adjustments Represents the addback of straight-line rents, DFL accretion, amortization of market lease intangibles and lease termination fees from segment portfolio income to consolidated net income. Healthpeak OP Healthpeak OP [Member] Healthpeak OP 2553 South San Francisco, CA 2553 South San Francisco, CA [Member] 400 Harrison, OH 400 Harrison, OH [Member] 2967 Nashville, TN 2967 Nashville, TN [Member] 2026 Debt Instrument, Redemption, Period Two [Member] Adjusted NOI for reportable segments Adjusted Net Operating Income from Continuing Operations Adjusted NOI is a non-GAAP supplemental financial measure used to evaluate the operating performance of real estate. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles and lease termination fees (non cash adjustments?). Adjusted NOI is oftentimes referred to as ?cash NOI.? The Company uses adjusted NOI to make decisions about resource allocations, and to assess and compare property level performance. The Company believes that net income (loss) is the most directly comparable U.S. GAAP measure to adjusted NOI. Adjusted NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, the Company's definition of Adjusted NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating Adjusted NOI. 1985 South San Francisco, CA

1985 South San Francisco, CA [Member] Success-Based Payments Related to Service Providers Success-Based Payments Related to Service Providers [Member] Success-Based Payments Related to Service Providers 1419 San Diego, CA 1419 San Diego CA [Member] At-The-Market Program At-The-Market Program [Member] At-The-Market Program [Member] 3074 Cambridge, MA 3074 Cambridge, MA [Member] TX0025 Austin, TX TX0025 Austin, TX [Member] TX0025 Austin, TX 2476 San Diego, CA 2476 San Diego, CA [Member] 2694 Anderson, SC 2694 Anderson, SC [Member] Life Science Joint Venture In San Francisco, California Life Science Joint Venture In San Francisco, California [Member] Life Science Joint Venture In San Francisco, California PA0010 Hanover, PA PA0010 Hanover, PA [Member] PA0010 Hanover, PA Interest Rate Swap, 3.58% Pay Rate Interest Rate Swap, 3.58% Pay Rate [Member] Interest Rate Swap, 3.58% Pay Rate Share-based payment arrangement, amount capitalized Share-Based Payment Arrangement, Amount Capitalized 812 Littleton, CO 812 Littleton, CO [Member] 3085 Seminole, FL 3085 Seminole, FL [Member] Receivable [Domain] Receivable [Domain] MI0011 Gross Pointe, MI MI0011 Gross Pointe, MI [Member] MI0011 Gross Pointe, MI MA5394 Cambridge, MA MA5394 Cambridge, MA [Member] MA5394 Cambridge, MA Lease and other contractual commitments Lease and other commitment [Member] Lease and other commitment [Member] Contributions from noncontrolling interests Temporary Equity, Noncontrolling Interest, Contributions From Noncontrolling Interest Temporary Equity, Noncontrolling Interest, Contributions From Noncontrolling Interest 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five 3069 San Diego, CA 3069 San Diego, CA [Member] 805 Fort Worth, TX 805 Fort Worth, TX [Member] MD0003 Brandywine, MD MD0003 Brandywine, MD [Member] MD0003 Brandywine, MD Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] 2548 Houston, TX 2548 Houston, TX [Member] Outstanding balance Loans Receivable, Outstanding Balance Loans Receivable, Outstanding Balance Outpatient medical Medical Office [Member] Properties that are part of continuing operations, and which are classified as medical office. Ventures V, LLC Ventures V, LLC [Member] Represents information pertaining to HCP Ventures V. Cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 1065 Marion, IL 1065 Marion, IL [Member] Nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Equity loss (income) from unconsolidated joint ventures Income Loss From Equity Method Investments, Including Discontinued Operations Income Loss From Equity Method Investments, Including Discontinued Operations Proceeds from nonrefundable entrance fees Proceeds From Nonrefundable Entrance Fees Proceeds From Nonrefundable Entrance Fees Initial Cost to Company SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount 2845 Greenville, SC 2845 Greenville, SC [Member] Costs Capitalized Subsequent to Acquisition Real Estate and Accumulated Depreciation, Costs Capitalized Subsequent to Acquisition Carrying amount as of the balance sheet date of costs that were capitalized after acquisition, including property improvements and carrying costs (for example, real estate taxes and insurance), but excluding the initial purchase price. 3017 Midlothian, VA 3017 Midlothian, VA [Member] Number of interest-rate contracts held Number of Interest Rate Derivatives Held Secured loan Number of Secured Loans Number of Secured Loans 1060 Jackson, MS 1060 Jackson, MS [Member] TN0011 Franklin, TN TN0011 Franklin, TN [Member] TN0011 Franklin, TN 2698 Mooresville, IN 2698 Mooresville, IN [Member] 3110 San Diego, CA 3110 San Diego, CA [Member] NY0012 Lake Katrine, NY NY0012 Lake Katrine, NY [Member] NY0012 Lake Katrine, NY 1413 South San Francisco, CA 1413 South San Francisco, CA [Member] Security Exchange Name Security Exchange Name Loan, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate 3100 South San Francisco, CA 3100 South San Francisco CA [Member] MS0001 Grenada, MS MS0001 Grenada, MS [Member] MS0001 Grenada, MS 112 Overland Park, KS 112 Overland Park, KS [Member] GA0032 Dunwoody, GA GA0032 Dunwoody, GA [Member] GA0032 Dunwoody, GA Total costs and expenses Disposal Group Including Discontinued Operation Total Costs And Expenses Disposal Group Including Discontinued Operation Total Costs And Expenses 3073 Lexington, MA 3073 Lexington, MA [Member] Impairments of Real Estate Asset Impairment Charges [Text Block] State Current State and Local Tax Expense (Benefit) Legal, Accounting, Tax, and Other Costs Legal, Accounting, Tax, And Other Costs [Member] Legal, Accounting, Tax, And Other Costs 2574 Florence, SC 2574 Florence, SC [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] FL0008 Lady Alke, FL FL0008 Lady Alke, FL [Member] FL0008 Lady Alke, FL 169 Bountiful, UT 169 Bountiful, UT [Member] Settlement of Physicians Realty Trustâ€™s transaction costs Payments To Acquire Businesses, Gross, Settlement Of Transaction Costs Payments To Acquire Businesses, Gross, Settlement Of Transaction Costs [Member] TX0014 Katy, TX TX0014 Katy, TX [Member] TX0014 Katy, TX 2572 Springdale, AR 2572 Springdale, AR [Member] Concentration risk (as a percent) Concentration Risk, Percentage Assets held for sale, net Disposal Group, Including Discontinued Operation, Assets Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] NY0002 Walkkill, NY NY0002 Walkkill, NY [Member] NY0002 Walkkill, NY Common stock, shares authorized (in shares) Common Stock, Shares Authorized Intangibles Intangible Assets and Liabilities Disclosure [Text Block] This block of text may be used to disclose all or part of the information related to intangible assets and liabilities. Capitalized costs Debt Costs Capitalized Debt Costs Capitalized Other Other Non-Reporting Segment [Member] Represents the information pertaining to other non-reporting segment Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Entity Voluntary Filers Entity Voluntary Filers Net income (loss) Temporary Equity, Net Income 3101 South San Francisco, CA 3101 South San Francisco CA [Member] Segment Disclosure Segment Reporting, Asset Reconciling Item [Line Items] Loan receivable, extended maturity term Loans Receivable, Extended Maturity Term Loans Receivable, Extended Maturity Term Hedging Designation [Domain] Hedging Designation [Domain] Government Assistance, CARES Act Government Assistance, CARES Act [Member] Government Assistance, CARES Act Casualty-related loss (recoveries), net Insured event loss Insured Event, Gain (Loss) 1412 South San Francisco, CA 1412 South San Francisco, CA [Member] TX0024 Flower Mound, TX TX0024 Flower Mound, TX [Member] TX0024 Flower Mound, TX PA0013 West Mifflin, PA PA0013 West Mifflin, PA [Member] PA0013 West Mifflin, PA Assets Held for Sale and Discontinued Operations Discontinued Operations, Policy [Policy Text Block] Noncontrolling interest, ownership percentage by parent Subsidiary, Ownership Percentage, Parent PA0005 Hershey, PA PA0005 Hershey, PA [Member] PA0005 Hershey, PA Long-term debt Long-Term Debt Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component AZ0014 Scottsdale, AZ AZ0014 Scottsdale, AZ [Member] AZ0014 Scottsdale, AZ 1052 Towson, MD 1052 Towson, MD [Member] 3136 Cambridge, MA 3136 Cambridge, MA [Member] Variable interest, amount Long-Term Debt, Percentage Bearing Variable Interest, Amount 2703 Columbia, MO 2703 Columbia, MO [Member] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] TX0012 Carrollton, TX TX0012 Carrollton, TX [Member] TX0012 Carrollton, TX Amount that the tax basis of the Company's net real estate is less than the reported amounts Real Estate Federal Income Tax Basis Less than Reported Net Assets The amount by which the tax basis of the entity's net real estate is less than the reported amounts as of year-end. Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] 446 Houston, TX 446 Houston, TX [Member] Investments in and advances to unconsolidated joint ventures Investments in and advances to unconsolidated joint ventures Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 2023 Scottsdale, AZ 2023 Scottsdale, AZ [Member] ND0001 Jamestown, ND ND0001 Jamestown, ND [Member] ND0001 Jamestown, ND 2026 Leases with Purchase Option Future Minimum Annualized Base Rent Receivable in Two Years Future annualized base rental payments receivable within second year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. 2995 Port Charlotte, FL 2995 Port Charlotte, FL [Member] IL0002 Elgin, IL IL0002 Elgin, IL [Member] IL0002 Elgin, IL Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period 2853 Greenville, SC 2853 Greenville, SC [Member] 3000 Lone Tree, CO 3000 Lone Tree, CO [Member] 2618 San Diego, CA 2618 San Diego, CA [Member] 2618 San Diego, CA [Member] 2233 Lone Tree, CO 2233 Lone Tree, CO [Member] n/a Total Stockholdersâ€™ Equity Parent [Member] Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate WI0001 West Allis, WI WI0001 West Allis, WI [Member] WI0001 West Allis, WI Above market lease, intangibles Above Market Lease, Intangibles Above Market Lease, Intangibles Adjustments to redemption value of redeemable noncontrolling interests Adjustments Of Permanent Equity To Temporary Equity Adjustments Of Permanent Equity To Temporary Equity Accounting Policies [Abstract] Accounting Policies [Abstract] Revenues: Revenues [Abstract] 1208 Fairfax, VA 1208 Fairfax, VA [Member] FL0012 Atlantis, FL FL0012 Atlantis, FL [Member] FL0012 Atlantis, FL IN0001 Mishawaka, IN IN0001 Mishawaka, IN [Member] IN0001 Mishawaka, IN PEO Name PEO Name 3116 Cambridge, MA 3116 Cambridge, MA [Member] TX0018 The Woodlands, TX TX0018 The Woodlands, TX [Member] TX0018 The Woodlands, TX Government Grant Income Government Grant Income Policy [Policy Text Block] Government Grant Income Policy 240 Minneapolis, MN 240 Minneapolis, MN [Member] Award Type [Domain] Award Type [Domain] 1986 South San Francisco, CA 1986 South San Francisco, CA [Member] 1986 South San Francisco, CA [Member] 2025 Lessor, Operating Lease, Payment to be Received, Year One Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] FL0033 Atlantis, FL FL0033 Atlantis, FL [Member] FL0033 Atlantis, FL CT0003 Manchester, CT CT0003 Manchester, CT [Member] CT0003 Manchester, CT Non-PEO NEO Non-PEO NEO [Member] Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets DE0001 Dover, DE DE0001 Dover, DE [Member] DE0001 Dover, DE Government grant income recorded in income (loss) from discontinued operations Income Loss From Discontinued Operations [Member] Income Loss From Discontinued Operations 2028 Leases with Purchase Option Number of Properties in Four Years Number of properties for which future annualized rental payments are receivable within fourth year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Derivative, basis spread on variable rate Derivative, Basis Spread on Variable Rate Accumulated depreciation and amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Operating Activities [Axis] Operating Activities [Axis] 2708 Cambridge, MA 2708 Cambridge, MA [Member] Remaining loans receivable commitments Loans and Leases Receivable, Remaining Commitments Loans and Leases Receivable, Remaining Commitments 581 Corpus Christi, TX 581 Corpus Christi, TX [Member] Graphite Bio, Inc Graphite Bio, Inc [Member] Graphite Bio, Inc 2721 Dallas, TX 2721 Dallas, TX [Member] 2571 Wilkes-Barre, PA 2571 Wilkes-Barre, PA [Member] Gross intangible lease liabilities Finite Lived Intangible Liabilities, Gross Amount before amortization of liabilities, excluding financial liabilities, lacking physical substance with a finite life. Credit loss reserve on unfunded loan commitments Financing Receivable Allowance For Credit Loss Unfunded Loan Commitments Financing Receivable Allowance For Credit Loss Unfunded Loan Commitments Life on Which Depreciation in Latest Income Statement is Computed SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation Senior Unsecured Term Loan Senior Unsecured Term Loan [Member] Senior Unsecured Term Loan Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Investments in loans receivable Investments In Loans Receivable Investments In Loans Receivable Number of joint ventures Number Of Joint Ventures Number Of Joint Ventures 597 Plano, TX 597 Plano, TX [Member] 1487 Brisbane, CA 1487 Brisbane, CA [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Restricted cash Disposal Group Including Discontinued Operation Restricted Cash And Cash Equivalents Disposal Group Including Discontinued Operation Restricted Cash And Cash Equivalents Dilutive net income (loss) available to common shares Net Income (Loss) Available to Common Stockholders, Diluted Total noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest 464 Salt Lake City, UT 464 Salt Lake City, UT [Member] 2576 Statesboro, GA 2567 Statesboro, GA [Member] Capitalized interest Interest Costs Capitalized 838 San Diego, CA 838 San Diego, CA [Member] Auditor Firm ID Auditor Firm ID Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] 1315 Dallas, TX 1315 Dallas, TX [Member] Hedging Designation [Axis] Hedging Designation [Axis] Joint venture partners Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Joint Ventures Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Joint Ventures Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] FL0030 Pensacola, FL FL0030 Pensacola, FL [Member] FL0030 Pensacola, FL 2403 Philadelphia, PA 2403 Philadelphia, PA [Member] GA3246 Pooler, GA GA3246 Pooler, GA [Member] GA3246 Pooler, GA Dividends paid on common stock Payments of Dividends Loans receivable, number of extensions Loans Receivable, Number Of Extensions Loans Receivable, Number Of Extensions Needham Land Parcel JV Variable Interest Entity Not Primary Beneficiary Investment In Joint Venture [Member] Information related to investments in an unconsolidated joint venture, which is a Variable Interest Entity (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. Summary of Stated Debt Maturities and Scheduled Principal Repayments Schedule of Maturities of Long-Term Debt [Table Text Block] 2847 Greenville, SC 2847 Greenville, SC [Member] Reserve for loan losses Reserve For Loan Losses Reserve For Loan Losses Individual: Individual [Axis] Development, redevelopment, and other major improvements of real estate Development, redevelopment, and other major improvements of real estate Payments to Develop Real Estate Assets Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] IN0009 Indianapolis, IN IN0009 Indianapolis, IN [Member] IN0009 Indianapolis, IN GA0023 Woodstock, GA GA0023 Woodstock, GA [Member] GA0023 Woodstock, GA KY0011 Lexington, KY KY0011 Lexington, KY [Member] KY0011 Lexington, KY AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet Lease liability Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Lease Liability Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Lease Liability Accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Receivable 3140 Brisbane, CA 3140 Brisbane, CA [Member] 589 Houston, TX 589 Houston, TX [Member] Mark to market discount of real estate Mark-To-Market Discount Of Real Estate Mark-To-Market Discount Of Real Estate 630 Nashville, TN 630 Nashville, TN [Member] Residency agreement term, maximum Residency Agreement Term, Maximum Represents the maximum period specified under the residency agreement. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Suburban Properties, LLC Suburban Properties L L C [Member] Represents information pertaining to Suburban Properties, LLC, an unconsolidated joint venture of the entity. Deconsolidation of real estate SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Deconsolidation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Deconsolidation 702 Houston, TX 702 Houston, TX [Member] Funding period Equity Investment, Funding Period Equity Investment, Funding Period Current period gross write-offs Current Period Gross Write-Offs [Member] Current Period Gross Write-Offs Unamortized debt issuance expense Unamortized Debt Issuance Expense 2577 Naples, FL 2577 Naples, FL [Member] Number of leases approved Number Of Leases Approved For Rejection Number Of Leases Approved For Rejection Segments [Axis] Segments [Axis] Total revenues Business Acquisition, Pro Forma Revenue Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Principal balance on debt Long-term debt, gross Long-Term Debt, Gross 599 Texas City, TX 599 Texas City, TX [Member] Development costs and construction in progress Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Development In Process Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Development In Process Variable Interest Entity [Table] Variable Interest Entity [Table] 2203 Miami, FL 2203 Miami, FL [Member] Equity income (loss) from unconsolidated joint ventures Disposal Group Including Discontinued Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Disposal Group Including Discontinued Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 3149 Cambridge, MA 3149 Cambridge, MA [Member] Debt instrument, term (in months) Term of facility Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Present value of lease liability Lease Liability, Including Discontinued Operations Lease Liability, Including Discontinued Operations Physicians Realty Trust revolving credit facility termination Payments To Acquire Businesses, Gross, Revolving Credit Facility Termination Payments To Acquire Businesses, Gross, Revolving Credit Facility Termination WI0007 Appleton, WI WI0007 Appleton, WI [Member] WI0007 Appleton, WI WA0009 Federal Way, WA WA0009 Federal Way, WA [Member] WA0009 Federal Way, WA Receivables [Abstract] Receivables [Abstract] Government Assistance [Axis] Government Assistance Axis [Axis] Government Assistance Axis Repairs and maintenance Repairs And Maintenance Repairs And Maintenance Gross Amount at Which Carried As of Year End SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] CO0001 Johnstown, CO CO0001 Johnstown, CO [Member] CO0001 Johnstown, CO Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Other Commitments [Domain] Other Commitments [Domain] Proceeds from sale of buildings Proceeds from Sale of Buildings Net operating loss carryforwards not subject to

Expiration: Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration IN0001 Fishers, IN IN0001 Fishers, IN [Member] IN0001 Fishers, IN MI0008 Traverse City, MI MI0008 Traverse City, MI [Member] MI0008 Traverse City, MI Less: Healthpeakâ€™s share of unconsolidated joint venture Adjusted NOI Net Income Loss Joint Venture Partners Attributable To Parent Net Income Loss Joint Venture Partners Attributable To Parent ATM Direct Issuances ATM Direct Issuances [Member] ATM Direct Issuances Land and Improvements Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Land and Land Improvements Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Land and Land Improvements Lab Lab [Member] Lab MI0010 Bay City, MI MI0010 Bay City, MI [Member] MI0010 Bay City, MI Dispositions of 2024 Dispositions Of 2024 [Member] Dispositions Of 2024 Mortgages Mortgages [Member] Total liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities Mortgage loan on real estate, multiple due 2026 Mortgage Loans On Real Estate Interest Multiple, Due 2026 [Member] Mortgage Loans On Real Estate Interest Multiple, Due 2026 1200 Encino, CA 1200 Encino, CA [Member] 3013 Morristown, NJ 3013 Morristown, NJ [Member] Construction loans on real estate interest multiple due 2026 to 2027 Construction Loans On Real Estate Interest Multiple, Due 2026 To 2027 [Member] Construction Loans On Real Estate Interest Multiple, Due 2026 To 2027 AZ0009 Scottsdale, AZ AZ0009 Scottsdale, AZ [Member] AZ0009 Scottsdale, AZ Dispositions of 2022 Dispositions Of 2022 [Member] Dispositions Of 2022 Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Fair Value Of Noncontrolling Interest Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Fair Value Of Net Assets Acquired And Liabilities Assumed, Net Of Noncontrolling Interests Dividends (in dollars per share) Real Estate Investment Trust, Distribution, Tax Status, Per Unit Real Estate Investment Trust, Distribution, Tax Status, Per Unit Real Estate [Domain] Real Estate [Domain] 1443 South San Francisco, CA 1443 South San Francisco, CA [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] TX0027 Bryan, TX TX0027 Bryan, TX [Member] TX0027 Bryan, TX 3007 Denton, TX 3007 Denton, TX [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] 2870 South San Francisco, CA 2870 South San Francisco, CA [Member] Measure: Measure [Axis] 2478 San Diego, CA San Diego2478, CA [Member] N/a Seller financing provided on disposition of real estate assets (see Note 8) Seller Financing Provided On Disposition of Real Estate Asset Seller Financing Provided On Disposition of Real Estate Asset Emerging Growth Company Entity Emerging Growth Company FL0029 Port Charlotte, FL FL0029 Port Charlotte, FL [Member] FL0029 Port Charlotte, FL TX0017 Spring, TX TX0017 Spring, TX [Member] TX0017 Spring, TX 2029 Long-Term Debt, Maturity, Year Five 613 Miami, FL 613 Miami, FL [Member] 1435 South San Francisco, CA 1435 South San Francisco, CA [Member] During October 2024 to April 2026 Mortgage During October 2024 To April 2026 [Member] Mortgage During October 2024 To April 2026 Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] NJ0002 Old Bridge, NJ NJ0002 Old Bridge, NJ [Member] NJ0002 Old Bridge, NJ Interest Rate Swap, 2.60% Pay Rate Interest Rate Swap, 2.60% Pay Rate [Member] Interest Rate Swap, 2.60% Pay Rate Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Continuing operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Debt instrument, covenant secured debt to assets (as a percent) Debt Instrument, Covenant Secured Debt to Assets The limit of the ratio of Secured Debt to Consolidated Total Asset Value contained in the debt covenants. Income from direct financing leases Direct Financing Lease, Revenue VA0001 Fredericksburg, VA VA0001 Fredericksburg, VA [Member] VA0001 Fredericksburg, VA Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Debt instrument, covenant minimum fixed charge coverage ratio Debt Instrument, Covenant Fixed Charge Ratio, Minimum The required minimum Fixed Charge Coverage ratio contained in the debt covenants. Outpatient Medical Outpatient Medical [Member] Properties that are part of continuing operations, and which are classified as medical office. Real estate Deferred Tax Liabilities, Real Estate Statement [Table] Statement [Table] 3114 Cambridge, MA 3114 Cambridge, MA [Member] Option to extend lease, term Lessee, Operating Lease, Remaining Lease Term, Including Option To Extend Lessee, Operating Lease, Remaining Lease Term, Including Option To Extend Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] 2996 Leesburg, FL 2996 Leesburg, FL [Member] Schedule of Variable Interest Entities Schedule of Variable Interest Entities [Table Text Block] 3014 Morristown, NJ 3014 Morristown, NJ [Member] 3014 Morristown, NJ Segment Reporting Information, Revenue for Reportable Segment [Abstract] Segment Reporting Information, Revenue for Reportable Segment [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] 2023 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before current Fiscal Year Supplemental schedule of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] 2027 Long-Term Debt, Maturity, Year Three Noncontrolling interestsâ€™ share of consolidated joint venture total revenues Real Estate Revenues From Joint Venture Attributable To Noncontrolling Interest Real Estate Revenues From Joint Venture Attributable To Noncontrolling Interest Revenue of acquiree since acquisition date, actual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Multiple Locations Multiple Locations [Member] Multiple Locations Accumulated depreciation: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward] Common stock, convertible, conversion ratio Common Stock, Convertible, Conversion Ratio Other Commitments [Axis] Other Commitments [Axis] Income Taxes Income Tax Disclosure [Text Block] 2022 Scottsdale, AZ 2022 Scottsdale, AZ [Member] Physicians Realty Trust Physicians Realty Trust KY0003 Shepherdsville, KY KY0003 Shepherdsville, KY [Member] KY0003 Shepherdsville, KY Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] Line of credit facility additional aggregate amount, maximum Line Of Credit, Facility Additional Available Borrowing Capacity Maximum This element represents the maximum additional borrowing capacity available under the credit facility, subject to customary conditions. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating lease, area of square feet renewed Operating Lease, Area Of Square Feet Renewed Operating Lease, Area Of Square Feet Renewed 2850 Greenville, SC 2850 Greenville, SC [Member] MN0005 Vadnais Heights, MN MN0005 Vadnais Heights, MN [Member] MN0005 Vadnais Heights, MN Expense accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals 2021 Scottsdale, AZ 2021 Scottsdale, AZ [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Credit Facility [Axis] Credit Facility [Axis] Mezzanine And Other Mezzanine Loans And Other [Member] Mezzanine Loans And Other TN0012 Kingsport, TN TN0012 Kingsport, TN [Member] TN0012 Kingsport, TN Interest Rate Swap, 3.59% Pay Rate, Two Interest Rate Swap, 3.59% Pay Rate, Two [Member] Interest Rate Swap, 3.59% Pay Rate, Two Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Commercial Mortgage-Backed Securities Commercial Mortgage-Backed Securities [Member] Preliminary cash consideration Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] State Deferred State and Local Income Tax Expense (Benefit) 3003 Burnsville, MN 3003 Burnsville, MN [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] 2702 Bolingbrook, IL 2702 Bolingbrook, IL [Member] Maximum number of shares available for future awards to be issued as restricted stock and performance restricted stock unit (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available for Grant as Restricted Stock and Performance Restricted Stock Units This element represents the number of shares available for grant which may be issued as restricted stock and performance restricted stock units. Restatement Determination Date: Restatement Determination Date [Axis] Total Balances at beginning of year Balances at end of year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, \$1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 699,485,139 and 547,156,311 shares issued and outstanding Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Business Interruption Loss [Axis] Business Interruption Loss [Axis] 2624 South San Francisco, CA 2624 South San Francisco, CA [Member] Shares issued as part of the Merger (in shares) Stock Issued During Period, Shares, Acquisitions Mortgage Debt Mortgage Debt [Member] Mortgage Debt Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] TX0009 El Paso, TX TX0009 El Paso, TX [Member] TX0009 El Paso, TX Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] 1989 South San Francisco, CA 1989 South San Francisco, CA [Member] Deferred tax liabilities Deferred Tax Liabilities, Gross Net income (loss) applicable to common shares (in dollars per share) Earnings Per Share, Basic 632 Nashville, TN 632 Nashville, TN [Member] Mortgage loan on real estate, multiple due 2027 Mortgage Loans On Real Estate Interest Multiple, Due 2027 [Member] Mortgage Loans On Real Estate Interest Multiple, Due 2027 Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Commitments Contractual Obligation CA0001 Walnut Creek, CA CA0001 Walnut Creek, CA [Member] CA0001 Walnut Creek, CA Loans receivable, acquired Loans Receivables, Acquired Loans Receivables, Acquired Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] WI0003 Tacoma, WA WI0003 Tacoma, WA [Member] WI0003 Tacoma, WA 2872 San Diego, CA 2872 San Diego, CA [Member] Distributions of earnings from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Intangible liabilities, net Finite Lived Intangible Liabilities, Net The aggregate sum of the gross carrying value of major finite-lived intangible liabilities class, less accumulated accretion and any impairment charges. Bank line of credit and commercial paper Bank line of credit and commercial paper Long-Term Line of Credit Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Contributions from noncontrolling interests Noncontrolling Interest, Increase from Subsidiary Equity Issuance Property count Number of Real Estate Properties SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items] Total Leases with Purchase Option Future Minimum Annualized Base Rent Receivable Future annualized base rental payments receivable for the five years following the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate. Fixed income from operating leases Operating Lease, Lease Income, Lease Payments Amortization of other deferred charges Amortization of Other Deferred Charges Total revenues Total revenues for reportable segments Revenues Compensation Plans Share-Based Payment Arrangement [Text Block] Percentage of Total Company Assets Assets, Total [Member] Unamortized discounts and fees Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount) Debt instrument, interest rate, reduction available for sustainability metrics Debt Instrument, Interest Rate, Reduction Available For Sustainability Metrics Debt Instrument, Interest Rate, Reduction Available For Sustainability Metrics 2843 Greenville, SC 2843 Greenville, SC [Member] GA0026 Duluth, GA GA0026 Duluth, GA [Member] GA0026 Duluth, GA Healthpeakâ€™s share of unconsolidated joint venture total revenues Real Estate Revenues From Joint Venture Attributable To Parent Real Estate Revenues From Joint Venture Attributable To Parent Debt instrument, covenant unsecured debt to unencumbered assets (as a percent) Debt Instrument, Covenant Unsecured Debt to Unencumbered Assets The limit of the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value contained in the debt covenants. Lessee Accounting Lessee, Leases [Policy Text Block] Continuing care retirement community Continuing Care Retirement Community [Member] Continuing Care Retirement Community 2844 Greenville, SC 2844 Greenville, SC [Member] Reserve for loans receivable Reserve for loan losses Reserve for loan losses, beginning of period Reserve for loan losses, end of period Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest Total share-based compensation expense recognized Share-Based Payment Arrangement, Expense Other Commitments [Table] Other Commitments [Table] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] 3123 South San Francisco, CA 3123 South San Francisco CA [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] 3071 Lexington, MA 3071 Lexington, MA [Member] 2653 Rockwall, TX 2653 Rockwall, TX [Member] TX0001 El Paso, TX TX0001 El Paso, TX [Member] TX0001 El Paso, TX MN0009 Chanhassen, MN MN0009 Chanhassen, MN [Member] MN0009 Chanhassen, MN Deferred Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Decrease (increase) in accounts receivable and other assets, net Increase (Decrease) in Accounts Receivable and Other Operating Assets Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2622 San Diego, CA 2622 San Diego, CA [Member] 2622 San Diego, CA [Member] 2556 South San Francisco, CA 2556 South San Francisco, CA [Member] TN0005 Nashville, TN TN0005 Nashville, TN [Member] TN0005 Nashville, TN LA0001 Metairie, LA LA0001 Metairie, LA Ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Contributions from and issuance of noncontrolling interests Proceeds from Noncontrolling Interests CO0002 Trisop, CO CO0002 Trisop, CO [Member] CO0002 Trisop, CO Unvested at the beginning of the period (in shares) Unvested at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Proceeds from the Callan Ridge JV transaction, net Proceeds From Divestitures Of Interest In Joint Venture Proceeds From Divestitures Of Interest In Joint Venture 3002 Burnsville, MN 3002 Burnsville, MN [Member] 3002 Burnsville, MN Real Estate [Abstract

[illegible]

[illegible]

+ID;QJWJWBXZC5X+M=,X6)XN-&L!L+7+R:MI>75VJQIY";R@M6FDG.4C#JSD?H/HXYTFY^!/[&S
 _BM/\$7BZJT7P\$NAV:Z M1H\UY?:K<1V/D(WEQAMK2,H)=R\$4M\S 4)D*&8#+8R<9Z9-3T ?\$O P;W?#_XJ? G_
 (08_#;JFGX_/Q/X,/>:I M?48-=TCQ%HTD\ _OJ5O;B%X9L&*%<*1"=C\$H3A@N1GJ\/_11OJHK6/B5XQ^# M?B7_
 (04_&W3J>T+7KJR\,;G;+I\WA_Q!:(Y6"]&JRSPO6RNH\$CH01J JV^U MP4KZRHH ^(^%O !
 (32_B= P2A^)G!/[CSQ'IL7BGXL:AK7BOQ%KFGQ.;&T\4 MW^IMJR/"I %=X8 2%9R!YA^TAX-;#_&]?^"97AS_@EIJG\A
 MXN\)_GQ%9:#X<^+ _B16-***%H%A87%LJ_J=M?#^1J0N5M2+>"W:23_21YPA MV.1^E=%&-/_/AGX5?#W0?A?X*L?
 LNC>]&J&M=^TBVW9\FUMXEAB3/?"(H _M"MFBB@_""^L'+5+233)3LHKBWE7;+!/&1QZ%3P16/PJ[X9_J\$[T+_P40_\
 MQ-;M% 'S] P3IT13Q\#=646\$("=7 'E#@"8 # IZ5[W_9VG_P#/C#_WZ%>M P#1.K DA^K_ /8JQZ/LKWJ@""^SM/_.?&
 &'_OT*/[.T_\Y8?^_0J:B@" M'^SM/_Y8? \ OT*/[.T_GQA_P" 0J:B@""^SM/_.?&'_OT*/[.T_\Y8? M^_0J:B@""^SM/_Y8? \
 OT*/[.T_GQA_P" 0J:B@""^SM/_.?&'_OT*/[. MT_\Y8?^_0J:B@""^SM/_Y8? \ OT*/[.T_GQA_P" 0J:B@""^SM/_.?&
 M'_OT*/[.T_\Y8?^_0J:B@""^SM/_Y8? \ OT*/[.T_GQA_P" 0J:B@""^ MSM/_.?&'_OT*/[.T_\Y8?^_0J:B@""^SM/_Y8? \
 OT*/[.T_GQA_P" M0J:B@""^SM/_.?&'_OT*/[.T_\Y8?^_0J:B@""^SM/_Y8? \ OT*/R/\$=E M9IJNDJEI\$
 UX0P\$8Y&TUNUC^?)\ D+Z/ P! ?I \ 030! ?V=I \ SXP_J^A1 M_9VG_P#/C#_WZ%344 0_V=I_/C#_P!^A1_9VG_\^/_/
 'Z%344 0_V=I \ MSXP_J^A1_9VG_P#/C#_WZ%344 0_V=I_/C#_P!^A1_9VG_\^/_/'Z%344 M0_V=I_\
 SXP_J^A1_9VG_P#/C#_WZ%344 0_V=I_/C#_P!^A1_9VG_\^/_ M'Z%344 0_V=I_\ SXP_J^A1_9VG_P#/C#_WZ%344
 0_V=I_/C#_P!^A1_9VG_\^/_/'Z%344 0_V=I_\ SXP_J^A1_9VG_P#/C#_WZ%344 0_V=I_/C#_M_P!^A1_9VG_\^/_/
 'Z%>'_M' \ !1C]F? \ 90UU?A]J'B&\>.;A_+L/A_MX&LCJ>KSRXX0Q1\$) [_O64D<@&O,O^\$2_P""FG\ P\SQYXF@_9R\ 7/_
 !? M#EPMJXLOH3VDN\'.QR,\$&,>8ARK*:\RMFM"-1TJ"=6HMU'6W^*6D8_-W)F,
 MJT4^6.K\OUZ(J8_:7_:G_92_92ECT3XF>,(+KQ)=;5TWP7X>L_M^L7KMJQ\$M MHLN[|^%I"BD\JA\[_@I3^VN-
 N@^K+JF[P!<_\ON16R7_BZ^A\IV'B*PW# M(.[\$L9P06%>U LT?L*?LQ_LFQR7OPD^',
 (URZ#^40%NL2J\U:^90OM)=2Y<; MCR53:A\>O5EJ4Q^_UQ53DC)!M?^!3TD_ ^W5^YBY*M3XW9=E GOJUCPSJF
 M[_@G5^R[^S+J+^,/#?>@V;Q#XPN6WZAX[9W)/6+J0C\F1G H)5^J/C_)%B\ ZX&KFG?@^#_KBO\A7E_ZD<+ _J_\
 Y//_2, M?P?OXO_)SJB^ @P?Y^QQ^U\X8_0E: D7Q,OAS\;G0V\#?9!<_:+*>U
 M_P\;JMEV;?/W_<.=F,Y'WYJ7ASP\K.GS:3K&^V5W:W\$9CN+;YM4DCE0C!5E M8\$,#Z&KM%>UEV58*#
 <_Z&\$ARQ;NU=O5I+JW2T.BE1I4(\L%9'R[2?] @DQ^ MS?JGB27XD?LJZXK@^#_BYSN&M?
 #;439V\QZA9K+F"2/).454W9Y-<[_PE? \ MP5(_93_=\$7X5^&VA?"MO\ >USP=\$FC^(HXQU>2R8&&=NF(X?
 F>6KJ#HK.M63X;G/#-TI?W-\$_6+O!^O+?S\$Z\$[P]U^7^6Q\? O_ (*?L:?' +7?^\$\$ _MX2X^#?%Z.(IGP5)0M-_L?
 4X93_RSV3X21_\9C=S[5]_P!G?: \^/_?H5 MQ/QT_9@_9[_:8T+_ (1WX_"#0_\$JNJ%(9-2L@9[<'KY,ZXEA/NC*:^?O^'?
 M/[2?]-W^G?L! ?MBZOI6G0P_#CXH!M:T0KVAAF/^D6V=E\X2=G\I>D1&ZYEY:/G_F?6_I G:?.^/_?H4?V=I_\ SXP
 M\^A7R2G_4B^,/[3C2_P#@H1^R)XA&6D1VR?^+P0K:YX>VS^XZO^SM/_.?&'_OT M^/[.T_\Y8?^_0J:BNLT(?[.T_
 \)8?^_0H_LI3 \ GOA_P"IJ* (?[.T M_P#Y8?^_0H_LI3 \ GOA_P"IJ* (?[.T)8?^_0H_LI3 \ GOA_P"IJ* (?[.T P#Y8?
 ^_0H_LI3 \ GOA_P"IJ* (?[.T)8?^_0H_LI3 \ MGQA_P"IJ* (?[.T P#Y8?^_0H_LI3 \ GOA_P"IJ* (?[.T)8?^_0
 MH_LI3 \ GOA_P"IJ*_*SLK,^_IV(VD6T6<9^6_Y:-_9VG_//C#_WZ M%9ME_P CO>_]>47\$S6Q0!#_9VG_\^/_/'Z%IG:?
 _SXP_\?H5-10!#_9VG_M_P#/C#_WZ%'IG:?.^/_?H5-10!#_9VG_\^/_/'Z%'IG:?.SXP_\?H5-
 M10!#_9VG_P#/C#_WZ%'IG:?.^/_?H5-10!#_9VG_\^/_/'Z%'IG:?.SX MP_\?H5-10!#_9VG_P#/C#_WZ%'IG:?.^/_?H5-
 10!#_9VG_\^/_/'Z% M'IG:?.SXP_\?H5%KWB#0?"NC7/B/Q1K=IINGV<1EN[^_N5AA@0=6=W(50/4 MG%?+7B|
 (*DZ%0/\$\U_ V!_@QKGOL1V\GDW.J:0/L?A[3G]9]2F C/4, M FOX!<&N/%8_ "8)+VLK-I+>3I(JI?R1\$ZD?Q,^J7L=-
 CQR26<*JHRS&-0 M^*=OC#_P4W_9S\^+9/A)!O#6I?&QIRJ M?%?AS9^!6!LXS^!P= _9^!1^!/?@I=-\Z5^@FTTBR6+S6
 QOD8?-*JIDL>YKC MIKEN- AQICQ^O+6;I(DVCZR?>)>G>M4V7*O?/IO\ /ICYC'I G_!07IL4 :_V MI/B :_IGP;
 <')^'GPJG635IXC_RSN]5((4XR&\$*_#R:JW_&=OV,V8_V5 M=\$.C [X0:5I\$DJ::S57A\^_O.Y,US+NEDR>=I::">*10HK?
 #Y7A44EY%1HPB^=JW_6GR(?[.T)8?^_0H_LI3 \ GOA_P"IJ*\$U(?[.T)8?^_0H_LI3 \ GOA_P"IJ* (?[.T P#Y8?
 ^_0K\1V5 MFFJZ2J6D0#7A#_1CD;36[6/XE_Y" ^C_J]I|_-&E_9VG_\ /C#_ -^A1_9V MG_\ /C#_ -^A4U% \$ \ 9VG_
 //C#_WZ%'IG:?\^/_?H5-10!#_9VG_\ M/C#_ -^A1_9VG_\ /C#_ -^A4U% \$ \ 9VG_//C#_WZ%'IG:?\^/_?H5 M-
 10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% \$ \ 9VG_//C#_WZ%'IG M:?\^/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -
 ^A4U% \$ \ 9VG_M //C#_WZ%'IG:?\^/_?H5-10!#_9VG_\ /C#_ -^A4U% \$ \ 9VG_//C#_WZ%'IG:?\^/_?H5-10!#_9VG_\ M/C#_ -
 ^A67IT4] %X)U?)#17_P"QIUC_-UIU0 4444 M %%%11110 4444 %%%11110 4444 %%%11110 4444 %%%11110 4444 %%%
 16/XE_MY" ^C_P#7Z? \ T\$UL5C^?)^00H_\ U^G_-!-&Q1110 4444 %%%11110 M4444 %%%1112.Z1H9)"JHRS,<
 #UH 6BOF:XO_P#147X+>/'%OP>_9N\ M:Q:?'ZY7_A&_A_&] >U;-UW?8,%N@.0S N4(^917^GID_IN?JLC_3OVV
 MCN\AIX0N.3*/A/=F.2;_ \+_U.Y:7(X>./;9RI4UY4\UI3FZ>\$BZLEOR_M_"O\4WJ]I]>7ITQ=9-V@N9_A\ 3.Z^/7_!3A
 9W^\$'BP_"3P#_:GQ.^(<MA9+>P)\J0ZC=K()Y\$S';*I(W;VW*=A KA? \ A2' _48_:2_TGI+XJ) M\#? USR?
 'PWOEGUVZB\^WJA&V(X)!\$(*L#AE!YKZ^ @O\OP\$ 9@*#P7\ M! ?A9I/AJO(7SS86_IZY(Z--
 _V9F_P\IIV8UW51I0Q>,UQM33^2%U'YR^*7_D MJ?6(O9SG_?Z
 R6W^;_#T/_VG1HT: %XBV/+&XNS&JK: NS12N=<=620*6_&O%_U MDX=^O?40KE+VUI2S+/"*D)."2R%C_>?%
 1E%QD.60I27FMO=GY MHB<(5%:2N?(7ID_ %8?V40FT760#/[10A.WZ6FII-\311C^%91FWGP.Y9\R M.0_9Q73?"S_
 (*L_LO>+O\$Z?#3XQR:W(O&? D\,?%'3&TMV;..QW#_+B1 M2&gt

MYVV1VWCNP;^S+E^YM[1C!ADC' /1 +7BOISP[XD\.^+M%M \$GA/7K+5-.NXQ
M):7^G723PS) >1T)5A[@U!XR\$>" B+X>N"/Q \ (Z9KFE7:I;K3-8L(IFWF
M'HT<@*M^ (KYC0 \ \$I/! \ /6KQCS^P\; %WP0UV>0RRVGAZ\ -IH=U)ZSZ;< ML8W'
PJLJCLM9WSC";VK1^4) P#R\$G X+ \ #^!ON?A E^1J845A? #2? M 4@_9: T? \ A_9=M/BKX;M_O \
CCX,N6ODC\4VE38=WQDL8BL:X[I]:9 M9V; P#V2?VHYAI^PG^.,GOKBL4G\+ZONL=4AD\WD-K.%=BIX)0,H/>M:&X
M.M45*3<)OLUROY7TEZO:7F5&M3D^5Z/LI/^'^1D)1117I&H4444 %%%& / M9? \
(IWO_7E% _UL5CV7 (IWO_7E% _UL4 %%%& !1110 45\?^G @II^S7 M&O%) ^?%A&IU/XD>/Y&.:V\?"
#FR.IWWF#@K*T?IN#!QN#I& .=IKA?^%; \ M%-?VR_WWQ>^(-K^SUX&N>OA?P/=+?
>)KJ(PS:@1Y=J2#D&\$;AR&2O+JYM0] MHZ6'3JS6ZCLO\4G;.:?1N_9.O=:-[1U?E_GL>O?M*?M]_
++OI*!;GC^WO%=NNH>*;N(C167\$5F2,@B4IU.&5C7L?[-7I"7I+W])WOPA M^&5M'K5P&-
_XJU9S>ZM>,WWVDNIO5G]4S#&;XJIR1_OIMKI MYZ2?;JAZL7)5J?&[+LO_ *QI^L_ /!-+JF;X&>)O^%GZOI.H^/_ !I*
MXDN0'WQ#OCJFI*/XXS(-DI' .#&H8 X+&O*#BBO0PV\$PV#IE""BO+WW2FI M36\$(4U:*L%%%%=!04444 %%%&
!1110 4444 %%%& !6/XE Y""^C P#7Z? \ MT\$UL5C^)?^00H \ U^G -!- &Q1110 4444 %%%& !1110 4444 %%%& !1
M110 4444 %%%& !1110 4444 %%%& !6/9?CO>]>47\S6Q6/9?CO> P#7 ME% _T: %%%& !1110 4444 %%%& !1110
4444 %%%& !1110 4444 %%%& M!1110 4444 %%%& '@O_3J_P'2'ZO_-CWK'_H^O>J\%_X)U?D/U?_L>I M8_ \1]>14
%%& !1110 4444 %%%& !1110 4444 %%%& !1110 4444 %%%& !1110 5C^)? D+Z/_P! ?I_ \036Q6/XE_P"00H_
%^G_P!!- &Q1110 M 4444 %%%& _[Q_I/AOI]; 6ZAK%\D\$>[&0BEB-[G"+ MECT-3.<*<
<7*;LEU8FTE=G1UD^./O^CX9^&+KQK1?%^F:%HIDF^ [U35IZ. MW@A'JSR\$/SYKY5G; ^ _(:KG?0/^"?Q*:= -
MK#7%MXX?T MUSU6VTV, ^41UI,FY7 !*UY/IU,5I@?^AWI/LDI7E_VZFO[R,?;.\-7 M^G_?D4=5_X*2_\$\ :%U*?P7_
_,\$VOY?+ _P"(+QRM!)%P< M\$B5PLMX5/6;.*<8*EA4GA \XE:I\;M:MOB# P4: ^./J?%;4H)1/> "IGT
MIPOIKI[@EI\$5:X*]/,DP6'#JU?5^E:3I6@Z9!HNAZ9:V5G:Q+%;VEI"L<4* 8 M"JJ@!0!T &*L4UE7UAV.GI5_P NT%_VIK?_
+?QYI:COY=/N_SN9_A M7PEX5""^ [7PEX)\-: ?H^E6,0CLM-TNS2WMX\$"*1H JCV K0HHKUDE%66QO ML%%%%,
HHHH **** "BBB@ HKC/B)\=/'P^O%T R3ZMKDW%KH.D1^==2,1Q ME1IP= \MCCH#7-? \ " ?&/XT'[1]6-
::PSH4G(\+Z'<9GG3TN+@?J]S'L17R M^XHP,5+!9=3>)Q\$='+! P#3VH =I]^76HUK&SCU/E%5T57Q4E2I/9R
MWE_@CO+UTCWDC5I7?M"Z'9ZP_@SX9Z-/XM\0#AK+2V'DVYZ9FG^Y& >#U(! MQ7D?I0/I.'QL>Z,_P 50\$>H6-
_KD;:H^@Z/:\$+#+:C"?>+1TT'P=H-MIJJ+.W3!8_WF/5C[DDUJ5X&=<"5N,LMJ4.(<
MOWS+W84KQITY=:).^]5DN\K&M:J\$98WD:&*5CZLT94M^.:L _#_P"!PC""#5O"W/M:QM[L1JRW4BM+*AQU5Y"
MQ7]"* GW_B6?B'Z_R?7J7L+ !6GSV P6Y;^7M/F?IG_ !%C+ /JU J\ _:=KQ MY; XKW_ /E/&?V= V0I:C!+-
XT\4Z_JWAS7;DJVDMITWES6D>#S*I^IOR,H<8 M YP20/0 ^\$S^/?PF = \$+PLOC#1X^NN>'80EY&O]Z6VZ,? \A-
=%7&> \X#?#KX@W8UJ\TV33M70[H=;T>4V]U&W]I>OWC_O USOV MG]HKX17EO'X_P!\$C_Y:VZBWU2%/=?
NS8IOF;VKT_P"VL\R:3-V\STU_R^H* M4EZSHZU(2IN>U2WY'V3/5:*Y'X? M'#X<_ \$J4Z?
H6M>1J4>1/H^HIY%W\$PZ@QMR<=RN0/6NNKZ3+ \RR-<,L1@ZL;
MD'UBTUZ=5U6ZGEXG'XG!572KP<9+HU9_UYA1117:3_M\$ _L- _LI_M50F3XV_!C2=3U!5 @UZ',VNI0\$?
=*74)648(I"EB0 M'(->L45E7P]# \$TW3K14HOHTFOQ)E,U:2NCY' _X9); ^_9? _- 8] _Y'CG M0(.8_A_ \;
(VNRJ#^""#4X0)EP/EI^&08&2:L:3_P50L?A3J<'A+ \OCIG/Q= \& M=1DD\$*.I0K6J^K:3I6O; /HVN:9:WMG<
MOF.YM+N^9(I4/565@0P/H17F_P!F5<-K@ZKA =E[VN;YE_VI)+R.O8RA_#E M;R>J_P_N9F?#IXE?#OXL>&H?&?
PO= :1XBTFX_U.I:+J_=U QI-\;\$9&>1U M'>MNOEWX@ \)!IGN?Q+> \2OV:?\$7B/X)^+I#N.L?#;4FM+6U_P \$;=
(11QC)\MB^89V_M](X.3GEJ/[I0Q>&TQ=%V_FA>_P#7E%_UL5_) _17G_ \ \$30^H3_RI_ \ :&7IL?W/Q_X!_6!4 M5I?<
66EV4NI:E>16I0:QM)/<3R!\$C0#)9F/ ')KY,UC_@IIXG^>JW'@G_@ MG-^SSJ_Q1NXI3#<
<>.-6I]+ \.6#@X):YF"OCR%6Y(X5I^U^L/ MEP,'5_O:07;_7_MQ2/3]MS:4U? \OO\ \KFO\10^"I_POO/%5Q\)P!CKX>:
MY\,\$BL/ (8] _;_&O/I\A_VY_V MC#X0+W+?"GX13M;1R1G_EG>ZBV99\C >-,H>JLM?4GPZ^&/PZ^\$/A6W\#? M"SP-
I/AW1[4?N->T:PCM%5=MJ_L<3U);M+&S:~^UQM3F7D?>A]I>; M7S=G_ *@JE?^1W\EH0\<
@_UH<!)OV9/@%\$S#X7@_X" "G1_-D5-G-A?Q M1DCHTTS9EF;_&I&8^I=W117J4J5*A34*
<5&*V25DOD;*BK)!1116@PHHHH M **** "BBB@ HHHH **** "BBB@ HHHH *Q \$O\ R%!' P"OT \ H)K8K'\2 M_P#<
(7T?_*_3_P"@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ K'LO^1WO?<
^O*+^9K8K'LO^1WO? \ KRB_F: - MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M***<
"BBB@ #P7_@G5_P D/U?_ +^O6A_T?7O5>" \ \$ZO^2'ZO_V/>L?^CZIZ MH **** "BBB@ HHHH **** "BBB@ HHHH ****<
"BBB@ HHHH **** "BBOG_MO_@JE\3YVJ6D\$G[N='C;,< MKKRG&[(P0'.'?%XFG@L)4Q\$TW&7)VWLE=VUU)G-
4X.3Z:GT)6/XE_Y""^C_J M?I _I!-?@/_P_#_X*B_ \1SW_)96B? \R%4-S_P6S_X*=7DT,IS^TSN>W??" M?<
^\$;T4:3C&>+ /G;^&_XB1D?_ /NIIT?_).W^UL-V2X?YGI"U%?SW_VP^ M"HO_ \$<I_P'65HG_ \A5^I\I&G_!2+P1H? \<
P3F\! M(?MR?'W2X/\$&NIJK3 MSSV,5WJ7DZI=V\8@L]2-3(1'%&O[N/'&6Y)->IE/&>4907G3@I0Y8N3<^5* MR:6_ ^Z-
Z&/H5Y-*ZLKZV_S/LBN-^W\OWP0_9N(OXY^_GO/TCPSIBY\N;4 M]H* \9*11C+S/C^"-6;VKYN_P"&C\ @H-^V;_H?D)?<
P97X0^"KG@?\$OXI6_M0?4[B(\M++2@3@XP5>8E'4J5=-G\$?^"87P#^?BY/B_P#&34=6^+GO".&E M\9?<
\$6X^VO"P.O+:W;,-LBGE_S)T#UZQIH8G%Z8*G=?SSO&/R7Q2^Y1?21M] M6<_X: ^V_P_W_6IQG_#97I9?I8?_!+OV"?V?<
CX8\+7'RCXN_%>V>VMY(S_R MUL=/&9:C(R4D:*9&'5:Z/X6_ \$M_A3!XN@^,'I6?CG6?C?XIB^9-7\8*BFI<
MS?_P^ [^F,@@M8M5:6%(XHT"QQQJ_JJ!@ = !VI]%%>L:A1110 4444 %%%& M%%& !1110 45F^*_&/A-P-
I#Z]XNUVV^TCZS7,F,G^ZHZL?8 D^E>UG&-IQ<^H D;_W/&>@SR17%>9\> /C;Q' \W@/PW) _P#&: MM=I]#I:@_P#?<
0_VA71_ \$WX\$>" _=^WB2?I1K.O3PHO\Y3D\ MXX&>@%=+117T^"P."RW"OPV\$IQITX]1BDDODCR,1B*^+K.K6DY2><
[NPHHHK MK,3-8_BQ>_I<#5S3O^0?!_UQ7^0JGXQ_Y%BI_ZX&KFG? \ (@_ZXX_ "% M\$U%%&<
!1110!S'Q!^ ^GPI^)T:GO9X=BDN8P/(U& F*YA(Z%9%PW!YP_:%^\$GS^%-<3QUHL?_-<
UF40ZC\$OHD_W9#_O\I@*!5HKYO,_%LMOF)>+H MN5#\$/_E[2?+)]N=6<*B]D9KLCU<-<
G&+H4E1J6J4OY)JZ7^'9QI8N+.& \#_M M!_#_ _8ZC_PC=-<:%KBD+)HFNP_9YPWHNIY7SVVG..<"NYK\$/L.N+L<
MCE/K%-IQUSP#QGL#7H:LKJ'1@01D\$' @BO=RO.LJSJDZF"JJ?+D;2B^TXNTH M/RDD_ \I&8#&8":C7@XWVI-
=TUHYUIM"T445ZAR!1110 4444 %%%& !1110 M 4444 %%%& ?DW_P<^6EI=?!*^2UC6>5/\$:23!_'=5.EE5)ZD LV\ VW'U-?<
E'7ZP M? \W_-#_P#N9? \W%5^3J?S]QO_ _E1B\ MS_TB)QEF\ ODOE^2"BBBOE<
M#B/ZM] &T71_#NE6^A>'D)MK"QM(A%:V=G L44*#@*B*% [_#%6:** JM)6 M1IH%%%&, HHHH **** "BBB@ HHHH<
**** "BBB@ HHHH **** "BBB@ K' M2_ \ (7T?_KI/ _H)K8K'\2_ \ (7T?_KI/ _H)H V**** "BBB@ HHHH **** " MBBB@<
HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q[+_D=[W_ *HOYFO M/?BO^V-\+OAGJ.N@60GUO486*S0V#*<
(H6'57D/&?90V#P<&N\/_ +?AMO% M.V] > (/AY>VMO/\$L9:TODG=<'KAE0'Z9K]IS#Q6/J09-
KR3;:^2U/IBBL7P^0!_O,T%/\$ MG@O6H[VU8[7*Y#Q-W5U/*M]'ZC@YK:KIK"XK#8I#QQ&'FITY*91:::25-:<
M'SM:C5P]5TZL7&2T::LT_- ****Z# ,**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ #P7_<
QU?AD/U \I'06/_1]>15X+_P3 MJ_Y?J_ _&/>L? \H^O>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHH ****<
"BBO_/C+^U\^RI^SW")_PNCX^>?%T;Y-A?ZQO[k8?I-NL_K_M / 5-9U:U&A#GJR45W:LOO%*48J]=CT>OD<
(+A_P#*+KXG_P#<% \3W85 M& \P5G\ _\$AVL_V/ V7OBG\6W8X@U;2/#.FG:3VWWEV\$O/O'ZU\] \ %3_M<
!A_P4Q^ (W\!WCOQ%;OA!_AUX_C_LMM4/1:I-JVO3\$ZI:"%5GB ME593 M&S')"D#K7S6=9O@Z^3XF%"<
[TYZQBW%>Z]>:W+;YW.3\$5Z>'E"C6S MR?M(I\M-M75I/FCJO/7<|+*XQEB7= /U1I84445^X'T04444 %%%& !1110<
M4444 %%%& (S*BEW8_9)Z5YQXE_&L;K5Y\!OP\ /R^+M:3Y939.%LK0]S3G<
MY1I\G,9!KRLUSO+,EI1GBZG*Y.T8L4YOM"\$4Y3?F%-G9@ \!B?_QH10:50<

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

MTUNFM4SX+^*_I-7Q1^%.HRI>:#/J&FAB8-6L(&>)EI%P.F.^S=^A(YKC=%)+ M^)?\$=-\./\A
A^JOKEC@06EJ(C_DH)KI)JOI+_D=[W_KRB_F: FS./HT9+7S M!U<)CITJ+=^1P4VEV4^.:G:/9/NV?JN&16,?
3PRA7P9S_F4G%/S<:/YV:7H M2>+?LI?LI:EX!U*/XD_\$F!U-\$(TW30P;[+N&%(Y'!?!(&=N23S]WZ!HHK]U MX3X3R?
(S)XY;EL6H)W;>LI2>I/2I=[ET2222/SO.WGV MCJ/Y7G>L,NS;Y17WL9W<9P<>3_/#W/_T<I_J96M_
"%67GUAVRK"U M72K8B\$9+=. <4UUUV;OL92KT82M*23]4=M_P \$ZO\ DA^K_P#8]ZQ_Z/KWJOST M_8Q_X*Y?\$/A/)*I0-
\$+IH+^SIVX]5ZC>PP(GJTNZ"67=&^8I1@.CMG M(I@5ZW_P #_X)=?I'/?^65K?_P A5-3.??M._%
MIQ^R9_P3C??:I;R0^ (?B3=0>&K+;_SU1)BDZ>R]6/25YE3.,MISY%4YI=H MIS?W13:~9BZ]I).U[ORU_(^MJIZ_XBV/^%-
EU[Q3KMGIMC NZ>IU""Z2&,>K M.Y 'XFOE7_A1W_!63XW_#_%K]KKP3]*I.EYDT?X6^%FOIID_N= WY#1/ZO'
MD9Z<5=T#_@C[^RE>ZM%XH^/VL^./B]K,3;UU^XE^.;FI"-WVPQF./;V"LK # MBH^O9A7_(&':>=AU5^MU:~/L9!7- \-
H?M]_&>7^S^ \ \$Z-5T.R ME_U/B/XRZY%"!Q9Z6]/C+7##O^K=O>OI/X;_ =^\$OPGUB:; ?CE80-SS_
NOINBG')RM(%W37-U%1![D]5%213I4W.;2BM6WHDEU;^C&4Y*.5=OH6JQ_&OC MIP=\.I;?7?
&GB"WT^V&0K3ATA_NHH^9SI \$UP4_OH= (%.9I)_9I+AI3<4 MF7:W\$T5FG."84(W3\$?3
/48.:U?7I/GAS1=77QEX[U6X]5>(N"=4U*ZGX=?!#P+ \-YGU:PM9;_6)\F[UW59?/NYF/4[V^Z#Z+CW
MS77T5U8^AC#4L5^X^H\3B%M.=K0_P"O5->Y3]72C]U=(H****^G/("BBO-OCA^V)^R[^S= \GQM^.?AW0)D7=
M9IQ?B28>JVT>Z9_ ^H:VP^&O&+JJG0@YR?2*:?W+4PQ&)PV\$I.K7FH16[DT ME]
[T/2:*^3_ ^D7Q/^_W^B_L4_L1^_.&\.O\$'BKQ2B>'M%8'_EI'-90.2
MH56/0=:/^&= ^"F/Q]'F_'OI_K_1OAGI.W.OAOX.Z.QNBIZ_ZC=?O8G_ZF.%2 M>G:O9_U?KT-<=5A0\I2O/_P""-/
/_\$HKS/^_UAH8C3 TIU_...;O_ \#FXP:_P MN3\CZ(^*/QL^#_P2T7_A(?C\4- \,V>"4GUS58K828I('8%S[+DGTKY\OO^
M"K?P^/2DNA?L= ;X?&?2^1S+&IPI[H4EEI\$;CC;+?72JL8SQNV;#ZUT7PN_MX)8?L7?#?6?^\$OUSX:R^_O\$;\$-
/XD^(\VH/K-U,PZ.PGS\$?7*Q'_"OH2Q4+ M'2]+3M.LHK>W@0)#!&\$2-1T55'_I*!<.8/X(3KRIR:IP_P#_8N4FO^WX
MOR#V?F\$,^.<*\$>T4ZD_ *2C!/_ +64BV4XX#OX(.3Z5H>%_P#@DS^S96SDIXOFKR[U9]"\$*<5&*LET05X7??^":W
MI%G[4/Q#D^*OQW^#TNOZ]+:16QO9/%.J0!88P0B+!THJ2OWLТУ<^2 M/\$O_
1;_P""9^GZ%=7MI^S7LECB)10^\$QUDX/T-Y5JR_P""*7_!F6SBED_M9HRS1*6/_ "9:UR2/^OROIOQC_P BQ>_J<#5S3O)
D'P?I<5_D*]3_6GB?_H.MK? _@V?_ _D>7_JIPM_T4?_5#_P"1/\$?@%_P36_8L_9>^(ET M#7HK26V%['XIU2<-#(
'1HY[EXW4X!PRG!56&"_1I]117EXS'8W.*OM<55E4 ME:UY29_M#_L= LV?M4Z6NG_M
!Q^%&F:Q^FVSU8(8+^T[CRKF(K*@[YVAMI(Y!KQ\ X9V_X*#?LD_Z3^RS M\>
(OBQX3M^5^ \WQ7N.;C&^/6=KJBXRV.15F"QJIT-?7%=>N\$SO'86C[352 ME)- :^E;:YMK MVVCO+.X2:&5
 \4L3AE=2.A@1P01SFL+XF?"?X9?&?PM-X(^+/@'2?>DS_ZR MPUBP2>!.!/@'VL.S#!'4\$5/U7/_3N^+?I.MS)X@_X)W?
M*:EX/MPYD/PW M\;R2:MXM/9Y/5T+L<8R!73I+('GVE>=-^DDN>/I)3\YHY?
M:Y_EO\2*Q.;\;OJ+UBWR2\W%P\H,^M:*^3=-_P""DOB_X%W\A/_ (*&_LZZ MS_-
I7D\$.7CG1(WU7PU=L3@^SX0SVQ8XQ&X8@,D9'<=1WKAQV4YAE\5.M#W'M)-2@_24;Q?I>Z_MZH\#F^7YC)PHS]I;P:
<9QI82M)>MK/HS9HHHKS3TPHHHH **** "BBB@_KB M'?P^'OCF_.\$A6TGT?6D.Z+7-\$F-M5?VM^T1(_
MEU[3('NBQ_\OFFQB#4XD]6B^[-_P'YCU)KJ_A\;?AS\3=UOX9U/ML>1/I M=VIANH2.H:-N3CN1D>I=57*?
\$X*_#GXF%;GO+H"K?1X;_&JV;_&ZA(Z%9%Y.M.P.1]5]_9/\$.3:Y7B;4U_RZKMMI=H5TG-
?IQ65]8H]ZIEF/TQ=VD7_VXX>C.KHKRK^H_VB?)A)SHNHQ^/M%C_.734)!!J<*?I.OW9L?I M7S'H_*W_'\?OAYXZO_
/A'_MLVD:TAVS:'K<)MKE6]_K*_J^38F-)UL.U5IK>4-;?XHNT MH^K279L[BBO)?BO^V-\+OAGJ.N@60GUO486*S0V#*
(H6'57D/&?90V#P<&N M]/>(LCX:P?UK-,1&C#9.3W?;*5W)^239SY=E>89M7]CA*;G+RZ>;>R7FST^R M_P"1WO?
^O*+^9K8KYGV_M\>&V\4S:IX@^'E\;V\2QEK2^2=UP>N&5 ?IFO M?O ?Q#'_ \$S04\2>"I.CO;5CMYZ&'RG-,6KT*\$Y+N
MHMKI'HU%>8_-%:WJ_@OX!^_I_#IR6]L%LXF^CNOX_"C_(2W]JG7?^01 M)?#FA@_ =.6I=-SCW(MP*]_
%TR:I_NL:M;_KW0K27_(RG45YC_P@O[3NN_\AKXW:3HZG[T6A^'UE_-;!O^V:+_6C^W\]Q'^[974]:DZ5-?=&=2: ^<%Z!
M_9N74_XN,AZ0C.3_!C&W\2W/0M6\0;!H,7G;YKEG9)C.^[N4C^YL17(ZY^TQ M!_#^1??[39^O:Q=KD_ ^00U5])_96^
NDR.;?A(A:N8G+S:CGV^PCBQ_WRI1S<=8G\&H?;K7_3#_GMPMP]2_MZU:GRA3_%J"" _#4?AS4_E\%_#CQCKN?N2Z?
H#B(^Y9RN!][XH_X6?^T)KG M^AOIGD6<9^IG44?V'O9B/1YS2#_WP&XKTZBC_4S*ZNN^UJW^_.O5Y?_MP",XP_\
)0_MW&0_@PIP_P_-%)_IR_\$T@_9_#4DJW/B+3M2UN9>1-K M&LSRG/K@, ?RKIM#^#?PG_
X;1/AQHL#KTE738R_?1!;:Z6BNW!\),9?/ MGP^"I1E_J<>;YRM=-_F%?.6KB)M=N9V^Z\A(XXX4\$44:JJC"]JHP_*6
MBBOH\$DE9'E;GSI^U;^REJ7C]4I/B1-X\$?5'0#4M+! ?M6T8\$B\$ \ _@X#_M CGIWRWK7A?Q+X;O3IOB#P_>V-
P#@PW=J;9^C_5^DM8_B7_)""^C _7Z?_ M \$\$U^#<;> N0\5YK\<)7>&JU">:45.\$FIYI?Z-D'B/E.3
M8..%K4U5A%6CKRR2[7LI=-+K;[K'Q^*V):OBC\5M2B2ST&?3]-9@9]6OX& M2)5[E <&0^R]^I YK\:^'O@/0?AGX/LO!?
AN\$K:V4>T_P]Z5R^%F1>T)U*\$G5KS5I5))VWY8I?#%M)O5MM*[LDEXW\$W&&8\3
M2C"HE"GM%W45W[M]7YV2];A1117Z:?)1110 4444 %%%M%1110 4444 %%%M%1110 4444 %%%M%1110 4444 %%%M%1110
5CV7_(IWO_7E%_UL5CV7_(IWO\ UY1?S-& MQ1110 4444 %%%M%1110 4444 %%%M%1110 5XG_P49_*T? X)I?L2?\$
M/]L36O"OAU\0+KPKX%-^+CX?1^"KF+1]2M+B MTN;JXM]*N(IYYX)*C/E2R>>)V5-T;:LKII?
M+>+OC^X""^B/OE\O" _AS5 M_\$NF:3_*Z-PMD83N"SVT):1" JQL748MR0S M?
L=XI\4Z\IXX_9TUKQKX4U..JTO6\]5S?;>19VSVMHTD<@SSAE8\$26@#QC_M ((W_M<_%7]0#_@FU_-VM/C;:I47B?
QE!JEQJ<_AVC06D7E:K>6\;1(SNP5_M8H8Q\S,3C)))KCOAG^UW^T3^WU^TE\;AO\ LB?\$GP[X^#?_7QX3G\5ZGX
M7_MB?Q)X]2T,R7<_PSQ+!8V\<3A?WTSN2DL2J-V_ P_&SO_R@^ _V#-:_M_P#3]J->7_\
]I]9ZAI0)*Q]TSQ_&B&W_:Q61^ (EF&)1=BVTT/OSSG(X MYJZ_/O@/_P6(^&GB7_@G\1 P!M?X_ ^'8_#>M_4M8V/?
%WPGIMP91:>(= M-D\$.EI:M)@LMO('DI^GVA48Y5C7\$\$_\$;INWIN3IESIA_PC_P5+_*G\+ZAX, MU(Z-
JOQ'^\$^A^&Y(ICPOX?U26&.*6SOC,9+JIM/M-NTXD0138F"+_K5^67I_M5MAXWUC]@+_@IJK_(5CG?PVW]8EFMPT
)C"(3II'!_>/9L3_+I-?K#_M,%K+IPS8_! _#XK7%J]7IFM)\M.CL";2'DM\$@Q^+)C*/_N;0M:??%K'WT ?D_P_/W_-#_\
N9?_M_%5^4=K;B=8ATI_20U<_X;?O\FA_ _O_N*KL-*M_+AYAR_3Z5\9PS MP/+CWQ?^HU(WHOY^E7_KW&\$+Q_I?
=H?I07Z^YGOIG:R+ UJ]7[I]M&^')K?Y*_M]^0:I;H!^B\I_*LZMP@."I'IZUFS:?"(4^U(#V#\5^F?2)*<=B<[I9_E%
M./+52A57-""4XJT^N>44^:"M:-W[E\;GYOX>\4T*>"E@_7)WBIQ=I2T>ZT3M M9ZW??R/Z5?C1_P_%?V+?V?/-A^+/I2?
A73KJ#^FZ9;ZB/R\7;K6WF2C_OF MO^O^'H'C/XJ_Z\A_L= _L(_%+XA"3BVUS6;/%\#VCS9Z%;N]SD=R"@XQ7C?P?_M_&L?
^">_J?FEZ;:_\$RO'WPNY!:_\$RUCX9.I]CUN9B\QO]O7KFA_%P?V M]I
<;RQ\0KRS?&34=,E@*GN#N7BOFZV37*%6:7 <247#_ _E/ MWFE65UY.M26O_!(GX\ CBY35?VL?
CG\3OC%=!P]VGB]Q?-#_MIJ_#G]U:VIC\$;YYV[F%=5X?_ _I/[%OB?:NC?&S0I7;I'_*:[OQ':NVTCK M_P""FNO"?
20%^G2H>C_VC&H_ _D5X&(EPSAY6Q^)^C*7:K47_I#;BO_4>YAL MKXR/-2IRJ+NDY+ \-#8^\$/L?
[WP"MEMO@M_\$O" _ADA-K3Z/HL_,\@Z?/*%W MR'W9B:]JN&LOC_X"U'_T_6I,FZ"+6I9C^CUKV7Q
740^0=HSW&>GDW4;_R-_M>U@9E52"AA:D&NBBXV_TGA,1AU:=-Q14T=%16/_P)+J_ \$*%I_WTM'_ "M2ZO_-"A>_?_
2UZ\B:%%8_ _DNK_ _0H7O_?2T?) +J_ _T*%I_P]I+0!L M45C_/_2ZO\ I"A>_P#?2T?) +J_ 0H7O_?2T_%%8_ _DNK_ \
0H7O_?2T M?) +J_ _T*%I_P]I+0!L45C_/_2ZO\ I"A>_P#?2T?) +J_ 0H7O_?2T_%%8_ _DNK_ _0H7O_?2T?) +J_ _T*%I_P]I+0!L45C_/_2ZO\ I"A>_P#?2T?) +J_ 0H7O_?2T?) +J_ _T*%I_P]I+0!L M5C^)?^00H_\
U^G_-I-4] <^ (D/AG3GUCQ^I#V%I' _K+FN8XT7T^9B!7GNJ_M_M;?!K4-7L43Q&]M:W!=LH^UN,??V]?
QS7D9CG^0Y14C3QV+I492V4ZD8-^B MDU<[<+EN8XV+EAZ,YI;N,7*WW)GLU%'-(>_M)/I7V5)&:N?) +J_ _T*%
[_P]I+7J4ZM.M352G).+U33NFNZ?4Y)PE3DXR5FNC_M-BFRRQ01-/*J(BEG=VP%_ZDGL*TV4?M+Z5I6LMX.*^\$+ [7]?Y
TK39%1W%68+ _#[XI?%.I&H?87IT[<&B)Z^+Y-MP>/_D!W2GVR_"_M.#CBOE\5Q13JXB6\$RBD\36B]2Y7:E!_I/*MG%-
=814ZG]RVIZ](*OI^MC9^ MR@]5=7G)?W8:-^KY8_WC?US]H1M?U.7PG"?#3^*M2C:;/?JVS3K,^LDW1_7

M:07L<4W1?V2;GO-J47BOX\^)\V3W::X-+53TMF?1(?^6AI;GZCJ#UKJM# MGC\,Z7%HOAWX=2V5I N(K>U1\$1?
P\^17A\)=7 P"A00?^EK*GPQ4S*:K MY[5^L-;JDERT(OIIEVZC7U5RUUC&Q4LWAA8NGET/9K9S;O4? V\JE/M!+
MLW(U8+>"U@2VM84CCC4"&H"JIT Z"GUSVK>#H.FS:QKFA65L;H7N+JI MN8XXXE169B HJS7S_P".O^"M_P"R?
X7U\^"OI.HM00\$1)\$A;XZ>VL7I M^>[SG/&S7WN\RS'X\|F%I2G;^5-I>KV2|:(^7QV9Y?ET>,%58POMS-)
MOT6|?DKL\H:"0!DG 4FOD.\ :% X*D '1!'\%2V2-"^%NDS<+KWQ.U1KN^* M?WDL::|BM>E 8N&PVN.Q4(?W8?
O9 ^2/D7I*HF>9 ;>)Q6F!PLY WI NH? M^3KG?K&G)'K'OJ_X^* [%OP%NVT3QI=(M)O-8W^7'X?
\.%M4OGEZ",PVH'P?:/>O/_AL\JM_XZ_N/V4/V#M2T?3YO13XN^,|^~)@4=G^P1%KB5#U#* MW3MS7J_P5_9Y^
O\EFM\ \$?V9=*,\,\$V=Z?81?:I\Z/<-F63_@3&O0?^\$E MU?A Z%"I_P"EH^NYA\IWP\JA FJRT^4(==U>(ZA?F3J7%QU
M>G_) +J_0H7O_?2T? "2ZO_P!"A>_||+6&(S_-)TE4Y(I,\$H1^<8)^
MKN_VP_#^4X>JJSI\12;FW4EI3::|9>1L45C_/"2ZO\ I"A>_P#?2T? M)+J_0H7O_?2UXY\1L45C_\
"2ZO_P!"A>_||+1_PDNK_P#0H7O_ 'TM &Q1 M6_) +J_P#T*%I_ -|+1_PDNK_I"A>_||+0\L45C_ "2ZO_P!"A>_||+1_
MPDNK_P#0H7O_ 'TM &Q16_) +J_P#T*%I_ -|+1_PDNK_I"A>_||+0-XQ M_P"180?
^N!JYIW (/ @ ZXK (5S_B77M3N=|NH)O#%U"K1\$&5V7" ^YJS9>(I5_M2SB1?"5XP\$2@,&7!XZT :M%8_P#PDNK_
/0H7O\ WTM' "2ZO_T*%I_ WTM & MQ16/ _P) +J_ \$*%I_ WTM' "2ZO_- "A>_ \ ?2T :%8_P#PDNK_ /0H7O\
MWTM' "2ZO_T*%I_ WTM & CJ6FZ=K.GS:3JIA!=6MS\$T=Q;7,0DCE0C!5E8\$," M."#Q7S-X_)=?#+3/\$IQ4/V\ XB:I\ \$?
%TS;Y;GP;(&T)8<@7.FN?)D0 M?W%V+W(-?1' DNK \ 0H7O_?2T?) +J_ \ T*%I_ P\|+7?
@4HN\9+R::.#'97@,RBEB::DULI1?>,E:47YIIGRI_PU;^W+^R= H7I M9?I.8>=&(&^)?PBB:=HXQ RTN|-?
\$D>|\SNF(UP0H:O>/@#^U5^SS^U#H! M1? CXL:3XAB1 US:VT^RZM<_P#:W<+,%_P-1GMFNI_X275_P#H4+W_
+Z6 MO!_C\^P3^SS>|?Q";X5ZQX\A:Q.9+3QWX#OOI>J12G_EHTD7RS-[R*QOP"
M*!ZUDF8_P"TG1G>-35XOUIML>L)) +IGE25\RI_ =JJKP_DJ.TU.AD: ^D MXMKO-
'TA17OOI_B7_@J^R:QCUCPO: M!>"[?I/#&FE^*+6(>)JC=#=[1Z_R2_M\$;P'H5U?:#XOA?
R\OP3XNA&FZK#+WC\F8CS&'<1 ME\=5CB,BOE.BZ\|JM26\J;O: %&RG#_ +>BO*YOA\^P52LJ&(3HU7M&HN6_
M^&5W"?A VY)^=CZ#HK'_. \$EU?A Z%"I_P"EH_X275_ ^A00?^EKQ3VS8HK M'_X275_ ^A00?^EH_P"\$EU?
*%") [Z6@#8HK'_. \$EU?A Z%"I_P"EH_X M275_ ^A00?^EH_V**Q_ ^\$EU?_ H4+W_OI:A A)=7_P"A00?^EH_V*P/'GPN
M_\$RP^P>-O#-M>A1B*9EVRQ?IDBX9?P-3_) +J_0H7O_?2T? \ "2ZO_P!" MA>_||+7-
B\A_P\VL/BJ<E.6\9)2B_5.Z9K0KU\552C)QDMFG9KYH\\$_ :& MN?B5^SAX/72?"OO:O+
[2];+VEM9ZM&)+NR4+EFBG&#@#"CY=POSR/E\KUKZ M; :YCUG6/#GAW7)M"N:6WLJR>&1Y2""TJH5Z>T35\R5_
WC=3JX+CFIET")4 M*,8>RC*4I**E",INM^H5Z!\S96-0^\$ Q/L:X7A73;^=+75H2WR\$QQO/NA.X'V(Z\$UY_5
MSP\HUYXBU^QT#3X&EGO:N."-!DLSL%_6OS?(Y*+3|+;_ +=F??NN?/X.>' -PU?XF: +&R_>BC MOTD\$X-
=|0.#C9HNA3R\$GT&*#6CHG@7P#X;VG0 M_@58V\KTE33X= \ WT1N_6NA3QO\JD2"/.P;=JJC 52H %?Z_.5N-\3>)H45
MVC2G4?RE*I?239_+7M>'Z7PTJDWYSC%?ZF7Z;?D=M_PDNK_P#0H7O_ M'TM' "2ZO\ I"A>_P#?2T?
ZM9A7_P\ZS.O+RCI*DODX4U/[YL/[5PM/^#A* M:\WSS?A Y-)Q_P#)3B?^%1_ '/6^?%711W\$C=:?
O\ \$AMMOTDR6/XBC_AE3P+ MJ\|C/Q;XK\OY^ ^NK^O64_@FW\JI: A)=7_ .A00?A OI:/^\$EU?_ H4+W_O
MI:/11^&JG^4I5O^OU2I6_ "K.2^5K>0?ZP9K^~^A_!&\$/OA,P\#_&=O M@=X>VG3?A?I!*_ =|MA<\$?C+N.?
>NLT12M+TB#I-LFV\K'_. \>=%647E K/M_ X275_ ^A00?^EH_P"\$EU?_ *%") [Z6O_ \ ?2T?) +J_P#T*%I_ -|+
M7HG*:%8_P#PDNK_ /0H7O\ WTM' "2ZO_T*%I_ WTM & Q16/ _P) +J_ \$*%I_ WTM' "2ZO_- "A>_ \ ?2T
:%8_P#PDNK_ /0H7O\ WTM' "2ZO_T*%I_ W TM & Q16/ _P) +J_ \$*%I_ WTM' "2ZO_- "A>_ \ ?2T :%8_P#PDNK_ /0H
M7O\ WTM' "2ZO_T*%I_ WTM & Q16/ _P) +J_ \$*%I_ WTM' "2ZO_- "A>_ \ M?2T :%8_B7_D+Z/_ -?I_P#031_PDNK_ /0H7O\
WTM9FN:Y\^HZ:))X;N8 MS' P#?2T :%8_ "2ZO_T*%I_ WTM' DN MK \ 0H7O_?2T :%8 \ PDNK_P#0H7O_
'TM' "2ZO\ I"A>_P#?2T :%8_ M "2ZO_T*%I_ WTM' DNK \ 0H7O_?2T :%8 \ PDNK_P#0H7O_ 'TM' "2 MZO\
I"A>_P#?2T :%8_ "2ZO_T*%I_ WTM' DNK \ 0H7O_?2T :%8 \ MPDNK_P#0H7O_ 'TM' "2ZO\ I"A>_P#?2T
:%8_ M "2ZO_T*%I_ WTM' DN MK \ 0H7O_?2T :%8 \ PDNK_P#0H7O_ 'TM' "2ZO\ I"A>_P#?2T :%8_ M "2ZO_T*%
I_ WTM' DNK \ 0H7O_?2T :%8 \ PDNK_P#0H7O_ 'TM' "2 MZO\ I"A>_P#?2T :%8I_E P CO>_ |>47\ S1_PDNK_ /0H7O\
WTM0:#=37OBR M\N+BRDMV-G'F*0C(Y\I0\OT444 %%% % !1110 4444 %%% % !1110 4444 % M>7_ME?!7XG_M
L^:I-@K\6+?P/XM&KZ/J_ASO/>:0;^"TO--U6TU&-9;< M2Q&6*1K01.N?) *OPV-I\0HH_/?XM?L3?M^?ML:S\6_V?)
IH67X?> O\|Q M&TOPS8>./%W@V\IOM1NM7L+3SWN+73G\JWA2TDER(WEE>?R5D^596(9?LCXD_M#?Q01?
[L\U&OV>M&T&TFC\^O\ "AUVIGBLI" W%N8(V/E1R/((UVX3Y=V.;U_MZUZ!10\ P_ \ ?IC:XT?A\IOV(O"G\&?Q<2^&/\$\$?
@A+N/2? \$AV2X1KZ. MYOKF\836\T8VHH9PH99'#@9(3'.9H?I\$?QW_&6\VCOBQ\OV'-9\ \$?V3\:: MR'6?
%7A+QT\Y#;+X+XD1#'+K%HUHCFX6X4JT\H_E%Y(@RW\$88J/K&B@#YA^ G M_! *G\G\X3?L\$^)_V#O^Q<^,=-^ (HU:
[~*B2\A6WN_\$>K:F2UY)5.B"3=L M\H*28E@A&YF3,9.* P#AR= P3' Z-G_O\6O_DROT?PYXBX6X*CB
M\17IU)8C\$RBY2C&-E&\$5&4W-/FDI\K*W1_X\Q\|P\Q\O7FD:N'JTHT8KW5* M4T\|M+;E:2@UT26KT7F?@)535;?
S(?4H^)/ MB!\ O\008/%FI644W_ "5:K%M@BEVOIB.Z4' [XR>Y->N' @B;_P3&8%3^S-P M>O\ Q6>M?_)E?2|<=|&
<9\,8K)\31K)58M)\L=DM82_B?9DD_ /;J?_9-X5_M\79-F=+&4ZU&\JN:>JV: A\5='U36/XF^'O@#QJAC\9>|I'U92,%=3TR*
<\$ M>GSJ:Y**_%83G3ES1=GY'I\#3A'TEDKKS/_ !3_,\$^_PIASQF6:7OV2_A\MSO\ ?FM?"UM;R-JEX45B??-
>>:Y_P1E_X)TZM.U\IWP(FT:Z/2YT3Q1J5NR_M11<:| WS7U'17J4L^SRA'EIXJHEV4Y6^Z\ICRJW#^18B7-
5PM.3\N3: ?Y; M:A_P10^ <+F?P\ M' _&/P\X.4BLO&2PY_VDF@?A5OZ^?T MIRN;TZU:G_P'D3B?!A_8'_P""DO@Q-
O@?IH?X8:X4^XV N M::JNG%OKIDE;X4P?#K_ (*Z>"?FN?A_HWB^9_RS\(^?VXL4?Z" B;|: ^J\ M\IY\PA+XLHPR_P_%/V/
8E2_ZE+X?P\RQ" Q5:| ^GHU\Q/@C A>G_11 MKP;/^*U_9#^+MF\$^VA>- \1?D\$"%G\|^B_O4\+? \$+PM|=/#87\|^*?
@*J MPCZ26\SEA[XK\WHI?ZN<&2VPE6G_->L;C(+|I5IK\TP^N<4PVOL9_ \ 7S#8 M:7XQITW^)\(*Z)_P5V^\$EQ=?
V=+^U?X*M;Q<:[3Q5X)UK3V7_ 'F\$&P?@W:O0 MO"O_4._) JZ-? \ X#ZI(WW8+?OZMI* TCN'50TKZ\2VOV'O'
MH5GJ\$A SQO:5)5_)@17GGB0\B;ICKQON:Q7^RQV;V1NL\O@^S\$OX2",/P M-
+_5CAE_PL5CZ7_ 'O@_H6OQ8R9\|!>VLGITU:3UW_AIFUMN-8^"?Q\LL=7E\ED_Z5SFC_AK; MX0V_(8;6M.I?
MN@W"X^NU37D7_# GI5\AGCX9?%2/B?:!|?7_PE6DV.MX^ MOFA-U\^"?_!6WPGQX? VW?
AWXMY_=|BKX;"PW_IWV)SC\^?^JN?_P#;/Q\A MY>57#54_)7"/_DP?ZQX1?Q\FKKS A6L-?
BY2_PV)3V>R:N_9\O|>1|2|5<_M\K6>\^ |#05K67QY^~^NH8%O\5= !/0ZK%&3^#5\WNK? \ %?-%X\5_ :JG_M_P :JO?
0\9U"S>0>_P\|L4\|LUD7OQN_ :RTG*_%#_ @C;W<8^|>>&_&FCZB9_M/=8O*#K\|"(L?X6+P-
:T;I\I\B3_!C_P\9N\$O^7N&Q=+UA*:^~-*WX_MGUI9>/? V\8_L\Q\I\QGIY&HQ/G\FK4AGAN\$ \$L\$RNIZ,C
C\^*(+W\K7X#V! M;?Q4_P""77QO\X_UEU#-C-:KZ_O;>:G%\JA#^VU_P2\$26V\3ZKK_@V\|E3? \ M?A!^E5(?D?>%5-?
US3?#.AWGB/6)_M+^"U>XN9.9VHBEB? KSX:UK'PT :TU/Q6D=N MA.FGQC;ZA'/&94#_ ^7R0\)/X5\
[G^9<=V\Y1B,7BLG- &XS>*OC/XJEUS7+ITM M\$=AIVG! W=K'V_0L1C&W MK_JOI_9^Q_ =YK7|>^--
%^'/@S4_ /B&;99Z790/-@M@<(|ICA0\4BOS4_ MX73XS_X7\ PO'I7_3C^U_MWWCMZ_ZK_*GKP_#LY?Y9WF^85
MI?NJ+67^\$3RO_86FFEZ1.<4OAPV7: M;2_FDWIC>|C^Y^N/P9^,WBOX,>*HM=T&Y>2T=P-1TYGQ'=1JP1V8#[K=0?4\$
M@_4VE:5\7?VAI-(UWQ)X@_X13PG?0K+::7HER'O:V%AD&6<<(" #|U1T)!&>: M_/6W_:%\$^" M-^(>M>_!-
TVQU2R2YMT0+O%E(Y0)G5-?0W\|O_ M_4<4^ (@_HO@:IE;ID:X@?%#4\6*6(ZR:4:1H0S,Y0&_NN,A2N1L'3@UW> M
W"/.:8K%9-F5#\$0P%+F;4KT]*JQFH2ISJOE7\ S=-5%N,N,N,M3J2>*>\$L MOHT,?A:|*6|J>" AOI_T3P5X> MM\| "#C?
Y2Y>4C^)\W.6<^Y)I\OQ^~^?PLT)_%Q->:-X=TV/_^_UO4XK6\$=\ M;Y649\LU\U?^*G_X*_J_M_?A4?VA/I_P:T6;|VC?
#K2J|>J-|-=">*C%65.A"Z2I7?)32_PN?H?AM: <|S_JZE'#2O+>=;7+ M?SY5SS?I)0\2CK_5E^FN:M-X2_9A\|>-
C)K43>6\ @+PW-)9POV\Z\F M"1HG^VN(%=)AT#POH=GIMA;+MM*PMDAAB7T5\$ 51\|5RM |5RI" _|GA(W_FJ

MOVDO ;1I_P?J9_V3F6+_WW%RM_+27LX_\@5Y5/FIQI#Y7TG_@DI'\%VI M0^)^OVLOBWXI^,NJ1.)%C^8^(I8I-
AD18;*W*)&O^P6=>>E?0_P_/A+!+?@I MH8_\ "CXD5:*^21W8+))\KRZ3GAZ2C)IRM>3I9_\G\VPHHHKS3T@HHHH ****
"BBB M@ HHHH **** "BBB@ HHHH S?&/_ "+%I_ UP-7-_ P"0?I_ UQ7^0JGXQ_P"1 M8O?^N!JYIW_ (/@_ Z_XK_(4 34444
%/%/% !1110 4444 %/%/% !7F_P" T+^R) M^SA^U1HPT?XZ?"2I<--MIJ3Q&*J.M_ JIYC^RQ\X#8)'(->D45MAI3B,)6
M56A-PDMFFTUUJ88C#8?&472KP4XO=22:JIGH?_#_-I?D?I?D?I0 M?Q.*V_* #KXM3EKN*,2I35\$PP, *J2A8U
YW5N_#G_@J+\'W4P?'SII? MP:KGP49RG:FE>I/(?+L+ILX+6VH>1-'D@:V*9/3-?3=87Q&^%_ PX^+_ (6G
M\\$_%3P+I/B+2+G_7=K%A'<1\$IF"N#AAV88(Z@BO: M?'8I3,J"D_P#GY"T) M_-)5I.*_D9LV=Y9ZC:17^GW4<
M\\$_8DAGAD#)(A&0RD<\$<@BI*^2I_W_@G-2_V?:N7Q) P3N_:2U3P*GF-* P M\622:MX:N6)R45)"TUIN/61" I<_#%+8?
V%OB\I_ IV+PQ_P40_9PU:X?YD\$ M4?C_-1OJWAJZ8G 8RQI:4L>D:AVQRO%#R+ZVN:;JK?W?AJK_+<:;-_W
M#_ \$OX>?%KPO!XV^%_C?2 M0\$.D7(<:CH]_<0L>XW(2 PSRIY'<"MNO!G"=*:A-6:W3T:/>A.%6"G!III M-
IA1114EA1110!B#P^H/Q!+^W'O@OQ)"6M;V+:73IT3@Y5U/9E(I^TP>": M^)?BO^S5!4?
A3J,I7F@SAZIH8F\$5K"!GB9>Q<#)C/LW?H2:;^I**_O\$+PLR M+Q!A"IB).E7@K1J12;MORR3^**=VM4TVI.S:?
UO#;I&&8\,RE"FE.G)W<7W[I M]WW3I:'YLZ+X7/2^(IX:9X?VWM)=2C^) M/Q)@1-31"--TT.&^R!A@R.1P7P2
!G;DD_=IIL0^1WO?^O*+^9K8KY/@GP% MR'A3-89CBZIQ-2FIP3BH0BUM)QYI-R6ZO*R>MKV:IG/_!'S'.<+"T:;I0D
MK2UYI-=KV5D^NEWM<****_>3Y"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ K'\2_P#(7T?
*_3_P"@FMBL?Q+_ _A?1_KI/_ M": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH
**** "I>R_Y'>I_ZHOYFMBL>R_Y'>I_P"O*+^9H V**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** !/?^ M"=7_ "0_5_L>I8_P#1I>I5X+_P3J_Y(?!_8I_ZQ_Z/KWJ@ HHHH **** "MBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
9P\I_ZI7^I_VH^\$;*90KEXB<_J I M>:;^<Q^"3/_!_SQI%I]GI+I^A^V.BD:I(DN+;\$KGN\BL 5I\$UROQQ^A#I]G_M
_\$/B+XT>/+KRM)_Z5+>W>&:_3:/EB3/5W>;:PK=ZF/I;FGA_&MU;_NVQIHWD'D90C@Y/R I75?"XP>+_ _H# MXO>
(OC1X\NO-U;Q)JLM I=X8E8IQ^6),I\$1 J*.RH!VKE: JS@KAN7"?#='+I MUZE:<;N=2K-
U)RE)N3O.6LE&_+&^O+&*;_U/Y!XMSREQ%G];&TJ_*5-M*\$ (1 M4(OC%65HK1-VYI6TYFI'US_P2*^'OP^&.^?
QMD^"GB'PMHTFLWBF^TO5M2MTD M>* &(9G1 ^&=\$MA#9Z?:QVIK\$X8T4^H_M(5_C/#OC!XO_9_ ^+WAWXT>
[KRM6]-ZK%>VF6(63:FB?5'0LC#NKD=Z_I M0^!WQ@ \ (2M_?"PI/_/=UYND^)-*BO:3+ M'N'S1/CHZ.&1AV9".U?@/B?P
M+A\FXNK<1TY3D8HJ7-)RC3<(IR27I_ ^\$W%SS3AJ.1SC& M.L.VURQ47_.W?FDU\4HOW;O:*NK,JHHHK\U,****
"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
D6+W_K@:N:= R#X/^N^* R% \$U0%/% !1110 4444 %/%/% !1110 4 M444 %/%/%
!45I86.J64NFZG9Q7%O/&8Y[>.,DB\$8*LIX(X(-2T4)M.Z!I- M69/Q? \$+_
O=?":Q1/40V3?'6N_!+QC*=SZAX'EVZ;=L#D+I#/_Z I6"IX^"KO6GOWYTO[M1> \K=\$W*/IT"IP_OI3=7 3>
M'DI7R6Y&_P" I3?N_5I1D_YCSKIGWIK3IG3IJ70SKGP)^+&E:JY:IKJPAF,= MY: _I=K:0+ +%SQEE /8FO1._:"_X)U_LP?
M"ZX/N!>\$IGPMXSB2I6AE_YZ&6+B5O>57(I8KSG;_P4I_9 ^ZVF?M&>";:LVS2O%5I\$/F&\VC MZRR\$?PYJOI-RO,-
<#6Y9?^ZK47Z1J:0E_VII-IDR/I2S7+I_?0YH_\ /RDG
M)>I>L>LX_I N^T7=H^N*:^+_9^_P""BW\I/06NGP#9>*KKPIXTB<17?@3QS9G
M2I5AE_YYB*4I96IHVR_Y>I_ZHOYFMBL>R_Y>I_ZHOYFMB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M"L?Q+_ R%I' _Z 3_Z":V*Q \$O_(7T? KI/_H)H V**** "BBB@ HHHH **** M"BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH *QI+_)>I_ZHOYF MMBL>R_Y>I_ZHOYF@#8HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH \%_X)U?D/U?_L>I8_I'U I7@O_3J M_P'2'ZO_-CWK' H^O>J
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *Q_\$O_(7T? \Z 3_@FMBL?Q+_R%I'_
_OT_P#H M)H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH S?&/_(L7O_7
USPE.M1_TQN(RLL7/.%8 IP:+_X M9<:_N_9-/VSICWJH=?B%X7M^5^&WQ1C,CP&,K>WLX5?YX/EG/VOB7E)2
MCY'S^VO^"HOPJM? \$IO+OVMO 6N_!QA,=L=CXWC TR[8<=\$VVI/(E0?WVW M#/_S7MWQA^.'@'X*_I/7?
CWXHUB&30-#T:347N+;96R@7:;1L#AFD8JB8ZL MZ^M M:OO_&^WP^&+^ABX)%? \$IP3I7B#^2+H?O\
3=8L(I B%SV.UP1D9X/4=C7XP M?%D_#PD_9I_- %>FZ%JMHFK>,_ C>));C1:9I IJ(H)"S1R' M#2L"O&&A(
KZ7A)4*T5I&3IR?,_AYHI, _I=6X\FB?NL^B? \ @B= P40/6?'WXZ_ \$X5_M&S7_#=7/47MSXD-"24E8\OFL8L]I\$1-
COH.BI^>U?IC7\POP.^_B_IG_X MO>'?C1X#NO*U;PWJL5I:98A9-I^:) =4="R_.ZN1WKIU_A1_P6I_X)I_\$3K
M*2I^_\$.AG4+NW2273?%&GW%GY!8(X-NISM!UJ]"I7'KF)V%=%7Y'4IU*4W&:: M:Z/1GI[#3J4ZL%.#33ZK5!1114%A1110
4444 %/%/% !1110 4444 %/%/% !1 M110 4444 %/%/% !6/XE_Y" ^C_P#7Z? T\$UL5C^)?^0OH_\U^G_-!-&Q1 M110
4444 %/%/% !1110 4444 %/%/% !1110 4444 %/%/% !1110 4444 %/%/% M% !6/9?CO>_I>47\$S6Q6/9?CO>_P#7E%_T
:_%/%/% !1110 4444 %/%/% M!1110 4444 %/%/% !1110 4444 %/%/% !1110 4444 %/%/% @O_3J_P'2 M'ZO_-
CWK' H^O>J%_X)U?D/U?_L>I8_\ I>I4 %/%/% !1110 4444 %/%/% M% !1110 4444 %/%/% !1110 4444 %/%/% !1110
5C^)? \D+Z/_P! ?I_\ M036Q6/XE_P"0OH_ _%^G_P!:-&Q1110 4444 %/%/% !1110 4444 %/%/% ! M1110 4444 %/%/%
!1110 4444 %/%/% &XQ_Y%BI_P"N!JYIW_ (/@_Z_XK_(5 M3I8_\BO>_P#7 U+_P!H#XO>(OC1X\NO-U;Q)JLM
MI=X8E8IQ^6),I\$1 J*.RH!VKI^ _^B'I%OB_I NWX0V/P7T;XI? \ "\$:2NJK> MZUL.F_:40+!IF(Z3#I17)& MV><)<-
X.K7QV(Y:I1VMR3?+%;*ZBUJ I79I%U/Q:Q-R+B_B7&4L/@_B'I^N_L?"PI(I&N6F)=;A&6N MNV\$5S'SCI9:JLJD?
W9U4__GN35N^@_VQI[6YI&_X;OY,*R>9_PKKKGMC^T: M;X'X^&_?B_IG_XO>'?C1X#_&X?
*U;PWJL5I:9^")R:3\T3XU+E'0LC#NK MD=Z^NXGXR\$S_):N\$6+M-J'R5)=K6+OR:=GY-GQ_ "W!?'#^=TL6'>="IK
MGI_\D6YI>ZITCZ>I> _\$GO^?OC^I_+3N/V<=*T6I5MT%IX4N9I)>%OIR MK:21IGZJ I15SO_#M/X@^ ^OWGL_O
4*^_GA7: _J-/U I5HM>L/(0);W*K@>Q M8YKZLHK\ (I\29Y""A*O*<5TG:G+_P_ " M@XOI3Y4_X1'_(+ #G0 BI\OBC:1_?
_X270+K1:Z8?I'V0F%6/_UO2? \M#:_J:WPY^3X\?\$R?%D.?W11^&OB.TU I SAW9+9=DB_K'-.?5E%7_:5"M_O.
M#I2\TI4W\O9RC'_R5D?V)B*/^I8RK#R:C47SJI&4ONDGYGRIHW_I8A_8K74 M(I#^&N^?AWJS.3\$^Y..?AFOO
M"K2?E*1?)_4W\GZBI GQ\AIITJ\XSIOY.M.HONBOOI\THKY3_P""57ASP3^I M_9U_:Z^,_P/_=G^HTW3_
!HIYIR^FZVN5: ?CW>C_(4Q_P%: ACSX!:_#^' M?Q&AC_U=K1I/
SZ:Y7^Z9=.8EC_M'KWH_LK+^W^ [XV'I4C._I_3A]O_VMFE M'>_#/_UIRA-?BX3^Z I645I_P##5? \P4@^&GR?%_\
X)U0^ (I6/_6ZO-? M'5O<9Q_YI I/H-OIF'^L^I30TKS=+_KY"=--??.5IS:/_MJFBO+?AK^V I^Q_\
%_RX_AS^TMX+U*>7&RR7Q! !>GA'79'%O&9P?/MB\$N8)=89,-I;O ML;TKS_\X+_M@/_E_LAZI_PCFJ>1XL9I I\$-\
^6^)=(Z'I1=+W'E1\$X8=) M)(O6ORL_X(?M?K^R7^U I I3^)-3CPIXR^:)XD,CXC@ \QQIGNCV'ERID; MR^M?H7#_-
B,ZX7Q69*_I^&OYN76?K=:1_O)GYSO#QYALCXJPF6.W)+^*_MY>;2'I9ZR_NM'I^4445^>GZ,%/%/% !1110 4444
%/%/% !1110 4444 %/%/% M!1110 4444 %/%/% !1110 4444 >_"_Z0^2'ZO_P!CWK' *_KWJO!?'^"=
M7_)#I7_I'06/_I>I4 %/%/% !1110 4444 %/%/% !1110 4444 %/%/% !111 M0 4444 %/%/% !1110 5C^)?^0OH_7Z?
_036Q6/XE_Y" ^C_I?I_I!-&Q111 M0 4444 %/%/% !1110 4444 %/%/% !1110 4444 %/%/% !1110 4444 %/%/%
M&XQ_P"18O?^N!JYIW_ (/@_Z_XK_(53I8_P#(L7O_ _P-7-_Y\I' _7%Y")! M:BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M****,>R_Y>I_P"O*+^9K8K'LO\ D=[W_KRB_F:V* "BBB@ HHHH **** "B MBB@
ILT_-Q\$UO<1+)&ZE71UR&I_Z@@I13J*_ /OB5^P?^QE\7O.D^ (I/_?@N^ MGESYEI'H_-O(GR_RN3/B_'\CO4^>IA
MH*K6/_4Z1\2O_4+?I MIWEJWG-GCM2#XZ_\%7_AC\OQ&_8I"_\$""/_%I_- 'GV\$@?WE@U I2I_P"Z M.:^K**W
+>E5_WG#4JG;_G_C_OI.F_O/_I C2_W;\$UJ?;_.ONJJHONMYRG_M_P/7_G@O_=?M%?LN?&3X;I\A
7ZAKG@:6XT>I6XMB^#\U"5W_P_-?^"D M7I" /Q:M?I?I4_A I9<>5:KJ8TZ9SZ"*\$3D^V.U I:7_? \$KIE3I F:XQ^8_Q M3^
'@_7I9<[KK4_#MO+,">XE*;U/N"#1I8X=K_Q*%2F^)J2_P#_9QO_ .3A M I6XDH?P\13J+M.FXO_P*\$K?^4SN-

U72I;L8I4T;4K>[MIEW17%K,LD;CU## M2#4I]?+>I_P#!'SICBTOI-9^\$4'C/X:ZA*VYK_P"" C>|LG#?W@LCR(OX*!QT
MJO\ \.6_MU?#CY_@;_P4Q\17=O'IS2OB5X4M-9/T=@|U\J_55R:/I/R2O\ MP,9R_P#7RG*/XT_:KYZ?
(7IHYXO_CX+FU_P"O52,OPJ>R?Y_,/T4YQ1_JYF#3=Y0J_CQD&_ _J?_DH_P#6 M3+J?^1J4O\ '3FE_P"IVOAI_P %5_\
@GY1YQ8Z9^TOH6E MW6I;+:>|UFTXGJ|JQO\$C7|(B1|U|EX5);>#/'>FC6?|BW3-9LSC%W15_'<1 MG\
M1L17G8O+C_3^&'B26WL?A7=+!0B_15(K2+I:ZE#A)TQ_'I:|XH/.R1#WKU^O!Q>%KX' M%3P|96G|N+7FG9GOX/%T,?
A*>)H.)I23|IJZ"BBBNP?-_/B*V@QI=|C%:4Z56L|0BV_)7,Z ME:E15ZDDEYNQUE%>,>(O^"BW|!_A;<-5_ Z^"IE3AEL?
\$UO=\$'TQ SFN(U?_M (+)_P#!./2|C|%:2M#+|J5R3B.VTCPSJ=RSQT!2V*_K7ITN'\^K_/_/'5)>D M)\
0\NMQ#D&'=JN+I1|:D5^I|/45K?/XO-OL/M3#/XT?,_9_%=?_Y'G_@J MOKC(W#0^?_
AAI>G|1Z|U9C^)^YH_L?|0_B8ZDO3VLO_2:37XA_:-G_P%#9^K MI17_) -53_ ^J:*^50\
AV3XJUWYOBI_P49_:/U'/^LATSQFPGP0|%(X3Q|9 MH_X<|?LF:/R'_B'XD>*_?/B+XBWFI|JR?
+=.M'U'(8?C&_P#2;_!'E/_MK^?S^#|?)2XZ|7_I,9GTCXA^?(?@#PB&/BSQSH^EA1ECJ.IQ08'0085PGB+|N7
MIB_PGN7Q!^UA;:>1/0OGQG9-(/^+*6_2N!|_.\$AO^"9^OGSOFN|_I_*?L5^%-IT'IDSXM6*7W*E?_R8 M/JW\$T_BQ-
*/I1DW|IK6_ \E/E;_AYWX@USY?'_!.S|HG4_ ('5NDOB+XF:9INWT)5U8GW_YKZ|HH_M/*8?|_M@8/_!3JO_TF<_LO-
Y_'CYK_#"DO_2H3/E;_A:_!7SO)_R|?V3?A1X:W=/_M^\$B\=S7FSZ_9%&?PH_X1?_@LWXDYU7XH_L_ ^&E;D?V'HFIJWC|I?
Z20"?7WKZ_MIKY6_P""P|8/_#)?(I>J?_"_:IY'BSQGOT3PWY:XDASH?M%TO<>5\$3AATD_MDBI:|LKQE:-
_QI8/"82BIU&DO<:YY2T2U?DCS\UP=##LNJXW&8RLX4XMO_MWU&_9+DC'5O1>:/QI_X*\$_M+ _&3IH7X\WNE?%?
XT6OCB#P=<7&DZ-JVFZ1'8_MVDDHQ5M\$HKS=DDE=Z_MZ+<_D''8VOF&GB:TFY2=|6Y/R5VVW9::O9'|I_ \?\$OVP?)
AK3|D/2_ ^\$CU_M3S_ %GZ=S9HGB3S?)_L0?9|INYV(#+K)' +Z514U^G_1_ ^:_!_X9+ _&O= M+_X2/5/(^)_JFB>)/,?
\$<_I.QIGNF#R|2I_L>D'(>T=S+M+W)|W9>[+_MY:ONF%#%?%?%? MWP4444 %%%% %1110 4444 %%%% %1110 4444
%% %%% %1110 4444 %%%% M'@O_3J_P"2'ZO_-CWK'_H^O>J|_X)U?D/U?_L>|8_ \1|>|4 %%%% ! M1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?_ \ MD+Z/_P! ?I_ \ 036Q6/XE_P"0OH_ _% ^G_P!|- _&Q1110 4444 %%%%
!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &:XQ_Y%BI_P"N|YI_MW_ (/@_ZXX_(53\8_ \BQ>_P#7
UR_Y>|_Z\HO_MYFMBL>R_Y>|_P"O*+^9K8H_**** "BBB@_HHHH_**** "BBB@_HHHH_**** M "BBB@_HHHH_****
_8^/(P3^#7Q:@-K|4_A-X:21E=NS7M"M|L8_|:HV*_M.5?|\SAOV#=>U\$Z_X9^\$MUX/U7GR|5\%>(:S39(OIU(Y/*!
'Q7TQ17HX3-_MUP"MAJ\X+M+32^Y.OYN,R?^OA? \%)OBC#%IACATCP|XX2S|0B_NI&VQVJ-<(I0?>);#%\$1FPVW%?
C+_MKN:N:OXGUR\2^=(1EO+&_#%|DN:ZIG?<|TC%W=CW9F)/J: ^ _ ^ _J8A_MPN+|JH6T_9L\Z|YF^?<
#S=:GE/E+C6)%'F9QP?)CVO#_NKM,*^ _I_P|R_ %X_M?(HXO&)>VK>|?EC%(OV4W%)O3WM:VYK\^L>
(N8X3\$Y_+"8)OV-'W;_ \$E/VK_VG?AA|4V_9E^?CGP:I_ ^ (6H1^1-X|L|F>T@O_M8XGV>5Y#_I)_-L?(8,RQ#C@U^GW_
H/_@K#XD_Y#7|?W@OPUNZ_ \ (|H^+S_M;GT^U_,X|9K|#"US6/#&N6?B7P|J,MG?Z==OW-C=P/M>":_@Z.I|,K_\$'U%_M?
T=?L(_M2:/^V+^R|X8^-\B|2W|W:~9Q\$5I%TM=2APDZ8_A4M^ \4'G9(A|U|
M7XI82ME5>GF>&HTW&|JLW*G":YDM'|T7NE;:/F?;_%&_H9M0J97BJU12I^|_M!1JS@N105>Y*.TG??|7D>:_ \.'?M>:_
C \^14WXAW_|I_ \PCOANPTG_M(I0+#+:/^'5?A_5_F?_+;W|1/B+=| ^" _ \BR_P"1WO?^O*+^9K8K'LO^1WO?^O*+
_M^9H_V**** "BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_**** "B_MBB@_HHHH_**** //?
^"=7_)#17_['O6/_1|>|5X+_P_ZO\ DA^K_P#8|ZQ_MZ|KWJ@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_****
"BBB@_HHHH_M**** "L?Q+_R%|'_ .OT_P#H)K8K'\2_ \A?1_P#K| \A_Z":_-BBBB@_HHHH_M**** "BBB@_HHHH_****
"BBB@_HHHH_**** "BBB@_HHHH_**** _WOC_R+_M%|_UP-7-_Y|'_7%?Y"J?C'_D6+W_K@:N:=_P_@^#_KBO_(4_34444
%% %M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_M_ ".|I_UY1?S:-%8|E_R_|I_UY1?S:-%
!1110 4444 %%%% !1110 4444 %M% %1110 4444 %%%% !1110 4444 ?_N_ \ \$:O^":WB?7+SQ+XA_9XEO+_M_%&
|DN:ZIG|:ZTSS2,7=V/VSEF8DD^IK"US_@B|_P_\$TK/4=-@MOV:-J7%R_M4F'_F.LG<-N<H?_")W?_#D|_OC_P#1L_ \
Y>>M?_E>O_-G|_M(?|/7|(6AZGX: 9X\^2^'|#5|M+G4+1M8ZBZ.)Q52<'N|3E)::-M'1A,@R+_5U6PV%|ITYK:4:<8O7?5),
M****H|8**** "BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_**** M
"L>R_Y>|_Z|_HOYFMBL>R_Y>|_Z|_HOYF@_8HHHHH_**** "BBB@_HHHH_**** M** "BBB@_HHHH_**** "BBB@_HHHH_****
"BBB@_HHHH_ \%P""=7_)#17_M_|O|UC_T?7O5>_" \ \$ZO^2'ZO_P|CWK'_*/KWJ@_HHHH_**** "BBB@_HHHH_M_****
"BBB@_HHHH_**** "BBB@_HHHH_**** "L?Q+_ _A?1_ \K|_ _":_MV*Q_ \$O\ R%|'_P"OT_ \H)H_V**** "BBB@_HHHH_****
"BBB@_HHHH_*** M* "BBB@_HHHH_**** "BBB@_HHHH_S?&/_ (L7O\UP-7-_Y|'_ %Q7^0JG_MXQ_Y%BI_ZX&KFG?
 \ @^#_*XK_(4_34444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%%
!1110!CV7_(IWO_7E%_ _UL5CV7_(IWO\ MUY1?S:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10
4444 %8_B7_D+Z\A|?I|!:-%8_B7_D+Z\A|?I|!- _&Q1110 4444 M% %1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !6/9?_M(IWO_7E%_ _UL5CV7_(IWO_7E%_ _T_:% %1110 4444 %%%% !1110 444 M4 %%%% !1110
5\I_M?_+:/Q|!(?MO_?_ _"=P/U?0?#WBKXIZ/K&N7_M_(Q3:<|I%ING:?\$6,%I:+-
"+F\F8/@O(\$A2)W9)>\$KZLK Y7_P""HO\ P2K^_M%O\ P4L\ \$^'KZ?
Q_K7P| ^)WP_OGU'X8_%/PO*R7^@7;:"00K(986:.,L@9&|_MC4HZ'.0#FO\ @G-/5/V|:G0O@?I_QZ: ^'O'_@GXC_
2U\2KXN309K'6|*U>_M.UTMS:7CB>2"29+R619E2%|T\$@93D\$R_MF_M*?%_ _" [2#_LG_ /!+5O@_M4OB?
P:H%OK'Q.N_C3>:CY_*WK_+&SM(M.#2M,(X)9YBXVT-;P6J_/_@#<(FW*AV//I)^WG_P_&|O| \$O|9/C77OVD/|_-
QXJ^&/QUU&Z_M'3_M?BYX3|6:@+N#440+! (\+SE,QKL1=L0B<(H5'3_P>M6W|2'|OG| \$7_ /CQ5^_MU)_P50\1?
#Z|3>^1.OM5UVX1VMY'I:P^*RSL|8WYV2>5C&FXPB^9.%QM7_M>WB7Q&_ ;M_ ;D_9<_8?_ "\A_P5+_
&BI_ ^"H>#>2.C:K1_A/H?AN2.X)+^' M|4EACBEL|XS&Z2O:3|3.M)\$4V|@BP_*U?&_P#P4\$_.":_O::_X-8_B-)^_MTO\
Z5\0_AU\2HO!7Q)U6S4"/59-(2V|HUWA0_P!DC=L*#@?;G_!:_MR^ \V\ P0_ ^*UQ:O%_9K?";3HI_C&TAY+1C?BR8_"@#
|FT+7- \3Z)9^)?_M#VI0WFGZA:QW-C>6|AHYX9%#I(I'564@@|P:M5XA_P_\$RK^O'I7_3=_9|T
MSQ@LBZM;_!'P|%J:S9WBX72+42|L|MP.??>WT_%9/CKO#JGA3PC?^ (I\$ _M*W>N7=I_9(-)L643739'R(6XS|?2O(?
^&L/C9_T8_P"._P#P*MO_(J@"" @MG5_R0_5_ ^Q|UC_T?7O5?>?_ P3G\3:PWP)U.1O|UZ" _C35'9"RY0M(&*GW4D_MJ?
<5|Y_PDNK_ /0H7O\ WTM &Q16/ _PDNK_'A>_ |I+1_P)+J_ \$*%|_WT_MM &Q16/_)+J_ \ T*%|_P|I+1_PDNK_ /0H7O\
WTM &Q16/ _PDNK_'A>_ |I+1_P)+J_ \$*%|_WT_MM &Q16/_)+J_ \ T*%|_P|I+1_PDNK_ /0H7O\ WTM
&Q16/ _PDNK_'A>_ |I+1_P)+J_ \$*%|_WT_MM &Q16/_)+J_ \ T*%|_P|I+1_PDNK_ /0H7O\ WTM
&Q16/ _PDNK_'A>_ |I+1_P)+J_ \$*%|_WT_MM &Q16/_)+J_ \ T*%|_P|I+1_PDNK_ /0H7O\ WTM &Q16/ _PDNK_'A>
M|I+1_P)+J_ \$*%|_WT_MM &Q16/_)+J_ \ T*%|_P|I+1_PDNK_ /0H7O\ MWTM &Q16/ _PDNK_'A>_ |I+1_P)+J_ \$*%
|_WTM &Q6/XE_P"0OH_ _% ^G_M_P|!-' "2ZO_-'A>_ \ ?2UF:YKFHSZCILDGANYC,=R61&9_P#?2T?) +J_0H7O_?2T
:%%8 _DNK_ \0H7O_?2T?) +M|_ \ T*%|_P|I+0|L45C_ /"2ZO_'A>_P#?2T?) +J_0H7O_?2T_:%%8 _M_DNK_ \0H7O_?
2T?) +J_ \ T*%|_P|I+0|L45C_ /"2ZO_'A>_P#?2T?) M)+J_0H7O_?2T_:%%8 _DNK_ \0H7O_?2T?) +J_ \ T*%
|_P|I+0|L45C_M_ /"2ZO_'A>_P#?2T?) +J_0H7O_?2T_:%%8 _DNK_ \0H7O_?2T?) +M|_ \ T*%|_P|I+0|L45C_ /"2ZO\
|'A>_P#?2T?) +J_0H7O_?2T_:%%8 _M_DNK_ \0H7O_?2T?) +J_ \ T*%|_P|I+0|L45C_ /"2ZO_'A>_P#?2T?)
M)+J_0H7O_?2T_:%%8 _DNK_ \0H7O_?2T?) +J_ \ T*%|_P|I+0|XO_Y_M%BI_ZX&KFG?@^#_
XK_(5S_B77M3N=|NH)O#%U"K1\$&5V7"^YJS9>(I52S_MB1?"5XP\$2@,&7|XZT;M%8 _DNK_ \0H7O_?2T?) +J_ \ T%
|_P|I+0|L_M45C_ /"2ZO_'A>_P#?2T?) +J_0H7O_?2T_:%%8 _DNK_ \0H7O_?2T_M?) +J_ \ T*%|_P|I+0|L45C_ /"2ZO\
|'A>_P#?2T?) +J_0H7O_?2T_:% M%8 _DNK_ \0H7O_?2T?) +J_ \ T*%|_P|I+0|L45C_ /"2ZO_'A>_P#? M2T?
) +J_0H7O_?2T_:%%8 _DNK_ \0H7O_?2T?) +J_ \ T*%|_P|I+0|L_M45C_ /"2ZO_'A>_P#?2T?) +J_0H7O_?2T_:%%8
DNK_ \0H7O_?2T_M?) +J_ \ T*%|_P|I+0|L45C_ /"2ZO_'A>_P#?2T?) +J_0H7O_?2T_:% M%8 _DNK_ \0H7O_?2T?) +J_ \

I%&I P!+0L145C /'2ZO\ I'A>P#? M2T?) +J_ OH7O ?2T %E P CO>]>47\S6Q7*6NN:BOBFZNE\W+.JM&K0IE MW*
3R:T ^\$EU? H4+W OI: -BBL? A)=7 Z%" \ JZ6C (275 \ H4+W OI: M -BBL? X275_P#H4+W
+Z6C_A)=7 Z%" \ JZ6@#8HK' X275 ^A00?^EH M_P"\$EU? *%\" \ JZ6@#8HK' _.\$EU?\ Z%" \ P"^EH_X275 ^A00?
^^EH V*M_Q ^\$EU? H4+W OI:\ A)=7_P"A00?^EH V**Q_P#A)=7 _A00?\ OI:/ M^\$EU? H4+W OI: -BBL?
A)=7 Z%" \ JZ6C (275 \ H4+W OI: -BBL? MX275_P#H4+W +Z6C_A)=7 Z%" \ JZ6@#8HK' X275 ^A00?
^^EH_P"\$EU? M_*%" \ JZ6@#8HK' _.\$EU?\ Z%" \ P"^EH_X275 ^A00?^EH V**Q ^\$EU? M_H4+W OI:\
A)=7_P"A00?^EH V*Q \$O\R%! P"OT \ H\H_X275_P#H_M4+W +Z6LS7-@H_ZNBL? A)=7 Z%" \ JZ6C
M_A)=7 Z%" \ JZ6@#8HK' P"\$EU? *%\" \ JZ6C_A)=7 _A00?\ OI: -BBL M?
A)=7 Z%" \ JZ6C_A)=7 Z%" \ JZ6@#8HK' P"\$EU? *%\" \ JZ6C_A)=7_M_A00?\ OI: -BBL?
A)=7 Z%" \ JZ6C_A)=7 Z%" \ JZ6@#8HK' P"\$EU? M_*%" \ JZ6C_A)=7 _A00?\ OI: -BBL?
A)=7 Z%" \ JZ6C_A)=7 Z%" \ JZ6@#8HK' P"\$EU? *%\" \ JZ6C_A)=7 _A00?\ OI: -BBL? A)=7 Z%" \
M\JZ6C_A)=7 Z%" \ JZ6@#8HK' P"\$EU? *%\" \ JZ6C_A)=7 _A00?\ OI: M-BBL?
A)=7 Z%" \ JZ6C_A)=7 Z%" \ JZ6@#8HK' P"\$EU? *%\" \ JZ6C_A M)=7 _A00?\ OI: -BL>R_Y">I_ZHOYFC_A)=7 _A00?
\ OI:/ T&ZF0?E MY<7%E);L;/4A&1R?2@\#@?HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M*** "O_C?)
\ WIL?3OVGI- :3_9@^\ (^NZTV3P!:UM*K+*V?=I7WRB@#X1_8' _.">/OI0Q\$I'/I/I5/I9U MU!&FZY#\ @A:>%?AM/-
!CENKCPCXDNI? -Z?\$&\ V\$KDQVIM8 M9H:2X:")\$221V)9=\@D!\ NOK*B@#Q>/I@GIGB;IB_5OV\$=^U.>^DDFO-
0EF"@?:Y:F:2Y,JJ)6W*J@ #Y^\1 \ \$R?VE?CM^RI MX*_X)R_M0?&#PKJWP;\ (W&DP>(-
>TB*Z77_.D:5+)8:=0.HAL"3;VWVBX MCFG;:R6V) 9"5^Z:* (I6UM;&UCLK*VCAAAC"OPQ(%5% P%' ' J2BB@
MHHHH \ \% XU?AD/U? L>l8_I'UIU7@O_3J_P"2'ZO_-CWK'_H^O>J "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH *_Q \$ MO_(7T? \ Z_3 _@FMBL?Q+_ R%I' _OT_P#H)H_V**** "BBB@ HHHH **** M "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/ (L7O_7_U \ 7E% _UL5CV7 _".II_UY1?S-&Q1110 4444 %%%%\ !1
M110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 X+_ P3J_Y M(?)_ 8]ZQ_Z/KWJO!?)
@G5_R0_5_P#L>l8_I'UIU0 4444 %%%%\ !1110 4 M444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !6/XE_Y"^C_
/7Z?_03 M6Q6/XE_Y"^C_/7Z?_030!L4444 %%%%\ !1110 4444 %%%%\ !1110 4444 M%%%\ !1110 4444 %%%%\
!1110!F^,?^180?^N!JYIW _"#X/^N*_P_A5/QC_M_P_BQ>_]<#5S3O\ D'P'?<5_D*)J*** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH QI+_ '>I_ZHOYFML>R_Y">I_Z_MHOYFMB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "L?Q+_ P_A?1 ^OT ^@FMBL?Q+_ P_A?1 ^OT ^@F@#8HHHH
**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO^1W_MO?\ KRB_F:V*QI+_
)>I_ZHOYF@#8HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ \% XU?
\ DU? L>l8 \ M1>l5X+_ ,\$_ZO^2'ZO_ICWK'_H^O>J "BBB@ HHHH **** "BBB@ HHHH *M*** "BBB@ HHHH ****
"BBB@ HHHH *_Q \$(7T? KI/_H)K8K'\2_\ A?1_M^OT ^@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HH MH **** "BBB@#-\8 \ (L7O_7_U \ 7E% _UL5CV7 _".II_UY1?S:-% !1110 M 4444 %%%%\ !1110 4444 %%%%\
!1110 4444 %%%%\ !1110 4444 %8_B7_M)"^C \ 7Z?_\$\$_UL5C^)?_D+Z/_ P?!_I \ 030!L4444 %%%%\ !1110 444 M4
%%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 5CV7_(IWO\ UY1? MS:-,%8JE_R.II_P!>47\S0!L4444 %%%%\ !1110
4444 %%%%\ !1110 4444 M%%%\ !1110 4444 %%%%\ !1110 4444 >" \ \$_ZO^2'ZO_P!CWK' *_KWJO! M?
^="7_)#l7_'O6/_1>l4 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ M!1110 4444 %%%%\ !1110 5C^)?^0OH_7Z?
_036Q6/XE_Y"^C_IPI !_- &MQ1110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %M%%%
&;XQ_P'180?^N!JYIW (/@_ZXK_(53\8_P#(L7O_%P-7-_Y!)_7?MY"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HH MH **** ,>R_Y">I_P"O*+^9K8K'LO\D=[W_KRB_F:V* "BBB@ HHHH *** M* "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH *_Q \$O\R%! P"O MT \ H)K8K'\2_P#(7T? *_3_P"@F@#8HHHH **** "BBB@
HHHH **** "B MB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1W_MO?\ KRB_F: -BBBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@#P7_@G5_P_D/U?_+'O6\ T?
7O5>" \ \$_ZO^2'Z_MO_V/>L?^CZIZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ K'\2_\
(7T? KI/_H)K8K'\2_\ (7T? KI/_H)H_V**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
S? M&\ R+@! P!<#5S40^0?!_UO7^0JGXO_Y%BIP"N!JYIW (/@_ZXK_(4_344 M4 %%%%\ !1110 4444 %%%%\ !1110
4444 %%%%\ !1110 4444 %%%%\ !111 M0!CV7_(IWO\ UY1?S:-,%8JE_R.II_P!>47\S6Q0 4444 %%%%\ !1110 4444 M
%%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !6/XE_Y"^C_P#7Z? \ T\$UL_M5C^)?^0OH \ U^G _!- &Q1110 4444
%%%%\ !1110 4444 %%%%\ !1110 M4444 %%%%\ !1110 4444 %%%%\ !6/9?\CO>_]>47\S6Q6/9?\CO>_P#7E% _MT
:%%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !111 M0 4444 %%%%\ '@O_3J_P"2'ZO_-
CWK'_H^O>J \% XU?AD/U? L>l8 \ M1>l4 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ ! M1110
5C^)?_D+Z/_ P?!_I \ 036Q6/XE_P"0OH _%^G_P!_- &Q1110 444 M4 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\
!1110 4444 %%%%\ &;XO_MY%BIP"N!JYIW (/@_ZXK_(53\8 \ BQ>_P#7 UR_Y">I_ZHOYFML>R_Y">I_P"O*+^9K8H
**** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ K'2_\ A?1_P#KI/\ Z':V*Q \$ MO_(7T? \ Z_3
_@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ K'LO^1WO?
^O*+^9K8K'LO^1WO?^O*+^9H_V** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /!?\ @G5_R0_5_P#L>l8_I'UIU7@O !_K_DA^K \ 8]ZQ_P"CZIZH M **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ MK'\2_P#(7T? *_3_P"@FMBL?Q+_ _A?1 \ KI/_ *: -BBBB@ HHHH *** M* "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** _WQC_R+%I_M_-<#5S30^0?! P!<5_D*I^?^180?^N!JYIW (/@_P"N*_R%
\$U%%%\ !1110 M 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 %%%%\ !1110 4444 8JE_R.MII_UY1?S:-,%8JE_R.II_-
>47\S6Q0 4444 %%%%\ !1110 4444 %%%%\ !11 M10 4444 %%%%\ !1110 4444 %%%%\ !6/XE_Y"^C_/7Z?
_036Q6/XE_Y"^C_M/7Z?_03

8U%?/"E_P#@M;T>1+/"1_P#N:C_A2\ P6M_Z/(\%G_A(\ W-0!MJC45\< *7_X+6_I'D?"S_PD?
_N:C_A2_P#P6M_Z/(\%G_A(P#W-0!JC45\ M< \ "E ^"UO_ \$>1+/_ D?_N:C_A2_ !:W_H\CX6?^\$C JS4 ?8U%?/\ MPI?
(+6_P#1Y'PL_P#"1 \ N:C_ (4O_P %K? \ H\CX6? \ A(_ '-0!JC45\< *7_ "UO_1Y'PL_) _ .YJ/^%+ _ P#!:W_H\CX6?
^\$C_P#1+/_ M_ "1 ^YJ/^%+ _ /!:W_H\CX6?^\$C_/1+/\ PD? _ +FKB/BGH \ P6\I> _ M17AK7?VM/AS<7/B?
7&L=,EM?2I(91&7+2;K<: @8XR1+/"1_P#N:C_A2 \ P6M_Z/(\%G_A(\ W-0!JC45\< *7_X+6_I'MD?"S_PD?
_N:C_A2_P#P6M_Z/(\%G_A(P#W-0!JC45\< \ "E ^"UO_ \$>1 M+/_ D?_N:C_A2_ !:W_H\CX6?^\$C JS4 ?8U%?/\ PI?
(+6_P#1Y'PL_M_P#"1 \ N:C_ (4O_P %K? \ H\CX6? \ A(_ '-0!JC45\< *7_ "UO_1Y M'PL_) _ .YJ/^%+ _ P#!:W_H\CX6?
^\$C_P#1+/_ M_ "1 ^YJ/^%+ _ /!:W_H\CX6?^\$C_/1+/\ PD? _ +FH_M_P"%+ \ !:W_*/(\%G_(2/_P!S4 ?6GC'
)%B\ ZX&KFG?@^#_KBO\A7_MPM\;?"?_60^%_ PHUWX@>)OVN?AM=6&E6)GNK>R)#S9%!_PNZW_SSW-;?A
MGX5_%\I-< \ Z?K5E^V\+TAO+&*%>)"?/S*KH&_+; &< &@#I4HKXY_X4O_P6_MM_Z/(\%G_A(_1+/_ "1 ^YJ/_L:BOCG_
(4O_P %K? \ H\CX6? \ MA(_ '-1_P *7_X+6 _1Y'PL _ "1 ^YJ/_L:BOCG_A2 \ P6M_Z/(\%G_A(M(\ W-1_P_I?
(+6_P#1Y'PL_P#"1 \ N: @#I&HKXY_X4O_%K?^CR/A9_XM2\I S4?^*7_ "UO_1Y'PL_) _ .YJ/_L:BOCG_A2_ !:W_H\CX6?
^\$C_I MS4?^*7_X+6_I'D?"S_PD?_N: @#I&HKXY_P"%+ \ !:W_*/(\%G_(2/_P!S_M4? "E ^"UO_ \$>1+/_ D?_N: @#
I&HKXY_X4O_ %K?^CR/A9_X2/_ -S4_M?^*7_P""UO\ T>1+/\ PD? _ +FH ^QJ^*^?^%+ _ /!:W_H\CX6?^\$C_
/_1+/_ "1_P#N: @#ZNLO^1WO?^O*+^9K8KX" T+1 ^"P^J_ 'O7_MOA+;_ M;?#E-6TG0\6^N\I_M_ "2^1)%^Q"JN+?=N&.
<@ "NW_P"%+ \ !:W_*/(M^%G_(2/_P!S4 ?8U%?/"E_P#@M;T>1+/"1_P#N:C_A2 \ P6M_Z/(\ M^%G_A(\ W-0!JC45\<
< *7_X+6_I'D?"S_PD?_N:C_A2_P#P6M_Z/(\%G_A(M_P#W-0!JC45\< \ "E ^"UO_ \$>1+/_ D?_N:C_A2_ !:W_H\CX6?
^\$C_I MS4 ?8U%?/\ PI? _ (+6_P#1Y'PL_P#"1 \ N:C_ (4O_P %K? \ H\CX6? \ MA(_ '-0!JC45\< *7_ "UO_1Y'PL_) _
_YJ/^%+ _ P#!:W_H\CX6?^\$C_M_P#1+/_ "1 ^YJ/^%+ _ /!:W_H\CX6?^\$C_/1+/_ D?_N:N(\^*>C_ \!8?P%XS\
M^%>M=;T^"-Q<^)\<:QTR6U\+LAE\$91+/\ PD? _ +FH_P"%+ \ !:W_*/(\%G_(2/_P!S4 ?8U%?/"E_P#@
MM;T>1+/"1_P#N:C_A2 \ P6M_Z/(\%G_A(\ W-0!JC45\< *7_X+6_I'MD?"S_PD?_N:C_A2_P#P6M_Z/(\%G_A(P#W-
0!JC45\< \ "E ^"UO_ \$>1 M+/_ D?_N:C_A2_ !:W_H\CX6?^\$C JS4 ?8U%?/\ PI? _ (+6_P#1Y'PL_M_P#"1 \ N:C_ (4O_P
%K? \ H\CX6? \ A(_ '-0!JC45\< *7_ "UO_1Y M'PL_) _ .YJ/^%+ _ P#!:W_H\CX6?^\$C_P#1+/_ M_ "1 ^YJ/^%+
/_!:W_H\CX6?^\$C/_YDL)99KUY"(G2(>9*517*LOU\10\YW\! ?V4_ @+^S5\&3\ _A_M-X
M\7PU\)=3;K:ZA,II+JIQ=,S75S>S7#)=S3,S&225F9\X/ 'F/@K_@E_MC^S3X-7PEX8EU?Q?K7@7X>ZVNL?
#WX8:_KXN=!\WJ,S02P>6)IQ_78P174 MT50VB2,HA7Z2HH ****
"BBB@#R#JBGp+XN^WPGU+1/&F@SZ==S>_4NH_MX+@_ ,T,DY9'X/0CD5Z_110_4444 %%% %!1110_4444 %%% %!
!1110_4444 M%% %%% !1110_4444 %%% %%% !7D'1_ @7Q=XL^+^PDUOPYH,IW::XPDNM6GA *MVL)@90[<L\5Z_10_4444
%% %%% !1110_4444 %%% %%% !1110_4444 %%% %%% !M1110_4444 %%% %%% !1110!YQ^UWX4\1^.?V?:&/A'PCIS\$M_J5_H\16=G
7E? MBZAX/TZULM18#RY9HW8N@YZ@&O7Z** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH *)@_ :A_OB\ MQ9\6\A)K?AS09\INTT\O\A)=M/" 5M83_RAVYZ9XKU^B@ HHHH **** "BBB@ M_HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ KR#P:X%\76' MI?:C3X@7F@SQZ+J'_ 3K6RU%@/+EFC=BZ#GJ_! ?HH ****
"BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** /SZ^+= _P %"O\ @LW\1?V* M/\$NN:FOPA_9W\ Z=<^ (?
#>EZI/!>)?\$^J".)KUX'1I\ VMBZK;=GGAG8, M40+L_P#I/\A :(\9?#3_ (*1_M"?
\\$HO&WBS4I=T7P%9Z9XS^\$FH;YJ,MY>V
MV@7\.)N=,DGF9I9HK2ZG2.%I&= +DVLV\$0#SS_@G9X2U#X) \'"OI;G@'Q;" MT5S\0?
'A'QEX6DE&#>Z:D4D\$D>>JOW,YA)'&Z/'\O)A/5_B%_ P<|?M1?& MI1(GET+P)\O\$#O@W4KQ!\^Z.HWRZ=?
K&\$Z,ROVLFX#E>AQF@#4_ :3U#XO^!O^ M#B7IE_PJO\1?CC40"7C#P3XSOKKP/>ZK'T%K\;?<"-H\;WCB5R%EP'FV0
M;!_7/Z!_ \$+QYX6^%G@/7/B=XXU1+1/#FCWJ;Q>R?=M\6WB:660^RHC"* M^! ?VSO\ EBP_8P_DSX_P#3>U?
1O_!0G_BY'AKP+^R!?:_QA\=6FE:[\$.< M>'-6U/6-X_YS6MHUB3_>U&=Z/C'XZ_&WXW_"OX<_LL_L_>'O\$6J^#OB5
M^V3\4+IQ1\5=9=4U6SMYDPUO<1P74&GQ3K\T<5HQ3#*K+Z3^ MT%X[A_X)7 \!1WJF\PI*=3U2W^SW\0FIWW@?
Q=X0U#7+JIMK'75\$#:5JEK_MJDD:>629H)K\194VNRM(H:N;_X*V>?MO\%?%G/V ?VG-6A;_A&D\9Z_X.
MO:QOB.VU+4:(81DI)-TS.*%4^2:/^"X7A/5_C) P42_X)_PA\$^J\I>) MO&%S%"_M#IVB_8KNYE;'W5V\ ">I&!S0!J?
\.NH?%_P%_P3@O\ XO\ PF : M+<>#IM+ \5Z%9W>E>%M5CLK?4H+F_2"5+B2.,7+ K+R@F6,!E#DY_1NOSM_
MX.EO^40/BG_L>/"_IWMJ^VOVEOC9I/I-/_I/OC/X:S8/>1>\$ _#EWJ4>GP_Z
MR^FCB8PVL8')DEDV1(\R6D4#K0\I+X;^7I2WQ=^/7Q=^IGC2/PIJEKSM)EN-?
U2V1P4>X6XO:BW5'1I1I% @##: #GXP_P""E/I#_P_4_M_P#@D#IG@'_ @H)^PI^V\A:]<40_\$W1=#\;^#?
B+ \0+C7+3QS;ZA<"\$QROR_M SM(0.!@!R\8C=%:OT_8]^#5_ \LV_LM>\$ /AAXQU6&XUO3='-YXQU7< EYK
M5R\WFIW9\0'6\GN93S_ 'UIUY7:>#;#_@H3<_!_!0'B&'? \GX5ZRVM?#6W_MG7">.?*\$H\4>OD'_)
<+!1'E%FV_W+Q+*JTW4=M)*>9?V% _-H_QO\ \$+_ @M^K^SK_P2=^_
(QU7P_IGQ*74_%QO8U:0=1EL\Z3PIIUO)\#IT5Q"RRP)>7%_MO)%+)\$R2!\$VJX#M6?=?%2Z_X)W_ \%C/A;^QYX4U?41\
(OVC/ ^J'10#>I:K/ M=P^'?%&DJT\IS6C3N\007-LT<;VZG89\I@'LS\N_ &H-*A\?'+W\[*]2;7
M\%UX3^ (WP.U\PKX=UNVF62TFO;:/4-0_6524/FPWD>P@_ /GY\$16^ M-? \P<' _# _/_
K"\LO@#PIXO\9>)9(AG\%I\Q1012R8Z+)<6ZP@I'T@ M%_ 'Z7T444 %%% %%% !1110_4444 %%% %%% !1110_5C? '\$PGJ/CGP??
>%-*>:SX_M9FO8O+&M>'C;B\MP3R8C<0S1J2.C<4)&?\$IXC?\SW_M\GO\8/B=K_C'7Q\5_ \$IO>> (?
\$VJ27EY=>5>E%+RR\$!>P.@Z<5U7\2W_! M(S4_V_ \%OB?XB_M0?M>?%P_ =R:C_M3\1A5""%O;DAKN= /+&V-+B:\$
^ _ ^ M#>_XW_M1_ %K\Q^CQX#:_R\?'C+7_A+/_ /P_T\IQU>EFG\1V.FF\4NY_8DS_M-
YDDT7F\$EF\$(W,SAF/HW@+PSXW_ :6^?7QZ^~@#Q\ AJ_VFL_A:X\30V:7\$ MFGVNG.9\90;5) 8Q<&^O+JU!
<.@ETB!G1U4HW1V=E"?^"6_["VK">"OA9!\IL_MM/A1X&FU_/1IKU9M3UB\IE,IORSXPSW-_'?8>80!)/(X7H0.Z_8\^".H?
LZ?L_MR>#/A\X@U%;[6],T=9?%&IITU#6;AVN=1N_K->37\$Q\Y*_/@'XQ?L#_\$K\B'
M_@I^S3XS_8)_ :*^+>JZAX\;75M;/'?C;XA7VNV>J^&H(5EO\5ID7;L(G_MC+K&K\+YIS;".
(QP_P"@GI6'A+Q/XT_9W\7/X/^+B/P5J \WLMOKWA66W_MCO(66WD*A7GAE"?-@ID"N"HVLO.?SN_X+>_L_W7\I/'COP-
_P5C_8R^)/C?1O_MC9HWQ-\Z%/"Q\A^"-/P6?_ \$KQEJOB'7M5M;-G_MU/6MUO? MB7XKA4C:TL"MIVC6TF?
>^ES=7=VG^WHX.>_QC_@V= _Y0>? ?_L_ZU_Z'=1K_MVC\AO_BZ?C+XM?M?7\IR/QWXXET3PK,>WA\06DTVV"GO'+?
+JMZAZ+1J2.,2_M_?%OI8/_10^)\WQ1^ WBS\K\QU_P4&^,^A_M!:?X2N_ \$>GZUX<^C\JGX^/_
MWL+W":99V,018\CV^43OSYS@&5V+ ,RGGOB%_P %>_VG/A3_ ,&X@/\INGO)_M:P? \+M^ (FBV'AWPU=3V2^D^KW=S-
:0ZD8MNSPK9_ '#QEITFW^QM)F0-)HMM.(#J5\ VP@6.>"90I@;*(!&QC/Z3Z
M9J=AK6FV^L:5=I/W<"36T9RLD;*5A\\$\$&OSM_X.A\^7QI_P \$>|<^&/@: M:(KJ_P_3/'A30? "-
G9L';4KR5;>XABBQ\NL#\$8ZBOOI\X;>\$Y/7PX\A_M@::[S\Z+HEI8_,O##"D9;GUVYH_VZ*** "BBB@ HHHH ****
"BBB@ HHH MH_*_3_@J?J'Q?'_!5#1B2X\?M%>.(O#7C/XHZE9ZYX\$BU6.#1Y5M\&) MXE,\$<;3D\IS.\N" _R\O
*_1NOSM_X+^ *2W_ O\ _P#99-<_1-T- 'V) M^UG\;C%\: AA#\ (A\6-2)"#Q#JT5KXH9;L,D>K:5I_22= M/9U98\J5D
MBMUE\OAX>907C4\U_V@?V2OBI_P1S_&ZOV9?BG^Q?^U\5?J?A7XR?&_P_M\ _SX?:\$+QI<Y;A#>;G;4X_ ^9)
(8DGE:3DJRIAE1I%?I;/_B?PWX)_ MW_C'OCK\IGI6DZ59RW>IZGJ-RL-O:6\;EY)9)'(5\$506+\$@_DU\V^ _EO\MM('W3?
^"A_QXM&T'P=V=\$OX_ @QHGB%/LC65O6>!!%!)A_MK>U\QY_DMS)% =1_P %&_ \$6N#\IEFY^" _@O4Y:3Q\7=:_L_ .A7-
LV)K;^TW_M,5Y=OGL\KIRWUX/^O0URG\3?_!+WX<_M:(WASXP?&_XA:%X'T#1H--" ^#?A_MSXPN?#I\EHL<4"J;R;I.P-
Y^\$W\87P>U7X\$ _M&V'790#FLV\PZA;:#XKO\)>=&4J5=[*:]I4YR8Y-T;8&Y&Z4_?_O_!_T_M5) M^P'8?M3? \$75_&
L?_M6GPV7>(9&>_USPI%.(I/O9G-KR\#7FJQOZ1:3VNE7'_ME.EM;QQ+(O)L\YO-D&P?/US9_P""I_PZ^,?
LGB;IL;JA'Q\3M;\9_#;X+_M_15MM)^%>NZ\<_:]>TN=/(CO)=_W_!^SI-:ID4*JR2R\$*@8*#\MW_E8E_8A_M_P'Q^ (G_IJ-

'W[XI\;:>?AIX'UGXC^-=5CL=&VZ5<:EJII]*?EM[6"]I99 M#*BL3]*^_O
'I%7QON_:: 98\$>\$O'GO>=6 #72/B5=ZO\O C2W@C6#IVOWV MHZI/'=6>A"
[52]O:P0SFWF:/#LFG6O:/#AKU\ @H;GXC>#O?![(-F=\GOE\ M'OV) @W^T3X\]>_XR?#36-?O/"GO!\0R:M/X2O;#/\
L,\$TGS)% M)Y,OZ;_+0P?>T<;#M_+G[4/B X\ X)D;:\8OA) ^T7XX\&7&C^(-%M;G3/
M'NJQV4&IOW.H1V\J3R1QBY92DWW%F6,[1N0Y^DOV=098(TNWU_].517TW^RU R.M;\'.?^Q#TC TBBH_-7_(*?<
\\$H_B1^S;^R-XX_X*_K_."D_P=Q\>? MAOH4WBR\7:IXX<:9K#VP\ZYL_[51:V]JZATBMD'EJ-B.)5W!OT&_9Z_-U
M+7?V!_!'I6_[1-K#X=N[OX1;:XN\<0^64CTUVTN.\O!M/*K&3)P>0%P:_ : M(\+V'_!2'Q+~^RMIC^?
'\#GB""OC#K49_=>);NSF65?#%LX^_&)XT:_E4[5 M6/[&"TDEQ\FT_P\N[5=!\^,'@SP-^R-XO\U*TO8?BS\0HM
UY+"99(XM"TOI+W M7(7VDA5:&QDTUP?N27R*1GB@#CO@[\^QAX\^/7!'A7PW\7/B?XK\\$\+1+ 4? M'7Q8(Q(LGE/
P3\$ _M9T^~O\[(7_!4'X\?LY?)"[XR>~O%W\].6D>#M(O;C;\V\<>(9M5:P[XJNF65M-M;F MU*>[CM[VW:&:33]1FM)U5A@
ME.>!\TEB;T=&5>00;_+X\$ _L:ZO_,\$\$ P#@O'X7^'\I)/Q'"5W7PI^/7PY_ M1^(_B-X&U_Q)0F2=2[JJ_?'A!SKJ M'Q?!\?
!_ _^+_PE_+;+<>#IM+5Z9W>E>#M5CLK?4H+F_2^5+B2_.7+ K M+R@F6,!E#DY_1NOSM_X.EO^40/BG_L>/"_*=
[.OMK]L:XV:3^S?^ L^ ^, M_COK-@IY%X3_.7>I1Z?#_K+Z:.)C#;Q@-
(_#VJ6MSIGPG\#>*G@2;^OI.TF6XU_5+9^!1A;B\N+=4<%&G MT6_~H.?C#_@I3^P_P#%/_@D#IG@'_@H)^PI^V\A:1
<\40_\$W1=#;_#^?B+~\ M0+C7+3QS;ZA<"\$QRQR SM(0.!@!R\8C=%:OTI_8]^#5_P#LV_LM>\$AAXQU M6&XUO3='-
YXQU7< EYK5R[WFIW9/0^6\GN93S_ 'UIUY7:>#;#_@H3\< !_I0 M'B&'?&?A7K+;U~;=><)XQ\0JCQ1Z^0?
^7^"T1Y19M_R\2RO=#[U';22@&W^ MV;^QAXT_;\A4:?'#;QO\>O&G@KX4Z;I1N-4TKX<>(FTK4?S^IR2.HANKJ,>
M;'9V\2!Q%&5^2Y1*/%/[1?I0>LZ2WQ>^,^KVS>('O_>P@MK>0:~X?L<~9HK2 MW69BX4~*US<%5#A\$_/?****
"BBB@H HHH **** "BBB@ HHHH *212Z,BR M%"00&7&1[C/%+10!^I?%[P_P_]O[VG_@[XX_&!\;^~!#T;X7^%[W0;
M7Q9J]2QZ;:H+~+D,\$\$<50 IDH+\$<2<\$9SC?10I9O[%^C\N7Q8R_#SX@?'O MQMX-^%&EZ;][W10A0XC;2;_Q-
JLLLBF.\NHQYJ6EO#^&RPOE1-)=\$N<0*^> M?V4?^5D?IJI_+(WX+ _%)7V\]>/CKX0^ '@E?%?B2VN\00;Z\33_#?
AO28U MDU#7M2D#&&QM(R0'E?:Q)8JD:))+ (R11NZ@'Y_\$R?"7[0O["G_5_~?_ M 3!3X_ ^,?B5%Q\K3X@^~Y_>K/J-
X6N)=0CLOIWVEN2DG^DN\$X&V%&"A MC*S %I=O\ B_]2\$KQ7&N^>BOIFBP2#N'GN+^Z3TD
MTA3VJW^R5^SPWP-U_P 4?'CXI:IL\$WQ?^~6N07'BBXMIL>1 MM;2?8=!\TN% M:6'SM8Y<-
M#S/IJN&5/,*4_86_XNCXE^*_ [7]U^3X@^_IM*+2GMX=T-I- M,M-I[QS74>IWR'NNH@T?(O_5Q_P"";OBK1?
V5/&O\;B?ME?&A/VA=!\\$ _MH^~#M4_ ^~[VVL]=3>YCCM=#L-(B?R4@EDD6VBC56G=G5I)F:3?^AGP6M_B\ MJ?
[I/A*U^~VH)8>;CP98)XONM)2\$K;ZNU\+IX0R0A9S(515D%I)?2.W_ M_5U_P""8'P8_P""AGP_U6\]>/?%OACQX1TN?
5? WB;2/&U_>VFBZE;Q) M#75UXQUSP-; MSZIJ%^!\$!_&=>;[D]Y9YK=89F;^ (R%N\ _'@G_!(#60BQ;_ %/_VI?A;2OC
MOXQ\=VGA+QEX2M_#ISXQU?[3]96TIE?W!AB1%2&!\TF-D4;+~H.\U\]/%& M/\$^OVW\ M\(\O ^J2V?B;XL:09^
O#US;-B:UDU23R+J\CK_VK6Q^VWO?BT/!\ MZ5\Q_P#!*+_E+[_P41_['CP/_P'FBZKZ-U_(O;_P%(-\$/C\I[HOP.\#R;
MW=CJA\0ZX9:S\(_#T@TZVU/<_H75HCP",@'_G_I0W_!*_R_;\47F@_&O\
M;~")/A'X;>%M/L\]^%OP^~^%7C%\$M+6UBM(@^H7AB4MA?#KXA>+)7N+N\ M;B
MV>+=2ZESNE,"BW+98LOVAD!"^+&%^Q?VDOCIJ?PLL\A AW^*!M_ \$?Q~A6K- M%\$X)\+S3%(F*;1+J%ZZY-
OIJMO1IIL9.Y(HPVT;:T/V/V;_!^QY\H?@S M8^,TUKQ9XAU#4?
%7C+7KXQQ7_BC6+F9U_57B1R%;LT2!5RL_9@BS@+D ^O M^~M/_L'XM_SX%6O[97[+7]8WOLU\A:@@;:!)X;N&\
<7#6GBS4+R_AADT MU-)W?9+>T6*2>801H(XX;9_-+QB1Z_532?[4_LJU_MSR/MOV=(MGV;E^;M& M_9GG;NSC/_.*^~/\
@O+_, \$WOAG^TA^RUXP_!TOXI^~?GQ2^#?A34/%G@/_MO3I/CO4(+73[FPM&G*"U,OMK?S5AV--
#""0Q=L%6^J/V\$?'?Q6^~/[\$GP@_M^)?QUM6A;:>(\AEH6I>*XY(!\$PU">PADN"T8 \MC(S\$ICY22.U_ 'J\)%%% !1 M110
4444 %%%!1110 4444 %?#G_IQ\~5?"_2?^*WQ7^\$/[O/C3P]J MOA?18+F)O!\1169O0I\;00'-,(C<*ABDD7\$4L8_ _YMV
!IQU4?^%W_ "A4 M^/W_&*K_ZI>/9/V,O#&K^!8+;4?%#?#&RFT:/5IAEAN;_P#L
MY&B\$@\RP1I=NYNN'37YS_P#133_@E'2/V;?V10" _!O_P""?_!2?X[CX\ _# M?
0IO%E[XNU3QXPXTS6'MAYUS9_P!F*HM[>U=0Z16R#RU&Q'\$J\@WZ5?LM?AFQ_M_#G_+\$/2\ TBBKQC\HCP08?%\%(?
\$LW1*VF/Y_P<.\>((6^_.M1GIUXEN\ M995\6SCI\8GC1K^53M58_18+227^V8_!#_9Z_:-U+7?V!_!'I6_[1-K#X=N
MIOX1;:XN\<0^64CTUVTN.\O!M/*K&3)P>0%P:_>^#O[\^CSX\?L<>?#?Q<^ M)_BOP00Q\$O\ 4?'7Q
M8(Q(LG8_MW:KH/Q@&\>!\OV1O^&I6E\[#6?B%&H&O)83+)%H6F-)>ZY^TD^ MK0V,FFN#IR2^12,\51">(-
#LO\$VAW?A[4IIR.WO;=H9I-/U&;TG56&"8YX'2 M6)O1T96!Y!\H_ /3_@F)^S\;VVOO^"H/QX_9R^%WOD);>+OVV-M
MXX\0S;JWAWQ5=,LK;:W,Y+\$^T+3R(#E5N+3S,L5=X_ ^#G74/B_X" _X)P7_Q M?^\$W\1?CCP=-!^BOOK.
[TKPM]JL=E;ZE!4\$RQG8,H/PO\ _#G\DGXA>*[KX4_ 'KX<^(_\$?Q&\#;_P")+G5DTG4+
M"2\$+J8EN7>7,LUQI1+~*SR\$R3J78%53M_P#@Z6_Y1_~*^~QX\+^G>VH_1*MOD)?#?
QB_~6^+OOZ^+OP;:\1^M4M;G3/A/X&5/ DW\CV=I,MOK^J6R."CW M"W%[\<6ZHX*-/HL
8;0<_00I2WOLTGIF_JGWQG>~9L'O(O"?AR[U*/3X?I9? M31Q,8;6,#DR2R;(D_Y+2*!UK(_8I^#5_ ^S;^RUX0^&'C'58;C6]-
T;G=D\);R>YE/\?7O0!^87_!2G\A_XI_!\(3'/ _4\$ _84_M;'^~>N>*(?B;HNA^~?!OO%^(%OKEIXYM\0N!"8Y8Y_9VD('P
Y>,1NBM7Z MK?M\$?'CPC^S;)\-3^+^C^VN\Q+0Q6^EZ-ID8DO=9U&>18;33[5"1YEQ<3O'# M&N0-S@DA02/\$K3P;8?\
!0GXY^# _~H#Q#Q^#Q^#PKUEM;^&MO.N\$8^ (51XH MJ?(/_+A:(HLV_Y>)97NA^ZCMD)?*OVPO'G_
4BN/VV/#7Q@_9U_P""<6E_M'WX6>%?"L%[_J1@^_FD:!\C6;R.1;G56BN(IFN9%M76WMW_5(TGNF4N9P8P
M#A_~"/7C#_IJ35O\@K7^V[X\:_L^)_#ZSKVDV?P\N#H\G>2/IF@~>:5=W;:~9 M(QQY4'G"#S0JM/Y/FN-
SFOTPK;/_~6'10G\>N?^V_VK\OQ\ P3LMM^NO& M%X\B^+~HOQATZZ_X5Y\#HDJV*15%= KC=6K^SA^R_\
M""IE?PC\A7X4)J\IU?7=4G\I\U?>A\$A+S3A1V5%5414 M154>A44_2.WQ;_X)L??"XR M;:>%?VV?SWQ9^ (5KX_P#
MK=VG@N^TS6;6*VT M>VN4=)X8[8VK12JZR,K&99&(OECM7'K.H?!\PEJWQXTG\H?4[N_GUO0O"EIH M&D6TDR?
9;6WO+BUN+J54V;O.D:RM5+%L;80 !EB>PHH_X7[H\IFWXA_I5_P
MKN_@Y\;O#!U+1[FY@NX'M\J2VNK"\@D66WO+6XB99+>XBD5725&#*1Z\$@U\ M'OV+?AK*_BW=?M"^(?
%GB;QY\0KC0ET.'OKXYOX;B\L=+63S/L5M';PPV\ M M^T@#R&J)9)F53^A5<>OT4>&?MW?\$_\$ _O@W_%%?
AL="2Z5K;W=_)?\$^F^'/\$*+~#K8\ZX^G7-Y;_Q6SS(-WDOT=!\@_M.N5;^E@?D*X_X-I?^">!\I;:IJ?Q\$^.=WISP^3-
IMS\9=2>WEBQ@Q_F\I0CC M;Z5^@J%_ 'F?Q_9&^!_1WPYT3X;^_#DMI;^%=5LM5&E;H-TUE?>~0M+_ M6[L9H^8)
(QEO.%&1FC=61F4U?@7^Q__+X?S'Q^A;:[9UWQ4\0/%5I;V6O M^&O-Q-Y^<E<64!8P648ABB@M;9&=W\$-
O%\$C.Q=@SDM7JU?_!1110 4444 %M% _!1110 4444 %%% _169XQ\WOBKPU=^M'.6ZGH4UU&\$75=^\G[3_-P),
M9GCD0\$@%5W\DG;N;:\1^*O_!OY^Q?9?C!XG^_WC? MXL_!O\$OB_43>Z\?6'Q;OK43N!M1_D6U5CC3\$<;:410J@
8KIDHH^6_@!_MP2"_9)_9M^~_I,OA_=^,JJSU;X@Z-XOUZ\1^*9-2O-6N*FAGL;>XGN%9W MM8YX(Y1\$"/F!^#;#
I^U+^S;X(^Y^!>N?L_P#Q\$1>)M)TG75A_4O!_B" M;2\1MWBF2;-X;B\$AE(>~20#1#+X2O_BOXP?
5FTF8QM%IICC5(XGN1&[H+F5'G57<+(H=PWJ?Q M?^&L7Q@^'FI_#>
[9ZW\H5K]JK):WU[X>GABNF@D1DDC626*3R\RL1N4\QU5E M/-+=+10!XE^QU^PC\/_V%OV>U_9=^ ?CSQC;^#K.WN(I
L=5U2&ZET0SR32RO M;3-1OR99FDQ*9%5@~J@9!\WX8?!\P^!\OX\$;%^SQ\;B^TW0_#?A:WT'1[B
M*X\INX+>~W\$S6R)]]~P3_P'S\^P9^S3^5\ LJ2_ ML8^# _!\V#48M;L/%5TVHS:P+^222Z-
Y++EK@R>:RDM_ "%7HHKV.B@#Y MI^&G_!~?X#_#IO\X(UG6_%GC7QE8?"T^6K\.^~O\$(OK#PDPB,*26R>6KW\$T
M<),44[X]Q-\$A(C=,G/T)110 4444 %%% _!110 4444 %%% _!110 5^? MM/?\$X/A^~UK\O&_C9/#L=Y\!=;C'
MX91G2Y=5EAYC^TM;HHD0.!+Y8"iYBJVW*+CYU/_P#N=^P#HWB;2?>J^, M?C)K\6DZM;Z@NC>)?BSJ%
[87;P3+*D=Q!(Q66.L@#(>".BOO2B@#C_A=\\\$ _" M/PF\0>~/%6@75_=:CX\5MK_(@O-
1F1W:X^R6UE'&FU5VPQV\G;QHO) ODD MDDGR#QK_,\$UO!7BC\IK7OVIO#7[4?QR\

@XHX@MXO%A PM2)8M%0!#*L* M-ICFCE6%MB :HBA!+%=%I9B?H^B@#E?@S\$XOAA^S[X%A^"PE"+II>EQW,IJ
 M&N9;B>[NII#)]=7%Q,SRW-Q+(S/-)*[R.S\$LO->0_&#_OL";XU_M8^\$OV MU?%/Q8^(-KX^ VJW;^"+W2I9MH;:1H+J-
 HIB*.W-LT4JR(!*OF61F&,DI1C MZ(HH X_40@EX2UCXI;-^T)JMY?SZWX?^W^@Z;/23)JEMH+VXM9[F94V9\YS
 M96R[IV B%0!N8GR\IN_ (A_ ' (*)WOABX^/OC?XB6EOX1FDN-\$T_P?XU
 MGTJWCNG!4W3+#+@.Q.\$9D5RZM96[Q]!)YVW>=6CLH[R>&02122R"(S'8P! M"APF0"5) (IRHH R/ OA>\\%~%+/PQ?
 >,M7!026<93^UM=>=%[N9E>^/V;_9CL?BOXV;24T^@QK#71K,<6L6%F(5A1(GN&)5T08 M68@R@G=O) (I(HH_/;2?
 #;/_@GSH.EIH>A_ \$GXZV5E\$&G=?&748XD#\$D M@ (I &223QR2;^I?@+^PK!OV;KCP\$?AA;:I#;?#;X?
 W7A'PG87E)HK>TNKF MVN;NY8LN^2ZGEM(\$D)*6^;8< ;F)IDHH _ ;J_80/#_M@>)?!OC?6?C?5/
 M>N^!+FYET/5_ACYFTF1A.(Q*D>UX:A#Y2C#QDXW+G:S_I3\\$/V6/AG\#=-
 MU/QUIEYKGB+Q=KEI!::WXV8:Q)J&JWEO"6,5OYKX6"!&=V\$\$"1Q!W=JFJV8 M^D44 >?&MW?
 \\$_O@W_P45^%R?![+JH;Q3XL7PAJL@O+G0/#NKQV,=U<00OBED MD6(\$\$HV"%#A,@\$J2_:ZIQE^S;X>^)/PQT'X5?
 \$CQWXDUZQT+Q+I6MO=WIS;B MXU.;3KZ.^M8KHQP*LD0GA@+ *K.(@&9LONI%HH \U_:V_9;!_MF_C6?V=/
 MBEXE\3Z;X<\0HL.MCPGKCZ=ZU\1M>[3:5IUU9Z1-XZ?W>L0V N M%"2RPOSDA)#'NCWCG;(X\I<44 %%%% !1110
 4444 %%%% !1110 4444 % M%Q% 'SM\,? @FO\)_ A3^@U\XC ;DT^XM?*\$Y^ (C&PMK?%;ZCK-K);ZK9VX M18;=
 [46JPQ(HC4 PK&PYPP+3A_MM \!(SIFKIO\XI;-7/CO_\$X'6^H^ M'=;>RT&U*?;\$"YTNU\SD.9GCB@P!)\\H=|F"
 (I.%4#ZEHH ^0/V8 \ @B5^ MR!^R;5I/C\,^ &Q/OO%*>'KJ2-)U;Q9\0;G5FTA;M526XM%N0Z17&U=H?:
 M>&8\$\$\$OICX1_ "P5\$?@YX;^!/@"TFMO#_A7P[;:]I.33GS5M;>[88]SK@E] MJ@EQ@ELGK73T4 ?)_ P
 /^"O'P.^%WA74/A;??M\$ _/Q?X U.;1[OX=^-?BE MTLM\$70-#5=-@AM1;V8L(8 MU%J@7:GEH5#;:8!4J_8(XJU10\I_LX?
 \!-_X1?LN?M#>._VG/AS30^U MSXG^!)[]= \$(ZUK4%S;:Y-I'*D#/?[G_AH2ML\CRL#"K\ M>J?#?X)^\$?A1
 MXD\;>+!NK^ZU+QIXI_MJ[7[O49D=C.ME;V444>U5V0QVIG B)R1AB269B>PH MH^_ _PI3_@AG^R-^U;?

 M: :5^*WQ/^_B^*-/C+V2_15E=1W%IX^)_WQ\$EU32P8Y!)!"+\$XVNH\$8*1;W#2PY5^)/PQT'X5?
 \$CQWXDUZQT+Q+I6MO=WIS; MBXU.;3KZ.^M8KHQP*LD0GA@+ *K.(@&9LONB_V_9;!_MF_C6?V=/BEXE\
 M3Z;X<\0HL.MCPGKCZ=G\Y.YFV/QUEU\]>6+&#R;I%".-OI7W_I&DZ9H&E6NA_M;J_-I-1965ND%I;V\86.&)% "HBJ_ H4
 #H!5BB@#RGX3_L:?!/X+ _M- %3IK M?P18:C^XQ^_.;Z;/&L[SJ#26\HTNU:UM/)B(Q%B)B&QG<:>:J6HHH **** "BB MB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH ****
 "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH
 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@
 HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
 "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH
 **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH ****
 "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH ****
 "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HKS>I_:B^'MA>S6,VB>)"\,K1N4T"8J2#
 M@X_.1QUJ/_AJWX.IW7IY\KA\&KK#R^X\,MHKS/_AJWX-A+DBY64DV*IDNK?3S-J'#&>UZ_M:?!L+F:5VM%=VN_(O\
 Q>:_'^"POU:7PU\I/K>I6I%;F&TD5(H6'5'D;? MF'<*&CD\XKGO?!?W@36122P\8>\$:O18Y&"B\CN1\OY<;@ED.W\HW
 D9_O'T MKUG :C^M^" \$ _O\$^X3TW^%?U/PYXH<YWD=#'5L1"C.<;RA*6L9+1KTN MG9I59GX\FG".9_-6_#C_H\>)
 G1MO*/&K&AQ_T O\$ _A3?X5T?^O?!W_0=3_"1P?ZNY\!_ _N/3*5=!_X M*.\$ _OA^V9I1OV0!?!
 D&H:CXJ^&>CZ;JNLWX\96<-C=6E^A:W>!\Y%#L< AE M9%P'D\J_4ME=QW\G#?20JP2:9\$#KA@)_C(I'GI7YH?
 #W0/VB/\$'_IP5^U+;_M_L]?%:P=X4NU^\$G@C^T+GQ?X"NM>653#*\$I+?5+RF4Y)&+O-D#;_9/U<91 MG%26S/&:
 <79GTY8_MV_74I07P/9?L!>-#XQ3QG?;+>^'9?SVE)%:V=MIIC> MG5OM9F\E\5OJ%M"NPF3S6*% 58#@?AY_P5H^+?
 Q;XO6GPQ_X)W^_J;OO@EX MCN-"9Z99<--%PI\#_WCM5>9I\ _L?LO_!7QUXA\+^%-)U_QO/?>(X)=L=\$
 MBU..22PM#*R2O=S1PR2"-8_+5_I>5"Z@TXO^"A6IW7I?*Q5_:>D_9A\5Z/_M\K_ %:#Q;X\3ZA:6NI%--
 L(IRZ>!H7GMY=ROF\$B4),FV0.N\+7C'I<'!/_M/X^/OVI=<_:_X)3?M7VWP_ ^FBV=IX?^(7A;7X#=>&_&.<%M%
 <6UKJ,6TF M&9;YBV\$JKX1T"4VZ2N;\#_ +=/BW\I\ @E?^V%HGQU_9YB^%_QC^@/_OOQ7
 MH/Q=1,6DPEMI=37PI((KV)"8\$>9#+!&\$RSD+\$H\$R)I=@#W/P/_P4.^_GO_9 M+TC\IKX= _L>(<9_:
 [X)B\4Z7IUGXWTP:E/8R6PN558795,IC(=[EN\DU_MJ/7FHZA-X>?50#>GQ7=R\IYME;7-R8\$E8KE59PK%>I!G:<>E?
 W_3;^'OI_M>>O_/_!+K\EFZ^"IO'@:UV/6_A?X?WNH;)9?#VIMM4GT**2PDN\OZB^KO%O M-JL@=A:CS0&0(GF
 K^@.GZCI^KV,6J:5?0W5M<1AX+BWE#QR*>ORL,@@^HH_M^:/V)\ @J\(^VQOCE\3_V5+_P=J7@3XJ_";6'M/\$O@;Q!?
 6TTTJ"JK?VL MMN\<6Y=@I(Y"R;U7S\$SZ-H71/C36\VM\;_9#0_="CXCN/%G_"0 M(UO+9WES>6UO&D(CSS_
 #+&;>APBJ_1(Q(!^/CC_P3^^(?I047CO\;*_8 MPUJ\, _M) !\X\>)+SX?:X^\$AU^T_'I_) DM:A2ZKO(\$:R\$AE620GM?
 M^"=7_!0CP^WM^T^XC^'!_%ME\$>:;KXE^ MUP7:R%I,52)0S%-T9!;8VY5_/T\HKVJ?A+\9OC1X%_)_8CU;P?
 |=OBCXOT3 MXHZEK>D^_O'GBSQ>)_HWQ)1M+N+Y-1L=%NKF46\$ GB\$LBPV\,_*5X64UV/_MI(PO^X,GQZ_:Z_:3E^)?
 [>=:_!T/QD>+>@\BTFTO)-NXU MB*3V.IDV&T58TP6;I\;E /TEKB=%&=?&.^/^N_#O6/@N?P+8>;*T3XB_
 M\);R_VKJ\$LDJW%A\@4>=IY*)&_G,2DGFX4_J_ _KX'O_P%\$?V\V+?A9_P_M4%^_GQTT#PCXNU75(?)
 %NKZ_K'QTUQO#TNFIU?#FZ?^~O^"R7I0?I-OCKXT^_-.4\#7?P+;_:C8^'5\5W5E#I\$ MUY>7\,J636;PO:N4B0":-A-O_K"
 <&@#I*\$>/?!WQ)T)O\$ _@3Q#;:IJZZC>V_M\O+1MR?+2ZEM+F,'N4G@EC)'&4.'1S7@/I4_P#P4&USIF?IK/X3?LCV_P"S
 MO^ \ BC5_C4=87P/I6G^ (I>W@SFEV:7=VET)E!(C?Y"OF!_53D#QI_@VK\:_M'X: X)% "WQC8:EKLUYKUIJ9OX\I3\47I
 I;1F+6I25?

+LY1?&2YG<+EVB,=D\$ \$0W3-*?H+17YM_MF>'OVIO@'^Q\(/VM] M4 :5N_%7QG^\$.N:?:_\$/P7X!\5ZBNA_%B*![-
O50RY2 21SD M&T8&SZD_X)GZWX>^)7I*&@?M&:#\<-3??" "T"?Q/<I:=>(R]L!%[J1Y#I MME'T+&U\$>?%,!T:~@
'T1110 4444 %<~\5_B7H'P=>'6K_!/\ M466HW&GZ+&XNX-!L7N;ET! Q'\$GS.W/05\X?/COV7/^B>?%C_PVEI_/\$U
MQ8G,<#~@YJ->HHMZLSGSITW:3L?6%?) P#P^_9<Z\Y6/\ :70_Q-' #X MJES_HGGQ8_-I->_ \$US_P!N9/\
\X>318H?2S(/^(G_P#P4 \^';W_#" M/%C_P#A_ \A_ \J3_YF7^SOL?V3D) T13>90^U?L.W9WWKBWO M?J]>-B)?
7AB&J%_MVD_ ^\$' X10\ X23I; Q)?I3^V?9_LII; ZIRHM^IR- W!C=CG&3_07I&? \ M\$K?^"E?P%_9_8+\"?"/QIX-
^(5WJ>D_VIIN-#\#75Y:OYNJ7")\"DC'L%52 M3I\"OGIX4?%\1/V>_C%1=(^&'A?P12+?4:-NQ;VD^K>
KNVMD<@G,DKC:B\ M=37N7Q/7P(PT1)\4H[= #)T*'B-;M6,1L/)?I0\"E?WYQSC.*[-C,+ MC(.5\";DEIH7"
<*BO%W/E_4?^"HOC^T_997INK3?V?&J_ "2^T(:(WHN1:5XA ML'UJ72IS#V^I7&FNR\"TDC9)B4GEFCA;>*[75?
=/VOOVJ/A;^Q+^S7XN :H M^-.\$MZ/#?@W3!=W\>FP"6YN>+1(88(E9E4R2321QKN95W.-S*,D?FA?2A#_P
M4\$ _X(*)"O6"/%WP0\26O\27[\&G6LLGB+X7>.)E_X2+P9H?Q?\$_%0I.;_@D=\"VTZ2Z^+OP13Q[XF7>(8)6@~_
M>'I9X\IT=M&Z/<7TMTT)2,NB0JAE?S.%ADZ2SZ3^!O\5GBCQ\ &_5_V;OC M%?!?C/3?!MAXJ@LH?
\$\$.J6UQIEW<3VPS-&B>7<136TB21E2G*F,24;BO* M MX?%!-1_8=V_ " P
+W'I/VI^,Q\6O'5KX.,2Z+KUM;/'J]PKM%'.MSL5 M(F5&(D#-C;_!' !.SQ_V4_VDOAU:~L7+X_ \"PW_:Y(?!\$BVTOLICQ=
MI?&YU&3PYI <+Z22+['IRUG8Q[I\FE^[%:P)D M>9/-(R11H.7DD11R17SO\,?^">?Q"U?_ (*2W? \ P4U_ :
<^)\^BZEXDTSX? \ M(7X \(>\$!^E@L-\$TYIWGFN)[B:OR7ES\IJ@[(D1'(VN=I7U_P#;!_9!^#OI
MN:Y9_&3I@7X@_!C3M&Tl+B+5_'FJZ8=\L08HEM)Y&& MU59F9L #?7-?VR?V5/#'167_1-BY^.
MOBOXL^+&7JF74/&'P2\6^++HW>OZ.UW;ZG8C1[NZ !NE\$]L^<@\$ (K <#:GF M? [7C:9>_ \&= _@ [3/!2>]00A-
,K71X;_09=4;5M^V'/F'<.>./_.'@^X\$O\$OBROBUJ3I71I':1X16*2XD#_ W MERT4QA@VA2L+O+?^A1G1+JF'I+X7?
M= _GPI^TA&11N+C0\$5LIP1YUOY- MS:31R/#<6MQ'D^7I/#-') (F3M>->"1@GX\ X\F6/B33?^"P'I>T7Q D+:[J
M'PWE61NDMA_8\$ZP-'ZH&\$J\KR?LO?&'6I%<.'J? [4WCZZ\ M(M RS:3CJ)(0&/ML\I+CIQD-0I)[4444 %%%!17FO[2?
[4_P\99T/3-? \ MB)H?B6^AU6[>WMD\>'YM0=65=Q+K\$'47'0GO7D/ #WWI/F/_*)_ \5?_ VU MI _
\$UZN%R/,=15;#T)2B^J5UH>3B^R; UW1Q0>_9+HW9ZGU117RO_/? M?V8_ ^B?_ !5_ \M>_ P#Q-' #WWI/F/_HG_P 5?
_#;7O\ \371_JQQ#_ T"S^XY MOI:>^ \ H*A_X\$25%>5_%;ILX0_!WIH7P!^S9XNU3RI?^?(VG^R\ EOY;_ MN_ -
SR/DW11_WG4BO)[O_@L1^RS86LM_?^"/BC!!!&TDTTWPZO%2- _EF)& M !DDU^-_ [9O[8?C'I]#IKG6?
VEM.U&\TXQZI?""[JLNFVELW^B@8)"N,"1L M'F.'Y'6OJ^\$O#W,T\$[R^]>ZO-WZ'IE%?\$_P_!/^"V?
P!^ (PCT+Q#XP#>[7UXZ?% M'XA30?15Q>6L=J_3_2.+E2W\$=0K+GFNP_X>^_LQ_!\$ _BK_X;:] ^)KY
MFMPGO'0JIRIPT/[IVU?/_BIAJ02C4CBH6DDI7KKW\SZHHKY7_X>^_LQ_P#1 M/ BK_P^VO?_ (FC_AII^S'_-\$_ ^*O_
(:I \ B:R_U8XA_P"@6?W&G^M/ M#G_05#_P(^J*5_X*!_MB)^P-^RWXE :RUKX87GB00?!LESK^GZ5J4<%XD#
M2QQ"2%91LDPT@+ NA"@D:CQ5OI\FS]M;X3_M3:WJ>@?#OPWXPL9M*M\$N+E_ \$O MA:~3T96;: C2@!VSU [5XC_P<,:?
\H7OV@? \ L38_2VVKRL5A,3@:SHXB#C) M='HJ3UL)C,+CJ'K8>:G%15JM#UGXM?
MB>*/@_P#L*ZG^W#X@^ILUQ::%X*F\ M6:UX4M? \$41O(-+CM&NI-LC1B*2=8QDQ[@O#I9&(:K?V2/CW??M3?LW^#?
VD M9?_OAJQI='^++7M#TJZU^+FX2PNI:.X@::Y\>_AC\AT MSPC;72?;'J-I!/-:~*:[H561Q-&(KH)&-GC3X>?MH_LJ_
KIHNT^~GI?FE?# MOP1X@NM'O?A3J7OVM\PV2J9)899PL>YE& M=[ICCX?%KPI_P_?%?B!^S=,_P_1-
'\I:A^SYHG6C3/IOQ\<3Z>6-^=7NI_M\KE)9NI:T\$140W6ZSLH'95=F500?VO\BS_@H:X1_E_8IU/IL3XC>#%^&^D
M;+KVO:=K%EJ>LK>_8TTN_GM))7ECC0\$L82VQ_V"P52YP3? \ B? \ MN7WPS ;_M^~%OI#MY%\
[N:#XH>'=>U2P\OK<*OP'2X8I9H5ME5I)"?/B7:M%/HW[3E]+9?V;K\Y9HS3?\$F.V?SHJ]>5\$N%N9
MIJRAPC[9%"R(CKI=?MH_!&R?_@K1^OI&/"WQ%\8Z+8'P%\4(Y=9B4W5[K! MA:WTMY\$74+YY[A6;<4W>9(T.
(FC*HR_'Z)T5^?QB^,G[37PD_X)@_MI>!/ M' /I6WQ.%_P#_7XMW-EV//&5]XMENI>MM-
EMI,N%L9=1G#W\$J(UU.%D+B8*P' MF84"O9?C_P\"VF?V%_VTOV7_CIX-;%^)_CC2?C5\2(/_GOI\ ^,?)N]&F
M^VV\$UQ#?Z?9!1IIMS;R,?*&654#LV9#(?I/17Y<>)_O^"@_P#P4K_8^N_V ML?V9_C-I_@:XA3_35I_#?
B*P#C;KEKI>A6^FZL;?#2I_PY\IIV\$7V^WN M3SC)(\HG+C*HNO_P4%^ (Q(O-&_H\8^!_VE'??
B7Q+X\$^"MMK7AJ2/A9XL MO="TCX5W5MHMS?FXO:F&[ABU;:F5;A+=H9Y?LZ1(Z1PSI/V /K3XW_MMWWP7
M_ ;D^" \I&MQ\&+N^MOC2OB'DXS.MQ10Z: ^E::U\ (GV8^DS./+09,8&I!:: MM/O=?DK^WC^UQ\1_AOXX_P"">7I:I
 \,~7^ (OBBU^\$ _CCQ/J'ASP^D<=SJEU M)X(MIYV01;"WA),*OG,T8C*2NSAC0!B_MX? \!034 M?V?
%_PO\+W'I/VI^,Q\6O'5KX.,2Z+KUM;/'J]PKM%'.MSL5(F5&(D#-C;_M,S_?_@HYX"^/[5FM_L+?%(X5>)_AG\6I&\-Q^(:?
POXH:TG@US2?'R_ MMVGW=I+.%<1J^496N565_D^1ROS_P#\%Y1KI^ (?!%(\+M:#4O\ AL3PYIA- M^K&#S?
LUYM\$S8=VW.,XYQ7L.@? \-3XD_ \$+IO[6?^"B/[27QSMHO\$VPU;P M+V\M#^FG-:Q>&I.DF>>>I:ZNC(UU>_LH50*C2-
7("L0K* ?8-%?C)\/CM M^TS!?! @=@=8_P#I9Q)\US\6O&_Q.TWX3:18V?AOQ\XI-WX=>YO=-G;7IQ
M8R(OGN+5F\$@F3)3?&<1"../Z5_4U?JL#3_LT_M%_7X]>//%B>?BIX; MI! ;00%?C2^U>=K(G)KZ.VN99(K.
[CF"S1-+ F':E,05 ?H-17Y? M?![CIG;IH\I+N+XK MA?!_6_ \ @HY\=/#0!_& Z? \.KSPOXU:3WTR>31K2XB, MOMT4R6J]22?)
'HGE1,&D+AW9'CYS]B?_ (*%_M7_ += 'P_90^#?Q_N(1K7C_M_P"#/BGQ/XPE_P"\$IOO" P!(UB'2;<1W^F6TMPA:+[1?
210"(2'8=ZQH MT4H!^LE9'C+QIX.^MA9ZGXU\0V^G0:AJ]GI=BIPV//O+J=+>W@0EF>615 M'3))P
2/RT ;:)_%&_V./^":GO2'CKIM2_MM5T?XR^';SX7W/AGQ_?:KK& ME>=5UZRLQIFJ:A=6UO=WJ1B2X\$ KGPG<:A?
_ \$G_AI=/L>J)<1QQ:9_M_9Y'G2>9\$SR_:=B^7L(RPKMJ^ (YO\$7Q(^/' !=#P=\\$I_,OC6I\"3_+*F MJZF/IFI>
(IINS6]M=8T^UCNBLA+W%P8BP,*I2RDNYW_V?)"_@K>?%\$?^"@7 MI[#_PI_X*!LJ?&_0?IGC35=:_P"\$IN/\$&M_'37!X?
33X;Z9;O1:S0(I/GI! M' C6Q;F5H!^TS2QV8_5"BOS&:_(:9)=_LX?M0>_I/_GO_BYX+^&_BCQE
MIC?S]H;X=>,-0A;PW" L-G\$=(UJPLIA(I4M>170DGGDB,HNV_9%AIH_TY!! M&0<@I"*_!/^"DG]<IG_.\$X/V5I
<_:\4 "B_ \ %GACPO):CQ#;Z/J<4%I MES=P6D+Q), DJ^.;H;YU^CD!N<>Q^ -<2^)?!NG>(/%_A9-\$U"IMEFN-)34 MI!=?
9=W(115559@-VT%0<@% @ Q^ (O^#G?_E!E\=?^O7P_P#^I%IE3? \!0>_M^,P_X*%_L9?#7X??
M*>_O!V@_ \$#5/%FF^*M(\,ZK';WL5MX;N+F-FC,9#R! ML[6DWB-MDB*16 !IWT5^3'C3]LGX^?\\$ZOAK_P4\$'\>?%
C7XK\667P0\1^" M_P#A6VL_\$C7)I?OM!'B2PL/_=[BI9Y;B"UFNF2.5F4',J<@G/WIX-_90\4? M"WI\I3P1\9? 'I:/C23PG-
X9N]\4>_&7B:UZ#Q=>'YIK?VTEY=LEA<1B. M>1Q:Q!)8(C:B)P ?0I%%!1110 4444 %%%!1110 4444 %%%!
!1110 M4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1 M110 5@?
?P1#12/AJ_@B:81_P!HV;1Q2,.\$D&1C!PI_ "M^BN;&83#X_!U M,+7CS0J1<9+O&2LU\TSA67JX:O&M3=I1:?:
9IW1^;?BGPMK_ (*U^Y\,^)M- MDM+VTD*30RK CZ\$'NIZ@C@%Y4\$1Y'\$<:EF8X50,DFOT4;_ "WX>_SB%(?&_A
M\$SU#ROB.6:/B\$#T5UPRCV\K,\&_L^!_KP#J'ZMX5\ 6<%TAS'<2L\OGU5I6 M8J?
<8K^1L7]&?./5:PN.I_5F\Y*7M\$N\$W*ERR:[\4]I+8_.*'BO@?J:=;#R MIK;9-);5K?4M;G6XFM\IAH8E7\$;..S MWOC'QII
M5GIGB>SU&YTUM.N;2T4+;1+#+8HT0C_&1POW,69B;I]HH CNH9+BUDMX;J2 MIWC*K/\$%+1DC
8:@5R.HR"/4&O" _V3OV /AI^Q\3?B3I5/ 'O9<:Q>_?%Q M1)XB\96GB6ZT^6WGU-P5,\0@LXFA^7'!(%8)A5^7C->\44
>%(OV&K23XI>+ MOVC?A;^TO\2_7B7QP+)?\$2>:W3;FPN4M+5+; ?8I2LKJ!&54+>:BK*QI+_9:~?I=_P_<=%\ \$
MZ)X^X)MO;R^5;ZS;6=W" LKJ@#+.T-Y)\\$ \ M8%ECCX\7WB46WD2&.,JKT,5*J"06^:O:~ /COX MA? \
!\$KIESX_/_GPQ^+?Q=T;P5K/B1M?U+X&6'CYX_!\$VH-06D;3UB\$ MAC:0* [6_G>0^U4;-HP\$KU_PA^Q/X\&?<
MG>) P\N.Q^)/BZX\4^+?#5KH&K; M3=W%D=,^P6SO);O)&MJLJF-Y)&#>:6)<[BPP!+10!XI^Q^PE*!V!^AY=
M";X+>_&5IX:~4+BXT71?%&O_+?089KF:Y:TLD5\$=H7)KZ#HH_ \V?L^D1:7;=1B*6Y^RZ;I]HDL_DF6%9)=^V.XF4
>8: _/'_@JE_P_PN?A' M^O)_P3 ^ (W@;IG7XI?&36=(U7Q5H-SX#^" _B2;5-(T1_P#A)-/N[L;96\ MN&C2%;B0I-).B?,X ?
#5^N=%_ 'SO6OV#_@_ ^TK^T1X7_>:\)?"X@^\$?SMK
MX,/ARYU/X=^X(:'Q'H\$ES]K6QN_@E<(LS.ZR6[03H9&Q(#C;PW_#E+IEY? MV*_&7[I:-

O\3/B7#X"\>>*9!=\0Q)XC@>Y,LM^+IH('EMG6WA^T*K?NU\$C!0' MD?)SI@T4 >\$ _&#l@#X9 _&SXU?#;:IH?
Q3\4?'MEXQ&NEWNEVVMZ!KD-A)K>G MWGDFYM+X0P*&C=H4;., @=3DJR\8?'MKSX: _\%/OVOOAUXXN?
V6?'6B:7^X\$X MSUK4G\4?SCP;-!N-9\$1L;:TL!.:AXN^)=E86GC&TU6YTUM/O(&'R:-%BBLHVA MI,@&-
U+;B7+&DU[Y10\ 2"7 _@G5\?V>_C3\0?C)^SS\5 _'/@FXG:PVL>* MO\VC7EA+H;ZJ\8234(+6ZLYC;W\$A&^1HW42-
CO=9O+)F\ -7C/?7;[IB82W6BR2)O;YMJL%!) *@9-?4 MU% 'RU\;O^"3/P1^/W\I+FA IC^_OC\3IX:T?Q- PD5W?
V^N6;:GK.K?;9;[M\9>74UG(TDGVF5L)L3A1MVJ!7O/C?X6WGCSX1:A)M4^)_ B*!M3TN6OO?\$E MFEBFH/'(C(I#-L8%-
?\$ MVK>%/ #49N(& " *WOVG?V?\ 0OVJ M/@/XG_9X\7>,) >T300&.BW6D>() _#X@F"*)=%UOP%+%?;:6+J"XTA
M573%FD_L_\$T=N%&%9M:%JIT\|(O-\!^2X^RO MFK',TLKEM^X^8RDE/EKW6B@#X?3 _@@| ^SK#
M\\$+;:JE^#|IWXZ+L,-\5V>O^\$ _7 _":VIL _#<|M>|"IBALYOL7VLP"08\$< \P M0'G2Y MO%-C H2&+4C)#;:AD50HE&R7
7Y\HA7ZOHH \G\ -L> _#OPA\1 _OCKPWXH\ M16^G?#KPYE0F12AN6G,FV2<9Q<3^9C_L< _ML'?#;:JA^ \:Q?"#XB>+
[G1?'BR\127GA;6KJ\$3=,U" [E,DI\,4%K\$;6-C _M,L5;RQC(7<2Q\PHH **** "BBB@ HHHH **** /R?\ ^#G\FA_5YW_'K-
M'%OW>?%|J_-O&G/D_P#PX\X)=?|&P_ ^7KK?_ P_FU^7<1<\$YKF^WH?SWU_0A_P0\Y1=?#_#_N-?^GN_H_X_M<?>
 \ \$NO^C8? _"|=; _DVOH3X'? [X7?LW?"[2 _@O\ !?PO_8WAG1O/ LW3 M?ML\QY/G3R3R?O)W>1LR2NWS,<;L#
[N\$N\$LRR',IXC\$3@XN#C|K;=VXOK M%::&F\ P-7#57*36UM/EY'64445^AGJ\6-1 _^E_\$WX>; \:M^" "QJ_2*'_M??
#CXL_\$'X/_\$?PIX8'AJV\2?"K4'*U^W:*K%DL+FVO+2YM MI8D))4>4""\$R2(XPOU'10!\9 _%# _((??
LQ^/OB7HO\0G@_XU _&P/%6=,1X MM5^+W@OQ\8O\$'B*!|H>#49+F&:&XBPBA8Q\$B1*B)&J1HB#M?C?\ \ \$N/@U\=
M;#X3Z7KGQ>^ (VF0?!CQ5;>*/|W|FZU:2RR:Y"[N-2O)KRTGEO)W>25Y\,IVJ\!D\ _#BO-?V MHOV9[C|IGPIH6DZ;^T5\3?
AG?>'M?CU:QUWX7^ (XK"YF=(W3|/GT4 (M>,) \1^+ _\$JVD^HZIY M*LL'R-&D<4448=|D\$<4*&61EC#22,WEOA3_
QC_L\!\$AX=!'VNM^!)KGP\X M.\9OXX\?' "JIN\4Z!HNK&>2XCEA5+=;EXX;B:6;&WEN)((792D:B*\$1_15%
M'D\7Q4_8Y\!&\$XQ-^T\$X0^ (WBOPIXUN?"Y\.:QXB\%3V23:KI8E,T5O<)>6M MQ&3#*"CQ3(B31F60+I%=&F/8?
KX& _"W\FKX0Z!"?@KX4BT3POX9L%M-(TV& M1G\ M 2S,[N2\DCNS.ACDN[NS,2S\$GK:* "BBB@ HHHH ****
"BBB@#X" X+ M\ M@_ P#"G?V>K3|FSPCJGEZ_ \0IWJ|>4^'M\ 'C8>9G'(\Z3;\$S(LPK\6*_H MP^/O _!;|BS|J'XAR?
%7X\ !_Z77|>EM(K8WLGBG5(L,8(1%C@N4C11DG"J, MEF8Y))/%? \.3O^"8_P#T;\ ^7GK7_R97\5P=Q_PMPODD,
(Z55U&W*;486VI^ (<:>'O%?%6>3QB\JTE3248)RG=17>U-J|=V\7O: ^A\!?'\$ _M/VP?^%_ _M'W?I-GBI5/+T#XA\?
[+ \U);ZQ&\O&>|YT>Z(IV=817\35\ PZ%_ M_P \$:O\ @F\X8URS\2^OV>);. TZ\CN;&[@\:ZTKP31L'1U/VSAE8 _@^HKZ
M>KXCCC.LEXAS=8\+X3BY+WU)15VM\$URRENM'MMUN?=<"9'GG#N3O_9A.\$U%M MP<')VB\6GS1CL|M;
[I+|1117QAIJ%>3?ML?L?>|/V\OV>|<_9B^*WC;Q-T'A M7O-"D&OP^%|BU@G085E2416>WF*+OC4DQ\6(R"<'%>LT4
>- _\$GIC#PY\5O MV+W\BQC\;9/&S>&=4+OX;3DU.ITM\?LM^)/V9?BU9?BW MXTN?%-
|IUYJ/Q.\5>.#=>*8KC3YQ<:>\%WY0BMUMI-IQQI"(MTLK,C-+(S;G MP\ _X)C?"WX>?M-
VO\8,7QZ^+ .K^/X_A\".HZQKGC!)TU2V6XDN(KBX@\$"Q& M6.25BL<;I;9_8P,V6/TE10!\I;=_ P1_
&;+?|AWQC_P3UGQ_X^U7P)XRUV M76KF XO=8M\$U+3\0DU%=3-Q:W\$%K'L;|:BS@.LB@C&-*UU# _/!.GP)= '_GX
M6_M'ZS\>OB9J?B?X2:5J=AX>N=5UBQN5O\$U\$ (+|IOS+,M* T_EOY"LBQ\!%6%8 ME_%?0M%_YG_
/|6C|B7PA^S7_P3*_ :SU;X>:./'7BOQ1=Y(I2OM OXK\;D MO\9:6UCS9P65G'(#Y\$*@H-RA(MQ (9J^J _@/^RC_-_%5S_-
/V@_%7Q\I8_\$F M7P7H; \ _"O5\6RV/D:)+<6XMIKE\$M;W>6Z\G?; ^;=&61%;4_JDC-|"T4 ? M'8_X(E_LO:9\??
%7QF" _%WXO>%- \>ZX^L>/_A\X6\?9^\$/\$ED)S/+62Q M>81.?]=&DR1R\J2C*4)0\?Q_ X)# _+.OQ.^*OQ=^)-
U\3OB;HUA\=/#ZZ7\3 M?!7ASQ<+/1M6=+\$V*7AC6'SHYA 0I"RB&3;!+%"P/U310!\O>%/ ^"4WP?\ M\ B;X%>+=-
^_GQ1GO/V=|*N\#X?/J6N65T#%=626-S\J\VS8RI\5\$B"J42,+ MF-8V)8|;^OW^P'\ /V-3\8Q _!'XA>,%\.^,O\$|
[X@G#ZG=V;Z/I-|=2F28 MV\$=K&|I&2?|2C^7QG;NRQ\THH '\ _;!_8 ^'G\?:C'X=>,_B+\5 _'&BS?"S
MQE: ^* _%"KX8N\|^+;V\V"&%F4O-(RLV70D;6&U< M5/A+_ P_\$W_AG\I/X?:#XL^-'Q"^(&@?"6\2\ ^&OAWQWJ-A/:Z#
<1026UM,' MMK.">[DM\>62%|[N65# 'YOFKZ@HH ^6OB' P29^"7Q3_91N_V2?"QM^*NI;=K7B&SUSQ9XOU
M'Q3!=^(/\$ _:3036TMU>7%M((GM;:9' D4:K"JA0N0>^ _:N_8@^'G\8OPU\ M'^
OBG\0 _&EJ'@/QGIOBSPOXQ\;A;6>JV>L62RI%='A;F DI-K)Y.PB0X M48!'LJ%
'AMM^P5\/+3\KGPW^V;#4 '3>)"W@%O\NG6%SJEK<64NDM+'-+ M'.9K9KB:22:*5IFF,A9?O \$@^6^ ?\
@B5^RY*_ C/K7Q%^&WQ; ^+NA>#?\$ M?B->UWX'Z7X^>'P3>Z@|B22233UB\$AC>0!GM _AP!&T;1@1UIB44 ?.GO-
M_P"";7PY^+UAX\|\$>/?CA1+|P'3-?75?&'PWFO=-?2;\PF6"-WL3>6T\$O MD1\XX;A,G>P*L\LT _@;|F;XA>&?^"C?
BW\I_2OBO\13X0USP'\J^#/\$B> M.?P\ _:"&P^R3Z18(NZT\J""^ ^1R\EO?D\ ?'T)10\XQ^WE^P\|-O\ @H=^
MSSJG\+OQ\; ^*M+V\Z\ VO67A6ZM;>74%@N(KF%'EGMYF15F@C?|V4)QABR MG%9?Q\ 8 \)?
%#XL?!_XV^,OCS\0KCQ%\!\$+V7PC>)/I2+/+>6QM;F6Z1; + M.SV\&+Y0@)90')<^|T4_?4'_!_#|GK4/&OQS\7?
\$77O\$WC&U _:*L+S^)W MA\Q<69L+N.TL_L5MY"V\JM%);M%;@ (K)G*JY)=0XK_L8_ \!_#X7?L77\A> M:1^T%\8?
B'#X>L&L'G?%+QS _;EIX5M67RS%801PQ(AH"%"99!)*D6Z-'5' M=6^E:* //OV9_P\GJR_9E^&WPVL/BUXZ;1S;
[J&J'6/B'XB.J:@K7=P\|0 M+,47\$ \$9 XML 20 R1.htm IDEA: XBRL DOCUMENT '

Cover - USD (\$)		12 Months Ended			
\$ in Billions		Dec. 31, 2024		Jan. 31, 2025	Jun. 30, 2024
Cover Abstract 					
Document Type	10-K				
Document Annual Report	true				
Document Period End Date	Dec. 31, 2024				
Current Fiscal Year End Date	--12-31				
Document Transition Report	false				
Entity File Number	001-08895				
Entity Registrant Name	Healthpeak Properties, Inc.				
Entity Incorporation, State or Country Code	MD				
Entity Tax Identification Number	33-0091377				
Entity Address, Address Line One	4600 South Syracuse Street				
Entity Address, Address Line Two	Suite 500				
Entity Address, City or Town	Denver				
Entity Address, State or Province	CO				
Entity Address, Postal Zip Code	80237				
City Area Code	720				
Local Phone Number	428-5050				
Title of 12(b) Security	Common Stock, \$1.00 par value				
Trading Symbol	DOC				
Security Exchange Name	NYSE				
Entity Well-known Seasoned Issuer	Yes				
Entity Voluntary Filers	No				
Entity Current Reporting Status	Yes				
Entity Interactive Data Current	Yes				
Entity Filer Category	Large Accelerated Filer				
Entity Small Business	false				
Entity Emerging Growth Company	false				
ICFR Auditor Attestation Flag	true				
Document Financial Statement	false				

[Error Correction \[Flag\]](#)

[Entity Shell Company](#)

[Entity Public Float](#)

false

\$
11.8

[Entity Common Stock, Shares Outstanding](#)

699,564,637

[Documents Incorporated by Reference](#)

DOCUMENTS INCORPORATED BY REFERENCE

[Entity Central Index Key](#)

0000765880

[Amendment Flag](#)

false

[Document Fiscal Year Focus](#)

2024

[Document Fiscal Period Focus](#)

FY

Portions of the definitive Proxy Statement for the registrant’s 2025 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2024, have been incorporated by reference into Part III of this Report.

XML 21 R2.htm IDEA: XBRL DOCUMENT

Audit Information

12 Months Ended
Dec. 31, 2024

[Audit Information \[Abstract\]](#)

[Auditor Name](#)

DELOITTE & TOUCHE LLP

[Auditor Firm ID](#)

34

[Auditor Location](#)

Costa Mesa, California

XML 22 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Real estate:		
Buildings and improvements	\$ 16,115,283	\$ 13,329,464
Development costs and construction in progress	880,393	643,217
Land and improvements	2,918,758	2,647,633
Accumulated depreciation and amortization	(4,083,030)	(3,591,951)
Net real estate	15,831,404	13,028,363
Loans receivable, net of reserves of \$10,499 and \$2,830	717,190	218,450
Investments in and advances to unconsolidated joint ventures	936,814	782,853
Accounts receivable, net of allowance of \$2,243 and \$2,282	76,810	55,820
Cash and cash equivalents	119,818	117,635
Restricted cash	64,487	51,388
Intangible assets, net	817,254	314,156
Assets held for sale, net	7,840	117,986
Right-of-use asset, net	424,173	240,155
Other assets, net	942,465	772,044
Total assets	19,938,255	15,698,850
LIABILITIES AND EQUITY		
Bank line of credit and commercial paper	150,000	720,000
Term loans	1,646,043	496,824
Senior unsecured notes	6,563,256	5,403,378
Mortgage debt	356,750	256,097
Intangible liabilities, net	191,884	127,380
Liabilities related to assets held for sale, net	0	729
Lease liability	307,220	206,743
Accounts payable, accrued liabilities, and other liabilities	725,342	657,196
Deferred revenue	940,136	905,633
Total liabilities	10,880,631	8,773,980
Commitments and contingencies (Note 12)		
Redeemable noncontrolling interests	2,610	48,828
Common stock, \$1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 699,485,139 and 547,156,311 shares issued and outstanding	699,485	547,156
Additional paid-in capital	12,847,252	10,405,780
Cumulative dividends in excess of earnings	(5,174,279)	(4,621,861)
Accumulated other comprehensive income (loss)	28,818	19,371
Total stockholders’ equity	8,401,276	6,350,446
Joint venture partners	315,821	310,998
Non-managing member unitholders	337,917	214,598
Total noncontrolling interests	653,738	525,596
Total equity	9,055,014	6,876,042
Total liabilities and equity	\$ 19,938,255	\$ 15,698,850

XML 23 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Reserve for loans receivable	\$ 10,499	\$ 2,830
Allowance for accounts receivable	\$ 2,243	\$ 2,282
Common stock, par value (in dollars per share)	\$ 1.00	\$ 1.00
Common stock, shares authorized (in shares)	1,500,000,000	750,000,000
Common stock, shares issued (in shares)	699,485,139	547,156,311
Common stock, shares outstanding (in shares)	699,485,139	547,156,311

XML 24 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD (\$) shares in Thousands, \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:			
Rental and related revenues	\$ 2,087,196	\$ 1,631,805	\$ 1,541,775
Resident fees and services	568,475	527,417	494,935
Interest income and other	44,778	21,781	23,300
Income from direct financing leases	0	0	1,168
Total revenues	2,700,449	2,181,003	2,061,178
Costs and expenses:			
Interest expense	280,430	200,331	172,944
Depreciation and amortization	1,057,205	749,901	710,569
Operating	1,074,861	902,060	862,991
General and administrative	97,162	95,132	131,033
Transaction and merger-related costs	132,685	17,515	4,853
Impairments and loan loss reserves (recoveries), net	22,978	(5,601)	7,004
Total costs and expenses	2,665,321	1,959,338	1,889,394
Other income (expense):			

Gain (loss) on sales of real estate, net	178,695	86,463	9,078
Other income (expense), net	59,345	6,808	326,268
Total other income (expense), net	238,040	93,271	335,346
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	273,168	314,936	507,130
Income tax benefit (expense)	(4,350)	9,617	4,425
Equity income (loss) from unconsolidated joint ventures	(1,515)	10,204	1,985
Income (loss) from continuing operations	267,303	334,757	513,540
Income (loss) from discontinued operations	0	0	2,884
Net income (loss)	267,303	334,757	516,424
Noncontrolling interests' share in continuing operations	(24,161)	(28,748)	(15,975)
Net income (loss) attributable to Healthpeak Properties, Inc.	243,142	306,009	500,449
Participating securities' share in earnings	(758)	(1,725)	(2,657)
Net income (loss) applicable to common shares	\$ 242,384	\$ 304,284	\$ 497,792
Basic earnings (loss) per common share:			
Continuing operations (in dollars per share)	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations (in dollars per share)	0	0	0.00
Net income (loss) applicable to common shares (in dollars per share)	0.36	0.56	0.92
Diluted earnings (loss) per common share:			
Continuing operations (in dollars per share)	0.36	0.56	0.92
Discontinued operations (in dollars per share)	0	0	0.00
Net income (loss) applicable to common shares (in dollars per share)	\$ 0.36	\$ 0.56	\$ 0.92
Weighted average shares outstanding:			
Basic (in shares)	675,680	547,006	538,809
Diluted (in shares)	676,233	547,275	539,147

XML 25 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Statement of Comprehensive Income [Abstract]			
Net income (loss)	\$ 267,303	\$ 334,757	\$ 516,424
Other comprehensive income (loss):			
Net unrealized gains (losses) on derivatives	9,462	(8,900)	30,145
Change in Supplemental Executive Retirement Plan obligation and other	(15)	137	1,136
Total other comprehensive income (loss)	9,447	(8,763)	31,281
Total comprehensive income (loss)	276,750	325,994	547,705
Total comprehensive (income) loss attributable to noncontrolling interests' share in continuing operations	(24,161)	(28,748)	(15,975)
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.	\$ 252,589	\$ 297,246	\$ 531,730

XML 26 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS - USD (\$) shares in Thousands, \$ in Thousands	Total	Total Stockholders' Equity	Common Stock	Additional Paid-In Capital	Cumulative Dividends In Excess Of Earnings	Accumulated Other Comprehensive Income (Loss)	Total Noncontrolling Interests
Balance (in shares) at Dec. 31, 2021			539,097				
Balance at Dec. 31, 2021	\$ 7,058,760	\$ 6,515,470	\$ 539,097	\$ 10,100,294	\$ (4,120,774)	\$ (3,147)	\$ 543,290
Increase (Decrease) in Stockholders' Equity							
Net income (loss)	516,325	500,449			500,449		15,876
Other comprehensive income (loss)	31,281	31,281				31,281	
Issuance of common stock, net (in shares)			9,936				
Issuance of common stock, net	309,417	309,417	\$ 9,936	299,481			
Conversion of DownREIT units to common stock (in shares)			27				
Conversion of DownREIT units to common stock	0	880	\$ 27	853			(880)
Repurchase of common stock (in shares)			(2,418)				
Repurchase of common stock	(67,838)	(67,838)	\$ (2,418)	(65,420)			
Stock-based compensation	31,412	31,412		31,412			
Common dividends	(649,364)	(649,364)			(649,364)		
Distributions to noncontrolling interests	(30,389)						(30,389)
Adjustments to redemption value of redeemable noncontrolling interests	(17,006)	(17,006)		(17,006)			
Balance (in shares) at Dec. 31, 2022			546,642				
Balance at Dec. 31, 2022	7,182,598	6,654,701	\$ 546,642	10,349,614	(4,269,689)	28,134	527,897
Beginning balance at Dec. 31, 2021	87,344						
Increase (Decrease) in Redeemable Noncontrolling Interests							
Net income (loss)	99						
Distributions to noncontrolling interests	(160)						
Contributions from noncontrolling interests	1,390						
Adjustments to redemption value of redeemable noncontrolling interests	17,006						
Ending balance at Dec. 31, 2022	105,679						
Increase (Decrease) in Stockholders' Equity							
Net income (loss)	334,120	306,009			306,009		28,111
Other comprehensive income (loss)	(8,763)	(8,763)				(8,763)	
Issuance of common stock, net (in shares)			683				
Issuance of common stock, net	1,438	1,438	\$ 683	755			
Conversion of DownREIT units to common stock (in shares)			72				
Conversion of DownREIT units to common stock	0	1,272	\$ 72	1,200			(1,272)
Repurchase of common stock (in shares)			(241)				
Repurchase of common stock	(6,524)	(6,524)	\$ (241)	(6,283)			
Stock-based compensation	18,659	2,966		2,966			15,693
Common dividends	(658,181)	(658,181)			(658,181)		
Distributions to noncontrolling interests	(44,848)						(44,848)
Purchase of noncontrolling interest	(158)						(158)
Contributions from noncontrolling interests	173						173
Adjustments to redemption value of redeemable noncontrolling interests	57,528	57,528		57,528			
Balance (in shares) at Dec. 31, 2023			547,156				

Balance at Dec. 31, 2023	6,876,042	6,350,446	\$ 547,156	10,405,780	(4,621,861)	19,371	525,596
Increase (Decrease) in Redeemable Noncontrolling Interests							
Net income (loss)	637						
Distributions to noncontrolling interests	(276)						
Contributions from noncontrolling interests	316						
Adjustments to redemption value of redeemable noncontrolling interests	(57,528)						
Ending balance at Dec. 31, 2023	48,828						
Increase (Decrease) in Stockholders' Equity							
Net income (loss)	267,253	243,142			243,142		24,111
Other comprehensive income (loss)	9,447	9,447				9,447	
Shares issued as part of the Merger (in shares)				162,231			
Shares issued as part of the Merger	2,774,147	2,774,147		\$ 162,231	2,611,916		
Issuance of common stock, net (in shares)				434			
Issuance of common stock, net	1,094	1,094		\$ 434	660		
Conversion of DownREIT units to common stock (in shares)				256			
Conversion of DownREIT units to common stock	0	5,224		\$ 256	4,968		(5,224)
Repurchase of common stock (in shares)				(10,592)			
Repurchase of common stock	(190,690)	(190,690)		\$ (10,592)	(180,098)		
Stock-based compensation	19,916	7,991			7,991		11,925
Common dividends	(795,560)	(795,560)				(795,560)	
Distributions to noncontrolling interests	(36,354)						(36,354)
Purchase of noncontrolling interest	0						
Contributions from noncontrolling interests	0						
Noncontrolling interests acquired as part of the Merger	133,684						133,684
Adjustments to redemption value of redeemable noncontrolling interests	(3,965)	(3,965)			(3,965)		
Balance (in shares) at Dec. 31, 2024				699,485			
Balance at Dec. 31, 2024	9,055,014	\$ 8,401,276	\$ 699,485	\$ 12,847,252	\$ (5,174,279)	\$ 28,818	\$ 653,738
Increase (Decrease) in Redeemable Noncontrolling Interests							
Net income (loss)	50						
Distributions to noncontrolling interests	(468)						
Purchase of noncontrolling interests	(52,886)						
Contributions from noncontrolling interests	12						
Noncontrolling interests acquired as part of the Merger	3,109						
Adjustments to redemption value of redeemable noncontrolling interests	3,965						
Ending balance at Dec. 31, 2024	\$ 2,610						

XML 27
R8.htm
IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS	12 Months Ended
NONCONTROLLING INTERESTS	Dec. 31, 2024
(Parentetical) - \$ / shares	Dec. 31, 2023
	Dec. 31, 2022

Statement of Stockholders' Equity [Abstract]			
Common dividends, per share (in dollars per share)	\$ 1.20	\$ 1.20	\$ 1.20

XML 28
R9.htm
IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:			
Net income (loss)	\$ 267,303	\$ 334,757	\$ 516,424
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:			
Depreciation and amortization of real estate, in-place lease, and other intangibles	1,057,205	749,901	710,569
Stock-based compensation amortization expense	15,543	14,480	26,456
Merger-related post-combination stock compensation expense	16,223	0	0
Amortization of deferred financing costs and debt discounts (premiums)	28,974	11,916	10,881
Straight-line rents	(41,276)	(14,387)	(49,183)
Amortization of non-refundable entrance fees and above (below) market lease intangibles	(119,750)	(108,988)	(102,747)
Equity loss (income) from unconsolidated joint ventures	1,515	(10,204)	(2,049)
Distributions of earnings from unconsolidated joint ventures	12,000	910	943
Loss (gain) on sale of real estate under direct financing leases	0	0	(22,693)
Deferred income tax expense (benefit)	(1,693)	(14,605)	(6,001)
Impairments and loan loss reserves (recoveries), net	22,978	(5,601)	7,004
Loss (gain) on sales of real estate, net	(178,695)	(86,463)	(10,422)
Loss (gain) upon change of control, net	(77,548)	(234)	(311,438)
Casualty-related loss (recoveries), net	29,076	(3,085)	7,168
Other non-cash items	(6,133)	4,900	6,489
Changes in:			
Decrease (increase) in accounts receivable and other assets, net	(40,860)	(21,566)	(17,433)
Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue	85,635	104,511	136,293
Net cash provided by (used in) operating activities	1,070,497	956,242	900,261
Cash flows from investing activities:			
Acquisitions of real estate	(6,787)	(15,847)	(178,133)
Development, redevelopment, and other major improvements of real estate	(597,494)	(731,206)	(861,636)
Leasing costs, tenant improvements, and recurring capital expenditures	(115,784)	(113,596)	(108,510)
Proceeds from sales of real estate, net	648,548	141,651	47,885
Proceeds from the South San Francisco JVs transaction, net	0	0	125,985
Proceeds from the Callan Ridge JV transaction, net	125,662	0	0
Investments in unconsolidated joint ventures	(61,602)	(88,391)	(21,143)
Distributions in excess of earnings from unconsolidated joint ventures	22,906	20,640	12,518
Proceeds from insurance recovery	8,711	24,980	1,450
Proceeds from sales/principal repayments on loans receivable and marketable debt securities	93,445	204,865	115,988
Investments in loans receivable and other	(52,189)	(19,850)	(10,747)
Cash paid in connection with the Merger, net	(179,215)	0	0
Net cash provided by (used in) investing activities	(113,799)	(576,754)	(876,343)
Cash flows from financing activities:			
Borrowings under bank line of credit and commercial paper	3,741,250	10,344,705	15,882,153

Repayments under bank line of credit and commercial paper	(4,311,250)	(10,620,311)	(16,052,522)
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt	750,000	743,778	500,000
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt	(26,780)	(90,089)	(5,048)
Payments for deferred financing costs	(19,784)	(7,322)	(4,171)
Issuance of common stock and exercise of options, net of offering costs	317	278	308,100
Repurchase of common stock	(190,690)	(6,524)	(67,838)
Dividends paid on common stock	(794,783)	(657,021)	(648,047)
Distributions to and purchase of noncontrolling interests	(89,708)	(45,282)	(30,549)
Contributions from and issuance of noncontrolling interests	12	489	1,390
Net cash provided by (used in) financing activities	(941,416)	(337,299)	(116,532)
Net increase (decrease) in cash, cash equivalents, and restricted cash	15,282	42,189	(92,614)
Cash, cash equivalents, and restricted cash, beginning of year	169,023	126,834	219,448
Cash, cash equivalents, and restricted cash, end of year	\$ 184,305	\$ 169,023	\$ 126,834

XML 29 R10.htm IDEA: XBRL DOCUMENT

Business	12 Months Ended Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Business	
Business	
Overview	
Healthpeak Properties, Inc., a Standard & Poor's 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust ("REIT") and that, together with its consolidated entities (collectively, "Healthpeak" or the "Company"), owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States ("U.S."). Healthpeak® has a diverse portfolio comprised of investments in the following reportable healthcare segments: (i) outpatient medical; (ii) lab; and (iii) continuing care retirement community ("CCRC").	
The Company's corporate headquarters are in Denver, Colorado, and it has additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts, and property management offices in several locations throughout the U.S.	
On February 10, 2023, the Company completed its corporate reorganization (the "Reorganization") into an umbrella partnership REIT ("UPREIT"). Substantially all of the Company's business is conducted through Healthpeak OP, LLC ("Healthpeak OP"). The Company is the managing member of Healthpeak OP and does not have material assets or liabilities, other than through its investment in Healthpeak OP. For additional information on the UPREIT Reorganization, see the Company's Current Report on Form 8-K12B filed with the U.S. Securities and Exchange Commission ("SEC") on February 10, 2023.	
On March 1, 2024, the Company completed its planned merger with Physicians Realty Trust (see Note 3).	

XML 30 R11.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	12 Months Ended Dec. 31, 2024
Accounting Policies [Abstract]	
Summary of Significant Accounting Policies	
Summary of Significant Accounting Policies	
Use of Estimates	
Management is required to make estimates and assumptions in the preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP"). These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management's estimates.	
Basis of Presentation	
The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly owned subsidiaries, joint ventures ("JVs"), and variable interest entities ("VIEs") that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation.	
The Company is required to continually evaluate its VIE relationships and consolidate these entities when it is determined to be the primary beneficiary of their operations. A VIE is broadly defined as an entity where either: (i) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support, (ii) substantially all of an entity's activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights, or (iii) the equity investors as a group lack any of the following: (a) the power through voting or similar rights to direct the activities of an entity that most significantly impact the entity's economic performance, (b) the obligation to absorb the expected losses of an entity, or (c) the right to receive the expected residual returns of an entity. Criterion (iii) above is generally applied to limited partnerships and similarly structured entities by assessing whether a simple majority of the limited partners hold substantive rights to participate in the significant decisions of the entity or have the ability to remove the decision maker or liquidate the entity without cause. If neither of those criteria are met, the entity is a VIE.	
The designation of an entity as a VIE is reassessed upon certain events, including, but not limited to: (i) a change to the contractual arrangements of the entity or in the ability of a party to exercise its participation or kick-out rights, (ii) a change to the capitalization structure of the entity, or (iii) acquisitions or sales of interests that constitute a change in control.	
A variable interest holder is considered to be the primary beneficiary of a VIE if it has the power to direct the activities of a VIE that most significantly impact the entity's economic performance and has the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE. The Company qualitatively assesses whether it is (or is not) the primary beneficiary of a VIE. Consideration of various factors include, but is not limited to, which activities most significantly impact the entity's economic performance and the ability to direct those activities, its form of ownership interest, its representation on the VIE's governing body, the size and seniority of its investment, its ability and the rights of other investors to participate in policy making decisions, its ability to manage its ownership interest relative to the other interest holders, and its ability to replace the VIE manager and/or liquidate the entity.	
For its investments in joint ventures that are not considered to be VIEs, the Company evaluates the type of ownership rights held by the limited partner(s) that may preclude consolidation by the majority interest holder. The assessment of limited partners' rights and their impact on the control of a joint venture should be made at inception of the joint venture and continually reassessed.	
Revenue Recognition	
Lease Classification	
The Company classifies a lease as an operating lease if none of the following criteria are met: (i) transfer of ownership to the lessee by the end of the lease term, (ii) lessee has a purchase option during or at the end of the lease term that it is reasonably certain to exercise, (iii) the lease term is for the major part of the remaining economic life of the underlying asset, (iv) the present value of future minimum lease payments is equal to substantially all of the fair value of the underlying asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.	
Rental and Related Revenues	
The Company recognizes rental revenue from its outpatient medical and lab buildings in accordance with Accounting Standards Codification ("ASC") 842, <i>Leases</i> ("ASC 842"). The Company commences recognition of rental revenue for operating lease arrangements when the tenant has taken possession or controls the physical use of a leased asset. The tenant is not considered to have taken physical possession or have control of the leased asset until the Company-owned tenant improvements are substantially complete. If a lease arrangement provides for tenant improvements, the Company determines whether the tenant improvements are owned by the tenant or the Company. When the Company is the owner of the tenant improvements, any tenant improvements funded by the tenant are treated as lease payments which are deferred and amortized into income over the lease term. When the tenant is the owner of the tenant improvements, any tenant improvement allowance that is funded by the Company is treated as a lease incentive and amortized as a reduction of revenue over the lease term.	
Ownership of tenant improvements is determined based on various factors including, but not limited to, the following criteria:	
• lease stipulations of how and on what a tenant improvement allowance may be spent; • which party to the arrangement retains legal title to the tenant improvements upon lease expiration; • whether the tenant improvements are unique to the tenant or general purpose in nature; • if the tenant improvements are expected to have significant residual value at the end of the lease term; • the responsible party for construction cost overruns; and • which party constructs or directs the construction of the improvements.	
Certain leases provide for additional rents that are contingent upon a percentage of the building's revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant or estimates of tenant results, exceed the base amount or other thresholds, and only after any contingency has been removed (when the related thresholds are achieved). This may result in the recognition of rental revenue in periods subsequent to when such payments are received.	
Tenant recoveries subject to operating leases generally relate to the reimbursement of real estate taxes, insurance, and repair and maintenance expense, and are recognized as both revenue (in rental and related revenues) and expense (in operating expenses) in the period the expense is incurred as the Company is the party paying the service provider. Rental and related revenues from other variable payments are recognized when the associated contingencies are removed. In accordance with ASC 842, the Company accounts for lease and nonlease components as a single lease component for the purpose of revenue recognition and disclosure.	
For operating leases with minimum scheduled rent increases, the Company recognizes income on a straight-line basis over the lease term when collectibility of future minimum lease payments is probable. Recognizing rental income on a straight-line basis results in a difference in the timing of revenue amounts from what is contractually due from tenants. If the Company determines that collectibility of future minimum lease payments is not probable, the accounts receivable and straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period and future revenue recognition is limited to amounts contractually owed and paid. The Company does not resume recognition of income on a straight-line basis unless it determines that collectibility of future payments related to these leases is probable. For the Company's portfolio of operating leases that are deemed probable of collection but exhibit a certain level of collectibility risk, the Company may also recognize an incremental allowance as a reduction to revenue. At December 31, 2024 and 2023, straight-line rent receivable, net of allowance, was \$338 million and \$310 million, respectively. Straight-line rent receivable is included in other assets, net in the Consolidated Balance Sheets.	
The Company's operating leases generally contain options to extend lease terms at prevailing market rates at the time of expiration. Certain operating leases contain early termination options that require advance notice and payment of a penalty, which in most cases is substantial enough to be deemed economically disadvantageous by a tenant to exercise.	
Resident Fees and Services	
The Company recognizes resident fee and service revenue from its Senior Housing Operating Property ("SHOP") portfolios and CCRC properties in accordance with ASC 606, <i>Revenue from Contracts with Customers</i> . Resident fee revenue is recorded when services are rendered and includes resident room and care charges, community fees, and other resident charges. Residency agreements for SHOP and CCRC facilities are generally for a term of 30 days to one year, with resident fees billed monthly, in advance. Revenue for certain care related services is recognized as services are provided and is billed monthly in arrears.	
The Company's CCRCs are operated as entrance fee communities, which typically require a resident to pay an upfront entrance fee that includes both a refundable portion and non-refundable portion. When the Company receives a non-refundable entrance fee, it is recorded in deferred revenue in the Consolidated Balance Sheets and amortized into revenue over the estimated stay of the resident. The Company utilizes third-party actuarial experts in its determination of the estimated stay of residents.	
Income from Direct Financing Leases	
The Company utilizes the direct finance method of accounting to record direct financing lease ("DFL") income. For a lease accounted for as a DFL, the net investment in the DFL represents receivables for the sum of future minimum lease payments and the estimated residual value of the leased property, less the unamortized unearned income. Unearned income is deferred and amortized to income over the lease term to provide a constant yield when collectibility of the lease payments is reasonably assured. During the first quarter of 2022, the Company sold its remaining hospital under a DFL.	
Interest Income	
Loans receivable are classified as held-for-investment based on management's intent and ability to hold the loans for the foreseeable future or to maturity. Loans held-for-investment are carried at amortized cost and reduced by a valuation allowance for estimated credit losses, as necessary. When collectibility of the future payments is reasonably assured, the Company utilizes the interest method on a loan-by-loan basis to recognize interest income on its loans, which includes the amortization of discounts and premiums as well as loan fees paid and received.	

Management Fee Income

The Company provides various services to certain of its unconsolidated joint ventures in exchange for fees and reimbursement. These services are considered related party transactions under ASC 850, *Related Party Disclosures*. Management fee income is recognized in interest income and other on the Consolidated Statements of Operations.

Gain (Loss) on Sales of Real Estate, Net

The Company recognizes a gain (loss) on sale of real estate when the criteria for an asset to be derecognized are met, which include when: (i) a contract exists, (ii) the buyer obtains control of the asset, and (iii) it is probable that the Company will receive substantially all of the consideration to which it is entitled. These criteria are generally satisfied at the time of sale.

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide financial aid to individuals, businesses, and state and local governments. During the years ended December 31, 2023 and 2022, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenues during the coronavirus pandemic. Grant income is recognized to the extent that qualifying expenses and lost revenues exceed grants received and the Company will comply with all conditions attached to the grant. As of December 31, 2024, the amount of qualifying expenditures and lost revenues exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture.

The following table summarizes information related to government grant income received and recognized by the Company (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Government grant income recorded in other income (expense), net	\$ —	\$ 184	\$ 6,765
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	—	229	878
Government grant income recorded in income (loss) from discontinued operations	—	—	217
Total government grants received	<u>\$ —</u>	<u>\$ 413</u>	<u>\$ 7,860</u>

Credit Losses

The Company evaluates the liquidity and creditworthiness of its occupants, operators, and borrowers on a monthly and quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company's evaluation considers payment history and current credit status, industry conditions, current economic conditions, forecasted economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends. The determination of loan losses also considers concentration of credit risk associated with the senior housing and outpatient medical industries to which its loans receivable relate. The Company's occupants, operators, and borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the lease or debt service coverages in its assessment of internal ratings that it uses as a primary credit quality indicator. Lease and debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rate, reimbursement trends, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures. The Company evaluates, on a monthly basis or immediately upon a significant change in circumstance, its occupants', operators', and borrowers' ability to service their obligations with the Company.

In connection with the Company's quarterly review process or upon the occurrence of a significant event, loans receivable and DFLs (collectively, “finance receivables”), are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Finance receivables that are deemed Performing meet all present contractual obligations, and collection and timing, of all amounts owed is reasonably assured. Watch List finance receivables are defined as finance receivables that do not meet the definition of Performing or Workout. Workout finance receivables are defined as finance receivables in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the tenant, operator, or borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.

Finance receivables are placed on nonaccrual status when management determines that the collectibility of contractual amounts is not reasonably assured (the asset will have an internal rating of either Watch List or Workout). Further, the Company performs a credit analysis to support the tenant's, operator's, borrower's, and/or guarantor's repayment capacity and the underlying collateral values. The Company uses the cash basis method of accounting for finance receivables placed on nonaccrual status unless one of the following conditions exist whereby it uses the cost recovery method of accounting if: (i) the Company determines that it is probable that it will only recover the recorded investment in the finance receivable, net of associated allowances or charge-offs (if any), or (ii) the Company cannot reasonably estimate the amount of an impaired finance receivable. For cash basis method of accounting, the Company applies payments received, excluding principal paydowns, to interest income so long as that amount does not exceed the amount that would have been earned under the original contractual terms. For cost recovery method of accounting, any payment received is applied to reduce the recorded investment. Generally, the Company returns a finance receivable to accrual status when all delinquent payments become current under the terms of the loan or lease agreements and collectibility of the remaining contractual loan or lease payments is reasonably assured.

At inception of a finance receivable, the Company recognizes an allowance for credit losses expected to be incurred over the life of the instrument. The model utilized by the Company to determine such losses emphasizes historical experience and future market expectations to determine a loss to be recognized at inception. However, the model is applied on an individual basis and relies on counter-party specific information to ensure the most accurate estimate is recognized. The Company also performs a quarterly review process (or upon the occurrence of a significant event) to evaluate its borrowers' creditworthiness and liquidity to determine the amount of credit losses to recognize during the period. If a finance receivable is deemed partially or wholly uncollectible, the uncollectible balance is deducted from the allowance in the period in which such determination is made. Credit loss expenses and recoveries are recorded in impairments and loan loss reserves (recoveries), net.

Real Estate

The Company's real estate acquisitions are generally classified as asset acquisitions for which the Company records identifiable assets acquired, liabilities assumed, and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill is recognized, third party transaction costs are capitalized and any associated contingent consideration is generally recorded when the amount of consideration is reasonably estimable and probable of being paid.

The Company assesses fair value based on available market information, such as capitalization and discount rates, comparable sale transactions, and relevant per square foot or unit cost information. A real estate asset's fair value may be determined utilizing cash flow projections that incorporate such market information. Estimates of future cash flows are based on a number of factors including historical operating results, known and anticipated trends, as well as market and economic conditions. The fair value of tangible assets of an acquired property is based on the value of the property as if it is vacant.

The Company recognizes acquired “above and below market” leases at their relative fair value (for asset acquisitions) using discount rates which reflect the risks associated with the leases acquired. The fair value is based on the present value of the difference between (i) the contractual amounts paid pursuant to each in-place lease and (ii) management's estimate of fair market lease rates for each in-place lease, measured over a period equal to the remaining term of the lease for above market leases and the initial term plus the extended term for any leases with renewal options that are reasonably certain to be exercised. Other intangible assets acquired include amounts for in-place lease values that are based on an evaluation of the specific characteristics of each property and the acquired tenant lease(s). Factors considered include estimates of carrying costs during hypothetical expected lease-up periods, market conditions, and costs to execute similar leases. In estimating carrying costs, the Company includes estimates of lost rents at market rates during the hypothetical expected lease-up periods, which are dependent on local market conditions and expected trends. In estimating costs to execute similar leases, the Company considers leasing commissions, legal, and other related costs.

Certain of the Company's acquisitions involve the assumption of contract liabilities. The Company typically estimates the fair value of contract liabilities by applying a reasonable profit margin to the total discounted estimated future costs associated with servicing the contract. A variety of market and contract-specific conditions are considered when making assumptions that impact the estimated fair value of the contract liability.

The Company capitalizes direct construction and development costs, including predevelopment costs, interest, property taxes, insurance, and other costs directly related and essential to the development or construction of a real estate asset. The Company capitalizes construction and development costs while substantive activities are ongoing to prepare an asset for its intended use. During the holding or development period, certain real estate assets generate incidental income that is not associated with the future profit or return from the intended use of the property. Such income is recognized as a reduction of the associated project costs. The Company considers a construction project as substantially complete and held available for occupancy upon the completion of Company-owned tenant improvements, but no later than one year from cessation of significant construction activity. Costs incurred after a project is substantially complete and ready for its intended use, or after development activities have ceased, are expensed as incurred. For redevelopment of existing operating properties, the Company capitalizes the cost for the construction and improvement incurred in connection with the redevelopment.

Costs previously capitalized related to abandoned developments/redevelopments are charged to earnings. Expenditures for repairs and maintenance are expensed as incurred. The Company considers costs incurred in conjunction with re-leasing properties, including tenant improvements and lease commissions, to represent the acquisition of productive assets and such costs are reflected as investing activities in the Company's Consolidated Statements of Cash Flows.

Initial direct costs incurred in connection with successful property leasing are capitalized as deferred leasing costs and classified as investing activities in the Consolidated Statements of Cash Flows. Initial direct costs include only those costs that are incremental to the arrangement and would not have been incurred if the lease had not been obtained. Initial direct costs consist of leasing commissions paid to employees and external third party brokers and lease incentives. Initial direct costs are included in other assets, net in the Consolidated Balance Sheets. At December 31, 2024 and 2023, the balance of net initial direct costs were \$204 million and \$172 million, respectively. Initial direct costs are amortized in depreciation and amortization in the Consolidated Statements of Operations using the straight-line method over the lease term.

The Company computes depreciation on properties using the straight-line method over the assets' estimated useful lives. These useful lives are reassessed following changes in the remaining period that the asset is expected to be held and used, and depreciation is discontinued when a property meets the criteria to be classified as held for sale. Buildings and improvements are depreciated over useful lives ranging up to 50 years. Above and below market lease intangibles are amortized to revenue over the remaining noncancellable lease terms and renewal periods that are reasonably certain to be exercised, if any. In-place lease intangibles are amortized to expense over the remaining noncancellable lease term and renewal periods that are reasonably certain to be exercised, if any.

Business Combinations

For the Company's real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The fair values are determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant.

Other Assets, Net

Other assets, net consist primarily of straight-line rent receivable (as discussed above), initial direct costs (as discussed above), deferred income taxes (see Note 17), goodwill (see Note 10), corporate assets (see Note 7), derivative assets (see Note 22), other equity investments (as discussed below and see Note 19), and prepaid expenses.

Other Equity Investments

The Company has certain investments recognized in accordance with ASC 321, *Investments-Equity Securities*, within other assets, net on the Consolidated Balance Sheets. These investments do not have readily determinable fair values and the practical expedient to estimate fair value using net asset value per share has not been elected. Accordingly, the investments are measured at cost, less any impairments, and are adjusted for any observable price changes, with such changes included in earnings.

An observable price results from an orderly transaction for an identical or similar investment of the same issuer, which is observed by an investor without expending undue cost and effort. Observable price changes may result from equity transactions of the same issuer, including subsequent equity offerings. To determine whether transactions are indicative of an observable price change, the Company evaluates, among other factors, whether the transactions have similar rights and obligations, which include voting rights, distribution rights and preferences, and conversion features.

Lessee Accounting

For leases greater than 12 months for which the Company is the lessee, such as ground leases and corporate office leases, the Company recognizes a right-of-use asset and related lease liability on the Consolidated Balance Sheets at inception of the lease. The lease liability is calculated as the sum of: (i) the present value of minimum lease payments at lease commencement (discounted using the Company's secured incremental borrowing rate) and (ii) the present value of amounts probable of being paid under any residual value guarantees. Certain of the Company's lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if they are considered reasonably certain of exercise. The right-of-use asset is calculated as the lease liability, adjusted for the following: (i) any lease payments made to the lessor at or before the commencement date, minus any lease incentives received and (ii) any initial direct costs incurred by the Company. Lease expense related to corporate assets is included in general and administrative expenses and lease expense related to ground leases is included within operating expenses in the Company's Consolidated Statements of Operations.

For leases with a noncancellable lease term of 12 months or less for which the Company is the lessee, the Company recognizes expenses on a straight-line basis and does not recognize such leases on the Consolidated Balance Sheets.

Impairment of Long-Lived Assets and Goodwill

The Company assesses the carrying value of real estate assets and related intangibles (“real estate assets”) when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company tests its real estate assets for impairment by comparing the sum of the expected future undiscounted cash flows to the carrying value of the real estate assets. The expected future undiscounted cash flows reflect external market factors and the expected use and eventual disposition of the asset, and based on the specific facts and circumstances, may be probability-weighted to reflect multiple possible cash-flow scenarios, including selling the assets at various points in the future. Further, the analysis considers the impact, if any, of master lease agreements on cash flows, which are calculated utilizing the lowest level of identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. If the carrying value exceeds the expected future undiscounted cash flows, an impairment loss will be recognized to the extent that the carrying value of the real estate assets exceeds their fair value.

Determining the fair value of real estate assets, including assets classified as held-for-sale, involves significant judgment and generally utilizes market capitalization rates, comparable market transactions, estimated per unit or per square foot prices, negotiations with prospective buyers, and forecasted cash flows (primarily lease revenue rates, expense rates, and growth rates).

When testing goodwill for impairment, if the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company recognizes an impairment loss for the amount by which the carrying value, including goodwill, exceeds the reporting unit's fair value.

Assets Held for Sale and Discontinued Operations

The Company classifies a real estate property as held for sale when: (i) management has approved the disposal, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the

disposal plan will significantly change or be withdrawn. If a real estate property is classified as held for sale, it is reported at the lower of its carrying value or fair value less costs to sell and no longer depreciated.

The Company classifies a loan receivable as held for sale when management no longer has the intent and ability to hold the loan receivable for the foreseeable future or until maturity. If a loan receivable is classified as held for sale, it is reported at the lower of amortized cost or fair value.

A discontinued operation represents: (i) a component of the Company or group of components that has been disposed of or is classified as held for sale in a single transaction and represents a strategic shift that has or will have a major effect on the Company's operations and financial results or (ii) an acquired business that is classified as held for sale on the date of acquisition. Examples of a strategic shift may include disposing of: (i) a separate major line of business, (ii) a separate major geographic area of operations, or (iii) other major parts of the Company.

Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 5 for further information.

Investments in Unconsolidated Joint Ventures

Investments in entities the Company does not consolidate, but over which the Company has the ability to exercise significant influence over operating and financial policies, are reported under the equity method of accounting. Under the equity method of accounting, the Company's share of the investee's earnings or losses is included in equity income (loss) from unconsolidated joint ventures within the Company's Consolidated Statements of Operations.

The initial carrying value of investments in unconsolidated joint ventures is based on the amount paid to purchase the joint venture interest, the fair value of assets contributed to the joint venture, or the fair value of the assets prior to the sale of interests in the joint venture. To the extent that the Company's cost basis is different from the basis reflected at the joint venture level, the basis difference is generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company's share of equity in earnings of the joint venture. If an equity method investment shows indicators of impairment, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the equity method investment to its carrying value. When the Company determines a decline in fair value below carrying value of an investment in an unconsolidated joint venture is other-than-temporary, an impairment is recorded. The Company recognizes gains on the sale of interests in joint ventures to the extent the economic substance of the transaction is a sale.

The Company's fair values of its equity method investments are determined based on discounted cash flow models that include all estimated cash inflows and outflows over a specified holding period and, where applicable, any estimated debt premiums or discounts. Capitalization rates, discount rates, and credit spreads utilized in these valuation models are based on assumptions that the Company believes to be within a reasonable range of current market rates for the respective investments.

Stock-Based Compensation

Compensation expense for share-based awards granted to employees with graded vesting schedules is generally recognized on a straight-line basis over the vesting period. Forfeitures of share-based awards are recognized as they occur.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash on hand and short-term investments with original maturities of three months or less when purchased. Restricted cash primarily consists of amounts held by mortgage lenders to provide for: (i) real estate tax expenditures, (ii) tenant improvements, and (iii) capital expenditures, as well as security deposits and net proceeds from property sales that were executed as tax-deferred dispositions.

The Company maintains its cash and cash equivalents at financial institutions insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000 per institution. As the account balances at each institution periodically exceed the FDIC insurance coverage, there is a concentration of credit risk related to amounts in excess of such coverage.

Derivatives and Hedging

During its normal course of business, the Company uses certain types of derivative instruments for the purpose of managing interest rate risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company's related assertions.

The Company recognizes all derivative instruments, including embedded derivatives that are required to be bifurcated, as assets or liabilities to the Consolidated Balance Sheets at fair value. Changes in fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in other income (expense), net. For derivative instruments designated in qualifying cash flow hedging relationships, changes in fair value related to the effective portion of the derivative instruments are recognized in accumulated other comprehensive income (loss), whereas changes in fair value related to the ineffective portion would be recognized in earnings.

If it is determined that a derivative instrument ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, the Company discontinues its cash flow hedge accounting prospectively and records the appropriate adjustment to earnings based on the current fair value of the derivative instrument.

Income Taxes

Healthpeak Properties, Inc. has elected REIT status and believes it has always operated so as to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, as amended (the "Code"). Accordingly, Healthpeak Properties, Inc. will generally not be subject to U.S. federal income tax, provided that it continues to qualify as a REIT and makes distributions to stockholders equal to or in excess of its taxable income. In addition, the Company has formed several consolidated subsidiaries that have elected REIT status. Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are each subject to the REIT qualification requirements under the Code. If any REIT fails to qualify as a REIT in any taxable year, it will be subject to federal income taxes at regular corporate rates and may be ineligible to qualify as a REIT for four subsequent tax years.

Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are subject to state and local income taxes in some jurisdictions. In certain circumstances each REIT may also be subject to federal excise taxes on undistributed income. In addition, certain activities that the Company undertakes may be conducted by entities that have elected to be treated as taxable REIT subsidiaries ("TRSs"). TRSs are subject to federal, state, and local income taxes. The Company recognizes tax penalties relating to unrecognized tax benefits as additional income tax expense. Interest relating to unrecognized tax benefits is recognized as interest expense.

The Company is required to evaluate its deferred tax assets for realizability and recognize a valuation allowance, which is recorded against its deferred tax assets, if it is more likely than not that the deferred tax assets will not be realized. The Company considers all available evidence in its determination of whether a valuation allowance for deferred tax assets is required.

Advertising Costs

All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was \$9 million, \$8 million, and \$8 million, respectively.

Capital Raising Issuance Costs

Costs incurred in connection with the issuance of common shares are recorded as a reduction of additional paid-in capital. Debt issuance costs related to debt instruments, excluding line of credit arrangements and commercial paper, are deferred, recorded as a reduction of the related debt liability, and amortized to interest expense over the remaining term of the related debt liability utilizing the effective interest method. Debt issuance costs related to line of credit arrangements and commercial paper are deferred, included in other assets, and amortized to interest expense on a straight-line basis over the remaining term of the related line of credit arrangement. Commercial paper are unsecured short-term debt securities with varying maturities. A line of credit serves as a liquidity backstop for repayment of commercial paper borrowings.

Penalties incurred to extinguish debt and any remaining unamortized debt issuance costs, discounts, and premiums are recognized as income or expense in the Consolidated Statements of Operations at the time of extinguishment.

Segment Reporting

The Company's reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC.

Noncontrolling Interests

Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Net income (loss) attributable to a noncontrolling interest is included in net income (loss) on the Consolidated Statements of Operations and, upon a gain or loss of control, the interest purchased or sold, and any interest retained, is recorded at fair value with any gain or loss recognized in earnings. The Company accounts for purchases or sales of equity interests that do not result in a change in control as equity transactions.

Redeemable Noncontrolling Interests

Certain of the Company's noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time. Each put option is payable in cash and subject to increases in redemption value in the event that the underlying property generates specified returns and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period.

Healthpeak OP

Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, certain employees of the Company ("OP Unitholders") were issued noncontrolling, non-managing member units in Healthpeak OP ("OP Units"). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company's common stock, at the Company's option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company's common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash.

DownREITs

The Company consolidates non-managing member limited liability companies ("DownREITs") because it exercises control, and the noncontrolling interests in these entities are carried at cost. The non-managing member limited liability company ("LLC") units ("DownREIT units") are exchangeable for an amount of cash approximating the then-current market value of shares of the Company's common stock or, at the Company's option, shares of the Company's common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company's common stock, the carrying amount of the DownREIT units is reclassified to stockholders' equity.

Fair Value Measurement

The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:

- Level 1—quoted prices for identical instruments in active markets;
- Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
- Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities that are required to be measured at fair value. When available, the Company utilizes quoted market prices to determine fair value and classifies such items in Level 1. In instances where a market price is available, but the instrument is in an inactive or over-the-counter market, the Company consistently applies the dealer (market maker) pricing estimate and classifies the asset or liability in Level 2.

If quoted market prices or inputs are not available, fair value measurements are based on valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads, and/or market capitalization rates. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, the asset or liability could be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques used by the Company include discounted cash flow models. The Company also considers its counterparty's and own credit risk for derivative instruments and other liabilities measured at fair value.

The Company has elected the mid-market pricing expedient when determining fair value.

Earnings per Share

Basic earnings per common share is computed by dividing net income (loss) applicable to common shares by the weighted average number of shares of common stock outstanding during the period. The Company accounts for unvested share-based payment awards that contain non-forfeitable dividend rights or dividend equivalents (whether paid or unpaid) as participating securities, which are included in the computation of earnings per share pursuant to the two-class method. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units.

Recent Accounting Pronouncements

Adopted

Segment Reporting. In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* ("ASU 2023-07"), to improve reportable segment disclosure requirements so that investors can better understand an entity's overall performance and assess potential future cash flows. The amendments in ASU 2023-07 include, but are not limited to: (i) disclosure of, on an annual basis, significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) disclosure of, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition (the other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss); (iii) disclosure of, on an interim basis, all currently required annual disclosures about a reportable segment's profit (loss) and assets; (iv) clarification that if the CODM uses more than one measure of a segment's profit or loss in

assessing segment performance and deciding how to allocate resources, an entity may report one or more of those additional measures of segment profit; and (v) disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. During the year ended December 31, 2024, the amendments in ASU 2023-07 were adopted retrospectively and did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows.

Not Yet Adopted

Income Taxes. In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* (“ASU 2023-09”), to provide disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation (using both percentages and reporting currency amounts) of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is evaluating the impact ASU 2023-09 will have on its disclosures.

Expense Disaggregation. In November 2024, the FASB issued ASU No. 2024-03, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses* (“ASU 2024-03”), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date*, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact these ASUs will have on its disclosures.

[XML 31 R12.htm IDEA: XBRL DOCUMENT](#)

The Merger

[Business Combination, Asset Acquisition, and Joint Venture Formation \[Abstract\]](#)
[The Merger](#)

12 Months Ended Dec. 31, 2024

The Merger

On March 1, 2024 (the “Closing Date”), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the “Merger Agreement”), by and among the Company, DOC DR Holdco, LLC, a wholly owned subsidiary of the Company (“DOC DR Holdco”), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”), Physicians Realty Trust, and Physicians Realty L.P. (the “Physicians Partnership”); (i) Physicians Realty Trust merged with and into DOC DR Holdco (the “Company Merger”), with DOC DR Holdco surviving as a wholly owned subsidiary of the Company (the “Company Surviving Entity”); (ii) immediately following the effectiveness of the Company Merger, the Company contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the “Contribution”); and (iii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the “Partnership Merger” and, together with the Company Merger, the “Merger”), with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP (the “Partnership Surviving Entity”). Subsequent to the Closing Date, the “Combined Company” means the Company and its subsidiaries.

On the Closing Date and in connection with the Merger, (i) each outstanding common share of beneficial interest of Physicians Realty Trust (“Physicians Realty Trust common shares”) (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) was automatically converted into the right to receive 0.674 (the “Exchange Ratio”) shares of the Company’s common stock, and (ii) each outstanding common unit of the Physicians Partnership was converted into common units in the Partnership Surviving Entity equal to the Exchange Ratio.

As a result of the Merger, the Company acquired 299 outpatient medical buildings. The primary reason for the Merger was to expand the Company’s size, scale, and diversification, in order to further enhance the Company’s competitive advantages and accelerate investment activities.

The Merger was accounted for using the acquisition method of accounting in accordance with ASC 805, *Business Combinations*, which requires, among other things, the assets acquired and the liabilities assumed to be recognized at their acquisition date fair value. For accounting purposes, the Company was treated as the accounting acquirer of Physicians Realty Trust. The Company was considered to be the accounting acquirer primarily because: (i) the Company is the entity that transferred consideration to consummate the Merger; (ii) the Company’s stockholders as a group retained the largest portion of the voting rights of the Combined Company and have the ability to elect, appoint, or remove a majority of the members of the Combined Company’s board of directors; and (iii) its senior management constitutes the majority of management of the Combined Company.

The consideration transferred on the Closing Date is as follows (in thousands, except per share data):

	March 1, 2024
Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged ⁽¹⁾	240,699
Exchange Ratio	0.674
Shares of Healthpeak common stock issued	162,231
Closing price of Healthpeak common stock on March 1, 2024 ⁽²⁾	\$ 17.10
Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs	\$ 2,774,147
Less: Fair value of share consideration attributable to the post-combination period ⁽³⁾	(16,223)
Physicians Realty Trust revolving credit facility termination ⁽⁴⁾	\$ 175,411
Settlement of Physicians Realty Trust’s transaction costs	23,913
Payments made in connection with share settlement ⁽⁵⁾	11,315
Cash consideration	\$ 210,639
Consideration transferred	<u>\$ 2,968,563</u>

- (1) Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”).
- (2) The fair value of Healthpeak common stock issued to former holders of Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs was based on the per share closing price of Healthpeak common stock on March 1, 2024.
- (3) Represents the fair value of unvested Physicians Realty Trust restricted shares, PSUs, and RSUs attributable to post-combination services that were converted into Healthpeak common stock on the Closing Date in accordance with the Merger Agreement. Although no future service after the Closing Date is required, the value attributable to post-combination services reflected the incremental fair value provided to the Physicians Realty Trust equity award holders and the accelerated vesting of such awards at the Closing Date in accordance with the Merger Agreement. This amount was recognized as transaction and merger-related costs on the Consolidated Statements of Operations.
- (4) Represents the Company’s cash repayment of all outstanding balances under Physicians Realty Trust’s revolving credit facility on the Closing Date in connection with the related termination.
- (5) Includes cash settlement of: (i) tax liability related to holdback elections made under the pre-existing terms and conditions of Physicians Realty Trust’s equity programs and (ii) fractional share consideration.

Purchase Price Allocation

For the Company’s real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests were based on information that was available at the Closing Date. The fair values were determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant.

The following table summarizes the estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests at the Closing Date (in thousands):

	Preliminary Amounts Recognized on the Closing Date	Measurement Period Adjustments	Amounts Recognized on the Closing Date (As Adjusted)
ASSETS			
Real estate:			
Buildings and improvements	\$ 3,199,884	\$ (6,889)	\$ 3,192,995
Development costs and construction in progress	68,171	—	68,171
Land and improvements	435,353	—	435,353
Real estate	3,703,408	(6,889)	3,696,519
Loans receivable	118,908	—	118,908
Investments in and advances to unconsolidated joint ventures	58,636	—	58,636
Accounts receivable, net ⁽¹⁾	9,536	(254)	9,282
Cash and cash equivalents	30,417	—	30,417
Restricted cash	1,007	—	1,007
Intangible assets ⁽²⁾	890,827	—	890,827
Right-of-use asset	191,415	(113)	191,302
Other assets	44,691	(668)	44,023
Total assets	\$ 5,048,845	\$ (7,924)	\$ 5,040,921
LIABILITIES AND EQUITY			
Term loans	\$ 402,320	\$ —	\$ 402,320
Senior unsecured notes	1,139,760	—	1,139,760
Mortgage debt	127,176	—	127,176
Intangible liabilities ⁽³⁾	149,875	—	149,875
Lease liability	97,160	(113)	97,047
Accounts payable, accrued liabilities, and other liabilities	72,864	(2,976)	69,888
Total liabilities	\$ 1,989,155	\$ (3,089)	\$ 1,986,066
Redeemable noncontrolling interests	1,536	1,573	3,109
Joint venture partners ⁽⁴⁾	20,109	(3,043)	17,066
Non-managing member unitholders ⁽⁵⁾	116,618	—	116,618
Total noncontrolling interests	\$ 136,727	\$ (3,043)	\$ 133,684
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests	\$ 2,921,427	\$ (3,365)	\$ 2,918,062
Goodwill	47,136	3,365	50,501
Total purchase price	<u>\$ 2,968,563</u>	<u>\$ —</u>	<u>\$ 2,968,563</u>

- (1) Includes \$14 million of gross contractual accounts receivable.
- (2) The intangible assets acquired had a weighted average amortization period of 6 years (see Note 10).
- (3) The intangible liabilities acquired had a weighted average amortization period of 9 years (see Note 10).
- (4) Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7% to 99.7% on the Closing Date.
- (5) In connection with the Merger, Physicians Partnership merged with and into DOC DR OP Sub with DOC DR OP Sub surviving as the Partnership Surviving Entity. The Company controls the Partnership Surviving Entity via its ownership of its managing member, and the Partnership Surviving Entity is consolidated by the Company.

The measurement period adjustments recorded through December 31, 2024 are final and were primarily the result of additional information obtained during the measurement period by the Company related to certain assets acquired and liabilities assumed and updated valuations of noncontrolling interests, resulting in an increase to goodwill of \$3 million.

Based on the final purchase price allocation of fair value, approximately \$51 million has been allocated to goodwill. The recognized goodwill is attributable to expected synergies, cost savings, acquired workforce, and potential economies of scale benefits from outpatient medical property management and tenant and vendor relationships following the closing of the Merger. None of the goodwill recognized is expected to be deductible for tax purposes.

Merger-Related Costs

During the year ended December 31, 2024, the Company incurred approximately \$129 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust. Included in this amount is: (i) \$38 million of fees paid to investment banks and advisors to help the

Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters, inclusive of \$21 million of success-based fees incurred upon consummation of the Merger, (ii) \$26 million of severance expense due to certain Physicians Realty Trust dual-trigger severance arrangements that are required to be recognized as post-combination expense in accordance with ASC 805, (iii) \$16 million of post-combination stock compensation expense for the accelerated vesting of Physicians Realty Trust equity awards pursuant to the terms of the Merger Agreement, based on the fair value of Healthpeak common stock issued to holders of Physicians Realty Trust equity awards, (iv) \$35 million of legal, accounting, tax, and other costs, and (v) \$13 million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately \$11 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations.

Unaudited Pro Forma Financial Information

The Consolidated Statements of Operations for the year ended December 31, 2024 include \$473 million of revenues and \$6 million of net loss applicable to common shares associated with the results of operations of legacy Physicians Realty Trust from the Closing Date to December 31, 2024.

The following unaudited pro forma information presents a summary of the results of operations for the Combined Company, as if the Merger had been consummated on January 1, 2023 (in thousands). The following unaudited pro forma financial information is not necessarily indicative of the results of operations had the acquisition been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the unaudited pro forma financial information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.

	Year Ended December 31,	
	2024	2023
Total revenues	\$ 2,765,670	\$ 2,771,468
Net income (loss) applicable to common shares	353,347	24,630

The unaudited pro forma financial information above includes nonrecurring significant adjustments made to account for certain costs incurred as if the Merger had been completed on January 1, 2023. Transaction and merger-related costs of \$129 million that were incurred during the year ended December 31, 2024, were excluded from the unaudited pro forma financial information for the year ended December 31, 2024, but included for the year ended December 31, 2023. The year ended December 31, 2023 also includes \$11 million of transaction and merger-related costs that were recognized during the year then ended.

XML 32 R13.htm IDEA: XBRL DOCUMENT

Real Estate
Investments
[Real Estate \[Abstract\]](#)
[Real Estate Investments](#)

12 Months Ended
Dec. 31, 2024

Real Estate Investments

2024 Real Estate Investment Acquisitions

The Merger

As a result of the Merger, the Company acquired 299 outpatient medical buildings (see Note 3).

2023 Real Estate Investment Acquisitions

60 Loomis Land Parcel

In January 2023, the Company acquired a lab land parcel in Cambridge, Massachusetts for \$9 million.

Wylie Outpatient Medical Building

In April 2023, the Company acquired the remaining 80% interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for \$4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of \$0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023.

2022 Real Estate Investment Acquisitions

67 Smith Place

In January 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for \$72 million.

Vista Sorrento Phase II

In January 2022, the Company closed a lab acquisition in San Diego, California for \$24 million.

Webster Outpatient Medical Portfolio

In March 2022, the Company acquired a portfolio of two outpatient medical buildings in Houston, Texas for \$43 million.

Northwest Medical Plaza

In May 2022, the Company acquired one outpatient medical building in Bentonville, Arkansas for \$26 million.

Concord Avenue Land Parcels

In December 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for \$18 million.

Development Activities

Construction, Tenant, and Other Capital Improvements

The following table summarizes the Company's expenditures for construction, tenant improvements, and other capital improvements for its consolidated property investments, excluding expenditures related to properties classified as discontinued operations (in thousands):

Segment	Year Ended December 31,		
	2024	2023	2022
Outpatient medical	\$ 356,273	\$ 236,135	\$ 237,761
Lab	313,749	428,961	658,542
CCRC	66,741	109,465	65,691
	\$ 736,763	\$ 774,561	\$ 961,994

XML 33 R14.htm IDEA: XBRL DOCUMENT

Dispositions of Real
Estate and
Discontinued
Operations
[Discontinued
Operations and
Disposal Groups
\[Abstract\]](#)
[Dispositions of Real
Estate and Discontinued
Operations](#)

12 Months Ended
Dec. 31, 2024

Dispositions of Real Estate and Discontinued Operations

2024 Dispositions of Real Estate

During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for \$674 million and provided the buyer with a mortgage loan secured by the real estate sold for \$405 million (see Note 8), (ii) 14 outpatient medical buildings for \$220 million, (iii) a portfolio of seven lab buildings for \$180 million, (iv) a portfolio of two outpatient medical buildings for \$23 million and provided the buyer with a mortgage loan secured by the real estate sold for \$14 million (see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company's CCRC campuses for \$12 million, resulting in total net gain on sales of \$179 million.

2023 Dispositions of Real Estate

During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for \$113 million and two outpatient medical buildings for \$32 million, resulting in total gain on sales of \$81 million.

2022 Dispositions of Real Estate

During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for \$14 million and five outpatient medical buildings and one outpatient medical land parcel for \$36 million, resulting in total gain on sales of \$15 million.

Held for Sale and Discontinued Operations

As of December 31, 2024, one outpatient medical building was classified as held for sale, with a carrying value of \$8 million, primarily comprised of net real estate assets. As of December 31, 2024, liabilities related to the asset held for sale were zero. As of December 31, 2023, two lab buildings and one outpatient medical building were classified as held for sale, with a carrying value of \$118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were \$1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65% interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023.

In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein. The Company has successfully completed the disposition of its senior housing triple-net and SHOP properties.

At each of December 31, 2024 and 2023, the total assets and total liabilities classified as discontinued operations were zero.

The results of discontinued operations during the years ended December 31, 2024, 2023, and 2022 are presented below (in thousands) and are included in the consolidated results of operations for the years ended December 31, 2024, 2023, and 2022:

	Year Ended December 31,		
	2024	2023	2022
Revenues:			
Resident fees and services	\$ —	\$ —	\$ 7,489
Total revenues	—	—	7,489
Costs and expenses:			
Operating	—	—	6,452
Total costs and expenses	—	—	6,452
Other income (expense):			
Gain (loss) on sales of real estate, net	—	—	1,344
Other income (expense), net	—	—	169
Total other income (expense), net	—	—	1,513
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—	—	2,550
Income tax benefit (expense)	—	—	270
Equity income (loss) from unconsolidated joint ventures	—	—	64
Income (loss) from discontinued operations	\$ —	\$ —	\$ 2,884

XML 34 R15.htm IDEA: XBRL DOCUMENT

Impairments of Real
Estate
[Asset Impairment](#)

12 Months Ended
Dec. 31, 2024

Impairments of Real Estate

Impairment Charges

During the year ended December 31, 2024, the Company recognized an impairment charge of \$13 million, which is reported in impairments and loan loss reserves (recoveries), net, on the Consolidated Statements of Operations related to one outpatient medical building that met the held for sale criteria. Upon classifying the asset as held for sale, the Company recognized an impairment charge to write down the building's carrying value of \$21 million to its fair value, less estimated costs to sell, of \$8 million.

The fair value of the impaired asset was based on the forecasted sales price which is considered to be a Level 3 measurement within the fair value hierarchy. The Company's fair value estimates primarily relied on a market approach, which utilized comparable market transactions and negotiations with prospective buyers.

During the years ended December 31, 2023 and 2022, the Company did not recognize any impairment charges.

Casualty-Related Charges

During the years ended December 31, 2024, 2023, and 2022, the Company recognized \$30 million, \$(3) million, and \$6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to damages as a result of Hurricane Milton, partially offset by recoveries from proceeds received for water damage at an outpatient medical building during the year then ended. During the year ended December 31, 2023, such recoveries were primarily attributable to proceeds received for water damage at an outpatient medical building. During the year ended December 31, 2022, such charges were primarily attributable to damages as a result of Hurricane Ian. Casualty-related charges are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. Also during the years ended December 31, 2024, 2023, and 2022, the Company collected business interruption proceeds of \$0.7 million, \$4 million, and \$3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations.

Other Losses

During the year ended December 31, 2022, the Company recognized \$14 million of expenses within other income (expense), net on the Consolidated Statements of Operations for tenant relocation and other costs associated with the demolition of an outpatient medical building.

See Note 8 for information related to the Company's reserve for loan losses.

XML 35 R16.htm IDEA: XBRL DOCUMENT

Leases

Leases

Lease Income

The following table summarizes the Company's lease income (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Fixed income from operating leases	\$ 1,530,493	\$ 1,236,502	\$ 1,182,463
Variable income from operating leases	556,703	395,303	359,312
Interest income from direct financing leases	—	—	1,168

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital under a DFL for \$68 million and recognized a gain on sale of \$23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL.

Operating Leases

Future Minimum Rents

The following table summarizes future minimum lease payments to be received from tenants under non-cancelable operating leases as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 1,427,402
2026	1,339,275
2027	1,246,068
2028	1,138,062
2029	1,003,394
Thereafter	3,681,731
	<u>\$ 9,835,932</u>

Tenant Purchase Options

Certain leases contain purchase options whereby the tenant may elect to acquire the underlying real estate. Annualized base rent from leases subject to purchase options, summarized by the year the purchase options are exercisable are as follows (dollars in thousands):

Year	Annualized Base Rent ⁽¹⁾	Number of Properties
2025	\$ 16,109	12
2026	19,071	8
2027	8,415	4
2028	16,209	5
2029	6,053	7
Thereafter	22,364	9
	<u>\$ 88,221</u>	<u>45</u>

(1) Represents the most recent month's base rent including additional rent floors annualized for 12 months. Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

Lease Costs

The following tables provide information regarding the Company's leases to which it is the lessee, such as corporate offices and ground leases, excluding lease costs related to discontinued operations (dollars in thousands):

Lease Expense Information:	Year Ended December 31,		
	2024	2023	2022
Total lease expense	\$ 22,768	\$ 17,010	\$ 16,689

Weighted Average Lease Term and Discount Rate:

Weighted average remaining lease term (years):
Operating leases⁽¹⁾

	December 31, 2024	December 31, 2023
	48	51

Weighted average discount rate:

Operating leases	4.79 %	4.23 %

(1) As of December 31, 2024 and 2023, the weighted average remaining lease term including the Company's options to extend its operating leases was 66 years and 67 years, respectively.

The following table summarizes future minimum lease payments under non-cancelable ground and other operating leases included in the Company's lease liability as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 21,514
2026	18,423
2027	18,434
2028	18,489
2029	18,687
Thereafter	738,666
Undiscounted minimum lease payments included in the lease liability	834,213
Less: imputed interest	(526,993)
Present value of lease liability	<u>\$ 307,220</u>

Depreciation Expense

While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company's Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company's Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had \$38 million and \$39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is \$8 million and \$10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is \$2 million, \$3 million, and \$3 million, respectively, of depreciation expense related to corporate assets.

Denver Corporate Headquarters

During the year ended December 31, 2022, the Company recognized \$7 million of charges in connection with the downsizing of the Company's corporate headquarters in Denver, Colorado which are included in general and administrative expenses on the Consolidated Statements of Operations.

Tenant Updates

During the first quarter of 2023, the Company wrote off \$9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. ("Sorrento"), which commenced voluntary reorganization proceedings (the "Filing") under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, \$4 million of which was received by the Company by drawing on Sorrento's letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento's assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023.

On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 ("Graphite Bio"), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio's lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of \$37 million, comprised of a \$21 million termination fee and \$16 million prepayment of Graphite Bio's contractual rent through the amended term. The \$37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease.

In July 2024, the Company executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health ("CommonSpirit"). The renewal, which is subject to a master agreement, extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%. In connection with this extension, CommonSpirit was provided the right to reduce the amount of space leased by up to approximately 200,000 square feet at any time after the original lease maturity dates. These termination rights were evaluated for likelihood of exercise in accordance with ASC 842 in the determination of the lease term. During the year ended December 31, 2024,

Leases

CommonSpirit represented 6% of revenues for the outpatient medical segment and 3% of total revenues.

Leases

Lease Income

The following table summarizes the Company's lease income (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Fixed income from operating leases	\$ 1,530,493	\$ 1,236,502	\$ 1,182,463
Variable income from operating leases	556,703	395,303	359,312
Interest income from direct financing leases	—	—	1,168

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital under a DFL for \$68 million and recognized a gain on sale of \$23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL.

Operating Leases

Future Minimum Rents

The following table summarizes future minimum lease payments to be received from tenants under non-cancelable operating leases as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 1,427,402
2026	1,339,275
2027	1,246,068
2028	1,138,062
2029	1,003,394
Thereafter	3,681,731
	<u>\$ 9,835,932</u>

Tenant Purchase Options

Certain leases contain purchase options whereby the tenant may elect to acquire the underlying real estate. Annualized base rent from leases subject to purchase options, summarized by the year the purchase options are exercisable are as follows (dollars in thousands):

Year	Annualized Base Rent ⁽¹⁾	Number of Properties
2025	\$ 16,109	12
2026	19,071	8
2027	8,415	4
2028	16,209	5
2029	6,053	7
Thereafter	22,364	9
	<u>\$ 88,221</u>	<u>45</u>

(1) Represents the most recent month's base rent including additional rent floors annualized for 12 months. Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

Lease Costs

The following tables provide information regarding the Company's leases to which it is the lessee, such as corporate offices and ground leases, excluding lease costs related to discontinued operations (dollars in thousands):

	Year Ended December 31,		
Lease Expense Information:	2024	2023	2022
Total lease expense	\$ 22,768	\$ 17,010	\$ 16,689

	December 31, 2024	December 31, 2023
Weighted Average Lease Term and Discount Rate:		
Weighted average remaining lease term (years):		
Operating leases ⁽¹⁾	48	51
Weighted average discount rate:		
Operating leases	4.79 %	4.23 %

(1) As of December 31, 2024 and 2023, the weighted average remaining lease term including the Company's options to extend its operating leases was 66 years and 67 years, respectively.

The following table summarizes future minimum lease payments under non-cancelable ground and other operating leases included in the Company's lease liability as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 21,514
2026	18,423
2027	18,434
2028	18,489
2029	18,687
Thereafter	738,666
Undiscounted minimum lease payments included in the lease liability	834,213
Less: imputed interest	(526,993)
Present value of lease liability	<u>\$ 307,220</u>

Depreciation Expense

While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company's Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company's Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had \$38 million and \$39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is \$8 million and \$10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is \$2 million, \$3 million, and \$3 million, respectively, of depreciation expense related to corporate assets.

Denver Corporate Headquarters

During the year ended December 31, 2022, the Company recognized \$7 million of charges in connection with the downsizing of the Company's corporate headquarters in Denver, Colorado which are included in general and administrative expenses on the Consolidated Statements of Operations.

Tenant Updates

During the first quarter of 2023, the Company wrote off \$9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. ("Sorrento"), which commenced voluntary reorganization proceedings (the "Filing") under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, \$4 million of which was received by the Company by drawing on Sorrento's letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento's assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023.

On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 ("Graphite Bio"), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio's lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of \$37 million, comprised of a \$21 million termination fee and \$16 million prepayment of Graphite Bio's contractual rent through the amended term. The \$37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease.

In July 2024, the Company executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health ("CommonSpirit"). The renewal, which is subject to a master agreement, extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%. In connection with this extension, CommonSpirit was provided the right to reduce the amount of space leased by up to approximately 200,000 square feet at any time after the original lease maturity dates. These termination rights were evaluated for likelihood of exercise in accordance with ASC 842 in the determination of the lease term. During the year ended December 31, 2024, CommonSpirit represented 6% of revenues for the outpatient medical segment and 3% of total revenues.

Leases

Leases

Lease Income

The following table summarizes the Company's lease income (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Fixed income from operating leases	\$ 1,530,493	\$ 1,236,502	\$ 1,182,463
Variable income from operating leases	556,703	395,303	359,312
Interest income from direct financing leases	—	—	1,168

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital under a DFL for \$68 million and recognized a gain on sale of \$23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL.

Operating Leases

Future Minimum Rents

The following table summarizes future minimum lease payments to be received from tenants under non-cancelable operating leases as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 1,427,402
2026	1,339,275
2027	1,246,068
2028	1,138,062
2029	1,003,394
Thereafter	3,681,731
	<u>\$ 9,835,932</u>

Tenant Purchase Options

Certain leases contain purchase options whereby the tenant may elect to acquire the underlying real estate. Annualized base rent from leases subject to purchase options, summarized by the year the purchase options are exercisable are as follows (dollars in thousands):

Year	Annualized Base Rent ⁽¹⁾	Number of Properties
2025	\$ 16,109	12
2026	19,071	8
2027	8,415	4
2028	16,209	5
2029	6,053	7
Thereafter	22,364	9
	<u>\$ 88,221</u>	<u>45</u>

(1) Represents the most recent month's base rent including additional rent floors annualized for 12 months. Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

Lease Costs

The following tables provide information regarding the Company's leases to which it is the lessee, such as corporate offices and ground leases, excluding lease costs related to discontinued operations (dollars in thousands):

Lease Expense Information:	Year Ended December 31,		
	2024	2023	2022
Total lease expense	\$ 22,768	\$ 17,010	\$ 16,689

Weighted Average Lease Term and Discount Rate:	December 31, 2024	December 31, 2023
Weighted average remaining lease term (years):		
Operating leases ⁽¹⁾	48	51
Weighted average discount rate:		
Operating leases	4.79 %	4.23 %

(1) As of December 31, 2024 and 2023, the weighted average remaining lease term including the Company's options to extend its operating leases was 66 years and 67 years, respectively.

The following table summarizes future minimum lease payments under non-cancelable ground and other operating leases included in the Company's lease liability as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 21,514
2026	18,423
2027	18,434
2028	18,489
2029	18,687
Thereafter	738,666
Undiscounted minimum lease payments included in the lease liability	<u>834,213</u>
Less: imputed interest	(526,993)
Present value of lease liability	<u>\$ 307,220</u>

Depreciation Expense

While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company's Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company's Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had \$38 million and \$39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is \$8 million and \$10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is \$2 million, \$3 million, and \$3 million, respectively, of depreciation expense related to corporate assets.

Denver Corporate Headquarters

During the year ended December 31, 2022, the Company recognized \$7 million of charges in connection with the downsizing of the Company's corporate headquarters in Denver, Colorado which are included in general and administrative expenses on the Consolidated Statements of Operations.

Tenant Updates

During the first quarter of 2023, the Company wrote off \$9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. ("Sorrento"), which commenced voluntary reorganization proceedings (the "Filing") under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, \$4 million of which was received by the Company by drawing on Sorrento's letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento's assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023.

On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 ("Graphite Bio"), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio's lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of \$37 million, comprised of a \$21 million termination fee and \$16 million prepayment of Graphite Bio's contractual rent through the amended term. The \$37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease.

In July 2024, the Company executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health ("CommonSpirit"). The renewal, which is subject to a master agreement, extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%. In connection with this extension, CommonSpirit was provided the right to reduce the amount of space leased by up to approximately 200,000 square feet at any time after the original lease maturity dates. These termination rights were evaluated for likelihood of exercise in accordance with ASC 842 in the determination of the lease term. During the year ended December 31, 2024, CommonSpirit represented 6% of revenues for the outpatient medical segment and 3% of total revenues.

XML 36 R17.htm IDEA: XBRL DOCUMENT

Loans Receivable

Receivables

[Abstract]

Loans Receivable

12 Months Ended

Dec. 31, 2024

Loans Receivable

The following table summarizes the Company's loans receivable (in thousands):

	December 31,	
	2024	2023
Secured loans ⁽¹⁾⁽²⁾	\$ 638,482	\$ 178,678
CCRC resident loans	61,273	42,733
Mezzanine loans ⁽²⁾	50,314	—
Unamortized discounts and fees ⁽³⁾	(22,380)	(131)
Reserve for loan losses	(10,499)	(2,830)
Loans receivable, net	<u>\$ 717,190</u>	<u>\$ 218,450</u>

(1) At December 31, 2024, the Company had \$85 million of remaining commitments to fund additional loans for outpatient medical capital expenditure projects, of which \$49 million related to loans acquired as part of the Merger. At December 31, 2023, the Company had \$29 million of remaining commitments to fund additional loans for senior housing redevelopment and capital expenditure projects. This \$29 million commitment was reduced to zero in February 2024 in conjunction with the refinancing of the Sunrise Senior Housing Portfolio Seller Financing as discussed below.

(2) Includes secured loans and mezzanine loans acquired as part of the Merger (see Note 3).

(3) As of December 31, 2024, includes net unamortized discounts of \$3 million related to the loans receivable acquired as part of the Merger (see Note 3) and an \$18 million unamortized mark-to-market discount related to the Outpatient Medical Seller Financing as discussed below.

During the years ended December 31, 2024, 2023, and 2022, the Company recognized \$40 million, \$22 million, and \$22 million, respectively, of interest income related to loans receivable in interest income and other on the Consolidated Statements of Operations.

The Merger

On March 1, 2024, upon the consummation of the Merger, the Company acquired 9 secured loans with an aggregate outstanding principal balance of \$89 million and 10 mezzanine loans with an aggregate outstanding principal balance of \$36 million, for a total of \$124 million. Typically, each secured loan is secured by a mortgage on a related outpatient medical building, each construction loan (included in secured loans above) is secured by a mortgage on the land and improvements as constructed, generally with guarantees from the borrowers, and each mezzanine loan is collateralized by an ownership interest in the respective borrower. As of the Closing Date, the secured loans had maturities ranging from June 2024 to July 2027 and stated fixed interest rates ranging from 7.00% to 10.00%. The mezzanine loans had maturities ranging from June 2024 to June 2027 and stated fixed interest rates ranging from 8.00% to 10.00%.

As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were \$1 million and \$2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans.

Sunrise Senior Housing Portfolio Seller Financing

In conjunction with the sale of 32 SHOP facilities for \$664 million in January 2021, the Company provided the buyer with initial financing of \$410 million. The remainder of the sales price was received in cash at the time of sale. Additionally, the Company agreed to provide up to \$92 million of additional financing for capital expenditures (up to 65% of the estimated cost of capital expenditures). The initial and additional financing is secured by the buyer's equity ownership in each property. In June 2023, the interest rate on this secured loan was converted from a variable rate based on the London Interbank Offered Rate ("LIBOR") to a variable rate based on Term Secured Overnight Financing Rate ("SOFR") (plus a 10 basis point adjustment related to SOFR transition).

The Company received partial principal repayments of \$246 million during the year ended December 31, 2021 and \$45 million during the year ended December 31, 2022 in conjunction with dispositions of the underlying collateral. In connection with these principal repayments, the additional financing available was reduced to \$40 million, of which \$11 million had been funded as of December 31, 2023.

In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinancing, the Company received a partial principal repayment of \$69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0% for the first two years of the extended term, but increases to 5.0% for the last 18 months of the extended term and is now subject to a fixed floor of 9%. In connection with the refinancing, the additional financing was reduced to \$1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a

partial principal repayment of \$5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of \$58 million and \$131 million, respectively.

Other SHOP Seller Financing

In conjunction with the sale of 16 additional SHOP facilities for \$230 million in January 2021, the Company provided the buyer with financing of \$150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of \$102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0% for the first six months of the extended term, increasing to 7.0% for the last six months of the extended term. The Company also received a \$1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024.

In January 2024, the loan was refinanced with the Company and the maturity date was extended to January 2025. The interest rate on the loan remained as Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 7.0%, but is now subject to a fixed floor of 12%. The Company also received a \$1 million extension fee in connection with the refinance, which is recognized in interest income over the remaining term of the loan. At each of December 31, 2024 and 2023, this secured loan had an outstanding principal balance of \$48 million. In January 2025, the Company received full repayment of the outstanding balance of this seller financing.

Outpatient Medical Seller Financing

In conjunction with the sale of 59 outpatient medical buildings for \$674 million in July 2024 and the 2 outpatient medical buildings for \$23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for \$405 million and \$14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0% for the initial term and increases to 6.5% during the optional extension periods. The Company also received a \$1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of \$21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized \$3 million of non-cash interest income related to the amortization of this mark-to-market discount.

2025 Other Loans Receivable Transactions

In January 2025, the Company entered into a secured loan to provide up to \$75 million to fund a portion of the acquisition and redevelopment of a lab building on a campus in San Diego, California. The initial term of this secured loan matures in January 2029 and includes one 12-month extension option. The stated fixed interest rate of this secured loan is 8%. Through January 2025, \$28 million has been funded under this agreement.

In January 2025, the Company received full repayment of the outstanding balance of one \$15 million secured loan with an original maturity of July 2027. As a result of this repayment, the \$85 million of remaining commitments as of December 31, 2024 to fund additional loans for outpatient medical capital expenditure projects was reduced to \$67 million.

2024 Other Loans Receivable Transactions

During the year ended December 31, 2024, the Company entered into and funded a \$15 million mezzanine loan with a fixed interest rate of 11.00% and extended the maturity dates of the following: (i) one secured loan with an outstanding balance of \$12 million from June 2024 to June 2025; (ii) one mezzanine loan with an outstanding balance of \$2 million from May 2026 to May 2027; (iii) one mezzanine loan with an outstanding balance of \$2 million from October 2024 to April 2026; and (iv) one mezzanine loan with an outstanding balance of \$1 million from June 2024 to June 2025.

Additionally, during the year ended December 31, 2024, the Company entered into a construction loan agreement to provide up to \$36 million to fund a portion of the construction of an outpatient medical building. This secured loan matures in December 2028 and has a stated fixed interest rate of 8.00%. As of December 31, 2024, there were no fundings under this agreement.

2023 Other Loans Receivable Transactions

In February 2023, the Company received full repayment of the outstanding balance of one \$35 million secured loan.

In April 2023, the Company received full repayment of the outstanding balance of one \$14 million secured loan.

In May 2023, the Company received full repayment of two outstanding secured loans with an aggregate balance of \$12 million.

Also in May 2023, the interest rate on one secured loan with an outstanding balance of \$21 million was converted from a variable rate based on LIBOR to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition). In October 2023, the Company received full repayment of the outstanding balance of this \$21 million secured loan.

2022 Other Loans Receivable Transactions

In May 2022, the Company received full repayment of the outstanding balance of one \$2 million secured loan.

In November 2022, the Company received full repayment of the outstanding balance of one \$1 million mezzanine loan.

In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of \$61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5% for the first six months of the extended term, increasing to a floor of 10.5% for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above.

CCRC Resident Loans

For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the resident’s previous home. At December 31, 2024 and 2023, the Company held \$61 million and \$43 million, respectively, of such notes receivable.

Loans Receivable Internal Ratings

Refer to Note 2 for a discussion of the Company’s quarterly review process over its loans receivable and the related internal ratings process. The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of December 31, 2024 (in thousands):

Investment Type	Year of Origination ⁽¹⁾						Total
	2024	2023	2022	2021	2020	Prior	
Secured loans							
Risk rating:							
Performing loans	\$ 433,801	\$ 48,663	\$ 25,232	\$ 105,088	\$ —	\$ —	\$ 612,784
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total secured loans	\$ 433,801	\$ 48,663	\$ 25,232	\$ 105,088	\$ —	\$ —	\$ 612,784
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Mezzanine loans							
Risk rating:							
Performing loans	\$ 13,653	\$ 5,284	\$ 4,446	\$ 6,572	\$ 10,094	\$ 3,084	\$ 43,133
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total mezzanine loans	\$ 13,653	\$ 5,284	\$ 4,446	\$ 6,572	\$ 10,094	\$ 3,084	\$ 43,133
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
CCRC resident loans							
Risk rating:							
Performing loans	\$ 59,321	\$ 1,790	\$ 162	\$ —	\$ —	\$ —	\$ 61,273
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total CCRC resident loans	\$ 59,321	\$ 1,790	\$ 162	\$ —	\$ —	\$ —	\$ 61,273
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —

(1) Additional fundings under existing loans are included in the year of origination of the initial loan.

Reserve for Loan Losses

Refer to Note 2 for a discussion of the Company’s assessment of current expected credit losses for loans receivable and unfunded loan commitments. The following table summarizes the Company’s reserve for loan losses (in thousands):

	December 31, 2024			December 31, 2023		
	Secured Loans	Mezzanine Loans and Other ⁽¹⁾	Total	Secured Loans	Mezzanine Loans and Other ⁽¹⁾	Total
Reserve for loan losses, beginning of period	\$ 2,830	\$ —	\$ 2,830	\$ 8,280	\$ —	\$ 8,280
Provision for expected loan losses on funded loans receivable	2,744	4,925	7,669	2,088	—	2,088
Expected loan losses (recoveries) related to loans sold or repaid	—	—	—	(7,538)	—	(7,538)
Reserve for loan losses, end of period	\$ 5,574	\$ 4,925	\$ 10,499	\$ 2,830	\$ —	\$ 2,830

(1) Includes CCRC resident loans.

Additionally, at December 31, 2024 and 2023, a liability of \$2.9 million and \$0.7 million, respectively, related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.

The change in the reserve for expected loan losses during the year ended December 31, 2024 is primarily due to reserves recognized on secured loans and mezzanine loans receivable acquired as part of the Merger.

XML 37 R18.htm IDEA: XBRL DOCUMENT

Investments in and
Advances to
Unconsolidated Joint
Ventures

Equity Method
Investments and Joint
Ventures [Abstract]

Investments in and
Advances to
Unconsolidated Joint
Ventures

12 Months Ended

Dec. 31, 2024

Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):

Entity ⁽¹⁾	Segment	Property Count ⁽²⁾	Ownership % ⁽²⁾	Carrying Amount		
				December 31,		
				2024	2023	
South San Francisco JVs ⁽³⁾	Lab	7	70	\$ 446,145	\$ 393,374	
SWF SH JV	Other	19	54	322,551	332,693	
Callan Ridge JV	Lab	2	35	69,709	—	
PMAC JV ⁽⁴⁾	Outpatient medical	59	12	32,511	—	
Lab JV	Lab	1	49	29,916	31,761	
Needham Land Parcel JV ⁽⁵⁾	Lab	—	38	21,348	17,084	
Davis JV ⁽⁴⁾	Outpatient medical	15	49	7,435	—	
Outpatient Medical JVs ⁽⁶⁾	Outpatient medical	2	20 - 67	7,199	7,941	
				\$ 936,814	\$ 782,853	

- (1) These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
(2) Property counts and ownership percentages are as of December 31, 2024.
(3) Includes multiple unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70% ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and operations.
(4) Includes unconsolidated joint ventures acquired as part of the Merger (see Note 3). The properties underlying the PMAC JV are excluded from the Company's total property count.
(5) Land held for development is excluded from the property count as of December 31, 2024.
(6) Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). In April 2023, the Company acquired the remaining 80% interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for \$4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations.

At December 31, 2024 and 2023, the aggregate unamortized basis difference of the Company's investments in unconsolidated joint ventures of \$42 million and \$49 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint ventures and capitalized interest related to the redevelopment activities at the South San Francisco JVs. The differences are amortized over the remaining useful lives of the related assets and are included in equity income (loss) from unconsolidated joint ventures.

South San Francisco JVs

On August 1, 2022, the Company sold a 30% interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund ("SWF Partner") for cash of \$126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70% investment in the South San Francisco joint ventures (the "South San Francisco JVs") at fair value, and accounting for its investment using the equity method. The fair values of the Company's retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of \$311 million, which is recorded in other income (expense), net.

The Company is entitled to a preferred return, a promote, and certain fees in exchange for development and asset management services provided to the South San Francisco JVs when certain conditions are met.

Callan Ridge JV

In January 2024, the Company sold a 65% interest in two lab buildings in San Diego, California (the "Callan Ridge JV") to a third-party (the "JV Partner") for net proceeds of \$128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35% investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company's retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of \$78 million, which is recorded in other income (expense), net.

XML 38 R19.htm IDEA: XBRL DOCUMENT

Intangibles

Intangibles [Abstract]

Intangibles

Intangibles

Intangible assets primarily consist of lease-up intangibles and above market lease intangibles. The following table summarizes the Company's intangible lease assets (dollars in thousands):

Intangible lease assets	December 31,	
	2024	2023
Gross intangible lease assets ⁽¹⁾	\$ 1,468,985	\$ 739,228
Accumulated depreciation and amortization ⁽²⁾	(651,731)	(425,072)
Intangible assets, net	\$ 817,254	\$ 314,156

Weighted average remaining amortization period in years

	5	5

- (1) As of December 31, 2024 and 2023, includes \$1.42 billion and \$725 million, respectively, of gross lease-up intangibles and \$45 million and \$14 million, respectively, of gross above market lease intangibles.
(2) As of December 31, 2024 and 2023, includes \$640 million and \$418 million, respectively, of accumulated depreciation and amortization on lease-up intangibles and \$12 million and \$7 million, respectively, of accumulated depreciation and amortization on above market lease intangibles.

Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company's intangible lease liabilities (dollars in thousands):

Intangible lease liabilities	December 31,	
	2024	2023
Gross intangible lease liabilities	\$ 351,602	\$ 228,105
Accumulated depreciation and amortization	(159,718)	(100,725)
Intangible liabilities, net	\$ 191,884	\$ 127,380

Weighted average remaining amortization period in years

	9	7

The following table sets forth amortization related to intangible assets, net and intangible liabilities, net (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Depreciation and amortization expense related to amortization of lease-up intangibles	\$ 273,146	\$ 102,249	\$ 104,885
Rental and related revenues related to amortization of net below market lease liabilities	62,894	27,012	24,640

On the Closing Date of the Merger, the Company acquired intangible assets of \$891 million, inclusive of \$852 million of lease-up intangibles and \$39 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of \$150 million (see Note 3). The intangible assets and liabilities acquired had a weighted average amortization period at acquisition of 6 years and 9 years, respectively.

During the year ended December 31, 2023, in conjunction with the Company's acquisition of real estate, the Company acquired \$0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years.

The following table summarizes the estimated annual amortization for each of the five succeeding fiscal years and thereafter (in thousands):

	Rental and Related Revenues	Depreciation and Amortization
2025	\$ 32,618	\$ 256,925
2026	29,231	171,520
2027	23,304	107,925
2028	17,899	77,072
2029	13,168	53,829
Thereafter	42,816	117,135
	\$ 159,036	\$ 784,406

Goodwill

On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of \$51 million, which was allocated to the Company's outpatient medical segment (see Note 3). Goodwill is included in other assets, net on the Consolidated Balance Sheets. At December 31, 2024 and 2023, goodwill was allocated to the Company's segment assets as follows (in thousands):

Segment	December 31, 2024	December 31, 2023
Outpatient medical	\$ 64,680	\$ 14,178
CCRC	1,998	1,998
Other non-reportable	1,851	1,851
	\$ 68,529	\$ 18,027

During the years ended December 31, 2024, 2023, and 2022, the fair value of the assets within each of the Company's reporting units was greater than the respective carrying value of the assets and related goodwill, and as a result, no impairment charges were recognized.

XML 39 R20.htm IDEA: XBRL DOCUMENT

Debt

Debt Disclosure [Abstract]

Debt

Debt

Healthpeak OP, the Company's consolidated operating subsidiary, is the borrower under, and the Company, DOC DR Holdco, and DOC DR OP Sub are the guarantors of, the Revolving Facility, 2027 Term Loans, 2029 Term Loan, Commercial Paper Program (each as defined below), and senior unsecured notes issued by the Company prior to the Merger. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan (as defined below) and senior unsecured notes issued by the Physicians Partnership prior to, and assumed by the Company as part of, the Merger. Guarantees of senior unsecured notes are full and unconditional and applicable to existing and future senior unsecured notes.

The Merger

On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of \$400 million (the "2028 Term Loan") that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as borrower, and the other parties thereto. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan.

In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub's credit ratings as of December 31, 2024, the 2028 Term Loan had a blended fixed effective interest rate of 4.44%, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments.

Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85% to 1.65% for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company's credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was 1.00%.

Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership's \$1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) \$400 million aggregate principal amount of 4.30% senior unsecured notes due 2027, (ii) \$350 million aggregate principal amount of 3.95% senior unsecured notes due 2028, and (iii) \$500 million aggregate principal amount of 2.63% senior unsecured notes due 2031. On the Closing Date, the Company capitalized \$1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain

covenants that are consistent with Healthpeak OP's previously issued senior unsecured notes, as further described below.

Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed \$128 million aggregate principal of mortgage debt (see Note 3), which was secured by five outpatient medical buildings, with an aggregate carrying value of \$259 million as of March 1, 2024. Of this \$128 million, \$59 million was fixed rate debt with a weighted average contractual interest rate of 3.77% and maturities ranging from November 2024 through December 2026 and \$69 million was variable rate debt with a weighted average contractual interest rate of 7.25% and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of \$0.5 million on the \$128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one related interest rate swap instrument with a notional amount of \$36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024.

Bank Line of Credit and Term Loans

Revolving Facility

On May 23, 2019, the Company executed a \$2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the "Revolving Facility") to increase total revolving commitments from \$2.5 billion to \$3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP's obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company's senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company's credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was 0.88% and the facility fee was 0.15%. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to \$750 million, subject to securing additional commitments. At each of December 31, 2024 and 2023, the Company had no balance outstanding under the Revolving Facility.

Term Loan Agreement

On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the "Term Loan Agreement") that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to \$500 million (the "2027 Term Loans"). The 2027 Term Loans were available to be drawn from time to time during a 180-day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the \$500 million under the 2027 Term Loans in October 2022. \$250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other \$250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend.

Loans outstanding under the 2027 Term Loans accrue interest at Term SOFR plus a margin that depends on the credit ratings of the Company's senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01% based on the Company's achievement of specified sustainability-linked metrics. Based on the Company's credit ratings as of December 31, 2024, and inclusive of achievement of a sustainability-linked metric and an adjustment related to SOFR transition, the margin on the 2027 Term Loans was 0.94%.

In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company's credit ratings as of December 31, 2024, the 2027 Term Loans had a blended fixed effective interest rate of 3.76%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.

On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from \$1.0 billion to \$1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of \$750 million with a stated maturity of five years (the "2029 Term Loan"), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP's obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was \$250 million.

Loans outstanding under the 2029 Term Loan accrue interest at Daily SOFR plus a margin that depends on the credit ratings of the Company's senior unsecured long-term debt. Based on the Company's credit ratings as of December 31, 2024, and inclusive of an adjustment related to SOFR transition, the margin on the 2029 Term Loan was 0.95%.

In January 2024, the Company entered into forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2029 Term Loan associated with these interest rate swaps is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company's credit ratings as of December 31, 2024, the 2029 Term Loan had a blended fixed effective interest rate of 4.66%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.

At December 31, 2024 and 2023, the Company had \$1.25 billion and \$500 million, respectively, of loans outstanding under the Term Loan Agreement.

The Revolving Facility, 2027 Term Loans, 2028 Term Loan, and 2029 Term Loan are subject to certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the applicable agreement: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of \$7.7 billion. The Company believes it was in compliance with each of these covenants at December 31, 2024.

Commercial Paper Program

In September 2019, the Company established an unsecured commercial paper program (the "Commercial Paper Program"). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was \$2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company's other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized \$9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had \$150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65%. At December 31, 2023, the Company had \$720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70%.

Senior Unsecured Notes

At December 31, 2024 and 2023, the Company had senior unsecured notes outstanding with an aggregate principal balance of \$6.7 billion and \$5.5 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at December 31, 2024.

During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed \$1.25 billion aggregate principal of senior unsecured notes.

The following table summarizes the Company's senior unsecured note issuances for the year ended December 31, 2023 (dollars in thousands):

Issue Date	Amount	Coupon Rate	Maturity Year
January 17, 2023	\$ 400,000	5.25 %	2032
May 10, 2023 ⁽¹⁾	350,000	5.25 %	2032

(1) In May 2023, the Company issued \$350 million of 5.25% senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the \$400 million of senior unsecured notes due 2032 issued in January 2023.

During the year ended December 31, 2023, there were no repurchases or redemptions of senior unsecured notes. During the year ended December 31, 2022, there were no issuances, repurchases, or redemptions of senior unsecured notes.

In February 2025, the Company repaid \$348 million aggregate principal amount of 3.40% senior unsecured notes at maturity.

Mortgage Debt

At December 31, 2024 and 2023, the Company had \$356 million and \$255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of \$770 million. At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of \$587 million.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is non-recourse. Mortgage debt typically requires maintenance of the assets in good condition, includes conditions to obtain lender consent to enter into or terminate material leases, requires insurance on the assets, requires payment of real estate taxes, restricts transfer of the encumbered assets and repayment of the loan, and prohibits additional liens. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of \$27 million, \$90 million, and \$5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the \$27 million of aggregate principal payments of mortgage debt for the year ended December 31, 2024 was a \$23 million full principal repayment of mortgage debt secured by one outpatient medical building acquired as part of the Merger that matured in November 2024. Included in the \$90 million of aggregate principal repayments of mortgage debt for the year ended December 31, 2023 was an \$85 million full principal repayment of mortgage debt secured by one CCRC that matured in December 2023.

The Company has \$142 million of mortgage debt secured by a portfolio of 13 outpatient medical buildings that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026. In February 2023, the agreements associated with this variable rate mortgage debt were amended to change the interest rate benchmarks from LIBOR to SOFR, effective March 2023. Concurrently, the Company modified the related interest rate swap instruments to reflect the change in the interest rate benchmarks from LIBOR to SOFR (see Note 22). The variable rate mortgage debt associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument.

Debt Maturities

The following table summarizes the Company's stated debt maturities and scheduled principal repayments at December 31, 2024 (dollars in thousands):

Year	Bank Line of Credit ⁽¹⁾	Commercial Paper ⁽¹⁾⁽²⁾	Term Loans	Senior Unsecured Notes ⁽³⁾		Mortgage Debt ⁽⁴⁾		Total
				Amount	Interest Rate ⁽⁵⁾	Amount	Interest Rate ⁽⁵⁾	
2025	\$ —	\$ —	\$ —	\$ 800,000	3.92 %	\$ 7,432	6.28 %	\$ 807,432
2026	—	—	—	650,000	3.40 %	344,999	5.13 %	994,999
2027	—	—	500,000	850,000	3.23 %	842	5.59 %	1,350,842
2028	—	—	400,000	850,000	3.53 %	2,775	5.34 %	1,252,775
2029	—	150,000	750,000	650,000	3.65 %	—	—	1,550,000
Thereafter	—	—	—	2,900,000	4.51 %	—	—	2,900,000
	—	150,000	1,650,000	6,700,000		356,048		8,856,048
Premiums, (discounts), and debt issuance costs, net	—	—	(3,957)	(136,744)		702		(139,999)
	\$ —	\$ 150,000	\$ 1,646,043	\$ 6,563,256		\$ 356,750		\$ 8,716,049

(1) As of December 31, 2024, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were \$18 million, which are recorded in other assets, net on the Consolidated Balance Sheets.

(2) Commercial Paper Program borrowings are backstopped by the availability under the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.

(3) Effective interest rates on the senior unsecured notes range from 1.54% to 6.87% with a weighted average effective interest rate of 3.96% and a weighted average maturity of approximately 5 years.

(4) Effective interest rates on the mortgage debt range from 3.44% to 8.50% with a weighted average effective interest rate of 5.16% and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.

(5) Represents the weighted-average effective interest rate as of the end of the applicable period, including amortization of debt premiums (discounts) and debt issuance costs.

XML 40 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

[Commitments and Contingencies](#)
[Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company's business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's financial condition, results of operations, or cash flows. The Company's policy is to expense legal

**12 Months Ended
Dec. 31, 2024**

costs as they are incurred.

DownREITs and Other Partnerships

In connection with the formation of DownREITs, members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code ("make-whole payments"). These make-whole payments include a tax gross-up provision. As of December 31, 2024, the Company had indemnification agreements on a total of 41 properties within its DownREITs. In January 2025, indemnification agreements on 13 properties expired.

Additionally, the Company owns a 49% interest in the Lab JV (see Note 9). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the contribution to the joint venture.

Commitments

The following table summarizes the Company's material commitments, excluding obligations as the lessee under operating leases (see Note 7), commitments to fund additional loans for outpatient medical capital expenditure projects (see Note 8), debt service obligations (see Note 11), and potential future obligations related to redeemable noncontrolling interests (see Note 13) at December 31, 2024 (in thousands):

	Amount
Development and redevelopment commitments ⁽¹⁾	\$ 199,139
Lease and other contractual commitments ⁽²⁾	84,654
Letters of credit ⁽³⁾	11,929
	<u>\$ 295,722</u>

- (1) Represents construction and other commitments as of December 31, 2024 for developments and redevelopments in progress and includes allowances for Company-owned tenant improvements that the Company has provided as a lessor.
(2) Represents the Company's commitments, as lessor, under signed leases and contracts for operating properties as of December 31, 2024 and includes allowances for Company-owned tenant improvements and leasing commissions. Excludes allowances for Company-owned tenant improvements related to developments and redevelopments in progress for which the Company has executed an agreement with a general contractor to complete the tenant improvements (recognized in the "Development and redevelopment commitments" line).
(3) Represents 15 outstanding letter of credit obligations expiring in 2025 and one outstanding letter of credit obligation expiring in 2026.

Environmental Costs

Various environmental laws govern certain aspects of the ongoing management and operation of our facilities, including those related to presence of asbestos-containing materials. The presence of, or the failure to manage and/or remediate, such materials may adversely affect the occupancy and performance of the Company's facilities. The Company monitors its properties for the presence of such hazardous or toxic substances and is not aware of any environmental liability with respect to the properties that would have a material adverse effect on the Company's business, financial condition, or results of operations. The Company carries environmental insurance and believes that the policy terms, conditions, limitations, and deductibles are adequate and appropriate under the circumstances, given the relative risk of loss, the cost of such coverage, and current industry practice.

General Uninsured Losses

The Company obtains various types of insurance to mitigate the impact of property, business interruption, liability, workers' compensation, flood, windstorm, earthquake, environmental, cyber, and terrorism related losses. The Company attempts to obtain appropriate policy terms, conditions, limits, and deductibles considering the relative risk of loss, the cost of such coverage, and current industry practice. There are, however, certain types of extraordinary losses, such as those due to acts of war or other events that may be either uninsurable or not economically insurable. In addition, the Company has a large number of properties that are exposed to earthquake, flood, and windstorm occurrences for which the related insurances carry high deductibles and have limits.

XML 41 R22.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests
Equity [Abstract]
Equity and Redeemable Noncontrolling Interests

12 Months Ended

Dec. 31, 2024

Equity and Redeemable Noncontrolling Interests

Dividends

On February 3, 2025, the Company's Board of Directors declared a quarterly common stock cash dividend of \$0.305 per share, reflecting an increase from \$0.30 to \$0.305 per share. The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025.

During each of the years ended December 31, 2024, 2023, and 2022, the Company declared and paid common stock cash dividends of \$1.20.

Issuance of Common Stock in Connection with the Merger

Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) automatically converted into the right to receive 0.674 shares of the Company's common stock. Based on the number of outstanding Physicians Realty Trust common shares as of the Closing Date, the Company issued 162 million shares of common stock. Refer to Note 3 for additional information regarding the Merger.

At-The-Market Equity Offering Program

In February 2023, in connection with the Reorganization, the Company terminated the previous at-the-market equity offering program (as amended from time to time, the "2020 ATM Program") and established a new at-the-market equity offering program (the "2023 ATM Program" and, together with the 2020 ATM Program, the "ATM Programs"). The 2023 ATM Program was amended in March 2024 to contemplate the sale of the remaining shares of common stock pursuant to the Company's Registration Statement on Form S-3 filed with the SEC on February 8, 2024. The ATM Programs allow for the sale of shares of common stock having an aggregate gross sales price of up to \$1.5 billion (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an "ATM forward contract"). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract becomes effective, but defer receiving the proceeds from the sale of shares until a later date.

ATM forward contracts generally have a one- to two-year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company's election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (iii) the forward purchasers' stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract.

At December 31, 2024, \$1.5 billion of the Company's common stock remained available for sale under the 2023 ATM Program.

ATM Forward Contracts

During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of \$35.25 per share, after commissions. In December 2022, the Company settled all 9.1 million shares previously outstanding under ATM forward contracts at a weighted average net price of \$34.01 per share, after commissions, resulting in net proceeds of \$308 million. During the years ended December 31, 2024, 2023, and 2022 the Company did not utilize the forward provisions under the ATM Programs.

ATM Direct Issuances

During each of the years ended December 31, 2024, 2023, and 2022, there were no direct issuances of shares of common stock under the ATM Programs.

Share Repurchase Programs

On August 1, 2022, the Company's Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of \$500 million (the "2022 Share Repurchase Program"). Purchases of common stock under the 2022 Share Repurchase Program could be exercised at the Company's discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. Under Maryland General Corporation Law, outstanding shares of common stock acquired by a corporation become authorized but unissued shares, which may be re-issued. During the year ended December 31, 2022, the Company repurchased 2.1 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of \$27.16 per share for a total of \$56 million. During the year ended December 31, 2023, there were no repurchases under the 2022 Share Repurchase Program. During the year ended December 31, 2024, the Company repurchased 10.5 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of \$17.98 per share for a total of \$188 million.

On July 24, 2024, the Company's Board of Directors approved a new share repurchase program (the "2024 Share Repurchase Program") to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Program, no further share repurchases may be made pursuant to the 2022 Share Repurchase Program. Under the 2024 Share Repurchase Program, the Company may acquire shares of its common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of \$500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at the Company's discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. As of December 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program. Therefore, at December 31, 2024, \$500 million of the Company's common stock remained available for repurchase under the 2024 Share Repurchase Program.

Other Common Stock Activities

The following table summarizes the Company's other common stock activities (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Dividend reinvestment and stock purchase plan	\$ 57	\$ 70	\$ 59
Conversion of DownREIT units	256	72	27
Vesting of restricted stock units	377	613	820
Repurchase of common stock	10,592	241	2,418

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the Company's accumulated other comprehensive income (loss) (in thousands):

	December 31,	
	2024	2023
Unrealized gains (losses) on derivatives, net	\$ 30,707	\$ 21,245
Supplemental Executive Retirement Plan minimum liability	(1,889)	(1,874)
Total accumulated other comprehensive income (loss)	<u>\$ 28,818</u>	<u>\$ 19,371</u>

The Company has a defined benefit pension plan, known as the Supplemental Executive Retirement Plan, with one plan participant, a former Chief Executive Officer ("CEO") of the Company who departed in 2003. Changes to the Supplemental Executive Retirement Plan minimum liability are reflected in other comprehensive income (loss).

Noncontrolling Interests

Redeemable Noncontrolling Interests

Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company's noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time (the "Option Requirements"). Each put option is payable in cash and subject to changes in redemption value in the event that the underlying property generates specified returns for the Company and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period. In addition to the rights of the redeemable noncontrolling interest holders, once the Option Requirements have been met, the Company has the ability to buy out the interests of the noncontrolling interest holders. The values of the redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date.

On March 1, 2024, concurrently with the consummation of the Merger, the Company assumed one redeemable noncontrolling interest, which had not yet met the conditions for redemption as of December 31, 2024. This interest will become redeemable in September 2025.

In April 2024, the Company exercised its option to buy out four redeemable noncontrolling interests that met the criteria for redemption. Accordingly, during the year ended December 31, 2024, the Company made aggregate cash payments for the total redemption value of \$53 million to the related noncontrolling interest holders and acquired the redeemable noncontrolling interests associated with the entities.

Healthpeak OP

Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, OP Unitholders were issued approximately 2 million OP Units during the year ended December 31, 2023, all of which were LTIP Units (as defined in Note 15). During the year ended December 31, 2024, OP Unitholders were issued approximately 2 million OP Units, all of which were LTIP Units. When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company's common stock, at the Company's option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company's common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. As of December 31, 2024, there were approximately 3 million OP Units outstanding and 76 thousand had met the criteria for redemption. As of December 31, 2023, there were approximately 2 million OP Units outstanding, none of which had met the criteria for redemption.

DownREITs

The non-managing member units of the Company's DownREITs are exchangeable for an amount of cash approximating the then-current market value of shares of the Company's common stock or, at the Company's option, shares of the Company's common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company's common stock, the carrying amount of the DownREIT units is reclassified to stockholders' equity. At December 31, 2024, there were approximately 11 million DownREIT units (14 million shares of Healthpeak common stock are issuable upon conversion) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At December 31, 2024, the carrying value of the 11 million DownREIT units was \$310 million. At December 31, 2023, there were approximately 5 million DownREIT units (7 million shares of Healthpeak common stock are issuable upon conversion) outstanding in seven DownREIT LLCs, for all of which the Company acts as the managing member. At December 31, 2023, the carrying value of the 5 million DownREIT units was \$199 million.

XML 42 R23.htm IDEA: XBRL DOCUMENT

Earnings Per
Common Share

Earnings Per Share
[Abstract]

Earnings Per Common
Share

12 Months Ended
Dec. 31, 2024

Earnings Per Common Share

Basic income (loss) per common share ("EPS") is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method, common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company's basic income (loss) per share are included in diluted income (loss) per share during the periods presented.

Certain restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

The Company considers the potential dilution resulting from forward agreements under its ATM Programs to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. Refer to Note 13 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented.

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Year Ended December 31,		
	2024	2023	2022
Numerator - Basic			
Income (loss) from continuing operations	\$ 267,303	\$ 334,757	\$ 513,540
Noncontrolling interests' share in continuing operations	(24,161)	(28,748)	(15,975)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	243,142	306,009	497,565
Less: Participating securities' share in continuing operations	(758)	(1,725)	(2,657)
Income (loss) from continuing operations applicable to common shares	242,384	304,284	494,908
Income (loss) from discontinued operations	—	—	2,884
Net income (loss) applicable to common shares	\$ 242,384	\$ 304,284	\$ 497,792
Numerator - Dilutive			
Net income (loss) applicable to common shares	\$ 242,384	\$ 304,284	\$ 497,792
Add: distributions on dilutive convertible units and other	107	—	—
Dilutive net income (loss) available to common shares	\$ 242,491	\$ 304,284	\$ 497,792
Denominator			
Basic weighted average shares outstanding	675,680	547,006	538,809
Dilutive potential common shares - equity awards ⁽¹⁾	148	269	338
Dilutive potential common shares - OP Units ⁽²⁾	405	—	—
Diluted weighted average common shares	676,233	547,275	539,147
Basic earnings (loss) per common share			
Continuing operations	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations	—	—	0.00
Net income (loss) applicable to common shares	\$ 0.36	\$ 0.56	\$ 0.92
Diluted earnings (loss) per common share			
Continuing operations	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations	—	—	0.00
Net income (loss) applicable to common shares	\$ 0.36	\$ 0.56	\$ 0.92

(1) For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).
(2) For the year ended December 31, 2024, represents the dilutive impact of 3 million outstanding OP Units.

For the years ended December 31, 2024, 2023, and 2022, all 14 million, 7 million, and 7 million shares issuable upon conversion of DownREIT units, respectively, were not included because they were anti-dilutive. For the years ended December 31, 2024 and 2023, forward equity sales agreements had no dilutive impact as no shares were outstanding under ATM forward contracts during the year. For the year ended December 31, 2022, all shares that were settled during the year then ended were anti-dilutive.

XML 43 R24.htm IDEA: XBRL DOCUMENT

Compensation Plans

Share-Based Payment
Arrangement
[Abstract]

Compensation Plans

12 Months Ended
Dec. 31, 2024

Compensation Plans

Stock-Based Compensation

On May 11, 2006, the Company's stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the "2006 Plan"). On May 1, 2014, the Company's stockholders approved the 2014 Performance Incentive Plan, which was amended and restated in 2019 and further amended in 2023 (the "2014 Plan"). Following the adoption of the 2014 Plan, no new awards were issued under the 2006 Plan. On April 27, 2023, the Company's stockholders approved the 2023 Performance Plan (the "2023 Plan" and collectively with the 2006 Plan and the 2014 Plan, the "Plans"). Following the adoption of the 2023 Plan, no new awards may be issued under the 2014 Plan. The Plans provide for the granting of stock-based compensation to officers, employees, and directors, including stock options, restricted stock, restricted stock units, and with respect to the 2014 and 2023 Plans, profits interests in Healthpeak OP ("LTIP Units"). The maximum number of shares reserved for awards under the 2023 Plan is 31 million shares, and, as of December 31, 2024, 28 million of the reserved shares under the 2023 Plan are available for future awards, of which 19 million shares may be issued as restricted stock, restricted stock units, or LTIP Units.

Restricted Stock Units

Under the Plans, time-based restricted stock units and market-based restricted stock units (collectively, "Restricted Stock Units") are granted subject to certain restrictions. Conditions of vesting are determined at the time of grant. Restrictions on certain awards generally lapse, as provided in the Plans or in the applicable award agreement, upon retirement, a change in control, or other specified events. The fair market value of Restricted Stock Units is expensed over the period of vesting. Time-based restricted stock units, which vest based solely upon passage of time, generally vest on a graded schedule over a period of one to five years. The fair value of time-based restricted stock units is determined based on the closing market price of the Company's shares on the grant date. Market-based restricted stock units, which vest dependent upon attainment of total shareholder return ("TSR") performance that equal or exceed threshold levels as measured against certain peer and industry benchmarks, generally vest in their entirety at the end of a three-year performance period. The number of shares that ultimately vest based on performance can vary from 0% to 200% of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, respectively: (i) expected term of 3 years, 3 years, and 3 years (equal to the remaining performance period at the grant date), (ii) historical volatility of 26.0%, 33.0%, and 38.9%, (iii) dividend yield of 5.2%, 4.4%, and 3.5%, (iv) risk-free rate of 4.5%, 4.4%, and 1.8%, and (v) post-vesting restrictions discount of 10.0%, 10.0%, and 5.8%. The total grant date fair value of time-based restricted stock units and market-based restricted stock units granted during the years ended December 31, 2024, 2023, and 2022 was \$11 million, \$9 million, and \$27 million, respectively. The total fair value (at vesting) of time-based restricted stock units and market-based restricted stock units that vested during the years ended December 31, 2024, 2023, and 2022 was \$7 million, \$16 million, and \$27 million, respectively.

Upon vesting of Restricted Stock Units, the participant is required to pay the related tax withholding obligation, as applicable. The Company reduces the number of common stock shares delivered to pay the employee tax withholding obligation. The value of the shares withheld is dependent on the closing market price of the Company's common stock on the trading date prior to the relevant transaction occurring. During the years ended December 31, 2024, 2023, and 2022, the Company withheld 123,000, 241,000, and 356,000 shares, respectively, to offset tax withholding obligations with respect to the vesting of the Restricted Stock Units.

LTIP Units

During each of the years ended December 31, 2024 and 2023, approximately 2 million LTIP Units were issued to officers of the Company. These awards are designed to qualify as "profits interests" in Healthpeak OP for federal income tax purposes. Such interests are initially not economically equivalent in value to a share of common stock until reaching one-for-one parity with the Company's common stock, subject to any vesting conditions applicable to the award. When certain conditions are met, LTIP Units are converted to common units, which may then be redeemed for cash or shares of the Company's common stock, at the Company's option as managing member of Healthpeak OP (see also Note 13).

Under the Plans, time-based LTIP Units and market-based LTIP Units (collectively, "LTIP Units"), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of three to six years. The fair value of the time-based LTIP Units is determined based on the closing market price of the Company's shares on the grant date less a discount for post-vesting restrictions, liquidity risk, and uncertainty of the time-based LTIP Units reaching parity. The market-based LTIP Units are granted at the maximum potential payout, inclusive of expected distributions during the performance period. Market-based LTIP Units, which vest dependent upon attainment of various levels of TSR performance that equal or exceed threshold levels as measured against certain peer and industry benchmarks, generally vest in their entirety at the end of a three-year performance period. The number of market-based LTIP Units that ultimately vest can vary from 0% to 200% of target depending on the level of achievement of the performance criteria, and any difference from the original grant are forfeited. The fair value of market-based LTIP Units granted during the years ended December 31, 2024 and 2023 is determined based on the Monte Carlo valuation model using the same assumptions as market-based restricted stock units described above less a discount for post-vesting restrictions, liquidity risk, and uncertainty of the market-based LTIP Units reaching parity with the value of the Company's common stock and the vesting terms of the awards. The total grant date fair value of LTIP Units granted during the years ended December 31, 2024 and 2023 was \$13 million and \$29 million. The total fair value (at vesting) of LTIP Units that vested during the years ended December 31, 2024 and 2023 was \$3 million and \$2 million.

Dividends and Distributions

Holders of time-based restricted stock units and time-based LTIP Units are generally entitled to receive dividends and distributions, respectively, equal to the amount that would be paid on an equivalent number of shares of common stock. Market-based restricted stock units receive cumulative cash dividends upon vesting for the entirety of the performance period based on the level of achievement of the performance criteria. The market-based LTIP Units receive cash distributions equal to 10% of the quarterly dividends paid on the Company's common stock during the performance period. Based on the level of achievement of the performance criteria at the end of the performance period, the market-based LTIP Units receive distributions in the form of additional LTIP Units for amounts ultimately vested during the performance period, less cash distributions already paid.

Stock Options

There have been no grants of stock options since 2014. Stock options outstanding and exercisable were zero at December 31, 2024 and 0.2 million at December 31, 2023. There were no stock options exercised under the Plans for the years ended December 31, 2024, 2023, and 2022. No compensation cost related to stock options was incurred during the years ended December 31, 2024, 2023, and 2022.

The following table summarizes Restricted Stock Unit and LTIP Unit activity for the year ended December 31, 2024 (units in thousands):

	Restricted Stock Units		LTIP Units	
	Number of Units	Weighted Average Grant Date Fair Value	Number of Units	Weighted Average Grant Date Fair Value
Unvested at January 1, 2024	879	\$ 29.91	1,894	\$ 14.26
Granted	597	17.69	1,511	8.75
Vested	(377)	28.88	(199)	17.43
Forfeited	(224)	27.20	(304)	12.70
Unvested at December 31, 2024	875	\$ 22.70	2,902	\$ 10.88

Total stock-based compensation cost was \$20 million, \$19 million, and \$32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included \$10 million of severance-related charges resulting from a decrease in the requisite service period of restricted stock units associated with the Company's former CEO, as further described below. Of the total stock-based compensation cost, \$4 million was capitalized as part of real estate for each of the years ended December 31, 2024, 2023, and 2022. As of December 31, 2024, there was \$22 million of future expenses related to unvested stock-based compensation arrangements granted under the Company's incentive plans, which is expected to be recognized over a weighted average period of 1.6 years associated with future employee service. Compensation cost recognized for all Restricted Stock Units and LTIP Units is net of actual forfeitures.

Departure of Executives

On October 6, 2022, the Company and Thomas M. Herzog mutually agreed that Mr. Herzog would step down from his position as CEO and from the board of directors of the Company, effective immediately. On November 1, 2022, the Company and Troy E. McHenry mutually agreed that Mr. McHenry would step down from his position as Chief Legal Officer and General Counsel, effective immediately. During the fourth quarter of 2022, the Company recognized total severance-related charges of \$33 million in general and administrative expenses on the Consolidated Statements of Operations, \$10 million of which related to a decrease in the requisite service period of Restricted Stock Units as discussed above. These Restricted Stock Units continue to vest in accordance with the original terms of the grants. As of December 31, 2024 and 2023, \$4 million and \$8 million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets.

XML 44 R25.htm IDEA: XBRL DOCUMENT

Segment Disclosures

Segment Reporting

[Abstract]

Segment Disclosures

Segment Disclosures

The Company's operating segments, based on how its CODM, the President and Chief Executive Officer, evaluates the business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in an unconsolidated joint venture that owns 19 senior housing assets (the "SWF SH JV"), and (v) loans receivable. The Company's reportable segments, as determined in accordance with ASC 280, *Segment Reporting*, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. The SWF SH JV and loans receivable are non-reportable segments that have been presented on a combined basis within the Notes to the Consolidated Financial Statements herein. The accounting policies of the segments are the same as those described in the Company's Summary of Significant Accounting Policies (see Note 2).

The CODM evaluates performance based on property Adjusted NOI. Adjusted NOI is used to evaluate performance because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. Adjusted NOI represents real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.

Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus the Company's share of Adjusted NOI from unconsolidated joint ventures (calculated by applying the Company's actual ownership percentage for the period), less noncontrolling interests' share of Adjusted NOI from consolidated joint ventures (calculated by applying the Company's actual ownership percentage for the period). Management utilizes its share of Adjusted NOI in assessing its performance as the Company has various joint ventures that contribute to its performance.

Segment assets consist of real estate assets, intangible assets, and right-of-use assets. Non-segment assets consist of assets in the Company's other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, other assets, and real estate assets held for sale. Reportable segment asset information is not provided to the CODM as the CODM does not use segment asset information to evaluate the business and allocate resources.

The following tables summarize information for the reportable segments for the year ended December 31, 2024 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 1,205,744	\$ 881,452	\$ 568,475	\$ 2,655,671
Healthpeak's share of unconsolidated joint venture total revenues	24,041	19,733	—	43,774
Noncontrolling interests' share of consolidated joint venture total revenues	(37,643)	(196)	—	(37,839)
Operating expenses ⁽¹⁾	(405,993)	(239,620)	(429,248)	(1,074,861)
Healthpeak's share of unconsolidated joint venture operating expenses	(9,034)	(6,366)	—	(15,400)
Noncontrolling interests' share of consolidated joint venture operating expenses	10,582	52	—	10,634
Adjustments to NOI ⁽²⁾	(38,967)	(64,449)	(3,123)	(106,539)
Adjusted NOI for reportable segments	\$ 748,730	\$ 590,606	\$ 136,104	\$ 1,475,440
Plus: Adjustments to NOI ⁽²⁾				106,539
Interest income and other				44,778
Interest expense				(280,430)
Depreciation and amortization				(1,057,205)
General and administrative				(97,162)
Transaction and merger-related costs				(132,685)
Impairments and loan loss reserves, net				(22,978)
Gain (loss) on sales of real estate, net				178,695
Other income (expense), net				59,345
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI				(28,374)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI				27,205
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures				\$ 273,168

(1) See reconciliation of significant expense categories below.

(2) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2024 (in thousands):

	Outpatient Medical	Lab	CCRC
Compensation and property management	\$ 56,066	\$ 33,058	\$ 277,686
Food	—	—	26,513
Real estate taxes	95,286	78,488	15,472
Repairs and maintenance	61,409	30,555	18,373
Utilities	69,690	50,793	22,309
Other segment items ⁽¹⁾	123,542	46,726	68,895
Operating expenses	\$ 405,993	\$ 239,620	\$ 429,248

(1) Other segment items for each segment include:

- Outpatient medical and lab - (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC - (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following tables summarize information for the reportable segments for the year ended December 31, 2023 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 753,479	\$ 878,326	\$ 527,417	\$ 2,159,222
Government grant income ⁽¹⁾	—	—	184	184
Healthpeak's share of unconsolidated joint venture total revenues	3,033	9,924	—	12,957
Noncontrolling interests' share of consolidated joint venture total revenues	(35,073)	(619)	—	(35,692)
Operating expenses ⁽²⁾	(263,132)	(229,630)	(413,472)	(906,234)
Healthpeak's share of unconsolidated joint venture operating expenses	(1,189)	(4,092)	—	(5,281)
Noncontrolling interests' share of consolidated joint venture operating expenses	9,921	156	—	10,077
Adjustments to NOI ⁽³⁾	(14,314)	(36,524)	(1,618)	(52,456)
Adjusted NOI for reportable segments	\$ 452,725	\$ 617,541	\$ 112,511	\$ 1,182,777
Plus: Adjustments to NOI ⁽³⁾				52,456
Interest income and other				21,781
Interest expense				(200,331)
Depreciation and amortization				(749,901)
Corporate non-segment operating expenses				4,174
General and administrative				(95,132)
Transaction and merger-related costs				(17,515)
Impairments and loan loss reserves, net				5,601
Gain (loss) on sales of real estate, net				86,463
Other income (expense), net				6,808
Less: Government grant income				(184)
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI				(7,676)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI				25,615
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures				\$ 314,936

(1) Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2) See reconciliation of significant expense categories below.

(3) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2023 (in thousands):

	Outpatient Medical	Lab	CCRC
Compensation and property management	\$ 29,752	\$ 18,096	\$ 260,624
Food	—	—	25,076
Real estate taxes	59,255	77,690	15,851
Repairs and maintenance	38,277	30,554	17,295
Utilities	43,348	45,490	22,787
Other segment items ⁽¹⁾	92,500	57,800	71,839
Operating expenses	\$ 263,132	\$ 229,630	\$ 413,472

(1) Other segment items for each segment include:

- Outpatient medical and lab - (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC - (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following tables summarize information for the reportable segments for the year ended December 31, 2022 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 725,370	\$ 817,573	\$ 494,935	\$ 2,037,878
Government grant income ⁽¹⁾	—	—	6,765	6,765
Healthpeak's share of unconsolidated joint venture total revenues	2,999	9,921	—	12,920
Healthpeak's share of unconsolidated joint venture government grant income	—	—	380	380
Noncontrolling interests' share of consolidated joint venture total revenues	(35,717)	(268)	—	(35,985)
Operating expenses ⁽²⁾	(253,309)	(209,143)	(400,539)	(862,991)
Healthpeak's share of unconsolidated joint venture operating expenses	(1,178)	(2,883)	—	(4,061)
Noncontrolling interests' share of consolidated joint venture operating expenses	10,317	87	—	10,404
Adjustments to NOI ⁽³⁾	(15,513)	(62,754)	2,300	(75,967)
Adjusted NOI for reportable segments	\$ 432,969	\$ 552,533	\$ 103,841	\$ 1,089,343
Plus: Adjustments to NOI ⁽³⁾	—	—	—	75,967
Interest income and other	—	—	—	23,300
Interest expense	—	—	—	(172,944)
Depreciation and amortization	—	—	—	(710,569)
General and administrative	—	—	—	(131,033)
Transaction and merger-related costs	—	—	—	(4,853)
Impairments and loan loss reserves, net	—	—	—	(7,004)
Gain (loss) on sales of real estate, net	—	—	—	9,078
Other income (expense), net	—	—	—	326,268
Less: Government grant income	—	—	—	(6,765)
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI	—	—	—	(9,239)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI	—	—	—	25,581
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—	—	—	\$ 507,130

(1) Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2) See reconciliation of significant expense categories below.

(3) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2022 (in thousands):

	Outpatient Medical	Lab	CCRC
Compensation and property management	\$ 27,807	\$ 16,817	\$ 251,804
Food	—	—	23,641
Real estate taxes	59,992	75,459	14,090
Repairs and maintenance	36,439	26,884	16,522
Utilities	43,329	41,087	21,219
Other segment items ⁽¹⁾	85,742	48,896	73,263
Operating expenses	\$ 253,309	\$ 209,143	\$ 400,539

(1) Other segment items for each segment include:

- Outpatient medical and lab – (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC – (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following table summarizes the Company's revenues by reportable segment (in thousands):

Segment	2024	2023	2022
Outpatient medical	\$ 1,205,744	\$ 753,479	\$ 725,370
Lab	881,452	878,326	817,573
CCRC	568,475	527,417	494,935
Total revenues for reportable segments	2,655,671	2,159,222	2,037,878
Interest income and other	44,778	21,781	23,300
Total revenues	\$ 2,700,449	\$ 2,181,003	\$ 2,061,178

At December 31, 2024, goodwill of \$69 million was allocated to the Company's segment assets as follows: (i) \$65 million for outpatient medical, (ii) \$2 million for CCRC, and (iii) \$2 million for other non-reportable. At December 31, 2023, goodwill of \$18 million was allocated to the Company's segment assets as follows: (i) \$14 million for outpatient medical, (ii) \$2 million for CCRC, and (iii) \$2 million for other non-reportable.

XML 45 R26.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Dec. 31, 2024

[Income Tax Disclosure \[Abstract\]](#)
[Income Taxes](#)

Income Taxes

The Company has elected to be taxed as a REIT under the applicable provisions of the Code beginning with the year ended December 31, 1985. The Company has also elected for certain of its subsidiaries to be treated as TRSs (the "TRS entities"), which are subject to federal and state income taxes. All entities other than the TRS entities are collectively referred to as the "REIT" within this Note 17. Certain REIT entities are also subject to state and local income taxes.

Distributions with respect to the Company's common stock can be characterized for federal income tax purposes as ordinary dividends, capital gains, nondividend distributions, or a combination thereof.

The following table shows the characterization of the Company's annual common stock distributions per share:

	2024	2023	2022
Ordinary dividends ⁽¹⁾	\$ 0.720440	\$ 0.909692	\$ 0.872948
Capital gains ⁽²⁾⁽³⁾	0.295060	0.116992	0.183208
Nondividend distributions	0.184500	0.173316	0.143844
	\$ 1.200000	\$ 1.200000	\$ 1.200000

(1) For the year ended December 31, 2024, all \$0.720440 of ordinary dividends qualified as business income for purposes of Code Section 199A. For the year ended December 31, 2023, the amount includes \$0.882312 of ordinary dividends qualified as business income for purposes of Code Section 199A and \$0.027380 of qualified dividend income for purposes of Code Section 1(h)(11). For the year ended December 31, 2022, all \$0.872948 of ordinary dividends qualified as business income for purposes of Code Section 199A.

(2) For the years ended December 31, 2024, 2023, and 2022, the amount includes \$0.215960, \$0.036256, and \$0.017760, respectively, of unrecaptured Code Section 1250 gain. Pursuant to Treasury Regulation Section 1.1061-6(c), the Company is disclosing additional information related to the capital gain dividends for purposes of Section 1061 of the Code. Code Section 1061 is generally applicable to direct and indirect holders of "applicable partnership interests." For the years ended December 31, 2024 and 2023, the "One Year Amounts" and "Three Year Amounts" are each zero, since all capital gains relate to Code Section 1231 gains. For the year ended December 31, 2022, the "One Year Amounts" and "Three Year Amounts" are each 89.6708% of the total capital gain distributions and the remaining capital gain distributions are attributable to Code Section 1231 gains, which are not subject to Code Section 1061.

(3) For the years ended December 31, 2024, 2023, and 2022, 100%, 100%, and 10.3292%, respectively, of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.

The Company's pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was \$272 million, \$325 million, and \$509 million, respectively, of which \$217 million, \$318 million, and \$527 million was attributable to the REIT entities for the years then ended. The TRS entities subject to tax reported income (losses) before income taxes from continuing operations of \$55 million, \$7 million, and \$(18) million for the years ended December 31, 2024, 2023, and 2022, respectively.

The total income tax benefit (expense) from continuing operations consists of the following components (in thousands):

	2024	2023	2022
Current			
Federal	\$ (2,389)	\$ (1,663)	\$ (632)
State	(3,654)	(3,325)	(689)
Total current	\$ (6,043)	\$ (4,988)	\$ (1,321)
Deferred			
Federal	\$ (3,429)	\$ 11,682	\$ 3,157
State	5,122	2,923	2,589
Total deferred	\$ 1,693	\$ 14,605	\$ 5,746
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

The Company's income tax benefit from discontinued operations was zero, zero, and \$0.3 million for the years ended December 31, 2024, 2023, and 2022, respectively (see Note 5).

The following table reconciles income tax benefit (expense) from continuing operations at statutory rates to actual income tax benefit (expense) recorded (in thousands):

	2024	2023	2022
Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax	\$ (11,601)	\$ (1,404)	\$ 3,698
State income tax benefit (expense), net of federal tax	(1,389)	(1,035)	911
Gross receipts and margin taxes	(1,774)	(1,647)	(956)
Return to provision adjustments	(287)	(90)	1,260
Change in valuation allowance for deferred tax assets	10,698	13,797	194
Change in tax status of TRS	3	(4)	(682)
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table summarizes the significant components of the Company's deferred tax assets and liabilities from continuing operations (in thousands):

	December 31,		
	2024	2023	2022
Deferred tax assets:			
Deferred revenue	\$ 103,470	\$ 103,530	\$ 102,504
Net operating loss carryforward	50,041	54,136	62,280
Expense accruals	11,787	12,324	12,399
Real estate	195	850	150
Other	49	58	689
Total deferred tax assets	165,542	170,898	178,022
Valuation allowance	(2,306)	(13,004)	(26,098)
Deferred tax assets, net of valuation allowance	\$ 163,236	\$ 157,894	\$ 151,924
Deferred tax liabilities:			
Real estate	\$ 47,268	\$ 43,488	\$ 52,266
Other	876	818	674
Deferred tax liabilities	\$ 48,144	\$ 44,306	\$ 52,940
Net deferred tax assets	\$ 115,092	\$ 113,588	\$ 98,984

Net deferred tax assets are included in other assets, net on the Consolidated Balance Sheets.

The Company records a valuation allowance against deferred tax assets in certain jurisdictions when it is not more likely than not that it can realize the related deferred tax assets. The deferred tax asset valuation allowance is adequate to reduce the total deferred tax assets to an amount that the Company estimates will "more-likely-than-not" be realized.

As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses ("NOLs") of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primarily NOL carryforwards) would be realized. During the year ended December 31, 2023, this conclusion was based on estimates of future taxable income for certain TRS entities in connection with the Callan Ridge JV transaction (see also Notes 5 and 9). Accordingly, the Company reversed a portion of the deferred tax asset valuation allowance and recognized an income tax benefit of \$14 million during the year ended December 31, 2023. During the year ended December 31, 2024, the Company recognized an income tax expense of \$12 million in conjunction with the closing of the Callan Ridge JV transaction. Additionally, during the year ended December 31, 2024, the Company completed a merger of certain TRS entities and as a result, reversed a portion of the deferred tax asset valuation allowance and recognized an income tax benefit of \$11 million. As of December 31, 2024, 2023, and 2022, the Company had a deferred tax asset valuation allowance of \$2 million, \$13 million, and \$26 million, respectively.

At December 31, 2024, the Company had a NOL carryforward of \$193 million related to the TRS entities. If unused, \$2 million will begin to expire in 2035. The remainder, totaling \$191 million, may be carried forward indefinitely.

The following table summarizes the Company's unrecognized tax benefits (in thousands):

	December 31,		
	2024	2023	2022
Total unrecognized tax benefits at January 1	\$ —	\$ —	\$ 469
Gross amount of decreases for prior years' tax positions	—	—	(469)
Total unrecognized tax benefits at December 31	\$ —	\$ —	\$ —

For the years ended December 31, 2024, 2023, and 2022 the Company had no unrecognized tax benefits.

The Company files numerous U.S. federal, state, and local income and franchise tax returns. With a few exceptions, the Company is no longer subject to U.S. federal, state, or local tax examinations by taxing authorities for years prior to 2021.

XML 46 R27.htm IDEA: XBRL DOCUMENT

Supplemental Cash
Flow Information
[Supplemental Cash Flow
Elements \[Abstract\]](#)
[Supplemental Cash Flow
Information](#)

12 Months Ended
Dec. 31, 2024

Supplemental Cash Flow Information
The following table provides supplemental cash flow information (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Supplemental cash flow information:			
Interest paid, net of capitalized interest	\$ 249,471	\$ 188,213	\$ 162,115
Income taxes paid (refunded)	7,862	1,923	(1,903)
Capitalized interest	69,256	56,849	41,046
Cash paid for amounts included in the measurement of lease liability for operating leases	21,277	21,488	12,594
Supplemental schedule of non-cash investing and financing activities:			
Increase in ROU asset in exchange for new lease liability related to operating leases	15,457	3,951	9,454
Accrued construction costs	136,767	105,572	178,626
Net noncash impact from the consolidation of property previously held in an unconsolidated joint venture	—	993	—
Retained investment in connection with South San Francisco JVs transaction (see Note 9)	—	—	293,265
Retained investment in connection with Callan Ridge JV (see Note 9)	69,255	—	—
Non-cash assets and liabilities assumed in connection with the Merger (see Note 3)	2,926,141	—	—
Seller financing provided on disposition of real estate assets (see Note 8)	418,389	—	—

Operating, investing, and financing cash flows in the Consolidated Statements of Cash Flows are reported inclusive of both cash flows from continuing operations and cash flows from discontinued operations. The following table summarizes certain cash flow information related to discontinued operations (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Leasing costs, tenant improvements, and recurring capital expenditures	\$ —	\$ —	\$ 21
Development, redevelopment, and other major improvements of real estate	—	—	18
Depreciation and amortization of real estate, in-place lease, and other intangibles	—	—	—

The following table summarizes cash, cash equivalents, and restricted cash (in thousands):

	Year Ended December 31,								
	2024	2023	2022	2024	2023	2022	2024	2023	2022
	Continuing operations			Discontinued operations			Total		
Beginning of year:									
Cash and cash equivalents	\$ 117,635	\$ 72,032	\$ 158,287	\$ —	\$ —	\$ 7,707	\$ 117,635	\$ 72,032	\$ 165,994
Restricted cash	51,388	54,802	53,454	—	—	—	51,388	54,802	53,454
Cash, cash equivalents, and restricted cash	\$ 169,023	\$ 126,834	\$ 211,741	\$ —	\$ —	\$ 7,707	\$ 169,023	\$ 126,834	\$ 219,448
End of year:									
Cash and cash equivalents	\$ 119,818	\$ 117,635	\$ 72,032	\$ —	\$ —	\$ —	\$ 119,818	\$ 117,635	\$ 72,032
Restricted cash	64,487	51,388	54,802	—	—	—	64,487	51,388	54,802
Cash, cash equivalents, and restricted cash	\$ 184,305	\$ 169,023	\$ 126,834	\$ —	\$ —	\$ —	\$ 184,305	\$ 169,023	\$ 126,834

XML 47 R28.htm IDEA: XBRL DOCUMENT

Variable Interest
Entities
[Variable Interest
Entities \[Abstract\]](#)
[Variable Interest
Entities](#)

12 Months Ended
Dec. 31, 2024

Variable Interest Entities
Operating Subsidiary

Healthpeak OP is the Company's operating subsidiary and a limited liability company that has governing provisions that are the functional equivalent of a limited partnership. The Company holds a membership interest in Healthpeak OP, acts as the managing member of Healthpeak OP, and exercises full responsibility, discretion, and control over the day-to-day management of Healthpeak OP. Because the noncontrolling interests in Healthpeak OP do not have substantive liquidation rights, substantive kick-out rights without cause, or substantive participating rights, the Company has determined that Healthpeak OP is a VIE. The Company, as managing member, has the power to direct the core activities of Healthpeak OP that most significantly affect Healthpeak OP's performance, and through its interest in Healthpeak OP, has both the right to receive benefits from and the obligation to absorb losses of Healthpeak OP. Accordingly, the Company is the primary beneficiary of Healthpeak OP and consolidates Healthpeak OP. As the Company conducts its business and holds its assets and liabilities through Healthpeak OP, the total consolidated assets and liabilities, income (losses), and cash flows of Healthpeak OP represent substantially all of the total consolidated assets and liabilities, including the consolidated and unconsolidated entities discussed in this Note 19, income (losses), and cash flows of the Company.

Unconsolidated Variable Interest Entities

At December 31, 2024, the Company had investments in (i) two unconsolidated VIE joint ventures and (ii) the PropTech Investment, an unconsolidated VIE investment in a limited partnership. At December 31, 2023, the Company had investments in two unconsolidated VIE joint ventures. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company's equity interest in the unconsolidated joint ventures (the LLC Investment and Needham Land Parcel JV discussed below) and the PropTech Investment, it has no formal involvement in these VIEs beyond its investments.

LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC ("LLC Investment") that has been identified as a VIE. The Company's involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of three hospitals as well as senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).

PropTech Investment. During the year ended December 31, 2024, the Company made an initial investment of \$1 million in a property technology ("PropTech") fund that makes venture capital investments in early-stage real estate and construction-related companies (the "PropTech investment"). The Company has an aggregate commitment of \$10 million, or approximately 5% of total fund commitments, which is expected to be funded over the next five years. The PropTech investment has been identified as a VIE. The Company's involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner and given its rights and ownership percentage, the Company has virtually no influence or control. The assets and liabilities of the entity primarily consist of investments in certain PropTech real estate and construction companies. All future investments will be funded with capital contributions from the Company and other limited partners in accordance with their respective commitments.

Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a lab development joint venture in Needham, Massachusetts for \$13 million. Current equity at risk is not sufficient to finance the joint venture's activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development costs and debt service payments). See Note 9 for additional descriptions of the nature, purpose, and operating activities of this unconsolidated VIE and interests therein.

Debt Securities Investment. At December 31, 2022, the Company held \$22 million of commercial mortgage-backed securities ("CMBS") issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie Mac) through a special purpose entity that had been identified as a VIE because it was "thinly capitalized." The CMBS issued by the VIE were backed by mortgage debt obligations on real estate assets. These securities were classified as held-to-maturity because the Company had the intent and ability to hold the securities until maturity. These securities matured on December 31, 2022, and the Company received the related proceeds in January 2023. At each of December 31, 2024 and 2023, there was no balance remaining for these securities.

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company's involvement with these VIEs at December 31, 2024 was as follows (in thousands):

speculative or trading purposes. At December 31, 2024, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to \$53 million.

During the year ended December 31, 2022, the Company recognized a \$2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026 on \$142 million of variable rate mortgage debt secured by a portfolio of outpatient medical buildings (see Note 11). In February 2023, the Company modified these two interest rate swap instruments to reflect the change in the related variable rate mortgage debt's interest rate benchmarks from LIBOR to SOFR (see Note 11).

In August 2022, the Company entered into two forward-starting interest rate swap instruments on the \$500 million aggregate principal amount of the 2027 Term Loans (see Note 11). The interest rate swap instruments are designated as cash flow hedges.

In January 2024, the Company entered into forward-starting interest rate swap instruments on the \$750 million aggregate principal amount of the 2029 Term Loan (see Note 11). The interest rate swap instruments are designated as cash flow hedges.

Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the \$400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on \$36 million of variable rate mortgage debt that was designated as a cash flow hedge (see Note 11) prior to its maturity in October 2024.

The following table summarizes the Company's interest rate swap instruments (in thousands):

Date Entered ⁽¹⁾	Maturity Date	Hedge Designation	Notional Amount	Pay Rate	Receive Rate	Fair Value ⁽²⁾	
						December 31, 2024	December 31, 2023
April 2022	May 2026	Cash flow	\$ 51,100	4.99 %	USD-SOFR w/ -5 Day Lookback + 2.50%	\$ 1,050	\$ 1,602
April 2022	May 2026	Cash flow	91,000	4.54 %	USD-SOFR w/ -5 Day Lookback + 2.05%	1,870	2,851
August 2022	February 2027	Cash flow	250,000	2.60 %	1 mo. USD-SOFR CME Term	7,224	7,933
August 2022	August 2027	Cash flow	250,000	2.54 %	1 mo. USD-SOFR CME Term	9,122	8,973
May 2023 ⁽³⁾⁽⁴⁾	May 2028	Cash flow	400,000	3.59 %	USD-SOFR w/ -5 Day Lookback	4,887	—
January 2024 ⁽⁵⁾	February 2029	Cash flow	750,000	3.59 %	USD-SOFR w/ -5 Day Lookback	10,967	—
						\$ 35,120	\$ 21,359

- (1) Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.
- (2) Derivative assets are recorded at fair value in other assets, net on the Consolidated Balance Sheets.
- (3) Includes interest rate swap instruments acquired as part of the Merger (see Note 3). The interest rate swap instrument on \$36 million of mortgage debt that was acquired as part of the Merger matured in October 2024 and has been excluded herein. These interest rate swap instruments were redesignated as cash flow hedges on the Closing Date. As a result of the Merger, the aggregate fair value of these interest rate swap instruments was determined to be \$7 million on March 1, 2024, which was recognized within other assets, net on the Consolidated Balance Sheets on the Closing Date. The aggregate fair value as of the Closing Date is being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related interest rate swap instruments. During the year ended December 31, 2024, the Company recognized \$2 million of related amortization into interest expense.
- (4) Includes two interest rate swap instruments each with notional amounts of \$110 million and one interest rate swap instrument with a notional amount of \$180 million.
- (5) Includes the following: (i) two interest rate swap instruments each with a pay rate of 3.56% and \$50 million notional amount; (ii) three interest rate swap instruments each with a pay rate of 3.57% and \$50 million notional amount; (iii) one interest rate swap instrument with a pay rate of 3.58% and \$100 million notional amount; (iv) five interest rate swap instruments each with a pay rate of 3.60% and \$50 million notional amount; and (v) three interest rate swap instruments each with a pay rate of 3.61% and \$50 million notional amount.

XML 51 R32.htm IDEA: XBRL DOCUMENT

Accounts Payable,
Accrued Liabilities,
and Other Liabilities

12 Months Ended

Dec. 31, 2024

[Payables and Accruals \[Abstract\]](#)

[Accounts Payable, Accrued Liabilities, and Other Liabilities](#) Accounts Payable, Accrued Liabilities, and Other Liabilities

The following table summarizes the Company's accounts payable, accrued liabilities, and other liabilities (in thousands):

	December 31,	
	2024	2023
Refundable entrance fees	\$ 236,563	\$ 251,874
Accrued construction costs	136,767	105,572
Accrued interest	76,040	59,492
Other accounts payable and accrued liabilities	275,972	240,258
Accounts payable, accrued liabilities, and other liabilities	\$ 725,342	\$ 657,196

XML 52 R33.htm IDEA: XBRL DOCUMENT

Deferred Revenue

12 Months Ended

Dec. 31, 2024

[Revenues \[Abstract\]](#)

[Deferred Revenue](#)

Deferred Revenue

The following table summarizes the Company's deferred revenue, excluding deferred revenue related to assets classified as held for sale (in thousands):

	December 31,	
	2024	2023
Non-refundable entrance fees ⁽¹⁾	\$ 615,723	\$ 562,026
Other deferred revenue ⁽²⁾	324,413	343,607
Deferred revenue	\$ 940,136	\$ 905,633

- (1) During the years ended December 31, 2024 and 2023, the Company collected non-refundable entrance fees of \$143 million and \$127 million, respectively. During the years ended December 31, 2024, 2023, and 2022, the Company recognized amortization of \$89 million, \$83 million, and \$79 million, respectively, which is included within resident fees and services on the Consolidated Statements of Operations.
- (2) Other deferred revenue is primarily comprised of prepaid rent, deferred rent, and tenant-funded tenant improvements owned by the Company. During the years ended December 31, 2024, 2023, and 2022, the Company recognized amortization related to other deferred revenue of \$53 million, \$68 million, and \$44 million, respectively, which is included in rental and related revenues on the Consolidated Statements of Operations.

XML 53 R34.htm IDEA: XBRL DOCUMENT

Schedule II:
Valuation and
Qualifying Accounts

12 Months Ended

Dec. 31, 2024

[SEC Schedule, 12-09, Valuation and Qualifying Accounts \[Abstract\]](#)

[Schedule II: Valuation and Qualifying Accounts](#)

Schedule II: Valuation and Qualifying Accounts

(In thousands)

Allowance Accounts ⁽¹⁾		Additions				
Year Ended December 31,	Balance at Beginning of Year	Amounts Charged Against Operations, net	Acquired Properties	Deductions ⁽²⁾	Balance at End of Year	
Continuing operations:						
2024	\$ 2,282	\$ —	\$ —	\$ (39)	\$ 2,243	
2023	2,399	—	—	(117)	2,282	
2022	1,870	529	—	—	2,399	
Discontinued operations:						
2024	\$ —	\$ —	\$ —	\$ —	—	
2023	—	—	—	—	—	
2022	4,138	—	—	(4,138)	—	

- (1) Includes allowance for doubtful accounts. Excludes reserves for loan losses which are disclosed in Note 8 to the Consolidated Financial Statements.
- (2) Primarily includes the write-off of uncollectible accounts, dispositions, and other net reductions in the reserves.

XML 54 R35.htm IDEA: XBRL DOCUMENT

Schedule III: Real
Estate and
Accumulated
Depreciation

12 Months Ended

Dec. 31, 2024

[SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure \[Abstract\]](#)

[Schedule III: Real Estate and Accumulated Depreciation](#)

				Encumbrances at December 31, 2024		Initial Cost to Company		Costs Capitalized Subsequent to Acquisition		Gross Amount at Which Carried		Total**		Accumulated Depreciation	Year Constructed**	Year Acquired			
		City	State			Land and Improvements**	Buildings and Improvements**	Land and Improvements**	Buildings and Improvements**	Land and Improvements**	Buildings and Improvements**								
Outpatient medical																			
638	Anchorage	AK	\$	—	\$	1,456	5	10,650	\$	10,740	\$	1,456	5	21,390	\$	22,846	(10,227)	1993/2014	2006
AL0004	Birmingham	AL	—	—	—	382	8,522	—	—	—	—	382	8,522	8,904	(376)	1975	2024	2004	
AL0010	Birmingham	AL	—	—	—	2,975	9,317	147	2,975	9,464	12,439	2,973	9,464	12,439	(590)	2005	2024	2024	
AL0012	Birmingham	AL	—	—	—	3,925	17,289	36	3,925	17,325	21,250	3,925	17,325	21,250	(747)	2012	2024	2024	
AL0003	Fairhope	AL	—	—	—	1,714	6,265	125	1,714	6,390	8,104	1,714	6,390	8,104	(305)	2005	2024	2024	
AL0005	Foley	AL	—	—	—	569	991	—	569	991	1,260	569	991	1,260	(49)	2002	2024	2024	
AL0011	Huntsville	AL	—	—	—	4,771	25,836	461	4,771	26,097	30,868	4,771	26,097	30,868	(1,155)	2006	2024	2024	
3026	Montevallo	AR	—	—	—	912	21,724	735	912	22,459	23,371	912	22,459	23,371	(1,768)	2001	2022	2024	
ARD005	Hot Springs	AR	—	—	—	108	8,819	—	108	8,819	8,927	108	8,819	8,927	(411)	1998	2024	2024	
ARD006	Hot Springs	AR	—	—	—	211	4,124	763	211	4,124	5,798	211	4,124	5,798	(240)	2001	2024	2024	
ARD007	Hot Springs	AR	—	—	—	464	9,076	464	464	9,076	10,285	464	9,076	10,285	(193)	2009	2024	2024	
ARD008	Hot Springs	AR	—	—	—	49	3,667	—	49	3,667	3,716	49	3,667	3,716	(171)	2001	2024	2024	
ARD004	Hot Springs Village	AR	—	—	—	656	3,238	384	656	3,238	4,778	656	3,238	4,778	(183)	1988	2024	2024	
ARD001	Little Rock	AR	—	—	—	822	7,018	—	822	7,018	7,840	822	7,018	7,840	(460)	2012	2024	2024	
ARD002	Little Rock	AR	—	—	—	780	3,123	—	780	3,123	4,103	780	3,123	4,103	(195)	1988	2024	2024	
126	Shenwood	AR	—	—	—	709	9,604	242	709	9,846	10,555	709	9,846	10,555	(726)	1990	2006	2024	
2572	Springdale	AR	—	—	—	—	27,714	—	—	27,714	27,714	—	27,714	27,714	(7,329)	1995	2016	2024	
AZ0002	Aurisdale	AZ	—	—	—	2,694	11,388	564	2,694	11,391	14,646	2,694	11,391	14,646	(657)	2006	2024	2024	
520	Chandler	AZ	—	—	—	3,669	13,503	6,076	4,041	19,207	23,248	4,041	19,207	23,248	(9,866)	2005	2012	2024	
113	Glendale	AZ	—	—	—	1,585	7,050	175	1,585	7,225	8,790	1,585	7,225	8,790	(5,491)	1989	2006	2024	
AZ0001	Glendale	AZ	—	—	—	640	2,473	(9)	640	2,464	3,104	640	2,464	3,104	(131)	2004	2024	2024	
AZ0008	Glendale	AZ	—	—	—	2,692	6,538	—	2,692	6,538	9,230	2,692	6,538	9,230	(329)	2015	2024	2024	
AZ0003	Goodyear	AZ	—	—	—	4,139	18,196	457	4,139	18,653	22,792	4,139	18,653	22,792	(974)	2006	2024	2024	
2040	Mesa	AZ	—	—	—	17,314	3,895	—	17,314	21,209	21,209	17,314	21,209	21,209	(5,448)	2007	2012	2024	
AZ0012	Mesa	AZ	—	—	—	1,124	2,121	100	1,124	2,221	3,345	1,124	2,221	3,345	(131)	2013	2024	2024	
AZ0005	Phoenix	AZ	—	—	—	405	32,432	236	405	32,668	33,073	405	32,668	33,073	(1,277)	2008	2024	2024	
AZ0007	Phoenix	AZ	—	—	—	2,528	3,495	—	2,528	3,495	6,023	2,528	3,495	6,023	(164)	1988	2024	2024	
AZ0015	Phoenix	AZ	—	—	—	118	17,922	332	118	18,254	18,412	118	18,254	18,412	(166)	2020	2024	2024	
AZ00A7	Phoenix	AZ	—	—	—	2,526	694	624	2,526	3,138	3,844	2,526	3,138	3,844	(35)	1988	2024	2024	
2021	Scottsdale	AZ	—	—	—	12,312	5,124	—	12,312	17,436	17,436	12,312	17,436	17,436	(7,674)	1984	2012	2024	
2022	Scottsdale	AZ	—	—	—	9,179	3,733	—	9,179	12,912	12,912	9,179	12,912	12,912	(5,455)	1996	2012	2024	
2023	Scottsdale	AZ	—	—	—	6,398	2,370	—	6,398	8,768	8,768	6,398	8,768	8,768	(3,694)	2000	2022	2024	
2024	Scottsdale	AZ	—	—	—	9,522	1,700	—	9,522	11,190	11,222	9,522	11,190	11,222	(5,264)	2007	2012	2024	
2025	Scottsdale	AZ	—	—	—	4,102	2,557	—	4,102	6,659	6,659	4,102	6,659	6,659	(2,901)	1981	2012	2024	
2026	Scottsdale	AZ	—	—	—	3,655	2,087	—	3,655	5,742	5,742	3,655	5,742	5,742	(2,905)	1992	2012	2024	
2027	Scottsdale	AZ	—	—	—	7,148	2,410	—	7,148	9,578	9,578	7,148	9,578	9,578	(4,722)	1995	2012	2024	
2028	Scottsdale	AZ	—	—	—	6,659	5,237	—	6,659	11,896	11,896	6,659	11,896	11,896	(6,013)	1998	2012	2024	
2956	Scottsdale	AZ	—	—	—	10,151	18,925	20	9,234	25,096	34,330	10,151	25,096	34,330	(13,138)	1998	2020	2024	
AZ0009	Scottsdale	AZ	—	—	—	2,563	9,361	—	2,563	9,361	11,924	2,563	9,361	11,924	(449)	2000	2024	2024	
AZ0010	Scottsdale	AZ	—	—	—	1,096	19,515	—	1,096	19,515	20,611	1,096	19,515	20,611	(882)	2000	2024	2024	
AZ0011	Scottsdale	AZ	—	—	—	2,880	2,646	—	2,880	2,646	5,455	2,880	2,646	5,455	(217)	1991	2024	2024	
AZ0014	Scottsdale	AZ	—	—	—	506	43,211	3,451	506	46,662	47,168	506	46,662	47,168	(1,448)	2021	2024	2024	
1041	Brentwood	CA	—	—	—	3,064	9,176	127	3,064	39,018	40,140	3,064	39,018	40,140	(14,525)	2004	2006	2024	
1200	Encino	CA	—	—	—	6,151	10,438	6,680	6,373	16,896	23,269	6,373	16,896	23,269	(8,545)	1973	2006	2024	
1038	Fresno	CA	—	—	—	3,652	29,113	21,935	3,652	51,048	54,700	3,652	51,048	54,700	(25,001)	1984	2006	2024	
859	Los Gatos	CA	—	—	—	1,718	3,124	1,393	1,718	4,439	6,215	1,718	4,439	6,215	(2,056)	1990	2006	2024	
421	San Diego	CA	—	—	—	2,910	19,984	15,149	2,910	35,079	38,043	2,910	35,079	38,043	(19,150)	1986/2013	1999	2024	
564	San Jose	CA	—	—	—	1,535	2,595	1,293	1,535	4,323	6,258	1,535	4,323	6,258	(1,905)	1968	2003	2024	
565	San Jose	CA	—	—	—	1,460	7,672	2,273	1,460	9,913	11,405	1,460	9,913	11,405	(5,460)	1995	2003	2024	
CA0001	Walnut Creek	CA	—	—	—	1,333	5,116	—	1,333	5,116	6,449	1,333	5,116	6,449	(255)	1984	2024	2024	
CA0002	Walnut Creek	CA	—	—	—	1,189	1,179	—	1,189	2,179	2,368	1,189	2,179	2,368	(74)	1984	2024	2024	
CA0003	Walnut Creek	CA	—	—	—	1,168	1,368	—	1,168	1,368	2,536	1,168	1,368	2,536	(81)	1984	2024	2024	
CA0004	Walnut Creek	CA	—	—	—	3,143	5,390	—	3,143	5,390	8,333	3,143	5,390	8,333	(299)	1984	2024	2024	
CA0005	Walnut Creek	CA	—	—	—	1,140	2,260	—	1,140	2,260	3,400	1,140	2,260	3,400	(118)	1984	2024	2024	
440	West Hills	CA	—	—	—	2,100	11,595	12,817	2,100	24,409	26,612	2,100	24,409	26,612	(9,359)	1992/2023	1999	2024	
3008	West Hills	CA	12,137	—	—	13,795	13,833	1,872	13,795	17,777	23,600	13,795	17,777	23,600	(1,536)	1985	2006	2024	
728	Aurora	CO	—	—	—	8,764	2,794	—	8,764	11,558	11,558	8,764	11,558	11,558	(4,589)	2005	2005	2024	
1186	Aurora	CO	—	—	—	12,262	5,923	210	12,262	18,295	18,499	12,262	18,295	18,499	(8,389)	1981/2018	2006	2024	
1197	Aurora	CO	—	—	—	200	8,414	6,235	285	14,564	14,849	285	14,564	14,849	(7,259)	1994/2018	2006	2024	
2965	Aurora	CO	—	—	—	—	—	39,026	—	39,026	39,026	—	39,026	39,026	—	2023	2024	2024	
127	Colorado Springs	CO	—	—	—	690	8,233	367	690	8,705	9,395	690	8,705	9,395	(6,267)	1990	1989	2024	
882	Colorado Springs	CO	—	—	—	12,038	8,913	—	12,038	21,846	21,846	12,038	21,846	21,846	(11,516)	2007	2006	2024	
1199	Denver	CO	—	—	—	493	7,897	8,612	404	8,428	10,832	404	8,428	10,832	(4,874)	1993	2006	2024	
808	Englewood	CO	—	—	—	8,616	6,221	—	8,616	14,837	14,837	8,616	14,837	14,837	(7,838)	1981	2005	2024	
809	Englewood	CO	—	—	—	8,449	20,199	—	8,449	28,648	28,648	8,449	28,648	28,648	(7,329)	1980/2023	2005	2024	
810	Englewood	CO	—	—	—	8,040	16,738	24,778	8,040	24,778	24,778	8,040	24,778	24,778	(10,816)	1989/2023	2005	2024	
811	Englewood	CO	—	—	—	8,472	12,707</												

|--|--|

	City	State	Encumbrances at December 31, 2024	Initial Cost to Company		Costs Subsequent to Acquisition		Gross Amount at Which Carried As of December 31, 2024			Accumulated Depreciation	Year Constructed	Year Acquired
				Land and Improvements	Buildings and Improvements	Land and Improvements	Buildings and Improvements	Total					
LD005	Palos Heights	IL	—	2,324	5,087	319	2,324	5,406	7,730	(181)	1985	2024	
LD001	Sandwich	IL	—	116	10,126	—	116	10,126	10,242	(569)	2007	2024	
IN003	Bloomington	IN	—	622	3,440	—	622	3,440	4,062	(222)	1996	2024	
IN004	Bloomington	IN	—	841	2,089	—	841	2,089	2,930	(134)	2004	2024	
IN005	Bloomington	IN	—	2,830	9,994	—	2,830	9,994	12,224	(584)	2000	2024	
IN006	Bloomington	IN	—	588	1,414	—	588	1,414	2,002	(91)	2004	2024	
IN007	Bloomington	IN	—	1,383	7,207	—	1,383	7,207	8,590	(146)	1995	2024	
IN003	Bloomington	IN	—	1,730	7,304	—	1,730	7,304	9,034	(184)	2008	2024	
IN002	Carmel	IN	—	38	8,930	658	38	4,588	6,626	(197)	1993	2024	
IN020	Carmel	IN	—	259	22,311	308	259	22,619	22,878	(763)	2014	2024	
IN021	Fishers	IN	—	383	34,648	191	383	34,839	35,222	(1,381)	2008	2024	
IN008	Greenwood	IN	—	1,365	6,934	—	1,365	6,934	8,299	(132)	2008	2024	
IN010	Greenwood	IN	—	1,015	2,238	1	1,015	2,239	3,254	(122)	2001	2024	
IN011	Greenwood	IN	—	1,565	10,588	211	1,565	10,799	12,364	(528)	2008	2024	
IN012	Greenwood	IN	—	993	42	993	42	2,039	3,032	(91)	2001	2024	
2697	Indianapolis	IN	—	—	59,746	1,018	—	60,764	60,764	(7,389)	2002	2020	
2699	Indianapolis	IN	—	3,772	23,211	747	3,772	23,058	23,858	(1,142)	2002	2020	
IN009	Indianapolis	IN	—	764	4,084	9	764	4,093	4,857	(209)	1993	2024	
IN022	Indianapolis	IN	—	3,772	42,213	—	3,772	42,213	45,985	(1,766)	2002	2020	
IN005	Lafayette	IN	—	845	9,980	845	9,980	10,825	10,825	(559)	2001	2024	
IN016	Lafayette	IN	—	1,433	9,059	—	1,433	9,059	10,492	(605)	2001	2024	
IN017	Lafayette	IN	—	471	1,130	—	471	1,130	1,601	(74)	2001	2024	
IN018	Lafayette	IN	—	421	1,170	—	421	1,170	1,591	(174)	2001	2024	
IN001	Milwaukee	IN	—	3,468	8,175	452	3,468	8,627	12,095	(623)	2007	2024	
2698	Mooreville	IN	—	—	20,646	997	—	21,643	21,643	(2,768)	2004	2020	
1057	Newburgh	IN	—	—	14,019	3,659	—	17,678	17,678	(8,867)	2005	2006	
IN025	Newburgh	IN	—	2,182	13,074	—	2,182	13,074	15,256	(707)	2008	2024	
2700	Zionsville	IN	—	2,969	7,281	871	3,075	8,046	11,121	(1,658)	2005	2020	
2029	Kansas City	KS	—	1,400	23,211	389	1,400	23,461	25,002	(842)	2006	2012	
112	Overland Park	KS	—	2,316	10,681	312	2,316	10,993	13,309	(6,428)	1989	1989	
2043	Overland Park	KS	—	—	7,668	1,425	—	9,093	9,093	(2,765)	2009	2021	
3602	Overland Park	KS	—	872	11,813	8	872	11,701	12,593	(1,121)	2007	2019	
483	Wichita	KS	—	530	820	8	530	4,086	4,691	(1,831)	2000	2002	
2018	Wichita	KS	—	3,946	29,795	8	3,946	29,806	42,141	(5,560)	1972/2017	2021	
1064	Lexington	KY	—	—	12,726	2,262	—	14,988	14,988	(6,952)	2003	2006	
KY011	Lexington	KY	—	4,797	18,987	4,218	4,797	23,205	28,002	(1,253)	1992	2024	
KY012	Lexington	KY	—	1,905	6,918	182	1,905	7,100	9,005	(621)	2008	2024	
735	Louisville	KY	—	936	8,426	13,260	661	21,961	22,622	(12,967)	1971/2019	2005	
737	Louisville	KY	—	825	27,627	7,774	567	35,706	36,236	(18,509)	2002	2005	
738	Louisville	KY	—	780	8,582	583	780	13,330	14,115	(10,660)	1978	2005	
739	Louisville	KY	—	626	13,614	3,861	630	18,421	18,501	(8,268)	2003	2005	
2834	Louisville	KY	—	2,983	13,171	5,223	2,983	17,872	21,407	(11,276)	1990	2005	
1945	Louisville	KY	—	3,255	28,644	2,836	3,421	31,874	34,735	(14,486)	2009	2010	
1946	Louisville	KY	—	430	6,125	243	430	6,368	6,788	(2,933)	2002	2010	
2237	Louisville	KY	—	1,519	15,386	6,679	1,672	21,912	23,584	(9,361)	1991	2014	
2238	Louisville	KY	—	1,134	12,172	3,079	1,594	14,991	16,585	(5,989)	1996	2014	
2239	Louisville	KY	—	1,464	10,872	31,093	2,103	20,466	22,569	(8,103)	1988	2014	
KY001	Louisville	KY	—	1,801	4,672	—	1,801	4,672	6,473	(302)	2013	2024	
KY004	Louisville	KY	—	383	3,144	383	383	3,407	3,790	(372)	2010	2024	
KY005	Louisville	KY	—	680	7,568	253	680	7,821	8,501	(522)	1964	2024	
KY006	Louisville	KY	—	1,774	29,814	—	1,774	29,814	31,588	(1,814)	2003	2024	
KY007	Louisville	KY	—	3,430	19,016	167	3,430	19,183	22,613	(1,021)	1985	2024	
KY008	Louisville	KY	—	125	12,503	(72)	125	12,431	12,556	(525)	1991	2024	
KY009	Louisville	KY	—	227	3,864	47	227	3,881	4,029	(193)	1979	2024	
KY010	Louisville	KY	—	315	2,585	1,113	315	3,698	4,013	(174)	1974	2024	
KY002	Shepardsville	KY	—	973	28,735	571	973	29,306	30,779	(637)	2005	2024	
KY003	Shepardsville	KY	—	795	—	—	795	3,355	4,150	(193)	2006	2024	
3023	Covington	LA	—	9,490	21,918	(298)	9,507	27,403	31,110	(2,765)	2014	2021	
LA004	Lafayette	LA	—	27,463	353	(69)	27,794	28,147	(744)	2010	2024		
LA001	Metairie	LA	—	68	38,037	—	68	38,037	38,105	(1,124)	2014	2024	
3121	Cambridge	MA	—	40,663	23,102	—	40,663	23,102	63,765	(2,596)	1983	2021	
MD001	Brandywine	MD	—	4,757	17,285	—	4,757	17,285	22,043	(907)	2015	2024	
1213	Ellicott City	MD	—	1,115	3,206	2,758	1,357	5,722	7,079	(2,734)	1988	2006	
MD002	Lanham	MD	—	17,283	27	42	17,283	17,326	(543)	(543)	2017	2024	
1052	Towson	MD	—	—	14,233	1,231	—	15,464	15,464	(6,881)	2005	2006	
MD001	Waldorf	MD	—	1,759	6,038	53	1,759	6,091	7,650	(361)	1999	2024	
2650	Baldorf	ME	—	1,341	17,376	3058	1,341	17,850	18,598	(3,945)	2007	2021	
ME001	Brunswick	ME	4,592	920	10,394	920	10,394	11,314	11,314	(522)	2014	2021	
MD010	Bay City	MI	—	15,205	16,282	35	15,205	15,287	16,002	(695)	2016	2024	
MD006	Grand Blanc	MI	—	671	12,097	22	671	12,119	12,790	(675)	2006	2024	
MD011	Grass Pointe	MI	—	138	12,400	—	138	12,400	12,538	(482)	2011	2024	
MD012	Pontiac	MI	—	236	17,990	166	236	18,156	18,392	(870)	1993	2024	
MD013	Rochester Hills	MI	—	1,100	20,278	21,378	1,100	20,278	21,378	(993)	2016	2024	
MD014	Sterling Heights	MI	—	210	28,116	84	210	28,200	28,310	(1,005)	2009	2024	
MD008	Traverse City	MI	—	1,709	18,502	99	1,709	18,601	20,310	(1,045)	2004	2024	
MD048	Traverse City	MI	—	255	1,854	—	255	1,854	2,109	(158)	2004	2024	

|--|

				Encumbrances at December 31, 2024		Initial Cost to Company		Costs Capitalized Subsequent to Acquisition		Gross Amount at Which Carried As of December 31, 2024				Accumulated Depreciation	Year Constructed	Year Acquired	
				Land and Improvements		Buildings and Improvements		Land and Improvements		Buildings and Improvements		Total					
3010	Springfield	OR	20,802	—	1,014	51,998	1,979	—	1,014	53,977	53,977	—	107,951	—	(7,268)	2011	2021
PAD006	Camp Hill	PA	—	—	2,376	183	—	—	—	2,559	3,573	—	6,132	—	(173)	1980	2024
PAD002	Carlisle	PA	—	—	680	1,468	—	—	—	680	1,468	2,148	2,828	—	(116)	2002	2024
PAD004	Carlisle	PA	—	—	456	2,333	—	—	—	456	2,333	2,769	3,225	—	(161)	1996	2024
PAD014	Erie	PA	—	—	251	21,584	—	—	—	251	21,584	21,835	22,086	—	(808)	2007	2024
PAD010	Hanover	PA	—	—	1,777	8,437	1,001	1,777	9,438	11,215	13,026	14,803	16,579	—	(526)	2003	2024
PAD007	Harrisburg	PA	—	—	1,800	4,397	511	1,823	4,885	6,708	8,531	10,354	12,177	—	(422)	2000	2024
PAD008	Harrisburg	PA	—	—	586	1,115	102	586	1,217	1,803	2,017	2,603	3,189	—	(68)	1999	2024
PAD005	Hershey	PA	—	—	196	2,896	123	196	3,099	3,295	3,518	4,015	4,511	—	(122)	1994	2024
2570	Limerick	PA	—	—	925	20,072	(119)	755	20,123	20,123	20,878	(5,801)	19,077	—	(1,801)	1999	2024
2234	Philadelphia	PA	—	—	24,264	99,904	53,233	24,288	153,133	177,421	(48,972)	128,450	—	(48,972)	1973/2019	2024	
2403	Philadelphia	PA	—	—	26,063	97,646	54,119	26,134	151,894	177,828	(58,093)	119,735	—	(58,093)	2000	2015	
2571	West Easton	PA	—	—	2,065	7,718	—	2,065	7,718	7,718	7,983	(265)	7,718	—	(265)	2017	2024
PAD013	West Mifflin	PA	—	—	957	3,193	—	957	3,193	3,193	4,150	(203)	3,947	—	(203)	1992	2024
2571	Wilkes-Barre	PA	—	—	9,138	11	—	—	9,149	9,149	9,149	(2,915)	6,234	—	(2,915)	2001	2016
PAD011	Wyomissing	PA	—	—	298	3,410	—	298	3,410	3,410	3,708	(191)	3,517	—	(191)	2002	2024
2684	Anderson	SC	—	—	405	1,211	(162)	243	1,211	1,211	1,454	(270)	1,184	—	(270)	2012	2020
2573	Florence	SC	—	—	—	12,090	90	—	12,180	12,180	12,180	(1,100)	11,080	—	(1,100)	1998	2016
2574	Florence	SC	—	—	—	12,190	87	—	12,277	12,277	12,277	(1,206)	11,071	—	(1,206)	1998	2016
2575	Florence	SC	—	—	—	11,243	56	—	11,299	11,299	11,299	(3,516)	7,783	—	(3,516)	1995	2016
2841	Greenville	SC	—	—	634	38,386	(2,283)	13	36,724	36,727	(7,237)	29,490	—	(7,237)	1991	2018	
2842	Greenville	SC	—	—	794	41,293	(3,459)	317	38,628	38,628	(9,762)	28,866	—	(9,762)	1999	2018	
2843	Greenville	SC	—	—	626	22,210	(2,778)	—	20,060	20,060	(3,676)	16,384	—	(3,676)	1996	2018	
2844	Greenville	SC	—	—	806	18,889	(1,811)	—	17,884	17,884	(3,947)	13,937	—	(3,947)	1998	2018	
2845	Greenville	SC	—	—	932	40,879	(3,309)	—	38,502	38,502	(6,226)	32,276	—	(6,226)	2005	2018	
2846	Greenville	SC	—	—	696	38,486	(3,670)	—	35,712	35,712	(5,831)	29,881	—	(5,831)	2007	2018	
2847	Greenville	SC	—	—	600	26,472	200	27,272	27,272	27,272	(3,264)	24,008	—	(3,264)	1996	2018	
2850	Greenville	SC	—	—	211	6,503	(1,008)	211	5,495	5,495	(1,044)	4,451	—	(1,044)	2008	2018	
2853	Greenville	SC	—	—	334	6,430	(1,388)	—	5,042	5,042	(1,231)	3,811	—	(1,231)	2016	2018	
2854	Greenville	SC	—	—	824	13,645	(2,812)	—	11,657	11,657	(2,048)	9,609	—	(2,048)	1992	2018	
2848	Greer	SC	—	—	318	5,816	(791)	—	5,025	5,025	(851)	4,174	—	(851)	2019	2018	
2849	Greer	SC	—	—	319	5,836	(777)	—	5,078	5,078	(879)	4,199	—	(879)	2019	2018	
2862	Myrtle Beach	SC	—	—	—	—	28,496	—	28,496	28,496	(7,945)	20,551	—	(7,945)	2003	2018	
2851	Travelers Rest	SC	—	—	468	1,015	(299)	615	299	614	(114)	500	—	(114)	2009	2018	
2865	Brentwood	TN	—	—	—	36,965	52	—	36,913	36,913	(5,487)	31,426	—	(5,487)	2020	2019	
TN0007	Chattanooga	TN	—	—	139	10,350	281	139	10,631	10,770	(532)	10,238	—	(532)	1976	2024	
TN0010	Chattanooga	TN	—	—	17,612	17,612	—	221	17,612	17,833	(813)	16,800	—	(813)	2004	2024	
TN0011	Franklin	TN	—	—	3,056	5,484	—	3,056	5,484	8,540	(293)	8,247	—	(293)	2014	2024	
624	Hendersonville	TN	—	—	1,566	15,230	1,581	266	3,112	3,673	(1,497)	2,176	—	(1,497)	1985	2006	
559	Herritage	TN	—	—	830	5,036	13,203	837	18,232	19,069	(7,630)	11,439	—	(7,630)	1999/2019	2003	
561	Herritage	TN	—	—	596	9,698	4,657	596	14,155	14,751	(7,773)	6,978	—	(7,773)	1993	2003	
562	Herritage	TN	—	—	317	6,328	2,936	317	9,464	9,781	(4,965)	4,816	—	(4,965)	1994	2003	
TN0002	Jackson	TN	—	—	1,124	5,631	1,247	513	5,631	6,755	(358)	6,397	—	(358)	1991	2024	
TN0001	Kingsport	TN	—	—	2,778	10,365	57	2,835	10,365	10,365	(1,783)	8,582	—	(1,783)	2004	2024	
TN0012	Kingsport	TN	—	—	511	59,215	—	511	59,215	59,726	(1,990)	57,736	—	(1,990)	2010	2024	
625	Nashville	TN	—	—	955	14,289	9,058	955	23,247	24,302	(10,821)	12,481	—	(10,821)	2000	2006	
626	Nashville	TN	—	—	2,050	5,211	5,984	2,050	11,195	13,245	(4,320)	8,925	—	(4,320)	1987	2006	
627	Nashville	TN	—	—	1,007	181	986	—	1,113	1,014	(660)	354	—	(660)	1975	2006	
628	Nashville	TN	—	—	2,980	7,164	3,670	2,980	10,810	13,814	(4,561)	9,253	—	(4,561)	1998	2006	
630	Nashville	TN	—	—	515	848	351	649	1,065	1,714	(596)	1,118	—	(596)	1975	2006	
631	Nashville	TN	—	—	266	1,305	1,171	266	2,476	2,742	(1,266)	1,476	—	(1,266)	1980	2006	
632	Nashville	TN	—	—	747	7,642	3,165	827	11,207	12,034	(5,708)	6,326	—	(5,708)	1987	2006	
633	Nashville	TN	—	—	5,425	12,577	5,876	5,425	18,453	23,878	(9,429)	14,449	—	(9,429)	2001	2006	
634	Nashville	TN	—	—	3,818	15,185	12,001	3,818	27,186	31,004	(10,703)	20,301	—	(10,703)	1992	2006	
636	Nashville	TN	—	—	583	450	424	604	853	1,457	(449)	1,008	—	(449)	1974	2006	
2967	Nashville	TN	—	—	—	—	53,773	—	53,773	53,773	(7,540)	46,233	—	(7,540)	2021	2019	
2720	Nashville	TN	—	—	102	10,925	789	102	11,674	11,776	(4,415)	7,361	—	(4,415)	1986	2021	
TN0005	Nashville	TN	—	—	16,857	17,681	(230)	16,857	17,451	34,308	(946)	33,362	—	(946)	2015	2024	
TN0008	Spring Hill	TN	—	—	628	13,821	628	—	13,821	14,449	(653)	13,796	—	(653)	2012	2024	
2611	Allen	TX	—	—	1,330	5,960	1,232	1,374	7,418	8,522	(2,021)	6,501	—	(2,021)	2014	2016	
2612	Allen	TX	—	—	1,310	4,165	1,683	1,310	5,848	7,158	(1,899)	5,259	—	(1,899)	2005	2016	
571	Arlington	TX	—	—	769	19,355	29,901	769	39,256	39,975	(10,455)	28,520	—	(10,455)	1995/2023	2006	
TX0025	Austin	TX	—	—	22,885	16,662	1,065	22,902	17,710	40,612	(1,037)	37,575	—	(1,037)	2006	2018	
TX0016	Bedford	TX	—	—	4,706	6,106	627	4,706	6,733	7,339	(239)	6,100	—	(239)	2014	2024	
TX0026	Bryan	TX	—	—	105	7,013	153	105	7,166	7,271	(344)	6,927	—	(344)	1996	2024	
TX0027	Bryan	TX	—	—	197	4,080	—	197	4,080	4,277	(223)	4,058	—	(223)	1997	2024	
TX0012	Carrollton	TX	—	—	1,723	857	—	1,723	857	2,580	(847)	1,733	—	(847)	2011	2024	
TX0023	Carrollton	TX	—	—	3,461	5,211	208	3,461	5,419	8,880	(477)	8,403	—	(477)	2003	2024	
2621	Cedar Park	TX	—	—	3,417	11,640	945	3,417	12,585	14,280	(2,570)	11,710	—	(2,570)	2007	2017	
576	Conroe	TX	—	—	324	4,842	5,020	324	9,862	10,186	(4,575)	5,611	—	(4,575)	1983	2024	
577	Conroe	TX	—	—	397	7,666	2,973	397	10,939	11,336	(3,542)	7,794	—	(3,542)	1995	2006	
579	Conroe	TX	—	—	988	7,975	2,576	988	10,551	10,939	(4,616)	5,923	—	(4,616)	1996/2012	2006	
581	Corpus Christi	TX	—	—	188	3,618	1,226	188	4,844	5,032	(2,633)	2,400	—	(2,633)	1995	2006	
601	Corpus Christi	TX	—	—	810	4,429	4,429	717	12,610	17,042	(5,782)	11,260	—	(5,782)	1995	2006	
600	Corpus Christi	TX	—	—	328	3,210	2,456	334	5,660	5,994	(3,040)	2,954	—	(3,040)	1995	2006	
—	—	—	—	—	313	1,771	1,458	325	3,217	3,542	(1,318)	2,224	—	(1,318)	1985	2006	

				Encumbrances at December 31, 2024	Initial Cost to Company		Costs Subsequent to Acquisition		Gross Amount at Which Carried As of December 31, 2024				Accumulated Depreciation	Year Constructed	Year Acquired		
					Land and Improvements	Buildings and Improvements	Land and Improvements	Buildings and Improvements	Total								
2839	Cypress	TX	—	—	—	37,654	—	37,654	37,654	37,654	—	113,848	—	2016	2015		
582	Dallas	TX	—	—	1,464	6,785	3,781	1,793	10,437	12,230	(3,154)	7,076	—	1979	2006		
1814	Dallas	TX	—	—	15,230	294,802	24,630	207,682	184,052	207,682	(94,144)	187,617	—	1977	2007		
1115	Dallas	TX	—	—	—	—	4,485	17	4,485	4,485	—	13,431	—	1978	2007		
1316	Dallas	TX	—	—	—	10,361	—	10,361	10,361	10,361	—	18,070	—	1987	2007		
1117	Dallas	TX	—	—	—	—	12,298	267	12,401	12,298	—	12,042	—	1995	2007		
3119	Dallas	TX	—	—	18,840	155,659	7,152	18,840	160,969	181,809	(81,644)	174,707	—	1974	2007		
2721	Dallas	TX	—	—	31,707	2,000	—	698	2,498	3,445	—	1,998	—	2011	2024		
TX0028	Dallas	TX	—	—	488	189,390	1,310	—	182,949	190,390	(6,737)	183,653	—	2011	2024		
2707	Denton	TX	5,673	—	9,560	1,338	111	9,560	11,911	13,737	—	1,760	—	2021	2024		
TX0033	Denton	TX	—	—	1,524	11,381	—	1,524	11,381	12,905	—	(434)	—	2019	2024		
TX0001	El Paso	TX	—	—	724	21,029	779	725	23,801	23,028	(92)	1987	2014	—	—		
TX0002	El Paso	TX	—	—	1,429	5,104	877	564	6,811	6,811	—	(294)	—	2024	—	—	
TX0009	El Paso	TX	—	—	2,156	10,909	889	2,156	11,111	13,327	(157)	1983	2014	—	—		
TX0010	El Paso	TX	—	—	913	2,014	918	89	3,054	3,054	—	(158)	—	2011	2024	—	
TX0022	Flower Mound	TX	—	—	910	3,696	95	910	3,791	4,701	—	(157)	—	2011	2024	—	
TX0024	Flower Mound	TX	—	—	1,429	12,643	362	1,512	12,222	13,834	(652)	2011	2024	—	—		
8045	Houston	TX	—	—	902	2,428	192	902	3,423	3,815	—	(114)	—	2014	2014	—	
TX023	Fort Worth	TX	—	—	888	4,866	4,763	898	9,629	10,527	(464)	1995	2006	—	—		
8002	Fort Worth	TX	—	—	2,441	4,416	435	2,441	3,897	4,522	—	(2,650)	—	2019	2024	—	
806	Fort Worth	TX	—	—	—	6,070	1,775	51	7,794	7,845	—	(1,676)	—	1985	2005	—	
2019	Fort Worth	TX	—	—	1,180	13,432	2,000	1,180	15,432	16,612	(2,509)	2006	2017	—	—		
2020	Fort Worth	TX	—	—	—	14,555	2,000	—	15,555	17,515	—	(2,721)	—	2017	2021	—	
2082	Fort Worth	TX	—	—	2,720	6,225	6,335	3,719	12,561	15,280	(4,245)	2020	2019	—	—		
3020	Frisco	TX	—	—	27,201	133	—	—	27,852	27,852	—	(5,841)	—	2004	2019	—	
3021	Frisco	TX	—	—	—	26,181	2,272	—	28,453	28,453	—	(3,485)	—	2004	2021	—	
TX0023	FL. Worth	TX	—	—	866	24,845	63	—	25,408	25,774	(351)	2006	2019	—	—		
1061	Gresham	TX	—	—	1,286	1,286	—	819	819	819	—	(1,017)	—	2006	2019	—	
430	Houston	TX	—	—	1,827	33,140	22,722	286	55,401	57,789	(33,744)	1985	2018	2018	1999	—	
446	Houston	TX	—	—	2,200	11,122	9,236	—	22,087	22,087	—	(1,993)	—	1999	2013	—	
589	Houston	TX	—	—	1,476	12,602	16,193	1,476	28,795	30,471	(8,990)	1985	2022	2006	—	—	
702	Houston	TX	—	—	—	7,414	2,716	—	10,130	10,130	—	(1,006)	—	2006	2006	—	—
1044	Houston	TX	—	—	—	4,838	7,769	1,321	11,667	12,986	—	(4,271)	—	2007	2019	—	—
2542	Houston	TX	—	—	304	17,764	(004)	—	17,764	17,764	—	(4,822)	—	1990	2015	—	—
2543	Houston	TX	—	—	116	6,555	(116)	—	6,555	6,555	—	(2,767)	—	1990	2015	—	—
2544	Houston	TX	—	—	312	12,094	(312)	—	12,094	12,094	—	(3,830)	—	1987	2015	—	—
2545	Houston	TX	—	—	316	13,931	(316)	—	13,947	13,947	—	(3,309)	—	2005	2015	—	—
2546	Houston	TX	—	—	408	18,132	—	20,132	20,132	20,132	—	(9,778)	—	1977	2015	—	—
2547	Houston	TX	—	—	470	18,197	429	—	19,096	19,096	—	(5,762)	—	1985	2015	—	—
2548	Houston	TX	—	—	313	7,036	(313)	—	7,217	7,217	—	(2,674)	—	1985	2015	—	—
2549	Houston	TX	—	—	530	22,717	—	148	22,899	23,389	—	(5,798)	—	2006	2015	—	—
2966	Houston	TX	—	—	828	5,160	40,944	828	40,944	40,944	—	(5,143)	—	2022	2020	—	—
590	Irving	TX	—	—	—	5,620	11,780	—	17,400	17,400	—	(1,988)	—	1998	2008	—	—
700	Irving	TX	—	—	—	8,550	2,965	8	11,507	11,515	—	(2,999)	—	2004	2006	—	—
1207	Irving	TX	—	—	3,719	4,707	—	27,423	28,455	28,455	—	(7,447)	—	2004	2006	—	—
TX0013	Katy	TX	—	—	2,567	3,105	276	2,567	3,381	5,948	—	(256)	—	2005	2024	—	—
TX0014	Katy	TX	—	—	2,533	21,149	—	248	21,147	23,570	—	(1,158)	—	2006	2024	—	—
244	League	TX	—	—	3,035	28,373	1,422	1,919	30,807	30,807	—	(2,816)	—	2016	2024	—	—
901	Lewisville	TX	—	—	361	8,043	1,447	361	9,490	10,051	—	(4,784)	—	1976	2006	—	—
144	Lewisville	TX	—	—	102	7,998	102	898	8,986	8,986	—	(6,023)	—	1988	2006	—	—
143	Lufkin	TX	—	—	338	2,388	239	338	2,602	2,940	—	(1,722)	—	1993	1992	—	—
TX0019	Lufkin	TX	—	—	80	6,314	217	80	6,551	6,811	—	(1,188)	—	1999	2014	—	—
TX0020	Lufkin	TX	—	—	100	7,994	160	814	8,986	9,800	—	(4,866)	—	2004	2006	—	—
TX0021	Lufkin	TX	—	—	155	2,668	—	155	2,668	2,668	—	(1,702)	—	1999	2004	—	—
TX0008	Marshall	TX	—	—	3,475	11,425	111	3,475	7,811	12,286	—	(2,239)	—	2004	2024	—	—
568	McKinney	TX	—	—	541	6,217	3,292	541	9,509	10,050	—	(1,574)	—	1999	2003	—	—
569	McKinney	TX	—	—	—	636	8,330	—	8,966	8,966	—	(4,914)	—	2004	2003	—	—
3116	Midland	TX	—	—	—	23,125	—	23,125	23,125	23,125	—	(3,023)	—	2004	2003	—	—
TX0029	Midland	TX	—	—	2,933	12,903	—	2,933	12,903	13,836	—	(6,663)	—	2003	2024	—	—
596	North Richland Hills	TX	—	—	812	8,883	4,631	812	14,326	14,326	—	(1,808)	—	2014	2014	—	—
TX0030	Pasadena	TX	—	—	1,520	8,648	—	1,520	8,648	10,168	—	(1,888)	—	2018	2024	—	—
2835	Pearland	TX	—	—	—	4,014	5,853	41	9,826	9,826	—	(3,409)	—	2006	2006	—	—
2838	Pearland	TX	—	—	—	18,054	—	18,054	18,054	18,054	—	(5,887)	—	2014	2014	—	—
597	Piano	TX	—	—	1,220	9,588	7,510	1,220	17,163	18,308	—	(7,007)	—	1997	2006	—	—
672	Piano	TX	—	—	1,389	4,751	1,389	1,389	6,067	6,067	—	(1,844)	—	1997	2006	—	—
1384	Piano	TX	—	—	626	22,686	8,430	626	31,068	31,068	—	(26,707)	—	1997	2007	—	—
2653	Rockwall	TX	—	—	788	9,020	(069)	536	8,905	9,439	—	(1,761)	—	2015	2017	—	—
TX0031	Rockwall	TX	—	—	906	15,815	606	735	16,796	16,796	—	(7,124)	—	2014	2014	—	—
8515	San Antonio	TX	—	—	—	9,193	3,637	75	12,903	12,830	—	(1,700)	—	1997	2006	—	—
2837	San Antonio	TX	1,180	—	—	21,022	599	26	21,715	21,715	—	(7,048)	—	1992	2006	—	—
TX0005	San Antonio	TX	—	—	—	26,191	4,413	—	30,604	30,604	—	(13,873)	—	2006	2011	—	—
TX0006	San Antonio	TX	—	—	4,100	20,829	101	4,100	20,930	25,030	—	(9,663)	—	2017	2016	—	—
2852	Shenandoah	TX	—	—	—	2,796	42	—	2,838	3,525	—	(1,961)	—	2024	2024	—	—
TX0017	Spring	TX	—	—	—	29,802	—	29,802	29,802	29,802	—	(9,601)	—	2017	2016	—	—
598	Sugar Land	TX	—	—	1,078	5,158	4,447	1,112	10,631	13,460	—	(1,866)	—	2015	2014	—	—

	City	State	Encumbrances at December 31, 2024	Initial Cost to Company		Costs Capitalized Subsequent Acquisition		Gross Amount at Which Sold			Total*	Accumulated Depreciation	Year Constructed*	Year Acquired
				Land and Improvements ⁽¹⁾	Buildings and Improvements ⁽²⁾	Land and Improvements	Buildings and Improvements							
599	Texas City	TX	—	9,519	2,067	—	—	11,586	11,586	—	(5,526)	2007	2006	
2550	The Woodlands	TX	—	115	5,141	(115)	—	5,141	5,141	(1,395)	1984	2015	1984	
2551	The Woodlands	TX	—	296	18,282	(296)	—	18,282	18,282	(4,342)	1993	2005	1993	
2552	The Woodlands	TX	—	374	25,125	(374)	—	25,125	25,125	(5,304)	1984	2014	1984	
TX0018	The Woodlands	TX	—	715	13,972	—	—	13,972	14,687	(724)	2001	2024	2001	
152	Victoria	TX	—	125	8,977	535	125	9,512	9,637	(6,120)	1994	1994	1992	
2188	Webster	TX	—	2,220	9,802	142	2,220	12,744	11,964	(4,328)	1991	2013	1991	
3024	Webster	TX	—	3,196	12,911	325	3,121	13,220	16,432	(1,393)	2007	2022	2007	
3025	Webster	TX	—	3,209	23,782	141	3,225	27,132	27,132	(4,487)	2007	2022	2007	
TX3249	Webster	TX	—	2,265	—	—	—	2,265	—	—	—	2002	2024	2002
3215	Wylie	TX	—	874	4,122	11	874	4,133	5,007	(421)	2005	2007	2005	
1592	Bountiful	UT	—	999	7,426	2,807	1,019	10,213	11,232	(4,260)	1999	2005	1999	
169	Bountiful	UT	—	276	5,237	5,377	599	10,890	10,890	(4,934)	1994	1994	1994	
2039	Draper	UT	—	3,748	10,203	—	—	11,670	11,670	(4,810)	2012	2012	2012	
469	Kaysville	UT	—	530	4,493	550	530	5,043	5,573	(2,373)	2001	2001	2001	
456	Layton	UT	—	371	7,073	2,910	401	9,953	10,354	(5,596)	1998	2001	1998	
2042	Layton	UT	—	10,975	44,915	1,794	44	12,725	12,769	(1,541)	2006	2012	2006	
357	Orem	UT	—	337	8,744	1,042	306	9,817	10,123	(6,590)	1998	1999	1998	
351	Salt Lake City	UT	—	180	779	280	273	976	1,249	(693)	1999	1999	1999	
354	Salt Lake City	UT	—	220	10,732	4,567	309	15,210	15,519	(9,481)	1999	1999	1999	
355	Salt Lake City	UT	—	1492	14,792	5,604	180	20,396	20,576	(12,561)	1993	1999	1993	
467	Salt Lake City	UT	—	3,000	7,941	2,158	1,598	9,480	12,499	(5,395)	1999	2001	1999	
566	Salt Lake City	UT	—	509	4,044	3,828	509	7,872	8,381	(4,071)	1974	2003	1974	
2041	Salt Lake City	UT	—	12,426	1,000	1,009	12,325	13,335	13,335	(8,813)	2007	2012	2007	
2033	Sandy	UT	—	867	3,513	2,920	1,356	5,844	7,300	(3,667)	1989	2012	1989	
2864	Washington Terrace	UT	—	—	20,163	—	—	20,163	20,163	(4,116)	2020	2019	2020	
351	Washington Terrace	UT	—	—	4,573	3,091	17	7,647	7,664	(3,862)	1989	1989	1989	
352	Washington Terrace	UT	—	—	2,692	1,581	15	4,258	4,273	(2,042)	1990	1999	1990	
2034	West Jordan	UT	—	—	12,022	(1,777)	—	11,844	11,844	(2,262)	2006	2012	2006	
2036	West Jordan	UT	—	1,383	1,378	—	—	2,761	2,761	(1,677)	1982	2012	1982	
1208	Fairfax	VA	—	8,396	16,710	11,995	8,742	28,359	37,301	(16,235)	1974/2018	2006	2006	
2230	Fredericksburg	VA	—	1,101	8,370	156	1,113	8,714	9,877	(2,554)	2008	2014	2008	
VA0001	Fredericksburg	VA	—	2,674	14,182	2,448	3,043	16,261	19,304	(789)	2006	2006	2006	
VA0002	Hampton	VA	—	4,865	11,976	1,876	4,865	11,876	16,041	(713)	2007	2007	2007	
3001	Leesburg	VA	—	10,252	3,549	24,059	5,717	35,491	29,776	(33,325)	2010	2021	2010	
3015	Midlothian	VA	—	12,734	—	21,442	22	59	21,405	(2,288)	2012	2021	2012	
3016	Midlothian	VA	—	12,038	—	20,811	(147)	20	20,831	(1,156)	2013	2021	2013	
3017	Midlothian	VA	—	13,928	—	22,531	(1,031)	—	21,500	(2,539)	2014	2021	2014	
572	Reston	VA	—	—	11,862	(860)	—	11,042	11,042	(5,962)	2004	2004	2004	
WA0009	Federal Way	WA	—	397	6,502	368	397	6,870	7,267	(357)	2007	2024	2007	
WA0006	Gig Harbor	WA	—	87	1,938	—	—	1,938	2,025	(118)	1991	2004	1991	
WA0002	Kirkwood	WA	—	3,611	25,463	—	3,611	25,463	29,074	(1,458)	2015	2014	2015	
WA0001	Lakeview	WA	—	3,967	5,588	21	3,967	5,609	9,576	(1,661)	2001	2024	2001	
WA0010	Lakeview	WA	—	400	3,465	90	400	3,755	4,155	(1,086)	1999	2014	1999	
448	Renton	WA	—	—	18,724	4,630	—	23,354	23,354	(14,684)	1993	1999	1993	
781	Seattle	WA	—	—	52,703	10,268	—	62,971	62,971	(30,822)	1994	2004	1994	
782	Seattle	WA	—	—	22,382	22,359	125	46,816	46,741	(14,603)	1990/2022	2008	1990	
783	Seattle	WA	—	—	5,625	2,164	69	7,720	7,789	(6,215)	1984	2004	1984	
785	Seattle	WA	—	—	7,239	933	—	8,236	8,236	(2,333)	1982	2004	1982	
1385	Seattle	WA	—	—	45,027	18,577	—	63,604	63,604	(29,496)	1986/2019	2007	1986	
3022	Seattle	WA	—	35,624	4,176	1	35,625	4,176	39,801	(2,741)	1963/2012	2021	1963	
WA0003	Tacoma	WA	—	1,900	240	383	—	2,383	2,352	(1,892)	1977	2004	1977	
WA0004	Tacoma	WA	—	479	6,955	237	479	7,192	7,671	(1,462)	1991	2024	1991	
WA0005	Tacoma	WA	—	440	6,718	429	440	7,107	7,147	(1,381)	1989	2014	1989	
WD006	Appleton	WI	—	1,892	13,696	80	1,892	13,776	15,668	(587)	2015	2024	2015	
WD007	Ashland	WI	—	2,477	15,188	—	2,477	15,188	17,665	(862)	2005	2004	2005	
WD005	Brookfield	WI	—	1,183	3,391	46	1,183	3,437	4,620	(1,511)	2016	2024	2016	
WD004	Milwaukee	WI	—	3,052	13,111	612	3,052	16,173	16,775	(5,413)	1896/2003	2004	1896	
WD002	Shawano	WI	—	347	1,571	—	347	1,571	1,918	(96)	2010	2024	2010	
WD001	West Allis	WI	—	980	888	—	980	397	1,377	(63)	2002	2024	2002	
2038	Evanson	WY	—	4,401	—	1,204	—	5,605	5,605	(2,202)	2002	2012	2002	
				\$ 250,503	\$ 860,676	\$ 6,577,057	\$ 1,629,467	\$ 877,185	\$ 8,190,005	\$ 9,067,194	\$ (2,005,342)			

Lab	City	State	Encumbrances at December 31, 2024	Initial Cost to Company		Costs Capitalized to Subsequent Acquisition		Gross Amount at Which Sold			Accumulated Depreciation	Year Constructed*	Year Acquired
				Land and Improvements ⁽¹⁾	Buildings and Improvements ⁽²⁾	Capitalized Subsequent Acquisition ⁽³⁾	Land and Improvements	Buildings and Improvements	Total ⁽⁴⁾				
1483	Bridgman	CA	\$	—	\$ 8,498	\$ 500	\$ 83,876	\$ 8,498	\$ 84,376	\$ 92,874	\$ (5,494)	2022	2007
1484	Bridgman	CA	—	—	11,331	159,859	—	11,331	160,344	171,655	(15,892)	2022	2007
1485	Bridgman	CA	—	—	11,331	600	154,111	11,331	154,711	166,042	(17,187)	2022	2007
1486	Bridgman	CA	—	—	11,331	129,416	—	11,331	129,416	146,147	(26,636)	2007	2007
1487	Bridgman	CA	—	—	8,498	—	76,411	8,498	76,411	84,909	(9,682)	2020	2007
2874	Bridgman	CA	—	—	26,895	62,218	76,313	26,295	199,231	165,326	(16,804)	1989	2019
2875	Bridgman	CA	—	—	24,092	56,623	11,039	24,092	71,744	150,300	(17,187)	2022	2007
3139	Bridgman	CA	—	—	35,805	—	7,726	35,805	7,726	43,531	(—)	—	2019
3140	Bridgman	CA	—	—	35,805	4,312	35,805	4,312	43,127	113,117	(15,892)	2022	2007
3142	Bridgman	CA	—	—	—	—	3,768	—	3,768	7,688	(471)	—	2007
3143	Hayward	CA	—	—	908	7,100	12,066	1,118	8,086	19,310	(20,006)	1989	2007
3144	Hayward	CA	—	—	1,500	6,400	6,837	1,323	10,767	13,737	(1,865)	1999	2007
1403	Hayward	CA	—	—	1,000	7,100	7,873	1,900	14,973	16,873	(6,858)	1998	2007
1404	Hayward	CA	—	—	2,200	9,000	8,007	2,200	10,407	11,507	(4,007)	1999	2007
1405	Hayward	CA	—	—	1,000	3,200	646	1,000	3,846	4,846	(1,000)	1999	2007
1406	Hayward	CA	—	—	1,000	4,000	4,000	1,000	5,000	6,494	(1,000)	1999	2007
1407	Hayward	CA	—	—	677	2,761	774	677	3,335	4,212	(2,174)	1996	2007
1551	Hayward	CA	—	—	661	1,995	2,960	661	4,595	5,556	(2,111)	1996	2007
1512	Hayward	CA	—	—	1,182	7,187	1,775	1,182	11,051	16,051	(6,051)	1996	2007
1555	Hayward	CA	—	—	1,189	9,465	1,045	1,189	10,101	13,699	(7,258)	1996	2007
1244	Hayward	CA	—	—	1,244	5,179	3,197	1,244	9,997	17,603	(9,997)	1996	2007
1555	Hayward	CA	—	—	1,189	15,144	7,516	1,521	20,162	22,581	(15,597)	1996	2007
1425	Hayward	CA	—	—	1,212	3,516	4,728	1,212	5,848	6,716	(3,516)	1996	2007
1424	La Jolla	CA	—	—	11,715	25,283	44,524	11,889	69,593	80,982	(20,050)	1982	2007
1425	La Jolla	CA	—	—	7,127	10,883	31	7,217	19,944	21,161	(6,895)	1981	2007
1426	La Jolla	CA	—	—	8,881	24,411	20,834	8,881	47,627	47,327	(17,327)	1984	2007
1427	La Jolla	CA	—	—	10,127	16,983	13,272	10,355	30,020	40,382	(13,912)	1982	2007
1428	La Jolla	CA	—	—	2,648	11,048	17,501	2,648	19,330	20,330	(9,330)	1982	2007
2229	La Jolla	CA	—	—	8,733	32,528	16,664	8,733	49,168	57,945	(15,310)	1986/2009	2014
3549	Redwood City	CA	—	—	2,600	1,000	2,602	2,600	8,095	11,552	(3,751)	1989	2007
1500	Redwood City	CA	—	—	2,600	4,100	1,038	2,500	5,138	6,638	(1,678)	1989	2007
1501	Redwood City	CA	—	—	3,500	4,600	1,895	3,600	4,645	10,095	(3,765)	1989	2007
1502	Redwood City	CA	—	—	3,500	3,542	—	3,500	4,000	7,442	(3,500)	1989	2007
1503	Redwood City	CA	—	—	4,000	17,300	8,351	3,800	25,551	30,451	(16,467)	1989	2007
1504	Redwood City	CA	—	—	4,000	15,500	11,098	3,800	24,800	29,998	(12,781)	1989	2007
1505	Redwood City	CA	—	—	3,000	3,500	6,366	3,000	9,866	12,866	(4,028)	1989	2007
1506	Redwood City	CA	—	—	4,000	14,300	14,300	6,000	26,600	34,600	(17,972)	1989	2007
1507	Redwood City	CA	—	—	2,000	10,900	11,683	2,000	14,983	19,983	(5,983)	1989	2007
1508	Redwood City	CA	—	—	2,700	11,300	17,193	2,700	28,493	31,193	(13,068)	1988/2011	2007
2709	Redwood City	CA	—	—	2,700	10,900	14,300	2,700	14,400	16,100	(5,200)	1989	2007
1510	Redwood City	CA	—	—	2,200	12,000	6,243	2,200	18,243	20,443	(8,259)	1989	2007
1512	Redwood City	CA	—	—	2,600	12,400	19,007	2,600	26,797	29,397	(14,437)	1989	2007
1513	Redwood City	CA	—	—	2,603	13,900	17,587	2,603	27,186	24,241	(9,274)	2007	2007
679	San Diego	CA	—	—	5,289	23,566	39,960	5,289	46,139	55,825	(20,624)	1997	2004
680	San Diego	CA	—	—	2,023	3,382	3,622	2,023	4,623	5,965	(2,023)	1982/2002	2007
838	San Diego	CA	—	—	2,040	903	3,354	2,040	4,257	6,297	(2,439)	1988/2012	2006
839	San Diego	CA	—	—	2,040	3,184	2,995	4,036	6,035	10,139	(2,887)	1989	2007
1418	San Diego	CA	—	—	5,660	1,486	4,573	5,830	9,370	12,780	(2,780)	2006	2007
1419	San Diego	CA	—	—	11,700	31,243	9,338	11,700	90,581	102,281	(17,029)	2022	2007
1420	San Diego	CA	—	—	2,324	33,315	2,324	11,700	42,424	49,499	(14,424)	2022	2007
1421	San Diego	CA	—	—	4,200	—	41,225	4,200	90,251	94,455	(3,755)	2022	2007
2461	San Diego	CA	—	—	7,061	33,770	7,061	33,770	76,779	76,779	(7,061)	2007	2007
1422	San Diego	CA	—	—	7,179	3,687	2,081	7,179	17,947	19,947	(7,179)	2007	2007
1423	San Diego	CA	—	—	8,400	33,144	34,038	8,400	67,172	75,572	(24,422)	2003/2020	2020
2547	San Diego	CA	—	—	2,581	40,531	4,481	2,581	44,112	46,611	(2,581)	2022	2007
2548	San Diego	CA	—	—	5,879	25,305	8,311	5,879	38,616	39,495	(14,802)	2021	2011
2549	San Diego	CA	—	—	7,521	3,931	7,500	7,521	17,123	17,124	(7,521)	2022	2011
2476	San Diego	CA	—	—	1,981	9,918	18,298	7,661	28,819	35,877	(4,442)	2000/2002	2006
2477	San Diego	CA	—	—	9,207	14,613	4,804	9,207	14,094	32,301	(6,775)	2001/2011	2016
2478	San Diego	CA	—	—	6,000	—	160,761	6,000	20,761	128,761	(16,000)	1999/2002	2016
2479	San Diego	CA	—	—	3,234	5,195	9,363	2,704	12,558	17,292	(4,166)	1991/2021	2020
2618	San Diego	CA	—	—	4,200	12,390	4,200	11,800	32,300	38,500	(14,400)	2018	2020
2622	San Diego	CA	—	—	—	—	17,201	—	17,201	17,201	(2,093)	2020	2004
2623	San Diego	CA	—	—	10,172	2,444	2,444	10,172	20,324	20,324	(10,172)	1995	2007
2627	San Diego	CA	—	—	6,052	14,122	1,445	6,052	15,567	21,619	(9,241)	1997	2018
3069	San Diego	CA	—	—	7,054	7,794	24,061	6,954	3,975	38,929	(16,467)	2007/2011	2021
3111	San Diego	CA	—	—	19,120	9,373	20,587	19,120	9,373	49,493	(19,120)	2021	2021
3113	San Diego	CA	—	—	24,729	—	2,141	24,830	2,040	26,870	(18)	—	2022
1410	South San Francisco	CA	—	—	1,215	11	1,230	11	1,230	11	(—)	—	2022
1411	South San Francisco	CA	—	—	4,900	18,100	12,327	4,900	30,427	45,327	(16,142)	2000/2019	2007
1410	South San Francisco	CA	—	—	8,000	27,700	23,198	8,000	60,896	68,896	(21,778)	2013/2019	2007
1412	South San Francisco	CA	—	—	10,300	32,722	10,500	10,300	44,122	44,122	(14,122)	1998	2007
1413	South San Francisco	CA	—	—	8,000	28,299	8,603	8,000	36,902	44,902	(19,128)	2000	2007
1413	South San Francisco	CA	—	—	10,000	21,620	27,990	10,000	31,580	38,580	(15,580)	1998/2018	2007
1431	South San Francisco	CA	—	—	7,000	15,500	10,711	7,022	26,949	33,211	(12,767)	2007	2007
1435	South San Francisco	CA	—	—	10,000	25,800	25,800	10,000	41,800	41,800	(10,000)	2007	2007
1436	South San Francisco	CA	—	—	14,500	45,300	42,147	14,500	67,447	70,947	(26,760)	2024	2007
1437	South San Francisco	CA	—	—	9,400	24,800	36,750	9,400	41,550	105,950	(24,133)	2008/2010	2017
1439	South San Francisco	CA	—	—	11,900	13,745	11,900	11,900	25,645	25,645	(11,900)	2023	2007

				Initial Cost to Company		Costs Capitalized Subsequent to Acquisition		Gross Amount at Which Carried As of December 31, 2024		Accumulated Depreciation ⁽¹⁾	Year Constructed ⁽²⁾	Year Acquired
City	State	Encumbrances at December 31, 2024		Land and Improvements ⁽³⁾	Buildings and Improvements ⁽⁴⁾	Land and Improvements ⁽³⁾	Buildings and Improvements ⁽⁴⁾	Land and Improvements	Buildings and Improvements			
1440	South San Francisco	CA	—	10,000	57,954	15,024	10,000	72,978	82,978	(24,005)	2003	2007
1441	South San Francisco	CA	—	9,300	43,549	22,639	9,300	65,188	75,488	(18,875)	2003	2007
1442	South San Francisco	CA	—	11,000	47,289	42,668	11,000	49,957	100,957	(26,528)	2023	2007
1443	South San Francisco	CA	—	13,200	60,932	3,283	13,200	64,215	77,415	(26,657)	2007	2007
1444	South San Francisco	CA	—	10,500	33,824	13,824	10,500	47,600	58,100	(14,058)	2024	2007
1445	South San Francisco	CA	—	10,600	34,083	46	10,600	34,129	44,729	(14,848)	2007	2007
1458	South San Francisco	CA	—	10,900	20,900	6,024	10,900	27,824	38,724	(10,864)	2005	2007
1459	South San Francisco	CA	—	9,800	—	157,274	9,800	157,668	167,468	(11,273)	2023	2007
1462	South San Francisco	CA	—	7,117	600	5,280	7,117	5,880	12,997	(1,956)	1984/2012	2007
1463	South San Francisco	CA	—	10,381	2,300	17,197	10,381	19,497	29,478	(8,763)	1970/2012	2007
1464	South San Francisco	CA	—	7,403	700	9,060	7,403	9,760	17,163	(1,302)	1965/2012	2007
1468	South San Francisco	CA	—	10,100	24,613	11,565	10,100	35,578	45,478	(18,168)	2006	2007
1480	South San Francisco	CA	—	32,210	3,110	160,550	32,210	163,660	195,870	(7,004)	2023	2007
1528	South San Francisco	CA	—	—	—	188,739	—	188,739	188,739	(275)	—	2007
1559	South San Francisco	CA	—	5,666	5,773	199	5,666	5,972	13,638	(1,923)	1998	2007
1560	South San Francisco	CA	—	1,204	1,293	2,683	1,204	3,976	5,180	(1,267)	1966	2007
1983	South San Francisco	CA	—	8,448	—	90,582	8,448	90,582	99,230	(13,738)	2016	2015
1984	South San Francisco	CA	—	7,844	—	—	7,844	90,761	98,605	(34,910)	2017	2011
1985	South San Francisco	CA	—	6,708	—	122,716	6,708	122,716	129,424	(43,270)	2017	2011
1986	South San Francisco	CA	—	6,708	—	120,758	6,708	120,758	127,466	(38,078)	2018	2011
1987	South San Francisco	CA	—	8,544	—	100,777	8,544	100,777	109,321	(28,885)	2019	2011
1988	South San Francisco	CA	—	10,120	—	119,625	10,120	119,625	129,745	(35,906)	2019	2011
1989	South San Francisco	CA	—	9,169	—	100,395	9,169	100,395	109,564	(23,508)	2020	2011
2553	South San Francisco	CA	—	2,897	8,691	4,478	2,897	13,169	16,066	(5,172)	1988	2015
2554	South San Francisco	CA	—	995	2,754	3,132	995	5,086	6,081	(1,757)	1988	2015
2555	South San Francisco	CA	—	2,202	10,776	2,527	2,202	13,303	15,505	(3,917)	1988	2015
2556	South San Francisco	CA	—	2,962	15,108	1,557	2,962	16,665	19,627	(1,704)	1988	2015
2557	South San Francisco	CA	—	2,453	13,063	3,842	2,453	16,905	19,358	(6,725)	1988	2015
2558	South San Francisco	CA	—	1,163	5,925	315	1,163	6,240	7,403	(1,626)	1988	2015
2624	South San Francisco	CA	—	25,502	42,510	14,832	25,502	57,762	83,244	(14,353)	2001	2017
2870	South San Francisco	CA	—	23,297	41,797	28,804	23,297	70,568	93,898	(21,151)	1996/2019	2018
2971	South San Francisco	CA	—	20,293	41,262	32,121	20,293	63,343	83,676	(31,377)	1999/2019	2021
3100	South San Francisco	CA	—	14,245	—	15,095	14,245	15,095	29,340	—	—	2021
3101	South San Francisco	CA	—	61,208	—	29,603	61,208	29,603	90,811	—	—	2021
3102	South San Francisco	CA	—	43,885	—	6,358	43,885	6,358	90,244	—	—	2021
3123	South San Francisco	CA	—	—	—	—	—	6,456	6,456	—	—	2007
3154	South San Francisco	CA	—	—	—	—	—	56,590	56,590	(807)	—	2021
2705	Cambridge	MA	—	24,371	128,498	197	24,371	128,695	133,066	(17,582)	2011	2020
2706	Cambridge	MA	—	15,473	148,051	850	15,473	149,901	165,374	(22,324)	2019	2020
2707	Cambridge	MA	—	25,549	229,547	8,097	25,549	238,144	263,817	(31,377)	2019	2020
2708	Cambridge	MA	—	—	17,751	539	—	18,290	18,290	(1,902)	2010	2020
2709	Cambridge	MA	—	—	15,651	79	—	15,490	15,490	(1,578)	2019	2020
2928	Cambridge	MA	—	44,215	24,120	3,154	44,215	27,274	71,489	(5,108)	1984	2019
2929	Cambridge	MA	—	20,516	—	159,436	20,516	159,436	179,952	(15,859)	2022	2019
3074	Cambridge	MA	—	78,762	292,133	14,635	78,762	286,788	345,500	(41,328)	2018	2019
3106	Cambridge	MA	—	20,644	2,982	621	20,644	3,603	24,247	(340)	1950	2021
3107	Cambridge	MA	—	19,609	12,627	1,878	19,609	14,202	33,811	(1,209)	1973	2021
3108	Cambridge	MA	—	123,074	7,513	8	123,074	7,521	130,595	(969)	1965	2021
3109	Cambridge	MA	—	5,903	—	637	5,903	637	6,540	—	—	2023
3112	Cambridge	MA	—	23,402	47,623	1,385	23,402	49,008	72,410	(1,706)	1985	2021
3113	Cambridge	MA	—	32,244	—	8,417	36,119	4,542	40,661	—	—	2021
3114	Cambridge	MA	—	22,969	—	1,179	22,969	(1,179)	21,790	—	—	2021
3115	Cambridge	MA	—	66,786	—	2,536	66,786	2,536	69,322	—	—	2021
3116	Cambridge	MA	—	—	—	17,413	—	17,413	17,413	—	—	2021
3119	Cambridge	MA	—	—	29,667	—	—	29,667	29,667	(2,984)	2021	2021
3120	Cambridge	MA	—	18,063	—	1,417	18,063	1,417	19,480	—	—	2021
3122	Cambridge	MA	—	25,247	—	3,293	25,247	3,293	28,540	—	—	2021
3136	Cambridge	MA	—	4,118	—	(161)	4,119	(162)	3,957	—	—	2021
3137	Cambridge	MA	—	41,327	—	4,680	41,327	4,680	46,007	—	—	2021
3141	Cambridge	MA	—	72,466	9,303	72,768	72,466	9,001	81,769	—	—	2022
3148	Cambridge	MA	—	2,277	—	67	2,290	54	2,344	—	—	2022
3149	Cambridge	MA	—	5,690	—	5,746	5,690	5,690	6,315	—	—	2022
3150	Cambridge	MA	—	1,651	—	360	1,659	352	2,011	—	—	2022
3151	Cambridge	MA	—	8,532	—	904	8,583	853	9,436	—	—	2022
3152	Cambridge	MA	—	9,892	—	1,325	10,507	910	11,417	—	—	2022
MAX394	Cambridge	MA	—	4,441	—	113	4,441	113	4,554	—	—	2024
2620	Lexington	MA	—	16,611	49,682	(2,284)	16,611	50,842	63,809	(12,431)	1999	2017
2631	Lexington	MA	—	7,759	142,081	30,473	6,978	173,335	180,313	(34,532)	2010/2023	2017
2632	Lexington	MA	—	—	21,390	126,772	—	148,162	148,162	(25,261)	2021	2018
3070	Lexington	MA	—	14,013	17,083	(959)	14,013	16,814	30,827	(1,110)	1974/2012	2019
3071	Lexington	MA	—	14,930	16,677	(121)	14,930	16,556	31,486	(2,782)	1970/2012	2019
3072	Lexington	MA	—	24,598	42,022	(280)	24,598	42,744	77,342	(9,256)	1967/2012	2019
3073	Lexington	MA	—	37,050	44,647	144	37,050	44,791	81,841	(9,883)	2017	2019
3093	Waltham	MA	—	47,792	275,556	26,887	47,790	302,445	350,235	(49,524)	2018	2020
9959	Denton	TX	—	100	—	100	—	—	100	—	2016	2016
464	Salt Lake City	UT	—	630	6,921	2,563	630	9,484	10,114	(6,260)	1996	2001
465	Salt Lake City	UT	—	125	6,495	68	125	6,495	6,561	(1,413)	1999	2006
466	Salt Lake City	UT	—	—	14,614	(1,401)	—	13,213	13,213	(5,702)	2002	2001
1593	Salt Lake City	UT	—	23,998	—	250	—	24,248	24,248	(10,516)	2010	2010
				\$ 1,874,225	\$ 3,195,405	\$ 3,742,955	\$ 1,877,791	\$ 6,935,084	\$ 8,811,785	\$ (1,644,460)		

			Initial Cost to Company				Costs Capitalized Subsequent to Acquisition		Gross Amount at Which Carried As of December 31, 2024				Accumulated Depreciation ⁽¹⁾	Year Constructed ⁽²⁾	Year Acquired
City	State	Encumbrances at December 31, 2024		Land and Improvements ⁽³⁾	Buildings and Improvements ⁽⁴⁾		Land and Improvements ⁽³⁾	Buildings and Improvements ⁽⁴⁾		Land and Improvements	Buildings and Improvements	Total ⁽⁵⁾			
Continuing care retirement community															
3089	Birmingham	AL	\$	—	6,193	\$ 32,146	\$ 7,845	\$ 6,670	\$ 39,514	\$ 46,184	\$ (9,716)	1991	2020		
3090	Bradenton	FL	\$	5,216	88,090	29,437	6,037	116,706	122,743	(27,956)	1985	2020			
2997	Channahon	IL	\$	64,402	6,680	132,521	23,978	7,317	155,862	163,179	(27,404)	1991	2020		
3086	Jacksonville	FL	—	19,660	167,860	27,057	21,211	193,366	214,577	(38,594)	1989	2020			
2996	Lensburg	FL	—	5,941	65,698	20,758	9,817	85,360	95,397	(19,236)	1990	2020			
2995	Port Charlotte	FL	—	5,344	159,612	21,429	7,102	179,283	186,385	(30,007)	1987	2020			
2998	Seminole	FL	41,845	14,080	77,485	14,623	15,047	91,341	106,388	(14,930)	1990	2020			
3085	Seminole	FL	—	13,038	116,819	11,766	11,834	127,789	141,623	(28,053)	1982	2020			
3092	San City Center	FL	—	25,254	175,535	25,544	26,918	199,415	226,333	(46,178)	1992	2020			
3087	The Village	FL	—	6,311	123,063	19,819	6,707	132,464	139,191	(26,539)	2008	2020			
3084	Holland	MI	—	1,572	88,960	13,297	2,134	101,695	103,829	(19,395)	1991	2020			
2991	Coatsville	PA	—	12,949	126,243	22,116	13,616	147,692	161,308	(26,697)	1998	2020			
3080	Hooverford	PA	—	16,461	108,616	32,712	16,461	141,028	157,489	(57,476)	1989	2020			
3088	Spring	TX	—	3,210	30,085	13,679	3,544	43,430	46,974	(7,776)	2008	2020			
3091	Fort Belvoir	VA	—	13,594	99,928	22,394	11,594	123,927	133,516	(55,893)	1990	2006			
			\$	106,247	\$ 356,503	\$ 1,857,459	\$ 396,154	\$ 468,009	\$ 1,877,107	\$ 2,846,136	\$ (433,448)				
Total real estate assets held for sale			—	—	(20,341)	(20,344)	13,844	(14,141)	(6,520)	(10,663)	2,921				
Total, excluding held for sale			\$	356,750	\$ 2,887,257	\$ 1,134,757	\$ 5,692,420	\$ 2,918,758	\$ 16,995,678	\$ 19,914,434	\$ (4,063,630)				

(2) In January 2025, the Company received full repayment of the outstanding balance of this secured loan (see Note 8 to the Consolidated Financial Statements for additional information).
(3) This loan includes an option to extend the maturity date to May 5, 2028.
(4) A portion of interest is due monthly with remaining interest added to the outstanding principal balance.
(5) Includes various construction loans each related to one property in Arizona and Texas. In January 2025, the Company received full repayment of the \$15 million outstanding balance of a construction loan in Texas (see Note 8 to the Consolidated Financial Statements for additional information).
(6) In January 2025, the maturity date of this loan was extended to July 12, 2025.
(7) Includes various first mortgages each related to one property in Arizona, Florida, Georgia, Texas, and Wisconsin.
(8) This loan includes an option to extend the maturity date to December 20, 2029.
(9) Includes both (i) loans that are interest only or (ii) loans in which a portion of interest is due monthly with remaining interest added to the outstanding principal balance.

	Year Ended December 31,		
	2024	2023	2022
Reconciliation of mortgage loans			
Balance at beginning of year	\$ 175,717	\$ 341,749	\$ 390,291
Additions:			
New mortgage loans	486,667	—	—
Draws and additions to existing mortgage loans	30,745	11,602	5,525
Total additions	517,412	11,602	5,525
Deductions:			
Principal repayments	(77,643)	(183,084)	(47,591)
Recoveries (reserves) for loan losses ⁽¹⁾	(2,702)	5,450	(6,476)
Total deductions	(80,345)	(177,634)	(54,067)
Balance at end of year	\$ 612,784	\$ 175,717	\$ 341,749

⁽¹⁾Excludes reserves and recoveries for expected loan losses associated with unfunded loan commitments which are included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets.

XML 56 R37.htm IDEA: XBRL DOCUMENT

Pay vs Performance	12 Months Ended		
Disclosure - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands			

Pay vs Performance Disclosure

Net Income (Loss)	\$ 243,142	\$ 306,009	\$ 500,449

XML 57 R38.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024

Trading Arrangements, by Individual

Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 58 R39.htm IDEA: XBRL DOCUMENT

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024

Insider Trading Policies and Procedures [Line Items]

Insider Trading Policies and Procedures Adopted	true

XML 59 R40.htm IDEA: XBRL DOCUMENT

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

Cybersecurity Risk Management and Strategy
In our business operations, we use information technology, enterprise applications, communications tools, cloud network solutions, and related systems to manage our operations, including to manage our building systems, tenant and vendor relationships, accounting and recordkeeping, and communications, among other aspects of our business.

We have developed and implemented a cybersecurity risk management program intended to protect our properties, confidential and proprietary data, and information technology and systems, from cybersecurity threats, including unauthorized access or attack. We leverage the National Institute of Standards and Technology ("NIST") Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to the business. This does not imply that we meet any particular technical standards, specifications, or requirements.

Our processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting risks, reputational risks, personal data theft, fraud, and other potential risks, are integrated into our overall enterprise risk management process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management process to other legal, compliance, strategic, operational, and financial risk areas.

Our cybersecurity risk management program includes the following:

- a multidisciplinary team comprised of personnel from information technology ("IT"), internal audit, accounting, and legal, as well as third-party cybersecurity experts principally responsible for directing (i) our cybersecurity risk assessment processes, (ii) our security processes, and (iii) our response to cybersecurity incidents;
- risk assessments designed to help identify material cybersecurity risks to our critical systems, information, services, and our broader enterprise IT environment;
- internal and third-party security tools to monitor our systems, identify cybersecurity risks, and test our IT environment;
- the use of third-party cybersecurity experts, where appropriate, to assess, test or otherwise assist with aspects of our security processes;
- a cybersecurity incident response plan, business continuity plan, and established policies governing cybersecurity risk management at the corporate and property levels;
- cybersecurity training for employees and key business partners with access to our systems;
- a third-party cybersecurity risk management process for service providers and vendors who access our systems;
- requiring employees, as well as third parties who have access to our systems, to treat confidential and private information and data with care, including performing controls relating to such data; and
- cybersecurity risk insurance.

We also seek to engage reputable service providers that maintain cybersecurity programs or controls.

We have not identified risks from known cybersecurity threats within the prior fiscal year, including as a result of any prior cybersecurity incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Please refer to "Item 1A, Risk Factors" in this report for additional information about certain ongoing risks related to our information technology that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.

Cybersecurity Risk Management Processes Integrated [Flag]	true

Cybersecurity Risk Management Third Party Engaged [Flag]

Cybersecurity Risk Management Third Party Engaged [Flag]	true

Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]

Our processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting risks, reputational risks, personal data theft, fraud, and other potential risks, are integrated into our overall enterprise risk management process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management process to other legal, compliance, strategic, operational, and financial risk areas.

	true

Cybersecurity Risk Materiality Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Board of Directors Oversight [Text Block]	false
	Cybersecurity is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.
	The Board, in coordination with the Audit Committee, oversees the Company's enterprise risk management process, including the management of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management's processes to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes. The Audit Committee periodically provides updates on these matters to the Board of Directors.
	The Board, in coordination with the Audit Committee, oversees the Company's enterprise risk management process, including the management of material risks arising from cybersecurity threats.
	The Board, in coordination with the Audit Committee, oversees the Company's enterprise risk management process, including the management of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management's processes to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes. The Audit Committee periodically provides updates on these matters to the Board of Directors.
Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Process for Informing Board of Directors Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block]	Cybersecurity is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.
	The Board, in coordination with the Audit Committee, oversees the Company's enterprise risk management process, including the management of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management's processes to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes. The Audit Committee periodically provides updates on these matters to the Board of Directors.
	Our enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including an independent third-party expert we have retained to functionally serve as a virtual chief information security officer ("CISO"), to identify and assess material risks from cybersecurity threats, their severity, and potential mitigation steps. The CISO is primarily responsible for leading our cybersecurity risk assessment and management processes. This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief information security officer of a cybersecurity firm focused on commercial real estate. He is supported by an internal cross-functional management team of IT and internal audit personnel who regularly review and assess cybersecurity initiatives, including our incident response plan, as well as cybersecurity compliance, training and risk management efforts.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	true
	Cybersecurity is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.
	The Board, in coordination with the Audit Committee, oversees the Company's enterprise risk management process, including the management of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management's processes to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes. The Audit Committee periodically provides updates on these matters to the Board of Directors.
	Our enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including an independent third-party expert we have retained to functionally serve as a virtual chief information security officer ("CISO"), to identify and assess material risks from cybersecurity threats, their severity, and potential mitigation steps. The CISO is primarily responsible for leading our cybersecurity risk assessment and management processes. This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief information security officer of a cybersecurity firm focused on commercial real estate. He is supported by an internal cross-functional management team of IT and internal audit personnel who regularly review and assess cybersecurity initiatives, including our incident response plan, as well as cybersecurity compliance, training and risk management efforts.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	The CISO is primarily responsible for leading our cybersecurity risk assessment and management processes. This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief information security officer of a cybersecurity firm focused on commercial real estate.
	Our enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including an independent third-party expert we have retained to functionally serve as a virtual chief information security officer ("CISO"), to identify and assess material risks from cybersecurity threats, their severity, and potential mitigation steps. The CISO is primarily responsible for leading our cybersecurity risk assessment and management processes. This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief information security officer of a cybersecurity firm focused on commercial real estate. He is supported by an internal cross-functional management team of IT and internal audit personnel who regularly review and assess cybersecurity initiatives, including our incident response plan, as well as cybersecurity compliance, training and risk management efforts.
	true

XML 60 R41.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies) Accounting Policies [Abstract] Use of Estimates	12 Months Ended Dec. 31, 2024
Use of Estimates	
Management is required to make estimates and assumptions in the preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP"). These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management's estimates.	
Basis of Presentation	
The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly owned subsidiaries, joint ventures ("JVs"), and variable interest entities ("VIEs") that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation.	
The Company is required to continually evaluate its VIE relationships and consolidate these entities when it is determined to be the primary beneficiary of their operations. A VIE is broadly defined as an entity where either: (i) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support, (ii) substantially all of an entity's activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights, or (iii) the equity investors as a group lack any of the following: (a) the power through voting or similar rights to direct the activities of an entity that most significantly impact the entity's economic performance, (b) the obligation to absorb the expected losses of an entity, or (c) the right to receive the expected residual returns of an entity. Criterion (iii) above is generally applied to limited partnerships and similarly structured entities by assessing whether a simple majority of the limited partners hold substantive rights to participate in the significant decisions of the entity or have the ability to remove the decision maker or liquidate the entity without cause. If neither of those criteria are met, the entity is a VIE.	
The designation of an entity as a VIE is reassessed upon certain events, including, but not limited to: (i) a change to the contractual arrangements of the entity or in the ability of a party to exercise its participation or kick-out rights, (ii) a change to the capitalization structure of the entity, or (iii) acquisitions or sales of interests that constitute a change in control.	
A variable interest holder is considered to be the primary beneficiary of a VIE if it has the power to direct the activities of a VIE that most significantly impact the entity's economic performance and has the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE. The Company qualitatively assesses whether it is (or is not) the primary beneficiary of a VIE. Consideration of various factors include, but is not limited to, which activities most significantly impact the entity's economic performance and the ability to direct those activities, its form of ownership interest, its representation on the VIE's governing body, the size and seniority of its investment, its ability and the rights of other investors to participate in policy making decisions, its ability to manage its ownership interest relative to the other interest holders, and its ability to replace the VIE manager and/or liquidate the entity.	
For its investments in joint ventures that are not considered to be VIEs, the Company evaluates the type of ownership rights held by the limited partner(s) that may preclude consolidation by the majority interest holder. The assessment of limited partners' rights and their impact on the control of a joint venture should be made at inception of the joint venture and continually reassessed.	
Revenue Recognition	
<i>Lease Classification</i>	
The Company classifies a lease as an operating lease if none of the following criteria are met: (i) transfer of ownership to the lessee by the end of the lease term, (ii) lessee has a purchase option during or at the end of the lease term that it is reasonably certain to exercise, (iii) the lease term is for the major part of the remaining economic life of the underlying asset, (iv) the present value of future minimum lease payments is equal to substantially all of the fair value of the underlying asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.	
<i>Rental and Related Revenues</i>	
The Company recognizes rental revenue from its outpatient medical and lab buildings in accordance with Accounting Standards Codification ("ASC") 842, <i>Leases</i> ("ASC 842"). The Company commences recognition of rental revenue for operating lease arrangements when the tenant has taken possession or controls the physical use of a leased asset. The tenant is not considered to have taken physical possession or have control of the leased asset until the Company-owned tenant improvements are substantially complete. If a lease arrangement provides for tenant improvements, the Company determines whether the tenant improvements are owned by the tenant or the Company. When the Company is the owner of the tenant improvements, any tenant improvements funded by the tenant are treated as lease payments which are deferred and amortized into income over the lease term. When the tenant is the owner of the tenant improvements, any tenant improvement allowance that is funded by the Company is treated as a lease incentive and amortized as a reduction of revenue over the lease term.	
Ownership of tenant improvements is determined based on various factors including, but not limited to, the following criteria:	
• lease stipulations of how and on what a tenant improvement allowance may be spent; • which party to the arrangement retains legal title to the tenant improvements upon lease expiration; • whether the tenant improvements are unique to the tenant or general purpose in nature; • if the tenant improvements are expected to have significant residual value at the end of the lease term; • the responsible party for construction cost overruns; and • which party constructs or directs the construction of the improvements.	
Certain leases provide for additional rents that are contingent upon a percentage of the building's revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant or estimates of tenant results, exceed the base amount or other thresholds, and only after any contingency has been removed (when the related thresholds are achieved). This may result in the recognition of rental revenue in periods subsequent to when such payments are received.	
Tenant recoveries subject to operating leases generally relate to the reimbursement of real estate taxes, insurance, and repair and maintenance expense, and are recognized as both revenue (in rental and	

related revenues) and expense (in operating expenses) in the period the expense is incurred as the Company is the party paying the service provider. Rental and related revenues from other variable payments are recognized when the associated contingencies are removed. In accordance with ASC 842, the Company accounts for lease and nonlease components as a single lease component for the purpose of revenue recognition and disclosure.

For operating leases with minimum scheduled rent increases, the Company recognizes income on a straight-line basis over the lease term when collectibility of future minimum lease payments is probable. Recognizing rental income on a straight-line basis results in a difference in the timing of revenue amounts from what is contractually due from tenants. If the Company determines that collectibility of future minimum lease payments is not probable, the accounts receivable and straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period and future revenue recognition is limited to amounts contractually owed and paid. The Company does not resume recognition of income on a straight-line basis unless it determines that collectibility of future payments related to these leases is probable. For the Company's portfolio of operating leases that are deemed probable of collection but exhibit a certain level of collectibility risk, the Company may also recognize an incremental allowance as a reduction to revenue. At December 31, 2024 and 2023, straight-line rent receivable, net of allowance, was \$338 million and \$310 million, respectively. Straight-line rent receivable is included in other assets, net in the Consolidated Balance Sheets.

The Company's operating leases generally contain options to extend lease terms at prevailing market rates at the time of expiration. Certain operating leases contain early termination options that require advance notice and payment of a penalty, which in most cases is substantial enough to be deemed economically disadvantageous by a tenant to exercise.

Resident Fees and Services

The Company recognizes resident fee and service revenue from its Senior Housing Operating Property ("SHOP") portfolios and CCRC properties in accordance with ASC 606, *Revenue from Contracts with Customers*. Resident fee revenue is recorded when services are rendered and includes resident room and care charges, community fees, and other resident charges. Residency agreements for SHOP and CCRC facilities are generally for a term of 30 days to one year, with resident fees billed monthly, in advance. Revenue for certain care related services is recognized as services are provided and is billed monthly in arrears.

The Company's CCRCs are operated as entrance fee communities, which typically require a resident to pay an upfront entrance fee that includes both a refundable portion and non-refundable portion. When the Company receives a non-refundable entrance fee, it is recorded in deferred revenue in the Consolidated Balance Sheets and amortized into revenue over the estimated stay of the resident. The Company utilizes third-party actuarial experts in its determination of the estimated stay of residents.

Income from Direct Financing Leases

The Company utilizes the direct finance method of accounting to record direct financing lease ("DFL") income. For a lease accounted for as a DFL, the net investment in the DFL represents receivables for the sum of future minimum lease payments and the estimated residual value of the leased property, less the unamortized unearned income. Unearned income is deferred and amortized to income over the lease term to provide a constant yield when collectibility of the lease payments is reasonably assured. During the first quarter of 2022, the Company sold its remaining hospital under a DFL.

Interest Income

Loans receivable are classified as held-for-investment based on management's intent and ability to hold the loans for the foreseeable future or to maturity. Loans held-for-investment are carried at amortized cost and reduced by a valuation allowance for estimated credit losses, as necessary. When collectibility of the future payments is reasonably assured, the Company utilizes the interest method on a loan-by-loan basis to recognize interest income on its loans, which includes the amortization of discounts and premiums as well as loan fees paid and received.

Management Fee Income

The Company provides various services to certain of its unconsolidated joint ventures in exchange for fees and reimbursement. These services are considered related party transactions under ASC 850, *Related Party Disclosures*. Management fee income is recognized in interest income and other on the Consolidated Statements of Operations.

Gain (Loss) on Sales of Real Estate, Net

The Company recognizes a gain (loss) on sale of real estate when the criteria for an asset to be derecognized are met, which include when: (i) a contract exists, (ii) the buyer obtains control of the asset, and (iii) it is probable that the Company will receive substantially all of the consideration to which it is entitled. These criteria are generally satisfied at the time of sale.

[Government Grant Income](#)

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") to provide financial aid to individuals, businesses, and state and local governments. During the years ended December 31, 2023 and 2022, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenues during the coronavirus pandemic. Grant income is recognized to the extent that qualifying expenses and lost revenues exceed grants received and the Company will comply with all conditions attached to the grant. As of December 31, 2024, the amount of qualifying expenditures and lost revenues exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture.

Credit Losses

The Company evaluates the liquidity and creditworthiness of its occupants, operators, and borrowers on a monthly and quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company's evaluation considers payment history and current credit status, industry conditions, current economic conditions, forecasted economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends. The determination of loan losses also considers concentration of credit risk associated with the senior housing and outpatient medical industries to which its loans receivable relate. The Company's occupants, operators, and borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the lease or debt service coverages in its assessment of internal ratings that it uses as a primary credit quality indicator. Lease and debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rate, reimbursement trends, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures. The Company evaluates, on a monthly basis or immediately upon a significant change in circumstance, its occupants', operators', and borrowers' ability to service their obligations with the Company.

In connection with the Company's quarterly review process or upon the occurrence of a significant event, loans receivable and DFLs (collectively, "finance receivables"), are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Finance receivables that are deemed Performing meet all present contractual obligations, and collection and timing, of all amounts owed is reasonably assured. Watch List finance receivables are defined as finance receivables that do not meet the definition of Performing or Workout. Workout finance receivables are defined as finance receivables in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the tenant, operator, or borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.

Finance receivables are placed on nonaccrual status when management determines that the collectibility of contractual amounts is not reasonably assured (the asset will have an internal rating of either Watch List or Workout). Further, the Company performs a credit analysis to support the tenant's, operator's, borrower's, and/or guarantor's repayment capacity and the underlying collateral values. The Company uses the cash basis method of accounting for finance receivables placed on nonaccrual status unless one of the following conditions exist whereby it utilizes the cost recovery method of accounting if: (i) the Company determines that it is probable that it will only recover the recorded investment in the finance receivable, net of associated allowances or charge-offs (if any), or (ii) the Company cannot reasonably estimate the amount of an impaired finance receivable. For cash basis method of accounting, the Company applies payments received, excluding principal paydowns, to interest income so long as that amount does not exceed the amount that would have been earned under the original contractual terms. For cost recovery method of accounting, any payment received is applied to reduce the recorded investment. Generally, the Company returns a finance receivable to accrual status when all delinquent payments become current under the terms of the loan or lease agreements and collectibility of the remaining contractual loan or lease payments is reasonably assured.

At inception of a finance receivable, the Company recognizes an allowance for credit losses expected to be incurred over the life of the instrument. The model utilized by the Company to determine such losses emphasizes historical experience and future market expectations to determine a loss to be recognized at inception. However, the model is applied on an individual basis and relies on counter-party specific information to ensure the most accurate estimate is recognized. The Company also performs a quarterly review process (or upon the occurrence of a significant event) to evaluate its borrowers' creditworthiness and liquidity to determine the amount of credit losses to recognize during the period. If a finance receivable is deemed partially or wholly uncollectible, the uncollectible balance is deducted from the allowance in the period in which such determination is made. Credit loss expenses and recoveries are recorded in impairments and loan loss reserves (recoveries), net.

[Real Estate](#)

Real Estate

The Company's real estate acquisitions are generally classified as asset acquisitions for which the Company records identifiable assets acquired, liabilities assumed, and any associated noncontrolling interests at cost on a relative fair value basis. In addition, for such asset acquisitions, no goodwill is recognized, third party transaction costs are capitalized and any associated contingent consideration is generally recorded when the amount of consideration is reasonably estimable and probable of being paid.

The Company assesses fair value based on available market information, such as capitalization and discount rates, comparable sale transactions, and relevant per square foot or unit cost information. A real estate asset's fair value may be determined utilizing cash flow projections that incorporate such market information. Estimates of future cash flows are based on a number of factors including historical operating results, known and anticipated trends, as well as market and economic conditions. The fair value of tangible assets of an acquired property is based on the value of the property as if it is vacant.

The Company recognizes acquired "above and below market" leases at their relative fair value (for asset acquisitions) using discount rates which reflect the risks associated with the leases acquired. The fair value is based on the present value of the difference between (i) the contractual amounts paid pursuant to each in-place lease and (ii) management's estimate of fair market lease rates for each in-place lease, measured over a period equal to the remaining term of the lease for above market leases and the initial term plus the extended term for any leases with renewal options that are reasonably certain to be exercised. Other intangible assets acquired include amounts for in-place lease values that are based on an evaluation of the specific characteristics of each property and the acquired tenant lease(s). Factors considered include estimates of carrying costs during hypothetical expected lease-up periods, market conditions, and costs to execute similar leases. In estimating carrying costs, the Company includes estimates of lost rents at market rates during the hypothetical expected lease-up periods, which are dependent on local market conditions and expected trends. In estimating costs to execute similar leases, the Company considers leasing commissions, legal, and other related costs.

Certain of the Company's acquisitions involve the assumption of contract liabilities. The Company typically estimates the fair value of contract liabilities by applying a reasonable profit margin to the total discounted estimated future costs associated with servicing the contract. A variety of market and contract-specific conditions are considered when making assumptions that impact the estimated fair value of the contract liability.

The Company capitalizes direct construction and development costs, including predevelopment costs, interest, property taxes, insurance, and other costs directly related and essential to the development or construction of a real estate asset. The Company capitalizes construction and development costs while substantive activities are ongoing to prepare an asset for its intended use. During the holding or development period, certain real estate assets generate incidental income that is not associated with the future profit or return from the intended use of the property. Such income is recognized as a reduction of the associated project costs. The Company considers a construction project as substantially complete and held available for occupancy upon the completion of Company-owned tenant improvements, but no later than one year from cessation of significant construction activity. Costs incurred after a project is substantially complete and ready for its intended use, or after development activities have ceased, are expensed as incurred. For redevelopment of existing operating properties, the Company capitalizes the cost for the construction and improvement incurred in connection with the redevelopment.

Costs previously capitalized related to abandoned developments/redevelopments are charged to earnings. Expenditures for repairs and maintenance are expensed as incurred. The Company considers costs incurred in conjunction with re-leasing properties, including tenant improvements and lease commissions, to represent the acquisition of productive assets and such costs are reflected as investing activities in the Company's Consolidated Statements of Cash Flows.

Initial direct costs incurred in connection with successful property leasing are capitalized as deferred leasing costs and classified as investing activities in the Consolidated Statements of Cash Flows. Initial direct costs include only those costs that are incremental to the arrangement and would not have been incurred if the lease had not been obtained. Initial direct costs consist of leasing commissions paid to employees and external third party brokers and lease incentives. Initial direct costs are included in other assets, net in the Consolidated Balance Sheets. At December 31, 2024 and 2023, the balance of net initial direct costs were \$204 million and \$172 million, respectively. Initial direct costs are amortized in depreciation and amortization in the Consolidated Statements of Operations using the straight-line method over the lease term.

The Company computes depreciation on properties using the straight-line method over the assets' estimated useful lives. These useful lives are reassessed following changes in the remaining period that the asset is expected to be held and used, and depreciation is discontinued when a property meets the criteria to be classified as held for sale. Buildings and improvements are depreciated over useful lives ranging up to 50 years. Above and below market lease intangibles are amortized to revenue over the remaining noncancellable lease terms and renewal periods that are reasonably certain to be exercised, if any. In-place lease intangibles are amortized to expense over the remaining noncancellable lease term and renewal periods that are reasonably certain to be exercised, if any.

[Business Combinations](#)

Business Combinations

For the Company's real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The fair values are determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant.

[Other Assets, Net](#)

Other Assets, Net

Other assets, net consist primarily of straight-line rent receivable (as discussed above), initial direct costs (as discussed above), deferred income taxes (see Note 17), goodwill (see Note 10), corporate assets (see Note 7), derivative assets (see Note 22), other equity investments (as discussed below and see Note 19), and prepaid expenses.

Other Equity Investments

The Company has certain investments recognized in accordance with ASC 321, *Investments-Equity Securities*, within other assets, net on the Consolidated Balance Sheets. These investments do not have readily determinable fair values and the practical expedient to estimate fair value using net asset value per share has not been elected. Accordingly, the investments are measured at cost, less any impairments, and are adjusted for any observable price changes, with such changes included in earnings.

An observable price results from an orderly transaction for an identical or similar investment of the same issuer, which is observed by an investor without expending undue cost and effort. Observable price changes may result from equity transactions of the same issuer, including subsequent equity offerings. To determine whether transactions are indicative of an observable price change, the Company evaluates, among other factors, whether the transactions have similar rights and obligations, which include voting rights, distribution rights and preferences, and conversion features.

[Lessee Accounting](#)

Lessee Accounting

For leases greater than 12 months for which the Company is the lessee, such as ground leases and corporate office leases, the Company recognizes a right-of-use asset and related lease liability on the Consolidated Balance Sheets at inception of the lease. The lease liability is calculated as the sum of: (i) the present value of minimum lease payments at lease commencement (discounted using the Company's secured incremental borrowing rate) and (ii) the present value of amounts probable of being paid under any residual value guarantees. Certain of the Company's lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if they are considered reasonably certain of exercise. The right-of-use asset is calculated as the lease liability, adjusted for the following: (i) any lease payments made to the lessor at or before the commencement date, minus any lease incentives received and (ii) any initial direct costs incurred by the Company. Lease expense related to corporate assets is included in general and administrative expenses and lease expense related to ground leases is included within operating expenses in the Company's Consolidated Statements of Operations.

For leases with a noncancellable lease term of 12 months or less for which the Company is the lessee, the Company recognizes expenses on a straight-line basis and does not recognize such leases on the Consolidated Balance Sheets.

[Impairment of Long-Lived Assets and Goodwill](#)

Impairment of Long-Lived Assets and Goodwill
The Company assesses the carrying value of real estate assets and related intangibles ("real estate assets") when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company tests its real estate assets for impairment by comparing the sum of the expected future undiscounted cash flows to the carrying value of the real estate assets. The expected future undiscounted cash flows reflect external market factors and the expected use and eventual disposition of the asset, and based on the specific facts and circumstances, may be probability-weighted to reflect multiple possible cash-flow scenarios, including selling the assets at various points in the future. Further, the analysis considers the impact, if any, of master lease agreements on cash flows, which are calculated utilizing the lowest level of identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. If the carrying value exceeds the expected future undiscounted cash flows, an impairment loss will be recognized to the extent that the carrying value of the real estate assets exceeds their fair value.

Determining the fair value of real estate assets, including assets classified as held-for-sale, involves significant judgment and generally utilizes market capitalization rates, comparable market transactions, estimated per unit or per square foot prices, negotiations with prospective buyers, and forecasted cash flows (primarily lease revenue rates, expense rates, and growth rates).

When testing goodwill for impairment, if the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company recognizes an impairment loss for the amount by which the carrying value, including goodwill, exceeds the reporting unit's fair value.

[Assets Held for Sale and Discontinued Operations](#)

Assets Held for Sale and Discontinued Operations

The Company classifies a real estate property as held for sale when: (i) management has approved the disposal, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposal plan will significantly change or be withdrawn. If a real estate property is classified as held for sale, it is reported at the lower of its carrying value or fair value less costs to sell and no longer depreciated.

The Company classifies a loan receivable as held for sale when management no longer has the intent and ability to hold the loan receivable for the foreseeable future or until maturity. If a loan receivable is classified as held for sale, it is reported at the lower of amortized cost or fair value.

A discontinued operation represents: (i) a component of the Company or group of components that has been disposed of or is classified as held for sale in a single transaction and represents a strategic shift that has or will have a major effect on the Company's operations and financial results or (ii) an acquired business that is classified as held for sale on the date of acquisition. Examples of a strategic shift may include disposing of: (i) a separate major line of business, (ii) a separate major geographic area of operations, or (iii) other major parts of the Company.

Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 5 for further information.

[Investments in Unconsolidated Joint Ventures](#)

Investments in Unconsolidated Joint Ventures

Investments in entities the Company does not consolidate, but over which the Company has the ability to exercise significant influence over operating and financial policies, are reported under the equity method of accounting. Under the equity method of accounting, the Company's share of the investee's earnings or losses is included in equity income (loss) from unconsolidated joint ventures within the Company's Consolidated Statements of Operations.

The initial carrying value of investments in unconsolidated joint ventures is based on the amount paid to purchase the joint venture interest, the fair value of assets contributed to the joint venture, or the fair value of the assets prior to the sale of interests in the joint venture. To the extent that the Company's cost basis is different from the basis reflected at the joint venture level, the basis difference is generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company's share of equity in earnings of the joint venture. If an equity method investment shows indicators of impairment, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the equity method investment to its carrying value. When the Company determines a decline in fair value below carrying value of an investment in an unconsolidated joint venture is other-than-temporary, an impairment is recorded. The Company recognizes gains on the sale of interests in joint ventures to the extent the economic substance of the transaction is a sale.

The Company's fair values of its equity method investments are determined based on discounted cash flow models that include all estimated cash inflows and outflows over a specified holding period and, where applicable, any estimated debt premiums or discounts. Capitalization rates, discount rates, and credit spreads utilized in these valuation models are based on assumptions that the Company believes to be within a reasonable range of current market rates for the respective investments.

Stock-Based Compensation

Compensation expense for share-based awards granted to employees with graded vesting schedules is generally recognized on a straight-line basis over the vesting period. Forfeitures of share-based awards are recognized as they occur.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash on hand and short-term investments with original maturities of three months or less when purchased. Restricted cash primarily consists of amounts held by mortgage lenders to provide for: (i) real estate tax expenditures, (ii) tenant improvements, and (iii) capital expenditures, as well as security deposits and net proceeds from property sales that were executed as tax-deferred dispositions.

The Company maintains its cash and cash equivalents at financial institutions insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000 per institution. As the account balances at each institution periodically exceed the FDIC insurance coverage, there is a concentration of credit risk related to amounts in excess of such coverage.

Derivatives and Hedging

During its normal course of business, the Company uses certain types of derivative instruments for the purpose of managing interest rate risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company's related assertions.

The Company recognizes all derivative instruments, including embedded derivatives that are required to be bifurcated, as assets or liabilities to the Consolidated Balance Sheets at fair value. Changes in fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in other income (expense), net. For derivative instruments designated in qualifying cash flow hedging relationships, changes in fair value related to the effective portion of the derivative instruments are recognized in accumulated other comprehensive income (loss), whereas changes in fair value related to the ineffective portion would be recognized in earnings.

If it is determined that a derivative instrument ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, the Company discontinues its cash flow hedge accounting prospectively and records the appropriate adjustment to earnings based on the current fair value of the derivative instrument.

[Income Taxes](#)

Income Taxes

Healthpeak Properties, Inc. has elected REIT status and believes it has always operated so as to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, as amended (the "Code"). Accordingly, Healthpeak Properties, Inc. will generally not be subject to U.S. federal income tax, provided that it continues to qualify as a REIT and makes distributions to stockholders equal to or in excess of its taxable income. In addition, the Company has formed several consolidated subsidiaries that have elected REIT status. Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are each subject to the REIT qualification requirements under the Code. If any REIT fails to qualify as a REIT in any taxable year, it will be subject to federal income taxes at regular corporate rates and may be ineligible to qualify as a REIT for four subsequent tax years.

Healthpeak Properties, Inc. and its consolidated REIT subsidiaries are subject to state and local income taxes in some jurisdictions. In certain circumstances each REIT may also be subject to federal excise taxes on undistributed income. In addition, certain activities that the Company undertakes may be conducted by entities that have elected to be treated as taxable REIT subsidiaries ("TRSs"). TRSs are subject to federal, state, and local income taxes. The Company recognizes tax penalties relating to unrecognized tax benefits as additional income tax expense. Interest relating to unrecognized tax benefits is recognized as interest expense.

The Company is required to evaluate its deferred tax assets for realizability and recognize a valuation allowance, which is recorded against its deferred tax assets, if it is more likely than not that the deferred tax assets will not be realized. The Company considers all available evidence in its determination of whether a valuation allowance for deferred tax assets is required.

[Advertising Cost](#)

Advertising Costs

All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations.

[Capital Raising Issuance Costs](#)

Capital Raising Issuance Costs

Costs incurred in connection with the issuance of common shares are recorded as a reduction of additional paid-in capital. Debt issuance costs related to debt instruments, excluding line of credit arrangements and commercial paper, are deferred, recorded as a reduction of the related debt liability, and amortized to interest expense over the remaining term of the related debt liability utilizing the effective interest method. Debt issuance costs related to line of credit arrangements and commercial paper are deferred, included in other assets, and amortized to interest expense on a straight-line basis over the remaining term of the related line of credit arrangement. Commercial paper are unsecured short-term debt securities with varying maturities. A line of credit serves as a liquidity backstop for repayment of commercial paper borrowings.

Penalties incurred to extinguish debt and any remaining unamortized debt issuance costs, discounts, and premiums are recognized as income or expense in the Consolidated Statements of Operations at the time of extinguishment.

[Segment Reporting](#)

Segment Reporting

The Company's reportable segments, based on how it evaluates its business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC.

[Noncontrolling Interests](#)

Noncontrolling Interests

Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Net income (loss) attributable to a noncontrolling interest is included in net income (loss) on the Consolidated Statements of Operations and, upon a gain or loss of control, the interest purchased or sold, and any interest retained, is recorded at fair value with any gain or loss recognized in earnings. The Company accounts for purchases or sales of equity interests that do not result in a change in control as equity transactions.

Redeemable Noncontrolling Interests

Certain of the Company's noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time. Each put option is payable in cash and subject to increases in redemption value in the event that the underlying property generates specified returns and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period.

Healthpeak OP

Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP. Subsequent to the Reorganization, certain employees of the Company ("OP Unitholders") were issued noncontrolling, non-managing member units in Healthpeak OP ("OP Units"). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company's common stock, at the Company's option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company's common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash.

DownREITs

The Company consolidates non-managing member limited liability companies ("DownREITs") because it exercises control, and the noncontrolling interests in these entities are carried at cost. The non-managing member limited liability company ("LLC") units ("DownREIT units") are exchangeable for an amount of cash approximating the then-current market value of shares of the Company's common stock or, at the Company's option, shares of the Company's common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company's common stock, the carrying amount of the DownREIT units is reclassified to stockholders' equity.

[Fair Value Measurement](#)

Fair Value Measurement

The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market

assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:

- Level 1—quoted prices for identical instruments in active markets;
- Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
- Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities that are required to be measured at fair value. When available, the Company utilizes quoted market prices to determine fair value and classifies such items in Level 1. In instances where a market price is available, but the instrument is in an inactive or over-the-counter market, the Company consistently applies the dealer (market maker) pricing estimate and classifies the asset or liability in Level 2.

If quoted market prices or inputs are not available, fair value measurements are based on valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads, and/or market capitalization rates. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, the asset or liability could be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques used by the Company include discounted cash flow models. The Company also considers its counterparty's and own credit risk for derivative instruments and other liabilities measured at fair value. The Company has elected the mid-market pricing expedient when determining fair value.

Earnings per Share

Recent Accounting Pronouncements

Earnings per Share
Basic earnings per common share is computed by dividing net income (loss) applicable to common shares by the weighted average number of shares of common stock outstanding during the period. The Company accounts for unvested share-based payment awards that contain non-forfeitable dividend rights or dividend equivalents (whether paid or unpaid) as participating securities, which are included in the computation of earnings per share pursuant to the two-class method. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units.

Recent Accounting Pronouncements

Adopted
Segment Reporting. In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* ("ASU 2023-07"), to improve reportable segment disclosure requirements so that investors can better understand an entity's overall performance and assess potential future cash flows. The amendments in ASU 2023-07 include, but are not limited to: (i) disclosure of, on an annual basis, significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) disclosure of, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition (the other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss); (iii) disclosure of, on an interim basis, all currently required annual disclosures about a reportable segment's profit (loss) and assets; (iv) clarification that if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources, an entity may report one or more of those additional measures of segment profit; and (v) disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. During the year ended December 31, 2024, the amendments in ASU 2023-07 were adopted retrospectively and did not have an impact on the Company's consolidated financial position, results of operations, or cash flows.

Not Yet Adopted
Income Taxes. In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* ("ASU 2023-09"), to provide disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation (using both percentages and reporting currency amounts) of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is evaluating the impact ASU 2023-09 will have on its disclosures.

Expense Disaggregation. In November 2024, the FASB issued ASU No. 2024-03, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses* ("ASU 2024-03"), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date*, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact these ASUs will have on its disclosures.

XML 61 R42.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

Accounting Policies [Abstract] Schedule of Government Grant Receivables Cares Act

	Year Ended December 31,		
	2024	2023	2022
Government grant income recorded in other income (expense), net	\$ —	\$ 184	\$ 6,765
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	—	229	878
Government grant income recorded in income (loss) from discontinued operations	—	—	217
Total government grants received	\$ —	\$ 413	\$ 7,860

XML 62 R43.htm IDEA: XBRL DOCUMENT

The Merger (Tables)

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Schedule of Consideration Transferred

		12 Months Ended
		Dec. 31, 2024
The consideration transferred on the Closing Date is as follows (in thousands, except per share data):		
		March 1, 2024
Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged ⁽¹⁾		240,699
Exchange Ratio		0.674
Shares of Healthpeak common stock issued		162,231
Closing price of Healthpeak common stock on March 1, 2024 ⁽²⁾	\$	17.10
Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs	\$	2,774,147
Less: Fair value of share consideration attributable to the post-combination period ⁽³⁾		(16,223)
Physicians Realty Trust revolving credit facility termination ⁽⁴⁾	\$	175,411
Settlement of Physicians Realty Trust's transaction costs		23,913
Payments made in connection with share settlement ⁽⁵⁾		11,315
Cash consideration	\$	210,639
Consideration transferred	\$	2,968,563
⁽¹⁾ Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit ("PSUs") (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units ("RSUs").		
⁽²⁾ The fair value of Healthpeak common stock issued to former holders of Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs was based on the per share closing price of Healthpeak common stock on March 1, 2024.		
⁽³⁾ Represents the fair value of unvested Physicians Realty Trust restricted shares, PSUs, and RSUs attributable to post-combination services that were converted into Healthpeak common stock on the Closing Date in accordance with the Merger Agreement. Although no future service after the Closing Date is required, the value attributable to post-combination services reflected the incremental fair value provided to the Physicians Realty Trust equity award holders and the accelerated vesting of such awards at the Closing Date in accordance with the Merger Agreement. This amount was recognized as transaction and merger-related costs on the Consolidated Statements of Operations.		
⁽⁴⁾ Represents the Company's cash repayment of all outstanding balances under Physicians Realty Trust's revolving credit facility on the Closing Date in connection with the related termination.		
⁽⁵⁾ Includes cash settlement of: (i) tax liability related to holdback elections made under the pre-existing terms and conditions of Physicians Realty Trust's equity programs and (ii) fractional share consideration.		
The following table summarizes the estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests at the Closing Date (in thousands):		

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

	Preliminary Amounts Recognized on the Closing Date	Measurement Period Adjustments	Amounts Recognized on the Closing Date (As Adjusted)
ASSETS			
Real estate:			
Buildings and improvements	\$ 3,199,884	\$ (6,889)	\$ 3,192,995
Development costs and construction in progress	68,171	—	68,171
Land and improvements	435,353	—	435,353
Real estate	3,703,408	(6,889)	3,696,519
Loans receivable	118,908	—	118,908
Investments in and advances to unconsolidated joint ventures	58,636	—	58,636
Accounts receivable, net ⁽¹⁾	9,536	(254)	9,282
Cash and cash equivalents	30,417	—	30,417
Restricted cash	1,007	—	1,007
Intangible assets ⁽²⁾	890,827	—	890,827
Right-of-use asset	191,415	(113)	191,302
Other assets	44,691	(668)	44,023
Total assets	\$ 5,048,845	\$ (7,924)	\$ 5,040,921
LIABILITIES AND EQUITY			
Term loans	\$ 402,320	\$ —	\$ 402,320
Senior unsecured notes	1,139,760	—	1,139,760
Mortgage debt	127,176	—	127,176
Intangible liabilities ⁽³⁾	149,875	—	149,875
Lease liability	97,160	(113)	97,047
Accounts payable, accrued liabilities, and other liabilities	72,864	(2,976)	69,888
Total liabilities	\$ 1,989,155	\$ (3,089)	\$ 1,986,066
Redeemable noncontrolling interests	1,536	1,573	3,109
Joint venture partners ⁽⁴⁾	20,109	(3,043)	17,066
Non-managing member unitholders ⁽⁵⁾	116,618	—	116,618
Total noncontrolling interests	\$ 136,727	\$ (3,043)	\$ 133,684
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests	\$ 2,921,427	\$ (3,365)	\$ 2,918,062
Goodwill	47,136	3,365	50,501
Total purchase price	\$ 2,968,563	\$ —	\$ 2,968,563

(1) Includes \$14 million of gross contractual accounts receivable.
(2) The intangible assets acquired had a weighted average amortization period of 6 years (see Note 10).
(3) The intangible liabilities acquired had a weighted average amortization period of 9 years (see Note 10).
(4) Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7% to 99.7% on the Closing Date.
(5) In connection with the Merger, Physicians Partnership merged with and into DOC DR OP Sub with DOC DR OP Sub surviving as the Partnership Surviving Entity. The Company controls the Partnership Surviving Entity via its ownership of its managing member, and the Partnership Surviving Entity is consolidated by the Company.

[Schedule of Proforma Financial Information](#)

The following unaudited pro forma financial information is not necessarily indicative of the results of operations had the acquisition been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the unaudited pro forma financial information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.

	Year Ended December 31,	
	2024	2023
Total revenues	\$ 2,765,670	\$ 2,771,468
Net income (loss) applicable to common shares	353,347	24,630

XML 63 R44.htm IDEA: XBRL DOCUMENT

Real Estate
Investments (Tables)
[Real Estate \[Abstract\]](#)
[Schedule of Capital Improvements](#)

12 Months Ended
Dec. 31, 2024

The following table summarizes the Company's expenditures for construction, tenant improvements, and other capital improvements for its consolidated property investments, excluding expenditures related to properties classified as discontinued operations (in thousands):

	Year Ended December 31,		
Segment	2024	2023	2022
Outpatient medical	\$ 356,273	\$ 236,135	\$ 237,761
Lab	313,749	428,961	658,542
CCRC	66,741	109,465	65,691
	<u>\$ 736,763</u>	<u>\$ 774,561</u>	<u>\$ 961,994</u>

XML 64 R45.htm IDEA: XBRL DOCUMENT

Dispositions of Real
Estate and
Discontinued
Operations (Tables)

[Discontinued Operations and Disposal Groups \[Abstract\]](#)
[Summary of Dispositions of Real Estate and Discontinued Operations](#)

12 Months Ended
Dec. 31, 2024

The results of discontinued operations during the years ended December 31, 2024, 2023, and 2022 are presented below (in thousands) and are included in the consolidated results of operations for the years ended December 31, 2024, 2023, and 2022:

	Year Ended December 31,		
	2024	2023	2022
Revenues:			
Resident fees and services	\$ —	\$ —	\$ 7,489
Total revenues	—	—	7,489
Costs and expenses:			
Operating	—	—	6,452
Total costs and expenses	—	—	6,452
Other income (expense):			
Gain (loss) on sales of real estate, net	—	—	1,344
Other income (expense), net	—	—	169
Total other income (expense), net	—	—	1,513
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—	—	2,550
Income tax benefit (expense)	—	—	270
Equity income (loss) from unconsolidated joint ventures	—	—	64
Income (loss) from discontinued operations	\$ —	\$ —	\$ 2,884

XML 65 R46.htm IDEA: XBRL DOCUMENT

Leases (Tables)

[Leases \[Abstract\]](#)
[Schedule of Company's Lease Income, Excluding Discontinued Operation](#)

The following table summarizes the Company's lease income (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Fixed income from operating leases	\$ 1,530,493	\$ 1,236,502	\$ 1,182,463
Variable income from operating leases	556,703	395,303	359,312
Interest income from direct financing leases	—	—	1,168

[Schedule of Future Minimum Lease Payments Due Under Operating Leases](#)

The following table summarizes future minimum lease payments to be received from tenants under non-cancelable operating leases as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 1,427,402
2026	1,339,275
2027	1,246,068
2028	1,138,062
2029	1,003,394
Thereafter	3,681,731
	<u>\$ 9,835,932</u>

[Schedule of Tenant Purchase Options](#)

Certain leases contain purchase options whereby the tenant may elect to acquire the underlying real estate. Annualized base rent from leases subject to purchase options, summarized by the year the purchase options are exercisable are as follows (dollars in thousands):

Year	Annualized Base Rent ⁽¹⁾	Number of Properties
2025	\$ 16,109	12
2026	19,071	8
2027	8,415	4
2028	16,209	5
2029	6,053	7
Thereafter	22,364	9
	<u>\$ 88,221</u>	<u>45</u>

(1) Represents the most recent month's base rent including additional rent floors annualized for 12 months. Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

[Schedule of Other Lease Information](#)

The following tables provide information regarding the Company's leases to which it is the lessee, such as corporate offices and ground leases, excluding lease costs related to discontinued operations (dollars in thousands):

Lease Expense Information:	Year Ended December 31,		
	2024	2023	2022
Total lease expense	\$ 22,768	\$ 17,010	\$ 16,689

Weighted Average Lease Term and Discount Rate:	December 31,	December 31,
	2024	2023
Weighted average remaining lease term (years):		
Operating leases ⁽¹⁾	48	51
Weighted average discount rate:		
Operating leases	4.79 %	4.23 %

(1) As of December 31, 2024 and 2023, the weighted average remaining lease term including the Company's options to extend its operating leases was 66 years and 67 years, respectively.

[Schedule of Future Minimum Lease Obligations, 842](#)

The following table summarizes future minimum lease payments under non-cancelable ground and other operating leases included in the Company's lease liability as of December 31, 2024 (in thousands):

Year	Amount
2025	\$ 21,514
2026	18,423
2027	18,434
2028	18,489
2029	18,687
Thereafter	738,666
Undiscounted minimum lease payments included in the lease liability	834,213
Less: imputed interest	(526,993)
Present value of lease liability	\$ 307,220

XML 66 R47.htm IDEA: XBRL DOCUMENT

**Loans Receivable
(Tables)**

**12 Months Ended
Dec. 31, 2024**

[Receivables \[Abstract\]](#)

[Schedule of Loans Receivable](#)

The following table summarizes the Company's loans receivable (in thousands):

	December 31,	
	2024	2023
Secured loans ⁽¹⁾⁽²⁾	\$ 638,482	\$ 178,678
CCRC resident loans	61,273	42,733
Mezzanine loans ⁽²⁾	50,314	—
Unamortized discounts and fees ⁽³⁾	(22,380)	(131)
Reserve for loan losses	(10,499)	(2,830)
Loans receivable, net	\$ 717,190	\$ 218,450

(1) At December 31, 2024, the Company had \$85 million of remaining commitments to fund additional loans for outpatient medical capital expenditure projects, of which \$49 million related to loans acquired as part of the Merger. At December 31, 2023, the Company had \$29 million of remaining commitments to fund additional loans for senior housing redevelopment and capital expenditure projects. This \$29 million commitment was reduced to zero in February 2024 in conjunction with the refinance of the Sunrise Senior Housing Portfolio Seller Financing as discussed below.

(2) Includes secured loans and mezzanine loans acquired as part of the Merger (see Note 3).

(3) As of December 31, 2024, includes net unamortized discounts of \$3 million related to the loans receivable acquired as part of the Merger (see Note 3) and an \$18 million unamortized mark-to-market discount related to the Outpatient Medical Seller Financing as discussed below.

[Summary of the Company's Internal Ratings for Loans Receivable on Net of Reserves for Loan Losses](#)

The following table summarizes, by year of origination, the Company's internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of December 31, 2024 (in thousands):

Investment Type	Year of Origination ⁽¹⁾						Total
	2024	2023	2022	2021	2020	Prior	
Secured loans							
Risk rating:							
Performing loans	\$ 433,801	\$ 48,663	\$ 25,232	\$ 105,088	\$ —	\$ —	\$ 612,784
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total secured loans	\$ 433,801	\$ 48,663	\$ 25,232	\$ 105,088	\$ —	\$ —	\$ 612,784
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Mezzanine loans							
Risk rating:							
Performing loans	\$ 13,653	\$ 5,284	\$ 4,446	\$ 6,572	\$ 10,094	\$ 3,084	\$ 43,133
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total mezzanine loans	\$ 13,653	\$ 5,284	\$ 4,446	\$ 6,572	\$ 10,094	\$ 3,084	\$ 43,133
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
CCRC resident loans							
Risk rating:							
Performing loans	\$ 59,321	\$ 1,790	\$ 162	\$ —	\$ —	\$ —	\$ 61,273
Watch list loans	—	—	—	—	—	—	—
Workout loans	—	—	—	—	—	—	—
Total CCRC resident loans	\$ 59,321	\$ 1,790	\$ 162	\$ —	\$ —	\$ —	\$ 61,273
Current period gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Current period recoveries	—	—	—	—	—	—	—
Current period net write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —

(1) Additional fundings under existing loans are included in the year of origination of the initial loan.

[Schedule of Financing Receivable, Allowance for Credit Loss](#)

The following table summarizes the Company's reserve for loan losses (in thousands):

	December 31, 2024			December 31, 2023		
	Secured Loans	Mezzanine Loans and Other ⁽¹⁾	Total	Secured Loans	Mezzanine Loans and Other ⁽¹⁾	Total
Reserve for loan losses, beginning of period	\$ 2,830	\$ —	\$ 2,830	\$ 8,280	\$ —	\$ 8,280
Provision for expected loan losses on funded loans receivable	2,744	4,925	7,669	2,088	—	2,088
Expected loan losses (recoveries) related to loans sold or repaid	—	—	—	(7,538)	—	(7,538)
Reserve for loan losses, end of period	\$ 5,574	\$ 4,925	\$ 10,499	\$ 2,830	\$ —	\$ 2,830

(1) Includes CCRC resident loans.

XML 67 R48.htm IDEA: XBRL DOCUMENT

**Investments in and
Advances to
Unconsolidated Joint
Ventures (Tables)**

**12 Months Ended
Dec. 31, 2024**

[Equity Method Investments and Joint Ventures \[Abstract\]](#)

[Schedule of Company Owned Interests in Entities, Accounted Under Equity Method](#)

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):

Entity ⁽¹⁾	Segment	Property Count ⁽²⁾	Ownership % ⁽²⁾	Carrying Amount	
				December 31, 2024	December 31, 2023
South San Francisco JVs ⁽³⁾	Lab	7	70	\$ 446,145	\$ 393,374
SWF SH JV	Other	19	54	322,551	332,693
Callan Ridge JV	Lab	2	35	69,709	—
PMAC JV ⁽⁴⁾	Outpatient medical	59	12	32,511	—
Lab JV	Lab	1	49	29,916	31,761
Needham Land Parcel JV ⁽⁵⁾	Lab	—	38	21,348	17,084
Davis JV ⁽⁴⁾	Outpatient medical	15	49	7,435	—
Outpatient Medical JVs ⁽⁶⁾	Outpatient medical	2	20 - 67	7,199	7,941
				\$ 936,814	\$ 782,853

(1) These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

- (2) Property counts and ownership percentages are as of December 31, 2024.
- (3) Includes multiple unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70% ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and operations.
- (4) Includes unconsolidated joint ventures acquired as part of the Merger (see Note 3). The properties underlying the PMAK JV are excluded from the Company's total property count.
- (5) Land held for development is excluded from the property count as of December 31, 2024.
- (6) Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). In April 2023, the Company acquired the remaining 80% interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for \$4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations.

XML 68 R49.htm IDEA: XBRL DOCUMENT

Intangibles (Tables)

Intangibles [Abstract]
Schedule of Intangible Lease Assets

12 Months Ended
Dec. 31, 2024

The following table summarizes the Company's intangible lease assets (dollars in thousands):

Intangible lease assets	December 31,	
	2024	2023
Gross intangible lease assets ⁽¹⁾	\$ 1,468,985	\$ 739,228
Accumulated depreciation and amortization ⁽²⁾	(651,731)	(425,072)
Intangible assets, net	\$ 817,254	\$ 314,156

Weighted average remaining amortization period in years	5	5

- (1) As of December 31, 2024 and 2023, includes \$1.42 billion and \$725 million, respectively, of gross lease-up intangibles and \$45 million and \$14 million, respectively, of gross above market lease intangibles.
- (2) As of December 31, 2024 and 2023, includes \$640 million and \$418 million, respectively, of accumulated depreciation and amortization on lease-up intangibles and \$12 million and \$7 million, respectively, of accumulated depreciation and amortization on above market lease intangibles.

Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company's intangible lease liabilities (dollars in thousands):

Intangible lease liabilities	December 31,	
	2024	2023
Gross intangible lease liabilities	\$ 351,602	\$ 228,105
Accumulated depreciation and amortization	(159,718)	(100,725)
Intangible liabilities, net	\$ 191,884	\$ 127,380

Weighted average remaining amortization period in years	9	7

Schedule of Amortization of Deferred Lease Costs and Acquisition Related Intangibles

The following table sets forth amortization related to intangible assets, net and intangible liabilities, net (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Depreciation and amortization expense related to amortization of lease-up intangibles	\$ 273,146	\$ 102,249	\$ 104,885
Rental and related revenues related to amortization of net below market lease liabilities	62,894	27,012	24,640

Schedule of Estimated Aggregate Amortization of Intangible Assets and Liabilities for Each of the Five Succeeding Fiscal Years and Thereafter

The following table summarizes the estimated annual amortization for each of the five succeeding fiscal years and thereafter (in thousands):

	Rental and Related Revenues	Depreciation and Amortization
2025	\$ 32,618	\$ 256,925
2026	29,231	171,520
2027	23,304	107,925
2028	17,899	77,072
2029	13,168	53,829
Thereafter	42,816	117,135
	\$ 159,036	\$ 784,406

Schedule of Goodwill

At December 31, 2024 and 2023, goodwill was allocated to the Company's segment assets as follows (in thousands):

Segment	December 31, 2024	December 31, 2023
Outpatient medical	\$ 64,680	\$ 14,178
CCRC	1,998	1,998
Other non-reportable	1,851	1,851
	\$ 68,529	\$ 18,027

XML 69 R50.htm IDEA: XBRL DOCUMENT

Debt (Tables)

Debt Disclosure [Abstract]
Schedule of Senior Unsecured Notes

12 Months Ended
Dec. 31, 2024

The following table summarizes the Company's senior unsecured note issuances for the year ended December 31, 2023 (dollars in thousands):

Issue Date	Amount	Coupon Rate	Maturity Year
January 17, 2023	\$ 400,000	5.25 %	2032
May 10, 2023 ⁽¹⁾	350,000	5.25 %	2032

- (1) In May 2023, the Company issued \$350 million of 5.25% senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the \$400 million of senior unsecured notes due 2032 issued in January 2023.

The following table summarizes the Company's stated debt maturities and scheduled principal repayments at December 31, 2024 (dollars in thousands):

Year	Bank Line of Credit ⁽¹⁾	Commercial Paper ⁽¹⁾⁽²⁾	Term Loans	Senior Unsecured Notes ⁽³⁾		Mortgage Debt ⁽⁴⁾		Total
				Amount	Interest Rate ⁽⁵⁾	Amount	Interest Rate ⁽⁵⁾	
2025	\$ —	\$ —	\$ —	\$ 800,000	3.92 %	\$ 7,432	6.28 %	\$ 807,432
2026	—	—	—	650,000	3.40 %	344,999	5.13 %	994,999
2027	—	—	500,000	850,000	3.23 %	842	5.59 %	1,350,842
2028	—	—	400,000	850,000	3.53 %	2,775	5.34 %	1,252,775
2029	—	150,000	750,000	650,000	3.65 %	—	— %	1,550,000
Thereafter	—	—	—	2,900,000	4.51 %	—	— %	2,900,000
	—	150,000	1,650,000	6,700,000		356,048		8,856,048
Premiums, (discounts), and debt issuance costs, net	—	—	(3,957)	(136,744)		702		(139,999)
	\$ —	\$ 150,000	\$ 1,646,043	\$ 6,563,256		\$ 356,750		\$ 8,716,049

- (1) As of December 31, 2024, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were \$18 million, which are recorded in other assets, net on the Consolidated Balance Sheets.
- (2) Commercial Paper Program borrowings are backstopped by the availability under the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.
- (3) Effective interest rates on the senior unsecured notes range from 1.54% to 6.87% with a weighted average effective interest rate of 3.96% and a weighted average maturity of approximately 5 years.
- (4) Effective interest rates on the mortgage debt range from 3.44% to 8.50% with a weighted average effective interest rate of 5.16% and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.
- (5) Represents the weighted-average effective interest rate as of the end of the applicable period, including amortization of debt premiums (discounts) and debt issuance costs.

XML 70 R51.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

Commitments and Contingencies [Abstract]
Disclosure [Abstract]
Summary of Material Commitments

12 Months Ended
Dec. 31, 2024

The following table summarizes the Company's material commitments, excluding obligations as the lessee under operating leases (see Note 7), commitments to fund additional loans for outpatient medical capital expenditure projects (see Note 8), debt service obligations (see Note 11), and potential future obligations related to redeemable noncontrolling interests (see Note 13) at December 31, 2024 (in thousands):

	Amount
Development and redevelopment commitments ⁽¹⁾	\$ 199,139
Lease and other contractual commitments ⁽²⁾	84,654
Letters of credit ⁽³⁾	11,929
	\$ 295,722

- (1) Represents construction and other commitments as of December 31, 2024 for developments and redevelopments in progress and includes allowances for Company-owned tenant improvements that the Company has provided as a lessor.
- (2) Represents the Company's commitments, as lessor, under signed leases and contracts for operating properties as of December 31, 2024 and includes allowances for Company-owned tenant improvements and leasing commissions. Excludes allowances for Company-owned tenant improvements related to developments and redevelopments in progress for which the Company has executed an agreement with a general contractor to complete the tenant improvements (recognized in the "Development and redevelopment commitments" line).
- (3) Represents 15 outstanding letter of credit obligations expiring in 2025 and one outstanding letter of credit obligation expiring in 2026.

XML 71 R52.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests (Tables)
Equity [Abstract]

12 Months Ended
Dec. 31, 2024

Schedule of Company's Other Common Stock Activities

The following table summarizes the Company's other common stock activities (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Dividend reinvestment and stock purchase plan	\$ 57	\$ 70	\$ 59
Conversion of DownREIT units	256	72	27
Vesting of restricted stock units	377	613	820
Repurchase of common stock	10,592	241	2,418

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the Company's accumulated other comprehensive income (loss) (in thousands):

	December 31,	
	2024	2023
Unrealized gains (losses) on derivatives, net	\$ 30,707	\$ 21,245
Supplemental Executive Retirement Plan minimum liability	(1,889)	(1,874)
Total accumulated other comprehensive income (loss)	\$ 28,818	\$ 19,371

XML 72 R53.htm IDEA: XBRL DOCUMENT

Earnings Per
Common Share
(Tables)

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Earnings Per Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Year Ended December 31,		
	2024	2023	2022
Numerator - Basic			
Income (loss) from continuing operations	\$ 267,303	\$ 334,757	\$ 513,540
Noncontrolling interests' share in continuing operations	(24,161)	(28,748)	(15,975)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	243,142	306,009	497,565
Less: Participating securities' share in continuing operations	(758)	(1,725)	(2,657)
Income (loss) from continuing operations applicable to common shares	242,384	304,284	494,908
Income (loss) from discontinued operations	—	—	2,884
Net income (loss) applicable to common shares	\$ 242,384	\$ 304,284	\$ 497,792
Numerator - Dilutive			
Net income (loss) applicable to common shares	\$ 242,384	\$ 304,284	\$ 497,792
Add: distributions on dilutive convertible units and other	107	—	—
Dilutive net income (loss) available to common shares	\$ 242,491	\$ 304,284	\$ 497,792
Denominator			
Basic weighted average shares outstanding	675,680	547,006	538,809
Dilutive potential common shares - equity awards ⁽¹⁾	148	269	338
Dilutive potential common shares - OP Units ⁽²⁾	405	—	—
Diluted weighted average common shares	676,233	547,275	539,147
Basic earnings (loss) per common share			
Continuing operations	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations	—	—	0.00
Net income (loss) applicable to common shares	\$ 0.36	\$ 0.56	\$ 0.92
Diluted earnings (loss) per common share			
Continuing operations	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations	—	—	0.00
Net income (loss) applicable to common shares	\$ 0.36	\$ 0.56	\$ 0.92

(1) For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).

(2) For the year ended December 31, 2024, represents the dilutive impact of 3 million outstanding OP Units.

XML 73 R54.htm IDEA: XBRL DOCUMENT

Compensation Plans
(Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Restricted Stock Unit and LTIP Unit activity

The following table summarizes Restricted Stock Unit and LTIP Unit activity for the year ended December 31, 2024 (units in thousands):

	Restricted Stock Units		LTIP Units	
	Number of Units	Weighted Average Grant Date Fair Value	Number of Units	Weighted Average Grant Date Fair Value
Unvested at January 1, 2024	879	\$ 29.91	1,894	\$ 14.26
Granted	597	17.69	1,511	8.75
Vested	(377)	28.88	(199)	17.43
Forfeited	(224)	27.20	(304)	12.70
Unvested at December 31, 2024	875	\$ 22.70	2,902	\$ 10.88

XML 74 R55.htm IDEA: XBRL DOCUMENT

Segment Disclosures
(Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting

[Abstract]

Schedule of Information for
the Reportable Segments

The following tables summarize information for the reportable segments for the year ended December 31, 2024 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 1,205,744	\$ 881,452	\$ 568,475	\$ 2,655,671
Healthpeak's share of unconsolidated joint venture total revenues	24,041	19,733	—	43,774
Noncontrolling interests' share of consolidated joint venture total revenues	(37,643)	(196)	—	(37,839)
Operating expenses ⁽¹⁾	(405,993)	(239,620)	(429,248)	(1,074,861)
Healthpeak's share of unconsolidated joint venture operating expenses	(9,034)	(6,366)	—	(15,400)
Noncontrolling interests' share of consolidated joint venture operating expenses	10,582	52	—	10,634
Adjustments to NOI ⁽²⁾	(38,967)	(64,449)	(3,123)	(106,539)
Adjusted NOI for reportable segments	\$ 748,730	\$ 590,606	\$ 136,104	\$ 1,475,440
Plus: Adjustments to NOI ⁽²⁾				106,539
Interest income and other				44,778
Interest expense				(280,430)
Depreciation and amortization				(1,057,205)
General and administrative				(97,162)
Transaction and merger-related costs				(132,685)
Impairments and loan loss reserves, net				(22,978)
Gain (loss) on sales of real estate, net				178,695
Other income (expense), net				59,345
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI				(28,374)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI				27,205
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures				\$ 273,168

(1) See reconciliation of significant expense categories below.

(2) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2024 (in thousands):

	Outpatient Medical	Lab	CCRC
Compensation and property management	\$ 56,066	\$ 33,058	\$ 277,686
Food	—	—	26,513
Real estate taxes	95,286	78,488	15,472
Repairs and maintenance	61,409	30,555	18,373
Utilities	69,690	50,793	22,309
Other segment items ⁽¹⁾	123,542	46,726	68,895
Operating expenses	\$ 405,993	\$ 239,620	\$ 429,248

(1) Other segment items for each segment include:

- Outpatient medical and lab - (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC - (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following tables summarize information for the reportable segments for the year ended December 31, 2023 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 753,479	\$ 878,326	\$ 527,417	\$ 2,159,222
Government grant income ⁽¹⁾	—	—	184	184
Healthpeak's share of unconsolidated joint venture total revenues	3,033	9,924	—	12,957
Noncontrolling interests' share of consolidated joint venture total revenues	(35,073)	(619)	—	(35,692)
Operating expenses ⁽²⁾	(263,132)	(229,630)	(413,472)	(906,234)
Healthpeak's share of unconsolidated joint venture operating expenses	(1,189)	(4,092)	—	(5,281)
Noncontrolling interests' share of consolidated joint venture operating expenses	9,921	156	—	10,077
Adjustments to NOI ⁽³⁾	(14,314)	(36,524)	(1,618)	(52,456)
Adjusted NOI for reportable segments	\$ 452,725	\$ 617,541	\$ 112,511	\$ 1,182,777
Plus: Adjustments to NOI ⁽³⁾	—	—	—	52,456
Interest income and other	—	—	—	21,781
Interest expense	—	—	—	(200,331)
Depreciation and amortization	—	—	—	(749,901)
Corporate non-segment operating expenses	—	—	—	4,174
General and administrative	—	—	—	(95,132)
Transaction and merger-related costs	—	—	—	(17,515)
Impairments and loan loss reserves, net	—	—	—	5,601
Gain (loss) on sales of real estate, net	—	—	—	86,463
Other income (expense), net	—	—	—	6,808
Less: Government grant income	—	—	—	(184)
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI	—	—	—	(7,676)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI	—	—	—	25,615
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—	—	—	\$ 314,936

(1) Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2) See reconciliation of significant expense categories below.

(3) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2023 (in thousands):

	Outpatient Medical	Lab	CCRC	
Compensation and property management	\$ 29,752	\$ 18,096	\$ 260,624	
Food	—	—	25,076	
Real estate taxes	59,255	77,690	15,851	
Repairs and maintenance	38,277	30,554	17,295	
Utilities	43,348	45,490	22,787	
Other segment items ⁽¹⁾	92,500	57,800	71,839	
Operating expenses	\$ 263,132	\$ 229,630	\$ 413,472	

(1) Other segment items for each segment include:

- Outpatient medical and lab - (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC - (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following tables summarize information for the reportable segments for the year ended December 31, 2022 (in thousands):

	Outpatient Medical	Lab	CCRC	Total
Total revenues	\$ 725,370	\$ 817,573	\$ 494,935	\$ 2,037,878
Government grant income ⁽¹⁾	—	—	6,765	6,765
Healthpeak's share of unconsolidated joint venture total revenues	2,999	9,921	—	12,920
Healthpeak's share of unconsolidated joint venture government grant income	—	—	380	380
Noncontrolling interests' share of consolidated joint venture total revenues	(35,717)	(268)	—	(35,985)
Operating expenses ⁽²⁾	(253,309)	(209,143)	(400,539)	(862,991)
Healthpeak's share of unconsolidated joint venture operating expenses	(1,178)	(2,883)	—	(4,061)
Noncontrolling interests' share of consolidated joint venture operating expenses	10,317	87	—	10,404
Adjustments to NOI ⁽³⁾	(15,513)	(62,754)	2,300	(75,967)
Adjusted NOI for reportable segments	\$ 432,969	\$ 552,533	\$ 103,841	\$ 1,089,343
Plus: Adjustments to NOI ⁽³⁾	—	—	—	75,967
Interest income and other	—	—	—	23,300
Interest expense	—	—	—	(172,944)
Depreciation and amortization	—	—	—	(710,569)
General and administrative	—	—	—	(131,033)
Transaction and merger-related costs	—	—	—	(4,853)
Impairments and loan loss reserves, net	—	—	—	(7,004)
Gain (loss) on sales of real estate, net	—	—	—	9,078
Other income (expense), net	—	—	—	326,268
Less: Government grant income	—	—	—	(6,765)
Less: Healthpeak's share of unconsolidated joint venture Adjusted NOI	—	—	—	(9,239)
Plus: Noncontrolling interests' share of consolidated joint venture Adjusted NOI	—	—	—	25,581
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—	—	—	\$ 507,130

(1) Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2) See reconciliation of significant expense categories below.

(3) Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company's share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests' share of income (loss) generated by consolidated joint ventures.

The following table summarizes the Company's significant expense categories by reportable segment for the year ended December 31, 2022 (in thousands):

	Outpatient Medical	Lab	CCRC	
Compensation and property management	\$ 27,807	\$ 16,817	\$ 251,804	
Food	—	—	23,641	
Real estate taxes	59,992	75,459	14,090	
Repairs and maintenance	36,439	26,884	16,522	
Utilities	43,329	41,087	21,219	
Other segment items ⁽¹⁾	85,742	48,896	73,263	
Operating expenses	\$ 253,309	\$ 209,143	\$ 400,539	

(1) Other segment items for each segment include:

- Outpatient medical and lab - (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
- CCRC - (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.

The following table summarizes the Company's revenues by reportable segment (in thousands):

Segment	2024	2023	2022
Outpatient medical	\$ 1,205,744	\$ 753,479	\$ 725,370
Lab	881,452	878,326	817,573
CCRC	568,475	527,417	494,935
Total revenues for reportable segments	2,655,671	2,159,222	2,037,878
Interest income and other	44,778	21,781	23,300
Total revenues	\$ 2,700,449	\$ 2,181,003	\$ 2,061,178

XML 75 R56.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

Income Tax Disclosure [Abstract]

Schedule of Common Stock Distributions

12 Months Ended Dec. 31, 2024

The following table shows the characterization of the Company's annual common stock distributions per share:

	2024	2023	2022
Ordinary dividends ⁽¹⁾	\$ 0.720440	\$ 0.909692	\$ 0.872948
Capital gains ⁽²⁾⁽³⁾	0.295060	0.116992	0.183208
Nondividend distributions	0.184500	0.173316	0.143844
	\$ 1.200000	\$ 1.200000	\$ 1.200000

(1) For the year ended December 31, 2024, all \$0.720440 of ordinary dividends qualified as business income for purposes of Code Section 199A. For the year ended December 31, 2023, the amount includes \$0.882312 of ordinary dividends qualified as business income for purposes of Code Section 199A and \$0.027380 of qualified dividend income for purposes of Code Section 1(h)(11). For the year ended December 31, 2022, all \$0.872948 of ordinary dividends qualified as business income for purposes of Code Section 199A.

(2) For the years ended December 31, 2024, 2023, and 2022, the amount includes \$0.215960, \$0.036256, and \$0.017760, respectively, of unrecaptured Code Section 1250 gain. Pursuant to Treasury Regulation Section 1.1061-6(c), the Company is disclosing additional information related to the capital gain dividends for purposes of Section 1061 of the Code. Code Section 1061 is generally applicable to direct and indirect holders of "applicable partnership interests." For the years ended December 31, 2024 and 2023, the "One Year Amounts" and "Three Year Amounts" are each zero, since all capital gains relate to Code Section 1231 gains. For the year ended December 31, 2022, the "One Year Amounts" and "Three Year Amounts" are each 89.6708% of the total capital gain distributions and the remaining capital gain distributions are attributable to Code Section 1231 gains, which are not subject to Code Section 1061.

(3) For the years ended December 31, 2024, 2023, and 2022, 100%, 100%, and 10.3292%, respectively, of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.

Schedule of Income Tax Expense (Benefit) From Continuing Operations

The total income tax benefit (expense) from continuing operations consists of the following components (in thousands):

	2024	2023	2022
Current			
Federal	\$ (2,389)	\$ (1,663)	\$ (632)
State	(3,654)	(3,325)	(689)
Total current	\$ (6,043)	\$ (4,988)	\$ (1,321)
Deferred			
Federal	\$ (3,429)	\$ 11,682	\$ 3,157
State	5,122	2,923	2,589
Total deferred	\$ 1,693	\$ 14,605	\$ 5,746
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

[Schedule of Reconciliation of Income Tax Expense at Statutory Rates to the Actual Income Tax Expense Recorded](#)

The following table reconciles income tax benefit (expense) from continuing operations at statutory rates to actual income tax benefit (expense) recorded (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax	\$ (11,601)	\$ (1,404)	\$ 3,698
State income tax benefit (expense), net of federal tax	(1,389)	(1,035)	911
Gross receipts and margin taxes	(1,774)	(1,647)	(956)
Return to provision adjustments	(287)	(90)	1,260
Change in valuation allowance for deferred tax assets	10,698	13,797	194
Change in tax status of TRS	3	(4)	(682)
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

[Schedule of Significant Components of the Company's Deferred Tax Asset and Liabilities](#)

The following table summarizes the significant components of the Company's deferred tax assets and liabilities from continuing operations (in thousands):

	December 31,		
	2024	2023	2022
Deferred tax assets:			
Deferred revenue	\$ 103,470	\$ 103,530	\$ 102,504
Net operating loss carryforward	50,041	54,136	62,280
Expense accruals	11,787	12,324	12,399
Real estate	195	850	150
Other	49	58	689
Total deferred tax assets	165,542	170,898	178,022
Valuation allowance	(2,306)	(13,004)	(26,098)
Deferred tax assets, net of valuation allowance	\$ 163,236	\$ 157,894	\$ 151,924
Deferred tax liabilities:			
Real estate	\$ 47,268	\$ 43,488	\$ 52,266
Other	876	818	674
Deferred tax liabilities	\$ 48,144	\$ 44,306	\$ 52,940
Net deferred tax assets	\$ 115,092	\$ 113,588	\$ 98,984

[Schedule of Unrecognized Tax Benefits Roll Forward](#)

The following table summarizes the Company's unrecognized tax benefits (in thousands):

	December 31,		
	2024	2023	2022
Total unrecognized tax benefits at January 1	\$ —	\$ —	\$ 469
Gross amount of decreases for prior years' tax positions	—	—	(469)
Total unrecognized tax benefits at December 31	\$ —	\$ —	\$ —

XML 76 R57.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information (Tables)

12 Months Ended

Dec. 31, 2024

[Supplemental Cash Flow Elements \[Abstract\]](#)
[Schedule of Supplemental Cash Flow Information](#)

The following table provides supplemental cash flow information (in thousands):

	Year Ended December 31,		
	2024	2023	2022
Supplemental cash flow information:			
Interest paid, net of capitalized interest	\$ 249,471	\$ 188,213	\$ 162,115
Income taxes paid (refunded)	7,862	1,923	(1,903)
Capitalized interest	69,256	56,849	41,046
Cash paid for amounts included in the measurement of lease liability for operating leases	21,277	21,488	12,594
Supplemental schedule of non-cash investing and financing activities:			
Increase in ROU asset in exchange for new lease liability related to operating leases	15,457	3,951	9,454
Accrued construction costs	136,767	105,572	178,626
Net noncash impact from the consolidation of property previously held in an unconsolidated joint venture	—	993	—
Retained investment in connection with South San Francisco JVs transaction (see Note 9)	—	—	293,265
Retained investment in connection with Callan Ridge JV (see Note 9)	69,255	—	—
Non-cash assets and liabilities assumed in connection with the Merger (see Note 3)	2,926,141	—	—
Seller financing provided on disposition of real estate assets (see Note 8)	418,389	—	—
	Year Ended December 31,		
	2024	2023	2022
Leasing costs, tenant improvements, and recurring capital expenditures	\$ —	\$ —	\$ 21
Development, redevelopment, and other major improvements of real estate	—	—	18
Depreciation and amortization of real estate, in-place lease, and other intangibles	—	—	—

[Schedule of Cash, Cash Equivalents and Restricted Cash](#)

The following table summarizes cash, cash equivalents, and restricted cash (in thousands):

	Year Ended December 31,								
	Continuing operations			Discontinued operations			Total		
	2024	2023	2022	2024	2023	2022	2024	2023	2022
Beginning of year:									
Cash and cash equivalents	\$ 117,635	\$ 72,032	\$ 158,287	\$ —	\$ —	\$ 7,707	\$ 117,635	\$ 72,032	\$ 165,994
Restricted cash	51,388	54,802	53,454	—	—	—	51,388	54,802	53,454
Cash, cash equivalents, and restricted cash	\$ 169,023	\$ 126,834	\$ 211,741	\$ —	\$ —	\$ 7,707	\$ 169,023	\$ 126,834	\$ 219,448
End of year:									
Cash and cash equivalents	\$ 119,818	\$ 117,635	\$ 72,032	\$ —	\$ —	\$ —	\$ 119,818	\$ 117,635	\$ 72,032
Restricted cash	64,487	51,388	54,802	—	—	—	64,487	51,388	54,802
Cash, cash equivalents, and restricted cash	\$ 184,305	\$ 169,023	\$ 126,834	\$ —	\$ —	\$ —	\$ 184,305	\$ 169,023	\$ 126,834

XML 77 R58.htm IDEA: XBRL DOCUMENT

Variable Interest Entities (Tables)

12 Months Ended

Dec. 31, 2024

[Variable Interest Entities \[Abstract\]](#)
[Schedule of Variable Interest Entities](#)

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company's involvement with these VIEs at December 31, 2024 was as follows (in thousands):

VIE Type	Asset Type	Maximum Loss Exposure and Carrying Amount ⁽¹⁾
LLC Investment and PropTech Investment	Other assets, net	\$ 15,815
Needham Land Parcel JV	Investments in and advances to unconsolidated joint ventures	21,348

(1)The Company's maximum loss exposure represents the aggregate carrying amount of such investments.

Total assets and total liabilities include VIE assets and liabilities, excluding those of Healthpeak OP, as follows (in thousands):

[Schedule of Consolidated Assets and Liabilities of Variable Interest Entities](#)

	December 31,	
	2024	2023
Assets		
Buildings and improvements	\$ 4,669,914	\$ 2,392,375
Development costs and construction in progress	92,710	47,481
Land and improvements	472,232	307,166
Accumulated depreciation and amortization	(761,759)	(665,791)
Net real estate	4,473,097	2,081,231
Loans receivable, net	550,829	—
Investments in and advances to unconsolidated joint ventures	39,946	—
Accounts receivable, net	17,357	5,906
Cash and cash equivalents	32,421	18,410
Restricted cash	1,029	613
Intangible assets, net	629,802	56,975
Right-of-use asset, net	270,918	97,575
Other assets, net	173,435	79,248
Total assets	\$ 6,188,834	\$ 2,339,958
Liabilities		
Term loans	\$ 401,895	\$ —
Senior unsecured notes	1,151,801	—
Mortgage debt	247,776	144,874
Intangible liabilities, net	95,315	11,884
Lease liability	193,421	99,725
Accounts payable, accrued liabilities, and other liabilities	125,688	54,975
Deferred revenue	65,358	48,316
Total liabilities	\$ 2,281,254	\$ 359,774

XML 78 R59.htm IDEA: XBRL DOCUMENT

Concentration of
Credit Risk (Tables)

Risks and
Uncertainties
[Abstract]

Schedule of
Concentration of Credit
Risk

The following table provides information regarding the Company's concentrations with respect to certain states; the information provided is presented for the gross assets and revenues that are associated with certain real estate assets as percentages of the Company's total assets and revenues, excluding discontinued operations:

State	Percentage of Total Company Assets		Percentage of Total Company Revenues		
	December 31,		Year Ended December 31,		
	2024	2023	2024	2023	2022
California	31	38	25	31	31
Florida	10	10	17	18	18
Texas	11	10	12	11	11
Massachusetts	15	17	9	11	10

XML 79 R60.htm IDEA: XBRL DOCUMENT

Fair Value
Measurements
(Tables)

Fair Value Disclosures [Abstract]
Summary of the Carrying Values and
Fair Values of Financial Instruments

The table below summarizes the carrying amounts and fair values of the Company's financial instruments either recorded or disclosed on a recurring basis (in thousands):

	December 31,			
	2024 ⁽¹⁾		2023 ⁽¹⁾	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Loans receivable, net ⁽²⁾	\$ 717,190	\$ 729,637	\$ 218,450	\$ 218,450
Interest rate swap assets ⁽²⁾	35,120	35,120	21,359	21,359
Bank line of credit and commercial paper ⁽²⁾	150,000	150,000	720,000	720,000
Term loans ⁽²⁾	1,646,043	1,646,043	496,824	496,824
Senior unsecured notes ⁽¹⁾	6,563,256	6,373,528	5,403,378	5,144,667
Mortgage debt ⁽²⁾	356,750	350,292	256,097	244,135

- (1) Level 1: Fair value is calculated based on quoted prices in active markets.
(2) Level 2: For loans receivable, net, interest rate swap instruments, and mortgage debt, fair value is based on standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, commercial paper, and term loans, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company's credit rating.
(3) During the years ended December 31, 2024 and 2023, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

XML 80 R61.htm IDEA: XBRL DOCUMENT

Derivative Financial
Instruments (Tables)

Derivative
Instruments and
Hedging Activities
Disclosure [Abstract]

Schedule of Derivative
Instruments

The following table summarizes the Company's interest rate swap instruments (in thousands):

Date Entered ⁽¹⁾	Maturity Date	Hedge Designation	Notional Amount	Pay Rate	Receive Rate	Fair Value ⁽²⁾	
						December 31, 2024	December 31, 2023
April 2022	May 2026	Cash flow	\$ 51,100	4.99 %	USD-SOFR w/ -5 Day Lookback + 2.50%	\$ 1,050	\$ 1,602
April 2022	May 2026	Cash flow	91,000	4.54 %	USD-SOFR w/ -5 Day Lookback + 2.05%	1,870	2,851
August 2022	February 2027	Cash flow	250,000	2.60 %	1 mo. USD-SOFR CME Term	7,224	7,933
August 2022	August 2027	Cash flow	250,000	2.54 %	1 mo. USD-SOFR CME Term	9,122	8,973
May 2023 ⁽³⁾⁽⁴⁾	May 2028	Cash flow	400,000	3.59 %	USD-SOFR w/ -5 Day Lookback	4,887	—
January 2024 ⁽⁵⁾	February 2029	Cash flow	750,000	3.59 %	USD-SOFR w/ -5 Day Lookback	10,967	—
						\$ 35,120	\$ 21,359

- (1) Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.
(2) Derivative assets are recorded at fair value in other assets, net on the Consolidated Balance Sheets.
(3) Includes interest rate swap instruments acquired as part of the Merger (see Note 3). The interest rate swap instrument on \$36 million of mortgage debt that was acquired as part of the Merger matured in October 2024 and has been excluded herein. These interest rate swap instruments were redesignated as cash flow hedges on the Closing Date. As a result of the Merger, the aggregate fair value of these interest rate swap instruments was determined to be \$7 million on March 1, 2024, which was recognized within other assets, net on the Consolidated Balance Sheets on the Closing Date. The aggregate fair value as of the Closing Date is being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related interest rate swap instruments. During the year ended December 31, 2024, the Company recognized \$2 million of related amortization into interest expense.
(4) Includes two interest rate swap instruments each with notional amounts of \$110 million and one interest rate swap instrument with a notional amount of \$180 million.
(5) Includes the following: (i) two interest rate swap instruments each with a pay rate of 3.56% and \$50 million notional amount; (ii) three interest rate swap instruments each with a pay rate of 3.57% and \$50 million notional amount; (iii) one interest rate swap instrument with a pay rate of 3.58% and \$100 million notional amount; (iv) five interest rate swap instruments each with a pay rate of 3.60% and \$50 million notional amount; and (v) three interest rate swap instruments each with a pay rate of 3.61% and \$50 million notional amount.

XML 81 R62.htm IDEA: XBRL DOCUMENT

Accounts Payable,
Accrued Liabilities,
and Other Liabilities
(Tables)

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

The following table summarizes the Company's accounts payable, accrued liabilities, and other liabilities (in thousands):

	December 31,	
	2024	2023
Refundable entrance fees	\$ 236,563	\$ 251,874
Accrued construction costs	136,767	105,572
Accrued interest	76,040	59,492
Other accounts payable and accrued liabilities	275,972	240,258
Accounts payable, accrued liabilities, and other liabilities	\$ 725,342	\$ 657,196

XML 82 R63.htm IDEA: XBRL DOCUMENT

Deferred Revenue
(Tables)

Revenues [Abstract]
Schedule of Deferred
Revenue

The following table summarizes the Company's deferred revenue, excluding deferred revenue related to assets classified as held for sale (in thousands):

	December 31,	
	2024	2023
Non-refundable entrance fees ⁽¹⁾	\$ 615,723	\$ 562,026
Other deferred revenue ⁽²⁾	324,413	343,607
Deferred revenue	\$ 940,136	\$ 905,633

- (1) During the years ended December 31, 2024 and 2023, the Company collected non-refundable entrance fees of \$143 million and \$127 million, respectively. During the years ended December 31, 2024, 2023, and 2022, the Company recognized amortization of \$89 million, \$83 million, and \$79 million, respectively, which is included within resident fees and services on the Consolidated Statements of Operations.
(2) Other deferred revenue is primarily comprised of prepaid rent, deferred rent, and tenant-funded tenant improvements owned by the Company. During the years ended December 31, 2024, 2023, and 2022, the Company recognized amortization related to other deferred revenue of \$53 million, \$68 million, and \$44 million, respectively, which is included in rental and related revenues on the Consolidated Statements of Operations.

XML 83 R64.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Narrative (Details) - USD (\$) \$ in Millions	12 Months Ended			
	Feb. 10, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]				
Straight line rent receivable, net of allowances		\$ 338	\$ 310	
Residency agreement term, minimum		30 days		
Residency agreement term, maximum		1 year		
Maximum period available for occupancy from cessation of significant construction activity		1 year		
Initial direct costs		\$ 204	172	
Advertising expense		\$ 9	\$ 8	\$ 8
Healthpeak OP				
Schedule of Equity Method Investments [Line Items]				
Noncontrolling interest, ownership percentage by parent	100.00%			
Healthpeak OP Total Noncontrolling Interests				
Schedule of Equity Method Investments [Line Items]				
Common stock, unit redemption share amount	1			
Building and Building Improvements				
Schedule of Equity Method Investments [Line Items]				
Property, plant and equipment, useful life		50 years		

XML 84 R65.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Government Grant Receivables Cares Act (Details) - Government Assistance, CARES Act - USD (\$) \$ in Thousands	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Schedule of Equity Method Investments [Line Items]				
Government grant income	\$ 0	\$ 413	\$ 7,860	
Government grant income recorded in other income (expense), net				
Schedule of Equity Method Investments [Line Items]				
Government grant income	0	184	6,765	
Government grant income recorded in equity income (loss) from unconsolidated joint ventures				
Schedule of Equity Method Investments [Line Items]				
Government grant income	0	229	878	
Government grant income recorded in income (loss) from discontinued operations				
Schedule of Equity Method Investments [Line Items]				
Government grant income	\$ 0	\$ 0	\$ 217	

XML 85 R66.htm IDEA: XBRL DOCUMENT

The Merger - Narrative (Details) \$ in Thousands	12 Months Ended			
	Mar. 01, 2024 USD (\$) property	Dec. 31, 2024 USD (\$)	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)
Real estate acquisitions [Line Items]				
Goodwill	\$ 51,000	\$ 68,529	\$ 18,027	
Transaction and merger-related costs		132,685	17,515	\$ 4,853
Physicians Realty Trust				
Real estate acquisitions [Line Items]				
Exchange ratio	0.674			
Goodwill	\$ 50,501			
Transaction and merger-related costs		129,000	11,000	
Revenue of acquiree since acquisition date, actual		473,000		
Earnings (loss) of acquiree since acquisition date, actual		(6,000)		
Physicians Realty Trust Fees Paid to Investment Banks and Advisors				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		38,000		
Physicians Realty Trust Success-Based Payments Related to Service Providers				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		21,000		
Physicians Realty Trust Severance Expense Due to Dual-Trigger Severance Arrangements				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		26,000		
Physicians Realty Trust Post-Combination Expense, Accelerated Vesting of Acquiree Equity Awards				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		16,000		
Physicians Realty Trust Legal, Accounting, Tax, and Other Costs				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		35,000	\$ 11,000	
Physicians Realty Trust Severance Expense Related to Elimination of Certain Positions				
Real estate acquisitions [Line Items]				
Transaction and merger-related costs		\$ 13,000		
Physicians Realty Trust Outpatient Medical Buildings				
Real estate acquisitions [Line Items]				
Number of properties acquired property	299			

XML 86 R67.htm IDEA: XBRL DOCUMENT

The Merger- Schedule of Consideration Transferred (Details) - Physicians Realty Trust \$ / shares in Units, shares in Thousands, \$ in Thousands	Mar. 01, 2024			
	USD (\$)			
	\$ / shares	shares		
Real estate acquisitions [Line Items]				
Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged (in shares) shares		240,699		
Exchange ratio		0.674		
Shares of Healthpeak common stock issued (in shares) shares		162,231		
Closing price of Healthpeak common stock on March 1, 2024 (in dollars per share) \$ / shares		\$ 17.10		
Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs		\$ 2,774,147		
Less: Fair value of preliminary share consideration attributable to the post-combination period		(16,223)		
Physicians Realty Trust revolving credit facility termination		175,411		

Settlement of Physicians Realty Trust’s transaction costs	23,913
Payments made in connection with share settlement	11,315
Preliminary cash consideration	210,639
Consideration transferred	\$ 2,968,563
Restricted Shares	
Real estate acquisitions [Line Items]	
Shares of Healthpeak common stock issued (in shares) shares	200
Common Stock	
Real estate acquisitions [Line Items]	
Shares of Healthpeak common stock issued (in shares) shares	1,000
Restricted Stock Units	
Real estate acquisitions [Line Items]	
Shares of Healthpeak common stock issued (in shares) shares	300

XML 87 R68.htm IDEA: XBRL DOCUMENT

The Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) \$ in Thousands	12 Months Ended		
	Mar. 01, 2024	Dec. 31, 2024	Dec. 31, 2023
	USD (\$) joint_venture	USD (\$)	USD (\$)
LIABILITIES AND EQUITY			
Goodwill	\$ 51,000	\$ 68,529	\$ 18,027
Intangible assets, weighted average amortization, useful life		5 years	5 years
Intangible liabilities, weighted average amortization, useful life	9 years		
Physicians Realty Trust			
Real estate:			
Buildings and improvements	\$ 3,192,995		
Development costs and construction in progress	68,171		
Land and improvements	435,353		
Real estate	3,696,519		
Loans receivable	118,908		
Investments in and advances to unconsolidated joint ventures	58,636		
Accounts receivable, net	9,282		
Cash and cash equivalents	30,417		
Restricted cash	1,007		
Intangible assets	890,827		
Right-of-use asset	191,302		
Other assets	44,023		
Total assets	5,040,921		
LIABILITIES AND EQUITY			
Term loans	402,320		
Senior unsecured notes	1,139,760		
Mortgage debt	127,176		
Intangible liabilities	149,875		
Lease liability	97,047		
Accounts payable, accrued liabilities, and other liabilities	69,888		
Total liabilities	1,986,066		
Redeemable noncontrolling interests	3,109		
Joint venture partners	17,066		
Non-managing member unitholders	116,618		
Total noncontrolling interests	133,684		
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests	2,918,062		
Goodwill	50,501		
Total purchase price	2,968,563		
Gross contractual account receivables	\$ 14,000		
Intangible assets, weighted average amortization, useful life	6 years		
Intangible liabilities, weighted average amortization, useful life	9 years		
Number of joint ventures joint_venture	6		
Physicians Realty Trust Previously Reported			
Real estate:			
Buildings and improvements	\$ 3,199,884		
Development costs and construction in progress	68,171		
Land and improvements	435,353		
Real estate	3,703,408		
Loans receivable	118,908		
Investments in and advances to unconsolidated joint ventures	58,636		
Accounts receivable, net	9,536		
Cash and cash equivalents	30,417		
Restricted cash	1,007		
Intangible assets	890,827		
Right-of-use asset	191,415		
Other assets	44,691		
Total assets	5,048,845		
LIABILITIES AND EQUITY			
Term loans	402,320		
Senior unsecured notes	1,139,760		
Mortgage debt	127,176		
Intangible liabilities	149,875		
Lease liability	97,160		
Accounts payable, accrued liabilities, and other liabilities	72,864		
Total liabilities	1,989,155		
Redeemable noncontrolling interests	1,536		
Joint venture partners	20,109		
Non-managing member unitholders	116,618		
Total noncontrolling interests	136,727		
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests	2,921,427		
Goodwill	47,136		
Total purchase price	2,968,563		
Physicians Realty Trust Revision of Prior Period, Adjustment			
Real estate:			
Buildings and improvements	(6,889)		
Development costs and construction in progress	0		
Land and improvements	0		
Real estate	(6,889)		
Loans receivable	0		
Investments in and advances to unconsolidated joint ventures	0		
Accounts receivable, net	(254)		
Cash and cash equivalents	0		

Restricted cash	0
Intangible assets	0
Right-of-use asset	(113)
Other assets	(668)
Total assets	(7,924)
LIABILITIES AND EQUITY	
Term loans	0
Senior unsecured notes	0
Mortgage debt	0
Intangible liabilities	0
Lease liability	(113)
Accounts payable, accrued liabilities, and other liabilities	(2,976)
Total liabilities	(3,089)
Redeemable noncontrolling interests	1,573
Joint venture partners	(3,043)
Non-managing member unitholders	0
Total noncontrolling interests	(3,043)
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests	(3,365)
Goodwill	3,365
Total purchase price	\$ 0
Physicians Realty Trust Minimum	
LIABILITIES AND EQUITY	
Ownership percentage	56.70%
Physicians Realty Trust Maximum	
LIABILITIES AND EQUITY	
Ownership percentage	99.70%

XML 88 R69.htm
IDEA: XBRL DOCUMENT

The Merger - Schedule of Proforma Financial Information (Details) - Physicians Realty Trust - USD (\$) \$ in Thousands	12 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

[Real estate acquisitions](#)
[\[Line Items\]](#)

Total revenues	\$ 2,765,670	\$ 2,771,468
Net income (loss) applicable to common shares	\$ 353,347	\$ 24,630

XML 89 R70.htm
IDEA: XBRL DOCUMENT

Real Estate Investments - 2024 Real Estate Investment	Mar. 01, 2024	
	property	

Acquisitions (Details)

[Outpatient Medical Buildings | Physicians Realty Trust](#)

[Real Estate](#)
[\[Line Items\]](#)

Number of properties acquired	299

XML 90 R71.htm
IDEA: XBRL DOCUMENT

Real Estate Investments - 2023 Real Estate Investment	1 Months Ended						
	Apr. 30, 2023	Apr. 28, 2023	Jan. 31, 2023	Dec. 31, 2022	May 31, 2022	Mar. 31, 2022	Jan. 31, 2022
	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)
Acquisitions (Details) \$ in Millions	property	property	property	property	property	property	property

[HCP Ventures IV, LLC](#)

[Real Estate](#)
[\[Line Items\]](#)

Investment ownership percentage	80.00%	80.00%					20.00%
Property count property	1	1					

Payments to acquire equity method investments	\$ 4.0	\$ 4.0					

Gain on investments	\$ 0.2						

[Massachusetts | Lab](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate			\$ 9.0	\$ 18.0			\$ 72.0
California Lab							

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate							\$ 24.0

[Texas | Outpatient medical](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate						\$ 43.0	

[ARKANSAS | Outpatient medical](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate					\$ 26.0		

XML 91 R72.htm
IDEA: XBRL DOCUMENT

Real Estate Investments - 2022 Real Estate Investment	1 Months Ended				
	Jan. 31, 2023	Dec. 31, 2022	May 31, 2022	Mar. 31, 2022	Jan. 31, 2022
	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)
Acquisitions (Details) \$ in Millions	property	property	property	property	property

[Massachusetts | Lab](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate	\$ 9	\$ 18		\$ 72	

[California | Lab](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate				\$ 24	

[Texas | Outpatient medical](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate			\$ 43		

[Number of properties acquired | property](#)

[ARKANSAS | Outpatient medical](#)

[Real Estate](#)
[\[Line Items\]](#)

Payments to acquire real estate			\$ 26		

[Number of properties acquired | property](#)

XML 92 R73.htm
IDEA: XBRL DOCUMENT

Real Estate Investments - Construction, Tenant, and Other Capital Improvements (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Real estate acquisitions [Line Items]			
Funding for construction, tenant and other capital improvements	\$ 736,763	\$ 774,561	\$ 961,994
Outpatient Medical			
Real estate acquisitions [Line Items]			
Funding for construction, tenant and other capital improvements	356,273	236,135	237,761
Lab			
Real estate acquisitions [Line Items]			
Funding for construction, tenant and other capital improvements	313,749	428,961	658,542
CCRC			
Real estate acquisitions [Line Items]			
Funding for construction, tenant and other capital improvements	\$ 66,741	\$ 109,465	\$ 65,691

XML 93 R74.htm
IDEA: XBRL DOCUMENT

Dispositions of Real Estate and Discontinued Operations - 2024 Dispositions of Real Estate (Details) \$ in Thousands	1 Months Ended	12 Months Ended		
	Jul. 31, 2024 USD (\$) property	Dec. 31, 2024 USD (\$) property	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$) property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Gain (loss) on sales of real estate, net		\$ 178,695	\$ 86,463	\$ 9,078
Dispositions of 2024				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Gain (loss) on sales of real estate, net		\$ 179,000		
Outpatient Medical Buildings				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Number of assets sold property	59	59		
Proceeds from sale of buildings	\$ 674,000	\$ 674,000		
Investments in loans receivable	\$ 405,000	\$ 405,000		
Fourteen Outpatient Medical Buildings				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Number of assets sold property		14		
Proceeds from sale of buildings		\$ 220,000		
Lab Buildings				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Number of assets sold property		7		1
Proceeds from sale of buildings		\$ 180,000		\$ 14,000
Two Outpatient Medical Buildings				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Number of assets sold property		2		
Proceeds from sale of buildings		\$ 23,000		
Investments in loans receivable		14,000		
CCRC				
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]				
Proceeds from sale of buildings		\$ 12,000		

XML 94 R75.htm
IDEA: XBRL DOCUMENT

Dispositions of Real Estate and Discontinued Operations - 2023 Dispositions of Real Estate (Details) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024 USD (\$)	Dec. 31, 2023 USD (\$) property	Dec. 31, 2022 USD (\$) property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Gain (loss) on sales of real estate, net	\$ 178,695	\$ 86,463	\$ 9,078
Dispositions of 2023			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Gain (loss) on sales of real estate, net		\$ 81,000	
Lab			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of assets sold property		2	
Proceeds from sale of buildings		\$ 113,000	
Outpatient Medical			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of assets sold property		2	5
Proceeds from sale of buildings		\$ 32,000	

XML 95 R76.htm
IDEA: XBRL DOCUMENT

Dispositions of Real Estate and Discontinued Operations - 2022 Dispositions of Real Estate (Details) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024 USD (\$) property	Dec. 31, 2023 USD (\$) property	Dec. 31, 2022 USD (\$) property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Gain (loss) on sales of real estate, net	\$ 178,695	\$ 86,463	\$ 9,078
Dispositions of 2022			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Gain (loss) on sales of real estate, net			\$ 15,000
Lab Buildings			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties sold property	7		1
Proceeds from sale of buildings	\$ 180,000		\$ 14,000
Outpatient Medical			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties sold property		2	5
Proceeds from sale of buildings		\$ 32,000	
Outpatient Medical Land Parcel			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties sold property			1
Proceeds from sale of buildings			\$ 36,000

XML 96 R77.htm
IDEA: XBRL DOCUMENT

Dispositions of Real Estate and Discontinued Operations - Held for Sale and Discontinued Operations (Details)	Dec. 31, 2024 USD (\$) property	Mar. 31, 2024 property	Dec. 31, 2023 USD (\$) property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Assets held for sale, net	\$ 7,840,000		\$ 117,986,000
Held-for-sale			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Assets held for sale, net	8,000,000		118,000,000
Liabilities related to assets held for sale, net	0		1,000,000
Assets held for sale, net	0		0
Liabilities related to assets held for sale, net	\$ 0		\$ 0
Held-for-sale Outpatient Medical			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties classified as held for sale property	1		1
Held-for-sale Lab			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties classified as held for sale property			2
Discontinued Operations, Disposed of by Sale Lab			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Number of properties classified as held for sale property		2	
Discontinued Operations, Disposed of by Sale Lab Lab			
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]			
Investment ownership percentage		65.00%	

XML 97 R78.htm
IDEA: XBRL DOCUMENT

Dispositions of Real Estate and Discontinued Operations - Schedule of Results of Discontinued Operations (Details) - USD (\$)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other income (expense):			
Income tax benefit (expense)	\$ 0	\$ 0	\$ 300,000
Held-for-sale			
Revenues:			
Resident fees and services	0	0	7,489,000
Total revenues	0	0	7,489,000
Costs and expenses:			
Operating	0	0	6,452,000
Total costs and expenses	0	0	6,452,000
Other income (expense):			
Gain (loss) on sales of real estate, net	0	0	1,344,000
Other income (expense), net	0	0	169,000
Total other income (expense), net	0	0	1,513,000
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	0	0	2,550,000
Income tax benefit (expense)	0	0	270,000
Equity income (loss) from unconsolidated joint ventures	0	0	64,000
Income (loss) from discontinued operations	\$ 0	\$ 0	\$ 2,884,000

XML 98 R79.htm
IDEA: XBRL DOCUMENT

Impairments of Real Estate (Details)	12 Months Ended		
	Dec. 31, 2024 USD (\$) property	Dec. 31, 2023 USD (\$) property	Dec. 31, 2022 USD (\$) property
Impaired Long-Lived Assets Held and Used [Line Items]			
Impairment of real estate		\$ 0	\$ 0
Insured event loss	\$ (29,076,000)	3,085,000	(7,168,000)
Outpatient Medical			
Impaired Long-Lived Assets Held and Used [Line Items]			
Impairment of real estate	\$ 13,000,000		
Number of real estate properties impaired property	1		
Outpatient Medical Held-for-sale			
Impaired Long-Lived Assets Held and Used [Line Items]			
Aggregate carrying value before impairment	\$ 21,000,000		
Real estate held-for-sale	8,000,000		
Casualty-Related Losses			
Impaired Long-Lived Assets Held and Used [Line Items]			
Insured event loss	30,000,000	(3,000,000)	6,000,000
Casualty-Related Losses Rental Revenues And Resident Fees And Services			
Impaired Long-Lived Assets Held and Used [Line Items]			
Insured event loss	\$ 700,000	\$ 4,000,000	3,000,000
Planned MOB Demolition, Tenant Relocation And Other Costs			
Impaired Long-Lived Assets Held and Used [Line Items]			
Expense on other			\$ 14,000,000

XML 99 R80.htm
IDEA: XBRL DOCUMENT

Leases - Lease Income (Details) - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]			
Fixed income from operating leases	\$ 1,530,493	\$ 1,236,502	\$ 1,182,463
Variable income from operating leases	556,703	395,303	359,312
Interest income from direct financing leases	\$ 0	\$ 0	\$ 1,168

XML 100 R81.htm
IDEA: XBRL DOCUMENT

Leases - Narrative (Details) - USD (\$)	3 Months Ended		12 Months Ended	
\$ in Thousands	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessor, Lease, Description [Line Items]				
Proceeds from sale of lease receivables	\$ 68,000			
Gain on sale of direct financing lease	\$ 23,000			
General and administrative		\$ 97,162	\$ 95,132	\$ 131,033
Corporate Segment Continuing Operations				
Lessor, Lease, Description [Line Items]				
General and administrative			\$ 7,000	

XML 101 R82.htm
IDEA: XBRL DOCUMENT

Leases - Future Minimum Rents (Details) \$ in Thousands	Dec. 31, 2024 USD (\$)
Leases [Abstract]	
2025	\$ 1,427,402
2026	1,339,275
2027	1,246,068
2028	1,138,062
2029	1,003,394
Thereafter	3,681,731
Total	\$ 9,835,932

XML 102 R83.htm IDEA: XBRL DOCUMENT

Leases - Tenant Purchase Options (Details) \$ in Thousands	Dec. 31, 2024 USD (\$) property
Leases [Abstract]	
2025 \$	\$ 16,109
2026 \$	19,071
2027 \$	8,415
2028 \$	16,209
2029 \$	6,053
Thereafter \$	22,364
Total \$	\$ 88,221

Number of Properties

2025 property	12
2026 property	8
2027 property	4
2028 property	5
2029 property	7
Thereafter property	9
Total property	45

XML 103 R84.htm IDEA: XBRL DOCUMENT

Leases - Lease Costs (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]			
Total lease expense	\$ 22,768	\$ 17,010	\$ 16,689
Weighted average remaining lease term (years)	48 years	51 years	
Weighted average discount rate, operating leases	4.79%	4.23%	
Option to extend lease, term	66 years	67 years	

XML 104 R85.htm IDEA: XBRL DOCUMENT

Leases - Future Lease Obligations (Details) \$ in Thousands	Dec. 31, 2024 USD (\$)
Leases [Abstract]	
2025	\$ 21,514
2026	18,423
2027	18,434
2028	18,489
2029	18,687
Thereafter	738,666
Undiscounted minimum lease payments included in the lease liability	834,213
Less: imputed interest	(526,993)
Present value of lease liability	\$ 307,220

XML 105 R86.htm IDEA: XBRL DOCUMENT

Leases - Depreciation Expense (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessor, Lease, Description [Line Items]			
Corporate assets	\$ 38	\$ 39	
General and Administrative Expense			
Lessor, Lease, Description [Line Items]			
Depreciation expense related to corporate assets	2	3	\$ 3
Other Assets			
Lessor, Lease, Description [Line Items]			
Accumulated depreciation related to corporate assets	\$ 8	\$ 10	

XML 106 R87.htm IDEA: XBRL DOCUMENT

Leases - Denver Office Relocation (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessor, Lease, Description [Line Items]			
General and administrative	\$ 97,162	\$ 95,132	\$ 131,033
Corporate Segment Continuing Operations			
Lessor, Lease, Description [Line Items]			
General and administrative		\$ 7,000	

XML 107 R88.htm IDEA: XBRL DOCUMENT

Leases - Tenant Updates (Details) ft² in Thousands, \$ in Thousands, squareFeet in Millions	Oct. 26, 2023 USD (\$) lease	1 Months Ended Jul. 31, 2024 ft² squareFeet	3 Months Ended Mar. 31, 2023 USD (\$) lease	12 Months Ended			
				Dec. 31, 2024 USD (\$) lease	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)	Jun. 30, 2024
Lessor, Lease, Description [Line Items]							
Straight line rent				\$ 41,276	\$ 14,387	\$ 49,183	
Litigation settlement, amount awarded from other party					4,000		
Cash paid for amounts included in the measurement of lease liability for operating leases				\$ 21,277	\$ 21,488	\$ 12,594	
Operating lease, area of square feet renewed squareFeet		2					
Operating lease, percentage of annual lease escalations		0.030					0.025
Area of square feet with early termination right ft²		200					
Sorrento Therapeutics, Inc.							
Lessor, Lease, Description [Line Items]							
Straight line rent			\$ 9,000				
Number of leases lease			4	4			

Loans receivable, floor rate percentage	7.00%			
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months Secured Mortgage Loans				
Loans receivable				
Variable rate	6.00%			
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, Last Six Months Secured Mortgage Loans				
Loans receivable				
Variable rate	7.00%			
Loans receivable, extension fee	\$ 1,000			
Senior Housing Operating Portfolio				
Loans receivable				
Proceeds from sale of buildings	\$ 230,000			
Investments in loans receivable	\$ 150,000			
Loans receivable, net				
Number of assets sold property	16			
Senior Housing Operating Portfolio Secured Mortgage Loans				
Loans receivable				
Loans receivable, net				
Sunrise Senior Housing Portfolio				
Loans receivable				
Number of properties sold facility	32			
Proceeds from sale of buildings	\$ 664,000			
Investments in loans receivable	410,000			
Capital expenditure funding, amount committed	\$ 1,000			
Capital expenditure funding, cost of capital, percent committed	\$ 92,000 40,000			
Proceeds from the collection of loans receivable	65.00%			
	\$ 5,000	\$ 69,000	\$ 45,000	\$ 246,000
Capital expenditure funding, amount funded	\$ 11,000			
Sunrise Senior Housing Portfolio Secured Overnight Financing Rate (SOFR)				
Loans receivable				
Loans receivable, conversion of basis spread on variable rate	0.10%			
Loans receivable, floor rate percentage	9.00%			
Sunrise Senior Housing Portfolio Secured Overnight Financing Rate (SOFR), First Two Years				
Loans receivable				
Variable rate	4.00%			
Loan receivable, extended maturity term	2 years			
Sunrise Senior Housing Portfolio Secured Overnight Financing Rate (SOFR), Last Eighteen Months				
Loans receivable				
Variable rate	5.00%			
Loan receivable, extended maturity term	18 months			

XML 111 R92.htm
IDEA: XBRL DOCUMENT

Loans Receivable - Outpatient Medical Seller Financing (Details) \$ in Millions	1 Months Ended		12 Months Ended	
	Jul. 31, 2024		Dec. 31, 2024	
	USD (\$)		USD (\$)	
	property extension_option		property	
Outpatient Medical Buildings				
Loans Receivable:				
Number of assets sold property	59		59	
Proceeds from sale of buildings	\$ 674		\$ 674	
Investments in loans receivable	\$ 405		405	
Loans receivable, number of extensions extension_option	2			
Loan receivable, period of extensions	12 months			
Proceeds from loan originations	\$ 1			
Mark to market discount of real estate			21	
Non-cash interest income			\$ 3	
Outpatient Medical Buildings Minimum				
Loans Receivable:				
Loans receivable, interest rate	0.060			
Outpatient Medical Buildings Maximum				
Loans Receivable:				
Loans receivable, interest rate	0.065			
Two Outpatient Medical Buildings				
Loans Receivable:				
Number of assets sold property			2	
Proceeds from sale of buildings			\$ 23	
Investments in loans receivable			\$ 14	

XML 112 R93.htm
IDEA: XBRL DOCUMENT

Loans Receivable - 2025 Loans Receivable Transactions (Details) - Secured Mortgage Loans \$ in Millions	1 Months Ended								12 Months Ended
									Dec. 31, 2024
									USD (\$)
	Mar. 01, 2024	Jan. 31, 2025	Oct. 31, 2023	May 31, 2023	Apr. 30, 2023	Feb. 28, 2023	Dec. 31, 2022	May 31, 2022	
	USD (\$)	extension_option loan	USD (\$)	USD (\$) loan	USD (\$) loan	USD (\$) loan	USD (\$) loan	loan	
Loans Receivable:									
Outstanding balance	\$ 89					\$ 102			
Proceeds from the collection of loans receivable									
Other									
Loans Receivable:									
Outstanding balance							\$ 61		\$ 85
Secured loan loan			1	1	1	4		1	
Proceeds from the collection of loans receivable			\$ 21	\$ 21	\$ 14	\$ 35			
Other Subsequent Event									
Loans Receivable:									
Outstanding balance		\$ 67							
Loans receivable, number of extensions extension_option		1							
Loan receivable, period of extensions		12 months							
Loans receivable, interest rate		0.08							
Payments for loans receivable		\$ 28							
Secured loan loan		1							
Proceeds from the collection of loans receivable		\$ 15							

Other | Subsequent Event | Lab

Loans Receivable:

Outstanding balance

\$ 75

XML 113 R94.htm IDEA: XBRL DOCUMENT

Loans Receivable - 2024 Loans Receivable Transactions (Details)	1 Months Ended						12 Months Ended	
	Mar. 01, 2024 USD (\$) loan	May 31, 2023 loan	Apr. 30, 2023 loan	Feb. 28, 2023 loan	Dec. 31, 2022 USD (\$) loan	Nov. 30, 2022 loan	May 31, 2022 loan	Dec. 31, 2024 USD (\$) loan
Secured Mortgage Loans								
Loans Receivable:								
Outstanding balance	\$ 89,000,000							
Number of loans loan	9							
Mezzanine loans								
Loans Receivable:								
Outstanding balance	\$ 36,000,000							
Number of loans loan	10							
Other Secured Mortgage Loans								
Loans Receivable:								
Outstanding balance					\$ 61,000,000			\$ 85,000,000
Secured loan loan		1	1	1	4		1	
Other Mezzanine loans								
Loans Receivable:								
Outstanding balance								\$ 15,000,000
Loans receivable, interest rate								0.1100
Number of loans loan						1		
Other Construction loan commitments								
Loans Receivable:								
Outstanding balance								\$ 36,000,000
Loans receivable, interest rate								0.0800
Payments for loans receivable								\$ 0
Other During June 2024 to June 2025 Secured Mortgage Loans								
Loans Receivable:								
Outstanding balance								\$ 12,000,000
Secured loan loan								1
Other During June 2024 to June 2025 Mezzanine loans								
Loans Receivable:								
Outstanding balance								\$ 1,000,000
Number of loans loan								1
Other During May 2026 to May 2027 Mezzanine loans								
Loans Receivable:								
Outstanding balance								\$ 2,000,000
Number of loans loan								1
Other During October 2024 to April 2026 Mezzanine loans								
Loans Receivable:								
Outstanding balance								\$ 2,000,000
Number of loans loan								1

XML 114 R95.htm IDEA: XBRL DOCUMENT

Loans Receivable - 2023 Loans Receivable Transactions (Details) \$ in Millions	Jan. 31, 2024	Oct. 31, 2023 USD (\$)	1 Months Ended May 31, 2023 USD (\$) loan	Apr. 30, 2023 USD (\$) loan	Feb. 28, 2023 USD (\$) loan	Dec. 31, 2022 loan	May 31, 2022 loan
Secured Mortgage Loans							
Loans Receivable:							
Proceeds from the collection of loans receivable					\$ 102		
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Secured Overnight Financing Rate (SOFR)						
Loans receivable, conversion of basis spread on variable rate	0.11%						
Other Secured Mortgage Loans							
Loans Receivable:							
Secured loan loan			1	1	1	4	1
Proceeds from the collection of loans receivable		\$ 21	\$ 21	\$ 14	\$ 35		
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]			Secured Overnight Financing Rate (SOFR)				
Loans receivable, conversion of basis spread on variable rate			0.10%				
Other Secured Mortgage Loans 1							
Loans Receivable:							
Secured loan loan			2				
Proceeds from the collection of loans receivable			\$ 12				

XML 115 R96.htm IDEA: XBRL DOCUMENT

Loans Receivable - 2022 Loans Receivable Transactions (Details) \$ in Millions	Mar. 01, 2024 USD (\$) loan	May 31, 2023 loan	Apr. 30, 2023 loan	Feb. 28, 2023 loan	1 Months Ended Dec. 31, 2022 USD (\$) loan	Nov. 30, 2022 USD (\$) loan	May 31, 2022 USD (\$) loan	12 Months Ended Dec. 31, 2024 USD (\$)
Secured Mortgage Loans								
Loans Receivable:								
Number of loans loan	9							
Outstanding balance	\$ 89							
Mezzanine loans								
Loans Receivable:								
Number of loans loan	10							
Outstanding balance	\$ 36							
Other Secured Mortgage Loans								
Loans Receivable:								
Secured loan loan		1	1	1	4		1	
Principal repayments received							\$ 2	
Outstanding balance					\$ 61			\$ 85
Loans receivable, term					1 year			
Variable rate					0.10%			
Other Mezzanine loans								

Loans Receivable:

Principal repayments received	\$ 1
Number of loans loan	1
Outstanding balance	\$ 15
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months Secured Mortgage Loans	
Loans Receivable:	
Variable rate	6.00%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six Months Other Secured Mortgage Loans	
Loans Receivable:	
Variable rate	8.50%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, Last Six Months Secured Mortgage Loans	
Loans Receivable:	
Variable rate	7.00%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, Last Six Months Other Secured Mortgage Loans	
Loans Receivable:	
Variable rate	10.50%

XML 116 R97.htm IDEA: XBRL DOCUMENT

Loans Receivable - CCRC Resident Loans (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Loans Receivable:		
Loans receivable, net	\$ 717,190	\$ 218,450
Brookedale MTCA CCRC JV Investment Other		
Loans Receivable:		
Loans receivable, net	\$ 61,000	\$ 43,000

XML 117 R98.htm IDEA: XBRL DOCUMENT

Loans Receivable - Schedule of Loans Receivable by Origination Year (Details) \$ in Thousands	Dec. 31, 2024 USD (\$)
Secured loans	
Loans receivable	
2024	\$ 433,801
2023	48,663
2022	25,232
2021	105,088
2020	0
Prior	0
Total	612,784
Secured loans Performing loans	
Loans receivable	
2024	433,801
2023	48,663
2022	25,232
2021	105,088
2020	0
Prior	0
Total	612,784
Secured loans Watch list loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Secured loans Workout loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Secured loans Current period gross write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Secured loans Current period recoveries	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Secured loans Current period net write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0

Mezzanine loans	
Loans receivable	
2024	13,653
2023	5,284
2022	4,446
2021	6,572
2020	10,094
Prior	3,084
Total	43,133
Mezzanine loans Performing loans	
Loans receivable	
2024	13,653
2023	5,284
2022	4,446
2021	6,572
2020	10,094
Prior	3,084
Total	43,133
Mezzanine loans Watch list loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Mezzanine loans Workout loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Mezzanine loans Current period gross write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Mezzanine loans Current period recoveries	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Mezzanine loans Current period net write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
CCRC resident loans	
Loans receivable	
2024	59,321
2023	1,790
2022	162
2021	0
2020	0
Prior	0
Total	61,273
CCRC resident loans Performing loans	
Loans receivable	
2024	59,321
2023	1,790
2022	162
2021	0
2020	0
Prior	0
Total	61,273
CCRC resident loans Watch list loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
CCRC resident loans Workout loans	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0

Total	0
CCRC resident loans Current period gross write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
CCRC resident loans Current period recoveries	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
CCRC resident loans Current period net write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
CCRC resident loans Current period net write-offs	
Loans receivable	
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	\$ 0

XML 118 R99.htm IDEA: XBRL DOCUMENT

Loans Receivable -		12 Months Ended	
Loan Losses (Details)			
- USD (\$)		Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands			
<u>Financing Receivable, Allowance for Credit Loss [Roll Forward]</u>			
Reserve for loan losses, beginning of period	\$ 2,830		\$ 8,280
Provision for expected loan losses on funded loans receivable	7,669		2,088
Expected loan losses related to loans sold or repaid	0		(7,538)
Reserve for loan losses, end of period	10,499		2,830
Credit loss reserve on unfunded loan commitments	2,900		700
<u>Secured Loans</u>			
<u>Financing Receivable, Allowance for Credit Loss [Roll Forward]</u>			
Reserve for loan losses, beginning of period	2,830		8,280
Provision for expected loan losses on funded loans receivable	2,744		2,088
Expected loan losses related to loans sold or repaid	0		(7,538)
Reserve for loan losses, end of period	5,574		2,830
<u>Mezzanine And Other</u>			
<u>Financing Receivable, Allowance for Credit Loss [Roll Forward]</u>			
Reserve for loan losses, beginning of period	0		0
Provision for expected loan losses on funded loans receivable	4,925		0
Expected loan losses related to loans sold or repaid	0		0
Reserve for loan losses, end of period	\$ 4,925		\$ 0

XML 119 R100.htm IDEA: XBRL DOCUMENT

		1 Months Ended			
Investments in and Advances to Unconsolidated Joint Ventures - Schedule of Equity Method Investments (Details)		Apr. 30, 2023	Apr. 28, 2023	Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands		USD (\$) property	USD (\$) property	USD (\$) property joint_venture	USD (\$)
Schedule of Equity Method Investments [Line Items]					
Investments in and advances to unconsolidated joint ventures \$				\$ 936,814	\$ 782,853
Medical Office JVs					
Schedule of Equity Method Investments [Line Items]					
Property count property		2			
Number of unconsolidated joint ventures joint_venture				2	
HCP Ventures IV, LLC					
Schedule of Equity Method Investments [Line Items]					
Property count property		1	1		
Investment ownership percentage		80.00%	80.00%	20.00%	
Payments to acquire equity method investments \$		\$ 4,000	\$ 4,000		
Suburban Properties, LLC					
Schedule of Equity Method Investments [Line Items]					
Investment ownership percentage				67.00%	
Lab Buildings South San Francisco JVs					
Schedule of Equity Method Investments [Line Items]					
Property count property				7	
Investment ownership percentage				70.00%	
Equity method investments \$				\$ 446,145	393,374
Lab Buildings Callan Ridge JV					
Schedule of Equity Method Investments [Line Items]					
Property count property				2	
Investment ownership percentage				35.00%	
Equity method investments \$				\$ 69,709	0
Lab Buildings Lab JV					
Schedule of Equity Method Investments [Line Items]					
Property count property				1	
Investment ownership percentage				49.00%	
Equity method investments \$				\$ 29,916	31,761
Lab Buildings Needham Land Parcel JV					
Schedule of Equity Method Investments [Line Items]					
Property count property				0	
Investment ownership percentage				38.00%	
Equity method investments \$				\$ 21,348	17,084
Other SWF SH JV					
Schedule of Equity Method Investments [Line Items]					
Property count property				19	
Investment ownership percentage				54.00%	
Equity method investments \$				\$ 322,551	332,693
Outpatient Medical PMAK JV					

Schedule of Equity Method Investments [Line Items]

Property count property	59	
Investment ownership percentage	12.00%	
Equity method investments \$	\$ 32,511	0
Outpatient Medical Davis JV		

Schedule of Equity Method Investments [Line Items]

Property count property	15	
Investment ownership percentage	49.00%	
Equity method investments \$	\$ 7,435	0
Outpatient Medical Medical Office JVs		

Schedule of Equity Method Investments [Line Items]

Property count property	2	
Equity method investments \$	\$ 7,199	\$ 7,941
Outpatient Medical Medical Office JVs Minimum		

Schedule of Equity Method Investments [Line Items]

Investment ownership percentage	20.00%	

Outpatient Medical | Medical Office JVs | Maximum

Schedule of Equity Method Investments [Line Items]

Investment ownership percentage	67.00%	

XML 120 R101.htm IDEA: XBRL DOCUMENT

Investments in and Advances to Unconsolidated Joint Ventures - Narrative (Details) \$ in Millions	Aug. 01, 2022 USD (\$) property	1 Months Ended Jan. 31, 2024 USD (\$) property	12 Months Ended Dec. 31, 2024 USD (\$)	Dec. 31, 2022 USD (\$)	Dec. 31, 2023 USD (\$)
Schedule of Equity Method Investments [Line Items]					
Difference between carrying amount and underlying equity			\$ 42		\$ 49
Gain (loss) on deconsolidation			\$ 78	\$ 311	
Life Science Joint Venture In San Francisco, California Lab					
Schedule of Equity Method Investments [Line Items]					
Investment ownership percentage	70.00%				
Property count property	7				
Callan Ridge JV Lab					
Schedule of Equity Method Investments [Line Items]					
Property count property		2			
Life Science Joint Venture In San Francisco, California Life Science Joint Venture In San Francisco, California Lab					
Schedule of Equity Method Investments [Line Items]					
Investment ownership percentage	30.00%				
Cash proceeds	\$ 126				
Callan Ridge JV Callan Ridge JV					
Schedule of Equity Method Investments [Line Items]					
Investment ownership percentage		35.00%			
Callan Ridge JV Callan Ridge JV Lab					
Schedule of Equity Method Investments [Line Items]					
Investment ownership percentage		65.00%			
Cash proceeds		\$ 128			

XML 121 R102.htm IDEA: XBRL DOCUMENT

Intangibles - Schedule of Intangibles Lease Assets (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023
Intangibles [Abstract]		
Gross intangible lease assets	\$ 1,468,985	\$ 739,228
Accumulated depreciation and amortization	(651,731)	(425,072)
Intangible assets, net	\$ 817,254	\$ 314,156
Weighted average remaining amortization period in years	5 years	5 years
Gross lease-up intangibles	\$ 1,420,000	\$ 725,000
Gross above market lease intangibles	45,000	14,000
Depreciation and amortization of lease-up intangibles	640,000	418,000
Depreciation and amortization of above market lease intangibles	\$ 12,000	\$ 7,000

XML 122 R103.htm IDEA: XBRL DOCUMENT

Intangibles - Schedule of Intangible Lease Liabilities (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023
Intangibles [Abstract]		
Gross intangible lease liabilities	\$ 351,602	\$ 228,105
Accumulated depreciation and amortization	(159,718)	(100,725)
Intangible liabilities, net	\$ 191,884	\$ 127,380
Weighted average remaining amortization period in years	9 years	7 years

XML 123 R104.htm IDEA: XBRL DOCUMENT

Intangibles - Amortization of Deferred Leasing Costs and Acquisition Related Intangibles (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Intangibles [Abstract]			
Depreciation and amortization expense related to amortization of lease-up intangibles	\$ 273,146	\$ 102,249	\$ 104,885
Rental and related revenues related to amortization of net below market lease liabilities	\$ 62,894	\$ 27,012	\$ 24,640

XML 124 R105.htm IDEA: XBRL DOCUMENT

Intangibles - Narrative (Details) - USD (\$)	12 Months Ended Mar. 01, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]				
Finite-lived intangible assets acquired	\$ 891,000,000		\$ 500,000	
Lease-up intangibles	852,000,000			
Above market lease, intangibles	39,000,000			
Intangible liabilities acquired	\$ 150,000,000			
Intangible assets, weighted average amortization, useful life	6 years			
Intangible liabilities, weighted average amortization, useful life	9 years			
Weighted average remaining amortization period in years		5 years	5 years	

Goodwill	\$ 51,000,000	\$ 68,529,000	\$ 18,027,000	
Goodwill, impairment loss		\$ 0	\$ 0	\$ 0
Other Property				
Finite-Lived Intangible Assets [Line Items]				
Weighted average remaining amortization period in years			5 years	

XML 125 R106.htm IDEA: XBRL DOCUMENT

Intangibles -				
Estimated Aggregate				
Amortization of				
Intangible Assets and				
Liabilities (Details) -				
USD (\$)				
\$ in Thousands				
Estimated aggregate amortization of Intangible Assets				
Intangible assets, net	\$ 817,254	\$ 314,156		
Rental and Related Revenues				
Estimated aggregate amortization of Intangible Assets				
2025	32,618			
2026	29,231			
2027	23,304			
2028	17,899			
2029	13,168			
Thereafter	42,816			
Intangible assets, net	159,036			
Depreciation and Amortization				
Estimated aggregate amortization of Intangible Assets				
2025	256,925			
2026	171,520			
2027	107,925			
2028	77,072			
2029	53,829			
Thereafter	117,135			
Intangible assets, net	\$ 784,406			

XML 126 R107.htm IDEA: XBRL DOCUMENT

Intangibles -				
Schedule of Goodwill				
Segments (Details) -				
USD (\$)				
\$ in Thousands				
Finite-Lived Intangible Assets [Line Items]				
Goodwill	\$ 68,529	\$ 51,000	\$ 18,027	
Outpatient Medical				
Finite-Lived Intangible Assets [Line Items]				
Goodwill	64,680		14,178	
CCRC				
Finite-Lived Intangible Assets [Line Items]				
Goodwill	1,998		1,998	
Other				
Finite-Lived Intangible Assets [Line Items]				
Goodwill	\$ 1,851		\$ 1,851	

XML 127 R108.htm IDEA: XBRL DOCUMENT

Debt - The Merger				
(Details)				
\$ in Thousands				
12 Months Ended				
Mar. 01, 2024				
USD (\$)				
building				
derivative_held				
Dec. 31, 2024				
USD (\$)				
derivative_held				
Feb. 28, 2023				
derivative_held				
Aug. 31, 2022				
derivative_held				
Apr. 30, 2022				
derivative_held				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative_held		1		
Capitalized costs	\$ 1,000			
Net discount on mortgage debt		\$ 139,999		
Cash Flow Hedging Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative_held		2		
Interest rate swap instruments Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative_held			2	
Interest rate swap instruments Cash Flow Hedging Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative_held		2		2
Senior Unsecured Term Loan				
Debt Instrument [Line Items]				
Face amount	1,250,000			
2028 Term Loan Senior Unsecured Term Loan				
Debt Instrument [Line Items]				
Face amount	\$ 400,000			
Interest rate, effective percentage	4.44%			
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]				
	Secured Overnight Financing Rate (SOFR)			
Loan, basis spread on variable rate	0.10%	1.00%		
2028 Term Loan Senior Unsecured Term Loan Minimum				
Debt Instrument [Line Items]				
Loan, basis spread on variable rate	0.85%			
2028 Term Loan Senior Unsecured Term Loan Maximum				
Debt Instrument [Line Items]				
Loan, basis spread on variable rate	1.65%			
2028 Term Loan Senior Unsecured Term Loan Interest rate swap instruments Cash Flow Hedging Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative_held	3			
Senior Unsecured Notes Due 2027				
Debt Instrument [Line Items]				
Face amount	\$ 400,000			
Interest rate (as a percent)	4.30%			
Senior Unsecured Notes Due 2028				
Debt Instrument [Line Items]				
Face amount	\$ 350,000			
Interest rate (as a percent)	3.95%			

Senior Unsecured Notes Due 2031

Debt Instrument [Line Items]

Face amount	\$ 500,000
Interest rate (as a percent)	2.63%
Mortgage Debt	

Debt Instrument [Line Items]

Face amount	\$ 128,000
Interest payment	\$ 59,000
Bearing fixed interest rate (as a percent)	3.77%
Variable interest, amount	\$ 69,000
Bearing variable interest rate (as a percent)	7.25%
Net discount on mortgage debt	\$ 500

Mortgage Debt | Outpatient Medical Buildings

Debt Instrument [Line Items]

Property count building	5
Debt assumed	\$ 259,000
Mortgage Debt Interest rate swap instruments Cash Flow Hedging Designated as Hedging Instrument	

Debt Instrument [Line Items]

Face amount	\$ 36,000
Number of interest-rate contracts held derivative held	1

XML 128 R109.htm IDEA: XBRL DOCUMENT

Debt - Bank Line of Credit and Term Loan (Details)	Mar. 01, 2024 USD (\$)	Aug. 22, 2022 USD (\$) loan	May 23, 2019 USD (\$) renewal_option	1 Months Ended		12 Months Ended		Feb. 29, 2024 USD (\$)	Jan. 31, 2024	Dec. 31, 2023 USD (\$)	Oct. 31, 2022 USD (\$)	Aug. 31, 2022 derivative_held
				Dec. 31, 2024 USD (\$) derivative_held renewal_option	Sep. 30, 2021 USD (\$) renewal_option	Dec. 31, 2024 USD (\$) derivative_held renewal_option						
Debt Instrument [Line Items]												
Bank line of credit and commercial paper				\$ 150,000,000		\$ 150,000,000				\$ 720,000,000		
Number of interest-rate contracts held derivative_held				1		1						
Interest rate swap instruments Designated as Hedging Instrument												
Debt Instrument [Line Items]												
Number of interest-rate contracts held derivative_held												2
Term Loan Agreement												
Debt Instrument [Line Items]												
Line of credit facility, maximum borrowing capacity	\$ 1,500,000,000							\$ 1,000,000,000				
Bank line of credit and commercial paper				\$ 1,250,000,000		\$ 1,250,000,000				500,000,000		
Number of loans loan		2										
Debt instrument, covenant secured debt to assets (as a percent)				40.00%		40.00%						
Debt instrument, covenant unsecured debt to unencumbered assets (as a percent)				60.00%		60.00%						
Debt instrument, covenant minimum fixed charge coverage ratio				1.5		1.5						
Debt instrument, covenant net worth, minimum				\$ 7,700,000,000		\$ 7,700,000,000						
Term Loan Agreement Interest rate swap instruments												
Debt Instrument [Line Items]												
Fixed interest rate				3.76%		3.76%						
Unsecured Term Loan												
Debt Instrument [Line Items]												
Face amount	\$ 750,000,000											
Debt instrument, term (in months)	5 years											
Unused borrowing capacity				\$ 250,000,000		\$ 250,000,000						
Unsecured Term Loan 2029 Term Loan												
Debt Instrument [Line Items]												
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]		Secured Overnight Financing Rate (SOFR)										
Loan, basis spread on variable rate						0.95%						
Interest rate, effective percentage										4.66%		
Revolving Credit Facility Bank Line of Credit												
Debt Instrument [Line Items]												
Line of credit facility, maximum borrowing capacity			\$ 2,500,000,000		\$ 3,000,000,000							
Number of extensions (in renewal options) renewal_option			2	2	2	2						
Length of debt instrument extension period			6 months	6 months	6 months							
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]										Secured Overnight Financing Rate (SOFR)		

Loan, basis spread on variable rate		0.10%	
Debt instrument, facility fee (as a percent)		0.15%	
Line of credit facility additional aggregate amount, maximum		\$ 750,000,000	
Bank line of credit and commercial paper	\$ 0	\$ 0	\$ 0
Revolving Credit Facility Bank Line of Credit Variable Rate Component One			
Debt Instrument [Line Items]			
Loan, basis spread on variable rate		0.88%	
Term Loan Facilities Term Loan Agreement			
Debt Instrument [Line Items]			
Debt instrument, covenant debt to assets (as a percent)	60.00%	60.00%	
Term Loan Facilities Bank Line of Credit Term Loan Agreement			
Debt Instrument [Line Items]			
Length of debt instrument extension period	1 year		
Face amount	\$ 500,000,000		\$ 500,000,000
Debt instrument, period after closing	180 days		
Debt instrument, term (in months)	4 years 6 months		
Term Loan Facilities One Bank Line of Credit Term Loan Agreement			
Debt Instrument [Line Items]			
Line of credit facility, maximum borrowing capacity	\$ 250,000,000		
Term Loan Facilities Two Bank Line of Credit Term Loan Agreement			
Debt Instrument [Line Items]			
Line of credit facility, maximum borrowing capacity	\$ 250,000,000		
Debt instrument, term (in months)	5 years		
2027 Term Loan Facilities Bank Line of Credit Term Loan Agreement			
Debt Instrument [Line Items]			
Debt instrument, interest rate, reduction available for sustainability metrics	0.0001		
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Secured Overnight Financing Rate (SOFR)		
Loan, basis spread on variable rate		0.94%	

XML 129 R110.htm IDEA: XBRL DOCUMENT

Debt - Commercial Paper Program (Details) - Commercial Paper Program - USD (\$)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]			
Maximum borrowing capacity	\$ 2,000,000,000	\$ 2,000,000,000	
Interest expense related to fees and amortization of debt issuance costs	9,000,000	9,000,000	\$ 9,000,000
Short-term debt	\$ 150,000,000	\$ 720,000,000	
Term of facility	25 days	37 days	
Weighted-average interest rate (as a percent)	4.65%	5.70%	

XML 130 R111.htm IDEA: XBRL DOCUMENT

Debt - Senior Unsecured Notes (Details) - USD (\$) \$ in Thousands	Feb. 04, 2025 Dec. 31, 2024 Mar. 01, 2024 Dec. 31, 2023 May 10, 2023 Jan. 17, 2023			
Debt Instrument [Line Items]				
Long-term debt, gross		\$ 8,856,048		
Senior Unsecured Notes				
Debt Instrument [Line Items]				
Long-term debt, gross		\$ 6,700,000		\$ 5,500,000
Face amount			\$ 1,250,000	
Senior Unsecured Notes Senior Unsecured Notes 5.25%				
Debt Instrument [Line Items]				
Face amount			\$ 350,000	\$ 400,000
Interest rate (as a percent)			5.25%	5.25%
Senior Unsecured Notes Senior Unsecured Notes 3.40% Subsequent Event				
Debt Instrument [Line Items]				
Interest rate (as a percent)	3.40%			
Repayments of debt	\$ 348,000			

XML 131 R112.htm IDEA: XBRL DOCUMENT

Debt - Mortgage Debt (Details) \$ in Thousands	1 Months Ended	12 Months Ended					
	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2022	Feb. 28, 2023	Aug. 31, 2022
	USD (\$) loan	USD (\$) derivative_held	USD (\$) derivative_held	USD (\$) derivative_held	USD (\$) derivative_held	derivative_held	derivative_held

	facility	facility	facility	
Debt Instrument [Line Items]				
Principal balance on debt		\$ 8,856,048		
Number of interest-rate contracts held derivative held		1		
Cash Flow Hedging Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative held		2		
Interest rate swap instruments Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative held			2	
Interest rate swap instruments Cash Flow Hedging Designated as Hedging Instrument				
Debt Instrument [Line Items]				
Number of interest-rate contracts held derivative held		2		2
Outpatient Medical Mortgage Debt				
Debt Instrument [Line Items]				
Property count facility		1		
Debt instrument, periodic payment, principal		\$ 23,000		
CCRC Mortgage Debt				
Debt Instrument [Line Items]				
Face amount	\$ 85,000		\$ 85,000	
Number of loans loan	1			
Mortgage Debt				
Debt Instrument [Line Items]				
Principal balance on debt	\$ 255,000	356,048	255,000	
Debt instrument, collateral, healthcare facilities carrying value	\$ 587,000	770,000	587,000	
Debt instrument, periodic payment, principal		\$ 27,000	\$ 90,000	\$ 5,000
Mortgage Debt Outpatient Medical				
Debt Instrument [Line Items]				
Property count facility	15	19	15	
Mortgage Debt Outpatient Medical Mortgage Debt				
Debt Instrument [Line Items]				
Property count facility		13		
Face amount		\$ 142,000		
Mortgage Debt CCRC				
Debt Instrument [Line Items]				
Property count facility	2	2	2	

XML 132 R113.htm
IDEA: XBRL DOCUMENT

Debt - Schedule of		12 Months Ended		
Debt Maturities				
(Details) - USD (\$)		Dec. 31, 2024 Dec. 31, 2023		
\$ in Thousands				
Debt Instrument [Line Items]				
2025	\$ 807,432			
2026	994,999			
2027	1,350,842			
2028	1,252,775			
2029	1,550,000			
Thereafter	2,900,000			
Long-term debt, gross	8,856,048			
Premiums, (discounts), and debt issuance costs, net	(139,999)			
Long-term debt	8,716,049			
Unamortized debt issuance expense	18,000			
Bank Line of Credit				
Debt Instrument [Line Items]				
2025	0			
2026	0			
2027	0			
2028	0			
2029	0			
Thereafter	0			
Long-term debt, gross	0			
Premiums, (discounts), and debt issuance costs, net	0			
Long-term debt	0			
Commercial Paper				
Debt Instrument [Line Items]				
2025	0			
2026	0			
2027	0			
2028	0			
2029	150,000			
Thereafter	0			
Long-term debt, gross	150,000			
Premiums, (discounts), and debt issuance costs, net	0			
Long-term debt	150,000			
Term Loans				
Debt Instrument [Line Items]				
2025	0			
2026	0			
2027	500,000			
2028	400,000			
2029	750,000			
Thereafter	0			
Long-term debt, gross	1,650,000			
Premiums, (discounts), and debt issuance costs, net	(3,957)			
Long-term debt	1,646,043			
Senior Unsecured Notes				
Debt Instrument [Line Items]				
2025	800,000			
2026	650,000			
2027	850,000			
2028	850,000			
2029	650,000			
Thereafter	2,900,000			
Long-term debt, gross	6,700,000	\$ 5,500,000		
Premiums, (discounts), and debt issuance costs, net	(136,744)			
Long-term debt	\$ 6,563,256			
Weighted-average interest rate (as a percent)	3.96%			

Weighted-average maturity	5 years	
Senior Unsecured Notes 2025		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.92%	
Senior Unsecured Notes 2026		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.40%	
Senior Unsecured Notes 2027		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.23%	
Senior Unsecured Notes 2028		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.53%	
Senior Unsecured Notes 2029		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.65%	
Senior Unsecured Notes Thereafter		
Debt Instrument [Line Items]		
Interest rate (as a percent)	4.51%	
Senior Unsecured Notes Minimum		
Debt Instrument [Line Items]		
Interest rate (as a percent)	1.54%	
Senior Unsecured Notes Maximum		
Debt Instrument [Line Items]		
Interest rate (as a percent)	6.87%	
Mortgage Debt		
Debt Instrument [Line Items]		
2025	\$ 7,432	
2026	344,999	
2027	842	
2028	2,775	
2029	0	
Thereafter	0	
Long-term debt, gross	356,048	\$ 255,000
Premiums, (discounts), and debt issuance costs, net	702	
Long-term debt	\$ 356,750	
Weighted-average interest rate (as a percent)	5.16%	
Weighted-average maturity	2 years	
Mortgage Debt 2025		
Debt Instrument [Line Items]		
Interest rate (as a percent)	6.28%	
Mortgage Debt 2026		
Debt Instrument [Line Items]		
Interest rate (as a percent)	5.13%	
Mortgage Debt 2027		
Debt Instrument [Line Items]		
Interest rate (as a percent)	5.59%	
Mortgage Debt 2028		
Debt Instrument [Line Items]		
Interest rate (as a percent)	5.34%	
Mortgage Debt 2029		
Debt Instrument [Line Items]		
Interest rate (as a percent)	0.00%	
Mortgage Debt Thereafter		
Debt Instrument [Line Items]		
Interest rate (as a percent)	0.00%	
Mortgage Debt Minimum		
Debt Instrument [Line Items]		
Interest rate (as a percent)	3.44%	
Mortgage Debt Maximum		
Debt Instrument [Line Items]		
Interest rate (as a percent)	8.50%	

XML 133 R114.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - DownREIT LLCs (Details) - property	Jan. 31, 2025	Dec. 31, 2024
Callan Ridge IV Lab		
Loss Contingencies [Line Items]		
Investment ownership percentage	49.00%	
Indemnification Agreement		
Loss Contingencies [Line Items]		
Number of properties, indemnification agreement	41	
Indemnification Agreement Subsequent Event		
Loss Contingencies [Line Items]		
Number of properties, indemnification agreement	13	

XML 134 R115.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligation (Details) \$ in Thousands	12 Months Ended		
	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024
	obligation	obligation	USD (\$)
Other Commitments [Line Items]			
Commitments			\$ 295,722
Development and redevelopment commitments			
Other Commitments [Line Items]			
Commitments			199,139
Lease and other contractual commitments			
Other Commitments [Line Items]			
Commitments			84,654
Letter of credit			
Other Commitments [Line Items]			
Commitments			\$ 11,929
Letter of credit Forecast			
Other Commitments [Line Items]			
Number of obligations expiring obligation	1	15	

XML 135 R116.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - Dividends and Issuance of Common Stock in Connection with the Mergers (Details) shares in Thousands	12 Months Ended					
	Feb. 03, 2025 \$ / shares	Feb. 02, 2025 \$ / shares	Mar. 01, 2024 shares	Dec. 31, 2024 \$ / shares shares	Dec. 31, 2023 \$ / shares	Dec. 31, 2022 \$ / shares
Subsequent Event [Line Items]						
Dividends declared per common share (in dollars per share)				\$ 1.20	\$ 1.20	\$ 1.20
Common Stock						
Subsequent Event [Line Items]						
Common stock convertible conversion ratio			0.674			
Shares issued as part of the Merger (in shares) shares			162,000	162,231		
Subsequent Event						
Subsequent Event [Line Items]						
Dividends declared per common share (in dollars per share)	\$ 0.305	\$ 0.30				

XML 136 R117.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - ATM Program (Details) - USD (\$)	1 Months Ended		12 Months Ended		
	Dec. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]					
Issuance of common stock, net		\$ 1,094,000	\$ 1,438,000	\$ 309,417,000	
At-The-Market Program					
Subsidiary or Equity Method Investee [Line Items]					
Aggregate amount authorized		\$ 1,500,000,000			
Maximum shares issuable under forward equity sales agreement (in shares)	9,100,000				9,100,000
Forward rate per share (in dollars per share)	\$ 34.01				\$ 35.25
Issuance of common stock, net	\$ 308,000,000				
At-The-Market Program Minimum					
Subsidiary or Equity Method Investee [Line Items]					
Option indexed to issuers equity, term		1 year			
At-The-Market Program Maximum					
Subsidiary or Equity Method Investee [Line Items]					
Option indexed to issuers equity, term		2 years			
2023 At-The-Market Program					
Subsidiary or Equity Method Investee [Line Items]					
Aggregate amount remaining		\$ 1,500,000,000			
ATM Direct Issuances Common Stock					
Subsidiary or Equity Method Investee [Line Items]					
Issuance of common stock, net (in shares)		0	0	0	

XML 137 R118.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - Share Repurchase Programs (Details) - USD (\$)	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2022	Jul. 24, 2024	Aug. 01, 2022
Share Repurchase Program [Line Items]				
Stock repurchase program, authorized amount				\$ 500,000,000
2022 Share Repurchase Program				
Share Repurchase Program [Line Items]				
Common stock repurchased (in shares)	10,500,000	2,100,000		
Average cost per share (in dollars per share)	\$ 17.98	\$ 27.16		
Stock repurchase program, total value	\$ 188,000,000	\$ 56,000,000		
2024 Share Repurchase Program				
Share Repurchase Program [Line Items]				
Stock repurchase program, authorized amount		\$ 500,000,000		
Common stock repurchased (in shares)	0			
Stock repurchase program, remaining authorized repurchase amount	\$ 500,000,000			

XML 138 R119.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - Schedule of Other Common Stock Activities (Details) - Common Stock - shares shares in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]			
Dividend Reinvestment and Stock Purchase Plan (in shares)	57	70	59
Conversion of DownREIT units (in shares)	256	72	27
Vesting of restricted stock units (in shares)	377	613	820
Repurchase of common stock (in shares)	10,592	241	2,418

XML 139 R120.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) \$ in Thousands	12 Months Ended	
	Dec. 31, 2024 USD (\$) plan_participant	Dec. 31, 2023 USD (\$)
Equity [Abstract]		
Unrealized gains (losses) on derivatives, net	\$ 30,707	\$ 21,245
Supplemental Executive Retirement Plan minimum liability	(1,889)	(1,874)
Total accumulated other comprehensive income (loss)	\$ 28,818	\$ 19,371
Number of plan participants plan_participant	1	

XML 140 R121.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests and	12 Months Ended				
	Feb. 10, 2023 shares	Dec. 31, 2024 unit	Dec. 31, 2023 unit	Apr. 30, 2024 USD (\$)	Mar. 01, 2024 interest

Healthpeak OP (Details) \$ in Millions	interest	
Noncontrolling Interest [Line Items]		
Number of redeemable noncontrolling interest interest		1
Number of redeemable noncontrolling interest with redemption conditions interest		4
Redemption value \$		\$ 53
Total Noncontrolling Interests		
Noncontrolling Interest [Line Items]		
Issuance of OP units (in units)	3,000,000	2,000,000
Issuance of OP units criteria redemption (in units)	76,000	0
Healthpeak OP		
Noncontrolling Interest [Line Items]		
Noncontrolling interest, ownership percentage by parent	100.00%	
Healthpeak OP Total Noncontrolling Interests		
Noncontrolling Interest [Line Items]		
Issuance of OP units (in units)	2,000,000	2,000,000
Common stock, unit redemption share amount shares	1	

XML 141 R122.htm IDEA: XBRL DOCUMENT

Equity and Redeemable Noncontrolling Interests - DownREITs (Details) \$ in Thousands, shares in Millions	Dec. 31, 2024 USD (\$) entity shares	Dec. 31, 2023 USD (\$) entity shares
Noncontrolling Interest [Line Items]		
Non-managing member unitholders \$	\$ 337,917	\$ 214,598
Total Noncontrolling Interests		
Noncontrolling Interest [Line Items]		
DownREIT units outstanding (in shares) shares	11	5
Common stock issuable (in shares) shares	14	7
Number of DownREIT LLCs (in entities) entity	8	7
Non-managing member unitholders \$	\$ 310,000	\$ 199,000

XML 142 R123.htm IDEA: XBRL DOCUMENT

Earnings Per Common Share - Computation of EPS (Details) - USD (\$) \$ / shares in Units, shares in Thousands, \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Numerator - Basic			
Income (loss) from continuing operations	\$ 267,303	\$ 334,757	\$ 513,540
Noncontrolling interests' share in continuing operations	(24,161)	(28,748)	(15,975)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	243,142	306,009	497,565
Less: Participating securities' share in continuing operations	(758)	(1,725)	(2,657)
Income (loss) from continuing operations applicable to common shares	242,384	304,284	494,908
Income (loss) from discontinued operations	0	0	2,884
Net income (loss) applicable to common shares	242,384	304,284	497,792
Add: distributions on dilutive convertible units and other	107	0	0
Dilutive net income (loss) available to common shares	\$ 242,491	\$ 304,284	\$ 497,792
Denominator			
Basic weighted average shares outstanding (in shares)	675,680	547,006	538,809
Dilutive potential common shares - equity awards (in shares)	148	269	338
Dilutive potential common shares - OP Units (in shares)	405	0	0
Diluted (in shares)	676,233	547,275	539,147
Basic earnings (loss) per common share:			
Continuing operations (in dollars per share)	\$ 0.36	\$ 0.56	\$ 0.92
Discontinued operations (in dollars per share)	0	0	0.00
Net income (loss) applicable to common shares (in dollars per share)	0.36	0.56	0.92
Diluted earnings (loss) per common share			
Continuing operations (in dollars per share)	0.36	0.56	0.92
Discontinued operations (in dollars per share)	0	0	0.00
Net income (loss) applicable to common shares (in dollars per share)	\$ 0.36	\$ 0.56	\$ 0.92
Outstanding equity awards (in shares)	1,000	1,000	1,000
Dilutive potential common shares - OP Units (in shares)	3,000		

XML 143 R124.htm IDEA: XBRL DOCUMENT

Earnings Per Common Share - Additional Information (Details) - shares	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]			
Forward sales agreements that have been settled (in shares)	0	0	
Down REIT			
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]			
Antidilutive securities excluded from computation of earnings per share (in shares)	14,000,000	7,000,000	7,000,000

XML 144 R125.htm IDEA: XBRL DOCUMENT

Compensation Plans - Stock Based Compensation (Details) - shares	Dec. 31, 2024 Apr. 23, 2023	
2006 Incentive Plan		
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]		
Maximum number of shares available for future awards (in shares)		0
2014 Incentive Plan		
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]		
Maximum number of shares available for future awards (in shares)		0
2023 Incentive Plan		
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]		
Maximum number of shares available for future awards (in shares)		28,000,000
Maximum number of shares reserved for awards (in shares)		31,000,000
Maximum number of shares available for future awards to be issued as restricted stock and performance restricted stock unit (in shares)		19,000,000

XML 145 R126.htm IDEA: XBRL DOCUMENT

Compensation Plans - Restricted Stock Awards (Details) shares in Thousands,	12 Months Ended		
	Dec. 31, 2024 USD (\$)	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)

unit in Millions, \$ in Millions	unit shares	unit shares	shares
Total Noncontrolling Interests			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Issuance of OP units (in units) unit	3	2	
Healthpeak OP Total Noncontrolling Interests			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Issuance of OP units (in units) unit	2	2	
Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Shares withheld to offset tax withholding obligations (in shares) shares	123	241	356
Market Based Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	3 years		
Expected term	3 years	3 years	3 years
Volatility rate	26.00%	33.00%	38.90%
Expected dividend yield	5.20%	4.40%	3.50%
Risk free interest rate	4.50%	4.40%	1.80%
Postvesting restrictions	10.00%	10.00%	5.80%
Total grant date fair value	\$ 11	\$ 9	\$ 27
Total fair values (at vesting) of restricted stock and restricted stock units vested	7	16	27
Time Based Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Total grant date fair value	11	9	27
Total fair values (at vesting) of restricted stock and restricted stock units vested	\$ 7	16	\$ 27
LTIP Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	3 years		
Percentage of performance metrics during performance period	10.00%		
Total grant date fair value	\$ 13	29	
Total fair values (at vesting) of restricted stock and restricted stock units vested	\$ 3	\$ 2	
Minimum Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	1 year		
Minimum Market Based Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Percentage of performance metrics during performance period	0.00%		
Minimum LTIP Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	3 years		
Percentage of performance metrics during performance period	0.00%		
Maximum Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	5 years		
Maximum Market Based Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Percentage of performance metrics during performance period	200.00%		
Maximum LTIP Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Stock-based awards, vesting period	6 years		
Percentage of performance metrics during performance period	200.00%		

XML 146 R127.htm IDEA: XBRL DOCUMENT

Compensation Plans - Stock Options (Details) - USD (\$) shares in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Total share-based compensation expense recognized	\$ 20,000,000	\$ 19,000,000	\$ 32,000,000
Accelerated cost		10,000,000	
Share-based payment arrangement, amount capitalized	4,000,000	\$ 4,000,000	4,000,000
Nonvested award, cost not yet recognized, amount	\$ 22,000,000		
Total unrecognized compensation cost, period of recognition	1 year 7 months 6 days		
Common Stock Options			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Number of stock options shares outstanding (in shares)	0.0	0.2	
Proceeds received from options exercised	\$ 0	\$ 0	0
Total share-based compensation expense recognized	\$ 0	\$ 0	\$ 0

XML 147 R128.htm IDEA: XBRL DOCUMENT

Compensation Plans - Schedule of Restricted Stock Unit and LTIP Unit activity (Details) shares in Thousands	12 Months Ended		
	Dec. 31, 2024 \$ / shares shares		
Restricted Stock Units			
Unvested restricted stock and performance restricted stock units activity			
Unvested at the beginning of the period (in shares) shares	879		
Granted (in shares) shares	597		
Vested (in shares) shares	(377)		
Forfeited (in shares) shares	(224)		
Unvested at the end of the period (in shares) shares	875		
Weighted Average Grant Date Fair Value			
Unvested at the beginning of the period, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	\$ 29.91		
Granted, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	17.69		
Vested, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	28.88		
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	27.20		
Unvested at the end of the period, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	\$ 22.70		
LTIP Units			
Unvested restricted stock and performance restricted stock units activity			
Unvested at the beginning of the period (in shares) shares	1,894		
Granted (in shares) shares	1,511		
Vested (in shares) shares	(199)		
Forfeited (in shares) shares	(304)		
Unvested at the end of the period (in shares) shares	2,902		
Weighted Average Grant Date Fair Value			
Unvested at the beginning of the period, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	\$ 14.26		
Granted, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	8.75		
Vested, Weighted Average Grant Date Fair Value (in dollars per share) \$ / shares	17.43		

Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) | \$ / shares12.70

Unvested at the end of the period, Weighted Average Grant Date Fair Value (in dollars per share) | \$ / shares\$ 10.88

XML 148 R129.htm IDEA: XBRL DOCUMENT

Compensation Plans - Departure of Executives (Details) - USD (\$) \$ in Millions	3 Months Ended		12 Months Ended	
	Dec. 31, 2022		Dec. 31, 2024	
			Dec. 31, 2023	
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Severance costs	\$ 10			
Accounts Payable and Accrued Liabilities				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Severance costs			\$ 4	
General and Administrative Expense			\$ 8	
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Severance costs	\$ 33			

XML 149 R130.htm IDEA: XBRL DOCUMENT

Segment Disclosures - Narrative (Details) \$ in Thousands	Dec. 31, 2024		Mar. 01, 2024		Dec. 31, 2023	
	USD (\$)		USD (\$)		USD (\$)	
	property					
Segment Reporting Information [Line Items]						
Number of facilities owned by unconsolidated joint venture property	19					
Goodwill	\$ 68,529		\$ 51,000		\$ 18,027	
Outpatient Medical						
Segment Reporting Information [Line Items]						
Goodwill	64,680				14,178	
CCRC						
Segment Reporting Information [Line Items]						
Goodwill	1,998				1,998	
Other						
Segment Reporting Information [Line Items]						
Goodwill	1,851				1,851	
Operating segment Outpatient Medical						
Segment Reporting Information [Line Items]						
Goodwill	65,000				14,000	
Operating segment CCRC						
Segment Reporting Information [Line Items]						
Goodwill	2,000				2,000	
Operating segment Other						
Segment Reporting Information [Line Items]						
Goodwill	\$ 2,000				\$ 2,000	

XML 150 R131.htm IDEA: XBRL DOCUMENT

Segment Disclosures - Schedule of Information for the Reportable Segments (Details) - USD (\$) \$ in Thousands	12 Months Ended			
	Dec. 31, 2024			
	Dec. 31, 2023			
	Dec. 31, 2022			
Segment Reporting Information, Revenue for Reportable Segment [Abstract]				
Total revenues	\$ 2,700,449	\$ 2,181,003	\$ 2,061,178	
Plus: Adjustments to NOI	106,539	52,456	75,967	
Interest income and other	44,778	21,781	23,300	
Interest expense	(280,430)	(200,331)	(172,944)	
Depreciation and amortization	(1,057,205)	(749,901)	(710,569)	
Corporate non-segment operating expenses		4,174		
General and administrative	(97,162)	(95,132)	(131,033)	
Transaction and merger-related costs	(132,685)	(17,515)	(4,853)	
Impairments and loan loss reserves, net	(22,978)	5,601	(7,004)	
Gain (loss) on sales of real estate, net	178,695	86,463	9,078	
Other income (expense), net	59,345	6,808	326,268	
Less: Government grant income		(184)	(6,765)	
Less: Healthpeak’s share of unconsolidated joint venture Adjusted NOI	(28,374)	(7,676)	(9,239)	
Plus: Noncontrolling interests’ share of consolidated joint venture Adjusted NOI	27,205	25,615	25,581	
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	273,168	314,936	507,130	
Operating Segment				
Segment Reporting Information, Revenue for Reportable Segment [Abstract]				
Total revenues	2,655,671	2,159,222	2,037,878	
Government grant income		184	6,765	
Healthpeak’s share of unconsolidated joint venture total revenues	43,774	12,957	12,920	
Healthpeak’s share of unconsolidated joint venture government grant income			380	
Noncontrolling interests’ share of consolidated joint venture total revenues	(37,839)	(35,692)	(35,985)	
Operating expenses	(1,074,861)	(906,234)	(862,991)	
Healthpeak’s share of unconsolidated joint venture operating expenses	(15,400)	(5,281)	(4,061)	
Noncontrolling interests’ share of consolidated joint venture operating expenses	10,634	10,077	10,404	
Adjustments to NOI	(106,539)	(52,456)	(75,967)	
Adjusted NOI for reportable segments	1,475,440	1,182,777	1,089,343	
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	273,168			
Operating Segment Outpatient Medical				
Segment Reporting Information, Revenue for Reportable Segment [Abstract]				
Total revenues	1,205,744	753,479	725,370	
Government grant income		0	0	
Healthpeak’s share of unconsolidated joint venture total revenues	24,041	3,033	2,999	
Healthpeak’s share of unconsolidated joint venture government grant income			0	
Noncontrolling interests’ share of consolidated joint venture total revenues	(37,643)	(35,073)	(35,717)	
Operating expenses	(405,993)	(263,132)	(253,309)	
Healthpeak’s share of unconsolidated joint venture operating expenses	(9,034)	(1,189)	(1,178)	
Noncontrolling interests’ share of consolidated joint venture operating expenses	10,582	9,921	10,317	
Adjustments to NOI	(38,967)	(14,314)	(15,513)	
Adjusted NOI for reportable segments	748,730	452,725	432,969	
Operating Segment Lab				
Segment Reporting Information, Revenue for Reportable Segment [Abstract]				
Total revenues	881,452	878,326	817,573	
Government grant income		0	0	
Healthpeak’s share of unconsolidated joint venture total revenues	19,733	9,924	9,921	
Healthpeak’s share of unconsolidated joint venture government grant income			0	
Noncontrolling interests’ share of consolidated joint venture total revenues	(196)	(619)	(268)	
Operating expenses	(239,620)	(229,630)	(209,143)	
Healthpeak’s share of unconsolidated joint venture operating expenses	(6,366)	(4,092)	(2,883)	
Noncontrolling interests’ share of consolidated joint venture operating expenses	52	156	87	

Adjustments to NOI	(64,449)	(36,524)	(62,754)
Adjusted NOI for reportable segments	590,606	617,541	552,533
Operating Segment CCRC			
Segment Reporting Information, Revenue for Reportable Segment [Abstract]			
Total revenues	568,475	527,417	494,935
Government grant income		184	6,765
Healthpeak's share of unconsolidated joint venture total revenues	0	0	0
Healthpeak's share of unconsolidated joint venture government grant income			380
Noncontrolling interests' share of consolidated joint venture total revenues	0	0	0
Operating expenses	(429,248)	(413,472)	(400,539)
Healthpeak's share of unconsolidated joint venture operating expenses	0	0	0
Noncontrolling interests' share of consolidated joint venture operating expenses	0	0	0
Adjustments to NOI	(3,123)	(1,618)	2,300
Adjusted NOI for reportable segments	\$ 136,104	\$ 112,511	\$ 103,841

XML 151 R132.htm IDEA: XBRL DOCUMENT

Segment Disclosures	12 Months Ended		
- Significant Expense			
Categories by			
Segment (Details) -	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating segment -			
USD (\$)			
\$ in Thousands			
Segment Disclosure			
Operating expenses	\$ 1,074,861	\$ 906,234	\$ 862,991
Outpatient Medical			
Segment Disclosure			
Compensation and property management	56,066	29,752	27,807
Food	0	0	0
Real estate taxes	95,286	59,255	59,992
Repairs and maintenance	61,409	38,277	36,439
Utilities	69,690	43,348	43,329
Other segment items	123,542	92,500	85,742
Operating expenses	405,993	263,132	253,309
Lab			
Segment Disclosure			
Compensation and property management	33,058	18,096	16,817
Food	0	0	0
Real estate taxes	78,488	77,690	75,459
Repairs and maintenance	30,555	30,554	26,884
Utilities	50,793	45,490	41,087
Other segment items	46,726	57,800	48,896
Operating expenses	239,620	229,630	209,143
CCRC			
Segment Disclosure			
Compensation and property management	277,686	260,624	251,804
Food	26,513	25,076	23,641
Real estate taxes	15,472	15,851	14,090
Repairs and maintenance	18,373	17,295	16,522
Utilities	22,309	22,787	21,219
Other segment items	68,895	71,839	73,263
Operating expenses	\$ 429,248	\$ 413,472	\$ 400,539

XML 152 R133.htm IDEA: XBRL DOCUMENT

Segment Disclosures	12 Months Ended		
- Revenues and Assets			
by Segment (Details)			
- USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands			
Segment Disclosure			
Total revenues for reportable segments	\$ 2,700,449	\$ 2,181,003	\$ 2,061,178
Interest income and other	44,778	21,781	23,300
Total revenues	2,700,449	2,181,003	2,061,178
Assets	19,938,255	15,698,850	
Operating segment			
Segment Disclosure			
Total revenues for reportable segments	2,655,671	2,159,222	2,037,878
Total revenues	2,655,671	2,159,222	2,037,878
Operating segment Outpatient Medical			
Segment Disclosure			
Total revenues for reportable segments	1,205,744	753,479	725,370
Total revenues	1,205,744	753,479	725,370
Operating segment Lab			
Segment Disclosure			
Total revenues for reportable segments	881,452	878,326	817,573
Total revenues	881,452	878,326	817,573
Operating segment CCRC			
Segment Disclosure			
Total revenues for reportable segments	568,475	527,417	494,935
Total revenues	\$ 568,475	\$ 527,417	\$ 494,935

XML 153 R134.htm IDEA: XBRL DOCUMENT

Income Taxes -	12 Months Ended		
Schedule of Common			
Stock Distribution			
(Details) - \$ / shares	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]			
Ordinary dividends (in dollars per share)	\$ 0.720440	\$ 0.909692	\$ 0.872948
Capital gains (in dollars per share)	0.295060	0.116992	0.183208
Nondividend distributions (in dollars per share)	0.184500	0.173316	0.143844
Dividends (in dollars per share)	1.200000	1.200000	1.200000
Qualified business income for purpose of Code Section 199A (in dollars per share)	0.720440	0.882312	0.872948
Qualified dividend income for purposes of Code Section 1(h)(11) (in dollars per share)		0.027380	
Unrecaptured Section 1250 gain (in dollars per share)	\$ 0.215960	\$ 0.036256	\$ 0.017760
Section 1231, capital distribution percentage	0.00%	0.00%	89.6708%
Section 897, capital distribution percentage	100.00%	100.00%	10.3292%

XML 154 R135.htm IDEA: XBRL DOCUMENT

Income Taxes -	12 Months Ended			
Narrative (Details) -				
USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]				
Income (loss) from continuing operations before income taxes				

	\$ 272,000,000	\$ 325,000,000	\$ 509,000,000	
Income (loss) before income taxes	273,168,000	314,936,000	507,130,000	
Income tax benefit (expense)	0	0	300,000	
Income tax expense (benefit)	4,350,000	(9,617,000)	(4,425,000)	
Deferred income tax expense (benefit)	(1,693,000)	(14,605,000)	(6,001,000)	
Net operating loss carryforward	50,041,000	54,136,000	62,280,000	
Unrecognized tax benefits	0	0	0	\$ 469,000

Down REIT

Operating Loss Carryforwards [Line Items]

Income (loss) from continuing operations before income taxes	217,000,000	318,000,000	527,000,000	
TRS				

Operating Loss Carryforwards [Line Items]

Income (loss) before income taxes	55,000,000	7,000,000	(18,000,000)	
Income tax expense (benefit)	(11,000,000)	(14,000,000)		
Deferred income tax expense (benefit)	2,000,000	\$ 13,000,000	\$ 26,000,000	
Net operating loss carryforward	193,000,000			
Net operating loss carryforwards subject to expiration	2,000,000			
Net operating loss carryforwards not subject to expiration	191,000,000			
TRS Callan Ridge JV				

Operating Loss Carryforwards [Line Items]

Income tax expense (benefit)	\$ 12,000,000			

XML 155 R136.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Income Tax (Expense) Benefit (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022		

Current

Federal	\$ (2,389)	\$ (1,663)	\$ (632)
State	(3,654)	(3,325)	(689)
Total current	(6,043)	(4,988)	(1,321)

Deferred

Federal	(3,429)	11,682	3,157
State	5,122	2,923	2,589
Total deferred	1,693	14,605	5,746
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

XML 156 R137.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Income Tax Expense (Benefit) Reconciliation (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022		

Income Tax Disclosure [Abstract]

Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax	\$ (11,601)	\$ (1,404)	\$ 3,698
State income tax benefit (expense), net of federal tax		(1,389)	(1,035)
Gross receipts and margin taxes		(1,774)	(1,647)
Return to provision adjustments		(287)	(90)
Change in valuation allowance for deferred tax assets		10,698	13,797
Change in tax status of TRS		3	(4)
Total income tax benefit (expense) from continuing operations	\$ (4,350)	\$ 9,617	\$ 4,425

XML 157 R138.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022		

Deferred tax assets:

Deferred revenue	\$ 103,470	\$ 103,530	\$ 102,504
Net operating loss carryforward	50,041	54,136	62,280
Expense accruals	11,787	12,324	12,399
Real estate	195	850	150
Other	49	58	689
Total deferred tax assets	165,542	170,898	178,022
Valuation allowance	(2,306)	(13,004)	(26,098)
Deferred tax assets, net of valuation allowance	163,236	157,894	151,924

Deferred tax liabilities:

Real estate	47,268	43,488	52,266
Other	876	818	674
Deferred tax liabilities	48,144	44,306	52,940
Net deferred tax assets	\$ 115,092	\$ 113,588	\$ 98,984

XML 158 R139.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD (\$)	12 Months Ended Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022		

Unrecognized Tax Benefits [Roll Forward]

Total unrecognized tax benefits at January 1	\$ 0	\$ 0	\$ 469,000
Gross amount of decreases for prior years' tax positions	0	0	(469,000)
Total unrecognized tax benefits at December 31	\$ 0	\$ 0	\$ 0

XML 159 R140.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information - Summary of Supplemental (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022		

Supplemental cash flow information:

Interest paid, net of capitalized interest	\$ 249,471	\$ 188,213	\$ 162,115
Income taxes paid (refunded)	7,862	1,923	(1,903)
Capitalized interest	69,256	56,849	41,046
Cash paid for amounts included in the measurement of lease liability for operating leases	21,277	21,488	12,594

Supplemental schedule of non-cash investing and financing activities:

Increase in ROU asset in exchange for new lease liability related to operating leases	15,457	3,951	9,454
Accrued construction costs	136,767	105,572	178,626
Net noncash impact from the consolidation of property previously held in an unconsolidated joint venture	0	993	0
Non-cash assets and liabilities assumed in connection with the Merger (see Note 3)	2,926,141	0	0

Seller financing provided on disposition of real estate assets (see Note 8)	418,389	0	0
South San Francisco JVs			
Supplemental schedule of non-cash investing and financing activities:			
Retained investments in connection with joint ventures	0	0	293,265
Callan Ridge JV			
Supplemental schedule of non-cash investing and financing activities:			
Retained investments in connection with joint ventures	\$ 69,255	\$ 0	\$ 0

XML 160 R141.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information - Summary of cash flow information discontinued operations (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Schedule of Equity Method Investments [Line Items]

Leasing costs, tenant improvements, and recurring capital expenditures	\$ 115,784	\$ 113,596	\$ 108,510
Development, redevelopment, and other major improvements of real estate	597,494	731,206	861,636
Depreciation and amortization of real estate, in-place lease, and other intangibles	1,057,205	749,901	710,569
Discontinued Operations			

Schedule of Equity Method Investments [Line Items]

Leasing costs, tenant improvements, and recurring capital expenditures	0	0	21
Development, redevelopment, and other major improvements of real estate	0	0	18
Depreciation and amortization of real estate, in-place lease, and other intangibles	\$ 0	\$ 0	\$ 0

XML 161 R142.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information - Summary of cash equivalents and restricted cash (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021

Continuing operations

Cash and cash equivalents	\$ 119,818	\$ 117,635	\$ 72,032	\$ 158,287
Restricted cash	64,487	51,388	54,802	53,454
Cash, cash equivalents, and restricted cash	184,305	169,023	126,834	211,741

Discontinued operations

Cash and cash equivalents	0	0	0	7,707
Restricted cash	0	0	0	0
Cash, cash equivalents, and restricted cash	0	0	0	7,707
Cash and cash equivalents	119,818	117,635	72,032	165,994
Restricted cash	64,487	51,388	54,802	53,454
Cash, cash equivalents, and restricted cash	\$ 184,305	\$ 169,023	\$ 126,834	\$ 219,448

XML 162 R143.htm IDEA: XBRL DOCUMENT

Variable Interest Entities - Narrative (Details) \$ in Millions	1 Months Ended	12 Months Ended	
		Dec. 31, 2024	
	Dec. 31, 2021 USD (\$)	USD (\$) hospital joint_venture	Dec. 31, 2023 joint_venture Dec. 31, 2022 USD (\$)

[PropTech](#)

Variable Interest Entity [Line Items]

Payments to acquire equity investments	\$ 1
Equity investment, aggregate cost	5.00%
Equity investment, percentage of total fund commitments	\$ 10
Funding period	5 years

[Lab | Needham Land Parcel JV](#)

Variable Interest Entity [Line Items]

Investment ownership percentage	38.00%
Payments to acquire equity method investment	\$ 13

[Variable Interest Entity, Not Primary Beneficiary](#)

Variable Interest Entity [Line Items]

Number of unconsolidated joint ventures joint_venture	2	2
Variable Interest Entity, Not Primary Beneficiary Commercial Mortgage-Backed Securities		

Variable Interest Entity [Line Items]

Number of hospitals hospital	3	
Debt securities		\$ 22

[Ventures V, LLC](#)

Variable Interest Entity [Line Items]

Ownership percentage	51.00%
Downreit Partnerships	

Variable Interest Entity [Line Items]

Number of DownREIT LLCs (in entities) joint_venture	8	7
Callan Ridge JV		

Variable Interest Entity [Line Items]

Ownership percentage		98.00%
MSREI MOB JV		

Variable Interest Entity [Line Items]

Ownership percentage	51.00%

XML 163 R144.htm IDEA: XBRL DOCUMENT

Variable Interest Entities - Schedule of Variable Interest Entities (Details) \$ in Thousands	Dec. 31, 2024
	USD (\$)

[LLC Investment and PropTech Investment](#)

Variable Interest Entity [Line Items]

[Maximum loss exposure and carrying amount](#) \$ 15,815

[Needham Land Parcel JV](#)

Variable Interest Entity [Line Items]

[Maximum loss exposure and carrying amount](#) \$ 21,348

XML 164 R145.htm IDEA: XBRL DOCUMENT

Variable Interest Entities - Balance Sheet Disclosures (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021

ASSETS

Buildings and improvements	\$ 16,115,283	\$ 13,329,464

Development costs and construction in progress	880,393	643,217		
Accumulated depreciation and amortization	(4,083,030)	(3,591,951)		
Net real estate	15,831,404	13,028,363		
Loans receivable, net	717,190	218,450		
Investments in and advances to unconsolidated joint ventures	936,814	782,853		
Accounts receivable, net	76,810	55,820		
Cash and cash equivalents	119,818	117,635	\$ 72,032	\$ 158,287
Intangible assets, net	817,254	314,156		
Right-of-use asset, net	424,173	240,155		
Other assets, net	942,465	772,044		
Total assets	19,938,255	15,698,850		
LIABILITIES AND EQUITY				
Term loans	1,646,043	496,824		
Senior unsecured notes	6,563,256	5,403,378		
Mortgage debt	356,750	256,097		
Intangible liabilities, net	191,884	127,380		
Lease liability	307,220	206,743		
Accounts payable, accrued liabilities, and other liabilities	725,342	657,196		
Deferred revenue	940,136	905,633		
Total liabilities	10,880,631	8,773,980		
Variable Interest Entity				

ASSETS				
Buildings and improvements	4,669,914	2,392,375		
Development costs and construction in progress	92,710	47,481		
Land and improvements	472,232	307,166		
Accumulated depreciation and amortization	(761,759)	(665,791)		
Net real estate	4,473,097	2,081,231		
Loans receivable, net	550,829	0		
Investments in and advances to unconsolidated joint ventures	39,946	0		
Accounts receivable, net	17,357	5,906		
Cash and cash equivalents	32,421	18,410		
Restricted cash	1,029	613		
Intangible assets, net	629,802	56,975		
Right-of-use asset, net	270,918	97,575		
Other assets, net	173,435	79,248		
Total assets	6,188,834	2,339,958		
LIABILITIES AND EQUITY				
Term loans	401,895	0		
Senior unsecured notes	1,151,801	0		
Mortgage debt	247,776	144,874		
Intangible liabilities, net	95,315	11,884		
Lease liability	193,421	99,725		
Accounts payable, accrued liabilities, and other liabilities	125,688	54,975		
Deferred revenue	65,358	48,316		
Total liabilities	\$ 2,281,254	\$ 359,774		

XML 165 R146.htm IDEA: XBRL DOCUMENT

Concentration of Credit Risk - Schedule of Geographical Concentration of Credit Risk (Details) - tenant	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Concentration Risk [Line Items]				
Number of tenants				2
Percentage of Total Company Revenues Customer Concentration Risk Outpatient Medical Largest Tenant HCA Healthcare, Inc				
Concentration Risk [Line Items]				
Concentration risk (as a percent)				7.00%
Percentage of Total Company Revenues Customer Concentration Risk Outpatient Medical Largest Tenant Common Spirit				
Concentration Risk [Line Items]				
Concentration risk (as a percent)				3.00%
California Percentage of Total Company Assets Geographic Concentration Risk Continuing Operations				
Concentration Risk [Line Items]				
Concentration risk (as a percent)				31.00%
California Percentage of Total Company Revenues Geographic Concentration Risk Continuing Operations				38.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				25.00%
Florida Percentage of Total Company Assets Geographic Concentration Risk Continuing Operations				31.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				10.00%
Florida Percentage of Total Company Revenues Geographic Concentration Risk Continuing Operations				10.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				17.00%
Texas Percentage of Total Company Assets Geographic Concentration Risk Continuing Operations				18.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				11.00%
Texas Percentage of Total Company Revenues Geographic Concentration Risk Continuing Operations				10.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				12.00%
Massachusetts Percentage of Total Company Assets Geographic Concentration Risk Continuing Operations				11.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				15.00%
Massachusetts Percentage of Total Company Revenues Geographic Concentration Risk Continuing Operations				17.00%
Concentration Risk [Line Items]				
Concentration risk (as a percent)				9.00%
				11.00%
				10.00%

XML 166 R147.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Summary of financial instruments		
Bank line of credit and commercial paper	\$ 150,000	\$ 720,000
Senior unsecured notes	6,563,256	5,403,378
Mortgage debt	\$ 356,750	\$ 256,097
Derivative Liability, Statement Of Financial Position, Extensible Enumeration Not Disclosed Flag	false	false
Carrying Value		
Summary of financial instruments		
Loans receivable, net	\$ 717,190	\$ 218,450
Bank line of credit and commercial paper	150,000	720,000

Term loan	1,646,043	496,824
Senior unsecured notes	6,563,256	5,403,378
Mortgage debt	356,750	256,097
Carrying Value Interest rate swap instruments		
Summary of financial instruments		
Interest rate instruments	35,120	21,359
Fair Value Level 1		
Summary of financial instruments		
Senior unsecured notes	6,373,528	5,144,667
Fair Value Level 2		
Summary of financial instruments		
Loans receivable, net	729,637	218,450
Bank line of credit and commercial paper	150,000	720,000
Term loan	1,646,043	496,824
Mortgage debt	350,292	244,135
Fair Value Level 2 Interest rate swap instruments		
Summary of financial instruments		
Interest rate instruments	\$ 35,120	\$ 21,359

XML 167 R148.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Narrative (Details) \$ in Millions	12 Months Ended						
	Dec. 31, 2024	Dec. 31,	Mar. 01, 2024	Jan. 31,	Feb. 28, 2023	Aug. 31, 2022	Apr. 30, 2022
	USD (\$)	2022	USD (\$)	2024	derivative_held	USD (\$)	USD (\$)
	derivative_held	USD (\$)	derivative_held	USD (\$)		derivative_held	derivative_held
Derivative [Line Items]							
Asset at fair value, changes in fair value resulting from changes in assumptions	\$ 53	\$ 2					
Number of interest-rate contracts held derivative_held	1						
Notional amount	\$ 180						
Senior Unsecured Term Loan							
Derivative [Line Items]							
Face amount			\$ 1,250				
2028 Term Loan Senior Unsecured Term Loan							
Derivative [Line Items]							
Face amount			400				
Mortgage Debt							
Derivative [Line Items]							
Face amount			\$ 128				
Designated as Hedging Instrument Cash Flow Hedging							
Derivative [Line Items]							
Number of interest-rate contracts held derivative_held	2						
Notional amount	\$ 110						
Interest rate swap instruments Designated as Hedging Instrument							
Derivative [Line Items]							
Number of interest-rate contracts held derivative_held						2	
Derivative amount						\$ 500	
Notional amount							
Interest rate swap instruments Designated as Hedging Instrument Mortgage Debt				\$ 750			
Derivative [Line Items]							
Derivative amount							\$ 142
Interest rate swap instruments Designated as Hedging Instrument Cash Flow Hedging							
Derivative [Line Items]							
Number of interest-rate contracts held derivative_held					2		2
Interest rate swap instruments Designated as Hedging Instrument Cash Flow Hedging 2028 Term Loan Senior Unsecured Term Loan							
Derivative [Line Items]							
Number of interest-rate contracts held derivative_held			3				
Notional amount			\$ 400				
Interest rate swap instruments Designated as Hedging Instrument Cash Flow Hedging Mortgage Debt							
Derivative [Line Items]							
Number of interest-rate contracts held derivative_held			1				
Face amount			\$ 36				

XML 168 R149.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Financial Instruments (Details) \$ in Thousands	12 Months Ended						
	Dec. 31, 2024	Mar. 01,	Jan. 31,	Dec. 31,	Feb. 28, 2023	Aug. 31, 2022	Apr. 30, 2022
	USD (\$)	2024	2024	2023	derivative_held	derivative_held	derivative_held
	derivative_held	USD (\$)	USD (\$)	USD (\$)			
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Notional Amount	\$ 180,000						
Number of interest-rate contracts held derivative_held	1						
Designated as Hedging Instrument Cash Flow Hedging							
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Notional Amount	\$ 110,000						
Fair value	\$ 35,120			\$ 21,359			
Number of interest-rate contracts held derivative_held	2						
Interest rate swap instruments Designated as Hedging Instrument							
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Notional Amount			\$ 750,000				
Number of interest-rate contracts held derivative_held						2	
Interest rate swap instruments Designated as Hedging Instrument Cash Flow Hedging							
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Number of interest-rate contracts held derivative_held					2		2
Interest Rate Swap, 4.99% Pay Rate Designated as Hedging Instrument Cash Flow Hedging							
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Notional Amount	\$ 51,100						
Pay Rate	4.99%						
Derivative, basis spread on variable rate	2.50%						
Fair value	\$ 1,050			1,602			
Interest Rate Swap, 4.54% Pay Rate Designated as Hedging Instrument Cash Flow Hedging							
Derivative Instruments and Hedging Activities Disclosures [Line Items]							
Notional Amount	\$ 91,000						
Pay Rate	4.54%						
Derivative, basis spread on variable rate	2.05%						

Fair value	\$ 1,870		2,851
Interest Rate Swap, 2.60% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 250,000		
Pay Rate	2.60%		
Fair value	\$ 7,224		7,933
Interest Rate Swap, 2.54% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 250,000		
Pay Rate	2.54%		
Fair value	\$ 9,122		8,973
Interest Rate Swap, 3.59% Pay Rate, One Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 400,000		
Pay Rate	3.59%		
Fair value	\$ 4,887	\$ 7,000	0
Interest expense	2,000		
Interest Rate Swap, 3.59% Pay Rate, One Designated as Hedging Instrument Cash Flow Hedging Mortgages			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Fair value	36,000		
Interest Rate Swap, 3.59% Pay Rate, Two Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 750,000		
Pay Rate	3.59%		
Fair value	\$ 10,967		\$ 0
Interest Rate Swap, 3.56% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 50,000		
Pay Rate	3.56%		
Number of interest-rate contracts held derivative held	2		
Interest Rate Swap, 3.57% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 50,000		
Pay Rate	3.57%		
Number of interest-rate contracts held derivative held	3		
Interest Rate Swap, 3.58% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 100,000		
Pay Rate	3.58%		
Number of interest-rate contracts held derivative held	1		
Interest Rate Swap, 3.60% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 50,000		
Pay Rate	3.60%		
Number of interest-rate contracts held derivative held	5		
Interest Rate Swap, 3.61% Pay Rate Designated as Hedging Instrument Cash Flow Hedging			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Notional Amount	\$ 50,000		
Pay Rate	3.61%		
Number of interest-rate contracts held derivative held	3		

XML 169 R150.htm
IDEA: XBRL DOCUMENT

Accounts Payable, Accrued Liabilities, and Other Liabilities (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands		
Payables and Accruals [Abstract]		
Refundable entrance fees	\$ 236,563	\$ 251,874
Accrued construction costs	136,767	105,572
Accrued interest	76,040	59,492
Other accounts payable and accrued liabilities	275,972	240,258
Accounts payable, accrued liabilities, and other liabilities	\$ 725,342	\$ 657,196

XML 170 R151.htm
IDEA: XBRL DOCUMENT

Deferred Revenue - Schedule of Deferred Revenue (Details) - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]			
Nonrefundable entrance fees	\$ 615,723	\$ 562,026	
Other deferred revenue	324,413	343,607	
Deferred revenue	940,136	905,633	
Proceeds from nonrefundable entrance fees	143,000	127,000	
Amortization of nonrefundable entrance fee	89,000	83,000	\$ 79,000
Amortization of other deferred charges	\$ 53,000	\$ 68,000	\$ 44,000

XML 171 R152.htm
IDEA: XBRL DOCUMENT

Schedule II: Valuation and Qualifying Accounts (Details) - Allowance Accounts - USD (\$)	12 Months Ended			
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Continuing Operations				
Movement in Valuation Allowances and Reserves				
Balance at Beginning of Year	\$ 2,282	\$ 2,399	\$ 1,870	
Additions				
Amounts Charged Against Operations, net	0	0	529	
Acquired Properties	0	0	0	
Deductions	(39)	(117)	0	
Balance at End of Year	2,243	2,282	2,399	

[Discontinued Operations](#)

[Movement in Valuation Allowances and Reserves](#)

Balance at Beginning of Year	0	0	4,138
Additions			
Amounts Charged Against Operations, net	0	0	0
Acquired Properties	0	0	0
Deductions	0	0	(4,138)
Balance at End of Year	\$ 0	\$ 0	\$ 0

XML 172 R153.htm IDEA: XBRL DOCUMENT

Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Outpatient Medical) (Details)	Dec. 31, 2024
\$ in Thousands	USD (\$)

[Held-for-sale](#)

[Real Estate and Accumulated Depreciation](#)

Encumbrances as of Year end	\$ 0
Initial Cost to Company	
Land and improvements	4,141
Building and Improvements	20,364
Costs Capitalized Subsequent to Acquisition	(13,844)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,141
Buildings and Improvements	6,520
Total	10,661
Accumulated Depreciation	(2,821)
Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	356,750
Initial Cost to Company	
Land and improvements	2,887,257
Building and Improvements	11,334,757
Costs Capitalized Subsequent to Acquisition	5,692,420
Gross Amount at Which Carried As of Year End	
Land and improvements	2,918,758
Buildings and Improvements	16,995,676
Total	19,914,434
Accumulated Depreciation	(4,083,030)
Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	250,503
Initial Cost to Company	
Land and improvements	860,670
Building and Improvements	6,577,057
Costs Capitalized Subsequent to Acquisition	1,629,467
Gross Amount at Which Carried As of Year End	
Land and improvements	877,189
Buildings and Improvements	8,190,005
Total	9,067,194
Accumulated Depreciation	(2,005,342)
638 Anchorage, AK Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,456
Building and Improvements	10,650
Costs Capitalized Subsequent to Acquisition	10,740
Gross Amount at Which Carried As of Year End	
Land and improvements	1,456
Buildings and Improvements	21,390
Total	22,846
Accumulated Depreciation	(10,227)
AL0006 Birmingham, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	382
Building and Improvements	8,522
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	382
Buildings and Improvements	8,522
Total	8,904
Accumulated Depreciation	(376)
AL0010 Birmingham, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,975
Building and Improvements	9,317
Costs Capitalized Subsequent to Acquisition	147
Gross Amount at Which Carried As of Year End	
Land and improvements	2,975
Buildings and Improvements	9,464
Total	12,439
Accumulated Depreciation	(590)
AL0012 Birmingham, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,925
Building and Improvements	17,289
Costs Capitalized Subsequent to Acquisition	36
Gross Amount at Which Carried As of Year End	

Land and improvements	3,925
Buildings and Improvements	17,325
Total	21,250
Accumulated Depreciation	(747)
AL0003 Fairhope, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,714
Building and Improvements	6,265
Costs Capitalized Subsequent to Acquisition	125
Gross Amount at Which Carried As of Year End	
Land and improvements	1,714
Buildings and Improvements	6,390
Total	8,104
Accumulated Depreciation	(305)
AL0005 Foley, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	569
Building and Improvements	691
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	569
Buildings and Improvements	691
Total	1,260
Accumulated Depreciation	(49)
AL0011 Huntsville, AL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,771
Building and Improvements	25,636
Costs Capitalized Subsequent to Acquisition	461
Gross Amount at Which Carried As of Year End	
Land and improvements	4,771
Buildings and Improvements	26,097
Total	30,868
Accumulated Depreciation	(1,155)
3026 Bentonville, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	912
Building and Improvements	21,724
Costs Capitalized Subsequent to Acquisition	735
Gross Amount at Which Carried As of Year End	
Land and improvements	912
Buildings and Improvements	22,459
Total	23,371
Accumulated Depreciation	(2,768)
AR0005 Hot Springs, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	108
Building and Improvements	8,819
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	108
Buildings and Improvements	8,819
Total	8,927
Accumulated Depreciation	(411)
AR0006 Hot Springs, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	211
Building and Improvements	4,324
Costs Capitalized Subsequent to Acquisition	763
Gross Amount at Which Carried As of Year End	
Land and improvements	238
Buildings and Improvements	5,060
Total	5,298
Accumulated Depreciation	(240)
AR0007 Hot Springs, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	464
Building and Improvements	9,076
Costs Capitalized Subsequent to Acquisition	745
Gross Amount at Which Carried As of Year End	
Land and improvements	464
Buildings and Improvements	9,821
Total	10,285
Accumulated Depreciation	(503)
AR0008 Hot Springs, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	49
Building and Improvements	3,667
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	49

Buildings and Improvements	3,667
Total	3,716
Accumulated Depreciation	(171)
AR0004 Hot Springs Village, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	656
Building and Improvements	3,238
Costs Capitalized Subsequent to Acquisition	384
Gross Amount at Which Carried As of Year End	
Land and improvements	656
Buildings and Improvements	3,622
Total	4,278
Accumulated Depreciation	(183)
AR0001 Little Rock, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	822
Building and Improvements	7,018
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	822
Buildings and Improvements	7,018
Total	7,840
Accumulated Depreciation	(460)
AR0002 Little Rock, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	780
Building and Improvements	3,323
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	780
Buildings and Improvements	3,323
Total	4,103
Accumulated Depreciation	(195)
0126 Sherwood, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	709
Building and Improvements	9,604
Costs Capitalized Subsequent to Acquisition	242
Gross Amount at Which Carried As of Year End	
Land and improvements	709
Buildings and Improvements	9,846
Total	10,555
Accumulated Depreciation	(7,236)
2572 Springdale, AR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	27,714
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	27,714
Total	27,714
Accumulated Depreciation	(7,329)
AZ0002 Avondale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,694
Building and Improvements	11,388
Costs Capitalized Subsequent to Acquisition	564
Gross Amount at Which Carried As of Year End	
Land and improvements	3,455
Buildings and Improvements	11,191
Total	14,646
Accumulated Depreciation	(657)
520 Chandler, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,669
Building and Improvements	13,503
Costs Capitalized Subsequent to Acquisition	6,076
Gross Amount at Which Carried As of Year End	
Land and improvements	4,041
Buildings and Improvements	19,207
Total	23,248
Accumulated Depreciation	(9,866)
113 Glendale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,565
Building and Improvements	7,050
Costs Capitalized Subsequent to Acquisition	175
Gross Amount at Which Carried As of Year End	
Land and improvements	1,565
Buildings and Improvements	7,225

Total	8,790
Accumulated Depreciation	(5,491)
AZ00021 Glendale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	640
Building and Improvements	2,473
Costs Capitalized Subsequent to Acquisition	(9)
Gross Amount at Which Carried As of Year End	
Land and improvements	640
Buildings and Improvements	2,464
Total	3,104
Accumulated Depreciation	(131)
AZ0008 Glendale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,692
Building and Improvements	6,538
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,692
Buildings and Improvements	6,538
Total	9,230
Accumulated Depreciation	(329)
AZ0003 Goodyear, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,139
Building and Improvements	18,196
Costs Capitalized Subsequent to Acquisition	457
Gross Amount at Which Carried As of Year End	
Land and improvements	4,139
Buildings and Improvements	18,653
Total	22,792
Accumulated Depreciation	(974)
2040 Mesa, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	17,314
Costs Capitalized Subsequent to Acquisition	3,895
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,209
Total	21,209
Accumulated Depreciation	(5,449)
AZ0012 Mesa, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,124
Building and Improvements	2,121
Costs Capitalized Subsequent to Acquisition	100
Gross Amount at Which Carried As of Year End	
Land and improvements	1,124
Buildings and Improvements	2,221
Total	3,345
Accumulated Depreciation	(131)
AZ0005 Phoenix, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	405
Building and Improvements	32,432
Costs Capitalized Subsequent to Acquisition	236
Gross Amount at Which Carried As of Year End	
Land and improvements	405
Buildings and Improvements	32,668
Total	33,073
Accumulated Depreciation	(1,277)
AZ0007 Phoenix, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,528
Building and Improvements	3,495
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,528
Buildings and Improvements	3,495
Total	6,023
Accumulated Depreciation	(164)
AZ0015 Phoenix, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	218
Building and Improvements	17,922
Costs Capitalized Subsequent to Acquisition	332
Gross Amount at Which Carried As of Year End	
Land and improvements	218
Buildings and Improvements	18,254
Total	18,472

Accumulated Depreciation	(668)
AZ00A7 Phoenix, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,526
Building and Improvements	694
Costs Capitalized Subsequent to Acquisition	624
Gross Amount at Which Carried As of Year End	
Land and improvements	2,526
Buildings and Improvements	1,318
Total	3,844
Accumulated Depreciation	(35)
2021 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,312
Costs Capitalized Subsequent to Acquisition	5,124
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,436
Total	17,436
Accumulated Depreciation	(7,674)
2022 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,179
Costs Capitalized Subsequent to Acquisition	3,733
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	12,912
Total	12,912
Accumulated Depreciation	(5,455)
2023 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,398
Costs Capitalized Subsequent to Acquisition	2,370
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	8,768
Total	8,768
Accumulated Depreciation	(3,694)
2024 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,522
Costs Capitalized Subsequent to Acquisition	1,700
Gross Amount at Which Carried As of Year End	
Land and improvements	32
Buildings and Improvements	11,190
Total	11,222
Accumulated Depreciation	(5,284)
2025 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,102
Costs Capitalized Subsequent to Acquisition	2,557
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	6,659
Total	6,659
Accumulated Depreciation	(2,901)
2026 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	3,655
Costs Capitalized Subsequent to Acquisition	2,087
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,742
Total	5,742
Accumulated Depreciation	(2,905)
2027 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,168
Costs Capitalized Subsequent to Acquisition	2,410
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,578
Total	9,578
Accumulated Depreciation	(4,722)
2028 Scottsdale, AZ Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,659
Costs Capitalized Subsequent to Acquisition	5,237
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,896
Total	11,896
Accumulated Depreciation	(6,013)
2696 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,151
Building and Improvements	14,925
Costs Capitalized Subsequent to Acquisition	20
Gross Amount at Which Carried As of Year End	
Land and improvements	9,234
Buildings and Improvements	15,862
Total	25,096
Accumulated Depreciation	(3,118)
AZ0009 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,563
Building and Improvements	9,361
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,563
Buildings and Improvements	9,361
Total	11,924
Accumulated Depreciation	(449)
AZ0010 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,096
Building and Improvements	19,515
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,096
Buildings and Improvements	19,515
Total	20,611
Accumulated Depreciation	(842)
AZ0011 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,809
Building and Improvements	2,646
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,809
Buildings and Improvements	2,646
Total	5,455
Accumulated Depreciation	(217)
AZ0014 Scottsdale, AZ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	506
Building and Improvements	43,211
Costs Capitalized Subsequent to Acquisition	3,451
Gross Amount at Which Carried As of Year End	
Land and improvements	506
Buildings and Improvements	46,662
Total	47,168
Accumulated Depreciation	(1,448)
1041 Brentwood, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	30,864
Costs Capitalized Subsequent to Acquisition	9,176
Gross Amount at Which Carried As of Year End	
Land and improvements	122
Buildings and Improvements	39,918
Total	40,040
Accumulated Depreciation	(16,525)
1200 Encino, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,151
Building and Improvements	10,438
Costs Capitalized Subsequent to Acquisition	6,680
Gross Amount at Which Carried As of Year End	
Land and improvements	6,373
Buildings and Improvements	16,896
Total	23,269
Accumulated Depreciation	(8,545)
1038 Fresno, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

<u>Initial Cost to Company</u>	
Land and improvements	3,652
Building and Improvements	29,113
Costs Capitalized Subsequent to Acquisition	21,935
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	3,652
Buildings and Improvements	51,048
Total	54,700
Accumulated Depreciation	(25,001)
659 Los Gatos, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,718
Building and Improvements	3,124
Costs Capitalized Subsequent to Acquisition	1,393
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,796
Buildings and Improvements	4,439
Total	6,235
Accumulated Depreciation	(2,231)
421 San Diego, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	2,910
Building and Improvements	19,984
Costs Capitalized Subsequent to Acquisition	15,149
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	2,964
Buildings and Improvements	35,079
Total	38,043
Accumulated Depreciation	(19,150)
564 San Jose, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,935
Building and Improvements	1,728
Costs Capitalized Subsequent to Acquisition	2,595
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,935
Buildings and Improvements	4,323
Total	6,258
Accumulated Depreciation	(1,905)
565 San Jose, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,460
Building and Improvements	7,672
Costs Capitalized Subsequent to Acquisition	2,273
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,492
Buildings and Improvements	9,913
Total	11,405
Accumulated Depreciation	(5,460)
CA0001 Walnut Creek, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,533
Building and Improvements	5,116
Costs Capitalized Subsequent to Acquisition	0
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,533
Buildings and Improvements	5,116
Total	6,649
Accumulated Depreciation	(255)
CA0002 Walnut Creek, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,189
Building and Improvements	1,179
Costs Capitalized Subsequent to Acquisition	0
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,189
Buildings and Improvements	1,179
Total	2,368
Accumulated Depreciation	(74)
CA0003 Walnut Creek, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	
Land and improvements	1,168
Building and Improvements	1,368
Costs Capitalized Subsequent to Acquisition	0
<u>Gross Amount at Which Carried As of Year End</u>	
Land and improvements	1,168
Buildings and Improvements	1,368
Total	2,536
Accumulated Depreciation	(81)
CA0004 Walnut Creek, CA Outpatient Medical Operating segment	
<u>Real Estate and Accumulated Depreciation</u>	
Encumbrances as of Year end	0
<u>Initial Cost to Company</u>	

Land and improvements	3,143
Building and Improvements	5,390
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,143
Buildings and Improvements	5,390
Total	8,533
Accumulated Depreciation	(299)
CA0005 Walnut Creek, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,140
Building and Improvements	2,260
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,140
Buildings and Improvements	2,260
Total	3,400
Accumulated Depreciation	(118)
440 West Hills, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,100
Building and Improvements	11,595
Costs Capitalized Subsequent to Acquisition	12,917
Gross Amount at Which Carried As of Year End	
Land and improvements	2,203
Buildings and Improvements	24,409
Total	26,612
Accumulated Depreciation	(9,359)
3008 West Hills, CA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	12,137
Initial Cost to Company	
Land and improvements	5,795
Building and Improvements	13,933
Costs Capitalized Subsequent to Acquisition	3,872
Gross Amount at Which Carried As of Year End	
Land and improvements	5,823
Buildings and Improvements	17,777
Total	23,600
Accumulated Depreciation	(2,536)
728 Aurora, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,764
Costs Capitalized Subsequent to Acquisition	2,794
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,558
Total	11,558
Accumulated Depreciation	(4,589)
1196 Aurora, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	210
Building and Improvements	12,362
Costs Capitalized Subsequent to Acquisition	5,923
Gross Amount at Which Carried As of Year End	
Land and improvements	210
Buildings and Improvements	18,285
Total	18,495
Accumulated Depreciation	(8,389)
1197 Aurora, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	200
Building and Improvements	8,414
Costs Capitalized Subsequent to Acquisition	6,235
Gross Amount at Which Carried As of Year End	
Land and improvements	285
Buildings and Improvements	14,564
Total	14,849
Accumulated Depreciation	(7,259)
2965 Aurora, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	39,026
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	39,026
Total	39,026
Accumulated Depreciation	0
127 Colorado Springs, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	690

Building and Improvements	8,338
Costs Capitalized Subsequent to Acquisition	367
Gross Amount at Which Carried As of Year End	
Land and improvements	690
Buildings and Improvements	8,705
Total	9,395
Accumulated Depreciation	(6,267)
882 Colorado Springs, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,933
Costs Capitalized Subsequent to Acquisition	8,913
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,846
Total	21,846
Accumulated Depreciation	(11,516)
1199 Denver, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	493
Building and Improvements	7,897
Costs Capitalized Subsequent to Acquisition	1,642
Gross Amount at Which Carried As of Year End	
Land and improvements	604
Buildings and Improvements	9,428
Total	10,032
Accumulated Depreciation	(4,874)
808 Englewood, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,616
Costs Capitalized Subsequent to Acquisition	6,221
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	14,837
Total	14,837
Accumulated Depreciation	(7,838)
809 Englewood, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,449
Costs Capitalized Subsequent to Acquisition	20,199
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	28,648
Total	28,648
Accumulated Depreciation	(7,329)
810 Englewood, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,040
Costs Capitalized Subsequent to Acquisition	16,738
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	24,778
Total	24,778
Accumulated Depreciation	(10,816)
811 Englewood, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,472
Costs Capitalized Subsequent to Acquisition	12,707
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,179
Total	21,179
Accumulated Depreciation	(8,346)
CO0005 Englewood, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,994
Building and Improvements	6,363
Costs Capitalized Subsequent to Acquisition	575
Gross Amount at Which Carried As of Year End	
Land and improvements	1,994
Buildings and Improvements	6,938
Total	8,932
Accumulated Depreciation	(638)
CO0002 Triscp, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	370
Building and Improvements	3,235

Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	370
Buildings and Improvements	3,235
Total	3,605
Accumulated Depreciation	(196)
2658 Highlands Ranch, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,637
Building and Improvements	10,063
Costs Capitalized Subsequent to Acquisition	95
Gross Amount at Which Carried As of Year End	
Land and improvements	1,732
Buildings and Improvements	10,063
Total	11,795
Accumulated Depreciation	(2,730)
CO0001 Johnstown, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,254
Building and Improvements	5,646
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,254
Buildings and Improvements	5,646
Total	6,900
Accumulated Depreciation	(271)
812 Littleton, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,562
Costs Capitalized Subsequent to Acquisition	2,383
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	6,945
Total	6,945
Accumulated Depreciation	(3,582)
813 Littleton, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,926
Costs Capitalized Subsequent to Acquisition	2,189
Gross Amount at Which Carried As of Year End	
Land and improvements	246
Buildings and Improvements	6,869
Total	7,115
Accumulated Depreciation	(3,058)
570 Lone Tree, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	21,731
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,731
Total	21,731
Accumulated Depreciation	(10,737)
666 Lone Tree, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	23,274
Costs Capitalized Subsequent to Acquisition	3,959
Gross Amount at Which Carried As of Year End	
Land and improvements	17
Buildings and Improvements	27,216
Total	27,233
Accumulated Depreciation	(13,399)
2233 Lone Tree, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,734
Costs Capitalized Subsequent to Acquisition	34,699
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	41,433
Total	41,433
Accumulated Depreciation	(14,519)
3000 Lone Tree, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,393
Building and Improvements	31,643
Costs Capitalized Subsequent to Acquisition	10,249

Gross Amount at Which Carried As of Year End	
Land and improvements	4,552
Buildings and Improvements	41,733
Total	46,285
Accumulated Depreciation	(5,919)
510 Thornton, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	236
Building and Improvements	10,206
Costs Capitalized Subsequent to Acquisition	14,228
Gross Amount at Which Carried As of Year End	
Land and improvements	455
Buildings and Improvements	24,215
Total	24,670
Accumulated Depreciation	(9,530)
CO0004 Thornton, CO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,843
Building and Improvements	2,302
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,843
Buildings and Improvements	2,302
Total	4,145
Accumulated Depreciation	(158)
CT0002 Manchester, CT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,159
Building and Improvements	4,828
Costs Capitalized Subsequent to Acquisition	62
Gross Amount at Which Carried As of Year End	
Land and improvements	2,164
Buildings and Improvements	4,885
Total	7,049
Accumulated Depreciation	(251)
CT0003 Manchester, CT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,620
Building and Improvements	7,364
Costs Capitalized Subsequent to Acquisition	11
Gross Amount at Which Carried As of Year End	
Land and improvements	1,620
Buildings and Improvements	7,375
Total	8,995
Accumulated Depreciation	(346)
CT0001 Plainville, CT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,515
Building and Improvements	15,515
Costs Capitalized Subsequent to Acquisition	113
Gross Amount at Which Carried As of Year End	
Land and improvements	3,520
Buildings and Improvements	15,623
Total	19,143
Accumulated Depreciation	(865)
CT0002 Plainville, CT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,445
Building and Improvements	3,161
Costs Capitalized Subsequent to Acquisition	7
Gross Amount at Which Carried As of Year End	
Land and improvements	1,445
Buildings and Improvements	3,168
Total	4,613
Accumulated Depreciation	(216)
DE0001 Dover, DE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,483
Building and Improvements	34,034
Costs Capitalized Subsequent to Acquisition	379
Gross Amount at Which Carried As of Year End	
Land and improvements	1,577
Buildings and Improvements	34,319
Total	35,896
Accumulated Depreciation	(1,555)
434 Atlantis, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	2,027
Costs Capitalized Subsequent to Acquisition	182
Gross Amount at Which Carried As of Year End	

Land and improvements	0
Buildings and Improvements	2,209
Total	2,209
Accumulated Depreciation	(1,530)
435 Atlantis, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	2,000
Costs Capitalized Subsequent to Acquisition	738
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	2,738
Total	2,738
Accumulated Depreciation	(1,723)
602 Atlantis, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	455
Building and Improvements	2,231
Costs Capitalized Subsequent to Acquisition	729
Gross Amount at Which Carried As of Year End	
Land and improvements	455
Buildings and Improvements	2,960
Total	3,415
Accumulated Depreciation	(1,475)
FL0012 Atlantis, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	100
Building and Improvements	8,120
Costs Capitalized Subsequent to Acquisition	305
Gross Amount at Which Carried As of Year End	
Land and improvements	100
Buildings and Improvements	8,425
Total	8,525
Accumulated Depreciation	(340)
FL0033 Atlantis, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,219
Building and Improvements	29,984
Costs Capitalized Subsequent to Acquisition	48
Gross Amount at Which Carried As of Year End	
Land and improvements	1,219
Buildings and Improvements	30,032
Total	31,251
Accumulated Depreciation	(1,321)
3217 Brandon, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	10,057
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	10,057
Total	10,057
Accumulated Depreciation	0
2963 Brooksville, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	13,292
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	13,292
Total	13,292
Accumulated Depreciation	(2,141)
604 Englewood, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	170
Building and Improvements	1,134
Costs Capitalized Subsequent to Acquisition	1,118
Gross Amount at Which Carried As of Year End	
Land and improvements	230
Buildings and Improvements	2,192
Total	2,422
Accumulated Depreciation	(965)
FL0004 Englewood, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	478
Building and Improvements	1,974
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	478

Buildings and Improvements	1,974
Total	2,452
Accumulated Depreciation	(125)
FL0032 Jacksonville, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	60,025
Initial Cost to Company	
Land and improvements	5,738
Building and Improvements	88,295
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	5,738
Buildings and Improvements	88,295
Total	94,033
Accumulated Depreciation	(3,747)
609 Kissimmee, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	788
Building and Improvements	174
Costs Capitalized Subsequent to Acquisition	798
Gross Amount at Which Carried As of Year End	
Land and improvements	788
Buildings and Improvements	972
Total	1,760
Accumulated Depreciation	(364)
610 Kissimmee, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	481
Building and Improvements	347
Costs Capitalized Subsequent to Acquisition	465
Gross Amount at Which Carried As of Year End	
Land and improvements	488
Buildings and Improvements	805
Total	1,293
Accumulated Depreciation	(378)
671 Kissimmee, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,574
Costs Capitalized Subsequent to Acquisition	1,052
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	8,626
Total	8,626
Accumulated Depreciation	(4,000)
FL0008 Lady Alke, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	921
Building and Improvements	7,403
Costs Capitalized Subsequent to Acquisition	81
Gross Amount at Which Carried As of Year End	
Land and improvements	921
Buildings and Improvements	7,484
Total	8,405
Accumulated Depreciation	(217)
603 Lake Worth, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,507
Building and Improvements	2,894
Costs Capitalized Subsequent to Acquisition	537
Gross Amount at Which Carried As of Year End	
Land and improvements	1,507
Buildings and Improvements	3,431
Total	4,938
Accumulated Depreciation	(1,609)
612 Margate, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,553
Building and Improvements	6,898
Costs Capitalized Subsequent to Acquisition	4,180
Gross Amount at Which Carried As of Year End	
Land and improvements	1,553
Buildings and Improvements	11,078
Total	12,631
Accumulated Depreciation	(5,692)
613 Miami, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,392
Building and Improvements	11,841
Costs Capitalized Subsequent to Acquisition	11,642
Gross Amount at Which Carried As of Year End	
Land and improvements	4,454
Buildings and Improvements	23,421
Total	27,875

Accumulated Depreciation	(9,527)
2202 Miami, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	13,123
Costs Capitalized Subsequent to Acquisition	10,870
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	23,993
Total	23,993
Accumulated Depreciation	(11,737)
2203 Miami, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,877
Costs Capitalized Subsequent to Acquisition	5,310
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	14,187
Total	14,187
Accumulated Depreciation	(6,044)
1067 Milton, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,566
Costs Capitalized Subsequent to Acquisition	1,555
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	10,121
Total	10,121
Accumulated Depreciation	(4,470)
2577 Naples, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	29,186
Costs Capitalized Subsequent to Acquisition	1,805
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	30,991
Total	30,991
Accumulated Depreciation	(8,021)
2578 Naples, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	18,819
Costs Capitalized Subsequent to Acquisition	667
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	19,486
Total	19,486
Accumulated Depreciation	(4,270)
2964 Okeechobee, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	17,797
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,797
Total	17,797
Accumulated Depreciation	(2,120)
2962 Orange Park, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	18,302
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	18,302
Total	18,302
Accumulated Depreciation	(2,649)
563 Orlando, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,144
Building and Improvements	5,136
Costs Capitalized Subsequent to Acquisition	13,014
Gross Amount at Which Carried As of Year End	
Land and improvements	12,830
Buildings and Improvements	7,464
Total	20,294
Accumulated Depreciation	(6,902)

FL0025 Orlando, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,905
Building and Improvements	16,988
Costs Capitalized Subsequent to Acquisition	144
Gross Amount at Which Carried As of Year End	
Land and improvements	1,905
Buildings and Improvements	17,132
Total	19,037
Accumulated Depreciation	(669)
833 Pace, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	10,309
Costs Capitalized Subsequent to Acquisition	1,621
Gross Amount at Which Carried As of Year End	
Land and improvements	28
Buildings and Improvements	11,902
Total	11,930
Accumulated Depreciation	(4,886)
834 Pensacola, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	11,166
Costs Capitalized Subsequent to Acquisition	481
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,647
Total	11,647
Accumulated Depreciation	(4,786)
FL0030 Pensacola, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,475
Building and Improvements	20,675
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,475
Buildings and Improvements	20,675
Total	24,150
Accumulated Depreciation	(864)
673 Plantation, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,091
Building and Improvements	7,176
Costs Capitalized Subsequent to Acquisition	2,778
Gross Amount at Which Carried As of Year End	
Land and improvements	1,091
Buildings and Improvements	9,954
Total	11,045
Accumulated Depreciation	(4,894)
674 Plantation, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,273
Costs Capitalized Subsequent to Acquisition	1,354
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,627
Total	9,627
Accumulated Depreciation	(1,496)
FL0029 Port Charlotte, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,244
Building and Improvements	6,801
Costs Capitalized Subsequent to Acquisition	285
Gross Amount at Which Carried As of Year End	
Land and improvements	2,244
Buildings and Improvements	7,086
Total	9,330
Accumulated Depreciation	(357)
2579 Punta Gorda, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,379
Costs Capitalized Subsequent to Acquisition	139
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,518
Total	9,518
Accumulated Depreciation	(2,250)
2833 St. Petersburg, FL Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	13,754
Costs Capitalized Subsequent to Acquisition	12,662
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	26,416
Total	26,416
Accumulated Depreciation	(10,982)
FL0022 Stuart, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	869
Building and Improvements	4,496
Costs Capitalized Subsequent to Acquisition	100
Gross Amount at Which Carried As of Year End	
Land and improvements	869
Buildings and Improvements	4,596
Total	5,465
Accumulated Depreciation	(176)
FL0026 Stuart, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,882
Building and Improvements	9,104
Costs Capitalized Subsequent to Acquisition	692
Gross Amount at Which Carried As of Year End	
Land and improvements	2,882
Buildings and Improvements	9,796
Total	12,678
Accumulated Depreciation	(470)
FL0003 Venice, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,344
Building and Improvements	2,910
Costs Capitalized Subsequent to Acquisition	67
Gross Amount at Which Carried As of Year End	
Land and improvements	1,344
Buildings and Improvements	2,977
Total	4,321
Accumulated Depreciation	(185)
FL0031 Wesley Chapel, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	313
Building and Improvements	29,074
Costs Capitalized Subsequent to Acquisition	44
Gross Amount at Which Carried As of Year End	
Land and improvements	313
Buildings and Improvements	29,118
Total	29,431
Accumulated Depreciation	(1,083)
FL0034 Yulee, FL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	793
Building and Improvements	7,994
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	793
Buildings and Improvements	7,994
Total	8,787
Accumulated Depreciation	(406)
887 Atlanta, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,300
Building and Improvements	13,690
Costs Capitalized Subsequent to Acquisition	(1,800)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,300
Buildings and Improvements	11,890
Total	16,190
Accumulated Depreciation	(10,602)
GA0010 Atlanta, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,330
Building and Improvements	25,942
Costs Capitalized Subsequent to Acquisition	719
Gross Amount at Which Carried As of Year End	
Land and improvements	1,330
Buildings and Improvements	26,661
Total	27,991
Accumulated Depreciation	(1,253)
GA0024 Atlanta, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,031
Building and Improvements	89,809
Costs Capitalized Subsequent to Acquisition	424
Gross Amount at Which Carried As of Year End	
Land and improvements	1,031
Buildings and Improvements	90,233
Total	91,264
Accumulated Depreciation	(3,394)
GA0028 Atlanta, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	603
Building and Improvements	40,071
Costs Capitalized Subsequent to Acquisition	86
Gross Amount at Which Carried As of Year End	
Land and improvements	603
Buildings and Improvements	40,157
Total	40,760
Accumulated Depreciation	(1,530)
GA0030 Buford, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	32,131
Costs Capitalized Subsequent to Acquisition	10,387
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	42,518
Total	42,518
Accumulated Depreciation	(867)
GA0026 Duluth, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	135
Building and Improvements	11,586
Costs Capitalized Subsequent to Acquisition	233
Gross Amount at Which Carried As of Year End	
Land and improvements	135
Buildings and Improvements	11,819
Total	11,954
Accumulated Depreciation	(478)
GA0031 Dunwoody, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,741
Building and Improvements	3,818
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,741
Buildings and Improvements	3,818
Total	5,559
Accumulated Depreciation	(153)
GA0032 Dunwoody, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,219
Building and Improvements	16,064
Costs Capitalized Subsequent to Acquisition	14,146
Gross Amount at Which Carried As of Year End	
Land and improvements	2,219
Buildings and Improvements	30,210
Total	32,429
Accumulated Depreciation	(346)
GA0025 Lawrenceville, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	182
Building and Improvements	15,112
Costs Capitalized Subsequent to Acquisition	283
Gross Amount at Which Carried As of Year End	
Land and improvements	182
Buildings and Improvements	15,395
Total	15,577
Accumulated Depreciation	(571)
GA0027 Lawrenceville, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	346
Building and Improvements	28,592
Costs Capitalized Subsequent to Acquisition	1,738
Gross Amount at Which Carried As of Year End	
Land and improvements	346
Buildings and Improvements	30,330
Total	30,676
Accumulated Depreciation	(1,204)
GA3246 Pooler, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	10,810
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	10,810
Total	10,810
Accumulated Depreciation	0
3214 Savannah, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	33,381
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	33,381
Total	33,381
Accumulated Depreciation	(100)
2576 Statesboro, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	10,234
Costs Capitalized Subsequent to Acquisition	1,430
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,664
Total	11,664
Accumulated Depreciation	(3,528)
GA0023 Woodstock, GA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	967
Building and Improvements	26,658
Costs Capitalized Subsequent to Acquisition	324
Gross Amount at Which Carried As of Year End	
Land and improvements	967
Buildings and Improvements	26,982
Total	27,949
Accumulated Depreciation	(1,100)
3006 Arlington Heights, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	4,877
Initial Cost to Company	
Land and improvements	3,011
Building and Improvements	9,651
Costs Capitalized Subsequent to Acquisition	2,821
Gross Amount at Which Carried As of Year End	
Land and improvements	3,187
Buildings and Improvements	12,296
Total	15,483
Accumulated Depreciation	(1,998)
2702 Bolingbrook, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	21,237
Costs Capitalized Subsequent to Acquisition	4,108
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	25,345
Total	25,345
Accumulated Depreciation	(4,203)
IL0002 Bolingbrook, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,464
Building and Improvements	8,832
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,464
Buildings and Improvements	8,832
Total	10,296
Accumulated Depreciation	(360)
IL0002 Elgin, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,723
Building and Improvements	15,327
Costs Capitalized Subsequent to Acquisition	563
Gross Amount at Which Carried As of Year End	
Land and improvements	2,723
Buildings and Improvements	15,890
Total	18,613
Accumulated Depreciation	(662)
3004 Highland Park, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	5,872
Initial Cost to Company	
Land and improvements	2,767

Building and Improvements	11,495
Costs Capitalized Subsequent to Acquisition	1,981
Gross Amount at Which Carried As of Year End	
Land and improvements	2,767
Buildings and Improvements	13,476
Total	16,243
Accumulated Depreciation	(1,728)
3005 Lockport, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	11,048
Initial Cost to Company	
Land and improvements	3,106
Building and Improvements	22,645
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,106
Buildings and Improvements	22,645
Total	25,751
Accumulated Depreciation	(3,102)
1065 Marion, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	99
Building and Improvements	11,538
Costs Capitalized Subsequent to Acquisition	1,986
Gross Amount at Which Carried As of Year End	
Land and improvements	100
Buildings and Improvements	13,523
Total	13,623
Accumulated Depreciation	(6,489)
2719 Marion, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	5,098
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,098
Total	5,098
Accumulated Depreciation	(684)
IL0005 Palos Heights, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,324
Building and Improvements	5,087
Costs Capitalized Subsequent to Acquisition	319
Gross Amount at Which Carried As of Year End	
Land and improvements	2,324
Buildings and Improvements	5,406
Total	7,730
Accumulated Depreciation	(181)
IL0001 Sandwich, IL Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	116
Building and Improvements	10,126
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	116
Buildings and Improvements	10,126
Total	10,242
Accumulated Depreciation	(369)
IN0003 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	622
Building and Improvements	3,440
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	622
Buildings and Improvements	3,440
Total	4,062
Accumulated Depreciation	(222)
IN0004 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	841
Building and Improvements	2,089
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	841
Buildings and Improvements	2,089
Total	2,930
Accumulated Depreciation	(134)
IN0005 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,830
Building and Improvements	9,394

Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,830
Buildings and Improvements	9,394
Total	12,224
Accumulated Depreciation	(584)
IN0006 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	588
Building and Improvements	1,414
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	588
Buildings and Improvements	1,414
Total	2,002
Accumulated Depreciation	(91)
IN0007 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,383
Building and Improvements	7,207
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,383
Buildings and Improvements	7,207
Total	8,590
Accumulated Depreciation	(340)
IN0013 Bloomington, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,730
Building and Improvements	7,304
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,730
Buildings and Improvements	7,304
Total	9,034
Accumulated Depreciation	(384)
IN0002 Carmel, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	38
Building and Improvements	3,930
Costs Capitalized Subsequent to Acquisition	658
Gross Amount at Which Carried As of Year End	
Land and improvements	38
Buildings and Improvements	4,588
Total	4,626
Accumulated Depreciation	(197)
IN0020 Carmel, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	259
Building and Improvements	22,311
Costs Capitalized Subsequent to Acquisition	308
Gross Amount at Which Carried As of Year End	
Land and improvements	259
Buildings and Improvements	22,619
Total	22,878
Accumulated Depreciation	(763)
IN0021 Fishers, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	383
Building and Improvements	34,648
Costs Capitalized Subsequent to Acquisition	191
Gross Amount at Which Carried As of Year End	
Land and improvements	383
Buildings and Improvements	34,839
Total	35,222
Accumulated Depreciation	(1,381)
IN0008 Greenwood, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,365
Building and Improvements	6,934
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,365
Buildings and Improvements	6,934
Total	8,299
Accumulated Depreciation	(332)
IN0010 Greenwood, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,015
Building and Improvements	2,238
Costs Capitalized Subsequent to Acquisition	1
Gross Amount at Which Carried As of Year End	

Land and improvements	1,015
Buildings and Improvements	2,239
Total	3,254
Accumulated Depreciation	(122)
IN0011 Greenwood, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,565
Building and Improvements	10,588
Costs Capitalized Subsequent to Acquisition	211
Gross Amount at Which Carried As of Year End	
Land and improvements	1,565
Buildings and Improvements	10,799
Total	12,364
Accumulated Depreciation	(528)
IN0012 Greenwood, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	993
Building and Improvements	1,997
Costs Capitalized Subsequent to Acquisition	42
Gross Amount at Which Carried As of Year End	
Land and improvements	993
Buildings and Improvements	2,039
Total	3,032
Accumulated Depreciation	(91)
2697 Indianapolis, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	59,746
Costs Capitalized Subsequent to Acquisition	1,018
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	60,764
Total	60,764
Accumulated Depreciation	(7,389)
2699 Indianapolis, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	23,211
Costs Capitalized Subsequent to Acquisition	747
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	23,958
Total	23,958
Accumulated Depreciation	(3,142)
IN0009 Indianapolis, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	764
Building and Improvements	4,084
Costs Capitalized Subsequent to Acquisition	9
Gross Amount at Which Carried As of Year End	
Land and improvements	764
Buildings and Improvements	4,093
Total	4,857
Accumulated Depreciation	(209)
IN0022 Indianapolis, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,772
Building and Improvements	42,213
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,772
Buildings and Improvements	42,213
Total	45,985
Accumulated Depreciation	(1,766)
IN0015 Lafayette, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	845
Building and Improvements	9,980
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	845
Buildings and Improvements	9,980
Total	10,825
Accumulated Depreciation	(559)
IN0016 Lafayette, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,433
Building and Improvements	9,059
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,433
Buildings and Improvements	9,059

Total	10,492
Accumulated Depreciation	(605)
IN0017 Lafayette, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	471
Building and Improvements	1,130
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	471
Buildings and Improvements	1,130
Total	1,601
Accumulated Depreciation	(74)
IN0018 Lafayette, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	421
Building and Improvements	1,170
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	421
Buildings and Improvements	1,170
Total	1,591
Accumulated Depreciation	(74)
IN0001 Mishawaka, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,468
Building and Improvements	8,175
Costs Capitalized Subsequent to Acquisition	452
Gross Amount at Which Carried As of Year End	
Land and improvements	3,468
Buildings and Improvements	8,627
Total	12,095
Accumulated Depreciation	(625)
2698 Mooresville, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	20,646
Costs Capitalized Subsequent to Acquisition	997
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,643
Total	21,643
Accumulated Depreciation	(2,768)
1057 Newburgh, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	14,019
Costs Capitalized Subsequent to Acquisition	3,659
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,678
Total	17,678
Accumulated Depreciation	(8,867)
IN0025 Newburgh, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,182
Building and Improvements	13,074
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,182
Buildings and Improvements	13,074
Total	15,256
Accumulated Depreciation	(707)
2700 Zionsville, IN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,969
Building and Improvements	7,281
Costs Capitalized Subsequent to Acquisition	871
Gross Amount at Which Carried As of Year End	
Land and improvements	3,075
Buildings and Improvements	8,046
Total	11,121
Accumulated Depreciation	(1,658)
2039 Kansas City, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	440
Building and Improvements	2,173
Costs Capitalized Subsequent to Acquisition	389
Gross Amount at Which Carried As of Year End	
Land and improvements	541
Buildings and Improvements	2,461
Total	3,002

Accumulated Depreciation	(842)
112 Overland Park, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,316
Building and Improvements	10,681
Costs Capitalized Subsequent to Acquisition	312
Gross Amount at Which Carried As of Year End	
Land and improvements	2,316
Buildings and Improvements	10,993
Total	13,309
Accumulated Depreciation	(8,428)
2043 Overland Park, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,668
Costs Capitalized Subsequent to Acquisition	1,425
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,093
Total	9,093
Accumulated Depreciation	(2,765)
3062 Overland Park, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	872
Building and Improvements	11,813
Costs Capitalized Subsequent to Acquisition	8
Gross Amount at Which Carried As of Year End	
Land and improvements	992
Buildings and Improvements	11,701
Total	12,693
Accumulated Depreciation	(3,121)
483 Wichita, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	530
Building and Improvements	3,341
Costs Capitalized Subsequent to Acquisition	820
Gross Amount at Which Carried As of Year End	
Land and improvements	605
Buildings and Improvements	4,086
Total	4,691
Accumulated Depreciation	(1,831)
3018 Wichita, KS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,946
Building and Improvements	39,795
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,946
Buildings and Improvements	39,795
Total	43,741
Accumulated Depreciation	(5,560)
1064 Lexington, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,726
Costs Capitalized Subsequent to Acquisition	2,262
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	14,988
Total	14,988
Accumulated Depreciation	(6,952)
KY0011 Lexington, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,797
Building and Improvements	18,987
Costs Capitalized Subsequent to Acquisition	4,218
Gross Amount at Which Carried As of Year End	
Land and improvements	4,797
Buildings and Improvements	23,205
Total	28,002
Accumulated Depreciation	(1,253)
KY0012 Lexington, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,905
Building and Improvements	6,918
Costs Capitalized Subsequent to Acquisition	182
Gross Amount at Which Carried As of Year End	
Land and improvements	1,905
Buildings and Improvements	7,100
Total	9,005
Accumulated Depreciation	(621)
735 Louisville, KY Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	936
Building and Improvements	8,426
Costs Capitalized Subsequent to Acquisition	13,260
Gross Amount at Which Carried As of Year End	
Land and improvements	661
Buildings and Improvements	21,961
Total	22,622
Accumulated Depreciation	(12,967)
737 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	835
Building and Improvements	27,627
Costs Capitalized Subsequent to Acquisition	7,774
Gross Amount at Which Carried As of Year End	
Land and improvements	560
Buildings and Improvements	35,676
Total	36,236
Accumulated Depreciation	(18,509)
738 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	780
Building and Improvements	8,582
Costs Capitalized Subsequent to Acquisition	4,753
Gross Amount at Which Carried As of Year End	
Land and improvements	585
Buildings and Improvements	13,530
Total	14,115
Accumulated Depreciation	(10,660)
739 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	826
Building and Improvements	13,814
Costs Capitalized Subsequent to Acquisition	3,861
Gross Amount at Which Carried As of Year End	
Land and improvements	630
Buildings and Improvements	17,871
Total	18,501
Accumulated Depreciation	(8,268)
2834 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,983
Building and Improvements	13,171
Costs Capitalized Subsequent to Acquisition	5,253
Gross Amount at Which Carried As of Year End	
Land and improvements	2,983
Buildings and Improvements	18,424
Total	21,407
Accumulated Depreciation	(11,276)
1945 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,255
Building and Improvements	28,644
Costs Capitalized Subsequent to Acquisition	2,836
Gross Amount at Which Carried As of Year End	
Land and improvements	3,421
Buildings and Improvements	31,314
Total	34,735
Accumulated Depreciation	(14,486)
1946 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	430
Building and Improvements	6,125
Costs Capitalized Subsequent to Acquisition	243
Gross Amount at Which Carried As of Year End	
Land and improvements	430
Buildings and Improvements	6,368
Total	6,798
Accumulated Depreciation	(2,993)
2237 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,519
Building and Improvements	15,386
Costs Capitalized Subsequent to Acquisition	6,679
Gross Amount at Which Carried As of Year End	
Land and improvements	1,672
Buildings and Improvements	21,912
Total	23,584
Accumulated Depreciation	(9,361)
2238 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

Initial Cost to Company	
Land and improvements	1,334
Building and Improvements	12,172
Costs Capitalized Subsequent to Acquisition	3,079
Gross Amount at Which Carried As of Year End	
Land and improvements	1,594
Buildings and Improvements	14,991
Total	16,585
Accumulated Depreciation	(5,989)
2239 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,644
Building and Improvements	10,832
Costs Capitalized Subsequent to Acquisition	10,093
Gross Amount at Which Carried As of Year End	
Land and improvements	2,103
Buildings and Improvements	20,466
Total	22,569
Accumulated Depreciation	(8,103)
KY0001 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,801
Building and Improvements	4,672
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,801
Buildings and Improvements	4,672
Total	6,473
Accumulated Depreciation	(302)
KY0004 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	383
Building and Improvements	3,144
Costs Capitalized Subsequent to Acquisition	263
Gross Amount at Which Carried As of Year End	
Land and improvements	383
Buildings and Improvements	3,407
Total	3,790
Accumulated Depreciation	(372)
KY0005 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	680
Building and Improvements	7,568
Costs Capitalized Subsequent to Acquisition	253
Gross Amount at Which Carried As of Year End	
Land and improvements	680
Buildings and Improvements	7,821
Total	8,501
Accumulated Depreciation	(522)
KY0006 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,774
Building and Improvements	29,814
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,774
Buildings and Improvements	29,814
Total	31,588
Accumulated Depreciation	(1,814)
KY0007 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,430
Building and Improvements	19,016
Costs Capitalized Subsequent to Acquisition	167
Gross Amount at Which Carried As of Year End	
Land and improvements	3,430
Buildings and Improvements	19,183
Total	22,613
Accumulated Depreciation	(1,021)
KY0008 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	125
Building and Improvements	12,503
Costs Capitalized Subsequent to Acquisition	(72)
Gross Amount at Which Carried As of Year End	
Land and improvements	125
Buildings and Improvements	12,431
Total	12,556
Accumulated Depreciation	(525)
KY0009 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	

Land and improvements	48
Building and Improvements	3,864
Costs Capitalized Subsequent to Acquisition	17
Gross Amount at Which Carried As of Year End	
Land and improvements	48
Buildings and Improvements	3,881
Total	3,929
Accumulated Depreciation	(205)
KY0010 Louisville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	315
Building and Improvements	2,585
Costs Capitalized Subsequent to Acquisition	1,113
Gross Amount at Which Carried As of Year End	
Land and improvements	315
Buildings and Improvements	3,698
Total	4,013
Accumulated Depreciation	(174)
KY0002 Shepherdsville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	973
Building and Improvements	28,735
Costs Capitalized Subsequent to Acquisition	571
Gross Amount at Which Carried As of Year End	
Land and improvements	973
Buildings and Improvements	29,306
Total	30,279
Accumulated Depreciation	(637)
KY0003 Shepherdsville, KY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	795
Building and Improvements	3,355
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	795
Buildings and Improvements	3,355
Total	4,150
Accumulated Depreciation	(193)
3023 Covington, LA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	9,490
Building and Improvements	21,918
Costs Capitalized Subsequent to Acquisition	(298)
Gross Amount at Which Carried As of Year End	
Land and improvements	9,507
Buildings and Improvements	21,603
Total	31,110
Accumulated Depreciation	(2,765)
LA0004 Lafayette, LA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	353
Building and Improvements	27,863
Costs Capitalized Subsequent to Acquisition	(69)
Gross Amount at Which Carried As of Year End	
Land and improvements	353
Buildings and Improvements	27,794
Total	28,147
Accumulated Depreciation	(744)
LA0001 Metairie, LA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	68
Building and Improvements	38,037
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	68
Buildings and Improvements	38,037
Total	38,105
Accumulated Depreciation	(1,124)
3121 Cambrigde, MA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	40,663
Building and Improvements	23,102
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	40,663
Buildings and Improvements	23,102
Total	63,765
Accumulated Depreciation	(2,596)
MD0003 Brandywine, MD Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,757

Building and Improvements	17,285
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	4,757
Buildings and Improvements	17,285
Total	22,042
Accumulated Depreciation	(903)
1213 Ellicott City, MD Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,115
Building and Improvements	3,206
Costs Capitalized Subsequent to Acquisition	2,758
Gross Amount at Which Carried As of Year End	
Land and improvements	1,357
Buildings and Improvements	5,722
Total	7,079
Accumulated Depreciation	(2,734)
MD0002 Lanham, MD Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	227
Building and Improvements	17,283
Costs Capitalized Subsequent to Acquisition	43
Gross Amount at Which Carried As of Year End	
Land and improvements	227
Buildings and Improvements	17,326
Total	17,553
Accumulated Depreciation	(584)
1052 Towson, MD Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	14,233
Costs Capitalized Subsequent to Acquisition	1,231
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	15,464
Total	15,464
Accumulated Depreciation	(6,681)
MD0001 Waldorf, MD Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,759
Building and Improvements	6,038
Costs Capitalized Subsequent to Acquisition	53
Gross Amount at Which Carried As of Year End	
Land and improvements	1,759
Buildings and Improvements	6,091
Total	7,850
Accumulated Depreciation	(361)
2650 Biddeford, ME Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,341
Building and Improvements	17,376
Costs Capitalized Subsequent to Acquisition	(558)
Gross Amount at Which Carried As of Year End	
Land and improvements	309
Buildings and Improvements	17,850
Total	18,159
Accumulated Depreciation	(3,945)
ME0001 Brunswick, ME Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	4,592
Initial Cost to Company	
Land and improvements	920
Building and Improvements	10,394
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	920
Buildings and Improvements	10,394
Total	11,314
Accumulated Depreciation	(522)
MI0010 Bay City, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	705
Building and Improvements	15,282
Costs Capitalized Subsequent to Acquisition	15
Gross Amount at Which Carried As of Year End	
Land and improvements	705
Buildings and Improvements	15,297
Total	16,002
Accumulated Depreciation	(695)
MI0006 Grand Blanc, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	671
Building and Improvements	12,097

Costs Capitalized Subsequent to Acquisition	22
Gross Amount at Which Carried As of Year End	
Land and improvements	671
Buildings and Improvements	12,119
Total	12,790
Accumulated Depreciation	(675)
MI0011 Gross Pointe, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	138
Building and Improvements	12,400
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	138
Buildings and Improvements	12,400
Total	12,538
Accumulated Depreciation	(481)
MI0012 Petoskey, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	236
Building and Improvements	17,990
Costs Capitalized Subsequent to Acquisition	166
Gross Amount at Which Carried As of Year End	
Land and improvements	236
Buildings and Improvements	18,156
Total	18,392
Accumulated Depreciation	(870)
MI0013 Rochester Hills, Mi Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,100
Building and Improvements	20,278
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,100
Buildings and Improvements	20,278
Total	21,378
Accumulated Depreciation	(993)
MI0014 Sterling Heights, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	310
Building and Improvements	28,116
Costs Capitalized Subsequent to Acquisition	84
Gross Amount at Which Carried As of Year End	
Land and improvements	310
Buildings and Improvements	28,200
Total	28,510
Accumulated Depreciation	(1,005)
MI0008 Traverse City, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,709
Building and Improvements	18,502
Costs Capitalized Subsequent to Acquisition	99
Gross Amount at Which Carried As of Year End	
Land and improvements	1,709
Buildings and Improvements	18,601
Total	20,310
Accumulated Depreciation	(1,045)
MI000A8 Traverse City, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	255
Building and Improvements	1,854
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	255
Buildings and Improvements	1,854
Total	2,109
Accumulated Depreciation	(108)
MI0018 Apple Valley, MI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,541
Building and Improvements	8,011
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,541
Buildings and Improvements	8,011
Total	10,552
Accumulated Depreciation	(494)
3002 Burnsville, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	7,763
Initial Cost to Company	
Land and improvements	2,801
Building and Improvements	17,779
Costs Capitalized Subsequent to Acquisition	1,151

Gross Amount at Which Carried As of Year End	
Land and improvements	2,861
Buildings and Improvements	18,870
Total	21,731
Accumulated Depreciation	(4,793)
3003 Burnsville, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	5,176
Initial Cost to Company	
Land and improvements	516
Building and Improvements	13,200
Costs Capitalized Subsequent to Acquisition	461
Gross Amount at Which Carried As of Year End	
Land and improvements	533
Buildings and Improvements	13,644
Total	14,177
Accumulated Depreciation	(3,137)
3009 Burnsville, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	19,110
Initial Cost to Company	
Land and improvements	4,640
Building and Improvements	38,064
Costs Capitalized Subsequent to Acquisition	333
Gross Amount at Which Carried As of Year End	
Land and improvements	4,664
Buildings and Improvements	38,373
Total	43,037
Accumulated Depreciation	(5,513)
MN0004 Chanhassen, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	919
Building and Improvements	2,457
Costs Capitalized Subsequent to Acquisition	211
Gross Amount at Which Carried As of Year End	
Land and improvements	919
Buildings and Improvements	2,668
Total	3,587
Accumulated Depreciation	(125)
MN0009 Chanhassen, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,609
Building and Improvements	9,198
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,609
Buildings and Improvements	9,198
Total	11,807
Accumulated Depreciation	(452)
MN0008 Coon Rapids, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,032
Building and Improvements	4,568
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,032
Buildings and Improvements	4,568
Total	5,600
Accumulated Depreciation	(256)
MN0003 Crystal, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,852
Building and Improvements	7,888
Costs Capitalized Subsequent to Acquisition	36
Gross Amount at Which Carried As of Year End	
Land and improvements	1,852
Buildings and Improvements	7,924
Total	9,776
Accumulated Depreciation	(358)
MN0001 Edina, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	377
Building and Improvements	7,984
Costs Capitalized Subsequent to Acquisition	87
Gross Amount at Which Carried As of Year End	
Land and improvements	377
Buildings and Improvements	8,071
Total	8,448
Accumulated Depreciation	(479)
MN0017 Edina, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,654
Building and Improvements	3,468
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,654

Buildings and Improvements	3,468
Total	5,122
Accumulated Depreciation	(164)
MN0010 Hugo, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,285
Building and Improvements	2,966
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,285
Buildings and Improvements	2,966
Total	4,251
Accumulated Depreciation	(147)
MN0016 Lake Elmo, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,939
Building and Improvements	5,435
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,939
Buildings and Improvements	5,435
Total	7,374
Accumulated Depreciation	(356)
MN0013 Little Falls, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	75
Building and Improvements	5,980
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	75
Buildings and Improvements	5,980
Total	6,055
Accumulated Depreciation	(317)
MN0014 Little Falls, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	580
Building and Improvements	1,618
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	580
Buildings and Improvements	1,618
Total	2,198
Accumulated Depreciation	(122)
MN0015 Little Falls, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	59
Building and Improvements	4,932
Costs Capitalized Subsequent to Acquisition	3
Gross Amount at Which Carried As of Year End	
Land and improvements	59
Buildings and Improvements	4,935
Total	4,994
Accumulated Depreciation	(277)
MN0012 Maplewood, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	716
Building and Improvements	2,031
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	716
Buildings and Improvements	2,031
Total	2,747
Accumulated Depreciation	(119)
MN0019 Maplewood, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,884
Building and Improvements	38,366
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	4,884
Buildings and Improvements	38,366
Total	43,250
Accumulated Depreciation	(1,685)
240 Minneapolis, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	117
Building and Improvements	13,213
Costs Capitalized Subsequent to Acquisition	5,655
Gross Amount at Which Carried As of Year End	
Land and improvements	117
Buildings and Improvements	18,868
Total	18,985

Accumulated Depreciation	(12,664)
300 Minneapolis, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	160
Building and Improvements	10,131
Costs Capitalized Subsequent to Acquisition	4,694
Gross Amount at Which Carried As of Year End	
Land and improvements	214
Buildings and Improvements	14,771
Total	14,985
Accumulated Depreciation	(9,794)
MN0006 Minnetonka, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,701
Building and Improvements	14,026
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,701
Buildings and Improvements	14,026
Total	16,727
Accumulated Depreciation	(654)
MN0007 Minnetonka, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,927
Building and Improvements	5,979
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,927
Buildings and Improvements	5,979
Total	7,906
Accumulated Depreciation	(272)
MN0002 Savage, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,762
Building and Improvements	6,075
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,762
Buildings and Improvements	6,075
Total	7,837
Accumulated Depreciation	(318)
MN0011 Stillwater, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,161
Building and Improvements	1,676
Costs Capitalized Subsequent to Acquisition	34
Gross Amount at Which Carried As of Year End	
Land and improvements	1,161
Buildings and Improvements	1,710
Total	2,871
Accumulated Depreciation	(128)
MN0005 Vadnais Heights, MN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,028
Building and Improvements	12,993
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,028
Buildings and Improvements	12,993
Total	15,021
Accumulated Depreciation	(603)
2703 Columbia, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,141
Building and Improvements	20,364
Costs Capitalized Subsequent to Acquisition	(13,850)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,141
Buildings and Improvements	6,514
Total	10,655
Accumulated Depreciation	(2,828)
MO0002 Creve Coeur, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,622
Building and Improvements	7,209
Costs Capitalized Subsequent to Acquisition	287
Gross Amount at Which Carried As of Year End	
Land and improvements	1,622
Buildings and Improvements	7,496
Total	9,118
Accumulated Depreciation	(365)
MO0001 Fenton, MO Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,457
Building and Improvements	3,589
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,457
Buildings and Improvements	3,589
Total	5,046
Accumulated Depreciation	(250)
2032 Independence, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	48,025
Costs Capitalized Subsequent to Acquisition	1,654
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	49,679
Total	49,679
Accumulated Depreciation	(13,551)
MO0003 Kansas City, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	312
Building and Improvements	23,251
Costs Capitalized Subsequent to Acquisition	719
Gross Amount at Which Carried As of Year End	
Land and improvements	312
Buildings and Improvements	23,970
Total	24,282
Accumulated Depreciation	(884)
2866 Kansas City, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	13,903
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	13,903
Total	13,903
Accumulated Depreciation	0
2863 Lee's Summit, MO Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	16,416
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	16,416
Total	16,416
Accumulated Depreciation	(3,452)
1078 Flowood, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,413
Costs Capitalized Subsequent to Acquisition	1,487
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,900
Total	9,900
Accumulated Depreciation	(4,512)
MS0001 Grenada, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,200
Building and Improvements	8,523
Costs Capitalized Subsequent to Acquisition	491
Gross Amount at Which Carried As of Year End	
Land and improvements	1,200
Buildings and Improvements	9,014
Total	10,214
Accumulated Depreciation	(373)
1059 Jackson, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,868
Costs Capitalized Subsequent to Acquisition	639
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,507
Total	9,507
Accumulated Depreciation	(4,340)
1060 Jackson, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,187
Costs Capitalized Subsequent to Acquisition	2,038
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,225
Total	9,225
Accumulated Depreciation	(4,107)
MS0002 Jackson, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,664
Building and Improvements	9,691
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,664
Buildings and Improvements	9,691
Total	11,355
Accumulated Depreciation	(463)
MS0003 Jackson, MS Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	19,684
Initial Cost to Company	
Land and improvements	1,681
Building and Improvements	42,202
Costs Capitalized Subsequent to Acquisition	9
Gross Amount at Which Carried As of Year End	
Land and improvements	1,681
Buildings and Improvements	42,211
Total	43,892
Accumulated Depreciation	(1,666)
2657 Shallotte, NC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	918
Building and Improvements	3,609
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	918
Buildings and Improvements	3,609
Total	4,527
Accumulated Depreciation	(1,290)
2655 Wilmington, NC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,949
Building and Improvements	12,244
Costs Capitalized Subsequent to Acquisition	(613)
Gross Amount at Which Carried As of Year End	
Land and improvements	1,336
Buildings and Improvements	12,244
Total	13,580
Accumulated Depreciation	(2,521)
2656 Wilmington, NC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,071
Building and Improvements	11,592
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,071
Buildings and Improvements	11,592
Total	13,663
Accumulated Depreciation	(3,005)
ND0001 Jamestown, ND Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	482
Building and Improvements	10,262
Costs Capitalized Subsequent to Acquisition	(74)
Gross Amount at Which Carried As of Year End	
Land and improvements	482
Buildings and Improvements	10,188
Total	10,670
Accumulated Depreciation	(418)
NE0010 Kearney, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	183
Building and Improvements	17,068
Costs Capitalized Subsequent to Acquisition	851
Gross Amount at Which Carried As of Year End	
Land and improvements	183
Buildings and Improvements	17,919
Total	18,102
Accumulated Depreciation	(846)
NE0011 Kearney, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	

Land and improvements	133
Building and Improvements	1,228
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	133
Buildings and Improvements	1,228
Total	1,361
Accumulated Depreciation	(96)
NE0012 Kearney, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	147
Building and Improvements	13,382
Costs Capitalized Subsequent to Acquisition	(23)
Gross Amount at Which Carried As of Year End	
Land and improvements	147
Buildings and Improvements	13,359
Total	13,506
Accumulated Depreciation	(600)
1068 Omaha, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	16,243
Costs Capitalized Subsequent to Acquisition	2,718
Gross Amount at Which Carried As of Year End	
Land and improvements	24
Buildings and Improvements	18,937
Total	18,961
Accumulated Depreciation	(8,745)
NE0002 Omaha, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,919
Building and Improvements	21,041
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,919
Buildings and Improvements	21,041
Total	22,960
Accumulated Depreciation	(1,112)
NE0004 Omaha, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	151
Building and Improvements	15,812
Costs Capitalized Subsequent to Acquisition	89
Gross Amount at Which Carried As of Year End	
Land and improvements	151
Buildings and Improvements	15,901
Total	16,052
Accumulated Depreciation	(581)
NE0013 Omaha, NE Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	445
Building and Improvements	36,048
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	445
Buildings and Improvements	36,048
Total	36,493
Accumulated Depreciation	(1,413)
2647 Concord, NH Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,961
Building and Improvements	23,516
Costs Capitalized Subsequent to Acquisition	(473)
Gross Amount at Which Carried As of Year End	
Land and improvements	1,053
Buildings and Improvements	23,951
Total	25,004
Accumulated Depreciation	(4,227)
2648 Concord, NH Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	815
Building and Improvements	8,902
Costs Capitalized Subsequent to Acquisition	227
Gross Amount at Which Carried As of Year End	
Land and improvements	419
Buildings and Improvements	9,525
Total	9,944
Accumulated Depreciation	(2,449)
2649 Epsom, NH Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	919
Building and Improvements	5,868

Costs Capitalized Subsequent to Acquisition	(577)
Gross Amount at Which Carried As of Year End	
Land and improvements	348
Buildings and Improvements	5,862
Total	6,210
Accumulated Depreciation	(1,242)
3011 Cherry Hill, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,235
Building and Improvements	21,731
Costs Capitalized Subsequent to Acquisition	409
Gross Amount at Which Carried As of Year End	
Land and improvements	5,235
Buildings and Improvements	22,140
Total	27,375
Accumulated Depreciation	(3,706)
NJ0001 Monroe Township, NJ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,026
Building and Improvements	2,847
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,026
Buildings and Improvements	2,847
Total	4,873
Accumulated Depreciation	(256)
3012 Morristown, NJ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	21,703
Building and Improvements	32,517
Costs Capitalized Subsequent to Acquisition	6,855
Gross Amount at Which Carried As of Year End	
Land and improvements	21,703
Buildings and Improvements	39,372
Total	61,075
Accumulated Depreciation	(6,543)
3013 Morristown, NJ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	14,567
Building and Improvements	20,548
Costs Capitalized Subsequent to Acquisition	9,252
Gross Amount at Which Carried As of Year End	
Land and improvements	14,567
Buildings and Improvements	29,800
Total	44,367
Accumulated Depreciation	(3,851)
3014 Morristown, NJ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	20,563
Building and Improvements	31,849
Costs Capitalized Subsequent to Acquisition	1,986
Gross Amount at Which Carried As of Year End	
Land and improvements	20,563
Buildings and Improvements	33,835
Total	54,398
Accumulated Depreciation	(3,751)
NJ0002 Old Bridge, NJ Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	19,864
Initial Cost to Company	
Land and improvements	444
Building and Improvements	36,220
Costs Capitalized Subsequent to Acquisition	172
Gross Amount at Which Carried As of Year End	
Land and improvements	444
Buildings and Improvements	36,392
Total	36,836
Accumulated Depreciation	(1,199)
729 Albuquerque, NM Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	5,380
Costs Capitalized Subsequent to Acquisition	2,485
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	7,865
Total	7,865
Accumulated Depreciation	(3,216)
571 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	24,349
Gross Amount at Which Carried As of Year End	

Land and improvements	0
Buildings and Improvements	24,349
Total	24,349
Accumulated Depreciation	(9,435)
660 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,121
Building and Improvements	4,363
Costs Capitalized Subsequent to Acquisition	9,587
Gross Amount at Which Carried As of Year End	
Land and improvements	1,147
Buildings and Improvements	13,924
Total	15,071
Accumulated Depreciation	(5,896)
661 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,305
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	1,371
Gross Amount at Which Carried As of Year End	
Land and improvements	3,676
Buildings and Improvements	0
Total	3,676
Accumulated Depreciation	0
662 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,000
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,000
Buildings and Improvements	0
Total	1,000
Accumulated Depreciation	0
663 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,717
Building and Improvements	3,597
Costs Capitalized Subsequent to Acquisition	12,948
Gross Amount at Which Carried As of Year End	
Land and improvements	1,724
Buildings and Improvements	16,538
Total	18,262
Accumulated Depreciation	(7,657)
664 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,172
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	633
Gross Amount at Which Carried As of Year End	
Land and improvements	1,805
Buildings and Improvements	0
Total	1,805
Accumulated Depreciation	(496)
691 Las Vegas, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,073
Building and Improvements	18,339
Costs Capitalized Subsequent to Acquisition	6,038
Gross Amount at Which Carried As of Year End	
Land and improvements	3,116
Buildings and Improvements	24,334
Total	27,450
Accumulated Depreciation	(15,329)
2037 Mesquite, NV Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	5,559
Costs Capitalized Subsequent to Acquisition	834
Gross Amount at Which Carried As of Year End	
Land and improvements	34
Buildings and Improvements	6,359
Total	6,393
Accumulated Depreciation	(2,240)
NY0014 Brooklyn, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,632
Building and Improvements	39,687
Costs Capitalized Subsequent to Acquisition	1,161
Gross Amount at Which Carried As of Year End	
Land and improvements	11,632

Buildings and Improvements	40,848
Total	52,480
Accumulated Depreciation	(1,273)
NY0008 Cornwall, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	110
Building and Improvements	9,091
Costs Capitalized Subsequent to Acquisition	147
Gross Amount at Which Carried As of Year End	
Land and improvements	110
Buildings and Improvements	9,238
Total	9,348
Accumulated Depreciation	(348)
NY0009 Hudson, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	68
Building and Improvements	4,931
Costs Capitalized Subsequent to Acquisition	230
Gross Amount at Which Carried As of Year End	
Land and improvements	68
Buildings and Improvements	5,161
Total	5,229
Accumulated Depreciation	(325)
NY0012 Lake Katrine, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,950
Building and Improvements	31,897
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,950
Buildings and Improvements	31,897
Total	35,847
Accumulated Depreciation	(1,051)
NY0013 Rhinebeck, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,312
Building and Improvements	4,015
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	4,312
Buildings and Improvements	4,015
Total	8,327
Accumulated Depreciation	(313)
NY0001 Wallkill, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,304
Building and Improvements	5,957
Costs Capitalized Subsequent to Acquisition	63
Gross Amount at Which Carried As of Year End	
Land and improvements	1,304
Buildings and Improvements	6,020
Total	7,324
Accumulated Depreciation	(214)
NY0002 Wallkill, NY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	518
Building and Improvements	1,338
Costs Capitalized Subsequent to Acquisition	310
Gross Amount at Which Carried As of Year End	
Land and improvements	518
Buildings and Improvements	1,648
Total	2,166
Accumulated Depreciation	(70)
400 Harrison, OH Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,561
Costs Capitalized Subsequent to Acquisition	373
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	4,934
Total	4,934
Accumulated Depreciation	(3,333)
1054 Durant, OK Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	619
Building and Improvements	9,256
Costs Capitalized Subsequent to Acquisition	3,040
Gross Amount at Which Carried As of Year End	
Land and improvements	666
Buildings and Improvements	12,249

Total	12,915
Accumulated Depreciation	(5,672)
817 Owasso, OK Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,582
Costs Capitalized Subsequent to Acquisition	(519)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	6,063
Total	6,063
Accumulated Depreciation	(2,976)
3010 Springfield, OR Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	20,802
Initial Cost to Company	
Land and improvements	0
Building and Improvements	51,998
Costs Capitalized Subsequent to Acquisition	1,979
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	53,977
Total	53,977
Accumulated Depreciation	(7,268)
PA0006 Camp Hill, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,014
Building and Improvements	2,376
Costs Capitalized Subsequent to Acquisition	183
Gross Amount at Which Carried As of Year End	
Land and improvements	1,014
Buildings and Improvements	2,559
Total	3,573
Accumulated Depreciation	(173)
PA0002 Carlisle, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	680
Building and Improvements	1,468
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	680
Buildings and Improvements	1,468
Total	2,148
Accumulated Depreciation	(116)
PA0004 Carlisle, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	456
Building and Improvements	2,333
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	456
Buildings and Improvements	2,333
Total	2,789
Accumulated Depreciation	(161)
PA0014 Erie, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	251
Building and Improvements	21,584
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	251
Buildings and Improvements	21,584
Total	21,835
Accumulated Depreciation	(808)
PA0010 Hanover, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,777
Building and Improvements	8,437
Costs Capitalized Subsequent to Acquisition	1,001
Gross Amount at Which Carried As of Year End	
Land and improvements	1,777
Buildings and Improvements	9,438
Total	11,215
Accumulated Depreciation	(526)
PA0007 Harrisburg, PA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,800
Building and Improvements	4,397
Costs Capitalized Subsequent to Acquisition	511
Gross Amount at Which Carried As of Year End	
Land and improvements	1,823
Buildings and Improvements	4,885
Total	6,708
Accumulated Depreciation	(422)

PA0008 Harrisburg, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	586
Building and Improvements	1,115
Costs Capitalized Subsequent to Acquisition	102
Gross Amount at Which Carried As of Year End	
Land and improvements	586
Buildings and Improvements	1,217
Total	1,803
Accumulated Depreciation	(68)

PA0005 Hershey, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	196
Building and Improvements	2,896
Costs Capitalized Subsequent to Acquisition	113
Gross Amount at Which Carried As of Year End	
Land and improvements	196
Buildings and Improvements	3,009
Total	3,205
Accumulated Depreciation	(117)

2570 Limerick, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	925
Building and Improvements	20,072
Costs Capitalized Subsequent to Acquisition	(119)
Gross Amount at Which Carried As of Year End	
Land and improvements	755
Buildings and Improvements	20,123
Total	20,878
Accumulated Depreciation	(5,801)

2234 Philadelphia, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	24,264
Building and Improvements	99,904
Costs Capitalized Subsequent to Acquisition	53,253
Gross Amount at Which Carried As of Year End	
Land and improvements	24,288
Buildings and Improvements	153,133
Total	177,421
Accumulated Depreciation	(48,972)

2403 Philadelphia, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	26,063
Building and Improvements	97,646
Costs Capitalized Subsequent to Acquisition	54,119
Gross Amount at Which Carried As of Year End	
Land and improvements	26,134
Buildings and Improvements	151,694
Total	177,828
Accumulated Depreciation	(58,093)

PA0012 West Easton, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,065
Building and Improvements	7,718
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,065
Buildings and Improvements	7,718
Total	9,783
Accumulated Depreciation	(397)

PA0013 West Mifflin, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	957
Building and Improvements	3,193
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	957
Buildings and Improvements	3,193
Total	4,150
Accumulated Depreciation	(201)

2571 Wilkes-Barre, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,138
Costs Capitalized Subsequent to Acquisition	11
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	9,149
Total	9,149
Accumulated Depreciation	(2,915)

PA0011 Wyomissing, PA | Outpatient Medical | Operating segment

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	298
Building and Improvements	3,410
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	298
Buildings and Improvements	3,410
Total	3,708
Accumulated Depreciation	(191)
2694 Anderson, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	405
Building and Improvements	1,211
Costs Capitalized Subsequent to Acquisition	(162)
Gross Amount at Which Carried As of Year End	
Land and improvements	243
Buildings and Improvements	1,211
Total	1,454
Accumulated Depreciation	(270)
2573 Florence, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,090
Costs Capitalized Subsequent to Acquisition	90
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	12,180
Total	12,180
Accumulated Depreciation	(3,100)
2574 Florence, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,190
Costs Capitalized Subsequent to Acquisition	87
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	12,277
Total	12,277
Accumulated Depreciation	(3,120)
2575 Florence, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	11,243
Costs Capitalized Subsequent to Acquisition	56
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,299
Total	11,299
Accumulated Depreciation	(3,516)
2841 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	634
Building and Improvements	38,386
Costs Capitalized Subsequent to Acquisition	(2,283)
Gross Amount at Which Carried As of Year End	
Land and improvements	13
Buildings and Improvements	36,724
Total	36,737
Accumulated Depreciation	(7,237)
2842 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	794
Building and Improvements	41,293
Costs Capitalized Subsequent to Acquisition	(3,459)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	38,628
Total	38,628
Accumulated Depreciation	(7,133)
2843 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	626
Building and Improvements	22,210
Costs Capitalized Subsequent to Acquisition	(2,776)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	20,060
Total	20,060
Accumulated Depreciation	(3,676)
2844 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	

Land and improvements	806
Building and Improvements	18,889
Costs Capitalized Subsequent to Acquisition	(1,811)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,884
Total	17,884
Accumulated Depreciation	(2,947)
2845 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	932
Building and Improvements	40,879
Costs Capitalized Subsequent to Acquisition	(3,309)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	38,502
Total	38,502
Accumulated Depreciation	(6,226)
2846 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	896
Building and Improvements	38,486
Costs Capitalized Subsequent to Acquisition	(3,670)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	35,712
Total	35,712
Accumulated Depreciation	(5,831)
2847 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	600
Building and Improvements	26,472
Costs Capitalized Subsequent to Acquisition	200
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	27,272
Total	27,272
Accumulated Depreciation	(5,264)
2850 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	211
Building and Improvements	6,503
Costs Capitalized Subsequent to Acquisition	(1,008)
Gross Amount at Which Carried As of Year End	
Land and improvements	211
Buildings and Improvements	5,495
Total	5,706
Accumulated Depreciation	(1,044)
2853 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	534
Building and Improvements	6,430
Costs Capitalized Subsequent to Acquisition	(1,388)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,576
Total	5,576
Accumulated Depreciation	(1,231)
2854 Greenville, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	824
Building and Improvements	13,645
Costs Capitalized Subsequent to Acquisition	(2,812)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,657
Total	11,657
Accumulated Depreciation	(2,048)
2848 Greer, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	318
Building and Improvements	5,816
Costs Capitalized Subsequent to Acquisition	(791)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,343
Total	5,343
Accumulated Depreciation	(851)
2849 Greer, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	319
Building and Improvements	5,836

Costs Capitalized Subsequent to Acquisition	(777)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,378
Total	5,378
Accumulated Depreciation	(879)
2862 Myrtle Beach, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	28,496
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	28,496
Total	28,496
Accumulated Depreciation	(7,945)
2851 Travelers Rest, SC Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	498
Building and Improvements	1,015
Costs Capitalized Subsequent to Acquisition	(399)
Gross Amount at Which Carried As of Year End	
Land and improvements	299
Buildings and Improvements	815
Total	1,114
Accumulated Depreciation	(309)
2865 Brentwood, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	36,965
Gross Amount at Which Carried As of Year End	
Land and improvements	52
Buildings and Improvements	36,913
Total	36,965
Accumulated Depreciation	(5,487)
TN0007 Chattanooga, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	139
Building and Improvements	10,350
Costs Capitalized Subsequent to Acquisition	281
Gross Amount at Which Carried As of Year End	
Land and improvements	139
Buildings and Improvements	10,631
Total	10,770
Accumulated Depreciation	(532)
TN0010 Chattanooga, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	221
Building and Improvements	17,612
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	221
Buildings and Improvements	17,612
Total	17,833
Accumulated Depreciation	(813)
TN0011 Franklin, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,056
Building and Improvements	5,484
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,056
Buildings and Improvements	5,484
Total	8,540
Accumulated Depreciation	(293)
624 Hendersonville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	256
Building and Improvements	1,530
Costs Capitalized Subsequent to Acquisition	1,581
Gross Amount at Which Carried As of Year End	
Land and improvements	256
Buildings and Improvements	3,111
Total	3,367
Accumulated Depreciation	(1,497)
559 Hermitage, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	830
Building and Improvements	5,036
Costs Capitalized Subsequent to Acquisition	13,203

Gross Amount at Which Carried As of Year End	
Land and improvements	837
Buildings and Improvements	18,232
Total	19,069
Accumulated Depreciation	(7,630)
<u>561 Hermitage, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	596
Building and Improvements	9,698
Costs Capitalized Subsequent to Acquisition	4,457
Gross Amount at Which Carried As of Year End	
Land and improvements	596
Buildings and Improvements	14,155
Total	14,751
Accumulated Depreciation	(7,773)
<u>562 Hermitage, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	317
Building and Improvements	6,528
Costs Capitalized Subsequent to Acquisition	2,936
Gross Amount at Which Carried As of Year End	
Land and improvements	317
Buildings and Improvements	9,464
Total	9,781
Accumulated Depreciation	(4,965)
<u>TN0002 Jackson, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,124
Building and Improvements	5,631
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,124
Buildings and Improvements	5,631
Total	6,755
Accumulated Depreciation	(358)
<u>TN0001 Kingsport, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,778
Building and Improvements	10,365
Costs Capitalized Subsequent to Acquisition	57
Gross Amount at Which Carried As of Year End	
Land and improvements	2,835
Buildings and Improvements	10,365
Total	13,200
Accumulated Depreciation	(476)
<u>TN0012 Kingsport, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	511
Building and Improvements	59,215
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	511
Buildings and Improvements	59,215
Total	59,726
Accumulated Depreciation	(1,990)
<u>625 Nashville, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	955
Building and Improvements	14,289
Costs Capitalized Subsequent to Acquisition	9,058
Gross Amount at Which Carried As of Year End	
Land and improvements	955
Buildings and Improvements	23,347
Total	24,302
Accumulated Depreciation	(10,821)
<u>626 Nashville, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,050
Building and Improvements	5,211
Costs Capitalized Subsequent to Acquisition	5,984
Gross Amount at Which Carried As of Year End	
Land and improvements	2,050
Buildings and Improvements	11,195
Total	13,245
Accumulated Depreciation	(4,320)
<u>627 Nashville, TN Outpatient Medical Operating segment</u>	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,007
Building and Improvements	181
Costs Capitalized Subsequent to Acquisition	986
Gross Amount at Which Carried As of Year End	
Land and improvements	1,113

Buildings and Improvements	1,061
Total	2,174
Accumulated Depreciation	(660)
628 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,980
Building and Improvements	7,164
Costs Capitalized Subsequent to Acquisition	3,670
Gross Amount at Which Carried As of Year End	
Land and improvements	2,980
Buildings and Improvements	10,834
Total	13,814
Accumulated Depreciation	(4,561)
630 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	515
Building and Improvements	848
Costs Capitalized Subsequent to Acquisition	351
Gross Amount at Which Carried As of Year End	
Land and improvements	649
Buildings and Improvements	1,065
Total	1,714
Accumulated Depreciation	(596)
631 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	266
Building and Improvements	1,305
Costs Capitalized Subsequent to Acquisition	1,171
Gross Amount at Which Carried As of Year End	
Land and improvements	266
Buildings and Improvements	2,476
Total	2,742
Accumulated Depreciation	(1,266)
632 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	827
Building and Improvements	7,642
Costs Capitalized Subsequent to Acquisition	3,565
Gross Amount at Which Carried As of Year End	
Land and improvements	827
Buildings and Improvements	11,207
Total	12,034
Accumulated Depreciation	(5,708)
633 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,425
Building and Improvements	12,577
Costs Capitalized Subsequent to Acquisition	5,876
Gross Amount at Which Carried As of Year End	
Land and improvements	5,425
Buildings and Improvements	18,453
Total	23,878
Accumulated Depreciation	(9,429)
634 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,818
Building and Improvements	15,185
Costs Capitalized Subsequent to Acquisition	12,001
Gross Amount at Which Carried As of Year End	
Land and improvements	3,818
Buildings and Improvements	27,186
Total	31,004
Accumulated Depreciation	(10,703)
636 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	583
Building and Improvements	450
Costs Capitalized Subsequent to Acquisition	424
Gross Amount at Which Carried As of Year End	
Land and improvements	604
Buildings and Improvements	853
Total	1,457
Accumulated Depreciation	(449)
2967 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	53,773
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	53,773
Total	53,773

Accumulated Depreciation	(7,540)
2720 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	102
Building and Improvements	10,925
Costs Capitalized Subsequent to Acquisition	749
Gross Amount at Which Carried As of Year End	
Land and improvements	102
Buildings and Improvements	11,674
Total	11,776
Accumulated Depreciation	(2,415)
TN0005 Nashville, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	16,857
Building and Improvements	17,681
Costs Capitalized Subsequent to Acquisition	(230)
Gross Amount at Which Carried As of Year End	
Land and improvements	16,857
Buildings and Improvements	17,451
Total	34,308
Accumulated Depreciation	(946)
TN0008 Spring Hill, TN Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	628
Building and Improvements	13,821
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	628
Buildings and Improvements	13,821
Total	14,449
Accumulated Depreciation	(655)
2611 Allen, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,330
Building and Improvements	5,960
Costs Capitalized Subsequent to Acquisition	1,232
Gross Amount at Which Carried As of Year End	
Land and improvements	1,374
Buildings and Improvements	7,148
Total	8,522
Accumulated Depreciation	(2,021)
2612 Allen, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,310
Building and Improvements	4,165
Costs Capitalized Subsequent to Acquisition	1,683
Gross Amount at Which Carried As of Year End	
Land and improvements	1,310
Buildings and Improvements	5,848
Total	7,158
Accumulated Depreciation	(1,899)
573 Arlington, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	769
Building and Improvements	12,355
Costs Capitalized Subsequent to Acquisition	25,901
Gross Amount at Which Carried As of Year End	
Land and improvements	769
Buildings and Improvements	38,256
Total	39,025
Accumulated Depreciation	(10,485)
TX0025 Austin, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	22,885
Building and Improvements	16,662
Costs Capitalized Subsequent to Acquisition	1,065
Gross Amount at Which Carried As of Year End	
Land and improvements	22,902
Buildings and Improvements	17,710
Total	40,612
Accumulated Depreciation	(1,037)
TX0026 Bedford, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	627
Building and Improvements	4,706
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	627
Buildings and Improvements	4,706
Total	5,333
Accumulated Depreciation	(339)
TX0026 Bryan, TX Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	105
Building and Improvements	7,013
Costs Capitalized Subsequent to Acquisition	153
Gross Amount at Which Carried As of Year End	
Land and improvements	105
Buildings and Improvements	7,166
Total	7,271
Accumulated Depreciation	(344)
TX0027 Bryan, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	197
Building and Improvements	4,080
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	197
Buildings and Improvements	4,080
Total	4,277
Accumulated Depreciation	(223)
TX0012 Carrollton, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,723
Building and Improvements	857
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,723
Buildings and Improvements	857
Total	2,580
Accumulated Depreciation	(111)
TX0023 Carrollton, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,461
Building and Improvements	5,211
Costs Capitalized Subsequent to Acquisition	208
Gross Amount at Which Carried As of Year End	
Land and improvements	3,461
Buildings and Improvements	5,419
Total	8,880
Accumulated Depreciation	(477)
2621 Cedar Park, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,617
Building and Improvements	11,640
Costs Capitalized Subsequent to Acquisition	945
Gross Amount at Which Carried As of Year End	
Land and improvements	1,617
Buildings and Improvements	12,585
Total	14,202
Accumulated Depreciation	(2,570)
576 Conroe, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	324
Building and Improvements	4,842
Costs Capitalized Subsequent to Acquisition	5,020
Gross Amount at Which Carried As of Year End	
Land and improvements	324
Buildings and Improvements	9,862
Total	10,186
Accumulated Depreciation	(4,575)
577 Conroe, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	397
Building and Improvements	7,966
Costs Capitalized Subsequent to Acquisition	2,973
Gross Amount at Which Carried As of Year End	
Land and improvements	397
Buildings and Improvements	10,939
Total	11,336
Accumulated Depreciation	(5,342)
578 Conroe, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	388
Building and Improvements	7,975
Costs Capitalized Subsequent to Acquisition	2,576
Gross Amount at Which Carried As of Year End	
Land and improvements	388
Buildings and Improvements	10,551
Total	10,939
Accumulated Depreciation	(4,616)
579 Conroe, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	188
Building and Improvements	3,618
Costs Capitalized Subsequent to Acquisition	1,226
Gross Amount at Which Carried As of Year End	
Land and improvements	188
Buildings and Improvements	4,844
Total	5,032
Accumulated Depreciation	(2,633)
581 Corpus Christi, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	717
Building and Improvements	8,181
Costs Capitalized Subsequent to Acquisition	4,429
Gross Amount at Which Carried As of Year End	
Land and improvements	717
Buildings and Improvements	12,610
Total	13,327
Accumulated Depreciation	(5,782)
600 Corpus Christi, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	328
Building and Improvements	3,210
Costs Capitalized Subsequent to Acquisition	2,456
Gross Amount at Which Carried As of Year End	
Land and improvements	334
Buildings and Improvements	5,660
Total	5,994
Accumulated Depreciation	(3,040)
601 Corpus Christi, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	313
Building and Improvements	1,771
Costs Capitalized Subsequent to Acquisition	1,458
Gross Amount at Which Carried As of Year End	
Land and improvements	325
Buildings and Improvements	3,217
Total	3,542
Accumulated Depreciation	(1,318)
2839 Cypress, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	37,654
Gross Amount at Which Carried As of Year End	
Land and improvements	11
Buildings and Improvements	37,643
Total	37,654
Accumulated Depreciation	(13,846)
582 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,664
Building and Improvements	6,785
Costs Capitalized Subsequent to Acquisition	3,781
Gross Amount at Which Carried As of Year End	
Land and improvements	1,793
Buildings and Improvements	10,437
Total	12,230
Accumulated Depreciation	(5,178)
1314 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	15,230
Building and Improvements	162,970
Costs Capitalized Subsequent to Acquisition	29,492
Gross Amount at Which Carried As of Year End	
Land and improvements	23,630
Buildings and Improvements	184,062
Total	207,692
Accumulated Depreciation	(94,164)
1315 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	4,485
Gross Amount at Which Carried As of Year End	
Land and improvements	17
Buildings and Improvements	4,468
Total	4,485
Accumulated Depreciation	(1,431)
1316 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	10,361
Gross Amount at Which Carried As of Year End	
Land and improvements	64
Buildings and Improvements	10,297
Total	10,361
Accumulated Depreciation	(3,075)
1317 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	12,298
Gross Amount at Which Carried As of Year End	
Land and improvements	267
Buildings and Improvements	12,031
Total	12,298
Accumulated Depreciation	(3,024)
1319 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	18,840
Building and Improvements	155,659
Costs Capitalized Subsequent to Acquisition	7,310
Gross Amount at Which Carried As of Year End	
Land and improvements	18,840
Buildings and Improvements	162,969
Total	181,809
Accumulated Depreciation	(81,664)
2721 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	31,707
Building and Improvements	2,000
Costs Capitalized Subsequent to Acquisition	698
Gross Amount at Which Carried As of Year End	
Land and improvements	31,707
Buildings and Improvements	2,698
Total	34,405
Accumulated Depreciation	(1,998)
TX0028 Dallas, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	448
Building and Improvements	189,390
Costs Capitalized Subsequent to Acquisition	1,552
Gross Amount at Which Carried As of Year End	
Land and improvements	448
Buildings and Improvements	190,942
Total	191,390
Accumulated Depreciation	(6,257)
3007 Denton, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	5,673
Initial Cost to Company	
Land and improvements	2,298
Building and Improvements	9,502
Costs Capitalized Subsequent to Acquisition	111
Gross Amount at Which Carried As of Year End	
Land and improvements	2,338
Buildings and Improvements	9,573
Total	11,911
Accumulated Depreciation	(1,786)
TX0033 Denton, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,524
Building and Improvements	11,381
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,524
Buildings and Improvements	11,381
Total	12,905
Accumulated Depreciation	(434)
TX0001 El Paso, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	725
Building and Improvements	2,729
Costs Capitalized Subsequent to Acquisition	74
Gross Amount at Which Carried As of Year End	
Land and improvements	725
Buildings and Improvements	2,803
Total	3,528
Accumulated Depreciation	(92)
TX0002 El Paso, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,429

Building and Improvements	5,104
Costs Capitalized Subsequent to Acquisition	377
Gross Amount at Which Carried As of Year End	
Land and improvements	1,429
Buildings and Improvements	5,481
Total	6,910
Accumulated Depreciation	(295)
TX0009 El Paso, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,156
Building and Improvements	10,909
Costs Capitalized Subsequent to Acquisition	262
Gross Amount at Which Carried As of Year End	
Land and improvements	2,156
Buildings and Improvements	11,171
Total	13,327
Accumulated Depreciation	(557)
TX0010 El Paso, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	913
Building and Improvements	2,014
Costs Capitalized Subsequent to Acquisition	89
Gross Amount at Which Carried As of Year End	
Land and improvements	918
Buildings and Improvements	2,098
Total	3,016
Accumulated Depreciation	(150)
TX0022 Flower Mound, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	910
Building and Improvements	3,696
Costs Capitalized Subsequent to Acquisition	95
Gross Amount at Which Carried As of Year End	
Land and improvements	910
Buildings and Improvements	3,791
Total	4,701
Accumulated Depreciation	(158)
TX0024 Flower Mound, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,429
Building and Improvements	12,043
Costs Capitalized Subsequent to Acquisition	362
Gross Amount at Which Carried As of Year End	
Land and improvements	1,512
Buildings and Improvements	12,322
Total	13,834
Accumulated Depreciation	(652)
TX0A22 Flower Mound, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	992
Building and Improvements	2,628
Costs Capitalized Subsequent to Acquisition	195
Gross Amount at Which Carried As of Year End	
Land and improvements	992
Buildings and Improvements	2,823
Total	3,815
Accumulated Depreciation	(116)
583 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	898
Building and Improvements	4,866
Costs Capitalized Subsequent to Acquisition	4,763
Gross Amount at Which Carried As of Year End	
Land and improvements	898
Buildings and Improvements	9,629
Total	10,527
Accumulated Depreciation	(4,661)
805 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	2,481
Costs Capitalized Subsequent to Acquisition	1,416
Gross Amount at Which Carried As of Year End	
Land and improvements	45
Buildings and Improvements	3,852
Total	3,897
Accumulated Depreciation	(2,650)
806 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,070
Costs Capitalized Subsequent to Acquisition	1,775

Gross Amount at Which Carried As of Year End	
Land and improvements	51
Buildings and Improvements	7,794
Total	7,845
Accumulated Depreciation	(3,603)
2619 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,180
Building and Improvements	13,432
Costs Capitalized Subsequent to Acquisition	2,000
Gross Amount at Which Carried As of Year End	
Land and improvements	1,180
Buildings and Improvements	15,432
Total	16,612
Accumulated Depreciation	(2,579)
2620 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,961
Building and Improvements	14,155
Costs Capitalized Subsequent to Acquisition	1,599
Gross Amount at Which Carried As of Year End	
Land and improvements	2,000
Buildings and Improvements	15,715
Total	17,715
Accumulated Depreciation	(2,732)
2982 Fort Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,720
Building and Improvements	6,225
Costs Capitalized Subsequent to Acquisition	6,335
Gross Amount at Which Carried As of Year End	
Land and improvements	2,719
Buildings and Improvements	12,561
Total	15,280
Accumulated Depreciation	(4,259)
3020 Frisco, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	27,201
Costs Capitalized Subsequent to Acquisition	731
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	27,932
Total	27,932
Accumulated Depreciation	(3,041)
3021 Frisco, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	26,181
Costs Capitalized Subsequent to Acquisition	2,272
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	28,453
Total	28,453
Accumulated Depreciation	(3,485)
TX0032 Ft. Worth, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	866
Building and Improvements	24,845
Costs Capitalized Subsequent to Acquisition	63
Gross Amount at Which Carried As of Year End	
Land and improvements	866
Buildings and Improvements	24,908
Total	25,774
Accumulated Depreciation	(951)
1061 Granbury, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	6,863
Costs Capitalized Subsequent to Acquisition	1,326
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	8,189
Total	8,189
Accumulated Depreciation	(3,973)
430 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,927
Building and Improvements	33,140
Costs Capitalized Subsequent to Acquisition	22,722
Gross Amount at Which Carried As of Year End	

Land and improvements	2,388
Buildings and Improvements	55,401
Total	57,789
Accumulated Depreciation	(33,744)
446 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,200
Building and Improvements	19,585
Costs Capitalized Subsequent to Acquisition	11,112
Gross Amount at Which Carried As of Year End	
Land and improvements	2,936
Buildings and Improvements	29,961
Total	32,897
Accumulated Depreciation	(22,553)
589 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,676
Building and Improvements	12,602
Costs Capitalized Subsequent to Acquisition	16,193
Gross Amount at Which Carried As of Year End	
Land and improvements	1,676
Buildings and Improvements	28,795
Total	30,471
Accumulated Depreciation	(8,996)
702 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,414
Costs Capitalized Subsequent to Acquisition	2,716
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	10,130
Total	10,130
Accumulated Depreciation	(5,100)
1044 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,838
Costs Capitalized Subsequent to Acquisition	6,769
Gross Amount at Which Carried As of Year End	
Land and improvements	1,321
Buildings and Improvements	10,286
Total	11,607
Accumulated Depreciation	(4,127)
2542 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	304
Building and Improvements	17,764
Costs Capitalized Subsequent to Acquisition	(304)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,764
Total	17,764
Accumulated Depreciation	(4,822)
2543 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	116
Building and Improvements	6,555
Costs Capitalized Subsequent to Acquisition	(116)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	6,555
Total	6,555
Accumulated Depreciation	(2,076)
2544 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	312
Building and Improvements	12,094
Costs Capitalized Subsequent to Acquisition	(312)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	12,094
Total	12,094
Accumulated Depreciation	(3,830)
2545 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	316
Building and Improvements	13,931
Costs Capitalized Subsequent to Acquisition	(300)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	13,947

Total	13,947
Accumulated Depreciation	(3,309)
2546 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	408
Building and Improvements	18,332
Costs Capitalized Subsequent to Acquisition	1,582
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	20,322
Total	20,322
Accumulated Depreciation	(6,978)
2547 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	470
Building and Improvements	18,197
Costs Capitalized Subsequent to Acquisition	429
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	19,096
Total	19,096
Accumulated Depreciation	(5,762)
2548 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	313
Building and Improvements	7,036
Costs Capitalized Subsequent to Acquisition	(112)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	7,237
Total	7,237
Accumulated Depreciation	(2,674)
2549 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	530
Building and Improvements	22,711
Costs Capitalized Subsequent to Acquisition	148
Gross Amount at Which Carried As of Year End	
Land and improvements	530
Buildings and Improvements	22,859
Total	23,389
Accumulated Depreciation	(5,298)
2966 Houston, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	40,944
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	40,944
Total	40,944
Accumulated Depreciation	(5,145)
590 Irving, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	828
Building and Improvements	6,160
Costs Capitalized Subsequent to Acquisition	5,620
Gross Amount at Which Carried As of Year End	
Land and improvements	828
Buildings and Improvements	11,780
Total	12,608
Accumulated Depreciation	(5,308)
700 Irving, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	8,550
Costs Capitalized Subsequent to Acquisition	2,965
Gross Amount at Which Carried As of Year End	
Land and improvements	8
Buildings and Improvements	11,507
Total	11,515
Accumulated Depreciation	(5,499)
1207 Irving, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,955
Building and Improvements	12,793
Costs Capitalized Subsequent to Acquisition	4,707
Gross Amount at Which Carried As of Year End	
Land and improvements	2,032
Buildings and Improvements	17,423
Total	19,455
Accumulated Depreciation	(7,447)

TX0013 Katy, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,567
Building and Improvements	3,105
Costs Capitalized Subsequent to Acquisition	276
Gross Amount at Which Carried As of Year End	
Land and improvements	2,567
Buildings and Improvements	3,381
Total	5,948
Accumulated Depreciation	(256)

TX0014 Katy, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,153
Building and Improvements	21,169
Costs Capitalized Subsequent to Acquisition	248
Gross Amount at Which Carried As of Year End	
Land and improvements	2,153
Buildings and Improvements	21,417
Total	23,570
Accumulated Depreciation	(1,156)

2840 Kingwood, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,035
Building and Improvements	28,373
Costs Capitalized Subsequent to Acquisition	1,199
Gross Amount at Which Carried As of Year End	
Land and improvements	3,422
Buildings and Improvements	29,185
Total	32,607
Accumulated Depreciation	(6,930)

591 Lewisville, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	561
Building and Improvements	8,043
Costs Capitalized Subsequent to Acquisition	1,447
Gross Amount at Which Carried As of Year End	
Land and improvements	561
Buildings and Improvements	9,490
Total	10,051
Accumulated Depreciation	(4,784)

144 Longview, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	102
Building and Improvements	7,998
Costs Capitalized Subsequent to Acquisition	988
Gross Amount at Which Carried As of Year End	
Land and improvements	102
Buildings and Improvements	8,986
Total	9,088
Accumulated Depreciation	(6,021)

143 Lufkin, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	338
Building and Improvements	2,383
Costs Capitalized Subsequent to Acquisition	219
Gross Amount at Which Carried As of Year End	
Land and improvements	338
Buildings and Improvements	2,602
Total	2,940
Accumulated Depreciation	(1,722)

TX0019 Lufkin, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	80
Building and Improvements	6,314
Costs Capitalized Subsequent to Acquisition	237
Gross Amount at Which Carried As of Year End	
Land and improvements	80
Buildings and Improvements	6,551
Total	6,631
Accumulated Depreciation	(318)

TX0020 Lufkin, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	100
Building and Improvements	7,954
Costs Capitalized Subsequent to Acquisition	560
Gross Amount at Which Carried As of Year End	
Land and improvements	100
Buildings and Improvements	8,514
Total	8,614
Accumulated Depreciation	(366)

TX0021 Lufkin, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	155
Building and Improvements	2,668
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	155
Buildings and Improvements	2,668
Total	2,823
Accumulated Depreciation	(172)
TX0008 Mansfield, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,435
Building and Improvements	3,375
Costs Capitalized Subsequent to Acquisition	111
Gross Amount at Which Carried As of Year End	
Land and improvements	4,435
Buildings and Improvements	3,486
Total	7,921
Accumulated Depreciation	(229)
568 McKinney, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	541
Building and Improvements	6,217
Costs Capitalized Subsequent to Acquisition	3,292
Gross Amount at Which Carried As of Year End	
Land and improvements	541
Buildings and Improvements	9,509
Total	10,050
Accumulated Depreciation	(5,404)
569 McKinney, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	636
Costs Capitalized Subsequent to Acquisition	8,330
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	8,966
Total	8,966
Accumulated Depreciation	(4,914)
3216 McKinney, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	23,325
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	23,325
Total	23,325
Accumulated Depreciation	0
TX0029 Midland, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,933
Building and Improvements	12,903
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,933
Buildings and Improvements	12,903
Total	15,836
Accumulated Depreciation	(663)
596 N Richland Hills, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	812
Building and Improvements	8,883
Costs Capitalized Subsequent to Acquisition	4,631
Gross Amount at Which Carried As of Year End	
Land and improvements	812
Buildings and Improvements	13,514
Total	14,326
Accumulated Depreciation	(6,093)
TX0030 Pasadena, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,520
Building and Improvements	8,648
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	1,520
Buildings and Improvements	8,648
Total	10,168
Accumulated Depreciation	(388)
2835 Pearland, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,014
Costs Capitalized Subsequent to Acquisition	5,853
Gross Amount at Which Carried As of Year End	
Land and improvements	41
Buildings and Improvements	9,826
Total	9,867
Accumulated Depreciation	(3,409)
2838 Pearland, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	18,054
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	18,054
Total	18,054
Accumulated Depreciation	(5,867)
597 Plano, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,210
Building and Improvements	9,588
Costs Capitalized Subsequent to Acquisition	7,510
Gross Amount at Which Carried As of Year End	
Land and improvements	1,225
Buildings and Improvements	17,083
Total	18,308
Accumulated Depreciation	(7,807)
672 Plano, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,389
Building and Improvements	12,768
Costs Capitalized Subsequent to Acquisition	4,751
Gross Amount at Which Carried As of Year End	
Land and improvements	1,389
Buildings and Improvements	17,519
Total	18,908
Accumulated Depreciation	(7,944)
1384 Plano, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,290
Building and Improvements	22,686
Costs Capitalized Subsequent to Acquisition	8,430
Gross Amount at Which Carried As of Year End	
Land and improvements	6,290
Buildings and Improvements	31,116
Total	37,406
Accumulated Depreciation	(26,707)
2653 Rockwall, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	788
Building and Improvements	9,020
Costs Capitalized Subsequent to Acquisition	(369)
Gross Amount at Which Carried As of Year End	
Land and improvements	536
Buildings and Improvements	8,903
Total	9,439
Accumulated Depreciation	(1,761)
TX0031 Rockwall, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	606
Building and Improvements	15,815
Costs Capitalized Subsequent to Acquisition	375
Gross Amount at Which Carried As of Year End	
Land and improvements	606
Buildings and Improvements	16,190
Total	16,796
Accumulated Depreciation	(714)
815 San Antonio, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,193
Costs Capitalized Subsequent to Acquisition	3,637
Gross Amount at Which Carried As of Year End	
Land and improvements	75
Buildings and Improvements	12,755
Total	12,830
Accumulated Depreciation	(6,170)
816 San Antonio, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	1,180
Initial Cost to Company	

Land and improvements	0
Building and Improvements	8,699
Costs Capitalized Subsequent to Acquisition	13,052
Gross Amount at Which Carried As of Year End	
Land and improvements	26
Buildings and Improvements	21,725
Total	21,751
Accumulated Depreciation	(7,068)
2837 San Antonio, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	26,191
Costs Capitalized Subsequent to Acquisition	4,413
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	30,604
Total	30,604
Accumulated Depreciation	(13,873)
TX0005 San Antonio, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,100
Building and Improvements	20,829
Costs Capitalized Subsequent to Acquisition	101
Gross Amount at Which Carried As of Year End	
Land and improvements	4,100
Buildings and Improvements	20,930
Total	25,030
Accumulated Depreciation	(968)
TX0006 San Antonio, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	687
Building and Improvements	2,796
Costs Capitalized Subsequent to Acquisition	42
Gross Amount at Which Carried As of Year End	
Land and improvements	687
Buildings and Improvements	2,838
Total	3,525
Accumulated Depreciation	(196)
2852 Shenandoah, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	29,980
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	29,980
Total	29,980
Accumulated Depreciation	(9,663)
TX0017 Spring, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	892
Building and Improvements	25,022
Costs Capitalized Subsequent to Acquisition	(3)
Gross Amount at Which Carried As of Year End	
Land and improvements	892
Buildings and Improvements	25,019
Total	25,911
Accumulated Depreciation	(909)
598 Sugar Land, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,078
Building and Improvements	5,158
Costs Capitalized Subsequent to Acquisition	4,447
Gross Amount at Which Carried As of Year End	
Land and improvements	1,112
Buildings and Improvements	9,571
Total	10,683
Accumulated Depreciation	(3,860)
599 Texas City, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	9,519
Costs Capitalized Subsequent to Acquisition	2,067
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,586
Total	11,586
Accumulated Depreciation	(5,526)
2550 The Woodlands, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	115

Building and Improvements	5,141
Costs Capitalized Subsequent to Acquisition	(115)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,141
Total	5,141
Accumulated Depreciation	(1,395)
2551 The Woodlands, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	296
Building and Improvements	18,282
Costs Capitalized Subsequent to Acquisition	(296)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	18,282
Total	18,282
Accumulated Depreciation	(4,342)
2552 The Woodlands, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	374
Building and Improvements	25,125
Costs Capitalized Subsequent to Acquisition	(374)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	25,125
Total	25,125
Accumulated Depreciation	(5,304)
TX0018 The Woodlands, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	715
Building and Improvements	13,972
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	715
Buildings and Improvements	13,972
Total	14,687
Accumulated Depreciation	(724)
152 Victoria, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	125
Building and Improvements	8,977
Costs Capitalized Subsequent to Acquisition	535
Gross Amount at Which Carried As of Year End	
Land and improvements	125
Buildings and Improvements	9,512
Total	9,637
Accumulated Depreciation	(6,120)
2198 Webster, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,220
Building and Improvements	9,602
Costs Capitalized Subsequent to Acquisition	142
Gross Amount at Which Carried As of Year End	
Land and improvements	2,220
Buildings and Improvements	9,744
Total	11,964
Accumulated Depreciation	(4,325)
3024 Webster, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,196
Building and Improvements	12,911
Costs Capitalized Subsequent to Acquisition	325
Gross Amount at Which Carried As of Year End	
Land and improvements	3,212
Buildings and Improvements	13,220
Total	16,432
Accumulated Depreciation	(1,393)
3025 Webster, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,209
Building and Improvements	23,782
Costs Capitalized Subsequent to Acquisition	141
Gross Amount at Which Carried As of Year End	
Land and improvements	3,225
Buildings and Improvements	23,907
Total	27,132
Accumulated Depreciation	(2,487)
TX3249 Webster, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,265
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	0

Gross Amount at Which Carried As of Year End	
Land and improvements	2,265
Buildings and Improvements	0
Total	2,265
Accumulated Depreciation	0
3215 Wylie, TX Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	874
Building and Improvements	4,122
Costs Capitalized Subsequent to Acquisition	11
Gross Amount at Which Carried As of Year End	
Land and improvements	874
Buildings and Improvements	4,133
Total	5,007
Accumulated Depreciation	(421)
1592 Bountiful, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	999
Building and Improvements	7,426
Costs Capitalized Subsequent to Acquisition	2,807
Gross Amount at Which Carried As of Year End	
Land and improvements	1,019
Buildings and Improvements	10,213
Total	11,232
Accumulated Depreciation	(4,260)
169 Bountiful, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	276
Building and Improvements	5,237
Costs Capitalized Subsequent to Acquisition	5,377
Gross Amount at Which Carried As of Year End	
Land and improvements	599
Buildings and Improvements	10,291
Total	10,890
Accumulated Depreciation	(4,934)
2035 Draper, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	3,748
Initial Cost to Company	
Land and improvements	0
Building and Improvements	10,803
Costs Capitalized Subsequent to Acquisition	867
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,670
Total	11,670
Accumulated Depreciation	(3,194)
469 Kaysville, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	530
Building and Improvements	4,493
Costs Capitalized Subsequent to Acquisition	550
Gross Amount at Which Carried As of Year End	
Land and improvements	530
Buildings and Improvements	5,043
Total	5,573
Accumulated Depreciation	(2,373)
456 Layton, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	371
Building and Improvements	7,073
Costs Capitalized Subsequent to Acquisition	2,910
Gross Amount at Which Carried As of Year End	
Land and improvements	401
Buildings and Improvements	9,953
Total	10,354
Accumulated Depreciation	(5,596)
2042 Layton, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	10,975
Costs Capitalized Subsequent to Acquisition	1,794
Gross Amount at Which Carried As of Year End	
Land and improvements	44
Buildings and Improvements	12,725
Total	12,769
Accumulated Depreciation	(3,561)
357 Orem, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	337
Building and Improvements	8,744
Costs Capitalized Subsequent to Acquisition	1,042
Gross Amount at Which Carried As of Year End	
Land and improvements	306

Buildings and Improvements	9,817
Total	10,123
Accumulated Depreciation	(6,590)
353 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	190
Building and Improvements	779
Costs Capitalized Subsequent to Acquisition	280
Gross Amount at Which Carried As of Year End	
Land and improvements	273
Buildings and Improvements	976
Total	1,249
Accumulated Depreciation	(692)
354 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	220
Building and Improvements	10,732
Costs Capitalized Subsequent to Acquisition	4,567
Gross Amount at Which Carried As of Year End	
Land and improvements	309
Buildings and Improvements	15,210
Total	15,519
Accumulated Depreciation	(9,481)
355 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	180
Building and Improvements	14,792
Costs Capitalized Subsequent to Acquisition	5,604
Gross Amount at Which Carried As of Year End	
Land and improvements	180
Buildings and Improvements	20,396
Total	20,576
Accumulated Depreciation	(12,561)
467 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,000
Building and Improvements	7,541
Costs Capitalized Subsequent to Acquisition	2,158
Gross Amount at Which Carried As of Year End	
Land and improvements	3,019
Buildings and Improvements	9,680
Total	12,699
Accumulated Depreciation	(5,395)
566 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	509
Building and Improvements	4,044
Costs Capitalized Subsequent to Acquisition	3,828
Gross Amount at Which Carried As of Year End	
Land and improvements	509
Buildings and Improvements	7,872
Total	8,381
Accumulated Depreciation	(4,071)
2041 Salt Lake City, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,326
Costs Capitalized Subsequent to Acquisition	1,009
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	13,335
Total	13,335
Accumulated Depreciation	(3,813)
2033 Sandy, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	867
Building and Improvements	3,513
Costs Capitalized Subsequent to Acquisition	2,920
Gross Amount at Which Carried As of Year End	
Land and improvements	1,356
Buildings and Improvements	5,944
Total	7,300
Accumulated Depreciation	(3,667)
2864 Washington Terrace, UT Outpatient medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	20,163
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	20,163
Total	20,163

Accumulated Depreciation	(4,116)
351 Washington Terrace, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,573
Costs Capitalized Subsequent to Acquisition	3,091
Gross Amount at Which Carried As of Year End	
Land and improvements	17
Buildings and Improvements	7,647
Total	7,664
Accumulated Depreciation	(3,863)
352 Washington Terrace, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	2,692
Costs Capitalized Subsequent to Acquisition	1,581
Gross Amount at Which Carried As of Year End	
Land and improvements	15
Buildings and Improvements	4,258
Total	4,273
Accumulated Depreciation	(2,042)
2034 West Jordan, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	12,021
Costs Capitalized Subsequent to Acquisition	(177)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,844
Total	11,844
Accumulated Depreciation	(3,282)
2036 West Jordan, UT Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	1,383
Costs Capitalized Subsequent to Acquisition	1,378
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	2,761
Total	2,761
Accumulated Depreciation	(1,677)
1208 Fairfax, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,396
Building and Improvements	16,710
Costs Capitalized Subsequent to Acquisition	11,995
Gross Amount at Which Carried As of Year End	
Land and improvements	8,742
Buildings and Improvements	28,359
Total	37,101
Accumulated Depreciation	(16,235)
2230 Fredericksburg, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,101
Building and Improvements	8,570
Costs Capitalized Subsequent to Acquisition	156
Gross Amount at Which Carried As of Year End	
Land and improvements	1,113
Buildings and Improvements	8,714
Total	9,827
Accumulated Depreciation	(2,554)
VA0001 Fredericksburg, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,674
Building and Improvements	14,182
Costs Capitalized Subsequent to Acquisition	2,448
Gross Amount at Which Carried As of Year End	
Land and improvements	3,043
Buildings and Improvements	16,261
Total	19,304
Accumulated Depreciation	(780)
VA0002 Hampton, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,865
Building and Improvements	11,976
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	4,865
Buildings and Improvements	11,976
Total	16,841
Accumulated Depreciation	(713)
3001 Leesburg, VA Outpatient Medical Operating segment	

Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	10,252
Initial Cost to Company	
Land and improvements	3,549
Building and Improvements	24,059
Costs Capitalized Subsequent to Acquisition	5,717
Gross Amount at Which Carried As of Year End	
Land and improvements	3,549
Buildings and Improvements	29,776
Total	33,325
Accumulated Depreciation	(5,670)
3015 Midlothian, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	12,734
Initial Cost to Company	
Land and improvements	0
Building and Improvements	21,442
Costs Capitalized Subsequent to Acquisition	22
Gross Amount at Which Carried As of Year End	
Land and improvements	59
Buildings and Improvements	21,405
Total	21,464
Accumulated Depreciation	(2,288)
3016 Midlothian, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	12,038
Initial Cost to Company	
Land and improvements	0
Building and Improvements	20,610
Costs Capitalized Subsequent to Acquisition	(147)
Gross Amount at Which Carried As of Year End	
Land and improvements	32
Buildings and Improvements	20,431
Total	20,463
Accumulated Depreciation	(2,156)
3017 Midlothian, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	13,928
Initial Cost to Company	
Land and improvements	0
Building and Improvements	22,531
Costs Capitalized Subsequent to Acquisition	(1,031)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	21,500
Total	21,500
Accumulated Depreciation	(2,539)
572 Reston, VA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	11,902
Costs Capitalized Subsequent to Acquisition	(860)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	11,042
Total	11,042
Accumulated Depreciation	(5,902)
WA0009 Federal Way, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	397
Building and Improvements	6,502
Costs Capitalized Subsequent to Acquisition	368
Gross Amount at Which Carried As of Year End	
Land and improvements	397
Buildings and Improvements	6,870
Total	7,267
Accumulated Depreciation	(357)
WA0006 Gig Harbor, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	87
Building and Improvements	1,938
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	87
Buildings and Improvements	1,938
Total	2,025
Accumulated Depreciation	(116)
WA0002 Kennewick, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,611
Building and Improvements	25,463
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	3,611
Buildings and Improvements	25,463
Total	29,074
Accumulated Depreciation	(1,458)
WA0001 Lakewood, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

Initial Cost to Company	
Land and improvements	3,967
Building and Improvements	5,588
Costs Capitalized Subsequent to Acquisition	21
Gross Amount at Which Carried As of Year End	
Land and improvements	3,967
Buildings and Improvements	5,609
Total	9,576
Accumulated Depreciation	(361)
WA0010 Lakewood, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	400
Building and Improvements	3,665
Costs Capitalized Subsequent to Acquisition	90
Gross Amount at Which Carried As of Year End	
Land and improvements	400
Buildings and Improvements	3,755
Total	4,155
Accumulated Depreciation	(286)
448 Renton, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	18,724
Costs Capitalized Subsequent to Acquisition	4,630
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	23,354
Total	23,354
Accumulated Depreciation	(14,684)
781 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	52,703
Costs Capitalized Subsequent to Acquisition	10,268
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	62,971
Total	62,971
Accumulated Depreciation	(30,822)
782 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	24,382
Costs Capitalized Subsequent to Acquisition	22,359
Gross Amount at Which Carried As of Year End	
Land and improvements	125
Buildings and Improvements	46,616
Total	46,741
Accumulated Depreciation	(18,601)
783 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	5,625
Costs Capitalized Subsequent to Acquisition	2,164
Gross Amount at Which Carried As of Year End	
Land and improvements	69
Buildings and Improvements	7,720
Total	7,789
Accumulated Depreciation	(6,215)
785 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	7,293
Costs Capitalized Subsequent to Acquisition	933
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	8,226
Total	8,226
Accumulated Depreciation	(5,253)
1385 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	45,027
Costs Capitalized Subsequent to Acquisition	18,577
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	63,604
Total	63,604
Accumulated Depreciation	(29,496)
3022 Seattle, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	35,624

Building and Improvements	4,176
Costs Capitalized Subsequent to Acquisition	1
Gross Amount at Which Carried As of Year End	
Land and improvements	35,625
Buildings and Improvements	4,176
Total	39,801
Accumulated Depreciation	(2,741)
WI0003 Tacoma, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	269
Building and Improvements	1,900
Costs Capitalized Subsequent to Acquisition	383
Gross Amount at Which Carried As of Year End	
Land and improvements	269
Buildings and Improvements	2,283
Total	2,552
Accumulated Depreciation	(206)
WI0004 Tacoma, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	479
Building and Improvements	6,955
Costs Capitalized Subsequent to Acquisition	237
Gross Amount at Which Carried As of Year End	
Land and improvements	479
Buildings and Improvements	7,192
Total	7,671
Accumulated Depreciation	(462)
WI0005 Tacoma, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	440
Building and Improvements	6,778
Costs Capitalized Subsequent to Acquisition	329
Gross Amount at Which Carried As of Year End	
Land and improvements	440
Buildings and Improvements	7,107
Total	7,547
Accumulated Depreciation	(381)
WI0007 Tacoma, WA Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	186
Building and Improvements	15,111
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	186
Buildings and Improvements	15,111
Total	15,297
Accumulated Depreciation	(747)
WI0006 Appleton, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,892
Building and Improvements	13,896
Costs Capitalized Subsequent to Acquisition	80
Gross Amount at Which Carried As of Year End	
Land and improvements	1,892
Buildings and Improvements	13,976
Total	15,868
Accumulated Depreciation	(587)
WI0007 Appleton, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,477
Building and Improvements	15,188
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	2,477
Buildings and Improvements	15,188
Total	17,665
Accumulated Depreciation	(862)
WI0005 Brookfield, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,183
Building and Improvements	3,391
Costs Capitalized Subsequent to Acquisition	46
Gross Amount at Which Carried As of Year End	
Land and improvements	1,183
Buildings and Improvements	3,437
Total	4,620
Accumulated Depreciation	(151)
WI0004 Milwaukee, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,052
Building and Improvements	13,111

Costs Capitalized Subsequent to Acquisition	612
Gross Amount at Which Carried As of Year End	
Land and improvements	3,052
Buildings and Improvements	13,723
Total	16,775
Accumulated Depreciation	(541)
WI0002 Shawano, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	347
Building and Improvements	1,571
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	347
Buildings and Improvements	1,571
Total	1,918
Accumulated Depreciation	(96)
WI0001 West Allis, WI Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	980
Building and Improvements	388
Costs Capitalized Subsequent to Acquisition	9
Gross Amount at Which Carried As of Year End	
Land and improvements	980
Buildings and Improvements	397
Total	1,377
Accumulated Depreciation	(63)
2038 Evanston, WY Outpatient Medical Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	4,601
Costs Capitalized Subsequent to Acquisition	1,204
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	5,805
Total	5,805
Accumulated Depreciation	\$ (2,202)

XML 173 R154.htm
IDEA: XBRL DOCUMENT

Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Lab) (Details)	Dec. 31, 2024
\$ in Thousands	USD (\$)
Held-for-sale	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	\$ 0
Initial Cost to Company	
Land and improvements	4,141
Building and Improvements	20,364
Costs Capitalized Subsequent to Acquisition	(13,844)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,141
Buildings and Improvements	6,520
Total	10,661
Accumulated Depreciation	(2,821)
Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	356,750
Initial Cost to Company	
Land and improvements	2,887,257
Building and Improvements	11,334,757
Costs Capitalized Subsequent to Acquisition	5,692,420
Gross Amount at Which Carried As of Year End	
Land and improvements	2,918,758
Buildings and Improvements	16,995,676
Total	19,914,434
Accumulated Depreciation	(4,083,030)
Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,874,225
Building and Improvements	3,195,605
Costs Capitalized Subsequent to Acquisition	3,742,955
Gross Amount at Which Carried As of Year End	
Land and improvements	1,877,701
Buildings and Improvements	6,935,084
Total	8,812,785
Accumulated Depreciation	(1,644,660)
1483 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,498
Building and Improvements	500
Costs Capitalized Subsequent to Acquisition	83,876
Gross Amount at Which Carried As of Year End	
Land and improvements	8,498
Buildings and Improvements	84,376
Total	92,874

Accumulated Depreciation	(9,494)
1484 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,331
Building and Improvements	689
Costs Capitalized Subsequent to Acquisition	159,655
Gross Amount at Which Carried As of Year End	
Land and improvements	11,331
Buildings and Improvements	160,344
Total	171,675
Accumulated Depreciation	(15,892)
1485 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,331
Building and Improvements	600
Costs Capitalized Subsequent to Acquisition	154,111
Gross Amount at Which Carried As of Year End	
Land and improvements	11,331
Buildings and Improvements	154,711
Total	166,042
Accumulated Depreciation	(17,187)
1486 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,331
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	135,416
Gross Amount at Which Carried As of Year End	
Land and improvements	11,331
Buildings and Improvements	135,416
Total	146,747
Accumulated Depreciation	(28,636)
1487 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,498
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	76,411
Gross Amount at Which Carried As of Year End	
Land and improvements	8,498
Buildings and Improvements	76,411
Total	84,909
Accumulated Depreciation	(9,682)
2874 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	26,895
Building and Improvements	62,318
Costs Capitalized Subsequent to Acquisition	76,313
Gross Amount at Which Carried As of Year End	
Land and improvements	26,295
Buildings and Improvements	139,231
Total	165,526
Accumulated Depreciation	(16,804)
2875 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	24,092
Building and Improvements	56,623
Costs Capitalized Subsequent to Acquisition	11,039
Gross Amount at Which Carried As of Year End	
Land and improvements	24,092
Buildings and Improvements	67,662
Total	91,754
Accumulated Depreciation	(10,300)
3139 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	35,805
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	7,726
Gross Amount at Which Carried As of Year End	
Land and improvements	35,805
Buildings and Improvements	7,726
Total	43,531
Accumulated Depreciation	0
3140 Brisbane, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	35,805
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	4,312
Gross Amount at Which Carried As of Year End	
Land and improvements	35,805
Buildings and Improvements	4,312
Total	40,117
Accumulated Depreciation	0

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	3,768
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	3,768
Total	3,768
Accumulated Depreciation	(471)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	900
Building and Improvements	7,100
Costs Capitalized Subsequent to Acquisition	12,656
Gross Amount at Which Carried As of Year End	
Land and improvements	1,338
Buildings and Improvements	19,318
Total	20,656
Accumulated Depreciation	(7,075)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,500
Building and Improvements	6,400
Costs Capitalized Subsequent to Acquisition	6,837
Gross Amount at Which Carried As of Year End	
Land and improvements	1,500
Buildings and Improvements	13,237
Total	14,737
Accumulated Depreciation	(3,865)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,900
Building and Improvements	7,100
Costs Capitalized Subsequent to Acquisition	7,873
Gross Amount at Which Carried As of Year End	
Land and improvements	1,900
Buildings and Improvements	14,973
Total	16,873
Accumulated Depreciation	(6,858)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,200
Building and Improvements	17,200
Costs Capitalized Subsequent to Acquisition	9,007
Gross Amount at Which Carried As of Year End	
Land and improvements	2,200
Buildings and Improvements	26,207
Total	28,407
Accumulated Depreciation	(11,504)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,000
Building and Improvements	3,200
Costs Capitalized Subsequent to Acquisition	646
Gross Amount at Which Carried As of Year End	
Land and improvements	1,000
Buildings and Improvements	3,846
Total	4,846
Accumulated Depreciation	(1,805)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,006
Building and Improvements	4,259
Costs Capitalized Subsequent to Acquisition	4,080
Gross Amount at Which Carried As of Year End	
Land and improvements	1,006
Buildings and Improvements	8,339
Total	9,345
Accumulated Depreciation	(4,984)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	677
Building and Improvements	2,761
Costs Capitalized Subsequent to Acquisition	774
Gross Amount at Which Carried As of Year End	
Land and improvements	677
Buildings and Improvements	3,535
Total	4,212
Accumulated Depreciation	(2,174)

Real Estate and Accumulated Depreciation

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	661
Building and Improvements	1,995
Costs Capitalized Subsequent to Acquisition	2,900
Gross Amount at Which Carried As of Year End	
Land and improvements	661
Buildings and Improvements	4,895
Total	5,556
Accumulated Depreciation	(2,111)
1552 Hayward, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,187
Building and Improvements	7,139
Costs Capitalized Subsequent to Acquisition	1,725
Gross Amount at Which Carried As of Year End	
Land and improvements	1,187
Buildings and Improvements	8,864
Total	10,051
Accumulated Depreciation	(6,135)
1553 Hayward, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,189
Building and Improvements	9,465
Costs Capitalized Subsequent to Acquisition	1,045
Gross Amount at Which Carried As of Year End	
Land and improvements	1,189
Buildings and Improvements	10,510
Total	11,699
Accumulated Depreciation	(7,258)
1554 Hayward, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,246
Building and Improvements	5,179
Costs Capitalized Subsequent to Acquisition	11,972
Gross Amount at Which Carried As of Year End	
Land and improvements	1,246
Buildings and Improvements	17,151
Total	18,397
Accumulated Depreciation	(7,808)
1555 Hayward, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,521
Building and Improvements	13,546
Costs Capitalized Subsequent to Acquisition	7,516
Gross Amount at Which Carried As of Year End	
Land and improvements	1,521
Buildings and Improvements	21,062
Total	22,583
Accumulated Depreciation	(15,597)
1556 Hayward, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,212
Building and Improvements	5,120
Costs Capitalized Subsequent to Acquisition	1,516
Gross Amount at Which Carried As of Year End	
Land and improvements	1,212
Buildings and Improvements	6,636
Total	7,848
Accumulated Depreciation	(4,134)
1424 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,175
Building and Improvements	25,283
Costs Capitalized Subsequent to Acquisition	44,524
Gross Amount at Which Carried As of Year End	
Land and improvements	11,389
Buildings and Improvements	69,593
Total	80,982
Accumulated Depreciation	(20,050)
1425 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,217
Building and Improvements	19,883
Costs Capitalized Subsequent to Acquisition	61
Gross Amount at Which Carried As of Year End	
Land and improvements	7,217
Buildings and Improvements	19,944
Total	27,161
Accumulated Depreciation	(8,695)
1426 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	

Land and improvements	8,381
Building and Improvements	12,412
Costs Capitalized Subsequent to Acquisition	20,834
Gross Amount at Which Carried As of Year End	
Land and improvements	8,381
Buildings and Improvements	33,246
Total	41,627
Accumulated Depreciation	(17,322)
1427 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,127
Building and Improvements	16,983
Costs Capitalized Subsequent to Acquisition	13,272
Gross Amount at Which Carried As of Year End	
Land and improvements	10,355
Buildings and Improvements	30,027
Total	40,382
Accumulated Depreciation	(11,912)
1949 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,686
Building and Improvements	11,045
Costs Capitalized Subsequent to Acquisition	17,501
Gross Amount at Which Carried As of Year End	
Land and improvements	2,686
Buildings and Improvements	28,546
Total	31,232
Accumulated Depreciation	(9,932)
2229 La Jolla, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,753
Building and Improvements	32,528
Costs Capitalized Subsequent to Acquisition	16,664
Gross Amount at Which Carried As of Year End	
Land and improvements	8,777
Buildings and Improvements	49,168
Total	57,945
Accumulated Depreciation	(15,310)
1499 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,400
Building and Improvements	5,500
Costs Capitalized Subsequent to Acquisition	2,652
Gross Amount at Which Carried As of Year End	
Land and improvements	3,455
Buildings and Improvements	8,097
Total	11,552
Accumulated Depreciation	(3,743)
1500 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,500
Building and Improvements	4,100
Costs Capitalized Subsequent to Acquisition	1,038
Gross Amount at Which Carried As of Year End	
Land and improvements	2,500
Buildings and Improvements	5,138
Total	7,638
Accumulated Depreciation	(2,678)
1501 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,600
Building and Improvements	4,600
Costs Capitalized Subsequent to Acquisition	1,895
Gross Amount at Which Carried As of Year End	
Land and improvements	3,600
Buildings and Improvements	6,495
Total	10,095
Accumulated Depreciation	(3,705)
1502 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,100
Building and Improvements	5,100
Costs Capitalized Subsequent to Acquisition	3,542
Gross Amount at Which Carried As of Year End	
Land and improvements	3,100
Buildings and Improvements	8,642
Total	11,742
Accumulated Depreciation	(3,548)
1503 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,800
Building and Improvements	17,300

Costs Capitalized Subsequent to Acquisition	8,351
Gross Amount at Which Carried As of Year End	
Land and improvements	4,800
Buildings and Improvements	25,651
Total	30,451
Accumulated Depreciation	(10,467)
1504 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,400
Building and Improvements	15,500
Costs Capitalized Subsequent to Acquisition	11,098
Gross Amount at Which Carried As of Year End	
Land and improvements	5,400
Buildings and Improvements	26,598
Total	31,998
Accumulated Depreciation	(12,781)
1505 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,000
Building and Improvements	3,500
Costs Capitalized Subsequent to Acquisition	6,366
Gross Amount at Which Carried As of Year End	
Land and improvements	3,000
Buildings and Improvements	9,866
Total	12,866
Accumulated Depreciation	(4,028)
1506 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,000
Building and Improvements	14,300
Costs Capitalized Subsequent to Acquisition	14,300
Gross Amount at Which Carried As of Year End	
Land and improvements	6,000
Buildings and Improvements	28,600
Total	34,600
Accumulated Depreciation	(17,972)
1507 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,900
Building and Improvements	12,800
Costs Capitalized Subsequent to Acquisition	11,655
Gross Amount at Which Carried As of Year End	
Land and improvements	1,900
Buildings and Improvements	24,455
Total	26,355
Accumulated Depreciation	(8,804)
1508 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,700
Building and Improvements	11,300
Costs Capitalized Subsequent to Acquisition	17,193
Gross Amount at Which Carried As of Year End	
Land and improvements	2,700
Buildings and Improvements	28,493
Total	31,193
Accumulated Depreciation	(11,068)
1509 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,700
Building and Improvements	10,900
Costs Capitalized Subsequent to Acquisition	1,565
Gross Amount at Which Carried As of Year End	
Land and improvements	2,700
Buildings and Improvements	12,465
Total	15,165
Accumulated Depreciation	(5,360)
1510 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,200
Building and Improvements	12,000
Costs Capitalized Subsequent to Acquisition	6,243
Gross Amount at Which Carried As of Year End	
Land and improvements	2,200
Buildings and Improvements	18,243
Total	20,443
Accumulated Depreciation	(8,259)
1511 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,600
Building and Improvements	9,300
Costs Capitalized Subsequent to Acquisition	17,497
Gross Amount at Which Carried As of Year End	

Land and improvements	2,600
Buildings and Improvements	26,797
Total	29,397
Accumulated Depreciation	(14,437)
1512 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,300
Building and Improvements	18,000
Costs Capitalized Subsequent to Acquisition	19,072
Gross Amount at Which Carried As of Year End	
Land and improvements	3,300
Buildings and Improvements	37,072
Total	40,372
Accumulated Depreciation	(21,007)
1513 Redwood City, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,300
Building and Improvements	17,900
Costs Capitalized Subsequent to Acquisition	18,365
Gross Amount at Which Carried As of Year End	
Land and improvements	3,326
Buildings and Improvements	36,239
Total	39,565
Accumulated Depreciation	(18,383)
678 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,603
Building and Improvements	11,051
Costs Capitalized Subsequent to Acquisition	3,587
Gross Amount at Which Carried As of Year End	
Land and improvements	2,766
Buildings and Improvements	14,475
Total	17,241
Accumulated Depreciation	(7,299)
679 San Diego CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,269
Building and Improvements	23,566
Costs Capitalized Subsequent to Acquisition	23,990
Gross Amount at Which Carried As of Year End	
Land and improvements	5,669
Buildings and Improvements	47,156
Total	52,825
Accumulated Depreciation	(20,424)
837 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,630
Building and Improvements	2,028
Costs Capitalized Subsequent to Acquisition	3,302
Gross Amount at Which Carried As of Year End	
Land and improvements	4,630
Buildings and Improvements	5,330
Total	9,960
Accumulated Depreciation	(2,648)
838 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,040
Building and Improvements	903
Costs Capitalized Subsequent to Acquisition	3,354
Gross Amount at Which Carried As of Year End	
Land and improvements	2,040
Buildings and Improvements	4,257
Total	6,297
Accumulated Depreciation	(1,439)
839 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,940
Building and Improvements	3,184
Costs Capitalized Subsequent to Acquisition	2,995
Gross Amount at Which Carried As of Year End	
Land and improvements	4,036
Buildings and Improvements	6,083
Total	10,119
Accumulated Depreciation	(2,847)
840 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,690
Building and Improvements	4,579
Costs Capitalized Subsequent to Acquisition	1,486
Gross Amount at Which Carried As of Year End	
Land and improvements	5,830

Buildings and Improvements	5,925
Total	11,755
Accumulated Depreciation	(2,789)
1418 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,700
Building and Improvements	31,243
Costs Capitalized Subsequent to Acquisition	59,338
Gross Amount at Which Carried As of Year End	
Land and improvements	11,700
Buildings and Improvements	90,581
Total	102,281
Accumulated Depreciation	(21,029)
1419 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,324
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	33,175
Gross Amount at Which Carried As of Year End	
Land and improvements	2,324
Buildings and Improvements	33,175
Total	35,499
Accumulated Depreciation	(4,422)
1420 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,200
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	41,225
Gross Amount at Which Carried As of Year End	
Land and improvements	4,200
Buildings and Improvements	41,225
Total	45,425
Accumulated Depreciation	(3,755)
1421 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,000
Building and Improvements	33,779
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	7,000
Buildings and Improvements	33,779
Total	40,779
Accumulated Depreciation	(14,708)
1422 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,179
Building and Improvements	3,687
Costs Capitalized Subsequent to Acquisition	2,081
Gross Amount at Which Carried As of Year End	
Land and improvements	7,179
Buildings and Improvements	5,768
Total	12,947
Accumulated Depreciation	(3,687)
1423 San Diego CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,400
Building and Improvements	33,144
Costs Capitalized Subsequent to Acquisition	34,028
Gross Amount at Which Carried As of Year End	
Land and improvements	8,400
Buildings and Improvements	67,172
Total	75,572
Accumulated Depreciation	(24,422)
1947 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,581
Building and Improvements	10,534
Costs Capitalized Subsequent to Acquisition	4,497
Gross Amount at Which Carried As of Year End	
Land and improvements	2,581
Buildings and Improvements	15,031
Total	17,612
Accumulated Depreciation	(8,664)
1948 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,879
Building and Improvements	25,305
Costs Capitalized Subsequent to Acquisition	8,311
Gross Amount at Which Carried As of Year End	
Land and improvements	5,879
Buildings and Improvements	33,616
Total	39,495

Accumulated Depreciation	(14,802)
2197 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,621
Building and Improvements	3,913
Costs Capitalized Subsequent to Acquisition	7,590
Gross Amount at Which Carried As of Year End	
Land and improvements	7,621
Buildings and Improvements	11,503
Total	19,124
Accumulated Depreciation	(7,733)
2476 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,661
Building and Improvements	9,918
Costs Capitalized Subsequent to Acquisition	18,298
Gross Amount at Which Carried As of Year End	
Land and improvements	7,661
Buildings and Improvements	28,216
Total	35,877
Accumulated Depreciation	(4,442)
2477 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	9,207
Building and Improvements	14,613
Costs Capitalized Subsequent to Acquisition	8,481
Gross Amount at Which Carried As of Year End	
Land and improvements	9,207
Buildings and Improvements	23,094
Total	32,301
Accumulated Depreciation	(6,775)
2478 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,000
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	120,761
Gross Amount at Which Carried As of Year End	
Land and improvements	6,000
Buildings and Improvements	120,761
Total	126,761
Accumulated Depreciation	0
2617 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,734
Building and Improvements	5,195
Costs Capitalized Subsequent to Acquisition	9,363
Gross Amount at Which Carried As of Year End	
Land and improvements	2,734
Buildings and Improvements	14,558
Total	17,292
Accumulated Depreciation	(4,106)
2618 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,100
Building and Improvements	12,395
Costs Capitalized Subsequent to Acquisition	22,843
Gross Amount at Which Carried As of Year End	
Land and improvements	4,100
Buildings and Improvements	35,238
Total	39,338
Accumulated Depreciation	(14,493)
2622 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	17,201
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,201
Total	17,201
Accumulated Depreciation	(2,091)
2872 San Diego, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,120
Building and Improvements	38,351
Costs Capitalized Subsequent to Acquisition	1,044
Gross Amount at Which Carried As of Year End	
Land and improvements	10,120
Buildings and Improvements	39,395
Total	49,515
Accumulated Depreciation	(9,481)
2873 San Diego, CA Lab Operating segment	

<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	6,052
<u>Building and Improvements</u>	14,122
<u>Costs Capitalized Subsequent to Acquisition</u>	1,445
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	6,052
<u>Buildings and Improvements</u>	15,567
<u>Total</u>	21,619
<u>Accumulated Depreciation</u>	(2,941)
<u>3069 San Diego, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	7,054
<u>Building and Improvements</u>	7,794
<u>Costs Capitalized Subsequent to Acquisition</u>	24,081
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	6,954
<u>Buildings and Improvements</u>	31,975
<u>Total</u>	38,929
<u>Accumulated Depreciation</u>	(4,467)
<u>3110 San Diego, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	19,120
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	9,373
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	20,587
<u>Buildings and Improvements</u>	7,906
<u>Total</u>	28,493
<u>Accumulated Depreciation</u>	(14)
<u>3111 San Diego, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	24,729
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	2,141
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	24,830
<u>Buildings and Improvements</u>	2,040
<u>Total</u>	26,870
<u>Accumulated Depreciation</u>	(18)
<u>3153 San Diego, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	1,215
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	15
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	1,217
<u>Buildings and Improvements</u>	13
<u>Total</u>	1,230
<u>Accumulated Depreciation</u>	0
<u>1410 South San Francisco, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	4,900
<u>Building and Improvements</u>	18,100
<u>Costs Capitalized Subsequent to Acquisition</u>	12,327
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	4,900
<u>Buildings and Improvements</u>	30,427
<u>Total</u>	35,327
<u>Accumulated Depreciation</u>	(16,142)
<u>1411 South San Francisco, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	8,000
<u>Building and Improvements</u>	27,700
<u>Costs Capitalized Subsequent to Acquisition</u>	33,196
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	8,000
<u>Buildings and Improvements</u>	60,896
<u>Total</u>	68,896
<u>Accumulated Depreciation</u>	(21,778)
<u>1412 South San Francisco, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	10,100
<u>Building and Improvements</u>	22,521
<u>Costs Capitalized Subsequent to Acquisition</u>	10,501
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	10,100
<u>Buildings and Improvements</u>	33,022
<u>Total</u>	43,122
<u>Accumulated Depreciation</u>	(14,123)
<u>1413 South San Francisco, CA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,000
Building and Improvements	28,299
Costs Capitalized Subsequent to Acquisition	8,603
Gross Amount at Which Carried As of Year End	
Land and improvements	8,000
Buildings and Improvements	36,902
Total	44,902
Accumulated Depreciation	(19,128)
1430 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,700
Building and Improvements	23,621
Costs Capitalized Subsequent to Acquisition	27,995
Gross Amount at Which Carried As of Year End	
Land and improvements	10,733
Buildings and Improvements	51,583
Total	62,316
Accumulated Depreciation	(16,385)
1431 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,000
Building and Improvements	15,500
Costs Capitalized Subsequent to Acquisition	10,711
Gross Amount at Which Carried As of Year End	
Land and improvements	7,022
Buildings and Improvements	26,189
Total	33,211
Accumulated Depreciation	(10,767)
1435 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	13,800
Building and Improvements	42,500
Costs Capitalized Subsequent to Acquisition	26,593
Gross Amount at Which Carried As of Year End	
Land and improvements	13,800
Buildings and Improvements	69,093
Total	82,893
Accumulated Depreciation	(24,860)
1436 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	14,500
Building and Improvements	45,300
Costs Capitalized Subsequent to Acquisition	42,147
Gross Amount at Which Carried As of Year End	
Land and improvements	14,500
Buildings and Improvements	87,447
Total	101,947
Accumulated Depreciation	(26,760)
1437 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	9,400
Building and Improvements	24,800
Costs Capitalized Subsequent to Acquisition	36,750
Gross Amount at Which Carried As of Year End	
Land and improvements	9,400
Buildings and Improvements	61,550
Total	70,950
Accumulated Depreciation	(24,113)
1439 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,900
Building and Improvements	68,848
Costs Capitalized Subsequent to Acquisition	13,735
Gross Amount at Which Carried As of Year End	
Land and improvements	11,900
Buildings and Improvements	82,583
Total	94,483
Accumulated Depreciation	(29,994)
1440 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,000
Building and Improvements	57,954
Costs Capitalized Subsequent to Acquisition	15,024
Gross Amount at Which Carried As of Year End	
Land and improvements	10,000
Buildings and Improvements	72,978
Total	82,978
Accumulated Depreciation	(24,006)
1441 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	

Land and improvements	9,300
Building and Improvements	43,549
Costs Capitalized Subsequent to Acquisition	22,619
Gross Amount at Which Carried As of Year End	
Land and improvements	9,300
Buildings and Improvements	66,168
Total	75,468
Accumulated Depreciation	(16,875)
1442 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,000
Building and Improvements	47,289
Costs Capitalized Subsequent to Acquisition	42,668
Gross Amount at Which Carried As of Year End	
Land and improvements	11,000
Buildings and Improvements	89,957
Total	100,957
Accumulated Depreciation	(26,528)
1443 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	13,200
Building and Improvements	60,932
Costs Capitalized Subsequent to Acquisition	3,283
Gross Amount at Which Carried As of Year End	
Land and improvements	13,200
Buildings and Improvements	64,215
Total	77,415
Accumulated Depreciation	(26,657)
1444 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,500
Building and Improvements	33,776
Costs Capitalized Subsequent to Acquisition	13,824
Gross Amount at Which Carried As of Year End	
Land and improvements	10,500
Buildings and Improvements	47,600
Total	58,100
Accumulated Depreciation	(14,058)
1445 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,600
Building and Improvements	34,083
Costs Capitalized Subsequent to Acquisition	46
Gross Amount at Which Carried As of Year End	
Land and improvements	10,600
Buildings and Improvements	34,129
Total	44,729
Accumulated Depreciation	(14,848)
1458 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,900
Building and Improvements	20,900
Costs Capitalized Subsequent to Acquisition	6,924
Gross Amount at Which Carried As of Year End	
Land and improvements	10,900
Buildings and Improvements	27,824
Total	38,724
Accumulated Depreciation	(10,664)
1459 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	9,800
Building and Improvements	394
Costs Capitalized Subsequent to Acquisition	157,274
Gross Amount at Which Carried As of Year End	
Land and improvements	9,800
Buildings and Improvements	157,668
Total	167,468
Accumulated Depreciation	(11,273)
1462 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,117
Building and Improvements	600
Costs Capitalized Subsequent to Acquisition	5,280
Gross Amount at Which Carried As of Year End	
Land and improvements	7,117
Buildings and Improvements	5,880
Total	12,997
Accumulated Depreciation	(1,956)
1463 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,381
Building and Improvements	2,300

Costs Capitalized Subsequent to Acquisition	17,197
Gross Amount at Which Carried As of Year End	
Land and improvements	10,381
Buildings and Improvements	19,497
Total	29,878
Accumulated Depreciation	(6,763)
1464 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,403
Building and Improvements	700
Costs Capitalized Subsequent to Acquisition	9,060
Gross Amount at Which Carried As of Year End	
Land and improvements	7,403
Buildings and Improvements	9,760
Total	17,163
Accumulated Depreciation	(3,302)
1468 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,100
Building and Improvements	24,013
Costs Capitalized Subsequent to Acquisition	11,565
Gross Amount at Which Carried As of Year End	
Land and improvements	10,100
Buildings and Improvements	35,578
Total	45,678
Accumulated Depreciation	(16,168)
1480 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	32,210
Building and Improvements	3,110
Costs Capitalized Subsequent to Acquisition	160,550
Gross Amount at Which Carried As of Year End	
Land and improvements	32,210
Buildings and Improvements	163,660
Total	195,870
Accumulated Depreciation	(7,004)
1528 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	188,739
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	188,739
Total	188,739
Accumulated Depreciation	(275)
1559 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,666
Building and Improvements	5,773
Costs Capitalized Subsequent to Acquisition	199
Gross Amount at Which Carried As of Year End	
Land and improvements	5,666
Buildings and Improvements	5,972
Total	11,638
Accumulated Depreciation	(5,923)
1560 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,204
Building and Improvements	1,293
Costs Capitalized Subsequent to Acquisition	2,683
Gross Amount at Which Carried As of Year End	
Land and improvements	1,204
Buildings and Improvements	3,976
Total	5,180
Accumulated Depreciation	(3,267)
1983 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,648
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	90,582
Gross Amount at Which Carried As of Year End	
Land and improvements	8,648
Buildings and Improvements	90,582
Total	99,230
Accumulated Depreciation	(31,738)
1984 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,844
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	90,761
Gross Amount at Which Carried As of Year End	

Land and improvements	7,844
Buildings and Improvements	90,761
Total	98,605
Accumulated Depreciation	(34,910)
1985 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,708
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	122,716
Gross Amount at Which Carried As of Year End	
Land and improvements	6,708
Buildings and Improvements	122,716
Total	129,424
Accumulated Depreciation	(43,270)
1986 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,708
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	120,758
Gross Amount at Which Carried As of Year End	
Land and improvements	6,708
Buildings and Improvements	120,758
Total	127,466
Accumulated Depreciation	(38,078)
1987 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,544
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	100,777
Gross Amount at Which Carried As of Year End	
Land and improvements	8,544
Buildings and Improvements	100,777
Total	109,321
Accumulated Depreciation	(28,885)
1988 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	10,120
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	119,625
Gross Amount at Which Carried As of Year End	
Land and improvements	10,120
Buildings and Improvements	119,625
Total	129,745
Accumulated Depreciation	(35,906)
1989 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	9,169
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	100,395
Gross Amount at Which Carried As of Year End	
Land and improvements	9,169
Buildings and Improvements	100,395
Total	109,564
Accumulated Depreciation	(23,508)
2553 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,897
Building and Improvements	8,691
Costs Capitalized Subsequent to Acquisition	4,478
Gross Amount at Which Carried As of Year End	
Land and improvements	2,897
Buildings and Improvements	13,169
Total	16,066
Accumulated Depreciation	(5,172)
2554 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	995
Building and Improvements	2,754
Costs Capitalized Subsequent to Acquisition	2,332
Gross Amount at Which Carried As of Year End	
Land and improvements	995
Buildings and Improvements	5,086
Total	6,081
Accumulated Depreciation	(1,757)
2555 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,202
Building and Improvements	10,776
Costs Capitalized Subsequent to Acquisition	2,527
Gross Amount at Which Carried As of Year End	
Land and improvements	2,202

Buildings and Improvements	13,303
Total	15,505
Accumulated Depreciation	(3,917)
2556 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,962
Building and Improvements	15,108
Costs Capitalized Subsequent to Acquisition	1,557
Gross Amount at Which Carried As of Year End	
Land and improvements	2,962
Buildings and Improvements	16,665
Total	19,627
Accumulated Depreciation	(4,704)
2557 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	2,453
Building and Improvements	13,063
Costs Capitalized Subsequent to Acquisition	3,842
Gross Amount at Which Carried As of Year End	
Land and improvements	2,453
Buildings and Improvements	16,905
Total	19,358
Accumulated Depreciation	(6,725)
2558 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,163
Building and Improvements	5,925
Costs Capitalized Subsequent to Acquisition	315
Gross Amount at Which Carried As of Year End	
Land and improvements	1,163
Buildings and Improvements	6,240
Total	7,403
Accumulated Depreciation	(1,626)
2624 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	25,502
Building and Improvements	42,910
Costs Capitalized Subsequent to Acquisition	14,832
Gross Amount at Which Carried As of Year End	
Land and improvements	25,502
Buildings and Improvements	57,742
Total	83,244
Accumulated Depreciation	(14,353)
2870 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	23,297
Building and Improvements	41,797
Costs Capitalized Subsequent to Acquisition	28,804
Gross Amount at Which Carried As of Year End	
Land and improvements	23,330
Buildings and Improvements	70,568
Total	93,898
Accumulated Depreciation	(21,151)
2871 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	20,293
Building and Improvements	41,262
Costs Capitalized Subsequent to Acquisition	22,121
Gross Amount at Which Carried As of Year End	
Land and improvements	20,333
Buildings and Improvements	63,343
Total	83,676
Accumulated Depreciation	(23,373)
3100 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	14,245
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	15,095
Gross Amount at Which Carried As of Year End	
Land and improvements	14,245
Buildings and Improvements	15,095
Total	29,340
Accumulated Depreciation	0
3101 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	61,208
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	29,603
Gross Amount at Which Carried As of Year End	
Land and improvements	61,208
Buildings and Improvements	29,603

Total	90,811
Accumulated Depreciation	0
3102 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	43,885
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	6,359
Gross Amount at Which Carried As of Year End	
Land and improvements	43,885
Buildings and Improvements	6,359
Total	50,244
Accumulated Depreciation	0
3123 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	6,456
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	6,456
Total	6,456
Accumulated Depreciation	0
3154 South San Francisco, CA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	56,590
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	56,590
Total	56,590
Accumulated Depreciation	307
2705 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	24,371
Building and Improvements	128,498
Costs Capitalized Subsequent to Acquisition	197
Gross Amount at Which Carried As of Year End	
Land and improvements	24,371
Buildings and Improvements	128,695
Total	153,066
Accumulated Depreciation	(17,582)
2706 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	15,473
Building and Improvements	149,051
Costs Capitalized Subsequent to Acquisition	850
Gross Amount at Which Carried As of Year End	
Land and improvements	15,473
Buildings and Improvements	149,901
Total	165,374
Accumulated Depreciation	(22,324)
2707 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	25,549
Building and Improvements	229,547
Costs Capitalized Subsequent to Acquisition	8,597
Gross Amount at Which Carried As of Year End	
Land and improvements	25,549
Buildings and Improvements	238,144
Total	263,693
Accumulated Depreciation	(33,377)
2708 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	17,751
Costs Capitalized Subsequent to Acquisition	539
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	18,290
Total	18,290
Accumulated Depreciation	(1,902)
2709 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	15,451
Costs Capitalized Subsequent to Acquisition	29
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	15,480
Total	15,480
Accumulated Depreciation	(1,579)

2928 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	44,215
Building and Improvements	24,120
Costs Capitalized Subsequent to Acquisition	3,154
Gross Amount at Which Carried As of Year End	
Land and improvements	44,215
Buildings and Improvements	27,274
Total	71,489
Accumulated Depreciation	(5,108)
2929 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	20,516
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	159,436
Gross Amount at Which Carried As of Year End	
Land and improvements	20,516
Buildings and Improvements	159,436
Total	179,952
Accumulated Depreciation	(15,859)
3074 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	78,762
Building and Improvements	252,153
Costs Capitalized Subsequent to Acquisition	14,635
Gross Amount at Which Carried As of Year End	
Land and improvements	78,762
Buildings and Improvements	266,788
Total	345,550
Accumulated Depreciation	(41,328)
3106 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	20,644
Building and Improvements	2,982
Costs Capitalized Subsequent to Acquisition	621
Gross Amount at Which Carried As of Year End	
Land and improvements	20,644
Buildings and Improvements	3,603
Total	24,247
Accumulated Depreciation	(340)
3107 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	19,009
Building and Improvements	12,327
Costs Capitalized Subsequent to Acquisition	1,875
Gross Amount at Which Carried As of Year End	
Land and improvements	19,009
Buildings and Improvements	14,202
Total	33,211
Accumulated Depreciation	(1,202)
3108 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	123,074
Building and Improvements	7,513
Costs Capitalized Subsequent to Acquisition	8
Gross Amount at Which Carried As of Year End	
Land and improvements	123,074
Buildings and Improvements	7,521
Total	130,595
Accumulated Depreciation	(969)
3109 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,903
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	637
Gross Amount at Which Carried As of Year End	
Land and improvements	5,903
Buildings and Improvements	637
Total	6,540
Accumulated Depreciation	0
3112 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	23,402
Building and Improvements	47,623
Costs Capitalized Subsequent to Acquisition	1,385
Gross Amount at Which Carried As of Year End	
Land and improvements	23,402
Buildings and Improvements	49,008
Total	72,410
Accumulated Depreciation	(5,706)
3113 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	

Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	32,244
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	8,417
Gross Amount at Which Carried As of Year End	
Land and improvements	36,119
Buildings and Improvements	4,542
Total	40,661
Accumulated Depreciation	0
3114 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	22,969
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	(1,179)
Gross Amount at Which Carried As of Year End	
Land and improvements	22,969
Buildings and Improvements	(1,179)
Total	21,790
Accumulated Depreciation	0
3115 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	66,786
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	2,536
Gross Amount at Which Carried As of Year End	
Land and improvements	66,786
Buildings and Improvements	2,536
Total	69,322
Accumulated Depreciation	0
3116 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	17,413
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	17,413
Total	17,413
Accumulated Depreciation	0
3119 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	29,667
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	29,667
Total	29,667
Accumulated Depreciation	(2,984)
3120 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	18,063
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	1,417
Gross Amount at Which Carried As of Year End	
Land and improvements	18,063
Buildings and Improvements	1,417
Total	19,480
Accumulated Depreciation	0
3122 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	25,247
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	3,293
Gross Amount at Which Carried As of Year End	
Land and improvements	25,247
Buildings and Improvements	3,293
Total	28,540
Accumulated Depreciation	0
3136 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	4,118
Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	(161)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,119
Buildings and Improvements	(162)
Total	3,957
Accumulated Depreciation	0
3137 Cambridge, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0

<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	41,327
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	4,680
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	41,327
<u>Buildings and Improvements</u>	4,680
<u>Total</u>	46,007
<u>Accumulated Depreciation</u>	0
<u>3141 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	72,466
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	9,303
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	72,768
<u>Buildings and Improvements</u>	9,001
<u>Total</u>	81,769
<u>Accumulated Depreciation</u>	0
<u>3148 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	2,277
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	67
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	2,290
<u>Buildings and Improvements</u>	54
<u>Total</u>	2,344
<u>Accumulated Depreciation</u>	0
<u>3149 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	5,690
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	625
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	5,746
<u>Buildings and Improvements</u>	569
<u>Total</u>	6,315
<u>Accumulated Depreciation</u>	0
<u>3150 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	1,651
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	360
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	1,659
<u>Buildings and Improvements</u>	352
<u>Total</u>	2,011
<u>Accumulated Depreciation</u>	0
<u>3151 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	8,532
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	904
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	8,583
<u>Buildings and Improvements</u>	853
<u>Total</u>	9,436
<u>Accumulated Depreciation</u>	0
<u>3152 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	9,892
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	1,525
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	10,507
<u>Buildings and Improvements</u>	910
<u>Total</u>	11,417
<u>Accumulated Depreciation</u>	0
<u>MA5394 Cambridge, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	
<u>Land and improvements</u>	4,441
<u>Building and Improvements</u>	0
<u>Costs Capitalized Subsequent to Acquisition</u>	113
<u>Gross Amount at Which Carried As of Year End</u>	
<u>Land and improvements</u>	4,441
<u>Buildings and Improvements</u>	113
<u>Total</u>	4,554
<u>Accumulated Depreciation</u>	0
<u>2630 Lexington, MA Lab Operating segment</u>	
<u>Real Estate and Accumulated Depreciation</u>	
<u>Encumbrances as of Year end</u>	0
<u>Initial Cost to Company</u>	

Land and improvements	16,411
Building and Improvements	49,682
Costs Capitalized Subsequent to Acquisition	(2,284)
Gross Amount at Which Carried As of Year End	
Land and improvements	12,967
Buildings and Improvements	50,842
Total	63,809
Accumulated Depreciation	(12,431)
2631 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	7,759
Building and Improvements	142,081
Costs Capitalized Subsequent to Acquisition	30,473
Gross Amount at Which Carried As of Year End	
Land and improvements	6,978
Buildings and Improvements	173,335
Total	180,313
Accumulated Depreciation	(34,532)
2632 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	21,390
Costs Capitalized Subsequent to Acquisition	126,772
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	148,162
Total	148,162
Accumulated Depreciation	(25,261)
3070 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	14,013
Building and Improvements	17,083
Costs Capitalized Subsequent to Acquisition	(269)
Gross Amount at Which Carried As of Year End	
Land and improvements	14,013
Buildings and Improvements	16,814
Total	30,827
Accumulated Depreciation	(3,110)
3071 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	14,930
Building and Improvements	16,677
Costs Capitalized Subsequent to Acquisition	(121)
Gross Amount at Which Carried As of Year End	
Land and improvements	14,930
Buildings and Improvements	16,556
Total	31,486
Accumulated Depreciation	(2,782)
3072 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	34,598
Building and Improvements	43,032
Costs Capitalized Subsequent to Acquisition	(288)
Gross Amount at Which Carried As of Year End	
Land and improvements	34,598
Buildings and Improvements	42,744
Total	77,342
Accumulated Depreciation	(9,256)
3073 Lexington, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	37,050
Building and Improvements	44,647
Costs Capitalized Subsequent to Acquisition	144
Gross Amount at Which Carried As of Year End	
Land and improvements	37,050
Buildings and Improvements	44,791
Total	81,841
Accumulated Depreciation	(9,883)
3093 Waltham, MA Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	47,792
Building and Improvements	275,556
Costs Capitalized Subsequent to Acquisition	26,887
Gross Amount at Which Carried As of Year End	
Land and improvements	47,790
Buildings and Improvements	302,445
Total	350,235
Accumulated Depreciation	(49,524)
9999 Denton, TX Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	100

Building and Improvements	0
Costs Capitalized Subsequent to Acquisition	0
Gross Amount at Which Carried As of Year End	
Land and improvements	100
Buildings and Improvements	0
Total	100
Accumulated Depreciation	0
464 Salt Lake City, UT Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	630
Building and Improvements	6,921
Costs Capitalized Subsequent to Acquisition	2,563
Gross Amount at Which Carried As of Year End	
Land and improvements	630
Buildings and Improvements	9,484
Total	10,114
Accumulated Depreciation	(6,260)
465 Salt Lake City, UT Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	125
Building and Improvements	6,368
Costs Capitalized Subsequent to Acquisition	68
Gross Amount at Which Carried As of Year End	
Land and improvements	125
Buildings and Improvements	6,436
Total	6,561
Accumulated Depreciation	(3,415)
466 Salt Lake City, UT Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	14,614
Costs Capitalized Subsequent to Acquisition	(1,401)
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	13,213
Total	13,213
Accumulated Depreciation	(5,702)
1593 Salt Lake City, UT Lab Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	0
Building and Improvements	23,998
Costs Capitalized Subsequent to Acquisition	250
Gross Amount at Which Carried As of Year End	
Land and improvements	0
Buildings and Improvements	24,248
Total	24,248
Accumulated Depreciation	\$ (10,516)

XML 174 R155.htm IDEA: XBRL DOCUMENT

Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Continuing Care Retirement Community) (Details)	Dec. 31, 2024
\$ in Thousands	USD (\$)
Held-for-sale	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	\$ 0
Initial Cost to Company	
Land and improvements	4,141
Building and Improvements	20,364
Costs Capitalized Subsequent to Acquisition	(13,844)
Gross Amount at Which Carried As of Year End	
Land and improvements	4,141
Buildings and Improvements	6,520
Total	10,661
Accumulated Depreciation	(2,821)
Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	356,750
Initial Cost to Company	
Land and improvements	2,887,257
Building and Improvements	11,334,757
Costs Capitalized Subsequent to Acquisition	5,692,420
Gross Amount at Which Carried As of Year End	
Land and improvements	2,918,758
Buildings and Improvements	16,995,676
Total	19,914,434
Accumulated Depreciation	(4,083,030)
Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	106,247
Initial Cost to Company	
Land and improvements	156,503
Building and Improvements	1,582,459
Costs Capitalized Subsequent to Acquisition	306,154
Gross Amount at Which Carried As of Year End	

Land and improvements	168,009
Buildings and Improvements	1,877,107
Total	2,045,116
Accumulated Depreciation	(435,849)
3089 Birmingham, AL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,193
Building and Improvements	32,146
Costs Capitalized Subsequent to Acquisition	7,845
Gross Amount at Which Carried As of Year End	
Land and improvements	6,670
Buildings and Improvements	39,514
Total	46,184
Accumulated Depreciation	(9,716)
3090 Bradenton, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,216
Building and Improvements	88,090
Costs Capitalized Subsequent to Acquisition	29,437
Gross Amount at Which Carried As of Year End	
Land and improvements	6,037
Buildings and Improvements	116,706
Total	122,743
Accumulated Depreciation	(27,956)
2997 Clearwater, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	64,402
Initial Cost to Company	
Land and improvements	6,680
Building and Improvements	132,521
Costs Capitalized Subsequent to Acquisition	23,978
Gross Amount at Which Carried As of Year End	
Land and improvements	7,317
Buildings and Improvements	155,862
Total	163,179
Accumulated Depreciation	(27,404)
3086 Jacksonville, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	19,660
Building and Improvements	167,860
Costs Capitalized Subsequent to Acquisition	27,057
Gross Amount at Which Carried As of Year End	
Land and improvements	21,211
Buildings and Improvements	193,366
Total	214,577
Accumulated Depreciation	(38,594)
2996 Leesburg, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	8,941
Building and Improvements	65,698
Costs Capitalized Subsequent to Acquisition	20,758
Gross Amount at Which Carried As of Year End	
Land and improvements	9,817
Buildings and Improvements	85,580
Total	95,397
Accumulated Depreciation	(19,236)
2995 Port Charlotte, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	5,344
Building and Improvements	159,612
Costs Capitalized Subsequent to Acquisition	21,429
Gross Amount at Which Carried As of Year End	
Land and improvements	7,102
Buildings and Improvements	179,283
Total	186,385
Accumulated Depreciation	(30,007)
2998 Seminole, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	41,845
Initial Cost to Company	
Land and improvements	14,080
Building and Improvements	77,485
Costs Capitalized Subsequent to Acquisition	14,823
Gross Amount at Which Carried As of Year End	
Land and improvements	15,047
Buildings and Improvements	91,341
Total	106,388
Accumulated Depreciation	(14,930)
3085 Seminole, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	13,038
Building and Improvements	116,819
Costs Capitalized Subsequent to Acquisition	11,766
Gross Amount at Which Carried As of Year End	
Land and improvements	13,834

Buildings and Improvements	127,789
Total	141,623
Accumulated Depreciation	(28,051)
3092 Sun City Center, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	25,254
Building and Improvements	175,535
Costs Capitalized Subsequent to Acquisition	25,544
Gross Amount at Which Carried As of Year End	
Land and improvements	26,918
Buildings and Improvements	199,415
Total	226,333
Accumulated Depreciation	(46,179)
3087 The Villages, FL Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	6,311
Building and Improvements	113,061
Costs Capitalized Subsequent to Acquisition	19,819
Gross Amount at Which Carried As of Year End	
Land and improvements	6,707
Buildings and Improvements	132,484
Total	139,191
Accumulated Depreciation	(26,539)
3084 Holland, MI Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	1,572
Building and Improvements	88,960
Costs Capitalized Subsequent to Acquisition	13,297
Gross Amount at Which Carried As of Year End	
Land and improvements	2,134
Buildings and Improvements	101,695
Total	103,829
Accumulated Depreciation	(19,395)
2991 Coatesville, PA Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	12,949
Building and Improvements	126,243
Costs Capitalized Subsequent to Acquisition	22,116
Gross Amount at Which Carried As of Year End	
Land and improvements	13,616
Buildings and Improvements	147,692
Total	161,308
Accumulated Depreciation	(26,697)
3080 Haverford, PA Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	16,461
Building and Improvements	108,816
Costs Capitalized Subsequent to Acquisition	32,212
Gross Amount at Which Carried As of Year End	
Land and improvements	16,461
Buildings and Improvements	141,028
Total	157,489
Accumulated Depreciation	(57,476)
3088 Spring, TX Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	3,210
Building and Improvements	30,085
Costs Capitalized Subsequent to Acquisition	13,679
Gross Amount at Which Carried As of Year End	
Land and improvements	3,544
Buildings and Improvements	43,430
Total	46,974
Accumulated Depreciation	(7,776)
3081 Fort Belvoir, VA Continuing care retirement community Operating segment	
Real Estate and Accumulated Depreciation	
Encumbrances as of Year end	0
Initial Cost to Company	
Land and improvements	11,594
Building and Improvements	99,528
Costs Capitalized Subsequent to Acquisition	22,394
Gross Amount at Which Carried As of Year End	
Land and improvements	11,594
Buildings and Improvements	121,922
Total	133,516
Accumulated Depreciation	\$ (55,893)

XML 175_R156.htm
IDEA: XBRL DOCUMENT

Schedule III: Real Estate and Accumulated Depreciation - Amount that Tax Basis of Net Real Estate Assets Less Than the Reported Amounts (Details)	Dec. 31, 2024
\$ in Billions	USD (\$)

Amount that the tax basis of the Company's net real estate is less than the reported amounts
Life on Which Depreciation in Latest Income Statement is Computed

\$ 21
50 years

XML 176 R157.htm IDEA: XBRL DOCUMENT

Schedule III: Real Estate and Accumulated Depreciation - Summary of Activity for Real Estate and Accumulated Depreciation (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated depreciation:			
Deconsolidation of real estate Continuing Operations	\$ 0	\$ 0	\$ (89,766)
Real estate:			
Balances at beginning of year	16,620,314	16,211,621	15,506,658
Real estate assets acquired in connection with the Merger	3,696,519	0	0
Acquisition of real estate and development and improvements	668,803	754,225	1,102,593
Sales and/or transfers to assets held for sale	(909,629)	(137,731)	(82,350)
Deconsolidation of real estate	0	0	(189,605)
Impairments	(13,118)	0	0
Other	(148,455)	(207,801)	(125,675)
Balances at end of year	19,914,434	16,620,314	16,211,621
Accumulated depreciation:			
Balances at beginning of year	3,591,951	3,188,138	2,839,229
Depreciation expense	749,376	609,461	575,125
Sales and/or transfers to assets held for sale	(132,604)	(12,711)	(30,428)
Other	(125,693)	(192,937)	(106,022)
Balances at end of year	\$ 4,083,030	\$ 3,591,951	\$ 3,188,138

XML 177 R158.htm IDEA: XBRL DOCUMENT

Schedule IV: Mortgage Loans on Real Estate (Details) \$ in Thousands	12 Months Ended			
	Dec. 31, 2024 USD (\$) property	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)	Dec. 31, 2021 USD (\$)
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Prior Liens	\$ 0			
Face Amount of Mortgages	638,482			
Carrying Amount of Mortgages	612,784	\$ 175,717	\$ 341,749	\$ 390,291
Principal Amount Subject to Delinquent Principal or Interest	\$ 0			
Arizona And Texas				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	1			
Alabama				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	1			
Arizona, Florida, Georgia, Texas, and Wisconsin				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	1			
Mortgage loan on real estate, multiple due 2026				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	61			
Mortgage loan on real estate, multiple due 2026 Other Operating Segment [Member] Multiple Locations				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	6.00%			
Prior Liens	\$ 0			
Face Amount of Mortgages	418,389			
Carrying Amount of Mortgages	399,209			
Principal Amount Subject to Delinquent Principal or Interest	\$ 0			
Mortgage loan on real estate, multiple due 2027				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	5			
Mortgage loan on real estate, multiple due 2027 Other Operating Segment [Member] Multiple Locations				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	4.00%			
Prior Liens	\$ 0			
Face Amount of Mortgages	58,090			
Carrying Amount of Mortgages	57,177			
Principal Amount Subject to Delinquent Principal or Interest	\$ 0			
Mortgage loan on real estate, multiple due 2027 Other Operating Segment [Member] Multiple Locations Minimum				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	9.00%			
Mortgage loan on real estate, multiple due 2027 Secured Overnight Financing Rate (SOFR) Other Operating Segment [Member] Multiple Locations				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	0.10%			
Mortgage loan on real estate, multiple due 2025				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Number of properties with first mortgages property	10			
Mortgage loan on real estate, multiple due 2025 Other Operating Segment [Member] Multiple Locations				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	7.00%			
Prior Liens	\$ 0			
Face Amount of Mortgages	48,000			
Carrying Amount of Mortgages	47,911			
Principal Amount Subject to Delinquent Principal or Interest	\$ 0			
Mortgage loan on real estate, multiple due 2025 Other Operating Segment [Member] Multiple Locations Minimum				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	12.00%			
Mortgage loan on real estate, multiple due 2025 Secured Overnight Financing Rate (SOFR) Other Operating Segment [Member] Multiple Locations				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	0.11%			
Construction loans on real estate interest multiple due 2027 Other Operating Segment [Member] Arizona				
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]				
Interest Rate	7.47%			
Prior Liens	\$ 0			

Face Amount of Mortgages	25,654
Carrying Amount of Mortgages	23,528
Principal Amount Subject to Delinquent Principal or Interest	\$ 0
Construction loans on real estate interest multiple due 2026 to 2027	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Percentage of carrying amount	3.00%
Construction loans on real estate interest multiple due 2026 to 2027 Other Operating Segment [Member] Arizona And Texas	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Prior Liens	\$ 0
Face Amount of Mortgages	21,238
Carrying Amount of Mortgages	20,135
Principal Amount Subject to Delinquent Principal or Interest	0
Proceeds from repayment	\$ 15,000
Construction loans on real estate interest multiple due 2026 to 2027 Other Operating Segment [Member] Arizona And Texas Minimum	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Interest Rate	7.57%
Construction loans on real estate interest multiple due 2026 to 2027 Other Operating Segment [Member] Arizona And Texas Maximum	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Interest Rate	7.84%
Mortgage loan on real estate, multiple due 2025 Other Operating Segment [Member] Alabama	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Interest Rate	10.00%
Prior Liens	\$ 0
Face Amount of Mortgages	35,350
Carrying Amount of Mortgages	34,592
Principal Amount Subject to Delinquent Principal or Interest	\$ 0
Mortgage loan on real estate, multiple due 2025 to 2028	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Percentage of carrying amount	3.00%
Mortgage loan on real estate, multiple due 2025 to 2028 Other Operating Segment [Member] Arizona, Florida, Georgia, Texas, and Wisconsin	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Prior Liens	\$ 0
Face Amount of Mortgages	31,761
Carrying Amount of Mortgages	30,232
Principal Amount Subject to Delinquent Principal or Interest	\$ 0
Mortgage loan on real estate, multiple due 2025 to 2028 Other Operating Segment [Member] Arizona, Florida, Georgia, Texas, and Wisconsin Minimum	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Interest Rate	7.00%
Mortgage loan on real estate, multiple due 2025 to 2028 Other Operating Segment [Member] Arizona, Florida, Georgia, Texas, and Wisconsin Maximum	
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]	
Interest Rate	10.00%

XML 178 R159.htm IDEA: XBRL DOCUMENT

Schedule IV:	12 Months Ended		
Mortgage Loans on Real Estate - Reconciliation of Mortgage Loans (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands			
SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]			
Balance at beginning of year	\$ 175,717	\$ 341,749	\$ 390,291
New mortgage loans	486,667	0	0
Draws and additions to existing mortgage loans	30,745	11,602	5,525
Total additions	517,412	11,602	5,525
Principal repayments	(77,643)	(183,084)	(47,591)
Reserve for loan losses	(2,702)	5,450	(6,476)
Total deductions	(80,345)	(177,634)	(54,067)
Balance at end of year	\$ 612,784	\$ 175,717	\$ 341,749

EXCEL 179 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L#!0 (\$F\$1%H'04UB@0+\$ 0 9&|C4')O<',O87!P+GAM M;\$V./0L",1!\$ _\IQO;=!P4)B0-!2L+ (/>QLOD&1#LD)^OCGI:CVX>;QA&WPIG M*N*I#BV&5(_C(I(/_!47BK9.7;=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0UIR:UEA_6#MI7E!+ P04 M " !A\$1:(.0B>\ K @ \$0 &108U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NDW' #E&7"]- (" \$Q" <0MG_\$(P>=" M.1+(HEB#)S;6L(\$)F(6%*1M46\$DPUV\X"TN^/ 9FQEF\$:@A3RTG*,2A)XF MAO/0U' #3#"FZ--W@>Q"G*M_8N<.B\$MR2&Y)I7V?I]6<&WWW\65>-W-M M8M,BC;^24WP.MI'7R: 5PW: \$UH6\CXK9%:L|K)45:56Z_?)I8??3=AWUAW< M/S: ^"NH:?MV%_@02P,\$% @ 281\$6IE&UL|5L;<|HX%'|OKI|X9_9M" \8V@:;T\$W-I=MNTF83M M3A^%\$5B-;'EDD81_OTV23;J:/ 0LZ?O.14? GZ#AY\^XN8NB&B)3R M> +|O6N|!3+ MUES@6QHO(!JM-O=5H1I;*\$81V1@?5XL:\$#05%%;:U\@M.4?._@5RU2-9;.! M\$U=!)KF(M+Y;7\VMX^9<_LATR@6XP&U@@?YOI^1.6HCA5,+P&IG/U9K MQI'22(""R7V4!;I)I|J/3%0@R#3LZG5C.=GSVQ.V?C.K;=#1M&N#C\7@XML02 MBW A(5M>5 TR M6!'VULS2 Y9>*? IUE!K9';O=05SP6.XYB1'^QI4\$UFG2&98T1G*=D 4. #?\$ MT4Q0?*!|MHK@PI+27)#6SRFU4!H(FLB!|4> "(<7K;YH| M5Z%82=J\$ ^!|&&N* <<^9ST6S|!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=\$Q+ -E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"\$2M"/F(9 M-AIRM1;!MG&IA&!;\$L;1>=\$[2M!'6:PUDSY@R.S-D77.UI\$.S9)>- T(^8LZ+ MDI& 'H8X2IKMHG%8! /V>7L-)P>B"RV;|N'Z&U3-L+(|W1|072N0!)J<_Z3(T MIZ.:60F|A%9JGZJ' -#ZH'C(*! ? &Y'C|E>G@*-Y;&O%"N@GL!_|':-^*K^ (+ M.7\N?<^E|!GT/:'2MSAD6R4)RU3393>* M\$IY"&V|I4_5*E=? EK|DHN#Q;Y.FOH70^+, _Y/%_GM,T+T.WF)&Y M"M-2D&_#^>G%>!KB.=D\$N7V85VWGV-'1^ ^? !4;"C|SR6'<> (|A|J&F_#_M0X=Y>U^89Y7&4#04;6RL)"Q&MV^XU_\$L%!.D8"V@!X.O40+R4E5@.5O& RN0 MHGQ.C\$7H<,>77%_CT9+CVZ9EM6ZO*7<9;2)2.<|JF!-G|K>9;'!51W/55OR ML+YJ/;053L_ ^6;W(GPP13A8+\$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X\$G;V#P(RN;LYJ7IE,6>F\MM#_DL6XA9\$N)-7>W5YYNTB42%(JP# 4A M'%W+CI^ ^3;G>,U_HL@6V\$5#)DU1?*0XG!/3-R0|A4)?_NVB8+A=OB5.V|&KXF M8\$O#>FZ=+2? _VU|4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH_1JV*^NJI/^26<.[1|!8\$@F_S6VZ3VW>_? -2K6J5D*Q\$ _M2P= \Y(&8XQ;|!#?CQ1BK::QK<;;.0QY@%CS#*%F.- ^'19H;.|6+K#F-"FI! MU4#E/|O4#6CV#30,9FV- J/D3@H\W/|O#;#"Q(|A|8N_5!+ P04 M" !A\$1;G4%U;C (8,@ &'AL+W=O%24R)FMBLXT#| MI>|Q H14QB179EY.(>0) <7|8SGGLPV&|=D28A |W%\$D|O&4HC5UU8K\9/^I2(**9EP ME*1QC/G"8G8YK9A-W8!N'K4L@#K?|-"K^2&1\$_5A,. |UI|E2",4U"1A\$G MB|O&P/XZ=*|E0';&7R'9) >OD;R5.6-O\LTXN&U8LD4D(KZ0\$AC^K(E'HD@J M03O^W8HV|J>4@8>O=^KWV6++W\K=Y7+.\$3G;00^_BF6" M1C0@05F@!6W;-|!#9-?#.T2H.B7^)7/L".9;35C3(TX? _@>D^O*,'YX(3V6X MI;JZZ6|0\#5989_<-F"@)X2O2:/_ MT|VU_I-1<>DV-"06(E<>T^NK5/O#YF?PGPCT/'|B|BPZ<-

MJ_FGBHVJBX? M0V(E/ITIGTXU/@-*4ORA*5DQ+E2@|#J"IRJ\GC:J+BA#8B50W3VH;C50\$)\)#
M9%LB)"L'4J>Q3)Y1V4I/1N4D:7Q>:(;\$2M*LJM"OMK7HIYY+9?9CXT+E>".9: M<'JU9M-VFJZM(J8-
K\$O,D%B)6&I/K%=QON(8LJ0LR3D^)O5:"QPERD&I#:#M+ MRY!8B=:UGM:UJ@Y'5(3B [I71-
!C&L)5U'2:UB6W;1Z06O58I]3AM8E94BL M1,JVBHS-JL)J2EY#F45 %WO\$L7(4GA#Z1G DEBN"WI"\$@Y/(@B3)1=[2,?
40 M51SUDG5!FE(KDSS(>?>T).%>8>1B>4@O4 S 9.;8AQY+*6"?#?0(U7K_XP M5 +4!M4&:\$BM#- I #I5 #[C=S0.8+
(+%Z&?4=0.XA.2KMNTK&O;O;I2TM,& MUZ9G2*U,K "MC9AWM\$;! &H)Q>I%^(G(>>J+K/Z27:71
M)@3Z,P=WJ*1IU!V84B03+/R!K<_PM32?-TO)4R\Y2T-\B9V+\$M)T*A_*56 M)E@X"%N?^G\FZ,EW,^LPU5TCOA2
A=*Z< 3QI8FJ\HYW(1=V E;|P(^4I|_ M/N"9N@ZIKQI&>DWO28G-J)TPI5;&5A@*6^W\F.;L\$2 L_A/N#K^O-4KJBS'
M53TC)H*4VIE;H6ML/5>(N4 TIP<4QZ@2M'/9,9I1*FU,J0"C=AZZW =R9= MZF3)J,Y.G!!L
[UFQ^JH:1GU\$3;4R@NLA:%P#|@.11@N|@ "VWQEB2LWM\$XH:/J,@Z\5@7,YKWUFU(K4ROR?J=2WC^F@O!\|UJNAN,=
M1B4UO>(O:D:3?E-J96I%VN|42ONXS8@<\$JOC*LS#;W.=\SAT3'P'O)/('D MDDI^1M- 4VIE?D7Z[^BSJRV_68RC"-
VE"7RLTWT)#+,SYQ2M,U=U+W@J\$2I|V+WWU(,?5# M,*#94EIV;,1YMJ\$ CX;WND?B5)= J&_S-\$>J(^K#?2.
<+L\$M70);:6-AMH3\$ M5S=<3\@/S M#(T?O?:IY&DZ>|X-T=T+FH[N1I/|HS="\$^DZ&\$WD2118\$EF|&=(P2ZPGG+U_
M'\$RG"YA,Y2E\OP?^T\|Q|I[Z+)?S?>YAL39AR"UZ/NO;(M.X>+<@L7Y59R41YJQR^L3\$-R#OZDZ@G>[V4!?
^NNIU>3[EBJP^N3>T<+LHM M7)2K=S\#& 5!GFPP?B6UK)(\STO=ORB)&?5*IM1R8JV#4GKI&K.?)3(MEZ5
>57I_NC^9P^#K-B_59R>_V;B 403E:"(+ "#4NKR" F9;G/T(WPBVR@KS MYTP(%F)O&!.|-(^Q^#J|A'4\$!#!!O (
\$F\$1%j)%&T0> M0@(_,% 8 >&PO=VJR:W-H965T&ULC91M;JHP\$,> MBI5)?
54U(0&VT2023U618\$4MW5Y,>V&2@UB-[0,0DBWB0^^^ [G M_JF^BVLNWF0!H- '+9E,O\$*I:N3L,BN
8GG*!V!Z9<<M)Q4J;8N_+F@Q#;1 M M_3 (ACI%AE!;26(HWY096\$P5H@>: 4BS\3*F=>#WO.;N3,|H4R\$WX:5W@/
M+Z!>J|70EM2X>RQ1*F0#|?4^@PK MC36+?M8@)(X17D#T0K3B3!42S5D.^? \ 7^MI185'49.PDSB#[Y%O5L4!F&_
M@Q>U24:6%UV;)/HYWDHEI)/X=2Y?1^N?IYDR&7J>|<|1V2K=|ON-<'0VS0=NVT|I02P,\$% @ 281\$6JBN M@1\$Q" OA/
!@ !X;"|W;W)K|D|:HG=YD<2M2*V3?OH;2IO5KDC) M#JX!\$ORD/H-7^:9H4Z>5?U%KX0PZ&M95/ITMC)F_6ZQT-
E*E%R_56M1P5^> M5%UR [?U|YVZ@L%B0(XD7)934I.VF??:S/3E1C"EF)CS7235GR^MN%
M*.3SZ0S(OC_X)N!;65<>E?IB;VIRTUE@%8E"9,9VP>'71ER*HK |@8Z_MIW. M=N^T#?>OO_?
^:~L^/!(M:A4Q;|E;E;G,S9#N7CB36\$^J>??Q-:AR/:7J4*W M_Z/GK6TP0UFCC2JWC4%!*:ON-
'Z'8B|!C@<:4"V#K,7|=BTK<\$;6=EIO#N'N/LMS=7YP_45NCB_ M/;^|O\$;WOUU?/JRC8_3Y_@JL.?H%'2%9H8>5:C2OI?
OKXY/6R^|JW3L=TZ3MCX|T|TGP@EMN!O?,YT MK4-;
[NOWNDUS3I#':.%O5&S,Y^ @G'P7N?: |09P>.TIVC=KWLXM&%KFL MEAK!O"%9KFNU\$;
)C7<.N|Z2MB^|_3=G.,8X(@S&?+/ODL>04I*&<;@S) / M|N2&DW*OO ;BRMH*1)G2IL.=J4J;NNFV|Q#<&
O0^5UH>L_WE/&6\$#3H0.N M61Q2@A. _&@G/YJ4?VO5OF:@(^?U),4LB=A IL*+ #L,LF|F&KUEZHV\N_V@4I|I&@Z#@-
& QH,Q'L.;93B-.)^|9BF|:@?D3FS(^CZPAR)"4YP.AQMUXQ@%D:|WX|T MYT&(6;RNY-
5^#&D\Y<))S@%R(X3*SR|3J|6HDGJ@D|IC\$TYP;_ 6AE2AR|)D\ MTGR|D+UJ7=@E+'16J6L%Y^R.;T|\$_T%-
O"X"@|'3=Z.[#C2EW>A23\$R9#> M'CL2|C@:6Z0|%_ \$T&#^8E:A?G'T7;"G(C*.A2M@7"QAZ,_@UGS8-
""33>'P0=8D*F|IXBR*78S@.XR <D^/ M89C&C(PL2-(3CTP3|UY4\$J)=4VF108:1HTH9?YY|7(S%44S)7NC=:G4-HS"@
M-!G!|=DK.,>|SNDT4N%)|A/WKC""|Y1J,XB8.3|;\$#X)T|O%|A/?#(JX%7 M2/XH"VED&(I
[Q*49AJJ%#:GGLR.)96/+LZ<>F;.>2|2\$KBN?(SDE\(#(F+ M.6>V:PDZ8CX'H/DA=I0<-V\AS>O-A=K-\$@(<01Z\!?
\$23B2'L,>?^3%NK!+ MC|?6Y<:ARRK&OCF@_5AXYEJ2;GWV.N0AX DHB\$9.N3:Q1'4.".Y!^E)2:9)
M>26>1&T#12V@*FF\M2)Q&9A",D&=2.&Q"Z+16IST|"33M6*^Y>+TJWO<.,18
M\$%,U.E:LB2AZ>C^ZIE&IMEV"0R3VY)P>RYC9+44569WY|L|",8(DU^\\B=|
M|E,9>0_3_O^.#@_2>CC2:3A^\$KD0I=T6@!U;JYI:%6"TA,+8"C9R)E:"T,2
M.S6BQRID4+ZIXSVQ*00U@(@P9:I"VJCLROP=X;=!)N|1E I-N(=PG/(+^9! M|J|.*>|G=Z|7'-
Q"O#\$K5Q6DZ#UDTQ|0|MHC"9 X9XYQB_-U<:FTC M1ALD&J,!,?8 TCLT'DBG*70_'!P?HY/1,HKVB*;3B#|/(3V3JFJ3,ID?
RPIJ MTI6\$|>B5ZW(8\$Q9"1!O&,Y|E\$ 91,K8'Z=YYIC2S+|N#M.'|F|O\$)N9"ZJO#V9 M\$5\$SH=M3)
<'KRI|X>EUPT7P.3TCO88IR\4KWNGCQU& M(#F&W;JRWX; +PF;JQ3H3:&T|@83Z@*:,/)3J=)WL7K=DNM
M5)&+6O_\\$R,X>=>P?C13EUD0PD.:=&0,A|F\$90-(XM|A|N=!KN_IH_G+!-
MP%0@W2O6Q3%\$;@XU.JS"J|T+&KUV*8OG/"JZKCD%5_:Z%J*E'8I%^:|7|I M-;MTAB0^QTYSF=
MYGDG>6+1>DYK@R@*G-:CV',S|J@_B5|BV\$,W?*\$B'>9&+5?&)6^L_@RY3_Z M%GZCSX6>Q17|9?MWWD-
"U.C0CQ|T^!M ENV|CX6=S=&K=OOK8_*&%6VERO! M8>5:_C|DX):7MC/^N/MF?_0|02P,\$% @ 281\$6HX>T0,(P
R0@_M !@ !X;"|W;W)K|C| M8B*Q9C3H>W7R=WEQ_M'@_OKI;D6GY#VYGX|)R=M3V:PG-RE MHE0TGZN^K9'\$Z-
G)IM?>NE?O2|C2,Z|)YX1S_*EQ31R|/W70;_3>#X#6# MX%5Z_A&J|8;
<&EJ(A;D(MIGC#*R40H5JVU\A.9TA)7W\|VJ5VT^YM=N&% M*F@ " PNWF0*Y BM^|):-G
|MQO^3V,XP^,TP^\$^|Q|>U(L&S@7!!PZ0:_7MU?;C@ZCO*|O-\$|I\$%#&CQ).N1X^N LU:PT M2429Z^=P@T,0+ _#W:-
N"NEXI|=C0AD_2CD26X2K"O9P\G)&"2K*BO 1R@IMH M+CBG4I\$"\&A-<;^=MJ&'AR.|Q_U4Q
YTUs!'KX"NT!2AI4Z%9|A7L'7K:W\$ MM7BTS1,ZE|>^F%H)|R/W+0:2QT7F^!54^C|Y8(IZO:;NOI^CZ,#(.,
M&T:~>V0"N@U|_7T>_K6B^V.)AY#&+|M9%8R|Y+U0N&9X3'!8 MZYQW*ND7CQJLIQU4)*[7U?YD5U.5IHO3H?
CZOI M0BY%=:96LH!OYJ|<"@T?R^=QM2JEF#6#EOF8^GXX7HJL&%U=-?NRZL+M=9Y
M5LC|TJO6RZ4H_|Z6N7J|)'1YL+7|FAZPOCJXN5>)8/40^~NB_ATWAK998M M95%EJO!*,\9\$3F>>U)9C'7YW1T?
8WZX&[IS?6?VG(YDG4:X?U1|YT76FU|;##)99T;Z*|YTC=@:0<& |090 M

:@6D|G>-^O,| ?P\$GJ'ZFI.7_E!+ M P04 ")A\$1:~??'M,) 3&@ &O 'AL+W=O<9RT32>|RZ1|I|/-S0U\$ M0B)J\$F
!4++>ZZ^_9!4B1MNPZF5P^Q|O+/:EV6=WH2.-=3>^4"J(VZHT_F)4 MA%"_F\$Y|5JA^~HFME<&:I765#/CJ5E-
?.R5SWE25T_G1T=-I);4979|SL_?N M\MPVH=1&O7? "-U4EW?:5*NWF8C0:M0^Z%41Z,'TKR6*_6K" I |J|P|?IIV4 M7%?
*>V-<&IY.;J:O7AU0N|MEYP6=M-K|W69 E"VMOZ,O;_&)T1 JI4F6!)\$C\ M6:MK598D)&K&GF2.NB-
IB_|S*_T'MAVV+17U|;EY#<3%Z|A*Y6LJF#!_L MYB>5| #DE>9DM/?O-G'M7ZPDLL8'6Z7-
T*#2)OZ5MAD/O0W/CQ|8,\$Y|JQW M/(BU?"V#O#QW=B,4A1@8AG?9*,-"K<,FD(7G:/PV"||9WW_W?/YI-E++Q:-
MAU'>3|3'H2;&0N!&.MY)S^|I@R,&Q^L@%|JK4:@W;*|D5A5S#0&URO=9Y\AMR M2SN"O%'0T*X4Z3^&Q2
(Y31DRWRM2%6U7O)YA#5|_5|"+#@8ZS,+V<108Y"< M!YEXTA6LZR0JA<-(0^D+L02##DWLO-6VU!E;#)^K6U V-
(BV9M:3K|D|M17D M"FVRQCF53|1KNS\$?WKS|&&Q3X|I%>X3.PQ)"UUA:-:2?212ZT:%@:V(QH\$=0
MM1,R%I6J%MC^CL.^X/2B"4K(&ED 8X/*82-T4C|@ "^DJN^T41%X/'7 @:OWUL1D:8RL MK
OZ#|ZW3S=67=UJ#EXT(B>?P>%>EHH_36\$36\$' M/NHC8>%B%WX)%?4<)(#)Y',! N W4^ "@FX9,
MR94X(*Z9'V|VP|O%\$:XI99;#@_F;T|:%-TSQ(RI&P@AITJ5LYZ_Z2I"0-K
M30W>1%PQ|Z'<1WW:DG7COEC"+0<-1N@/2=S%J,42%+@:/ "TV&=L^|G:1HJ M,3CM=PGTF??"
9\$@6LT>I5""B=7#Q7&250/3| ^3C|'&OG0UK9W\$8=RP|CDIY^ S:O\!BE?R0R:AY2S@| F| YT&0B^@W*1ZX^
/_&R"RPY7&@ M)?ZO:6VJ|S93LZ82@T 24*22V(|B2)*|!)I9Q(I1@K2X7^W_#X&7#.OOK>T4/V 6VV8?
&&HX\$7\$N6ME@= MB#^|I #>RU|OP&&VCBTW9.^VPYFA^)O8G9V M-IX=GZ'CA)?|S2'I!6 WPQ""@_FA>'XR?
GIZ@BTA\$)\$"4QF.00|W &5GL_'9 M_R2YV>GXV?SN?COE_UC?3XH|MSI("B 2:!)8V1/KUI?O)^..X|J_U1IQ_U
M4LQ|,SZ^3E3IE;WZ|)5Q\$_"|1-0"H5/H8\$E\$U1\$H8F@NG:G7|V98G-*|B(B M0K9%&T/|ZYFX+V\&Z8+
<>LX9877*U(CI03IW<8IH;W+FAYA/N2FOV8V|28| MZ#|6VE-%_F_N?U6D;TD^9KPD?|-H;/B?@|UJ|+8 ?

5*2J1*V=)SYT%J!ZAO MJNI2A=@S!%/R ,V.71EN(E.=2\$7ZBU,OE6Y!,R&J#V5-#Q6S4R(ML+W)(U1 MEO62K\$K7
LC=7 EC8EBU)=*N"O@*<)GUMI90XK".=<[QWP&T8-IT)/VW]%(M*59PC.,\ J01X9'4 ,1ABB=)L[+
<_THC5ZKS3#=G)=#5H-1)3>:T#I.D.1" MPUUMCOQ711UF<* T"5&DI-V(X.AX3BTZ:UWK+>9[C;D_JDL@9TJ)2I-
4+YVB M^@ !F&\$:8*F3Q7-5FB^IIXL3)EN790VPAA@0^5YGM"2?GOGS\,X VMD'00W/YUX =[47!>^ SL[?X,/2
91)YICl&QBAC6&6BYZ24..K1WA MH]>T9]IE3970:+R Q0?9!26"">N4KF%*; ;ISDL\$>WA@ M)1/#@=IDQOJTS>^X"U?
L1UQ3QS!U>!GSG2_BG@+,G*G0!L=UR!+:&M@!?!+3 M5>CZT-46\4-!R\$#Q'9+O@FAZ9GG&7AKZK+^)-'.)
@LNJ.G9]T=Y!;/XD MWGM"37T&*K6+A/- " !VT)S0YK"S::XR6+KL(J504H.I>+1J>B(BI8R+"O(F7 M-XE?
D=F4.K\$MHJ&QI46(KQ;(2QG\$@!!ABI -=!N;NNQ1!28-Z E69K/M13Y@@3W6X8/HDKI4-PJZ&MP#H<.LY_&(
M7A7#1#6)E&)X) _LN>J>I_B_I*P0;Z.8("CWXYWMEW3IM?/*[B1?|N>?RYY!>X
M@#*L5\$ML/9H.OT!) _P31/P2;_W7_@L;@JWX8Z') (X6X/W2HJE/7^B IG>@ MR_!4\$!#!!0 (\$F\$1%K<6.DKL@\\ \$XS 9
>@PO=VJR(W-H965T M+OD)+7^3G:G MT^D#1\$2&EZT &G'^^OI(G0.0!&E)EK;OO0ACBI P;E^YP+J17UNOMJE4H7X
MEB:92;.W+(K5RZ.C&R15\$FT_7ZD.WQSD'H";AWBR*Z,DC/>E"9'P'\@Y"B5
M.MM[^YH NS9O7^=ED>A,71MARS25YN&=2O+[-WO17O7!C5XL" K@Z.WKE5RH
M6U5\65T;O#NJFF;S@%ZWN;?!:D"33//I*;SL MWNP-B"&5J+@@"A+ _W:D+E21\$"&S\YFGNU4?2OO!U1?
TGEAVR3*55%WGRJYX5 MRS=IiWMBIN:R3(J;_YGY>4Y)GIQGE^*^I=VO%0D3\2E+?+4;P8'J<I<_ *;
MUT.PX72P8K.'R+*#W*F]MS_&\$)T, M7FUA<%PS.-Y&_4PT9I)7]S7=WJFLID55YGX24U-B6 6(I;^<4\42R4N\GOE
MLX#5L M:3Q0*[YF 38+RJR^B/K#05\|L+:46EH7T%:80^AAE3*RQR"=(%EF)WL/\8>!=*BMZI MF&THBZ0%=,*?
305G8 M MS3QVPO8NEZ^6!UK&5FX:(R@;=^~L!&L9^#B@&IF'_3FDH!1,02TD+4 D@7\ :%9",&
M_9)N#K:6I<,*&!^N.C="A6J2(R?<2JP>PO\$TQ6PM\^WE10M83QU*.LE"
MF06"%GF7_#9D>+P.C2WGLXI<+BA(>W"Y\$!QVFAA>+W LEQOCHGZQV+J0VA? M'XCI0|LCER80%TLX M1G
8VZ3#DWR.RKY4D%\$;)YR^J2[I4SFM)C8K1; 7/\$2@ (OUH>5D M0X&T*"N\$%/N\$X)2:0J>KUG(U
2::SE>Z)+ENH3>9;6LR%XG/2I+G|V^+;)U= M ?; M2\2UJ?"B%?B.TY\|Q: ^CG;9J, % M6^QB:X.U%8YX?|;/UB0N772T 2?
@A#)"JGJGALUU@WTOT"6I1K7?QB=-P? MMHL,2=+\$D&D2V*|3UFJEYOQ#8;RIR",@@SK.*S2\$0P?9G6GCPUQ
&>Y'O< M'T1;^:9ZV;9I=,0/FZ|=V>F,#BM>.UW;;YS.=JN1E%_9GE1^<+3KA "MO-& MUS'4I;G|<^IEH ;7/@%GN(99+
(7? YJ2PB<|;AJ\$;5<%EDW/0(9V7"RK.#?# MG?LCN2(%<>W@4.XTY*M2P?%SOI3QLJ7V." \3:(Q186#CEL#PY3E->
(002UP^M:P5;<[E;_#0>W6G8)EN%\$=#?!?^V^VJ7@K*2^BFC3U39E84\WLH;ZKVVYFV M:
O;Q2/2@|QYW4H_5|7UD5E4-#067\$ZGE6>)|@PG%* MB67F6P9'K>=+Y4/9 NC#MW7C^!COW!V@#-4_7 W:-
_5718C;./0PTD _FG0 MTI4WB(0"BF6\|D(C1MD&W6!II'.|LKVKF>--^LO&J!T^!|J.IKTSTZ*#(Z M#9(X/%O)?
@1^GOJZ C=58;\$;#3>_GL8E'.R78A^ZJ"\$:O\$ZM=C/5E13 Q MRU=%4=M;/9'CC\$O#0-
!5PI;Q54J9^I1Z_04+Z\$]MS\$0.@Z=IWUI U9V:&8! MK0D!E\1S;ANAL!'*.MG0%+%E>E)D\$2H9;K'\5&:4X^1
MT+B%;0M2CH&*I>|/B#A-RV0AFV_IM/ 8T'IV:MTY4VXV<_5#_X=Y\O.3NE'? M5IIDT14.#88G3,8KS99VY9R'&I%FJL0-
Q8/K*DE9R+3N9*IV(1U*5S;8&IQ& MO'I%""#3L6D8K%VC5+C7!?!48DI!2PG3UX*?Y|J?)R?:IT72^C M9W63
1%U=J=LP4,.LG\|K?+|B>@7+|3Q!'\F WIU1NTQDI_URGV?WV4C=@/5I(8S2+^IN%)>2I9=:S0,B5_Y@.B(M?
9_Q+BZOZAJG#0:HX7!>_<.GO,F"GP:@/|@I2Y;%5N?+?>74W#|W2._)JIF^& M>|SE?O+<&.+JOU245W?\$8N2G) F
M6*B\I)1LIC+&A4I(A\$G M6*BA6MFEA;YL+4YY8#M3I4BWE@S+Y?3? M-
RA:PCOGCH+|7XGDU)5I2GS|B|Z"TGK^3!W|6 4ZC!S6 +T&E\$1A%4FLS6 MP|=,UP7P >0-
;V|J.C+^1H\$|B3UVT=5.KY8N9ER,R:GR1;?-X*5Y*';NM\$7 MEF7RCK|!WI;|>^00TC:D265&XJKF,I?<
12#K5<|Y%\$&O*/#)PVOG? "96!K# M>I-17F9<|I# 2N= KK^IY.H?">X@2- _L%CPWK>X,17AE6EJ5/LUEY>9TA>R|
MLC6>%117|2K;*EYZ| W"8UKR+)_8_#00IWR%&3-?3IA:C^I 3N,\$\+U.-F1LJ65#WP\$,EQW).L\$^>YZ!#@\<
MFI:1\1#XZ%RJPBDW8WGD)=Q2CNI&H,8E5_&F1JS63.DW-FUK\|H| MYN O=2HE\$;+IX""E9=#M18'?90V4POL4
UJ=X\&GURZO.<4GBBYP>A7"!\ MTZF3H'F.PF^Q.QJ<+B@2GI'YX.\$C/G|^4%&AAQ*JRA+_S@|A1,<'SQ@0_@ \$9
MMO/6| ^BC"N38A#B!\$U _;.KZN4X)D9-W*%)@R&I2+>C>""D\$QI+@4) M/NLGEI|LQBO):BI>28A?1W7LB7O>^L+
|U;B;/?ZE>J6M:W2I52J;+IUA. M7\$E7I9"59B\4'T _FT.;-J^1\$|FN<:|L0\$6NZ+KFD-)C38W/L#@0T78.C M6*L?
^"KYJ292TI9Y2S"#;|OYZ'&HAA.B3#61MQ.3U2C"S5E X+KS&[NL,\$)F^WD6LI/..MID*PIG+R." -;H J(M\|
|I/5&-2"NG7;W,\$4(/!&IO>=0VP^K+0I6;E>) MID-%H|IM'I6H/.NOM+-F M3I'C;@\$!NR6UTI63KTM
W8H%S.WU48"">3Q287=A5O)NIZ3';3B""KG2Z3FO\^?+V"\$
M>8/UCR^V78\EQ=J2!82/:#;_.\$@K>/X6|326*%V5/ITLUZHXG@QBH)1_1K: MVR+ >*/&) \MA5OJB)^E\U+M<I-
'\4_8AI2%?LE! M828<3|WJ#^M?RQR|GXCT2QWOS1!<|2@T6.BYM@ZZ\$^_JUP94KTIA7_8F*; M%T6>\LNE0@UN:
&G^>HO_P;J#^&^ULU5C;;MLX\$T15 MP@V*!%I;M72T|-R"WH@6V;9"DNU@L%@M&HE,B%*F2E-
W\ _6FXDD2SV='@)H_35">"?S.V=I.L MK EZ:@WQ(55I)<=^GOG.FR M2PTI4^(/7MKYT6 R(6;T4;8*
|7P%I _LOKE#N/UEZV20FO|'L;AQ6%R3:%N%6(G=U^(V?E.;7T^%"K)=\$H#6BX<*XZ;3".2TS*M=7P
M*P<|>WQ!M>3RSI!+ILF9JBJ(U/6<:G8XL@"/OJ.BA3KU4\$6J"|@FGY2TJZ6\NOAX00K)K0E:3%5C
MXX+;@FD+_17CX=JP+!@T1. M+|I;G+|VJ?KDD7_T'O(2""Y #F0J*;R >D0Y0<&D|&11SYM+G6R\$S\$WI M4NQI-V;;RY>-
|L.(#[D|J#7\$%)D%2.I;:&QVR6T&T36\9I^JJEVO. UM0AI M6 '8EC.(SRTK: -^EWP!|A)%'ISW""&513;.&,<-V0)PF?I
:ZFQ8/+CZ. M+*6"5*\QMK'72.! 7QE5>S2_6N\$)#_EBMD.0=,3V?;\$B%\$Y2X\K"O:/C)# M4I'FS U- \.)P1W _G*OAE|
(1BVDYM/Y%*K.TTKP;.. MLJ"B: 2U+4LWV7-B,8O.,37P#'|\$+Y4+"Y)'DO"9C/V2""O>0_NW8<6 R4" M6ET%.3HP
0S9#;@H(D6BO<%D/R02TA-SI8925&W6PO402NXPYL2Y@ :88 M
(*GD4.A+GK/>L(SMKJ,P'D62,N5QNU6+;YB,^8>?H:\$D2A!8%=H|L9|UO 0
M#??"=1L)GRKDQR;:LOZL5UK573C7I)P*"-KDMQ 1T1IJ%MP|)P'29C *DG2(|R6&51\$F1I"/&7
MJ*8A""C'(2|84DS;U+J1(I> |9I\$(VC/5A,@CR=P"+*@FF>|;W>0&JA@|TV M/OI B0^,"CNO&W'6@0YWZD ;TCB- FB-
"9). |"<\$K2:1YDXXS|QHS9)Y=; MVMOKG'R?|(|QS(CIHKW\$P :#/S#Z9(" ^9L=;LM.;LN."F\$ 727;>C;Q?N<%) M6>ZC?
S|?SBLE'Z>K/PY8CLCM&(R4U"\$FD1A_BP"O8WRN8T+RL5+|J;3*.) MYTPJ>,-P4?"%INQ4M>\$0-1J%O\!AQS8/N|?
8EFRTK2N X;:WS=*5P'H;G?NVP>^0.\|1(^J?IYY43_U7A M4=Q_F_E\$|1V\A#|9J :#O-L0+3_WN%OK*K=-
X9;9:VJW+.*!Q84 !^GRDH MXO8&^@_AW "U!+ P04 " !A\$1:74^5NJ<, X)@ &0 'AL+W=O MRM>F= MIO8T2?
MPYSY)3AAB04 +2C_OK|G0-PD2PY=M,7FPMPIJN4|H|?&OO9+93R MXFM95.1%WL+|Y=/C8YT2N:|J2R.T^P|+B4
MNM|J?;|/KNWEJ,+CIZ^FM!Z7O""5K>N=RU(DZDOG^GFE \$% MWI
\$4H7*/%&0^>C7JNB(\$ (0XTNDN=>RI(W|ZX;Z3ZPI=)E*IUZ;XD^=^6+ MO?;JD:N9K
O_N|E|I|Z(^)T0O,X7CO^ (VK)V,IT16.V_N!D2E+H* ^77:(?> MAO/AC@UIW)"RW(\$12_E&>GGYW)I;86DUJ-
\$%)J|I(9RNR"D?O.5:C7W^|K4I MX5\GV437A:S<|V/NO3V.(LT7@4;Z0X;HU2\Y5?./&VRE6^3N 8 K52I8U4 MKI)
[*;Y162+&HX%(A^GD^GKC5LL0TQ00H/=A:(TZ>@7OY>):KA!47KRT5E9S MQ=? >3EUWB)"_KM-^T!
|LITV9K&'M'#*WJBIRO|_&)T.G|TC^:25 M?'(?|0?ZY|TQ =OLL_1(&NOKRKO7J|B&T_!T(OU""OE:K'WX3T=GSYQP
MM'MABEQ9)^1R:5J465* ((^24>,QZ(VX7.%N)68A\LCV@1 MLLJ1W-M ^+YMB.\$G-K2BTX;-@#+=?9&
M%2M4,+|8%XS7;&C6\DO^?7?C1Z;OBD1\$=.MYHD|\$.%QH6(C.D,HZ5P)ZJ|Y MBH\$GENB#"UCF:3P!JIG.H/5!D*5R!*LE,
(E:9=K"P,8>J.KK*AS(L:4 M1) ?+RB"K.XHAOC-W2<06_M(DX1'@&?SGB)^+U;QK4T/??1N#H M&P|\$S\$T-
L.V7V)O#09^7O7W?0SI%!DSK;Y6B40P3B5PALH ^R&B>U2.I:|43|P1-
E*8B!G();U&)DYWJ,L%3IC)S,5(>=6<;L>B'K)D- CY(|#*;(=%=7/: MG
&+6%.PRPP79THA!/=|@I6ZPW(68GTEMH^7%C2QJUF>'7Q'>ZBL5 CQ'K0PN
M7BJK3=ZS%>A^RJU-.*928OB\$(T*_2)23N'FKF"#ER93#!R 8,4M\$F"XUK1D,Q&9>|

M+!I9C0C0LF>YUF0/"5I8KQ=#86D4@: C.I2TA6&:H=26)H=@:&6@KLDZKND' MLJ8[P%9U&6IKOSPU\9I7MMFS4A*
+G3H;86(&V4LJ^F@*:J<:4 %@3YDYI-2 MI ,I/OXT!IT%:8WXD!J671%&T\$*7!9.F;-+HKYA,++7+@B\,!(+E0L.
M,"7HW)("&5BFT7Q'KJ#09/@'C,?JCMN?)Q1/>AGVYIK3"TY56I8?#29+B[229 M-,N3\$UYI8.LR4X?^H M&0U9M/B/IJZ
2H@=:SPTZM3#**9 KEY^:Q@P ML?M4UM/(8ONFM:M9^>=0_Z M,=/7M*?> 7P=:7?XS^KJ%Y^T=^O;TVA =I/@?
3I16KB8F<9#:#O*:W7F5Y2 M!&AJP5IJU/&57AD\$59GRM!S+A#<0KH6\$2P>82ZVYW6F M')/J\$ V@7\$E0@.6)@
!%!AIL<&^0W3WL [N:G\$3*)Z2CPN>51NN:2&6I<5 MANM8I#HH:UFI?Q.CKXD:IV-&94\$X<;":P&M38U#*R:)8
K@:CCQ,EM76+84^V3KD1U@R'0ZR>C,(%%Y:34IIX5\ _1@81/3OHO=NN;BOJI046W6X/
MKJ2'SOIU%=:I:L^M>M5M,/OCC\$- P3(R^D\I80LD>I/X;U9H(-3W*.N :71ASE MI+P*NZA#Z-
F*XCABN3LXOIFP[L!Y1KTJ)V1 TX8I0ZPN:XL"K6"*#S44I^8! MXHT.Y#4CB3Z:(Q![:IAHJ_N9M/HO=L^1-R=">/FOP^
M;A-D#>H^"N1NFEF ((3R)@*:H,.\$:30),Z^#V= \$LX^%=8?I2.E6&#H3\D4(M&0SWB@Z(\C4A\KX0F_5N#0/*DL\$1-
^I:4Z.\$3BE;-,-@3@6+PS@V_D7R> M/P 2-)G=5D3>J1+BN1.@:K?LYMS\$-(9@15JVQ 0';*WO_> +\$K/%NA@Z1I
M#I[26'.6]!F3P""EMX:I,J:FWVRI9QT5/E/O/H>+9L"0#1IR%#: V6*=:M M\$&=CHL3BY*NP3*I3P+<;S:IR85O6ME=?
+A-ID(YM\W^LJ!O/BNV:Q+I[E4< MONI2),Y"0MRI0@FM3"=@KCU-:I [!]/%HZQ&B+&-U-[YV683BFWU%=E,^VX
MIG/#_4M90X;=WKR'2=>JMRP:)U%*)@4!U6*S-:.#<.:!1),8CT)-":KV^M% A MAL&I@I6;I EZPS :I\!X.-
LWAV>LNG"US:I% ^K(5MS\$VIO@("5_)J(7W)=Z)
MF@[B=\$I1:6H'4NIPZ:XSE%Z\$_M:6N'#_)W\ P_J=+SY5,7SAVW_+"HD?C_A MQ?G9A=@7Z45R,<*S\XLI)IA!?
Z:GX.3:PDXLS,3I+3B_P @0CW7ER=B+^" 0/ MQF=GAR(I3\
/I/Q<'HXN*05D[\XB=C9TKSBC2=8,59D@ZQ>HCK49J<#==DNFN; M<I" 5+PR'5P,4Y)J2P^F"X\Y290X6'?
#K36;T^>X" _B_%2;:KJ[CH': M8^858H8/YV)'Y^TR+X\$CZ5L9=Y1X)A8/U.X)E30>BN/5_FC8/_9U**>6*M!1
MDQW9@/@ZK^&R6JA[KICINIZ'^<6"E?1?\$/&F?TR53"/VJ062(F;]>I_8H.8UF MYG1PHULSTL=
(2=:>L;JW'+D#EH4NRK96LGDPU*^0 //*&462@=8(S,>*/(MR768HIY^55E-ZCOZ5'>5>4,^AULF;6)R<>?*>@OIPFF
_N7P;A0\$P,T?& ;JP%:PF-+D9O;*F3. @)B+M3-(\X#M\NZ26QG!HZ7X=X[4>LC3\$' M8'8V"Y5"ZI*3D69(P=;?X[-]&).
[6P9B7> K9FIU2%NKU3B6;!PI0 \$IN) M7I4(>I'E#4VJFC(HE[B/JY:IHKS<*Q;_IZ M.86CFS.-
'1OHTXNNPNDICW+T"2C+C,T98I8EUUB-Z9?PO+)E&VP!,^ZL8+TS MFEY1Y5:X^2'1J7O?A-%09%V-
D!U,^P=0C4LR=L^)\U2N/%FR;\-FAKO3D#9"FZ[9A78MD+Q\N+BYDF::URI(GRDFS7W^?0TJR9,M.TB6IP\$4*M)5%
MZO#P\+P\#RF|NBG*SVHN9<6^++)+,T/SEI|>Y_*LU?%JLK27'XJF5HM%G%Y^T9F
MQ[6,9]*5K/N/Y7X==Q*E:0+F:NTR%DIUZ/SNV3 M-R[UQU^2^6-ZEPSFLEX*#
[3C >3UP<6*20SF50D(<9_U_) "9AD)@AI UC(/ MVB'IP>YU(V=GCOF,HZ5O"BRW[-
)-7I]I\$|ZPB9S&JZRZ+&Y^D/5V\)*7%)G2 M_[C(T)>)#EBR4E6QJ!^&!HLT- '7VH|=!X(K1T/./4#CM;;#*2U?!M7)=FK
MLKAA)?6&-+K04I5/0IDTIT6YJDJTIGBN.KN2,YBX8F13E62%6I52O3JNOB: MCY-:R!LCQ-
DAQ';8AR*OYHI|ET_DI" _@&I|JU:CF-6F^MK*H23O'OH?D::>ZP- J4\$I6,\$_GZ_)&@ M9'DM#Z^<;VK=,INKJMKNX^Z?
==D@<+8;_);LH%LLXO_WVF|"Q@U/%\$-UE MK VBS!.*:R^?,(3.'(JGE6(7'I|^X*S"XY\@)YV0X#B?L(MY*I?LNRIR65%L
ML8_3:9K(DC-Y'6>KN,*8I-!XI:"=4OJ9..N*1#=#!5+\$JXD1XU*R6+%/I@<8; M=<)&Z2%#!EE".QIK(2=I\$F<<I|&0Q6-
|A|45*VYRQ>P(4_3HL1T2=\$9-%2LQZ1I|F0H MOSJ|OT=N_J?_?
B;_FV?'G(I\$1&\$SHHXIDD.KV.OYD&K1SJI\VCN&QIOG M-CHCKJ\$@:9TD13F)\T0B#51S=GYUP9S0XFS;?
I_&:%KEUG!&T79FNG5S,GJ0 MO,A?#NAO:#B/L?IC*7.F0R&OC.O\$+"D68STON%.JI'PP0I+ISX7VC\$+_N.BN
MT;LTQ^33.&-7%6Z88>98U#0WVI*!5KDVP!))2D\$%5,MJ%4KULN+&_%"&ZB:
M%TK"T"HIT|&QF+)&XJW26IW#E&&8\7X_XJ1EQI*29!7..Z^5&A'2\ M'D&EZR4M9!M-RY*"K;IEYY,_D-
AQ\^>|XIZOQ@.M;+N,\$XCK2I.)C\$Z("D MW#5"D58K0I\Z)-\$X7668HZG75/C&MU0|=1G\$(H\NT4S5D?J!|8)0'Y!I=>R
MY:)>7#(E^J|\$CKA-IFMG09&E9F64;\|"8%B11UJU%XVZ\|Q3|B3>8:4QW(C
M:FFJ)1D)5V1AC)HA(N3%);6(2'6,S%":K:/7IR5F:D:92FA1#"3DU>06_9@74 MR'7TS\$HR4V?RDMG\$[ZH
X(8R2UL9M^RE3OM3TS)I79#I6 +&E6S;NK5J MW)K%"W(KQ?1\$)|8M<|EJ-T+25H<;5I-
9BE31YE4YG6)1=0I0*2A\|9+J@+87 MS7YIN>(OXP7H!/?2^64\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';45M"[N9)Q452:IKI.0:>6=Z&AOZ>RC
M8ZR8OJ0<;IJ.4 CREVJG|K.CJ)\L.N DM# A"@@73+M\8Y@KS=K:T6RS)% MZ*>9KFUK>>NY4@:B%4AB-
3>#TH7?#Z=A\5A#M./9+0871_-L6SQ?YH|E\>W(W\#E<-_SN!_8I >L3S5?ROCS=B;<#Z#I8SHNMUP;8)H'0FC4;#NG
MSI4""R*D/LA?N/Q(!IUQR\$9YV\^V]+M4\$2'I-6F49/I\$9R&=,JPZ3Y+\$5 HZ?)0:8CF9\$36EK%):E<%SA*"-6>
M0BG1GIAD<;K8R@&MLXQ7%?)&5><I.3%K05JG"+ND(GT GJ3NC!DO5GD*&V/P M_OIH\$V\|1):LC*>@
COM4I+8L%ZF;]>P93FM<1Z#X:_FI.S0ZMM8?L*"5RU MHPM"+5XNLUMRCZ%!M%4SJCNR5/-
T2;&=D'/I#;OCB|9IL6D3ID7@Q>E4CR M.KQJ'U6UR'UJ_P^4/F(?XASWM8<#\$V3I7QB,
(.2PGE3R4&R5,JFCGCCWD+! MR12IADNB2&_1CNA-E.*OY.4/3>\$';

<6V9J#4#?(?<191&G%P69:L+3,F6Q MD0DM,Y*7+#+HNA)L0IGD\$S240\$X/\$;1A? .IZ'+BWN*4+RNM7P!<@"/Y&M@M*8\$)(B&>Z6(T0E*4 /X&C*!+ZH.:(S!P*;*6BS;1FE,Z086 MNC5[F[T2"(T3/9/@8+!-;\$28R3ZQ#Q"TMDDZ)=?@M?C#:*<3VOXTMFWK;24) M)<14YZ)\$1\$>YN!,YC\$!;H+45#;;<@B|+NR>XA5 Y06=L,\$07<)&BI0D!|Y MM=)6LX* (JOV96J,L4JZKG1;N *;>UOHE,6T+*%L &7\$G\$&L"V4+(\$-?Y4_80,M ^,U#,Z9H1'\^N.R=P\X9C- GSLZ908A\$ =)+!#&Q>.\$R;8@08<^T%G\$)\$&J!|AJ4^1Y3D@70A?|/LYS%LC) M^?D^K^G_5,L(?4JZMD& MF6K#SGG MK)C?T^N5=Q*QV7H^CM#(XS:@Y4 "T/"..)U@B2T M+24Q+W2#T.H%Z\$01/3\$A2T55BW"U9.6EQ1ND5,&J1@GYJ*F4XJ>S)? MUE6!V*Q.,=EFF+[3N@\$IN19;|S"HY! (5?)>*3M)KIU#C6N;.=R77H?)2*;A+ MNFIQEY/7-3^R"MF-ITC-? "ZLAC\$G7%ES*,<841-?|^HW'/TBE/|Y"_"2>+ M.,+C;SM5-A6A/K"%8; FK2PYM0FD7D|MIC2?J-O=)H (H%AC5-6S;!0>&18 M&70JWW9L>UON|ITU|7GINXWTVXXZX1;#+FKN2J:X:=RZNZVM 2^(IHND+S ME\7U BM! 04HLG-SOS=? T4==NY*)*PK00>SSW&# 386_P\$|V M=QX(5:OY*?B'1)SXD(C;/U>G^TH181_7F&..<%5JMK21@7OP+A:(%!D55,H M\$J|0WY+3@H85;./R13<_55&A@+5+;F?790T"X1=)%B M83/^> M%- WG2_*6%R=47LX<*PP|=15Z2,W7JAV8>588^/ZA&'A,Z35-SHJ&6JTPD| MO=>WDC@V|#P75= [KKG<9'.I9QJL.=7!H3&6L9SE!9,X,+ =872LAV%80)^:\ MO*.\$? 5:8>/3I6Z\$=X"*P(C(TZ|Y6@J|%)|@+\$+%"..0YX\$TF'3PB5.Z@&/(M ^F.CF-SDKZKZE,O+_2_MA, (L&HWB^83SC7VJ_)PZO";^OM)^;R:I H^*ZETKN0'6R\$"-042Z%,4^F:W0 <%UP*%,4+1| M/ZLP=5A'KI5FP#S\$QV#@R? E"S: '\$US,(B3H#[55&Y<@@A^91\$S\$N0\$/OT5_MZ(^/,>^KAT<|W=^L^1U'Z'/8;"/,1|:Y"CO|A8|N^ ^QG2.\$\$WJ6"W9Q%40X68U; @=YT!|3&RCUZ8A? M^\$L\$QX_I L*/Z2^_\,+0L!|'(8M1VX71<9*T;.8<->WQ?6)/4TE6^EM2F24 MR0/PI;HK:%L=G<0H|ORCFU)=RE'F|3YIM1|J(C497&V\$M9%2)7|?&KM%#RNJ;W M\$N/BV^07FCM/23A5;<\$T%AS? S8D_MK60NZ'#R:|X^PTY|^WIF?%AC;C@_9PBB'* MR&4W)%\$ AP,)|V(O8J,R|0_71|:?\$W!/-W!- B|@F8ZSK4)>|80P%_J>+0D7YX MK P:#SVJC4|LUS^>S_)B1Y9D!R7|IHJ|H&#LJ7!_..|?_8S^FIN+^_/WQ7=^FG!|U8+_T!4FT9BR2*/I MNW@CZ(|M>2#I;H+8%0"!0_YIE-&\$O|I_/F'YK|9%ER|&6;7M|B(4Z>- V2 MN7KAAW:D+1KK_ZE%|Y/;LUJY|!M I>:#=/U>6 MZGKN."V\$XQ_3LJ6>P\$%MHDYWGXYN_# OG9G)FQ!\SC.:^)^L6 #\$.?U7J!/U M8=|/&#MBW><,->G8|NP=@1==_55<|8'9E96Q_&BZJ5&A:4+2(-#%|M2W| MTMAZ^-:8;JP0CC+D(M, J^85M^C^);"Q YVF&M>5=|+X\$^&(JJ) S-:\$G MSU:M?&:::?? XYW9B709+J|=Q335X+ZKWK9R6G=8FZ\$)"SF+J%Q87@U^_J A(C MO_&AY KKT#^\$Z>_V/R.ZU+^>V2_70T'Z2? 7WDA5A:WV(@K.6*U_ UZ..--56 M_99F635-M5&7:XZZKZ8%>+ZJD\$'-%SJ@_W'5R_!4\$|L#!0 (\$F\$1%|HJ M\$DY9XP4 *X/ 9 >&PO=V|R:W-H965TD+1=+!;|P\$ATS%8259)RDG|I'E*VXSJV MT_:(N6YGC,S% (INE/YJID)8NJVKOAP/IM:VA\A*::BYN9 M:+|/O.E:VZQ MU==#TVK|2Z|45|-P-\$J'-9?-X.3(O_N@3XY49RO9B ^:3%?77- ^=B4K=' ^" MP>+&A;R>6O=B>' +4FMO*>RG|H/&;KBT4L1-:\$JAK28' L.@_SV,E|@<|2 MW)B5-;E,KI3ZZC:OR^/!R 4D*E%89X'C,1/GHJJ<(83Q:6YSL'3I%%?7" ^NO M2.|(Y8H;<:Z|OV5II>#?\$"EF/"NLA?JYD\QSR=Q|@I5&?|+|JUL' VHZ(Q5_M|5P9\$=2RZ9_=HI#BD(^VJ(0SA5"W?OR?\$Y@EM^/:GLVK820-GRBLZYF=(K|S2OFYYO '701 MKV7|LGI6Z- 3*V,U* N:_3=GWMN/-MET'7'9J6%^X@#8Q0L_X\$3IDR =/=!-H M>;R/_YE_3?YVFES<|2/_Z*/4T\$35>&U*;* D|JM*4Q53);"H,M7| NG/W'Z M"W*?>_Y6E(1LCM@T'Z1M\$^>H K@Q(VS,\$DI25D>CRD.V"A.>U"1201. MO%:=*SW9%>57>F6 (Z@6W'3:I^M2J+ 55\$E^)^2M|I|P|)K1&WN#_ VLH%#B8 M9>X1YSD%(40&8^PN>%>=N +)AO5//,PRF:&8)T=\$\$(3V?"F#LW:.65PCA@ M"^U#0'@7|S\1-P;88B- NBREOKH6/J,\$T7H|4BXL;Y&75PX"#A,5)1A\$;)P&! MC"2FTZ+0'^<0+U: 5NWZ&%\H HB!*699F% (P2EF0@(_M9&J;T#I\$@F3Z7&@5M M::)516%T9E0ER|JRD#4*%5\$@+I33*(J|SN:BLKCSAOJFGL-1/%%@4N: 3QP M04^?Y&\$0/J?Q.%|N+X3%\$>AY>T)7A.B1E 5Q\,9)0YD M2-|7VWR"E 2:I32M,G+!&2JO(B0+2A:QW7O)|I%8.8OR\0.? IQ?UQNYKG*?T5 M^7*0F\$7GG;6P*5SVA\."&0Y#P\$&ZD&+5FGK\$4'S&GQF.*K\$4!6S/I:|!&#P MWCF/ARZ %Q_*NF3I;L+_.RR6L@<;QV|_386A8Z4 57-'S<:9N|)%6QS|EC^ M"ZWL@70|RL@* (&M='X+/'KD>>|F7R,/:#&>N|S\$MTL|>+6*";A+!|Q17N W MB=J|/=|8H"^VU,I'Y0@|\$|>R::S*A.X0Q6"? (:6\$_8|DHVZ*8)FR,T^UB#9LDP"3(*8E9/@HIB?R9LHV3C<+GO"\$ MBV/, '(988=#E4>R+>F!9'#R6U\$9- 'OQ|LC\64C'+\$26N'|J;O, '*:IV)YB|*:(?W5=9?YU: MOEU>1D_|.|B|>^'3?_R<*|I|XOPLK^@G_P-02P,\$% @ 281\$6K(%/RZL#P=#< !D M IX;"|W:W)K&ULY5MIC|LV\$O|JQ%Y:I **U_+; MS0/8;% (T1:8)LFGNCV/A0\$NTS8LDNB2USO;3W\R0DBA9=I(VZ+5W!=*U)6HX MS|*#_>* W!; (6P|&.>%>):V=:;W7>7ER;9BIR;@=J) NZLEJMD|LQ|O-3)GG7-_ \$YG:/SF+SZH+ M;^5F:_"Y=/. |X1M+^>O'NCX=ME3265N2B,5 7380WD|K^<|MD\$U_| |U+L M3?"9H20KI3|@EY? ID|A,B0RD5BDP.'/G;@668:\$(U/|,VS>DM|/Q<4?^> M9 =95MR(G;Y7|7:9V^ ^1L<<92L>9E9M^J_0_"RS-%>HG*#|V? [=W:,2Q,2F-5 M|A\&#G)9N+ \H|=#\,!B>.2!D7|@1'R|C8C+Y|SRIX^UVC-.JX\$?:B!1Z6E@ M3A9HE%NKX:Z\$Y^S3|UQ+OLH\$>UE8H86Q|\$5AI97"/+ZT0!|772:>UC-'W2\$ M5COB- ZJP6P,T4I&V"5P"8S5WHX|J9Z,3%)^+9,#&<<1&P|'D!+UQ+>V8Z(V_M6%KVCZN5L1J_KMW^+9|- \$)IB9(7?>_LD|FT(H6_?'4S:>|9XAX&0MRR+3=L MH^Z\$+O#IG59W\$B' N+M<"|IO7184USQCXI=2WO%,%):I=4!_QI4MA#9;N1NP M=PV/*NRU,#"7.0K=Y_)2G19M.6+\$\$A@L9,RYP7? (%ON4=RONQI\$%|^%3JO! M_ W++ /L,CO@7SIA(Y9*DVBI+S+OE"02-ALA'F6F7E-_M.HA_'\$;BMS+UMIK MP)Z)A)? &Z;-0A:>3(7^5/9_08J6(QJOA-D&\L+1\$90&@<QY026&L',1*W| M'V3RX2'@NK)|0&6W^)^5XB)C2K=6H?)G(G?!.BIX-KO Z306P"; &UB+K'K@6 M9^>|2POFA9+T):=.P0\$3\$DOE-I5*")6L ?KJ6/ 9@G_GU%U%NJUS!=8W8 M%:BVE2C\$&BFLMEZ8E!@KROBH-F-08(N*"35C'&6'= MQ2KTT1R5WCIZ0NI668CO@ (WT")\$(% T@ (MBYT|)%CRONMFP-A4>/T;4@!(3 MJMV69VATB%A8_7;9R7JW'M<^ BL+8O6)5'A*T)! "213=|2|!0|I*Q@|?*S M! H.,&_M|I7ED%B=0!6)=N:")#=_ 4(@|AR+F'8':ONI)=+)_*W!W M=@2|)%I-L3ICL|X#^_C3_+^67RW4T0 M3-)BX"!DG@>@>'ZE04B+8I\$JX)X(|I39@-6P_>*|&TC72PF/<8_ \$Q\$30+X\$)OUL94'EN'\(7+LKK&/P< ME|QZ=1W8F/3QDQ#IEN?L%7YYPW4B,O:C^ \#G5|@37-0HU^LKTA4\$A6(D1:(V M5=F=J/RDI=5|0^>O|4#=#JL|9<""6=C:E_T5_:'CHNTSU)|H^&C|CYT,7YT MT10U*R\$*)E,,_K4D+.E); |4I#N5TL\$P7K\$+/H+BUF9KJ-I-G%"?M=#P.M?'I MQ(W)O90^ZVIE Y&@P3|^%R?-\$.SWH.4%<;\$D,TH? 1AKKIFLAP"YF)P%|J?+: M0L:&?P&M)7_ "58^ C^IHXA%QU'VZ70SVEB@QCEY7&:0|> ML)D@)5*P0?R40+5)N.#> 9N9XEYP"%5LESZ'R3E/T5A@9(F9*C0V.:U!#-TAE'Z|<.)93/\$:((M|)%ZH3&WN:S^MF^H|)%&I|7W_E_-(Y". |%K<#I|R=O|0|+X1H0WJDL'JDDKS MAUID9_97WLL**CIL,1,T;1F4&HS4:+#6X\$|,"Q&|&'E>Q4A?=(^/13&8% MF&SZ#3D597*2LWD8TO9^*X\$|""BT:.(C:D7=|9JDI0%"? 30Q/!_@_E_W M DG':Q,(|PY_ZN=|#B29_?@DPV@)C\$;0/P!#Q)HV^R M>*>:=HYC&5\|H-U!T;L|JS#DVV)*&JHJ'@0CZM@'+#K4FLD MX-V6HT^9#U4U9% (/0*C,E6#>YCAK4@&FQ&%L;JJ=-"0P06C\$9UW@(&T+>Q M= +"Y\$K;#0#PQ5//@ ?IMFGRF/7- \N|NZQPF2F=;;X7*>'4#|@ ^O5*0.6X| M+=@;M*!=(WV.FY'AH&@76CO+ 3|!#Q|3<?"YDXNZ.>4,PP\9YJLS.^KN_0H MZH?% AXN>N9|UT5345.^1N|R123G+*%|T<@&| M'+R88H;X"30)1%,KA?%W= M?"|@=|U;5=#08 MJ03%@@%DIT1Y6Z|8FW;+|=HFH6+ #TSVJ'*%54WQ'NZ?)*,(U)G-\$.XIX(# MRFG@Q%Q1R|V|GXGV!4R|I|>.>.9> (7,O:N: |6NN|3VJY2I78%UV'E_TM8%| M9=)KRGY.+1%45Y8|8/\$T6L338UWCRW8V)X=+|I ^!CWN=(^Z6\6;| ?=Y_M)\$A?J=9OIWJ0Y"9B09E:Z8<|_8_138GE9MB<7IE>GSR<:6*#I&\$X5!LN" P> MU<+GBDC:V+>KRL74VREY@F?,%YF Q:LRXL M?>|>DSHI:YZ|^<9O49JL6TJ_V#\$'076H'8%RL5*GAY15U|>E)|@-@HTR@)D)DC50 : MLJ= J;"A:@PP^!PH|0*"L%P2@|8ITJ-"S:;_I_WE8._CRCR^F<;T_B;H_.. MM!H*|YQL|\$EYS,>SF'

P*DD&VK(ZA>GJ?^K"C:Kl:Rl! MAJ=ZH\ZF?I#,.7l;@F.3Q:IFJ\$XVOL98\$/75S/IZ!X1!9=T6O!>2)C.GU;2!
MBC,\$Z#TN(B8)FOT"1N#.!AEUQ^:.SSSB) G+&9ZM^Z=Q51SS8:A@/#=G/IIL5+S\$Q?&'31Z:B+/AUV5^6F!%(0=8O?
\$G7!*:2H1UWM63R M#PFQ@XIO*T6:#47Y"1:B1_ J6AK2?9;X^TY>#F0>&?8T:*1769*.
MQX^GP_WODWYZPX<6&8%CKYJC"C.9/X"-O_B4568LQNA-WA6G3:C7S?L MSMU;VX,?,EIS:H
IILIPUZ^ECE37,2!FPL3!VVOVY8L!P7!G;.%T!9< MN7OM2U"PWHS+8TWJQ Q)WM8W7SC(3?
5K&%\49^!PMHT*S3P\4I4'2"?88DUF^&C:8\$-* M)UC!8_GLPT)%?,T#'?
#4U\$^M+!;+EV)4% JE(%NIX7D39995>>*5LB!" M:#?O!&
[LO1):GJT/WNPZ\$L1N=ESQ_KGQFWZ5^'6;_ \8(KE@^B!_ 4PG\Q?-WV MOSM,6IY\$0?
@E\$4C=PQ7PEO7,@>MC6U_DIK_Q"II68'E:M0?_4G7(-%5l/*Y? MO@H7X"O6A6*9*J!=[.:?96P3E3YO+\M_O_XI
BV&K(>)Q^!29J7+/\$ (KN?M MZ^-G&X<I!PUWO16?U6A!14N,@W3AL/L!FT2SV3):OA/X/(K&2_@WGP+!OF; MUEL\$P
(0 H0SAL%3\WC\O-O-HLHC=Z<;!5I/Y*!J-1VP\G\$Q?;90!; @&3* M%(\9T*ST8Q9)&D_Y*^-;^BZ/Y='G!SF>S:31?QA?
LIW;4@!B3^3@;+N<@ MQ' 1PTXQG8^XVPAC;3H=1H01DD S'CWZ?83RV[PXJ;Q/I! MYVP;+8 @/#-HOBQ2):C+W'H
JF" 8J\=W0N-\$FH?'&P81XOE%#Y56KIU MK[IJ5!1TT"CK^@?B*)["TF%<+IQI'0&/P+WFOQF+Y-
H.9^\$2FA%\$DJPG\$;C M>_IBH+>8L%=453<_R8B78I+S+Q-\$EV*3H2&;I8TLL:C:31; M+-AT0CI_7IVW:QRC0(D-
#CL&I4P6P-#,JS)\G4X0H>=HC!4V)9.OI:N8J_M\J+53OZ7=5*6:MR^K@5/I4:%#IM0*3^2^X0?U#NZ?_5l+ P04 " !)
MA\$1:=EI#7OL# 4'0 &0 'AL+W=OBG(+;DI,D2VT"2KM@^! B2=,4PI_MG24B%*F1)SOYIITC M9=7IS@,;
(\$A\N7ONGGLA-=V_Q0:1(+GUMBPR!JB[F(R"66#K0K'KD/+_VOG M6T4!I?
4D=!Y5%95;_RFFT^35FF;+>=Q!>0A!VRK_085KE5OZ-YM?!\SZG@EYU>)I/B"V(W*0.3
M0^C_4/_ 'PU>;0+;=.NEUW%;X1M@ZQG\$9R_UGD\$0JLLA2/@X(UG9>A!IVYL.@XG4(NM5& M<=?
U@5F\$D%I8QWRQA;T9"PMV4"U"C:I\YJLTAP-K)A+=:=0&1T_LG74M"ZQ1
M4<I8VU%?'[TIH)2I4R3X32;6&FCZ45;^_6\$9+U8)+TRB6"*U!\$[4]J^TK9F M12?JK\>@R7PUVC,OQUVPC^'Q!Y PZA-
"ZZR6 M8;,&^+Z 'K%\$5.F^9/YSRMG=.%C*L0)("=XVR19N_+0ZD>C+(VGIF1E%H9 MA,ZIC:ZBI^DV2 =SK?S _9_5?
I9ONAWCZ7IA5OM9<4P;7K#H!N;UJ<I.\$W(M=?>6SGB6S0.&_YM02"O+I\W W#1 R,/T++[U!+ P04 " !)A\$1:96O!
MV6T\$ #! '0 &0 'AL+W=O4K'J(DI\WX M@WF4IAI>J_T@ZD +/O>U-) <>I6U!<5;HH*&FYFJ@6);[9*-ISB5N_F MIM7 2V?
4U/H"+)YPX7T-FOW[\$YOUJISM9!PIYGIFH;KPO74;G_IA=[QP6>Q MJRPIF&_6+=_!/=A?VSN-
N_F(4HH&I!%*,@W;2^I]>'&5D+Y3^"I@;R8R(R;Y M4@^T^5A>>@Y!#44EA X+HIP#75-
0.C&MP'3&XDPZE1/_@N".7G!NX5O5O MHK35L;T6 E;WM7VLJK_@.?E/
*51OWS :I;IOXK.B.5/\$ 4[TI1J@5L37L] >YLIJXXI3 MI'Q(Y#0D=0TLI^X<_E\AA5&Q^*K@6A^\$W#>J(I(TN2S9EK
>"I\ZK2F I'/A&%G M0B*^Z@R>:\XO&!8\$-#EB'(N"G<7G),1.N#ZZVS.=D'YIS2?%I:Q2(PF M<1">1>?L)
[8(%WZX"DB*5GX6+U"*PJ6!L%\$^B@M8.HMT!P",WO>,FX,(&%" MB5,_C(+C\$H5^G*Z.R067#XQ217\$-L-)3"N@>7JFE
N_BUO\$6Z!!2F@!\$P;@N MHJ?K%I_!JQT;I^YG2>8'23R1DE7F+S%HO_4>I_D=-)0W#\$)4EE,ZEEXSC(
MS6(2C.4XD7LI!&2I7X2Q+@C*4P2\AL6V/'!G!VXQS,[4 X\OYR4^@%S,7.^I7@1XB'M^E3F?31IELY)\$?LN02HC':?
YO'I^-YGW_0?^AWE^+;KG> M806R&K9H&LP6J<=T?I7H-U:U!O.>*XN7!2=6>#L#30KX?JNP-88-'3#>IS9_ M U!+
P04 " !)A\$1:9BS@9#H(!)&0 &0 'AL+W=OVY&?;)\$ >#=#K!9%HD!%360FOFAFBC3E>GXM\$C6IJ
6UY8T'.9E:NM&Z/_Y1#P*^RW_HG'56FF) M92HR(U7&M!A?U*Z"=I|=6N!6 _G(S)2^_V(R4NJ)+C!%@[4V
1*)B"QIX/AX M%CU(8U%HLO+Q+IH&8? MQ8)/C_1%*C'N/YOYM7TLC@IC5;H0!H)49OZ3ORS\4!(8MG<(A N!T.'VAAS*
M6V!YY;E6,Z9I-;31%T?520.WDKM'SFY!EV)S.>19(G!%-F MK"[@>FO.6Q96:&TK6FB\AK#^1J#D-VKS\$X-^Y#%(JXJ:
'>"F.XQ'@=[M5X M*Z(FZP0-%K;#IAYIG17GCM/7.WRUU^"?OO!DK=%:7N
M/NW_!M_3B/I.A7L1J4YS^:L.!4O):0I756(6ZMG' KF(6,&(^1D8;I.999 M 5I8INGA."DB6W!*5CS-F,E%),D3"10D
MDWICR7B%5HT2,NOU:2PS @6,?;RD7_3+N! S!4*N/ +@D2"9ZA2KF!6IHG MPE!++J'Q106"XUX"6*9L7/
ML8+;3%ER^"(T)9S79X9IB\$UV+BFQH=X;IRH6B^@2ZXHD;_ZF9/VZFY&I2(<);E(8M W") (DPEFD M-"YSE<5>9K?
J.8?GGGE2"/(UW=>0 S&F+3GH=Q%J28#^;+!09<DYG N M\$U2-7K\$&Y5!+L419R?A4ML;YU9LTIH-
ICROO)Q).X6H@IPF92H5!%2H+4: M46-P3-@FDHM=Y5HF6V!!-6J "R"<=C#V6;.0\$FY%3"L5LS.U(6F&S)VRBWC
MFIQLY,3:0F*M(I%-41H708UF2"\$+00=I3G#I%,@G07?M,'CEF6O)1XGP!E.E MI81B*A8CRPSBD!AZSBB3-
NQ@AA)87#(L<7 Q%(1RPBY,BID\$KO<.#5"L#^0 M1"P(ZLYC=V*D"TP3A*)3=5JJ8I2/EL2HGO79IM5-
\,M""56<\$'PIG#H_S5!78@\$7: CBM'_#>>+?>RNX?Y/V4I/Z/T@ZL,UZ_3Z:LXEM0^T'+F
M#0)ZSW4T9:N**D,B:*A+YFI(N(\$ _V&AFB[R#2Z=R_T1.BJUWCTO9!PVSMV M*NMXHL5!T\$M?
=7\T0H8E7_U(+3F5@9M9RVP5U\Z_6/+BP,PXV8#-^\$4-U5 MHD?=4KF"[HJ08MK_Z\$/I2@<53FAAT%X9773UV-
M486!1TSI\;NCIO*G:R^G89W=DM""10J< NC!\$IM\|M%1N5U0)?> D0LJ=N6W MZ00"!,M?4#
[H_1+BJIL*QID/K"G^SAKQG(GIBX7-7OL-9Q)&&_E'G_UV>.#"18I;_WN\$K;O3?0 M.ART6=@8IH)R_:STAT')0MAK.Q-
AL]^&B0 !U%P;NKG_X_-YT C#+OZ?=3H5 MM>OOVY4ZW+N4GC4"J!@VS@:=)?D..^W43IOUY?
6PI!6IZ+1VFKU#WNXVAL,! M<<5;R;.@=;2%H-|Z:Q.GK-.#&IK7,&AT(/I??7N>!^\$
M.P!EKX:F(3.)3I2=HW;.YZO*52T)KA)@P\$"U?!.^4=C-JNUZ_EB^^-92NN^S MW\$ \SF!UXBO5E?
50N@#Q>")',^W5SPMW(RI8V<1%3HJTL(%GXXQ&@ITSI MM8<;<_VHB_HJ2^+PU@_S!E+E+7/_Q%0I!>@4
V*Y>K.=D?^BIV@7&\$IO5 M6.J7NF'T.SN=.IIVE!2Q.+B3RTY\$3LG1M:M=JU2&.^?TUBW=8\$?I/V#7#I+Q
M9HEWC6D*D9\$0&1,OCB/N)',+Y7C_@KQC/A7'Z@ R!JC/VE^*1RCJ&_M7B
MS+2ENZ_!;L3TA&P7%/TYPD:C14X8C):N_+5"##;2ES,JH?LRGGFQP)G.^>O MNXAQL_1!68I)VARZXK3S#L;#5?
T%X>KK8 >+3X656/L/N/ NWQ+@X+AEI.# M5H;7D_I^UOYI\NSN/ &>5Y/2ZL+@KZQ: ^6(5.R64O&
(@X!@M*4T3F;+2<\$/_ M=(IS21"4AC^DPN'QS.GBFJ\LF%I?2BG+K0&6IZC%C/JCV#G5/SI^AA"\^J_M<7!/2G/^!J+W?
MX\A3>8VAPG*&C)MOM%H8+"T%IKXGG.KK7\TIOZ;>/H.+F M!>?=EL_&BKN>U=:*OT>CNE0D@O\5%.2<"_Z5I=7?
U.<5?CZ^7^Q\94-LF M_L2,89HNSGHU9CV+^I\A56Y>UD^4M;JU'V="HX>3POP?*S0I1879&#Z\AGE M_P!02P,\$% @
281\$6M5+(N34 @ UP8 !D !X;"IW;W)K&ULK55=CI,Z\$/TKHX 02-\$F.;<_V-GLM@K_15SZI2(6QWG4I5_L@=H*PP=
(Z!\$ZO'WB#3>.2.;W\$3.8 M*%WB!J_LK73K5LN,\$:U7P6E;V7P3R "K>\;^R=VK_&L9LX96J!X)@R\$V M)\R-
U:U8S+9K9#F_F<^W"4_!Q2&I'C.O.Z!R'O!@6W?+70;@_!11;.6_A2 M?3:)\$I(=RGNK:5=0GEVMRU+UTAJXY?=\TV (Y-
\$15O!6I(UHA!5H0N'R@GIL MC?K80R@L^7 X43ER70IL\&VA,\$D6UMX*6LLH_0\$32)_WLH/^:G45\@>4% MS)
(06.S2,WBSJ!SCS=I_&L@_ \$5^U;POL"7I<9833?HZZF:\3T-*+IJJY, MQTMM93D?;S>M-);_WH.:?^WUFUT[7B03X4"-
L54.S0<@= M6)<_#@COBI8I'FY4VW%Y_ ^31G"7%T":^KE#T8CF#ZEZW^!5!+ P04 " !)A\$1:TPJ.JT# S'0 &0 M
'AL+W=OB*&AI;I%+D2I)Q?%^?8>4I'A3Q@\^U \6A^09V!^7I"[OPWYJ_-3LE2J2_.^+FVF@?3 \$I[7Y"7LJ
(X=7*&'\VRZN6D<0-\$:J^K>F1C47'9?J]M3OPX'#I#6'M'=(I>IN M(<_REEFVF&FU >UF\$YIK>*G>FAQZ8+R8#6-
6!J^477#Y;I MNVF:3#X:=YH![-UAA(!/A6A+!_!RC+Z"6;*M F8,6@.%H 9?<>ID!BH4)1&@ M L!HY3,N:4G5&B9+4
MJQ4.DCRC B\$#SKV4\$-DC2R:XC)#VF05_AQ^X9E9A3ZDGEWY+3F.AUD)."6S
M5MKRKQ74L=F>O&I\F"/1N>VN3B+.0-A4O*N &N'0GBZ WW%;<%7C#2U+=
M"78H+L=XX=3+GI8T0#2GIH"2Q^Z'S?G_-L_-#W87SD1M&RCN,NYG2AH>.SG1D+\$HFI0<7'IQ9P E!/>YH;"2-
++>^6_A_1^(@ M!I5QR2Y6HX/P#;.3%I'[*?RL=I6B;ZVYUO:NOWQ6H8U4S.KC(:M1K?UU3 M85&MM-
V=MN_=OPBNNHOP>7KWG/C\$)I+ P)7Y!H/Z, '==%X95C;6E\K2 M)>N%;UJ4+L)-+Y2RNX,M#^G;3X%U!+ P04 "
!)A\$1:L7@&J%\$# #^ M!P &0 'AL+W=O!["2.:QNPDQ3SAPY9@W48AF&@I9-%E")=DJJ3?IC*:ONZGC[4\PWYYI
MIKGCB3?;*_W)U(@6GAHAS3RJK=U-D\04-3;.#.4.)9U42C?.TE)O\$!/3R\$IO MU(@D3I.KI&%<1HN9WWO0BYEJK>
2'S28MFF8?EZA4/MY\$6'C0\6UNWD2QF M.L:;%I12_[1XTK9>I>0-2L.5!(W5/%IFTI78X3W@(\>I.9J#BV2CU">W6)?S

M*6"4&!A'0.CX00>HA".B&1\|CBCWJ4S\|X?V- _YV"F6#3-XJ\300+3U\|I\$ M4&+%6F\$ _J/W/V,5SZ?@*)8S_AWW
7EU%4+3&J|8S)|@4-EV%D3UT>C@PFZ0L& M>6>0>|W!D5=YQRO;S+3:@W9H8G,3'ZJW)G%R5M;>|>
MEEA^2Y"0V%YQ?E"RL\RWFSQA%\$60Y|FXS-\HSX^(\W>BD#|I=PR\$(,6?XF
MO8G _Q(PYW)CK*;B^NM44H+&|6F7|D.;FATKM\$T%OE _JS-27" _P\$>9Q/I"O _Y _W|C:UF(MD0#K+|I
MZA%0JG9CJU;0>QNN=PCW3QVJR|W7C@4(Q27 &T'P?Z(&IA%*RA1M4IJXA%^4 M19B 551 Z.[j5*,%+9NGT'9?
DDC.!CY8VJ\$TX3ZX2'C2G|L+%,S%T?IWU7G.+ M;U15@:J@E?1N^L:PH3H^*
(V=|YTRH1|C7|&*;#5(ZH|Z:;%OZ2D/X0Q/?;3) MT9OPK/<| _J-=E>-. _PD-G?, _TEI-;@169IL/KRPATZ#9A8=7. MO _;9:E?
&E-#1JU |IYI2B1W<(YZ%O^XAI02P,\$% @ 281\$6JF"3T|P M- C98 !D !X;"|W;W)K&UL|7U;<|M&MNY? M07F?
VH>IXAZCKVC,3E(E7Q)|8CFNV">9S*GS0\$NPQ3)%:D@J'N|??|:WK0;0 MD\$!Y'N9Q'DRHV^*G1E 62;W^|O-
N _^PU77'ZA 7F^WANT=7Q^/-GO _/EQ< M==>KPY|V-|U6 _N?#;G^L.DIS _'QX6?;K2|YI>O-8UO7^?U:KU|I|VW|'NS
M _|;W>UQL|YV; _;5X2?>K7 _J3|_|#Y _|@ZCM^67^|J+c|??WJP^=F^|
MX _Y>;.7UN,|Y7)|W6T|Z|VVGU|A0M^DNCND|8R>.|FFWV0|(AO'WC/EH^)/X8OESC_X#WUW>Y?WJ
MT#W=;7Y;7QZOOGN4'E67W825|>;XR^|SBRZ 3P#>Q6YSX&?U.?|N _BZN#T< M=|?
YRS*"Z_56GZM_Y'GX9|Y@|O _=*M-|?OP7|V|:K6|K,XN M+FZO;S?2O*R>=;+|J%^L5)O|;QT?
YVT|X?|' _SA|I. _;SWS&V.M|MCU>'ZOGV MLKN< CR600\CM_W(G|@ '\$9|U%W^JG%E6MK; ^ 3PWS(0CGCLU\$|^?
5OUL+"MC M _\NFY61"GNZN;U;:=7=85B^W?W2'H^S-8I7> _M.S5CU;RXVN\MOJO^|IGI
MPW\$O> + S:P7^ 7ZUO>@.U>HH?^*BNW|?|8>%EJE?'|IP|SZ M|O*J?&'|4#U=W:R|JWZ?
V1X;V _?'|J_WV*1Y/?.+OY^NSZLN0X+|TWUXWYW M.%1GU|M; ^7_Y2|I=K2^NY/O| _|I8 D7X9QJ|VZUE|^WE06\O9RO?
UXX^ _G/RW _>;\$ M%Q_XTKN=O'JU\ -|4|/\>;V2|>7/KIG|I
(=W1|>|L>W>UVPNMK30#2NU86K*Y_P,O6ALHT2YO:RL6Q|>0A4V|E
MVT94I0A^98@Q8B,J5|(SC|L=YL)F/RRZ8QE0W+*. GH^D| MXK)NF\K5RQ23K.W2!!U85\$Q76UE3V5"
|;8;98|L,17R;O)KC0O:E,D|;67= MT@GXPBZ;F CG &?EVWS/%|MC|?9FS^U<)HZR?PDT|TR"ZOC;RQ,=OY*; _R
M+|QT) "LP6LZC" * .0DA&4M\Q:65@ 6UNL,0560">/8771%I&XZR;Z?%R))R,KPWE^ (OLO+=7W?|S;G-
TO"\$GNC.CP7(04MDG%I9IK. M|97/ _MAM%?EO|86*K;R#4\$|YGR"|Q604B3K*;0-=.SH6V%6*5E(S.W"\$O?
|J(C)#')1^+)|F%BI*|=I"#W@BROSD M%M^9M,XXW+D P0DC"=S|E, ^#/R2?H2#VTK;3E: B=Z>?.N.)50_7F:M=M
MU _^8O*ET.| ^_.8Z@-\J.OM2=DQV#R5D0+=;*L".:3 KC#EARY;O6/3)'K1
MCY"4"?6LX.S0C5DXEHA(0X#1#.)5_5X>#F>BZA|O@| '5VJ3-X+Y/<^%>KC.
M=4&>OS962&+"R^4|SBJ9JO&PEL.TR9?|61##5Q|!U"W6)S3%T*.(! HILD%; M*X\$Q VC\|JB\FA|1NZS3"!!I\$8K7YDZ
ZH78 _;X"VBQ-Q(1Z4Y?ST:3\N1!) MR=|1|A,T?765)| (R<6X0SUU4D7U '4ESYSKXS&2Q3>JE9@\"M3&#T+L
MO;|-8|B9C7;|JLET>MT10C"|5ZJ4\$0UX|L|2,42IZ>W=^@D*,|C|Z, @JD(Q92#%@9N6..79 I\$ 5UO=R5@U/6NA?
PD;"81EN3@"QD7|P> ML'R1"1:B0GEN^,9EO%J^|(HUE,AG|S9*#(PL!)961'8M2_(HCP\$#P/_P)| M*9 _+|S)LY%>
|0_7CZBB?|2;4&I!=T\$VHB0X|X+-4P\$3|<5@4>9CA|&"209|7 M.
(IT'R=#|V\$R+;\$7Y:=;3S6MX4<(6, "4TR4@J*,CDUAQ@?DS<*>DLI"! _MV1VZZ3#QLM!3<.|#&W*/I _IPPOQ!O?
S _;|WA6+T0|>HPW9V4 MT(QN.CQ5F|TL%O9|R%LD;@Z4|@VH)|C'9.3>G@|0U1180(|Q|.1<0G>Q) M!QFF 3-
+^Z)H'0V% ^\B#B9GE# @U*DK"?SV|WN _VJ>OKS/4H\$80R4=|ZD@\$%
MV>SY(7PMI'94%Z"=R.F|_VEQ+++%9,++6.NU(U'LAO\GPA0ZY|,MC<"13)D9" ME^8 :RRJ5QN)G\$0"R6A@O?
\$BQ;74XO(L^@+/_XN5/O _P>411M _%N|T|O.I.C, MM4@)3W<;P;W<#2IV1 L=35@UU#V O7V8@\$PX3D;CLD_U#IM%,S
?)| :ZXVX|M5|A""7N#22(X'R(7^*BA\$2 M=:'4|'?&?0VR%;IK*7=8CBR)X"HBMB%<5(FG(0+LF%?|;9=|4X8^D,T'H9G
M9^XV|P.'O""*&>+G|?CP|'0J|L8=EJ1='V@RT;!PC| M#T""@FB%X5|'->1\$3Y8GXLP/?.;Z":0E*T2RNIY#M0-T=#
<|'1>7K(L1| M0S.#*#|JC|9^TH|V%-0%NA&Z^N|KMMW<6":8B (&I>"RHJE P98?#1|IED,D MFN"RI?
QQ5H;\$ _'W^EE4,"Z'753;V3X05?O1ODV7,|JD.\$L&SYR6.'&39@#7V80!/XA(*1W.M%"K M:(B
_JA*PZ"7WSX|'BTIK@_5#Z_N'Y4EK"HEV;*|DUU?QK=+S*1H5?+ _SG M*WBRY2<0M#UD*
QSMWN4W81|H0N%+&U=Y0Y M(>S">#0/0&--2W!PEG'(_&|JV8: ^"@:J"#5^ ^#1.=S"E4|JC+\$L=E.87E&QA
MV_B9'O@>!!U;5 M.X#S"8ZRUI;'P|KZ^MN,HI-@K7;5XT<3 _S<-C2MPF'KU&+>9'TF"EF>A? B
M2SO?"\$S\K,;!9M0AH-O-&D'T9AYB-&|1K,?|W&I1096WBR?HI2(-,|4)-^ M _|/(OY=?Y./3|+6%XBGZKN@LIF_(SDYJ|J
%SL*0EV?(*+##" _4<(>5.H #-.:D\$=3:ISCXA5-;:& M%=G+@ "7&5HVX05E+Z.CY>G6|GLR|<%B:OY.G 1|JE*CW(E):>
#+E8@#2:@\$ M>&*, @0B#G ^1 SL+FAQ@(PEXTZ%|5Z J8|I |H>)=9=|T0-SA)'A)&@2,|@1 M7&|I-B'IG _T.S|<.,
|DBBQ)ZO-=YBZ(T+D;.8BA)BWJ|^) |XYMZ@&R| MK|Q>W6RZ>0HO3# !\$QNY,):"6)L?HCK55BV%T T-,=#F\$8#
THWNO|:GV+ _M6,7H78| ^"|HJ7/7S|ZZN-J|GS\N(|\$2J;RYVP/\$#|+9&N5^ FRK7X6BOVO MJ|ZL|I>A\$Y3R4B;^;&
2;LMH6&1_WD|S6)7HH+^0MHWS%\$CC8,24D.@&R< MKZ)|>6|GK"V@""K%G4R2.MU""^&4@:0:\$|PWT&|I-
PAPCK4E58((;93;\$L5,@EQ M?+._ZF)U,V2ZN;BE?R=&AY:FE6U|> \$US1"KU4*1A\$>|Z;:'U<5NLYH%A*TQ
MDCP675\$H97| 63|%)|VOYV\$=) *Z)|HPWRDRL\$'P3X|^|S|&.9QO(#6HECJ9 MPIH%580#P->+H#TB 00&|-00?
3THWQ#A03+N3P".IU*-S2Z,O*^5B6WR)|0; M5>Y--A|RH=OJC1!A|7L-|OCE'2*K.1A:D@810JY+?
*T')YVZ>AJGT8HR)\$4 M0%'A5|6/N _WE|K)-R%|NK;H'2:E3S@\$0CU@XE|B|T|_DF62,3TP_O; _<<3
MU+.)W/_PT0RO\$\$6VB_T#>E^;|S"7<3#|/0| _|?%V)7-1@\$.5|9@W%?'8"BT| M2A\$28Q-
+|9DP<09&SEV""P#A#I%RC;A#<& Z44L"&;&DI| _|;KBSO'S'F? MG2&Q&9M-0X%Q,44!@V|W
_C,L(C|L0NDVDTV.X2-T">;MOD4YK"6_E8U3 M|DU?ZNB8CH|I|O-W<\$&QH8V*B|/8D.7(15!&T+)|GKSVZWD-;
M3">O|?"P)|F^T1G1BR T<7H8S)|;&MN:E,74Z|F B>|/;:(O)|L9J\$+OII*^4^;=WHG
MB|I0#KA' _UAMMZNKAZ"=;.6"O>9F?LAYK,=I1>1|\$|7N>GB _V^ _F<&%>HNKG M73%@X=:TO? |JZ)-I>C'V76B-
^PN#T>\$A; K5|%.<@<#L&*_WZ^U'R+R:|W&H7KZ""0D&D25T%N&CHHU;AG4ZE;|E:X&\$!|I1 MX"1N5?
D*CWMPT|01;9|L /X>BC5@9ZR5B 1|4\$QAY B,|MO,R*|>;C^MM"6=A9.&>EUT-D7/H(#E. M;G<2UCN-
#D94;K9|J|PKD(%3,3^4BSSZG&'=TBI(&|!%G&%+;SX<| ^.(H0^(
MZ/9%*OT&@HO@&8U00#0A5"R1|TIAK>B4F6Q@3T&G'<15"*-P<|S=(5H5|IR2
MI'&P\$.-3&0!1EGA0|^.=2,|^C4'6^%|/@*?>A|CX1D9/NM|1S\$3662IFM^|<+ MYE_C@GFI\$?
105IO=H3S@X_X&L0@.'8/QLV^+P"(23 -9U^2HA5"<%,|J7|& M1)5GST15A>-<%RWS%B=O# (%WFM*?
\$|VN|UU)D007X|2 8*%EH@ N- CA=M| M,|Q1|+' _Z?P8,! H%P|TV-5_3N#|L<|(I/%4MX> _VLWT@E8@6"^D^:#P%
M&J|G,A#&?@^,PK -3F""=><@C/T6S6,B9|K SNNL_%VY.3 -"?Q7|O-"; M^MF^EK;UAE;
(9(HA.O#E6A8T_0/P"7.P+3@<8_(D) M-/?>+0DUZ3K*9W=6(-)7Z/OL'TRJ\$,Z7Z|5V=2,L?;
(P_87G1&Y#)|,BU@SEB< _\$|E1L"1H6G O M?@W9;K|CXYNRPVI?X|KYIC,C,N%|HWRP5E@KZZ,M(3U"Z\$>*7>|1V#O
M)=U#&@Y&L=Z42U,Z#J|L@,MJ=)X7MAE&SLM(UR84I14/DC+|B8:BAZ7 _EVD MNYV.#03KTG0GB'A8YC0N\$#FL9>-
&2R|@=_%RYX'30@T;4B _%&@KLC\B P(M M,OYQJ|! 1\$*L"W4O,"AA'@ _YBPG14)B|X\$1R9100|A7L4@PXD".5ESSU<_VI
MX>G;)|LTMDO>- (*WT50<%CUDMDBGY4|3#6|)1.3>B- (!"PJ+RRV8VO+F#JK=1E| MG=HRA@?
8MCPN|YW.4,@"3>^|+L0|I3^<312PM\$) A>;L<_DISH6+5;94=U; M"HAY!;1T;PI|C) Q\$?P;37K;P>5M-
M86G:@ES7IUZ5>A2)%G."T(8 !KR@YEM|I'A3KH=%1O:-Z)"7,T0;|0J)YS\ (MR6%3SEE-
J|=%;1THP36(|H'\$,\$A44740AC3W;+FDP:QFH%KGJZ^R.SIU>% MT5A\$|UK) &@*S+BMQJ| S&90I3%U(8V8G#OZ2G-
71H&|_4@JK*)(PR%#EA*WW*6*;T(#QH,5?FP&,1'O=M| M/LB^*6 *>8O,.\$87#IU!*X|H8X\$T/5J&!P1GC"2\$6+P>74H
&P9@+O4'J.SOLD\$A'94UH MQ|F&C#19WVX/G|<7GP#IZ;YJJ7--#|U%EU%.K^1Z5'W.7VJYEM67O+ QOT-;
MTXEFZ5;6I! HJ9L=43%TC _BGO8?N6,33?D"7% M9E+ A ,SV?;|9K?>RA\$NX(QCB|ARP6;Z0* 1B^9U7)

&JWB!C:@QD"iYL^3i%*SX+HT!\$77=2C/"5 V*!0 MD!iY9[6AC;4JL5HZ6/IVI F#<6H+1L&4E@B@GCV
"K%36'D1^C+V0!""TZI. M)>* W2K \$K?N=J:SFYNA#? NMH@Q.2!-&O \i#H/iWK8U\$6))ZU\$V""T:JY MN^!-
)8(H:)-.1TBKS'ODEJKZ8R-5(1-1OD=T%>+:C9T&KH|B(\$Q6,&H%BE| M&N:1X-2WYS5Z (Y)AS3,4BYI=54"N0::/+.J
MX=)KX-YA3 VRIA&CTL:R!D+8>^!P;:FLW\$SK@!50>Q0Z2060Y+M\+VXX* MIE%T;8RS?
3Z/^_OFI+2Y/RI\$^GH^@YBZU!&PKLPVP>NSYHGL12TSM6CE4LO M ; B0RD,IPA|+ZWB0X_41S,*,^?9
M9G!*L&4,N&C; 8^0IQ%NM& %&X,.K1\$(4>\$W.5.@? \$MP:X9JW>^QB.6'!:= ML'6@M?-
H"%75@UZL:03U22HDH@4&ID#HMJ0NOMMLM^CW)Y#<,A(!<'EC9A M1V(M-MKG
@U=.;AVXR&1YC<*= "+9%O&G002:02+XR M:A|T0!.|B\$2CG"S,/32AJ+^N+K>K|1B").E*1
0:&K3F.T4P!K|8Q*PXN<&O M +5V(P+6J:Q3 @T7|6|R#1.\$/F R;U1N)#7RHY4\5*.L&K4MW"N2<1/|IT?
M*":W>Y+8\$.C:Z-97:D9VHB4U>!145!"|@:HZVNRZ@|L%3B% F#-VMG^P)| M(NK%3T&?
0<,YN7VLKOIY\$.N!)RM(4PAT?I)=#9TNZ7'YB4H!F!O2^\$(W43 MOTJ!
[=1,"\$*-2_)VKDOS^V\$WWM\$AJMW=YIW>T56FZ+&(MN^Y_ 'T0*Q:Y>'Q^\$URCH.\W\6*#.C2T3M@SR8W|8I)36W7?
=H\$0*RYL4:.4M MXKU\$P4DS,3K:TK?GA@4S&:9QYW>1/&5R9I?*,\$(<'!K&/)GJ9./B"B)IY+1.I-?(A\ M73N'J7&-
|*LW5GV08O&L?1Q\$H5,0%<"BN 940Z'OCGXP|J%5%4U4N\$0M.KIK M8IR\$J|LHA^SME;!7!OZ_?EK(G(D%
=J9'H_)CI_M'C|JR08#"SKRVWK3Q\@4 M<(9AET;3!Q:15:V6SL6^"VBIWOA!@?Z?'K5=2H
M|* _5|/*7U76G>?2.O"^5TLA(Q%|!P|G;)K%(!M.=?>82>19?/Z>L|Y-H95M1 M?EX7EI?\$(BTU_(.HUJ1-
2/!0^=4+&TNB1B@S"Z6V)9MF>@RK<2VRA4RC8WM5V> -?KY>7:U*G(**6&9NH|B3 M9<6^UJGL-(GU?A0'@J.3-
|!|IAS^C#PI6SG5:S=6'E5++22U"\$|\$.0F/6P M1%4#.*6UU=;TR<"F2AV=F'LCA1+!#PI%HIQ>P
MR+U^4;X4?5("T<2&JF:C\$S= *_+.)U\$|!KQOH%/ X^S0\$FPIQT\$#(YFMZT MK-
?2!8<.#N44FTP#3EL|OSGLKDL4S'30,K|!8K1,U2_6CXN,G,>1|V/8K(&@ M*;OUZ56WWW^A6:IZ_9=12-?
*/:J/H_Y1|K|:8TF3Z9\$TJPDAD3G|I5_4+|: M|G<=[*W;P|7ZI@2V%"I1;:J9[4\$MLOZYNB:=N3LN_U^G8|_0@3E\$-B0)!W
MBB(CA:\$/N4KR_H92XD)\$)J_TV!7QW0X_S4.S:!!V@WR1U4EET_5|2!BI91\M M43%H='.C\$H54?VI
=>LPN<,2R%i:'?)SAPL'@6@<3TAK&&8C^|B>YO%.0I!6ZDT9|MWM_ ^ _;;R|_J|?D| M|@!?'^N|!LX N\$1" _EQ
O1EKSM3J'7HEPM*OW4?Y?/WK27'&@H6W=YOYL4#R M4E%)#O4^ZGE<#: OK+&3T|JBEID|PNH H:MA?
\$92&MN7TD/4P2P@JEB4BH9C M0 \TA4&*G+3&A26J/37,NKZ?O#MG?^=C.M.X3:&PG;+R*v650A0M-MH45U4
M|B(|7+(<.:QT1RJS29%K06S\$F<#K0|;U:IO9VI.TE*9Z|.UG%@AJC@-2D^;B1|W M^O=L:-MO/Z|
3DM42L.L#=#WDEF7%8Y#1A=-"E+U3X|5ZB%<7D).2%WZV&DO M.;RQH.:KR/ /ID39?2EC/8KN><;QS?
8D)**JN|'677YA>M(VG|9W9HYAV,+W M1=B+C=1H)@1V@A)MV92IOCU|WW5Q(M8R).S6N9-5D|:+\$K&K-
%|MODE@.' MT0M8^;\$&|/^XM|W !X0N-*[H00RT?B)CT+DC+5FS,:.)ZKNKF|43GLS25|E,@6|P|10"TR|F=G;
LS/@N&"\$8M#,-.CVD:"|28|P>,(M)H_-CLB) @BV&FL8V373A3**B\$E+V3_8%%@XP%L639K,6\$-G@F==S\$| =|6E9 MBQ?
Q*U!ZA>%440A:O"3LHA\$RZ= M@ NLI(%H"2B9VD+|/(P91*(4=KZ,%*H7W?YP)3IG:J6(C4K4CNVH\$DSKX*Q
M)MD)D\$5!R\ILZ^MNCV"! D8+4@OKMMF@W@1V&-95U'24+?>I+0'4D+?7*TW M|MNAN3X.U-#H MIDI_
:5S:./5HSWC|Z23)8KD!/+JAJ9AL3'1(1&>-RP."MR?D7&RFNOSU0&& MBQ)|65/X;4R:|6ME:-JT3:E+DE,IYCGZP?-<
NL):\$MSJ2GLQF-/#H6R>8;M ML%X&I|5W>&_GL@VFR8T;\$S%8=3=O@V?R|I(78;D UDU#E)00^RN47%H.|F5
MN%+&38JHCSU.-|G|&3|J\$#/'9|M+V9HRA6|'VX_7:DJ90|L.#=RV-7FV+MFHBSPLI|6%E&N-KB>I/H*::3):/6&29<&?
0.*4-G7;Y M@3WNFW&5B|L.H+99Q&^X%*Z>S@#B7?(&|8#M6(1&4>.IL8+P)BU8A'>L"|0@ M%,/V#U!15Z0V\$+4Y-
:U:UZ@8*TM-\$94LVOL_#%#NI:'.0LR?"S.4CQA3ZZZ M|1K;H?
XNV!!+I2TT_6.1.^_0T7A!/F=2,OGT)Z%BA(L&*U|2F'*3XN2LZOC, M|)6%=X@T?;&JT1@>RN0FI0_%ZEIITBBE9|_V<-
'_J1:B1@|0S.&U4GTS=UI MYL>BZ:/_S' B14!BM-4&":&_@.V4|)@B;T*K;0(R4F&\$1)2|R/O:Z=+(LOM MO!;AW?
T,K6\$:XA(J7:#)J55ZA [4RT|-Z9MZI|CIU>KXU%\$M-W'58G+.WQJ MT>_1J&:Z9M02* V_ ^,I3)
EQW<L'\$"#L6MD2AF|P72_4* *9|6X,M OK-X<.VBC?BJP,+N+J F*YQ @EFY\C\$;=)LX9N1_/_=
Q<[C02\$+96*F2XD|!#,U M""E9>1W1+VZG|U;Z.T.N>XR1!IJ8D=N) /|R1ZK3"Y=-3)
|G>^3J|18TPY0AXTBLE@5\$^5IP_2?;:=+R#JE= M+V|6+VB" 6CXJ|O\$K.0R6FJJ\$16.> M.MH0!60-
P(41"8PW35_ G7@Y9F BH)GE(A-9++N\$1ZAOBJH:++@S0R+F^_I\W MG5E\$K>"\$HDF)P,R29)|M6.W1&?
5S@2;78R(A,4_LMH!P?=E=R%!#/=G\$X'A0 M%+V&*
(>0ZE40)S:8/;O\$LG=W69^""D*:OIE/180NL:>V!_0MI\$4*Y/68'MH M)4-4|D,..D-!VYNQE*T@OM.@H'FXR%1YU/I)>-|I
MC==40Y(:? I8G!ZL_>+"AJ(+F7G0|:|6?#:#*B:'^TP&*.3SKZ5IE:P"7EFC M|('QA@U-/7I|*V0L|;H8"T^U%2>P6(
K>&1BK1\$T."L/&|ULK3*JW9K_/NKTS|/KL|'-<3 M4%3/2"R "2>-G\XI6L* 0C|00Z,X2&NW:0P(C -:DJ|9'Y& 0I"Z"D?W^\\
M-'8MG|MXW3@^P=I_64VGD FUO.\(QT+3R/*UUCXKYP?1?D>I9E!0;6*95V\$ M?XX|7E57.Y3;'M^~!L'|K.YLQ
LSEVL@KUT&UL_.822\$,#LR=@'-.8E=V M8^LTM#VO@&696A&0
M5=KO:.*SX96S2Y,J@H_S|T'3GOS3.:!E\$|9958 MH8YRE)|F!W4Q,LN""|OK#F(I:X_1?<[X\$9;:#;F^>-
YH(+4S0"WCELD7X&M\$ M&V3%4=%'V,P"JL5XXOR1TAO2PLDA3Z*VY*2*)>C-80!|_++7DS-J8\$8%I_>L MR=?HW*/H-
0)2+\$/EFS1Y4>BMIQ\$=:Z"TC,&\$L1A>P8 <:Q"IEDZ5NBCN0|R' M1N@H>S X5O!03XX9:.HN56;M@51&>_?
GI!_S84IJ##T| LN@#^4"W)/86P8 MYPDMIV%YD-S|6-?%;.R1OBTG|TVF|7A#@E Z1S99EA9: ^X;<7IS7|JK'|
M|=[;DLN|Y8JQ!DML,7.#OFV@U)+1EQ1=I(6Z1\$#CG;7"MYH93(.7KA5M0L-36XA6\$R!:"?0J)M I-6:@\$W?L6
1DG'W\$|!#Y M9P M+|]V_0NBIN|HO7C^2-B.S>/B7=(BW|(HBT-18&^_VJOQ%"\$!>JG#;M\$F;D?LBFV8CW/*PFY|K.*6
M"/F|B,<&_F\$LS2E|>;SUIT>QV?2^T>L=@[+M:N*D3#?OUI|AVI6 P_1J)7D1CC<\$G8?#@8G2_#02
X0*7TZQ:J;+1USGI(VF-13KS'BS32G0^J-8.D4X22!PE#R#7A+L M+,-8A|/|SO(Z27:)"Y*|#+ MY!L>(6R)-?)
9;RE4Y!0F8D%|4|@RP"6BR#J|!4K|N5?8U(>,%0=AX3A|3F MG7QP'SO'8ZL9T#0,=>:T?DVM*5-U>&G?
&O5GY0NBK* M,2*(\$54%3R-&2G^6SH;2-U<_X K*842DR1/7OWXIYG=&!D,AI7%7M16RQ*(M+/ZO:./D'AT#LQ(2R= _?
|K_.;YVD,4-%J" _7#8_%B=WNX M1X^1O.2<1K|:UBS -6J|J@Q*BI,HR\$-#M6@-
!X|:B=7I'DXQRLI3D15REUIV^H""|58^7_# Y0|2,|S|1DY(E M@2(KNNM5)#:1&41-|S"V*1\$M!/@91(2'X=2Q|C3*;P|_#U,
|^_W#7F|TB=F%| M"4*>YR:3%V3BLA0E|^/>0E_ ^'V0NQ*%4C|+-OK|3RE|3FYFXL+1S^#_47AU8 ML@*&>
<"HM\M"X*L+|R(Z8O|?..21 M_H5_6SI,SDRVJ6\$E"1IJZ+%;KR.O)D|PTT!06MR.\$I\$FEE%0YK76_%X9|NT
M;.MXZUFO/(H@&"3 M|J^|7@!:"\$R;"/(N/O>EF-Q6^NOWP:6H7=;R+#+6_M>-\$"6^<")ZHM8|+5\$X|>T,D-YB#^8@9Y
-V*|BWM"5+2UMH:C?KX|@L(G M#2^B",QV9EHAA'J1SD 8Y YY+7+(-:>7K.XY.9BX"9M;JYOO-*F"(FIQZ|T\$K|FUY04?
UE? MZ\$T\$6D.GW'A(\$5NFO(H=N,|%4+\$*FAT/Z0|GH1VCEC(EPL51J|JLMNN|FK? MV':QR!@K^R#F(^_*
<2WC/2X6GN(WW6L_iIW'7022):9<\$SLS,LVTLA,_NSK M=B+@0"(JT;Y|?/S^V?K@WQTP-1>P M*G|WR#PJ>JM|I^&
|1V?FSV?VT6/YOOCKWW|IL_K8X>Z|I?90;:H\AM7Z3TUX M5.V1Y-XWCKL:0%:O=V?C|IH_7G4R=WO\@OS_A|WNV#?
P!S|OI|XO._/U|+ M_P04 " !)\$A\$1:@OCRK|&\$!T\$0 &O 'AL+W=OAOS:@(\X=9##L-,\$15\$4U"YML=E=
M*B37LOKK^|@|)"N.XR|M|4'B+LF9-V\.#K6W%/*3FC.FR6U5UFI_--=ZL>NZ M*I^SB|J)6+
:,U="5E3C45Z|B\$9+>RFJG0\$STOL5ES4 M1+*K_=&AOWL4F?
5VP0?EFIC3(PE,R\$^>F8>S8G_D&4"L9+DV\$BA^;M@Q*TLC M# ^=S)'@TJS<7/<2S^UML.6&57L6)0?>:'G^Z-L1
IV19M27XCESZRS)S;R M@V!!9W|BB/*&:'NQ)L232 MK(8T,|FVMT QVOCE\$LM,
ML'Q"0M|A@1=\$#|@+|^M#*R_!FO4OCDG/@\$|X*=@ZFS:3(Y%M: U9\HA9_4- M4QKQJ
FO'Z:*_8X4UHBXGZ_C|464W0_|L.%NVI!<[8_OIH)F_8Z.#9#W|B M/7_XFBP.'I(^G?Z^|^23<:@4,|%HVA=J|VLR:E-
TDMV;1D^JS6#|9I2BX#DYIRN|^SV3E2+G>"O):XX*0DI! M)SFL1(-9<36_4^282KGB|?6|DY|0YWP!V-
WL93/[|^6\$:\$%&S_W!AUZV70 M-R_Y1+?U2!LA(V0A,V)SY92!16J1%:X HEA"|@USL|9Y(D\$\\C3SNK4|>?

MHL0&"1GI.VOIHBY7Y EYJD,6^,%SC"(< \)LBE\$XG3J!-JV8?0A* !"2EZCS M4&A8F0+44V-@9
<_DO'ENJ,+ /H>F2W@P\$YF>L;P.D6V!Y.G#G>U"-QZOAI M^BB(T/ XC'I0@TRW0?I;('1HHS).-BFM<<4
2D\$\$.7%/O/M>B1FXW!:%2 M(KC08!4UZ!&N=LFAY!)FG9(TTF4#GX-W*1E:1SND?T,\@/8B>)(Q*\$3AOD
MPJ!M60KZM6Q&SD*4L%O>- '0S0!+IA22""#IX85+31",\#G=I0WK54(') M.-X9,7I4V-\$.LFB'J"2,GG@9;1%UMZ?
Y^EM(U2R:T:%C:40LS<4.O MA6EF#&+SE)%Q!M#3#=">DR+I0P^,!10INQXE8>9\$66!&?N"D6:0Q^?C/K94
MO)ISU<8GJE/9%&!!+\$\$S@* .1W6I6%R" H9OHBFEABBG7C7@QY :4S;= E" M7M&Z0=MF7L:.W=@>CBLX-
F=HK0IRU90EGA9=&3:L8AE:011|< |9|2D-4JQ MG0(^Q?)&8J?%.5.;D;<"(#(#HU51*U%R@ZP
TS4V<|CITAPB1HE@ \$FK.@LVV1E,1P@'33FY5G/=Z;+@B _EOXVLUK1FXEE M^I2^ D\$3CL5;|/?YV4GQ/K*
(W9M4,|0IEV!@RG=C",Q@R\$XC*,= |@>E#Q\$IV3H|I=D'JL= \ M6 0IEG,.0^G_%?> _BK;Z+:H+|A-U^A^0K02X*VG)>
<|J|ZSW3(CIJ A)\$S M=LKBPCC+5D;^\$^*GL9/ZJ>F6(E3DJ.V:4)2G/CGLO@VMQEO<*K<\$1UGB),FZ
M<>E_3R1=*NO3/E2L.LN5?/2VQ. 2*,8?8F3>%J3(R3XIT|@M;:8S|U(ERB
M|BPZ08N= #6C>>OJ.L:D2ITD,DV%GX6.ET7FU\$Q01N),.+3=H%M&.(R|NP6: M(I-?-
NA*H929PLHOCAX/A3IV(IRQX\2)4B1:BI 8("H/2>.8J/J V-LCAR MO 0IM.\$"[1K|M?GVI=N^
6WO^Z9PXC!O+!7#V^\$OAWOX? \88B6V%BR:ZPU9ND\8C(|H|?/FBOL/=J)9NZ78X9|1@TBS _)5
MG>L>C(+ACY:#OP%02P,\$% @ 281\$6GM(WYE @ B 8 !D !X;"|W M;W)K&ULK57O;YLP\$/U7+%9-K;2%GTFW#)":LFF5
MUBE|JUNVS Y=@%6QFF#^ ^IL-H4E+HFCJE^"S|IV|>R:L/&'0>0 \$CV6!161
ME4M936U:I#F46(Q8!52=K!@OL50A7|NBXH S RH+VW.L ME@6A,.(=U&6)^=, "M9\$EFMM-|(.I.=ZPX|#"JIA ?
^*FG,5V3U+1DJ@C"* M.*PBZJ|=)H'.-PF "31B9XWT)\$O&'G1PDT66HQN" E*I&:IZ;. :BD(3J3;^
M=IQ67U(#=|);|F|F=C7+|\$@NX9L4?DLD|LCY9*(.5K@MYQYKOT,TSUGPI*X3Y M14V;.QY;*V%9&4'5AV4A+9/ _-CIL -
P)P< 7@?P7@"" P" _BG H(.8*2V MVU&.#@F6. XY:Q#7VR1+XR8|,JW&|)U1?^T)R=4H43L9S (0V LV!FU>(IH 2
M(M*"B9H#^HCN%PDZ|/M 9XA0!"MGM< T\$Z\$M56W-8*==G5E;QSM0Q 70+.;R M%^@KS2#.)
|I5TWWGWK;SF7>4.8%TA'SW _(<+QAHZ/ITN#\ 3TZ'>T>F?M| M\ V? _S _W, '1W2Q<,TVFSF(H*IQ!9R@T\$ \ U8)?
MW|L3Y,B356Y(E;T2V)V/0 MRQ@<8X| *_J.H2DK 9W_8\$)<#\$G74EP:"FV+Fl|@+?#*=0U|C9%>5UFN|,.'?S M?
EKR.FWL.\$'PG-8.8N _|1TO@: ^-U |6LIK|)Z?O=WDZOC(NV)|FVU=|9FF M|)>A;S->\$"E3
2E\$ZHTOE:KSUO3:0K#).L&12^8I9YNI3 5PGJ|,58W(;Z +| MQR?^!U!+ P04 " !A\$1:+'5HOD," ""!@ &0
'AL+W=OV(HEXHRAAL!5(-E6% MQ>L:.*&|CQW>."SM2E,HLN\$E4XP(>0?VLMT+/W(&2D0J8))PA 7GLK/SE>F'B M;< O
JT|2-3R9|S9S/99+&C2&@D" I#P/IV@&N@M@TQ| ^>Z0Q:FL33|9^ ^MS=:N;|EC'7>
< _B:9*F/GDX.RR'%#U8ZWVZ&O9V9X*:27F';Q8:?'90V40&J
M3|8&%6='; _TYW"2H#GG\$X(^ (;#>W4:6\AXKG\$2"MTB8:\$TS UNJS=9RA)F7 MJ|B\$?DITGDHV^G@S\$.A)X(RP
JV\$P*P ?>Q*1J|2.Y@X-^UIZXX67""%Z(\$S M54KTE660_90O:K-!+SCJK8-1X#VD\$Q3Z-RCP@ND(+QS*#2TOO, |5^8-
VK^B M#J|J|3U#SW2OEC5.(?UA2! '<)*' _RYIV5\$>3HH3?HR:ZA M@'QO/IOU3|71*N.U^O^0.IUQ8(ZIA!&QV2
V&^7X.SV"KEQZ'MRIT%N?M6I M/8'07Q&^X#;.;2|J.M.;@MKCZX<:|QID4 |Z0_5" *VP4E2GG#5-IWF2A7Z?
H.E\W4;RVW6;/E>Y==ECJGP4(\$Z"?YYRK MX\1L,/Q^DC=02P,\$% @ 281\$6CRE,S@1 @ W00 !D !X;"|W;W)K
M&ULI53;CM,P\$/T5RT@/H3D+Z"21&IW0:S\$2M4N MEP?<Q@/QMVMI";S6?X>VTE#0=T*B9?88\Y>I%"VP(US
M|9H06S4@J9W1%|3?2.6@CJ?A|8EM#5 605*0+&E61%N<|G'M9TI<|ITYP17L M#+*E-3W(+0?8%3?
%RXXW7CP@(|Y;6< _N<|LS/B(3"^,2E.5:(0.' F 2 M|781|F"/%PZ|/9FCX&2O|4,(EB!DR (!%0N,% _/(5"!&(O(P?
(R>>2@;@ MZ?S(_CYZ|U|VU,*5%E|YYT_P%&^O 5VEAXQ?U0^YRCE'5 M6:?E"/8*)%?
#2) _&4T=+7.C>V1"MF<+DV@UHKTX MKL)/N7?&|W?/<^6-/UX&!GTRE'%5HYT6O.)@54,|8RN@'4&;\$Z<+Q8@!|J)
MMP-Q|@QQFJ%;K5QCT3O%@(U)0+S*26IVE+K+C)>0S5#\ _05RD)L<8%O/EF?
M1|IY _UE'WSYZ(+IQ(.WW<^1A<8G|GSULF&|=WW|AD'^Y@#.=G-)|3JZW0Q7 M|G?ZT/BWU-1<623@X*)|/42(S,TTQ
XW<8+0?..MT.<-O| |1.2 _Y|W<, M0H'I12M_5!+ P04 " !A\$1:4 7I+F@+ O.@ &0 'AL+W=OOR")O"(?
VEUXZ)K0:1<67---V?I M#X=XA(5*Y2CPM(2
%GKMZH"/>5@..09M&|D^:;&%^WJ|IGXD',E73JC^IV|.IRF2=^PMS\ZMJ""I*ZR4F= _R N&G&'NZ)I';>%,UD("AT&?
|*+PTC M|C)ATDR8.,ZP\$;-*[T]>67-C; T&|JO1|9/*LP%.ER253|IBK<8?)F<:6L M4TEMM5^(" ^VNQ0=90A|@O!>R3
5&2Z^F" _%6NR0WKK;JU8"UK3 0=)|LSIL M,|FPS7@B/IC2SYQX5Z8J75|@)@|X),6^ .O)X(IO5:(O'H|'8G(X>3*PWN..
M\$8IYO<=?PXA1QX41|^0?9JYL*2_1#8"WIW%DI3 V|JX\$ \ 2\ M\$=| G-
U(W"A1.R5T&7P3V:A7R:PTN2\$Y82UE*ZLQ1%95KI-V7F**HBI;>^\$- M3
A/O(AP)J^X83'JAQX4N\$6C@2-..!!0LSH8E"Z3/(Z)5XMC|FJ M= ;F>|X+U^"(UXJ976::|4GFO!&|M%IYA "1PF,%2M8+
MD5|U#,.NL\$5:0^";=OK4M9^9JS^#U2O)*PU8(?W,KEFZG,0;DDNX)/XG?<\$
MMK/2>>UKKXACGSOYECVUC."R|_3HQJ|>3";|I^??;KDR_13V)9G|^#-8J5 M2&*ZF-
8@GS@T4WD%A16ZL2X0SB87&-"HRFW&.U(+2=5P2(\$N1?EY4P|D1I8 M<&D\BY!8(CV91D\$A798+44F(|JES:0-
GH2ZY<"V!(T%ZHK->B5@1 _ZJU96%C MEX|!D)&OD+VOT*N^HFA|10! _Z%U%@1H/ _2UN1?26NLJHSUW9(C>E#
|E>%8 MP|\$|Z12Q*?.D;.). ZQ@%|64-*AB,TU:Q6H\M6S?N#3|I\$E%COV(FNL(G\$ MYV:T\$MDC%+A04,"4%(9-H,?>
S&19|KR9.^V#2,|>%A Y*RA 8HUS+/+M,\$@Y M H|VYFL|S(UA @01)IT@>- "59/=>82(!)(I2,K@/@O
F*.P&=|!;WUEG>R.6GB7! M0|3:QUXST->P |9X@|2/ _OJ9MNG/9!:+%1K5% _);#K2!*EU! 4"W\$%0:.\$RKT B5+D\$\
|M\$""52ECRS95K5 .(LP8|_ Q/XV;8 M _OP:-/P.L09)!MP5".VBM2+V4-#.(\ K+MVB _J.MR\$(4('19'16"Y|5:|*B) MU27F-?
Q).L_5RSCFR6;Y;/*"M^CH/1L#B9:~^58V'EFNK1@W:XAJA\$M'1VW MO4<|(B|JLQM64EI85SQ@NW5YD)X3EV-71\Y?
C%|\$OCB.\$A"#\$24)0G16|*3 MD#&;-/5R8RG" _%"ZR7%C-A.EJC@*#9P/R=QALE+7M(G@|JY2'A!++N/V-SE\$
M4<'O|6|E^28J<_K5@NQ33LY2@@5KJ|B4(5R7YF9UK29/8&9@U).. T+9X@E MX.)"21OSA|MV
O"#9D+\$OSG/L30@R.%?L MVD8 _J)88GXY"Y?1>)O"2K@F(@AFE79-TA&PM#0MB\25ENS(U!+636)\$X6#Z
MK*VM=QIUWA".B7^@.B,>Y91OCQ|&L9@G#^;>0/GM"N?G_XMY?-9GT!^?I _+
MZ=J2>^@K;VLU@/A9A _C9WXYX2RD_O.&N-OCN:H,!-7W>J>GS|ZC|4?
8_+?.@|:BV%33>H#F6TF;1A3AN1CB+;Q8= _/KPO=;^ - MM%Q=ON6:C*_ 7E+; _ZIMM.48U(#!L9,
|*#TL\$W|6W>QP3B;_IG3R;Q4F:2 M.OA2FKZB+Y?1 M1|TB#8>0V8=S&PG\$Y>-\$DKS\$57'X@VP>X)EE--
MW8|G?|(E2B+&SX _NFA1+>-MQ?V@<0.CXRF5_V_QC:\$*%-%|%;)=5VIV6V^GJ| MKTU*-7Z^!|/IGK6&, C\5%\EW?
W% M2E/F'F8|C.5;_4AH4OZH4SN*Y3SJ,8^*|M2|'H|JF&\$WX*H=E|O6 _Z_7'S M>|/D#>YV!79B0SC<'6>==?
75GU0)!0SA*%7FM""S|51\$G|2+I38E M3+!,545'YW2H&ZE#4 ZO>6NI%74F@MMN!Y7ON">K K|SKFVOJ;_UTRK;*E1
MURF-R5"+ EU|>O;FI-/ _OPLDGLP<9;8JFT,M6J"-CHZ5UFKL\$7#U)EL+K6BK@H8S%|C\$"?3 MT-
=7=V\$BM|C*|ARKT13*=I1M&E+XC|YA?-|D|O:|X51&G75V1W?0J|T5\$07Y;|R->L|@Z|/YBN-
M^*PU.K0EXXC=X)P^QXNT;:4#YV0|7>K1;PIG.OZ !F>:VXE=6=0O'G,BL1 M067@|L;LN/^N:OR@#ZN,T^';
(BA+Y\ _4B|JN6&R9>LMS:|QW|P>/ZB|?1<; MMB4G|P&P2TYVR<|)*3-8&|P,>/^00^!UKG:KG89|!9A M
#L;^K_T"2|">RXWL|R:|O|T8J|X#,IP&WZ=&Z&ZJ?@/7@5?&>U/PY4S1)|PT _S M W?OW- &W6|3_X+4\$|L#!|O (
\$F\$1%)4SP|GTCL (K1 9>&PO M M=V|R:W-H965T74UR*#D)<+|DED0VJZOK _>|O M;MON01B499|IW-9-
^/K!|IN|W7SYZ%::|^|K|Y|JMWV==64/W=9V&^W>?7XMJS;VZ? M7#S07|ROKC<| _N+1-U M|NOR|NQ_W?W7'SY
M|>4S?(&>^'=5W@;W|PRWLFS;#_C#V^+K|^<(45F7|JQZ7R.% _^7+LJYQ)8#C M#UGT@7T37_3_UM7?
T.9A,\LIE" _;^K>JZ#=?/_C|O5:4ZWQ?|^ _V^|+V= 3 M7&_5UH^F|WRLT^>Y"M|J%OM_(R0+"M&OY _E\$0X5|X_/S("Y?
RPB7|S1|B M*% _E??!-5UUIFW7X-*R& _Z"MTML 7-7@J5SU"?RU@Q?Z;Z|X+)|VG5U5UTVU
MKE9YTVOC5HQX^C0L6LEGON7/7|Y|S,5E M|D;|)N006Z*LD@7>

0P&~^7"OBWELKOB179IGCBT15V>7[YVOY\!MK/-#-K/YE; YM=0XI&1#GT%F%F*&?@^;87LAIP!-@2&ZLJ./IL:~Z
MLLCZ%LCM0YF5JF#>%%D>@ (UWR% M7L-UZ=%5VZ LJ?H#4J_R7X\NSK+KLNFI/*Z/@ "7KLI=#] -XWGLN@I6VM5(
M@_J7YI?7IX_1^!%BY_IGQ?/YYEOVP P3,0YNLU" &"\$H!L.UJ_BL'!!4> M+7M^JZIR9557?26KX"M%%59U&_8=
(0S@1Z 03XR5J_1^@/^&EP(0%?ZJ MF.;?2P*OJZ!9N10%1^!(\$\ \$ ZI?C^ MOBY@ (X""+EMW[1L.5\$;T7CQ!F(^#N; (=
G1J! /9LGKVSQ4! /S/2/Q-3W0Q M1:5_8AD\IWN@ (BFWA+KOG M;CUO!P<-QI\$.D1S_J>^@U+B@4J!Y_-E70(0 M?
0E/IAF/PN2AJ_SII6MI"6 \$JJEZHJX.1#KHOFOWUYOLIJ5S15"Y /1=UL)V MNFO;YDTX YAAI56IW>7-(0-)U81)20/0"SS&K
"GISD-V6V+,LF*~L'E CA M;+IK&X=%>(L8*7LIRPV\$-/IGIBTO,GK/9(W8@OV 0_6M\$+85+0MCL>/ /ID M3T7_I08
J4C%~"7 #P#Q)Y:E")**5-(2A *HHTK4\$ _RI@NW#>?&G@.CIV[0, MLFOS N";40KY0@#? " GP/+.20\$VY?92?
60/H(I@S)I6S0T<#@Dl.("N"AI P MO:H)^S5^&GV/@#%YE7Q*O*OQ#9D5LC'X!A@^65X4%8*(Y+A?META&'=4NMIA
MORX '('2:P'K5NQ!*QK\$DK-S)=X-PAJ6V/1 EGD';%\$L5_AE^!DE^4FKI>R M\$F3'J,;=; (-1V0/PH-EJ\$#CZ\IA,J;
<%=+@P03J&LJ0*A.;L&.MUE=;[Z MD""5B,; P>UMI 48#SGUW?M;=D-Z1H^\$(BZIQ3\$@=T%T!S(JI=GCU.>!_ ;
M%O@J1*L%JE !IJE5/4KN1M"= M+UM8 2C1*=<;=KJZ83Y""<5%0MSW\3*~H!*>!K,%*&@/O&M\MSR0Q@H!\$0!<
M0224XTN@6D\$A_-YVB%HY>%,A"*1235F[(= &#X#W+(CD<#6@#L68,M5%4@J MR=IRB(IDDQTT*0^#XS
;2N_U3?)!.GPA;H"*E2I8BPN<+?*[Z\$J;C.&N\$0 M^F +TF?%&Z)4;8EL)YIOT)!EG" K H\$7@S9"+1Y?(8BT;&I0E24"/@
V6H MJ!9\$S6/D IA?9\$B!KVMXPVK,FE)0 MG'S(5W
LH6+=@TR=U\PLJO~"LRRJ!7AU#^=GWV2C\$>4>BO2QYD3"0V\$7Z.T* M_GT?=2\$GM49-@P+/B; Y"4-
O_3W2A5A2/STI8\$RF\$ "8GI0CO"M""5EM"M0/ M-.QV;5^J^EBFO"<:L2MVOT/H+(*S:D;%/U"R'\\$
JOGDY;0#L3\!\$Y4@Q"3 MTS'.P;-LJP Z(WUA1ADS!&KF.*!7R6FW@?P!1S 0+W;V*!;BQJCTPQ<1 M=+3I2+ ;&?+?
P=+VAFc;*8-C&N075V#(G;9%H>%,/_/_CP9F52MB(G;5>T/ M7E_A-'= [+ZUV'U1^8I%
[@=[U@.*2ORZ"=UT87+GT/2GWXZW*;Y6%*X9T\$LF5OV5G-W@, _N.><_J^>9'L'8"!UP#L"0.S!/4
M.U)_G!1SFIZFAT!1F *?BWH!2:MBE!MNK(2!W ?VJ-1L3D8*\$6I\$7*F4 M4)JU7ZB3Z%[(SI6GMR0%;'=Z#1.
3#I.R7./IKR_?&5\$T4 P0LIR4 M3ODOG-WNWJ!(PD6B)3+4IX#!=;L@&"9*ZVIM;-HW0-+U ?!.@0_Q(WJ!9*)
3#&3(=;_>\$Z6!9U=MIUN!8) _/OC MQF&#L\$>_D@4PPRNT9X#SP+)*V!PJS4H">.@@;4!UX"PAB7A/I@T5%J;.Z4S
M(%M0\$#4QVGL4IR7^7V(XGF(I)N _E'B<I(J\$>CA&0Q)ZWZ/QAMC=E@60/2I; MYTO0HE6-%B;)2PQP= 7I/
JKN7#F%>"WR+LBP">+R#H:AWAQ!="+\$)I _=KE@ M1@O^I_CJ)-H6>:I=PIFN;.152EFE>ZG!49LF-
BX%!0@65TV;+>0W01&/ZHU M=EK8?G4!\$J"HS2\$0208-DW&N-#;9W0.X9NZK)GGR4?XR7#MP%>8=OQFJG6LW!*
M-.0<2D>P.*0BNN0AD0ZRXEGVYZ+"PN168""4#SR"1B%I":^O\$96"7X6P>E!
MI/4HI))=KU"957YN@GDC.>H,+8C\BAT5_[&[66;? M@!\$I_ CPC,1I4* _O6CIAT3-Q^>HHE=*(R7DO3@+!'%"G-
^_8.LT_.11XZ MU(S&-0M1=NDK"@&#P8KTU>V;)\S.; KII@IYI^Q\$!4MNV&H"C\]>>(9BH-2L
M642H\$2@N5MH1+LS2=XD6.K@<30D&W1>Y#J_LW!4G!2,Q'4\$ML!*#V7U?" M C&SHLT?@-
H0L=0+U"@%6"5%0%ZRB\C2Q08NF;D12-V:C(G+6F KV<-S M(\$U!M! F0N-HW9;S=8BH
70Z;!!7E=CJXFI9D":3.PY21,3A\FB\LD-WY/0AD%?\$[1L\$)Z0T,=%OB= MO/%V;!!IXV"=O1+FN*ZOMR3^2+1^\$?
<S4)7;G\$#ZV*)FZ+,0V/*;\$TGOV M75LPG'&A2'/D8-\$+1"8A1J;GVPTIN:))>&0\<76 5#1%>^?T!H"OXP "A29
M;JYKE6WV1_-@5-8Z->D)Y>_J5L.- (QHC(I5-P5+7HIJ35AKR(WNZ*ET%\YH M5XL#A1,6"J_/?
XJ^+'(U.B!CK>RLV+,BE(G6IBK;DC>_A;4?"^*ZC MWC<8;\$#/_JM[X-
XR;PB!!&TKEDH3\WJ0N@JE>5(1@)E8MQ4F&C&9JO2A!;A>V M'I=4U%JDA?9G^7\$#,*+%N#*
IX::L_9.R!92_ZI!50SW8) *LU1G1<(_BWEB6V1-26K)OK3(N%;_WC M^',@I;I6X?2/OQ?G^HL%66KEBN/Q8(;,DG-
L471T?42JW+&K"8P_G (MN\@P#0=9M4 MTZNH4,/%GBT#T?>UX^6E-1D7>-NAE#4."6H6M3EFHO M\$T?8F_*L
05FH>*9<&3-0?I@),Q@/OJ!U3 M@%HS6>"^_ ;\$T?;HFJ(5X.O!31!'*7 T4I(-W_+<7 M^6D(74@3L6& IT?
FS(G0J!C6*UZ@;B!9*;L45BJ14^_IJB;^S=55YRRP4\F M0T<2Z2/R)W\$GLKZJ!IS[W>//Z:>H6HQ,1^+<5YP%?<,E22
P).I!Y)Y2TZ9: M"K4M^TU+X0=7J.EY;!\I^G0,^:HP>07FG(55 M/>LW*IN2< #*J=0X7YS",>1ES!6I@NC805LQWZ
MFZZD!!_@\$4V'.@% R@>5<7L'Z(<^.;/IJT@>I'.O#AR?%BI@=%3I\ MU^9-;L>C6-
POF=N@_W_.9\$ "2NYICUC.N;EJ7*)MDI?5'J_P.U ME/I(8J\VPXPOY \$#):09Q"@J"%40J =J!#FFQ(#6'FG4?CI(QW;)-
GFIY8PM>6LU:.1L<"\$76Z/)SB M_60Z+U-;2I%;P0I@/_;K2N1I>2V,7Y,5J%CSGX1&6E .M5^2VJ_ ;5G7E +
M3Y/Z1!)=734)/+E=3"JE""[++\$B0;[35MB+;O:FUR\$16^28N)!Z0&\$KE4 M"8ILK59<H?
2(O1\$*;MLDZISB67I4EUF\$HJ8/#E26;_P9WKRE44PT*AR^T8= M&H6(LPQ0/0R.)YI\$!816NXHETX"0GUR!I7>(I)-W0)
(\IZCP&WUO1P M6V0_@CP^8L?FV36M4.L*6!8VC-A9L,FRIR3S&TFPJ0'N;1\MX4L(C1:RRCHQ M3.'HJF!E;APR/B
>EIPY&*3V)*^,^+.\1L*YJR2T>)9Z1;,+*05.IK+7B65 M410I< Y^I0QXP0"DJ*\$*+I&>#EL!9QXQTIO.EA-
F&NFBK>^%,+93\U0+|=I/OR&7G4YY)*@M*G5S'U")XE0(81ILO_RF MZH""7U0%4=5KOF07FNAPE6Y(I&-C0JF9;Q\?
[U%?XFEME'M1F+L5&\D+8M MJAO2I_'S8 \$#)T\$="B95RKRWJP38D.A+I_'P2-&J'\$80'FL\$X7(44"2QYC%P MC8A3T4
/ZUZD""^J#UR5?T/561RS7TISD& M9Q406N\L>T'2;:2I6:C*V;/C/P055B5Y>@QN MAET CB(H-
ODK!JA&,1IN4IYV&8U!50S!XE2;"LL!0.8#D("8?RA#-I3;JO8 MAIXL.)9V+-6NN7_B);N*^@^I"V\$E?
X^BC\TOB^2J>Y,V30@9;!/GZ50P@/I_ M1V"DP@<'.^C^_N\$L:4X4RK9_#7H*)V2KV,OZ38D+8'G!T:4QWONL!2[3,S?
M_FD"1*13VUPF%NTQZA2T_G_@4I,1*F=,8>5X8/"O%045I!G!"O40N;P9,3NG MZRA4MY60'2%G!7-PEAULQ":J=
(*U=Y;8H#P2OKT'BZSW75.%C?->@I=CYT6M@ M&5BCI!I!&J<7 MD^62^0-QRPKQ<28UJ91IG/IT
G9EG\$JZ)IE#I\$'8^WH22C^D\KV!,=6P;J M;1%SVY2-L+@PJ!2%DLCL+#+T/EGS;7*=F6.A_2")^A0+I-
NWOIQZD9VXUCN, M7X^;-I13*@-AG# M8CDU(16XK5@QK*0^TN^9C(S% M6++@7EZJ>1>R\$XTX8\$YJD8E5K1

<&/>\$\$HV8!57G4WP*!'\;# .YCXOS>.'% M^?P(>2GE1@Y;2FW?9!'KGUGG:#!?T;2(X6'4XZ8UYR@!"I_Q1(Y?^:\$\$,VB0
M#?>DYJ<;V\I%'^DYA83!'B?C0%-J!4RMSN13GZN:Q<,)IM*#2Q1=8N&53 M>M0*=8T2,GC1^F?<6-*Q-
XU*8Q2+>'V,T:UH&+TD8H,\$IY.G=P(FM)_CWR\OL9B!4#"ZPV(*^LE'B"@G_J";JB@ M>\$@5.T9F3_PRCOE/4[K-O/V-
@(>?2!_JG\$6J)B*!\$B"@I\IS4,(/'EQ<+ MORQ)\HOG\CWD\T)VXI;^2 88.JCO4S#"Q8D1"
M^CL,%%K\$NM";*2P_X^0ABOH3A_);RHEN4"HASLSU*-EK/*.!H51WIX46'F3N MN)-
LCB3+I>69HO%4&V,3\$ID9)2I^WP>3NW@UQ!(#LA+FI3)I-B87YC!NG'T9
M/8IH\;IHOHOH:"^*5!=!15C)9EU:2CD(@)*C9K)US-D>9:<@J>A3UJ6JG M#_+ADOMYW8T:>O> E\$:CG=A@':/U
9=K^'Q_EOUT9/M^_AIMOM@ZZ1&= BV* M&35YN,4W(2/MEJMA4EO2N&7#PJ:D>1PIG;(Z=U9,QV6O\OJ>E%.E+1?U(F
M'"8W?U#(V=?GINV=@ZM)0,KU7;7 FII^WZ=!_4L?_CYMCPMQS&(:3BY)!R6H;M MJ.\$*.'M.,SYL/I\Z\MI1T+S;GA M1;
(9D;@*JT!?:.^#6R^&WM+&6+Z1A9+<Q#=[V*_3TKVOV_YZ6HZYB6I@3 Q,I%NI,+&8!W.T#W\BC7\$ M4WB-
&SBD=%K#>[X/'JAYX"8@#"!#(X;-2BT)YLKH&" X@_/*F:T"4J=19PM M#U+P9Y'.O54'64A1Dj5_?%XNI
(YN\QHB\$.8PU!8&#ON[@6?5F<79QH+RYHV+4QS6/A%^DF[5@5I"PIF%KL;.]^2RT0I&5"XFVTUNZ
MD58CC@SM%JO.Q\$F3QMOQ3^1)NZ93*%P.((PP9)%&"4')\OP>'>@LM!'14BC\$\$ M8VS0MF'-
&3&_1MX%E4AHI&_!E1@!K9V1\$L/HC.'=E^4XZ1[+,4DHM[=8'V]C M(Y/J84\@&HNC;U(8)IDLX0BGV?)H
MLYS;j%/B.NXVC E8+2RI0U>G!LS7#52DVYID3I2"N5\$S?;LD1!OL;V8OWI6 ME/7WFDI["\$4C<.(N35-
\$TF304 MY/'+ SR'.EKZ9.DE%N3)+K Z1:B7:4%K+
MCT%8(6AIVAB&7=:S4/K2I>I]Z[K51@FY(E"O8,>%KKN8":#284CPUU2(Y):GS;:^1FO!-VP5AB<'!K4)#(0::8?:!K
MXHS,I OEQKI>I]TWDMM#Y!)3;0-OQH>J>=>)^3 T%_UU^VB=,).6DU)5SN* M.-I2IY+N32UVVDDZU!%>_#/'6I5JH,8
ROEOI0E5,EG&I.PX05^CD^VLGZ)% M3X;Q WIOXCTF^ODOS,_VXMZXG@_OG1GL,1?Q.U@\$F";JM47:7;;C..%4 A
MCC#3@?>IMT_7C="ENU1=:R/S[6I?8B#;/!WR+X\RF*\$:NX_9IX)0]"YNJR1/' M^_(+<-
&PJ=9I_"A%0JW95VX7*_G>I7::UXM7.;>M6\$?&M+5EDW?2V)I.2VD MG-N6?%AO8G<92*P>R[<[F6:TQIX%#N=.I;U<
+?=:_7J%&*">_Y IU= MJSIX[KI\$R;<#K8=F9^XF19.)8M>IRB7?=D5;&-# V7#P\R\=6O6G/TIH\OA8 M:IOM\RIZ'P'+U.-
MJ\$M40Q%664Q:10D@[DV/4/2*"OX6-F-FS9JPO,Z1D[% M!_71)(X)*9\$44=!F(58'4))Z_N J6;I: SI-
_RG.PZECC\$G2\$454/E_U?E MKN>Z)\#PQ6!TJM7(N7+28HCI<3/I?5!NU4)(*Y+>)\IY>R>)5UH<I92O/GQ M8O[6QK?
I%9Z_IF_U_T5C?_M8S4G#(v7_ _EL""IEV!|I]N'M%N(RXJIVF5Z M-
89L\$3V6W+WH\!S(*TIV(V7'_B&OU*PJOM;*>O/3&B46+I\21SIEJK<93P M/1Y;3\$I>S@_*67\$FJRQCSY?.I]Z&!66\$8TT-
L:N*9,MIRWI-R5_.C5,4@^_! M/S(U_="PZ]G(='C>,,=UT&G7HE64[H-G?BW]_5-!|H[#^)|XL!=""<0|<34N6X3-@%W
6"L YTW/ID;)=5U;EQX#/V^DH_-\$05 M_*:6HZ"*IY(RR<3(?#>Y@RZ_(5,&\$.5[N:F,9,QNN:^Y(&4XSW.41D?
5LX8812EO'RI#J3>*"S-XI M9NQ>Q"&I%_/#<: Z=O7A]LZ9-O6V7"/RJ0^'_+I3|HH(F,8N2'4Z:P_):N MA*41I.6@?
ISB7?_79"VMMM?+L<)XRH \$(^^^ID078H.)EK6I31PH(DV\FI\ M*1LE" &FLV>R!Q-
&F%W<,)68'4H8^@>6_P!|6[O&^Q*K#\$@&XMG3^EO7#^S MIRF46+JG71_ _0VPO>%F_@+4M?
S7\$LO67A^GDYQ\$;>W4KG;@54H%054IHY""^AJG'!9TGTM(IBZW';M0@SO!|I,%.>8T M?
1^KSPMZ,I,PSC\$(A,Z*,F49HRCE4R3C"22 K/HBHAMVELU&@@7;I:=OG'_M4ROYVY0'J&H[8A\$\$\$PO?8Z>9]!EP2V"+?
J\^15=927I7!YR^XCV_72LMFC@8 MF]*Z5-LKE;XWKI|&RYYR7OT?ET_._%?GYQ3I=E^BZJ|=I[62-
I\$B"33H8N\$(9RIF88(O!;FP6!6#G_8,9.Z.M"* MVO.BQ4!AS'@!(L70?!TVI1\$(Q605R@AL>A7D^'69^
A'OK,/4A9!)^7"=/+A MD&WW"7VT:G?)AGFA"!<|+E!6;+J0P6J9"8BP/P1F,UAG6!^5^AG<F4#>J-
MVVY"8OB4"8VGFCH*GP_!8\$*!FKEPU.>Z*W3T_54+"OPIE<<2->Y2RSO75V_ MW6T_6I#EPY@O8YU :I(>H20##
IUM/GRI5I@P\#>T<143&OZ@6)-Z7AH+%C) MKOJI8@H|I.)=I<I F* XKUI#
[.0DYA+U;_&_W7.EXEVEPOAN#7>^WDOO6 M-GW0DR4H\!O.]|=P=/^L%3Z/M"!>|K!QXV-
RR\$8L33WK4[I<3T/?_K3F^)^ MYZ!=86 RHF*QIU*W.AWPPFAAE_*V-RE83W'4U :28@8-Q6Z+JSG]+6=D);
M+OLK(\5U-!GI4\$R=@75\$N2PJ*%,?+ Y#|K\$&G30W\NVJ<\$'NEQ_.B#V#&\NU2C@I&Z3CHD_:Q;S3F_*Q2 Z M?Z5MN"
[*|JB3E*I?=&_1ME092PP_N<5WX;<+@>^>.C3PB8?V7I;X52(Q-8*GV) M:P*V>-
<:1M.B[4BC0,=#@!QO8;.CE*Z?)8"P!G#9QY5");TY47BI,0.8TV(MZX3N."=#FU"V6TR413(K>::/W0>
MG%YX4%X:S=3!Y8EWHNO3T3+ RO\$Y'/28^)\W1V7F,' <=!'_Y,@+UOM&?A2?E MFA1KKB0"OLDYL1
CE%@H_@@=_)Q2SQ-!IEOOH EL_YO_8;=C5%JW#JS^
MLTE18RSNCH\$_I_%6')31^I&Q/B!78OQ42_BO9:69'176X|BV'IS9F>-XD,CTR\2!3HYN:7N/(E"IQ"G6Z3G#-
JE4S|G'G%I6-2#^ZQB"WVHR6^I1|1'\$;|UTARX\$E<(" M&P_9UMIR+-^W' 1UZI*&XCCO&_L>6C2(KG*.YT^P3?
MP5O)9X_.,+S9):X_M!UL5'(I+!;T%U9+*2C(^8B4-O518YRX7DNM&S\$5Y8L)%|S/AL|G*&_>T0-X
M%Y62E3LHSMG=23R>=J]M:E#C*4HW2EFXSBS>=<\$=1:2IMS/YOY)8F4%I 2(8\$ M(>05VO.O:7HMUMOL--<*\$ER#
[;MXXDIC53F M#&=:?\$WL.K?TIY^SM^[NK3A*BESWLN\VN\T9*.NZ(LEA%),)?_@%C H0146H=8
MN#@_V>&XR)IOPD\$;!L_MY*?UK&_62%I\JX>,.C7HO^B9|B)QWGNP*6 M*:(7I MGI:A\$9'Q;8&H_.75X"O.H>0IP-7-
3@?3TFW(" &P*7&1VTA^,+9>\.K# (G!""^+= =>) MCYAY6:YR;!.LN_"98A\$+;;P@>D?|BLE5-&9#\$!;8%A=1B MWI
O7P%I,3OPD(P;G3O_);:O/I\N@+TP_A%&@S%" B3I%Y7VXI=" 4Y5-G4
M^_")>6T,Y9"A198AF@O:7GE4QK\$NP(9E#?)PRV#7R1W;+;'S47T*S%\$.O'OG M4NV\$MN%>^~?V\$*
<7V1BP9H6\==RD,9#J_&CC@PG\$@/_I64@?2V&7G>GR\$S MO_YMEB<7G|+;B5/+%HNSW(<;9<6/AUVM)1B@^Q+I%
|O?>MU1K9*VPJRS%(F6_MYZ7_.1;_2HQWLMM@;:898Y7W(O,N,Q).6?J=A+=CG?Z/4&QI%*WVE">2C>@?
7<3>E!>%V-Z6A>;;HP(H"VY@&_M:L699GVYVC3@HY5'P50-&'V!71!_RXK;S&\$!(=CW4P:ZN9Q/Y.AS;Q!
MLPV3>3OR/6N"9A8"@97;Z%4N!?!+IOZ\$%JI_DAN.Z"XM67"*_6N?R^AL(& MR"IB3'0Q'XN\W8?
&6#R&\$QMNHM3I0@_GAMH6HZ8C.R";MNU|RNNOI^P= M-4A?
\$,R7S_8MSP"#M@N2S5!B;Y;'1EC7P,87@^6/#RZ(OQZ+I\T4
M/8\%/-=4'S(C%D"ARDJD,7KKKK^,&WPG8"5=SH'NB/IL6(*!8MC4U/_/1YF M2(XTE=057&FK^>_I2;>XG88UG?
U4<%RK(;%#QIS12B_)3POJ*?2EG\$A)9UP MR!25W/I\NAU7Z;=;!1A8_5O"N#
+9;&0\CC#1945;H0BM8OZ!EEN*&I94/ M59!R:1"V3"X\$ _&*J/+4YX'H?M3-P*\$K"&N8ZW""+A0%I#_R<""&:)NX<\$
M#Q4_Z9RXP1.MX<#7!HWB=BU73J)1\$HM,XLHK4I'Z/MY+8;_P03.5,H0(XN M&Q@I#F3SK!YEL&%
<,2K8ZD\$(XN_V0GML4DEW86;&QYAW/XXNV2,W,&_I\$ M\$+OW&&O)MRYPR4%L_7H0C'_OL&L^&-
MAGX"MI7IMV.GIW'WHI#_95WYA*&_M6APIYY66I3APT =F5TI(%1R46AE0P'WEUOL13\JJ4%IX007|L+TTZI+!
MJC3'I@4R+Z/*-2Q'3B4>;Z,T<3-&2904P\I\Q#_DI2I1J_!W=5#>%76^>
MI\$YU?;Q8+9I030I)K4!0+Y2!G>YK8I3QV0Z;(FG/9Q4+BQ'/>;=7_9V_N;>#?/&%K.O+_MUY;_7A0@;S"N/BZM?I;4?
VS/Z_.GYL\48S.SDEW97K;+;S\??FIH4// M073P8V2UZ)NOV\$(@)>X^IY^(MIQCY(&7DI@?
W\HHRQ2V3%J\$UH18S(Z^OM M&KS&KJ<#_)DSU^_IMF==TK%1I5>_C2%9%NR78OZ\$/ \$^NCZ1^8UJOB'WM.5-
@R\$CRJ\$N\$LF6>+!99TX&4CT02,%8 M^"4SJL_Z7I(M&T;)<532RD02XG<;+GUH\$,)C5W>9I/67#P652/+(&Y_9J#B
MQ4*8"GG.G19S&^208_'M5C<;8Q9TE0^)/EV7S;7E88HPZ,BPMG;5519ZE)"5 M-3M3/=I4FEC?_UV-NERXBI\$?
4%GIHWV33IG22F@R;N8662&DV@_M\$ _W&FOY2J'A8D)Z%B>ROB6P7E(A+;7RVP"76\$14Y'W\$\
MB_6H\$.@)TCBYDM+""9"CY'(WX6LY%(RNMZ*U=%ZJ(F7=4V%*(A>MUI7I MJ'2YJ_SE-
=*3>7Q^1U)7Z+O:@U3HN>D+@RD77D#_"I_ \V#QJ+KU=<;D:6V?_M3M."C2E"3N,BO"+1,*
ZL!GGTWP/CD;KOBT3W;3;_D%I^?0U"71H9%)"S" M@W)CDLU6BPAPN(Z+@W%?M05F(^YID>TDH4;"?
L|BQ;('M6=FA'Y=>E!G=URRSQ5@=M|")6TF6IQDGC MDL3LA'8A4;VAC!60LFB:P>(H'^<'I'3Z?"

(K\$XU8#+%51&Z%_l^SA(S(BI+0 MY3UH2<76:>=^>DBD;_C4LY.&@XN=>4:3,(X&??A@-N6A/EJ6CQ(T/5I@7(R MFS!JD^/L_5D,Y^AU,8WBNJ&!S.0?4+,OKJB\$/DHLV3+Y>/&\$!DCJHF&.5,(H(%\$+J-OH,ZG%&C=S4 M!XS!F(<,3/RHSZ,E>Z?G9X_-NENQ4823(U>S^ND\$8H?EX>.P')-(JOHf>W MZ?+E+3&X&DXDR\$,NL&1ZD^0\$!4Y->5@>|HH32EH!W4(UJK^5-<=5.JJ5,(MIM\$643!0F7-AY%WH("5J:M<^9IQ(?7="<31(C^M_I4#;X!(Y0F.6^>)Z? G%_J-EV2,Y;W7QMFO4)3I,RQ^GT/Q*2\$H&_ M*B&A3QWRXJGB!1! /0%GMU3V_N^W81YF7-5+3I\$15=K!R; H:X@U;+!&P MDMC?UP^P)<%^B^(6!_B_?"YX!&!&1_YJL=V#@_T,74.)U#;^>GSU!H!K M:_0^.#U<\$FVCOMW2/S=E#HH^"X" _XY!9_0\$ _<MV^PB;_X?4\$L#!!0 (M \$F\$1%IQ ^*<#@,/,&_9 >&PO=V!R;W-H965T IDV;EB;MVC+;2GN!PO>D:1T@A/C@)H?4S/%UMM-N_K_M3H5Z?J^_#H!GGN?"!9KDQAL#M!XJ89XN4_%J^"71 MYN!6EG/G#^+)."%*G*+IO+@Q+4M2BXXU%:2!H!%#1/SBYZ7C(H?)&XLEM!M!)^B.Z!#? 1QW0\$^K,G\$<0_%GB)2KE@=B-AS5FU%)ZP^W!|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l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|N/=RU_M3QAE15F+YM(I&7C)T&N^P%\$XDA!\$44*? %2!#A^YQ?087ZUR^*YU-B_RT+; M!\$5H/D+T;Y^!#/@7/1>>G.YMEZ =*BD&4!_O_M E!+ P04 " !)^A\$1;B5HI1B #_#^!@ &0^AL+W=O;0EZJZ3 MQ-5;:(6LAUJHR_07QTFX2UUD430^U^LE&HS)IA=318A9LIW8Q,STH?> M@NQ;5MB76U1F- X_ZZ&!XD)LM>4.RF^5B@X!^?W;WEE?)D;61+6HGC+^ZWET MDUI?%CX^!/PE<>=.YN S61GSU2_NFGDT!H)084V>0? #PA\$M4RA.QC^_WG-%Q_M2P^G1_8?PVY32)H<^"UZ10!F!QON!QEIOMHH%{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|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

M(5BPI&NA0M&%TZP2*.0G"BBR\$14.65@I^:146;2'SE:W0DL!SSV!=V87=Z4P+FK185C5_M5GVHS-
0_4!4IH#8W"AMY9^NOA\$HF/(5_M;>JVX%<+B1U+?X8M&)"ZC5'V_C_,\$YV2(S\FKX_23M1#7?8^ONE=S_H
MCL1JV\$JK6UF18@,R5%EP1;SY8N5UF7;1E.6223C,,P5X1@.*+|SFE'T2B&f
MDAIS65)RA<46&CFSZF\$\"EY/6_A\$G0S\$*!&OHLJ1YV'FK;>?R'R-M1_+T%_M/ISAQ>*Q)8^?I@4WRH)?7AS1KW|#
<35AD;L3H(P*GW0YL64_>IZ/BV=M%+QI
MP;+H.5*UE4\$1&9YM38\F4_8M+K#1M_15MCA_H5Z2YF32P%%C_2K5IM/(+N)M
M,S(X(>Z0&1"Z6?.\@.*_!O#QW&=T3+I_X28!#S4JX%I)ZLR1,BR%,BI_7-5W_M:KG@?
=4ITGA7T.XIXO_0(NUL@_J@)'IEV^>F;5/RI4/MY<AJ=L*REW?R= M/BI&SOVE?25\$?>
Q.7^C9%L&4;L^=Z10!P^JH\$3M%8Y2(1&M2<^!_!D\5_M>ZI(D:1!""7PJ#""3#;KSKK%?=M^D,5Y,)TFA^S*5TUVR^O.4>
(ITAN6A!_4_MY!IG"S=^#K="UP'PTHB4)Z_V8IW!V^2YSIU_'FY?ZCQF>N%I(EGRQ_3R:MH
W7_D:GUBUGOA+QA*6*BY1(-CENG3B' MISW<S;S=S=E<+;G7_M;I\$P5UHD)3!0D/!T&.EM*8?'
+@E@&OH+@XR5+ZAF@Z/I)@3B;I!&TX;JP8: MB;_!N522UCE *>"P5-%;E@(>,W=1PSLG@%VH?
=32@QTV=L\$1U6J!RMZ!R_M7'(F4CU3Y&T:L6@500?HJHES*^).W9T8WI#P@'B.15S:17?@VIE/8/!VX)O
MP:8B_YZ,E99@%AU<5K@90QH*,F.%^6@"CAZ^HHG4WMJL9(Q,1@_ /Q=\$JTT7'A@?P>Q*A>222C*9W_M+U\$KM-
_K4AL#15+-L%3V"AR1=(M0)Z(4E8R9KW>#+(YZ7F!Y08\$-\$)=S_MVB!&HRH0AS1HX:44;G5LRQ\,<+15>+|#IXYH
+))">PC2:=O.0.;9JX#/'5M_M!O_C'A0&=&@K.6%4!F-"H01?/(XQ9(\$12<1%547BB3A&N(A<*D%F>3_M*8TBCL&-
QJ6Y10521C\$J-8\$C\&9-3)@^:V/:V'!SV1/ ML93#@.:(<\$_1NX'5CP?<^D(&#ZHA8
MYI"Q"E/G")^@RI,BK2*P2@+@M^7!)^#T8)#<@+ M<0S'F?<F.1TO.P2HC,L:\$>6_L_T:QGD\$EJH6/
R93=8<;>6R+YBC*P2_MFA&OQ6\AY\$3AE@;#Y-6A/MYH!;X)179#%XXD84>0)IAC5PT#TGJ-\$ODP#1
MZ_15%JPI;HJBM9)^+SPA+I2\$QX&QATQO%O\,IN&@14_16+I0?I4"5FDDT_MZ_L@+!T6)KV1A('=3PQ((Q9BWWPPJ#5E
AVD10I\$5AD?&?N&)5XD)!^@)"M^I8;P2ON)!+7*PKO(B:@*1>"P3IBVC;G,Y%)DME_I3=:YD9\$^I!>./5_M7<;
(/R4GGQ>9@=NI;KF81G=RTI'"&169;WE6<^!9!>?XY"O5\$'QCKJH<_M6&UYZO@5"F"(_L_\$4LAH-
=3\^C9^N92HH(R!E",RE;:C,I=%W4_*@#1@E(LW^^AL^UNOU")_M90!PP0/_F_V>Y4!A15O;VGH2>P9_?XQL!14-9?
=#AM8=6)Z+7N18?5/Y.CWW_MP0/+6OZWM+4F(3R/S3FMWWVI/YH4>UC16_J"A@AI;_!L*&%55(HZ,OJ_"F_M\$&+!
I4M5?&\$-_H7G90NRH!7IU;==I=^<^J",OENJ>\$ZRR3"N_!WB'@\$MH6A+BN;2C:XAK86;;8M_M4+SX/N2?@=LE?A!O
'BYWJE.+K;146_867MC<;B7B".P5%<+*HZUNNM+M_MNE!0WOC>*C9H>E<\$UH646:109,&D3G\PV")ISAMW9HVQ-
5&9<LLW54FV/GA_MC:PBIBDHKBWKO_6E!TEQU!G87MP8GU\$);D(S'8_A_TH0&2Q2U1A:%9FX<MQT)KD9CIC%&
(*+@!UB<"VLWR_P^HKK"/P!02P,\$%<_281\$6@<(W=)G_M!0A0P_ID_1X;"!W;W)K&UO5?;MLX\$/V5_M@=L4-J"-
K8MO:6+ 25LT;=&=2VB/6"EB86MQ*IDI3=_/W.4+9CIXZQ3YN'_M1!:'9V;.G!DRYRMM?M@H;.5.FU(X>C6+
MKJT,BLQO*HMNU.L_NJ60JC4YIHNS>156._W=?JUM!;=XN2R1*5E5J!P;N+UC0NTS8WAM\DI\BR._MF*6+
!S)S^45KU(C;IT1=N,IZ1;7^?09+16%1IAU=@.QRU(^(MTN=Y,\$912_M-7_%KS4/QM&O22C?"65:F5U(3/A,(-
W6BH'WABZ-F30_M_B+F!=K.>==1*_S83==N+QNWT1-NPPANM'*YA=3OJ
M>*J.S64%)_Z=Q<6_8IC1A,MA)A2\=0NTJ8:WGVCGH@f\$'.80C#^CR')!D\$
M8=#GIW@RH^64C*G<I045CNZ^U%L\$S9/O?ZNS5K4&5F6=#;)BKJ_WI_C!15R/P;N_MG0.2#EB(DH/2<\$FJURF^1X-
N2XR"HG4?G(P7-Z%<G<M3M=T_XHB%PLDJB:@DF/3).I+.&MVR:D@N%OIOW
MFF!&EIO,^1X8ON1CUI&XJHWRGZH!37'Z13/^_ES2:KRHXHZI?@?8@C\$AGL_MD.)6^C\$Q^O?6^UTL3RI!98!1==
>GL&=&EY.#NO:6)\$O9_.KUU;TM*LGM=F_M3D"W6X8#^/#AB@(?GA#YUPJFE9&%\3!7@S;
(O)@WPKY*.;2R;@X>#UPHW_MY>7)=RKICYX5&6Z.ITXCPG(E^AYOG>THN#KYH->DLI_1/9#UX7NSM6P9"7S
M!:=@V"FENB=NOVSOVM+E;I@W%_0:81:230_"IVAK!W38;S4S;O/B=.40FG/M_MZ-KJ'W/Z/P\$_.&1#ZG28ZUB_18/N?
Q^1?4\$!#!!0(-\$F\$1%JD1=9/JP4_M_/L0_9>&PO=VJR:W-H965TCM3&L_%8)VM1<'TJ-Z*\$-TNI"FZ@JU9CO5&"
MIW91D8!>OPG!'<_*T?3BEQN+T9LM!NXRE9K_M@P/CZ?F&K!2U_!M/BKHC5L1:5;
(F4>R)\$HL+T8S=G89XWP[X>I;_6G3="3_MA91?L?VO1@Y;)#(16)O_H+O&S\$7>8Z"P(QOC#_M-7*F-SP1R,H
BW4C1A-GSYAH?P\$J_M=(PDCZIAH+JUP0N21W%I-W_G!_M9EH+H_M,'A;Z:2W(4N90?EFY(@9SW-
1@!@.B8>#U7!8;7MX^?1*!+!JN27;G_M.I>ZN=5-CE.0PQ5.@'6RTKO,I7@3@1C'=MJ;924P'Q')&81=0,?6A!S*0M"MD6-
&CB-T(!/P\$%_M(I9"J(W;J_MNV21Y?G.Z;/(#8_6I_%_5&6)K+;RE*7=E_V^@^JS;=B.MZM=^NKKO0.?U08_M7@>
0RDOD+!L:41G!Y2/A_M&>"(H.6(X/I:FB7?JDOG_M=MZ5J/5V6W!8#AH!?
&6VXLLW"W@7&K6^\\%1C15&=M/=Y7NT.QM(S2%/>I" M0:Z!-CVL9M\$%#Q?>#>%#?
(>3M!9=_A/O>XE+;IBY%'FAX@3QZ6N/I\$M'I_3
M0,AA:FZU!00K<2/*"E8.:\$(O>ZJY6PVA2^)_N1=1^C2!2E210#*HA9ET<\$H_M>ZE-5E@;9ZN5\$BMHWD->IX;J(Y!UML-
TB_RDB=KG(T<PK(FUQ722)\$BG!Y_ME>D\$803\$E@HN!C3!#69IA.J#YZ#YOP#/?>(3K:N!+"M,6==/==\$%T7%BB"_K_
MA67MPFWK@FE=N(?6#B1V!7FU@0IB.Y%&U".YRW/I2'LP@\"(*03&(+OD+AP_M'/_881&C@>O@6\$1@+<<\"8I>;%
%P_X04X9\$+AR;\$_7I#F_O>C.%W%WWB_M_1982!BL81ZJ1@YU/(1Z%/O4=\\(AQ,4MXN*#\$?=:RG0+>WU?X@>E!\"=^9@;/
M.:M&&JER2!O@<ID59-I>J,4*IKMF=Q#FNL&4OI?BZV;FGNZISH?*;""I.*D_M""%XCD@<10RI#
(09SKA13.;SJSF3N'E^0%B14I;E-@_,"R089.*6/,\$_M&3&DWS)03!\$\"??D9=RZDA5_K>^W&DT15FOINVHZV-
M9?;&fUI+!/>JU56_MXB%V\"4N=TPC.,*J^:M<=(S?V>KN0!BI+MKD6/!4*)\\#I91FUT\$%I>\\=T_!_M4\$!#!!0(-
\$F\$1%J.D*A@2_8_\"40_9>&PO=VJR:W-H965T^ZYE_<>DCG?://)KH5PI'.1*WO16SM7_MOA@.;H6!
<#70J%+TMM\"N!P:E9#6OK!_V14Y;_H#\"?#&DO5NSSW8!F!EQ7
M+I=*W!HFJZ+@YO%Y!ST1OUVH\$!N5H!&AA>GI=\\>Z%<^UC>&KP_Y1.%D)9
MJ14S8GG1NQHN\$YHOI_PFOQ:N_7,*)%UI_HY2;IZ(5\$2.0B=83_\\2,@7HD_M)R#0^*?;I'4NR7#IN45_ZV-+
MNQ2N=_RXSMHHS7HL\$TM>Y>Y;WX633R>_M8*ISZ_IGFWKN9-YC:66=+AIC,\"BDJG_YYR8/6P:S\\(!U!A\$GG?MR+
\\S1V_M/#=ZPPS-!AH!^%\"I-V?#QT@Z<,P:6V=IUU;E6<_VDM157*6P@_MI-
IN47##!1*TZPYD)8B%,NVYC=L;1*3>6287)NK)<9;.,@MT_1C!4JF!7A:Z4_M@_NJ1'?>T=IHBHCW2/I@I!_X;J'3K#1M
\$187\$8!F\$8LF00>P4HV/4\\>4_ML/4I\ZK_OLCOH__IY^UOE,4ZJ@K4B/Z!TV99AG")M0<=
V:YFN6;J5==)5C,X1^G+)'D3SL, S+)'WQ&M3H(K9JH<6<6:TCK)XP\$_MD:Z=>9DWG_MC0?S"\$UUPJ9!C%*.*##9?
YV%10#)IW9U!^316)0UB-XSB8S^=HH_\$8K_-Y_M_OJ(Z8YITOB?=1_1V>==HJ_TT<+%)Y@4J)@WE"+!EH+JZ7*5!3
M&@4MF4DP:95%N'60J_M!P:IGC(V#>3+MH^I&\". M2'^<53C=T8SY_1+H*TOIL=(.T\$-2TI7B!2H+
I\\WPFX/NO;_G\\@U7C+4YG3_MUD-)V6FV6Z-7AA=L@15D)Z-9H:MIJL-4&Y%JD16ZJ@%N<I6M.G4JM\$A974N
M,Z^USSWG.IH&8'C/KYH.N%-L8+G/7>%CSIA_A60)G>BQ^0.7.5_48538_MF_%.#*TV2I=/IW>4IZG5=!&!
(J%\$_.^5YB2720?XE4?@_A_MRGHK@!;M#D9((A##\$DBWRR7PA_:D=)&NHRGUR3SP#YGN_+;I=\$%&PV2^!0U_M
9V:34_IHEH!=\"34IKI7C7KHL&\$WE9&OU98DCDCRSQOR-T_C
M<13M5N!+=8L^=+*F/OLDX0_1A13^\"/VHI0_ILCNTL2OF528\\=XG:21TA9,+*ME?%_92&W?
20SA5WX+;9NFHPV2_FYAGL;@&I,Y5QOZPF?N-W7^@1_W_M%&H9S_YW\$:6?>+MJ?OI4;MOJPQ&V?402:CZ%M>=
=G2@J_KJHVZ?8%<^SIT*:6;Y_M6,(T'\$QQ:C+UL1^<@5SXB^!\".UPK_>;HWAA:*^+S7ZIWDALHU?BI_U!+_M_P04\"
I)A\$1:TI+MAU8\$\"R\"@_&0_'AL+W=O>>:9%<^I;^OQEQ_YL2L+I191IGUU_AJY_M-*=2NJ&I2;-VMA2>MS:ST+I>G&
M'E>7L1?+JDPVT441P;M4FI_O@M)Q7*O@YY=7IBR5A^K>\".DS<66T5WI#.E7D1.^37!7D^O.1_M1RSV&*4MIF6#FIR
&R?B&E\"Y\$OHU1ME3@!%(HDF#TPODU<1/U_Z%\$?Q0\"3C_M9/(WM\$^Z._=15F7I0+BV,JRV)WRY6SENTS^^^9&B\"3
X'X9\$ZXJ6H!_%Q^/S5U*8I%.80C(^O&LF29BUN):>K)%%Z*1UB.IK@!HR\$FM3_M8%*AA!
<_9,U\"NIOIQ_<YK\$)^<_O=@&3A\\#P3MTJ+.&2L\"K61_M/(&0N8%1SDB4:QK;1ZL9%QV-

%WJ.W_UD/(F3_J"+*KP1:S@)F66*1&T M,*XV\$T""Z<#"@Q%29E*F9&LE,<'E42D] MH?OH%L>PXT:I<(<=6
?"Z#IA=>TL%!,F8JZ6,L\$%90VUTBO:RD)8S51J:D7O" M(C]H"^D%NIS%071YZ'314QJHF=HAMNN?B8O2U)H-
H[%1*U8FL)HCT^ZLO7B-MOOA&Q+/9(#Z:B1]9Y>|A4 LK B\T= _VTA**7I,7I9\^G<#%@Z_C-DL11GG1 M
JDX'LX2&93V71PDB3BC[?H3ZW%,! X\$ QJMNFW2'5V<^0^SGTG#=#.UFI
MYT(X:,TUWR:AUHHDSTF<OVESJEIG:OOI6:#67CI2\$C*!\$ISVUI9>C/TT1 M\$#EX\7N%|<<<9>AL8X=|O\$Z*A^,FR;C
N7\$=M%/AU(9IM"/!O: JU',|?FI M->>=|9+,OV_M-F;>7"P0-KQ|D-QI=1L-|8?JQ?,N'C)^/S-MHO?LXW/!:
|8_#%/3Z8IXRDO+>4 TZX^GK#-DW;6"%:9LLSJXIM-F4#2|>?' M_?#0Y^?4><<49+=A-
,2MRH63G.DV#_="|@NFG/(HWESFKN6=J,TM_4:KN/A MR302MCDA-3?>5.%4LC(>9YOPF>-0298-
\YML!7:&PZP/Z8N_P%02P,\$% M @ 281\$6N|,>DR3 P /P@ !D !X;,"IW;W)K&ULK59M;|LV\$/XK|S7H\$D"(7FQ'2FH;
<0%Z'!5C;(\$X|_,^T+9(D*1*DG9-MR7|H|C12MN9AC;,"^2"1U|HOSY,|C3=*/YL*T<)+;+29|)6US544F:+"FIES
MU:~D+TNE;V9|JE+1:32RTC05(DKC~"J&9?!=.S7'01TK%0HKN,0'#:M:Z9? MKU&HS21(@MW"
(U|5UBU\$TW'#5CA^|5YT#2+>|22UR@-5Q(T+B?|+>|FZ'CEI M;,"X;LC<%ELE#J4VSNRTD0.T(HL+
:@=%KC3VFH2Y &4N&2ML(|J\$S-N_\$S"R6,?A*FLOV1<=\$J^JM M.S&HN>S>|&6|WL>?
R&0|HU2#WO+!IG>:OG+RL|.|HRVWK|D'8|8(IWX0B\|5K)0TFHER'X%|B1F,-G#ZY|^9L M'%D*
|B"B8AOHN@N4OA\$H2>\$3058&|F2)Y8_\$;N|<|ZM?I4<1;+YAD(20 MQNGP"-Z@WXJ|QOLB*&-1K#*;O
MWR47|8\$Q|F<F39TO&H)=RHNF'R|2<#7VR%VLUK\$OG5I%1\MX M6|JRG|;=:!>O%V\$IM5%17<4&L\$DG,
HHT<6N|E,207|L);>"MVL'C'N_LG:"4G8>C M"\A22#/X1K N2|DQFM>\L+C#|VP'6087R0#R*9+T)P=\$F0PP32
M<)CD<\$0"HUX"HWAM@5E1M'4KF*/7BX#.K'(EU'LT>1;FL+1_(4SG3H4);/M+U'S-7+4W(4AJ M;,"HU
IOXFV.X%BI:9TVE;KOTR/#@%4<'E=5N#X&S! MA:L|TF8YY=G|T-S^|).83_EB.QR,N5;ER^@ M5MJNOO>K?7>
<=4WA;,_NM7YB>N4V2>?27./SC\$Y>=^VJFUC5^!;Q48;CA|6 M.MU%1.LP/ZOE3*|B8N0/./T+4\$|L#|!0 (-\$F\$1%IH?.K-L-O
)L,9 M>&PO=VIR:W-H965T)H5LA|M:%4PV)*S5S-EK7D|P)(Y1M:\$C44-WPRTK(DFB.|^Q>?&'KC3801O-I
M3=;TCNIO|4+B;-2C%*RDE6*B DE7,^?2GUQ%9KU=|NC6|4W|J-D*<2|F7PJ M9HYG"%%.Z#7EW AC>|=IM-
Q:0SWQSO?#U8|ED21:|%_YT5>C-S M,@<*NB(-UU_\$|B/M|,0&+Q=5P4M MG@.,D&#/,MBQO J.(M|0?
BA|T+@!=\$10+!75JW|35K=P+Y=*2PR2OPX) M;N&BPW F<2;J)CF=.9@9BLH'ZLS?0O\$3|^((V:@G&QU#G|HA(A8-
IR|6YH3J M1A,T#B|HKE0'H",AAO-"W@M;#)5) M2UG!&01)ZH9>B*,PC-PT3G\$4^Z\$;1Q|M'Q M13F'P<^#R/43?
X"#S\$VC#=#|(|3>'Z0:'U9,NF|;X6|)\$2KCPD&=# M9A2=B'A#"**+0|;,
0B|Q/6,T3AUXR2&7ZA2\$U@07)NS&H%Q"TT7S1C)C?J8 M+8"W#2(C2(WB=,?T5'7G.4|%7E|P|@M%?(.W#"^D'?
D|OB,Q|S|HK)'X 53 M'3|F&Q|Z%1%<|, _S1#H%|J9>P9RC,993^2LIW)FG9B.GP>9S3*L(O_HH=%
M,3'ZVO.VJM"TV&V%LA,;1ODIF):V303F(02?"HY8&>8_6:XP-A |C%:,P? M|'A#*X'%QWJA3;2M+7=X%@3)8?
7>X6#=5QH)FBA(TMA, @_B*,6P3"_,S?# M;.P9UD)3|%)/"7Y|Y|_1|P_03D"V1|88@H(?99BR8TS6|!2 7Q?PS3KK/!A
MY_6'W83\7PEYCI2DB1N\$H=40|#%J&&.J|9T7^DNN<|YR_M;X^?/EXPS"Q MC|A|&!^?&.>T/-^OX.|O?
BHOX?:OC|M#\;O-C\$>|;MRV|2UK8^|5B|15V;^N9C|X6UP|2|O0!_\$:6F1\$B6&Z=BWY;?|Z5K.Q>U=<=@
M:*/2\$#+;/9EB|P\7NU.XA0>Y|!)>^*#@&&>TUC'B|K6U;K_#C6'_WK%_VW?>
MEVW#^>_RMFW_3.2:X1%SND)3;YC&#LBV%6XG6M2V_5P'C.KP'?!&X,T|L<)6LE+IWSL=J&L1.\$#986L? Z>|!
M|K%|T'|^+;G#(4+O'T6|_YVNG6E;A>Z-V'W|? MS|CQE:HQ A=V/7;=Y (JWS# M+9|_M-J|=FAB3."=I2RMIEU!
<79VK5|JZ7/|52T:|+@V|V3L&,*\$P604L M9ND)OM%0|LCSC9|A6|9YW?.Y-%M>XC2@|V%0/V P^<_
(%4)Y.BA/3|/EO0QVV-L%8-O6\$A-V!=A^P? MLOB|YGV|AX-EO@>D6M URE |XSM"O5PUW#648P|(|0FJ.D-4YOSR>!
|S*XF! MOSO/0Z?4^U_INR3|LQMW|H%8R> 6/G'9T6R"@XH*^ EL"(L\$EK+BY2) W9 M|;RGIG%|XR*#)
LO"MH?)PGD83;&+SWAY2C+SH'E89|'65(4YPZ9CH#FR1J% M1S'6\$B(+64SHF.R\$A5G\FZ; GDU.*4B51|D)71^!EH
MH%2=M/V@&%:'7053Y=?Y&?^9Z(VA\$+BFT)A*#4#W&UL|5IK;|LX%OTKA*<8._M"5*2L_3K3*3|(|GL?
E@L(HK-V)K*DD>2DV9^_9Q+RH^DMI/,OMAD0) -M%(GDO;R|CW-(EU7|=F|S+ODV*LCGCNC=MV>GAPT
S&;I(U^|74E)AR6=63 MK,6?|>B@F=8N&_L,D^|)"6\$|EE>|DZ;+O/|+48;YQ)5-7|6L=I?O=?R M|
(VA|K|H4)WW:P|YK)155H3>#XH@|A1RA1NT-*&?U?NU|4%#00U_NG&M|U\$4L25Y GH/ NY8RX76>-J^*?^;
='>2^ANZRVO6M&?5|2^NFT|SXPVJ MHO\$ _V75H&ZD>&R;M|ITG:'|)" #|^Q;9X>5#HG8T\$%U'937.PCR6K|VNSD
M|*ZN64VM,1H|^*GZWE N+VE1SML:7W/T:T_W0@F;MG;O|D453.K7|Q7RU'T_?;|S-ZWJ-B|!|^O+YJ|VAG?
>|>|U|P|VAF_6@4 M,8?-|NXXQY"HC'UE>N= _/B#M.+5%EW-0E>S;?
23.JRKS_>D"@90*TOEGM33PK|U795\$4^S%IH^GN50P7<|!\$4K+TM
M4QDNC&0RY;'6S(^E7C&C>1P;|K&BD=H:|B3S81@'R|9-)W(|>'R^CKFUN@| MUI>IW5L(|>)|3O?8IZFK,^_.|AOR=4-
=)%H;V"5-J9_2*;*T#N5/^\$T"8)^+67.X29|.*&(|V_&503QO 8K%(<
MU#)U=^MW|T|T*;*7:1.Q7U|H#?2|N?;RTX|IU#%<_Z|8+M0|TU0O)K@?4_|PF&N'#P;S>?9)M|<A&;
|H|9WMXL)A:7|59.N\$R#M5#+^V M"?O/P |YU"N**=CW\$%>=Z\$B37Y|_POD93+I?-(^14U3E\$71#(V_??.9)
M.2%7(+|B9B@^/B<& M5_+1F)>+ %DY@|9%ED|03N.L9>,3GSA7\$G&FM4U;('Q:UE9M5WXXNB\$GZ.9J
M"@ "71|K"3K7CH22>;&VB(HNB*M_NT3,5LZ|H?TTXK.'MY|UWW5Z?D8|R
M6|6+FWO6R;_OMTY\$^5|7VR)NBI|JMJ;+RO|ABG>L_@W;Y+C|C\$_.071RPPW
MK:D68.TF60D>X:52|>?^4AK6&CDO\5&_H8|G-5#1<58OY;(25*#;|=))XN M|M*
(*W1'_C)|PJB"Q8J<&XDN+!DQGL:5W@DM,KU(F48ABB(F*7EH|EN+"&K)
M0A8E:4L\$CQ.-4,2U&<4MK<7'GK)J^VHQ#QR^AF+ (^590 S'27 |O>="|95 M>9ICJ/+T+E3Y17A.E5H_5PV&|^|?
AR@X|P93|M7|8DVZQ?+)"POFK2M1^2;1 M=HK0+E<4YWB+UZ.ZFJ\$U985;7_H&=PK'Z|V6%V|?H9H7.S|AV?
&X>8|UA> MO*6F_2N,&*KHG6K7-=M?3,B|V5K5::!F-IT6.66)_D8EZ4-(+@1D33C2RG05K8.\$|H|6B<^
M|BSJM/9/B%ZK/5J79%UZEP(>*L+5.7JDLN\$D\)(#;FVT)72GGPRJ\$XK?H4 MV56H+N)X+33V@-QP+8E3
%1'RGCR8B61F\$B|H|D'(W5P0^138H56QDBPDO Y M7"&2_@G6P'#E/PFM;K@\$|HR*ZJ|@70|\$,|".?
2HAVA+^7!\$GUANK-X*Z"U/1+^A^HMJRP+SX\$-%>F*&HG% 6A
MHV/RN81@34Q4V:14((W"D<9#V9"UQ|PB<)|M(4&%)HG@1>Q\$5"F^IZ.OL*,K>Q(>V5 M^YX-R|CBC;F?
#='1CDVW|UI(9 RP_?R&X,J|1|Q9A%S(WLMP?(K9,<CJ.\$WGV^|O<)|Q(Q,(5XYCC/'>9X^R XSP:CV4 MXQ
WH(U@?7D2=H0C'2QB>_H;HUW5*;GY";AFR6*3L|2S62-EZ\<)<(<6> ESQ1S,> MKCQSGA+CG-?
9"X0|_H8O|M>MP)P?C/-'XCZ'0^=,*R.JP/ M(F;28AA
XLS7IPSM9=K3M8N0+|A1Y=|&R0>F=E&VY#+MXN|H^*#E_4\$"%C=L3_X"4\$|L#!|!0 (-\$F\$1%H1S0;@H0@-\$09_9>&PO
M=V|JR:W-H965TM*8M*OE=,MYN-4\$|O9%_D_7DSX9'OC|KA?&|JO
MN#QOQ+V|E>9#|U|AVY*0DA<6>FBKIB2JXO)3|HD|!;^&70C|HT9B1)Z\$9;TV|:9?# 2;HNJN
MXE/OAU_6>/T"S^+N%F4,X41E^>J?F2*9D;.#;R|=C7_14%Y=8H/"VPSES^M6&7U1K(|4EJ-KT3RU+JV?G"0#1-
6&2|F#>=&.^&ZOG^K*K#7|OLIE_ES M|@&8-X6V|OOJ.2W.|LSCSO,<|W@B#Q_-2W|OS_:"A|6^BLK'6K)/O'U5<
M=3XYSZ;XG|?HE\$ES=BSQ>3,^+6#G%Q^|PV/W=-^8#WN"8|M;T"IO M2|GJ%;NN-
QMD*V|LX^\$WJABV5)2ZWVHC|N16TNV|DN0L;CNF;,&|VN'S4S M>)*M|7E#JN*SL'R|=KH/!
(VHGK|D)O%X_%HS456M*%G6=,66#X&QAH)ZD.; M/&-_ET)U><\$05;E9XM\$VLO3ATX?'WJFVJ%
8<_BAR&65(R'YC'W+W'GLN4^@ MVF'JIE'JV6\$2>VF0L&O1% 9@|E&"L,2;3?T9GGHZ\$8N|HQ*59@D/B>F|"?
MZVJXKX05FFA*\$KET4^SZ|!;#X21|_Y^CT.'OP|?|U9DU|/K%>?R#%ROV,<M)|J2?3O8CD#47SKH-
T2A6!40(#1;MAK|UIH57;ZC9+.F54VMP6V;1KEDMWTFY MY&EZ-
3\%B>_8&6)3MY4AT66;0QZ0)8GG@_B_!S(D6\$XJ7"_V\$VO|3MX0O).\$ M3=>S*>>SDTSU|J?WJ?7L.|T|^@R-/P#G?

)&1V\Y'P>)A&KF,JYD=>#&F# M WDUE)A>@^,=\$T99'9P@>->0\$&NN
MHNJ_K.LRE\JH8KGN:!\:QJA#\$3I==%@!4JEU&B+!#S^ ^K2X;@:/4ZO7\;Z2
M7:F\L@'66Y\$TN9\RMU;RP"1L9E)D:_99JMA<'L>V@QMDY) MVX"
HUV45ZK>T!1PI>AF0;:'^>T<,R&A4>GIE7G;I2!1:R#Z,RN3-+;,PS\;
MW*K;TGM^S(^T.>_0YH0GMSFC%NW\3SAU;_FF;T#;56'@9++I&CUF4;44!'"

M4A3@'V1.90R=Q!1S_"2E_FC*G2CRI2CRL;?<M&N+XU'>B,)C1U?="7";.?=?1JI=&*QPWZ-8&3IHDO3S?
0YOR5JZDHNUI-1W M L\JY5";4! F.SR,>YVAPX'5D\3'6'>TJ;:= M\$G!1VZWM*C/4-
N!90X+5%R>G+IF/PCNEP=7U0;_6<_4F1X,SITX#NR:*(AO3<-HA01 HU815A30A*^\$A'YKZTVFZZJ>(F="P9PQ\;Q
MYWHMJGN'S!Y\$V7;9'B@?!\#4&5-'3A)2H;6\$&Y;:<IGOO*CI/ U&I'!^7=%3G'
M1NJOA5B"*_0>W>=HSA;YKW@JSX+!LSN1YAS@YA'DIF^)\)*T,L=1&.1>\$G/ M8YQ\^Z6JLHU-
)1IDU4HJ2YVC=CM1Z'?C;_N 'IF5C3J0<02\Q,*/6\$#^T4 M*F>AB_V)LS!PN!^QR'\^>'0IME'15'TV84)TA8;(E
2)0D5);ZO(T M9 F._1S_!^ VQ8*4A0F+OMRBOG2(0B<_/.9CUTTF(%W'BD.&_!*\$4;<=N1+SU
M'9=JQ!3#UIHFLWUN&JK%/G+";.9'O># 7HS"&900Z(>385H/GTD9!/7MF+^@3 MHPXD-
(#S\$QJ\$<%X4!>8G<<02#@?>SAT72XL3AINU\$)IYG90T<&W<IKF,&H,0 M=GMVA&A;U6F"WB(X1N9D\^
R.ID_T!&V!CD^IT3MFT7;_L H:LLIA?81!;B. MKR;J2RJV8WRCFOC?L;Q+S\RL ?^150MO;+@<+75IKU^@_IBM-
IW^C<'<%XN M,SKOR_Y@K0RV@;_#!JV1T@ML*VUREDSDI!_C+M+KM;_IV+!\$9OMC=2W=OW MH!1HPXKN)?
=P= _B)X*H;[Z;WOV^)\)/=934KY0I+W7F,X+JWMEW7TS=V?D MRJH8>F;:RFPF!,\$/%_5M=E^@07#R>7_P902P,\$% @
281\$6E#&\$B M!0 (@\!D !X;_!IW;W)K&ULG5=K;Q,Y%/_TK M5V&%6LF0S'M2VDBT@!;TL*%5JO5?
G!GG,8P8P?;TP> ?HJ>;5_0IDO&7O& MHQSW _AE3;?I\$P(1)=MH^S18;_<_&XM-5,M-P^UW.A\&6J31PSB_\$F7"?YQ\^
=L_52BU;H:S4BHR8'@U>1@?'F3?#GR1XLINK,E; M=6 MG.CF+UFIV=&@'% MIKQKW*F^ ^ETL!
D\$*JW8\&M7_=DL&U#56;?;A3_8M%+U M3WZ\;_&0#EZO"!>_2!:=ZHL'S%'9!<&GU%QA&FE\&4X,TR\$GE@W+F#+Y*
MR+G)63>?_P)>=KRA\$VYG!_9QHK>JCI=WW_XG?MX(NW\X=%#HQ8;5 ORX!X? M
(!B>J^5FUEZK611WP88@NF*;KRD>QSO!_PEJN>41(SB49SNP\$M6YB;I3UVNAW;E!;!G?-*! U0+U;82S&8/'T2Y;_7.YBG
M*^;I+O3&)&DH_#^@V\COQM\/_!;TU0W L;H@Y_"YD9?REI8U/4& MBJ\$F'H6K*!W8A!
M^&HICEA<%/Z1EB5%,LU&+D7\$DWSH;_0OQ"PQOCW6LK
M3>^ ^6\$);49;W!_>L\$/1!;T'C_17^!AF/\$Q;GV6/UG?"F@;)362;THHHW+4F5\$6,&LE9E\$;WE)UA M!/_T.ML6';0F8-
;2SK65RY@A\QJ"LOC)DMM:2[F/PBI94HIQZ7AD8_D#R>@9 MA"QCY 0H.9!D8-1/_!9!8435&1;_!L6.Y;??
HEKZY+!H'DN\JFZLX@NY+_V9 M>R0&D'ISZW\$UO&5IX-LKX90O!>R4O>!)LHU,0 M-K+R!>B_;QM;_4?
FSU_T+1M&V8**R?*V+_9QGY%;%PX!_L-W;\$_Q)DJKS MY!;_!\$IV(7OE6\$3!XTEB_Z1!AZ+!ZE4\$)G2#5@<H!
IUL^;XJ=;5+_R;_J M8C9*8O\JP^@KBP>RMV#%J'A_ _8&//E\CYOL@BU6%*6LG(44Y;\$KOY03FT! M?/+(D?
QLSI\$"NTFC)0!%K\$BCGQFMU51)C**UL!_KTC\$K48E;?;1-WJU M0_2N4_4(IVXXZZ'G+KU"\ZM4O9;LH><-)/S-
HANZY#?#N+_V?>(PYVAGKT M_XOZ*SIJ>H"^^+* JZR/H?'HR@'BSZVQ2BH<^<%VH3!;V3!ONEYN 6=>X<I M55C;
<(D5QA_IJG&2%EO@+5M7CR_U!+P04 ")A\$1!NRS:~00% "I M"P_0 'AL+W=OEZ6F1!ED@ZV1J@6-
_Y/1E!^=)LI>@JQ*7)N=-;A,9DI! M<0_GUD<=I?WZ+_XW"F7F3!XINK? M9667)Z\!!7.15;_SVK!_3?Y>
(*EJHW_A/5@FY%QV1NKFHTS,6AD.WR+_YLZ MI#CDP3;_X<8A!+R'0)IE.V'%Y%BK-
6AG36ANX5/UWD1.MNY0KJVFMY+!\.16 M;"EF<)>Y;U&CL?""^M=)*!PXUZ8P^_Q14#_.?%QN0\$'\T/ 94!!"I6KMTA!8
MA=5#@\$#QW-(JVF>AGL1WV'Y!B+.(S">_!>M\$THGC1SZ?IQW1FK":U_/E4 MX@_L_#2LZZ
CTXD23T;4(@;U"D>35RIX&KS=0SK>DHIWH4^N!J2.KGDBK.3R? MP%.LI!/>+!*"6A@CYI(4OEDH@J5=C;6P6_&I0VM
M!74%;60ZG&>JZ41H!^!%O+LK0'9KE2!0FIR2!JW2V=D M\$&/_WY.O!3IU;_&HMR%A>
M;LA=;'@M0^2(^IG0^DZV"Y@VJB<&!_P0+BL;J!0KJ@;@GY\CBIM#VPJ%;B+_F.5D?EJHU MJH;5+_C?
2E*4%5D360.A9U&X- W0OW2@KZETY6K^Q*FK9EG5?>1\$IHUM&&G4VINA)/<9G^<%%;9<=BB_P
MZ8KM\$IEC5=)'=%^5TU!6#GF(*IM;JT'@AB02LS0M6,%C6H+70="* M\$)1&G\$4L*#)*
(L@Y12(>2K2&K\$J4R>!H2N2)&!Y6(#O^/#M_ ^N"B\$H7IULL MRLFU!>_@/&-1DD""BB"E)C?+H9YN@5!
H!JQ!_"AD<1KW_1L"Q.OH;)^Z&(Q-EJ7O M3X>Z\$U.^5KNIS<_!\$7D.2>OK_@IGJ^U.FCJH!1%(L!&5)Z)4+HIY;Z_JV'H
M!)NX>D8)4+_SZ708R;Z;#X/MI= +2;=3 MXYQ<@S<9W7MZ&!;!ZLZ/Z#-E*5QSR^7-%^C=;@;T?JHHR#8/+L!V8I'\^U!+
M_P04 ")A\$1;Z38X>!L#_!IP_&0 'AL+W=OVA\$)_V8XP!'/8E%I4E M3SHGZ;_?27;_%* L76GN^^^ ^G.HXVQKZY)-
B62KM05!!5UW'LL@)+XG\$H5HW>95P*J;)*.AF=C(R-2FI<6;_U64H!_L=

M*K,91TFT4SEJB"OB">C2!JSP">FEFE6FGX@XEEF5)XJTB&BMQ=>M!0HZI(%W\$RBPO!#_YJ?VA)!'E M7"KSC%_#Q
SOXYHNB-ZEQY%O,2L/K)&:2]=' \$K!EW@IX_0_P?(G.MA,IAA2M@B>_O273P^W;AN!P9_3F4=8.Y.(SI&^C;52+#+
<<0=XM"N,9J*PRG=.38#0\$^COQ<("R-X@:5>@7D#QTJ;18RYX)(MW;1^TX4K8?_@Q"Y34U9"OYV>#-
/DZL9!MD_*\46F@CU*0>Q>0 MAY4"#\$&I Z!UK/ER>_!0E1(8!T#;_!MINI0B5PZ3IPDZW/@8=FF?PVS M+H#"?
PY8;02X;3"/F&ULC59K;HLV%/TKA#H4"2#8>EBRDH&EBQ T0-%GW81@&2KJVB\$BD2E)Q
MO5^>RE941#7FSI8!1Y>_Y!D3DVC@1=N45U-HR!(IS47TELOW;L'O5ZJUE9"PH-FHUKKO?7
M4*G=R@N!PXN08EM;>C%+=QN^A4>POS:7)7K+R "\$\$\$N24\$CH7N(&J(B"D;W!)(8M:>%X?;\$#-
MI+2CEH@M;'5'Z*PY*R_#6%K^U7M?H>3T)XN;J^V>[SG8>>2QOC55U MOQ@9U\$)V3_ZC\!-HP2+XR8*H7Q
YWWM&CN4MMWR!U&K'_%DC&@V<5+<:R0E) M07FT&K*7&?7GIG0HNO6F#WP\$VK
3UN#3MIXED%YGPYM;@+V4IS'O&Z0XQ^ M@AA&I%Y)6QKVJRR> LP17H#Q^C
3HZB7@+^83%H<^B)J=P(L'S;#B_]; MZTP>:5(MF%_7F7&DR3OXZ)B!GOR&I="Y-PW-8>5@;_!00+>_N/\(T^'2"
M!&P@/#N%OGH!H;I#;_EL!NNI5I(G;?!,X+HJK)D-EG;G;_! 8G411K0OJ M,5FG-W!^W2PE LN?/O2%?
_@)D0D/Q#AM6HI;XC)AIB!#\$P<854W7_X_?EA\$ MX?
R389N!G7AEQT"@K<9*SY7&Q&%*LZ(+!#TVP@_E3JS5MB(4H,\$F%1'S5&MS7 MG%\R3!2H\0X)
L!B!H!&0!6!<-7;_BRO?%;!&:R0(WPFL5;_>1>?L%S8/ MYWYX\$= HNO#3>(ZC*%SXLRO8C>ZD!4P)RS2WP,R_XP;
U1CB!G?A@0!AT<4 M^G&R<7A<<_G,*"3DQOUQ@&SS<*J&K3S7!;_E\$M 81+X01_SWGTHOD\$NF;5
M4^/_726^L\$!L'HUF%ZF_0*=<GH@!0:AE8;ACD&0RF)0S)SEOD&OM1DN(H MGL=^\$BU8XL^"&&60_861*8!]=#
MD&XYZJ5.4NU?_=&Q?>O@KJ40!1XX;@;H_#K2%0B3 MNH)3AV1V!]<5(PF;?
(" @#0;BT)&KI57!>4'(GHA)6(,=JBW7B&"LO12@ MN<[+_>38_3=G=@8*VIEZ
H;J/=X3V!;X^5IV) VK>W9ONN=YB!K(*_K@T MF.P3C^GN+M)-K&K<^9\IB!<)-RSQ^@::#/#
!1F%HI!;8+@0KO%4\$!#!!0 M (\$F\$1%J87UJK^04_#D0_9>&PO=VIR;W-
H965T+!^=Y1LRX%C9VL_Q*+\$>YIGCG="LA<+I;^;&-"JU4R*PVO'#O!O7P0N4VD1G>;S!Y MF@HO.)\$+2YK?
FWUXD%.8\LO6L+_F9CB(!JOLWM-HH8;)9(I9D;J#1+_FLC
M_ ^RJP_/_=A&2%Z;R#S)6*GO//@<7=8%HO)AI81!/_W\!J3A%(OH!2LI;F
M9_/!PK!UOE.OHR%P6N5_"\$C&U_6!C6(<+_RO#ZHO2DR7J@2X_I"HC; MH\EA;JQ*2V-2D;H_!^!7/91PH!@/O%8;_@-
B<IH+(J;P15@POM%J YMF\$Q@_ M56=-XF3&B_)H-7V59&>'_ZCE7!DX%9F(@NE2;IS9JS.*?36P,F3&="HZA(-A\$H^
P(O_MZ.S!;Z^=;SN!F^GJRZ+_+O/&\$UE-H419XVT\$@W<2!FRN0;X<_1F*9310VU M*RP%;6ESMJESCITX2-5;90G"&H"
MNIW;I7@_YE...%)U2!Q'(^E\$4L_Z&X6/TK=*9R);OWPT"OW!N0&86R3D+_ M6EB;O! S>E5)*IF1F4*?0;P1!A_Z>
MMMM;L)OGW;_!VN@IPV?(-TWYIY7P;3MKUDTY!_1Y44#M>@=IN=@!%N!_8 M#/K@LBXXAU!%MG*!R?
=^E8P3BL_>Z;&7RO<=K;4!Q!NTO>+H&?J_-YG_O M^>>2!P%=G7/>'R@+&PL+L=4@;X;'5R\$8POC M)80JFZ.VKE;I-

+1B+;(J<,(E.7YHD#4J1.DIJ4PA/S-CJG ML32F)D!HUM39Q:*Y9\$8E,G)65R*A70KAD;<\DNWZQ;:1"6/00N EC15O2\$7I
M7\$QM0\$9^GSO41.DC_#@2HKP1RZY>U%09D);CB\$3W*>=O6)0>2FA="N M%Y'Y?B?RCMHIVO^3A-
L=@:5*VRF=FHI5>=^NP\$ =Y4^ZCQ4I^:WBJN>A7>\ MF\$S&B!G@L_1WI BF3EJYH!:" PMT(:\DRJYA6,69UI?
SDJMYT:TDETP:~2V MJ3;88!98QJ!J Y 7AD>"5=YK<[<5Q_Y_IG\$IQ MV^7HT=)/V34F&6&NFPLBAJ^FX!6A-K+IT?VB;
<\$-IY^KN>O(WZJ)=?IS23B4DVJ MC:XQ!A^*PK=VJR:W H965T MU*%I B^1:LIS4 I^D&S9@Q8*D6Q^&
M/= #2V2)*D2I)U^2^1U!HWWW1U/RITV7VR#Z.I^*Y5=18US MW562V^K!EML+W:&B+UMM6NYH:W:)
I0SR.CBU,F%L.DI:+E2T7H:S.I->ZMY) MH?#.:@.W;EIO^&Y1ZOXRJZ^!P+W:~P?)>MGO^3Z@^ZNL!I+!)I1:M*BLT H_
M;E?1=79UDWQI8/"WP+T!6H-7LM'ZBI\7J^BU! "B97S")O>W_6I?1 1./K MB!E-(WC@?J_F003EHVW.*MEH%
I915M(B@QBWOI;O7^HPU% XO\$!+&YZP M^VS+-(^JMTZWHS,O:(4:WOSIF(E>.0MW_)%(O,9)Z:'&OX0?"D<~)M#%S5
M^*=KT!P?P!M/WL6^6R:J^C I^K#W@QAVOMA,P8?M7*-A5!4C?6/ EIF(2P M@Y;=A;Q U87,,MB8^G+S^+~IL3,
M!L^;PQ^S9(^SGATL^UQOK^B M/FGLX:ZG-)R^-YV.K2=/&X!H0A4JY8^VW=70*7'=D-&A_+
IOPSN<=NK.K!! M1453Q=%\$G^;#:/B.G,KXHL7I3YE)U**RIP/XR,2ENBF)%Q.2^AXNX^ED M^H1#RH&#0K%99Q?
LO&:/!<8D\$0**PLXDM^97D:LV+Q5+N^RST.G"?S86Q_Y&8GE 6) M6W)-+HB C.,PF^C=!?&ST8I&F9AV=#?
XTWH.I:K=UAXP-,Z/U_U!+ P04 M " !A\$1:E-ZD:\# W^0 &0
'AL+W=O:,D;Z4#I8"+FS!D.9^C91NFOID^T^%0+>:9!96US&46FJ+!F M9J@:E+2R4KIFED2|CDRCDD97>J!91&L?CJ&9
2IS28MJZ9 MWEZC4)MYD 2IB7N^KJR:B!SAJWQ>YOS9TF*=JCE+O&::B2H'\$U#ZZ2R^O<
MZ7N%WSANS.\$87^1+LXZX>=R^L2.\$ HLK\$-@!G\$&Q3^ 1&-OWO.8. 2&1Z.
M=^@_ ^M@IEB4S>*/\$!HRTU3R8!E#BBK7^WJO-3|C,W)XA1+&~.FTTTO BA: M8U7=&Q.#FLONRY|Z?
3@PF:,O&*2I0>IY=XXRUMFV6^FUO.TTR8T- "A>FLB MQZ5+RH/5M,K)SBN<85:8PGW^(BR13CPI8^S?
DLL@3OE**BAIKNH)7H)(4 M/BEI^P_ R!+!P\$BXX4GE^I(7:XKY*23% M
U5=V0H\$M8*7N3G&I33:EPIAI015^I=KL"ZS??GO:I0-EI9O5-TPN7W_,IHF MDX_&G>C.I>ZG+H^0T%FHMZ;10/FNE
M+?_&?#=U;*87SIX^T^Q9^-0F%>9A;"I>=%\$!-^E.UD\$O>&VXJ)@UY2U%W M#L65%R|<I+*G)8T2O/2GIL^2ARX(ZS?
GIB%_W/HB5WG^IESY/\$G+A#?>=>=>I|UQJ?\$G6L848^EUF->NVO;&HL MJ16VNI?
VL M7P55W&3ZK=T^*3TRON30@<\$6F7 R"D!WUW0G6-7XJW&I+!%VT M^2EC1RP:U4Z#UE5)V)S@'^!2XA|02P,\$% @
281\$6MF/!V0V!0 B1T M !D !X;"IW;W)K&ULO5G;:N,V\$V/5@;LH=H\$T MNMBYUC&01%IL@&8;)~WVH>@#
(XUM(I^H)2DI^OKQ^4J;:#D*\$1?SOMBBQ#D< MGB,,9!3Q4L@G-4?
4)QGA:H8S+4NSSU/7/F3H4)1;T9^IDSC0UY#R;B^=R<|DZ@HSL;P8!:(7&_ =\ M?F
MAC<9EVR&#ZB_E7>26EZ+DO(<^5% 1^G%XY+X#P.3HU!W>-/CDNU=0UF^H!^ M)G&37HQ|
(U^F&&B#02COP5>8Y89)/+C^OIT(YI#+>O7I_UY.GR3PRA=GXQ.!U BE-69?
I>+!+_@>D)!B!F:I_8;GNZP@J906^=J8/AYT?RS MYS416P;:IZ V#<&T0IAHJ_!T=J@GKK7S+TF+F^*:3<92
M+&\$&:WH1F+FKV:VOBBQ?F17G0DIYRLM.3A^8% 3&%;SXX^)^0GK-!PF22B^C0O M9G G.IYP5/+?&52,B,I?
(Q0.YZI3W3WVT,\$S!^@@"ICE648O@HIFKPS M8WC)VI/KOI/P#4^" \$&Y%>H><*XB+%M O@T;3:N84O<IL^K8B^?&\$0
O\0C\< MJCED-X\P.81A4)N/>LRCIYOWC1Z_WSRTD#%LA1H6>,.WA*80DU89&J7C|Q77 M^IA%1%8DV+?2KJPC|^M3
W92@YE|9S\$9#D_WF^;_9X^@=_M\$SMR MJD/44OJ9D974>U0AQ2)9 9M)1/.R@T:9^YB8RO,JIV/1^KDOBW;_ACZD;-6G
M9>32BI@16\$>#XU:#X_K 7M^2P.KY+X.VT+8(5,IDG@THG8\$5A^I-6@A/K M%&~;HJ^\$R2GRLP7MX2:I
&6<()D*IG19RI^%A1:%*N3.0HW:BLW2&A!UI+;
M2O1H,^G3SNK+OMK9)_V=BZ=B!V!:=;0I;4IM4IQIN":LPQ23MN!44!TWMAO M1=F7]=7<3WT1SNQO^ESO-4G;
EW8K\CISK\$G;7\$G5F)NTP7*#57)IG%9ZJP M%/:Q9@79EI>S5IR=I;#VNL?.GAK;>G2(^/O-LN!J?B"+/S\$MD3_!71X+=
M^2E6G^)%3M^B5VA=);:*KN _I/K05S)Y1(MK*&C; MTU)0=4MAA!>4N)!*IR^6!4HUYZ794Q,2COTW I^H M;
|LW>ROA\$BUVA=958E/&!M;BJOQ^X% X0VC:%?TN5GKTHM!V@?8>I\$XK6^=
MHL6NT+I2;0K98/0C8IS38M8I6N04+7:%UI5K4R(^AKT6N0Y921^B^3I "I^ M-T%BBGE9)_IJ3A\$-6&X^";*=/OZ#=R-
BY+V<@I6NP^K6 MR>|HD5|_N>CHN?4D=@56J.)MW7DE^*UJ=H_>O MS3EC?
92U@6D.*6^9G/%^0893@00/3RA\$R^;_HZ^0102P,\$% @ 281\$6IC^S\$W: P XA\$!D !X
M;|IW;W)K&ULO5A=;|LV%/TKA%8,"9!&GY&=S#;@ M6%D78 &">-T>ACTPTK7%52)=DK+3?
S^2DF7+4=QD?)B2I0AIR^!(O1QO& MOX@<0**GLJ|B!12KJY<5Z0YE%B(FENN5+5ZPXX,R RL(-/IV
M2TRH,QF9MGL^&,%*%H3"/4>B^DO.OUU#P39CQW>V#0IDF4O=X\$Y&*IR\$.WV=CQI(B@
M@%1J^JS^UC^#HM!;AQ?&U^KI5.#I^Z^WI+^Y%4RCUC C!5 _D4SF8V?HH P6 MN^KD
I0\!DU^"YHO984POVC3Q^H.2BLA6=F U0A^0NM _-0(L0?PXQ< 00.(M#@"1^X"P 82O!40-
(#+*U^D8^1(L63\$V09Q:W8|4G1TZ!5^H3J>9I+KIX2 MA9.3>3W?B^W0G"PI69 44XF:8
4R!H^BIFAKGZG:2G\$2G0+2G\$J8+00:9"\$Q3>\$S.8/-W.3 M_!%IGB?HY,I^H (17 DK!^89F+D2I6J^K";-
FE=UVD%+Z3E!^B.49D+=,\$S MR+H\$KM^H%2K8^G4='&5,(#U^H7^& B^(>@8T>STI(\$GKX<'H0VVD/#5_X
MTK3OS>3-UXK(^@.9,XR=\$O7(*2>)(^_EW!T^V\$4OS3-P=U^U%^_J=256 M.(6QHUY) O@:G,G//_FOITN??
C;) \$DMD^6VC5MOH&/MD;YDOC3,(35D)?0+6 M1 -#I_0ZXDWM6GC^M:7^R
MF0?/CB!) 4M\$G!ZABC(OF2/=OC6U6*3++%\$UA\$Z:H6.W&I4UM;9(EEL@Z MV@Y;:0>VG%@3Q4>
<^#S^T8^3GP>\$P_BBWXG#MLDAC_L1^@7SM:*I1/J@I0@ MK\$25:J)"?<(S+!7LOXPHAK4BJY3_1;OU#5EE2VRQ=
<4/=N(^!^#1A;_ MMD2VRQ M=0I>U0S^T6WSFVP?G=G^_V0I^ZO&M;VX.* MJ2G^#JJOI0&&*.IW-
/7IQQWF2T(^*F^A^+WS@=HP^OI H;Z1;5^1\$ZPS^0I02P,\$% @ 281\$6E1A SG6!@ 134 M!D
IX;"IW;W)K&ULM9M=;|LV%G; "N\$50P:2T:3HE^5M^ 2I=D9YWA!<%=@Y>!*+3^4Q*>L5Q0D2/JGY;-
^\$EB2+;H6CQC;5 MVGB/!\$%^O=?OB87+<"R.6LHFV^I>EFS\$TM22S#Q^5-#6>DS;IMX\=S^4.ZU-
/_EIH>/_P8NF5RRB0Z M19^IE-0^A!^3%>JM_0.\1S!# 3^T7S1^VUM1G4=FU/J@%&Y0!XSP
A1KBZXW\$@Z2YHM4Y)\$I05EC3J62I^=TF M:"*4;O^*H9=ZZ(^TA/4VPQ1A\$^M:#8TZW?
#K5:DNQ/SSGDW6C=RHM1;1ZGG MC=)XIJ+XA)M0;NL|0MZD.94T108+^C0P\$#^8D@8 8(Y:O37:O2/XZQ|2&T@
M83\$DC_#!&W.UH<>U<*>9L;#YER.YK1),(9?^PW%B@P5FOW|DR6.PAX87 M\$D: 8\$YX+L;AO7CSB>MB|05=(
P^ZY>_J^QA801@)3US^HM^7!44Z\$?NRA MIE+1G;IT^9 M/- "N(=[&!!\X@HT&/2_)5 T5X|Z-0R|VX>9T-
)9BR1_VQ^5 N=HNSVTN- MR05EIOEUQ?IK3SB^DUH|L5E8T7NH?^_1TL&R0M!J41^J)JK;EV/P\$>Z
M5HU!"PZ@M!B41|HKD)UP0^IKUB_V?E ZPT5S2DI-SD?:"\$IBN9&OBXD8^A M8;_S26)3FA8V)Q^Y=;<3I\$"?
3PHONB9V>2-ILH^6F4 I<6@-)%<I6KBQ&X M=R1G RTR@-)B4!J!HKD^U44&I\$V1W^YLH#6&BN84ZKH-SM;?
O.;GX;H;U-S< MD-95 >RO^AR2FVX4WTC^L]=G-FGC9C4E.=V@U>NF4850 L)H+08E\$:@:*ZF
M=;T!7QS)R\$#+!Z^T&^1&H&CN|9YU^2 ZSAT\$?NS!-WP&NPI5<^D;=% "17.C M7Y<%(G|98+__??
5GHN3\$T>P7UEB5^8M;0<^'3Q%X;_I0^M% 2HM!;02^YDI6 MUQ,B?PIBT^K J^T&^1&H&BN0ANWK_OO4?BARIY-"F.V
M6=_IRIU^M&\$K.T M//?_#RNT4R&IV+HY>N0?_ ^#8PIZ<#HKMMS<>%RG."O8Y^86^M+!%#&/H?I9 MH)OB^9BMIT?
A)2F?Z^DOY0^MU1.N5D^7^7LRR_"L;(N63ZS4WI08EXE|H MM!99^7;&.*D;6#^_R2\$?OU@!U@_37X#U!+ P04 "
I)A\$1.U(\$)?I.\$ M^X\$0 &0^AL+W=O;:=5480K4E=A AF160|J9.XZU<
MNVHC@45Y4)IXON<;LIXYLPF^;YGS\$W\$5B<\@|DD:INF3+I<0^+V4X^;@+S%'QSVJG%-M#)6E\$\$_FYELT=3R#^!
((M4G!&^MY D)A/B^%DF=;H^36#S^C7IEYP^DEDR M!;35^2C%|3W_#YY7-R13V?GS?Z+OV\$+H14*>572OEY
M3IV.G@Q! DHS#5A+I/=<^<:- (GHQY;DFX94_=U&H\$C;T!K9MVUVK 0I@Y. M^P5R!|
ILXP<:>)MH^L5Z)XM^ZQK@*\$!HCBNI48H?>=0XGLM>;AQY(O6%V2^ M>;1?&W2/5P2>PYAE;U;_#7E.?
G5JGRA2(\$YR#&:96.W_ M>;!Y/W%T+UWI%

MM6_E^GN)@^1%VI90\$4HHV/O^ACVV_L=5/T.K/TN"A%QTGPUL4;8\$^5P%J\$ M3X0KM?T7A@R.Y*&!
I_=H.A.R@&AE88=XF00%L338XFF!#BQ%5!XEA16)H)?&%<4EV+~E:&91Z:T\$T+F_&MNA!U+!)-Z MD7#T!^33_B_2*
!3^"AY5:S):!H1@;H?0E\EQB6_X(!Y2+J(W)Z^@,+_,Z_M;\\V7&M\$-1VO!P:M>4 MO1B<"C<&\$1A#Q3K(RFW/GNNXX
Y5,6H%1X^!#TZ!7VR:U&MQLWJc2D^GX ML\$A;D?C',E\$OZ^7X ZW-D-K=\\!3H^M-32N^WO%,!@>C0=
U7+5/4;M1W=?KZ
MRJDS!3G:~0&M/HX/WV>U0JUF>BKL.V.6IWN3!6&GZIB;39T!\$ZC;W6Q4W^7WD+MYO+VHI_B+EI7\NUM_AV;VFN M
#FL_(C4>GBP)C114+!V%I^~TZ"ZEBGXFRZ\^:%X!H4N^H#MS&.=Q\ MT\!M!)JC6 FL,,H&N+~:(O/!,6-
%IO\;+X4&@_Z^64,Z:~2_#W*R'TZXTY MI5ZG@V(SL399Z:E(?UIZB7GZ M6-6_W/6^_+HBB;IT?
SMEV^~SEHG.^R)JWU9^7XI^HEYDK?BV?CAIEC7/ M9MU!B^*\$~#XI661Y>71VVOWLICX!K59MD9?
!IO::U6^1U4^70^@>WO\%1U!_M#%_F+?R!R=GAOL@7_B!:_+FUI=^D3F>4+7C9Y57HUOW!_!=ZAFP0^E4=T
M3_EGSA^~WM>>O):!JOI=?G,U>W_DRU/B!9^V4B,3?ZWY)2\^*25.Y/-6!6A7 M5!
!8_JK^@_=U8NKNJP^US_RJHFK1::@49+/DRW?V9>M\$IX"O/G_V1Y!@<0/LP!X?:_M!-
#HNT!4>?_YE(Z^R99FYV=UM6C5\MG"S7Y16=F=[2X_+R4_?"VEHAFHOC MVK!~.?<^V!UIZQ!TG<5K-
5P;WJWOO(!H5#F?_!9H5C)=M?I^++\^;AK>- M=S!H.O.IK!7U6SKSK/+O+BI\$->2,?7RW\$S!^=\#;+B^8H!OLO+
!W;>;5JO!~; MTY-6G+0L^3+=GN#EY@3),R<8\$.!#5;;SQON^G/&9+G_BKG9WR>3K)5\04!/%#
M5K_U_~"1WP2>;!^FGC?2O.=!UN5E^U_UN)*5S6WG28L.N^3MUXX\$+7(3_Z7_M">TRVC6^NW_FL_,
GI&IOCJ_N+J^~NKWZ_I-W_O/\$^X?OUI= MMR?A<;GA=^TRF^+W1V*~>7BIYD=C?_U+0/V_V3S#%!)L@B6G^13O_(DCI
L>JFCWF M16%\$;~DTATY!GU61SXOGIZLNY;83Z+IC%O^A^K,FYK."U"?!)EG:R<>[DX_!MD!JvZQ^R_.\$P,ZZ?<
O&>^SF0SF_U!P6\$!R7+;JZS?_(Y&3)QELU_Y5>\$5^M%QL^*%V_YUW!\$O/8>^!)9;9LW)BAX4+!/NRCAlH7J^GNM1H"-
=FSEWT^N@Z_MH#\$_.%>3G:!)>(TWAZ;_FOY.YMK^*:9KF&(3)!~;9SC8&WW<4J+V9Y^=!TV)(OEG6U
MY@)E6!MHN^V#&A!P&C#_6#Z9WL^*:K/4ABFCV!KXC0!PV;+7H!Y;2\$F!~>W&_MJ&E5-
FVIVM^Z0#IAVX.H;C5M6X!J+W9!\$@P\@_#U30L-=VU^D<^H&O7TJ1#_M!JBM3M^<*(S%GZ\$!8#UG=Y#4=^>(<
!O2F^JLGO/ DI(S&_1N;_I9Q_@5)_M33=%,7D_(NO9=25?^VH^Y?DZ\$WAA=28TG_F"E/GIT!A4U,92TXU1L!W_M^U5
MKL6!THT@.=5T(VNVS!JLZ##.REN5P^3^48S_M.I_*28MLMJ2F.3IQNNH/(VEIKNBB+N_\$13LY6V^!C:OL@9FOC.H#
(UEIKN_MC^+J_~J;LGXN+H_%GWOQANK==X_M+K.G3=>93:~?U2DPZVKLGLO>J.C#:=V^9_~\$U9F@X70."S!&:L!TD
MYGT\$UW-V9PS4^A5JA_~"!L!5>;S(RNQ!WCH+OKCCDH_R=EX5L^=L_E>I@X#2_M8#~@5P96=?1J#H!~>
<60/37=3D=-0LRQ9AR_~HJZ^N.F0,0@!5(0=PH3!0Y;7_MWCHK5EUXJN3MMK<5+WZJ!101I>/RZA4MRC;~>~
BL4GIA_6I3X?K^!9.WL\^M!J6^BM)^F_*\$A\$YH_GKLO_YPM0^NX.S'S^P>~CX/83!/?#WEJH!)8DNZWQJ_M?
0!~.F<.)K&=+C"!~S=F<./\5GH.R+V_MP948!_D^D1GH@LL!FS4&M(<^VD!/=>W7QIOVU*//YVO@YU!^0/D0P7R(0SR
MXV3!IA0%PF/PD<[FCM\$*1^H5B.!6X.=51VWBM5_~"IC!HXTIT5DB:@,\$YNH
MS0^6FNZ5:@8BN!EX)FPGK+J!^3JO5DWO)!Y9BKM&P&+>>&H8)_Y>H:A.L=U;
MU4!\$^*K!OAO>A+I6CZHP5+3K5/=101W%VYAO^W8(W^4J_U@*LZ>S1^*KP7_M/8=;BI?
G^2^S7;#E!>#S<^9MC&8A4LU"!#<+!^?Q(K~SL:~QX^K.!HS1.D2J_M=8C@UF%/'B^R!^X2/XR.V!E)\$E\V++X\&EG(T9
MHSN('5<0!>L.6Q_MU/3?4A(L^L!Y3^BRV+^98\^ES2U2_L=T@!?:_Q#/_Y/%BRS^*F<>#ZSBI_M,@9ZQPJH8W@5_Z
V7ERNYU0U^M9V?&C.M8D74.D_5A>;S8LE;!@B@8OG\$!<
M^W.V9@R@CA50QS!0!OCQ28N1Q%EOUR&JSA!@8NQIU?#\$85Q>5!>+!MKT>B
MS+N%1.OE+375&8'%PLS\CO=C@O_EJMH\$2TTW46%U#&UG,>+3:"VYO^@_M(LZ6C^4L0+J&_JP_XL8G^!CP>7-
'9GS%@.5:P',PO#>~%UNR+!8'ES'_MV94Q&)DJ!J8P(Q^>OZ,F(%OS>!!YU^F^X.OJ2)DNN\$8/898V/IE_6Q
M_>I081H+3;=&P32%8?J%>3QJ.G9@+G'_M9V=&@.QJ4)!^B/VX7D^L(L^7-G9IS%HFBJ!GMHVCF/!RU+UB%-
MC.4/N+^S36.0_E6\$36"-G/S>-2D=.)(\$D>HU(ZEIKNL:)T^E,ZE,>C)J!^M26!.*A^CJ6F?YR1XO,\$YO_#WB)2>?
V//YW#X^P=&P/I_M\$X7^~"5(8)3^WS&E?JQU^1C%/4GKJA);A6T<7^N!CJ>F6!#X5?4IE,1\$ M>N.VP?
Y8PS^H/E\$TG_RY_93\$Y^7#/U12QU+3_5.DGN^%3Q^3W(!)^%S>@PLZ_MVS.&N^<^W%/)\$EJTOOPWH+^N9J#L;;H!@!?
77P)#67U0U+4.D;2TVW1_%U_MBI_Z2O2)JF)P<(<!)A_7(6^B^LR=CH^"J4#C%RIJD!^D3_M5+4)EHNHH+G!#59DWO_~
L/ZSFZ^O^@O<^!QXJ9!N!&^!ELP80)PJ(\$Y?_M&3!)30HV#\$%8"PU_3/1^0(SK&P)V^<^"U79!#4=&
<4_D)7QTJ8R^!6J(K^M.+LR!@.(SA<^LSTV5.).6CPDS!ESP63El_8Q,T7,##"5PBS_!K&\$AAA^ACNH2(VEIKNCD)JA
M9TJ8N>)LO+JA_C.6FFZ1_F&^2=A)D1;;R14D,92TUU2(W^G!DS(3QXS"D_MQI8S!\$^~.I:8!W-
N4Y^59\$F.RN.T.W^UXQMF#H!)#TZ8Y^M.LQ8>VJY>H.F.M.S^GM!>_~
(LR8>\S!>KA=TIU+P(KMP\$36Y@*NF9B07AXU^5T)S\$W=4^2V!@_M9&!^?Q^&^U!>)87-
!Z6WY/54P%GV,S8W>@!\$!~!XW^:4LOY_QFC&W>L^2VY@_M5V^W^Q_&?6_T9U^>^V8"^^)*S=;!DQ8VMO^QX_11C/J?
!ZXB%WAI;C;Y!^X256U7!^!7;H)_!#U!+P04_~)A\$!1.W+6Z_M^C"~"F!@_&0^AL+W=OKW_@%_M/QF4=4S,
_E5~.;UDR5H#03_IB8#GTKCM7XZZ=-P\$ _&&STSIC83!92(MK)_M;3;T
BL(.^3&E!K6\$G%LBE/^4<^KMD1.X.!ZRWC<_9<%U3^6_~"?+3#IT_M+CV2P9)6W-S+S5=HAG\$^4FU>Y)-
\$QMX)*VTD44#1@4%\$6;/C=UV_%T>D<_M80.(P^Q\$4#4_~*7:*W,I36AAB8#)3=\$V6ADLP-7&X?&);BP7W%F%.XRO)ED
MG@_Y!4^13Z1&^29(5G\$@3=,4)\$RRLFMJ+O&EO\^H8RKC@;)J_~M:(810!~H~R^D+^E^Y;CS;N0!
L/Y(PP0>~YK#05F1!X!7^~VT43FJ589^M5^9"%R37Y(C+(7A/XF^*=!C->Q2>9)Q>D&BSD<2!F%\0_#XW^~1"3E1
M^QDBQQ<=X;_U(Z~-8"=-50Q\$S6R9^?GU#2^D)K8%"_SY4MYHV/DQK+>!^ES2%_MH8=W7(-@Y>^?I?H:9V?R?
R%Y)(\$XK\$)JB3^;28_D4K\$4<+!%GS?X:TY_MK9.PW^OV^L^7^JF<2BNWXE!EVW<^X^=5F^W!_#O~E,I+(!
%R)JW>N?&^OKW5^C2(G_M8>I.T^ZV9GOM^90Q^80F7^OF7YK.P>^~H6C^L00Y+I_PN^+JA_U;Y83XPLG;\$L
MI\$&;&PO=V!R:W_H965T_SP!92;G)T&T\$25V(#_M!X#?JH4A^~A0,EE::4NF8^UE%_U)!AB_PJ?REE:ZOEKVZ
112V==Q@,3(X0;IOOJLK1Z=J7XG3(^M_3=ML@>93\$G%K)8JD^7&LMHL
MD>^L3^4@!DXA!MA70IT^>#9.FYD)K82^4PYS80%LP6>O^S1^X7OGU\$QZ%0,
M//K@^PIGYR=RLCE"87^=XCGX#SR"<_ALIW^7!&ULM=M;~^)&&~;@OS*B_MJVI7V@;,\$"
!02+XV^9ME^33BZH7\$Y@\$;WU@9X:02/OC.S!\$8&0F907V)H#Q_MIW@,+WC.%XW*?
!JEHO^A)B;CH+^5!8KYD,14GZ8HEZIG^E.=4JH^?_MJ2M6G-%%7A1^740UZR^~U<=,S,
MVX+^A^DILP7=R7A^G!@=&DU16_UPIZE,*(!HQ9(L(T(9P!7G2FYGE@&5E!OL9!
MR#9BYSD=N4A3;!F#X+%11R^!RI\^VTJZ63.TPWA_MV=I^R^!D")EG8!R17SX;J3DYN&8V((R25C_3),Q-
2)5D^!@NQ^*M^MFI^FT_FW=2C"+^Z"?+29I&\$D!\$/\$)S\$=(1A^V?)Q5ZKQ95OISLNQ7!9CLOZ,
MQ237:2^*7@CC)@BWJ!5VU7!7.66!F=VEIP>F^GY">;G8ERIW_OGXX1_95KPP!G+3QKU_ZS!^YO-%^C,^M>^/H&9O-
^;2_~Z>N::O;13O/86W&HS?_M_J71,4^!EZ:Q252O^KCT?0+6G_D2W^F5U>S!J!KE>P=BY6_M=,XN.NH)1A_9IW)SS^9
^/7IE_B,1N).4C,16(>\$O.16_#~O^M5_~MYWJO_MQ:2!U?J21)(%HM_FR+<1T88B=E(S\$%B+A+SD)B/Q
(05H0P:17A4^TWA_XL_M)-TDC(MEN"+J^#M72!3LO^G)!6@:N9C_!GQLEHW^W>36B;E6SMT(Y~A)S
MD9B^Q^PD^C2^2U;U+M42~;@2=-FZJ:D_Y=MP!8.Y!@4(3\$7B7E(\$S=B_0BK!6U8!6VH3QM!+!J1N5OYC)
M9;IOYU#5:5A3^M^N).O_EX^WUW#U@IQV_0B,1>)>4C,1V(!~*LE<%0E<*1_~MH\$?567!O!)>S
CD!\$U;)~\$V!H6.G=4C,06(N\$O.0F(\$_A!6"^59%J>5#_AVH!2JN">~.9.A^6C.XW4_M!%+;G1"?
U2GAP!N>.#!%2,V&@;Y4:A72&H9D,U!ZJY4,V#;GZH!~;KP)!KN:(RS)H_5N\$ M5!A6H#2ZG^>~IS,
6X6@>Q^S^~;#>4;Q#;WW_M9A^(7LH,JME0S8%J+^E3SS(8^8;I^W/>A6PQ06CVIV!Z7J6H36!_G_YO~!UK_M/Y%
ME=F4,V&@;Y4O^83\$.U&ZHY4.TMM=H!_Z!^Z/>@6_2A6H#2_MBJ1V=RZ?B1E_RJ^~!L6_~
Q87FU1+J^N!H!OE537O+~!USOI^A^~L4^XU=4_X4

M)H)\$!%&1QLE0G8#RXCJLXH%.5_E%.@^IE&F0\$KE#5!"H_N\$BITK=BIJE #K-C=+\$!1N-CIM2ECG#?M|V M+
(9!OEOR^!9\$+E*4RK>[B'AFX'C.=N&%S9?*/-@#OM+.H=?S.WC=. TC\$>00*P,@NJO M-3Q DAB2IN-
K"76J.8WA_O66'N63UY.94 D///F;3=5BX/0<_H49727JA6]^ MA7)"<.+>2+S3!(I^S8<\$J^DXFEIK#U(659)T|=R(?
8,7/^,@5\;^)<.-\$N# MYH%!\YQ+K=*&=6C@G3%HEP;M2UWJE .YF&ZQ6/E*!U3185_P#1&FMZ:9BURN
MW%HO,,O,SAHKH9\R;::>+T 3\$D1%%9#'; U2Z6VC)/F9^ W?)ZB>7-(;HP.H!+&\$9_CC#UZG\

• 4MBU,;3%A 28LQ(1%2+";MNU*VI;U)_M_MW XI30%"H.M0+T"-16Bl(=?E.0%L)L#S=O,>GC;=|?
[NAWW^'KU+H'5JVO5 MP(1%QYVW_Y6V/>R8: 5>*S\$F+,"\$A9BPJ'<4;AW6 MZ4!
I6PEW:07N3WB EYKWSCY5:4L7.WY<4IBRFR2G-K*OK<.\$!9BP\$!.6(<%J MZGJ-W1_8!EK0+5%(J+2_E1:B\$J+L&AUB?
=R%!\YV!+43KU8:DO:@TL*2MAIR M6WZBW6\$-6)=/W^GGV_5HJG8 @?+9-3S"06R&G.C1;DA;W=O350F+2_E1: M6-
(Z^V?2H8Y([19UW&5R/'LJ9_3R^C3>#2^#2U\ZX6#S6M@TH+46D1%JVN MRZUX^E=CS4Y XJ+4"EA:BT"
(M6FEWB7X?04SOVXM5*8I("ISA!XW?JP3-\$ M'3'"HM7UVV6//^OZZ^=J:AY)51:4+V#T'O4\$?
4?!"\$6K=#1W:O\$!2#F>&ULO5AO M;Y\X'/XJ%C>=-JE7_D/H)9'6L&F55JUJMH7IWOAPB^)-;"9;9+=MS_4!H2-MBEJ)
[DV"X?<[JO.8!VSF>\;_BRV 1#_+@HJ%M96RNMIMD6VAQ.*<54#5E37C M)9:JR3>VJ#C@W(##PO8<)D+3*BUG)MS-
WPY9I4L"(4;CD1=EIC =PD%VR/L MUWHX<4LV6ZE/V.MYA3=P!);=-<5R^Y8Q00IA?M&IK'OMEM9"L;.%J
M!"6AS3^VHQ""C)P!>" ".<\$3+!%^^\%!"T@,XT4HP/*99X.>=LCIBN M5FSZP)AIT\$H^H7K>[R175XG"R>4MX
J)\$!)+0%=T!T*J294"-8%6C K);S;_M9^@K4\$SE&<(T1U_D%CA:X8I(;XJ*YVT,#+>IB Q*^<0!1?#M+D5OWIQ#;Q"A
MZN6U4!Q=R6:MBZ M*G,*V3GRW3/D.P5XP,*#5\^!^#QJ/MP;4>-W4^@;/GHL"J&90ISJH(D@>LX\$
M^N>SJD17\$DKOIY M#6TP3*1?!.>BPADL+/5\$&\$H!"^UK+ D2@*ZAIQD MN!A2.LKOTEMF2K)T(K*>=U'G7?
0Z"8RFM-*LG0BLIZ=<6=G *L3V'08'63& M#R.O/DI@:9GG1ZX?'B5PJ'R.#X+;DSWK9.1&97_&IT-#'P6H!Z9DBR=B*QG
M5M*9E;Q.Y)(H9R2+)V(K&>GZSRN YU?;JVQUJ7#_DJ4#>0%WBPY>?-\$ MU\$7A+
R\X=RY\VM@=U3I;G6I&A0P"GOIS3(I6SH56HRI[SR\W7RU_)Y>F4 M;.E4;'U'!?
QINBZIE4BZ)\L%J.H#MSCI)Z6N4X21."IV3\$?G; 4WQ3;/O>1IOD@<8WYAJC;K8"UHG3. M8I7^X\T>OVE(5IE=
[SV3:@IM#K> <^"Z0%U?R8?&KJ#ID0+IGI02P,\$% M @ 281\$6CL.%T#;!0 J2X !D !X;"IW;W)K&ULU9I=;ILV%
("N\$50PMD E41_9XZ!QE*!#;T;).UV,>R"ENA8I"2Z)&4W MP'I\2\$F13\$=A+>/L(C>)-9;/J?
=0Y_2E.=LO_E6L'97H>YIDXJ*WEG)SIC@B M7_-4B+=L0S/US8KOE\$AUR>\=L>&41\$6G-'PZXZL.1R_-4)
(=+FK#>1<_K/=ZXC>-74MIPYK_N;=W5'[9W'!UY=24*\$YDF*6 M(4Y7%I UWWGF)H#T>+F.[\$WF>D'V7)V%=1
<15=1%PI(YK04&H\$47^V=\$&3 M1)/4/+Y5T%XIHNZX_F1_KYX>/4P2R+H@B5_Q9%<7_0F/131%R7\$7H>^!TP'7'7
QW;H5QWZ M!QTP?J;#H.HP.;\$8=6A>'2G7/9").I(HQMD-2Q(EX@UZA.\$.?URP7"BEFCE03U\;
[837)RW*2^E)>NA:S6\$M M4)!%&KIO_A!VP!;\$JO6C;*LEMA)_SY.WI.^=E2IN?/IZU=OT<(K%YC+
MAI89VGD^#;OQ_-Y 4=>"R8X'H_- "U#QWZ!/_K%/_UG!KC*0I92=*<7C\$H_M@Q=DH1DH;I5I\$F!-!%4;!
U.K2JS%A(N=4H.5M?K4_0^E%3Z5E0?F6IN8_ ^2-W%_ ; M8@X)R%A 1#;B/F@COG
1H_4_4+O59A5)E!E0H5/UKD#JYS:RURQQG*J&P+ MCY7<-3PE;%S
=\$=SKWQ9#0=SI8MOO!FTU&@U?2;4;35UQY.ZD:4L%9J M:%7J+OJY-"FBI72515(F
)"X!@1BA&=2A&+RM1C2!C#@GS(6\$!\$.R(^;B.M^?A_2U16)_H:2W?HY7656Q(F
)"X!@1DBF=4BF+RO_32%C#@GS(6\$!\$.R(N>X.758_14"_M2O-!;0\$4S8Q\LPG@V7V&W\IK<_DN4/B@VHJP:E^:"T
(FIJ+QW\HD MA14;4(L/2O-!;0\$4S8Q\8_HJZ\K=B>O&*ME\LOH=9#11BMPSHM>_X\8X M8I\MOJ&
V(E=5:QHQHAI*6_@X:M(UJ6%&3SL8^8IM]_KOCG9V)=E93TB: M#TH+H&AFI& MAQD.=!< BF8JWNP"8/MOYZ?
4%5"?CI^SHW\+64%U(!#T4S1&P_.I0;A.U&M.[&SZ&W^NT5T4_L13-%;RPXMEOPQ>)VT:HLJ_&I?F@M_"9@:@<>-
X_-+*M.JCI\Z7YH+0 BF9&OG_V/IS^RE%!M2?5S3#1N"6? =JO*HI>C.WI'ZWOUN>MWQ6GC_N+
[SSH#PUW6#*0!S7A_-'ZKU)Z\$HAW;=C ME;Y>ZZO)!L4QS/73(I65H7%,24;X;J.17C,G""SU_?3H_AI02P,\$% M @
281\$6EW?L<4! H14 !D !X;"IW;W)K&ULU5AM;ILV\$XKA&8,*91%;WL;-QU'4!FC9(UNW#L_ ^T=++4J)&4G\$#
MI,>7I&39LA4U+K@/^6*+Y-W#N^=THU--HQ_\$6L B;ZF-!39RUE?NFZ(EY#
MBL4%RR%3)TO&4RS5DJX1HHU4C*CG\K4>^ M4RON/V_1?S/*V<66;
UHW^11*ZGSLA!"2QQ0>4IV_P.E4(&P)A1871IH+U M"070K*T4E86I"0K_ '7BH@!A2!X1B&H%
((#A=!_1B&L%.*7*00JA9YAIG3% M\!AB6<3SC;(:VF%IA\F49;N4R'?<'R=4I47IR%A&1,T^T#_1B2W0/F*)W M0FQ)"&
<)4N=")&\$(%)@4+_M7'010Y?(G3VYFV+8=\$SUOP MD\4L!2@_Z2R5YZC:.8XB166J3(ZY%=-)8@*J(JFC3YDH.
BT?>*JBK?>?*ML"7Y0;S=5%I+D;(:IHJZ/ X(INSNG MG_R\VM;L&R'19; &F'JU6J'=/'WJN"CY.A8;#7J#L'D5'4N-
O>H&H%FHXU?>=ZWUUM04?BW0!7*<!%@*D0(+1/W717\$XIX8/EZ/0B7@R1?IQ MOY(?I='6I0IV/6=/'TJ9*
[24;4NH6\$Q)BV4M.)Y4*RW\$S(%DQ*EIK'-> \$N!90 MYTO&Y':A+ZBGLK-O4\$!#;!0 (\$F\$1%JVR:UU>@0+(:_9>&PO
M=VJR;W-H965T_.5XS_M_E6L "3ZGJ6YF'@K*8M+WQ?1"C(J+E@!N7JS8#RC4C7YTA<%!QH;HRSUPR#H M^QE-
%+@D?:P(SX(X&UV'E&VI4Y8U\UXS)>>(>= M\$;0020U!U=4QON/C^C_V*<5LJ8_+/TSB>5JX@TI M%.. "EJF9^M?
H7*HI_\$BE@KSB=;5V;1#42DDRRICM8(LR3??IM%QCY!!Q\P
M""N#1% B#3F70.=;@6OET#3;5PP/A\$HZ'7.V1ER/5FCZP9!IK)7I2:IC_B'Y M>ILH.SDEB2B82'0;!&(+=\T11^%I!
(0S6.DWD0HP^%)#I9NA/* S" M\$-G.SPA(FJ3B/7J'DASIOF*E4)!B!\$NU<#V'I'U6+G&T6&1Y8) !1K5K\$2J"/
M>0QQ0\$17'M=NA\INST(K(H'G7PN?;BBIX\$3VICTJN.HG+H;5OCA>+S.M;7CD>+SP/_
!;3JN"?;DT#=\$USG\$A(326YVA&4YTJLO(C8H)51R; MR*J0ZFV0.E%R\$&C^+5(=17_BK"SC.5)P;1DG^?+@AOGK1JT
7:09Q-IM.V"S MW&[H#GJN"Y1*..)KA*E;AZEK0Y\^4LJ- MSA3S*HN42BK*P>09UWD&)_L_40ZRC=\$-VL
@:_E_G.+!L#_JC?W'7;IVAPW\ MW7ZG.8KLCQH%@V\$J.%CH4OZIJ6(T#F;XM;I'IKGF-U#FM<2JT70GKA'NZ25Q-
MVJ1I6H@ZIF11#1C<[A\HC;!= 'IR6&4S3B"JU)YK;*P(W)HY.BQ>G;.05_M6C-
6VS(^V^N<5XNCT_K*1JIT(XY.FIK&FPICH*1YW6'DI12(764.7^_L'2 MW_DS/P.^)9Q!30&K@>HIPO&Y'-#3U!?
4TW_!5!+ M P04 " !A\$1;R3""%YL\$!P'@_&O_!AL+W=OO*S"=J M1E/R))#
<)>D6KW>@YIT'49VW@1X>ZWB@1X,XF&5Z3!5%;?LB MQ)G_-Z=^!GH&@K%41*8X@&H6GOB;^51#0,>OX)@Z
T"/8;@MX)@UYIT'NO MAWYIT_9*5!+>0BOPK;X#LD1N IBIR;G-K2)<FNNX+> H!3LU"ZG.N*2Z MIA+Q%7HFF*%?
L**Q(S&")Y'/%4TFW9(8?N@I"U8SB*13S+U#@!7WT91&B#S\^1)F>2_4ZQ&\
MN1G0\$8L&G@G?_!_\$Y4)JKH\$55V""W\$'OA(/I_.000M="AFZ@+=88;3 M"(R;J#YOHWCO!0.4TJXW(KB\$3+5U14%
<9_\$WR;R0L\$<&P;TW1HLDA_/4 \$ MZ;ZAR;^/U:D(MW\7-V=;F2&(S)UH/U((EZ(_OI!W_H_7RL2#;10DM@K3+U
MJC+U3.BS6RF)DFCSMA: U ML ((=V%D=;!#C.-S\$QKI@8VYL\$X^F M;36-663NU:RUU6RU_]
IV\OFSV.3#&T)4#DIL6!Y7;X>HW^KH7_1YZW* MH)%HT;^819D_Y.E\$5H&EDI&IX*(00N@*PHLXIT^_O#
(*N2F^MMKS7^LP!:=;/_MY+ #-2;W!\T\ /V&(^71W.UN6F?6T4+;.&U&:QU@M_LPY@59E810MMH;5K
M58L3WIBIMMX!K(H+JVAAB=9L%L&)9E&+!M^L&DLR(MR%L,@_N3>F'N)39U
MPMPJ6F@+K4UP+4WAT9GUS\ILZ9FX5+;2%UJY5+9YLWJR4MLRJ>Y?ZB?@O;> M)+3EL\$U?+
<=VLOIKWDL'<6FD)L10MMH;5_9J%7^"=5T<)K&D)JVB+;1V MK6HM&1CU#13JA4BEJX3X+B5";FB&@-
D(10#ZZ(_09L3;.)^5[S)X>KX6"O M<IAR6M#D-DIW\%GL(O9K"A.)D17 >U(U2'SI#102P,\$% @ 281\$6J22++L;1 !I0 !D
M !X;"IW;W)K&ULK5C1<1!7;.6F#ZID5M%*?E;J M=7^07%W-5)O:(YNA:02\$"U3I*XGK)19N8.4?="IS7T M
CVH\$DOW.=110N6Y(N@+,"@:9+ M'EK4C-K5'%5\HOZ^;W(#&5EP@I_9_"L=@F1=\$D9E(I\$978DL36'AJ M.Q'
G\!_O\$;CH_34D:DHP.1'2P*A-8&1C7WZI4R?LWJ\$\$E.9I-)HRF+- M-JG8H!;IM SF_M-
Q:IP(AHQ"01?"SM1.FZ5C*U*/D.>7JCWPH6@.9BF;@U_ M;P;\$248&(CM)6IRF+;8^0??

P!&KK\$!9G)AXR94.2D8'(3E(V:5,VL5::VORS M%\$)D5@''B>FGH.V0)''%...Z!8\LOX\$>0U8A)-9!V/S+05,K4*^9M)!!?+C3068-M)C!U3MZ)(^!1ULG/VLG/K(5!PX2LL!_L5^82G@U9PD.2D8'(3!*'@!X&!:=.U
M;YQ*N3::DL'Y!FX(4#B;!SVKCP^!G#X#86;O*H HQ;LUN*\$\$/SKB7LM(1# M69B&::!B'I2-#,5VFL7.!V*K2UK^!I;
[XTP%G.A/+;ZNM*>X#G7-M!Z&R!Q!0 M''=8UI&!0!P08H#@413U5TAGT;#=#HYDK!%L.Y);CA! #!1,?INS;N;J!V^!3Z
MV67OU*1V.W)'B-&'QWC4+ZHS4=AJ. XYNBG 1U ^% !JE+=N;+!W&7R5ZNZ
M!JX*!L.#96'Y5FJ'C5% !%,V0OU6I8!WK.KQ>Z\$. ''\$ G'XWXOCCN+A.T> MZ;W?%=AMD!P08H''\$XNA&T.C'D'Z-
:CSC!H !?!!UU4X3RA?L2FEW1-K1MF7WL6I4 MO1B_UJVJ!KW4T=1!P*^4K!-2H!Q6BC*XG*@MA->MM?
!\$!LFW5;!D4K*B.MP M38%K@+!J^8DP>3O0-V@;G!G!02P,\$% @ 281\$6B>L>P'C! KQP !D M
!X;''!W.W)K&ULO9G;;N.V\$ (9?A5''+8A=81R>? MDMH&8G.7&R!H J=I+XI>,-+8%F8279*R\$Z /7U*2)
M*8EMSW&&=D*BU)!-!K8'-!O03,11''@!_!2Q)''N=0TSW4!NU#@W+:+!T!JL&> M3;9D#8\@GK8/3-
!9%26,\$DAY1%/\$8#6UKMTK!FJ0V!Q!P1!?'G2-E''O/E/Y0 M-S?AU'+4C''''&0''@D1!N6\$ <*Y*TOH5<_!43#Y;23!B=E-
!B41DP!2<\$!7: DD1E^Y(+0)PR'1#''/+&% M'\$G9VT%)G1=4!PVJZZ\$!FHH-1U_3\$. (FP)93K;I'>8Y!H1\$#,\$% \MTOR^!
M/G!ZQ.C3SY_1ELD 8.*U8X;+! !A Z#@!^!A;HQ#7?I!ZK'X.=?7/A8(T2U- MU!U; &1HANN8V
VOVRT_NT/FU2U*3.&P(U!''W7!G;U!& /5KU;!\$PM>L@7?9>\$6M2Y M\$A:P40Y3.7DW==7@Y:P_!2V^!_!RT!W+;KC=SA^<-
BPX<^P!F>H!><^\$ULB(N7,'8110.(N M?I2,0=5_*.S>65<2OB7-_)_TX" M3COFN?(8@C7DN:SDN=3^!UN6/_
!D>;P(QX!H!%)A>?ZK^VF27!8RBWLB!F78> MYTH''_!0S'7J#9!S9KJ3ZJA@!WY7N^>=+8^2XN9_!00)
<%QMT1&=^VF:\$V) MZGV!H!^X+PC/2"Q>>TN(!4PJAF7D=FYH!;2SH!D#9NB-56L'P)W!\$94%MY
MG*VQ21HV16MJ7!5_554*:Q51W&+YW;1=QA.3PQ;/!4P^N=OA M503)_5B!LO3=X9KI>MC(A)FDJ!IN!G"\$-\$
''XTB!V_''H>42 !E!-. Y*'_>563>BXTLS!;4 MBT_Z!6.=NW''.TK !6E/GN!KP!JB^!
(Q6\$T9IV!2MJ7%=37CZ:N+KRO92#D@N M5JH6J=!)BN!A5\$!IMKUC'N:#PH!*.3G 38.C!XRB@62J*PY*JM3HUN^!
MFD!Y^X5+L!_!DOQE'='V#I*.8IA)9'.Q4CNDUAQ.E; <' +K-SXN>J1-TR2!W M0\$)@RD!^OZ)4'&!4_49Y>P_4\$L#!!0 (
\$F\$1%H>YA)HS@(<\$(<9 M->&PO=V!R:W-H965T!M<"7D MHRH!'FJ*ZY&3JGU_!QU55Y'3=6QF /'G:F0=4XE3-
7S270PH+JR@T!+W%K
MRKB3#NW:C4R'8J\$KON%&\$K6H:RI_CZ\$2JY'C.^N%6S8KM5EPT^&!BVEWNP3KW<;"7,8!F(3^!Q)X0=23T,7;
MX6\$/'!L!/-BC)NS>1&CYPOUOX!Y1!&F)G!V!//HL;BJB?PI2(-S6G.3P#WMW9U*41.LBY)JOF>D
MLK;V>=EP#BRGJ8!+U(!#+SK%N!#_!ADB))GOBUO<2(H^!{(1E/6'Q;:>@'_>*23ERR5!P5-MUX#W06^)*YC\$KD'FC%.>
!H>8O/&#&ULM9?;MLX\$(9? MA5'+10ND!+?%A:0YP:\$R_A9.YUF2B_!O-!3W!B!XU!N!J(*% MR!JFF5!G8E#_EC23:Z_B-
T!H!DULM2Y#G8X^+JLR''ORB4D3)=#(BQ@T9:EZB;U? M;V!RXOE+!PP30Y:BXVB!%S5^/4!N'F!337U33!
(!.\$Y*/@>JU(PC/(6O2+M;KT?=-!N@D_B1RDL2^A2!QH*!;TM!A5XT XV M!R5*FD*

/_05R'TITQS-_Y/W9YGF?L+A/6-(3!'@Z@R8Z@RYZ=-%''I I MLI2B((KF0,22Y''96>%2GP+;T+H?6M!('CRW8I(QM-
)XGC=SMX=V=TY_KNU! MPI*>8\$>V#QO;AYVVO!4L2_!V!N>;31;DR7CE*>,KZH(M+D^/'\$!\$!=[YS! M7-?
!A'4!P8Y<'S6NCH!=PZ2Y@3S#<#<#99CRF=)68VISN9)U!^HQ.PC8=@Z/@ M.&QQRZBA!SX8E9R_!D/?''!FV)\$YX!;
<<<_RA&E*!L\$;ST+M'G>M4G+X3EO0\$.XK!H(G/Y'2ET4FT?D3%O<)2WJ' M'45GYD1GYN!1TLDZ-
R!H!PN(^8WS%N,*DND2D=SG&)"2K*JH;%'!_!N9. M:"R*!4."V.09@#>7PJA!PTS05-J!H_4\$L#!!0 (
\$F\$1%KF\$U6,>(- M
*P&_9>&PO=V!R:W-
H965T0VD95)ZU2E;3;P!0'A!P\$JX'9;9+NV!V*1;QE!\$!2#1.U.W8N)44G97KBO*''AHB+ED'K7JR8KPA4DWYVA4=!
!(THJ9V ML>?%;D-HZQ2YN??(BYSUL!8M/'(D^J8A_!_U&P!<7SG!<;KBNI!A%W!\$U MS\$&^=X!PFC7_M5-
!M>;!:=!L;7>&_E*%HR!Z;G7Y<3Q M=""HH93;@;C+!FZAKK61BO%!Y^F,2"W<'!^YWYG:52T+(N'6U3_H4E83)W70
M\$E;DK^6;,>!A5T^D_4!6''_+ML/;*!)0V0O)FIU8)6AH.US)ZVX?;!@08OR/
M.P\$VN0>023DEDA0Y9U0\$!6KE!@>F5*.6X6BK7!A<Y&3CX'=P%!A_!T!Q!8,?>U^!_! S&@,\$Q!T+5&!DR#;K\$J!0_9U/X(4Y''
M#^?NQH(+1UOX'A?;<CJWL<%08;3R(Z+1EQT!P8<_!\$A#H>Q%Z=V7#SBXE.X
MU(+!#W%<^D'KQ.YN9C+CD%''ZSX9)#G.>H0SMN'3\$I4=Q3Q6HOKJ2P&W0!_! MQ*F?!+X=FHW0!#B425+;>-G!
!#;QPF6G6F'RV85-W-#''OU.0&N%ZCG*%;DVT2WN!/\$#5?P%4\$L#!!0 (- M \$F\$1%INJ'8_!P_+L*9>&PO=V!R:W-
H965TM;L(UGOAGC^363+>_!/@&0Z'G/'C&U\$BG+''!L6<0(Y%>>LA\$)! M63*>4ZFF?&6+D@-
=5\$9Y9A/^>V+F0RM4(++6!)UYF!9=L/L\$O(T_YBEHCJB;_!U7D!MCM="" MLGQ GK'+(TZ)^TZ?=01P9N-
A@0'8&I(JH!E51WE!)HPEG6!3U;N5_#Z!4^VL5 M7%KHOW(GN?J;'CL9?0*5DD!OT3T4M)!HMN9OHL!0UU*?FD'G-
R!HFHDS=(+2 M.MTG;'UHL! 36R!A=F+!_!H5C2(&U W\$YAC%;Q!OR @!W-V@TY,S5')UPIA! M?NG/5FDTN9
F%U(C!W/Y3J= _!LBK%V>IVH6O@0!0TAJFE+KD O@K M>OT*^Z!G@#=#)D''WSWND\$O?
0;W32%5=M&526NI0V\$?;Q.Y!8FPI@J^!AH'^ M'5A;^L? L!/@_!J#7 +TA8& ">BU@.,)>_!H!O>/X0+S3Q_!_'/C&=:- @R'@
MV_0,6D#?^!>QN7MCPPE!>?0)*;<2N(D:MJB\$N/ZH&SMNL.^+),T.Q'K;L;
MAH08;@YV#DKDD);OEW4^!UX7&UNB62T,*71+C7,?ZA@?J2;^ETKN%J!>A+A! M_XCAC
X*AWOU:5_005S2KC,#H!;>%''X@B&LVA(!B ^!<>F*!P"-N6.8.D MXC.&X4\$1&P!AVV(6&+
!B)9674G&ULK59M;YLP\$/XK%JNF5NK"2PBD78+4A\$V; MM&I57!8/TSXX<
E6P6;V!) /!LOE2\$M56_@>WLN>7SW^#C?;WX@!@)-H4 M.15C*Y.R/+>MD6108-%C)5#U9P"\$VI%(!-V
MQ;16!J<4+CB2'R+ O!''>1L;9<@!MP31:9U MV "QO FY W!577.WLAB4E M!5!!&\$4P7)@G6E>V@!^!R5)
(5M1@Y4!<!/7&FUJ'8!'.#5_!P#^! Z> _G_! M?@WPCQ5*\$%\$!&L&#\$.6H5!J#@!V&G55Z)P.OH&2C2!B S
M0%;FI\$#!4A.0.ZMW5!XG4RQ!#T4_!H!9C^2T.39V!H? X^?# MO8YH^!LU!H!U?O_L@?ELA.3!_C5)G%#X;=3Z
IQ+DJDBQ^(!(!Z?Q&K^+!;IE\$N6\$P M'-FK757^M7)#QW7VK>(6JR_8GC56>W\$,FC@&G7'A MBSHX";Q QX^<
N3A!B!^!WA!B VW+A6!DP#V(C#N1KSSXH!\$L>)E@*1\$)6U*) M.)9PBM3EJ;-?JU5JHK!H7;.TNDY?
GCV)"_V.G2L9<9G!Z_4H^PT2/LU_!M>Y2R=1O((&F5=BG)F_8N!F''X+#+?<?9'@X7SJ1+!7'WKGX"N+TT (9'*@
MND B;U:9'N3!7!Y/UB>I=JE;C+TW5^%QBOB!4''GGBM+!A2KA>=5,5!/_2G.! MSIA4E!499JK_!JX-U/Q7A_9>-
K%C*!8K6<\$ND&RKBH7*V!^_5''!W7@CJY*90!_!_0 M%=R>=>FSF00?^7J6@%=22!AH)6\$Z!RW!%=H
N^<(A8W<2;3RH+X!)Y7\$R! MPK@''!KDR\$D2_UG C!DE!>/75M3KF29PM_VJ?F.3U!DLB(1KSK!30!53+_50 M
402.G7'-!L@F!#0Z.6<2?M\$FVYMK!GK52V@9K!Q6MNS=YWFI\$3@#&=>P+P M-
@!;WQW(NIP11,*)X!LDS&JM9AHV51NMS='?)5D?0LU7\$JNP6=DD3GZ*95
MK0!D^<^CK@M\$5,=LFT>D,%*%,GJ\$31&OT4)!6DKJ0\$U!HOE'Q!RWKJF/A;P9 MY!KR?H=.3L!HE?
&V.SP'W.6''K&QW.X!OY=&_H/!4(25.YSMT>>JB\$AMECL!ZP^\$P M'\$S!M0.VZ&I#8!>NBXAU8F YPY(8-
>!CP&"QQP88N6+0GL!B'Q<=@!J0L6 MNV#IR U+>EAR#>#9RP1(!+X3-RSM8>E!V\$;N!J0N%0@7,GV#3*(TCF,W<!0S
M!P>9CW5!9<!6D%*A@NMV@HQ>_P!J(+KY+ZO.>L+?2V/OBJA.TTHV1!&54O M+K.C-V;3;
(#/?!9&R!4!%N!<@Y!C!JFF5!;W''!J!R%!'@C87S(8Y'HWT> M=FIE>-##W)2&6J\$U82T@OOR?_>A*
!AIR*\$@P#OXQX^_4<'??B%B!77Y9;#4 M@<%%HH^4Z*Z8KJ_X8!OZ@BM!2=AFJ;!E\$&_GE!R!KEX!YJ;H+_KL-U!+
P04 M''!)A\$!_!\$SE!#@#_#&#0 &0 'AL+W=OM!1)GMMNR M?S_24-2TJB=PDL;_<?PI2HQOQ3_O/
M&_8O6KP4!X0Y3&G!DT1B,3(N#!3!#"!C<4_7WZ_0=*!X0AIS_8O6>S7,U"X MY((F!5AFD) T_!>AI9W(IVH<_<^P/
M&5TCH(EFWK09FJTE\$!2->V@LFW1.*\$?P/2-(X^H0#DN@D)UK-Q!2+7%0=T M'(#_).8G,N#Q(4#1R?
H'')\$4W9(XEH%&_!J9A*(RPV+ 23Z@LV- VT&W-!4+ MCJ!2''(Z@2FS+R4X&PD3!Y4Q@/_N28!?
NG!#.*3M%>F).Y;3PD)%_SJO&QF+K@4D_>3!3EQKYE8;2'7/_AC PY MTQS8"@S_XP?;LSXWF=8E6=
16^>S\$T5U4_&D(&!9"@-8_5'E>JCOO5?D54F X1CB-T#B2&P7A0HJ6>^JF MF)MTMW(>N!F*Z)

LZ(JMYZ95>>N15@EZ7AG9)%G1\$5C.T7OK;:UVPMKR)C M?0#?ZI^H*XH^K_2Y/;>6(SF).4HAIFDM,I ZAOO#\BM#WA
TFX?H)RKDD5P_ M+N0U"Y@*D.JGE(I-0PU07MSI?U!+ P04 " !A\$1:XKU!*NL"!G"@ M&0 'AL+W=OYCVX"878C6Q.IM
)^W'SW9"!C2@5LI>P'N.28Y-!>Y MPQ7CCR(#D.BIR#D869F4Y;EMBR2# HM35@)53V;.%UBJ*9_.HN2 4P.J6HP\ \$
M.212,V#UMX0)Y+DF4L?X57-.S98.N#E>LW;RV166!RQ@PO+O))79R!OIH11F M>)+.I;Z K6>@>9+6"
L+!U5L<&9A9*>D*RHP>H\$1:5/WZJ?=@ N.\$>=<# MO%U ?P_ KP^2P!&M WSE12C\QEC@.P<9
M8TA.D>_VD.=X_98#35X.IUO@ \L B!..I9+ +34ID1"2>E
M2<> /*Q6+ +B44XF> \150OYU87R+GHL0)C"QU2PC@2I"BMV_

1ZK8==DL7ALPH.J(W:'K+Z"l02P,\$% @ 281\$6D>0WKEG!P (T!D !X;"!W M;W)K&ULO9QK;ILV%
G_"N\$50PMDL24IMLFIKH MUJ%9@R;=/@SIP-BTK4VWDG3< /WQHRZ13%MFxN'-OB26Q/0HEZ1A^=(E^G
M_!^Q0\$R2!W&4B(O.4LKLK-L5TR6+J3A.Y.H(.4QU2J3;IHBHPS.BN.XJAK MlWK#;DS#1#.Y!+;=\EYND)1F+
;3L0JCBE_O&11NKIH6)VG'5 "Q5+F.IJ3 MXPNV"V37L.KK:Z-646QBP189H0SN87G0_666"/X5)Z1.YIX* M=I5&?
X0SN;SHC#MDQN9T%"E!B>5PE:F1>57=->BJ;) "IT\$6
MN4X3N13\$369LUF+OF.WISFISJ1O&P!=U;MU%JM/77OI&XF?I_*8V,,C8O?L
M/OEZZY"W;I Z1*. XMNXQPWY=1<>D;O6P07-MFMYOZS\$S!IKR&OE\^UPSS&3 MC?8!|-
>#JM;UH+Q7XZO^9C@N.Y!/%*97GH!%_WZUNL7O/I>6T^(E!^1XA8\
M(@X34QYF08C^YR=5EGR4+!9_M33TL@0/VL'Y='24PH1W\$;K7*1*8!1*8S\$;B9<4*)V77H;F.AJ&(7RL3!5BS;N-)LL
MRJ_M#N;EL2F'RA\$)MHNZ4L^1TL#5;@9JO M*6A4^VAD5-!G_<*K<4HMU7.5E*XOF>L?5)WK;:CTUI^IT8= M?
6@9HM:A7!)&>?1O)-QF0>&"^< \UBKY-2\;*M72Z>ZHM>U^_.,@*723, M0\))"P
P32!6;TFFMB;2!_3G<"!2ZT3@!^Z&T \$73!=7\$!"UC-;RVRJ^9IR_M3@CELNU+;ER:40?+"AJGKVA;_&E;4\6:;IMJ&T
\$73A=+\$U2US8'U^*#3+ M>/!0!"?Y*P8;:(?2"C-K6B;XNIOBPM9H0^E!2B;+JXF^NV7H63D_M,DP+HY53-
"P)3F0&DNE.9!;3Z4%J!HNNZ;+XU?#7G'AJ5A!(<*.V%TCPH MS8?2 A1-5V.3\$;#,*8&#?+'=*+VESS=7YMH.UA0TZ
^E>5";#Z4%*)JNJ2;R M;YE#_IKHK)JR^;KC_:6=Q=F9M!L#"A^0\$HS8/2?"@M0_%T83;I!;N<2IG;
M2!;V1XIM03UK18!0/>#I3F0FD>E.9#;0&*IC^3VF0*;'FX(:SC#X^C6#I M(F,51)LVA!N*,M=UJ**@-!=*Z
T^TH+4#1=44WDWS;&*Y<+I2G.MG!-!=*Z T^TH+4#1=E M^5!;@*+I0FRR'O:K915L;%8!2G.@-!=*Z
T^TH+4#1=C4U6P39G=?!I MI MG0?OA0?-!@;HKG?GE!OH.3/GYB&O*%Y\$B2,3FMDI^G!FI=?9"@W9)H5!_??
MIU*FB;R_CY/4_FTD5=0?Q=CBI02P,\$% @ 281\$6A#?9WM6 M!@_%C4 !D !X;"!W;W)K&ULO900;Y!X&_?
M%2MW.FW2UL2&_FED=8_6J555!7.W8030;#@)&B<|AI=_OKS_PHQ/_Q@O2L M?9\$2XN=C^_GZ!WP3EL^L_)WE
KT-< \?C79";&_G\$Y YO*-YQ"_8GA;RDPTK M^TC(M^5VRO*!/(_*ZYI MOIZO)GCRY\$=6*Z6NZC+7V@XO/^KI3O!ATE27-
A)05!2;J!D'?F2 M1150E_@SI< \Z!A577EDI\$OUYB;YFLRJ%M&_QP"1!/?\$UW3+*M(LAW_MM!)
M5V<5>'S!O@_KSLO;/\$A*6*6?H5 M/3=E'5DX/G# \C98MB!B^9_!+5-Q%\$ =DX\$D#; ?!|@GPBPV@#KW "I#;#/ M#9BW
?-S YPVP*ESWR2KSK0?B6BU+DS*JO2DE8=U^+5T3+!;5&-K=1RD!3
M&2=6GUA<1!8YH<18!9!>_1@QR!R4\$>L@T;?/S&IR)*_Y6%OS\X*WO!Y=
M3H5L2(6;QFVEUTVEY\$2EF*!;5H@=1T&1T\$0%3&4/NFZ0EVY<\$R/I!_\$%LO+ M1&;\$UC1H?7ZXI0GWSP\GFO#
"X;E1=H=KKQH3DM(A7B"QTX4HNK6Y(6#7/ M.L5+BZB(TV)H/L/H"&3BY
 \3Y%3/YMYP^;0*%E3HLNT,) ^X,I4%TN5YM3!ITX*&9YG@IY MU2NT\=(9-ZKTSZ0R-B L5L;)"QP!S/07NBZ\$
+5JBCD=0IYH!0 !+ M*X>QMK%R0, ("2%@(1%,D6W22+8R2W12"2J!_2\$G\$;WW>B9VM-3IMACH9MNN
MZPV%&Q8DV/4TFIVFH&5IAD)@L78A /!E(3C67_ ;3.F_ %0E"FGZ(\$6!)=S_ M/I(#KQ:U.SES-BO+F?;FRH@<>R4-2O-
!;0\$H+82BJ5(2W6'C5IV?;JN#&@:0 M-!^4%H#20BB;.@Q/(PS(3!IR,8-"TZ&RZW*/L('K3< I84M!A;J&^ ^JE#O
M>V#C;?7JCX/8!R*5;J!;1WC*\$7AS1+I&9Z74"=#5;#TH+0&DA*\$V5N;RG8;*;<>Y^"AP8)IK1W*N8*1TL'20M
M:2&4396NMV6PV9>YE;IMHRTIFL!Y2!=CS4HS0>E!;"Ts(fJfMLI/AJW?49 MTH-9@)D)4%
2@NA;HPZ&TD;+!F^P;+IN2RFY5N6AG+1@XGJV9HT&M91 M:0\$H+82BJ1+YMA(&D)6POEB;Z?=9C6%\$!?'
82Z1WEPB/S'7 M:R0"V1SHZG+M3E^D)((2O-!;0\$H+82BJ;KV3A)Y72>)@#D)H#0?E!;TD(H
MECH,>B>)F)VDD3LC&1H^CN79^AFNK)JBV/4UB^FGZVLU_=K M.2%XFE0&WNFM#I2M:7YH+0 E!9"T51U>
!>&S%IWZX/T0!;@-!^4%H#20BB; M.@QZYX>8G9^Q6!_PYS;53;&E65Z')6U9<%C2-
! =PM#J@S@T4356G=VZ(^<PFG>"+;O'OIY9\$*PO#I&ULM9EK;ILV%G;"J\$510MDEDA?
D!D&F@1#!Q=D+3=9UH^MHE*HDM2=E;L MOY>Z1#?+1*S2^1"+DLY!^%"U&MZ>N#BF!P"*/0N*_TMA%3V M^
XB?67-14B5;HJ_*W<"Z"H"-@;7>-[(#2F+G/DT/?<@YE,>JX!%"0C.0 MBO!N(>"F8.=EQ./+5R0EW/MW1#3R!^K)
!B+KE% BHK%D(D&8^0@/7_8!O M!L@P'4CO^&C@("O)*%9TB.(P%>);!4>|B#(\$B4=#^<^YZ);
MD3;)K!Z_J/^9PFN8)95POX_V4IM9\!\$02M8TSA0C_SP\$7*@M(,^#V3Z^QVR M>X<#!_FQ5#S,@W4/OA9EG_0YXA*
!F?""!Y &D&D!;_3R@GX)F/4NOJFB_MZG@!R22N!5:P0>V!L T_HQ:0 M
L0&!'W#XJR0+Y';Q"+T((%@1YI.7653IT(N'Z>YC9+0TZD65#10QZ^0L0C M_3EZ1Z!>_>|3IYB!:=6>L>_!HJ-
|3!JX>A6(H2#\$4)-7MOW(H;MHP.XE! MNT0RYVIDCOHP<_2DDB#VX.S?
_H9'WA!MG);\$K3!@K9O4LH14\$KK_24^AXS M:LVI DOLG(HE2^ \CLE@ZNNK;.\$'7\$&!<| B/;\$?JR!CA9?U#*UT9B
MU#GW"5H2JR\$/"^3AK!>KT";M);\$;I:B@!D2?^9 MSJA2JM>-0C5FZL@Q+CC&1HY_8B45C58LVNCW3T C^IH@QD?
S;=D;_I2#\$! M**9&BLH+X#4%K%P%RL!_5BD0&=3;4A&Q7+<7*!A7+4R+HBN.RP&NLW6 M+&)A'+81&17!>;
(D5H?7FD#0%!)23^(-2!)"YU.K%K%>#SWH!7A7?6BP15K;R M5!3!2MEY/6_LU?YP8YZ; \J&5LW0UV&@C#(5-GT5MEGR!
=| "9^#2Z.#^Q9* MVY)YR8DO885PZ86PV0QU*>U!6VD?E?(E_XN#0V.HSY G!H)\$^F7F 5@ZK
MAL>66IVWM#QX9*#R+;F9G/@2W@B7Y@B;W=K75XN5+5YV&N6ZR4L\$BX!\$C; MI%=-/7SL9?JC)HDE\U0G*;T1-
INC+G;+!EV75X?#1)I-WRD!\$S\$Z#";RXG9_MZYFUSO!F?PGO0TKO0!"%K0Y+OB4GOH0+
(6!^+ZO!*S!6;F_2F)KFO*W! M2G=#S/LX+45VM>9MOL;7 MF?>R^56MJ.3WP(65&R8!G@:RWO!
<8ZF\BVU!&XKMTAWK)E>)A>K@%N@*1 MW*!OKSE7+XUDTHOXD6/^\$U!+ P04 " !A\$1:0.0OYV<_(L &0 M
'AL+W=O!OXD8"QO"9<15IU;VV!C M2+*7C=2L?IN!76W;GDZG>^)"\$*F>9"/UCS^F;@!9#!_1JBFP#SL2\$)
M!=(AL2>L_SWXE!*4GQ;S/BX^"^^)=/5W* > M/7X<&(/-#5^3N_NRON^D!F(9WAEK6Z?)7WYVA+>+
D(=,BR5*1R!N/@Q^_M#I'8K>L'_%;(A^+K;I%_51NLNSW^IM@!G\$PK=(SN6TK(FX^N=!?+!S>2U5
MZ_?'!AV!+>N/WU1G?73!YZ,C=Q(3!E!W!FL+^X^!L(&R;E!RZ_9HR^;
M)S2NO6DV+!;_X_-8X<#_5T59;9H!E=KL\$C2YW_C\T+L37_%X98#8#S-T! MYBL#1LV T<-P/COU@##
<_N>'10UY^V.IONN=WR?HM9L=E?F19X\BKQ!>?47Z_?I M>GSUSDK2.E+795! =FU3CRLN?
LC@MQ%I7F22% M4R3+! =^ MMBJ2!\$YAR?+R-ILG677?"YSX29IG\$IKN^T)CZ7H5M>W=I;LR3N;%#^(!
MD;3BE_M*JOY>7)R4U=K7ZW R;=;TZGE-S5?6U!_9VEY7P@GGV^+HWH6*!/>L65-^<^%>7Z0 ML?5.&*?
OCUD;YP*"SJGAFAEU#"/>3)GS;U:=\$=V2,#2-NXVD3\HGL/G6!'"2P+:/@\$E#>.7-(RU;B6TU4N
M9!7+;"OJETXL8Y5QRT3MXD)A-8@Z)N23FD9A/8&A)A20609@2KB=>5!^6_G6UE_4E;2!Z35
MB&J+5>7N/UTATRW\A(S;- (INIS<_5%CNM/VO;^J"B?BG\$H>?W;^=1W) MM7!S".QG\0"\$@M)+
((P)9;&L/W(;=AS\$GD!S!)/4<42YE/JI3&=YV;_!W< M-WJH9C=;_<_6C-\$P=^+Z\$)=5/-0S4>U-5"5(LH30W4UF?81L!
R>>-635O MO)7=0=**O8-\$G:CJ1.RW>F8@R!3134/U7Q4"U M1+6(TM0U-5"5(LH30UD6\ PwM!_-*!JK9J;@
MFHMJ!JKYJ!;@6HAJ\$;6! 6O+&G;^C2?;H>S^O&ITX7V,%#-036WT0Y^?;"A MB_51+4"U\$-4B2E.#T_8V#^UQXRW'_
JZK9C;9S#&-X.E3^V T(%#T!%I4_ M5/-1+4"U\$-4B2E/SU98W#.W^V\$?OBK7W!^E;?A/7C_&R;:SO)GE1BNODVZ;W
MWFNW#;V&H)J;-@ZJN:CFH9J!;@&JA:@649H:WK8D8IR^?;<-7Z@FHUJ#JJY MJ;:AFHJ

j%J!91FAJPMBABZ)LBAW?;T!X(JMFHY)";VVBI\J)DX;V@5! MM0#50E2+*\$V-
35L(9#^@VY2^5^ACDEVAM!-105%1S4J_V1ZE:CF-IKVM-ZV1^70A<;HEHTVC_QBO7ZOM2H_M+46.#1Q7X\
553HC@K8B4,U&-0?57%3S4,U^M0#50E2+*\$T-W-.%2X KE1^7 M+ F&O7<)>O(2!>@E1^1+V^B7L!4S8*YBPES#Y?
W0E1FU78J3J^CKZ&S/#"1 M+T<(-Y=IZ@P=VH-105%1S4K*W
MDM!6!*HYJ;BFM=HRJ\$#HZ,5#2XU0+40U2)*4Y(4MB)&^E;\$IWB9E/%JHV?7!0 MN\UISPXD^U(H)J-
:@ZJN:CFC3K/ 8F*!E!E1S4KSOA@/5;%1S4,U^0-0_5_\$93)K8= 5-T
MH2&J192F9JHM% CZRL&ACU:WVG7!K_!T!5!X\!RA/0546;&ZCD<-SW>C@E844,U^0-0_5?
%0+4"U\$M8C2U\$ "U909+7V;@=L+NV?079631D7<;G*D_) ME#)?= 8*+5<<6\$!3/+TR+!71!7!0S44U#!5!5_M0+42UB-
+4C+5!"^O :2G_M_3U)4&<^A%2!LUU03K#B9Z! M5L5'-0S44U#!5!5_M0+42UB-*4P(!:LCX MI>>N&*,_\$52S4!Z
M"KAU:Y6MV_K^CA1^ -!=?&1\H^ -VW_@0KF\ :?G+BV5)W^ \!NDFDG. MY6VUJ.'!T_%
Y/6^V^,,EM6FZ6!N,G*,ENLO!R7\4SF!0.J^V^SK-Q\4R_@_M,?@0-46_9>&PO=VJR_M:W-H965TB1<&ZOB73
RB\$62_ ^=NX'8"^\@3.P2P70 !M^C0\$P&=74_VK!5> !<7;R_M2?'\$D'I(06SX3)Y!H!Z!H!
8DE4XASR"5YP&\$&33Z(A">A2!;D!2U8+J!Y_M0UX1D9"ID!(GO8O\BYO29#_<17^=!\!L\$_)5"5V;#C
M8!0CPIY^Y)HY\$7!?RPO2H6)"UB7?^VX):!P02\$KC2M^V\ \$GFR>Q^ ^K59J(_M=93='=Q"Z.C_H: !3S&DGZZ!
[HH.;>Q>"QGAQ-7.D!;MK2-79L5#&'M8* _SH_M#7B3GW^B_>"7.NTM@56\$=POAW0R!\YW)?%6GMMNFV!
*FHA=J>N5(R!QSLD>@/N@=\$W6TJ3<_%TX&3Z<=D\;B+H6CB65- M9OFDBWRJ8SHX8M\$-
>@=, !T=#NM^FPG18,!TFZ7XZH/:6)\$4Z%"7*8#9!1VZ_M^A!O8P<*G&3.S//+0NKEBU(K2C&[A8JJ2NMDN6%QYXBSG:-
N73M#S!1+@W)/_M#AHLF#0+B=)B@;NO/G+!D=Y2_FT-WIN+;VC_9UBHR_4BL0O.B^!&>1L*\$ _M:HU;%\$XC^D!)
<.%Q6!O\$W, !-2_8.K9+MM^XQ4E.*8^Y:K)W(3+=K!H6D(3%_MAU#%!7* <4(WEL*)\YQ04_H^>KZ!P)
(R!68F(UW&MME!1!MMU6\$HW0!MP4!0_M5OU\$6VA5Q:6CH&Y+<;RK%/FL3RW_>2O00,+H+^8?%Q=GRNL-*!4+
<=%>2FC_M^=)!C'8"-Y!^EM"JPU#; &SIH(.=!JFOX!0JH!+FT2;^J27,W!8G!&'K!L= M\!G*2E=\$W?
[ECZVJ.ZH!3WINR,93^R-<\$BM=\$@O^?S*SEDS/[F#_(RP4*RT4_MC_V!B,8!"*!3S4D,^;Y'6+QM;BS?9_=5/IE_S"%"^T!^E
_MD3#^T;!B@!N^SN!0Q>K5MDUY\$O9J^+L<0D\ITVP-_G2MGGE!2#XB9!A!0_M2P,\$% @_281\$6LX.%QUY!@_!S(!D
!X;"!W;W)K&ULM=OK;H(% ;@OS)BJU4K=8-MK!D2!"^2^JU&C9K0!<65@_*N^M4^M(6JD_?
L<7#&/(8)1WOR3@^#QCFW/PF!\>8V3;^F:4D9^A\$&4WG;6C&UN_MNMUTOJ:AEU!%&OKQORSC)/08?
YJLNNDFH=XB#PJ#KJ8HPV!H^>5%G.LF7/273_M2;QE@1_1X2DVS#TDI_W-(A?;SMJ9!@B!H:LVO!=SK9>"OZ3-
G7S5!"GW4K_M9>&'&'K!."Q7= YV!M0;5!R@R_OWWZFAX)!MFNS+X6_;\$6=QVE&R+;\$G_M+";_NN%/M
@R"2^=!+M%._F04>!/MH!K!S?&=F7DH?XN?^?6MYUQARSH_MTML&!\$O!M-RAP:9_X^#-
/)7LMUE0Z9;U,6AV4PWX+0CXK?WH_R0!P\$!\UM_M#M#* *T6T.^?".B5_!VV(3+@_X!8'@B8% &#.H!HQ;!PS)@V#9@5
:,V@:, MRX!Q+4 =GPBX+@.NVQXE5=F!0<5+GN>+!C%O.DGB5Y)DZW,O>Y_G7!H/
MT2/L0IX9@G_J\ CV/13!\$4!^4+GU'_Q9@SEF2Q!T0;D:/E?"5_@Y4F=DOV.U+TF%1^!Y(HHZL?L^/3)UY>=
MO'_WH6G^Y(SK15>D5S"#^4/H#U:AY_P;_+WC8?Q_9Y)M_!M_MZL!CY=06F7+J;L_/6D!H9UERRZ2S*Z*-VUFVW-
+!O#!2VCG+;7VXM%.\$VWYS_M3B27D+2!JKQ!N=MK6=XW#9MV7Q#!9B(!0=^D&V!;SO!#)S2Y(5VIK_!@Z5
M/YNR^XG!2_Q_8B82LY"8C<0<)." *\$0^E4A!&7Z!;6!%3PIU52+S_STLIOZ+9G0F:LE^ZPJ4G_B2F(S\$#
MB9E(S!H_O!3HR6AEV:TTA_1V(&_M\$C_1F(7\$;3F(#\$7A_G)/ZJ2?_3V6?X(60A(3\$=B!A(SD9B%Q&PDYB-Q%X0)
MA3"N" F&_F.5+D4M+ 8GI2,Q_8B82LY"8/3Z;-_U5<<[!D<=SC\<;#ZKQA+2!
MKM+V6!JVNX!0!SDZ^77J(Z1!^7)IVB(Q^8D9!38\G_2++Z=Y=@WK!KV!K! M6M*
<-5S0;@LYHRK!3^Z5_V*3S!\$!3D%U?12.RPTK?8*&"W6.10646NOM=6P_M3F!0RQCHWCE0S45I8BH>)-^4!U=?
_JWK>3M+Z2G'%+3_MH9H!U4RH9D\$U&ZHY4,U%:6)!:/O2T_Y^;58;D!:_C!4_Z"!"=4!J&9#-0>J_MN2A-
K(E!4U*5MGK:7J!)E8NKHG=\G3_23_\$Z=\$0#JE0S8)J-E1SH)J+TL1<_MW_<=57GC!5-M%OZ!1-MPOF=+?
(9>_==^RN=.;7!;!;P(9+OJH=0D5S@Z=\$#_MJJE0S8)J-E1SH)J+TL2"V/V4!5(V^_M_V_-4R)H.Q*JF5#-
@FHV5!@FHO2Q*K8MR!5>?_R^#3A!XSRD!A)/-8V/8^V_M-DOM^N!DH%PIX_KY-
J!A&HF5+,@F@W5!*CFHC0Q\>12U7;9H!>3!#&K&4_M+;D4!SV<@VY2Z*OF17Q!JB
(!YE/!1#"=5,J&9!-1NJ.5#-16EBUN^E:\4!FRY2-7_M+L!U?D)/!0#"=5,J&9!-1NJ.5#-16EBJN^;FZ!NPGI4T%IGZ4F=
(0&!4*_M!C2AF@G5+*AF0S4!JKDH3?S^T+YAJD;MJ>Z9^S1)V_6E/9R!_*TAVHZ5#.@_MF@G5+*AF0S4!JKDH32R0?
1M94!>*_!@_6.H!D,U_ZJ94,V":C94JN2BMR/7NP=?2_M0YJL!ML@!^SVOXU8;WK:FEUJX6!-
8#M>4/ZHU3W#!ASQ3W:WCTD!7/SQD!_M77)2N!H_-B0!HE0/&'Q)O_R^RQF+
[SAVOJ+6B2K<#_OHQCMGN2#5#&F+Z_M^U!+P04_"!A\$1:N!PZ;U("_.0_&O^!AL+W=OJW^1
#9A!);J=&!U_A3%7Y*UE,KX&OAA!_MO^TF7!Q^6^5!H;R)C60!&!\!WTHZ>+@3EXON&3H!6V0W#Q?G&?9"W4GW>
MW,3HM6&EK+Q_AHD7A48L!R!&E^9&(<R^?D!_O+D4!SV<@VY2Z*OF17Q!JB
M_,K62!R!J3+"37\!RBO!^YF4KL<_3)JHEID-W+W!K_!\X!_-N7.3>17Y?WLK_MM;X8S_&2MZ!6U!H!BIZX+?#H-
/_6D9_D_QM/Q7TGXX&QW"8J"LK!Z!H\$7EC\ _M=+^6#^3_&MZ8(!5#K#V!HBS_P/L_!)=Q:O%'Y(;)4DN!??
HWOG2^6P!M;8>"!GW%Z@YLG_#'^>_M%*YGI^!V!^J="4R:K@L%WA5+-_ZL\$#3N(Y"M4X,\$J!D!JF6,#+>T@#=#.NK
MA!Z?@C>6UKOVHU/C)YKMCP\$!>_!>:GMX:7/@!M6W2,^E:8!64?(API<E)M5\<>Z0VB-
ZB\,S&LF=Z@>L.1RY/C;.&_/2Q;_WV(^JMM!@X9O/-#>Y_0W3=)_MITPW8F17?TEVCHV/X+=RN8WE*DUCK!
!2!XGB3ZAE)=!KG>S=!2S9N\$MY,4C?_MOA(9AK!XI>?PS,GHM!8
(C\$^B!5D!H\$80V(5\XDYUPS0=2J5U2WU0B,8+3\$!)C2(P,C0"!!&JF<_M5JF<_E_Y+;!_!=V/TQB*5;7^4_GW?Z9&8@!0(\$J-
(C"\$QCL0!"&LD=U8E=;_Z_M*G6&S"X2K!195J3!JUK5.W2^B83B!SD_M!H\$80V(!5WCF&HKV@&H%JM-1V
M=PI57=D*5V56J!CXC=MSO&[D_-WH2UW&>_!J">T/%U\$J!@%-!PNM=C^FGVE)5@AX.8>JGWDPYM"TSU_M
M4H5&-0C4,U@=*:6:Z!0^8\$4_(B^PY74,V!:@2J4:C&H!J':@*E-5<=Y-,_M?3NI:PD(!2E!_0>J\$A&H!J#;ARJB5+;+1--?
9E8!XU,!^!\!4VKEY!WQE>_MJ&2Z3LJ(7=6>5V@?":HY4(U_-0K5&%3C4\$V4FFGO!9T8!H^PEHWBDQ!HZC'
MT7AD#^(^JCE0C4_U"M58J6EVFCAT@0*E-3!Q7W>+!^VWZ^D7!^H*\$Q5OBR^N
MY#O@RR@(!/7(4+7ND.G=OG&%;@Y4(U"-0C4&U3A4\$RBMF>RZS629K!H!ALZ"=
M):CF0#4"U2A48U_-0S6!THHKCM+EO:8?J!<=,KW2.!0WA)4(U"-0C4&U3A4_M\$Z6F_3!2_Z-
UWAC2!XW^PPZ97NR=5V@/^":H!J\$A&H!J^J)4M0;(10_#H2U_M;C)9^B;3C?LMKVF-
^R@NHGJY+9&%=IN@FH.5"-0C4(U!M4X5!EMOO2>N@U_MM6Z-6=U:8!XVSM!Z?J!^&LOBRJXJ!Z>1/D2E7V#O'\$,
!;%"_0#4*U1A4XU!-_MH+1FY.L.F@7HH%G0#AI4*85VTJ:@6H4JC&HOJ&:_M*+4.1.^!^7@D;!>8O>;
(K\$M,R=9#5O>7G:K>35+Z=W?+&3\$F)G)<1.2XB=MEQ_L2%V9L+_8V!^N^Z_V6-_R0OMN4\$U!ZH!J\$A&H-J^*H)E-9,
<=V>LR'3_M%.J5WCF&IMR@&H%J%*HQJ;_AFK!ZSF2!/7T^U^NYB3V_*(!%;H0AA!4_MJ\$A&H!J#;ARJ"9363!"=
MG;_A_Q_JE=XYAG>H!J!A2J;C&H9JP7TZ.J2UQW53;8R:_%\$!4T!5'_@_M&H%J%*HQJ;_AFABW3)&YE^ASCF;_AD_Y"?
\2HQEM_U5<>ZBZM;J!&*7^:FT_M!FZ_-L!X<6JPFBG.5^MQ@!>FF1?WJ?DZ&2;C3&QKY2K:_ZA1LBW!4\$L#!!0(!
\$F\$1%HIJ!JW/@4_M&J_9>+&PO=VJR_M-H965TU+VWB_M^R/_+W!LGR+WUY3!X"-!"!I-
X!0/G;A9%G>@P<Y23"-_H@N2RB!3RA(LY"N;_M&7S!")YD!1DELV^;9.1(CYFUWQ M96?&F),1C;!%\$S\$?^H--
%3O(S%,UT^!A06%"&O/L+UKG=;NR@6T?2.6@6!LU3;0*@!^A^X1@W9AT#15
MH%,8=8,K.LC!MW"H+MO<&Q8>X5!+YO=?#JRN72PP_,^HVO\$5&U)4P^9(#)K_M.851JK3!(IC&DD!_?Q\$<D=
!,12E>1!>7^0Q8>/!A^CWG_P<4%,LA_MK4&Y>M3M@LD6F:>Q!#W+(^,K9/=8_EZED/^J8O!?)M"A+F0,)
<2)@""2,A80\$0K**Y5JFY5D9OGKB(WM3)K04!TB8_PES(6\$>);R'_MA_5_L(KR;+61LU!H!0J9N!/LG9^!
M>66:EE7!Q8^TS3!7=9_P%Q+F0<)\2%@_!^NHKE>JKJ=5W:/=6AY_MVYZD#_!\$N9^PCQ(F

\\X!:@%>U=EHJ OFHXOI2;I P!Q+F0L(2)@/!"0N M8!6Y6>8V56B>=#13!85<\\XID?..ITE,U'TIS"EIGIPQ?W<-=IZMXIU?
Q:ZJT MJE4"+:4Z13O97.L #PWU+LZ>/^L@:K+W!LLYH8Y;4\\=JL<+89UF>WIB(L7 M0-&JTVUOH0^GX(TO>.S10!)
<IX9E\\?0.J@!1 .3XH+8"B586[3=);^BP! M>+2FIW>V7D'3<07M,3<7^) 4_6@-!^4%D#1JNK;INLM;7KV6:@-6;4"
\\W? M@!(4)H+2O-.3XH+8"B566X3>;I9\\X"S03*THS0&EN;T#Y3F+I(""%I5 M=IO,OG5;BOV\\ XR-
SP"\\3D6;3=VLO=W4I'D.RC-IZ4+2+2JG+)=TN?>0>) M.2\$SPB-0FE/0*1G@=A <^V@-!^4%D#1&ULM=Q;;H(&;@
MOS)BJU4K98;'+')4A/V",U;91LN\\<3F 2KQF;M(8>J\\WYMXIC8@0\$K;WK1
M@/\$VO!BAOE@3A^C^&=N5++DVXWF<IE0B3'T5*&Z2-W4;P0
M*KT;WW>392S%+t^T"+J680RZ"^&'G%ESHW.5+>A.3I?B7MY(I7UY%=?
WNJ4RQC"W(I\$742"O/U/SL\\ZH0V;R3JP"=1TI>K(XH'IF3;.@ MR?GC6Z1H=-.5XF*0D7C=-!6?KC^*YZ*\$I'1P!KN:&
5#;Q&W.THX%=-+"; M#<8I^O2*!KU#&+2+!OU#CV0%0-!@TM#=-!ST5Y0JR7\$W)N:<5+\$1\\3 MPSS*3D;/?
+IQR,B;VFK)W\$8Z>^+Q,=\\A K MI#>8WG#DI/CE6*Q\\H756U^CA_*8IEK>P;=X+\\4/A3RF=&>!>KML'OD>
<;MN#YE=).8@.8K\$&\\S MD9B'Q#=(J\\V6W7Y;WKI\\WX?ETM;F5,HKO\\32\$AOW>J.9ROG4'N9!\\1'B;CT^!#
M9BJU6VJ;2B1&D1A#8BX2\\Y 8!V&U5 !*5 ZTJ?RV4HD2X

WC\\=(.;+Q!PD1I\$80V(N M\$0.0&=AM>R.R^R.0?W3;O^J6DT.@/!3;6-)1*C2(PA,1>)>4B,@!;+\\\$VC M&A/K>K!MAT J.9
-0K5&%1SH9H'U3A*JT?;JB)MO;T76QBH%";U!ZI1J;.@ MF@O5/*C&45HIQ56MRSRLV)7U8C6=6;W2.L?
VZ\\YQ00_BI%^%IE^%;5FE5U_*MA1Z9MW^?.;&J#12>J@V9VN'IR57LAU-_*0(2RZ5X7LA0)>G-!JVM;.!_KO=;
M/ 704A%4HU" 0347JGF%MODIP&K&I#VJ0&95;C+U;#\\AX@2PP74,V!;A2J ML4+;#;#;%X9H;4@J;W\\H^H7^Y_/7-
5D!?!HC8SI_Q%PNU1H)M+0-!0>J4;C&"LVT-BXROK^AO+!0JL4(VCM'HVJT*/J1V+X=1#JA5ZJ76 M*8562*
;A6H,IKE0S8-J'*75LUP5?LPQ8+P'65&X@&H.5*0C4\$U%ZIV4(VC MM/J7Y;LRD;40\$\\7^~^* WVB8;JCE0C4(U!M5?
&/7GS8>Y^%;/H&;1';5SA*&\\2)(C?^T00I=K4I06IUSKVT%I&034* MU1A45..HK1I-JH1FZ2LY MI\\;#;\\AM0OUNMGX%0
MU4(U"-0;57*CF036.TNH0E*IZ9PTI/1%HI0^J.5"- M0C4&U5RHYD\$UCM+J*;IJ?);^SK>)P*MID\$U!ZI1J;8*K5F#-O6-
S7_ BC1T M'SRH0E%/:E5%<_2_WX+T#^Y(MXP.@*M#T(U!ZI1J;@F@O5/*C&45HZJ;J M/F@;;^~^/V-";
(%1SHIJ%:@RJN5#-@VHJ>5"-HI1Z4JM'HJTO)+Y+?Z3I.(E^+UN_!J"%2JA& MH1J#;BY4Z;1VGUUA&G(PVH%^"G9
1.R,C=DI&@)R,V\$D9L;R8J=E?I(^Z MHUW5'6UM1>B>@FTY@C5'*A&H1HKM,8XB6GT&R,CT*UZ4(VCM'4VNQMS3"ID
M2)\\4)Z0;0*U7IIVY7)I.0GZYWSJ\\V;R" /\$6TE7C'KF=4017SOIU?E0-ZE MI'\$I'=(O)ZL?U'1&PO=VJR-W-
H965TF7*1865'HJ9*VL!N+!"@BKJ\\Y5NA0ESTL3.W8DTX7-%"8.I@>2JK#X M=0V4+X>.;JZPFOF16*C/AIDF-9W
/ZK&^\$WKD=BP%J8!)PAD2;ITZ5_X@BT\\V M#7@BL)1K?62<3#A_-H;8NAX1A!0R)5AP+I90_4&B(MXV?+Z71;&N;Z?
\\7^ MV7K77B980L;I#U*H;+!+!#ZZ1F^G%-IOVC9Q/8C!^5SJ7C5 M@K6"BK"FO2IM'M8_EN H
4\$AP+!"%A!;HXTR;VN\$%4X3P9=(F&C-9CHV-Q;M MW1F_N*!\$GJ5;O*OW");I#F#F2)DQ30!Y1EXTS/2%(-4Z@).!V!PH3*
\\W^ M>#I"IR=GZ 01AAY*\\I>8%3)OE99C2-VW?JZV3IX8^L1Y!4+#!\$S\$8)>CAB+;36%.W\$#6.(>AHX^4!+)\$)WW_SH^I
M3IO'8ELPVW8NOWW\\;=N1>?V'#!%0NOPW-U+8ZZ\$1=KW^_Y+W\$7ZUZVPP+_
M,NKI"=M0&74JHITJKX4^_U!@79>W#ID5>FV*^\\L3NF\$+D*HR%?J*OJL2Q"IO M+IG_\\7<=B6PC\$;TN\$;W_+\\
I>;=T>B6S#;=RYC8I3G/%6U<6^Y_U=FIM14;@> MU6ATURY1X#&=8C\$C6@;.%J<9Y%\\WV=\$=\$\\!LU
\\=K>JQ.NI"UMNZ5^1T&8+T^ MY5RM!N;JIE\\FI#&=02P,\$% @ 281\$6IO1<.)2"P-5\\!D \\X;"IW
M;W)K&ULM=OO;^/&\$0?@KT*H09\$ R6EG^?JJ&^CY M4+1 @Q\\ND@9JR;-HFX@DNB1M)T\$ _?
\$A9IYT<9W;F5N6;\\DV=TC)^UCDSH\\7 MSVWW5JO\\H- ME&;XO C_VJYQXICJ9C^=BV/TI/_K&Y7)EIE^IM?3_-8U3C?
T_U;=W=3D_- M_-+?XZBK4I%I0_SXT^A_.QS!>#0?JIZ^;K<-90A_G)5K*)-?5L!;H?W!/? MZ^,1I=X-
^V\\V/_P;/1I_UJRB\\F=^;?'C<<\\V#7IE_^K7XZO!-K 6F8#>\\S M'O;
H=\\A+\\H60W5UT;7/43?H#C;I;P\\J>MOYUKIM\\F'HQNVXW;#U3_- M;MI^\\N;NGFJ/FIKZ+OHP_C6;Q!A^UM-
/OVQU^C?W7-7;0#B_J^?JBJB^\\ M6P15L^V_B;Z*FGWTPWWIV%?I37^Q'L8IG;JL;XY\\^9E;RRS-V_KFU=1#-I&
MUM@D^O^?Y^CKKH\\YS#K\\0/1VE/1VD\\X\\B;N! JF>NWD3;Z7"HW?)N/DV_ MU_U#&=5?KL?;\\INGNK5U9_)GYBV?
GXM/;Q8?18^I;T)U>8VK_X@7V+SGM M7^)!;:W@MJGEZWRPU;3I^Z2N*X;"Q?B*JL=JJ50MIJH;7A:D66Q72Q
MI%0LDXI9JE@V*V93&UNZ6'XJEDO%@"J6SXJ!24U1T-6*4I5"JF;H:L6LFJ\$+ ME;="I;?0NZYL.ZI2J;T\$QF%EO+5^<
(=J2I)B9L4RL'F1;\\41CZ"7C_\\I2I*IN MIK^%S?Z.Q0_9;IL6<=V+;I@27_R<>>.%B23ENEBE_4<8B(\\JAPW4I("'
M#C\$0%2-A@3EC'EG_.08B9*0M;J)APLXRT#\$C.0%YHOLY)!GI*6&% C1DX MS<#/&4_W#;?;=A9OVH?
4L3I5P^=-9Q9D3-2%SOCC*OE)+.B9*0L=BX95\\LI9D7%2%7L7#&N MEA/;BH*1H-BY8%PMAY?
UX\\6"8M5Z6>7I>O@+F+5>EFG_E7K;-D/4>3!8I MD'C^"SWSDK3X*3.6T=A7)Y/ MRQ+Z)4Z_Q/)CIVR,C^<9=
I0X&6&B(R1M"\\JQA+^6"(R1M*2JIE+&R;A) M2Z)F+\$\$\$7PD3&2%#H2-
6.)8RSQ\\;2DJ@&=2YQCB=\\QEI9\$\\5CB'\$O^C@FTC#_V M?1H?UB0J_K%#9ZQC;2G.1B59PKW\$N9?
X/P*RJ*BOQZ4.L%0\$C+Y8JP8L=8"E M(F D*JD:L-0!EHJ D:BD:L!2!U@J D:BDJH!2OU@J1P%I54+5B*+N3I!6-1
M2=6"\\4ZPU"\\8@J^_H1/*_IO V=MZE!_A29>P+W7VI>** @E+JCZ/3IUB
MJ8@8#8L;L_KW\\WZKIN;7^6LH_A\$ "YV6&UC"SL^G(EM M M<HEXFH;24=&K'W&635SYU;N=XNU))_#%1ONW;L\\M-
\$RDA;"O6I9.\$<*T3;.%C4IY*E0ZST(\\WPJG/)4LG6.D7C!6E M5)\\EHZOTL\\7H8FTM.P?;7">ELZ_\\ORVVG()
\\4JG71G665NJSV+QU89UE=; MJMDJ'5ME6%MMJ6;K=&R585VUI9JMTK%5A074EOJF6M15&H6^P5IM;BQ-KBS
M5DT7&-16;_QXS3T6&6BH2VL1K4;FO^@\\VV9I!F6X;Z;4U@NZU17YT#M@WIM M36"SK5&H@;UVIK
7ENCI@T;ZK0U@;V\\V1JT;&-1G;P;8V^T!@5EL3VFMK MJ;V\\V!G7;FM;V6Z-W#@<(A 2!ZK^_5D8/G0N R&/<'\\K+2R30;
1!^ @!<' MU(L/@;.\$'&^(\$Z \\P1"HS 41UZ;%DH\$)XH0F_\\VEU8 M))0 *)4_DP!KXY5GQ\$#2AB_!#&@U=%G#
"%#\$\$.&=#JZ&.&@('(&(-<-'7T M20-40.0LP;T.OJP;"T 0AQ UX=?>4.(A,@!KXX^

?'"^+Q\\PX4_M3"YA)IXZ> LS\\PZQ*^=\\3HPT>NG->G6N%+3IEB_\$=80N8,SPC(@C)\\!C6X MS;LV5I<;T+%;_9(YN=8!;#S05'\\V#@=RE MHTU89_FF;3IH-
\\V8Z/;\\VVR)S;_KL\$\\Q28D@Y^FCHM-1;\\3\\<3-*F_RHF?S(_/_/ M6U'(#E#&=8<3\$J/;..HR_0MUC\$Q99@FG;18UVP0602!-36W"(DLP3=-QH^GX
MNYMI?')1"89!>_0F"R_ K02G*>\$0CL/NG@N;5D-CC80%PZ*K/F-4W05A\$Q99_M@FEJ31JU)A7LLHE-36W"(DLP35/HM2[5^X^JT/UN_MZ\\;
\\I\\B4LV\\WH\\M\\K32V55=01;2^ "2_MCX;MVG^KM;@6312VXK\$\\T04;^__90!T)R0MQG9=C;7+8-4KJVI'T*)B;_D0M\\LW-Q0E\\F\\ILC725Y2YQWU7JAY<3C_-M'U!+
P04 "1)A\$1;?1;00M0;^<9^>_M^ALW=06ULQ900<\\LV\$H_ "D7M">9_)_D*GMF42\\JIEIFD52WKVX_MN1>T!_ML*_(E*3N\\N0!_H\$@&SK"
))=VWB02_.*NP"!9Q5G=J+Y;_*JEUFK0\\97T^:F5MEBW6A93_E"-M8KK;\\G)R?KH^\\K\$^/ZUG;9&7ZF;=-;0E;J0>J_*ZNYL@B?W!S\\E5!>M=V!Z-M?
GJ37;G;JOWIYF.MOTTW5A;Y4Y5-7151K2I/\\J_0JU3(KL^<\\!;CD\\U0=0W\\/\\;_VGM_M0^;F(F04K^K^E2_-Z!-)/(D62C);%>VGZNYG-3C\$;W0SJFC6_T9W@Q9-HOFJ
M;0ET#B?P3(>_@SKT,@MAI@X6E_A@;\$L_\\#>C0@!\\@_T-M\\VHRO20K_*19_MFYV?UM5=5=J;+W\\L [FNK5V/R^\\?0_?1_E9?3=;5JL6+1G\$Y;?<;=
\\T\\FGPIFIZ<;>_X.D^A15;+7_M32?\\WS_*\$\\;TX^M_M\\I\\U;\\JG_K;R;NKF=YZH0_?JG*EUMMF=EGT\\!<7350K^_4_?0S?ZF_MHU?
-339790_\\W52J0E63\\Q^PP+!^5U3&/I2;9V(LXV\$6_56U6Z_EO-M'5AP1?MY;I!^0>GA.)\$&/)Z?1V.R2_#L<8;\\JK2P\$=\$AC>*/;_<810^_.%!
M15X6J*95I'KQAYYC@NKK;\\)7/IR7;HMB;U3P\$AP;G0DRCAA?3^C^N\\K^A_M;13&G?TYEW9*MN9K9YOYM5217JZB2H14160_\\Y_\\D5C0I;UP5T4'^EC>
MBE=\$86_DQAMY#?J3JU\\Z6P4Y\\T7Z/B\$Q8A19-D_Z/NOZ<("H6CYU;S\\W#_BN+;X9VTMT57GZIZ%;%A>+;XU+0P!\$&#C(F)\\C(-" MR3&W701T+;8^\\XEQD(0GHN5-
EM?\\M_Y6;19J?I\\FF@8\\L\\V+J%0MZ";)IAZ2_M;LH_ "N8@A;\\VJZG^0\\;_PL+Y6YT91<ZCYV'NA;_K-#\\JZ?7IU!^IG=@_MW8J^#ZF\\+;I8)\$XGNKI8;6&0\\X
L0;Y5^AM>P6@%="M@Q7^XK-A5GKN=XJY MW9@YQCDRD2;8MLE5Z5-NI\\G^J;_N^_P0/RB@TO;ZM;59?K>?*=XGWB5_H_M5M#>L5_N=AGF;_?VG
NIA!3U1<;1;A1NKY!>J[6MJZ+H^MU^="FB(D)R<\\)B(M&!_ 12;_!-M.U5#;K\\I^E;OQ;\\R^PZ#U;K^"^[GLONF<3J\\U\\FWV5743N/ISE;+;+;?76Q9
M5\\OQF\$\\7;1-LB&18_!;\\JZ-8;09*Z;_X(FIAZ6Q-34<\\K4/&R8;_E_F0U\$9_M;1&KZ5&6=0LFANX("F9@A\$QV/#_J3JU="QKNV\$W<GVP;7>2@_QJ8\\(SH6T
MZ6D&^3%/+^1&1(B^F;7AA!\\#DB1;DD>LU6+1X\\)E05=I\\H0^5=J8NB2A.GR_MP6MTN[_075ID5J+~"##). '21A^4<=42PQ\\DC!_C@_5T<E^_I^#U_*TC
((\\Z5EX?;_>DMN)\\&N\\439T2<-T_MZ;1XT?>B#ZQV1A_KOKQ7BWR%6"X1H7-4;VE8UG;#>K6W0(WN#P=>W=VW.WE_MQ1A?
IH;9Z=>=8;8N56^N63V>04(\\);=;_R;T!@G(I)\\#JM20*\\V3ZA97I^C2_MT2^\\A4UD.QVZ\\(IK4)2&47015SX*\\#1K1K#A9#1I9VNP77-6))X;K+48^M_M)P\\I
(MT+G\\1XV1;_REU0=0W\\I_P\$T)_X_&#\\!+3J50U\\Y>D(XCZ0PP4?_0_MCQD__#B\\DAGJ<_LC^S\\D3Q!Q_20-U-9#(*46>BX89^F9A^G\\I\\D7(\\!N^3(M26TOF69E>Z6
9;IR(\\#_8S_*8_2I^6Y6^>V5<7+(D\\7;F^QJCE^_#_R_M_>END08^_+H_..8KN>=>HXQYXDB\\F29_5ZZ\$;3/>6)26+I7;/_
M\$Z!CG&B\$\\IV\$B38D=^T*Q+9N'MRSR0D^\\I\\D\$Z!\\HY8K1\\66CF5M-XJ\$&AG_M9@D^S0401\\66CF5M^P6ED86@^XI=7%Q3C&^A\$SKT-\\)V_*\\(H2I_..22!\\\$
M8P^4A0^TB^PC;_GH_1\$80^\\I@^&S63A83A\\Q^R#_47;1-390_R0Z77265E_ME;=S_P;LC_/_D6^\$3Z^H1?)J#&.;!=\$/4_*6QSE81Q\\FGR#00R96///\$#%()

M;#; ,II+>8\8-DO(PDAZ6:7#9SDM"\$T\$1L@&FCULF\$E!(4JPKQ)-#57R;4^M>9@E7&A^:8G#@H94\$ M"->2,6F10H'04-I-!=;I-B5&;79J1305/'KEFC6D0'LK8; M1D.(7'ZS'./B1Z2C6BDO'LK8;=@J/ R3\W. #MS^*6[F(=ML(1V1M;M'NH'')2RAGMM-N'<'.H;.(W* L*6C1X1+>Z=;#(1?R>);.0H'JE(N1\A8MO-COM-MEZ1R; 13A@1'F'?'(KT(G)*Q0V14;ZEP2=@J1YHP%'K"/HT"89P;=\$957LE-M;5'RZ\14!4&T;/R'N\$RWPDC-K-V'E;A)@R;0;U*\$2(^Q'f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

MRZ,K+@^B^~932A5ZS#N:V:I4KOK^5S&*KI2A5QCC17~!9YCDIOM_23!QN9GAVNG#/MJC2 M%~:KY8YLZ9JH+
!O!8SF-4K"XNO(QSJ!!/OE=&#/N-)-4' M<:IP?OD9F:I&=&QDI#\$/BWIW/5 M?)X%.(L ?M)-
C'!+N;X#Z1X:IP3G\$L3W&.:Y2IJ!@=(J+(:EF(RIT-#*I M?T,DPWT&=?KOE8%W&60IU:KE91>FM=H714%
M\$A04BK^~J"(LDRIAYLLZ00\$E\$KT'=8=I M;E'IAAAT@_RL66ZP!36=1\$%L!0@9UKU@/V
M!20Y*+F20G.RL1P0RJE**\$EH79L:HP,QA2E#RP##FOIM4Z *V/916IT= M=-Q%CX&-
!<6BH!90E!L\$!37Z4=CV0G=8C!6(I CX:F&)4#MI>,*7M30D63036DCNLY0Z?,X7"E!4V7V? M7Q"1\$IP!100Q3@G?
4E-9)JIV;L45-,*ZE.)BPHOI!>+YWK=PNM!..7<=&H M'Q2ZWA-EAZVF^!%&E7@;QT4)?&+!H2K*JA>-
A53#G8O5Y^/X"/H+,"G.IKQ% MQT>CH3AMMTIX"SYKZO HK4^PG+!UJHV30QTIM"E\$;CQ%4Q492ZKF#O;8KM!+
M"8L+E;9GT+AEWU%*V-"A*.2-QF@U#1"?!2M8:N".0V*A'NDK*X^_9 P!+X_ M1G'-NMB-
+O:X+B<L140C9>0,OD./DV@Y:6CIV.UV!@:.15E>%L9"V"DT'B4=JIM4:OK* 1F.B4 *%I MIE\I0#9A+SG6V7;XK64-
GO"LU?Q@)H^#JW!>1?03U,2E:~15:6!6FK<3>SWECK%I^ MJH?VUS8T!6BV^!+*JED4/%W:~I^UY!+AT4"(
M'3JV_!0G"VYZ8 Q<O@PQ&G\$7ZX3*9\$BZ9",Z07!+X)S73 M>-)N>E*F*:"JTMN9-0XW":H)MV:8.P?
0GZY>=WOVPWK;2#4\$KDYF=*24(+0#W-P):C>- /Z \$E_!#U!+ P04 M")A\$1:OED!9_@# "L#& @
'AL+W=O&ULS5==CYLX%/TK%EM5K30=OA)(IDFDSM!J1^JHHV:~!^!#J@P=N@K> J6V2 MZ?
!Z7AN&DH0PLU*TI4N"S;G'!QQ?+GBVY>*+3 \$4N<^S0LZM5*GRPK9EG\$). MY3DOH< !*RYRJG
HUK8L!=#\$.69!3E.8.>4%=9B9N9NQ6+&*Y6Q FX%D56> M4_ M\$C*^G5NNI3#QD:U3I2?
LQ:RD:UB"~E3>"AS9+40":+>2;-+IDV6.1&!HBR3+Y'DTS(B M+YZI).PDORI!DK2(I\$S6Z\$*G8L=-OE?
UAE!1S)V7*#:Z62O" T22'8):!3? M>N !>'!#13\$&!)3WSTCGN.->A*Z>GJXWQ,>/3W<&U#CMSOJ&S!_V(YB:TBJ
M#(1NO?U:~!26-W(*>8*:N@&H)Y+!O=I#~!7"G+YN6/ZC5&-6OH9G0A2QK# MW.)N(T%LP%HI_!T-G-
=!_IV2+*H1Y8ZWHL!;T1#!XCU0R8HUB:E4HPH*BA M".M+P3?
F(<!)K&ILB'\$EA\$'2DNE""ZO4R=,59A4G! UNJ%95_?JS<)UO^\$ \$ MRW'3=:(YH^GP2XLZH\$YDI'KM+ =!>-6_7A0?
00;? \$^46N<92DRZ0ZV:JO0\$ M-J= _N-CO1%P2> &?M O M/VCE!X_ (OXJ*6=WQM%Z:=
<9AYXSWO/B\$(>&31UWSXL> &/(%TwxOPM: +<-B+;L/ T#;V/CV#1/^U MDYR2+#H1V8Z!DI_ R?_0I2>G!/:49-
&)R'!G;:>3G!2EYX>/ \$S.WE/Y*"(Z M1'AN_!H.C!^XIR?U9F:E8B#NY(CJS)>K^RLTY":+<,B!1R!1C*0V
MP.Y!QN<@UN8X)&J.T+57!M:OD>F..&GOSE_HH9HX/VCI<IP-%6N&^'89
MK)#2.0_Q52GJHU\$!4+PTAX4!KO#H82Y3/\$Z" T "\O^)&PO=V!R:W-H965TQ"IC: M3M+^ ^!K
T)#2EGUE:JZL&V9;:E M!9'WO**EOK/FHB!"GXJ+2M!R:HF%;GM.DYH%X255C*MKSV*9,IW*F>V&:KS
4!F59D0Y=4?>T>A\$S.Y45*V@!K&2^!H.N9
M!0\$ _+!+!K"#7B7T8AN@8&2O/G!S)U!6.!LO*Z(Y\$921/(G3^RO!PG>K02_)BW\$H*6 M4%NW&^!UX%*B2#
!5_ ("06LU+'2%.I2"7V7:9Y*EKNJRJG.O"(Y MFA.Y19!T!: O95.#)I= _HF5318BO468@!J/N.
!4FN21*10°F"7:6+O1CLU#WPD)3FMT C M#!AUW%!@#Z_G>X!H!VN@00%{?3<9!NZX1U67.
!K+FUGG=!:AY+Q1AF!1Z 5!6'H.BUS' M<_NH!2
6Q&X<=:":>:~!S!5^U_ =1_YR&SC4!X!.#0IX^>VW@!1P78BTBD@ (H M/W9.K0(HSP!V&G0.0T&\$WQWEMTH/-
!40C.UH!ICWW-!WQA&VGC"%TC"%B.):!(1 M==F(OFL!T5E!."<%(A!Q&+1*2#B,4YXG)*L?/HJ,9KW9;K5!3@Z8FB
!&)H"YB8D%P:3 MR85Q@H!N?%K!H5&J= P-GA.FX0H/+XO+! 5O'5!Z_7UGFKWON @28H MA(-&*(2#9BB
<_%\$9^\$D'O:1!LMLKO!F8L-*B7*ZUD3G/M+ #6#3!U>9\$!K> MD#USL=W!>%6!_&L !?VY>CDQ>ISNOP:)+U!+
P04 ")A\$1:>O>/ M!D(& #7,0 &@ 'AL+W=O&ULM900;HXX
M',, %8N;3IO4%6*~!L!Y%&L33>FJJMUZ+TZGDYL8"V)F6W**MT??TX("4Z# M2TY?WD
2XH^=YPFVG_P8K87!KA:~!70SCA)UT5HO3QOMU6P8#%5IV+) \$O/+ M3.B8:KJYVYUE(R&6:\$X:N_ YZP=4YZTQJ-
LVZT4O_E!V!9A'JMA41'_P4"N6L,6"ME,KB)D)! :67Y_907B\$AEGVB= M!HMH6"EM(CSPJ8%,4VW_1G+L1.
8SW%,!Y 5PIT.OO*#="W2K-0SW%.CE M:7J'_JF?%!@.O;TY!DPXGVHZ'DFO1C+=V!#2A4SJK+31BR?IB7*OI?
F5FW)Z M_ \$EIX!10Y>)9I(IC4BBN>9,H?HADDA9/16YHRB/U#KU!/\$7!Q.S6K4 MUJ8-*D=Y/5-07A?
5YZ%HD>J%_-2\$+:!H/7RF/8"V.?A":Q58(*=1)!% MIZCKG2#U37L<\$QOBT\$+H99Z)+S6+U5YTW/4A0 M(&\$^)(P
P2QO^H4W??=?@SZ:T54KI(49&W^LN&2(F2_C#D^>C%?9KW7F.+E_ MS=G_!ADLG4(C;U1^VE7<TTZ!(#EDE
8)9@@!P0@= !5!R&9@%,^%\$8F9_ 70@G*V2 MT.@?QWS_>^LJ*D-@Y?G?B 61! AF>3 L!/@Z/?
ADQ.7)!6>B!K9U<19 MOJFTIL;TT3.CLLY@!f(5! AF"?ZA\$/R#!QBOZ"/Z%ITP%BYHC*ZH:;=OJ3GI
M(C_3!0YV\3E!3^2%A/B2_..\$L2!Q.&6DZQYD(X5P@>T!H/BB-0_%LAW9"1^2!
MVUP6@P02ZX!M>#>+G=&BUANO;CCM#NVN?JNN+!HD#0"1_-%QZ7H^/_06.F M%R+<&MK'<
O1)N57YG\$QK+>TDC4#1:_C(<>^YTO*!7.D\$W0J_R=,+6C" M\$C;C 3?+M1Z_YFA0F@!*(U
TVZTR25W""M.>:~!H&I?@_-)%!LQ!T!\$!7GCM0W MJ_B1R318K))! \$!\$/#39+MQ<4YU3%EH>O72Z;N&MJ-
F&=K;33^)*X'A! M%P+5)EO=,CUHOC5: M_4%S-RC_!Z41*)KM:AG1O<&1>C702 Y*!T%!
(!F.U0&>|=FLM>;7OK(W! MMLNUUH!&^IRVVS-UJYT7:'JHMEZE_G=IGL:~O8S3PVK7!7*7025Q M0!7)UK9,W-
B=N*!IF-0FL_3*K.N#!-JOW2,A(S+A(S="?GZWO3S MZ/K+9%G!J!J06D^*(U T>R*!L@W3W2;>TN:+P&I?F@-
)%!LQ!TJXW7725O! MT\$D!C6EL2.V=|12A#~12 D7;*W>>8 !9G*>O3F@4"!6B=X!R5UL+=Y.^)@!
MDU_9/O7_&PO=V!R:W-H965T(CVYR:~SY(=A.VWU!:#>+"G250.J:Q&??_?TI
M7W).UU(JZ1+1P(8SH8=1:4QU&88Z+Y\$3?2XK%_9E(14G0IH&>I*(2E!\$&=A M\$D7!D!J@BSU#9R_=WBDN-
8!8W)9S*5(V_2&+!1#-HM7?#N^4?7JL=YC(G&AE^T8+4PZ*BP*7)"_ MF3NYOL\$FGY!3RR73_@GKQC<*<
(*~!UD;P!M@2&H<=&69&657!8TSV2-1E,P9PE@85*%?!*!&M&HH:WL/2@)%!1?E @XXGH!0\$,KT&9P %7!?
REH34>@T-):0!1/F#01\$D7'F8C.#TY^UTFM_FV629MEHG7!ZB.YE<6^Z5L;?DP\$+
M!U,EJWO,RYWY?P'=T7/^!9L**Y,*DUX*.2NE;H3SPG2CU3L03" M9:W_M+?2
R_MVLDJBWL7<2!-5WN(>BU!HR#15!2B)!PFONQ\$YY!5O*_G&*W3!"!""'AROV(_BIW\$G>
!%~4.=WJ;NR9NB5I2H8'APL9% MYP;-+5MO5O#R,JWN!DTMGGZ86EO*U3.P:XO!#0OANN@!2V7_0)02P,\$% M@
281\$6H)37HM5"0 S4\$!H !X:"!W;W)KJIG(C*VM++F2
M!F3VUR!ENZ9;HS54C5B)9=HTV^12&833=)%DQF5UWGWVJ M9M?
EKLFS0GRJ@GJWV235USN!EZAW\$S#YXX/V6K=M!H,9!2;9"4>1?E^ZF2
M!Z:G*ML(XHZ*~XN@B!WBUOUP<8%9VZ!3)2)U_KL==!>RG-9 MJ^N5_>3;(V
M(Y&+M&E#)/*_O9B+/@CR3Q^_P:=G'YGV_#!11_1 JE=O+R8YZ06!S+_5LV MZYL)FP1+9+L!N9S^?
HO<;P@TL9+R!SN_@U>CHP\$J2!NBDWQ!8R@TU6'/Y/ M?C!:<=8 X#<:P&,#>&D#=&R+FY
CPWP!0W(L4%WZ=~/M72&Q4F3S*ZK!C6H M6K6.UK!HW.J:2!^RHNTHTCTE?
YK)=LWLIZ3*DN=5*D(GCLNFRUCN!KZ-19-D>?V=5^UYC(-OQ_DN^":(BN!H7>H MI%C6U!&IM?^DFEZ3.7ND-I
(Y58I!"/!+X/8 BQI?G!N:(TCR^O#FF-%!< MWASTFT_1+3G=%WBZ+!"+A!Z(=_OXN'AZM)EX:(?
M!>IOY6.135)Q,Y\$#1RVJ MO9C_ OXW\$ (7_L%GJ.UCL!_1C"4!"/>^>AD/G)%G!HMLGR9%;LZD#TYR#;JMP+
M.3HVUEYIB\$6!6.VXO)!^! "F>R^&+W.S+4*\$<(<H@MC9W9#C?204K&INEN!N31BSEM"A_09HEAXE7^!MLRJK)
M_M=18/4&&9=X9"A\$(6:JQ8A(AQP C!2GD_56 M'LB94)IK6X0HE*."I7>V)G24/<|!>NYIT_N4:=[#V52 MU-
5&3!MJCX/BA\$8.0&M900_7^Y!I@X!AHLEB9U)#_?4K.ID0!J'=54\$<@ MWD^=60TUT%.PGH\$@5-
00.BV<)_7Z,)>W+!10.VEC_E!=(S5&PD!9XH+EIU M-\$)!_&H.R^D* P!L6%ID7?S5I4!_9\$9,X%TL*(Z Z_ M.BH?
+JPCBCNGP0Z_2E 40!P8!3VALL38V.N:+1^673UZJK'5)-X)H!5>HRU!1>O?_D56T\$U6PW:H06@ MHHAS8Q7>
(H2(0T3UQ2MW>H/-_UH\$(MZ\$;MO!Y#=#\$VRX!_2_06&~:8Z3N9 M!G0'FSL&?D&%7!"-7P_=#M(EG=3\$*RPK7WU)?

6f1R1(91\$8UYA7#?2\$7KNZ@P M# +Z17?3G1HJA"5M7- *4<-U:BS"2I2XW>JA7+/.5K7.1F\$9= MTF #QX MI&
+N6'+I28LH\$+<8YU+K/(#)N1(IFO:V: SX[4N9%LR*8/IL 9 M1<1XX\$T9X:\$ ^%(GS&NSB&\$R&%)A-Y-
VG=>YF84@ACJ=&N1 8;U BIV9S;8 MQS\$P"BF.ONIS5%AV)N,\$HKP&NS@&JR#%/< FN ! OUNM(B-
"ST2CB^HO4M5(2#W83SIF\$;/(*Q)12^0TM.H4 Q MH J9W<^@/T:Y8M"9I4E:++H8-
-5GR#W7SC^Z0#MARU@R1B>OEN MT1%LH I ^V%>CT%16%\$02F WY V##MAVO H9>7<(L,, 7TUR)W08/O&H!^I
MZ>[Z>>B8P!&=?@X"0 ?-+"!8A(IR:TX Y7 O\$5I6#A1.R: T2.O@AJ599 M40>Y>)'APP14CBW5X6! "-XTY:;I%N
ZL::O#IO@ B7I.D^/L=YL\$=K+AID M@C&%GM(DDV-OH=3RI-.1T8*E5!IQ)9-
1T78E)B.^4DFK1%WSI3FK.M3+12*>R.(W6E>VOH>BE50K9QU!&F
MNOMQEH JC1+Z::SIU&3*LXAE2M!B%/@H@HVBQ6ZCN4#^AG=Z'DV6R4L? *9 M: F@RT48\$IFD\$1M(NH)OAZ9-
-GOAZ#O M J)&%B08 0*SB.S61'9=Z)/?5ND=\$ _D4+J>J;*.NA.@7\$DI'9SH.7ST:2H39JX MEHCXC+ZNU%
(WZ'9TJ>M"7C>+T10H(1(#:KG/KU./6A" T?DDA((\$9A\$YJ(D<.">13:0H% C J\$47+
M.A.^M%90@;<1D7PC R: T\$C1KAG&?RH# +J& 67# TN.T+ "HKE9QB)N M 8OP1KKOH(8\$(T!@U@=@=UR-
T#%T=CB&)A 0C0& 6D8%OOI!J^/I0838+1-BH M".Y7I/L3%)I-U:4"-Q\$T2362C2+J(G2CBK-5G.W1
M5IUVI:SU^IP=V:Z3%Q2-0*9HX+-J&#H2E A0K\$)B4:@T&PVC>H*G%KDP&(0
MMA6#L/EYL.5L:)L1=X2'F#D4N#62SMG^<:' %R>0JL*2@: @4*SQ\7(MJ 'MGN>@R@H4C4"AV6P:<14X)
<>!=>YO2V#<:<9YJUF\$) WS>RN&D3N/7.IX2+ M>8=UFA(^3.%12-0:/0&#D5#.%S%U3W@*(1*#2:32-I
J<@.#IWCINR|=42 MO8L5<=<=W8/^Q\$2S8+5AV2 #W6)I=@>T!4'1"!2:/2A&'. \$ _L4QJ* @I12-0 M: #::1M1@YV?
^82E>83:3=1#(12UFS< _P+WLKAF% @ =T*XY8I4?F2+V\NH/;> M:Z"IOU!HJH 8P8.IX)D+*E-
T0@4FLV8D2G8O;UT6-.V6G.MN3IO.6LFI GLH M"VR4I:78KBWUW^UW69M#='U T H5F#XE11'@
GN&@8@84C4"AV6P:8/='FT.' M92BP-76;N^Q:S%ZE^%MF=M>;LLIN97%)I:318J577 4=UFC0!H0- *%9I^%
M.9(GI.%/PXIJ%5 T H5FLVFT2OC&1LXA&5QA-G.N^<^O+6: CW#BCO!0HR^ M"-WZ8H\$2X %VAW>WL3=
<=&"LT>FHUS: _WV/!OL\$>?7L/<1:;<1. ^L9MS M4*IW6S>WCYNWFKV:K'>8M98JSL;9UQ3)N;%66&)
(K!5'D&M&ZMSR.2%J=P M&^UGP0DI3Q4.F/*0R45ISB3*&'W&M(&FBA(,ISP^6-XLOB).T=5XJGQ>6"
MTID3N8%^2L^Y>KG)7U"2WHI^U!+ P04 ")A\$1:J^<^\$ \$!P&0 M&@ 'AL+W=O&ULM5EMCHX\$/XK5JXZM=)V
M\$SMOL=(M)I5*^U>5Z7M?3:!(+5)S-D&=J7^<+ -#FA!BS*7IHY&:8YLYH4#QIY*!VIB4YN21
I'),LO?;DG*=D;'.C1?2*!+E=0/ MW-%@C9=D2N2W12-7=VZ%,J<9R05E.>ID.73^A# =CU,,A<5W2G;BX!HH^C/&
MGO3-I G0I71\$)"6)U!8?6S)F*2IIE)Q _%." M68VOV^P^B?Z74%>D9EA0<8L
M 9O.Y6KHJPP)PN>2>47MOM(2D*AOQM8*HK 8%?;>@Y(C*RK'16\$60TWW _B MYS(1!PXP..&2@?T6@> _=/
+HOO("EH3+/%HP-D.<&VMT/1%D9O"6I&AN9I& MJ>3J6ZKIY.@.4PZ^XW1#P /!8L.)FB,IP-L)D9BFXAUX#IY-
)^#MFW?@#: Y M^+IB&X'SN1BX4HVO4=RD'.MV/Q8Z,=:\$) ?AU< >2@PN(I?I^XWW5W%N]*. M*NJHP/-
X\$WW*Q>P!5C0'.<)Q:EB*32%#DP\$=PC:FE9\$O>5NQ!HG9.BH/24(MWQ)GI/MO./+< _
'M"*Q!WJ (<S:TT2W.GX!^J.DGG.RH&I60<*RC/ B%6N\ M)MR4A#UR7"#K.K\$=P=!3?P-W>TBO;1.CAEDC**/+
&/B4Y91QI2&.=JCQ.=C!^%D8 _"Z"C.MET8>+X?IAR!AE6@H370!;E4E5"551FTA1?
MVJ/T9Q>)S&MFBX5C"F+>)Q6Z-A.150F(KSAAS _D+SY:X8FLW^E^ZISL".U#M551HG1>^7I?D
M.P)KD.I7Y/O6>;YG.I=*="1\$K7^UCJH 3HS;LHN7S& _>/MV39!L>=\$)ZH< MJ.J^/VR EU"1^W?BAM;5>T\$-*H/-
Q&!H12*P.M30WJG/HI'2/SK72 QVMDX"ZXX. M12VY63K!# _IET3M7 E4>R! I/#Z7'FOCW!I?
>D*K9F/NO'#L/Z"JUBXN(\$ M=(363\$ "M+;")D)S?G _QSSR+!(6JMWK89@GI8/I%XXI8/I7W_X 7H!H@G6Y(" M: RST _;?
%5J3="T 8/<* '8J I!":R:@%@'0K@ (NZ #I=@?P8S!O>.%VC8. M81!\$T8GZBFH!@.Q2P+!\$D?'EU IS!=MI1VA-
TK6\$0+ #IMW.K*KDX 1VA-1 P M<#IA%RFO%JHH+3UBU%>+I&B!&NQL4A75"@7INK,\$U!8E1JEJL+-)552+%V07
M+U:IBMIG V:I.C"T2554:PGT/T120IF^ _10'QU'V+9#0: ZZ(D(ZV:/L.W>
M5)W^DP:TCW/QINT(K9F56E:@N/ORU:G\$Z JMF8!8B!K!JL Y98S;.PM@8T MF)DTH'MP*Y _BWC ?*D"
"E9*# _O.E9:>@>^/L 6*X#GA MVD!HOV!*90W^M"J^I^E!^I02P,\$% @ 281\$6M\$)=/#N!P 35!IH M
IX;"IW:W)KZ7?D+>SVO# M@U _3 #Y8UYI57.I2 (M33) U9F7Y>*LVU63N4R%.LH7.M.OW=.%DKIM)AU
MU: *08EH'I4G7I 4&W53\$66=T7A _I5(S.V69Q)G!5! "U3%-1 'RO++XE.AGW77E&F48*>7 _1N?3.># "L NHS
M_HCEHJIX3*JNW.7YU^K)I?2BTZM:);Y*2N\$TA>Y%@F2472I?BW@7:6:O MS<=/_=%IW7G?
F3B@YSL_XYDYO^@..VOJH4R*3 _GCUPV'3JN>);4?5?MB< MV^N0R5*5>=H\$ZQ:D<;Z+IXU;1&@.IH _@"?"W
GS_F8"@0@.S=IO QI' M9CAN HZW.SS7Z4\$3.#BT22=_P.FA<_FH)9+= _5QU)E*\$HQ_B_R1U)49VM: M! 61!VM!
(XJH16Q:ZU5C'E:0%O&#J/I#:)R);!+A%QGJBR66J&E(N_) M1U\$4JS/>AK(4<:)^ (6I
(G)&:.\$FT _M1YM10MJ7C=29U:I75?R:KYY:/"OG MBD395\$YM0%=W8=T/_ZD?
5I23&K)0\$0F=130^47WRY38D;J^HD7U+M_YC*9
MIFGH^"L X3=@PG=F!M1)%>^I9%;NOO(MOMI!X.=6.HO#LB K#&!>TBKEQ ME\O9IGMV
) _:@%WHIS#HM<%;2@K6WXB@SA. _ (WXZX ^C5R7.E5 _IQ/Y" M3?
M#ZJJSIE:B(FZ.BRHF3Q(#NCGW_RIKU?IPD1"0N1L @)HT@80)(X"&)&KKI6 M7=I%UTJH>9)0 M>@:(R*)\;DE;/>EH:
<2=IJ" F+D#*"A#>SDC(@EH9.UAHZ<6KH5F9Q7I OF9*392&GY'=9 MI.1#+K)IE:UKN>4D- _SAZ9&ZFE\NP+JHK?
5&)060FD1E\$:A _E<13-5N3&>K* MJH0 _".4^)"V\$TB(HC4)H\$K\$C*)JM/M^HSW1-275'MU8;5XM:M&F-
W:U!K#NHN0&D42F-0&D?1 M: T9B\%S>PP'F/+>GN5\;JN5=Z=I+28D+8+2*)3&H#2.HMFVW!JWP7>I#=?
ML\$7J84LJBH4>R=3Z5N'OY*6IWSIYN7.V+;106@BE15 _A=(8E.91%NGQH/P M81Z\$#_4@H+002HN@ _JE,2B-
HVBV^HPX;L! ".0TSYVIM3RAA@64%D%I%\$IC M JXLS79YJB\$MN:;7>&H8I-\$> YB9Z;T5L4.L"2HN@-
JEL89FW8> _I?Q M5\$I;3L:)UKS8=<:;)K<4\$=2"@M*BA;7Y@)HMW.U%H2@:E<13-%LQ%GRW ML?
#JJP9IRHMKV+L-K>4(M2>@M A*HU _:@(XBF:KUO@8 _@I^V%0&U*J" T\$J+ MH#0*I3\$HC: _HMOJ.5>&I?
PEQV(P:_E) :2&4%D%I%\$IC4!IO: 9R: _I<;MAR M.MZ#I 8>\$7X(-?6W8I6DH1Z&%;!;*51*(U!;1Q%LI5K/ S _%>:
(H3^: @)" M**V"TB84QJ TCJ+9NT\$8TR-PEQI(Y3QWJK:RA-) "M*V" TFA#_IV*E16 _OY1-"\$%\$IC M4!IT6S-&
<_D>+5AXB:TEA+4 _EV+8I=WYY!4U(HC4!I\$6SQ60.D^#&R:I M)HHOFBCN=K66*-1\$@=(B*
(U":0Q*XR6:K65CH@0P\$R6 FBA06@BE15 _A=(8 ME.91-%MIQD0)W"8*="H(I5J@M+"A:;FBZ
)93&H#2.HMF: TY+X'9:70@ = MI3NZM8R@ _DA#VYP&H M'4% =#RB-06D<150H+NO1W&PO=VJR:W-
H965T %U@LED;#/\$&5S#VXAX;X!/VS"IVCN^6JU _RJRPKO% _GLT7^KG=5% =O M^ _W! "J!_G1CL;E% ^Y6*
IF:5% ^NKKLYI>K+ #W2;#2?I?W!(.K/T^FB=W*
M>>SSZN1X>5;IHOL\K+; ^;S=7;AVRVO'O7& _8>'OAO>GE5K! _HGOQ?IY?9 MEZSX^?KSJORLOU7.I-
LD4^7"V^57:SKO1^<^U?%XO<F_XYS>IRG8^H5Y MNES^LOHDX_FIWF" IJDL RO61%K^
M?EDQJ9Y=KJ< _6MZ7ERIZXU!WGEVD=L.BA^7=SJKGE"XILZ6LWSS?^<^N^MY! MSSNIR8OEQ-
JXW(Y=" _IKJ8/8V2 8/I*!7VW@US:P _4S _'OO.V^Z!ZZ6MIDZ>(V^X7Y6ZM?Y9M0L? MfG?I?
V07AK(W:;DHKQ)/+ZS*279VY 7#-YX _I\$?> MSU!2L _225!F^N&I O _ADI _?^Y6*!5 X>G^Z"NRY_Y.%@'Y*2K"-?
I?Q@Z?C MOQON;LB>SLXOIXM+I WZK^NTF&YETSLIDROUF5' _LR7E?2RR>2ZMLS?
MCSMJ'W=I1J:7Z=GV:M>> O:;DDL83\$(E)\$E.DIB' MRNAHF!&12S_Y^W)IE" _+Z?+V161508IH%X ZS/5FY/AN-
!^=IQ_W8W1LYO MNL:(Q 2)21)3)*8AS(IIN(U1Z(I1S?QKMO*6%^7ANLA*O _AAE1:9=U8>>U?E M*63NK?
^F>K_O4?IP_U(T6I>:E%SIDO7D)&8(#%)8HK\$ -(1948NV48N<44NR M?JY*;
UHJ7YIDJ#K!ER\$[3 _J3Y)O^<\$#G>3&94I)+2\$R0F'0Q16G:PJR.CK<9' _T&_ Q2JW25I^EUZ7X3.G8+I
I3IT66L/G+/K:1>J:@F M4\$VBFD(U36EV3GV34 _I 4X1J8"JLD:@FD UB6H*U32EV6\$UM<70N>*SUS! M+71.'5I!5-

KN:5P<-B1W201.9!HM8%J M4DJBE4TY1F9I<4 M' /H4">+..F!:@FJ"523J*9035..5,3?0R=R;LP1WM.U
M036!;K+2' (=C MA0ZHG0/03(%Q=#=4&R/V#^NX .E/&* \49'D'D?
O<_L_HFG%G:74<)U(5RK8=P#=8T3J@E4DZBF4\$U3FATG4\X\AKFX0C=FJ/J&@%
M)TB#H%G.HJDG"2U4\$4V@FD0UA6J:TNPDE:+\$=ZYM!QQ%WZPO&YKFWOUE4JYR
MX=VFJVGZ=99MUG1:H^:W1LT/ZTE#6PY4\$Z@F44VAFJ8T.VFFY?#+=+8?H2Q^
MLT08#L+&P0\ M+E!-5)KU.NIH4)L72G1.A6J:TNR F-K"=I
<6f1/2U!-4\$JDE44ZBF*#)NO3W8/U#E:."N!;A+5%*H2K/C9%H)W\U*.">D,M!*"L"P9;7FE^ZAZIKHF17I-KI!*!Z24"
M=R_AGB94&UM7Q_A^26G#/43G(*\$%0:7M3A/B21#4I@GHF K5-*79.3\$+_&> MUSY8TX17*J!<^!+YS-OM E!
H)IS-85JFM+L_)HN(#C4I0!>OT#JB6H)E!-MHII"-4UI=EA-TQ+_H MHWH)I-8EJ"M4TI=FY,GU#X.X;G-.\$
M1^J\$1G/E'J-SDM Z=4DJBE4TY1F)\G4"<%+ZH2@62=,AG\I)CON(3H""T3 M@F:=-,)
f\$C7D"6B>@FJ8T^J_Z-IDX8=:3@J-PYXJK-JX_%N1DP;U#7<^_4"U! M-8%J\$M44JFE*LT-
L.H71H3J\$%\$=HHH?J":@+5)*H15-.49H25= JC%W<*HV:G M;JTW6X=1103;"1#6%:IK2I#R93F'T_\$YAU-
XL-YG>>H>HW.2T?@U22J M*533E&8G:=M(%Y2*HR-I<)H/(HK06J\A\ N!+WCG0.2+_LJ THT0\$5JFE*
MLW_KIBD8I=-D49+_I>9XN\ 7???#\&O^5PA"[_+ M^%IW0ED^JFFY*B\3RZSUC<#<_I?Y?U=W\$'>F>'
M\$7JK(U1+4\$V@FD0UA6J:TNRPFN9@Y&X.GCB%&S<_XT'4HEJ":0#6):@K5-*79;TAGVHUP<*!C M=XBV&*B6H)I
-8EJ"M4TI=EA-2U&Z+Z!TAX+PY7PU&W-3ITC=-,N M2>EIXD5J":H)5).HIE!-4YJ=WYWWK3\439)"L
((5\$M03:"1#6%:IK2I+_": M?B5\4V2PN9-DEHG"6B\@6H"U22J*533E&:"R:0:X?-ODA2VWR0I".N7I+K' MZ)PDM'I
-8EJ"M4TI=E).M5#^_2\2X-O A(VBXXZJ!+=>_LY M7TI\$C\43\45E\QB=DX36\$Z@F44VAFJ8T.TFFGHB>>_IJ<_.81-
=IQ:AG#BTR M4\$V@FD0UA6J:TNS,FE;G,7Z5F8=17S?S&=I\ZH)5).HIE!-4YJ=7I-Y M1(?
J/"*TT"U!-4\$JDE44ZBF*3HEH\@3K""2TI M4\$VBF@U36EYV\$S\3^_K@?
*3WJK\9R#I\$Y2&CG@6H2U12I:4JS@V0ZC _C; M=1YQ_L.HOS>=>V\Z9P\I/M/%!-HH"-4UI=N9.YQ\$ _I_-
(AJR\7#02^=S:;3S M0#6!;A+5%*H2K/S:SJ/^%"=1XQV\JB6H)I-8EJ"M4TI=EA-9U'_+_.(HO
M.@_W0)WCA%8>J"913:&:IC0\3J:RB)I?><2/5!Y1??G9/4;G)*&5!Z\I)5%.H MIBG-
3I*L;)O5WG\$+3>DJF<_K3Q03:"1#6%:IK2I\7SZ^RK\$C2\CTYGF>K MR^PTF\WR,D'E@:
f;J3;>=1;91=E)H=OW_N\?KFE^?3X^OT.ON4KLH3MR; M91?EIH.C\5%/_
_V\VGy2+*_7I=U613+^>;#JRPML\G^AO+K%K\ME\?#>H"[_ MY>J7S>Z=_I02P,\$% @ 281\$6M.+[_D'; @ _" @ _IH
_X;_I\W)K MJH\YGF9?Q_Y@%2/94"% MU_JEK*YLG20YE%AK)BO,123?G:%A4'G)EDLK_IQXGL\$A-J)1.SMN#) MA-
6R\06'FZ+#+% NH&":>6:_T6;LDZEWK\3B857L=R\MJP=Z_I0R4@(\5 MA%'\$836UKMVK6:SC3</_
EO1&R\M9.G8@YY\SJ:6HX&@%1J!;S^_C"#HM!" M"N-JVEUK\2) _?%_:/QKKPLL8
9*WZ23.93Z\)"&:QP7"U"=YK\$ _PVP3=&&S)C:XXE M3B:<_1'7T4I-
#TQM3+9R0ZC>Q3O)U5.B\F1RG::LIE*@\7I"RP)&2*WP&C+T MA> E*8@D(\$8(TPQ\DSGP_C(ZGX/\$H#OT'MT?
S="YV?OT!DB%'W/62U4CIC8 M4D\J5IEI"W33 _DG@:_07B#?2'2\A8*H-GKT_WI=%N5HN/UI7_.WK^_:_VY
M+_4P)0&%P+INEX*R=41 _#UDL%\$;AA7U9WDE*IS"U^+?G0""2MY^_:_G I# M=O^3V)YYOS/O/Z>>W_*JHGVGX
JOS0%M (8W-5+*39*NG5L\$ _L/PDCMP:9O M9R L=" _CH_O; PTZT:I9T-V93IE5^U(W'2)E0@ZB-EI1C\UHSB*#U
M^P*Z\&JHK"W5K=6K&X\A6SS+;_R^DH:IZNMV1TR>;O70V,T:V:6>?420 MHZCGS<+LA\57YUF5R)-
TBZOBXYBL4Z?NO^%GF2%"3""FE@4C_2 @H\NC*B _:_P.H%9M4FZF*N=-P=&-MR/_0
MN2/_L5W#.V#NK>I,9K=A=GN9@Q-HW1;&R#%,^V#HAUAQL"U#TP)>NLYDI9K
M;+_U>VAFc(4#4\$XE\ID.I8X7:4.VRCM;_fJH?LO4S6B=Q(W)1QE\$M)XJ3YPVKFKMJ(BJ!<65.CFJ;Q;9#;_M3
7(^S&E8CM0#V@Z:A?4\$ L#!!0 (\$F\$1%JP*89&0!4:_M>&PO=VIR:W-H965TZWBCSP)I-MGA-
MGHCZLGT0^LZO65*;\$R8I9T"0U=2;PUL\$1;_(KY2LI<"U"\$LSY-W-SETZ\I
MPA\$ _I(H0X\UWXXL2989)NW\XK4JH# _^O7IC_L_'K8)ZQ)N>_4U3M9EZ
M(P^D9(6+3#WR_9^D"NC&\4D-87I"MLX(&DD(KGE;V(*)>L_<_*B\$_.#&@ MC\$%8&83!O\$9@Z@RB%YK\$%
<&L56F#,7J@+#"LXG@>R_6K.9"RNFM=;A4V;6
M_4D)_99J.S5\THF4%AD!=W>WX"O."EPN!TO\IP)G=/63LC68)PDOF)+@/2(* MTTQ^_%=@GNFDP2PAS>LK\4)@??
O/H\W@#+P><_+J:GDQ%?5-%/ZG\6I1^_MA6?@B&XYTQM)/B=I21M\$ _@ZR#K2)"721>AD1"2Y\A"[_
f@C#L<6K\>_HP M1Z\W#QW11\6Z1980/L.WU.)05IC%^6M+A%VU3IF=-_*JW;HM3LC4TV5#K\$C MWNS77^
@^*U+HCD)4\$ID+2GB6K\8LD=GY+OG.Z*KES)9VF1IG="2;H#^K.=
MLL9JRMHG>>J^K"7K32WKC3.K%SB\$0\$K!"\KRIC)3\X" _Q_LNE0LV8:6S72H MW2P,1WHI\I5Z0!%XW\$;A\$Y!
<#0:_E KFD\$=S<99)T\T6?WU:;#;_B3#5\$ MUDL6\$LV=;_/_;P7*#Q9JD8+I6HX=4!S7J(V!\$=0E;\$@_1.5C X2H2+""2*
MN_G'W4DRJB;_N2_OA=4Z%>A!ZVA*+=!6!TT?N+_1."M^P2UIZ/G;XCW=J3 MLQD\OG<572TK98=&B'1WZ?
@L\X#8-F*E>6TAT_W>5D(IHT*HA<7041R?J MN_*@+M1AJ6D'6E9Z94_I;55#_I5P _W95?_M?6G;)QOJBZVM;3-
_0OW M7ME07VQMW9K9#;J'M _ONRMF9SY6IZ3(\$=4"N"#NQ&9V@>W9Z0QP33T)1G9?>Z^<B- S*RTI3!
MJ5"GM2B/GH;Q;?V0:.9*!5S>_IDA."7"/3I%>?JY<9H#X\$G/T+4\$ L#!!0 M (\$F\$1%JL>WON\$PI"\$L#@:_
>&PO=VIR:W-H965TBB+\$#46QM\W2EV@<5* MNJJ:M_I.CS^1*7:E6ZIUV=?KYI?_SVYO%?3M=I? _
_RUI\#I>_W_I>K3Q^_M>SC>O+O\2I>?6JW+7IZI^_GEGWWY\N?G3X\W=W>_I\I.#Q^</_;_MFX>_?
7;_WPIT_)Q_P1H0UEI _=X/G_ \B9I _=?W\ZOCT?H\AF'_YI^M;^7=I;?^I?;T_WAX?
C7GW_RQOSK9J\$UAW _;_C93XY7?^>^>_M;OW?7EV?#^I\Q\O_? CAQ\INGQS>?GA\GW\X\^I
H&WM= _HW_WCJ8\ P5KF7I _M @OVLMI 7^BRE\^I>;KYQ<I>3C\<LZ?WK=V @^70I\W\O.W=Z?_RY?3WLI
M_I2; _=H^L57^Q_ZW8>IX^%WO_O=OQ\^>+RY_ SJ>GFZ7BXN7\W>_V\I8=O M\ISM_7=X9?_0 _IO;F'#TW?I?
SS>/QU^_M?WOW^_fH\/_3CEOY\#V\M _>/IT_?7CF;I MOSW>O?OI_A7XZ>_W9;+?
%?A^_S_07QNYNWQY\ LI^+Q^/_#I=/?O& _H>) MV_ \CQ\Q\WCEWV;IC=JHY%/_H1;LMW _>_R^>U% _=
_I_OYEX>_<I?QV_I8\^M\ _FX7"1?T?MZMWEBX; _>_fW^Q>S3\XGUP_/Z03000\N_2;K=3IWGH>G MPI_I_I??
G=S_S=JL;#>_7GW8SB:2KB_#<I_ \MM\H\G+X \BWQB?QJ_ TS M\$4Z0_H0YR@I+Y\I\$Q3_I<^OWIO_<ZL_-\$I9@?
I\^SFHJ?W@_ _001\WX/S7_M>3Q\O=I=^W>W_N\?T5Q_ ^GC\KP_G%K+_U=Z_/MX^_7\G5_0T4^R
M9W;J\I4\$4OG_P^GQI?#FV\I _;_N'DZ/_GH=OW^TX^/_SN_ CF6LN_HFNy M+_*@GLUT_C;GHGI<3EU)&0"J2HQR?
4TUI_A%W).8+_ _S+6M&fFO ^FT M%Q6YGGVUGMEBY HVJJ-V% _T=*;?I54BJUV7+I<&V\I\NZI?_CN^+ ONG^I
M_X\?G\XN;BXC=X2O;9F(_?F\$;_9%=W:7_NUD?MU(I;ZL;M0DR\J^UKYS9I M%MZ;"(>_W;M\9N\?
7IZ'4WMSDG&Q)SLJH\W(@MMXUS\VK17,PSOG\$|8>I MMF8KM^9\VMG7#3O\$8CW7*>VU9UNSE'A61\$)GB5FX?
I<_276)V=>-WQ;34C_M&_RV?BNW_@JYV=<\$V&I_R\X>(K.W5PA8&0(L^7\I\UZL68KQWC'73;_U*W8
M>90@I^_F7L#;_IEMCBOE;X.V;N6;/@)%NZ+% MVVN+MW*+_X2B)1IIV;+FF+_JM<I^<*I 8IVQ46ZNY+ 3;I(=ZH?

HY:3,SW MO%U:OJN[3*IBHJ,NT%/:."2Z:~MV1*(CKN2C+3YR.P:/7>3G+J-("L> MOK@K
9Q.@/H">TV\$G)+)A3F!5QXXF0<=1'2OL9!-V;8M.#MSI8*3J<-"T:V^M0" [U\44H?NVL^="E4Z'=ZX;
MKX)_,SYWV<=<C-27JRWJH-WLD-?NAAZ(J.IZI=WIL=O_5YZ.N^S/I1?VWY M7KJ!;+"C7W%!
fZi4I).NZ#W1_WU@KI IM?G|NJOY*CAZXCI^BIPMOH<'Z'(+ M^T2C)RIUM^2YW.KV=2I_O!D%HU_Q,=?2>
G/7#WKID@E-85"i|NF7L#%CWQ_MZ-VXPOTEKVCP,AI8*KB_MUFSQWIM7U|~3E,2IOVKQ_#_-1LUC(7=N^B(/<
9B~IL5I0Q_GMP_?IG^&|S?2IE#i8@B*H*=%1VN;3WQ;7T\$BF%GP_7/A_D M/M(Q?)ZVW_\$EY?;
m^OUM@I)UQO21^N/B3+NG#ZHO.GA>#WU+KK^2HF M|N)*EAN^ZL_+G->Q|X75+Y^KGVL^#_-AF%=(AO;:
<&5 F/1T/KQF E!4 M5R*\$NB?S#30.K^! EU;|8B'*6&|A&(DG,&5C;@_CM6M'^?E+2Y>_KO^_1Q M3XGCM?M&N?
N>26BVF224%^P=L;CV|KAN5B:N:|QVMSCU'^9^+K%,YTL7AM MG#8Q\$Y>_S, #,S*RAF=<-WY;\$/\$V*UYX?)|I-Q-
=7!49YC(V7AMW7#HY\$U^W M<^Y.G;JV|AV\$;3K@Q(DYI*H|=X.LJ79F0IH_!-H*)Z;RDI7^*3.
MT9E\$/"QWC%/B|U:=+YHS.&.)TW.UPNK;@)+?@P|M3!S**_.6H6AIW5C M-
FE%AT_7#I^FCMFEDZ@OI^+1TR9LTHIK^1%09IT#9^G_ ABN;9U|HXGA_ M(L9KDN5^;LK7WIV7SM;DUQW=,1?
8^=<KAIHQFESBZ4R^0B!/>@J27T.IKZM M94#>/E.3B6?QR;&|=XT32.F:1)W,9>O/3C+ M?CRH-0=?GUS^_#^I-
UQF6R=U35FIIX#,R4^<K|FOY5Q7C|<> MGZ>-UN05%_E"H(RZ2*^O&
fY)AG.^@V_3)OL*80@S4V.NVJ7#MW63I54ZB+ M?&ZGKNV|K)VH*2N>T)0K
LJDQ^<^%^.&5KZLK\$9KR&@R1_ =VP7.%0.H=I MRNO+|&RX1Z7EVKG+O\$F:0DS2.&Y^J%P|<)&|I(6%X?
#KTIWQ;+@E_?J+62P MF|8-T90U;A/*35!;.#YNKH*%9@/%;9LV2?_Q4I-/F86=G709_W%#_R-8<*+MM*AMXC-
QXVIZ%J%|Z(V\$*V|2.T'S=254J|@0FUKQVD^;GIV78\$1M4UZ&OIQ M0Y7U|2I4-GVFN.F*ZL,*>MJA?
JZ*Z#I^2I)I.QAC=ZK(KX_+W*#HL^|I#0AEC|BI2(#8E0*L4V_ FMP|OJ MG)P+5JQIM%CI^TR>>RFVY.K:F
>5R\$H\$S.M,7^S?_68NTH#XJH1S%6WV7CX M;#_GI_N/T/SCE!70+&T188|<-X1C9LNW>>R"8LZV0I.0:MGW5@
\$!+1I M**KN=VG#\$BAA+?U_9N<26+#+FEF^&K&\$6;I&0)4_ =XM?&_I.%VIST0)%K6YE).+<<T,W-
6|>&W%D=;?IE \$!M%"NWH9|13XTV|FL3)|UT9F.F+H/ANND8\$5:Q0M=A29I9ZL5'6**L.#"7 M^+.&I%HSRZ
UE\$++%A@HM*;2H6T!)J'22F6&+T7KG_!QA";"V<9&M|DC2RR MMN'24R_\$,>S+X*W*[KKF99;G(M+>-
|AC9S^W>>^C|BG;BDO" MQF5;+I_AV@QIA;_?K H\$2BK_+WIT",9G/2H_L36R"=N(R_#ZPM|H@X3 M?
%FC"+.CN"0_VA29IRX9D&B-8M\$.W.)6VM KC6S|I#Z+76<<_&+Z0_<
MAO|LP;+I@BBK5%.6QZ8A\$0;.&&|HJZK+JV_3-0;|SA7FYAP(|BAF8?UHW|&%GA|7IC*G1_1\$*)0;_I-
1P6X|V;C6I=|Q56^C|L^DU)M-YO9("H^V M+ONP;<2.Q_/-|Y_-I^L4:S9"S'S7&+*2_96-
YBX)BT<:9\$UW^Z|A_+OZ+NM MQ"(2L708-Y8" _&_T1I;#NTI9@*\$Q?&?|A'5"#K&EFL01F>GWA|R+W
MUE.#XJU15-M18-.KN";AV^X73_TL470_+IFEJ1K"#N7KR^1.6EVT)+0M85
MJ@QD7;/8NCPM*1\$W&>Y*\$%Q<(INR;.#.U.O/^R.J*+5&<6HOL/0(RI_W-I=M_?W=K/(0E)?N#GJ
A|7COH.G#WW@,1%,>W%9J\$^LMU.O!^39XW^B,IQ_VG M#&"A*_(V1ZOL1"YEVD;D^J-K-XV4C_0OIW_+
|C|DG:R="&779>X6";Q= MHVB|PIQ<(O;+L'G_+I)W7\$#XO7V+@|YI^H;.<%G(37ZR+WDCH#8JH1S%X>G(2F
MZVWB;ANT72.+M6W@+3JWBIPSE82V1?"*OG27I M6D+V90O.@NQK*V7?EB0L0OF5R@QRL!3GEP_"(FS>E+D?
"T(O586;MMRL#9J M|H?I_="E^L5?>"2SL5EJ2W<4_"5G;PH@LV2^NWGL(R5+X;+4;.(79|L# M(K*V>1E9LG?
<>|I^K;SLEPM*6;IN+B.&=<+!%DZ_8;3&XWH^TK+N|H M+N0=7@MNKU7_@DO^I7*#BA2+H
M+BF=U|")?>#S6MFW;.<E;G^9^IOL@;B^<@-RM.|F9L/SU_OCPP^GT;IR4FK= M=0U=WJP;^+&R/
R=Y@IM7Q&"6TE);+<-Q.S<950W:92+@K !4#B|E1D-W MYO\$(|SQTF\$"^K1Q|LD=>"16OGY>-(B"7/5F
@|TW#I;S|L&X-K'O M%+7@IEK%W1W%9;W+!EM8K+.PS+)|8*O!<'7SA)|+2^XLF<02%&IH;@DI|I
MI2H#R|S|EBX|MFV|L2|3W*6NV8;\$=G^ M1U;^YQ@KY25Z2QO\$7N073?
E861KNWGMH_(H)W.I^P@_FOIX@!ULE1+>%E4L" M|NVL5=W<4EX3+&S@5 MPH+
_Q6;=QB82Q1?"XJOG;7X6D+Q=9Z|NP+UUSZOBW)|\$Q?8PSW(ED+JH5 M5%^>F83\$;WOD|VE!X|6R9MO&S\$",^L3
#=:4^MHN(&NQ^?I^?_KOCPS@O_MX<6Z^QMZ?5@WX&-
E9IA|HZ^Y*R)P*R.K.W8M%.62=EMX>621%T+"K&=E.EK
MJ5#=#R+T1VX+P.RMS=>MX243J&L>Z81;47.NHNZ.1)%3>R|JA%FQ>H|B|P|<-MHOC;"R(LY|X1V(R=/_+G%
I+;B|I;+RFWEZ|PP\$6EV|N"2|+PM>S+ABP8OE8Q
M2'E<4NXNFWH0=ZULES;ALM.3/L8QI\$2!%RK"+@76N;|L)37ZZUL\$IM63CL
M(O"W7L/G5|Q@%MA27C|W'<3I&"KA|FVP")<*I%=|C.BNZU1^O?G2.C7^"
MZ6LKTWOK.\$D%|P;N/046E%VK*+NCM*Q7>"THO%91>=(AN<3KM>#UVEE>KR6|
M7JG"@!;58F+|+0FJEZ|S|WJO4_1>EL;\$'+>=4P1.7|WG>S6_MRX|9>T)=(M|W"@WSK%OIW0TAU^L<T5-
K+&T^J;UHWL;D|I|MY|W|WL==S_MU82I.G""G1+RVT|MR3|UX\$Z|&E^3HBS|&QWZ+\$NS^O'\$2IT3YFFP*[|N*
M_V77*1YB|OI&|VN|JU=X& M8#I"|5Y1R;W-P.Q?#EB4FXN|8FI|+!@;_K9+^V#9F&&/#@.L7!_MM9O?
=BP^WHS#4EZINZRAT9MULSY_H6|HOXZOZ+_ML*2D((Y6((1D)2\$WQ98 M+@GS=2
_NUEAOHX(V5%?I@_LFWCH|S|AJDCINV=Z#L.D79'24EE22;+M@<7K%(MW&)5+U%X^J^I?8Z0NWE2@S\$7E+
MPMUI|WU?L7L44DXP>Q7\$H_\$NS;@LHE&X.K&\$W*|7\$1F^QG#Q60XT7U<9 MXEM'2RJ^UW!9\$0Y|7?
XNJ.P|Q=LW'E!_O4PS>858NT7H=;+UNEM;K"*U7 MJC&1.79VX)+RN^U?*4L.A2IEZ|NYX2|X)WU|EN;1LL?
5""Y72P2^MLK5AV|MSV#X|OWI^_|HW^X.E)?KKFOH|6I=A(^39>^>O0B^/2T+?7H"9
MY@37JZWMLF\$=6^E(^33>N082NK|B_K<DG&_E.#.R76MP682Q)|6C# M;E;"KZ,2?
(E^>@HOJXRPK>_F\$1X|_X%YYHJ_+M.<79^|5GO|IP>)WB|IC M(O5%
2TJO=X67A)ZKU|G8/IE<4EZN|P;AUXNTIV M.MMH&D4+VX8V\$7HSE&2|C\$3|RIEY7HK&TQ>%Q<.^0^=7S-166!
(^M_??P_5V2J|O"RR7I|Z3W6BZ:P8'DZRK3>^M82>3VFE2XO_H'MNJY3=-U16|+ZKF|Q>D^@=8K_XS+|5:Q
ZO7S;|Z'6^U|C4&4J^KE!;\$FH MO2;P%\$#W%ZGN+T|+BEK_O\$51%XNTIV;MMXF;@W^K#WU>#>.L6I|/?RS<2;
M2WFI|M*7A6SOG(EG#WWD/S5|3?5E|69_HZL(&=DNG;P|LE|T.G&\$W*|I7 M\$&|Z4_1
f@1%|7&>|;TPBN|=|SY#5|TJOZF7T.D+I^4H.G%Y7Z?2V)|P>XUCX0UFKU;7AZ7A+|_

!5A22B[TI+0TF6GMHV5GICPL65C7D_@0;SUBGB[LS).9:6\ M7G=A0Y WZV9\O"P)=^|
Y%_&UE).\$#LU!..!/*BF+*Y<\$IGH0AOVLP%Y/ M!/(9R)PO\7E^9UEO*2B*GUT7V\Q40=,TBZHZRDA\W\98Y5H*
I/Q05=WB52X1> M#T*OGR7T>D+H92L,6%#F\PDG\Z0_+<-1DX05YQ>GE6\$K;NM*2T=%FH;6-E-M(
9)=E:RWS*HS8HUN\,R366EO%YW84.?#<L&?+PL"/?N/5B_7K%<6UE)N,#+<MEQ-
\$8*.\$^+;P8E4M\7@|<KY_E\WK\YV7/(!"BTN9M827A\):0V#H# M8BA*+|!*0M:5EH26+MNT;:R.Q'B/3^RC8%!\NO:~
<[JS,4UDIK]=,V*#P^K1P MO\$?6@|OW'AJ_HORVLI(0@;DO)TC_7@GO;6'EDIQ>#ZZPGY73ZXF<7O9D_0LJ
M0WKK6\$G\$PH/JL#118JC_|!PMD-UG'WE;#M>D7;_6;E\$I?7@|OK9\FGG;Y MV0H#5E2*O"VL)'1>8S*7<~
/Z/6*T,O#DE!UQ36AJL5X\&_O;VF#P.OSP@;\$?60\NWGMH_8KQVTI+P@/FOIX@_7LENK>%
MEDM2>CW(PCY62J)G4GK-9@+W8P;HO;XRI>_F\$1"K_&%2\3W;IZ1=0=128A
MIEJVGJ#=#^;N;#""7Z+P>=%X_2^?UA;Y;K;_&2\#H\95&;PLS*;WY;C=9H'7
MZQ6O(EV\$;L+;_!&77RTIM\$S;+,>7C#/=6!:@>K5>|VMJ8LM4;LHK=M9&>KMW0#V;E#LW5%DAB5*;P"E-IQ2
M>@_AJ/(5S/L#J#956;P.R^7V"G7F86T;4JB77_30=H.LU381^_V.M7CZ3Y5*I
JBW05%O+^<^*W68"4UFQNIH3'_Z89\@J+=>YIAJZ<_<P1""F9\ M7(&F#;L\$Y;\$10;0AL.LN-Y Q/4;JOHW@.<_*N-ZJX
9)*#>\$@QSEOG-V V* ML3M*S\J#-X#!&Q2#=-YB82\3>_%IOF*7U\;D+KE4H,@%%\HK80D_HQ4(#<"B"
M+X\,2MW=HN\$P#>YND-W;-F0:8N0G>LF)W>4.I_<MF M?H+L"?N/4C_09&_6Y%)J,)%#K-B>P,1VVLSEUL; M0/<_
E+M\79'B5GO0;P>(<B\0X3X=7_05;&N<>FK^B_?RDI"#N18'8G\0\GO; M>+DDNC>_AQF1?<(&(KHW;%S_
TW5";WUN&2R.SUSK(7X2#N\;D7<^>4E%>WK MN1\Z_B\07%YAY&Y\I-(<B&68)O(<1?
HW8WH\$4K)J\9O#E\JK"?|I.IW<_7S^ M9HR8\G*JM0UJ_#K9G^"K UW\SVT?|4%;B4F80ASQ_0\."B1OBW\$7)+>&T
B.M#K/2>P.1WLN>+;|9790'2^IU_XM3=H,B\H\PD9_YB\$M?KP><-BL\ MS,LEDF_R3?,DGP#(<
D;SE@(<H/F&2LYWA9>4\!L^_T2P/8-BNW+Y\I+P/VV.M>>YK\B)OD\$7;-EX&80#*Q_";
UP70<8.BXQJ\;7NEOKV\XW34EZKN*ATX=U.M.S\!H>|HOY;OV(#M*R/M\$W@_"|H\!<6>&|@0COC>R@;_#O-M-
U2&|H8\DXCMW;J9'=??P.-BL\$|DPJW3=FKJ\ Z@V*U#L,S'6F;X@_B#CK MJ7\#8SH\$C?W
DOP)1\6XA)*+_JO1\HFRHXOT%Q?GEB4C;OLY%|*@TZ;Y\U MVS9B1F+P)^7\HQNO)-6G%RSN7SX15YG,X
IK\5=V=#LX*9\;D>|MY\Z/Z* M\$MP*3\$(49OL;\$#)\&T\Y\+XW@_N<9@5WQN(^%ZW7W;RYPQDWU"9WUL'3"*Y
MUQ#;B6(!-Z@;+RCP"2T7FL%Q880.T-BMH\3;PEOF\ WS2;_GT#X?M*90;_ MJ*1^6XA)B+|AOSSCKL|_
V^<X@!2;Y"EVS9B)N\5A'CWHL'7 M0.T-BH\;0SE\<7H_;FZ?0X#DUYM>|BAH;??D\|R\IQ\|Z#&AP4;_@5FHOP MS-
4ER;|)2?9M@>;2\$+2G&8%>(<B\!>D\IAG5_A\H0WSH\$O&JCHV8#"?S M\;D7F'64F(<5;5B8@|V;+|W&)E+L|
TF^8)2T&2Q\I&T=+<A\TOEM029A-M GKON/L\;\$#(<O\|RQ"24WFC9ZRZ0>H.LW;8\;U.#\|9QO_0S-RAFKC\I'= <
M'WYY>_QZPDVFO%IO98/F&K"J\1\9(>|>>VC^BA;_EU2&;RE_I\93&^<|V'8;B3\?_K%CI
\$X5N;Y5C\$S4DF^R3*WNA%;WJB8O/((C(39;W?*"W\9=+TGPCV;1Q5HO)-)\C8_L^0(<5;ZUN&2B)- M;3&_*
B\8\BDK\ZK>5&5B*(O5\$1>X=QN<3VC6#|QEFV;R\1LW_/\#IF3_M"+BHM'U;
<\$DXOZ5POYA'<ZCXOSRN"1L7E\|RHP>J-LW+;QTA)C/X'_LH.6 M&Q4M\;WV\;9PY\O\NX_/\T^?
S@>OQG'IKQF=X%#R\?KQG^B;!\%W\STP0%&# M6\!)"_L90_&E+3?%FPN"?_(<1'6<&^D0CV-<%Q300;-
BLP\BLUZN3>"W\;L5N7>8F4N;WPC&;YQE\$;\$#"4J#)\$1J?RV;)_0 M?Z4Z W_HWB_/3;+HC9%
H\A|Z(VR<=<N&3\$2_7#@|BLW'E;NA9AV;C'E;_O+ M&|H6S?|YV6+N?<
OP0R.BAG<2DS"%^.;'+C"40G\;2'FDFS?"\$9QG)7M&XEL MWW.R G>^ J5\;YUQ"2"?8UA?
UT"F3OEW@AR;U3DWF%B+C%^(QB_M<9;Q&PGC5ZHP(\$;E\ M'3\$+|E>H;P*&8OSPQ"?;7.N\|M\1&11-"
8V7&;QTPB71?PW<5\FCXO.. M K>|XW@|T;%(QT&YA+I-X+T&V=)OY&0?J4* V\42K\MP*347H.P/R-BOG+ M Y-
P>FUPW%TM;+U1=FL@|FJ\9_ S.G&";TY*H\PSL#TDX\$IK\;E;W6#ZQKAP MD>YB+OW'KJ_8@;W
I/PA;D>|ZYP5*)_6X"Y).4W@E\$<9Z7\1B+EUQFVB_ \T MX%@9\%L'3"+B\|C" MF@L2L^|R@PZ_W>""YO5/S>86
ND7XC2+|QEO0;*>F7 MKS"0?F.E\I-L'3\$+|%>H;S-^HF+|V; FG_/\|S\IC;RVP;_1(S\IV;+=6H.6
M&Q4M\T+;_F8\K=Y0W=/BT<_I\$MXNZJA_<OF&MQ"1\828K_010 H\;B+DD MZS>="4\QG9?U&(NOW)? G2^
0F7<;Q\TQB;|?;FQ\!YHR+SCA*S7NZ-(/=& M1>X=)N82X5>"1MG&;^L.GY"/@C-U8;ORW\$)+Q2\ M\$;HC)QVT;_3
S^L.F8\$;SQ7&03@_M6)GS6P=+*N'7\ (J+Q147E;4FHO<86+NPA@MX;%UWF)A+G-|SF^|2HUY?6ZJQLZ?EDXIB;
IQ)UIG\+3HH7W\$C-1-C" MQAK\+D\$MG\2;H;R)F6Q/TF4(K3K+C?1,3\AL01*X\$&G"KC?JO(F8B@W_/_
M=9C6FD#H38K0.TC.1 B^+G/V2P+^_RF;|R@XTQ+Q-X'XFV;O)XD0?T/F;_@\$ MXF^J%+;P)E(72_?IS>9-B;SOF?
J)FI+G)7J G4WB2KMTW@_+BM?QB9Y7Y6 M3>#G\;L7/338?WGQX_#W<L.S\PO SE;5Z"QM;WV363?
XDV2+NWGMH_HH;W.K; M^@3@|+9P4A* 6WBY).PW@5.<9H7\B+LESU9P(+*I-Z6\;(9OSEQ\X1)8/F
MQ>8=9245\!P\$NV/0YA7=|YB52ZS?|-9OFF7\|L+Z92L;_%&I+; DA\ C0G< MJP02F+J);7Y4\);K\@F'59NFT#I24&?
WS@H83F+E);7_*7\$;*>6U>LL;M)-|DXWA\)%D@|MYL;N\$%>=Q*ROKDW2><%*2?UM(N23D-X%-G&;%"8JY)=|
M/UX"IS=59OS6L9\)(S7\|E3=W_P8;_U(ZX3_P*;_57=C0ZMVZ>9\DNV=>P^|7Q&"6W%
M;+L5Q/ZOY+ZVX+)+0&_ "53B-"O@-Q\$|OY9\|@3;ZH_<^*W#)1'MFIWA\N# MWTV*OSM*2\+GY=^_E42L+
|L/T;T5;W<4E(3'Z\IFN9\XP.5-BLL\3;HE M@F\|P3?_\$GP3(?BR?UN@1*7=V))PO\$5_YX
_T7RY3E)Z+OBFM#29<6VC9\A M\;_JH_?5EQ<(U->Q>|VQ'Y\G3XZKN\|HC';RHMVU#8T^K)OS2;(SW+OW M(
(G101NA26A\W.E 6YP4O)^6V"Y)-HW10\!G'79'XDW0G;R6@+?_U4F^|A MDLCTS8Z+CTX@|B9%W\TE)B'RNLA-
@X#*FQ25=|YB72_S>|YOFN7W)L+O%4H; M>%&H\80DY\|<^>)Z)I\|DV*Y.L#DJ\|WBV;?
PH+|FV3#MHV7D9CNB98M=|P MDZ+AYFP7%->M+>^>O>U;_>|&("97)OG7\$#)\JC>6'8L<38JY.XL;PN3-|N'Z\$B\I
M29%YAYFYQ\I-8/BF6890@Q?ML2)&J5Z;PLO*^* M;T)7EQW;_F9F*M2?+L;HN0E;W*28N;_4LN;
_??'AW%6RFOUUC5(O2DOG/21 MA>'NO8?&KUC K;PDW&#NNPEB<%*B?EM8N235-X\$ G&E^B8BU=SR<@)A-
J4 M&>L1TLBSC?EPEW\@KF;%'-W%);\$R6NBYR;00.9-BLP\#;LEAF\|PS?_GP3 M8?C&C?N0\$3?
5"GXMN"2T'R+Y_+C\$EB^2;_%|>5I2_NZV;_Z(P-I-LE_1LM" MS/GXS+U"-H&\$FQ0)-
V\Y+I.O\XX_G\$|OQG\$IK\9=V=#JR\))\D6\|MY\Z/V* M=R*2\(+Y\G)3G\2\;9QF1?HF(M*7/5D@|HWSI8\$DF^_7(7
MO1F\$W;P(NX;PS(3 &ZUE7KF9P=-BK\|L\N\1.K-(7F65)O)J1>IL(R&+VY MTNAM0&6FO%Z2_1\I
|@|>;%>7964FC%UQSO\KS\IOR^BMEU_<F?O\;(X-WFQ7O M-FJE(BN5U;H+|QK)OSR;@W+WW&?
9^ZIQ\|E1@|JLM98">FS?GD)6&&63A M/O;_Q-AOMS) K\W5R;Y5K\$R\$QF^V7->@QE\$W;R(NJ.L)1=NQGN;9L9Y-
VL MR+O#L%OB\&8P>O_LHS?7&|T9C-Y<?2VP\+P>FV.GB;B+U9\$7MY6%+*KK0F M=79J6V#I2>Z);
<94L9VK.BWNXM9"8LY=6Z"QL;O5DWYY-E2;AW\T\|S8KX MVPI+0@?FOIR@_F"17Y" S MNP\$-77%U1V%)Y?
S&Q%Z.@|<_%7\W&)9+I-X;4F^>)25F0NIE_|BDJEMP66-MA-AK?4KLWQ_(H8B\|P)95=<\$JZ\2VP=(2\A>|V.D\I
MK\9;V>#Q9K=NPB?+CG#WWD/K5\;S75EK6)_ME_(&SDNS;0LLE\X92;\$*10W M\$R&^|D"&%0F^<_
1DL;CNS9Y\N5P&53+V6S\;S;(9F1>SE;4DHN^*T;5EH- MEH*|'+;ATPBO#>ZR\$P; M9?|UL^+KCB*3\=#8A2#
9O5@S>86 NT7HS+UYEM;_";U7J#\$P>W.EV=O" M3;+OC85\8_*;U847QZ9A+R;"S?ED\=S;);VT;_0\$SY1/I
H3\K_<N%F/P MIX?Q\?P?C=27J\|L*3AW5\|EEVA;OW'EJ_XO^VTK(^U#>#9R54+66B\I
M\W@#N=9^<Y9R;JUB3U=0\(*^<XZ6\+|O8Y\TX&7SVP\$|S952;PLI\;57*C; AJ+V\JODI5U;LQ@
M\H6;9IFTC9;3"NPIW;PGF;5;6QM#OSV\NOW= L?X'PQ\U)OQ\|IKQH=WE#
MLX\+|WUD5;A\Z\|* YO*S#K0WTS%;%9"?5M>;2_X.XG">E=^;B?Q>\$|FA
M/9\1>LVWL_27HNEG1=4>12>B\G&&>P=-BK\|S;PE4F\&J3?/ MDGHS(6;Q-Y>@=>;*|W>%FA2=J\4:0 /Q>
|EJ4EXN^7Q=HV;_9B MYLIC#X=I\I^|GTX_W\;S4UZPN\RAWZ>% S^R+R\HR M9T4;F5F7;QO\B4X^I&^+W3
M\|WQZ32\|E?J\O84-F\N\|=I9%;X>^<^A\2OZ;RLK"2F8JTP0@K;2Z-O"RB79 MO1FTX3PKNS<3V;WLR0(65

WUHQ&2B.SU@#K9L7704EE>OK.G858N\7HS>+UYEM>;ZIW>#%YOKO1Z6T)V+VQ>.8NKX#=#6Q2|EP5EH;Q=
M84D#2|Z;1?FXK1>@="SW| "FU1Y-MLW\$12*JMUEG4|F;=LZP9|BBP*=-^|
MA|V?..NA3"68^6H6T(&+DN#;0,JR)*RW@#1<9H7U%B*LESU9"=;?...53B(Q>
M7|>74|>P=8MBZPZ2LE!|OH8+;BH@!9%XI7E95EB|1:P>LLL|J|<05J_E|N,*M>+VETNMM8&4A|
Z8C<|NW*80STK"VTW&<P\$;2(6FE*PTQY>;Y+FFS.M@'M;%/G^>/C3P.\$XSDIYM>|ACYOUHWY%
D3|MY|;R*^|O*2L((MYMH_V.1%2?|M8>62L-X"SG"9%=9;ZL-Z"SB^I3*LMXZ51\$POMPI@ZA;%U|T%_M)6^N6L
<|J@+U;%MWF)1+E-X"2F^9I?26>J6W@-);*I7>%DX28J_X|P1<M*&8O#TK"V177A)8N.|5MI+34E,^6N.&\$
N9M4LLL<0_M2J_AFC0XO:72Z6W|)6^VVF0Y1,^VEL4M9?)2^MIFMR>0\$%I-TB2|5MN'3\$M=
(|QCGLO50^UMBCKJ=V/9B8OY>6Z:QMZO5LWW%_D3|AW|1+8K|V|+P@CFM\$V<%\$2?%MXN22LMX
S7&:%|18BK>|68"#RJC>..EX2(C:Q.0Z78.H6Q=0=MQ25A|CH?V18#|FY1|
UA7BY1@>LHO666TEL(I9\$K8XK6MVX1-3?;PP7"V#>%L4|=9MV|0GL?)RO:4-&F|)
MZ^9|BJP(=^|H|1%<VW%)6\$#T=477^44FH>^;S7+OL2V@!|9%XI1U&YA*OMX#7_M6V9Y087P>GT(W(
)B+VE4NQMH2A|WJ36(*WUL40Y>G)F^N^F@S|^LEV+M%MMFO;J|F)29|06&A&Z-|1|M+L;
(<_O3|W\$|9D)\$7ZRUM'E+7#CH(IO"W7L/M_5|1@%N126C|!#+"!2Y*DF|+I>\$|A90A|NLT-Y"A/9:QSV
LNW5(VUA&3_MB.O=N;2Q^P%=7?%U1XE)^+O&6R|HJ8#=#6Q2'=YB82|3>F)OF27V%D+LW8G)
MG\$P>DNEU|L"3,+NM=ZRH\$=|Q:2|N6|27B|UD?N50T%U-TB|H5MP\$S\$N;1^M?
<N|O1HQ;^|)=^(C/E|J+&_H6CCP(ZO"W7L/%#TWU9F\$E(P6Q4_27)_MMX692T|)"VC#959H;R%>TUF;^|
|RV5N;UUT^02>|W&W8:KUL47W>4F?7^M;@%_MRC^|C OETB|!;3>,DOJ+934RU<82+VE4NIM
2:A|DHU|M:0U%Z>EX2T_MZPUKDH"W6V2OM@V7F9KY88=CP;TMBGO|^9|N|!#|?F-/L?|TLV|)&>"FO_MV%W_?
K>XQ#;B^I3*MXZ71&2OS^R=#B|177V1WE|+R<\$%I_XBV*Q#L;S"5F
M;P&SM|PR>PMA|EH3N1^I0>XME7)O"S_IQ3>S3T=|2V*XLL#DY|WT|8^UP=Y_MM|AR;1LP"5.G|^_ZH*6Q0|IP|)-
Q68|HK=Q0W-OBP<^Y&%XM_>B_MP3BNP>X?|H|G2^>GK?_|HUF|X%W+;UFW@_13W_>;|Z1P)>OXW<=5W=W'
;JMF1WK1M\$@5DW&_2|>D^@&Q0A.%F|H(>M;?M|_8@?)?VW";I+DG|WS2)\$9F7|/F_IQ7A.X|^_V3^_P*A_>V\$*A^V;X*T
M^|CV%>5WF^J\$V_P|PAR_S2R0/&O|&ZO_I>_XL_F>4^V_I9<^Q6#4(E\$|+_MN_FKA^QLOK3LW18B6|1E6;
J80:8KBCV0OGL?+OFXC6^T5|Q:9KYW%|JYH_MO3|^VIT^5GG)|FJWB_!H+H>>/3#P#YH_C&S6
EO&V&VL1\$4I2TLM9>Y7F_WCB(S*=-!L|+P;Y\$|H08M|7_!AKA+;...G_M|H|%"C^!#A5EXC\$9G.(CUDJ|?6:JO-
(4TJA>(FJA)>|5YSS;+^<1^H|8_M+^5<^9|Y"3/9|V>IM9^HC9HM8UW7_/9N1?|JY;|N-ZN_W_>P|_O_S5_M(\$|EU?
K+""@U|T7|6|1^@&%10|N1FGA)?_XM0A&0)HX2;<+HD-WC>+^>5_M^R|U9<-CGLAZ_YQ9\$5E2?
E3HGD8..K_C#PSPEA&+!0SOGT8_M*%+Q.%&7J;|9I\$=LV3CYRV|O"LL6)1Y94*L=-1^7.8^<=YW?LGT>F^/*Q
M@%3**PZ92_3/X^_7S9_&YGJR0\$D;G|Z_SQV<_40|LX?WCS=W=P_W3|^Y/#K_M+P;A^J_67^F(KIN_NEX|_|-F@;K-
K^7L91;J^O&@Q_TW075)M+^#9_C|D_M5KCP|Y;J3EE_5E2&"U<2E<@5MOM=*|LGV/5PW@8J(1R;+C79^>?
1@HHV0\$X_M4)?(R/MFD1RS=-.3G+=45&U^D4D=NHBEA)5N|L3_R|)%2Q9@2AC^X|K8|V4E
MN)&E@7HC\$>N^D^_O|JVHP|Z?F2R55^LO<+|SQV0<0\$0F^O-S_TOHT_MXOVS"8EC|B|H4NRA_?(C|BM/N%V/#;
|VB_M@^SE""IDV.?^49D@.(C|_TB:6|Q;|_)_0|8N|6L|&YV)DOEU;J+|^_TLJA_M)_F|C|1+|B-3>SE=->V>|J0C_H.<5-
+^Y22;Q0%Q\$Q^Y7X>4M5AOS<01%_M92YQ|4V)2&K)=MIQ^_J|H(R<_T)2SE9_EJB8044\$SE<9HN9?WS2(Z9AG;
MSUNJ+3T9&7FBR_P^3PE/V7E^>BYCSY=EXD;>9F(>R7A^MT^EC|U;DXU|_L6UF^E+E|L;K/2,(L|Q)_F1|C|)
(.B/C|ALTD\$)_M_FY^ZI+0XGVS|R);9L<7/6WKY4B^I^I\$M^H.+*Y%*9|9GP|_9FSYBK<|C%1" M9^8;WW@0!
(K;/(H4)8JSV0K28Y;D_+RERG(K")_*S;D)J83MG+UE_|(%D+>X
MS@|2^94Y|V%5|FR;MR(U\$|EFWG^SX&|6|&2ST|U;B91Y07|I^QTY4%9);D2_M=?|!(|@4-
|J9J(ORS9<^PD&)_VXBZD|HXWVSB)!9X<;/6WK1XBP_CU&0%I4I_MQY50)=*
_2F9FT@R*#8;16P>9;HA1&?//4S;#H;Q70>1J|9HS|;U)--/W9_M4|HS7V|&|6=3J3^W_-40\$K3;6<#1-
F|O@C_*|Q7VSP<=<=N) MTL>_O;Q1=9>DXA|(C?P?3|H-G>P^=WQ|XRE1EM?Y*3WA\$^P>2C^Q4|Q|
MQ@>8.Y|D:6:8Z|;|HHP<@M3#5+0|^0;W:S(H|?MY2U2E#%=I4YB#7=40_M\$8SP_-9S|^?#;.\$^&F|K7CX7XOP9V;
<5.MB6Z^2G_MTS>||Q|HPS"55^PO;|H+^P_#(K_M1A&QV&ZQG8V;#N;...S(6QG_H^,\$E4G9M@2@C/A|6>;
(8SP);"9=97A8;_MOJP;-+4\$B)_UGCVSA2E9*(R7'S>|^>?7?X71Z-X&F|G+=8Z&LW\$+9Y*
MK\$W_P|^05&BFVE^B+LUQ4M;..D*S?1=\$F;|KY99;BL).7G+;WX=G.9%?NG_MD165;.%4LO?AM;+^U0?
S;5D1RH_V1G@|^SF28|&T)V%HH=-6=3J3LW_960G|620^G9_M*%S_1^9|>2VO=XX=7|_&X\$;B)\$DPIY&&722C>
(D7T;2L_?;MY^|WBZ_MG_745UZTO|B|!&A6)*1>K^T_T^IT_U);83INFU_FB_@E|+F)|JTL"F??
M(DAF13(_PE/6^#=(.NM^E;9:X\$*Q(G+EWQ|NT&HVBMA4-3&R|F@Y6P4_MRWF@0+HH\$+;^5T)N+W|CP_M|?
WSV|E_|1K|&83|^|HS_KHJ5L%\$LY_N7POV^V^_?8X@ZOR39^6Z_P0#8HFW\$X+S_!9/H>%L9^Y\$;>)>%L2
M^=DT%(VBJ4YZF^#^>2OFYB;4_LUJO@8-*8_MT)-";29V;+>G^+
<.&3WN)&FF0IRXQ_\$HZ|L%\$\$Y)C.5IO)RW56.NK;I^V>3_M9)>Z_P0"HH?W4Q3PHF:8K*M%\$2H)MHN3M>=|L|F-
6WO/SEN|&7*B_N^Y_MDJ5\$U^_*^T|^LU&\$9J^84H(SN>7^|+|A@00'=QFJX1GPV^SV;^&P(9FO_M-L1(I?
7O93K.>+6\$|^16&WK.M|Y;D&H)^SEY_M|FTB%@5H|PC0_EQM3E|H|H8HME|9?X\$;F&S&
|C^@E9M).M8B?^S>TX>9X_M^/|X>G|H|I^Z_77.5+|^!Q^LK)+W7|_B_5%CV|F^2%-LSQ%8=HJ2=|^/T3
M^FQ1K;30H_M?^JLPL9_IQ_6E;^E4_EXIYM+QOS0Z?9^D|S.%_QSDX|B2A_MY6P5RWFWG6VD-
R<5<^X6WL_B|3%_U:0^HA_M/O^SF59|)NMK|W(M52;TJ*|^_14G9^DR|^P^YN^K==F0|4>;^<D<_MV(732%;VJ?
L|^+F@^+0^7\$;1:H%M|)02Z";AK|XKM|J5V6MZSI?>0V#O_M^J&M5YSY5)9*>8V;?
BOJS5;1FH>|2N5|F|S6%IK.5C&=OXFZ1G^VJ#;_M;2|SI?1GJ>"0)97^6E^LL<.>63B19V;N/|_T|^UB2#<3
ME?"FV;Z^TK150J|^B+H|H|FB6VVG|Y3U;(^N_9_!KA^ZTKPQ;S5:QFH>12EC.9_!|T|(^L5T^F?J&OW9HOYLI^G/EM*??
6^?1;#_!O|MYR;F\$A;TSGW^231|T%;1H_6F\$H^S39D-?+\$H.5O906YDJB=&DTI@DX@MFLI6
M.96MW>PTJ;K==S12^93A.2+2\$^|<1.5)H3?AE""2|YL)=N36HOML%?=9P^EA_M-&G\$8JR-
B.T|RNUIY^F|FU1YK>XJ1|/9Q|5S2;)&W7|_MB_7%C&F^>%+LU|6=*6M\$@;=Q_-UN<|6C6H|+??9_N0^6S2@;67N-
&FB9B+BENGGU<@&R5J+>9Y9Q2FZS%9QF8=Q2KC-AE?+>K-5M&QW&ZQGFVZ\$S;+3K/
MMM)Y;L(83Z|K126;Z@>6T5|%G|^2_WRLMCS9>FX\$;>%F\$^&P|V5);MHB;O_M_WS<="HOUE_F"(&RT4;
|H5IX|PL|DOJ^9VBD9T^TX=60B_MGAT|U6Y;W+CX|HY4^9P%V8.(SDBY=GDS.9..S29G6(RC^+4\$69SC-RC.8=N
MLU/G6_||31WA_M_|O+^EQVXAS2QXV|O#FUL_V|O_R_9^5|IR?M^@#W_XYGA|^_ITEQE025(6|^YT_M|D|R=63B.Y&2)NO|
\$R*&-U.5\$*7YLL#|:"D0#<1=4W@LT.EVDT+?8-@<|.M#6A7&?A<250BZIG?
#>SYBL<|3%;J#=#JEPO(4W6;GN.WC/%TC/#L4GMTTX=D1_MPC/_1T;5-K.33PEG&?Q#XO2LU_D9X&GA_XL+XL_7;-
&WEJB4\$D;RSI^T\$K_MV2E6|LY3>_C#WKF_/AZ^O^GX9@|0Y16|2QTM9V<73B.Y6;N/P#D@J)%_P.5_MD^7Y^D
Z*\$G034!=\$_KLT*=VTT*?74/HLT.#VE6&E<"E8A|Y^G<#V|WB;0|#_ME0J\$SON-/MS"
+%;1X^ZAKAV;P|^8)SXXO_GMD_.MK.KM)V@;(JX3R+^UB4_MG|TB|0M^71F>5EL+^|)NW_A41|TC^7KVJ1|^R4Z1DD-
T.T_O|K_&0|^Y<7Z_M|QP)X|;(CE9GNX_2;D.WLY2PI|DO^X)|R8|N8NF;N&>"K6;%O?LJ+AG_MPP|W.=2?767>#
|/!%;25#2>7.7QW\$15PGM.GHU9<@.L.T5|%J|^U.VL^P;_MP1P\$S4|VC1NAZHF1I%AXO*.5|H0K^?
PN7QLEK|_6D09^X522DP7J|_@-M|^A.=#-7&Z*^5K23HF";N+JFM1GARZUFY;Z|(C49U/8B1N^!K2KC^VNY"H5
M^|P+&T|BT&5VBL|)%%;";1:N/M|N=HK=/(H5-;.\$BP6^*FT
MGINH2KG;..I9W<(J.*XSP)6*;NY;*SZZ=J=K)TW(C50(PFQJ^9|0S_M.3MW^!^OO_D|E5?J+W^D0%@XEN1D@|K|
%*"=HH4WI^D:X=FA|RF"(<^.)XM>|6\$QK-K)Z;6\$IXS^>0);E*#X|17P6_M6\$HHS>>\$*OY|ATU?

5HX:61JHP:3.CTBAF.P4.3DI? CR>/IX\ 9T=S.IJ/R MW86.HK+*!>29(NZ_P 0#(H8W4Q40I=FRQ15::?
D/S<1=4W4LT.AVDV+>G9\$ MU#- RA 5E4/E40E(IZ-..R&ZE!F=HK./\$Q40F|FXV(=ZLU.T9O^@:K&>7.H M/+MISK-
K<)X=..L^NTGENCEXBEA/I?)LG>)*+Z|I3U6> I)36+RV/+EZ7C1HYF M*KXM3QO=-DL.O+YD:;IB)57K&|U-
%V=GGE8)*L4OL /L "T4=JM"N.O"YDJH\$U+!=HK KV/45 MJ7F8J|V2LT/V2F2|SA3UYC/#LUG-
|U|=H3Y+|4:RL^N46YNPBJE0\$M%APJT MAQ1H.N\$W&R!^6Q)H=WL9/EX\$:N%&\$ * ").:"@I05".R1V^O+NY?
|HL/X&I M&GKH8XD" L'E&2?NO| \$ V*(MW,5\$*D)TMHE-)?H.GO%=1ZF MJE|C0'L4H/TT =H3 K10\$:%YJ'I"<39F
M|QS+/4K.7G:0VZ#Z<6/ \.R7'93R:"H052.R4^EJK)>?ZDG/*:%XTE>|JK| M#R#C 1^H- |JC >VG&="P8#V M:\$#
I2@.ZB:>\$!UTBF|7B487VB@HM)20G,55L>+ "G(C3@TQEFF|82|C453V MBJA|F78MARI|/T^'S|_?/
R=GF:DHRK+|E<|LL L'%'RLEW=20 H3'M%F&ZF M*J%1LU|:5*BID@G=1-4U|<|>16L_+?I9\$ /|UK+CK!
I%:%9 UP)5B+X.>:- MO8E|PIDKAO.P6 GCV6:VQ@*=9ZXS^<72-">Q2A_301VA.BM%AO")5*%|H)
MK801G3:Y5T6/4K17I&|K83N7|P|I>31=O:RC.R(5DM,*;G_AZ:9:8RS:D MG:M|1#=?
A1U5EQ>V21PG:NX52EXVK/L/-F@2-/4"54.K904/V M2BOT\$U37)\$|E*W|M 1H3R1|Z<.85\$9_UQ)5"+XN:C\$#?
YZDR|XCD/\$Y5* MAW:|KB\$&%/YG*AK=&B/K2?ID-|0H?FBPU|4NE"-^&4.*)+..Q#?32BO6)\$
M"S@E7&=Q5>SWLHG025O>(KV|-"|730OR^/#X='Q| \N'A MZPE(E1?MKG4TH+U?.*?D9:VZ_P"0#
(HRW8Q40J3F2P3YH*1"-R%U30"T1|7: M3PN |D0-'_D|:5Z<^52"5RG|_SP.S|"SK.7G&QZGZAH9VJ.,
I:2)T)Z0H=EZ0Q/5YK0350E?&@:O6'O4M&|HH/+6"5.)WE M9:|RRR(U<#::5DMI+9TD9CV20&N41L-
W1^N'FX6D"4N7E^@L=01-6CB EY MV:WN/P D@Z)+-R.5D*CYIROR08F%:D+|F@1HCYZUGY8 |8D\$Z.S*WA|U:%^9
M 5T)52+|V0L_|Z#G|/7/>9BIA=-L-K:RT|SVBOD|3M0U.K2/2(XI9>&^)^HF M0KFA\$.TKA>@FIA):!%Z(?-\$A4|0K6D
JX3L"|E?2\$M|WJK.W\$C42(PH"9.1 MZ"Q|O5F^#3.XZF7^9(P7BR@SEV: N/P#\$\$@J).-.4\$*GYKH=H4(*AFWBZ
M@|:HYKMY5>R#^YE^%\$A7M:%|9 UT)5^ (N|B-O4E%\$=DKFO.P4 GM.1;^ M)"\$&%/%Y*AK;&B/-K2?9D-
|PH86ZPU94BE\$-Q&5T*)+XHF*5K17K&B|J(3O M:&SDY|C1>/:RD-R(U\$2.*?QJ1ZM9:|8RV>D:N|P|^?
|VQFO4%*6ZRI|!\$%: M.9TD*|=-!X#6M%>LZ6:D\$BXU6QSH47LE':H)J6N"H#W:UCY:\$+0G@J#|KR%F
MSQK2HG(+NA*H JTW9G*|@FV?5\$S'D8JH3VST6X>O6>O>_C1%TC0WN4H?TT
M&=H3,K18:HB22AFZB:B4\$ET2_Z=%HBA&M\$|4PG7VCGTGET?>V?|V'OSHG@W@:ORJMWECAJT+RL'E&3'NOI
M\$^*MW.54*F9OLRBM1>B8ENXNJ:1&B/OK6?E@CMB41H9UB'|05I7YD)78E5-M(@W:EBVQ+1=59Z^HSL-
<)=1G@:/H/GO?2|GZAHAVJ.0|<|)T9X0HJ5R0Z|4 M^M|-6"6LZ/U:CIT7"JA%:T6+YKD:*.&Y>,>|!:#Q'&0AN0VL'S?
V#S^G9NXO M\$E|:MHJ?'"&K/ S?#WW?5D M)|LW@RR5%<LO*M|B8EN8NE:1.B
MHG68E@=@B\$1HHBAFX|:=*@A:Z\$*14|6A=P7MYJ#8S<_D6SGGYK,GR MLXE&6!9:ORPB-T+54O-)6V0#!
+ZRD'OE7_S9MO-I&L|GK|Q8X|L M'E(*L M5O4(P.E>G0 ME60EJ/B'|3%>9BLA/*<#>J&E|Z#HKT/|5-29T0|Z3#-A
V%" MBP6'/*F4H9NX2BC1-L/(H-%)SHH3K3 5<|VMOLM,K|L-GY91V|DJ|>I60# M^_
I>6@2.MGK%_H_\$:OR>OVUCC|P|I>4@JQ8=Q|:M-!T::L4K(U.SW%4WJ MH(1&-V%U33YT0_|Z3,N'#E0^L:;L(-
R=*B_AZ|I\$A\$.G4MFP|X".LY|T9R' ML4HHS|ZRCPE1?Z*^#R.U34V=\$_.DRSH0-A0XL%ASBI%**L\$|HT66SCJ4*
M:M%|T:(%K|+ "X_*2#HDTW8Y60J5FLHD@=E-#H)JRN8<.:%N':?G0@1RJ:WSH M@#YTF.9#|1*ELH-
65+|0SAIAOQ M(|F1J9&:4@K|PX.(|3O*|?O.5+<=|OOPU|/#NPE(E9?KKG2TH\$<.:8D*|I
M|X|D4+3|9J02,C5?2"3FZ":EK0J(#M=A6DAT(\$B^5.&K*C,B*X\$%I\$. M|:SA:V|0=0Z*ZCP,5"1#>GA9
G|ST'1G|>9NL:)#NA\$AVE,="<+|>4(@. ME4)T\$U\$)+=L_ CV|_WHH'C1
E\$)XUE>%IN^K"0W\$C6186|L8:.W'|10^7*3 M&@^_'#WX>G|!#*#R_67.6(@K9Q5D@WK_@-
+BC6=#-0"9>: |8B'93DZ":@ MK@F)#JA:AVDAT8\$(B3:4|0""M*A,B:Z\$JED0'3@|P11=0Z*ZCR,5\$)|%IX.
MHOP<%|EY*AKC.B 1G289D0'THAFZPV%Z%_I|0_#Z23N:Q:@*B_8 M7^|C@KOR3\$F6K/L/-F@B-
/-4&V(C@|H4@K|H3(ENI*J1#ZTR_RE.WK.0?&6\$DNQ7|QY 1&4Z*LIT*U\$C(5)SC2^B1|V5
MV.@6HL8U"=\$15>LX+2\$Z\$@G1UK*7Z1'UZ%B9\$%U"U\$AD0^_D)W9B"@Z1T5T
M'D5J|""DO?<371\$^3D|H0.P5N:|(SJB\$1VG&=&1.*+%DDNX%-GE"(A1KO-MLJ_PBF&+16,YKD:">?
966_YU!PV8D52A|W|G)&B:|M=)>CXYB?GOZ&POW=W7&5HFQ|Q|0D(QD|OIGC5F<|I>|H M)\$@WT75-
6'1\$|SL"XN.1%BT85_ \$&M&7C15Q795P)8*BSWH^OR08^A7S>1BN MA EMV7?1'2AH^)"CZ-UC2=49".TP3I2
C24KTA42K|Z":R4I9T<(5|*AW1 MDHZ*)2V0E?"?SR-GW,^9\$?WG*.O)C62UQ*128,<#(SK,47&8+V1-T|DJK|H=
M|^A%1|MP7BG*TG7_2 @%(^ZF:R\$7_6SBQ% MV:CN/P|D@R)1-T.54*OY:P?
R08F1|H+JFL3HB|UG)88"1L2HR.ZTK\$R:H2 MJ416-
+L::#Q'Q7@>QBEA0|LMT|T8*.B@4|SM,U:G1\$-3L4Z.CH4:SYQ\$| M4NE%-
|&L\$E/RS"1+&C|9H2WK.|+9|64QNI*E_7R(WPOLVHJZ|*SQAZ|N MOK^YO|<9,AVK+=?
XJC<|)H2A+UOT@|I0Q.EFDA(V-5|6H&_N7 M7U'=X<^GT|O'H|::R8P55ZQN|H1@HYTY6R2:%CW"P"B09&FFYE*J-
3L-Q8U_MZ|A\$1S^(<G2L#(FNI"H1#VUW8/#2_VSZBND\ M3%7"?_LJPCNL|H<9_H:I&B(XH1,=I0G0DA&BIWA
GE4)T\$U8)+=K&P@|+ MH18=%2U:P"HE/*?BV:E25)ZC;"0W8C53;U\$2|E316XZ*M^RV+|I>/.S_^.NG
MT_WAM?:K|_|/?|D|+O|U#>EW>Z21QTZYI7C2;|KW7|_R A%GVZ&*R%5^|R/
MTZ%3'94@Z2:~KLE.CJA>QVF9T9'(C::89|H2L=*S.C*P%+I\$67&|@JPZQ
M2_#?2"4D:)O93.F'C14/AQP*Z1HR/*T7&:'|T).=H9|NU4\$>7H6'E'-Q&6 M4*2-M86=%4)'B|_M\$|8PGX^OQ"8G2=|
SK*G(C80LUHE0*>V&+&G-4&:: M-GOX|0F|%)>3J=O)K|57K&-VA\$'9>64DNQ<|Q|>D|Q)O92MC5|48JM51
M29)N NN:T.B|G:<%AH=B=:H_10A+RHCHRN12H5%<^NX?|O0?Z*^3R*U428 MT-YL7.=)\$\$.G188>QFI:8T@G-
*33-\$Z\$88T5VX|>A4|4>W.#41DK0-SG-& M34)|.BF2_41.CAK(|EYTXJ|Q8RI?
JV39MS\$G=)B3XC#_|HMMFTU59|1&IT3D|H|L%<0N38=-LGU)>3HB_2-5?W7U|>S^|I)_J_76.%#
+1Y:2+%IW"P"ZTTEQIYMY M2AC5;+V@39V4_.DFG|X|CDXH7:=IP=&)"(ZVR;+7J2A(|K@Z\$J>4I'1P5GV
M1A55YZ2HSL-) =3G\$/FSA|Q0Y.=Q|*XQHA:|T6F:\$9T(UHL.&1)H1+=A%1"
MC#Z:|30&|@418P6F\$HISSD: CO@XY>5Y\$:F6F)N*4.VF@*|Y:1XRVL_&W
MMU^_OSO+;Z|>9AQIRJOV5WNJ\$(GMW|P*=?|(" 4=:J9K(10'7+BBP0Q MH41*
|%U37IT0NLZ34N/3D1ZM\$WL_ \$E"43I5ID=7PI7(C3;&LZ^X2:@)|T5Y M'H8KH4";PDH1"2WHI%COXW1=HT8G5*/3-
#4Z\$6J|T6%"(E4H|NHFA") MG&=?MQ)00DTZ*RW0E3*^H_4|7=&3K*^W\$A73XT0)78J.'&G|2>>=<K_ QO>OO-
M=Z>|PEDE9?K+G74HI-?+.649.>Z_P"0#HI&W4Q62JXVF<+|!"&AQ\$HWH75-M@G1"#3M-2Y|.1(*T.OO25Y
9E0G2E6@ELJ.MC?R/3NA_)6|'D9K@Q.=T(E. MBA.|SM4UHG1"43I-\$Z43(4I+Y8:N=*IT9NX2AC38M&A-
9T4:UK@*N%#VY#8 M&:V\$/G22=>5&K@9B:&G_B|!W)"@U)T5JWO^PX?#|FX=|0E4E1?K+W3D0%@X MKY1D_|K-
|_BE+=3%5"M&:|DK62G0E3XG<:&,"<S:A)T4B3H89X24O1^|HR +WHI'C|XTA=(TNGB.R| MTWYYB,0
+*MU)-2E4Z4NW4142HV@7PC=)T4|H@:B4#NVBL"RV?5E7:B1J
M)\$:6HL|L"|L2E2LTVFS|.JO%A_G2,'XLI9)=F_|C|_|C.B5#<3E1"M^2|K
MTD%)E&XBZIKPZ(OJ=IH6?T:PIJ.3>M.I.CRZ\$J\$#2_&|CK%?MY&*. \$#1TV
MUCM(*\$0G18@>A^D:2SJA)9VF6=*J*3YOS\$B|*1.D(I84J+?U<\$B2)*"R0E M%&AQ5>SVLJ+<")\$#"G%S-Z-H<>
<%(Y|04#E>W)T>Y^FJR|KIM8X82"N' ME63SNOI
4*9.BDS=#%1"L6:_LJA7)R51N@FH:|*C\$TK8:5IX="+"HRW_FH.\$
MNG2J3(^N9"J1&QTV5F),Z#TGQ7L>QBKA03LVMRRA:IT4#7JK1A6PI:TJDR/+H2J41LM-F.Y7<% M>
|HB.PISM<%_3N@_|5_B2J&BDZH12=IDG1B9"BI6I#E%1JT4U)>1HJ>8R MRM%9D:-
YHF9">S:|=R/EQF|YRQKR6U(-BQ?Q|JN(O%C.YR5MSEW_W|CE|W M^_SN=/KV|RI8VJGZ|V-

45=>LK2?>0G3>%HXH9=FVIC\ CP\$QZ=4;S.T*C.O\$>2W 4ZX\$S.GDS*5&NTI_?^+N"=KAY-R
M@_Z<47_.BOX\#-6\QHG.Z\$3G:4YT\IOHH=A0BL\+30Z\$Z1V7./?S**TKDR M+H2J411&I\IB_-FP>189S>6L
MF.L7I(2)77*IU\!(%=>*49=&Z_P"0#(H\W8Q4PJCF2Q7IH"1(-R%U35AT
M1NDZ3PN+SD18M.W\%QP5Z5R9%EW)5"(GNKC?L1=9NL:&SFA#YVDV=*9L.*G:\$">5-G035 DG6JPHY(JB1
M0I63G.2:07Q: M0BP6-U+5\$7.*@9U3RF@L91580E U3J:JO&9_M2.+W.(H2P+UMT"@.YT5ISI
M9JH2)C7\|C46+.BLYTDU471.9G=&USM.BHS.1&1TR-X>8T8\I.E:'1E5"EXJ*I M8: @I#EG17,>ABJA/?-UA210E.=QJ*
IOH#-ZTF':\YT)#UHJ-H1)IO:=Q%1" MAA9+ #IFBN- "4PG+V6ZL"YI1=,ZRAJR(5\$!.*!7VL0&ZREEQE2\|39.)_*J_9
M7>IH/^>P<\$8IRVIU_P\$&@:1.NIFHA\$/-=CITH.2)HU\$U#71T1DMZSPM.CH3
MT=-&L5\$9&=7H7)D>78E4(CQHP"=X\H1)=FN\|C\ 9C.B3#=#E="H^0\I_M/"B1TDU079,>G5&TSM/2HS.1'FWXL?
Z.=G2N#)"NA"H1'WO"O3@)IS5C3G
M8:@V:19M>>L:_.C4%WCVF=TH?T%SH3+K14:;A#YTH=N@FJA:0MU1QZT5GQ MH@6H\$L9SV?@?M% XSK*0W
C51+T^B7_VBI9R5JSEYVJ/92RM>|3R5E^NO M 6%"TZ6:>\$C(U_UU%,BAITDT71.MYG*=K5.B.*G2>
MID)G0H7FJPU9%Z%PI0C?1E-"AO? 8&G7HK.C0-DVIP.? (RSMH.F=91&ZD:;F MDPHAXZVEA*=B91H&JB:1\2BK>
RAH2Q?%EFYE.B\$<:HZI?WIHN1&MS"UK(F(M+JA9EVD1T86(B.9_URKH1)?
*D.@ZIA8B'MKYR&8>+2;BV(WCS*U\$+:S86CL?I'TZG=^8
M55:L+G:FGXM9.)U49+FZ_P"0#HHPW8S5AN3H@YU49*CFI"Z)B2ZH&I=IH5\$
M%RHDVD4NB\I.@&%TIOZ(KN4K\$0\?" KQ4T' NBN\$|C-4&XIF@|5P4XWDZ*.G134A=\$Q)=4+4NTT*B"Q\$2.3;#-
CD4HTME2'0E4HEX:&O97IH* M&LY%.9R.D4IE2+JAQ0C.=Q*1IH MJT&6:|ET(#5JJ-M2@2Z4&W8140H:>
M:XZ%&K019&A:02FK.S@04YFLY%I\$;D>J(V23#WR^CK5P46_F"5#;5J?M_*6:|'+QY.*K%:W"P"20=&EFY%*2-
0L4E&@+DI<=1.2UR1#% 2LR1IDZ\$(D M0YO WS>@%5TJDZ\$KD4IE0F \M\$A:IOHDH?Q.P4PG?V:
(JA8TGHMB/(I3=8T& M75"#+M.TZ\$)HT%+!H0==*CWH)H2-O26^'M&U*&+HD,+6*7RG:V+!+%=1=BZR
MBIS(54\)*04VB;R@L%P48?G"53N5J_*<6.-/+!Y6*K%?W'P#B05&FF|G: M\$!:=T*(N2EQT\$U?
7)\$,7M*W+M&3H0B1#E\+^R(5J=*D.AJH\$A\$);0H|A%C0-M<2Z*XSQ,5<)Y9M|V7E|Z+HKT/|5-
29T01.Z3#A"V%"2I6&+*D4H9N82NC0
M=N/O5%&' +HH.+2"5\$)W=QC|S1=>YR"IR(U\$#:.3\$CPJ@KEP47=G&D@Z_NWIW M>W-
_JWHG:"F)"R9'^E(P?"PC&E(L05W0> PG11A.EFHA(:4M4=*B+DA:= M1-0UP= E(D+BM|N'V/ 3-
%K13(6N)*G1"IT*:ES>D%:IO|DH?Q.P4*G8Z.VP MU_*H\!=%>1Y'ZAH\N|
7.9YIT(7PH/ER0Y142M:0"54Z+@E_FX17>BBN- "M40G+65X6>[XL(CH5IF0U5>LKO6T7\N:>60DBQ7 MJQ|
LD\$1HNA2FC4I%<6'>JBI\$8W075-0'1\U;L"X@N#0'1=7H4AD070E5 M(AK:.N\$.*TK.19&9^H:%J@"UVFN=">
<*Y:D.6 M5*K034PEA&CK"JL=%S2BBV)\$"TPE7&=Y66SYLHSBB>-\$"50GCV>?
M7J2A|EQD(HD1JH6*>=08PD9MN2C\|D50M:.9*B_:7^Q(@K)R4\$GVK/L/-&@ MJ/-3&W(C2XH4Q>*3UOI.7X.XK
|RH MYR/N2<6<4CA\4(2V;_?; MOF(|#T.UWG|>/XLD4.SG<:;@N4:+WS2(I9BG1SUNJ+39D2.4IW<14PHL62PZ)
MHGC1 EOXIELV?*G 5N^+"4W(M5026_MIXI_.P" 9%G6XF:GUP|Y9A(2'-U\$U"49T?MF\$2&S.J?*M_3B^AT=
M>Z%ND1>5(=&52"7BHLQ2_MH\W5%UM")-
*);JJ808+=8<.D41HP6F4LKSX|M|NVZQZ^/0#0#0HIG0S4^N#H_?/(AV4X.@F MIB)B-
XWBPR9E1'IO*47CZ\$2.QVT?QIY41D178E4(AS:&.XM^OO'L>DKMO.P M4NOMY_VSR_%?
AYZA(E>M|LPF.6\$OVI=IB0Y14&M%-1*6:.*D/I)%T:(% MHA+"|H+
I%GPV/%E(D1J)Z84DK.SIOH|H%Q*1+RA:=Y*D_E%:L+W2,%_+H! MI>>-3S| Q((B33?SM#XS>O\LHD')C&
(BZ9)XZ'VS")I9)=#/6WKY:Q+ Y498 M5.9#5_*4"H8VB?_S8<=7+.=AGM9:S_MGD0**|3S.TR4JM-
T"HF.6"OVI4\$ "V47\$ "B\$*TP% "-3:|DT+WCV/EUWDHIX&8D")YVG QJWX
MRI>97W/X_>WC^YL2;KZYF<7^0D<*A'7#2<|GWX B 7%F&|F:7U@|Y9_M1(2&-W\$TR79T/MF\$2"SLJ&?
M_1B6L1'9J9_ SC2HC(NA*H1"IT-HE\ A2Q MY2N2S\0">G9\ 897400*KS.%*7N-#|9I\$><=IO#)&83A+J+2)-
G7H)I82 M4G2.EAF W3^5%&<:(&IE.ULM(C7.I9V49NA&HDALB_Y-NO:M.LVEGSX
M_>FT5|WWWW=W_ ^Y2Y17I:QU9\$%?.)LF*=?\|(P4:|J9JO6)T?MGD0I*8G03
M59>\$0ILM(45FA4_.ZGJE"6D164R="52B4SH<^|A)P\3|GS%<1YF*A4=S:W= M:?
|T@D"QGL>9ND2%WG>+|)BE0C|OJ:I:D"25*G034"DAVD3/|JZ:D"B*\$"T0 ME5"=Y66QYOGX_@:R39+VZ^P
R8D\$QHHMY2GC4I_?+G(C4#_Q MF)1S9"15"S9OQ5: ^F*EA)E+EL: LKO2 (RLK|)FMIC\)(C.B2S4LO+Y@S^TRS("XJ
Z(KJ4I\$0QNW_.L%&SZ MBM\|3-5ZWVG_+*) |9W'D:I\$@MXWB_B8)4\$_.ZFW) FE1)T\$U4)%5HJ.H.J
MM%#4:|ZJA\<3;"/>R)C4'0VLH?<1M6/&WOY: ^K&0=6@K&P46=FF:3OY|HR MK.>^RH*|M6|023;PND D(XO5_0?
@|0#E3B<9PJ#F6H|>|HHJ= M4#5+ J+WMOY:4.3#"S|9W9_MU: #N:|3=>9BJ9HT#;="!-M;
<:\$.XT#O\$N%_O#K0IE*";J&J(53HO+&-QA4 MH8VB0@M0)23G?
4_802V#HK.1/>1&J|HJZ2URKTCOCUIQ>SJAIO?K%C#;+! M34|M17S)X|U.+RT.ZOCUZMZOD\$'=-!A
MFX_.C(/.2:P).N@PR*!=464P_*4B/Q|LBH&AE:@RS#E>E_2&/:T#CI\$=C:5 MF!U*3;K7|WC>.TVM/+|N'A=W|
|/3^Z1_BWH^>FY#4_5#SBIU+ \$=W*(4 M=%L|?P*8IL-
+NYO**&HQ#RBH@S\$XVM74(S.B*2"T#KMF1+|TJNK2@SB2W6\$ MT6%P101@5)GIT/<;:2
F|A+G8|G Y:IR0Z2#>|0%|P.|+Q>U3.2J"\$=*MLD M=& DM+K@."B#%-J550Y\$7^+LN?
OG,2R&B%:ZRECQ^Q|2NL_N_?XX=F10\VP6)=@Z)?FGL5X;%&)P2/=A59CYT+>(^Q(#2.1C2
M>3FKW|!#D)+*#@/Y&AYO:MG1'1 \$1VVB>C B&AYM6%|CVT*Z|BN|B/23Q_M\>D&"I:2KCG=6CX@5?
%|G.I"9FIQ)5:48\|73+P7#++|2K|WZW|QYQ>ZDBA M0SZX6RGHSGK^!+ AIUV)Y41U>)?
++|J8.R.=B7UR)CH^V&Q(KO&1+|TNNO M#.6W8.BDP^"8Z.&H.@.B0VCBWN=@>..?
EJC+^6S: F'GOA?|ZIU:./CCO9S00ID-/4/ KW.D4&'F1&|VPV(I=,Z)?'NG55USBG=D"^N@P."5Z
ML*2.?.@8Y2_.\$#H' SHOYY2|SXWD7Q)FP*#|ZT\$IXZ\$#>NBPS4_QD/+MY8- M**+ #H(AV|95QT>EJXD?
1R**#P.*5GC@+.17Q1DH|Q7/00:(SIY7:I=2B_\$SP MXFVPY?AT8\)/=6/-K_.L0+UY
XEG5C/GP|FP5#3|HXREEJZK&C#L:0%=-/MC|R'OA6 |K|O3+ (IW*6)#R@R'CKV*MY8)2)V#09V7B^J@
MSP'I_||^7+QPIW5|JK:KZ M|>7J: @G=RB|K^1/-AARVA5QE/|JP|S8_R=D7UR'QH"BBNPZ|YT"/^/M-
/0K0Q)=J=#0Q:5F0L=J)XM47T' SIO%Q541CX3?&S2L3/P<#ZU\$|Z(# MBNBP340\ID3+RPU+LBA747E43J3?
PX'U%T.%"T4E2&.^N'Q6N^+I*=1>W_ MJ32Q9MN!G3+P7#+O_ZOZPIA:U/U(XO=2Q/|HDW24?6LR=Z;)</>IDC
M9#2AI"9C9+2GJ71F.C0AN*9MTZ&)F0Z=JGC:/4(A38/3H<>R2LOQ?XL2,3*: M(HF?1A/2: #)HM%Q68M S-
1G4\$+)&GTE6RKZP/_=CKCW\I2|_K\$MIE.NSRF9\$-"&ZIFTC
MHHD9\$7V_@Q4Q*XBD:7!&|&9F>G0I#BLW0UJ|1"A2R;#/Z|W MJ0R*)D31M U%\$X.BU?
6&/1E4T.ZN.C:ZADN|J"-JL-&*UEEU"-Y+|LF?2
M5*;*SJL3L42KB%B5"NDP&7:XQ/_SFX_UW|3^W4ULJGZAZ86.\$IKHX"XETIGU_M-
E@&0PZ|4Z|8VXTH.8F8VZT*ZEG1D03HFO-B*\$F|'1/4J?NQ(2:1|<\$#U8
M5&8V=\$OB)|"\$UID.Z|Q<5&Z"="3QIR=" TR&?UYOZAD438BB:1N*)@9%%-%. M"X0FF@9-M"NIC(Q^HA6?
D(8%4-&*TUES//3=PKBJS14SZ2C9&=4(I=3B;IX MJU|NTR&7:ZO|LVJ?KSYM8XQB ^-(231-
\$BB75EE8'3.I8HOYU!&DR&C ME:PRYCD6DE /(GHFW20|LYJ8W4JA9?F%(1TF0RZ7&|FU7|>/K'6.0#FY7
M(AU:SY|_UL_T^ZL.D9(\$WJ.D9(ND)Z9EHTH;JE=-.BB9D679OX2T.B38/3 MH@>SRLR):EG^D'6M.QG6>;FJC'U.5?
|N"?DS&?QYO:IG3#2AB:9M)IH8\$YV; M^#(C.330-FFA753D9'6541BBCR9#12E49\QQ2"/+O_2_L.DMV5C4S.Y;5>07

MJB7R=#+?;15=6/-1 6L07YX(8ETJ7U1-D@GB8#3|NKRIJ<74@IR9CBK2K MJF<&1E/|C)1MIQW* PU&DSIY12A-
@.B|ZO*3(H.L07Q#2&29S+(W)6&0(= MF Q| (2IH.A3T>E;T&A"&DW;.:#00+K(%4;38.TVI55|DB*HI+| (329 AI
M):N.??YZAR@?%J|L.DYV9K5PX|H(O|9(6\$F@S|3BVEO504#3J|U).%43^Y6 MTKWU_E@'0Q#|@ZA-
|E06@DK0Z"?K(J?N>|#)ITI>P;V-V+(5 MN?@B)G)P.RAAV.E00#3JHVM_43FY:TN'U_E@(-Q+|2XK(ZS%LJ*N)F.B
MM*NL9X9*QO|YV8|FICAT9R^D4JED:G|H|6|9E.C|T2^JF_.#|*17M8S3IK02=-V)TV.DXY)WGJ*5)H&J;2KK
R8CO=+.G'=M(9@F TPK964H=\$Q5WMB_%HTJNPL: ^>V+;4DWF&*4#23(9KOLL:19=4/+.+_ML0?|Y+XE'6#|GP
&PC#5|K(Z|DL3*FLR|DN|RGIFAC2AQ:9M,Z2)F2&=Y\$_F MD\$|3X CIP; RPZ+\$.|>|1% 1+
KW8U;B;:DO0N*Z**CH:*7LY|/\$_E(U+I MN(U*1XY*B|LMH2.@U+;4I7(>_D2Q8|!(W+I:|L:J1@="E=OFH&8^Z<<_2
M3P_VJHDDC^N)DFCH9F?G|N3:IQP|F570&D#NY9BKJGC^|AB>P=|J29(BU
M_?;|8GLV|4SPR0CHBPX|8|TI\$9(|URD/8|1D33<7"1% A3(S.Z.N0HOF2.
MR)^CP9^7H|IPZ)?|L7GABTP1|1Z5<|PZ8A_.FYCTI*CTD4^2(\$CKJ4-D9UL|L6^I1W#L0D3-'@S_
M68;18=4/+_8.02AX+|EJ-/KZ1-3AT-3NT.*X.LQ_*|BL(|&8&E76;_D(X(ML>_V&=*1F2\$=8A3_O)%Q|SATH-
A9<9'AZ>_D8M|/;|IH)>#BL|95H.*|KH M;+CH|;">P=(1L734X M=)'W14?DT%?'7RLZP\$K-Q*2W+@4=8+|M?
P+8|!-4N|V|*2&LQK*BLHS%;VA76.V.D(U+LN&V.=&3&2 ?Y.|V(>#H.C|S> M#"|I0+I%;S(H*/|H)?
#RHV9ON29F!%I=#1H|'I9SWCIB%XZ;O/2D?'2%"|Y M5XE%&033KK)R;/T*1?RH!-ET-BT4E8&1#_O&
I%G**C#I;=94W.SJ6F (L@ M;XX&:WZZ@^\$5|K95/^3T.VT9)1V:4=&CBGO^(@CH.3L>_;"LS1SHIGQ(BA8X&A5YJX-
&M1Z31T:#1ZUDIXZ4C>NFXS4M'ODMKJPW!=|P\$TZZL.FQ:6W/(H|/H6|B"Z MI"JF#%\$TU+VR.ZI9V:04Q?L31T3-
T4#-STW="VV.0|ZO=2Q|/KAI*>H&>_X\$ M. T&JW8WE<'6XJ4/H74T!DRIFGIFEG1\$C1VWS9*.S"SI**J'B/PZ#LZ2'DPJ
M.T4Z|OF;SKH:#CHY;0R+1J*^H\$M^1T&T>U3<-A;_1HGVO4A-L*RPVY M=|SDTJZF.F@ZRM@EHIF.AIE6FLHZ-
K*Q5JZ*AC96=3"J-1*2N)1U@^SY|L\$S\$PU>ZE.M;?JF8|V/|M*MI9|9)1H38 M<=LXZ
M;^H9*QW12L=M5CHR5EL;EB302KM;BH#IFL3N4|+\$+QT+ZTTE9'0ROT@ (DKH MI\$-E9U.KLU|IBSG+ #DFZOIT|
.74T.+6| MJ8XYTQ&!=33F3+N;>F:D=\$2%';>-E(|.2.D@W^XV(IN.@R.E|Z/*#).F+M|H M*2* C@;_7JZJ T1!'!-1-
'K33VCI"JZ;A-24=&2;O+ #7,RJ*1=4>6LM+KH M;"N&E5:JRBCH&+(X;S4B@XZZ4G9FM7%3X91?
%KF;%CFYZYN%G;Z(>7.^+H MV\$ _N5|+E|P2P8|X;3.WN*D.LQ:L2|NIHC)HV=?7,5.F(|CMNFRH=F;G246&\$
MB*;CX&#IP.YR(Z7|I%<1M|B?H&?E|O*#9X6QWQ\$!-'1-'K93VCI"JZ;A-
M24=&2;L+ #HLRR*1=966P=.A|_PZH99.AL6RYHX|TTER(<->-B-NY5^>K#_M=5|@|0U|0LZ<#;|I7-
|Q;8XY.0R3PBDTW5PMU+2|?7|"20|@;V|E1+CK*4_ MV83(CAG3IGUE36<&2R>DV&G;8.G\$#);6;|*0D\$ZGP;G28V%-
S\$3I^XF(VQ\$3 M(NAD.C5L"8&L|1OX%*R**3P;*7PYK.6.F\$5C|ML|*)L|+R>D|JG0;IM*>K
MB0/3E**8%033R0#32E<9"GW_%K+T*C*AA4XZ579V-3;EK+R#X*7|L.S/V=U M+|
Q#CF_V#\$&X>"&L;3KZ_D3P#H8H-J=5899BUE%8IV;8=-NK)Z9*YT08J=M MKVI9YAT0B;=MC'IO#|I>;\$ADDZ#2-
J55(9*Q|;\$HJ*43H:45HK*>A.\$JM) M;*33I2=027N%DOB+/6\$CGD9CODJ;.&U3|D|K'3-
|WL|+ JZ3G9&-7)3X<00NA.2YF00YN=WJ?3P-M^V1?2
_CV|=WV|J'W9^N6;_XL\$M2TE'U|G@ (XZ&8|'59&5XMA15F=C%G3 MKK">&2N=T% ^G;6.E\$S-6NHMR+J&63H-
C|H0?R@R4B|?>3RA>TZ>UXN^_.@ MLSA=)Z&S3H;\$7@_K&1Z=D\$>G;3PZ;3Q:6V^8E\$=\$=
10HK2Z(IQTO|);1=#*0 MM%)6AC_'B|H=B4DT\$D7RLZT|E+4HGBYS#(F|/F) 3&O>G53 |I0^&YWR MP5U+28?
7|R> A3 PM3NM#+\$6TXJ^_AD#IUUI/3-;B'#3MMF2R=FMG3M8L|0 M3;?|V=*#:66F2L9Z_@2P"H:C
M=N>4T=7R.L4R&(F73D|U.ZH3FH#(5^0_)A:BADZ&AUYMZAD@G-)I&Y%.)#N6;SQ0D(C MG0;-
M"NJC)2F^WM9@6I=#*HM%)5|D"\$ (+XEX<_.NE*V9G5RNO6HEK\$EQ5H MF9-EF7_VC_LKQ?WSVQ|?
QWQYW%|6_8CSJOU|4\$ _N5M+EI?P)8"_.3>TN*V.L MY96*C3|&3;O*>F;J=\$*G;9-
E4|5.DHWN4@H9L@T.F|V/*C).FVL2;&"7T
MS|GPS|MA93ST&_'&K0E%=#)\$|I7SS#IA\$PZ;6/2B6'2RGI#)9T&E;0KJYR5
MKE6|ZW|""YT_*ZUDE5'0U\$(27UZ@A\$XZ5'9FM3|EJIX5|\$_FCE9FOEGSW<" M_OKQR|MW|VK>\$%7|@/-
+5/03NY8TN7U_E@&PQ.|8X|0ZS%J*"O3L:4;5=4 MSPR43HBPT|!THD9*"W>U"BAF\$Z#XZ0'F|H-DFZ7-
T/VN=DV.?EICHL=\$(+ MG0P+O5|4.T Z(9|VX|T8H"TLM@P)(\VA54|DGK2PZ#8B|I);@.??XMR'MO M\$4
GW2<|@|HY_4|J|Q**B8DZ&8HZ|PKV2|OWN|I|;7^F8@7YR MIY(KF=/(*_ASH;A|@8U;I);NO!E5-
79F" M"6H^_THZH|W.VT9)9VZ4|1%7\$ M-X<9K70>"8|UM3.C)% ^&@.KB=";ZGD;ZGFUJ=FAH#JZ&PHZ.6FYC;T.B.-
MSMMH=&9HM+|>^CZ_-7N5.D.D|577|G_|E7*#XN4?|0-2- SKL|F7UIP=| M_?%O|M)FK8R&.1N&^>M_?
MZL|/I&O|CW^_ |N|K/^|5E;CD-/K'55T#@UC.X.B..SMMP=.9P MM+;#/-
K5509|JXL.E70VE+325<8_\$U|U)S#D2Z*P+96=7B=FMU;6OE3.R MYFPYOO-.GSXY?OW|_IT|DBC.QWG20|VE9DC
M4E4#AGUME|L.D.RKIO\$U)9T9)ARB7?9ET M'E32KK(R6#I73;S&.%T-
K"TsE:&0=+M#49&736E;*SJY=KA2ECX\$S6N9L M6;G|ZOT<^"_.H|^OZ&I^N'F\$SJ6(|I3"HS0/KI78/XIAGA&&3
D|I1S_#HC#PZ;^|1F>'1RG)#'IT>;0KJ R2#C62^\$(.D70V MD+125(8_AYK%+5L9_736?;(SJ8G9J|2;6%1\$S-E
S.'|/""CW_*1JEGNJ M'VQ^F6.%TL%M2EG7UO.G@%DP +6HXZITAE)=3:F2KMZ>F;=\$9YG;<D;L M
&G05X9"@L.COZL*3.W.B2*XA4&K7,VK/R31G|'\$B|26Q&_IP_KS>TS.F M.J.)SMM;=&9,M+S MC"HS.+I<4?QD%
<%S-L#S7JXM01N=#1NM-)51S|6)=W|(|ZSCL*=22W_458Q--N9P-MN4PE7P|_?_?
X|_OCIF|NHOUP|JGZ|Z86.#CK7D_N3=&0|P(8|L-NXO* M:&IQF.*DSL9:5=1S|R.SNBM|
I;9T9F9'1UBDO^FL|;#PZ;B|J.C0XU5O'S M-
Y3.V9#.RTEEY|;+^1BO@Y&_AY|IG1'1&\$9VWB>C.B>A+;"J*Z#PHHEU-
M95QTT/*&+CH;+EJ)*B.>0POR.PLTSUDGRK&CA;|MY8EG5G/GP#VP9#3|K RGCKE
M+FXV0Z\$=C<'2KK:>F2&=45WG;3.D.S-#NI\8<%F#(Z0'DPK.SPZ7%4^|F|
M|^H9%)T11>=M*#HS%|9;:BB|Z""=G65L='JFD;_ MG0T;K7254<|A1%;>\$;YG'68|QJ9|>_B=;U.O9T.M?_I0SM)J?
Q_WQIVV_M_|985?V|TL=0|/;E'2K?7|"6_9#|IMKBJ#JN6_5ZR#;5'E=0SPZ;SLNN|
M;7AT9H9'5U&A9W32>7|V|&12N;G1F9KTYU00|!=#/*FM3_6MP;79|_X-
M+S>UG"1!5UTV=B"^.BY>564\$67017M;6IA;|2|Z+JT9ZJ@C2Z&C9;6ACU M?
#JG<=&6E|%A|F^IOIT8/_K'F'R(TC|)?O9^>I6'?WU"J@_|?W|?Q>=S M:AQS?
K57/*^#_Y6*JWG3Z#A">S=J5085'UEM2"H+L8;4|6RYG1T079==DV M.KHPHZ;+.(E|O
(N@Z.COD)V*1EWR%0^Y<#.Z|G%6&XNOYPOZYV+XY_6L
MGD'1!5%TV8:B"X.BM>6&.1DTT;ZL=)3NS&KB|2E7_*MKE8MCEY|>JX>\$*_S?/H|'3WW^6NZ@>=7^Y8@W!P
MOU+1K?27T"2"?+@;?>G>50=7B6D5078R9TJZNGAD?7!=EYVWCHPLS/GJ(FX0* M(NDR.#|ZL*O.Y.A Z9+__?
#";W#GY:XZ^-'! EP_KR>U3;FNJ")+MM;=.% MM|++;.">#) J5509&ZVL.LV+(-"6KC'D.3|9-/Q>I'63L.P|?
N5DK@#N"!< M+@9/G|H|W")L" Z:6.#KK\$@QN6BHZLYT|RV#_7=2&4XM
M_GF@I2|&2&E74L|CRXHKLNVZ=&%F1Y-4=HD5-1(E'IT8-)9>9&AJKEE^H MG8NAG9>3RNCG4.3?J;
|_K43V#H@NBZ+(-11<.120K*6.RB*)=4>5H= M9 M2\$)(HXM;HHY6H.N@YM"CN "GHGHO.DIU13&K=^_??
H|^FZOK?IOIU<|DNB2#NY9*KJWGC|3(1|J-UM96"U MO\$HP\$|94:5=;SPR0+FBOR|8|TH49(|V" ((=P709G"
I&%=N=O1%57P1C_2Y M&/1Y;.X."EV00A>#0J^G|8R/+NBCRS8?71@?K2TW)-ED\$B|VLI:771(90N M;I16VLH0;
I1.2Q>|G6B|&QK9K8L=7&T:D"7 S'-S6|/#!Z.OOGRX#7SV^
M^|NW7SYO>_.J'WA^S6.2L&M2T7GU_G@ (TP1+4|KH|IT@6=-3%&2|OB>F;* M=\$&)>7;9-D2|;%.DH#GHL2*?
+X|3IP;8R|Z.IA2"^A4 \$70P\$O=Q6|D6+MZ I

MJ**+H:+7XWJ&2I>"%2G;OGHHW&11<:FAE"Z#4MK55L9+4R,YI@BFBP&FE;8R
M%)I:5GX/>77L;*SK879NG2-V!&-9\$727S2+QWJ3WAX=/:OSU^~^ORX:5.P
M<=3Y!8!J*="W+~^D>_X\$,"!&JW:7E="6!FK%2!@#IEUE/3+~^NJ#(=~^MMF21=F
MEG2H(BDL,*C+X"SIP:0R4Z1#R).2=30Q=#0RVEE="27?TD8!(-KZ?UC)DN M:*,+~^C=,.#.MK3=LRJ"9=K65D!M7:
(7G2BGBR&GE;8R)IHNY34&HNBFBV5G M6RLW\$^X2"6M!V5P.V?S MNA@>>CFMC(^6UQ7EP.#1ZV4I
(Z8+BNFR34P71DQKBPV#.BBF76'EW+2VY# K M!M6NLJ: KRRPLTT44GRIZL-F: 4KC\$SZ71-1?#-3I_'-P>?
O:##^!?'_JS MI?OW6_8PZ0>=7NQHI4L_N8=)A!CS)X!L&RUNZF.,=%M74QYDR!FGIFT1!
ME%VVC90NS\$CHYNWB!U+,:@4.G!J#+CI-L5Y&>"EWV#0R!U<&C"_+H8O#H
MH:B>=,%S7399J8+8Z:5U88I&433KJHR=%I9I/6V8/'&&!5IH@=,5X73=JJS
M.+&H(IRN@W#%:5:,3!>2Q/=LR*>KP:>5L#(P.J3!E:1X6+SRZW:9&59B=B_%M\$.5G@I=P0SC?8>UIPZH?
<'ZM8POHX:,EJG/L^1/!C"VAU6SEWW(&X'J.BN MJS!LVE76,W.E*+LNFVN=&7F2J>2Q-
!>NHZ,%=Z,W+1.G&+G%V5D4970T.MO9Q61DI'.0AHL!MAE=23>@905P34=1N@K@R@3D7Y5!F#
IJ5UL91QU:K/*_M+,:%<-1*6QDAG>(E%PV=-4)L!.MD=F!E'.0?P%X%3>@!I> O:XX/?SBVZ=9
MYT/_W!84%2ID//+~^7L0#^Y!^H9/%T13!>M>+HR>%L;IB303OMRBHGC\$N1-NI4!-35-1*51D: M'7.3ESI>|W6I
!(QJXO8ND;25K*)PKH9P?FYJW!M4_9#32QW)=,T'=RY5W6// MGP"FP2#6IJ8R!%IL*J+K:@R>=C7US(SIBC:
!-!LQ79D9TT_W.A9_:!B+P3'3 M@U%E!DS?EUOQ^H8:NAH:>CFJ#AU=44=70T>O) 4.F.Y(INLV.ET9,JVN-JS)
MHDEV-961TH:0SA=#3BM-)4AT2&T2XPJNBHJV5G5_NW0E7PXEY,>R_1MHFP_N+COP/_W'_Y7WS>4-
5I6-.KW:\$TK6K^HBDZ^FV12!>M7+IR7%I9;N!H=>+^H9(UW1 M2-
=M1KHRIEL;HBDZR^2=A65H=*UD_@5+U+L!E!H:,@NY5WEF)#KKJ3-E9 MU_9M5LKRWQQ>O
W+_%S4I/#+~^Y DI8:>ZD>;7^98@79RHY*!NKN=/:+~^@2&IW M3QT#IROBZFH,G':ULQLZ8H&NYZ:+5V9Y=)IWH:
(7KH.SI8>S"DS5:IV!0:~^M%>%S>#SCVG9WAT11Y=M_'HRO!H;5A1P9UM*NFK)\$6 MQI55--~^+5,-)*31GIW%(2(X8
NNH^V5G3SFO(2K)E0!1<#<3!5--0M!54!IK_ M*L<&I);,DW1M/7L"#05U,P2UMZ:-
<=5231N;ZF:,FO;4M)V9*MV07K=M4Z4_ M,U4Z%/%V,@VM=IL<*SV6T!8,E(Y)_BM(7IN!GI>S6EC\$+2!L#
(^~^LJ:,A!9CG!7FL\$K=?Y3+S9#~^SSF!K!ZZU!^KM?4-CT*D<\$W<+!+4E-%!S)X!1 M:-
"TNZ8,I18O>LBHFS%AVE73,~^D&V+KMFV8=&.&20=JTDZ_ACJZ#4Z3!JPI
M,T>:NCAUK2\$S:@9S7JXIPY(EA84),,SS>DW!0.B&\$+IM@!'"@=#J:L_.\$IH
M5TT9#ZVM.>30S>#02DTYZ\$SB/40:2N>F0V1G38G9D122!E!0ZW<#*W!7-/R M)NWWST^/_+HSN2JAIQ>JDC?
VYT<#!2TVWU_E@00PN!4ZJ8!IT0T#>C.G2 MKJ2>+23=D%FW;8.D&S=(ND?I(Y^&+KH-
3I(>3"HS0SJG*%YN\$3@W S@O)Y4! MS_+"P@X8V'DJH6<\$=\$.~^!W:8)Z,8C:&VUH8!N@P+!E53&06MK#AET,QBTDE0&
M.-=8Q?>%)R:#!'"=28W,?J0H!D=JJ)2;H92?DQH??O/NRY?WCP_!O8?TU57 MJZH?='ZU8POBP4U)35?5!R>
<3"@M+~^NJ#)16+~^WY(QYLQ7MI5U3.3H!L"ZI9M MDG1C)DE7^~^J"P1@<)#W85&:\$.=Y_-=#UMP.UKS<5
=S;LB_,D!4TJ^N1F^~^3GHJ;=1=4/_K_6L0!IX+~^DIH/J^1/_!A(VEU4QU3IAFZZ M&5.E744!T"ZG!INVP9(-V:
=)8O*XBAB^~^#Z,&D,I.C0PGB=UJHFINAFI>3 MZE%#.#95S.Y3S>E+T.>~^J+EMH!^~^
H<_8L:~^JG5U,9_ZPN.8R*X9^5IC*R ME60!VQ-W!T>:YN:N9%O!O>Y")2; 92?FYIW-U4_Z/OBQQ+D@YN3F@ZJFI
MD70SD+2!J0R=#0JBD4TW8YBTJZEGYD!W@A\$IVIXY%:,~^%B9_~^%H81N@V.C!Y!M#(Q.752*#4ES,TCSPJ*F>?
N_RY+!KG9MAGI:B:,DY=G_3\$#8WW1T!BUJ8C4DD;KMNBJ):@9.? MBTH/7L_IX?
WCWS!^_&9#304C3B!TO,ZMGMRI=\$OJ^1/_*A@ZVIU3QDR+.44P
MW8P!TJZ&/6N+~^#5,R)Y=067LL!DT#XWPSXK M0654!I!=\$.6CXA5?9!?.H#9N;Y)X1!B&-KD9-
QDYJ!UK4/4C3JTM,ZMG=R: M!\$J^1/_+A@XVAU4Q!SHAEZZ&7.C74\$!R*ZG!MNVIT9\$-V9\$=&JB &U(H=O@
MC.C!HC+3H6:+~^MY+1.W-0.W+274@YX;(N1G(>3VI9^1S0 GT/'^1_V_&IKW!^<6.+>@G!R;IH'K^!#_.!DV5!4Q.+JA
MFV!&XA75<_~^B&!(JINV&=&-F1\$=Y!T***+;X(CHP:@RPZ#)#'\$81D?;W W:
MO!K5SECG7,0=)1VYX!W)7^QD#W=)~^JVT&NG,&6EOP'0ETR30GJQV!D*!
M^Z6FL5F1PG=#0DM9!4SQC6W4W)7&26E76-EI#,:!2#/'!H^R?OGXX;L~^JU R#CF_VC\$' MX>
VI:XCZ^D30#C=#3CM#BO#J<5&H*7NQM1H5UC/!(CN2*HM@'1G1D03?42 MKRM(I/O@A.C!LG*SH=-
%TB=R:~^%S-!#SWJ*N.B!46'63%@M-)5;L9S!22^~^T?VW'65!P!J;N5Y+M: M=:3+W:~^#+SUFM>[.J'W)ZM:~^%
!O'@=J6N0^OY\$! Z&^C:G56&5(L7/_34W9@8 MI'0'=EUWS8%L1B<"CW84V8>=+G\$>P)TL!>H,
!+!770YX!TN1OT>:VC9SQTI P=MWGH MSGAH:4AB.Z#(-
K54X9%:VL.670W6+324P8!UQ:%5Q5HGKM.DIT!S=R=E\$2B MV!\$M=,M/V!_#@^_+N_?N_WT GTX:FZH>
<7^M8@GQPKU+7F?7!~^6:~^#K M M;JIC5'1'3=V-4=&NHZ9"MT17?>M4Z\$!Q4ZA")^~^H="N@!A1YL*C,./A1Q
MXE5_ZMP_ZKS<5(8^1_~^C:3/W:~^#ZU\$!ZHP7R4=IT%&ZGDKSW WEYR!>BOIQYU?~^B#B
M.ZKJ!HR+=I7US&3HCOBZ:YL,W9G)T'3)?UN(I?O@9.C!LC(SH0/U+FX#1O;< M#?~^AG%8'@^!>(H+O!H?+>L9&=
!31?9N-!HR-5I<~^F40!H*RA!I?>=%A6PPC
MK:25T<~^A7R2V%05TUX&RLZV5V:Q4+OG!2)M*&J3X/(JZ_K^~^OGKY0_=UB M407#S:IT#\$\$!N4)!I?3)X"
(NAN(VIU4AE:~^%SYTU=V8%~^U*ZIG!T!WY=+~^V M&KSHSZ%32.+?>
G+I/C@>~^C"IS%!HNJ*!P1_A(=\$E(O.NAM.6LDJ(Z#~^#I6@M M5-!>1K.K#;NSDI-?J&#E+D:E/GKWSU_L?J+3X!>
!ROFX!_!0AKOHQIY<~^!MXNC>3^Y6TN7U_E@!PQ_!8XK0ZS!JQ_RZFY,CW:%!4=(~^ME73?J0!HIZ2U!89%&632KK
R6+~^JF+GS_~^%~^~^PTL_82JL+~^!+&H/TM>:!X!_M/J^~^4HO#;Z^~^!4B!/^!<<G8NQ7>LH>/CE_~^O_&~^YJ;A)M?Y:~^
13^G~^M?2!67!H^~^@E8.M^!I9?&RCL_~^9G!BV_4HOC!7!%U?P^6YZZ_#R2*!>019B MQ<~^2RZ!~^!OXR-
Z&H!X!W?~^9!IRN!/~^8PNKXQ!N5WHYP.!5%K< MNW3TRR-KK:)IGDT8Z>OCSEFZ)H+&~^!3#2"LI9?
1SOD8!8#7?~^!TG.WL:F/U* MXCV>[A_~^!~^!5_-3=4/_~^6L03AW'ZEEP???@*8 M!L-0NYLZ/D?Z_EFL@S%'VM74(R.C!X?
%ANP:&?WR2&_~^JS%~^X+SHP: RDZ)3 MNTA!N4QXS3?5!W)1&0\$=1,YW_SB6P\$#0ZU\$!H/OA!5!D)+1+X!TM-P(6S+~^
MHEU%97#T_095(C7WSV-3#~^!RM)5AS_!A!9JQRVIG4XG;KA2S-"O!_A_@U=L MS_04N/#KH^~^~^Q?NW_Q!LN/&
!~^J'W-~^M6_-Z-QFI9<'WWX'6>~^#4+NS.CY+ M^OY9:(0Q2H5U2-CH^~^5.22IQD:~^!-
~^K%~^M!^~^SN_FDLQN#4Z;&P.O.B*9+~^!M%Q!QNF^8Y^6P!E7!?)SK)&9K.2>~^&?F^!~^?Q!FT0YJ?) M1)NKJAIQ?
JUC^~^~^Y_4HO#!H!+~^~^P34!JJ.3Y_~^?Q8#84R3=E7UR.#H^Y&Q
M(KL&I!H!TMBO#&LQ.#=ZL*K,Q&CY:>~^#UWC#~^RSUE#~^2(7=HC>?~^!>L!PT.M% M/8*C!X?%>NS"~^T2^~^!~^/C!T9E-
&NGC(^60^~^Q9X80%KI*4.2! MIO_!~^9#XKY'QJFWXY:=1C@^~^>75!~^Y_OO!70OW_WYGGPI2> 53 (M3NGXY.D!Y_%
AB3I%TY/3(T^~^GY8C,BNH=\$OCS3V*!~^4#(Z, M'LPL!RO:~^?AIXL3>X!W).&?X<2D)FEMT_CQDP"/1Z3H^~^XZ/MA,1V!7/3+
(XW! M(V~^&E&T*Z:7N8%\$U!;D!2F?7!~^6 3#~^#KM CBD#JL6_UHDE
M.&9(NV)Z9%ST_~^"8D%WCH\$!>~^>Q7AJ\$8G!8!&~^%F3G1+TH2:~^!~^?Q:F!@Y^6> M.N@Y)&FS!_WCF'~^#!~^G!B&CE?
%>S"~^T^~^!~^+3~^*F9D4\$~^!~^NRBT^~^!~^+K>~^M9DD\$~^!~^FIJ_Z'Y)+/7^~^<6R*X:&5IC+2.5SBB)H
MY_&RKSM9U0!LS4I5OFO#B_?E8!_O_AU!_>=WGY_US&H!~^!~^KW/L0#NY M)4E7U?G@&\$PI+2H_~^3L^~^?
Q388\$Z1=13TR+~^!>~^ONR:UCTRR_~^3VG1_#S;~^8CEWX^~^>61
MOA8:1F10/KM:ROCGGB_O+3^~^!LH21C:K1!7K02Z/G2GMS%ZD%)!IX\$7 M;L.GAZM<~^UNJ^VU^D6,!~^!~^LF-
2#JDGCV!@#>~^Z&#C:VI+ D&E!03TTL&8&NUI M:3@R(!~^T^6,+GN^O=0F&1,N_LHA/8>~^&L_AJY!_~^\$ UH&
<~^AF=>~^6E@?#>= M4>H0.(~^<#~^*!~^!~^POQT'=!AFWL.C'N65UO%~^H!~^*U)@Z;G\$6H%L_~^!H,IR M3
~^FM6C=CSJQHUC/SW8ZY@&~^>L!<7(P+~^H#-P?4S<~^0S>LY/4.> Y+GL(T!~^X8! M)JZL-
6S*HGEU%9>RSMN:0/@>~^#BM%Y5#SD_T4#XL7?1T=,Y~^*S&:D5*2/>@~^/* MY&~^~^C.Y>BQHU%U8!WO=*1.@5

=.A%U%3!033P9@5 MI:KJD:0!B17:A7YYI?7N2925S 9@V.A!ZO*#(1.1)>T0R* @9@Z&9E! M*J!H8! ^KF8.CF!R>
(<|R7/8!IX#0YUZUY8:F.0R:9U=6&2E!+|H@/R! L MBB&?
E:XRICG%UL6UCJHYZ.C8V=7(|\$NZ7^A(VXT*TN1@T&0JN3! MNW|H|_M_/+E!9!>?ON+Q: #JOYM?ZYB"> '!74M
9!P#8!L;>T.Z_BHZ/MG.0_&J&A7 M5(!A.X?%ANR:RKTRR!JOK^H^*DF"N@P.!1ZL*G...A8D)OZQH"4.1B4>3FI
M*MH MZ26:<R!>5!|A!&QT<.%909"!Z(D2LR G#D8G'DYJ0Q02E.\$UQ.0.=.#*J7 MJ0Q!#LB>PS;V"!CY2
+!7\$M!6H7P.@ +9E57&^OK#KMB&&BEJYONCKF)URO4 MS4"Q!ZP9F:##\$F5IQMS!|W@) XCR'=:R-ZSZ->
<7.^8@'IRC%'11/7T"B*2# M@:3=867HM+A0D4T8UZT*ZQ!1D/?#XL=*O>/)3_6PRZI*(|X|C.09'0P^&
MEIL*?;!|2,Q!W!H.W+8750YX#4.1C4>:VJ9_QS0A@&V!G50NS4^E!XH?T3% J!T.J_=:?
MGUGJKIY^_CYRI>_ /N7UGO>SJA!Q>K4C?@IUY%XE75;/GP#6P=#2|JR.#XN^M?
Q8#80R+=F7UR*SH^V&Q(KOF0K!|TJN/H0|C 9TT6%P+/1@5;F!T!<5^:G@ M==!0SLM59<3SFRJ^HT'S' SSO!5.Q
Z((.0.VR!T8""TMMXP)X..V!551D.' M*S3Q0VGD!T@T!6&>@4#@=@=0ZZ1'9FM7&IE>0Y9\$K!X,K_:=7=U20 MAU_?
J_?>XXIW4W^YV?3!>_K'2P.S="W^*ER>OX\$. V&EG8WE3'4!C+?%#B# MHEU-/3<^GY8;.BNF=
OC_3JK(N)+YE11H?|D="#366&0=|03\$6=&M X!|X M+S>5,<|O)% 0/4<#6\WM0S%#H@A0L:*1@*+2RWA!#AT\$;
!6HJ0Z+OSHJ# M\$ *:Z&"8:*6IC':^ZR:ORD/O'2.1&QJ9W8J'7'(7\$ "S' RS _S4L+&I^O'F M5SJ6H)_5SGAH0@!-
MVSPT,1Y:7FR\$(H&1;0GJ,2X:7')7P^LQN5B!/(1;1!1JA>"8=)/MR^M.# MO
XQ7V+*4#V3C!*=20W.%J4BWAZ24"Z3(92#5=K#|FY_ ^W; M#3W5CS6_RK\$ "X>#F)*|J20)O!HF
TVI>|H0:G%E(*F8SBTJZ=GYD 3:FO: M-@>:."@ "7\$T#IXC=A.J9#/6!GM.S M%)J00M.V"DT.A2;IVVA""\$V#\$.
!54X9#A!CF?DT&1P:*6F#*2^#RN_047L M3+!%=M:4F*U)K29L:Q*A6"9#+#^!1;UH6U#UHTVO<|3/%
!N2R*=5L^?_! MT+NH#*6JP#^FDRID*|@GIF^G2A!J9M Z")&0=Y*^0""TT#4Z 'FPJ_ LY M7\$F!S!*P)D,X+S?
5(9X)Q3.2XGDJH<8_&#HFT.FA@&K2XW3.F@&W8EE!0 M ZP)#&DT&AU:2RD#G.VY%7%*
(G4FWR,ZD)F9:4@CB\$!|L4R&6'Y.:MJ65/UH MTRL=^3.E@|N22+75|R>_93"!M#NIC**65RG&P1@+|4KJF0G0A-
_:MDV)F8" M=|#WVQ#":|J< 3U85&|Z|PWBO%Q4ACPWL0_HGLDPS^M)/0.A"2\$T
M:8;0Q\$H>;FA@Z9!!^TJ*J>A<|_D)X1!_32T4E3&.= /69Q,2@B=27?(S)F M9E-
2%NIG18B5R<#*SU^COFU!U8!VO!XQ _G@EB325?7"!6 7#"CM#BK#H6@ M(HTF8S" T*ZAG9D 3 FO:-@.:F!G02?
!0!T\$T#4Z!"@PJ_!YEBN)'ZTB;2:# M-B!U4&=":DS&=1Y0:=G_#_5+\$?9!A5#86!\$)Z!VY_!TR!]=/640M+|FL"<&
M@E9ZRO*F6%(70^% XDRZ0;VM""W3Y)\$.Q.Z93<|GV;|Y2?OC3QT_?W\$| M:C&H^M'F\$S!FH)S!|J0:;&FR*7)&
_M MJNF92=" \$JHJV38(F9A*TL\$&30-SH(>K'DS!3K+@|<|/3.9GGFY!H0Q?L.K MF\$,DSF00Y_6H=GV|L|
(MO\$H^O'A MJW2OWH! <^UJ!FG%WJ\$<%SO_YN38JZ!X_@80GL'=K4F3E%>D0.'0>0H!5-3+CH"G4*T
%Q\$V!P,VKV8U M.M YB?*(E+G:;%GY:K&_XYHG^_V_QS9/RSMN 00.=!_W):F08-%(XG4#
M&70T&+32508X4XU5_CW@A5!7R.ZP!F9W4JPBC8WHE*/AE'_|J^>| ^W!H|<.G MCXV?_CX!P^?
OWWWPYW77RWF53_N_)K*(2#&Y6B;JOG3P K87H=UX=8Z.C M NIHC(UVY?7.A.B(SCINFQ
=F0G1=)!MX7A&)P0/9A79C8T-?%&_!&9:./CH/3H0>3RLR%2M(.XO4!7.TI/R4QGY7%H6WU!@?HX&?EH/
MZAD!5%\$QVTB.C(B6E!R4)1!\$NWJ* @.C8X!5_ "P4870T8+025H8!EW#)HUF1 M/4=)30+&KF.*&7Q:BL!17(T!)
C5:ZTZ?<'ZU8Q*BP>=H:M=M-J=5L?
DZ(B8.AJ3HUUIH3.D.B*YCMN&1\$=F2!1(N8@!0R<=&|=\$#Z.5&1!_M5O:_?8LHG|AGI?3R@CH3B(LC(B@HX&@U|_
Z!D9'E-%QFXR.G(Q6EQPF9=|& MN|+* &GJ3:P_7T0A'0TAK:25L<|I>7W@=-^72<|TYJX86_R=(B(ACD:AOE;
M:J!50V TZL=373.!_3FMW"CIWL2/MS)!#1X_#KZ?UC)&..*3C-B,=&2.M+SE,RJ"2=J65L*QR5_!HI6.AI56TLHH
MZ/N=8A=2?J*\$CCI4=J:U,%N88I736O_B7HP!*_WJ'S0>)EU?SY_!L(U>ZX;LSZZ0HH;6"/R*RC,4G:=%=@S0Z,C
M8NRX;6AT9(G&)W'72T0_0=G1@_FE9D6?AD?@""25T-
"3T@9.1P33<1N8C@R85M8;>NDXZ*5=;674!WU\$V>41U33T5#32EL9
M#WV0L2B^7D.0'760!&QK978QA=#%5!6HFJ.AFBOUAY^|_ ^_WG!GG^|_N!OZ MJ6)9!0.KW5L03VY?
4D7V;G@'\$P4+6!K RU#J_*R*RC,4?5=4S(Z,C8NRX M;6!T9\$9&R!RK,7@P.CHC*CHG-LXC-!|AT-
!KV<5(9%4VKBFOJ4T=&0T>M_ M/<.E(W+IN(U+1X9+R_&6)!+T.J?D.F:ROROROVO"#32E 9#*T>%2_X.E9V
MIK0Q>Y>>QNB(SP2OW_9ISC4|_.:^8O_GXU>?MY@;?3#S;|R;\$ |N75)U!\$S M)X!L \$2UNZ;LY_6#\$-Q@!15TW/#
(N.2+!CMF'1D1D6+?|*4\$ _P5'1@S5E MAD3+3P.O!(!7DXI8Z(!1?F3:731T7#1ZRT!@Z4C8NFX#4M!DO+|A8D4\$J
M!6H!Z;U?UB,B2&FE9@R%EH_+|P=;OLK&EG!BOU)_TC:(Y&J*YE&MK3?7# MS:|S;\$ _N5M0Q!>S)Y 05"
<#5'MKFASCHQ:ZV2.C_4_)V9%)U08J=MDZ(3 M-
RDZD!E2D(YG09'18!%-3%#HE,4OVA+2*30:17FYH8\$MUSD_:5)%31R5#1 MRTE-
9ZAT0BJ=ME!IQ#*H(!234BETR"5JE0U;6_ZW*^AI^A\$X+I9(!IN:J) MH= A7U7^P^MXV(U;E7YZL-?
W.FGB?*\$HCD9HFK4K>|!C<-+W7DT2DDZV1G36G!8Z&?CD9?KD4
MVEI2_7#3*QPO=**#NY*2+JWG3P"#8.AI=TD94RTO*FR".3!5=(SDZ(3NNNT M;5)T8B9%ATN\$!
FA=|J<%3U84F9*M/PT!\$)O<.?EDCKX#*3%0M))1ACNKOP*|VNL.V9G1^'|_M#)*?|5ZR#;|<2MR:4?
UP!RL<+|QX!;DI_|J^1/ &AA6VIU1Q!#HA'HZ&4.C M71D!Q!ZH;%_V^9#)VX^=:7OL9
01.?!^="&64F0)?NCD9NGFYH(QV M#M1%+YM0!=""#/*_7!R#3LB@TS8&G3@&7>6/55%HT\$%
!;HI8Z%#R5^!M!6J M&!9:*2JCG\$.C!8:#"9ESTA6R,ZF)V8M42Y;_!O 2:ECE4M+6K!JFU_J&(-T M<"!2TE'U_
E@'0PG!6OS'0!<#_!W%2&.9,!1P5WB#4<3^N2W M;0B;DP&;UX_Z1CLG_UYFW9.C_:0<09';ES&N3.KJ_RZ)E2C.)
!9D3/R4#/M2E09SDSU?FDK!A:O_+HW=E:U;N!10HXD_N4A2TX&2Z8KUKN>G^&_KR^/&|J M'VYZK2-
R3O7D7B1:4_2_!0_NKC)46ERGR*23;2Z:U=4S(Z(38NJT:41T M8D9\$R!RK,7@2.C!J#*3H7;|EIV70(-PIS<5.8T-
FRBZHY&:IY;EGJ' MZIRV4>?\$4&?E%XDA&;3.KJ_RXKE\$>Z\$>%9ZRECF\$K0X0A8M<|!L3.G MC;E3\$I\$XE"/H
|_</330C_!&G^@&G%SH2Y!1. M!DC2_?3!"6 6#1/M!BDCI>7E@7\$PAD:|>GIF/G1"3)VVS8=.S'SH^TU#%#_T
M10"=|B=\$#S:5F0T=>Y%="E+F9%#FY:@RM/G^/8D;2%\$W)T.WKU?U#E.2)!3 M-O*
<&/*L+CEDSVF0;O"RN#G=#7YBW(\$T.D T\$!9&=J<*8FW.\$E(FY.NCYUI M!<R-DDC^M H0N)9U3SY
M!L0(TNZZT.FY:7JC8"&. M"NM9V9%)Y35:=NLZ,3,B@|BE.2\$%CH-SHH>#"LS M;I?76I71M2<#=#2\VM7.(?&
93V9DSME@SLM9S6?L9^>Z&0#=#2?QD/R. S@: EIN:;HL#VC/2)NS+HJ2?WIP5!*"TEY(@6? MB!M?BYJ?
CJKH! KCAK:IQN/EE704#FY/RCJDG^!AB>P=W29L2T+?;M8GLVYZ4STR)SEB!J
!8IT9F9\$EW\$R/AS?EP0!0183C.S'2!<12WCF%#5S-C3S M@8!9T3>1MZS@QZ5E8;=F20+MJRL#G+^|D-\$&
M9L_&*S5E5'.F!>O+C*HYZ^C86=/_%*).V4RBB3LR&3GS_Z?*=HWST^/_KM MET_W?|VAJ?I!Y!D;G MG'6&|
PK<7N4+G"!3\$;LG_VL_%S6^/?WH_!^_W&|*J'W%ZM2^SO^@ M+J6LR^KY\$|
Z&#;G56&48M_L6BHLS\$RVI75;L.A.VKKO&TZ=&:F0Z<8!&^X M,@+I/#@<>C"KS%CH=7QE3-
*YVO(Y^6!N1S!OF<#?F!7M4S'#HCA!L_!F M.+2ZVK F@QS:554&16MK#E#T-E"TE6&.|=(8E-1.V<=
(SN:FKB!D'Z.C6C M6;Z&6!^Z#<|_/'M^_?Q=0Q9:IQP.F5C@_Z!X/|E+*NJ^=/_@&@&EW41E&
M+5!XD!>G8U*!TJAGAD.G-9YVU#HS_V%CI>T&3.CCUL_V9G4S&Q0HB_\$.QX&V3Y_:FT.ZGZ M>=7.H8@'JR?
E5>/7!^6_9#3;N3REA!^!#XV!B'8E!F;|V9 M8= YB#IQH9#.@Z.@!XO*#(\$.4=XJ@M0Y&|1YN:@;78IRKAK\$S!G
S^M)D.2.B M<|%XE&U?_11FNZNW!!\$YT\$0!2HJQZ*+O\$\$.570V5+125.8!4R@2TLWHG:/
MD9U%+=S!D^1UC9=N@RRGZWKXZFD5/^!_ ^MU7BS75CS:_R+\$!Y>3N)_U6SY|
M1L'@TNZ;HA:7AL8!F.BM*NF9X8_9U36>=OPY!P.?Q9_9;BB!<#HY!&6.D.? M4Y8WBB!OS@907FXI-QE:1
89P7.VP-Z2!HZ(P*F!3T-FAH#JZ#RHH%TE M92QTZJ*3S6BALV&AE9(RRED!)*E!O=87L+&GE!B9%:9@&:UR-
JORN')Z^>_MWE?N+W=*?IV840U@!VL<U!/:DK25?7T!."4SH:4=J>4=|BGRKBZ6P.@G:E

ML,S,YXS\$.F^/^9R9F<|EB+L.D43GP:G/@S%EYCUWRN*K=;3-V;#RS%EK'+M1 V? D3MG@SNOU_2,@58=/B50_)=#:F0:N''>F:P/P/F%- FY.Y8R!<\$|S:&YYY.;>:WZ3Y1<=2)RS09S7|Z,>Y97&T9D4#V|8LK8YW*)WXD7M_ %L|JR2PNCFM6C!CSJOKU(/SW8 MZRLNSA*KJ|+H9-CE>X'G|PZ?|G<3|Q|??W_|3_6@FH<<7:A%|3.Y3JX M&ZGHDGK^!|*>P- l=2(4QTW2U|HN%T33Q9<|'8E|3|ZN:'M+MM&Q=F|+-T.MF2MHHQ|9FXO/=K2Y|D550-1=#- :|6M7|SH7N5JEH0.A<#.B|7M9S1 MSP7U<|FFGPNCG|7EAOBY#.)G3U4+OZ|S|7:1%?00!7#0"M9972S?EB|NO| MV-G5P&Q(JB0^X8)(N1A(^=|_EU7N9?R|S|7/6|)>G??:85?V(1L=2Q_ M;DDJN|JF>/P%,@^&DW5UE|+3|XN! 9"NY|Z909S06%=-MLU^+|LSLYW")^_P*M*|NMF=-,W%<,W+566<%2|ZNO^V%E58C8E M|>6)X-7:0,K/4:6GI? S^W>?WQCN:|A|P?J5C">C@Q|2B@^KY\$| T&\$:W53' M=-,B":KH8TZ%=33TS"+|@K2|:D\$79A|T\$6|R6H|'E|\$YT(- :929 AR2_9\$;3 M7 S3O)Q4AW\$N:.)R+89S7@WH&/A>\$SV4;?^X,?86&Y9DT#V|>LKH9W7|85_ M_ STE"- %;2MQ051<|'EL:GD=F:)(|S*LB3B|&3GWN:=O94/>#|0L<*Q(|MDX|J:=- /ET.7BTNZ<FA:6E%F:Y,^M*NG9T9|9%X359=LHZ,*@D|BG|'"M\$+H.3H(>|'"DS YKD?8<%17,Q1/- R3QW"N:|P+H9P7N I&?9RY.Q9 M6VQ8DD^U|H8Y 5)8=|>RSTE-&5-MXKMB=,U%9|?GB;N;DGBYOJ"-KD8 M- OFHR\$| />QQM:JA|L>I\$C?@"&=MM6%&|L&S*Z8,>U;7+KG8KAG|:: M:*.0HK3/MZ|I+CHY=N:T,|N3VB6^3RYX|2|ZQ?LYIT|.|3RLQ_ BG*SP20^89G7BXJXYO#?<\$0GQNF#".ZU\$|XYX+ MNN>RS3T7QCUC"P|H*8B:BVZ| MG5&MS.ZD3_|'|@B4BP&4GS_SK2|SLKP@:BX&E|N*H=C"&C02/RD M%1%T&430KIPR%#JU)08-*70Q*+22508YWR|XQ)|@C<7^08@G9R:Y+N|N=-/-.@4&EW51E+?8!70QYD.|JGIF M%1!8EVVC8(NS^CHW,37JNBBR^@Z,&H.B.@0Y!2OB-P+@9P7HXJ YZ#K+0 M|>#/'|18R#|NB@RS871@K2TWK.F@A'8UE?0|WM&|94<NAB>&BEJ8QT MOE_|B|L4#H72(4F|J9W4GRWBS\$RL7 RL|D)S0|?7|Z|Z.WCCQMZ|A|O2IEC M|? K)O4DZK9X|@8IEK/S("NZ*SKMAG0E9L MW:4+7\$4670=G0(UM#+3GZDISR3A.SF|ZDRWCF(XSD|N=J:~? EGM8S|+HB M@:|'1E"+2VW"H^B?V|DRI#H>-U2?N\$*DKH:DAHN:>5,,G|!'G*Z6LAG;U|P0Z(J^NFX; EV9(=|=#M#RD#G^|(C7G?1.E?#.|J7|0R K@B@ZS8 M71D 7:|X+ E@_I9551.05|!|BZ(H.N|H-6DLH 9H:E=X;5B3.51?(S|82 MLT4I-W&G0\$6G7 VG3|33P| |^>HVV|>W PLNW&|J'W|ZM2-KG1PFU+5 M5?7|"6-? #GM#JMC.G1%/%V-Z="NL)X9!%W16=-M@Z K.PB:\$A5|V-%5T' M)T\$/H69=U|V=|5?3-U?#- RVEE0..E.4+|!::K;3T#H2M"Z+H-0E<&M0M|KKHE500I=-RFTJZX+GA B>JP&> MEP/+ .BOB""K@:#7 WM&1E>4T76;C*Z8Q*82Q)DL%6UT;31KL R0CKD M4+K|C+ NAI%6 LOHYSNPC<27&DB@J|Z4G8%- S:;E^PULR|S")FK 9F2E0T| M /OOGS^|NWG+T#WY8+|QIS2LUC%|+|O4M5A|S)X"A,#"UN|,L18+B|ZZ M&G.C784|,R*Z(L.NVT9\$5V9\$-%U% *P.|70='|S|&%AF.'2MXFC-B@BZ&@AZ MN:|.%%T115<#1:~W|8R4KBBEVS8I73DIK:TV#H@E7:EE0'3ZIK#JAA>6@DK M(Z%|96|H61%#5|T| L:N:~%OXB:|B|'Y&J#Y.KQ'U'1^MV?_WS_ |QNJH|IT M? K5C"- +'4Q5%|C3)X"HNA|HVEU5AE|+~%SIDUM48>V|ZIDIT;5@1P=\$4L M7;=AZN9J>&.*3S||=W|H|QX_O_GYO9PWW&|)..3T4D<@7>O)/4RZOIX_0R# M:(K=166;FGC(<6U6I%\$%T- \$+T>U#~*NJ*2KMNA=&64M+S6,"2#1-J54P9* M|JR' 4:T(|L|I96<,@1:/2|>|G6B|,Q|8T>_B::M(F2N|F1^? H|Z?_7'G|~ M^SY_H2T9%|D-K'65T;2>W+NGL>OX\$.L&I7:WE'6XALZN|JC)|V|?3,MM.B""+MNFQ9=F6G1) (Y;|TB|FZ^"TZ,&B.G.B8PKR|Q|>|@W|O%Q4AX6N:~&K M8:'7@WH&2% <\$TG4;D*X,D%86&P+L.@BD74EEF+2VY)|5X)*TEE '24|P)1 M44|7'2@|D|J9W4JABZ|443%70S%3Z>GA9Q^>? ST^>E;U_8K&F^N'FESDV MH) &15?TUV7;L.C*#(M,|Y# M.%T'QT4|UI09%|U(?!?84#XW0SZOUK0Q\$OI*- (>R888NAD8>CFH|8R0:BBD MVS8AW1@A34GZB+6AD&Z#0MH3U,8X:775)7P^L N3&B>@4Y9V134DT\$T7RKZ@ M_O1@K|C5NF:V9_Q-X.Q4Z|QX5->? ST>%^UX-J^Y^F5<|8|DIHNKN=/MH.\$)|- V6U|A;+2^CD|DW|:D=F9.=\$_W:~B6Z:=\$_O70;G|JEM/&3(@. M='7YJ>#EWI#/RSUE)+3RS+ :|H5>K^D9|W01H=M|KHQ|EK^/6)%|G6TJZ6, MD;Y*~DZ?VBDVF&DE9@R^ED+|+|Q=9WLK&G@- B4%|2:E#0US, PSSG(=,T?Z Z MX>:7.48@-R/U'1N/7T""B;(;C=.65|TZ,<#&Z G|(|R|:FB@VS8#W1@#~+2|VS,B@? W;EE%0|Y+KTL:@ MA@JZ&0L:R2GCF 7#XA5?Y?G'9F/U+XC3RADBY&4B9|D= ^=-/CX|?_O;N M? L=0=4/+.W2D3RW=' W4M,H?P)8!<(>T.JF-J=\$,RW8RIT:Z@GAD0W=15 MMVT#HALS(+J(XKXA@FZ# Z(CD|J,AGZZ LM_WGC--SCSE7/N.>&|KEM<| ^<< BW9;JN=3|M#NKC0G1#-J:A@FZ#HZ(' ML|H,B4|WZW? Q@HN>N|F>>3FKC&|^\$U,6WUR@<6Z&<5|ZAGXW H6I&S|HJ\$X M/DQ"|MP&V:KJAO^OI^AM.6VH7YNAGY6JLJX9OVP>-G7Z;&S|H79F%3E.S.V M|K_ |W5>|>JNH'G%_IVOR MF17=T%:W:~B&S,KNHBCB1M*Z#8X*GJ|JLR0"(2(4#0TJ,TFQ<5<8XOZ%: MY=|3UL|PSNM5/8.?&^+GM@T_- P=|&HB?YR|^E65(=,T?Z Z MX>:7.48@-R/U'1N/7T""B;(;C=.65|TZ,<#&Z G|(|R|:FB@VS8#W1@#~+2|VS,B@? F| MJN|94=\$ A77;B|Z:~BVR7^3&~H.3H>KRLR(M#J|TU>T@RN9FR;E|C+2^4UH,K5|P, |Q>U3.\$NB&|ML(=&(M/Q'BC49 M|-"NJC(.M3|GUM0A@5PT\$K566\$LWY80.SK"-E9U<;=-ZDG|1-@L.K-H,IW M5?/>JNH'G%(H2)|/E327?5|R> <3"LM+NJC* 6_V"13S=C@+2KJF=F13=4 MUFW;K.C&S(KN4227Z^+X*SHP:HR4Z+3=;^V\$Y|*70_X;Q<548|OXE1G+G9 M4#TW0SV05_4.A6Y(H=LV"MT8"BW_D6)-|B&TJZH,AW|ZZE?Z ^CHH;OAH>6J M=D8ZZX<->-B-VY5^>K|7* |N0^&E51Z<#;|5|5LK|Q|P-F5WM\$ _|O@=J6N MX^KY\$TAX GNW*W6&44M_L|T=3?&2'NJVL|C.Y(K? NYB=&=F1@MCP7OB^|MX,3HL;IV:E9T2^)|V18|N1Q;>|6JG6'3Y^3R8NKXY,IO%VIG_'03UTW^A MN|_#=#_30? =|>#>ZK;4+<7^G8@G|PMU+7E27|"6<##G MKBK|C>4_6 R\$.4K; M5=4S4Z;|BNN^;6|T9Z9&%Y%|=S32? 7|H|&5N7G1)8G3'#M|JYVYHY^6JLE.E MQ=|2^N=N^..?UHY|T1U1=- ^&HKL#17=\$T7T01;N:RM|HJJ2L.4R*0_.5IC+H M63|L7O1UENQL*G\$CWN19RAWQX=\$=>73?QJ|PZ/E? V2,R2".=B65(=(YB|M?.PKI;@A):F, M?5;/BM=|728|DYJ824|Y|^T2|WPR_?2=V|^|F1;N2>F8P=\$XW<- AN|8.@F|O>.4+H/SH4>3"HS M\$3K\$DL1W#\$B>NT&>EYO*\$_.@WU.1OP)!|=X-|KS?UC(WN:*4-AO=&|LM_Y%B M309EM*NIC(|.H8A#7#OZZ&|X:"6J|C'S6#XN7?1TF.ZM:N#%O5Q)?+1:|A=S MGU|K|NJG#4'5CS6|JR- %"|JW)RBY(K>=|+M@V&EW4|V3HCMJZF,Y,BG8%|BF#GH4<1)6 M1_<#? ^|GM,S*+HGBN|4|G4+3X)XHDN@^2%;=&1B=HWA?S(XNNALN6JDI M(X|5H^(E7? (SIA69G2M2^*R1K3<#;1M|10:ZE^K/D5C@6H)S4<=3R|RIFP1@2|6K|F7G0'5UWS8/NC/SH&.0<\$A'&=T')T(|MI29 M|9U:~%N*Q+D;Q'FYI0QY?E/%&YYW5_=-4_K+3U#H3M2Z+Z-0G>&0HM_H@BA M^R"\$=K64X= Y50&5)&KH;FAH|:6.OCZOT|WC|^/SO|9^~W9!4_9#S"QU#T\$|N2|D|M|P)8|D,+NU.JF=-,\$= MW8TQT.ZDGI|D(W9%9|VT3H3LS\$5K|E2&*|H|SH>#RDR"EH&7NP-VKQ<4X8Z M|W|T%E_/W+D:W'DHV<,\$<#W;<9Z,X8:/D?&4,R**|=64#*=-/|O?A#Y>-NWQ>.GSP_12CY MRX:FZ>=7^U8@GYR6Y(NJR=/(%V I9_P|FOCS>P|_M_|G|BV;4DOC|7| M%T?X?#>|7AYIT%>W6.C"2^; |H|^B8W;DEX>|=772E#N|L+O^T_X3(YN2WY M_-)|T*X:71WK5%.4W6?%);-^7|~8K|80 M* (NXX=-9W);T|K|L_0UJ\$<8NW#>|:C|MB6|C-K=2W=P21=;=|E.^WZ?F MAY|NG.S? _X|9M>OC#;Y>".AUO>ID'S\$ XMRGIY<WGP|VP7#2|J R>EH, M:L V&..B74\$|A?Z?E@LR*ZYT"^/-/8KPU |SH4>S"DS\$51^&GBI-TSS|'M.C^/E^6 S'+OS||DBO/O 4|G7=/XP9&3/KI8R OK^ MEY4&Y*2+,">&@%9JRMFAF=4\$170%U?S,*3|D7*2Y@'?X^7;H,H_ ^&WHN; M^O"+;|H^>?+VP|>/? WTHH;GZ:~7.Y\$)Z-R^D<^WWX" F;#2;N:RNA|&0|/BR79-1SZY9%>|Z|57Z82%F-P|/1@5;G|T?;K|?70<- MV;Q<5D8Z4Q.V<P_C3DPK/-Z5X| Z'1%3,@N /WR2/(K+6)0!@&T*ZP,@PY7 MD?3(?8%<-

!%V%EA'XJG0KK00G!%0 V1G6"-WZR3ICJ3WC^/EVU##3UT-MU^:NZL><7^U8@WANC1++@V1
/\$VF/)S5&1&=KHP)V34B^N617GT:=65AR31X1B+ MP2'1@TUEOD/G) WIN^!<+ H&:FY.ZCAVOG!60V!@Y 6D'A'0H-
B/'8)Z)= 'M&EYMV)! NUJ*^AU36'23\$2:02P%71F/+5.0SVU2>GGPW2=0L V&E'9'E'3 MXE(MF=C:K0KJD<&1-
1/BQ\$IV1XY%.:=@WR5*QB,P1'1@TUEAD.'+T1Z'YQ MO.H:OGFYJ8QW^EG^+=@ "PSRO)15(P1Z?E@,R"X'?) (H^L-
>S+HH%U5931T M#-+1\$>1?QZP8&EJ!N<8R5BEYD%+ HZ0W96M7 W3TH=? "85KJX&5LZYWUGJ
M1/W11>7'475#S>ISBMVH)I@Z1 MI/L/WS^(3#D\W12CW#H^V&Q'KLXL LCO5YP\B4<8S+(H5U)95!T:'1_I=BP
M*8:*5IK*>.20H!)A\7KONZ1G5%MS%ZE6N1+0.,+N*6;3#8M#NJ#*:6%P?VP1@8I8KJD=G0H-B17-
AGYYT'E,/>.AT=:S' M+@_HDB#ZZUC2P9%M^NIC(L.*61Q(VI'!@V6FDJHYX#JM*=B^Z?Q\N^CI*= M3>W-
J5-J.AZL>UVZ#++N=#6INJFU I60^C'1KJ8>F0QI/RQ&9=-DZ)='>OW9EUB+CK48G THV%1F*G3))#4UH'.. MAG-
>6I@W#-U4UT0/H<#JW-1PQD,'1!AFX<.C(>6UUM #QT&2GJ8%1 MT3U)\WN'T_X2&W* 7&_>/@f8H&
<>7^<5S^G@%J6@_OY\$VAX GNW* 7&4DM)00BI@S\$K MVI/4<0L= KHK<.NL=
OC_2GTOWS:J_!&LQ:JEZK*F1F0F=9=<0D#H^SHO M-15/GP2YV#0Y 6@GO'0 3UTV::A ^AU=6&+1DDT:ZB,C!77-
8%_&*T5E MU'.IXEOC@.vYZ":96=3;,%&*67P9BW Y&#Y.:CAX==/ R(2/ST94-212/
M+W4,03BX02GHSCKZ!)!X.NY/*&KORH>8.ABCHEU)/3(5^GY83,BNJ= O MC_3J#5B5/COZ_SCV8G
PI&12F9'0IYL(^14S4N=@4.?EIC+T6?SD-Z!H9I M7H J&1=\$\$2:2 Z,":6I3_D3\$G@R+:%57>12NK#K-
BN&BEJHGX2QJ"7KY: MX752)G.K!\$S1RE)D^920+<#>?1&EH:U;U(TXO=H30(1H%N:1Q(A.@W.A!ZO* M383N)-
XH+B!T#@9T7JZI SX'A,!@_K43VCH0-JZ+!-0P=&0VNK#5LRJ*%= M365,M+KFT\$0'PT0K366T<^Z5Q)2A>
XZ2'8V-3%;E\$+OXMI&MAP.MEPH/ SV M!>=O-
TD.XW#3*QT1=\$@MR@%75C/GP^P4#3H(RE%I>!'@'8U*TIJA'AD+? M#XL%V344^N617GV\$W\A3HZ#
(Z%BBJ.Q#Z_B-JTDI@.XY&:YYN:B:>^Z7 M_"\$9TN=@T.TUJ)IQT \$!=-
CFH0/CH94%AOPZ#)H5U09%\$TQ)O%#""%31P5#1
M2E09/TP17M)VXX#F.>@DV1G5S.O1"E<3\,14"X'0RX7*ENKJAIN?JEC"-+! M34I-!;S)X)Q;-
RTNZJIA:KBI0Z&+.B754I.A;Z?EBLR*ZQT"/.I.K/^Q+O M"AC01X?R="665F0F>2W\0@= X&=%ZN*@.?
870P8+2258X\1Y+&PMP CQ=^G20I MLUJXC4J1Y\10(G<+E0W5I5_7\$S2QU:4\$IN4)*J2P)8!P,^VN*J.IY<6! M?
3!&1KNJ>F0Z=H(KL.NZ= OC_3Z2Z5+?F.1CH.#H@>K"HS&CK(VR'1.@?# M.BI'E;/O8D?
UJ%#H9^7F J&1=(D\$2';20Z,"3Z;IB\$-P*Z#!HHEU-961T MN(JZK HAHQ6DLJ89I!-
>)1!&OBY1G42NS4.D4I9J);#D8;+E0VQ14_7#S MZQPS4\$ N4M*%J20)O.H.HV1Y6AU.+B0\$8=C+G1KJ>&1%I/RP69-
>(Z)= 'M>LU\$FOQ:PU@.3HD>#"HS'VH&F34@= X&=%XN*^:8Q'Q>A10!>#JIG10R(
M#@BBPS80'1@0K2XXC.F@B'8EE7'1X6I17G<8%0-&*TUER'.(31SX%M\!YTD M.Z/N&U*67Y1@7 Y&""YQ&MK5?
7#32IU9-"AGIRDI!OK^1/ !ALVEU5!E.+ M?ZX(J8,Q/MI5U2.3HN^'Q8KLF3\HDBOMXV(T\$AD Z#LZ(HH\B6Y)- (2
MH7.PH/R4QG X\$6A'Y ^\X ^KR?UC(<Z*# @!&= &J=DOBM.7KH..BA745E M5/3)E5: 80JF@P5+0>5&+P-X=2L1
:BFGA(J:C*G1GIS2F0'1A:: MM@V(YFY=)' HBH^B9TIE(@9#1WB)5_&CZ3LON4B)T@7:6@(\$L)G,N#SHQ)!HDB\$)
(8DF@T0K066P,14D;4BI.ZD M+"HS(+H6^2J#R)D. MY+Q<5&Z*=?;R*!I)L.IKQ?U#(8FQ-
"T#4,3@Z&51886F@8MM*NHG(@.).XC M(1319(AH):F.=;Z/GI63.B=2=? (Sj82LS)-)UJ?
P)8!H...UN*L.HQ:8BH29C;+2KJ6K>L9"\$UHH MYF:AB;/0VHK#G QB:=%6&1(=6LK2?
BE"\$DT&B5:RRF!GBDV\U0HA>";=(SNS M&ID-
2CV1I)D\H5HF0RV7F+9F53 <_%+'&2#Y1(!;3)X!FF@PS|SRLV0INL2/_1% \$P&?EIOZAD132BB:9N()D9\$JTL>S)
(HEU=96 TU2!N MZ2:\$T63_*6K#F.X;K\$MZMHGDDGR:FJ#Q.XHUJ">DS&?1YO:EG/#2AAZ9M
M'IH8#UWDE""ID\$.14HJ@Z*_ \$853309)EH)*J.=@SSGB%IDXZ1G3TMS!ZE M)&X9HX)7(J)?N:F7K335.-[T,D?
_3.7D)B4=5!^? %;!+NG#**6KP@HZ F M8VJT*Z=GID03.FO:-B".F
_1J\,0S\$X'GHPIQ@:/EIX*7>T.W+*66T%Z/Z1D&3,T0A=-@.A!X/*C86^ MNOPM&PIG,H3S!:_M-
_<Y.I=EZLU CB/+6/03FY2TFWU M_E@0PNJ3FL#K^*JXNM\1\,IKY?U#(.B*^C@P=&0RM
M+SELBR""=K650=&A)M\$=(1V31T6#12ELY)Q(WG.+Y#GJ(MG9ULYN4Q(CCVPY
M&FSY2UK.PV ^/'E00#SNZX:XJH?0%".DT&G?&E1A0 M+5W^#"4U&=.C/7&E.X.B"=\$U;1L43Q?Y,2L39:6W-
MGI#L)B7BV'.2O\LD=,^DLV1?57JZL+=W)Q3G&A#:93+L0=&\$*)JVH6AB4'0@12-70A5-@RK:553.1@?QIEV\$-
H.H&ZT\$E5'/+4=Q M0:%Z)ATE.WL:F4U*19+_H\$ "Z3_9=OH:MP55/I;T*D<%32'@#B72B?71"6_7
M#7M#BICJ<4+;CJL9&NX)Z9D(TH:;F.1.BB9D0>Z_1L72&J9B<\$+T8%"9 MV=
O!S+\$9X+7>T.Z+P>5&R!>Q'W1A/B9#/R\ M0S(H01-V\$4V.B-86'(H M&A31KJ R+CK+M.D9-%DL&@EJ QXKD&
<('\$@GDGWR.Z@\$G3RHR&OM\RA\ (7.F@SDO-Y5A MSS%W\$;<2TF6EEQR*%ID\$.IFLJ@:HQ2UF\$J)H
M"E\$T\$E6&U_Q)UYA-R9=(WLK&IB-BJ\$*XY) MDX&6? OOUWU2#U_Y=.= MS U9U0\WOJ0Q;NG@-B72>?7!"6
=##"MSBKCL6LHJ\$F8VZT*ZMG1D030FO: M-B*:F'1,3;Y-84XF@:'1 ^&E1D"4HIX@=BR)S)8,
I+8678LW*O=4+Y3(9) M7N J&0Y-R*%I&X/-+W;L M03ZX1XET93U\ DBGR:#3IK(RH%I!>."F)F-
VM*NL9!9\$4!&E&UO'PJW1TE\ M2:&2IL\$IT8=>9>9#IWJ)QNO.YI/G9>SZN#/A/R9#/Z\WM0S)IK01-V\$TV,
MB=86&Y9D4\$6IBLK8:"784\JT\$E87)ZA@Z9=:;L!&EA-B@1B1=H%TF
MPRI_E-//S(N>)NJ'VUZE2.%IGIRBY+NK.=/)M@T&EW3!E0+5IT\$%.3,33: M%=_S1Z\$)R35MFPI-
W'QH<1P.H9&FP?0@S%E!D/72QO438B=R<#.RS%EV!0 M;15#R)X_K.3UCH@E-
&TST<2:"FY84@&3:0KIXR.KD&+H5LEPRU_R6G=EE/I-.K'!\$TM9;E'1A M/7!"6_4#3;MSRE!J:?
(J.D8&W*Z9G9T(38FG-AB9F-G3HXMLM*P.T\JZ M.#2,4.ATB4.J'9\$S&:A@Z9!
M!^V*:.AM26')H.#W\$E&'+S>*\$8^5WQ=(3MCVIF123&*?R4B52:##K_ \$ M_00*_GY ?LIVY/T0XO=>Q /IDJ27?
5IR> 83"HM+NH#*"67Q18!V>M*NH M9T9#\$QIKVC8:FIC1T*\$J+ROLO>!LZ,&D.E.AY7L))3-R9#-JT5-#NF<4#HG
M0SHO%\$6=X<!)^7:QA3PY^5Q9;0/Z=!)^Q):F(4M+;D\$CZ=V8U)B=-,8L= M3PB?
GL:1/2)"9%R.I#REI>GM+6HOB'GEWK%TSJX,RGHGK^ M!J>P-Z=28G!T)*!2A\$INU,2F=F0R?
TU6G::C\$S(CF5,27%;KH.#@<>JRH MB1D+G:A D?>G S>O)Q4;GBT>*;>A. Y&>Y/Y:IG%1"!19VV*>C\$*&AU06%/
M!A6T*ZJNH^_/CIAJ:YJYQZ5B"<'!4M)5!20)H)1.A1V-Y7QT^Z
M13R=C)'1KJ>F0Z=D%BG:=.A\$S.=.I0@OJ@01J?I!="#364'0Q?Q5MX)B7.R MB/-
R5!GRW)/T151"DP.I+P>U3,2J&3MLD=.(DM+@.">#\$MH55<9#A M= MH_QOBUD00+1258XZW18M
W)\W+P>5!<YBO+2P@P8 MY'FJH<<=<=(C;8YZ.OX.&V184@&'0KJ(R&IDTT6PDQ=#(PM-)3ACF'2YI3 MFI
Y)UTA.WN:N %ON8I_4*!53H95SK7NZZE^K.E5CNPYI8-DY)NJN=/+@ M,&EW3OD\+5IT\$XG8TZTJZ=G1D(GU-
5IVTCHQ(V\$%G>+)/30:7 B!&1/F5G0 MM8N;+A/YF3_YN6>,M Y=C\$B5T+KG SKO-13,P Z(8!VP:T8@ "TLMZ0/Z=!
M_NSJ*8>@KRI:D80(GAD(6@DJQYL#D:C.T3#>L8HX+I*^N^8RA_Q)EQ:%
13H/NV1541C^'XLS:1+RYV3P9R6H#&Q6 M.XZX>GVV!G4PFQ/NI>40+;Q^FT(Y5SIOJ#JOYI?YIB:F8F=\$)7G;-
A\$1,3.@>7^"00J?J="067F05,) MAC//ZHUAFI="RACG\$*XT4'FG SFO!14_8YH7U.V^Q\$XNRSLMXP)(VY154
M1D')GK.A(Z&O):Z2ECF_E3E1(B)N3!H^=-;W.OJ18Q+M.)!3*R1#*N87! M0OGQSW^Y7WK?75WZ?
I#5G5CSF V#\$&I>3>)U43Y! *NED&EW5ADI+685
MX70RAD6/LGIF+G1"7YVV585.S\$SH*N1401*!N="V:5F0C=@C@M-%M3H9M
M7LXJ8YU?IG2(SPUC8#G!R>.=)#73:9J 38Z"UI89!&330KJPR\$CK\$(MZ\$ M_"&%3@:%5KK*(.=)-
XZ*B'T3KI#>H:U.3N3OX\$1 ^&F'.E7'4XDL\$74R9D6!PGIF+1".YVVC85.S\$AH M\$1=7)I31:7
HJ&18F7'0%.4K'!+G9!#GY: RY#DF>;J"=5S.M3S>EC/4.B\$ M%#IMHJ)H=1\$XOM#E-I4\$*

!PLIXZ%\$Sf8(9070V0+3.D2-HG).09(.OEVOI^U3CFI&+B*#S=7"C4M.%I2P)#!MO1N5LF-4=\$9)G8U1T9ZLYC-
3H3."ZIQM*G1FID*3>"/C#PZ#TZ%LMJYN9!M5_\$^1F=AQ3\$&3ETM^N30GJQF!D7?2\Q)
IQLSHNALH&@EJPQWIBQN*#LKHG;./D9U9#=-R(-Q*?F(CMEK.IEF.C.O://(XLND);@JH?;7Z98P;"P8U*6=25\|R>
73\$#M#NHC*,6@XJ(CM.ANCHEU!|3.5J.USMNF0F=F*K3|*!-0#(Z\$^LPI,PQ;?|KHF|AFY=;RGAGMJB6+|RG0/&?
?/*-JRS\$@BAIS8(G3D(+?I)A PZ\$S)H5TL9#W-RR;OCTG\$MT-GT\$&>.;L+RBI\XNL.V5G3R-
U"B5J2/G-)R)6SP95SBP___/C^>..F.K'MFEFF(X<)-2UE7U_E@\$PPH|8XIPZ?
E2S*6P1@3|8KIF8G0&8%UWC81.G.3MH4L17|K(HO/@1.C|GC*SH\$L5Q7U&WYP-WIR<5.8|4Q6_ZLU(GK-
!GM>+>L9!M9W30>9N#SHR#K6+4.(G0D<8B3Q|2V=E48G8JW>|(Q'>HZ)6SX970=
H|7U/U@|TO="P!-=RAE'58/7T"B*6S_M@;7=364(M;A(D4|G8T|T|ZEGE|D)G|1-9YVT#HS-R\$#EEY;..SH.CH0>CR@R#
M#B5V|3XN&9E5-ICS.5)1%MAT\$9%-&NL#(N.K1TB?=-R"BCLR&CE;)RYOFJ15E5>/W74.(SK8G9JM13D/^|
M1KN<#;MMS7O;ZM^L.GC@XZYX;E+*.K.=/!-AN&EW6QE+;Y>45)G8U*T MJZUGAD)G|1-9YVU#HS
R^EGJEF(O!@="765&03BHW+|K|Z+1M/F?#J|7|0R(S@BB|S80G1D0+7|0B1XZ#WH5TX9?<
VB|J3G@RHZ&RLB2GC MC;7EA-XYZQS9F=-";\$*B<2/8-I>MXM^W;Y+60;55#_8|")-W+R7U)NJZ>
M/P\$,@&@FW25US(?..2*BS.1_5=(SHZ_S0NN;11T9D9|R|RS.3@(.C|DC(CMH.6G@1=Z0S@OEY01S^\$B|4;O&=5S-
M3S>DK/4.B.%#IOH|'9H=#RFR"4T'E0M0KM2RGCH<\$7Q9DX9070V0+324HXZ;PL*K7/6*;(SH79E\$27>(N5C&
Y&V#Y MCFG=%U/|8/+|+03^Y)TF7U_E@\$PPM|8X|8ZC%2S("ZFQ.AW;%|P@Z(S;
M.F;|)V90=#RKPO#_3@&>C"FS_IH6F@;|Z&:UZ.*>.<0XQ=?N"UCD;UGD|MIF<=\$8G;"&SH_VE53AD&'>.GOS-
!|9|!\$S5EA+.^HO"2 MKPMD9TT;LRF)+O%>RQF=U3/Z;.-^SMOT#_MG5
M549|OWQ7^25A2U+025D8XAQ;)|17+|Z07.6M3;DYJV|1&EO8\$^C+I8CH;U|+8TYT03E=C#G1GK26.R.A"_KJ
MLFTD=%&0E.HE_3VH2""+H.SH7|VH*K^#3V|TLJ#(.VK|MP^B-FY)^>K"WVWZ1V^1>
3+D83/G+/'*VK;K&X;.:7.J+G\$@|N2BJZD)X_M
8R#H:3=567LM'A11CA=C\$'1KJJ>F0E=D%>7;3.A"S.3.B7Y%86Y&|P)/=A4_M9AAT;)VZ_^(5WT#-R|7E<'.|YML:6-
F0>|<#_.^|GM4S"+H@|B|;\$1A\$+2V MXK F@PS;%54&0X=^=?&."P5%=%#\$M)5QCJ'T3UCMBYZ!;9V=7(|%J.8M-
MZ*|8+H98INN|HU/X|GYPX;JZ@>;7NG(GTL|N\$.IZ+9Z_@0P#@;7=E>50=2Y
MB*X"AKJ8@R+=H7US%SH@M'Z;)|L+79BYTJ7/5Y=|F<"SU85F8B=._B9.:"
MSKD8SGFYJJS8;|V|07E'0D4A<|BARR""=G65M0=\$IRU<-1-'0-%*51GN'.ZLBB|*07/1;.(S|J3=|JF*
UP+HN5BH.67-ZM\$M^|*JYV^I6.)Z.;|>+SZOD3P*088MJ=5<91BW_IH;\$NOKAH5U//3(8N**W+
MMLG0A9D;.*XZ;\$@CRZ#HZZ\$FHLA0Z|Q/LJ#(3.Q8#-RUJ@UP>|"|+D8|D|M|J6-3"LM+NIC**6KWQ8|V-
DM*N|9Z9#%Q369=MTZ;).AZ|B35<+JN@R.|UZ_M.*G.7.A8Q<\$O!7ES.7CSNA@>6@DJ(YTIB_J"DKGHD-
D9T|SLTM)O-M\$0;Q<M#*S);=Q8T|UX|TOBR>OH\$4\$L70TN|<|H8:C&G"*B+;3#;E=,S MLZ%+P7Z4;>|9"O.>01Y?
5M|&E|AT(|9<9"YW")U4+D7_SDO-Q3|CU3%;|O_M0Q9<#|A|M0S*KJ@A2L;+1A++2ZWK
E@QS:550&1>|S)!%WJR2U*NK">M/P\$|@X&FW4EE*+6X3)%1%V-DM"N|9Z9#%|369=MTZ;).AXY!%Q64\$B7P?0
M@TEE|D_|JXN^H*|U+H9U7FXJ8Y^C>.|NZ@OJY&|YO.EG2'1!\$EVVD>C"D&AU MP6%-
|E6TJZF.C0XAB;|/"OKH80AH)|J M+H9>?JEJN*9653_>|%)#%W:R2U*NK2>/P&.@X&GW55E2+585>34Q9@8|KJ
MF?_0!=%UV38;BCHM8 M>R30Q2#0ZTD|XZ(+NNBRS447QD5W<918015=|E6TJZF.C8Z70#D/970Q9+02
M5.8|TQ7\$ORO0!/!>=)#M|VKF|25F|8D;+H9;N)HXL|WC_V3QX5?W^OYV M0U3U@|XO=DQ!|E!26?6|R>
;3#@M#NJ#*>6EPCVP9@6|8KJF<'0;|EUV388 MNC"#H96/H9|(|E'|T(-1949"T_T/*CR3BM:Y&M9Y-
;J5L<_B)V05|7.UV/R M5.L9\$5U11=-M(KHR(EI>;14|=|WTT)ZH5D9%4^W2N|2**KH:*EJ;F6|H_N_MHWC4C\$?
=N#GHP?|FZA*2U_41.Q50.M2HHHV|14XZ|QBKWAB|W5&QPM?OY;D3|7@S^O=_6.B.YHHN|V\$UT9\$QURD^5
MF)1!%;T**T>C(T7Y"6%;#!FME)4SS|3\$|;85T7/53;(SK8'9IU1\$?5T1+E<#
M+M|J_7K|^U7CH/K'8.0#NY6|KJTG CX|M-/5L-/NM#*B6DPK8N|J3(YV|?7.MD.B*Y+IN&Q)=F2'17=P 6)%U|IT8-
E9>9#QR)NB;SHG:OAG9?#ROCG(+|A M1?Y<#?Z^M8S)KJBB;|3'1E3+2VW+G@R3;U54&1L<6Q;_F\$97_T8K667(
M|14<|K>|YNLDV5G5R.U.22PXN);KH9;SHT>?O;|5|H_X;D-0|>--KW-4 MT|4.
|E6|K&>|P'L@L&FW4%E+485(34U1@<|0KJF1G1%;EUW38CNC(SHIOX MO5)%(%T'1T0!|I49#IU;D5_<>.\$W|/-
R4|GYG&H1K|N(GZN|G|>+>D9\$5Q31 M=9N(KHR(UM8;MF001+N*RK#H7N2|;E!%5T-
%*T5EO'.XLKA1J;)YKCD)=B8U M.1N57@2#^\$SP|FW Y7;EO4W5CS>|T|T%|UW|PIU+5C?7|'6:##;M;B|J|<6F
M|G2NQM|H5U//S(>NZ*WKMOC0E9D|+?_*L|6#LZ\$'B|LA8ZR.*CHG*OAG)>+ MRKCGD.0_Y9\$^5X.^KQ?
UC(>NZ*K^@|=&0^=Q#=-GR*K((=V|95|T=3D3SX1 M15<#12M|9;@S-
7*7\$7P7'6|I.QI9C8JQ2+N5*JHEJNAEMM5|O94|H.L<*MY(;E*HNK;=/+/-
@J&EW3QE+|+|.CG.Q.MK5TS|3H2N"ZHM.G1EID|+OS(|
MQ>|PZ;&>F.ARU7%9X+0N1K0>|FG#P.59PR6=\$^5|. ^K_?T#(BN!=M1MGW%
M4/Z^)|5G|HPDY=|WDT*Z>|BBZUBY^I8DHNAHH6NDIPYUKD_^J0.|<=8|L|&GA M|KX5|887%=%R-
=|R+*O#;I^P/F%CADH)S5H=3R-1GK M8
R.=@7US(SHBM|RZ;|L179D9T2\$T;|>&0+H.3HD>|"HW"YH2B>|7D#I7@SHO
M|Y6AS|K4G(KZN1KZ>3V|9TAT11)=MY'HRI;H=<5A4 9)M"NK'(S.VKK#KA@P
M6ND|JOYY#*2)+43/53?SK|69H=2S%7Y|OE5+1>0Q3_A43M70SLOAY4.*)V|>.U!%T-+T>UC.JN|J**KMM4
M=&54M/8W"K+H.LBB76%E<3(5=XMA#JZ&C|2OCGD/5#HM7?ETF.V;N|LJ M5?DO"_3+U?#+L>X-ZSZ-
<7.WKHVD|N4|Q|2P)8|1.0.T.*|JQ1(=82N"YVJ_Y^6N M.@^Z\$G/#6-&C.UKIZ|T15A=-T&HRL#HV-
X|H**KH(QV=97QT2%F|4 +MAD"Z&4!|FICZ'/(47SCWE_QTG^|KZTX|W;D4L_0OT|P-X.PT_7RAO7C
MNT^_WW|!#)>@LPN|(8=NU|%M2DVWUO.GD/|\$FY3;HRJEA=IOB>R;YM2.S.N
MNJ&|MO&13=F7+3|*ZOX%'9N4VK%3;M|J3'ZN9+|U#H^M-8/ MBY=|G20|QJ8?
4|T)7%E(UON|ER^:QKVU50_V|PIQP.\$@YN4F@ZLYT|HV"8 M;7=-&4DMOU@Q#<;H;%=-
STR);HBMV|8IT8V9\$BW_RK_3@S.B|VO*3(>.)8B|_M?AL"YV8_Y^6;N_YWJT7GOMFP##/ZSD|
Z\$;0NBV#4(W'D*+RPT9=|MDT*Z<M|W6(|QIY+8H29|)M*0S>#*W^9G1H? M?O;YO^SZU-
+^H9"JW00K=M%K|O;EI9;EB300M|JBHCF|JEX1E&Y+H9|H|H;=HZY MBM.#&VKG|F-D9U6)F_8F|L5N*);
(9;#5<+|BOWK|R|QO|ET^?GS|L;E^L.DUCO2Y8|DIKNJN=-/)|@6&EW2QE|+;Y4 MD4W8UZTJZ5G1D.W1-
9M|VCHQHR&#EVB4M#%MT&9T/YI29"DT4DOP/B)=|M S@O|Y0|SR|?^HJ?
^B)Z;@9Z7@_J&OG=4\$*W;1*Z.1(Z4A/?\$2*&H.8VM54 MAD3GG.30|M%\$+
\$*U%EM//|H#E6N*G+G|EMD9U4+LRN)J";QW7+|BWC1+^(|ME8U9U0|VO=)|10+=RE5%1-V-JM"NK9P9\$-|36 M;=N
Z.8.BCY1%T<70;!'IF%5F.'3H6?Y6|YES.YCSES_M.^CS>E;|>.B&'KIM|'|="QD_B6'SUT&_30KJPR*CIVV9\$U5-4-
%*5AG0_M3%&^C5)#|_QTC^S;N5NHQ2S_-4N|N5FL.7<^L;LZ@>;7^D8@WIR?Y+J^=|M
_M@B&EW5AE'+08"#74S"D>|LGIF1G1#=-VVS8ANS(SH4*RC<-<#Z('LPJ M-
QTZEDL%R+G9B#GY;QR;Z|Z.%%|^%S.^#S>E;|>.B&&KIMT|"T|*#DD-
MW08UM"NKC(F.IVH4_YY#|T.\$ZUDE='="5Q&GI#|MOTC>S;F.V*;4N3EEL
M.);89;K%3=653_8_\$+^%K23.Y1T6SU_A@^@TN|JH@;K&J'*B;3O:5=4S M8Z(;.NNV;4QT8|9\$B|A1-
%M<\$CT8%*9|=UB2|&^KF9NCFY;(RVCE6|5;_M#
<%S;|S>E#/*B&'KIM4|'_4=#R;L.*#|D|H5TF9"|VN0/(3PI@8\$EJ|*6.<M|;7^88@7YR>Y).JF=/H*2
M|H;2|N:T.W;6AL=W70WID9|U)G8'.|WLJZ;NOCM;Y&I9Y.;?|#(#N"*#|@#=#&0=*\$KO-MRSH;Z#YHH#U%

I8R\$#E=LTH*25T-R2T7-3.&.=P/VGI8I^-.RKGK"-E7U)> ML.TI^H*XL:(C5>X&58XY:7R#:AQM>J6C?-IAX":EKKJ^1/
_!A2VEU4QD^+ M>4 IW8UYT:ZBGAD-W5%8]VVCH3LS&IHNZ8UA1Q7=!R=#S:5FPE=.:Y&?"EIS
M<#=-\%?&.W^E_9JP! 9Y7H J&Q?>T4^W:0ZZ.QOT1P?>!QVTJZB,AE87^6KH M:FAHL:B.
<I8/BU=JW2\$[BQJYNR8U,2C:5=0S,Z\$(NN^>29T9V9^RT.(YKH M/C@3>K"HS#3HDL4!_:\$S=W S#^H9!-T10?
=M^!HS M""B2\$!H, \$VA54!DK:PX==<# B WE*! 7RF MM3.W=#.ZSTI0Z !\$NB^C4!W!X^N2*#
I((%V192!T/JBPZ 8\$EH)*F>C5.Z&5+Z+FC<653 : #+!#J2#>Y*ZKJG3P##8\$AI M=U\$9/RVO#8R#,27:5=0S
Z\$!\$NN^,2!T9P9"D_S6"UET^YP(5A49A9TH^I> M/KOR)Q!T9^!P^!Q>U#,0NB.\$[ML@=&<@M/Q!Q)(.*FA7 M41D+?<
2^Z)"Z^B!Z&Q9:*2JCG/7#XE5?1!C.HF9F6Q+1)>X00*K<#:A#W4C M236.-K_L0YX+:DKIOJZ1-)MT-
>NTN*H.GQ5L^!E MVUN&IO>M2.)IV#^Z#XX\$WJPLPTZ-!O(%X1!O<#=#N!7%3&.H?&)3"X
M^W1SQCHC@:Z:S/0G3^0!FL42S((H^U%91ATO\$C^#A\$9=#<8M%)4!CCKA!6K MONZ/G44MS+:DTJMX 4"EW
VE?>U:BRJ?K3I98!BN=>3VY)T3CU_A@&0TB!
MBVX:~5BE:Z&T.B744!P^Z(ZSNV^9!>V8>=K^R+PU3,3@>K"HW" #H%#D3S
MWI\$U=X,U+Q>58#^H9 =Q1/_M^KDS^EE>,1B20?KL"BH^MH/LE,LR.+H: %H)*D>,U@G=R7IDGK^!+
*!HYVY0AT)K M%J+IO&_ OZ1N&UT<:6F W3Q,^ MB>W:DEX?^VJ:~P!^?OG\$SZAR6U)K_<
M!S!\$M4ZVOQ"KWA&YI8EO3!X!A-H>),MR6!MY 4N^?I!A\$ MMFU+>GVLW;^X@ G9-0#Z!9&&?F4!4S\$X
^HHJ*^/-O8T&)O8:EF#*X.5U= MN!X 2.8.0.XK^2TB^J^Q.#L4L!OSI2V#R!F30/+MBRLAG_1!66V+(9R6F
MC&G6#XL7?-T<.:V.:V!LE2=.3!Y_!^LY/4*>[X?% M=-.PBSZ^/-+K>,"2#Y-D55
8^AU^":^+!3^DLQ)4QC2_W+=: CW@95!WQ!Z@ M1F9#4B:YF1!>OPV97*^~0=6!/:W,"3-YI8C03!X!A/
+A@NVAU41DN++PW" M-ACCH%U!3+Y^Y8+!,BNR<^OCS3V^!-0#,Y!^LPL_&YY2P_!\$S:&Y1Y:~?< M6.A>Q+_A^2-
+Z:UGIXAS_?#8CAYD>?71WKSSR^>C^B@^#9%5...8! W*O%Q4AC:GJEQXL02&;EXO MZA^RG^~,J=A%GE!?
Z6^MB/2KS!B30?/LBBHGGVN*KK+V!1#/BM194QSZ\$E^<
MY66!NOFV!G5S&Q)JDGBL?/XR7HIV!50_V/PJQPI4DIN1=(\$!P*8!4_%NWO*6&FQ MIP7+8 R"=O7TR,SG?
%7LQZZ9SZ^/!/:Z%J0!P_>/8RH&9SX/H2;IAR"--+E M_GF^X!N6>3FHC&V.1O6O8@4,W;P>U"/D^7Y83,5
=B.FW8!V..M*NJ M1T8^WP^+!\$=DU!OGUD=I!E7Z1^ZP82!&15X/5!4=IDQ5O-XVO.H:H^FYJ@QP
M#D^!RJE^PSCO)I5(#Y?ECLQRI^/IG:U9WCXY=:/IS!H M]=WHT^N!JH2;WJM=ZO!/^E!2>?4!R>>3"
(M+^NK#)=65P<6PA@/^>KJD;6<4!OSKV8G#V!V!6F:G/I4B53M>I W7O%Q5;C2THU3 MQO08U^F!JD?
H_VPF!>OGUD4:7&I9DT^!^!HLHHZ)ZZ=(\$B*!#&:~#E!@: M-U!7EGX-8%STVQKZD_>B:H;:~L34"D^0RG?
+Y&^7SY^-.?W\$WIL^Y4 MXVBSZSP@>0!7P4U*Q?24R>0! 3V:E^#R67QP9G^B^34KAR/#G^V\$+/M]=M!Q!<-
_SYDMXV!-3087#V!UA1 S/UN791F@=DS<@S:M%#0QS!DU^:AV?VN\$= M2N&.?@ZHG!V 1P8 :PL-3/8=->X(&
7=NC!H_YOI(D!H96@,L2Y7)Z M0N\$<=(#L!&E@MB>52QK!Q!7KP-IAP2/?SR+W_X MV&FSL8QYI?Y-B <!^W
M4M!!H?P!8!0.(^VN*2.GQ9JBF@!&*A738!2:X?%0.Q: ^KSZR/IS>X!9>& MH1B<^SQ84V;B <>Q^O5-B<@^Z/G36-
S-ZD M4,7/X_JY6 HY2^D J^H.J^FU GF(%X<^M2T\$^U_E@%PPC!0XJ(Z?E98IM
M.#9!NX!Z9.IS#FBKPYZISZ^/H/9S5NEWAAXZ#(Y!NPI_ "9@OC!\$!+F8.#F MY9XRT%F!^K!TU@!@SJO!_2,?
P!HG!V_QP8_ZRL@S)(:(VY91AT^7+!^LB M@PX&@U9RR@#G4J1AA?>/XQ5?H^2.G!
(WP^V(2!T!@4X&4GZL:SVU50_W/PJ MQP:0P6U)0125TR> 2#H82-I=4X9.BZ!59-/& 3MJNF1F<_WPV(=LU?GVD
MO_DF1_RE82D&ISX/YI29!UOI%G.*LCD8LGDYIXQTSN^!G):YV!8Y_6@E>6&)1GTSZZ>.@JZ9?
EO.\$30P4#02D!9WMR*ZH>;7N;HG4,^N!TIZ)AZ_@0P^X:/=O>44=/B M:Q7%=#&0+MZ>F3B!_VP&)!= \$Y!^!G-
!4YDY@\$M=I B<^3S84V;:~.)@+(YZ/#86=/"\$4*5?RLM^~5NQC?^!UO=K#KQX_?/K# MNZ?W&IR,
<<3IE8!_923NY%T2CU_M@%@T>I@!J@:?"AV(Z&%.@74\$!LO^Y M?
E@LR*Z!SZ^/!9>0\$ET.P\$U=I B<^3O85&:~.U&5GPE>|PW60%Q4ACD^<11.M0.@<#B!WM0S^CF@?@!^!
@!+VWE_AT^H(HJ8Z IR?N1D\$ @T K465P M<^WR+B#4S4^Q!ZH5FZ^FS3H_YQO^H;0CF7NZB_!6!#Q^>-
MS>P3C_#!+M.#23Y)T2CU_M@%0T>I@!J8:3&HZ*6#.07:%=0C_Y_OA!6 !KX^/G:SL M3/(K&U;Q./Y!^?;L
<2164?&#0! S00HY0!SA2!<+<I&N=@&.2UH)Z!SP^A
M<I@&GP.#GY7UANXY#^IG5T!9=SS)08%I7.P!+/24XXU7Y=X ^N KCGH!@9 MU,+-
;TN7^_DSXN1@X.1<^LZBZD>;7^?8@79R1Y*NJ.=/, @P&AW41DN+;I2 MC@Q!MI5U",3GW-
4!UV37Q^?2A7QGZYS X!7FPARLYR*%J!&J_VAF->MSBGCFAN)!#T@:0X&;5!Z1GO^!AVW>.3#>6?
X!8D4&M;KHQYIO(7B&B> M@V&>E9@RFED!E!O=6SL&EGIB.E+G^3BR0Y&"298B@I8ZH?GZ58P+ZR0U)
MNIZ>/8&((CH:(MH:T!@X:>G%M%(1V.(M">F!<_RKXSP M*>SDHZ(J.V6<^1F?4<TD!(R+2YS@X!GFPILR@YQ#
I)3!5O X:B^FYJ_14 M^!\$U!P,UK!^TC^2.)WGC-ND<&^FL+C&,R2!U=@65<_JHD/Q^WQK 25LK8V!G4R&Q(^D4^?
IQ!&R^Y!+P_SWAZIV@7YKZ!^WH!_VE!6 M_:G3"QZ9 MUC^!)YCMO.<^3.LIS>\$W^0?3L^BM#GP^);B:B?8Z&?
5;*RJC^D^B*9477 M^5V!^PKL7=)\$J.GQV^?/CONJ^!P/FUCBV@@SN3 MHDZ!YT
XV#P:~5&30M5A7%=#1&0KNJ>F;Z0H_Q:PV, M#H>S^HS^KD5<;A+1-0<#>2!G%4!>D8^1Y3/<9M!C!Q!5E8;
MTN^UN^@!8!S!0L<I(;DZ)NJ>=/+M@^&AW4!DU+;I8,0W&1&A7 M4,^?XXHJ^_VX<^1&?
XL_L!00L?R<^#65F!J=+?K> I#D:~FYI@QQSDV< M/19!4=#.:!10Q!CDB?XS:Z!GZ+!SC2B?XZ!^N64!
<^IR>|5T3!PS!K M.65D<_RT!+O:&9EUO*Z:0+O\$>3A&%&H1B<^#P84V;6<^!RITZ(F:~!F9=IRN#FFI7?&F;
M!WK:3V#GB.BY!@/4<&/88RSB7> (43.9!FUJ<0@ MYY:\$FSL0.FY!^C(*F\$(*!A(^MH=E-2<089ZKID@^!^+<
R7H&IO:SI8JO!@E5 JDR&58!GT!^/_O_!A?W MH!>I:AQN?JU7/*6^VY)(9!7S)H#P!9N2R+&3!NOUXY9-
^V)!HS!9E06=.V MB< \$3^RNXD>NA^R:B!B<^CV65F%G/ 1^W@!+Z9C)!W)5&>_!%17!W0PA 2:~#
M/*!7!8R#)G30M.U!\$^.@L^@Q^1DT#3)H5U09#-UDEDIHH7<\$!GK M^2_ZND-V)C4P.Y-!+=)G.(1:F0RM_7.A)U-
U0!XO!^Q!^@WB329?7T^2^6 M)@-+NYO*\$&KOHQ!FHQAT^ZFGIG!3^BL:=O<9V+F/A?
Y#V8\$T30X!WFPJ^K#Y^?/IS!A^P<<#H8!NF>C@-B724?7!^6,;#"?MGBJGH67 M!H,B9^NZ)Z9O@SH:~F<~?
B1G^+!/:!#LY!DL?>Y!Q:~\$K!D.UKQ< M5(8Y4Q%G1^9S^DIWI2S_!G00Y.V_@S,?Q9_ML\$!3,-XF=741D^6(5!L1
M&F@R#^+125\$8WA!CD:Q-0.).D!U^3=S=DT^5GPE>O VFW\$+9G%3!@-+!^4S
MI8!E\$@GU?G@&4PF+0!J1R>#DU>(9@8S^TJZIG9D 3\$FO@:~F!G0!J, M>S\$X 7JPJMSLY!+%#130-I
AFY>KRECG0>6!OA#Z)W)!J!K63V#H D1^!U# MT.0@!&^SB!H&E30KJPR#CJ&NY\$)L309&!H):L,?
7.J8@!IRK1+JMGCI!/(AI=U=)U!XDP&<5ZN^D>= M4PKB^VA4SV2HY 6HGF05+ ?9=07#
<7Q81)2:~JDT*ZF.B":KB*.-^\$T62@ M:*6!#?6#XO7?%TC.YM:F^U*^5J5ES9>00VT_&7V^Y/@/5CSJHVC\$Y\$YN55)
M9!S)X!U.,2T.ZN,IY9?M-@8T2T*ZMGID\$3BFO@:~V:N&G0X1)_PBE:7:
M!&!9F3G0!6KB)&1^!DP&>5XN^T.@PR5&Q\$T&0AZ!QG9#2AC*9M.IH8&.TN M.&S^H(QVM97QT?^JN>Q^*3)-
)^6QGZ^E!8Q_#I=K:U.MN5NOQV%?TR M&7IY2UEW?Q^L^W^N6_/ZLD-2SJWGCX!%1D^&IW6!E7+2Y5-
-5DS(IVE?7, M6A^>4W:QD(3.Q:Z-/!0_32-#>6>C^LS\$#HJ&SA0/A!GQ>IBH^H9/X(3!^M:~(D!^I6S_!H0AY-
VW@T.3Q:6VU8DT\$=I!HJ8Z!2;JHG/A^BD&DE@R^M_-\$SXF?2;~Sj8W9K!3DEQP^9C(=/
+M@&^EW4!E5+0851349T2)=03TS&!K07=VP=#D&Q-2^5!M<#^#T8\$Z9D=#RT!+00&>EUO*
_C8N_QM/2)H.A#T>DI/R&A^&4W:9#0Q.EK^ M/6)!&EFT*Z8?4F(M:Q_M.SZ1?9N4TIGIT
G!==HV&CHOHZ%;E!YZ)232:7 X!%A/\$S<6.E!1?BH-G!K9 M?4D)P<I?R9>=CL_L!^E=(9\$)R31:1N)3@R)5I8;DN@T2*
(I24T.C+X7G7@O MI80R.ADR6DDJ8YXC!D^Z(B\$A>DZZ278F-3^!E+IX! R\$<#D9<#GW=K_ GBO
MW5!NN7V^<:SYE8XA">W*^4=6<^?);!@_!N!J&1B>TU.D8&NU^ZIGYT G%
M==HV^SHQ^Z^#5:4/O1(2Z30X^WJPJR\$MR)>-Y\$N)X.NY!X??OOTO^!+IS^!^_SCAJKJ MQYM?ZMB">^!^4M^9!?

P)8:P.->VN*N.IY=6!23#F1:NJ>F8T=\$)RG;:ADL M:&CQ5X9-.@T.AAY.*C,2NLLW7TTHG9,AG9>3RLCG>
(G#>Q+BYV3@Y-6DGA'1 M"45TVB:BDT-\$)Q31:5!\$NWK*N.AP-ODG78^8\$5\$G T8K067(LWY80.3K)-D9
M5&+V)N4LZJ:\$<#D9<#GF?#W\|KNGAV^>G|H|&23V:4-4|6|+W9, 1W & L:0|Z_D3P#88=-H=5094BZ|8Q-
3)&|KMBNJ9^=)R77;-M-A|Z,2.AH|C|+Z803H, #H@>CRHR&#BTV|8-|M,|)L,|+567L|U?:KPEK8/#G
MHJ>,=\$)373.9J*3PT0G--%IT\$2|HLK<71H8Q.AHQ6LLJ|89_VP>-773:*\$S
MJX79I91(W,Z>"EZ^BW|YOKL:MW=5/^;T8D<.G&16=4%VG;:B\$S,JF|JDT|,2Z30X+|PJ|R8Z)B#" P2-M8N=D8.?
EKC+X^2OMUX0|/SS>E?/H.B\$*#IM0|&)0='B:Q1%='H4T:ZN|762|.QJ9;8JO8S0\$9\|7KX-N/QEIV_7E:|J|/+
M'7M03^Y8TJ7U_E@(|P|2XK0ZKE5RU&PA@E|2KKF:G1"-5UVC8U.C%3HZO| M 2<2Z30X-'JPK-RX:;I5_-L9L7,RL/
R61WX.2%~3@9^7L J&1&=4\$2G;2(Z
M,2):66THHM.@B':%E7'1^IK#KA@P6@DK0YY#DJUN006<=)3L#&MCMBO5*185-MY7(RY'*XWZ|/^V|O??
W|/^YQ0T_UHV0-63#GC MA|J1YM?YEB|?G*;DLZL9T|@HYS.AISV|C0SGEL&QDM=39F2'MZFL^,B|XH
MKO.V<=&9&1<=H_B*RHBD|^"XZ+&@9F90="~7=&W+J|VSH9U7@YH9-1S\$KYTR M^N=L^?<?
EH.8S*#HCBLL'4'1F4+2ZWBH^B-T|E3|CHWM-TCNTC#0Z&S1:~+F|F-MT, (OS@9>IBNF?4DUCC:|T%%"YW|PDU+6
MF?7|'6-9#&GM3BKCJ<47*UKJ- R0=B7US*SHC.0Z:YL5G9E9T23?FBPCDLZ# MPZ('D|L.B0Y1QO 9N7,VN/
R4QG^K%UW, 0&@%YOZAD5G5%%YVTJ.C,JFJ+X
MKC"CBLZ*#MK55.9&|U(BCS@Z&SA:B2K#GD.Y6R8>#B-DMV1C4R^Y0"B>,6 M,^+E, #E.ZIY8U3UHTVO=
(30-1|3V|9U|T|A2=MZ'HS*#HNV'BWR2HHO.@BW9%E='1D?HE?0J: MD4=G@T7@|76-|&O|&K_#=D:OG VO
M3#<:TY_?/N:4-#|6|+V^|V>?#6Y*R+JOG3P|38&A|T.90RVO*#R|,3+: MU= STZ\$S,NN|,3IT9J9#-U&%9#31>7
|&|'E<^0*8BW^&0&NK#1,R2*!=%64@= HD?M*)#CH;#EH) M*2.<|R6_%T;AG'6 |Q19G8DI2@O;+QT&THYY|X?
-0%F6<|PU>_>|H_ SM MRD_UX|VONT>OH\$D\$EG@TF|>|K@;:&G"*>S;2W:U=,S@Z%SP8'4 M;6|ARM^GHG?
QDUZIT'EP-/|@3YFAT#6)MT;+B)JS@9J7>|H@Y|CD*R ZYVPX MY_6BGL|/&?%SWH:2.X:?
@WRC^HSZ.0_J9U=2&0,=KB@.F<|HH+AH)6F,KHY MA"A_THN|.>OZV|G5PNU)BN)-?
C,:Y6P8Y5#ZUJCJAYM>ZFB>C"HS M#3I'\$1-DL\$9|,S+465|||OT9O&Y80D,XKP>U3N:.-|SMO<K-
V9YT>.YO:N%LG=1(-.\$"@ MG V@|'"_*#_||2?/U^+=A=5|CT.D?LG-O)'4FZ|X_0R#@:|=167(-4D
MC3|)*S,22:~%=4S(Z\$SPN|,21T9D9"RR|MC,7@0.C|I#*CH.^KS"6^84#3 MG W3O-Q4QC@W|<:Y&95S-
I3S>E+T>.|#EOH^9H<_B.D|XG?ALRNH#" MH53Y"6%/#|/L|)61S?|A|JOTV-G4#NS'8E"%X.*0#D:0#G=;U)|?<?
GCH^&M>_>^4-2|?V&=YN16DSV60/GN26A@ G;4D+|J\$SV=V3U)|A:|/ M9UOB43,>=>.>D|>
LW^7E*2>2%GHE^|ARX|OWS||2/SA-6;L>:7^05S^2@ MOJ2B.^KY\$VAX GOW|15&3,NOU(Y/9-
^&I')F(1'4UVV#80NS\$|H\$D=%F30 M97 @|%A-"S,*NEIR"Q|L|D|N.>|KEL<|^&%
M<<_IDM<_AF20|;MRRN#GWK.|ZC GAGU6-5#*5V, M"=&NH)X9|EW04Y=MPZ+,PQ:_I5A*
8G00_FE)D|'Y>490D#(7@S(O|Y0-M%5W%3|4*ZN9BZ;UGIXASP7)
<|E&G@M#GL4:\$Q4\$SV40/+MRRK#G\$*L(8@NR MYV*P9Z6G'&B.M4C?)|1F97\$MW7?
NF9H\$LNADNF7!>_X|?|H0 M4_U(TVLF8,=\$%7:~ M@2L&&@2MP\$5A,|E
MK^D9Z5Q0.I=MTKDPTIDN|=&SMKFIC|2'6+Z,*HN1BH&3*|/'Q>?|W>HWS|_|.|SS|NZ*I^
MS.G5CLRY|(|:DH|N|,=|/|@T&AW5QDP+|03(0Q-K5U3-SH NZZK)M#G1A MYD_Y66%Q1BSRB#GV.32\$;:8,
|K53UCGPO: MY|+/-A?&D?YDWTSTV70|KNJR@CH+N|YR+PB@BP&@E:ARM#DF<:4C:BZZ/78V M-3-
:DDH7_U|H\$H%P,H\$PY|4^J|LSYI8XAR>W)14=5,^?)|:0+N|N|)T6KSR MH9LNOF1H5U+|/(\$NR*O+MB'0A1D"+=|
M*"|+H-CH>3R@V O|H(|K*YF+(|MYN6H,M(Y97&G;T'L7_SLO%|5,P*Z%"Q(V?9%0_G|H|XK|N" KH,"FA751D'
M'7*4OR1""%T,"*UTE2'.X>7FPN|A|JO\$V1G6 NS-.FG)G|TBU'Y&% "9U|,E'2727^'6-@# "KM+BL#|67"\$'F
WM*NN9,= %B779-@:Z M,&.@@-Q&#%T&1P\$|5A69@1T2?7^VOEY|L|F|3?&|8 T_|KY?U M#(NR*#+-@9=&
:M+3@LRB"#=I65P=#Q(GF|/FKH8FAH|R:27T":8+H:8=J?5
M,1^ZH*\$NOGQH5UK/C(|N**W+ME'0A1D\$>=>^I7:QZ,KP:'&Y M(8ZN@SC:\$|7*\$E 1-
*M8I&NAI&6JD|HY UP^<(U7|2)S|P&|G9*3;S|<47# M7 W#"|ZV1#|X=L=-=6|/-(L0'AX*:EJEOK^1/
|A^VEU31E7+KU5,@S\$| MVE73,T.A|KKNFTH=&6&0LOWW:MHI>O@3.C|GC+3H"G+VVO\$S|5 S|LY91|T
M|,+6KHH.NAH>CVG9W|T11Q=M^HRN#H0%G|JPE|=|WTT:ZB,DHZ=_'#D8H(
MNAI(6@DJPY|KB=^Z5.3|5=?S|Y&9LL2%?D"@(|Y&H8YMI(>OGG|H-W|_+Y M^N.H'GE_RF(|X<-|2U>7U_E@(|PQ,
|8XK0ZSE|8N=M,"9&N^)|Z9CAT181=MPV'KLQP:/%7AG*Z#DZ&'DPK,Q-:2AIXV32||W)7N:G1 M5RAB|_%5|-\$KX?
U#)2N""*7K-BA=&2@M_R-C3P:9M*NJ#);6_V\$Q*X:65K+* M.&C|H'C|UYVRLZO\$#7P+0?P|S5S-33S_6?Q4%:=
|UGU|XO>(P|'=RS5'6|M/7T|J*JKH:C=677.C|HK*|Q_H5U3,CHBM|J+IM1'1E1D3+OS),QN^|Z,&L
M,|ADWQ+U(H"NAH">K|FC(BF2YQC4A%5P%KX?UC)2N**7K-BE=.2DMOC|"
M*%T'H,2KK|R7+DE^/M@5PTLK864D="U%?)>, %&KJ4MG9U<3=7;G)A4?/7 W/M3#F>Z:I^W.GUCDRZYH,
|EJ|NL,=|/|@P&|W5QEN+48"K74U|DF|NGIF9G1%
MDEVWS8RNS,QH^5>&Q1B<&#W85696=)1|>D4&70T&O=Q5AD6'+.|O01E=#1F|
MWM4S7+HBEZ|N'1EN'00OU\$+5T'M,2KJXR93E'#3"M=Y3"TF&.,
MBABZZE:9V=7~%>*|BW\$;L%+=S'GOJ6';Y|NR^7^_SOV|<-MP(VCCB|T|I%(-MUW)RKY+NK^=|/|
@D&|W41EH+>8|D74U|DF|BGIF9G1%BEVWS8RNS,QH^5>&
MK1@<=&U85&Y4+=|RBF"WTS|7PS|M)93ST5T&1*|G|8R3KNBDZS8G M71DG+2XW5-)U4\$F|BLI9Z=#DKU;12E?
*2BM)912T'EB|YNM*V=G4RNU5BDUL M*EKF:ECFNZEE:3 PM;NI#++&67|8"&..M*N|
M9T9&5S38=O(Z,|C)9_91B+P8'1@TWE1D53\$|T1=<#>?>|G%1NGC15|L.\$BD2Z&D1:*2J' MGI6CX@5?
M|G.H#9FLU(H|I^*)BK(9COOX?;P||>WWW|P^/_H>'?_MZ:;Z MT>87.2:@G=RAI%/K^1/
|AA|VAU3|E7+KU4L@S%|VA73_|.B*|+KNFU8=&6& M13?YQC(5D70=G|<|V%
N4G2IXMWC*G+G:G#GY:"R|Z2|B.0K\$NA|S.CUHIYQ MT15=-W|F|HBOCHEN5|VE\$&%T'8;0KJ@R/CHVRB*701U?
#1RM5Y>3SO=S%K")| MKKL=F:U(Q"/E321?7LR?04%\$W0U%|H|H86RU=G1O"ZF;_D_ DM9T9'=V07|=MHZ;:
M.S|HZR*_QAE:Z#V, MC6YHH|LV&|T8&QV"B*@|N@VR*_|6T.DFXU2)_-%C32S3#2DXV5?6GO|L|>J69SRV|P-
X,P_|J07UW6%|6DU|CNJ|X%&MW|PLU+3 MW?7|'6
A#\$KM3BL#K,5+|^+J9LR6=J7US|CIA@2L|LCW9@QTK%4^:6%U1B< M(SV85F:=\$A|_)ZG(8%N|H%>|BM#HF-
TD?|.#55T,U3T>ES/4.F&5+IMH| MH=)T)3&N:*7,H)5VQ941T_?_O&#V89DNAED6JDK@Z%#) \$^TPTU=-.QLC.O
MD=FT5.5;-S84SZL,LQ:7AT8"&/\$M"NK9Z9)-Y38;=LTZ<9-DVY%^BBH(9EN@_D|H/* M39(|BNAOBY&?AY:;L.#
T00S<#0Z|W|8R0:BBDV8SAW1@AK2TW1)M\$S|F|MFLI0:771(9=N|H=6FLI Z%":>|/KAA"ZZ4|9V51B-BU5^1,\$Q,S-
P,STG|U METH|N|IZ|H>7^D8 C|X8:GRGK^|+_|J9V)Y4=-1VS^&8'B74S9DV|LGF MK'1#B-VVC95NW%CI+
Y_.\$BFV^|0=\$DW:8AZ<8@:6W%H9-N@T|:559&2|=>Y:(BEVX&EU:~
MRD?HHBC^A8\$2NNE0V5G6Q.Q>>AEM)3X30(P:G)FND|I^|>|;|^>?OWOWN./| MJG| ^<6..4@-'S
U5_/GP*VP0#5|K@RS#K2N)"^BLFS%RVA77,|E&VKL
MMFVZ=&.F2XNO*D33:7"V|&|9F:G2,21Q9TM# MP_KQ<5H9#1_F980P,#|W> MU3-(NB&2;MN0=&.0M/S'\$RKI-
JBD757EK'2X_YP3GQ!&Q<#22E49|GT?5KPA M1\$,'W72F|*QJ9C8OQ=C\$+S@0,S<#;H5+7NKJ|A|P?JEC|_|+?4M-H?
3)X"<MNAF)&X1%|9-V|DM*NJ9Z9+MX(=*O>0|3'=|H(HO@:;G|J|C)3 MI>-5Q'W|'#0ET,PCT_#BK MBN9FB:;
|HW5Q5_4#3B|U-*MGMRT|/L^1/|_BFYMU53EI3%X=W-936S1@X M|>KJF=G2#3UVVS9;NC&S|<68(9YN@Y.E|
|O*\$S92.6:|'|(8-N|H>|BK#HK|* ME_|DL<&C5X/ZQDOW=|+MVU>NCF|=\$.OW0:|M*NKC)|^|JR>^>XAFVX&FU:Z

MRH!H_!;XX=?!LK.KC;014B;0\$P1DS8UB&XPATZZVJ*6>F@WS70H9FNAEF6JDHJZ&UP^(U7!/?*SHV9K=25EYU2)J;
M09J_>=D"W!H^!N)K(DOG-X\ _L/#-ZM5U8Y0IBQ!P2WDGB5=8,^?_!0-7N
MJC+46G!-8B*, "=.NJI9)MW08K=MPZ0, TR:NOBY)KKI-CA,>K"KS!CIDL47 M>\$< W0T O9K5SH!H*M+"QU)=#=
(!5^QDGW=%)JYU.NC-.6EYN'9ET'V32 MGJYV!DN7)N!4Z8BENX&EY:QVAD'7*(YBZ^B@N!Z4?
57IZ<>WK@PRT^DX!H1 MKIU2HEH>_L>I/SH /C!YX_KC25...3!4JIX6>W*G5=7L^?0...3V+M5J3/&
M6GYI='PB^!8H!3.3I#LR!+YMDG1G)DDW\46%7KH/CI(>2VKGADAW!>OPCO"Y M& !Y:.D." T10G<#0J!18R.
HBC^S8=W1D=K:PU+,F@C7;UE!/2VHK#H!A M6NDI1Y!O<>=01_K<=9GLI&G@;K DSH+KR)>
!P9>_0^G^HNG#Q^>?GCW^!^!W MY%0_XOO"QPB\$@WN4NFZMIT\ ^70W^+0HPRJ%JH!"JL5!E=,SDZ0!NNN^
M:9)T9R9)4PG25X0=I70?G"0!&%1FAG3;VZ-CN;Y&^9YN:@. JW10?#0*17 MI0R.
!@BC^S88W1D8K2XWK.D@C'8UE>'1^J+!#JA@!6HDJ_Y_C_09&VOG;\$3!W MW28HJ0J9'4HAB2-
!:@KE;@CF;[CYD]'3/S^Z8?GYVW5%4_X/1B1Q#>Z>. MI:YKZ_D3P#@8@-I=5895B!<^)-7=F"WMJNJ9,=(Y77?-
D;V.DJKRLR0SEG1QG9DSU7H9J?P)8!D>_U"N.IQ:2BI>I& M5&E74L!D.XHKONY
==*&2"=Q*V""85T'YP@/5A49G8T%?%F.QVIH!W)1 M&?K3FEW%#I0N*O";ES-ICS>DS/&.A>L!ME MVW<,Q?
\$!\$AKH/FB@72GE)#21>#?YCA*Z&Q)::2ECG/7#XC5?^C.F!9N_EJ
M37XJ>/4VJ)MX>\$W3X^?/H_VM!3_6#SRQPK4\$!N2=)1!P)8!8,)^WN*:.G MY5=17FC+SKG;CCG!:">P<1=17?AI^!
SIWQ.H\$#^!@LH0Z!+OM2@^M(^P;F4V)M'5Q!N#>23*W2*#M<6-0=4/-K_..0/U MY*XD75-/GP "Z6X
+7=0&38MOEJ!3'=CB+0KJ&?F17>\$U7W;O.CNF!?=T4+W MP7G1@T'E)D4G\$F?2=%3-W5#-
RT'E!DI>>)F1^G<#>F!M0S_+DC?^!;^G M^'.0H!B@.Z#-J55(9!IU+DO:(H+O!H)6D.L
YE2K>/!^C<XZ08FM7&! MDEH19SYV=,K=<,JUT<:DZ@>;7NBHGG!_N25))!7S)X!E,)!2T.ZF.G1;!@&ZZ
M&U.D74D!S"ZHJ!NV9&=V9@M/PPKU0,3HL>3"HS)SH7^5*+HKD;HGFYJ(QP MGD&!6M'Y-P-Y+P>U#/RN;-!
!MOD^V^@#/?/9GPBV58C03!6E!

-8?20\$3;8T.P6BP^0"X9 MKK>!9!;G

%VH!A!R=3>B?OW3>^=M+DBMX8WNXE_+G(F(P+?"R9T_E#
M!RZ/%ED8G3FF74.T!X4D#M!FNDN'),J0DC_E:9I76*%Q+BB(>'C8F87M.H M!A@P!KM;Q+LN2)T!H
N5#SHO!WFP>XZEOR+!#N_'.AV#V^325!K1&!6!DF&\$ M=C_@9QU\$7"D?60%GCLB!R?;Y-X_!HSW11/_DJ!MJ-
*NF#49CWYRW;_BMA\$/I-G&."@9JMR+SA7K>KR)S<=QG&;D;<#F4BJ\$!MBNY4;TB0V\$36TH;7)#
M<\$!4T6Q!RW2UH3B_!5.(!(*CI7974?(Q_).D.X\$ZAR0S@3IG_!E.4'ZEU77 MQR9PV&Y+VS\$;O>3!_@Z\$*
(^)^G#9RO.Z@U\$ _6&2WIC>!!Q8!6Q8!8"!/3> MRWQ>>U55GC&.0#Z;TMI".E%*>2A!:@-H\$WD!)&/1%>..9;
!@*!O+FI&8,W! M-I8W!IM@X&-EC-^4+Y(A#B*^06@@DIZ&GZ\$YA/F#CNOKC'_.!4?IY!JY\$)K> M-
Y\$3A_Y6&1E!^DO32%&!8!#B-NR7LZT%,,K@B. 7!E+!,9WRC4!3/KK+C+R(!" C!C?3-V7GOELD*8=SOK*OFVY1F0^!)
M@&\$?+>5_E_>!,9#D"Z_".(NUPM="*T!K75&-(R(CA@!H/>MB<^)^3H0.JT!K*U3?GL&^R!C9@!@0!=%8M-OM
MENB!ESB#?O!CC_!F!^WVZ);. ^NDR\$;EX7ISEC';.PUN'=&>L(YF>=%OMR
M8.9=,9;Y@O4ZBG<6GN7).J.EXOO"^_U5D@QR0'1&.0+XE3+AL3A_0R1GA"-P MWTCMGN0!|<"
!WR&!68^#0!=LW9PL;"9<")X^+>HXV"SK4X>V=;A@Q^4.TYR M:FY!@62G>/+B=1=BHBH2UHS5SESE3-
7>9NYRC_W2V*N!B^KKM^U>_VS0\$K M0!>G)!>B+V"U.E3YU8!J!2O_%PH\$!TCHZ!VEIYR#_O%VTCPKWB>"
UD MC9A(DHJK0@&^(M6!2;_HMO;?LIV%@;WQ_/SENTH?WF5XX?&Q+)=BNG(Q
M!PD!RCFKC'JN1"*6T#2EL!X(M!4ZVM+<3!8;+@!S.%W,E"W"!3B\$^(W3 MRA1^KE>BU!SNMP>L;)^^_9U%=;
!C5"0!O-Y;T'UC^CH4<N!N57#Y95XCLGN(0X@_*Q!M.V8Y#>_>HG+ZRDJZYA??"1RZ@@!(B'OQK^
MFUMQ?TTSJ3BL043U!&E92L^=R2#>I9+A/2!U!OEK;NYF+8Y;HX&F!
M79MF)678ISV(?/AZ3H>2.B;W+J5=)2!>'31G?5?J?Z#=-CX*E3.WUM)!73 M2CSH,%+%(+OQNPOUP?\$CUI-5U/E!;
M4!S?IS9BP(0C!L#UQ5 X">WC3!HB=;LO!P!W=U##>X_@!3T-SUNJT)3' M:P.8-
"W8BN"1WV4\$ESAPP>B7#FWDI,JZMH;"K\$_.NN5 @/+88.[N*3ZBX M+PK_J.G.JWV.6!7
L_..6!WY@_";>L!N8K*..L0!XTY\$Q#_@< RC3DZ35! M'K"='1Z'U!43N_\$04-
T7^TZMLUQ+D8Y@GI/7)>%=;P^XT%5(=0XS;G)_ M0^!0'0_!B.A0Z*\$K=|TY2B3NFR&U0;1H;/NEG!8!UR3N8!X
/!H>?*!L M+J X@'BHU@<9SW&AV-YI+;4*DUT!OEFLL!>MUB1/GSQ4Z!H3=?YH MUUQ%\$^?;N64.5#_..R!-?
RY!H7X>!O#A,K"KWC># (LE2.TY\$W!2D!C!R M5679W#1%=1CUT)Q>!R!@L1=&Z>IXCXI+/F>>-2F>-
J+/9)MLB>/OO<.C!# M_..EBS"R7!AT >7XB9!G"ZXOQU N!EY75DW=XW=|A@+@OM: ^8H5S"!5RX! M;L54POLK?
U+Z*RS"X<"7SE%; #LZ0V5TU>N1#;7+E!ZW>=N=ACT0!&MGVM? MA9?IG;FW?5MD!/?B\$53XE+=HXH%
!3.VDM2OERI@;!8%\$+C#DUJAX.07OI@-!
MKTU;7*KP6.5&P!19>I%U\$>@8!M=%O);\$BT>*@XBSEXBXB=#EK'9&W#*V,<0Y M'@-0!HBK!)YCY51<)V-
D8YC_Q@5RI>@?J3E4E65\$OT!R9FSG#G+!E;S9SE MG_LE;6?YEU77!YJ_YK3.#23(5@QLQ4*9@/CL!Q_>
MBKYY4;Y;*E/Y)A!*"Y">03YURCGEH&TJ4W;,>?CC'O6S'.+!^DKACB>^Z.B M>_KN#P&
!GIN#^GUF)D9\$TM7&;J#J3.E-9AXGIQ W !LRP!JH8VCS0A'&>W M#0NKHV?ZY6X M>|!B#VX!Z8QLVLIK*"K3F
^*LB!7.%ZS<;C50!_E/L!P0' ?24L*!46 MW;DAK1<#>=DW8YD_YK&!#5!_OTO_\$NY4&+48P<>AWRIC8;_8=75
=1GRL9 M#Z3QG@D8!2.H6UO.G"YX83, (=BEC.O+!YD!"(C< MZT)%<5;I\$;0_V=H!^!N#0?F..A.+22Q@;"^?
KX!+O!S>1Z+#!IECJ?2U6* MT9J'TIC F.F.F<"8"8S_S)?\$!;9?5EW<4-X5;NY7(!G+!)!K_!E)#D3^
M_O@FV2'9Z0!B/A6=5KLM)M?]>XHG+MYOR+/!5?>[#!1BH)>Z4L4^YTX!+L!B MD'PQ>!O>1!(!?
\$W^@JZI4X2WS!4L 9_F82B.ZIK&6Y8_S!P.R/&GCZ(=Q7> M95;I#<\$QP_!5.Y^X^C;IA_!U*"6"D8SC;6OL7 M79;
<30-C/E1%?"HQ>GK2OZK?601 BL#H4OS;U37G!#K;N>XXTY!<_XW! M@WLHW29F+ 2PW!IP\$;?HZ\$+_KI?
Q@MR.-W1YV.O:G@.TN "?:J.MD!T.W# MTW!8W!\$@.)2 @_U!8W(BAFHY8X9.(#@8I^..W"#
<|+>GC0U&YHM414HOXPB= M>9:99YEYIEHG^?;).99_K!+J^GVKU^!W*X!-0,^L*%TW7ZUMWIU5O!=(H(Y+G
MHVMMQKYR3.6,<%RIOWDQK95' 3 M/D87R;90>_!21^3!MISH;_!2?
+&RKMJ>Z=;Q=@16!=\$Y9F#;5Z5C2Q5X1!/DIE.'&("AN4J=-.W2W5 M.N;68"X5&I: UD3&P?
!@=8PUC_2&L6:88U#S>8;R)K82-C4AM%FYROYZD'M M%V+07!Y'ZK2IAUW1LV61!P9O!J!WYEUZHLQ=#6
MH+ZMVMY@E-JTCH_!^KC5&F&2UT;D^_OM="G?@G64!6Y7.6!2UJO*!6E5D4=V6!9&YT CG37
L<)ZZ@_#^X!)#1GCRXOFOO\$D.1DIOY+VM M4V(2KS+P5&3T!Z5^*RUDTGS!>)J&X! 4*R_6@!P!MWY-
U1DMQ;VWAY9*%@86!-0)P(8C/(L>%V IV)8"%@.6_Q8!V""PVUG+\$@!; M N!4BV0!@!"!_!U;5W/EMI-
&G"\$S+0!CGRM;LD;+0^C4AK+HPC8!;JMBRR M%H M!)-X!H % +< W"MCE/!<*?5N M:<.!X^G#3Z!?
\$T=M4!61_&DQ4>7HLV!76CB>+!

>[MZ?W"ZR._

!^VM=>_Y!WWCS=)D>W(KT^_INM2"0_M8Y!H>Q> MI<#!%YL;N02SR_/M+08@L8D4!P!\$CIZV.^(!;\$Q"N!
!Q_!E!CL64DIYK5 MH^+U7B?SI0&IE9).80K.N"%VX#)@;V5#_;"_!H1SEY%>WS!6-2#!2M
M;BFCI>77*H;F!+M;NF1@=#WPV(^=@V\$?GVDL5!99F)P&O1@2YDYT"E?44 4 MY8IXL3<@!W).N6G1+5?
YR6\$&#-R!GM.CXOE^6&S'+O!^DA#ZRUB2_YLRNG
M#HN5*0QX/?8T!_!STE;_!F'QHJ^+8V=0(L;_*?4Q;9'O P;.)GN?^R- M1=6/-K_!LO/QW:~DUP???)@(!@-

%NLZ/B/Z EG,@S\$C7E74(^.@RT78D%WC MH9\?Z8T6R\$7.5WO /-9B3FIW+AH8EA" S7 MOH4(ICY?
EB,QRIL /I(?I05::RFAFZDWZ MRO+^>:SLZIH8V53BIKF)W^/>/X 7.T.E?,OUW71PVI??-I|<-3=4/-I 4 ML01T:D?
2ZX/OHC\$3:1,M+NIC)06FYHP#L9T=3CPR"OA6\$D)K\$/3K(IWY M;E#Z1NO^-XS3<8W)1N3'13?QL+&\$'#+
B!WM0C MYOE^6(S'+NW+DBCRPU3,JB=745E5",RKIL14PSTH1&XC*D8G IV%-FJG/I M\$G*_?QROJP9E7NXL-R".Q
H,U-P,WK3T8GN^Q73LSL^OCS2ZW+ D@^-9 MU5-/M20Q;(5#
(H:GY6>J2Y%DG,W#^UWQ='#MI6I@-2:G(IX 7IF+<(FE MIWE?3 7#32 S@A4H)W4P=)B3PNFP9@&[>KID<'/I-
B M0'8-?GYH#<7N'3 TC 5@Y.?!WO*S'PNMOK,| YOO-X;E'FYIPQMIBA6H& % M#-
R!WM,CXKE<%=Q2SR /M+@*UVU#)7WI,| 54/IS,|L<*U).IDG1"/7I" MF
5#1,M|REAL^6*3"&0+MZ>F3>| VP&)-=IY?^GMCAQQ\$Y^*IJB<^#S8 M4V;6<|A!NF5ZNH>|
W*O!S4<=I| RQ&P*#-ZSD|XIWOA5RI/+KX|TN-H: MAF10/+MRRKAG?-7P:\$SJ(W9E53ELC>|>|IJ M^4M0RV?7
-|S^Z?_N.O@ORPF53_@_%+|\$+23VY)T0CU_E@&0T6|DI8:G* MAW4P)D&
IDGIDZ?_Y.B9DUJ#GUT=Z>Y&3/_3JY(O|N<^#3>4F/E.3IQQVO.H; MEGFYJ8QM;N+2ZI@-" S>O1_6(>+X?
%O.Q2SR /M+P>L:.*#)G5U49^ARHR N2
M.E.%L1*51G5"3;KQU SQ>|W5U|*QJ9_8E96F@WOWC>/TV:/_ODW=6%7I M@/-K'5003VY,TB'UI D\$Q-'P-
'>J@:&3\$N7OH!>.AB3H#U5#4>&M/|&_Y M|GKK\$)BASS&),B0@A0Z#4Y 'JAJ8<_WNP9IULS|PF?RMFM2<&I'G
_BYV @MY^6HAC/R:|!#MOD>|<30P<#02E49YIR*>|^F@_HYZ C9 M&=7(.%"Z_ZP0GPA>O VI_}|?<
G UIOT/CW_Y NEI0U/U(TXO=<3/(1L:RHQ1#B1 P150. =#."I'E1'/I_12?&J8 L_KU?U#(0."*#-@=@= M.
BM+@ATT&'00:NJRFCH0#6*F4<.'0P.K625@ZE5O'-'F+GH%MD9U>)NWW2
M"%,#@N5@@.4078T0_GN8??"#|JH?WZIH8POHX\$ZEH-/J^1/_IA XKG8(CGI:.*>8=I&738QJ
#PZ"5Q88..@PR:*=0.0RM M+3GLB8&AE9XRS#GT(C|DG.XYZ S9F=/\$.%2=S\$SLK|H.I2:AH>OGFZ+Y=?
MOW |M.&H.'G% IF(%T<)|2T&7U_E@%PPM|0XJ8ZCE"Q^VP1@(|0KJD=G/M):"S#KMF/I^TIL|UXH|<+*Z#
X^WDPJ_S49_F;+13.P1#.RSUEQ+/D: **MYV"(Y_6>GF'0 1ETV:|@ |. @M;6&)|EDT*Z>_AB:Q/VW 2UT,"RTDE-&.=I
M@LM'Q>N|KI"=|/ @&\$TL& TNZ4,GQ:?"6BG0|&.&A72H|?KX??"N-1MKU=*XO
MG|%\$A|)SX_A968^W&8U/WC>*TW;/_R21GK(*)X): W#D8W'DHF<,\$ # M;89Z_8:'FU844&|0KI8R#SNT2/W-
%|QT_|ZVTE'|.ZE'Q@|+9&=+/_I M*K8TONMO/WO_KY^>WKZ_/_GO_V_IY|</_OWJ>?WWWX|/#^Z0_W?^Z
M+R_@N:|W|W^A|^-/_Y_F|FO@|YX?W|^TY?_W=|C|^?7SY@?O_H?G MY|_|8?>C_#|1?O_JRC/_V?P!02P,\$% @
281\$6JY|9RC|:0 NIH\$ M_H|X;"|W:W|KVW|TD5)1<L:(\$4=|T?RR-44MK/(3%/0ZA_?L8US|S?9XS+'O|R)
M4V579L2,%6.-)R+6>_+H01>O?_7#|H/GY|<D_OO_OAPY|>|W'C|_LZ^M^O^UMX_?
O_GPI^|^-C#;_|R|OWWI_Y>/_C^H|H>'W|Q_?/?/37_K^NZ_B M=960OG_S|H_?
CONI<_//H^X/OWG|^\$^_OWISH|;R5;IY^M_C#A|?O?GAX_@O?_I%K|?_47HN3|IE9_@S/_UIO\$/"^"/SP=S&_?O?
O7 MIW_XFV^_(OK:4V/WSU^_2%|V_N_CWQU|_?O?=TL:NE?S:SYO|XGFO3W|1 M_NGK?/_GPI_/IS?
OOGP^_MWW_WSVV|^?OOG7|00'KYY_)>&O M^W|^I/RTO: ???2AI_X0|_IGKBX>O? SP|=WW/_E>P?7
O_WAO_!SS7_|M_%' 7XA1^_OOY|0?UKW?^WHU7^Y9N:W|YB_?O_O#P_NE/WUM|^B|_>I/M?_M>W-L?
GL|^_SZ@_7M_??^C+W|PG^IL?OWM|^N_9L>_B'QS??7S5 MAXJO/CX^O/GAFX=???WUC|_~W|CH|_|7C?
>?_?OGEIP_SRL?|FY^J^V MAW?_OZW_NAOW_SVCQ_@Z>_LO'H|Y|HY+S^>Z16Y;ZUY^>2G_VX?
=OOG|H_R N@_P M^/I?| XY? ZOX1R_6 *XNAY>=5W7G?_CV^>^>?O#|WY: MP_!8"ZBO%A O*HE?07M>05-
7|1V/CS|^LWOWWY|H|W;_>NZ=|^_L/C_V MX|V^H/VJZ_|<>W|Y|Y!=Y>K>G+0^T)B^K/B^HJZ?SO|H|^/#PJ^?
7@O MXLW^AW@|NW7W|Z+?/_|^W 7|W4|E_QM=P/U%_X7CK|M:;>B?M|.6\$D%(\$P8 M*JH/_W5,
(Z7UA09Q)25'H0&\$E|8>|+|^C^_NHF+|W%U_M+URE2(^?TJ#VE%_MZ>G_/_V_JL|+4IK>&F|0>^|^?O?|_?
|V_U|>?_?TB;_|5|%\$MPX0|3KH_=_DM??"Z;5_N-4NU_*=Y0|V%MZ|_|8/83>^GP06_QX_WH M=3>/K=68J_!AO?
3SH+9<|^=^WM9GS2\$0I2JM(|ZTYJBWYD7:Q=<_Y<>D|0I MXTO/CN\$H|:**A,D2BW#JKC?
ZX1*+KQM_|*5W(1A*7U|H|WU3U_OOB9_*+W? M|:(JWF|0-
0A0+OY| WV3Y|H^F1C,T47YIZ5#N0*'WX_/_H\$^*6KT452*|T MZ&A=4/_VX?|
|&***@OJ79JG|UX5%OX2L4C"=Z>GSIZ5'OZ4X*QM>=73K/+STI_MZA?I#&#&\$Q?D|_
+U:=,%;WN|W=O2C%F_L.BE_Y.8|?D0P"DUU?C%.ZV=\$G+ M>.G3I/?H|?|1Z^Y_|?3L|0P>.;B/V19Y1^=>_
)|^+^V>|'8_7F%_^V^UUDNX M|:"7IDIZ|Y_@|V&0.F4KR:@B%X80#H#1/S1Z|OQUD*L3;J@EV9.^J,4UV.Y
MUX|20@PEI5*\$KD@OC9GTQAQ2HX>_>|VPV_?/X#)P^_M7-0@<1H:W/UO%+ M3R>HRI|ZSS1Y-
+DT|ZD<^|GS=ZH5SGUZ?- (OXAUS3">NUL+|H*FZ_7T MNN.WU(6+|?32IM/8Q?
H0#M/KR_122<+GH|K+7L1A>EU(V_4U^N|^+D_YD M9A6\$Z<33F?32^_.FI^F) 8%
<6"42&_/UIT43*|AT|*9_*%|!\$DG@N3U9M?&GC6 M&_@*_O*CIY?GK6_|H3?_EU7Y=^|GMIZEF_AO?X?B-8?RJP"
M_|H|X_) ?NG|>|+ |OZ: 5EH0%.ACC|H=|S_=_RD?0K;GFA0=%I("P_|: M:BA5J)
|RTL&+_|IS%T|^Z|A06|=+B|Z+;PCF|0CJ6Y|=AWAIX^7< MO\$LYT=?
+2U|06T=>RNON+D"PO'3VLFWJ|1P9>X&YEUV#+TRKESM5>>GT9>/P
M2WE|E5ZDF|RTJW+T>F7P03PG\$*0|J7)EL_#L"4\$|BZD0?KYL>N%>&W|I
MU1<_U.TC_/4U#>YS6:5S65IH4">'8"HS!%/*E03^U)<.70=-P51F"N9&<1^M:J00:CJO?B&8%F H+
|UV01?>/_W/C|/_=7ZTM?KUL'9.KK|BZTU0I3C=MF M8^JDR_7Z
H"ZZ7?|NB|7ZTNGKQLG8^KK"W7A7+677MV.CLOTH|3S4#A|5E| M:;>'M|\$1._\$|KUT_?I"7MC*" 75GN|0-
L^#1.8>1CM7+ZPH\$U.PS3F^4HJ M-OGT:2 |N^V:A6G,+QLA:3#?NG\$3>_P+K_@+UK<|6|\$L3;^>F8J)KMY@
MIGWK=\$P;GHY|+WV|:9N::2DGGL7TEY|?_SUC|POJ7)901"@Y^'
MZ:|H)W)%P|TR6F8SOX(>@G/IOM+Z^|H9F\$Z,P032Q-N0OM+#+YZ#W|Z17,| M?
OK69ZL7!1S@S#1CZ\$ M'649A/FQMHJN\$""^G:~@WS:5|H|((BHUTN?YI M0Y|L)?
6A5|NP@7NTK5Q*:3QCY|H|""TS7_074FA^Z<_?5YG4:XS\$)>N|3,RGS;Y^:UAC|M:KC 3KHF
MYV0^<7/Y#F'(4:LW""|CW3MFY7YM^W-B|+N^WT8"J|&*WI1<^:G0V/QL
M07_FF|X:F0FZR#J|>F|C|A|J#J)27CK4JD1&DU:|N<";H_ V1 1T,076|@X77
M'(CIDGX>#VBOZHIZIDY3A|65|+CL+^|YJEO^* M6FK0Q5\$?)R.W4:1|H-1+|T&+|I?7
G85SBLWZVG,%.#?<5\$W0U=2IU4/3 M-W16+R<9RU4L FCI<=ML3=!=V>F/#-A@:K"C_2MRKRAHDNP7P&+
NH7JY&1 M?8TOGC3HXX:INLI(1EVM5:P%_TU&|H.B*/6*T|M:-PRVL-C-BJE1AXK6%0
M;|4@DO%:E5,*=FLP|:9D(RYFBB+MZ^\$;YS9^N^'+|B\$4"OIWWOH|5VNF/#!@6+*
MSO6Z_~N="J_+J0ZX4C#HS.C|PK%@T M^K1M&B?HENWTJ D
"H9#_|ZY|O@/MR#!|EU5=8(Q#T_D|+!9@Z&SKH*1|5N|M%NG'47|<@R&Y+H/QB/H:P^T-N^37P-BOXJG%5TIN^P)C
*KG4Z@^V|RE!D M!%=ME|H#|=0/5Q|3.3>D*MVV@J8:#\$_UOG0.#W_IYC_~|:|Q_4U+<^7<70 MT?.Y 9V@*
|33K\$"%F^<|>Z7F(XW>G|E0|DWH:|M|_?&1^A|+J>+Z|H?Q=_M@P_O_NCVJL+Y?5U?
WR_|_&Y+K^AH9ZS7\$D|7^Z""^L_176:C\$2_V?R^W M^Z|H42R3A:38.&C%>O#(R+&A|_|X_<&0Y"5^DDO\$@C@L
9#8KT)&1<(|6HMI9!@0WUX&2_|M=KQ|O6">@G|R+3B M^|ZAY=|DSFZE#O|D0\$8#_VO'E5!@B^14"6+_
|=UN=B*S,BVV2O_QHXX8" MNXI(QHDMC:3G817?&7|X+.>(+AO EPV|A-G &:-
*D0\$?H59#R\$98HWN|TQ|9<,&P=AW-BWG^\$^7FA5%16|BF_O|JXC7A@5=3@KBAG*ORXQ
MP@JBH@RQ=CDKZHAM&|&VC;MLV|C9MLK9A:2H0=G6\$Q?%*>Q1/F40EJ4H=S*
M<5&3|M;DO<):5&Z|J+|B|H8=^2\$^W9>"JT")38:2NS-R#S/2&KT|4.(5+7 MP10I7=6=7CWD2|GVK3=

(BG%RQ6)C1\$E=^J*D=+WIB,#9S?NRG>3.#K??#R4! M0V)<%RZ6 7D7%Z-@H-@Q-#(Q,"FF 4)/V(&K&-
KN*1L6C3U<1Z M@M9NB+3+?#QBUT,F-UEUT:&KM6*#/(P*-Z^,@HMHVDISU\$C(U+%N9CXP-
MVRE)8,+X5!OQ(?)\$Q,F,ZJ4M:DO\$DV&A(L" G:X/&^M9G*QD\$VDCGQ2B+N=,
MKQZ:06<>OG(>+A2R,,MXVIA.),5L77CKJS8R(3%EBHJ^0'=-@Y&Q8(A MD4F)C;4((^@10-
EH>+K>&0!VBJEZ\$4P::ATB13!8A>&T&OC:OTVLCHEM4D) M 1P&Y5H!IG%EC)H++A!6K0Q\$SI^-DFP9P9^
NM-J@V-B)G3N.TJIE\$&" MC88\$>|QP?(PMCY,R"#0QG1N0B?JN!X M)#TV@JT;=^7'1B9 MHA4 MTV#B;
(CL&1"8)-77D)9P1O-AK>|H<&8!VBK,E M\$53::BTRW0\XM=&!\&OC+K!V,GZM7&-
@V,9!P!9#1!S3>)KAR.HMM%0;64Z M,A)MSI+A\$4&BC;KDZJ-C9J9SHIBQ%L&\$C88)>|QP? PMCY=R-#9!GIG*A;
MNM.KAU9QJ!+=.C)"KM3.P;+1MRLAXYHF4C2+!M05!AL9-E!5"W" YM"(R7 M'<C.DRQ:@ B|"P3:: BTJWAD
VBCU\$W!J8V&4!N.QR.B;2S @|+K^7WAHJO\$ M(@/3-@Z:MAX^,KYM:T6ZAP+?AJ^K-A@Y!\$W)!#""V/EW+T-
WKP>D< MW=-=73VXM!P;IV\$9(QI1^/P*F-AE.[C;@CHFT\$T3;N\$FTC M)HJ50: &!\M/8AD=-M0@WA#;!YM-
'Q:&9&,21L;=>DN&E3;J!NN/D0VICT7M19(0?3YL-S8&Y\$K2H>^!E:HDVJH,#.KJH.IUZZ/>&?M%)*D2H@.\$3<;
M6;8>1!D)K8T@|<9=R:61B:X-4KM KS;A>X90K?V*==J@T\$;#H%UE
M)&/4UBSER4>0J.AU2XC\HAI&!\&TC;M.VB8MEJ5-2&35L/(AG?-H9+BKYXY"RAFD"04.(O3=3YAEI M;'VRF
EL6KK.S>F0;N!KSI\ZK?;Z1#CY J,)/QROBW=3"2CN38\$DB|M"O' MEI@5"-P*0E MW73U 3(PDSHID/;+
(\$2X8.&U)-Q\$? HJWWWWWW9@*0^N:G2QF>S@WJD.Z MJ#N!>NCVAGWK!23CY\$J=%H1<.C)M/8
!\$E!+H.W2KOA:8N)K0PC2&XP)U%L: MC*!=(R037!MS%*^R0:(E0Z)=120CU::4H!170*PE0ZQ=9N0!VY;
MJ5=MBUQ MMFT@Z== (MV6!G5;#R09Z;TW.5J U88UJU,2<G;5=OTF4""+6D"Z!^3\$9F M7B=>5Y9;)BQ9&BQ-
R?S"B?US4^7_3X>&YBAW1A=WKUT/0"12+2<;%8L MVKX1.OAY)6P)JEW9EV!*385NC%)'8.#28(3M&".9)-
K0FA)<&G)<&E7 M,.)1\$5Q: M9=X28!YJ90:&(%!0!9D!-S!0DCZ!9O P"7#P)4AR;BU*90H72: 7\$NZ_J#
M9&)&=D*H_%.=8 B2X8B>U.RKE!2W_QL-8-A2_G M^@HG!&=WN5E0)\$:=7#QW?L_!J
MD&2<70F2X.N2D7SK@>21D%L"JY=VA=P2\$W+;;L:NX4#,I<&0VS%(O&V!#2\ M(ZP%#%LR%-
M52'(AN*5(IV4AT&!)T&Z7(7G\$Q25P<6F7BTN,B!NJH)Y6 A>7 M!EU<#R09(S?U4,1B
U(82JX,24:VS;6+5X\$@VY(NP_H@V;@8K\$S22Q0(E%DR ME-F0>G_XA!<O_O#NW33
MC);+M\$6!"N7#"M7QB3CVX:GMYQ*^X3.K@NQ/DQV9GSGOHV3+H0!FB7#F@WW M=W65DOHNINL9.GP_,*C;
IV3J)X22;#TW52,C'VKM!N\$YB!R0C!<5 R'43+3:#EIEU;F*7*W(!#5JX'DHR;
M6Y)X1D'-38;.*T2D6!O*TYG!#9=2G6!IG(&.10E8\$5YBSR3!G;TK&54KJ MNYBM9U!O4SPWOY-
TK7=Z!<#R#5772TE&X)6^D"#O)B-UT/!G+W"0S?M"OX M-C!MR3?PX&CFP:#!9F49T,H-
V7:5DHQ\2SD)C!H2^+?)&^7*7E\$ MRDT@Y:9=4FYBI%RER\$#*38-2KH>2C)K;BGA&PB5V @DW&1+N,B:/F+D)S-
RTR!Q-C)FK5!F8N6G0S/5@DO\$S M8R!R*058&'ZNS\$G&O*4KR?N\$WJZ;L3Y.)FY^YTI%~%\$V@3^;#'_V!F5!;6^
MB^F*AB;?5LWQ)-WNG5X!<W#V/6"DO%XO!D-XC(<#RB-9N_E\$W!0K"S'D:'\$3<9(BXRZ0!
M8N'=FO@!5RLRH,2@G>OA)/H MIB:744""H>C*F.3DVZCL\$SJH+L?Z,%F8(9YT2>)5
H.V&0;M3>'2_<WKUT/(-9!<+2<;DE;Z08;F(S#70!DCV;@)7-^T*QLW,=FX M16Y@8.NFP6S<4IRJ;A)?O *WFTRO-
M53+9N=K*H,4+&NXR)X!N@D\$W;1+ MT\$V,H*N5&6!B4_#U<)+1=&JFB:L!33<9FJX,2D;
&65.#03W@(&N^4ZQ'MJ^(>Y2Z,E%PX;H-Q+O-A6>I2HIN0C= M4"3M+X&+FPP7=YF41P3=!
(NVB7H)D:05#HYMW M,;J9^89Y/V IO M[W6H!<197!H!^2WJ1&>,)N^DZOO!JMPIS9\$;J%;^2
M'5:Q;9@G!G+S>#JYEUYN9G)RU5:&%B!>3 O=XB4F4G*#9=XSX'!O!V&?IM* M2L;#;D(MP(9E-
QL*+G+H#SBZ6;P=,N3S7)5,03-4W:T&GOHUE!8^QB^F"AAAX? MSHWR9%WVG5TI&+S9,'BIG&2!7JD0P.G-
H!NAY^,G.SF+IY5V9N9C)S8Q0! M&B!>3 R=XR33%ANB.*O6!D.W&P8N*N<9(S<\$J47?660G%Q!
(X^QB!F"!B4WT!EAGJSKOM.KAZ90.+Q>3C)FK-2- M!*LW&V&Z'DX>R*,009S_P_FYHYQDDG,!?#5U!PLZ'@
MKF*247)#3=*[0#-HN=G0<35S>#JYEVN;F9<7.W*@!#*KJZ'DXRO&TL5
M3RD8N!DP=F5;,BYN!30\$WJH+LOZ.)FX69X;U^<ZH\$!2NT-RM67AB!F*UH MD)S.C?+DW7A=WKUT/4-B=
<+2D;ME;Z2H!5F(U#7 !HCV;D9W-^!SLW,JFY M)!,*S-T!F)TH!DHF-3;2!WF91'9-T,
MLF!>)>MF1M95R@QDW3PHZW!R2B!5.53"LIN-I!<F92,C)LNDO<)S5V797VD MS.PL3PS7)9\$2E-IL*+4W*5=?
S&/L8KJBH+VD9-1> M2L)G=_(U/60!DA;@;W-^&S!U;?*[6PH_#@^FY8Z1DF!GTW\$OZTH"YFP?3<|

3FAG!)K_?X;!FP!%=I227KIN; M=/T-6FXVM-QE2!YQ=3.XNGF7JYL95S=6R;7/X.KF05?7 TG6V\$U5-A88N!DP
M=F5(K=;4H^),97-ILN+2-ZM*-I+IYV6H&\$S?W@Q,INN4!O7IH^8:YZZ4DX_* M/OU20Y-X/QFW)L-
M!785DHR(2W1)OR>|BYL-%W>9D4<\$W0R",MXEZ&9&T-6*# @Q*,AZ&,EHNIFD MQ12P=(MAZ8J(+
(Q_V!OD8130.XNNQIH(<6E;GO.R2&\$A!1S:8CBTC9:>M!J; MGRSE @9NN?
8+5;YW<*8S*!9BAE5LE!PI1T)S"XB^95=H;N%" MMY;0+5C;+E
M%M!RRRXMMW!:KEQCH.6602W7P0\$WMOANKLO'QKHM41IO+6#= M%MV*!]?\$Q,\$!(4F_PA909XNASC;J2WS4-
S!<RM#;P!EYG;)+O=,KAV9QB+I> M/C+ZKOA=A'YOA.AZ^@D+I> X%M VY>46+B^WRIT+ #!"8ESO&1R8IET*3.
2> M;3\$!VU5_,MYM!%*<@'UMACJ!3(@C BX!7SZ=5#NS<472!A&7%7ZO@.@!H8C0=#R"-9N074 MWK(K*!H6QL3-
37RJ"29N&31Q/81D?-SEBA09.YV9UBFI R MSJX>|QBV+E>1#+.K01M!%^W&.&Y'D0>R
&G;3&,VV5*"M6P"VBX99>& M6Q0-5ZTSH,2+@A^O!)&C!BM+48L%;-QBV+@R)SG/HH1WBGT=UV\$!8\$R<>,Z
M!THD4H(N6PQ=JB;EYN-622NS!0VY;DG)+O2%Q)H
MW6*\$YWI(>20GMX#46W;EY!8F)S>2-160.DM@SFY8Z!D\$G+^A2D!2! K)M.63;94@>,7 +&+AEEX%;&-7*\$S\$
Q*!!ZV\$DX^%J!Q0!W&)X MN#(C<.<6W&-ZN3\$C&KDTYR?N\$QJHKKSX"5F9BA^2' MON#
(%L.100D9E@B!W^ZFJ&JUX,C.JJ^JUZ;*>DNLE)/JBE!Z/A&8*Z' MD\$>R<0NH0&57-FYALG&K^!X-C9N&F
M2HDG-'9=Q041LG&OUTGUDGXW \$6V&(KLCW=Z=5# MOS>,7"4B&4!7_#Y"RS>2UL8!U8K,D#\$
MH'OK@21CX.8J92H6,"+>#*C&3+V.L?GI6H;NW@^!CNIN3J*PBYU!RG82LC*8K\$+*"HUN-B%P'(>N1 M-
P*)F_=E89;F3331!P*PB!<5<6;N6R<,41 MOP!;AW.PAW#))>">V62;
ER;37DVE5,K)M\$A*R*OBVU?MEREY1,*M('6 M71)N9212C(H;AD72:L#%K8;+*U.2L6Q#+4&B\$VVB5==@?92,
MS.A*F7ZFH\$K6PU7H!DDOYA;^VFD&UK?" M-BZU4C!4#R2!N!>W!@K"K4P0;FI2@!^5FX=#,
(=@R03@1LS7<(X006_MMAI^!2HD&=^V41 [*O1W0!E=AN01!#!>"AUMW>;B5!W#E*!/MPYZN!Y;C8N
M40F"!5!QZV&CBM#DA%MJ2?I71053-NJFI^2!+IGITFO52Q@B!;#5!VAKYV M*ZEO?JNAY)\$8W I>;!T5
M@UN9&-Q:H@0!\$!K8-SN&"69_%SJ05-D*QBVU3!L5R)&+2#(Z;GBZE916-Z P=%P9DHQH&WJ0 MH)
<*HFW515@?)L;SN%-O=\$K+@!YMV+(QU;+2'WIT4_3V=FININL<IO7IH-M^(:ZV4D8^R*!0UZOI&*ZV'DD0#
<"D9OW16-6YD-W%J*U+Y R;V#;ACC&2B M;WL/TD! X-96PZU=923CVH86N!@RZ.^&;
!L;R2;+@4)M^Z2<"LCX6I5!H@8 ME' !D&14W-BB>"<).FXU=%P9DIOH>H+2T_M0;2MN@CK@V1F)G=22M*-)BR
MU;E;TBNW4CJYV^N9FJP=<SH3M5!WMC65@YQ;36G?TE&V94@;IN-O)Q/9+MDGU!7WK#8G==XY?
Z\$.A1RB:Q8.76P>S;4;R!B!Y)/NV@M=;=V725B!MH@&6P4Q MPPYFWXY!DDFI%=< 7=S0.U7BWKU=Q
4"Y!8:SNTR(H^<N!5\$W+I+Q*V, MB*05& !B4,3U)+1<=5S"CYN-7Q'=G25=WKUT.T/=<+2\$;:L &KZ1ANL!Y)'@
MVPI6;IT5?%N9X-M8Q8E2T'+K8/#M&""9R-LN,I+Q;3L5Z>X6 ME-MJ*+?+A#SBX5;P<.LN#
!OC8V=F-E*XI(2.H.M60Y>I&;EY\$ZEO?J!H;_W@R;! MNLDIO7IH^(>ZV4D(^U*C
1AMQHIN!Y\$&^F^K;#UUEW!MY4+O@WB!3Z(N74P-M^';D4SD;8@D0;*18ML.Q781DHU1.F-
LT@O7&VBWS=!N5RG9CKBX#5SW#;JX#DHVSLC-4713?0.CMQE&KDC)QKFV!MOQ&!BV37=A793! MM*W-

ME:NEC.!-9A3.V4M;2M&-N?+N<*1W!N:J2!N.TZANL?N043F.T7?I
MV&\$5VZ9VVI\VP9>:IN5?IN8_%OIPP(KMPV&WPXQLC&OM^(:H(<:,NTJ'OG7.MJK\EWY#:N#:-
L.W7>:C\$0FW@83;=DFXC9%PQ7,+!@T<*UPYQ<[7P^(:P/M5X8C8!BJ^X26KBNP/C@&+AKKZN(RH#
<:GFQI=8V^O:G2QGZ>C@WK-TA7=V.MJ;#E-D/+!;*1D76EKR.(NLW(P_6P!4CT;0.=M^V*OFU,I&VX0A0_,"#8;/M
M&^9U!MJE^60+ZBUS5!K5QG)AN^*PJ8-LVP!9=1N01!;>[!MMV^;B-47#5.M,@-(##JX'DPR)NY!R<^L
3MODFKHQ)QK%-/0=QCI#==0G6A!G(C.MTIN8-LVP!9=1N01!;>[!MMV^;B-47"U*@\$#"JX'D@R(FI(N0@3M@U,
MW&:8N#(D<&)/94NM2M\$#MR;I\$JP/DIE;V4GB!0&8LLTP92F\$I?Q(8_03U0P-/I^V6FZQ#N!>NCXAICK
MA22CZTJ0!%6W&9FX'D@>B!IM(2V7?&WC8F_?7H!B/B!_00&V_*_DDWTIK-M
+&V&6+M^B(9T;93E081C(=;NS3-V4#;8:&*Q.2\$6QCD^=DP+!MN@'K(VIAYW6D14!_-B39FX!+
MZ9'&H=K&7H.3BLH_N/TZN'9FXN5X^J.NV&JAW1N)N!X^@F;:>#RMEWA.MMXT)OXVIBE>W8..VP?3;.3XRN;?
220.GMAE.I2H?&<YM8)S:F!J)IQ?P,"C?>OC(*+CQ2N)B!&A20SD?%K8IF>=(!MH;K^JN/CY49V9'>8M7.D&V&
(4LAK.T2J6!N!AM!>#SNZO#N!>O!QF^C'M>ODXGH?2;0!MIAZNAX!HF;J+QM5_1M8Z)O0Q3'"#%;8/1MY-
X9\$)OQZ;M/=PP:E2QR!BVD<#;=U0;?A>_2L>#=#MEW>;6.V\N^T^M^!&L^H?K82-C
MWTHO<&K@WC;#O97)R%BU(8I7!F#5-MUZI8&QC3^_2VV&5KL?9UX/?SFW8!>MO.T)CO_SJ4&_?
#U#^"U/G50!-G!OVR(WMG^NK5)F0(I!H;#2<;I2M)H2#@=L-MU=\$96?<6LIB&75P!ONOKI8^6E;GH\$EB"IL;6#
(=L-0_8&9M@#3&-/DX7=-M0;7MUIFOG;YKO_K3!#ZK6;IG1%YA6!F!UFW&^X#F#V(QFX'8S>OBL#MW,9
MN.)KPCHHN7TP-W<(F!U)OXVURNMHL(ZC0'909KNAS#I-HF!"IKZGZ<*&9A_.C?IT7>V=7CUT?T/7
MJO*3D7C%;R8.P.C(I0#S2!QN!VW!XK#I4P<;KC\$6!L.HFX?S;=(R:3A!MC
MEM*4.BBW5!N5XG)Y>5>67+!VBXW=PEXEYQ.WMX;V76YNYIUV#M;JX'F9RA2Y?D'G4P=+MAZ;K(9-
S:1*+OU\$&^L;H17=0;+NA.MT-
Z;H4W(U/^XG0G'52!^P=GM@^&X8!1D8G%CBUT8+NI@WW;#OETE)F/CMB)%\$780.MKL1GNOAY9&RVQEE
M!ZXS*0>X@/!;YU=#S(9^W;35_#8;=5=&)B/EEDA2OF4^*?KTJP/F8EY.M+T!HU*1Z!K6V&VKMCYJM;T>SXWH-
U_W=Z!=#_#;?7BTS&J)4(M)90-Z)T/(<@DIK;P07NNU)S.Y>*U!@!S;U-SQXC)Y.6&G.5U0%HN\$.@!O!W^V!-
W.^+M5?@H^FX?U<I!P&0DWJ?M^EY!HB!W1Y96-RBBY1%;L^VN;!0^8!9N!N>JTOL>H\$V7:RY!J;@*GO
M;PP=CMY>#NK^A^J!R8B_4N;%Z;<L;H>8!Y)T.T@!=="J=M2=-U\$12@=I!R-TOXC)A.>F*!31-
UNB+JKQ&3\$W5BRY)%WD'>I(>IN\$_.C(MT=O!Z.V!C!&+U;G8'1VP>-7@!R&^W!\$LI^#V=L/ME9')6+LM-GF?T-YU
MK=<S;I-J16Q%;C=J0;V!DEDW(U//P2!P_KU(I-Q.M@<5Z(8;L>9!Y)U.W@_"==B;J=2=0-2485&+H;%)W#)E,F&
I*)\$S;I-U-MN+NKR&12MAL^!C;PCDF;R?0DGPD)_DJ=0;6;Q^T2?#W(9%\$S?M5I-
I3@;\$ANIK(Y.S>;0Y9U"?I=M6Q!S&S/Z!Y0@+9X*Z-2&DWLSLVYBIKZG.MZ=*?M!.CO!HXO#TZ@\$
A@_L929C"8OU_@P@G<I\$#R2L=M!)NZL;G8!DI^MDIC*P_N@QF!8!ADTG70:U!Y'=#6#9MW%9F.W4NE9G%ET.P-
PW<9F4>TWPI.M;I^E_79&^I?#^Q!U/ZB;G(O^7!5P!I-0_0_Z5BO;K0^8.MGI@L;FGT_/NC&123J!7;\$_<=&9#YO
M.X"9IY-N)!M.T#V!K^P45<I;@."GO_FYY<32=EMQ!WN&PQZWMCG0+T!+(O!M!LD0@I48^FYC;=XK;6KZ4(!
(-P;CSH>>I;#P#I8-C#;JPR4K'X70W(R_-MUX75(UF!H81(KO2>I^W!FC)7%2Z/!SB(O!T-Y!K#)YO;F*81;WG!>F;RC
MRUCE@GW5%>7%(0H;W@=JT=X7NSB(I=QO#SEL9K#G\$R^V!L;JXPS5VZ24.MX8H(%<;>5K#^B;%-W2TV?
UW==6(U3^!6SCAN-18W73R^VU!^E" MCPB#&Z(Z^GCVP!Z6-8QFZL;N^Q^%V-R^%U2/YOO=F\$2!\$GZ?M_39
M%;XD^3IQY\$6@QF_@U!EXGT3Y21,1=Y^GN^80DO4Y71AE,4(P!O/X!D;3A.M=;H>48K#14B/75+Q!Y9&2XX0)H-
>L0NJC%Y<2B@BW0B18@C^E09=ICFI.P6.M6!^N!SJA2LR\$T7W4A!_1>PB1L>I W536!7LG8U7^>(
CHW902!>T'@&PP.M&0W5!DI6?ZN(AZ,B&75(\$=^;18;L"@1^WM+GC^4^P9^6@R&@I2EIBHC%Z=8Y!;8\$
6&8K0.U2/B!U9Q.\$XY6N.M;A5_W2G8!TK>9EJC*8.TA3@8I9A=6.9VY%F5!;15#%;PRKC*6D48U);#2IH>/7!2
=#>G9CE7&A0!JM.MR=I24?R&=SPDD/*;1=3I5U^WI#M\$K23T!TJZ/SU_
(@&PXIV.Y61I<70.D.X&+G^J8>R3B^XL\$V95R+RESUN<
MXGDTQ;5@TO\$@4YFOXZ@N!9N^8380.Y51G4N7!U0;DL#PG=>I>L2"?BH#.(A=M'O3SEH9+KB-
!E!UH%U4Y);HJCR\$Z.L60HA6!^7=Q0EV^J;K)5K5W-%SJRH)!<5I(=Z.D#0#@8YK2;JHO0+7!7\$0!&2K*+MJD<2D>=
(D-V92(^FS@4SQ'0OWT=;#8B#T*52T06E;F.YG.PS.=5L;MA.ZYQBJO+N#J#@KA3;=#!F.QOSI
/C2"L5%U"1#H.*M(>I@1&E!Y;K3Z(%M^*6#84K+4V<UVJ/0<4((N!J/LH^JGC7U.U1"K!)H!H<#)4YI+)K"-C8
MU7RE5SR<@+*0?>MYP^@X0'L'58*C%@M?ULI+!F3?L%(X\$IL<IK785=P!O.6.M/IN8'\$&:4@&H3(?!I.OQJ@8V-ED!?
2@^!T!7J8!T+GV.2U!0@.%WJ=J6<\$MZ8'"=-@F2=&D%;K#4DRZ\$>I.F!9TDITYM8@30Y)6B.KIS!%W^6/
MJ_R4Z@M!C9.+4L_0!TF(A_!W37!^QJOLJ!N^F%+01>OI.T!W.ACNMONGC%\$M.M?C/OI@Y&T+*+IT="E>=
(D!VQ2H_!GS!W'4A2+!H^C*P.3E0>RHQ!H!E@M#.@!I!
Y7B8JXT^N0&B!YT;#SH=;2>D;#RM%AFQP=&#E;+SF\$R;=I6(J.MXTB!GI23BTPQ^&D%JHS!W)OX_H>
JG/0Y60G5^SI5!J\$6!246\$.AL)0W77.MJ^@Q!^DZ1Q)^H9.SJ@&1VVF=&L;5>D.0#(K1+I.R>G077Q-
_WV(C3@P!6N\$!MXSW?UV@RQ=I!#KJ6!118B;4B*3H!O/8_VY.6;H!&E(Q=35!Y^CF_(SLM(9>3G\$*1=,*
G0P!AUHZQH@-;MT6%;%1TX^UJK;2BPZ5!8(JXT93SO+M(KK1P7^C%;HRUG/*1=DM-G_=2G92.M-;O5))?
*1507@Z&O^Q=W;I_78U7RA(PSRP0FEH!O6!P>=#"D;3=6&95;
M_JXB^XPI9Q=6CV0WWYM%B.Q^W!>TNK;\$<PXY6N.IYSSVW^N!7V!N)30!6I@AI7I=X@P>VLO!L!>Q
MZX=MMZOZKN8K'6E03LXH28KU_@\$@QKVL5QJ662Q0!8:0^NIAZ).\$Y!)2M.MPZZ.Y^!M>D;
(#BA\$AVU"=\$\$;DL(T!&96@73!DEVCBSB!+&B59@RMC.OGZQY^M"LA.F
ME7N!DOC2WX#6;VKP=">UW%ZQH4.Z\$*;2YT8%QHM=Z0(XJM(NHC!)"=
M>Q5_240?A@^M.)3QG1^NE.6G!2BZAQT\$!F)T!;)N4>Q!>=^LKI!)5#+MN>M^>J!F!YR!)Y#/\$F!\$O5!P>6#
I;3=^/7M;Y^F.T!(BG;Q!\$@N!+U9Y>N
M9.CG+7T^R2!_ZD\$K.@R&0P_RE,F%#K^+7VSLIX;>O.Q31G>.17RS4T#C.IG&M!S!0SVG0
37HL\$V#HP&K18<@ZCM.M1+2T:3(B_-RB69);#I!PW1>IFD!H\$!U)_C-OTY;QJS5FZH
MA=I=E#T!A(T.JY10TZ&AJT@E<_!W3;%8!V@X1UU=O(T.\$)^%IXJOS1.M4XZ&IWP#>9<I8^QJOLX1
^@4%+4;>KY.T.N&(T&B;-RW7^*+!B(QV?5.M.G1\$LSIN2X>.3#IT;4FZ7X@H1;!<A!H#*QT.+0ZTY&EKS;E
9S;E?M4@M9435.1J!S!0S-C?WGN;_CHS_K)4;ZL!Q4!V.961H/5BS&Q+&@%J(S?MW%NYH)M(K_4=>/G4"-
S#_2I2Y.B\$6TE*^A=I^W?7&2&-7!W6.&(I^Y&B-MKE+!/P!R;"CW4!EG&FY!
1EJT^ZAG@J\$C6M5Q6S!T9(*A2!W\$ZU.4H>-@M/0@4)E@/DH=
(<#;5Y&B.XOST!0CB4T^TG^A;3!8S!^%M^CMODYC(MSVJH(4D&Y6<741D%VCBY"!3#@E:0ROC-(?
8DOMLWHN\$<=0^9R51B9I(217'6.M.**G^U/^69JY<54?5?SE8XDH(-325&WJ;-GS#;5YF^N.XA^NJ59S>0-
\$Y&J+S.E/V!H>>XS7Z.C/VL.MUAN29%I^=C&54;#UDXL2=#0D;(6IG-Y!>8KB(V74FZ-N^SN96ICA!A;\$Q!#
M%<SAQ9Q.VF6B&KN;KG24G6.Y.9VDF!3S!X!H_-QH-U.98UILRRA+1R.EVL74.M.X'0\$97JN^T0.K^!T/>5NOBQ(2!&
Z\$H_-6_S;/1=S5KY.T&^*TFZ;BVW9;2#D1+M8NJ90.B(M@G7<%@@=F4#H^PC\$9U_H1
ML_R#J!K.43>1G4CMS)I2#N^K+B+ZRM^PE6^B;A-H%W-ESERH)^<4=*MZMD#
M(#2ER3^EO40EQI^6B\$HH3Y,1\$>TA^IU)@R94K&E;C1Q;=#B)3IA&\$V#8=IC.M0^4F!CK6+%VT\$QK.9!C;IT
EOGB.1%+/(92>R9">EX%*9TOH0A;MIG0Q)C0_M6KU57.3^\$25B=.CHDSB&J\$13881+>.4&->Y7&*T;'J3+J)
I^/HXU!1M-0.MLW!H0^@KD^\$KWS3=9=\$8NYJN<12?*1R<3B+=JIX_(2"(4J!4;\$)56C;MID(3HT)K%81RD1
/STB%)>"AC.9.MAO.R4AGCF5H2.8#2.OG2!SI2SYC0A^8T;3.AB3&AM8I#\$YH&36@74AD?I0N
MWRZB\$TV&\$ZT@E;=.XD^+*!L3+J+I\$!J8B;32A7GG0F-93^Y1NINQ0;8U?S.M98X@2

<'DTCWJN)ROC.%.2E(04,XWD=J&,J9S3?S902<2=>0G3C-S%12 M*%'M05E93)DY7A_D+MPJNJJOL@1
OG@5!+I207T+D388Df<8IHTZ+7PRT MILD(A7,AI\$S^,Q7\$1IEVOU"8^X6^*%EIJY02@ZD^XA.ZE:N.FD1)S
J25R="58ZNJ8MV,74T7 M.FK/5\$^.)^E.I?P!(T,2J-5<:=ILR:M-D1\$.JL'HF!9K0K:9M*="#\$!\$!' MBJ+.0.A\$TV
2)!"6F0SH%*JR%&SZAMVC%7&=H2MR3XH?%,AO&CM4S&C2A M'DW+&AB-AO(GP\$K0-A!N!#*V-URD5!"
(M&-IE&M050G7NU+J16VS^MNHGLQ&KCW4A0A.GCU%8)D-8OK\$:=F%5WJ5TH:X3.WDB)*N5<1?--+!\$*7=
M6&7T:2&IBN8T&1'1+JR>28.FU*MI6QHT,6G0!9)#2@FU:J, @QI\$*A,\$G9Y>
M1'8N!9N^(3@08Y41GF,,XBOD"5G,J3G=:R>,:\$)36C:9D(39T)?-U>ESQ)5 M:H4H5U8983H0I3D!2%4#"-:P2KC.K?
fSEE\HJR, ^DNLA.KG9E2NHTJOP) M8/LWE&4*UJ:f57U7X6,,,@QY1TL7K^).ABOMQBIC4(M817N:C*!H%U:/
M9\$(3.M:T+L:N\$SH%,5WHQ&ZT308"CV(528.6CH"0WCG9C.JTA-C/\$<B4* ME0FMVY18S\|M(36=4Z(OJ=-
JF0B=&A=:J+:\$G09E-12\$Z-\$ZRP-X)I<0(U)A=%S(O@FE="83.J%CG:9E0B9VF9U3HA"ITVJ9")T:%UNL-
M*3+H0KMHRAC1^LE%H:A&M%)3QG7N5P020X^LG/2760G3%@L#Q>EDI\$2L'HF\$#JA M7IVV!4(G)A
ZD1QID5"+3H.)T(T9,*@Y:O=Z0FY=IRLC.A+TJKJ\$OG,R M?:=UF)Z1H!-T&E:J)T8"5HO-X3(H
7M@BCC0JOG%G%BJ- *2QG).5 R:%) " MRSGI\$K*3I="Q0 @UY61HRA3BKI?Z&KN:+G'TG1=-G\$I*NDP?P"(L,/=K-4
ML:EPD H&/G0+I:>B8).Z%6G;5'0B8F"EC\RA,1@#00@1YD\$:D9V.8-HWF9 MHXSA7%*6?
N%*#DG0W)>Y^@9|SFA^9RVF<^).9_E70QEQ&?MO*+I MG SW66\$H8S6K>|5NKTO'3H0FQU,@U)*3H253V/867V-
7TIG-2G-*IR>0DBY/MSQ|DL#PH=T(92QIN3"0!T8!G9XPV!>1BAC->2NIPX|V&U:S.T#J->_R3AHISTU/?
P7Q=8|_/P>-DFY\$SQ|_0L"PG|WT9)OHN2P1!4.P MLXN>9S*>\$VK3:5O&1XD*!Q'0%L2-8&\$YG(RS.5E
MC(AT**RD|E3H;+O+I|X)S*|B.LNWW@+|J\$SDI.121HF80*|(-8R=""-I%|SDX:G\$XK(R1"1.YJ6-9KJ.M.Y@O<&1
3EHI02P>4#*T9S="&H:E!T^T.E(2?;1J\$RX,K+&6Y9;EFU-4EY.A+J_CH(S/G-IG3MMY13YS&K-(40& M?
6873AEK.5(+N+LW)TH5G+!6D"5.G*F74A5,4-1^X M&=|QC=:YAE-1J,%CM9RZB=GC70E>OX D
J&Y>S&*^,BSA%ISD9(<|NG)I) M5D MR.KK(#UC,"FG\$V-..H^V)H.8.9BL|HZ25N 0D M\$C2CCIP-
'7F5H)G1DZ,\$T(Q^-LBXISQ|_QFN3"1!D:,LPN@9Q*,SK0>5MB M1FBC)7|--HOK@W;OR\$F MKV/TC*VLH)0QDNO3
MHU5QM|C|=6/8B=+(S:HH6<(90>H>,4W2A?O1?4=S%"#7*NO(A?P|(M!\$-
C=J.4D9OE1HQ...72@|D|2<48'.VY*,Y24?W7)+ANIR'HQJ'D0I M\$J
(LGCT4D+A"(ICE(MQSCV1-"%A|S>LY'60GE&5,ZK*>9NJG!E562\X|B@
MKNP"*2,M&V<706*8RPD)22L2|..E!*709;.^#**C&YQ-MQB MNFI:8ZF^@_D"1P+0P4&CK*O/TP>
.G.V=&8W2QG6>S&.*AG(f?2Q=(S\$B1+:(Y,O-M57QS?9>8!F.\$R% (FG3G>=UQB|E-&3D;O(R4+D0YU1(
MOE"13D;BO(Z3|XRXQFIY:S-6Z,MZP7'5)DT*UV!90QF&,IM8DW9J|@Q9T-C M5GC*"J4-L>,84% C488P?
3:8ZFQ,M%USD9LLXNG9Q*,SK1>5M";T63.ALFLD)1QE&.*XI:Z1DLVZQ*Q\$Z2% MF3>27Z.? "S:P8KWC:-
%,78P7=OH*>=RB|+94Y,ZG,H5^7^' '=>8!F,H|B%\$FCSE\$BC)GP3YOB,G+
M'&5\$Y="J>%,*KG(V7.5UD)X1F#,*S'F,P|PY@5DK.128Z#-I (J\$S%>7-5
M+>9L6.P*21D_F2B*;Z|/:"AG72|VDK1R@T2:|X|W-;Y0N#A|LYBO;@1 M/3EXH!O0P>1#"<
<9C=*&=-91"E*SMF(9W:A|P2 MND'9.0!&,0^RE MASD&+T K.1M6|C)*&4M9?/:%EG(V+.5UCIV1ES.JRWF:
MNIP9=5FO-W27Z"|| (I8S#7+#!M0^Y&_ZRPE&3 YT9?52AG=Y*RKPTZ0 M-F:LJ!?
QR@:XFXSQ3="Z>Z;JHW,5S=V_W9RZDA7G^%KYGE^J^J)S*,0!F+P|2E.E<%D|>FLC9.)&7 M\$96@A3&3
XF!7P7EY&+(R,Y8+& MY8'7>|<<3H MT8^MU _D0TM%|2+BV\$7WRBE)90.YBN;O232S@X851T^7G^)
(AL_L1BEC M.8N%B89S,6*772@|D|4RZ"VI M.,K8RRDG\$>LH+Q=#7E8HRFC)Z2I%>HA3%V,%W8J'67>"XJ.C.|_P!
f@,C=E-4\$9NELL!46|D+;L(>B96N:#^7+,% M*A0@(@)S&8Q5'B0H\$Z@LGSUL(:&O\$Q01DO^,@3QI2|U>1BJ,GK
M"#WC*Q?TEB50N|J#V7:9*A8E4?A+FO&Y#&8H#|*324^.,XO\$9>"W=VPC)?YZ;."UK'Q:."UHEY1D4N
MJ"*7,2IR851D^7-\$9@QJR"YV.C*R7G&(#T-&5MC);.Z;K'AZQJPDYV%F2&* MO8G3#R@+T.6IA"O-7H.YBN;%2-
2STY0Z1|S|;@!@PU&0W/QEA6?R"HJQ< MC#AE%S_/)"<75)K+MN3DPB4GMZN(U(H)9?Y.1!AC*9R?
+9PPYQJ7+_.1" ME949(K2-BV\$;KR/TCO<4\$ \$NVQ3DPBG(KDA/@-8-9!:=&0I9.|?H(1?0U8H MRAC&H)"@3
MDRR?6SPA213%&J8HIB@7I(R+X1FOS_2,2%Q0|B|Y."/R.=JN:|17;M M8Q=|&0=9.1>H(1=#0U8(R@C&L^
M@_G"QK|?3TX0Z?IR_ \$@" PIV4U01E66RP%18\$0GNPAZ)B6YH-%?E;&0KY/K33(4U%"KH:\$+/.S.GH012Q=
M1534BZMN_KP^6EC8U^Y@JNPOH=H|0VYQ@|FR|KB01P<'ZJZNCQ_T/8_X M4&4<9;D<.BYDW_A0/9.17-
%BKMLRDBN3D?P4UR|^E|%#KH,YR6AK\$Q"LGCV MT".NADV|S\$ _&+DY%?-
Y643"NAF""SL|SUG%Z|ANLXXK8QWKY8;H&+2.70!E MW&/UW")\$#;/U8_2@C%J=R7?+!@&U?%W^=!
WC3WTJ|L'54C.H+!&4'T^X6-M?3|<""*JNK4!20!H(E?#1'83E/3Q7)-|D:FN M.15IAK^BAUP'XY\$""^@9Z|BB
M=5RW6>>5L8YKK\$5ZXK'1JZ#UK&+H(Q|W*|+?+J ^G\$U|&.%H(Q8W\$(59=B*
M8G'505!G0;GL0^:P=4P@V^""KKU:WMC|&C&5USIX!A1U:7E^0_ \$!@>LIN@ MC)TLEP.BP
A+=A'T3"YR18>Y;LM%KEPN&XHG!A,CB<^:17PPB^T:EFL!@|F"YI MI(EK.C@_5'59>?X D-"&@.Q&)Z,ER^6
\$#!RD5WH/!.17%>KMLBD"L3@9R+ MW.10/JZ#" :!U7PSI6X,GXQ(6"6\$^H\$U?=>|G7" M,SL>J|/7 T?^#Z8-
7W%V,%|56/+SP='AZJN*||? #+.)#=#&2!9+D<\$-& M\$+((GF"PKR'HF215J@;UT'=V-5/1CJF+ X.H7)<
M#>58@29G..*ZG+=EG-U|&8 MXT%X.@ "XLE#@|@!O\$R/FCN%_B8S9TBJOA%* _#XQH7%\$TKMM\$X|J(OBTW
M)?=C|K(SKH&?L@B=C&|_%+RX'6+XQ@H|&9.X) _%=@15-XJ|+ODYX5L>C'E2! MJZ\$ "W |G)F2+>4PI|S>-JF,=N>#
(^LE@.Z")7C_8!<|S MX<85K>6Z+=RX,N^O741CJ@=U|HXT%X,J^&LG#YF|(P|OPY"/L_S<%GWB M:OC\$Z_0|
(QE7E(SK-LFX,DON+(A;8J2<1V4C%WX9%3C+B|)592-JR\$,*_AD M-*@O*VAHD=<=#J#(G
U1_ ^U6FOA:~8NOBNK1)!"|Y,R0;BG/M'P""P#"W01E?&2YQ)
%1MROBZ!GDHTK6LMU6|)Q99*4TKBDR34CNM@LO\$@_M09E,8 GD88,WY.%E@C(R<1#?4U1)ZZ&3KP.T#;.
<47'N&YSC"OG&&O%AN08 M=(Q=_&1.8_G_-G2-F^\$:R_QLC\$60A;Q_XSX;|_J,_%/8P>S5=W0(F17P:FAIBO*P>0|
#V3@TU1D:6RR'C M009-#;4SF<8-G>6V+=.X,9G&3TD>4D-K;VWP4SC,7HV-LVX-.E6N*\$ _W_Q_M>)6@C?
&)OXQ1?SMH0Z>X&4IQ.D|&=&XH6C MB#9&-1Y7\$Q-&RK'S5".%8PR.G&A^UR*N!7FKIN^3HX&|MT1,9'8!M
J;H83 M?.,TK,%4W|!>2,"PL\$IHJ;KRO, '@\$PP%&0W3!DQ680I2LG-B#MVP?1,LG%# M?;EM2S9N3+)OK>)|@1T/_N
T&P^P^RE(DT#BE>3?Q"HTK<#)5X&::,6DQ7JN)M M^"K\$S=">+UVVZOCENZ|RW;/TEH)*VN;V@? M-^_5F#*>,5/-
S'RO3":Q4T7?YTC;7- WU)29Z(L;.@-|_/OFD:UVBJ|V^" MOI\$A>|84=/5Y?D#0"@8.K*;HHRD+-
(4!>5F)!^|_HFY+BARMRA1PW)N18 M_A01&Z# <>#*#6BC6,@4:QH!0W0RE>)BFC&
(=8:A5;#7K&S?";UU%Z1CYN M*!^W?;)Q8^1C^2PC/0;-8Q='&?X|NB7#ZS"!%#0E8XRNC%QGZO|^L&L).C
M|J|T)|^@|FBQNI/QV<,&JZQ#Q|_*@F-T-=G.4 M\$9,%|RC:RLV(W9Q|S\$2<4.ON6U+.FY.TG%
(EWQAC&9R&TPZ'F0IDW|J^I& M>2G8Z W">JFEC^A910EPH;.<3.TXW62GG&1&K&C;9N+W!@762|Y9,B@C.RB
M*.;DAV66B(O44MNAI;LP)01CNE|XCL&RK'33">"G2Q-3.H9!7'2JH\$WW_QO M^\$;IX@->?0?3U8W;<-V.
M\$G(S).1UE)XQDQO:R6V:F=PX.UDM.43(H)KL0BDC*#|E<\$OR24-)N1F2LH)2
M3C^>TSEW+OU_U@)TK+ZP="78JSRD4;+>#W151>?|NH|F*YNE);.3EX MI|O.P>1#"T93=*;H-/>6VS5-N
MC*>LEAR*RFU05^AE&54ZSBZ<.*LO4)85E&(RGAGH|_|M-|/<%3?_QM8=O)P>.,=%Y_@_0!X;-
1.8HXSC+7T|\$@I&3L+HF4CDAB9T MVQ;W)A(Y%2K^"Z&AB9S&XQ\$N0H\$X8<:U;:>LJ&4W
PI>1FD7&ARN;|EXN*P M_1NB|C|*S|C+#+>WEMLU>;IRI?|>=^%U%2;D-ZLLNE#(2,UTQ)7&_%TWF9IC;
M"DL91YGR%>7!8=24FVX1.V^F<&CU',4KQ51-FZ&-_SO_W>OX8>?;DK_1?_V MPE3?
^GQU(P+ZR:DCW8*>/'8";.G.WU&803#LC/\$M2T(ZV1D)EW%YVJ@|_6.MG(W;.5E@O8S"G-'MA;EO4Y@HS
KE59Q\$?M'C3JC,4H/NV8.3.!^,7<=ZCH|3@M.SB)Z,NJR2^.;.CN-P<5E!*,DARN(|(E>2N&|-.B\$9FO*A\$,6FA MHU?

<#:#XE;P!|L:ILL;U>0>#XX8==U|GC|Y(%A,KM|ROC-4^F(X|""%(F%|F0F-/<443NAHB|#%)&3%96
MALW2.)|7,7I&5^ZH*=MNG)G=&6EVE|8|H/|L@NCC+9%L'97B:BC%J90-%5W,E=V/OIX'11UZWG M^0-
&|@>LYNBC-TL4A3%YFYD|)LH>B8FN:|W+?%)'+35|7A9T<3V|/3P?&BK@O/P>/#<9C=(&:_9-I8B%8P@91=
(SV0F M=W2?^|,Y,YD)HL?&9K+?3 P>|D331RI^Y:|T=Y&XXR;L@99SD*(Z5=K22
MNV\$EKV/TC<457NVU3ESJC^N>(^|C4E^T18963E^&2:PXI8LC^"D89#5G? M+;9|71-V803GC=7/+A^O^|H|_?
A7|YI2|SXE^V^OOG^E+W| YG>|? ?F>_> M O#AX;O^?|G_XO6G3T:'^|>_>Y'SZ^_>V|B|>?OONX|=WW_T7|H|?/-
MX_NG/W#_|_R|MW'3_PU;W|/|Q|_Z|_|>.7_S|02P,\$% @ 281\$6M%M MV&;9#P_H4|H|X;|W;W)KE?^ET-
P_6+X^/_>^I>_M5_VW|76|W6U>_>^I?_7575Q>|B|:K8U:6ZGA=-9NCTY/=W|W03D_:MEV'5;KW7=?K=5|>?
K>M7>03R^HX>_>^FYQ|JV?W%|>G)=7=8?ZN^GZ>=>M^W3|6;I%LZXW?=-NBH^_>+H%:QXS4|OK|G|RB|?>
=>CGXOMO7QJV|^V^IY= MO#PJM'R'5|_I^V|91N3|NZ|_ZM=H6Y0+Y_>|4H|=^MQ?BGQ|*_WYWI^YN/E5|_M?=:N?
FTNAJN71^:HN^>_5S>KX:~?V|FU|?T=R6|YYN^IW_R_N|G^W^/K.;_JA M7=|?|")8-YLO?U9_W+<\$NH QX@)V?P?Q?
VEHEV4;ZJA.CWTVKNBV_ZV^VW| MP^YU=U>|X)K-
JFOY_3N7QMWW7#ZP7W/%S>KNGCW|MV+X|>Z6A72|4.UU\$6U MN2A>G9_?K&|6|N-%:9VW MY4^T:|G|_%3-
JB_>S_M?|?59NQF:S4VSN2S_MJJYV5PY_5|MO>2C.VO7Z9M_?WY3?^U?|C?%5T6S^3Y>M3>|*|<_>|<'6_C
M/CZ_O|O77^Z.\$7?WIC| MN#PK& E\$|7|'IX47W_US=-BCEV#;8>VPUMBM7 M\$.6^K5<7S|TS;R05G4HK.CEVT?
M17|=G=F<^&|?2KR_4_||0MWB_6T0;|N-B_35VW_Z|ZH=CWKKWW75%?2F(A3|_ME|+TKK^M^<_<
R>EB?^MX^ZY6/L MIN|USO:US3G;7|4 SMMD=>5YL_0W7+#+_VD M'L-4T6;Z8?N=;O|KUM==>|M|>H^/QI=B%&H@
0+";_0?|?1RE_?^N+|>_>|M#>#=#1!Z% KN1+A",QC!"8:P?;Z9UZ7#=#M6K^X_KTAYM/??W|S59\$W+?V
MZO\$WJZ90J_YN1C|H^|VX\$%91|H#_I&N|?N|OBU?K|L8%40W%KU?^<=56XKK& M|?C^|_?0PGW99NA/4^H+*
^TJ|MR|N^M^>P^Q|N|4_9=|VJ=KW9>((U&2\$0C_M7M8AKN|26|>I@O6Q47U0^D7=NI=JB^KJZ|QMOB_J2=JEA\$Q>-
F%N_|^|KN M7^7NH>|KRVV+|RN/EK&TBW|IAK@V^>^ID\$.MPU^E4>6>9
MWWU13|Q/E(:7G.K^7J|97^*#1|/1.RGM_*3T_&%26ORWV_LFXU4M|=9>XUE< MXP^Q299#|)D7?
187_9DVR<_>2|P9D3%""ZY6?Q8?R_VR2Y1BV<^|_>PG8|=-M_*22)0^W%?_V03HD^X_862DD
&^*W_LYGZ^VS%G|Y&Z^V|!<=&D%|U'UZ9>5R9>6EL;KI MUNZ;N^*K6SXI7|S@|3.F^0^6=G00^3PN^0
MAF5|&5<|&N^C_|#YK08S#^DE|X<9*(A0QS_&@3DP.XWX_+(>5XJ&^_M>Q")(+R8RZGUH(<4@>F
U9P80XAO<+>+^K.H18|45W65-1M^|5|>@>7V;J&3 M)^3HT.J^-(|0|_U-
0R|_R=&E|SE;Y8|H|>Q76ZG;P=RLG|HB1FM=KKL8|K M_2^>OY1G?_6MYO;9K6J|AE/(2EO=OKO_P"Y_XS^BXSD!
(324>K^E^F7Q|""3P<^>_ME1#^NU=C\$U=C^*U7Q0UWWGVZZ MRPP&&|_|>1^2W2F_R)268^|O4^Y^T|0>_S8
2G;|_|>MD^3PFQZC?>H.PB4;|_M=FP%QE|_|>8|@4V8S6-#"?C^\$C.WZ_7<9LWEL0&5+|ED3>M5WN9_Y;Y\$Y5G>L_M-
P;_>W?CHW^&F|"";U-V_2)/#>PNN|FE(0>6&|6=F\$;CQT/TJWDEKIW+|V M71^*/#23Q@&6<&E8+|0V+L3.
(F7QONV&XNRJZE;M_284;_#6-K+\$825+X_ MYD&P_(:5-
)G|H_@|0|)1^*5R9)Y^HI^*W60_!9MH|/|0T|/7E9R^"J|^>^9 M_*7GH;"GBV16_%(|B5BN_JL:3T/Q?_?#
(\$1BVE0(G^K\$)O^U|^>ZGZ^&XR MT5+_0T%/UF!>BL^")6^WRN0)/@|%/NEMVC)#O\$R\$%@%Y<(DGX<+G^>?^C?_<
MHRI%2%:9+M^GH:RGD|VRI^*=R\$|BL^U|3?^C7S^"-LBP|4?_2#O^>Q|V7_M|@-QV^@|6)B#>N4X^8^L^D^F-
(?>2>|X^W^0>^&S(0>9P(^W5SD(Y^N+MDAJ_Z9|XRSN3#N@|11;T%*#49V)YC=0|TT^&|_>|Q27^SQ3E^|H|H|K87
MP|W)Z_X W@NRI! OP^3OGGCOK|T^QHYB@9_|R#&%R8@W|BN X%|H_*Y*&_> M 8C?A3AA_|62 E"(2EV\$M
("Y_D+|_|#^KF|K7|KA\$><+>+>|6\$;0AXL71 M(UN8_(/GNFF %R9|""3(&EBPO^+4)>(F0^XQ_13OKW
LX!_Y_3CC7PBCNO_M=|(6F^J_|D!_>Q#6^Q<|Z%6&@)H05|OR@!"OC!!^AYL|5GX7T_*0B@&^\$ M^'-#(R
\$DP&>8Z4A%)A|_>CNAE!@F&^"|_2|-8+X@0)&#_HXW|4FYBT|P M&Y|2DGL)(Y>
(^9Y_9E|O#_%V=8@SUS|9|FRG0AC<<=>L S_@<4AXX71X_|M88(DGFNI<"8LE3\$%@-/M0|0G%-
>W&3(1288Y|E^%T@IE8R^"0%1PA|G>6=;M^>_D\$6D|34|13% MT2-SF\$^_Y_H@2F_1AR^"2)H|^E>O)LBLI
|8^E_F9-CLU^<2|L\$A|X^M^/R=::QSN MG>>F_|^\$Q)3D9(<=&2CT|_3LW<7;UCGIYN)9>_|U\$8:KWOQ?T?96M?
OG("4&5Z2^0X|JKRXR9|YJ%3S|16P^FIW! \$^4<_M#9YH&H43#&4G@+((|8)A^B0W7T|P|0|T:42.
%|Q3!|0%1_LHUE88U|X#^E4 MKQ0^N#\$#PP1Y3/MH_"J&DALREPUAQ1^ M?^?YJ JD(^EY,TC/A@F
&%F+3A==^T|W#H^U>IO30>PM(^CR|DT|FSD.*\$ M|^+HD3%,<_MSO32_Y;OB-OT.DRD.)8|
(FOP8RP3SO+W(Z8|7_4EM=F^2 M(4X.SS13^9@G_6H_5H \$<8P@1@>ZJ8|YI@Q*99FT^DP5C2+\$U^\$^9O\$E(3^9.S?
+"99H&6_5^+D L_A@^W M^MHB%R&|^E_68:0A|0_DH7L_..TQ_S+29|OADD%J0F4^<(48X0SS/3&T@
M^"9|_>=J)XW7OKB_(Q>P&7_/XISTXNB1 M+4S@SW_=-\$!^4TZ^D&BPZ7^XGCUXB9^YC^|3L|0N)!->
E>#>#2R|>1C<|>MO^PI+H:5^>#2RS>1A>=>0%96GP1^XS^"Y8//(|M^_S\$^_|4^#_+T_R<3^|B MB&9F>|+>Y)QU)5@>2
MCK0FSY)Q#&:(Z=AT+Q_7|AM?UZK9MNE?%+ZGG|L_Q+|QZ^&R_N_I97%@ M>G^TZ+RR^"09Z|H^E_3*?<
\$C0:65ENN^*XGSUTB9^Y#1+= P^YPT#\$|N%<8 MGUN9_V(|YZ;W9>DG4U)I|LLVEP^B^0\$S&
(Q\$NG(7535=KUPI0/M)CF(5)GU3.24UWEN@_MJBBS?1NA.NM|T_ZV|PIRF3M_\$^_|4BQOANZIO+>|W?&;38((D|
(%::(|PA^K7^_2GD@IO%W@OGLK02) M^>^LM^K=;_VN9^|Q4<|R<_D@N D@PX6HE^LPZ^>XT7|H5^CJ|^>A_>9|6
MY\$RQ268&A=3-6|QN?A+B_./\$N)-0ESS:BZ|64Z\$&TG?FC58^UH?E%+K_9 MG_2^>#_G^>OD)?N_I91^FTVD^E
HN^4G^<+0&0S3M^H|Q=L_||A53Z6H MS3R^86\$H<#EPL&C>(61(\$E@%O^3_VD?9TB\$CN_B>Q^YI3D^*8SUJ_T-P
M.D\$GI^&S_&I8225XGNH^SH6Z:F&Z4;0J^4?R|H@ND%=-HMB^X^T^S^9R> MG+V^="FCG5^QSJBXQNU9-
3M&+9FM:=G|MRW^>_I&4^D_51?@JG|SW+^_>CG0_>T>9N|XQZ5(L5|P_."\$=H5^|OE3^RKZ
M^L2^SLZ^SC^T+>NO|^S_?UMX?_#Z|22^0W G6B|&=&|>_>E65C^=0S2/7WD9P1L^2X?#_>^7C^?PB|E-
L_M6^LZ_+Z_@#;_MS)9FXTQ9_|SXW@ZU_N^#@4+05_>+>PO=V|R:W_H965T|JROB|E6J=V5X|C5EN547O(=*_0G
M:RYRJO10;|RY\$XPF95">_1A^XN0T+6;+>?GL02SG?^>RM&/_L|A|GE/Q>L_R M?
ES.T.SMP6.ZV2KSP%G=W3#G|CZOGLO>N0T+^F:LT^FO^""K1>S:W058V@^ M2L2_*3O^UGM@I#QS_L_<
H+%)#)H9L8RME*&@^N7;EF6&28|CYUZ:SY3A/8 M?Q_&_EP_|L_K_U)^*2_0 M4T67<|&0|BT9C-ORF26T5I^6IAU?
U)"?YKJ_+5|TH64|&_&|N|NKL CHQG^M^A55#-B=>KU3|?
9WJ8@)CIPEJEM^RN^_14%0K@>XW2_Y>J5Z^Y+V|T4GV.F M^>K)>YKL^U_/_G_Z CZ|M_#_>E>ZE Y=Y16::|K&HU_Y4:?
\$8-PN^>%VHK MP=^XQ|U;K^_M;LGGGN^K+T_26HPK6ZHK^L|9?K1E=S1%5O_-(JDXL|FRJ|_0P3^>4O3E&3Q
M1>2>%^I-"KTQ=K,D0)|2Y_JC^7|U/RK^QY6QXKOJ^D_VWXL(1SY|_|SB1 M|I|Q\$48|(0V|H5OM/BC6FIU7DF+?
5|LP+<=\$Z4>ZZX;|?EH^4Q)%D|\$UDD? M:=)1G?3XVG=K1N(3)FU^V280^U> M1J^_"EL:*SK2JGU\$"(8N|GK;R
\$R/SU=I_%Z/N0\$#^>T|Z>PD1_2FL5!^12 M_J5%KG|N4Z^K3|8=;_H:KMS3-46J^T#|TOLF%5V.)BD2R+BHZBG>HCK-
X|Q_M1\$=GU_B_1G5>&U\$RM22_|LA/V\$^H9UYAZHOWU_<
|A^\$S|L1^Y=LT(GIP2%7|H#-3M47B:)NC!"WDF@D|^ZRW+MDM(#28VTEAHCS_Q_A<_OY9^?0N-
^9X0<<A>=3&| M@UUN^<#;1:<^|T|EGATZ6|XU|GO_>&@XRG89|V+^%1AAO^|1#38@)_45
M@^\$T\$ED8&YA/M^_Z;V3TX|ABYT^X>Z|6C=@;\$_V-N^E2RG=9V5&W|LK@6E MML_|0E4W-
|W3YNKQNKQPSV_05=Q=8%XHJGN_>^|T|U%@HRM_26|&#3;|45 M8350?=>FCUSI7A>OMTRFC|A/_KS->?
J_6^>H+FH7?X/4\$|L#|!0 (<\$F\$ M1%HP^DHL?PT^&J_>+>PO=V|R:W_H965T|SFT8:Q_|51M>Y:6=|D?@E(<X)A&_<
C/)1.WS8M.7Q|L:7.50_44)S?W MQ|B(ZT>P_>^>L>?>^>(-OM9>|YXQ^Y8K3B?/^|
M=17%>ZKUFDWQ56N=MLDN+|^|G_>Y|_|GA^>_3ZYNJ_L7TXGR;7_M+6?VR M?5>HGZ9^RBK=R^Q_||PJY-
6SR7|H|G;MUBO|FOJ;PM3UY;|_|S/_Z|> MK9Y_9O4NR;5<5C4C4^H@>NY7MGK WE_NC5T7Q_2KG|
MUQ_2577S;|_K)6|2G;KZGU^>Y_LCLBO>|_|JTVVXFUQ)75OFF::SV M8)_F=|FGYM(G#1PI7L_.\$T#H7<>YIX#8-

W(5%=-J/#>ITG66FI+Z7R=H29954TOH^EE62KLL?K.^L+.^OLEW99*M MRO-H7:DQDV73:#B1^.<1B,>#C&
[L>0 M]+G^Y+M[KGM?L7".IP 9Y;M..)SDC%*.EFFV2I+.^L5IDG65;JIE1UADS MY:77JB/K524WY>H9?
=7GG>U77QJ?E-EG*90-\$I9?)3B[-S9[-MF7 M2*0L1L(\$92ZQU3ZW^TBW=#FA?6ZU35]+X,W#4.JHWK-Y-/%
I/SZ:3L+)+X MTI B80(\$V^UCV^UV;"^5&#K+2?JHKTQOB/-3V(=T,O=%J:9CLT M#302)D P\$NCY_=#S-M"+I^B^I-
GUOX;HP;=H+0:P5I[WCGOI</(N%GC9+))HYD7WZKKJW8JFV M-G-75V&JE:K07V655\$FH^D(3#%[K]/Z86H)(F
#12I"8QY"-@/B_0>998 MS[-5I/AG/2>=RS"1^T,"8N1,&"D3Q\$QSQ\$HIQ+B9"11<)B)\$R 8"2UIDP/
M/V;L1?:OW>:C+.KRWMLJS2J(5!U8UVE15E9FT/1M_-+W49:19 M+52"D:082A,H&DVP^FS;I(-/5^K)F1?
7J7JQO|DIHQ)UO_%IR2R>V*IR8.>I?0&DQE"90-JHK
MI23L<)PE\$2HZH+082A,H&DVPEATV.^#&E<2HQXBV:R+42D:I D6CCQ.UEW!X
M+V%8\$U4RWE8W*FI054*2JA;7E_)Z7^GHD;6&?U=;?+FT.QUODSJY^2I2I? M;I-
+ #4J+H32!HM\$<:OAV*.LI0Y4J4!I,90F4#2:8*U4"9\$?W%*F*15VGI MS<1=^J^Z8>;IAU XW5#=#
:0)%H^6NL^A^Z;/G-VND X MW2AR9IV00P4 E"90-HR+0<7@"/GW4IW4?RG7H#%0%0FD#1:#.T""0(B#H
M30!4!\$IL90F4#2:*RT^G^&* \$H3*!K-L?8 [C@]@ OU %!:#*4) M%(TF6^L IY\$>P.WW.W9HWPWQB&&>@
4C8;XY).\$C-([K^X#LP#BYV)O^W M^N]@ NS@.X70_@ALH\$VVH:H#2!(I&HZTU@ (O5^Y7 /13RH-VQ*\$6 \$H3
M*!J-N+8 IEJK=QA"!#OD7\$VH:8 1:/9T!; A5J K|WEK7^99NEFM^E-(=0C M0&DQE"90-
)HM1^<<7H\$%^H1H+082A,H&DVP|@N|Q&&WZCWI0?ML7FNS\$.M,502H&CTHY9:\$GAH27
IE|M^KIRWGV21U9JEMUZF6;+>W53U2+_-L/7EVY?O M?T#J|X83"X*^V&T@2*1L|&K1-
<>H\$#ZH3H+082A,H&DVP|@G>(W5"TIYV M:\$6=M>=?T8QOCJ\$U T&F/M\$SS>)YB55+|W"IEJ" T&\$H3*!K-
UDQC6 M1.C-(U)P+*^T&\$H3*!K-L9807C#.6@K+5!:#*4)%(TF6/L6CU|58OCF,>P= MC@^PS>"S?M6_?"=F<)>1>P:
MBMA%&+^%."U_#1SN#_&B*P:C"PYJZ T@:+1LT;17^<=L&V@4H+8;2 M(I&\$ZSM@O|
(N|^T|SZ:ZHP)H\$(!2A,H&@VR%@H^+Q06JHQ5Q>YNI?OUX7HX
M*:SJ@FG2|)6SI9I%JGH3"%V6\$DJ+H32!HM^UAI79F;J&62OGT^D:4%HLI0D4 MC298RY0Y+U,&V73OETK Z|IM9?
OR#C(4^"HM\$@:WR^_0GG^R=#^L00@/C MX\$)U" (I&@ZMUR)S7(2;R=+Y=-+QYWYG@72HCH#2!
(I&HZUUQ)P=#9L02>IU M(^IZ3MB..0/0&D^1;IUWY@SOL^M^QMNF.K#50E0&D^1:/9/E&AH&O9/CZ
MV|YYG;IE@S@NS6^X8&.J\$T@:+1!K1 WR/9FIG^N@=LNBE 7^4)%(V&7+N^3=S<>B M..0\$^*CX?
6^*#V@H3:|H" MZM^T(OFD^J@=)B^*V@:#3!V@X\$O!T8 M&+@VK=EO58):2A-H&@TN-H^!+P5;FX-B@RC+
f(=MSV,XGLTCC94\$ZIH-I: M\$P2)C=N 8JFIFN^U5@A>C2,504H&HVX5@4!KPK@7^650F=:@/5"" M0-%H-
K1&"(8T0KZ41 N^XQ5@1I /I060VD^1;)U@A;&_M@>E|K(8W-!+|I8XY^A/HI&0Z^Q%VN_-402-
>3>F;17.=NE(O?H1Y<9VJ M%WMQ>F8EVB :G&!/5Z;UMSM)-!<7^A9@!%H|59B#BS8#)X#7J^1L.^A|V3C?
MHW&TH:H 1:/1UJH&I@S83AXC7ITPF.K390E0"E"12-9D.KA(A7^6.Z:>G\$?\$8OSN#O494)I T>@IH7U&%(WS
MI@T|Z^T&\$H3*!DI|W3J|^_CG.P>X5^H_V:1AV+^S!<^*IV2=QY*\$S^V M:GO_5*!(S&|&K&X&
(L3,%SKO^!3@QGE#7WL%^P\$.M"!8G8+A6FMV3-/2 M!WE W74?F|IH! S.\$/M! QW%^=I>2-E%2=5!!16IR
MEM53Z-J-#QHIDRFJ7>_)JRZ2-XFJA^HJ6&UL MK5=-^;V\$/TKA+HH=H\$D^L;LU#;PL;-H@*8(G-
WMH+B:D<:VL^IDK2=-/L.M)5FQ)5KU82V2;UYG,<9CD;3/1<_Y9
D=R^9LR:3JU)S&:*W*P9/@LAM45#Q=@S8IZI>07TKGP3.D8ES0I@N..""A-K<N|^*M#"K\$
MIPSV|FA,M)07SG_HR4,ZM1SM\$>20*\$U|6|^LASS81^_N06NV>VOIX?&# M4HE,2I4PISG?V6IVDRMD4526-
%MKI9|SLT@D+^E!<5KIDWV=BR1;J7C1 M&*,1<J? K:'.21@1N=,?:ZIK\$)PQ|L#_U*^H#\$(JLH53GL**SB:"
M|XG0:&33@^HP*VN4GS\$=IV^J7.LX2S)HQ6,>.KKL7^12B:Y?(3@K|+|C^#Y_(Y|Q|G7#
MMY*R5\$YLA5|KO>YD|?"NIM |XZ^KX2Y;22Y9RFDIP0VRFU>P?-=|X@XP^2 M&^*
f5|1SO,#@T/OR<H|@OKC\$|QH>RK2?TPOK^T.S#|JXG4K M2YK U,+D\$^LP)K|^HL;..9SO|GDBU^\$ME);(V-
L\$0^~R.YIOE0^@B+|\$.M&,O86E^;Z#"=(HU6URQZ8JFIEQ&+OOQ-X=GT?Y@=N^O/80L#;.QX8|>%
MG6@*6TWAH*8_L987AVS)=::8E-0P2B*HJZ2/LSIB|A^G/@?M?Y^@_XO M!-U+@K6(T#3-
="&31\$^KYE4.CS_KRWJN>0|<1|V|51+F:5UY^71X6A^YH5 MQJW">%#A5Z|PZK;J3|+B_K:80&f^NWD?
9M)@(#NK8=1J&UJ>!(9OFF*U" &@ MI&^Z3!F%Q^C^H7=Q%/@=(0:8.*=4="18L %<7CNRHQ;,>-
!SL_9E^_B9AGZH86,L061NLY:#1^NV%!"2,G;G)KDXQ^|K:1 MR-NAL=C=T\$G^X&+\$SF\$SL'<24^H0/&_Z>)<86-
V^f(X1+7F\$1K6|;76^7 MXXK^?%6*|B/?-@)^?>\$^#?T0X&TL&K(SDC)^_*(I.D.V.&1;I?0WU8SV
MIFSR*EVO9\$%^&CS7W1%U^9*6WDF:L45=7V2-4PIQ-5)6?+E)ZF(f>FAP<'M^/BN2-
^LE^ZVB0^A/=0*70/5&IV&2SY9 O/!;RZIALNH>OT?|BG7L)N/C-QDEQ^_1OJ>-
MNIG>*9@|A>GNOMG_A*3X2F8)R^R>@43|f DJL>SH|9&"/\$!OGE*U32M/J MP6EPX^~R5?|_7&
<185\$|8Y8VE^Q;#BI979.SIMKZ^/Z49F7UT(?!#?UW^ M1E.VSY/EKCL8"O7NOP5NA?
&S5%4QV(BI0N:CFQ53L=UT=,%=5^@+^+W-8? M-X)Q#.9&_/B8 XPCF%AX 2-)W+..Q0\$&-@M8|D|=OS(*3\$?
4\$L#!:0 (\$F\$1%J7BKLLTV5LEE|JA4ODY.6|UFIW0M=KX M^N7ML^;V-/S!Y^K.M4G=@_Z!ZU>LO?G_8_B66?
Z7B;=K0J8;HJ@W64.DI9 *L%L%J6./K MJ7UQ6PRNIU.Q+?1Q>AJ/6+H|H2(; / =FV XM+;X^D\$
>2%%9D.E59%EZCF^@BW>3E613KM;2_A7D0^IU*M7N; M3^QBF-3I+D.;%+F&5R^ZC\$;K^C>DD8C9(S=*)F)?
KV3W+/*DRO\$0:B9@J.EMOI+9ER^U1AH3(C1&S1^Z4S!0Y MK\$@6\$;M+HQTO_-
&Q4H_R^*KW|F0^R)F000|O.C4GV%BM^R6;PRD1L18B)#
M1,R^F+G10+KR7TJ.^)Q^R\$B;K/PY\$QDD&+609CLU|KUZ/H#^839_<3\$;E ML28-UDQ;#&K8/K?
PDW12KX;M53N|H\$WBRN3QH|6FA-33C.8_3^5-G5MEXFY
MLL(WK\$G%XE^L.NVD"%W/;LW;OSLHGQ#QQUY60#\$FAQ2R%A5KY5PCGL#@Q
M66^IR8=LT&^VP7?_*@NS0XIY N&N(>X7==@DW^E;Y6L8 M-SI^AF1+EK.NCAWPR5Q)Y/"CX>E|QO|P|XV,DB;V2
39=W Q!/?Q+E.G?^U M.R=G:9;HITA)G)(FILVM9W>N(NS_.WR/7_1^8\MU%)LTB)41QM6J)C5L7"?
L2Q|5YH+\$&8_Q2QZ|D\$F(B3S2YO:(M.Z;CW)L!B5&
(B9S29G;.*^=3W%L+Z2^R6V(WW7JB\$FTDR;63.NJXCG4BFEV|=6OETHV^Q.A.-^_O\$8BS;39)R&4<6X2I078
MY5DY#PL<;62;K-IQK_OEC-F_PK1D^0ZS+YH.#VOAEBPALCS^!A3=Z M/B+I=(Y2UJHAR\$@RG2/7MRH!D6
Z=1.ZZ.%%CNDUC&(BZ?2.7^VKN3UD^YZW&4S.?LA4.(3UNY4#; M;HB)K-CMDXP53T15|+;4?Z-%&YU
GIXW|Y%|f- WC%/Q^|2YR<2?K_-/L2<6^,^,1\$ _NDO^>C6L6):#5;G;"D MVT^>Z3/HV^V^2;R3Y 9/Q^S13^1? KUK
ASF+ZOA>^>LA" 3I7AI%*9!|9 MJ^IK^2V491|9J.L(8P9RK^/+1GMA#&|(68<)DOLX4P9C_\$1!;JB_(-XG;..#9#"8?&\$
66C;*\$=YN\$@CC B!0V8%;1C M"/JR-YL4EWZ|4;%VA|Z<5H:82\$#\$9@7M;|5ZL;L|+&C_|87V_V=N,D(I&MS
K;S")O-6^7,D8\$&S;:/^9.V.O|1*_|BT_9*#!<=>IDG(B)VE@5ZVUI M9OK+5S85/361@0;<=W;=>=W8R(KK|HYV
R4FEF2CP0 9;LH/T>|&S="2|MLS/\$A%M=F UT<)^.SH9^3&2@>1#C^#.PIYA 9;AMH(K6+%K7?I9J#0|M-X=
(0D-N^1UB7A?YQKW0WR&X#&1A<(<\$CK\$=/.TINN^IG!OX!);.@MH4K
M3A4FLM^0VT^5F.TJ3+2A/>=%C%;59C(0L-CKR|PD^QS=@IXHMQX0|HB^PT MY+80NKR3BOL066AX?OYAJP?
F9=HB FW7?);"" 9""L>41/OQ63V\$;M\$%X M&I/);*)P>0D=>93\$%\$X2;A|"(2CI2U(3;-90,J^@Hf6QN?ZSN|LZ(;|P
MPV;3>|.#.YJW^X18=P5?V;.FW.'99^2^<0WF3Z)"YV|8)&"OYX24+CO MLWF.97
GY>HH9%8K00L.H4QAPEPIP6@J9MD*(IS|KB#|C H&8KBX ^NY\$;VB6@
M4\$S56QV|:1\$^AF;CC#D"+^KNY7|@H+!W/@)H4?4 85F MXDY(@^!T%@I#\$B+^E(0/0?TF"@(*S<0?E?
AZ(44E|HDNZP|+S+G.SK85|" MQ|^7@(\$#)O|F|43|@0D(E.SK86)"QIV9 ;N^LJ 85FX@Y0@*+F(#B3%F M,T^0;
f1%H9FX0Q3@;L@3,BB|J0H1=ZS^A_LA^V_-P72%B#M>>^<I=1;"N M@_4,2J^CT\$S<0MX|R9I41C</p></div>

\$%G!QLW OP26.\$(Q@B!@R&'555^AD=YL\$0 MAH@IA2\$ /RR2>6^' >BVS=_UMJXO4?>/R! ?>?Q>H^U!+ P04
M ")A\$1.84/I^S4\$ >70 &@ 'AL+UJR96QS+W=O\$-\$'+K 4LB07@>_H6%WVUWVVS2GUL?&YM/IV=>??UU
M6/_B?Q;VX>;>_J53I/_Y/P!>_M@?OY_NU_6!N?JZ.IZMY^O-JN?CVANG M!>?^O!RIN;J!F?KS?'S-
VYVEQZ4;5^~*!B@!KEIU4;5^~!J-F@=OE!W!O MRP!-FA5<^~"U^P!Q);3+8#9F?7.P/TSN&?;8#>V77.+VSZYT!
M>F27.P/TSJYW!N=7>_!T#N!WAF@=W!J.T#OXGH7@-!%J2X O8OK70!ZE !A M^4#OXGH7@-!%J2X
O8OK70!Z%!>_! /ONKG%:!W=;TK0. J M>E> WM7UK@'!- BP&Z!W=;TK0. J>E> WM7UK@'!J^M=
7I7U!L"!&ZN=P/H MW5SO!M"!N=X-H'=SO1M [-9Z-X#>+7Q9"= "IN=X-H'=SO1M [-9Z-X#>S?5N M +VIZIT!>G?
7NP/TJFYW!^C=7>_!T+N!WAV@=W>_!T#O^FXV>C=7>_!T+N! MWAV@=W>_!T#OX7H/@-!#11X O8?K!O!Z#1=I
/0>K0<Z#U<[P'0>IC>Z#W M"#<+ 00>K0<Z#U<[P'0>[K>\$Z#W=+TG0. I>D^ WM/UG@'H^L! 7I/UWL"
M!)ZN!P3H/5WO"=I[AIN] 7I/UWL"!%Y<[P6@!^]Z+P"!%I=I>B!N-X+0. % M!5X>B^N!P+0>W&I%X#>B^N!
/1>7.1%>28AV WDHOUP^XK12"G0007"DD M.CPE@N%*(=A) <:60!22 XTHAW\$D R95^NI, EBN">_*X4 IY\$
M!>T&F(P',R:8!>@CA(FH,&B>@P8XB)*%CBHEH,6,B:OQ8XZ)Z#%CD(DH M,F,226@R%);\$.!A2Q3A^Y3.6.U!
%#FBE^FZD09XI09RKDF2+TF0!I!@B% MID*B*4^CJ!IBE!T^F2:(G2;)"I&F^*6F0JH0JNIS&N^4&NJO\$>E\$S0/P:8(
MQ:9^LBE^LZD0;8IO;2IDFR)TFPKAI@CEID^Z*4^J!1OBE!O^N2;(O2;"@&G M" 6G0L(I0L.I&A! 11-19)PB=)P*(
<O:="RBE^RZD0^4^Z^_/8!6S0Y=V!O5?;?I^~&*W!GNJHMA!VX!_ PQSWF-I>?I+^;_ WL!R%!H9JA7!TG
MV!KY! /3PN.LU;P>Q!99USY<#S25!Z!#0U&SN!K2? I>I^JNC01LX_MM8MSV_QQAF!L99VAVPON_" +4LW
M3K;>N)VUOFN73YM>G9_LPO.V3W!U!^S3-N<&AI6WTS^Z!8F^_YO+Z-D>/_=B M#!O9R3?G?
^+K0+#+UO;_/'M_VOF!^0<">0<*>0<&>0<,>00<)>0<=>0<_I2#4\$05A5113!4%55%4%85545P5
M!5919(TILL8466.*K#%UI@B:TR1-;(&E-DC2FROA19\$XJL^476A")K0!\$U MH\$J;> M\$B;?TG_MM!X/P_X?
CSH!+KNZZ5_F1!=W! K@ \$0 &O M9R&I&4)O<_O8VJR92YX;6Q02P\$""_4 ")A\$1.F5R<(O &R^<I>P M\$P@'-0
>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 QO M (\$F\$1%J=075N, @ !@R 8 " @0X(!X;"IW;W)K M&PO=VJR:W-
H965T&UL4\$L! M A0#% @ 281\$6JBN@1\$Q" OA! !@ ('!!('AL M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
281\$6CNZ M!E,H! OOT!@ ('!OR< 'AL+W=OK 8 M " @:\$K !X;"IW;W)K&PO=VJR:W-H965T M&UL4\$L! A0#% @
281\$6LF!^+!L^P;S8 !@ M ('!^CX 'AL+W=O&UL4\$L! A0#% @ 281\$6H7;YY(*0 6(8 M !D ('!O4! 'AL+W=OX90VD2
S:@ &O @(\$!>0 M>&PO=VJR:W-H965T&UL4\$L! A0#% @ 281\$6E3^! !@ E! !D M ('!)\$ 'AL+W=O&PO=VJR:W-
H965T M&UL4\$L! A0# M% @ 281\$6I15S)V!\$ #T\$!D ('!+*L 'AL+W=O MO >&PO=VJR:W-H965T&UL4\$L! A0#% @
281\$6N;2 M&<9V% LDP !D ('!<L 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 281\$6O^RZ64!@ @!(!D M
(^!\$H 'AL+W=O&PO M=VJR:W-H965T&UL4\$L! A0#% @ 281\$6H@!6 !#:"4 !D ('!M1L! 'AL+W=O% "N#P &O
@(&I* \$ >&PO=VJR:W-H965T&UL4\$L! A0#% M @ 281\$6G9?0U!P % D !D ('!ICX! 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ 281\$6M5+(N34 M @ UP8 !D ('!I4! 'AL+W=O&PO=VJR:W-H965T ;H40, /X' 9 " @=Q6
0!X;"IW;W)K&UL4\$L! A0#% @ 281\$6JF^3TIP- C98 !D M ('!9% H! 'AL+W=O&PO=VJR M:W-H965T&UL M4\$L!
A0#% @ 281\$6BOU;+Y# @ B@8 !D ('!#YD! M 'AL+W=O&PO=VJR:W-H965TDN; L "Z 9 M " @=&=
0!X;"IW;W)K&UL4\$L! A0#% @ M281\$6I3/#V?2.P BM\$!D ('!<*D! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
281\$6L^9:9"!@ %A< !D M ('!I \$ " 'AL+W=O&PO=VJR:W-H M965T&UL4\$L! M A0#% @ 281\$6HZ0J&!(@)1 !D
(^!10 " 'AL M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 281\$ M6FAZLVP! FPP !D ('!&B,"
'AL+W=O&PO=VJR:W-H965T@H &TK 9 " @3(K @!X;"IW;W)K M&UL4\$L! A0#% @ 281\$6A^!N^A" 1!D M !D
(^!XS4" 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 281\$6NDV; @; P 0< !D M ('!\$H" 'AL+W=O30(
>&PO=VJR:W-H965T M&UL4\$L! A0# M% @ 281\$6C6^2&PO=VJR:W-H965T&UL4\$L! A0#% @ 281\$6A;!)9#!#0
_WT !D M ('!S^0" 'AL+W=O&PO M=VJR:W-H965T&UL4\$L! A0#% @ 281\$6N+MJ4ZP!0 &3< !D ('! M.H@ "
'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% M @ 281\$6CL%T#^!0 J2X !D ('!I8" 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ 281\$6A!F\$FC. @ 1P@ !D M ('!K, " 'AL+W=O&PO=VJR M:W-H965T (*P&M 9 " @::Z
@!X;"IW;W)K&UL M4\$L! A0#% @ 281\$6FZH=C!^P NPH !D ('!5;T" M 'AL+W=O&UL4\$L! A0#% @
M281\$6CA^Y0X P O T !D ('!U8" 'AL+W=O&UL4\$L! A0#% @ 281\$6A#29WM6!@ M% C4 !D ('!M4"
'AL+W=O&PO=VJR:W-H965T+? @!X;"IW;W)K&UL4\$L! A0#% @ 281\$6A"<6!Y^! U18 !D M ('!L.P"
'AL+W=O&PO=VJR:W-H M965T&UL4\$L! M A0#% @ 281\$6BHBK<^!0 8RH !D ('!G # 'AL M+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ 281\$ M6IO1<.)2^P-5! !D ('!NO # 'AL+W=O&PO=VJR:W-H965T; " @:L@ P!X;"IW;W)K
M@!P!X;"IW;W)KZ P!X;"IW;W)KZ^ P!X;"IW;W)K; " @1K2 M P!X;"IW;W)K?R P!X;"IW;W)K04 !X7; " @?5U
P!X;"IW;W)K MWON^P! \$^L#@: " @7A!! !X;"IW;W)K^#@4 +05: " @0\$+ M!@!X;"IW;W)KA, &<9-"
1DB!@!X;"IS="EL M97.N>&UL4\$L! A0#% @ 281\$6I>^NQS \$P(L M !^R^4& %JR96QS+RYR96QS4\$L! A0#% @
281\$6E^=W!^" @0Y@ M !^L28& 'AL+W=O7!E&UL4\$L!@ "G -*< !^X DY!@ \$! end XML 180 Show.js IDEA:
XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.
Data and content created by government employees within the scope of their employment are not subject to
domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null;Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e.e.style.display='block';Show.LastAR=e;Show.hideAR=function()
{Show.LastAR.style.display='none';Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
fa.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML 181
report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */.report
table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; }
.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */.pl a,
.pl a:visited { color: black; text-decoration: none; } /* table */.report { background-color: white; border: 2px solid
#acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr {
border: 1px solid #acf; } /* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-
align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial,
sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px;
white-space: normal; } /* word-wrap: break-word; */ .report td.pl a a { cursor: pointer; display: block; width:
200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /*
Header rows... */.report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report
.re { background-color: #f0f0f0; } /* Even rows... */.report .re, .report .reu { background-color: #def; } .report
.reu td { border-bottom: 1px solid black; } /* Odd rows... */.report .ro, .report .rou { background-color: white; }

~~report .rou td { border-bottom: 1px solid black; } .report .rou table td , .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num , .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 183 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html12977651false8970false22 falsefalseR1.htm0000001 - Document - CoverSheethttp://www.healthpeak.com/role/CoverCoverCover1 falsefalseR2.htm0000002 - Document - Audit InformationSheethttp://www.healthpeak.com/role/AuditInformationAudit InformationCover2 falsefalseR3.htm9952151 - Statement - CONSOLIDATED BALANCE SHEETSSheethttp://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSCONSOLIDATED BALANCE SHEETSSStatements3 falsefalseR4.htm9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParentheticalCONSOLIDATED BALANCE SHEETS (Parenthetical)Statements4 falsefalseR5.htm9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSCONSOLIDATED STATEMENTS OF OPERATIONSSStatements5 falsefalseR6.htm9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)Sheethttp://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSCO STATEMENTS OF COMPREHENSIVE INCOME (LOSS)Statements6 falsefalseR7.htm9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTSSheethttp://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENON STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTSSStatements7 falsefalseR8.htm9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (Parenthetical)Sheethttp://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLE STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (Parenthetical)Statements8 falsefalseR9.htm9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSCONSOLIDATED STATEMENTS OF CASH FLOWSSStatements9 falsefalseR10.htm9952158 - Disclosure - BusinessSheethttp://www.healthpeak.com/role/BusinessBusinessNotes10 falsefalseR11.htm9952159 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm9952160 - Disclosure - The MergerSheethttp://www.healthpeak.com/role/TheMergerThe MergerNotes12 falsefalseR13.htm9952161 - Disclosure - Real Estate InvestmentsSheethttp://www.healthpeak.com/role/RealEstateInvestmentsReal Estate InvestmentsNotes13 falsefalseR14.htm9952162 - Disclosure - Dispositions of Real Estate and Discontinued OperationsSheethttp://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsDispositions of Real Estate and Discontinued OperationsNotes14 falsefalseR15.htm9952163 - Disclosure - Impairments of Real EstateSheethttp://www.healthpeak.com/role/ImpairmentsofRealEstateImpairments of Real EstateNotes15 falsefalseR16.htm9952164 - Disclosure - LeasesSheethttp://www.healthpeak.com/role/LeasesLeasesNotes16 falsefalseR17.htm9952165 - Disclosure - Loans ReceivableSheethttp://www.healthpeak.com/role/LoansReceivableLoans ReceivableNotes17 falsefalseR18.htm9952166 - Disclosure - Investments in and Advances to Unconsolidated Joint VenturesSheethttp://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint VenturesInvestme in and Advances to Unconsolidated Joint VenturesNotes18 falsefalseR19.htm9952167 - Disclosure - IntangiblesSheethttp://www.healthpeak.com/role/IntangiblesIntangiblesNotes19 falsefalseR20.htm9952168 - Disclosure - DebtSheethttp://www.healthpeak.com/role/DebtDebtNotes20 falsefalseR21.htm9952169 - Disclosure - Commitments and ContingenciesSheethttp://www.healthpeak.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes21 falsefalseR22.htm9952170 - Disclosure - Equity and Redeemable Noncontrolling InterestsSheethttp://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsEquity and Redeemable Noncontrolling InterestsNotes22 falsefalseR23.htm9952171 - Disclosure - Earnings Per Common ShareSheethttp://www.healthpeak.com/role/EarningsPerCommonShareEarnings Per Common ShareNotes23 falsefalseR24.htm9952172 - Disclosure - Compensation PlansSheethttp://www.healthpeak.com/role/CompensationPlansCompensation PlansNotes24 falsefalseR25.htm9952173 - Disclosure - Segment DisclosuresSheethttp://www.healthpeak.com/role/SegmentDisclosuresSegment DisclosuresNotes25 falsefalseR26.htm9952174 - Disclosure - Income TaxesSheethttp://www.healthpeak.com/role/IncomeTaxesIncome TaxesNotes26 falsefalseR27.htm9952175 - Disclosure - Supplemental Cash Flow InformationSheethttp://www.healthpeak.com/role/SupplementalCashFlowInformationSupplemental Cash Flow InformationNotes27 falsefalseR28.htm9952176 - Disclosure - Variable Interest EntitiesSheethttp://www.healthpeak.com/role/VariableInterestEntitiesVariable Interest EntitiesNotes28 falsefalseR29.htm9952177 - Disclosure - Concentration of Credit RiskSheethttp://www.healthpeak.com/role/ConcentrationofCreditRiskConcentration of Credit RiskNotes29 falsefalseR30.htm9952178 - Disclosure - Fair Value MeasurementsSheethttp://www.healthpeak.com/role/FairValueMeasurementsFair Value MeasurementsNotes30 falsefalseR31.htm9952179 - Disclosure - Derivative Financial InstrumentsSheethttp://www.healthpeak.com/role/DerivativeFinancialInstrumentsDerivative Financial InstrumentsNotes31 falsefalseR32.htm9952180 - Disclosure - Accounts Payable, Accrued Liabilities, and Other LiabilitiesSheethttp://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesAccounts Payable, Accrued Liabilities, and Other LiabilitiesNotes32 falsefalseR33.htm9952181 - Disclosure - Deferred RevenueSheethttp://www.healthpeak.com/role/DeferredRevenueDeferred RevenueNotes33 falsefalseR34.htm9952182 - Disclosure - Schedule II: Valuation and Qualifying AccountsSheethttp://www.healthpeak.com/role/ScheduleIIValuationandQualifyingAccountsSchedule II: Valuation and Qualifying AccountsNotes34 falsefalseR35.htm9952183 - Disclosure - Schedule III: Real Estate and Accumulated~~

Depreciation Sheet<http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationScheduleIII-RealEstateandAccumulatedDepreciationNotes35-falsefalseR36.htm9952184> – Disclosure – Schedule IV: Mortgage Loans on Real Estate Sheet<http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateScheduleIV-MortgageLoansonRealEstateNotes36-falsefalseR37.htm995410> – Disclosure – Pay vs Performance Disclosure Sheet<http://xbrl.sec.gov/ecd/role/PvpDisclosurePayvsPerformanceDisclosureNotes37-falsefalseR38.htm995445> – Disclosure – Insider Trading Arrangements Sheet<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsiderTradingArrangementsNotes38-falsefalseR39.htm995447> – Disclosure – Insider Trading Policies and Procedures Sheet<http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProcInsiderTradingPoliciesandProceduresNotes39-falsefalseR40.htm995550> – Disclosure – Cybersecurity Risk Management and Strategy Disclosure Sheet<http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosureCybersecurityRiskManagementandStrategyDisclosureNotes40-falsefalseR41.htm995551> – Disclosure – Summary of Significant Accounting Policies (Policies) Sheet[http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPoliciesSummaryofSignificantAccountingPolicies\(Policies\)Policies.htm995552](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPoliciesSummaryofSignificantAccountingPolicies(Policies)Policies.htm995552) – Disclosure – Summary of Significant Accounting Policies (Tables) Sheet[http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesTablesSummaryofSignificantAccountingPolicies\(Tables\)Tables.htm995553](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesTablesSummaryofSignificantAccountingPolicies(Tables)Tables.htm995553) – Disclosure – The Merger (Tables) Sheet[http://www.healthpeak.com/role/TheMergerTablesTheMerger\(Tables\)Tables.htm995554](http://www.healthpeak.com/role/TheMergerTablesTheMerger(Tables)Tables.htm995554) – Disclosure – Real Estate Investments (Tables) Sheet[http://www.healthpeak.com/role/RealEstateInvestmentsTablesRealEstateInvestments\(Tables\)Tables.htm995555](http://www.healthpeak.com/role/RealEstateInvestmentsTablesRealEstateInvestments(Tables)Tables.htm995555) – Disclosure – Dispositions of Real Estate and Discontinued Operations (Tables) Sheet[http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsTablesDispositionsofRealEstateandDiscontinuedOperations\(Tables\)Tables.htm995556](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsTablesDispositionsofRealEstateandDiscontinuedOperations(Tables)Tables.htm995556) – Disclosure – Leases (Tables) Sheet[http://www.healthpeak.com/role/LeasesTablesLeases\(Tables\)Tables.htm995557](http://www.healthpeak.com/role/LeasesTablesLeases(Tables)Tables.htm995557) – Disclosure – Loans Receivable (Tables) Sheet[http://www.healthpeak.com/role/LoansReceivableTablesLoansReceivable\(Tables\)Tables.htm995558](http://www.healthpeak.com/role/LoansReceivableTablesLoansReceivable(Tables)Tables.htm995558) – Disclosure – Investments in and Advances to Unconsolidated Joint Ventures (Tables) Sheet[http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesTablesInvestinandAdvancesToUnconsolidatedJointVentures\(Tables\)Tables.htm995559](http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesTablesInvestinandAdvancesToUnconsolidatedJointVentures(Tables)Tables.htm995559) – Disclosure – Intangibles (Tables) Sheet[http://www.healthpeak.com/role/IntangiblesTablesIntangibles\(Tables\)Tables.htm995560](http://www.healthpeak.com/role/IntangiblesTablesIntangibles(Tables)Tables.htm995560) – Disclosure – Debt (Tables) Sheet[http://www.healthpeak.com/role/DebtTablesDebt\(Tables\)Tables.htm995561](http://www.healthpeak.com/role/DebtTablesDebt(Tables)Tables.htm995561) – Disclosure – Commitments and Contingencies (Tables) Sheet[http://www.healthpeak.com/role/CommitmentsandContingenciesTablesCommitmentsandContingencies\(Tables\)Tables.htm995562](http://www.healthpeak.com/role/CommitmentsandContingenciesTablesCommitmentsandContingencies(Tables)Tables.htm995562) – Disclosure – Equity and Redeemable Noncontrolling Interests (Tables) Sheet[http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsTablesEquityandRedeemableNoncontrollingInterests\(Tables\)Tables.htm995563](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsTablesEquityandRedeemableNoncontrollingInterests(Tables)Tables.htm995563) – Disclosure – Earnings Per Common Share (Tables) Sheet[http://www.healthpeak.com/role/EarningsPerCommonShareTablesEarningsPerCommonShare\(Tables\)Tables.htm995564](http://www.healthpeak.com/role/EarningsPerCommonShareTablesEarningsPerCommonShare(Tables)Tables.htm995564) – Disclosure – Compensation Plans (Tables) Sheet[http://www.healthpeak.com/role/CompensationPlansTablesCompensationPlans\(Tables\)Tables.htm995565](http://www.healthpeak.com/role/CompensationPlansTablesCompensationPlans(Tables)Tables.htm995565) – Disclosure – Segment Disclosures (Tables) Sheet[http://www.healthpeak.com/role/SegmentDisclosuresTablesSegmentDisclosures\(Tables\)Tables.htm995566](http://www.healthpeak.com/role/SegmentDisclosuresTablesSegmentDisclosures(Tables)Tables.htm995566) – Disclosure – Income Taxes (Tables) Sheet[http://www.healthpeak.com/role/IncomeTaxesTablesIncomeTaxes\(Tables\)Tables.htm995567](http://www.healthpeak.com/role/IncomeTaxesTablesIncomeTaxes(Tables)Tables.htm995567) – Disclosure – Supplemental Cash Flow Information (Tables) Sheet[http://www.healthpeak.com/role/SupplementalCashFlowInformationTablesSupplementalCashFlowInformation\(Tables\)Tables.htm995568](http://www.healthpeak.com/role/SupplementalCashFlowInformationTablesSupplementalCashFlowInformation(Tables)Tables.htm995568) – Disclosure – Variable Interest Entities (Tables) Sheet[http://www.healthpeak.com/role/VariableInterestEntitiesTablesVariableInterestEntities\(Tables\)Tables.htm995569](http://www.healthpeak.com/role/VariableInterestEntitiesTablesVariableInterestEntities(Tables)Tables.htm995569) – Disclosure – Concentration of Credit Risk (Tables) Sheet[http://www.healthpeak.com/role/ConcentrationofCreditRiskTablesConcentrationofCreditRisk\(Tables\)Tables.htm995570](http://www.healthpeak.com/role/ConcentrationofCreditRiskTablesConcentrationofCreditRisk(Tables)Tables.htm995570) – Disclosure – Fair Value Measurements (Tables) Sheet[http://www.healthpeak.com/role/FairValueMeasurementsTablesFairValueMeasurements\(Tables\)Tables.htm995571](http://www.healthpeak.com/role/FairValueMeasurementsTablesFairValueMeasurements(Tables)Tables.htm995571) – Disclosure – Derivative Financial Instruments (Tables) Sheet[http://www.healthpeak.com/role/DerivativeFinancialInstrumentsTablesDerivativeFinancialInstruments\(Tables\)Tables.htm995572](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsTablesDerivativeFinancialInstruments(Tables)Tables.htm995572) – Disclosure – Accounts Payable, Accrued Liabilities, and Other Liabilities (Tables) Sheet[http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesTablesAccountsPayableAccruedLiabilitiesandOtherLiabilities\(Tables\)Tables.htm995573](http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesTablesAccountsPayableAccruedLiabilitiesandOtherLiabilities(Tables)Tables.htm995573)

Payable, Accrued Liabilities, and Other Liabilities (Tables) <http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilities62falsefalseR63.htm9955533> - Disclosure - Deferred Revenue (Tables) <http://www.healthpeak.com/role/DeferredRevenueTablesDeferredRevenuefalsefalseR64.htm9955534> - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) [http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetailsSummaryofSignificantAccountingPolicies-Narrative\(Details\)Details64falsefalseR65.htm9955535](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetailsSummaryofSignificantAccountingPolicies-Narrative(Details)Details64falsefalseR65.htm9955535) - Disclosure - Summary of Significant Accounting Policies - Schedule of Government Grant Receivables - Cares Act (Details) [http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivables-CaresAct\(Details\)Details65falsefalseR66.htm9955536](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivables-CaresAct(Details)Details65falsefalseR66.htm9955536) - Disclosure - The Merger - Narrative (Details) [http://www.healthpeak.com/role/TheMergerNarrativeDetailsTheMerger-Narrative\(Details\)Details66falsefalseR67.htm9955537](http://www.healthpeak.com/role/TheMergerNarrativeDetailsTheMerger-Narrative(Details)Details66falsefalseR67.htm9955537) - Disclosure - The Merger - Schedule of Consideration Transferred (Details) [http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetailsTheMerger-ScheduleofConsiderationTransferred\(Details\)Details67falsefalseR68.htm9955538](http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetailsTheMerger-ScheduleofConsiderationTransferred(Details)Details67falsefalseR68.htm9955538) - Disclosure - The Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) [http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed\(Details\)Details68falsefalseR69.htm9955539](http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed(Details)Details68falsefalseR69.htm9955539) - Disclosure - The Merger - Schedule of Proforma Financial Information (Details) [http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetailsTheMerger-ScheduleofProformaFinancialInformation\(Details\)Details69falsefalseR70.htm9955540](http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetailsTheMerger-ScheduleofProformaFinancialInformation(Details)Details69falsefalseR70.htm9955540) - Disclosure - Real Estate Investments - 2024 Real Estate Investment Acquisitions (Details) [http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2024RealEstateInvestmentAcquisitions\(Details\)Details70falsefalseR71.htm9955541](http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2024RealEstateInvestmentAcquisitions(Details)Details70falsefalseR71.htm9955541) - Disclosure - Real Estate Investments - 2023 Real Estate Investment Acquisitions (Details) [http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2023RealEstateInvestmentAcquisitions\(Details\)Details71falsefalseR72.htm9955542](http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2023RealEstateInvestmentAcquisitions(Details)Details71falsefalseR72.htm9955542) - Disclosure - Real Estate Investments - 2022 Real Estate Investment Acquisitions (Details) [http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2022RealEstateInvestmentAcquisitions\(Details\)Details72falsefalseR73.htm9955543](http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetailsRealEstateInvestments-2022RealEstateInvestmentAcquisitions(Details)Details72falsefalseR73.htm9955543) - Disclosure - Real Estate Investments - Construction, Tenant, and Other Capital Improvements (Details) [http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetailsRealEstateInvestments-Construction,Tenant,andOtherCapitalImprovements\(Details\)Details73falsefalseR74.htm9955544](http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetailsRealEstateInvestments-Construction,Tenant,andOtherCapitalImprovements(Details)Details73falsefalseR74.htm9955544) - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2024 Dispositions of Real Estate (Details) [http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations-2024Dispositions of Real Estate\(Details\)Details74falsefalseR75.htm9955545](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations-2024Dispositions of Real Estate(Details)Details74falsefalseR75.htm9955545) - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2023 Dispositions of Real Estate (Details) [http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations-2023Dispositions of Real Estate\(Details\)Details75falsefalseR76.htm9955546](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations-2023Dispositions of Real Estate(Details)Details75falsefalseR76.htm9955546) - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2022 Dispositions of Real Estate (Details) [http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstateandDiscontinuedOperations-2022Dispositions of Real Estate\(Details\)Details76falsefalseR77.htm9955547](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstateandDiscontinuedOperations-2022Dispositions of Real Estate(Details)Details76falsefalseR77.htm9955547) - Disclosure - Dispositions of Real Estate and Discontinued Operations - Held for Sale and Discontinued Operations (Details) [http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuedOperations-2022Dispositions of Real Estate and Discontinued Operations\(Details\)Details77falsefalseR78.htm9955548](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuedOperations-2022Dispositions of Real Estate and Discontinued Operations(Details)Details77falsefalseR78.htm9955548) - Disclosure - Dispositions of Real Estate and Discontinued Operations - Schedule of Results of Discontinued Operations (Details) [http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResults of Real Estate and Discontinued Operations\(Details\)Details78falsefalseR79.htm9955549](http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResults of Real Estate and Discontinued Operations(Details)Details78falsefalseR79.htm9955549) - Disclosure - Impairments of Real Estate (Details) [http://www.healthpeak.com/role/ImpairmentsofRealEstateDetailsImpairments of Real Estate\(Details\)Details79falsefalseR80.htm9955550](http://www.healthpeak.com/role/ImpairmentsofRealEstateDetailsImpairments of Real Estate(Details)Details79falsefalseR80.htm9955550) - Disclosure - Leases - Lease Income (Details) [http://www.healthpeak.com/role/LeasesLeaseIncomeDetailsLeases-Lease Income\(Details\)Details80falsefalseR81.htm9955551](http://www.healthpeak.com/role/LeasesLeaseIncomeDetailsLeases-Lease Income(Details)Details80falsefalseR81.htm9955551) - Disclosure - Leases - Narrative (Details) [http://www.healthpeak.com/role/LeasesNarrativeDetailsLeases-Narrative\(Details\)Details81falsefalseR82.htm9955552](http://www.healthpeak.com/role/LeasesNarrativeDetailsLeases-Narrative(Details)Details81falsefalseR82.htm9955552) - Disclosure - Leases - Future Minimum Rents (Details) [http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetailsLeases-Future Minimum Rents\(Details\)Details82falsefalseR83.htm9955553](http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetailsLeases-Future Minimum Rents(Details)Details82falsefalseR83.htm9955553) - Disclosure - Leases - Tenant Purchase Options (Details) [http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetailsLeases-Tenant Purchase Options\(Details\)Details83falsefalseR84.htm9955554](http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetailsLeases-Tenant Purchase Options(Details)Details83falsefalseR84.htm9955554) - Disclosure - Leases - Lease Costs (Details) [http://www.healthpeak.com/role/LeasesLeaseCostsDetailsLeases-Lease Costs\(Details\)Details84falsefalseR85.htm9955555](http://www.healthpeak.com/role/LeasesLeaseCostsDetailsLeases-Lease Costs(Details)Details84falsefalseR85.htm9955555) - Disclosure - Leases - Future Lease Obligations (Details) [http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetailsLeases-Future Lease Obligations\(Details\)Details85falsefalseR86.htm9955556](http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetailsLeases-Future Lease Obligations(Details)Details85falsefalseR86.htm9955556) - Disclosure - Leases - Depreciation Expense (Details) [http://www.healthpeak.com/role/LeasesDepreciationExpenseDetailsLeases-Depreciation Expense\(Details\)Details86falsefalseR87.htm9955557](http://www.healthpeak.com/role/LeasesDepreciationExpenseDetailsLeases-Depreciation Expense(Details)Details86falsefalseR87.htm9955557) - Disclosure - Leases - Denver Office Relocation (Details) [http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetailsLeases-Denver Office Relocation\(Details\)Details87falsefalseR88.htm9955558](http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetailsLeases-Denver Office Relocation(Details)Details87falsefalseR88.htm9955558) - Disclosure - Leases - Tenant Updates (Details) [http://www.healthpeak.com/role/LeasesTenantUpdatesDetailsLeases-Tenant Updates\(Details\)Details88falsefalseR89.htm9955559](http://www.healthpeak.com/role/LeasesTenantUpdatesDetailsLeases-Tenant Updates(Details)Details88falsefalseR89.htm9955559) - Disclosure - Loans Receivable - Schedule of Loans Receivable (Details) [http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetailsLoans Receivable-Schedule of Loans Receivable\(Details\)Details89falsefalseR90.htm9955560](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetailsLoans Receivable-Schedule of Loans Receivable(Details)Details89falsefalseR90.htm9955560) - Disclosure - Loans

[falsefalseR92.htm9955562](http://www.healthpeak.com/role/LoansReceivableTheMergerDetailsLoansReceivable-TheMerger(Details)Details90>falsefalseR91.htm9955561 - Disclosure - Loans Receivable - Sunrise Senior Housing Portfolio Seller Financing and Other Seller Financing (Details)SheethfalsefalseR93.htm9955563 - Disclosure - Loans Receivable - 2025 Loans Receivable Transactions (Details)SheethfalsefalseR95.htm9955565 - Disclosure - Loans Receivable - 2023 Loans Receivable Transactions (Details)SheethfalsefalseR97.htm9955567 - Disclosure - Loans Receivable - CCRC Resident Loans (Details)SheethfalsefalseR99.htm9955569 - Disclosure - Loans Receivable - Loan Losses (Details)SheethfalsefalseR103.htm9955573 - Disclosure - Intangibles - Schedule of Intangible Lease Liabilities \(Details\)SheethfalsefalseR105.htm9955575 - Disclosure - Intangibles - Narrative \(Details\)SheethfalsefalseR107.htm9955577 - Disclosure - Intangibles - Schedule of Goodwill Segments \(Details\)SheethfalsefalseR109.htm9955579 - Disclosure - Debt - Bank Line of Credit and Term Loan \(Details\)SheethfalsefalseR111.htm9955581 - Disclosure - Debt - Senior Unsecured Notes \(Details\)NotesfalsefalseR113.htm9955583 - Disclosure - Debt - Schedule of Debt Maturities \(Details\)SheethfalsefalseR115.htm9955585 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligation \(Details\)SheethfalsefalseR101.htm9955571 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures - Narrative (Details)Sheeth<a href=)

Interests – ATM Program

(Details)Sheet[\(Details\)Sheet\[\\(Details\\)Sheet\\[\\\(Details\\\)Sheet\\\[\\\\(Details\\\\)Sheet\\\\[\\\\\(Details\\\\\)Sheet\\\\\[\\\\\\(Details\\\\\\)Sheet\\\\\\[\\\\\\\(Details\\\\\\\)Sheet\\\\\\\[\\\\\\\\(Details\\\\\\\\)Sheet\\\\\\\\[\\\\\\\\\(Details\\\\\\\\\)Sheet\\\\\\\\\[\\\\\\\\\\(Details\\\\\\\\\\)Sheet\\\\\\\\\\[\\\\\\\\\\\(Details\\\\\\\\\\\)Sheet\\\\\\\\\\\[\\\\\\\\\\\\(Details\\\\\\\\\\\\)Sheet\\\\\\\\\\\\[\\\\\\\\\\\\\(Details\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\[\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\\\\\[\\\\\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\\\\\)Sheet\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails140>falsefalseR141.htm9955611 – Disclosure – Supplemental Cash Flow Information – Summary of cash flow information discontinued operations</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails139>falsefalseR140.htm9955610 – Disclosure – Supplemental Cash Flow Information – Summary of Supplemental</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetailsIncomeTaxes-ScheduleofDeferredTaxAssetsandLiabilities\\\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\\\)Details138>falsefalseR139.htm9955609 – Disclosure – Income Taxes – Schedule of Unrecognized Tax Benefits Roll Forward</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails137>falsefalseR138.htm9955608 – Disclosure – Income Taxes – Schedule of Deferred Tax Assets and Liabilities</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetailsIncomeTaxes-ScheduleofIncomeTax\\\\\\\\\\\\\\\\\\\(Expense\\\\\\\\\\\\\\\\\\\)Benefit\\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\\)Details136>falsefalseR137.htm9955607 – Disclosure – Income Taxes – Schedule of Income Tax Expense \\\\\\\\\\\\\\\\\\\(Benefit\\\\\\\\\\\\\\\\\\\) Reconciliation</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesNarrativeDetailsIncomeTaxes-Narrative\\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\\)Details135>falsefalseR136.htm9955606 – Disclosure – Income Taxes – Schedule of Income Tax \\\\\\\\\\\\\\\\\\(Expense\\\\\\\\\\\\\\\\\\) Benefit</p></div><div data-bbox=\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetailsIncomeTaxes-ScheduleofCommonStockDistribution\\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\\)Details134>falsefalseR135.htm9955605 – Disclosure – Income Taxes – Narrative</p></div><div data-bbox=\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetailsSegmentDisclosures-RevenuesandAssetsbySegment\\\\\\\\\\\\\\\\(Details\\\\\\\\\\\\\\\\)Details133>falsefalseR134.htm9955604 – Disclosure – Income Taxes – Schedule of Common Stock Distribution</p></div><div data-bbox=\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\(http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails132>falsefalseR133.htm9955603 – Disclosure – Segment Disclosures – Revenues and Assets by Segment</p></div><div data-bbox=\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\]\\\\\\\\\\\\\\(http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails131>falsefalseR132.htm9955602 – Disclosure – Segment Disclosures – Significant Expense Categories by Segment</p></div><div data-bbox=\\\\\\\\\\\\\\)\\\\\\\\\\\\\]\\\\\\\\\\\\\(http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetailsSegmentDisclosures-Narrative\\\\\\\\\\\\\(Details\\\\\\\\\\\\\)Details130>falsefalseR131.htm9955601 – Disclosure – Segment Disclosures – Schedule of Information for the Reportable Segments</p></div><div data-bbox=\\\\\\\\\\\\\)\\\\\\\\\\\\]\\\\\\\\\\\\(http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetailsCompensationPlans-DepartureofExecutives\\\\\\\\\\\\(Details\\\\\\\\\\\\)Details129>falsefalseR130.htm9955600 – Disclosure – Segment Disclosures – Narrative</p></div><div data-bbox=\\\\\\\\\\\\)\\\\\\\\\\\]\\\\\\\\\\\(http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityPlans-ScheduleofRestrictedStockUnitandLTIPUnitactivity\\\\\\\\\\\(Details\\\\\\\\\\\)Details128>falsefalseR129.htm9955599 – Disclosure – Compensation Plans – Departure of Executives</p></div><div data-bbox=\\\\\\\\\\\)\\\\\\\\\\]\\\\\\\\\\(http://www.healthpeak.com/role/CompensationPlansStockOptionsDetailsCompensationPlans-StockOptions\\\\\\\\\\(Details\\\\\\\\\\)Details127>falsefalseR128.htm9955598 – Disclosure – Compensation Plans – Schedule of Restricted Stock Unit and LTIP Unit activity</p></div><div data-bbox=\\\\\\\\\\)\\\\\\\\\]\\\\\\\\\(http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetailsCompensationPlans-RestrictedStockAwards\\\\\\\\\(Details\\\\\\\\\)Details126>falsefalseR127.htm9955597 – Disclosure – Compensation Plans – Stock Options</p></div><div data-bbox=\\\\\\\\\)\\\\\\\\]\\\\\\\\(http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetailsCompensationPlans-StockBasedCompensation\\\\\\\\(Details\\\\\\\\)Details125>falsefalseR126.htm9955596 – Disclosure – Compensation Plans – Restricted Stock Awards</p></div><div data-bbox=\\\\\\\\)\\\\\\\]\\\\\\\(http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetailsEarningsPerCommonShare-AdditionalInformation\\\\\\\(Details\\\\\\\)Details124>falsefalseR125.htm9955595 – Disclosure – Compensation Plans – Stock Based Compensation</p></div><div data-bbox=\\\\\\\)\\\\\\]\\\\\\(http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetailsEarningsPerCommonShare-ComputationofEPS\\\\\\(Details\\\\\\)Details123>falsefalseR124.htm9955594 – Disclosure – Earnings Per Common Share – Additional Information</p></div><div data-bbox=\\\\\\)\\\\\]\\\\\(http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetailsEqandRedeemableNoncontrollingInterests-DownREITs\\\\\(Details\\\\\)Details122>falsefalseR123.htm9955593 – Disclosure – Earnings Per Common Share – Computation of EPS</p></div><div data-bbox=\\\\\)\\\\]\\\\(http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsandHealthpeakOPDetails121>falsefalseR122.htm9955592 – Disclosure – Equity and Redeemable Noncontrolling Interests – DownREITs</p></div><div data-bbox=\\\\)\\\]\\\(http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherComprehensiveIncome\\\(Loss\\\)Details120>falsefalseR121.htm9955591 – Disclosure – Equity and Redeemable Noncontrolling Interests – Redeemable Noncontrolling Interests and Healthpeak OP</p></div><div data-bbox=\\\)\\]\\(http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockActivitiesDetails119>falsefalseR120.htm9955590 – Disclosure – Equity and Redeemable Noncontrolling Interests – Schedule of Accumulated Other Comprehensive Income \\(Loss\\)</p></div><div data-bbox=\\)\]\(http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails118>falsefalseR119.htm9955589 – Disclosure – Equity and Redeemable Noncontrolling Interests – Share Repurchase Programs \(Details\)Details118 falsefalseR119.htm9955589 – Disclosure – Equity and Redeemable Noncontrolling Interests – Schedule of Other Common Stock Activities</p></div><div data-bbox=\)](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails117>falsefalseR118.htm9955588 – Disclosure – Equity and Redeemable Noncontrolling Interests – ATM Program (Details)Details117 falsefalseR118.htm9955588 –</p></div><div data-bbox=)

[falsefalseR142.htm9955612 - Disclosure - Supplemental Cash Flow Information - Summary of cash equivalents and restricted cash \(Details\)Sheethttp://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandr](#)
[Cash Flow Information - Summary of cash equivalents and restricted cash \(Details\)Details142](#)
[falsefalseR143.htm9955613 - Disclosure - Variable Interest Entities - Narrative \(Details\)Sheethttp://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetailsVariable Interest Entities -](#)
[Narrative \(Details\)Details143 falsefalseR144.htm9955614 - Disclosure - Variable Interest Entities - Schedule of](#)
[Variable Interest Entities \(Details\)Sheethttp://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetailsV](#)
[Interest Entities - Schedule of Variable Interest Entities \(Details\)Details144 falsefalseR145.htm9955615 -](#)
[Disclosure - Variable Interest Entities - Balance Sheet Disclosures \(Details\)Sheethttp://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetailsVariable](#)
[Interest Entities - Balance Sheet Disclosures \(Details\)Details145 falsefalseR146.htm9955616 - Disclosure -](#)
[Concentration of Credit Risk - Schedule of Geographical Concentration of Credit Risk \(Details\)Sheethttp://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationof](#)
[of Credit Risk - Schedule of Geographical Concentration of Credit Risk \(Details\)Details146](#)
[falsefalseR147.htm9955617 - Disclosure - Fair Value Measurements \(Details\)Sheethttp://www.healthpeak.com/role/FairValueMeasurementsDetailsFair Value Measurements](#)
[\(Details\)Detailshttp://www.healthpeak.com/role/FairValueMeasurementsTables147 falsefalseR148.htm9955618 -](#)
[Disclosure - Derivative Financial Instruments - Narrative \(Details\)Sheethttp://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetailsDerivative](#)
[Financial Instruments - Narrative \(Details\)Details148 falsefalseR149.htm9955619 - Disclosure - Derivative](#)
[Financial Instruments - Financial Instruments \(Details\)Sheethttp://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetailsDerivat](#)
[Financial Instruments - Financial Instruments \(Details\)Details149 falsefalseR150.htm9955620 - Disclosure -](#)
[Accounts Payable, Accrued Liabilities, and Other Liabilities \(Details\)Sheethttp://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetailsAccou](#)
[Payable, Accrued Liabilities, and Other Liabilities \(Details\)Detailshttp://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesTables150](#)
[falsefalseR151.htm9955621 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue \(Details\)Sheethttp://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetailsDeferred](#)
[Revenue - Schedule of Deferred Revenue \(Details\)Details151 falsefalseR152.htm9955622 - Disclosure - Schedule](#)
[II: Valuation and Qualifying Accounts \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIValuationandQualifyingAccountsDetailsSchedule II:](#)
[Valuation and Qualifying Accounts \(Details\)Detailshttp://www.healthpeak.com/role/ScheduleIIValuationandQualifyingAccounts152](#)
[falsefalseR153.htm9955623 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Details of](#)
[Real Estate and Accumulated Depreciation \(Outpatient Medical\) \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEs](#)
[III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation \(Outpatient](#)
[Medical\) \(Details\)Details153 falsefalseR154.htm9955624 - Disclosure - Schedule III: Real Estate and](#)
[Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation \(Lab\) \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEs](#)
[III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation \(Lab\) \(Details\)Details154 falsefalseR155.htm9955625 - Disclosure - Schedule III: Real Estate and Accumulated](#)
[Depreciation - Details of Real Estate and Accumulated Depreciation \(Continuing Care Retirement Community\) \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEs](#)
[III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation](#)
[\(Continuing Care Retirement Community\) \(Details\)Details155 falsefalseR156.htm9955626 - Disclosure -](#)
[Schedule III: Real Estate and Accumulated Depreciation - Amount that Tax Basis of Net Real Estate Assets Less](#)
[Than the Reported Amounts \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationAmountthatTax](#)
[III: Real Estate and Accumulated Depreciation - Amount that Tax Basis of Net Real Estate Assets Less Than the](#)
[Reported Amounts \(Details\)Details156 falsefalseR157.htm9955627 - Disclosure - Schedule III: Real Estate and](#)
[Accumulated Depreciation - Summary of Activity for Real Estate and Accumulated Depreciation \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActi](#)
[III: Real Estate and Accumulated Depreciation - Summary of Activity for Real Estate and Accumulated](#)
[Depreciation \(Details\)Details157 falsefalseR158.htm9955628 - Disclosure - Schedule IV: Mortgage Loans on Real](#)
[Estate \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetailsSchedule IV:](#)
[Mortgage Loans on Real Estate \(Details\)Detailshttp://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstate158](#)
[falsefalseR159.htm9955629 - Disclosure - Schedule IV: Mortgage Loans on Real Estate - Reconciliation of](#)
[Mortgage Loans \(Details\)Sheethttp://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageL](#)
[IV: Mortgage Loans on Real Estate - Reconciliation of Mortgage Loans \(Details\)Details159 falsefalseAll](#)
[ReportsBookAll Reports peak-20241231.htmpeak-20241231.xsdpeak-20241231-cal.xmlpeak-](#)
[20241231-def.xmlpeak-20241231-lab.xmlpeak-20241231-pre.xml peak-20241231-g1.jpg](#)
[http://fasb.org/srt/2024http://fasb.org/us-](#)
[gaap/2024http://xbrl.sec.gov/cyd/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024trueJSON 186](#)
[MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "peak-20241231.htm": { "nsprefix":](#)
["peak", "nsuri": "http://www.healthpeak.com/20241231", "dts": { "inline": { "local": { "peak-20241231.htm" } },](#)
["schema": { "local": { "peak-20241231.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-](#)
[31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd",](#)
["http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd",](#)
["http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd",](#)
["http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd",](#)
["https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-](#)
[21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-](#)

2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": { "peak-20241231_cal.xml" } }, "definitionLink": { "local": { "peak-20241231_def.xml" } }, "labelLink": { "local": { "peak-20241231_lab.xml" } }, "presentationLink": { "local": { "peak-20241231_pre.xml" } }, "keyStandard": 531, "keyCustom": 234, "axisStandard": 54, "axisCustom": 2, "memberStandard": 65, "memberCustom": 818, "hidden": { "total": 13, "http://xbrl.sec.gov/dei/2024": 4, "http://www.healthpeak.com/20241231": 1, "http://fasb.org/us-gaap/2024": 8 }, "contextCount": 1297, "entityCount": 1, "segmentCount": 897, "elementCount": 2009, "unitCount": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 6058, "http://fasb.org/srt/2024": 737, "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.healthpeak.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R2": { "role": "http://www.healthpeak.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R3": { "role": "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentBuildingAndBuildingImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LandAndLandImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R4": { "role": "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R5": { "role": "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R6": { "role": "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R7": { "role": "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R8": { "role":

"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
"longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE
NONCONTROLLING INTERESTS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY
AND REDEEMABLE NONCONTROLLING INTERESTS (Parenthetical)", "isDefault": "false", "groupType":
"statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": {
"contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare",
"xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"
] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role":
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952157 -
Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF
CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",
"order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3",
"ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R10": { "role": "http://www.healthpeak.com/role/Business", "longName":
"9952158 - Disclosure - Business", "shortName": "Business", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true } }, "R11": { "role":
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952159 - Disclosure -
Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11",
"firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first":
true, "unique": true } }, "R12": { "role": "http://www.healthpeak.com/role/TheMerger", "longName": "9952160 -
Disclosure - The Merger", "shortName": "The Merger", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first":
true, "unique": true } }, "R13": { "role": "http://www.healthpeak.com/role/RealEstateInvestments", "longName":
"9952161 - Disclosure - Real Estate Investments", "shortName": "Real Estate Investments", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef":
"c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true,
"unique": true } }, "R14": { "role":
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations", "longName": "9952162 -
Disclosure - Dispositions of Real Estate and Discontinued Operations", "shortName": "Dispositions of Real Estate
and Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true } }, "R15": { "role":
"http://www.healthpeak.com/role/ImpairmentsofRealEstate", "longName": "9952163 - Disclosure - Impairments of
Real Estate", "shortName": "Impairments of Real Estate", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:AssetImpairmentChargesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetImpairmentChargesTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] },
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R16": { "role":
"http://www.healthpeak.com/role/Leases", "longName": "9952164 - Disclosure - Leases", "shortName": "Leases",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16",
"firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
"us-gaap:LessorDirectFinancingLeasesTextBlock", "span", "div", "body", "html"] }, "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "us-
gaap:LessorDirectFinancingLeasesTextBlock", "span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true } }, "R17": { "role":
"http://www.healthpeak.com/role/LoansReceivable", "longName": "9952165 - Disclosure - Loans Receivable",

"shortName": "Loans Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVentures", "longName": "9952166 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures", "shortName": "Investments in and Advances to Unconsolidated Joint Ventures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.healthpeak.com/role/Intangibles", "longName": "9952167 - Disclosure - Intangibles", "shortName": "Intangibles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "peak:IntangibleAssetsAndLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:IntangibleAssetsAndLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.healthpeak.com/role/Debt", "longName": "9952168 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.healthpeak.com/role/CommitmentsandContingencies", "longName": "9952169 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterests", "longName": "9952170 - Disclosure - Equity and Redeemable Noncontrolling Interests", "shortName": "Equity and Redeemable Noncontrolling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.healthpeak.com/role/EarningsPerCommonShare", "longName": "9952171 - Disclosure - Earnings Per Common Share", "shortName": "Earnings Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.healthpeak.com/role/CompensationPlans", "longName": "9952172 - Disclosure - Compensation Plans", "shortName": "Compensation Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.healthpeak.com/role/SegmentDisclosures", "longName": "9952173 - Disclosure - Segment Disclosures", "shortName": "Segment Disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.healthpeak.com/role/IncomeTaxes", "longName": "9952174 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure",

"subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R27": { "role": "http://www.healthpeak.com/role/SupplementalCashFlowInformation", "longName": "9952175 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R28": { "role": "http://www.healthpeak.com/role/VariableInterestEntities", "longName": "9952176 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "peak:VariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:VariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R29": { "role": "http://www.healthpeak.com/role/ConcentrationofCreditRisk", "longName": "9952177 - Disclosure - Concentration of Credit Risk", "shortName": "Concentration of Credit Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R30": { "role": "http://www.healthpeak.com/role/FairValueMeasurements", "longName": "9952178 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R31": { "role": "http://www.healthpeak.com/role/DerivativeFinancialInstruments", "longName": "9952179 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R32": { "role": "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilities", "longName": "9952180 - Disclosure - Accounts Payable, Accrued Liabilities, and Other Liabilities", "shortName": "Accounts Payable, Accrued Liabilities, and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R33": { "role": "http://www.healthpeak.com/role/DeferredRevenue", "longName": "9952181 - Disclosure - Deferred Revenue", "shortName": "Deferred Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R34": { "role": "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccounts", "longName": "9952182 - Disclosure - Schedule H: Valuation and Qualifying Accounts", "shortName": "Schedule H: Valuation and Qualifying Accounts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "R35": { "role": "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciation", "longName": "9952183 -

Disclosure – Schedule III: Real Estate and Accumulated Depreciation, "shortName": "Schedule III: Real Estate and Accumulated Depreciation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstate", "longName": "9952184 – Disclosure – Schedule IV: Mortgage Loans on Real Estate", "shortName": "Schedule IV: Mortgage Loans on Real Estate", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 – Disclosure – Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 – Disclosure – Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "c-1297", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1297", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 – Disclosure – Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "a", "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "a", "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 – Disclosure – Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9955511 – Disclosure – Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9955512 – Disclosure – Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.healthpeak.com/role/TheMergerTables", "longName": "9955513 – Disclosure – The Merger (Tables)", "shortName": "The Merger (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R44": { "role": "http://www.healthpeak.com/role/RealEstateInvestmentsTables", "longName": "9955514 - Disclosure - Real Estate Investments (Tables)", "shortName": "Real Estate Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfCapitalImprovementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfCapitalImprovementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R45": { "role": "http://www.healthpeak.com/role/DispositionsOfRealEstateandDiscontinuedOperationsTables", "longName": "9955515 - Disclosure - Dispositions of Real Estate and Discontinued Operations (Tables)", "shortName": "Dispositions of Real Estate and Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R46": { "role": "http://www.healthpeak.com/role/LeasesTables", "longName": "9955516 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DirectFinancingLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DirectFinancingLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R47": { "role": "http://www.healthpeak.com/role/LoansReceivableTables", "longName": "9955517 - Disclosure - Loans Receivable (Tables)", "shortName": "Loans Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R48": { "role": "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesTables", "longName": "9955518 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures (Tables)", "shortName": "Investments in and Advances to Unconsolidated Joint Ventures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R49": { "role": "http://www.healthpeak.com/role/IntangiblesTables", "longName": "9955519 - Disclosure - Intangibles (Tables)", "shortName": "Intangibles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R50": { "role": "http://www.healthpeak.com/role/DebtTables", "longName": "9955520 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R51": { "role": "http://www.healthpeak.com/role/CommitmentsandContingenciesTables", "longName": "9955521 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "R52": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsTables", "longName": "9955522 -

Disclosure - Equity and Redeemable Noncontrolling Interests (Tables)", "shortName": "Equity and Redeemable Noncontrolling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R53": { "role": "http://www.healthpeak.com/role/EarningsPerCommonShareTables", "longName": "9955523 - Disclosure - Earnings Per Common Share (Tables)", "shortName": "Earnings Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R54": { "role": "http://www.healthpeak.com/role/CompensationPlansTables", "longName": "9955524 - Disclosure - Compensation Plans (Tables)", "shortName": "Compensation Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R55": { "role": "http://www.healthpeak.com/role/SegmentDisclosuresTables", "longName": "9955525 - Disclosure - Segment Disclosures (Tables)", "shortName": "Segment Disclosures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R56": { "role": "http://www.healthpeak.com/role/IncomeTaxesTables", "longName": "9955526 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDividendsAndDistributionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDividendsAndDistributionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R57": { "role": "http://www.healthpeak.com/role/SupplementalCashFlowInformationTables", "longName": "9955527 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R58": { "role": "http://www.healthpeak.com/role/VariableInterestEntitiesTables", "longName": "9955528 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R59": { "role": "http://www.healthpeak.com/role/ConcentrationOfCreditRiskTables", "longName": "9955529 - Disclosure - Concentration of Credit Risk (Tables)", "shortName": "Concentration of Credit Risk (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }, "R60": { "role": "http://www.healthpeak.com/role/FairValueMeasurementsTables", "longName": "9955530 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } } }

gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsTables", "longName": "9955531 - Disclosure - Derivative Financial Instruments (Tables)", "shortName": "Derivative Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesTables", "longName": "9955532 - Disclosure - Accounts Payable, Accrued Liabilities, and Other Liabilities (Tables)", "shortName": "Accounts Payable, Accrued Liabilities, and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.healthpeak.com/role/DeferredRevenueTables", "longName": "9955533 - Disclosure - Deferred Revenue (Tables)", "shortName": "Deferred Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfDeferredRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:ScheduleOfDeferredRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9955534 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "peak:StraightLineRentReceivableNetOfAllowances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:StraightLineRentReceivableNetOfAllowances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable", "longName": "9955535 - Disclosure - Summary of Significant Accounting Policies - Schedule of Government Grant Receivables Cares Act (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Government Grant Receivables Cares Act (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-61", "name": "peak:GovernmentGrantIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "peak:GovernmentGrantIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.healthpeak.com/role/TheMergerNarrativeDetails", "longName": "9955536 - Disclosure - The Merger - Narrative (Details)", "shortName": "The Merger - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-151", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-79", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R67": { "role": "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "longName": "9955537 - Disclosure - The Merger - Schedule of Consideration Transferred (Details)", "shortName": "The Merger - Schedule of Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-67", "name": "peak:BusinessCombinationSharesToBeExchanged", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "peak:BusinessCombinationSharesToBeExchanged", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "longName": "9955538 - Disclosure - The Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "shortName": "The Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-151", "name": "us-gaap:Goodwill", "unitRef":

"usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "peak:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildingAndBuildingImp", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.healthpeak.com/role/TheMergerScheduleOfProformaFinancialInformationDetails", "longName": "9955539 - Disclosure - The Merger - Schedule of Proforma Financial Information (Details)", "shortName": "The Merger - Schedule of Proforma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-79", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-79", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails", "longName": "9955540 - Disclosure - Real Estate Investments - 2024 Real Estate Investment Acquisitions (Details)", "shortName": "Real Estate Investments - 2024 Real Estate Investment Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-68", "name": "peak:NumberOfPropertiesAcquired", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails", "longName": "9955541 - Disclosure - Real Estate Investments - 2023 Real Estate Investment Acquisitions (Details)", "shortName": "Real Estate Investments - 2023 Real Estate Investment Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "us-gaap:GainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails", "longName": "9955542 - Disclosure - Real Estate Investments - 2022 Real Estate Investment Acquisitions (Details)", "shortName": "Real Estate Investments - 2022 Real Estate Investment Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-88", "name": "us-gaap:PaymentsToAcquireRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-93", "name": "peak:NumberOfPropertiesAcquired", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails", "longName": "9955543 - Disclosure - Real Estate Investments - Construction, Tenant, and Other Capital Improvements (Details)", "shortName": "Real Estate Investments - Construction, Tenant, and Other Capital Improvements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfCapitalImprovementsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfCapitalImprovementsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstate", "longName": "9955544 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2024 Dispositions of Real Estate (Details)", "shortName": "Dispositions of Real Estate and Discontinued Operations - 2024 Dispositions of Real Estate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstate", "longName": "9955545 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2023 Dispositions of Real Estate (Details)", "shortName": "Dispositions of Real Estate and Discontinued Operations - 2023 Dispositions of Real Estate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-110", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-

20241231.htm, "unique": true } }, "R76": { "role":
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionofRealEstat
"longName": "9955546 - Disclosure - Dispositions of Real Estate and Discontinued Operations - 2022 Dispositions
of Real Estate (Details)", "shortName": "Dispositions of Real Estate and Discontinued Operations - 2022
Dispositions of Real Estate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-
gaap:GainsLossesOnSalesOfInvestmentRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R77": { "role":
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinue
"longName": "9955547 - Disclosure - Dispositions of Real Estate and Discontinued Operations - Held for Sale and
Discontinued Operations (Details)", "shortName": "Dispositions of Real Estate and Discontinued Operations -
Held for Sale and Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-
gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R78": { "role":
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
"longName": "9955548 - Disclosure - Dispositions of Real Estate and Discontinued Operations - Schedule of
Results of Discontinued Operations (Details)", "shortName": "Dispositions of Real Estate and Discontinued
Operations - Schedule of Results of Discontinued Operations (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1",
"name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount":
1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name":
"peak:DisposalGroupIncludingDiscontinuedOperationResidentFeesAndServices", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDi
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R79":
{ "role": "http://www.healthpeak.com/role/ImpairmentsOfRealEstateDetails", "longName": "9955549 - Disclosure -
Impairments of Real Estate (Details)", "shortName": "Impairments of Real Estate (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": {
"contextRef": "c-6", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name":
"us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF",
"ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true } }, "R80": { "role":
"http://www.healthpeak.com/role/LeasesLeaseIncomeDetails", "longName": "9955550 - Disclosure - Leases - Lease
Income (Details)", "shortName": "Leases - Lease Income (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1",
"name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:DirectFinancingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation",
"body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:DirectFinancingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation",
"body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R81": {
"role": "http://www.healthpeak.com/role/LeasesNarrativeDetails", "longName": "9955551 - Disclosure - Leases -
Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-131", "name":
"us-gaap:ProceedsFromSaleOfLeaseReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] },
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-131", "name": "us-gaap:ProceedsFromSaleOfLeaseReceivables", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation",
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R82": { "role": "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails", "longName":
"9955552 - Disclosure - Leases - Future Minimum Rents (Details)", "shortName": "Leases - Future Minimum
Rents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "82", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation",
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-
gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation",
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R83": { "role": "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails", "longName":

9955553 - Disclosure - Leases - Tenant Purchase Options (Details)", "shortName": "Leases - Tenant Purchase Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-4", "name": "peak:LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleofTenantPurchaseOptionsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleofTenantPurchaseOptionsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.healthpeak.com/role/LeasesLeaseCostsDetails", "longName": "9955554 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails", "longName": "9955555 - Disclosure - Leases - Future Lease Obligations (Details)", "shortName": "Leases - Future Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails", "longName": "9955556 - Disclosure - Leases - Depreciation Expense (Details)", "shortName": "Leases - Depreciation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails", "longName": "9955557 - Disclosure - Leases - Denver Office Relocation (Details)", "shortName": "Leases - Denver Office Relocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R88": { "role": "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails", "longName": "9955558 - Disclosure - Leases - Tenant Updates (Details)", "shortName": "Leases - Tenant Updates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StraightLineRent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R89": { "role": "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "longName": "9955559 - Disclosure - Loans Receivable - Schedule of Loans Receivable (Details)", "shortName": "Loans Receivable - Schedule of Loans Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails", "longName": "9955560 - Disclosure - Loans Receivable - The Merger (Details)", "shortName": "Loans Receivable - The Merger (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-151", "name": "peak:LoansReceivablesAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }

"peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "peak:LoansReceivablesAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R91": { "role":
"http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi
"longName": "9955561 - Disclosure - Loans Receivable - Sunrise Senior Housing Portfolio Seller Financing and
Other Seller Financing (Details)", "shortName": "Loans Receivable - Sunrise Senior Housing Portfolio Seller
Financing and Other Seller Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-5", "name": "us-
gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-188",
"name": "peak:LoansReceivableFloorRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals":
"INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R92": { "role":
"http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails", "longName":
"9955562 - Disclosure - Loans Receivable - Outpatient Medical Seller Financing (Details)", "shortName": "Loans
Receivable - Outpatient Medical Seller Financing (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-191", "name":
"peak:NumberOfPropertiesSold", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-191", "name":
"peak:LoansReceivableNumberOfExtensions", "unitRef": "extension_option", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "unique": true } }, "R93": { "role":
"http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "longName":
"9955563 - Disclosure - Loans Receivable - 2025 Loans Receivable Transactions (Details)", "shortName": "Loans
Receivable - 2025 Loans Receivable Transactions (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-158", "name":
"peak:LoansReceivableOutstandingBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-195", "name":
"peak:LoansReceivableOutstandingBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R94": { "role":
"http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails", "longName":
"9955564 - Disclosure - Loans Receivable - 2024 Loans Receivable Transactions (Details)", "shortName": "Loans
Receivable - 2024 Loans Receivable Transactions (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-158", "name":
"peak:LoansReceivableOutstandingBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-199", "name":
"peak:LoansReceivableInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US",
"decimals": "4", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "unique": true } }, "R95": { "role":
"http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "longName":
"9955565 - Disclosure - Loans Receivable - 2023 Loans Receivable Transactions (Details)", "shortName": "Loans
Receivable - 2023 Loans Receivable Transactions (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-181", "name":
"us-gaap:ProceedsFromCollectionOfLoansReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-209", "name":
"peak:LoansReceivableConversionOfBasisSpreadOnVariableRate", "unitRef": "number", "xsiNil": "false", "lang":
"en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "unique": true } }, "R96": { "role":
"http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "longName":
"9955566 - Disclosure - Loans Receivable - 2022 Loans Receivable Transactions (Details)", "shortName": "Loans
Receivable - 2022 Loans Receivable Transactions (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-158", "name":
"peak:NumberOfLoans", "unitRef": "loan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [
"span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true
}, "uniqueAnchor": { "contextRef": "c-211", "name": "us-gaap:ProceedsFromCollectionOfFinanceReceivables",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation",
"body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R97": { "role":
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails", "longName": "9955567 -
Disclosure - Loans Receivable - CCRC Resident Loans (Details)", "shortName": "Loans Receivable - CCRC
Resident Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "97", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-217",
"name": "us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R98": { "role":
"http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails",
"longName": "9955568 - Disclosure - Loans Receivable - Schedule of Loans Receivable by Origination Year
(Details)", "shortName": "Loans Receivable - Schedule of Loans Receivable by Origination Year (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98",

"firstAnchor": { "contextRef": "c-222", "name": "us-gaap:FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }], "uniqueAnchor": { "contextRef": "c-222", "name": "us-gaap:FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }], "R99": { "role": "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails", "longName": "9955569 - Disclosure - Loans Receivable - Loan Losses (Details)", "shortName": "Loans Receivable - Loan Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancingReceivableExcludingAccruedInterestCreditLossExpenseReversal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }], "R100": { "role": "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesScheduleofEquityMeth", "longName": "9955570 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures - Schedule of Equity Method Investments (Details)", "shortName": "Investments in and Advances to Unconsolidated Joint Ventures - Schedule of Equity Method Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true } }, "uniqueAnchor": { "contextRef": "c-270", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }], "R101": { "role": "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesNarrativeDetails", "longName": "9955571 - Disclosure - Investments in and Advances to Unconsolidated Joint Ventures - Narrative (Details)", "shortName": "Investments in and Advances to Unconsolidated Joint Ventures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }], "R102": { "role": "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails", "longName": "9955572 - Disclosure - Intangibles - Schedule of Intangibles Lease Assets (Details)", "shortName": "Intangibles - Schedule of Intangibles Lease Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }], "R103": { "role": "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails", "longName": "9955573 - Disclosure - Intangibles - Schedule of Intangible Lease Liabilities (Details)", "shortName": "Intangibles - Schedule of Intangible Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-4", "name": "peak:FiniteLivedIntangibleLiabilitiesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfFiniteLivedIntangibleLiabilitiesByMajorClassTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:FiniteLivedIntangibleLiabilitiesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfFiniteLivedIntangibleLiabilitiesByMajorClassTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }], "R104": { "role": "http://www.healthpeak.com/role/IntangiblesAmortizationOfDeferredLeasingCostsandAcquisitionRelatedIntangible", "longName": "9955574 - Disclosure - Intangibles - Amortization of Deferred Leasing Costs and Acquisition Related Intangibles (Details)", "shortName": "Intangibles - Amortization of Deferred Leasing Costs and Acquisition Related Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "peak:AmortizationOfLeaseUpAndNonCompeteAgreementIntangiblesAdditionalExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfFiniteLivedIntangibleAssetsAndBelowMarketLeaseAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "peak:AmortizationOfLeaseUpAndNonCompeteAgreementIntangiblesAdditionalExpense", "unitRef": "usd",

"xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"peak:ScheduleOffinitelivedIntangibleAssetsAndBelowMarketLeaseAmortizationExpenseTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R105": { "role": "http://www.healthpeak.com/role/IntangiblesNarrativeDetails", "longName": "9955575 -
Disclosure - Intangibles - Narrative (Details)", "shortName": "Intangibles - Narrative (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor":
{ "contextRef": "c-279", "name": "us-gaap:FiniteLivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-279", "name": "us-gaap:FiniteLivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount":
1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R106": { "role":
"http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet",
"longName": "9955576 - Disclosure - Intangibles - Estimated Aggregate Amortization of Intangible Assets and
Liabilities (Details)", "shortName": "Intangibles - Estimated Aggregate Amortization of Intangible Assets and
Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "106", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first":
true }, "uniqueAnchor": { "contextRef": "c-281", "name": "us-
gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"peak:ScheduleOfExpectedAmortizationOfIntangibleAssetsAndIntangibleLiabilitiesTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R107":
{ "role": "http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails", "longName":
"9955577 - Disclosure - Intangibles - Schedule of Goodwill Segments (Details)", "shortName": "Intangibles -
Schedule of Goodwill Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first":
true }, "uniqueAnchor": null }, "R108": { "role": "http://www.healthpeak.com/role/DebtTheMergerDetails",
"longName": "9955578 - Disclosure - Debt - The Merger (Details)", "shortName": "Debt - The Merger (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108",
"firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "unitRef":
"derivative_held", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-
gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-279", "name":
"peak:DebtCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique":
true } }, "R109": { "role": "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
"longName": "9955579 - Disclosure - Debt - Bank Line of Credit and Term Loan (Details)", "shortName": "Debt -
Bank Line of Credit and Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span",
"td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-324", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R110":
{ "role": "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails", "longName": "9955580 -
Disclosure - Debt - Commercial Paper Program (Details)", "shortName": "Debt - Commercial Paper Program
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "110", "firstAnchor": { "contextRef": "c-335", "name":
"peak:DebtInstrumentMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": ["peak:DebtInstrumentMaximumBorrowingCapacity", "span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-335", "name": "peak:DebtInstrumentMaximumBorrowingCapacity",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["peak:DebtInstrumentMaximumBorrowingCapacity", "span", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R111": { "role":
"http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "longName": "9955581 - Disclosure - Debt -
Senior Unsecured Notes (Details)", "shortName": "Debt - Senior Unsecured Notes (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": {
"contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount":
1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-341", "name": "us-
gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R112": { "role": "http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"longName": "9955582 - Disclosure - Debt - Mortgage Debt (Details)", "shortName": "Debt - Mortgage Debt
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "112", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-356",
"name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "unique": true } }, "R113": { "role":

"http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "longName": "9955583 - Disclosure - Debt - Schedule of Debt Maturities (Details)", "shortName": "Debt - Schedule of Debt Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R114": { "role": "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails", "longName": "9955584 - Disclosure - Commitments and Contingencies - DownREIT LLCs (Details)", "shortName": "Commitments and Contingencies - DownREIT LLCs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-383", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-383", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R115": { "role": "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails", "longName": "9955585 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligation (Details)", "shortName": "Commitments and Contingencies - Schedule of Contractual Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractualObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractualObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS", "longName": "9955586 - Disclosure - Equity and Redeemable Noncontrolling Interests - Dividends and Issuance of Common Stock in Connection with the Mergers (Details)", "shortName": "Equity and Redeemable Noncontrolling Interests - Dividends and Issuance of Common Stock in Connection with the Mergers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-391", "name": "peak:CommonStockConvertibleConversionRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R117": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails", "longName": "9955587 - Disclosure - Equity and Redeemable Noncontrolling Interests - ATM Program (Details)", "shortName": "Equity and Redeemable Noncontrolling Interests - ATM Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-392", "name": "peak:AtmEquityOfferingProgramAggregateAmountAuthorized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R118": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails", "longName": "9955588 - Disclosure - Equity and Redeemable Noncontrolling Interests - Share Repurchase Programs (Details)", "shortName": "Equity and Redeemable Noncontrolling Interests - Share Repurchase Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-401", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-401", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct", "longName": "9955589 - Disclosure - Equity and Redeemable Noncontrolling Interests - Schedule of Other Common Stock Activities (Details)", "shortName": "Equity and Redeemable Noncontrolling Interests - Schedule of Other Common Stock Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-407", "name": "us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-407", "name": "us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-

20241231.htm", "first": true, "unique": true } }, "R120": { "role":
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom",
"longName": "9955590 - Disclosure - Equity and Redeemable Noncontrolling Interests - Schedule of Accumulated
Other Comprehensive Income (Loss) (Details)", "shortName": "Equity and Redeemable Noncontrolling Interests -
Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-4",
"name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": {
"contextRef": "c-4", "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R121": { "role":
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres",
"longName": "9955591 - Disclosure - Equity and Redeemable Noncontrolling Interests - Redeemable
Noncontrolling Interests and Healthpeak OP (Details)", "shortName": "Equity and Redeemable Noncontrolling
Interests - Redeemable Noncontrolling Interests and Healthpeak OP (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-
151", "name": "peak:NumberOfRedeemableNoncontrollingInterest", "unitRef": "interest", "xsiNil": "false", "lang":
"en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-151", "name":
"peak:NumberOfRedeemableNoncontrollingInterest", "unitRef": "interest", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true, "unique": true } }, "R122": { "role":
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails", "longName":
"9955592 - Disclosure - Equity and Redeemable Noncontrolling Interests - DownREITs (Details)", "shortName":
"Equity and Redeemable Noncontrolling Interests - DownREITs (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-4",
"name": "us-gaap:MinorityInterestInPreferredUnitHolders", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-51", "name":
"peak:DownREITUnitsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "unique": true } }, "R123": { "role":
"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails", "longName": "9955593 -
Disclosure - Earnings Per Common Share - Computation of EPS (Details)", "shortName": "Earnings Per Common
Share - Computation of EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body",
"html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-
1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R124": { "role":
"http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails", "longName":
"9955594 - Disclosure - Earnings Per Common Share - Additional Information (Details)", "shortName": "Earnings
Per Common Share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-1", "name":
"peak:IncrementalCommonSharesAttributabletoDilutiveEffectofEquityForwardAgreementsSettled", "unitRef":
"shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"peak:IncrementalCommonSharesAttributabletoDilutiveEffectofEquityForwardAgreementsSettled", "unitRef":
"shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true,
"unique": true } }, "R125": { "role":
"http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails", "longName": "9955595 -
Disclosure - Compensation Plans - Stock Based Compensation (Details)", "shortName": "Compensation Plans -
Stock Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-416", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-416", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R126": { "role": "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
"longName": "9955596 - Disclosure - Compensation Plans - Restricted Stock Awards (Details)", "shortName":
"Compensation Plans - Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-42", "name":
"peak:UnitsIssuedDuringPeriodNewIssues", "unitRef": "unit", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-429", "name":

"peak:ShareBasedCompensationByShareBasedPaymentAwardSharesWithheldToOffsetTaxWithholdingObligations",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R127": {
"role": "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails", "longName": "9955597 -
Disclosure - Compensation Plans - Stock Options (Details)", "shortName": "Compensation Plans - Stock Options
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "127", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-
20241231.htm", "first": true, "unique": true } }, "R128": { "role":
"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails",
"longName": "9955598 - Disclosure - Compensation Plans - Schedule of Restricted Stock Unit and LTIP Unit
activity (Details)", "shortName": "Compensation Plans - Schedule of Restricted Stock Unit and LTIP Unit activity
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "128", "firstAnchor": { "contextRef": "c-441", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table",
"div", "us-
gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-441", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table",
"div", "us-
gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R129": { "role": "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails",
"longName": "9955599 - Disclosure - Compensation Plans - Departure of Executives (Details)", "shortName":
"Compensation Plans - Departure of Executives (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-446", "name":
"us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c-446", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R130": { "role":
"http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "longName": "9955600 - Disclosure -
Segment Disclosures - Narrative (Details)", "shortName": "Segment Disclosures - Narrative (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130",
"firstAnchor": { "contextRef": "c-4", "name": "peak:NumberOffacilitiesOwnedByUnconsolidatedJointVenture",
"unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-4", "name":
"peak:NumberOffacilitiesOwnedByUnconsolidatedJointVenture", "unitRef": "property", "xsiNil": "false", "lang":
"en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R131": { "role":
"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails",
"longName": "9955601 - Disclosure - Segment Disclosures - Schedule of Information for the Reportable Segments
(Details)", "shortName": "Segment Disclosures - Schedule of Information for the Reportable Segments (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131",
"firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"peak:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedNonCashAdjustments", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R132": { "role":
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails",
"longName": "9955602 - Disclosure - Segment Disclosures - Significant Expense Categories by Segment
(Details)", "shortName": "Segment Disclosures - Significant Expense Categories by Segment (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132",
"firstAnchor": { "contextRef": "c-452", "name": "us-gaap:OperatingExpenses", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-449", "name":
"peak:CompensationAndPropertyManagement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "unique": true } }, "R133": { "role":
"http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "longName":
"9955603 - Disclosure - Segment Disclosures - Revenues and Assets by Segment (Details)", "shortName":
"Segment Disclosures - Revenues and Assets by Segment (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "c-1",
"name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true
}, "uniqueAnchor": null }, "R134": { "role":

"http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails", "longName": "9955604 - Disclosure - Income Taxes - Schedule of Common Stock Distribution (Details)", "shortName": "Income Taxes - Schedule of Common Stock Distribution (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateInvestmentTrustDistributionTaxStatusOrdinaryIncomePerUnit", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfDividendsAndDistributionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateInvestmentTrustDistributionTaxStatusOrdinaryIncomePerUnit", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfDividendsAndDistributionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R135": { "role": "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails", "longName": "9955605 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R136": { "role": "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails", "longName": "9955606 - Disclosure - Income Taxes - Schedule of Income Tax (Expense) Benefit (Details)", "shortName": "Income Taxes - Schedule of Income Tax (Expense) Benefit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R137": { "role": "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails", "longName": "9955607 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) Reconciliation (Details)", "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R138": { "role": "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails", "longName": "9955608 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsDeferredIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R139": { "role": "http://www.healthpeak.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "longName": "9955609 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R140": { "role": "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails", "longName": "9955610 - Disclosure - Supplemental Cash Flow Information - Summary of Supplemental (Details)", "shortName": "Supplemental Cash Flow Information - Summary of Supplemental (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",

"decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R141": { "role": "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued", "longName": "9955611 - Disclosure - Supplemental Cash Flow Information - Summary of cash flow information discontinued operations (Details)", "shortName": "Supplemental Cash Flow Information - Summary of cash flow information discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-481", "name": "us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R142": { "role": "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "longName": "9955612 - Disclosure - Supplemental Cash Flow Information - Summary of cash equivalents and restricted cash (Details)", "shortName": "Supplemental Cash Flow Information - Summary of cash equivalents and restricted cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R143": { "role": "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "longName": "9955613 - Disclosure - Variable Interest Entities - Narrative (Details)", "shortName": "Variable Interest Entities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "c-487", "name": "peak:PaymentsToAcquireEquityInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-487", "name": "peak:PaymentsToAcquireEquityInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R144": { "role": "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails", "longName": "9955614 - Disclosure - Variable Interest Entities - Schedule of Variable Interest Entities (Details)", "shortName": "Variable Interest Entities - Schedule of Variable Interest Entities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "c-492", "name": "us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-492", "name": "us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R145": { "role": "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails", "longName": "9955615 - Disclosure - Variable Interest Entities - Balance Sheet Disclosures (Details)", "shortName": "Variable Interest Entities - Balance Sheet Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentBuildingAndBuildingImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-499", "name": "us-gaap:InvestmentBuildingAndBuildingImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "peak:ScheduleOfVariableInterestEntitiesIncludedInTheBalanceSheetTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R146": { "role": "http://www.healthpeak.com/role/ConcentrationOfCreditRiskScheduleofGeographicalConcentrationOfCreditRiskDe", "longName": "9955616 - Disclosure - Concentration of Credit Risk - Schedule of Geographical Concentration of Credit Risk (Details)", "shortName": "Concentration of Credit Risk - Schedule of Geographical Concentration of Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "c-4", "name": "peak:NumberOfTenants", "unitRef": "tenant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:NumberOfTenants", "unitRef": "tenant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R147": { "role": "http://www.healthpeak.com/role/FairValueMeasurementsDetails", "longName": "9955617 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:DerivativeLiabilityStatementOffFinancialPositionExtensibleEnumerationNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["peak:DerivativeLiabilityStatementOffFinancialPositionExtensibleEnumerationNotDisclosedFlag", "span", "div", "ix:continuation", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R148": { "role":

"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "longName": "9955618-Disclosure - Derivative Financial Instruments - Narrative (Details)", "shortName": "Derivative Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R149": { "role": "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "longName": "9955619 - Disclosure - Derivative Financial Instruments - Financial Instruments (Details)", "shortName": "Derivative Financial Instruments - Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeAssetNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-548", "name": "us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R150": { "role": "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails", "longName": "9955620 - Disclosure - Accounts Payable, Accrued Liabilities, and Other Liabilities (Details)", "shortName": "Accounts Payable, Accrued Liabilities, and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "150", "firstAnchor": { "contextRef": "c-4", "name": "peak:RefundableEntranceFeesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:RefundableEntranceFeesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R151": { "role": "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails", "longName": "9955621 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue (Details)", "shortName": "Deferred Revenue - Schedule of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "151", "firstAnchor": { "contextRef": "c-4", "name": "peak:NonrefundableEntranceFees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "peak:ScheduleOfDeferredRevenueTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "peak:NonrefundableEntranceFees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "peak:ScheduleOfDeferredRevenueTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R152": { "role": "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails", "longName": "9955622 - Disclosure - Schedule H: Valuation and Qualifying Accounts (Details)", "shortName": "Schedule H: Valuation and Qualifying Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "152", "firstAnchor": { "contextRef": "c-558", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-563", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R153": { "role": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "longName": "9955623 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Outpatient Medical) (Details)", "shortName": "Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Outpatient Medical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "153", "firstAnchor": { "contextRef": "c-115", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-461", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R154": { "role": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "longName": "9955624 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Lab) (Details)", "shortName": "Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation (Lab) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "154", "firstAnchor": { "contextRef": "c-115", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",

"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-1243", "name":
"srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R155": { "role":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"longName": "9955625 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Details of Real
Estate and Accumulated Depreciation (Continuing Care Retirement Community) (Details)", "shortName":
"Schedule III: Real Estate and Accumulated Depreciation - Details of Real Estate and Accumulated Depreciation
(Continuing Care Retirement Community) (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "155", "firstAnchor": { "contextRef": "c-115", "name":
"srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "body", "html"],
"reportCount": 1, "baseRef": "peak-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1259",
"name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } }, "R156": { "role":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationAmountthatTaxBasisofNetRe",
"longName": "9955626 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Amount that Tax
Basis of Net Real Estate Assets Less Than the Reported Amounts (Details)", "shortName": "Schedule III: Real
Estate and Accumulated Depreciation - Amount that Tax Basis of Net Real Estate Assets Less Than the Reported
Amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "156", "firstAnchor": { "contextRef": "c-4", "name":
"peak:RealEstateFederalIncomeTaxBasisLessThanReportedNetAssets", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-9", "ancestors": { "span", "div", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name":
"peak:RealEstateFederalIncomeTaxBasisLessThanReportedNetAssets", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "-9", "ancestors": { "span", "div", "ix:continuation", "body", "html"], "reportCount": 1,
"baseRef": "peak-20241231.htm", "first": true, "unique": true } }, "R157": { "role":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst",
"longName": "9955627 - Disclosure - Schedule III: Real Estate and Accumulated Depreciation - Summary of
Activity for Real Estate and Accumulated Depreciation (Details)", "shortName": "Schedule III: Real Estate and
Accumulated Depreciation - Summary of Activity for Real Estate and Accumulated Depreciation (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "157",
"firstAnchor": { "contextRef": "c-1", "name":
"peak:SECScheduleIIIRealEstateAccumulatedDepreciationDeconsolidation", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-1", "name": "peak:SECScheduleIIIRealEstateAccumulatedDepreciationDeconsolidation",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true, "unique":
true } }, "R158": { "role": "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
"longName": "9955628 - Disclosure - Schedule IV: Mortgage Loans on Real Estate (Details)", "shortName":
"Schedule IV: Mortgage Loans on Real Estate (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "158", "firstAnchor": { "contextRef": "c-4", "name":
"srt:MortgageLoansOnRealEstatePriorLiens1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-3", "ancestors": { "span", "td", "tr", "table", "div",
"srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name":
"srt:MortgageLoansOnRealEstatePriorLiens1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"-3", "ancestors": { "span", "td", "tr", "table", "div",
"srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef":
"peak-20241231.htm", "first": true, "unique": true } }, "R159": { "role":
"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails",
"longName": "9955629 - Disclosure - Schedule IV: Mortgage Loans on Real Estate - Reconciliation of Mortgage
Loans (Details)", "shortName": "Schedule IV: Mortgage Loans on Real Estate - Reconciliation of Mortgage Loans
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "159", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:MortgageLoansOnRealEstate", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "peak-20241231.htm", "unique": true } } }, "tag":
{ "peak_A0126SherwoodARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "A0126SherwoodARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "0126 Sherwood, AR", "label": "0126 Sherwood, AR [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A1038FresnoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A1038FresnoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "1038 Fresno, CA", "label": "1038 Fresno, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A1041BrentwoodCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A1041BrentwoodCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "1041 Brentwood, CA", "label": "1041 Brentwood, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A1044HoustonTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A1044HoustonTXMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun

1. "lang": { "en-us": { "role": { "terseLabel": "1044 Houston, TX", "label": "1044 Houston, TX [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1052TowsonMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1052TowsonMDMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1052 Towson, MD", "label": "1052 Towson, MD [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1054DurantOKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1054DurantOKMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1054 Durant, OK", "label": "1054 Durant, OK [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1057NewburghINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1057NewburghINMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1057 Newburgh, IN", "label": "1057 Newburgh, IN [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1059JacksonMSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1059JacksonMSMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1059 Jackson, MS", "label": "1059 Jackson, MS [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1060JacksonMSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1060JacksonMSMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1060 Jackson, MS", "label": "1060 Jackson, MS [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1061GranburyTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1061GranburyTXMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1061 Granbury, TX", "label": "1061 Granbury, TX [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1064LexingtonKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1064LexingtonKYMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1064 Lexington, KY", "label": "1064 Lexington, KY [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1065MarionILMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1065MarionILMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1065 Marion, IL", "label": "1065 Marion, IL [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1067MiltonFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1067MiltonFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1067 Milton, FL", "label": "1067 Milton, FL [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1068OmahaNEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1068OmahaNEMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1068 Omaha, NE", "label": "1068 Omaha, NE [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1078FlowoodMSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1078FlowoodMSMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1078 Flowood, MS", "label": "1078 Flowood, MS [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A112OverlandParkKSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A112OverlandParkKSMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "112 Overland Park, KS", "label": "112 Overland Park, KS [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A113GlendaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A113GlendaleAZMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "113 Glendale, AZ", "label": "113 Glendale, AZ [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1196AuroraCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1196AuroraCOMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1196 Aurora, CO", "label": "1196 Aurora, CO [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1197AuroraCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1197AuroraCOMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1197 Aurora, CO", "label": "1197 Aurora, CO [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1199DenverCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1199DenverCOMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1199 Denver, CO", "label": "1199 Denver, CO [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1200EncinoCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1200EncinoCAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1200 Encino, CA", "label": "1200 Encino, CA [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1207IrvingTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1207IrvingTXMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1207 Irving, TX", "label": "1207 Irving, TX [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1208FairfaxVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A1208FairfaxVAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEStateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "1208 Fairfax, VA", "label": "1208 Fairfax, VA [Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A1213EllicottCityMDMember": { "xbrltype": "domainItemType",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"documentation": "" } } }, "auth_ref": [] }, "peak_A2024ScottsdaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2024ScottsdaleAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2024 Scottsdale, AZ", "label": "2024 Scottsdale, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2024ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2024ShareRepurchaseProgramMember", "presentation": ["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails", "lang": { "en-us": { "role": { "terseLabel": "2024 Share Repurchase Program", "label": "2024 Share Repurchase Program [Member]", "documentation": "2024 Share Repurchase Program" } } } }, "auth_ref": [] }, "peak_A2025ScottsdaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2025ScottsdaleAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2025 Scottsdale, AZ", "label": "2025 Scottsdale, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2026ScottsdaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2026ScottsdaleAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2026 Scottsdale, AZ", "label": "2026 Scottsdale, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2027ScottsdaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2027ScottsdaleAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2027 Scottsdale, AZ", "label": "2027 Scottsdale, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2027TermLoanFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2027TermLoanFacilitiesMember", "presentation": ["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "lang": { "en-us": { "role": { "terseLabel": "2027 Term Loan Facilities", "label": "2027 Term Loan Facilities [Member]", "documentation": "2027 Term Loan Facilities" } } } }, "auth_ref": [] }, "peak_A2028ScottsdaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2028ScottsdaleAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2028 Scottsdale, AZ", "label": "2028 Scottsdale, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2028TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2028TermLoanMember", "presentation": ["http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "2028 Term Loan", "label": "2028 Term Loan [Member]", "documentation": "2028 Term Loan" } } } }, "auth_ref": [] }, "peak_A2029TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2029TermLoanMember", "presentation": ["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "lang": { "en-us": { "role": { "terseLabel": "2029 Term Loan", "label": "2029 Term Loan [Member]", "documentation": "2029 Term Loan" } } } }, "auth_ref": [] }, "peak_A2032IndependenceMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2032IndependenceMOMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2032 Independence, MO", "label": "2032 Independence, MO [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2033SandyUTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2033SandyUTMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2033 Sandy, UT", "label": "2033 Sandy, UT [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2034WestJordanUTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2034WestJordanUTMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2034 West Jordan, UT", "label": "2034 West Jordan, UT [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2035DraperUTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2035DraperUTMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2035 Draper, UT", "label": "2035 Draper, UT [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2036WestJordanUTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2036WestJordanUTMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2036 West Jordan, UT", "label": "2036 West Jordan, UT [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2037MesquiteNVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2037MesquiteNVMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2037 Mesquite, NV", "label": "2037 Mesquite, NV [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2038EvanstonWYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2038EvanstonWYMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2038 Evanston, WY", "label": "2038 Evanston, WY [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2039KansasCityKSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2039KansasCityKSMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2039 Kansas City, KS", "label": "2039 Kansas City, KS [Member]", "documentation": "" } } } }, "auth_ref": [] }, "peak_A2040MesaAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2040MesaAZMember", "presentation": ["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "2040 Mesa, AZ", "label": "2040 Mesa, AZ [Member]", "documentation": "" } } } }, "auth_ref": [] }

"documentation": "" } } }, "auth_ref": [] }, "peak_A2041SaltLakeCityUTMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2041SaltLakeCityUTMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2041 Salt Lake City, UT", "label": "2041 Salt Lake City, UT
[Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A2042LaytonUTMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2042LaytonUTMember",
"presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2042 Layton, UT", "label": "2042 Layton, UT [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2043OverlandParkKSMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A2043OverlandParkKSMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2043 Overland Park, KS", "label": "2043 Overland Park, KS
[Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A2197SanDiegoCAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2197SanDiegoCAMember",
"presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2197 San Diego, CA", "label": "2197 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2198WebsterTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2198WebsterTXMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2198 Webster, TX", "label": "2198 Webster, TX [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2203MiamiFLMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2203MiamiFLMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2203 Miami, FL", "label": "2203 Miami, FL [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2229LaJollaCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2229LaJollaCAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2229 La Jolla, CA", "label": "2229 La Jolla, CA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2230FredericksburgVAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A2230FredericksburgVAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2230 Fredericksburg, VA", "label": "2230 Fredericksburg, VA
[Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A2233LoneTreeCOMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2233LoneTreeCOMember",
"presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2233 Lone Tree, CO", "label": "2233 Lone Tree, CO [Member]",
"documentation": "n/a" } } }, "auth_ref": [] }, "peak_A2234PhiladelphiaPAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A2234PhiladelphiaPAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2234 Philadelphia, PA", "label": "2234 Philadelphia, PA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2237LouisvilleKYMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2237LouisvilleKYMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2237 Louisville, KY", "label": "2237 Louisville, KY [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2238LouisvilleKYMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2238LouisvilleKYMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2238 Louisville, KY", "label": "2238 Louisville, KY [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2239LouisvilleKYMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2239LouisvilleKYMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2239 Louisville, KY", "label": "2239 Louisville, KY [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2403PhiladelphiaPAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2403PhiladelphiaPAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2403 Philadelphia, PA", "label": "2403 Philadelphia, PA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A240MinneapolisMNMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A240MinneapolisMNMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "240 Minneapolis, MN", "label": "240 Minneapolis, MN [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2476SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2476SanDiegoCAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2476 San Diego, CA", "label": "2476 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2477SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2477SanDiegoCAMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2477 San Diego, CA", "label": "2477 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A2542HoustonTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2542HoustonTXMember", "presentation": ["
http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t,"lang": { "en-us": { "role": { "terseLabel": "2542 Houston, TX", "label": "2542 Houston, TX [Member]"

[illegible]

[illegible]

"http://www.healthpeak.com/20241231", "localname": "A2631LexingtonMAMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2631 Lexington, MA", "label": "2631 Lexington, MA [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2632LexingtonMAMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2632LexingtonMAMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2632 Lexington, MA", "label": "2632 Lexington, MA [Member]",
documentation": "2632 Lexington, MA" } } }, "auth_ref": [], "peak_A2647ConcordNHMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2647ConcordNHMember",
presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2647 Concord, NH", "label": "2647 Concord, NH [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2648ConcordNHMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2648ConcordNHMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2648 Concord, NH", "label": "2648 Concord, NH [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2649EpsomNHMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2649EpsomNHMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2649 Epsom, NH", "label": "2649 Epsom, NH [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2650BiddefordMEMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2650BiddefordMEMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2650 Biddeford, ME", "label": "2650 Biddeford, ME [Member]",
documentation": "2650 Biddeford, ME [Member]" } } }, "auth_ref": [], "peak_A2653RockwallTXMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A2653RockwallTXMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2653 Rockwall, TX", "label": "2653 Rockwall, TX [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2655WilmingtonNCMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2655WilmingtonNCMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2655 Wilmington, NC", "label": "2655 Wilmington, NC [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2656WilmingtonNCMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2656WilmingtonNCMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2656 Wilmington, NC", "label": "2656 Wilmington, NC [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2657ShallotteNCMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2657ShallotteNCMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2657 Shallotte, NC", "label": "2657 Shallotte, NC [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2658HighlandsRanchCOMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A2658HighlandsRanchCOMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2658 Highlands Ranch, CO", "label": "2658 Highlands Ranch, CO
[Member]", "documentation": "" } } }, "auth_ref": [], "peak_A2694AndersonSCMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2694AndersonSCMember",
presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2694 Anderson, SC", "label": "2694 Anderson, SC [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2696ScottsdaleAZMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2696ScottsdaleAZMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2696 Scottsdale, AZ", "label": "2696 Scottsdale, AZ [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2697IndianapolisINMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2697IndianapolisINMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2697 Indianapolis, IN", "label": "2697 Indianapolis, IN [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2698 MooresvilleINMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2698 MooresvilleINMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2698 Mooresville, IN", "label": "2698 Mooresville, IN [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2699IndianapolisINMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2699IndianapolisINMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2699 Indianapolis, IN", "label": "2699 Indianapolis, IN [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2700ZionsvilleINMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2700ZionsvilleINMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2700 Zionsville, IN", "label": "2700 Zionsville, IN [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2702BolingbrookILMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2702BolingbrookILMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "2702 Bolingbrook, IL", "label": "2702 Bolingbrook, IL [Member]",
documentation": "" } } }, "auth_ref": [], "peak_A2703ColumbiaMOMember": { "xbrltype": "domainItemType",
nsuri": "http://www.healthpeak.com/20241231", "localname": "A2703ColumbiaMOMember", "presentation":
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun

[illegible]

[illegible]

```
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2872 San Diego, CA", "label": "2872 San Diego, CA [Member]",  
"documentation": "" } } }, "auth_ref": [] }, "peak_A2873SanDiegoCAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2873SanDiegoCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2873 San Diego, CA", "label": "2873 San Diego, CA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2874BrisbaneCAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2874BrisbaneCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2874 Brisbane, CA", "label": "2874 Brisbane, CA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2875BrisbaneCAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2875BrisbaneCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2875 Brisbane, CA", "label": "2875 Brisbane, CA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2928CambridgeMAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2928CambridgeMAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2928 Cambridge, MA", "label": "2928 Cambridge, MA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2929CambridgeMAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2929CambridgeMAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2929 Cambridge, MA", "label": "2929 Cambridge, MA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2962OrangeParkFLMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2962OrangeParkFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2962 Orange Park, FL", "label": "2962 Orange Park, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2963BrooksvilleFLMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2963BrooksvilleFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2963 Brooksville, FL", "label": "2963 Brooksville, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2964OkeechobeeFLMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2964OkeechobeeFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2964 Okeechobee, FL", "label": "2964 Okeechobee, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2965AuroraCOMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2965AuroraCOMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2965 Aurora, CO", "label": "2965 Aurora, CO [Member]",  
"documentation": "2965 Aurora, CO" } } }, "auth_ref": [], "peak_A2966HoustonTXMember": { "xbrltype":  
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2966HoustonTXMember",  
"presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2966 Houston, TX", "label": "2966 Houston, TX [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2967NashvilleTNMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2967NashvilleTNMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2967 Nashville, TN", "label": "2967 Nashville, TN [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2982FortWorthTXMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2982FortWorthTXMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2982 Fort Worth, TX", "label": "2982 Fort Worth, TX [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2991CoatesvillePAMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2991CoatesvillePAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2991 Coatesville, PA", "label": "2991 Coatesville, PA [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2995PortCharlotteFLMember": { "xbrltype":  
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":  
"A2995PortCharlotteFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2995 Port Charlotte, FL", "label": "2995 Port Charlotte, FL  
[Member]", "documentation": "" } } }, "auth_ref": [], "peak_A2996LeesburgFLMember": { "xbrltype":  
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A2996LeesburgFLMember",  
"presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2996 Leesburg, FL", "label": "2996 Leesburg, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2997ClearwaterFLMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2997ClearwaterFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2997 Clearwater, FL", "label": "2997 Clearwater, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A2998SeminoleFLMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A2998SeminoleFLMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "2998 Seminole, FL", "label": "2998 Seminole, FL [Member]",  
"documentation": "" } } }, "auth_ref": [], "peak_A3000LoneTreeCOMember": { "xbrltype": "domainItemType",  
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A3000LoneTreeCOMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
t,"lang":{ "en-us": { "role": { "terseLabel": "3000 Lone Tree, CO", "label": "3000 Lone Tree, CO [Member]"
```

[illegible]

[illegible]

[illegible]

[illegible]

"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3152 Cambridge, MA", "label": "3152 Cambridge, MA [Member]",
"documentation": "3152 Cambridge, MA" } } }, "auth_ref": [] }, "peak_A3153SanDiegoCAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A3153SanDiegoCAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3153 San Diego, CA", "label": "3153 San Diego, CA [Member]",
"documentation": "3153 San Diego, CA" } } }, "auth_ref": [] }, "peak_A3154SouthSanFranciscoCAMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A3154SouthSanFranciscoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3154 South San Francisco, CA", "label": "3154 South San Francisco,
CA [Member]", "documentation": "3154 South San Francisco, CA" } } }, "auth_ref": [] },
"peak_A3214SavannahGAMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "A3214SavannahGAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3214 Savannah, GA", "label": "3214 Savannah, GA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A3215WylieTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A3215WylieTXMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3215 Wylie, TX", "label": "3215 Wylie, TX [Member]",
"documentation": "3215 Wylie, TX" } } }, "auth_ref": [] }, "peak_A3216McKinneyTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A3216McKinneyTXMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3216 McKinney, TX", "label": "3216 McKinney, TX [Member]",
"documentation": "3216 McKinney, TX" } } }, "auth_ref": [] }, "peak_A3217BrandonFLMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A3217BrandonFLMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "3217 Brandon, FL", "label": "3217 Brandon, FL [Member]",
"documentation": "3217 Brandon, FL" } } }, "auth_ref": [] }, "peak_A351WashingtonTerraceUTMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A351WashingtonTerraceUTMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "351 Washington Terrace, UT", "label": "351 Washington Terrace, UT
[Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A352WashingtonTerraceUTMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A352WashingtonTerraceUTMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "352 Washington Terrace, UT", "label": "352 Washington Terrace, UT
[Member]", "documentation": "" } } }, "auth_ref": [] }, "peak_A353SaltLakeCityUTMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A353SaltLakeCityUTMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "353 Salt Lake City, UT", "label": "353 Salt Lake City, UT [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A354SaltLakeCityUTMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A354SaltLakeCityUTMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "354 Salt Lake City, UT", "label": "354 Salt Lake City, UT [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A355SaltLakeCityUTMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A355SaltLakeCityUTMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "355 Salt Lake City, UT", "label": "355 Salt Lake City, UT [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A357OremUTMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "A357OremUTMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "357 Orem, UT", "label": "357 Orem, UT [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A400HarrisonOHMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A400HarrisonOHMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "400 Harrison, OH", "label": "400 Harrison, OH [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A421SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A421SanDiegoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "421 San Diego, CA", "label": "421 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A430HoustonTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A430HoustonTXMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "430 Houston, TX", "label": "430 Houston, TX [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A434AtlantisFLMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A434AtlantisFLMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "434 Atlantis, FL", "label": "434 Atlantis, FL [Member]",
"documentation": "" } } }, "auth_ref": [] }, "peak_A435AtlantisFLMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A435AtlantisFLMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "435 Atlantis, FL", "label": "435 Atlantis, FL [Member]",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"nsuri": "http://www.healthpeak.com/20241231", "localname": "A817OwassoOKMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "817 Owasso, OK", "label": "817 Owasso, OK [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A833PaceFLMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "A833PaceFLMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "833 Pace, FL", "label": "833 Pace, FL [Member]", "documentation":
"" } } }, "auth_ref": { } }, "peak_A834PensacolaFLMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "A834PensacolaFLMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "834 Pensacola, FL", "label": "834 Pensacola, FL [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A837SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A837SanDiegoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "837 San Diego, CA", "label": "837 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A838SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A838SanDiegoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "838 San Diego, CA", "label": "838 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A839SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A839SanDiegoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "839 San Diego, CA", "label": "839 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A840SanDiegoCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A840SanDiegoCAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "840 San Diego, CA", "label": "840 San Diego, CA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A882ColoradoSpringsCOMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"A882ColoradoSpringsCOMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "882 Colorado Springs, CO", "label": "882 Colorado Springs, CO
[Member]", "documentation": "" } } }, "auth_ref": { } }, "peak_A887AtlantaCAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "A887AtlantaCAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "887 Atlanta, GA", "label": "887 Atlanta, GA [Member]",
"documentation": "" } } }, "auth_ref": { } }, "peak_A9999DentonTXMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "A9999DentonTXMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "9999 Denton, TX", "label": "9999 Denton, TX [Member]",
"documentation": "" } } }, "auth_ref": { } }, "stpr_AL": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/stpr/2024", "localname": "AL", "presentation": {
"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
"terseLabel": "Alabama", "label": "ALABAMA" } } }, "auth_ref": { } }, "peak_AL0003FairhopeALMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AL0003FairhopeALMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0003 Fairhope, AL", "label": "AL0003 Fairhope, AL [Member]",
"documentation": "AL0003 Fairhope, AL" } } }, "auth_ref": { } }, "peak_AL0005FoleyALMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AL0005FoleyALMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0005 Foley, AL", "label": "AL0005 Foley, AL [Member]",
"documentation": "AL0005 Foley, AL" } } }, "auth_ref": { } }, "peak_AL0006BirminghamALMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AL0006BirminghamALMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0006 Birmingham, AL", "label": "AL0006 Birmingham, AL
[Member]", "documentation": "AL0006 Birmingham, AL" } } }, "auth_ref": { } }, "peak_AL0010BirminghamALMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AL0010BirminghamALMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0010 Birmingham, AL", "label": "AL0010 Birmingham, AL
[Member]", "documentation": "AL0010 Birmingham, AL" } } }, "auth_ref": { } }, "peak_AL0011HuntsvilleALMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AL0011HuntsvilleALMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0011 Huntsville, AL", "label": "AL0011 Huntsville, AL [Member]",
"documentation": "AL0011 Huntsville, AL" } } }, "auth_ref": { } }, "peak_AL0012BirminghamALMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AL0012BirminghamALMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "AL0012 Birmingham, AL", "label": "AL0012 Birmingham, AL
[Member]", "documentation": "AL0012 Birmingham, AL" } } }, "auth_ref": { } }, "stpr_AR": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "AR", "presentation": {
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails", "lang":

{ "en-us": { "role": { "terseLabel": "ARKANSAS", "label": "ARKANSAS" } } }, "auth_ref": [] },
"peak_AR0001LittleRockARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0001LittleRockARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0001 Little Rock, AR", "label": "AR0001 Little Rock, AR
[Member]", "documentation": "AR0001 Little Rock, AR" } } }, "auth_ref": [] },
"peak_AR0002LittleRockARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0002LittleRockARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0002 Little Rock, AR", "label": "AR0002 Little Rock, AR
[Member]", "documentation": "AR0002 Little Rock, AR" } } }, "auth_ref": [] },
"peak_AR0004HotSpringsVillageARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0004HotSpringsVillageARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0004 Hot Springs Village, AR", "label": "AR0004 Hot Springs
Village, AR [Member]", "documentation": "AR0004 Hot Springs Village, AR" } } }, "auth_ref": [] },
"peak_AR0005HotSpringsARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0005HotSpringsARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0005 Hot Springs, AR", "label": "AR0005 Hot Springs, AR
[Member]", "documentation": "AR0005 Hot Springs, AR" } } }, "auth_ref": [] },
"peak_AR0006HotSpringsARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0006HotSpringsARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0006 Hot Springs, AR", "label": "AR0006 Hot Springs, AR
[Member]", "documentation": "AR0006 Hot Springs, AR" } } }, "auth_ref": [] },
"peak_AR0007HotSpringsARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0007HotSpringsARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0007 Hot Springs, AR", "label": "AR0007 Hot Springs, AR
[Member]", "documentation": "AR0007 Hot Springs, AR" } } }, "auth_ref": [] },
"peak_AR0008HotSpringsARMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "AR0008HotSpringsARMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AR0008 Hot Springs, AR", "label": "AR0008 Hot Springs, AR
[Member]", "documentation": "AR0008 Hot Springs, AR" } } }, "auth_ref": [] },
"peak_ATMDirectIssuancesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "ATMDirectIssuancesMember", "presentation": {
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "ATM Direct Issuances", "label": "ATM Direct Issuances [Member]",
"documentation": "ATM Direct Issuances" } } }, "auth_ref": [] },
"peak_ATMEquityOfferingProgramAggregateAmountRemaining": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "ATMEquityOfferingProgramAggregateAmountRemaining",
"crdr": "debit", "presentation": {
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Aggregate amount remaining", "label": "ATM Equity Offering Program
Aggregate Amount Remaining", "documentation": "ATM Equity Offering Program Aggregate Amount Remaining"
} } }, "auth_ref": [] }, "stpr_AZ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024",
"localname": "AZ", "presentation": {
"http://www.healthpeak.com/role/ScheduleIVMortgageLoanonRealEstateDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Arizona", "label": "ARIZONA" } } }, "auth_ref": [] }, "peak_AZ0001GlendaleAZMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AZ0001GlendaleAZMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AZ00021 Glendale, AZ", "label": "AZ0001 Glendale, AZ [Member]",
"documentation": "AZ0001 Glendale, AZ" } } }, "auth_ref": [] }, "peak_AZ0002AvondaleAZMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0002AvondaleAZMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AZ0002 Avondale, AZ", "label": "AZ0002 Avondale, AZ [Member]",
"documentation": "AZ0002 Avondale, AZ" } } }, "auth_ref": [] }, "peak_AZ0003GoodyearAZMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0003GoodyearAZMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AZ0003 Goodyear, AZ", "label": "AZ0003 Goodyear, AZ [Member]",
"documentation": "AZ0003 Goodyear, AZ" } } }, "auth_ref": [] }, "peak_AZ0005PhoenixAZMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0005PhoenixAZMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AZ0005 Phoenix, AZ", "label": "AZ0005 Phoenix, AZ [Member]",
"documentation": "AZ0005 Phoenix, AZ" } } }, "auth_ref": [] }, "peak_AZ0007PhoenixAZMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0007PhoenixAZMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l", "lang": { "en-us": { "role": { "terseLabel": "AZ0007 Phoenix, AZ", "label": "AZ0007 Phoenix, AZ [Member]",
"documentation": "AZ0007 Phoenix, AZ" } } }, "auth_ref": [] }, "peak_AZ0008GlendaleAZMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0008GlendaleAZMember",
"presentation": {

["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0008 Glendale, AZ", "label": "AZ0008 Glendale, AZ \[Member\]"](#)
[", "documentation": "AZ0008 Glendale, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0009ScottsdaleAZMember": { "xbrltype":](#)
[", "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0009ScottsdaleAZMember"](#)
[", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0009 Scottsdale, AZ", "label": "AZ0009 Scottsdale, AZ \[Member\]"](#)
[", "documentation": "AZ0009 Scottsdale, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0010ScottsdaleAZMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["AZ0010ScottsdaleAZMember", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0010 Scottsdale, AZ", "label": "AZ0010 Scottsdale, AZ \[Member\]"](#)
[", "documentation": "AZ0010 Scottsdale, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0011ScottsdaleAZMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["AZ0011ScottsdaleAZMember", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0011 Scottsdale, AZ", "label": "AZ0011 Scottsdale, AZ \[Member\]"](#)
[", "documentation": "AZ0011 Scottsdale, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0012MesaAZMember": { "xbrltype":](#)
[", "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0012MesaAZMember"](#)
[", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0012 Mesa, AZ", "label": "AZ0012 Mesa, AZ \[Member\]"](#)
[", "documentation": "AZ0012 Mesa, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0014ScottsdaleAZMember": { "xbrltype":](#)
[", "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0014ScottsdaleAZMember"](#)
[", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0014 Scottsdale, AZ", "label": "AZ0014 Scottsdale, AZ \[Member\]"](#)
[", "documentation": "AZ0014 Scottsdale, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ0015PhoenixAZMember": { "xbrltype":](#)
[", "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ0015PhoenixAZMember"](#)
[", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ0015 Phoenix, AZ", "label": "AZ0015 Phoenix, AZ \[Member\]"](#)
[", "documentation": "AZ0015 Phoenix, AZ" } } } }, "auth_ref": \[\] }, "peak_AZ00A7PhoenixAZMember": { "xbrltype":](#)
[", "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AZ00A7PhoenixAZMember"](#)
[", "presentation": \[](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "AZ00A7 Phoenix, AZ", "label": "AZ00A7 Phoenix, AZ \[Member\]"](#)
[", "documentation": "AZ00A7 Phoenix, AZ" } } } }, "auth_ref": \[\] },](#)
["peak_AboveMarketLeaseIntangibleAssetsAccumulatedDepreciationAndAmortization": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["AboveMarketLeaseIntangibleAssetsAccumulatedDepreciationAndAmortization", "crdr": "debit", "presentation": \[](#)
["http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails" \] }, "lang": { "en-us": {](http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails)
["role": { "terseLabel": "Depreciation and amortization of above market lease intangibles", "label": "Above Market](#)
[Lease Intangible Assets, Accumulated Depreciation And Amortization", "documentation": "Above Market Lease](#)
[Intangible Assets, Accumulated Depreciation And Amortization" } } } }, "auth_ref": \[\] },](#)
["peak_AboveMarketLeaseIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri":](#)
["http://www.healthpeak.com/20241231", "localname": "AboveMarketLeaseIntangibleAssetsGross", "crdr":](#)
["credit", "presentation": \["http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails"](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Gross above market lease intangibles", "label": "Above Market Lease](#)
[Intangible Assets, Gross", "documentation": "Above Market Lease Intangible Assets, Gross" } } } }, "auth_ref": \[\] },](#)
["peak_AboveMarketLeaseIntangibles": { "xbrltype": "monetaryItemType", "nsuri":](#)
["http://www.healthpeak.com/20241231", "localname": "AboveMarketLeaseIntangibles", "crdr": "credit",](#)
["presentation": \["http://www.healthpeak.com/role/IntangiblesNarrativeDetails" \] }, "lang": { "en-us": { "role": {](#)
["terseLabel": "Above market lease, intangibles", "label": "Above Market Lease, Intangibles", "documentation":](#)
["Above Market Lease, Intangibles" } } } }, "auth_ref": \[\] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype":](#)
["stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": {](#)
["en-us": { "role": { "terseLabel": "Accounting Policies \[Abstract\]", "label": "Accounting Policies \[Abstract\]" } } } },](#)
["auth_ref": \[\] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri":](#)
["http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": \[](#)
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails",](#)
["http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",](#)
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails",](#)
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi](#)
["http://www.healthpeak.com/role/LoansReceivableTheMergerDetails" \] }, "lang": { "en-us": { "role": { "terseLabel":](#)
["Loans Receivable:", "verboseLabel": "Loans receivable", "label": "Accounts, Notes, Loans and Financing](#)
[Receivable \[Line Items\]", "documentation": "Line items represent financial concepts included in a table. These](#)
[concepts are used to disclose reportable information associated with domain members defined in one or many](#)
[axes to the table." } } } }, "auth_ref": \["r507", "r1461" \] }, "us-](#)
[gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": \[](#)
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",](#)
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails",](#)

["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails),
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails)], "lang":
 { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation":
 "Information by type of receivable." } } }, "auth_ref": { "r177", "r182" } }, "us-
 gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
 "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": {
 "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } },
["http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails"](http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails): { "parentTag":
 null, "weight": null, "order": null, "root": true } }, "presentation": {
["http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails"](http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails),
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails)], "lang": { "en-us": {
 "role": { "terseLabel": "Accounts payable, accrued liabilities, and other liabilities", "totalLabel": "Accounts
 payable, accrued liabilities, and other liabilities", "label": "Accounts Payable and Accrued Liabilities",
 "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that
 date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent
 and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement
 obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": { "r255", "r257" } },
 "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
 "presentation": { "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilities":
 "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable, Accrued Liabilities, and Other Liabilities", "label":
 "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for
 accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": { "r161", "r164",
 "r169", "r1545" } }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember",
 "presentation": { "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails":
 "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and
 Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts
 payable and accrued liabilities." } } }, "auth_ref": { } }, "us-gaap_AccountsReceivableNet": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr":
 "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
 gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails)], "lang": { "en-us": {
 "role": { "verboseLabel": "Accounts receivable, net of allowance of \$2,243 and \$2,282", "terseLabel": "Accounts
 receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after
 allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal
 course of business." } } }, "auth_ref": { "r1067", "r1141", "r1246", "r1609", "r1610" } }, "us-
 gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit",
 "presentation": { "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails",
["http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails"](http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails)], "lang": { "en-us": {
 "role": { "terseLabel": "Accumulated depreciation related to corporate assets", "negatedTerseLabel":
 "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "label": "Accumulated
 Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of
 accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business
 to produce goods and services." } } }, "auth_ref": { "r73", "r365", "r976" } }, "us-
 gaap_AccumulatedDistributionsInExcessOfNetIncome": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "AccumulatedDistributionsInExcessOfNetIncome", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS)], "lang": { "en-us": { "role": {
 "negatedLabel": "Cumulative dividends in excess of earnings", "label": "Accumulated Distributions in Excess of
 Net Income", "documentation": "The amount as of the balance sheet date by which cumulative distributions to
 shareholders (or partners) exceed retained earnings (or accumulated earnings)." } } }, "auth_ref": { "r1644" } },
 "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember",
 "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING"](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING),
 "lang": { "en-us": { "role": { "terseLabel": "Cumulative Dividends In Excess Of Earnings", "label": "Accumulated
 Distributions in Excess of Net Income [Member]", "documentation": "Cumulative distributions to shareholders
 (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": { } }, "us-
 gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
 "crdr": "debit", "calculation": {
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom"](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom),
 "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } },
 "presentation": {
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom"](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom),
 "lang": { "en-us": { "role": { "negatedLabel": "Supplemental Executive Retirement Plan minimum liability",
 "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation":
 "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been
 recognized in net periodic benefit cost (credit)." } } }, "auth_ref": { "r6", "r7", "r39", "r183", "r1518" } }, "us-

gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag":
 "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } },
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom",
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom",
 }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel":
 "Total accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income
 (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from
 transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r38", "r39", "r184",
 "r373", "r973", "r1011", "r1015" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedOtherComprehensiveIncomeMember", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING",
 }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI
 Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from
 transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes
 net income (loss), and accumulated changes in equity from transactions resulting from investments by owners
 and distributions to owners." } } }, "auth_ref": { "r5", "r26", "r39", "r809", "r812", "r882", "r1006", "r1007",
 "r1423", "r1424", "r1425", "r1440", "r1441", "r1442", "r1445" } }, "us-
 gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesNarrativeDetails",
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed",
 }, "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, weighted average amortization, useful life",
 "terseLabel": "Weighted average remaining amortization period in years", "label": "Acquired Finite-Lived
 Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of
 finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS'
 format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } },
 "auth_ref": { "r590", "r1159" } }, "peak_AcquiredFiniteLivedIntangibleLiabilitiesWeightedAverageUsefulLife": {
 "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "AcquiredFiniteLivedIntangibleLiabilitiesWeightedAverageUsefulLife", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Weighted average remaining amortization period in years", "label": "Acquired Finite-Lived
 Intangible Liabilities, Weighted Average Useful Life", "documentation": "Acquired Finite-Lived Intangible
 Liabilities, Weighted Average Useful Life" } } }, "auth_ref": { } }, "ecd_Additional402vDisclosureTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {
 "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text
 Block]" } } }, "auth_ref": { "r1308" } }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel":
 "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue
 price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is
 not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r178",
 "r1226", "r1647" } }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING",
 }, "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital
 [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and
 amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": {
 "r1028", "r1440", "r1441", "r1442", "r1445", "r1564", "r1649" } }, "ecd_AdjToCompAmt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to
 Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r1321" } },
 "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": {
 "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": {
 "r1321" } } }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO
 NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } },
 "auth_ref": { "r1321" } }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO
 Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": {
 "r1321" } } }, "peak_AdjustedNetOperatingIncomeFromContinuingOperations": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "AdjustedNetOperatingIncomeFromContinuingOperations", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails",
 { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethc

"weight": 1.0, "order": 9.0 }], "presentation": {
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails> },
"lang": { "en-us": { "role": { "totalLabel": "Adjusted NOI for reportable segments", "label": "Adjusted Net Operating Income from Continuing Operations", "documentation": "Adjusted NOI is a non-GAAP supplemental financial measure used to evaluate the operating performance of real estate. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles and lease termination fees (?non cash adjustments?). Adjusted NOI is oftentimes referred to as ?cash NOI.? The Company uses adjusted NOI to make decisions about resource allocations, and to assess and compare property level performance. The Company believes that net income (loss) is the most directly comparable U.S. GAAP measure to adjusted NOI. Adjusted NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, the Company?s definition of Adjusted NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating Adjusted NOI." } } }, "auth_ref": [] },
"us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] },
"peak_AdjustmentsOfPermanentEquityToTemporaryEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AdjustmentsOfPermanentEquityToTemporaryEquity", "crdr": "debit", "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING> },
"lang": { "en-us": { "role": { "negatedTerseLabel": "Adjustments to redemption value of redeemable noncontrolling interests", "label": "Adjustments Of Permanent Equity To Temporary Equity", "documentation": "Adjustments Of Permanent Equity To Temporary Equity" } } }, "auth_ref": [] },
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING> },
"lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r88", "r89", "r711"] },
"us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": {
<http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies> },
"lang": { "en-us": { "role": { "terseLabel": "Advertising Cost", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r294"] },
"us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r749", "r1208"] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1366"] },
"ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1279", "r1290", "r1300", "r1333"] },
"ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r1282", "r1293", "r1303", "r1336"] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r1367"] },
"ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r1321"] },
"ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r1328"] },
"ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r1283", "r1294", "r1304", "r1328", "r1337", "r1341", "r1349"] },
"us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": {

["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"](http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails),
["http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails"](http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails)], "lang": { "en-us": {
"role": { "terseLabel": "Other Operating Segment [Member]", "label": "Other Operating Segment [Member]",
"documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling
items." } } }, "auth_ref": { "r464", "r491", "r492", "r493", "r494", "r495", "r498", "r1177", "r1178" } },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllTradingArrangementsMember", "presentation": {
["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"](http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements)], "lang": { "en-us": { "role": { "terseLabel": "All
Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r1347" } }, "us-
gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": {
["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails"](http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Total share-based compensation expense recognized", "label": "Share-Based Payment
Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment
arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r741", "r747" } },
"peak_AllowanceAccountsMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "AllowanceAccountsMember", "presentation": {
["http://www.healthpeak.com/role/ScheduleIVValuationandQualifyingAccountsDetails"](http://www.healthpeak.com/role/ScheduleIVValuationandQualifyingAccountsDetails)], "lang": { "en-us": { "role":
{ "terseLabel": "Allowance Accounts", "label": "Allowance Accounts [Member]", "documentation": "This element
represents the allowance accounts including the allowance for doubtful accounts, straight-line rent reserves, and
allowances for loan and direct financing lease losses." } } }, "auth_ref": { } }, "us-
gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": {
["http://www.healthpeak.com/role/LoansReceivableTables"](http://www.healthpeak.com/role/LoansReceivableTables)], "lang": { "en-us": { "role": { "terseLabel": "Schedule
of Financing Receivable, Allowance for Credit Loss", "label": "Financing Receivable, Allowance for Credit Loss
[Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } },
"auth_ref": { "r275", "r1477" } }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParentetical"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParentetical)], "lang": { "en-us": { "role": {
"terseLabel": "Allowance for accounts receivable", "label": "Accounts Receivable, Allowance for Credit Loss",
"documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r374", "r508",
"r558", "r562", "r564", "r1610" } }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
["http://xbrl.sec.gov/dei/2024"](http://xbrl.sec.gov/dei/2024), "localname": "AmendmentFlag", "presentation": {
["http://www.healthpeak.com/role/Cover"](http://www.healthpeak.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label":
"Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed
or accepted submission." } } }, "auth_ref": { } },
"peak_AmortizationOfBelowMarketLeaseIntangiblesNetAdditionalRevenue": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname":
"AmortizationOfBelowMarketLeaseIntangiblesNetAdditionalRevenue", "crdr": "credit", "presentation": {
["http://www.healthpeak.com/role/IntangiblesAmortizationofDeferredLeasingCostsandAcquisitionRelatedIntangible"](http://www.healthpeak.com/role/IntangiblesAmortizationofDeferredLeasingCostsandAcquisitionRelatedIntangible)
], "lang": { "en-us": { "role": { "terseLabel": "Rental and related revenues related to amortization of net below
market lease liabilities", "label": "Amortization of Below Market Lease Intangibles Net Additional Revenue",
"documentation": "This element represents the additional revenue from amortization of net below market lease
intangibles." } } }, "auth_ref": { } }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit",
"presentation": { ["http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails"](http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails)], "lang": { "en-us": {
"role": { "terseLabel": "Interest expense related to fees and amortization of debt issuance costs", "label":
"Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt
issuance costs." } } }, "auth_ref": { "r198", "r653", "r1432", "r1587" } }, "us-
gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit",
"calculation": { ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS): { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS)], "lang": { "en-us": { "role": {
"terseLabel": "Amortization of deferred financing costs and debt discounts (premiums)", "label": "Amortization of
Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt
discount (premium) and debt issuance costs." } } }, "auth_ref": { "r653", "r1195", "r1196", "r1432", "r1587" } },
"peak_AmortizationOfLeaseUpAndNonCompeteAgreementIntangiblesAdditionalExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AmortizationOfLeaseUpAndNonCompeteAgreementIntangiblesAdditionalExpense", "crdr": "debit",
"presentation": {
["http://www.healthpeak.com/role/IntangiblesAmortizationofDeferredLeasingCostsandAcquisitionRelatedIntangible"](http://www.healthpeak.com/role/IntangiblesAmortizationofDeferredLeasingCostsandAcquisitionRelatedIntangible)
], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense related to amortization of
lease-up intangibles", "label": "Amortization of Lease Up and Non-Compete Agreement Intangibles Additional
Expense", "documentation": "This element represents the additional expense from amortization of lease-up and
non-competite agreement intangibles." } } }, "auth_ref": { } }, "peak_AmortizationOfNonrefundableEntranceFee": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AmortizationOfNonrefundableEntranceFee", "crdr": "debit", "presentation": {
["http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails"](http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails)], "lang": { "en-us": {
"role": { "terseLabel": "Amortization of nonrefundable entrance fee", "label": "Amortization Of Nonrefundable
Entrance Fee", "documentation": "Amortization Of Nonrefundable Entrance Fee" } } }, "auth_ref": { } },
"peak_AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet", "crdr": "debit",
"calculation": { ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS): { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {

"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS" }, "lang": { "en-us": { "role": { "terseLabel": "Amortization of non-refundable entrance fees and above (below) market lease intangibles", "label": "AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet", "documentation": "AmortizationOfNonrefundableEntranceFeesAndAboveBelowMarketLeaseIntangiblesNet" } } }, "auth_ref": { } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r453" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r55" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r55" } }, "us-gaap_AOCI Loss Cash Flow Hedge Cumulative Gain Loss After Tax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCI Loss Cash Flow Hedge Cumulative Gain Loss After Tax", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom", "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom", "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on derivatives, net", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r378" } }, "peak_ArizonaAndTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ArizonaAndTexasMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Arizona And Texas", "label": "Arizona And Texas [Member]", "documentation": "Arizona And Texas" } } }, "auth_ref": { } }, "peak_ArizonaFloridaGeorgiaTexasAndWisconsinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ArizonaFloridaGeorgiaTexasAndWisconsinMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Arizona, Florida, Georgia, Texas, and Wisconsin", "label": "Arizona, Florida, Georgia, Texas, and Wisconsin [Member]", "documentation": "Arizona, Florida, Georgia, Texas, and Wisconsin" } } }, "auth_ref": { } }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Asset at fair value, changes in fair value resulting from changes in assumptions", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": { } }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": { "terseLabel": "Impairments and loan loss reserves (recoveries), net", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": { "r19", "r71" } }, "us-gaap_AssetImpairmentChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentChargesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment Charges [Abstract]", "label": "Asset Impairment Charges [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AssetImpairmentChargesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentChargesTextBlock", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstate" }, "lang": { "en-us": { "role": { "terseLabel": "Impairments of Real Estate", "label": "Asset Impairment Charges [Text Block]", "documentation": "The entire

disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r253", "r274", "r369", "r405", "r458", "r467", "r493", "r497", "r552", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r800", "r804", "r842", "r969", "r1072", "r1177", "r1178", "r1226", "r1256", "r1508", "r1509", "r1594"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee", "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale, net", "label": "Asset, Held-for-Sale, Not Part of Disposal Group", "documentation": "Amount of assets held-for-sale that are not part of a disposal group." } } }, "auth_ref": ["r217"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee", "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale, net", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r4", "r140", "r156", "r219", "r361", "r362"] }, "us-gaap_AssetsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsTotalMember", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDei", "lang": { "en-us": { "role": { "terseLabel": "Percentage of Total Company Assets", "label": "Assets, Total [Member]", "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date." } } }, "auth_ref": [] }, "peak_AtTheMarketProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AtTheMarketProgramMember", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "At-The-Market Program", "label": "At-The-Market Program [Member]", "documentation": "At-The-Market Program [Member]" } } }, "auth_ref": [] }, "peak_AtmEquityOfferingProgramAggregateAmountAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AtmEquityOfferingProgramAggregateAmountAuthorized", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount authorized", "label": "ATM Equity Offering Program Aggregate Amount Authorized", "documentation": "The maximum aggregate gross sales price of stock authorized to be sold through an at-the-market continuous equity offering program." } } }, "auth_ref": [] }, "peak_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": { "http://www.healthpeak.com/role/AuditInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r1262", "r1263", "r1286"] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://www.healthpeak.com/role/AuditInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": ["r1262", "r1263", "r1286"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://www.healthpeak.com/role/AuditInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": ["r1262", "r1263", "r1286"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r1344"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r1345"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r1340"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r1340"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": {

"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r1340" } },
"ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiCnsdrdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r1340" } },
"ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r1340" } },
"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r1340" } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {
"http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails",
"http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]" }, "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r1343" } },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r1342" } },
"ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTable", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": { "r1341" } },
"ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": { "r1341" } },
"us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": {
"http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]" }, "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r606", "r1613", "r1614" } }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BalanceSheetLocationDomain", "presentation": {
"http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]" }, "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r119", "r123", "r606", "r1613", "r1614" } }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": {
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { } }, "peak_BrookdaleMTCAMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "BrookdaleMTCAMember", "presentation": {
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Brookdale MTCA", "label": "Brookdale MTCA [Member]", "documentation": "Brookdale MTCA [Member]" } } }, "auth_ref": { } }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BuildingAndBuildingImprovementsMember", "presentation": {
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Building and Building Improvements [Member]", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": { } },
"us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionAcquireeDomain", "presentation": {
"http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/TheMergerNarrativeDetails",
"http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails",
"http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails",
"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other

type of identification of the acquiree." } } }, "auth_ref": { "r588", "r589", "r590", "r591", "r592", "r794", "r1203", "r1204" } }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails", "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails", "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": { "r91", "r93", "r588", "r589", "r590", "r591", "r592", "r794", "r1203", "r1204" } }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares of Healthpeak common stock issued (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": { "r240" } }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails", "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails", "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed" }, "lang": { "en-us": { "role": { "terseLabel": "Real estate acquisitions [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r794" } }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": { "http://www.healthpeak.com/role/TheMergerTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Proforma Financial Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": { "r1387", "r1388" } }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Closing price of Healthpeak common stock on March 1, 2024 (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": { } }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) applicable to common shares", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net income or loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": { "r792", "r793" } }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": { "r792", "r793" } }, "us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed" }, "lang": { "en-us": { "role": { "terseLabel": "Gross contractual account receivables", "label": "Business Combination, Acquired Receivables, Gross Contractual Amount", "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables." } } }, "auth_ref": { "r94" } }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Transaction and merger-related costs", "negatedLabel": "Transaction and merger-related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees;

general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": { "r90" } }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "lang": { "en-us": { "role": { "totalLabel": "Consideration transferred", "verboseLabel": "Total purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } } }, "auth_ref": { "r1", "r2", "r24" } }, "peak_BusinessCombinationConsiderationTransferredAttributableToPostCombinationPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationConsiderationTransferredAttributableToPostCombinationPeriod", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Fair value of preliminary share consideration attributable to the post-combination period", "label": "Business Combination, Consideration Transferred, Attributable To Post-Combination Period", "documentation": "Business Combination, Consideration Transferred, Attributable To Post-Combination Period" } } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } } }, "auth_ref": { "r1", "r2" } }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/TheMerger": { "lang": { "en-us": { "role": { "terseLabel": "The Merger", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } } }, "auth_ref": { "r234", "r795" } }, "peak_BusinessCombinationExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationExchangeRatio", "presentation": { "http://www.healthpeak.com/role/TheMergerNarrativeDetails": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio", "label": "Business Combination, Exchange Ratio", "documentation": "Business Combination, Exchange Ratio" } } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/TheMergerNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) of acquiree since acquisition date, actual", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } } }, "auth_ref": { "r92" } }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/TheMergerNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue of acquiree since acquisition date, actual", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } } }, "auth_ref": { "r92" } }, "peak_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedIntangibleLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedIntangibleLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "lang": { "en-us": { "role": { "terseLabel": "Intangible liabilities", "label": "Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Intangible Liabilities, Net", "documentation": "Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Intangible Liabilities, Net" } } } }, "auth_ref": { } },

"peak_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseLiability": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseLiability", "crdr": "credit",
 "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight":
 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Business Combination, Recognized
 Identifiable Asset Acquired And Liability Assumed, Lease Liability", "documentation": "Business Combination,
 Recognized Identifiable Asset Acquired And Liability Assumed, Lease Liability" } } }, "auth_ref": [] },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccrued
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedLiabil
 "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight":
 1.0, "order": 4.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities, and other liabilities", "label":
 "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable,
 Accrued Liabilities, And Other Liabilities", "documentation": "Business Combination, Recognized Identifiable
 Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Liabilities, And Other Liabilities" } } },
 "auth_ref": [] },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsReceivable": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsReceivable", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0,
 "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Business Combination,
 Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Receivable", "documentation":
 "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Receivable" }
 } }, "auth_ref": [] }, "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at
 the acquisition date." } } }, "auth_ref": ["r95"] }, "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
 "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Business Combination, Recognized Identifiable
 Assets Acquired And Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildingAndBuildingImp
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildingAndBuildingImprovem
 "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag":
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentPro
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Business Combination,
 Recognized Identifiable Assets Acquired And Liabilities Assumed, Building And Building Improvements",
 "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed,
 Building And Building Improvements" } } }, "auth_ref": [] }, "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0,
 "order": 8.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed

], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r95" } } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMortgageDebt",
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMortgageDebt", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Mortgage debt", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Mortgage Debt", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Mortgage Debt" } } }, "auth_ref": { } } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesSeniorUnsecuredNotes",
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesSeniorUnsecuredNotes", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Senior Unsecured Notes", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Senior Unsecured Notes" } } }, "auth_ref": { } } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopmentInProgress",
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopmentInProgress", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentPreDevelopment", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Development costs and construction in progress", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Development In Process", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Development In Process" } } }, "auth_ref": { } } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancingReceivableExcludingAccruedInterest",
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancingReceivableExcludingAccruedInterest", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Loans receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Financing Receivable, Excluding Accrued Interest, after Allowance For Credit Loss", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Financing Receivable, Excluding Accrued Interest, after Allowance For Credit Loss" } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": { "r95" } } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInAndAdvancesToAcquireBusinesses",
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInAndAdvancesToAcquireBusinesses", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-

~~gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 9.0 } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Investments in and advances to unconsolidated joint ventures", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Investments In And Advance To Affiliates, Subsidiaries, Associates, And Joint Ventures" } } }, "auth_ref": { } },~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLandAndLandImprovements", "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLandAndLandImprovements", "crdr": "debit", "calculation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag":~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentPre", "weight": 1.0, "order": 2.0 } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Land and improvements", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Land and Land Improvements", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Land and Land Improvements" } } }, "auth_ref": { } }, "us-~~
~~gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": { "r95" } }, "us-~~
~~gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": { } },~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncontrollingInterestIn", "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncontrollingInterestInJoint", "crdr": "debit", "calculation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-~~
~~gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestInJointVentures": { "weight": 1.0, "order": 1.0 } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Joint venture partners", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Joint Ventures", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Joint Ventures" } } }, "auth_ref": { } },~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncontrollingInterestIn", "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncontrollingInterestInPreferredUnitHolders": { "weight": 1.0, "order": 2.0 } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Non-managing member unitholders", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncontrolling Interest In Preferred Unit Holders" } } }, "auth_ref": { } },~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsNet", "crdr": "debit", "calculation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-~~
~~gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": {~~
~~"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets, Net", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets, Net" } } }, "auth_ref": { } },~~
~~"peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentPre"~~

{ "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentProperty",
 "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0,
 "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "totalLabel": "Real estate", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment Property, Net", "documentation":
 "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment
 Property, Net" } } }, "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentPro
 { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealEstateInvestmentProperty",
 "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Real estate:", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Real Estate Investment Property, Net [Abstract]",
 "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Real
 Estate Investment Property, Net" } } }, "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRedeemableNoncontrolli
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRedeemableNoncontrollingInt
 "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interests", "label": "Business
 Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling
 Interest, Equity, Carrying Amount", "documentation": "Business Combination, Recognized Identifiable Assets
 Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest, Equity, Carrying Amount" } } },
 "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0,
 "order": 4.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash", "documentation": "Business
 Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash" } } },
 "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetNet": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetNet", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0,
 "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset, Net", "documentation": "Business
 Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset, Net" } } },
 "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTermLoans": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTermLoans", "crdr": "credit",
 "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "parentTag": "us-
 gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight":
 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Term loans", "label": "Business Combination, Recognized
 Identifiable Assets Acquired And Liabilities Assumed, Term Loans", "documentation": "Business Combination,
 Recognized Identifiable Assets Acquired And Liabilities Assumed, Term Loans" } } }, "auth_ref": { } },
 "peak_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedFairValueOfNon
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedFairValueOfNoncontr
 "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 { "lang": { "en-us": { "role": { "terseLabel": "Fair value of net assets acquired and liabilities assumed, net of
 noncontrolling interests", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill,
 And Liabilities Assumed, Fair Value Of Noncontrolling Interest", "documentation": "Business Combination,
 Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Fair Value Of Net Assets Acquired


```

    AssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterests"} } }, "auth_ref": [ ] }, "us-  
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollin  
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingIn  
"crdr": "debit", "calculation": {  
"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed  
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {  
"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed  
}, "lang": { "en-us": { "role": { "totalLabel": "Total noncontrolling interests", "label": "Business Combination,  
Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",  
documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of  
(less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree." } } }, "auth_ref": {  
r95" } }, "peak_BusinessCombinationSharesToBeExchanged": { "xbrltype": "sharesItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "BusinessCombinationSharesToBeExchanged",  
presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails" },  
lang": { "en-us": { "role": { "terseLabel": "Physicians Realty Trust common shares and Physicians Realty Trust  
restricted shares, PSUs, and RSUs exchanged (in shares)", "label": "Business Combination, Shares To Be  
Exchanged", "documentation": "Business Combination, Shares To Be Exchanged" } } }, "auth_ref": [ ] }, "us-  
gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
localname": "BusinessCombinationsPolicy", "presentation": {  
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": {  
terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]",  
documentation": "Disclosure of accounting policy for completed business combinations (purchase method,  
acquisition method or combination of entities under common control). This accounting policy may include a  
general discussion of the purchase method or acquisition method of accounting (including for example, the  
treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price  
allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific  
application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses  
the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the  
acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": { "r235", "r236", "r237", "r238" }  
}, "us-gaap_BusinessInterruptionLossAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-  
gaap/2024", "localname": "BusinessInterruptionLossAxis", "presentation": {  
"http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel":  
"Business Interruption Loss [Axis]", "label": "Business Interruption Loss [Axis]", "documentation": "Information  
by business interruption loss." } } }, "auth_ref": { "r203" } }, "us-gaap_BusinessInterruptionLossDomain": {  
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
BusinessInterruptionLossDomain", "presentation": {  
"http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel":  
"Business Interruption Loss [Domain]", "label": "Business Interruption Loss [Domain]", "documentation": "Type  
or name of business interruption loss." } } }, "auth_ref": { "r203" } }, "stpr_CA": { "xbrltype": "domainItemType",  
nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": {  
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDei  
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",  
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails" }, "lang":  
{ "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [ ] },  
peak_CA0001WalnutCreekCAMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CA0001WalnutCreekCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
}, "lang": { "en-us": { "role": { "terseLabel": "CA0001 Walnut Creek, CA", "label": "CA0001 Walnut Creek, CA  
[Member]", "documentation": "CA0001 Walnut Creek, CA" } } }, "auth_ref": [ ] },  
peak_CA0002WalnutCreekCAMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CA0002WalnutCreekCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
}, "lang": { "en-us": { "role": { "terseLabel": "CA0002 Walnut Creek, CA", "label": "CA0002 Walnut Creek, CA  
[Member]", "documentation": "CA0002 Walnut Creek, CA" } } }, "auth_ref": [ ] },  
peak_CA0003WalnutCreekCAMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CA0003WalnutCreekCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
}, "lang": { "en-us": { "role": { "terseLabel": "CA0003 Walnut Creek, CA", "label": "CA0003 Walnut Creek, CA  
[Member]", "documentation": "CA0003 Walnut Creek, CA" } } }, "auth_ref": [ ] },  
peak_CA0004WalnutCreekCAMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CA0004WalnutCreekCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
}, "lang": { "en-us": { "role": { "terseLabel": "CA0004 Walnut Creek, CA", "label": "CA0004 Walnut Creek, CA  
[Member]", "documentation": "CA0004 Walnut Creek, CA" } } }, "auth_ref": [ ] },  
peak_CA0005WalnutCreekCAMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CA0005WalnutCreekCAMember", "presentation": {  
"http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun  
}, "lang": { "en-us": { "role": { "terseLabel": "CA0005 Walnut Creek, CA", "label": "CA0005 Walnut Creek, CA  
[Member]", "documentation": "CA0005 Walnut Creek, CA" } } }, "auth_ref": [ ] },  
peak_CCRCJVINvestmentMember": { "xbrltype": "domainItemType", "nsuri":  
"http://www.healthpeak.com/20241231", "localname": "CCRCJVINvestmentMember", "presentation": {  
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails" }, "lang": { "en-us": { "role": {  
terseLabel": "CCRC JV Investment", "label": "CCRC JV Investment [Member]", "documentation": "Information  
related to the unconsolidated joint venture formed by the Company and Brookdale, under a RIDEA structure, to  
own and operate CCRC campuses." } } }, "auth_ref": [ ] }, "peak_CCRCMember": { "xbrltype": "domainItemType",  
nsuri": "http://www.healthpeak.com/20241231", "localname": "CCRCMember", "presentation": {  
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",

```

<http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate>
<http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails>
<http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails>
<http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails>
<http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails>
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails>
<http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails>], "lang": {
"en-us": { "role": { "terseLabel": "CCRC", "label": "CCRC [Member]", "documentation": "CCRC" } } }, "auth_ref":
H], "peak_CCRCResidentLoansMember": { "xbrltype": "domainItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "CCRCResidentLoansMember", "presentation": {
<http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails>,
<http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails>], "lang":
{ "en-us": { "role": { "terseLabel": "CCRC resident loans", "label": "CCRC Resident Loans [Member]",
"documentation": "CCRC Resident Loans" } } }, "auth_ref": [] }, "peak_CO0001JohnstownCOMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CO0001JohnstownCOMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CO0001 Johnstown, CO", "label": "CO0001 Johnstown, CO
[Member]", "documentation": "CO0001 Johnstown, CO" } } }, "auth_ref": [] }, "peak_CO0002TrisepCOMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CO0002TrisepCOMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CO0002 Trisep, CO", "label": "CO0002 Trisep, CO [Member]",
"documentation": "CO0002 Trisep, CO" } } }, "auth_ref": [] }, "peak_CO0004ThorntonCOMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CO0004ThorntonCOMember",
"presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CO0004 Thornton, CO", "label": "CO0004 Thornton, CO [Member]",
"documentation": "CO0004 Thornton, CO" } } }, "auth_ref": [] }, "peak_CO0005EnglewoodCOMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CO0005EnglewoodCOMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CO0005 Englewood, CO", "label": "CO0005 Englewood, CO
[Member]", "documentation": "CO0005 Englewood, CO" } } }, "auth_ref": [] },
"peak_CT0001PlainvilleCTMember": { "xbrltype": "domainItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "CT0001PlainvilleCTMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CT0001 Plainville, CT", "label": "CT0001 Plainville, CT [Member]",
"documentation": "CT0001 Plainville, CT" } } }, "auth_ref": [] }, "peak_CT0002ManchesterCTMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CT0002ManchesterCTMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CT0002 Manchester, CT", "label": "CT0002 Manchester, CT
[Member]", "documentation": "CT0002 Manchester, CT" } } }, "auth_ref": [] },
"peak_CT0002PlainvilleCTMember": { "xbrltype": "domainItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "CT0002PlainvilleCTMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CT0002 Plainville, CT", "label": "CT0002 Plainville, CT [Member]",
"documentation": "CT0002 Plainville, CT" } } }, "auth_ref": [] }, "peak_CT0003ManchesterCTMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CT0003ManchesterCTMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "CT0003 Manchester, CT", "label": "CT0003 Manchester, CT
[Member]", "documentation": "CT0003 Manchester, CT" } } }, "auth_ref": [] },
"peak_CallanRidgeJointVentureMember": { "xbrltype": "domainItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "CallanRidgeJointVentureMember", "presentation": {
<http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails>,
<http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails>,
<http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth>
<http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails>], "lang": {
"en-us": { "role": { "terseLabel": "Callan Ridge JV", "label": "Callan Ridge Joint Venture [Member]",
"documentation": "Callan Ridge Joint Venture" } } }, "auth_ref": [] },
"peak_CapitalExpenditureFundingAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "CapitalExpenditureFundingAmountCommitted", "crdr":
"credit", "presentation": {
<http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi>
], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditure funding, amount committed", "label": "Capital
Expenditure Funding, Amount Committed", "documentation": "Capital Expenditure Funding, Amount Committed"
} } }, "auth_ref": [] }, "peak_CapitalExpenditureFundingAmountFunded": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "CapitalExpenditureFundingAmountFunded",
"crdr": "credit", "presentation": {
<http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi>
], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditure funding, amount funded", "label": "Capital
Expenditure Funding, Amount Funded", "documentation": "Capital Expenditure Funding, Amount Funded" } } },
"auth_ref": [] }, "peak_CapitalExpenditureFundingCostOfCapitalPercentCommitted": { "xbrltype":
"percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CapitalExpenditureFundingCostOfCapitalPercentCommitted", "presentation": {
<http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi>

1. "lang": { "en-us": { "role": { "terseLabel": "Capital expenditure funding, cost of capital, percent committed", "label": "Capital Expenditure Funding, Cost Of Capital, Percent Committed", "documentation": "Capital Expenditure Funding, Cost Of Capital, Percent Committed" } } }, "auth_ref": [] },
 "peak_CapitalRaisingIssuanceCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CapitalRaisingIssuanceCostsPolicyTextBlock",
 "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Capital Raising Issuance Costs", "label": "Capital Raising Issuance Costs [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred in connection with raising capital." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": {
 "http://www.healthpeak.com/role/FairValueMeasurementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r132", "r133"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "parentTag": "peak_CashAndCashEquivalentsIncludingDiscontinuedOperationsTotal", "weight": 1.0, "order": 2.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash",
 "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r48", "r363", "r1165"] }, "peak_CashAndCashEquivalentsIncludingDiscontinuedOperationsTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CashAndCashEquivalentsIncludingDiscontinuedOperationsTotal", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinued", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "lang": { "en-us": { "role": { "totalLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Including Discontinued Operations, Total", "documentation": "Cash and Cash Equivalents, Including Discontinued Operations, Total" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r49", "r251"] }, "peak_CashCashEquivalentsAndRestrictedCashIncludingDiscontinuedOperationsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CashCashEquivalentsAndRestrictedCashIncludingDiscontinuedOperationsRollForward", "presentation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, and Restricted Cash, Including Discontinued Operations [Roll Forward]", "label": "Cash, Cash Equivalents, and Restricted Cash, Including Discontinued Operations [Roll Forward]", "documentation": "Cash, Cash Equivalents, and Restricted Cash, Including Discontinued Operations" } } }, "auth_ref": [] }, "peak_CashCashEquivalentsAndRestrictedCashPaidAsPartOfMergers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CashCashEquivalentsAndRestrictedCashPaidAsPartOfMergers", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid in connection with the Merger, net", "label": "Cash, Cash Equivalents, And Restricted Cash Paid As Part Of Mergers", "documentation": "Cash, Cash Equivalents, And Restricted Cash Paid As Part Of Mergers" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents

include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r48", "r209", "r401" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "lang": { "en-us": { "role": { "terseLabel": "Continuing operations", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": { } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of year", "totalLabel": "Cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r48", "r209", "r401" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRate": { "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r3", "r209" } }, "us-gaap-CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": { "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": { "r117" } }, "us-gaap-CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformation", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": { "r204" } }, "us-gaap-CashIncludingDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashIncludingDiscontinuedOperationsAbstract", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Cash, Including Discontinued Operations [Abstract]" } } }, "auth_ref": { } }, "peak-CasualtyRelatedLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CasualtyRelatedLossesMember", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "lang": { "en-us": { "role": { "terseLabel": "Casualty-Related Losses", "label": "Casualty-Related Losses [Member]", "documentation": "Casualty-Related Losses" } } }, "auth_ref": { } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": { "r1319" } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": { "r1316" } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype":

"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r1314" }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.healthpeak.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct", "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r304", "r370", "r371", "r372", "r405", "r439", "r443", "r450", "r452", "r461", "r462", "r552", "r620", "r623", "r624", "r625", "r629", "r630", "r662", "r663", "r666", "r669", "r676", "r842", "r1021", "r1022", "r1023", "r1024", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1060", "r1081", "r1100", "r1126", "r1127", "r1128", "r1129", "r1130", "r1374", "r1433", "r1446" }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct", "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r370", "r371", "r372", "r461", "r662", "r663", "r664", "r666", "r669", "r674", "r676", "r1021", "r1022", "r1023", "r1024", "r1197", "r1374", "r1433" }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r1320" }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r1320" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Commercial Mortgage-Backed Securities", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans." } } }, "auth_ref": { "r1213", "r1215", "r1217", "r1465", "r1466", "r1467", "r1517" }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": { "r223", "r619", "r1247", "r1248", "r1249", "r1252" }, "peak_CommercialPaperProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CommercialPaperProgramMember", "presentation": { "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails", "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper Program", "label": "Commercial Paper Program [Member]", "documentation": "Commercial Paper Program [Member]" } } }, "auth_ref": { } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "erdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r170", "r259", "r970", "r1059" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingencies", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r221", "r610", "r611", "r1143", "r1495", "r1500" }, "peak_CommonSpiritMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CommonSpiritMember", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe", "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails", "lang": { "en-us": { "role": { "terseLabel": "Common Spirit", "label": "Common Spirit [Member]", "documentation": "Common Spirit" } } }, "auth_ref": { } },

"peak_CommonStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "CommonStockConvertibleConversionRatio",
 "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS
 t", "lang": { "en-us": { "role": { "terseLabel": "Common stock, convertible, conversion ratio", "label": "Common
 Stock, Convertible, Conversion Ratio", "documentation": "Common Stock, Convertible, Conversion Ratio" } } },
 "auth_ref": { } }, "peak_CommonStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "CommonStockConvertibleSharesIssuable", "presentation":
 { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Common stock issuable (in shares)", "label": "Common Stock, Convertible,
 Shares Issuable", "documentation": "Common Stock, Convertible, Shares Issuable" } } }, "auth_ref": { } }, "us-
 gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS
 t", "lang": { "en-us": { "role": { "verboseLabel": "Common dividends, per share (in dollars per share)",
 "terseLabel": "Dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends,
 Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of
 common stock outstanding." } } }, "auth_ref": { "r231" } }, "us-gaap_CommonStockMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember",
 "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct
 "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is
 subordinate to all other stock of the issuer." } } }, "auth_ref": { "r1243", "r1244", "r1245", "r1247", "r1248",
 "r1249", "r1252", "r1440", "r1441", "r1445", "r1564", "r1645", "r1649" } }, "us-
 gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" }, "lang": { "en-us": { "role": {
 "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per
 Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r176" }
 }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" }, "lang": { "en-us": { "role": {
 "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized",
 "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and
 bylaws." } } }, "auth_ref": { "r176", "r1060" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype":
 "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued",
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" }, "lang": {
 "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares,
 Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to
 shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares
 represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number
 of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref":
 { "r176" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" }, "lang": { "en-us": { "role": {
 "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding",
 "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership
 interest in a corporation." } } }, "auth_ref": { "r27", "r176", "r1060", "r1078", "r1649", "r1650" } },
 "peak_CommonStockUnitRedemptionShareAmount": { "xbrltype": "sharesItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "CommonStockUnitRedemptionShareAmount",
 "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Common stock, unit redemption share amount", "label": "Common Stock, Unit
 Redemption Share Amount", "documentation": "Common Stock, Unit Redemption Share Amount" } } },
 "auth_ref": { } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "CommonStockValue", "cred": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": { "role": {
 "verboseLabel": "Common stock, \$1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 699,485,139
 and 547,156,311 shares issued and outstanding", "label": "Common Stock, Value, Issued", "documentation":
 "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at
 the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number
 of nonredeemable common shares, par value and other disclosure concepts are in another section within
 stockholders' equity." } } }, "auth_ref": { "r176", "r972", "r1226" } },
 "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation":
 { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually
 Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text
 Block]" } } }, "auth_ref": { "r1325" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" },

"lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r1324" } },
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": {
"r1326" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation":
{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r1323" } }, "peak_CompensationAndPropertyManagement": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"CompensationAndPropertyManagement", "crdr": "debit", "calculation": {
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": {
"parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Compensation and property management", "label": "Compensation And Property Management", "documentation": "Compensation And Property Management" } } }, "auth_ref": { } }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": {
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": { "r232", "r233" } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" }, "lang": {
"en-us": { "role": { "totalLabel": "Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r40", "r381", "r383", "r392", "r961", "r985", "r987" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" }, "lang": {
"en-us": { "role": { "negatedTerseLabel": "Total comprehensive (income) loss attributable to noncontrolling interests\u20192019 share in continuing operations", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss); attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r14", "r100", "r112", "r381", "r383", "r391", "r960", "r985", "r986" } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" }, "lang": {
"en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r112", "r241", "r381", "r383", "r390", "r959", "r985" } }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe":
"lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r58", "r60", "r134", "r135", "r505", "r1142" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe":
"lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r58", "r60", "r134", "r135", "r505", "r1017", "r1142" } }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe":
"lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r58", "r60", "r134",

"r135", "r505", "r1142", "r1386"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRisk" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r213"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1142"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r58", "r60", "r134", "r135", "r505"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r57", "r58", "r60", "r61", "r134", "r250", "r1142"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r58", "r60", "r134", "r135", "r505", "r1142"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": ["r309", "r329", "r411", "r800", "r801", "r804", "r805", "r884", "r1148", "r1415", "r1418", "r1419", "r1507", "r1510", "r1511"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": ["r309", "r329", "r411", "r800", "r801", "r804", "r805", "r884", "r1148", "r1415", "r1418", "r1419", "r1507", "r1510", "r1511"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r272", "r309", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r411", "r458", "r469", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r499", "r620", "r621", "r622", "r623", "r625", "r626", "r627", "r628", "r629", "r1177", "r1178", "r1416", "r1417", "r1508", "r1509"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in

consolidating a parent entity and its subsidiaries or its operating segments." } }], "auth_ref": ["r272", "r309", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r411", "r458", "r469", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r499", "r620", "r621", "r622", "r623", "r625", "r626", "r627", "r628", "r629", "r1177", "r1178", "r1416", "r1417", "r1508", "r1509"] }, "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued construction costs", "label": "Construction in Progress Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred." } } }, "auth_ref": ["r51", "r52", "r53"] }, "peak_ConstructionLoanCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ConstructionLoanCommitmentsMember", "presentation": ["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction loan commitments", "label": "Construction Loan Commitments [Member]", "documentation": "Represents commitments to finance development projects and related working capital financings." } } }, "auth_ref": [] }, "peak_ConstructionLoansOnRealEstateInterestMultipleDue2026To2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ConstructionLoansOnRealEstateInterestMultipleDue2026To2027Member", "presentation": ["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction loans on real estate interest multiple due 2026 to 2027", "label": "Construction Loans On Real Estate Interest Multiple, Due 2026 To 2027 [Member]", "documentation": "Construction Loans On Real Estate Interest Multiple, Due 2026 To 2027" } } }, "auth_ref": [] }, "peak_ConstructionLoansOnRealEstateInterestMultipleDue2027OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ConstructionLoansOnRealEstateInterestMultipleDue2027OneMember", "presentation": ["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction loans on real estate interest multiple due 2027", "label": "Construction Loans On Real Estate Interest Multiple, Due 2027 One [Member]", "documentation": "Construction Loans On Real Estate Interest Multiple, Due 2027 One" } } }, "auth_ref": [] }, "us-gaap_ConstructionPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": ["http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued construction costs", "label": "Construction Payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables." } } }, "auth_ref": ["r257"] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": ["http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": ["http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "peak_ContinuingCareRetirementCommunityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ContinuingCareRetirementCommunityMember", "presentation": ["http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Continuing care retirement community", "label": "Continuing Care Retirement Community [Member]", "documentation": "Continuing Care Retirement Community" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r678", "r679", "r698"] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["r1437"] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": ["http://www.healthpeak.com/role/CommitmentsandContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Material Commitments", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes,

but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": ["r1406", "r1438"] }, "peak_ContributionOfPropertyNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ContributionOfPropertyNumberOfProperties", "presentation": ["http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails"] }, "lang": { "en-us": { "role": { "verboseLabel": "Number of properties, indemnification agreement", "label": "Contribution Of Property, Number Of Properties", "documentation": "Contribution Of Property, Number Of Properties" } } }, "auth_ref": [] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails", "http://www.healthpeak.com/role/LeasesNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Corporate Segment", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r1449"] }, "peak_CorporateNonSegmentOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CorporateNonSegmentOperatingExpenses", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": -1.0, "order": 14.0 } } }, "presentation": ["http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"] }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Corporate non-segment operating expenses", "label": "Corporate Non-Segment Operating Expenses", "documentation": "Corporate Non-Segment Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"] }, "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r189", "r191", "r923"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": -1.0, "order": 1.0 } } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"] }, "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r201"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe", "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails", "http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesNarrativeDetails", "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails", "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r353", "r354", "r408", "r409", "r635", "r664", "r883", "r906", "r966", "r1166", "r1168"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r619", "r1505"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r619", "r1505", "r1506"] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": ["http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } } }, "presentation": ["http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"] }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation":

"Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r1394", "r1436", "r1551" } }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.healthpeak.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": { } }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails", "lang": { "en-us": { "role": { "negatedTotalLabel": "Total current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": { "r776", "r1436" } }, "peak_CurrentPeriodGrossWriteOffsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CurrentPeriodGrossWriteOffsMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails", "lang": { "en-us": { "role": { "terseLabel": "Current period gross write-offs", "label": "Current Period Gross Write-Offs [Member]", "documentation": "Current Period Gross Write-Offs" } } }, "auth_ref": { } }, "peak_CurrentPeriodNetWriteOffsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CurrentPeriodNetWriteOffsMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails", "lang": { "en-us": { "role": { "terseLabel": "Current period net write-offs", "label": "Current Period Net Write-Offs [Member]", "documentation": "Current Period Net Write-Offs" } } }, "auth_ref": { } }, "peak_CurrentPeriodRecoveriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "CurrentPeriodRecoveriesMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails", "lang": { "en-us": { "role": { "terseLabel": "Current period recoveries", "label": "Current Period Recoveries [Member]", "documentation": "Current Period Recoveries" } } }, "auth_ref": { } }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r1394", "r1436", "r1551" } }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDetails", "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": { "r214", "r505" } }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": { "r1271", "r1360" } }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": { "r1271", "r1360" } }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": { "r1273", "r1362" } }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": { "r1273", "r1362" } }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": { "r1275", "r1364" } }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": {

"label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": { "r1273", "r1362" } } },
"cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
"presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": {
"en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing
Threats [Text Block]" } } }, "auth_ref": { "r1266", "r1355" } } },
"cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
"presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": {
"en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": {
"r1267", "r1356" } } }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": { "r1267", "r1356"
} } }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label":
"Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": { "r1265", "r1354" } } },
"cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
"presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": {
"en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } },
"auth_ref": { "r1265", "r1354" } } }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": { "r1265", "r1354"
} } }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
"presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": {
"en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": {
"r1268", "r1357" } } },
"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } },
"auth_ref": { "r1270", "r1359" } } },
"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation":
{ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role":
{ "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text
Block]" } } }, "auth_ref": { "r1270", "r1359" } } },
"cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
"presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": {
"en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee
Responsible for Oversight [Text Block]" } } }, "auth_ref": { "r1271", "r1360" } } },
"cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } },
"auth_ref": { "r1274", "r1363" } } }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskRoleOfManagementTextBlock", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": { "r1272", "r1361" } } },
"cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": {
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, "lang": { "en-us": { "role": {
"label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": {
"r1269", "r1358" } } }, "peak_DE0001DoverDEMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "DE0001DoverDEMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
t", "lang": { "en-us": { "role": { "terseLabel": "DE0001 Dover, DE", "label": "DE0001 Dover, DE [Member]",
"documentation": "DE0001 Dover, DE" } } }, "auth_ref": { } }, "peak_DavisJVMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DavisJVMember",
"presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth
t", "lang": { "en-us": { "role": { "terseLabel": "Davis JV", "label": "Davis JV [Member]", "documentation": "Davis JV"
} } }, "auth_ref": { } }, "peak_DebtCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri":


```

"localname": "Debt Costs Capitalized", "crdr": "debit", "presentation": {
  "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Capitalized costs", "label": "Debt Costs Capitalized", "documentation": "Debt Costs Capitalized" } } }, "auth_ref": [ ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r222", "r403", "r601", "r602", "r603", "r604", "r605", "r618", "r619", "r631", "r637", "r638", "r639", "r640", "r641", "r642", "r647", "r654", "r655", "r657", "r854" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r163", "r164", "r254", "r258", "r411", "r632", "r633", "r634", "r635", "r636", "r638", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r1192", "r1193", "r1194", "r1195", "r1196", "r1224", "r1434", "r1496", "r1497", "r1498", "r1586", "r1588" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loan, basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [ ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "verboseLabel": "Principal balance on debt", "totalLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r33", "r258", "r658" ] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt assumed", "label": "Debt Instrument, Collateral Amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r138" ] }, "peak_DebtInstrumentCollateralHealthcareFacilitiesCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCollateralHealthcareFacilitiesCarryingValue", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtMortgageDebtDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, collateral, healthcare facilities carrying value", "label": "Debt Instrument, Collateral Healthcare Facilities, Carrying Value", "documentation": "Carrying amount of healthcare facilities which are secured by mortgage debt." } } }, "auth_ref": [ ] }, "peak_DebtInstrumentCovenantDebtToAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCovenantDebtToAssets", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant debt to assets (as a percent)", "label": "Debt Instrument, Covenant Debt to Assets", "documentation": "The limit of the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value contained in the debt covenants." } } }, "auth_ref": [ ] }, "peak_DebtInstrumentCovenantFixedChargeRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCovenantFixedChargeRatioMinimum", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant minimum fixed charge coverage ratio", "label": "Debt Instrument, Covenant Fixed Charge Ratio, Minimum", "documentation": "The required minimum Fixed Charge Coverage ratio contained in the debt covenants." } } }, "auth_ref": [ ] }, "peak_DebtInstrumentCovenantNetWorthMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCovenantNetWorthMinimum", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant net worth, minimum", "label": "Debt Instrument, Covenant Net Worth, Minimum", "documentation": "The required Minimum Consolidated Tangible Net Worth contained in the debt covenants." } } }, "auth_ref": [ ] }, "peak_DebtInstrumentCovenantSecuredDebtToAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCovenantSecuredDebtToAssets", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": {

```

"terseLabel": "Debt instrument, covenant secured debt to assets (as a percent)", "label": "Debt Instrument, Covenant Secured Debt to Assets", "documentation": "The limit of the ratio of Secured Debt to Consolidated Total Asset Value contained in the debt covenants." } } }, "auth_ref": { } },
 "peak_DebtInstrumentCovenantUnsecuredDebtToUnencumberedAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentCovenantUnsecuredDebtToUnencumberedAssets", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant unsecured debt to unencumbered assets (as a percent)", "label": "Debt Instrument, Covenant Unsecured Debt to Unencumbered Assets", "documentation": "The limit of the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value contained in the debt covenants." } } }, "auth_ref": { } }, "peak_DebtInstrumentDrawTimePeriodAfterClosing": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentDrawTimePeriodAfterClosing", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, period after closing", "label": "Debt Instrument, Draw Time Period After Closing", "documentation": "Debt Instrument, Draw Time Period After Closing" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": { "r632", "r854", "r855", "r1193", "r1194", "r1224" } }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate, effective percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": { "r166", "r660", "r854", "r855", "r1224" } }, "peak_DebtInstrumentInterestRateReductionAvailableForSustainabilityMetrics": { "xbrltype": "pureItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentInterestRateReductionAvailableForSustainabilityMetrics", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, reduction available for sustainability metrics", "label": "Debt Instrument, Interest Rate, Reduction Available For Sustainability Metrics", "documentation": "Debt Instrument, Interest Rate, Reduction Available For Sustainability Metrics" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": { "r166", "r633" } }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r411", "r632", "r633", "r634", "r635", "r636", "r638", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r1192", "r1193", "r1194", "r1195", "r1196", "r1224", "r1434", "r1586", "r1588" } }, "peak_DebtInstrumentMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentMaximumBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Debt Instrument, Maximum Borrowing Capacity", "documentation": "Debt Instrument, Maximum Borrowing Capacity" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r33", "r411", "r632", "r633", "r634", "r635", "r636", "r638", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r1192", "r1193", "r1194", "r1195", "r1196", "r1224", "r1434", "r1496", "r1497", "r1498", "r1586", "r1588" } }, "peak_DebtInstrumentNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentNumberOfExtensions", "presentation": {

"http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of extensions (in renewal options)", "label": "Debt Instrument, Number Of Extensions", "documentation": "Debt Instrument, Number Of Extensions" } } }, "auth_ref": { } }, "peak_DebtInstrumentPeriodOfExtension": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentPeriodOfExtension", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Length of debt instrument extension period", "label": "Debt Instrument, Period Of Extension", "documentation": "Represents the length of the debt instrument extension period." } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest payment", "label": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": { "r33" } }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtMortgageDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, periodic payment, principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": { "r33" } }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodFiveMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Debt Instrument, Redemption, Period Five [Member]", "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentRedemptionPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodFourMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Debt Instrument, Redemption, Period Four [Member]", "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r265" } }, "peak_DebtInstrumentRedemptionPeriodThereafterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentRedemptionPeriodThereafterMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Debt Instrument Redemption Period Thereafter [Member]", "documentation": "Represents the period after the last period separately disclosed of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Debt Instrument, Redemption, Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r265" } }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": { "r33", "r81", "r84", "r137", "r229", "r230", "r411", "r632", "r633", "r634", "r635", "r636", "r638", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r1192", "r1193", "r1194", "r1195", "r1196", "r1224", "r1434", "r1586", "r1588" } }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": {

["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails),
["http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails"](http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails)], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term (in months)", "verboseLabel": "Term of facility", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnTnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net discount on mortgage debt", "negatedLabel": "Premiums, (discounts), and debt issuance costs, net", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": ["r1513", "r1585", "r1586", "r1588"] }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unused borrowing capacity", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date." } } }, "auth_ref": ["r167", "r618"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r964"] }, "peak_DebtInstrumentWeightedAverageMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DebtInstrumentWeightedAverageMaturity", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average maturity", "label": "Debt Instrument, Weighted Average Maturity", "documentation": "This element represents weighted average maturity of debt." } } }, "auth_ref": [] }, "us-gaap_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecurities", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt securities", "label": "Debt Securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r514", "r966", "r967", "r1241", "r1242"] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": { "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average interest rate (as a percent)", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on deconsolidation", "label": "Deconsolidation, Gain (Loss), Amount", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": ["r103"] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1436", "r1550", "r1551"] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r19", "r299", "r1436"] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities",

"crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "totalLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation":
 "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": { "r171", "r172",
 "r256", "r767" } }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation":
 { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS":
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel":
 "Deferred income tax expense (benefit)", "label": "Deferred Income Taxes and Tax Credits", "documentation":
 "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": { "r211" } }, "us-
 gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
 "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": { "lang": { "en-us": {
 "role": { "negatedTerseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)",
 "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from
 continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense
 (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r1436", "r1550", "r1551" } },
 "peak_DeferredTaxAssetRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "DeferredTaxAssetRealEstate", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Real estate", "label": "Deferred Tax Asset, Real Estate", "documentation": "Deferred
 Tax Asset, Real Estate" } } }, "auth_ref": { } }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDeferredIncome",
 "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Tax Assets, Deferred Income",
 "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to
 deductible temporary differences from deferred income." } } }, "auth_ref": { "r1548" } }, "us-
 gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation":
 "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary
 differences and carryforwards." } } }, "auth_ref": { "r768" } }, "us-gaap_DeferredTaxAssetsGrossAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsGrossAbstract", "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Gross [Abstract]" } } },
 "auth_ref": { } }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation":
 "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to
 deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": { "r1547" } }, "us-
 gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "totalLabel": "Deferred tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net
 of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset
 attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": { "r1547" } }, "us-
 gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails":
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Net operating loss carryforward", "label": "Deferred Tax Assets, Operating Loss
 Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset
 attributable to deductible operating loss carryforwards." } } }, "auth_ref": { "r1548" } }, "us-
 gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net
 operating loss carryforwards not subject to expiration", "label": "Deferred Tax Assets, Operating Loss
 Carryforwards, Not Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of
 deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration
 dates." } } }, "auth_ref": { "r1548" } }, "us-
 gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net
 operating loss carryforwards subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards,
 Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset
 attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": {
 "r1548" } }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
 "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to
 deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other." } } },
 "auth_ref": { "r1548" } }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Expense accruals", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves
 and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset
 attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": { "r1548" } }, "us-
 gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance",
 "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be
 realized." } } }, "auth_ref": { "r769" } }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } },
 "auth_ref": { } }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of
 deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": { "r1548"
 } }, "peak_DeferredTaxLiabilitiesRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "DeferredTaxLiabilitiesRealEstate", "crdr": "credit",
 "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
 "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-
 us": { "role": { "terseLabel": "Real estate", "label": "Deferred Tax Liabilities, Real Estate", "documentation":
 "Deferred Tax Liabilities, Real Estate" } } }, "auth_ref": { } }, "peak_DefinedBenefitPlanNumberOfPlanParticipants": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "DefinedBenefitPlanNumberOfPlanParticipants",
 "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofAccumulatedOtherCom
 ", "lang": { "en-us": { "role": { "terseLabel": "Number of plan participants", "label": "Defined Benefit Plan,
 Number Of Plan Participants", "documentation": "Defined Benefit Plan, Number Of Plan Participants" } } },
 "auth_ref": { } }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel":
 "Depreciation expense related to corporate assets", "label": "Depreciation", "documentation": "The amount of
 expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets'
 useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r19", "r72" } },
 "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails":
 { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth
 ", "weight": -1.0, "order": 1.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
 "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS":

["http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"](http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails),
["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued"](http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued),
], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "negatedLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization of real estate, in-place lease, and other intangibles", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": { "r19", "r72" } },
 "peak_DepreciationDepletionandAmortizationNonproductionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DepreciationDepletionandAmortizationNonproductionMember", "presentation": {
["http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails"](http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails),
], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction [Member]", "documentation": "Depreciation, Depletion and Amortization, Nonproduction [Member]" } } }, "auth_ref": { } }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "presentation": {
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails)], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "verboseLabel": "Notional Amount", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": { "r1112", "r1114", "r1116", "r1119", "r1560", "r1561", "r1562" } }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": {
["http://www.healthpeak.com/role/FairValueMeasurementsDetails"](http://www.healthpeak.com/role/FairValueMeasurementsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Interest rate instruments", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r375", "r376", "r821", "r822", "r832", "r841", "r1040", "r1041", "r1042", "r1043", "r1044", "r1046", "r1047", "r1048", "r1049", "r1050", "r1065", "r1066", "r1112", "r1115", "r1117", "r1118", "r1120", "r1121", "r1168", "r1213", "r1217", "r1245", "r1567", "r1568", "r1569", "r1646" } }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeBasisSpreadOnVariableRate", "presentation": {
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Derivative, basis spread on variable rate", "label": "Derivative, Basis Spread on Variable Rate", "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative." } } }, "auth_ref": { } }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": {
["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails),
["http://www.healthpeak.com/role/DebtMortgageDebtDetails"](http://www.healthpeak.com/role/DebtMortgageDebtDetails),
["http://www.healthpeak.com/role/DebtTheMergerDetails"](http://www.healthpeak.com/role/DebtTheMergerDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails),
["http://www.healthpeak.com/role/FairValueMeasurementsDetails"](http://www.healthpeak.com/role/FairValueMeasurementsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": { "r1048", "r1050", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1088", "r1089", "r1090", "r1091", "r1094", "r1095", "r1096", "r1097", "r1112", "r1113", "r1117", "r1120", "r1243", "r1245", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1577", "r1578" } }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFixedInterestRate", "presentation": {
["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "verboseLabel": "Pay Rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": {
["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails),
["http://www.healthpeak.com/role/DebtMortgageDebtDetails"](http://www.healthpeak.com/role/DebtMortgageDebtDetails),
["http://www.healthpeak.com/role/DebtTheMergerDetails"](http://www.healthpeak.com/role/DebtTheMergerDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails),
["http://www.healthpeak.com/role/FairValueMeasurementsDetails"](http://www.healthpeak.com/role/FairValueMeasurementsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": { "r120", "r124", "r125", "r248", "r1048", "r1050", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1088", "r1089", "r1090", "r1091", "r1094", "r1095", "r1096", "r1097", "r1112", "r1113", "r1117", "r1120", "r1168", "r1243", "r1245", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1577", "r1578" } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": {
["http://www.healthpeak.com/role/DerivativeFinancialInstruments"](http://www.healthpeak.com/role/DerivativeFinancialInstruments)], "lang": { "en-us": { "role": { "terseLabel":

"Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosures [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": { "r247", "r807", "r814" } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": { "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": { "r28", "r120", "r124" } }, "peak_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "presentation": { "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration Not Disclosed Flag", "label": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration Not Disclosed Flag", "documentation": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration Not Disclosed Flag" } } }, "auth_ref": { } }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r814" } }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": { "r1561", "r1562" } }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": { "r28", "r113", "r114", "r116", "r118", "r121", "r124", "r126", "r128", "r130", "r814" } }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Derivatives and Hedging", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r28", "r113", "r114", "r118", "r127", "r410", "r433" } }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": { "r28" } }, "peak_DevelopmentCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DevelopmentCommitmentsMember", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Development and redevelopment commitments", "label": "Development Commitments [Member]", "documentation": "Represents construction and other commitments for developments in progress." } } }, "auth_ref": { } }, "us-gaap_DevelopmentInProgress": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopmentInProgress", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": {

"role": { "terseLabel": "Development costs and construction in progress", "verboseLabel": "Development costs and construction in progress", "label": "Development in Process", "documentation": "The current amount of expenditures for a real estate project that has not yet been completed." } }, "auth_ref": { "r1604", "r1605" } },
 "us-gaap_DilutiveSecurities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "DilutiveSecurities", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Add: distributions on dilutive convertible units and other", "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": { "r54" } }, "us-gaap_DirectFinancingLeaseInterestIncome": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectFinancingLeaseInterestIncome", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/LeasesLeaseIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest income from direct financing leases", "label": "Direct Financing Lease, Interest Income", "documentation": "Amount of interest income from net investment in direct financing lease." } } }, "auth_ref": { "r459", "r878" } }, "us-gaap_DirectFinancingLeaseLeaseIncomeTableTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectFinancingLeaseLeaseIncomeTableTextBlock", "presentation": {
 "http://www.healthpeak.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Lease Income, Excluding Discontinued Operation", "label": "Direct Financing Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of lease income from direct financing lease." } } }, "auth_ref": { "r459", "r876" } }, "us-gaap_DirectFinancingLeaseRevenue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectFinancingLeaseRevenue", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "lang": { "en-us": { "role": { "terseLabel": "Income from direct financing leases", "label": "Direct Financing Lease, Revenue", "documentation": "Amount of direct financing lease revenue." } } }, "auth_ref": { "r459", "r877" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlans": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r709", "r714", "r743", "r744", "r746", "r1206" } }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont": { "lang": { "en-us": { "role": { "terseLabel": "Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": { "r144", "r146", "r148" } }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit (expense)", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": { "r145", "r146", "r147", "r148", "r154", "r158", "r754", "r780", "r782" } }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee": { "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label":

"Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": { "r11" } }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Held-for-sale", "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": { "r10", "r12", "r361" } }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale and Discontinued Operations", "label": "Discontinued Operations, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": { "r23", "r37" } }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": { "r361" } }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held for sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "parentTag": "peak_DisposalGroupIncludingDiscontinuedOperationsCashCashEquivalentsRestrictedCashAndRestrictedCashEqu", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash", "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r4", "r140", "r156", "r219" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "parentTag": "peak_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on sales of real estate, net", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r155", "r362" } }, "peak_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Disposal Group Including Discontinued Operation Nonoperating Income Expense", "documentation": "Disposal Group Including Discontinued Operation Nonoperating Income Expense" } } }, "auth_ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "parentTag": "peak_DisposalGroupIncludingDiscontinuedOperationTotalCostsAndExpenses", "weight": 1.0,

"order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Disposal Group, Including Discontinued
 Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group,
 including, but not limited to, discontinued operation." } } }, "auth_ref": { "r155" } }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncome",
 "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": "peak_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense", "weight":
 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Disposal Group, Including
 Discontinued Operation, Other Income", "documentation": "Amount of other income attributable to disposal
 group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r155" } },
 "peak_DisposalGroupIncludingDiscontinuedOperationResidentFeesAndServices": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "DisposalGroupIncludingDiscontinuedOperationResidentFeesAndServices", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "weight": 1.0, "order": 1.0 } },
 "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Resident fees and services", "label": "Disposal Group Including
 Discontinued Operation Resident Fees And Services", "documentation": "Disposal Group Including Discontinued
 Operation Resident Fees And Services" } } }, "auth_ref": { } },
 "peak_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndCashEquivalents": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndCashEquivalents", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash
 { "parentTag":
 "peak_DisposalGroupIncludingDiscontinuedOperationsCashCashEquivalentsRestrictedCashAndRestrictedCashEqu
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash
 }, "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Disposal Group Including Discontinued
 Operation Restricted Cash And Cash Equivalents", "documentation": "Disposal Group Including Discontinued
 Operation Restricted Cash And Cash Equivalents" } } }, "auth_ref": { } }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr":
 "credit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Disposal Group, Including Discontinued
 Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not
 limited to, discontinued operation." } } }, "auth_ref": { "r155", "r362" } },
 "peak_DisposalGroupIncludingDiscontinuedOperationTotalCostsAndExpenses": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "DisposalGroupIncludingDiscontinuedOperationTotalCostsAndExpenses", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Disposal Group Including
 Discontinued Operation Total Costs And Expenses", "documentation": "Disposal Group Including Discontinued
 Operation Total Costs And Expenses" } } }, "auth_ref": { } },
 "peak_DisposalGroupIncludingDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInter
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "DisposalGroupIncludingDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
 "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Equity income (loss) from unconsolidated joint ventures", "label":
 "Disposal Group Including Discontinued Operations Before Income Taxes Extraordinary Items Noncontrolling
 Interest", "documentation": "Disposal Group Including Discontinued Operations Before Income Taxes
 Extraordinary Items Noncontrolling Interest" } } }, "auth_ref": { } },
 "peak_DisposalGroupIncludingDiscontinuedOperationsCashCashEquivalentsRestrictedCashAndRestrictedCashEqu
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "DisposalGroupIncludingDiscontinuedOperationsCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalen
 "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash
 }, "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents, and restricted cash", "label": "Disposal
 Group, Including Discontinued Operations, Cash, Cash Equivalents, Restricted Cash, and Restricted Cash
 Equivalents", "documentation": "Disposal Group, Including Discontinued Operations, Cash, Cash Equivalents,
 Restricted Cash, and Restricted Cash Equivalents" } } }, "auth_ref": { } }, "us-

gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations" }, "lang": { "en-us": { "role": { "terseLabel": "Dispositions of Real Estate and Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r139", "r216" } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": { "r1203", "r1204" } }, "peak_DispositionsOf2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DispositionsOf2022Member", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Dispositions of 2022", "label": "Dispositions Of 2022 [Member]", "documentation": "Dispositions Of 2022" } } }, "auth_ref": { } }, "peak_DispositionsOf2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DispositionsOf2023Member", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Dispositions of 2023", "label": "Dispositions Of 2023 [Member]", "documentation": "Dispositions Of 2023" } } }, "auth_ref": { } }, "peak_DispositionsOf2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DispositionsOf2024Member", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Dispositions of 2024", "label": "Dispositions Of 2024 [Member]", "documentation": "Dispositions Of 2024" } } }, "auth_ref": { } }, "peak_DistributionsInExcessOfEarningsFromUnconsolidatedJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DistributionsInExcessOfEarningsFromUnconsolidatedJointVentures", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS" }, "lang": { "en-us": { "role": { "terseLabel": "Distributions in excess of earnings from unconsolidated joint ventures", "label": "Distributions in Excess of Earnings from Unconsolidated Joint Ventures", "documentation": "The cash inflow from unconsolidated joint ventures in which the entity does not have sufficient US GAAP earnings (accumulated or in the current period) to distribute funds to partners, thereby constituting a return of investment." } } }, "auth_ref": { } }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF EQUITY AND REDEEMABLE NONCONTROLLING": { "lang": { "en-us": { "role": { "negatedLabel": "Common dividends", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment in kind (PIK)." } } }, "auth_ref": { "r13", "r231" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r1262", "r1263", "r1286" } }, "dei_DocumentFinStmntErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": { "r1262", "r1263", "r1286", "r1329" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { }

"r1307"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r1260"] }, "peak_DownREITMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DownREITMember", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails", "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Down REIT", "label": "Down REIT [Member]", "documentation": "Incremental common shares attributable to the conversion of DownREIT units that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [] }, "peak_DownREITUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DownREITUnitsOutstanding", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Down REIT units outstanding (in shares)", "label": "Down REIT Units Outstanding", "documentation": "The number of DownREIT units outstanding." } } }, "auth_ref": [] }, "peak_DownreitPartnershipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "DownreitPartnershipsMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Downreit Partnerships", "label": "Downreit Partnerships [Member]", "documentation": "Represents a joint venture, DownREIT Partnerships." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdNsOtOthrRwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNsOtOthrRwsRflctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r1318"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) applicable to common shares (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r393", "r423", "r424", "r426", "r427", "r428", "r430", "r436", "r439", "r450", "r451", "r452", "r457", "r790", "r798", "r818", "r819", "r962", "r988", "r1169"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Basic earnings (loss) per common share", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) applicable to common shares (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r393", "r423", "r424", "r426", "r427", "r428", "r430", "r439", "r450", "r451", "r452", "r457", "r790", "r798", "r818", "r819", "r962", "r988", "r1169"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings (loss) per common share", "verboseLabel": "Diluted earnings (loss) per common share", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r55", "r56", "r454"] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"EarningsPerShareReconciliationAbstract", "presentation":- [
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Denominator", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [1]
 }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation":- [
 "http://www.healthpeak.com/role/EarningsPerCommonShare"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r435", "r453", "r455", "r456"] },
 "peak_EffectiveIncomeTaxRateReconciliationChangeInTaxStatusofTRSAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxStatusofTRSAmount", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": {
 "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation":- [
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails"],
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in tax status of TRS", "label": "Effective Income Tax Rate Reconciliation, Change in Tax Status of TRS, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Change in Tax Status of TRS, Amount" } } }, "auth_ref": [1] },
 "peak_EffectiveIncomeTaxRateReconciliationGrossReceiptsAndMarginTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationGrossReceiptsAndMarginTaxes", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": {
 "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation":- [
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails"],
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross receipts and margin taxes", "label": "Effective Income Tax Rate Reconciliation, Gross Receipts and Margin Taxes", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gross receipts and margin taxes." } } }, "auth_ref": [1] },
 "peak_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": {
 "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation":- [
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails"],
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Return to provision adjustments", "label": "Effective Income Tax Rate Reconciliation, Return to Provision", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments." } } }, "auth_ref": [1] },
 "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation":- ["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, amount capitalized", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r742"] },
 "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation":- ["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nonvested award, cost not yet recognized, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r745"] },
 "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodFor": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodFor", "presentation":- ["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost, period of recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r745"] },
 "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation":- ["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [1] },
 "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation":- ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [1] },
 "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation":- ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such

as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } }, "auth_ref": ["r1259"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.healthpeak.com/role/IncomeTaxNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } }, "auth_ref": ["r1259"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, "auth_ref": ["r1259"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } }, "auth_ref": ["r1369"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.healthpeak.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } }, "auth_ref": ["r1259"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"EntityShellCompany", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r1259" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r1259" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r1259" } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { } }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r1370" } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": { "r1312" } }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": { "r1365" } }, "ecd_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": { "r1365" } }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1365" } }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": { } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres", "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r27", "r358", "r385", "r386", "r387", "r418", "r419", "r420", "r422", "r428", "r431", "r433", "r460", "r554", "r557", "r598", "r677", "r777", "r778", "r787", "r788", "r789", "r791", "r797", "r798", "r808", "r809", "r810", "r811", "r812", "r813", "r817", "r843", "r845", "r846", "r847", "r848", "r849", "r857", "r860", "r882", "r983", "r1006", "r1007", "r1008", "r1028", "r1100" } }, "peak_EquityIncomeLossFromUnconsolidatedJointVenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "EquityIncomeLossFromUnconsolidatedJointVenturesMember", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable", "lang": { "en-us": { "role": { "terseLabel": "Government grant income recorded in equity income (loss) from unconsolidated joint ventures", "label": "Equity Income (Loss) From Unconsolidated Joint Ventures [Member]", "documentation": "Equity Income (Loss) From Unconsolidated Joint Ventures [Member]" } } }, "auth_ref": { } }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity Interest Type [Axis]", "label": "Equity Interest Type [Axis]", "documentation": "Information by type of equity interests that are issued or issuable in a business combination." } } }, "auth_ref": { } }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableTypeDomain", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]", "label": "Equity Interest Issued or Issuable, Type [Domain]", "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination." } } }, "auth_ref": { "r240" } }, "peak_EquityInvestmentAggregateCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "EquityInvestmentAggregateCost", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity investment, percentage of total fund commitments", "label": "Equity Investment, Aggregate

Cost", "documentation": "Equity Investment, Aggregate Cost" } } }, "auth_ref": [] },
 "peak_EquityInvestmentFundingPeriod": { "xbrltype": "durationItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "EquityInvestmentFundingPeriod", "presentation": {
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Funding period", "label": "Equity Investment, Funding Period", "documentation": "Equity
 Investment, Funding Period" } } }, "auth_ref": [] },
 "peak_EquityInvestmentPercentageOfTotalFundCommitments": { "xbrltype": "percentItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "EquityInvestmentPercentageOfTotalFundCommitments",
 "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Equity investment, aggregate cost", "label": "Equity Investment, Percentage Of Total Fund
 Commitments", "documentation": "Equity Investment, Percentage Of Total Fund Commitments" } } }, "auth_ref":
 [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstate",
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Narrative Details",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Schedule of Equity Meth",
 "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails",
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of
 investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r548", "r549",
 "r551", "r786", "r1376", "r1377", "r1378", "r1552", "r1553", "r1554", "r1555"] }, "us-
 gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "crdr": "debit",
 "presentation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Narrative Details" },
 "lang": { "en-us": { "role": { "terseLabel": "Difference between carrying amount and underlying equity", "label":
 "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "documentation":
 "Difference between amount at which an investment accounted for under the equity method of accounting is
 carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in
 the investee." } } }, "auth_ref": ["r550"] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": {
 "terseLabel": "Distributions of earnings from unconsolidated joint ventures", "label": "Proceeds from Equity
 Method Investment, Distribution", "documentation": "Amount of distribution received from equity method
 investee for return on investment, classified as operating activities. Excludes distribution for return of
 investment, classified as investing activities." } } }, "auth_ref": ["r16", "r19", "r185", "r978"] }, "us-
 gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Narrative Details",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Schedule of Equity Meth",
 "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Investment ownership percentage", "label": "Equity Method Investment, Ownership Percentage",
 "documentation": "The percentage of ownership of common stock or equity participation in the investee
 accounted for under the equity method of accounting." } } }, "auth_ref": ["r548"] }, "us-
 gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Schedule of Equity Meth",
 "parentTag": "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "weight": 1.0, "order":
 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Narrative Details",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Schedule of Equity Meth",
 "lang": { "en-us": { "role": { "verboseLabel": "Equity method investments", "terseLabel": "Equity method
 investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount
 on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an
 indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings
 and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment
 (OTTI) losses recognized." } } }, "auth_ref": ["r458", "r478", "r497", "r546", "r1420", "r1472"] }, "us-
 gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-
 us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method
 Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures" }, "lang": { "en-us":
 { "role": { "terseLabel": "Investments in and Advances to Unconsolidated Joint Ventures", "label": "Equity Method
 Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity
 method investments and joint ventures. Equity method investments are investments that give the investor the
 ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are

entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": { "r302", "r550", "r553", "r1378" } }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Investments in Unconsolidated Joint Ventures", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": { "r16", "r136", "r549" } }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": { "http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company Owned Interests in Entities, Accounted Under Equity Method", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": { "r547" } }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Other Equity Investments", "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change." } } }, "auth_ref": { "r545" } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": { "r1322" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": { "r1279", "r1290", "r1300", "r1333" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": { "r1276", "r1287", "r1297", "r1330" } }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": { "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": { "r645", "r841", "r1193", "r1194" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth_ref": { "r1328" } }, "stpr_FL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "FL", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDei", "lang": { "en-us": { "role": { "terseLabel": "Florida", "label": "FLORIDA" } } }, "auth_ref": { } }, "peak_FL0003VeniceFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0003VeniceFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "FL0003 Venice, FL", "label": "FL0003 Venice, FL [Member]", "documentation": "FL0003 Venice, FL" } } }, "auth_ref": { } }, "peak_FL0004EnglewoodFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0004EnglewoodFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "FL0004 Englewood, FL", "label": "FL0004 Englewood, FL [Member]", "documentation": "FL0004 Englewood, FL" } } }, "auth_ref": { } }, "peak_FL0008LadyAlkeFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0008LadyAlkeFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "FL0008 Lady Alke, FL", "label": "FL0008 Lady Alke, FL [Member]", "documentation": "FL0008 Lady Alke, FL" } } }, "auth_ref": { } }, "peak_FL0012AtlantisFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0012AtlantisFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "FL0012 Atlantis, FL", "label": "FL0012 Atlantis, FL [Member]", "documentation": "FL0012 Atlantis, FL" } } }, "auth_ref": { } }, "peak_FL0022StuartFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0022StuartFLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "FL0022 Stuart, FL", "label": "FL0022 Stuart, FL [Member]", "documentation": "FL0022 Stuart, FL" } } }, "auth_ref": { } }, "peak_FL0025OrlandoFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0025OrlandoFLMember",

"presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0025 Orlando, FL", "label": "FL0025 Orlando, FL [Member]",
 "documentation": "FL0025 Orlando, FL" } } }, "auth_ref": [] }, "peak_FL0026StuartFLMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0026StuartFLMember",
 "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0026 Stuart, FL", "label": "FL0026 Stuart, FL [Member]",
 "documentation": "FL0026 Stuart, FL" } } }, "auth_ref": [] }, "peak_FL0029PortCharlotteFLMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FL0029PortCharlotteFLMember", "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0029 Port Charlotte, FL", "label": "FL0029 Port Charlotte, FL
 [Member]", "documentation": "FL0029 Port Charlotte, FL" } } }, "auth_ref": [] },
 "peak_FL0030PensacolaFLMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "FL0030PensacolaFLMember", "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0030 Pensacola, FL", "label": "FL0030 Pensacola, FL [Member]",
 "documentation": "FL0030 Pensacola, FL" } } }, "auth_ref": [] }, "peak_FL0031WesleyChapelFLMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FL0031WesleyChapelFLMember", "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0031 Wesley Chapel, FL", "label": "FL0031 Wesley Chapel, FL
 [Member]", "documentation": "FL0031 Wesley Chapel, FL" } } }, "auth_ref": [] },
 "peak_FL0032JacksonvilleFLMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "FL0032JacksonvilleFLMember", "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0032 Jacksonville, FL", "label": "FL0032 Jacksonville, FL
 [Member]", "documentation": "FL0032 Jacksonville, FL" } } }, "auth_ref": [] }, "peak_FL0033AtlantisFLMember":
 { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FL0033AtlantisFLMember", "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0033 Atlantis, FL", "label": "FL0033 Atlantis, FL [Member]",
 "documentation": "FL0033 Atlantis, FL" } } }, "auth_ref": [] }, "peak_FL0034YuleeFLMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FL0034YuleeFLMember",
 "presentation":-
<http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
], "lang": { "en-us": { "role": { "terseLabel": "FL0034 Yulee, FL", "label": "FL0034 Yulee, FL [Member]",
 "documentation": "FL0034 Yulee, FL" } } }, "auth_ref": [] }, "us-
 gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsDetails>], "lang": { "en-us": { "role": { "terseLabel":
 "Summary of financial instruments", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions
 [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
 used to disclose reportable information associated with domain members defined in one or many axes to the
 table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsDetails>], "lang": { "en-us": { "role": { "terseLabel":
 "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]",
 "documentation": "Disclosure of information about the fair value of financial instruments, including financial
 assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } },
 "auth_ref": ["r132", "r133"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueByBalanceSheetGroupingTextBlock", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsTables>], "lang": { "en-us": { "role": { "terseLabel":
 "Summary of the Carrying Values and Fair Values of Financial Instruments", "label": "Fair Value, by Balance
 Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial
 instruments, including financial assets and financial liabilities, and the measurements of those instruments,
 assets, and liabilities." } } }, "auth_ref": ["r132"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueByFairValueHierarchyLevelAxis", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsDetails>], "lang": { "en-us": { "role": { "terseLabel":
 "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation":
 "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical
 expedient." } } }, "auth_ref": ["r645", "r701", "r702", "r703", "r704", "r705", "r706", "r820", "r822", "r823",
 "r824", "r825", "r831", "r832", "r834", "r889", "r890", "r891", "r1193", "r1194", "r1200", "r1201", "r1202",
 "r1213", "r1217"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsDetails>], "lang": { "en-us": { "role": { "terseLabel":
 "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by
 measurement basis." } } }, "auth_ref": ["r645", "r1193", "r1194"] }, "us-
 gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation":-
<http://www.healthpeak.com/role/FairValueMeasurementsDetails>], "lang": { "en-us": { "role": { "terseLabel":
 "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation":
 "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at
 other than fair value." } } }, "auth_ref": ["r645", "r1193", "r1194"] }, "us-gaap_FairValueDisclosuresAbstract": {

"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } },
 "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": {
 "http://www.healthpeak.com/role/FairValueMeasurements" }, "lang": { "en-us": { "role": { "terseLabel": "Fair
 Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for
 the fair value of financial instruments (as defined), including financial assets and financial liabilities
 (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair
 value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and
 liabilities would include: (1) the fair value of the required items together with their carrying amounts (as
 appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a)
 information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity,
 and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk
 including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b)
 the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy
 for requiring collateral or other security and information as to accessing such collateral or security, and (d) the
 nature and brief description of such collateral or security; (4) quantitative information about market risks and
 how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information
 regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial
 statement for which fair value measurement is elected: (a) information necessary to understand the reasons for
 the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups]
 items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value
 of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and
 desired information." } } }, "auth_ref": ["r827", "r829", "r830", "r831", "r834", "r835", "r836", "r837", "r838",
 "r956", "r1213", "r1218"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {
 "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for
 identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [
 "r645", "r701", "r706", "r822", "r832", "r889", "r1200", "r1201", "r1202", "r1213"] }, "us-
 gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "FairValueInputsLevel2Member", "presentation": {
 "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices
 included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not
 limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar
 assets or liabilities in inactive markets." } } }, "auth_ref": ["r645", "r701", "r706", "r822", "r823", "r832", "r890",
 "r1193", "r1194", "r1200", "r1201", "r1202", "r1213"] }, "us-
 gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain",
 "presentation": { "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]",
 "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } },
 "auth_ref": ["r645", "r701", "r702", "r703", "r704", "r705", "r706", "r820", "r822", "r823", "r824", "r825", "r831",
 "r832", "r834", "r889", "r890", "r891", "r1193", "r1194", "r1200", "r1201", "r1202", "r1213", "r1217"] }, "us-
 gaap_FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": {
 "terseLabel": "Fair Value Measurement", "label": "Fair Value of Financial Instruments, Policy [Policy Text
 Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial
 instruments." } } }, "auth_ref": ["r22"] }, "peak_FeesPaidToInvestmentBanksAndAdvisorsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FeesPaidToInvestmentBanksAndAdvisorsMember", "presentation": {
 "http://www.healthpeak.com/role/TheMergerNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fees
 Paid to Investment Banks and Advisors", "label": "Fees Paid To Investment Banks And Advisors [Member]",
 "documentation": "Fees Paid To Investment Banks And Advisors" } } }, "auth_ref": [] }, "us-
 gaap_FinanceLoansAndLeasesReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FinanceLoansAndLeasesReceivablePolicy", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": {
 "terseLabel": "Credit Losses", "label": "Financing Receivable [Policy Text Block]", "documentation": "Disclosure
 of accounting policy for financing receivable." } } }, "auth_ref": ["r276", "r277", "r278", "r283", "r286", "r513",
 "r1456", "r1457", "r1458", "r1459", "r1463", "r1464"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis",
 "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation":
 "Information by type of financial instrument." } } }, "auth_ref": ["r515", "r516", "r517", "r518", "r519", "r520",
 "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534",
 "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r559", "r561", "r565", "r566",
 "r568", "r571", "r572", "r573", "r656", "r674", "r814", "r839", "r886", "r887", "r888", "r889", "r890", "r891",
 "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r900", "r904", "r907", "r908", "r909", "r910", "r911",
 "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r984", "r1188", "r1213", "r1215",
 "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1227", "r1395", "r1396", "r1397", "r1398",
 "r1399", "r1400", "r1401", "r1468", "r1469", "r1470", "r1471", "r1566", "r1567", "r1568", "r1569", "r1576",
 "r1579"] }, "us-gaap_FinancialInstrumentPerformanceStatusAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentPerformanceStatusAxis", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Axis]", "label": "Financial
 Instrument Performance Status [Axis]", "documentation": "Information by category of performance or non-

performance status of financial instruments." } } }, "auth_ref": { "r1478" } }, "us-gaap_FinancialInstrumentPerformanceStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentPerformanceStatusDomain", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Domain]", "documentation": "Category of performance or non-performance status of financial instruments, including but not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": { } }, "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails": { "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETSParentetical", "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Reserve for loans receivable", "negatedLabel": "Reserve for loan losses", "periodStartLabel": "Reserve for loan losses, beginning of period", "periodEndLabel": "Reserve for loan losses, end of period", "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease." } } }, "auth_ref": { "r1476" } }, "peak_FinancingReceivableAllowanceForCreditLossUnfundedLoanCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FinancingReceivableAllowanceForCreditLossUnfundedLoanCommitments", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Credit loss reserve on unfunded loan commitments", "label": "Financing Receivable Allowance For Credit Loss Unfunded Loan Commitments", "documentation": "Financing Receivable Allowance For Credit Loss Unfunded Loan Commitments" } } }, "auth_ref": { } }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r308", "r1477" } }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": { "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableCreditQualityIndicatorsTableTextBlock", "presentation": { "http://www.healthpeak.com/role/LoansReceivableTables" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of the Company's Internal Ratings for Loans Receivable on Net of Reserves for Loan Losses", "label": "Financing Receivable Credit Quality Indicators [Table Text Block]", "documentation": "Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics." } } }, "auth_ref": { "r279", "r1478" } }, "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Loans receivable, net of reserves of \$10,499 and \$2,830", "totalLabel": "Loans receivable, net", "terseLabel": "Loans receivable, net", "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease." } } }, "auth_ref": { "r1476" } }, "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails": { "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 }, "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Financing receivable, gross", "totalLabel": "Total", "label": "Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of financing receivable. Excludes net investment in lease." } } }, "auth_ref": { "r567", "r569", "r1476" } }, "us-gaap_FinancingReceivableExcludingAccruedInterestCreditLossExpenseReversal": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestCreditLossExpenseReversal", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Provision for expected loan losses on funded loans receivable", "label": "Financing Receivable, Excluding
 Accrued Interest, Credit Loss Expense (Reversal)", "documentation": "Amount, excluding accrued interest, of
 credit loss expense (reversal of expense) on financing receivable. Excludes net investment in lease." } } },
 "auth_ref": { "r563" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "Prior", "label": "Financing Receivable, Excluding Accrued Interest, Originated,
 More than Five Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest,
 of financing receivable originated more than five years prior to current fiscal year. Excludes net investment in
 lease." } } }, "auth_ref": { "r567", "r570", "r1186" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestSaleAndReclassificationToHeldForSale": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestSaleAndReclassificationToHeldForSale", "crdr": "credit",
 "presentation": { "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails" }, "lang": { "en-us": {
 "role": { "negatedTerseLabel": "Expected loan losses related to loans sold or repaid", "label": "Financing
 Receivable, Excluding Accrued Interest, Sale and Reclassification to Held-for-Sale", "documentation": "Amount
 excluding accrued interest, of decrease from sale and reclassification to held-for-sale of financing receivable.
 Excludes net investment in lease." } } }, "auth_ref": { "r560" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 6.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "2020", "label": "Financing Receivable, Excluding Accrued Interest, Year Five,
 Originated, Four Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest,
 of financing receivable originated four years prior to current fiscal year. Excludes net investment in lease." } } },
 "auth_ref": { "r567", "r570", "r1186" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "2021", "label": "Financing Receivable, Excluding Accrued Interest, Year Four,
 Originated, Three Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued
 interest, of financing receivable originated three years prior to current fiscal year. Excludes net investment in
 lease." } } }, "auth_ref": { "r567", "r570", "r1186" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "2024", "label": "Financing Receivable, Excluding Accrued Interest, Year One,
 Originated, Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing
 receivable originated in current fiscal year. Excludes net investment in lease." } } }, "auth_ref": { "r567", "r570",
 "r1186" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 4.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "2022", "label": "Financing Receivable, Excluding Accrued Interest, Year
 Three, Originated, Two Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued
 interest, of financing receivable originated two years prior to current fiscal year. Excludes net investment in
 lease." } } }, "auth_ref": { "r567", "r570", "r1186" } }, "us-
 gaap_FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear", "crdr":

"debit", "calculation": {
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails): {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight":
 1.0, "order": 2.0 } }, "presentation": {
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails) }, "lang":
 { "en-us": { "role": { "terseLabel": "2023", "label": "Financing Receivable, Excluding Accrued Interest, Year Two,
 Originated, Fiscal Year before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest
 of financing receivable originated in fiscal year prior to current fiscal year. Excludes net investment in lease." } } }
 }, "auth_ref": { "r567", "r570", "r1186" } }, "us-
 gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails"](http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails),
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi),
["http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"](http://www.healthpeak.com/role/LoansReceivableTheMergerDetails) }, "lang": { "en-us": { "role": { "terseLabel":
 "Class of Financing Receivable [Axis]", "label": "Class of Financing Receivable [Axis]", "documentation":
 "Information by class of financing receivable determined on the basis of initial measurement attribute, risk
 characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": { "r281", "r284", "r285",
 "r287", "r305", "r306", "r307", "r308", "r507", "r509", "r510", "r511", "r512", "r565", "r566", "r568", "r1183",
 "r1184", "r1185", "r1186", "r1187", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402",
 "r1403", "r1404", "r1461" } }, "us-
 gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails"](http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails),
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi),
["http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"](http://www.healthpeak.com/role/LoansReceivableTheMergerDetails) }, "lang": { "en-us": { "role": { "terseLabel":
 "Class of Financing Receivable [Domain]", "label": "Class of Financing Receivable [Domain]", "documentation":
 "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method
 of monitoring and assessing credit risk." } } }, "auth_ref": { "r287", "r305", "r306", "r307", "r308", "r507", "r509",
 "r510", "r511", "r512", "r1183", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403",
 "r1404", "r1461" } }, "us-gaap_FinancingReceivableRecordedInvestmentLineItems": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableRecordedInvestmentLineItems", "presentation": {
["http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails"](http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails) }, "lang": { "en-us": { "role": { "terseLabel":
 "Financing Receivable, Credit Quality Indicator [Line Items]", "label": "Financing Receivable, Credit Quality
 Indicator [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
 concepts are used to disclose reportable information associated with domain members defined in one or many
 axes to the table." } } }, "auth_ref": { "r281", "r1186", "r1478" } }, "us-
 gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails": {
 "parentTag": "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight":
 1.0, "order": 2.0 } }, "presentation": {
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails) }, "lang": { "en-us": { "role": { "terseLabel":
 "role": { "terseLabel": "Unamortized discounts and fees", "label": "Financing Receivable, Unamortized Loan Cost
 (Fee) and Purchase Premium (Discount)", "documentation": "Amount of unamortized loan commitment,
 origination, and other costs (fees) and purchase premium (discount) on financing receivable recognized as
 adjustment to yield. Excludes financing receivable covered under loss sharing agreement." } } }, "auth_ref": {
 "r1371", "r1460", "r1462" } }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {
["http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails"](http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails): { "parentTag": "us-
 gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": {
["http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails"](http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails) }, "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "label": "Finite-Lived Intangible Assets,
 Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding
 financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r367", "r574",
 "r593", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": {
["http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet"](http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet):
 { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": {
["http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet"](http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet):
 }, "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected
 Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and
 goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following

current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r1492", "r1662" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r594", "r1159", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r594", "r1159", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r594", "r1159", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r594", "r1159", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r594", "r1159", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization of Intangible Assets", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r574", "r593", "r925", "r1190" } }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails", "http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to

disclose reportable information associated with domain members defined in one or many axes to the table." } } }
 "auth_ref": { "r587", "r593", "r595", "r596", "r597", "r924", "r1159", "r1190" } }, "us-
 gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails": { "parentTag": null,
 "weight": null, "order": null, "root": true } },
 "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet:
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet:
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails" }, "lang": { "en-us": {
 "role": { "totalLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation":
 "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a
 finite life." } } }, "auth_ref": { "r924", "r1491" } },
 "peak_FiniteLivedIntangibleLiabilitiesAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname":
 "FiniteLivedIntangibleLiabilitiesAccumulatedAmortization", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails": { "parentTag":
 "peak_FiniteLivedIntangibleLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails" }, "lang": { "en-us": {
 "role": { "negatedTerseLabel": "Accumulated depreciation and amortization", "label": "Finite Lived Intangible
 Liabilities Accumulated Amortization", "documentation": "Accumulated amount of amortization of liabilities,
 excluding financial liabilities, lacking physical substance with a finite life." } } }, "auth_ref": { } },
 "peak_FiniteLivedIntangibleLiabilitiesAcquired": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "FiniteLivedIntangibleLiabilitiesAcquired", "crdr": "credit",
 "presentation": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Intangible liabilities acquired", "label": "Finite-Lived Intangible Liabilities Acquired",
 "documentation": "Finite-Lived Intangible Liabilities Acquired" } } }, "auth_ref": { } },
 "peak_FiniteLivedIntangibleLiabilitiesGross": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "FiniteLivedIntangibleLiabilitiesGross", "crdr": "credit",
 "calculation": { "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails": {
 "parentTag": "peak_FiniteLivedIntangibleLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Gross intangible lease liabilities", "label": "Finite Lived Intangible Liabilities, Gross",
 "documentation": "Amount before amortization of liabilities, excluding financial liabilities, lacking physical
 substance with a finite life." } } }, "auth_ref": { } }, "peak_FiniteLivedIntangibleLiabilitiesLease": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FiniteLivedIntangibleLiabilitiesLease", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Lease-up intangibles", "label": "Finite-Lived Intangible Liabilities, Lease", "documentation": "Finite-Lived
 Intangible Liabilities, Lease" } } }, "auth_ref": { } }, "peak_FiniteLivedIntangibleLiabilitiesNet": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "FiniteLivedIntangibleLiabilitiesNet", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails": { "parentTag": null,
 "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangibleLeaseLiabilitiesDetails" }, "lang": { "en-us": {
 "role": { "totalLabel": "Intangible liabilities, net", "label": "Finite Lived Intangible Liabilities, Net",
 "documentation": "The aggregate sum of the gross carrying value of major finite-lived intangible liabilities class,
 less accumulated accretion and any impairment charges." } } }, "auth_ref": { } }, "us-
 gaap_FiniteLivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FiniteLivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation":
 "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an
 acquisition." } } }, "auth_ref": { "r588" } }, "peak_FoodExpense": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "FoodExpense", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": {
 "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Food", "label": "Food Expense", "documentation": "Food Expense" } } },
 "auth_ref": { } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery
 due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax
 Benefits, Amount" } } }, "auth_ref": { "r1283", "r1294", "r1304", "r1337" } },
 "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation":
 { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery
 due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } }
 } }, "auth_ref": { "r1283", "r1294", "r1304", "r1337" } },
 "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
 "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel":
 "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation
 of Home Country Law, Amount" } } }, "auth_ref": { "r1283", "r1294", "r1304", "r1337" } },
 "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
 "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel":

"Forgone Recovery, Explanation of Impracticability": { "label": "ForgoneRecoveryExplanationOfImpracticability [Text Block]" } },
"auth_ref": { "r1283", "r1294", "r1304", "r1337" } },
"ecd_ForgoneRecoveryIndName": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery Individual Name" } } }, "auth_ref": { "r1283", "r1294", "r1304", "r1337" } },
"us-gAAP-ForwardContractIndexedToIssuersEquityForwardRate": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gAAP/2024", "localname": "ForwardContractIndexedToIssuersEquityForwardRate", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forward rate per share (in dollars per share)", "label": "Forward Contract Indexed to Issuer's Equity Forward Rate Per Share", "documentation": "The per share price of the Company's stock at which the contract holder of the freestanding contract has the right to purchase or sell the Company's stock at a future date." } } }, "auth_ref": { "r29", "r131" } },
"us-gAAP-ForwardContractIndexedToIssuersEquityShares": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gAAP/2024", "localname": "ForwardContractIndexedToIssuersEquityShares", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum shares issuable under forward equity sales agreement (in shares)", "label": "Forward Contract Indexed to Issuer's Equity Shares", "documentation": "Maximum number of shares that could be issued to settle forward contract indexed to equity." } } }, "auth_ref": { "r249" } }, "
"peak-FourteenOutpatientMedicalBuildingsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "FourteenOutpatientMedicalBuildingsMember", "presentation": { "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstabl", "lang": { "en-us": { "role": { "terseLabel": "Fourteen Outpatient Medical Buildings", "label": "Fourteen Outpatient Medical Buildings [Member]", "documentation": "Fourteen Outpatient Medical Buildings" } } }, "auth_ref": { } }, "ecd-FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "F
"rValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": { "r1317" } }, "peak-GA0010AtlantaGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0010AtlantaGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0010 Atlanta, GA", "label": "GA0010 Atlanta, GA [Member]", "documentation": "GA0010 Atlanta, GA" } } }, "auth_ref": { } }, "peak-GA0023WoodstockGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0023WoodstockGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0023 Woodstock, GA", "label": "GA0023 Woodstock, GA [Member]", "documentation": "GA0023 Woodstock, GA" } } }, "auth_ref": { } }, "peak-GA0024AtlantaGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0024AtlantaGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0024 Atlanta, GA", "label": "GA0024 Atlanta, GA [Member]", "documentation": "GA0024 Atlanta, GA" } } }, "auth_ref": { } }, "peak-GA0025LawrencevilleGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0025LawrencevilleGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0025 Lawrenceville, GA", "label": "GA0025 Lawrenceville, GA [Member]", "documentation": "GA0025 Lawrenceville, GA" } } }, "auth_ref": { } }, "peak-GA0026DuluthGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0026DuluthGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0026 Duluth, GA", "label": "GA0026 Duluth, GA [Member]", "documentation": "GA0026 Duluth, GA" } } }, "auth_ref": { } }, "peak-GA0027LawrencevilleGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0027LawrencevilleGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0027 Lawrenceville, GA", "label": "GA0027 Lawrenceville, GA [Member]", "documentation": "GA0027 Lawrenceville, GA" } } }, "auth_ref": { } }, "peak-GA0028AtlantaGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0028AtlantaGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0028 Atlanta, GA", "label": "GA0028 Atlanta, GA [Member]", "documentation": "GA0028 Atlanta, GA" } } }, "auth_ref": { } }, "peak-GA0030BufordGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0030BufordGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0030 Buford, GA", "label": "GA0030 Buford, GA [Member]", "documentation": "GA0030 Buford, GA" } } }, "auth_ref": { } }, "peak-GA0031DunwoodyGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA0031DunwoodyGAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "GA0031 Dunwoody, GA", "label": "GA0031 Dunwoody, GA [Member]", "documentation": "GA0031 Dunwoody, GA" } } }, "auth_ref": { } }, "peak-GA0032DunwoodyGAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname:

"GA0032DunwoodyGAMember", "presentation": {
<http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
 }, "lang": { "en-us": { "role": { "terseLabel": "GA0032 Dunwoody, GA", "label": "GA0032 Dunwoody, GA [Member]",
 "documentation": "GA0032 Dunwoody, GA" } } }, "auth_ref": { } }, "peak_GA3246PoolerGAMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "GA3246PoolerGAMember",
 "presentation": {
<http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun>
 }, "lang": { "en-us": { "role": { "terseLabel": "GA3246 Pooler, GA", "label": "GA3246 Pooler, GA [Member]",
 "documentation": "GA3246 Pooler, GA" } } }, "auth_ref": { } }, "peak_GainLossFromChangeOfControl": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "GainLossFromChangeOfControl", "crdr": "credit", "calculation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS>: { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS> }, "lang": { "en-us": { "role": {
 "negatedTerseLabel": "Loss (gain) upon change of control, net", "label": "Gain (Loss) From Change Of Control",
 "documentation": "Gain (Loss) From Change Of Control" } } }, "auth_ref": { } }, "us-
 gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": {
<http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails> }, "lang":
 { "en-us": { "role": { "terseLabel": "Gain on investments", "label": "Gain (Loss) on Investments", "documentation":
 "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": { "r196", "r199", "r1372" } }, "us-
 gaap_GainLossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "GainLossOnSaleOfInvestments", "crdr": "credit", "calculation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS>: { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS> }, "lang": { "en-us": { "role": {
 "negatedLabel": "Loss (gain) on sales of real estate, net", "label": "Gain (Loss) on Sale of Investments",
 "documentation": "The net realized gain (loss) on investments sold during the period, not including gains
 (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity,
 which, for cash flow reporting, is a component of proceeds from investing activities." } } }, "auth_ref": { "r19" } },
 "us-gaap_GainLossOnSaleOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "GainLossOnSaleOfNotesReceivable", "crdr": "credit", "presentation": {
<http://www.healthpeak.com/role/LeasesNarrativeDetails> }, "lang": { "en-us": { "role": { "terseLabel": "Gain on
 sale of direct financing lease", "label": "Gain (Loss) on Sale of Financing Receivable", "documentation": "Amount
 of gain (loss) on sale of financing receivable." } } }, "auth_ref": { "r899" } },
 "peak_GainLossOnSaleOfRealEstateUnderDirectFinancingLease": { "xbrltype": "monetaryItemType", "nsuri":
<http://www.healthpeak.com/20241231>, "localname": "GainLossOnSaleOfRealEstateUnderDirectFinancingLease",
 "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":
 { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": {
 "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on sale of real estate under direct financing leases",
 "label": "Gain (Loss) On Sale Of Real Estate Under Direct Financing Lease", "documentation": "Gain (Loss) On
 Sale Of Real Estate Under Direct Financing Lease" } } }, "auth_ref": { } }, "us-
 gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
<http://fasb.org/us-gaap/2024>, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag":
 "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 },
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails>:
 { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth
 "weight": 1.0, "order": 3.0 } }, "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS>,
<http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate>,
<http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate>,
<http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate>,
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails> },
 "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on sales of real estate, net", "label": "Gains (Losses) on
 Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals
 of real estate owned for investment purposes." } } }, "auth_ref": { "r290", "r291", "r292", "r1427", "r1428",
 "r1432", "r1602", "r1648" } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag":
 "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 },
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails>:
 { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth
 "weight": -1.0, "order": 7.0 } }, "presentation": {
<http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS>,
<http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails>,
<http://www.healthpeak.com/role/LeasesNarrativeDetails>,
<http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails> },
 "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "negatedLabel": "General and
 administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of
 expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity,
 which are not directly or indirectly associated with the manufacture, sale or creation of a product or product
 line." } } }, "auth_ref": { "r194", "r1084" } }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "GeneralAndAdministrativeExpenseMember", "presentation": {

["http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails"](http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails),
["http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails"](http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails)], "lang": { "en-us": { "role": { "terseLabel":
"General and Administrative Expense", "label": "General and Administrative Expense [Member]",
"documentation": "Primary financial statement caption encompassing general and administrative expense." } } },
"auth_ref": { "r194" } }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": {
["http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe](http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe)
], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration
Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or
income statement in the period from one or more specified geographic areas is to a corresponding consolidated,
segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic
political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US
state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": {
"r59", "r1142" } }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Goodwill", "crdr": "debit", "presentation": {
["http://www.healthpeak.com/role/IntangiblesNarrativeDetails"](http://www.healthpeak.com/role/IntangiblesNarrativeDetails),
["http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails"](http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails),
["http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails"](http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails),
["http://www.healthpeak.com/role/TheMergerNarrativeDetails"](http://www.healthpeak.com/role/TheMergerNarrativeDetails),
["http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed](http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed)
], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after
accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in
business combination or from joint venture formation or both, that is not individually identified and separately
recognized." } } }, "auth_ref": { "r366", "r575", "r957", "r1178", "r1189", "r1214", "r1226", "r1480", "r1487" } },
"us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": {
["http://www.healthpeak.com/role/IntangiblesNarrativeDetails"](http://www.healthpeak.com/role/IntangiblesNarrativeDetails)], "lang": { "en-us": { "role": { "terseLabel":
"Goodwill, impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss
from asset representing future economic benefit arising from other asset acquired in business combination or
from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": { "r19", "r576", "r582", "r586", "r1189", "r1214" } }, "peak_GovernmentAssistanceAxisAxis": {
"xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"GovernmentAssistanceAxisAxis", "presentation": {
["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable)
], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance [Axis]", "label": "Government Assistance Axis
[Axis]", "documentation": "Government Assistance Axis" } } }, "auth_ref": { } },
"peak_GovernmentAssistanceAxisDomain": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "GovernmentAssistanceAxisDomain", "presentation": {
["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable)
], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance Axis [Domain]", "label": "Government
Assistance Axis [Domain]", "documentation": "Government Assistance Axis [Domain]" } } }, "auth_ref": { } },
"peak_GovernmentAssistanceCARESActMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "GovernmentAssistanceCARESActMember", "presentation":
{
["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable)
], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance, CARES Act", "label": "Government
Assistance, CARES Act [Member]", "documentation": "Government Assistance, CARES Act" } } }, "auth_ref": { } },
"peak_GovernmentGrantIncome": { "xbrltype": "monetaryItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "GovernmentGrantIncome", "crdr": "credit",
"presentation": {
["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable)
], "lang": { "en-us": { "role": { "terseLabel": "Government grant income", "label": "Government Grant Income",
"documentation": "Government Grant Income" } } }, "auth_ref": { } },
"peak_GovernmentGrantIncomeFromCARESAct": { "xbrltype": "monetaryItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "GovernmentGrantIncomeFromCARESAct", "crdr": "credit",
"calculation": {
["http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"](http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails):
{ "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": 1.0, "order": 8.0 } },
"presentation": {
["http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"](http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails)],
"lang": { "en-us": { "role": { "terseLabel": "Government grant income", "label": "Government Grant Income From
CARES Act", "documentation": "Government Grant Income From CARES Act" } } }, "auth_ref": { } },
"peak_GovernmentGrantIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "GovernmentGrantIncomePolicyPolicyTextBlock",
"presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": {
"en-us": { "role": { "terseLabel": "Government Grant Income", "label": "Government Grant Income Policy [Policy
Text Block]", "documentation": "Government Grant Income Policy" } } }, "auth_ref": { } },
"peak_GraphiteBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231",
"localname": "GraphiteBioIncMember", "presentation": {
["http://www.healthpeak.com/role/LeasesTenantUpdatesDetails"](http://www.healthpeak.com/role/LeasesTenantUpdatesDetails)], "lang": { "en-us": { "role": { "terseLabel":
"Graphite Bio, Inc", "label": "Graphite Bio, Inc [Member]", "documentation": "Graphite Bio, Inc" } } }, "auth_ref":
{ } }, "peak_HCAHealthcareIncMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "HCAHealthcareIncMember", "presentation": {
["http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe](http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe)
], "lang": { "en-us": { "role": { "terseLabel": "HCA Healthcare, Inc", "label": "HCA Healthcare, Inc [Member]",
"documentation": "HCA Healthcare, Inc" } } }, "auth_ref": { } }, "peak_HCPVenturesIVLLCMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "HCPVenturesIVLLCMember",
"presentation": {

"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails"], "lang":
{ "en-us": { "role": { "terseLabel": "HCP Ventures IV, LLC", "label": "H C P Ventures IV, LLC [Member]",
"documentation": "Represents information pertaining to HCP Ventures IV, LLC, an unconsolidated joint venture
of the entity." } } }, "auth_ref": [] }, "peak_HealthpeakOPMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "HealthpeakOPMember", "presentation": {
"http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Healthpeak OP", "label": "Healthpeak OP [Member]", "documentation": "Healthpeak OP" }
} }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": {
"http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information
by designation of purpose of derivative instrument." } } }, "auth_ref": { "r28", "r806" } }, "us-
gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "HedgingDesignationDomain", "presentation": {
"http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation":
"Designation of purpose of derivative instrument." } } }, "auth_ref": { "r28" } }, "us-
gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "HedgingRelationshipDomain", "presentation": {
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation":
"Nature or intent of a hedge." } } }, "auth_ref": { "r28" } }, "peak_IL0001SandwichILMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IL0001SandwichILMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IL0001 Sandwich, IL", "label": "IL0001 Sandwich, IL [Member]",
"documentation": "IL0001 Sandwich, IL" } } }, "auth_ref": [] }, "peak_IL0002BolingbrookILMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"IL0002BolingbrookILMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IL0002 Bolingbrook, IL", "label": "IL0002 Bolingbrook, IL
[Member]", "documentation": "IL0002 Bolingbrook, IL" } } }, "auth_ref": [] }, "peak_IL0002ElginILMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"IL0002ElginILMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IL0002 Elgin, IL", "label": "IL0002 Elgin, IL [Member]",
"documentation": "IL0002 Elgin, IL" } } }, "auth_ref": [] }, "peak_IL0005PalosHeightsILMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"IL0005PalosHeightsILMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IL0005 Palos Heights, IL", "label": "IL0005 Palos Heights, IL
[Member]", "documentation": "IL0005 Palos Heights, IL" } } }, "auth_ref": [] },
"peak_IN0001MishawakaINMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "IN0001MishawakaINMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IN0001 Mishawaka, IN", "label": "IN0001 Mishawaka, IN [Member]",
"documentation": "IN0001 Mishawaka, IN" } } }, "auth_ref": [] }, "peak_IN0002CarmelINMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IN0002CarmelINMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IN0002 Carmel, IN", "label": "IN0002 Carmel, IN [Member]",
"documentation": "IN0002 Carmel, IN" } } }, "auth_ref": [] }, "peak_IN0003BloomingtonINMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"IN0003BloomingtonINMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IN0003 Bloomington, IN", "label": "IN0003 Bloomington, IN
[Member]", "documentation": "IN0003 Bloomington, IN" } } }, "auth_ref": [] },
"peak_IN0004BloomingtonINMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "IN0004BloomingtonINMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
], "lang": { "en-us": { "role": { "terseLabel": "IN0004 Bloomington, IN", "label": "IN0004 Bloomington, IN
[Member]", "documentation": "IN0004 Bloomington, IN" } } }, "auth_ref": [] },
"peak_IN0005BloomingtonINMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "IN0005BloomingtonINMember", "presentation": {

[illegible]

"peak_IN0025NewburghINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IN0025NewburghINMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccu", "lang": { "en-us": { "role": { "terseLabel": "IN0025 Newburgh, IN", "label": "IN0025 Newburgh, IN [Member]", "documentation": "IN0025 Newburgh, IN" } } }, "auth_ref": { "r1262", "r1263", "r1286" } }, "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": { "http://www.healthpeak.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": { "r1262", "r1263", "r1286" } }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]", "label": "Impaired Long-Lived Assets Held and Used [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1432", "r1494" } }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": { "r1432", "r1494" } }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets and Goodwill", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": { "r1432", "r1494" } }, "peak_ImpairmentsAndAllowanceForCreditLossReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ImpairmentsAndAllowanceForCreditLossReserves", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": -1.0, "order": 10.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "lang": { "en-us": { "role": { "negatedLabel": "Impairments and loan loss reserves, net", "label": "Impairments And Allowance For Credit Loss Reserves", "documentation": "Impairments And Allowance For Credit Loss Reserves" } } }, "auth_ref": { "r1432", "r1494" } }, "peak_ImpairmentsAndAllowanceForCreditLossReservesRecoveriesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ImpairmentsAndAllowanceForCreditLossReservesRecoveriesNet", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "lang": { "en-us": { "role": { "verboseLabel": "Impairments and loan loss reserves (recoveries), net", "label": "Impairments And Allowance For Credit Loss Reserves (Recoveries), Net", "documentation": "Impairments And Allowance For Credit Loss Reserves (Recoveries), Net" } } }, "auth_ref": { "r1432", "r1494" } }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "peak_NetIncomeLossContinuingOperationsAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails", "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": { "r99", "r186", "r211", "r423", "r424", "r426", "r427", "r428", "r448", "r452", "r798" } }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interests\u2019 share in continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": { "r97", "r241", "r428" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from continuing operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": { "r406", "r755" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInv

"crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 },
 "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails",
 "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"},
 "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures", "netLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": { "r273", "r989", "r1171", "r1448", "r1450", "r1451", "r1452", "r1453" } },
 "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag":
 "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 },
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails"}, "lang": { "en-us": {
 "role": { "totalLabel": "Income (loss) from continuing operations", "terseLabel": "Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r241", "r273", "r405", "r421",
 "r428", "r552", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r790", "r798", "r819",
 "r842", "r979", "r1171", "r1448", "r1450", "r1451", "r1452", "r1453", "r1508" } }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag":
 "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails"}, "lang": { "en-us": {
 "role": { "terseLabel": "Continuing operations (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r186", "r263",
 "r393", "r421", "r423", "r424", "r426", "r427", "r428", "r439", "r450", "r451", "r790", "r798", "r819", "r962",
 "r1611" } }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag":
 "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails"}, "lang": { "en-us": {
 "role": { "terseLabel": "Continuing operations (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } },
 "auth_ref": { "r186", "r393", "r421", "r423", "r424", "r426", "r427", "r428", "r439", "r450", "r451", "r452", "r798",
 "r819", "r962", "r1611" } }, "peak_IncomeLossFromDiscontinuedOperationsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "IncomeLossFromDiscontinuedOperationsMember", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable",
 "lang": { "en-us": { "role": { "terseLabel": "Government grant income recorded in income (loss) from discontinued operations", "label": "Income Loss From Discontinued Operations [Member]", "documentation":
 "Income Loss From Discontinued Operations" } } }, "auth_ref": { } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
 "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 },
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails"}, "lang": { "en-us": {
 "role": { "terseLabel": "Income (loss) from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r144", "r145", "r146", "r147", "r148",
 "r158", "r362", "r783", "r980" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit",
 "calculation": {

"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from discontinued operations", "label": "Income (Loss)
 from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income
 (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss)
 from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-
 down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": {
 "r144", "r145", "r146", "r147", "r148", "r154", "r158", "r241" } }, "us-
 gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
 gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Discontinued operations (in dollars per share)", "label": "Income (Loss) from
 Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
 "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of
 the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": {
 "r187", "r393", "r443", "r450", "r451", "r1603", "r1611" } }, "us-
 gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
 gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Discontinued operations (in dollars per share)", "label": "Income (Loss) from
 Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
 "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of
 the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": {
 "r246", "r443", "r450", "r451" } }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight":
 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" }, "lang": { "en-us": { "role": {
 "terseLabel": "Equity income (loss) from unconsolidated joint ventures", "label": "Income (Loss) from Equity
 Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method
 investee's income (loss)." } } }, "auth_ref": { "r19", "r185", "r262", "r458", "r474", "r497", "r546", "r978" } },
 "peak_IncomeLossFromEquityMethodInvestmentsIncludingDiscontinuedOperations": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "IncomeLossFromEquityMethodInvestmentsIncludingDiscontinuedOperations", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Equity loss (income) from unconsolidated joint ventures", "label": "Income Loss From Equity
 Method Investments, Including Discontinued Operations", "documentation": "Income Loss From Equity Method
 Investments, Including Discontinued Operations" } } }, "auth_ref": { } }, "us-gaap_IncomeStatementAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract",
 "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]"
 } } }, "auth_ref": { } }, "us-
 gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
 "presentation": {
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate
 }, "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]",
 "documentation": "Information by name of disposal group." } } }, "auth_ref": { "r1203", "r1204" } }, "us-
 gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLine",
 "presentation": {
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinue
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by
 Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet
 and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
 "documentation": "Line items represent financial concepts included in a table. These concepts are used to
 disclose reportable information associated with domain members defined in one or many axes to the table." } } },
 "auth_ref": { } }, "us-

gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTabl
 "presentation": {
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued
 "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont
 }, "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
 "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of
 information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified
 as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } }
 }, "auth_ref": { "r23", "r31", "r36", "r140", "r149", "r150", "r151", "r152", "r153", "r157", "r159", "r160", "r220" }
 }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails",
 "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet
 "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails",
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable
 }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement
 of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where
 disaggregated amount has been reported." } } }, "auth_ref": { "r599", "r606", "r607", "r826", "r828", "r833",
 "r1003", "r1005", "r1085", "r1159", "r1216", "r1615" } }, "us-gaap_IncomeStatementLocationDomain": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeStatementLocationDomain", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails",
 "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDet
 "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails",
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable
 }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label":
 "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where
 disaggregated amount has been reported." } } }, "auth_ref": { "r606", "r607", "r826", "r828", "r833", "r1003",
 "r1005", "r1085", "r1159", "r1216", "r1615" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": {
 "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]"
 } } }, "auth_ref": { } }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxes", "lang": { "en-us": { "role": { "terseLabel": "Income Taxes",
 "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } },
 "auth_ref": { "r407", "r750", "r756", "r760", "r761", "r762", "r765", "r771", "r779", "r781", "r784", "r785",
 "r1025", "r1210" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight":
 -1.0, "order": 1.0 }, "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails":
 { "parentTag": null, "weight": null, "order": null, "root": true },
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": {
 "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
 "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails",
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails",
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails"},
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit (expense)", "verboseLabel": "Income tax
 expense (benefit)", "negatedTotalLabel": "Total income tax benefit (expense) from continuing operations",
 "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and
 deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r289", "r300",
 "r432", "r433", "r458", "r475", "r497", "r754", "r756", "r780", "r990", "r1210" } }, "us-
 gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeTaxPolicyTextBlock", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies"}, "lang": { "en-us": { "role": {
 "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of
 accounting policy for income taxes, which may include its accounting policies for recognizing and measuring
 deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating
 loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective
 income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": {
 "r384", "r752", "r753", "r765", "r766", "r770", "r775", "r1020" } }, "us-
 gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": {
 "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails"},
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in valuation allowance for deferred tax assets",
 "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
 "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income
 tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income
 (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax

assets." } } }, "auth_ref": { "r759", "r1210", "r1546" } } }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit (expense) at U.S. federal statutory income tax rate on income or loss subject to tax", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } } }, "auth_ref": { "r756", "r1210" } } }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "State income tax benefit (expense), net of federal tax", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } } }, "auth_ref": { "r758", "r1210", "r1546" } } }, "peak_IncomeTaxSection1231GainLossTotalCapitalDistributionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IncomeTaxSection1231GainLossTotalCapitalDistributionPercentage", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Section 1231, capital distribution percentage", "label": "Income Tax, Section 1231 Gain (Loss), Total Capital Distribution Percentage", "documentation": "Income Tax, Section 1231 Gain (Loss), Total Capital Distribution Percentage" } } } }, "auth_ref": { } } }, "peak_IncomeTaxSection897GainLossPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IncomeTaxSection897GainLossPercentage", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Section 897, capital distribution percentage", "label": "Income Tax, Section 897 Gain (Loss) Percentage", "documentation": "Income Tax, Section 897 Gain (Loss) Percentage" } } } }, "auth_ref": { } } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid (refunded)", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } } }, "auth_ref": { "r50", "r400", "r772", "r773" } } }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } } }, "auth_ref": { "r18" } } }, "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in accounts receivable and other assets, net", "label": "Increase (Decrease) in Accounts Receivable and Other Operating Assets", "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other." } } } }, "auth_ref": { "r1431" } } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Changes in:", "label": "Increase (Decrease) in Operating Capital [Abstract]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": { } } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": { } } }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Redeemable Noncontrolling Interests", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": { } } }, "peak_IncrementalCommonSharesAttributableToDilutiveEffectOfEquityAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEquityAwards", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Incremental common shares attributable to dilutive effect of equity awards", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Awards", "documentation": "Incremental common shares attributable to dilutive effect of equity awards." } } } }, "auth_ref": { } } }

"IncrementalCommonSharesAttributableToDilutiveEffectOfEquityAwards", "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Outstanding equity awards (in shares)", "label": "Incremental Common Shares
 Attributable to Dilutive Effect of Equity Awards", "documentation": "Incremental Common Shares Attributable to
 Dilutive Effect of Equity Awards" } } }, "auth_ref": [] },
 "peak_IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnits": { "xbrltype": "sharesItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnits", "calculation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-
 gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Dilutive potential common shares - OP Units (in shares)", "label": "Incremental Common
 Shares Attributable To Dilutive Effect Of OP Units", "documentation": "Incremental Common Shares Attributable
 To Dilutive Effect Of OP Units" } } }, "auth_ref": [] },
 "peak_IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnitsOutstanding": { "xbrltype":
 "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnitsOutstanding", "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Dilutive potential common shares - OP Units (in shares)", "label": "Incremental Common
 Shares Attributable To Dilutive Effect Of OP Units Outstanding", "documentation": "Incremental Common Shares
 Attributable To Dilutive Effect Of OP Units Outstanding" } } }, "auth_ref": [] }, "us-
 gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype":
 "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-
 gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Dilutive potential common shares - equity awards (in shares)", "label": "Incremental
 Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation":
 "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share
 based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r440", "r441", "r442", "r452",
 "r713"] }, "peak_IncrementalCommonSharesAttributableToDilutiveEffectOfEquityForwardAgreementsSettled": {
 "xbrltype": "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "IncrementalCommonSharesAttributableToDilutiveEffectOfEquityForwardAgreementsSettled", "presentation": {
 "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Forward sales agreements that have been settled (in shares)", "label": "Incremental
 Common Shares Attributable to Dilutive Effect of Equity Forward Agreements, Settled", "documentation":
 "Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements, Settled" } } },
 "auth_ref": [] }, "us-gaap_IndemnificationGuaranteeMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IndemnificationGuaranteeMember", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Indemnification Agreement", "label": "Indemnification Agreement [Member]",
 "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the
 guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or
 actions, such as a patent infringement action against an entity that relied on certain representations as to
 ownership rights made by a software vendor." } } }, "auth_ref": ["r1504"] }, "ecd_IndividualAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang":
 { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": ["r1283", "r1294",
 "r1304", "r1328", "r1337", "r1341", "r1349"] }, "peak_InitialDirectCostsNet": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname": "InitialDirectCostsNet", "crdr": "debit",
 "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Initial direct costs", "label": "Initial Direct Costs, Net",
 "documentation": "Initial Direct Costs, Net" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": {
 "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems",
 "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r1347"] },
 "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": {
 "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r1264", "r1353"] },
 "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": {
 "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "terseLabel": "Insider
 Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } },
 "auth_ref": ["r1264", "r1353"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "terseLabel": "Insider
 Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted
 [Text Block]" } } }, "auth_ref": ["r1264", "r1353"] }, "us-gaap_InsuredEventGainLoss": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuredEventGainLoss", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
 "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": {
 "negatedTerseLabel": "Casualty-related loss (recoveries), net", "terseLabel": "Insured event loss", "label":
 "Insured Event, Gain (Loss)", "documentation": "Amount of excess (deficiency) of insurance recovery over the loss
 incurred from an insured event." } } }, "auth_ref": ["r1503"] },

"peak_IntangibleAssetsAndLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IntangibleAssetsAndLiabilitiesDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/Intangibles": { "lang": { "en-us": { "role": { "terseLabel": "Intangibles", "label": "Intangible Assets and Liabilities Disclosure [Text Block]", "documentation": "This block of text may be used to disclose all or part of the information related to intangible assets and liabilities." } } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } } }, "auth_ref": ["r587", "r1491", "r1493"] }, "peak_IntangibleAssetsWeightedAverageAmortizationUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IntangibleAssetsWeightedAverageAmortizationUsefulLife", "presentation": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, weighted average amortization, useful life", "label": "Intangible Assets, Weighted Average Amortization, Useful Life", "documentation": "Intangible Assets, Weighted Average Amortization, Useful Life" } } } }, "auth_ref": [] }, "peak_IntangibleLiabilitiesWeightedAverageAmortizationUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IntangibleLiabilitiesWeightedAverageAmortizationUsefulLife", "presentation": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "lang": { "en-us": { "role": { "terseLabel": "Intangible liabilities, weighted average amortization, useful life", "label": "Intangible Liabilities, Weighted Average Amortization, Useful Life", "documentation": "Intangible Liabilities, Weighted Average Amortization, Useful Life" } } } }, "auth_ref": [] }, "peak_IntangiblesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "IntangiblesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Intangibles [Abstract]", "label": "Intangibles [Abstract]", "documentation": "Intangibles [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Capitalized interest", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } } }, "auth_ref": ["r852"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } } }, "auth_ref": ["r458", "r467", "r471", "r477", "r497", "r851", "r1177", "r1178"] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } } }, "auth_ref": [] }, "peak_InterestIncomeExcludedFromAdjustedGovernmentGrantIncomeFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestIncomeExcludedFromAdjustedGovernmentGrantIncomeFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Less: Government grant income", "label": "Interest Income Excluded From Adjusted Government Grant Income From Continuing Operations", "documentation": "Interest Income Excluded From Adjusted Government Grant Income From Continuing Operations" } } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 }, "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails": { "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": {

"lang": { "en-us": { "role": { "terseLabel": "Interest income and other", "verboseLabel": "Interest income and other", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": { "r470", "r1082", "r1123", "r1124", "r1177", "r1253", "r1254", "r1426", "r1651" } }, "us-gaap-InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest paid, net of capitalized interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r395", "r398", "r399" } }, "us-gaap-InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails": { "parentTag": "us-gaap-AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": { "r257", "r1606" } }, "us-gaap-InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Interest Rate Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all derivative assets not designated as hedging instruments." } } }, "auth_ref": { "r122" } }, "peak-InterestRateSwap254PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap254PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 2.54% Pay Rate", "label": "Interest Rate Swap, 2.54% Pay Rate [Member]", "documentation": "Interest Rate Swap, 2.54% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap260PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap260PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 2.60% Pay Rate", "label": "Interest Rate Swap, 2.60% Pay Rate [Member]", "documentation": "Interest Rate Swap, 2.60% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.56PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.56PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.56% Pay Rate", "label": "Interest Rate Swap, 3.56% Pay Rate [Member]", "documentation": "Interest Rate Swap, 3.56% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.57PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.57PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.57% Pay Rate", "label": "Interest Rate Swap, 3.57% Pay Rate [Member]", "documentation": "Interest Rate Swap, 3.57% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.58PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.58PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.58% Pay Rate", "label": "Interest Rate Swap, 3.58% Pay Rate [Member]", "documentation": "Interest Rate Swap, 3.58% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.59PayRateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.59PayRateOneMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.59% Pay Rate, One", "label": "Interest Rate Swap, 3.59% Pay Rate, One [Member]", "documentation": "Interest Rate Swap, 3.59% Pay Rate, One" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.59PayRateTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.59PayRateTwoMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.59% Pay Rate, Two", "label": "Interest Rate Swap, 3.59% Pay Rate, Two [Member]", "documentation": "Interest Rate Swap, 3.59% Pay Rate, Two" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.60PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.60PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.60% Pay Rate", "label": "Interest Rate Swap, 3.60% Pay Rate [Member]", "documentation": "Interest Rate Swap, 3.60% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap3.61PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap3.61PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 3.61% Pay Rate", "label": "Interest Rate Swap, 3.61% Pay Rate [Member]", "documentation": "Interest Rate Swap, 3.61% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap454PayRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "InterestRateSwap454PayRateMember", "presentation": { "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 4.54% Pay Rate", "label": "Interest Rate Swap, 4.54% Pay Rate [Member]", "documentation": "Interest Rate Swap, 4.54% Pay Rate" } } }, "auth_ref": { } }, "peak-InterestRateSwap499PayRateMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.healthpeak.com/20241231", "localname": "InterestRateSwap499PayRateMember", "presentation": {
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails" }, "lang": { "en-
us": { "role": { "terseLabel": "Interest Rate Swap, 4.99% Pay Rate", "label": "Interest Rate Swap, 4.99% Pay Rate
Member", "documentation": "Interest Rate Swap, 4.99% Pay Rate" } } }, "auth_ref": { } }, "us-
gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestRateSwapMember", "presentation": {
"http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails",
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
"http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Interest rate swap instruments", "label": "Interest Rate Swap [Member]", "documentation": "Forward based
contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract
with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": {
"r1161", "r1250", "r1251" } }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentBuildingAndBuildingImprovements", "crdr": "debit", "calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS",
"http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Buildings and improvements", "label": "Investment Building and Building Improvements",
"documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and
building improvements." } } }, "auth_ref": { "r1604", "r1605" } }, "us-
gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight":
1.0, "order": 3.0 } },
"http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesScheduleofEquityMeth
f "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS",
"http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Investments in and advances to unconsolidated joint ventures", "totalLabel": "Investments
in and advances to unconsolidated joint ventures", "label": "Investments in and Advance to Affiliates,
Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee
and investment in and advance to affiliate." } } }, "auth_ref": { "r1422" } },
"peak_InvestmentsInLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "InvestmentsInLoansReceivable", "crdr": "credit",
"presentation": {
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate
"http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
"http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi
l", "lang": { "en-us": { "role": { "terseLabel": "Investments in loans receivable", "label": "Investments In Loans
Receivable", "documentation": "Investments In Loans Receivable" } } }, "auth_ref": { } },
"peak_KY0001LouisvilleKYMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "KY0001LouisvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0001 Louisville, KY", "label": "KY0001 Louisville, KY [Member]",
"documentation": "KY0001 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0002ShepherdsvilleKYMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0002ShepherdsvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0002 Shepherdsville, KY", "label": "KY0002 Shepherdsville, KY
[Member]", "documentation": "KY0002 Shepherdsville, KY" } } }, "auth_ref": { } },
"peak_KY0003ShepherdsvilleKYMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "KY0003ShepherdsvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0003 Shepherdsville, KY", "label": "KY0003 Shepherdsville, KY
[Member]", "documentation": "KY0003 Shepherdsville, KY" } } }, "auth_ref": { } },
"peak_KY0004LouisvilleKYMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "KY0004LouisvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0004 Louisville, KY", "label": "KY0004 Louisville, KY [Member]",
"documentation": "KY0004 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0005LouisvilleKYMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0005LouisvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0005 Louisville, KY", "label": "KY0005 Louisville, KY [Member]",
"documentation": "KY0005 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0006LouisvilleKYMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0006LouisvilleKYMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "KY0006 Louisville, KY", "label": "KY0006 Louisville, KY [Member]",
"documentation": "KY0006 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0007LouisvilleKYMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":

"KY0007LouisvilleKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0007 Louisville, KY", "label": "KY0007 Louisville, KY [Member]",
"documentation": "KY0007 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0008LouisvilleKymember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0008LouisvilleKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0008 Louisville, KY", "label": "KY0008 Louisville, KY [Member]",
"documentation": "KY0008 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0009LouisvilleKymember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0009LouisvilleKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0009 Louisville, KY", "label": "KY0009 Louisville, KY [Member]",
"documentation": "KY0009 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0010LouisvilleKymember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0010LouisvilleKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0010 Louisville, KY", "label": "KY0010 Louisville, KY [Member]",
"documentation": "KY0010 Louisville, KY" } } }, "auth_ref": { } }, "peak_KY0011LexingtonKymember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0011LexingtonKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0011 Lexington, KY", "label": "KY0011 Lexington, KY [Member]",
"documentation": "KY0011 Lexington, KY" } } }, "auth_ref": { } }, "peak_KY0012LexingtonKymember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"KY0012LexingtonKymember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "KY0012 Lexington, KY", "label": "KY0012 Lexington, KY [Member]",
"documentation": "KY0012 Lexington, KY" } } }, "auth_ref": { } }, "peak_LA0001MetairieLAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LA0001MetairieLAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "LA0001 Metairie, LA", "label": "LA0001 Metairie, LA [Member]",
"documentation": "LA0001 Metairie, LA" } } }, "auth_ref": { } }, "peak_LA0004LafayetteLAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LA0004LafayetteLAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "LA0004 Lafayette, LA", "label": "LA0004 Lafayette, LA [Member]",
"documentation": "LA0004 Lafayette, LA" } } }, "auth_ref": { } }, "peak_LTIPUnitsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LTIPUnitsMember",
"presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails",
"lang": { "en-us": { "role": { "terseLabel": "LTIP Units", "label": "LTIP Units [Member]", "documentation":
"LTIP Units" } } }, "auth_ref": { } }, "peak_LabBuildingsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "LabBuildingsMember", "presentation": {
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstate",
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstate",
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth",
"lang": { "en-us": { "role": { "terseLabel": "Lab Buildings", "label": "Lab Buildings [Member]",
"documentation": "Properties that are part of continuing operations, and which are classified as life science." } }
}, "auth_ref": { } }, "peak_LabJVMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "LabJVMember", "presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth",
"lang": { "en-us": { "role": { "terseLabel": "Lab JV", "label": "Lab JV [Member]", "documentation": "Lab JV" } }
}, "auth_ref": { } }, "peak_LabMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "LabMember", "presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe",
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstate",
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuee",
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails",
"http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails",
"http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Lab", "label": "Lab [Member]", "documentation": "Lab" } } }, "auth_ref": { } }, "us-gaap_Land": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit",
"presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Land and improvements", "label": "Land", "documentation": "Amount
before accumulated depletion of real estate held for productive use, excluding land held for sale." } } },
"auth_ref": { "r1421" } }, "us-gaap_LandAndLandImprovements": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LandAndLandImprovements", "crdr": "debit", "calculation": {
"http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-

gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel":
 "Land and improvements", "label": "Land and Land Improvements", "documentation": "Amount before
 accumulated depreciation and depletion of real estate held for productive use and additions or improvements to
 real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and
 parking lots. Excludes land held for sale." } } }, "auth_ref": { "r1421" } }, "peak_LargestTenantMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LargestTenantMember", "presentation": {
 "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe
 l", "lang": { "en-us": { "role": { "terseLabel": "Largest Tenant", "label": "Largest Tenant [Member]",
 "documentation": "Largest Tenant" } } }, "auth_ref": { } }, "us-gaap_LeaseCost": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit",
 "presentation": { "http://www.healthpeak.com/role/LeasesLeaseCostsDetails", "lang": { "en-us": { "role": {
 "verboseLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized
 by lessee for lease contract." } } }, "auth_ref": { "r865", "r1225" } }, "us-gaap_LeaseCostTableTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "LeaseCostTableTextBlock", "presentation": { "http://www.healthpeak.com/role/LeasesTables", "lang": { "en-us":
 { "role": { "terseLabel": "Schedule of Other Lease Information", "label": "Lease, Cost [Table Text Block]",
 "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for
 finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost,
 variable lease cost and sublease income." } } }, "auth_ref": { "r1589" } },
 "peak_LeaseLiabilityIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "LeaseLiabilityIncludingDiscontinuedOperations", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails_1": {
 "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails", "lang": { "en-us": {
 "role": { "verboseLabel": "Present value of lease liability", "label": "Lease Liability, Including Discontinued
 Operations", "documentation": "Lease Liability, Including Discontinued Operations" } } }, "auth_ref": { } },
 "peak_LeaseUpIntangibleAssetsAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseUpIntangibleAssetsAccumulatedDepreciationAndAmortization", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Depreciation and amortization of lease-up intangibles", "label": "Lease-Up Intangible
 Assets, Accumulated Depreciation And Amortization", "documentation": "Lease-Up Intangible Assets,
 Accumulated Depreciation And Amortization" } } }, "auth_ref": { } }, "peak_LeaseUpIntangibleAssetsGross": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseUpIntangibleAssetsGross", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesScheduleofIntangiblesLeaseAssetsDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Gross lease-up intangibles", "label": "Lease-Up Intangible Assets, Gross",
 "documentation": "Lease-Up Intangible Assets, Gross" } } }, "auth_ref": { } },
 "peak_LeaseandothercommitmentMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "LeaseandothercommitmentMember", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails",
 "lang": { "en-us": { "role": { "terseLabel": "Lease and other contractual commitments", "label": "Lease and other
 commitment [Member]", "documentation": "Lease and other commitment [Member]" } } }, "auth_ref": { } }, "us-
 gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } },
 "auth_ref": { } }, "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag": null, "weight": null,
 "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails", "lang": { "en-us": { "role": {
 "totalLabel": "Total", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent Receivable",
 "documentation": "Future annualized base rental payments receivable for the five years following the balance
 sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate."
 } } }, "auth_ref": { } },
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInFourYears": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInFourYears", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 4.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails", "lang": { "en-us": {
 "role": { "terseLabel": "2028", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable in Four Years", "documentation": "Future annualized base rental payments receivable within fourth
 year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } },
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInThreeYears": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInThreeYears", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 3.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails", "lang": { "en-us": {
 "role": { "terseLabel": "2027", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable in Three Years", "documentation": "Future annualized base rental payments receivable within third
 year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } },
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInTwoYears": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInTwoYears", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 2.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "2026", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable in Two Years", "documentation": "Future annualized base rental payments receivable within second
 year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } },
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableThereafter": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableThereafter", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 6.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "Thereafter", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable Thereafter", "documentation": "Future annualized base rental payments receivable after the fifth year
 of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } },
 "peak_LeasesWithPurchaseOptionNumberPropertiesInFiveYears": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname":
 "LeasesWithPurchaseOptionNumberOfPropertiesInFiveYears", "calculation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeaseswithPurchaseOptionNumberOfProperties", "weight": 1.0, "order": 5.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "2029", "label": "Leases With Purchase Option Number Of Properties In Five Years",
 "documentation": "Leases With Purchase Option Future Minimum Annualized Payments Receivable Number Of
 Properties In Five Years" } } }, "auth_ref": { } },
 "peak_LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInFiveYears": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableInFiveYears", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 5.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "2029", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable In Five Years", "documentation": "Leases with Purchase Option Future Minimum Annualized Base
 Rent Receivable In Five Years" } } }, "auth_ref": { } },
 "peak_LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableNextTwelveMonths": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseswithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivableNextTwelveMonths", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeasesWithPurchaseOptionFutureMinimumAnnualizedBaseRentReceivable", "weight": 1.0, "order": 1.0 } },
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "2025", "label": "Leases with Purchase Option Future Minimum Annualized Base Rent
 Receivable Next Twelve Months", "documentation": "Future annualized base rental payments receivable within
 one year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } },
 "peak_LeaseswithPurchaseOptionFutureMinimumAnnualizedPaymentsReceivableNumberofPropertiesAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseswithPurchaseOptionFutureMinimumAnnualizedPaymentsReceivableNumberofPropertiesAbstract",
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "Number\u00a0of Properties", "label": "Leases with Purchase Option Future Minimum
 Annualized Payments Receivable Number of Properties [Abstract]", "documentation": "Leases with Purchase
 Option Future Minimum Annualized Payments Receivable Number of Properties [Abstract]" } } }, "auth_ref": { } },
 "peak_LeaseswithPurchaseOptionNumberofProperties": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "LeaseswithPurchaseOptionNumberofProperties",
 "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag": null,
 "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": {
 "totalLabel": "Total", "label": "Leases with Purchase Option Number of Properties", "documentation": "Number of
 properties for which future annualized rental payments are receivable for the five years following the balance
 sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate." } } },
 "auth_ref": { } }, "peak_LeaseswithPurchaseOptionNumberofPropertiesNextTwelveMonths": { "xbrltype":
 "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseswithPurchaseOptionNumberofPropertiesNextTwelveMonths", "calculation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeaseswithPurchaseOptionNumberofProperties", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "2025", "label": "Leases with Purchase Option Number of Properties Next Twelve Months",
 "documentation": "Number of properties for which future annualized rental payments are receivable within one
 year of the balance sheet date, on leases with purchase options, whereby the tenant may elect to acquire the
 underlying real estate." } } }, "auth_ref": { } }, "peak_LeaseswithPurchaseOptionNumberofPropertiesThereafter":
 { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "LeaseswithPurchaseOptionNumberofPropertiesThereafter", "calculation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag":
 "peak_LeaseswithPurchaseOptionNumberofProperties", "weight": 1.0, "order": 6.0 } }, "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "Thereafter", "label": "Leases with Purchase Option Number of Properties Thereafter",

"documentation": "Number of properties for which future annualized rental payments are receivable after the fifth year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate." } } }, "auth_ref": [] }, "peak_LeaseswithPurchaseOptionNumberOfPropertiesinFourYears": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LeaseswithPurchaseOptionNumberOfPropertiesinFourYears", "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag": "peak_LeaseswithPurchaseOptionNumberOfProperties", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Leases with Purchase Option Number of Properties in Four Years", "documentation": "Number of properties for which future annualized rental payments are receivable within fourth year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate." } } }, "auth_ref": [] }, "peak_LeaseswithPurchaseOptionNumberOfPropertiesinThreeYears": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LeaseswithPurchaseOptionNumberOfPropertiesinThreeYears", "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag": "peak_LeaseswithPurchaseOptionNumberOfProperties", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Leases with Purchase Option Number of Properties in Three Years", "documentation": "Number of properties for which future annualized rental payments are receivable within third year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate." } } }, "auth_ref": [] }, "peak_LeaseswithPurchaseOptionNumberOfPropertiesinTwoYears": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LeaseswithPurchaseOptionNumberOfPropertiesinTwoYears", "calculation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "parentTag": "peak_LeaseswithPurchaseOptionNumberOfProperties", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesTenantPurchaseOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Leases with Purchase Option Number of Properties in Two Years", "documentation": "Number of properties for which future annualized rental payments are receivable within second year of the balance sheet date on leases with purchase options, whereby the tenant may elect to acquire the underlying real estate." } } }, "auth_ref": [] }, "peak_LegalAccountingTaxAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LegalAccountingTaxAndOtherCostsMember", "presentation": { "http://www.healthpeak.com/role/TheMergerNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Legal Accounting, Tax, and Other Costs", "label": "Legal Accounting, Tax, And Other Costs [Member]", "documentation": "Legal Accounting, Tax, And Other Costs" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Lessee Accounting", "label": "Lessee Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r864"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.healthpeak.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Obligations, 842", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1590"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Undiscounted minimum lease payments included in the lease liability", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r870"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r870"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in

next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r870" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r870" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r870" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r870" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r870" } }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureLeaseObligationsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r870" } }, "peak_LesseeOperatingLeaseRemainingLeaseTermIncludingOptionToExtend": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LesseeOperatingLeaseRemainingLeaseTermIncludingOptionToExtend", "presentation": { "http://www.healthpeak.com/role/LeasesLeaseCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Option to extend lease, term", "label": "Lessee, Operating Lease, Remaining Lease Term, Including Option To Extend", "documentation": "Lessee, Operating Lease, Remaining Lease Term, Including Option To Extend" } } }, "auth_ref": { } }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://www.healthpeak.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": { "r859" } }, "us-gaap_LessorDirectFinancingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorDirectFinancingLeasesTextBlock", "presentation": { "http://www.healthpeak.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessor, Direct Financing Leases [Text Block]", "documentation": "The entire disclosure of lessor's direct financing leases." } } }, "auth_ref": { "r872" } }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorLeaseDescriptionLineItems", "presentation": { "http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails": { "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails": { "http://www.healthpeak.com/role/LeasesNarrativeDetails": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r875" } }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorLeaseDescriptionTable", "presentation": { "http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails": { "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails": { "http://www.healthpeak.com/role/LeasesNarrativeDetails": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": { "r875" } }, "us-

gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": { "http://www.healthpeak.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Due Under Operating Leases", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": { "r1591" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/LeasesFutureMinimumRentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r874" } }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Letter of credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": { } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {

["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS): { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails) }, "lang": { "en-us": {
"role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": {
"r33", "r163", "r164", "r165", "r168", "r169", "r170", "r173", "r405", "r552", "r620", "r621", "r623", "r624",
"r625", "r626", "r627", "r629", "r630", "r801", "r804", "r805", "r842", "r1058", "r1170", "r1256", "r1508", "r1594",
"r1595" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS): { "parentTag": null, "weight": null, "order":
null, "root": true }, "presentation": { ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS) },
"lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r181", "r261", "r975", "r1226", "r1435", "r1473", "r1581" } },
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails) }, "lang": { "en-us": {
"role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { } },
"us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType",
"nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": {
["http://www.healthpeak.com/role/DispositionsOfRealEstateandDiscontinuedOperationsHeldForSaleandDiscontinued"](http://www.healthpeak.com/role/DispositionsOfRealEstateandDiscontinuedOperationsHeldForSaleandDiscontinued)
}, "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to assets held for sale, net", "label": "Disposal
Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r4", "r140", "r156", "r219",
"r361", "r362" } }, "peak_LiabilitiesRelatedToAssetsHeldForSaleNet": { "xbrltype": "monetaryItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "LiabilitiesRelatedToAssetsHeldForSaleNet", "crdr":
"credit", "calculation": { ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS): { "parentTag":
"us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS) }, "lang": { "en-us": { "role": { "terseLabel":
"Liabilities related to assets held for sale, net", "label": "Liabilities Related To Assets Held For Sale, Net",
"documentation": "Liabilities Related To Assets Held For Sale, Net" } } }, "auth_ref": { } },
"peak_LifeScienceJVsMember": { "xbrltype": "domainItemType", "nsuri": ["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231),
"localname": "LifeScienceJVsMember", "presentation": {
["http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails"](http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails),
["http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails) }, "lang": { "en-us": { "role": {
"terseLabel": "Callan Ridge JV", "label": "Life Science JVs [Member]", "documentation": "Represents information pertaining to HCP Life Science, an unconsolidated joint venture of the entity." } } }, "auth_ref": { } },
"peak_LifeScienceJointVentureInSanFranciscoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname":
"LifeScienceJointVentureInSanFranciscoCaliforniaMember", "presentation": {
["http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesNarrativeDetails"](http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesNarrativeDetails) },
"lang": { "en-us": { "role": { "terseLabel": "Life Science Joint Venture In San Francisco, California", "label": "Life
Science Joint Venture In San Francisco, California [Member]", "documentation": "Life Science Joint Venture In
San Francisco, California" } } }, "auth_ref": { } }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType",
"nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "LineOfCredit", "crdr": "credit", "calculation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS): { "parentTag": "us-gaap_Liabilities",
"weight": 1.0, "order": 1.0 } }, "presentation": {
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails),
["http://www.healthpeak.com/role/FairValueMeasurementsDetails"](http://www.healthpeak.com/role/FairValueMeasurementsDetails) }, "lang": { "en-us": { "role": { "terseLabel":
"Bank line of credit and commercial paper", "verboseLabel": "Bank line of credit and commercial paper", "label":
"Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make
loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings
can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be
classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing
agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender
except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the
agreement." } } }, "auth_ref": { "r33", "r258", "r1608" } },
"peak_LineOfCreditFacilityAdditionalAvailableBorrowingCapacityMaximum": { "xbrltype": "monetaryItemType",
"nsuri": ["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname":
"LineOfCreditFacilityAdditionalAvailableBorrowingCapacityMaximum", "crdr": "credit", "presentation": {
["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails) }, "lang": { "en-us": { "role": {
"terseLabel": "Line of credit facility additional aggregate amount, maximum", "label": "Line Of Credit, Facility
Additional Available Borrowing Capacity Maximum", "documentation": "This element represents the maximum
additional borrowing capacity available under the credit facility, subject to customary conditions." } } },
"auth_ref": { } }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType",
"nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "LineOfCreditFacilityCommitmentFeePercentage",
"presentation": { ["http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails"](http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails) }, "lang": { "en-
us": { "role": { "terseLabel": "Debt instrument, facility fee (as a percent)", "label": "Line of Credit Facility,

Commitment Fee Percentage, "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/DebtBankLineOfCreditandTermLoanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r162", "r167"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.healthpeak.com/role/DebtBankLineOfCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bank Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedFromOtherParty", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/LeasesTenantUpdatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, amount awarded from other party", "label": "Litigation Settlement, Amount Awarded from Other Party", "documentation": "Amount awarded from other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "peak_LoanReceivablePeriodOfExtension": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoanReceivablePeriodOfExtension", "presentation": ["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loan receivable, period of extensions", "label": "Loan Receivable, Period Of Extension", "documentation": "Loan Receivable, Period Of Extension" } } }, "auth_ref": [] }, "peak_LoansAndLeasesReceivableRemainingCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansAndLeasesReceivableRemainingCommitments", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining loans receivable commitments", "label": "Loans and Leases Receivable, Remaining Commitments", "documentation": "Loans and Leases Receivable, Remaining Commitments" } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.healthpeak.com/role/LoansReceivable"], "lang": { "en-us": { "role": { "terseLabel": "Loans Receivable", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r854", "r1455"] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": ["http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loans", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_LoansPayableToBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableToBank", "crdr": "credit", "calculation": ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"], "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term loans", "label": "Loans Payable to Bank", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer." } } }, "auth_ref": ["r33", "r258", "r1608"] }, "us-gaap_LoansReceivableBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableBasisSpreadOnVariableRate", "presentation": ["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Loans Receivable, Basis Spread on Variable Rate", "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable." } } }, "auth_ref": [] }, "peak_LoansReceivableConversionOfBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableConversionOfBasisSpreadOnVariableRate", "presentation": ["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, conversion of basis spread on variable rate", "label": "Loans Receivable, Conversion Of Basis Spread On Variable Rate", "documentation": "Loans Receivable, Conversion Of Basis Spread On Variable Rate" } } }, "auth_ref": [] }, "peak_LoansReceivableExtendedMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableExtendedMaturityTerm", "presentation": ["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Loan receivable, extended maturity term", "label": "Loans Receivable, Extended Maturity Term", "documentation": "Loans Receivable, Extended Maturity Term" } } }, "auth_ref": [] }, "peak_LoansReceivableExtensionFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableExtensionFee", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, extension fee", "label": "Loans Receivable,

Extension Fee", "documentation": "Loans Receivable, Extension Fee" } } }, "auth_ref": [] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, net", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": ["r1580"] }, "peak_LoansReceivableFloorRate": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableFloorRate", "presentation": { "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, floor rate percentage", "label": "Loans Receivable, Floor Rate", "documentation": "Loans Receivable, Floor Rate" } } }, "auth_ref": [] }, "peak_LoansReceivableInterestRateStatedPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableInterestRateStatedPercentage", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails", "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, interest rate", "label": "Loans Receivable, Interest Rate, Stated Percentage", "documentation": "Loans Receivable, Interest Rate, Stated Percentage" } } }, "auth_ref": [] }, "peak_LoansReceivableNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableNumberOfExtensions", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, number of extensions", "label": "Loans Receivable, Number Of Extensions", "documentation": "Loans Receivable, Number Of Extensions" } } }, "auth_ref": [] }, "peak_LoansReceivableOutstandingBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableOutstandingBalance", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Outstanding balance", "label": "Loans Receivable, Outstanding Balance", "documentation": "Loans Receivable, Outstanding Balance" } } }, "auth_ref": [] }, "peak_LoansReceivableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivableTerm", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, term", "label": "Loans Receivable, Term", "documentation": "Loans Receivable, Term" } } }, "auth_ref": [] }, "peak_LoansReceivablesAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "LoansReceivablesAcquired", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loans receivables, acquired", "label": "Loans Receivables, Acquired", "documentation": "Loans Receivables, Acquired" } } }, "auth_ref": [] }, "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r33", "r258", "r644", "r659", "r1193", "r1194", "r1224", "r1608"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r21", "r411", "r1514"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r21", "r411", "r649"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term

debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r21", "r411", "r649" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r21", "r411", "r649" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r21", "r411", "r649" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r21", "r411", "r649" } }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingFixedInterestRate", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Bearing fixed interest rate (as a percent)", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": { "r166" } }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Bearing variable interest rate (as a percent)", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": { "r166" } }, "us-gaap_LongTermLoansFromBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLoansFromBank", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/FairValueMeasurementsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term loan", "label": "Loans Payable to Bank, Noncurrent", "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion." } } }, "auth_ref": { "r33", "r258", "r1055" } }, "us-gaap_LongtermDebtPercentageBearingVariableInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtPercentageBearingVariableInterestAmount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable interest, amount", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Amount", "documentation": "The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": { } }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r33", "r1496", "r1497", "r1498" } }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails", "http://www.healthpeak.com/role/DebtMortgageDebtDetails", "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails", "http://www.healthpeak.com/role/DebtTheMergerDetails",

["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails),
["http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"](http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails)], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": { "r33", "r75", "r1496", "r1497", "r1498" } }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": { "r612", "r613", "r614", "r617", "r748", "r1016", "r1191", "r1501", "r1502" } }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r612", "r613", "r614", "r617", "r748", "r1191", "r1501", "r1502" } }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": { "r612", "r613", "r614", "r617", "r748", "r1191", "r1501", "r1502" } }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": { "r612", "r613", "r614", "r617", "r748", "r1016", "r1191", "r1501", "r1502" } }, "stpr_MA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MA", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe", "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Massachusetts", "label": "MASSACHUSETTS" } } }, "auth_ref": { } }, "peak_MA5394CambridgeMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MA5394CambridgeMAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MA5394 Cambridge, MA", "label": "MA5394 Cambridge, MA [Member]", "documentation": "MA5394 Cambridge, MA" } } }, "auth_ref": { } }, "peak_MD0001WaldorfMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MD0001WaldorfMDMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MD0001 Waldorf, MD", "label": "MD0001 Waldorf, MD [Member]", "documentation": "MD0001 Waldorf, MD" } } }, "auth_ref": { } }, "peak_MD0002LanhamMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MD0002LanhamMDMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MD0002 Lanham, MD", "label": "MD0002 Lanham, MD [Member]", "documentation": "MD0002 Lanham, MD" } } }, "auth_ref": { } }, "peak_MD0003BrandywineMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MD0003BrandywineMDMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MD0003 Brandywine, MD", "label": "MD0003 Brandywine, MD [Member]", "documentation": "MD0003 Brandywine, MD" } } }, "auth_ref": { } }, "peak_ME0001BrunswickMLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ME0001BrunswickMLMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "ME0001 Brunswick, ML", "label": "ME0001 Brunswick, ML [Member]", "documentation": "ME0001 Brunswick, ML" } } }, "auth_ref": { } }, "peak_MI0006GrandBlancMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MI0006GrandBlancMIMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MI0006 Grand Blanc, MI", "label": "MI0006 Grand Blanc, MI [Member]", "documentation": "MI0006 Grand Blanc, MI" } } }, "auth_ref": { } }, "peak_MI0008TraverseCityMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MI0008TraverseCityMIMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "MI0008 Traverse City, MI", "label": "MI0008 Traverse City, MI [Member]", "documentation": "MI0008 Traverse City, MI" } } }, "auth_ref": { } }, "peak_MI000A8TraverseCityMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MI000A8TraverseCityMIMember", "presentation": {

"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI000A8 Traverse City, MI", "label": "MI000A8 Traverse City, MI
[Member]", "documentation": "MI000A8 Traverse City, MI" } } }, "auth_ref": [] },
"peak_MI0010BayCityMIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MI0010BayCityMIMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0010 Bay City, MI", "label": "MI0010 Bay City, MI [Member]",
"documentation": "MI0010 Bay City, MI" } } }, "auth_ref": [] }, "peak_MI0011GrossPointeMIMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MI0011GrossPointeMIMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0011 Gross Pointe, MI", "label": "MI0011 Gross Pointe, MI
[Member]", "documentation": "MI0011 Gross Pointe, MI" } } }, "auth_ref": [] },
"peak_MI0012PetoskeyMIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MI0012PetoskeyMIMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0012 Petoskey, MI", "label": "MI0012 Petoskey, MI [Member]",
"documentation": "MI0012 Petoskey, MI" } } }, "auth_ref": [] }, "peak_MI0013RochesterHillsMiMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MI0013RochesterHillsMiMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0013 Rochester Hills, Mi", "label": "MI0013 Rochester Hills, Mi
[Member]", "documentation": "MI0013 Rochester Hills, Mi" } } }, "auth_ref": [] },
"peak_MI0014SterlingHeightsMIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MI0014SterlingHeightsMIMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0014 Sterling Heights, MI", "label": "MI0014 Sterling Heights, MI
[Member]", "documentation": "MI0014 Sterling Heights, MI" } } }, "auth_ref": [] },
"peak_MI0018AppleValleyMIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MI0018AppleValleyMIMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MI0018 Apple Valley, MI", "label": "MI0018 Apple Valley, MI
[Member]", "documentation": "MI0018 Apple Valley, MI" } } }, "auth_ref": [] }, "peak_MN0001EdinaMNMMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MN0001EdinaMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0001 Edina, MN", "label": "MN0001 Edina, MN [Member]",
"documentation": "MN0001 Edina, MN" } } }, "auth_ref": [] }, "peak_MN0002SavageMNMMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MN0002SavageMNMMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0002 Savage, MN", "label": "MN0002 Savage, MN [Member]",
"documentation": "MN0002 Savage, MN" } } }, "auth_ref": [] }, "peak_MN0003CrystalMNMMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MN0003CrystalMNMMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0003 Crystal, MN", "label": "MN0003 Crystal, MN [Member]",
"documentation": "MN0003 Crystal, MN" } } }, "auth_ref": [] }, "peak_MN0004ChanhassenMNMMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MN0004ChanhassenMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0004 Chanhassen, MN", "label": "MN0004 Chanhassen, MN
[Member]", "documentation": "MN0004 Chanhassen, MN" } } }, "auth_ref": [] },
"peak_MN0005VadnaisHeightsMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0005VadnaisHeightsMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0005 Vadnais Heights, MN", "label": "MN0005 Vadnais Heights,
MN [Member]", "documentation": "MN0005 Vadnais Heights, MN" } } }, "auth_ref": [] },
"peak_MN0006MinnetonkaMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0006MinnetonkaMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0006 Minnetonka, MN", "label": "MN0006 Minnetonka, MN
[Member]", "documentation": "MN0006 Minnetonka, MN" } } }, "auth_ref": [] },
"peak_MN0007MinnetonkaMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0007MinnetonkaMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0007 Minnetonka, MN", "label": "MN0007 Minnetonka, MN
[Member]", "documentation": "MN0007 Minnetonka, MN" } } }, "auth_ref": [] },
"peak_MN0008CoonRapidsMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0008CoonRapidsMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0008 Coon Rapids, MN", "label": "MN0008 Coon Rapids, MN
[Member]", "documentation": "MN0008 Coon Rapids, MN" } } }, "auth_ref": [] },
"peak_MN0009ChanhassenMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0009ChanhassenMNMMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "MN0009 Chanhassen, MN", "label": "MN0009 Chanhassen, MN
[Member]", "documentation": "MN0009 Chanhassen, MN" } } }, "auth_ref": [] },

"peak_MN0010HugoMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0010HugoMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0010 Hugo, MN", "label": "MN0010 Hugo, MN [Member]",
"documentation": "MN0010 Hugo, MN" } } }, "auth_ref": { } }, "peak_MN0011StillwaterMNMMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MN0011StillwaterMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0011 Stillwater, MN", "label": "MN0011 Stillwater, MN
[Member]", "documentation": "MN0011 Stillwater, MN" } } }, "auth_ref": { } },
"peak_MN0012MaplewoodMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0012MaplewoodMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0012 Maplewood, MN", "label": "MN0012 Maplewood, MN
[Member]", "documentation": "MN0012 Maplewood, MN" } } }, "auth_ref": { } },
"peak_MN0013LittleFallsMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0013LittleFallsMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0013 Little Falls, MN", "label": "MN0013 Little Falls, MN
[Member]", "documentation": "MN0013 Little Falls, MN" } } }, "auth_ref": { } },
"peak_MN0014LittleFallsMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0014LittleFallsMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0014 Little Falls, MN", "label": "MN0014 Little Falls, MN
[Member]", "documentation": "MN0014 Little Falls, MN" } } }, "auth_ref": { } },
"peak_MN0015LittleFallsMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0015LittleFallsMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0015 Little Falls, MN", "label": "MN0015 Little Falls, MN
[Member]", "documentation": "MN0015 Little Falls, MN" } } }, "auth_ref": { } },
"peak_MN0016LakeElmoMNMMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MN0016LakeElmoMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0016 Lake Elmo, MN", "label": "MN0016 Lake Elmo, MN
[Member]", "documentation": "MN0016 Lake Elmo, MN" } } }, "auth_ref": { } }, "peak_MN0017EdinaMNMMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MN0017EdinaMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0017 Edina, MN", "label": "MN0017 Edina, MN [Member]",
"documentation": "MN0017 Edina, MN" } } }, "auth_ref": { } }, "peak_MN0019MaplewoodMNMMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MN0019MaplewoodMNMMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MN0019 Maplewood, MN", "label": "MN0019 Maplewood, MN
[Member]", "documentation": "MN0019 Maplewood, MN" } } }, "auth_ref": { } },
"peak_MO0001EentonMOMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MO0001EentonMOMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MO0001 Eenton, MO", "label": "MO0001 Eenton, MO [Member]",
"documentation": "MO0001 Eenton, MO" } } }, "auth_ref": { } }, "peak_MO0002CreveCoeurMOMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"MO0002CreveCoeurMOMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MO0002 Creve Coeur, MO", "label": "MO0002 Creve Coeur, MO
[Member]", "documentation": "MO0002 Creve Coeur, MO" } } }, "auth_ref": { } },
"peak_MO0003KansasCityMOMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MO0003KansasCityMOMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MO0003 Kansas City, MO", "label": "MO0003 Kansas City, MO
[Member]", "documentation": "MO0003 Kansas City, MO" } } }, "auth_ref": { } },
"peak_MS0001GrenadaMSMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "MS0001GrenadaMSMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MS0001 Grenada, MS", "label": "MS0001 Grenada, MS [Member]",
"documentation": "MS0001 Grenada, MS" } } }, "auth_ref": { } }, "peak_MS0002JacksonMSMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MS0002JacksonMSMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MS0002 Jackson, MS", "label": "MS0002 Jackson, MS [Member]",
"documentation": "MS0002 Jackson, MS" } } }, "auth_ref": { } }, "peak_MS0003JacksonMSMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MS0003JacksonMSMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"lang": { "en-us": { "role": { "terseLabel": "MS0003 Jackson, MS", "label": "MS0003 Jackson, MS [Member]",
"documentation": "MS0003 Jackson, MS" } } }, "auth_ref": { } }, "srt_MajorCustomersAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDel",
"lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation":

"Information by name or description of a single external customer or a group of external customers." } }],
 "auth_ref": ["r505", "r1199", "r1236", "r1240", "r1516", "r1612", "r1616", "r1617", "r1619", "r1620", "r1621",
 "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633",
 "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643"]],
 "peak_MarkToMarketDiscountOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MarkToMarketDiscountOfRealEstate", "crdr": "credit",
 "presentation": ["http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Mark to market discount of real estate", "label": "Mark-To-Market
Discount Of Real Estate", "documentation": "Mark-To-Market Discount Of Real Estate" } } }, "auth_ref": [] },
 "peak_MarketBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MarketBasedRestrictedStockUnitsMember",
 "presentation": ["http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails"], "lang": {
 "en-us": { "role": { "terseLabel": "Market Based Restricted Stock Units", "label": "Market Based Restricted Stock
Units [Member]", "documentation": "Market Based Restricted Stock Units" } } }, "auth_ref": [] },
 "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MaximumMember", "presentation": [
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails",
 "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails",
 "http://www.healthpeak.com/role/InvestmentsinandAdvancesetoUnconsolidatedJointVenturesScheduleofEquityMeth",
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
 "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed",
], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper
limit of the provided range." } } }, "auth_ref": ["r316", "r318", "r320", "r321", "r323", "r356", "r357", "r613",
 "r614", "r615", "r616", "r707", "r748", "r825", "r922", "r1002", "r1004", "r1016", "r1049", "r1050", "r1105",
 "r1107", "r1109", "r1110", "r1122", "r1157", "r1158", "r1183", "r1197", "r1205", "r1217", "r1218", "r1222",
 "r1223", "r1237", "r1512", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601"] },
 "peak_MaximumPeriodAvailableForOccupancyAfterCessationOfSignificantConstruction": { "xbrltype":
 "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "MaximumPeriodAvailableForOccupancyAfterCessationOfSignificantConstruction", "presentation": [
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Maximum period available for occupancy from cessation of significant construction
activity", "label": "Maximum Period Available for Occupancy after Cessation of Significant Construction",
 "documentation": "This element represents the period for occupancy, upon the completion of tenant
improvements, after the cessation of significant construction activity." } } }, "auth_ref": [] }, "ecd_MeasureAxis":
 { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
 "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r1320"] }, "ecd_MeasureName": { "xbrltype":
 "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name",
 "label": "Measure Name" } } }, "auth_ref": ["r1320"] }, "peak_MedicalOfficeJVsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MedicalOfficeJVsMember",
 "presentation": [
 "http://www.healthpeak.com/role/InvestmentsinandAdvancesetoUnconsolidatedJointVenturesScheduleofEquityMeth",
], "lang": { "en-us": { "role": { "terseLabel": "Medical Office JVs", "label": "Medical Office JVs [Member]",
 "documentation": "Medical Office JVs [Member]" } } }, "auth_ref": [] }, "peak_MedicalOfficeMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "MedicalOfficeMember", "presentation": [
 "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
 "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
], "lang": { "en-us": { "role": { "terseLabel": "Outpatient medical", "label": "Medical Office [Member]",
 "documentation": "Properties that are part of continuing operations, and which are classified as medical office." } } },
 "auth_ref": [] }, "peak_MezzanineLoansAndOtherMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MezzanineLoansAndOtherMember", "presentation": [
 "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails"], "lang": { "en-us": { "role": { "terseLabel":
 "Mezzanine And Other", "label": "Mezzanine Loans And Other [Member]", "documentation": "Mezzanine Loans
And Other" } } }, "auth_ref": [] }, "peak_MezzanineLoansMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MezzanineLoansMember", "presentation": [
 "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails",
 "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails",
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails",
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails",
 "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel":
 "Mezzanine loans", "label": "Mezzanine Loans [Member]", "documentation": "Mezzanine Loans" } } }, "auth_ref":
 [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MinimumMember", "presentation": [
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails",
 "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails",
 "http://www.healthpeak.com/role/InvestmentsinandAdvancesetoUnconsolidatedJointVenturesScheduleofEquityMeth",
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
 "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",

"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": { "r316", "r318", "r320", "r321", "r323", "r356", "r357", "r613", "r614", "r615", "r616", "r707", "r748", "r825", "r922", "r1002", "r1004", "r1016", "r1049", "r1050", "r1105", "r1107", "r1109", "r1110", "r1122", "r1157", "r1158", "r1183", "r1197", "r1205", "r1217", "r1218", "r1222", "r1237", "r1512", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601" } }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Total noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r180", "r260", "r405", "r552", "r620", "r623", "r624", "r625", "r629", "r630", "r842", "r974", "r1061" } } }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": { "lang": { "en-us": { "role": { "negatedLabel": "Distributions to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": { "r231" } } }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase of noncontrolling interest", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": { "r101", "r231", "r242" } } }, "us-gaap_MinorityInterestInJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestInJointVentures", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_MinorityInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Joint venture partners", "label": "Noncontrolling Interest in Joint Ventures", "documentation": "Carrying amount of the equity interests owned by noncontrolling shareholders, partners, or other equity holders in joint ventures included in the entity's consolidated financial statements." } } }, "auth_ref": { "r98" } } }, "us-gaap_MinorityInterestInPreferredUnitHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestInPreferredUnitHolders", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_MinorityInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-managing member unitholders", "label": "Noncontrolling Interest in Preferred Unit Holders", "documentation": "Carrying amount of the equity interests owned by noncontrolling preferred unit holders in an entity included in the reporting entity's consolidated financial statements." } } }, "auth_ref": { } }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests": { "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest, ownership percentage by parent", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": { } }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests": { "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": { "r98", "r102", "r180", "r188" } } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": { "r1340" } } }, "peak_MorganStanleyRealEstateInvestmentIVMember": { "xbrltype":

"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "MorganStanleyRealEstateInvestmentJVMember", "presentation": {
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "MSREI MOB JV", "label": "Morgan Stanley Real Estate Investment JV [Member]", "documentation":
 "Morgan Stanley Real Estate Investment JV [Member]" } } }, "auth_ref": { } }, "peak_MortgageDebtMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "MortgageDebtMember", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Mortgage Debt", "label": "Mortgage Debt [Member]", "documentation": "Mortgage Debt" } } },
 "auth_ref": { } }, "peak_MortgageDuringJune2024ToJune2025Member": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MortgageDuringJune2024ToJune2025Member",
 "presentation": { "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "During June 2024 to June 2025", "label": "Mortgage During June 2024
 To June 2025 [Member]", "documentation": "Mortgage During June 2024 To June 2025" } } }, "auth_ref": { } },
 "peak_MortgageDuringMay2026ToMay2027Member": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MortgageDuringMay2026ToMay2027Member",
 "presentation": { "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "During May 2026 to May 2027", "label": "Mortgage During May 2026
 To May 2027 [Member]", "documentation": "Mortgage During May 2026 To May 2027" } } }, "auth_ref": { } },
 "peak_MortgageDuringOctober2024ToApril2026Member": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MortgageDuringOctober2024ToApril2026Member",
 "presentation": { "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "During October 2024 to April 2026", "label": "Mortgage During
 October 2024 To April 2026 [Member]", "documentation": "Mortgage During October 2024 To April 2026" } } },
 "auth_ref": { } }, "us-gaap_MortgageLoansOnRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "MortgageLoansOnRealEstate", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"
 }, "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Mortgages", "periodStartLabel": "Balance at
 beginning of year", "periodEndLabel": "Balance at end of year", "label": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Mortgage Loans on Real Estate", "documentation": "Amount of investment in
 mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real
 estate or interest in real estate." } } }, "auth_ref": { "r1138" } }, "srt_MortgageLoansOnRealEstateAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MortgageLoansOnRealEstateAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real
 Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]", "label": "SEC Schedule, 12-29, Real
 Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]" } } }, "auth_ref": { } },
 "srt_MortgageLoansOnRealEstateByLoanDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateByLoanDisclosureTextBlock",
 "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstate" }, "lang": { "en-us": {
 "role": { "terseLabel": "Schedule IV: Mortgage Loans on Real Estate", "label": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Mortgage Loans on Real Estate [Text Block]", "documentation": "The entire disclosure
 for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and
 holding investment real estate or interest in real estate. Includes, but is not limited to, information for each
 mortgage loan receivable equaling or exceeding 3 percent of carrying amount of mortgage." } } }, "auth_ref": {
 "r343", "r1140" } }, "srt_MortgageLoansOnRealEstateCollectionsOfPrincipal": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipal", "crdr":
 "credit", "calculation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails":
 { "parentTag":
 "peak_SECSchedule1229RealEstateCompaniesInvestmentinMortgageLoansonRealEstatePeriodDecrease",
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"
 }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal repayments", "label": "SEC Schedule, 12-29, Real
 Estate Companies, Investment in Mortgage Loans on Real Estate, Collections of Principal", "documentation":
 "Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business
 acquiring and holding investment real estate or interest in real estate, from collection of principal." } } },
 "auth_ref": { "r341", "r1137" } }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": {
 "http://www.healthpeak.com/role/IntangiblesNarrativeDetails",
 "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
 "http://www.healthpeak.com/role/TheMergerNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Real
 Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by
 type of real estate property." } } }, "auth_ref": { "r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334",
 "r335", "r337", "r1133", "r1144", "r1145", "r1146", "r1147", "r1150", "r1151", "r1152", "r1153", "r1154" } },
 "srt_MortgageLoansOnRealEstateFaceAmountOfMortgages": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateFaceAmountOfMortgages", "crdr": "debit",
 "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Face Amount of Mortgages", "label": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages", "documentation":
 "Amount of contractual principal due at origination of mortgage loan within investment in mortgage loan on real
 estate by entity with substantial portion of business acquiring and holding investment real estate or interest in
 real estate." } } }, "auth_ref": { "r340", "r1136" } },
 "peak_MortgageLoansOnRealEstateInterestMultipleDue2025Member": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname":
 "MortgageLoansOnRealEstateInterestMultipleDue2025Member", "presentation": {

["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"](http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails)], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan on real estate, multiple due 2025", "label": "Mortgage Loans On Real Estate Interest Multiple, Due 2025 [Member]", "documentation": "Mortgage Loans On Real Estate Interest Multiple, Due 2025" } } } }, "auth_ref": [] }, "peak_MortgageLoansOnRealEstateInterestMultipleDue2025OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MortgageLoansOnRealEstateInterestMultipleDue2025OneMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan on real estate, multiple due 2025", "label": "Mortgage Loans On Real Estate Interest Multiple, Due 2025 One [Member]", "documentation": "Mortgage Loans On Real Estate Interest Multiple, Due 2025 One" } } } }, "auth_ref": [] }, "peak_MortgageLoansOnRealEstateInterestMultipleDue2025To2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MortgageLoansOnRealEstateInterestMultipleDue2025To2028Member", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan on real estate, multiple due 2025 to 2028", "label": "Mortgage Loans On Real Estate Interest Multiple, Due 2025 To 2028 [Member]", "documentation": "Mortgage Loans On Real Estate Interest Multiple, Due 2025 To 2028" } } } }, "auth_ref": [] }, "peak_MortgageLoansOnRealEstateInterestMultipleDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MortgageLoansOnRealEstateInterestMultipleDue2026Member", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan on real estate, multiple due 2026", "label": "Mortgage Loans On Real Estate Interest Multiple, Due 2026 [Member]", "documentation": "Mortgage Loans On Real Estate Interest Multiple, Due 2026" } } } }, "auth_ref": [] }, "peak_MortgageLoansOnRealEstateInterestMultipleDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "MortgageLoansOnRealEstateInterestMultipleDue2027Member", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan on real estate, multiple due 2027", "label": "Mortgage Loans On Real Estate Interest Multiple, Due 2027 [Member]", "documentation": "Mortgage Loans On Real Estate Interest Multiple, Due 2027" } } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateInterestRate", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate", "documentation": "Interest rate of mortgage loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } } }, "auth_ref": ["r338", "r1134"] }, "srt_MortgageLoansOnRealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateLineItems", "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": ["r343", "r1140"] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails", "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]", "documentation": "Land and any structures permanently fixed to it." } } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r1144", "r1145", "r1146", "r1147", "r1150", "r1151", "r1152", "r1153", "r1154"] }, "us-gaap_MortgageLoansOnRealEstateNewMortgageLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageLoansOnRealEstateNewMortgageLoans", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails", "parentTag": "peak_SECSchedule1229RealEstateCompaniesInvestmentinMortgageLoansonRealEstatePeriodIncrease", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"], "lang": { "en-us": { "role": { "terseLabel": "New mortgage loans", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan", "documentation": "Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment." } } } }, "auth_ref": ["r1137"] }, "us-gaap_MortgageLoansOnRealEstateOtherAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageLoansOnRealEstateOtherAdditions", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails", "parentTag": "peak_SECSchedule1229RealEstateCompaniesInvestmentinMortgageLoansonRealEstatePeriodIncrease", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"], "lang": { "en-us": { "role": { "terseLabel": "Draws and additions to existing mortgage loans", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Other Addition", "documentation": "Amount of addition to investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, classified as other." } } } }, "auth_ref": ["r1137"] }, "srt_MortgageLoansOnRealEstatePrincipalAmountOfDelinquentLoans": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MortgageLoansOnRealEstatePrincipalAmountOfDelinquentLoans", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Principal Amount Subject to Delinquent Principal or Interest", "label": "SEC Schedule, 12-29, Real
 Estate Companies, Investment in Mortgage Loans on Real Estate, Principal Amount of Delinquent Loans",
 "documentation": "Amount of principal due on delinquent mortgage loan within investment in mortgage loan on
 real estate by entity with substantial portion of business acquiring and holding investment real estate or interest
 in real estate." } } }, "auth_ref": { "r342", "r1139" } }, "srt_MortgageLoansOnRealEstatePriorLiens1": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstatePriorLiens1",
 "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Prior Liens", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans
 on Real Estate, Prior Lien, Amount", "documentation": "Amount of prior lien on real estate securing mortgage
 loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring
 and holding investment real estate or interest in real estate." } } }, "auth_ref": { "r339", "r1135" } },
 "srt_MortgageLoansOnRealEstateScheduleTable": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateScheduleTable", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
 "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate
 Schedule [Table]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real
 Estate Schedule [Table]", "documentation": "Disclosure of information about investment in mortgage loan on real
 estate by entity with substantial portion of business acquiring and holding investment real estate or interest in
 real estate." } } }, "auth_ref": { "r343", "r1140" } }, "us-gaap_MortgageReceivablesMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageReceivablesMember",
 "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails",
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails", "lang":
 { "en-us": { "role": { "terseLabel": "Mortgage Receivable", "verboseLabel": "Secured loans", "label": "Mortgage
 Receivable [Member]", "documentation": "Amounts due the Company for loans secured by the collateral of
 specified real estate property and which loan the borrower (debtor) is obligated to repay in accordance with a
 predetermined set of payments." } } }, "auth_ref": { } }, "us-gaap_MortgagesMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgagesMember", "presentation": {
 "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails", "lang": { "en-
 us": { "role": { "terseLabel": "Mortgages", "label": "Mortgages [Member]", "documentation": "A loan to finance
 the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } },
 "auth_ref": { } }, "us-gaap_MovementInMortgageLoansOnRealEstateRollForward": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInMortgageLoansOnRealEstateRollForward",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"
 }, "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in
 Movement in Mortgage Loans on Real Estate [Roll Forward]", "label": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]", "documentation": "A roll
 forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } },
 "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "MovementInValuationAllowancesAndReservesRollForward",
 "presentation": { "http://www.healthpeak.com/role/ScheduleIValuationandQualifyingAccountsDetails", "lang": {
 "en-us": { "role": { "terseLabel": "Movement in Valuation Allowances and Reserves", "label": "SEC Schedule, 12-
 09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a
 reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } },
 "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Material
 Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref":
 { "r1348" } }, "peak_MultipleLocationsMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "MultipleLocationsMember", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Multiple Locations", "label": "Multiple Locations [Member]", "documentation": "Multiple
 Locations" } } }, "auth_ref": { } }, "peak_ND0001JamestownNDMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "ND0001JamestownNDMember", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
 }, "lang": { "en-us": { "role": { "terseLabel": "ND0001 Jamestown, ND", "label": "ND0001 Jamestown, ND
 [Member]", "documentation": "ND0001 Jamestown, ND" } } }, "auth_ref": { } }, "peak_NE0002OmahaNEMember":
 { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0002OmahaNEMember",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
 }, "lang": { "en-us": { "role": { "terseLabel": "NE0002 Omaha, NE", "label": "NE0002 Omaha, NE [Member]",
 "documentation": "NE0002 Omaha, NE" } } }, "auth_ref": { } }, "peak_NE0004OmahaNEMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0004OmahaNEMember",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
 }, "lang": { "en-us": { "role": { "terseLabel": "NE0004 Omaha, NE", "label": "NE0004 Omaha, NE [Member]",
 "documentation": "NE0004 Omaha, NE" } } }, "auth_ref": { } }, "peak_NE0010KearneyNEMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0010KearneyNEMember",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
 }, "lang": { "en-us": { "role": { "terseLabel": "NE0010 Kearney, NE", "label": "NE0010 Kearney, NE [Member]",
 "documentation": "NE0010 Kearney, NE" } } }, "auth_ref": { } }, "peak_NE0011KearneyNEMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0011KearneyNEMember",
 "presentation": {

["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[l", "lang": { "en-us": { "role": { "terseLabel": "NE0011 Kearney, NE", "label": "NE0011 Kearney, NE \[Member\]",](#)
["documentation": "NE0011 Kearney, NE" } } } }, "auth_ref": { } }, "peak_NE0012LincolnNEMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0012LincolnNEMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[l", "lang": { "en-us": { "role": { "terseLabel": "NE0012 Kearney, NE", "label": "NE0012 Lincoln, NE \[Member\]",](#)
["documentation": "NE0012 Lincoln, NE" } } } }, "auth_ref": { } }, "peak_NE0013OmahaNEMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NE0013OmahaNEMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[l", "lang": { "en-us": { "role": { "terseLabel": "NE0013 Omaha, NE", "label": "NE0013 Omaha, NE \[Member\]",](#)
["documentation": "NE0013 Omaha, NE" } } } }, "auth_ref": { } }, "peak_NJ0001MonroeTownshipNJMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["NJ0001MonroeTownshipNJMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[l", "lang": { "en-us": { "role": { "terseLabel": "NJ0001 Monroe Township, NJ", "label": "NJ0001 Monroe Township,](#)
[NJ \[Member\]", "documentation": "NJ0001 Monroe Township, NJ" } } } }, "auth_ref": { } },](#)
["peak_NJ0002OldBridgeNJMember": { "xbrltype": "domainItemType", "nsuri":](#)
 [\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NJ0002 Old Bridge, NJ", "label": "NJ0002 Old Bridge, NJ \\[Member\\]",\]\(#\)
\["documentation": "NJ0002 Old Bridge, NJ" } } } }, "auth_ref": { } }, "peak_NY0001WallkillNYMember": { "xbrltype":\]\(#\)
\["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NY0001WallkillNYMember",\]\(#\)
\["presentation": {\]\(#\)
\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0001 Wallkill, NY", "label": "NY0001 Wallkill, NY \\[Member\\]",\]\(#\)
\["documentation": "NY0001 Wallkill, NY" } } } }, "auth_ref": { } }, "peak_NY0002WallkillNYMember": { "xbrltype":\]\(#\)
\["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NY0002WallkillNYMember",\]\(#\)
\["presentation": {\]\(#\)
\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0002 Wallkill, NY", "label": "NY0002 Wallkill, NY \\[Member\\]",\]\(#\)
\["documentation": "NY0002 Wallkill, NY" } } } }, "auth_ref": { } }, "peak_NY0008CornwallNYMember": { "xbrltype":\]\(#\)
\["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NY0008CornwallNYMember",\]\(#\)
\["presentation": {\]\(#\)
\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0008 Cornwall, NY", "label": "NY0008 Cornwall, NY \\[Member\\]",\]\(#\)
\["documentation": "NY0008 Cornwall, NY" } } } }, "auth_ref": { } }, "peak_NY0009HudsonNYMember": { "xbrltype":\]\(#\)
\["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NY0009HudsonNYMember",\]\(#\)
\["presentation": {\]\(#\)
\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0009 Hudson, NY", "label": "NY0009 Hudson, NY \\[Member\\]",\]\(#\)
\["documentation": "NY0009 Hudson, NY" } } } }, "auth_ref": { } }, "peak_NY0012LakeKatrineNYMember": {\]\(#\)
\["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":\]\(#\)
\["NY0012LakeKatrineNYMember", "presentation": {\]\(#\)
\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\]\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\)
\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0012 Lake Katrine, NY", "label": "NY0012 Lake Katrine, NY\]\(#\)
\[\\[Member\\]", "documentation": "NY0012 Lake Katrine, NY" } } } }, "auth_ref": { } },\]\(#\)
\["peak_NY0013RhinebeckNYMember": { "xbrltype": "domainItemType", "nsuri":\]\(#\)
 \[\\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\\]\\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\\)
\\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0013 Rhinebeck, NY", "label": "NY0013 Rhinebeck, NY\\]\\(#\\)
\\[\\\[Member\\\]", "documentation": "NY0013 Rhinebeck, NY" } } } }, "auth_ref": { } },\\]\\(#\\)
\\["peak_NY0014BrooklynNYMember": { "xbrltype": "domainItemType", "nsuri":\\]\\(#\\)
 \\[\\\["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\\\]\\\(http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun\\\)
\\\[l", "lang": { "en-us": { "role": { "terseLabel": "NY0014 Brooklyn, NY", "label": "NY0014 Brooklyn, NY \\\\[Member\\\\]",\\\]\\\(#\\\)
\\\["documentation": "NY0014 Brooklyn, NY" } } } }, "auth_ref": { } }, "srt_NameOfMajorCustomerDomain": {\\\]\\\(#\\\)
\\\["xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain",\\\]\\\(#\\\)
\\\["presentation": {\\\]\\\(#\\\)
\\\["http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe\\\]\\\(http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe\\\)
\\\[l", "lang": { "en-us": { "role": { "terseLabel": "Customer {Domain}", "label": "Customer {Domain\\\\]",\\\]\\\(#\\\)
\\\["documentation": "Single external customer or group of external customers." } } } }, "auth_ref": { "r505", "r1199",\\\]\\\(#\\\)
\\\["r1236", "r1240", "r1516", "r1612", "r1616", "r1617", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624",\\\]\\\(#\\\)
\\\["r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636",\\\]\\\(#\\\)
\\\["r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643" } }, "ecd_NamedExecutiveOfficersFnTextBlock": {\\\]\\\(#\\\)
\\\["xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":\\\]\\\(#\\\)
\\\["NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": {\\\]\\\(#\\\)
\\\["en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers,\\\]\\\(#\\\)
\\\[Footnote \\\\[Text Block\\\\]" } } } }, "auth_ref": { "r1321" } }, "us-gaap_NatureOfOperations": { "xbrltype":\\\]\\\(#\\\)
\\\["textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation":\\\]\\\(#\\\)
\\\[f "http://www.healthpeak.com/role/Business" }, "lang": { "en-us": { "role": { "terseLabel": "Business", "label":\\\]\\\(#\\\)
\\\["Nature of Operations \\\\[Text Block\\\\]", "documentation": "The entire disclosure for the nature of an entity's\\\]\\\(#\\\)
\\\[business, major products or services, principal markets including location, and the relative importance of its\\\]\\\(#\\\)
\\\[operations in each business and the basis for the determination, including but not limited to, assets, revenues, or\\\]\\\(#\\\)
\\\[earnings. For an entity that has not commenced principal operations, disclosures about the risks and\\\]\\\(#\\\)
\\\[uncertainties related to the activities in which the entity is currently engaged and an understanding of what\\\]\\\(#\\\)
\\\[those activities are being directed toward." } } } }, "auth_ref": { "r293", "r301" } } }.\\\]\\\(#\\\)\\]\\(http://www.healthpeak.com/20241231\\)\]\(http://www.healthpeak.com/20241231\)](http://www.healthpeak.com/20241231)

"peak_NeedhamLandParcelJVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NeedhamLandParcelJVMember", "presentation": { "http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth": "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Needham Land Parcel JV", "label": "Needham Land Parcel JV [Member]", "documentation": "Needham Land Parcel JV" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange": "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r397"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange": "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r397"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange": "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r209", "r210", "r211"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF OPERATIONS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF OPERATIONS": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Healthpeak Properties, Inc.", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r192", "r211", "r264", "r362", "r379", "r382", "r387", "r405", "r421", "r423", "r424", "r426", "r427", "r428", "r432", "r433", "r448", "r552", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r790", "r798", "r819", "r842", "r982", "r1080", "r1098", "r1099", "r1254", "r1508"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF OPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF OPERATIONS": { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) applicable to common shares", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r394", "r423", "r424", "r426", "r427", "r436", "r437", "r449", "r452", "r798"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri":

```

"http://fasb.org/us-gaap/2024\", \"localname\": \"NetIncomeLossAvailableToCommonStockholdersBasicAbstract\",  

\"presentation\": { \"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\" }, \"lang\":  

{ \"en-us\": { \"role\": { \"terseLabel\": \"Numerator - Basic\", \"label\": \"Net Income (Loss) Available to Common  

Stockholders, Basic [Abstract]\" } } }, \"auth_ref\": [ ] }, \"us-  

gaap_NetIncomeLossAvailableToCommonStockholdersDiluted\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\":  

\"http://fasb.org/us-gaap/2024\", \"localname\": \"NetIncomeLossAvailableToCommonStockholdersDiluted\", \"crdr\":  

\"credit\", \"calculation\": { \"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\":  

{ \"parentTag\": null, \"weight\": null, \"order\": null, \"root\": true } }, \"presentation\": {  

\"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\" }, \"lang\": { \"en-us\": {  

\"role\": { \"totalLabel\": \"Dilutive net income (loss) available to common shares\", \"label\": \"Net Income (Loss)  

Available to Common Stockholders, Diluted\", \"documentation\": \"Amount, after deduction of tax, noncontrolling  

interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of  

common shares for dilutive potential common shares; of income (loss) available to common shareholders.\" } } },  

\"auth_ref\": [ \"r394\", \"r438\", \"r444\", \"r445\", \"r446\", \"r447\", \"r449\", \"r452\" ] },  

\"peak_NetIncomeLossContinuingOperationsAvailableToCommonStockholdersBasic\": { \"xbrltype\":  

\"monetaryItemType\", \"nsuri\": \"http://www.healthpeak.com/20241231\", \"localname\":  

\"NetIncomeLossContinuingOperationsAvailableToCommonStockholdersBasic\", \"crdr\": \"credit\", \"calculation\": {  

\"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\": { \"parentTag\": \"us-  

gaap_NetIncomeLossAvailableToCommonStockholdersBasic\", \"weight\": 1.0, \"order\": 1.0 } }, \"presentation\": {  

\"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\" }, \"lang\": { \"en-us\": {  

\"role\": { \"totalLabel\": \"Income (loss) from continuing operations applicable to common shares\", \"label\": \"Net  

Income Loss Continuing Operations Available To Common Stockholders Basic\", \"documentation\": \"Net Income  

Loss Continuing Operations Available To Common Stockholders Basic\" } } }, \"auth_ref\": [ ] }, \"us-  

gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest\": { \"xbrltype\":  

\"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\":  

\"NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest\", \"crdr\": \"credit\",  

\"presentation\": {  

\"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING  

\" }, \"lang\": { \"en-us\": { \"role\": { \"verboseLabel\": \"Net income (loss)\", \"label\": \"Net Income (Loss), Including Portion  

Attributable to Nonredeemable Noncontrolling Interest\", \"documentation\": \"Amount after income tax of income  

(loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion  

attributable to redeemable noncontrolling interest recognized as temporary equity.\" } } }, \"auth_ref\": [ \"r35\",  

\"r243\", \"r244\" ] }, \"peak_NetIncomeLossJointVenturePartnersAttributableToParent\": { \"xbrltype\":  

\"monetaryItemType\", \"nsuri\": \"http://www.healthpeak.com/20241231\", \"localname\":  

\"NetIncomeLossJointVenturePartnersAttributableToParent\", \"crdr\": \"credit\", \"calculation\": {  

\"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails\":  

{ \"parentTag\": \"us-  

gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMetho  

\"weight\": 1.0, \"order\": 13.0 } }, \"presentation\": {  

\"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails\" },  

\"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Less: Healthpeaku2019s share of unconsolidated joint venture  

Adjusted NOI\", \"label\": \"Net Income Loss Joint Venture Partners Attributable To Parent\", \"documentation\": \"Net  

Income Loss Joint Venture Partners Attributable To Parent\" } } }, \"auth_ref\": [ ] }, \"us-  

gaap_NewAccountingPronouncementsPolicyPolicyTextBlock\": { \"xbrltype\": \"textBlockItemType\", \"nsuri\":  

\"http://fasb.org/us-gaap/2024\", \"localname\": \"NewAccountingPronouncementsPolicyPolicyTextBlock\",  

\"presentation\": { \"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies\" }, \"lang\": {  

\"en-us\": { \"role\": { \"terseLabel\": \"Recent Accounting Pronouncements\", \"label\": \"New Accounting  

Pronouncements, Policy [Policy Text Block]\", \"documentation\": \"Disclosure of accounting policy pertaining to  

new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to,  

quantification of the expected or actual impact.\" } } }, \"auth_ref\": [ ] },  

\"peak_NonCashAdjustmentsToNetOperatingIncomeFromContinuingOperations\": { \"xbrltype\":  

\"monetaryItemType\", \"nsuri\": \"http://www.healthpeak.com/20241231\", \"localname\":  

\"NonCashAdjustmentsToNetOperatingIncomeFromContinuingOperations\", \"crdr\": \"credit\", \"calculation\": {  

\"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails\":  

{ \"parentTag\": \"peak_AdjustedNetOperatingIncomeFromContinuingOperations\", \"weight\": 1.0, \"order\": 7.0 } },  

\"presentation\": {  

\"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails\" },  

\"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Adjustments to NOI\", \"label\": \"Non Cash Adjustments To Net  

Operating Income From Continuing Operations\", \"documentation\": \"Represents straight-line rents, DFL  

accretion, amortization of market lease intangibles and lease termination fees.\" } } }, \"auth_ref\": [ ] },  

\"peak_NonCashAssetsAndLiabilitiesAssumedInConnectionWithTheMergers\": { \"xbrltype\": \"monetaryItemType\",  

\"nsuri\": \"http://www.healthpeak.com/20241231\", \"localname\":  

\"NonCashAssetsAndLiabilitiesAssumedInConnectionWithTheMergers\", \"crdr\": \"credit\", \"presentation\": {  

\"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails\" }, \"lang\": {  

\"en-us\": { \"role\": { \"terseLabel\": \"Non-cash assets and liabilities assumed in connection with the Merger (see  

Note 3)\", \"label\": \"Non-Cash Assets And Liabilities Assumed In Connection With The Mergers\", \"documentation\":  

\"Non-Cash Assets And Liabilities Assumed In Connection With The Mergers\" } } }, \"auth_ref\": [ ] },  

\"ecd_NonGaapMeasureDescriptionTextBlock\": { \"xbrltype\": \"textBlockItemType\", \"nsuri\":  

\"http://xbrl.sec.gov/ecd/2024\", \"localname\": \"NonGaapMeasureDescriptionTextBlock\", \"presentation\": {  

\"http://xbrl.sec.gov/ecd/role/PvpDisclosure\" }, \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Non-GAAP Measure  

Description\", \"label\": \"Non-GAAP Measure Description [Text Block]\" } } }, \"auth_ref\": [ \"r1320\" ] },  

\"ecd_NonNeosMember\": { \"xbrltype\": \"domainItemType\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2024\", \"localname\":  

\"NonNeosMember\", \"presentation\": { \"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure\" }, \"lang\": { \"en-us\": {  

\"role\": { \"terseLabel\": \"Non-NEOs\", \"label\": \"Non-NEOs [Member]\" } } }, \"auth_ref\": [ \"r1283\", \"r1294\", \"r1304\",  

\"r1328\", \"r1337\" ] }, \"ecd_NonPeoNeoAvgCompActuallyPaidAmt\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\":  

\"http://xbrl.sec.gov/ecd/2024\", \"localname\": \"NonPeoNeoAvgCompActuallyPaidAmt\", \"presentation\": {  

\"http://xbrl.sec.gov/ecd/role/PvpDisclosure\" }, \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Non-PEO NEO Average  

Compensation Actually Paid Amount\", \"label\": \"Non-PEO NEO Average Compensation Actually Paid Amount\" } }
```


], "auth_ref": ["r1311"]], "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1310"]], "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r1328"]], "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1348"]], "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1348"]], "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental schedule of non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashMergerRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashMergerRelatedCosts", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Merger-related post-combination stock compensation expense", "label": "Noncash Merger Related Costs", "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger." } } }, "auth_ref": ["r19"] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net noncash impact from the consolidation of property previously held in an unconsolidated joint venture", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future." } } }, "auth_ref": ["r51", "r52", "r53"] }, "peak_NoncashOrPartNoncashInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NoncashOrPartNoncashInterestIncome", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest income", "label": "Noncash or Part Noncash, Interest Income", "documentation": "Noncash or Part Noncash, Interest Income" } } }, "auth_ref": [] }, "peak_NoncashOrPartNoncashRetainedInvestmentsInConnectionWithJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NoncashOrPartNoncashRetainedInvestmentsInConnectionWithJointVentures", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails"], "lang": { "en-us": { "role": { "terseLabel": "Retained investments in connection with joint ventures", "label": "Noncash or Part Noncash, Retained Investments In Connection With Joint Ventures", "documentation": "Noncash or Part Noncash, Retained Investments In Connection With Joint Ventures" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersNonredeemable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestInNetIncomeLossJointVenturePartnersNonredeemable", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Plus: Noncontrolling interests\u2019 2019 share of consolidated joint venture Adjusted NOI", "label": "Noncontrolling Interest in Net Income (Loss) Joint Venture Partners, Nonredeemable", "documentation": "Amount after tax of income (loss) attributable to nonredeemable noncontrolling shareholder, unit holder, partner, or other equity holder of a joint venture." } } }, "auth_ref": ["r188"] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests acquired as part of the Merger", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": ["r25", "r85", "r96"] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label":

"Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } },
 "auth_ref": { "r25", "r85", "r242" } }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING",
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests",
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" } }, "lang": { "en-us": {
 "role": { "terseLabel": "Total Noncontrolling Interests", "label": "Noncontrolling Interest [Member]",
 "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable,
 directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } },
 "auth_ref": { "r97", "r677", "r1440", "r1441", "r1442", "r1445", "r1649" } },
 "peak_NoncontrollingInterestsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "NoncontrollingInterestsPolicyTextBlock", "presentation":
 { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us": { "role":
 { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interests [Policy Text Block]",
 "documentation": "Disclosure of accounting policy for noncontrolling interests." } } }, "auth_ref": { } }, "us-
 gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth",
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" } }, "lang": { "en-us": { "role": {
 "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation":
 "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding
 major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r197" } }, "us-
 gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { } },
 "peak_NonrefundableEntranceFees": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "NonrefundableEntranceFees", "crdr": "credit",
 "presentation": { "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails" } }, "lang":
 { "en-us": { "role": { "terseLabel": "Nonrefundable entrance fees", "label": "Nonrefundable Entrance Fees",
 "documentation": "Nonrefundable Entrance Fees" } } }, "auth_ref": { } }, "peak_NumberOfDownREITLLCs": {
 "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "NumberOfDownREITLLCs", "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails",
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of DownREIT LLCs (in entities)", "label": "Number of Down REIT LLCs", "documentation":
 "This element represents the number of DownREIT LLCs for which the entity is the managing member." } } },
 "auth_ref": { } }, "peak_NumberOfFacilitiesOwnedByUnconsolidatedJointVenture": { "xbrltype":
 "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "NumberOfFacilitiesOwnedByUnconsolidatedJointVenture", "presentation": {
 "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of facilities owned by unconsolidated joint venture", "label": "Number Of Facilities Owned
 By Unconsolidated Joint Venture", "documentation": "Number Of Facilities Owned By Unconsolidated Joint
 Venture" } } }, "auth_ref": { } }, "peak_NumberOfHospitals": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "NumberOfHospitals", "presentation": {
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of hospitals", "label": "Number Of Hospitals", "documentation": "Number Of Hospitals" } } },
 "auth_ref": { } }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": {
 "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
 "http://www.healthpeak.com/role/DebtMortgageDebtDetails",
 "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsFinancialInstrumentsDetails",
 "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of interest-rate contracts held", "label": "Number of Interest Rate Derivatives Held",
 "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } },
 "auth_ref": { "r115", "r116" } }, "peak_NumberOfJointVentures": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "NumberOfJointVentures", "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed",
 "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of joint ventures", "label": "Number Of Joint Ventures",
 "documentation": "Number Of Joint Ventures" } } }, "auth_ref": { } }, "peak_NumberOfLeases": { "xbrltype":
 "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "NumberOfLeases",
 "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" } }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of leases", "label": "Number Of Leases", "documentation": "Number Of Leases" } } },
 "auth_ref": { } }, "peak_NumberOfLeasesApprovedForRejection": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "NumberOfLeasesApprovedForRejection", "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" } }, "lang": { "en-us": { "role": { "terseLabel":
 "Number of leases approved", "label": "Number Of Leases Approved For Rejection", "documentation": "Number Of
 Leases Approved For Rejection" } } }, "auth_ref": { } }, "peak_NumberOfLoans": { "xbrltype": "integerItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname": "NumberOfLoans", "presentation": {
 "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails",
 "http://www.healthpeak.com/role/DebtMortgageDebtDetails",
 "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails",

["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"](http://www.healthpeak.com/role/LoansReceivableTheMergerDetails)], "lang": { "en-us": { "role": { "terseLabel":
"Number of loans", "label": "Number Of Loans", "documentation": "Number Of Loans" } } }, "auth_ref": { } },
"peak_NumberOfObligationsExpiring": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfObligationsExpiring", "presentation": {
["http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails"](http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails)],
"lang": { "en-us": { "role": { "terseLabel": "Number of obligations expiring", "label": "Number Of Obligations
Expiring", "documentation": "Number Of Obligations Expiring" } } }, "auth_ref": { } },
"peak_NumberOfPropertiesAcquired": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfPropertiesAcquired", "presentation": {
["http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails"](http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails),
["http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails"](http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails),
["http://www.healthpeak.com/role/TheMergerNarrativeDetails"](http://www.healthpeak.com/role/TheMergerNarrativeDetails)], "lang": { "en-us": { "role": { "terseLabel":
"Number of properties acquired", "label": "Number Of Properties Acquired", "documentation": "Number Of
Properties Acquired" } } }, "auth_ref": { } }, "peak_NumberOfPropertiesSold": { "xbrltype": "integerItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "NumberOfPropertiesSold", "presentation": {
["http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate"](http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate),
["http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate"](http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate),
["http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate"](http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate),
["http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails"](http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Number of assets sold", "verboseLabel": "Number of properties
sold", "label": "Number Of Properties Sold", "documentation": "Number Of Properties Sold" } } }, "auth_ref": { } },
"peak_NumberOfPropertiesToBeSold": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfPropertiesToBeSold", "presentation": {
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Number of properties sold", "label": "Number Of Properties To Be
Sold", "documentation": "Number Of Properties To Be Sold" } } }, "auth_ref": { } },
"peak_NumberOfPropertiesWithFirstMortgages": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfPropertiesWithFirstMortgages", "presentation":
{ ["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"](http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Number of properties with first mortgages", "label": "Number Of Properties With First Mortgages",
"documentation": "Number Of Properties With First Mortgages" } } }, "auth_ref": { } }, "us-
gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NumberOfRealEstateProperties", "presentation": {
["http://www.healthpeak.com/role/DebtMortgageDebtDetails"](http://www.healthpeak.com/role/DebtMortgageDebtDetails),
["http://www.healthpeak.com/role/DebtTheMergerDetails"](http://www.healthpeak.com/role/DebtTheMergerDetails),
["http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails"](http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails),
["http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth"](http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth)
["http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails"](http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails)], "lang":
{ "en-us": { "role": { "terseLabel": "Property count", "label": "Number of Real Estate Properties",
"documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": { } },
"peak_NumberOfRealEstatePropertiesImpaired": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfRealEstatePropertiesImpaired", "presentation":
{ ["http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails"](http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails)], "lang": { "en-us": { "role": { "terseLabel":
"Number of real estate properties impaired", "label": "Number Of Real Estate Properties Impaired",
"documentation": "Number Of Real Estate Properties Impaired" } } }, "auth_ref": { } },
"peak_NumberOfRedeemableNoncontrollingInterest": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfRedeemableNoncontrollingInterest",
"presentation": {
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres"](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres)
], "lang": { "en-us": { "role": { "terseLabel": "Number of redeemable noncontrolling interest", "label": "Number Of
Redeemable Noncontrolling Interest", "documentation": "Number Of Redeemable Noncontrolling Interest" } } },
"auth_ref": { } }, "peak_NumberOfRedeemableNoncontrollingInterestWithRedemptionConditions": { "xbrltype":
"integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"NumberOfRedeemableNoncontrollingInterestWithRedemptionConditions", "presentation": {
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres"](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres)
], "lang": { "en-us": { "role": { "terseLabel": "Number of redeemable noncontrolling interest with redemption
conditions", "label": "Number Of Redeemable Noncontrolling Interest With Redemption Conditions",
"documentation": "Number Of Redeemable Noncontrolling Interest With Redemption Conditions" } } },
"auth_ref": { } }, "peak_NumberOfSecuredLoans": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfSecuredLoans", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails)], "lang": { "en-us":
{ "role": { "terseLabel": "Secured loan", "label": "Number of Secured Loans", "documentation": "Number of
Secured Loans" } } }, "auth_ref": { } }, "peak_NumberOfTenants": { "xbrltype": "integerItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "NumberOfTenants", "presentation": {
["http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe"](http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe)
], "lang": { "en-us": { "role": { "terseLabel": "Number of tenants", "label": "Number Of Tenants",
"documentation": "Number Of Tenants" } } }, "auth_ref": { } }, "peak_NumberOfUnconsolidatedJointVenture": {
"xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"NumberOfUnconsolidatedJointVenture", "presentation": {
["http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth"](http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth)
["http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Number of unconsolidated joint ventures", "label": "Number of Unconsolidated Joint Venture",
"documentation": "Represents number of unconsolidated joint ventures between entity and an institutional

capital partner." } } }, "auth_ref": [1], "us-gaap_OffMarketLeaseUnfavorable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffMarketLeaseUnfavorable", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Intangible liabilities, net", "label": "Off-Market Lease, Unfavorable", "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition." } } }, "auth_ref": ["r169"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": -1.0, "order": 4.0 }, "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating expenses", "totalLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [1], "peak_OperatingExpensesFromJointVentureAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingExpensesFromJointVentureAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests\u2019 share of consolidated joint venture operating expenses", "label": "Operating Expenses From Joint Venture Attributable To Noncontrolling Interest", "documentation": "Operating Expenses From Joint Venture Attributable To Noncontrolling Interest" } } }, "auth_ref": [1], "peak_OperatingExpensesFromJointVentureAttributableToParentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingExpensesFromJointVentureAttributableToParentNet", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Healthpeak\u2019s share of unconsolidated joint venture operating expenses", "label": "Operating Expenses From Joint Venture Attributable To Parent Net", "documentation": "Operating Expenses From Joint Venture Attributable To Parent Net" } } }, "auth_ref": [1], "peak_OperatingLeaseAreaOfSquareFeetRenewed": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingLeaseAreaOfSquareFeetRenewed", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating lease, area of square feet renewed", "label": "Operating Lease, Area Of Square Feet Renewed", "documentation": "Operating Lease, Area Of Square Feet Renewed" } } }, "auth_ref": [1], "peak_OperatingLeaseAreaOfSquareFeetWithEarlyTerminationRight": { "xbrltype": "areaItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingLeaseAreaOfSquareFeetWithEarlyTerminationRight", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Area of square feet with early termination right", "label": "Operating Lease, Area Of Square Feet With Early Termination Right", "documentation": "Operating Lease, Area Of Square Feet With Early Termination Right" } } }, "auth_ref": [1], "peak_OperatingLeaseIncomeAsPercentOfRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingLeaseIncomeAsPercentOfRevenues", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of segment revenues", "label": "Operating Lease, Income As Percent Of Revenues", "documentation": "Operating Lease, Income As Percent Of Revenues" } } }, "auth_ref": [1], "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" }, "lang": { "en-us": { "role": { "terseLabel": "Rental and related revenues", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": ["r459", "r873", "r876"] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LeasesLeaseIncomeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fixed income from operating leases", "label": "Operating Lease, Lease Income, Lease Payments", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": ["r459", "r879"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": {

"role": { "terseLabel": "Lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r862" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails", "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liability for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r863", "r866" } }, "peak_OperatingLeasePercentageOfAnnualLeaseEscalations": { "xbrltype": "pureItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingLeasePercentageOfAnnualLeaseEscalations", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating lease, percentage of annual lease escalations", "label": "Operating Lease, Percentage Of Annual Lease Escalations", "documentation": "Operating Lease, Percentage Of Annual Lease Escalations" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r861" } }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseVariableLeaseIncome", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LeasesLeaseIncomeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable income from operating leases", "label": "Operating Lease, Variable Lease Income", "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }, "auth_ref": { "r459", "r880" } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.healthpeak.com/role/LeasesLeaseCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate, operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r869", "r1225" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.healthpeak.com/role/LeasesLeaseCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r868", "r1225" } }, "peak_OperatingLeasesIncomeStatementLeaseRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OperatingLeasesIncomeStatementLeaseRevenueMember", "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Rental and Related Revenues", "label": "Operating Leases, Income Statement, Lease Revenue [Member]", "documentation": "Operating Leases, Income Statement, Lease Revenue [Member]" } } }, "auth_ref": { } }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/Leases" }, "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessor, Operating Leases [Text Block]", "documentation": "The entire disclosure for lessor's operating leases." } } }, "auth_ref": { "r872" } }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r774" } }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": { "r774" } }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating segment", "verboseLabel": "Operating Segment", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r491", "r492", "r493", "r494", "r495", "r498", "r1177", "r1178" } }, "peak_OptionIndexedToIssuersEquityTerm": { "xbrltype": "durationItemType", "nsuri":

"http://www.healthpeak.com/20241231", "localname": "OptionIndexedToIssuersEquityTerm", "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails": {
 "en-us": { "role": { "terseLabel": "Option indexed to issuers equity, term", "label": "Option Indexed To Issuers
 Equity, Term", "documentation": "Option Indexed To Issuers Equity, Term" } } }, "auth_ref": { } }, "us-
 gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": {
 "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label":
 "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_OtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherAccountsPayableAndAccruedLiabilities", "crdr": "credit",
 "calculation": { "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails":
 { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order":
 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails": { "en-
 us": { "role": { "terseLabel": "Other accounts payable and accrued liabilities", "label": "Other Accounts Payable
 and Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and
 services received classified as other, and expenses incurred but not yet paid, payable within one year or the
 operating cycle, if longer." } } }, "auth_ref": { } }, "us-gaap_OtherAmortizationOfDeferredCharges": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherAmortizationOfDeferredCharges", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails": { "en-us": { "role": {
 "terseLabel": "Amortization of other deferred charges", "label": "Amortization of Other Deferred
 Charges", "documentation": "Amount of amortization of other deferred costs recognized in the income
 statement." } } }, "auth_ref": { "r19", "r193" } }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight":
 1.0, "order": 10.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS":
 "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails": { "en-us": { "role": {
 "terseLabel": "Other assets, net", "label": "Other Assets", "documentation": "Amount of assets classified
 as other." } } }, "auth_ref": { "r252", "r368", "r968", "r1178", "r1256" } }, "us-gaap_OtherAssetsMember": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember",
 "presentation": { "http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails": { "en-us": { "role": {
 "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial
 statement caption encompassing other assets." } } }, "auth_ref": { "r119", "r129" } },
 "peak_OtherAssetsNetPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "OtherAssetsNetPolicyTextBlock", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "en-us": { "role": {
 "terseLabel": "Other Assets, Net", "label": "Other Assets, Net [Policy Text Block]", "documentation": "Other
 Assets, Net" } } }, "auth_ref": { } }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]",
 "documentation": "Information by type of other commitment." } } }, "auth_ref": { } }, "us-
 gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "OtherCommitmentsDomain", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments
 [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": { } }, "us-
 gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "OtherCommitmentsLineItems", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line
 Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used
 to disclose reportable information associated with domain members defined in one or many axes to the table." } } }
 }, "auth_ref": { } }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]",
 "documentation": "Disclosure of information about obligations resulting from other commitments." } } },
 "auth_ref": { } }, "us-
 gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit",
 "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
 "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation":
 { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "en-us": { "role": {
 "terseLabel": "Net unrealized gains (losses) on derivatives", "label": "Other Comprehensive
 Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount,
 after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash
 flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r377", "r378" } }, "us-
 gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
 "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS":

"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r27", "r32", "r380", "r383", "r389", "r428", "r843", "r844", "r849", "r958", "r983", "r1423", "r1424" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "lang": { "en-us": { "role": { "negatedLabel": "Change in Supplemental Executive Retirement Plan obligation and other", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": { "r6", "r7", "r183", "r184", "r983" } }, "peak_OtherDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OtherDeferredRevenue", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Other deferred revenue", "label": "Other Deferred Revenue", "documentation": "Other Deferred Revenue" } } }, "auth_ref": { } }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization of real estate, in-place lease, and other intangibles", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": { "r19", "r72", "r193" } }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont", "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": { } }, "peak_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OtherMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Represents the information pertaining to the Other [member]" } } }, "auth_ref": { } }, "peak_OtherNonReportingSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OtherNonReportingSegmentMember", "presentation": { "http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails", "http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesScheduleofEquityMeth", "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails", "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Non-Reporting Segment [Member]", "documentation": "Represents the information pertaining to other non-reporting segment" } } }, "auth_ref": { } }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": { "r211" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r200" } }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": {

[http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable](#)], "lang": { "en-us": { "role": { "terseLabel": "Government grant income recorded in other income (expense), net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap-OtherNonrecurringExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringExpense", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expense on other", "label": "Other Nonrecurring Expense", "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": { "r202" } }, "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r1320" } }, "srt-OtherPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OtherPropertyMember", "presentation": { "http://www.healthpeak.com/role/IntangiblesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Property", "label": "Other Property [Member]", "documentation": "Property classified as other." } } }, "auth_ref": { "r1163", "r1164", "r1652", "r1653" } }, "peak-OutpatientMedicalBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OutpatientMedicalBuildingsMember", "presentation": { "http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstateandDiscontinuedOperations", "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outpatient Medical Buildings", "label": "Outpatient Medical Buildings [Member]", "documentation": "Properties that are part of continuing operations, and which are classified as medical office." } } }, "auth_ref": [] }, "peak-OutpatientMedicalLandParcelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "OutpatientMedicalLandParcelMember", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstateandDiscontinuedOperations", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstateandDiscontinuedOperations", "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinuedOperations", "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails", "http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails", "http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesScheduleofEquityMethodInvestments", "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails", "http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails", "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccumulatedDepreciation", "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails", "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outpatient Medical", "label": "Outpatient Medical [Member]", "documentation": "Properties that are part of continuing operations, and which are classified as medical office." } } }, "auth_ref": [] }, "ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r1281", "r1292", "r1302", "r1335" } }, "ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": { "r1284", "r1295", "r1305", "r1338" } }, "ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r1284", "r1295", "r1305", "r1338" } }, "srt-OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests", "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt-OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests", "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "peak-PA0002CarlislePAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PA0002CarlislePAMember", "presentation": {

["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0002 Carlisle, PA", "label": "PA0002 Carlisle, PA \[Member\]",](#)
["documentation": "PA0002 Carlisle, PA" } } } }, "auth_ref": { } }, "peak_PA0004CarlislePAMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PA0004CarlislePAMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0004 Carlisle, PA", "label": "PA0004 Carlisle, PA \[Member\]",](#)
["documentation": "PA0004 Carlisle, PA" } } } }, "auth_ref": { } }, "peak_PA0005HersheyPAMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PA0005HersheyPAMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0005 Hershey, PA", "label": "PA0005 Hershey, PA \[Member\]",](#)
["documentation": "PA0005 Hershey, PA" } } } }, "auth_ref": { } }, "peak_PA0006CampHillPAMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PA0006CampHillPAMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0006 Camp Hill, PA", "label": "PA0006 Camp Hill, PA \[Member\]",](#)
["documentation": "PA0006 Camp Hill, PA" } } } }, "auth_ref": { } }, "peak_PA0007HarrisburgPAMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["PA0007HarrisburgPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0007 Harrisburg, PA", "label": "PA0007 Harrisburg, PA](#)
[\[Member\]", "documentation": "PA0007 Harrisburg, PA" } } } }, "auth_ref": { } },](#)
["peak_PA0008HarrisburgPAMember": { "xbrltype": "domainItemType", "nsuri":](#)
["http://www.healthpeak.com/20241231", "localname": "PA0008HarrisburgPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0008 Harrisburg, PA", "label": "PA0008 Harrisburg, PA](#)
[\[Member\]", "documentation": "PA0008 Harrisburg, PA" } } } }, "auth_ref": { } }, "peak_PA0010HanoverPAMember":](#)
[{ "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["PA0010HanoverPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0010 Hanover, PA", "label": "PA0010 Hanover, PA \[Member\]",](#)
["documentation": "PA0010 Hanover, PA" } } } }, "auth_ref": { } }, "peak_PA0011WyomissingPAMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["PA0011WyomissingPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0011 Wyomissing, PA", "label": "PA0011 Wyomissing, PA](#)
[\[Member\]", "documentation": "PA0011 Wyomissing, PA" } } } }, "auth_ref": { } },](#)
["peak_PA0012WestEastonPAMember": { "xbrltype": "domainItemType", "nsuri":](#)
["http://www.healthpeak.com/20241231", "localname": "PA0012WestEastonPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0012 West Easton, PA", "label": "PA0012 West Easton, PA](#)
[\[Member\]", "documentation": "PA0012 West Easton, PA" } } } }, "auth_ref": { } },](#)
["peak_PA0013WestMifflinPAMember": { "xbrltype": "domainItemType", "nsuri":](#)
["http://www.healthpeak.com/20241231", "localname": "PA0013WestMifflinPAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0013 West Mifflin, PA", "label": "PA0013 West Mifflin, PA](#)
[\[Member\]", "documentation": "PA0013 West Mifflin, PA" } } } }, "auth_ref": { } }, "peak_PA0014EriePAMember": {](#)
["xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":](#)
["PA0014EriePAMember", "presentation": {](#)
["http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun](http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun)
[", "lang": { "en-us": { "role": { "terseLabel": "PA0014 Erie, PA", "label": "PA0014 Erie, PA \[Member\]",](#)
["documentation": "PA0014 Erie, PA" } } } }, "auth_ref": { } }, "peak_PMAKJVMember": { "xbrltype":](#)
["domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PMAKJVMember",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth](http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth)
[", "lang": { "en-us": { "role": { "terseLabel": "PMAK JV", "label": "PMAK JV \[Member\]", "documentation": "PMAK](#)
[JV" } } } }, "auth_ref": { } }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-](#)
[gaap/2024", "localname": "ParentMember", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING)
[", "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders\u2019 Equity", "label": "Parent \[Member\]",](#)
["documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly,](#)
[to the parent. Excludes noncontrolling interests." } } } }, "auth_ref": { } }, "us-](#)
[gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "xbrltype": "monetaryItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "crdr": "debit", "calculation": {](#)
 [\[gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 },\]\(#\)
 \[\\["peak_NetIncomeLossContinuingOperationsAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 }\\]\\(#\\)
\\[}, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",\\]\\(#\\)
 \\[\\\["role": { "negatedTerseLabel": "Participating securities\u2019 2019 share in earnings", "negatedNetLabel": "Less:\\\]\\\(#\\\)
\\\[Participating securities\u2019 2019 share in continuing operations", "label": "Participating Securities, Distributed and\\\]\\\(#\\\)
\\\[Undistributed Earnings \\\\(Loss\\\\), Basic", "documentation": "Amount of earnings \\\\(loss\\\\) distributed and earnings\\\]\\\(#\\\)
\\\[\\\\(loss\\\\) allocated to participating securities for the basic earnings \\\\(loss\\\\) per share or per unit calculation under\\\]\\\(#\\\)
\\\[the two-class method." } } } }, "auth_ref": { "r449", "r1373" } }, "ecd PayVsPerformanceDisclosureLineItems": {\\\]\\\(#\\\)
\\\["xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":\\\]\\\(#\\\)\\]\\(http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\\)\]\(http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails\)](http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS)

"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": { "r1309" }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": { } }, "us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLeasingCostsCommissionsAndTenantImprovements", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued", "lang": { "en-us": { "role": { "negatedLabel": "Leasing costs, tenant improvements, and recurring capital expenditures", "terseLabel": "Leasing costs, tenant improvements, and recurring capital expenditures", "label": "Payments for Leasing Costs, Commissions, and Tenant Improvements", "documentation": "Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred." } } }, "auth_ref": { } }, "peak_PaymentsForLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PaymentsForLoansReceivable", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails": { "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Payments for loans receivable", "label": "Payments For Loans Receivable", "documentation": "Payments For Loans Receivable" } } }, "auth_ref": { } }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepayment of rent", "label": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": { "r17" } }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": { "r207" } }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedLabel": "Payments for deferred financing costs", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": { "r9" } }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid on common stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": { "r207" } }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "totalLabel": "Preliminary cash consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": { "r44", "r796" } }, "peak_PaymentsToAcquireBusinessesGrossPaymentsMadeForShareSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PaymentsToAcquireBusinessesGrossPaymentsMadeForShareSettlement", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments made in connection with share settlement", "label": "Payments To Acquire Businesses, Gross, Payments Made For Share Settlement", "documentation": "Payments To Acquire Businesses, Gross, Payments Made For Share Settlement" } } }, "auth_ref": { } }, "peak_PaymentsToAcquireBusinessesGrossRevolvingCreditFacilityTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PaymentsToAcquireBusinessesGrossRevolvingCreditFacilityTermination", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Physicians Realty Trust revolving credit facility termination", "label": "Payments To Acquire Businesses, Gross, Revolving Credit Facility Termination", "documentation": "Payments To Acquire

Businesses, Gross, Revolving Credit Facility Termination" } } }, "auth_ref": [] },
 "peak_PaymentsToAcquireBusinessesGrossSettlementOfTransactionCosts": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "PaymentsToAcquireBusinessesGrossSettlementOfTransactionCosts", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "parentTag": "us-
 gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "Settlement of Physicians Realty Trust's 2019s transaction costs", "label": "Payments To
 Acquire Businesses, Gross, Settlement Of Transaction Costs", "documentation": "Payments To Acquire
 Businesses, Gross, Settlement Of Transaction Costs" } } }, "auth_ref": [] },
 "peak_PaymentsToAcquireEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "PaymentsToAcquireEquityInvestments", "crdr": "credit",
 "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "Payments to acquire equity investments", "label": "Payments To Acquire Equity
 Investments", "documentation": "Payments To Acquire Equity Investments" } } }, "auth_ref": [] }, "us-
 gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit",
 "presentation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesScheduleofEquityMeth
 "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails":
 "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "Payments to acquire equity method investments", "verboseLabel": "Payments to acquire equity
 method investment", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash
 outflow associated with the purchase of or advances to an equity method investments, which are investments in
 joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and
 exercises significant influence." } } }, "auth_ref": ["r44"] }, "us-
 gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": {
 "en-us": { "role": { "negatedLabel": "Investments in unconsolidated joint ventures", "label": "Payments to Acquire
 Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or
 advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary,
 affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a
 subsidiary (controlled entity)." } } }, "auth_ref": ["r44"] },
 "peak_PaymentsToAcquireLoansReceivableAndOther": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "PaymentsToAcquireLoansReceivableAndOther", "crdr":
 "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": {
 "en-us": { "role": { "negatedLabel": "Investments in loans receivable and other", "label": "Payments To Acquire
 Loans Receivable And Other", "documentation": "Payments To Acquire Loans Receivable And Other" } } },
 "auth_ref": [] }, "us-gaap_PaymentsToAcquireOtherRealEstate": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherRealEstate", "crdr": "credit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag":
 "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": {
 "negatedLabel": "Acquisitions of real estate", "label": "Payments to Acquire Other Real Estate", "documentation":
 "The cash outflow associated with the purchase of other real estate investments held by the entity for investment
 purposes not otherwise defined in the taxonomy." } } }, "auth_ref": ["r206"] }, "us-
 gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails
 "lang": { "en-us": { "role": { "terseLabel": "Funding for construction, tenant and other capital improvements",
 "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and
 capital improvements on property, plant and equipment (capital expenditures), software, and other intangible
 assets." } } }, "auth_ref": ["r288", "r1557", "r1558", "r1559"] }, "us-gaap_PaymentsToAcquireRealEstate": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PaymentsToAcquireRealEstate", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails":
 "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails": { "lang":
 { "en-us": { "role": { "terseLabel": "Payments to acquire real estate", "label": "Payments to Acquire Real Estate",
 "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it,
 including buildings, structures on it and so forth; includes real estate intended to generate income for the owner;
 excludes real estate acquired for use by the owner." } } }, "auth_ref": ["r206"] }, "us-
 gaap_PaymentsToDevelopRealEstateAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "PaymentsToDevelopRealEstateAssets", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":
 "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinuedo
 "lang": { "en-us": { "role": { "negatedLabel": "Development, redevelopment, and other major improvements of
 real estate", "terseLabel": "Development, redevelopment, and other major improvements of real estate", "label":
 "Payments to Develop Real Estate Assets", "documentation": "Payments to develop real estate assets is the
 process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities,
 subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow
 from investing activities." } } }, "auth_ref": ["r206"] }, "us-gaap_PaymentsToMinorityShareholders": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": {
 "negatedLabel": "Distributions to and purchase of noncontrolling interests", "label": "Payments to Noncontrolling
 Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to,
 reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } } },
 "auth_ref": { "r47" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers,
 Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } } }, "auth_ref": { "r1319" } },
 "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total
 Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } } }, "auth_ref": { "r1319"
 } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang":
 { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid
 Compensation Amount" } } } }, "auth_ref": { "r1311" } }, "ecd_PeoMember": { "xbrltype": "domainItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO
 [Member]" } } } }, "auth_ref": { "r1328" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label":
 "PEO Name" } } } }, "auth_ref": { "r1321" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation
 Amount", "label": "PEO Total Compensation Amount" } } } }, "auth_ref": { "r1310" } },
 "peak_PercentageOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "PercentageOfCarryingAmount", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "Percentage of carrying amount", "label": "Percentage Of Carrying Amount", "documentation":
 "Percentage Of Carrying Amount" } } } }, "auth_ref": { } },
 "peak_PercentageOfPerformanceMetricsDuringPerformancePeriod": { "xbrltype": "percentItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname":
 "PercentageOfPerformanceMetricsDuringPerformancePeriod", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails": { "lang": { "en-us": { "role":
 { "terseLabel": "Percentage of performance metrics during performance period", "label": "Percentage Of
 Performance Metrics During The Performance Period", "documentation": "Represents information pertaining to
 the percentage of performance metrics for the performance period which is multiplied to the number of units
 granted to the participant." } } } }, "auth_ref": { } }, "us-gaap_PerformingFinancingReceivableMember": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PerformingFinancingReceivableMember", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails": { "lang":
 { "en-us": { "role": { "terseLabel": "Performing loans", "label": "Performing Financial Instruments [Member]",
 "documentation": "Category status of financial instruments in which payments are received or paid on a timely
 basis in accordance with the terms of the contract. Financial instruments include, but are not limited to,
 financing receivables, loans, debt instruments, and investments." } } } }, "auth_ref": { "r280", "r281", "r282",
 "r1478" } }, "peak_PhysiciansRealtyTrustMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "PhysiciansRealtyTrustMember", "presentation": {
 "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails":
 "http://www.healthpeak.com/role/TheMergerNarrativeDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed",
 { "lang": { "en-us": { "role": { "terseLabel": "Physicians Realty Trust", "label": "Physicians Realty Trust
 [Member]", "documentation": "Physicians Realty Trust" } } } }, "auth_ref": { } }, "us-gaap_PlanNameAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis",
 "presentation": { "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": { "lang":
 { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation":
 "Information by plan name for share-based payment arrangement." } } } }, "auth_ref": { "r1519", "r1520", "r1521",
 "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533",
 "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544" } }, "us-
 gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PlanNameDomain", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for
 share-based payment arrangement." } } } }, "auth_ref": { "r1519", "r1520", "r1521", "r1522", "r1523", "r1524",
 "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536",
 "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544" } },
 "peak_PlannedMOBDemolitionTenantRelocationAndOtherCostsMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "PlannedMOBDemolitionTenantRelocationAndOtherCostsMember", "presentation": {
 "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails": { "lang": { "en-us": { "role": { "terseLabel":
 "Planned MOB Demolition, Tenant Relocation And Other Costs", "label": "Planned MOB Demolition, Tenant
 Relocation And Other Costs [Member]", "documentation": "Planned MOB Demolition, Tenant Relocation And
 Other Costs" } } } }, "auth_ref": { } }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjSPrvSvcCstMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments
Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": { "r1312" } },
 "ecd_PnsnAdjSPrvSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "PnsnAdjSPrvSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {
 "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost
[Member]" } } }, "auth_ref": { "r1368" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits
Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": {
 "r1311" } }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": {
 "http://www.healthpeak.com/role/FairValueMeasurementsDetails", "lang": { "en-us": { "role": { "terseLabel":
 "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation":
 "Measured at fair value for financial reporting purposes." } } }, "auth_ref": { "r840" } },
 "peak_PostCombinationExpenseAcceleratedVestingOfAcquireeEquityAwardsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "PostCombinationExpenseAcceleratedVestingOfAcquireeEquityAwardsMember", "presentation": {
 "http://www.healthpeak.com/role/TheMergerNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Post-
Combination Expense, Accelerated Vesting of Acquiree Equity Awards", "label": "Post-Combination Expense,
Accelerated Vesting of Acquiree Equity Awards [Member]", "documentation": "Post-Combination Expense,
Accelerated Vesting of Acquiree Equity Awards" } } }, "auth_ref": { } }, "us-gaap_ProceedsFromBankDebt": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromBankDebt",
 "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS":
 { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": {
 "en-us": { "role": { "terseLabel": "Issuances and borrowings of term loans, senior unsecured notes, and mortgage
debt", "label": "Proceeds from Bank Debt", "documentation": "The cash inflow from bank borrowing during the
year." } } }, "auth_ref": { "r46" } }, "us-gaap_ProceedsFromCollectionOfFinanceReceivables": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromCollectionOfFinanceReceivables", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "lang": { "en-us":
 { "role": { "terseLabel": "Principal repayments received", "label": "Proceeds from Collection of Finance
Receivables", "documentation": "The cash inflow associated with the collection of receivables arising from the
financing of goods and services." } } }, "auth_ref": { "r1429" } }, "us-
 gaap_ProceedsFromCollectionOfLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromCollectionOfLoansReceivable", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",
 "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",
 "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi
 ", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the collection of loans receivable", "label": "Proceeds
from Collection of Loans Receivable", "documentation": "The cash inflow associated with the collection, including
prepayments, of loans receivable issued for financing of goods and services." } } }, "auth_ref": { "r42" } },
 "peak_ProceedsFromDivestituresOfInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "ProceedsFromDivestituresOfInterestInJointVenture",
 "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS":
 { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } },
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": {
 "en-us": { "role": { "terseLabel": "Proceeds from the Callan Ridge JV transaction, net", "label": "Proceeds From
Divestitures Of Interest In Joint Venture", "documentation": "Proceeds From Divestitures Of Interest In Joint
Venture" } } }, "auth_ref": { } }, "peak_ProceedsFromDivestituresOfInterestInJointVenture2": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "ProceedsFromDivestituresOfInterestInJointVenture2", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": {
 "terseLabel": "Proceeds from the South San Francisco JVs transaction, net", "label": "Proceeds From Divestitures
Of Interest In Joint Venture2", "documentation": "Proceeds From Divestitures Of Interest In Joint Venture2" } } }
 }, "auth_ref": { } }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": {
 "terseLabel": "Proceeds from insurance recovery", "label": "Proceeds from Insurance Settlement, Investing
Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified
as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": { "r15",
 "r41" } }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag":
 "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": {
 "terseLabel": "Issuance of common stock and exercise of options, net of offering costs", "label": "Proceeds from
Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred
stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": { "r8", "r1021" } }, "us-
 gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-

gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }], "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS" }, "lang": { "en-us": { "role": {
 "terseLabel": "Borrowings under bank line of credit and commercial paper", "label": "Proceeds from Lines of
 Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but
 not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": {
 "r46", "r1434" } }, "us-gaap_ProceedsFromLoanOriginations1": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLoanOriginations1", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails" }, "lang": { "en-us":
 { "role": { "terseLabel": "Proceeds from loan originations", "label": "Proceeds from Loan Originations",
 "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a
 piece of real property) or lease origination." } } }, "auth_ref": { "r41" } }, "us-
 gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS" }, "lang": { "en-us": { "role": {
 "terseLabel": "Contributions from and issuance of noncontrolling interests", "label": "Proceeds from
 Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but
 is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } },
 "auth_ref": { "r45" } }, "peak_ProceedsFromNonrefundableEntranceFees": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname": "ProceedsFromNonrefundableEntranceFees",
 "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/DeferredRevenueScheduleofDeferredRevenueDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Proceeds from nonrefundable entrance fees", "label": "Proceeds From Nonrefundable
 Entrance Fees", "documentation": "Proceeds From Nonrefundable Entrance Fees" } } }, "auth_ref": { } }, "us-
 gaap_ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment", "crdr": "debit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS" }, "lang": { "en-us": { "role": {
 "verboseLabel": "Proceeds from sales/principal repayments on loans receivable and marketable debt securities",
 "label": "Proceeds from Principal Repayment, Loan and Lease, Held-for-Investment", "documentation": "The cash
 inflow from repayments of the balance excluding interest (principal) on loans receivable and leases held for
 investment purposes." } } }, "auth_ref": { "r42" } }, "us-
 gaap_ProceedsFromRealEstateAndRealEstateJointVentures": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRealEstateAndRealEstateJointVentures", "crdr":
 "debit", "presentation": {
 "http://www.healthpeak.com/role/InvestmentsinandAdvances toUnconsolidatedJointVenturesNarrativeDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds", "label": "Proceeds from Real Estate and Real Estate
 Joint Ventures", "documentation": "The cash inflow from the sale of real estate held-for-investment and real
 estate joint ventures." } } }, "auth_ref": { "r1380" } }, "us-gaap_ProceedsFromSaleOfBuildings": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfBuildings",
 "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2022DispositionsofRealEstate",
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2023DispositionsofRealEstate",
 "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstate",
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
 "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi",
 "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of buildings", "label": "Proceeds from Sale of
 Buildings", "documentation": "The cash inflow from sale of buildings." } } }, "auth_ref": { "r205" } }, "us-
 gaap_ProceedsFromSaleOfLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromSaleOfLeaseReceivables", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LeasesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Proceeds
 from sale of lease receivables", "label": "Proceeds from Sale of Lease Receivables", "documentation": "The cash
 inflow associated with the sale of receivables arising from the lease of real estate, equipment or other fixed
 assets for a specified time in exchange for payment, usually in the form of rent; excludes proceeds from sales-
 type lease transactions, which are classified as operating activities." } } }, "auth_ref": { "r43" } }, "us-
 gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "crdr": "debit",
 "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag":
 "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS" }, "lang": { "en-us": { "role": {
 "verboseLabel": "Proceeds from sales of real estate, net", "label": "Proceeds from Sale, Real Estate, Held-for-
 Investment", "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is
 part of an investing activity during the period." } } }, "auth_ref": { "r205" } }, "us-
 gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Proceeds received from options exercised", "label": "Proceeds from Stock Options Exercised",
 "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } },
 "auth_ref": { "r8", "r30" } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF OPERATIONS": { "parentTag": "us-
 gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF COMPREHENSIVEINCOMELOSS": {
 "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
 "weight": 1.0, "order": 1.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASHFLOWS": {

"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }],
 "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": {
 "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss), Including
 Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the
 period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r362", "r379", "r382", "r396", "r405", "r421", "r428", "r432", "r433", "r552", "r620", "r621", "r623", "r624",
 "r625", "r626", "r627", "r629", "r630", "r790", "r798", "r799", "r802", "r803", "r819", "r842", "r963", "r981",
 "r1027", "r1080", "r1098", "r1099", "r1211", "r1212", "r1255", "r1425", "r1508"] }, "peak_PropTechMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "PropTechMember",
 "presentation": ["http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "PropTech", "label": "PropTech [Member]", "documentation": "PropTech" } } }, "auth_ref":
 [] }, "peak_PropertiesHeldForSaleNumber": { "xbrltype": "integerItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "PropertiesHeldForSaleNumber", "presentation": ["http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued",
], "lang": { "en-us": { "role": { "terseLabel": "Number of properties classified as held for sale", "label": "Properties
 Held for Sale, Number", "documentation": "The number of properties held for sale at the reporting date." } } },
 "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]",
 "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not
 intended for resale." } } }, "auth_ref": ["r20", "r871"] }, "us-gaap_PropertyPlantAndEquipmentGross": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/LeasesDepreciationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel":
 "Corporate assets", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before
 accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business
 and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment,
 office equipment, and furniture and fixtures." } } }, "auth_ref": ["r218", "r364", "r977"] }, "us-
 gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]",
 "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to
 produce goods and services and not intended for resale. Examples include land, buildings, machinery and
 equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture
 and fixtures, and computer equipment and software." } } }, "auth_ref": ["r218", "r871"] }, "us-
 gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Property, plant and equipment, useful life", "label": "Property, Plant and Equipment,
 Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business
 and not intended for resale, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported
 fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery
 and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] },
 "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs
 Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r1309"] },
 "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
 "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } },
 "auth_ref": ["r1309"] }, "peak_QualifiedBusinessIncomeCodeSection199A": { "xbrltype": "perShareItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname": "QualifiedBusinessIncomeCodeSection199A",
 "presentation": ["http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Qualified business income for purpose of Code Section 199A (in
 dollars per share)", "label": "Qualified Business Income, Code Section 199A", "documentation": "Qualified
 Business Income, Code Section 199A" } } }, "auth_ref": [] }, "peak_QualifiedDividendIncomeCodeSection1h11": {
 "xbrltype": "perShareItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "QualifiedDividendIncomeCodeSection1h11", "presentation": ["http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails"], "lang": { "en-us": {
 "role": { "terseLabel": "Qualified dividend income for purposes of Code Section 1(h)(11) (in dollars per share)",
 "label": "Qualified Dividend Income, Code Section 1(h)(11)", "documentation": "Qualified Dividend Income, Code
 Section 1(h)(11)" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails",
 "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails",
 "http://www.healthpeak.com/role/InvestmentsinandAdvances to Unconsolidated Joint Ventures Schedule of Equity Meth",
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
 "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed",
], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement
 [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum,
 maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r316", "r318", "r320", "r321",

"r323", "r356", "r357", "r613", "r614", "r615", "r616", "r700", "r707", "r737", "r738", "r739", "r748", "r825",
 "r892", "r905", "r922", "r1002", "r1004", "r1016", "r1049", "r1050", "r1105", "r1107", "r1109", "r1110", "r1122",
 "r1157", "r1158", "r1183", "r1197", "r1205", "r1217", "r1218", "r1222", "r1223", "r1237", "r1245", "r1499",
 "r1512", "r1568", "r1597", "r1598", "r1599", "r1600", "r1601"], "srt_RangeMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails",
 "http://www.healthpeak.com/role/DebtTheMergerDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails",
 "http://www.healthpeak.com/role/InvestmentsinandAdvancesToUnconsolidatedJointVenturesScheduleofEquityMeth
 "http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
 "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails",
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
 "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
 }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement {Domain}", "label": "Statistical
 Measurement {Domain}", "documentation": "Statistical measurement. Includes, but is not limited to, minimum,
 maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r316", "r318", "r320", "r321",
 "r323", "r356", "r357", "r613", "r614", "r615", "r616", "r700", "r707", "r737", "r738", "r739", "r748", "r825",
 "r892", "r905", "r922", "r1002", "r1004", "r1016", "r1049", "r1050", "r1105", "r1107", "r1109", "r1110", "r1122",
 "r1157", "r1158", "r1183", "r1197", "r1205", "r1217", "r1218", "r1222", "r1223", "r1237", "r1245", "r1499",
 "r1512", "r1568", "r1597", "r1598", "r1599", "r1600", "r1601"] }, "us-gaap_RealEstateAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAbstract", "lang": { "en-us": {
 "role": { "terseLabel": "Real Estate {Abstract}", "label": "Real Estate {Abstract}" } } }, "auth_ref": { }, "us-
 gaap_RealEstateAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "RealEstateAccumulatedDepreciation", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 }, "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Depreciation", "periodStartLabel": "Balances at
 beginning of year", "periodEndLabel": "Balances at end of year", "label": "SEC Schedule, 12-28, Real Estate
 Companies, Investment in Real Estate, Accumulated Depreciation", "documentation": "Amount of accumulated
 depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring
 and holding investment real estate." } } }, "auth_ref": { "r1151"] }, "us-
 gaap_RealEstateAccumulatedDepreciationRealEstateSold": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "RealEstateAccumulatedDepreciationRealEstateSold", "crdr":
 "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 }, "lang": { "en-us": { "role": { "negatedLabel": "Sales and/or transfers to assets held for sale", "label": "SEC
 Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in
 Real Estate Sold", "documentation": "Amount of decrease to accumulated depreciation for real estate
 investments sold for entities with a substantial portion of business acquiring and holding investment real estate."
 } } }, "auth_ref": { "r1148"] }, "srt_RealEstateAndAccumulatedDepreciationAmountOfEncumbrances": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "crdr": "credit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 }, "lang": { "en-us": { "role": { "terseLabel": "Encumbrances as of Year end", "label": "SEC Schedule, 12-28, Real
 Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances",
 "documentation": "Amount of lien or mortgage outstanding on real estate investment properties for entities with
 a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": { "r326",
 "r1145"] }, "srt_RealEstateAndAccumulatedDepreciationByPropertyTable": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationByPropertyTable",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 }, "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real
 Estate and Accumulated Depreciation, by Property {Table}", "label": "SEC Schedule, 12-28, Real Estate
 Companies, Investment in Real Estate and Accumulated Depreciation, by Property {Table}", "documentation":
 "Disclosure of information about real estate investments and accompanying accumulated depreciation for
 entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": {
 "r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r1144", "r1145", "r1146", "r1147", "r1150",
 "r1151", "r1152", "r1153", "r1154"] }, "us-
 gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements", "crdr": "debit",
 "calculation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 { "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 }, "lang": { "en-us": { "role": { "terseLabel": "Buildings and Improvements", "label": "SEC Schedule, 12-28,
 Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Building and Improvements,
 Amount", "documentation": "Amount before accumulated depreciation of buildings and improvements for entities

with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": { "r1150" } }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLand", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Land and improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Land, Amount", "documentation": "Amount of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": { "r1150" } }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Gross Amount at Which Carried As of Year End", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract]", "auth_ref": { "peak_RealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisition", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Costs Capitalized Subsequent to Acquisition", "label": "Real Estate and Accumulated Depreciation, Costs Capitalized Subsequent to Acquisition", "documentation": "Carrying amount as of the balance sheet date of costs that were capitalized after acquisition, including property improvements and carrying costs (for example, real estate taxes and insurance), but excluding the initial purchase price." } } }, "auth_ref": { "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": { "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]", "documentation": "Information by name of property." } } }, "auth_ref": { "r325", "r330", "r1144", "r1149", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661" } }, "srt_RealEstateAndAccumulatedDepreciationDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]", "auth_ref": { "srt_RealEstateAndAccumulatedDepreciationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciation", "lang": { "en-us": { "role": { "terseLabel": "Schedule III: Real Estate and Accumulated Depreciation", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block]", "documentation": "The entire disclosure of real estate investments and associated accumulated depreciation for entities with a significant portion of their business acquiring and holding investment real estate." } } }, "auth_ref": { "r336", "r1155" } }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationInitialCostAbstract", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Initial Cost to Company", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost [Abstract]", "auth_ref": { "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Building and Improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements", "documentation": "Initial cost of buildings and improvements for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": { "r1146" } }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfLand":

{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfLand", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Land and improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land", "documentation": "Initial cost of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": { "r1146" } }, "us-gaap_RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationAmountthatTaxBasisofNetRe": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationAmountthatTaxBasisofNetRe", "lang": { "en-us": { "role": { "terseLabel": "Life on Which Depreciation in Latest Income Statement is Computed", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation", "documentation": "Useful life on which depreciation was computed for entities with a substantial portion of business acquiring and holding investment real estate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1154" } }, "srt_RealEstateAndAccumulatedDepreciationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationLineItems", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst", "lang": { "en-us": { "role": { "terseLabel": "Real Estate and Accumulated Depreciation", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r1144", "r1145", "r1146", "r1147", "r1150", "r1151", "r1152", "r1153", "r1154" } }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": { "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails": "http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]", "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center." } } }, "auth_ref": { "r325", "r330", "r1144", "r1149", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661" } }, "us-gaap_RealEstateCostOfRealEstateSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateCostOfRealEstateSold", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst", "lang": { "en-us": { "role": { "negatedLabel": "Sales and/or transfers to assets held for sale", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Cost of Investment in Real Estate Sold", "documentation": "Amount of real estate investments sold for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": { "r1148" } }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestments": "http://www.healthpeak.com/role/RealEstateInvestments", "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": { "r266", "r267", "r268", "r269", "r270", "r1156" } }, "peak_RealEstateFederalIncomeTaxBasisLessThanReportedNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateFederalIncomeTaxBasisLessThanReportedNetAssets", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationAmountthatTaxBasisofNetRe": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationAmountthatTaxBasisofNetRe", "lang": { "en-us": { "role": { "terseLabel": "Amount that the tax basis of the Company's net real estate is less than the reported amounts", "label": "Real Estate Federal Income Tax Basis Less than Reported Net Assets", "documentation": "The amount by which the tax basis of the entity's net real estate is less than the reported amounts as of year-end." } } }, "auth_ref": { } }, "us-gaap_RealEstateGrossAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateGrossAtCarryingValue", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst", "lang": { "en-us": { "role": { "totalLabel": "Total", "periodStartLabel": "Balances at beginning of year", "periodEndLabel": "Balances at end of year", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross", "documentation": "Amount, before accumulated depreciation, of real estate investment by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Excludes real estate not held as investment or interest." } } }, "auth_ref": { "r1150" } }, "us-gaap_RealEstateHeldforsale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateHeldforsale", "crdr": "debit", "presentation": {

"http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Real estate held-for-sale", "label": "Real Estate, Held-for-Sale", "documentation": "Amount of investment in land and building held for sale. Excludes real estate considered inventory." } } }, "auth_ref": { "r1604", "r1605" } }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "negatedTerseLabel": "Accumulated depreciation and amortization", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": { "r965" } }, "peak_RealEstateInvestmentPropertyAggregateCarryingValueBeforeImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateInvestmentPropertyAggregateCarryingValueBeforeImpairment", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate carrying value before impairment", "label": "Real Estate Investment Property, Aggregate Carrying Value Before Impairment", "documentation": "Real Estate Investment Property, Aggregate Carrying Value Before Impairment" } } }, "auth_ref": { } }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net real estate", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": { "r1604", "r1605" } }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyNetAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": { "role": { "terseLabel": "Real estate", "label": "Real Estate Investment Property, Net [Abstract]" } } }, "auth_ref": { } }, "us-gaap_RealEstateInvestmentTrustDistributionTaxStatusCapitalGainPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentTrustDistributionTaxStatusCapitalGainPerUnit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "parentTag": "peak_RealEstateInvestmentTrustDistributionTaxStatusPerUnit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Capital gains (in dollars per share)", "label": "Real Estate Investment Trust, Distribution Tax Status, Capital Gain, Per Unit", "documentation": "Per share or unit of distribution classified by tax status as capital gain for real estate investment trust (REIT)." } } }, "auth_ref": { "r1257" } }, "us-gaap_RealEstateInvestmentTrustDistributionTaxStatusOrdinaryIncomePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentTrustDistributionTaxStatusOrdinaryIncomePerUnit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "parentTag": "peak_RealEstateInvestmentTrustDistributionTaxStatusPerUnit", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary dividends (in dollars per share)", "label": "Real Estate Investment Trust, Distribution, Tax Status, Ordinary Income, Per Unit", "documentation": "Per share or unit of distribution classified by tax status as ordinary income for real estate investment trust (REIT)." } } }, "auth_ref": { "r1257" } }, "peak_RealEstateInvestmentTrustDistributionTaxStatusPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateInvestmentTrustDistributionTaxStatusPerUnit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Dividends (in dollars per share)", "label": "Real Estate Investment Trust, Distribution, Tax Status, Per Unit", "documentation": "Real Estate Investment Trust, Distribution, Tax Status, Per Unit" } } }, "auth_ref": { } }, "us-gaap_RealEstateInvestmentTrustDistributionTaxStatusReturnOfCapitalPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentTrustDistributionTaxStatusReturnOfCapitalPerUnit", "calculation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails": { "parentTag": "peak_RealEstateInvestmentTrustDistributionTaxStatusPerUnit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Nondividend distributions (in dollars per share)", "label": "Real Estate Investment Trust, Distribution, Tax Status, Return of Capital, Per Unit", "documentation": "Per share or unit of distribution classified by tax status as return of capital for real estate investment trust (REIT)." } } }, "auth_ref": { "r1257" } }, "us-gaap_RealEstateLiabilitiesAssociatedWithAssetsHeldForDevelopmentAndSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateLiabilitiesAssociatedWithAssetsHeldForDevelopmentAndSale", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued" }, "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to assets held for sale, net", "label": "Real Estate Liabilities Associated with Assets Held for Development and Sale", "documentation": "For banks, amount of all liabilities for which a financial institution is required to include in its calculation of net investment in real estate assets held for development or sale." } } }, "auth_ref": { } }, "us-gaap_RealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateLineItems", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",

"http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Line Items]", "label": "Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1157" } }, "us-gaap_RealEstatePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstatePolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Real Estate", "label": "Real Estate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise." } } }, "auth_ref": { "r0" } }, "peak_RealEstateRevenuesFromJointVentureAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateRevenuesFromJointVentureAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interests\u2019 share of consolidated joint venture total revenues", "label": "Real Estate Revenues From Joint Venture Attributable To Noncontrolling Interest", "documentation": "Real Estate Revenues From Joint Venture Attributable To Noncontrolling Interest" } } }, "auth_ref": { } }, "peak_RealEstateRevenuesFromJointVentureAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateRevenuesFromJointVentureAttributableToParent", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Healthpeak\u2019s share of unconsolidated joint venture total revenues", "label": "Real Estate Revenues From Joint Venture Attributable To Parent", "documentation": "Real Estate Revenues From Joint Venture Attributable To Parent" } } }, "auth_ref": { } }, "peak_RealEstateRevenuesFromJointVentureGovernmentGrantIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RealEstateRevenuesFromJointVentureGovernmentGrantIncome", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Healthpeak\u2019s share of unconsolidated joint venture government grant income", "label": "Real Estate Revenues From Joint Venture Government Grant Income", "documentation": "Real Estate Revenues From Joint Venture Government Grant Income" } } }, "auth_ref": { } }, "us-gaap_RealEstateTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateTable", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/RealEstateInvestments2024RealEstateInvestmentAcquisitionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Table]", "label": "Real Estate [Table]", "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions." } } }, "auth_ref": { "r1157" } }, "us-gaap_RealEstateTaxesAndInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateTaxesAndInsurance", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Real estate taxes", "label": "Real Estate Taxes and Insurance", "documentation": "The aggregate total of real estate taxes and insurance expense." } } }, "auth_ref": { "r195" } }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails"], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": { "r177", "r182" } }, "us-gaap_ReceivableWithImputedInterestDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableWithImputedInterestDiscount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized discount", "label": "Receivable with Imputed Interest, Discount", "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount." } } }, "auth_ref": { "r853", "r854", "r855", "r1224" } }, "us-gaap_ReceivableWithImputedInterestNetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableWithImputedInterestNetAmount", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Receivable with imputed interest", "label": "Receivable with Imputed Interest, Net Amount", "documentation": "The receivable or note face amount less the unamortized discount or premium." } } }, "auth_ref": { "r853", "r854", "r1224" } }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables [Abstract]", "label": "Receivables [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": { "r69", "r70" } }, "us-gaap_ReconciliationOfCarryingAmountOfRealEstateInvestmentsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfCarryingAmountOfRealEstateInvestmentsRollForward", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationSummaryofActivityforRealEst", "lang": { "en-us": { "role": { "terseLabel": "Real estate:", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "peak_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedNonCashAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedNonCashAdjustments", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Plus: Adjustments to NOI", "label": "Reconciliation Of Operating Profit Loss From Segments To Consolidated Non Cash Adjustments", "documentation": "Represents the addback of straight-line rents, DFL accretion, amortization of market lease intangibles and lease termination fees from segment portfolio income to consolidated net income." } } }, "auth_ref": { } }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": { "r68", "r70" } }, "us-gaap_ReconciliationOfRealEstateAccumulatedDepreciationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRealEstateAccumulatedDepreciationRollForward", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationSummaryofActivityforRealEst", "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation:", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": { "r1276", "r1287", "r1297", "r1330" } }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interests", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": { "r77", "r78", "r225", "r226" } }, "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres", "lang": { "en-us": { "role": { "terseLabel": "Redemption value", "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value", "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date." } } }, "auth_ref": { "r227" } }, "peak_RefundableEntranceFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":

"http://www.healthpeak.com/20241231", "localname": "RefundableEntranceFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": {

"http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 4.0 } },

"presentation": { "http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Refundable entrance fees", "label": "Refundable Entrance Fees, Current and Noncurrent", "documentation": "Refundable Entrance Fees, Current and Noncurrent" } } }, "auth_ref": { } }, "peak_RentalRevenuesAndResidentFeesAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RentalRevenuesAndResidentFeesAndServicesMember", "presentation": {

"http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Rental Revenues And Resident Fees And Services", "label": "Rental Revenues And Resident Fees And Services [Member]", "documentation": "Rental Revenues And Resident Fees And Services" } } }, "auth_ref": { } }, "peak_RepairsAndMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RepairsAndMaintenance", "crdr": "debit", "calculation": {

"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": {

"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Repairs and maintenance", "label": "Repairs And Maintenance", "documentation": "Repairs And Maintenance" } } }, "auth_ref": { } }, "us-gaap_RepaymentsOfBankDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfBankDebt", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } },

"presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt", "label": "Repayments of Bank Debt", "documentation": "The cash outflow to settle a bank borrowing during the year." } } }, "auth_ref": { "r208" } }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": { "r1430" } },

"us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": {

"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": {

"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedLabel": "Repayments under bank line of credit and commercial paper", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": { "r208", "r1434" } }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": {

"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe": "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails",

"http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesNarrativeDetails",

"http://www.healthpeak.com/role/LeasesTenantUpdatesDetails",

"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": { "r353", "r354", "r408", "r409", "r635", "r664", "r883", "r906", "r966", "r1167", "r1168" } }, "peak_ReserveForLoanLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ReserveForLoanLosses", "crdr": "credit", "calculation": {

"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails": { "parentTag": "peak_SECSchedule1229RealEstateCompaniesInvestmentinMortgageLoansonRealEstatePeriodDecrease", "weight": 1.0, "order": 1.0 } }, "presentation": {

"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reserve for loan losses", "label": "Reserve For Loan Losses", "documentation": "Reserve For Loan Losses" } } }, "auth_ref": { } }, "peak_ResidencyAgreementTermMaximum": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ResidencyAgreementTermMaximum", "presentation": {

"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Residency agreement term, maximum", "label": "Residency Agreement Term, Maximum", "documentation": "Represents the maximum period specified under the residency agreement." } } }, "auth_ref": { } }, "peak_ResidencyAgreementTermMinimum": { "xbrltype": "durationItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ResidencyAgreementTermMinimum", "presentation": {

"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Residency agreement term, minimum", "label": "Residency Agreement Term, Minimum", "documentation": "Represents the minimum period specified under the residency agreement." } } }, "auth_ref": { } }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": {

"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Adjustment", "label": "Revision of Prior Period, Adjustment [Member]", "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": { "r418", "r419", "r420", "r430", "r431", "r457", "r817", "r818", "r858", "r1381", "r1382", "r1383", "r1384", "r1389", "r1392", "r1393", "r1454" } }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": {

<http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed>
], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": ["r355", "r359", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r457", "r555", "r556", "r788", "r789", "r790", "r791", "r797", "r798", "r816", "r817", "r818", "r819", "r856", "r858", "r881", "r882", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1018", "r1454"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Text Block]" } } }, "auth_ref": ["r1277", "r1288", "r1298", "r1331"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Text Block]" } } }, "auth_ref": ["r1278", "r1289", "r1299", "r1332"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r1285", "r1296", "r1306", "r1339"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed"], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": ["r355", "r359", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r457", "r555", "r556", "r788", "r789", "r790", "r791", "r797", "r798", "r816", "r817", "r818", "r819", "r856", "r858", "r881", "r882", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1018", "r1454"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r48", "r251", "r363", "r401", "r971"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r48", "r363", "r401"] }, "peak_RestrictedCashAndCashEquivalentsIncludingDiscontinuedOperationsTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RestrictedCashAndCashEquivalentsIncludingDiscontinuedOperationsTotal", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinued", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashequivalentsandrestrictedcash"], "lang": { "en-us": { "role": { "totalLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Including Discontinued Operations, Total", "documentation": "Restricted Cash and Cash Equivalents, Including Discontinued Operations, Total" } } }, "auth_ref": [] }, "peak_RestrictedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "RestrictedSharesMember", "presentation": ["http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Shares", "label": "Restricted Shares [Member]", "documentation": "Restricted Shares" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails", "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a"

specified period of time or when specified performance conditions are met." } } }, "auth_ref": { } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "lang": { "en-us": { "role": { "terseLabel": "Resident fees and services", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r271", "r272", "r458", "r468", "r469", "r491", "r497", "r501", "r503", "r505", "r696", "r697", "r923" } }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": { "r303", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r1160" } }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.healthpeak.com/role/DeferredRevenue": { "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": { "r303", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r699" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "parentTag": "peak_AdjustedNetOperatingIncomeFromContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMeth", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "terseLabel": "Total revenues", "verboseLabel": "Total revenues for reportable segments", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r271", "r272", "r388", "r405", "r458", "r468", "r469", "r491", "r497", "r501", "r503", "r505", "r552", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r842", "r963", "r1177", "r1508" } }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsScheduleofResultsofDiscont": { "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { } }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { } }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Increase in ROU asset in exchange for new lease liability related to operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r867", "r1225" } }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties [Abstract]", "label": "Risks and Uncertainties [Abstract]", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r1348" } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r1348" } }, "peak_SECSchedule1228RealEstateCompaniesAccumulatedDepreciationOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SECSchedule1228RealEstateCompaniesAccumulatedDepreciationOther", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "SEC Schedule, 12-28, Real Estate Companies, Accumulated Depreciation Other", "documentation": "" } } }, "auth_ref": { } }, "peak_SECSchedule1228RealEstateCompaniesInvestmentInRealEstateAssetsAcquired": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1228RealEstateCompaniesInvestmentInRealEstateAssetsAcquired", "crdr": "debit", "presentation":
 {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "terseLabel": "Real estate assets acquired in connection with the Merger", "label":
 "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Assets Acquired", "documentation":
 "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Assets Acquired" } } }, "auth_ref": { } },
 "peak_SECSchedule1228RealEstateCompaniesInvestmentInRealEstateDeconsolidation": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1228RealEstateCompaniesInvestmentInRealEstateDeconsolidation", "crdr": "credit",
 "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "negatedTerseLabel": "Deconsolidation of real estate", "label": "SEC Schedule, 12-
 28, Real Estate Companies, Investment in Real Estate, Deconsolidation", "documentation": "SEC Schedule, 12-28,
 Real Estate Companies, Investment in Real Estate, Deconsolidation" } } }, "auth_ref": { } },
 "peak_SECSchedule1228RealEstateCompaniesInvestmentInRealEstateDevelopmentsAndImprovements": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1228RealEstateCompaniesInvestmentInRealEstateDevelopmentsAndImprovements", "crdr":
 "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "terseLabel": "Acquisition of real estate and development and improvements",
 "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Developments And
 Improvements", "documentation": "The total amount of real estate investments acquired through acquisition, the
 amount of real estate developed, and the improvements made to real estate investments during the period." } } },
 "auth_ref": { } }, "peak_SECSchedule1228RealEstateCompaniesInvestmentInRealEstateOther": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1228RealEstateCompaniesInvestmentInRealEstateOther", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "SEC Schedule, 12-28, Real Estate Companies,
 Investment in Real Estate, Other", "documentation": "" } } }, "auth_ref": { } },
 "peak_SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansOnRealEstateProceedsFromRepayment
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansOnRealEstateProceedsFromRepayment",
 "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Proceeds from repayment", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in
 Mortgage Loans on Real Estate, Proceeds From Repayment", "documentation": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Mortgage Loans on Real Estate, Proceeds From Repayment" } } }, "auth_ref": { } },
 "peak_SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansonRealEstatePeriodDecrease": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansonRealEstatePeriodDecrease", "crdr":
 "credit", "calculation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails":
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"
 I, "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deductions", "label": "SEC Schedule, 12-29, Real
 Estate Companies, Investment in Mortgage Loans on Real Estate, Period Decrease", "documentation": "SEC
 Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Decrease" } } },
 "auth_ref": { } },
 "peak_SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansonRealEstatePeriodIncrease": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECSchedule1229RealEstateCompaniesInvestmentInMortgageLoansonRealEstatePeriodIncrease", "crdr":
 "debit", "calculation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails":
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateReconciliationofMortgageLoansDetails"
 I, "lang": { "en-us": { "role": { "totalLabel": "Total additions", "label": "SEC Schedule, 12-29, Real Estate
 Companies, Investment in Mortgage Loans on Real Estate, Period Increase", "documentation": "SEC Schedule,
 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Increase" } } }, "auth_ref":
 { } }, "peak_SECScheduleIIIRealEstateAccumulatedDepreciationDeconsolidation": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "SECScheduleIIIRealEstateAccumulatedDepreciationDeconsolidation", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "negatedTerseLabel": "Deconsolidation of real estate", "label": "SEC Schedule III,
 Real Estate Accumulated Depreciation, Deconsolidation", "documentation": "SEC Schedule III, Real Estate
 Accumulated Depreciation, Deconsolidation" } } }, "auth_ref": { } }, "us-
 gaap_SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
 I", "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "SEC Schedule, 12-28, Real Estate
 Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense", "documentation":
 "Amount of depreciation expense of real estate investments for entities with a substantial portion of business
 acquiring and holding investment real estate." } } }, "auth_ref": { "r1148" } }, "us-
 gaap_SECScheduleIIIRealEstateWritedownOrReserveAmount": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "SECScheduleIIIRealEstateWritedownOrReserveAmount", "crdr":
 "debit", "presentation": {
 "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst

1. "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairments", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve, Amount", "documentation": "Amount of write-down or reserve recognized in the income statement on real estate investments for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": { "r1149" } },
"peak_SWFSHJVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231",
"localname": "SWFSHJVMember", "presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth
1. "lang": { "en-us": { "role": { "terseLabel": "SWF SH JV", "label": "SWF SH JV [Member]", "documentation":
"SWF SH JV" } } }, "auth_ref": { "1" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": {
"http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation":
"Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } },
"auth_ref": { "1" }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe
1. "lang": { "en-us": { "role": { "terseLabel": "Percentage of Total Company Revenues", "label": "Revenue
Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other
sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": { "r505",
"r1385" } }, "peak_SanDiego2478CAMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "SanDiego2478CAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
1. "lang": { "en-us": { "role": { "terseLabel": "2478 San Diego, CA", "label": "San Diego2478, CA [Member]",
"documentation": "N/a" } } }, "auth_ref": { "1" }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation":
"Information reported for future period. Excludes information expected to be reported in future period for effect
on historical fact." } } }, "auth_ref": { "r708", "r1405", "r1444" } }, "srt_ScenarioPreviouslyReportedMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScenarioPreviouslyReportedMember", "presentation": {
"http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed
1. "lang": { "en-us": { "role": { "terseLabel": "Previously Reported", "label": "Previously Reported [Member]",
"documentation": "Represents amount as previously reported before adjustment for retrospective application of
amendment to accounting standards, other change in accounting principle, correction of error, and other
revision." } } }, "auth_ref": { "r359", "r418", "r420", "r421", "r422", "r423", "r424", "r433", "r457", "r788", "r790",
"r791", "r797", "r798", "r816", "r817", "r818", "r856", "r858", "r1006", "r1007", "r1008", "r1009", "r1010",
"r1011", "r1012", "r1013", "r1014", "r1015", "r1018", "r1389", "r1390", "r1391", "r1392", "r1443", "r1454",
"r1474", "r1475", "r1565", "r1592", "r1593" } }, "srt_ScenarioUnspecifiedDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain",
"presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation":
"Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and
forecast. Excludes actual facts." } } }, "auth_ref": { "r355", "r434", "r708", "r1375", "r1444" } }, "us-
gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
"presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails",
"http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
"http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails",
"http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi
"http://www.healthpeak.com/role/LoansReceivableTheMergerDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Accounts and Financing Receivables [Table]", "label": "Accounts and Financing Receivables [Table]",
"documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not
limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": { "r177", "r182", "r507", "r1461"
1. "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": {
"http://www.healthpeak.com/role/LoansReceivableTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule
of Loans Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
"documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the
gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized
by current, noncurrent and unclassified receivables." } } }, "auth_ref": { "r177", "r182" } }, "us-
gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": {
"http://www.healthpeak.com/role/AccountsPayableAccruedLiabilitiesandOtherLiabilitiesTables" }, "lang": { "en-
us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of
Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a)
carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been
received) and payable to vendors for goods and services received that are used in an entity's business (accounts
payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used
to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if

longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r39", "r1582", "r1583"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r55"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails", "http://www.healthpeak.com/role/TheMergerNarrativeDetails", "http://www.healthpeak.com/role/TheMergerScheduleofConsiderationTransferredDetails", "http://www.healthpeak.com/role/TheMergerScheduleofProformaFinancialInformationDetails", "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r91", "r93", "r794"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": { "http://www.healthpeak.com/role/TheMergerTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Consideration Transferred", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": ["r91", "r93"] }, "peak_ScheduleOfCapitalImprovementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfCapitalImprovementsTableTextBlock", "presentation": { "http://www.healthpeak.com/role/RealEstateInvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Capital Improvements", "label": "Schedule of Capital Improvements [Table Text Block]", "documentation": "Tabular disclosure of the amounts of funding, during the period, for construction, tenant and other capital improvements by segment." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Tax Expense (Benefit) From Continuing Operations", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1549"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.healthpeak.com/role/DebtTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Senior Unsecured Notes", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "peak_ScheduleOfDeferredRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfDeferredRevenueTableTextBlock", "presentation": { "http://www.healthpeak.com/role/DeferredRevenueTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Revenue", "label": "Schedule of Deferred Revenue [Table Text Block]", "documentation": "Schedule of Deferred Revenue" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": { "http://www.healthpeak.com/role/DeferredTaxAssetsAndLiabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of deferred tax assets and liabilities." } } }, "auth_ref": [] } }

ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": {
"http://www.healthpeak.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Significant Components of the Company's Deferred Tax Asset and Liabilities", "label": "Schedule of Deferred Tax
Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net
deferred tax asset or liability recognized in an entity's statement of financial position, including the following:
the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized
for deferred tax assets." } } }, "auth_ref": { "r1547" } }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDerivativeInstrumentsTextBlock", "presentation": {
"http://www.healthpeak.com/role/DerivativeFinancialInstrumentsTables" }, "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text
Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives
on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include
a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged
item, inception date, maturity date, or other relevant item." } } }, "auth_ref": { "r28", "r113", "r114", "r116",
"r118", "r121", "r124", "r126", "r128" } }, "us-
gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDi
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclos
"presentation": { "http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsTables" },
"lang": { "en-us": { "role": { "terseLabel": "Summary of Dispositions of Real Estate and Discontinued Operations",
"label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular
disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation,
disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually
significant component." } } }, "auth_ref": { "r23", "r31", "r36", "r140", "r149", "r150", "r151", "r152", "r153",
"r157", "r159", "r160", "r220" } }, "peak_ScheduleOfDividendsAndDistributionsTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"ScheduleOfDividendsAndDistributionsTableTextBlock", "presentation": {
"http://www.healthpeak.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Common Stock Distributions", "label": "Schedule of Dividends And Distributions [Table Text Block]",
"documentation": "Schedule Of Dividends And Distributions [Table Text Block] } } }, "auth_ref": { }, "us-
gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"presentation": { "http://www.healthpeak.com/role/EarningsPerCommonShareTables" }, "lang": { "en-us": { "role":
{ "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share", "label": "Schedule of
Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's
basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of
the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r1447"
} }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": {
"http://www.healthpeak.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Reconciliation of Income Tax Expense at Statutory Rates to the Actual Income Tax Expense Recorded", "label":
"Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure
of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense
attributable to continuing operations for the year to the amount of income tax expense that would result from
applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": {
"r757", "r1210", "r1546" } }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperations2024DispositionsofRealEstate
"http://www.healthpeak.com/role/DispositionsofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinued
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails",
"http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by
name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r548",
"r549", "r551", "r786", "r1376", "r1377", "r1378", "r1552", "r1553", "r1554", "r1555" } }, "us-
gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable
"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails",
"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinuedo
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label":
"Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": { "r405", "r548", "r549", "r551", "r552",
"r842" } }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancestoUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",

["http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable"](http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesScheduleofGovernmentGrantReceivable)
["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails"](http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails)
["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued"](http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued)
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": { "r362", "r405", "r548", "r549", "r551", "r552", "r842" } }, "peak_ScheduleOfExpectedAmortizationOfIntangibleAssetsAndIntangibleLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfExpectedAmortizationOfIntangibleAssetsAndIntangibleLiabilitiesTableTextBlock", "presentation": { "http://www.healthpeak.com/role/IntangiblesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Aggregate Amortization of Intangible Assets and Liabilities for Each of the Five Succeeding Fiscal Years and Thereafter", "label": "Schedule of Expected Amortization of Intangible Assets and Intangible Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the estimated aggregate amortization expense expected to be recorded in succeeding fiscal years for intangible assets and liabilities." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on financing receivable." } } }, "auth_ref": { "r308", "r1477" } }, "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable", "presentation": { "http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]", "label": "Financing Receivable, Credit Quality Indicator [Table]", "documentation": "Disclosure of information about credit quality indicator for financing receivable." } } }, "auth_ref": { "r281", "r1186", "r1478" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.healthpeak.com/role/IntangiblesEstimatedAggregateAmortizationofIntangibleAssetsandLiabilitiesDetails", "http://www.healthpeak.com/role/IntangiblesNarrativeDetails", "http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": { "r587", "r593", "r595", "r596", "r597", "r924", "r1159", "r1190" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.healthpeak.com/role/IntangiblesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Lease Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r1190", "r1490" } }, "peak_ScheduleOfFiniteLivedIntangibleLiabilitiesByMajorClassTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfFiniteLivedIntangibleLiabilitiesByMajorClassTableTextBlock", "presentation": { "http://www.healthpeak.com/role/IntangiblesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Lease Liabilities", "label": "Schedule of Finite Lived Intangible Liabilities by Major Class [Table Text Block]", "documentation": "Tabular disclosure of liabilities, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { } }, "peak_ScheduleOfFiniteLivedIntangibleAssetsAndBelowMarketLeaseAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAndBelowMarketLeaseAmortizationExpenseTableTextBlock", "presentation": { "http://www.healthpeak.com/role/IntangiblesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortization of Deferred Lease Costs and Acquisition Related Intangibles", "label": "Schedule Of Finite-lived Intangible Assets And Below Market Lease Amortization Expense [Table Text Block]", "documentation": "Schedule Of Finite-lived Intangible Assets And Below Market Lease Amortization Expense [Table Text Block]" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": { "http://www.healthpeak.com/role/IntangiblesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": { "r1189", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489" } }, "peak_ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ScheduleOfGovernmentGrantReceivablesCARESActTableTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Government Grant Receivables CARES Act", "label": "Schedule Of Government Grant Receivables CARES Act [Table Text Block]", "documentation": "Schedule Of Government Grant Receivables CARES Act" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Asset, Held and Used [Table]", "label": "Impaired Long-Lived Asset, Held and Used [Table]", "documentation": "Disclosure of information about impairment of long-lived asset held and used. Includes, but is not limited to, description of impaired long-lived asset, facts and circumstances leading to impairment, amount of impairment loss, income statement caption that includes impairment loss, method of fair value determination, and segment in which impaired long-lived asset is reported." } } }, "auth_ref": { "r74" } }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": { "http://www.healthpeak.com/role/DebtTables" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of Stated Debt Maturities and Scheduled Principal Repayments", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": { "r21" } }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": { "http://www.healthpeak.com/role/TheMergerTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": { "r239" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r65", "r66", "r67" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information for the Reportable Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": { "r65", "r66", "r67" } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails", "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails", "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails", "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r710", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740" } }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": { "http://www.healthpeak.com/role/CompensationPlansTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit and LTIP Unit activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct", "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": { "r79", "r80", "r81", "r82", "r83", "r84", "r224", "r229", "r230", "r231", "r370", "r371", "r372", "r461", "r662", "r663", "r664", "r666", "r669", "r674", "r676", "r1021", "r1022", "r1023", "r1024", "r1197", "r1374", "r1433" } }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Other Common Stock Activities", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": { "r34", "r76", "r79", "r80", "r81", "r82", "r83", "r84", "r175", "r176", "r229", "r230", "r231" } }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": {
<http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails> }, "lang": {
"en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "label":
"Subsidiary or Equity Method Investee, Sale of Stock [Table]", "documentation": "Disclosure of information about
sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but
is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref":
[] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname":
"ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": {
<http://www.healthpeak.com/role/IncomeTaxesTables> }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table
Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref":
["r763", "r1209"] }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "<http://fasb.org/srt/2024>", "localname":
"ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "presentation": {
<http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccounts> }, "lang": { "en-us": { "role": {
"terseLabel": "Schedule H: Valuation and Qualifying Accounts", "label": "SEC Schedule, 12-09, Schedule of
Valuation and Qualifying Accounts Disclosure [Table Text Block]", "documentation": "The entire disclosure for
valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r315", "r417"] },
"peak_ScheduleOfVariableInterestEntitiesIncludedInTheBalanceSheetTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "<http://www.healthpeak.com/20241231>", "localname":
"ScheduleOfVariableInterestEntitiesIncludedInTheBalanceSheetTableTextBlock", "presentation": {
<http://www.healthpeak.com/role/VariableInterestEntitiesTables> }, "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Consolidated Assets and Liabilities of Variable Interest Entities", "label": "Schedule Of Variable
Interest Entities Included In The Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the
VIE's total asset and liabilities included in the consolidated balance sheet." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "[http://fasb.org/us-
gaap/2024](http://fasb.org/us-

gaap/2024)", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": {
<http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails>,
<http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails>,
<http://www.healthpeak.com/role/VariableInterestEntitiesScheduleOfVariableInterestEntitiesDetails> }, "lang": {
"en-us": { "role": { "terseLabel": "Variable Interest Entity [Table]", "label": "Variable Interest Entity [Table]",
"documentation": "Disclosure of information about variable interest held, whether or not such variable interest
entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": ["r104", "r105", "r106", "r108",
"r110", "r800", "r801", "r804", "r805", "r901", "r902", "r903"] }, "us-
gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
<http://fasb.org/us-gaap/2024>, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": {
<http://www.healthpeak.com/role/VariableInterestEntitiesTables> }, "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Variable Interest Entities", "label": "Schedule of Variable Interest Entities [Table Text Block]",
"documentation": "Tabular disclosure of the significant judgments and assumptions made in determining
whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined)
to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate
(as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its
liabilities reported by an entity in its statement of financial position, including the carrying amounts of such
assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how
involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of
recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general
credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit
arrangements and implicit variable interests, if any, that could require the entity to provide financial support to
the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the
entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant
factors considered and judgments made in determining that the power to direct the activities of a VIE that most
significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and
classification of assets and liabilities of the VIE included in the statement of financial position; the entity's
maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum
exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying
amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity
arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of
the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support
(explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the
entity intends to provide that support, including the type and amount of the support and the primary reasons for
providing the support; and supplemental information the entity determines necessary to provide." } } },
"auth_ref": ["r104", "r105", "r106", "r108", "r110"] }, "peak_ScheduleOfTenantPurchaseOptionsTableTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "<http://www.healthpeak.com/20241231>", "localname":
"ScheduleOfTenantPurchaseOptionsTableTextBlock", "presentation": {
<http://www.healthpeak.com/role/LeasesTables> }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Tenant
Purchase Options", "label": "Schedule of Tenant Purchase Options [Table Text Block]", "documentation":
"Schedule of Tenant Purchase Options [Table Text Block]" } } }, "auth_ref": [] }, "us-
gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
<http://fasb.org/us-gaap/2024>, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"presentation": { <http://www.healthpeak.com/role/ConcentrationOfCreditRiskTables> }, "lang": { "en-us": { "role":
{ "terseLabel": "Schedule of Concentration of Credit Risk", "label": "Schedules of Concentration of Risk, by Risk
Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark
to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r57", "r58",
"r60", "r61", "r134", "r250"] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri":
<http://fasb.org/us-gaap/2024>, "localname": "SecuredDebt", "crdr": "credit", "calculation": {
<http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS>: { "parentTag": "us-gaap_Liabilities",
"weight": 1.0, "order": 4.0 } }, "presentation": {

["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS"](http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS),
["http://www.healthpeak.com/role/FairValueMeasurementsDetails"](http://www.healthpeak.com/role/FairValueMeasurementsDetails),
["http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails"](http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails)], "lang": { "en-us": {
"role": { "terseLabel": "Mortgage debt", "verboseLabel": "Mortgage debt", "label": "Secured Debt",
"documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of
collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if
longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of
the borrower." } } }, "auth_ref": { "r33", "r258", "r1608" } }, "us-gaap_SecuredDebtMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": {
["http://www.healthpeak.com/role/DebtMortgageDebtDetails"](http://www.healthpeak.com/role/DebtMortgageDebtDetails),
["http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails"](http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Mortgage Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt
obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } },
"auth_ref": { } }, "peak_SecuredMortgageLoans1Member": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname": "SecuredMortgageLoans1Member", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails)], "lang": { "en-us":
{ "role": { "terseLabel": "Secured Mortgage Loans 1", "label": "Secured Mortgage Loans 1 [Member]",
"documentation": "Secured Mortgage Loans 1" } } }, "auth_ref": { } }, "peak_SecuredMortgageLoansMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"SecuredMortgageLoansMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails"](http://www.healthpeak.com/role/LoansReceivableLoanLossesDetails),
["http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails"](http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi),
["http://www.healthpeak.com/role/LoansReceivableTheMergerDetails"](http://www.healthpeak.com/role/LoansReceivableTheMergerDetails)], "lang": { "en-us": { "role": {
"verboseLabel": "Secured loans", "terseLabel": "Secured Mortgage Loans", "netLabel": "Secured Loans", "label":
"Secured Mortgage Loans [Member]", "documentation": "Secured Mortgage Loans" } } }, "auth_ref": { } },
"peak_SecuredOvernightFinancingRateSOFRFirstTwoYearsMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.healthpeak.com/20241231"](http://www.healthpeak.com/20241231), "localname":
"SecuredOvernightFinancingRateSOFRFirstTwoYearsMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR), First Two Years", "label":
"Secured Overnight Financing Rate (SOFR), First Two Years [Member]", "documentation": "Secured Overnight
Financing Rate (SOFR), First Two Years" } } }, "auth_ref": { } },
"peak_SecuredOvernightFinancingRateSOFRLastEighteenMonthsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname":
"SecuredOvernightFinancingRateSOFRLastEighteenMonthsMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR), Last Eighteen Months",
"label": "Secured Overnight Financing Rate (SOFR), Last Eighteen Months [Member]", "documentation":
"Secured Overnight Financing Rate (SOFR), Last Eighteen Months" } } }, "auth_ref": { } },
"peak_SecuredOvernightFinancingRateSOFROvernightIndexSwapRateFirstSixMonthsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"SecuredOvernightFinancingRateSOFROvernightIndexSwapRateFirstSixMonthsMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap
Rate, First Six Months", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, First Six
Months [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate,
First Six Months" } } }, "auth_ref": { } },
"peak_SecuredOvernightFinancingRateSOFROvernightIndexSwapRateLastSixMonthsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"SecuredOvernightFinancingRateSOFROvernightIndexSwapRateLastSixMonthsMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi)
], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap
Rate, Last Six Months", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate, Last Six
Months [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate,
Last Six Months" } } }, "auth_ref": { } }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SecuredOvernightFinancingRateSofrMember", "presentation": {
["http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails"](http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails),
["http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi"](http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi),
["http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails"](http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR)
[Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S.
Treasury bond as collateral." } } }, "auth_ref": { "r1563" } }, "dei_Security12bTitle": { "xbrltype":
"securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": {
["http://www.healthpeak.com/role/Cover"](http://www.healthpeak.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": {
"r1258" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri":
["http://xbrl.sec.gov/dei/2024"](http://xbrl.sec.gov/dei/2024), "localname": "SecurityExchangeName", "presentation": {
["http://www.healthpeak.com/role/Cover"](http://www.healthpeak.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name",
"label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } },
"auth_ref": { "r1261" } }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentContinuingOperationsMember", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe
"http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails",
"http://www.healthpeak.com/role/LeasesNarrativeDetails",
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst
"http://www.healthpeak.com/role/ScheduleHIValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role":
{ "terseLabel": "Continuing Operations", "label": "Continuing Operations [Member]", "documentation":
"Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": { } }, "us-
gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIValuationandQualifyingAccountsDetails",
"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinuedo
}, "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations
[Member]", "documentation": "Component or group of components representing strategic shift that has or will
have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means
other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as
held-for-sale." } } }, "auth_ref": { "r12", "r141", "r142", "r143" } }, "us-gaap_SegmentDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinue
"http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails",
"http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesScheduleofEquityMeth
"http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails",
"http://www.healthpeak.com/role/LeasesNarrativeDetails",
"http://www.healthpeak.com/role/LeasesTenantUpdatesDetails",
"http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails",
"http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
"http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails",
"http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails",
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
"http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails",
"http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity
that engage in business activities from which they may earn revenue and incur expenses, including transactions
with other components of the same entity." } } }, "auth_ref": { "r271", "r272", "r273", "r274", "r458", "r464",
"r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r482",
"r483", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r499", "r505", "r577", "r578", "r579", "r580",
"r581", "r582", "r583", "r584", "r585", "r597", "r608", "r609", "r991", "r992", "r993", "r994", "r995", "r996",
"r997", "r998", "r999", "r1000", "r1001", "r1174", "r1177", "r1178", "r1189", "r1239", "r1612", "r1616", "r1617",
"r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629",
"r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641",
"r1642", "r1643" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area."
} } }, "auth_ref": { "r317", "r319", "r322", "r324", "r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334",
"r335", "r337", "r503", "r504", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935",
"r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949",
"r950", "r951", "r952", "r953", "r954", "r955", "r1042", "r1045", "r1047", "r1106", "r1108", "r1111", "r1125",
"r1133", "r1144", "r1145", "r1146", "r1147", "r1150", "r1151", "r1152", "r1153", "r1154", "r1162", "r1198",
"r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1238", "r1245", "r1516", "r1612",
"r1616", "r1617", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628",
"r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640",
"r1641", "r1642", "r1643" } }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": {
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe

["http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails"](http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails),
["http://www.healthpeak.com/role/LeasesNarrativeDetails"](http://www.healthpeak.com/role/LeasesNarrativeDetails),
["http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst"](http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationSummaryofActivityforRealEst),
["http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails"](http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails),
["http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinuedo"](http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinuedo)
l, "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } },
"auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAssetReconcilingItemLineItems", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails", "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Segment Disclosure", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosures" } }, "lang": { "en-us": { "role": { "terseLabel": "Segment Disclosures", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r274", "r458", "r463", "r464", "r465", "r466", "r467", "r480", "r482", "r483", "r495", "r496", "r497", "r498", "r499", "r501", "r502", "r505", "r1172", "r1175", "r1176", "r1177", "r1179", "r1181", "r1182"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails", "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationRevenueAbstract", "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]", "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Other segment items", "label": "Segment Reporting, Other Segment Item, Amount", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": ["r458", "r482", "r483", "r497", "r1177"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r484", "r485", "r486", "r487", "r488", "r489", "r490", "r500", "r503", "r1173", "r1174", "r1180"] }, "peak_SellerFinancingProvidedOnDispositionOfRealEstateAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SellerFinancingProvidedOnDispositionOfRealEstateAsset", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Seller financing provided on disposition of real estate assets (see Note 8)", "label": "Seller Financing Provided On Disposition of Real Estate Asset", "documentation": "Seller Financing Provided On Disposition of Real Estate Asset" } } }, "auth_ref": [] }, "peak_SeniorHousingOperatingPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorHousingOperatingPortfolioMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi" } }, "lang": { "en-us": { "role": { "terseLabel": "Senior Housing Operating Portfolio", "label": "Senior Housing Operating Portfolio [Member]", "documentation": "Represent senior housing operating portfolio." } } }, "auth_ref": [] }, "peak_SeniorUnsecuredNotes340Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredNotes340Member", "presentation": { "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes 3.40%", "label": "Senior Unsecured Notes 3.40% [Member]", "documentation": "Senior Unsecured Notes 3.40%" } } }, "auth_ref": [] }, "peak_SeniorUnsecuredNotes525Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredNotes525Member", "presentation": {

"http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes 5.25%", "label": "Senior Unsecured Notes 5.25% [Member]", "documentation": "Senior Unsecured Notes 5.25% } } }, "auth_ref": [] }, "peak_SeniorUnsecuredNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredNotesDue2027Member", "presentation": ["http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes Due 2027", "label": "Senior Unsecured Notes Due 2027 [Member]", "documentation": "Senior Unsecured Notes Due 2027" } } }, "auth_ref": [] }, "peak_SeniorUnsecuredNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredNotesDue2028Member", "presentation": ["http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes Due 2028", "label": "Senior Unsecured Notes Due 2028 [Member]", "documentation": "Senior Unsecured Notes Due 2028" } } }, "auth_ref": [] }, "peak_SeniorUnsecuredNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredNotesDue2031Member", "presentation": ["http://www.healthpeak.com/role/DebtTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes Due 2031", "label": "Senior Unsecured Notes Due 2031 [Member]", "documentation": "Senior Unsecured Notes Due 2031" } } }, "auth_ref": [] }, "peak_SeniorUnsecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeniorUnsecuredTermLoanMember", "presentation": ["http://www.healthpeak.com/role/DebtTheMergerDetails", "http://www.healthpeak.com/role/DerivativeFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Term Loan", "label": "Senior Unsecured Term Loan [Member]", "documentation": "Senior Unsecured Term Loan" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r19"] }, "peak_SeveranceExpenseDueToDualTriggerSeveranceArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeveranceExpenseDueToDualTriggerSeveranceArrangementsMember", "presentation": ["http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance Expense Due to Dual-Trigger Severance Arrangements", "label": "Severance Expense Due To Dual-Trigger Severance Arrangements [Member]", "documentation": "Severance Expense Due To Dual-Trigger Severance Arrangements" } } }, "auth_ref": [] }, "peak_SeveranceExpenseRelatedToEliminationOfCertainPositionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SeveranceExpenseRelatedToEliminationOfCertainPositionsMember", "presentation": ["http://www.healthpeak.com/role/TheMergerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance Expense Related to Elimination of Certain Positions", "label": "Severance Expense Related To Elimination Of Certain Positions [Member]", "documentation": "Severance Expense Related To Elimination Of Certain Positions" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation amortization expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r18"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": ["http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated cost", "label": "Share-Based Payment Arrangement, Accelerated Cost", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based awards, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r1206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited", "presentation": ["http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r731"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitu~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value (in dollars per~~
~~share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments~~
~~Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average~~
~~fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not~~
~~exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r731" } },~~
~~"peak_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGr~~
~~f "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantD~~
~~"crdr": "credit", "presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, "lang": { "en-us": { "role":~~
~~{ "terseLabel": "Total grant date fair value", "label": "Share-Based Compensation Arrangement By Share-Based~~
~~Payment Award, Equity Instruments Other Than Options, Grant Date Fair Value", "documentation": "Share-Based~~
~~Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grant Date~~
~~Fair Value" } } }, "auth_ref": { } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGr~~
~~f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsI~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation~~
~~Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",~~
~~"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for~~
~~example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } },~~
~~"auth_ref": { "r729" } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGr~~
~~f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsI~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Grant Date Fair Value (in dollars per~~
~~share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments~~
~~Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted~~
~~average fair value at grant date for nonvested equity-based awards issued during the period on other than stock~~
~~(or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,~~
~~performance target plan)." } } }, "auth_ref": { "r729" } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo~~
~~f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvest~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at the beginning of the period (in shares)",~~
~~"periodEndLabel": "Unvested at the end of the period (in shares)", "label": "Share-Based Compensation~~
~~Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",~~
~~"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit)~~
~~options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r726", "r727" } },~~
~~"us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo~~
~~f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvest~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "terseLabel": "Unvested restricted stock and performance restricted stock units~~
~~activity", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments~~
~~Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a~~
~~reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo~~
~~f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvest~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at the beginning of the period, Weighted Average~~
~~Grant Date Fair Value (in dollars per share)", "periodEndLabel": "Unvested at the end of the period, Weighted~~
~~Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by~~
~~Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date~~
~~Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-~~
~~based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r726", "r727" } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNo~~
~~f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvest~~
~~"presentation":-~~
~~"http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"~~
~~}, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label":~~
~~"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than~~
~~Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": { } }, "us-~~
~~gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVes~~

{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"
 }, { "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation
 Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
 "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that
 vested during the reporting period." } } }, "auth_ref": { "r730" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVes
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, { "lang": { "en-us": { "role":
 { "terseLabel": "Total fair values (at vesting) of restricted stock and restricted stock units vested", "label":
 "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
 Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee
 gained the right by satisfying service and performance requirements, to receive or retain shares or units, other
 instruments, or cash." } } }, "auth_ref": { "r733" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVes
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails"
 }, { "lang": { "en-us": { "role": { "terseLabel": "Vested, Weighted Average Grant Date Fair Value (in dollars per
 share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
 Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted
 average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option
 plan for which the grantee gained the right during the reporting period, by satisfying service and performance
 requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the
 arrangement." } } }, "auth_ref": { "r730" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
 { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "Postvesting restrictions", "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions", "documentation":
 "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested
 awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in
 effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the
 sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's
 fair value." } } }, "auth_ref": { "r740" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
 { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated
 dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying
 shares over the option's term." } } }, "auth_ref": { "r738" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
 { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free
 interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r739" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatility",
 { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatility",
 "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "Volatility rate", "label": "Share-Based Compensation Arrangement by Share-
 Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of
 weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": {
 "r737" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {
 "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails",
 "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails",
 "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails",
 "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails",
 "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails" }, { "lang": { "en-us": { "role": {
 "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label":
 "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line
 items represent financial concepts included in a table. These concepts are used to disclose reportable
 information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {
 "r710", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726",
 "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740" } },
 "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {

```

"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
  "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
  "presentation": {
    "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": {
      "en-us": {
        "role": {
          "terseLabel": "Maximum number of shares reserved for awards (in shares)",
          "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
          "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } },
    "auth_ref": {
      "r1207": {
        "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
          "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
          "presentation": {
            "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": {
              "en-us": {
                "role": {
                  "terseLabel": "Maximum number of shares available for future awards (in shares)",
                  "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
                  "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } },
                "auth_ref": {
                  "r87": {
                    "peak_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsR": {
                      "xbrltype": "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsRestr":
                    "presentation": {
                      "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": {
                        "en-us": {
                          "role": {
                            "terseLabel": "Maximum number of shares available for future awards to be issued as restricted stock and performance restricted stock unit (in shares)",
                            "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available for Grant as Restricted Stock and Performance Restricted Stock Units",
                            "documentation": "This element represents the number of shares available for grant which may be issued as restricted stock and performance restricted stock units." } } },
                          "auth_ref": {
                            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
                              "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
                              "presentation": {
                                "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails": {
                                  "en-us": {
                                    "role": {
                                      "terseLabel": "Number of stock options shares outstanding (in shares)",
                                      "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
                                      "documentation": "Number of options outstanding, including both vested and non-vested options." } } },
                                    "auth_ref": {
                                      "r718": {
                                        "r719": {
                                          "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
                                            "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
                                            "presentation": {
                                              "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails": {
                                                "http://www.healthpeak.com/role/CompensationPlansScheduleofRestrictedStockUnitandLTIPUnitactivityDetails": {
                                                  "http://www.healthpeak.com/role/CompensationPlansStockOptionsDetails": {
                                                    "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {
                                                      "en-us": {
                                                        "role": {
                                                          "terseLabel": "Award Type [Domain]",
                                                          "label": "Award Type [Domain]",
                                                          "documentation": "Award under share-based payment arrangement." } } },
                                                        "auth_ref": {
                                                          "r715": {
                                                            "r716": {
                                                              "r717": {
                                                                "r718": {
                                                                  "r719": {
                                                                    "r720": {
                                                                      "r721": {
                                                                        "r722": {
                                                                          "r723": {
                                                                            "r724": {
                                                                              "r725": {
                                                                                "r726": {
                                                                                  "r727": {
                                                                                    "r728": {
                                                                                      "r729": {
                                                                                        "r730": {
                                                                                          "r731": {
                                                                                            "r732": {
                                                                                              "r733": {
                                                                                                "r734": {
                                                                                                  "r735": {
                                                                                                    "r736": {
                                                                                                      "r737": {
                                                                                                        "r738": {
                                                                                                          "r739": {
                                                                                                            "r740": {
                                                                                                              "peak_ShareBasedCompensationByShareBasedPaymentAwardSharesWithheldToOffsetTaxWithholdingObligations": {
                                                                                                                "xbrltype": "sharesItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ShareBasedCompensationByShareBasedPaymentAwardSharesWithheldToOffsetTaxWithholdingObligations",
                                                                                                                "presentation": {
                                                                                                                  "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails": {
                                                                                                                    "en-us": {
                                                                                                                      "role": {
                                                                                                                        "terseLabel": "Shares withheld to offset tax withholding obligations (in shares)",
                                                                                                                        "label": "Share-Based Compensation By Share-Based Payment Award, Shares Withheld to Offset Tax Withholding Obligations",
                                                                                                                        "documentation": "Represents the number of shares withheld by the reporting entity to offset tax withholding obligations of participants." } } },
                                                                                                                      "auth_ref": {
                                                                                                                        "srt_ShareRepurchaseProgramAxis": {
                                                                                                                          "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis",
                                                                                                                          "presentation": {
                                                                                                                            "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails": {
                                                                                                                              "en-us": {
                                                                                                                                "role": {
                                                                                                                                  "terseLabel": "Share Repurchase Program [Axis]",
                                                                                                                                  "label": "Share Repurchase Program [Axis]",
                                                                                                                                  "documentation": "Information by share repurchase program." } } },
                                                                                                                                "auth_ref": {
                                                                                                                                  "r1515": {
                                                                                                                                    "srt_ShareRepurchaseProgramDomain": {
                                                                                                                                      "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": {
                                                                                                                                        "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails": {
                                                                                                                                          "en-us": {
                                                                                                                                            "role": {
                                                                                                                                              "terseLabel": "Share Repurchase Program [Domain]",
                                                                                                                                              "label": "Share Repurchase Program [Domain]",
                                                                                                                                              "documentation": "Name of share repurchase program." } } },
                                                                                                                                            "auth_ref": {
                                                                                                                                              "r1515": {
                                                                                                                                                "srt_ShareRepurchaseProgramLineItems": {
                                                                                                                                      "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramLineItems", "presentation": {
                                                                                                                                        "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails": {
                                                                                                                                          "en-us": {
                                                                                                                                            "role": {
                                                                                                                                              "terseLabel": "Share Repurchase Program [Line Items]",
                                                                                                                                              "label": "Share Repurchase Program [Line Items]",
                                                                                                                                              "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
                                                                                                                                            "auth_ref": {
                                                                                                                                              "r1515": {
                                                                                                                                                "srt_ShareRepurchaseProgramTable": {
                                                                                                                                      "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramTable",
                                                                                                                                      "presentation": {
                                                                                                                                        "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails": {
                                                                                                                                          "en-us": {
                                                                                                                                            "role": {
                                                                                                                                              "terseLabel": "Share Repurchase Program [Table]",
                                                                                                                                              "label": "Share Repurchase Program [Table]",
                                                                                                                                              "documentation": "Disclosure of information about share repurchase program." } } },
                                                                                                                                            "auth_ref": {
                                                                                                                                              "r1515": {
                                                                                                                                                "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
                                                                                                                                      "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```

"SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award
under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r736" }, "us-gaap-SharesIssued":
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued",
"presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING",
"lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)",
"label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date,
including shares that had been issued and were previously outstanding but which are now held in the treasury." } } },
"auth_ref": { "r27" }, "us-gaap-ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": {
"http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Short-term debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying
amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle,
if longer." } } }, "auth_ref": { "r161", "r254", "r1226", "r1607" }, "us-gaap-ShortTermDebtTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis",
"presentation": { "http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation":
"Information by type of short-term debt arrangement." } } }, "auth_ref": { "r163", "r1496", "r1497", "r1498" },
"us-gaap-ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShortTermDebtTypeDomain", "presentation": {
"http://www.healthpeak.com/role/DebtCommercialPaperProgramDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation":
"Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing,
project financing, letter of credit financing." } } }, "auth_ref": { "r161", "r1496", "r1497", "r1498" }, "us-
gaap-SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {
"http://www.healthpeak.com/role/SummaryofSignificantAccountingPolicies" }, "lang": { "en-us": { "role": {
"terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text
Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } },
"auth_ref": { "r212", "r402" }, "peak-SorrentoTherapeuticsIncMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthpeak.com/20241231", "localname": "SorrentoTherapeuticsIncMember",
"presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Sorrento Therapeutics, Inc.", "label": "Sorrento Therapeutics, Inc. [Member]", "documentation":
"Sorrento Therapeutics, Inc." } } }, "auth_ref": { }, "peak-SouthSanFranciscoJVsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"SouthSanFranciscoJVsMember", "presentation": {
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth",
"http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "South San Francisco JVs", "label": "South San Francisco JVs [Member]",
"documentation": "South San Francisco JVs" } } }, "auth_ref": { }, "us-gaap-StatementBusinessSegmentsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementBusinessSegmentsAxis", "presentation": {
"http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe",
"http://www.healthpeak.com/role/DebtMortgageDebtDetails",
"http://www.healthpeak.com/role/DebtTheMergerDetails",
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2022DispositionofRealEstate",
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2023DispositionofRealEstate",
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstate",
"http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperationsHeldforSaleandDiscontinue",
"http://www.healthpeak.com/role/ImpairmentofRealEstateDetails",
"http://www.healthpeak.com/role/IntangiblesScheduleofGoodwillSegmentsDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesNarrativeDetails",
"http://www.healthpeak.com/role/InvestmentsinandAdvancetoUnconsolidatedJointVenturesScheduleofEquityMeth",
"http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails",
"http://www.healthpeak.com/role/LeasesNarrativeDetails",
"http://www.healthpeak.com/role/LeasesTenantUpdatesDetails",
"http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails",
"http://www.healthpeak.com/role/LoansReceivableCCRCResidentLoansDetails",
"http://www.healthpeak.com/role/LoansReceivableOutpatientMedicalSellerFinancingDetails",
"http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails",
"http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi",
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestmentsConstructionTenantandOtherCapitalImprovementsDetails",
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
"http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresNarrativeDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresRevenuesandAssetsbySegmentDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresScheduleofInformationfortheReportableSegmentsDetails",
"http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails",

```

http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails }, "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r360", "r458", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r482", "r483", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r499", "r505", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r597", "r600", "r608", "r609", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1174", "r1177", "r1178", "r1189", "r1239", "r1612", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMPProgramDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct", "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r304", "r370", "r371", "r372", "r405", "r439", "r443", "r450", "r452", "r461", "r462", "r552", "r620", "r623", "r624", "r625", "r629", "r630", "r662", "r663", "r666", "r669", "r676", "r842", "r1021", "r1022", "r1023", "r1024", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1060", "r1081", "r1100", "r1126", "r1127", "r1128", "r1129", "r1130", "r1374", "r1433", "r1446" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDownREITsDetails", "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInteres", "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r27", "r176", "r179", "r180", "r358", "r385", "r386", "r387", "r418", "r419", "r420", "r422", "r428", "r431", "r433", "r460", "r554", "r557", "r598", "r677", "r777", "r778", "r787", "r788", "r789", "r791", "r797", "r798", "r808", "r809", "r810", "r811", "r812", "r813", "r817", "r843", "r845", "r846", "r847", "r848", "r849", "r857", "r860", "r882", "r983", "r1006", "r1007", "r1008", "r1028", "r1100" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDe", "http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails", "http://www.healthpeak.com/role/ScheduleIVMortgageLoansonRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r317", "r319", "r322", "r324", "r325", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r337", "r503", "r504", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r1042", "r1045", "r1047", "r1106", "r1108", "r1111", "r1125", "r1133", "r1144", "r1145", "r1146", "r1147", "r1150", "r1151", "r1152", "r1153", "r1154", "r1162", "r1198", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1238", "r1245", "r1516", "r1612", "r1616", "r1617", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING", "lang": { "en-us": { "role": { "verboseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r418", "r419", "r420", "r460", "r860", "r923", "r1019", "r1039", "r1051", "r1052", "r1053", "r1054", "r1056", "r1057", "r1060", "r1062", "r1063", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1077", "r1079", "r1083", "r1084", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1100", "r1246" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionLocationActivityAccrualAxis", "presentation": { "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Axis]", "label": "Statement of Financial Position Location, Activity, Accrual [Axis]", "documentation": "Information by location in statement of financial position in which disaggregated accrual activity has been included." } } }, "auth_ref": [ "r1556", "r1584" ] }, "us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionLocationActivityAccrualDomain", "presentation": { "http://www.healthpeak.com/role/CompensationPlansDepartureofExecutivesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Domain]", "label": "Statement of Financial Position Location, Activity, Accrual [Domain]", "documentation": "Location in statement of financial position in which disaggregated accrual activity has been included." } } }, "auth_ref": [ "r1556", "r1584" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri":

```

"http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": { "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": { "http://www.healthpeak.com/role/ConcentrationOfCreditRiskScheduleOfGeographicalConcentrationOfCreditRiskDetails": "http://www.healthpeak.com/role/LeasesDenverOfficeRelocationDetails", "http://www.healthpeak.com/role/LeasesNarrativeDetails", "http://www.healthpeak.com/role/ScheduleHIREstateandAccumulatedDepreciationSummaryofActivityforRealEst": "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails", "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofcashflowinformationdiscontinued": { "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Axis]", "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": { "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://www.healthpeak.com/role/CommitmentsandContingenciesScheduleofContractualObligationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": { "r355", "r434", "r708", "r1375", "r1379", "r1444" } } }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": { "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r418", "r419", "r420", "r460", "r506", "r860", "r923", "r1019", "r1039", "r1051", "r1052", "r1053", "r1054", "r1056", "r1057", "r1060", "r1062", "r1063", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1077", "r1079", "r1083", "r1084", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1100", "r1246" } } }, "ecd_StkPrOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": { "r1280", "r1291", "r1301", "r1334" } } }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { "peak_StockBasedCompensation2006IncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "StockBasedCompensation2006IncentivePlanMember", "presentation": { "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2006 Incentive Plan", "label": "Stock Based Compensation, 2006 Incentive Plan [Member]", "documentation": "Represents 2006 Performance Incentive Plan approved by stockholders on May 11, 2006." } } }, "auth_ref": { "peak_StockBasedCompensation2014IncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "StockBasedCompensation2014IncentivePlanMember", "presentation": { "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2014 Incentive Plan", "label": "Stock Based Compensation, 2014 Incentive Plan [Member]", "documentation": "Information pertaining to 2014 Performance Incentive Plan." } } }, "auth_ref": { "peak_StockBasedCompensation2023IncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "StockBasedCompensation2023IncentivePlanMember", "presentation": { "http://www.healthpeak.com/role/CompensationPlansStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2023 Incentive Plan", "label": "Stock Based Compensation, 2023 Incentive Plan [Member]", "documentation": "Stock Based Compensation, 2023 Incentive Plan" } } }, "auth_ref": { "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued as part of the Merger (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": { "r175", "r176", "r231" } } }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING": "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct": { "lang": { "en-us": { "role": { "verboseLabel": "Conversion of DownREIT units to common stock (in shares)", "terseLabel": "Conversion of DownREIT units (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": { "r27", "r81", "r175", "r176", "r231" } } }, "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "presentation": {

["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct)
[", "lang": { "en-us": { "role": { "terseLabel": "Dividend Reinvestment and Stock Purchase Plan \(in shares\)",](#)
["label": "Stock Issued During Period, Shares, Dividend Reinvestment Plan", "documentation": "Number of shares](#)
[issued during the period from a dividend reinvestment plan \(DRIP\). A dividend reinvestment plan allows the](#)
[shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity." } } };](#)
["auth_ref": { "r27", "r1100", "r1128" } };](#)
["us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype":](#)
["sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["StockIssuedDuringPeriodSharesNewIssues", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" };](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net \(in shares\)", "label": "Stock Issued During](#)
[Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } };](#)
["auth_ref": { "r27", "r175", "r176", "r231", "r1021", "r1100", "r1127" } };](#)
["us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": {](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units \(in shares\)", "label": "Stock Issued](#)
[During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued](#)
[during the period related to Restricted Stock Awards, net of any shares forfeited." } } };](#)
["auth_ref": { "r27",](#)
["r175", "r176", "r231" } };](#)
["us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Shares issued as part of the Merger", "label": "Stock Issued During](#)
[Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period."](#)
[" } } };](#)
["auth_ref": { "r27", "r176", "r179", "r180", "r231" } };](#)
["us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri":](#)
["http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit",](#)
["presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Conversion of DownREIT units to common stock", "label": "Stock](#)
[Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period](#)
[upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment](#)
[trust unit \(UPREIT unit\)." } } };](#)
["auth_ref": { "r27", "r176", "r179", "r180", "r231" } };](#)
["us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-](#)
[gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" };](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value,](#)
[New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares](#)
[issued in an initial public offering or a secondary public offering." } } };](#)
["auth_ref": { "r27", "r175", "r176",](#)
["r231", "r1028", "r1100", "r1127", "r1255" } };](#)
["srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname":](#)
["StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": {](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails"](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share](#)
[Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under](#)
[share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } };](#)
["auth_ref": { "r1515" } };](#)
["us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {](#)
["xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": {](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails"](#)
[", "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining authorized repurchase](#)
[amount", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount](#)
[remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to,](#)
[repurchase of stock and unit of ownership." } } };](#)
["auth_ref": { } };](#)
["us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-](#)
[gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsScheduleofOtherCommonStockAct](#)
[", "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock \(in shares\)", "verboseLabel":](#)
["Repurchase of common stock \(in shares\)", "label": "Stock Repurchased During Period, Shares",](#)
["documentation": "Number of shares that have been repurchased during the period and have not been retired](#)
[and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire](#)
[its own stock and prescribe the accounting treatment therefore. This element is used when state law does not](#)
[recognize treasury stock." } } };](#)
["auth_ref": { "r27", "r175", "r176", "r231", "r1024", "r1100", "r1129" } };](#)
["us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-](#)
[gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING](#)
[", "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock", "label": "Stock Repurchased](#)
[During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during](#)
[the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances](#)
[under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element](#)
[is used when state law does not recognize treasury stock." } } };](#)
["auth_ref": { "r27", "r175", "r176", "r231",](#)
["r1028", "r1100", "r1129", "r1255" } };](#)
["us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":](#)
["http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": {](#)
["http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-](#)

gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }],
 "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": {
 "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent",
 "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity
 attributable to noncontrolling interest." } } }, "auth_ref": { "r176", "r179", "r180", "r215", "r1061", "r1078",
 "r1101", "r1102", "r1226", "r1256", "r1435", "r1473", "r1581", "r1649" } }, "us-
 gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
 gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS":
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING",
 "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance", "periodEndLabel":
 "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation":
 "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } },
 "auth_ref": { "r97", "r98", "r111", "r358", "r359", "r386", "r418", "r419", "r420", "r422", "r428", "r431", "r554",
 "r557", "r598", "r677", "r777", "r778", "r787", "r788", "r789", "r791", "r797", "r798", "r808", "r809", "r810",
 "r811", "r812", "r813", "r817", "r843", "r845", "r849", "r858", "r882", "r1007", "r1008", "r1026", "r1061", "r1078",
 "r1101", "r1102", "r1131", "r1255", "r1435", "r1473", "r1581", "r1649" } }, "us-
 gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterests" }, "lang": { "en-us": { "role": {
 "terseLabel": "Equity and Redeemable Noncontrolling Interests", "label": "Equity [Text Block]", "documentation":
 "The entire disclosure for equity." } } }, "auth_ref": { "r228", "r404", "r661", "r663", "r665", "r666", "r667",
 "r668", "r669", "r670", "r671", "r672", "r673", "r675", "r677", "r815", "r1103", "r1104", "r1132" } }, "us-
 gaap_StraightLineRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "StraightLineRent", "crdr": "credit", "calculation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":
 "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "negatedLabel":
 "Straight-line rents", "terseLabel": "Straight line rent", "label": "Straight Line Rent", "documentation":
 "Difference between actual rental income due and rental income recognized on a straight-line basis." } } },
 "auth_ref": { "r18" } }, "us-gaap_StraightLineRentAdjustments": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "StraightLineRentAdjustments", "crdr": "debit", "presentation": {
 "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Rent
 adjustments", "label": "Straight Line Rent Adjustments", "documentation": "Amount of the adjustment to rental
 revenues to measure escalating leasing revenues on a straight line basis." } } }, "auth_ref": { } },
 "us-gaap_StraightLineRentReceivableNetOfAllowances": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "StraightLineRentReceivableNetOfAllowances", "crdr":
 "debit", "presentation": {
 "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Straight line rent receivable, net of allowances", "label": "Straight Line Rent Receivable,
 Net Of Allowances", "documentation": "Straight Line Rent Receivable, Net Of Allowances" } } }, "auth_ref": { } },
 "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "SubsequentEventLineItems", "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS",
 "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line
 Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line
 items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated
 with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r850", "r885" } },
 "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "SubsequentEventMember", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
 "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS",
 "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails" }, "lang": { "en-us":
 { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies
 event that occurred after the balance sheet date but before financial statements are issued or available to be
 issued." } } }, "auth_ref": { "r850", "r885" } }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": {
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS",
 "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]",
 "documentation": "Disclosure of information about significant event or transaction occurring between statement
 of financial position date and date when financial statements were issued." } } }, "auth_ref": { "r850", "r885" } },
 "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "SubsequentEventTypeAxis", "presentation": {
 "http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails",
 "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails",
 "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS",
 "http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails",
 "http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails" }, "lang": { "en-us":
 { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]",
 "documentation": "Information by event that occurred after the balance sheet date but before financial
 statements are issued or available to be issued." } } }, "auth_ref": { "r850", "r885" } }, "us-
 gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "SubsequentEventTypeDomain", "presentation": {

["http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails/"](http://www.healthpeak.com/role/CommitmentsandContingenciesDownREITLLCsDetails/),
["http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails/"](http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails/),
["http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS/"](http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsDividendsandIssuanceofCommonS/),
["http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails/"](http://www.healthpeak.com/role/LoansReceivable2024LoansReceivableTransactionsDetails/),
["http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails/"](http://www.healthpeak.com/role/LoansReceivable2025LoansReceivableTransactionsDetails/)], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r850", "r885" } }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee [Line Items]", "label": "Subsidiary or Equity Method Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsATMProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": { } }, "peak_SuburbanPropertiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SuburbanPropertiesLLCMember", "presentation": { "http://www.healthpeak.com/role/InvestmentsinandAdvancesstoUnconsolidatedJointVenturesScheduleofEquityMeth", "lang": { "en-us": { "role": { "terseLabel": "Suburban Properties, LLC", "label": "Suburban Properties L L C [Member]", "documentation": "Represents information pertaining to Suburban Properties, LLC, an unconsolidated joint venture of the entity." } } }, "auth_ref": { } }, "peak_SuccessBasedPaymentsRelatedToServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SuccessBasedPaymentsRelatedToServiceProvidersMember", "presentation": { "http://www.healthpeak.com/role/TheMergerNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Success-Based Payments Related to Service Providers", "label": "Success-Based Payments Related To Service Providers [Member]", "documentation": "Success-Based Payments Related To Service Providers" } } }, "auth_ref": { } }, "peak_SunriseSeniorHousingPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "SunriseSeniorHousingPortfolioMember", "presentation": { "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivableDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi", "lang": { "en-us": { "role": { "terseLabel": "Sunrise Senior Housing Portfolio", "label": "Sunrise Senior Housing Portfolio [Member]", "documentation": "Sunrise Senior Housing Portfolio" } } }, "auth_ref": { } }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": { } }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.healthpeak.com/role/SupplementalCashFlowInformationSummaryofSupplementalDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": { } }, "peak_TN0001KingsportTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0001KingsportTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0001 Kingsport, TN", "label": "TN0001 Kingsport, TN [Member]", "documentation": "TN0001 Kingsport, TN" } } }, "auth_ref": { } }, "peak_TN0002JacksonTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0002JacksonTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0002 Jackson, TN", "label": "TN0002 Jackson, TN [Member]", "documentation": "TN0002 Jackson, TN" } } }, "auth_ref": { } }, "peak_TN0005NashvilleTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0005NashvilleTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0005 Nashville, TN", "label": "TN0005 Nashville, TN [Member]", "documentation": "TN0005 Nashville, TN" } } }, "auth_ref": { } }, "peak_TN0007ChattanoogaTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0007ChattanoogaTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0007 Chattanooga, TN", "label": "TN0007 Chattanooga, TN [Member]", "documentation": "TN0007 Chattanooga, TN" } } }, "auth_ref": { } }, "peak_TN0008SpringHillTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0008SpringHillTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0008 Spring Hill, TN", "label": "TN0008 Spring Hill, TN [Member]", "documentation": "TN0008 Spring Hill, TN" } } }, "auth_ref": { } }, "peak_TN0010ChattanoogaTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0010ChattanoogaTNMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun", "lang": { "en-us": { "role": { "terseLabel": "TN0010 Chattanooga, TN", "label": "TN0010 Chattanooga, TN [Member]", "documentation": "TN0010 Chattanooga, TN" } } }, "auth_ref": { } }, "peak_TN0011FranklinTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TN0011FranklinTNMember", "presentation": {

"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TN0011 Franklin, TN", "label": "TN0011 Franklin, TN [Member]",
"documentation": "TN0011 Franklin, TN" } } }, "auth_ref": [] }, "peak_TN0012KingsportTNMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"TN0012KingsportTNMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TN0012 Kingsport, TN", "label": "TN0012 Kingsport, TN [Member]",
"documentation": "TN0012 Kingsport, TN" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TX", "presentation": []
"http://www.healthpeak.com/role/ConcentrationofCreditRiskScheduleofGeographicalConcentrationofCreditRiskDei
"http://www.healthpeak.com/role/RealEstateInvestments2022RealEstateInvestmentAcquisitionsDetails",
"http://www.healthpeak.com/role/RealEstateInvestments2023RealEstateInvestmentAcquisitionsDetails" }, "lang":
{ "en-us": { "role": { "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] },
"peak_TX0001ElPasoTXMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "TX0001ElPasoTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0001 El Paso, TX", "label": "TX0001 El Paso, TX [Member]",
"documentation": "TX0001 El Paso, TX" } } }, "auth_ref": [] }, "peak_TX0002ElPasoTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0002ElPasoTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0002 El Paso, TX", "label": "TX0002 El Paso, TX [Member]",
"documentation": "TX0002 El Paso, TX" } } }, "auth_ref": [] }, "peak_TX0005SanAntonioTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"TX0005SanAntonioTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0005 San Antonio, TX", "label": "TX0005 San Antonio, TX
[Member]", "documentation": "TX0005 San Antonio, TX" } } }, "auth_ref": [] },
"peak_TX0006SanAntonioTXMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "TX0006SanAntonioTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0006 San Antonio, TX", "label": "TX0006 San Antonio, TX
[Member]", "documentation": "TX0006 San Antonio, TX" } } }, "auth_ref": [] },
"peak_TX0008MansfieldTXMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "TX0008MansfieldTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0008 Mansfield, TX", "label": "TX0008 Mansfield, TX [Member]",
"documentation": "TX0008 Mansfield, TX" } } }, "auth_ref": [] }, "peak_TX0009ElPasoTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0009ElPasoTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0009 El Paso, TX", "label": "TX0009 El Paso, TX [Member]",
"documentation": "TX0009 El Paso, TX" } } }, "auth_ref": [] }, "peak_TX0010ElPasoTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0010ElPasoTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0010 El Paso, TX", "label": "TX0010 El Paso, TX [Member]",
"documentation": "TX0010 El Paso, TX" } } }, "auth_ref": [] }, "peak_TX0012CarrolltonTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0012CarrolltonTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0012 Carrollton, TX", "label": "TX0012 Carrollton, TX [Member]",
"documentation": "TX0012 Carrollton, TX" } } }, "auth_ref": [] }, "peak_TX0013KatyTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0013KatyTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0013 Katy, TX", "label": "TX0013 Katy, TX [Member]",
"documentation": "TX0013 Katy, TX" } } }, "auth_ref": [] }, "peak_TX0014KatyTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0014KatyTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0014 Katy, TX", "label": "TX0014 Katy, TX [Member]",
"documentation": "TX0014 Katy, TX" } } }, "auth_ref": [] }, "peak_TX0017SpringTXMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TX0017SpringTXMember",
"presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0017 Spring, TX", "label": "TX0017 Spring, TX [Member]",
"documentation": "TX0017 Spring, TX" } } }, "auth_ref": [] }, "peak_TX0018TheWoodlandsTXMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"TX0018TheWoodlandsTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0018 The Woodlands, TX", "label": "TX0018 The Woodlands, TX
[Member]", "documentation": "TX0018 The Woodlands, TX" } } }, "auth_ref": [] },
"peak_TX0019LufkinTXMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "TX0019LufkinTXMember", "presentation": []
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
l, "lang": { "en-us": { "role": { "terseLabel": "TX0019 Lufkin, TX", "label": "TX0019 Lufkin, TX [Member]",
"documentation": "TX0019 Lufkin, TX" } } }, "auth_ref": [] }, "peak_TX0020LufkinTXMember": { "xbrltype":

[illegible]

[Member]", "documentation": "TX0A22 Flower Mound, TX" } } }, "auth_ref": [] },
 "peak_TX3249WebsterTXMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "TX3249WebsterTXMember", "presentation": [
 "http://www.healthpeak.com/role/ScheduleHRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun
 l", "lang": { "en-us": { "role": { "terseLabel": "TX3249 Webster, TX", "label": "TX3249 Webster, TX [Member]",
 "documentation": "TX3249 Webster, TX" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular
 List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r1327"] },
 "peak_TaxableRealEstateInvestmentSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "TaxableRealEstateInvestmentSubsidiariesMember",
 "presentation": ["http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "TRS", "label": "Taxable Real Estate Investment Subsidiaries [Member]", "documentation":
 "Represents information pertaining to the Company's certain subsidiaries which are treated as taxable Real
 Estate Investment Trust subsidiaries (\"TRS\" or \"TRS entities.\") } } }, "auth_ref": [] },
 "peak_TemporaryEquityAdjustmentsOfPermanentEquityToTemporaryEquity": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "TemporaryEquityAdjustmentsOfPermanentEquityToTemporaryEquity", "crdr": "credit", "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "terseLabel": "Adjustments to redemption value of redeemable noncontrolling
 interests", "label": "Temporary Equity, Adjustments Of Permanent Equity To Temporary Equity",
 "documentation": "Temporary Equity, Adjustments Of Permanent Equity To Temporary Equity" } } }, "auth_ref":
 [] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit",
 "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance",
 "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
 "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and
 outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption
 features that are outside the control of the issuer, is not classified as an asset or liability in conformity with
 GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or
 determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has
 conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option
 held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } },
 "auth_ref": ["r174", "r405", "r552", "r842"] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityNetIncome", "crdr":
 "credit", "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Temporary Equity, Net Income",
 "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref":
 [] }, "peak_TemporaryEquityNoncontrollingInterestContributionsFromNoncontrollingInterest": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "TemporaryEquityNoncontrollingInterestContributionsFromNoncontrollingInterest", "crdr": "credit",
 "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label": "Temporary
 Equity, Noncontrolling Interest, Contributions From Noncontrolling Interest", "documentation": "Temporary
 Equity, Noncontrolling Interest, Contributions From Noncontrolling Interest" } } }, "auth_ref": [] },
 "peak_TemporaryEquityNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "TemporaryEquityNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr":
 "debit", "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to noncontrolling interests", "label":
 "Temporary Equity, Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
 "documentation": "Temporary Equity, Noncontrolling Interest, Decrease from Distributions to Noncontrolling
 Interest Holders" } } }, "auth_ref": [] },
 "peak_TemporaryEquityNoncontrollingInterestDecreaseFromRedemptionsOrPurchaseOfInterests": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "TemporaryEquityNoncontrollingInterestDecreaseFromRedemptionsOrPurchaseOfInterests", "crdr": "debit",
 "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of noncontrolling interests", "label": "Temporary
 Equity, Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation":
 "Temporary Equity, Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests" } } },
 "auth_ref": [] }, "peak_TemporaryEquityNoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
 "TemporaryEquityNoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLING
 l", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests acquired as part of the Merger", "label":
 "Temporary Equity, Noncontrolling Interest, Increase From Business Combination", "documentation":
 "Temporary Equity, Noncontrolling Interest, Increase From Business Combination" } } }, "auth_ref": [] },
 "peak_TermLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "TermLoanAgreementMember", "presentation": [
 "http://www.healthpeak.com/role/DebtBankLineOfCreditandTermLoanDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Term Loan Agreement", "label": "Term Loan Agreement [Member]", "documentation": "Term Loan

Agreement" } }], "auth_ref": []], "peak_TermLoanFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TermLoanFacilitiesMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facilities", "label": "Term Loan Facilities [Member]", "documentation": "Term Loan Facilities" } } }], "auth_ref": []], "peak_TermLoanFacilitiesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TermLoanFacilitiesOneMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facilities One", "label": "Term Loan Facilities One [Member]", "documentation": "Term Loan Facilities One" } } }], "auth_ref": []], "peak_TermLoanFacilitiesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TermLoanFacilitiesTwoMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facilities Two", "label": "Term Loan Facilities Two [Member]", "documentation": "Term Loan Facilities Two" } } }], "auth_ref": []], "peak_TerminationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TerminationFees", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/LeasesTenantUpdatesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Termination fees", "label": "Termination Fees", "documentation": "Termination Fees" } } }], "auth_ref": []], "peak_TimeBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TimeBasedRestrictedStockUnitsMember", "presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Time Based Restricted Stock Units", "label": "Time Based Restricted Stock Units [Member]", "documentation": "Time Based Restricted Stock Units" } } }], "auth_ref": []], "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }], "auth_ref": ["r1319"]], "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }], "auth_ref": ["r1326"]], "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }], "auth_ref": ["r1347"]], "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }], "auth_ref": ["r1349"]], "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.healthpeak.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }], "auth_ref": []], "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }], "auth_ref": ["r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r656", "r674", "r814", "r839", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r900", "r904", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r984", "r1213", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1227", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1468", "r1469", "r1470", "r1471", "r1566", "r1567", "r1568", "r1569", "r1576", "r1579"]], "ecd_TradingArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }], "auth_ref": ["r1350"]], "ecd_TradingArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }], "auth_ref": ["r1351"]], "ecd_TradingArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }], "auth_ref": ["r1351"]], "ecd_TradingArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }], "auth_ref": ["r1349"]], "ecd_TradingArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }], "auth_ref": ["r1349"]], "ecd_TradingArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }], "auth_ref": ["r1352"]], "ecd_TradingArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": {

["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"](http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements)], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": { "r1350" } }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails", "lang": { "en-us": { "role": { "terseLabel": "Average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": { "r86" } }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails", "lang": { "en-us": { "role": { "terseLabel": "Common stock repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": { "r27", "r176", "r231" } }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsShareRepurchaseProgramsDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, total value", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": { "r27", "r86", "r231" } }, "peak_TwoOutpatientMedicalBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "TwoOutpatientMedicalBuildingsMember", "presentation": { "http://www.healthpeak.com/role/DispositionofRealEstateandDiscontinuedOperations2024DispositionofRealEstateandDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Two Outpatient Medical Buildings", "label": "Two Outpatient Medical Buildings Member", "documentation": "Two Outpatient Medical Buildings" } } }, "auth_ref": { } }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt issuance expense", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": { } }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": { "r1346" } }, "peak_UnitsIssuedDuringPeriodNewIssues": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "UnitsIssuedDuringPeriodNewIssues", "presentation": { "http://www.healthpeak.com/role/CompensationPlansRestrictedStockAwardsDetails", "lang": { "en-us": { "role": { "terseLabel": "Issuance of OP units (in units)", "label": "Units Issued During Period, New Issues", "documentation": "Units Issued During Period, New Issues" } } }, "auth_ref": { } }, "peak_UnitsIssuedDuringPeriodNewIssuesCriteriaRedemption": { "xbrltype": "integerItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "UnitsIssuedDuringPeriodNewIssuesCriteriaRedemption", "presentation": { "http://www.healthpeak.com/role/EquityandRedeemableNoncontrollingInterestsRedeemableNoncontrollingInterests", "lang": { "en-us": { "role": { "terseLabel": "Issuance of OP units criteria redemption (in units)", "label": "Units Issued During Period, New Issues, Criteria Redemption", "documentation": "Units Issued During Period, New Issues, Criteria Redemption" } } }, "auth_ref": { } }, "peak_UnrecapturedSection1250Gain": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "UnrecapturedSection1250Gain", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofCommonStockDistributionDetails", "lang": { "en-us": { "role": { "terseLabel": "Unrecaptured Section 1250 gain (in dollars per share)", "label": "Unrecaptured Section 1250 Gain", "documentation": "Unrecaptured Section 1250 Gain" } } }, "auth_ref": { } }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesNarrativeDetails", "http://www.healthpeak.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "periodStartLabel": "Total unrecognized tax benefits at January 1", "periodEndLabel": "Total unrecognized tax benefits at December 31", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": { "r751", "r763", "r1209" } }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross amount of decreases for prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": { "r764", "r1209" } }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebt", "crdr": "credit", "calculation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.healthpeak.com/role/FairValueMeasurementsDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails", "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes", "verboseLabel": "Senior unsecured notes", "label": "Unsecured

Debt", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": { "r33", "r258", "r1608" } }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebtMember", "presentation": { "http://www.healthpeak.com/role/DebtScheduleofDebtMaturitiesDetails", "http://www.healthpeak.com/role/DebtSeniorUnsecuredNotesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": { } }, "peak_UnsecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "UnsecuredTermLoanMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unsecured Term Loan", "label": "Unsecured Term Loan [Member]", "documentation": "Unsecured Term Loan" } } }, "auth_ref": { } }, "us-gaap_UnusualOrInfrequentItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemAxis", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Axis]", "label": "Unusual or Infrequent Item, or Both [Axis]", "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": { "r202" } }, "us-gaap_UnusualOrInfrequentItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemDomain", "presentation": { "http://www.healthpeak.com/role/ImpairmentsofRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Domain]", "label": "Unusual or Infrequent Item, or Both [Domain]", "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": { "r202" } }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.healthpeak.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r62", "r63", "r64", "r295", "r296", "r297", "r298" } }, "us-gaap_UtilitiesOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UtilitiesOperatingExpense", "crdr": "debit", "calculation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.healthpeak.com/role/SegmentDisclosuresSignificantExpenseCategoriesbySegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Utilities", "label": "Utilities Operating Expense", "documentation": "Amount of operating expense of regulated operation." } } }, "auth_ref": { "r190" } }, "peak_VA0001FredericksburgVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VA0001FredericksburgVAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun" }, "lang": { "en-us": { "role": { "terseLabel": "VA0001 Fredericksburg, VA", "label": "VA0001 Fredericksburg, VA [Member]", "documentation": "VA0001 Fredericksburg, VA" } } }, "auth_ref": { } }, "peak_VA0002HamptonVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VA0002HamptonVAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleHIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun" }, "lang": { "en-us": { "role": { "terseLabel": "VA0002 Hampton, VA", "label": "VA0002 Hampton, VA [Member]", "documentation": "VA0002 Hampton, VA" } } }, "auth_ref": { } }, "peak_ValuationAllowancesAndReservesAdditionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "ValuationAllowancesAndReservesAdditionsAbstract", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Valuation Allowances and Reserves Additions [Abstract]", "documentation": "b7d34adf-2bf5-147d-53d6-c162579b23d2" } } }, "auth_ref": { } }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Balance at Beginning of Year", "periodEndLabel": "Balance at End of Year", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": { "r412", "r416" } }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amounts Charged Against Operations, net", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": { "r413" } }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Deductions", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": { "r415" } }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": { "r412", "r413", "r414", "r415", "r416" } }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "crdr": "credit", "presentation": {

"http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquired Properties", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination." } } }, "auth_ref": { "r1439" } }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": { "r412", "r413", "r414", "r415", "r416" } }, "srt_ValuationAndQualifyingAccountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "auth_ref": { } }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance Accounts", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r310", "r311", "r312", "r313", "r314", "r412", "r413", "r414", "r415", "r416" } }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": { "http://www.healthpeak.com/role/ScheduleHValuationandQualifyingAccountsDetails"], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve." } } }, "auth_ref": { "r310", "r311", "r312", "r313", "r314", "r412", "r413", "r414", "r415", "r416" } }, "peak_VariableInterestEntitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableInterestEntitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities [Abstract]", "label": "Variable Interest Entities [Abstract]", "documentation": "Variable Interest Entities [Abstract]" } } }, "auth_ref": { } }, "peak_VariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableInterestEntitiesTextBlock", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntities"], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entities [Text Block]", "documentation": "The entire disclosure for variable interest entities, including description of the terms of arrangements and categorized by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available." } } }, "auth_ref": { } }, "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityEntityMaximumLossExposureAmount", "crdr": "credit", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum loss exposure and carrying amount", "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount", "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)." } } }, "auth_ref": { "r109", "r245" } }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "verboseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r800", "r801", "r804", "r805", "r901", "r902", "r903" } }, "peak_VariableInterestEntityNotPrimaryBeneficiaryDebtInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableInterestEntityNotPrimaryBeneficiaryDebtInvestmentMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "LLC Investment and PropTech Investment", "label": "Variable Interest Entity Not Primary Beneficiary Debt Investment [Member]", "documentation": "Represents a debt investment with a party that has been identified as a Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary." } } }, "auth_ref": { } }, "peak_VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesScheduleofVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Needham Land Parcel JV", "label": "Variable Interest Entity Not Primary Beneficiary Investment In Joint Venture [Member]", "documentation": "Information related to investments in an unconsolidated joint venture, which is a Variable Interest Entity (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary." } } }, "auth_ref": { } }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Not Primary Beneficiary", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the

The VIE that most significantly impacts the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE are not included in the consolidated financial statements of the entity." } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": { "http://www.healthpeak.com/role/TheMergerScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumed": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": ["r107"] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesBalanceSheetDisclosuresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": ["r104", "r800", "r801", "r804", "r805"] }, "us-gaap_VariableRateAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoanonRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "peak_VariableRateComponentAxis": { "xbrlType": "stringItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableRateComponentAxis", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Axis]", "label": "Variable Rate Component [Axis]", "documentation": "Variable Rate Component" } } }, "auth_ref": [] }, "peak_VariableRateComponentDomain": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableRateComponentDomain", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "documentation": "Variable Rate Component [Domain]" } } }, "auth_ref": [] }, "peak_VariableRateComponentOneMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VariableRateComponentOneMember", "presentation": { "http://www.healthpeak.com/role/DebtBankLineofCreditandTermLoanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component One", "label": "Variable Rate Component One [Member]", "documentation": "Variable Rate Component One" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": { "http://www.healthpeak.com/role/LoansReceivable2022LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivable2023LoansReceivableTransactionsDetails", "http://www.healthpeak.com/role/LoansReceivableSunriseSeniorHousingPortfolioSellerFinancingandOtherSellerFi": { "http://www.healthpeak.com/role/ScheduleIVMortgageLoanonRealEstateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "peak_VenturesVLLCMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "VenturesVLLCMember", "presentation": { "http://www.healthpeak.com/role/VariableInterestEntitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ventures V, LLC", "label": "Ventures V, LLC [Member]", "documentation": "Represents information pertaining to HGP Ventures V." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r1315"] }, "peak_WA0001LakewoodWAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WA0001LakewoodWAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": { "lang": { "en-us": { "role": { "terseLabel": "WA0001 Lakewood, WA", "label": "WA0001 Lakewood, WA [Member]", "documentation": "WA0001 Lakewood, WA" } } }, "auth_ref": [] }, "peak_WA0002KennewickWAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WA0002KennewickWAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": { "lang": { "en-us": { "role": { "terseLabel": "WA0002 Kennewick, WA", "label": "WA0002 Kennewick, WA [Member]", "documentation": "WA0002 Kennewick, WA" } } }, "auth_ref": [] }, "peak_WA0006GigHarborWAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WA0006GigHarborWAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun": { "lang": { "en-us": { "role": { "terseLabel": "WA0006 Gig Harbor, WA", "label": "WA0006 Gig Harbor, WA [Member]", "documentation": "WA0006 Gig Harbor, WA" } } }, "auth_ref": [] }, "peak_WA0009FederalWayWAMember": { "xbrlType": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WA0009FederalWayWAMember", "presentation": { "http://www.healthpeak.com/role/ScheduleIIIRealEstateandAccumulatedDepreciationDetailsofRealEstateandAccun

l, "lang": { "en-us": { "role": { "terseLabel": "WA0009 Federal Way, WA", "label": "WA0009 Federal Way, WA [Member]", "documentation": "WA0009 Federal Way, WA" } } }, "auth_ref": [] },
"peak_WA0010LakewoodWAMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "WA0010LakewoodWAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WA0010 Lakewood, WA", "label": "WA0010 Lakewood, WA [Member]", "documentation": "WA0010 Lakewood, WA" } } }, "auth_ref": [] },
"peak_WI0001WestAllisWIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthpeak.com/20241231", "localname": "WI0001WestAllisWIMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0001 West Allis, WI", "label": "WI0001 West Allis, WI [Member]", "documentation": "WI0001 West Allis, WI" } } }, "auth_ref": [] }, "peak_WI0002ShawanoWIMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WI0002ShawanoWIMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0002 Shawano, WI", "label": "WI0002 Shawano, WI [Member]", "documentation": "WI0002 Shawano, WI" } } }, "auth_ref": [] }, "peak_WI0003TacomaWAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WI0003TacomaWAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0003 Tacoma, WA", "label": "WI0003 Tacoma, WA [Member]", "documentation": "WI0003 Tacoma, WA" } } }, "auth_ref": [] }, "peak_WI0004MilwaukeeWIMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WI0004MilwaukeeWIMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0004 Milwaukee, WI", "label": "WI0004 Milwaukee, WI [Member]", "documentation": "WI0004 Milwaukee, WI" } } }, "auth_ref": [] }, "peak_WI0004TacomaWAMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WI0004TacomaWAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0004 Tacoma, WA", "label": "WI0004 Tacoma, WA [Member]", "documentation": "WI0004 Tacoma, WA" } } }, "auth_ref": [] }, "peak_WI0005BrookfieldWIMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WI0005BrookfieldWIMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0005 Brookfield, WI", "label": "WI0005 Brookfield, WI [Member]", "documentation": "WI0005 Brookfield, WI" } } }, "auth_ref": [] }, "peak_WI0005TacomaWAMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WI0005TacomaWAMember", "presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0005 Tacoma, WA", "label": "WI0005 Tacoma, WA [Member]", "documentation": "WI0005 Tacoma, WA" } } }, "auth_ref": [] }, "peak_WI0006AppletonWIMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WI0006AppletonWIMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0006 Appleton, WI", "label": "WI0006 Appleton, WI [Member]", "documentation": "WI0006 Appleton, WI" } } }, "auth_ref": [] }, "peak_WI0007AppletonWIMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WI0007AppletonWIMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0007 Appleton, WI", "label": "WI0007 Appleton, WI [Member]", "documentation": "WI0007 Appleton, WI" } } }, "auth_ref": [] }, "peak_WI0007TacomaWAMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname": "WI0007TacomaWAMember",
"presentation": {
"http://www.healthpeak.com/role/ScheduleHIREalEstateandAccumulatedDepreciationDetailsofRealEstateandAccun",
l, "lang": { "en-us": { "role": { "terseLabel": "WI0007 Tacoma, WA", "label": "WI0007 Tacoma, WA [Member]", "documentation": "WI0007 Tacoma, WA" } } }, "auth_ref": [] }, "peak_WatchListFinancingReceivableMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.healthpeak.com/20241231", "localname":
"WatchListFinancingReceivableMember", "presentation": {
"http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" l, "lang":
f "en-us": { "role": { "verboseLabel": "Watch list loans", "label": "Watch List Financing Receivable [Member]", "documentation": "Represents a financing receivable that is being monitored closely in order to spot
irregularities." } } }, "auth_ref": [] }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": {
"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" l, "lang": { "en-us": {
"role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)", "label": "Weighted Average
Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and
outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing
of issuance of shares or units in the period." } } }, "auth_ref": ["r438", "r452"] }, "us-
gaap-WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
"presentation": { "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" l, "lang": {
"en-us": { "role": { "terseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of
Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-

gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation":
 { "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails": { "parentTag": "us-
 gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.healthpeak.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS":
 "http://www.healthpeak.com/role/EarningsPerCommonShareComputationofEPSDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted average shares outstanding (in
 shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of
 [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not
 deemed outstanding, determined by relating the portion of time within a reporting period that common shares or
 units have been outstanding to the total time in that period." } } }, "auth_ref": { "r436", "r452" } },
 "peak_WorkoutFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.healthpeak.com/20241231", "localname": "WorkoutFinancingReceivableMember", "presentation": {
 "http://www.healthpeak.com/role/LoansReceivableScheduleofLoansReceivablebyOriginationYearDetails" }, "lang":
 { "en-us": { "role": { "verboseLabel": "Workout loans", "label": "Workout Financing Receivable [Member]",
 "documentation": "Workout Financing Receivable [Member]" } } }, "auth_ref": { } },
 "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of
 Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of
 Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r1313"
 } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "05", "Paragraph": "1", "SubTopic": "10", "Topic": "970", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482170/970-10-05-1" }, "r1": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7",
 "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-
 30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
 "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
 "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-
 230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
 "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
 45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",
 "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15",
 "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
 "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r11": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
 "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r12": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D",
 "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-
 45-1D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r14": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
 "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
 45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-21B" }, "r16": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D",
 "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
 45-21D" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r18": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r19": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
 "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r20": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"},"r226":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"},"r227":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"},"r228":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB",

"URI": "https://asc.fasb.org/505/tableOfContent"},"r229":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef",

"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"},"r230":{"role":

"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "505", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481112/505-10-50-7"},"r231":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147480008/505-10-S99-1"},"r232":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r233":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r234":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB",

"URI": "https://asc.fasb.org/805/tableOfContent"},"r235":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef",

"Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"},

"r236":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "805", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher":

FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"},"r237":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147479515/805-10-05-4"},"r238":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147479515/805-10-05-4"},"r239":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification",

"Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-

50-1"},"r240":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "805", "SubTopic": "30", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher":

FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"},"r241":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-

10-45-19"},"r242":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "810", "SubTopic": "10",

Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147481231/810-10-45-23"},"r243":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147481203/810-10-50-1A"},"r244":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147481203/810-10-50-1A"},"r245":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147481203/810-10-50-4"},"r246":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147479836/810-10-S99-5"},"r247":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB",

"URI": "https://asc.fasb.org/815/tableOfContent"},"r248":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef",

"Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-

4B"},"r249":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "815", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2)", "Publisher":

FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"},"r250":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-

10-50-21"},"r251":{"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "942", "SubTopic": "210",

Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-

03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"},"r252":{"

"role":"http://fasb.org/us-gAAP/role/ref/legacyRef","Topic": "942", "SubTopic": "210", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher":

FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"},"r253":{"role":"http://fasb.org/us-

gaap/role/ref/legacyRef","Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI:

"https://asc.fasb.org/1943274/2147478546/942-210-S99-1"},"r254":{"role":"http://fasb.org/us-

[illegible]

gaap/role/ref/otherTransitionRef, "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481962/310-10-50-29](\"https://asc.fasb.org/1943274/2147481962/310-10-50-29\")" }, "r283": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481962/310-10-50-6](\"https://asc.fasb.org/1943274/2147481962/310-10-50-6\")" }, "r284": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481962/310-10-50-7](\"https://asc.fasb.org/1943274/2147481962/310-10-50-7\")" }, "r285": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481962/310-10-50-7A](\"https://asc.fasb.org/1943274/2147481962/310-10-50-7A\")" }, "r286": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481962/310-10-50-9](\"https://asc.fasb.org/1943274/2147481962/310-10-50-9\")" }, "r287": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "310", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7A", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481774/310-40-40-7A](\"https://asc.fasb.org/1943274/2147481774/310-40-40-7A\")" }, "r288": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482740/230-10-45-13](\"https://asc.fasb.org/1943274/2147482740/230-10-45-13\")" }, "r289": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482659/740-20-45-2](\"https://asc.fasb.org/1943274/2147482659/740-20-45-2\")" }, "r290": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477875/944-360-45-3](\"https://asc.fasb.org/1943274/2147477875/944-360-45-3\")" }, "r291": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477875/944-360-45-4](\"https://asc.fasb.org/1943274/2147477875/944-360-45-4\")" }, "r292": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478586/944-360-50-1](\"https://asc.fasb.org/1943274/2147478586/944-360-50-1\")" }, "r293": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-1](\"https://asc.fasb.org/1943274/2147482861/275-10-50-1\")" }, "r294": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483406/720-35-50-1](\"https://asc.fasb.org/1943274/2147483406/720-35-50-1\")" }, "r295": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-1](\"https://asc.fasb.org/1943274/2147482861/275-10-50-1\")" }, "r296": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-1](\"https://asc.fasb.org/1943274/2147482861/275-10-50-1\")" }, "r297": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-11](\"https://asc.fasb.org/1943274/2147482861/275-10-50-11\")" }, "r298": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-12](\"https://asc.fasb.org/1943274/2147482861/275-10-50-12\")" }, "r299": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482685/740-10-50-9](\"https://asc.fasb.org/1943274/2147482685/740-10-50-9\")" }, "r300": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480678/235-10-S99-1](\"https://asc.fasb.org/1943274/2147480678/235-10-S99-1\")" }, "r301": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "[https://asc.fasb.org/275/tableOfContent](\"https://asc.fasb.org/275/tableOfContent\")" }, "r302": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "[https://asc.fasb.org/323/tableOfContent](\"https://asc.fasb.org/323/tableOfContent\")" }, "r303": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "[https://asc.fasb.org/606/tableOfContent](\"https://asc.fasb.org/606/tableOfContent\")" }, "r304": { "role": "[http://www.xbrl.org/2003/](\"http://www.xbrl.org/2003/role/disclosureRef\")

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } ,
"r1658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } ,
"r1659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } ,
"r1660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } ,
"r1661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } ,
"r1662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 187 0001628280-25-003748-xbrl.zip IDEA:
XBRL DOCUMENT begin 644 0001628280-25-003748-xbrl.zip M4\$L#!0 (\$j\$1%K#(HIY2B< KU 3-97@Q.#\$R-
S\$R,S\$R,#(T
M+!FAT;>U=Z7/R)7_OG!%KUT!D:9H18=M^J:P24:%DI6)1ETEY*3!%JOPL'CW25QWG^T617%Y58GIW_XGXE!>?
MDVQ)OU=>E:K?S7->_9G_?05G>LFFK21XO?G!5)!J2!IN3R=YS M^?CQZ=2/3^8/MEHNR9FCY_LG_VWL M+!E?
\$!9+5+UEP>S)MTI?#!+P[W MY!7+FR2NKE!L!>[^SP.Z!O=7TSRKX&4%W.P2.^HU)?JD4R3R^P%S>0!WV1^
MCO(T+UX\W*7_O<1?DWE+\$D7+_YT5^0R_=@E%GY!%1%,N6?R^3?^L8_PZ\$
M_3XX.XTR909!IX^#G+XY2!9))78V!W9V!Y!>Y,*@!+^DJ!FNL!P#,3)Z?^719W!2,&FCP0,-W9Z,/1Z?^0QSK
M^!H!O>A_!-HIZIDL+H&R)GE5Y3/8*7C9:B=R>G;ZZ!X)LF.QBV.WHZ&PP!P(3&_EG75)=,%?)5D,\$WMQ!^1^;RQ
O:AA^M4BQ1!WM1:#7V7FX+6!DUG:JH2JZ5D*7(H!2S->"Z^0_XA/HD!C^?^S@:QB MZLV!7B)1J+6DB1M9Q.
(UZ.D5\$5L5D(606BFXJ;I3^Q#LET^HKN1G<5!DG0_\$^?^?;MBY!^H
M,E645!E!E2N!^/9+JY8!I(HF,Y!;PW0!^@AL7@&H.4^>WAX!7>2\$*55;D+D^+?^J9*9H&/C?M651 MF;
H>^!WAT^>O!Q0-B>?2A43B!>B^E=E#5(5)9T68D(2!BH6YSE&E3(Z#&
M(HF0^B^J//HL/F9))=A.M!/\$0.1\$L8X=#_IZ>OC\Y8I5^!QR&=V>%0G0ADS% MBIQ?VH3&U#A+8U>@;,%RQFH*
Z!)G.8WVY>J.LDK\MT(2X+V#;X18LH1TN" M,!&2)A3_!Y8V4)&=Q\$ M@D"!U1QJ0!P+Q+Q1DZ(&UT
<#EC%KBN!N",F6GZN?JEH!&B/6LYR!+8G(T M1*!%<^)SE-ODN!#)#9EXD8)=H0;-GM;6&"^!+SU5*E-UXXQ\$+R-
N@+!>B\$O MZHG^?1V7M!GD^I>S&868X<=8W"35%2TH&_Y2W\$.^>6-IVH1)^61?7R37^MI9F
8TY1/L/O)/P^*9,X01\$#XB:XE>LM49]=P^9N33F0U368)?H!F"JHHW_6+KZ='MKI\$=+;JCN^!^AO#;W@9VL?
BQL+!2PLB E(HFF M"V>726K*L"N@?>2H7#!%YH=^)^M);5LPD(8WAW>27A OP\$5_&6A7Z(I4; M-\$%:
K'ZS_!S^E7.2LQ_ "Q.1%H@UB2+TAHCJ>(&D@<==1P,2?8S(##DS M.(39>5;*LH7Z193?3H0_*)+JY4H?
+IX.Y>9J\$P?@9Y6555K#QN+N-ZVEW MJM<>??
L>M<.!*E61%NT1QB%38KA"55.9J;08+NJB1_BWR*&Y=@%!OV5_C M.MJJE/G^P:W_
^#!R)D8/T*:QR^Y_H45GMVP1UP.TU!1:VG^!C?A^!Q.1 MHW\$+M I1*+Y F?JDP*LIXH2<-JD5_33@"OBE5!=99
9R!^V"=1:6@Y1-# M2^CXZ!24%L2OX2+FNK11A9KWZ/GZ098%Y%0ZTT &F7T28R1"
ZZ;T!8^FBD*+U(X=:@L.IL^!K1#5?318=ZH KP^*8YJR.)BH#MK7! MY9#6P+6K^YJF+;G^4EO^F8!12=:^1C^NU..
08^Q0E<4^@F^7@NR7X7 M\$LD110<[!2!GC5;5/5(T,JIG1!):%WOIS+&*V-1ZF.5B_V#W>>^HU":N3 MUUT^CY?
!WNT#W!_H00481JZ!1#7!-\$AX2P%D JO0\$* MMYL7P_09J**WG-9L5,R0SQ\$\$(X)5
>FR!E#1J2G^WHZYS)783GH)79GY M/4_9J?J@6LGG6>4G^Q(M^H>2!5AUHKIE+!WENW4_FT!M?
<\$V:>S!MPRKV_N?^&^*LS@Y_)2/9H4X,T DE.8VPN9WLA% M^>^!X:9O&<H2;+H9=D;XL?
C)U9(PGV^94BTO6!6D!41T^+1WL^!# M25_XL1K^Y5MXZZ1C7I@HG/3Y=+4!+!^6>X_M^Q#8)N4/7SQ5
=3C^Q(A3X M#FZ C#"MEZKX4G^6CZQ^2K?BI=9503!5HUA2EG483&#LW!D#9^*ZKM:R:CM
MD7K@0G@G^\$1S&5^RI<2 L^*8(KI@.&1^N;?VR-R4C5!WX!X.(="Q6I9&I?
M33O9C8:0C3)H149QE3#TD=9YU!T!L=<<0!4ZA_U1AC"?D8P7D(!45%8^CT/QL'+L4_MX1B;!!^!..!?
L8;Z!6!3H:EXJ=CRK?L406(*BRH2/W?3.Y".#5B^KH1QW MVH^C?XRV;0N=L-/>+>1^4,1\$9A:(Z#G?/
HY=NFZ9H52350!\$=4YN^3R_M@?L^D+!6?*=!#)E11ESD6 M/H?
=2_RSB22P!N0IF@.#8^R+M!HK5>PSWE)2E&@\$_9=ILUG+!S JH=;NF T5@I/SR0:% MU4IN>!\$?
#)#3TT!N32AGVG>3MH;I/GF 3!05FR^Y76M+3%2R--2>6_MAC MZ+_!58T&A&G=CUTJ\$9>%66VX'
M>"2(DRRX25R6-ZYE3@?QHAHZO<=!!;Y>S!LPAX6&C" 5>:)=_"*_1^M>3ID0WS/X-WJFY^3U9N?^XIQTD?
(*5:F&J8B7O.T>X@4T^#.WQ9!N:CO607 M7^"Q-#X0V<IEY(+;2;7Q:5!<%)@D!MAS/Z%(BM9:&\$\$S.*R;?
WNX!W3W);X! M5BD,I&A@Y9Q+EX2V^FI*!J9BHN!1HH QMR!43@2JG0.B)!14!^#3(AJTI&
M5SH@VG=DE^X3E_U*5(^6H5EC8NQ)=?1V?^V>(5..!+F5@).V\$3?JD8\$!" 17%*"U!<
!;W!H(C)\$R_W!K#73FXJ3DCBMD< MK^!>!,0 E)0FA_!\$23/O/B;ZY^&#CZETD=43H-B!(ML RDP52!0X7F41M)
MA!QY%OE%9!H RGR5&P=E-ABIOQ?^D?2X.Y:24(\$VZK5O.L!E)0=+Y!2WR M1=<=NYTOCN&!25;F-IP-
D_SO8IN+!!>K?OE%8=Q?+!L;D6#51#24%565) M@#30)3^C/(P2><;<8W!M)1INX)8;-5&BP,XN\OKR2BB) M0!;.\$!-
/C,DK(YW8?^L!9!)*ZIK6YVZ :FNI"%5JN^D57-/OKG+8! M=+E6,KB:P^",,289ZA+Q1QL""?H9T8UA_W)P4=#^T
D4PW1UM:PN0E1WUKM M\$JPI51W%C,9Q1ONBIT&#PTX==/%UGL3X80;+&H-DE+6?Q2KH:T/\$69A;3H%%
<&V0P&4#?^*P-KE3@(:Q#=#A&L)=P MN7M6\$&G247?ZMB7BSK5?
CNLVI3A8^U\$R!4C^A!+5XL0:W)NO4OAP1&!53 MV^JCS>LHGL,<40QX<5U^ T;YH#\$E^;P^NV_L7
^R88;1:05!U""NP0#P0E!X.K9!&EHK01/V#+5E4,K 1JDEX#^Z9M)YJ#;DHM"6VMN!
M)0.GCM^T0G50\$=A@2MZ<0BEFAT8!F.L&94V22!+ M#G4&J#AH%6R?S.#5^!UT_QZG\$MS=V%AMW-Z%*
#&6V;1Q&8ZQ>3O_A77= MC227V,ME#G34TR\$4678&I^TNO!TV^6@8,%(GJ0+XY_H!1P!A!>6@;"POS1 M^B<8+
6SP#Q(.3N+!L56^PFMIC5*=9(CX4?0K%-ELNR!Y@G1CR0S-MK#1#3PW8U=*8-
A9;3J.6GQ7G!CD_HFD^X@MD!H#GBL2BF53#0!/I>EV;6 MKG3EAP-<"+A>;=%"/Z1!|=L%@T1W,E-
C;V08+)=%CKG3P)8.MGWP1\$5H^C5N MRBHEV;TH" M2X(F5@;_IH\$G<-?IWH"
!_1^2U_!Q@8.SB:CC!^Q*PSB;J4Y@@\$* MH ESG\$ _BU@N7%6\$!HIPN.) (BOSCEL)(2AV4"*7^#1%1!"0ICSIP.
M.)O:&.)U\$@BLV\$JKV!J2Z.Y^22; (=12IOXEVI!PD0!LCYGPQ(W_#%#EN&(-AXN^CW; M#L55T+2_D4Q9W+;.
ES.ST2S;#4!Q131^@H7A.H M=!!TS+^2>!CF>0.37X4.;@;0^HZ3P<+;Q\$)C/+0^!K!N9IC9T_OWUT^K!EJK;3T-
0/+C!^E(E9^8+ M+K\$V7AC+R5KC2+H58T.0\$^ZEN!HTL^>JDI@420>F(HB;Z!D^@H(K@ZWT M\$1Y(0_!HE?<=<
MTA!MHW\$^GC5^&PF)S=6<-1(H;@#P&^DL3U!2V\$6TK^0^>/(Z43?M6B7!/<1E:L&TZ#;J>34(MQ>=J!%)
<&HK9^+T;JU0=' #F+JV%#ZG9B!0^DCE7K(XY6>C U,#ILB9=+(I@;PTRG1-2434\$ MK4HBBR9_.L&CYL
(#3QYLVGYQP9DOT^P^T5HY.^GF14%IR;\$H8 %2-.7\$D6 MH_D<+72LXN(86/E9D\$>E^?X#TPFH^1\$JL3A4-
UX7//5T.V!X\$YMO4^_2R^:U>1#N4_/SCP M#B=9UV2D/_15^Q+E+7PD.UT 9;
(*4W&ZBQ%>I\$)R;GM%Y4(JBRDVIV)N M7U MG@^O-JV1T=F>E^T!HP")B\$F1?X:9;

(!5P(N#F"\$N/^IQX-4K5'1+*E*;"IA MI-U&RW"U>AG.MLMY/0&?W/
!0^NZNHU6DXQI1M5T@W0"\$&A)LT90FP0\$ ME5_\$48PNTT-1-ZA-1^0*X71@<:"
4.G!VJ/(APE9PI2149Y*Z@Z&VE0#PUX M&ZXU!HP)ZC(EU\$;FN!SF.)G11HUU7E&5EJV+N<
*XIMU4*L>NUWKT+7 FO# MG2NHQ 7=>8F V4/TP75(W7!OZ!_7?G%V->JU,R(31;!DC"%6FQ0M-8WY"V9 M:'247V9
>X85>8+5(CY!V'A58T-BJFM0N:0ZY_2L'1CA5GGK5<*T8P/=QH MJT8OP'2T+!P@;Z=50
_KV3EUHY<,"IB@DQX%"/223#S\$*EXCE'(HC1:&* M+A6UNKO#?BW*V,ERD:M^RLRECf8Y!G4D"R=4
:\$#1'#77S*>[A5M/N#1 M9":!LP!,-P6\$>+"EU"W.XO !G%0!!C9Q1>E2#=#SL+L!?!H7J.2-\$8P8
M^&_J"!LX<:IA/TI7Y&?KGT'CMCZXI&_DFV" !L.C. M=&UN%>HU00E0B10W#./3/95/BMF OFY!M5GS?I8B4?
\$7M7U*(JS=UL98)/#AL ME(Q8ID<99,AS"O VZ MB+?_9@Y0KDK4(5L_74NN'TK!_U:A68!
[A3!FNE!&MB=AV:U!AQ7%08!*[Q MMVF'1\$>X:H\$!&TLTMG/8H(7OY9?Z72HXFO.(A2>"UJ.2;P7"Z,5L5!^8!/
M'93Z!07X05" >ZVR;Q^Z9"B@R4=KR!)1HWF!OZC0!\$DJ0XY_&B1&_&3&JN MY:G8YVLBK-MFNW9#
!+KP8KH(8UM&GJP!HY;"U1>C*="IU_R!G#C66!K_M>D0TS-@TP+D6_U2%P?X
K-WMP!6^H-T#WPMOPZ)CQ0JHIR'J-DCG==RY MIJNM>J8W72.^L+/_XEQT?6RL=
(%8PG8P9"V"YL0/WVBLZE8H4)*MA(IV#@5
M^_M@1VTIV28=3"4RI=.)NMVJH^<4NFY#BRS^!>'CPY=DCL^4VXCJKSEI!-8V
M!H=-&NML_4E!8\$%LI=WW:#=:G!HF%*_/!<_9P6FDKK_*K7)AKD>M^/!\$!M!9_1V\$@4K8EMR5-H
N\$VG@Y5VP3!PE@+RU9?.\$2+5M21/4.)Q!14D@7=MLJ M!H&V.ZE%5%>19U9"JQ&JQK=V.!'TIESFVPO@\$23:0*
!/<10IG_*CKGN'S8+FX5_M>GQM;!%UV!15-TMXHL%/4P*&_S1Q/RB-M,<!= \$M_&N3>_H!G5!(-^RO'#G0-
WLPP,V-6NK7=M!>TWY-2Y51!> MW S/+>=>DMCU9'4K)SQ10*K@!N"!J4SRVK!C@TW_Z!1HHCY!/'&AA#U!J?G;/
MB>J!#="TN7Z=0!L"W!>16J!8_1U6TR.LLE1V!9"/">%XYLLB!W&HYD(NR53F!<ER@J8Q7LV_J!+6!MH-H"
X(VMHYNX"8?^!_"K341\$YD2'@YHIG3!7S1LK/\$\$,M))O5>0#_SNH.6!|_"Z'1>M7<=&H%F9A!SW'XJ6-
<7MFZRG.DV;W4!V!O;9_M;C8'W_-1KM_"P:/F+D1/F4U)F<[4 LZ@7LIM!S&6PZOZ_0H90J6;IH<#
MWI.=Y>UNA4E3WN24&^+T3A.M))F+9/+PWELML"YZ!OD5@^N#MH49VKX7E MTQ1B!L5.H:1H)
:=O>Y*S)HROP0BME)R0UX!U:*NN^:/UY7_#X_H#V6XO M3Y_A1)SRML)EJW\$H=US*RG33X5E3>?;4&UVS@ (4
MYNB!OP8HL_E!\$R9!3'EKO+B*;"=C1""W0G?Q5V@Z"JA\$S04)FJ=[TKUV<
M_&VE(4F8"H\$L>VW>7PXH11BGT4DM_Y\$ H69F8MHRZJ48K1V_OT8?G8B^" M)/VZ&I(0!+\$S".VFX-
OYDNM&X3U!<AB;IU%886@!C;26_Y!J!<?>ZBY\$ M>7;=G)Y@>,KN%4%V*O\$Q.OUA
K_"N@K+!+4;\$LOS1+20V00@!K!<H= MF9!90!J-7TPBL53!64NTARE!J2/Q!A92>S1!\$ _M/!BO/84=CAH.F>!9R^T)-
^W.O9/5)JH:UNJT_<43Y;8ZP_/'4!0_M9,1<"T>ZRS DKR'#MS)J!J%KVAPJ=-F\$!B>-%!_!ADLP&*S3=U!H/EVV(#
M&)Y:<1;J_V!WL9ID#H;I&2PJ5NIQC+&8?%;4TG?D+QCD\$K>^(Y5!_1T6_V M^E:46X:BS/0"C_M:@ZJ_*_30+4
S<&3H-U@-?W&I3X_5=U!%\$\$_37_35N*? M=<9YGO*%R-2H7Y-Z7A@0.1V2G4=*!5:5VN@!K*@E
O("ZZHS(^PITTN)RI MKNU@VI+7O25#(S'5HD)2V;715@*>EHN!5"t%@0\$O""0LS9;N*RS^Y=A(M_M^0!5O:
<&R"N1_VXG7R!<OT!RTM!/\$VLI"Z:0_OT^DH5)IS:S-(V>_XK6_MP>&V?K**&R/LI4KI^>@2^2JX<8^8(T^?_
TS0_SC@FZI>6>Q8X)19AK!3!_M&B^J8E!Q>3!OCUP.UR_J+/%*F<7AG6U6EZ;UJ@70?190!=""Z4V_YN.G9 M&M-
*)_FN@6IBD_J!2?NST>9)E:EOC=DOHX=CY!L-(U-R.LR<D)=J;J!D M?QO_9_'^_?'!NJ*6T2:S0WWE\$J!J!9S!%VT->
!\$?_E6AV@!&N^A^Q9?D#F MY@IQUNE_39_T@5UHZ82JV!EKG_KFX5X0!29MT8T\$AM=M!<"L1S6:>6'14=M-
'N213MB?W?_O=6HL4OD7C!<J<N;CHLZX6R\$H*.<X&F_7T\$#XEE!@J
M&%REFV1HGL_6U#!>FQ89V8V*3W!VI^\$AVFU;(U3,4;P7U.OX8LN?+K.C=A M+G@Z2F6JS=S^;MOGMW:/E^!&T-
-MK_VOI_XID?JOG;.&G@7+#!L*^>^!2IA"<MYM5/U
D\$K9N_9JSC:9QM;HP4YZBM!&53AR0A%8<8PU8TS?""_VK*!\$!+S#Z_M_9L#R!AN":7A_L+!FJ>X!L5.^?_RW0
JQ.;8)08!M5':M4OAJX*P4VN,832EE\$@J<4!XYK1!TQ(L5B3"4_O"APG)-%OUDPRS!\$TZH
ML:B+GMS>/2V'E%,,6!>#PY_&W5!JZW"8)XW'MNO*4)T\$14<4_B)I!MA10
M_4_.M8^@;_&81C#@P5LW5^2L4%=BF_*D#K?2X/-5*<1-C2!%\$\$18@BXD-YT? MN)M!8>@C.9\$NKA.%_J=MK36-
LZ.03JW3Z"#6;IAW9.%;'E9_M>2NGVP6S!9T'D2L_B;P>NTA0BC(7!)>[>TC4M!@;\$!1N!>TF>0_!WPN(Z/6
MGAQ)CFVDY;VV_1/JU\$\$_GG2.LY/>MCWTV@=1WWI:IO+AA=IEM!D""S@TW_MBIQTHC;Q..=LYR(GZ\$CM*
IQ+0/ZR\$&#QOK6I=0-9!/\$\$_L_I>E#V_*@H!MHF@S=M=3A8_80P_7IK&8J1R>Y_!O"XIS#SJR@!65W6:-
BKF(O%N#;TP/R66ZK;P).6\$0!9#I MP&I02;\$D@UP+OZ-/ZA_U0T##3V9^9!%T_O&?-KWMX=I3W=?MMYVM;<
M;H+2<I\$5\$>/MK*\$/KV=AP_&_&2V#HX#FNI\$0"VI=Y+T64Y)!#3W!BR!6) M2!P0V!VG!M\$+RYQ0ZSEV61&
S!40&'SOA!H714TK#1X1<="R'Z?LEJ T9!
M!J%6.?:>1LX98S*H\$@G.KN.DNPYKZ@2=Y(!/@&K;/7_1B=-_0KD%NE&UNJ MY\$.76RM%-Y@ZVJ-ZE3?
H;^7Y=Z#V8@P'8@EI?(FO!54;-?1UW;@4,T/+<MIM^%>7>W.P"V#VIN:V!8G?9@0Z=4-5K9M;-
W)%KS%IMMD);F_?7KOU@/ MI@J4PCI+3&K(W3.YF*K<6V/#*_W!9 (PQ;\$P0DQO%8O&T2&U
M;V)6!Q2=\$+_SL(4R MKC,H_9YZ(+M^!AR75Z6F(XV-E3!<," K_WD!0^+@G0W-
):Z&C!HKRN85_J51C+WA;SHU>1C3)W"UDL MAK>)PW15L_B7P_T!JBCUB-M"SVPL4<[>X7-T#0+N1U/'#8JM-
61@"O1F"\$BJ!2;S!_BM>J!KIV!@WV/MI!<@S?R0YB:P5!L4KZC72#V9HN@5N3D4K
M6.US!DHC.R\$=FLD)SFAAYV8AV""FP8@N5XD9AXS:N)+A6)\$K9W8+JR MZGX=5#:'-9*Z"L?O(6NZ
Y%JYK94;O!G:.(@#?J\$F>S//O5!^/T?/IBR(MR(CENOJO:AR)F".WD2RO-)%%&0C-6U@P?2>Z!>8(-!(=
IOYE;PU4U%1LG6!U MMM#=#)NBHJX3JX) "1&K/V4#E^LH?QK>HLXF4'M+(1;2HRL2E_-W;_M;
M\$V!E!5_22)4VJ*LF?FF:7!TQK1'UO"C0_#11Z#OTK%L3%+6TI^F:X?G@!IV=GAR+ MB_9!=\$^?NC4WW=:A!
GK!M^P_3TK;CXQ!5X^\$%!.#HY<_PI?BK_@M1!%YV>CH_V)DX&XF3!85X/PX>7LZO-
!+!8GXX_CX87H">;T7#X87@Z M%N.SNF@!V_KT!X^VO3_#!%+>=<#0!>S.@K!OCL;?%XNQ-L1!&&I/T
M!7!\$UIPI^_MPY(PR^%!"I+>QG>O").YZ=;PU61W3RP9T@!U_QH/N10?_+F>7N_MQ_M_6*O)T7>8+_)+K#=#J
!^SO)9L\$"(C?);\$#!J6S0@>5MBH6(TTL_M4IEIWH%I#HHE)M3Z/G21XOX#17U2S!_?V!4L#!!0(-\$J\$1%H-H2T;
MN3!_#>2+0_1_97@Q.3D!C;Q.C.Q.R-"YH=&WM?>EWVTB2V_?I!#NW6YI_M'Z72Z;ZWE)K:_C00"23)+&
"H=DJE^<64B_8*;\$D!DS MXO)) (E.R+CC%\$S^RG!TX!CK_*?_L>/_W-O+WB;AM58)V40YEJ5.@JHPB3# MX+=
(%U^"O3WYU7E;37(S')7!T<1:2;FG!OUXJ+!T9ZJL27!@?_!0=Z MR(C_!>K!&DK@_3_?69>?R^7QP7?T>G!?
+_!>I>@=J8.#4W5R>JS" M_SXZ?X,+H8+^*JBG,3ZK!&)MD;5S!ZQ='62GFQD3EZ/7AP<'?M;X7-F_MEGJL-L/D-
:T7OAVD20GKR.&N)H!ZE!-!TOE>F,9I_OI!_0_!^1#^LGK M(HU-9#_B%1SO'QS TM_!C!GKO7WJBC-8+?
F_\$P4'\$)6S56_M0_W?I_N_9!G09&'4_X'K(G)P?9US=CE0!AF_H6;:CUZ>PK&N=ER94L3R%_M!LA?RP8>O7B9?
>W;_VIM(5!5YL WP_U-O'D!5_0_!X+CK9(H^*B+\$L_ZG_IT^O)-!%J!50^"8X/>G2Z
M!^3%IRIV#V^6%J8T*1Q1':O27.N9QUEX^:"^1/7A%%;E!^4+EE(O:%DY!J= MBU%NUY!"=SK@Z3!LJ<&
<"I>J_A38!GLV35ZS3NCWLM/14NST M^>=>SGOU\$!X%YQ_>?
!YX_F376VI^K&>%JFOR@K!VO!F!@46:PFKTU"MZ;+MOD5^P8Z"8*5=+6"RL@^6;
!>IZI^**/HUZ^W!QPW46FDK!^_WY6.S_KJH/@D-210==_!0H^XH_M?M-
FZS8AF89WQ+""BQ@6^(-7%.DPS16)D0J\$88Z_>O;3U=DO%^ZLW6(+UXV MUH/5ORLHM/T@#"!Z^+CORXO?
FN!VG91^J3S!0^_@Y@!_GMTNI94/4J7B9E_MGD95B\$S!1-DMH>S/2-FS+_S4_5;_K)\$VFWA+3G2-
J+KZ!_!069'!_H#D MS8LG&F)C=BC?J9@5.%)YT9#W;N;)K*2+JYNWUY!#Y_/M!^?Z7X.KB
M_=G?/U!>?HB!Z:3E^AH>'OE^=SN#L_=O@ZN."XNWOWYA-0IWE*93,8R

M!*"JSP=F;ZI%3#&OW(3/DYQ =T4/SE>,<5G6! =D1-^H7">Z*(OT\$/O#E1KO M&IQ/DIVKJ@_ /H3C\WZE&Z3IM^*2.D.<<[J#X3.5KJ/X&F/Y*KB]G"D M"AVD? ?)OQ?K1D?UD2\E^3&OW60;K?2+JEA#U! (GZSB0J]"5%RPT&78UUY2(P M27.ZU/ PKPCSCQ>7GQ? ? M16T\BZ3JE.JPX*>CRL6BR?1JE>4GR^_\$1_/! M"? YIU;Y8J\JLHLMT*,<3HK:~@_9XS3+MY7(23K5C CT/MJ2 7CL17<8")D#_0<4:P5D8IA589T14WQ*JOT2J_V(&3R3= M&!*^(I+JL1.2@4L JM>@GUL.TMH3.;U64;2MD;H/G>.ZT+30.0UU92(7P6F<^E-3WQPY;P.Y>S1B;/ M@BN5EQ.@^1^5R:1/8^6>UT3=/9-T6LAY- M'^^1ISO:L)84^(>LYF51*LJ\$ W#FLLAU@JPA3^V5I^.?^!NNO_F@G- <(I M\$AL!S7!T= ?0#/<%(I-\$,2 X!>&8/3PZKP!?-GE&H#3X(U!*.BE?I^&/'@K/ MX? B86L;M;SW4,UNH/@HJ2U.C^IDY2IK /H7T.M^I"%JKB(JU7Z19ARE%0 M5.&H7D@#"#C_?H+&F09Z.@XCC^*B)73((7Y?PZ8P4+Q5K^'Z^J^BKPE"- M"OIAW6I D!G@.VWB. 7Z(W5BHY)0IS8.ICC\$HSW18 ?6%NL0U0_0#17IT<& M^Y1/7>|P3Q0908PJQ^NX| 7;K6S^49C@85W# MW3EG4;AB9IRD%0M^O%E;P;\$V#&R!+(8- L=J(D_DP*.)3KHTG!E*M>#FX@_SS01NQ%B-M\$XJ\$D>*PI351%J8^LM7.(4F226O:)01E1^|<\$F7(\$ MD2/TCCH3M!..EQ.;!AOK;PH)2L0+YV^NB#Y0B JE2^FVC\\$/=WKG M5?%1B;^19KS9F2-5;V? 1RD>'\$1/129M,3DI^S@TKC3:0:_@_/X(A)8IY MD4!09" (KX+QE*B_!@("U&)BOPYWR\$W.V!;+PRN4T.HA!^58)>,\$1GEIX8@^-MSH|XTW"IRC3-.(MS?5 YI@4VGC@ W- MH@K.+MSP&KZA6W@G.X"GPXWX=)LD MC*M(AV%U^R^*G?"IE#FP61' @91H(M+FFK0F?;EIS_ A8PQH3#> (%#S2V2R4& MX2@-8AKJH@QVM\$*A0^18<IO\$ @O_IV/P.2M5^H5&H8@GO\M&P|F0%C&21^ M|LO17Y QJ-2C. ((V&90M<6KG>X@A;P^QQVD|FI>21.XC|AZ!;5Y- MUA/G_7\$ KBI!P.F79999V@|D".Z^28W "8MJX",#N^YO@Z& (.I+)%E(*;J M_3RMDD+UG#_.07S!IG!6WA@-6A.&&0Y&URY)7)R1|P2=-1 L.GSL|5#CK8VTG MPRY^A|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|H0^09|B%1BR1 L# MDUQ9K=4DH^9^H^*#JB;H(E^C10U7.I1\$%>_*V3^13=M!>CZ/94DF|FURL9 M^B_7(=B!;Q^D5C^Z)189;!CR:(? V\W;&87M9M*)BM[G+4M;N7DS]# M61&P|FKMX0+;DB6QT0?TP|&SQD4)(>N\$-6@!4T5QIGC6^GS- TH9(LTCM.;8.;OIK^&Z9)(8)!\$3 MS^~M<+LAQH^3AK|IY^UAX2(HIZY61A&UO)Y%F^*QAJ>^|J2ZBA#W)_#"<1 M(92)Y|JXGS.3(NW\$4MP&TWL@J>+S5EG5M:FNA3@M2.(ZO|=N^XW;RI@5M? M;ISR..O)_G- ZZ>#!ES&O.FC!6(+;\$I^&#ZX=|<I63/KG%&*S=5CSYP/""LYV4.I+X&*V@WN!GIO-4W.#6Z;/P!=O^R M;.)9YL\$- /)!%_V18_L|3D#=#WWPUA>AM^9^HFR)C"!^*Q8<; PK4IE*.W2 M#K_!|!#2IE_9. VH61^V56;765%O5LOWA3^AHM+X^RH!QOEC!>R5C!8/^ MC0.>98O>B""%1<6#K<.;BY JTN^70%; I9FM+M>=^I(HYRSUCF50V#YJJK@ZC3KZUOO M\$5Z! (D.'8JQ%\$MYSG+W^6&)?7#%(SP^?G<(6_.IM_U; M:5|^@K_!^!_UY3=L>|A|+4K_DK5T1^;=JEE>M=X@>*.396QQM9HH<4X|(M90TU<8W.U2G)^OH4|VN MNF8;W>_9FH_W%BCQX^%3\$5Y>ZH<_-<3RCF^IS\$>5B|TP^Y3-0S70 ML:0D&RVS;#5)*L%>U#26/4%+3@D8=QC+TYR|6T>NY>9.S@;F_2G^*K541K4J^'88ZQ5OM0KM9N% ME^GBX @TUPJ4U%1BO_*COM3QH!;P7.'8A3?%#|31B0V|O(= R.- \$OG5OM|_ MZQ(KE? C9YIK&C1JN1!OZ\$/<@L=IT;OD^|.5|V2#"251PKM=P55QN|_90LZ% M.;T)LSUD)VA M4O715DM(Q;Z3;8=&JTN^PN^"2^Q@_.1O^ZN>IBF(VZ\$|NL-1SF ?3UBHHAAD/ M<|S^G2AN^986I7K?)F+82. <0I2@DMP+TY?. ++9)M-VAMDKS-M7|QE2^JN-*I M6>_7M1(+9I!@%20N&RN(3(&TKK6+<(%8FA#)58- K^"YJ5_Q|H/MC-4FN^*_MB)MK)4\$UA^J06DEL^=C+TLRY?V1BQ!)?>IT3H9E/UL(D;HD Y+Y&7R\$WX; N07FY@CF3&UY6D4WL R05+KLS7DFE;WT;KKP+QK>+H.54UYPI_!(BORCYGS= M9^IB""M#;/7G\$7W#N".WA_N|S1 L-Y7A:X+_(MY.M+^IGS8V1%K&I7(= &FRXG,+&\$0N0LMBEY^Q^BA8L- OUY&74<6|O^E!2W MYI9>N>L^IK0M/Y=|>>KUTMO.2|>*O|VG;STCL=K\$2&0ZHY-IO^7#^W7O3_H MFA^2C|^6TSYH^|8L_7F/0I0IRC2D *9^GU2^;+S+_.6^*5^|43*)2>6; M^N).^OZQTZU_HV77L1U=1;I_-Q&4T ^/=^7NA;FE64K#Y?O.V2=3!7!\$>E;U! IP3Q@YN. M?B|Z;_ ^H_0&81M6?JDXZD&J2^TBA\$6%;W3F0^IOP)A MXMO/%K=@S5/Q&I^BM2&1L;5(HC&^DT#ON+A..N7>A9^T6V&D^H7-AT^CK=8!/ @)_Z+?B<%7)7XMM;TZ5L\$ M0ED!%#%(+JL_3.7K1^XX.#E!\$JAK MOHX/1158!%/V0&1-8=LR2*@WG7Z;W14@UNWT^VP-3^FEV6H3|X<_RP7 P MC;H^H^H/8/3P! K8!/=^ZKL;E6;JNNW.F!TN1^!SQ@1HHPM;Z6V(RIU MC^MJA^K8KG^Z^G&53UXSX6=OX5H&AJKYKXSEK+ZF^9&*G6"!@7%|H#QL!N- M6\$TUBLOFIV;QDXUJ5 >PT|8|OCT+1T61\$!|F)"N_&@.EAF#.O2G&=4IXSY9 MO^F^B^IXVPB8EU.89T3 MVIP-W^ % (0XHNX\$S^Q^;K^2O^LMM56H9@LGYVIT1I6L+9S8=Y_6JU<|;.* M?4E^4IB<^3V@2\$^9 ULU8<H;.#%OP#GL)5N^4M8^Y<3T8E#^*!6R_"E;F! MN&P&K("1<(9K!37,EB(RNA=2VB2Y..A^>3E@A MODDA85X&^TIRYN&^#L%6J7FBFZ.E&5TJE&J)ZYG5^8^!>D1#;@^N.TQ2 M.2WN2)OW GJ^B=-46(OB1 >@SL(D+W/2;.>@JZ>W+^ M|D#0=^@S#TKH3UY9Y\$(YM&K(^H=L3.6>RL(3G(6=ZK;GOOS^8X3QRB,+^P< M6%V|D)(U1M098B+Y&\$H^HOCQ)"3C=+(/;Q!@^*0XQCI\$%>&@LOK%2@MU!R! M^;^WR^AE!7:7F&LPB\$8C:0=74#9#C;JIGS^J^G9>@S<.*XEP?X.Y@X.8) M&U_BWR(0VQA=7- WYQ^J2^"2RQ5>@IMU>.*NH=O^WKD?>@7Q_4-U8#"LMA#| M^|94.7S>1^|PP;I5)"O_/0\$9^*1>W#)^_DZ./G(!SV_B9EJ^N8#)R?;+ MY&RI"!^F|BPXJ>DXYW@_M0JZXD.G%O8"=? AMI 9P)OQIX;LQ! +@4>^GL|57%AJ^|(^9"=A6|=6^*P;@ M.@P/04A -(&(*7!^9)Z80JR9&J;JYV-7^7!5WX91Y4Q^D|. (.&B|HP8K)_S MNP+YOPZOOTK3ADON/%3"@;MK1%#OO)(8W4|_0CM3)D(%\$3NX^90=+J.8V1D M:1.X41DU^L2QLHAL3E-4253LHIMR;Z|PM J9UH<;MU(!@=\$;U#;4IHVN M#X? 2IWZ#)PD|)SOXVJH9|8V|0_4XH(DC| M^H7!)MJ^WA2-D8XC^37@+17PE2. M&32^#P;Q^P@6^NR?AJ&:3^ Q^U&%#^HUT-9W!2=|^DG&1X|^5-01M\$NS^&. ML;8^%SL1LULJ;R:C5V-1X(FYL>4N>IS<4^QXHT)B^C; f@|;"4GP5QT2V1 M(SEYXU|T&0WW1(. 8.4^5)XQC<@ZP+4S;LS24O^6.*5A!^H;09BI>NDE M,F7KH,>>U/B^U7G=R=D!%I;B;^\$T0!_-BN\$9!^;1>+33(S M3;IR^52/85%FQH.NHD/|?N20B^VX6QPV5%;P< RDQY&VZO/;"ZM|^8+DV2 MR;^*8%HE>(F57FYVZ2%^2%;4=;2\$A|^FV-5RZ;OLFGZ5=B).O+ M=AIW@Z>7.@_\$? F18^9;UJ^AYWN&SX#.^IVAU%3)7;D1CT^&=L#;+!RW53 M=C ^9>VDIA\$M=;_J_7/HCFEM+|+JS|BUAPEZ8K3PV\$K^?CUCBB=3|>H|^!L M(BS8X |D;#)#=K;+ %V&^|NT.E@>58L>CYUMRX|2ST+?_ZO.949Z<;9)5. MYFUL0F.HED30;\$" N=[MZ'\$1RS? 7U^!NW.&20+;\$-B\$R7#7;PX-L;4VBSW&;?_..DIOI7I>PPX)/ MU O^)^1A\$))C>?KR|ND-K *GPH; YU=;Q=J856!;0B"">ZZ@#^@TI5Q+U2? MQWO3#GDVP)M D8)-SCJ++=|4A5|P^#%>YBB(-;&3G3L;FYMZ>D& <==;QI7%M(MVKN.M+<|T/G|W|RKACDE+;SVT\$|ICVOMX5*(Q%+A^%HT\$-42B|_3^%@_*T M^FD^H|^SK6=UV)UVPH&S#|S&-5I6H^YUER/35|1RWT85;UB 'M!L1>^)-J5;^#P.RYZQ5;Q%|E_JB (?TC&L^Y M#42|V|^F#RXTSN8>4^Y)?\$&3;29?&+4 =M\$6_.4<<762H1L; >|8@/D).*K;.TIGE MA00)!? \$AHB:1A>"DT@HAX.*2\$W#^#R7!.IZWKD;/&S_?8@!_O5S9ZBZ\$3;/U| M3^J&.%\$C^H6(^R_9Y|W-;L582Z\$4)R)%TKL.. I7^2K;+419NW5L|HU^XC M^79-D7QUJ.^7L5K1/4%B_^-^29PQ++H^(+6Y(^K2IW%;RM@H|)(Q#&73Q&7V@<4 MONAT/1^5^X2F-TK^/9BH4;_Q)R15+4#O^-= \$YF|^XCPFB%+P0K>LD3Z M|^&ZXX#_LHJM_4F+S\$C#KWV-

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~*~7;\$[Y!+M=\$WY!S& (8>JGH)SA!="">K!KW5<JBM,J7S750 M!)GZ51C+!F!QCEU1!Z? Y4!DFCOK3&Z0,? 4MPML8%Q!NHDW!BOV3)O3 ML9!C5.E%@/!X!> 5JR54S!&+!4#16W!ZW O!OL+90XP@ ^,Y!H>E)YU7#9AR_W3T!QG:N\$=OKK!AS!0K\$,0SO M!WCP!5,R3:C,"!6M_@^D9YB!-Z^V\$!^7?50XJ=E!KK? \$B8+%ZY*6)/:\$J9 MIH!?!?E!F"5R+Y5+OH*,3KZJ^Y>|/*T8-!H#IV0K2;P(V5?) M%T\$%(6 N7P62"T,%!%N=XF!U,R4.H+,,NC,J!P!="">*#5PMK%!,;8#ME8! MR*O:%C%@">MM)/R!YQH?>R (L.2E4H.KG!9H4U\$3!131WM>QU30GL-(E!M!L&+@,X"W!9F=X#NH MY>X6/1C?M1@ES5G4A=-,L*R MVA929;0N5!FKW!&E2*Y-GM;OF)!2>|NX!6;500EP_2P=1Q0A5;8T!L:@KO: MKV? 0+D(Q!F0N?#10(<~*S58JS=-_7A3XR-63KB3G4\$=IX5,50-B MHQ9QK;Z59XCKXW=Y!&9F!#30^#=-4NP8WT)F^K!)J*6MC-!(@%>@3;HK!^*9. MH1.3^A4>O>" +GDBN)=&Q=930\$#?KHC\$A>U"7ET/!>O!_#3,!,F\$Q&77 M!5!6A>&YASK9TN.=K@LUX2CAM#<2YOE::AUY#S.&2EHEP!9LCQGMBOXDP3!D M7F4E1G;," ^PU4IS"Q&U0\$M04Z@?2/00>WBR86%4A8 MW Cl=;3PM;ZU*FK1QSR1ZO"AM6" R@/KR;R:4=3!P!/@DN9_-P;XLKM=HU MDV"4Z.MEJK::=2QY!@"^PM+0*1UR/POB0/6!6.1!%X9O>A>+ MPUD6?1T?:VM%5;7IX(EAN1NU*O)^A:_%FXR?5! !V=1&*?/\$Z6^W:Z%(UJ M=|!T693TO_9/(25!T3OED&RK46!->7&^,2' ?W<35ZLBBLRM2NZ0_9+@ MT!ST!EPY5;O+YS?MR9)F-Q"<!QG7<6<. 83NJ%V4,B.%&+R:9T2B"GO CNP MF\$ CLYQF=J'FNBXL*":V,13V!OT F! S'IZB@_79RC!34>5XDA6F+-\$GM M"0GUL!3Y3N;TB*FX":1YCZW0L,95@Q!/?&10!6^Z"K46C7V6S!3G!WT D7 MI" +KXRB*M,7E9ZEOSI?&F-PBGOM!7!1L8O!A)C2T?9T!+WCO=H'F!OPVE M4:KN!56!; R!;>^B#.D?ZC A*UZ49!MI7CP4\$B@%-%S"G#G8.=WD(E.WM MCT!A^12KRTHQ;"\$L(IQG"U^Q!#F*R@W!A%U(<?> 6DAFL&P7Y,2Z5&#WM)# M*>HUN\BP-U>N;+ #R7!5'W&49!H!)B'L:HN!R3^2>6 R M=*0Q9GLA1B1U!%4,3,@N"DB!>"NS0T.=D)C5!IV",S2T7@5*TIB?<"NC!M2+ XV^/9G8'BH+-G(JH UZ,8VU7N=X!LS#7!>EN4:#,(@9HD0!9V/9QAM MHI7!0E5G_!2* 1XKF!QU7H1-DCOR8=8P*!8*!E)6WW! 5VXT(? 2/!O=>;G+ MF8)!>9;@8UQ9-G>LE.>32=3(W5OZZPE3UL F@+ML MN^KE468;+*=,+"!RDCI+1L!0!5O_8!Q J!K!<I:OKTG"4+U,1!@70<9!S MI(=*J!34@);R^/GZG,10%A<18C33UD2(299=140=6<+!JHHM,"\$!HK7(Q4/FK# +?Q!HMD;M@WB "6419;-2,*P!0(NE9"" M;L5!0!1FQ32\$!B!9TA;P;W@_#0.Q28+! S'QNV/X/FZ\$7N MH,190_R^;B('&DL!^T9TX/AZG#3R!LS==@Y GN0Y^~^QH:-W=C;K3^TL5) M8,S9!F8.QY>33.!LR#3 T8;,DXRXD8/!YG0!N1.M,J!-!ROX2P7-N;Q*#;Z M'=-9X4L_934V>8HXAPL!U(6-(\$N!SI8S!R"#1 K!Y8S",7;13%19!T>OGZ<!MG"!>P!A+;HQAEP"V#(QD\$G!NBLEC4Q:%Q*LIHHRCPCG^!SU&Y2:E>;_UAO4 M13(<1>9C)\$!PRX^@)A.XPS>P^UV%AJEL#&(I+ B@_Q44@E7L7#E?C)O%P! MCG14Q>P;D!G7=R);+O&#PC;Z- #9>#&10AWMT&K!8>(|S&1%HZNH:N><(< MX0ZK%W'VJAS!H>"@&D#A*#3%AN'0!L,,ZDQD7(!&6J^Z^S!/: ^J!D!S M/L(*UW!S,K>MW!VCD2(#F8<<_&BN!P!JWKB;*ZX@!9!WR1KT)0'8J!;EF M>|ATX*8S.+! :A&L!Y;7_JB"3!6=TAXM:U%|A!=- MW3MT#|UB5UV5)=8_10!6M&"DHGAP(3A/39UEQ(!?@!L"%U>T@G< MY5"!9(3!70\$U!T0HBC(*GM!2_?Y7E!^!E?<#G1YO^>)J.Y0!5_39ZYK4;54.SAFQ@VMA M#<CE#!9Q8; <(+4AOD9"\$NS-24SU6G8LP""*VWU(>\$_G419\$4!F;77!|ZK5) M55P#A1CM%=2(!/ <);#!W"EXOS;EMRNB4W5W!LQ!ZV MZ"\$("6.9)E\$!P*^!B!JES\$L@J^V@SB#;&JH3OM0?K9+YV@&UM!;S3S#7(M^"!|4!R"&7C@APQNH!#^,68K>T&^6<3/L?T!H!ALM&>MACR2^T7+V""N7Q<3-!>U!9!F9A MWS#>>G=QJ(7 _M-5;0\$T08=NWE,*>/_O=>H!7!D8!+NLTQ\$8KYD(FEBCUD4VM^E6@1WG>5&L4#MZ&9%8D!Z0!ZR M"=N039B#4-"E^VS5NQISC<; #EY%O(M,,PZ+^10L2Y#X#4T%4>4!B5*NI^K M5&1JD*@C!L;L;B^#S# (<6<J8ATL!T^7)^!>P=P.TA?G6M=5S*=<32_@-E!K!<W?>RA_BBN&E)XJ%HA!OJLYM!23VIM&K!7T>EZ>? EF08(="75!UN_+>|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|PLY!^_OKW"U7!7X"KOY^!_W3;WEI(* <|!U=;BLN!^F%/FM/52!JV!7C=C/AY?O/ M'S^!_? 7!|<6^!M!6W9L(L%0W2M@MD<0D;0(+*&I(6")6SSMNS+;@&=HPN6DX^BBN4FKKP!C"> M:;XD& !AU*1;!GB&2&1#2@!O!26 PO!F^,0T<+5N8,#PSY<,,|CMT!VJ#" MC@UK5&=^8Q!\$!ZFH,0CN;(<C!V!OU;| EQAO&E8L#2Z"NXX,NMV"ZLHV;41 M_P7JHZ,RZZ&7YP7^;T8&&Q**_PV\$V",# /4*#8<;<6^9RF69!8Y"6_W(R; M!DI3#(RXDG552@A!@VPPORIE>>&S64+L!&\$3!J,JY<3+SG>5;f;JZL=IY"9N M!_Q1BI!DWWC4=3K8=9& 1B<@89,,TBD0!KA1^A!Y!<T%5FV!0!8Z<#@!>;B@_KSN&AY25&LN!2(,7Z,M>R&U9D;O+5C!O6^!;*H4@DZ M4A!O>7!2@R6>J.YT.G(RZZORWT"7;1A5)=MEC>0BM IE"#S!PUN)*(PH=M(P!7#@_VKC2U'5S#\$D; (T;3YTTK#WQ.ZU&Z5%;">|YA"!"^*+2BK@!JV96 MYFK<'46;D!XGG!<)5E+""Y# IQ=^!P!Y!TN0+,,TC8!*XL&!"14!0'4 M2>9;Y" "5G"7C!Y&JU>,,1N7!/#3'R"#Y^Z<;#YK"IZU>|FW9;>-Y)V+U?/ MO=EG;6SOBP;#;GK5U\$415KBX6!M!R!9!_9\$;F.W,6!156PV+WWA0)-%Z4JR&2 MEU3%0>U7R!;XX!/@P.4IV= !AQN6C%U=Y!7X<@FQ!0T-PI<0;KN+!A!M!WQ M;M4VQZD4DSH;D9W94@IR!#6!;@&?#0QW-SB3GKF? B=Z+\$8X MSPES0;|!71X?;Z!L3)(NT!0!<!(BUAH8&VUC!*_SP!L!G!O!8!9;L,26*Q. M8!V^(<=HG@)^>_!_!E%2:P@_O@K/@G!>_?WRW>7%VV!6*O+Q18WOTQ4@ M""A;*V:-#,\$@JG+MM5(U7 4N*!SHB&0V!QQ7)5_/&UU84%">3A&KDNM>; M!\$S%10/N+ CBW"7"(V.J;\$%2HFWLQ6%&NAAI?*(2!_EME+=EE^GW5@1 MMA"R9,>>^NBK#C^&HL!Z4L,X* =V?>|M!A3N!&A&Y (QHK5&?<P:=SMA-M@; (L:B!+_A'/8N-"VL9^,H9L,9K"R>@4*8RQPMO'B7D!5<6'71MNP>FWO(6F8%MBO)N!A!+(AB!T@5&S^<:> <(XIDYT MG+WD41YK^2WR=-!Z4!>38.25P2YBR5M,9NZ?=\$0S=19%^^TN,,1PCFPZ,UN MI_ =O=9!U.I4VP&- >MB_P!|LR:AH3X<T!%&^OL*CV!&#OG_@<^!>=5-U MZN+U=P;+K;#!+!WA8H09BT;ZV;LX;O?5T?X F60T;33HT;BKV9+(1LHE'(B1+@34L,3E/4QQ8NO=A, BNZ\$565W&R0NP M)4)J,Y*55DAQ^!F;H_#@4- L05KDQZ#V;%M@Y^A&8 H2SH;+H";1=@Q9+!|?0YV5DC?QIM-8AISA M2\$I=XGR!|!\$%Q8!V+^A^!Z&Z5P=KABA

@NE@7TO@V*.\$WWOZC=\$*1MD;JXUXF(P;=>/N6Y4%\$6A?>9/F%*N1J#D1'8@{6FXI9.BVWF
 M.M(I+'H#.YT.Y1JE8050RLPC@)O.C3Y2A!.EL*O M3A;@CEI/ F3CN.I.MTIA6OMC-
 C#B;JG0F!=?.+UJ8(SIX)5@ATU>8).I+ M^TVU, +IRP!H/7^&2*O\.\$>6)L-8-W+FTFI%E6D<(9-^=G+;G1C6L|\$B=>
 MHEB/PL=>F^**N1\$80D0VB3|LB|4%'C%J>Y9.=6"A.R&Y&5<1)9FFK/6GRV MP^V, >1^ \FC9VZW/5ZI>Q%U-
 MPQ-PAA>I.Q*M08=-A> ME9\$=;\$K>)%44.6B4@Z*FY|FV\$|XZI8.IQO#^XGC%?#,.7-Z>3.#GDL;7-PP\$
 M6"DL_2@|QSJ@+<'.(*.A@0ACY|TD(LX M_L<#X3DOF>"L;EUL5OWF>#@_KV.Q+*0E<>|IG#7:B(<*HGX
 MN21H#X;|9XSZ6A+1+@OJO9AQR+!"@X\$*B=;^WL;JH;=F0Z;VEFO=;|OI> M4F.&X@3WI;+|"E+2K (. (MYH6>?E|
 <""HEG."^HSHA-/53&O|9I|H|Q.MGBLTC\$U15&SO.R1|/03.291ZDW J9BI3=|@SWIO5W2QWX4H|K;FNZ(SJRYM
 M\$4.-L=.=OJ;=>(J5GNT=;UBL=,4%Q**RIZNRIGBT8!>9|(+A/6\$|H\$C-%)F M9?P&B.>06B|G'SD-|B:T8|D2+^#I
 MP\$|E;4(-?K|6;+J49NO>%OA3IH MN#A|RWLW3P&T|:4W|<|*Z\$O.48ORYR;C@|IVR|GRU@ER/#\$E<1D;|LA79^
 M1G;GECT76WYR|G;HZ+(GISNOYJ"GK4%KIA2(I3D*7H:D+EZ<\$9F2>7*4@DDB MZ_S9;
 HGU#V@4;E@E&/XK\$M|E%<16V1"G2;6@O|BY<XP_&!)<=<8!2^A M&7MB?>;K9R0?
 1.&*0F)I67).PH0M*02LEB,?YE7?^12\$+6S#-O|9/T^
 M.;#O;7IT(BUU|!*8;BL!^EQS@/B=RX&KE8WHY|U_%%&RFVN)L'PPB,^YOX M48;.@A("D|B+*/KNK^,U-
 H|)89V&E=7=%%PP.#\$A>P,*|YHXW.98%);|V ML\$YQ| M1O P87.PG2Z5B8M9P.9)|J6I9*I-R-
 &^N=)DS.NR<76I&YJU&""9GK;GS0RG MI#%GW@0QOQVOX^"Z6W!..094U)V VCK52"C-M
 "O=2J|U_8V3>CO=MOD(=1 M7E1(/8.% SB2/?2YQAI8"SH+5GVK*ZW'=3;^_ ^F|J*^#V(HV@Q4.8|N-
 MTFNIE7PZV#.|1-Y%NUHA,)+W3+1|"T|D% HCZR|X)#>X.KY1(*+P6-S(=SA^B&=*G@Y">15ZR.J/E%FEO@0L:3
 M.BZFW<*V\$3C/Q\$|B.O.L&7^&>5Z|;W4OCISEZH9NO4CC-R>S(|<_M|HPG| M.RK^4 _U|+ P04 " !*A\$1;-|/OC8T^
 "Q|H \$0.&5X.C\$Q.3(S M.3(P.C0N:1M|=UKR;BI2;|L|WC""IU(*M(D4/*DKU? M-L|,2\$0P"=|
 IECTKW^!)^FJ+L2.&R|<=T>TNUU4D2E>>#&@W_ JV7Y M_3_G2A;?_Z|_N^# W%EW|HJ3"5RIV2E"E%
 L;9I%8Z!0AP<|XJLZN-T| S M2G1;G1Q;?U"O|CMZY6N2O7|_GW^<^8 MO_S4V' ^FB|WW_RSTB|?%?WRE
 M3XK|H|BTR) RINGQ^?%L\$|>"+4W5^?D?P|G|U_XJ_7PXIN_XZM-J2IC M|JZ4V|W.5/_X|
 |AV: WP77SEXDDM=;K|H|U>*B NU%L|!%*:O W=2^_/O'+Z M;?N#7O^BOFVWPX|M;9>)|2&
 |5_P'8G/M+UC|W^9?|>=J|7^ (^| M|!_6H|^="^_ BU3W|Q#WZ;|RYROVW_SJ=?^G7Z2E95O.5D@LQ=G:E7*65
 M_|OHF_SPD|_NK_|LTWK|=;&E"X_|EW_8KA?V2=RHf:NEVXCVWYN ^|W"7DKW
 M'&*CLJMO8U#|UFIHR5FHC|_LZY0|B#|J5<>?7M_OH5VB_*N7F6VV;9VK^ MTG>|=Y_9JK++Y@->HGPNR|V'-
)^W??E|0|ZVMD%9A=)=%%M|WKU|V+STCZKY
 M|+73XV/CX^/??:EUV/Y3KW4.CT|_W+O^T<;>M0|/+CK TMO^H_DBME|&^+|I M2IK ^.KHJU^1|+
 |D4+L6;TM=B'U96|F#7RMYW5.|^V+A43Y^0;_ G_ | M.KS&_J'RWX@|N52O17;W|S&;
 H_S5KQ| KJ#W TC|DZ/ J&ME'PE |.WM1. M^T+GE;8FQOK(4NG?Y;?W?BQK|E|R|28/ 6B&*|<"74H*? /;?"45|KG
 M-CS41HRE6XBKZ|^+P2#|'RE0GWYA7|2W=;5*N99.24Y1^9)^OW;K|+;+QU7|_ M_Y?T;2/?-
 PZ;+=.6N(Q=C+E4DPKIU0E|LJ\$&T?"/XOZ=M)7?^HU6D='+6. M6B*3H2|JPGO*0KOY'.R'|@V|LD|8|D|URR^TO|0?
 K4U3WQ;2\$|/ ^B5|Z03' MG6.QK9=+7>WG\$3?LWZ4M?M|JB)Z2Q<^U=)5R7HRM#H_1_R_*5Y;=^|3Y3T|
 M1" |>ZCF^U(G37W6;HE+|YKRM=R(X>B2W\$ESGY|Q;BYUXVYQ).3*FE|H|_IO_|FDB4W1|JL|WH>JHW/TST'_AZ-
 2C=)G98 MDW6?9&*B|_G2FD*.2YDK.5&R%->^DI42/5O&7|6#EX+D*WO7;JNW.#R/?^S9 M;4_?
 O;62='+OH1&^&9\$|PY|*3>=>TIT|Y|K|77<.\$9Q#^GI+A2+Z|TJ|CS MGNQ|P=B;UYT62HQ5\$5|+ #%Z>M*Y8D<|
 <7D;.^HS9^V'"#7KZVDZ;(@S** TA MO5F^Q?O>W'(^E;AV;H6U18SK|48W3W\$8<49WXM;ZDL9H*2ZUK50^%
 |>R4G? MQ\$ O=5KZ&4M7Q9B2ZQ6+0?K%8;_2H;8); GLRU;H5D\$6 1>_C'0L_+Z M^'9WDH<\$-
 QQ.WL8O>A;MYJ#)0|UE7B'NG7U0S|. ^#!_VMLNY9RW2|G?; MY9>CUM'KH%|@|J|U3;F2;=(SZ<*S|NQ'Y4-
 P;P;??:@^FFN;+^@V MR<0W7Y|WVNWOQ(U3JK|+<2.U6|N-%|>V?|*9K9U'C_OD&_K?*>|H;RL1#57
 MXB%4|O*9>ZN02L) +E0H|JX2TYBM@+7 |G_H|D/^_VG^6A_E;1Y9;<|DK|U MX;T|_) ^VWS+K-GZ_U?D3-
 OR|KZ|*|H3M_ ^OV8A^12;P8EZ5B;2 MB)%2XC%4 HQ^_/X226.*F|_%C71+|@%"4 G|P(CJAQQ=SA|_<^<^GD4'|_ |PI>KTWB+|MM_|I M_ '%#C|YP_ES'02|V7.F|+P|PPNE (4W|.#Z|1?JF;<-
 U\$Q|DW_|R/X|1%W;1U4F>#/G|^_4| M;J>M?37>=MUK6?V91#SZ_|H?|@UDFGF(O;+6-J|)+0Z0?U7+HRO-U8ON@R
 M|HK95>9D3YQ=;=JYMX9Y #_VMCM01MKBA1F?4^7>W3|80;HUL|.. ^2=+?_ MEO5RIB7K|_0#?
 +R|KD7\$*WO@.@S|Y;=:13#BY|0PWK=WSZW4.3HD;F8>;>|6|
 M|SH.#H&+P<#6VB>=Z|HM0GM>OM|G<5EK#M6^ ^GZHXX4>MDK7O2|+|'9B'*M| M5O;)>5-8?
 8+ _OMQ.=;=R9Q|U|W-M_X_ZY7Q+3N'J9=2W^2.BM#*;FV2C*A>6T M^SSA|_MT5(-GOR@YD|J%OUB)S'(|0?
 @VND|_8M.=N;@:9>)JTBPMYQ;<>BC= M|AYZ2=N;R.DCW|2F&S&UPZ.2|9J|LH+U=>_B^%0.SL?|J^T?
 M+9#N6|^>M2O4A74|J%_|@5VOZ5K?RF2)>2W+P K B7A4H?&?5M8H5OU@ M|BT0019#&|2%U" _|KV3-#X-
 =APZ?K|29X&F=QRZ_-'(IMW.I METKF|C_+&6&Y8'E K@O+UK^X?YE5W'55DV \$#^H>|_ (@8R_H/G|)#L1^%
 M_HV39L\$Q'YK^N6@W8|YFHC-. 2B/|<|N;|> ^+MAD7|?";X>60AP"L&%F_JZ MFHOSX_/KO>+?<?
 9|N|J=XZWJ|W#_&T8|NF5YZ@/ROH|A^ET|6S6EE?B42_ M.#8GYQ|_M_?G;?)Q0;?"RX>|5>9Q=G#;MQ|H?
 M/@|H42=Z&K'S.\$3=C9 M|UCJZ;2.Q'09_I830|T)2K"0;W=V77VI#4?Y;A'HGU2S?2C>T|OPC;Y;>E/YHMZ1|6=9J;>-
 Q/18 I)PWKK8% H K6SPKXD/A7UR(MOBEJ7SG_ \$SQ@^\$>AT;^4;B;=%&^L*Z3A01|H0L|575C|=NN#J|B@^&?_&
 |I MSP* 4 Z+7|I0G|_#U5-W,W-OC^2_LD)SW\$@^U^"">3_2M|1?+Y
 M;5MXTA8|Z9PM_*QV|IB=83"|+>GGXM0X&^;VZICZ1_&OAO92G2;<6);S3| M|W-Q'1_|M_2+|V

GD\VPi&5^+XW\$+P%#G< TL MX2S)#L"/\XZ5=L=3CS"!%7M'YWL,,L:'S3J3IKGX@<3A E7JCE-27D4^4Z+
MI#RIR?BIE!D85BOFMW\K/*A^.,6YS@0!4;UV(JG(FO9>%=2*33T*,<1X ML>9F+I#^GG02/OU!-(H/OV,?
C^J^KNYR*Q!(MEN@I688N<-)/, M@ O><6@W1*7I^RG-/>+&!% U!9C9Y^4JSKE,N!2-Y;^ MD;A>;OJ*R4N: YB?
M!992DYZYB=3V4_EGGN+-2CSR,^08Q!/?Q^W MI3)K:POV!;DS!\$=*FK^3=?
GW2:9! Y18W#CZ@,G#4.HJ!8MGM0K?WYI M+*!@A.\$ VFIENIC@901P^L>IU9S,EJ5Z5FSIH?AC4N+M%-
!%,00"#OF@L, : M,6^!RS?LI@&QGX?>WI%IG=^918B92G"VZYS\$ MP;5!+H.ZU>\$9N#U(I B?;65SEF<2S+I=
M/A>79:UFUIC OJOWV>+ #E8/3ELBDL!\$2!#R3!Z?>4U(I<'/O\$Q\,ZI^+> MUOF\XM\$L+/GP'_\$V;ML,D;IAV\$/A7I-
^# Q#&_SI%7)4!@HIO63=1_LTA9! MT39B)S MRL?(<52 %*>OWP5OEB'=.KI&P9YIN M
_ZCNVD!=%,09!5GQPX\$?3+XBI^J7T9:OUDL!;!\$#JHTMQ4YN""3PD;151Q",YI@LT?'
M\$9>O(P@Z^8J^OV>;BW+!>\$!X^X>QR-KGX2P^NK?M8=B*PI^P)7WZ!#?3 MGK@NQ5AZ*X;J>-UOHEPI-
E89!;/&+P84!;!#?RJ-Z)K*F#W#N,ZO="5+VN/9
MLZV/P!KE*\$S\$G2Q+SYD<*"8C"!DHA^>+.,%W+W_%*W&=E1V/73D^>O?R3S-MGG3.%GY6N^=7=PI=>#
HM#22"2,<"IRI#>^1AZ,9(OX! *ZO-Z^PW!PGX M3^C)#L/^\$)IU^R\$K,10ZJD-
B>,"E!71:DJNS;IE*_GF>.EIZ%5)SL NS\$R#YVXN"M>;S?%CNONXA9!<'H^,S449J^XE5V+D
MYPOKN28)0C^I)\$A#H/3^+&3J>_0E7*!#\$YIN\$G,6S\$N-2_L+L+2CP:;\$8
M6N.IXG0UB/AV<>*RM*89GKOB5A,4^?N!F(91=ZSI*0XA_H/9WN_D)#>JHJ= M!^@'PB#
<'Y6OPGM9KUY468EIY92JN-L(-^GNE3J-95'9I?A!IF PR=, &0B MLO-83!89+46 W! IH! *_@L\$ T!W\$?7J/WI.
I^1^C"YFL<.UD^2XRV0HC7R. MRVW(W,E!^OOT=I0.VWM: E<*C&V.I+OSG! ?UGK;9X>6'VICE+=5LA7!M?35
M6AMFS?H^J!%Y2N8R!OJ!;G)M>+T M0&O^\$OIRZRG>;?MQ+>=ZDH5KP\$ _URL6@52+P\$WW.A-)R(;7S'8TY?
>3!.) M?^O.9EKS!S1_K 4!&>K"OH#N6>69;=1&^<.)ZY>U27-GPO'P&D,6@9YU7 M?FY57&5=*I=K6;
(H0!:%NR8!VXVM3>^8&J I=C@D.!!)+,6Y8+N M6.XV7P1V3N1@L>L.OE\$!??
6#M^%IMYGUM!MS;)ZVN:S+1=Q1V!F#.&^>?KX MI+MI/O=3!J! ?F7.6V6J.EIL,/'A:TQ*GO JIN AR,
<+!L8Q4UF_+!.,KL(C M!DQDXM7^!_043U0Q:/IVS3LQNCMC8CP MG3M0=;(GSCX='URI>-
U"-9!_3063+W^R<27GQ!6\$^>UDVMLEWAI C*M^K=I*G2MR3N5:FD&):61/> M(N;=CL!6?CQ-L+).5JK
I4!P^O25>N8AK=OC^W9!E!RN5S5G*4\$@1^JY4PY M:F-HWT_0<-6E3!V)*TW;2IS4-.0AM,F=.'?X!8I=JK!K2-
!7S.P#50)^4>6' MVT5?S\$6-^K)YV_K90='YU6"/(<7)49RL;I(X;+BQ02OT@AT)^!7X8?L)J3KT#F M!RKV7;U21\$="?
R<9Y>F#MUOM.#!W;J955 'HQY6+0SBNNJ 4@%@"AK+0GK? M@I^?G1R=I*W4*_W7=Z.Z0!HCKM"L!M-42E!
I*8BTWK-XAR,^CQD0V5!XR M=47NY+FI<^<UWIXOXH_-@+N JZVV7K,IR"NGZV63>H/6J5O7+JZM
ME/K).A.B02O&,F<.CO3A+Y6L8V==W/(-?AL*>;Y0524&:B4> M.3*#(-_FRA=2*#!
(CD(>GJC13T3;SE((H60UU/=TAW>J?O!;1T MSZ^OOE4U\$&_!LWK=6441Q?I?S4O, "">VY:ISN0
MR*V7W!;&8>V4!PLQJ,)!VZ)RWVN)*.7.MIS!RS2DH//<0J""7W0UUUX_ME"S"/TS1C-
DHG(H)P!27!+O:HHX\$)=:'I&=D0Y!A.Z!L&T @, 'SW'Z!% N&>LPY&S\$8?@'H=QF>6D*R(Y M(OR!FK)*H?
=QDJT;JCF*.P\$QH\$^HW_%!X:T>^+ M(=EAV ?2Y-)7RK!SAJ3>I%"F-Y8W.^H8UN_TIO+NMS!OPE^4A!+%Q+I
_4N=,DD6S. MD=3M.BXU#Z!(&D?_AL-Y&31Y,N,3(I/PX^IT5C(>6Z8!E'S!+%UIY!9D=COY7(EFVJ?3T&
M_+1>2Z4N.URW@Y?I0GG*N%_H_*9V^=&WB!18;5N@PY_225!^R4F!_7GJV M:8LK^+!_*DZ^!WGLP8YDQ"@2/?
+!*+5GN1PY*+;,CM6C*Z8;CW:<-956/* M?^Z7Q)3G7U9=OV_IV.(!^Z8FQ=%=I%,>1! ?0#00IG0IS4!
MW)\$;@KLM;F5X<7>U!@UW^.:P!RYW""< ME^1&XN:* PSU71B0ST4FG0T_Q;4F6^G.OT&HDSE!YJ4UA1>/W_*+
(KYITJ8Y ME!4?C>N)I@_X!1CF/?X66AC<88&@/9='\$^&.2,8ZC^O>IE=(48C0A.PHH_*5 M&,@GN5%5I=BNX^#
!2E:A+7^8=D/IGA!2.VGM^<L0TX=C,B?2""/+64JLIP=\$EQ^&EC)H99!5= MQHH=""V;IEE:04
7;H#JG>HGKQZ3_ZB2!\$%>^8 8FIRIB9G;G*F)O_+XFI MR;^LNKYI^2XL462VXX..!CFRKG-
=G!86!+T^SU!_WJIG"R+>*M!7^TG*K& M<&J&.FN=S!5!7SWY@+=<2ESQ2(-402VN5^9Y<-2;XY-
MR\$KMX('5G_2KVZ3=B)! ?LS6.H3^7^&J.J-NYH M+9FEPY_5%6RGE=*#%1E7;-.9%JDA X6-8
B<"2FJIAZ(Z9S6=BU9Q

)_1& M!FZS <;R9OL-Y=WI!O*^YC>2-Y';+^QO#L!30_E?<(-9QYGYG%F'F?F<68> M9Z
!SDWC=!!#%)GYAI^2SO_YIM", 8X@C>72(C<3-V4@HIN-39FU!XCXC M-Q+W^3=?YH=WQ!=2#UDQ:YD;@O.
3'\$C!H3B8^"G%P<3/*0XFSG8<3/RL M17\$P!3;%P<0!% <3/Z8XF#C^XVCB9!S6!L1!WFG642#X9C?;I=P<!
H)./;:!O@J(Z!Q+_2Q_+O,2!OQS\$C,O!5_I.V)> MX@!;P'.V@(#!GA.JXZFWV=L%5/_X!C2J@Z?4QO/_>+/+)J@.H?
!Q46RB0Z#_MT8%L%&.(L"A-R Z^WM_L!BPZ?_2%"Z!CH;-!T=FFXZ\$!7\$!#?>3(HF_ MWV=(=C1VBJ.
(JYN8O(C!H!E^!)GJU!90W5(=0!H BK_!M.<13Q:93W M+#!.L0:# N@/0X I>UOKE'_19:E\$!&=T)Z!MG
YAO3816S!U(A8WO<&!"8X% M_D#OM+W'P5A3*9W3=BX+T5/&(<-95G- M!_"!PB^((00VCT#I?;))%7JYW\$Z5FQ?
E*^L!GCJS?>K!U_<PB;&+ZX:AM,RZ,^##F>3! M.TZ:9R7&TBVXW)"^=GB8.+E;PSOLKJN3A!Y825^T3GE,M84.)!
MT3DC.19Y,#^G.9AY7!1#H&IW(8E^R8L;-H=9!H-HQX,)CH.NE!LD_EW MO=>^4H48Z!<?<
VU^ZHF!QM!H8F0=V68F)+H5K;QX>0@X)U!4B^2K9&ER)J# MN4VJ8,(G#C^1=F!JL DP2W2_#GUGMT!7W2KH
MSCA/YU>!HOD@O/8X\$HY:FC9C41MQ*5R@C>C!_!<?2!H&(BN=:C2V9S# M->?!OI+AC;P4_29=3V:OP=,/A?
YK,10%?)Q&6M>8WN5H!M3^VRK9M!Z! MWI+YY!6+*\$&^UR9UVW2YTZNJ=IQ=I^Z,543;=B#+MIS=
!OLEY&S!3^C.E.M!_!S)3^Z4P9DIAIA3^LXU?T_9=-N^GBV+!#X?PDM(M/8QM6=6#^@5.
<3ISD&.3.F@*36TH;7)C<# \$UD=-X6ESYU-? AP\$\$(PU.&O M)B(+3_)DG=\$RIIE*JXH5/JW%MMJLYA MP\$-H!+Q-
U!GWT7Y8=J.>-JRF#HGJ!8Q!DE!M.G@&*/L^HA!3?<9DW;- M_)A!>/C\$1X ?
JB+@VY52A.>2@RECQ63!4)_TY!+/RFLW<@KLM2Y^!1*8K M9D/&+,W3BM3^+E>L0!
%H"!#V^DOB8^\$KY6>W0<[!@!DIEM7&BITO&/V@! M6-G*!H7;1D\$<L M6AR;2E9P#0"P!-
.:Q.7^5N/E!@Q/O6EF5X^X810%6 M+KQ99==<3\$U1VA<60\$?PUQIY19ZWS.<1H:22_4H^*S&6Y5(YR:XI
M#KPU7DQJ-NN)B^!;U/MMDA=*IG/R9XV^S!0F^9 MW,@Y.\$G5:XK'NS#!Z51G""/7^K@U?LS7^ELB)^Z18
MHX.HCZ5%Q(HK2V?Q)H>N#@Y0S8:S_1(JB?HBD?<1#R_E3GE.RV"Q M-
X=4.2N^RN^L7!65MPVWRRP&PH0GJUN7DUCF&X3T^!DTP)S<*=R5%5LJX MHX+F:9006_+I^N8=\$=-
Y7/Q!4AV=IKYP)WO\$;_BU+WJD!BA8QNXT3!O!
ME=SI."/O,9!&PCZ7#7GVHD.XK#B!G+0LGS3/ZDR5S%3)3)7,5,E_XDMB MJN0OJZY_/99!YW-
P<@H<3^9L@6\$Z8!R%*9G.>Z4;A5Z-!6<;ZGIG!;?)! MO?X0&C?+U U
WF9WMM:L9>+@KT&OF\$P31WV//M=5H16Y\$^=^#7)= MEG8!<L;R6 @^72P2!ABRX)7M2*
(5Z\$!GTB3S_3<JN!F4F/1D!Q)/%?7<5.
M+3Q>WMP7FL!1Y\$Z8#HS)2;LY4Z6CD328NKK*!@5;1)O)F)QF8T)C9Q' M>JG;/!U0Z-PD">5^T-LE:IE8+I?
K;01!/Q^KEVU;_C1+Z^E^UTVD1^D6LN M8/A-N!^<(EG)H8T)&+?I>U@, (O!TX66G+^+ 27 MJBOE&_0P91^HOZW+
(C0#K-602T&S)6<=3U#1^!_J9Z6L>+KUD/O>#6!F) M%Z3N)H)9!B#+@)-SN:0H+TIQ-A)!7B(%K;
(Q^W98A3X#8>\$P"7@T;J*=Z3# M^G,LP&)@UXY!\$S#IZ^H7RC/Q.O._%SFXF?/_+=8N+G+ZNN_YU6!^X.@<1\$
MY_RSHKP!-L?VBT4DY63# &JA!00E\$!""@%_.(6N1>MUM2^U+>Y!@Q1 R: M?K!5=Y685H=B4.=<\$H,K TT-
+,%UZ!H;Z-T!#^!2+SKJFLTBF_! MG*8^HOZ# 7X=@GQ5,#).T@E.SPH?)_U M/8A!_<
_V;41TY_K!+LVM3!<TW;O=3-PXFXI9W*9IKZON7R1QC:'(\$4O&X-K MIQ_0M^*J-
G&:%OVX!S810":=#;^E&|^VKN;*3&V.GPZM^CRP5S=BALG3;Z! M&(XNP>,>WIAUA!+55);

CL&^U#3<[0!M"N9[6;22;R:XS**^O P=- &Z<5\ML4D> \V.&L%3^K^7RY7D>#OYFOS^NL?
##8B_)O(KJB=N'8V\$!>U_Y%E_&D M%#MJJ8.K=I(MI(D7DA7QH<3USW4:JW+J?AMX,XI@IV.S+KJ#\$.JXT:
MIV=LV5:;H*K@:K[1'3D\Y5:.)U4P\2P!*"5"RK.8K)1?B-G"S2X=EO@I^ MV1/9DSMMI@&'Z.DC6^?41HS#"UY.0?&!
(/F-ST^H)G@I=RM>>B13D#N1ZD\$3QIFIO%\$*A-%7JZ MVI-V 7X(I.5,H6_U31W145H+;9I= *)/QOK8B>.K69^
_Y_P\$R(C82-K53 MU_5Z.FRY\$%+#+.QEZ%*%1.9X&T&[N:A\I(V08Z(\$3)1#+_1YN_ACW+@G;R!M
*JURO1-9FK6Z,G'>@J T3^;TF7>73E Z=>G_*WS4NFFBI?MDGOA+VU>BZ5_M.^@Z_8LU4G2.P\A?O<&J^3W<>P%
I^2)S>BG/NRX;T!Y?A:N!:'<8\FCD MYR3'(I_*)HGI\;P_M>&.:15!F.8HYO\$<+:MT\$.177U2T3VF.9MYAM?X'
MYON'V?^D^8W_V\?OILC_IQD;#?OZT_=4^4GU5SQ(HH^9+3;A?^;5LOS^M_P_02P,\$% @ 2H1\$6J2#
(R.3\$R,S\$R,#(T M+Fat>U874_..1HWZ_P.J&I-&GSU3IH#3!-I O(#;)QIF;UJ+)(YL%^A^
M_1PG@4*.*#20T)KH^5(GN)7?QNZ?B'.ES+YM_1.YN^BIX:!*#FFRRJ&0*.*M)1"TSK18H\$!X@H91I-
UP,HUHXNE1;8IM EXU?T&M=Q264&[9_*.*KOHY&> M)(H96<[C0J1)?L#;OG.9&I/CU& MR'4&^X.
<L82JOE#WRIE(82N0RM7AOH//F4OHHNIPH_\$@.#TKJ&0N%1DVHF;))#43!(DFI,"4S'FO:&OZ;5
M&_M=6=LS+=_*.*=J.IZ2R(U\$S8:B6Y2XY\X@TA(E.L\$RG M+1'7"6J MIWM"=-F"J/OI DI(%TQLT44W_I%
(ZE\$IS>53CV\$.&"5\$D3T^D) MB9OYYR5%2P00W1<)*;6Y^'9_3J M0\$_.9>@S\^F=TVPS4F/
MASG/LG;=L2FCO\28\OM*5VO?N0IFW;3M961_H\IXC=BN_+ \$XN2"?6^SHJO M0X8EO8;.&<9ILW67Q_=#<*R:LI+=
(7XIFC^ZQ.8D3IY^0502P,\$% @ M2H1\$6G8R=8MQ! /1\$!\$ IE>#(S.3\$R,S\$R,#(T+Fat>U8WV_C_@Q^
MWU^AI5CO)4ILV/F=%NC2%BW678.V0_&DD3/A M+<#N/XHZK7ZW..GEIK%*/#17OK;IE3-43N6QL@+:(I%R9W,J?
C0U%1H3X-B6:6HV6>H M-G&SY6/75R'.P%KGX-P@%Y>_EU>OU^F\$K6#2MOH;D58N(55J=%OVOL9& M_5-
4R>QR^?70?%.M2WK5Y UMF&+,&D@CH9AV-V:D4VD39N1.1% 70Q Q M#N9,HU=(UUD9V31-R-I)+4P1E) MS
((\$XE4A534,"E(O)(\$QY)QD-D-#+)N7RV.58_U*KW\@O7UIZY.E2H26N
M@X^IJ^A+B%5)U8I\$35>^391SZK"JM\Z8H")AE",*FVM=>5F40H(C.F"U"-M@6YB*I(6H2)UMHED\BV!
'Z:/CHT\$GZ(HU\H39\$[&?8F"4Y\$0N06VX405@ M/:0%KJ3LG0.!:7(F1(DJ=TZ%8/R74N4D\+W? \$"#E?%JA^%;
<2,^XQUM).QM=X.Z:*I7S%7CR-OH-(>& MRS*JT_L2V^%=V(8KB%I=BX6CY+T7GMW?;A<2 ?98N\$8>AU^KUA-
W+5L_W* M\X.Z.)&U=>I+P5G.I N\I)ZA>".I6&D\$S^TT8F3TU2.&+8IEB_P(8I.3.V
MJ/6"*EN%SU0IBHRPPABA@J14S:;H\VB:;0*E 'M5-[X7;6)#D6XMU*.S3,D_U#89-%3I#[X%D"SDIFG J76EJQ(3#
MS\F_M\^T=F'860<3RFN'.6)5XJ^S1.NOY@F#IV63KG>N02TG:IOTM2P.MC(^M;K'?G;*J-EV
IERFU^1A=4G<3"Q@OPUD? LDK.40)FK4UN4=XA)MBO1 M\NT5>+(X?;WZ51U&>YT5W)^<7-[?!P08Z/PL&8/
S^;VZ.#X>OIXYE\VA M60K+M6/3_M)HQUHAOX.F33)Q+""I*.DL9#.I>>)2J8
MZXB_VEVSSGVQ:SO3C%XYIE5<L2=DJ-<[KR8T1J:7YK7).Q-W?;W^OFBI MOTW^ 5!+ P04 " !*A\$1:"F0:@@(
"E+ \$0 &5X,S\$Q,3(S,3(P M,C0N:'1M\5I14^X\$GZ_7Z&#NEFH2D(2D@4"0Q7+9&I3>SM#L>SMOEW)=ANK
ML"VO)"=D?_UUM^PD)&\$(-[I.F&.JL16H6M_M3I2=%9XK+T_"PI&9W_I>SQ
MS:;XL_R@R)T(T\$G2IOQ6_!;O1-9B5UJ8N14;>) \$IUVMR\^T^9.C:5O M=JE<%IK.3OPSV<^A9H^/I^5FDQD)%
IW=4KW12':.W>^#XY>3P:R?738 MBV44I^IQ>[HKI.I@5Q7T?ZZ8IO-)5_Y.@.8?I+JMHWA3BT*H_8U\$>_EQ
MXGTX0CVIRJ^V=E+X: _SCZ873S;K?S?OTL-/J/I CJS\$SHK?7 FIZ)V2%: M"N8K3?
3E\IEI^%T>7\$S^QO)?XHKJY'GRY'5Q?_Z;7AY>_WHS<^<37*#& MWMR9+0_"US^FU!" A-HY7+_&4?
@>F(4(P3L53X1+IWNWVCYI_3#6EG>_M MFI(MLI+3\$B.1R#\$(V.%\$)SE+E%6R#PO98HO"VVJTF\$)\8L?
M0:8N*4#>B2NC"XH/V(:7&>5ARW^+M4&-(+! =Z4@>ASYE@100A: J7-7@I\$ M#V-
ILO6SICIBV17E(RU&%.73<5=KB4F3X9'3"(I8AOC)"9\DIHWE0>IB5F#&@++0M0:"#1ETJDH,-8\$4X)OFLYQ6\$'+@V-
M4(4^6Z01)FB(^4I\$Q^F>VJ9IFZ5=4.B0))>>KO1RL8"P&QM
MS(JU:QA\2MI+7'S("#O=H^IG:-36Z&H8@N4"G0<*WSD4(V\$-,"@P""K(4* MG@!\$8I JFY
XB668\BD5TG.D)AJ6V(2I!&IOX=A=\$A1/C:BCT\$0P2(+A_Q MX7V8R/P6Q_7FGNLR!5O5S4/9I/3W8-
_DD)/_OJEFNG(DJ8>WS22(2U0)I M/8S(JN<-&.:&.>0=6E>A#5\$%!OX%AA6(2.JI+ZBV7MROR9
M%G<"&\$&N:T!#K4\$E_Y2EW;P+U;X \$"K52+Z:ZM?@_DQ78V4Y":(4Y*R/Z/4I M?2ZF8
_I9.Q5Y72.FD:5GJE182I%6ZQ.5<0G_I8.K(J4-\$0.A?)GXM"3H* M2X68%ZWEJLTI4UM @YQB1BD*B:
/RU12ID>WV(AY0<<>GAXLLAK\%@)8C+&_M_L0YOY1MQ4KKQ7BP5J(:YS?5I" ^>6;<@/"X2,8J(AQ+JW-)Q4!:7-
\$.PG< MTD0UT\#Z2@8J56Y*5&#&=L+3L&).;HIB'H@NT%:N.?>50T5I"H2I9>H2AMI\$ M;
3V%Q(D9&DB'IL@8*6\$XD@.??(QF6G'DIV:IC^ZI=5M@>CF5:K#ZU
MIZU*DU1%\J9O:IX@XF+ "U\$E^JE(U1VDU;'\$DGSC?YZBH? EF#G=6SU^O_M M5HI/-Z633F.8M2Z"
(TY^F+P/4,DK+^A&>F263#3ALXP7\ E5FF7(X.L% M(M#(/*@I4F@?*JE# &^MI3O\2IQ\GK5P1^E00-YA95YR*
<7^Y[MIH@JW:1 M(JE#DJD0<I1UINUXJ_4I47PY2J)O*:K(G>5R5F9IR"6HYO0LZ4:G^8
ML2:KR0@I6I@EM4=A6I%{I080^I9\3 (BNP99;AKNU/8>J8K+V=.ZMZ'^M MI=4%UO;88&YI("TR%BBL_"_U?
&E4^5BG8Z#ZF.O;ZDC?5ID4LB+54\#6 M2:)\VI0/H(U0?!"RT/IF?
AB=W3&0YE;E3;>+09IM=+R1K%H#7%#@FFAK*@L+
M@_K+*5:E(I73@\$H0XOO.1RX:+6M=IPZ:3 >W&YU'FUI(G:4'+(W&R?&%C)_OI/= M65H@VYQ+IJ"/COU ER\Q+
_I:IX<:_AI1VM\<\$E(>+SJ#^MB=JH:U*IF M?/CN+T/A M>5Y667IK 'RWV\4SY BE\O/S=I>.>
ZI.FGA>LNWU)_UZ_G-1Y529Y*"UM M/OD6M7VO*+5V\^OZ.Z78%CC0/E<*AP R^O#.XOB#DQ=;I.%1B>
IA2:># MXXK(?)_%JH7&=^_* TCMUX)Z_YJ7^87ZYFO"1 PI>3_%I+ P04 M"!*A\$1:AM2K7_"'+ \$0
&5X.S\$R,3(S,3(P.C0N:'1M\5IM3R_Y M\$OZ^OI(+NEF0DI'SL3(+\$.%1#8A#VOYVQ\>DA M\$:53^4#VEH!
I\$5Z)75IBHE5@Z\$7I6;I2/QF(I:R=#NE=P/M5S=A">SPYX MD+/(O)/SLT2-A\$H^JAN)*?
HRYTNNW#SDD<19UF4\;DU:SF\4NG^T=K K MBH<^SDIT?S)5%X? HW?ZIO;QT>%/QVKQ I
IK6:S'SLL>GZ6FMSC>[IAZH MS8HR#UH76HUR'OLTFB_4F"UO>.VX77".JF\K'1QO9VF_SOE%KJJ9DINH.K\$J#H%-
_1DHO+C:/APC'JTRFJ4ZM-7ESI M FO_E_HAJW6S\W3PU:C_ =B/K?@LI:#8/HF9L=H*=AO-&75W?W>O^Y<5J
M^_SN+D6MW?ISY?JVM_B>O^YPO\BMJNKE'BZFY59I8"-&F'Y-W).CKAH MB'_QON:B,%ZE4Z\$'TK_8?
>H^PQ>J@EM=;M0K?;RE9#1,50CD:8&'D8(Y/I MH7)'YGD\XLC/7"Y.+Y"RXU&K6_RE,*GX%J?VP/D@JTI*#
I@:D&FGI>- M"ITU"G6P'9E\$@H<2<I00Q91'9*6C7*#QT,ZIG63IC;"NI(7Z1#F<:(Y=- MQ\$ NQAJ2=1"=*NP)'9'S
IF<50H58Y1GX@RH8\$^C3.F=X#+44&3Y9A8A(M98ROK#"9I*:(L.ABH?E20QIS&"Y422AQ(TLM@-
UI96P"8FQIS8NTIQEI-RDY#W#*R(=?;KMU M?_HJ%6% E&:25.%CORJOI 6&!089;5IH.)0"1&6KDAB9-
8AC1(5\$C/B7*Q M-JH\$?D20UNB CL*:&I)\<0>@B\$1I%>(^67>"CS_8@+Y)Z\4H.K4N:AK+>. MIF
_I*2UE\$27NVS3D6U8\IP22)\HJH%Y_88D54O&S)=^3+%(=9>1'6*\$&% MP/=07\4RH5Q0UY#ZWDGQ>*?
S#DU4X/H'^+0!&D//^T"K4DVIT*Y M+P*\$2C52R*.FM*@_Z6JD').@2D^>JBRGM/G(@5;T)*Q5Z73.6H%3U3HT(I
M15N)F!>MXZS-E&D<3\$I"HF@ MCTLMB>G1+39BGM"Q1R@/%JL: !8!"2(98W\ODZ^VXJ5MPKQ:"W\$-^:W%:1O
MSHP: QX7R4@EA&I3"XI&4B':X#*3@*WM,D4: A)2.EE9I0*;!N6%IVC\$F&
M6U@QCT07RE...5JAXK2%@AWQZ5+!N:L %

12 .N;^"530F M4Z8-&5X%#&WGJ^J06I:B\@7I2@6"B>/2\$BP6LOS:K9EQ'M_3&2?J(.%DPO-1\$?U\$ M:/4
NCJ66)*Q_<I3I/P:V!+LO(VMWM%_NI7C_IUDNBQJ<XB'EY\$YIR^"%PO M%)6*N&9:1*K86^LF14%_)59IGR'N
K"2(R6'E0>Z+0/E:RAP!&G:\$I_B7 M:O+IJJ_2X7F\PHK\YA/+_?>V\ P^I M0F-1AT6F0LS1UIFVX\I\$"!\$F5PF>I
MJ#'(AK)HP,U4R67LZ\YITOI7VZ@)S>VJ16VJ\('Z1\$SQ67@% MOEI(C2H?&3T"RH^Y%'1^K9B4,@*2;

K>A"0ITs;H2@J04/CN_E%=:Y M0-J!RNO>+TCMM'S1K)JC7!%@:VCK5H6#GK3+Z>8E0HM)SV5\XC4VK
JF:&IR0T5U<83DX:Q\UCNL7@+?Y/I@-7%OP:2.'AP">K:9UN MXZ3Y='ST7JR[974'K#)P6R<&?<(->V=H?7:Q1?
1%/39FB\Q=L+RU-D MBE<'RG.X87\2T\Y\VB_ZB\W6ENZ_Q4U6R.#M?.T=+L&\$5MS>2LF9NUT=J
MSY[E\W;M\$ (LEUOB&);TH<='?XA^V>9'B_SLF+IK?>SPVXJ9X_Q>W5_=4= MWJXO+F_R\#NGXUK_&HHGA*
+2P^=Q:3.U0_1%2-/F_SNEVQ4VUMA3'H>*M_#RSXNLFH(G?<IF(HW&PIZ_9@K8=U2C>L15Y.KM_26W&Y=J&:7
M+L@60Q'UB%IXT6\$*U=FY_S'U6ISWD5&2(*E?IK+4U+KG/\$U_EAY/\$Z#1\2_37ULM\EJR(@-A-M"%-
#42DT%QUG>E1 M^3PI\MG@,1T,^J.(A0\$-NX_<GPZ?9_UAL,XH*_NU/DS M_:!2G%ZNT6:5PLM&QD4K;Q_N-
QV\KW<3&YY9)QX/N_-=S4XVDLA<'1%*XO M_RW_:!DS<&=:578NQ.MZ<,1<1<0.U3T+9> MS#^16;Q:+/?
W@KX_Z:218-/G?*@^U4/2NC/@@H(0W0%.3Y\$"OR;F2.2C#_M03=+ZPO\!-R>O*
JE5(1\$295+A6U^Y.#.W1_!AN^Y.9S'(J5NXIF\PV20(* M\$ "NSYF)KT/J8<\$VNA:Q-
(-H""XJ_-W>|EQ&O5=SMHJ0K4\WPSE_3L@=K0 M4_:~J^A7&16BH"E1@.%#7@AR*E56<4F<685?"ZX
ONJU;K#4H' MG0_>N8\$H-H=Z\H&ANP\T1Y,ABGRJ_8_L\$)ORUXROV.)%5=07X)@U.F6RS+G M'K)N_.\$SB9Z7(=J:JY-
Y3S%OG7I<((&R.DTP?>NY33L;D_1@,1> M#_<"RZBZPG+0R'Q<_M/8JU"/AE)AJFAUI3F&L;U/Y;
(ZSREJS\$7;D>W:%+9 M'J4Q.K/F)C_3J->D_>HPH0Y.N=W M),BKJK(AQ3B\1.1^7_.D*<(XG^%
077/Y9#NQ^J)R^S<^TUIC17Z):3"%6! MQ13INI=GH_%KTI9.^/G_EYW_>NDUS.SI9+|LXCKU!70%W3\$#128)H":N;
M;/_U.D2T3'E\$;GS?2480Q&X&7%05%1>@_M11W.W_8MC;G_KI@POS1%RXK;_M<674+\$.08IV_>3A-T#_2H'X;
H2?7P/SO&*_IYCQ;P5UL/MN!ZY80_)@;&I_M!2?&='1.2-U@41R+;CQ\IT0X.E^4I@8\$ L)BP/6;*Q^I9Y_@F(U)R?WG#
MK?HV.2R8\$G=U6&EP_HA#06203HF\JLM"JP;A>5T:3\$H\$ P M.X(S7)^!H8\X513Y1=-.?_NG90\$KDUJ2FIWR1PQR
W11D@66P\$;-JX"L MP2.2.V;#&GR_Y!AP;B?+3UOD;2\HW7&JG8<*>4FJOYU8_-|Y<-K.OU\! M0ZPA"O/XDL?
ZS<^%JHEC15^F22/X&4\$L#1!0 (\$J\$1%JAQY?04 M_1<9 1 97@S.G(C.Q.C.Q.C.R_"YH=&WM66UOV580_KY?
P3E8F@>V(OEV M_>(W0_>J+\$M.1(W>:DDX1\$8E422D)^MW)*4FCALDP K4I>H/AF22Q^=X
MCTIWG*>9+O*3:08T?EI^G.G0IZ)N"J:Q)+H!H24BG&K\F!-0-Z73J63-1 MKB6(SC0)O&!
/AAYPVZI&|=YV#2V)D>N?OID=UD&HED?3)-V"UAR=L6&I^X MEXZ&GI>_CON0\NDXB))>FD+J#:/>8/2WW^E-
VM47J=PIM6P7@G_I/IHT MAX-2AWI2V=FRYB&>JVA;OF\$^M2:J@/\$T MDV%0ZLSU;_B!2AR#G?
D4A240VDKRE5^62I MFZC8/X @.\$:107.^H/MASC@T/OF\!>+LK_>+7Q>K_3W_V MI03?8I&.G/_A-
MU@_>36P8T0^BL=J.SLJ_>L2@WT8.@_W\K\$ZH^M):9H3:X@UDOP-V\1.1\$IT:N(RHAQ4Y^(>AS4YC;49"3PO-
QQ^OV5">F_ M9D2LABDF?>.*ZS\$N@-64H1-M97_"XB\N3\ZA_11+1,I" 6&-C+G4&C8I94^2&B\H\WQ;
MZA>G\>F;M/J&#XU5>L\$_.U(2&QK&+BGF548^HQC@QJ M7JH<2UE)NDP;N/D.\$)2RB22HY2@#_W:9ICE.
<%E",%R5948?_6R5\HXY;Y M'0TFS)HV&0EG5;ECD4E>=D_UA,|=1^X%5E\YC>6@%N7\$.5.1Z\$9C83\$5-1!
MK#DM%4R:BS\AJLSI>L^XW=\$N^FM;D=!:%.9<>&NR=DSS^F3LD;CANN(MZM&OKT2.=;(-U1IVQ\RP_U6??"
M"9H\19<.#T8A0=ZV M>JUF04F3!!/F)COB5_65:4\AQS2L;1Y1=GR\$LS\$3Y#D-KK\HAW0_5BP^S M=>T=IC1;Z)
Y1++"8HKTILG?%S?Z_)7D\LSU=DE.>V2JHG% M:O5=AO75CV"=CTVV1H>
(\$CE+2(O&XK0\$A".C6F;X/_=TQW*VS6XH1W"1^ MA9>SC\$%*YH^J@LG\W\I\$)N-
Z,%2,HQEB<^<"NOA=ER;_>GW@IS8W?)W1_HW MIZ1HTB&32>N-4=#)4N"E\$-'AJHIVEFO)^_D.3H;2-*
<7TIQRXS6UF)F_ MCONE1=10.45&/_=Z"BTIG9-6DC_5/LAX)(K_<^="AC(I*H142BR&0HHA)JF
MI^KQ%X,5E,8\7\59T\.)G9RS*+C0!DD"ZO=*C*.KVD_.6@24I#_8S."VQ7
M@>6F%V\$;44_1/2CUWF.EWB9B;^I+ZKY-X#Z&4C=G@&0Q\$3#MIHT#_>+2.F: M%(-@*SR/#0^V\>.SC?
9?)W2JR^%LJHU(B"HIR%K>H0FE@E9CWL(1&6#_4 M^ODESW65G_TKH/YV?TP1KJ, M!T! M!\$!E>#0Q-
3&R.S&R.#(T+FAI>U\9:5G;V\ P*Q!-A"ITNUN+K<7C MJAY9?JT:QU))H9KD4^J2N"1A@0"#I2GFUJHGO0L
DMVRNB4ZG%0LJ1NXN-09 MGW/_JXMV6?SP_<*.I(= ^?Y?
3TZ2'ZMIM\1EFTQK:UJ;)5V3E_/DGYEMWBG*UXG/RSJM_G5X9_W^9M87_0<;_I_AO_1_3?TD>|G5;;Y MX?
LLOTKR\I?Y9-09X^GCIV3)J^9Z;_S\Y#R9#)J^03A@_>_I=G3Z6SVWX? M?@70POA4M-N^ONWKY9Y>.*P.
I%GWSU8M<7>=8NGIV?G7W1%3WWP>SJESA M:S6\\$_E.88CF7H.@TVJMJV6S\YQL-9^:\$.L.D<_+9\3&KW@T26-
:%57H"IG MI+G^N3F5GFO>_9OU_F2ILD0HU\K9:FO+?T\4S4ECZW5&#S;Y_HGY^?P M\$?KG6I8
XQ1Y:75)YPIP'2_1^=7?WJUF3PZ/7\<+^+;TY_"=CZD_|%K5
M_>ENQ=07IVY?7ZU^3U3\F+BS>O+BI^2=Y=OG\Q#_S\SR\O?KG\^6KE^_2Y-6O+TYOO-R\&S^IS^Z?K#
H;G5THCAA;V=AJM_I^H M^M_>F:UM.85QM%7RU\!>?#@/G:IO2W\^?ZDZ\H_Y@RTQI67:T_S1-
MTMAIFU=E4N.P_+UA3M8F7-^1-7:ULW>:V@?TKIQ^I?P^_O87^7=NF)38I
M@>2MFVL.R0^2)KHC0TW"UZN;5)6+>I%JK"MI_@#YMN\CM<(1B%9_(-=SC M60Z?IAMF\SJ!*Y#7MMW
^/Q)O+W\T0K.MPR>I(-G6%>F\$EA1T\|>+LZ6M MX>1>5/6JH@T=|B|E29K\5.&H?
L;!>E*^DW5X0Y<9\1=ISU^V06\$TCM+>DI7 M!+N5E\BHT-J\$OMAD4_REL@87\DH2\B\Y^V%;
I8)?!+FO_SK7\Z_/7M^?G;R M#_I;#-: \$WEB#^XLC_FBG=CFQ-3_W\#Q%&?KH\$&GV_5\FKEU42)U9 M,C4K9(Y":U.X
GG3TD:~IX_/SM(S_O^D@2WG P@)-DU6L\$57INAL\F_GIV=G MO#KW2AZBZ_NX\&Q>K0^&"Z\I?D?
CQ&VWURF09<*23PLY@Y6>G3WK;2\(^TPR M\@5OX#M<10%>H LZ.26(1&DA10P\I:PFE-10QN M4N?
7U<+&IYC<*.?>= *0684 M2H\H>9I<@_3\AQ00)MAQ4(F.0BORIV MR.SA:NIP\ED#>VR<0-
C6U^9NL1JEPO;EB"2@OGX4\$#V^*&ME;I9FF96 MIN;2= T3*WRPM^T.T%A@IN;*Y 5I\$QED!@RBSB<=>[MDT
>6^3_T^698;\$ MHS55T?>8!S0&7 SDFYUFKPT(#>+(-&0R)L@JL\$M8I^+O\$WTN;7%6P7_@
MH=J&RW_."3G.FH14?4ED=8@M\X.O/3Y_>I6./0ATC?L(IQ5)K.X%2&VX1^4PIS_"JTIMI
M.NOPXJY.SJ.458F7J6GP&EUOPU=-.FTE1+EW\W1U\<0_>7Y:0J_OI7QT^> M)S^>?
G'_3R1XWCAI^Z>3/;Q+@Q>L^W*142JOF>+<&4"CKG.X:|= M"U>Z1A\$7\H\3)4_HDTP@8NV8_*9!44%?+I(4=
I("T8_DR\W>?H4AG;I M(P+V@OP+ONR0HL_-L\7_M)HO&T;PV^XZO^1 N9\$1 O("GK^JUO@2
M&32.U="2/7_P7'D=?+I"Q:ISL%WT=XTM\ZIF;JJB+<&GX_7%9)D_/NI*?U> MTPIPZPS;-8
ZL0#B6\8UORK(%!9#D;4^W"H"75%1GS\$6+.8#R"&86LV19F M(RN";10I," 3*).13E2V=95D;2PJ8T>
ZZ)=97EY5!8QK\UEWBWASWS* MLO%RXW\2P3_@F7\7_LPG_BH(EQ;)K&R(M'_NKCE<-
1+."K10.3P\3Q#>0:3-1"TF>)GD5 (&8M\@YH>G\MS(0>8@KQ
M3R@PF^!JD#^!>+=MN7+>#@:5\T7AL_\$)SU>OA#_MO&YZ.EB\IO/S:02>9D=-);
6JY+| MI+.@EY\!P\\$/+_"\$_.4%|+U3G:EYO9D4EOS_L3,X)H_17:;)JO/DUL M^X_&O8\16.\$+INX\$NL:-
=I^7M>MT^T\JHY?Y;LSCS*M;L\PTB\W7N0H-2P M\I&5_-38'&S>H1N'#6@PP?(809#
IE2.G'=9I2U^LK'3KLY;IVQ5X"<\$#FB M#>!OK |RGS24SB5E;P?>R&2_>TV+^EJ#_GTGTTGJ4@_1"1^H_.5N.=D_3EI
ME;7H\N-JB_0FYI(O\J+WX#>4-5*?>@;JUI^11M9_V'1 V:U MLB5I)#-43U9VRF%N<#_H6#H3X58\LJCI0203
M1DF6)9C"N3^9S.\$PFD^N;N49"R.6X\UTAJY\$S4A;^>>9H?NQ@WB=AHDC;
M\J69X)@>_TN8>16^2YX&R\O>TCL\$202N@OAW#8P.O \XP>=I/#&N/S9%EO MN>T@#J\$|-
>90_N2D3\MXW0G;H40EJ2CR"SAD\C?SP\$#5!S8_5\I>D->|TR:A^K\H\>67OZ^3&@^"
I\XEP86DRZ5H<%M\$4E:@R8TUWH7\$(Z)P.MPY1D6Q!>"X2T\$<:DBA@>C@
M>PJ_ZXK6WU5\12#%\$C'Z\Z&-3YY_VIO?TIG^L\DY_ M!_M2-L3%I<2-8DIUODDS@*4J_R>;
0MNC:X2AK;D.W8.M7%L\B6_6\ M1\$P\I\$ZAO1_>VGM_I\>W_?LQMB\!|JB7RD\H^ZQ\G-B>28M043P^= M*?PO
5\$0NY\$Y\1+J\K0\C;G\44ME3YKZNFT0\LA>>*>QFNGL=JX\&QN<@

M>54"ZQ"Y&^&7DI(>^A0&VSC0UA7B+VH=8)F<+(O1!A>^.-8+V!M4R(B,L@0;E M\$Z"E1?;O@0U-
H>!X3FKZB7'3RD5A6;'PPOCI'#1 M\$+B 4CDIG!&# M;#
(I=ZNE51WC"_.9K!'"1;=M#VA;AS^#KTT,GLXI:MJ\$BP\$E"88;2912J; MUU>\$)5#9&IA;G;J&NI0
*02;1(#IFSICC)"K+&#)P7/DOTE752P13YS1+H0F5:MJ322?IG7E;*H?CIG)AH*ZD=&C)Q"(&4\$!>+MXHC2/W;;X;+="(@
(33-&EF)=># 20#(C)JG:X M2AA34")JT280\K R=-.W\$W^"70IU^N!) - /0Y4)HL?H64+L,R.1&G7#)F0(P!Y
M8G!S\$* 6^G=0^TQU;S!8C)11>93=6^(P\$%"(,ST7,0;=5C%Z7;4WY4"4
MZZ"Y"U;7^OD@""O"O<5AOY,BHD:X3WV#X)F674P'5&BYZIX8RXJ0\$Z!3HS6QA+K(S H2&2;R.4 M25-ZW?
=YTL*PU5N16! ME"O8D)=>X>8 _134F" M5-S@ \$MSF^Q M\$OP0TW; #ET>8!02DY 2*5@>GQ+K!2H(^S
M9;JOC4P350;EGB53BRF-"&&R)N&3K;2'# \$U2SRFZ5/X0!*" \$Z-2/+DB & M2IGSETR LM'4.\$3;@-
\$!L5TM"6!&&OFF3)-^N 9H<JG"ZL18OERDUY)? MCZQ%W&L.T(20>B F@%:96*+Q7!44.X" T=D-"W?
F031;JEMR."KVJD?T7S+& M!&+L.7MO"/+,(40:YGF!\$1L\$Y,"S7U>JORI%DO#G^B#IZ;AB)C8'S.8:2
M(NIBC1H'B!5*QOC""%\$PEGVQ!T.D;^LV^5L4N:8C.X/K^ZI-KN8B\$!;*0 MC9;UP9?C;/_@T^0V%NHG8+4={Q?
DIHC7FD?./D;SY;"D)H8 ZTJ=;A#BH=
MJS1%Y%YLIKA*#O\$X7^V*^FP1G;P^<3>*;R9IH.IXN4N.XQVP/"\$@B>*5;< M.HWD6?
8*039296#+04VPSI@!=6-N MR2302+=L1A3F!FTG(0/NHZ=5P2?C!520IT4LEW5C MA#!!*+D8 LQ9+8?I91
HTK& XD& \$QLMS7- 5R#2;2-9 *(CO9453Z!ERN>5 M8DOSJLH0Q-(N!#*#FA@K("S5>A@(\$V)CXC Z"/%)8M"6?
GCH!6D<0?V=P!R*X M!O)Y";!/+ %DX+BQ FAM A4)I@)S5ZQ#XOD'?SY%\$S\$KY\$!4\$!CJ#/?MFH# M?
+NH6N!C6%I#0)I(K3%6H C^4D^<'6;XJ8.'?!)E)2R<'SL/+Y&33?#
M&P^GDNH5T9M:S2(-MX*KE1/4FW#M4;U!MWE/=>VKT(560?10%;K1 \$00@% M9J+
Y85@WNA+^S7R8U#PE!MZXVY!& >IK*J=AE=S@9HJ9^&P.X 4PJ 7:EA! MZ3R&
(IJ&M.0Q0B828T+V2*&JUSNQ0I!%&OB?C1!A'U\$ 6<V>0>D H^A&@ M2MHM5^HR&.^E9T'^WI%0=?BAWIH'7
ZWB&I#N>6S MJNSDGM=6)1*VB!2:RJ49!FFOH:0#KA61X+;@DL7*!K@1+))!\$)1)\4#&H
M.^NYLONJ#.H7@E0VDD87?K/Q%)8!8-J,W=S&E6T O8R+?L;BM_>[PQ10 M]#*#='\$E*J-*#@4L+K/5>V7P?
QBZJD& M9-VIE^7S-5D#?28R!?)Q7B;)(E"VA#"AJ.Q [B+*P-U50A6-6#(4+7P M7K-9 D'ZV!2XMM?
5;M)+B76WKB3/D!&J;.2I"1 MI94I3XP\$D/F;UJ-NB7*(LI(EJ)?1 J3OB&O@;+M&N-&@OV.1Y?8C1DYEP8
M@>X67C(#E)"1DX>'Wfj;DK J\$(4YV?>NX*=-.XP.5T(+2<2-2!X8'<^1N\$YE MM+V X61AHR=IF?
IS;/3Y&+7CKK%&B& M9L2#IGC\$;9JC4^N4F>6MIZSW8!9%U4A)6OXJ(C(HO1K@N'RJ8.)>U-SC(X#M/W'!%
!\$%"F0U0XQ5%)I>..&Q)* M?M=-D-L9=O@ \$R5B1N93!836U3K^H?N'A!.*E0@?9*5=R@>'SA&&?QTOW MA?
\$#-J'X0&(>T1T+@7ZQ7*%'SGTZ=D!R;N\$P=M3' [X\$!\$)8TUQ2&"G4%10% MDH6:&Z#PK9FM AH<%@.S
Q@A""09Y#!F0U;^B+VZ1D5M634M!+*#B7AIAEL!6\$T^C0HDI-4JO)"^?6_&^9I MTX=K1)=(LF+H!'+
{QUB/PWF\$;\$ZS9!0*_NJK MJ3!IE-PPIX Y&>O&?I5>\$%;?TI+(H&+6LER4#2"/P#G>'BK/M*US%
M'U8@Y67XW49>DOPPL0N4'0A^)*B>Y,XWPLUS\$ R/VO=;1=;0!!HEU=PPD5 MF _;R-N0H,D5*UXBH>H=?
!&B9%GV^X4R(I.DKV%=N\$*ED9T)3-'=,*P!AIDE>("N@W/8E
MWEBI&DH!%;^;.\$"S>R;DKW%"YG52>=>9T6(N\$Q13PI@/33!A)PIGUPA2+;KV0^B&?4;Z
3RK'(%&R@K;.9A!7D0\$KE MJ@!%WD(SE"A"2WZ7)/S2CTC<1 QZ7EB2%;98H!15U1*\$Y;# '@JU&0/@I/V_+ "
MY;BR@0_H ((A'U-H) #;I+WN';0IZ# 'K= JBI M;@I43DK >*WY1JRE"EF>MS8IYE433 4SEZWG9
Y#BOM>O^FGCA<2J!UG+&# M.P&^,*9MPOFFS//;8+22L40R;I UEA;"D>6MO>H6>O<7:69L5;\$!/_L2E0%
M+*&Q)*DFY>H/2 _FIH^=P Q@T;RKD=?W/HU#V#BRA(%6(!%EL&W-0/6SI.. MJ#-LP;QSQ;? R)GB=I\$?6&&>I;I!
M4VM3FAC';2B)8'87L?2AF>E&+6T(,9<^8LF?7D?FG @UE.B*KX#!7@P>Y1 MS=205?OPH/L7#J9!0H5M64\$TJ(!#-
_Q\B-F8>;5!IP8 >[T6XWL.*B1P M8=RBCVNN=D!J^0Q;X5" =/P&*"QP8=Y!RMX*&'LMJN*7>/6W7U0FR1Y\$
MNIU\$(_ 54X;O@B:UK+J&G#D61;7Y;8!W#?";QP"2."B/69^#XPHS2&Q\$7 M(23.OE F!\$8AW!8Y.NC.ZY?^U!=[U#-
_@#>;2I&#%;9N@C&T-56W!U#IV8ZT50;J!15LZ0B# @U@2@WC!FQL4F I?JML\$Y7I#9 M_GFRBHQIU0CX"&+I#
X)8VA*F6XP@ YJ3 1 #/H\$<4H-C%X/64CES!DKW
MLV@X"H!X4NK=Y2U#V\$K*F=M\$*0.76W<8UW6A(<2XCVT!@;C&GA W2+ M ^QMD 5+;DN)
<+3G"!+V0!"@N4W?)QOERL=R1XOG&B)J+W)*/_0!;77A
MN;J&ZF6"PI206I(B)&O3C*>+XF=O=FE;+MJT!C,2KT! =V/\$/MSN+HUL;HE5B H MS&Z;^SWQ("=VA(2F!27Y
QCB!&S!H^NSH+ *R!E=R7F?S0VD+;@;Y5@GB\$+TE=Q&;JB-Z!CX=W+5MH^MLP-
%7&&"8@=*PDGL7(L" FUG)GA257*^#1^78-
_O/ZCWPH"B0K_E2"=E(988,2SF!N%AI;A>95GFFC"#67S%*>QTJ5M;W*JZI'O-B@ M+J66T;!UM:7_15ABSDZ 45M?
Q!Q= M0_*P3W%\$ 19NT!7N!/H2Z;_8_8LR^X@)'0;C.(O%T30?8%AY>5%Q-MZQUY-
RZ"7/((#O%816@9G1C@X2I^#J> MAHOV EG-A'Q^6%RIA?PF %BC-QON>;R#N!6.S1)AD?=-
D'0AQIPH6=LN2JJC?6%NZ/-8!<9>M@R:9!GR^R';H3 M5(3VZ&AJ(Z&0)AX!f=V)MJ/J MG;
*M.W>C!Y_9W3Q5\$;Y!^#;*2!DIB_ M2+IBN!X/E;KKY1CUQI/8G)?3QC8\$Q2:&6 KOJN* 2MP^A! 2C'Z0!8NGD/X
MJ>@+N<;PH"5.C&J(2U%46U!KN*2LZF!6C+7;VCL&CC_8N?+!I\$-H!H.V.L2A#E\$ACN6;6F!D-(8
M!V"TM%./>1:L0 _O: M&A'GUFU^SA6 \$ZQ%-C;\$!\$T;%L)XI9NUQ=50.8;("GZ/3VI=+J!;QN
M^,%@4TKVS92(D7;BV,A^\$;ZDS+0%&D^#X=;+E2T"FU2+;QH^TNW@(!\$=
MR=*BRL+C7EL-Z9W15LZD\$;5HO%&M<=.DU=4HDJ!E+&FJ9M!SEN6!H(7 E8 M^+;8)5+&F!1P(I&9V(! JZB+?
IU:RWAUK!S!D!XCEP1^=*G@VX1%99IG22 MV2*G.*ER^!U^9\$EZ"?
HNC#CM);+1#6/QJL"/J+Y>FXVSB6L%F(T8.(0 P MVX/PXZYXTHP+0_2?9)4IWL_G_F&
H!C(6UJ=#H1/M/>Q;'6#N!_%;RM MIR\BOZ"<I6GRDUL\$A^%>C/A>[H?";-
E>3!>#G#E;?IWFCR=ZHCMYU_C%@Q MDNF_C="QU**S;0;\$V!LA_)Q2N^7&0>') +?M!+8BT8
K#2==48W5K4)384 M>0.0WA8K.PVMP %RO7G@F90 FR&N0TN;^J./Q-
7NDX<N!;2WG8C6:#X8!2(ZAVT!NOU,S)PI-'1C>[=1.62-(2V?)N^PDIS2?5!% MG_MUA:Y-
IZD?62I.A>1#UG>H/B\$&R^!+V.<=C 3PPD(OLBML_R"7LY:YM M5XGG92?O"F9/"L%"L%1V)CS^CG@V\$@PAAM?
8W;*QC?IB?H?;/1N7/CMB# M>L KH?D?&8&B!W-Q3_2**U@)'IAM)=J)^*/TS!HVLW\$F!U\$F&)4QK,TFKZ
M\$!H*8T==BRFA)*I7UAIL^&7Y#!>+C56U;"JL NG""-4=>3-QX2OZ(2*='O M;9^ZRX;R*L'UUGJ!8#?
Z/)."9IY*3GUAQ@*&/_#;G'LLUL M%UR!N!>_SO ^Y=*VQ><17!^!.\$C5_DX_*4T!=8:EYQ4@YNULK1C05P!*G*S
M!3;BD/(J^I-&VL@IRY+CA,+9#0J&O<+"O4 B6@#V!TZE.B.NQ\$**C4NWDLT
M@).GWUJ);"\$YG&H=UQTQOP%=R7;+D*BB+2;H0N(#0;>77Z-TZ>VHRH M4;"XM(%/_C M#C!L>)X=-.DC.GQK6-
=ET+^# \$M7%&QMO>\$LK)SV4/P" MPX(JIAO5E HG8(U^X!\$B='RH! Q3G8*SE_K<6<>^CC5H<.SYM9@"/I+0+L!
MQ8"L&1^1_JP0@Z0;_G!Y! M;J%:PO?8+7/3W@=W3V(0J>BB49ESL*.M(5G Z08!'+P<%'Y-KGB#;Q3B MO
@2P.8;010;@T!4&53<?39ZQ6S<&I7*2X+&'JL '#KL(WW'17*JD/ MOH3=U67QV2!H0X)L7+VH&"D:Z#0^W1.9I
I8\$73^&YS!H^%HIP30:B<'M2R9?_LUIKASQ=RO5^4HJ!C%9;0;O!!&42V^4A^J8-94V#NZ=-MX>5#<M?
>^HA#7(3*S5I2_FJ@D2;_N>7RV.ZIZ@ ^V5\$>ID)/K!91UCI2-KN)!A">+78IY=I8FPP;8440L!3\$;CO-U;WR9
MOQC3Z)-5%;I77:N@HB*B1F! (^.;5^1%(S"XX1!ER6879Y M@%K>68!+5H?J) F';=-<+(8L?
KV_7!0A/7H=/L)OCO;+CM?A M(3=>6XF1\$5A@Z0"YU&M2/ TJ;507\$Q?L!S+1TCSH_0CZ9==46F 7ZG?6UAV
M!7ZT=I!D1N+X!U48"#B&VQ!GW42I7@G&) _4%W_+0-O^C2!2MVH+=VK&16 M&6P2I(%FD"?#*?
0'Q3:A,BHUC2^Y51AN6X>|C#I 8T\$BR-6%8;J!@"K0A!2 MRN4CLJ!VX;.KKL9R&ZVJ!%;6CK

!%=015WT&7<'1>,+VPOMOWSOS1U'=S#A'B MB@'K:X(1(XY/BC7F))3C7(V?
&>>HZ,966@^/LR*(8KXF*)CJ4)OKLDYQ%)% M,F5DZ4A1V^.#C)3J6I<>F--"XIZBVA017'QJHJ&KH-
19L1S3)H'D>.C/\$>"JM*5 MHD#|L\$T1+6^|,HKZVJ5VXS<_G9H0IG&S17^'K#W?V?(TJ@|Y8(BLLQ3I<
M=139D18GDI+>VL'IG/T8;*,JTK^\$ _IBVBP3P>EC+Y>95(-,6?Z4L,3&GVIT MF(BM/!EF-74JIV-
M(TMJWJWBQ165S,BW&S&ZC22_3N'^.;,XJKSQH:T4E,*ZAHTE'H'9G.;
M13*EB*:1G"0+B798,XTTZ>2GKD8'(Q)\$VDNLQC\$|ZL1E*H<6 |V)"-1E++F; M@MBR|7-QA39D8LT"-
B)1%YY+9(Y(-VU76'8DG3^R)X|"S%D\$*|I9!W))H? M5*BC6TNX(:?ZO5J4_HI9#
_MJG'BI-6/-86\$HEK2*N'&B@>Y7Q<@R14Q0(_M+GYO:=M#5,DNR:?
T@=3. @.8#0GACP54&V\$&F0\$;\$K|L\$;P/U*\$&ZXDX@=L M)DS(FI8 =R^ S|=#)-
_17'_PP.L^\$4Q+0LP^DX2R1S<+W09:HO>8J** (FC5U MKZ&')S6@:_C=^"|H*7QD.D)=^0\$+4@M0H-
::3BC;06SG*8S(M4 BW3T3C< M*0V_3W.AO'41<0%; #R?HC>MGB&6K,?KN:J4%ZRLR?"4>X ;;G &4+=E%7:
MACHXA&%U#K?7ZDW"(NIHQJ2CFZ0"A*YUN4"0V3X|NBQO!
N|/S=R)1AT!5(*>|5R1*=B9G&\$66W6)1==@\$ZC.^H M7WBM8(N'6-?Z;RCM|U M;+K'&LEUY4J0:%&8N;4,,?
4P(H\$HWL>)9R2E1"#1KE|P_"WXOOO'S>F%/: M8%>S,%-107^N5;#-
FKSV:8*0G8V|VJ^ON/B'NO@|MH|H/%CU5FP@2#(F|5 MP=I*2G\$05G\$1=-7HU0?E#GHM|<>2*
JGZIB^LZL<>@8!6&20XL:3>I4#U\$9 MNAED:IM\$5;M*_)YCCEHW 5+V1MX;J@UQ JH&22HY?0"PZ77M^G@J';4 "R
MT25@SS)J3 K==_F4M./C)<&|_7G%7U#%N'H.:IR\$:&WU,>550UFX7XOC MG"WE(OETO0*H16"P908"%
|@UVHP"QJN#|7AHZN:O(.4Z)50M(.^M)D'|U@#90L=)3;(FXW4QV3|1XGY1F\$T+J|U 7UJ-;7EO9P_2L/"R"N?
MY4(>|/7K)>=&Q8FT=(<Y>?Y\$NV_WA9OL;W|U6X)9Y4X"H9R=Z= M;RK+>04UFMZ4,\$
|*^<6L2U5+ZPF<&T5|=9G#A@GB<4+6%#&O|&H)K7UJ M"1:2P3ZUVD'&6AL|GA;'C241|L"O-
EF+|H|&11T%9VXS=+|+O+?&)+QB>;Z)2|=+|3|<6H-JL?Z1_VI4BRRS@O MH_2489=46+@ZPZL|'@%214+QE-
'MR=H)BCJ3H|LCKNY;->DL@F0'ISWZ\$ M^R\$;8IL:Y7^VL=|_8XICO+LW/&N'.ND%@Q@,D<&XFY0M2ZZ7P_T<|:
(|\$/A M.X0'B=(N'RTH|HBY&I2)XT%#J4^(#CS@_7|@T@,|*&H;|4X;S|Y;K-@/4P4. MRR&VH(VO<I?
2+L2|JR|6;KJB67C2YYN6|G|HY?/B/YO94FP|W^)|322'AGOP2N@ M167I MP*"-;3U|H9JBVA()**
(PDQ_H(Y&9JN;Z)FI+&CU(U\$E:=8V7+|3+H|KG'J M'R?H8;KZPN&L L%+@|7'R6XYU<%|N9ZKXC*5;
(5W*H/I&=Y(M(/#F(EWR?)I M(O^60DBUA.YVFCV(BJPG\$2/&F,-?162KM9Z40|>|=Z8I3P'E-Z8YT:H@
M04A9|XTW=;|G_*_|J.CEA>&M1^TD);)%XCM8;YTUC8#EFWG?M1XJ6\$%3 M(*8AZ9*%8I.
(%L.P""VXNVFDW/5XL17PI0 |UVI>6S^D3^"W9=M=40AWDG?M*"E25U&F=*&GGM#4T"Z487K|^3'!F\$Q?
A@-.DQ'CFK*Q(8(C.K.ST6*+T M|DX7=@=S25%(4MF*#V3.Y-(AJ2@4Z*Z-U_5F:8Z3233"CURGTX&X\$;?
D)Z.\$1H=>E3NTP'TJ7&H"&*X^>#%*I7=)| M184 |WIBA.|=VW\$D; \$CDH.04J#1E(*Z,.5>3_&FOY4L;?N'8:8O:8&"T
M80SKOFGL9Y#02A._U-)M@HYYZ66FBZSKDA=|@|LIXV|MZDZ'C|PVO*)L@F M5F34%6 '+/;.#(XT?
BG|H7)ERGU|V0\$ N49Z<^(K&IX"O)%:VBG+\$\$S"\$R
MI"U6|=9+D'/-5M)^|+6>^A.;15&1*OP71|V/.NIM:S%J,3?;A;3TJR8)1A M|NAQJVI|HS&L>=SF6|_FOK;BM&B.
|H08L/'7#|I*4BOER/3Q*NESW.(A>_ MW*(P?;,\$J5(7B:\$6D1%7<^4C,5%;G|L/LZ1
L\$ZIT/R33Z3HH+|4.@P2B< S*RYXW|@1OPIY.#CA
M45S(0"H3@_B5G'LI:5IPW|E7^SC*.SNXG.;70/'7QV<.@R".40-ZSZ)8VMW
M#.SHE;V#D|1J|B:PXFL*Q10|F:9;"7|ALC"XPH%!"MY+%'|BGUFLJ96/B ^M9EUQB!+P|J6T@|;P\$13U
E&3_3*\$"EL?E*5*/G8'_ M;.=^="LI &.)I?8("(&*7%_*#Q.BBGCG("(&UFS;|>3|OI;XT'D+|;^P(MR?F+AZI
|:74_*89H3(VF'.1:CQ-2I*PF#YAXH@N#N'LZC">:NWI#OD3-& M|.(9G%>5REN;#
^|9^E603\$SYB|OZX*^)|L.L9L.0%1@8A"Y>\$C5B6X.;BYU251L).ND'2+|A/-.N7 M0*.8 9Y<4N;#"VXFDR: _/ +B2X^(?
C.IL@W|L6B7Q0_"U|+ P04_"|* MA\$1:TWV7U.|)|@ +^H8 \$0 '!E86LM.C R-#R\$.S\$N:'1M|+U|<^XENW|
M_WP*7<|YTU41Y4R^|)5YPE;MG= Y=>U7E=<^/!&"S"ML4H08LJ6?_@#4 MPY(?=>#>DD|Y3.6;D#?
1+;N.4HEOO?-?K MG<OM(C"16:MR;<;C;#JN=5FO>\$OW1WPL#M+=CC;%>9\$VX'5Z&|W72J5|M>
M|HGG:K3T(>%V&CWG&YVVPV7|XXP?65=Q54&|Q1N|V|TWZMEE^WEZEG5L^=
MI#L#SFI^OM7+LL:QX|W=WIS%64|_*\$C^A_5/0>NY|M:D^_7|DXC&:_ MT'|^\$+*KCG-J|=?S@Z-HV3QW'=^?
JRZN^;_OYLT8+AlZ?V|A8)6G&D@Z? M'AH|S|93WEGXA?K|0U?>47"=|=%#J.BOKU@ZB|HPW>XR-GA<
M4).O%N|Y%8"" D=|'Q|Q_4%GLQ=JR16SOPIC9X*A3JG^_\$2)|2M3H_WV?83 M2#U|+S_BR7.V'6;I?
*3L1.Y8PMGFS_V=|Z|D|N|J2&GW_H|8Q5|VFW^KV%T
M^>MED@RE3^V+T<#=>W.^*^_V7|>_8QY^3CI_XC_X+8NRF'_2U7|H6@5_M^SC^|+>XU-?
B7#TZ:9+ 4WU_H*8C#KCZW/+OCUW|_*ROS|2CG8-\$76|44G;#UZ9K% M*7_|>:=I^C|*.RS^BS-
Y|Y)9U>H;GW2Q4IU@7-UN_@7+U^;^G3X5|\$+&K3 M2TQJS.X^O|J.%*DRO|A7)B-
V%?.C|2O)T^Q"M4":HX/O"J(T4M|<)/K.;9|3 M&W\$=5Y7GCZKD?
f9Y9RAY>*:P42W5(=1HJJ&:@'U|=KB6I|P_A67A|H&9C:6AZFZ2|C87P5|_4_C+^INE/"T8W M8SMG
WU3>4|"PTMQE*9#U>L^4*UB-KKDL^|7=7EW?TIA;+G<%C#MHD)OF> MZI^\$+==\$?
J/+|)2V57JD:RW5|HHWN#SEG(W|H|AV38?Z?KZIX50&.;|L|N|FZ M_Y|:|W5W%Q=-_44FUTS%4.9_Y;W|G6\$29?F-
M#|50IA_V.4L5B9|F?;^=|O|OWU<-&KZM_|H|HW.ENLS21Z<_S7^LM#YU+V|M0LXC,3NIZG%%
(9)_1|G2^V.U.ORUTR&***G^YU;5B>%<8|;NW|C MH9?'7(HGCQ|E4Q(AU9+H|F.SI.XZ/_U3?%SSM|>3JO|COZBY-
_ECSS ML_J|OJ>Z9ITHG|C+|I3;0J?DXX9)ACIN;CZ5;_/*K0)=0_*I5V?>6 T^/ MQX|347Z!P<5N|5.(JUG/3TE:??
%CJERJO|CL4_+)|3%8PJ=7ES%49<|?^K| MIXLE M70_ ^ R2S|1_.6|/%C'AY5Z!+1I&T|*FGWQ9K M0_GCZ=-J88S?F0
M^AF&|^|*G:XGTD&4L?CI\$TZ_+71*58^>#BU/#PQ|_16#S|(.|3?|*P74ONK.YL/^;<=5 M_SOIW?UWL|L|P|UO6W?
O;_\$^)|OIW|+?%QX|J>+P;.@&;B5S8IA)H:"LY. M-/GF_4_FV_5D51W>^YB|Y;*J74_FTSU9S8(G6T@WOGFZ)>G2
M3=VV80#;B|&C*X;&LHMA|C2|T?HXS|=#;O@UCU7|*Q:E0H_ZX@SHG &3J MD?10Q@|H5@%\$HOY;=H':@
|/4Q|WA=).Q.=FZD&|^0E9J4QNY-B%="EJX#- MDA?Y;AA&NF_+XG.6A4=)B^7J|+(40^N4Q?P|G6%-&&MW?
3|*.QE=#74XTJ/D MX'N'I^G9J2G/CI*_Z||2Q&3I?>#5Q>0LZW&ICY.|H|VRTL6BZ5WQ)<J3E@0(*_T8^E5:1DV|*OI
M@^Q5:7T>71<*_M@>AUB^V7YEWUT;8081QF3IO^Y|S|FMJ18E%TC6('81UG<
M91_1KT|LHRQ<&TS?)3W;|HUQRSVK6<^@E?V|>*YQ+|UQ.8Q^S|W+6+2FF)5
M|E'N^L6^-06N|S/EU8E|PI0Z+G/A<+DXV*(@%X/D65Y^>M?'7S7RX.^E)>O)5| M;_/_OJ_PJFIA-TVC-%|
7= _\$^\$>:/2U>W'OWNULIGQ0M58^ #7VSC^H6JM=
M@|H7U&K6BNH"):/%CCGL|XN&.1H=2|/_4W854Q%&H>|N_ZR5WQ_)HQ=WT
M'3"TI0:*6IT'#)6FL|6MP|)#16G+K-7>7F9HD9|H*6/%B5#IX-)KMGO=P MUM2_62L0
ARK6ZV:M6HFP+&ZJ:I9AN6(%3K:1QJUFFX)0C5FM*Q=<|)H^4*U MI@1HK5IY/MG^Z3QF*ADJ\$=W
WV.O9>V&Y1M=R:D)6CCIO^|Z@_D'J:~AC8I5&#T8,Y|U|HGI/DO1" M^*4+6*DG7\$3)*B="9EW65<-=%>ZS1)_I
(45>Y^G M_1GE&|KIUO^L=MI\$MW5Y3_J\$DUI-EPJC_XFE3N83VT09XK%63K^C>BSM^MS1?
Z6|K8NK5\$S|H|/324V-BW);F^QN'9U+ _?HUEWQ_K^7"ZIG>W8R'N;:
MRVYF|Q;HR4'I2UO&BR#DRL4WU*B7?"|ZEWRL#1=#6NE*YOB/|A^\$|UI3Y? M^K1YNA!;IX?9&.)55F4;KMU.IZ-
4*RHWMO_PSN2|K_I6JAQGA7JD_AYRGNI7 M|R_%47++Q^WW'DMNTMTDW_UOHU3(%2B#ZZ
&RN#KJ6D|W|U@#YV6|O"CL M.G|(R?E8TMZ|8S+<4)Z@5KZ>IV|>9;"IPSSXR_9=|4)FBS|DFXJ_H+V2=>.MS;I
|W'4GV2EL^L6EQF+I6M(I/7+\$K*\$>32LB>|J|PC|6D\$;).HDV=76.*0GMB_/ON?8?SQ@M1-M?

U04K1/S3*)^8_51'WR-LC9I774629^IZY59P?2A1_ZI0WD_CO7FQD_*OF M:J2Q=VZ+>VJM?
6NM_IWVY06*E1F47GTM MY&JL-:4F&V.T'KFI:9W<9'. MUK..1JZ<A*:ZUBG_=@5EO7D->Q3IPI\$196ZV+9
M2NFZLIAUAHEE<5E7&K-.UK L+NO*8I!)#6_J.*JPF9BU9+=2RP2'8B@SSI-W M%[52"P>J"]?
A2FU:YIY=A:)607BPA08>B_7,SG:ARO_*VJZ4:EF>.SL6_MJ9ZVL#-=2?PQ\$RN+/4@P'J31%/-3!>WH
L:G(CW)WG@IZ=JW+>#/#15JK3*PW MW/YF#A7JJ^:QHRN*66/AZUE<1: B&!QSO>;4/2L5:@ P&H L%:SLKEAL\$&
<HJQ5PTH3N37IS)ZU MPEAI(KIF>XJ MMDU92VJT5H"R.TSKRH/62E-VAFF=2<1: %6G:AW>9'#?
&NE8I>=DN<WIOYN-SGKRL/6JDX@Q_*FP3J)#.24H17R MK56T7@Z3WL8[X>')V=X^X[XLXGS-
PR1.69"IP8C(6^>NL*X=(UJ:46!-F* M*YOK<0S/V7F6#RE\$.20JH4YZ=Y5W?6F'&GO*F,):^64!S/\$GBIRSSSA
MDL7YE+%^E\$1HG6PV^EZNIO9I>MU59*\$+,U1:9I:X66\$1L1L79T@:U67%RS0_M^6CY4#HC0S(K=>)X9/T=SL*
J5+YM:6+R#R8?C=:R'>BN%F5.OH>LT#2NCLZ9^M36"=;O!"=#
IGJ^E?"12JZ@RKK/MU0P1+O.'OBTHUBD:BLZZ^3:.=3(ZEZX\$
M%IUU+SS:FT:1@76CIA=J7DOT^R)H#R(Y_3%AY:;B5=K6E8FMA4P7H>"AK2*P= MI:J&"4LZJFI_P3LNF57,5?
_.\$C+D.7M@0J3.4#@P1.NNR M+C16:ID#A25IEX&U8_Q2AXA2I@RL=)3AD@0634U/\$M6A.P:/I<_/J3UQ[H!
M1#B<1+ _6^6J#Y@N2I/U:KQ<F#0UESJC:;HQ^P>(0/9NU)KG)F*XJ3&24
MAC9/(B&_""U@IUSU;JY%'(GR)&7=\$+X<_5#UP-OVFC0QL&[8:N"FLMJ:T= M)\$V9TU/1<;30.7:3<(G&KJIT?
V_JS=YG9YE.NBZ/V9#IRU7KIU*ES60:YKW_M4+5VP%W60*DV*Z^BY_Y:12MAQG6=*NYX>^+9X8R6I
)&O08MC_BIKYXGUJ_M4^F")=W)=??)U\$2I8?IY2>033TKEFI>\$09@|^EROXUNHN:OAIZ+.6ROU
ME"OL9:OMI5:75JSP+73,7/ADTNWF|=;LU:LC!@5FFL%9*6'0/C M&_G*9)1G:G4_#V?
OYIVNLULNDZC;R^X3MCJT+;IE&C6KFODL=JVHJ46VLU_M*POK!>L3+9TV5;-6FI(I8&L2\$VO6BD^VIVQ-
_GI=6HW)H#E_K*Q*#A0L1M M8-;JONCW6.N.M7*2Q*\$8R32IO!<2:7/9V":CY+W5JA"4"4MOYI6IUIJZ?
0I6U%L(ZBP(K%_TRM5WW99F00RW>OK_M:=6WE;)1(1RRW3SD9JM?J2>ITUA@%RM2DQ&V.OCE*0OZJ_M?
<<&^IM<.&M'WU<@>Y!B9*T8ICXQTEI)"2FR5CP#190:2I)6:"MYK!0F16\$ MHQAK5:/RIA I>KT!X:39AK527?
EJ_)?"9*V.5Y:.*?72M22JL6FMW@A:J/((MFM9*G;8M9&/#RM1-ZX3,5HD65H.EK0P=J,ZI?5+U(BM I":ZTB^+;5<<;Q
MT5NA40%1FAI!"H=;RIY<*O^WBOH<'K++'"K)3=^5Z.IHTJH9S2ME411
MC:RH1F7EVEK=%5R7E>NYGDR54(EJ6BLI17U619T+YVK16C-YFO52^=MQ:R MK-
70099MHJCG6"NAVP;+/K_*CE11RZ%^D/G(3QJK:~%4-;L:;SZ11=BJ^J MC;2^FW;6^N&^4GV%3,8")M
M.F:;+5@TFR;PEZ7K_P"~(KIX:OP)RO@&BM8!^MV)7^R 3=J.6G6_3% MO"6,, \$ M6_06199?
M6%J:;+<L2?>8L/DCU&X^*9(7WL#^,U1_AAI(WHF8-AW>=J1 MT4#_1^SZ7_KUV-EHWGAL7:1^WH?
S:;>BH^<KI>L9EP/5I)QJ=LOX!7M2B)N0_MQ?SDLK5+A:G16)*ZZIZ*Y((/(\$*TLDQI7%77>O<"2:8_@0)%!
IQ7&OJBTG3_MP^+I&6WG7%X+V5UN68GF7:9-X?4YXY(9ZU
MEH0Y.GGE_<R3NIX2C/@LDQA9L5:*WLC&IG7_"LTW857A-WM-Y6Y HIU4'MLN.>AGL%WW*VLI
(@V2I<):B>J1#2N1_MIK9+8Z6J=%9\$U'8)JZPUU#>IT93VNEIM+7T'5%U':5JE017=HSCI%2+IR MVU97#
(>Q&KP?&NH:NJ\$9STO%YO'GW+^X-734B#>5(0:~%B?F%"U3O&AHN':8?O+IU17"4#IUXRH6JC.\$=8(\$1#G)HM
MK+BU&&8#ED5Y^Q!&'17)RM8H\$!@M5G NN\$2((55%)>+0/E!E8IP(B_*NL_M_9NJ+YR'098_Y@EX3F3'IYO*
RDN613Y<7W_@E9IAJMKJXSVC=)-IAYOI MH:;JLN+&4T":S953YP\$XNSZ.NKP%7M.)4XFZHF4N.0+YO-
DNID&OK/DRB) M^L^0#,"5-5RE6_QKX#-&/O-E4)??1^&E_9U.UT8(X6%1!-U6F-(ZGWB6
MZ='7X^<6>2*RJW@UE%W5\$=YLI" M9*:C9'YF=(O%T;602<0H:HT_V#QKQ7=3T%:9:K+QMIW&'AO2S:;I:1#QH^
M-E7C0C9;)ZWIXE;I'IS^J%<C:&NI-5=66-.OX!83MF.NY)&PXU*AN: M*N*!@V(<,*ITB"RTM:ST*
(9"ZB^K<'<5\$VU3*A:E+F6KN6^HEIXYO7"1^I(M-JR44!=6?3E+I0='GIL%72)O^'G=AW:;173Z>SEN98=+/+
Z^>M:6D3+Y>I09RM:/I?70!;G@R7G4SHC*&=&:JI>3CV M^4#R3H_K/X=<_T/EH2I?U^J_K_SSTI%I
B":T^6)BG7JH+TS\$C+W3K5_MS=YRIYQ9TI!;BI2/GIUX/(@:IW^8551DU)MG<1@_7(GI*1;-VRVOOA)Z;=N
MRM&T^/?Y57;-OU^J(FA<18)-U.G5-?L;R&FV>1\$+>F:3C MJ4(K_QF)<*G,BE;U@W_R3\$19X31K>JSW7+
IY_V(DIO%C=Q.D)2&\$^S"Y5V_MVG=LL_RKXI9EIR+T?>A%U_1Z^8FDO&BS>5XNEO<-8W\$T.I+JMR>GV
M>1IUDIEIX_UMCI_@X6XZ.?:^LM3^:P54DI>^0A<@G6HH4UKE9R2\#BE5_I
M/EI92;-6G7J/HFIT%=6TJS5XTL.&@\$/Z/@^HFFM3FA#A);5T:16,7RV\$CXH
MAGSGM_TA5P53+T^Q6ZL>OJ+8&^4I=FM5P^+@IKOE?;RJ873B1HZ@+*4L^4^4 M3I(K4,I&%WN5G;JH?
L(HUT^C6BYMZI?DT M<;96OGFG<9YQ_AY&^@?W1_#W1:16:QAO%,HYI^N^TTB9:3IUK9:-W&N>%
MOFI>:;^IP.HWE;YK16UWBD4RYE|YS06JFCO-X/KXJTBMW;WS'6HT/4*S+ MTO-
=ZP3)7"XRF24IS"MJPE^@.1+"HB3WY_EI"J PPUT>DM+LX5B.1/4 M?;=,NOTILN5W*^',GO!0H!GF=2_Q!
<^K8:~T^2:;9-17YA2M.OHHXY2K> MEM3YI2JIK-Y:JT?)"%5Y*=-5T*55/(?A:;ZYU7JQ55ZTFBG"\$9@U4A*VD
MM>JLU5!>W@E_I3Q4UDK!@J=I+ZLU9TM(E" MU+?S"Z8#0QZULG<8/"I"=N> MM<+V>N>"VCOLLI 1"-
&_/EIO7RIK904Z^1#9?/WIK83O>MM>D*>S-EY;? M7-AD,1>J@FH7WQU_?IS&^C15>?#I0MVJJP%A:UH^
4L/DHK7(1BU=5N M78/XI@E)FTI"FH;2?OGDG_TD83D;B^Q3J)3UZNM;5WWQ9XFV%33GET=H
M8<#XBG3S4"RJ3-9I\$>V>D-GETRU%2_3I7'8B%I^S0:J_35>R):QHMZQ*9:TF
M85FADY)NK39A0Z%;T46V5J.P+D*>>80R@A9*VQ8%Z'U:;F^J8*#C_VTF=C MOQ6LC4:7I@36#NIM*6W*;E-
@I2C;EM*FI*"!@VSGUK6LNI55S:;)5U2C4M_M:ITFRN4:WI^?*>W79J5=0)K1_F%HJS:6_NB:-
Y%5ZE_I#J9@'M^H_CZ_Z MX(E=U"K>D+60=U?&A TD-K^4^4) (*49Q+=_H>ENBLU;D^7&4VV4<_%@K
MUIA1UJ1#YVN%ZJR-LJ=UNUK3%J12IK2K"G09=I(V^65"UZ%Y68.EM72RI4_M:6HE)HYMM+8&GLI-
KB'56N5+%L"LR9+JFJM^&1+8;-DYE9+)<5L?F_\$BBOI MK8#R/IE8UE#\$6NW&PC"7JWJHK5+T:B+IH-EO'(Z:;?
+6AUIQ1A8.>(M;1 MLU;#PNYP95NH)*#:. *A64KVME!NUU\$HJ@#V8:5R>|BZIKJ5?B\$K/V4CO>5&> MPK96JUKL-
EWPDP/<I^?YX_W,*O_Z-B5K6A;SCG=M9*H8J5_H(SS6FHED<#> M L#*UHHM:0XHB3Q6"@1*F0_*HJ"1"8">Y.@)-
B"DFAH)8&@CF@;K<187 MH1B^H^UVF@;JVZ5\$8&2ID%K6) F_G:M\$9^!\$#ULIP962@E\$F@U-I@JCN^MU!?
DDK/KI\$5Q_ TG@E+K@Q9B4.I<8)U&F,ILYX(EW4GGAZC/HB3J#UI:Z.9I M5V;KA+ZGXLB^XXOQ-
%:O6ZMI6W%*Z=2K;NE-E&1NAG5"V+H392FC*V4 MI:2)M=3-1BJ@22?BZ=
HHE&6J@;^N(SI>9S+ISJNB;IP)Y_9JGG(I"J9%<5L MB)AK:ZTPG_8WY-0K1?L\$Y:TLFTK:X8#F,5)8_-#>5-
G?"L)~CY):G MF3I_XTYI/V7I^84WCZ-KWE;D)W^U@>R31E-JE@TZOR9_%K=:6SK;>EGC<9_M90(++)_?
IE@_I=S:IY2GS*T5<7Y0YL>QU6G36E5%5Y HC)@_M6:=I-F-IP+IOL1,F.WBVT1N!
T3/86(:-R:O,B++&WEJUPX|8&UD898V| MM:K+BI'7RW_1F_1LK4YC70/JFD?(I8R0M==1'RS-??
H5Q:KYFMXC(G)K1B_MEJ8+\$2H^1*#CXO)D/Y^DQVEZ9_EG65LH6I%;K57?@\$7ZULD-7#LE7W_Q?K6_M:
VHZ15E'A^I#-2AI_I A=^MBI<,>&FG=P+5NNH-N,, N M\$BIO%U'.V1@OG.593 _SDQJOF/IU2C-3D60EH!U
MK*WGX%JG#DRCL^O.\$\$.Q4*_*GK^M%V413P^<^>^)AR_-##?HZ?L.L?UWH/J
MR41%*SWG,NHJXV/>L^6Q#B+KDX+KL^3!^X'YF&"/I3S4054_R"/J.4M*.GH*YR_-NE2AR^|BQI|IG:
MA^LL6RMQ%*AI-RAIX5NK8!0H2.I?7>3B6GNM0+M%IAV3X>-W%2Y4?UQ&G8R'_M>2C^3*
(LO6C_B=FQ>+N63MM8?UQW^"9O(CGG2ST3-SS;#N>YBGVZ?BOZ\$A
MLDZH65Z(D)4<:X&IT6P?'6K7%M@M"E9J8C8%J:ULCWH=J4+_YIT,*6ER|NB@*PW.FO* M;'ZIO(C_CRZ-
SR!RO"7.I9(ZEAGF3!0V_5(*&:9C+&HQ221>K"L:Z>B%E\$2FF_M'Q_T!|S8<9FW0<|R78=*8W+|91\$#<)=+
^E\$0*=J9G\$1|U|+EI EUL_%HQUM*I+ M'_V6I2'L'9G_L#V|HP2EG0B%I^+--(\$STCN%>+53>IV.G*H&%X
6WTHADF6_MGK,1NXJY!EP?QL/CB%U%I6^ZU=I:8PB>|F=#:;NCC7.TJ\$48?%FUG=JH8-WJTG_M8RFI_%G!@G5R@?</p></div>

4LM%#H7K0V%P3HI8QDPE#4XUND@UM?245;?G;^KI5:T3;*PG M8 GM^H8L\$YWFBS?BU=Z&4E2 M+RN^\$-
L*5^:L MQ^6I2"IX0,BYFRA/S^&CV9W *6<5UJ"369? 2>/I+J20B=PTIA;IZB%/-HY MYET6^3WVVI6+&P'BI)I*
MJ8.TU17#8(GYWPk"?^Z)^ "GG#>J\$,.LUV;)H=10C:0=I?073>VO M6"EUE#.\$Z^K)6*=\$Z^KC6"=Y\$(7P?75%K)-
+2AW%:-73AG522ZFCN*, MVK!AWG!50+4KYF\@QZ0A/39-7F7RXKUM=25DR,/3T6RH;W2AG7B3"FC
MMZX;.HUB4KHK2MS6B>H+)K2\,QUE#ENN=-0764RTNK*!=0SL2HR*K)S&269
M-.WOA%^K"ZA ED9@:5@H)0G%I03!!I6*B6KC(5QFIVMMG*D"EP.Z?5ENCW MN=1'G B9=5F7H'.#0_O=I
(N3Q7=5/7E7(KI)>_T K2'N:F*R_+"MJP*M*FJ MR2GG88_UCUD2GC/9X?O7TO_5ML< RXA-U-
U5PVD8&%)U38):^7<+TW;1. MWD%GD5YQ*;(H)IC_&(J^D!9C8YU?9??XI31/?M\$X0H@W+24B.DN5*Z\L*
M4.DTCW&_QH6\BA30=,LX3+M18/R:"I-*I47VTJ<4@1M6BF;O%#BOISU;WRZ;J6"EEE"00A*FJZE@IS?
JN18*5NA@CQ50=HLYND% MO^0?7D)_REZ313:PDZVI%K)0.44E026QJ2:P4JB3KF7A<=:S4SU^J M)
(?H&2O_QR+JZ6E;:~@J"V=+.L=*00=#-LJD5L=(H1"5!);&H)7&M M="125!)+JPNZ5TV" _\1XKR?
L>CZRIJ^66TF%?7E_%61=W:Q2.NSOLX^@ MF16N5J24@CLJR?NL).MJ24KIL*.20.J*LJX!>RD=H-W.0WE?
8!U'M75*J7# MC@KR_BK(NKI9I738WV<%03=K7:U(*1UV5)+W64G6U))XI73844G>9R59TX#=
MLIYA+P1Q:YAFHL ETA V60.QZ#;S1GGBA/U3R.GC+;ZX*+LS2YYPEYJP7/"!D!D/= _N: MJ-G/I?
XBL4A+M&1DU;:E7XB*+~?E%G9++3&QVKNA(OQF9VT%\$R&&9I?H1' M596-
"3E(LZBOJLC9I>PGI<#;C^VT^66^M3HS+ A>UBK@JZW M-?G"PZJJP^SS-.HFN6*^>_WI%ZHDZT.O;+
JHLX%DE7/5Y2;1T;1%;IT/ M-1727RT5-F-;".9IAP8V;17=|<+VU-73SRQ^CD6;HTF?%WP>#PKH1<^O.X
MTIYA+XF!Y:A#KPU SK>MM>@@=):.37ES,^!;NT>.2I;^62M>_SCZ>2/P;1! MLWG.10H09*UL4G8-
RNI<@XV1623=-Q@K83_&C:K=C M*RU\$E!HE=SP;FY,W
6B7R)O^A^I41#I+P.=&Y,Z2NB_@TUX^22G)OE#W@GPN0GYDZY^AN=56WL;G)HDX'J?2-
JP'E!UDUPGNTEXP5.N;WGZX\$WYV3&IG8Y>B.@E^< X+NQ>:Y9"KVUQ@V@*(?4K/6
MXP%!:VMK:M8Z'8"B\$10>)136V@N HF!;LZ;MH&K6:OH@J%!:<2G3BK5;.J H MF%;6M(%6S5K!N!P\$Z?
43QQ^QL(1CXYJU4C.P*;WHV%I%& RM79I M+H6ZCVPTSW+;^PFG9Z0K,MW_R
GF7"G77MZSG7K).!R,WBLR!^V%F^NKD> MZ^> T.C#*T3G4N/H>L P(86)=UEQ "ZI&(^0@&\$A)HG:I?
>@)=IXM6>6ZC.\$8B-.70.A>AW!CZCE?4WH2F<\$QH1DG M<\$YXRL"?7^P2JB3H.L!P (
PB0A;X6KYSW!D^@ID"8).8.U;B,05@D MY TQ!F A!FL"!J!G>1!PLR"(N\$>\$#LN>V.R+(4VF !"N&24%/H@<+ "%,
(F MH;0!X6*81/0DUA H+4PBCA)K^B^L3"LSFH*.Z"P.(7P3*IK("PA3" M-:&FL \$*"U,
(WX26PEH3+7A)ETX)0.P.PI(8PCTAQ^F M7G\$89^08PCENC&B\!IH7-IT
G=/JEO2ZX" T=@&A\$82P3V@A!SG(.E\$B0"! MA@3".B%.@WIC4/(4!!H3"-N\$E;:M7DLTL!L\$RD0-
\$00G@DI@H'GMEFR'_ \$N MLJ I@C!;)=J@4*P=1%RD&@&8\$>S!)B JL@L!B!\\$DH"6SMZD600K\$X&68M MR?
D-.#3D\$8).8<>."S:(9P2<@YI<%B<0U@EY!P&X+ XAW!+R#FL@L/B'(S MH94+ ^<3L O41Q@LC9E\$*)*8.^XS0
85\$(X9N00ECW&KM*#21KG0% (P#A MFA"OW^L@< B!IP3:@)K(/ 0@3"-.%IU;Y9IX+ 0@3"+R&>Q5IOB5@!&(K)
MAL<@T9!\$.":D)#8:DA!8GP3*CI8S2S@ (&B(PX1X;<)JXT04!<4L"=,+EG1Z(-&0!@GY.G0_5WT
M5\$S\$70(*#2F\$;4/!&HRR+>2; H"F#L\$N&23!8%\$&89C00@!?=XY%PB!E MYT#0\$X);1K(=5J0+
@K!+&?GN^#48(PBZA?KD)37%1IF&7T/8?7>R M)V2" 8DQ@E5X)>3R8
("T(MX04PDMMV)UHEX2G&9>M2V!HA"&L\$G(.?6!8 M&\$X)>08NN\$SL/I YT-I4ME L'(-(
M0!@FM\$MQ^<%N%JMP1.GA,1 T0A"&"3&"52!8\$X);2VL>.!P8((PBZA1/#P M6/4\$ 6%!"&LP3*@A!U
6!!"&:TDQ<|M|XG61**! @:(@BSA'D).I" G&3 MYO(@, #3\$8&8); DF+UO# 8-&8130MTE!
(7%8110CXPI7YGG9M4)&B2BX (MOX2X26!^\$.5IU;S.&C*(P36@9=PP691" "2V#<1<.%F40E@GYT*1QS,+1
M;GP#" TAK_R(>X0^L2LAG!3.NN!04.&X9@0=PB!\$R;IZG<@T)!&:\$.!HG M\$>M'X,^0/S@EM(:=XWD L B
L\$F(5_UPD \$+OB'A'. '*=6/XGB*)-FC F\$ M-4*; JOU^BD;Q!PS!TT)A#%"36 #!18B\$+8(I<3!X.R&TY/7,\$8:80Q@U
MA=Z99\$F7GS-Y PK-&S &%= *IFGTF!X0 @88\$PA>A-HB!A@LOB<\$=J%
M^7W_G?70%33%#18(.7H!N3HIZXB8@4%#IN&-D\$ >=T!A40IAD!#16/7!80M M^=& T!!">"3\$\$.L#\$L\$G(A!7-
3Y4Z?"S MD"%ZAJ84PBZAI;#A^ ^WLG&=.QLRF0!0P3AF) C M6 ."A1"\$84+^5J? E2<13!-C!&&:D
06IC>>OGRDAL@#@-\$0Q#AG)"#&/PU MC#&5T)A N":T_G&C/EX/F'W>!8%&!(RH23P\ZICN X8+8@!'J!KT #!9C
M\$X);8-.%B,03@EU SZSM!P6L@0"!HA6'=@DI"GP=K^!YF/2!HB"!;O(I
MZ.X!\$IT@^@@0&D((FX0<0@10%H001@EY8UPI9G>2)QV>KIL/\$@U)A% "3F(= M)+Z&1#@FM"3Z7E I%R+F\$@@:
(@C+A-2T!STW;+-EB0.@V13!F&9\$ \$ MK!5S M8M(K(04H-*00I@EYM!#_IH;(:28Z-
Z#0D\$+8)K3ML>/4=M4#)JU;)%IXU.UE MZ1S F=:FOZ,(-H6V7ZXZW)S2+5WJ#8V!HB"\$!%\$H.C_0L?
W#X"@YAH!S>!!W MHP0\$&A(("#X6Z\$FL/JL!HD#X3,P* A@_!J#*"CL-D%@(0)AG)/2*KG+18IE.)BC.(I(0?
L;M1R5W4 MZ0%"0PAAG9! ">*I7 IF+A>B/W9.C4W!HPI\$VX2'0P%B#!0R.\$A2&\$;4(.80.0%H80I@DOA\$U
M6!A".:TSEW# #T!A80KAE!\$AX)SU@D(T!H"B&.%KVV/7<%NM?R2CL MA- :8A;1! "\$ V!AD3!(D'-
TI6DIV@:;\$1AK!1;-1!\$S_ (%97\$5G64L4) M#LTX;!(4^WC%+>JP! T1A(="O=V\$=RGN4I& 0\$,"89^0)T'W&XM#(:-!
MH'&#!\$V(IWZJ.GM1&A)K!<3 TH!"\$<\$)>*3X9X<)NE=U+DY.0.%1A3"
M.B&E!\$A/IMECHWO1/L(&87P4Z@H\$%A M80KAJ!3V 2%A2F\$H4+;.SS5K^U>GK":YKR!!@:8@@-A1S#)C
LC"\$<%7(. M&RTAD@LVB.(4&IAV'#@IH;CZ+?D2)TG!H.&#;)% (670/0BCA(% 0P)AGU 3 MZ-9!8!\$ "89N0\$^A!&78%
#0\$X);8."U8W;# #^<(^#2%\$8).83<^91E,3!D M>HXA.#3C\$(8).8D&-8!X%;.82%0HZAUV;WK(LYUJ8(PD A'R*
H2R\$XSOU6PD.#3\$ M2T">".M?69BP?)TNT0 4S5"\$A4(KU)0=OR7B8J8B=G8-"(0=@GLGP3<.,M6Y+?
L;@0PD.#3&\$?T*.H7N@;DDD0_-00 F"6UKI/C>41+R 5?_23H<'!R M"/N\$/17Z?I
D96E++Y8\$\$.TPA!"FPX;M1HH+\$PAI!J"OUCSM/VL^/L@P8 M&F(^X040I>I-PYCD<_M;@-!
(PIAGY!V"IMZA/Q9)H2%# P;.@COA#@-5IN MLZ-WI01")HA",^\$&.& P2+(0C+A+PEH!@;0;AEY
SZ(/!0@SZ.\$QHM9E; MM=INL3@66<9/6X#0"\$X)=005K!%<5 =6R824&A(^LSI-
_W"6G^Z#0B\$)X).04NCEXOI@3"9)=H !HT8A"E"SI +!HLO M"+.G\$'O.\$HZ(DI H'&#<\$NIHW9+&69-U&
T!!>?742=#P06(1."7D! 8@ ML "I 7P2!HZ@#P*+ \$ B3A#B>#NKHCM"AJ=?@* 1@G!(J!%L ".B".(>H4.P M>3!(11!
&((9X1X84S7;?6XE*,041R2_@X*C2B\$ T(Z'E=N!0G(I&"7XJ M).U% Z!HB"(L\$NJSZ)T!";QA
50;\$8A3!)J"GU06)A". "74%:@L#"%<\$O(C.M;X?>61SNR2GL2@6"1@C"-2%L%9S@&!!!&\$.&".(+%@40?@FQ AZ0+
@@C!-B!T M@6!!!&&6\$".8.&"".(H46PB;Y@401ADU"OTE\ X>F AE'&P: A@S!)2\$V2 MOQS'#?D\$#?
Q*#G!Q":0%B#1T(-H=-H"9G N6*=VY H2%&L\$K(&V3WF^H1 MWD3H%1I#"+.\$'(\$!:\$8)J5
8.X7H=3JP/POJ<9@K!+J+?+?"2:4L7C MI!0:\$0@W!)2 AMN_>R.I:D @8 PBJA?JO:0^DNC7UI"%X=@.\$33"LPRRA
MO!15Y5%K<7Z IWPPODN(#2"\$8&).81>BZE?3E." TAA%U"#F\$ " M""^&\$ M&D(W.) 1 #0%\$8&).8#.%Y:(6R!H"&#
<\$G(6^+Z6**^&LHN.#3\$#\$X).88- M8%@80W@EY!A6OW"9IO@(#!HR"+>JMV2.MTY5N>54>
<&#^!HR".,SED?#YI M41-?7<00.33F\$8E!1/3#&\$?T*?#MUO@H/4D4+1\$3 M#&A&A_ HU S4SIE,1=)N@4\$C!N&?
4+?(\$L!)\$Z? P;.@CSA)K! P69!#F M"36#53!8D\$&8!0).@+WL^0!N8WB&8!0.4MB\$=4) H0<""U.(XX2:0A!4%J80
MO@DUA0\$H+\$PA7!-J"JN@L#"".\$VH*:R!PL(4PC.AIK."@M3"->\$F,*I PH+ M4PC?
A)I'C)&+4PCGA)I'C)&+4PCOA+I?V- 42@!H!@6U"#6 3 !8!\$(X) M.8 UIV0DLYCO<=:I 4-
##&&94<'W40);GG.97K!TPP@&H((UX0Z'U;WI+JE M.R"RU- :0A3!-
*""I)=5FT>BQ3(1&BR!A(8>P3:@Y=IUP6)Q#&"2D'+J' MDB4W<90 OD.
(X9N0I@QK70"%3IZIRT5K@&@((JP34A"KU>87+OM1QKI@T)! M&">T#-9<.%B001?

>"3&#A@LRB#L\$W*EQON==6Y4IQ_&C(IX2<0?#11F\$5T+&BS(IX280>B#A1F\$3T+|FE.S!H&P.
(0P2F@AK'M09PI#M*=>\$7/8./!/%.(K(>PT1Y(=612%(?T!#V"6T+7+|=7=5&DPN.P\$C0"\$M5T(-H<
"P#HPRBA?FD|N^JYTVZF0"#I@S"*M#/#<:SJ|C!5-P<\$#1\$M3T*.8&V/A|="AF#0D\$X)\$M@4(X8LJI@7!)R
FL@|B!|(BH2;015L2A" M&)&88PB3A#P1^L"P.(9P28C50<|M|9#)C-(0
MH2&L\$AH7R5Q"#X@YAE!|SB\$SX*YAEQ#OWN0W6R/U@50%&H8(PBHA|AIZ M^RR.&0 T!1 F"2FKN&(+
0@7!(J FL@L!|!|(BH2:P!@*+&\$B%1T)-8!T\$ M%B(0)@DU@4T06(A N"34ZWNX(+ 0@?I'R.>M-H!|@01AC9
F05!5Q;ZZ(R: M-B80I@AU\$01|(%@09@BU @Z|D%|SE(! T1A"U"CJ"! LA"%^\$!.\$F\$R\$
M((P1|O>)'2!8!.\$G!%R3<8|C.4=ER=BF&Y&5.X8^08?4!#7 1">"6T|S0Y?>S9.G54(| H"&#|\$E(&0Q) MYXL8HA-
4X@7!D): H: ""Q&(#P28J^X"0+&\$0B'A)3 NN.IP&(\$PAXA^HL\$ M 1 LAB#.\$5ISI|H@Q9\$8-(8(^\$R\$8 />"#6":(=@+
(@ASA|K!A LAB"L M\$6H\$H0H61!#."#6"=2!8#%\$8(|0(-H!|@.03AC5 C"!.D((P1X@G3=?0%RR(M(-
P16H>XZ|5)6W5G-00?@CQ 8Q"P@Q1P6G_8<^H@L B!31@C(Y(N|^7^P M#%.E30&+4.68"P(4X1V(-
P|G#4C=T)@76U3|F\$T@|G:/^5V4WD9Q MS&A(83P16@'(T|C(P+)|+N:<30@*A@O!%B!|TCX?27-Q\$D:5.
X8|0CT:0+ 0 M@C!%R><=H!|@03ABY CZ +|0@C"2?2Z=QPD4/7P.7<:0E<5&C-D%69J MC9/U&2<.C3Q@S"
(2%FL D&BS((DX1V;4/K0"HA#")2\$?EC1/HC!FV" M*\$X).167>U4+V|Y\$75Z&L0041RGH-41A@FY"NN.NN|
<3EH2"8=-88PSAFY" ^%EO#R26XC)GT(-U0FP>-|K# M+I/F.%0 \$*X)|00-B_Y=Y:V(BS)90XAW!|B|=&KSCJ"P.
(5P3|C'QXW+@>)A4F\$@4(IP:#|28TZF9-17G@R9A#F M"6V;|#8;W A5FG\$)|DT9A%"NR2#B@|8+,@>7!-
J|JM@L|B#|EP3VI&)|P5-M0%@00K@FU.LC5;^X@B+|QL3"N\$>%C<|/;\$4#_L/|S\$A2:40C+A);"6A.0
M%#H80C@FM.N/XU7W)U.= T!1V"6D":UYA|L-|/"1":0@BGA!";NV8C3*1 M@\$!3 N&3\$+?
\$@0<\$BR\$|FX16F.G6SR30@S|3_F"1\$|GMUF<:;KJ=4@T-# M#@/8).0M\$KYS*FH@M"Y2: ^&
ML@L435&|F\$X)M=-518N6P=B_15R%GTOK#^0 V:.\$IA/4B=-I<-QCS|S)
M"TS(6X480K=Z\$H6QR'H10RXTQA">"C6&-6!8\$.X*=08UH%A<0SAH!|/ZQ|
M%SS\$V.2Z\$"\$&A*84P3Z@I=|U06)1"N">T MKXH&C0NNMTD&@:8\$PCHA);#><-N<95G,@: I@K!-
B!T@&!!&9\$"/H |&" M".(N(4:P"@2+(5B'7T(|U|!@X49A%="O>|3>H-%&8110JH-JFR|!91_09 ME\$X).8,!&"S&
(#P2<@:K8+ 8@W!|R|FL@|B#.(C(6>PMCL8Q%PI=4>@ MT(O"V"3TF1
4%J403@E|GW!/"G&CGCX.P:\$|A|!+Z,?)U%|QX8WG-#0PP;ML\$S(??3:/7:\$.@\$\$(32&\$9T(H:07BMN-
XR@%#AJ88PC:A7K&P<7#+&\$OW.Y|>_ M*\$9A|!-: ^W%HT\$| M=- TFL'L9.W@8Q-@%#K!|&3MX%M38>
<#N9>S@4A"/9:WV"QO=,1F"NN>I@TE!M39TZEZD#AX%-74^JN1.E@4U-0%#H.Y%ZN!04%-7!7404>#@I:Z:M
\$=2|2 M|W^"F+|J ^I>H.YU8\$|04P2EY&7JX\$Y04P2EY&7J8\$Y04P2EY&7JX\$U04P2E MY&7JX\$U04P?
EY&7JX\$U04U<#>2|2|V^"6"7V@F/VNXAC|NJ>|PI>|!#5U55#W M(G7P)|B|JX&Z%ZF#-T%-71W4042="V^"EKIFT
1U+U^C;X+V/3'/ W404P=O M@KB%;380>*AWSVVIT@1YSY.'X)8LW,1Z|"VKRZB#| MB#SX%|3D-
4">\$7GP.*C)@X=A1AX|&#&+R7!@89N3|PZ F#QZ&&7GP.*C)@X=A M1AX|&#&KRX&&8D0L'L9.Q@4U-CYP.YE|!0
M4*/XOB9>P"6!34V\$%,<.'@7MNE!N\$IG.#N8%+38!24:L'L9.|@4U-@A
MVQE@!Y>"\$KLI<8J^|JA|GCJ8%+3)KN8BVIE@!Y."&CL.9 VP@TE!C!U."A/L M8%+08M>H SL#
|&|24&: ^QE|HP*4BQ|Y|T:IML98 >3@A8|U5T.P/L8%)0 M8X?I=:@8P:0@QJZ*OIT!C HJ% ^E<-
|BF44>X>2|29TH8" _NX\$;/Q2| M%> /O@4Q|QX\$?# QJ_ GSP5X_!G\$ /GH_Q7A#Y8&-7_H_Q7@KP90@Y|_
M*O@KP!L#FK^N'O'IP.ZCYJX_ OS!|H#FKPG^"O' X.80P#CWR+|P?^@ MY@ CWR+|P?^@Y@ ^1Q'^X'10P?
HPA|#^H^00_7P'^X'10|P?|NO!|=??@? MQ/Q5&^"O' P/ZCY@_Y7A#_X'|3|U3#^+<(? _|J_C#^+<(? _|J_C#^+<(?
M_|J_C#^+<(? _|J_AKP?XOP! ^#EK^JA_Q7A#_X'|3|07|HQ!| ^V+^:FA_M" #7@/H'O%'_I+\$?|@?
U#S!_YE"" P/ZCYP_R#(OS!_Z#F#^ ^%>\$/_@YK5>@O12B#_T'_ 27(OS!_M_Z#F#_I+?Z:|#^H^8/^4H0_!_4_\$%_*
<(? _|J_I'_%\$/_@\$/ _@0|!#V+^XA6X@_!^WXM^Y46ZQ_):.PRT_W;/<MP?>@YJX&
|@RX@|H|S5T#W!EP!Y^#FKL&N#/#@OX&-7=<&?_7P-6NZ:'O*=M"7?P,ZBY0|X\$X0X^|JV.Y10#<&?_?<?
P+O|_HH!:=RY|VKNH*.8<>_@|H|MC"M,N<-?0_@O|P?!"^X,N<-?0_@|H|Z"@FW,&O MH%KW_#J*"??
P#ZBY0_#A#OX%>3<0!S\$X0Y^125W|IM5OXD)*0:@^3 LB!2F M|HUC_EW=6B82|2&ZC..8_|5@P|J@SI>U8|3JZ'L M
LK70@GK@AK*ZKF06:O'9"RR#.GRM61686U0DIEH_ZK&X:S+4W#Y6B|A|U!S
M&7P1"LHD/#D"DZ|C\$B8/|7C';0GULS27+<|7.F=ZD|B\$S4.=*YTO|);+R%# M4/E:*N'R4%/9: ^DNK75SO?)?3A|U
CZ1X*F>WQ^%9\$|BM2Y2NYA,7SCJ-2M>QGN=K+H-LHB|JT\$BU&8?A?&R8_5%;:CQ|TGA8IXZ7
M+AX>:3RLTX1+&P^7-|H6::EB(|/70C> MDM7|L|ZT:"\$P2/_@>3|L|Z9:V\$P2/_@>1|L|Z:H5\$R\$S+
MNOQ8L'0|2^YUD3GUXW(TX\$^OV?S9B?#.(L&=|?H=I2.D.(IYFD-97K8;AR?93TNES>(MZ(3 M5K=28@'I-:
Y6>FV;ITD616ZB4*EG5ZU;O)B|18G3#%R\$SO\$|Y/7P;FOI?P?!"^X,N<-?0_@O|P?!"^X,N<-?0_@|H|Z"@FW,&O MH%KW_#J*"??
2FE4X/ZJ|ZPKZCOBRMOI32KD%|JL9;H0UFER.#C?2QV4H MYV:9Y/B7RM;^061.MF8.MB|YC(:.0J8-D-Y)Y
MITIUKKY%|7I*%:ZU=|'6H@EA|Y:B^AX|A|&|957(2L'56B30%|.#|I* M+PM:5&E|M2,CE|G|>UM&MBFW+
T7*LZCZRR7QX_1|Q|U5V<50=G@Z_K'69C? M;|C=?OI_2G60_7H7A5EQOW6<|VU>"A3_3;F1CL^JP_00#
M*.ENQ_PZVW\$;ZA-|Q|LLCKK)SC^J2K3T?BC*-%O+M#U*G3_NU>NKM:|X|X|W|WRX5|&GEE-
I5+D2?)7_D55Y<#M5Y30Y.(W^MS=5M|@QG?|Y-GL)Q?
HU5QIH^E>LY WM|&R'OB/&R:#M#=4=2'Z5NAUES+Y6> MY=_W_K/ET.I*L*EG@Q?=\$<50>R:3KV_?
60JOKIPV^'^.S|"-86X|7ANE%1 MI9'EIYTD_@VC=!'SD:K/^>/E/_IU=7+WZLA**(<Z+|@5" GO.X M%5>=9GJ-
C_FS_|BLZ^4J3.505WK-?#5L!7?P*^K4|_GAY=NO?7VI|EP?M M15SF:MZ6NVT?M/Z+|H.FA7=D_W*P?_.'W9/?
U4&F=G9PX3F MAZK1.WOC:4|QDXGDE|K^A|BN:4@V:A^UYM|2:SR_+6&E5|6NBJZ_IHZ M:006AV<7)_UGV|
^24WU9XG(CD=|M69.I5)LW^AFP'5X|FD\$QW9D(>|>R+ MSE#WP/2882MO|_5_914_^.|O%=P?
Y9/01.X)BWTNFK%3R=,WE3.\$O|SLS<|
MET&K3_8NUM%_KE|7+DX.#^|N*R<_WG1_GAW|+R>591+>VE:DI'6YC?|ESJ1Z47OKQ=L?
=KGG;&NH(>EB^#_4M%#50.&Q6!D ML9:P"HGF|YI^TBW)6AF'CY_GNH?GN:
M_W1:BVM/W:WG4:C67U5VUBU0G7#'_9_RBJ%WP:I3JW)"=JF^FN-6W/GWA
M+,YZVLV|3&S"B*>_C.OE4=+Y*JA_ZIYU/RMOKY'WQGG2PO BU?R|FC5UA: M20>|H|V8L!
(EE2A+^YT>D^IFRZ02J:P@S|R7A2I7T'J0^#_N/=E^KGWH|Y M)%W" _*:*^T2KK?
|4K3FJDHHY&#BY>2&:\$L.DTR.6JH^KASF|OX REN|7GN M|V-
K4|G3(YBEH1OZ!_.DN2|C.OE^WXTL7+2_LLMW-K4^ ^O^TX3=>OUW|8
MR&4%^E&ZS8OQIOS*BN|_"CU1H_+/H8S2,JGEJ|C|^|N5_/@IFH0|>ZPLO?W2WNS2|M:G|C#* M^+A'5'4R4MO-
VM%7\$|K>LFMGLU#5.AY|CB3|N|YJY+\$O?D MJU'6V>.R?MU%SH5J%N/_C@:C-G-
RB6#K4/Q_>YVJ|C/M%G3R8|M.I"JX M:.#B"O_..LNM7=7I4_>|SY2?UT!7IU_W;ZW|I*^"K2.K>1L(9|5K4|U
M|U|_+D-'K-O0B)|Y(PW)7C8"C3 MH1X 9J*BCLC:5=2|Z>IG77^T.K:;R7;>|PKE0\$;'YQF87G%KW_PG&+&#O.=
MY=4^N'4:2|W/_A>W6|+&#B^CK+QM#K.KU*)V9I^C:G|W|F'E"S)|U1_TK\$ M/Z5%NO@E>
<33B;R4AY%_J_3T^TMY|UXEE|M>I#ZIST!AG^3|S?2-R94D& M..9-
|R1QCUSO*|A|Z:W/L:5:&V.I&Y^:7ROU0J<2H#)BNW+|R5|@9KRWA
M'WIAEC7|!8M_4F"|756|@W5W3|K|5O"XSG_1.6|&20?3+^6'|_J-/IC+\$H MT;E-E534W?XEY.V8|L6|JCY-
MF%#E5/5S|9|W#78=8N% MH2O_|7AJ3=?OQ"R7)KR%\$2:@V05ZY&E4Z/JW30US-:HW%#F'.UHK3"*G<|
MCK=O\$G&G;I2S5_\$7|B_2H|I9L:02|NLH&9M>%|XHF8%3G5:K^JHZIB'O:<
M^8*:RS=U)W_H&VE|N.HOXW97\$AGZ|-?/V8TA9G BO|LL|3|3Z:HUGH)FBC MKG+%M/ GLWE^G.PV'NU\$9.J3?

PTCW3ZH9B&?<"SJ5'I4^W%.../D\^TM. MYMJ1!<@5D00%7EAI "KB89(QF4 JD.F.=EH'D#VDSN9
M'=93B5+C%598'18FX?OBD1.4"=^@K<%Q.92ZK0?H'37^M)9I50?:N&R/K0
M@>0=6@^876!HOGQ2;5KY29U4!1PKZ5-)J>T#;5IO.ZLAJ+^C!^*4L25Y;J
MOY.G^5FU!DE8^~0KUOE5!UW!4SV0_E^@/JOEOL'R?)7K_{R6^7I5FE MZ8S/\$+)1^J;V8C+5>#S;48H!;I8-
IRN0A^;B1!W%N"#><./Q3*768'NF^U&6 MJ.K 8!6V%(GN!L>C"E==XE\$E7^.=7+9)JEK'(X;EH6J00J.>,,ED=HJ
O> M'<L/A^TMR\K/^E_UG_U?. #K*~5Y1..!GK"T4H2P/CV9U6:IS^~J:I.%9DN
ML4G5G=55'W45=;5X7>HQGIG#_&OWU^EA+QIP_/U_#11-1.3@9^YU>N3">.[UKK:1?=<COL_Q MX35SA\OUDDK@?
6@TBDUN?/94'YHNC4I&?%_..GG%);9.D.P76~\GTLN6JG%= M(4=/:*WY07E=I\$P.NI==O6#KT_'3-
9OV31J"4J9K%)VGAH#K>BQ:>'8?AW&C MGNIAOV\$9.TK7^~BG3S7KIR"\$Y7^JG/HF@U[ISJ]*M4UXNTU7N3%<.,R?
T!#B M&TZ;HY=O<8@'3S=;WIG*\$Y+Y7->.*UQF9@B62N.LG=..L&K=<_&ISJ^9&&
MIH66G+12>5VW(1\$7/5M=J2<=K_WPO&N:Z.FKJQ6!70(G5I==E*HAY.MZ)QZ&Z5Y.YAO/:YZ@:J-
U\Z8\UDH^4AR.F M&HD3>M(8);(4.6I^SYHOWSA(8;.< MK-4VDU=;G7;H^O.1!FYX);.K?SYH:U7
:MI-3W%162IX/=./9EF<16K=#&' MT'4D^V~!<."NS?1!BKK<O [S.V;#;..HFJ_4\$+^M5!S3X%'G6N!J1Q%RISZ@
MAS'KFF;1^LMK^92XLEQ7TGO;2F0=1;ULVEROKI=8EP7S">GC
M20OCGTTLJ>LX=ZK41QTA)9^~.99G;RFU224TQK>1&*;Q;\$KQ4U?I4*F8AF> MPRAI9_WL0%^K;N#1Q#M7\$??
>:@B%:>SZ8Q>X^5&M.3X_#CVNCW+PRO4SR.IUVHRD_/34I.\$*YUA^3GRFO"1N'1EKYDP9YMH\$9.N.
M8Y5IM5>T?CU81UYUNTJ@/1?&BR>C2=X3IFX%7E/1?%M/4S^..SGANNDT0V MHC8YW4HX:N=8.ASL:F
ZS<1H0S8=JS532T%5V!+VJZJZ=Y)^~F9?ZCD MVE..192'5.1AIB'E-ZO2@.KJ5:ZB<-P_3&IT&YF?3-UQIK@NG"?>
AS=YE0QT M5Q)H!^V6FODCSO*/BIJS?C J;..HG\$423M>5^~<W&XSQRQ>1 M#V:/LJV*+F+U;7.VEIZSHF?
YY%..VHHDWZD\$) GL^CTI.G9D2E*21_'~ MG^LE.7C297%GN.R;." 8IY7=IPAFTS@Q:=~M3K=G!H5H+?
JG=O_9IS^IX M^G^0BAZ!>C/..VG^LH*XOI\$!1?N8?*WBYIP<@IT.4W9E^IW>[&ZV.R15#7F MZCD'6EF2PP?OX2Q6-
7^QJKF>3:(I)^U_CPY..UL5XY.6V<7YV<7NWH5J;V_ M*A<'AP<7/Z>M@U>|GVI_ CC7HL9D4L7V/
O5ZSZ7XONH.MMP9#;7! D*=:6K MC%?AK9QPGG<#U GS.M)33;JN_ ^R.%DS%];>3.G43?9; YM;SRT1JG'.\NXL
MTI_1!2.ZO!K_ =ET/=.%!1#4NFISL!X&F4T!^YB;R_*U"V=JT9ZLK;6T=%L M1MAXZN.#2O-
P=&CS>F;O.O"@ZU+!F*LVNZH\$2'3X#ZIFKLB3>OLI?WTJ:TXBN!84I MV-;.%?) 16JWKR1G-ILYI3LLOE-5 M0!
<5MG7!MBX_1.L0JH5<^!Q@~M%7)*;+KIO\$D=KO?>T4N\$5PYR:~OI1O+%^&8CS3VDK;T_4G0V?5MG!4'-H%GHL
M.1!+R Y5>U#K?N9"UUYZW/5MH(H_RBL\$;Z=1/39+O.*CQD;U1(NT.WK%
MMA8;ZL_OLOJHL5^V+!5!7O.ND#L+X3Y5.[M3?V]="W.P^G(T&GFICR%8S
MGX_N\$XV\$U(5"GFI>./)PVYR18JPN_ \$"E5RS572W_IT\$;4WE4/6R81.*^UA M7S4C(U2MDB&M0I)^QG&7UEEDA-I
Y MT@ME*"GAIF1&U8="U1*A6W?HIN'61\$VH!3?'.17YE#4M67'IKJ0)G>+Y4F\$ M9P7AF5>L.#8N3=A?/1+5>1-
QJK0S=GV=STB#156J M&H-Y#K@Z/G/>O15W%;2'W6L:8UNN)R!M(HS.CRO WISM;@H!/=0!ISIKH
MW.151;XK3=#!)O*=G<&IS^<I' G.NN@<RZ+!0S1#L7N4;.*T_L @H\$K@ M_L.YV@N0HR+SHDZ9Z7-
KGDVFIOZA^17G@B^E/PP^X5P=O.^7"!YT/APEQ M&S4A3@&>[RKFYXQ7F44#;JVVGSWJ(KI<.4*WS.^KTW8J-
O+ #DYS/BW7;JJU+CK_WP57UHEX?^/@6H@A;4D.^L#\$YU
MX.X.O*===\$Y;R(OQ;KAN/EX'3W<7=NM>G#V2+B+9&\$XPT<1#\$J:0C12KF M9P_ ^OALH?>6A
G4TN"H_V>!U)D>.)?)\$G*B?>%IY:NOZIWPI\DRH.HJL*_DD^.;+ MMN^.=ZAC^09AR?
3/Z38PI\$GUOH^Y%F>^+N87&AK>+R%47<3HVX+XZ.7H9:J MV/\$;f-? W%
IW9>RAX\$66C7D3)0^L&KS1A14K#6O.XOI\CL MJ(W44H6O/U(AGQ%TEVJ;HY9YA;3FI0HXZT!|=6M.-7RN?
A2IS;4T4*SBOCHPIJ)OHVP*EL6)94JGG#5DI0S6<.;YQW*^S=3J^8 M/N6.QH>4A (K4W/LKH182M#"^\$Q39IX-
M9.A4FFZD!OI;I#-K8Y?IE. M+!R/W2M'2G2.6WAGU4*A64+WL'W7G053=[B?>+UWDJIT^/A...J@AL3IE?
G6M3(I8=G M.F79Q:.*"H;F4\$@5&F?ICTH.V\SB9W>2A0\ M^J^+>TM;P2!*I%L>9M?6JK MLF.9WA
M5J3AW15W>M I/EBA3LRJITUN^;JW M49CUIB4SJH-Q>^<Y^P*!4)6;_ T3EIVZ4Y%W6VB(A_QRF670JF@3!TVJ7
M/N/#1YG!KSYE%YIRV3ME.WICWKRGM0NWZ2G-ULL^N.R0T6W!%1JO;_ VJ M.WU0.;/Y>LR-
>\$;8W!CMMX!DG" T7.8LIVMO5!S!~?T<1+PGT!NJ.Y+Z MJ&>JP7KNO;PNU+<^76K2\UD3ZH+/H(W!L!9;
{CAA^H=P+B\$WY&?V_ ^Y+;1K(O^*XBY;TY(M\$>BV%DM>I.Z);\$NRK7/ML;ZD.8!STPL0++(Q
@\$;EFFYQ_OJ77RZU@&1W:W\$O M'DI<=>ZPF0:10E965RY=?=O;ARM&DA&=EH6MEGKUJRN.5\$!'.NK>55T!)/CI.1->
<(ICI3\$ GX@WW9<+ET/A;2&C@;..ID0*GDD497LVK*KAK# P_@K)Z7HS842. M^Z5HEB.IP+0B)S^>?
1+VH'WX%X!+)WO!8708H& (=LE<*.9MCAIFK&HZ75Y M=[1-%EP;+GHD.;^I-? KP MY8Z?OOQ0.D%2=
(^OXWMDJZ)M^U^LXIU_+!+%!>^&\$UF68J\$VG;#JL7;A&f; M2RYI>T77=5ZH2\$'PT'?5LL?
E#B9I@:JG&1@+S6K'9I/EGQ(1W.U9G0MH(M>JQAEBF MAM8?
GI+^JERL_XND^K2X;6#S)*.D#2S/HXD02*F9Y4IHWQ(>OBA%^2<96R M?(MI2>H:"XMSH*OZ!+ %2\$<#
(X!XB_!YUG(R@*RI#N!\$SKN7 7?L_#! MVC(A)>X"B7?K2;QOS&7S:D"4H8UZ.AW!29;=.V*M_2.^G5Z)<I"37-5K5;
MURK?.'IV*Y7CI'_ :D=IS)+F9XRDE_48XY*9JB/1^@~NL
M@Z<&=H64\$CUI68C3UIUEXNWH+>F/FT.#;O/FH@JY@HNCW/V'PSN0*!
M_9CP951%MPH8S4I5XIP.F3/(M_8I>FMLYO=N<J MV Y9X5K!X)DN\$6FY M?
ERMPVXHC&.)YHNJ%SEL11U"@9+;0R?#143K^2Z(#KB!MMJ<)-8VG1=O M>8CL0>??
DX;KF17.DR@UF@A9IC?%IB55F2SEVFJH?IUB3UEW35ABZ%#E7\45)HRC*#98'6H/(MKT3P?8PWWJW<2.Y
MPH.TA6AQ_FOH "AYID=.1%WQV!1LG/0733H_<K2BT?1L3;<.*9NB_<.#=KO!
M.H+9%F0L.&JSQUSK#H;G5QSN\ _WDX+ 0#Z289+ X)NHAU5U&M'XYJ|=K"2O_-I&+Z%/-
BR;V\$!K/LK!A8> ^5BK<.6^:UO _IWSNG M.U!U9%CP&ZA\PXNL3*GL.^#FKB^I;@9IY&/ILPZ\X^P=
fYM@&.U!+\$M8B_OP M01U&8D6WNGM1H^L28^8N9RFB1#-7Z*#;3S5?/HJZ>TO=7 DV^=+3P#JV"
M;=/GIF!720)M/UJ3\$#%E=%V;6.EJ==5;5;-V%5;4E@_K YW_ =6.H2UN13 M='FTE745Z6
I6SK0GQU6/!6L%2*YRAT4E<+!NU*.6=IYF@BNXVL5T!S6RW(ME"6CJ!/+L5;S;4%;@IT=.4#4.\$@W_8&H@FV.3"-
F"/BSX-ZZX>0W3 M.1<~<T3#1GENC&+OJ'E'3;=>UY%#DJ9E6-ZDDZ"%>.S@Z2HZJ+^~@LYO@J2.
(U2@+Y>H5TPJGMJTO<H&H;U(CY1VSAIR)!<KFKXA^M M%Y%(-E*A.*SB_-XBO_0!L^VLI #;MUYMA-
HR6&H!%YAUXT?TC7OJ5K25= M XL/>L^420>MBTO/IG8ITX"4+2-BW(ISOOR%90Y'YTVH.V\$;>"W@4?TI<+
M6.+R>+L!7(TE^1H5:MZ4YRZ4%8KGW+UW5%I_0^28\$^_ %1^&X\$D>E5
W+V6J;^+!NUIQN7H%&P5IDR9_ L42R7;@_ =.V9 MK"#1Q:9R\$?^\$ T4V4H!ISBSCE#SIL:@&05=T9%?'TM.J"
IX^%XKC2Q2Z1;O M8I_.TDBUP_%P\$)IKUK>VL34H>MKV;R!>HF.(G=3%JOUV--(&<I#FLZQI&. M*S?
GK.%LK&K<6X);=5LR>H-EBLUL.N#IS?QA=++W&SIV5VQ8DT>&G_.\$@&2
MLX=M9)V3#W!609P.LG\$S2E_U19YAJ> PYJ?YV"J"HW&IK^NKY96;.L=#'= MPF\$=KW.=+089
IUIWY;R'QEXA97N75/1>IZV^&Nf=1 \$'3%+\$(M^BZ.0!2 M H^<^/13^21R\$F?=NVX)%G@ZJGH.FK534;
<QLSX2HO20G50?D.S(U! M50X!>J" M'40:287MWP^EMG!H53UIZCAF*KHHJ0VJ>TM+^~R-R!20>2LR M>U\$AR.
1(Y_?IE:PTODI\3O\GND7I<0;) (6=I P#VN3-JON%NZ8ZVYHHSSA4M>+!4R^2F&IKR9I/5#.OOFEE0PM3VYIQR6
MDQ@.=85;ZT98L:MC'G1)\$M/^S":U_6TR\$MM> "%JD?;*VG2.H.1EV;7G MO%IAFV4 O"S:NFH;W=S\$13WP75EQ?
I^ATK3!H=."A;'G2ONQI#7K!0N*VJLEJUI#;L'!#WMVSI4+GR%78B85T/S_JH(
M5I#R).F!;WFS).O5VJH**6L5D49ZU@; YZ!\$P(3VAOZGM9Q7_7H<=.^M6ZK53A/79FP2
V156L<)O7'F!JSJN;."_&"B-ZK:P%+P!MEB;CM^1FC@@ M0&I9.N89+U(MH9JE;U;6W?EI=;)3#;V944\$.\$(S7E2-

5D52J%?E>3B"Z MH:BL1W60MJV(BZT.7M668WQ_3Q.)K/(@% N' YM^PF\$HJ;F6!Q9W"-7XP%O
MT*)91SLL^N4B1.1:NO#OXH;2A=>8L2=1 Z!#SDKJCH"GT#5OW<.)C(MFE<M?5C
:S:PXS+0J/HU&UQYVM#8EEJ=U6QIP18J;FO:C5CL8DZJNR# WN1C:&I; M2510W8OTN# MT7N1"9Y0
^Y3W+1HL&R8M1EM(I3Z'Q;E6G/>9UHXY\$N'=4,=^C&A;EA;\$ M,.<(?R('("DY:GK X6%?IA;6_\$C/4;5"Q/<('\$H-
I7011PRH\$MIN2TP<AK M.1H/*W;=^E+!#C/8= _H2ENH<4X[*KMC&B.\$KJBH>="U9I5O'.Y(#[O2@>M;^F
)TH1:=YGLL=P1FIT;N:JK;# "K-F;I.EUOD MEIU;*XUI?(>#3%VC3'EB-EWUMML(1=19"@%)>!@1
0;+ "VN%#FMVS.%DY\$#DVPI>3O:CZD%1%+1/3F%78B+)>G8SQ_M.\$/ZWB-ZI@:MTWF'UN* M>X-A>
fFSJC0,1*3L#VMTS6=N?#A9X-RLHJ'--0^N0(2.5:O92(32I'4RZY8 M:8+J7HERNF/\$DORf4D;OVBVKOO8DES084
+@1TH::6\$Z5=4@%B3LRW-7 M*G8IT"?A+9YSX5_/@2< "OS>AN';^1X\$!+J9&H'TX9*7JFW/AWH>I9I-
/WKQ&I.YH ?!&?-BRDVR'=F'IT G'fW>&-0AH_U M:-8@-| \$^2;-T"!1Q(QM=N13@f^00!3R'<9 \$E0!C4UFQ0)
Y9Q*!&IT. M9?HA.^BS!JCZCPH/(F36H>#Y L%Z="AX_KA|<"AX/BC3&P62QP%E=:9>GVYZ
M("+H\$S=0@90!^W\$|@QZ/(BKG_!4N-I0Y)Z_2"*=N9 M?5J@D3/7T(="";P#H!XIV/L#5+=+
"HZOX+"H '.DJOPD(F0Rf0\$M9P.+C%EH MH"YG# "DL)A_R&(Q0=6R9&KJ3)2M)Y^NC2A%>I: OXWJOPS)?
*Z'I+MGE))79M,T1JU,L MEBNXP93\$#X02LD_12H=UNF8=2JLP.*JM6'9.8YDfX@0QfU_50_\$RNXOVGHKX
M:K"V^*D&1'('M')@N&XABYUG MO_SRW/M%R5<^>JT8(\$00#Z#E:Q6%E F(@\2^>8X_2+;6_-HLf#IMMFBA1VH
M7\$IQY*1\W\$K+1C8HIX<12_U.LTG:(RIA#BPEZ5H03IE3I?_TWOH;U3/21> MK9I4
0W>JZAH+K31_HWFf85OP@KIR#>LNW.MfGYWO'>Y=HQ>ZIS-).Zf-fY M^?GQI5_!8Q*)^IXN^*5JWKQY*T:JMR-
fFW385CWWW_U%7Y5H=5@HfI;+T M5:C5?86NK4CM@U<fT
+X"C;AF9<==EX;HP)&LZ75#3:U8&A6+K4PF=MR\$CE MEYPWTA0BHRC1G4H@8I&H'T'Z7BJH+T(>NHUR-
Y7ELD7BF3DfCMZ7.V7TVY?/M_U'C<f=LMK+&62UDG-K\$B/PWJ8WI+GF2J+R-J5E\$>SHM95_L64K-5TfTf5X
M(R8MOBVEN29&IYPV<_C5C6929GfECNfVfL;LW;Y(?GV^7Q_L3?1ZC#f_YR MR!8>LH57S1;JfN'A7O!Q/P?
_OATP?/MO_0#H\$|<(KFA^Nf'_Q\$^NX0#O;V= D+GSRT:K M@BH#EF(X?
P!TM&N.fIUQW;OOI1_/\$(PBK^fJN"X^>I;)>#CCM#=(f.3EUM_M7F7Y.JB_XP>B H>_O_fVVG?9Sf'VHX"U_YX,\$
MLE^>/'C@f4fITf>^_H(*XK6AB9)=DfC.N(4+A_3@T6-f%2I-DfR&VWSNHW-MMRP:105DfS_.RS_G7_E0"AMVM.+C
MBDP(VEN_f/@'T?P_Z-D.TZ'NG5\$Y6=Cy!4Yc)_M7TLZ5;P&fR:6BH8#L0:
MH8V==;R0_+W+W\$K>UfG8<1\$!)%*^NF6^M!OA=FP@4J(27'BYN
M'GB;==88f'<O==G;Y&R#SEf1/QSGR7Jf;+^7'GH MH7f^_fOXW%<K/;\$?>K>AX'KT08_W/Xf"XU^CK=-;M94;Y?
=E!R1RHf)_? ML^N6&XDG(f\$H>#%-f#IRO4f=E=A4_.D-fH0*)>+Hf%Z%>^8(Bf.=1F@Z
M450);7XXB\$BS3TNH5&G>PT3;P2;fCfG;Gf/_^N^\$/f>10fF)FBP\$+OJ#/_f MB\$#OIKX-O_4?OUS<444636PQ<7"
=F=B;XMZ*GTUYB\$G=\$_.\$=O<^JLHK MO/@f#_SfM=-f8I>Z6f3GCf3AK)52X_M4=6+WYYG+JYD/Y)4K:<9;JE;
f1&SWDfN%AK'>L-ASG^V0_M^>2VfL;G;<19NNP=CNNN+7XY?R>S\$EWR.EAS=fH16?LPK"O.J%*N2DTN+57R
MZNDRJ_fJ"Q&&+T6'R<_ZD7SfL!%Q%TSY9N?fW_H?OZfS=MAXK*3HP6K%<f! ML>\$_G;K>YN.6BWfJN
H2#F)#.NG.(Q;CMX#V#fLHBRF+!S9_M/48(^63-DS=K/XEO(UJf@M?*"YE(@_18E^XCB)KfX>5P_1\$!^49_M&?
IDHUfZXMRZ%;Q0S8Hf+U)(K9&F%:"\$W_OfU_3Q.K;fTfYKX7KU08!Q MA.+C6KLfE60^Sf_JY*f>OJf_>^\$P27VQ)
M_>B9?CFP(f8M2E@C+SM.^V.G76HG:f7MfF0_A#<fJfU>12=RSV=-6J)BK_M(W+9(BR>;f6+?f7T,\$\$0@ENX1>@?
OL_3fHZ)BOVQ6_>BfN1.M+"3fA\$C!@B MY.3^A?Q.N^AX^f%
5f(#Z2YXD5fAQ>4;fW>7\$^1_%MY6D:72BBH>\$5AX= M+4J?9(fRG_M,*fW2f/==f??/CF8V/DWWOJf_Cf1DPMCfY?<
_GCQO_UBWV#>OCMf;=?fH*MX'Y?E-ZB(f_6'Q""WUZ>Z7S*5'YfY?M99D83Ff%6GUHC;+WLMGUSXZ+=M?
FWONT?B_8>GY*fV-2=SF?7.M7_Hf17H5QEDER:AGGRH% MUWQfCfIOGTA7V_UfYV37-
ODRf_@>NPN\$^?f)_)>fOZSfTNP#W*fJW_N;K;-O_M'C^0<_VfF0%I5\$SV+Qf(Gf1?)Z^ZUAHf"%3M7_'WCYA??+=
M@_Sf@Z./%f)7KT+(@fY\$N?)(5>2R1US=4=DfN'Cl_G#fUf_f@+fM(C*Y%R;SQ_OYEfJCl_?>U?
fWU6fQCf"MOEE7GUWA",R6Z_JZ>E\$?7O&E@fVJ26_S0&>XZ%DK_M,N)=WV>H5?>H#U_MZ7XV5S0H.W+A#X
M(Z#R4395>N8"l*GL3'K2+.(YM+&VDf)%2_.HfT<f)FW^39KQXWY%fTf\$X9_M^H@4'XRZ4%l-
\$ABM)HfUfP)fO;ET^>X2.?OON9WJ+&FOC_@H3"JEYEYE_Z_M<.&R?WW@##M4_7PV9f@-0<\$_L\$G"5fBRfT5\$S)
fD2X>/B7A8??NE/N-RXN_M%6\$!^AL5528_M0=0YLDZT7KD?F6J3?TONS3F%N78MLY-
Q0#f_4MKOHV/U(4"O%WF:C"OO^T M@OH_A@?Xf/*GfHf7fRC7Df?_"@/A)&(GF30(XOY>!
M#7fCEMAD2Z:9S)=*VGHDfIQY;f57Vf=2f_04=0YM_GOGfL_f"4M2_%EZ_*E8>f;08Bf;+0*8.P=>E#EM MH
Y*1UEV3ZLUC64X;_&9^?/SMf=S;O@EG?f;fP!#f6V"N=P!0AN)4?+KB!!GA4U8fSZ_M4^<fE6D4)64U"7fUQ^:/&
f_X0W-1?7S(ZZf82XH?6MZf;^#5-MRR=N,O'0P_Mf2LfM;_UOFGH/fP!X*W2;-
HfZ2PL4;_HfS^4^fN6f1fB+^f'MW%Y18=O_M;f#SMGLO_Ef
fZ7*V/BVZ55&Z<9#*HEG5AL:88O3;\$3A'(Q#CMY#6KF&CQ=;N_M523V&SfJZ5G0=^BM5C.=<&R81-
NfXfN/^+f\$M>fDf8<<7VDGfZL66fITNKU%9N_MG(f_M^fN_?%;M73_'BVJ#HCLL0XU9>
M>_>XXfUV<5+HC9E,N620&C8U?)4/B8M#RX;fBJ?*D)fKRC|<#2UUF'&R^M_%5TS#B\$(7(f?KB6PTE!&G>;L
5D>YfH/B(\$fH\$Q>N;^fK7+8;3>Z_M8UY^H)748Z&=@Z5'M@5)D;^>A\$!3%fTM6T5D#%2=4G_<CG!&f=T.3U_B/Z)+
MZ?_f+=fEV15=QQ'QBAA18BWBD-O;Q80;-2@Y.PXF-VS/EYf"5UW+G>7M.ALc*
MfA'D2R'f/Q.fH(#+_99fLCD7?;J>=&f/\$&fJfL2S)7D_Mf(XfNfQ;:>2NBQfH)VG/M-f=HTf,>)LUYU+1:8R6fDG?
0LQSYJ'=W0ZJfL=N.C^<="<#25BG_#&BfX#F-8=4C"WV%<N>_MDG7f_Y0;_fZB:P&MUJ?%OCEOG?V'2+85@9).F-?
S8>=3,^A\$Y(Qf)fLFG_M"e5f1=IQCD4A9"==M+^HR*Z8&L'HQV-A2XUAZ7NF99+(6#X+)!*^)#fZW5_MZ<+
fT>TFM./Z_fA8/C8%-"N9+?7f133<Y3S53#W-4_MX#L<.7\$==B)f'f6B';@F0M6G;P(RfL-f96630f)Q(?XY;-9LS7@%>;
f7*BE_Mf?72^>A&fKQf&8\$'T/4f;5RZ3-KB3'^(X0%ZK-(^<#1Df;f;f=-.EO5f!f_MQ+^>)6/H;--
"#HMYf^>H7COXL*%;WGV\$fBE5fZM62Z6+H3f-Bf)H;_#%=MU7NSC5HZN9fO34S+C-W/O4_%AWS4H04C7f7
3V76f4_LWf_QC^<f;f;8<8A_Mf(OHDfS;OIT6?7H7K9fHf>8;f)P*@&_EQA2L9L++R(#\$%_5B.f=UR<'AXf89!
MfP-) +^6(E0.=#6GX/f<\$_EMVJ=7B_9fU<^N_\$"MfLAMD)W(8_A1"*N=;48Y6X0_MH^B\$GA7-
^fAGEP8-!fY(9=)013GH;4QR2QE27<%Z%UN&O3TFRUW9%T#fUB
MfO/>")C5+T&EVWQO;F&AD(fYEPO2%N;=X0X_DZZ2KO)fL3RYL4RfJEGXf;M"/9TO(fI-C'.fER7#
<=>f7X^E8D_*@_UKfBVfR&NfI_QR_M;YKfPZfI?ZfJSPIfRZ)4;="E'<#-M60#%f;6NQUW/_WUHP^0_ZFR7P#>><2<9
M;:ZB7GQ(<0DBUf/>#f;_HP1#fMV#OYHf8@J37'(<9FWM-f6.P7=.7HK'<=Hf;ODO"Y6K6_M;NfN)fB)N.+%?<
4.8CfTf^>fHf=E26;NV=;'\$TXK_5+_897(UfN@05FY@;_MfQfJN;Y&XAXNQfC;\$4X&%77N_Hf*EK9'%?<
<A8RXRF#;fIT-SG6Zf=-5BV_M;UPV22f@<_HX(25f5(fE;_R;_fA@fG<=Vf'K@E8/BfCfLBM5AL;YQfL;H>?6X\$
MXAAE87_8QPF7L3%P!-DF#fIDA#_R38f6;+L;f;^Y3/>QP6f86_NXf@9VV_M9J8WKf|_"/4CL_fI+3fJSE&_L7?
P*Q5ZYH3_I<4@*/?DB\$K?=-f%)CF!*0LD_MfMC(-2S7/L_V2T"H5+3NB@SN"G7D\$;S=EYf1+%0_?LB7+>VDY";
fE9UW9)K7f M4AJ^MfCf3fJZfV;H;^<^<4\$UfJX>Rf4QY+^P26CZCf'\$_WKNT\$F;CUV(f;fL
M;fAKf1GfIOZR_ZZRM&*fL84B" M'J=Z;=\$30KfC&_&Zf;DfITAB>(f(*f0>?fE_MfHfZ5f6C*=F&0-
f9>f=W'7=;Hf1\$KfL=+fC#BA673fI90f1-KE\$MFR(f?CfXGW-VE"VV%<HfT6f^_KSMfL9"G;-?7BE7*^fZ(f
MCR>6>fJ;^0f;_CfAGEZ_X>@(-WE>Qf1.7@_fFAf(3fXH2.MR.*^Y&fCZA)
MRZ^3)BUWQ=2f9f*#KfZ8L#V?fT7Mf_C(f)VYCW=U4P07#fILUfJf9;f(f-D_fJ
MfTRNAL^fSW;fHfWKMfH_O;NR\$(50>@(<#0W\$205?MHQ#fW-fX2B(fLFK;C2
M#f-7;f%AOf&3&5(fFY;3f+Z_N7.G4DX@>X\$M6)4ZG'fQ.>f'=-f<1+44%XR_MR+@^f;@9

F9#17KJ>%%IXY1/0\$9#9BZD"ZU<8R47&@9EV/."5*MA57#/" MR20D3(B:RM)J*3<##DX.?.*1.1.>\$R!@;MF?
U%1P:E+YP&1BN\$HA+5.R\$ M2Z50PR:SPU%7P+1N3U&OQ3 XIWD%C=GNMJS:AJ\$DIK2UNLI:1>^NQ^1ZW/
UXX2:0\$>1.Q8 GE>_ M7IBM1Y17:/OGOXU*TCVZJ@T=(L0H&#1>5+1P8"19_11_11K1QIP:KA/LUJ6
M1:.(.90V755=1C>^1/L/N\$FE(5PZ%:AIGX\$S2D3:;S@EB>?3U"ZB_ M_VCRN0L?_LW3JDI-
1\$EY0(Z)V2P5:S#8NL16K1/C/N"@X[NK9&162AHZ=Q8QF7\$1:**6(L_P1ED(U"QLT:==@*I= MJ:"GE7+'W^V:QFMOX?
GDZ<./-7N??GWZ.LOU+SZR_3PO/)=??25PWT&L: MU_6W^O2^HM?7>MJK3/?;:YEJ:BMZ^EZNNXH.W_G75?
F=N;O2%;KADCS:._M^11(IZ.=T_+>Y+&#O=:"+W1_.3I&=OO.:9JZ8ISN1H1>O(#Y_6&NY*T_O
M7>DH^0+1^S<(68?UX_N9N:AKP>A^G*3^OOO*AF?D=/9&UJXB0C-BTH=VG@A&:4H6<M!7I&6QP0V\$SU?
D:4I^?G7WY17X.BA)8DE:G%a?)^3?(MF5*2^1IPG33^VQ<4:(D2GS\$@&R/XW21KIQ39)?BV:K1-C.VNCIFG.91J'O
M"/2)1^:9?REF=^1+E44Z(&VW??\$DG'T:IRB@9H=VVG)F.MTFY&(FD)443\$<.:#1+TGS1FBK_F)!\$75" M!<57-:B!
(0-2>G>_%=>35, R7-44O571B8NN*L M L5-W0HQE+XV^ROVDYIN15(F489Y) 19BX-
@>1YEG5^@>3,_%=>@1.Q"IR MA,<9YT?"XCL,CUAY:(&OI@W%:H!>=J&VG8,6"7WUZ(I3 MM ?QH,J:7-
J13WN%CXWJX)%3FKQX=1:.(PJ:#F?_P
MTI\$KL%7%N9H8U!P>H72EEA5CUN9),IMD6*2W/'4KE)1NA+TWE>5(1"L&3IY1 M5M>?6Z,8?
DF4P@07S10)2ZXVJ9I&4^G&YGUF8L1^P"\$NC2MX'W?M.>2\$=REX!BOTHW+0.X;_%>1 MI?
7_>8:OLSN7G15V'VQ^DSQY^1U>R&ZC++KMFFJ0+?=#VPI\OY: MJ#V9O".FDPR/11_2#2X&
NS/S/:FHK?IDQ>F1^4O:ISZ-D/LM3BI7V'^&4 MW8IY^TBK\$CC=JAFEOH.I9CJDI8D4%>LV/@8>OIS2.IY99BT*(^=
IR7YI.T MHP*(<)"1XZ'.F:S!6? MDG92_0\$R6-YA?@M@*H%SS# M)JJEK5/!_N6Z2TB^OL7RL1I9ID!@M4:Y*+1?7CV-
W(2IWO=X.B'E78YW5%P MAP4M5\$QG10<1?;Q&6)9V&L6&1+*6)B*GB2D1!NWR+!\$RQORON2+!J+IB
M@X3.PF=JU8S\$@>1-W:./11RIVJ1*VY"15V**TYE)9)=FG)J3E73K:U5LWM M 4?VWK5FD.&L8H%MMW%YLE-
=H(KSA11>_?F+? KX:/N33-*QU(2=D)>* M>_J35-3&X&-?^XJ(\KH*M9SC-TJB(#?I-*VJH!HKNLJ6-IWWWWK!\$I3
M%\$=4N5 I2=>9X33^:8NCTF.0.WIXIQ3C9I!Q=UXN895VGWZ\$UTHG+@P,>JH
M)G\$@FE(.48O/5^#U)6GV92643>\$FS.W%L:R2(0#R@ZF^J*MI)\$16/Q6W@D% M D-I-<'MIF?
UJHC6@3/H)7+1+1DB\$ H7?N307:1XT6::1"+CSV?M:Y8I!>=>1C+R8D=S A!\$XW/86VDZA^32 MZ9=1+
^Y.8A.)1ZOJE7+7.G:PI39I2Y7H.I6K)(*JU1&VN+27W%K#N&9_199_ MK3OJ!6!>N*45(=HZ5:78(I>
(2#2S&F160GV!@J08.1!<\$IFLW)""L! W_ 78YL M\$QH!K?DK95U45G6%40=CEUWDV-SU-
X7CC)>&QK"VA:ELLV13!V: 58=% M2M\$+ 4_ G=PK+GZ?H #J!M)&*FCL/KI-4R@.(U_9=G1J-9Q^1H.YL\$) M@:
M>/@%\$H!PK\$3VRBK<1AY#;EA\$VTIAQ^OSU^L8*(DT.IHBQ:8^V YV76S8
M<%\$>BYTKB2+^J\$HNU.&S4!EO&_EPV,><1%Y)/L"M=S'^9CV(7P/!T*B08_ M^M#;J=7TC'2KV#G?_ I0SGA?
HV4OW\$%LAE+15SP(G=,?D.18EZ!8H2GC%GR M6#&=1J\$(I5/VW6M!U28N)DKBU%,OTU416?G.?@B4
48K94RG4A2.9@>S><M.I=\$;KW1_=QGWL+&\$;TTR*4Z/QW)0.FI\$@0%,""3AV:(IRWP(BTX)_\$=-M?
=T:NS)I:\$1_7S#_6\$TW1_M@8R4L(T%NLU72V<IS(CDHL(T1"J#X L:(M\$SJRJC,:^SG\$1217I4?
6+1.MJO"R:4T.VM#3<:US18U!=MJI!>/>GW1%(U MMVB<=:IHIO:W2+Y5>M!/*=4+WA#&SOSD@SA?
JG50+LX#84 MQ8J3UN\$N6C#HS@3"53H!@G9 M_NH2S3,20"@A."5#;T+YJ.7WLX:&Q'DTP0,VJ\$4.J.49," M.Y-
A1N>25.8T4M&-OZC=D.27FH2C147U/A;D:KZ!>N1C" M%Q)EX61!>B_VQ2:OT.F>BL MR.0:
(WZ^0\$ YC..0LKTUW8:L:2L%:1F#KW(0!3E#IDXN!>ZL_0899T*+ #SQ7 MV0G4(9Y' 7_!^8IX"Q6@)YR:N)JNZ(5VKF=
(C6&^*IKG4AZ)@\$3(8BK:B-%, MYWZ7!!@9-XQ=(XLOYJF4S0D',2UF:K'6W?7.6'LFY%)FQPA8DK16%>05>
M(UL)S&G!<". \$B2.?<-(F\$1%Z5ISY0Y!N:1^P3PE=ZS5%-C3/ MHLU;NV75UQ%%8'3XR:#OGL02MI-R(?,*&
(=\$;6:."5BSPE6#" 82'LB"- MEWG AOYB=\$N/AQ.ZYIB?%N:V'3Z)EYG.Q_D)OI%RID*M(C:YLA\$>Y3IGC
MR^*.B>JL M05X#RWCN3AW5&Y.YQ_061/!=\$1"@P.N)WC&G:>GJLASOI8N MCB5TVGO=&M?+M7KG?EPCPR
4R5 @OJSJ@IGWJ@W(W(J^H#^)^L6_6."?/D@ M4@:P.OI43IJ6H"/=X"@3TW0'Z/7HUBWTICOYAKL?
PI@^N1%)6Q@UV9DPU=C-\$4V!FB1(5GJLU_4_QF(A"#10=63G1+8&:(&J(LM!TFIN)/Z8>GD!0^V-Q%_0
=)\$Q!&.*U0G4? M6E=XI#0P0:B%E88((QGB1TH%6: PJO@BW<5*35IR_FI\$2%#0.P:3I2IWJ.BN.94J0"8*#?RRJ!:
MG*/H9V'&BCEGX3/K_#Y8VD9Z6.13.&O3UYQWJX5BI6U&L?9"?L<:KIG):6M MWAQ!F\$14\$4>ORE%X8V.L&3L?
IAA9@JP+@X*\$'_7G%5=*SK'TM/L=)KW0>)8 M>%MSHOQ&\\$5;&L.%R%XDM51<6LD-T@?I2)@UQ!63HTR#:)4+;
f6G)X(L@Z"=CUXBDS14(HE\$PAM6"TI'D= M-%&K_7-(TM?I@%Q J2Z63 C%S:I7_UM@:24D921J9!_5:G=-U%=19HU
M602*B6+*BBOPIFZ17&ZS12\$OW16QTC:'5A 1S&^5!P5)6*D.U:P*5SIC>Z&2JZB_?
A8WZ>KQ8W1/^Z\$@HW:JA7?)?+0' MKO+D!8 EPOTNJ%I=+Y@:;I9=I5\$X+CLZIDK?ZH
M!)7&5>1U#1Z'9A!*.V\$5AMU!:@A!&^BI^79 +?TOQ7FH2M%=\$YDW=B+\$R.QPIOA)BMYS(>P0"16S
MS1TL@Y4"TK-9PYA-C15(8MXTS#Y94Y0TH%6: PJO@BW<5*35IR_FI\$2%#0.P:3I2IWJ.BN.94J0"8*#?RRJ!:
L_5>F!F>9F*0K!G^1V*\$619_17 M)X=F>*HWT\$D^Z\$%6+ISPL.F.Y.1/#18K RA&HLZVEBR?BP0+YS!-O Z)
(1JB1)^@VO93 M?9@UYU+3:I='G3+116+L8IT>"/\$*GNV^20"8?NW"WO-S%LU2HMH+?
f5JH8&&+11(YW1OXC+O#_N8%V&FFA<\$L<IEC1S?UW &B(TL MM8R>H5&H?CJHZK"6W?74I
M>ENKL/SS*0SQ_F^R3AK MT&:15M%.W6Q^MVXR^YMXTPX0OR9Z?C<@MPQ@F4_=ORZ8B7%P(5KMXQ34R
MPXHOJB=(X!?"(1=Q::0>X4H"4>>1L8 ^1\$TA@ST/9:3+X 3X1=O6H2
M;Z7!++@<@.S1X5%HV8C/W5HP'3VC::5:/16HQU@N\$O:FI>WBYJ.NQG#KV M3_.9S06_@=?
6"K6JG5OW1+8!&RK!HW=NNC.Q!HH7+Z:=H@U":1-:VRF M>1WB
^Y3XP.E:2M\$#+#Q)IQ@6G/HCI&W!24#@_9I/VIN29/UO+LC_1\$@ MV_-2PP"CB+\$U.AJ/I_!T-:XH)- MT!+7%
2IPMHBB/I@%5S?FTOP_8C; M:ICOI> Q3?" 0*2^R(6^K:IP:IQ&8=S4QO1V)!FEOY)>!TTB=WU>>1.D:1-
W74/0D> BD/^_A@R7I\$?WSVWSVR@ MN!+R<3:
fBK'3_%BC8Q6Z52FH:Y0XY^TBOBN_L5"+T/35+;&ZNB0ZL@IZ\$.Z M7?R8XKUK=IC/Y_6@*
1U@HF6!MQ:>WF3DF@JB!PP.F6DLIT^PLJR7:R1% MF1&5K).R+(S\$IVW18GMIQ=XY!VJ87B(T40P5PCXIQ2&&C-
FY0!J_CVF&RM.\$ M>'2FYJE8BGSZS\MKZ"-WSM/ALE1Y#C#1V#EW+5ET=1?2.1%<:R?7IUI^?QG
M?SD=&J)65XJLD!3?I=,0\$E3T_2%8DULBCK35)!*6Q9.O(FMS71=-?6Z
M)571^J)W>GF0H>F1+1^J.K\$2H3>CJ#&IC>3'1NVS<:=+R=MJ/X1LM-"J
M0_RYL^H2/&^QV*6^BN.LA:#MLR/C5P M?>_0)F+H0A!(2P'V_<+E*A.#!QQ>'\$8LS'F0?ML\$. J2EMWO,8L W_#N1
M0<1 L=\$0H6_1UN,(F-Y:ID5"*\$3\$+,\$PFB5JV!"\$\$.Z!HDEQBV07B5K&6I! MZTRD)INQ0N+K)Y-
(XK*CRCD>BV'6EIOZTY)IW#V3\7&(G+-*%3/J_ U6 M9E.OSIV.'>21IT\$(I\$H^&@*#-1?
=16H*A4.JZCU:/JOAAIR+-OBRYYV/58 M'37^JPAM_@:F\$T2UZSX5Z-"K*IF%,9#VY@W>-
K(=&XX;SMGMO(=0@K-&K ML%2#"X4#RY#N""CMTIUC\$<IAS"VV&7C8T/T<1'8D.+FPW
MJAIDNX^%Q!YUPD!@5+>K\$^K_I25X#3VM5/#.>5+1_5X2IYAL*DI'0!BXJQN M0JFI=-KV^=1<EATD-
H2SU7Y1+K0.2K1&K1M3B^4EUMOFG)M6.B=-1> M.Q!RN.#/7D+T@1.
fTSG=HL'VOI3'QMF%Q^P3IKD9>"3IK(I2@/H.U_1B.W M"1"FD.*P.X8FCML-VW2C.*P^JU2A6HZS069)Q)A35(P E,
B"MI!AO778X(M:Z9@\$_"4 X.BYR:&I>@1KW>*P8Y&3@+PT:&1N_<?CI.2V,BD7-6Y+J1D
MPV4H'PKYN7WU&+"PK:Q0Z8(O+F7#6_V\$8SZ=#J.37D:K1I8 +NE M&JB.X<)+-6.N?_8.0XZ.5I H:
(817Q:ZX(S1^E(OXEC MMG?N#TKU68""&".J'3T8KG/LDR!>A6WA=(M?E" M2<%<(D R-
1%HI+8.O58X019=%7.LQ>@GGHE*YB)_1GB.2W^+>^CDV6N2
MH:3IA3%7I_65_BUG7/I MN_9CI=U&/N@!'M^_FUX*H&OUXFZ^8%>&HA? MO4&_-D6L:IBI75-9D

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~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~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~^Y3P2\$AJ05%W#K5FCPY+E'(<) ME1=^X1FD=E?UQDY- _HBU6P1+)G1Y1XPMJP@_5040-AN.CB1"-8.P@T M1<V+D\$S+O?G19MBS*^N6V%C+ER8R@WH1N(FUA MCL3FM=(14S%.V%P>3-9C3>AENM6N12NM78(1Y0YLH(US.)%SN-10(&M&N)FK8HA+Q1:VIT_.\$YA^5 M1@O1%+:(5EPD_1F>1<89FR91X;PU+5.G=@_1155Y1S9&D7_U>V>YH(&A MJ0TSX77@&R/T.H3C@HJC00_1YNX3B<=G-41#MXJWSDS_K/16V?1Y2-3C" M@TUVXX>P%V&IF8?T- S@RO)3%&IC+U=LY11U_L%WQW.Y:;21+GL\$VHQO51 MFUWO/"O*1TONY7VDK1 @_SVIKLD1Y1UC1? C:~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~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~>^"9S4NNT1(71^1)T#1H%2/LY_1U=1%*KHW1(8&901@85-JF#D61217A1GK73KT_@J MAH".AO&X61HUS<\$0\$M_1441F9-?1AXL_CK_?P7N*%H33'8:5HFE(^B2 M#:&1C6TY_15AG.T)1\$8:L.Q71*&1"9X! (L%YC^"J.C8968PF\$@=[F:?'7 M3C5.MUC3(NNRK2S=R3^+*F1SKGS66><3=H10?415Y1X'O-AZF74>_3RI/;

M1*VEW0<0PCAID, 8A,B*G?Q 5N<5^%@^E(1^%?:A(O'0?3M\XGMI/&%,86 MBG<R#%8E*IO(1/2?Y+8E_JH?
P'=DRKF=-.#S7JHK+^YW>.,?1IU-+J29H* M+;J(C3*01Z?
Z6K84(Z+35N8Z_Y(N9H%+VP.BL#VNXJOJO6/K%RP3W1*WJ+ M.H%.17%BL8EAW"V"XQ:@-R-
\$A::@EB:&TAS=WI3VBUAYW\$ONHT91%U4QFDE M1>BC(E&J/TH:ERK1>6BJ:EF:P1V\UT
MS?2"C/N6S:1@9+QN!>B5,WIWA:ABL=J1-0Q9T-1%37Z2/2FY9_KIUP25;2?FG"JIGLX^0%TN@+H01-J
MT(1"^^^EY>&-N@ M4!/29M.2"MO6-4R3>M<:LIVA 9RQ,= %X/\$<%CK2?I/4DQD0DT2R0PSI0(YP M;B'1 989-
>X4(I55)%=P\|BYF\1?GSGVB>+L/4%2%7\$16\2RG4L%FK%QJO M3V%
K7;_8LJHDE_"^,'2K_'E+KPWGI:TP=TL:6"\$4TFV2%<6!,>XB3L/T MG>?1*,P6%::W3F>R)PL.G:7;=F!+1T\RR1@-
;H#IM *S876P\$Q&0&WE)&.7 M2:%@F)YO%N0\$:%WH"J@30QNSZI!8'NW7&E V=HMI-ZQ724I\$&6:9%RY,1
MY+FW'L":..M07G:J7=4C\2HJ\7W\KA)BS;@#Y'7/*FQ>TLSQ;0S'-U.ODX,UJF:(L1CV02;WUM6E?R&E3C+/U91
MM,=L@NZ&S;87+NMB_-/I-5M91-Y#MW<+C12S#=#G4SV2G89@HQ8)D@5//G0
M\5WZ\I\H%J:34(P)ZEOZR6GYEG.*CYB-725EF_-?+R\JW:&7-?J#)D\$0<'T'6
M/C(JL5\XRYC8(^"87G>B1M5UHE8L;ZIH7-T\$U;:F MX@IY-
_73,T')OO/0D7\$.V3WK@CA@P6;##AC5#7:B3I^ (HKLL&:2M&::<,BE M&D=M8K*(. KC. +S.)^A7LAGY&?>:J*EG%
<(H&1S;IU@:=,D_V.!\$8+TN-GD<\$>4VP6B4FS*BK5\$8I SW^K/@Q:1BB8_0C5' MZ-YL,L9^(^5);V?2UEH?
OQCK@PA>HPBJ'D_5^\$8\$18M2FI M.*M7:U7+>GL>2MU\$FP@BR=R6)>.:F\CYI3!
M(&:/Z5KEIB""BLS5)LI"\$SIW"F8\$58NQU*VPC_DS(^<-D*OP/I!4-2LLIUEG MIV%===Z*(Q'2,OI*G0.LG2-
LH05\$)DAURTE-W?>@RU)#MVF F5.O"JG\$-0 M*,H;1R*9. =JQZ)1L7C9\181!076"7HAX@X6(ZY6LU&"M;-Z-
>M%:HUUV""(+7Z.6&Y7. M/L@VL07D%+HN*H-Z)SUI\;5;J8+ 'N\$7P.6):?X>/#2E\2GJT211>H<&
M\5Q)8U0"30QSY&8G,1+=D3):T%V6?F44+IZE%LA0MR2\$PH9IY<-PI<0ZY
M(GOPHKHY2='+.BA89:C;IGTXC5MVRNHX83_KFO>>/WXO:A1(4P%ER6LM*M+8 MN5?
#\$M'4'ANDBL<9*6X+)N91P%?CBGNR#1QR\H^@C8IK1/9D\$#BDT<*2K=-PL\0H:BG93&B5>ZG6C?8X\I
MXI/ONMA#+ "36OSMLS)@;="17-2\ANUMR8U12M^M6>8"1X%Y"E/>J2"F 1T. MYMP.H.# *Y#=#>87+H+,7@U-
%B."-DLY1 #^?S^JH@7W@%@FTBJWF?+K\$Z M#%4"P9\$9N0\$.F!0)\$OATX7IM8P9VJF7-DAL""6?
08ED97\F&YS0NXYP0H MRW\$-5G\#%1>#57HUTF^F!&D@?" +9OCN2>.ROZ)H?FM.)&N5.Y.VQKV\$2;
M#H.LBRN\XV*+E_W9-\$U+14=Q7PZL7:F M Q*(J2\I9TK%ST"VVVQ4#E7\#T)\69?
T3P47>QJA7704DPA0R'A!&3R_0 ME*(IQ9IQH@EZIHR<4LX-MA:V*FVHHXZ,P^ISA"V_6/&+;C;Z2_VA4P@
"M"JH0V#X..C:9'4;NMP4PM MS8:) "%AB; :KH-UL..6IGQW%1^5^<RVD \3P(HCADD\$) QQ);0PRM4)DCU MX^4*"
<3BX3=79#QXNH=9R>^AL%;3DONC!;.:F:(3K'Y=\$)Q'8S7RE'+)X1+ MWD/1RX-0D#5OSQ01P1Y_3SYERST-22*
)6CV%VXHA(R;./YH+/7DWVRA#+8VR2M6YKS*;;787+DG5-MTEPJ_K52B0,MFK:BY4*-8N2W*
%_U!MH=S%:%%VQ20(KCA?5R4= _09X\JB: M4+H'K7I8\$?/(<OAY^2XKKI?6I?M0^Y_J\$40^VY_)IO2;^_#VL64!
4'Q#C2 MH86ALH^YUCIRF(A4BF5\0IXAR<8!6B:C%&Q3+@@.U)/&@N*X^V%C"4&E M.G\$-LVP=M*X%3I\JFLY
6>^U8,*Y0\$J'Q4*F?%J>H M*!(P^:R^@I\U1>A!T=,16@#>O"@X M*MS1@YL\O+/-&_*IE5;5F.THQ9-
9EXS&K.FLO+6%F%NSIT!.,WAH-331!>"O6XZ+Y\WZ MO*)/-9GI_!!JWJE,+N7?
@4JH@*D_0W.37A(ZDW\X;1%KCK6DJ=6D>1+P1P M;& X1.2=I4N^*O\I7KIP=[#&^22#03Z,7?Y?
PH\W):1+2CYA8!@BBG5_@@ M%^!R2.D* H.>H \ASWC=-A^?B\6-%DEBFMV"35!8 1.S&CQ_#-,\$U#\ZK)
M.:Z1*B\9X>4_&M?'V0_AX<+(X)\J.1.4ILR\>+*'(K&1&F(9^;1213-F@4K
MC89_1%5A"Z3OMQV?XCBF=S!>!!^US)S93Q1%(HRI:GD#B W>Y\B@;6(N M\$--
IV:*6)G/\$THDE# 7""F=I11QC�%8=S0?ZL+L&=SLMX_L\$BQIC "E.8'R MEYB8+&BRZDD35+FR)U@0/#:M(G:T<
#)E'8IU1.2L+1^%1M'.1Z=0#)GNG?Y2CZ"4 M)XD-"#AY)7BT2M(BCS?#GY2%^BG/=!BDT\I8_-#LE@U-?
C&UQGO3\U@ MZM01Z(2-LCY6.L8\SRRB;NM: \$1\$;2)&HB\17MZA03N5A+DUXU21EMUCF"
M2?HJV\2I2?0f0(0^4^K&X/ZL,8PV+9CA&> MH#7R0U\I\$#*)3NS>LS\$YAN'J-1HDS J2800E*2'2&F>I(+{6.Q)\+3;
<+PZ M&*9L \M18B9)=,PPH"WO.IHB93G\IDZ*5J M#MJ& 8L&\VTIB=#BB/3H
HDF%GPDIZ:25+;8&J78^K\$&A"RH\$3%%'#P #MJE.S\2(BM1R3/7N^E7SCS0L=QTFVN\$D\SSR_60W4(!17K\$?
GB8*HU?W(*5X M=C@*G#"<1> "TXD'8&1'D.C7LT15\J74' 2D M-6Q7/-R51.GB\9XT&\FUUX'043"S'^,!!QC1!&IX;&
M(M-AXB?6VE")^&PLI&56YHF1 \BK*1&7=MOQ:K 0*V/E(G MZ5J\VZE+P&\$06\>KFS 7&.C>O(JFH
<IQ9<.60I%YG9CK+12"BN!QSC+<=M3 MB0QIH55UE(>U4.=.A<=FZHJ3=+0@+=YSO:C M'"29-
4%DT\$B>J_?;6V54^B^195NU+G\K@#5X@BFK(KM>U-G1%PP\XLOKL81RV M0HJ*#H1"/"BU3SL-
L6G1U69IV,WKSU6G&G#MK3H54J&AX&5W.A;1:C+Q_X68 M)XU;MAQS7C>;B"9+*59\YI
I..THCWR2IE\$K3QXG2(=,WV^&J4N-Y9B#NSB M#T04.#R,1+" I T7\$D480%!\SXEDPR'8K(?
RXS5.R>PO_O&4R8)OI>RHFWC8 MB/*&\$KFS"BZ\$5..8%+H\H"MO\$8E^&JLH+\5GF*.3C=RX P=^_9G\ (S/T000K
M#;KN*:N&L;-W1>,%3HDU0V(&DMX5W*9B8 M0N_25WE?H0!(5)PJ+2M5\+3X1IH9UH6GF\$-"TN54?)N=I&-
)ZSHJ\FEG(-8^S0E(+VK\6#XF*L%D,2'85'5>A=[,H M2=&.<^A_N" _OG>H+_"(R^)\=3UX-
DO782T<86DW1@X.MT\^V\$2-CF M\I(0N7HQW.VBH U"1\$5C4\8^T-F X+1BQ+/+1?7H;IQ1 2R=[_60'F0G9) %M<;
MH\$71.9_1H<^C.F5^5M9\2AFL/&C4.G92-6N3T.K5=C+1F-2U@Q^M_)!<86"+R MK\B_HJ_ISL+%4M+)5L_P_!
H%+!=.BTZ+RSHZ)_O5W7,<7JL7%7H;1E!; MJP#@+GK#;HFN#H@^L!O<I/=HDAV-LD&C*37RNZ9=@5=
<#1-4PN.#%P16DM M4;JL\H(Q=)W>O6*LF068MA033MO>1=U2BY208:>2P_WXS>IN%NX25-EY T
M1:LBAUKX6^FGR -8CYGP^_0 Q#T#,SP=B'M3:YZNU>:JF"KIC&Q@FKA^MQ<=549;"/W/PV_<^(@YD?
O4:@B)P379&PCFY=(966)U.I**EM!2WVFUKCEE M)LR*P>>...H#L5^S=!:T/LN\B_L\H4
".@5UMY)LA21)4EK21E:ZL54 ?& MD!JGI\ZU'1=HDF:UK\$NVKH6&IV#12+WJC&1%5-
EW<\$4\763('PK#BJR%5X*=EV_IPB@L/@Q M\IR-3P^"G1^/;<,6ZF/J7@&(2_9G+-RDH6?EU\$^9I0*'CO-
EQHLZOL/&9KJTO MJ?222MX+_\$I\Z-FCDEIK8Y+N,>%&261%T%8U^G,>%9/Z=4H2?^B5%R#5FB+
M"X.YY5\H#H\C\UH(%!)3SENKK8.+%SZE\UAK53I7GO5\FK&H\>.*W3*^ M#]=6D\K+V#I\$@B\BD%MM
N5;07N:3;ST+2DA9G)ZY7"Z7:F(RB*W\WCQJP_0<@P_9LDRO/G/5";.B:"6HJLG/=36ML_2XAE64*
M9V5J4J&16U7R;\$5..GM1M:\$ KFD\$X!"RQIAQK_XPGF5FHH0*5OM7+=* M*(PD4^*5.%H'AG^EJ;1^2=0%;DE"
DGT7,P\2A2IK#5"N.TRL7)JTM M@H!\$33SLY* A1^<+W*.GY0*1^1 UVT\$U/E,J3KE01^6.Z9AXH\$WQ:<406(JVK@&
(H\W6>(.@MD" 4YIK>Q^<1>SD(2NA@-.TOY0(I\2.)TM; M@ERR\$QB^O).YCHDRM^3^"G\BBDHFC,X59&VQOR-!
(@T'U0142B,I+HASBMF\I P\A@TGT2.@+3\$= MT3CD&1?JW\AMJOZ)2!+0B
G8+BW>)#!%JON7#.TWM:AQ\$Q06SLX&M)Z?W.MTA\DL\IZ\@B\I*(\$-W)YWT?COF?
9Z4BT.NV9Z(\$F0_A2I*QM:6P@S1>PT_H MNDMTF;CUMTI97?B;J(R(^L\$56P_Y0Q_M\4HBB1&Z;
1-2L/6^Q'<*8%9ZKE#0%\1HVLX)UNOH9JB\U<I&?SOPE.SSDD^3.Z\H=77>Q/N_W'256"B/* M?0&G^",?UCP-
ID^X#1&KHJ6T;T\$PVG;3JOUK9Z1037\8G4G#=#@98UQYTF%4E MO<-
E>D(*YXBTOK1\$BBD9M8J%VYNK*24^M+I5\90%14_T\H.996(GI0K2%IX M.*#40*%61=L9!!"1;Z3
P1.%SXNE(8M/OG:K^4;!OD>J?80^X^>C/3HG/0BM M\$H^I@F_B&K6=&+YD!%5-&MU/96-
#J.F*^6N05J84L_ FGWI?+7Q9PSXDE. M2X PS?
O1^4@H.M.00GGUXN5)YFNBC(SLW\RIO(0+&3MB.G';L\SI:N52V"R M.;G36J-WTS)H6:C?G4\$ _SI"D&I_L"0\AEI-
Q9A3*(G/73N45%1S=(Y))! MF5\$/"UAP26_@2B+CU<&+YF5,"IV-/="Y:U" 7?3%I+IQ%Q^J:CP_?_IF^?
/_WKLNN7%"4&B4"51AZM)-Z.E\IK4ON3.KT-VDK6:W\G_&(S;

MNN1EY|ZLO5;OB3+=VB57""X;??US|N7G^W^_*I|WB.T.SU1\$T^*OHTO M+6TBL/C>/+9FK|HHTLO+*
&"4|9458)%5VSI*Z|H=|. >HF;7-Y*VJB:\$ MW|DG\$*F-YY?|OD)^G|:R;=5^~;5Z|1L2EIX?/4C*(F,*):8NNOFLXFFN%
M5(=3.1Q;=+S6/9/<;7FL;\$OUKV4-17Y71|D)@ MX<4N%CLGI6/6L|H:|EH);9B7;<-T0.\$J|I KB0BR*%W9>"/T/
YEYL/B-V8-9B\$*MY*OCWO.B4M\$|>PM|UFZFN|/*#H^49ZOE(*26^?NSC:O|
L^|WD.UYXHH0;|00!=""J|C8NG9#8B;86E%6WC=0 MDG L0TN3*FTKI9)6-16-
+1.2C>|B|^*)/H@G|FY0\$T\$|TVHEY)F"/|"?SY1GW M<1./|H"MA,|FK"/-=\$R6*8M^GMW:\$+|DQ'
J'1HU05:A6OE\$ZZ.M);VC6G M2MN^0!!UHRBC3M7BBJ|@V7|PV|= #RIB?0RB QG/=|*%RQ=).4*.BHIE*%C)Q/A
MPQ=SR8|S|SD=%OU \$*.;@/92(M8|YD&(.83.JLS*"1"5NR6#ZUNR=^(#G7)|T:U'D<#B?8?_4.G#O |9CW.OGY"!
<%36)I MH=E<55|J-SW|H%BM.^5SY1(%>R|B9NY4-YD@%K,1QU,<#ZR1G73L>62SC)Z
M6A9*NU7LJ9W:Y^*)3CCZ33E7%454;7TY7G\$|L8 Y("0N=>CM6QGKZ^\$*=I+A0 M'6KNF2EB^XR|JO&N81%"W _"?
0%HLA*2*_3|7O H|!B+|B+!10>=AQ^|C;O+U+G.M.S+M+|CYH+?06J4F CA|BN)C(A7IZ6/R.Y.^> _"&_SX9GZ3V3+-PGIZ"
MN#6.G;U5/^|?=>GXC""0KZ,|>G40=0J@6<<&@|>:"X^3ST>8 MPB-
HO^1.^)3F'93SC\$;HTL3%B8RF)#5"R0./TABZ;%Q-1Z2?W)^E.#(Y3G M>T(S*&T&:~@7V% ^-1Q:'2.?RF7Y%/%&
<%"ZEO(S.TON42DA.#"IVYI2L U@ M"XV*REF|0Q'>+E==5GWJHD^S5W%"?)|4CO1N|GOAA?
3_M|T9302C=ZS|3>F M^IV|D33W;L>.R'4;F-D0&""|T&D^>T:Q4G7%@P?=USW.W)&W)U/=1;~;@&
MUQX.GIK*5<_F_06\$|9L6>7|)+S.@1#F27P3RGU1%0AL1B5P+X;@7*A5,-M\$8;LN(Y<(Y5WA.Z1NYW?
5J|..MIX"&_!A>)T;C<|<<FMH.MXSZ=T7A/VQW<U MD| PI+ #R3H27\$6Z-O3MPGP>=IH|V1-
_N@7|EB!@|!#M|JF|XC-LEC(PMANCZO MB</_K)8*7ZE?0 MG9=|VRWYTV6U;Z_=@|E ZX'7OI527%2?W59NP@N&
M'4#0)O1PRIPC8&6<;<\$U9-7@F;|R3.ZPC?1MMO>X&YRDAK|D^~^3#FIX:7|JA8COZ;UZ/\$W-.)N<%?
0DU708|2PC"-M43">|4 MK+1.)AW2ZF35S:@T|G.Z
K|XO;RSV/?GZS@Y&U.>+GS7B;@NY'1N4#TDJX|8%V<<&Y3/C/C# 1 MB>\$#
(UL9>|"/_Z_05=:. "W;Q9.FMFHU@)|:/%GO&B07W=3CG:&3_7H M|H=/O_KBLV+Q^>?_YI&
(<^#XH7+|""\$;AJ40=-013|+8A3X9QP"X>3(8| M|UY\$&=B?#G8Y%|GK ?EO|W0!EM5G_Q|_BDMPI?
%Z<# YBRO< &KS^FUX ME7|HATF-VXX|OQFMDX00Q*P%5PXSZ>97.QYYQ
M6B+3R)RDQ"P)Y%1/+Y@8D;/9"=8;XEQ'68FEE+;(+F/D%2DX9;G|*F*0 M. 9F=FG@?C_XB5W7?
|L1M;YD7\$TLVOFG2|>F\$1JS6S'|O|C@W M13\$48.W(,5 #+Y6 I9+#+&GAGQ)%U_|D.W1 MJ
6|MR%/63'|39H98MUT@AN6NF7<|?GXN89YW(3SN5|9YS+&>?R&|*Y4 FS MF9,HBYT|D.N>P4_4G.A"ICP1Z8>
|5H9T;3208X%VS|T;B18IOU"&-3|W+ _M>=>I^H|D;HOBKYSR;""(Z+|V0N3|H7LR\$5;JA94FBHUAQUVR|I.O:R @1Q
M%QFQ_8^0U!"BA>1N==5(8)SS|TV0|B?I+ET!IP.9 R9&6|Y|AJET4L T MC98Q|9MHT@#9
\$KW;*#*^=CFP%N|_G| MNN,|3|I3&O MPNVX^+< T@1E|U,5KLF)NZ8&5;JV0*EE<\$047IX?@05;^HBHE!
<\$GGWJZQ.S M+U+D#|@K|OA-D3|9V@SJ6;FI&DC+QKHUYA8OX?&69PD+YC0ED+KW_8L&>_M?
X\$1^AVYYL'9_<5H6\$@_N5*RB_N5PA>HSO;#12/V5P^I.4T&SY\$ M;ZSU!> MXF3OJ|HHU07O_8.M3"/V(>N>_W6@|
|R\$MW_*UQ?IE=BHE2NU083=%_5\$D)KI M1&2_V|JB58_U|5YZHC/BE%_-CT5L"2_S9&T|OOS-#^K;G|HHP4LY+
9E4&F|MA|BVJUO>_O.B.U"G>_|B4|E6\$1&_9(^FF8T'C7
M+2@!\$LX9*IN9+>_9(PXK|<4SK%T'W@+|E|6ZL0A3UK M-||8|I%#N>0F|P>)|/I"# '&SQ.&K|
|+LTX|L*+ Z|MM)|U|CC%8SULT1S?|*4.4L'3XIHJ\$^D4#BLC@E0|8.<7W|OI<5HT1;)G59/Y'KHKY M(@498TG(_"
LH6%|(X;8'?W(-&W2Y67L3)|L.V.RJ=|7DL|I#<0\$B6D#_HH_ M/>1AF=|LWTX/\$Z0%A2) B,8*7>'! V|327*M:3=E-
J|L3<%%>#A3*BA7BXI9 MV\$2KNEN->^I(F_I&M)Q3'PA_|6H|MCOR:XFEQ+H2) \$6G;K+ #R J93CQ7P@
M*+*%|IG'W?%?#%C#;C7|T;N#!UV=J3;O4:(A3'R|YCT)AIB*3DGI&E1|NER M|9>)YH&HJZ!! X7-
%/L42HU3OE58#B' IB|(E\$ (V2P64MT15%%6|?2R|Q&E|*U@R^G9^OFU54SOBLSV+T95CV/<=\$"R6
M.W# "IM0LV@N/9W_#B.A9#ACR@.@/S0;K=6=(Y%UDR4P|QB|OYQH|'6P-.)|I\$ M4(|L<:^0S+
|<0Y>V6PY&P;A\$N_JU:C*4JR_@U\$_.^GR87^M52R.GV<>(J5|M"O:60H6.Q|N.=C4_U+&V*L_9Y5@9CYE75D? H?
+2ULH\$M6QY4>J%066B/A MQFL>Y\$ _/ APK.O2Q3T|J7.38HZ,7>2CQ_*=U1G)L27G.<
MHWBC"49-%X=&7*MX|'5K=#M)=Y#B#QXE_B|EAI(M6@+CU)2"7#L=(8O.O8#|MF3(LOSU;D.D;WR|1%6|GOPA
M|DO|5^A'7;\$Q\$,%*H"7&S;-#_(-|TXF7'I9LNVL12>/'C"RMG4 M'0GY5<'PE+!HDO&|Z^KZ;G%>|0|H%5S6VG;??
2EK|U_JPRWKJ;779_V;|!#> MIDR<5K.+Z0ID#2/&K^YQ:T/0?ME\$;|B/+;S4_#6R;A|*T""DJ*4_(D MHA+TCUL_8.?
3R5#/_M0H5L_N36ZD%X8|IE&3|A"=NYT.3).>1^SK;85)'%5;|WK)%W08F9YX@T5K?6
MD|H4Q*W|V93IY.6UCIP.HXK_ OQC9GPAQ7PGYL|4ANSJ|ULZ8U*|VTY;ISUCX=CU8|GM*S|J<% BKD^U>S80VWA7
MI=S"A4=*A&|W|D+9HM;L5YN(B.>H<097)A_&3_0M'L""#%) (I*A.);R B
M|LH&RTP|L&2QK=W|J>Z&'Q+=D^Y'PG&N MT|B|N50?^67&Y\$S1G5YQV.<H%WWSB..KN>1AQJFO|8AA(?
8\$+X8"?I MF|+99>Y.)C3VA6'3KI@J(5Y.0?>)HH>K|+9N? A|/).C"! FX '\$LZ2|B|<
M.S|H" (JU)R@7#7(H/+&)Z1|T&.) NFO|'8(0'=L7;=HO|&TQCGD?DK60 M@K">0XJ|@L_Y#DYZ6J@NR|M09YE ML*
<2(-!+J3TQ);|MX82(5+*AM|6ZT)ISPV"H(%T4Z/#H)P-WS"3|(ZB4|R MC'N+ %K"K|L+ C|+I0_J8917')YMM;7V_#|!'
M/&\$GNZ7+Q;+M.IC&=4L31%68Q|U|5-)D(&T|0|P'W(C_G \$L|^6X_ZU_MBS8YC8PYHAI?2
+|7|5\$^T@DY;LZFI\$D3*^*Z3*"I+Y|_ZT#(C_S9A(I ML*.2K|3.V50Q.HNI\$HOAK=%+S/U17'KHJ;IG=RSR8H>E-
L\$E<@C|10^<" MB-#B&>\$>.JSBOZX;:OJ/<0K&|Y577I=|@ZBJDM"/AW:F&&A.%G'MO!<3T|*
M_@(:GWTQ:Q%9Z?WCP+P=9S|YHXY(VUJKF1U-R20Z.B:<23<^CG&>|U^BI MKJIN>L9>+XJRY*/ADOF?V^|"
(^@|_50*A7|HK=3.78CR@2UW@T.NA-(GAU MM&F&YF0G*(2^@_H|24.;Q);S"HH|EW@#;6AL^T4|_H^J@G&Y%\$%
<+1ZAI@- M'6PH\$N=W6%"=YZ.R^!O#5#=%1M)E#^02;HF_+B;X"C-^B-GE6MD7|U51< MMFO*|QJ<_<^QC|0|29-
HBZX|F)V8|Y|LHX(=H;|6?)(S#CBC59R,3P"H8S3&9 MPW"0AG>Z6'R3SD+DC%HO>KGEV*U)
MWH&7V/PJ<&)DLB\$/%ZZ5\$A>TWQ#1&/MUW^A/+KV5Q5FO4=ZGW9#=(1#% M3"?F8Z7&<-9-
JRD@&L&\$@L|;^<|=N1LM)|M|>.2:MD#G:T2:UD#_Q&#U*PUF> &D&JK'&1D(PG6%7|R/D\$;Y+| "TU|:4_
MCQRNN^)|M@=DXD;/&^|F=@X_ E+PR3!>|F0 2.3WJ%_UDY>ZF D-O+|N*C)D=^3C>2\$ M(O(GCS"-
^O4|_VB|JF2D5&DSQ/V)D3A<@|BA(D/<M)G|2;=,IVX1.E5|GY@OX*TO%,1ZOMB:N25^X2P1LGEB=NRI
M|1K|2#;NY|1|1Y86DOV8^IWD&#57FYF7NG(C)|KFB@RX">R=R>3LTF>UM5> MU<|?@AMX6.4;L=|
(QY;51\$"=3E(B;E8A)3)7H|Y|G|Z1X10W|X>^XY;Z MK78CC8T4O@MU'ZP2Z=43,+ICE&G0>#VX3+\$
%|JLZNDV4BUI6U|0%+R5^NAK M)O+3G'S-1ESX7ZI=F'Q*5.L8\$0*.A=%LL&RLW%#EB|CXQ\$21-F.*9;N2)*E
MC25)H6U|DJ2S|=??&4/17I5AIN:6Y^<^|&R(T_MZBV9C4HL(OMBO1+;NJ23RI?Y3DG5V?_|TIF_N/_ MO\$-
_VD(D;YM)H#|@F\$5""|BSRHPGCGO|QG;?3|9|S*TMQ5)8*&|@DY;+&*H MI8(2SFQ5M|H|+7GZ6#9ETI"|
<Q)*N|3_3I69C62_V|&\$B(1X"4.Y+^+)|5 M?^R'.H|2>-AW;|9C2;98F|60'365D%30H>2&@U7\$M.A""?C7FE;&J|
(JPB M'ZMJ^)|SO(FPBEC_||RH|7)K;F|B;JW#U'VW#)Y?->OR57JGJRO#)PO39OZ88C1ETO77&<^E?
UWG^CFJG9C#UH)1-|A|DZ>|I,UT)Z|FJF_1 M35MM40573|5\$W^*;C|?4V/#IS&06
M%0MAP3QR.G|WJ|KS'Z<|5B8903'R|6*KK<5|T|ZA;|RX5;"3^C7EZA|H"JL MN+;+9(^KNO;L.C.ZZ=VY>)
|Y>YQY5V.F0=IS+ &#&Z(1Z7.P=M|"><(^.W M)X45|O\$B|LOXWL|?>5:9<|5VXR75Y1INU;|J_9)V*1?"N\$>B/S=2?
T002.B& M.G_H EOY^"+3)&|XQ*U|'+E/#C2ESTSZ\$@RG2E>\$A5T?IZ<@I^E|>Y_*AKBN7
MZB4L4;JEF&|YI3B.FIC^2^0.5G&XB|9C@9>QRHX_0NZK(M^&4/= "F"*MY;
|NM|5;&|"EP1L|XLB|9;2">TQ*H|PO0&4(NJT+C W?)#Q(\$RBPLTTEC.M28*> 0U><-?M6RB9&|OI2;";
<#%B7XZB%|*9\$;A/5|P?Z|)@_2&5ZZVD+7* M=5^L|6<9#NZ-J1G8C0VX2;=&N.9P?5^/73RXMLV&>2;AG(OL5|C?</p></div>

2.Z=7G MM38M%16TT/5IU5T2#U:8A@4L Z=? ? Q^5>O<)%7;DY>SEZ%7H2OPNOD1X@." MUH2">U5!*,9-
%U8U+O[95RP4?,9NW(3=^/R.W3AC-WZ3V TO1!,O[6 @%(Y
MLD,GI,M&="TTD61S(K:W,*;RGU[3">U\$9%4UE:),I0Q4>'QG1|>E>\$ F-D9
M17^RG#0?),(L(ZB,D<:ZV8.4S8!C*L/@-PC)PAL*RU# 'J6 MPXG6(2W=Q8KS!&+
O4U9ZB8+@,ULZG7ZFU/>CKVE&R8O'2&M&2A# 'TJH'AONVG-N\$N&:JS5\$=?2EID#M4#65- R/L^83X MF*8?
W(72O:\$U (@3+=/JK,(@/&'1'BXI1P(LHDV@B||#F|@Q@J7J?9NT\$+J- MXX9O=HM+D0&^\$:+ D5VM'?Z)
(:MU^#;TWXFNL*@C@_Q'X4\$J8UP@|EPBG>@ MVM(GO.&J.IQ2BP*HH0BUJ^C5E0\$90M- <1%|IGK?
FG3AUJ\$FQU0@(+ #T+ > MC-/NFM;'NMI+)#,RA'G#JJ:@J:(6^Q^Q/74G%&D\6T >+>\$Y8-<,*9"IM%64
MOOGZYV17KH;,-=%:KZQ0,?.Y\$Y-,SjY=?2?'84(5^*N-,F^V=&WDO'3>T\$ M+EFV#?
GRO^B2:JS>)D2EV695A6/(43K-F5|@|2PQRLC|L4H+L8-"N2V|AMS9HO\LN|^8
M|Z*V\$4M9'FB1-,28O+A/^I82D^G|BH^5HF:R0Y^=2<9"N.5JZ5P,T,7B M^S!VE'DH:&I+1E^2 MI*
=8Y>9&I%NESEF/\$!) -V0J3A9G|RX|E+J|F+I+&;MOYIN=J2|X%-%J|W"MAP'N7QI^H>P*N@#@GELIV@7W0;
|U40AP@|QY3-6^D:K M'K'?^XS/FOJDFK-2FW!-"K&=|R#566.VD+4L)=|QT)5#9 HD-JLP.?(%@)W>
MG/0W|HFD5O=@84?<^7W\$N%J0AJ"-2 *)| YD,XO,R)S:MBEFW>-\$L|Q"N=IR,|OG\$G* M'I|0/2>J,Y&*2AK1+|29V-
Y.(2FADHDYS%+!UQ0M00|2:9)E5!/7*0.27. M|UFFG;C(IR-)L\$NZARBOD61
+BBVL^W0K<>,>Z@24RG(@ R^Y/N.R8+TUD M<&\$9E,"73W6* "G6E)^Z<-;Z#='(4%() F:-
=/3CMKTYLY1)J%5M;:HY'\$# MX#;C^4JN?SQHO68-1Z*!XR'M (6:M^&OG-?|58>J@%=@QU@R7W|TUL*-|F@ M'-|V0-
|Z^"|JV";PNDX*5 MMN G3>|<92(^G3H|<-S"4':U^(\$P3.S@|'I,09-0&UQ>S1,B82|/?-5NKHE(BG'D3S/R@ (G,|>?
L.IYZQ969* 38:7 MS\$ "LIUJSG3Z-B>RX(T=GUN>XT"&2=|2W06^*281V-=MJS0U53""7%F4-^+&
M:H9*Q6XA:1PWMSJ25#|VH78&6J* 1.@6R*VAYL|@HVL>JG5Q82&L\$P)54 M%=:
EO^\$K9J*WT'L|MZI7.V8BP' LW3,%/0-7#%O/?E7E76-Y/HB8&|#-,J(S|J|T\$OMJ|>|<.^0KDROQ
M%\$2DJ75IN,6;Y3QAG5,(*DVM:D*5Q"W31'8#?08BSB !G5IX|M2K<|<>FD> M@YAZD5<5S-
TLT|7D76W&A8Q_@^Y^AM""V^09L\$X<|+^*H_K.2Y.QO%1 5F3Y8KU9,R++|F%F,|39<J|J2:\$A?0Q0M8I7R\$105H2?
M7@|E5W);&<(<0XW)\$F+D)+# +K+0M\$O""I0<&- 'H2<L7G;|ESA2(B&Y(*R MMH2H(*
M5W3TQ13NO&U(M(YYO+ F\$3B\$|B341=(5/6DCZ*3\$WO.&7< MI+|V|FI2Z>5^A56;:H@9 T|VDX=F,PUR8;
VXB#L#LC>7\$EA\$P|JP|Z5CLJ MT1TY+|B#%|S=V@:695\$Y.S|3(ZWB1':TE|G/2?"I)
M3HRK|344VCRM|+>9P,2ZF)P\$DXN81)W+(HGJ'3A%=<# N|A#^B26V'%2U.VY^H#9E5 T(S&
M>,VHGD91A*32,#R@?4I2HZ(V=C3Q92:EP9"7S&?57A%E&LB|IM =AS.YF=G8J7=?M\$.A<|@>F0S*Q6HJ39#+
M6C^|RP)6H J-/74-@D.- E\$1LP&HCY5%|_RCWNC92C H:'3CL3%|JX*0B/
MA6BS|PEKN'=DK>+R>CY\$RFN"BO6|X'I6E|);5EF.\$'3?APLHB)|>Q;\$^ (8 M,|DIG DT|U.AHB':T?"?U
*RKP\$W(VA@, B7U\$R|UO)FRI+G9\$NLD4=W1SE(
MPQ0I08BA|C3H!"8SCT=M|K73#7D;9G;13|D96I#BF9^CDG8B14T)OJR:5HB M_EG+V004)\$P9
/HG=^R>,08K7BC"=,|9^74YE""LB09JCZ3_H\$/(4Q|A.&GR M:S9&Y8JX0S\$HL)FQ_<2H9TR_D-?
03Q>O+UR8*RY0P>G*XY,|*+5,?>FB= MH:V,5T).65XZHQ5AF0P37&38EBR\$TC@K,OY,-G_A\$#(*=SE-6^7B(1-
GL2F3E3H|XE3K M*5%;Y+M)|4N48'P8*AHZ:H QY.S359"\$=8 M8SU_\$(|AW)L_BA:IZBG1QT3'0_5:N#A>
YO)M,)|1T0N7HE^QNHHS+5Z) _:M",,=3RFK8<.'NPQ|.\$7Y(6Y= U_%10T=2(7DQ0EQ>/3/6-VB_9^*<@|+%1" M-
Q%_8<=PS34I7)\$K3W9;MC/;#S^R3T72.(&XR%_9E).3QD5M\$/(56M0F2N#K M9S+YW,=W2,@|YK:V
%#>4AQ#2L,1340@C?ZG'2|U P8CU)9@""& M_@5%1+SNA68>ODFY(?IWL?TAS/PCY+;|Y|:-&T>'@<4F7JN
M182|Y&T9|A|YOV6>%%J&B^MOK|V|>2"B@0-+KGHS'X5T|U 5IROCR"|L(9 ML-W4L-
_HDI@0LNU*>+QQ)0/DGL>7"IT"AJFW684LZV1FI8,72|Y;C>3GKA MHD+\$ XFP<:!8?
%JVNJK\$.IR4W;...)%|T"635JZ+ 1!.\$Z_#_|)=3_/OP4K MG0H#N32ZH|2E:9|F;/F,-@=61R!#J("LC MK1)I3.\$2VX?
3ZEE-RXM,%GY&,Q#|L%_M|LVU>#_+A?K=^1.D9?;@C1U%X" M-O85,5P:0*.2NRMD,*E),97Z|)Q(85P?3Z(B#6V,-
>\$8';|?2HSDI%24 M|A8|DPLJL@%L,%\$U'Q|S2V?2L^X10ILHU%WO@B,=O\$0V3>=>Y^0)FA58+% M'4680/Q/<4-
|_U|KO#"X8TC=YL MW9'+|P|)G-LIPA5N,D@>QCI1UO%_5 MKN\$F' 2EA|,LW%UWH M"-
DE+\$-5+3|9F)^SLU8R:65-+|Q=|J>5#DRV99&_OG,(WE|K(KKX)^'|2? ML,*Q3EG;HRT=(,(&7C5.&U-
_O/QRT4*,TLBU|5,9E;:Y7D=B*|!|=,7D06T0&D73|ZM)8/\$|H M-DK|DN;Y;+D|?2;>A_7#HCB%K=|&PR?OOJ-7?
0U7%=R1W_6L%_|VKH|F2)=,%_I9Z,,HJ"HMT">?2|ZQ;D|H-K29G0 M/:7@B%C96G>*1FE3Z8/NHDHWW*#1+
X1\$NS?;BSDT|Q:X"0(E|MW5L&|O(J_-<6";B#+A#L:&*E#1P)B0NWM M|Mj2#W8-H>WF_BX0YA>2^+,YU?30:
(U|M(Z"WQGJ96=CJN&GD-)10,9#9ATG9)QY MS"JP8AL>8J>Y:@M_"#1F",>+)DQ!C8F7>DNO^ZPF%Q S+)<
MECY?7K5URHE|ZT'OW)"|FL'('7?*"JK8X|A=#(|0@2PHHC ^#RW(T MK
<3G8>#%P<>VBRIPF+5IEV|7AK5Z.>@#YRj3/M.I5V.*>&="GL@0:98.0
MK%&E23P|7U(Q':@!'\$C|2*C^55@J'%\$#K-K72G,J=" \$R1M/44S>VZ6Z:1&X6 MLRH@/QZ-SG%9=
<_*82A7;UUA\$G^V%Z3Z|)I+H6 4NFDCS4)4'5TB|NK;|Y MCR.A"OCE|C@TOVS);3)1W|8NK9J1?
QODA;F""&;CX=BKEM|A+QX>'WEHO) MF_OT<#SNC-20JZY0=|KLRFNEG"\$,BEJG|0|=|AG_9
CM*P(YPCK3A7C*" \$F M|S0/86AHOM=<=,4%0ZL6 "A-QL'ITM6DG|U;Z'X\1,2@*C#N|FVY* M|J|PT>Z
X&+5Y)VO#G1U%JN'DKP'3A4+DVF,,QO:ZYLKNQNJMZ0,^3HHP MLMEBYC|EF|1N^Y2WGOY2M-
Q>@G^R0M3UH4Z*K4C8/CO9@'T3NRQF'2G&JW%" MH|)1|H^P)RC+)A|6WHE>51H,4N2B"W"">#S-
8S&6.G%>=TT6NRR|TJCS&E73HS>M;3#;)W8BSWD3/CE\$C&F M'192EC|TKC+>388M);2MDM;%ZJU@@HCA-
DR& M:UHDX\$H8UW;/#B|_JD@,+US;L2G^|)P=|NABX|%3ROVA8@XG_T+<|)H_68^HD M#6NB8FEW|1(6V'CM?
02_)IV|U7+;;9H\$F:<(|G|>:96C_|G&8|PXPQ_-3 MKCDS0U|5U/I#|H%L:BY|KM,|0^!>58IH_78I9DDA1M|CF)L*
MMJM|NFCGK<3\$?J2VA4,|M\$7?C7.50%-HO|Q>YFF;5A#&7 94Z4EMY728>G\$?OX&WB MSI?;IZ-
A+ZL; &F|+=R.^*|H;:8GB5G?W^ZE>6H M:53-+8G;78X9V%*2'MMT92S7|Z1,Q7(RTZGG(^NK32,'ML
P#*@@@#5#&07 M|\$@2(G3\$)\$%8B36 W5=89I/I_IYA^VE9W;+DW3I"%HJ?/U3X4'C8Y9&>'
MX8YQMI7Q960F*4@=08SM3|)(HQ#0&I#>OQ<>Z&UY1?3A*,D-|*JM05|PCFC M-
1U+>C/E|12.IW^&G.638WS:C-(U7,Y^J9R7|VH=L^X8J|Z|JK*\$#NL=@2G%CVV:ECZU2|&JP*L^BM;%VEM-4N
MRV^5J1.OPURZXE|P%'|2?CQ=-|I94<;X'XE_D?B4|2^L1+|F3|2|LPTNA
ML\$CX0<,-+%,H/EEL4191^EY47:CMECA'T6&!:0X38J"- 6X 1(&&06>#"Q&W? MFJXR>5P.E6?N/6PM&(A-
")9Z_22'J5:*|@6K5^/8LG8GI 25MHR Z|F|HZ\$KF*F!/:|0B\$@PT8166=0D| MOJ\$LEW2=,;YF=ES21ST7#
)44|X|56XQS0QP|&T'(3)"U_4WP*|Z'(Y2&& MK*^KA^Q&HU_9UY;U8%P>(BM*S|F|JU5+HO6,+Q)
|7NBSID2A:1)8PMNVM MV(VB5RYWQUXNU"\$8)0ID7BZRJ#DS&JID2P:2.HB&@6'^Z^:6@9'5-+|S1-#
MCD|HFU@77|X.3RS@:QS_)BOY)H4ML; >5C_8V_9-+IP@CR66/6%00;"X(Q?U M.3ZA"F63EV0WTA6K3(|_4?
8FAYBQ@E=")<\$S&5N=2BY,89H53D?JV9;3AU= MRYA^XN^30)%#6 3D2A^N@|).U3IFEVY(*?IEV/RE DT8W\$'-QIQ-
KFZUIK*^ M2@OB5Y2F8_X(9LN MEM,|H&E2%*?2;D|E|L|L|FML;."3AY(V4"<E8SL^\$E33DJC=A::PX-|I
M%01HX:|SQDZ3@Q1L/W=,BH2=-F(LN|9<@RT AA*Z-/X#6C+HJNS'C|G)"? MNB'C(+D)E)\$HH=W5K3I'2X=W8<
Q;:6D|05>RO&Q:*X.%51NS'|9+-N M#Y-)D&2TG*RI>"N|ZATGL7?4,+TJ#U4^KH45JO!ML7VE|17LPZJKE|1=E^U5
MY>4C3CY\$JB*%M|4ME262DZ)4\$:*H^H=+Z"4L EWMO|SB?|HB.K1R)3SQTU5-MK1F8Q
UKIYG08;B9+@VY;N3|QD/85&QJY0|VEEGVMK+HTQS<-%G&N?TKYM MVG8@P@DC^YMI=7H5N&'&)&5-
ES904=;=I<8L+|A\$D(|X|U1ZN_ M5G|U6R_KP=1%@K| M\$&X9D^-1MMEQ.@Q)>|:-

*J"09E18JF.AX>OVS@+Y\$Y&KP?IT.>/*2ERANX M8****PU"1\$VENTYDQ::088PYHAA<#2P32&0069HH&T
(+!+JXMH0):0\$1^HJ) MH9W'A7P"30ZF1\$C*U0CJ*!MCY_@#A*2S\$76 IQH M; >B&<!QC3!2AZL2K9MH)39.Z:W3-
0B.LBM=M0HJ7!9,7B!K!5SE^LOG M?SA7NDKT+!C PA1L_CEOH MXE/>1D,7 F^M=Y;+!+)'OYO^_4!?
70SIT_F//KWX#'_!793;Q/_@=R00? MT: #!GT^!^!1H67G!SP!# 8CKJ4!G5W;SGS!=?!NHK?X'=H\$!VD_VKI%&=
MVP(8+!)BB0!G!CAHKQ!#!HC>Y\$2DT<=W\$Y8UP!8E.&"2!GB_O#KL(8R;"# M67A)<3 M*\$S=7V?
R!3_7PGYFCA%QJ30*ZX_1RYN4RMA6D0_MHU+BC(&NUXVIA9>26HY)R.YBEE@&UPPVM/-4EU%"-
(8<\$6)J\$&K/\$=S&31=T9CL!_8N):&W@U=K%AZL2Z) 4)C:D_:/@L=Z*KQ'\$ 6*>P MK<8!^C(0!C@BITDJV6'6F?
Q+MURI?/5A=^F%:W2!S-7&DX7E!L!2RS'SXERIG"+ M2*F/-PSA'@7Z09\$D^EMA@ZLS!#-
G'8LQ.NB/Z!EQBF\$MK=M^X^64G,T@:(G M; <4'KQKG%1.4,20G^B.JKF5*)X>5)1J!)**">->40T3.
M.G^YRHNL7;MFHT4'8HFV/Z@MX&T!W"N/Y2B6, T,RZ+SJN#3_H(J>6:~!2T!2=O/@-R
(U0TA/5!1:RE(0J/(\$8_NZ)2L4F3\$8V:5H6C MI/B:4LL7BZ!9P*5N-HP6*X%GZ^IVW1?Y#?
\$T5)ML_!\$!L;^5G)2\$@!INV!9E MT6!_!/? AR@4+7#M#:#G(9!LV>?KXJ4_*52(Z*5+3.\$W):F% UTRZNK12;6!J
M>^\$!9!\$<+!+P8GG+K!>4V7>DSMXG\$=VN)BZBCY+8^>Z.500E=[8D@T/<>7L3HA-5/(K#V0+"W/
M3ZU\$=,%YW=,8X!JWX7_KKH3IE!N.IFA%G!&!78!WUOI&4YFW+=!L6"9J!
M!+)*ACRS0X1D<>&^+!VMR!#T'BV?BQ"FE%B&SG&".H^TVB0CQI7EY5'0FR)TQ\$!9RA3DFAM\$P07-?
ZJA0@!15F10?TT-5!U_0? MQKJ\$TD-?>1XF#C7X2=->4 "- @3:QW'6#9!O+!S_\$AR95^1STA>&2.KM!4::B;);8VX
ME!HMA1D3P0%PEKWC4B07*:@#EW! ZIN7:XQ=1_2:~8TE130>6E@(6NPT9>Y&
MY)ICU+\$4)N^2&A" C3U=HYNQ.A0.4589 E*=# 'HSO-?_ (=)=/2"F:LT45
MZ^V!\$04.C^2PUQ0KZ;D4B8A37+K(1!A3LJRWB+6^X1P\$1G.&H5V!05C!5:@D
M!_"WQW_C!28!BZM&ESW#-8YUM4!TGUVIDY%\$!A-P-B^T!J8<:PB!JKVWUVAWI MR8"H37_!WU"1*WLMXYQ:<:-
*D-7+YD>@^B>FW1UC#N=\$!+B!C(MX0R(H1% MLTZN@#2(D=:(CXD%U-\$!L:9&=P;3UGT81!_+4M@!<4_O%U""
!#!+!#P0KN*QHD<70_?W&F?.HKK%5?NY_Q97CGDO,3/W\$R9)\$ M)^!;W*:WU2!30<^R%HH2Z.J5)2C232SL
4E^O(W^ (EL9A1!_D^!\$@!9CV^ M%J=?6(N8\$@\$GL0=A PA+>> 5=J!(M3*+=!Z2_-/FPRC2G!ZJF>P*6D6F'#6
M&W=JWJ@16T!<+HPI"2Q;K9#
%!'@P:2M*8F<@4.ND:>1S1**!4NUH"E3*KNO/31@MAG6X%:3;KTH56/(!>5=RN#^TJ-32FY.^_KQ>2PA<_.74IF0OE?
XL^OL)B8C+P3WQ#53I26G) MCZ=+8^F5!(Q%0GA5+RG)""#0/K MCC2M,9DQ\$#UJG-QUWA(!^,7!3+Z!/?
Q5YQ9JCG_X2M_M!A!A.S9^2P'0C=#N M3;=#H AQ>=T\$69BS<5!JH(4G%90/?5>?;O;_GP@90D!>+KHH!6Q.!4=
M9!F>YQFHW6-8!4YC2K#J!T937I M!H LJG7_#(O6C^J>E&6MEF1#1)
M!C;B!H.G=F7^75M&0I3(S9'6.0\$C2TN^#MPFU5!@6033=B/D!+S@!G!7 JF M!LOA25HODC_.
(^K2SER9HLT:4>JG#+%A'(O0Y-H!T=,&KGY7+/JHFT!1-M&_\$83Z#DSO/ST*GB!<7 MCDU;B_\$62E\$ABV'6_)!
!@/<4;Z?0-ER%8-94(W;LR>>IOK^!HK0+>OY5^!AA MV4@X>N+!(8@:&UNYT'3%N&71525^_8;3&AZM#LJ\$+.^Z7F.
H<>)WT.2&(V M&F?1*N_)3%0_./4U^G3=#'" LDKGCT*(.+D+!3W6#;/[4=U*(^)!7I#PH MG!0?T*
!C*9M#C%,>IPU7.0:ZX%!.*\$!S@5#7!MJ@A!N 5M)%?&"+.80&.! MFYYOSTJ4JN:X3 KPIG
J^5%51;K4!R;GP;I69RB+ST.Y@_EU@HJ+WCYRB
MA>3&B05%M_B@)3(OWY=K2HBY_W_79\$HJZHO/BL7GGW!^!4U!9H1A!F!
M>L_LZO_IRXL_V!>6E!\$@RA0A>IQ_UM/*A!F>A!Y>M!^OY<8D4T>*@U3)9 M=T@LIWTN:U
S\$;T:ECQP'"GL%>G(#4FY>U FZ^000J!G&290!>+_TO,9!+!M\$G^G>@IPD4CDSX
A0.0!C"O0Y(\$7Q=&H=T\$W&W2.G!C:LPTF&(@>G5R!T!_PX MHW9\$EOV!H?JH>&M8I51XN02^/@*@W8002A#16'B
!_@_Y<:_%8HTF*NGDU< MS1&""M<: 5!%(^GL!;R34;GC+V0<+;54DR-"D_5B1LG;)0@!IGU:HH AF MLL!3T*!_8+
(RD#H)Y*^-!2H\$#(3P=OZU!_I-2W/P+HUWES&KAZDD8CVLAL MP!_!"/((U/D#V5FSVM)YKV6UK!_Y!)70!Q!C-E?
67Q>6T^#HAE<NO#"L85^E!0PCF(HA) MZE!8F,)!3;ZK;D@IZ2IRZX)7 CSM4T8SM19J M,(>T0V?J!^~\$0!;2ZAY-
F%#78=3;IN_!%2X9!N65!ZY3@%<7GK;#,@\$ _T0LEDZHRGP)K!P=CMA%:Z-O!;2D!;43' MF?0P;+P\$Q+
(#=#!^4PC1O_H!@11M!24%"?%?%?%;HH=JNX0%7!V<U7F-KY9"F+7Y M!O:YW#AF2%RW?2!L^Z>1P6_!H9T>)>0J@?
4C7P=,(P< V&383FH#*J?>9* MAZ!":03ZM*J(L4!Q_.*C:8LOD+VT)DZ>C>C2\$OBLFG;_#.#/G3Y6<,08.
M#2EG8.U?/O_R#*PI VM_0!#;-SFR"@>G^-.788_N9WLT3'F665=5H4BOE.CEX6U8,'@Q^E8X\$-
XE&O^*%.&.&%Z^DM;_#.#V>Z^L>A7-BD M9^?;8EB0XR!H1M2@!N.C!X)2>YC.IXOH!;B) 9!@A)787U"F*U!9;3X-
;BC M>S37TC6LC?;6)S%1^SC5*);A^=+'2U?BQ>*UX)B9'8G;+3C_-4K;+2WGEKKL%^G*!0!C!/%""3(RHV<+S!-
SG3L_2Z:&PC;MA*3KY!/_M7E_!LD5BO<^3=1_P!JUYNZS!F'G@/_GW>W9ITM:A_*F-RS\$+G&?DOA\$B4#LP M!D-
R?#M3.M20!Y MQ\$!CPK+A<2@;(?V""3X>J2!VU70!E!5IW KCI%\$6#RLG/21,H3 M9:@
!F(62;4#2!J7W3G)!TY7!ZKMKWB;UY-8!9JQD^!<?_DQO*ZGCI+V<0!T M2\$!;\$^D?Z= M.Q_%"<9+=Y*1>
(L=H_!-!\$!XFK8+G>C_PNKN^!=WVC!VBV;:76L.QS@RS MP!019RW&@;60=(9!2*CB;#H0?
FDQN\$O^_5)6SN^8+*P>QT.SNUD2H00*T.K M3(AM)ZBSQ" SXBSIF3K%G)N^4?;\$!XW1\CFB**BUWJ(^)HR
2688@31P%) MZM!5 A47M3MV8OCN!9&XXE+!N^:/FP;/5_/O"278TG""%)7_0Q3QEA!=08UF MO&!QE)HN?
PS!7!ZW>5DV41#*2T@A2A9P%Z93J="4>9XN6?MC*M.R!NVEA M4)0_V!J>FS*FW:"E=P8J_7S/YV!^F>@PF!
(J#!1_"/H2KZ0M!\$Z=NS8-E9 ML_P!6Y5B.&)I2S<'B8KC-4%<*KDX!5'HAT M#I%+\$4(Q%7'F2/
SFSY(#^D)32!7BX6KX.GAQS.IU^!*"K!XK-B!5?Q(@@U M^?RK_QL:5_9+XO%W!45#W@ETJXK!>Y&??
Q0;=@^FJPE=?V;+";?WJEK M 3H!DT0)>AUQ!Z7 H""#V#(49_X!FHC_!5Q1N=54=L1ETP0JG2M@9Y-01 M!F-
GM!UFV!H.88J!H1K?%"D>%(C!@74L1K%082B.MM9PN@;5F'P95#X;_MIB%WR&305Z!TXE)/VTU8\$3Z!40B;3?
E\$7\$RPD^W_"&.(BM2LQ.)%%F@3_MX4?IO#F".8UW+6MWA<_L6%IL7\$7MR *WB3=F@KN7%8!28;
J(F16+75!%L M!MNF&ECP)EA#3K*Y;@?>P3WK-P<^!IOR!CX!K#71_YH-TR:X7!JX-B"C4(>NK 18MO+OC5
MCF429#Y.4%Q4!HB!P)\$Z%Y41T:RE(TW8!\$5X!V,V6Bf@HA=Y?DT!X87E8!O MM?=HBO/V/5MTB%U7Q\$80&2@Y
THG*7/40%-@QS"!#@H&+5RZ^>4!M>R(C*U=+_>+5"IV.INV!_OG:Q>00%Q_Y7ZP\$USC>
M34C8&_?IBTH!3BQ=Y-60_-Z!)F>YE7:1DJ!_ M2#??@9);UZIEF3;LE)U(O07/2%-P@-6M&J-K.IN->Z=-
=!.FHKZ;GMJ6!RD M7@HCJ3DQ&;<46#VM^1Q!/_E!MQ^623-U^Z*(G_5@8G!C<->-
D!0A>+5\$!%+WU=L7L\$U1X79H!L\$T=1 M!)A!;!)1R^0N!)6""8X!^QBUI=L=YN2K4@R@%Q?1U.92\$ _!TJ5US?
D!+J MT>W8<12%U5Q_V!3#F!-8+!C9!/T!5!8D+ WE,F&DZ!BMN5_ \$F(V_%^T(U V4?;AS MH \$G?
DEI>CG=X0\$Y+!I1+Y%SR^OFA SPU78TG"4F<.)-BW!9+\$<\$@ :D.Q
M5%IGV!8CW)^X!Y!A\$G&O!S)%/_O"YH>FT;=").1)?&.94E8"O/(FP%!4GB
MMT2_9EAU5\$8A9^FZ!03M\$FM!M_*/!^%A=_MM=M9;+MOHX9\$!K-3;)PGYU!
M<+^D:""7A(CYZ8BQ^9T=&.\$PVIC!_FHI>FV.SX18"MU*XOGH!2_-H1 %E!EG9 M%QW!J
(Y4!\$)B!XJO%>OZNHZ(PZ.S@C= MU9G11!/L8!D!M*U*#=#07P=16B %)00-5C2=[&%H\$^BTQ#U1*MFRP*%)_K
M4O)!^<4E!B'N.9.T.Y.)J%#JH;D&8IG=@C4'WVFCEOIEP-3;28&\$K M+R*9+6K82(%
!Y3^@LH!H!Y!C0\$DDNX95C!LP_6D;^25>WC=;M MRFFC\$HEBVC+(5OD7+B20-
;C\$Y10*5;=4).P53!AH;^9\$C/LN:80-09/27 M*!9KUK.EY61XKQ!+D MC_ \$#(F/OSF.+^Y>M"C>C!9!D+Z_0CIYMFU
M^OSKYZ.OH!U+!O;>.R'3F?S#2QY^_!DM;+ #C!>8\$EF4DDSW1@%^^8)
M1@23!)-2!>_>HKP60;1UN2^%10G!UU!)8""4.C\$VQ_""-;DPMN2+9';^*XD MTC7)5/^L!PD!O'2&#;I*D;!CEK#;
LDJ6BK""ZP3=-+CE#RV!L!C:X54!G MINNK)ZQC_YXM.S%N2;7F46) 3)*P>^)?GS7W9.SVJ\$(^G+L&FEG#6JO\$N
M!HPI(H%QY*U@AC?M#2D81GSJ0!7""P^6KS"JU#+.(XD M^N3S3S_!ED!&-D1\$+N@IT^OH

J_ "V7"89.POG10:1XF..78M3*DU1_5U6 MZKO.># 3'.2L#>=8@=1%"ICO"^-W@ "J0^M>4- 2*|XI#1&?F9TP"\$P6/
MJ_:I79:(;S/F'9TG9%#1M_YL:?)3RN4_0+X_*?N"KXEP<|JO/FK_*KFXI
M%KQ)1XDFB&8ES\$7X>MCL88P(ZA*W!@H>_=-B#IF|H7(*M0CLUZC="|K|Z:MLI(^B5/-2,3LP5P_-+K!!M\$96-
QQJGD_)WJ/3@38AP3/G&7 MT|H0^7.HVO_2+PAG;ZT.SD=G:IN^M4:F^O8+X: M-RW;\$0
>P@|A:|)XJ571_5#6:R=1+J2T+>S\$R7QB0?&X37J|HBJ*)U"Y-LN MN/2K(Z+7+12R*)OWC!
K8QC4RT*RMAL&7N!|UFFS+%=O=^TEMS'H?TMW_/M6-M(S6%2TN#M(R\$66| "1L.NYG^K=(;3'T2|Q-
H\$=^7CG*G!*WOSX|HEILKH\$^29Y_|@V7:3>=*8VHJ_K>1: M#2MA2LQ.?A| (74IZZ@ \$R,0X M?_N*2Q*Y5E5)NGK
C*F/T55*UX*|ZS=7P-0?*"P MX"34E/H|X- #/|1^I&?<@6,8|_3R7|) #BK2D&|R^MN?=.X5(L>"4Y2@>: MN?
X9'HJU%!/4ARZ<&5W8 M\$DQ!FWO2X8A41 CFY.G+*Y7N\$S|U|DD(0C3C7 MY)JD1&?" 3G.07:1U+4Y#)C?
ND6: |C(OTV|TA4.ETO&S\$E9_F9D>8>UX&2 MSX?YW&R4GG|GXP_|Q.\$P\$I?B/%_W.%_NN&+1CG)-
(Q>#QF#AVY_U9X+12YQ3 MY_FYU_F|Z@*C FYN'3&DE(=G|69SGIC|G)@;-4(/6-3'3=-WF#T,6
ME_"H8I8\$(BG#RRRC@C\$@W<FZVTS7Q+V2DB;0=9=C_4_#|4X#_M)\$V/#&D|A_/N+&!
|_U.@:5_EW\$&J#GBA3=YO(-)BSLCK(3;>*5P(Q.\$W6?MS'
Q^T"@"(^F4CT73)V#65|1#1#4|KMR+,@^.)BX6K%Q1INEY'N_53R1YR3PF MAMR?U#&2V%CSG.?-
=I^3Y&CD9N:I6.RKX VN!09/K=&7,G=WR&|^S 3+F7|U M/H_6KGHFW3^|P/6NY5Z3V3P@37%)MQ4NOG!-
S&8!^L8I2SWW/I|OK_-N>< MVL>8<A_*W7C0:F|Q10A>K5D_J?BBW_:Y,DO'.?L.TD|T29XAP0C6XAUI"-M.?
0'Z4K:F=HJU_AY\$|UV'(C@4)A+PB5WX6FJM71-.8WX9OK?_UKX+U|=-D8+
MG|'"SQ^&Q|_Q6.I6\$C^K&5(D0>@18W MT&%_TZUPC 5"H*7SV;)S"AlXO15EE7=P*) M&D#VTVL4;4CK=4\$L,&
(HOU3 MN?^65L#6.^HE;GJF7L^*^5NB|_ "4JE-38|+^*FS/RW4GP#R@=-.E"..5:CA
M6B@^"..#.%BOMUG|B8A2PR^>O_KF.77^0^6/:=#9!QPP<33|2|4Z",@%NHJ
M(LJ8M:0>0|K"&^44#2&|H5Q2>#00M(AA%E,JD)7G|I3*>O5TP3MX#6'9ZK=
MR8RS6#;DJ6(A5)8|@^.%T@*PS"8A\$;D5P2+;9,WX&E*=JWC_G*Y5)+T.Q"BA M36G^6M/&-T&#S#.T3|E+6)-
&9HNR#A|_H" X|OHM_(MPM M|BIY=8JBN29F
MXEVUW!%^1:SPUH|H^O#G>B:Q|:F4ZONJ|_>S3Q1.BBZT\$>|4MGK)J9FXL: ^>I M;"4^CO/^X1|AU>6-^=" 2"
M/UB'_8U>D^,@L CV#_P.E4IP%1;+;59=US M=%_X|2|B&E1R7:|X-_|#.#@E|"Z>|B9'O=?^Z':WT:|3+4L';JAD-
*&Q\$880Q.K|EFGAXPG L+2_?2 MJ/7H4A,6>IT"3ZIT=-A_Y6LGX|8\$#|RR|&B/DN|P8*_GN:\$YQG9NW^JNB+Z#
M.W'7;"G8@^QC2|AEN)_+MX4ZPX67H^U, S5;\$C&86" \$CDK7B_Y2-NWD%Y MK0|?<?
L=Y*#RPYS3P'0_-C"=|90:QS732A>UHKVA,USW8N|TW7Q%)2NB54Y 2KE0"D9H|YJ08|3RWX^P*018|BLU@C-
1/AXO(42N22?LR_ M3:??5A^*T82U:KR^2TXOFJ8*<|V6A|8U8.!FKR\$>O=' 0/16F'^B99%W:
MG=9DVXC;KQ99K|E%"J|56G,Y%<2;SB,B|:%&_14+ZKK|UMEJ,RDMW4W9T MX8|6"CX/W#?: 71H3J0|:
G8,20ZJNLUM.34GW_K)&_#F|Q1*^H*U(>4|C M9G5C=S|F)*VZ|>,|7GWS|DU_DUSAM493U4.>QQ-
0_F'"Z/0,X):#0SIW*78 M>*9WXBFS/DF(Q79H-)|Q)PO%G:3N#2%0)B&>MB=KC>=&VVOY|D^8|_T4_
MT_J_-E,QUVM31^GUK#UGTINHQ52MB_-|S(W|M(LE6?MTNXJML#_8X*6_M;=06|^<1 DV(1RC|CC%-
=HP5WV3;6H|Z_3UE1BX6_W=S@""|I&UH\$;F3 MS0'94NM;TU1=M|+6:|/|E".295\$TD\$X|K7>(?_C*4462
4.%K(N5,AIUX M_"J-K|V_+R+W)&ZK:/C%*_+Y|TJ\$*2Q|M/C>BMV>L<|DH5ST<);C2.9
MR4GAH@SN("HJZD^U4->U:VME9?O|8.@ZOUK78>2|E'O%%"H+C&9Q89)\$_M.#G\$8Z|4V|=-
TD,^AN;=""/8=3K0Z(|:UD|BO;947L%!.KBV|9.Y|2|9C M^PWOLAIWHR:T|_SA1,*
QG6A'Q:MA0Y")D/Z_PYR6:F'82?I@E5ZU^3=C9&%LLH.X^A6*AW@8P<-'692ARJP_|LS|^R54*=@PM
M>YR%WGS.)&^C|S_15W47^G=8D;L9/AF7W7,J(AU|LOE:>86DE|8D+POU??
M:B|D_0_7:R^6'O=T2K5K>SN_|T81CK>_HE7ZU\$'E*|S5+^N^N_"ZN8O(82,*1/?"
|+WU'_6_Q69SN70_Q4:#3)'"F5O|,SNQ(|H#?=S4|Z8632L"3UX=;77U?9M:#
M9Z|WYR|YEMGN(|5=Q0NZ|S|U2H&07"@7:_LOND|FLN(O>_|TS:O4HC?I5|10M\$9|/E^WG M+J|
<Q*ROZ*SMN%|8FK&E>3CG@|HT|19S.A=L|^1?2R#7M1QXHD#RJ,1R1A| MHW"#1#U9.UE/B63@4/5NTT;NF?
|L(|1*4XZ35?F:74QSY8DE"U|L=-@E#YK@%U.R5+CDQ?|8%V(U5T:N&VM9#_A(FC|H'|
(B>2*Q^V(C.X>TOP))3L=K4CP=J'55"/|9\$8)A|PE@ZC0S?F M-AD 346,X&I5H2|&7*7,M-*W|F4*
|X|LE9ESJZ9=7\$14.?IMHWXDJ(|L+< M0EK|S:>TG60|;W;6|9>5T:SO_N@0IR'_1\$3U(|L8XYTO/K,E')|U8#DF&
M+L:ZT1(E)@T^">^J5;K9Q.Y_6X>?C%|J&=74@Y9ON54_6|R|E^\$80^QBK_2/M6K_1GTFE;7+L.ZJW_A|WV;,*
^3|F#|BPW?|8:3DJ=XH|!_IFA.F0|5:E MR\$H#+!%U+A_\$M|:M>|66;# AQ|6:CL(340/B"
I)#18N3+TD|46P0Z0=@V\$'_M>D6NSFLUK7(PK8.*>BBK|_3Z6#\$(^TL-|BV|R|0+V'S/3C.X|_KE0;"&B
M|Y2>7RG:8>0R3?E|AJ6|C#>J&4H9:1QSI^8R@Y012A:@D|V0GQ|K\$=| M2EV9F&BE.M"/|PUOR|8?
R:)L)U%2S*P&55(%TGLYP)Q|@%\$4(P\$24%!!7X MUATR>)|YEF|>19^ XP*=D.UVC:\$GA*Q.&"UPI'Q77M-
OP+GHQ_2=775 MDKB+ W:XXN>(7:(|854. RR8(|U2:I_:%|QT:VCD>DWS Y\$'"A-'6H=X@KZ<^
3L*#E|X'(^41Q)#VE|##P12D>HB'@S:BH@_M_AO*R=IB_'#4*)HIV|H2#4X@OOKR"GRQW|+?<
L730|2.98@/P#|@>+L+L% M,3Q?3JFU_CB>&|JXSB+5X1@%|6#SKV>_W.??2\$4'2C*">S|M':T+KJ:TYQ
MQ5^<9^Z>9TXX33G8S|T\$&)|@_2BK2V>(S>154_7D@T:%E%?0<|/6E9=*FI M=M%>#->M^|G4J7*>^?N=>=
<91EG|8&3?5L=XKN"QJ9\$X%>|GJZ/1P|5<9> MVNHEK>QD\$ MM<.@WX?BSYQJF|<8?54?5IK M"2-5-ZJ>TX*
T.3J|7#;|H@HJCG2T2W|I^NIGGX#S9_K)GM^_RHAZQ|% M-/ ^XQZ-DO\$6*|*40"@>:1KUEO+5
Y1_.B2_\$0F@9+NJ@|2\$FQ"D+=4S&Q MYW;AK>3!ZROQ>Y<-IUB7*U+&_C6=X|I
M;^N#=#X;_C0;:7D=YY#E|>_TG&6#J?CP49"XL'Q|>N:U+^G7N%I_7=\$XH" M.W^&B-T\$??
OB#|\$|0|0>)43LUIH=PU7>E.^*Q4M+IE\$)|HE^C""^S_7*_(3(M?XY=W: ^COERX0-L=6G>"T+=>FX@X'=G-
XJ3EU38Y4::@?<4' AV)97& MHVPIA0U=)!#<4#%OP0^D%&V>453Y7(G%80%06RM(\$ N8W;L^>G2C_TIG
M\$(T)|_Q9576Q7B8_GJT&=K>_W@4/6LRH@6_1?@ \$R:FL_8"&_P\$FB=9N>_M>87)?RPXCZTAE%Z|2
"S(AO"9XE|D|V%T|H|XJEDNVS29TX+J+B2K."S^ MJ!_IL:ELFNY4\$D:Q+1,0CQRK,K,-A,@|X1D)8+HK2,-
=J>2BL?J?U=" MBH&6OD*;|I;=,3SK|K)#KS@*VS2?#_F_-BI/2#6%BTWLJW6G\$5X4744FC#E M^CL\$J;|1=C|X-
FHC(^CUXNWKQZS10AUGLB_L|I|=;9V%3<2W:X M%#X#)E%50J;PUEQ&#O&:7E0|G|J|I#^#
|&KM^L.HWV"1%WZ(3_E-LD&R(M;IWA V7_WHR|B\$OU35ZIL;7-6O7@W1WL0.HEJFKG|U|S>I%|NN*9;64)VEN-
N@3F@^PH7_U<3KN MNK*(G|6NSCW"/&MDI?KG;_-:C9CO>RD+2TE4;O%CG_XVPVN49G#70&\$(^L>
M5H'"|;L<^E7:5W:V:AFCT:C_Y#48'RAG2%Q&G E<,>2:XS4RZN^SG_8V9C
M7BR>KZ@Z'1Z.6A&NC0.%W#;5XMB.:9.8G" |KYFI?|6X|?|6N%|4/"_21F-
M1=P"1AZ=%:8!45WK1#_8)FR*XGAQ/B%_YPHD)TD4|JCRH;L:7Q+I@#L|
M3I4=C_N0KW9RCQFJ75IB2<_1Q|I3+2P.+|X|T\$SRD*_^|_ (8UGB(^JGNM+'V%"
M;X(26Y4SU@QPOT,2G&23|DY5'S6=?&W3*1RGLV|/INQ+)|B+U<=Y%7+0|V3= MWV2-S8Z*%*(+OP|TKV*?<
G<_4_..N*(642)TIB0B(2|SN=H|&W8^YU&SOQU M^PNID"LCIAI?_1V7|S|DX|13YTA1^?|_4|K:K&XN\$&
<40/&0D'F)B|Y;1 MJ&_2FESI+L|5:1_2I^0%*6ZDHI7^DY&A|H_F|>9|KN-!&+C_V7H,76JN<MUL0L_5/YRA,
|73ADRE(^H3RD|&9:)VXB3SCKEU?*EVD|T")_!R%Y#|H|*8==5<\$DV5I&YBW3H%
M)IMI0GLUL,@EMQTW;?L_1%WM) _&HKE9U**6 GB0LOY:L/_Y+U" +J@TXIE0 M^P6&@O,LX4S#X*A?
|F+|A2C:23L(7MY\$+96=*OFON#SS.N#7QT-0:>^SM0XXY
MA^0P@GR5\$|:7.28*5B)85H)B"PL73E_-W@@7*UX"\$^&^",24C-VUT?"LOB\$?N M%R%Z?|P9BLQN^N@>??Q-

Q52I7<6Q:6WLEEQC)K*NHP29&T4LN.B2'(612,YG M*AXC->8:&5--
+>|12EC*6L5SH#DZ|*>V=9+IHB07EJ:.\$W3I8W6_BRS->|_MEL#
I4ZO4ESLL,WDES25^9!^V2|EISZ>0D9'OJ46ZM)*ATU3;NX M',/PFL9(I(+(+>A!'"?:P27U2^,*2AO.PJH5J'@YD_W53
H^TL M3XMI9B 04D.J'@|6:V.Y)\$ _|HEN+L+PK|MA6;|_PI+L.S?*\$Q+G%*OIP3# M->,IP%
(*)>K1=3(<\$3I9R0S)K,+VW16O%PS3| MSGG(JH*I4#:#U6P*!0H?51UJJ%K\$44JATJ1T*3VH-
|8N7H^#UU3)3.FWP+YI"EUG\$.*5 MF|,H5|3UO""QTV"1|77%>\$1 ZX@3GG((W6JKEYHTAMV*2S.9|B\$BP3L,NSU
M|GWT6N&FX;F6\$2+I(7%*,:V|AL4/HW(A5V<"Q_Q0%)A<,>^87XE"Z1*,0V M\$ _5EV2H>XX#+
P@DIM".OZ@*QOI""XOC"ME0YCK,QML0J5IZV2OJ8N)S|TR MP(L75%
((K|!V|9I#Y;1S;&R|N8C)E/%|C.U7U@%W9#V| \$|IF=E(ST_6H)# MSE06B'&>N;6%VDU2L@EA.O?
7&"6"GO'Z&XRZ7JR(*\$K0H;IF(>_6XH?DHPD M1G/#5)O?K2@VFUW;S|+Q_4I*UV.'Y>|E6LIY%\$^84")|_G
V08P%6A M94^_U=|<|13,20M5|=-|JW("K8"?|D&RV M1-&CL81M>|H""CF:5N":L/7TJ5)(3-Y#2":R|@2=U?3>'2
JRSYVOC M|12^EL%P9%\$CT=-FHG5DE'18.DP5BB7Y?O*1H*019RB* X^5=4,<65WB
MEL.M.W=Y%>3YIW>@I8|C2T7LB\$V|C"L LGU|?Y9;=(B2+4)\$91;ECEVPJH
M#.>_G.Y|B'KGDEF_((KWN|KE2|+)_W@7M|^Y(/@Q%;OG/L4IQ:CA35LR6F
MGF(Z+6UH.5/9@|2FN^PS4UOEIZBU+1N3.8%0N2%#J|V_6LK)6=NIV**\$K2 M!SP'I^7,U0)(K\HC:Y,+
IP:.&LBN8YO>)&#3|NK6UY6X?""(Z*3Z4_2|?
MFV""22A.YM.|DP&8&_G|P%O>OV^O&Y.|8|>10E6|7/_PCYWI%7\$&|CI2C@GS5_M)&Q*+|_P"GBPB'4+_F%RZ4(
(#|E5#N8?>>6L"N|F|_\$.E=W05*+K0T.B MAALG|W;8M(NN;6>7 #HH^CYAG*3%?BRD(-
>V"/)R/B7-.PXN2=AS:FJO M1M42*6N=-/50N_2%Y5"ST&W<8SAS)NZ M."
(*S6|Z|6BGG^L;Z%|1+9YS0*4L#(L|\$0)|V9@YK=L|L#)|4S\$53A_J35% M':OX=@Q3V\$G@K/8>8^!_"|2^|*UO-
28W_AVPN M3V/2|A)H V&07|CH;E&(E-JXKLVN.Q7-,%JM=RC'XY.XRBP(BUMF")|SI^_10@Q|?R4M4:-
Y_@P2_#D/_IW_)_*B&7)DT| M5|7H6-?_3EC^PR6OVB&_LD_0*+N/N*W|&_00?RU#<<?&?8U|@L,"")_*!KFP|_RGT
FHWLO%<(_MD)W*M6%|S8 M.OC|7U||CTPF?%H*%E^&6H|^\$BC7&_9;^&ID|3G/J*+=?KGYQ'=.R0?T*E1
M|X9GQ8FLDIS|9E/O:L|?_B29^PT#E2D.YLH;|'|&9L_B?V3VN=K;^C3DB;LM MJO51DY^|G>%@|F&G63
1&B/_BFFKD?IF6I(F*=-MMP#GQ|T<=AC\$HCF+_6E M\$%&AA|_82&^L9^3A"ZFT\$F8O;G_4^8?E6EH=C/_LRY4("P
|2S52(&#S.' MPD*8%<@|B&_L%2&:SODF^_@WJV"/7MD;892XRZ#E|E.1^D|3=REBL|UA06:D MEHJZ_|HB>
|J4DCWJ84G58WKJWMFR6CM/4N_K(1NO\$)_Q;/_9U2MI'E*|S,XS MA8B&ZBF|^_Z:VUM6PW55I39|U@_U%\$SR+;?
|JDBC2BA02FEDGLL#|4|(72PY16| M9D.%-:">2P'R5|U-S.YY1U5""283S-
L/>%91|JOXAF45:V5B|7R0|/"^4KAD52C(S>CWY07R95CP_ZJIWM0DS\$?-?">(>|>7M0NODCX/_MB@(_4-
^+Z_=Q+Z;Z(I%B6)IUNB_D|R_X_R_73|_ZY'<<\$!939;HHBG#\|HO/_M(I>763@QZ^E_/_|Y=^=-
D%@ONB.O'SCEH2D.G|*6C+71*N4SE)_OXUQZ1P89| M5W;_&_W_Z2QEJ_EDRH|2>88'(LE\$S):@7+03EY>D4LA?
Q5(IW:|'K_5K01 M+KMUS=<:_O=IEVZZI3_R<|UX.0\$72^)^EYC;_VQ80'WY#L4(P>2QNLZ04_'9 MP_U_1NYO-
G(J\$1):S28_%3@Z2(@_G_7E?3O5XX2UBH863GA3VSP|VR+|@6 M*'YEY^
M<"H&6PD%|YG+|BVX017|CO3WZA3Q|HY)30?N<_JD5//'"3;0@W@W3,X ^MR.MJA:-4?
|0&B1&0@;:"N|E18_7BJEXCM|JO3P8O#DSVHU)ZN/+OG(TV<6O=V3 M|U|_7CT-
CPQ|_A0T#S_Q"H#P|06A^/QC;UL>*444L3(V\$@(_MF_XVE(W(W M.TJHV|J1?9%WNYKEO@EM%\$S-T79|J3&
4/5:RQUCT^>_VCZ_V_=3RR|Z_@_MV82-N|W1@MU_5X|_:.QVFW&W""|"\$B4C;_>E6N4;ZC+%"(P|S4
MEF0"8((%01BP@WX?&9=_D1>)QD:>MPP>.5U6))8,BQ;ZH;+BL+";_I&PF/_MZ|GY4KFS&#^|QCZ|US&J9A12L
472K|DL_"0F*_F"/2|U_LE_LUY%_V=5_Y' MFT*XU8*?D=30A7|C6Y(T*F4&KZ%'-Y7Q?3@F|HG"BR7UWU7H
M%|J\$M(V0I8%5|9R)&8"V4_J200@L1=EALY\$(KEG,='U;_&UTS.M"(I<>?^:A M|ZFL|B/H*!H0>+S">_F=DYD?
Y93I8@|QG7J2AWATKLC?L?I#?%6M M+<^81?5APJL=3@TF|=F6?
43?_Y10ZVV&|FMU%#_"#LE@+BH|LW%*C1N#&|_3 M'\$)W|Q1/9Q?I3.6:KQAI|BMO|3&_21|Z,MF6|E|)(F+?
V\$#;_5T%>%=97.R\$2 M1N#|ET#O%_VG#=#HER6UB4"G_Z|H8HOAS#WV_+WR7L)01EXN|9:T*^UP->
MS/RVZ5.<418WH2S^<\$99G%\$6OR&4Q8LI|N(&_S47_G(ZC_42IA|F?)7N4@F@0
MN2&@E|ZT21J.WOY4'HL|A\$KJ\$'O'\8#H0=Z7)-H"V7#;J#|O+MC_@J(|0@O3 MBNO=/^W2'\$LH&?|_|/RZ#4/&_IY:"
(?&EV)-&X'Y_9|U4|UTFN.<9EF_M.2A&W\$;_VWFMT;2|Z-MST(2XSTZ2DK5?//^PX_-B=_865('N\$LOIY_C&/3 M6F-
@+)|YJ&S2%FY&1#*HI&R%XHR5^A|3TSA>065DZ|>)>_\$.<>D&KJ6&>ZG"3=1)|@-
_5;@?"@^&UF2|GG26W/T)4&L%_DD&_YP;|1*_MELYP|1|@8%)9LAW|7.GN&>=NF/%_4-O.R.1XLI->)\$T^
|LBX|X%#EZU5P3X_M?M^-J|(BE;&RVK2B)I" Z;!*439ON_ \$PK(Y33ZJK MVNZR;
(0\$GL\$NPF|MDT|FY_C\$B0Y)F8|>4G.ALM-"(9;_E6R'36#^5I2>_M>P_E;EIT%\$5!_X X
&"TH^|W;E<=E.YI(^GRV7T|/7Z_WOR>|GER|_=-28 MSC6VNI;89/00/K@I%_""^XPI_2E?_G>^?Q.7NK+
_H|O_CLKO?_K|^|^G M7TW_|ZT_OP|BH|'A|L|S9OV|I'7>_:(FOOW|3
M;O+7X'2|_02SN'GVQ1|_653|JCR\$NP7_J&)K?_1X6?_055P_Z8+>M5%?%NO>S*M?_
4*^|6QR?|3@|;|>BW\$Z4*^591-0"S5@YE(3230DXEA1#<31\$^8H|1K
M>SKPI4@%N)%L|TA)GOKUJ\$|_92K<_DZO0&R/D25.1P.HA|L+EX2M^EPQ M|5<|+TB|D);Z7IZ(PY=R
|+WU;PW|M|OR|L%Y'|@|+P;_KRIWU7K9Q@9 M';\$ _<4G@H#|G|+>QX4M/+_W5FOA=7:W_676:_PB_*Y
KT|'CX"+K9+DG#H M81RRKUO#_VU_6M&_H=#6DB*46Y&=#|VQT"S M_X1.H%4Z37)5J6>G8MZE7A1YJ?
PHTS7.EDUHZP/9.UEX=%Y8%BWZX->|ER26(S)=UBOO_T<>QIE-GN>|X"2<_KP&32SU"R>X4M
M|;EEAY",==A3D-TQ_#MLSD=NS+|D-Z5NY3HV_(79GQ/KD^/1FMM3,RZ%X|D>FL|MKZ
MN38_4L_RV(8YYSDJ*TGX\$WM|ZD|H%5|88V'L_%UV;4F5"W>6O7P3_G55=VVS M/R/W|GX2:>E N_9ML72LS2T0*SZ
M#+|YS_)A56_MJFMRRY%|H&%0+CEP_UF_&_9E7)BHFT(C|&N+&Y?SU_94R/A_1WZO;_G_B
MODAYL"N|YASH|U%ZQXSA\$S36AX|^N.O|+75HHA&GZB5J031SH_|*@C3=|P;_MDXPXBFI|>4W*|
|^|0A|Y4:V\$2B|V6\$\$.H03F|_R=VVE|9T\$WOG//1Y9O|5#4N4_Z4M;=MQ M&O_9|QS-&#+_N_X^|_
V%NVT@_AO|*RD_RE5P%T<3|RTY2I?6OZVW3V*_E?;_V MOO|J'R2'(F(08'|9G|H|UTS_8D2
\$4*O+DN^85B<0QTIW3IU%Z)G_-W2S ME?G*W7MG?70>-D%|QQF?T^+P7)W4.R<_K0%
<|S|W+9ECA|>KM/F3|G0Z_ZX?_M)2&Z_5H813J(|SOW*;ZGQMZ5_-RVP?_M.6\$0.YCPMB/4%YO|FI%WLE#1?)Z
M.O2M@_WAP!_SF/FQ|>E8/7>4<2^#M|J|A|A%L^BG|DC866OWJ?F/>ZFNP?M47 MG'B/V>3Q-KS;
(LY8LT|_GQ+%;_H56"E|X.X'=?R);_6QO'2_|D%|43|0ZOM|@1\$|+7|T3|45,A&-% M6^PL|H|*MD|Q
->Q(WT6=^%B#X<59_-92Y6332'|=7/1.\$04,W7R7|&1EBQQ MG\$S6A*60B/AX<)+ZH7SQX9V(_S_O\$(RS|;
(|TMOS10LGL\$;I%)F1"|E.8F8 MA+@_<8=FK1DB(HE9'F(SI=|*E)J""9:44\$\$/E!\$G\$G#3_4+^|HVK/(F"^D M)GT-
B"PKV2U#3L?K"?_NL\$TG|3+NP"G6.?MIZ.TOVK68VZ3=8T6.K^K6I9
M"K4L0|7Z396E5"U+&A:DK.HRMKQ|S\$1M8;_>|2SQ)|+!"=8|8|32&9N;H=,6UNN!_*20&*D9Z30|T>N;
M.F=APU;_W|9@^B_6JA_%>6Y%Q&9SU&0R;ZBP+|S|=0S"">S|FZ_X^6"+M;_9+EJWK3*Z+3N)9^M+;C|>?
|@0F231SW9N\$ZKHZLRL5E"L.\$291|XUZ*C.MU C|44+\$;"B%+N6#
MP6!%%4W6CBAG7%#>W|&_NM@O'ZF02BJ0W++&7A4HC;>\$ M3G/CO%"K1|G|5|6;/S
""6<_6:C8H5|SH9|F@N|FQK|5G@O|_%>@_V'=&M)/KE_"VKV-
3%_|\$0|E&R%_Y1ORMH|XFLY|@2YT%EO+QJZADD#,\$I51#Y"BR M>G_O|@?Y""|HJEG-UH
Z|ZN;1D^4@^J^"PYOS@+)|E_-S)KEPV;8E7@IY?_5

MFC58JLFZMEBO/L^D/H/L7J9U8:/5'/_:QX@M#M^G^N>M.%S;_MJ_)(F_-U137\$3F6Q:2D
SNG*GT:#D;M2\$*K+!+!#_@M6(1%+>%13LEQ1M."POV8=4S9:U!15)P3%:.\$&Y1XB@BB9AC(MW05=
_7<,3WWQJ<4A/FO4B=U2DW:~+YM%6TOM-TQC)\$NYZ VH:~6&E%IQ^ES MJIR>13J
<_BRWD;Q:DD^+QJGPG&ZR)Z(NK?K%3(97/9 @HO:IP<7A+RB;/87R MYT1YVE>&RIJ^+WFP\$W6&:V>*<
(.2)R\$;DUM8M(=+!":~)4@+Y/30PUWX M6V'Q1-
@+Q5#+O^V@:'V4^1N=PF\$#='QC<8K=+):~A4DIT+C,Z)QFH1"7C\ M3(5IE+4/IQZ^NC-
96A61NG\$O).6\$_.6K\%6F#":AEZT+!9.%%-)(B8.I#VJ M1("U#"0RPKQSYDPOHUB\$2&-72P10Y8I<:~*Y-O."AZQWE3-
E@/G)*FN+5DB) M_) +QD3DKY#UGIBIO798 _IL<3Z+-(O)SQL,YY(ED5\$N873-E%):D:X3/U.H
MV+YU&QJ#>V\$PMRO1O244&*JXO:~CW#6-\$%124:HH.OMA MK)'BUX"1513S)P+\$HI(Y8PY7_96IKOGX
H)PVKW5""+K#GSU:O/ST;_SZI9_~MU>T8I/DK>EZXQJF(X>\$IL!/<I\OK!=KFQ7+-Y>Q1O/\$M:0+XHRHFFH&/'5I
MQ2O:>XL2>:I*+0LU@>YD@8F(2I\$HF1K)1ZDQJ3V,E'6#?FTJHYUF(^6QIE;C M38+?L0F-
=,~Y3Y:A-V:7M+6KZ,^\$O\$*17^U4FR(UA<(W%)2PJ6GTLG*~3BE MGY=Z1Z/L&25)5YKT+&
_1_9W\$6_WSGF76NF;HH:=07>DUO3HF@RCTI<&:E'5 M%F7O2I3@T=L85W9+GRB4<I9_U\J-Y:*XZ?
\$R.DO3ZP*TT^U7D?~6 M<:%X^MCV,GE2&PI<16T2"Y/Q\$SHG\AJ00J_4 M(CRGH\1:59F&+I5_'2IA+20_4Y'?
5IQ^P6S\HY1MWW3R^X(CI;Y,C32 I+@5: MB@*WHO53FGK:=/K#4D_~6J_%(50^HIF.G 4(UT+1BT,7E=0Z;:"J">*9>*8
MHWWR15=V8CU^;Q*XNOYSHWV(.R15XLIV9:79WHS^~8VYI,3CK^RI4I4>272S MI2@PZP&KJY6+~35_@H1M?
BSMQUN-4D#-IMM^I>:Y#ZY:FI%M6>Y'S9(OT MCKW\10L5C;^~29FZL (I(&MZ*TY.#EK>AOUI*'=5=36&(R<,
I5=C4;Z;-3= ML&^~.36C\^AK:I'1_@->X4^=HIN,NW:X\$7"W1I:Q13=973AE'8WV7BQE3-[M]
MA9QF(40.DH4UL=I(XPIEU IQX,R:YN*~&=VRAPHYS42;~1NZ;2KT~10I M
T/O>=MJH0HS^82LO3^J(8>I%Q"E6I%M-C3/E#JHG;)7H:~8 3G:XOR@ M,T>:~?<
9TVVIO0LV9HZ=GZ[V^J;#~33.Q<6:9NH0IZ\BP_3L+PKLI@V*7JY@; MRF1J*F9TVU#>AH8BQQH-
I4%M"~T*AYIF45\$L?~DIJ4I%S9=BZ.324,^@/(L/U\$ M?~6OK+YVB_T;HOU*~2I70S>~'=F&,IZ>2R\$:Z/VA,FT;BAU;
HMJO=?B4JLS M1U#?Q)1VEBJ+=9>+Q,ZC4PEUP?V'O&;13U_@2/ETF15S80IVA4ORIT>'H
MDA\AFO:~K\YXOI;5:SS"O=+^+0_:=,@P8D;6V>D~)U)9B_@I:~&^%?&7&X@U5_~:HJFH
JKIW\$V\SE/1DCC>\$OME;U%BCEHY<9(M'7:F\ZDZ*U-I~W3:~N=0/0BMH4M>T76.V;NFF8*MWL",#1S8DB9S)/(A:'
MJB-^3>V\;@.IE8OQ7\$F JAI5DY\$SM(9Z;Z00U%0\$V89N#>IZ%AI2GDL?&EBZ MJ7J4'S\IWN#)H
<_B\J5BMA0Q)BUL\H5:H+=V?KINKQWU3L#"334"&6 MAB+GRM8-
8IA6MU#K\^I19WQ*AI%9960;YIZ^I~.G\I"TEEL7EI<&^W>H;C=\$C
M8K%QMF#M.6=GD>0YU(>&J0^&BGH5I;:0>H>&:O?VK#%7M-L0+%XF15Z9UDCO
MF_4=NPU*KV^FRI>F>?/V\9>W^~775I'%~IR_/47XR8I^AJ6U-K/^7IX;HJO
M1R&^)4N(A)R>IPS:O=RPJDKF:2AB;~W0XJXW3T9(XIC+~.C\~W1KU_~+<H M4_36)GJS^@.17WOJC;
(V16W\>1B&IMIKIM2Q(Z:~19I4M_5R@_DIRZ*AB#%U MEQ4-LXV/Q.O:02&DR;_~T MHW8:Q2)C1<8-
VGB0/13MP9F*6\$7\$ET'5I8YTLTZ\LIS#/CUM#4C9:>LWK M M\SL:3N_JJN>X2J&J-5;=1D&2UP4.VEI-
X\$>#H^=J>_M\W7#~.K4A<6L_XGN/S\IG8TU M6@4 S3Y^V+38L'7;VC;IKO%'29 RI9"RJ?=
I\U2:I~O%~E1R08<<~>"/^=NO>_0 TD5)S_DCB6)WMCHT_(:/=TF@N^_ MU?YEH%W2Q()IUP_M6-2H%WC 7EM#
(NG1FR4?^3Z4^~KZ_QHF-O?8_R3\$XY M&<4^IN+@!IV^@2%IHG7C*%5TRYBIDIGF^@)3I9P! MML)P\4_1G
5PF5@+9H4\G%G,OHV_2\$-FI#F32;)/(\$+K%~&^*8#7W/A*3X\$ M..I?I\$%'RTAB="TU6")I(-%F.X;UH@61_I+TB"
M*16%P&W\!~;%/XQ="DLLW"IGX6H2/_G(.IZ#LXI0CY"W"/M; VD%:~IQ#+LIF1P,97;438*0>~.IK4-Q8 MB%?!OJ
7B(7L++1I#^~.KYY,\$7;Y? M@3%;H<40%~@10R(MIL=9=*R82>LXS8Z_27-VE8R25L733FXW'K2Q8A!^
M=4I\G2X_)#+MXLON\ 5Z\VO\~.Z-N^5?~CO^CID#7SCA7P.0PM^8>%!W\ M6ZV\$[3SM2\$9#1;~V%43(~/8/*
F(="~+&^Y)!("PK\$Y&@~W\IT14*&>T MF(B*%(X@~0&2/L&I)\$X>~:~O45RMF!-&&MP"7IIC\$[88LY K/I:A7:4OH->B
M/A\IF3@A0T\$5>Z8&3P@2V.TT>OEZNIIZ=:MR\IVZ66'K MC3^1;2D_IR=6KI+ZM.&K>%)3N\>
I#8@I>I<5M;"L_/51)EM#BJ#~N6?*"AR M(VO\$1(B#1HT<&3X\BE,JW^E56%B)
PAH=KJE"C\$8R=BW.J7/7"5EIG!^?9
M26RT9V/(@)T6N3K/5^U7WOWJDL6>5I2(-11J711HM5\$F>J.YO54G,D^LCL@L0 M-
+I,41<\$<005\$G.+6E(L>>67M2^>>U6>[M%*4)K%:~5K<96A*8G2I"JSNJ M_*B\$UD(%:(= &W))B-
6I\VOQT*~T:WD:0Y:IV\>2>X-2&_<^R8AFY9=:MI M*NP\W;LP2EK.SH@*D+N;^%Y*VB9\UW4UUIH&S/#GYGZ@=7
MFHU\$&D~&HHTF&FHZ)F*GJGHF?(U/V6">7N">2A":Q6AU75\$*4)3A+;7#(-& MS;IHO*FHF=G8PSI=HN"?
9XYV9=14X1FR^V_2P% MO=10%+&U4"/;4ZS&DI<@I\$T5+2V#_8Z3Z.HKW=M58+64.3TI%&_46\$A9P" M/BQ%K*~
""*GSUX*QPEL?386NMNZIO>#CWEQ_HDP=IB\$B+I0C>""I2;_SI<I_~7EDI
M6ZY3TW=RM<~*8*=R9^>RWUPR.HY9N"!I M/C,G&T<~+^ZXD3S=,&~;T7B((%TNNPCLYE212'#@+M&@%
(3XXV)N\@+!9. M^~VV050,ZXP=_\X%OAN\I!~2;=R0FKJDNFT@#?UQ%P^~8AH2Y\$%N;Z<#O;
M2<5DGF0,TIFXGHN,ZDC42&IQ%TMG0@_XIFS&D/9QEPM9;X\X%\$A*N\$LE>54
MDLD\$~;@I8ES?P'GB;X*F1BD%I;V2(CB/SD@6I=PZ7^C0&C\IH_O(WLO" M"7_121MR0SS3I'_BQDF823;XP6-
+JN;2G7=)@P'IA8O!"" @/G?;\$4B4 M1I&+UQ0<9&KPMO7Y);J&XPBTJRD20MCN10P:~O.SQ@U;~!OV/U^@U;4Z_3
MM9LV~\$6M2:U)K4FM2-VICFSHW7/CCKLC~2R_JCIDWU&52;ZL;~&M\0%TL M^~(DK@NVD8>)JNISENN7A)C=M'?
4BFR&M("O0>QX5?(TJ^SX2%~KFC-WJ*~&U MU4_*IDGO**XAN\;SXDJM6IE:F5J96IE9V"2L\9;~MH#;X6?
N\K)*ROYMA69Y%U_L4 UPEI6;@U,T\ L2I2R~\$0X6:9N+&UKLG
M&7FM<%/EW'3IC2K@4KB1<#~.RU+EI*FZ;@9J+V\$S# M9C5\$55KC)NU7K_~ZR;YJ*&WNDVKPW\$S>VWC-
/= &Z;TMFO?_B*TVJP_OL6Z(52_M4O1\UV\U1D\HW&AVC)UYJMMFGSW5A5T^~2=NCU8-R;WLCE9M;~H0H-X92
MK?@4K>VA0W1M?="KZXE3M*9H;0I;_J@%:EI?8U!R!G3VK"G6Y8BM<;@XXQ) M;01/UF+;JG:E&KBJOK*&8.<5
6(68"HBLW\I2(>:~Y M>)E"3#;1HV:X*~0HQ-1 C*J247A1>~%~X:3M>5_5S_~&BJF*;B9=3&?W/71)S M'~#2_ZNW\?
O5&9^T3Y^Z7IVOIE?WJ_L;~<(C5%:GN8;3C84I%:8_IQQJIF#~6!
M<2(7IF65QZCN5/52;~&B>LLU%#&J\$+~9>~&IY.W\$BZ\$R MR1N*~&7OMZ&(477+S43,B<~;~[PHT_~PTMQJE-
EAY80;?I5GOM&T5M M+~(VNZL/6MS'2~&FVC-UGO*JOHY%:VUB=8;W;3:&^Q0M-8B6K-LW>JW-TZ@
M%U%M&~WJ&~MGC&*UA2M\I1#='3#>7R; X^SIG4NKHM3=179%>IC-Z\FZ.6IWIE>:"D1C MS-
Z8GGH@1.VI""#^~I\J=N9M5*IH;"~+6MA=0B%&(48A1B-DW#5WA11T8
MA1B\$F.8A1G\$RA1>%E^/U;E\X>1ZM+>C\7GCY52"G_QXKV)G\+&TWD\$)I&> MAT<2Q>YL=6CH#~
>@_UB'CHG0^6^U?I6Z#6D?~R>I<_UK+/^PX(6%&AEC6"0- ML5^~D>MFI1^_OL;+CKWU#
<~@K5\963G*LI^I~!*"AAIT10^~A/O&0*KUC I7; MZC7IHGG.B5C4V8I\$5D=;~K4O\X9_~R*M9;L\$TAP?S_~9^A:0S>1-
I5\$&I1 M.HI8C\G&E\KFSC1G\FBAFRJN;X6ESWJ9>I9AAL(Q; >"52.1U\H.R\ M0GBDX_L)8.XO>~.C.WIUV-
~%~11TMJ_2I@&~Q0I84RFQ)~7&B.5QWS_R\$P;U(ONZZAKML(I.E%~H8,0
MO4;HJ?2"\$Q8L;~"~P7\AG8PC<6<~!%~&~.2^<~"(Q30FK(9"Q%DXEW1R^VT M+=IGFSR4L5EYJN\XIG@I?~
G\~[N;W...H))X^RT2,^L7#Q%BDX6'/C%&~MMJ*1L8VULCGDZI>G?IPII:Q.#&:~IT&~VUYZ;S'~&DAS:S>E;_UIK
M\~*I;1IFG...78I#YGR\=F;PP\>_I^~L(I1?EP_*MXJ_#"8I8#V>QH<~;+ ME,+A"8F.7X~*P\$)>N?
B3TYBU;~.057Y^~13^/(QSP_16U#SR;^&~>%)>N7\ M4D9,FQ@4QP?/P=JQ*~;I6A5PBA<=_~.R8E?2;CU_?
_Z99^O6^~OTI6' MN3N9%RYW41!<2^1ON\$=XQ4\60"IR>~RU&XXB\ C&A*\$U9B>W7UQ&21N
M;R7QWU\,WSHS\$J^T=VXT\8(H"5E50B>~:RJE_Q\X3&D.NS0\Q":@VTIS4%I M#G4UAQ-QCFH\~/_EZ_~QXJ

IBY7^XV*E:/I%N3+HJ*(I%KKLE+*EMUVV<#./MM8\$OLY%TI"/IY.;JU5I#_900+^A"H^\$ 6T<3+I-P_H400-
B8%W1^05 M?HRB!#[ZG(23.?H/D/KXO=HMFROAL.+O5:C9-2G)-0F! 1:AQU'Pl@:8 (MN., 7_2?/S&
.:I_Pl:|^81B>7KHA6BW^@I0K=NTJO.T*:QTT:@BK_W3|MQ E7FCG2-;KID!%9-
KYP#%#F#DSB!F#03CN*5JOCROMZW>Q>|^RAG"\$0> MZ.;HJ05!0?B"/D%TL>&QIH">I0VW.?#9SR1*3@!6L!9?
M^G")IQR!= 3 M^S5YL.VI<^|=D 332+MZAQ*^2>HN\$006!?
V!O/6VC3;7PMXR!%;11H3OKE\$FYX<..YYBR7!\$A2S<#"OG>!R^3X*KAOA8.7.O\$=|H.PE9Z@K MA?M
&,>_WCGPEF.@Y#|QLX\$CZ6#)CHM!H3_RL,SZCD/;V.WX!6)E+N!TW ML4ZEY@30,V8:B+K0F0!
(.G_WC.'V@<31/H!@6NQ!UY9)"88X_D \$J^7 65^ M!D =GK5\$;M/N^>/_W 3H!IER'NS4^US&&9!^&B;T\$LXZ&08!9X'G!
|*_.MHG9;-|>(@*1M\$Q^!A3WU1=W5@3V\$D1X!>SUT|B9I&@U#X_488K02<9<1>
MH|^@5R+_.C;_.EQMHHA!|O%EW8&O7FU^ MWK<|/=LJ;.K;4H_W :H46?8MVL!;?
OG/O!>>RIM")SU23K(S!#H;5Q7 M\$O^G^HIG">?D_&M0FJOT/B%#("GP\$7*L^!^!\$<|N
MY@B00U1+|H;E^D3KX4!^EJ6 5AJH9IVC>|/#>YB2 GUE!DU_VE!> MCF)7I.FO!-ARMC5QM3HE.H+4Q-
78TL3U.6Q05)N 35|H6Q&7M;C5|W^B=+J* M&^|V!F;7MO?_JJO#QIHXXOE=1;E0!;@|ZH_J=E!45*RHNS\$;|W;&-W-
DU^UA MIAQ47-&^:HWNJE9V.K50;3-?7EF/M=|OV<"FRH?\$^/6Z?35|MK'X.8S^J+8H M5OAY/OP,+;-
fHD:9K1Y5A""OV^+6&SU+;6L4JL&I=F!KJK4;BY^!H9EJ\$K'
MYN+^MH9VW>'4ARQX?_)HKCK=H3I(H^:UA*KH1(.D:9 OE@+|_.C;_&QV3 M7K&?
=G(X.#6TK:0Z*J@J(C.B#HHZ*!-O4 I-)YXWME^CG83)D\$XT:2 J:M>N!A0=@>FL2P>NC*,W0Q*3- M+\$.3"H.F#
LV*\$_2&(UN.EJ\$E5CZ#NCGH|=#7?2>^NIFZ\$B!_1H+U<8@0 M^A.1G42?!!>?
7PBjXYL(-\$|OQYFINJTL.NYB^O#_.E)02;G&QD-612\$WU
M2#DZ+XFX.Q.ZR\$1?_.EQ^VAQQSHWC1ZHWY7U^CL67YSU|>SHV@.I0B5R)AW
M|YFWT!""\$SID\$V<9)|@M4CN9H+P<@.5LQ%"79^B0/M;|B<*(\$C187=)1Y/ M5LINZ1C=OG'=OYTH(HK+
28HKPM88TQ=)^7K8G>@/(R?;2N5T_FMD|X8UR M@4)G;1?XM1MI=|S'K'IO)9713AA#(^*YX2
M^|XP@&@5R6B4R3NG7TN4V"!!|IE%>|0W1<|9% 2!6EWR=AVS+10!HYDSF MVE|L#^0 P#UAQ X+I0L"U+CO-
5!;|K^B^J<|^+JHTY_TFW^F**2=^Q2HX5" MD0FOW8(M+>|+!)^!=%X=8C.(2#&-!0)H-PF!7L?17ESLA.F<>@A,E
MBX_B/Z1F8(0ENAJAOGX;+3A:H^%|CF&/F12P74Q8V9?;XS?^1Y52G5D_G2 M KE'+0XR-
7/C>08GQ)YJ,K^K/M5:2RN2?J!^ (65;5?4+D3%8WH8)&U0JGW6USFRIB2^N M&6^4%A={GZV71B|E.MNHDZ9"!?
\$**Y<#7E4^9G/FVE3H\$-%2KCI+ _S|J! MM;G&GJ2|2!2C4<G5IV.IUK\$&|TMI=1;J! Q7HFL^Z3+79 P|(%<:N*B^
M>8@2ZY-&^:N59GZ&NP!T_&^:V!K|F'M.ND9G/NGCSBZMEL-0E_)?)%|@LQU
M*S=MR%K1#8=&U79=I2\$+336MZ9K">\$RZ:UY=|VL8PDI7/H3MA/X_#5+Y_1 MR\$7.F-"HCN/NXZBUC|XUI_EK=
<(8(?LY&7ONQ%LU?;TWOAD_@1@^|ES_:# M%_3ZSV%P%SJ+XQ2513J/-GK<451F=H9|H0)0K.G%+
|YWIU%LDB9TU70>'WA M9KD_U@TQJ#>H3T7:Q_K> G;WHFM(00/&#^8PDZL>:LM/^PN.FK'C.M%P3_
M0K=;TU>_S@;BJMH9LJU!"WV;*6.6=+H;|I:O;G_-09CQ*H7BD+|ON@Y4RPT\$|CG=;|Y%|>J-5!E(&2)
M_EH4>A1Z?%H.8D>VJKJK&I!^2MX|<|J-YE/(DR^5< MNK^X1.Z0Q_>&K92;80-IM5F^"6VEC =OV;ID*V;GK=7
MTU:4!PF;6GB|G7_IEX*TV4TMM;|f8=3-ZI9|SK K6QH0X|0M+^|S2C"TO M6)KW47C 6;
K5G6!F<"C>|!Y>26;RZ=5!TOFPRITQ|N+TG""|A;Y TGS&K9 MM)A-YK|H9P+|NN*#7H8#1Y!TTS=?
(@HC;=V9CC^_1QC#Y""6_-O^4@)HSL& M6I^86<3LF|FM_YC#_P&7ZT"& S2TI5_U+5DB8\%6G#N|D*&%^>
I7&*F/E6_ |1 0>+ +O3+!PMP#!_RVX.(4K& M3&/63AQ*4!)H1(HUHSZ,4>ZJQGV!^E@4B8(5_
KT#BH!4G.WXQI0V!W^8T/(|_6N;(4BC.G70&I_K*|R(2HBR+"3 MA(YKVO:Z!^*YX*.JXY"V!%*|+
fF^BQ^O|BJXYWL^3B_J5=BW(EJGY66J M#>?;Q8)MK^6+J@X'C|@RU>%@^8.GI&?PF854?
HY")|^ALYRKW@496!4IP(4 MP7=(%KQI%Z%|S+S@@90U%?4+2=9))SAB^9?H(E(MG8^V=#30> 6@M#JQ+C?
2QB2G2=OY>@*(A!L6HAZ RD:~Z*%)YKSG>|DR(M8&P|+Y|W&Q<5<_JE" M=\$S1C11E_&SG?
4EYISKD9BIZ#W L)3^LHDY6)=A=P1CK|O^EU2AOGSV;3 M1%(\$&G_J "788% @W8!*/+ _ESW!0G?
<%K08S>4TTKR<|H-OGFR?;S_1 MKGWZH^WX^+ OK _S_N;+I09?Q WKUYN0!+2V!>7FU^10+ ^ZIOO!|=PS6^?
M?Q_IQJG4M??_IUA?Q_Z^SN&M=O/I.^T?|V|^_?J/S^|O_H_V^T9X/I+S=?WB'6.6NWKE >P!9P@VK_!?!J^+;_1L?
_O.C^H_6)K|KBAP@FY)XN#+|2A#|_7 M7Z@7P6&?ZR|NM^B<@-&\$YA+2(;X_ ^=T?EC>?="|
|G||XM>UQZ!6%/7I&%W M^7T?Q;)O6.OOI*/M4,MZ;6YH!_D=S=J*;_S8'4FMJHMU|G2JV4"J|UPY*
MJU=EIPI0*\$|KY+T6F7#EP0T0P&M/M!;3Z0+;4 MT.H#S;
|#|_BF_#U|OWPM&WZ00\7M7JF67DG%G5|LCN#.O.%E>%YXJ\$&|IQ
MP|F3V68BL;A0J+Y>+N|U.WU0TK&BXQ31LE|V NK6A8T7";7C0Z351E|B\$ M_C4B1|JUNML=CN?
9S.\$PAUUK=\$YI3&20 MH76YM&HDSZHTQZ_(A9UGPLI0!S5T6DH!_RA.V
M9MI.C:3*_G^Q>|O+_.G^U|O3G%X^7!MJC%ZH65-6"UJD%|I:CL#_HE.>>%W'(M+S0X;7ETU_Z?
BOWU_6^:I04|G)MM_OO_OS!X|V;_G^;M0+5CE+/?+\$=<_5C MPML+RL%60/|F^_ ^L\$(P*_I_YT:3).*&%17>_.
fWBIRJ7_!!|=W_(GK>\$B_M4^+|=U@(_%BNN334M03/CJUO)%?|+T|(C%V4QM+9X#""#|&;^A-L"B3OLF!N
M^J=5NG2C|O<876T#_!P)UV*U&OBT5MKO|S4M;7L-\$L\$WJ#|0;1B&""^?T\$;OS"E@\$.M_01^@O-Z%
|_GPSL.W@S7/(X M0&N!UIFW5ANW|^E!DQ2!7.HT_7C_5P9.O)"T(IV/Y=3YX(33;R|(ON\$9 M@L4BPXO-
(+|/|^#XNQW>@;_.J".SE#O)GW??D\$_.F<4*%Y!QC\$RI5GKHS MI!<0ABZ=&*H(CR>8|VU W=/W^65_-
^1!^M18-B>>CP2!6^")IK>_.? MSWLB8DSH!) B5Z&UW! KO2O""=|NF6P/B!TJO?._G2^A+|K!|
M\$ASM^X7=P4KQ?1 _HG|5BH!%|T^;OD^P=&U_."TDX1F@0>\$@|N8%L^RDYFE M4;
(^YFR;|XCR_P!RR=L)\$G+;+*->_!OP@YCSVI#% M0?M@^&|L7N1Y*?1\$ _R0NU@@L^1A%>ZX%NUK2
T=\$%7_DKF>0L7SH4)TS=+^==Y>*V" _C_"_UW:U40!_M_?F_B2#3R^@Z0CX-6MYB*S_K;_T8|(R(A#4\$|7^GQ_50P?
^|=|O;CY+9N)O M8(4FV|Q"P/M<)>)ZKCHASRZ5L>TGV M4WH.TGH!2!GOH>((?6GD+\$LH*C+S(M;|@R-OC^FXZ?
4;_W""9 ME^C9Z^|CQ!VWJ|TNZ!8_O^EAL;\$|N\$Y""|@MW(AKQ\$M_RMV@D
MN30Q>W@&FJ9>_)OE"Y_0.NQT\$8);#@=AX_AWN(%KP<>J*1PHC+Q!_D\$2*LKB89-^Q+20#AC9=)PM=MZM>-
OC4 L)NUJA_>^+AS6;N!@('M IQR_N.W.H6.D_7"F83;NY R%ZE|L3 MG|=20_@-.1\$Y8P/X|AO3ELZ*_PR30O@(-W
I4\$<|NG(QI^+B8I^QWTS" M#N?LQE+^>|ZR>69&1P!_MXHK#I?^|QY+A+)|ORXDCL;P|W<;>K.3L|4.2R
M.K5^W%84)UT72E;|H4>V(2HCFG4)I9;#E;J@R^7?P.IEW138"S6N9_?_M^Y;4I9025/D3V.0?<%24T?
X|=SW&O:62E(H_52*P@_M&UWC\$=7D4\$HM@*^@2< M+NZ<_!BPP|NV(UI^YY=#<%#_OD^;5U!5BWDH;\$7H(D_F0I
M^_11"+\$6((MRU:0#|!;?B2%1<T.'RUV_|TJ&^R|(^T^G/OL#L?OJE(4+OJ3G^D_ATL MAG|""ACG_DF\$?
_FJBM++%AK9 LSM19|CY|@NE.5|Y#BD0>HPT*Z@|SIUW0 M;I^SJM_Q-
(M\$8BHS9QYMI|V;G^N#+_ |EKZ/1PK3K00Q M^X;?Q^Q5>-6_K<=+1?XSG3A^BZR6>FD^N")CY.VI|SM"2X|YN
C5UY MD^42Q1F&L^T!>|^S;+^B^NNT)P4 M!;6#^_X+X9X4Y7&4JBX#QH"83.^7!H6_"R\$ 3-
Q>#_\$.+&R2I7J|< M 6*H.P28E!2Q05".9=N7N|0^1N|<_JMPIE;M7.7>OW(%|KH7>#&#J|H\$=[6U
M%(^Y)W|B^|H3|Q|H3.QN4|_#Y*BL5BY_5O+^+Q+5=SAU7D|DCVT=D+4G2E?0UA M;_F8Y>PU2R^APZ|RK<4H
MQIN3"D2"4\$^*|K)7W;_N@ZI%+B85;X7G^#>6|O=LQ_! 1&1NX@IT\$WU/|I M^W.E% GX(4"L"=/_/6MO^!9-
OE!)1/D^-F\$O\$|^_3%?(IP#1YQ:8.S""4D7|@HV49!MPIDQ(=Z^X+|VRG M?|X>_&|SW%>39E^F4V^F;_%?E7GV?
NA9Q4EGPJ_C|95_M|U8XWWNA>XL)A9.MQ9V/KAI= 0^(A%C*UD2#\$)1URDC<*JT+|>_&V^2T*>BS4F3<_P_7I
M<7M7|GWQ\$;@HA?S@S^+CV_ZA3C09TT*;>F;|H;7|NA&X09LZ<|Z^?6 MCOMBF6".U^#^71)T|B|Z-
V;F_)P4UY TK2/7&+1LJ#ZTH/1DDU>;?_HU? M|HIF";_8L3S&S(%I^Y&C;J>#S8M?

=I6;Z&OIOZE"/7@H'X7+HSX:EFBY\$R:S MU-3U)33).L^\\$)DDTL5G>03AAZ&E%:D?JJ\$=_5_7 B9-
GR@N\Y>A\JO8A&RD2S M-="R.1--).R:F\$W<|+8V"DPHTF 2CD4=V%&3UI85O7E=ZX\$^@N21'K9/
M4QXLT0E)JGNWVM.2YRC.Y)J|+X;2|E:|3@'V;?5?R<;8)*\$QU=H/@H: MY.<90KQ(T|5 G%R=9<+97-
>C>2/N*7 T*7V56/81?Y QO,(#)YS)CRW M(X'G3_14N.13|9F>>|/PYR/(JJU *P|C@GE&:1K1@.1.4&%QH7*A
M%61%::I&JU.KW@ (Q)HUP>4+|(UHY#>|/6&Z?7315#4E.UH M0#H5,+ZDJ? -WQI-36%(4=
MU*>5%="8"YGLI%3GN5/O|LH=KIG|FH+T^E@VZF'8.^&#&=ZV.W?T1M&'?#60V
MR|L%@4H6#JB'P'#/0/Y_HBC_Z63_<|AHMX*502^!POEZ2ISE,(4V=8200:ZM+HEKU)|@#)^+Y!FF&)MR+K
MS\$|7*(*D1>G#(HDFKD'/.0V1.=.HZ3MD8++|04D@<1F+^:WD>7U+@OIVZ0)=BIGM:1P7B|>3,5EN
M%+9:~!\$H@:DVUFUY7(/\$-V<|72LJX&U PAT\$ "NA.2IX'FP(@V9-*>1G*4QI\$21=@7|Y9B= MWH_X9*Q3?5S#/?
*14A)9"ZE"/HE@D;/\$DW@A4!=WNB&R?UA75H(DSAK2C '-M/M=');.^*||7SO_T#4:O|AM2Y8>.P;1)3A"Z0"V4UBB\$
ER=G802N8H6U3KJ4+.;&+PX%_D_+? "2D0|_13R_<^P+| BTBFZ':O; MR|JHR;DH2\|0FZ/I;Y\$|DJVFM:
I=16G#>NJ.H.S^XV|J&V:2P.2%5S MUTG'3\$MC3P8+H=TXF\$ &2ACG\$0|RC:?)YA|<I/I|=9Z#0^1Y|FV5YZGR
M/&OW:&R.T#F/7G|_OOH+OTO(0XM%@"EKI'P>CQ=[8C8F|Y>0UB@4:CHB=D>&M)5>E-@:!
(@#I>.,T8(@Y'R)61X(A3YTKBQ|I^X-V^P_MG_^:|JA>:JA9O'9 MYHK(FRV)1O*6%V.RO _|Z++/H1>);.2T?Z5N?|+
J%4W^F.LQ>02AH|^&GQ M@:B4%-&UG4DJNC8/(BH.\$P9+(06%PP%7Q+_+@\$5+^*J*P"@Q%\$XEJC/\$NQMS3ZV
_+T\$<_Y.M)A.=J"\$DU7=AE>R#|RTZ|A+VO" H!<0#+4RKN<5FF.13HB3X \$Y.7F*!*,05S,'3' M>?9RE"P6:|@HA"
<<?7F4AI/V1O@CM^F EU)DV|>RL?@+Q?1MZ1:G1=?|!# MUS|DZW|_W11:1-
7N%R:BR3|1G8,O)VT#|D\$|NALCNI&|DPL:D_%)_!W=; M>K"4|(0CSK/S2^5V61@U+;CA* E\$3>#B8C54?
BTR660W9"7G2N0.98,#(S MLZB0|AB|A_6L5|1S2)50)S:#G<@NS9M,KT12*T)Z)T97&A:M(^A%L_"ZX
M9R&516W(1417W)2.C+).L:(V> M.<6E@'G%2PY+6C:*Y\$Q6G\$D,AEQRG|HHHHH)TS?L'0-*?G9FMK0W+/GU'
M|B4*V:|A|HZOHC.OSJ&PRC-V_G#1=13CUN*..P.7X=RI(+^"QJ92\$|F+_Y
MC\$"/3CWL:8H(PD;9/(2|)=.29;""W47\$N?..K.8H!MQ2A6K6*W*Y6=:G8U+ M3|LKS##DR>ABM*\$3'UTWL((BE@E1:
|P.P|N31(OC<87OB5+|NJ L+;6|0DN@ MFF)JS>;-|H6(0+|"QZ|WB%KF)OE?9J\$|Y04&/ WIZ|2SQ6:)-B_S;-|?>
M|L\$T|H=%M> "BM?"N93|(#(DDM2:#QUL|H0P=PU;14?I^V1N0L6GG\$32#-ZU MQ8|">8""V1#|9RUAW
=K0SEHB|K\$MN87-O(5+B7)DK&P.IC?"8B9.@N#SP MO=7:|<7V Z3K1_20E*-"%?I:"VZYV7?AN"/C#J<\$
"H/AMS'5R&_&5#*/K)E"QAJL*^BT59V.V<1+D97&: M)D^~)T"ZB91H^*6%:|\$!\$T'ROA\$%2+QF0SS LJE"4"
<27L;J\$S\$#6Q7MASYEDBRB9Q+L5C+6)34R4|3|A)Q'D3 M|J34ZGQ|/+Q\$20D|9 M++1-
@5|PDT1Z7)9ML|6&5(RLG) *NR&#"I2:5.\$8Y17@EAG*Q.X=|D#EPR8
M.-8|2_7)#YD|+&^!OZ:ZP%M*17F6G;/BJP).-R'BFP8L\$H*.*"OC<4*9F'(J MZF@?
DA"9BR|C.#CLD+.PDZPPC|C91DHTE82V7T15^A@/5Q1^?+^XU?J/R.K M9:P3-E_N*A*T/SRU"088?IP=-M@2CE
>8'WB^>7Y?57LF)X.D)|_08..6U?A6CHI(QQ
MMV82+EM|ZL.3?;.\$XCCY:FI^F.=#V#B%974LF>K6=|J+|IR+|0I'6<*8VC
MWHK|2@WS""CJSIFLMK59D)LXDH8"DC|S9+_+D@.6B^!U*W.^_BE J5T'K*
M*B|37A;94|9.J.@F'G|;2M=S;D3DCZG0/D6|TH.G#7?POK0I\$N|T57#E.B2
M|H&#DQ90|YB7%+D1M=|;L0\$RU3AU*-S0V+3:10.UAKCU4H)0-JHGB\$JN M%)SBF)&+B>3\$%EU(PIS&_FT%MY-
|T6=0V=W\$VYLO|V|QG7:3'91Y7@37\$|KB(E>SQ)*%)_HG%:3(ML M\$9D9Q45+4(9F|J3\$O9::3FG0C|LA&&78T&?
2X(B\$.FXQJ:R#5D'P^U9|RJ! M0"40-"B|H|I?R|V599=|X L9; .9X)L|L3TFURJ4D^14"YDL@H=RR%FKRZ,?
FH|0|+D W:9TEK^A^O'L&?5|!#5H =82|XM#;4>%L@K4'M"1 M ^7IF^CXF^LW!%A|A>#S\$9|YV9|0ICF*A5-
\$Q%2%?N|:WR|+P|J& M2;H=^@Y^Z0P1^ED-7C^ (P:1%;<92^>6>M&#NDO9*#&*>N.#+0HCXZ|H|62NY=4H_00_9-
(T(*-|J_32DL^|?46T1-0T5C M=(5?3+Q&NO2:V)N%G@B/\$1*J40WLOX|'8.H2IDFQTY&5L|B|+|RYW^EHA
MQ6CPI|1UY|N6PAB)(-0MKHFM|I#+8FFJ4:IB51Y6VK|4L'Y0:%B;&(*AW M0_|#>|J4.X#S
DVBZL(YR\$94&E";A*?C|D0|<"VMD05|X:?\$2LJZ:GY7=@ M2B#L/WSX=,IV*QU-^Y|@|CQ)|SSQ.G_P_I2O|2^%LW
|J.BWC1K0>\$|0C M=U_12#R?S\$N|G|XAT^?;IX20%0.R^P% MP&#=#;14S.H #>;+@U0LW2?9D8T@?
7*=WI7>D7D.9 M>-):CPYJYRP40BU'Z MG#XYG(I.D#2&EH<)UIPD#O6HSQ()2\$GE42|A=-(D'P?6\$ 1B"&K|C|=3=;
<| M8TC=DY|H08|I-13Y|_*?B=|X4|<9|"/^ICP& MPS5:6)B&MG5:(+NY?);>'CG&9|HKN30;-T0?WW#TH-
|7,IUYXYLY|9D&H M*O"3GB1T'AZN6J_-6=QR|*4GITYULYX@LH+1|^ZZP5:| M9T"6%:_LS*>|5=F2ED@G-
|+X(T0@Y@X+|#+BY|C4L546Q4Q8M|H|D/|_1 M)T|SN&?B&W0|Q&P?6.@_7BB8MIS+P|DP#AC
U)|T^5EWE4C(@W2:R;..LOK: M+."3#ATF4YOT9^EMA0S+PG/=U>/Z6ABIE#KM,"O|S6EF_-R)Q+Y#Z=@O|Y
M*U3F1*)OF3>QUKHM(KQ).R*C.? (TT4G|E>C>J#;3.1TR\$%3|:H|+3|9.# M+FY;#F:G-
3|H?F5#A.84I2B\$C(W2|9LR2^R;J%*DGD|+1
|@D:1S::B@^A(FM9'.HL|U9*78SR:E>N3&R) 6>)&SA:@W"3|IAG//%"E8@7&F3^+9'X D:CR)OBD@|^!^9|!@:N4
M9|EM3;=#W^Z2D8,7W6|AFCTGI^"M9<)8|*3L1=8|S A#J8T_|I0" THDS M|EE<-L_KXIA?@O7-
D2FFQ5"V3MD;=2V)4L@|LN6U-"6F#*E3BER5F2-BE MI7-&
I9&>7Q66D&U+X_/3BH5%.NUT:TH6|VR\$^4TYJ2+2YB|Z*&ZP
|XT.F|@1=E2OB@AJF5'T6THS*YD6AYW+F#|E7JD< M\$LC\$W\$C.2YS1|""N394_-IM0&C95H1ST?\$(^AU@Q|L+P-
S@L:|SIG1^I> MU#-3+PN)EAYX&B&BX:I%\$C.4)X9U3^M6TXE#1ATRYEM)W0)9128W9D6F8K' M9-*&AG-
!\$Q+9@H*M5I E(9469<+H0?C,CLB)|H| ML\$39:ZH68P|WJ0+|WC\$|87|N;!(6|3P|K178V)|8-
|ABG3178;M|&YQ3575D|VF>S"XY)5X|E268H5:B=-89\$2 MJO>|RTV'=2*1\$212G11B2YD|+HT1L-KC|IC0\$VW?-
>NHW9_N|XQQSOZ^!|MF/==&C::RFI8EB>R)J&+=ELF|SY)=DLG;D.6U;-98LY5=6;PH_U)07J4"
M/Z^|V8:|&='^9RER,V|RS6F=H>|AJ(7.N<6TT=|?3-!NNSN1|PN:F#9^ M'7L|7G1=G/4JIN^F(-
\$)|32+F@35'UP_SP_0GCH-NQN V MG@_-/(MW&2Q'6X5M+..JFD_I3*#PU|1_A9 BAD_L;O1CK6T:6#AC:|J'@U> M?
S1JVG+;52A:|C#P71|L8F:3KY&RKIC4WG@4-I(9J.GSM9DK'6VD%6E.NCC M|N&M6(Y:5LN:@CUE+F'B7U-
W>|9|JFH7-BK@)F|AY34"A<1%#XIZ)F_9|9 MSW+5.\$WL+Y9JYZVF|P4@GQ1?). "HV#7BIDTEP"9
2X^K3\$N51|0>.CJF1 M-\$5>JLFA)PN6M(S>C:/TGN|E(C\$K';X_YW #B|4D|#Z@5)-? M\$MZ3O|RW2RIW8|IR
|M'H3KDC9:5F7@JRA6?BRHVV="F|OT_=-2%G|
M'436RL++&^2H|A.%#%#D\$#16|H|^33.*RL8|VEM;"9|.RB\$+6D@H<|LKUN3PM5
/EAS+*4=>IDCKJ2\$/"S%^V|JLO MRC>6=BL)|L|QG-HT-4|MGL..@7%9-.5|2IU-X^U2PL@A|CHGY8V/>5|24|
M212XIZDXH&UXSI9"Y|S+2.HRAG>+J&_>*BW;|COXP-1.6L*R3@L+GHW@>9D7 M|!-7A5VF4*=K\$6@K5H_7=&FN
MOW2G7_..LTF1N7W:6F%..S.M4E9>IV3CF^|G=|GB;H|)O(10>*)E57|26 MI D0TIWFUDT6T"4|7"Y-
\$PIOX\$|H|9RY9FKZUP/&<>YFIQ=I4KPRY1CE?9) M(LZ3/5>N+..23R=:7P_VH*\$S&D97M7)3@Q8B89KT/8
H=0H9=TRFLB3VO *;> M9^W8?>|I9:|/6ZX|N%R_)= "Q?2O*>U)\$ ^F8P?.T*.)?27LCH #|+;*UH
M2I+PEC<("OXTE:1|+0\$8 G|A|@=HJXF_ ">MP|+*2_-/3%I*W/76+)|P|5|7LS|(-W.9T4)ZP<8MZ:\$1%|X T#29
M8Z/M|C9H OK6KG@LD182KRF"LD4D\$6@<S'W"1^4D |XS&CW+*)D'5.TV A M A Q7CPI|<C)""7+R@
N91Y4N(6=<-UB5N^8CWW1_1R-A30KI|D<C'. M|O.0KW&Y^NF|8FFS^WNNFE@ANFI?5R2W9<>W:4
>&:5R:|LT3#CYRO*2Y>R MJ0<;#6(R09|:#>?E5^1?<|ZQ2#(9>/&L#+6#:#GD3W^);192=%|RE
M_HP.W_|34A:D)+XMV0NT|P1?4#MI(4C;"N:+R@F:48B'8P|Y2F^J5|18@A MY=FH6|?E:.-#\$'Z3^7=*W?
P\$Q@)E!7O2:XXG:~^<%M3.@|8F.35 M4AR-Z73:W+N:QU"Y9Y%66_K 1BR.19>|W.N83>FN\$2?.ETAJ>2BS9&C"8^)
ML|QU2XX6D2.=)I0Q|6F'?ZD4BP%HEC\$|78V1=-<>PUW.86XXP@L*|5MHL

M#Q18W;U8ZN@IF6>1\VR2E,I*)G\36@1>40ZN34E2<4/M(& M=W<6TP8?+^T'5Y%E\W3Y.Y&DJP?
LJW/9#U#_N99LY)4EL-VP[O7/<00D4%7 M#1#1J1&5>X"49)=2+ I&N-
#*6JZ_S7WD0FOZ#U9UOH1U9T:7X]=.%7T.IZ= M26R9D6J/3=+90\6LY\XV/(J^&"D/#8'N<-
:DYRPCI\CKJ\Y0T(@:7GK%Z\I\JV\$ M;GJS^89\G+^0B3>0B_D7^<,I-/E3"0.X?_3\,WBZPY\I6KS\I&P,^J6?I7M
M&B\3Y*WI>N"9&::H=W@.I03C_)ZL:99L7P=(T,9RW%P=I\EKIN: 4D)7_&*
MJOXHO!&+)RS_RJT:@5^:ND%5#G)6?JH&(<K9\X&T OE\$"17?1Q-^#B'W%0\$ M\Q=6YT2ND// F?
D5\+DZ8.7Y&^"I8U@#I\Z^?D08OG\FC46?0=0J\VI M8\BCG0>U^N?
6L%_KCGJWAQ7F.6FW;#I^C^A@^5H<#I_3\$TC.EJ@Y&C#VC\I%TVUR MJ\RM# J%.YUZI#2@1=E8@...3-GO)0+.->
K2J\$&L\$>SMK3+XEMW8=1K\YSGXR M80SLZAW\ID _\ #3QW4ZVQ;O=;H:5:"TOX B\$ _ICI\U2FKJ\H6\EC_L_Z_P^U?
MWG>(KVS4QDW:U*VAS>VPHP\$!OZT% C.U<31&Q(N+UC5M=6S?/E8@;H4Q\LMZC4 MX3KSPW75-
_11M_NR4>>JMOXWHW_MTO\VFGW64N\6=ES*4LQZ\$ "LJLC\I\EMJK MFZ^W7H<I30<A#>J_G&4B5-
3UO1UYSK1J=Z= M=GCY-Q\H&4Z0;?;0^J9,=(Y\%LOS_(5DAE;<7 37LI D*DJ\NE M\VG\QD9-
3*3C +.C\IV78DF?>;50;YEJ#BZ;.3RZ<2FWGUSIM%3LAI^HNH\L MJSQ3\BG8N^&%T0I_3>GRIA=8RMVA_+#+P?
5+N7:YOO:DH\I2C(+ #KG"@= MPTJUXOR\?/:#-I3=. ^1/UF&P1\AW=F\T"ISY_I8=J4EUQB\E2:C6V_.1\Z
M.@J>:1%LRBXW%N&K"L&M7_R2<:EW5#Y_1T1H@_2P:2M3S,^MCL9B+4 MLP8X2;+8QD'DUAX_&\VSIXU=SR-
2N\O#7@:88@_XQ.1=8J_RZH5"O5N8IU(? MBPA+K1D5NZ*@_P_VIBWV>P2;^<=\$7>N6;O"WX4Z?
QH'W%.W^%.Z4IA"!2 M?C#@_NVJ+P>8N=WSFSSC.V>HX"\$,2K9\$TIOY>.0%CR36WC^;79 M"(C.B-/I08JG#
(OHZUY91#T6^\$ \$29XADQ5\ 8? \$^*^EVNE.S.") M<: \$NS&IO\Y-^@JL=3%Q,>_N5Z,S1>Y2L=-^R5H?V9
(!X@%#G"TI;2@% M-PC\>6.XK_+5H7.*;W\,06/^O>K?5\Q;G5#X\$FN>;M7'B>E;2=?A+;SE MG M8\@N"
IUG0EF_Y0_XY6RWIMJ1@O#R\<I3^+I\$A#U.5DZX#X2\K;7;IUX\I@ MXLMJN'P
8=K\$3W2<6I7>A\$7')0TY<81K22M'I4(TB7KQJ#>W7SYH7.Y1Q2-(
MT6\7.B0#KI\$D%&Y/BUN.SF2)DZVH6(Y\>OB\$YYS)/_D5RKEZ8EBBZ\(*"82 M5>16H>C6*EF-
E2U\$<:_GL5#JERS:QFU50S"u* IMX./Z\HFX+^#C\$ _7*YH1^MY(F4E>(Z#C;^7_YLW MJB;:
(R%T\$=:UM\$Y\;8R#9M/N+ %G42&Z*!I9"TF M7_(9Z:9M-/J#H:24SJ^DJ\F2R2?%454%2_F\$&X"GIEJPI-
PSU.#9>A2INJM68W2-L7PV)K;=MOOS)K9/MJEHUZPM:\$ _C1@F3 PF3"@=H1M%(H.@Z(M6>EB9T<,X^DL#1R
MF%V%V7"/2X@YW;f\DO)GW+&9W'=D\J<_A8H\=OO\P5@R>JR)HUB;'A3,M' MTY5\$PC8_
CMFS>G;H7MG&G14W"8\O9CE\Y,IMM\B^C\)\$2=0GWKF"XY MJX2/BBFAP(I3JP?>
IA(3M0S_98">+4;FF\B1A69(CV\J2>QI-MWE\KWT?/M)S_EPKXD"2)X+O'8<4J\?ALLQC3.Y-99L.O;.! "#4N(
"4B.UUUL.*&WN@& M=I\ZG\F?P^?7\#;5(I;AY"D?<9WMAG7'UL+C4Z)N>A;_D@;_9Q"D1W4@_
MGR5T,K+=XZG&L7.8TAH';6R,KT.T_1?^2S1'^9D*5;Z*C_' +UDP;A"3%.VLXC++HS0;#+!"&I-E-#%/
MS.U*Q^GP;)I+&OI*>V_X_@?G&-)80G@9C4WP5WF4(?2^<9N;@2L.%IM>SG0 MYL_U:8*1I&T=
I5.2J#PECG^+\$.I3K->=#IKV5TLF10'K M%/"5S,I/J;79002;9>@_+"A)T=I(6)39\>D#6TD\I5(C@L6@9^GV8*0(ZJ
\$=:CM-YIX\I)X) M.GC=000-F 39K*\$%ZJK'KVKUQ)MJI^D?F*^I7S+G&^:T&H.W\$>_*(@:ENB8\)
MJGA\$R"R1^#ZL8;UTG(1#+K-B2)OM!*Y>?HF-4 YO9Q\&>1YL4=*Y0LP%J
MAH:3;CIW;#*VAZD9BNHU82;I7>M2B&32QBO59'0#B>=>=>LJD&P5<I>^>+
M%C@>K^3BK>;BH:WDR\IQ5942P+7E3%I9H*L,K9>'MK;/'VX\W>KW%-S\PFU@_M#!70:A/0;_ZI#NB
M\>7%>4;NK\;\$>R=%^1_*";\K;VC\WM/V7G)@#_W;C;I>Z<+I/7TIVE-X M7C+@S+ZE&Y9Y\;"=I:2DRK!-?
=C?/*C*37Z;\$YP&(6ES2:\$T=6\W8\$RO>K" M;B/AGT%MMKDIG?-/9652P;2.I:M@);?6HSAGO:8I?
K'AGH0W03;O<(XY\I
MYAQ(8VFO_8\$*RT#%MNM#S;#WRSF\8*A=#91#;@I*ZPU5_CK3UON\IS3AV2OQV'.9FQ^PUVWF734F3M*;JIL>9EI
I6 M.3//KI;UH?I@WL\%\$%\$=+\$%9AFX87450BJ_.5*\$EZ8/>2=VQM0':=(UK8_U M@77P,WK1,.6^@.S=TH/^--
X8;.@:H\Z>K;=MU-(75BT(2/Q5.I6SR&Y\H,(M-&WB+@R\XZ)5+EG\ "Y9B>8LH^HD."DF\JM;C_E4%&KNRQG5-
_0K=%0N?#J M0<62\$K=3!*4(ZJ\Q.T50%I4F2PHVM23^QP&RCDVSUQX8\$K0\9I%K\WWSZY818L2_Z7L\$F
M\$S\N9>BTIUCH\I'QC'KUN?SHYZDJC8I&70)FFATR/T^Z,>WVTU98L8<#=#J/ MF7WN?V\SI51:T'M_BFUC0\ R
_AM,DE@#9-5*16A_E/4H=::H".S8RD;5'DG MRDFCKF\5I*\$<9\I\$FLISIDBCE#2ZG;I*IR*
@W"=2W'IW<""G#MVR>IN:RW2 M/=3=0YBD+>C(%^NL_*HV\9-D493\$NH4:2K2O\$S2Z"K2N P?
I2DU79=JGVJ4>L;G+^I'&IM^CR&CC?5BR\H9T=8(M\HE#S3-IL" M56XP(?
SXO.R'85WSH;K=WUY.5+;#1G.B<I\A;X8BLQ:1V1G\$(DYTOR+S%I'Y
MJ+5DKLA,D5G3N2F9#ZJB9^RO5.>\$^ESTU@IO)WMCHT=H9KV\FL8=\$I/RW MVK^B\BSM0VS\&@_4:V-
8J&29_PCUY^"4?2GBZ\I%*X'G4=M\Y/(GMX%_E MYO0?%(_UZI@#A.1&=T%GP.YOXP",+=>?>.DAWO\H_DEIY?
@PI7QW(FU\80A M%Z9-V\$|^@>I8+RBI-_*L5F'XA_3U+/_^, M1<=>#Q42B/+#\$"YJ\N1@^&LZI\I\MO\GOW\N\FL?
7_-Q8=\$>+,")DI!%=(7Q M1G/C&P3W+'EMUL9USH46S>;3XE>*GX,PG@6>&^0\$"%A+O#A"S""I.8BF2)N%
MP4+^L,M\!"@J4"&PR+LYORM\I\$Q\$=6+6T(U_I\IV#EP\I3G<I29-U)ZV4OIU9S,*_YT-N5G-
(H\VO#UX1L"42*8ER+V\VM ML*=_J;I\I-1C\G/R N;-/EX"MSIG<;PP=I7TAYLR2\$BT/8;T'UZH+VD>*MDSZ&%T">
(;G^~""A#_9Y6L#!<#3PL63+L"(HY>_F.V\$Z(\$XR=I\I3\ISL MS\0%5*F YT
AD6_DCG(^I;WC1<^AN+V3M;Y<^:C#IP&-577 M;9RW8\6?MP9O1+I9M.V\YRW'W LXE\,2GI0D\ND)RO4C'?
DG\(-7VM7 M\DO_5EY#D3\@AX\U2OJ43QG&SXI\$K7#K<O<9;8,I@8Z3URO';0 MHQ>^VCUW4%+ZOHU-
AWH>JAUB7(#Z\Q@;D)05=VC-DOD6 M\B\$.7-@VL=;B784\$JWY;LD=ME9K3D)\$\N/Z;DZ&G""S#HF21%
I_@T01X7A>.*IQC\@#VZ1N%B&=# MO\PN0*_>O>._I@C%I2>#0I"12*9RJ*JXW&GYQLR\I5\$U#AG\Y-%XIM#SW
M\1>:/A.)D8E\I4(7Q&(B1R\N%SX5)*Q4#1:"KB,I(LNT+3:L\$4X9JC.5 M=
VS0;K&NE6XCZAUT*)NP>XH%MAL70FW/6Y*10%NEH\I3I/>CY2";_RQ2IP_MWS\$I^B3Q)"#&@B1>PAE
EK9@4XSU;^/\$I:9T7G;I\I;\$P&B34@6>#XGY\=ON2RIHIM^I\LPZ_#6%I#_HSF=7\$ =*8K;PP<*>X?&
MWI2EQW23ZV9\I\LO1>NE("ZT7><0;I7-S@="0INI^@_N)Z+O##YIIZUL;I;
MW^*;H\+XNVW;/>E3;C2XZ&1;70K8;MGK9492#IQ\>I\TYQ?N=#B8&P8C88& ML\OV;&R;I=Z0#?
NSF=6S^OW_#D8OTIOF8>YOO&/78T#;MVM*57CM>_*L< M.QDN)0U/%0 H;5^J I@SYS-
C@9G0@P@X8;G0;PE_SZO(C;B) *G5\XO9<2TA2V;AV=P&- LOSR\UID_QKC%2?; MY-(64B//@WL@+5ZSC)BKI-?
WB#+\9S5;I>G-D);S8>MY\ 2Y1O5BS?W#K9KV(2 M:1\$;R_?W<-@@"2!=IX?
TDY7PY7"=,DD15SPDAC<)ZFVCM0)Q9C M%G+O67H7#" "65I5U,DG) GMTBMM%#I\B;=I JN?@KF-
8.EE;)"\$!>UH;9 M;.<I+2Q;>5M@^+VF\I\AVS\ZI+V5;W,S",G91=^9:T^KUZ3\K^_?I\ M2;UID:N MR;XB!
I8Q_9V5\49OBW\X=.SKILK\I%4?C\85=\$M\BBMKM;87^DL\J<U\O M=#30<OY_9BX\$5D\AL
UU_0Q@AKIRE0_539\24"S_-I J NUMU5'K'P<9=0;5 M&3S9&7SNAJC/&^:~77_!>@A/5/IQ4%:_DUFW=55E4FAGQ
\$=3%\$H1MZX-I3Q&4JA#=#9_2NZ:AZ&4ITV@;1P;NMTS M%4\$!@CH000V&NF4J>IY^P57WWZCB!
I05\BSD\$5Q)3/74\KN)9 KBV&B'E+G\I M;I\J.%%>4V\38#NS7S+O^L;H>\$"KX&I)OG_9H\I9IQH=@&LTT:?
ME4QS<5T90UL?6GL>R@NVHZ^_05\W;.%\KBI@AGI_-%I@IPLVTOKI?;K %<; M<"8 SCHBX,
I2Z74UTD>C3;"=V.%U#OZ1O:_QFUWA+LTO)_F2K2X MVV#/_;.%@VTP5\K;I\K5E\Y16J#S=;
I\HSTMB8OUBUR9NCFPJRLHRBORG &< M^DJ+;8\IGN)6OV\!S38%->WYP+9GN<.%0\SH\9?0?IF.%*
_0TM1>4\JB;D M#5\$+I\A.3A#6MC3.OF*YC7YY9";I=&^CF<+^E.SLL
M=D50%TM05D^WK8,7>"J"NE2",@UL;7;#^0%(8V0)NNL_>K\O6@5S?3^_!C8\HE=G71U8-NZ

N&%3Z82GI^9>R;O*.)HEX WUJNRX"F DRPU>F.L7@K+Ll2JASH M ^,49J5RE7"3>|, <"/J^1^2-
D:81:SJM'&6N#&ZV#VJ XHAANW-0%-DUAXR&YQ!PEI# M"V85F3=G-1.3A%4F5T&78M<6>K0^KN<OP3J^3.37?
ZO1*VK3 MTLX\$(*IOB+TVAJ4IXO^Y_A3,C-?7> &QIHFR;O GR*9,E;> *0:JV.D3 M%+Y2!:=S\$,:SP',#S?
4G7C%0.5X8L2KXPGB),>LV1"-M%&@8+&#6>W11'8:O> M,&%R^X,Y\$.G=^H+Q/=D-6DX,I=S^K@SEFX;
I+VP6*)1CC_4@T:~59RQ!<YIAF7>QO IWQ<169LE(5PNP?/(Q^XX3UT.\$H11R8L3-01LDD;>B
MV>RARWRV|B(1W!LH:'B8^?B?%\$XR\$6P\$' F KL@%G+3I:PWw8?36G_I
M@:UD"X(C7%AKNJZ7VD!SHHC%EW %*9G;(U=)OT7-R_E*^9,V1^*XP<|UR4L5I3"!W9M0T@!|!\$*?Z?SN
M7T^<.)Y>4M#@KMP.Z^C*9Z-D@J7V|+R&?2M.(X&J9+&L#X9G F0#7 9F\$N(\$G(+) M4!#O<." A;"(K^Z9%P2AP&
%:M&>F5"\$0P2:S>!...B6B6/<11!"BIE M.\$I8Q9?G\$FO=JN\$B^V4(BX@\$=X,F@IHIIS@WQ!CU&<"GU85423>?"
A2-B M|4_\$2RK"B|2" IO3H:P(+L/N| 60IP03V\$1V//<\$?-&6SIPL/W0T5C!HHF MV.15\$JK"RV'P.H?O.5V|N|A.S(U
@YJ<_H%\$7-/5D-L1P!+&0F#V\$CM> MIEU'88V@/'^?X.<6&R^3) X=,NM-(!Z5?-OY7F-DX;JE4A \$4U9)\$#CH
M T+!)%)DW>Q=";<48D|8:D126J(#T5D,3+!>Y>#BA1DJY."GKRUE T3E> M<4B3<OMAS6B924.A"J<@^E|)=
<|TH6_91@:A.PNUW &8^<9 /M|C2>B^"I?*,XN|W%F<3D03/7LMEU/ZB.MWIS^<*2# MP<1@QF@T-
)C=M6=CYO^6.78!M=^NG1GL M+7C/3BK" /Z.EP *MXJ!":.WL'<"?Y.L=C_H&4#H
8VOR;)D^G_B2^:G5XO9<2T|1 3+LS)PO:Z? MH KS%O.POI#8Y7H@;&6Q2'PW?M3>% R^<
=(M":L@9JF0Z!9QE0%ZGO|Q! M&>,YH>N3TNBFIYL&X1"9>0Q;_ST6GR|^&R*@7:Q9?=<"K5YN?CX:=4;2|
MJV|^%!*TE CCF*Y2D|?+B^>:6P4H9?(TVOPH:.*")C%VAI_21DF#I=/ M:2!FQ9PPTAB5.K"2I&M3 M.
(U>@+0+8.%EOU>QIG?3:C>F:0.)2W3O.DA(9:O*3!MEI)*6RL-|#"^5I? MNT@I?0WT_?
9IZT!@|1P"6S%=WP#/\$?XLTIVZPS(\$'6B=|F@M-5/79>=NKKP4&F MX<&!W?&@P?0WO6:13;&<+&?
*Z12\$.G20=5.N<^<"C|&2XD^C*5!:=B+GLN|_5 D W^|:VIXTT'6P!&7V14%_U!40U@<46WK7='9D-/#3UM2^<_<
I>Z@UQ!4 M0U#;TG@#O6L,&H)ZU08DY8I?<^+I&G|H5W7"2U40/*5JR.%T,A=RZ|<2F2Y
M|RW*A_,2_KWL,6ALFOE7\$7I2_M9|T@#F:|KF"O|Y=C|I=|9@*T!6P.V!FS; MFZ(R+'5'TDS,DP
|HHB=E#;EMM0K>H.U)/_70_T="=-D_5YZD&H6_LJ0.X M|H.M:*3|>1DQBGY3E<=?LZR/37)'_SPW&O'W
&8>ZXP:P%6V-GIZ9|A|X%:=M4T>ZV1TV@*O.J1V|WA!\$?>)UJ9APVY7GLUC-J K023 M/M\$9/&2P03"30M%
|F#17MUN.BHY4D:GW@%5M;524S*1SYN'E^|G=-:ZV>3| M-02U-8(R,J#_FA3WAJ"V!_L3Z*FH0SW*K^O#-
"Z6UM&IZ|I:>EXC0P+9|) MIMXSMEY|^*";OO|^3|^_3\$>9=O*IM!|I#_|D2!|=NRP(#AYOS(OB-H=WZAC M.HC|JH
@I*FWH1.J.K6MW_4A&(9G>%"TQ=>#1@FY!79:"UGZ;Y#C;>@9@5 M%5L3|:H,X|5N?MJZ(-AKFK_-
|Q|7OW'QER|D0U!\$)O"&HQZ|U!?"8!<W MV/4E|Z+<B.G;+O+>W%:_OY->D9FNU6UA<0V?*=G/6779)V08-
_VIWKUVO MMZNTW.IRY.<\$#A/N94IN9U-*|N|L*#&>:..|UZ1I2GT. #'5KH.W*>T:LMEC
MLFD04U/\$:7W!U.8E!VUO9=&4/>H#7JO;>)Y-4"/-#I-4&+W|:Z& M-
|NIU4BM2E)KU)#&+J3.H03I4N:NS:8TDCC82YNW=Y"OH|>-JO*B|JZI&12 M-SUIU*N:)EA#W.SZIV^2-H|ON|_<T|:Q
WP:~^|_|C9AS#?#DT>RW4CRI%| M'+P9'L:|J.O?W&DL/R3EAKIAU|U|?9P%W|3=|I=#:GM#ZD-AWJO7;7\$3ZD
MMNO?Z2^/Z0.4M788U)O2&U_2 VEJKF+P@-I"(9X+^&UMAA.I %_Y'K+"S_MSG9/^7?<
9IKW;/:GCV^<E!S\$W'VKW+2X?HE),0)PBF|TWAQDGXQ_9+HX1 M?W^*#|WT65?HT^C|DAIMJNIO_Y
"U+&5)RAI<_0@HG FSH|F MF8*W\$VZ9=GYV?7&CG4U"77N8VY.Y9@?X&*9R3>%GF@*#U-
K!NUACK2B|'I8*I"~L'P|ZZ(\$F MD0-8217.(O*L">+9I#N#N>9%OC9E,INEV#OB3_V%0B!1!^-'<D'YU>?
MON)KV+WE1/@60/G,|Q>T+R!S_ALZ?DDS|2 W=\$.6|H-8|HW#WY@|/W*Y3T MV79A#10<|A|0B0
MU=*NV0SV;SF!AR_#61F^P-VY|CH.R|K&);1MTA'9MOL:(+Q+(F!&VO!3F|"(40CQY|37GT-D N|!/*!0\$|
M1'+0./TC2"16S:;&E^M-""(L=S2:KTI05OL.\$F0&O.XE"8:~XGBB.3\$ M(ZZ"Z|SC0>E|YV)_<^Z9XRU)YNCP"7P4
(+M&=BD("U|MO(-&R!PDG=?Q2,PVIO@ M8^:T|UB#*~<_@=E|P:UH+T(F)5^>2(VT#8).F14B&3-MXB-+
(ZO:~&78&I*/M:0041\$ZX*ELVD8CP&_NP;85H)|I8N|T=|3U)0%*HKO_87:JOF#MK1 &5J|.@XIY% H ?
M.WYL\$+J")EX_8|H#*W("T2@/E|I %5X/RA/M'QT8R9MRFEX9)+R5T9+>%
MRE%LJ6NY|I@^MH<|F|/P|D|(^H %*RG2\$S&H-7%*X7%AD0C\$(>\$S@!W=\$ M"U>&CKJ?W"W|O2O1_9T.)@8S|B-
A@;KMKN5L3GNIH9LV)-.KU.O_<O8>|(-M_FCN)|B'3L=|13|<6K-X(3O+>?|>@PPD*G"18"2P4.)\$':R/+
<%8W0V>SF" MIVU,,7Q&Y/R>:'*>F_@7JS9|T>8^F_WUZ|V(WOP|&6@B/I^?P0MXGU/J8
MITSY,5Y!_>H*Q(4ESPZ@Y+C@DL*|3)DBZ"DG40BZRI|B0B2E M6YPC\$<
M:QFPL (O^<0@+INES="|JPLE|UW(#SOKQ.6:+4Y6X@T/'%F74+OO|U|?1 ML#5JYW_5:AF_*DI&<\$HSIA_1\$/*
|9Q0;#J79YD2,>=^NGW*HVM":0'2W0 MX/XOO_5-;&YP!S*FF0J.4S104)>-U!5|<8_ I^N1C|^<0F;#%F/K_5ZA@Z
MOI&Z|I;*,U30-V+X"#3X&2C)|6B'M|L?UAJ|TSU|LV:7^1HU"JU4_'FO MLYZ+|GU/PS(RHD@<K+WM-
HKS<57|+5_A5+M@C:D&)&EZ M>X:7%;DZ6ISL77ID_4#&JN_L4Z&TH..JU9"Z 1>|ZWRU=QK%V.JLA%"
MOIY\$+/+ @5*T*.C.:45|O=|Q:FI|UN_I@4+5B_35Z6#9=6!L*+M<&TM 'PR=6 M.#447"=,'BP'F_IH-
*@A!>|UD595>TB\$5H4"UO&S^8P|>|52M0:QA"O3; MQ\$Z|K7U)>P<@<@W|W.W.9
M;SE<2\$|7MFL'H4|9+X=E38|&NM'?T:R^QES;A)R>;G0:Y-03:;>WI47>@BF MJ*T//I8FL26|X|GSE)O(ICQ-I|
LZH|HX>/5U3|_STWEMH@AVD6.)AWL MJ&_9(9C3EXNE9?
N|3ABEM>/'K#P%|_#F7V|:SK&HF/8L|T"7B=6(8VWIA4 MOK5N;+G70F)GV>|_K-UAKDO%+\$RM3-
RA&KU|&S94V:JZ|F|&?|HMOA.157Q3VV#LMWZ(WT3K>J|FILU=|3E!2MAN_KIZXZ9EZKU,U
M3/0'RID(LK6;HJ8N6QFAXFG>EEU|_:"=71/VK1M>C+9N5DY^:Y#S6DQCZ-C M|I-
UD/069Y=J.9\$|FI9MA5M7^B:KG=AX(S;+>2G=V/B_BGHM|H"_:? M_UHN;G>%|I)>)0%2P0(U:H^9HU
=|4OX\$UL>L|7,>V*+_NS8|9TY#OOI MQMO3@?)^?MZ|+>:O@<\$W@_IX=3#;Z|S\$ID*9H2(IK|@W-B|(EF
O89'C|HBL MVCBR'>3N0)M&|JZ*H|SFM|B9VEX|9(&82ZM1S&|Q5T|>\$R'M6)CG7=4OW(-MIX7ZLT7F-3I2IO.L)?
VB'H3K"7|*QB%|&42+(FI6|H"|U|F3QO:8.YB3OO= MG<_N:~#1.3&:6_K01K1_PUX9-
I|HD(M<+6:|K|^<LV|+4\$K@).-0NV7^00L" M_OH+|SX+R2V#QZAWVZ<>#BED.8|_WJ1MDH\$Q+@<O>,U/?
PB3@3QPLXMWZU M?/@WYS3|W|3@>8?4; H_IG?+>#>R_\$?ZR5?KD9@LGU4=|P&VHNS.XS.80/HM
MF\$#_+9863K(C%7+G6XNWP*EBHUK=+ZG<8%>1C8EV'274MN)U0F_#JLZ2-ERHA:SR7W5===>
M6G(EBCWWA4V'CQ(W?>|JDRB+J0W|+0W>"L2GH:"A6GR=P\$0=X|J2WK>T1|6 MB7S:8.KZEB8:W|<9-
9V@YLF7|GZK<1X'G;UEN\$ OI?8U1O),|QAA|AR-D)AKG|G!G!"Z8 FLV.^SQ|&|0@/_L: MY'3XJ-WZ@
PXH|7R>6DQ(Q5X0=+P+%0M1>#DJPH|50|03<"RDZ@75>P4;HQ/ M_3|_/_A4H'C0:DI>?
WZXO+6X"?TWP|E)H+=@H#VK**K64FKKOWX|P|Z. MMZ%-Y@_J5!5|X*&)"4L25<*^R.X2SZ8&P*9&PH\$G-
&5.0O/P0|EA)-B<\$R8+ M\$5.(30AAH_7V2\$1#P_2RLH.T>10TXCFE_9+(LSN@'UP6J*:"|P_2G#>Q5#
M+LV\$F#74W.L73XAIAKWD@*P9IK)O>JIR%5B-CKKY8.M.I'B=|79/64.2?_L MD"6+LIVE|H'9F\$)U|>C-2-
P>L08|RE:3TO0EC4SK2N|H|PRK>)N)T1OW6QU9VB|0L:SQIO7-89AQCCE@&=PD(U*^9VOY-GC<100C@9:
|SWV+_FUT+50 *_6Y=F|Y M"G7*CJ"TF*_K95<.TG4(*LXGHF8#IRJC>A*~|ZH-4>|AY(ODD|+^S M?
(HKKXNM(0SP58K==Y3:(GBA69N M<*=>=DI4T3@+B_@*16O_=>+G.6\$#|S+U3<H\$|VN_T8G'AEVZML5?&LYM
M?WJ*|OFC>OM1?*\$YL8((8P2Q+R|H'LKS_0A#AR9#5:~|81P\$H5A9^"/@TSY M#ZP?XM#(V3.#0I6A|(%*?<
MBOBB'>:G|SOW)6LC3*|~|87.=C+A5"8W9+QZ MC#6AU@_RF89FB-IT>>?D-%6B8W>0F#JN<4|_3IYA7-N/J
&GN+V@LJ"BH:S MUK|T77 FGX@3:~>#GIU |>G'CN.X:G|6#B:7_|^YHIP'LCV|>4+|R_ALIS M
+|=XK92O@Q|X|YS.W|:EE:~J0IT#*Q25_E:<_DG.>SFDY|%)R_//P MJ'9"TPC(Q%)F)
M>%5Y#QXHPSL|V@>WCIE0.ABUG-!>|H&G> W<|YO%Y^!7^R@#%Z^RPB9B|O M//+!L:6X%:249I%+G.1CY-

I7F%L9IOZ!FTP+QNA2E"3&2@^(\HG W_J#FH8% M2P2S1WQ>O@+X8HD)!?8XXK(CI.CL=,TY!\^?^?>
P.KN>>YLDV %*DZ %EI^Z M#@!H!0!"BP"*G*9>J7)3K!!N+E P12_8L%MC2WWAX9T0\$OPZY5C!"U*1K/I
MX9K=>|X|OO"S-;,\$=H"WZPOAPPO%;D"2F)Q&16+U*0?2+#+_6|((O^5/12? M)-DL #_JK81|-6:N2S>.R>"A),50F"7A
VOLW3.=D),D%GJOY"\$Y4 MXPT=P M;1SS7"R(4I5%\$X6B7VXQJ%UJ"YFZIVZ*QYXA7H&S'N'BZ.)0
MB:H9K2%\$S,1P+G10/2Z9N2\$SMX>46D"BI D'FSI\$15_090#Q>2DE<M.&LEI@ ML259A@F+U|6/7A|G!&'D>"ZF
=V%UB(*,|09'QAH M= ASHWI"X(^,44I1@+)X@M%0XZKLT|5, ^9HTS:5G/P"Z@C.Q&G;14 A3; M51^T!C;
IQ(PP*!7D'8SN6WP'ERPG^?V,O'SX6^Z8GCB+V11USU\SPW|!H| MQ.9*=0Q:P*ONQUJWHT'A3E&
(Y4>4UTMYP?M,R^12FS?E=(L;E-@YATW1%+< %
M4V0\$ ^H5EXXVJ'UEU"+W8PM;DV!A/ZX;3)M%R7;3EH,BV;3,OIRK3(&ZE^3-4Z96LXC,>>,8X:L@S M;I
0Q^"HNK"KQ|H7GH#16& 8,70#^>^%|WQR_X"=4C*SY9FJ?2%N(^6=LXC ML#PT'<07L;G04\$Y!/?
=Y\$CJ/ZB16H,%U|!0N-FR8_P|B"L%19/08H^X|!^ M|: HZJ0*8&T9I+M>.YW\$F
HNPR&R28"%5GFNDKPK"XR"2<3/V)! T^k^VYN M.,+5/?-=")Z9*P>_O<8="XMJW%Q|OH|#VDLGPOLZSAG\!F3*,
(B75\$;GD80> M|P;XLY##@,DI08QPNT:C;V8.S.X+LL.V.W."1T.

TCAA#+-B-Q36&EI9X09D1>3NIOMZ<(VMQ24;2*TF|LR^>
M_U?/FR99L4B'O WVV_#O|OY7VNO_!/=^|WQQC(&S!?BU;|ONI6;3IF?PJ MO>C^A00/M"GXX&#(3?
F=>AH(X)?_V8%KTB<&YGL\$&#D4'-1N&- KI1L+D_|MG2O|CH6K,1^N\$@PA714T?JYPR8I\$N@Y4R95?N02I
(H5Q+V|,)R(Z|4.X;\$ ML(MA6-\$)J^_0TO|QIS&FJ0T?%>I7WOP(@>KG\$R!2Q?+<3^G\$#&-DVJ#")
M*^M2(2@Z!>."J&#>>JFJB#&H=3&'H/R,KT?F3|@+?>^"NRCWDYQAKM3"T3 M7PSC70D"+%|OHU)"5#%?
Z"0\$ \$JOYAZ+2'07K0\$R"CVY"Z9;%|W@|@93JA75 M#V=UPCDI>|>C5B94TXIZV<5|H(7-3CBW
Y%TK21T" WSE>"FW?HDRQ|X?|HB MLWA0H91\$&)V2NCG4*.F?S9D;(&O 22=1\$(B+8")(#RU I*TD5P|,3-=;V!N
M8Q,7PT=3F0#."6F, 6E=%F|^(B)C|5XRNPO(_G_|?PI+5R@5^3@;I^9; MB3_H RUA1S'6@;LO?
S+|HFXRW9I(2C#ZQ7\$9FN9B2.^=>)|H5JL'15 MIS|U4|, P|>U(EH(YY(=BS,0#;7&)(C>=RBQP;N"L,
|G|F@ZBR9PP R)N M\$CDI00PM!LQ|W05B5X<|O,U=6+Q# X%2F&4KB%#C_8',@^&...>QFRGN1%|G
M9RZ:TYUXK/GW L?OC%80H<)WG79710HO|4)XKR.""OM?!|?L
M*V1'4)K@Q+8'2;\$>|5WCG".+=&PW;T|C^95W<;RFN"R5A)0YWYL0DNO2.1)G
M53GM+@0IA7'6IYXH>|5^C)@S29^ZO>(&K'F4G5;2AQ'#)=MV 6V0;\$4? 1+3 MFC5(&L9^ 6.BXKBDUA;V)F|L;)?
JV<|C;F!)R=0.O,7SI8^_08F|,T8C ME45+PPHM?"=AZ@|=Z"H?%2H=4XDBLHWIQ@%NIPK|2ZV4
M8#L0A*4+51\$ 2AC/R1,"4:XJ0@&QXZBD%BC\$7YWFTRF L#?RZ@="^MY0Y|Z\$ M_7SB.Y0B3(7P@U5>2#,U+AXS
O\$D^PG;DS0_AH%|1NN+P+|V)|JM28AYY|B MY>,P83GD;\$Y7%*G2M(5N|M*.(KZ^|?7C\$4;6+*)K0C1C2XI-
;C6+\$M59,2U M\$@W|;MA9M0HJ"Y|GY!256*.;@6U)+N|H:WWFJ3|56|IO\$WPC%N/8;+I9D)=O;3A2'@TH|
M@3+|76R|8R'HF=Y31|LD.>7*"D6RXCR"&R?S\$M|H&E|ADK2M#;\$XG5%A>X- M6X;1?0J&#+8;0&/G|&^&-
GXW|+XXT\$7L|H3BG,06P3)7J7|OLVS EZ5'R- M1V%B8ZP&C,F);,9FL6@0UW.GY%L;HAW7M(AU|O/#+
X21X|@#+)3%1)93< M#U^@E8HW2I?9KT@|H_.R8J+Y O8&S;Y?S^T^WWIE|U6-KBK%S22F|MGH1%?
MKO.JP79B+|+0JMS7\$D3=Y%>DZ>2F&W**8CKOC%# T0TBA#K+M9;<2\$1SX8(MT>1.4Z4T6(0CWA;Z|HR:M
W9;HFY2 N@_Y+*P8NBKA';&M.,+N\$UUN8V&I M)8K)4"E0*B0I |J2=,^D+|82D,16RJBE C-J?L_94-KIP'M.HH")*(;
MN=WJM|;\$229)9!>%<.,|+X_ MSR_|^+G&U/6#DN8HE='V)|\$";W0P?@B>#MX(4GL3HXAX)-ZU8H FL6*/LX>
M*7W?2LZ-LD;09I|0WWIA"NYDCKYWY/H@G,B;E)\$F9225K^H|>->A9*5+Z;6A M'16R93
|R<4|P*Y\$)VA46F3N;5|1B;C\$A_\$3.85!40SKE.7U|30**KA*C M(!= >G/I%V|GV4'B&UW|G(#K0KW8|85-
7=95H<^%HF|V1C+EQ^/BJ:FRBZ M08A%|D\$;4FLDC|2SN+W0'GD>Y<-L=&C%|JWMEAH>AP)+(>E>P<'D?A;1.2
M8 C|N;1%OGD>|H6, NQW+*|3VP;A?TCRIHPBL;|@;5V A;9_9,B(BXQB449/HI%;KEN1
V|@1Y\$;H|VAD;9I9|A|;5.&+|OQ0I MS>+*P4X,P4**|3MT0(8 _IN/32TNP3#^B=^|>8OWI^)2%-Y|SYNG%|D(| MB
|SYQ0_HZ\$8-@W X%\$2;M7%+777;RFN?4I"0/7,UUE+-5I%&CLIR|6+)|0\$| MX46IU|VAK\$3A^CH2/68302GC#>-
KH.2QMCDL;)+/*|>.(8N+&.<(ANHC&J M%-S3V20\$*\$M9IMQ>D\$_*T=7ID M#W'Q0+1%R?C)Y.?
E'MC|1)|%=Q0TQ.LZ+DW*PE=)=B)TXT=N9,"_A;8+A MT3142T7G*L7N|>_FK'IX8ZT|B7H?;PQTVT@^"T| MJ_T?
X)>=RJK8Y M;|&)9"1.BTH0?%F_%IU(N'S|T*HE/Y&4%F.D+2D(H FPW29F)IQ3B*"BF M49IJMAFFR("5D-
<%M/H\$ S'^^T.9B,GH%# <\$SF!O>,@I._KP MT+VB0^|P_=&+7.XGN'++F48K;XQJK14>>|SAO?E&F6D;)%
(G5%9*J&;V5 MY|SE3WQR|5HP2UBGO0UKMR%-^+@0&_K02.8NFTB4_5Z=;0|6&0|;C7U|VN MV1|Q0|3|2|2&T=7-
7J^&1\$S2@ID'ZMI@&H|6V40P|Q<"N0Q6VHI-HR. M/AB-
3@HHI64\$WUH79+ AV10T|4&OV!S_#LIDUIM\$;OK!<P1G;&1;5 F! M5PHT>T|IOZ.NH7>?<
A'GEB6#7=B&;QTUG=0<|"(19V?% MTY?U5-X8WC3SU|W1*9D2..+IH? ZJFNC7L^N|GDI;F*.BIO%\$;OH|>M3"!4
MLU9FU#(C\$*6+>0HT+X;#|9|HY1K|SI'YWB&=G|N>/5 M;=1G4R096"/;U25'F-H^9<-
(7^K*NJEOR=*Q)CP%6XZ8\$HD^M&|H+6KBWZM MJ:PZF6GP#X'^F+QE\ EV>^P?
^3%GNH)RR/L01PS,Z&5CZW,P&U! M(CA';?_T|P9W_SU6"@SHPPDGB/55%VN|H<-5673=7EFZZZO(R#2V|Y>=%
MS4CY)|F9Y'#*8L=T)V=5>>AY""@7H04D"UDG |QAN36|IV8I*,"DVY2O^+<
MQHT>1?C^5LDNXXRV?QYR MF2D>3ONOW.3C5I9EQAGN?3P/AP_78KSW#N^9 MX"IPV-R*,&<16+
190W">0@|IRV|W<_<|JO?D>_M?F=THP^*T3<5@PGY8 M721H-0PD?0)N%DA|9S^:1%5K#4G\$L_#
|HW&=14=6Q;L;L&LU*O3"\$O&?;PG M;.*75_/U33/U_^KA+ RO%+&(P(|S|F="AT9>:O|F6'
MFF2V27G17H^#5A;VN?/CT|*>M|WGAK>>GK|Z\$ J==PK&&22G9B7-Y"D>K#L7I%S).OT!NY8%(Q'Y|MQYBGM|
MHBO&S|("K%+H0S";T,9G,FS8G10J9V0^4_U_\$/DMD1N4(|@PG/32TNI\$4" M?
DPNCQZQ,@E.6*H\$;F4,X"5(YS36'ID5*D\$M>(80Y>@FM1D)-U23=3IH'N M !H8Y*T&=|C|?
1@JPH/3_9@9QX.M6NXOA1'4|6+|;C)P8")R6%0I12"FI2
M4+*"|JR8H\$F\$RUNJ6""9LE@;4!&@MX4ML(02|AS2*CK^R%;+_.?PAE1S.1PP;A|I<;3_!%>9|44 M?GA.OZ)
_<CFK|D5E&=;+>+O;5POL#^UN;0&G 7,08IZ@;&;/\$(%VXNX MZ83JE2'<' #FZ8-
)^Y5V50<2X*+6U+OC)8I&D%6%)(HC?
M=3/3*P|6@GG\$KB9_XPA^D)GP70SHRK2;>|;.;#W%'>L+>H)>9/9J=|,R>.+E/ML+F*H|L7LI0P1NKY#Y8_
M;2L'0*U72K>AVK!@|54)8|H3D%WK6BKD4UE!4K+NSF;WLEN'8P;VH#I")C% M4_?8L8,Y_D
TQTB_2W|E;1A@S)+V5,2B9>.,?;W;P-MM|2N_!|0V4WB MI2 "NDG BLOHY(&*0B-E^>,S7POK,X76K?5|?
YRL.01WYH|+CM8(*RE7.29 M=YU^6H\$ "W=Q;ODU>H|_?XYW,N=|I.M|+4CH8|;W.32"WWVKJF@S/HZ\$J?
|H93|FBL3P|1W>CEJ<_E.#KWZ.?(MXKYRPE".|I@'FRV#+ AJ(|A%|QFS6IU" L(|R|FBE|FC NT+I>50@)G-1
M%SW>03HY;M(V\$W"FP;GB'AP#O-^!|)KI| 2(&84^Q
MD;6#PF'E8U|Z7>Q@BI=Q3(|>Q@39|@W.=.W_#QEAQPB& XP)'_L0CR-1| MI8PDK1C9?0WKR?'-'OD>6# M#
&I=)D89LU%3-/F+J&7YCEA;EB#;MZCL-&*L%|&I+!CY+9X8/VK*KU.N M4W&X(K<7>167@V<0D)VU8?
WT*42;TCC*JV|_NX4=+>2@&D==3\$.5BABS); O M;=&(<|S@X:S\$><_!\$B'Z!5;=^X|CFV NP"^C.OB-
/=>W3U;GVZ5K| MPW.F\$X^_6WP\$N|V)QMFH<^I+&N*|B="W;?;Y+9"0V\$E5#|G|; 40..|
MY8&FELOCC=CH40093@TJ#1@|19V MC/H@1KY>5*\$S\$H?S\$FO+D%\$&#9V/(F\$6_.MY9S M|&+E,*
(8K6BK\$SLH"CLVNR>B>|H&U'\$OUF, M*7;.@9LMG6S^.=*Z%\$S|J#2P?
A0CGXOO\$2LAZS|;XH|SBQ90Q;'Y%!'9'E\$6(MM#;|Q9%'2NA>S5I6@OJZG\$-

*VXP@W04.K2Q/9#Q<-1*PT*..@5UFB#B.9 MI?K.Z+9ZIN>I9Z^*..NWL.VI=IKO>V;*>J.4I-
AE6S39ME5G0CN3.29ZW.<M: @6^1.5.3&+YCLE5S_Q7 0%LIA&M?HW?IP<.U844)%SZA5!O&(IQ.AX44
M#M=%0AE&5%R3*2%*-GVB61'F[Y%PHB%Y+HHJF6="XV81-'PH(57N:.U6?I!5 M^-!\$!K&E..V?WAGPOIKJG6-Z?
AX%-+M6YF3JV\$N%9F7%GR?7L%4&X!T^IA4I%-W47NP=V=&2'8*\$TNF>??6:II M7XN7%SYPMK?
YI0M2\$@Y2M#VPBLA:@6TMR.66)Z<I(3XX.W6:@FT* MROWV&I+FD M 43PJVA)\$S-12
50N\$'9IHWTR@QE6Z.NT.4MU3^12I18.I2+K&R.3ZY>B&&H
M!=O.CKH6=K|HY(&BX@Y'CPK'1/(G2IK/P)#@JG2X5Y@@|N.BG+Z65##4D^FB
MDJ/EVY0A&B%O%.:I9>4)4LJ!0('XU*3)=3Z_.I9>@+,<4YBHVC8D"K M0.6T?
%K.EXE13N>1.10B285O(\$)P7665@L67K+)<I>PSH_H>"V^-I3:B2!M=IG/LI%:+VIS.P<>T?
44I/U=@@XISUH"AIH=&\$%=(QD\$Q^%#R"+DAQ7-.6Y MQD-2-
<3I9NCEH9IK..KCL6R'8@HJDE.)W6RJB#6S0@.3%@.NZ^L+(T33/C MW;+XG89%:22,Y^:)EE3J..AQ%%
(1QD*TR!B'QVYIVTRY"2+L@%5E)U7 M=:AQ7+I%\$59" KO"E@%R.^2I2^UQ?NIV I
I=T#X)+V8.@CA9\$Q..E.GVJ.Q.FG.YP'FT)M9F.J7\$PI0=OTI M;H:H.V(F+7*')>6*!==(XX572*7E2.*\$IP9#T/I7.SI?
1LOI\$+/%YLZ^6 ME;9*-.OI3TR@..Q&DBLOO16>I.O EJCXLE:@97EJE>EO^4Q2XC9U3SQ"),F8+I@2;#.
MW^93DEV67IRL. 9RI_&OZ\$+:@M/\$MTG*.W43T4220C8X_WY&:(LA>H(IJ ME\$D!8/
Y+4\$D%>5LOOF+81.^99GB4B@1.0/<9UREXP#A.L65.%FM@5<27)U\$@VZEL*HG WS NCAHYA_"OI"1580"FKCL'
MHOQ.SI9%"/...S1!.ID29^3?D7Q%*?T!6^83:/7KB!O.8%TA|N!T%OE MO#D6'@%
(LC"Q(>J;NQ"R+U\$SODQY"WZ4_"B+_WN97#I0(4I>|B;^P J/ MC85+*=4.K6(\$A>)"I=9S?U4O)XW17:(BP-
/B4Q@PY(U03?2H&*ARTF-M+ASW*;288Y>"3F7-'UJA4HM11"&\$2=KQ#1 KXSC7S+QZU%\$D\$V+R!4*."RU, M^@!-
H45W?Q.I"1AO"HYMA&NTS.TB.^RGWPF=QP(M&(UGZH8M79RBL229NZI M.*QDA>R1E5Z?
L8BWN\BUY0RR##/FAX/EHX=MW-/UI@%)VOK M.ZFCO)F&3#QQ 6>>CF\$BT9#;+7W+7T=6J*A7BGH?
UM+_W118Z2RZP!0. M3@TFKXOIS<-3A3U8)53V)KC^YYNRKFEO2*C"&>0@YYM8)Y2B*I@_K*%TH M
_#;74DA'3U1@ G@>E47"10^I--PD\$S\$NSZXR\JR F8H"2
MA#W 43I82H=NGL24."QX8DIREIU67J4.BDH%0I%*"X EL\$7("(T(4=N MM%N!L@*A)BI-
<=&*79"#:.@-1J2W!8)E*0Y3.CWP.3G99J*8DV<6L&|H9 M%=-."ADVPR|=C>Q"%T<1P!BP+
(F.HH5LOE|+^Y/NQ#9>I."WQ2_%HV-N"=> MJA2!.)JWL*9L)35ETUY4HENW 9E#B0IALGK?._I
(E)S(L9).Y"RR'<<*\$ MC?S=.IEA7QJH'V^08*GQT(FP.O+G4>/5I#ILU M^04PAZ\$Q\$BFSJ|HT:~*Y%Y-Q9R;?
9U4 TD:6G^E16XQ6B3F#T+@;H% M^HFT26I+!#V^R+J@."4A %2I&NTE>SYE">NHA|M(3 PGM.7C;G>B<.;I I
MYWH'WX1U).\$!%4Z*DG#A#J?@99BY!449G*L&#DRY3.3?%&Q) MQ7E'(*&J(H4D:84W:P4"E
EUV/5%M&9FD+E5ER):I0F"WF%CH@'RC'X|J^R0^WSYRL=_X/VDOQNR_71&7YZ3&J;7V\$)^+_M^".I
(M+;"WN_#_:.^5IK|Y==.MCJMLU**Q5_WNNLIT'V24^# AY6D3NU=GZ| MT5MY+F="I#<47F=\$_"3T"2J_2P50M*R.
K@7(^@.W0\$V VFF NGV@FE582;7V.S)A#\$S=-.&XWXW9UZQ MI>C.WZH825F*VP2TJ31UO8.5.I>|OCJL2E'N\$IG-
KNFWAF*?)<7@P%^6PD6 MQ0)K\$UNJ JAX4.@X4ZJYI."3\$O/<.G7I3 M!&HC8Z."&.6*LR-
)G\$Q%YHNLF.P@RN4*C72S&H|R>V1&KH|Y-JN| MBF2ZAB>0IAF7I?K+U) RD(WW4AKLU!|1EOO14>
IPG"Y4E(?^T^W:X^ZE<5.FO(Z97M MZ>+K#V5^78.H0T.RIX_H9ZQQR>M.*9D#13I|W4:Q-
0/2/PCXU71P&Z2X30%\$9<5XW>G#LF7^8(IDX_O+L1 MH.%)LEFCU%(TTC/18CJF11V6.W)L#\$
8CGKE>:XQ=U)|.^WNUW&L34#C%& M6^:YJLCYI!D'5!*.<)0ETO\$8@Z+.^\$X&I^.*+=#78:
I%2IR>M4S99H|B%> M+@R%FD#FYS5&_O.D26-/OIKT.7I>M|@IYH(>6)244V._=I'7JF<2I=:FMNO
M9*L>N^&I&GF2&6H20WHA)*UM'F+?GHB3"(I-5O#U7JPL14P7@-Z MK 0X>>7D03@%T-.SI MQK#!Z-O:Z'
\$&T|=QY3!Z2I?)VR?:(C/B(3I.C4=B(XJ7&*XGA5)D MP(&Y>WW=-)J'FHB9ZIW1CO*VIPLO\$WW?:@EJ|>6W
(J&@9E/M:8I|DI5K M*4NC;K ZU)9\$AFZTA_JH^12"Y:.05IV0>:A\$!IU|=Z@:0W7D/#^DG;2?B) MJ_ZI_VW^!N\$Q-
K9CX.Y-W=W1=/?&SK9(AU.DI#N+8Q4EO%P7@=X:^I% M:%I7I<I|)(?PT'97FX0_HV7V=I;SY!-O@:EVYH%I^I
AKCMC1VRQ3YF^G4*M.OY>G;-4WE4V:S9PO&K@2U:M&EJ2W+B&UO:(UCKZL-.06FWP!89)K;L/
MAE4S^>J55IK?%L1532"WB).DR'E6%G-1"E><+*O17?=@RRZ&^F=87-6D<
M'(N!6;RKNZX0704KG@84_O3NM7>W?@M"/)F&\$@|=)"04.=H_C0F-G?#*W MP#G?
IW>|=Y"%=TUQ5YV08^B=_HHL|8WFU21J0^Zi2R^V_TM2W.IM2?74_6S M.LZM(+*
<I#%K4J1F:/7W8;2I#ZXFIE1H9=S@Y;5BL-U= M#3QK-.Z!^?43I|XE=89*%C8>6 XU-|BWG\$B.BW\$<I\$P\$|?
2J&83/F^Z":0^LG MJN)AX3XZ (-#=/B/#4.W1OVF=7W!\$_.%Q%3H|M8@Y@!"9(TJ?ENYF=>#EJ M7F95V^X9A
MC;AV7J@IR|IMMO3!_TGEM>"<N0.Y8QX V*8I7N+WQ04)SUZZV=K3:CCV MSZJE*OM.R.SEDVW4G%?G!-
UA4EKH(TT-W>P8^KIR2D)H@P..ML2:AL- MAGJG7:4-5D-K#;Tl@=:Z;7U4N0|ZURW58HM-
HW5IcI>:/3U=O^)K6F.RX"7 M%A1ZMIVCL6.-.C87U)@IFM5W #Z>.*SV@KI>H7;UJ7S!6K.A>(G=@3YZ:IU.
M+5I3O43(N""B/2+BT7"@#IK;OJ9K2+@AX=>E^J MI.'N#L C:&YI#B(VVMSZ-.36W/HTM/8&.:VYI7D=0-
^\$WN3!*=>X%D72^8& MHJQHX<\$F_I0_P7IB%^S;GMZ>J;C+ZN*7*Z>O>IHJ4:Y+SV/6FO4S6WLUIW
M/7LAO.I4&4T3KT7UYIQV+7>"O: F7B#NZZ=L#+ZQ'4S@-BV<.FSA1TM@I6T M!5*T6=9FJAUMFD-
I5'DV1WV.V+>-/01I.^>AAO'#EM2:BKMIA*X";T+?P MGZ?XE>.K!8I.W&%7H? M-
=Y#=>I:;XDFUM+&NG>*I\$SM.JY\$GK;9LTO3@H9#N7SS8&YMCJH/WJG3\$ M:3#S6IAI#_6>I?<
IMVIL X/S!^EP#ZY<?VLSMI<=04<Z0;T.GI M*.P:&Q M;NIT&I0>:VYI(4V)!K1^U#<@D^R0L\$VYUX"X9=)
-->CKQI"0<3 M|=#HW\$&ZH>5+@CGU+>(67I9^IZK;W\$SI3C.7IAO-M82D-6*Y# QLD-RA
MY=YAK7:0:L5 -&".V<:>M#WJ)J!;128/7TP.AK\$U_IQ';TSK!#):VMA6/T==/843YQ8WYNO_H2K7N!-9MR.=E3!
MLHAFYVVU!"OK*;R/W)N2I@%35ZCE4/M3;5I^-1.^H!V.-Y.T_LYIDL.W(
MM6CXI.&34Gf8T*JNW#9F>TEUQR>+T2?PW1"):&HYC|O!# M.ILE./?
2G(BWG2:L<=O\$9.0W492)YV2F(I&^!SS0M<+&85BPCG37-BBMK3N M6"MM#2N\$BMUS=8 #I5J:C-8TW
NZ%CHH:#=O(3:PRD|PY%44 /4.3)PP M-V3^CN#7IV1!>6 |AQ)H+Q=PSZ>I-8/-OK>NO!CF\$AC_R'.G*
IWI_A0_8I!0XF!C&HZ!NNWN&R.NITA&_9GLTZOT^-.W#T!98I7V^F
MG<+>=>*I3&+E8QF\$CF#144_D(BJM_IKD4_JI- RN4#MLFRA=2LB8OUSIY MD4!%F>GN7?8ZA.4;D\$S/S++UQ@
9ZJH8A.V&C|H|ABZ9K;+B@:I\$4IFH M=Y.M;M\$2I>D;KEW1(H3>*OO.1K)8E@-1#Q!<#BE&H_=XOF
K)?!.\$!V"6\$IZU&3"K-L#RY'A\$F=-!NR>N=K29>V%P7.HY8!6I:/47 MP8)XULI8-(8=@-
+G_1W.\$!0=PO*9/"^6!?"+"ED?<"P:PYU0JBG!&0YZKF(G M)H0_*-)5IU;BZ.@F*INU>
<9>XO9X%I=SJQ@KE2I"\$;_T\$7^E@:H\$E;3E ML-YL%@"|C!_5=X^9RV9VF'TW6J+^CN);6I^<
/ZHE#LTK>O=2%IX2" P\$LF MS""6N;=I9I#XY&M453FQ%LLH8&^%#MU)WMP*3)#-Q M(6R|YL5R3GNP0?
I^GS!&ILO>&K7*. ?M5L_ON\$ MT(0^5S&1E1Z-8U!7"&_M@05_NY#!IA'T=(K??6LYMT.F M_68#;U^ZDY9\$
N+UO:(&L'LEXMO_QJN%WI"(G"@_X#%I?>47G)H=#-? M+
(IXB4.N'IQO(4WM6MLH.9WHAZ=95OFRYVQ"AH\$(<MIP\$#0-JQ2*!&VBP2T>0%-A!0.IPI5)&
1N6Q"E\$043LK>W!AU|3R7). MM|7TB\$CGS)K^<P+^9#YIQ4.\$SI)2*\$K*FG"C"5&I #J"JTI4^FDE#\$ M00J?
H)*EIH*H\$)O(GH YP1VM<@Q>2AR51\$1I.W.OX-UO MR#.&#SY|_B+WEY\$06S-IM2(MR\$.@4@C3?
SNZE,4QI0J@&N&<I.O:!.P"B MLEEP0OC#C4W(" _#8X7(G:QH3L7>(M.8B^6ENWSK>\$:9)TNJR!VO9I_97
MO+WKE"JKQS;J51N4KSE.S:~@'2HHT("S0I-KYW&8SI>(GF_!\$MJ09S)X@ MVIC3I" ?T A*??
VI\$&GG8'T%8)T+7\$NJE!>0:(=A^ MW0CV4JK@++(W0>(JYB|XI\$.R|MH0IX'C2+^_Z|82>VP)?L^"GJ_6.22HM

M%M<(>%UC_XGL,'96CU%:GG#3+G)3P9=>^<vY\$@-Q!0U^M@BF.@.Z3T'M_L_0l.82."91+@%@\$K7>A#
(Y!W8BW?P%40441PX(F17WEA,XPE-S-B;M%271#+5@1*6'KNE!/&2B@DQ^JTN)=%TE(&>G%*.OKB\U8)H'
A3VT)J M;VGE>!,#?ZJ?P.)^~!;T0"5R!2@76W7'S^&4@+)K>WK^M+_J73L.P_Z MYH\$%/(H?42GY.VI.#@/H>D3J
(FS.%6%*EH%A%ZSDX?*(=J@-PG^A)A0&#T?*_R_CBB="B1\$,160<0-U1((X+=GJ.)3^/BJJ,HQ701K%EM^.#;
(30U9C.R\$52.2R.Q/IN>2#JK>V^0=%P@B=4.C.22.V\$6=TL7L.YC6.M.P@K>OZ=YVY8!B;1H1P;*_#HUCTM?
M_V4N"5P%P-EZ)6*!>?F>TC+8VYA)'UIX-NX-6'CBSIX;C-JM3O(9ZB2\$MX#WH\AR6LZ=-/JN.?H7\$'
&3_3N;IEA"D+M\WT0"-D"TI@%*(DI;\$&T6(H@W3^MM=&>3QX1UP!C?N\9VS2;=6_9CN2J")8*Z3GX&=-
H^A*^A4(S"SNC-SX8!+I MG,J+I3PAVWJ.DL<*P(KBI8*H(\$G.V\XD6@#88.D@#I;\$&YVOM6O-9L!\$/P3
M@SJY1_61S2*JSA/B4Y>|H/!\$W\YPKH"IM!&.@CG@400API(DB1>?5V5N M8\$U\$+;00S@W;I=#XW
+3FC\$LD81-HI;6T:P'@0GI#A.DBSY^&L5A\RVGUW MC*!I.&=379R/6!8@>9_79R4N!HK^C^/-%O:9_3V\$;MD"1-
VR3X_9=S89AS9 MQ21UR0D(+8!0L!T8!-=;|H\I4Z@!;!A9CD2PSI/&M-1P.F(H+!+S6,VZ98AT&TDZI@WB74Y
SW"NOES!_K_~9IG<|M-IHL<_M4_Y6T2"?\$1L<1*!2@/Q/C9U(DI\$R+!5GMF45*!<<D4+!\$OZL/M;Y.O70V
MQ7HY,-X\$;\$O!-I3@2MKDF7FE|2F*6L6*_-T+^RNZL.55L!B^RT*X#P.MOZ32_F-
"B_!\$T^QYW;2S(SE+!T4BSE@%|+_R0:8\VRMB7\TCUZ;|6J_MCA0L_SK)96VU>3ZKR P7;Q9?
M^"K7U<_PU;HW;^5^V6\4OOL/K>NEGJ>QX_MLS#_/3T8?5..=R!U.?YBV)= \$HF"(EW-MC)Y,<
&R*)1%I.SB@N>87_45XK<4_M.4IOGZ1!%DWGC=-I #L> UX9.*@R_<7(6)L#MYI?&H\$G07Y>@WVT2)H\$L\$
M_6SH.%J\$T38M19F".RZ>K/VHHE.L+!T(D)EN(B4H1Y M9X_0.=K.OEJT"!P.Z<G\N:/M!L_6:B"?".P?Q@/(O
/AK3OP2;E>U-K MQ^UA)GB*JR.NW0Y(9H24WIBQ_Z"08QKRJ.PKG3>*.MYL>>#H+EL\M/IQ+4AU0GH&S
#BD#^G!B>?J!"^IWTI") M4!SRX>2;3_P&),8BLXM6>G/!#8IP1D#M257LRQ_S>1UXO)I2J40MHQ7IRP
MH!IS)F!>3CA""%2ZTN4R\XV!! *_&1P_*#08NA>0BL5Q!0W3\$-!>#W_5.O*) (7 MPQBE8\IR%|P; >4/!8(%L.N)R-
_R+@BKL8C44PE.00G*(3_NH6A@C@!U\$ MI-'M/N 4!\$J UP_Q'GD.FIA=# @;P;6#1ST_B\$4!'W)
*56*SZ#H_@^77AR_MLT5X|*4IUV'89G0!^% (J7\$UX)VGVVL'CJLHIV&?A-MK+XT'EOD_W+^BB8JR*NPM-
C=ER0N@J3H\3C|_7^&2DG6T6,)4+K/Y&Y+T MI8E85N)?6M4H.A1W_\$-6% (7BP.9K;|H182Y.J"N/T>F*A)*"
^3B)'PA>C@CVF^"14VPD)HP>U_8<@/(H+; MIFB\$1\$)B<26(0W%1M..T>XPVQ!6?T)?&!!M>JYIGGJH8OKK3YY5?
J)@5! M95L\$G\2E4F9W&""%3\F5APF^<(>6MJU_>7MI0"L7(.T!Y%T0^EY/<8I8W MP/&+\$N.#&PDKRPA?
*KFT50Q(8;-5RL\$%T_O! WC>_#H\HJ?4/Q!<70#;_MQ|PB(5GW*SCBTBZV"%-V8L%-E4|P&^/-I#<6L!*DPL-
4!8T)WB.M02!\$UU&X MKU/I MD\IAG>|J@)E#YQ0!HJ#DV6!BM5_%G(T-W'\$W6W\$KT,!)F0J";+!0X\HJQ
MHT7%*J)BHD@OENU8.N/@9TP>%#(C<5!9P2\$>@K?;V3^%U)LH8=I%,*)>FD M&\$0D2R=F&^=I\$
U)>5YF=QA@9M.@(B\NFG6QKU41>?1/A%|E?ZW*MG5N6" M0)W(JK5YF#N5|
(H\WWL.UN"HL8GXVI/(EU<_X_4ECZ4\$1_D4+RNQD+>\$*M?RS\$)9W,@&|?U)0#&33.DIGE*_J_!OPBDL1WR^#Y*?C
D?_&K7!0+R_!H MZ>0K%|?7=O!C|U+VT"WB%|D>P.UA;|*)>+ #J4!)N*^<(C"4/NJA@804256E
M!"W90CR;8H%#R\$5>.DH\$+!D"\$20)X\$TMS83X6;|0>A^<=H@3_7U%_-T+C/ MH!Q/3/L?@&B^@Z%>^IU=
IZY=0C>RKSYSOSWD;8&E1>)FOYD-MB%>^,?_08
M%M|JP1QM9D_3=R3%!/!_9CF4!7LS9VSEGO\XD_Q37@Z<+2X:D=WMYF.TY\$ MI:9T!H8*)3_9M@!3-X7Q-"
IC4.E#G\$)-=2Z"8_P*VQ1,1",X\$*#SMGTCE^~MQ5@FJA#9A#MDQ7-/3B@_%#AT|@#YG>WC^H5'M\6CV?
*40)"7\$D?&UMOEN+I M/6YQ\WY,|\$!'"\$. LAH55XQ83_??"!EW
M%=F7XN<:Q4!9NZD)YK|>+|VML(-2@*+|@GRHE4*R,M>'B1XKZ2&P)SB?L*_,LG)I:V*;O M17?S#
J"!VNI6@#OU^R;7/PLH#<)"P^10B|=V@UTZ9/DAC(VI@IGWQ+%>T M<+)>^VVICPU2)
|BW9ID<|WT!0R%|=)MMKOOQ!6@5/T;K"D38:5+!@NNK#C M8^3\$#|D>+=\$X2|@SZW>Q\$7.@2.99>Y\NTW)O*S9
B/KZO>OT2IKY=54^5W2;_M)9.F<@!M%<&3_-\$^J3^484TT>E#IX'M5=+,"H|H|VQ2!^|ZT%AWRZ?6F&
M3B|3&@Y\$5;_R9"JXRA7")0\$!D)*LAW(@&KZ>52S!7U!_*X2X.RDO;""! MT45'5&8M+>B+
H|H7!#;)|7@3!5QD@P\$6|XYNQ\$)3%3%O!)*K5E6B>Q\P MJD-FE-V?&I>3SEF.G8%4,0XQ?G M2JN+&
(TWZ^%#KGXB4X7L7IVA.JQZ/HHAHLZ(R-3!K,B|ZZ.O|V;),79&D;K!7H!FIS M)>HPB?
G!TFFLMX\$Q39K|_B"1!7Q_7?..*J89C.6UK!N@^DVS%&X MB*W\VR1CW752WGS7,H^!%_F-UXT6F90%
|EZ>THEHZ;Y*OJ!6_(!45!#& MW,L3HX&%9!)>A8TLVP^<#<=KK95DC8&J).L,")BBQKI"U.1U&2T6/WL)#CV1 M/?
NY?45|FH\XW ^L#8Q&?XCZG|KQ>1 Y&EO MO^5IKY&G^IF4
L!L N(NN%:>7K!1SPA0UZS^6,+BK)^2S=GD\D6AV^R#O=; MQ X;\$N?#?KH-)V#U%G&NM-5LSD^8R9/(RP^>?
8;+E_6!OT&O&Y MCZCK'GW\$.N^@0AY+!H;HJA9@?]=4SY IWT/OYE|_ZL+!|?
SGVZUV??"IY^3AAV/89;PT_-UB3L;BQU77MCG^UM%WJ3;SZY^B%BKLKM_-,\$#7/6
M92<1P%N,8F4V+36.QDVYZHHMCD%TB&9!6FBX!SD#-!4!|3Q?NF(H*0"%+YG2P59?HIV3*.T
M|3/*+3VKT(W%\$A5.X\$EYP9%TIA),2EV"%#/_EID6.K<:IDVEYAO1N^1^B0 MXQ3(3D0;
|HFNTDP(C8)*E5QJ4;MM.\$AH3F^ (Q?WBTE|KTLLOSA)\$"J_. MH|*#8;|1^.(E|+3B>^HT.BF!ADMYXG-Q8A"|
(UO)QJOK?_M!7OP_!_L=DV M.B\SH;H\|P(!")>VRL0_P4.C+V;I8HQZE-H4RR3PFFEML"09F/O!5'QH
M^P9S&K" F6=CA+R#CXVN4>3T%T.PS;+!^PL2#UBO;06?S)H;\$!QNU M6T.Y*\$V9A^A\$XF0.6N)E?
V6*!#|\$1DM & MLLG=46KR#DE.T0/Q^ZS2RX1#84RPZH#ZE+ B*4I+T2@JDH?2BFQ"QMEIG M!6P7;57-
%DAJF@@|8SC-"S;/EC6C;:8STDIH@R|_PCBX2W&|B+G#3#WB2_MOR0X+6!J1C;|=439U!P>"R;E"2S"T"52B
M|R+! KZ*;H3'U*U"&6>-U<^+&E7JFR54.A\$4>=J'TF6J4(RPUQ)!DVCU_M^=AYVQZ MPY9T%6#9+2!
<19=%SA@T2!BWTM)N<^Z0!G!^/;3XKW)=>H&KX58%"U:O!-I MI/T_84HC_3/>Q!/4I,M; &4'QIQVT@HHR;I*
B#&=3)) MA^98CQ!5B8?EZD!DV-(BR+Y"-L;(CQ4NWOP_DL;9K*Q;2Q?)VC8HJ%"5(=IT%#G<&SOF1'Z-5!'"#L!5<
M=|YUJA\$Q-5?E4!|A5?%UM#_E+8!8'DR:N2N>-2Q:6^EO_-?E);YR00(+
M'ALGPJ\$6>PYO)!C\$Q_Q@Z8BDDQ_7F2DML|F6>R\$"4S<&D>BD<";@X\ M.1\$40R3Y4.A^AE1ZV+B;U)&<2%:
A.G^&P*RPFXV&RAR-8H5H^F2_M+S5#ZP?V_!S|S3S:0>&R;IDN)M; (GIGW9J)|LZ;R6> MFI)&.#PU-
IE;E&U3MV<#Q?8.E!014BOGD2KG-;|S;&.^&(IEPF&)=!U S M^6N;_!6N|@)=N/VZAR;7PKJP@4X&T/Z7%A-6;?>
&95"M;@@5HJZ1)DI_ M49G/S&T!0I=M#_GWZ;_U/7SO6(=GC<2B,+@?@R^+.^+CNZYZY\$&U3FL3^
MOKJR.GM&#C!="72;|PGF;@C6E.)6PAE8FW5!;W%KKWA,6IP9;_U8*CD?G;I&CH2Y53C@F,H
MSC*WT100.+;+6T+1>NQ/Q_HLWN\$C/T<+I9Z)EVI1&RG&%P6;P@K 9!N M;6;8C!UH\$F">WN!K#VSI/|P+H)S;?
Q_@H\$@T' LH+3>\$1HIU81>QY@B#K|XRMX7UH#IOBZDP^E*@S|HG CX|_87.%F<.K*!1P7!"CQ1FS|P=|5|D
M3W!;1"MAW%Y<<6?HKBIS&86!:=DP+@_G3A/86;_!H M+!7IM%;86CDH9 MJH4DD?6^7T+!>7?Y(1&
<74DWQJ8TAVO A)3F81@<"W7TDGR<1JC_UOIXD M%=A3D86);
ISKM,34G;2\$S)I9Q(UN6UJ)".U\$W09%54I9G22\$&M@;IEAWC MB92I")FCD\$S.FLHGFF!Q9R^ (Q2QZ
F/9.B:8_1UY2@(@F*)B:P!_YVW\$SN@_M*SD!>J"#MDAEHGB;3*.XU2\$%#&(U)|K(BVW7MW7!DI\$<649)'-H@>FY.X
M!7=&=LQ1_F^4DW.4*_W|3!B8P(P8MS0)F\$C\$|NQ37*"!0*FP3!UH M@2WE?SR006!;_V*/L/7B-
B&CNGELE4)&8;.&*H!"<1%#E.S.I* M(I*DY!3E!%;D,"D")2Q8./>F +.|1UXUP^6Z%#%IM(FMO2;|=3CP'X-D^5
MB.=;Y6H5B@=(C3@M5HGD)><2#72A0;_!FZHI!02AWPE""\$>RJ A78"3J6R M'3Q72-M=8
|GR2VE6.O&\$^"SB_@.G48Y#.C@-W8;|#68193|\$T M'@Y18Q|BI;R"VP@ER;J^MJ2F27^518)X0^D)TJY M

M8'SI6."QW)JUT.H429S!2R+*V?<|!"O&7P^'.JB>1-=)K@ANM11=X:29/9E_

MTMTUUGN+2VUHZY,>|VX4C@.OV1@&4+!+Z2B-!K|6GVWR#3Z()YMTCCY^NOAR M=7E|>Z'IK|58?M!NK_X|_

^_+E>W;@2>7N.AMFJN|P*6&U@=ATL4PZV)G M-|#.VE<6@)8|Q^!\$SW=M:SW=MO|(A|8V=K+E1WOME9?2

L|SL7)SP*3|'MAH.M)YEMH|VD*JU+51HMLV;:H=?!L;.:K*;WGAVDV">3KI35_ZLPEK_XN-1^OH#

M^>H|Q;K;S=76RX_G=U>?)^_MRJNW40KQYX+|BH;.:J2D24R/+2:SC2|H37

MO0C6P#QK|A/;FH^!?:S2=E#E.328(@\UIM+O>|F-(#4%^=[9C2_MAM|J^&MG"9;_O+?%39GK7UZR;6?N?+91F?

Z|7\$<7=H#<*A^_O\$OD8C;|R2F_M|0HM3#?JA/\$3EYE%7\H^U+>SIUV&X_19V150|X|'"!+1.%;H:6Y;?=U2+

MU77&XV|R3LO+Y|98R9|)7Q-8K0*MMK8?)/SN62=43T;|JNMT-!&3^<Q;\$_PK+8_D:1>2B8'J4"=%UCS3P;>V%Y01_

M/3KMR(!=%)S>6=:R_:5|!#VR.%"%)Y*O1RI/%.U|>V3_#|VZT;|UZ MY'"|CTL_!E&G"2B?KVCCT9?2_

XR>.;@X|M(G=-R1.XS/P9|DPM*8VHY6;=CD_M;.);T=LT@=@=-04T(Z;#|D2|197B|*U**(|K:6WO-

M\$1M\$D(3|!#|XSDVR.CHHZF/C*\$Z_UK8H)_YS|!2T0:YNAXKZ;2B?G>@_M|SMU|?<S)

HETRBI<0S;.:9LZ6;.:U*9NL|>WKSPLY+|LV.M2ER_B_(&AHE' M*|!'Q7P?U*=@7Y6/C*;7:7|H.CM3GN%CTX_W>?

J6N#)'X%ZC*/G;FWLC0_M|SUCH2U3>07|/%Z6+_P'Y10MP@W&5N&_U\$ M+;3:EWSJM>_OMY|?

7C+HXEE4USUA|CUFX.F.RT3?+LH8IR*=@_UL4P6)?^VOJASB;|N*GJ_8"Z|;V%2.H*O*&WC9V:|H|\$*7_#&

M\$5ODZE<_6Q_IZF&.+|'AOJ2\$M7W_LKLZ!1?A|PP3^/-)H"JJ|T7A#K"V1HULV|3*Q;|f(+@W|3_M>SX_(/2

P%+=F|AMV6ZHX>0|_|;17.\$_|W|JN'3/9C/L;\$MSXTR"|@L'+P)_M?7KF3O^&8/^|@'T5EAL=21QU^OKQ|\$NF2'-

LXL4D>GM\$\$(+)\$AF|V|-W:5_M4WM?|4R.BSR)\$:26R*|C1DH_-B=EMB#;1&TKF*D>#1MT0\$A)MR6;EGSM#;)|H-

|+X_NH>?>SU_M|*%9%P(Z?E'%M84VXM_@7;3_X#4IH\$|>+4H0HF'KXQT4"SK/P7_R|PT;7_ME?4>|E_-.\$'=4E

|PS7U|P(V^X_M#<&?3;|F*NK%ARP?95T83_MN"Q|D#-@GA|E;|(|FN#(Q5=7OWO>|;3KZ_1KP^PU4?W2%

H^L_1)M_ZAA^<ACQ^C|JH|?X\$X(Z+58T^.;X2/S^Q|D7M0=A?P*NQ)\$_P" ?O;_M&P#G-R|;OGAU>R3?P|/#O+_

E5>8PCCX.|&W+|F&TO|Q|Q3CLRU"4R;.%_MH^&SQ6UCUL;.%N#?3|W9:10(P|Q_YAC;|JDB_HOV-

R>H^LU^S/@1DE5AN@<_M?>R:8^|ZG(9WQBTKR=DMTD)W;./9K<-EFP3B'TU6KC"P53/#A8T6FXA';_#)H%

M>"/Y|;JN|G=0730_W)Y|MOEE|O;RXL|/;>S;)^WB_Z|O/WGC&3;M|Q?;_YV_MG6DN

|J^1%ZWZU'K\$ZZ|=|L|\$KX|LA_O=-MZ^V<\$LKFWF_O'6B3S'PV_9E'_M'|NCOCXTZY(>0#^P0US;<|'O

=L\$H&^TUP0?&)WC8.XN=D@1?^4ZW=T|_F)F_4QH1O;*2E_GT4|6|VL=|L=O3-HBBM>#?M?3^|L^X8

MX'7)|WL>TRKY?|@25;_NG.K'O/?T+OH|'E#1CZ<%B7_MO*|&GS?+_M41>D9L#O3-L8I^OURP|D:6:S_@PG=

366C;JD<|'"_C0-8N_MF?7COU+|E;P|D6V^UG"B;X#ZS?|+IZ7^9|<4PR^@(|F&)|H&N;'FM@<C>WZ|B*W

M(C%EB0_V@==+|JVWC7ZOU<0KJL388^UL+6M%)A)X#GBL;&\$8;0+_O9-V03

M|Z|Q5'=56_9T(L)_J>V^/GC^165CIU9N%+SD=X2Z9O%6_^EH'_G>52|HGS<

MV*S/;%TK|F7/W*F8KZ"8(>1|S.WA.^>>Z\$Z_R1V%|6|G=|JKW8<;8W;O_MJ:QD?|L7H+NT<=^#^?->

(UM7HU_/K\$9|S\$SP&?WS(V>_@3R(|R73;UOX6%<_MYA|V.#^/C@2|Y|NPE"|<%LW.DV|P|L|D|4U;

|=-*2GT@I79O&V/0ZV4_|U'-_M|)9LW0.;.:OL"\$&<&7^&-"PQN&P#2RR.H.ZAH5_KVSI'C#5;:PG>#K5#8|^

M#07|H*_/GG^;=L#5|L4'K4&Q:8G-079D;%=SL_Z|Q<(6PP|Y@;.*+@3|F3O|B_M|_B;_%S+;_|VVC#*J+_|VJZIB?@?

W>M9V_'H4^CA7(FE7Q&.;7)MGJ"A*|_|L5_M_4T|+Z>M*O>#0B670B.(HF2VOW^_+\$_+UVS*V)"#21H0|Y*>

|SGPV|UEB|&P_M343XZ;A)R_I4_K|^YB=-P44Y;5M@8*^|J6+0|+W^|V>=;_|@'M'7Q|S1_MKT|?

6"DVU(=F708^_0KKZ0IK;@=+QW|\$+|+|BUIWD4X=D8GOX4F_R0U|_S_O|_M|V_FEL_6_O_EM|Y|A|_GWN

|OEO^E7|38G83S>|*EA3|W\$|XN;=>|!7MIOLR_MN^D>?31;.>7|JW-AEY:OW>-R|H'7"_0?XFN

96Z=|F=1./=|0;TG+14SH/S_M|?1>FWH2Y/8E((>KX@\$J4_*S#X!+_7MKML|WJ%GQ&V(%D_-EC)D#L_MR7*;M

M>??_|B6B/_R"*(|GX&_P|CNIHL@|!#(&>5OY>|_CC_W12;|>|K164VMW_V|

M|!'4H|J@KKRS9X#;|^)_UQW@9|J|8ZS&T@M9VR9H;2@Y/7/F&M|\$*_ZQ@O|M&+|

/F9)H\$;..#6QPOM'|S7OH)D|/68L"VT"/O>0S';&T4(4|L_>W|JN|K\$M6MJAY31|H/4|L8Q|^AT@>NF>0)A_-B(-

|A1X_|R+RDPSPFSD;ML+WA;X;HF|?Y_T-ZF)GWI/KU;&_OB_M=GIMO=O="|H|_"O|Y|MAMH|<|/|9Y@&\$J

W^>8TX48>>|L|T^T?|5=SP>F_MD>ESERZ|N|

<|I6K2CK8/L7HZ;|SMV3|E;|_'MCBCC|HO+@)|Y;_Z+=/=Q7E=V6ZZQH|DDID-3;:OE3KRC(

MVB8NK4%O'R1Y\$|5^S2CVI3MO@3(=|_'U<|'"?GG/1|EUQ|6YKK|T<>1WN|U_M|+;OQ;ETM9#W3>3|U2/?

KT*O6_VB#P4?E|4U)*O_M_TKJ;WZ<|QT_PM2+L&N"/;7SF+NH*|L|NWJ+|DS0JMA|G|OS=|J%R|L195N_M.D|/=

|#V|3&CK>-V10|4P=L/8NVM%MO7&|K;|L7MZ?S34A|^?QE@+QB9+Y%>R_MQF1_*?Q'EI9YH|L\$-

JS1T\$3'_|R|O'7;BUJF=|MC9;_|B9B_OFH9X8M|H|T'_MO|M|KVC84RW_65^AG&GGGD00L39S|9KN|;#15JF4"-

O%J%)Q1OZ?1A&TLO_MH"J6|S2*RYK^Q|L;3B7|*S|2B"YG?S\$&L;_HK#X)PO+O|=PGX_+=F\$#_WE

M'0%YT_X4(BO_Q=TCQ|C3X6|B;.&T&AJLV^|Q.N:XVONR87VZ_0Z_?Z_J^N_M^4|;B6SM;|8Z=AGUH|3:P9'?

&Y#|9C@_2|_@;@HF*A|_"Q+Y@F%/4|^&-M81|D@ECY|H|8|0B_/6'B|J\$|F|T8E/DV0|OY_.\$B_6\$!/_Q*=B.59N|;?2

MI?';\$W_%P|ZG#FS9#W0F2OQ_OJ?7|_"F<|H|B|Z|S0377SOY)+;8@/K8U?&KV5YW+<(6X|L;N7Y\$SI+/_R2Q?

NP"M_M4^ML0E/R^D8>LJU@D&|&68+>SIUV&Y@9K;_N"%2|4#^Q+0.@W0J@/_MK;_**^Y4HF'_F:S|)WA?

AEJ>=8^PG7;6U7_&C_WU2L5LV76_.\$KE&B2\$Y=-|MBAR+695K610;OPLFYGKQPZ?

9O|3Z/2W%#|S|/Q^O4V;H|W_H_NOK4)C=L_M3;9H0|;.&%BB|D^N"C#|K8N^1JV;_

CBA=AB|ILT;_.RUU#P|SPJ90;3S;_>K>H^N+!+9|P|A|&6^CMU%7

M^W7|J(L\$+|D|Z=EPS#J8_MDJ>T_4^TG=^0(T|K<|8_*;+%G3V^T-MTM&U;XM&AIBT;(^&-EAUM#0_|>V?2

G#;V|U(^%15G|KU)E>Q|S^D^O|*+M8SLS/D|2Y|S|>|2YZY1_"Z"|2(PDG^@^>U>_>D_A\$&&EZ5^U)_D;6OWK

M|U|=Z>|H|)0'S|D|S;|0"RS-|S07_|/8C3"<@W_1Q=EHZC_L6@'|GH_MKU755WP_A7;R4-8TNC-L|G8_3E57_MA"&-

_'3\$&-J@JK?&T&9U;?(4D|E+C6'.K.ZKJ;BC.%ZJDWVM@NIEV|>9|H8

MCF^UL37JZM2*NO73JTLGFB/VG;|1?8PT9AJM;3U;|;(*P1UK8/M)?_FLG+MK+J@'|L+\$U*?T|W*?

R_|)*=G|_F1=65PB|=BW3H6V35|;J69D)#PIR;-C_MDN=;|&-IP=W%P3U@CAIUB;I29/MLSN0|0|?0)?QC_HK7.\$X-

DRK?_!;|8_M)TM7^YV=N_11/N6TF)|L_K%YYSO=G3_MTAR'K;C4MFFI^NY%^A2_KQ^4-B5TJH-

2M|T:6|V^VF_OK^D)2/4#TJ;L3H5_MT@|6ELUNSN'K^N8UZF_UD|*9AC?J6&QM#8|?

M|WWW=X8SUYNN3>GSJEF8&G_M_-M6IW|8_'E_C42?|@5=(9*;UJ#?Q@&@ZA6&.\$&<|';.%J|;KTN_-7|NLBC_M\$W_J?

V<>Z&2|V|)V9JGAE'|VJ21_U*22VW%_W7WG;_N|4_4_46BH|HYH8_ML.O)O9W&K|A|+7<2J6H&8>D(L;|!;U>-

|0N<"0/<"6/G8AWRK%|5-|G_|R4L_M4'W/6|/(<@K_X017(WW'_WW\$SRP8E_MLBA_N'X:4_&|J>B\$2_-EZXH|XG=AC

M7K12FF|PCV3H;K=7EXX=Y#J|G4+?(ZXP^V*HD;P.D)8;=#M^X.5U6X-.FK/

MK*HB=|!*/F|Q#0MEZT'8E*M;+|AQ_YO;_|L'"@7"+9NK#S|J9^&'H|PZY*|*|W_M

|OY|L&27A>|5Q6_1A2E*6C@X/^%#9J?1_YA_1^V-V*?_R8(X;289_OY+|M?|?L^%=6>EJ@A?TL=;6_>Y4U>9QO

|%W_UD|C2P?_G8@L_FM@;EV'"VH&WA/_M;@;S"HR?2

P_7TH8;KM=U8S>6D4|&G\$^+=+1R1F0O)T6/_U5%#@4'R\$PR;%C>M9>_';I=4S7TJM)Z=1^X2S|6|AKTG(VZ*D82?

D_M=1%Y01X@KU_5^8|Z345OWIG26^S&+G?*=MAQ?|S#3|_8H|F1E+@MM)6UE_M-5MY8DG=WW74|YAS;|J

AHM!#43X@37@(\$#Q\$|VWL|OQ&>8&LOAG_'VWS=|FT_8#E\$%9|/28|_W;\$|I4H4O5/6P_M/E;M=-N2?B-0O6'!UKY

U6|^F|J_OVQ*5|O"G=8A^_K<|!#10\$/?WJ>WY|MM\$YT.GYE'6>OW1|@P*Q#1|;|;\$J|O15'R6M-

>B|O3;E^H|029MFVE6+)+TU_M;|2NJE;|WH.E6_V*53?E(#;H|>JX|HOV&CVUW;GJ="XEP8X"@|NL@>H_V\$/_

MTU|UB|+|A+M;8C|&>"^6'8X-14-4=+;8O(C_BE'_MY|*_%VITG-@>\$|^+M>J_LM(UBE28WB?

\$%YIC'QFZ4|GE;J|JDU(FGK8PF8#/IN?PF_MMK8TZ_3QU*UAKC+_|B>9*_-

2/V&^Z:Q>RSFR9_D7JMHWO!5O4.6.H<-U3M+0!1%98.MP%):U6MS-)D0=2C_ORI\$=?@YRMTIE-6K^*(^>AGV;!
E7I*.DF*/X232'2B|.MD^N*Z8+W*!O.(S"IRZB*""B|@>3MF#_J5'(RP*_.F4YRY%8*TTV^%4TJZE M&ON??
TMYR:A=^>TOIN@MXM)|XYJF56%&PB|1X'>G3,8;X)>J54P-4,UFU\$S M=W(E(JPBD_B@&T@HC@AM_BMCTHXL?
F! MD0J3(HTUJZNO5WPI^/92L.T+H^>2LAI@>NJ%K!#& (J?F@TV',4^P!)A3 MZZE69_6D\$(&MT6#;..VP!
H!A%V!3I5LU*NBKEI'Q)1I Q^EJH=; H%3&E!86%)I^A:IV=; &2UWL<<-O4FY.G MN/5: Z/=5=OM/L&-X+9.*XZ=X-
'@YIMM=.I/IS(3#K>H-(W&Y?BSGE#&25D MHT7@HDVT\$E1B=N#!)11>GVR*;O5|E.7^&4>;11F7/A.7IZ3OKO:
JGG*!&^MLT-W5"! (M'9K8)GDN1|9EC8EDZK 4CF-I6EXX.\$J. Q(4<U#;ED@X-9U/ MQRM(=|8M1'2D49/Y?
J+DS\$3^&.&BJL7NI6D-.6! '\$@>^/DRV|PHL M8""MH^K\$@<2!)J!92*>^! LS7H!"W5ZN|H#%>1+SL.O!7M:|>%K/_
MO*@!K^+X"S2"EJ TM7>GU67N?@*>%>?>)'<@>U=S%N1JM=-VTFMW.*OS^Q M^U.M/."K>?.:ZZO?7V-
DC1&S:6S/C&@GN4&^"ZW"KY*B^X+Q=5|N:2H&BG M:|D6W-6B?5|9UN0:A7^*(X^:(KXYPD*.,
(DCB';.PA'6OCFBAQRN)=9K|O- M4|S JPJ|A3L1#.RGOLVG5^4K_\$(N:-F08HJF#2|@N;EA:|53J?3B_-?
%NSDU*GIK(G8J4ZP(G;J MRK+=FITZE|JZM?7MGDYBMWBC7^C^V2|ZEPHJ<|E&MCO+OE_|M=Q*!2EW
M*0:7AELRL 33S2))RJK(P&-BB2|EX(DGFL03%>3@- &\$15EXRL(WCC\$JS<+G M663H&AU\$SDH/5I?
J%6:AW|MU*CDXO2@5FDF?H/B-J4BZ=<-Y R><|2B7 MBY?BH4@R:)2-)X8BABJ9C7^!H73*QO-
#\$4.5S,>_P%#&T63D#1^_J UH1Y^ M@?2R-Q@76')?_@_F*/8L"CID4D'3/\$741C9'G|JBEIQ.I.K*:\$5ZZ=5I_E
MM>.:8-J2/09CUK|0G/HU.1NRX;.:S9#P-N7_5W57.CJM0=<4(7 ZRH\$N!-, M%0&5*_=L?
BS+)Z59Q\$+UWE5UHZK!WI2;K1>^7J?>*_|73RAXO6 (N'K&/#U M.@5?&:YPL)315|5.5|WMM MPL@=/U=-@Z\$OV>,
<4>C?P9/L9CW=|J2.X>^0KT80IEH'X|HV|I@^ MN9|MC5OJHMQ\&.>5&8C|)C'N M.KI2V_FAG?|5'L(* #)K?
Y+9V6Y^9T<.,9XQCKMSGBH*SMFC_6ZXL%&A&MWNVK8Y%C^+I+T|IX#0YT-V9_H/^(H?<
MLD^|SE\$%&WQW|G9%+JFCGUMH.FZQP|A7Q:22|H">9J5|H>(5|%)1ZIGP"9_..+ MUF T^+|RWCL;+
#GABUJB#|H8+."K8#EV;=.B3 *4FO^UF>)@ESWPDAL C.P7 M(9?|ZU=[4(2F|1|_FB;PI?OU O:S MS=7%P_65
XOI^OJYV-_M7-?UPJ_.YUKAY^MNI6GG7<J=.:OUGYO&D2^J4_Q5?*L_H907I7;0ILO7%5CF MPFZH4Y+O?Y@=*
>@31SEBHT8FM**H.DY\$W>7?)SFQ<^I4TS;-/*YI>AA6WC3+7.<*|4@U.%=|43|?;W.# 'IO1.X;_ M=|K @UU+
=H|Q!16)68JS;O7>4@Y=N;26P-3ZZH=?>C<@_8A'FA^|3R=BZ-,7O#;6:' MKR"GTONW*KUO^
'HA1;=>3#1Y9^%X|Y0(BV7WBF<-7=4DYOJ+! MOXAER76<&P(+N\$' M\$Z8/IL_2JMIH#?JHUN7GD-
4K|H!>N|VI835USV^_)R8GN/Z.(HJXOY?K+KNRIP9DYOQ?
8.%CZ@>.&G8Z^N*S;&FBK'+;|8^LNEMFKD=|J1"L:C#QJ+J;"8^&@5 M^INBUJM\$G|F%HY_ Q8?#- U2O1:/9QJB3
MU5VMKJFNZHN V.QAN\$.DZM7PPPH43=5|6NVEXOBB(6A4:6)L=HPZ:2X;H.) M42|5|H(4>P_+"|9@I># 1A\$
@ZJ*!T(%&(W&V>L-FKW@K LX MZZE6IT(CXF/B8|W=9+*|G&WC6UD=4R*DYM'8*/J0-M M40?:N/2I23:AU?;
|HHEM+TJFM#V-.I>|BU5-V|MIAVO&5J;3JS:A-0_.J^ ML|?_H^A_|J1+KY>*7?75|?77RY^>WRM?
+W|"KIYN+O|_/GFZ^_*S=>'Z|OK M^X?I|>?>B6R>MD6M&JRKLYXB|Q@02RU0.* Q|8X_;;5YL|!A|&N)|LOFNIN| M;
<|D+&G:2%ERS2|U3OG5M>LD6K>6ZVR|:17?>YT2GWB_5KLK1>S=.;4/3>Z M5;7AK6L-
UKEN+5;4|_ =P&65|A^7ILYJ'|MJNT.O M|R'V:N)\$4AOVVS|!+;U8N8OO* @ZV:5IYVJU;.:6C_O84^|5?+
=Y^S&XW^_MM.=N|) 3QA7JQ<5L(-*&RI7|Y#H.O\$X%7-|K|>O#D&_@|5BYM@/7FD;IC|F% M3:P8C<OV.D?
A|4\$|++|2/D.C.P2<2SB<+3WDM>7<-WB|MJ\$W|Q:7&_//MK |>N-\$S;=|+Q4GY(CJ)5FY31NW
7>\$KQ>VZ8XYC.UXQ^V|J488\$=UF*)X M2|*#BQ2|K6NIG'K8K0=|R GOX5G<1.&^:43HAK8JYJNT_M_JG=
M_VFV^|_ \$7AF#2RC|MS@BV-6).8DQ3YLO^|5D3*.UT-HJO(VJ|W|>G'B3>+;V
M|UWNI&Y|RO95|V+33FO0436|K5K6*I?N;WPA.2@Q:\$T8=.684|T8%+O.JUI! MST-B3F+;|C)G*=
|4.VG;=EN#KFIJHM|Q=CX?0:Q)O^F:IR|F%FT8M>=|'EE& M^)S\$F<29)|J9G5IR9JUL-2VB2V3B3>)-
XDWBWCS@A_ =^|P.?SENDJHRYCBPE|J=|Y ML#0.T#N:5W5T*N:\$D38:P|VEA(F"12+@-)H#?
IUT8U'=;2QF.JW^QR|W3S0 MOIXH'\$U1|VB#E&'J\$/4>0.G<|AWWT.K?;B@>9\$Z+JA*@-;.|(*I+B&H6
MHDB#U)DZ%;KK>V%WBJB|68_Z+N?0*\$3-CFRO1&253\$2O8M#+/I7%8^M;P)Z M6|&XAY2VC;--
\$0J:M%(@%N6)7OB-Y2L&+^5>F;.:Z07&O35OD|DZ:CJL@_ M2AYD_FU|/%@SUB.H3HHX64?
I*3Y\$W0%2OC;.=^VIG=S.+,%5G.XNH010AZE09 MXH|/; ZVV#/-9VIGQ(F"*)^I4&.7;#V/KO/-@|1!&?X\$*HPN?
0I6\$R*W M^F/ERO_AW5W?"/#Y;.2L|&OTRHV>LNP5TJ^V_&?N/5%PLL |H&I%LT4GZ^1 M*MPEO+45*-H+
GZ)1KEKT2^BI678N(+**052ZZ37AIT:B9X>P60%HLN&SL?N3.6?_ ML_O E,OT5|DE9|!JH0V^_ ^WK'Y(AA-
I'"E1NRTRL/6;A= F7YA9\$RTJ'_M_?NM@:YVM-
X.NI#B_8=&TVL#9VN@Q%5B623UVX2DHT325H&T2I&DM09=4^WH MNQCH|*4ZFU)\$'-(4:>
<0M|FL%I&:9!#%MJSR"-7G|H\$:/7F3JE^V;.;%E M?&X0GS<&276N^3A%WFZBJH>;) |PH5N4HX&Z(VX
W|E1?;*+|J|RB1|@B.C.M.D2=HQ?2673A_+<|)HOKPH?/O8"?PCO:TF^TZ-JZE/7J3%5Q@76;DU1W| M>^&&;L3N6?
#DCI@P.N_8R'_ T^%U>9HV>-/CJ93>K89:"190=0AZAR^5JHV MDMPD2=XL-)*LJ#_U*HQ*UDY4=\$E4-
N.)U63Y|A|!SK2RDOQX/&NPSPG5-|H MI|O %|D3/NB,+CY^FE9&HC^+|45?RH^%Y7;#2%/YR\$=|LITUJM@79>4/:A
MS%F@|)'Y-"|M_TR@|IN4?4(>H0=8Z/.N4J8#;SDQ434;IE+8;>ZU|M|_7 MC6Z'LN&UAP|Q=YV14VEY6R7;W2?
F;@YB+GK3)TJ2IHJX&VCW2;>.;@YZZES& M=@P505=N*.;B_OQYKS(O-PQ5<>4TU)!*A"@3-0AZA|UB#I\$;
(.48>H4R_J M|A!^NH?G\$|W"CYQMI_UZO4<#LD'T*_%G.9GIPO^8LYO@'? A3AP5EVVP8
M;=Y.7S5ZJP|BJ>=4HQ%75|H|+B3 MR=.P;|KQ-AL|66E\$P&=UD|3C?|.\$W.H M^&Y;V6:3.0F/I7<
9<;1"/@9F|G#*/*;K|.\$W6(H?NYL|5549R MW8Z;=S'OQ=*T?TF-E=9\$)F@B2VWVNX?%Q*FB..).D2=P|OC=>
<>WT> M=TD>P93Q%UIDYE|5S|97B+&XOD-I3|F_.NM|=AIM/7.*TZLXL>;.1F M0Q8HA|8J>EO7=RE)&?
J|PX*SR)|P.T_.;GK*/*K'|\$/%4 ?U+4-DU?XK|0\$ MX=*LT6|_S\$Y7|79V;DA8EE8'2@WL%VMUB_G^LC?
R;4VV>K%84>A|S|W|AWX>) M*#87"NC&&TT7N|/?_!O?Q&)% D&SM=5JY?E3*U-G\$F<>>*2.S4P)|NJ
MT>FK76VUJPLQ)S%G4YFS7.K&6;..\$-8/?ZL)F^JM04?5N|E.YTV) 8E|JW- M>Y?BSTXMM:71&N@|53-(JXT6P-
3MH1>WR+.;X|3<|<9@#|VW-FMS6P5*VGJV9_ =5 |69N_?2 MF"?E4NI^TL|)YA%RYFL?2I:QBT=,LI#3?
TP7\$EY">E(I4F\$W6(.D2=XZ-.?*^L|D- M|DKBANN(SZ A-OICZ?GPBJ|G/6P'W%7;|9ULP(?B0:B3BGIT^*U.;B3:#AB
M|EKS007_WQZ6Q2L*|LGP@E|HAA3O@&.(SE.CJKI|= &(NPU#GO+;+EB M*!8|16|-NL_|J0|TF';.M|&S@Q; R|WF
9LP+W226_7QM8)|.J|4<@48>H M0|0AZA|U:GM&R\$|YV|OFC|7H=9W9|Z &""W8X?D^E37FC->B|5M>@R>'
MA:K5R-E;HJ|H|&H*|DB3U)DZ|7A^Q7%_2Y8WB>6;JH|LOP15#5AGR/&_%V MY|SR%D'F6"&STA:D|CT6@|+
DRS8_ MU0D1=8@ZAZ_BVE+K'9\$7O7'RI7_P|N|OGG@? MGZV4#4Z=5%?26;F4"K?C/W'KBT27 M|EYC51V4*7A>
(T6X2VAJ)*^3HA)PC1.>X0 MA4LWMR 45R2?K-9 |ZP>H*>9KLV|RVO#;FNPPG5>\$51Z!)5CA,HV<;7H5+2 MPN|C"
NIH*Z0D%0W)%%% E&'J.OPXHEL*=DIA4U=|52N&Y(CZO.W5V M.Z'X:S;7B;V;J0ZUX;=OA<|7457|3P?
H'E%CG%PCG U1&?"N9LP+;93?IU6P_M2 4\$1|VBSN&+|BZ%#|X%| 3>\$=|^LUVG100TIZ|D3WEN08NL"XS
M|NJ_ :UP0S=B|ROXOPNKS-O|=9_5_O=+B57FP%&\$A5\$';+. MX>OT:B?
(#1+D1P0&36.\$=@&K#;UU6Y_Y|8GA;ZH7?#"-+9V8;2"U)|;.:L: MC\$M@/&8KZJT+!"WWZ4">WG=
(#S>=9CGA;J|7UX2 L|^+G&E?% 8W7S|M2P|Q M&7\$S^NXH2%=- KBHV|(>3.&T|9=HN;..UYP7
09B:C+|H3=B.T:S9Z|H:ADM |P(>:N.W4|+>6KA+EI MQ-S_@O|Q=YV14V7|7B6|W2?>.;@YZZERT=PSU3U=N*&Y
OQYUS8O-|5<>4\$ MUY *HB@"3-0AZA|UB#I\$';(.48>H4R_J|@_*^H?G\$|W"CYQMI_UZO4<#L
MD'T*_%G.9GIPO^8LYO@'? A3AP6E^V.9|=;@TU|G=4VX|0@J|&(VO#;.:|C@ M-+<20%NSNSO'Q|8;X'=O|_|?
<"0">_J=#) #6JT^?7.(G4 #L&^9 M|E^51G.HB\$@A7|C.48>H0|0AZA|UB#I\$G7JX.KM\$<^Z8 |X0|VN*'|><5&+N
MXAL38&H(F'V",1OPTB&|_O5%FR|Q=7J:R9 R<O|4EE\$4BZA|UB#I\$';(. M48>H0|1I"6J#84YTYOO-

3%0%!.01=QD_0L#LZR05!1U! 3VU=8U\$CE""&T M(491+8RZ!*/3@M'V92 Y1OYQ57Q9\$;JLUL#0ZM)S! 1*/S+-E?
L3Y"\$*I4G MI(V\$%2'X&9O9PRFCXI#OP\$12D04.3!U=NMJO#1_F&NDC 2!7!C:P0_B!4
MTX. !*!UJKV6@/34DU! 3!# *LEP(C!B3!SG4/T.WYIX=PGX=PL@!/'!UYDZ M. !4(WIS!NVWB_F;A;I=ZJR*
+4!HOWC3UN+MS4NU;.#8<7=6XJXZJ@LTHHW\$
M!FPV9(%B;#JBMW5GESJUH1X+#+B+ /D'E!AW4=)7Z%YDG_M<*? !.5X(MG0V#6?
FO.\$&% .Y+BG(=1'G'4C6SJD\$#UK0Z4')K0UBK6U+CE!V!VNRU80% MBH*KF_@+R.5.Q/%LF0SV1M,%
!LOWA#;7T0BR8>9H77GNTMSID&<29QYXIQI
MU! (S!9A*6^VT3=7JK8!1(.8DYFPI6"W95PUKE2=)E&S!9V!N^!IO=TKI-Z"1ZFFA:YJW%4\$6KJJ<5=Q MT/I*=4T!H!
!^\$UIM!&AG9N@.N=^Z*+&^!"P!JYV3^SC#!>)K&ZS/Q.2!(/ M!70GIA TQ"): Y.9'3RZ'M0YMOBZTP<-
N%.CU#N. "# MULMO#A:YNN-G!9K.;!7!VPHO7!-1!O;."G.L*6.'DOWL!A;@5;
%y.6TT-!4E4.9'U3.2(!A_GD83K)160@7^!"TO%JH*"-G MFUY&?;ZXN'JZOE/L'^./+!>=>^7VDW+!J^_!>?@?
MY/>+KE7)W275!>7BM! 7RM2;K_";A!O:SY!OOOZWN'Q!N+Z!OH=?O.;/H^ M>7WU?2LMJZ;_1FPGKJ
!>=>SHT!1=P#P2(RWZ.&C?0&Z%EU8JCAW9ZU!L!6L_M_C4.2EV/^E*>XEGS'5!R354JEZX!P%L.K7G(?L0_^5CK-
U=M(9>E02>?+!+^AZ!^7?U<!YQ;7;/PJ.Y5OCYNEN9YV;! M^!^?K!K3^V95LD
W!KVI?RGC:XPRI>>>NO7%80)Q5^P;(PG!F.V55;L>5D<^MQ%QYA0?BUY!VW'+Z+*3NFP7;LED.4H\$93>STGZ"
!HNOCC2LP43;27*!M M(Q-00>QIQLO#6M'3MZ?P>_3&&_DSIKSH(?A2@WUB>S5@Q!)LL6?";'M9'_KE(=)
!RIBCYS*W\$ MSJ8FB2>P.82/N!2+9AXD2C% CJKWZ#Y/R!OWIM/R^SHM.VF5G'9
M+!+.6^M5^O6;R6*.2U05=?@CB3.+V!HWT_*64>5!>6).8L!O/%J>6).8LS;0?5RGY?M5G99-"QXJF;ZQ>CZ
MRB+^ME857TQ<+KXYR8B^=R?J\$'6(.L=C'G3)F0Z>!8.8!BT!Q+L;F;K03TE'6
MU9CV079KH<5.NL#1;1CT3#";5.GE&C0;BT-!(-QPP^O=;@TQ%)J!95U6Z<ML%O-P6IU/VQ13F9!O-MA)?
+G&VL(+S6V&'\$(H0=8@Z=36V.L;+UA97Z;EN!GA#Z;7!P! M_EG.?C=;@H;Z5@594\$)4'4"U;S?2^
ZA*@@&4HTA!UIDZ%SOI>N-TB;F4 MG@!/*!2=0Q20Z;R@N;VAV*\$RMX.(6XL#!RE?6/#(@M.J;RK9V;2S3>
<%T=CD M:A%@H!M6Y3MBVR!&?RI<8V@=#U@K!<.;%U=U0U*HC0=6D6F.MPI6!HNF !
MP;I/L#IF6&US!&\$/L;IC)9+;U32UKU4U+9.540;BZA#U!"J5!GVYIM0QAHP MU;(ZJK;10TS
(K8GZE08_MH;U^O\$!8W#U4&Y_@2JCY#;/&_ \$A^J-Q.B4\$/E/M53RV?G;1449AVJVJ!2!H!U\$U""J\$'7>*B25\$;
!";\$G5'RM7_@_O!OKF@?_MJ\$1^+C!%15G!MBDFE5+@=_XE;7R2Z>JV!OOM4&XJ>UT!3!A*;V@HZ?8+.L4)GAQA5
7!65.P M>IP5TN_NW!Z2D%5G:XJH0!0AZK0%&MWJ8S#255=W!G!62!#;)*C0!;L;+U MTOBPO6%,7X>Q!2>\$;S)J
!CV)!2&D_FG/W# K!3D;B_4AH-0-55!VYW_V!M8_%)K8X4HV&F5AJU7CCO\$X=+!
+0C&E=.%3!8UNRO=C4M/2Z3!@FULK5V MP!+7B;6A9!4CA1*V!3!H42%C;TVF!HOOJ=
(RS5#4M4U4#4(>JA!S>QL.M M5_YCQ4F_K7;J!P6_)(?KAB7B!#I3!Q2GOSFC!XC1FP.E.M>5.6XXG!K/B""V
MGIAT%5WUEE>=0#\$DUPEG0UQ'&S=;R^T47Z25N\$CE2\$0=8@ZAR_=NW#^6H31 MC'E!^!2P\$!@>W!
!MU;KQ>+^Y&H!IG+!C NLS(!SLF6G6P>Q8!N2.FK-H! M-O(?/7Z7UQFX=;40M!M+7\$#"2!"#J\$4.7^U7-
T&NM4F0!R!8-TSAK!T8 MM=8 6!3J)!^Q^#8_.FH8PR7^@4W!XPG58;HN\$!'.B3.JP_A;I#/'=4WOWR MDA
7N1.^Z(PN/GZ;5D;B;P(C-Q5_*CX7E=L-!4 G(!HVRG3&L"TY_HUD69
MLT#A58)!_H5OX6E43E(NDZA#U""J!HURE7!M%<V0!5DU\$ I>W&#GC425.U M"!KZ4>Z_0
AYIXS=2HMYZN\$N4UB!N;_AYB!SM2!LH*O\$M!N\$FW!SUU+MH! MAOJG*S>;G>XX#.^L/L!L
_R9./!X>)'Q07N#%@8A50011%@H@Y!AZA#U""J M\$'6(.D2=>E%GOYY;>4_SB^OY@1L!WTC!HXJ-
F;!%/(SW(V!X/-6@ M)JL-GU/6AG)!J!VB#E&J\$/4(>H0=8@Z!V3!S\$Z%D>;BV-V-EP;HA?#T'7<M)#R(XQ!L!1*C'?
0VY6=-R"(09BV!>6GQU6;I5"&X)U! MR!RDH.)_*@;@Z!UB#I\$;(.48>H0!0AZA!U;N!Z;E-!<<!\$VYRUDEF*3
MLJ&X>EP=7(9B-T&L>M;XXO+5V>J!NM@;FKO=VJ>J*ZU M-0"YBAVJ.SM(.H2#1ARA<6/+*
JCLHC\$04(>H0=8@Z!VB#E&J%OZE!Y M-G)S<%OBO!6\$&;GJ'K!>I-I!T?+%N&#JWMWHPC3#6>(SM7*-2!
<1.@MCI M06S!N!\$!5<.NV!H;JM?LU=L)U*YDA@U;ZL@+!WIB!J3P&GO>+M*#UVG.S-LK3*SB-
N!LQ&9#%BB&IBIZ6^14A\$T!_!62B?3X8L...O! M52P;H+(GW!>H3^U'7XE!2\$8'R*7!ABI75?
3ASPR8\$A'EC%P8\$E^49K#;K! MOMKH!^0^>_B(21X8Q6+^N!65IGM>)YXGGB>?WQ/-6+7D>IP?K;J!CJ;I952P?
OA;301 IS4P5@@HJ!WK2!L3RQ!/*!L+RY8=KZ@5B^VQKTU\$Y; QV_>G;6N)ZX MGKA^Z!?
4.%(*ZW6H.N;B609J>>)YXOF+CO!8LWVL^FK;--6V5M4YF)Z M8GIB^JV8?JE6Y=(!@F?
8A(L9!&WT&OXOW2+'Z(-SKW;U=O.9GU?*_JW!_YT MW*?Q!^_!8IG=O#H>ORY72"S?@9LMP'K9?
GORPOA#@=\$7?/F&*/1OX.GHWX4+!Z\$>_LK"+SJ70!5VT(^8HGUS!D;N/57N M(-B
%TF=)T1_=G_XNJ135RG9XTTIO7!8UUVTWQ4!JV MS!K=<=CPS2ZW?_5L*^V_-4DB-!A;C^RLV'
!JGIAA>8;1.6\$ _AXC5!; MKL!E=2!S"PFOQ1X;>!#P+RWC1;+ #\$\$\$TH!C!20""_J6(Y=FI4HDP#E!GJM
MICBX2@_!W*_.1@;D;_!L!L!\$)3AH*K!H<J JFFCN.^S^8/8TF6%VI?O! M.ZO/UZ?_OYYNKBX?P*N7^
/!Y^1F^UG7AZ=^!C!<7<^G?+V^87KY9HPE=A<I<^ZI_8!9!_B MOWR.)P^Z^G!Z_!%N!U2S*_
(6M*Z_(-B;RFM^OWSGFF@P)+%JO+!4!;=P!O! MNOJYV3_7=;WPJ.Y5OCYNEMIVGG7L\$K=:OWGIG'DB^H4?
Y6Y58\$C57)*Y8L% MXYJO_GM;%2Q_#L#Y1HTA!_DZY;7EBSO9_K!P!W
MSKY8^5WRA4!TTPS;M/*;IE?/L/4^BK'=SES:X4093_T?MQ_ X&U#2& W(+ZH0!MK@)\$OZZ+S)Z(W_&E'=3
M/PQW.B6X=3VD&^!2=2VZ TW!MP.^6H5-DD#KW?L!H!\$65\$HTV;)"N!IM
MXZ!G!"4AJCF(2EQPC%RPX=S0#ER@M0&T5\$MTR(N("ZH-Q=Z.L\$FS-Q?HK8&I M=6.0G/V?*J<<!"!7YI#X6&E?")
8N=BI<-DBQ*OPQ\$Z!/_?W(QNC-15MXM M00B+Z!VOW@!ZM#2!D-
_OR6\$1HEL_UUZ8_B*S0&W+D!3*;G*/8;.P^\$1_P M!ISV5&\$AIG!5_H9;-(*5-LO*KR'_C1A
78C=V'MWAE!V@V=3E;0&A^\$6 M=S)+D_O/N_*=3!;H;^VF!KA*;C M0L&\$(9R-)F
)JVMFMV=V!7R;!=OOP4KJ(MV9?ITQ0SDM>6GPUM!&;PBI!Y MH30!L^8D^XE?L+E!6!7S\$)3-3L!Y=WFG10
M7HL?*=Q&4R" T30.VW2%D_80Z;J=755\$W0:A&\$-K4%;@;"/4PQZ5VS*!_J;" M^CNV)"8GWO&R_5!M<_L
((72V;LP&I!^W"X5=*(X D_MGY*77!7!HK0;C!C;S_"4.JC*TBQCM@;=XNYY;S2FB-RR_0!GXR"&'8'3Y;%! MH!;=54W
_3!P-G;SWQ\$X%DB'_A-3W@W9U/_Q7IG9P7<6B=+G>LY&VLM!Z;CE_KHBV&%;/Y MJ^E+!F6)/D\$%;%R*J3;TB-
+YP6GY\$4_RDEO&+R3_M#=#ZVO6N9JJK7!)WUR MU>H\$0A4!H7!@PPQ4NZ?V>ZOM7@E!C0;?
BJUL_!UVP@^Z;4ZNQBZ=8HG+ZJ ML92UE(=?(&U)*XZL4=;%-98.O6M%?
G7S!8!\$Y_09.6NCP6!D6NMV#.K3C;"90! MK<0T/)E;G!JR&HJR+2=SBT23P-H!>7\$!8UB?_0TBH-
#1X;.08V!6!W=AGO M1Z'\$!X+=T/1"AZ)B!%\$9@<>O\$>X+S.CL5YSA2G!8M;f\$MT&.*J59 MKL/ZL)FU#K'3@&9?
50#E876*GK;UJ!VOP!@DZ-H+;A;@!>+H G9H2?J08_M"!58!ASTF0=7FW>FPD>;HM)#EV.J?ZJ
X;L!&4.94FB=0*=A2U@KBOLCO ML^X!H?>6SXI?@.MON;L_?N-E72*^3ND;>)2AQ!%K>;X GFY5=L;P&L
M^<K8<"J+RR!^V<-UPA)JN=OM4>55/8^\$/C ENSY&H_X#265WEL!\$8G M=CZJTCJIV!>)HUF\$+!_LGIQX/ZVA
_=#N<+*P!V)&OR*6M(-VU4;M#5;+M+Z(N!O1!)\$OU&E&."HVABB>B!H8*6BS4!U(G""6YF<JL-!-HK*F>^K\$
M7ID1+CC\$SSH'7;AB6!+R08AHB@V!H!T&+ (HW?+B!T!LO!97!SNF^M
M5J62LU9+U.U%IU<\$IDYK8(+WT4^XSD)XDVG82N!CS8 Q>4^U&=CA!J!(! MR9%FQSL*DB/ARK"
UQHZI^%/_+!TEJ.*F5*!TD(&#_Q;7;)Z?TR\$TH>JG
M2A!9K4&QJW;Z%"HL@OM_2!QO"/EQ=W<#1N/3%TXK&K%I?S \$WHXGM/?*Z
M!LX\$!H_01A5;0Q!QOJ2;^SM^%N;VE.ZH/28^EF9Y=SM>1UUA! V!OP M%)H!2;I")KT\$F.(P(-J4(%4B8'@Y?
U32U8!16Q)RX#WY!APM!&CTGS=G% M<=!*<@V-

M7SW471PXX6+@#G7>+XEYK#2I(2M6/MJNZL:6YW*H.F'VHL?7@F" M#1#
(:KM'.9S28V9YV<|.'-QN0:FAV7(*GN3MJ/(@ M:3=BLQ:|7U%E:H'OHSN(*J4KD6L:FEQ8F)IDE:4MBJ9?QJSE&L44G5
:G; M&G34 NXGDPE-|4/3M@9.=6BR4"QU>D|(9Y9&<4< |&6.#-/ZWIP|Q1D)N44!&S'WB3=&OK)=GYN8-
E9UA93DVL^ MO)!'5@QKN0FWZ7|F%YW|Y+SL(>8^GJZA0H#PZ&MIKH-#+)MA@+RCN"%5D3<_L9
MX: #B)|\$ "DW&N/72G;N0R:"? \$Y\$1Y1#A@3IQ:O&X^DE\$Q%IM7GP3L.IVXH(*
MGU.BE.9(K37HF6K7V+GS*B5=Z=>Q5UL7E4*.=UOMJ*96|ZEWA+|%|Z(XSA
MM\$ZCJ^H%+0|JA+&|BOZ|:8MOK)(X7FM>>|C4SU'&3XK|Q8A;R?R7O%CTU)! MNCUQ&.P2G|CZ@<."|LB??|
=XEU|1EARL1+>+>+WR^O0'C^96TJ6HHX)7 UDTI?S8<+3|<:H<1WAXW51|.TT3)2#5\$ \$@;
M_)W* @=07|5AJ7#=#|U#LNG*Q)S:UYTAI%12YD UG6A|VL _R|6=8:26B9Z/
M^>C|QJ9#H/W)2E2#GM53879;K<&9MJ2. _U=SL|39JV&4-L:|5<%) :TUL Q- MU=NIU(1E&H(I:V5?
U50TK&EJ9VC=F"B8(G:"44|REJC|7L\$*:/S_ \$0P(1
MVPORF#PE8.V&@1|/Q*>Y&:SB22?/ <Y|/LP\$3_Y@23%)5+BTI _W#\$\$ M*!QVYN=4N=9%GO+_8(W%Y
M8..?..J'F63%L>E!6^W>AV>H6-6>M4:DW1HGW4:NX76A9-EM/4KDFG18X0
M6IL,Q|U""T_16VJOH+=@G9|U@A&GO#\$039AR|R^BB7(*P\$:>2.W'/G*?_H
M5"+X5RB(=H+M*ZJIT9YELRN75|'RF|V:/8@8_ "6Z?|;=[WHW|F|6^_8QP ML|VG&>% '*N7&K?
Q\$U9:FV|UQ+!Z|=W|CK#::|AH..U8-|7^|H9|G8))QQUK85-U3>VV=QF22)Y<#<%5IL#2 M/L#5:0UZ/=7HT|3Z(P-
7V4.^P"7Q1NE:ATZUU0? \$%VY812XPX4XI RF ?LY M8B\$O*6|VX.%:R!!|2:#29CB+|4.2D|E4>2'ACG&\$ |++:
|>P|K85P5C^%N.!'|+5CUAM= M=(R#MH2VA+:\$MJ0.6W(.=R"(V&_S@/7&|ES>PI>UUP&|Q50X%?.?GK|W"!F
M|H9Q|_IL&DA-B@X/6#|\$XB\$%+"5?L6T^<N(<6MIQD)<>\$Y>Z7A7A&XY.?
MW+SZCG>:0WZAMKI|U/N.|D7=|N|VY00G83
SQ=M1>E|I|VA&@KX1WH9'DME987&|>^>5HAWRJRD2QYCG)9|F>MU?&BI5G*:@U_7=5Z_ J6 M8E
_KM(BLOVB"5M?H5>0>"-T-1H-+U82+XO-&'_Z|9JU;>1^@F&&|/(G|GM MXLA|Q(C'|A^N-
&\$GRH|PH)"%IS@0;+*=#UN.?|_&ICI'7@ "6 M8Z(YA3<4H M8@X?J@44N
B_V4%T:Q8|7CD80:1XGU5UU9|MYHTF"6WK?2L\$K |>+A'T-K MQN\$?E?E=5|O "Z|&>"B? QMR<:%:8Q_#,.NBT9!
|&6;=0'&|FZ49PO+A;UM. M:ZV@&LD)W6P+2ZJF56T|>=-ET0*Y8 MM&V2+U,Z
\$@C2L1+XU(|Z"+>=.NOZV&+Q3>88_TRE^_JW)|VRDXP;?N;
M'P3^#WZY%|Z#|!V>^QT?S'CGKL=^;_9'T:N/57F|OS4TKA|*@?| M# |*|>??)M+ZXQN:P
V=4=3|9K7N5|;.=^E7K|L|R>)|L-J|34:UYO=|W\$|+V M7<:U&Y+DY.N>KFKFJB5;)R0=M=%:C)BT_|M='UC-
ZZJUH%?-JXGB1^|HWC("KP=-M#?H@IW/"BLM@O&5=<\$Q3>H"VA+:\$MH2VIPY8<OZ@T/M>.FA+TZY@%
MZ|BEM9XC/XOH1M;..DNOVB/7|_ \$N|J%&TIPPTOY| MF-R.L9="|PD6|36P-!6>R/5J0T"!?3V|H|C:
|C@R(W=D|P\$E_K|H8|#\$\$+>Z2'.^R.J=(Q:Z|BD|^D&|OI?B2;^X|H|FUI
M|NI@J**M=004*2/(L+1EK*)"+.\$<>_74*>IU9\$C;.EA1(9*Z@ "1+|HFD'GK M%*XX|M_|RL5N(YX3BJZKOK>
|4F^L4:RG|\$.PZ7YQ6H-K'Y'M7JHM&TACZJ& MX-D^X_|J|V1)VJ6VM;F-Z1@6?|+_.KP=,^|Z:GN6WNCD>U>MJC-
CSY7(MY^"SK'L>X%(")?SI%/(F+H F8%1\$4{6?}_N)X?N'_S<0.V,2?JHHB=YM MMLP:|OFJU:VL
_DR^U5WU>58RTU|CJG|Z>#.#9:;O:*8*1CE*TU_L6=S435 M Q2A: TNT:1)SH>+L-
'S=35%"IX=-8)V|/0%0%LF95G&_JE6-5*=-|3F< M^RX7V|8K'|!@ "LZ)\$5@:#Y82Q0*5&#F2|W5*ASU@E+
(AC|2".HMI6>QG\$ MT3|^3O.|SN+X%)/B|9WFNW@&N*.I':V|OT|SRZ1L@_.ZRK#<<2)'%:"TP-4U M+?7?
ZX@8@F6C8+GC7(XJ8(DGRK2N:AH51|(. \$N*SU|1AAXKC*&&:AW@': M^=_>|P&^P#>JL/Y8.K-1E=V"XK&-
O=0C5?)L4JC.43.S.C|MB4)" ^>+G|'KW^.)K;WR.
|LB%V/QVQ4NNE'M|;NAR=15K;+P% H&ZMJ#>B|U9/5#>_H|I.KW'Z%=R:N0J6|PM0:FCR-W%5|QJ|"
M(6@V'H:|A'0|+0&NM97.P5=*NL\$S1_.096R<1A|N:;ZV=)B'?I|Y|^&\$ R MQU|ITP,@MUAQ'7=-
O27@^S,T8BY)DLYK^CH=51C|V&=%4+C0+&D@WE-Y|Z>CGE@DK;GCHD3X\$+|B)DG|O&'ZT23 M6%1F?
BBYOW^Q|I"(A:1^L_1#1L:ASZ;5Y(CAT9|F|UEYGOE=E9 5'F> YO| MX0P06K_1X_>-EHL
23+Q38|SYN'J^"Y=BU68LR"5#7|=FBH_ ^?4"Y@4\$|
M/.R&C/:O7^U|S9I6*2CY|TFVGB_V)73TI3VR"AGC#V9/H|D;I6'/ZZ5R|NOH>?;ZXN'JZOE\$|W7R^ ^7MY< M?
%:N'^"#+|+=2^Y77WA_V6"UUF|3MY#T968V_.\$^Q9R+G^Q=1*|?)D4|%Z1? M_|TH:|N9G#|T6JIVU)AKATM
G8|SIHRL8W:\$Q8W-W4O(OD9WH*|3M'C1PL M0%|M@AQ6'D8&|+RR8.M\$=GE&F5?
JK.N+4* &SJUYR|'\$/_E8VPPN|!2%OZC MC_G;H;Q>_E8YX<37J2@_PMQ+BTP^63Y|3E|>OJY_W>>|=_%7|7/M_ E;=
MDD8WQ3L6^<|XYP|U?6|.1N-%5A)LO*04|V%*0:16 0WU0CV6\$F1)1.P/Z/R. M|JP(" #7:PCJX|S'JM Z@+ #;SM
IEN<*BG)5L= %<|P|<|1GV|Y1^6; M|P?_IW_U=,WZ&'IENZU(\$U15W|!^|L4.GJ>8K %%.I>Z%"Q2.|*O_>#1JF|Y
M#H|?R|@|_/BHT WMH"AR-YJGB>D_P-|12%>#M.%+>X?T|L>|ZYL'E?M MXWN>\$_.+JG"O1P8V;Z#|
<*)XD8A@BVU?N\$^O*9?>8<B*|Y|ZC"XIS|E0EL|AE_L^@Y|U)C?1|/MRL%N3|/31W; % ?|>
(#3L|S+U.7_<#V^@C|J^U^&^UAL@M_GM^?QZLY5|++ MUZS.1V7"J|!&X5. 1)\$8|@*GY|HXB^B.=6:31C#HJYC-
Y2#&U|U(9%X|O1_"9Y'W>_AJO%:(M#;@;PEL48GCE.7FIR|N|R^3UCH#%K@WET"(LW.&WR#8|+(X D^U^|M7
M#*#@3|/K6*M^)B;B1("W(8>OJ0E=|'X=\$>.DO\$2F@/M57E@7FH\$AE3 ME? P@!&H2^S+S+W88VJ.)
(#**DZMSP?_/'KPN"B<_IG|AH#P_|XZ|4>V;#LU M)?%XP20(*L"Q|KMK0Y|93/K%A
#1X5K2VJNAMV5"E#<V|QCEGR13A6R)=SU@4IX)2?%O93\$#|Q"L"64.E/>_H-WKJ|T2Y6|6U;8 MG2OWBR'(\$6
C>SH?83&=|KG;|= :2CL(Q2U0W%GP=+FD549.*+225.7SY|OD MB;FOT@=GX(NWQ\$=R@ " SS|AL"&(75|+|L9|E|H#
(Q&T3_@3_#&@(-|W+\$)% MH\$Q=>^A.7:%P?"Z_09Q|R5)=+IH230_0S#WD7/D\$-|EP@^N)X">2PI?RDV^B
MDB<&CK|FA5MWN0?"-0=EW|X\$WC\$3.F=_1|_TT9NU/82*YB8K@K|S@#6R@7 M7.>X)A?O|/'#D*
N|=2+5^>V7(?\$.|N&5.-%7XOV(0Z9STP'T831>-|MTF)|<#B|F'F.: "QUC5?YLA^|(A?4|S0
;S|J#L|>0PA@.4PQ4(MS5Z|4N|S#N77(+|O6C"M| MT|"+F9C^%L6<_H:;D*PD;DW1\$F*0C^|E3GZMP=-X>_BT3;:
ML3FJ SL5|>#1P)U_3:3NT>|7%WGS)7QIA38_.L-7*=P>O|A:Q_B4J6Y@K_*MV"O2|Q3NV|0/%X&O
MS9D7PC^\$EW/(O_KNJ/7H%DZ6FK^J_|H&_.9+O&U|HES MQI&XNIOQ|*B|F&"2U8.EWR(U5@4FH_)C|*?
|VH\$A.\$2NX|H|O^@O'UPK M|7@|X|B|+CO?X=|W 99Y
FNYXH_|BR8B0D W_S|YCKYD0Q<18KL29@XOX5|MC|SR0WQ+L*O-KK5M01"QFG;:HS8;\$!LB=[NN
1/|A#V'=%|D)CAW<\$? M%GN5@1."|F5Y3+? \$|@XEZLD|IP\$4|R>>_202:WC0 MX3M|/%A\$ FRXS3#P;0?
6Y<#U>".MWCB@<_X.!#SS\$4ZBQ@8/H3QL6A9|O4 M\$|CA=|R?ZX4+C*#P;|DL3+ #Z@2MTU\$;-
HSBRL_C^IDG%M_UAM\$B\$9KEK_M4:RK(O06%L4(DAD)X&UR|P4HHD.=L\$S8) X9|L.I9W\$J_|XZ.V"\$>A
M@0S.BCK&Q|7|!> H|Q|H'AC\$0F|(^O;&A|!S%+PG8|@#FIVS/OG-T3|IXS'^1 F|H+XN8%?^
M=&GW&R./P/M|@#B_0<@*S_4"S.'P+WR9BWKV#Y0S 4=P=S+<4S(5P:15B M?T:B#GSY^&-8.W.76/47(+)
<1ZAOD'1>_C|GRF7@8IP%PPY|N^VA#W<)&:L MJ/E|Z@H^O9F#-
|T\$H033R-\$JF|OJ2-4JDP^O'9FS=AB|L?7.A9_|P_X# MZ^<OW@HPIN#R0Q1L#YA"18EF"(67+?7.11*
_SQ#%EYF%W(I*N|MB0B|Q|R4I MDS2WM9|%|LY|^6G|2VZO|B+Z|!"B.I4K"XI+Q108B9"#%QXHG.80_T?LQ(|M:~
&F;%(S?Z>)T| EC138#L_SNOTE,FL>5K"5\$N:)|H*E#3-M_*|5#D=#>N M6%25(>PD|@|C|\$2^\$)NV(|-
DLE2)ZU9;6*5V\$.17PE!8H;+\$1QC7"3#"=W M.GV81XL2)&W"93O|N|C|&=(V%DE<8JXLQ9|S+";Z";HSR|E(|L\$+
L|L.F5>2(P*UBPC?DL<\$XSD=F3+*7+|^ MJVJL+6ZBQ(|N+@2&TN-
<_DK5I5XJTATH<|H<2FO.2HR|Q%)PIP>YFT1J3|O MV>=29"+U;XL_VDG"5|6-K<77GG|VT'Y?A^XU:?

1U>I\$ZBF9&4_@*6#IN&MIK-TJ(7&%??-%T5'NZ.)EF"5\$."7,KH3V.2>G#A.N.A2EH^NLITO#,7WM
9MG0B%Q_@Y>/UG&(Y9)1'8F0HY5J5Q^(18"OS23:S.?)0W#1>9Q)+DWH M6/KMJ3.R:H.;>4*34=>F*\$YF_8Z\$8-^.?
KKZF\$NOC&#G099H)C-S5..QX27 CN<.=T1HROB"TW>1SB&\$ M00B+Z'G.BB4.)BP*61F7>"PO
ME%&AFV.;(612N)Z1-\$52\$AA"R0 M914K;I'>;P@B5,WB1E3>I\$C1K1Q1#4_1X%5=MQN,1>>^1.N1H6151#QO=
ME>^KW(D1I&136SW-\$Q8LNGO.V1*>CD(C"\$M)=27VCHN.9*O@LD39#,-1,7F#E2U1L1F2OUXPO42^%IN
M;#&3*YC+\$5FX"H9F%2ZX.,3)J6*#K\$QN6+P1-KE\$I_5\$0^)^ER@H.2\$YAPSRAX!=AHN1CK+U\$I=27.-9&-
MRAX3;E M"N4.S1R&?XK\$9*%1" D^#1,^8>_HLRWBD0IM_16ZF1%TM<>@C7N3C\$BP.T8
M3'0%#K>=>6X141X2%UF1%PGD:U)/NKB/BJ@?MN5X(HRF%U>0 MW2G+;12PT9CSK#J1Z6:301Y3U@Q4-
D(M*1K03MR:9AYX@1T3MIPP=1!\$6 M%Q"3.H0A1FO5(1+1\$0MB-0XCI ^8J7R2M*1RONW(KXMGA+?O1X?D7&/\$R\$
MC'R&@FB:9J72F4BDQH^=X527N.0-15%4C').YXX_XGILE2MRG5PO".%"^)^VH(GCU%++1#16-MEQ.1-HU\$?
G)15TE7&RO1&=>2#U><3+1#1D_?%.4!..<11%1HE5!^AHI M"9Y"121_H1TZ^@NOU9VM1+7BBF,+H3(TN1?
OY19P1APD."?PI?JG%:X#8Q MW"#+1"13SH;7FTHS@TLR8=HJ2O)S1LNUU5AYSWNJ5<+<_DY3+&U7YYP7
M20J8PE;-%1+V \$D^171PO_)? "0P1NLA;#1!#X>./1+VWHYZ0MTD.D(EYV9C8;&Y2R^6Z0C6
M@*QO0&=YIG(=)9TWHN;4M1=;Z)PXJTXS1FD2E+= (ASYE1QFHND;TE2\$>1(Y MNB280A3R=BR<'%\$DX?
*BQ3#B1E^P1,*J#^)^2(=1A0E9>%&R.R%2;EY0C#) M55DF;51BZ%*&1EL"&_E*,S4T 9<F4I(RI?IN5Y;.%'@87X-
KH"\$42G'Z/O\$AE??)X21.H3.%7_! M2Z="Q\$^"8N".D+1_1+BD5<_A12TX^H*"2X318J@?7FM1SB-
+;#DRR0_\$QNIF4A.EMXB>SDL!+5&^Y6.VA1O2'5&^Y8;A+&5ZJ
M1C0*JQ\$1S:@W_+2.11'G61(D;SB;.&.+N4).AFX.&B.QAJ8L#8^ M10R?C%8.IF17_11"=L==?1J8WY9M
B0Z3O>5S\$18_HB;URJ:Q.8;9OWD MP41;7Z+L37H1901W;C%PK_9!1^DQ5)1Y(BG..PM@+>1HF34)%%C"6?FD.
M3LI-C@ (6E / =G).Y/Y0:1NP>)Y153+J4(-%F*1.M)E(OO"EOM1)MO_)CB<&-#?
D0A9S20Y^G_)9KL052=LZ897).J.E.H1#P"YT MDON)01B85BVMHC Y)K &C' /4KJ'69\$VU1>QKZ*5G%&;&1
MZ.V\$QE<2(51*&J1D1<-^4B4JX / =A*1K2A,&01\$XST81G1<2IBL>X19L
M3E5^V" _EHG3+;VSSYST(1/BOIQ^ODDW+M1#81@?1N6N?X9'H#EJEVSYSQ;= MCB_B1=ZR\7@WK>TS6@/#6#=
1";9D&ANM1=1%/_B1@\$HYM;+1Z+R^%G<=>^Y< MN7H1@KD)33,H8)HGD<(-=>1(11#9W M+64LBOGBS18G1H
O."/112-#3C&U;9P778OD"T@HAB?+P-EKSSPK-C.\$Z<);!A75LU+^2V/KX\$VG^*!A&1@QOS MTOQ1K @R-
1@*1_B15U1+ 517'DG;0WY_#&1;FH/&<9APWU0_0_7_#SN;8+8;W\$ _OZ0# MV1H71?4@!#1ATT7XPZ
+BNN6+N_5+KM;MWJS^ZRQ+7ETM2(RXQ/VAY&OH0 M&6(NA71#)PXQ20K'X21/U1QXR"1%V10\$?
CPLKQ^GP>S)P1ND)S29IKPI#BZ MRY51DMY;.*H\$0B)QX#%4^)1)BHFO41;U^K40^+X^O(RP)IMMV) *Z(
MDP=?Q.H@)M1\$6Y)3OG"CH^_L X7.J;4W0MNWED)4"EW -L/LZ1)IKU_ \$# MJ14R+UU+MS7 PG-Q?
C"_(E4@,,O'O'!&_6=K"J"7:@12X3&N))100='S7*K11'>GQ_-GPIYYX\XYR!DORM1.%.;%3,H# MY?ACK+;3D671'2..
fYZM?E50Q2@3&^@V+?TF^VPU*>^7H@3HFU0>YCSJ%ZW% MHB+%E8^*_.F\$ _K^=1^>(-RG05R1B=1H5631Q
^=.A.NY0)Z1@&*@/Q A\$M1A ML?L9L2JX^+15UDK(V1LN-B"-P'74ESDG*F2R@1L5U;?1C5D L/AH;-S^
M9L;BB<1K.C*=W.397 !Q NJT"#LV8ZX^?<1TT5JE:U@XRR*N"?VR<%/D8'@ MDR)R(7RG;\$19_12^3@^@9H=Z?
&7<#';\$+#+Y>F0MTJ;F79<<=EU5^UD<=> M2TF9<.&E/8X_XJ7_#/_@2A!+2PR?K'F\$LSF22W13T
>@C1+1Z17L;P3>^R M#1AFSA1A21T TUJ7>NXL1N+R;6^=1+;_E 0+L1>..A;R;..""OP2&_MZ CB'8+SD6\$T1>-
#=5SIXK';V"ALPS/).7216T& M>3(Z\$F1.CS SAD\$<@?R).40"G1"PC#1;J4?B'8\$39E?CY7Q1*+5L'7"H80
M7VB481U>PR1"U@H1++>PQ+1.P@ M/H0S%7+4>%"MLHS34ZT)D>-8Z&*H6KWWT<<1
M1=_?;VPSSQVYTR(OP MA)-4)W7*LVKSASN=)NU_ U1XC'^6;1?Z01YPI=WOK%-97F=L.*N QY-1Y4R14@;^#
MA10.W1#&W.K@0W+T_ =4^(LVU>)-H1H%B1Q;T1=DGBT)Z\$& M"<?>W(#.(LO7/#&P.ASV5@HG^NX^8F
K59)13G.@1*I@WE_1'N<6F1="3*W7A)LP"X.J&J/@A?5\$ M1EO1*4&*_- \$O^1T1Y1&KPBV-"RF91H019=#-
_XEW<1'E;9@2#H1/O^R9K MSC-#&4890.\$2""?1^>2LPI;2ZXWU1AW.NJV=OQDN1)RYE" M#E5
*M>110JHMWT?H(H=GPMTOAY3)'9"4.D(64L1M;=1Q1(&_@41X?N-
1E*1FT;8&JWS173.0%"53%4Z;B=6/KM#UT@149Q/L/K1\$^7 MP1;X.FVH X+1#1)-:O6 #G%L;.#1^5Y2R=8VB(??&"
H1#1S)Z)@N1#4"3 MXR^P;P7D&U76G9LX=JM^;1(*+V3RW;JSJP4P7U#N3O\$125U;\$LZ^H.UCE MS7YKT-
\$XDOB2^++BOCR%<4*L;LW7;1;#47G==V_AFLVVAK (K/HXTQ'8 M17CV;-OS#Z)W)N/MW2X1S303\$
BM8+Z5YK*YT>X#;1Z^OI!SB8&QQ:X9+ MT7CN.VHUB&#-EN1\$QTV9.MYZ;NWPO7P7PU1W/-
W_*1T03WA0A;D7FCT+ M.2J\$J@PM^X%LEP'8#_P2+ A%2IRX_S%>)5M2PK^2WGC)^18EGD#;_1W^;1\$>
M1NK+QEA*YK19<1AUF2+D1S+IH%;BS;1K"H6S%+6PO&K8?9\$; Q WAA>0. MX#@1/*@NZ(W=(191M1#1 R>;P?
8U>3>#?Q1DOLFSBRPR@S/B#W?>J\$0C3W M2R;Q/U*^<3(EW;1+Q<#_F^&_>CD)-B9?M03X&"0?
D.5<^R7U1HWN'33.0%"NNAX)2*TV>4M#27_1B8E&1QO1LRQ1?7<8&9.=FY@;SI@1A7 MR+OV3V37?
KY)BV@.OT>ZS>#'(SYIBA/7%1".U)1HW9UIOBR'LQPK9AD?B M1-OPDFE)FY!=7/H(+ /W(-2XWNO(DZ/Y;IX7
M80.661'CN'D:7P*7ID1'1;_&A@ST=+<1.S*1+4Z19<_H&90 ^W38CRO1.8WM MP1(PGL31^1H0;.%)=H*-
"AZ\$S.'P\$+NVEA+Q_F>Y+_H1F;.&C&6VJHZ6Q/B@I&1\$A MLG5J#)1LYJ;8^7H?+1#105S
2;HD%OMHV1(7SV1W#U87RSF% +EWW0X1 MOJ_#AAR;=1A4<3B1*G=K#E1V1;1>K;Z'MLMX%@RNQ-
JAIFL.7X^'SS1421 M+.%SHD#2.Z0P^""Z7;1C<1AEPVK10&_&XP6LRP41R(MUK/<1)DKPO3)9_D
M>#M^FFUH&R.#7L;C-G:@AT5_-14AE4..7GABLR3XX86WZA1"JEC1@=>'1 M'@Q4CD0).\$?
X68'8G>@Y>3)1+OSJ*NBD+<_M/GT/EW4@VW.6)2ZHB&S+1% M/<@S3;1CUDRJG+R1RXE;H?
X2Z/91F1* HF61#^12K_12.0SH=A#_1PW_1MX#M(129YSWWP)7Y;E1_1H=A@1K8C5S^C1+10\$2@;1%,<5ZQ%C\$)+
M9U'CZZSIUYTN6RG8&KG(A)N++N\$OX_1BAY?/>_XCK1)QNAEWB^1?1(OKWTP
M1*>S_DQASCHVFXMYMHJP4YE.*GX3*PM<0+2F7&DG"/WD/H2%OS1Y; M2_KQON>V&69D\$1I(K151931S(-
+16PIE2D<3%DD3T>P>& M\$R.Q>0?M1_BDI=TVJUJFZ>FG3.71P_8R#3.8KTE7F33W W3DWA^>@A;.< M;1%?
RS;Z:*0E'>9#QK1LZV78V1L;R3T1(@A\$;+10GHTBU1T4ZG%R;A4"=1FY M?U8\$QOK"C62-
+NMAY5W2TE@HFXG1Q-88'B6(QZ0L6?+4\$;P-N21N^<((.S9?0-^7;'L' M^(4KW@@0)D+A.6X*VI\$0@1&SYSOS
1@V\$DVA=*75>X-G-C0#T1JB;V1L5J;=D+;W>YF^T80K11A;K#514+RA@4+4742;S*WC(J9? M.G*;M1?
GF*3FUY3AK=>W1XSH*F\$12;GC1%JZ7A@%BV2@AS+S 2NQ=>%SI MYD+M1.JO\$S9W-
P/C1L.R;AS_YE#B7N_^9*?1RAJ18HW_DUO;1IRN5G MV19F-NU<^0-TV%.L)16R.SS&G<1*%P(1%1YF*
1^1^QQSE@H0A>&<3BR' M1YF'H)2/P>%"&-1 <9G(S5ROWISRXX'FC/9>&S9Y5RINPMM0QV\$R1HJMQ*M6
M.BZ14612>%1PY^&4&SR4Z8&1/7A;6^*T2N173&1'EY9S&F =_PO1?%O
M>&1'1'H8Z;F@%YBOB&_#4Z=1RT4)PI2^\$N5*1;31A0X-O.)%11M@-ZZS)H
MO7SG92G6XU&IN6.17!&FDBD)>"\$_.Q5_3GXM6*^>K@FLI&E@19XJ#213< MDC6=Z;MMO<"RU1?
*DQZV.WUF)DOCPJ5&9OLR151!P79K)CF0'HN5EKPGG(-M731F_+(<(1.X1-6)+CGV;Z-
13&@.(S1H;G.@A8A&64;""(7*)RIMM8QA1"YPO.*S1LK;_11@_MAV??X?
9P3F218LKHZ1PHO@.(Y6DHD+9+^X4NO(7#_*_NF0DP;G;D?Y@1Y+4
M6_19BH4<1Z<3"Q1^60B@N=NGHI69^C*=1H.S.P16&K2)1N=1C>6NCN7KI+T
M3BF4QF;C.7.1'27F6P.-1=ML'\$^4'0NFOLH9U1K;J6"LA*@MT<3QN8^,%31" MDYGGGRL7>7Y#X"6@41.U?3.XIB1
<""^1< MYPJ?O^G1%IRCI.*60)B9;9K<_YL4Y1SD+7@K71Q49-0S&^1J92F^8 A%U_. M<7_WP"&21(_#N4Z2U1M1
FY.+Y'1'OU2R1.%\$R>X/H.T1NAE)(AS-6)ZDM0.X
MD31^%62@WY"18@CN6#O&3C79+L1DC.WW'6R(340;0E24*0X8(\$ELONWE>-\$1K2V1%CPY#1S?UX?1E1YQ3T1'

/"DF0P+*?+H(TID>J%2XQV*FVGA4SE'WF_-%G9(NP.A.M M\$TH%(X/^F"D1LBU6YE'<8RCR90C,>RQ33
%2SMN(C.I<1-Y9&7K6&2FY'X M0AA7PD\$Z@#\$0.%PL'U'.5UN3+(6\$8 43WT78D!3"KG,<AXO2PK-
W&B@2AQ*\$7E%MJI<#&71 7A)F5+802(0J%Z+P)OLM4C:(("IL M&8<0YHMIWI_76+Q&\$-9E)9-&F3-IWQ-(J>
(P@R85QR!T'<#>#/?/SL7:PIL%<PF74<6RC"N%I2
M&Z*X)9UT)!:"9A9.EF4BSI>Q+^(KSE*9D2!S"/IS,3PK'>VFDI86K!14J-E
MEIHW4C(K2K;FF7+1.V&^UZ9<-.6B=I%<PMST=8+H7",337.%4@#&\$#AP>(9
MB8A#%"S2.BX'2VOIN<5_SJNL!MO?E6T8::9;WH'&\$1 MGPO%13BM_M&7%59SS# '+!U!S"U77FDD+>I%R,Z5S)3
B3IU9!U;IM'"@E(3 M&WKEE>(P4,0S(CQVQBN1>1),Z!^1.2SRHZ3"E'K6#V0B+@U(9Y>|I R?*_<+
M,3IY=2X@KTSFR<"LI9U9@HQ'2 LK3Y;\$6+/\$9(E _S2/CTGE_,"8\$(Y85.G M\$IGIC4_*B--A/R)7)Q)DG_PTLM?=#;
3A,LG)N(@PT,<+G!/?7\$=+PQ MIDIWMAIXI2B-?VR0JNXY5=H.ZYQ_9N*;;7V:&G;I\$'N!-=P->@#&._
M,&S*O#1>;K0&6#B @R>7K09!VE!#(1.5MAG&; 6|@!5G@"3COA4E+ST7 M!%?) A UGDN9
?>RIL1&>RJI\$% #FLC M.LE 2<?77?%AA@JHP EYJL6*!.'GF-/S%^T
M.1>NSLPSM(>P,3XR3^9UPUIS;R^M9E!0X8@ BBCI/U>NLX,WQYR8F)<2CB & M-3A+8KIU+02*)
<@H#UQ!H+|67H9* 3N+G<(L!/%*15B_1*Z,QOIRCB3/*<.! MIB1Z\$";UQG '+A*?TE
'#M!%;9IF!&0(+Y!+)Z:(UHE5(CDX')ZYC+,*O4^M.?
7"!1P&;3IAT+9Y&+R1H;G\$**D@:8!O8#1IP(T7T13FB\$F'DG+!-.R8!5NE ML8\$P+@3)9.)>IL4V>Z^L>Q<->*U5-
'\$#Y,7-@EJ3F^,Z':I?%C!P\$>!A\$" M\$!?)|@H@5/1!%5"Z2=E0X,06U_%+ "&.%1D\$/?^ M,V-QY\$;6!F:S7V/
IZ"+>X&@:!,*Z?9%OCGN3&?A&\$=4CA5M FRP7X M80Q-
BXMHS2#@>JR(714G)C'N;KIU@4K^&(FK!+F1!/^;8W9Q5(% ZZOI6 M!V;\$T>RO>&OHO"=?
L,5(=/L2_6!+BV!4J4E V4W=-OGW!F9)08=8/\$2,(N MSZ=SCF9*4VD\$")JXMIK*!BF7LR^_0V!@2?N-^?
D:MONALN_B"+0LZ'E@ MOIE46X76W=OINGL7X!:@O7I=V.F%X1?>*I.&3\$1G%J>3M7U;.1CV-L""%)D*
MBASIKH%"Z0H%5% @%Y0>\$45CE'QS9!0)A NCRG2Q7%85SU6;HX+;9GIF#CQ
MRDJ>.!H&MB!*ZSD7!O!V.\$SU9T%&@9*YIEH+2RUQ@1@.4R B01(40G,WS\$J4 MD7%WP:8UF"E!?
UBGHP*%|MK#4+@%9Y\$P&ET+PF&>'4=|KJ(K P!K3#RN+ MW#TO;E*#IB.Q
IGPB1P&"GIXU\$IX%3;H'B9N..ORDOLSVO#F7C"?J!64:FY MGUC/@?)YSMVZD.%DC1//0XF,0Y\$!E*
IQNF(4+Y4TMJE"BNTT%)+6^FF.M)" M!5@?D'N!KX#A'T5!F1='JAB:E)T
37V(CJ8R*P.Z3#ZZ8:GF!4.4C@C406!TW1!;; M2QZS+!B#I!>026K4V!C@Q<<+DHJD| RB/0T!FI
RSS.#W.%350ZQ.YO^IM MXIYD&IH?NHCX&4006L9D)A5VY!FP"=H!)=>FQ2+.;DI%*T5:H*J;K\$;\$
M:&.S9OIX&O4:7-.U@*F:66VT.37RBTLLBB(% MKQ^!TT4)R.'71.#E!%;TFCX3
N!9R!X2"S_80\$GK^#CA@F7!TE6J&.4&|31 MOU :9;+=Z)S8CA,F)+!C65R7V78377WJ,I>F)|JV2G)'D+"W?."URY/H-
+C6PY.2); M7.VJER30+B@?"Z)6#++M%*!NFV@:BPFU)H1=9P&42T!Z.+)<43%RN/TOV#CB MIU32/\$-3
XDG""TR'L5&"T=@3|BV/W7)^+6@N%'4YF-%%C7VO*H_*I+XU6 M\$ _E%&E/P*><1JWM\$S1!A&_&P@!X\$A&=*J""*
89B)/3D-=V+W?T&XSKHMJV?DN^";.\$^E/+Z5.7%MJ3F="DO"-4 M?G!*\$E^>9GI(P!+!)R'G DY"U4S+Q;/H*ZH
Z1@.ZD@8Z(27@!Z-!XNV!W!F ME5= J);<2.8.N+L1+@V>'E!_1A:T!W!4>5W3!RA_!XL"YZ!H%*!I8@.
ME\$2MKK&;+<L;U9=8U;7E.U>8S9(K3\$;7A2TRK!B>)QQV-DL<I053!93MKG
M@CK+3X!;#H%P<2;A/=T012)*A :K4YA&!61Z4E\$&OI3,*H#@=J5CM 0F<5 MM*4E ^!>=J<^5S-7S00*"-
\$CX|=EH3PF'=0R9S#G(UTP4=Z5WA4*_Y\$RPOQ M-4T9J_)6V/82(IHD^GY
QF(A5ARMP?"5:@XFX&*U2Z7(/,OPA;7S'CH1/#P0 M9.=YNSH9UC8N! A*4Y06!1:N>EP*
I@9^ Q=G_58%HP\$!;EE!X2 \$P 7 M9&|13J;Z%!.UIVE;-H/3!LE#E""!*.LFWBE37NH54:(C %H0>3EY5?&I
M52!4MJ'XY;.(%?+2A==XQ7U*LH1*OGBFA*GA493J2.V\$CWJ7U"<5^8;.6D% M35 A!6\$+OHP*(I^AF4T5E0)>5-
0)7_.1B/ SBT(+S+>)\$4QZM.ERQL4 MY04/+|6%&J-!BQ)^#19563DVY650"YM;..+>,<3*@9Z'M>3@V1(>Z#&^*(
MM)H;X@_ \$F 4A;.'\$J%+SM!1*-<8(F;('1PZWZR// UC/GMJ"OX9E^1KWA! M_9ZCC=|LI?
_@IM/F4;43N;2D6RCL\$*01!@KN@D1*J+O\$?I0Q!<@&IU*9 MKGI\$ZV.@=5-
JZ%7;14W!7XIFZ.17)#@O+PCA8*T"LS\$P6I*@@@S9X,*I"P)6V M,@Q^!."91&SA>&21+CM*EJ^E!8)*K\$.I_CQ5>
2!+4YJZ I."B"\$1T (*M# M6T?I!)=@L8DSY!4A27PQ>9|N.SU#NH%1090H@?(&7PO)7HL*370\$N0!E"
M4'H.9)XRT@(>=/'ATX75JHZ/+H\$4N"U&EH"@.%F;PE>|6.U!XFO(.?SJ&L9 MMW1%*L>.&_ =T92G!
IGR6DUL^T'>=&E8Q%>F*TT9.3 \$@-(Q+"NF*HU%DB7U>=*T;@Z07HH@MTDN;67XQ*X V; M-&
C5%2Q.XRQ(7E&0;^?;)QZ8NH*/L1215=90IV3YD)^4!D6KH%F7:K^W*(Z<)H_1763A!|@A"PHY;KC5DV.>
M2)U%)Q>K&U511Z*!3W)N.TV7ZBBR3_0Q<>S4 ""FVZQHLMD"13+J5*4YG!5>AB*5R.
M!\$U)VR5HKOBAHJ@W"IS""E> 2B1563!#);.9=IH?D)H!;#B(82W7V2AKS MJ?P3GLA+6IYV;)P9^H/A:=O J*
MB#|B1V((JLYO.%I&Z/7T:X+1XKYL+ 2\$|%8L@)!-H3<AB0)A'YWG=62 |^ (M#PFK(Y!0H!OW
V70*5/&J8"HB! (GX@5R:"9#YI KWMS:RI'IZ4ZB0"(V@ MB3!1|FLZ1=?220^ .F\$ \$EF?P;PQ6? AX=|58+N@2?
P<+A|T8#6R/W;0_NBI8PW;/)+!B;R/;@8 M2+CZ)A)NL=>|E'UNV\XJ*.9NMBD!-!Q)=1^!L)A4!6"IV#&3S)E9_G
MR(-&P@8L050Q!_C8#IX'BZ"2UA5+.U4LM>N*!IB:??*16%JQ=*H;.42K!2^ MC5J'E&KM6/IAJY-2LI0Y
01X94LH@7_?K4P ?E/C/UK_!DAGN"-D)CFI.\$ M 77HJ6HC2 HK&^=@2M0XFSXGD0)PH=,EJSHB@6/0".#8\$&
#/B@L)XAJVR42 M\$06T!9;X3R%4V%\$E7#;Q)L&W%>.C^FI1CLOB^FD>!)19B FB*26^RQVWJ+=S*JX!E J>D!+
<6)@X(O)B#(IXK01L'QWRG@1!1* M,5!^4%<KX!L1R86A*\$=97S/_ "U*6.*7E"40-RF!1EH;5!&3"8PHS3 MM
+H2: J!06B6!&29 @G;W=0LA!I30+D(F0!L)C%S'V14;?"TWM)+5D M+!E5\$/_TM#^D\$;C4@;
&0@#0UXI!0Z0X'Z#I/L9JA=8^1TK.SSWR!A @+!A(< MJAKML2C"@T>YUMUAM95ZA 8M85.N-79A!SK/P!
(.2UESX==A>./+!P*ZD M<>FSJ/EI^@16K;Y!45C 82%EO>ZM0)/4^# P(=U/B>1C!*\$EDQ)3!XTWV
MB.E@MK!6"U+/- M5CGS\$6=|3,Y1\$PH^TBFP^5)B&DP 2^"W2|CU"&NDGI?)5?@X;J9S9\$FOW.! M3G!1F5G);N4-
^GL?%GSU@2Y+W=D64WJXH/2! H(HX*!XN1HO!@XD>F)BLUC M2&I4(0&_05TK\$)I MV^;U@
@Y!3Q!)O\$P3|ZH&6??"", 7XNJH!@WE7%.'F^C M1XN1 J.<0C"X2^,?L1"& (<@X8U&DU!KA*4HAG=PI5^7
60&VKT_L0STX1? M2Z8I!ZSR !ABX*X!B_.;|XPDYHS/O%UVXDD#JDK=U\$*_2 M*%W^!NGF8U"LS""C_M;N-74X
"J%4H4T*XE?A.W;@OF)JU_C*4/BP\$M!SZ M\$&X.X;KV06!+=P! M=M|KDLMA!HG6 H<6L(C@)
<"@XH*0EO<3*;B2@ICH+!MN |Z*M@Z#RQ2!0P MX5TK3S226TK2-2BQ9ZV@&.6V4!".8U.T<80@?QUQ*Q>
I@^!L<*Z*<46@Y ML:&5!8Y*0VX@.AIPONE#%\$>!O)E92SFYE@_D>_XN=|=U9G2QMX9"% AXJQ
MR5.!>J3'D<|YB>=P))|BJHX2#WA..4:46H-,<|C734"E.RYHF^:@A=RO0 MD7)(&F%CI84+ Q>=BQO\Y
ML8H&FU2!WC|T _EC UVF_+"6XFL"N^!UW<^@_0=&3D7/@V8G8QC0K(6&|T
MB:EY!0014T!&T6.46Y(<3C4&2K!8SG)C>=&\$!H5HUY#C4L!T8V!3>OS;2K) MA#L0SBG/ZH!
<\$^OCF.*A66<+FK.C9S=J<2D).6F7P(?/2C+3-X\$IHZP3G1 ME!B2#V@W42%:T2,*IT#JD2EBC
D>1*;4.6F%0H%F1 C1%>4!H6YJ_H&I7 MU*-383 X&S%2I2RW..BH<1.
CV0!90\$!&F%JRLV!TPHU.79M2%&L79HQ2 M\$S:S*5&3>D3!Z_YFN4!T!GYV\$D49I"8?\$.ISY%38K!R8^S-
\$M=7NE'\$U ML*<U4X(U#WM^>.!T3Z!5>>A&+GF0+= (F0W!!U\$ _IYSZ\$8C!<*?Y=-.CRD
MZ.B)O'#B7HX2';Z^+EAORE5PXTMFGF_B^ZWCXY)%T.#?O<%WP 5"7^'\$1 ML_/R2!%##!PW89);X9Q9M\$!
!T>:2P5+.SWQGU#FXIX20CCJLMMHF1DH!5# MINZ;#R+ZBWD1M#7>5H\$!4PW82 N&A;DXJ5H
5J;G@SK_2GA<2M7@1#!8! MXKVP9UT)(6*V4G+M!N:5#/CM+0!6N>OIA7AZ(#W& MW'R;AHX"DO!^%MHB\$W
D_%2Z&TPW_%SU;L5N>'K&><+UP MXQR*?/8+TG%+DW@N.+/(F1QL<-%.4;%<#TQ.A RB:O*) MYULI.8A53_#"

(.TLA"(V"Y(>N#Q*5@>F,"Q-BL+(:4WOY%U*#6* &12AF0S&44FIC"L+V%(UD7#STL%*8VR,=IGBIS
MXG6,KY\$>E3V'L32)FO(CI>/9P-898&HC-M48A=(:6)FMQ7FIP\,CX<>,53'MOB,K>BRO-M4D>KYICXQM+^=:?
2/:2<>!XRK)7MD3<5:JQZ'R18)P')^!G@Y>EAP59#>TZ-M-D(8L#I'O@56(TF7LRC,?G+YX-
QE"-2L#%Q%\$&6+>G6%*T%|B'@23@8,"P-MGY7ES?C!O*W5^4F5W9(%6:2-L,2:"80L3+J9-5FL+Q-
9I05%*9K,*Q!2W-M%KR?2(UAZGE14(=O-GA%\$V7<?YI0>&K2=TJO8SM>K6#7-4+%Q+=CYV?H\$L,
P@I2I#G/L;WG:%|/+U!W!_,1@3AZ:SQ%I!O>K0"R,19
M^4M8\$U7L,RJK\$T6:X#&K19D?/W\6)S2S;M!@((11GCR;7NBDGW2WBX%9G
M6\$!TZT%|Z_1,NFM5I9,&S!B,JCD,FA!A!(XN5I7/KEI/(86Q5E?#YT%=0P3HC)28W.1V@J-MZPW?
BKPVH_0F\$F43%2\;BB70^54O-Y;I7:4W7JH948N42=1+&C'L%N%L4-M5"ESF"J9-2D(K2=J!<,&Z2PLQ\$%&9!;)
(+E-J)(=I05V1H66X%*3G1+KR-M3=B#%Z)B4ZT*+|<%86(!1S)B5M0LX#%#%+0)%-G,&\$=4FK"@/:2G56T*;
4JHM,-NO7(FPX>^MR|P2?&WA\$+W'H>I(=,B%9QD"E5VNU"6.:4R7Aj+@?+MMR00C-"8/A@#%Y
M#=#8/1:0:0:6,">J=DN1XH#D;FN&4!+6:@>,?MQ:XR6AG515+5A0UROU#|=(W)Z25
M:Q:H\$X(XGK^&PXAX#0YSW"?#%GWI&JEFO3CI8"-"A"KQ+B&VJ*S*R%O<+M)/(M/35S**VIVQ=0JU@R?
|=C13981IS##14UFC#+)"K3M8-M35Y'L/449*P<9&OOD*CX8G&JC-"S&2%JHA<\$Y;D(YL8.'_%XIBO5VDR(-
M\$B08^4CF1*D2<6XM+)|^D2XF81K9:H%<6\$|1DX*RG1I-NR5H)/3HQ78L%8!O8M@N@4#(+I=I:O&P0W7J1
MIUTJ7GA0:QGT&'GA!%|^<6|YEV@IX:I&-HPX"7W)8&22\$#J18I0*!W=IUB-MHAZEN,*IQ)
I@*A3BZL-IN7PA"EAUZB-6BBYI4\$<K-P^FZG7V3W-TV8-MH^AAI0)YA&PBUJM\$2M-V9@ (S-
N!2EW(+O0PP^!,4W=^2IN:B&D((01VB-MT)3IT'9*98"AS2SF&NYDAE/LE4)
(GTUFMO4?%8(HOJ?P>7JYX^Y0EL(-M#S!<3I47,2N#FEH@?)OB@US;:;<&Q/6T&I57I+
I@<EI7"B!C#>(D3SPS7%MU.%@O+L96:-6?QMD0>FL:IXB8*6A>C;&#D\Y\$&VM9I19_Y27J,@F6)2A/
M)47@!V&EU-M&STIG:^(+DKV5I\$&NU?K-R:.(73?7B2(HTNVXB4%5D>[45S+'AA.#|N-NJ
M;1W|J|R=I7MS*OTP!##OIHU%ZFMHX'LIXB01W\$+^*_X6%_A.N|HN9G!#V3
M|B^S"OOHPC%)#THI:|F\$+L+\$Y|A|K-Q,10;"WR_)LR*\$&9'\$&:Z4O4T21JD-MI%+U=4
L,T*2)&:+E*HAJAT'=H^K*2N=CBM1RJMRSQ(\$P9+)CEYAIN":E-MP0E:S:0-KD)3G94-)S.#3I/@SM0|T;.*
DX12S'CR"=1-R#&B0%4IA(XP-M*X3LH:I6D>%4-TBUF6XA:PC<#&71"%\$<5J+VMA01O\$6.8%>&GE!9(8;QU7G
M!F"-8&%Y-H47I\$XN6>|HL\$+S"CYXQ4%87?";Q\$P5!*|C-N,0%.*64R8P|?MN10+P;98IQVMASH.)QJ?
(N^Q+%6@6A>P^VY3X^";Z;IETZIOUSX2RT2WE&6M|(B-P"8@8HEB!;G%5D5WI=8%A#9?
3>M@57PMH0L>0;?";4HB@>M@#E4"?=1M;"G\$K'C"25U'BN0*Q\$PIA7DV;CINPY^1L<2T
M+TW.MU+%93)8JAPUH=P9HNA%SZ++B<2^49:#>0,>?A8DBU-A?^U060\$|S%D|
MS032G6@DI3I8%|&O""#1,1'1:";?3J'@1,:|PB,C?#%19A5T&X83N;)-@MEF,51-
AP&S;K|5@MB0;,&81>%Q5YO=@1N+YI-J)26!F2M|L*:LN2(4RP)TM-M+/-
83+9VF12O21Y;Z8ROG@ (U8-B^*K-^928B"S1#E|H|"CV4"0*1\$%#ONU2!HE:PO#4&H:\$VS-CF#(-)M&ORY4N-
9U6C8-AJB!3&E@^T@P|R4RC/^I1UJ&10BP8<::TWVMOI5PIOVC%)?19AS"MM<-'H4Q35R^U*E9*XR6;K+L-
2+Z\$<:4NB;I7<<="VZH14-MOWT5E!B0\$S@HUH6WC+^1#1""UEZY)TE@*;;2A28RXE,&T:@QN-#O-/BZ-*
M)M|J-14E/IQS37H=277ADJN7EW)55=R%;CDRF^JP!>O-UC-I>QX^3IF74-M,FY74<)*65-"EEEX-
5K7|TW>&:*Z%|Z)%3^0TAJ(6#*9=FZ"V:.0X4GN+=&7-MUM"TXT4:23M-13/%Y-3JRI#-*Y*N7=BTB6IWUPT%X(4-
JOIS|\$M0&BOBSU-M;|O:4JS_-IU>_!U|XY#7K|57.@|L=KTOI?+!68(<:P^;|IYK-H-K3L-MOH=-
=_*;GWB2E<)^QIQKY>#E8B3N(<|A0\$M1-M(B-\$US9-57#YN'T-F5ELJB"M8!\$?
6:X4=0S8X/M|J-"TAK;#&T+@=6B=")@-M8(Q'(BL9;XH>/4FZ;U2^|I7+=!OE;\$)=Z(3<;EN^@%|8#'+Y/+C|^H&
M&'1E"#|<:V@6%/4RP63E0DN,>V9V%WZY+B\$;47AV7#D'M#0"PZYEUIP!2;C-MG
^&CX:E@FN1I0S<*REX<3(PMD7C)S<2V8:S.\$+W!D=9@R>04/N3;C22+J(0)2R05H(T@
MA9*X%IZXOR-W8.33>5A2ECTMLN|PB-MD;(:JQ&2XJA)6DA4)*5MA14;?!#2;L|TJ@;)N620*0'D'\$8\$(^ZCVI"DUH
M-%5'TZH"D%9I1Y.->#@E|AH|=HNB'(Q9,+DLJ\$G1S2O-IX7@6PCI8!|JZ%@QJB*6B9EW)!|DLX^F7I+7F!^3
MG%"LH.I2H!IGUE(5)5>IO&EY(DU#BEN'06Z/+0UZFG)-O/K\;P'FKR\$YJ4P-MH(6L."1H?
FN@E|+KF&RHM2|K/;|L+WE|R1AT"J-J_-JU(B0\$24C@^+^+0D-MI3_H@"ORCL-B|P0I;Y1?CML?
75;I>O\$C0+5%@8_5T-M%;LFWW3F&S-RM#|P6I0\$@8W'B&S./O_40\$0Z"0!5ZWWC<<|2L/Q-NG'+H-MGIA"
<@>%3(E8WO):@!AS-GI2GTI84(R-A0EF^L-M'#E):T&@/:+2DE2D#|HIAMZB@B0UTM5=:S9TKYJ=BIH-?
R+*.;@+XU(?Q.5-M^,?%A|O)!*9NKQ?/2HL-5N7I\$Y\$OLT,%Q|=#IGZ7E7*+"%EQ>Q24"NN94JYG.@P#|!\$HD)>+
f@0@2HF#*=(%4'\$_UG-MZN-XVLIF;=S7(I,X@|8Y%36G,3=N5T>);)*H(U94AU5<%XV,^N^L#58_IV
MEBU"@VYVQ\$K|'7C36WDXD.VA=X^2-8Z;U8)<4>8)MTNU1S*<(%4VR?J*31<6R5K|U%@_L;<)^8F
;#R^C)PCB(3(F68"l>.\$=VY-ML?38>-F77W"8^MOX?6-9="KTI5^BCLF)9SYB3\$7-\$;WQG|=F^CR7G8=^'_M3?
EF>L&_.KGY;|P|HF?ZK9J-%/_9GN?&Q'B|Q\$KWN9X*/_1>^?OV(4<*7F8.CW1#Q1YE|MIH%VO-
Y2/A6_N,|#TW'Z1&A9^81D^|FIVZEE@O-N>|AV-|ZHIN'#UW*!M_O)KXZX1.2;E(W>&ZPMT)/E|CQDO\$-
X!&.\$C64|H#H:Q"7O|H/C-A%N@MIT>_H+MV7HF>|K<_I+|L/GO0YB\$|C:T5ZW0.%8*
MAH"%|\$.1"NH\$>*452=|E%HN|\$*;&R!M8-Q@N"W%?
|OK>||3KM^(#UR%EQ>#>=0L2K8Q2REH,R5IE%&FD@7JK,BBR5
M^V4X)R4%BYM>#Q(=9I|RQ)TZC^WT&LYN|<1Y".H(G>\$A+Y=B\$%C&H;)#I'0>
MKHWG0RCD\$32(P8^SO;IE4H1%2AI9@I*Y+TP)^@F6IO"XDF@_MHU|Y&Y#G2;_L.Z%=@!MDU|U=1.L^C|1*:-
<L_H-AW812|R/R>3@18+5X-M-"Q0;|COU*PSJMBW&ST1|TDI!A*BO)QVCTG.!"^&V<5F53I\$QB8>E2&F-M|
(1C9ZI.1"QZO@_BF|6W=?I<:C26BB/+DU=&1-1ZI1);!*+.\$%NPW5(=M^(M1&^G(?
3CM7A3&JF!|=L>)6=PI8PBT|Y7UMP,D<>7+BS
Q72AX3EY@.\$"05Y3F8BID>)>6XU<|9+QC-#;A5O+FE0|D)5>805RIC:HE-@N^(-MY;EK="XTS"M\$?
Q1!*NNA7%Y@DL_|GL?U&DH86-R-(7M32%PG#<@IGS*5XGR-M3=ZMO%H0TD-H>GX)RS42(D<=TFUF*U;
+8/1#/@.0%|H@&P-ZR>#MB-I-M(0/M&C\$^Z6+3V,%5J:Q7#J@ (76.FH(G\$<_B3('E0SG@8.8|@MTV40<
MJ2@"M6-"N)|H*7+;:(L;JFV#3P:A\$X/#72FB%JM-"QCQ?"Q+K|KX-
T4&3GHN@0|F.F;LYNYU*57H=:A3OPZORKY2H=I?;XYVR-MK;28VE-4BL/B2UN>_I8+9"D'I(
UF'P6)5OZ2B|Z(@>^RXWVEWHL)Q&-'8:MO5%O:2P^_||PVZA;V0M|JM5J|OK7RZ2"ED9A\$2&H)2/M9<_(-
)12_'GXS-M9;&<%JC*Y?I@?^_NC^,8404#\$OKGQW)+-^!?,1#&:XX-U4_F1#C"%A
MT#DBT"EQ_+Y)U5H!|JTKMW=-RX%+YCI8-\$.3;WXJST\$;NXTY3I'^42E>=M1HK80+00KG006^|BJ@JH8TNBV,
^F=|70I'RRYE)OA2*(UOI_#R7D|J*CBR(MS@7?&%@DO|HOP?G-9-S-#I%N-UMZOV4H-IN\$D*T%VTK(8YQ7=%(
M9&3I6^ZZ_ML/K43HO+!1.H6='S'26@X#?|J#=@=WPT.W=NC<"*TJ&-F=|I65@+|BW&KW|;:
MG5;UE,~1S\$3H(G+U36,Y,0*;TfOY&OO8O*MT7=%B**IG8)H+>XP"RTQ1.5-M9"O/E.B7"6DV4J59.XP.9BP
M#ZY73A-24D\$9I;W^Q8|JLIV%5\$-M%K7"MO6>I>S@;%UYHZ=Z=*^_V;BI5^!TM|JK42W-\$R'I)(OA_)6"89,V.F.
MY|^_S81O64G:"|W|AT3;1UF&W.V*F4)W6N%\$A^<Z;IY4MW
M1(&%Y>X(O6;IW>XDA.Z|HO*VEJ|U5.W,0;GLV9E3F;R8M3-U)*BB,8<|_M8K_RL|LG^;FSS#Q|^_R-6>&D#>|X5
/OP1&%SE(L_?KN-YWR4;?20N^B*8-MZ""DH:(H-O\$P\$1/H:2)=M|Z#AR9.-1|SWQ-'A0I9DC.H\$22BGT\$?>%X
MYUU"IGG4W#K#++6^4PUS:GBYMI_|H^XLT5YM\$6>,<=?=1*6FE0)GIX)'&-MW+^V,\$R6UI?&/48ON.P3-
&%ZM0M8:4DB2^D.7AVVW>.:8&E4+GR\$0&:

(&NX^1+VW8BHMCF\$UW<0DEE3*5-OR1Y>Q)U:A^S.C7*+KW.2;JBL:(#MOV,ZIU:AS>AN3)Q
MSSH'Z3#;V\$9##6; SO> S ZOLILSRJEK!COPV OR\+= 'NUB'C3Z=PHV<-K!;
MV6U_XT5_9!9>|A8D140AN.X|KWT(X4@74QJ K4J\$JT(L)8!>9J;|@LHPRI\$F,ITX=,ARB3-W_KH!(N6PJ1L,+G.2%|
<-:K!;G:TPSGY3GAH!92MZ M?^U*TO;P8MS9GK9+NL+TJ=^:C7U7;BP;8.>D-&'!;AH0&JRG!;MRMZS(W;\$+
M%L%B.)^+MONPBWZR;72%F5!5IV4I9V)(OP<^29*8,%0^U.(H5X2F^@-A*TI M RU\$!/>B&'K2"2)Z9 /+; "A7<|1=#|
-N1|U+.%2@3N?IIVAJ<>'XF:=?"W|HX062@_A(3ID*,-!#6^0!E1--6!% M_\$3?1*0NW>|P'F;
(G<"+B&SJO!6T50!KHC03=TK2KL1MA/"L0;3%)7IB?>1 MX1NWP42M,^!;L5Y/P&RAID/ERUYN)G
Y!|K5!\$6'HTYDHK'YQ9OK-(KG++M8.4TF%)1DIAW)G01ZJH!XW\$0)GEJ/(Q#=#C!|L-UK>#., "20,/ \$T")J*
M1R4'G\$|X?#UVQ7Y87#;A77+I|32;IZJM;U;"L8=<("+,2^(-03RW*,"2L+) M/LFB|929(QD31DYG?
MC="HPEL+DT:K\$#14;SU.O@AXT:@XA@3)H26@00(V=^9)(&, 76|XJH5@!'B!<91(L&I@|8A<M%<*H9T-
BR3*8H'LO8OK1?"P<1:7L|13B *2PG"?;7*#|P?@RJ4\$B|!#3!; MB,|X,OET4AKT;7+|231>%GRTP|,S*_E
>9ISSE^A+0V,U5M_/&M+4PU|E,\$|W%8XSX6.K;|S\$5H&3BOO8W1|W70@DMW@C=-4WFN2EQ(C-HV
MOX;R|H+2H*\$A*R.SI52\$AE&@='7T0481<>(@("IZQ?TMSL"-+D6X"4| T; MH^&@@I'2K5&H'R+;G=;
GPS;WWTWLV'2,B<=V I61C%<%^U:S|57@L%=UI4 M)'?|Z9L|R|^8@4/Z*#!|NWVU:Q,%Y8)KY/K>.\$|FIG5\$|*G
M)1U)=V&9YIP=?JHD/Z\$|^|VY4\$STLIS:IV|5UZU5HESO+HM<\$%5086T%F_ MAZ&_IV47")=T9F?
%7U7%B;@(\$@00IVXWYKV^|T'<>+QQ 7F%QF47NH|F2H M 1G6EKT/L7@>9*)XPVY
@I26*%7|J_WB@46|1NKM>|&'?TUFBD#X=)@.CC M-/6C/;&&*T0\$-;@&^D01\$M#?Q
MJX8?;IA=fMSXC7WG.EA=4YAS.Z 9AWIKL.#*6\$D0134MEDJ+)(OX#|N10|BW&WTL|O9TA)ZKCU=?
T>|BK)1<|KC=H!C1EAV0<|78JF"6#% Y9IOF&6M&1 M6<|=6*YO7YCA=%=>R,,H Z;:W;,%8>Z|'FYK-
Q)5,U WEHFWFPK3,Z5 MM*7*)N(6"N2^J*_W6B<#1LPG/^C|(@<|+QWY819ST@3QXP-O5EV|BMJ04>
M8\$ @)+!% Y9IK=23R;N"TXH^MJNL8D5(09>\$|CB^/R>3M?MP"?|A/@_E?
M|6Z0|7VP94WR9Q:8V@?)KXUC|3MEQ|f;CIU:C^8078D=|I'0'_%GH0EO= M(| WS&:SQS&RW>
4B@5T49I9I&2|_EC.AG)|G_XG4|!|H#(4%0>|BW|OJ_4Z_(OG^FH|/ MTFC;\$P&OM|OZ=>4.1/OP6RPXTG?
0<6D|YL9DGG-X?+40)|T.HG. NS5< " M|L|4)|EZ P6%BG#B_%(|^TN4>J2G#HKFD622;H;78S;O61|TRFV&X)YN572
M MM=|@V;*/?;PW9%Y-Y;B%K1)|JM.. (|M,IS*MO7JM5.TBRFR9N#AUER) MIPN_!|Q>;&&NQ/*!IMYM#2KBX-
3>|(CPTC<@6VH;-"N0T7G3(A9ADI%I6*G
M8E+QS81|H0>CL=|FJ0,GYQ(X"2I6V;P0V(Z7&V=^;VHNMA(\$>*@FVC@C7 MFR>|NI|NG"GP@-7?XG!?
KZ\$X*%C\$)<;WL- MZ|!#0=|E(4-#Y00-4=6\$YEMHL?N.2HRIE79-&E\$FZ;V&W3A+4HJZNJ1RY53;JM+OD;W|)
MUVG6|36'|(R8R'V.1H3JL|>G14%6C6F@I/W/B(TV.2 MY+H7XWX_V2)<&,"HDK4J";R#&1X|'KP>,"QF>VJ-
PY%|QDW/SYR.1#IG9XAI+|(SZ%^.>WNP.16&WK.A|6%B;@8| M=P8MUSJM\$*L+L8#=?0NH1VMYM"*T.K;Y-
"JYCFWY;LA5Z%-X.V=8QB'@IV2 M*Q#W;@+N*|<=K;|_ O(8D|88C2=B3|,4A'BKVY_G#S|>;AYO.I=QWMD_Y
M_Q^| " >TME|W9^U1.^Z0+I&=5F>^ A.3+ W.7VAQ|ELM.N>P<=;S<6>6W MRM*V6&WVKV0&"8F3,
+VUZCBW&WV=8|H69%@JDU0|4.=?R6K0R&6ELOQ/&J> M8<5PS40GRDL'R_9MK9Q&K;HHH=0Y7S/;MQ@70|
EG|G6JYXV^)|EW7^U7* M2ORX_RZO^AC=^F\$NQ|E|O=4;ZH+|SG|8J54DT\$-97=L0Z'J3 MK|01'C5E5HDR#V;#
|E|T=JLG.MJ<=UOCN|&4;,"CIKW04S|2(D4?)>ZY M;C;2V@;\$-|TUJ H4>TV69V+|9)|E>LFGFYQUA1Y1)-
F|T\$YD|J@?#/@A0I* MT#R|S!;\$"NK4\$RM.R Q+\$2Z0";P+1;|LT>DQ&H0Z8|TX;|NK#|+;BS/^MJ9
M&M<;7;ZCG3.A%BBT;5_L3AH-JLF%M| " =A7!H9*8&|UHWV)VZDT'T&/RS, M@ZV+|0C'2;LN40'%!Z*>.GU39-
DW^>Z.7_|UOWSU<;\$LF|3/ZU,E1:U.#+=I5T-QAV:1MXD| M46SSYR/##PG>M(NDQLH%?
30SQ'T0G=^T9;NEDM/G4NKC^"T"|;+|8= MO3D<|IX+K=FI(3|
MFTJC!NS#GB^O3OM|LEU4(6&TLIZIBLK\$U|H^%DH3O MS&1L@5RM 9NAP""=.7SL2;0=8IV|7R<|@%A-?|+7++-
^*2<>2|_K1<-U7 M^_GU H;105W""VN*|%ZG*M7;-E6M-"R J3;(E(=5 7^02;5D|P""(14V^BK
MMH|7_6HE1.UP7N&WWASC=O="ZU9Z|V5;)OY(|ME+|= #9SYN9IFFJINC7|H\$VU.Y=- MF00?
^AU6^2LGU<(R|X|M.GV|WZ|W5|J^I^<92-Y>2-94ESGM06;XXYCOECS>7JY\$SPO79P5 M%EQ8 =3IZX-
V6;VR=85B18CX;N|0J)#|3\$|69ITRM"QV^3>RM07WPH MGL62H\$Y|PIW;F72.^06-1CG^ VW4'3|Q;!
<|=F8KYCF3#6;^9I!+*|9@N<) ME\$3LL7?(HOK|&'3NU:UAJN,J|E+J&QM>H-&>5?R">WTY*T7)N0+|HMO5L|
MF#4#GP;#5Z=@M^J&TO,DFXPZJ)W)HJE%|=4 M<_I4LRG)L#75#"|&O;+>;
I8J0C;UX76^WW+|AAC5@;|PKGKGX|M67!#|I'Q;*U9;A57/ MD (- " ;>ZY<%2%'&158|WE|;<=HC7|' #PKDW+?
V819STBEWC|X&6>J/>.:|_B=3@VRZ%;|6FZPIL9YD%FI:F3V M,&-8S">'T&J1D;?RI6"8*0,Y|@8PL'A-U_B7ZT)2S&?
\$F!;5^6RW@_M1Y,4=1(E1DEY7RR@;:/>5>E;|?*;|_BS=?Q;H;+J;?|6F+;\$*,BT/Q;_ZMMVQOOGV)4
Y|ARBOYHZ'Q_P;NQ.Y+E7/7;2J|<9)X%R=M5|^6/L;4X@1R(K+|/7)O|XMB|;SC;HNAJ?
QVNV==K|ZY+^+|A.N<6 M;|ZHX%=%U\$?>|_D5-30'A16%+5HF|&F/5N&9@&/AGP+V@M_\$-8XL-@-S|
M|JDRX_%5%1\$QJHRII1? \$WW<_D\$E;N|GN;H;+M"EX-G,ZV1?F4B8,-@ZKID,#
M\$;&:4TL+4B(2"S6LKET)X_DT3=@A;8&6A_OP\$|?7/0-(*FPN4YVH2Y^(2| M+3;T|J62WRSVZ-RO'5-[K8!;|A/
#^G+@X;IK?R0R|OB\$0LYCK\$ DX3P6 M2_4KCN#@8IP5Q!%^8\$+|C\$NSK+Y<43(6-!M|T8(
)8\$A|LO3+|F8QX*5|4 M099F^!7C\$;AJY6=)9ME4*N NCH.Q^DI=[NW(^#).E")\$4.17L"*7(7|W;C;
M6K29B|SX|Y8Y'\$Q;K#4;#5NLV^Q.'|N/W=Z0#?03;.:?Z?Z?_#3SU0%-@\$_LQ M5(-2|N|_&^TNH@QD^#>?
J=YU:A|Q:T4P!;<@JY+ M;|(W>T-S-HC8|8D96Y,2&7+5\$W:*X(M3P8AX;ON|CBE(|&'7V8PFV-'S(
M@P6;|@E.#1UNY|UST\$S\$OX&"7@POX%ESAAW1=,BA(+,O>)/M+!_7ZB MEX35V6R*5BRYG;
|*7P+|H4D\$5@QF/H 5;".P&E,Y>;2V3@_ML0?P5GUW1< M;BZAF0/V+CP/#!SG11L;\$^%QP7M#>Z"A?7-
L)G|6;%XY\$#B'8-JP|H;2-A< M 87AH<6= _X@5(#=#_SLCVY(XI>N)|RX?737(0#^#8J^_"OSHJ.W8%=K6
MVDU|"HULC)H0|ZPEW3C7H|8W&#RKERRJVL|7U3 #|9.\$W&K65 <\$5QA%8!P M6^TL;|RWK@-
Q"TX5TM_\$L4VR&L>=%PPI6<7=-,QGRW/<5UV;LR=CKLOL&;"5
MCC)/Z'N^5>3|"HUCV|VT.SR<|N3/Y"UZT6#+;XQ|06H0BGW>*!%B=-
|9|8<|,"#"EH8EP+89H@ (5185%"\$43V>^W26A>- M.N_K+L2SP^:Q>+;+Z%I9L)Y*(G?*X&B6AD5D;=G/C=OM\$?
#_LLC4A*TN\$* M9ER^C ATFTSY8'KXC'X'NKE"D_K>QU(2_EJ>*6;+Y5P-A7%=J%T_N4PQ.P1S
ML_AK<*U\$T3%;@P!;=P*064BMGO6,UD9-FKE|LW4TTFQ=C-L;/ HR8%>3"2S@
MZI\$<22+4P'Y8+1V*/WNKQ2+P(-7X|Z55RZB6.HD!=S,,QJ3V9X9/\$6B7"?>*R**EP).7D(=
MRY5@* ">86YZ,JG4Z_N/VK#9(QJLB3 G\$7;.1H0=,&YS&&'2(LTP;CG"L((M*(/-T=|"+
%H5N\$A9Y\$KHTF(FO%BN*.;J^W0A<(^&V"";8 MK_B2&>);<F+8.V6YZTXO8N!(G'D7A|3I7)-
V/M+>D*9(CVGO*BL#M_;;FI=S1ZQT%4&Y*6Z?;\$X|HC44Q>59F)?HOS"N9G0RL0^>KD
MB7P5R4.^T<|A61JWL_ED|Q (B3\$CQ=0|EOHF.N.L-6X1NJ#TG-00R9HAM5CC MWH?>D
^T+D(|L|P13"35A54<6|BQ) MR76-@8&V,7PMR;D6_7L^40;.@DJ=|<=Q+-.4&*BUI\$=PR4P19)A6=|U=1T4
MEF.#1.O9H">+!%T#C|C|!"GR|Y;|84>;SS<-(87X|QLN4NOF16>KXWE|X8&A MTE1K7PSD3BV1M4
*R|Q(XBK)!F%N@V65 MY6!2@CI>00NO?+DF*Z1*FF";%3+8;7 *C_P|FI|LIY5P_9#&-C0*IKJO
M.N;13EA2E7.VHIPZ6=PZANVL2+0\$&U>H6B,(-.(R3|>X7O\$8;|=DDI+V<%
MFS;|=XWU+2RM+Y7F#6%SQ_@ "1_FSN2OD"1'7+18(-:U|H) /@(>7|;? M7;\$|QSD-K#GU8"U/LQT?
^J#ZMP0MVRL_2%YVF3-&>|/7A6L"5^D&PZY<4; MPHB6Y;%H?NGP.A??:D5?2H6O_+TB;.^!4;=%-5-E4\$B|K-
33>8J"1 5"=4V\$S\$P&BJP@>Y M7Q)XC)9-5<1XO'XO4=|8U04\$ZL=CXB'I'I'3E>%A0>050KJ#;\$|P(%:PA&NP

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l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x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{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

#2)43271BR6N@?G/KRP^3/I#1X *UP" *02@&YI MH'=/H IFI>5Y9=I ;UDTID.5: XNZSVI.&@I%&O-
ZN5ISA.36LM575^>J+LW*W8ZLI=8Z M0V"KG2W\$6ET58:M1K:XJSU:POW9L42V:C8I>F=T(A.OST):45:(
IKG55U MY@K)JC:W2CJ&T: F#3M8@F5-36LJ:PT<0D4R?Z8AT5HK#)AB.KIYND8M^U M4I'O.FNOIU*^
SI=JYUAZG>&D)WJ%<|<#7NY4IF6%|R2TIDF13PT-#>IG M,V:NYLR9I@?+YXK9M3K\$X2%>ICJFL_I/E:/
%_ =2J6S%|DT%Q?^5* M-H&QNSI>:8:(4%BW8TS^LD<1K GS\$(S(UT)HLO_ G5@><2#^V_!\$89*G7918
MH..*0/U"!4&9EW<*!4F/4KV1!T""BSIIV+V*52FMW7@ZN.Y^+B<)4R! MO,H# WS,E7X
X<=|2Q>W7Z>JLY.H6RN@.G%W?CUA.BVB57\$;JK25>9EKR6 M=KD*62-|,?V&N'&WK;DNM2XE\$?
^\$SOMG8NSZ_1 M:8Y=OL7UPJ5)07V('M.FW=5I>B5^#(*B2PMZY1'PTIUM+>|=92V1?)KNJ
M"VR%RI+R>G0QKGORZB:4V2<0P2(05YOV?PP:C8OQGVIV2L+=+ZVKTI17"=M
M:2ZN:Q5Q'2&RN+@>-5L7XT%&.:@MF=UTPEA/8.1O:6+36C)F+ZM?5.2V=-MMK:OCTUU>
I:Q52)+RNS.O@J:MI.;+SSWJM&CJ:K(S5GV%5|W8CP0_L0:1T M8%NV(YI6I& AC#00-I'JG||=3>Q'Q/F\$28R?
YE.H0<1=F.P>>>F:UBI%6|M>0I'2&DU6\$/G_ SYKH\$GOYNTPV9:|+3/DNIUT.WWSSI(KCHIOSR0@?X:9W
P6'I^!#TKL'1W^*78/MIH!>QKHI&?+1+@-A&2B#->40QD\$%I'+*+ISWQQ@VM_|&#>Q/=)78DXM-M5-K@HC?
0&-8EA?T MNDH,<6P;+*!O,&@&.H6VP'ZG:;A<6R#L9%BO*=^:NF4T*N;LITKJ6*MWFGU7 M&/O7/MLX'D3.#-
Z+;U(QU4EPC7Y=LLUV6<^ID2I"<7S^QP1G+Q(05OVF56/ M-G:DI)I(5IX-
QZ5#Z12'5OS0VD5\$CK06P|HDV>=S7I-JCZ0^DOI(RC^2LTA# M/3@XJXI|>V*J6ITB7K>('WE"=A#R*OP<&E UQ*
TI/FJYWYJYHJ9^#(A.V9 M"OY!WJSU:R9: WZWS1GG2M:9B>OCU:C:A+IC<R+GM.^R1FIF=F6.0\$U
M:3>MMJ6N1.("C1Y\$14%\$APM!X>KT@DO%A.2IUF7ZN*BVJOC_223X#Y#_H' M,I5K6)3QQ.14^0?
F+BA/PGS:BO;UIX;/BLQZ'Q2T:Y(H@%\$2,Y+U|YBTZ1
M4.A9A"!MC\$YVIAL85AVE.#YD8\$N\$>Y6S4:7W=)6%HI@F..D2EE<|F'HJ=1 MKO(6=\$AJEK2:>XV-
CEI+W56_48OQV*R\$.|C1039CO.T.T: W8CB,KZ">D5 M2IVX*Q"=I2%EE-#LWZ6\$HE^B@FI%/
98XN2|N7)19@4^0JMY>X.DI,FIM3M MI::NKW> ZVM=C'NMM=P=Y% M0F6^7Y(%3&&2_1|>4V72R#):;@2'W6*!-
C5WK.T3*68"2&<??D|Y)S&<0% M<9J.UHM4J-05EAP9V"2I>YDIH\$MXG"??V3(=).%V)0!%JD#"=|4W3=5
ML& JFGJ09+BATVGI6L8^Z30_ ;^=&KY>.D5#0N|JM:2N0<*_-1X\$88/_R
M/=GI\$9@6VHOA:07F@GVE9I2H1\$EZ4C=R9:RRL Y3"O(X5IU+|I?MR_HBE7 MO,UEI5+|!UUJ#Y8Z2%^J#A?
F+=D\$ SGSUPW-7@5|J)*;^FH9C|;<|E|_R5 M"-
Z*JG4M_53@'S'=FU)ZN+7A_NF"/49AZRL>PB5X_>|+FJ&W1*H7DY_#G
MN\$FF\$IV&F^"RFC6TN:RW+&K*YNU+H6)I6PU^@63!P>:;9I(CVD(|VRZQZ
MR:3K!|=JRI:2H6&M%/2VJ* C559UQ6E6.Z>;E(L>4?UKM.A=JU,+*X9;>:Y6%
M"UI/A*EG|KP!OD.KX>_%\$U;=KMYNE54D4P<=>=Z0:O.KWFK58KGSB4A#S'/KQ5GH
M\$"/Q7NJRI/U.F+TIFU>8\$;L7XUZ|KXI&249|5RO-/9+*;<=>%UIZ_^0K1:;>M M\$7.*T'I(CTDHPA&8'\$"FK'/BE@RK:
IW+=AF7I3JS!1* M4_1O<7)T9OE^HA1-B5ONMGE7I|*..LIX^"E:|B:|IE^Q7B\$|8.ED/F5'5:
MORB0&W5C|87*GI_@#VUI+^&K1Q>(^('K'!^~^~80QZN\$H5N\$<6.-=I*V M>#K=VY'Q90
2.IQ1WU.5(.^H_ M1F:5H.Q<%TOI8YGP_:'6:#1LL6ZS.WUL M/W9I0S;L3Z>=7J?>??
>8DPEGZARZ(LLO&GWBQBG746.F>1@WD\$3%)WE_NC MM:|=TE.SP|KX<XS)YQ<:;XXC_0!
(+0==4JD+VCYD%=Z_4J0:#'|_A &G M@S7I2!M8 "ZGY>C: M('IF@S_D_6@^P@=CCN7" MVQV,T<-
IAH="P)@DY:ISV!):0PNCH15H*1'7.C_-I6_&T3|N%G.1B6IWN%7MOF9WF+_W =M+Z<1U^H#X805F@C|I
=CWW MG##(F\$G4:XO)0D@918ZL5:GO?I.KB>3U6)%|T14N0I_GSA"QSCM3(E)_I
MTPYP>#%.DH"VI>YV.IWC|05K.9+VO-Q.LYUO\$DC7\$Q4ZBC36^*DTI|N8G22 M1_1P|<5\$>PV+S("'
(TI\$NY(@@I_86Y+1|BJCGGG*.G>:%N+WF% LN9H|V+28 M% C#XFL5L0:#IWI:47K^@I(VE:K.U)6S;>5HEIT-
JAB*OS*#/_.*%3I?;MHN/FN:=IY4KN_J0-6.X/UM/6_YNAL\$W>YRWPB|)*84TDY%/
MYD4AJF"IT%:HEKE^N|TV|I#S^2I6/3+V=V|JR<99V.;+>0>"S57.\$H5-/9%X MZJS<7&7CH85,<:2K7QK @8QF\$-\$
H*%0+OYB_P_M_;/URSM=:07 M'PIX23Y0<_829I82":O5DQ|H3I8CJZT_W)72W_R'E1F@LP*"1*V9#EF Q8/
MAM0+^?L"DD/FI\$5.0|_N#?YHK?DF73Q0J1)+6UG"E93I9HZM'#_QMX?3 MTIE&8#%6
P|:A_+T.)HYPC^LONM9:ECB(M2X'HA:=>-MVUO&-YY^9:VRKB|70*NA4;:/BOEF|I\$?O=,I^?SUOR#/?UBX\$1
MHR^NL|A%|I.H"6:14%..U9_0**HN T+00-Z?8_-K1I"/TW7H&YI^ (HJ M0T7ONT^&%)XRR";+Q: FR7H ?0L.*"
IP<CZ)@\$.(41T3<I0PH6 %I_ M9>^4D2'F+?C @M%BJ_*DX(VM72I=:RZ!H2IWE(R&Z(&D9AVMKMQ?0
VSWI103J0_"/3/498IR_0>81S-0I=H' MR^\$&DF0K9|U76S|PM.3)?OWA|?^F651PX|A9+GR%
(UH(8TA)0S+S+OC915F|E)W-1GBJ)5EDW|W*NK.DU^5>9Y2 I%V3I(5!U% M|T:9/U=:@;H0VF=1P|>8F82+!H+|<.
4A5V:.07E):S+3JGSGSBO:13SVEL|HG>)*L8 LI|PT18AQI_M3IB "70Z|9..)"IL#PU7\$:.3%|H(*.S.CT)D&T(6-
2A/#KP+4@B0(\$^Q?C M^_@>-V|I*W#Y61!7V:.*"@;"9PA%BRBSB_#6@I9:%C4QJ2 M^).CI:" W-
W_+ID#<CMD_VR(G>O"2KZX<"?>>|:W#@S&FW_%N=)?>SC6+K^ MVLMI|S|6'3|/3)H^;/(P9OB6-J4O?
(FT>6C@LIMQI&Q5Y9"GM)F1<1SE M"N"X#V A.5-8Y89!^48#CDF M2(Y% /O/L*!>3&@P?VK>T NE3I2:M3:1#I:1
MH2(B9%BI9VCW:617@#V TINSUHTC6Z*IMJ:R".S.XR^<D %DM:V>KVIMLM M=I'9.UKYG#1:;L;N>
<)@-1.L43<% "Z>KR7UEU|6L2H&^QI?MS&ZRG=Z::|I MI'%'I2I&R_Q_ OK+|:Z LZ<*=AJ%|*X
M,N'D.2&G>^&H^UP|KVMOH?VBUQ|+<:FB#!+Y@:QW(F|KWI%:OK GXI:9 M?2?(DIU^BN;4-IZ%S-Y\$4?
JF:VL#/@L|WN+?)?K|A\$|+0@<3_U(CM|>6RO=G9#XI@0Z'IGG5Y0^4^Y5Q-
4P^YI^\$+EO=;@%8:6FYA9R(8HVV0D0.IP3_2IKYP+I:1 MI8Q_%R8QP
=GZ7"GLSC\$|>&_&_OP>T"N|UXG)I#)6"M%8CT:CAFPTRB5@ MFHTVA L1BQ!18U:**9*[2:4,4&3W7>8D8&
(;9F^"O|I"IO_DP5LC:&|S M@P8K_O?:V0(DI,B<C Q5NSWM8-(8M)WQB=_#_GDJ^L%<ICR7?C%<@D2%-LI
M*&Z8SES|%&|S>.FE&&'H&Y I6LW8#C PF=0HE%K#)7:IW094X4RE |XA\$C8 M=2NI:TMP'D_JN-2N'5?9X%0^A-
JTP\$UZIS:@*8A!7S0S9Z|U%YK*9QY%S MTBQY%G%"RN9@H*1U:|+7X5X:9;2UM,<I.\$@I*YD+";
M35XJ&OK2B0C4W%|E/SY0T%J&+R4R0K#*HKAM*DPH9_+BRP5X-%U:|MI@_M80I6/'\$=3Z57C
@J7Q&Q#1:/FKGP+*S@SS.H.WZ"QF>=Y12I9N9C|YE'2J
MWJEAZ/WO\$8'UYI6D)SI^<#QN@|B=TF%WD5XY+&67* "TP/6I:@S21Q"MLLM MM/3(0BD&*P?FR8I'O5DXR'@J?
7XZ)%!'9WUX\$?)_B MM& "RV-JK^"R? BGE#9&H8+9A9MW/F_7&W>74X%:6Q5.NIB5D5J2@?HYI
M\$/6FD|0=A%\$PEG'+U6S_+8/0L<35H!IMUG_..HAZF/S#54&5A_ :S>A\$#;> MAPG'IU2_..QE(IZK-"OQGB-6:
(NDG%4X_#?#Z^(>@SFZR"/&5.\$|N@2R8E' M1_ "PH>BP@F|<\$83??*Y+"2K7#&@_M.WI:~F_I3S">"!SS1N2/L
K+|S|6<182I302.NYIDOO_OODNF"TSR_:Z%H6 \$^B|KON"0' MAS?#I0;V*GEGAG&UZ:;GQI-(J8:=NG2L-
H>"33N6D:8"0ZQ*C%Z1ZPYD?| M>(@3#@T733;10:C%HN%D2&RN=>D930%6C=|S\$%LM&ILXW>"^U
M#68:_.4|6-71N#<9#7)P?7> "=C:D%I=JTL+;W+4RV|IMY=C@(-D_VCI(4N#K M?:D#|K|)IR"K0^H+|4I|Z%L
M>#DO^%58B72H11<*_MR:TB%QV1M)J^~/?25PHAU>|_?N;^2|NYSE.%QJ M5J:/&26400_HJL4;MX.P?D|>7+-
=+91D1#X&@IYPIF2WRV%)2XMF&:66%&#
MRVP852.FCWG(H/C_83E178"DAHRP^8M4E\$%;!S:.#HIS#HU=WJ)#H)+S MT7DFX2BJC|Z68=?
X".|I|UW+%"MMN;WP1S=B4R4A=X:@5>TK2XS^Q>@*Q6W-
MUL7|@U<7E|ELCV^DTX%HD#6D;#B+A2/I:EFUSN^;8IT:OKI8)8&JRL)FD5|L#0PZ>AKQ5|TOKT|>
I_0:SHCJ^"9_E(MBL!=|V_9#N|G1\$(S|=SO=Q|VCWVS6JYQX=C|G:(N)*WE#8XAPEN APK|WWE M\$6MVY_PSW
^N:|_<6LP^XV%^P)3-IENY-E:8Q5/WDCD8W*04@&/DC?K006-WUF&G>_H9

M8^ND5C47LGR:=E2)*N_@C:H%.8JVMZW #905DKOL6CFJO=M)V5:O4!/:/\$.(
MECB"S&:AO++:WR@T73!:#D.!>9)V3.KWMV=M:RY&Z\FRE_3BV*K(2@>96FC MMNRFL9L!K
5JHFO(^(?>\$_=MB!.E=:51@-8J/P/A#BTZIS5LR6BD5+1/Q M!OBXIE1//%.S"l+J*YI-EEQ5.-E-RI3>H3\$SZN-7(T&
<.#75D/2&T#L MFS%>Z(EF%+LVPL+V28<&9JA1?DYCN9'D)FM5IE=FMSLW54.6))?M-IR^W M3K\$)TB
U*)42=C/GV)5NUH_31M&3F!>?>31(>%)P19V.S/\$V>71VZ42K) MJH7CSA740S1WYR2ZR!9!+>K5H!U:39:8W:;4.
<8PV1YXXGCD:QSVX-S+) L M-E++*//R"F70QI"8T\Q*RB%Z35X"B^N-.)LUFBLW*%^=)U:4BU\0DTB=)P+
<4D/LV>><5\$1-WLYH M_ERW9"IGI\$C7M^F_!F4RB1X7!6RXU#@IL,S?CM'DJX3T*0JO'2'C=9FS'
M3399)H+AR>*KL(JP2329'N9GZS7GM:W=V\$<)-.\$Y@K56%7\$IZO!;!J8@>% M#?2919X7:SPDGXQ% C*1S?
FLH16SKD+;R8_?UBOZ/YV#:3YA,444YS:%. M6<^*RVMN#F#TA4ZZYF5_62ZS\$252L>J5*(L8\$;HS-
)W6R52GZ%"D@!^C_9 M!\$;RDLZK&&FF 5=E_VQ M&Z\$0K*J-L@PZ:YMGLOT/!)^*XR'IHPJSI\$U-!1/@W@XS!
(Z&H!;0Y=B@U M9).FJO:3GBRPECF;LF9!#TKKIBQ"@0KJUF^F6#0V)5(MPA?KJ5J3-
M1+H29ZW%BRN=N'7HYC\$K8U1"(6YC3VFTW^@2M45JL_#17&1 MKVF2"J56V7NGEHL_IFZ_/H2:
IX2S5PSL9!XN-XXLY"B"\$8IK^R?5PMI-B_ M->4)<.)L-X54WT/QJ*L#-:K'UD#CIC%966C0!_%
7S^066SM!FIV>)V%%; MU/G'23\$68%SP5XQF6XK1KM*+3J!:#'2VM^%?6U'"J:W0Q7R>.&8^G&%4IW
MD?:A@*6I98.K53YC^B!2"S(_5RRU_"CR49).\$6(4/1\$%CL0^X.9!+IF%U MPE07(YOI!;H:OI3&I4WEI6-
J"K@>@ZZ20F\$PBY1M7\$#YWI?DH"SH4QJN!Y MPG!)%%6P!9^G!P%K1.C7-0\SHJ>1_#L\$&HMF'@#W""4">I?
\$"H#RS+I M26Q!O6W!.*"2->M-N1=7 I%UBGPP.Z3X0GR/S\!I*H@S/Q*K#9/Q6=
M>PLIP!A!A>SEM(CSB;Z!%G;IR087I2;BAJ@JKT7+*R^7S\$3RH#@Q631%BH
MA62.3="W17^H&G&W)SI^AB"IK/5LH!>ZHP%J(E2ED54E!)@ZO<6M9F M55_A&^XLL:HZQ5*P%
KT5X7M4MP7!MCNQ6'C%K%Y\$K\$ZQ-WD-1XFFVC8\$=.\$F.A(5Y1A2)!^9Q/+ M_>=&JRXW5ERI7.ZTEG\$WKRGS1?
&S"3?T@3"^(V=T=QLOHZ+L.U!A.5B M!+->#.*&=S%+L R96:16BPS;V6(=E<=;A/IHS-HP!>S? !@OI
MG:ZK^7\$BK&;5>=;K#-/'40/QUO\$XDUVI,YMVH:+#ID""VP_H3J_2>E!5MD M;TY=#Z!-PH(\$&PTPK^&=&8?
CJ/?_64AFCE\$S.DBM*H?S%DAHJ^D4J MZN*G**3WI80KJ!)+).C^WQQ;0,[KROEA>\$ _TBGG#9G(4X8.*G4%T%-
-\$ MN:+&6 F<*RU?974/"7Q/VR_2*><N8-A XD5+I&AD)N!6+K?"+?Q:TV2+L MA:9H;QK3=1@G3!4_IX2<&%?;1.*(N
EB#[IKJ;H-BZ?:2"ODIDTU*4F"PM< MV4V:.'F#&172TGJ(7F&73FUGE9KZHE!W*IMFCVY=NXR,PM<)
(R&_RFR2661DYK@H8"77:1?PW:P3^XWKIQ"!5!4:5J#@+& M!Y+!PKOP)N?.*7/FI-
*T\$>Y3C+V0%:%ZE*7IYE3I\$>#G:X[N! MX&ECW9G%6!E-F?B0F*50W6YGI@^K'EB=J/ C:L+\$""D
M\$Y=E+>H:OJ\$H8S!WKK2W-M>1Z2+QS@Z!;'5XT!4*8?K9XP5)SQ2 M=#AE-
6N!@FTHO2%G'B'G%*.I_UXO3M:*IO!\$K1)>
M/P@;,,, 'MVQ')7#Z92T5W1S!TU3"11MA:Z_2"#H.B&R21CB1OI\$JOHQ=N6,P96D+ M(A>F-
/DPY9\$0PO1Q=2^X.3)E&+6JSY(^(Y6O\D^2&<."PK)DW)3_?QXIUC\$ M448(P*
IEZJCM_7#H#19CVIMLFJF^B4M<8Z!64RN'3!A6!M:UOHEJC9K) MR!PZ""<_J4*L_#(REHIGF5,@LWC)#YS?
!M1Z(HS.Q=J@:E(SAI2/@LX-ME#1J_.0)WN3_?3ZECL_72=5%FE:+C(E@")@|E&X&P8GL)68-+F>+6"@_*@:-
A=Z!%;>8/FU(>86EC)3OR5#2I?2(5' M+ALO60&TL^<=>X/P?7LL;#12Y_%0=IP\$K%^E"H*FHS+!;#Y+K40BS)
MN O!S_J_1\$F>IR#L"0C8V^67^8(Q2W<D<1N+5E4*HCHM!<4!_M.N:5!KJRIX*W&>1_%Y/ONEVY*
UP/O(&C!;*A1D8)F>#)MJ9&B473 MQYY%&6R:AK)83_+1W&U"L"(ZN35V!#;NKW!@L>EFIC-0ASN+IXH(I?_Y
M(<0+L-/>"I?B_1_ZROL^U+^\$^L146&SCFF#YUI26A/8;SQ;)5#WQ?4S! M8;;5 D;X5F#IE3"4.0@?#MD>
IUF7IH6%^Q1VI#&MQ=?UEC^\$,(1-(9I2W&NMYZ1+VQ^XF9+F39L(A<7MM)P+F166W'7&R_>6/8
M(T7NYLR6\$;B#6@6J0!HCB0YH!-23!6*XDP@_"=PIY(L_ZONNLPBG!42NNR*^_0!U>AWH8%5GX^K^/8MU_
Q^6!K3'YMK#F>Y;D(A? M1>127_+ KAB01R3;6M20+?EKY_@<(D/@W#T#I=(%H"=JN?2!J!TVT3K M@T%-
@|=K)T2F<)%^#/P0C"C_7X(W0\$<1\$PVCX\$P-"WY;U&+&Q=8"%BT! MPW!HO1W22?_
SOI02=7T3@VI%UW;'NC*SI2_&63Z^@O!W\$W)ZO;8=RKOT
M2^_2R3FIS3"JC*6IX40H^JBOPXMN/HYHLHYW?>#1 V;1B!K<"R!&OVYXHV MT\$PSIU?#@=SPYHJ-
_I&T: +&@Z\$V\$FL2: ^K@FM2&TG)*.OH-!&X!\$F_4MT2 MV^;Q14L-8O@2;#54I_34WN2Y!ZPORNIC2U!>UK9?
53DM-:\$!WO;27!MO MN!&L G2+;_5(2%*I\$K\$E!3P2RST:W-#7%K(1\$W!M^KBD1\$I=/ZOYSE?
*P,S>GYA188I3&_GMEKNQZQ\$W97EV=%UB M^GL7G)04JS<1^I)S2AM\$>\$3P.<0#MV=2M_3HAJ:F37T0ZT-
7Q+15\$&TYD13 M!&.\$TT61&M.M->L!9TN6K9!O>+H0)+D""F5&24^GA.SGIW8EW>'LZ>HX
M*7<IV0&O8X!%E&D+L M1=%='RX6)Q8G%G>TQ376LG/ZWI8BE?#_1RR-V&6= M^LWV?X3!1>N=5.K6!AL?
DOB^+/[X/@<I#M4MDWI(5@9*UQ715^AXOWF#%NQ M!YK0;2B=@CGWJLD:K3Y-8!?
&JG!M:L_"S=YZON41B4!>@IAT3A:#\$[77L> MN)?_S!PM_6JPI3\$XES&O#U+XY+H%W<<(Q&O?9YI
!/"A34*;ZDG3_8N! MD:;&/U&0(P(!^E2<*ASWS""C""<6_85PM21<"XID+BN0-?RISTVX\$+Q" M!RMJ4;NR\$X_*
0KG:\$ZX_HA*RA: +&5!HHZ/>'YI%\$XV\$>'6_185XM21> M!G/BZD)AJR!=-BF2<2>Q-
:0JR!X(E!N2!&LC4)!BNX7EH-BQDVP#""8 M0K
N4K"8!S3;H4HQ\$V!BO!D5D\$J7IH.>*9I3R%...K&"ZD):V^R1::B3
M^E&:T3!7P9RX%"K#HX7G*ZXSD!MU5B<_5QG@O_P7G!A+(K.'\$L_%PXF'B MON6<_IX*3A2<>*_
@:04KRH(5!2MV<: X5@0G'D!LO@1NK L%)S(V15P7- MUWCNTFIC_&5Z/ISU/J&J!T49=)7-Q9^ZM(G=S14-
3!E*#@O-8XKHU0U?>@<M SDH!7#?>_R M4:6HWT(D^4QO%"*H2T;2%MMYU<'JHVF\$S
J9!#&CRJSK7;IRT-5Y>Z MD%DALOW;^#%EMN7F=WFH2 MUY:S+ R*(X2)"GGMT:/):!\$0#DH_0XLFIX+K3
A6J6VD%7W=G\$NS' MJZ47SP!(E3N?OR/.'&>*IS8S%WC*-!+T%?-7!."DOM9@6Z/1>6%3_@#N*
M#"1\$5(AHATOU06:%R J1%2++7V3;ZFF_X3("I\$5(LM=9-MK_I!E?N@00F:% MS'9KYT>5V=:R63(&
TALD)DN!7S8XELNPDMF1*B1!9(+=VOFQ1)97WY7_ M'9ZD7>&A*ZLK7R61Z8N+;F NNZ3=G4.H^D;G7;W6@Y\$-
P7FN<>.!EM(Y M!A++++UV2-"PNO+ZA-IO/IS4D5Z1^V2IN9ZN/U<0GY%)Y1/GD'T<N)N2U MS32UD-?
CLZV0UV/(VLO8*7-S+60U^_SK9#7!AKBY%RA?O!\$2&PG>);(C# M\$-
CV!@G>T4VPIY/;"MIQUX3!1LAKIHA6R.N!Y95;;J!^(X.8_:= M8(WU9+77Y8#/VYGZD63H!<^QUZ/H.M3KI_9_@-)
MLP)<>FMK417WQ??"JYMIJYEQ!PE9:TF719!)1Y;Z;#TXPPW_V4:8>Q-9!ILZKYE"2BP%<(DA*D3H!14N3?
1^PHW@&VVAWY MI>JLS;ZF&4*VA&Q=FTRU/9I+57L3HZ/>(W3\$!(EA.MTA&N/OI@ZLJZAV+O^ M<"RL0B%
<%R5<^U:MU!\$NO3=1^T/A<0G9NBS9XCJ:2C7 MU+I8_9V1(QXICU/ M(=WP+RN8+J2E!0=H!OJY!/(AR:'B6\$
2CCO;HMS+ICM0:2DXKS7:P^O M3^5>\$"PX!PYL;5>395! :S@O/FQ!:\$#7NH!4\$YXU*!67Z=QGO@F/%<
M;.'=SC&^QPLP8GGRHF>JTHO!8'6ELIUHE>OI<-?IA*KJ-%.(M\$Q%,3L: MJM+X05YU)_B.*USFLO5*7Q
W_2G'@)G-A:J\$H3XW8\$)W8D5"7F!0A6!\$;H M2LS;\$9S8C5"5&+W0QH!HHRUWE.L*IXYR()9#NT!;*+N-
ZKK*J5%=B*P0 MV0YM_)@BVW_ NZYQZG!7.BMDMD;ZK.MMM6K^N!VNJ%S J9!#&CR6S!^C6 MUPU.W?
I"9(7=FCCOQ)9KB ^H@7"(-8=*C'38C^O.R51#^"M1>M#UYZBN
MFA/C/25.NQH\$;K.O:;H_@%W%!(M(B*^@T2Y7Z^OW6SHJLZTURAC!D#2\$R J1!=-. MCR6R!784&?R
2(3("I MULZ)*!6J![@E!0KG)31F;>6S/#)U87DV\$7#7
M;3V"O+88*1Q'T\$B!+93?"L\$!A@VUH^8<1!4(N0UTZQK9#7 !MKRUD7 M!M-LA+QVBFV%O!Y87KGEIMI\$X.@
9M">=-8S^_E(V:O;f!<2+0!PQQ6>OX% M713W0NL:WZ!7/I_KT!7JO.K\$ZHZ!JZ#L\$>#4=?G8^S_1^29P6X!-
!&8(OO MB^+^!S2!B=#CSE/RD#INB+Z2CPTVF!QQEV=LXN9!X6S!EK5+L!LFPT!DWT
M<5!5Y(I4/@IA\$!L)T.&%J>;:8>Q-Y/YH/!2R)63KXF2K8?U.COC@.\$V#U!0@

M(3Q">%Y&>%HLIC'Y59<+R1*2=7*2U5K5B\FO%#P(EA'L4Q*L=LM33'IUVD*P MA&="=DF!QG3IEZKV)(?
>5\$: Y4QWIIFOX,2SYL36.C)-IF6N@A/F1/- M#(IR'Z F6/&L6;&U>.*8^UPPP8GGRHGM!N#&W*=="4X15TIDU?
DTY<Z"U9'F MIM.)5KG>#W>J3ZA*8&+6DSZJHZ&J3EF-7GM<9YI86JQN>8 A2.JIPC8L\$N\$#3,ZW:"M#
(>+KR:GK&JA,R>J8RVFFJN#*4 M.26-"Y55(MNAC1J59=-M1U>&"I=V="&30B8!M!%CRF1JL7%E*8R"8\$5 LM;
M8-O*(A#&9-JR*N05XIRVFJ>11F*D4QJ7H6L ".DJ-B(M8!#5UKQSV(OISOQ?
JXD7JX|^>HKIH3X)STU:B;I>.*D'L%4?T#|B@ "D!1 M:(=KLE7AMQ+K83("TMR,Z/*K)M-
2IH0^Z5:D)DAF+BS/)>+4NDW9-#N:OI&YEVIUH.)#<%YKG=>
M5D+F7I@D;(&L;.&U8+LL@/X%)W8DABR0_@4K=B,T*1#^!2=V(^G@/X%)OXX MD*5T#M+_DNO'1(H M (1-
(&R"UI4IM^QH6Q@P1IKI:6IUUP!)%PTB@3^B13J9J'Q0Q-IXIY*8ALAD:Y03US+9EIX 'OM!_!E?W(=G \R_45?
JCMO68\$ MA_IUC?PVVL?W_XN12AS8% JW,#/D+^MI30'JH7?^R"VP)(2^6D#I9Q'-LY&
MLCPBV0!*YGI:7Z1@0:17N8E=RZYX66,,@_ Q% 9/(HV/12_-B:A0.2A;K M=M;T*WD_29QON 5-
&8QP8/7*]>F"KSVRA |DW;KU@/ M/C% KH@KH4B@_!H1H2U#6'UZNA;<C+0HF EQX&T%X)>MD8PM
VX7UZ,,=4U9&C!%R!\$ZLO9I MX>%E^% VS!Q-92*/QZ9,M*\$V?U>--TDIC&?JHJ&_"Q72:AS%ZQ:Q42?P M_:_K-
ID^IM@/@E&D;OI&X%!/!.JMZI.H#PFO M<>(77@%#0ALRY9&D%@P=4*.*WUO R(I=#^6-
'9.WI"55YZSH:ZEZIX3%Z M!YH6=^L_8<\$0?&(:U@Z1GRRL:7="FE+3!A0K?HP^E"EH+S:3),N9@1)'0Z? MQI^"f?
7T9_?X3"!@A6;:E 43;&RZ99?YVW98OEE% #LGQT+S*9?>P^_6IK3 M'PG3RF0&('EF=T\$TQ_Q=00.L16;
"3#MA\@2>/!12IAIHNDKI^@D.&TONY M!/:2#\$-W&I+I+V#VFW#4QV9=.^MV0G7VK"-9;+3;C(Z-:A!ATPV=);
M^>0Z^LL/C5TGJHMAW**O1+H(V&"KC+6.._9G^NZ@-9'^7^:CB0I"AS,#:/:GXYH_PZQIO3/55.3:SKLFL9&
M29_J"EZ.M.LIOUB/J9_/67Y<"/&5FI+7T5J?72N!&R@U5I43J, SN%(& M9M9B?
+APCS=1+2I>@KQ47BC>S)%YSGO>U&<56\$IA&1FB:MC7):3"?>9+RJ+&O-IR#E1S2+DLN-1QIXIX\$Z9QJ
MWL.SFOYKM^M#A%A>D%@JVO"@8EE>UZ&VB6 N9/+XK"EDLH9.ZEVI*%597)1" M*!;.*15-JQ8*KV)V5=;
(99+"I7+)4NV:JMPH+I+3P^:PJ9K".3S><"M'U3 M:B=T4U9\$EZ/R-@%*19B:GN?H;5C|C|B@N:DZ6I>+O M-
J7+R<+FPLRS !M5-)5;UWRIEPIQR??")#%QSNPZ06I8X1GI&D= 1O=4; \$ MP&T!SVE=Y#FC-I'Z8T47"/>&/<16G8
CAOUJ_>88P%QYTAORE:113) 7C. MQ)MU:J)I"YI2ZYI7M>S)5IYFV S;<2+0Z&#P1NZ*/HG(F@4/OD95ESRH@
SWP_?NWERIL'U/=+5+W&'4^_DDP7NM>.W<>8\|<+O@ MO2IQ'C_OG3OG<4^Q"YKF-/>'N-AYI=>N
MJKCC'0O>ZY3;R:KU5%Z1F>4GBBG.+/B0,JLT]=0GU,87T<68f=\$:'%=@=
MAOBLBVDY4Z?9D.SKNK-.8MHIY\$|L'LDG7J5\$G JI2\$DK(?!"X/GZJ)TKKM=, MOG5<0N""P
N!CP2^>0ZH;7\$?JR:RL^>571"7D7BIDC>X22JO R#\$@A M!\$+@.XW
I/:K*A+2+J1=2'O7L9UTY6PNJ PI>B|*4=O\$KNO.2X=A\$47/M4BN4O/E |U|(\$:/-/>*6# JJ^T PF%?"1^
MNQGU54IK&PFMK8+6'A1%8(42|P.'GBC/>J=VJ/6FPP'H_(HJE>L00"?B;C M_8F&AY):;(4SUZ07RTI-SI2F4ICDX!?
X(4;2Y"-25^DM(N0,D? M#ZK4>WA)HC+JFE|*6_3A>4DEB6:.*6RXLO&SMV3@1+IH2BBE"W22#93U
M;P:MWR%;QAN/-%%#"271@M3/\$FO#V0;+&(3_*0.FSTI6F YG;>.G+3PZ M+XAF^TFWB/Q:FEIY/J@8R>DRE%
|BLM#FSL=0,^7)W_JLT'DCX7I-A@K|# M^8+7SR18N&I;PF\$P^7AO^U.X9CB'G-&NIXS.E#7LZ,#\$P^D,@9>3-
I1D7B MX_G_X+D MSIFZM3SO%V.FR_0T6."B^5^HDO9422U(X:X0IGJ*12&4R1%R/ QI M!9VQU_->
7G:DELT_41(P@'N0).-+I5J=P6)2I=NDI7I"K?2T9GSJH2OIXY|^*^K"&.@UUE2D+M13B@YH2I4;L.N=I*M;
(LQ#BDH;GB MD_50IHL'NY8*|@*3;IL>:"9+KX^7#=#H+LRQHK;OY-V(M? <#*R"A&6<3
M/ZZK&";29(B"G:FJV.=PIY4?I"IM#J\$SATI5Y.#;POA(/:6 IDOC|KY0\$ M YC-EZ3|IBS>=LSZTRNMGFSZ?
P>8NELZ7!!7G^Y@7-XIY\$TXR^K.W=D-Q4 M^9W4 #XA96/#2)DQI\$W4L=I7H?Y:%W*+@&.Z/N_/DC?
PY^VDZW>IWL M?T(UD&:I|K=06YVO<I"%GSI60>Q.Y6_0NSK M-R1I@IS=\$\$A/3?3LI=:
M:8KA(5OGV:)UHOUH'A179<LA\$.I)?1JH B.?&2!HPDIKTC:;.\$48ZJ!"9
M8I#K;5UKWZY&Y*=%K!T,2H6W08EC:UL/A%|@\$1.9 MDTJ;JJO!=T4VYM?::9XG:'TS,T YD!DPZDV,
<7TW!MS3@P_Z?0?J1SXJH8 MR#"I-D#CT&I)HQ64?/U\|29N0%9!H^Q207&2\$Z6X=K(# B*_R1&X*A&=
M:J\$@UG@:Q/>1!<1U@::Q%J+&O%HV)O(G/P.\$1BK9'E4X#7SLHA,D98^HHL M JSGR4<50(\$<+;
(1QQFN(K:.)\$0H0JHBL-H9"J+@;&\$.5+ Y1\$CU<:DT:8! MJ?4F&B=W0(3"ZEW\%?# W O(3'V,^V/9Z\$@X3/
17SZJF!/%C8|PZR+W1|> MCH@JIS9CAR^\$S!;6D_0)1_6J#(EZ<99=5%E/5 1O%%\$FL'HWB_EKL*%SOI M+
(^*77IQP*V9S&TVUXU,N^S4I)%S+5%4^= G66C,9C,C23^WU;NG:23O58IPD9\$T3J4(%TFIYC:SP;O9
MR1FKP.6YEJ;S+J:SFEUR*0? YLQ*5 MJHP2P=1\$;>Z1+.*\$D?
29&4DGB05FB""R*.4JO@8MMHIYJZZ9_K7VC "SD#E MMF4JVVW:S@8"E6:.6KJ2&B^SS6IC\$YNT2H_%VU'+
(FZYI5L-/01-I OC=-N MPA@AITZR\$8^2XSL-8V&FM=J5R A*KCV M*CA\$|3JH/=0LNUV9; M'GBI-
H03NEJ_Y9G8H<#45N2>/AFW)6#7ZILP9OG/?^VBJXO=B'L M82J MPI0^L+#+8";2M_4JP9I|ZPIX:0!
MZ(X;H"Q2CK-P+OH#F5IK^%020F+,<^<^3X2<#SUWVX;? YX|+Z=D-X"T294)? M0V\$<%HT29VLT6K3C2?
1T?V<+3.3*CO*2T MBB.1I- M.*JY% V>9#I-E?L2SL0:2.T>46%,AL#1>.*_DVG!^8BZ G0?AK>R-9^<
F@;6,GA;>IV=_ M)^I=XQ+I+D@RODZ;Z"-GLG27;&82K:O'F2L|B;BYLM M\$IC22VZF?"G?
BZ1)W1>PT8=.XNE^Z+?RVIL=I*4.Q"OA/Z4WC*H5IF>U MEEM,LEV^L6'QWIXA>X/Z2/CG2S
MANPE:@BUGSK(^+"WKDR:(=O%@:;VW;5 MUUM"D>|B>N0K#R&%W SY8 V;f%HN'RS0)TDI)@8072"OP('=?
N*2GV9>80 MO03_NU%UPBA=AFQI_VK14JMWGOWAC^X7N4*1H(0.\$^P(&X*-\$25|ZQWK2W M1|FP^4|_#I-T+.
(Q6@/NPT0(TL@U"X?8* OC?)8AM3,GL^IJ,Z41#33+6="JO=G;?BQ=/:#FF:5
M4L.CWDAHD>Y<*9Z*KL98UDE=K:JP2-C M4N&V-E"EN1XWQ:4@>Z=E,KE,MYA#T GT2^
%/'M\$3IP!GCBU5C8X_50MOHN(AIN M#RS A!.*%L.DR@!_7U.A XI0UAL8D;./X>:V'WF7A;EN7:)/U4EH"X3.+ M#
I>\$B|:H&1\$ZPA@GHJR /W*?B/1FZ?K^6^8@EZKLG(L1F=AVUA8K1TYH_%K8/BKQ1?NL0>88;-*U|CC;2H/
Y:S1CRP!M MY#)3)I%YV@7TM^LSJQ%6GBHM/ +GIFCJ4SD)=B4B3;4Y@_*@Z;Q#3F-A%/NJ>(#V;Q%?
0^6T=I^M;8+I^F76I*F&J M@_O6>;S/Z-2H.F>2M+ MQ?9+M(U?Q-WCG2S?H0E2.R.5D)Q"-
"7LQV2;61TBI0V|BE7<8:0>SG%7 MAVIOXL/5|F1=|S%/(SM):K:6FDXL!5 H^&=#@?
K@*MO+>"S!S5&RM^A4H:O MS3VX%VT+|+D\$ER5P4T?Z05H
M9GUTZ"/+*+2(HGH4")MI:M2J"6+6;X21AWB>M;R.8RBK)%I('XI:G|Z-A MT_!&SR"!BG83XTEL,5>-W6H%Z13-
VYIM.DIO;UE#+_JST6.FJ F8Z8%NW=N M;W:HLXSDW1*TRIG,6I19M/'RUGI\$8E#4_6)HIE9RM^46IB/@_ \$L^DP:0'
MZD&@8RJ!O^!EO!*= (LU7?2E=6 OV1E:&\$GR0!BNUBOX+*UD FJMP87P@:S4 MO9G"1IB7 DR*K&&#>#< MO
ZDI VLOVO@KL3R).&BQ1Y\$;21GR\$G;&=J1BB!@-1<\$!IT!"DI M*65QHf>;9S: AF'XR,%QP8 M8D:=-N;
I/G6;^ODY:J&\$WNZM/YH/CK2/ROP(KQ7&N#E8QGJ;=Y+V-R<1;C9 MVS+<_Q"0NP**63M0N!(I
I-Y#%M#29QTRT&C&I*OYP@7BS*ZOR>4UIZ1_ MS#45;:U" @V!4S&BAN@29-
QC"9C\$29HKLEJBW&#.U.WV!L,0NNRL/O#;TIW^2)RSPA<-CH#;H+HA_@ " M ERQ@E<\$WJH@^1*PI^DWN!%
ID9%UAC+0<5Y!MI&+>PM#8^N8I^FYF^ZNE MI7IM.Y26I\$OOFI_(@P|^S?Y;|&P_Q?M#0?
R+PE4A:U4BTXYK^A;J54J3:QI*=8W'29JH5K#0^4YBWMGEAZT!:#! M!==(O)57T/TH7HB)W!|H%D:<2BIV!
I<9Q)=+ 13R8\I'H"%BG8|L% MF:V7Y&I^P08U33I9SV2V+7@TJ9 G96K>2:A9*:.WZL9J8H*Q?L)=_T6KC_*
M.V(RL4V&Q'HS0IGQ?&8*N&LXBIG |KI<> N9"?F&L.*|CC|<#4U:9R/9C M8Z-
51M/H6I0L#PQUU,5%C>MHP")U=Y; **6X(^Z>S!DV%JEQR|# MC4I\$-E.D.(4#KK?%C>IF)TUU)_LK4Z#
I'GWFEIJVAB>O^)/@ " 1WZH#.U-GP M)1%-2)\$T7T(ES0HL_Q/R6VT:5/40KIMJN<=1;^7JUR/TB40XEEN:00* M-
ZXX-WB?&OL_P"?K2N\$K>72EU3C|Y5QKJ3OF:8;-):Y!\$VW68= M(7<7 M)'<5P%G|Y0|KC=1Q7RE,X'5*ZBYF+L7-

=+I^6K.F@1E9>02QT.)FG:C=@/I@ M!.T8I>U1%><)9EW7Y!YO/NU MIH74K'M)*AFS-S'E45_1.-.\$"Y>T&ZPG9*
[5RWXGF1MC@X'6E_6B]J1.R5Q^MF8!<6N?3IORQ7:~?(<%0.I/6)K>X2IMK\B_X#JTM450A#M@\$=2(8(%*C.=FDY
M)A:PUDEFB!\$J"2U9LR@LO^V:E2C\$Z;NV^G!09\$A/MGS^+["V=K#P]HH1F78 MF^B%!5OB^/%D%4/&B]9ALH@&
IBM(%\$KX2" T^~5 MHA1F 1@3^PC+58HK^_F@49&-WN#A="?:1TTW3>G76NJB5:Q;;Z"UM(^=&"
M"K3#PL.KJ#\$. #YSBSDW*.*#>JZ4V\$A^N]XG\$W8VS0!IR9F83M&RR! MBMB! M-X@1?;FRRRRC>U;=3"EV&Y?
O!9%/1.;<+ND@-O.*\$[/;9=)&NGQ;-MB_5:1 MBC:B1-O>;Z^?
K7^-[WNW2\@O]BM3A=@/1.>)F);+RPT%DEU>#V3IOIOT<_%H MG\$J^NK!JG:KHVB0\$@U2F4>=00^.;)
2#5+E#5012FZI\$27E.B2\$NU%IVTO MZE!G43-5* HS1&%%&&\50U+6LGD1OW*&
I=\$ZB04=TN1RLRZ66)/+J1#5WD36Q_U13NY"!+F<M-
G_MH^FY9=&H3TXH*1*+=+RIR2GXL0!2!"TNRI!+=+V*Y2!CN6^:HN%% M2-
VE2MT^M_Y.4F=@[:HK^.;?Z@U(F6EXN3K2!B):7P!2\I *PLB:)A\$K< MIU-""?4F8!TTFK3R^\$.TTR4!M5M>|E!7
RTK1AH^XN!MHUHD@;:Y@!;4K= M!MNUK,M<!=G!AO6;B;*AI.OL=_9>)#" M=QC0+7SI6SYA:C(B8_Z,M@D;9:
M\$C/*\$4%"8P5FEVPBX-2TIME);EYVNLDC\$8!L"0R!LLF!H^BMM+:S!A\$>-
M=;&H6HLRAN4OKUE\$66^0E7Y,UD^SV3_P+QB_8+?<285^VNF\$VJ7DM1J"FF
M!8FBBG/O*DY!M!\$4YI(!%E\$==Z7MF2%4^_2UE&Z92M_I-(T(E40=NI_KDD M59#T;JF83,M>\$!?!? >[STA
;G">)0ZA3,S3NYFOX^OD6?BK(E?Y@E@\$#0"V#?UJS+!9AMQOS>3@_DI/D+"38"
M_8T=>7.15GL30^E.XIT+V41E=@<9K;YUUSJC:>AM!8>%X#N"T4Z9T>H;*ZTS MF@Z,IO6+,<
ZU@MP_#;U(S7&E!>OG^0DTYW#0).6KH)!/=0?*&MA3_!3+Q^ MXO63H\$J2%18399/8^*U"&3*.)R/09:&G!^O-
@B7(3<&=&.,WL0<9^<6;<6; M44Q!"U!>=>%NR+I= JU4585^TGO3(!B47H415Q!;XX=5H!%802XY!"=FMF;
MJ\$41E<2^*G#=#DNEIR+@6R-6!WY0!";#H7K/EG#%@!+I^Y*;8O3NDD\$ E MJ)Z\$*";.%:U&J2*U BM9!^1N?
\$.F+!>LOF70<5FMA!=%%I>, M!KY2;.<6F*TTC?A8C+3;U?OU=JQ6' ?+@?B6_Y1SZF+86RQ6/XIHA^N3%
M#A.YF(9!;81.RD1/P"-5G!=-U)5;1=,ABJ"K"NJR7!0A3,->|V*;*522Z)J M#@!0\$!7U"UIJZ=!SQI#7!1\$#+@ M8,IECK/&
(&:2R>T)6).%Y%9,4<#TE|CW!C!;?@W.GY"!<.:0:Q2IM#>=>=>) MX8TJ V,L4\$*!#B(Y;@;+!D^!R/*9?
(;7+!)ICCNEZ;Z(!?;P M)\$G.N*B5D4(92M"J71+* VX4^2C/RZ<_4H;R\$A6XWXU"0TD4#E?;ICR M=/_B-A>
<\$9S4N^H14D=D:8_2[CJJ=WYC*;"@3U(HIXYWK!%21C"G60S!DIX-S93>I/IJ#!<=:4L^D_C MX;\$PA
^J@N&SS64#)P:H?>G@%5D7=G"WV(R_"MZ)S;3>1%?JL^KV5A8P=6, M6^T#&\$0=Y+7N&KC/7D-D=I!^Y+502,3
MYV,6MJE>4%)W5C,Q&M8XYN"OBWH;@0Z)W6S^!6VR^P(8!2FCPU5SF!/(ZU MVW410K"%8!-(CMA)!LWJ3ZYQ
!UOT6Z,SQ1-7?2V8B^U\$37;T8G=K*MSEW>J8IGJY+Y-X^";<64>< O!\$3>8>63/CJPF)GT&%*7!-T)(+1633N
M*\$S/O8E>U>Y!L1VR+PMINI!>+%^REDMW&B\$OY;4X2EUQ!DHA_4>Z*Y#%3&E^F_6TG^F1/J^(/"Y
M07E;HKPM^IL.OV@5.6UZHR\$3.JM9DIE-\$/T0GY;NWKL)\AM4=KRP3I58U&O MQ3PAI1-
UW!89^=OMIU)4N\$4F=*A%G0;)3S24Q&&"D#I?LAF!T<= M:%;.9KP*+
<>H4/K>UHGA^8I76L>4EX8B\$!^_7NAC_ET*+^3_KG""78^Y M#RPV-
1W&NXQY4UN\$1"N2;\$7;P"AE@<@FGD_B5#""(PB0^L;IS%<5HB7\$*!6 MQ*M@V/K^XH78TEI?IU\$(^VABS2.=I??
WGZ!W>V%MGW>E)5;\$QI?ZG"(KK^M>+RW4(FJC4R30""YHW6H+PY=@' \$!WXE&.C@5QY9N1X-A!7C/8E:U(0<
M%018[R!;J169@U\$37;ATW9EM8W2+X\$Q7Q?LJUOF;3HU=JH00H=B! M.6O/ER=ISD<M>;2CWH3P^SK^I=&
<#RW(WD=0E!M/*1UM9.D ML;6@!BY9JW"BI6-;_9&8*Y%N&8AW4B"JL4FUNV)SU;RW5<=>)9 IK;=%&3R
M=N4(IRAQ!;2(A9#)P<)BE30;B^A!GG>*WX!|WW)B7-1 OM;+!;Q MX&/6RZ O-
9&E!VJKA&G\$S)BE95">LL""&6HC*!P&KW6
MM4@;V""X3GHA3!Y4DGLEIO!WR59^C"IS_!9K&KM/7D(WMO^=.EBL6E.Q1H6_M9F3B9BR_I&GMWE,
HY@S7%\$0ZO!H>2??\$>Y(^MN4_\$^H/OY@=I?#.(S!2VEM)7\$#!/^N]YCYIU)+VAMS3K<-(D(=1 MC)(GAS2(+39M?
0FLZWZ_NJZ>/5MH)?C |&|P"&>O!;728C|X+-DMJB!+QV M!=(^EQ41XW_9B@D;_U6P#-S:?
+UD^/1K!Y@NFD/47KE+4\$H58#4L?MD^9 M\$^U7P?
PG(+GUKKNTMP!4P8C5!LKEXU5N.8V%EAC&VYW2UK<0SD?;KYB/8#(MK/(BKQ3K_U9T=R!U(
^5+8(E_ES\$>GAE/9*K!|!;?UQ1"(0%K;_EBO?JH3I-I MA UNT;0&.=1MDT\$V;_1J65+L;/H&WL_C<"PC|Y_L4BS M-
=EJJY(6%G4WR^P>#6RD4PD?EK;_P(>\$STB_%X>FX4/8U4MC=_3YB;4,I-L M^WTD)RV+&X!+B&73Y!7(H4A2AS'
V!;N^EBIX 34>/XVQ.)YJK2(E!_H_!27S MQG!+H" 4!NVWY=6<CP>_C
>PLV(Z7VC"K!ROYM;IGX/5<4Y8Q>I/O=Q^ MA725WM_6,7W3_%QCZOBI&GN!@5F^I^!9ZS9G?/R!-
Q\$|CAH:QM01C(A+ MSDCG!WR,M')M;*. _)C7@)2X=ZD (P*YEB^X!SA"L^%/@JWBYSSWUJ3A2%
M.U&2TAF!BC@S"!#U"VZ!H5K55M>*0!D!1MY;43TP7J5GQ;P#U#9PL@_1/4>I
MC_2MAE=:O9+W(JY4<@F=R)!;:"K;5@!#X-F2L M\$3!_D.)7)Z!S+(!W+L; A=+SH17&\$ NG5
MA_88S231Z!PA(8P#A3K@!JL1ZBB/XC26^:H\$>;&A_!UGOL\JK_00AF&:H!4
M%YT<^G:8*NHSRZKA68T.=5;@;OZ@<^JN!CWI!"V9R#<9I=4^Y6)E-4<=%I- M#|PIU(&!;T?6KC.E@!Q!+
#+7I@:GR0;J!Y4!P;6R@!@LD5PK69G.BJ(M#>.51;=Z J!?IMY?O/#Q-
JBJ;\$YKB>Z259=S,+W8WSB^A(+VYV\$GTG)C3#B^!8PEW%YW0Y!#%P:"OO^UX%<0 MJ;14<'1(9
OLW"GQV/_#&OPKCMOA-M#_L^U_C&C(V4IQ&8_6&S/MKQVP30) MT!GY;Z2!ZOG:HX!I&?
&GGOT0):E/SV3!9D!+V,M+^W24.T=*GTR1E!0*6I+ M+%-I",4"O (RH<%1=,FU0: ^+6*AU?A:6V?;GDX%
M\$F9Z!5!L.*<I_6H)JV?YEL!%Z^RC%YRLD"/24FF9CC@2L7M17N"!I^="SM
M_!ES&ZXIC_#)=1XQVH2DY5AKOQ\$+*!<_X^C35EV>%;<-T948C+)M"+!0JYJF MK&V:%;<P* H?C8!^@?N?
HFM1=,I@X;GKQT4<9_?&O3!?!D8!Q!4!3<* D5;
MWI6WP0!OZC#\$<_B^4^*);1H5LP4X+*.!L\$@Y6Z09(&*+)+.8S,S,P="U*\$0H
M)HIV*PK98AZ!7" \X<0&I_OPE5!97JLVLC62:488H""(L5_3/ANZK436!&
M6F26NGEN^K=;..3/W^!9^U'+3E\$2^XD\$ "W>69L^!2R!4857ZAW_)A38\$XHU MLF;5Q=K!M?
+*D8X&)S.L&=ZM!FWKR(N42QGLY))&(EX0_H^2@LD*ZZO_#QM MC;5=75-07)/POQ0E=L!801L%>
!Z;!FYD^VR7;HE2ZJ!2:E644HM2:@ZEU&I^ M*;5V&J74OUG_#^D3_)A2@67QT=K;4ZJ+0I@>;P
MNI!"F6<4(ACQ.1RGCTF2KZ!U;5;F"S(W9ZP2D?S!)-^6C_!1LN4@48;R!L\$+JD_ MXQIMK^!0*UD:"^
DEI9=V6SMQ2N+UZV!)KH!^H)7K78IGP%3@L2C^B^7UL M/QPW>*8@XF3%R JP!+>JQ3WCOD#Z;C?
2>K(94Y2(F#BOSZ5^1+VA!=%;.' M59*_ED!L&D60#<(OF+Y6&@<8%#@_&I^_1DLVDT5.4^JD0U^!;09"U?W_*U
M%K#|AIO2C|HIFK@NRNW&!23_*IO!9V^96%)'P(I_8<%UIF%72)!%3Z@RV5E'
M%&&D^!UAY.N(EDNZC";FIU?8S:4@!PPWT@#QX!)D8X7V4;HBH=R>_)YF^ MTG6P99X52:?
PB!LRC!|_WN6U2\$2!?!#_8_8?E!)=SA1ZQS"% M;.&?S;I=VMIMJLW;?KK!HR!3!#Z
71!0=>*.W>OJ!9;!AZUK1QIGK&1)7! M(ZDCI&C@8AXAI%L?^MS3V_/9 X=V>AV7SB>ZNG>6ZJ BG^;DV=Y-
KLP6Y M^KFN2*MK?LPO=N"PSCZL%*:AF!E9_5XQ?7.^;DM@HE MEB" 5!0M\$(!6S%-
L M86;_XYLA"E>8DC?J?4=BTURIK6&26B.*27F+X#"NRB ML5HYI=>^Q^489>FV;="HRW+4;H:
(;0U/D=#=&>5UY#C^*VO+Z+"(/_-(M(E.F*+0W(YLW^26NGT)GSBW746HF%_&RNR#Z2BC4Y35#Pl_2?-
R;1ICMR% M\$PZI7B6LH9N5P+&Q?DG+(^7^Q9W35-F&S@8V;Z=*7#;9B/5J!T>H)Z:7L1Y MQ-
KT\$MP!6_8263WC\$86>4N/\$A0+>WJBJ2CEU4!+_C28%XV4E'=Z!!=!\$F^F5
M@QK3_!DEI99<2E95.R>JY0^P35/T9A!R!ES5;K?S2HQZT%PV;\$)G?F=C3D&M^6G\$;QO&;3==73<1_)H!+J;GNS?
H0E2(A9N4&NS G=YN%/(Y4Y% ^!;?KD MSNRY5\$+FYI=1).P0!F#^!E\$#;-

E:RW&>:MJ3#8POE!5>3%9BB7#Q5@!%7 M1-)31TB953@&\$5.1OE8@J X Y!UTA0+91?
+ZL!RD8K9IU.ABU\$E!3R6G3. M.5Q@!<.,**KB*D [C22\$2!Q4\$!8'X.E!# GX67184 *I>%H= #LU&BF%IZ
M@WG5.,^=ZYC.K-<\$+;.!>3-A+G)K^!#?!P?T94!>Z6Q-YHP"V*-M!M_-XC>>&!@.H9O8D%T
S&*JS***EF!HOG!E\$3?5;TS7\$/"2?W3BM MJ_>8-;7QA@2<,2L*&[2\$;81BOHB
FY+!12GI/U!15RYS!AQ8A/8\$+@) MUL2!%>@J&Q*D H<N.,C%\$""#VD.<=XTJ2HNAKG!QF16!LE@D!0?R(UY+F*
M_KIV>4!B^?0GVC.:-;G)8!YTU"3#NRIP@#6@!AC>VX1JT&B3L &J!-M21U43A02?WNY\$86*.)NZ!7IRT%ALYO
P)AO&#U#<@.M "5D/5!%

9^4'0= M>OK&8U>@T!B\$0WH\$-6M LXD!;I0-VJUE.&"!SZD0B!E7@ M?Y\$GG?
6BJ72\$%>X!%YDK59&@%HK.U7&!QPN/>.&V17P.YM240?>#JN\$*!#1 M4G7&!6IT%TP_BR:[N@;JM]?R3?FFF#Z-
5<12H6*B!BN7@.-J0-;D"IP.@ MV:&3!\$M/R6L8?<5-%JT-R0GFI4@?F)T8X=D_-W6%Y\$?PL!OQFTR(G;HR;O
M!7BQ18F5V2Y5<.11J^T"CE453#6. 2H5 %HM;LL FN*NUKDNP)\$7B2?!@B
M#Q!8;5!5#A4RT!0-;HRKBQ!ZY4++R^LZYH<[Z5O-W,64CBOTF\$7NJL5H M!;CKRMB!O7OE6(XF&4@WE;?
KVEFCEME%25VL5Y0OAK!9OU!SR.CL'85.;U& MU.P\$!6;*0TH)D?TU4U1-7A)H5XS@U)-
(TEEP(+^*+J.+KG>H#!3<&5+4" M4*+YJA-YKEZG&J.2F"-T0KGH4^=;TCF.E0"^. \$9!H.FD!;!@.'Y !6/&5@6.
<('LJ?3760 M1RA"5!B8C-'=\$X_8.+BIZ>>Z_O &7-K00R+66D"KZ>/1L%Z0'N=(?X6->> MTT0)+(-XN?
T(W(HB^D9#6VUGNRP@+LYE;-/+^!EFG6J41Y+?D>?%M_)L>/H! M!2!_F%@+KC#Q@?
-%C4@W.\$5>+B=M%W6P^<\$154^%VI:2.X#;<+?TWJ6OS2!2 MT.7>Q.C! =7 'HL;EN_X>A!A;>4VBD%O8K-
HUON*+J.5.0_H)M5^HCSBDDK/S M/QSB3.E^X/<?)T"-\$. "Y&+*R*\$6<1SVTAJ.2AE.S3M1%.2TBV==R_
ANRD! M8TRK_?8IUJ!@G70!H_S=VZ>VL+S4NZIE9U1H!/-CH709PLJ!1WQ&5 Q? MX\$3_-!
f!%HGD&9.N@+NOOC38*;Z.OBS?8T.S6=02@S.*2HSL=,OK UEBM8TO
MV5&*D!9!+6WJ+=&X0!0M*5;BSM4N^Q>Y8.H%SC0QIR5^K+ 8 MJS;R/N7;9XL!7V!P5ZG-
L*!&W=+,%RSPFV84U@E\$E%CP!G%1#=(2K.,6: M663SYKLHUI_)O7%M<[07MW2X;C1L!U;.
(+;P6R4=X9&10*NT;L1Z.;24X+P7^#(>+MQ.+*9*96@S M/2*VM;/0!/^#IX.LZ"*B F&P<- \$3X0E+8B%D!(!8P++DH=)
(ETQ=/ P9!Y< M%N6_-+>6?OTSLD%*%U14L;N@9;?>UIC!@ MGZMXDRA^KW"):K\$6"&=E5-
Y(+UG516)JXIEZ246;2X*43.Y#25XJWXQ@+=+ M4!8JNG!N\$!N.D^YDT!0V-
DLWE.RVPJZRA;A7H%GY<"E089MX[NEQ1#00=HB# M#QMD5R*8Q583N6!E"
FD_WAZ&NQV4&57309/@G5C@GN%=@^<'L_9>O%05# MZJX%0ZDF24!/"HM.D="0M.@+V3A!O-Q4@=C0.X_P
3!%D MI^TVXC5S4#O_ZC*K1SL04/S1"VG"?PLY'X1X*%%3J>)=QP;N,FAT)AU M-+?
0H;9@'RX*U+M.O.WK9#;H@'A2IADL;93L@P'@"0R+?W7C/X_S^D MA?
L"A^"UTP@RU@/O_BBS\$E6MHI:\$URHS:A95)DD\$5V.4.9A25GC.OI@LS6
M2W(WISD9C#>#P!=-6IK3'YMECT#YP#F!T?<_/2 "->5!IQ%##?*"32>2MG* M@X?XN4&C7)IO9""!>2(D11Y"-
*&8X9!R6R777L(>9_-Z4)'D\$BQ<;E0= MXX%9?C7%YZY!4!(<T80D!AG,890H2!DOP!+ M2<9C.#U'6%\$2>/"_6?
3BL-AD_3!-?MS'0S6L9S!J^&@Z<IU56WTC.)%R0H MRA+JKDH!110U)V8"PI3(<_#J!M;_R2HZ;"_Z-
P2@D:5.AX=-.6 E4&*;7%>GZH@":9!CT0HE5>'K@L)#Y_%UX M3Z.E! PAT8H-"8_V72YMX MG#.?W#1-
C79JUAWNR)T0!Q5\$!4B=-GJ#B,ZM796T5XT4C#X5A@&Z_C3">>L?N%JN;1^ M77>/ALI059I8=%EZS.E_.QLI-
!*IQ)WC?.)H<%K_7YCH=-82\$Z?\$_+4E3K('M';X@X!WK;7DCOIWJ"&DB_UMGUECSYYSYJ>OW7.M"/91UH?
8FJL!%NL@7Q!9L M'%)M2V%*!T22T%C8^EP(.13LD>J!/^!U W;-4TUO_^%&5SL5OCK!09(- M2\$J01)!\$D\$20A!M)?
J5Y^\$.G>6C-PY_U JM34MH&B@2?K>>7>R39!C73JR5:7CW2.?3(*W*=?BHH9\$7L.#>EH
M!@T6G@5V\$_.C.V!LXU86=IJJ\$+#+?!(A*!F20CE@'4!P#YACV=-_AV%.6!D0 MO;U3 M!L2/4I5Y
N8F8!A5FG#K*H08GR_-L*NOHY12+2*)\$L!W63MLLFX MYZ_B90KO>LTN=QL4MI!(-J>Q'GZ=HC-D,W%
<**)JUO48NGSRHIEPN?2!6 MRPX83@M2>!)U8^U;U(L2_N.\$24_#JD2(5808QUW66VRI>T/KM>!(C=1\$BV
M#J^>6R?+Q;90-0=%?W1M5HW\$JK"Q&\$>A;;FXJW;&[U\$ZJRM0LU0T*_1I+OG M&f6OU-L_Z^>N!
(0,MFT#R?0@4R'N!*"6#=#/9\$9QMVEA!6! MG##P7J=D_?QF56A4C<^_Q6X.RN;M!??OU^3F/?-!0FZ9D"<5TP"C?
K9H+ M5!5\$F_/6K)1\$D!R\$F(P"%&VHP"H>7J*VR>SNG#C?3MX&)/K+0GGK!^U8>1 M955">
(-LP;@9_2Z<IUJKIW84!P.A^VE;>FOL.H-I-HK!B2"(K(2!9WY_M3HG*(W&0?,L8E!1ER0D6!(\$X^%I.%6+_K#V?
#*3T.H+7%7)-.AWHET*3\$H?B";H^MB4#R MX7#R.D5"?-PA06WZ.AMG#6&&V28";L*^>\$14F F=0B_K;
\$QH%@D(UR.M!AKCRW&22PF!8D\$!E*2"H'UDSV(H<+Z;#%"X?IBK3C!S"IR6>AQ!QH"TM*!^V^(-8Y.
(\$BY!B_@#Z.O!%);KK141K"U=PS"WF/8.XJ^12<@_2THS;W!
MIN4D+"RCSN;K%%LM@HIE(9IU=)###FQ.8'H78;HK0M\$IT8T\$XC>^8C>^=#=
MG;N=MD+!/^#;/5DX\$SO'E8!UJY_CU3>U5O2*.0MI@^4K4.4%.^!K6!#7;\$W-MK1.3C+(*XZ3?="N-
LGS%6!E9!@W&1?I-T= DEZ19Q!H6.<A%R5J3X2+I M#?D9(8!L,9(37>8X?9EVL_L6
JK#3F>V'ZK!OQI64RHU&L#)CTJ(7*=64&F^7B!S_%66!OYMI9> MTF*SH=ICM3=Q'=+(!96L*354;7Y!97E!&HJ%
_W2!_Z3E2_N.P*A"JJ"+DLT!A=-#G!D3N!P"BX#3">F-K,>/FU/6<9!W/?2!Q MW1!17A!
2@#!ZY2U;-172&X!4*FB7AN&YNZ0S8"Z61#08!+SSHV-PD>6L MP7VQ1U*.:THH7AI?
#XN#;2E!HN\$98Y\$98X;#ZCH.KDI^WG#_*;H!ES4SO
MM7T<24+G+K.O!P4!+7>4Y.%"YH!99YL/A!+HS!S;4S>LE*!#>OP_U_TX? MVO#"&_>S!QC_FSY4T7S*;!F&X,0!H5
MP_2WZNX!FM^YTLZFO#13-E20S>XP6KSIG"7RFC-D=RIQ79F.O?IME8#2D7N?8_O!+L"LF!>A;>H
(@A^"5BK/JP#UMD)"PI-&NPF9>=F#F &L@/ MJ3?+TH48CLW1FJM0!F K?P^%@R#*39!%;7F@R1HW/-+!ES3%
(QT=-\$7G MM";5;+!HC69_T7GA!O*BTYC@!29!;3V!QUC\$!&8*PU>U+!(-+)X_SX;=BY MLQLSK;8_-'%-#-
<+!AX;TCG?#SS=NIVZB^>ED^AX;H@?;#46%(13)@R.SMA
MPM3Z;&7=BY75@G=+8;ILM^=CY8+AGH*NY\$.KTA8!Y;-19S@_!\$ _R2%JF! MPK-/42:8")>W#EOC^0!R>-
JHX+3+QAC/9(-*7+FT;6+?#4 M7H4!9+9_)#B>OMN5#-GR.4H MI,E.YR8#FH19BDNZ!SI?X.'W+V3Y3#
f!6Q9;1!%HOGJ+^*Y.2CM^E!&=E4 M9.5=V^X.JH!&(8T7-M+HWJ^@U42!HJO8EYF)&%!1^)/MG;
f5P3R8M0_-UM#;17/4A@H/OD7= M1^47&?62BN(7\$E>='OL;GJ345!36!<&XA+DHL674+M0HKKPU%Q
M8@R4(IQT<0F)2TA<0JU=0EJGKB_3/&3N80;/8+Y2+E#H!5QG2/(ZLY+4 M<-JAUA^/L!MA)(+28K4!^CEI6DCJ-
!*=-1VF2.SQON6HA@KGP"&D4_QCQ+FD!L>STN7.8!QAF8PXS!8>= M-8=QCV)F;.R.23
&^Y=K(A@LRZQ&?H@YDYLI@QQYH_@LW_@LR/O6HL^9Z> MNB)C.+PR-)!^>>\$/7!O!
<)9S(UF;)%="A<_WA!8!%2XJTH)5@R!VU8(Q MOBOUO8.Y0@M>_A>
(EZYFZFHH!29R7P5CL3M!D*J+DV1"SB=F.4'=^TU"2@I MNBA.FL&XQVR;Q@AF"PLV8PWA'++(/5.0!&O8G&V
IN#R?7.8!8+D;EYG< MXI6"RIKH8^JO@7NZZF;5ZIB!HBX4<0+QR)RVI#L%M!H!&1<_A8X!%1XK
MT!%RNSI2E3&;!6!<X!^A(T^8?P!0S<Q-ORH8S%3TB+FG)RG_(!M\$POD%._^WG M1M5Q*G=(29%)!12#
<0!F9ABLCO;&5)2H6CI?+N.>T=R)R_3>9"2XI&RYC!\$ M(VJ.+Y!_#1#2;NA2BX>9L&*Q(0:H<
M%60%9Z44)S_-Z\$!+YRU#Q!TW.6^U(88Z=0!96%>0MGF_0)TE#4/2)TYB*5 MU2!VB29@Y!Z;Q_B%!!?
G.7YSTP2/=9""^4!<^B M;^<L>*Q(1_*>=J;9/3OS\$FH!RE!R+3"?J/+
M3EKX*D.BZ3OEUO"\$5Z#&S1.0.6ADGW#G5W\$D.A+X."*&E!#IRAY/4A!U)0 MP89GPH85.56^;"ACEI5O'9!@Q/-
@Q*K *UI&Q/E\$_1%7Y-B38<1C?U!(PEYA M_-Z""@%.6=*_U%J?)BW\$0(@!M_ (7R'0>A.S;YZ.&%Q"9=A7CSS9ZR>+
fV9 MV?X4#J9_VY_#^@P_KA;WOQ=PX+CWN3 MT7!O4'3!PY?!PXUTZ"F.M^6)(XB+Q?M8NZN;.BM%0\$*(18"+\$0

MXIW:U)L+L4I+*#6L5>U3%B(L1C(<:I(\$TV,-"U!IFON*,@@QIL:WA1H1 M:N2H72+
U8C.RG='NC#I.)H42\$CEBKWAS%6)@|2-(1H/Y UOLO)OWV/IXL MIH%V* F!P!1KE#^KV4SK13"C:(?
V!3K*G10LB/2- M/+09WB%I:&:VDL|>5%Z!NTO/QIC8|Z:NU(HITU7,2/>M)>B\$>D?YI=W5@
M;N#9'D#UCV\$R SJYHX?DY ""A(\$:JB5S4@@"LX1_1:67A3U=2:9LQ2-3
ME_Z99#N2"P3Q).QW25BB+16D\$BWKD%0%Q9L^L):7C|P6!SPVD0IX *297 MNL:DA1P(VMAS7^#S/GU
5.L^Z)45'.W#*STNZ|FRE|8#XV:0|Z2(U0<2B)*_ MGB|ZX3\$ P=Y?6"JZ7H)A^W3|'.EP^,M4.+6(+,DV4|^*
|C&411LDJLZ" MUS|H% CSTB:&DO\$K(5/B(<@A6>|W>I7>.NW^=S IKA8F#<,P0FR:,"DJ|3QP; M-.0:5-!T|<'9.R| ^UK
<./^YYSY)C8&AC';|PPLN1WHV7K;7^I&:++1.40%OMM+3M\$H^I^&0|P+M/KV=I)9:7V.Q8U6^IYZ(N%G
M_#-10=JH5ZTIA^15:C9NH_&';>KPT8*.G|A^1.&M<C<\$) MI@N4R3-1C^K7%..WLH(3P(*N1U75>)H^9'_0(#OP|"?
R_M*3TX|5L=|8/ MN0>|B|CMJCH4@X^3:L*6|B3>Q%#>Q;+1#%P_3?*\$VLZ:O8\$R"?&_/S-%4
M(O)X;I\$&VKS|^5!TTUB&O.YJJN&|>,"0JE 219V8X@Z5K\$A%?X4|AP+(M#Y5|N;O_79*5_0LY9ALU37RMF9\$KJ
|J|C>.+2M1XDOMXF.WR+UP3VY MAP?MG2G/Q+*Q6_Z&(X=%,0_1?20\$9KC"VZ*T)|H/#%X21G|0KLB=;M|+
M8ZAZKN3#>=P9QR096%5.)>EM?+)=?27=USAM.U0ZM(OOL\$EHTBKFM7^3OX_-.K \$!\$6U!_/ITB.D&89-6E@2&
M"/Q^2;>|VFRW+RVM%WIMAS+) I/3I64_X=U@!1)N 5J=?;@?1 EC9Y M!H(I6;-2
NXHO&#@8.S9VEJ"88'Q9>L'@16ZCP37WX<=H|GE883.FH^T^M&= MMHFSIE<|AVTY*(&S#VS
QHA8MOO0SHG>?"U49%_0B&*I3A31?NB_I+<:/M6X'\$3>F.@>:.\$!9C#O;*@N\$5OWE<5X3;G MB|IVR-
+"FWNCF^Y)2V8HDL/-5ZP^4|.#KH/|KQ9R;|@#8X=A?^EH:|L|>?" MVYB^C^3JP0-|^HH.5+NVEB_6IX^+|^E^V:
636N0HXT.TWS>&LW8.F:8B* <M=4U#UO@I6(I5F.5("P|ME/|J-N%&OA|1-&<0-OB;|:DSR^*+G3&EY>
MH7|]>^S|Z+|^WWC_=G=H|=?X5M+|^2G|AKRJOMVY|NG2+QU4T@YA|0-:
M4D"5SKS@T.^|(R="7GFCNDMT>R ">_-.J-OB\$=#XZ.R_P#|S|S^C|4+@NITL&KAPL#;.*|^I?!"6KX|AB|}%K#
M|KK^%P/C<\$X?17MAED.R41N MKHTLE/F|Y@;|14LFW0 KA)?X*B#I'8QGV M#G^X4|H;9;4TC'
MOI8NUGKT"&&.1L@>KD|B1GA9N"D;)3EA0R|G7&BTAH^T|Y3?H_90T1O9(6SV M4.1GR16\$QQ\$M\$.F8<='A-
\$0|9WPIW%DEC" M|I&'+|^%2.NM120RJC1&Y| RO@&C@^L:6YD1Z0T:7.H0--4/<@7'BB&(<X\$ M_8W|FTDHCD?B8-
|H6R0/QO<+|CZ.8PX;|#;|E|V%|D@#? MBM@+2818(JFL_L."RQ2|_2"WT_8_@Y|5EK;P4_*MTS&.UVGDU^DA?
FS8QY M-"AT;Z%TT3WL'\$&(<=7)HVQ'DG|_#_B3KY_1%W-G'OWPW&C0Y^XEM\$&JT@=C
M8.ALQ=TOFUADZ(Q^LAZD?_Q3>N.3(GUQ03&0=H_SK>N32;9?|OP:0E41|V M2*Q@BQ1JQH/>7.?N
QQH|+BGG^ELI^QXHX752/XFIWT*;:=RY>5>S2I=Y^M>+|^D%&VH1U,K^0ZB=XJ#&|JYB6|B>G^U8IZ^%S_%
N>|MI9WI%""|@A|LY\$@< M&A2E5|Y%V2V7A+J9^2S\$S;EHSYSGD+OZ)X:S#_ OM R(18L73_IDIZ-
U'(ZW9B(47A#6A(?A9=-XV\$|(3ZY)|8+|^D(INAM/_E49.Y M&C-KL>*2EB|LE@J3NPY6|SX(O@)|.IOT):
^, @Z+M;|7J|OY|K_!F\$B^QH37 MT!0#\$_.W9GI+4DCD-%WEW#X<|M|=|12,/&P.?CP>FKC8-@9O&0#:4TA|X
MW4?)|L|0S3K1|*+0^2GA0->>DU6R*1_-.|RV*|JN_Z.X84GE|J5X<>>D8E|I@G M^AY8Y4Y@69405?|K\$='/'(":9V%1&5f
M&)+,%RZ^2QT-<|WUY;2|LT?J9VGY|X;-06:%|TIN39;X|8>\$|7<MV%_Q4JL|J3L.T.KLS:0|R#5.M>
(9TK.U#OP4;=Y%T7)'5WQ(=8|f\$?11ZL9W?ISZE.R7*|V>V)A%?J<#1YC6>V-U9.B6VE8<^S9V<>|>)Y?MV9|ZD0>2
J3&Q@|)964+AS%O| MQ-1HG;+D|GC#KJBT6#|HDE|EK.J_!A|8#L^,W|PH?^O|<'V3\$S;#3%!
MP>^<^<D_2\$S|63;R1Z;+|L.MX3V ZV&3W MDE|I^#6P3|Y @B(|F#L_8B=*RE>1%7WH0F?Q|L'@%G(
PR,"/K2AY^|OC+E M.&E""?AREE24"P7Z228LD"<502*A*AY|f\$#- 7IAG#GHN2|>C2FT72N%
MQ&PT3K"@V19K7YJQNB1POJ7S"5DD9^H(8>0_80DEP3.)OB^@P8>|DH4M<3 M-
5*WTT0.&N%H.POTIL;V*|P0+_19|@&@&|0*E6Y)WT5ABGEB"<8PLM83.
M;C)9PVY.6&TCF|E)SZ^PL23>|K99)FE|W3N83|H&*3/^B@L.SUO.KBY_5_ MG^*6T"/NIS.IWY^1""=J94-
/3_C\$BDXL\$XKL\$YD_O#6BRE-MR&F>;Q-E".G%F3=T|0N2;|D^K+|^|G|J92;AN;|ITN.DXZ3AY*P.Y;@P5U M
CGY*9".7|V1UD^+|^JUBF("(0LJMN>DO^L:2*LR|^*O96/^\$@%|JDX MF67I1?G.V\$K\$-D;)=|_L)9+;R
A^5B2E^|CQ;D>R&S=#.(11.W^F0N_1* MFX L=G^A45V<6GM3Y?N(I#X^|Y^I(89AJXWC.RIX|FO"/%AJK0I&>8|>9
M\$>#RQ0XWD "CT\$8Y)B(69N2O5XQX8BJ6@43|OX_-=E1L9>X@QGQX03J2EXRGR#)S2H5?6#|LG>8P)6*<4\$/M-
5RU2,=+U+ (#%N |J482" "S|=/E1P;W0.X3J8|4AVME3^A4/M+CB M@4B0% F2>1R=;0T.K:4:&-|;_+7W%O
0@6OT 30JX@PM#*E|H@ M|Z;|.#\$)&Z2#1B.A^5KX?1@8QD% @?|4C8 M#Z|TD3SIF)&';>
RSTPKTD|_I4|=IG9SQR<3JFH#KP71"0W)\$SHA#|E#BXI5; M=#V<"U |J_LPY6N&#V^M3_R5^
_F|.*|2;ZJ7MPI_2CE10\$;16HST=9;A; M|L;#OC8HL\$)BG=A@3|5;.#P6F#V-|9E<.*|X_/.EKL;4*CIJDR.T|HQ";4 MGP|
(KAU;2%B\$RL5G.M(63-4W&=;P.FY6TB6C49|'V0>JL0BBR^M*I&EUX M9M&#|/83<^|3=|^_!\$F;.*|L.*JG%|
^<\$K0%|L589T'19\$B_!JS&|_Y2 ML^I4PA#0F<|PAYFV|^+MC#;3&JNQ>6K;D*AZDL6/CWNQJHX3+RI+ZMZ;
M\$RG;X7*QE-5BGGG;B|C;>JD/7.X|XP;Z;U/6J?5@OC3EDL|6\$=#YA22AB MNH;HA+LOJ^SRF@QQ#^|PFA?
USL_924%NC%)_0C5@P>|79|3|J|+|(3GV M6<#YB2?*>^H;8N=*RIJ)SW-AX3SY;7+I4A%K|P#E,Q
MNR>2|/!=D5L%K9 3W)|%) "SZP)WBPTPW;V)|DT&|D>PVPLT-N+OZ0K4M*I!" M;76X-
"Q=+4+0;MHTZW|448,B|L5HG\$T_+\$_6;D\$7610F+446PRK7Q.?K0L M);ZSM!35EWZUT9S)MRZQ?:9WK-XF)
>4%@#9D@_!*(#E*|A>5;&^<0XE=/4^MT78K+;A^*5EP_GVTF%VS*QLY(IQB:891&^O%M);KVS; N|8L0.C2! M6;-
&X%1NMN.FM9=|F+|T|A&SV|Z"3SS+KP%R?WVL^W !0R\$VW(>9C/FC^_M.Y|GJ7%M2(5@8O&3G&YK4?
B^2^VRVO|9LD#;.W#ZD1S7_5WZN>RPUOX|HLE M6T3"%M&+%G%NYCS'|/H#OE^_RD|F;.(XG;|C4|GJ1+^F5Z0?
J16_Y0?OP=E# MH_E|^VHE;I+EZM%Y|E%<LT@79_GVX3ZM3TM#IE'R^4WO-8N0C.WHF&7#^1N?^=V&?OE
M|9DIS)96H(8BBB(PP2V|K2|)(_2|965+H+EXR016R\$S^N&A+SK|AW/|
MRX0DHO4H==8M#E_ BQ_YF2.C2.F*FP6LXNY|ZU?Y|Q78-EZ-TUI&S|?X5 MH!N5KDBT O8+*RGE@|*EKO%:
|2IF_?6KD39X4|.W#WC<.^7/45V*@?;|H. MR&)|32NN|S\$S|F(6Q+SLY VXU4E\$Z@V^D&AJ2'\$.Z-XH
M/C7+&=;.@% T(|=5D%U)3UIP0=|F BH^C%L\$OG0YH9#=#O,|,DL4Q0D1>\$Q
M|""4:\$U#+DM&QSVQXQMPMIW_#65/-48\$8NW
Z@);G3LBBW%O%&B;Y8WH=H;A#^|6366Y#A%XC0>ENY#"G|JDNHIC+|B|MC' M>90KT)?\$?
98(GM&6M@#L^+0NXHH*XB YEC!!3L|92I0P2CZ;VQ"S;|C@O' 7 M2BMHC;.
|<CGDV0<8.65Q;@B/7HL^4A2J|AK1>X9#HC AQD-4GBH\$067H MU YP8UH_*&(9|*MIR81^F|>BY;>
<3A|_QX#M|BH|G@>GPIK>C|A46Z*|3 M33ADON#2ZY8PJ|@ B"UOW"";.%:
FUDIX&AZXEUFSD|2#==G81P8H;RQ_=-Q M6|00YR7TEU|Z69DFN>G|FTUOSW:8@M6K<^X^1C)./>40?2;BLID-
J?H8*ZA M97.YBS:ZH8T/%ZPJ+J6H) 9R4YX|ER**#8.5<882.>JC7.KS:Q_P/B%I/_V MO^421R2Y?
1K_9|DR&W41U4X.L%G(\$>5GA0)Q1N3=5B2US+B233TW-HTK M?N8G2H^+_Q=SKJ):95YQP@|P*L^
CXMMU>\$W91E#5*KH/3&FM%7MWN?8Q9-IGLDYL+N^%8P?P%&'3^16 MBZ HV^>U>^EC2V+|^!80#0E0#
R*9^NPZ+&8FT P3H|#\$0 @MX2%)45W@*\$ MJ_&SP=B<^4.1=5TJW: ^KJWUG_9B38"UTBO>Z|f#Y
_YQ|_1GO>E#9:Z8&6 MRIS/6=^S0UO!|JRVFM.F:OZ5PM>9^*|L-D>^%9G>|JY\$|3@^89.LP|RW(|
M:SD=4I20A^*|G#|7^<7>73.@:"%W5LVS^JHG_..TVP3-CDXP-3ZHU;P=7 M_->|Q0WU@BUFOUL1\$3I5T7I#T5#
(A%OOV|f(AI/7|AFK)UKF#%E?|CB2Q2 M.8F^7#?J7N2V>K|9(\$B;R1CS/G"%Q..?&MC M3
|N\$6SC#KWK0CVUJ&>3^8ZRN;J>_642|RYV)9; A6VJ=G8K+YD7DKIB.Q M^Y;27.L>|L;(<|_%E=6Z-
_RYJE0&QL3U|I5?V79;GT5WQY.|OM) (D3)+T; M-G&|+7|DO6MA|Z2.0^3?7SX^B<8P?1(6N|>B^<^CPP?
320EK.CVC|4XR|?T M9S^5TEIY2I3\$#_N AO/9|U A3X|E|f#|JLY1L.#" @3NFZ#1/WAN^8T'(7D; M.^N3|GV7Q=X*?
OP9G^8?^0|1%4^>7F^)Y&?KOD#;.F36W8YVZ*5:&@;AHC|TC<6'-7MAH@GC.%?^Z^45E(|/S2"

ML2E=C*IC=1HK5%V4%JLHK-/;Q4SCZ16:AHB7A+= "RND;PW+THK U@8JZB3
M>V*78,%-2: ^FAGQ0W6YUR(R>VAJB*>#86+W6J=)I(MG=PVHOC,+C:ZH)*+&1M\$9EV
M"B+385K#_*2R5'89\NP_UHM7B=NAJ*W\$68RV*Q5I-P0R05(C@HJE,Q066E9E&M8LMJ87/?04K^A,=I/:46T7%A?
@SY9^5D>W-UCZ5?C9G\$43"Q_*>DEQ86=58 MTB2_-0"/416IR?EQT8D Y,D%L,X0R&9S%V0YK
+4R(ATDC/Y6KA9&/- WM& M)/CP,IPQ97F&03RN0=-5L^WRC#%SKZ1R9K)@E@ED/5.06.U2Y2HM,JAU%T
M8QH+Z9NCK;>E@-*KJ+FT.L;2P"FI89RTIW%2 HZ@&A(QJV"@UVN%ZO;6S*| MJ&?
@_8=0A003*\$.44,9JJW:E(SKEIR?8K-4^7:L*Z1M' EXZ\$#U;2OX8L6 MK(,5
SXZOY,H:3L58H6+!;H1^S*Z@&AQENV=2IM+2D:%&;NNJ%1=(H4S+I M=-;3M-%KNF1 W X":8.1%>V!
I"YQJB92;4|+ #DGIYV MF57'M+ 'R%) *+JF+M;_2I8KML*P2?";GIPZ##BF#VZ&/9HP.WB3S849?^NOK
M_<(@GRU%0,9UNB6V:F%;*U_9E(U/>7>BM; ^ZOH^&J_ ^JK;8H%J|*KRWPWM MP@>EUZJXT^D.F:-
:G3(J&F2"O%QC4MWKD(FJB=G4/N0,> \$WZ9E|,3N:*/^5I M@Z0K/YW+J.DTM:\$TV%+GW1+ %HS1=-/6F_W5-
T48JJA8-X+C?^ANNH8FZ MG"J*+4 +VVM%>@F-BZM"U?C^9HJZTRHXJUO=_6UM# ")&/#4!^!7 5M-PR
MEI\$HQJ:A6I<6<+&+&+5V9"&UVN\$):KMN:AL>B=K406JLE5FB!+4):KL*:AL=
MBIHPE7@;=G;H+9C=V8_!4R2!EW4^ ^3J!
MV9^XV(6DHH+V5AKW=>Q6YBUT/A8:(D_ "J8<@#42;MMKV"@!U#D#I'-KU (3-MG_?
61%L"4.6!/'FI8*'D_&_G0Q7G\$6I(R)YU|(^##|Z/DSXH3K=\$F\$-\$LP>F/-LLZU0&56("I M:ED9U"9O;&I_)4EPJ?
225G4%EI<;#@B+PIP'5-9@34D%U&I'PIBP TF> MK&X|D=2+P\$Q3QO-3G&1C)/3#BT55G:|
E4%P_!4|TL^U2@YNO14^>L;I<7 M:9BW*^M*6?;=22P-V9Z|F^T:Q|57+D8#)9+I>LI6|<*K|RR9RX 5:F_>32
MH/L;K|H5P|=07Z0I.KLMFUQ>^M7|R:|57<6AY;J|< MOE?8HOK-
U8676VK?%UX)+09RB1#M"PYG%8>;P=N=I Z5+I;@!H84(2L;@)0#RG.^TL&,@8Z5>\$20M_LDJ\$XRW*XYWWL1!
M8?>#N8?013^G4Q?R#T3<@%GOP\$&|?(=ULO|LG|VUR)5+-PL6P,1.BUH\%H
MT#@Q#6IPVBNRJ|<5SNH4#5Z#3^>;K5B|8WLA?3A)YFL:1.B1Q+R.B@2ANI* M2|=UENNEM'#L9V?
AA*|7YK&Y:?.@JV?T>DJF6+CB5^+""^%7O.RY=RY|YJL7 MA'Z1|HA% ?5Y|D246-I_@|S8==OA+G^K(%8Q>V|!D2#
K&@%?31@7@M&B@# MO=I7C8Z?4T^T5F0CJ_>.L@2W3FNP.%OC;N:~EPL852OQC-G=
MN:4)LO10^N|O%FUWA|NM|0KJ%MI|I-EI=^JV0!8:R9JU=R3-Z:E|IW@)^>&M4)Z)WU4E^>_6RQ!S8M+?C.)&-
IO41C6C5\$EOYR01N%KNE17%KJ=DR*Y5: M'E-|;7-BZS^-(S-%:UH6#JH=&\$:/A55|H#=:&?|I-7EKT+3\$IS;DK:QS
M|_1=):K|P:0R|QLE3ND%FJ|1YE V<="OJ_P:L^WQ|B^L_9.H_2G|F%6+A MM:3_L0:|EH?7HA5?
8:H%N=^V)U7N>84=HOI?%.5.TR6K8|FLDVF0U6C|_M|JNX359Q/ZS.A=5H5S:U|5;+#"ZOQ|OV-D;LTC?
6;=#Z2*2%+NI6|SO(MPO/N?|_/%E85G)I0;G:R#I^L-/<60 T!|41L=)9C,6O:I_*:(ZQ|AN-/H+ M6F\$ _F!22A.LE>O
X<<;&I'ZUQZKYN_#|BY9YX*D;CD5M@)I3A:T+Q+>MWTX M<#:"9&8|I063JV9#;W3C@|5\$9"6?
L:DW+OCN^1&A+XBI^2.FX5C|X9@!7+) MS(&ID>|T&7%:-@O'4%2X|=3;-#9+GA)6!UN7|'83IRK(Z>;ACPP%;F
M,56S/>GA|0%;KN(@>><)>X"OO%*D8I#.YBS>F_KY_#)IDPY@D7(|PWO>|?ML7|
(U%V|CAW^XB7O>=MI947H/1@I+;+7<5PGN2*?LD7/MN\$+<|CU:&5H8' M#
32A&|0MBSP0EQI6\$|<_B#78P(NP|N|&_^(3-NR^!|@(^&@QF;K940R<*>QFF'K_H_P|S\$ M|GVZ;C8M\$|I1BMP;|Z?
Q3)|I|QMH>N3E>23G&^&|HJZ:IQ^EBT0P|&^&K M|QGI7;JXSU%|I'5*E2_)&%YB>=FL"G5?JM*W_9|N^N<5-\$V
1)VO?A|58 MO"8M*N|7&GF=;A?SF?@OO_N_:PDZ*|3JVTM4*|C1GC_Z;_&5NTT|D43B2(K M4'R*7IM0-
QV5Z*;5%|6U#YS;K|7|YS60/L13!C7"7@|@>2@WM*I RG;"1" M_ ^\$LE\$KPI|XX"#X1E8A"P^&YXQ+(\$#@U'<@
"T'FKXE062PK1\$ _L%_M#^6 M=*6L3W?*;@M\$K49BX8OY'BOE?W>:-"M?7X'@3=QZ/OCXPC6G74?@.|T%|I
M_)W8BW"- "DI?_VB.KR=HRU!_#| ODAE:TU|RNCY|_8KO_*?D;(4FJ>7YFB MX&#<|I=WTH=^<_I
4IQ@*P"#S"R9+P?851*4:R#UB9|F56MG3X|+G:T>HV(
MZ.\$*"S|W0%E|2;YM(7\NOK5QOEHA:L"%Y3"ZTV6^+;?)_?A%P@LZU|
MZ=OZ.0)FB0ZS;Z/R5L,941#VT|RCOY\$LY5YP;K,Y>P%_LCS%Z680|I# M@!;URM>4&S0'VMEJ;Y":8V5K
1/M&@@D.GNK:"|HADTDB=&^>^/H4O>4& ML|Y(41H^(*JHV*|J=OL5;^ ^D+K8>XDOZ_!T*<7HEXJ|VWB-*V4U!?
^M<<M-/K()_*2ZE&9CA7|1#2D|6'4U(|,C?<3.M\$\$.Q?6K:X"-@IH^8! T1>4K MST|U|JQI:"7|5OT804#ULY^0?
+GITB>(Z-1 90Q(H8SN@NSQH"* O_!LPAF M1AQJ=&Q8)< TM|G?K \$9+13P)WU/-
!:'X#UC&LL8OLE>A|KX%JG55RT'_< M8F9#7L6R|=-V|KH|Z|PZF|)LH85MM:1=-W9>GE.=PP%M/QMVMM+;37
7#C MD^/A.B0Q+;75\$>B0D+285&T5*VO:U%+RSR>|G:"R/P)ZW\$9=1.FODT| M_%H(|L_)%JN|F6HB+LZ1YN?
(<8|1LS>NTG|B.*")_+19<|:MXFF>6F- MYG7/5=^\$730.JM&MWM@JYJ@>|HYJ?3L#_Y3 5H:9BNEE:C&|T+L('H
MFD+ ELZSU9|/!7VW?>9Y;-_I+?*_P?|AA&|JB R*6#>KL>Q>5U(9*=U3& MO9/^YH(+
BZYT|9|U67S|Q|E(AWAW;C1K|Y+7@F4|=(C*51BH4)JH MRWT%47/L+|H|@%\$AOX@|Q5M?|&D-|B"
|/5@M'-|4 MVB=9IW; &N_.Z?6-5B=2|7_3=UDBFU+2V?3ML;ELO_))4L-(YG'WL%\$% Y^
M+@P|NRUM|BQ\$C=JB1K&L;FRSDD2|IIGS0|+Y&Q|QQJ W5LIB6;S9@;CY:E. M_|PDI72PVN:A SR 523# P8Y00-
9*3"K?+J24_QXPDO2ZF?6;6)6YLH-Z9Q M(|X|/R;C*)O*T4#-1&_KH=#&4NH AQ?_QQW|BM8ZB|,9UO7J;(7LN
@""^7 MV6F3MD5D0@AHK(>F@ZJE5/2U+|_G=2+XKW41D?9 M2Z,W+DOU;XGL;YW(89@^Z,ME-
42B29V6|V77Y""|S3I_/A6N|I_ \$UK46^ M=B1:&#;F!6|K5RLI-
&+G93MX:8^PB2MLG9U\$3NODOZ";ZR.FU=8#U;|75% MW4QM/1(A8_R&/"74X7"/|SQ|D|2|SQ8H_V^S.K(?;-
^>09?B4|9>D&6'/MH_*K3:9W823C;Y;P/0N2ZLK>XN.FKXTEZ16+Q"C_7MN.53E<&@/V"l\$WJ MIXZ&_=&@^<-
&?=&-Q"-#0FMKP4(|^?+6Z|F%|WF|_@C?TJ*=5L^U^/"O=@ D MD*WCNV*9;M(PHC3Y3Y|_1GRSG4K-8R|1)QJ?2
0Y=^X;C+=G(21LQ87 M6Y)CKB^|=Q9KE@JW=22M?E5;+=8|+ 9DA DU(@%OQM8>D7|L &8E|W>|Z1WHG7-
+|93%D\$Q+=YO=GPI<83^X09050*;=M(YO MI;\$H_:9X"^CB8\$X WP+;.. MT? \$&F9;6:0V|3<4X|5|/O-
"966M9;,\$ZB.7^=(W2VVG'-L@5&4 R4_ M?|?;^7A&F%0^SNJ|IHUPO*H^BQ&YWIZ6,<=>X8&K|PI?<9PV1??
7L9)A2#K M3F@Q2G8X%| UM|C X46X0XT>L.G;IQIEKC2""Y:*S&8D.3D9 XU?SK@H2%9H MG""|2""@IR:9-O#;V\$-
\$US 61"&K-I 7_K=^P\$|B=-)AW4"Z;4!<>GQF+ M+(L63;3 EX@;ZX;*MH&F7|MK2D5CVNM/
@9>EHQXXBFSHA;+OW"7F8LLZ MB9AU.HTEDO0V^X8X"Q"=0Y:"6@KJ|):MEV(C&YA(*>TT\$@|N|?02,08|57U
MTAN)="0>BWK0U63C;+ "H|QGAU#_A|&I(1?
+OTCSD|*TEELYTNB"B^H043YJ*9W8(XN*M1"6M.K#9JY9|9YVZL)|78.|AK+V
MGS+F2ZHQ<4;)65.P621C_04E;ZT4J|!%4|R<>|I*|GJ>2V-#T61#+PMG|5C/CC-3N(IQ MI*6D>\$R4+|
C;=QZTFZM7CD%JW2)O7+VE@^W4=D"J;E,8,D 9U63'SX?"- MNYMTH\$6#%N+DM,AX,8ZBEAZOJ.(@-
MYPVUOF>(0<.,6%X8|LO)1|4>'6TLV M,88-"1%WCF&2G-AWC |4;=NG'^1^C6B|1YE"%3N:DQT6>|U6='+2CXT
M%=P|T0BYI9:0UXS%Q662YE@<84|N4QX,RD|H!;O\$XMI"RR-L6@>F-|9,F& MN7=SZF-@|JL'7^0^@K?
2T)NQ|_=.P,1"KUSIW^ZT^2_ MH^A+)\$P:#U|(:|O:|E"Q|PT-%6(#ZV@|2E/QV+%LJ5V0_48#NF0>D8,_"
MT+)|9X&04YHONF#-6JP4,FALS,NE@PGS|JOF"U1DA82F%JH4O|O.@AD44X5; M> 6X^6D02V+KJJP-
RZIR=4H(C)PKEJ8T;|T;|@;8/758%4@52ZX@V|T,JB881 M71X-CL|Y%Z#8:1 I\$|S4IGE9O>;@|E>W|>6-
Z\$V|>'V9/|L|(2=9J< MK-Z8FH4= N2DU!_.PBK1EZ4F\$U%+"Z9%@U5>T)Z@O=HR\,%I3SF;4W0GJ"!M%>A;)P<-
I361B5-3IX>*DP%38L MT?&>5XQM|4H"*|2U%NC;-|I2ACG/HIK*_1Q4(7O"HZW"SW\$3J|V:6TK;V<@
M)@HJZ=+AKOH*T4Q_W2N%#|37H-M3)(V<5\$3'"=AV3X12|JN17IG\$HA=2!AF;ZP;|B|1)+S7^01(A812|) #Z
MH0|#\$5%ST>"L+ #W|\$ GXF;NP>P3|9GDYNT_DCYCI2!^5|;#N5+3T*=V/@@POE@Q;LTCM2H;CP;6EUP@R%&1X,%
M" T:0 0\$U L(>\$|<^FX&|(@X@#_.8G37H!"R:M>Y7M^YUM#|9.I?DIV\$K4Q#

MJ>=?WVOV)^H9VXV:T4V+PD^SR:IZ-D=H:FY8AF:NE 0 .K0IX M,+ZTWMCO+7DP,6^+A.2%0+K@?
&%+0VTH3QLK1KENW!2< HC.E7 MNI7(2I9.^"K9V%HX-@6W.E:S:J08;-++WB?8B?H!>8>"W*W6+^A#^VP'A+4
MOU&2'E'L4?B5NY%W\$F! 775L,VE!P954^I9L=?H3.9?K5?>8!W!>=%!:\$ MNI#PC=Y8*:AZ+YR'%X&IZHS!0V
*FRF8>Q!D E=Q%1U.OXA.&5A(!.N"FI MA=^E 7:PY,1%B)T/7Z4 ,0!P#^5.=1^!)V!4SFTE+&N0!0A\$V8S,@D?9@!?
M*6 *&2BP-!8?=>67!Y+U8C_N (-UI9X>RAOYNKB>)DSF+;U%AK M#11T-IFRJNW=*,W19IZ!HGW-J-S-
0=4>*E7FHE(+FAH*5%XM*G=S:I6'2G2< M:B-9T=O*KNI0399.!
!L4AV"Q8!?"XY\$B0!KXF4%M_*= "Y:=>,2Z:XIF>8.M@^!7X! #9*O*KS7LRPGLIZ^,O MYP?5('50Z;WQH*_M'=
!3?^9(H+)PKSX\$1A(%\$8@B@\$49P-45@)PH3B6+_MK!1L!HW-G-
!>AYD+!1"ZV)#=M;!VP01<53H(T0:17(Z.#WD.\$08G3?"R^!%?B6VG!"Y^+"L!K#3A-MAQ=D<5YDT8(?
OI(L=,&)%V1Q7F31@B>^DBP,X8L70O@SH8=6?2?9RJCO(E5, MX2!1K"UZHW?&6PBL-JP-J!HRS!K_R%>^39!
(NL!=TMH"71X;N;3 MCPO+!%!"8T2!^BUL6D=U=4&V@FR/933BPA6S5P2%"!P39"K(59+MO=,(VLE4,
M\$9!P(K*EZL OM,125/P_HD&G7K/ ZV#?D!FMKMDWAPZH0!!7W^!_U_!_M0!+V7QPW>@!H=,JH:MA'WIV
MH89!DZ!"1!^7L4"XS!<OI(*U"<8)^(5)9!PO!CD.(Y27!%L5T(CDS;9, MA1#5407#+.1TLF7)WZIZUA4X^6W/DETG
MGX#>&^=!9%_P XD@/,"IYQJ#91M\$2#=-P!A!..!@JPEUFJH3O!V!%S5YO
M^J4L!JQXJMI%GHH<!Y78OD1@=:2>S(A6-V(-*FR)(Z4'7!8UOBL:U3.*! MV:CZ5)K.C=ZXXK\$9?
\$15%9:@YNM2S!!144 _!E5F!)^Z5B1<IN MEA1!/+>P!62,3F!6(2*@(8+@(.!SXA!5GD.9VXVW+!)"??
OGQLRH##?;L<O'L(OQJ-M73RX;R0,%YOM6K=IB=7!7H=-OZ:C#7ICUZL6)G.2AAT N""44C"ESZ8U8,>7 MHX^Q_#
)<&7!=(4J QNB8"6A=TVU" F'7TTG-LA^W+ YKWY90S#Y2!L@'O^M9)1*Y5M^..EJW7"79H!1P
!G&LXC^U3J06!8&22/V,^!A!ETD?S^O)*MK^ MB8YD15\$V! (W40SA!A)0S'5H3A2BCT5 A^D"?;O/NC\$D0W,VTPS--
^MEFA MI*FYG^/!>3VY0>"N+5G, >WIN*_!J@C2JLKL&SM18Q\$8?2.9S0ZVTFP8 MP# !%FWPEM(2:U7Q=
!LS8Y'F/G*W ZG><3C6G^@!1D<61DXBI KI+ _X"\$W% M.ZBHFUMHZ-
\$61ON%OOP_18I2QI>'IP^28O09L!K _^>,1)X _+(B"8:<++Q@ MI9.'&0H?Q WHVC\BJR'3>R! 1K_9\$2EX@C?
^N@!E!<7:780T>"5NS#Z\$;!C MX"!8H8777Q/ETF^ (GU=V!@?N:E\$E/#%0H6!EH) Z3V:JB+A;T*R-OHCW=1
M,QW!2M*WK' YUSS8*V+?2#!)"^ _THW!>V.* S" WX=(O^=!P_YH4Q!MT%?^E@J6V3@##
(JS\$H=70JJOEMKKL^E860-!B>#:=ZYH0!5"UL<'@4?(Z;6! M8L+YAM:E6XIC*0W""DM^IZ96?%H^N-
)G^Y710T+!%EX\$!4D\$)VJJKS32T'H7 M,/:W%L <*,30*H! <>"<^ (X&J0:4Y=T(DD!6Q^Q((84BE(+/GI
MZL!4AG1V=K'UHQ\$2;ZJV,0^7F8""X&E>#!BR<^>,G,E'C?)_E0&FN/ M98I(Q*L3/IR&;ZHHW: ^O^>9U*
YG, +>2>=!2(D(1_@V?#1A*!6BC!2RX MF5MXJ?"^FB2L*9!.\$WC!PE
(W*U!9R&I5F0P:8H"V*8T"O"!& N&=R3!1C<< M#X-(8Y5^..\$.S!ZS!8>IEY)CZKZ..#?WP\$&UGG
0*N\$P1*H_+D0""QUN03S M-&?A!X!HLS)3@,>N<+CHKFUT"6(T(/+,V<"O)\$ELEPMO%=" M
F_ F3H^*K!XA9DE&49)P,U8V3<\$?E?H, OI&BAEL^!_QA^"(+!9N*C'.9 MH5O#01T*7HA_2!3>Q'.41%'<^H-!H8?
3Y^X;35!%R!^TOH+-+=R;7:1A>+! MJ;)HDO>1"G^A^&JGUY>/L: ^.?B&VRU8;6%O^K!H!7L
Q&;ZSFVXK&R!938P&CHXB)-AHCHB^26\$S
M6X=K_)&B!B9WL9.SK06CUJ9#K=9=V!C3?)7HMQIZCC8N)CM^Y=>8+1HYWL! M;^!L@Y'900.6
0N<=>Y/L-3@B9!XULGA, !-HB>R6!+=+6S23FWZ=F=DJ#_ MC*F&,_ 0WL!FRT>:YC.7R3-
VB\$X!2+!#W _!&7KY_ CYPT< M8FJT93=!.F:."LSQ@B'4^7^G! SL89!C!Y67OMN+-9U/ M!7KB&4A^ (NO!C.S0?(M9-
%&Jk>"!5=L=J!;XA,1N!&T;)4DZIY4=!.C\$#IDR MO\$!K1Q! FZQ<H0PU M-.KHV33VI+8TWLMJ!VH-
M34&W>HQ^*SY""^/0**QH!\$9V5.06 !B !,37/ ML_-\$O#2(H2@4'-G*Y@1'5=WFIX0M1HL
<-2'64JR^TR0#H/WU/6^!TA)):O M;M4\$#SHEFN!DO+^E6&?H6M&K!C"@G!\$N?2*""! 8!\$ (8JOXQY45Y B70R
M=^#OF/>P!RY!J^! WW3L(KY:1YK9PGD_XW))H!: !.@!F8*^!8P,&##!'8' MC!L@,IK,8A,*)!K)=/(T!IM)
!M>%J;QN"D(Q7>2C2.&RH2T)GA1#F_&U MYVJ^JKS)US!"@O!3U_LNF?
(/HIG&\$POE!_9L "AID*W8LY&5T:NFG>K9EH M6V;2BL !FXW1K=GHL;1:M@ISDU&(W"X8R8SH'T9F;2"-O9
MH;N ""Z_MZ)Z0GL8";# \$)=\$O249629&)-2X^"%K)CH=W#H!2P MORWVG+*9ZIV>J0F T8IGNC7^K&RV!J=G"
H+-NSG#2Y_H_@&@!\$=5"QAXJ, M64R!CNR(!SGHRZ?."A 1C^?P!5Q/>?XC<>C!&GH&*X!1P/\$2*V?;Q!_ML?
O!C>0!P5^W,U !D)!>T77H/L)H!A)@/W'O1/FT%=S:PFEW&KUYZ>>+73K MSQ&\$+*6?=R3P.=X>E=>\$-
Y&=L.T;1%8G=P(8R63NL.3@TCQO(UU"K2B-LYF3NX&HT!\$% %5!8_M6&IDUT0CP/ MGV??
2S1_ ^!HWQCO!X<\$!7U<^3X!A!MEALN?#WV;#H0: ^!H
MC'V/G(0+!AU7%&X!4F#TY4TF: !^G(600!_ *IP:8S+!H^*!ZRE" T5D.V+J-A M%NO!+SZ2)^!A-
@M(^&3_ %>R70_Q;M4L;)!1*6:Q!LHWJ5(\$)J+!C*("R!4?^".?+!+^DN7 MQ--
_HB#Q4!6@6G3YM7E!1JR79R\$S:7BJ!N.LHZ=D\$"6"!CS +!5 M/85!+K"W>)+ST-9<(E24D9?+AZ)!*62*.;E1%7TDP-
7:7WD!"?K2MS7L69)0 MA=IV8.@.#6%VC.\$UMM;8H, (-R")SF>%0!+C_7880VH J<+!+V0V+OR-
%>@)V=+S461"DY=, '\$Q?P4D(HS"9UEC\$SN88TAQ M%!=+; (45S2YDT!1!&#D&W7?J&R\$(D\$M(V,MP
D,")WWQ0-HM,T: ?UNK MAXFJ*&-4N%6=EY7-Q MY6:I6\$!% !EDBC3*&ML\$*K*#!(TGOU0.T-
(!HKOW/AJ7WQH'SLT&""\$!D MRV_K@1.#!4) %>16 P>H7!1!T<\$ *F,+T@ %B3-M.NQPZ+BW?"ZQ,(\$
MD"@KO!C!93RDS!*(%IYR"5 3\$)SB+<=>39!@#E9.(X&!XFOV8_E<&K;!TJD_G4 M.'A!C.U(&D&6VE@&D'2D#R+*.D
'\$N!J*%-G-@.E"B_2G<0G/-^!HS^C4+V M F^8\$7AV6ID!E+.3G%/23F-=.DB2C /8GDU!\$%95J/S9HM;!0S!A4GN\$8
M/A#C+UNU#=#?Z)Z9(W"K'3F!9A.#QO*#:=1R/A1%=M5?6UFSL M;_V!%P+RD4V9!;D9K+)Y+.T2;7((5)
!C#EPIX;#Z@KPI2 T MW!9'J32>5GMYNVW)5U3:LIPEOC!E^7U: ^CB!+9;!7!GM>)H0!56 U0DX!5_M
U0&+EG\$!=!8"6H-\$TSBY91FS:=29FT3YL6<.>EI+WU HNDPPGO4)\$&UBME
MLL!5(!BP5!>J4!\$!>+)>KIF1E\$E^DPFLTU!^J!;K 52(<%I&1Q;+/2^7 M??
B@V4C3.FF!FHT%= _TX@OM0Q02+\$KD=Y@SCHV\$)%J^!+8@_4"G156CDO^ZS M)1NZ;O\$WYJ9-
:*J);QHD#X)CJ<^*7-JP#F!J4Y_Y0X@DTE,WNP%XV)2N8% M8+\$7(\$5/7^GZGDGMK>KZM1(!LZ.0!% U^=VP"09T)
<+.=/U8D@KNX8U624 M0>;L+**?>XXCZZDB_XCZR4_@7*=@-K#T7IYM?"C2,XLF&UQ744=I2.#Q3 MG8F^<(Y?
\$;P6P(PBG2388D4\$.W!J^!^AD3G_5CR4!SQ\$:>*4SS1K=C)L&@>MC8XZ
M/+!A!3!48=GU6L54Q^5E3DR2!3Q5&545K%PMG;-KWY#V%7MZJUBX4TP.K:8 MACZP H:-5F_8!N8>8(Q-
L_HJR;?L8X&O?&7G5"8*5(!8(PB8#V-B"*%B@0
M>=.^OV_.U(8VZ@3R#=>E9)7W8HVS_!7"D_ Z3;%6H!D!Z7*,*+M1LL;7H,=2IO#>.? M!F_>
H4*G\$7W%W%WO#RQC: >4NJJ2U+X^,AN!JOOW0!O>TN6!Z7T3674P4&I M>IT^F5-
+J!>2)O=EW8H.\$S18V<!^4+= !R_A5*P7 M7Z^RV;Z1C7!U7056IWFJ.H H!DS<*B*98#@!M*#-
;HL74N!O9!R^QM:T9 M<52Q32'9!+FX;*6. Z9ZZQ<5 _SIL_+F%<\$!F!3QS&#&KJ/Z6_HE&,_4==<M#0A>UV*6@5'
!&@PK&#SS_!DKQ??6!O36SZSR820V6QGCGAD=*Q5!S!XH=
M2O^PW37&7\$!H0!R!O42E\$)!\$T!J6"5?!"S@B9:1!)QL:ES52W(C#Q_!7C M.HA=-52VK?&P^MLBB!D>/
MV!FCITZ7!H!>14!5=0!H+!F>Y:Q>6:<<10;_M_ M6OKO.1!Z64Z/8HRQ: %!J
M_!MG2%@WYR,39W,X" CZ<(!9JU9>)G!35+ _L@!GHPG%W7N)P%G!H/3A).& MA_UAOMO0:B80
=.'L<3R<_U6",FGX!RNI@C9W#W7G)NFVP1HU:"O2R@A/ MAN@U&(_106:KLP\$?&R;KQ%6_FZ#F%FO>-UN?
KPH;19;Y^!&7HV^%?AW M8NK8J=WJJ_F""!+&UDU!GI&6X!UFKVQ-A"L!0R@=UXBHJZL\$3UC:M_J"FN! M+;-
N=4!HE\$ K;>W%M/_5PV6?^JM.6VFM/5!OYJG8D!+#@CAACTOK>7!74L M=#3V! K""R!^@E
!QPC"X0!+Q+9Q9IZG&5.<E6GS,ETD3WCVX<*MN"31X.R MBK+B\$!T#D2ZM9#Z%2J!VWZ'D*)@!>?

N^""TX08+K;B3H*6ZNI140)GU*ER M2;2F.RU|Q00'YNMC-2|57M'UOFXUL%QMPJ&"G1+^H7NUKJHHH/I-L-
\$GUK> MW;M\&*O-I#%70C;4MQ1YWK6W67";M1|"/EDXKVX%)L_Q-5|&8|3Z9+ MQ|5:P:PD-
F'CYNTP'JIP148\$E35.PDMM(F#W-D' 8Q8PJS#[Y#U04|."|T/% M**Q M."&!E_C?
G;28+RVK\$H\$@3AWY|L_WF_TX;UCT=JG7+ M;UEX/ K2 ^R5T7+ M^<.O=|f&=O.;5CJLX*Q=F9;5K-
I59|A9Z8U|WS'HWJ|*DBAOPDHP%Z6-E M^R&C-2 #H#2:ZP<|JS7|A9POAGF;WB7W1VR8KV-
NZRTL%FO)\$BY94"%D\$U& M^<4+ Q)DZTLW!%JF"@_O6#VL57Z"N(C)%WL|K|CY4(UV2,55&RE;VX*QOS0F^=
(M%U|%M&|U)?N|.)VU%Z9*016 (L6_%+/|IB;|'#?L>;Z+O<;U\$WV/B_L>=Z|!<7&O MC_<\$#^LUZU/_X2>9K)'2*
fM^G\$'AY=7>IB\$'FI5ILPUN-0A1YGHTQR^\$TB? M^|+OQ/^OIR(MUA
%W#UQ6=-8.U0^NS'UUDS)3A15M+4^<^\$R;60.##CB?^C^M@H WQZWN'SVX%3"!9XZP.1#SP|V&BO*\$IG-
F&H;8\$#Y6\$V@T.+=;C|C>NW M|J;S|F11.03W27WQF8<*4|23".>>GTCJL/J4ZG^Y|VNMCI/|E6KVJ1%RTQ
M52B4Q@J\$JO3&6D5GOZO=JGJFH*0?ETM|)S;3|>#_2\$#;5A1=AOQ|A7NY@- M<5JE|L7|7-UP3N|>.
6*8FC339B;J;ITGH\$V1UT|014JF=E1X9D#7#1# M>US<>-V>@' X16W=8CM?W(\$ZTIF8-
0W;;G2(FIL*RIQ)F16&S+TI4RLR>W; M:E8?GC4>F|MI1SL^XGQI"ZO8|!#|@'9| M7-FOJ.W(^N_AHL+QWYV%B
&DH#9WCQJZTH7AF_6HO*%5|FQ,2UC,IX/2K M|3%' FZIM>>(HFZJS(8>;2*1?HR_G\$C%^O+PI\$%2S#
|;S_R_#;OGD!>4#|) MRO/|! (>6.+""T"#RS?|&|I&+^."T|LP^O\$VUQN'OU5*WA;DO+_U5\$+CK!O MC6|T6!
|!Q\$>X+QA-#.HO+86/>?#5TO#9.*XE0)7?(FE@6|FT1ZK73-E|TSB!>TQ8+@\$3A3W_9Y|/R0|W>|?
WGIF*N170"NVN&5|CYC>&ILR(MT5 M|1%1L|@Z|*F_Z^3J L03.F&IS?S/U+8*R.J&|#U@F.OMH|Z7@K73CO.&^H"L8
M&7X+55U_H_R_PX6%_4S_@C_O|Q_O|>_O;|#5LH/6S\$CXP'-FDN;..^?|=1!;
M7&J'H8HZ*.1!>=NWE8^@|F|Y|N|6)LMAUFP60/LX_VA+/PAQ|NF?|Z^F=F-/ MP?R3C;4H8D4UB|;
N(ZGB|AHRC+Q4\$--B?&UQEW%)U;L.OSY\$WWZ7_O%/M^M_*NS?2L9+FD)5IXV"*M;21%P#/?^"8B2.KN&>)(8\$"
(4&9#39R6B3@&|MUB"|>)68O+XQ|!'">G3@|TJ=4 M;70/BX;+1=-\$*XK>&KBD^CNCX=E4XJ\$'X'0<("N0?
B5^+S=XH|:7^CS=EH_M2_-OP%X=X#Z@2\$AWR1>_1E^|0B/A;2^.;&T5MX;.#E%*M-|I&.67C\$Q*2| M*0X8?
OSR|F?^2|TJT|JICU&|N^C\$SL>J3C/X.6YQ37RC|(#(W"@ T.HU|H|@248|ZFH(
M#4J|H|=2>_3V#|\$X(X2=|URWYH+| "IF7D">_4FL<_1.UDS1-.OS5RE|HF;
MV,212%/74%>"VD|'3X'YKQ6ODRMC|"/>X@|I&_&#N MK)'H0<;0QZB6\$-FV8JH"\$Y|%-
U|&XIF^"T%O|7;AOV'>=ES|KLU"1B00 MJ|>TZRC*W|7C1"D,Y+|@8"PP>P#8F8T".@FD|T;.(#NSH;2\$5TF|TB'6O
V M7G811|!)@EQDQOUU@ESH%+L|JQA5_|.1|B|V;W>|RR"VV0*MS;H/3M_|<2 M'8:QZC|I#3|)8O8*?>Q;JLM^|T-
;RJ&HUCY#O:P75|!7E2,E<|#!\$SN8 MLX_B'V@V|G&L254|>=E|K5B)YRGPZF17++2X(APL6=A/
R_M7;UIS&TX_M6Z".&(7Q1EXL=DUC"1PEOXC\$|>^I|B=ZV#;Z|27JEFGBCFQ*I8423+B*;
M1\$13@XBFG3JY;UBE/R7T_>LKOUDAG|*.)=6WCZ|S?ZI%ML_BP.PSD_H*.CX M'B0MWS.L,Q+6BLH|LW>KZW-
NV'UA|JPI8|CVG|H_"Z@OKVS5&SUO_|X(^ M|'MZUSJS#_OZ0.W=12_=A|34_)F9FMMKU'Q6" &'7RE M;TL_N
M%KI547'WD8.P<45E;|40>&_D'IR9Z#I54!%E=\$5D9@T.1%;8J&BJR;K1< MPD@0E2"JKA.5S|>G*PJM,K((
M3C.54*.XJNTLL|RF7M|J=-.HQM=^)OOCG&*Z=#V#;'C2^ MOS'E GL%'-&40\$/L_V|/M"(DNA
^>A|RW1\$ _5W@|IG0U_7D?4Q+YH8;_M W5YH(MNPY<(L3*U^J@0H4>9;LTL5|
|P*AP|DM@:QF2.33&_2WRO\$%UZ M;TPL/6=@_N<7KX^|HNNP&|Z|6|2P&\$5
MA00LHUMO ^|V9(C;PLV2SH#&N;_M|WG|K56LH@UL|HK#S MW;@4<_HIG\$ZG(-1A7A4*PI_UA4'_K9/33;1Q1L|L
NHJBABX%M"C N|11|*JYTMN"O2<.7HJ@KU;0_|Z1^6|I=(. \$3L_|KB"J MNXVXC9;DV*M5(4FQK;DC-
(Q|WP@&|L_V%T;*#B&M3L^T?O_\$X'^^?8BT MU45_M2C*|A^_?6=^7C+86Q=J6#DP@_#PPS0(KD(C_OL"
|GFT\$U4(|RNT MSGNF>%AN_2Q#_.1|0CB\$|6%'-2: "|@#>M-S9U&8A|X.W2|);3 M<J-QWXFZRH(L|FXN"64W*Z #
<#U1Q3-LX@2KV1:F5UVZ;?| M7W9D|XAQ?0->|S_X|NY34:UYZVAC'F|RBV> MIXF1OX(OYB@_!UMRPX%-
NS+3EMH'BT(6SY_V^L;JO(08|H@DFP,1-LSLZ4 MWEC79"W&F|UC6Y&-;.>C'X_|(?A"QVH<|?T"S6)AM+D|6=|U+
M\$45SEL;*NQ@6|G45Q5V;@.(3?B_O2|X+Q|L^G2<9T@|J^E|3@AF%_J\$;PJ;JG
M'61F&8K65#F6B6K|CY=\$|A|QV@N;T|SW/4|C|M;_S0%^>+24T4|PUD|X8'B M^8X|+|2U"N;VZSJ
|P?|O;|=EPFM4W^LW;8.^Z1\$#&'A|8'D\$WCC=Q+(DDM"'+2G-%AN3IK*)NCO\$S721_IZ:MAG/==5R-W/V#P3!1-
<|/T&^\$K'S) MSU^DK-SB 4)IXHOG>MGH|)U-GD_,BY(U?>|30S3Q.H>|KD_'^8,\$P5MIYV8(
MZ;1UH;9.@F;BSI;H1?;3|TB1^TTH7>'&%)E*P5=*\$7 MUNA#|IFU46|
L;U9Y#@+IM3|O|/(*3AE)YL4U63^YE4P4'O3)E) E1_ZR=|#4V9+"; M9|ZWW"JGJHT\$EO/MQKLP-1;8ZTF7;R%-
_K25/?;V4NAB%6-@L_V%U9TOJO ME%+8?4|)Y|=U_.|2"*V>=>=LV_Y0&GH.PGGWC0QF#="W"%K8\$M729,5L*Y>H
M#7#LS&=_H_)WE&0_-T3#3;T'A31G|MHVL(8;P+(V@:4BL/Y=[W_99'4|/|J MW2(|>:L;LXR%SXSIY+A30,3;6|SIT'/-
\$1&=ZKG|M-&_BZSA_|.25?A&R&2 MG|E1H>;|LAG|J|RX^N|P;0(T_N0<SGE2R|_W+V|&U;SORB%X_0T%PG;5
MO/L6GY10=0|D3*X\$|M72|O|BH;0@=H"216B|+PY0/(L8@MLGX=KV'7L1AQ+1
M0HN.&ZO|C**0)@O;60;LX5S.Y3F|G<"6TQ\$BCPDNN%O#PCF%F|CUDW_"K;N|OG|/"G=X;9C4-
WKQM>Y'YL/AAS4Y=6.R% MO0K(V^B/=Y\$|W"IDM&'WF4_6%#7A'Z077|WPYF&&A9<&?;7A|H0;_1\$V;_4M6|_
Q;J#FJT_545|L2;HJ&MQ7H M7L_|7\$X*D;E).B|>MPI2<&_HW/9(|#J|@7N)" &\$_7^G;|^-?IS-3OY;2
M7GC4PGF;|2O?'3@|TP%;|9?'|ZEAFZ75?7.59IUFLW|<@PW6RMAIS%ZYTZ_ M-JU#>K|;@+V9\$?<@<(0
MY.TMCRU#M#R'9;Q,OLE8|VQ8PI_/1F-EVGI=BIL|);<| MX0>|TJ@WMH;R/FS+BB&@U"DH5;0VM@FE(39
&3=RI=RZU|4|_7JX|H|JFP M|)VEG;\$Y+FZ@4;|J9|S30&^IQL27.4GIC4YUP=X|183BU4\$;5766T*0 MVAMK
|DPNE*C1"#H;H|2PC"PM.8*RI4^";X<_063BA(Y3WDROO4|H_71V MM8@=-3C01|I(YVKL-1"W.@BD'M6|12
9O;\$QD*W1WEQ9_*F+0*IOW%L\$%BO7 MJ>VO8@BU?8=2;U^02AQ.297"0Q*E#MYU5|FD|*Z3|_
N03WM3TD>8*8=8O0NL3 M.(IN"8O5/.)FB)4M54TV|+UM>4)K|'">JL24UO\$T|I(UU4|4O1U6-DY=A%.% ML-
(ZG\$:@1 WEX;G4W3V\$16(C&8EE|)OM)WW7E&4B*33*8CV0S;)F8>HIW*8 ME;DBYUQPK;
MR;12\$+G\$|1G5C+J;TL/1|P&FI*CFNX|L@V+T5;H/2SA(M78?+ 9FLL>O.=WNA1R&1;6T>WU2Q&)R"R
T2P)DLO&^K@O5JM7"P M|_M-Z;C|5;F+@_ANK.(B;T|NU\$&#_|+/*T==TV3=L?1?EE080I3S*;S^>F
M|JW+O4)YGU%70<_E;BUGLX.M&1L&
MR&X>JT7|%K@4|9G|H;Y9|8BS7Y45O_'F0ZMB4*4T6BH\$'V@SY|59|T8DJ\$Y
MFVF&9IK MGK(C)UK|S|MI)6&L7ZTC^_1=|7(2+>#|J*Y575PC+G_!9WH7QSVIO-MRU;&RL|YIXQ;O1
MI17|NE.C.4B*) *S8U(-+7+)RQSF*R&M4L@:ILE\$*= M.H_2A59_+0Z5I
/Y,V1T=*8#*WX&Z<2CJ|POPV63%&LJJV59GF MH/1U+?EOOWDP(I>&);SX_@M.);D(+Y;D0-
W_@RB1'6DE2X2+/V&4&)|+&DG MS+O'#|_N|F&3;0+(G;L)(L393MJU;#W"6CPBX_APOLYQOYO3B;;93?_\$|PY;S1
U#7D04'5Y3<"|0=|09Q2;AD* M"C;Q|+^.;@ULM.ZOP_W6?|G.K59;\$|D;JV S&HRP6Z8F*|H^'\$4<^|D
M>B|'L_='CS+_.NXCv=3R=LXBD&9BRJN7=-=\$'SQ48%G?VDWOF=9J|EGE32;\$MN4H4BP4%YBE6|+Z|_|"U*_-6
M|H;K0U"3C+;J6PA\$=0|1+4JR^SOIE5%K8JU_6Q?1U|D4V|*J6*BV\$>6"*X
M|BKNNH;\$G=3K3;D*GO3EX=-9QF|HHGS\$"8SQ40P_1JP9^"W|W8P3^\$* M>#_|8ZZ=RLQO;
UV^ (U?|'6U.5|6@_" KLJ;LXS<3MJU.XBVGQ70|V|OK)FR M49|.) |VYGC+Z3A=P|OU/9I*OB6;@-
N9PRVGY'0|C|64I3U_C|N9KRZ7>M M;IOTV?;2* FMN<4|>\$4'X#8WUS\$HT;+NF*IL*>G0\$&\$ M@@@|2H3;O'_|G
(A" <&;0U;Y^H=|X"BKXNUL%;27BL.MX4(N'?
B+|S*HQIE_2_ZGLS) S#"VA8Q5=N^WKR|E.QK'F;.>|RJU|385DNU|)"^?|T(=2O^|9Z_<DBVBKSAB"*8-|OSP;_
<3;/* M|8IL%21@=#(X|1(RB&-NQA,HNE|L3#POY+@#N*IKC|N<>RG_O08#6=-\$ M_M@Q|OX|6?FP&U3RID*8O?

1<@>O/!">B00K?CS0GRK M\$-X3:#DEJ&(G;5203<>=&=TH)7L%\$MR3#|R%":!6Q+ A?BWU*E*;<:;CA'0
MYR"/17/OS%RF|M6SX|+5-3)?18."SUX9\$1RCS32G_1903'& M?'KYD&MA?#N VV"YLA V?1:|@GUMX.(2%P223^"-
WTD(2RX)A1QWH<?|!S7 MNJ*:HA(4Z:8+|X?M3LA'S| WR93\$ASQR>FG_16BU.K/->"A EHLH9UB=F=
fYR#A7/OS%RGAM:F|H\$H\$R-5(A!^0)X MF^UR@:O1^+;DGU)S9F?UOD-3ULU%|Q.FN=:7 GGO.^Z A'Z
6;&HR#"&^!U-M>2/\$YDM^7HC-%1U(D^>^>Z7S8G9V?@YI(U->3G(5QT1(O*|P/ "'8*WTF|>
M#;FEWNL7WW:C6&DA%U_HQ>F-|BR&:|A|U#)EA5:2QBGD-EQ4 < M3.A|3|H|HY\$ML/0_DF8%Y|9^V\$K|%-D=T|
^UAJR|ZJH*:#W?:K #4V^ M-2)I22U1*VI/E;ECR2&NKD5 ;T-B9R_Y"Y>ZHQ@O\$PTW|1X4T9S9 M:|NP&F|
RMJ\$E8JP^G>|_V5KU:3FL;31%|>EZP=+&RW:+3*4MHPRV7X1-E/ MCCL%@+R|Q9L;/?4<1=&fWRAO#E(Y|
f7LPLUDMT%1XQ:2V@L6\$QO89@R2<3 MXGR'DPB 3GPIC|/I NIQPS?LA+*TH^Y.YE+#+@:331#84WB.U=@HH?
A9?)* M|!GW#1W+\$(M(N\$*4@W 2&@EH1\$4M_T2Q%Q5A:0NP:|X3N<:HX#FX""K3. M#-B.&|<:D":P2R_
E&\$XSV3A_?B0'&ZMB;IHL2< KS|%I^4T)(2R)GL:=PK MX(A_64MB|V@I:G:|HL#9P"+ZX3);^:|AU|S0=|TH+?
CANL23QODR8+YUD& M|P+YW8HS>WO!+:8N\$G#:Q|T\$>EY'4J|N%_(RX60JPWD_(S|F|%&#P*)XL&K M-
"/X791PX=A>|LAA^FM?@O;K>@:|9P|+6.W7O"\$V*Q* T"0+9|+|K|M#8R96 M_?2?<O;K9;LO'R|/CR=^>)L
@M2:91920MNX5P:U@/A\$N\$S;-(15XB7 M?E|O8:CPD|JN_*KP5EY"68|&6OQ/8EXN(9|1|E.4S|1GF-\$66U(&J23?T
M&O25AK|K0|W1\$V6# M4M2^12#JCFHT?975=B3:UKN&MY6H0)/"#+%XVB|R9>1SGD7_!T%|TUI
MVW|Q'(#2=(PYDP>CEJW<@M(\$I76=TK;U6#D-1EPHD#V2SHV-HU4KN61@X?M/6|_C6?
4G:\$2A.#IDY|AGTIK \$|PDR>R-J?E1?=>16!;|F;-)0:MBQA*8 MN6C;.#O/2S%3Y^0>TKBY04'4<8?
BYB|0^/685&5@;7*L71==JA_*V=U%+&5 M% @T5@T^HK|BYN3%:^^&\$QV6EU5'G4Y^ MNT
E_L_063BA(Y3WDR004;ZYL|MH3DQ&;ZQK|J9W|2Z3 -(Q5?<6@60"D Q9
M%XX|90*10G%Q\$A46;ZRLJC7<6|40:0L.13"CLXG2;O@/E'31G|HU|C0NY7' M>A&H1T|G_D'<9'W&H|2
|X|D."+XADX,I+ TGDD|X)|!FBN\$:> (K4^ MJ+LE+%;SB!MCV|N/5-
D8|'VX""6QBW"JD%):AQ/ZJROY*!TF7"JD%7:AL) M/BM%'FJCCL#I!
)C5PDEN|LM|_R75.4*6_3>HK;&E%=1U37V4^@VK^GJHDE MPTRML/O@>57!\$70KZ+8S=%LAN;9
MRJ:0T:R|:5E6!_T^<CVZNFV0D5H@6ZQ MA|FBR:|U|N?M|HS^4HMEU*|HQJ?6N|N%R!_9D6'B+V9)|S-I&O:VW|X;>
MZ3W_C|35?->1?5".ODKW(2FYLF0E5UB36/M9HBDTRCOIQGDCW2^(|:849AE^ MA9|9(Z)UR3)7X%)27BQUX?
L:R??L*8O|8P|J>MP.2"3-9;|3'|6V^<PQM9 M54\$|TVL|NJUF*3H|D1T@B59BL&
6Q_L5ZN@/T7?DJW?2^P(G49'&=140L MW=F_*F|X6.)H|AKFK_|\$M|J^ GL=+50H5LH|S2*BW7|+6N|XB?6('G\$?
H93 M@XS5V3E1G3=%3>6;7?OW\$|(Y87HXPP8*FUK;ZCQO|H_SG1H M312BC\$9#A>@#??;L/NQ&D S-V4PS--
AM|4:/|B=|X_*Z^&6\$?R|_8XR)< M;%(3)+\$.5>M698(R7"+3NS#^6>MM>_FZ-W|+|\$^|>%C%(ZB('V.2
M/BUKR2L;YHL>|K6K'J|:50_K%#X^|Q*9G^D%U|H7KC/T)|HJ6Q00B.C L>
M4UL%#KNY3M9@^|= %\$451566|AK3OR|SNE65ULN@V-R*KO?&EFK(FM6R|ZMZ>|KMXA+4=474-3P4
M=8&*E0LV;_T05V"NJZ4ND:'HBLB|IAW|&VRN((ZNH2R@1UU; NU U6
MB|5=27&8:3)|4M(UTO61O_T#=#^J?;*/NPM|WGM:1V|9RP0-C19|XV\$+9=L:3TUE1*_A.PFNK M%G_L|F;TQ@J-K/OEV
M?WR)|KFF7C;_|)-@2?|7@:|@(|\$3IO\$O\$T)YB:GT.C;H2LPHG|Q4_@.26^Q MP*Q'|+|@DR
_N%2_*?7GGJ0|Y6G4\$UN_6?^XWUAZ_R|90|4?2%WN-|V M=<=YP;LZ6@:W D31DH3YX#T|H|Z|Z726U#K;:
|O;_U2%9?7.X;.>|5J6FWK ML-3H83D:YL_PCL|=KB7PN+SH|UG%*LB|YOAD|G5|Y1^'.G;:UV1MD-|Q|A|
MA(VDD^BIR;=L 3T&H&|T9/ M53Y="^BQ>N.AB:%T^4"GHZ/G"BR.S.T<(>.5-3H1)|K@FV1S5U8G?^4)VT"N'
MO;\$B*P49K)|H=N;XVF:#/1Z^1AA%|1SN(W8*?)V;4:8=>&TWPXX&P@Q|9@:|K MT0Q|_8V4D#WD0?
F|K+KF=I=SS2JH"4Q|FKUOY-|L2VY2D8|B+0#62N(*Q_1 M91> N;EVO|A|2.M-|Z_@;P
5|+AHDH|G^I^XVZ*;4Y8;V43^+(A&XHPGEXH2T05=J|@BD'=AJWP7_-NJ+4,>
MF1U(-6K)BD^_W7;FL^VETQ1|*;M#00:'K9MFZ|ZYE|+QC>>?J=Y4GL^B@BC M|^_*BQ\$ZQK*K"?O6O)-
=W%\$|G|!\$*(FSBMCD&2J|L6&H|J|MW9H\$*%\$@ MPL|NST|!A\$2%WSFGS4|ZYY*8A0\$&%GYMV>|_
81*AAR/=(@.)*U@FRP#I+A MM?BKOB|6P5M)>*WJF=K\$Z=|_B)MG4T8^2.22G#00%DXE\$< S&)>_M7W9D|X
MAQ?0T(YOW CVY-VGXECSQM'F/%XO-7B*RKP'PDX4?|_+ZTJV.Y6|<\$|@X4? MB^=/^_S51|-55+V(*(|L\$#|/;|_
L|J|UH;A#@!;I>011QS.YY\$<;!48/&| MD.-Z|NR<5X3&YS|H5A7)8JC_0.Q-5<@1SVG|Q|V TJ>5.A5%YZ;+C_TA^\$
M+;ASU^D+8F&TN3Q9T|O4L117.69H%ZJ0QDH|C+4JZ*_%G%|=EXP;C9= M.JX3A#ZUQ@FO|\$*?%V)9|3_C-
(&L+\$_LXMI6_E'4^1|08" \$-/Q*3#|IR M&"|?6Q+ A?BWU.U<9|&|!XOF|/"^DM0KN|NLZ@/<P;VW?9<)K1_K-V
MF#/ND1)/=)(\$@>03>_W M\$LB22T(AQUWH|T*.V^8G35\$""G*+A??#B?DH^??^V3*16/G\$X;SIE %J|M"/A:Q?
RW %T5 MO|HOD^|D0\$0 NQ%07@I2?@.)*.*>\$W3G=.<@TU_1|19|<8&PTQB|T*|384_819NQP|U|E:1+2PB1|\$*?
QTB1L'W&M^85P5HC&A\$2ZUT*^Y|K\$#X|XJ3\$=GCS|&=2|6H)2;.%9+F;Y?#WYI3G(&)=
M^_7*6*VR2@C+;JX9/(GMY*PH^F1*RI";.G'EB|HLA&L.VZAXK|58>FWAH+JN\$REN?
A7W(MB397YG(9XF922|3LRO3G7RF=L/N>D\$H^ M.Z|G_XE\$3//.G6;2|H%2T&<2SKUIXMC:01\$W>V-C8.F*UE:-
T#;@L3.7_87* MW5\$=|/G&F|J/2BB;7MF\$UW|"5M0DK*6^U|WK_R|9S2,V#K|(M*&|.4DZCSM??919JV#?
I*COB7D9 X|> MB@W#DD|FO/D.1P|@F_A2."22 =WCAV_2W224|1S9S*7' PHER"2|_82SPO M|J#A9?
J*|*V#3W/+SH-U(F\$T@W 2&@AX1\$4M_T+P."M<@(|W0/4Y5C;|- M0 G6F0%?
<>_D7&D"N_0"7|B&|TP6WH|+V1&M:SN2(DK_*|_L_%^4TG@9Q) M*^2|6MK^7T|9"V(*0J&MOOB--
GL9UP^R1.V#ZB\$|KT|14>1)=.93C@9|3O"|J 5@N M41YXE68\$OXLB+9S32QX|3" M2W!@HU4|X
Q@":O|FK>|9F7@%Y|H@4SB^76L M;L.SDZ)|\$VY=X|66SYWY6#GT83->)>YV8A|MM&N3'H|?G6/.9AS&N|Z|
M#|N?<.%EY1L204/>"TH|4RAA2|D;80\$1=/A=/P@BR?B<|0|BFRI Y45;JA M1X&WAEF-
@S=OI:HEY0(4KFJ=1>#;XL(9D|@L1?V*B|OHS_>1?MCDN7C#|T M+OO!@E)3|(|L|KL?SC23AH*W"
M@/(76@#D3_80&S#8L%?; M* (S%XY9;>=Y*69JG-RJ2@L|FZVU_SJWQ(M3'<^/25\$&%@G6LR?Z*R_K*2
M_||;.\$6#J|AWN#E9;VO.9)'(4C|9T"2LLB@52ANK<)&T 0.(V MSUWT "J=\$S%O44@*2_@*K*J=
(4C78O:SH|@1DD=3DB6P4&R| |= "5S9IQ.X MD/+;D\$|XG^E'FBN\$6=X(K4^ J+LE+%;SB!M-
f8V'AFS|71'Y|9R.*6T#B<- M9)6A/R9 DZ7"*=<6:5U_*|/2|5;_L AYFH.\$ANY2"R|V6P_P;N|F*|.)H5\$2
MZX%_%C7D.D7Q%\$19S^!E.K:E|D|J.5P;"I?5MZU;F*W BZ?73;&JMD%Q;
MH%L3Z8PDA5L^E"TY@6T&WM525%NC6 AUS;J_ 4.E.EU4+E^H1929.^1< MSZ7.7(\$UF18*(O9DGO\$RD:|K;
<^AM|H|<".%5|UY%|4(R^2O2/=+XCMIA1F&7Z%GQDCHE7(E?@4E).+7A^QO)|^PI MB_UC#P>IZW YQ.U5O5.?
L5;|H#&UD-03O373VZK6;A.0&1'2""5F*P8|; M\$ZQ7JX6#)=YN2K<=+
|!"2=|D(T9U%3&S=V8TJ8'A8XFGMN&N:LUOT2VK|>^Q T MM6^A6RCO-(J+=?TM:ZGB)|8@><1^AE-S'98_4EZ#C-
79.5&=-P53_C+FW M|B>\$|D)NGWUB_W5KSV" T;^W%#_LUP",^/4>8X;:UE@.#9>^Y?R-CO8FK%
M3+%^<4746UKHE/D/_VYW9BS2W\$=Y|7^H4&F=H^4^JEM51|S|""/J*X^AY.16GZ|>L= ME-
%&G<^3FD.J|H9|DZN*0;HMW?;*I9:5 J_*MVNN8AIE77ZAM29|4MFB; 5+@N;L."GJ=08^|H
MN|22B"79>TE:5PNKX"5^CGJN5MXV.T(O-VI"*=Z_*L<^_H%Y9CX"9"9JL_S|D458&+1|H^|H^6=%Q1V311F;
(>BL!%6BM%DW6K9 MP2|HJQLP\$ 353IVO>E+^P|H8:L62UW13P.29U_FEY=*1;AXC|MD-1U>|0
M5*7TQ|A(NN&2&6|3.3HAT(YD!;0UE31=-;92*GLLSBKLC1_#F*)1O6M2:H MG6+OB|L6\$.0;\$T.E*|0B"G7>08AT*
/M0\$ZWD'H<|9N|H;Z2)=^6E=XS@GTZ<*(|@/DD= \$Q|_7T@;/% 0DQ?RD8+| M);W)?;
QD=9V|N2H'HH#;A:SOYMY_'LD=K"3|YHE#ZUAY_%V_O5U:X+C\$;ZD8#F17|+0O.G;J4 M*+A|8%*KL"5\$&-)
|DN<'Z8|@PLD|K+UOY\$)_3#|J*H0COH#46L0JHUW%LT M%2C|H|J|MH8CUPM.&%|8>AP%|!M&OQT\$6?

O"3JZ"+1)V37&MN)K(8%M! MD4N)FI_@2Z'-QW*YV)HJ)8@X&LZVVU%FIO T^D)L2%B1\="U=Q+6J0UK
MJ.B#05MQ!H*%10D+\$FZJ(>Q.P@8U"YJ*K+1M%CP1"1?4KMM:36AK/8_C%>+K
M6?D+I2BUZV.9HB2YCH+4LOGC?IX2P66_SF?QL9G%.X.C=Q1M_-SU8=F6J#Z+00DA/L#70\$!+5S6;
MK:/<KX6S+?D1_-Y_W)7BFW52?9:C@11530!4C7E@K%M!4FN'X6N'&OZH MWO!9>3*XY59QV!>E,@K3HJ
PH^Y.YQ@!VQDN2*T@GHS:*)B-@LY9RV23.MDG747O2&1#5+5HU"N<?FM)&M;_2KJ-COG\$KJR RZ2!X458Z3
M!)U!9N*!B6>>>OZ:\$M 8!0B)K8L!GDJ UNJ60("\$)"1 0\$ 5.#:HTKWZMRZ!
M>EV\$4NR75>1#C8GO*"L)AE84ZRH:A95^O(1GSR*!1^>7C!*\$A&7V!KMOTS M6:@O!Q>,-[VA6QZ9M\$C^VC_]
<\$)QZX?Q@%YA,O? T_^R*R)RI88J\$DF=U'Z M(3Z.P
HNX(%1\$!1#;2^@+01>KJ&R4@VZKH5&C#G78',0068'%EYHQG M@AU@0<'1?^!=^*0I@6DFA73#")Z8'M@C/4*P';
R2!^5"-AH9GMTFCMG7T.S@U.X(GD&%^L*&^-.!FDD&BS!>_C&9G\$ M+GF8?DC^<^=-
UFA#2X;FJ2AM4Q>=)Q!RZX+P.JE(.@L,*X4CJM@VVO,ZI
MZQA96SQA@97.X6DJ!IE7(=%QE;)EJ35=VJ.JJ?75JVFYJT*E7J_8Y:ZRF>J% M#VKWRRO6<6Q0IH)
[E>C^%V%CUOF0IWB=-808^7@CQ0*4A.M"9U(B!GC/=A MRQ_12,^O=^LC?9^7.3+5NMJ#RRQJ C15Q)!1W-
W9W30EJ/R&I^=CW30^=E! M)F&\$CNC' *S?D)DT?IK.UP2ARD3,2!8O!%W&.#2QSGC(%:TWG#0-S!O^RP* M%?
%")P^#B#^DEXT\$ >M.:6;C5.7^,R'FP0Q?AP>-D_ "@B3QH&K*EMI5=-MQ
QVM5(*L#L_=@/SVC5*P&:B3QGM4630^L(\$3Y/P3@+.,+12UD?G2:GIC M YA7ANLPM-
HTI:IRQ@@M"1)MYK;=1Q:'896FQ9+16A)%%JF(@_:"C4^MSH#
MIP#^EZ(3Z\$+_104EY!Y#M7!C41QX#1.\$678QBLP81=4ZDZG+!V!KMYKP\$NA M!#
(4161<5YC#J/P:E=UX"72N&E*F9K;7!L7C@^7T0^A^4!@>-!HOK!L8 M5.L-L;Y,IW1*7^MQ?==I@K#>A&SRQ-
4U:DG/SD01"YKL=C HBM4V M.6:2E\$<-DYZL#61#.2.LYKMTJE2:J09F_22+;2C"1&1#3#6YWRQ:4<,
MRX'8J5"XGY4TEJLLS<_-&T6K&\$2"QF4@:(UV;5#YO N!61L+Z(XO).4E:(V MP%/+7&324QA9TJR<(NQ=
<%2=W34B3!0=%G;=N*+^XN^4Q>=X34\$SR0#".7 M?DE^+DV"%I%1X!SC-[@6WD)CJ?K"US@(!NC;:V/;'#&"3#-
(4NRRA#U+66U0!N&BVU*JF23>G-B*%- M2;+!PYF_?>WY@-?@W#>")(>YA:[K]G,>7CCQ-DP;JFFXC_Y8^:
f8)+3MR3) MX=EL>SN(X%'AS'G':Q4<-A/!+W<>72R\$HY;,\$BDG<1>\$2@&7=WE#3"EZ
M<9I"/PM(P44!\$8@JG@F%*/1B'-.%OG!Y=,!)?U-LX4R3\$WZ!^&-+BNLGO M1';!4C'5"GfB:R7>YDZ?
Y)S=|D|/IJ^W8%#;/7.K(R/7>\$+;XKD<@)0F M&^J\$REK2<,@&C<8\$1%8E?
F4K6QJGAM\$>5V2A!0WGGZ0X5F%PT.ZDYZ5!^B MA67=IGU%SHFP"G',HQ0:(" "+N
5+IC9/0W!5ZZ2QGY3J^W_O<^7E/M6_3^@<@31Z!40" F.52M"0*8\$RN#X@<XJ5O\$ALD9R*8=EJ56=;/62S%@@0
M%N^)+O+-V XAF!9C9.J3RB??=:3_8D!W9N:3V_6I7B2J!9.H@B(C_!>.^7 MPWU8C08IP:5=0IF\$'^
76(%QH!+B52NXRS,6A!7YS/#JPHM>T^!|=ZNM.G_+QOS%|_1N)
M9OYD=DIH.E=1ON*KI79@HFC41AG=;/>U)OQ5KWG\$.PE^*UK M4I=R2Q:_72M N^ V)ZMZ*A6L7:1JLH
->MY.BES5+?UJO>Y>8K/(5+?8H MI-TX*KZEY+1E!7L9-E*N"AK!O!G_6KK?T3N1G!N"C3V%T=I:HOI&N+! M?
7,...\$FE8@QR&.RZ?3@!&.#0_XSF=|SBNY*4K>>E*7KJR&T0!;>G*(S?#8&5JXB" F=BK#VV=>D'E*HKS?Z!G=M
MG9<L<+!3>H7!E*AQADE5=1R<97T&4YD58+K0UBW<:"T@#JT3W#IO>"N&
M!6TXZUPL70TIVV=+^3>4D)U2;N?+^>+!F"4TUCKBE?)\$#2:4WU)7M\$(C M L^EO<IFB8N@U..8K"'''>*,
VG*1Z5G7#!&4@RO<IGJ MV\$6Z3^X?&09&/GNSXKU\$!8=|=|PFZ@X^0N2;M5LXX*XA?I:T@9)P!4K;?
MU9:JHQMSSF17Q635+-+6F,SL#571,G/B%#F3<2;f5":K9J>WQF08"0S!/:G+ M3)88NQ(N!P!)8TY/=R"<4Y2K0!?
5YS^Z;JCC?""3 @PIV2NZ8X=2N>K|K|TS M7S<,HZK'JW,3K=WL!E*A)+M;BI5\$F"T92Q(C W0JW('G'U':!3)V:-
+S"O8LD&4M**<(Z=(EU<" ^ M41U5@I.FSVY+T2IE@I0&V-2:#HARC)O-2C)4*LKKER&(AA?171DK>M#C\$
MSA!B=97!82"F(<2TG%B13K85/7V0QTD#1LXP4XX%CP*P*7!H!WI=P^,F(L!9 M#FG7M28\$=9JY8376L!46KJ->
YRU1R=>W8!SW(7R M7%W#OS6>.)%C8:AMM:|N>!)2R?9!PK?X*,f6(Q_1!3CKOW06K7?JN30XH:% MUZ-
>*M*+VUFJ57B\$UK2*A2!BK;=,*V %*MI>JV*=<9!D)8!A";j.983QIT MAI:H%U9@Y_S^>^;^_ JQJHU_1-
0!F\$S2TZQWIK+!000M.GHF=10=95F'.ME@&I@=IFU>9GG7+W70F/EW>KT#K/D@FYU.HDE2FM
MD!Q#*9Q*PZ8P6K%KI?FDRCMK2#+MXUETJM!V77_A34B(.6/B*"JW2CROV=I M<48.>/I28GZS(*P
/G&CNLD5,LO,"YKEU-@?%42G-7N#A(*D%PO4ZGJN!W! M1.PHCOS@58 /X5&1+P! XC+W +X!0)#L49-<Z(LKTG>C?
+?G1P4KTG.:Y+S MFN2))ODY\$>V2:Y+G!Y0?+7,>|/#B_<QJTM+&5E%/_ MY\$YQZF45JF1*!K382@*HFPN6&Z!
<"KKBRH @V:YZ%@GKLQ@K W4A_54X ML):7ZT!2QD@L_9*DSKB"%B79SH4
RP'0U)O:\$G;^&=.9HM>A%OOGP&ZX@ (R M)LXB NG9+SMQ0SU.MD""*f!0E937+U#D^V+ N*URM\$U)_RVA/#
(Y3N>PI? MVAW*.'A/D\$M#68%6/PW*0)K)JFYA'4G3?*"DH0MX.R""IH.>U!4PQWD'D MA 4A3C_DU:_.\$/OS#
<2Q8&^ZB+P!V0N1R>X)A5W/B1?L9;>)HSEJ<9(C M_A_30F?^*P_ (W91%OR#7?7P=/4)JL&AUT9).T-XZ=W,2F-
,%076N>GHC*M^C:&.NEN.:U)P8MSU>.+^YGM/>TD?LNS%K6!CJ+OMC0E-3\$@+=!%#(SL
MR9Y&R_GNT@Y1P*K \$26^P>Z MA+S.J<='1Z>9RJB876EG#1'7H<.GVHA:QM<*IYI6MM.14X6^C^14<^J:-
Z=&I#2>X-FYS5^ZH40V^D9W MVL6<0TE!GKO0&H\$N2/>J1BAJAZO&.&%)!EQ3KYZ3NYRC4-5.W*-0!6G*VO
MCZV/73H!U8!<.O'PB8:IZRKBWXD:3@WOM0I=R;*L.MML+/S0P6MN ^+;N"-MRF8ERYJY.9G08'6+/8*IQ5^Q+
<5UUE@=EQ.569.D:IV 62;C;-D*8&\$ D9M1 M /OU&WL*H!VUW1?I<1R.X1)KA!TPKD4)#T#
DW*3N)3.W7!K!R/\$F0*^_ M&|RHF&3Z<%HQH8QP6IP%&WP!4DP*M@.'9GOB+, A0Q_W FIC&6B&19ID34
M@.9H=R2-5.XFI3Z>^INCZGP:6L\$&+;1?4HG&B%I#_PL<%J5P9Z'H(KS.M M)@>@66V!@0S?Z8N+<(S(S21EU
W%3V%G.A!007B(H6) Y!&OQ#&#2.201#B MT10&=A"XH;2HBXJ=A=|SB(Y:#*1Z!@CQP7A;=BQ.24!6Q0I-
@NO!F>'N'= MBS@_4/8#?3^Y"%Q"/,%NS+>A_3BOK!OVR1#OLU:LSE1.MNT+;X% MN57(<5-W9!/?
@PV45!W!4Q++9R4+SNXY9-S8L!F*/O-ACUXAVR<4>B^30 MEL5Q6P4YC>KPU&X#5B6"[KH&UU+0%#N:I
Q&|_U/2XP&Y)F 3=|DS/O2?)Y M4|P<;Z*Z^!10.W^WWNFROC.1QK8KHFT)5.FA;=SAV7RAW:D;G#8MRA*9PI
M.'=TGCOD@AB!0!&AAD\$ UG4<@KAC3+4?JG7Z ?+)=B;+LN/#^@A56F4/2 M>V+
\$^C1"BB\$SN8)39UK8*#RF5?P4BWV=H7+18EB.UAMI '*B-RQGRQ.0. M(JNNF=TF!F1
EB!R8!+8ZL!T=6;1.U36AA1HDLRF;CS=QQT;T.OZ2?)53^1F"8SP2#/^X2>M?G%I5V_%#R2GR=K>N#@VQO
M%7G!|D&D_EE4Y*XX\$C3JKM*X0RG;VNX+T4DWU47M!H1VQ4(UG_8.L7D M=G&9SJ?9U9M<@A3!2 F."W:L?
&>UE1S=TI=0DFITMX"690;..D>G*4G#1* MBK3N/C#! |#P(2?5RH<^ AFI@VAJK'=D39Q;<\$G14K6C?I2P:DD/3:
(QS?OK9 M0:14H!60HH.2)%X+/PE(J6&J! 25(S>4#>Z4NO@>L_ X?MC-CPH:VQ3+ MUGX9(5#?N#9AXV*DMK!
P^),?Y!0663M9@&?J;DQ!S!)-)=)I5M6=; M831S0+U%EMI6_8B#GX"G(TCJH+^I-T^&.6CZ!A/C!-YAP\$MV
\$1&_LOA/XW/\$\$GU:S6!NSPR:U M1+CW/;JGM2.X!+WM8K*=|U&X+K^>J?ZLZ3!YWB-I!@1D#\$ #VN0E& KY
MD^UX83XU@8!CP!9<@PG*IQPXE"XAI++C'B"\$PE.*A^),OI(+OK_"#N*Q_7 M9HL?
PB!17C.&OP_1/F:4.H'Q*5\$SWEA7!Q:W^1.W!XMSTA_X7/X:D^/82 MCID:HJ+2G@=C.;>S.F XPRA"*P8B_08!5>'-
<5_H_F+!(>3NV&3N!) MW<#DZ?2.V%\$TJE-2E'3.8S A^7AD?KO69@EF!2>C!Y>'7,*O6QR@_W<_?
OLN\$!+;KIP@2 M(MR'PWPE=A#"55C"S9FHL-83_559GQ@OT1 H!JL<=&\$IGEC<M-XL(H/
MX@@P!K5N6>%X<6/W^ M<'WY""AD&V3B>%M(T#3U*%)T ^GUL9D-9L!AWT/# B_+9I/"RIKDD90??L
MC=6;CUC-&#EIB*#_9C:Q2%/JH&B#*#WLH2GZM_DXEY0D:093GY3*)BD/1\$': MEZ*\$@@S4_XF1#52/0;@@Q1+L!0
Y8!F;+?P-K@\$PIUZ37:2&:2!<\$E'LSTGP M!"L(K)_E102YC9HY(&'L1F)GV69P;+!A%#>V218<56!-@FVO"Y&BB
S;4 MYLO&\$E>D:00D*CG:H3TUX-H^!#T77UR&UA"8N(C27EH>>I<^5LDG@0PN3 M!JUM-
JHPDEW;"CP.FM&ZB?IS#X&.1X;:9K;U:2X!%_-%//DAB)Z B+7>B M4HD6\$Z3:H1&!!",R7X*+0P86\$5C>W6

C/C38A@-A/UQ_R\$P"3# "W\$FT>S6LOJR;J%: #D83UL.OI7Z0+N2MS_7E;ZIFKE?#2I2IN=%
MCY(&_8\$EUWI4)>>:HE_XH'8_JB3"86>A:1M79=SEL@>AR'OEDOU'NUAUUS MCSN/&8L=@ILNJMB/
MKV)8UY):>XR@&Q,>("0P06@0_-1A%XENCAO'"#^E9 M:)5V9!>=>T#:BS\$^1%3^1DJV@3Z?_G_<^%:G1%<;LX[5?
4R+74E?&GNKJ.(G M8M&*)>(WC&F1PC1?%(K3X?^YFR_4&2_P8K7QT7?GH2"F3CNC4?I:17=2 MQO/=>EPX-I!;
(U"WY4N+!8"-=IKR8"=G7(+!JGMK31G9<1*72(NRP.)LS)G M9<1*%<# E@?R9?R0=-B*K3N3*J
AJ:VAYV OPW:19^\$FIA*"LK-IH%/"A0=[R\$)^ ^ J_H_WA2D!-K9=M4: UR!G@7!^(F6: X_?3P/&_R=D.20!B>+
" _O" _V".C0V/>!'(7V.RH Z(MI6!OFAX*#_0P!R9D@;D81YS!;N_!FJ6E03D\&R6:3IZQ<|P-2.HYD?L-R9
M:;>JW3GS8D9\N6_ZE"9\$-63T@I84=+S_X,H,D#;@NC//IE9E?L&QJ&FSOY; M&M3N/)-
W:4PCU7:9&O/(#U:WV",0_G%4?%N%H-I3D_Q^A LIQ_<CX+\$F9C& M6"*299D240?="2/5.TDICZ=*HJBZW_22J')7-
@Y4)(C@<C@-@_NPI\$/'6_M=E_LUQ"56Y8R0):_E:A_1"OME6C8&[09;R4S5^*PCS!;W8MN; "B8DI/TP>C M-!O&+!
(^0Y08!P5P*M@:_9GOB+, E1-RA?<0.D*@"T"JZ=81" "H: _&P/ M!140X*2O+F\$FEIA"35UUQ(>RMW)A-
N7A!>/(F3V9FER_>ZL!1^YP00Y#JE"O@> 5!D M?2?8Y0"OF5+5M/R6I%:VYX& (B&_H")ASHI
9:9MP:Y7VU\$IV^H"&U7U<6U M78)<EE8IAO:*G_@L:/HU14P:P_0>:#GH4S?1MGY&H.63:+P'IV)O".
M,,LX8V2<*3*.LV*(<=A)K\$D =.XW&U)2Z/*_9?5FNEV92F!PB177%:"UCY<(' MI5825%>51O_6('XU95")Y1PS-J>\$9-
%XAVD1DU!(FW#B9UCRN0X7NI";%? M@^00X6XIXIR/J,L(6\$D+&QGDA0(G_X)X%Q3U?I,B M@NR*)AVA+NW
+V^*EW-D5Q+PFT+!F^R!FCS*B!@!KJ:B6!H%I8W.L\$|=YX9+ MY8:2T_&W(5GTQ3E M+/W%NZ IB.#=4BN%NS
T6<(NBY*D=80:+K0M2Y\$U MF)9*A&>B12B!"<@43XDF6!R.0D_ ^ =T/V^F*68EH7UIN4+=-;J*IM15! MI
/AAAP_U4V.YOC!(C6B)3>V_3A^SB*SJJPZ:0.DR11)@VTD%>53^0Q\$5^6H MN:_@DJG\$M?
1+!+VB#<^>#Z:P0KJZ!#TAKHEREKCIH=V;UQ&-7= #>D=H; M:KHJHVK1G_8=1!&%7?S6&D18;J)
14KDBC5G7&(D MBYK55A0&CNS#3ZW7F3A\$GH_!S6) _&QWC>_8IPS3MC" +S/%LTS_PJXG M-
(=KOWB@EOK37!SIUV9L?O98920T*!J)XT<((R%_CF>TIL1YX'KOLT+)_ M-&AAF9;AN8W?_S#1/>0T"XM#R-
L=X9ME3XFR_)#1950-J/H6^#L!S4DU4 M-6Z-7B+22JS18R)-O2&BFAIC6.U_-Z"+02B_6H0)-
Z0PLDVH59M6=C3=R- MQT%,<*Y>& 4QPX8/9+!F&E?D^ ^0!O/WM?_PI(&+6H!_!FQ:'8,%V-OM M?
1QJ!/_)31RJCIQX*&LHHN&WM@>X_<"819B3UP_)@I+_!)FI&XS@D#K_;
MPJS\$&C@:S+!EN&&*F\$367Z_=5C0?"\$1NK&8%VN^ -H+T!"?LX[B@_).H++3 MYMR+
'T(T2O!0IX=/PI=5V%&7'K:92/@5G> >? \$?W_ \$BX9EX"CN;_C7LOC" M5N14 MVY-;Q?#MX1= EZ)K=\$V!(' IL-&,*?U-
?7^8.KQ.(XH53.MZO(J?P:6T8 M&"@IQNFY7,4GVZ4!LGRR?+!)LD>*Z_C4SMMO"G1+?*)DKOA%VY!'\$<=;!H
M30= X1YF*7S@A6_0_LQ_H3Q?<(ZP4XXIH5_Q\$*?P5B)B:1FY_0X8L?<M9"MH<-!VG09G&T73;:"G;
!T):!6^L.N@-94L19?U,2BZ+! M> ::9WU@\$.10),"69"O#0^% ^R3TCW%>'&=Q%B)(_X&-!AC'NQZ"YI<1U
MP3Q8!PG;:(F_H*73D)!TL_PV(!0J\$|C!-C9&566%R?T83LX*MPZ=T&XF MJ_#@?5BMPV= MGW-P=1!/R-
KT3:8O/(Z =>A_N51ML+!L!2P:=RY3S.5531UQ_MHZC.LM16F%;9N\^F'7U"?
%?'&_U;G#;!(&#" +/P@HMZ2L1N'SC.MXP.\$ MF64?2S_@DO:H^_D<@HV;_>A:%XYP4BPD)=JYMJ^D-
>&%&QJ(#Z0):3&"T_ MW3:Y/4@SE5L*7K"!36EAOUF=HMM#(C-S8U^Y.AUVULJDMPTOM.@=!0!);
MZR%J7O:@9-!8E6/3,R+;0!J;GD?+ 2SH0TTK+ (C/A\$!6RO?"P_MXYDMQ8RP@/S"/.UJ@61J M2UP_O1<1%=P^I-
_G_VCZ19DNB>EDGJY<) M'EF5=1^=(0#<X!_)(H?DY@!PZNTAUP/8NLMHGRGLAYPIFO_Y"6>73.Z#&M&9 SX-
4RH'(@!LOA-!GKSW>>OZZJL=<"DQ=Q.)!%4T6H!TTH-EHZFB MIM^!IAS4:A4OB_N2!PVO>R"&UV>\$:FI
H/L/H_K9SPJP/-FX=ICPGHO M9/6!XT6V!^2,7-Z1H8EFSRX'6.EWF<6H)87;BU/D02R=Q%&)3F+1YVK,L=Q
M=%1MWA:...A=4=WW)FF0URK.*AM8D!(F";S:COE=Q!7WT_8PY3&W7L3_?C M?
V/G&98>K3HUR_!X+WKCWD@&#UP)@8VPMX5A3\$IT0GE_>)7%1 \$U1!81 M159\$24?PP@HC\$%1H(*=X4I
!\$H>=3!JO_D\$4'_A%"="^99ZLMZO:B=XL\5 M4VTE_D?O6^KN\!^C)CXF/B8^H_-2=L=,IE.&-
!RS3IHJ(8A6:Q4U4B\$>X MO_(Y5!77J&K4Y/YD:\$C@Q#+:#AF\G_6H%)(%)!8T9Q=6X+(#_7,5S\$7/<"
M/6A<9K)WK\$K\$D\$>#>_!^C?P57HD=W.Z%LRJGY:V0E#^YVT_N!LCX MDSD"^)/W>O*Q*Q_?5_F!SW1
CG+JC:9F(NVS:XZ_#MQOELURE5/>_N,X8E") MXJ-
K4XD7\$\$\$+MS3>*3_*Z2ZMX/@@:COA^W&I'8A0VW0&TJ2(>I*5UH9<0!A M%+(7)) +^P#L8C4&QJR.%!DSB&
<0!K-(9)Z\$@Z108EHIBB;F<1SB+=9I\$2 M_XO56:7=?P)%%I^QN"72(.M1?4@=JOG,5"GY;GV-T MJBCC"/,F/%-
DJAV=:0SN.N_!D:IP2*8SJS>Q!&ZMU:&NC8_6&FB0J9N/27KQZ3/P05.:2:AU_@#@I(KF
MH+!%P^4/3B5^6G:AY.\$<%)\$56NLZCFG79Z+&BZ>JC;I3;7Y:Y5P>*(
M.I: ^U20:^^.DT.N>Y#;N6T^%>3:.QSDD.L>Y;IU3(8<1EHVMDWIFY<-N!M5\$^#-
YWO0B!7;SLUZFGP9G1LFIHFMOQCVC=DI?5R_E>NQ<#UO#@CHB(UK B+(N MFELQ16<\$;N!241V36!LL;_-V"K>
<68!TN-LFLU8QA95VLIHXOW8# MNIOQ3?^BBS7+XBN_ACCR.K!^T*O?HJFH?X.F;FH^C
MXZ/CHSONZ^A04SSB%GPB&G*25O6+Q>>0!^"0X!4W1TB8PYX-6;...&?%.%UJ^&"V"@C*M&8Y
K^6S+>8EPNWSM7+MQ2^!HUI_7 M!UP<<%"PD%" HD#9=ZXC7V!UP><'EP>' _@B0:F@PP<:9/5S9;/X-
^)!SQ_Y_0EG@:,QNSOA&Z4 M8L?X+!)T3G,I>'(A.C=A 5#WO"748#/3JA_GYJY)X&-*K_@+@%C!YH&Q_7
M7O!_WKTDXVB6PBI8T* @P>H6>P2TB*/B6!_ER7,+!@K9Y11J4.8N.OY1D M:9TV9IX?_2;_S&-
L40DRS(EH@!4Z4>J9D3'TZ531^U_ ^4L#16Q ML) (S2B_?B-/84YWMKNB_T.XG)G*0-
DV5B)"D14<,\$8YFY0+M!^YCI9_Q_' MD3-191YW@2H?N#%Q53>CHJ&*79,("9?<;MM!); "K8#AV9!8BS (4CAH
M7W&C-WQ\$9L4V&_VO_J#_LP\$%:249&VWQ\$618Y)#P\$6YX!_KC^QF9 MKC(5177#791^B_!DH_\$6!_@HB
\$TZ3.%!%%"^M1MN5D@_K:9!4A)!?SE*Q M#R1W!45G M?2WDU HIGVZZWC4<+1F!XE_YL!^3C#6E/7!B^7K%X?
!#8/FP M3=Z_MPR^!8@_ZM!7_HI\$!2!(>HU"J<".W1^S@M1!J MQ=KOX_/.8E_\$=N-9LBDPL-7P0F%:\$9
G_UA**_44VN!P5_-P.5;:_FT+ MKC-W;!K:15YT7"=ZA36F_!#1\$B8V:'PY_7>'CW(O"?G1!-/?:M'1#ZOFGL M4:/-
=C_1URA75!7V\$DD2"<_8N^!+@:HS#SW4D(%!)?2,2^%YQ4(#B>L#8_
M40#C\$"YFLP3:V4!X+'8KOF_S!@B^8L\$8R<\$BD!CU4+6.WV&3%060^_ MX.#9Y8CPP'<%G#-
JR1^A56_@7_8"!D!F=O:N_K">S*VXY#1 V17!AP7QY?_ M)JR:\$%BG<#&2^9G0M8EL#^TV(!00<<)8D-
J=H:CV_0JG_/_&CZ/D2^~B6;X M)QV#%/C!VM5(?&L+!@&TN=%V54 FDX(#!-L&5@MNK!T+%/SY_7%L!\$==B
8MQ\$<C^H^>_02+Z0.2.C"/Z&:AL@JOH"/10T5(INJY#ZL?_GLHB M@_T1<"(UYARYA9_\$F!2:6Y!)I-
EZRO/5XZB9%1<RC_(OE#4/Z\$_9L#N6A MD\$3LPY3U<3E2NFW0"9!>82Y_=AB3@H>
(0&@0(D1XPZCR5ERU=YFZ_DO.H@=D M_2N\$C+6\$K>WBH@/PL7U7!^VK0GBLK? M;_W!A%)K_XJ^F)XY
2!\$LU@@:/X M\$0\$+JM*\$,@00+!BB89&19*[ZSN!OO!G4!+4HHH=%7H7"1^XU%V,<8
MD41!LCJHHA\$8#S#Y%\$#4G^QGDK%#IK_N.#X/GS&:Z-DUU&_N'29_O!IMS=X&RQ=&S!<7X9_XO/_2!^8!7
S_?H;WD!40-H!MXLSUI@3H:6=N<_MBR\$Q3P(R10MKXA-V1^-=^#48J!BL_H2:16)5I=2(Q3?
D.X\$P+Q)S6^A:DI/A'R&1FSX52!8^O=C_FKO#O/S**?D1_?J=FG:Y3.ZP79#G M_P9PD1HJYDF# +Y&U5KK;&
(T+018(FY-2A\$FG.)FF!6W@;...3:@;2 MX0+3(7Z6?+ "=ZD; JW#1Y&*!M_W"+N+>7.YYGT^T!(&TY"UL_@4!AL3T
M32;_A!_L!43DAWHR4;_<:"X=FY&J*IV*LOI7 MBR):BS_VOG!#Y!%ZU%3&POMC>_JP.16V4S_!0GR*?"W@UO=
M+!)#P_R?6E%CYOH1L+!&*U!33#SZ=V_0*0'Y2_7+BH053VWU#/_=@8!^"UJ@_MLTO=QFCX+@)T/*(A:_OFP;
(O2XE:J82YDZC:W\$!S2W?_J)25!Z#055_L2Q8K_NU:+^0GLR_47/"8B(' *I^1 MV5LRHTV!O3FEKR3_V-
8NX8XT:XCZH&1EWJ.PIF(NP!#J_MF-&_ \$0!3_Q MQYHJZ)"S5T7(^4FX1?6,HF/KS(NA+P>>5V1WT+
<IP9_!K3D:OQP9)8W@128-/N-1#_LIT#RF3K<1UOF"6>T-ENI3:3^OI+&U1S"&9IAQ+ZA<
M6=O#XR7)DHC";!1JG@6HXT<4D!1/25J#?+5:SK= IMH<_!U+2.)XJF*HEP3 M9=L7!N,@0

(DHM9&.1C^2%T183Q%KPY>")YZGB431\$\$.P1."O>55Z.I-N4.M5FM|B|S&Y\$A|GB06QGx8|=SP"-)8<GY#|LY&&MHK"(@X4?)F>&JU/RI?>A24X|VC.G|YM\$M|XYWF5NO#TCU|V0.^QU*E.O?^~W#P|81@S\$?R)3*-)2|K|5MAUG|ECP+.*\$'0N8%-|@RZA|LB4!.\$3T&S?X?)PX|'3Q^NXP&L6T#'%@MB|!|IWLJM|32:).YL.T.S"TS)V1G?<8+2%&A.MH0A|G|'X|Z82L%L&@F.PRHZJ*JD<828.6|C%|Y?CAK%|<.;|S%%#X|F.B>M|*D<_NW0J%\$62;4Z.T\$'./TZZ88"/+FCPT9RCT*IR3>GD"+3V|2>01*BP.M#U/|L^S?QV|!40Q-W|87X|\$0GBC2PT8"!A4JLWSG%'W|!001B|+"3CQ&MDO-MCX#,.86.#JC\$YMUD;(.VOGESB/6AQ(*_Z*(=1YISF/UQ&Q(R)7SH_(598I.M1"6QW:E|WT|(Y/8)0_3&H">DL:S=DG;#03N1@|4Z?EAJ@?&C.S)3B\$5K@7;MJE0PS^V.G'D|IW&Z&WT0|S44BT(9(S=;."\$+T.I>GX;))B\$;V|;|3&?1?B|;|!\$-P9/E.D)=&@**M@1T|*ID;/DSHEN6|4!2AF?CXNB-5"GOOK*I.IM_0REU.M/+L3"?.S|YC.55C3J|.4+Z5Q32'Y="&D3X01T\$KVC>WLW|^\$#'REI?KC#*M'(L8Q?6-W#>WY>G(#@FS@MYC;S=L|USW\$LY.A3@8"J1X_4|_U;|=MS?8O2.M?H2932G\$J45B?U.C|^8W2<*FF=KJW1|L2E.M'BK2LWJMAJKS/U\$UAXH3K^=JEG?7<IG=H+VRCXE^0_66.C@FSVH79I"P.KPF.MEE+C8D|IBN*3M;?I.!?EGUNWW<>F14|+M4.KX=L4.?MY|F=G""Z.G?F1<_MRKMZ>.50^=0|O.XB|Y|L.R#VC-Y0E45\$;=XK;(6(:%I4JWIPW(T5=9_|6>V_.M|6.".)&'WBJBURGS\$N9Y|R4#TW_?/C=ONV=7IR|&L\$|SLZZ74E=-2.);MS7ROZ#+9EV4M9T)JTUVX3;D77;9AC&<.;|DTF_0YD_BTW6\$;8?'9W'9"((8)MT5(.\$S)A9X-)I%!D@@QT&3|!6(20H2'MV&|6|A|E#G6964&.;12\$-A>6MP@M8+&#+PZ&QB2|H=L|&N9U0041|@|P3B>8PHZE/0KTD\$+D.PQ"X>\$S.8L"%..MXX"%*+D^3>D_|1/&O>%.QCHU'9=C.TYCP6N&5)S?S7YU7F280U++'P|<|+M/E@|9RD|'DE|KA.LDF44.O(|X"MZF\$)|#%<8P^X*H-2RG("Y|/QG&5R-'N8Q.M)|@3^4&X5K|C(|#R\$.%_'J709OG^DN9=_)B|@Q=^|G+S@|QHQL|Z.T8V.MWP"M"-K8@OBO.R%@JS\$25H@)*?*C;T1.YL\$XZ"MRXI7/(PCG|402QH#|KPF.M;PD.BU4\$D<8EH_2'NY|TU.8Q8Z+HGP58K1.X_R="V=WWZN;|&|=)DG:086C10S2)2-BGHK"@&UP5@L\$4(|M4|9D^4NF@^X|@=DXZOR7YV;JYBF>Z|&A%5KMB.(_/+X+X.J7M;|^_??R<M|?<1,PRO=N.K-4.*6NM.K)6W""UL07)H>Q<_5Q0V)K|"-M.-F*ZS.OB-OUT.M68+KL))U*|6@)0\$;9;=R|B)V;|P7)6379L%;"-3@7R/(8GMB4.6_5.M74|SL%|VH&4|BTW+E^(*BGM6%|(J%6Q(Z0L|AMHU&^1|TC)M%VS->THB-M@X|Z@U#N_?'O<2;F(F|)H6,>((S3(VP|:5B@|L)GK"^XF15=H|6L0#!MYT6S,"D_|)L=C&?"RGOT=?8;HF@%4?)U58\$*EAP>EB25)IE.OO#AX5|X.TK.M|GV|1^R|J8_".'@&F8L^.@;A|"-+|HDEM\$Z996GC);ZS*.M\$|9WM.8>_H_|B2F3("H|F2MY.L)H|DERW-NL|O_'NVI;Y.Y\$5YZ.QG(5+MLB44P^5>;|75RLGZ6|_VDKFIU*6UH=URM<6<84W>?2KB;0L*8VTD=6IHO-DD.M;.(D6V9SR>2B2M5%W3Y?DIHA"H5IK(|MSEV7C.%?|9'P|S|>CD5)G(=|4H;|.1_2#RW)O;.75Y0'M|@0)"HLBKJT.MMW(|WTLUCK=-.5K;7A!;XR?<=K)ZNX;G(E|(|D?);OF'BEDEUV.+.#YB=(ITE(|MJC|;QR4=D0@OWM\$|(&.!T+U.-TOX%QE)+TS'7M5^VC2BGW\$M7KZGA90.>+|@^MX3|&42S#)|-P0|7&V#F?Q.MA@E6O>%7>4;XYV2\$GSW.VGM6)^+|C)"(K"+W>=|!ACKD/MU'O>>LI>XS2|SM&N>EIVWA00*0|VIV|N.H<3>%VYTW27S|G.%<|ZU|6>T-5MU'5+M"2U(XF'G%ZVY@>_AU^X|(.A;+I=6?Y0+I(K'D2G959J<_>5ZP|&|!#H@.L'\$436+.D<=&T37MD>B|6_.03WB%4VJRV9_&XW>@LU("\$ZQ_@D?%M"8JE;&3?2.W_8|;R|7H^J95D8QQUBS..M.K;&EBF5G|;#YD%K.Y+R|W-'1)M-#1KBQ??0#4X)M8F-W.MRS'>&V|>S+MAY>X#RXA=NF+6J|#CZQ&HG>T|?EFGQ.XS|!+@MBC'-E|.IWMF'1SAV&9&/'ZR0_N:3\$X+Y;GU'5WE#3|J(|&|N&O|_'%7*OD/@;N|Q>9.MW/O-C|7)Y|?|.FJ-^)_PLW)?F@(|1WWN3?N')I;OZ|D'O#15+M-2N>&PYVDX40=-.8;24*P6A-(?'S.M@7W|K#<_=-|0=\$G8|VNRLLOYVHB;O.%DB(K6Y"7\$S?2L.HJA4B+>\$(|QG*EJ#MOI8-|CW@L|147XSM|9)Z|Q4<#LP7|^KE;D+DH|>?YANS&IS6KJ_*QN653E.MMMRFW.KN\$JH!?.14"6!&6""O;6FYA|X61;|'5"AQ:0-E.#>L3WGPFB|*M@7A!EX3|IRA?|P|JG"46A->.0A2>D=4CJ"GVLSMCH|D>T|5B1|&GK96X3MM>3W3E>\$Y>C#%G9Y105/WY^|.Y;7TRKP&2R)9H#L=^B;BJX|^|?JTWE#3.M1>M<D/3FDHP4%*.P=-?>77|!2S|Q|>8\$.JH.X|J\$6NAA@27^@*8J%"MND/TH#)CWT|PH-Y2-@6A)C1L|WU!"|^%4JGY.A|1&UJ&J#77.WS7L|FB|@|J73'A.'B.*YB;@.2J#0U+E-7&2KV#?G99M8V7|NRR&UTKCMFTME|W3+6D<|2L7FNJHOPO1YR4Q_'L)TFT06^HBY)IBJ;2.MN")W?4YT?;|AQ?GK_H13GORET2KN&&L|6#KQ;&6KY%D2G.>+757GZ>VY?M*MR?64<%5FKBQW@8U+@0|VE&=VY>TT<2S47TQN/;?Y=@0;Z4"537BD+|235.M2|6-1?SWMO>COL+|/R|)H65UQTG"4X2S0H.U;"\$KMS?C2%)X&>%@S?B>?X.M6-@).8>TMY?L33.T^I9'Y/E^(&=&4_-)4#N4--P.QX|?HD_*A7).P|4.M(HW;2|GOH-Z'3Q.WX0=E/A#8VYE>|Q/"WYN(8(SI4.W1+J2*.;?|?NA*EGAZHOM86#?H1(.EM%&(@.JE.@BDF0'I#8D@;5BB8;PVJD?|I2C@_|B6;W<0BS(D\$#\$.PO+&6BBTEHP\$S?7MNX2F|KIA(|;)ZPU54U2DKAQDM6FTGT>482WR^9.8>|5#'.F%\$A+|X.K.Q.MVB?0Y6Q.F|53|31X7S.^?@4X;|^CH#17-M\$HWFH0Z=X&)|JG/POX>V|.P?%>DNGE.R2.M*C.I9.&'#EYS&Q7+GXF|UZ<231+5S%S8S+?P>H6>P13BZ/B6^9V.1XE|;#Z.M.B>/'?;Y.3XV91RB)*O+6<\$S/\$X2-VG(EIC"4B698I\$76@3D?R2-5.8NK3MJ*!>OA3.F\$;E-PU"DD)+PG|K>V^V*AKAT6Y.7|E'CCX\$7%E)Y.#T9I-@S@33^@+P%M7B(|7@7#L3LS\$F\$6H|SZ1_F*@RAY1.83_*F>R|6%=T>Y|S|P4E>7.)35=-MPC2|).#X-^<|<')QRI|M?A@'Y|0N>^_ZXQ|906TROO|2BTSNHO1#?"P|L;Z'|T=|#!9>RQ="MH;3.W.M.;O'|ILKTDBU+1<-H)%H')V)0&I7(?%<_U2%&|37|ZE1_*1TE*WJW_88-MF4Y?R+Y>7|_P1LOU.WIQW8>O?M|^W#+|UB#_JT%?^BFSI=U0AH%6H%==MN\$EY\$(|MH|N:Z8-O109JEQ52.66|Z5?1G5/L.U>Z_<I48Q2\$.83OP>|Y.M9IM|>\$F+|I8GQT"YPI/Q'|L4.6#L@3S1.IR9_4R6#P0|ZOESN&|*_.I.M">ZV(^%'CUVL-HX5!.%Q#KR">8-P|"(KK;.'?%MLLFR"@EP@"2.IAPHX^WMKTU6Q+|R>|KX(|G1).VWST*HOGMO?)K\$<&P|H?9)V|<>5P_"&<7L"7.?MC%&D|S.LBQ^0DB>&|5AV1P|O/2#;.IH|_E6-|EQ.10W#LP^O&N|O|HZR*G.MEL#|/IZ12>R2|&&ZAJ>'*U*2C/DY-PS8#XK0|'4\$%M|"+PGYT)76AF_|T@06U@P0XV|ROQL4HO3C2#.|(%8=7=0RRV\$9&P3|\$X3OZMB.S#DS<"|2PWUHKTYP|T&OA'T|A2K(.VFAUSRCW2LPJLVE+OS+;+XCC\$.CHA7L8P|O|/;<^6&CN|&S<@UQZ?K;MDC+M4(<;>4"-K"?|W8*5=TZRNW/+J2K"ZVQ?7?'5/L|H^RZLK@XK;3E7AJWN;MU55?7EY?2^8.K;|6|N|JY.M|275A%KG.E^UF25|IFX+H\$X.HM.U?K#;5!M.V*)+V"5|31;7D=+^|Q%|L>0&Q\$1!%_IX"VBUO(#8P|^E7IE2P.H+*U.M7D"K?%;2MWOM/V2/ZR6V|CTA*Q+@&V+?OZ3*R9U:T=Y8408.ON/%JSW3C.M"UAE50VV)FTE!%?P..M8.M..5/A(O2X"JBRWPT3_.L6|K|K_986B/9W%(MHDHOGW\$GL1|H6_<^F>A|<^G(AR|@E05LV?MFZMOY<IP%;-G|9AJH<77|WCK.MU|+SS33;L^#X.E980+EEYYMIE6^"+Z1_.S5^A.KN|LW"7)1P\$>TQ3PK%Z|!)"%9M51'H"WQ<*9O;"K5)X6;|^|S0D_PJYH_2_*XNZ5_*F2#="3")VIP8\$6!N5@O)SBNSQC-0L+ S=4"|CK\$D>.%0#Y6LH@X.M5#P'6-D.|26(S@GC6/S#\$VS|*@X"?.(#L&4>4/ELO_#%"?AVTJE80K)>UQVWLZR^J2EUN4W%\$MQR6|4W=-.5HK2(|3Q|Z7N?ODYY^|7|V45'I.HSA7=QG.MM3ZHR=6PALU&K&N%TAQ|VYFM/|B_G6SQIO|25;7ZXP@)SZR4CN&IEO;BLT.M4+^\$5;|HHIS=|FH|Q.W;E?UU<%N1087(^HJ@|RLU_|ZEI3=K|IMH=9BRM.M.S0D0Y2L|4"&_1K8=:(-(U(Z9LYYG/V.4|N?IP'FR)>K*|FDLYSS.>=?"M>=KQ.<_H#67)%%6-ZSS.>=?>?KQ.<|H|C\$&|'|5M/6_M9&Z*S^@WPC!"M#*|4PA=|D32YN2|7Q>K0M=X"7F)S>=G8+3_P|B>*S|\$'_C52?|=C|'089LF.VINC|(|*9H^=RT5-V5-0(|7K7T.UQQ>|)|@+|H|S79O)M>27.GO*(0LOU#N;TK=3X.I00U>?@|S/@*BKNCAMLW<*A)0'I-\$"N%2"9M'\$B7#J32>*|6@&3UAJHEBR8F6'(872".2H.7VH"1-.@:C*|&L_R=>(X?A"MK|")H+G1^0T8;FZF_IRCX0\$;U-

YB2U!OJHJ8KHJST'=EB<@=%NX?:.MTD\$!)).%\$,1-7FIV1(T4J,PL;0@I3241'6@(@X@'X20(H4 "I'")I)
M545=-;RM=C'M)JW8H8/HR7XBL+ZC.POOX(I2%B50ITV85+.07%TTTT>1<=&\$ M)\%3XAQM!X=P3.096N[6OL'SR6
A3R; 0>S'0'R3.P&AFL' #R=!'\$^)&{01 M>#;19\$R0.2=EN\J5)Y^?IXWZ\>A4G''<<)IQ97.4)UUY/H/Q2KP>JKU! UX^6
MU^SVGJ5ZMHKEFTT).WTOUZCP^Z.13S^LD#D)._K;UPEEIG5*A5_).W&9
M*2='^1^670RP9Q+8^/814V3T)5''VQ!^_.;QIT7@C.GM%&3EC0''L.H\H7
M*JLVZ)=NLD=7C<9U@U\>25BQ1AB;.*V3.3XBT><4ZIT3A9UM1+2UUE2K M3.E?7ODN\$IT^CV''^'Z.?
THX77Q.OW<>.(N*%#HSNHX=/ISU#00C1A13C MQ2?7?EJWJTJ.7V0'9'5#DK'+K=
IN9B=J'T8I#WK#55^0W/9LF;^1XY9L%D:P M+G8P.9 P9L."LG_0ES*=%SS5@BPVV&^V&_%?5W1@XUY'IO4V
IP(GGFI M(DGIFDCZ\$.F-6GCKW\GYR_V%RX@EGZG4(*5?1\$2GB\@7@(\$7A3 &*(<9\$3/MLH\$.*S\#_Y E#.W
U%Z<.);T+LL.;>8 !P?CV>L&\$+.(VXR:(W>8)ACKV;O M.5W9\#V&GYRTIYC<4N^QE;SIO%(U=I
ID7X0T!BZ0PE\$EVQ51VN[VY2*4XV M6Y\A\NMR5:O\$Y;R7,B\><1>948WFB9=8(^RO(YAR5V=D1@W#.U^.-
D/C.VT\! "M@E#9X\ MCG''.TS@'\$2& 40&8D8)XW8X>Z?*'T'ELX3'QHK^1\$20&CTV)221>S(V2< M.5 -D2LLXF
J)AZVSHP* &JL.'@P4Y;=/&'0#K7!QFCWT.=.2\IH\BD/&! M2PVEJ24=OP&X.6/W0FV^ (S=B+HP
@!=OSTO0FIH_C1&5V7=)XKF/8(4+C M=7H_ =1SLZV%E^J;LQ52J)E:<3\F>TID?'SM_SD&YT5S_)CD)=?PWWQ?
\$%Q M4+G8H\;5UA0EXWMBY"(?WFMWW=6JJKUY*K10:FJ MI(9%(1:6%UIHESMX\#VT6OZ;=WAE&[26%-
J>)@_)H(GM>">"%Y2WU6?;# = MA;M% X+@YI\$;W U@OU-"9\$3\761#2X&*5;@>KO2+VWNO=-.;2^)NK9:B#PI; MM*
<+EG9I3^NA?H/QK'8FX; H0VMU;E=EM;:S^VZG'E#&CJ@G94+01T2I98>#)RZL'A MCD\$JD5(QD9KW.Q9FZ;Y?<
1^(>_.9^O_.;@=!) SZ^?W#-WS9IX=/WS97I>+6 MOLMJ"(5?-
1#R)%^I8/R63H\J(P"4.%C7NQ@^@LWJ#8L#JFN;S5HJ318 MZORRIF CRE;'141#;_A(8*PI
_RH.9\$<#W5=JU#*E\I9VW^>S35%>WMH(M(2G9UEHVN/ Q@Y@U9XXIS=6Y+U@F.4F4 DAPVE;2V@; /2VU;+ =
LI4BI MH=J_#8S+%7'(C-\$\$.H/@ C8\OM>73S4WF9LS" T"/J-H=>SSR1Z3?5\$
M^V"E*\$VZXBZ#+OF+^6XLN;VYZ.OB%&@%WFB?J3IWLRL)7M&(?AA'/KHA4/H
MYKFU#N>^C^&JL4L>IKG'=#D'<;@)63IQ.TIC 349H/5<&FH@)*=X*T#>;G; M84;15F1+HKVANQL AE%-
PK>WC93<69PI2H.^9FDI3Q5K/&H@Y=I2IU%6'S:M MK3S)Z.N*TLJ3M+YAM#;
I6>I;QNZ3W'.7KUHL;O476E5.H8O>7+^G\=E>IF\=MMD=2<\$Z(IV%.DZIW\F;#7-KVOJHOP(0)QR?J
DJIS^VS+N.OZ1=FG3W_F44_#S\$#6B% MZ5?+8+I@ (BEK1.(Y;3QE\ROVK?D9IW6Q*=HUV;ID#Y>Q6-4D7PMTV-
4JH M@G)02;@ (IP92XSJUZ;ZNY_H>Y7@/EM9R0N2N\0EU4H.;.'*U"J1M_Y0 MDT2IM;8B\^TU?
I4"!!"CYL*P%1SB?'D6?;# \$U>J;WA.F-G.&WANJ26N\ M6ZGPTRE;\$?&=?9?G+J_OW#S?#^2 XCBQ<9*V'U<^)%?
LKWE"MQ;573>V5'U20.5W&+/KE>?A= MF"2\$9K-\$-
+>ZZLVCJET+S.Y.DT7O%A^&=%SHM+7C2ZSXL6I64T;%RV\QB\ M>.Q:SN?GOBB?BG.
<<*\$S8CGG,ZL9>@C1;IYS\$ZX>D+J.WYVD+ MT)X%_&OOMLR6M\I
(J1A#WM>UF67MNI9MW#+CLW7+U\;NW6U9EW''T/MNO^%NR6
MN7BM+%X(8)FJ'EJFIM%MD;SKL(I#'#87G8>9'D)\$ #6I(S I=NO\$4^QQ5KFS M35S79V7T9/1C;N9=.;=3@=
I^ZNXHFL;ZHUU/;LUH\$29C\?6&YH_G_I2--^0B:6^1U 6SS@-#5%N
MWO(ZH%)LWJWIE<"LIHUN^V\F(LPL;B2;5WLSS#W<\$YND17^IYO.W''<^:G M(4D9\$F\WI;W'E9K>P^#-
+^WJ'L;S=C=O8\$VH.%F1SP&Z=XBM+DWX''I(T.; M)O6&EBC)W6Y%RT.=L).Z3L;Y-[0%"VC\=
I@3\$.VNIT7RM>.)F\>HOMBL> MU.EQ7U;O0'G\IJU>I. RW&_)8JD+5J<&LDPT3;/3DHP??R\$F79;
MF+%6J\^3P;I%F-X;TNJ;IKN.8.S8IQZGVMEDZZ2?X>Y&I*U.4?O83;HR\H;
MGRD_N*D@X8I;0T(S;)#7>9EEL WJLZ3 MEPI9JIT*J=+5F<;A?VYZ\J3;X4>\$TBBFY0I=Y*YKJ>3>;/G*!"S%
MM)D(WK;ZSR.YS%KK.W# MZ (8\1S(R>B)TJ'^)L;UP_#MVG(S7N@_2L>M=[V\6\1&^SPB)=GHI
M;07.Q*lw#7.KNPN6%8PIC96\$E8\@P\85\6\%)1\$AT/6NG=&WM/GMC-YZ0 M4FF3=01%QEW80;3>_3?
3Y5.ITE.Y=G-432OIDWNJ?4'FK;I>L;UJ02/5\$<K3 M9JE,+F9H=*>NC.X942(OY''Z&K")T
OZ,K\$9;YMWXAEF+U+FO>F/ K2%K4% MMN;J"W28IA4>;M17C_H52?
A=0T151H6\2X+EP\R1/41;.Z#XK7_-5\+I">^&RVMD;!=AB' 9 MB'\$Z)MJKC M\HN1E N;E\$S)BK#;
I;F+LMEU^5Q5K-I9%;MOU_-1_1QNIH>F8O?@UNYZ' M K%1.(S\$KRT#R#K'4\YMOXC;3C@4IU+?I+F19
ML/8AEM' MJ&L\$.^T\$L.;&>X%8VYHP;RC ?>GIO K2RPIA\ P M P-M"C>?3LBU'4UL#A\U.24BIT*=?DS4F=
(^0@YGL;81HSCX\Z43ZY=RV9= M&W@*I=VYX>V\@&<<%7AJ?>!MG(XDIP)48&1CIC?R?8(2C;UN\$+G8EIC"4B
M698I\$76@3D?R2-5.8NK3J;(INOZG9 \$I=VYV2_+F<;>FHO#=">(GQS_'K M.30="GY>/PHR\$J?57#IYR\KQ-
I8>VESK>_&8^JL^6J_XF'QG3>I3X*83'YU M\)'C.I#P@L;.'I;I(SSIO>N?V265V/X@K4@D\I\H_1#?1."PR\$@.2U
MANE.A.15HI"128QF1P&*O8/%<>Q&2 MV_27=VFLA^/I);
WO4L>SP*L;K7M## Z0Q;UNQ=G\$LTPIJX_8'P22A+I\N;D
MZSY\I?VYY;9MP;Y7PWZTD^9\CTRPOD&@5F03H+VVP?+FPY\@R0CHGP*46 MNKZ/9V02N^1A6@5GC_A-
L3T32S\LB\$ _FB\$0>0A(IDS@J(*1DX1HO.8=:0(M"4KC.OP7'A)FCRIH0+IQ#L\0\$YY;I#QE)SSE;O(4.R7*?
P&)9\^&#>1^ MO3TCGK*LQJO;=5G*T\NZ+NUDJU>D\J ART4FMCDB\I(C'+ID)PVES.BK2Y*2.BK.>OICP65.
MOX+8/VY7B/J8 .H3X.D^#@(&)B)7WQOS/ZHG;AA8H=X1I15^_0\O\$G\\$.IV_'^@KH^/U'I?E\I'X+ J61W*%A9
SOOU\$3_ MZ\$J1\VO8*6"-SUQNI1*HL<7M^GA6*L\(?6&ABX.U#;O(A;S_-2^:IT?F>+JSDB\I\H(TS) M&/5
_DWNFFV\I4\JX;H&87;2<+5E-5>X;&(RVW=JA&>YTWJD M83+9P>H6>P3SBJ/6BXI#ZUB\RXDB\$259WPC
SORL\$YJM+T.M9LXU81;L&Y& M_% W-A3E.M\H;8KRW(N798R0);E-A Q-8*E64H/9T>C-)L&LG\$1Q>0N;M1
+6(>07NS-C\$68\IIM_E*^XT1O2(%L F;A'4>?A.;IS\$/3&0??IRT%WW\ C MS\2+R;? GR.U4.3^CO/
I@&D/CP@)Q3;_G*B\2UC.IK^YF2_.L)>_@\$?3G M%4%/XS16X?/I2&)M?W;%FIH2YI MHB'ST'_.8E?
&8KM'_UMC;6TPZ TU718^XF#J#JU5?I&&E0UD55;FOEN>Q61T\$T"Y%U@Z 9 "0JHCZH"L9 M-U<5@_6A0
WPN"H>;W&;O+ZM;I@TU.*UOFQ1>D+8A288^0.PJHX.%3GDI
MQLSEV91M.K.*S#S01%UIV9_4D0BIPF/@#1/B0.>^I2<%Y7T.*W0T/*N" YWK M5+C16"?X30@8^_PDQ""
MALXO/2/M_Y04HMD0;9W2*V)%%0\$N1\$= SW*VE(O6++KP4LG/-W>M'DN\ MH2 F.\$@0(11/=1'?\$-F0U<,QGW
RUD/H'7>WV7(^3 M0DQIP\BJ MH5G4^7DEI90?ZAGF#^>+085Z_O06'E@I\$Z@V.TO7(AF_3<H)H)Y'D
MEIQX4/B8+V\SK04C.WHA_XO)Q+>Q-C\$5X.POP8#Z^_ IPKY@;I;U9J'T4# M9(P/QYLI\BNR;4+7<@ZW
'C:%A">#I<*U#15QR\$E(O:%>E)G; MNH8XY\$3DWE M*L9664%0Y>I%6*?FROY_&'\$1MJ\)^?439/M.E\$F-
S\ OA66\$Z8B<35E(9US62; *E2?YI0TS*FIF69Q"KG\YG.V3>2.LD3V MQ(IL\H\$;RVY8S?JH@Y*DOOR@^J@X-
J.^"NDO.L/"BIDH MRI@Y241@M?2/M.TSCHZ\ 3;79ZF"TOEQA.\$7!@'+?W"OU8?^J#8N;I^2#D-
*ON=#8).>;.S^27I?^= \$P2/%Y9IK MIF#R-5C6V MOI_0)X\&_@*MJ/DZ4EE?_I4F9DI\XN#NQ;F+WA%6S
MJS0@ZNR3C#KYZ-\$SP2TEDFIQ5(CRW%G#U31+K7;04.75;MZJE M'^HDL\$1.8.D&'=HD&\&(\$A(FLJEV(*Z\$ M59-
%V;R@8MR<1RZ71ZPF@)L51H>S_-\$T^_UH0+IS@F;GS%YG<_ \$T"/Y# = MM-Z0UL"2WW&&XQ0SX0R3_OLP?1^>)
PA*^326I''%L=;*J3NLI_V2+IV\$DRSD).4JRHKA01W&U3RB325J''U\0%V.4AK*U=
MJ"Q=;LS;+B\3.C6V\8UP^SN;9LLIX;2M)TD7GW?UD\$ 7B9HSN (1U9;.L\Y
M3J/D2SG;E=L^VZW\$25=2J%!73L)*LAET30;-I'OCEN-@RH#JD)Z=7MN=)P MI/6&FMQXN\Q1='DH;FTSPX_46MC;
<.C6W;O4 *AQRO#EH#J1+UHV6_%)'_14 MYUR.=2K&M#OALD.<-PANDXP\3E>U#;.TCM#M?P<%I.@0?
GP/U<*8I@?25&>>1R><0XIKY' M4;K&(#S8ET>3-&C\H_2MA(O>0 .8XH33JU^JS27OHL\HCEGRU#6HA^,=
MA!F\I.T09/PXYE;"X<4\UV8*O=/'J'KPS1<'ZV&I.^D'1!APOK%

ML"5CNUFVDWRIL"6>FORR:#3KKFN!XO@1.1&WZ
MQ>KBL0<#=#+&3*+8H2I=>Q/5,BIR'K&TJ.^KKD0C@D"TC7&Q19-J0G%:AO#%H M<6-0LXW&H/)
:Z4QZ*#/'X)>7%-00BIH2%?.S1?"-P+*X&.(VH#*F,OO.)! MKK%-Q!
I{(P,"CM*K8G1,Y/#-5WJSS.HU.L7-.BOWQD4D,B#"-B\$*PRP*=-,% M556V1Z&9;'-1^B&^I5*[W"+M=%SX6E;?
U)2ZZ%7I>DDCQJ?Z,Z:62G=&LR;M71N3W)=UHV-CTON;I1L3%9?25NLIJIACTA2S8V/2^L<-3QU<4Q&?V!9!N3
MUE?-KN%)IP^,MKKLMCCT+RWQC&A#2F1IK,M17800Z32EZL,M*47L0KV(H'W1+1 K"N(QP.(LD:W\$@G=
MDHITL9>IKW,*4&V;+1S/G+(?*)\$I5A^UT<7>B1>'N\$:8-^!^D9W3T9_RN>
M/-'SGP1^,L+N\$LL;U47=76EL,GE+PO(!=%Z<2LE--A-'GIW)ZIT %I
MU#U1OU/@G"/=H_\$%=GR(El9@+RT8ILRS%H'HJ,9@?E!&9IKAR!W>IXDLU
MF#S\$T0(6!_V7:LCQS5<"YGP^=8-ICG-ES3JTJN.-+!@YG#RNG/706-MVJL!S!OZG!&^&H6Y@!)I0T54^8@XB
ZX@&FIO6&IJC)"?7A+O#GOB5*,R+M;M'(>=&K,L-"O:DL%U)L?1*8Z,3*XV.73;F.O\$S\$60.5@.@\PU3R4J"(H
MB@XEMCG&#T\$S&=N%Y@S3H-MZ(E4ISSH#<!,KHQ>YXW5*2F?4V/(1MJI)VO\$&-Z-ZN"%I% ^IN=I@N@TH6
MJ?W",<8Q=K3C""WI#2UID:;CJ3CN+A=WHI'Y"!+A0V9RG%U3;@Z>DJ.KG&U-MR6%VDA;)74?-J>J-G<@<F<
O59.)1.;Y=%5;\$XFLX#336)*I+LAI'\$F9O-MJ.7DT/\$B.I-1!X,ICN2N\$!-3V2.;4"\$GNZ%5IYSL/6"IT:TQ3C43GPD
M8?&(SFO\$UW&)&R>!\$MN;%OA6/L&C#6FF/%D&O;(BRV7@OS(%W1L IQIF\$ M(8-
(UQ8@VJG&!UI")0^%JDV/L)\$<2ADHUT*Q=^78;^5,PM/HE3;Y>;E=-MCJ9.GDE4%V75SR0,O3)I\$=V-B=I?
CW\$%;76>:Q\$#IZ*E5HSLGVP G MF/D+WMZO TF(177D\$PEL6R:\$@^YXQ@I ZHF\$U1OJHJSS M*,-KPMTO#B3;
<9I1U079-7/(TPLCO8-K!XCD1W8;)S)'B.1.EY1<+>W7*
MQ-D)=DKQ1/CSBM66B<IC#-"UAZQ#7BJ-4.\$;:>VHZ%T/G(&ITVI #+*,W MU"V) ^N*@"7*9%A"FR37B-
6+N\$="TD@3(LK18ZC-LX2MK%#E;A>Y-AJY;# HH>=>MLLZ3%)X\$3#4!"ZI+JN'I'9:<&ZK;FHWG+G0')?)@P'.7>,"I
IGI*4D=/DSKE-M O'76&?AL^Z/'N'9R^J-5+IY&FOK"->N?9&M*B#\$VO-DK-MHR1BJD4?@PN@J0^=CJ)
I5O9FI/81Y03*3XZ2HM V6*E!";Z/LKP;7BEV_0 MOIW"/I.B=-,=|B|=^E_(N-PN;MC;*HLG"@WE9I@T0+X6N.K=;!
M"35,,?6#!\$2 J):3<\$ (OO86IRLIR (R.P\$O@))PPP^OUJ!SXNH".0BVW2+UCOZO=XI77WYIGZYV6*Z+;0>V-0;[3OL@
M&FN'T@9>H@&3VRPJXZXBIAIV7C%0X
M.#DR=PDC(37.3'4P\$A(@V.3Z!42\$M(F\$*)"I*83F;YB!T;V>;&3\$ZFG*D\ M-
EA(=#!1,88B+Z/DELKCBF'13@YU!!.#!;+N0<+GDYE&V%@RPW6)H@S0'X M6N.KO'!(52LGKI"
"!I=4=C\$U+M\$(< BKL;OR(5)F?GD;1?;
M#U(=#!10IS7S)-E6C<IY'D@B>JG4BIDB/%@!0#F;!=CC5X1J;#3"&DQJH #L1;=EJ%I309=JN@DJ84QW49
MB"KOP40)\$8D^@A)<*Z91A?"/+OJHO%50%2!S.UOMI4*NMP4:8*%!>!KC;-B
M5D&G0=%H_@N&;DH%;8=)C\YEQ_+!74?4DT;6#*3<)FF#E?A:XZNX=C/I-MF)Q%43D@JND=C\$X?>@MT(
%W'7%74(Q@S\$Q60!\$Z)ZXNX1;Q:D(CAK(!>.6-MN;"R9Y #O;
I1*R(73#*DH_*X9W4"TTZYLTGVR\$7PC#)@"P#94QD#IBI@"S#-MA^4"5?USZ17IYO'QIO#-
N\AN6"UF&MI=#VU@JE)OS3+""^RM155<*E@Q M3""_SRP@X@!1L9<3*X?)CT*B'3-GIEJ&6RY.
<I@KB/F+B\$+D0R4,5%""J+OHP37BFF:MX3Q"F)7EYPH'9LN%,,E+X+NK7"PY>8!\$ZPY
%IK?47#JF%>YKE3V%IOUQ%U+X> \$#DR.S\$U""#B).Q.<1.3N'8!J%A(3*>\$@ M3_3>ITPD8=HI'+9O9-
N%@S.I@OYXO@<2#G0P0<(!"8' M^Q-NIMY@K9!M:'LM!&U5@RLW_9E@M0'X6N.KN&IP;IB!0=-I0%13;AE^K,3
MV8UMP%U'W-5HF.3" ""H.Z<\$U<7T0D1YR(X;J-3-/T9X,&^KS1*Z(3-/T M9VNSIS^#)H(^8?
M.MN83IA*E4B)&Z>/M"?D&.A3)& 71-U*":Q4BMWR#LAH MABV^89G3!&_>I+%;""#>T03F&ML;EYL,3;#<
'RM195I'8_9@-8 &MA(IR= M;T1^I)HCFIUS+YX.O-C09S'3&7KRIV,(8X*AAKIC\$SE2P5IQCI-#4*TH
M/<;VK;R0QP@B>0RMC@T_8A-T*)(QY5I(OKR26RLEL,6F-CTO!2Y?9JXIO&^MOWMWML?
@ME;_A>3\$Y6Z.L;W""5&31.L8P!?:WP5!A;KI=J/I'U'@#L9J MJHR@YTNS"5 ^VM.X-5(5@0S3-
9A0^/55E=L67_LJF9CD&J.C"K;2R"6XY.M&2788U>\$6,1_\$R3&1UR/+W0M-8;-_*MG=R'F&8G/6(5A#&1
EIM54/P;7B-M-SK'JO.2-ARRI^IG3!>WHLN587IO%L;PIV>11-/81Y;94\$ZQ'%JK?7U-M\$#?7>G1N>R&%F,
V/0'E5B:D"@IXN&QJS NVRT8@MW.OXD/OJ?_?H"/#K" MKKJNB\$N!=F&RGXR!&1/RIVL2!W48GCT*POXFJ
(KHB!@BL'I7)KAL!311U-MQ8ZMK%# (KJECYW+;11%D*47%OH0"%AL7RO%+6-AI28JNTBT/ /_!H!T!=(5-M!*Z-
LJW-B.5Z#A L90!?:WQ5MAEA/IE&ZU"E'L;JVHS4%*X4-GO*++CKB+L*
MX0HOQ+RC>>QGG+BJ;2N!D#@V@5D+6^%4IMX!21XHU="5GBAARE/N(:U@E,
M.UW%IHVLC*OP(D5;1W.B^87D!1V*C@8U8*T^M%:16_-B:08EB=HL4D_P6;J" MV5HA2")BZ-JBN!*#=&FV"M
OA:XZOT&TOW# YD_V!!!!Q@<CI;VL9)VEY\$(W@J(CSD&(Y M'?;U@&JKM\$KXARD3
%J*0!3)\$S#E7K7RVSEYJ5+X.4=4W!B4J"!*+;B=1#.(3OR\$#0N!GJME)!EIN43;"H-RM54U ^&E>9HP MH<
8&*OH"*1-G76LOH)3MPUG)7M9:E9V6"N(^JYR.DOY*\$S-JXBH;3%>B5-MI!4Q\$BJ9537Z?
+4*FD@JB>U;VOXED9*G_CAP@_@\$'4S.GH;-4,->PV86"/CCX>\$;ZX3@1-M+H6TL(J-PB98C "^UO@J*",^#)@6-R
MM3-1.K5>Iz.6V?T# %Y'X+6>@^VU2FTK0D3?=4I8E145SYRI2+N"L5:60J<0
MKIR5R#9D8*IKIH18"FU!4UTL04VI>R0H.EM%L&2QCD*BA3I(3P1!J?";Z5-MS'R"25IY>^MU!7QKTVVV
=.)%7%IHUL>Z#"&RCH(Z)\$DI!Q^" M;404+T>*+!;8S4&-L7;^I.VI^Y8*J8IV%T/25D>8CT96=\$WA5A\$.8/T/HI-
Y@X*HCKBXOX=I\$'(S@-MJ(C%1L\$O3IM\$YC(W@S5X1I6#3B&L'I=-!@LTD70*VI>R0O\$'FP9@C/H?ME\$
M_(\$18KN&C;"5TK,1Y1EF9?TYRH'94B!<F?R>.N"N(^YD3L"VY29@/FE.F*N>CK>M1RHP;^,R
DY5H%="9<0T3ETH#"H*=")F/I1K8I'>?2-1AW-1E3&O.YZD*MAFO%1U!=D8ZJ?>WT".0CB!Q.8QM584K-
P",8*4"^%KCIW@ZPJ5TOT0A'B'J MZ2*<7N9*1(5T!"?P;J0CG\$GEH,"\$U>72\$;/7CS5:F;W+P%CI'A;?U8Y@9;<
M/H9\$M\$CG!%8-I>#5S!5;H/BJGJ&P6NY9\$=12I%-007\I_M2JOYAT0JX4,0IN+H6SK&WRY@=,\$RPW-UQI?!7W#X
%;-6N0?)QOS&K4 M\$E5WG,"I+;E#=#P%,4RVQ)A@8-<1=F5=Q8?/U(#@*1AK)2J"6F*#!L-OF+7
MQ0%0\$#9KZHFFGJMB^E14;'!;G1^9QN3-19>F%I!F#(2KX2FZME\$@?87DE
M)Y10BJCJ(O4XGZDRF*T6HA.7O#FJMBHCE!M63;"4-7RM155-902T4@=@351&M\,41^DCN&/\$77N3L?
15IQJML#EA515D(.X*QEJ9C"B6-H&87R-IKIFKXC) MB!(T14733LQ?
2LK9#*B2H4DQB*409DB&;C^O9*;JWR34;7H0Q-U'21>IM' M*.A#"HW1/HW69,1R,I)5C* KS6^JIF;-8&MA,J)-
TQ5U!\$IW3MPU-OG1 MI<8^V@M@QPBIFB8C(D@+QHJ9C#1,8?0GNL4#4IHEI\$9\$3!U!=-.CI%I(ROG
M,8(OJ8SD5%-8)#+H4*3F7YWHRR0!M6*9R#@OL<L8X!\$!A(95"Z.HG"")<MGP*="0S@:XVO6AXC"-7
%@#CO'F3U%3'&W^I&OPUQ%WK3U&\$N7>""^R/O:P MZPB!"XS6#B*UB,?
N!8SJHH@TF1M.R5<11!^H4GA'M8+33MEQ?M MK)2L""ETH4*K"#(THL+\$@BJ8Y4)KA7+T(4E*K-(/;C=
(0!96;HVTL*JU-M(B!8K "^UOBD)BND &K(6LD*8S"@%I!F%PXIZYK)JF:9L;ICA%W%T\$60
M"J"158F0YH4970VNRDCT.L:O2(B0UK U!5..SW&IHVLD,>02^ (U"HG0!6&* M9-Q4)S:36RNFH0NJS<5(O-M
P#8.5>7.(2)#_1\$!?!L8P!?:WQ5OJBFW-AO_8!L(O+GZ8-"C1 M89D5=^T11D@?I8W\$
Q.Y?ZUG;C0@K%6'D+I26CQZG&ITB'D-P-053#L1MQO;
K)#"T"IEL(V)1F7(8I"A2,9(M6\0N;5BFL<(1#T7J9=YY#&0QZ!R<0QM M/88NUZ.
8;T#^%KCIYK'T.6&>0,P#H'5>W\$IU;0-W'7\$77;/H=W2HEDCC(\$)MNYH>OR-#"!;:>8RPS#0(T8\$IUNR5\$1D1-
/5%TTZ3L7TK*V0RC\$BW?B\$U\$AF\$ M*9(Q4GVD)K=6+!,9+H768I9Q@")#0RJ-
P<8UN38@/C%EMY<">IV15UYGG\$ K-3%I(35F5U-MQ9;MRZ;*9:6/Y<"VIV46-ATDQO.P;'5.V2MB+(R?
#TLIBGCQ-9I&HOM M6UDI8Q%2WU@IC\,R%I0H>AL8!PK91('R=X92I^_>YEXI\$G1:I5WBD+Y""^

M()WE**QLRC7D8!@S0+X6N.KKK.P2X=XZXY+8L 8&+N2U_A! Y4
MCLQ5IQ5.XDP%9DUUA5.X5L%*>6*ADG@5X_S:@J8^+HI+909=N%A3/#%\$X_M?
4>^@<@XF9PL+EFN5*RS.*X)O+BP4.5%Z@D>^0KD*ZA<#E5;8>*3>DF6+(MOM:XJBLLG\$O%HS%@T
8JRDL7&I%,#J#WLF00<3&2+5MVAR.M:4V7F&(^BQ2I^^(5R!>0>5NJ-O:"EJN%CP?I>@7PM<97JTX 9*9/W4(U"H"
MHHzPMMa.GI4*.UC!5IS@=O>I2D!A-Y6&&7KR1.D.IQ:H*C%LXAS\$>G&QU&M5#!GKXQTB#--?IN>*(
-"))TTIKL'TK*S2B(H@4'S0&(RHH4Z2\$.DJ!%PK_M=A\$**0Q5:47JD?TWI_EIH>INS=8K.<7ZI-
/D9^XW,71M#42H=Q,;8(U">I:K MC:^^^8EG \$/#=@#6Q%8\$/4Q:C,&A!S\$G!)K;BK"TY<>Y<6\$5L1_#_9,0HC0%,?
-VT%=NWLE*V(C40_M=J-5QZD;9"CH8*2\$.!*1"GN=,;6X9"JG(=@0C!0+^+^>WIRPTI=S%6P+408_M=|
I:QJZBW"QM@J4*X&N-KJHGH)C=.%N#L;JZ(H8&F(F&C5)G;!KKBNB_M2ON="IE!^N(^RHWN*,F&F?28!,6#&I+-
R)ZM97@L#9J.P9Z<(S8AVF)0>_ME:2-J.I5M9(9L1W3"%T9H6)Y_QW5U/(L&26ZMF7%>C7S;
M!\$7ZY\$Y2=I%ZHO=,?>A3)G!;*400+CDK=&UEIFQW*1M@H4,X&N-KIHR(Z3;
M*IVIUUHF1)%NLO_Q3CYL1=:9L1A<2Y"LO: MV(PHU#I:9.8H3K5K_B?
V2MB,*/L.DQFI0#:.C\$YIVVHSM6UD9FQ&%F-I@=A3B MN(-V0PZ&.D8D.U-F/U>W8V\$K5=I-H/H/N/KH/>=
Q8+Z8RV%T?25&A\$ M46X2-!%B!O"UOE=5H1&%2WU*27YC C#&@;%RKRX^/?A)E=U+"MQUQ%UIGY\$:
M'8PZHFJ>\$W:U=49<3E44R.SVCI#BF\$RHJ&HIN>-7A&.(64*F.EI^P^82.J.MI1M9(9DATZ3N&:@GFV E
_A.XZNNRY"IAF."N(^ZIVPSIEW.56QQOILKH MC#C3%\$9AD*+MA*:=F/I5E.(9RBQ7/VE/I,B7
&'8QD#.YC)>1Y#:=8+EB.MW!(UIT7X&\$6.DA6X!_N'@Y8*P0TVEX>8UNI5%Z*6%6"
9QXJZYTU"+PI41VQTG!*HK#65QJ@*S)DI#N130 MT H1-!H%3\$;RB!#8M;6BR4D)C" AG7GY7>890ZR5
:SM4(^XX*W1B4:JXORD!)%C.KS6<ZJH.G8IE1N.0 MSP!C-56&EL/D1^?17)X3=I U5AGH=9
_H1G8=81=96A%U%K(G8W8%9996@S.M3&.&\$K%+TB*2D.G)3MO9">>GD\$329KVN8P=,UDAEZ'=-,
F3GS>1S:!!#T=G- MIABN5;I+Z"^6!<FG8IEI0I)VD7JB !OULOO^I^NSI<-H;U0CICI>UIME4: MNMP|
<(+U#.!KC:_*2F.IE!\$;Q7Q@K*K2B.FCC91H.,^)^N!JCO^?IT:./7(M7'6?822.5Q<<8A5.5Z!7R&4.G:
(+!X(F\$CJC.T;V9K.,',NL;V0Q*MF)PIZ)OA6BFA#+?LO>(K%&C1>KJ/=M7,%LO1#_N>3M4;7V%*3?NFV#-OA:
MXZNNKS#N+N&I9T\$X9C-7T%<8OW*&-RONFOJ@./4(W/U?247\$D0K.FO@**W"J_M KU"OL+*%?4+KN5%&
BZ2NV;V3;2855P^2/QT(A7D&'DK-U!<.URM<5G<8K MSIN+PBP@'@%XA5T+H>ZK.ZPY29Z\$RQ9_%IK?
-75%=8L'W#S/Y.,0Z,E7M8_M6=K%#_@L#.XZXJZEKK_YRE"YJKK"NMQI_*S-KHBX%0%>J5T15P&16ED=3J!
M:;>NV+Z1:=<53@Q3D\$A7*8\$Z0JD*YI5%52%JGG=Z0KD*Z@K MFV#) OA:XZNNKGJFE0H#?
HA@I&:NL+IU+=I"1PQ6X<1=2UWA#.Y3CLO5UQ7.MXD@%9DUTA7,X58%>(5WA_#%"SEWM!)7:)%I(INA*
(PJ7@<IJD*!@<@XFB%<@ M7O&LKSAAO@FSN_#B%8A7T+D=VL: ^HMQ_H(U" ^!KC: ^ZOL(-I0PV9I PP1@'
MOHJHK/BEU8#*P0/ICKBKJ6O\ KG*4?FJOL*KW&D_K.FOL(G*I KY"O!(MW MG;INP-0'3#MIQ?:-
+NOI*FYL#Q.=R%?200<3Y"NO_K_C0IVS2S96DSB+U^/Z7 MP/CU;_>W-X^8+40K6A!71M584O-
VB:8+D" ^%KCH*J2+4PHS /+&.#16 MIE\$E=7>7HXW'0_D_WLL%I^N8@-W(G;E9-4;IP1TCHKIBO"D8@7JDH%995+I
MU(R>&8W^>K>I!41%D/-+G1206: ^JHI'8OI6M&8N!I)EABJ.V" ^!0IDC&
MJ#Y60FTWPH#G@D5N*0PM1"JO4@JU&=J#6KA03&: ^/ _M):8L5P"ZO,%)G MO!(0K&P_8VN,U54:8>DSX/-?
E.\$8!;Q:<D3O!ZC/DI'0!>1^"U5QLAE98& MG_U0^PZPJZ^V8C!>T^NQLPJVPV8I*W?00>"QMXLU?
\$.2D:/7HD;7HA::= M9F/I5E;C\$2U-CL%40TZ%,GHJ#8.(K=62BC)+.KAU7E.@UGXX-/OIN_NKI%2 M&WS&GQ#3N-
RE;2-:<1R-IL)%C6 KS6^"KJ.9P!#2W@ UD1D1)MZ*WMGP!TC MHHC.C2IV@?
@1TGLIZC&>.5\$1KP5@SB1&>DHV>UPWV.N:03(2(X*FOFC: M*3&V;V5%)(:>O_ =A.J_-B&=0IDB=_T
+4BF2%E=\$0E%ZFW^0R+P6RESK08_M:(L5IAWSL;7%F _JZ%HXI8OI65TA\$A%2'I+IUD*47EA.0_R LD*
E='+1HJB7*SN@G6(X"O-Z*.PDIEO.6\$ &BBDY" MRO3!Q4B4L7/BKKF2D&J8W* @TYJPPNX22D*FSN_YSI+@B
E'Y4Y.TS2C!;+ M0^:L%5\$2TBXT!8-Q*)WOM\$)I(-C*"BD)Z8;)CPH#+\$A3)&TYRL)A@N6KR3Z MBTDHKNKW
2#VT(R:IF 2%JZ-LJR1DN<8!!&L2P<:7Y6:/@ M*R=: 5U" T#5W%4H;DXZC4,<-
DI'=R<6N7JNG&3\$5\$6!%8*Y&A%/8WL%="9"@-
MFD#35H_QS+%8KJDP8*H#T_L_KOI=%YUINDIBS1#I:'O'4&WIB;*(='#DIWBD0IEA.V3_M&JEYIXH@1TGI&H&-
S2BME"LFJJ/"8*4S'H8*2\$.!*1.GN=:<1R(\$8D*+U*O!|IO)_%*P4TA_MKXVF MK<ZYWN%\$>U>\$*NA0)&.01-
I>R:V5\$)R"U4\$@4S%Q3T&L!5"K.*2 MIT;7UF/8". \$7-/883Z:/ MN*2;P1T;HJ*#(W;#J#0
9OIHH(#*=-I4UAT!109V!>R0B+ # MF20RM#J^?B&008>B-.IBXZ/IT5BP"J;#E.9KR1*R-"DAE05Y/+HVH. M5V!\$-
L%:IO"UQEYL1YLJ;O3Y8!_! M74?<5;49B-*"L58VPR=:T;OL;_Q9J<(S? 2-/5%TTZ;L7TK*V0S0%H:E@4_MNR"-49I(?;
I+8Y@+.,9KSL#K.1<(9"&<0N3V&MCK#EVM80+"B 7RM!55-M9_ARI!L!&?
RKYIV"6"PAAX43=S5UAD>B*HPUTQE/MLINE1_B_-WME=\$8\$37W1M%-G;-*"NF,(-*U7Y!8:HJP!AV*TK2,9#/.JHYG
MN&_5@K&.#!6I/\$EZ#3!0+OLV?+@KB/NRCN-\$V298;+>@BM&7)5U%ENV
M+XMC\$Y@UT1;I9,S(F3&' +TBUB(L2=F8/^C;) &4%MLWLC5I<8*9,&I F'U!_M&A,EA"+Z@DIPK93A%JH8A.1YA#
+?#SN_N;A!1U6"O&*IO="(QK;B!*!PC6_M)("O_-XR;<0Q2%\$.D;_9G7D_\$0>(BCV:1#E3-RJ=_2P;ICKB!K(1B@|?F%'A
MP.3(7+Z*.,&2QID)CAJXAFAP;_*I0JXAV@23\$X"ISYCVN88=&JEVUQ!3!C4B_M
4\$9\$R6\$(H^2G"M3KF&CQ^OOIHIS/ JYN;JZ2?6_ ^IO! ^Q>OIU_/?_FK M?/O3K TJ_7;2WCUI+/GD_C#_-U?<
C5\$S=O'M ^=:I3!+H^I8_?_X3ZZ_M>KBJ_>YQ_3_Y^_7I-S?O/GJ^_83J! ^+^GJ^2ASN2Z^?%,MH%KB-NH?0IN?
M5NMG_ ^Y^ ^G&^OOSEH-7I_/GOH^NOY_ZD^O^;ZY_?QIG+! ?UI2 M#:NATH_C?
=1>G_1Q_7I_ ^JW#X!W7/SHK9MW;_JE^N2CI^ ^M+IG77U!L MR9Z^C^ECOKM?
=MEYA^@PWWZM^8OYYK.UW+UICZ=(_CYDWPK^5!QACDP0CS MI5?J*V/#(BOOI96._=#1.2VX7-U!??
59.H+FB^VO/IZ>3F\$Q_R2E4^KF MW7?+I_?^6%6F(_DTP\$V_Z/#FT?
MOJHT!KJK_I^IS/QITN7DWZ_IW_!LT87P6K M\$YWO!>7IW_@JN*IF<#1^ _OOFE9.G_XEX)??^?
IWLKOI6I6L*KY2GJC6I5VY M8E^3>V6E)O8U^5?*/N5:GQ-5@=B7Y-I%14UGBA^3?25B)8UVI?F4")= *
M>\$N:1+DIDS!2ML/ TKO:WQ^<.&69KFEG?X LO%S2L _VOW=#T?O&4WFO=W ME/31>?I@6ICA?Z!US.679+@
M2))_!==_K"7H/^!94R?XOK_JVG7^Y2SR9S>)>Y^+VY=ODSJLMS"E%B_MI_!P;3+_!\$>UAZ?
RJ^NTO_ =_R619^YIUJHIR*3A_? M>L=(E;LO\$B-Z&WU'IQP>OR9I?&C&WAL>USLSC;@I7MJVN0V:5MO@T;_&
MH(6I+I5_X.<%>H6RQ%JF;=I)<#&V0M;_M^A!OSC;5S!8+V8I+U@MU6U,A;/(5/DJ;J>

A?(\$(\$= M(^SR+<8)DNO,\$JK:P5%MAZ%<>EP.#EL8;_2*F KEAIF/4F;."L!\$TE1LW\A* MF8J03(5(?
&1MR!+D8Q1\$U=);=6^:BOIR%I>?AP2Q"V/G=N\5G^V6X;? ML5\LY"TN>6VTC4U%1.T>1IZJF0HM !@
*VXJGH&NG\%=!U!UUQ3Z-2S(T? M.&Y;.Y>+GR5DAC:@J: ^-IL;90984LAG;+!"Y_M8FHB
A=T,%)"&*)/KO372G,+7#CGB%HN4B_S=1J#V6(A<")BZ-KJS%TN18\$ M!(L8P<-7_4T!CJ^I
F@0L=YSN@'15"#WA.X#57&69I71 MRI4Y87>)Q(5) M(IE/Y2_3"ZJ*PP2P/Y44E\$27BS5T16&/USD\YNI B:2,J#
I5M9(5EAS'PN_MZE"XRL6.A=T.#IZ@,=:26BM'+2.A5J.I)(RB10#/\$("7"%T0N3GZMK;"E!O' M3;16_7RM!57-5LQW60
&P!K8BODKFISH=:L'_<=<=<=>5J3N!69T)SY*@[N7 MRUW-W(5!4A;.M5(95@R3D:)?WP&>UVS5T1E6
F: ^)JHK8OI454AE6#9,T MHY4Y*H.@3"N2R MT=7BFN5.;HO +YEM^SGGIUHHJ+U.L\@A<(7A"Y.8:V M*L.6ZT9
L)!(?WQ55!E;+E>FCIT0\$>47H&QFC;#VOE.)\$=G !XG!)KK#/O4 MQD_9A"X<5=69VSAS*=SU=KC\3
#)A=UFB\$Y0W:HYR>.7MEC\$:<7*C"IB' MT0E_-XW&JVL D-%P8ICL&+.\$!D&67ES>0%IL%:X5D;-L_*S;/8L\$Q_?
GMW_M_ ^I&V;G>'0.)XE7YDZXP1(J?> SFX) (@X0%3L4<7HW=C_M ? X@=2<5SBSEAI=3PI\$MRI7.XNT2S*V6\$R-

OL9#OPOX:CG27/A1Y8I4 M!GM=LU=\$2#B T.32/%;0U--X7\$JVL E) (PQ1JX^!0L*"#D5*"/GQT4H
M%NQ#"Z:XQ2P^Y,X=P*L^Q EIA@ME;(65SP^FA%8S%1KOL P:HS\$+7&5IV< MA1?#).>
#E?;!X3SER%SUB(77.%*!61.C MX0U.5:172&CXY&5:1"PZ 2F73YCOT:VYC-.)-BK(X)@0)"CJ8+4YPEH
M*\$\$!V1*JOP3%9WA6OS0T=&P6J?W/UZ>_WV\IXN.;J>*\$,8K+W0UE6UOA MRXWC)EBR +
I6^*JL*+T+Z2"OS)I2",0Z,E7M727\$A0A2U+T:OB)"(S>_Y6HA(7)NZ%N*R1BN:G9!L2P<:7W6%1#3S17*T:&D;
MQJH*B6A3!O@.0.OAI&(R:!*I&XZX*HCKJHKB>B7WGO!)>.*!%I*LL)900PQ3<|=4=*0DZF"B1/EN1?S0E
MN%9,4Q)4&WN1>F;E!+;5@LIB4M>#DU3*3&?4A)<.2KJ1283^4IVG021; MU9022NCTJ"
<=RMDY<5?I22AAALF#*D94U3822E@
MU^B5\$!)^*^0"S.4+?;.\$TD=LW\AV^C(4YU;02(Z0MJ9)CN&>/RZ#)H(TK331VS?RM9IQ%ZBEA\ UB(^09DB)
<1YNH+E M6O&+3QB\2&9?KT?;ZW>/-I;J^;7ZW>=(3ESNVNC:Z@I9;N UP5H%|+7& M5T%|=|0Q@-8
!L:~N(J9YL4*AP)T3=S54A4KV-62/NP97?7%55E5+^,04B+." ML5=0JET;"J1K2F 7M?H%=\$42@.FKF#::2FV;V2%+
(4RBZ70OPT.\$J@0Y& M\$9;GMJ15Y!;J)JH\$S12+^I9HE+96IU*~B6(^PIYWU;2Z?3<\$F6*(OM;X MJF8IE-@
*R%I5!^L10""=LY<5?%4H1A|CJH^0FXZHBKJH8"25G5!\$)1.IEW=D*9"EH%K#&TMA2XW&IM@B0+X6N.KTU*<
_D.DSD1Q 5\$ M@.AR)D+;I59/8IP\$)^YJF CMALDKU(IXBK?1)S@R.-&X92)^HDO\CSAP*S4!\$(Q")H7!QC6^%@RO4)
(%AM+I6^"HN"\$RJ5T\$) M.B"J*AR,J8P2@7N.%70SB8U&M=9#^P@*N.N+J\$<# 6YR(X:B 8:F08&AZ;72BL5
H%<DG6% OM;XJCN\VBFU M*BL"\$ (8X!8L4<5FV+^<5SJ< >&_J" >KALEDMX\ 5AUA57UVM=4X-H%9
M\$QUA%Y\Z"HV9-IS9*^(C);I=/>ID%DG33FC;)R1V;&6%\$A\VF5VMU3%02\$#0 MH4@)B:D0U7Q%?PF(-V6J\B102?
8RN8+17B#Y>|LJVML*6FUU-L%@!2*WQ M56TJA"TNWQJ <0!LVX/+;1"AK3I+Z.IKBIT?HEW2LF(4-GM@.KCKB+N;
R.E<M JMJ)K)7\$< KI&I)K)3&.98-#@6.X\I 117_WAZRETG_-0T2'E ML\FIO; Y8+28^VJPO5UIVX)4&I\$B#
AEB1(07Y)OKP27"N9.7"IOPI\$<^=-2&6%OB7 M=1<^GZXNWN#Q4("L.VI4;>U&+IRI2.Q@ABFZ'(E;A.\$Y85E
60,CN@3 M*;FURI^X?5YU>^OY&&<:IV91@#SCP&ROD)NXY-70M#4.H5P' X+U!N!KC: B
MOB&DCO\$>+>.!44WC\$)8>|M%C @8G|BYK')XY,,OU-@!S'3%W"=T0+Y,<-1 M-P2'8Q/H%=(P2^ZP2+|T
E,,W7#JHULAVY(^=(3 IR1;J"#B8SQO"<#>.* MXWB+91PWU8"MI%I0_VW^!A\NWIW?
J8G9>B^C<G;H;VT<=AR9XPI36*\$U<
MU*B17;JSN6.8ICLZ#7J@L%832D1Y3""*J(S8T3>"VM1%0(#G)DKOK0HJAO MI@*S)M(B&ARK8*^4M8AVF*
(9A=:@J0^=FJ+I5M9H9Y-T0V3'KTYJ""\$ 4= MBI20EN@;+&UXC=|PHE(5'J1>J+|JYN'AYN__V R1-(4#2^<
_JY'8JCN\TL M^2J>H(AAF^Q-2@&RI(5)"*J1D8:CTY@55>1AQOJ868-ZR(#8L35Q>(06@A MD I1?<
MY1H#98B A^<EIH6J+^OH M-XN:8#T ^%KCH0IT,(DPG\+ \$2#*.0);^/ECR8E")8#UQ1OMHH8
9GF/HJ(D+0"4PIC<#V MG6JH\$9!JOGJ?Z/F'C=3.XV @S7BN.@!>N:SEDL'JS1*Z,I(F#J")J=FF+IIE:FTY%68IC, M."!
<@V\$*9(Q(M> 7,.'YS<(JIZ+U-O\YI)=O?KSZ_/IOB#8@VM#XYAC;B@Q5 M;EPTP3(&+7&5_%H@TJY?(5H
R)"J2N43K+""|3L<=>*N1O)H>;DV;XX876) MX(R.I;140/AH-OR.H9LC0 TND:OB'IO/@D'@Y!+S#M%L;-
I+MN0@5ADE) MS\$Z@C(D2\KS"=Y9KQ7%V@B8JG\$BID">3/^3/K 1-%;.%C(RN4?H+ M^29%(O) UF*9(R>Z
_KN;7BF'P4A&56:3>W _JX??_O&-BJ1!;MIE&U5 MA2I7#X!@I0+X6N.KLJH(RYN+184Z&*NJ*N)(1I# C1?<-
<1=IWK;)FEDX, MV3,U@5U^V4W&4;B5 5F34R&43-ZU^P5<1DVI6/I&^QV MFRC01)E;_""KD,FYH*CU;E=)BR-
(+RQK&_W2BAJ^&6WQO#&>H&1'B MPH040_WYIH90B&;<9KYW+SM0\$8!|*#Q:G8
M^<L1ZE0N\PO.8ZPZ8>|V\ M\$;3MS5G+!MD:@%8U<1EA<1HPX5WFS5!9E M1-#4%TTI7<_VK:R0RW\B*2?
Q)YH(AA!R,9_7F5!PS72@G);B2&4IB)@61& M>X _IMF9AWS%OVGH,5VZ\LSZ!O"UOE//>/. M*X4T1MM;HVUL,U-
O!2UQ>WMXP\$HAB\V MUNC:6@Q?KCLIP0H&|+7&5SV+\$0_8 &MB,5*W@CC*D*TQ %Y'X#77&""U _IB# M0-
O3MC5U!@! 5HPUDIC!#5.6HPQ8CP&;_*(R@05-2_W4&-NWLD(;YA4 MO"1.>#&\$>A0)&_1I!2R;V5\$1+29 SK
U'-1>IQ/D-C.%LIA#>N>60T;35& M*->>@&)_ A.XZN:Q@.@. @&P%AHCI'8%80PR CO&X)77&"?02GT+78;#'#5
M\$5=5/04BLF"LE>(23K?I#7-7M%/64H*DOFG9ZBNU;62%/\$56*6RC\$ M+4A3I(2@VA2(X%KE>HKS*N.:?L_1&:
(>B13K^Y_<=CB?GOWU>+U4+DHNW_M;1U%/%<\$P""=0K@:XVO;JXBEAOC<X+;MS>49Z-
<GB5TS>.6.36\Z;M?;?B;N;B,B) O&FGE@/T\I75&\$T14733H^Q22LKXS'F+WJ8U'A5LC<@ MR_*+RQ H1?
3EE>!:R<@N;Q'=>7PP2Q\Z2\ZW3>'JR^N\ ^&Y4+HHNW5.385 M&4.4:T-L)!?WQ54MD&%%NCC<XP!8
9%A!K\$LX2NM<@PPBQ!RT4N&/\$ M7461801BLF"LD<@PPF%_
WN%1(81'G3U1=-,D;|*RLE,D(2&*71&9(FQIK1A5:4R(S JS +PZG4+CY?
T(*KCKBJ+BR4Q+D)S)KX"J66QC12HUZ>-WM% MA(72RS@.H3\$|JA:=@J+I5O9FK X
8U)X180KZ",B1+ "\$7U\$);A6RG"+5P2-M>;6&9?KB^C4&72!T?A.J-JZ"(66"SYJM8?2I4:R@W .!6IC4E=1I0HQ;9
M0ID7D?>-4I6J\$6".B6'2/L\CW%"9+B _V6Z;."(R88\$3LY=?"L\F1E,MCC
MQO#X1#Z?E\$TU@/5""TTF/L7TK*Q2/5S/OJP,H\$X8IG)B8@Y0%4R44%1?HREN568#J/Z2 M%DTA7W*P
J#R3N=T+135VS?R0JE+ZQ;^D2=F.B.14=BI00DN@# M+6U8I>^5DPULIC.)4\AE/9 M?7^7M?H%?
\$83@.FKF#;J3&V;V2%-(8SZ?)E(L9=4*9("8EQ%IM#&9);*U MD5*1J.@B13;_Q=WIXI5G;Z_O;^<KO-&=#
;60S+GEH&UMABLWHIM@.0/X M6N.K;C;#I=8#HS(HY0-C-86&|DQB:0O)FFA\V=T R;2TF+I1K;I591/S8?ML>9"
MN(C)D>+;S5!5M%G5<\$W_1(MOXI)SL+_%?>|OOKHW?T;C+9 O*+QU3"TM%1*^W!QN@F4)X&N-
KVYQ"H16|P"LB8WP=OD8G.Y\$X(X=S5LA?#)#6XXL15 MS?R\$1^85C#53\$2\$=FU9F=
IH#>EVC5T9%1,4#4PI5<3VC:Q0?B*(Q=&?&(" M_0=BLXV%2S72F;V@>HO/Z&"QE2+#+>OTY>.KJR\;CX?
IAZ^N_1&\$T1O+M8VPK*T*YO@(\$JQ?UQI6M1, @+60%2\$U?M>C1_MM5N U;P854C\)-3JG
MP!TCIFK;C(#_*QAK93."BL*ZT4@D*WBS5T1G! ^;_J)H\ 80I65\AEAOG^)
M,8;C^Q>B%W0PDC;CY605'O^D%LPCL,MEJY0BJCW(Q5* ^7C=I?WCU@IA"^; MWAZC;.PSRDW)DEC3 +I6^,KT&
<<@S;_1%P*D@%136<191K)=ZJ7+;A\N=S5 M"%A\$E3X59>O %<=<96O)\$YPI\$N@J;VB&:=#1.'(W,T2MB';
(=)GL;E\W^M\$#IIE X\K+M_9QBBJAZ3)F@C(D2\KPJ>)9KE=O/J;^4Q.(3J);(O5*GN\$3 MF*T4IA&7O!?
MCXAENL;0+"D _RM155WND1,O=C'<)B18R\I0QJAJ67@!H(
M2'#BKH)NL\$C.DXO8SSAQ57NZA\42QR8P;V\$CK%&8OM&P'TND:OA(VP0CIE M;GUV3R?01%)';-)NL(*Y(/I3E-
FPC")O)"JDVY2&X5OS&2R0=<28AS(KV M_?AW3%4376%>6" P2+\$<#7&E15=805J=)EU/E3;.\$8
M!;*/;J07@!CE*A2Y1I=1%T1A1LD=CV(\$5B\7J HV(N+I4&9;.(1<6KA^QOV. M-WI%);(1<JA;2<#4!TPI9<3VC6R|C)
I7H;TS3(1M#!L;@B3Z@DELKMD(C+8GJ*E)/I\Y/P>?KSZL.WUMX=;+!@B\$FVOAJMDY#EYET3K\$@_7VME6ZY
M9*49)IWRFX (\$%63#M+;U\TX"H0!"?P.E@'Z88I SD86'6\$U05;+EGI<2Z" MHQ9;(2Q'HRR?0SVNF:OC%>
(^TU&9XL%T\$12+&S?RLI>K!);,NPO'1B! \$ M'8J44%1?E2FN%H=2OW,@6EP8')DIA(N0EF<
MF>"H@8M0#L8ZF>7ZK?XIDP^5NA;_Q:2@W3H@F0'X M6N.K;KBV2Q^J97I">3UGA;@5D38;'O+G-
NQN.5^L%3\$6VLXT MN5&"IEYHRKVL73H\H5.37S\$Z<3PJ>O;UPM+L;CHW.E&YI#^GS=I;L2%T3-
*8#FCJA:>VV+Z5%=(6)FG54=F^L;UP<_7F8A-L.P?;WP53\$@|Y@" M8 "LA8QP>IBT&B7JBUFIUWQ A3-
+CV2>/R@4W'7\$7=GXQ#."G*M8*R5R7 N M9<-&FUZBP\YCHJ8#.=!4U\T1309VI>R16.U74C%(!?
W^X0CZ&IRI/R.M4(X MXI?AB/;&E# "K^/ M=I?2;I%2B\$;T2)BZ(5HK"K*#=#8F6*~ OM;X^IZ+G4 M15M!
(@JZ@@OEI&>%D7LK."KD8WPI?UZ?BL3<-415Y<(1WB-@Q\$<5 * OW8 M;XS(8\$;7@I4)3M-GMF\$
30:6P9RO;KA1LIK^6\$(A_4 '\$QGC>4J;X5JO M33I(HM*)U\$Y;|H\|=W9L?L5;(/I2I&LJV4L&7&VE-L*0 ?
*WQ57="A%I& M6GN#2G0P5M4YQ-1&-J^VCA5WETU ?/@\#0+G*4?FJ@/^")*C!K8BN"PJD* M|
K)B|'"R8I68H97)S#M=I7;-I+MKB(D79HUS)H@+|^LPI&X^KD;*ZIQ M;ZY(VBQ2I^I9KH+96B\$ <&"L MJHL?
KXTNU'D#U\$>|V!UIQ=4TANUHS2()2#B;OZPB+B7 5F381%%.DQ

MI@7P9J^(L8ARZ:MI%':R3FC:J2RV:V7:E45,S03\$%00Q"CJ8G-VQ"60%)EZA
MJ\$HM4L_PGU_<'IXI_KP_JL:FUXAJ&4)ZH>R+U4)YO%I@M&!(1EIP?FJ9FP8ERTZL)EA>KS6^2IL%_M)U:~4P
1(+J867#SYZ%)A= '&I)@<I@<1>*TC#TZ8I7>,<SFY@NPZPNX"XL\$)MBW,3'-47#TZX)=*~-2(-O-DK(1Z<1M-
SE,GZX2(QG>)A^U)V)AIV\$K5T_%7B M.,R,Q,=BI1(D3B2CZ@\$UXICXD\$K<1Z,;F8%_%IK%2B#JTO3?:QD*B
MW(Q@E4)X&N-KX(MFCX,ES1=0:67E81-UTYS0KH.H"NN:B0:OX4+<:0Wl@\$ MW"7\$7=6>3,_,L:0BG@K%6%D,;
I&I@KY3%D:8T@::M\$N.98I&IY&/QA44&-OL/MBN3K*
IGEXIBPT\$I2I>U%ZG7^R^OOKI^JINWZ+M4*THNUHJH.#%EN,#!,:@PMM<97/9,1!@JVTROE90<1=,U-
ADHMY/6H0_18G#7\$7+QI_3A MS3!%ESU&#QIQ@*CQUS5X9Z1!GFOP8301-?="T4SILWH*20>3I.BC_1M
MBI205)^4":X5OX\$56@CD)S:LTZ?WUJ_YG>AOIU^=L/6+3G%~FGR-&<;D+M9+RT>MAR"9#9,;@LS?SRP-
&)KB!5,4FOA,*EN\$3(IV@W&.#!6I'&Z&&*MH/(CA-WS,4QLR?1,:@!TGLIF*:9@E@9QCS+@Y@,~IL-XX9)JE"10/
I_)M8*IKJHJ8#9,RKW8T08.F/FC::3V;V6ES,;29HT1<0K%0,GH!<=GZPV&"Z9\$M^DS!*U.AO%\$!J>IE_K?
"W"6I>=7IW1TR9<3&VQK&78=_%*TS508M*QGR5>U M E"VW\$AN,8IL&(O+U,;5R(Y*HUZ9DI@-7<:5J4R
2D0I^&\$7ZS9*R(TK5-?=&T3VCLV,H**0WKT05+B6-#AJ@&8J42/=C MDH^O!-
=*6Y1C3I/Q_RYID,9KF#7)O!+D0TICDY5&VM1FVW%AN@C4-X&N-MKIH9#?O4!XM;<%87:\$1ARE,06?WR
!W"7%W69_QX?/4E9.W8*XCXJH')S\$ MD0K,FO@,IW"J KU",L/HYED2/OT0M-.G;%)H^FMN98=(NH4405A>7)I@
M3%_!Q:OLM#@8XI!8N3>5IS8%6B#ZP0F&J.N7!@FZ!"A<>*IOHZ(C.M.#>161,=X<5R=
(9X!X(ICBQ5!1^,15P^@D=K):~KI(909=MJA%?#Y-RQ M#T5^@@XFZMQ01BS7BN6HB_-L!+,XP+,.?WTI?
T2X^N+Z^OD)Y"<:WPXU@3\$7 M7@_3_ '\$HR""\$V)UO81?^KH!_%&C8(P#8^5>5^S!>5B.)F:W&P!X'8'7O">4
M=TN7Y8_Y%YRPJ^XMO,>Q"LS:>(L4BM6C!AIVU>&6!19YK,<6"LV,-+T/-54(T:919@=>R
M+50P""JR9*ZJP@69RHP,^S@L,Q"O9*~8S@ES\$7WF87(CDCYC^U96RF>\$
MIZ,1.0W%0"DA!=\$W6(OKE>LS^HMIS%?WP&LJ3!Z_OYZT*X5!1MM;HVW;M-2J4FI9-L)8!?
*WQE6DRCD&*8IAB!\$-@J*IB\$!<UNIL#0OP.@*O>?@BJJ?P M!2J3.6&7+RM.D+2T=|NS
..F!4IN@T2IK"YGR0C8BNF%RHPG"RF1KJ!#D:(4IGB6CENZ0KE921JITBIL678"&8K-MA6S%)6^~KJV-B.6F;1.L1
!2:WP5S%4!U@_8_!EN*IX!KIRCA70=01=:FWA-MA4AJ!%T5\$2)\$3=F4S%1_:R%Y:87##(2Q#&Y"@@+7:F9?
X^/ZJHO#_+IO:KZ?%M;3S!<N^6GXOI MU_?_NGK?/O3K_XJ_8;?WCUL;OGD-C#_-U!<_C5#S=O'M^=!CIV+H^J8-
M\$?_X3ZZ>KB!>YQ_3_Y^_7!S?O/GJ^_83I!+^GJ^3!SN2Z^@%_MH5KB-M%_H?Z9RG!K9__V_J
MYV_PGY=TPYKHM/O)T/V47NX_D>&?U?>?O?P>//UCTJ_Z^=FWFY/ODH_4OK
M2_!UUQ=,LJRS*&O,1>CK"YGIT>//IXW_;;WHV#YZW#1KJ!VE+>KV^MN^PR<_M<60WMP!2"MI>,G-
^615G^HU^!_!72_W0F_GYI@=+OI_2/WZ,9XZM@=:+S MO=A_ ON_!_?5#_!QW_?O'+RI#1K^3.OZ^#W?5?K^U-
X97RU+XF14HY3^OK MI!&NRKZ*BQA/%K!F_\$C\$2^YKL*Q.H!>1>"6_(M?4V:W)YI7VGIX5_I?6W0+RI6TBRWM,?
039^4NGY7IN_^^H1>H1O/^CI(^M!A?&I>7*6IXH<^?#W=CII^O(G/WWIO&CBZOKQZK>_UX>_?W6XOI)RO#J;
M_!C&L:C?ZV+=7G08Z^2);MZO)O_!^S%_%CIFI4Q>F#A7<NI!_?JMC5=
MC_/5SY3CU3^<8UKCGUG'GI:YZ>17ZDM7^B)X3T4>F#MX_4_^L7!?.A"35/?X,I,B5H!&9>TE_SEI-
QES!MM#%&LB_GJXOD_0^/H^JGK^HD@!^MD@1ZN^IRAIT:G_+Z_SJMU_N4LFGXJFKM+_W?
RLFI7+CY5YNW^@W_=D"GE3A^>HJ*AMJ1<<K!E:6WQ!M_+M<LXVR#_?/5I?>KD-FE;;X-&
MOJ#OZ1!^%~.HERIOIT\BQ%Q8-4#GR-M5764FQ=HL>HU7&M.!@#8Q=KD,J%7U(MP8,1MR5#QZ?"M-
"Y%H^,R)JK3-MVKR(,#!69-PL5QZ)YC!08%KVOTBH2+I1PF/WJ-/L^=P+0S7+QI(HL>+I:I
MQWPXGNZ^H=T,)\$Q4^UR)K=61!6E#_J?+E*:OR95N=M/G-B.IR8')FIP#BV)*#0Q,<=->Z!,IP:7*%0X=IB#^8_I-E-
5\$E1>H1_3>W=W=_G!_0 MOS/'KC%:KC_!S(0EIL=OK:096:XD&PY@!K?%5W#DH_40.97_H_0\$<("KV M=J+T_,%E-
;5=9RX:ZD+D0!#!B8R1D?T?93<6K%,_"3AL*5L/NJ_5SA MP&RYSA0_:L(=AWG2C06#A\$EFQSY*BXH%0D)!S(7
YE6^&@_M/OHV,?)5=J#3@4M8T",5S!6UT?88JCCFB3SHFIECI""RG')FK/@"2!RI MP*R)KC
*IRK0*Z0KC!XFJ4:43:JT+335VS?R;;!F&R88<7T\$0EA=7!^F MKV"Y5DP#N=N%);A5_",@@8_\$F=NA:NLK3+FIU
1+!%L#7&E_%Q+&I2MD_\$2 MJ**0,*F^EADH==<<=1TV%1,"IR9&Y2P0D3,29"8X:&_2.G"~+RXFK^R;;
(A63/1YIT(85:PCWP\$ M!A%D/H:ZK6^PY:9.\$RPY !K?_7-1I@TDGK408.Q.%911U@I3Y4Z5H\$MAP
MUU)^V(SJ<%<1Q5ST=8CR,5F+6Q%0&G*M K92OB,(711N2,H%HZW8OI%M
MMQ4N#P^;X&I0@ZF,@8J3;K!<=67,1IKR!U3 MUS@6@5%IF^#,)FQ0)D5L@K<))J<<8.H#HTV8?
M&MMTF^#3+AYG MKQ!^H(C/&TG&:4U_*"H3CLG!4:>81.8K1IR#Y>V%[JV-L&7&V-L)8 M?WQ5=XFI\$G5-
@B0(13)129.C5J>=QB%N"17/I^-(20!A SWY.7%W")P2)_M@Q\$<-1*02UGHY-@CS=18Q"TM-P>-
\$(2FG4IA^U:V72D\$,TS>'7<21\$"!M B9*2(Q_0\$#APTH\$15.I!H?W?S!V9P_X"E0D^A!K MC:_B3B&X5(J)1M2
J?93"XU@1V=024F)_J.(602KBR716XZHBKBSB!B(1 M^#5P"6%ID#X&G>T4P%
I7H5Q"C&%0>VH5/9\$=!\$TBELW\K6G,)>HM33!*<MB=,\$67IQE?EGID1BN58!4PQDNV:1>D?_?
WA\Z^N\IW6"P\$&=I>'4;Z1#+ MS9LF6',OM:XJCO (3I-
FW86C(&QBDXBVF%R8T1W8%;M(M(VG<"TTV5LW\@VYR."2#I5"LOY"/H
M8(C!#LA/'?)F+!A83\$):^&L:FL"*+D>_J),ZR\$W0P44)0 M;<9#<*UX9B2D>80PBP,@X!L(CVKH1:-=42YD=(\$ZQ'
UOI?=76\$%.EEQ:+0 M\$XQ5U1!2SMR)\$LU_5Y'X-7P\$3*U6,2L\$59<53<24N/J9!\$)1"2(W-UE6RW%R-
MN_IVIO;FO+4W-8+*8<+7@U56Z.@RHVE)EA2+I6^"J8(S_N^Q!B"W!>O,MV2OB*K0\$37W1M%-6-
~DR!@O/O_E1AV.5BG0\$8J4\$.?50K~<*R6XI2.4 M2_~*DK*+UN-
IKLS@MEZ(IUSPHC;R@Q=;MPUP7(&+7&S69H0T V M9(V M YU(CP7ZZ@"\CL"KD9W0;OI
)#)X<1535NA\$5H%8\UL15C.S6@Q=XDW>V5L M101-?
=TTU9LW\H*V0J3AEV\DIV%=\$+A2=;2M8KE6NK3BO/KYU+R=QGI_@ M%B9_+^+A"S*W1/65YAR\$Z)5BR
KS6^BK=S,JGF!254@*BJDS;ZF,PH KCC MQ%T)6%2-P)0Q8BJ2W1S,A:G(CAJ(IV,6PI&_\$9B0*IKH(HX!^,33,%F"WK
M1%(Y;- (MG=S,LEZ"B0@*&,BET:3)%!R:T5U_D0BHUHO5&C@P\$A!D:H>V ML5.HUQN
8%T!^%KCJ^I8:KN4K7B/%K-@K*9RL#+U^1^51(IV3N!=MJ?3API4 MJW"~*6:1500,4R!>H2=5ZD7N@_O_IZ^L?
#X^,!BX6(M1-NKHVN,K VRYX@\$2QK UOI?Q2,2-@Q3,-F?2 1XC*:\$S88KS)V\$!IAAQ MUU)Z,(\$#DR-SEPA0.
(DS\$QPU!%,X=@\$>H5TA-/#),48%#:R3FC:J2.VIY3; M\$Q3#).U2!>0QN3L@=@LUXIG@D(ZHD,*U!-
ZGFI@MEB(3USR;NC;^@97:AXV MP8(#+7&5JWXA*QI68Q&N1I8JZDCG\$ O*N+YQIPIW*Y:ZHC_LY3CLQ53T^X
MB",5F#6Q%5I@5_5ZA6R%EXNM,!\$QL\$YHVFDKMN\IDVVV%5VF^K^?0CJ"#B9G MVPJ6:4T?7%>?
H99P3_2\$4A\$+D;AK:VPI<;>\$VP7_%K?%5/!WA4P, GSU; M&!!Q@*C)=(3W.#/!400?*\$!L KU2OF^Q
MIDY@^L\$HVZ8?M&METW!#%_,GBN\$K(1="A!_@+9B&=M0R#JHT@JH",;@6P\$ MD9MA;&L:0KEQU03+#+
<#7&E_%4-OJ=UPIB<_0,0!HF+!D\$OSR8^~ID\$W'7\$ M74Q;\$ P-3(L7<(V!(LS\$QPU L W!X=@\$>H5L0-
)ANQCW4"TT!LTCVV\$; M0J9M(C*BZO7%X;HRC!M>*9,2#KHT@JH/_OYN'MJ0_7?IO&8B;T!F:\$1C MVU!ND#7!
<@/PM<97W4Y,<1ED;5P-8V"LHHR(J:7Z*~*UZ\$G/BKKR,_%6DJLV MNWL\$N.JI^K=EJ+&L0G,FOB(-
+Z90>JS1*^(C8DI@JE%\$W,,ZH6F?D-BQ MDVT7\$M#-DSLQ303YISJ8G#V+FN5:1I?
MCB(^NI@VW!_&A&@50J&LD(Z)0\DIYW,38T=XLU?"1D2A05-?-VT
M\$=NWL C4:L9'O\$).A0A/K%+5@AN0DI+%691>KU??Y5OOKN_INW M6"MD)IK>&U534Q%%N2G6!\$L5P-
<:7I5,113HHPI_6IB*%0('3,*F3UM\$^!U M!_YEV SAMX2ZDBG>7/^05V6\$7561@<
K&&LE,J28CU4_HJ\$#V_VBH@_*4%3 M7S3M%IG;MD)"(D JE/H*IKB,!D+,A0ID8:0DWQ!A6CEQJ(O6!4N<1PBQ(I
MD*4RF^T50A>7O#GJMBI#EAMQ3;"0_7RM!56U#5242YV.#-EM4_8!;*/ND M_@-Z%?2

ZVP*EPM>PZ\$44993MV"N(9JHXB*TN-!69M;\$; L0KVBMF,-"1; MCLHB'-
L)33MMQO.M;'.3J*C2C&R1HRL(PO+BL@2".A.@@FO%;VR%D(0U5FD-M'N#-.H8.GI\$.5LM)"N>34T;76%*M>-
@&"Y OA:XZNKE"J< 8'8J1P5A-M7:T-.*%F5"%? ".XZXB(EVB5.KJIL\$5)ZZJ&PEE4X9'8.@.,*MM)1+1D7\$@WX2J
*1KDY@VND=MFJDXV.0.M.EI/.7%HA\$=T+33C6Q?2LK\$(DP*9\$Z&H5(1&6*9.SGE;SS7*O+Q)A-%&S1:HI
M4;ZW8+9@B\$<1O+HVTH+4VY^1B!?"UQE>U^D&3=@16!-C,7JEDQ^=RYL,M".XZXJHY^&RS-
!@P*KOU#K#K"+N:XL-(JQ@K)7.L&*8XBCR70;0ZQJ(BI#
M2L#4%4P[5<VC:R0RK!+NV#OCB!?"&0H4@)0;5[#!&UXA?"T,+UE,+H6&4P.M6S#D+RYY=PQM588M-
S^;8#4#^%KCJWAG)IMT;\$<1B"J2NL75H=1XDJ44I@ MU0A8V-28.%0QHNH2C9VL'Z88<2R"HJK*(2PGHQ>
(O)FKXQS2\$%6-3JD<7JA.M::=TV+Z5%9C+N573XHX07Z"#D5*!IGE)-I("Z5C-SR\$R8@/K%AF?YR)_KM
M-!\$42X7@1-M;8VOK&URY=<\$"PI-UOI?Q6V#4!-D->9(***.ML'H)E%HTI M^YJR-7!G"?
L!)JTOH!F>"R0FD;.!19=W@W#"9483L3F% KVOTBM@&YO.,M+N>U0E..V7#JHVLE&Q8XJ5!Y!@&@BRIN*H
(8>AD5)<*)DOX2.41E%Z@DJ MQS8P6RID&RYX;J2BL6TH% DG6&D OM;XJCM.PB^&+&@1S88JRD(CO)RYBZ./
MV;H *C! "LJNG#!ZI7.% Y.E=JH37.%.!61.1X0V.5;17RF1X.TQ&CSZ M9-0T4509;1.R0BK#NV&RHW7'M2+
(3="A2.Y7F(^5D A//89*M-GI!>>D.(9.MHKZ+U"/HYX?-W^9CW?OL%@;C.9?D9^XW.U1MC4.OMRT;
(+E#;!KC:H@R=1M &K(G.>.HPX;4J2#F!UWSR1!"I^.%RV2UZ@%U^V-6@5CK71&2&.TMS;B;1@1HC-
DKHC."DUJT;139VS?R@KIC&'&R8W1'E^_D.R@0Y\$2@FI?XIK.MY;@E_!HKT)(2=1U45NL)W;1W.-H*QCVG?
BJK=\$Y49I\$ZQI%IK?-7-M.(2E.X&/HR!L8I2(CY)W*8/R!#/\$!@M9<.(>UW2F)^12?LJL(V8M*T>57ZO;1#7-
7M%O\$;4.TUA#.*#>CJA;.:27V+Z5%?(;7G74=6C>2F(
M="A2"ZCN4B^P^);*R64X9;06+S>82TB1WTZS7XK1>2&I>10.JV7B.6FZM-ML+P!?"WQ5==K1)-NF1\$-
O!%85;1H5*UE2^!^#XZXJH&(SHDC%#&C.35I?L1M120X-H%9&Y1A1F/4E#4#V.TREB+.\$OQ%-
C">H%IH78OI&M68M?C-66*^MNF=-W28(RIN+\$&01C4MT51)O->6J+6BME*?WT?K^N;T18.\$0MFA^/30M
MI<3!#93K1\$ "P-@%IK?%5>/SV_)6J^8.'1G=N0%3/LS?FAZF,IK!#E'@KB/N.M&HIG&6D2B.MKZGD%DPM!\$L9-H)?
@N&R.0E+Y&VL9TH-ZZ;8(D^%KCIJB=MD&*8@D91%""J;2=DZB'@YP_%V=U0.%Y'X#77\$U*EBF+O#;1CA-
TEI(34PW1J.ML"@X D<7M1.RS=RVH_.8<2;02)V0MJ9)C>J-/HDT\$323FS?R@K9";F\$4D3*3P2T
9.2"J*B9BBDW8.*8ZX*XC(HI"266X0.G.B.#NY>+W261MA)+#9.-8.CREY"J27Y936N;+S9*^(EU-
/P;"FQDW5"TTXOL7TK^0E5\$JF.MBM&=&9W*KQ#&RX/JV7D)18;V.M3W.L#9A#D0W)DI4(VL65B'+#%/(1^@
B#A"5>1CQRI-D"B:YPI>>R<2AFG&M+K1+1#K+N+;1#X3"171H<,>&HV-
&IQ7QT^C%XI&V2OB1+17UD/FCJA.M::<3V;Z5%7(B6J5J)^6.1AJD&(B6\$)OJ\$2W&MV\$4U5-"&J#(IM52/=HV
M*428K192&I>1.8-V-D27FIA-L"0"?*WQ57/BIDR9F0^G.094-8.OFL9"V158.MR/QG%X#7\$7C-
C85VPV1'A10^*^PJ3^2>?.X5H%9&Z\$1EB=HH)K U^R5.M\$1IQ&1B1'874-!\$4FALW!H""0V3A*L.AYT,%
(QGC>S&Z&14QY"&C.M.6IH=Y000JH&@JEJ(=1QR.MC;<3+EQW00K&L#7&EUC891J2996J-
1@.9#2)71R<.&XUR(IX)5C2.KS6^BK>-LJFY/-HR.Z*J.MRL+*87*C5&C@S(FIL;B!EJ_@QA4/W.B:M+M(6R&N\$
A\$**A="V58XV"*CNPD6"(O-;H1BAL*F@9K8Q@&S(S5.M1!%OYLZ.^D0A%UCU#.^G-SJ/_8X3=M4C%"XUAY1Q41.F-
75&4XM.M;7RB1N1V2OB.UR*NNK1!@1R.J"H#80I45\$AK.#%<18E!8DA0T*%(QBB)
M/L&26RL&L&6H%14QT.3^J^D*")BHW!Q56Z'A/C#S&4@+Y>OND+*N23RMHC5:(H.QFD+!L.G<13Y3WX
KR/PV@N-92ZWR!<P*XC1.H+C;C4"40QW6C&G6DG;1K+C216I@3)SH>@+N7RUUUH^&7N=U2.M#-
@5MMHA/3&AJ!"OILH8C32W6XW6(=/8"4TIC<VK:R0T0ABF,+)HQ\$1.M#3H4R1C.*1%GN%8<(OK_M?
YES!OQ,L=H"0:D(5.Z.JW3".4&=Q.L:0!M:WS5=1I);<1!"KZP%A-IQ%2C.D2;5G.74?<759I!>&IRG')FKKC."Q9\$*
MS)KHC!PJ@*10C8C^2@T7@.E.H\$HTR8.M&MB8S3C"3.K#B>M!H.C)DI(M3?1UE>1;7;YB156&*
(^B13I.Q(82&10N1O:OK.BW%1N@O4*X&N-K^)#N:.8.M;Y!H."J*..B#+UHI&
(HK#BKL90IB-P#OL9YRXNL10JJAQ+H*C!DXAFG0T.M&N&!"FOTBCB%:1-/@K U=..YW"JHULNU.(F:FA-)\$
H(C)Z0?0-E.O:MY3N%1K4FSL%210ZD7HE1P""0@J=T/7UBG\$.19YJUY@VND4MFJDFYV""&8K\$).@3(F,KKSJM
9.MKA7;G.)YDT285=XCIX"<16IH6_J%*0H-.J;8%4!^%KCJVI7)2F6T=?>HYP<
MC%54#E*D3NIO#1!+@<0*085LE*0(5(LU6ZK)\$7\$F0K.FN@**7"L@KU2OD*F.MK*D<;<@N#%)-
(7%JVL5)0(*9^>1)8GI"1H\$.1\$N*1ODLLUXH1L(3-5ZD.M7NB1D4!&@LK=.;3U&+;+Z.UQ%X-
3(4.BE;E1W4!%QUQ%5U9R\$1SDU@UL99A.7HE/DMP!>U^R5<19/MDZV=1\$V=T+3366S?R@HY"R62LQ.G(F#(8-
"A2.9.M6L/N;5BF&@.ON#L"Q^1HS!_?<
U=03R@S32^MY_+9JKZL6WN!P.1W#4P#PHMYR/1FIE""5QVFPEPUQ%W-72"3J8480=.6%W""6B-
4Q\$8U5<*>LE?AH_6_1S1^V(4.M1#*#.JH(FJ:9J0V+&1;1<*VJ5^V!RA0!"6%U9+Z.G^EQ.;JX9A4DU2GE.MD)(D55
5H*W5"V%0JZW.QJ@B4%&N-K)"(2NKRJ\$15C41*18V1@#M.MW%UVL0&1P2H?YW2*74287<(X&(EC\$OPU4
Y&I5=B%1&DGS=Z192#2=YTM%#&@/>X%HW+80I%M5PI&D(C'2@C(E_KPIU0S7BFV&01&54J0>T;1!>_CV
MI>^'7(CR#%0N!^JMMK!E!M33;#P.RM155<.Q@W3-&C:RL@JJD=3)I#4.O.MLO.N%Y'X-5(I@4I?\$.@DQ15.MH_)
(.W1"TTZUL.TKVZX6K!HFLX.CH\$@ST.%\$8")T@S?%@M4)TG3NJAO(!.M8+9B2#1<H*HVZH%6VYB-,\$"
_UQE=QM613B_*(TDQ-5%.MV"6IKRVXX13=M91-SQR8#@^W;\$&A@HD22TB321PFN%;X@Q;JL/
K#3.LIOOYR.S!>X=%FM#MLZE/D6.XW.70M)4-KMRH9X(E!^!KC;1V;#S1XA3PQ1\$!L.CX.Q#HP5>U1Q
M>KX'RC%*M\$30!+R=X2F&LP=J95"13%C7Q7HO\$JJN1HZ1W\$1/T+0"MTT&664IX=QR?CJ!&
YOH1H8">=3JHA12GP.Z(2FW-Q8;BVQEZB0NJ=ZAID/ME"E20H7A(GE6BG)+2GQ^?<
S+T^U31>ML.CKKZL!#P^B1Q.6_1M@9AWUEO
M&WN+Z+NAID6Q5W12VIB&1ON\$(CAJ(IV^6V!X_J8(3>T7\$P.S;MI6Z7TF0K5-#4QVVK0!
I"NV'R!N;=&.BZ.X+1)KA6/(0BUF01-T3J.MKV_N;S#8-8&(QE=#UU8L^'+SI.E6%H"O-!#BX4P3.YUY_?>O?<
MD>/&SO>_MRJ!^+_X)4!HS^4&1*#6;N(D^X38R".O@I:F974!GA%Z1A;T!?.%&GDMNINE
MJB;+1&S>+W9M2);40UU#LNHZISE@**M71-T@7<^_I(X%>)<+7LGN2XIAP&R1.MN351@^_X.X%1?MW@!(Y-L)=*
S@YT<09AFM50M-"W3!_!TN4X.W.SX8K^1^1XIASGB!BF%2^MJR.M<.FF3!L1@!7I.C*VYW)F6Y0K#0^
5M14)VJ+MS&7OVN0!#E5P5D9G>(95%>RETAD^2%EYM.L.;)TT*=7K2Z0S0.AMF10W.M""
<0IHA1W5!;FUBF;=%X?>.FO<1!8.<N^X3^"BY6%_OQX>(1^&1>)"MS:0+(8OU;I"NK?PZ49<\$RQK%^G^&KK-
P*4_"L1E\$?&N1-P>+1^V%PIU.M?RV15U)K^0CL%<1XDP%9F6LAL.Q"0:260W?#4+T34!M;S!TFK;
MWIFIX02C'6#/S(.!RD..I@QC71=ZP\$UZJH%87G*K6HK94?IRIW;T<-RK.MYIO!UBS-
;U%LI4*RPYU711;C\$<+JD=;Y"NKMQ@/Y2GMRU%O!<8R>@O!OM^"M7K#&LBQP=IGQJB+3J@C)%W#M'
MH4LN;42+#S#-IG&\$3%17%&A1@7F1^O&(AB5'ZNA88;1;HXYP=(&1'6*.MK13C+@0/0<SRD(44YEP?
FFM#H+BL.KR+P.DS/'D\$.E#JB6L5AAIG.C\$MN0B."D@'KJ:C48IHG0_VJF8OB77@3YE6K7\$B5D+3.NVP8"N;Y?
@P7LZ#*V@MC(E@S!-1\$4IPK1J.2S!GE5HK_3_N.MW#_W6"SD)(I?#GE9J#3#=\$F6%D.MODIQE3.G1G
T.8@!)4Q#GZ!ZE>21U;PFXBD)P4+YNI.MQO"2H\$.18.R!WDJMKKE6;(8GS9G"7J?LO-
E.ZIYO.F.OJ*RP51A&E+XZBK.D0.MZ29P\$ZQE%^G^&K;14F81+/ZNA-
QAK@%T:UUL>*IA.KKU#KKBK+L.Y103.O0D.#)KHNHROHN\$*NN-K>EDI3=(IGZKX.C.MW-A:0)V@C?
%8*HJM)HAZ1/7<_C.2EHJN.ZM79(OK\$P0.ZKP!&%5=^N+J.P.MWQ)HTIPK;AM+B3Q1X0D9HJ)=NIAW>
IESI@L583\$T6&2PIZ17.8F+1<^1M0?7.1X^Y(UB;_1.(99)DH02W>%BJ\$44IYH\$++-9+!TR_15!-ZZ?9T^
M;2.50K;P1>;6*B>A!\$@3IR4.3970M-1)S-.*YF^HFUZH1.2?XTQCC3\$.FP>7_U?>X'FLUARJ\$M(=;
1&NJR80B5.G0UP;(#1'6*K^3"0;-NL.RP:40+UA(F4XJBX;)U*^<"K

M" + P < 0 < 1.5.5@UAM893T! + G(C@JX!2T>CH:??38=+!7-7M)G((L5+3,X:+ M5B4T+70*
I>R^4Y!FVXP'D\$&RI@ (Q@W1MZ \$URK6*9Q7;E!*,#S"&FL-O!2 MI^,CP-
77MYN!EUBNU;1"LS4"RXYS4U8KZ'2SJPF6%8"O4WREUPINO\$):= @&
M1%FU0DCUBY!%OSL!>16!ET,K^1R#H2N*J%IH5:80Y7-UPHFC)&V,5J! ("P75WY/H4QP;5J-*IP
M7G<DQLKOWVZFE WNW%CO7HAK#Y>F>@>63;I(TP=(^!6*K^K^1>P83\$22S(C M7D#4
D3I7H8Z7%W !H!7D/@E>R/9!Q.S!;96T4Z>!R:X*B =+ ,YR:82R4= M+)HTMC):J%IH728OY7-EPY6=(-R,.,B"
<)RUY_L;6"D&&.-^&KJOPL.F&11,L.@!?! A*+ARL&L!<&3V4%Q"U M %&Z%R= /TZ !ZNN:
B!D,\$&@VJPH;7\$U1I2P5HS9%DHC.)IUX2?0U*;JV;33*<1TAC ME?G >?_R!2;A<;N ^F9W>_N)4.8H>P-T9=U"XZC-
+ %OB+=PL('Q<"^SU^ MZ!P8RZH>G SWP5Y85-FU!%DK(+PL:S%7\$7+R66+JW:9RIP*R(M7 &QRK8
M2V4M7)"OO>@J1:,%EJ+^5O9 FOANF%Z*8XH!%E,-WN.@37JM\$HA"+JM4B! M@Q_V<;L;?>
-3JIV^F\$SU/6S2V9HA\$K'A!)*RPMDD@W,H@10+X.L57DC\$^<-
MDJ,R!1#EJ!*>CS<^UW.,LL^6P.L1B?"B&YP"5@UAM48BPDNHW^WWXP?Y6%[]7SW>%XKIL86#&)-
.^/O*QW!.EF2A.L M/P!?! C*>Y?PH2M ,UGT>\$,PU@)CZ=Z!//4T"RZ?P# JPB\#%I".A;H8!5 M0UCE3D1(OG%L
K,2UD(R,9V!701-):S% *TMC M+213D!50,="(\$L7%P)@YY7#-IE6:08FOCK/6C16_!10+1L,*0EUKP^BJ+6
M0K)T\$ZL)EBZ KU-!4Y+2!;"_ KP\$@F(-%J6D*R,+&Z=QI5[2UQ5!")DV3I M!E:#N8J86R%)(9G'F0F."C@)SG!L
KU\$2H*Q&KXITJ8")D.9O9+!-!\$D> MI"@H,J%H 0=3.Y6#DVNU3'E!7CYL7M=OSGS>ZG86(!?&_M!MY.WQ?#
!_QQWFR^WW!Q8C^! 7ZQ>35^VF>_VW>_JP^!KX^_QO\$+/_62SE@-
M&5;^,^HOPA0X9!S!>GW^!^W#X^!5^ZLE>05ENRIXQ M:LWW^XFG9^_WT-0+;CM^G
V9SW+U>A!DO^WNWV)=IRIQW?J9>O1 OE9- M9UZIDEH:!!^V&X+WS!7!Z^NGH=#Z"ZTL!H,Q!#XS??2AX-
%:*7""27AH8W-M7SW^XX25XN^"Z:OWEY^T_?@5A2WJ=O/F8?OLYW_YW*G!E>,^,^)?
29IK1PUGLPULXK<9Y+D!DQ!+?6G?ZFDY*!>HCIWCUBU0,- R150QYCG9-^2GDMYGS0
M(Z!0PJ/%_S:'GD;>,%YV#X!/_Z3_??/&Z="0G7=7!//3*_ \$KYZ,2!A+_OYZ M!+_U57A#OAO_KG_8O_E!-5#>\$)-
OLDT_6WUT;OCJX!?'E?Y!03?0!U3<3_M;#?H!KHX7'_IN6(194D&)(DT-MUH_LZ>C<_(W_7'M_F^O!R+;=?YR%GEF
MP7MSZ_!MD)?I%B;%^GWXR:#)/G+FN/#X515^%_NX^J6:KBHS"1C16^T8B73W!0!\$;VM_L;3HW?
L_26>.:W98V+7=D&^=W! MX^_VRFU0E=H&#_ZS%AJ>_H4QCH;G,U;JJS=O;K=7_[6YO=VBW^DLLM#O=+TJ
M;UDV_2AYD?059HG>7&<@:+N>X&UT!3BL%=,JR5#!9S@_T M1>:RIT+E'DJMQQ;G/>JW1DKX2FA8&C^?
O9!;#QX)U@_*_M?0_0ZY0.)MQ;!#I^K!37!D80K)&7PTUKCSZ!INX>?>K>W!/*!*@WV-
X:B48U#2&6UU<(\$5ZYN/AA^V^L!<2Q5D1NEL;5UC_L7E!(U!KN6L,ON+(2>CE4#S(199F0K!ZW\$3E8)30NEQ?
RM+!-N&Z0?76^H50#-5.A1Q!ZA.YR*W M5H0^N=%ZBUH!-H;+40P%CSYJ@I.W?#;KGUJ^IB'\$DD!O MDVS\$B
B0)136D@>VK!W@F&8>4O@I9<6!1 2XU-Q.MB<%415VN;-)R!AE
M=,4C.&J\$HW1GHYK.1J.B9!2!Q:K92Z(=H!Y!4N-SH@5-=="T4#O.WH2:0=I
MND^V7!X"A2@%8JX!^>5RC>X5O^X;R*!+!P!54J!>I"-*@2@%E9NC(= MI
UG2!YB)!8BQOED).E2U&@3\$PEE5+^/%BY!FHE^!+R^P.NA)10:T8!_MG0RN*N(J>UA"!>G^H.FDC0M
MM!;SM!)\$UD*U4"ZL<(2E)D2C%FB!UD)KE5!88DPL8)1;1%&ZDW!H!>;N!>+ MAX?M'58+
<8FR=T=,=EZ%TNBOW2!2R,2RG2#Y!J!>@!1"Q"E>L,RZ=6U7&@5! M+7&7Q4FXT)("48F6N%HC*J!\$SD5P5\$
Z!;1.F'FIB,"00<3P9@F^GJ5X%K%ZHI*(Q!4A1:I%_#/_!>=IC_Q!2!RP7 M.A!E;X>^K*P!F(%OG*ZRM,*(?
IF3R!88(Q,+>KS"A74"O40?;%^<-N&XL+!_!W!<(&^Q5(A6E+P8.L8*JPJ/4M 6 M^#
!9U#\$6A+W.7HYF1#!;_#AV5@=;E89;<1 M5N+4!&9%;(15X>#T K-
VD8OB8VP4!#56AR7E<"TR\$8LY\$!O@9(!)*01E*H%IH4V8OY-MPE.=8.RAUT(D6V@PGW MJKRY
VN5:09!DYU7CFIE^3GVX3&%(K)AC60A:*L37#!IE\$3+^4 7Z?XRIML M<";4;J-
0CDPEE,V!OF)ZKX=A^@KB+N2C9A<@JG:8O,98!L!C%9@5\$16> MX50%>HE\$A>>A"1.7B&J5 M-
"43%_(YLO*GSHZ6L3S!\$NA@PKU!H^QAT^+M'D9499%Z_!V^_OL4Y(921%TFP'H3G?T'=Q5Q5!D)3^3#K<%
<1XD@%9FAA<_!^O12>0H? MDH(C71!)3 M!3S-!+9GF+7_9!PZCA A4T,%\$T!U<3""M&@U4&*(EB!3! M!S!M?
MA>_?VQ_-D16,+A5#%FE=#5516*)9NLC7!0@7P=8JOK+)"L6FRM9>' M@5TP!L96DQ5!)?0:*=!D!L!<%
<1=P5EA6+D)EN#N8J8RRTK%_X4H%9"5FA ME,&!^O32R K%;&BR*2W"897 M%!6S_-(%LB*T XX:K(U05@N+BC-
=&WJP37 MJM%0Q7F3K1L+_"QH_AXN!WZE!WM!0/6""^&*LK=#7=A7HMO3;!@ 7R=XBOU M2 G%V?
C<@4H!)331_!T@X!W#-PUQ%U)!\$%SLL6F5MAW(3B\$D#DU9W!#3C; F6_,ODIQE=XWN/\$A-OX1%A"U-%&Z
M5R=/K=W-B0^!A+Z-G)(%!BKA+ M+QR.D!5" Z"J(C!640H>AR(PRF!4)!LZ%U%VWC9Z28R"Y!-/KIG\$F B:13F
M;V3SC8(4W2_L@R4,%>GV<4&ERK9C,5\$>5TWI*OGESNWUW?W^#Q4* H>S5-MT)75"3+=&J")07@ZQ1?
R76"5-U@>?2 0D#4 D3HWM,XZ:9C)YE".XJXJYD M@\$F&S<-YBIB;@W;("W.3"40CV0Z,& B"="W3!_YNQ
M&U28)!T/13L"#0P\$72G!1-16!5U)!T0#I<%< M!L^C;WS9!292\$UA--L@_M9-
!\$DJ9E2F+!5I9(26@3!D3TOASJ>D0LZ&#\$O4!\$8OX!#M:Q\$(RJD/+J:U4 MK)9H<_60LUCQ
LG+F@F=;BXUP&F3"!&P0'1^ HLYDP83:UZJW%T=DV>TG,A)\$3 M30G,!&@B:2;F;V6)S(11W>!!>^2*A;
\$8JX=PA+S!<3KK6P1.C!Q*B!W*+ M%=S\$X_W=#OLL&\$(3Q6^0HJR,.,D&6;L4_!?!C^VP+*F\$DI+4_8S"6TUP8
M.STP.X&N!BV!5!(!E'\$X4%MD+GL+*_.QI@*S(E;#_ARK8"^5U; A^&IZ*Y< MJX2FA59C_E8V?V2%=%U@-
/(4E#\$1C"NB!U@)KE6;(RL85;%;K^BM\$6#"X9\$ MQ8!71!E66!AT@!OEB^ KU-Y=46-
O05Z!W@PD8:X&Q=;17=&C)X^WA1^YP M=[GKW"R&TS+!HFM1=25_A MT@W;!G,5,9?>5SB-(Q68%?
\$5SN!4!7D?6SP5Y&L;Q!WM!PQOJUQCP5#QJ+X#5\$7 M=A;YFD3K!L 7Z?
XRNLL?_@ET_.#!LE@+*>S!*"K0&L"OA:XBZ!LSA"EA@? MFS%KH"6LLFL)+W%J K,B6L)/H5C+;86L;22: FO0Q
!A_\$HM<"T4\$O.W!CF M:PD_3=..T1(\$8;FX_#9E!X\$UZK1&(4F*JZH+=9_6!N-KN'JV^F'SOOHG9!
MJX8!Q9K71%63?AT\$!4)UBB KU-!9783+CR=L" W33 &QE9T\$V^@MNB!EP"O M(? *BHT8SA06V0NM!G0C-
!68ES(5F L^WE Y!2WH!<4. M(RMF*HN(DZQWO70%E46FJ6:M\$VP?@%G>(KH!+0S'2#ZKE"0148RZ@L+!A
M,MA+@!+W2LL;^#1!0_!#^ 6_Y9'7LPAT'4#E!W3AX7)55<&7B1V7>|-!^"MXW_%9D7A&93F.%!1B^)!NN A^!VHZ-
BX&F.BYKB!7%4J+!\$E.-!H.T M1=Q!JN.6R.V58!(UE!KX^!PB!EN8!!7OU_!H!KQNA>VMV)EZH!EZA65G MOBNK-
WBZB=P\$2QS_URF^!NH_/C4?+MN,%83KW!>6B?+&%CT!P!P5Q%W&I%
M:6!&9PV MMPM<95=7""+8Q.8E1\$7+IRG^!)2=1;W1H!Q1@5Q%V;7%9!Y4A%_!6"EC(=5XK/K>6(03
MVV8OB;*0&C351=,R9!%@*TO4&TJ:J3&GUH=M\$Y!H(C.18.P0?0%+<*VX;## M@<\$7!Q;KA9?NGFX>KY!?
!50Q"C^!V2EY4;MVX;H+%#>#K%>^14N,(2*X; M)(N8P&(6H HW1L6/UY9"^.!/_ \$O.L%+T?D)6ZP7(4&!?\$5;R9.
(!Q!\$(MC@K8!R6FL!;PXIEL<2>TGL@Y(C3:H7#CM9)30MM_SMI+YB0FENL&YP^H. M)"H8"(8UT3?
A!)QFC!4.H#HKA+F=;0B'B"L9* M^0K-L+^!O52^0G/0!)KFAB4^?
2QJ<4OUI^WV_WNX^O;MCS_N^K%DR\$!L/_=E6;>AT_43(%C;+Y.197-6AT<@=@ MN9V&3F=J
5U?T!5W&CIT(#)XNC#W1)W.9V&1L(5C!5S&@H&A+YC0!_*J+ MH49C/E;6:(4";X.Z5!/SU(*)!AR+!!"/Z!7@6G'?
6D2#_<N(^JYC2_5X_M_Z0_-W_!W2W!S=8JAD2XUL\$;L!JRS!L.DFIY-L)X!?)WB*YQ\$;L==_/
MD@.6!H(6+D=W@QB=D5!VUQ%UQCV'4!_!918!%!G8589=38QB\$;<%8*8UA3#?X MWK/H3E) KVKTD@_8P%353
ME!CS-D4\$!L-U@^KUD1Z+F&)!AR)Q!HR"-M?* MM!;*_^/WXV_/B6HN4N_F_W6_O=O<+!4JVF.9NL5EIWTNK#&2-
>M@&-_@Z MQ5="C3^C=FE#6X)>Q#^N@+&6&\$OVSL7R8#*TB#89X*XB!G).MK B#!+!%Q)26 MN\$JK*N9L7Q+!)C
K8BNL'B^8&3_L_P_T6D(OB:VP.M37!@ (TU4+30ETO?R>_M/_ 2"FFZ0!O#FCE_%4RXYM!@:D7GPA5;\$_45Y%ZQ?
!OXQ?P<^!^!4*HHNR! MT)2U\$19!X90D*UNHPC!L"!J_@?5(0S#MPUQ%T.%>%8-Q@9/60;7%7\$5<44

MA\$2%8R5A!^A&4A..70\$.X"9BJ@FFAAIB D25*33@54A-2'0IZI".H M4"08\$T1?
K5)80N\$+4C<&UU9C>'3C>\$F6., ODIOE?UDY^ZNAL3 M?T&8RTPENZ=BPZ/R2.^10^XJXB|=4W&9I
I3=-86S\$7%7/V4-1B2 5F94R& MPZD*1%9C#""F_ =21ZL,T\$129GEBD-K=S"6T5<8)L?
G&M\$+=CB!#^!+=G+G&D09%GJY@ZJ&J.JM) S3 M.#6!60DE89AY.C@YV&N;011.PC [TB1]YV\$-
JX2FA4YB E:6)EYAFNR10;Q M"L(4"<:IOIFEN;M3;(01E-56M26ZMO7FIO;1< ?8KUFK==?GB-DL=KU4;*B
M(00#TO4=(%BW +Y.14I+0Y/XJ&' ?T \$"4TTIPW@VR^WO+(ZP)%F@J."3H(K')M
+Y&2X#KTYI\$ "4RLJ@6F9D5BPD24R\$MP\$ M(R\$IE90ID@P3O6.,_VU:B!\$(8RFVA",VE+I?7?
IX_A1'ZL*4E2H))JM05AV MX/R2H*G&D)-L"X!?)WB*V^.,@DIE+UZA\B.9346H:F Z(5"2*P2\8^+A^0 MIS!^
>.,_Y4Q4B#R\FZFR1\$YC.,_V4\#GA'((S0IP51HK!4"&1^ =|/#^MS MHM;+U*B&?Q WTX?^WFM8
HIZ^0H>TIZX4!>)6 M_!1^("F \$+;K!E8C5UWN=Y%L9=-4 MYO!DA:('S@J(1!<=#YR%IV##.Q5S5X!> GFHQ%F*
(2FF)O6PGF9:LP+_M(M#12JKT^7EP! 6@+ #)TZ_ OXC8YP1=4^D7I_ QW:SO\N^QU+@0HQB?5NAJL M5U
<59TMIH?<ZC0#L"AT@D0Y?0**K0-L#T\$Z-W>\$G@Y;02W> TBM\XFH- MIZ T#D9P5, I-# =C9YCN\$3;
I"5Q"BHD3EW/&:(OE="TT"C.W\H6. 4WWJ%4 MS\$|K@K!<6 4^H\X3?0U*.JWBGA%*:87@%)!66-DI-
+949SJ%9NL#EAWENK!3 M2#?*FF!) ?@ZQ5=RIZ!#%|&OSH!1"U E.R\B9YZJ@N!4LR6N"O96DFG&V4-
MYBIB;@W=H"7.3!40#=#HA6,3Z"6R#5I/CY:JV?R"(&JC2+U _/N;OR3;IKT4)MK;+9N8-E);LJZ
M\HUN1C7!4@/P=8JOI*XA)!"5!42 **=K|%.+8!G?UN5+!QD&C4((F=2+TJ_ ^N/F!<;+!3R M"V5OA;L4S#I1D<3+"D
7Z?X2C@Z^C. &0 &P\$KX!A-2 *87"@7"+8&W;KAA M#G<14>O&W!%DADPVG: %T*%
(.&Z)OH(EN%;M)2\FH4UYO+U MQ:HM?E&AT&BV?F9:;>+"@V7;BHUP9H&1'6*K^1=G5SH'Q
_Q!40M0!1LEXJQ,XZ)5"4T+K8J8FX-Y^ E#DUP5, Y>(5S\$^RE<@Y> M3S0I'JU"\$S11=
X+MK!)\$205DQX=-/K"58E@*I32.5MW>3=U&8"W6;16%YC M\$;H'R%ISZ(&+ (DL (I>?G'6UL69*R-
>7@&7!>ZJZ7HT619Z-7>,XV1.< L MK\FP3\$SGIT=2IW^V4I@+R^1(D^ZG?AR@J0;8FIC*YL+R1X!>J%.)R)4-7E
MZ^(" F0I|!;BV4*%9:>|* &HN+\$LW M)9M@|0+X.L57ZC"%9:8; '\$==*"#*J"8LLV%>GF?1G0/ 747<9? \$1H;'ZD4=B
M<^6Y7*V0E|!#.=X"/9 APE-LZ<-8-OM<"5!^VT4LB'3@/,D5!1P-\$TGG,1C M2^0<<)"B05*!R/2\$G0H\$HQ1?;=
<*UBG4-J1>W" A&|@DDZ^VE+|X15FR\$E29>S0)C7.3 MF!71%L*\$N%?5?2K9K!7-7M)O(6P(TVVEQ8!624T+107!
I>R5.+ "=8/L+3ML MP8J!|V*!/G!6AJRF-/I ?I>^W5I_ =O|M|>+U!M@U5;4U!T6!&P!-S7A?5%NM?1*L8P-2!.Z>B
MF^Z NXJX*S@8VIT@I'!7\$7.93<;4N)!(69\$S(94.%6!7B*Q(748%>".S&D"
M3"1A6N@UYFIDH\$&6."6M4QXH(@+!>6N8@>"Z(O6,FM5?Q8I/J*XB7CY_! M7G|@S_?I_>|A?I|=18,@80B|T-
3UEC(=).Q"98O@*I3?&4V%NZI)U%/Y< MLA8#>=RQ8I8(I%KGD\$!+8&WKK.8P9UBH3&FTZ@O;0F|I-!
<9RKX*R.MU!B M!%I+RUF.(7-7A)QH>1X8/*>(9%1"TT+S<7K2Q1(D.I< 73ZO!H1"*##D7< M. FE8%P2?
1E+;L%;C&7(<_EH+UX0:3?:6S#D,=+1-JR=D.EFY-L,8!?)WB M*Z_ =&.^V U>|BCA V0Y|88*;0S8^(R#/O(M@5?
>|K@P;51H)I0";O|=L/C M7-5G9>R&#AE;WSN&T09MLY?;\$FC>#4KU\$CM9+30MM!OSM!)\$=D.'^|H!?=A)
M%K\$-A1OIS\$H(YO8J)*^T7M+MIT9MJ1#;0&R#T/WIE14.MV0:H(U#N#K%|Y MQ8963^7#?#?B05,8:-
2>.,7%A@XFM_IEIS#\$17^VTH@-WPU:|)=^5Z")DB8_Y6EDAL-TH@2&P19 MNK 4 O>.ZH1G-2) E%-?
&#D^PYA>"12M@1>CCG?1HT' M8WS+?7!5\$5?Q?N((1QH'(S@JX!^,F\$O|@I\$23DQC<4PE-"_W#
M_*TLE7!PH02\$^|/*(P0KZ%TIB#O)M>JO7D85GBB>HK:2GUU^+M^,BY^_! M%9MG^Z,8,5JIT-
R@8K3+H)W@2K\$,#7*;X2!BL^#9AE R E; 2EG>#|I6+
MEA+@KB+NBFT%CYGN39"EBTL(\$/TY2O%M=*M2FT/2|LTUXR
MX\$^;AZO_VGZ_>QC0=>N*G_.Q>'S4?&!A;+YKA M;#>\$|9#H!|2=^6-QC3'6|OHJ;3 KB+LLH^|<'XZ514P
V:9G89G(WJRIR*Z MTQG8YJ)I\$|A#Z|\$NF<6SP>5T+30;0631 MF7(PU@)C*2C;AVL!70505=<;(C)WKKXIS/
KB+LL@L-|K;J.BZ3PP2RDT M/G;J(FT+|A+*#(I-###-5!F?W)D<2I?3F"!L,Q08Z^,=?%,D7L.26*YGU%=>
M;QYH|O;ROP@HX&;ITS7Q7U&8ZEZUY L*8!?)WB*ZO/<\$R\$=WSCJH Q.);% M9SB&I-O-
-0K>NS_@_Y\$#A#;0SJ;SYNO"@_MYIOD*Z_X*\$ M06JY=&L;.,-8"8GZ8CC.0 &?JN"N)>Y*YS,<#^Y6I%XY<-
<0=|F=|!23L1K? M10>8-8)9N1-5C>B97DML<6VSE!1K!"!G72I"02YHJH&FA1VGYFIE;3L.6I"
MB^FC#V_ ^F*)!AR+NK?I2.Z(OHHEMV!MQC3.FI327NP_0W\$_.A<(4U9L\3 MC04G6. ODIOE=ELN*GIMXU^<
%C+3"6HJ;4IU.V@*XBZ-)KC4.V!!OOVQ+S
M65KB*KNV\$*%?._B6S4"LT8P2W%L"H%C\$|PE4Q9"8A.K"J: %QF+^+G;*6!QA M1G6#PA,TI@:@:H&HQ>>\$A,
<<#<\$0M" F)9JL0EAWIMJR0\$&@7WR1?>86\$,*D MG=GH=WA@K 7&DA6\$ "CN5!\$GI
5Y#X!7/6@>W7LA|ACKDIK#+|RRF-O*0 DTDQ<7K2Q1U\$*%;5R1%(?MP_C4^KC%)D;|R!-%K"3S!Y1
|K@6FAE9B_D26R\$B18-MFUZH0V%M 4=B@I>L6.M/K%67+06M?C+_S#&SR.DO?3 U_OI^QJNWHAN6:R
MA;#%>M="7I9(I'1#N@F6)H"O4WSE#5NH4K">R!AMQ:0Y:022G: #I+UQF&S1 M\$GC%TQ9*3>WN#
=V#6&7/6VA_Y5<%9&:RC3#8KU#L-I&FXOE6E-L-%O*L.C-ZRPV\$#WJR,YBA0;AR#L);1S^6 *(6(\$KV M=D7S;O
I)|\$OD,%=1=SEB%/HX&)5M_!#5Q5QM4:<0DN0M8JO6I0HU% M|>-O|XF:)VJ+11DOF MFGKMXX?;@;\$6&\$OW?
B7T7N>|Z@|;PF|=LP?>9=3A06V0N>Q,FXW&F K,B MVL(R*M@+Y6WL^RD2?<.XV9/M2JR\$K0H>CL^DQ-
MKE6;60FR7;JH+=9_OAY_Z,7VY0J8+|0EBE|@95FI8=/_NR98W@""^3Q&55V18
M%+578IX31.36!61\$HX,VYO/L/(<+2- M7A(IX6PWV%X*|&.5P+102LS?R!9("=<@A12@OP%4RX=U0G%9-
J;U9S%.R|M_E#MY0*BI\$|RX48Q9KW0UU82J2;94VP_-%|G>(K^=0)S|I<_37!D0YK8/G
MTWN|(<=&X*XBIG)8!R!JH&3K3\$U1IC|HS\$NAB."G@%K+1.;+'#P.HJM%+ MXA6|I@;1R^5|FVZPAQL4?
+DU@0K"!#7*;X2!AT^ QZ MKP.P.KYA&G.MXX=Y@KN*N.O@&SP+K0\$L8@XM<94VYO#),I,SI\$ _16"\$7X9D(
MQZ;7*\$MO&|T4+L(S"9BJ@FFABYB-D:49)>%9&)#=2QG3EXD@2Q=6UL^|ZAO
M4YMKY5N+0!"F%5&716V! O!VOIE|O&+4Q7_@?C#>E="6U15>)9N-#;|!@7P M=8JOU/'\$ST**GWM-!(CRZ0C/;#?
X7FB4Y;7\$W;IC(N9@Y|(#,U-(12\$W0KI M",_|>RBJA@A MG;JOAU.2D)^@0Q^W_KRV3 VNE6#,M);?<-
P255;45NJOI\$8/# =8K#651+,% M",O.>E=62?I!T@ZT)%B6 KU_1Y4H/>*X & KH2NX#JVNMB8L>_0KN2#XE'X#W
M.'X|X|_ES%P\$ _KM'+|5|H4R+ARKZIO48H.'M8*R8L'#3F @.PFDZXLO'S8O;I?C/MFIU/P1Z^_
;W;V=OFV&WX|_//G?/WS|WX=_L WIT^/+,_VV_&|;??3|G?O M=C>/KW^_*S|Z=4I?|/VRR_9O^BXOWW|>|J7+_C9?
I^I^+Q_LTS|ME6?3G> M;.;IU"O(V>>64\$QV3|I27.QIO3|Z_I?IGS_ FWWVRJ>I_ =6PRIVK|9^VQS
M^V|S_BPI?7_ZIOU|2&LAPH_0?=>%(G C+M?K|_ O7UXW+UZ_1#N|N; M<F>?I^HI+|NK5;DOV|!#&;?
9^/_T/P6VNI#?S5^G_V9SW+U>A!.FO^W MNW^V)=|&"OD);&_.XP/1=^(:YNGIUI3R<4>|-I_=?
M;H9C6/SF>^G#T2*T4E^HIQ-N_*GMS5>/_AAO?B18/KN>4;3I^16&+NMV| M>=>@^_E??
G>S>WASNWG_4|_0%_IZ^= MEH'.#Y;SPQ_1=SK\$=PO#WJ<71M^_&?8-5_XXI+H;_BU&=RU\)^2^TSB6AA+
M|.#.9|TEL<|DKX5:ICOE^\$O_.F*225H08TGBL_)7C|OB7TF?>T<-9L;.,* MW&>2Y9;?
2WUIW^G#X5"OIE8;SZP_?EIL<7V_V5Y^W502?> M.Q:0^_QG5:S+|RH%039U>|I^,I?
QP_O/G8UTN+TR7*ICR|IJS^GSEO3239> M?60;KW|1C6&_O*\$/Z|STD\IK16<#WKD%4)XU/F"7ILC3R,O-@;_IP?^Y+
M_)O*K|X&K;IYIC2G5DY)>|G27^I>|OKX+!|WX|_UIU_LOQR^>@A|,DW
ME;._K3YZM7SU;OE*K^'=+OH;.)^ M9A|> ST|IM^+^+&HD@1#D@1ZN^|T MEST=G?M?
_J8_KOO_175>9+O.7|XB/|H|KCI7=RZ?I O<9KJ?2;% ^WXR;*_ M_IG+VN-#3=55^_
_NHV*7*C=Z/G^CG_5W""W@^"| B|6>JE "10I6.T8BW7V!
MP&Y\$;ZO_Y(93X_ ^6U9XV)7MD%^= ^XN:UR&U2EML&#_ZR!5JB2?F MMK77W?/_ OQDH;6|OL&+SPL?
_B7ZH2|6!^I7#QW.*>7DH?^P=B|H\$>Q M_L9_.98M@P\$FNX^L!(I9^0%#.+2^N08 O&; *IXP5:AN&+&S;#;8\$G8YI|D"

MG>S!6*ELL@%1%~2XOUFPUS1I2<+PH*FNFA:F\$Z>OY6E2B>L:K"l(>W?C13MI4.18)P3?0=+<*T\$/U94-?
^+KJ_KY=^8G3SZ106Z_GFOS=7W^QN:1%>,^% M2175+1"6E6VI*CP:=17(5T*C,>.>6*<-
(D9YQ\$4&8SFEA@RZMI=>B^1N1OE M+D5DK(=-.\$R%8G^30\$5:26.@1!&M@X1+!B "1/FT@P_OI=21HBIP=
IG3?>,<*UB MG4-U>KC:S^G/3E*^R.=0W0+A23F\$FO=#4=8YJ1M @A6'H"04WPE=PI*=(/2
M*#D1#F#=@D3U\$&BQJXEIHGHZIX<#LT7F5G\$>F@<_0T#D#PIAPIZDVUR&W5JWF\AYSJ&JPOT_I6?I
M."#C4\N*,OZ\BU1LMD87EJ@PY1?7UX@P1\$@&@JWZ#U2IWOM8MN3@+P*%Q
MI^#0:B=FB\RM(1RTQ:\$)CDH(IX=S\$^PE,PY^HLE)#9KJH&FA#J7/OK-KBKB+L<K<6^<(JNYBPTYQ)Z*Z
"S1C1+=W*J<^Z\A_KWMM%+(B;&VXPO3U2 M&@82,*TT\$O,W\CF>PD;NOT*%3%84P\$8^>5RC>Y5FV&*%F3I)
<45NL2"1 MWH(A3!F#=&4H(VW:1J@O4)X.L47FL-E0W^+0 1L0914/TZ1JCDJIKC+
M(1Y<4*GL+D87%TN5VLT:G(IE M#U@N9!6*WPY=6:O@TTV<)EA: +Y.197<*GC5#5Z@9AP0Y:0*/DR<9CVS*"JO
M1+R%CLY#V,7\X;SD%>P "E!^G:NZZNXXB001MTIXZ,R:KZ=G5A M=?
I,XG<K:4W%HDQDUKF08A)%4Y16V1_09Z=1NYYZ^>:W:8.D0:RA^@_0E M1<1X 4@W?)H@\$0+X.L57SB\$.
(Y5B/*14+XP"9<LFZ 8P9=X'WO&1LFTTJT!+=G&5U&R-IPV5P&BD2G!..#?E.V:H\CK!N5Z?
Z0!=""D*.AAQ;^67@O'S\$># M"S:N57L!"T5VD#FUI8IV" TN&4(6ZUTD'2OL-(-JB98ZP"^3O&5UW%P-AY2
MIF<&I7Z+*?CX+P;O.V-0D?VEL KICAXF&M^F/1#!WN=QE=QQ<3@Y5ERW%N\$(8RFX("K J"W6WH
M8#A!6V0NNID0\$YWI75\$@X' M9HO.I1^C;+D<6:"HP+>03(00!M4SS4#3'7 M-!S-(YGL*;*W
MV@A+\$.>W!>*7R#:Q7O>JK9A?BMI2_7UW^V\X8NOOW-VBR5#5J+X M#5&6M0XRW82T5_3_1?W/^X>'L9/
MBP5#2J+X!5*5114JW7ON@G4+X.L47E3\$BK407BTG05\$.9V\$DJ<4W%4Z+7\$
M7AE:1M%+4EFJ KVVW#Y@F.7.YOGV.A1Z MMT-V#BDFY9-L/(?)WB*IEQT*P.%\$ O.T"4TSAH/CZYI
+EZK5PM_HJP"1MA\$+M&M9QY"BY\$Q(RZK)NBX:=JTM*#T0%3'9>M!&LF'DLX=FL^K+T^45Z5.=14QPK01K+=
@M.78AWE+ MJ2_CG[*!>WE>1Z7VENM.M=ILK<"RJR450LZ7="78'D!^#K%5L:F2QHMT@%8
M&>W@QR=AT3./DLV6P,MA&PSK!F#5%8YNR19)\$S!6"D;8<1T;_*!_UMH+H M""14UTT+?01\I>R1/V7C)K&U;
874&0I0NK\N<^A#1)OE\EMU;Q_9?JHU<7 MVBOD4%7M+=<2\$*L>7NT976%23>AFF#)
O@ZQ51>!ET16N&UST9&@%51%6674%XJE@K)2NL&PZ-H7% M8V>TETA>6@J2Z: M%NJ*^5M9(EUAQ:0K!
(5E"DZ6U!6!ET-76,-V@KAK#* MJ2LL(JI@K)BN<\$ _IH^>1PSVJF8OC:IPH*DNFA:JBOE:62)=X5C0%9H?7K^0
MKJ!#?>>ZNMHR>?A_)6'S6QE\$ U MWKYIXOZM6-7E?A?)7O9-;^XD"A?<*>91_*,FMP+WMK;92R(GGVB
M22)+40E-L9>QU>6\$ZP;BR-57VYNK!I/>>ZLMG%983Z?H,\$"Q1%G^\$HN)8_+!^B\$7\$+4_4;W*YYW
M@PK%>DA.5+>LN?A0 "HR0D-12)0^K!M.KBOHMD+ NF%QNKI.BZ@K%2YL^K M2?P.XT^PE.1=>@Z:Z:
(JJ:UM+KP)YH++F+(0@BQ=6%2 ^Q"D(OFBE=Q: MQ9N+^DK?A5/GS=AN+R6 6 5B%83NCIRLN?#I6@X0K% 7Z?
X2FN7#<8@>IV M0)357/CQIB-ZP3&:HA+P%CX/Y!S%R,7U2(55@;TY8 !%WHIA=I+CA#Z!6;
M%3(7G(GP+J5GIF=KV^RE,1>>2=:4%TVQ-165S05GTIAM36JM_07GCMMN+!\$!S@D&Q!#5 M'1!E-
!>>3.16CXWCO.+ZORIR+9RHH19L+!>+! M6"ESPK0C2MLU>\$G/L.6BJBZ:8F1K:YH(LIH%=,MBB!+%Y8C.'OR
M=H-KU6CFXK01)^U%")Y0.: "T/U1EC47/%T_H+U""^#K%%"S057W>"E \$2 M**YX+H;%.N=C387(-D!
!>=3.10=X'O)8K1%>T+W?1BS05(A;.%3,7 M:NKOHQDN=6VSE19<>-14%TVQ-16US85@W6!Z<23G7_7-Z^R!
(SJEV":15D MYN*13\$Y0D)D+I"Y(C1_5&7 4AC7CX!@_0+X.L576%JUXO+31+!\$4KP:5J.G-Q
M'A M10B0N4#F@M#141E6CETL;_Z8 MJH(HIZYMK:0(MR11%2?)X(L75A*X.S9V@VN5:.)"D54:U%:*B0JD*@@=UT
M9:6%3M=M@&#Q O@ZQ5=R;.%5-S@1K2T 40L0I7NWHL>|L>R-0DUH)> M?IX^
M(^(M1HFO'WWIDCCL:K+_BZ2O>R:7JRWTFB@K%BWB(86=X;+<%>T^RE\$1<> M-5%4^Q-
+6US85BX>3%U86"6"PL1<.%1T1>MY:JS<"%HFIJY"U5.!=[K!6R M%L6OCKZLM##1QFH3+%T 7Z?
X2BXM.C.@&R0\OD((\$*TG+L!QU/!5PMW" M)^\$#1%9W%D<84JU@_84515TD7-
DWM5@189:T!6.EI(29&L!+=U"\$>A5C5X2 M)V\$L8*H*IMB+V&(E<809UPU.71C%ZN(2
&6IRK51,2RA!U\$E16ZKSG4+M:X6@Q'170188>>0KH4 P:!(#1'6*K^K3.P;+@#P@_D09G8.=^@8XB7;'E7"W
M2Z%"W""@%G6.5W6#M87UGU>5X%PE7IDT MUGE8Q%3!6GG8 7TFMA&UXD O:K1
M2^(Q%+X!RLZ09G#Q19JY875SM/@9+(<?P*>=@SLO!M%>[^?W M^12;1=77VW+UU@RQ!V*WQ!Y6?5@TW4!
(%A!+Y.161A8 Y@_8 \$NN)3X# M'7JR-PE=18Y+00<+WRR ^TQ%U.7>\$04 5CI72%\$IC?P%XJ7^\$D:*J+IH7"
M8OY6EJAODPO1U-X?:=F*# 4=B@3CY17(MJE6#68H0@B*! ^BME3?I3<_6^W M^X>K JP^/&+1\$*8H?
H<498V&21="@&!E _@ZQ5?R.(4SW: 1JD 4HF%W8XNK_K DG5 M#:Y5HXP(3=0P45NJK_?C>S= ?T-
UFN>.0'EW5FX2N>!S"F_%1VO3>1+_, W<5<,>Z/M5@FOUFW1(XF! XR O:6J-&BMEC/7V!>S=W!_?;
!B:SJ+9JL0 MEIWIYJBS+Y=!!Y:Y" MUX&A HW0#EZCH!09 PJB?&0...NE9@"O(?RY!S\$ M^&EL-!)6-OL19
/(ME)FEMQTZ\$F MIH787Y6-CL-(9CK!BT/Q3O2\$0PX=X:HF!R:V58\$UEH8(=H%314_4%BO6
M+K2W8DAS\$K'F(U7M EJJ+E7&@#8WG"4#K<\$ MWKK)AT^2F%S@Q&R1N37_Y0D0C25T+30/S?
MRN:;!QXF4Q^)72'70<3IKTD^1.4W%K%FX<:"\9XYCE.&^QOAWN!H?QAI%< M"#44OR":LMJ!TYM+3;#^
'R=XBMA(Z8YSR4AW-!S'3U_#HRUP%BZMRO^*2- MML0M<5=22@B&11%YM).HIZQM0F.
(Q68%7\$60N!4!7DE(60W>1ZK9"5J 2F MA<9B_D8VWUB(D#?U.<,"(P75_/%=\$7K 37JKVLA!GX=%>V?WV\N:1?IA
M_NZGW>WM%HN&K\$3Q*Z(M*RT\$^JPWR5?RK(OPX^\$; PH%\$+4_4;KW)/H:2VC M'WG!747A9^**>4+(<?&^!
W<-<5?<32C5#17&06A M+6&WAH0&L?_OSM\$1I0?_/GX#_?GS<-N;140E5CSJLC+2@F=;AXV
MP<(\$1'6*K!SSL/74BIV+Z"=@_8"8^G>O\$SSL(U\$ 51+W)6MN\$X4H959JA!\$Y5H)?(9Q@9RDHL\$CNUP+309)S?
R:/PS;JZ0^+!\$1 MB(I)MQHJKUIR*U5_#SL&DO=Q! ^/\$+RP71HBYO:G?V*JD\$H?D\$4996% M23<-EV#=
O@ZQ5=>96""J.S>6I2I@!&Y8*7WED<0R M^6+"BFY0IC"JBB0%'4S&1^CSYF\$WN5:Q8J+&^N%+6:T19
M5DS8="Q"=8G@13?50\&15-VB.CI E-,V*EK>R\X2O%: JID6L(G)@M M,K=&>R=K<6B"HQ+>P>'0^
5GSKAH;M1\$B/ M 6!WN=BMH26>B\$KL>;U M41?V\$NF&81.L30!?!C*V13)1!" @NGH#<#<8:X&Q9.1>/
1=L@6JD90BKKBUM M%-C=NIP\$Z EI++W>/(2IRHP*R(UO.H&SGOND;5HFFTD4L/KIOY/"C150M-" MJ3% *TLD-?
PT3%L*9"TH412LT1?PD)JWBG45!O!GX=%>=@19"V0MZ-P> M35FGX=-TB98UP"^3O&5V6E.L1090UD?&
(MR&D?0B-+!E: *R*P,HP>\$(R MU@W>13>T%<5<97;2DCV-!";2V &S+):"D +8&5(RG!33=(
MC3KBEKA:8>J\$Y9!^<(8F@.(KN9.0KIN^B^9^<=(A<%<1=16=A!2A_Y)&%7%3V*WA)*3\$
ML0F."C@)!3216F1.5^/L)9\$2_DRJ%CV+1<%FBA:B05;62(K(4TWZ-ZRPPPS
MDA)T*#JIP5*#15F4D(2E5;45@D)"20EZ-P>>5DK(=-JB98F0"^3O&5=VB\$ M=.*J00*VL%85FGAIX=E:~?00"BL
K;BU4:#W0.Y0A-X5=JD1BN-8!69% MH(8*@ZY=KW3TD'6P5S512:2&"L.NY7A@10?1!\$TDI<K2R1U%"J&_OX!XV
M/D34@&Y%W%NJ_7W(K56:40M%U'E16RE\$+1"UH"/%&6EADHW"9M@80/X.L57 M7JEA0H?
VWG'T @=C.:6&LN/%6?2IR6PV>:HL@U%8*60UD>A<'V59K:3#<F6-H ODIQ ME:R#E
!#LITJJP1XF'86G>#T@Q@-016CF'8VHQC7*."JQI6Z &EPS#L M^-=QX*1CA:=?X:!
(0C:51AQ.TZZ51FJU\$I@6>H/Y.17!:=>CLX55BW&'80WEJ@WHK94R#L@IT#G>JC*B@&3;MPUP>('6*KX1Y MAH
@_8 L>=O@=,ETIZ"K+KB00<3!&GK8U^F0?N*N(N;=#A.WL;JH@ MK%3*P1CL_V OE:PP%G351=-
"6S% *TN4(70#JSM2%'0HXYM1.9!# M;IT.)\$T#*8KO_C+!HJHFJ*V6.A1(\$=!YP)IRH'FVX8-L'Z
!UBJ^A^/OP+12!8^1^0!S!^>_Y904+K10EQ=6 MNG>1<?7U9).AW OU+ MT:.)A:G6ZM:X57VINKQJ?
ZJOGPFNE5"M)2.F0>&(*BQJB_7MF_WX2: ^>V=W> M8L60CBA^1H1E%85+USB
8*4!^#K%5_)TA#/=8\$3THP<@: @&B=&10PNQJV3L1 M_08%X%4\$WKHMG3YS8CJ7=26ZJO;
MV^T=UFJ>A.U.R.@F/."N(NRRAR6)G4I5^XIP*P1S-(=K%,3=ZY0W-XV

M>FF\$A>|&UVN\Xl(2F\ZBOD;69L3^.'#IV>V!&=BB_%8H\$8^?~RVYRK7CD~MO.SZ*MV%
(.N|J"W5^3JCO;4Z4VE=89BD|TU+GH\$*+"K"+O<.D.Q~MC5,5F)70&8J]F=F|B|
<90*|H|+H#;7LY,8T8*H\$IH4Z8_Y&EDIGA);"O?:"
M>1ZD,^A0),X=2|~D6L7JC/K*Z+651&T7M97Z:C_~V/>|PAH(*!1_/(H66&C MD6Y@~L&2!O!UBJ_4+;:\$49^~CB8G.A
_B,B*|E:%AV8\$H!=HN4 |W+|*^XL MN|B2.G30&9JYM3="FVA%)8D%6UDB+1%#S)7URL6TC2((TX5E!
|CW^DO!!~77S^~063#/#67~CB MN |FT|E TE|16ZROWCX|I"W0~ZB |V2E|43/~U;8(5"N^K%~|YQ;R MZ~V1BR8@
V0KV@L_C;U)KHU <"K"+SB|D*\$AO |0|"G">RR)RX\$G|Y5S|!"M@;U6.M;+C~UJ#GT=(>SF"K)R9 MX*B DY
_QR;02Z0D) |Q;2,|H(F\$@;B?D;V>PIW&K|30T_UE3&Y MM6HUQQ J8DAJ)VJ+=;Y4:&^MD&)8|W*HRDH%E6X;~
L&Z O!UBJ_D4D&%L+Y' M128@RBD5U#3NFKGH#A'@KB+N2|88E,*|V2)S:P@T7%F@J,"PD\$9")M+Y%P
M4%.25%CL8Y7 M% XS_~(B'J5W084WV=3&ZM6DTQA&9Z))44 MM<4*1^SH>VY\$ZO;6S!\$&=;|
(>K"UB'=QJ'A0'?>Q1?>6="Z"E%NCURS01C M8&R|E#B"%N\IZ.?)%616"5M Y:X;|LD;GL|QZTQ)D)S~)(B2~
T*1R;8"N) M==~Z&T2OXQ468")I>;O5;M@PY|47X8C\$';@0XF@C%;|4IP;5J~.9=4XY MM<6*M
|M+1BR#FO>\$\$U9ZZ#33;(F6'T OD|QE=DZN&Z003+1^6LPU@CR6HZ MM0_~A.61QQMP=
|GB09%AXU'#@JB&NLHL'PW^L K,B:0@CPLF|^&%3=;#7 M\$G|O(21W>|ZAVA+3 M|+S~|+Y7L*H;E!"C~
(0|#!1#!V7JU|DVO57AI" M&\$'56U%;JN?;F|W^ZF^_0|8,&0ABM|/5DK8=+~D298G0^~3O&5UTJ84/K2
M&X|_S"6TFJ8T%~|1\$^A3|E|+|H"=<~7J%=?TMA>8H*F&FA;*~F;V6GQ,12HL24P+&~WOD*>A0)!@|
MKXM3DVO%;6MY"FW/FRK27C;@^?W= _GZ+Q4*0HOC5T955%C;=)@J"A0O@ZQ1? MR8=&6~4~4AS_0~
\$&@&|)V%U;%CL5/23+~BKB+MUVS?~PFF,1%"KK.NPY;"|D;O9(F,A&/A8J_M
MH3;1%DH(1=P|JOU|R*V58,RTEJ30EJPHK92\$4;BO<5"B&+~JZ,O;R1Z0<~|X
1\$+4"4|+V*DIU@>V^BGX3|747<%3<23H4*F_1 M|+|E|8P\$D|CV 1'18R\$;1+Y%#@KVFV4NB);
Q36E5*7,0JH6FADIB_E;52 M\$BX4?<@CM48(2="AB'NOB;Y&);=6|4JBOFIV,1U18T5M|1"20\$B'QM51L<~)*
M(MV;X(U">#K%~)E81GW2=VJ|H|Q*PO~)21RH0)WE|M=<27A/S050\$UH
M2|BMH22|Q+)\$C@HH";|F);\$U|HFS5X2)>%U*L\$%FB@JB05;62(EX4U(21A^M>;5"2H(1=Q|^Z5@'\$,G\$)7XA)?
P1+45M95"5~1"2+W|U|62 AT4|)%B; MKU~|Y?<2;KREQ+|@ 40M0)3N|8H/9E\$1E!#;\$8(2"\$H4DBX|X9@MU?
|_Q^~^,MP|7SU_O=P^~.BX; 1\$; M|'"@)C1+~PB;8'D^~#K%5VHQH9G|!AL_L1,0M0!1NMQ"8X*B~G^~.C;
<\$S&9N)&~;"|J>RFPDU5"TT(U M,7|K2Z0FN BNR|J8'DX\$6;JP^O^SU42#;|5B5L(P1M1<45N|&JBO45#9F+~
M*Z0LJR9XNH7|&L4P~B_CW*^~N(NZ*JPEN M0DF7TLA,M(3=&FJ"AX'7\$H7KX"BWFIC;MQN#D|~M|~
*8"1|@AH6"4P+103 MS>R1&)"A|/5;"NQ,R\$W0H0F8"F8E/BPED)I"9H"8FFIU&6;F|D)B0J2; M>TVP0@%|G>
(KN9@08>XUCQX\$XA;@ "C9ZQ4A0U<=;Y&9;(F|XF)"A |MO=(8 M#M 2=FN("1'JL", ""464P(|Z3T4>3>~
GDQ(0(>K771X84 R;2;"T4\$ _W MLE1B(K0&|N61)JU(3~
"AB'N'Q\$24E/CRIF_?|I^|3|NIM_O|KYXO'_SS/QZ65^.=XWM/O4*TS_C|M?K|W|O'QYWK|X_=#N|F9K7;
MDCU|C'&O=|/|/T;OX6V^_?C|HGO^;S7+W>AX/F_~UNG'W)M|Q|Q|>*|5|9GP7OF&N|E|=|0IGU'CS_?
V7F^~8%K_Y7O|PM BM MU|?ZZ80;?V|I|7C|W|8+|XNF+Y|?_E&VX|?4=BB;C=O^K;/?OZ7W|WL'M|< M;MX_VIU~
BS+|HM|H^~T_?^<&_GZS64U_WM~/?T#3^VNG9;#S@|_|=/_Z M|/?+PQ|7UX8?_QEV51?
^N|ZT_X|9G4;|XF>RUQ|8H|D)7RM'C2=SS;PB|YDDN3U37TQ|Z= I M0TG0;R|67\$VWM_/(#;?
5&K^S_W|PY>>#S=;#|<4<+~| C@L+NY"G?%3SU| M=V|RCQ|V;_/7Q^71UQM'J_~L'VY_?%=G|E>7|EF%
S'F_N8#^X#^K8ET^ M6_FK(JN'N_?'_XX?HCWL;N1%J=/%D1|=&%?_3EUWH.T0J(^MX|8MV#&O| MD7C|>9V3?
DIY+>9|T'.O\$,*CSA?|VAYY&GFO>=@^/3C^D_SGWSQNG0D)UW5^ MSTQOS*^>A\$S82_|^>O?
R|55X@;X;_ZY_V+Y?#50WA"3;D~/UM|=&KY;N/MWRU7^3VD\$WT/~4W\$ _VPW^_~Z;Q_~EB\$65)!B2);
#;=>~|_GHW/_R_~UQ MA?|OK_~BVW7^XQQ=WOXM;EV^ VTRU;BO7|)|AD_GUSUS6'A_J|H" M_W8?
%;M4N='S^10|K+|P/~9>|Y1+|54A1(P^K?;1+|H@L\$=B~Z6_TG~YP; MOV?I+?';AL;%|NR#?*|~|?~
;97;H"JU#1H9PUT/A5.>J(=&I+|?S|F_WV M8=8>AM5"SI_5;|UX6BQ1_3%OF*C|;|TPR; DL>/_P=NH8)@*XBZ(IG
MGE5HL&|H|J|K27NU@;@=R|_U;G|E_C|J|*~DF6.IGK8P%=TE|N05S5Z2T+4 M;|KHFEAZGC^5I8H=2S~
/G/J<.&|^B2@WF/%G1WF*A#^J;=T=35E9(BSZH+?54%;N6!;6V, MB7YB 6,M);N080Q!M~
;ASZ#+7%77%FH;R(=>C.VQ)V|<9B*69|;@+MT7P<
MF&4V&DJ_Z+%;>2;11;9N|)\$9#;|2|K>B&CIP6")D&8_Y6ELAH*!4F!G*+|J4 M*>+>GE=?
W^~;Q0|X|Z|L_GDL^~W<(\$@511J_|Q4+18LV|HHRUK~)1&H7*+2.4U M&B|4S;@4CRR_K_7(TKUYL2~X1O3>@KR6R"LO~
=SX\$;|Y;_'W8"|BKC+;S7| MR)GL#4Y6<)9;V@V|Y;10_/PWL|V|F=F+3@M%|OS_|\$8D+~
M;O"JYT=*Z1#5H;|Y;JFVMR;R48LZU%;CD5"<(4ELJ9#60U2|R>W1ES8;6 MR&JTR>VQE);_3
EKEF\$|G;P%=1=5%QK=;(J%<)|36&W1E|F9PL*N|46Y=X;8=S|Q6.0JEM+|(R|GLJ8#JH"N9O9(E4A0DRM5?
R_6+~#8=BK@/_M(1F2+U2)K56J;BO5IY+LDW"J" T5,AC(8!"Y.OJRI|L*~67R3?&4S%48, "6
MV528=/X5T%4\$77%38=34;44;S"YHB;LU5(71W1#?AA\$8~8)1,E5AS+2%"1^M
MRU>PE<17&XD"LBZ;%LF+^5I9*5KC0LI/90_N%6~4=BKAWYY7~|A6C<8J M+%;&916VI\$*M
K(+&W5&SPK(BW;QN@N4*X_L47|EDA4TWKQN M0!8"EEATRE8 M0%<1=,5EA15/S;P|H|XFX_66'E^~!AK\$*P
1YEMA573'L;U"Z#O9;82V(K MK;.)6!~=RVS@~JTLD;VP9K(5(J8)%\$&6+BPNP+VGVN2'W%HU&JTX;_Q)>VD!
M1"L0K2|R=^1E;85~|";8+T^~#K%5|HQ%C8;|~|4VC"~P/LQ5T;W1 M'N0U1%YQ;>%8~|A><6&"Y4SO+<~5;6+*?
8<~1%_7C2H&|AKA+KS6.D.6Z MP;"VM"FNGL+CW;3G)7Q%Q%Z%HQ;7.OH);\$6GH;F>H5PYR+2FA;*~WF|V2)
M|4(6K7W1|8GA#H4,2|D12|LY);*\$;\$;RV|!=U_R;FX327L(<0S\$;8C<
M'F59;^1\$|Y|OB*MQ1&05#>AM";RF@O#9#?X7K/H M=R_@KB+N,N0I#_O~WSDZO|?
\$5>X|A6\$Z)M2XM@%9GFI|A6\$F.CGQ5~X>BFL MA6%A\$C?O/<|+6FA;*~WF|V2H\$70JKUU|G\$*PA0)Q|LK
=7D6OVF'5(C<0IY M7N"FO81 A+9H;|50IUCS|JB+QBD,2S>+FV#A O@ZQ5=>9|'95'Q|9'P;~&~C
MZSD+Sj>9>FB'Y8|7D7@K1NV^/2|R@4.U|;9RRXTN,29"LR*" VN<*R'O51& M@SI_Z;Q#;)~
\$TFC;7|K.V4TCD!CND%)3*V@C(E@9,00H21VM'O@X%515BMT;#)"(YC\$1P5|IBBK8ZAJ|\$
MV^~@ET0I"=H/LM4#@JQ*8%EJ%~109?~L@5#?XPX S46W.0VZMXJ5"
MC=7JXV|OB&HG;HL5(O7;6RT\$(<~|'=JR4D&DEX9_L+<?)WB*V|00DQ=V%7| MN|APU@)CZ=ZLV~"8CC,4"|"?
\$71;GX+|V|N@AQ>"J(|ZR9QV\$Q|S)S(HX"#FLA#3CEF8PJH0EKK);"6EQ;@*S;E;"31V8N,44
M@+;92Z,E@EZ5O131&A|TD?02V|>R^5Y"!3\$;~>F;("P7%@#@~WITW\$J#M6HU M+!%D~\$ES16VQ\$)9~6(+*~="711*~
(RS1(E_)S IT0V>1^?|5\$+~\$5|>Z)D M>'\$W#50#~|UPE|_|*~4~#E7J+6&U1@FVC MET0K*|LZ;#>|4YRJ
4=5"~F;K>\$U|H04LLL 4R4P+5,+"S;R^6|H|A|Z|^M|L(K|!Q|!~6|P 37JLW M@J#;HO;8D6KA?;6#*F%~
>^<(O*Q;T.GF|A.L;@!2|C*VTU);_2J|E;%S\$;~(M8N>*~H6@<(OAWH8|<~&=|~"5Q5Q%7V;DKC|QG/3 MV^PE<1~
&3MV4G\$2|M!%;%LJ)^5O9?~EA5#<8'3~ZFB L%U?+Z<~;~*MFLP|M?<7<
W/(Q;1\$LS4'RTYU459.F3S|PF6*8"O4WPESST8TPW>H_4Y;H^S4 M"JV(Z,81X*XB|K+
(A~13\$7QHB|JL|U@&~XUP\$1P7L@F7A;0BVLL#O;K12R(7 MD)0O=1SG824P+70+|S>R^6|!KUYI L7@~|T,\$P
<&'3WW~FFS++6HK|2_W M^|>KOX_~|QH+ALQ#|>NA+~L5;+H|T@0+~#;7*~Z2;P4|~39'7V! E%;K/_L
MO5V3);=UIOM7*G+;Q4P\$V,3W!^7("H^~GLLG^_P=*SCJXDBNRC6J~7%J&Z* MPW|_B;RF1"O|_|<6|M8V'@O;#%
(=K;|12 C6>|X4UYQ|H6@B/Q|V|5CB* MG5_2WA\$;4;"|AK6(007%P*BRL(A^K6P_TP;%Z(V\$'HFPB.OHZ9B*M?
05@8NPK|F|D5+XBKOGFHLG4#%FZL62 2|K@S2|M=+R%X_W Z0HXB|4#1^= MQ6VED*)
BH+|H=\$U|A5T0ZD9%BV KRV^JOF*)_\$8 &OA*Y*;9B|D)X(^~XZ MXJZYKTBV)X\$(H?BA&=AUA~TU?

\$4RT^R*;2LP&@0CNH/33G;0(;'+'-I)CHD?B*MY#).L=RI B:60F+_1D;D*)J4IT3;
B7I^HHMJO8IK5>XK^BN^UUXEICZ+ MVU(A8(& !;/KHVK+!+=J&N&500@:XNONJ.NTSKJ6L7BMV.P-
(@)C=\$!O:9VP.M: UJ14<^"KJ6T^"+MY+XL+;'+;+O:DJ"#5#A6@5D+J1%DUK(.)^OP!%#8C2#S M)and POO)-
G=IT4&OLWVHMH\$0-M_7#CM:H<8!A^*3EHA8:T^@CCJ;#T%Y+ MIMJ+VU(AAX\$P;_IL&_I&15S16(ZV.3"-VU@M-
JZW&_JV.R&KH=<:W=@AK<*9(RPN+18=@7PM<5-7.5MAZ.9I+1 M "-I=3\$JMH4*)&="3PEJBAT3@#4HSEZ#T@M
D0UK45N%6I%M.BP/I)X-3(65DZS+WYG-58=855N)IFIE6^A#1VFI-#3H(S)B?S%I!6^U,+ M=K2.8E12-7?G^_??
07I/XI8+B0EFEV=5N08.DZ"# L+P!76WQ52TI8 M#1-6 OG8\$.>%Q#+WX;!74?<0!^V^7XMM%3IG KB/L:@8E+
*M8*R5KGIR MFJ-0\$>-1QD:/Q%8X!9BZ@NF@K-B_D1%)S..8D43N_1B\$GPH4A+R?6MFN+: M^=%B\$M9@0,6^E?
JGI^-?07IZBI5"0J+YU=&T-1F.KGT PVH&+7%5IV9VIF MUIVD-Q@#8Q5EAG+!+QICE^T>Y@CP:@*ONF-
4V&G&:G1.6IYI&9XI&::2%IB!"N=, 32R=QOZMC.AI>+E>-8_IC?0@ MHL\$(Y6B^UQ+%9D^QC)
IN-6GIK/5/QO6VE2LS>>N%CN;8U;Y"VK=GP M+=.W&=8V@*MONJ:##?_2X%T6/S"#L1\$8(WM^!29?!84ITJH6X-
TN>_W-ALI F M5PEE-.%B).ZJEPV?>+&+9) 'E:5S8;AC:)Y\$*K;FSV2.R&#1LM(BIN/8) M+!\$T&_NW.BJS\$=?B\$G=F3
KB&GPP4BGRW&D M6:C;ZJZUW.3\$57IQ6"ID-M9#;XW"! =8I-!UAF-88\$#^_KBZJ9"#)G-GO-!#T8?
(AN8ZD9G=@I4WH^JOM#I(R-8+X2 MR-8B&UPND+ZMV ATXIH9UC> KRV^JHW5"!&+ F5B.M=R)A5?&-27#7\$7?
-MI4:4N8P^*)31CX1=S;\$;\$3%;,9*:,3L;*50!O^L=DC\$1K1@*:*^:#HH-/9O M941"(H=D*=Z0Z1-8?
BDI>YI%6&*SQ<^\$EK67JNK@M%5(2&EPN3R&MGC MTLT(9UC3+ZV^*HF.R+=C'-@)@=,N89JMB-9MYT?
BKKW.B'DT??#H\$3X2 M=M4#&C&IC*)63.PJ^PSDEQ?H\$5\$;ALIDA1E)KKT8O.7:O\$YH.^HSI6QFI
MST@Z7-S5F3F.^CPH>ABGXU&B*;H9U%. /A#8^8JICRA6.G?6SK.Q+=I" & M)0W@:XNO0HJQ!B2;<^,HA
=#-9U%>^6A#R5J?3 M%V<@+>WMJZK-6X2KNJH6FG.(B\$;_!>8E(PQ/LD7F)!)KZHJGT^G9E+Q&E M7
N2J&G+Y^YO7C>6^5 I2-8O?>S62DOE1LM9;&<-4V %*F0LT#>LOE.37U M\$E'2-21@6H OK;KH824>9F
N6=4@#1"!1!U\$;7)1NW-HR=T)=P< "Y^ M5U1+1&G/IVQ=%^W=)%S5-I5"+1\$E4IY@K)&6B+CI-1Z-
%8BR@"8NH*I")V M=2F1YW0+>6;04I?WKAL+ *@+L2 ZY5N93HKZ9=NPN;XU7_H^PI;.(23.Z.
M43:6\$G0CNAG6)8"O+;I(H822TVQ4!2AD0#0"1&0/*^IE!K=J-#K!+QC^X9/
MR6M@)90^0I5U7;)WDW!5W!5*K81^5A6.M;(2RN+P!M46D(YT-073:57L6M! M"95#JB*>F7+2J-K-W
M!#).GY#7P\$CHKUZ*1 MC8#K1G>U4B^AD54%8ZVA-8OAZ?%.(^QV2/Q\$MJ IKYH^KV*7=M+Z-P76!AY
M.MKZYO7S64)-=W9X9K-61>@NLP=6Y+A;P\$A)<+H^ZK9?0=&T&S)&8F@*M MOLBA/3;+7Q8&)-)\$=\$\K8?
DP"(4Q")J,%JKB=A1YH!8OE?8#<0=E6- M!8^L8^R5L3 ROZ\$(YL3V MEFTX+3<&1(H>L;^N-58+^=C@#
<0>#7R\$R8K6^U:00>N!>I>KFDK"(. *QIHI MB6QQV-1\$@DTI473026Q?RLC4A)63K.3P9>TU63(THT% U2*"%\$@
M1/\$Q)1&9*BMN2X40!4(47"Z/MJV2L'3=1A6)8"O+;I(E81=-L.0-2(*BH) M.Z8Y" & F*/PN#.Y.?A4-
+I#;R:Z3L#%S@CIU4BUA\$6\$%8ZVTA/7YI-2F MV.8#O:1I(\$2-@ "FKF
JO8A=74JLDH!L!UATO6I2I9J_ U4*B>DS*KNU&C0G M<1D?XU7^(R>IG 27NZ-K+"7H&@@PK\$1
7UMD4L)ERM:S@PM T2-ZI2PN6F M-5H\$A8D3CX%7PT6XW(=%K>J U<=<54N).YP9^P@L&TL'9I6R.#EFOL=DC
ML0I+30982)H2H2F@HA_U9&IV;J^>5E P-6*7^L!Q#) M8Z \$LA!LM.P50;3GO?5CLXNB8!#"L/P-<67X7:X0!@\$8
+.(E!0GHT(U! M2.B:YKP.H_5\$EO"!NIOEKF9^PB.J^L9J0ROL;^1/2J5X0UHZHNF@RIC
M_U9&1#%S2I#68<\$16.*M.RS95@^OG)<^SE;A(LER=1T<5NI?W!^_ 58K&0 MGVA^=0QM18.G:RO-L)8!?
&WQ19Z?^Z:HT:Y.2"JF9-P(8-(6P@#=-P QUIY7 MQ/QYV6M@-
Q)VUTA7^(1C\$OPU4!)!YE9U(D3L86.S1Z(D@EIH TL)+I&2=T'10 M2>S?RHB41-#YBF7. (5T!1^*5\$I(N%
M;4UKXZOK9((=*O&=8D@*!MOJHE^X(%8 "LA;X;JHC<*IXS07<=<1=1^PNUWLKJ\$K0E@V,% \$BBK+BKC*"B\$!
I(2F M@)DB_U9&)"OB.A;IM>8LAA*%(2VF9/K!R7*M'6=%?H;O2DJO.XK94""% @ M0.'DHC-VHH(UU>8.D?"^
KBBH!6I+@E@YF:N(KGB3RQ@; 3&R!Y>HEGK^D(J MCM8;^H^K!FOB;:K0CEIWW KB/L/M!<\$L-X47TIQ;.
=FP.RJ2B/ZY60- MPFJC&;3.L20!76WQ5-A(Q M/ZTHAXH,%;52*2%.R64/XV/JS;+^"DD@R2J;R-
Q9PU17M95\$D@KG)C!K MH222U.01:16"8E.S1^DDLONU0@7;+E\$YH.2HGJ6QE-BB)FW/HJA9,&3I
MUL16*LK.HO^JMUUM!ACL=-8+% G#T!K!P! MV-67&BD?JU87MX8"9H-@1G:RJBQMDU-15JQV2.1&BKG72-
H;B3&J!H-38 MOY4120VEIHF+9\$XM&8(8?"C24G)M-, PK=1PTRZ6GV.FSHO;2OWFX8?'=W!^ M?/F ON&+;\$SZZ-
I:S44W7ANAI4-X&N+KT*K<08DNQQ"OKB9 "-2*ZOY5U M!+>T*%8>B;OFUD+E=NIGVRD#NJO%
I@HGN).*#;+40LM\$;C16 M(L_@ED(Z;+2=T'302NS?R8BLA);KR+IH\$;5@3)%*5\$+*#S8YL-R'=-;5^
M_3V#W!^?/@!RX6D1Z+HVWK)#3=\$Z&A0G@:XLOA!YQMB9I/0%3326B3 M9^VEA%I(CW%7H_3MM.
<(K@:B:MK2 ?M<"Z"HP;20?NLZU/\$5)VQT2.1#CID M@R5Q'O8"TT'GL^CHW(.2S=F3')).1N+J&<3&YR(X:F
BQ&ES)_1F+H+@M M5H%T&^&Q\$.XYN71MY4.AFX-LJ-"UQ1>I=(C3^(L_DX^A1BB>A)N5C* MJ.-KB!7>YJ-
>Z8;I+<>B:MK>>K<"P"H_K*P.X:UY+QR@US5Z).K! MF@R3 X"ISY@_*H?I&H6KS:?
09\$&1@1"@GC(CAJ8!6S.6 MWHG;8B&I@*0"DIMA;&L5^V0:(5!>!KBRIRJ^#L-"OG !\$@JF@5W!K;IQZ-M@D?
B!KI#HC!Q8'H;@HTP(#+7%5Z%T./BYQ.MIML*.XO<5.#8"8V2/*SXW M1!W+X=@9DVT A/?YY+3E.Z2!7M?H
MD6@)_ Q(X/3/R\$S"QA.F@EMB_D1W0\$MF+ZM.96 A"!,%\$2!6U>0I#M1HO".^ M94YBO,+^?_WZ7QI?
QGWX\$#NUE1.D@U^_1F'E:5LO M1".X8(31#X<6IG1(A/7X;>/7_16YBO.5"7.JUT?5UDT\$NG2#.L3-@F
M8(2!B4!0D\$8""Q%F?HR@.E#;HZAR*KN9B(C:UMU8!#1RCN;_3^SIV(X*L M@*R9M(@Z:W#I3-VL#
<4>R32(AK0U!5-1YW%_JV.R%\$E\$Y.\$Z!&*!_4:7%;*@J\$*C@&A@K!HU@^Q+);+BWU<%F;=6 VXA@IS<;CZS?
+)PEL M(M8!4HTU9L)+J!V0RK&P#8)F!UQUA4+J#K!;KJXR2P+\$*SAKIC8B3?#1Z8VTX.1\$1+*V%YR.1C;V
M;V9I9USXY<+WS=Z?ID#(9#AY"1G@+7^C(N2_9E@B^K1WTKI/T/H^I^? MKI- N+NGOI?O^F!4;H U=T;T&#
I^06^XG &:0)&/_ "YRJ<.2JT?P=% M%36%SQ^YBAB+Y+7@I@="S\$S9;X0W&% S%'?VBP4EAY.3(4W\$0MY M?
H5\$>Y;Q;-Q1!"9BP2DL.%EA=+&) \$X!3<3^S8RD>=2"5.SCI&0J\$14. M8;JOX
&7AR2.G!\$D(7A.JZ=VV+IV_VI^H*L< MLEA(SA5P5D;M:\$L#E:P1V4VU;LH;^6!4RR_1D+Y:29Q%-DD+^@
MPXF6^C)H:66X5N-E+0TCJG:XK94_9P_WOQ>ZCOE@O!BJM>\$U<:0'WY;MP^K-O5@H(QO06#<*&
((SN<27EXG>))LM&QP&L>NM!RFIV(#F&?H;B!INA)JV4+ M0W@"-46\$UI/T;:;IQG4SK%T8)N 5=,6
M&CW>05CE<=T+=70Z%M/351%UI9Y&I04K!J!^ 66VODXUQELKY#2N>G=;V&I9O;S;"P 8!M;7:UB=GU!_M/
T# S)=D6087/K>"T" & BZ!15YSL6'7N=I!%;<G<I<5=;%B'DQ6"Q)&#20Y>%P>E6QL-NAZ&3 L;0!@FX#5-
1M.3K.7 M;J& &9!5-1M,+9=1+7Q\$ "AR&MN-IS.\$WS&MP8XW%'25S88S;%G!6INSX?Z S M>B64PN\$Z.PD9L.Y!;
<@K-1.G>!TT&P =B=8 NIZ'N.4.B^GV?B2"92@ MZU:WM;T#OKV:9F>*^X TB@@D1V1?A6M21-WC0)!?;-
'XB#;N';&F1U.J&I M^);U:07AUV;%P9I&7+N^7IU<8 #3, ZL5;&Z+\$*7DJCF#HJ;HM5Y"#&6RXD
M+*YZ@=1M'82GF_!L!&@T"1NX@O)IFC^H4%370?C<,<")J-5?BCRJJB' MF\$ L^=908%W%/R21ZW%PH)G-
'A(Q\$00:TXA82IK!YJ!^C M/F@I6C.#*Z(JHUB""1CMQE6&@P3<(FSAI@C
+PD!8\$ T0UIG;*J&^CB_DP#KM6(HR>B!DS-%K>5^E47 MXZT8TA%704::ZN+/9> 7;B5\$0%U5".5;742."
+^V(MH5!47.W=N5"!H!L<A(I\$7;S@ MY\$Y:0 GEC@=U1?I.S!>?%S!<^M#\$PDA=I,%(IZ<^UU)KIDRN!2MW&V5
MR.MHN#HN:DN%_7R%ZSND:YM_B+2#=%F6.L P#8I!V8PD@1A(*R)P4AJ^&G M4O&G9I#7\$WG-
%4;2TVR%50C^#;4=I03M3QRK".X"LF9Z(^7QV5)X>=JW!?-M!H^WD@;_6%TU&IL7!S(H;R;I5)#&D7F!Q
M<4?I;U6)Q6RP\$;!# 8'5+*#T=A9)T;I895BL L\$W J&=L^YEG;\$?T?=%-26\$ MDKDU
<701X#7\$WA5^06J5=H;I53UQ=H0N4D@DG(TJX1B4S(=C-
*Z3^!^I!H&H;I6IE^PZ!T!B)T>CM""H(QO<AB^7JM0PI%>F MKJ/CV@".YU+HMN'M!O'@*2I;
I%@B\$^TOR^MGI!T;4)8%AH_V:05WTDI-MNOG:(&P(PO:IKGR".CIM"NIZHJYU;R>E.E^IHW?/RE6^Q\$)EH?

WL:9V&5HA,#D8>61"ZVF."17&H*AJ9\$)-
M:16@05XGY\W11R"WKOE3I#15A/\$SG(3 #12*7(M>L/N14ZF2.^NHW\WH-1>9A^=-7CW^>M5LSSI
ICV^7YOYIY_-=/7>U/O_NK-!|NGETIT7SP+3IOCGO1^JO/I^U?J?IYS\OOWL=-W7_B_7=O
ME^O&PS/U"BKYJ274*V\FK\H9;U^10^??HR_GN-@|G\WUO'R_..S^F^6K_M_>+^S0_W/H1+?WASIC|
2IV27>1ALDK_P+=9_FU_PL5_W9J_M2WHX_20/C_MRHZ2/MZ6:XO/LO_TO:22?U9;LY_HPS;+1S|W3|<M_3H?
4LOE|^\^OY_/8?&+GZ4\XMVUG|F7XZXY1|JO/IR_5_-^CC|4I#^1|U_M!^UY^1/E+>K_7?O'K|XZ2|^\?
KOW7=O|G_XO'MNBCK+_K5A|_IPTIGYN|7_MF17ZWWOYQO_03.E5=";3^4&)?O@/?
P#WU0+NYZ=-_WHRZOP_D:4P;|OHCOT_M*!^IOA*|VY?DWZE?6#V_2E73AEFF7U_XI>VQWZG&U^1,9/8UN5=)
<^_X|<4_M7EF4F^U_H6-W^CRKY2P|+XFPV|H=^*^_COI*&JZ|<7;V776IKYCR-I/ZGT
M_*|I/_UP|N+Q|D=M/GV%LY^>?EYD<7?_M_NX?KY^>-7#|JW1HFID|*S"Q8PG?QK7:S+|W5|EV7:W?
NGY7_M|P1/Y:N_M|BU:"ZVK^MF%_>J?4>M2HFE|WYF|N_^JB:S&O|3OZTSJ1?17FE|WRA9YX0
MAD>=S12K<.;3R2?WIOY/CC^5_/220%QZT(HF.OS9YV9I.H|<3)Y+_G|MXI?M?WN7GI?
E^_UW\WU_/G|Y:O|95|DOGZO^IG3|MW\W|O)GR!|?#_U-Q^1^MW#_G9Z|W|Y^_WK|HDL2/\$L2^_VZZS=
1/3J?UZ?"PG|CJOJUWG;V>1?_WX_MGN+N=W/K|MOL_ND6AF+|OS#O_G|I3^YK3T^EU;=Y?|H_%F12Y<;O=J_T>_Z
MW@*>3+SEWJIES*4C-\$_IXZ1HKLO_-B^&WU^|UP>OR9Y;?\$.W|L>USLSC;(_MWSV|OW_3Y39H6VV#)_-:U074I,
(^S<5NIW#_I_MW=SH116#_T0KURG|A|MFU\$Y=&-"&8J_6";@%4;|F8B"-A;0+*;OU1H0|<6_U#RA;OYD1Q9.MS;V)
MG#XE"JU7^6"DI3L.GV\$YKE7A>+?^F_JYR33^#JWI?K=MPIWOW|Z>OUF^2"Q_M2I!BS=|^1;J72-U6;5B^|JM#
D8^X|WZ_/G\$@2)05%-?V+V#V5|7H=-<)>\$<-M%9^0UV#F\$FXWG|
I:NNWC=)%WUM|5B28&^<("LF:1P\$ZLZ:Z@*L4172&P5NF\$O*;*BT_0:V_IO#V_N75=MS7>3=-7?UTHMA4>6%9
ULQ3>X_P\$?&26P@?@U|=O=>QJUN^F_Y1MI8|>OF
M|@\$260ID*3|RC"REBDPI%KO%0IH".O|>UTC7V%/0M1M@6+\$_P#8|(<404YS_M*^_X|
(J&H(CLG26H:59&I(#RO:('N^|BH?FD^CT|P2NG)|<08F@W,3(+50_M%,'BZ
119(HBY%RK%3YBA%,G:|U5%/LWLRU%<88:00Q_NL1;_*3EYJK_-)=^M/0S72MO1DA(*08F=*_4?CU^_?
WT^O_=R(2/1_GHV|J^0=&@&\$=-@#;!(S>M/>26_"B_-D65W4:YBA2*|I_"I_Z|H&,"+F1NP&_H08%U#+T2%HQ\$@M=
+M44|S\$DX5VP6PUS=|_8AFDR3_|AK=4+34;FP?RLCRC|\$.|U>*V1?V",D4H)
M^8?|Z5^RS|HE9|^V+=4OW_XZMW|AV>L%G(|H6^H:U|B^3-1C6^P^P3<*_MWP18WW01|?-'8BY2-K|*)
<^_L|J+K8OY<1J8NDUP\$3_M9|0^8A+,%(H3:QOW63&2TV87X9%>&CMK@M58FZ&^U\$)NXZ04QME47B6X_M-
L|R|0"V"5A=9%R_N:W:ARN=C_I(A(*_I?F3|3B#/#U#1^O.C3L:VP|GM9)S@=E12|S;_M>:&E7)
2)AGD+AACM^R;+IN./>1:Z>%R%T9JQU1N<5LJY"ZONV|S?4Q-Y866_M='Q&18P+!_P*K^B^5_7E|@9_)D@*RBO-
RC|TV(D34QPI%7@5YH67NUVZ+MK1C_Z@FLVO)"2|<>G>62#)R-PAG=Z>G7TS-)C|_8^#X*>:%E^IH=A"J7%|")
MH\$8OYE1R8N88XGVS(P3)"_X8^2QO!ARK4KE18%|D;:Q%1O<5LL9"^0O>|R_M@32RL;Z@&Y?_L(0|@&T^5E=?
*_DVO_H5_9D=|KBXUN;HC.SH*XGZALTEY@_M_W1#0E==;RB#(Q6<74%K?&#*L|C@_IZ=TE
_VOAHVBLT/K\$W>>Q-G="TX=O5_M_W?G|A(@A5_-^RO4_|MAQ^2R<5NJW_XYO\$|X7|1_L+AFHK4|3=S&^&910
M;+PZIG?6L5IC@|=4%1U8""2KGUKM(H*1P^O|KY#IT;(R#>;1175QCYK;7"MR0B06N0V|_
J77IG3UBY@;RCY2%_M1LA\$08H|>#18W#FOE61+C#>1VY8+T_MZ2T^10P^G&@IN;X<VG;7B|E&@;
B*Z|Y0PC0^836&K@P%_MWG4C&^NX6|L:Q^*G%G#7\$W?54Q@ZMY,74N%@16>UY83)>E4*K8KM!_#K&SX2
M.V%>QGIK3;H!;>C>F+_9D;47JL^E3|T|S|F(S!|Z;+|<60;Z7D;+D(Y2_K_M+5>J7^9O!AOO2Z4%/V6(QP|
|TU>;6^HYGHS+&\$8)N_DE^H?G^>^|PIP+|^@ZW1WMM-|G_J#R9,A@(|P|1F^;1>@5DS<2%_M|6L=O_%;+V
KV_X2,2%#<"I+YR.BHO|FOF5N(CYW4^E\$G"!\$*9:CPI@K3ZV_M5H4SN_LK?K>(5>Q@&;0)&
M^JMPUM>1J%+AT#|^Z_JY0R%?_JK&G1:Q_R>6;|TU\$OW_B(SX5=SZM|I
MGV#\$(OA@I%*3%|3V:U5N9GHKWA=2WO9K.SQZOP+U,1XBX500%5OCZ&MFO:T_M+0,8%B<L\$W_JC5S|AZ\$@;
FVL*|_R"@|DC41>V^1>|B+<^;1+|B|8>ZN_MXBW2-%MP|XJ:|XN0IV1K\$30.S|A^_60;W@Y#%3IQ.5E)?-
#KE5LZ?^2M^"-TRU%K>5^G^?_Z\$14#>HOW5;..5_M%H%N0#;#N@4_M@D8>9XBV.4_*H3#(J&H(CN; <5-
8O|>1N0EHIOF+|R9B>O(4_#|!"F*OVN51LM3F|S89*FMN^W4;^_?O+|_MS?T?^Y^_?C^1RP:8A7M+Y&IK;&
("D7OOP)&;BBBSLE&@O.%\$I81Q\$-4D07|UYFL;_M|I8.B=M*\$4B"|18_-89K7A*M;"P)Z_92,RP7
&";@)%+@|3|H&MT20=%56,,_M2:VU<|&@GGPH|IKG&)+_D|="1PGP4-Q=PS\$DDW,,Q0|W
&D4D.A.3|NF@A#BPF1\$%&5)6L+&D@9+##&&Z|>|K|6"#_C_M*|Q3A<5MI1|D0)"|VR52M744B6YT<-
J|0"V"1B|H@|T5\$5#(HJ.XJ|(|#-D4J):SL=CFLU7|)#">DR!_M0)"|FZ08MC3AX*FOFTH*(^F&6#L5P|!FX_1#K">
<|7>=|8LBR_#|5=|A&MAFD.PMG3CS@_|X;+ZPXPC1KH5P\$=R_Q5ZPCG*6UH,5E7>+D#1\$|31
M/;XW*^EL^|G@|@|==<8C5V\$9=+##_74_<72;_H0).3H^40%#;\$|C0(|Q_M|@_"5E)&|PO4BE<J|@P+724IK1_M
AA_VLLFG8P7)D_"PD;I=(V|90;+IYUPQK%0#8)F""\$8Q\$*9!&AK8B^T_M68OZC"|N6@#R>B^ON;
|0N;|D)A..|9WM/F+3QRKB.X"LF9J0_ME@S"/F-/B_M9L_W%'PD;D_X-073D?EQO|
C\$INQ+6^1!FD+QACI^7DVCZ(X5H|5KZ0D0#_MM?L8MZ7Z|?(!_JD+I"X87|Y=8Z=|YZ;87D#-
L\$C#QU8>0TQ_)AM;H"(K^M7E>_RH=WG|+@#OAL%KKBU;AHODL;_@J&X|HXVRF00*XQ#_WEP5MM|J+_5L9D;-
|AYP_MKWA>_KL+!R">TODKZMO#|T_M|L9EC\$ L\$W_J@4S3_1A((Q><"R".CHY""^IZHJZYW;|RG6&J?+%6
W@|@5_NZSCU^A|_R*Y;|^|("C%QU8MD;"LW+^%WS_H:U#@_!L_M\$|JOWA@*O/9^8^UX(|;A_%W35F9M@TS0JQ
M1W|4VY_XF>O|O05|@|^|C"<6FGRR|T0M-1?1%_R^R%TZO7;7.&#&D_A@_MA^3H?GGA?ZBO|KYY<>8J|=
|BME(9R">=OZ^T^0O^&D4D+^_MH|J_Z^|X7DO#>=20|M7Z7<_H?_X^GY|?U;K|B2^>UOD*FMN?T|T0H8UC\$
ML\$W_J|D+3S?O&X0-01C9ZXM_F?+7^Y;^N)S^4);_M>X<Z|ADW35W|=^*T=Y|&_163-|X;_152)B;..H)"H^Q^
4UX%5_KNXO_MUHRKCB7^@B%;_Y8IT%)Z|H^M#=-JP.D8TES&QW@Y@E),=Z*(7EQS2NDDXW|M!<K^CPE8-7|1)
@#84W|15#K7-R(>K^AP&N>O_AZY2Z@:GDH|FJ^C8#\$\$+!"K_MDC;"S67/P2+CAI)%XG;-
#4%4T^M<;K8QC_X0U^N|+BDH8PG1S48|(M6|0_MN14JUOK15V;JV2B/032H^M6-H_P#8|(U0;>^Z8<9JC;.ET|H@
V37M|JYF:P704F0-Q)YS;5&E&O|4K%_MG8_7D_@T7J-/^I?+2&_UTUP|DXNZ|B^GFIW^O_4Y088AM;&Y6"-5Q+Q?
4)FIV"G:1<1DAN;_U_M.OFWI?K^YX?7RR_|^H_OOK^<0J8M^N:C^F\$K&PZ>_JMZ8ATW0T85CL_L\$W
MZ|H.N%;3S\$R\$61#0\$;W%O/A/R.Z+Q;(#X/4?7HYF4S^FB0;|A9@|016?9&1_MU13(8^S&FJ+C"17B;_*FP6|O;
I9C_824U\$US\$E\$7#Y(33PUQOZMC\$AGI^Q;_MA7.G^Q.R&GPPTO+&OPAUTK9T3C;_E|MLKIH|+VV(I*
(SQ%@UAC:M>(TU;_MA9^H^A@P+&D_8)N_U548:6U8X_ZYP*RJ@HCN6E65J@S^79|W@V3USRLD7S>M;PM|D\$%
|GKBKKKB2"%W\$)>V6^&LUS\$XHSM\$3G_Z^CGV;V9;DN.\$FN4+F^803TN4D,7@PPD&|Q9*UUH,7HLDU|^>ZZI
MR+@MUC_=_^F|IT8GX\$;H;_HFVJ+ZRD&_-L)8|@&T^5E526*FGV8KHBQNO_M+(A(*
Z8;2O+3|_B4_X|Z^|+3YR|F2JD-#5=A=6.ARKX^R)N|^#2XV0%_M2%3NPL|PJK|H\$=+N|^>C|F+9G;_7<1H#F?
2B4A@+L.%2QF8OK4R7*M2=1%?_M2;Q|_F+O4OWFX0^)"R0OF^P0W:75Q9YK8RYYD4(|E"TO|9J|UCDM4Y?
6^6GV8F@BMME@+N>N^MN;|3|R0K_VA@E3_U_M281R@P^X^H;O&_HMOVQE1AB_Z5*=X^348S?Z
S&A:3%GEIRW.G^D?BW&XRT_M5)?O|ARK:0+9QAF|_1|BW?K7Q|=OGMY_^WB=;_2&00NDZ|X^E"Y,D;+M8-
(=RC("17^Q^N5542|_@AKXS?2NQ#J>|NA\$C_/1EHJKIV!&*Y5J9_HKTS>2.6UN1BW12KT\$^_M&"(85|U|
M!@9^0KO53TB#3MU#05;-3VB/\$2L@K(F?T""?_857Q1.01H|S|PGZ+U;_@3+M7U4U%;D_O#V-6G1=Y^>3=-7?
UW9;BK1H\$;(%AS5MA1&KD>D_9AA,3A|);_"MJ|>75JP_JY9\$#NX|7R497A6@V9HN#;1HS;_M4B%#@10%IQMD9&
I3&X\$;T32Q9;"8<\$"(N\$K)JE;_GZ#L+;6_KC2>+BP_7|_PT|B_|DSZPJGXMGM9MPV&S@UWN_Z7+5^6Z8,LPI4:_M+X?
APF4QG?2!2?_^_|2=|C+18B&%>|^*V|PMW0|OAC4_&P3L&IBPVH0_M|L*:_B

Wl87fW1&%S)^0=-:A|@EZ#^(6UTOSIC7580DFZZN|KI>:"AR>@*R5 MN; O;|IE>7M%P-QJYN+F"=WP?/_F|O?
W/V+%=N*%>,:U+I%>-C88"<5! M0P)6:#!;27)Y3'Q@R:>
|F'_5K;?/7B;S;8/<9\$Y6280IOFZMRMU#C_7GRV_:=80ZM7Z MEX>W;Q|>/_SZCU@OA!O:7Q%U6_7@Z?+_#&L0
-@F8(3MF79|_D5+L(K# M9%75A;|#LAW%N\$;0UQ_Y3=5\$Q)DZ)'2TC9OV|&X)QRHX:~N@L3)"OC(Y\$7(
M<|63D\$."ISYP.FHOJFE|F1+Y;PE|ZK3NUJPA6!%(2^68/L4R7*M!@Q5<|1>W MQ2K_-1!2?
GAZ>HWE0JRB_0W2M4;P;|&=\$C_ZKJ-8/C3"J/?_R(2^C>X%Q_MN3>MBZ@>'0J|&GV=@L|S0_52%Q5MQ?
\$I*E47W%; MK"(Y=;YR(7AQU1NB;2LG(MU<:(8U"@L|S\$#RGD|13_/R|8;B4%33/D2SUA|H MXXF#
|G|&K8AYBG.6%#&XJK;_1UB@XG(T|JH1?BFG<-#H?CX.R1Z(48EGU_ M #4"TU|<+^K>R_7HC3K&-)8R>&M-
Q8/;|*D>M48G9K-6+VP=K(U#YQ6ZE_ M7ZYI3V^Q6(|M+|<_;"P"V"1AA|_CA"4T7P=A;:Q#4LNM;8J@
MB|L\$@+R>R+MN/Z<|X&7+*KPI?DT&=SUQ1QN^_2QBKPI(&NF+)*=9FV<3A9 M|X>/O%DD|YSZPNFHM-
B_F1'U3+!5U|L(ND*R|H6?2?U_`LM M4L"E;AH|'3AK@U!:=;|H7&-LV;1FLXF?L'2Q&U1E:#;4(C)5ICO-5"6..JUA?
05&LX23=-FV%F P#;!*R6UG#2@S 0 MUD(K;F';UMAXNDG&Y;WP^2UQJY|X\$6QJ&J^U#>7;&)E)-I^>ROBUNO
*11 M0"(H46<9NN%5Q@K;#A|).I'J16G8#"7JL.DUC>XDI%IPY
M4BG)S|747|^HV2U8N;_HKWP^Q;M2.^_#%#1#+0"R#S1TRMO47BJYG<_2!@`V M"5@U?Z\$|"-A3?
R%6@=L^+/_X#7\$WC_187*TI>=%|L6M;|=3IQ=PUZH_V^ MV(*|HU\$XHCL|XS0'\$32FKPS.'HV|2"M-\$3M9)S0=51?
fMS(B=;_E@_FKJ|BZ;BRV+^542F+FN1M#N|@%"LP0X0VL1L**UE|LV+ZL^G|P8@P&0*MM_*S&V0GV MJ 2&-
R0*PIE;DW;_5|TU\$#L7|KVS(09Z#1^446\$0G.G*#@4 M M/G4'9KI;4>;EK%:AR"RH4+=O E@|@74-N^" MCD;
U;0NK*.R52I^#P9|?;_8Q?64=D^(-_0'4U|<+^K6R_7?R?S|Z0;\$ M_?3E1*BNES*+NU*K<+|5;8+
|H1DL@N|%#>@Q;+W#P0+=M|8*GFX;_L;0 M@<M@<1FX7?5|J6Y20@Z'J=L&;|= "B !O)/JY 5OHEHE)P/!=8U|OW;|H!
4@N|X|U|%>0FW;S.HE!=""3Y"QHZH2FHW9A_U9VP"ZL"="2ID@;..FQ>GR5
M(B8|(+OP<;MP6;|EO')9|>07>|R/W2-I0+=W&J&)08_!;P|(QJV^B'0399F6C_P#8|JSM9.L3<M/C^61_@|V1"0T3VOI
4LY|7_+X'|GHBKT;X(MUH9|8MN;@X)\$>VOJ)2#8T97)S@=E1?|_|/B+I;8Z8&|&:\$WWI5(AUVK0<57 MO<5ML?
|<^>GICH|KQYCO5#O*+|D3&VU1>);C(UPRH&+8)6%U|D7(C@>6C MK@%D@*RFODANFHTPJ;B!!
<#K";P;Z9KD|A%<#42514%10HX;.%9(T&1N|X+ M;S J8'#V;Q\$6HY+X37RB)W0=%1|/-
*=NL)+U='BL\$3G#G14G'M|_PK0;- M5EBF HO;8OWKXYL?|K_X|_#U@OABO97Q-343GA)-|F;89D"-L\$K*J=|%+G
M#|K2>;>P+1#0\$;UPN*E6?M7H+_V8.15T!->VFGV"EO:4JA>_AR=X*R) MG_#2KZ=GT;5R#/#U#1^%H/
R|JU800D" HA.1:#1J04\$S=+O%>GCW_N|+V|>WV|D|H?T54;>6#HAN/MS;_8;M D8O")RD2R?
%@N0*AJ|H^PGE#%EIF@VZ7(1%5HV(|@Y;+E@6L1L+J M&OY*YQ| (G\$YR|*Y=+&+&# X7B2#0.2X|*#;5|)\$+344&P?
Z;+PATSH&> M)J203^#"B;ZT|S(M1HOFJ"EB4P%\$K>E^K_O/S;2V=3C|=#W4 M;_>6 HM-S;|* (|M
D;8/ND3A'D0!L*;H|9T6/L)2|1>#>@7>=5,+>|B+^1%& MYXZFX&X<|F@|*WWB5\$6B%) U"548.B;P"C1U1=-19|%-
M*|MR%D>_)TM.LEPM8R=|JAC#=-7"\$ VY8Z#=-*:=+00ZD(PJ_ZZ_U* YZNGY M|3UT_=2O7FX^PF;#_"^Z?
OOLA|S+NG-X^OUW_XZ<_AG2X(M9T'IOXY*8ZK%8?+C>WY5CAR8UE|L+G"#7+IN.D8RV.01%+K)*S'IH-
A|V/%S8=%E<=DAE+)|BR? MH9|C8JG85=L=ABL_4P6I7F6PS=|ZJX;#M")2GD&7N/C0<;#S8>1JMRI8V'
MH@H37;2TB|WF1_-XNM!|L)MA)&JW*H!;S08:H LS*7 &VW\$JL2558#?Q MXISUKU+G3Y_?|<LJO_KO_/*_?
SDS8X|OO|U^A_5O_0|?_039OQJD S=MT|NSW12?#PM4CW|<^4/CZ_??_03@?BS7?
A>RO ^DONOUJ^C=^ W_XE?H_ M_L/CV_6;IOIV\$ MZN4X_/%/_"KYJ1+K|_C?L+WR_K|/_G|_ \$/R^#J&
MKI6#2BFJ|ROM-U_IKZR+1|%-|XUOOOO_J:6>?OI5WS|_|(?X|OX/#YH|?OP M_|?|K|9_HQ?W+_YX?|=- D|I?569;E;
|1.1;0Y_7R|?_LWP?*BWZ|J M_K^W?O;WY|^5N;|U|OB_S%9_E?VE|H;|ZYVD* ?|G+^O3TO%+XQ0+SPW/^
MMY8OYY|UW+W|7/>A?_+H_A89|EW_HZ^N?MUWL"7CX1_|G|?ZF7_P\$ M?MAWM;|V|_R_2_Z_UE^_|K?
CX9^=|6?^KS^>ZP;|+>;^>_7SQTU_|MZO7CN^>W/_XQ>/_;=5'67_2K#|_|AY-IS-|O|M?UO_?
RCS^@F=*KZ\$RF|T-5 MY8?|=P7RW@?G|Z|<TKK|_ \$_E*?S|KI^OV+K;XJO=.#V->E7V@=F7Y-
MY5UBJ|C65|H>^YUJ?5TF?UO7 MKZ5X9YS_U.YY|_|T2B>?PA|Y<|_#CL_63| MKST_7_2& N;3YY_^|GRS;?
+|X14|U>#GU>DW|V_O_NAZ|?_035P_:=4>+N M|S&W7|6N83OZU+M;E0|G;7_Y|N7O_M|SOGY8OXL22U2_GZJ-
ONY^5M-SH>BGKS_/ROKNBS|2K<..3RU?W|QY> M/F3^5_/??O'1\$).E.OSQV85#W(N4_C9K1|JU(5K"
M35|X6T="F;|R_W^+;RLR|/|;7_7-CUO04_>_CY2Z7B2O5.)NF?>R=)T|TP M>_O)_/ACVX|G?
|D|EOEG3^W|_HJZ(QD^|7AR|_7QR^_QO^_*O'_N_UHN&QY4X;|Q/GFC M;#1_^WMR&|+T|@GJY|?
WWUU_/_ACNF|L>N*^K)LO_Z2?&+|*S%/_YE=J? M8CKW)V0-P<%FU*;MP"VK;G|P
WY<10MQJ=LLTNK<9"FB|9_@_|R-S9)|M=-/LY&E+5?R<<(\$)/R>?^#E|WK/YM;\$1L3@|6;\$Z->?XRJ|Z"S#IAA^R
JNV#LXC"K|<M_55C|X-7YM?W+-C'YB;?6;_YB;?O"8QD8ZD1GA@W;7D)P#8|J^MPCG5O_ M+^6;4;
_E!%K3Z>FV9^2?0*R;|BLJ+0Z65+P"GY?|V.(G|=J#7-WTD|L>YA>@A|X-COAZ;CTV+^=54D/EZ+A\$3 MP;
/3C3=V/(BQ=9CR+6J8ST^+82X60_5)S=HO484#=>+56XZXZPM^2#W; (= MO"*XMM;#A1O_X0&P3P-
6V7|S|JH<;4#8\$98>L1YIF?TMA+Y#U;_*6P^?1;ZS M0BGL;4.15|UZ>(7#\$Z ULAY>OVQS =O6)TU_K|
MWZ(K(?/9C8(%0.R'HPY0M;#G_7H+^OAF8JS6|0> ^I&9#UJW#E|6^OA;(>
M0P)6UW|XCW)54\$9B|0L;71&|3U1%U|Y(EKW"JN*&2'O)_+J&Y&\$@Q6@_M-3(B06*;
WUT1B1D06N|"/T^1H|L>3H|'9OYT1&9&@IUE'X%Q%RCXT5;A+RNADR|IRS#1|+8PJ M?
B|>3V1UUR(1+N^+1|E-Y(X%47(M&M9ZO&V0K0JAN|F&_)@F->+H|)\$H
MDIARRRPGG@;|J;_>CCJ|=L9E1|06=WEZV|4*4|SQ-OL/BEF M|J55;_51'0.&A2
@PE;#%#|W|T'Q;0.12|H?T=3I2UUB%|RED.(J#6=2SN;MN0(6.58#6QH8\$;_)@3TB M&1*DF69KA\$/>:'2<=KF0C|
|@|2W?/_N7?&#|H|MR|B&711|^A#^+5;G= MH@|94\$0B(E+CFJ";^I_@T6A_3_"J^I
@/_=7#*#2@;@C("O(DG>L%=3U1U|Z' MQ&FVPBC430_77T?DG" L K1&/D1;_)@C|J*+70)(52Q0/5@5/?.!X\$*5Q
M^>9_<^>_E_N0_9<+^9 M'Z*9*K5;|"\$#BDCD0VI<\$W1;_Z+H9JHSK*0 8)N M\$?J03Q|VT|4Z(R>;
H7HN@+|ZCKB;KF+D1E|2N"Q|R;H;BC=2&?V-P0Z@5D M|3Q(Q_8'IL@|2)-7=%TL\$26@;ULRX;
<0J.SB@VG22*!>#"6(?!>E7Q9G M;*8YE)6*J2GCJ3G^Z?|""^Z?7R/U@=0'HSNE;6LY-VT=(U\$0|L\$|!"RW&&
M)#W-Z4SW55 \$BJXW^"-HDWMQ*(W%GC-98;VR05<""^*F|O)|JY|LT&X| M31A3_P(SD;AC.YPS4WUDS_*|
T_XG1T"Y_N";|>GHTC_V9&_8CZ)BO M_S'T5G;LWR(9(A9|1E|@0AC#=
MY\$;C2HGK&|V;X7LQY8_4Q|V@W'D \$E|+|?2ZB*R9@E65(S&V MB(8 LMHR)"\$;B|XS66(76>@QV#
W4C<59XTNH9D"!^_5\$H1C|*|9\$A_R1#+U*?= MH_P94\$(B&5+CPNG;RA"+MOAC_E97AEB-G_- "HX 5D-65(38L-Z4
|D8CK|T_ MB=-'XW%_!2)2P_K*Z.L2Y)4G>"T\$>#V!1V|S|J#EHE; MM#>?"JSJNL,%G)S@K)'N6.><1^QOH|_8SO2-
%00U_|1V7'_JV;2';XM?UR ME!@*PAFCBUW'&@N%Z;=YA)SEJLMNT'4_Z|@1_AQWXQM78>GFX;L\$("@"&T"
M5M=U>_WR8EA_0>0#0\$9V7_-_D#MG8)X(T\$7O/DA|>9.OE1D34=|55B"@B25-1U7(_JV;2H7\$?-=+;\$/_
MSAA=|HP+5"|&-#A3C)U*_=H_H94\$B|E'COID;JQ"Z^>@;"R@_V"9@A2KD ME*0@|WGY_Z_(-5T'2&W3A#|*X
W\$G@USUS1Z)K0ANK2M1&C3U0=-161%_*R;0%6'MCJS;7+(0
MW_"#T<6V8L"U0G|CRU8H|L+K|FW%@)80P8WKWS>77|+65@2Z>8;QP_V"9@_M|+8B3K;O?S0&14-
01/<>D|8)O@GU?D;|USR9\$7_>HK)T>"N)^ZN(3.BPLD) MD%K(C*C7OD\$X\$=GCT|F1#/_3CB'\$%DG-
|V3&4>V;B*9\$>TJ|3IV8CH!1^_M\$+W@)S.NBQ2TE!F;J0^|09DOH\$1\$|*+&?5.UE1F1@_YPO((+8)6-TN5-'G
M)V<547X*R*JZCABF.OA5WBD#X/4\$7GO7\$?&.%S1JGH?BKGH7J|APL(*S-BHD MR=R%*GJ\$TP9GCT2%)+7L9%)
(AQ|M)S@==2|J|S(B%Y+T_|OE|H^')PQ0K"# MGPOI+IAAFJT&W0A_S|(|#MJ7#AU6Q>2Z*_/Z|@_&";@-5U(3,@
MJ^I"DLM|G|JU'Z>I0X#5W(6F50Q+|Q|T5C;LW|QH9\$B4_E="1<1#&&_8\$A_&3(98&^EC+\$;O5I M-RA#H20"

(4N""JC(D2KKOY Q+* #8)F1594B4ZWAR:8L#A(I/L",BH'FRB M7#LOJ(I@R%#@M98A4=KU92<%I"1?KS:-
B1*AY,5G#6Q(5%FXON\$0BW-Z/I1 MV) HL1B-PB2DW#KIZ:@-V,^94=F0F&W(C^(AC#&-"\$0?C:DOVB(8RK4:M"&
M&@&A\$0VI<>+TC6T(W81RAC44+P3L+HV1,G19N,T&IL#LJHV1.7F"T:X|M=" MD-<3>,'
M32Q1NI"IFJE1"Y\$VVFV0IG3J49(AO#1",D0?BJDMV2(U9?UR1HU&?*,^IO_M)?
3ES3VB(8B*T"Q:H+AP^K8N1JD@OIW=FI5HX%GGM14R<9FN%T16SC0%>3^#5-S\$OC?X-AI8
MM.HJQLAHDFA-UC,"<1-5\$M<#|DBX4RX.L/AK5DJ99:Z%P9Q:"TU'5LG|S_M(U(M5DYS%#Z=%ODA|
f(Y6BPH,O+|/27^Z%:Q>Y6S0M RI.Y%YJF):8UK38 MCPR(f|>T,*P-Z9QMDDI3&VS7-
2U6YQNOB>@9#|BJFA:AO5H8:7P"1&P.ONHJQ#D\$C43\$Y3+-5PNMB MK0R<>*J8_9L9E8K)LC@ (HT_O_TB)|.%
(HDJ MA:&+28U=S\$?&T_?C8AA6CW3.-LGJ0VVZ|H8EROR&LN8YQ>P#-"|TSI&-JZC+&F?25L:-ZXOR=
&P4TNN/53K.10N)B M-SI)#:&N6FVRUY6WH...&T.?LW.R(G:XU|:7Z9.N%9(Q M&PC9Q%3HW%.*&5"#
(AE3P<8HV=;&N'+H9A_4CG;+G-IBN'6"B/+&8AL4CG;-|FEJ@^VZ M*L|W\$DE.*03 %E5%>/#NE>"ZK0')
M|'1664\$:5QN@X.'XF"6J:71"IO&X&.%4.2LW(R5\$W(AV0FC)&(Q MC#E2*?
K/M91<7|/9+9B6:D17M^&R.38A&W/D=?2?U|_V3T^N|7C^|_1#X&M^1A&=T=5LH\$LRUE4|ATPX#5-
2.A=Y80RY'D&RFF8DN.7#MG,RSPFHN1 MX?H@\$.Y|5#<5?H?4#/DNG=JM"9\$:
MB91*C5NG:2M\$HB(3(@P+*#@8)F|UA4C,|1THWJ4|V1"0D3W:1#/-5BB-Q9X
MS85(M,LU74B#&N|JAN*LNI*+P0K.V@B1Z:Q@<(>-SI)\$(DAFD.PH.F7F@Z
MZD/V:V54/N2E570X)0H\$3X87>Q#|EPK#\$_9B%C3A^0U?4A264?O &Z^Y#TFY98.("87|0W%7
MW8|SH|XD.26\$U,*"9QZP>FH\$-F EQ\$)D>37@(@|M)0H!\$3X8(2#"3XA<%GQH*40T4Z=VJT)D0|N)@\$B-
6Z=K*T321R,*HS#GA&K M+\$1BOHJB3A^0U18B:2UB|7AC@==.B"2Y&F|GB|_@+N>N*LM1)4.%C|61A
MDJ3-:AJKC1V.0(DF:M6-6 \$Z|X14B.S2RVB32)+VY1*SA AGC) 0X2=\$ M^DN(&\$0.15.%R(
V\$@F1&K=.WU2(O/F1N>XHS+EAP*H*2D1|+M2|/*&0%9%6% M2)AN2X%84#>6.2U-R)K?WWC%+@;B:OZ1B3A9
5G;8R(DM.LG?#8Y\$:'CT2) MJ"QWI;# J1>HT=67|ZY@&A\$3X<(23"SXE<%GYH243V3)M' M2 0A\$81\$F%|
f0ULGHNC&JC,LIP!@FX#5=2+*YEI|@K'J@&P(R.B>:7(O|H*Y MZB"O) *_Y'E|W^N>94)7=&'J^Z%F^\$!RMX*R-
%,E|^-KUPV.1&AXI&BJH M-DHDX-0+3D>ER|C\$B*+E@H M@E872FB=0F1R|(+86(9^K4:E6(#&@CD1'I
M<>M.C84(W6QUAK44+P3L+I"Q,CVDCP:@/(AH"-|&J.6Z9"DZ9X&|GLAK
M;D2;|G@C@E=-B1B*HQ6FH\$|F_F1\$Y M\$>|7SKDIG ZH04J\$#T<72Y\$|UPHID2TILF=9D|)!2@0I\$=[73BW;2A%#-
U=-M832T-L\$K+4(BERC-C\$B*6)NGNL4|@:!! M\$;8892?RN99*X6V6EQBY+ 714HQP=6NW*D8&M))
(B12X>JHV8L32S5EG6%+MP#8JRM&K%!.>S2US)%E0S+PF|F(DX6@% M9VW\$B)-
K6L1BDQ|=A(OXM0Z4P1G9CL,*RL V"9@=;M8ZPY(*+8)6%TEXG.!!:%1T0K(ZBH1
M;|97&PGROB*ON1+QZ|!U;5'W.A1WU96(=SA9P5D)>*\$|HW8Y?B1+QV>Y* M88%3+S@=52+|
S,J)1)\$S\$RWM\$J|BC#"8!%^2J2|E C:%FRWJD0&D)%(B=2X M==K&2H1NVCK#:@H
M@E87242:8*YD31/@O@101>A P:X(T\$ M7G4I\$A6.5G#61HI\$O: 7L.D|/A(|\$LTT6RD,<.H%IZ-29/f1B1%8M:V2JSO
MR B*L.5(KQ-0"|"I+28KT%Q0Q3+W:K4J1 8TD@B(UKIV^K12)=(/6&=93 +| MP.I\$D>B)7FX V1"0T3W:A+5@'^-
\$|B.O012)|XTS(Z^T)GCUI4A:CU;MP1DX MJRQ%DES8IT*;TJXT@&H^\$BD2,I^-
Y\$&S1X'94B\$-|PA)0(4B* KIRAK1))=//5 M\$=92 +| P.H\$D612^GN@33 @JRI\$4IZOKH1T"N2-
1%YS(9)6!>QB<1<0<-<3 M=|5|2'J9K^Z+?0@X&X4SNL,U002E"<4/V("O: AH?\$A:BU>TQ5VM\$YR.^I#|
MFOF)#PG+'WZ:%Z(2AHEPQDBEM.>)'VOUHD,L,B)G=\$AB*M1N4H<,Z"&1#ZEQ-MXXPM=O=':
(0/1GFJ^N=;LIV+S6|H)0>"9\$S M0N2RAEE(B#!=G8->\$B(5+AU&ME6B"BZL>H,ZR@ V"9@E85(7-
^E+W8@-9/9'5W'AHN1H=UIY"YNE+OJQD.KG)S@K(WOT#K;-NV* MF_Z|O;
f9(\$S>VDRS\$SJ|DYH.F@|VFOE1.9#VVE6PIZ97X3T|Q^RHS'@ M6 MRWA:D,%3L^AA&N#U!%Y|G;
(fW130/"H|NH+D90?L7!A!P M5EN(&)F?L.69<<1@RCV2(3(I^;E11*%3?W TXIC>D,"RD
MV"9@=66(65LG>'3+|V1U98AQ^;0';3|PJYX\$+^\$+4R;.)S_E#<59!-%K("LG@RA|H@KB?JELL0+Y?
=3@E=WDD&X/4\$7649XA6.M57#61H9XC4T.V))\$&6G)RPP*D7G(I^D/V;9\$5L5G7GFW AF0(XR0#.\$G
M0H+AFC%U*?I P94\$.B&5+CRNG;RA|/-TF=81\$%-L\$K*X|7Z:@Y#EKS: M; C(Z)YLPEJ-&C
f9"SRKBM\$G&F1HRI0T)77X8D'*O@K(T,"1G^* CDR\$A M>UT)G/K|Z:@V;^9\$9#G9D,LB#RUM"%>A M=L.V9\$
/B6A(C3MG:&M# MTH=895% .|L\$|Z-B38_&RCRC_J+(A(*|L|GM M%#X3/P_H WCC@-4^!)|&G\$T0|^+N^H^)
0(AAZM1N4H@_MJ"(1#ZEQZXQMA4A\$=-TO_!LK1**>YB@LZE@!65TASLU+>W.WOI#D=?
3^155R+1X6@%9VV42/33|+/-^W-#_B&@H_\$B<1L=YUPP*D7 MG(XZD?V;&943R:/4.3V\$.T=:2OVYEA?.?QASP9 3.-
%51E.TJS=H894\$@B M)U+CXID::Q'TV1|3L+I:)*WSU|W*I@%972V2U")7DL*98BT"|GHBK|D627H=
MYE0|JH4=16M2#(X6<69&RN2|*X.B\$-X|L%5L1X.33BNS? MS(BL2/*Y9L#
fF|L DB)|+JX;1:0:Z7VC.L8+B:2;2JU&|2APOH(A\$3|7#E MM+*M#TET(149%E_L\$W
ON0M<5"1(M@0%:9AZ3E"NF\$D<63.D%>3^2U|B'+MGR5_\$C>J^*D0W/7\$76T?HJ3"R0K.FO@0)?6:P?3
fZQX/P(4KF2&2 N&N MU@E.1WW@JCA"Y+/C03(AHE1 004"\$ MKQ 9MFCBX|U!-14B2M*56=82 '-
@&K*D247>J>XU*0D|64X@HF<>JBZ0.MP|L)O/8^).8-SZ7B:D:@KB?NZON0A(C5G+7Q(4L|LU+"21RN@|^-XD-
4SO(F MH32RO)W@=-2'I_-B'R(TOET#.9T@T(^A |&*D6+1UE>_:(ZRX=H&SQ3HW:3 M.F1
\$8E12(TKIVZK0Q3=7'6&910_!PNCI\$K7/504>U-"KJD.4F^8DDL(P MAZ':ZY#E%|^YD6A\$|
;"KSJ/D00G*S@K)3R3WZETT.^9#1X/Q(6F:38!\$X|?U_A,B(V(" MC A?3) LX<3!>X)I*T4TW6QUAL44
&P3L+I21.O|JTE6NH&LJ21)LU>|L M\$AF+O.961-MUY#6&X\$5%774HHAU.5G#61HHHAW:")E0U3IX?"121.<|KQ9&
MXLSL!*>C4F3_9D8E1>(T>Q"':1LVA\$3X8/23%+FL<=:0"U9^BO27%,\$D\$21%
M^\$J18:LG#MX3;&I0C=9G6%#0#;|*RN%#R7TZE+XC|B&@&S?N|W'MS9# MYWM|74_4-11\$^#H1 MU\$|LNR?
XMD|fT@U89UA.<V:OK1):08KV\$CL2).+3@E88|3 M+S@=M2+|S.B*^>O*U-)3/6&=)T8V^-95IDP 6KI44NBT
TU"+ZLK\$TUS=K M-ZE%|A22B(K4N'B&MEK\$T0U:9UA3 <V 2/4(H@S((P\$%:|=Y:CTIV@KB?J MFOL0YU|J7M\$9?
2SP:W(O)W8W!P|63L9\$K'& 3XZ&9*4U|X'94A^SH,*RD V"9@=8U(>)FK|fM
>&|)5%2|:K7EYI4>4.0UOR(A.V|A+8;7#.5=M=2\$2M\$Y6<-&AX0L?9UP/@"^L>\$C|2'3;6PJL\$G/K Z:@V;^9\$?
F0X^"-M)M#DD1#ACI^+B.A;W5K5|B&=)42,|f1AKM\$S@B41"l,*5TfV/B30M5Q@ M6\$R6R|FHPH7B@.KCKB;OZ
M1B3E#|C"153I|3:2B3?7&^0I=|8|_8D22RIU/SKZ_!DXL<3H|L|Q95M& MY PUZ|QD)\$
88_*73V|X==TY4F6/&QHN!*(45V5VD|YC0-.((\$B-6Z5NZSL2 MW:1TAL42
&P3L+J^-(fFU)CJ@O@N45?=-B<|E@KJ>J&ON.I+BT&=Z<4 fZ8 MN^J^-(X7U6(T&(T 6G7?=\$>1Q|L#C>_(ZM:+&
(f3)S@=|HWH|+=OD+M.SAX'S!_?9>6=&|1 M&99*+|P*KZCN40SRWQ=?FX0T V|&0\$ND-
+I4+ZG|BCEYWG(%K|7/KD:B MJK.T*|GH|C:X"S8IMO|H|L4=@*+<.Z4Y5|5|4-TV|NE5|XMX>M;_G>?
G./A\$A0+|9>Y|MT1MO*"MAMZIATQM|W|_|BX|C7_..fZ/HY&C@.Y M#DXW!M08:|--V=8\$@'-
@&KZS64S\$U5DT21B"K.=?FA#(Y6<-8DRJ&S56-%A<4F-SH)'9\$N04GAS.S
M.YR.9CGV:V8TTSRTNRN|6"V4UPAZ.=+|L|YSA\$56+AT0|S@G2"YK:W5|MQW:C@F1
28G@1XTKJ&LK2!2:WX|)6&5!\$JS|4>-4%B58X6L%9&T&B|31|*2(VN='A(Q\$DVBXP1>#4
M#TY'!&K64YG)!N:"51\$D_25(IK0)0X(\$ M"9+6@F38HHJ#5P;?5I:H=-L?S|f"Z@D3G0AZ)0GY05MN0Z-
PL7PNG.95A*/+; M&Y*X;GE. KRAP*MO2|+.5H#62)&8%P^|MB|'?"/#1Z)(C)Hf:X0"3KW@=%21 M|
_B|2)68>C+TB=|@|\$AH0|IRHEQ\$>8V9+8A\$M|0BFA2 ^TH.=&:BXN!M M|G:2U(P;-I
<<\$K*X=-18UKH"L@1PQ;KE,1|SU1ODC4>Y=[W6W^VE| M9F|_FJ#\$DL49BM21E-VZ5_|*%*D1%*J(D\$4H

!L3VR*)5J!2B?QF)B L M&Y.TTKK"\$0!CT#A2!NDD60S*6IZ"ZI9:83Y.U(IPN0* &PO8&&E\$49<00?&J28H\$%
(ZD15[CV@ACKJ]>UDJ&S.?ZHARAX!0 MM>V0>%(4OAK147T*. *T 66B'AIG1VCCB0EQ9YC2LD?>D*XZ.E.0"O3> %
M5T@X=40K!>UH@+4./WNEH96"!!H#8S.V IQK&"!I&=V@B/5%[KN#2H#X)Y2.!O\$^1-ZN- M<^!T>88@&
f04LL#9B5)'A-5O&5)B>WF\$!%X.")YJL!8FV!%.. 0?G(3HE\$1*JR=5PB25"FA/*1 M*XH;E8B\$?Z.9HPR0(
VPM86(E\$""<^F3Q V6!)1(A>WW&\$07RTB*O>8E.M.6T.L^LW\$10"OP^""ET@TK*T 6D.2B)!)Y=X<(PTM86G
MNA)=6OF22.1Q.6JR*.TD@AIZEBXD>2\$06@V+GFD?14D588%*DB@@JH>239 ME(J:W@H5AZ1 LYFCS#+
@#;"UA8>42R7E!C!DFN %E8=43R.G!R\$N+O.;5 M\$2G2P\$VQ.KI%U7"!4*2\$ M^!S0+BAM5B!1_DYHCS#%
@#;"UA8@4399OP8:8TK)(JYS D>2'GU".X#7)Q""R2*PIH*H#4DD2CA>B)Y.*\$=X&LW7%XD\$F75 M7H88X-
06G.I*)-6-F2^!)1/7Z1".M&92/1.P1R7.*D=G3JR-O%H.+<6'^=SCZ MUG3.S!^7!RO5^^7EW#F.VLVVVFY\$3J?
%692CKX5!^!AHOKU:JR M:YR.;!S!5L&%/!^&ZQ-RTW@JG7T>3U8GH+AX/ J5Q2XJ9IW'^&4L#39S>
MLM&NJQORC?!)>SU:7T@JC M0>W(EVB^MRA+!5:/Q^>?=-/QZ.J^_5H.C3#=?!:"M^!(NZ.MTQE9=AK/%T
MYG@Z.Q.MF.F. IJUK MSP(W>I<3:6.NR!JR!>V7IRO?GB!FOFCB1L4IZ.WRT?SDI+WU.9FWY2?^?2
M3:W/%>6SJ6HNOSB).AG!MPWYHIG9P+O?B4 PS5-3Q60I8YIUZ3.B(SMFL@9 M\$3*R:Q)G@NO(KDF>\$5:ODT)
<\$!5UO_04U!3/-(F.IQB029IE.C.&^1E3*K)K M\$F>Y9.-%=\$XW.9O(SRL5+GU0!>^F)^XVY!^5V?
T3%74^;_VPV_.X5/BG!GJ4G M8S?B9GLQ&F.K#<\$S>[G2D6IF.R=W;N8V.S>RP2+I4%P6-Q2%+*.8916;*CPI
MAGKKSUHQ+DLX.+Z7+;8FO^!1=Q2^QH>"?IV<2W#>?^Y'O:./JY.YL0^_ MUH*G'>8-
R7.UU%ZODIZ1*A>Z(IQ@MT60!9G8 MMW:N#H5NHUIS! 7IT>9W9I/S(.N 7.S>I-!f6!6NYU)?69M!*RSS8AU
M*Z<1!S2-4H?B?XK!S.:YHO9W.4AHY4PB%AA.B. \NN?MUM#9^F'7KV!H;@ P MW--HUZ.X/UKX!;!2.EG*
f#Z&QM/0!A!W=JD+B)!LDKL_|VDB!>6Z@NO M"Y6>+!3A9^W*TRA:2!+M)!%_D8<-
BD^F^LY6G!S(UOE" M.SL:=!L MY9!H6C!NI3UD3=G#K3 K2L!9%FM5?L=+JA-L"P 19T.DK+&2ZHU!)Q-\$K"P
M)=4ZMT=MH!PZXP%E84NJ->[UN42;U=4 'D=)J ODFIMNTAPY+I J^!>(*7 M5&L*.RN UE!)M6:IOB1(RZ.IE@H
f8;/2TFUYJY"W!J#4YU2ZJK&S-)=5: MN*ZS>2Z@ZVS\$!U<4IWF6\$#V9WJ"(ZT*K_CZDB";0V@X6P(IY.WJXYH"0UG
MDP0LL#JBI+!%!*KB 62!Q1'=ZS.*--7DKD-2V.&%-G=C\$"\$0S@)05>+!&\$ MYAB65N"L\$6V\$YJ37%P)A
=W<\$X2!A59">[KK2XX8X-06G.H(6-F1)MA.:V M!J 2FZW_8=VL %P!UFXI+VEH@;PVD=>!.*(G>2)XP.1%Z; MP
LOCA86P&TAM0IG/?Z2B/-)<"7-GQ>U!&.;15<#CRUAZ>Z!DAU.^9)!L&D MUR<"<+MB\$!2#P!OS'Z;S B-O)?
(.ET>PZ/6-Q5.4N\$N) MN^#J")PM.)H3:DCRJRN#!&G9D-"4%GQIU1/?Z4B(&.+4%I!KB2'5CYDD<
M(GD3!0.00UJ1^+AJ&+ '8B:D>>4>JG+<+M2-0.J*?)L+D5;T\$U*XX0 M#>4C20(65APAQ'5&YY#?"I2%4<(!?2
4H5)N-QT&CL7N/B""GU8-6GCJ0% M7G!UA!86P&TAM01(EQH@#X4H2/BSI'9*_/!%<* 4UMPHJN.5#>FOM019>.F
M*. =0.A(S1!0=SP>1V9C4D<.*(H4I WBD EO'U9\$5\$4HH'0GA?>J&U1%-9D)!
MF%!!@.T%+*PZ0LLSV3ULHH&R)"CS%KZAN->G9G.\$*?QID=>?>=G!%NGUV=&J M&W#5)JZ"BQ^4PM(OH#4D?
E#F5D!X.RDQ.'S(CY0.A9.AB3@U!;JRKQ9 M!8/Z.W(IPO0) &PO8(%#^4B.H2OH"RP.*MMXDD)<.>8V7AK"UQ=
(0V5(M6MP%%T<8AJ450&M'(&&V9;^\$^C> SXLXPFP=KT(2<H+3C7%D1K&S).XPEB9
M.R"VD8+*D'@X(GE^6%I FF.E2\$!Q1\$=J!f6<7\$D08\$2*D->)"X67&\$^3MS M/<+T"!@!L+V!A01\$F>GV-%&2W
F1-B.(V)F1ZV/WDX#66TBJWGMPIJ7"(B M@;RDR NO?FA8.X&S9L0/GI=63HCMQ&N@+RGZO*@?
W"JY0B(&+6%JHKR1W5S MYDG^X+8G.S.V:M-J2Q./!P6?D)SE64!NR4 X0)%(KQ>R!X(2-2&A'_
M2;/R! =WIG!\$"10 V%[PLH?G/7Z\$IFK <@_L R!W>GID-F=%)D-2Y <-K MT-R'&OH.KH!@^*/?>I'K).Q!6!15(*X!
MX8'29M4/X>_0!CS)P"PO8""53!\$>6@Z51@H^I'=L82U'B3B\$+J=%K@-Z. M"-N102)!?
*P'P&L3>.'E\$<%A:070&M)'A&W*KQ\$#*Y!0"V%[!P HG.;9(KRX!^O!H@2P*R.N4A\$ANVH#PD M+;(%T DL3V+
<@^<)<5=;JAWSEFX35RC!/: M.10(&5A*U.D!/: =H1P?O=T!M!\$7N/*C.I=MVPN.('7\$GCH1F%86T%T!K2
M9A3H2E" &H04H2/BSBC.*./!.* 4UMPHJO.5#>FGL0994N\$!<(!#L!V!IX M.")Y+B
H")41;J5=SI'3PU!*>ZNHCU<BE239;(J:SH)L5A!1 @YUCS#!@#;"YA' M>>0%PA@0!H3YET9>H.Z?I
O4M8FZQG41;3O!X73;T!>2N3YU45>.&/E!L# M9_9B341!28.Z!HB6C@J64U=5\$JNS?9K(%C;FPGH
(K=KTFQYI/=8+ET720%/:HA%N 4HA1W9.Y*2A@N7(&
MBAQS5GN\$. '4LD(CU@:=).#A64/"O1 @0A_7#.KUVUG'A(T'Q\$0H^0CB?NF'A
MPH!Q!1F3P!@>P\$+*WQ@VS8!D1TER0 90'9"X0-C!YZ<*2 J_IL@^&B=G\$ M(*& NZ2X"ZZ+8
H+*W#6C"Z" F6TUJ>71FARPUVIVO.@BV"FI6.&91RVAJ:XL M4MV4>9)%L#O\$G0@)!)2\$18X2U@&-"(I-
%VE8/HE6LK=0Z+HLD*\$U"/4@ WU/E MS)"6X%13%JEAS#S) M(L3*MAC)'05(4"X2#T?U\$N9"@%!Q!2 B^!+J)A
M607.FM%/: Y&#N#SHHM0;'22.3;YST 3E'B5%<7J6!/.DBE/3ZE"&-MZ4V MJ!>)AR.2XRHU\$#16
761JM6+!\$BEM8!K(@EJDU O\$!+D).WJ(M3?N>D19E8 M8'L!"ZN+4;K"R1S2&P#R+I(M2?Y
Q4M8FZQG41.H!)P1)!*(<^)\$5><&S M2EA7@;.&A!\$%5@IHZB.V/3B4;""WS-D!Q2B/5S9DG:83EO3ZCB.ACD)\$(
M:>I8!/@:23-L8*2D9W22*\$S=V#HNC20H3T+!2 CWDS8KC3!_1ZM'F#P!@.T% M+*PTPHBG\$ Y
E@1D!J01YD_U!>K:1%WCT@BSAZZ3'\$D.IBXHH)+(XS#N@J<M-2.-,%6#NCS)XTP>_0ZD8@).+*F)3S5E4.JFS-?
THCJ!E"N3REFU;\$-'4L MU\$AR?-CAZVF.%52-D)1&8E77.BZ-)A'0M5(")/>3-2R-0"O^- \$+*XWPW+9# MY>W_0#
(DH#_AS3"-F^0%VJ&M<&N'SN.IYCJ3<&E\$4YA707. MFT&..K! 3YDT8XMSQIL.G1=F
ISBED>KFS).TPD603Q12:KM'&U2-Q..1 MR:&&L&QA:B2\$^!F:E48X=-./\$!# THAMO!C
M3(X^7A\$H2X(R+JH(4D7J&L3=8UK(R(WY@YK) BT34^O.C#;B."PL)H#8DC M@H"9
_K!B2."EBVUC.L&+6#HKB2'5SYDD<?284=HYTOEP\$!4C?/TL#B2 MYEA!WA;B0>CDANDSL@+!N3-)8/41C
MT@CAG\$JKG6<&DE0HG2ZD1#NIVQ6&F!0DC!P)Y*(Y^9Q0L!273S!8 L"!W'68N^5CQTH<5@Y:0FI TE;.:P
M5T>'HH&J=K/G1=E0LM<7AB8X*J0E--45-JJ;E "AI5>C7. +?M#Q4<!&!TL M;"0X5J&\$C<J&9H4-
JH."U!0.5'T)&LFD0-9T%W;"P=WTPP0L;.6'SFT8 MD.1AP\$!LB0@Q:ZT64G?2DAC3 !AH7/K1MPX
X@53!H+@+70*A*.RLP%DS MNHAFKN2#YA3@2QL^+!*(MJ>H<I!S.">D)3C554J&S-/RH@603Y%&A^CC\$0(
M4!^SM^/ <+<@H M+V!E1&>"QN_81R2"P&RD.H(SZ5+!T?D)<4>&=&P ML@)GS2@C.?&br/>*B(8D_13A!Z*.8.R4\$H2(DA.DF)4IB+ _CT2/. MG #J@ (650<@MJ>^;1."=) 65#A@!>GQ&D!='!&R"O3>0U7A)"K-
3+D#K^M '4 KTY@!5=&")>U%4!K2!HAH!UB214QJ4.GQ=MA.A>7U%\$V'9S(!I2ISJ
MBB!5C9D0<40Y/XSN)F\$JH.X")YCB\$R6UD=J=(8*KfJ\$'752 6YGLC"2J4 M4!42POMD#;LC_LY8CS"-
@#;"UA8=83;L-KD=#DV@+*@Z0G&OSS"20%Y; MY#6NCE K""ND=G2Q!O Z#%?YP=812Mf92"LG!
%IH=82R7E_FB_LXJ2MQ^+RH M(CY3W^IHBIO&GEN!45QVI;LPJ2/4MFK&""M2.1H1)!%@#87L "2R3VL/4<\$0V=
MSX&RL!*)=A0.?XT8B"O3>0U+I\$PJP3A.GVUAS ZS!XP242AMW:2BFLK0!; M;
(F\$Y9H%\$&^!4.GQ>)A%70"+D=B!DP"FE'G.I*)-6-F2>)A+\$R@T!" 4G;
M'&&M!>228(%#DHB:5D5"37_\$ZG*UG&))\$&9\$JH(0KB@HEFA/DI=3W"3 L
M;"!@8242)ERA.V'0BA!HR>1O&#;_F 0%VJ&M>'K%!J'3C*-9BH.++XJH M6%:L"(X>1!1-
YEWHSD<#Q9\$5ARN4.^*RA\$2 MJ!f6<7\$D08\$2*D=>=Rj67\$^\$#N=/<("P!L+V!A01!>GU&D5'09-B4A1'
MA#_A%ZAK\$W6-BR"/L&(<@W!ZD\$2%?29H M.)<=&HW3CZD\$=5ESHS<4:H&XE0&CFL!J!;8302-
6UCDL C"1YPF2G.WB./^\$^9!%I#)%ZAK\$W6-RR+2=N)' MC\$/GI*2X!RN+O&#(&Z-
E'7N!2B!EZ?"!0UM\$E/"KR06HB"VEZ K#\$M1!&P< "? M-5%\$4<"I73C5.W9!TIS>K1XA-OV*(4 ARHN%*
MK1:\$R)O" *H#J7R!JQMCHA#3T?P_*?3!ZQ\X+!+T^OM+3> U6&P@K?
M4AH63P"M(8U#Y^7Z*8X_/WHH.S=I7D0.C0U/G*)<0.U'2WBJHW4 V=5BCZJ M.\$4.4Q)Q18X0/R'DJ6.!14-
&K.=>1SA6)(>"CUVRAXA4/.NDI)&DYGB.D)%L M*DI-X\$T*WMHZ)N?)F!A90_-!&8'.7GTV9I 61*4^0Q;

<\$>TRCG1P<-TV MH1="JM"BUU<=[K\$X(HV48%;C/BX8CD6\$/P-2I9XJ JAB9ECRKMOZ#; M ZHJH-HC9J>3-
BIB/SZXJ<)6%#90QA7N\$XXNSH;*S)9(
M&-0@*3H)KN=B5RUNLKO*48)"WNOJLB(N>PM@)HS:@B(K=EO%0A?/P1UD!/? MN^GSH8J(7J>!\$5""ZWQ
DIQJ+5S9DO543U^I0B*H IA4A3IV+ QZLBB0Y M5E LEL549\$*;YU411+4(Z\$8)(33R1H61:1%?IJ A3KZ0V!_IZ
#84D0YBUD M@&K&C9=0Y(6>0J0 2V> IT8%*M-8 4WD-@*%RH3!MWE6(P'D MJS
"IJ%TYUM8IJQLR3UH&%00KI_)B^5Q""U+@\$@ (LEQE? IC!44@#PC M=<2JEG52ZDA09(0'D! N)V16ZL^#3CF!\$4"-
L+6#BIP|IYT!8\$H3YB|H MLEF\15('D- ME Y" :=VX517Z:ANS#PI<1JL8C+;1<BCKBP0B*.N)3.MI6U*\$)%5 44>|
M2D>RV1 U7031K)_|_IUL'F&&| "V%|("PK:Z(Z/490P0??3HF4)8\$9?YB-M*= M"HPIH!F15|CG:Z(;", (= &YDEQ%
IS3%=&PM)H#2DBU:J|S\$A\$XKB%U^+PH M(A3W^A(GHJ8LB4XU55\$JALS3XH(M<6W" L6.%#I\$2U&6"L&
<5FOZE%RM1^: MQ"JJ=5(125"+A-J/\$"ZG;%81H?Z:*42820& -I04LK")"F5W)\$<<"/*O"DB M+I@V?VHO4-
ZBDAU<^9)\$6\$Y*SM2!(H8N:(Y(1 8#8N2:1E12(TE|&J M:IV41!(4(Z%0)(33J9J51)B_K@L1IE(8'L!"RN),-+K2X6D.JO
YOE09FW ML VSYZ2\$@C _H!-0*1-Z#6NBS*!L(\$A02%|/RGP/LLBC/|B"J U)(LP>R Z
M\$B|H31LH""I^KS((DSV^HQQ#E4L:;IHR2*5SYDL64:T^PX@2H2)F2.2 MXU@;4X5E ILD.6P:F(5%GKI"R2H"
)E2(AG\$|=L"SB|T#T",I+!"|@ (65 M17CN\$EH%IK' E"6!&7>PC8<& *05I|F!1X(0X*X:37%P1.H\$D*K."B!Z>P M=
)H#8D>G-D&@("C J4 V&LW>UXD#IY='U"/).#4#ISJ*A|5;=D^Q6,'-<(*
M9=LB&11ZQ.)UORP<|13""N2VST#%IL*QHR4E&LDXI&@EHB%*H\$!"EQWJRB MP?V=>QYA)@0 MA>PP(J&
I9*49Y#FU^@+*RB8?LI\$3)T:MH(*I-Y#5>YR%L MTP6D)1Y).5=<.5#8%A:;2&%
I17#%;R:'&*XO\$@>@O:ZE""CTX3)RB ME#QJ&#-/11"G8^RT!C4<I&&\$M*<1EXU)\$#JM=:%
(1.0:Z/2B6<5D02U M2*CO""RXF85\$0\$=I,\$+*PB(FQI?)1?OQ!FH!9\$ICY)"IK(7E|BCB%--2GP
M0A1Y"-7K|WPL;J|SUA|A0!_R>0UI3B(7.W> \$(A6^KL>1\$|H5O:8ZX/CI- M'B*4 &H:LRJ%WE(TNMK
:=YQ.P)UH)#8#4N2:-11Z"7.11Z1#EMT.P^* M/\$ (XE.1924/Z.^ |PE0(&PO8&\$E#T/+(D(/-OQKGTH8"=6VB
M+H2:(460+R@4#B4%5G J0TI8-H\$S3VK&#KP4&#& RY-J.YSUWE7?9<^|<5CI08-Z!H|U@/M.ZAD)*HE0HA""3Z#-
MZAG*W^GD\$>9! &H ONK9RAB5G**V/-#8"R)"CSEF2J:*)/(\$2C22(J Q MIE7*=4N@"K)1D^ (NN::A."RM
%I#)1Q*F-75=DR#2K7\$X2.BBBA.3DL0PT>K M(HI3G"43-R(^(#N8!)D"@!L+V!A%1&=FR6+(^+Z:I
61*4^2CQT/I47J"N M3=0UKH9HTNLKQ# D3R?%77 U1-NV|P)A#\$=X &BAU1#->GV&.(3/I)GSXL8 MHKFA*4="P
D>B>/DH41\$BRY|_IV+T")2(2"R&E#TT*(BQ23:V3@DB^4B24 MB(3P\$WBS@HCV=ZYA(4A->P+P+(LJLY
3MZL4\$E#E)Q\$_. (F10%V<&8;: MV.W-9B?8I%&9.Y-|>R8SVH.PE?>)/G0Q61.8:UM5V@^;9R>@C,B=@Z=H"
MX*DLG0H1;4V#_. (H8ZD<1Q.EX:D3GKIAZ@4*\$L&4(I|V27\$77A7L1P"; UI(3@ (P2L^1D);#;F3"*H/H0H
M<9P|""*8=-GS|UR<\$6I%(A1\$#JN!:%(0\$9%J:IT41!*4(J%6)(2?0L51+" MXI\$CS*4 P/8"YE\$0>8&P3F?K
&^'^?AAF!_0B|0UR;J&A=#S_Z_CR5B&ZO M20H|OVK("I8-*GP|LN:4\$ 46#N#S)X5HP EP|B2%\$|GJT=(4^:1*6B=E
MD-0%2*@"(=">%RZH9E\$.BPGR9@85MD4=M\$7Z%<0-874!J*H3ZDWB!NC91UWA5-M""6=I#T:@+ MH?
Z.4X^0HL(%&:\$N\$)!T5UC:Y8I2:6B<%D02E2*@"> GD+Q9081"7 TT M 0LLB-A\$8X(@|POH"R8C)/H
7JVD1=XX((RXV'CH@^_DX-W+6)N^""",.P MK)H#0DBC("1_9!"2+UO JQ-G1@C@C@U&ZI< MP!|*/2)4-
EI7ZD%EL)8)Y6!#5%*4(X2>09I4-IN|T|B3@("PO8"*538X MZ_491H 3BI0%DK:X-
H/TWJ&B-UX\$|@RE+|"Z""R""NV55"BBAI"1""R)"6".7YIM5:L!>4NOY M\$42\$I/45-
J8,*MH2Q|F'(*Z|/EW+LX(%2+U)|\$JIUZD5R""5*2:6B<%D02E M2*@"0">GL(8%\$6B8GR9@8041F9N5!\$)Z5|
62@/1/K3>H&Z-E\$7HN.5)+V^ M &N6%?;|0Y)W:J|0GW.@*VTV?(B9TAN+15E0%/B-'E0.Z2_
MH|TCI*ES04(H|XA0S3BL;*)-4-*HAU4LU(4\$>\$|HX0?@)O5LV0T.X^3< " MJQG*)R1.#XN Y E 9D7-<.74
O4M8FZ\$&J&RGM|03B-E1)8P>4.A>VR*1D4 M10)G)Y S%#%X03YI2G|YT3.4-0LBHAB6Q.1HJ|G*^GDT=
(4^?"A%"=\$:&> MT;KJ#)Y*HEU4LJ(4\$F\$ZHP0?H)H5L10T.^_3<#"ZAE*I/H8"7YT:P.+G(
M?_@9RI|4"J2UB;H@>H8R/KB M/FDP JO9>ARV3PZY RVC MR &NI.#RHF=H;LS<@P>?N(T)= SM+_SR".DJ7-
A0JC/B%#/. *SNH\$DJ XI? M@/J,>/4.R'NHYB?904.#2WJTPOLK)ZA6.^O\$*='|YT|LB0@|Z%G:|2+5#7
M0NI'ZIG;H|/CVZN 6"U".S">H:6E4<(P+<8*4.90#C E3A&LOSQ'(YQ
=#|ZOTJMZ(MAB*TO.'RH7>H7!LA1'#8*L2Q|F' MX.'ON/ (>I<!'\$*.H)'A0*+; &Y==WG&H6J6K62 JZ8@A\$-
A8B.XD/V<%%C| M-0U.8=D\$SDXF:6 &1@S@|B-I8&Y-%3 _^J@J=TT>5 TL+|CPR.DJ7-A0BCA MJ*=H5 G;-
ZAD8^M"G M"5A@/4.9G;- #*KP F4>I8TJY&FSSJ9(**@>:@EYKXY%;VINP/P4344'R6WW M<.*V0ST _R1P1?>
I'D1|@>VZRM:6D"" (IVM)1%SYHGB.%G-E-G'XO"@C MQIX^3I"*X6"AEN|TM.=VE#92!2GFED=&M|>?
K7!LA9QQ%IKB.Y6U45L.1Q4 M>FSK(G!41T!=\$%%\$NH0OBSAYCIB\$/JDP NOB>A>7R M%7 &G 661&ANEE=)
M\$;5'M \$#^MI-GQ=-A%I5^6(00516WBJ*XI4-V>>11%*C"/&=IX365T4B9"F MCH4;28IS Q7L.L& !51&VE'51&
M7B".6%6"R".7&4<*\$NA:GA1YC:LB5-@.18&DA"3JLCS*XNL+!"L2J MUIPF8EN F48(E+G#X FH@&GEK&4UU-
I+HY|Z2).%NJRQ\$14"@2.T'BY/*R!UND5M4I*(0D*D5-H\$SL+ILW*(0RZY|<)6-A"\$6:I MYS.40 X74!96\$F4IK*B7
%Y+2&O|BY|'|V3-I#:.01FS&4K:97"MSD3L)%WA MI9J7:A#&80\$%T|J2/IAP|45AM,>\$H?/B-+I"NA5.3H;G^4TM|
M/L6(*^D)3@=I9*=60S@PA|0)G<<=\$AJ#ZQC\$46L97ZX^)'@>(42/PZK:&A2 M_(A5/^ND^)&@I
B5'R^3MZL^_J=5.G;"-L+6&#Q0Y5M6C7T.0?PHH? MINATBO(=#8*IQ"C)H03WD*O-?%#V)8+;MNXM3KOL)-
TA:=K7L0/@6\$!:=.M\$C|\$.6LH09)!Y42B|D1/P3M|:5\$E(#+UA*P\$+*WX(898LB7(B:M
65#Q0A>GS\$D&%)1)\$5>\$G#=<(.B(8+4)K"/Z MAX:QY*TK2/>0N5L^I=ZN:@/XDH+/B^XA<.^O.%G
<=H)3G5UC^K&S)N(8G5 M=2.MK90H\$|/IA4AX:Q@GJ/_9*CE4UBU/R^/M@O+>@W\$"U!U1|1.1PRF8%
M#>GOV/(LR4 L+V A14)!#/I9FGVS9#@190%3RD?I<."&- 7IKT^9%\$K+S+ M%6\$ EG. 4ZD"TM^I
(=;4X19\$/QNF#(I":@_E T 1R"D13M6L)I+|G7T>828%+87L".UD1TD MV0IX.22J D7^-(7)<-/1>H:Q-UTY4|7H".
71)0G>|U+(\$@)YK)H#D73!>9+|_E5D|T>+>RCAJ#5X?_T")1RG|5TPW*%O|/*(|QQ.#V M N9=KM!YKR^./TP5*\$J"
(FV|H;I)>><5(T@=-A!|HOT-#G\$H_)Q7:K!."N MPJR=0K30%9. *F)^@OM^MPS:0=Q),Z>E^H+
I<17A#^@U!*I'.BR/47L2#\$\$=:Z2IP>QLH&CF&VHL=F@/5!7KKJ.1H*)XG*8!^0^5 MW 26-ZMI:'^D\$>8\$@&
I07.OZ9AF|3HVO)@:(D*/(7EM%VUT/%T8?S GAM M B _1LZMRHM<)445R?0+2.864\$D!K0+1.L+|Z-
\$=&8;I=K/G0I/0N=5> M\$1=PAD9+*HI6=0P97XD"YVS7ABAK271CA#(QZ,<+R|J(CJU"2Q6^U!0U*
M%K&*7MV5+!4\$*%.(X37B1N5+3N|'CP""=+"|@D12>.%POPU*0#"DB#, M73&CM@2\$!>8%O(HO)WD)O;NI
_!1+M8;.K9"+6+X=YFEU'F\$GX0MOJEX^ M2..%M16*; &RQ@01G!O:1A!4(I6."O">%!&,
:=VX72TMW9J20237ACF6^? MWIAJHZMC@4.2VP<\$0=F8))&657%@?N"QXE#& 64<4.81F=)FM5\$.'2C3Q.P
M8)H(AM;S0%@SF@BV)XM3I#7DXB=%7H@:#VS/#N?07#PIL\$+J1@*;&RYO0. M9|@N6N\$00%VC1K4@.3#\$|G|_-
?P5_!7I7MKYHN|H*(@D|M=H4J31>5!|=>K|J+ZOM*V7 MWG.OG0V+V>ORQL^H2J'TH+<9%9-
V+UJHENYLAG\$ 'HV'YRHM:A>9\$=KES M>/^L:GJIEY&)Q"/20UITZT60V8X/V1QM6S;2S_H FX&LIY XL""N6T%L6C
MZ%&E0D-L/9"2#)\$=3:S LH/E /2_) T:US;9W<7";SP?C|X|N7U2FR-CAF7U(CB9M\$^BPB:2^V!^ M2EL;5>T?
N+&E_OBYUDVOVS7);&K |E:0WT73DRFX M7D(9^RU+E#RX MG1?GJQ->KHS(;
(&RKWH>OM\$P^3<*U7UB^O;U+""^17>8+HY^?9>>G MIN_9FL>^;U)GA(O(KHF<\$4\$BNR9Q)HB*
I)KD&:\$TNFOB MA\$=V3?Q.8PG75.'9Y2JY^>)G3.8V|19+P\$*=^*1F?^1EE^J5|EYLL25 MQIPY>+L_HN*NHLU_-
IM^WRIX?K3!>KR+WK&1KAPNVG#3KZ;J18ZV4RNSP:+ MI\$-Q6=Q<+,.8I21G+
GSNG^C>VSPZRW_FS'T)7C\$%-@:9G2E|E|FVPO?H M8R|BOL(V'Z|H9EA=^E*VD;^4K1.8|!#|OI#=").1.C:|>X4)W1#?<
LWNDU+G?<M3|=L_"\$S>DK^H.268-YE6G3LH2O=)FL%"NMQ?GH>CR.K.RSS^1E4S=+ER\$V|>->LKC0#W9
12A^)_BL'ALOFB|G=I2&CE3"(6&&(-MS^=RS|MY+/UPZ|?J2Y34ZGGH9M+>|W>WBT'RV"K&-L?

\$TA'05WVZM"C8# M./ /JK(\$SETH"K+PV5GBWP4X6?AR334KBW)'UL.TG\$GY.1-LFW36KUY(YO-MI:TX?
ULZWB#_1MT.1BWT2RIDSFUL_M:(2V\$0!LU/E%^^^+FW%7&UV.9@5 MV:Q8F\$V>G:#FEFIN-9FEC\$)
<%'P<7!Q%'P<LSB:5+M)J MV/L:6+J)9/I'1-.,EY>D2ML,ES6WC M!&S/8X8I U,FL2GCK?I(Q<8M)PBSI:-18!f%
AO,HQ?F4>--"2GH252,+O_ M!LRB6%"#6#1Q-?+2;8J2Z!>?11OC!K8-T<=;X<^L4UR-.fN(0=3*1;>
M8"K5GDI>&J11WNLS@?"_HLP.6(AJ.3HV1KQ^H+C:267U3T^AK)HXISC6=J M=579PEIG4
&K'N=+3G"lWKH="Q#=52@Y1-).Q8f8C'_.HDEY M:C1?%.%7&3!2;1V.D#1#5M+X\$W*UI3Z4VTWHWXR5P'.PHP
++O*K7YXCL M<\$T!H#LE,*HIO650LY: O+2(G:1Q*9'E9ONB\$;=? &!=, +KKXQ;-6W'#@#
MSH+K53XT%DCDX=HG3YT7B8=3P1 B2f.A14. I3E6DNCGSI(HP9APQB30_
MIA:;)D*_.11NQMJ=>060V)EGD9<4HME@ T5I&*Jf%-E3E>OI^7 QFWXV1G4%I M8A!=LJ />Q"H"Zf-
<&XWVQ(I0"MI/K71KAP M6_*<0T)_4N%UT:X-!A1/#1ZB^E@IH M9793TfBJB RI'\$Z?CCFAKS!CB M\$!-
EO:45QRI:LBX2B,Bf_610EP?(XY\$2%/" HY8W@<48)C:94CSU2_". MG%YBBVVHRO7TEZ*87S-OD+="-2-
11VJE:%\$8f!> @4 /8R8&&\$4%Z284T M@!J@ "RH+B+L60!<"0V9^TF1Uf@L(EP:AQQ)#N
E:5YP641PVT5=0VFA810APf(-,7!Q+1%ICTHC*GO=LIRI*%S%_5W\$2L\$82>B^MGO9XX741f1971.\$>\$T
+K8MHJ_X2B:2"135Q^KP(IJ)*O PC<7PZ ? 4IS!2 MW9OY\$D:T+=Y5*.2;VBW4C.3#\$=.*0 V+F&D?840--
>471Z>2VVH5H*(W>3 MJ/UH<9^1-PY@,8/2\$2@=BP19E8 8'L!"ZN/-MYGR/"CPIA M &5)4.80?F-!\$B..
{6ZD:30:UP?T<+9"YI&T\$ KTW@!==M#V\$72" (=4: M0 NNCLAF AHQ# MKXO3YT4?
L(>S&FE\$Y98MX:FN/E+=G'G11Y2Y^5Z?"83E MMH0+A2/Q<&26D5@CVI&-
%12.%,X\$FMGMMB&JEQ/OU7V=1&X_@J_G@2\$%2XO1YD\$8.3f4EVJ\$;AK+>&IKC12W9SYDD:4RQW@H!AD)*\$:
M.A9N)'FN(30;ES32OGH(FEM)\$J!+;A*M?3_YJ.QV?7 24CM4;MUXJ0.G)* MKY;UK(KX.X0fPIP* &PO8&%5\$6P;+R
NCSXN'B!+ C)O81N, >WVED:9PQ\$U2 MY3ANBF#B^AP1#><)5><%%\$4f+1OCX?EK 62J<^5M=K?
*,8R0TU(LD3f7 M403: ^MZ<(D6.3B4 GN(41J: T^B"18N.X7N.%%0+Q(fUA:(10BLS&)(NTK M@B"4HJOP.
(f(3FfOC\$CFfG!)0E09F_R(UMS9 KI(Z&P)Z M;4*O>65\$&3>=(+T.G@I@1=>&=&PN)H#2DC-
"fS3;F#NA+FSXOR@BU,B^7 MB"FH&FD)3W65D>KFS),R0DFO.Y&2VUL Jf)AR.LU6&MM!(<*Y+G JH&JB@C
ML>IKLOW5!A3VYFY7B@8J7WV)Y%&"(20P=2S42/(fUEfVA&.%12)Hf9%8Ff%-E3+L: GLT7V8S'^AW-
MHfJDU M#f:1%3NIXf9E\$>:OV/4(TRD L+V A95%F.VV@!7T 8=* NJBS#: MZVN-.2SfD5>XfH(8ZZ-
%@63EQ9XP741QF%M!:= :\$D:857f)1H 35SBfE1
MfH@f=YTbL6f!>&IKC12W9SYDD94KfY4GfJDRX4Bf3#\$=8ZU@9(T8U50f4B MQfL:fU^UJZSf5T-BQfKQ?3VW-
K...3f6B86:1>7BfVB3 7f15B>G-J6N5. M6O^HKG@f)=1=Y?G*-W6G3-55&26@>HLE#;M@Yf3F-W7fRf0@;:Z).PU#U-
7S) M\$DQ^F/RA)Gf8C8;O@f<OYQ^fDP^VVP^QOR>SW%MSCMG.'XHH@QK>K.f FM@\$T
FQ#6)C2N:G)BTPf%PGQ;0*# 8!#\$*3H(7M9Ff>UBXfJCGFf'O+HfFLASBf4%D82%MHI-9SY43U19
MQ;Rf6T^HK&TfC_8> ?FfC4S.fAfYB7&0KZPI7U<5P=7UYVYK:GfZ6& M8NZf.W:3'O>7Z6(PSE&4f'3OJfE3-
2:HfC.W 2GVU4B#;fC@L4fLPX*LM?E3 M?HOM2\$%4*=>\$ '2Q07:G:f1f.ZZ3ZL=78%A00?VFS:X7E)Nf(8U M'f
+GM0A2f0\$"?;+fNU2PfY(Tf&S*8(f\$CM.:@:382#J5_?2D00;50fL MLHT2N'Mf1*+E-O_XNf;+f2"BC&NCKfCS^
M'D2f1KSYQ@7"Gl&f9) VUEMSfH0BZ?3KA@P^6'R:S7YPVH>0CB?4\$E\$>)NK M#V#^1S458/Z'G_@E?2-
<6EEfFG (P"&4P"DTA:;fU0ML% E-\$f1fU_3 M'8f3\$?1H(C*=&FfJB^E2\$*M@f\$ f_1.)@f0'M M+?=>K191
Jf:=R#?2>H M@ETNPfVH6FfX"470=J6AMIX POVN:<09Cf44&?Y\$ROV<&@A@O*5M\$HfY MF2N*+
M@fE*SQZF>LG#)f;# \$>U_WMPYfC;_V Ff^L+G_YVZ_M=N\$Sf1>C MJ_OR5Zf)Lf@LSE_f/+M33^fUZF-
H+O75_B'DVP_JWSfVT<#fS MfZf%=3:99J-2J<_&@Xf%9VY>6DRSfQ76f09>F"N^SV;669^<2S_9G\$16#QZ M?
5P.YN:*KV;3FVQ@7AG-AMGM8f;XSUZ-SHHSE)7Lf+O_NAfN?%22DN=ZL0fG M9O:AC38fJBfH6'QKfA;f^W?
9N9=RPNS5^f)O:GRV(^S28SfPDWM^f^f_@Z MfE!f_UXf1F?YNO&SM6)7fS>:FP5:2_F#^Jf?Z#M?
Z.LDFQR*97YD%?CNSS_B9'Z#>S?V3YNRI&LZPP" RS#f15E<7-1S.K@&<4H(SEA'4&Q8:8NfE!
MW+O'f+E'_CZU3Y0fZ2_VFBMPf^QOB^fVf^5%Q)Z3_7fCCXFBX*HS?JfL MMACf=W>S0REYEZ^#^86f-
GTSYfAHG?S.BAS=3K/8fLL>A@TOUHBTfL4=A M-KTG_&Gf\$;H MC?Z_ZfJT2F@NfN.Q^5=YBFf;9f^NfA^P*+
MOEF:YAfM9;VfM;^R5W0fW=F*NfW :MOHCfR^BJ^NfXfG6W^&CfBS S&
MY;DQ^=;4;S#%>OUUA/Rf!"U.HG=H-3>-H9fK(8 M.9-6BC"+@7.YSF>%XPW%Lf"AFODG
>244.%5fFESCO_Rf:P8#96fQ 766N&"Y>Sf@EPP MK@HEKfXHfTf+@V#<6fWK>K:>\$U^+UQSP?
C+VfN=VRfY.F98 MGCR)"H-(fO/Sf>NKDXVTN5EF)5Lf.G.5XYVf3f^M\$LC8fU\$K5>%=TXF)72Hf&X^GW
M>?;*&47Uf.f6+RfGJM9G.I=VLBYKH)=?O)S'9V:WFS_7fSPNC.ME_(SO/W^SX^YV>"fGYWT?
M_SVG7;fHYfH9Sf.fGKf;f)WH^fJF+=V&4fHW" MH-4?_
%)G\$Lf:=1GKM8+A/f"=fT.f1R7M_KfVf+VfZf1WfNfX#^VO+fJTWfDf2F
MS3PO;)PEWCROS_fYXV#L.FMD@T5V4f@Gf1@5KRWFcf8.&RZ-7>%%
<^VfA;Z=:Y3O'D&P)4Z3#4X2\$G2+"31&"L9DF M^P03F"(18
13Y&&*Tf!3Q#;SX(CG9B794;Sf0)O='9fVAAYWXVQ.T?VX?f MN:2163&T"f4 &G\$E1\$N6RC6R.P*_%f&LQ>Q*?
Kf7:EEQU=;f_09.fXWf/fW_M?E=#_&f29\$K6=MAf6T_8U0@3O#W9ZNOB?CfOE#FZ3>2Vf@3-<)X\$14P*Df-
Nf2"U=M='FR0:JG MLNUFNO'3#*>fT=?G)EK5+4GKf)HfHf(HfZZ=Q="A7Mf(112.8W\$S?>9V0H(MGLBYf(H@Z?
4E9X@0@>AV\$1%3NfM>\$f0fB"<\$f1U+;04fBC-2f(9_-07fT MF^DL6fS.)UT5,U<f"5>O.X&ZZfW4:2^QQ.
f:=A647X6/fT_f16.4B07Z.M^<MD.Tf(1PXUfJ8^fY5^f4.fE>7G%\$=QQ3\$IREU&(* M'PlN6+3@&8fX@H0-@&?<
GCT&H%Z2fW_fULT>(DfCf1f@L)4fTfB")N=CXYH.G^STf)ZG8OH0+&696^fSM:M@f1@2KM?T:\$=Y^f5@7f2-
&39Z)1Z00)K.GF;+5Yf:6S_>=G<fJNRf6W&0* M.f1fE@9VT2=79R(@CMDZ98E4?HR\$ _1f%2MR64Q:!
<58T)8PJOAL7&f1C.U: MYV(RK%WE7>@O(O%:f7OAVYS4M.:R"5;5H>QS581NC.MU%fMB3PfRfF==X M9P(M?
78F@)Df_R^B&X^ZX8%6fAL>A)AYH2.%)T+&?6+UGE;OfC3?SfSfU7)(M3G1*3Y7=5U6UH.ANO_9BUfWUK+
(GZ>N<4:UM5P2N.=+YfC9)<*fD*(Df1W5 M:ZU.E&B-(fGY+/BSf)MB.H?ZD%.Df1.Z9-fL_U0?
_UY9*OXF494"DC8fR9T MfZ9*GA(ZVNN+7".F.M3'\$Z#SD\$Y2NCLH6B2(QQ-OY+4 D_0*f*)5A%fHM1Q
M%=HX=^7^f!(E6Q.\$ZHK6fTU6Y=12)Z++f!@f1)#+TD.@A7Y5Xf2)X)+fOHTfXQ\$ M4f>67Lf FDLW&O
MF%5PfNSfOHA&%;#Gf\$5(#3?ZR""OA&05=fJZfMfT-CJ>JDKWf+Z#2fZP>f> ME5SMZ)>+>^O6(^>fK-00ZQ:@.D-
TQNF=TSUfOEA&K+>-(8GfH<=>QCVK<8Z@D7fBD7Q+QCVK_1SC2N?>X9UfUd5>fY&K3E8<fJ
ML:E8WNC:S=#O: M'fHfUK2GA.GTC@fKfVQVEH3:A1^GYGL3-?E/05 MPfO" OIR;+fCf!?
W6?'-7L79DU"SF9_69HPF=^ZfR&OO\$U&SfJ3=)&fMf^/ MAHOKE5W>:~
RHN:KMPPNS)Rf6^Q_RP9^XC%LE^fRBUEX: ^O0PEO_&f;"_JK+ MMV9O-%3R\$A=8:X4+EK.K"W+!N"fJ4N+fJBG
KQ#V+W.MW7<f6-W\$Lf^fJOC#f/ Mf!^O!U?FfL'X^#^fIFU.9LC8X;ER9.H.(BGE-75R<;Z?(RS+(RG975_F8f1
M*&E/O*70337DEWfL.KZ:Rf_<=GK2f\$KA@W7O+>+LNMPNCOHJE<(W^fINS%7 M>
fF=f5*NV//9XOS7Z6SQU4fSRf3-S*T?f^VO/HSEf^fL^Y6?#\$?f_ X M>fOFOC759EMZfF>G%f_UBf40f!859Q6_M4C:
f* 8"A4D 76 WTK8*=9: Pf> MG6>K@T9XE:6B<fD?2.G25: fA_&M65SCH:Yf_@=Ez< MKWYXNQ)DfO-W>Y;f!>f
(F3X;ZP?"DJ< R>Kf4>ZW_M=+Hf?P_1=&W/2)<2_5VCTfF\$=N%IGK6#WN_:#74WHf&fJ+Bf#>Af5^>)MGB
M>GfGfE.X_Z&*Rf3WK%EAX='Z3'%.EQUU)Gf/f+K5?Tf5K_6.?>fPAGRGCGf1KMGP>7 M158>fV4C.*MX\$. "Y>
fA6K7f/+*J8Y'2D)KYfKD69.Y_C-C'5;RZ.AW^G:<_ER.FP=T:_.84S?MV-KTU-W*_0_A6Ff+WQfH^?
f0_&fO=S44Q^W3U>_G^43' ^VAQ Mf2fA85XfB_OYfA!>f2HfNfNQDMP^?BVDK_YLE.% MDfB00fJ5O_f7-
PLCfUfJfB90f.^R WF.'GM735H:;C2fL.fKfL\$ (M#=\$9fFO Mf_2C4E2:>1+_1.f^M)fIN.1#E>M\$Lf_%.AL:2OD&ZS@&-

SDNKG52;V.C'W6+W!!A2CP75;<)"RRTX*F)M.-%@HI43S<WRKC*IZN-'7G-7'2">WV&%.+JZ*.F1^5)M:I!>GVJ-2
Y3-Z9&BZ?&2Y:&7U?K27KR+S[VUL'(W-B3M8.4A=')#X%.(ML2W1G14&0!J(.0068<3PM-)4A'#_YP59B&86?
_S#_6_JBF;^+91L7;_5WK14;+V;2U&M9+;I0N-3(VVPB1&+SY%5;1#5)&2D_Q8A8KMCIR"!GV#;M.?
LB9.#N3O=SJOQ M5B.0>2"9GN+VNS4%;IU%0/D;T!\$!&O^XZ@TM^>@ (2RWF1\$ "2EU&5C+8
M5E6G.OX:=Q2GB#M2LGOO"X%"#Q"X+&=@4=YDI>M7V1B4A\$#DL7.1QY89(R&N+@D;V&N-(&YR'52'>\$*F#F
M.16Q.2X@-I-HQ.OV\$5*GL19E">1PE<1"1;6"4*JRJ-DD=[A50.*748I7\$@U-MNB-QTPFIOH.YHM9V;
<1&YLG=VQ057E(YMQ-Q1S7L;52WZ>SX;R8!JXLKS7M-QI(WHCK?:KQUG>ST?^3@;1;MACW+1!"X@+2#4;:
(X&;912A;.%!@LM("2?MZ-"PMM0DC?B4;9EBZ*:-ZH9MLZ0+QBIQI/Q%;0W;LU&B1^3DL\$E-J!4K!P)^.OK:KIA#M=
MA.5U-HJ8"QL-IP;VE.=Q.9IGBVMSC?5#('J*LFC".COOK/M-E5+O#&N*0\$
OWI-VRUZ:=F.Y*6+O*%M/%8)Q=KIL#JRGQA!|
M;0PWF\$UO9NW<&_XJX;1QA3@ES=:F/*X+YCXPI*QM3YMLQY?IX5AS;>Y6G-M22-FVEZEVMJZ_=X>Z\$A>-
SNS%Y0UU&JH"8=4*_-R>XBEPF9PATE6X.*IM-K.0C3UM&3ZB:9RW.L3C-B%\$%A;:/F/G)B4.H1HMN=^
"E+J.4+)K*H0!H-M5^KQU;Z2T).ECG(&J;14T?'@XO!#;2.1A+12VREV1=-T-E)FCO4DHAEK6JC(FIT+%1C2-M0E-
_Y6PZXTJ.)Q4N*A^O/@TK08\$V=L0!9"14\$U/*T4-H6);8RME6U=MSN28RXMO.+IX?W-M1_K^E!YS.9T-
B!GKM5N/^U\$G\$ _HV'YRHMV;H4-MXG^O;(9)#DUWEHJ0&S5_)P5!?:G!;J68"#-WA@#<:-&-&V.=:OJ\$);
M';VE;1Q@-D-\$JD\$H1_1\$+F9OYB@N2.#C\$P2V^POP-Z9YI'P.)?^>0-SRM-M7?CHS<*->+J2_C;DR9O!
I.MHLG%5FY|SIOY8G1U|QL7!806^9068FGY1!7_M>RQI;MS96!-PCM7..RM_-9H.#2+GK^T?G?
I>MV;&N1=7^(>3*/1500WM-MHX%29!*PI?KT;P\L.C.J?'=T'S91;2/I>);6;4BLDP6UP7F9E/=I/1XCX;
MFAEH7_OON%1AC7*;H63<>#XGM7R<9A!F-P-9O=VF*ERC^+H.9#^QLS@BY9U/S9!&YAS.7\$?
FAV.1@/H)=%9)YXO/B-MIFYTWF>*MY462.3-YEM19C-ML<_"S+1+1ZN|B||B&=^:F(1^@:S^VAQ::J56
TL?RX<_IXJ9MIQIF\$W-M=N7LK.9P1QX?C^WQ25S-J6JE6OG>IM8NO:U!6*TXV\$^2%JJS&JSY2%WQJ-
MLR_%GX/Y67;VO/O=7@1R45K16C.?G!T_O/E!2?%|&Y<8\$+T>A!07HL9HX^3-M;V8.V>_.'EFUS-U#OIP_O-
L>O/'ZGJKA0'\$QF#;=:1!7;@J&_W-W>OO(-M-MI.S0N^&17BWF1#QF8D=L^+Q;;DPER:C=)N)6XIY1QZ2C.1A
M;_E.PO2CC/D>E^S!_9H!2;.&T8HR)<&9'GV7=>\$HZMJ?T8"GG-M+;X'QB6?%6Q-?
#HQ9MNLMIJ&#WID)MOWZY&Q(X-&'E%3"&Q@S'Y2,HEO?-MR)FTM12;A1G?
1V%12!N_'&97@P7!JE<&GE=7)QNSIC^BC;=:0_R_YJ4.+JBG(JQ#^DL<(V&FYGY7N!>N/^2!O!OU=7)BY9-?
WD7!L MW\$1>+;E80!ETF!>*H;0%@^_)GO+?I;1=1>;7!M%_DW S@>W;Z+J4;U<)
M+Z;)&P;WIK>X_4L'JC<%Y80KV\$|RTL@EUFDR2Y?>OGQF7GJS_7N1GW'=[Z4-MG^&=O!_W41B28;7H7T2M?_WG-
H/9=U/.#_D(Z\$.ADT3-R8&+%/M#!RN2L'V:=8Y(CJ6'AR>=C)M!1#?+;OYN?%;%^:W@1\$!_X&>IKN5EQ&>'<^
M1=.*<-F/V;-'WMWJ'SJ-'K6W%SJH!J6V+5ZS,ED!=|MT!K>PQ\$G>J%8-M*;K&YL"43Z8.W3|=PY2*
ICAMGOXC)FZICMIE_#;?)^IK+Q5*N^RIFHT=Z>
M5HR*/S=I=HQ0!Z3/H6N|ZRW^X+C77ND5=KWD#OZ<.9G0&ZJ>PM0=>A"?RQ5-MI-2'&
(G<5!LOH"HFJ@Y=ZH^EBO;Z'"\$2BZE*3#_XLYP>5CF#UK+ER-0.?FA-M@Y-GST)?NUH1+A;+I9+6;N8CK\+F<%8-
Y-3BL8E!>88D8!M7 MDZR2^S;MN)39W>_.Q.0N1^5YI(1NUIG=XI#SQ*WPY-O4>M1>#U/RG5P*2PT+;6D_O!\$
M7-(9MI>J?85K&K*X_M2CF0U.V=3.(U&*5KSS189YM?=<_AX?Y62UE>7+M_+4;I>7THDY;1HS|
5*G55.W9702A2IEM@Z(HW1\$@%;IJ-U9IGA@6.E>_MGTG\$=R2T!;IFA7F0!S6I@?7BLCUNQAY_.BC8'0>WIKO-
>GR"Y(942;9#;DN\$!;M.MSV1N+M_1=*\$L(T#;YI8C/D2.7)D0!Q",I-<7B\$G1O-E*+F^E\$>#Q&I
M8^('7=.80"W37H/U'XH#@_6;!OHJ1W1'TE1MMSX*?@AR+<=X3:8-GHXMJSXQ
SE.X11X1+V!8_G^#B8_JKQ*3&C>X9MO?I-M@7TSGGU?QIY-FL=+>1Z=N*USE"?\$;>'MA#B_#S/2?
@8PD6\$B1!EV1TO2;7=@-M(L-!AHD*;-JG=YILV?E#D!D@SOYI=-MAR<1-YIFV!Z.YGIZ!M-JX?KXNBL7;N1!#^?M
XYBZ&.&JO_%8"??H(Q>Z5!2\$CM'_D-M2?;02HOEQR|_9KIL|YV?JO^O!Q)Y?9.V<5;2!O!UUFQ/
W.&_01R:Q5A;F13SP?+72M#T;F;+;NK9!;HB;ES;Rf&P'V:00KQK=SOS.^/#;=Z3N2CCL-W=W)7^!D_MM\$Z?
V5)>KL|KL|=F!H!9_*W10TOWSW7C-J^LCXJ_BPNIZR29=;0J!E&E8)R-ML%>07SW8P^7KR!Z8#R>?G?
^J-W\+W;K+PFR/FZYEG9\4/9I9D*YIW7!L.B/-C.BHK3B5MKC?_I-WLXL23R>E1|>|AX
M!VGVAI=7D\$TO_FD30+^MG.F-"W=+MUQ?%I+@;+V(7XIN|948+W@^LM>WY_-WGV.8ZRKV;F.(+NZS/19S!-!!
M;1Q?7?S@!A'SX?)?RI-U-RWG=^;Q?W.4-MNXIUSH)HX79@XPUF-
JQ.83CAW%K>07%U58(S.>9FITW'NZCZYXO=^+V<9_6\$W4-M#L+;B3@NOA7CYVAP1OIKKN6-/B#WL&Z!FY@-
JCC|PRT^UIO!+>QJH3CIRL3-M!T!@+536_ZE036&9?_7)^9P?FM/7+6/UD4^YC:2-S+V;;E2K%P\$1^~AL0SV-M-
#1ZH8O-V|XS>|L=&YNJ'L^RO-M<9F-IVX-Y:Q0MY1MS-ZI!L5^9+7!RRZ<>5B&?JYF@YOB^W3V+;1CX/\$<4R4
MYX@V;W1_OKKK#PK_.\$7!\$W>Y/M#CVY9+;N6NNJ3S)Y\$OE!PVK_-MVJFTW.H/F!?
9E^F9@E8_N.77WX03Z>W(8K;PL4H/YE+='#QON3>V26G!M5-MM-Q>PM7(+!WE1FY-6XZ/5RL\$^!6--FO-
T=K^U5O!ILG.9SE_-|W)I6CBZ-MR|WA;+4O14D.W!65;;B-7TM_-M74_'YJFN8KY%IN-T;')X!&V-
\$IS/G^_Q7.1@OKFW5A-W@WJH&M;_#BY-M/-LOL\$=QKY|NS;f=;DEJA"BJWE(3N!2BW+5W'0.JR_+SQ@B!+
IF(^&HX&M96!)^_%V?T2L@F5K9>|=O_#;YIXRMEJ94?KC?SE;16ZG69AZZ_P\$F&F#*8E#9U\$=H%|2SZ2%|N0U?
_ZIL&%WA//H;22L-MI=RREX-O!5CW'EM^!62KM.'!OI6%^.\$F0=%_2N_Z?B8F-V7/<9<^_BR&T-MS9RC;
_U=Q.S(1N7NO!TO48NKJ?SW7&F";_NY?^'P?S49G+N'('KZ%<&K
MC17622!M=S'XL6F5G&0K5U";)8S@TOHOV!2-KJ""XU*%FX+NSNS7^I68-MLD!N-
BQ'QN:AWMNQ^0"PLY19V3_.F-X;*1BL""^4MO'LM>I_-SE.4HPVY(>CD)-2*%
IQW))M2!OVH(IMNV09Y_/LJO"N/IV4A>7=L.R-MIW;_N#(9'6W.M;KOFD*6^25?
I;/_87/Z_?OW@(^6RX#ZN/=/<4L^G8
MNVZL9-V'QUHX7!WG7UQOG3IZO*1EE&N|T5V.QZ4(V7;9MC4SX\$!TTVD>;"MI27MU)T"%S:CX/MUX9*D#YGG-
N2_JMCV.FSE5%K=7('EU=66HLR!;2N<;F5-MJ'6.6@;SBA#_1O_-+6/_VG6UP=#|32%9RM/8=;H(C59
MCR3&I+;O^W5H.VG8S_A4C+S/3""0ZE#FJV2&Y*3PJ;K647WZ6MNQS-+NIN
M|'B9%YQUN"C&H^);L59KRC%>YOZ8SJO\1V;.L34N'I^?OLLN#EQ>;<f=*
_R4>+C*\$IMH=;9<&7RRJJ0XMZ;I+Z%_MWV4/V";1ZQR?G?YJ61^ROC;N!GM=+
L?YB;:63J^WQMF^7"U.3L.W7^\$?L(IVIG6Y=#HS6\$Q6F75EUF7Y-MYVZOL#&^P!<=>RJ5N!L?
FU<.M17@!Y>I=C=V2;%PS6.8E_5LY878#A+M&>!AG;#&9O'PK^4-O#4!OQ^>?
ICN3AY@_8RG11;X_6%LB"4ACKM:CT9(IX-MAFB=-VJN!C=+LH;MX5\$9G%8N&?
P^%;=95!4|BC%P2KC<<"E8_&TK|ZBKXPGNO)8L;HFVWW8H=H(=T4;+M9|^UE=C1L(LZ*7
M#Q5E=-/250;3_KY3RPO7SP;K#_4(Z'RVWJ>MTEKEZV'Q)=&[+VF<\$?B!N!
M&26W"C08K!A!N'XO1"@O/^9G"?3;+U4-S8^1>56;=T(V!>F>V_RZ)^I+MML?
E=OO^2;K28U?;3)RK.TOM0R:U!75^YU)K5!9CL;9!;JHP4_&NF;/_MZ6(7ZUO?&\$FMDSE:WK?;^2^3#8>%K1UQ?
VSC;_ID;_Y8_"FCJP0^17V_LW%_M6MM4R>MV=0C!^7#5K&LETY7.&D!&@JMY<1ZX>VJ;YHXIZV>J;QWD_UKI
MNB!L7UZ*>%J?R5Q:'6_9=&?YQ4N)I|S0!V;HTR=Z7SW2_D9WOGI(S|H!9Y-MC^J/7^R-1%
(IO7DZ#16.OYF_R3!|LNGCU^>)0MDU<^?7I?_WTD+Q2X3B2-MW;=N!^V1CL9\$09!PY!6LP*"MO
V33V60TV#N5HKG5;BO?&+F!^D-#R7-MTD#H#0(2&FEG*!M;_ID^:6-CXXH!"1G<8KMG1Y2.M2-A/E!+N;IV9?9
MP.T5WLUFUT!2Y2&VY03!7FE-E=O<6VISQOSENOYLPE!%MVE-GMIL9)Z^73
M9L=\$RU4+F>)R>&XS"7%^P;\$9NB^SFEB^/X/V5QIYBKT9_%T-SAV;2?;@6

MHQ_ZV%3HM^FDT_C.3Y<5_V:CBUN^2JWX9K?ML17T5Z?=0@K1D#+<>C7_?<1E>=Z5^7Y^HLB-
=9Z8+\$A8\$5\$VH.N+/_B^E("MKB^XOAY?8C(TLQN78PR^T;W^722_PAEI^M/*55>68L+0JKC3IZM2KAVMAJZ
MF(^+PM9;+6NI50>^JJ>RZ75F MI(N)5VR@X:PZ52^LT*,3D^67J^I M(OM^&U9;I>A6A2K.^/6GDK4SW*/67TM-
H:OH;R/H-1TX>%>(F^Y0) M+V<+U=JZS+4=5IG4C-6A)Z#?WYO(&+U;OM*7G\$XM JOYN-S8OK
M4FQ/4/-9.60.C_6N3(KF\$SGBW4*UO?BPCA HKG^J#^_25ZX24MO+JW@MIWP697L^E-..9F#S89ED+I8HHJWJ\$#
M^A M5%< PRG.@?(WCFPS\$.ISSYIMXO.LA_5^V5VSX^N7Y6SAN7KSM;^<CAQY(^B MI&2V\5#GIA67?L#
(.V:2P3FTHMSB:4RE^C^3I3+6?/1G>W^.;IF4CWPPM M>YR67HQO %)Z6W8QU6:-A2FS8031J8R=C>:7/(@WNJ
fNZ;_5PLDT\ VP9= ME\ TB^O X M^EV;EJ4#ZJ?SP^+O^K(UJH^I9;IVY_PW\$1*T.OI:#JGC&.^6VZ)^W UM;VY
MH6KZZ(2673>T=2LIX/9(OOX\$96.AD)WFE5=JKO;V^IMRUN^3;8#;H:BV?I MW%56)Y-)IJ51K&ZK:N-
W=;"9G>LZHB7W0HVN A3;N^RU8\$V<.#QT8X&?.%I_+O+9+FIUJY M%J^DIT(X-6HT2Z?@HV4C^K+@N)G:
fZ_DX<35 MKWZ9SN<_P+M^I?:S%9S<^;_0V+L8YB;I)RL)TJHR50QI8-9^9"J^MVUN6UHI&U6GFGK;OS=
MOG%?"PJSO-OC+ZO7L^@7MMQCD2V16_GV>JLW^P=JEN)WHR;PV.<8E>.PUSP MY6LS"O8\$X/RA*ODV7\$J
(61Y*Q^X;/_<48/F>;_M@IL(UK X78BM.ZA=CJ MC.AZ==CIZLQEGXINO\$9Y3JRBR+"C%1L%X7YF63/?
_D+M>/_U+76D5#)Z)O M3<6I3.1UD^V0*O;3_9ENZ6!^W-0#PF/I3CX;)0IA=%O=W8KY9^B=MSIAV)^
M.10=/O*%CAZ^Y?+F-E=U&FA\$.#YV>U!A8^K=18E&;5?;D6:9LEIWSS8OH(I5 M^GJ9=
<5YW6U;GU3#+1.9F^&@7@C11KV)#H_B30.9GUPLS6J^MCAHOSUBV?46G5IFOO>RKS?)_TA!; MKN)I%_?
+JH:IV=8 T#RROI JH0.9) M0\$FJ M^8 !C_N#4Q9-1\$XIQ\$V)-O&2\$=Y(OX7PC;-)IVWJ."1?V7JBC:D? MLKK&OCQ1X-
/E_1>N3>WB2P+_*M0V;HM9V^&\$=&[8>UREV\$[BC6-I]>_9NW^E MD(0L3A#H JC^<GOI "20*""8QNDZ:VM1\$%
{@F#ZUSTI_8@#ZJ;P@6JLC^+V M7+CH")^;_I/W@G7U^?*\$<2_E#IM.U-Z)TEK*?OO.U.KSCOJFIYU+O1+(*
M^#JIB15X)MR^TRBJEY7WKL6I%U\$E^R0_ZI1^A:ECB^))K2R6LJ@GIM41/J
M#H;37F^%4^9L;_@/R4N2JMM91G<K\$(LM_0U&O;Z#+_NU23X\$5JPMQ M_+K&^H ZO7MAWJ0+^".2\$7/ICJ
MR8!<+;/E01P#>0*8U9> G)6: ?2WJ;"_+IF-I\$+9HJM9MIM9QARINO?* M5HD8DDXG;IS4M..IT.5Q?
A^#ID.D#PV#9U!<\$T7>N%!"@:I;_SLB*YQXD? M^97.AYHFBJ*T3%W7U+ _I#J9:/ M53)BUO(*G24I6/M)/+T.1K_PQ?
\$!;K4F>Y0+LSV9^<\$&I\$MXGI@DJLE70= MYM#(+T)6P_5J I3E1DQI1^M#-
AK5+\$BC2W\$S7Z/+JZ+URCY0J6_FIHZE)#^T MNE\$TA?2IM1YR>MX#_5K;CX.TRIH4+Z!7G7D)
MfN_YC4N+GMN&=3=O@S\$N;Z!7BK^PIO&@47=QVLCSP;GLIWM9>
MPN\$^0Y;10S&.%XIHZY(C@%>+45P#;C\$6^;ND+ U^WMXUL%(-15f'@#\$ M^HQ#K6WXH#=\$/RKU#UJ\$WQ/_
))% "1*-0X-/I3IQ%3;(QHJZEM+N=DGK_ M=5QK;=1+ZA^7==+V^%.6_2Q)0U8A;H2RI1;)DD; MZK%-M)9-
+6P%3J.1QNQ@CSFCL<6Y;\$JZY3' M5HO(JFE)7.@_YV@U&_DJ^2KEJ2I;L\$JZJBM&9Z3SU9H+&A.5^1->.(%#
M1B/NX-EM(J;YI#1NBYKL!=*+%E1=2O=#\$VMYA07WT3DN2><6(AEQ/*K#DQQ
M%<9PV;PAFWECRLQ)ABYL/M5DA6B%_AHU2S>>YIGOJ(^>;_A@H;_&4JT MYL?&U#8NN;E7.A2^A<=<L|WK0A-
5Y80_M/D*EA""A>8Q>K&U<PI=/H M)F*L23I^4AIX>N;JMFWD^G_XE6(YXS@KHQI4+2\$M@?@NEVH.9R(?LQW3?@
MOBGE0FJ#877-D)>US6NE/RESYG/ST#G^OV;J6H)_HLF2GC?4(?=E>_Q#W&MC
MLT+1^TTWVMCX^IY8+W91XG;IXWUIROJ)1B+%)J=L^2I1^RM7_V5PEYWQ=
MEI04%I^A+IB20&6QMDI.05M@OXCMI57M^V\$4QA+I16"_.P7@?TBL%1\$5\$16@
MBN5F.5Y#\$%DQDC6\$1BPEW3(PL^KBOAN\$Z!<;_!\$=M82^I=;!Y?9?>K-!
MU<%.N!;OJ#6^>CPOVL&T_TOLBHEM?^ND^Y3VE\$4T+^A7VC)YRSYS26ZA^W M(OQ)<*F:S%K!R89N+?
>"XVWDIOLYGF#_X^X+J)W".F>{(NUN2=0f91_)IA^MWYL.LOJ.0^T&++7=%+3@1-
2S703Q/19#*8."+31^VPMXJHB^%:KPT.4@I@ MF6#4 SDI0*2=&PA=/_UYM^F*-
%M+0*96^B.D;E@J@5!F@NP>505X9+7R M;Z<+;OMQP%2IDJ5=U;T+9%&7M5)=H!#4!;@+4!>4ZH(R+QCJ
CYT06GXD+4 M+?^DV*%\$12C>.*0H"(A)FKFIT9P^C-S^G)GYO(-SUWX_"T-4KHJOT4;188HPK;\$_HC41F\$9/*%Z
M3O/SCA>38)G6?<N0X0G)A=S^_U;P6EB>IR_UJ4IXNPK;Y^SNJW6(-4W M(9?WI?
OZWEH9/I7?7A%1GXB/ZN#07EH>44P#ZFQ^*RIY8FV/3^KDCSI64G;M^WJ\$1_.\$;K@T=7>HX<(FBU7WQ95D!;
<231MX^E;_4D\$0CE)B0H)R0L*) M^J\$IR8^WE%A_@J<2/IOQD^_VXORIX5..Y3VRT02\ZM@%+GI\$;EG;NDI&R)
M>#MOX#>R=)^")VTLL^PM#+&VNZ>:-GL02O-.D:ENHOF(?6VTW^5\$X(UQ2N
MJ55T_-=WC2^<D#T.0%;W^KZ3@QF^X4)I>'23O)'R=RTQJ>1%Z;W9B=4LU
MX0C6G/269NMJ^UEWJ+FA*6O@7%?G)E^@F/A>_+H2GCO^JT36C221U4D ME1C.0IBPGY.2IXSB8!Q3Q';
<*&8D/P^=@1LOJ;*.MC6O&EF OK27LGT.IT@ M#(^?^O.IY>4@R/?3@KFI=D-Q/2N;?4I>C%T_K0^ZW1^L!WHWJ
f0E;DZ);59?;CN3^H/<-(6ZUO M5ON4^@7Y)Y5^UYG\$^B5386QF!.%\$AGYW9^F+; MJ
U0&VPW)O4.@55@)W24D4E(&RW^IMN=)S6IRY3HB;2KHED2H%)<_>2 CJ MAR?IAV/6=CL;EZ5.[86&
IL@T=;>T^<(C=BP)O&E=)>M MDJHP>GZ ^_0L.^KCZ?%)%+;"FSI.TJLIL;U^>O;+ MA%JZ<2K\$K<)
/W6.%A(R:1LP0P)(69^U/Y#*>0.9\DAE[4).&G;2=4#64IC M^AVT63T7F&JS7IR!;22)ORS+)
(XJ<.>W%;UTS^UX5#1%W_ M^U^L@7Z)1S M^H-TS*,22F>R1V^#SIY+4DA_LD7OULGD7.2O3@=N-
\$LYVWO=%&6C_)WZ^L&KD/O7M^;ULDY^ MJFD713314_?^_\$.M^##I#1<.^86#FFNMF5LY+^T:2@fMNI#
(*N7C.F(OY 67 M\$>AFXC?5#f5%N;9(-Z*^I^I%X^MSZDEYM\$=-BG=JXU:BOKSK;V^UM9G&FE
MWGB^B@.5/RJ.RD.W^SF5G^4A3 IN5=-SZ,N-H0U+<4GE<IG^89-6P)I EM>;RA:0;-YGB4!7
M\$;K1;T1CQD50AV>@J_2^110IS%64>_S9C(^>#&+>H=FG11<IW)Q8N_SMU MZ1+D=DAU#U3/ZIH>O<45U;CP-
1CY0_N=HZ) H8^6BI@;8U%SQ&X;=#H3(
M13S0A7!6=FPRI7=M1Q4J\$M5=TI5=;>.R.FE+AN/@5!INDW^K_%1)D2W+8JLA
MDRZ^DL707/>MjHRTGZ(*4F_9W%WV1#T_B#[A40P)\$/*?_J2WI@^?C=7?P MS7TFI@WG?AU#DI^I.9OC7C(J.1>?
3DC69(N2\0ZMB6KI4B& M97XEP;B)O)H67LSMN^!IQI^H7^1.8S.@_ '\$!;DE=6=9S?<f0DK/IZ^I&E
M4R)!@R).OTSQQ8^AF;>CZR M_0=^<'U6I#;_/"0MDO:U2(L5G;ZWK6O^"RY X4.)^*VR==S@QH9C^5H-
F^8ASHT%..R8I@f#&N;J1BPS2=) M^M&f1_U)2TYW_8#8#4JHD5(J90^(:@^"K<7-Y2E.3IH>OJHSNAT_UK\$8HM M^
F#8+8IMJDHHL:7=2Y3) M^RF;Y6?7B9\$QHPW#LE:9M@J58;M6H+.#=N^;JU1BZ:LVC^FK.8H8;8I=A
M5WTZ=E=*IR.\$<=(X1T@C&EOW\$)8E8AI2^HN(DW=C<=&+;6M<fQU0\$^G+0HAREI>D/^H>?1G;V/-
\$+H(783N+J8_X:070XHVO&Z/U_H M^7E/f8>SWE;?^'(X^7(LN?B;=K\$R&!D^8_-GZ#^JRR>MJ(YXTH?BJ)*\$Y;
M23WU74F.A3+<;A&AJI41H?M^IQV^I0f=OD/_<44O9.RI!I)%. _YI#?^3*K%BAK MC%#H8_YYN.G?="&
XGMLLI6X>>BB-@S& M52ULKJ/_H>O-^I(%^Y%X7Y\$AR)J#J71@=@HZ^C0+1\$@LI#0^NI:9%Jf#
MWJT?WJ@WTS^I^?fX.Z#;^G_V?T6>2/X=.%+I@?G%SY\$35MP_MPN#_BDZ^IPOFTXG!^2IT=_O.L\$5-/-7-6?HU
MPGUHPZ;7V)?*&1S%W*&7L;N^:357E^2=1W29=)0=^fTOZ5/<_<J>2^AS>M.<)Y^*.C.T??
LTJ5I91Q1Z.X.D#P;MVHQ@fBJ^IN^#IR^4H;IH6(1F<_M_CIT8^VQMU)X^LISfNF?
Z1G9Z.G^J+AD9=Q)>+ANUT(%LV)4!31NC_QE8 M^F_OB_@?^"(M^F+WHL^;QM4?RTV7?WCP?5;=%*?
ZfY#_NB3OCZ M&E9F\$K4F%9IST^C<#^;fTZK(D^5;LL>TJLIL;U^>O;N^" =^<)C>8&@GSI& M^CRDY!&W
XGQ.R/VG^F4>P.9\DAE^YI/SYIP4G5 SD_MN /3Z!^6)9)^52ASVYIVF8^K#H:(INOI5>'V# (%W#@^IR/HQ)29+^'
M19>=>9>DD/YDBIZO9T^BYR1<3IPHXEGSTYKOTU1-LK?D42RTW^JK!)CQT^4_I)*1\$6S M&G91LDY^JFD713314-
?^_\$.LAA1<#IV 3;84;#(*THCM-@U92,3\$8;1,2#;8 MG)#:97?3GN?VA7:_TSI&#P5^US8EC)E(H>.%
f@OK&3;\$#fH:GH)I.L.V/MTB/7UW=I^T=@_JZ.\$X_%5BAZ;>A2;R9T^f02\$;Z(POO0I;_IMLJB M8X=)JG\$:"7?
TO;XfL3WA!@==;f%HR#0>ZAWLQT=3NA*#;_9_%2HR>V1_9_H#

MQ91"8>JE8DT4.IUDNJ1C:&0I8JXC"*^R(N;Q#Q.X>J8Z\$M)K^0<_N+Y-M7D7*!H+^+ERC*^=
[+>=\$GVBQ5WGO+002(*?PE=L5S\$3X/%Y;="NZZ!0CJ MD 81*507A62DT.%0J!6!C)H'QA4VPZQ98@\$MX;W&D
\$.4JJ9*E'CL+!_S MI-)RJDGX%#&@N!9#%4T%81X=>Q70R3AV<0#G;J5FPA^-'">SN!F!C!&M%0S..FK5<*.JTGDX"
_(\$5?=\$9MAU=0S _H07 M7?A2S7/&+H#JE MR&"F#CEE)&S=P29NX. 7H?
Q((H4!9#&H6!./\$*PBDH=6%)=D\$HJTC\$Q%Z M3M^>101KXDA@QQ;.%Y%@AXY
Z2H#2)H2=/_1 #O@&L3LH3G ^YD)&Y49=8 M=/_1 <2X6!_:/P _&VHQU1HLARU L@9VW.YP9E9Q!P!U CS"S.S!;ZT^!
MQ+!_I=OUO/<@PQ7E.YSR!N/R !0X3R^N!.\$V;_9!@FEZWV^_T+4!3:IOG M>#A#ZW!_\$/O.I9D"FFP1)F;2(MKO
_4X!>1!S0=JUH/AM!G?P9CGTPR16."\$SU9AW=9G
MX2IVQH(ND;/_VR/YK2CL.HA/3KEYH7%E\$^_WJG!8OL4!\$RF(4L%8" \$X6+3 M(0AG21%*>K=AK
=FM=5^SPJQ"!K\$!&Z\$D1.Z.\$!_!D;7W DT!UH!0W M?8J1*U^_Y0>V)QC)6O6FXWCG9U+6_%^JO!RR!"
MT<7*9Y5M>PG=)6P!DGMR!ALEXUY\$ _A!Q!S1S6QJ;K%D/ABF!VPJ9+L^%M! 637 !G!7V:WFQU-6M!?
+R(K\$=4;M7V_!W!U+!K;4%ERY2ID!V!T!N1 M.F _A!Y !V!3#16H: 0?096&!&.H!SN!DJNHV^32Q%29?
&H23U>PH"! MFM8S@6T(#Q+K.DQ"+N@E!PAHH-"WZ#&.YCC/6=D>T.(R8,O8L,O.8%)<^A.M2?H!H7V!X%
_(:WU037\$F_H4+J!\$W/0?W!_9Z^6U>NE>>*YG4W/A)%0B _CJ>A M!RK!_!LV!_W!W!GB!_UAU;6'_\$FV_!R5P?4!FXV_
GGYL'8'0P!ZF&^FNN M&VL=B:WLTW?S#E,U0J3689KGR!3!5NLZIZZ7&O@;!179'S*S'9KG^>/8BG7 M7-8+>&
_IV+!#ZL@9("N;N!OZRPQ+_0=7P*2N)IEG)GD<!PK4>R9=>X%_RCM84 MET
M@EIDOD!YU/H!O@H"G _!DN" TOKWU1"A/FZ)=GE6BQ>EFIX MHJY!74/7+!/IT6?R\$XS)*
Y/N5G2=VLB@CJ!&JDFE!Y!W+_!-=FYNKF\$=7ZW M?7!10>_!MF&V#1(<@YH09(M%?)>+^2F!#+.VKN!D;) +A:
<".V?ZZ+=NOB>?DELM D)_>/_!7V3!F?S?MZ/TL@8E\$WP_A!&B !URUF6/GO-VY !MS!2%3 _8(GFVR@XS0H?V_HZ-
K_M9W-NA _%C" _^@8=V.TS@SK-M?+K">SH!Y!N:CLU6!9(Z6:@_4W!+4Q!&X_M)"2P_9>_!
AQM*4HSNBVGRYE!XV+GZ!_JYIWP1^<%Z@GMP\$X/1FJB!4V" M 00"HGH TDV79!1+AG!;00OMO!+
H2&I"7!>%/X#0W>J!U96;_*0S'W3> M-Z&YHY:S9S!<+!(*Z8'(IT;<7NM;NMH!>WGI'H1G0CNM>-4?NIS23&M;/6
M^R#XAE9WLT!CBL_WMU^_ _6! 3TW767=V=*Q-#)!^7(*)B&),45H0=*7 _/H7 \$F)\$D\$ "H.5QS!JHVHDL M!_W
@VI<&!#? _MH3<_>_T!\$OSZP?H!&_&! X>X7K#!|<_7>?7' H2 _L=? M O+W _?QXS _/L>_
<^+&:QQ\$C1%*)NX!&+5HUHA10?"_WW'E!CZJ-H0>CZ MX!_="+\$1V3Q3;F!&G;3!F2P!%?ZBWN!_OJ.1H!6?
QL=UNNO!W0^V+_W M.L!5&?3ZK?>?EK^X;6S!1N0S9;C:MG !Y/9X)Z(<4 MZWO!_1H28!Z&_
IU _Y#H4X@V!PVH>O_/_%C?>_Z!X>LE9#=#MNR6E>&X-J! "MOQ>=\$0J_&!)%>P MKW@E_26KJ!_XD?
4>A2XT!7"MP6#PL_B5=31"&%&\$A!7@W>4++!+!PE!_ MA8(5Q8M?/_!NXF/6!S?AN?26\$XR2"&!>_&_!Q2P"KJ
3?8Y0IH+7N%|_MA.P4/DZ**#)_%R!_<3.1+ _#^%_Q!_&?&GHE@_X&YOWX8\$39!<_
#@WWVYO:H:QHE4\$WBF+!X<!% _7_K;_W53C8T(-?WG M0^R!ECC\$!B3XA_A!6'E3X112(7A0+-IR^!5(*I9^F15?
1:\$.8!>+K@<^C1(Y MT2_?@J2RJ.W!HA8&CD-)U3LHG;_#*^_A_+!H/AN/AS>AB!OGB8CX\$!_I2 M%16&&SX3)?
! (P5!JD>J!D.K>_3*231%EK%8X!E@^CV"@27U*!IGZ MUFK!_4 W?YVH!69S!N_UQ _YXF9V!?
7BZH!>3>&S(Y@O#+%2DNV!2VYET8C2:3Q5Y!_M>U6<7%!SY>K^<_&_<^>W%<7%!>
#L%"S25T7!UNKJ97!Q>S.KV M@C734C1!H!DF0!+_W&+N^&?LJ;_+=O/F%@IR/TPL=(6.DMW=?REO?_O=BF
M#V>2+!>3!2H!K;JE!&N&70;C#M#J!>TA:YW%HI?@_0WRE9"629!H?T0L&A\$);2!;
!8XQ"D!X_Q2M+NWU8VHG@*94L04%XBQWL M/_!W!###P659=TIE#77T-
BI.*%2SW6;7L":W*!|P(&PHA!"1S>|ON>RZ;# M?R>=\$UE;%9B!NY?3!W2@MU"VI1+I^\$%HN_(DFI\$!&?
6\$.DULB2.REK1RA8 M>LS%C6RX\$U)!E>TS%;ZA KZ'-!%!D,MCE86;6%JSL5.J\$Q'9+WVDCK.ZO=(MC N7.#";BU\$-
!F!@S& MX\$O6"TF#&T&22;*!39:A>8=>_*!&DQ3(U'5\$+!R!B!_!@8!HB!_(\$A=EY7D=#
M*#FALL_A)6_7=P5BLN!;E%66?F&ZG2K)?7E*Q7_%6N(UGJ.GLY!J3DA9X(49 M=R+=\$. (G5-*S>+)_#O@@?
X3"U;5"/FL%+*H4*2U2F)?G-3.XR@;7>:(AC5!1 MJ?@H)1N57+"A9F0TJBW5H+1.8;Z=J=J.D!J9LA.R"!OM.RSWR:
!T68PH=KWH M@OO3;K!A5*FQ1FVGZ^!IMHJW!U9V052Z11!BA;7&8/2;=R;DHLKK5&8
MG!;#&HD= T0H8XQ!1!8"EXP)=!<_QD!5A!&_#2VBT*;T36'60E/8V&H MY%2>D(W24(%PBIYY<!
_!^!#%VOZQM!WS!G+_9B!89K!RN (0QWM*GOV"Y/Y M+)E&FL!&FE*C9S>OXG)OD@M_4)V?H<+S!E7<(M?
L!;_#G/Q146J@PF<|T M-%(5)U3J_%H"-V;#KBO>&8C;_\$.?!"W%|_MD+EIGS&HRS=34J!528!6>J&U=7 MOS2VVD7-
V>G?UK>3M.+57B0\$*XIXS7_!W7!_+*NQ'#29*A8;_=/B.L+!LRH MAQ\$6N70;^81.T;9?KPF-
EFB)Q7XP">J\$6^@H4!JPL#2QL^!77QJ9XG3;FM7/ MTPS%T NK?2UP3"2L_4^K!_@_X!%KPTU_4"%5*E
8I=&8E4;NG!WC&M3 MR!5-0&G5PEHS5#>4!IZ\$MH:LH!_5!"BOVB?A)%O=^?&AQN40%E08H+_!?
M!H>HBE!JA8;_&NPEB2C-6EGG?TGDZ6FZP#8>U-RPAZ)*5AJ<_FK_*B_%MA9:(TQ/44+50(6*W13\$H5*_U26*
HQKV>HD&*M0.S&*ZYE&I0F*48"%H-A3!\$FN0!7!H!S:C2")3=KL(V5;L?D6\$J_F.A(XZ MI9D**PWJL-E3-
_%Y9J*NIU11ZE.8JK""4Q!*>HIE*(V+_QP/5BI2&DISV*P^P M/45324-E3T-
HE0T8NHDP6EYT@.8!XSC90E.%WF6J(7.7VOL.&R!_3\$IVDBVVC
MVNJW".4JE"8NK.OD0N1.O?)OBW57N=BT+_3<_&!ISCPY3/K%>B;3UZVT96'Q M9V?+_JXEU(CE!2!F1-3L-
_!L;M!B!&FEDQ26G/8!F_Y+=CEH!+22/+2R#(C1NKY_7J;GW=72LPY MI42LM.9FRMN5UV.XBXY^!4!45K=?
2)+_F^&GEM*/D&C2P.B^1_NLA!\$M4DC M8XW- _^45(!0+JRAE<5G?^3!/K=+?F!DTW!WB9RE6M-)
!134Q!\$!DW;B4^T MWGW"!"T?L!^83VBDI?_*PK?&I\$ _!3YCX!^!_1S1VQ#0 LVXVRA9@1VCC1.R+
M7V!HFT!+!&TD^_W!K)G(KP*GV6CD!W&2^!B(^?WTV5" MQL\$S!JDK _BP@%GW?%\$Z;JD2?_H!9!24<^!3!W?
>JE?<_!NR!TAOQRS.O!EDDNE#Y66..MFV!7PV6 ML0/6?26YW=G4YLYOX0.QCY_8N>M;XX*FJW*!XW4-
OMH>81?XQW?24S!T M9.PX"CU*IQ=)3!8^>W22=DK.T8M_DW!X8PN5:E#9IE-
8JDT!_WT\$GFE20HKI5N3G/8^>E(ES\$ _YWI_U*!C!6VMM2N5(J6%"NN66PLE2ANI MUL;MR2XPI5>+B!6X:4R=?
MSLJDW<_0!31981%Q!D)\$;R-3W\$@UG!#5Q+!G
M\$M;N6D4%2ON4!%:X!8>\$MA.V2=*PB_<3.H:UIP#Z"A3VJKXV.%!Y>8+*?Z
MW7#RLOX_ZZBF8^K>C7=X^6OK!UXXB>XZPX#*S0!359V!_!>O>MU&ZG;DS97 M!(&I9+P'R+?
>+4BX_24:8T6O&RK!W!N.)&HKFQ4WW"ADO&8%V_&_XEXT/ M#W0HS518D3H<%Z8*3!X^?<
4!-8#>WXP!MYBA8J49"TM.A:OOJE<_BS?GO9MW M\$Q;Z4G;6%>G.URVN0A7-EH!THU8LSB@7HAG/_
!4SB4!SBH=&&^!Z98=_M-(VM#999\$;HUR<NM19*B1Y!BQ\$S(C2;RQ33T7&6%3X MZ=W%)!2-
BQ'C!U=CV6PR!CZY^!7.4E^_*SK%+K)&F!FYSB?_B:E!1XCRMXO?YY-X+BS2?EV#ZZA7&KRX!/"@U>/O=X!H& M;
!VNP774*PU>7*;2&KSU;G_@JNO:W =!4J#%Q>YI:WWPVN.OAH=#NZO?QD
M:A)"GUXJXE*%2J!J.ZS_V.#:&YGZ%!!NQ?(UD;OG"266;_#*T_T71B^>KING MI+!|<57-
<#GF!KF!2!O!\$W!W"E!_#8F85AGD52E26E4G34V_E4CT7N2HJKU M4.2N
B.W;E_C:\$7^U+L>_7W<=1P"&/_=2NL7EO/R#ZSL M-P;Y7Y*XA?1>D7<!%VPARB=WQCKU3<^!_ZWC:_A^N"8V!
M_X@_D45VTR(O)B!8BO_Y!O:TJ!C+19/_ZTE!*X!_!+B3@1 MDMTYF68F#25.7JK>YJ>19FC_-?<
3!JB7C!/*E2CM6UCZV!PO>V>=>EL5%&EK M!K/&Y9+6)?NT7PEWT*13W+_PZR4V/4!2D>0!;1=X1M+AK;_!0J?
ZI#2\$<& MAQ>_G;@3Y2_!_ZCY_OINRA'A^4.54.O!T6#XJR+(GG0Y3;_*_5JA !
MI95&*HGY&_SG7RL#B^%_Q3<_U4X>R:"M3MS3=_!@:R6<33T*J=J!Z\$&J!_!@L!V!F ZI6!T!J6 :M5J6S7ES^#F3R!
MF*AM"+V-5")FBP)_H2A-AA!>7>D#HAQ2!%2G-)GJ40YDJ#T!9:&T+MR1KK
MF@W7EFB)^>=;1H!4!JGL_4&B=3ECXQ>Z(VV0W>1 &C**_U9@PZRI2VDPKA MD52DW !0?+73?
9*6JWC2!YPL!K<75_/Q>&1N1\$.J2GO*GL:L>#>8@=-4&CR9 M=J/NFV#OVO>(*D_A!NW=;_VLF!72

PO*R@\$.KIS/DLX=43Q)KI/ /K<M>^#!-2XWZ548QGS?C%M1/#<<\$>?
>"UBY;EB\$4#UZF2K*)H+FS<5WS972UPHK M2(-/6G/I-)=)LMGXHK)ZHIJWQ3C^F.1S02?
HLWZ2T<::&19ONC2*1T86U+V/O2!YFVW4A MU(O)+E;>M=E#%G/^U/OLO(ZR2NIJ+ D9^Y%N>%1>LMUOF?:Y>G=
MJS3-.G2<>I+V+>#.PJP05C@:(08?T?C4>XOA=7,PP+RI_&Q26\$5_D:IG<170Q MEI_MJ7\$B_UIG^5-
E<"F)+/6Z^3%_1>I!F1>EJA5518^_307%MN^PU)M-W MSZN>B:4K+!ZVSM.0^DKA45;HE;EN9IVA_1@)5(-.T.4?
APD[?/<93&:5Q_ M9^8F-U*KM)A>3?3WYCF1C)BH"Q6BK)41"CX=/9NV:T)AJXK\$GC9VW-U="MM
M7%CRK;+Q+JF3?Q*.NSL;2(E<3^T4A&)\$?19FBI/^ISJ+O"9ZE?:5K>ANM31\$
M"GS<**8C(H5JP+MIQPP;2R4SR\$5&WUF;-@5JE800+IU+#+IM+(HPB ME7>
LJIM6W8MOM;0IK5A8QJRHGJ=1^6VQM/O^2KT9= Q%Q^-YU=3!3%98GD^ M@GUKHJCT@<)BI=P^IMJ4V*_5/-
TD>I9E(OTKS<:IN_CB5/P&47IDC(V G/ 3 M_ QCU(13Y2K5*PQ?6%Z6&WZ8AAM7:5\$12KFD0!;107G
_0D.7PH+=9F^+E6; SEH+!652QH/-U+;3"/8A6O^"/_XNJ#NK^N1TI/?S"@IG<^/MGY")SOXL
M\$1^WN7@M&D6;SEH&W!P41.GIR2,4X26A@/IOGGA\$=S#)VE6Q36QDK<M8I?HIG;H7;+DHU;
[MT9>)'=X@<>3MS6R4;4'#WMQI%M=VY9,+1HEU<:SYECG*EK26G7,5>FDBF\$167V_#-
MIW;JMG(I)"=9R)4K;24ZPIMGNM,=JTNJR_3+MIYPP-(T;W?K*%?:4W(0M;0N MIGYJ_#5-[K];8+OYE98Y;8I)'
WZNWLWRD)2N(#F6JN,*V["NX/IX?1JHW@2T!9_6"SE_1(M(Z6U)KPEOGI)*-1?.(XCZ*>CH(7B*Z?
EOH/5OA#EG#"HQA(DSY)=YC%FXV/M^40%^2,4KBYI!A:TIC%ZS6BSV21QYQ;SEZOB,H1K,*"74Y+@R?7X.GM+=1P
MD\$B3>|<>_MT^RLWCL_16I#=#O!YN;>_9U^K^15RH/2>XHJ?H??P+#+5XGAJY
M3#7RN6J0TWX7V12X^(-8>T!^>B";C?%^&^OZE4Z^2N=J:A.6,>94+BX:5EL^/2"N
IVZQLI09!OGYSID^X_S;_M%0!%;?Z0"? ME<=;*TA3;XCDIC813M^F(+@A!OY_JR:Y9NO?^=YL9Y@?T-BO^?E0IO\$;!
MQW\$35GD)XOISW_137>GC96BXGU?GZ\$.7R?_2D1_C.XQXY=++!JC4HK1N M88F2JVL?
8VPLTT#FF;"S+ASN7R;MO!^2=#6=C423U1V^&>I5&F-RLER70 MV*;0R"5Q!B.Y:@O(OCNRD:N24-L;-" M959?S!?
E#!4KS5M<=,ML>77U2V.;B*BZNV1V%?ZTK7MURVOT\$3(B6+P8L+U@ MX!PSBLI>=CT_)J\$&%IX9?H&+?,>?<*>
VL& VXIS/F;#SQ1D)Z^MC!HJZ&? 9\$ M^R.23(Y!\$KIM?BB|FG>V"/SC%&=Z"<9&950:6R!OSHA
M\$<,U^V)%*Q3Q8!4>LR3;G^T\$TWBL8X#_5N MSPM"#5K15-/>E^9+Z;2%I>W;3IN+<<@R*TI+Z3?
*I^RF7L;L43P/PUMIS(C MI5U,K5/T!H5%YUI?UE=IM_1FZO>/M9^QW>TK+?C!G2SV@*JA;*T\$E9Y0_M6\$XW!
(2A/YK(TXD/B3;10??WX*?T&:#0!@Y-ID?P>|-5!PS_=\$=I MIY<-IAYQ>3Y_>#&R!SAT88,S\$O\$@?
>9E2>WHD,"1"!_"(13HA<6O! MHHSY51^+F426XQ/7T8_4?*"^:BJC)Y@483?S(H)1??
O5XA#=#U_Q^G#U)%%#;_#MCG MY*";_9GC-10(C;DW)%Z4%8Z@%;F\$<9%1^&^0Y9FZ+0GQ)R3!_5#6<=\$IG_9^!J
MF(C:EA??*J?YI^IO?F;E.KG>;T&EZY^ADL;TP!W@%K\$/HARY4!09)YC^@%. Q'9'WG!6F67U*&2N4_2MD=IV=YF5*P
M995_IG>R8)Y_12(7)!7"OZ:R\$<8&(L1QOT;4IOA-NRX100>1^0^?Q3U15C MER.G K4!W-THSRM-
8OMK^*V(>Q6P45GB+@SDLY%IL#S/2J;_14E8_CJ(<MK"-^0EL R4T"/K;?
Y+8HO@1L+^N4>Q\$:@XC%3",ORSU^6P8IH6?UN3_7>Q.8PIYPP09 M64S^VQ1YIC"<(AI-%NG;^8HEK.GHY-V(?
N2?0NN7*\$M&HQ#*3L;+^J6>VOSEN50;4X_ M22CF^117;0^W2>1U#4VO!EJH!Z/7)& MW\$9HXT7(OT5>R!TI?
0)U1.(HU^5JH@*24L;_*MEK"L.A6ZV03I9-2_W2_1M_UB+V9#)YKSOI1%|!5!(HE)!&K!88R-LEHTK0<-1
(TX6;@BEE!036!K%E^1TPI7!RC#D)>=&N_5G^1NI_QB5ZW.3@%>?V.7=&87!2 MV+2DM#7!X2RZ42R!
IKTGR%IS>1&!?BU. 5V@^ASW_-.5;^@KA_+.NUWA! MMJ^FEHPRY"OR<(E;^0%.C9CF?66JVC!/?@6YT>+))
(U66SCCLJ7Q@PTU(->M>M4%TUL<IM;)>1XN*1!_S3%=7I/-2(EX1."?">OIS!6M(1S@,TOXYH+^B(C+^YS*>
(DCIO#VQ77% M8UJ1GVR"BD6\$RJA#_1HQ;<0Q&82!J!#AX^>2^_KXQD MMB<\$S995)@S9;MW%5H(XD;
(Y70>S!0K M6Z/3U7/H.9I8!V;#IN2Q6(L"18>\$M0KI">1IC.3F/D3^GWC*)Z?;W;4!\$XP4Y3%2U1"
M*);IX?PVICME;.06=CG@QSL?N618;2S
M(C^11(IEF#JMDP8UB4E/=3%H"D/@>>C.VVHX7OKU(R3Q0C3B.ECYO4TQM\$O MTPFA5"3G&RZ>'!\$W>|O_*AW)J
52;ZX8?;QG6WXF!R9;,%Y.DB.A)*J;_MOO5>(2)*9_@4\$!F5&1)*W0874R8JQVS# W4Y9).SLD9SGRHW\$JZXF^17")
M)U!0XR_1<<>-1QALK8_C)M(+&V3PZZEEF3MS:0X7I3_#Q*FQ"(4N\$P!^ M(X#OI-)3(@N\$3^SV8?
F*Y5A!*.H1KN#S\$Y;H.C*)&9+(2O("QH;JCG2I3 M^L.652;I-7+Y&KAH=G94;Y>62BW8!T;?;I^FN7(G_U^F(-
JW^3WO3_!AB MIEN^YON;V4FEW:0S!8B?;W"D"N-IDZR|=63P,4EGBOD|_|;IF|W,^E_7B|/M0#=?CED&YVQ*X9_-3^
J\$>7PN13^/*\$3Z#&Q_R"L4#|WW?W^_*T3Z#<=%@)6W3L:GRS< MT)V#;AGI7"!Z+D63)GD!H
MIQIM_4I=TGZ2IU#*!IRLO@2)N#O_@0)I^L;U_@O"IE/IADB=0RGR%4%P8 MI%T*);<:U+LACTEW%%/*!(_S#@?&
HE"+^#@+N#8F^T^A%-RNG:9;L#MQS M?/=I6AI5%OX<9I_4P?-V-"TY9'6|=KY6RG_Z0A=G!;=?
OGY1Z;WYRA@O1E(MZ5.*P^!)3BMH;F26L5;P&3I;@-?B#)3T9H.D+&J\$*!6YE4?
5^CIC)V^RCZ4!Q177G)=AGZ0/86Y0QAKY\$Y=L2?S\$ _#6;MX1+TFI9@L%IZ#JW;NA8(X\$_)Y_U#Q2G-O
M08.@4CB%8WAH!Q29T>A688L! D26+TE,(XR+!PIKGI+2EX=0^UECLE+A@1A
ML/DCJ6LK+5\$(9CKWPDUVNF*RL)MVNYI8.1X^F^YA!D;1QL<6TC@;H5!VWJ
M^UR<7#%&JO("PI!^B6H0>V^E@H=;S+4IH@XV!6Z+@A#X%4K?_K26#8G- MKN+GWXB+^#PD=7HE?
+F.P(WR5AB;I;N0+A=4>Z1W!\$3H(RKIS=W^F^Y?K!IX M(Z1%;DXBY(OS&(Q>GKQ**56HACJL2(#9CX^AZ;74@H-?
(8C!+^!D\$-M68^D.@H!@7"B";TNS^!W?CE>0U6(UCW-7";SXJGIZ,%PN*5ZRG!+MIH&\$ MGI9BV!P*RXN?
+EJJH=(NPA?2BU?Z=X)XR9^-.C/C)M=-S MR7P;?I9R?+W2_UYFVA5L=WG==C0BAL4D?
IN1XDZ%5TWRK>I_*-7S!+XPZ M^MJZR54_IYIN6;14V015+K#^_U/U(OZ(ZPC+7!*(1B/U+<14?IEK@U\$(
M.K;3M>8*OMQBN("0"0#4;.)IE&A,CZ+>+ME2;_#A=K\$!3(CG%T1#LH7 MY%ZH!>TC+>NVCV&JH=05!+U
6X&1&GZPBOIFB#F7;'O!^DN"BU6@C\$,%_?T.#3?B M.B<>6G&+ XVKGI61\$7US?KGI+OG642F9
@HJWO!^CS1D@X!D)8O9'C"AF^8YN M<8_?I;9_*7?W&S!^9QBZO_P26>+)*IN_CZ(G18D5?W7^.*7F(?^*5#=#)
M;CH#E.3.A>S.OX@A55WC7BX!8FC^3P%DV_8;?\$KA\$+KW;_R?_R_VMC|^\$GIQ;3IG_+(CO\$=4;(QJB(-
Q.E#H_5BB&);MUW>WDC0!A MO;CZNDPS)5!G/=L16N5U/@>H^_I#^+G)W^\$RXI/M_*=NM5BT)=5AWD/7M
M.5E=KCD!J^M!^QG.@A50481G;K^WOW.=E\$7ZWC3@=Q>0!D=BN@VMCK"(OK;
M=;!@RX4_!;C(K93;I3)Y>WVEZO_Q4^S13AOUQZ-(QFEW.RE:OUTCE.\$CIR MH8W1;Y>9-(4?HB\$N;--
N1<6GE07B!&<N?<@!B;@<5/R45^*C_B9A1_M4;?PY.%Y.W^B.T12+DBV.4;&#
(3^9BP%+!>TIW!B2C47OXD&OTD)<%#@8I(Q*PBLJ?HFLSE#HA;_QL!%JK.WK25_9B>43AUOR/^I4BDP9;
(PX_E^PQ80<.;2KIFTZZH?+ MBM MW_ F14!
(-7^FG;"K5=SZI5;4>ICL+1A9:BOSH_AFUKMNG<\$JYJ07!.BL_+XG"U81. M\$8W2/W:WP%4^@JXC"1.W."NHN
0A#P\$QXIM"8D_ =11)AH2D.8<>IG!HHLPOV>7/K/_1.
M>);JPE.Y<2+^LI889;BAGL\$S;L*U6@.\$QOSI69;ZB%QAM2JWP5.DNC^I4\$N" M;\$IE&16^1ZS!C8;4UI%_0KL7W
MIG_!NCNWK=HEZ%14!CH;M^D:3XAGE;Y3IG"P6JN:M2_!@OP>Z0?G!XS M(%<4@D?L!D=U!"83
T^N/!(ANYO&)\$KJ4_8\$+4EK(^!TNP\$S^O(Z_TI^ MRQ5#C3B;L49T-4!)>4\$0X?H6U_5DA
<(+9MIN9Y!^ZI@L0!D2\$18ID(M;CUWB2/WJ.MNVZH4@C#FGUX?U?98Q!#(==C=?*1IX\$0IYO_97;+V!#E7%
MH\$(1)4X1PI>I")Q_0@B+U+^I5-AD:A EF!5U_IU"P"HO7NU?2*0*5+8J M^X5?QQ@2WW-Y.&*^
54NZ%:)OOD)6V^!9XZ^V0 BG!K(-IOLY!#6Q_>\$C1 MRM53!L+.(ASRV;W)\$ORJ(V84%4?H2T5_AJM.
IQCLZADCRH/V_65;ZBBV MQ&)#QXG7L;B%I!QO*;N7OB+L!^SNF?J^KIO=UE!<6VK^4 RT!A-DIF/O
MH>05TNHJBD-M9JHL^SK9;OU;W@SI^U>.X6K)0^2_IRZ(BN^ZZ23N,@^VZ^YI^J(>M MI@F>89H2KL87DMVM-
(3PYK%9JP5;*R*JX(>K4;HE0;-%.4OZH_KJH3MC MQ8%\$?05@/?UP<'FLASN-M+U!_D_!Y4ORZ_0_IK*KE^OI

MU9SI+.:OS+K%Z8K#1.%Y(I?|2>68E,7I!^=7V-6E1U=RI95-DJ?IE5U!@+M&21!-VF0XOGW?K!-
OMGA%+RR!-01N&8ME'3-PMF?+I-I?J!M.NF-U MYZPS2+Q-R-I
&/F\$7UVFZ395"J#5GQ%Y\$^Q/F-G%G8U:0I%P5Q58P\H^GI MOQ=0E6H
S^@)DJR-(5UPH|HK!+BI^<A/E<>D187>T0G3)AR4>21-/BR# M4BUO>C^C/*-|A VAT:H>TX(TT+@2?
I*\$N8:-"EBF9E2LJ1HK7YWH5P&Q#10 MWRAL+UKH735M6BX.=0-7MMC=4=VH! "85=9'EOMIGFQG!
(8H>MB,1#TRCR M/V/D1RN'7I* 7>G:> A.NUTRT BTK=IGQ'85>"U>6DK&BKM7MU1L&9:+K' M0?1
=G^!BN42K-1^#I'D!ULD6.!6&M\$0G8;/8N3J* _LH?KBY>-5ETCHJG@ M!1='+K!/-DD3HWM+2K40"!.*B!04N(2?
1!VF52X9+40"&*9\$TWN?&^9O'-S M!<2?T*J8HE?&O/EI4^DS8!%QH-K3",>9!6!T53,-"JFFLTVRY+ #2/6+R51
M4%HC!(!"! D.RLM8T!50A-6Q8?SZW-/8B>Z"L.8#XA4.YFE>!AFBM872!LL
M.#!9+="#O!&F1#Y+=BED!@).K-AJ/M/(0B!WSE>> %VSW#-/D13YC+;833!S"!PI1QO@ZJN:.#%1!>:CH2QK M?
&+!A?+!"K^<EL!GB_-SG?AT7TXVY%,K> .NYAVY.^=,&NWD^&JHE^VJBU7K
M*WKHOD2>#%\$HNA@WN70SNS7J47Q93ETAM.^8>KLBKB.^+13VTLTQMMC)5:|
MG#P&MQ=7U7J<#KN&G(X6P!LQMEHCS(?%>Q?W.>L)OS#!K23(3 MC.^TO(1LE#|HNGR%AKMXU>F).
<35;\$=IGXEC\FXI0S M/H9NL*\$1C!H57R\$ _S:OPFV&4K.TEM.XIGR7!@-" 80-F))HO)5%33BI-D+U'Z M2HV7=GVHE?
MD)C%1-0!17!JTBHO;7M10? 6GILBOL'@E"D93>;74:7 M(1D5/BM3!B;*0'A.65YMMH*XGL^8:@%'-
I=023ERB!L'0AJFLART*4; 4 MT+/G'2!HD3T9=N'09+ZG@NZ<1DHV%XBWE80A-A5Q3+.,."Y2X(7?AT<&/
MU<14'EIX!%^LB!AF.KRISC.J2<.P2IY?&Y-EEJB\$#B.YU=3#3X%&(2!3IV>0S^8M7;SE R#=-D\$SH;B2?+Y"0;*/
M\$XI6ZIP+8T!6AV)J7TS 78Z+^" & .NY)O!|76%?8=^>\$7W2/HSEZ\$E!1G!J\$ MCB<=:Y@IN/?
_B^077SQKI>NOEJ4!A8> ?RC2!09@-G?.#@U)L'5H!)B>FM.R#>M!S^K'Z'^.,H4515IT/7#Y2Z!^@-M@\$KT<
EM&JRPW\$8ZF&A:PO<|O>+|OJ!47=)97^&2H(!>OVL'63WI! MD@I70-??ZIBW3+;.\$K)(GE9B+-
WZ@+^3L!JA7!)!O-(Z8 MT1&A&!)2YD\$A*9U" M8U2Q.ZTC#+5)OUIOV\$13&(C?
JBYH^H6AY@^5!2!F1*P1;WWO?%D^/'>G:Y MBV?1-GPJ0Q.GHZ8.O57C! OB?G\$78!JF1E*F-
K"ELJ=I%+C9F:K%#!D M\$:DJ4\$8E",6271+BJFXHW!-)7*+>9O'V!MKO-F1*Q+JA1%|3||>*.R>
MQ:\$7X#""JZ'A\$7#S#X@H<:S-8EG+7%7-EQ75CMN?>@^?BP"UF=V59;K8*<2!L MOP04.VG#^Q
WRV_=:7XZN*#L(.T0@8(KZ34>8W*.MBR>9YQSDG!/@DN<.T M7-JVFT)5T2#55,=%ZL%VJ'KT/L%K-&M+V
#;TH>O,I|VJ^Y\$+9!3B6!>;AA#%O/;67(FID7E5*T8:I&=XP6F-/9; MJ"2NPMJU'E5GLDI%P%Y?
LLUR|BD4,ZXE@E#O(>*K|BA<32B?*=*_L'J.^&Z M7Q%Y747!;FIO>L'Q=QUC1JIT3;K!;)CK!7CE9,J@1 %-
B8W^H21G-Q_-WBU)P."H+SY!P=SIV M4Y17RA#0QI3)
(6L'E%L<6!|GCAG*3T@OL^1K4X^!J^>)GBS293GD3L5N/1!M)9;ABR!>IQ.F5HOX1.HG(78O?
53U^,QK)/8Z17A'B(^1WB43N!>79HJHTOX, MV%"+_U7MSVHY")Y=R&6G78!>00XB.IO;K.6N*
>B@2UDLZ;QBG@Z:5^ZF15-M2/GLCYXL1!_-Y53Y**V>+%"6W5J^*A\$*RJH7E!^A(!^!^_K!#@5A!JO954@\$ M@?
*SZO(I%(3-IQ8OXL!%8C#)6/C!B'HYCRDPC#@!^*!\$1T^=%6*1@IM2DE#L.N.-UG;DM-:C!%<,UH9'W
MG_3,8QF|LFFN)@Z6>'|X:.PT..5>|=E.%!C-WY-3G)(.DLFVD(BSB)F+W6 M&PY3;N7K>H9JWCK49=AMJ8>|LR+|
;#AIPH3RL@#&#@<-YO-|E'UXSX"JV" M8P674CR\$X0'G=4T8R!/@V%C&!*1XJ&P;,,X15LKL%?B9!@V'2N20^?M:B
M<OB%PL&R/O_..Y8%EL!L> M'X5*J5X\$;AN>L:L!BP;#I&.*1XL&PZ1NRD>+!L&GO5YVFL@U48F"X
M66./7RE^R^_VU2\$EQ8-A8QNRD>)!L&^#KNYLA>DC(.Z2BAP,H^Q.STH04N MDG>C^W/Q.CP_-O_+G6;X0
*1N?|5V*4\$#<+!;G:3'U-T74R5/*18& :OK-8G M'^N90XJ%08-|BJ5-I-O-
PJHXWOI&3"1H,\$Q:GUB3^HR1NHZ4H\$PL9OMYC4. MD9)\$S\$0BF>EBV%@.)\$H0)N'MTIBN" ^)DRY>*8# |>B8|BF
H"/P3>TC 4^@, M3>PA-8/@83=M.^:0*JU^HTR.(SF2KPY;\$1&^@=#IF5&1@H'0Z9M1D8*IT.F
M8T9&^@=#IFM&1@H'0Z9G1D8*IT.F:T9&^="ICLP#!N3\$4TI@P:DXZS% ^"C=5L6V<|H|OF(Z&JF4C.1H&\$V#9
MS>8%OR&'J'E(H\$!(-%O)2XI#1(2* P2W_0WY01R*.;W M*K^J\$(#0?XCLV:9!Y)@^+1,^<@%P!|F_*1"X#ATS'E(Q>
P&?8;C>_X3#Z MS/(B!2OW^Q@I&\$3#-FPUFTW)B5H&%1Z=C!84T+1:.*@.(4""H&:9>ZXF!QD4 M#(F>)/HD""%
8)>1#M:)*004\$T4L=&Q&?Y\$!CH578H%04-T'VU=(E5H"WC;G'J!>H9AQ&9.Q4BXT4#X;.;H8!!N^0942N\$0?
\$S48OLWY-R'Z5T'6O6^1 ("(^8Y@|L/36:ZRN M.G(P"#<;=JVF 1\$I&-B1GF5-1
H&0434Y/X8N<|# _UZKHLCOO'D:XSN|3=" MHY5&)9&!09B\$^;W-W!&=D4X5*4*AD&A=>VCM:5 X!;(@P
_JE3(X6'4LOH%P ML)OE5CA<.2U-87"PFMW>M>=&L->&10&";O3ZIV@C8^EW*/L;B=QJ=OQ<#!E!0OEK|E-
\$IW7(2.\$PR'2ZK0GEVY\$240& M!4&""#YLCB:-\$C"(X52-U9HB1UT-"C@09F#9:DIQ\$""^B\$#@PP.@HB8FS:U
MJ93"0?A4MJ>_L4UD8!&M\$F!F\$6EKFV\$14I&@05T0@-IFPF!0HAZI-(/ ^H M% 'A:6SX.9C&K;
_>\$>I":TUAN"+@|@#0T;-I"R:X@C3!"ZF2W4_7RH @I#P M'WL6Q8A&6KY6P\$)P.I&SK&@+
A8#BV;K*PX!>6QH<;32.D8!"X5%RSJ! M IZ=>:OE#0D:#!B(BD\$#86)W1FC1XH#!XMM62T*Q.!PZEGSJEL:GEMWN
M3OFSRU1-1H:%P(+ 'S+1GZ %5(V9"5@\$.5-I7MHL3KW.\$=H41&Y7#J!># M8"!O-6-
M4YA1)O!KY)GPJ!"#X79*1"W_)T%L.#J!0-|JT.Y.)?*1 M*YUZ4R(PLEX-CICUD9M"(UTR\$C-
(A8S6!G&K\$TE=XEA<(@8?>L@28)&10\$ M"5%Y.U/DDU"SLM-A(T""8W/"5TS.?D'72DU _=*B4 M"X#ATS;E(Q<
PZ=CRD(K& MOI9!E@H+.RF/HLB%@P+ZI(+5YB&6C2*8"@FOU/%&Q/*GE5C(X%""Y6TXB+ M%
Z&BV7&108'P!4VXR*#0^#"T/H706NAP*TCZGK/L5-B F-#Q-U")0(@ M"(DFRHA1E00\$GO/=AVW*J\$P""B.K.T8+I
(RC"&NU""#(X&Y=RXR.!@N/3.N M.C@8+GTS+C(X%""Y-ZYH(-\$CND=:#9H.#H\$+IS_ZUX10G!PWU^EOY'@0W_?
::9?I&13BH=IQVZV6T9R@5@\$&HUNY8*A> M0:C;=WWSG)47(245&10&B18;F>BRD&)AT+^W?
88R5+H_2IV/*4.#H+!1 MO-ARBS:74CB\$WE)DSC(C(H-#X#+LM3IC\$GM)3ZYTL1(T!&CF>L949&BH5#I
M&U&1HJ%0&1A1D:)A4+!K;8!ES(X##+6H&U2|O@8.ATS#!N# M!KH<#X;-00M=C@?
#QF"L68X'P!9@N%F.IV/&8.19CH?#QFJ:L9'CH;IVK,5
MWJPP=0WL4RH#AE6K!JM2&0BLAJVFW1J1AV318JQ^I%2*!C',&8MW>K<;E2HN MI7
(9A&9LZYQA#S)Z5&1H"\$P&:8LVQJA!1WUW"6^5CJ8' W"P:I/150!OIK! M^=\$+V5Y-9ER/C#L))N7?B^YY
HXEMB*CH5-G#;8X|1L\$)K+=,4L#.#,TNS8 M<-(8DD!M\$-D4CBFL!AW"5UHV:(!F\$;NIMIGGFNB_G=#!>*=UK*T#!
(AZ1 M.-Q\$#YZSOVUXCA3*1R"6:ZO^/#W#V+5NA*P40.AL^CV?W\$.X@S'P6.#A4Y M'@H;'FI
PG!O"#6L!1"X#A8T!Q1)HK=>F\$C08)JU;DCY2HEE*.SV-/B4
MRHIAU9ZQS&C!<D14BTSE0M!X=7LSREZP#3\$NDU%F MX^OB\$WK|1H(N0
\$/OR4OWT6TS38|UH5&U@&S'8X;EKF9&1PL&0&9B1D<)! MD+D6)!%*\$S!S"D;
(0"H6#U=/F4("X=#!"^)%H4#)!@&7?|RU(6 _MUF.A08-ATAH4>3C2!1G)CIDY)@^+1-
^<@%P/|IF*1"X#A8U_S%X7XR6LM-M-C(X&"X#;RXR. 0N0!O=O!;" "=G>95#XS(XB*\$Q!B:D'F#@R-CAB)=D;^(
M!/=Z0Q4119AJ-612/!0V MS>-9O!\$#E8!6*D _"=K!#<+2AU>SU+WTB!O3*D^8R+ @; MUS/>-VB.\$ N4O\$H
8/P+JO9&?R&G'L>R*,VAP0+PAS!8'3GX8\$*X*#B-MA8.ATS4C(X6#(C8A!-8SD-(8W"A"DOA\$"K.S07??O@=
(QK@YQM\$S&O) M&P/RX1\$0R&ASWV H?X@!:/A@)"#JVGJR=KM\$(J\$C(DC&K.HUIM+0Y2*0S
MB(RU)3D<0J\$PL%K-!0"IQ8A!NC0BKJ-2I!>SL _"18%6"9ZUO0*(4-C M<+)\$R5J'Q"2!H46Z!%&*TSLX^VO?E-
N?|CAX,@<..))& DKPG V1PI6W M43|JE@%1YUM!7Y=0ZB7C/@T32>\$@3,1SUS(C(X6#(=,V(R.%@R C^H(|=TS
M<0Q2JH(X""J3,|>#|V!^!84,?S;7",&5P\$(89=GK6&(5?1*%0-U)53*18
MZW:8V#2D6"@U!TBQ4&C8!C0D6"@T6@8T)%@H-H&-"18(#0&!G5#AH5! MPVZV>M0"8/BT;E"-^
M9^D\$T>1W="V% YB5^3W>|>G*|'+O8W*PHL'F5 M_*HW6RI&-TOKI0*@ " DYEK!&PZC"Q1&)-JFZ5X""5'Y*
I%)A6*^<|!# MEW4B)BI SEE8!FX5!3NO0)Y;=I9\$0*/B9!@V'2-F(B08-ATC%B(D\$#8M)O M)T_)BYN5U!6E!

Z&C&U&1@H'0Z9E1D8*!T.F:49&"@=#IF-&1@H'0Z9K1D8*M!T.F9T9&"H="IM,T(B.'@R%CUHK)X6#
(F+5FE0:0\$#X5.OQ(7W?IL3G7+IO ZE:1, @JE,N>,C>\$C M?FQ|KKR628X&064NKO(9K5 4H8'0)5*QJ1"->?B|L)#?
F4"(#A8UU2V-SI M7J!%1H*P&38M=N?<:JP(GH_9<6ID !1>8:=SN SIFLO0DLU&SD8")&N94!\$ M"H9'Q#8A(@.#
(/*:V>SF!;TVN0B&4.M%UJS?06 9;@B-MDC(X% X6+81%RD< M A26MG9N4+C2;8AE8! 5A>6M:T)\$!H9"I&="1
:&QJ10D0&1D*DU30@(&5# M(6*9\$)&H1!Q38C(P%) (MSR(R,10B+1-B,C 4(B81"-2, PB|H|K T)&4H(%0 MZ=D&+7
)&@05,,#5'W&5PB&,'47F^DF0-P^,UB(CO4-@,I2|EC5DA1S, ZG< MO2I"07@7SYBMS^\$0"H-#H
<:4C^Y/TU&8W_J+@6#(#+_)YN,=X8QTZ|D(<=" MJ!8B9|TS|/+7K5H%,&> !GI&>,0R@8#CU|H=0*!PL?
@%*\$M_7J.'E">"AL M|)89&SD> AO6|)C6"+N(3A&J5!:)6@0C2_K&+JCY(HE=1=20\$*AT.,F4\$!" MH=#7IE!
Q|\$P!\$900 *AT+=&A&|B<+3B-T%Y:B:E C (=9M.,T+E E (&5JH M7 &G:Q?&HR> Q2H:H?
D6%AT.CT|7/\$J(F(4""H&"UK+8F!QD4#(F./HD" M% R)KCZ) A0,B9X^B0(4#(F!|HD""8)NV=,FB1D4!
DQ|RHK|="C@4Q:VHU MF|US"@L6.F@8\$S1:NFQD&AF(+GK&E=^%,4\$AT612P8%K8!BP(6#(N! 8L"
M%@H+JZG|HHB%PL^V^0-7F%Z3.-;R14+@.'3-N4C%P#*9VAJGS(!""S8?AU M26CTC?VWTH@|R<
@NL5A0|G1)R('OR'2-2\$B_.,@8G>M@3Z3\$C04*C,3A(H4 M#83*H&:,4)&C85!1-5DY4RTE|V^% J&A*5/H@
%04+,,^S+Z"GR8 =2UN6U"(G (OR)M3:6&#|Z87(\$2-TV2=\$PJ%CM|H@ \$RPB1D&,AU'&QJ=?49U'\$@F%&A; H8*&P
M;:/O41"!U^T-OQE<A)NCNX|EP?:<8K%,\$0>+ A1O>&;!/'<>LZ*9X|?YM6(D*Z6 N%J8@NI
M.44A*\$=7QMA(P&")!\$R(2, PBG4%ORO*EWI M F\$0 MZ/9L/0)%(P"5JO?
UF.@0<*@8'<|K50BW.'9C4B1F1@\$1\$XVGLBE#@^@/M^U9GAH(ACX;VU)Y5@@9A%)-YKA\$5*1H&%=83I
RXE,%|D!&S)0.G*|= #J# B M=P9^5HZ'P(9?4VW/5FP&+@\$;82^E<#!.)K52^|HT5H7*F!!F*0SZ,_B)-)C MG2&C'
S""QO@SE^N1(4Z, \$EX!\$+|G>8W0L15C17/P?20H'P4R XR*# M@-^%BFW&1P4P\$P>U1?H'E7P*+5B)!
(AVS.K87STG(MN+D;:(L2_.,|2M02;_ M91MH057>|,BP,&JVFV=,E(<6"H= %QH%\$@J_Q_V?+;@T>92
0=3QEFUUOCW| MCGIK5X(\$P<#J#-PS\$@>1MXC|+W.E.R5%@W"JH=4=&#"1@F\$0L9NMSCF%+%DE
M#1D4!HEV= _|>DY"&90TY& @1#K=,7IFDU(3BD>|AW6QE|&?H% H!|JL<8J<'68%)! */2|H6|H7*7746/*,J|>
MMRBD8%|K=2Q59M5"4(C9=8A5"<\$@QF|)^QL.H|(|=9'.F\$T.|T.F:T9&"H=!
MOK*, 4ODT05Z^C14'W\$H8F'0L.U6|Y)BER7KW(=W,5W*V|PL'U?
(@&#U=LO=*B4P1#X,%OS|/ &&&N9I00,PLU8WJP.#^XD MT|C.B=X1J9'P7"Q?|=!@|H9MZ?%108'P|7B4V-^M
%" +B@O-A8G5-&B0T@,FRW^|?BBED5"QD21.,U|6M&491Y&,E!QD4"@E; MGT01"H5\$2Y|)\$0J%1\$>?
1!\$*X35TF@8L"E@P+K#S<,'?%AQ|<%#@&;? MI&?S1(|&PZ1S1@FY%V?
&M;A16#8M*|_Q"Q!QAKD9!P7"Q9ROTBP*BO:0(M|L/#XCL'Q| W0BTE,C@S+GP3I' Q@
*^J|/M7^H=\$PD8Q!#E%B/ (HQ0A(>| M.W2<>|W|I _W'&H=CR1 (B\$43A"&R|"OO*V<41-
E|=|A'@<.,|HYD69I)M^L28 C1)^U|M|H?NN,>N\$= M"O!(!?6@D\$X|,|VX2(| R&2,>\$B 0,ADC7A(@\$#(9(SX2(|
R#B-WOZ=<1 M.1@,\$?TZ(@?#(*R6@-M(G(P%" +M|@ \$1&1@,\$=N\$B 0.,@P@K9^LS>GY\$U-5H MM"18.#1L
QI%+!@: +0.:12P8&FT#&D4L&|H= QI%+! :_/IG71HR+!0.C:8^M#0D6# W|E>&|4-#O|&58<'0T&IP95@P-/0;7!D6#
W|E>&|4.C:T"CB 5" MHVVWQ^@WPO*BT'U)L&|H= QH%+!@: '0:~!2Q8&CT#&@4L4:H#-H#;1HR+ P:
MMFU>7CAP,B> 8?"PVH|+79Y)|H _H* A625X'0ZS:81G3A&#J6(1TY@P= MVY". ' ^&3LN0CAP|AD|;D(X<#X9.OY".'
^&3M>0TGP|AD|D(X<#X9.WY". M' ^&CMFHH P|A8YE,"HHP8.A8S@J*,&H6,XBC!@Z% C."HHP<.@T^WU9R@X
M| "2**E(L5!H# QH2+ P:"3W9>O1D&*AT !W*BD6"@U|HY)B@=|H_5IR+ P.M:%AM2|^KY&
P1/3|2@Z&0L36|RPY& P1RX2(| R&B&U"1 (&0Z1E0D0"!D)D MT*|LTO=7DN5H,\$P,VE|I&
81VQKHCI+D8"!\$VKVNOF_)T6"8&-02.1H\$DRQ; M+(M|)1\$Y& 2/H=VU#"J)% R&B'ZS)0=#(6+0M|O:0(CT>P9\$I&
P1/0*7(P M#""M9E= 1B(R%B6?HS\$CD8#!|&8D<#(5(1|^R,\$@3GZR>7AS1N)HQ?)W M25'@>*C-
7NODH)A(I9)JQ:U*BDPU.Q:U*JDP%|KU;|6)06%6JM67:N4 D.M M5EVKE
)#K5.+6I44&K&=6M2JL,|0Z|6B5B4%AMJ@%K4J*2C4VK5:R\$H|,1J MM9"54F"HU1J-5\$J|H59K-%
(H89:NQ:U*BDPU&IUV9524*AU^G6H54J|H5:K M7ZN4@D*M6ZN%K)0"0ZU6"UDH:89:K1:R4@H,M5K-
2*44%&K16F(2BD@U#IV M:M52!%8ANS4.ONKL 8K5O'ZNE@% :|/7: 1-LHD\$HQ-ST&O1"MQ^@|1_T M|<;'16X_P
|YT*^SIE4M!8::W|I6P6P_P*+6H%^G:ZN6 D-KV|KF U^YV9W.M.G5Z (48&&YU>@%"&|AN=7H A1@8;GH10(\$;_"Z
9:).%Z 0|-KPLH<(!? M|A=N|92@D(*)+5^K|+1B\$%AEJ-/1N% QJ+:M9PVH**3#4:EA-(06&6HUU
M9(44%&IVC75DA104:|H#R<.@P;=I \$T:R%ZS,T+K_&JY2WRM;|CE!A&8IGK M&E&1H<%0Z1E1D:'4.D;49&AP5
9&%&1H8%0&=@F5|&CP5_QL8H<#8-*HEK MZU,100.A8IDTQB5H,%0,&N,2-!@J|M6^!
V&BDU+T%#H6+9)E2D:#!46D94
M9&@P5P:8SD:#!6#07X)&@P5HWY%B@9#Q:@%DZ*A4+&.)E2D:#!4C!IC*1H* ME99179&BP5-Q&H-
|T5"HM" T3'E(T&|K&PTDI&@P5H|98BH9"16/4&\$018*@8 MU14I&@P5HWY%BH:P9|H+0&^B|C4C@ \$+D.
|V|I.9,7+,"2J|>Y&@8#L8R-M9QE1D:'4+&J.C0.*BTFCT#|RM!@Z%BX&E:#14#!RL! V&2LN(B@P-AW4I9J+%
V#BCT8|8^1O0119@JN93!89!A7M/!#3GW(0D>6(P MAFG*!& 08L7='6,-YJO" @JE?F^>PEIY9I8XU#&/' ^&
M30LS?WPS<*^OU%2*6!@T6&VV1H3U@*H-;J&*L2/ PZK*2;G|\$#1@M"7269
M\$C08*QW9AK)AHVRJ>QP%K>:Q9:8N#(N+D7!1J|RJ7V(74^1?|0Y9XSEZ.D.A%XYQ M&,Y7*+C%&V8O|I@:|B&.
I+T3J*U27AQ!4X#&B4E?|N>\$U|Y M(V8>X);?U^|D|2:N=#!^+KZ#5WSG^ 'I9,. #H>|!>|7>4/(@=)
<|WZND|>KJ*M<.,4Z|CGWVR3W' M&XH=3V2NAI?54OL#%>)%Y0P?*ES5:L%6Q>OV7!@R: 8X*"<)*K%E=|FLN|
MRW7L1H&Q^K:4UDF+U3Z|Y9+=T|4=>?E>B4CJG3|^* <@E(6S9AVY|L\$42H M|L?S\$2F%"L)E<
A1"RN"8Q3"(\$6)7(*UIMDR1K/-49""| MI0TEYR#L1M>4K^<Q10TS|&:Z% C)|CS"JK67O|K\$F>M2!R%;
I>)%>H0R M-D@:~N">XA#3!WO)*&ULL;U9=ULYDB|ZWK|B;H7&Y68AU=29;20Y9|5->MK/I MW"2' M+SA?C&?
3O_W()^ _&G:9'TT|^ _WCZ|^?B_N/?NW?_Q^ _WS^|<- MO)RELO.<+G|X,<>PQ/S#U_'R|P+S_C#|V?S?
XV A!>3<RS.8G/_1=F+ MV>FW^?C3Y^4/@@E|;+W|I FB,FP6T":U,H50&;SR"/>YV_X|H0|KNW=Q|_U|WV|NW
M+L;W09\$^EQ-TOWH^R%|Q|L X^EB&::|F Q NNB> _M+(5E-^M/XOKAP724 MG^#B;5!2 BY|K_|L<@ _L>=?
##:CKFLPF^Q_)#_?K|^S8_G:C_6#" (A07*Q@+_V?|A/5PA3F*2S23-|T M.:L,P|O9O)ORY7(^CF?+\$"?
XX6(YT|EYO+;\$H M(4\$9="!"1X5-DHR9EPC>G2!ODZ3!/? |. (AF)'V|&6DK)5SWHU|Y-T68
MS|_1J|0B0(D<#J|A019)|D73N9\$8TIN@W= LKO@8| M"|\$9W5|3D|&RVK^UFEX05)\$G+54F7)-
(7A#41245BCP)(SMIK)CVI@< M>6KJD?@K\$;>|3V0IY5(AK9ORLQ*=I@&*T|I%4 9UT DVS*02HN0WP&^V;+
M^1MA(A=1%PZ6I02%0X00G 5\$%JT6,81@>Y^+(5F>|^!#8TU;#1F)JMMQ^4|G M|VX"+NP052,"HH)-!Y56
"/(D(QAHL0DBDH&I/E-H8AF8X#H.I.(FI&E*% M I>+49"12Q<9I*
/_5(|TEYC#)D1R:|G0<7FG|YAP_*6NX5=_G*_OHY3F9Y@OEMU1H:|D|GL
M:XU\$OH-7|PQCY=O9PNRE(SY*018"5ILL RA^!#!Z%SI8(7H|1&V0#TG5 M-N#8 <39C(I7IV+O9GI4"IG|M%86"|
|B8IS'85|_15BEKI7R5;_S|EXNOP' MO2V.AC="\$Q6M!*(KM|B5# ZVC_)198D%87Y(T9N!|@ (7GG#8BW/^&UV|3
M|H&C=52J58:8LL,0\$Q>TY:& /\$B|H\$| (4PZM+V7|_OP_(D|SP|OS8?;+; M|6""XG-U|>E+6B_A\$GG_ "O D3_").S'
6=7\$+R0|1E|,UX"2:~L;B=L5)@ M9*9Y;&8=8.OP0C|?7K81|8|(09B|UC^HX#6889_/LOH_GM^+ #13,{Y:FC%)
(F|CDJ0YE+) M2' L&_ 9A2^|2!%|^E?/7ZM(|Q|1L+>6SB^CL+L\$=GX^&T^Z4-
0T7WS|YN1T|ON"7>1@I2)5GH#TM<# MU|(B.&|Y247RK*)CR#N/26UP0XI&M^30PY&XA>F1:2.6<-
%:V?I/AQ#"B;W29&=9=",#6_#-!,| MZY<;U*0|V6K' MC:,'2>,Q9!4ZR33^Z\$,*<|)R=;2&(O>^Q1 M2F=GCCOOL S W#
MPOH^=2W""O.UOI9Z5B4EG024P44)V_192D@%N=" (G.SJOYSEEOD^LZFW>>N M@K|,25E7V%HE,RK<_4-
H0XI(Y_MC4 M7%CM7+YK%|N|0AX*F7G6)R(R!@_!ZP):19^C|L(TS|5|)|A-B.9XG%9I5V- M=+ #6:|

XE.D=T.T>0.:%0*:DD>&OB7W ^D^RK:25\PKDEO/CJNS.%V
M^H6J=\$ _A^F_1L\I(Z&UTX)0PH*0A^I&4\$&HIG: %N^.. ^B&)(1U4S:N\UU
M.YG /EU@.IM7U50N1PX74)&L^"3\8HD SX^*14Z2:XPVL&)98W"? #^D\%,K M26\ _P^V< _FL HM A%FW))>>26"82>
(A2A,U1>=?PI9^&2^'R BWH\^7C^ MV6UW %K^KV^ ^+UQV)^*_3TOX,IM7Q3(23I.WE0,\$7:, #R^ "9W@ \$4B@ \Q L+)
(60MZCP(9DBB)^*U\$WY:F=R9^+1\R24SOL^*A\N9I^%O4N<=>)"^ ^G> _@ERJ
<_HL: @S)@9>RP2)KN^8BUDE^J(8KS7S?/IMLOZI(2_5B3: MB\IP:UH>8+N^Q M& ^JIC^G_
1.:%.)/(M, \H0J> @+=+TC\ "U8H>4=?W)1:9\ _6E(;*=&/'4 M\?I=1-\$:YVN:\$18DU9Q_GXZ7?U^%O\$?/I.^OKWH\^.'X1?
&f5^ ^/ M/KZAW\IX\$ LGF-R@< ^M7UQRG7@-ZI2>7ELV-T^3T0^H9T#:= "#RH\$D^5@70<=H MG,SMU?\$_ +NJDW?
S63F_VJZXS(0^WFM=,^P^S:CP)D,B\$ \R6S(K> \27^U\ M2)O(IA^ ^K1.VG-V&\ _\$NAO&:1KD\JX75&?N.Y
SF^+AXK4?^*WDZFG2G2\50Z)YPFST0@AE0C*!2** M3;> ^C9<_,4K= ^I3Z03\#4J9;2?V)@->6TI
INIL5XCFEY65%F=3EN-6L2DJE^1^G1^ _R=INPH164\ _RRONY5_Y>\$G4D2RV M^M678&4F%2N4:?(5Y1H8PJH%
(RMC\> @#^D@ ^XF& @OY:UWM8O _^: \$^K& MU&^J\+1^1TTY75)%&>D.DWY-3MJO\H7^12^MS%?5M7J9
M.FERX2%9^ "5^" \$G6.J# =W\$.).?^@37:J<^Y^:XAV51\N-Q5Z^A> /HOVY5 MXUL46@H&^:Y:,JH\ D/6DS?
\$M%X=R:2\H\$4IV;P#O..(AJ1X M^ ^%+0XGLT1SX&:GK^X^_8K+S\ _K53KJ^#& ^IT?
M% %;CI#I+VL,D.1H:9\N4^:QY\;\$1^F_W=)Q%UQ7DG Z+D: ^\$+!,U(UT%7L) MF,E9\$EE:SU^KU%JWWA;PH0\O- ^
_5^K>S>K909\I)0\DS^5:\$&4N\PC.U& M+^E:(I55C:;5^E#R62CJY^*O-DM?P:EA="1T9A0FNH/ _FI@Q)),%E-C**
MGD)P@Z\H\UQHM)7<&B:2WE^2QJG(+ /FV-DAR<+- (+.^@ _!BZ^JE%N<80T@6^5^7N(I#"(I9 MT-
SD&#U7^%M^JFI!&-+ ^W)0^NTOUFPM?;TY.PWA^T00P_MXHF&AR_UFE*: M?<^:UZ)>2PH9T7H:K6.LD-
8GK+ZPZC)Z5\AFV9CU;H\ M#6%(^VT36NQ1(LVT MQ2\X)8MB4\^FD_&T5F2A^?
IR:0T6YKACE+21R^JN1X^XK\$XK9\$EZ+TLO5Q M^1.OAG3\Y52.M\1^4Q\KN-3^I%TG4Z+M..BPVR21R^%F\$JHR?
4)2=LQ\PXQ M AKME4\ \$8?HPMNY^Z2:Q4U9T4@ #:O97I4OK%0JH< _ \VJ9L@MN8S^Q9HU
M69LB)4T,)9 _"U@+71BJ:A=;ID?@#.G^<5^*M\!+!T(^#A9_VV4RL)M\2E H. M@JQ3IKT361,%96LZ\>,X>-
OY)2 _G#X_TTY1QLM1M^8\$EQR@)NJ0?+M;Y:4C M50@ _DY^H/7QRP-0GEF,MWG-
>P7TV(9C8G;QU86XIF\$B>0F^@M MXA52\LR5YDI:(^RRA0/65E\ _3 _/5SQ?4J?A6 MLX321R<-8 \JM-
DG,> \42=FSR\M9O:0 M92A%LAI=E.2L4-9RS Z434%(F6(*N< ^U.2IUOD_Z: ^" ^Y77>G^ \Z\OWK _ ^
MZKN@1_1;>6FM@C:IPK=6%1041LE(:N\UX+H6 M=I/5?F#HR0=,B+EY2?^ _ ^2T?N+L\C\>C+
f^G2,GI#> ^>IT9\?JHH\A^+ M< ^1FGE5XH2YS7^:HVL\RD,M^2PE_)BVIP<9 Y6ZN%<\$FWO@ _> A# \I2:; _>
MFUD^G\$;"W\#.)=?%+>C> \6Y&&S\NQ _N; ^KYB> \J29\NCO+,.50%QZ: M+WG%HG\$1BNP&4UX\$PN4:
(T)2(OK> ^+ \#240=4O.RBI\6^ALEL= \9Q_6B\ MR^N>2QD^V4.BFD?6@C<,K
Z^,6301H:E\9H/(2&%5%,9.2^AKD45N2^!G\ M7BB:#&9C9C+:S%I7W\OFF;R&3^CX6Z5J@.0_H,- \$!F7K-
ID/CB<^/'^C.).MBZV\XATA#IG. W MFXOU4 _"HPI_? WY^)JM0X^7^HS\$ / \^ _V^H
<0\YE:7\T:3\ ^WV\^ ^:G\X\H^8(>V5/3^G^D>H M@6 :UKLX# =^Z\+C5L\I^<=9K5ENMB^Y+ /5N@)<1XBUJG)Q"-
WRO:Y\2^YZ#X^&J;^7(MJG47V^"= \7B\^ \O@3%M)\;+G0^DLSFK\BN.NG_%Q65V#&0D=> \# \I\$<-1_5S4DQGLW3YI
@2^2RC\$9< M\EHY5Y C MY%66(1G0)MQ.% \>^%NU3Q M\H5%44EH+EC8^2H9-4\7^Q^N6SMX1D2JN9%) _^2^TP?
8E7864W= \G^Y.M+Z9.H.WK\$B#S3...&#GB@= /P&BS9%;FOO:D^Q&M%:ECWZFEJ2^D=J=6- \Z M_VI4?
2^SBN^ \QYKXGFIU1_K^T33??.^: \A?%QOC:=Y:8OV\$E=?+X_L7OU!
M6^ \T\$ \X/2WQ^VVO:CFB^):D5%\$5#LKS\ER\$UDI^K6R^Q8?6*1^1^6&#^/_I
MJ^C9=.P:%4WDP1B\H%VH73WK%6.G+&C+)%K+C8L\7,Y9\$ \V000\$#YO@JEP0Z
M\$^ _+RCWX5L5CKB%+Y&5)+0^&Y^VO:L81.L\^D^T<6=0%IMZ&7Y\= (^@7KV M\Q5 _W3\Z-O)8Q22Q@ \27^:/GXFA-
LQ^*0%<4MXRU#BEO>UO\X\^RSYZ> MNXK _\$ \3>ZV+OP^*610E^2^)!O1&0%#HKI8YNW@K+_ \$+3F:G5^V@
M:B_Y6+\$^S=5%W53V+= @N%L?EXD\N=4 M:33;E;:M.F _\>TL3L&LU?
21^1^D\IPXD;2)2@N<=>#%61+^C\I:UT<5Q^Q^FG+KX8:6.N M9:/2AEWM7D&6M; \(^YS4MTYG;#E =(LR6 YY
Y91#^Q\4#R<(^YX3OZ^VM M3RO&)(M\A^P^&7HV6)\&8L&Z\I46S\I0?3 A^4P;)D8\T:U(I=>+^5W\ _&T
MEM>97\$ \L=FW;JDIC_MOK_B\ _C)+ ^>S: JS8Y\$5%+GP(D\$DJ:\$YT^*K0O@1.9: MIX3TM4> _10,& ^94?!\?
DVZ>8&JE4UR" _"3T7D4M1OUZHK.F^EU5V.D&6E8 M0@*:.94O:UQ#\$H_1@2LPQ:56T?
CW;:L.G;YAH\9SYU+ \D>M%LJ_RS^UU: ^5UF MM_XN^35/0)6C7).GOHE; \J2 _XC1.EV\1.3FG: +PM M\1AC\3(R204>8
M\I)2<2NU\49O>P _>RAIE<^G<=D0:&6AB+2H3T^I^H73\HG\?5DSRI3.M.G"
M=3059#^6GE0%:C#HLA^V\;Q^6V3IC9<2^?Y1V7WV930G\VS358^6JZ\ += MKW&UYT1: \S_C9\;UUS#_%R\?
KL\DEVZ:4SOHJY^G+&E\$)A^NUKJEA583T_MCU:9T8QYO)VH\I
B:PK2%EE/9^NQOH\G\$S:5LJFM3%HKE;E.R\ZO@HO^2IC M \E-B
K^"(O90432^T&3%61:WPA _\$;QSN!>BEEM)=,^* \^ (SW5VWXZG^+ZZ M8BAJPEBDL67DM&MI S\$0>X/
9^RQV<76^3"W.6QX4/I=T&(G:;1L?W\$K9>PH MI=E932D+W\X/X.B5^1GFM^,0R8=:G=EFJ\1B @Q+^#E1^*
"9: @<^ZVO20\$;= MNBCZ=DB^U.U\3\3: @TC;M8\ _+V5\%V% C^YWQHL\B? \$R =, ^@ \DW4;M&? 0 MHV392N=L8XXI
N\^L7.R\X\JWY\^64\ _#EO^X2Y5HHG\Z\FY&PBCGO-(22R82RQ8%G MEI28(URL)&3_U: >C^09G%(VMV\Y%TF;V-
9:G58OD^O:TDV^L\$BTRR\R\I4 M\F.^8^JXD\FGEK^*TNNPIXXBW0(<XDT\+V+L WS+G:(KA=9= \6B%CIH
MJE..E(PBD2ZDN;1E^F=(@U/P+6QNC8.#K?J\@< \O<2^ \SGF\IWNZ\2^&-579#\Q5IV^6^KQ7^5-6 KA;?%8D;
(XM6 M2:0^2^7P^TZ9^@M^EYK^0JAGKNUE+HMW\$W/^I_UEKAO\3:C8_?L-R>G83SOBM61)_&)Y@H\I&AJZ4LO
M2+.BTA^3^D\;U;@0M;N= _ 4C68M&K^ZTDE^%F3345XLST\>O0A^0^Y-O M%^H=%\F@DJ80DF_YT
#_ \JG%^63ZM:75> _#L18W#GU)H\V^V5\$@ \53^C\; _MRSOG7=X-Z;C-
:R:;Q2L38:3<>9X+1^5.PTW)S+3^M8JW5GPT^H%85UL:U%(M^V?JH0^YM3T^?XFGV1-@F2> \A@K+H:
(=,^E+T5OMBE^M^ MX^0I3&NQZ#L+0S>54\J8T,4IR57^ \^ \3DL^+,.6%=70^ \2Q@9\$9KB6#2 L>: @ _MJE)#Z)9\
N>CR4GZ> \L:SA.QH0T>QA9M#EYDM)> @45\2:I= @MH265U0?^<3 M>C\ _5< @Y;=OM#&V\;W \!&L1:
#WZ\HK7?:2^;G MOD.^?/^*X(^T&?/9\&5E^R# _PW2Q^D^ \Q&483Q8W@:W7B6B+H\H
M3;3K\ \KUK^KISZ> ^GLT5M\+^ _Q2_S:A8\RS^F\$< @LK@9.J^6Y6+TCZH6R@K@G
ML^7BPE.8VI9+N/7A5^4=CDLG@Y^J.%;+PR2/RM8D:G^5^7:65H3=ZD+8)Q M\^ ^TE%BWA,(&^*
(4SH4/H_74NA+3CU5X;@% \^+WOX;KV?S\K3Y;@ @C3RX^ M^I\$ \I:4-
VD@ @3E=DQ^4HAJY.ME3N^&8TCUA0Y^K8:RV@ ^YWN.7V>1+ \3^ \^ \ML/SKD&H>W+> _# \A:
 \#S)%^R5)2((#^4X\2:C^E8@A14^:\$D\$4.;S^4TEB\$5_M\$CHPDG@-YR^ \A(\39+ (^H12?0,FLP#^# 3DO7.9\$%FGK
M8H\ _#6_8GN:2DPX5PLH+TB^5FFP6L3_%FIENE8YKKWZ\2/&D>^M0YZX\^3 M5V=W\$=0AEM+JT\B?MRB=J_!?
#3-71N:; & \1C)=G\$ (AN5Z189\^FX _& _^:3\C\$N
M8QI5ERIP0E^D,+U^<81^=6;2^J^T(XC>XDTM)Z=1..H> \LLRVIB\E@CY;* @C\^*<#Z&_0NR\INP^4CQ4N
M7QP5(9# \P;B8SWE5_6B46\>J^ \4A)T4O=DL M6TIM= <2\PG2CP(_BM>M53O:X6IU^N02T^CO^J<-SJH7- \<7>
_WK9\3M2L@MQ^"(^*3+OAHMO?IW_EY _^)^RZ-)/=YE^Q18IGGCP-0W8EKR^D^16^Q.7IG MUBOXNS_0PHH?
M=+H^"%UAK&5^#PS7?; \\$(MSMJDL7#.<VR4H<>R9\^*WS7:ZAWF@UO9=U5&QIP.H-?Y\N_-5\$W-IFM92A
MESE \I\J8BOH\^W. FL<^ _U+3&EI0A\1_0L& \93^ \^ \U#(A^AU@OCSA15^6W MK@VR^N+BOH14
(.WM+^J%Q1X0=X5HQ>%MT4GL5Z)Z=ZA#JF@Q#-?#7T397B; MQ54ZZ\7EU7?SV2G.E\ _JZ(1DF&,,8".3H\$J=>&8^
<%EX#&D97290<3T^>C^3 M> \Z;=6J^Q3N2^C(I%Y81D#+^*8: % \&#D\)#%HB66V^3V_IHIBG2(43Q\ILWW
MWK;=G7DS/^WS-DR\71^7& \6,2XA<?^MC=\$)5-\$7+L%ZR\CHJ<> _6M:JNB2

M.RJHTH<)NA/H(00' V>ND99LZC.G:YT! C*Y: CR>1^94"25Z 4K"KW3.HX MSS-Y1B(HYGUM!)K!U)68S;&
(!+!J@)7D?NK??D87(1+!% M(F5-G#.BD.V"\$KRM08ASH9'OYAC>I=@:T\$?@O!#191;JL/!^&M!-9W
M!_Z0+1/Q!N SR:Y-IPD(U!+Q8:60?CZP@60(!)\$:R+!+6:7\$OM0(QB) M!?SGBNJ!;83-(7-U+!ZB_/_%SF%IL&"-
C*6*Q!G!)!K!:"63!)@2D!E2Q&M2!#L M=8?P!>=>+D-GVC#;XG?5WH?% M>EG" C>5.SB\$!/@:Y
(8&CL&2>LM8%3K0<3%P!G/O?588T#S.YLYQ.U (MITUS)6VYY\$JO=VN\XS?:^+;H&B^/2N&1_&
IQ61EH6V%Y.K130H&8DD% MK'>8)(NVL-E<5!A_%ZSS(9\$11W9.3RZ7U:"NOK1JS..T^<)YI>A^Z."GTI
MFDQF7!L>D;YJC1%5QW5F7JGU#HPO&:@.FTATCH'(9SW1@G/#G LWF9LWVNZ
MVT!6U0%8.+REV/E&J>M#FEIE%K6NIZD4A1S' *OS1)93MJSVBIS_Z?I-S\$. MJ0_4!HHT=F#%(\$-
/U42D7122%E_"9?72+U)@.2LPME;5+!)%C\$X!+V0!FF00 MQ4!P=<YCLC4NB=88F+V=Q.<IC M,%_JU2QUKH)
!;OXTZY+0&Y' N92J<2,"_B!/'98EP_:#&[5AHIG?DO!-FIWHUE;49;2FS/ SR; Z+A_#S<+&KW'TUIK?_KI%?W!MM(
M%"FM8P1JLF!+D=PT1>01D6IO+3Z=F" _16^H-N!W!LAVWZ.OIR=AXS00"H?T_(!Y!)/M%);8"FUQM>2'=EW?J
R>*R!MSK!UE70 MMP*ZX;EWO_7L!LS:I@!OXY=<+!Y?YK.STR>:;H;2;AXI<=R'DB^9!3.O!TA
MJ3R4^>>066%*O:_%"B@K:C!KKR%YG;4*Q1BQWB7!O<=TAGV8=D!4(KLG?J\$ M>7;1#64UN%=_U&
!M!.*662Q*00228&N"";+OX)7.OC@1)5LO!D%F@:FU+H8 MNOCAN&CG+7)H8J-
T.E*L*2QL&7'O:3;TEJ8KVVI062(=@7!V&>O=L3WU+ MNJ7MM!"f652.%^:RD%T9)^1"U\A!5274Y*5D)2A!JW7,DG:!
S+S'.6^MM?W M6 M!3Y>OL8OS?<#YEW&J!A!"BQR!4G41H1H!+C\$3@D27+!7>"Z!>Z)8A M;U!HNMNVQE!+>
!-=LOLX6X;)10/5<IU%D+57#*.\$Q!5!CB%"\$#(<O>Z=M#)Z M;Z!>Y!LTZ*!T..7&AQID3:H"
(*7>OFI5O!7!4P8I36UTD!4Z8!FW2VX0UB@_M^R??+G;=+O+N^4"EJ^F!>'U63WI^4_"V):X!?
R;"!H#ND>U;#8M!48#!"9XAQ#028R2D6RY*6!1L<@>6!\$L>\$XBL67!"
M.Q2MTXPV1SEDT" T:XMNA6@MQ+R..C3L-T^>YLGGL3C!>GNNR!KO&I+0.?ZV? M.2;11=I6S_SG>/GYYA-
OA%^_IM.S.*F9RC_3&VHPYMHERUAB;!\$ED\$HR7KW M%KSFY#(*Q02WC)4U^Y/O#&6G>/?JZ5^W?
_H=#SI')!M3!&"NKL-D:K*(E)!C MQA""=F6#2:F(0A1\$\$P+X;AS*E7>;YJ=I^-!-!O-T)'E!4!;">-7,#
MP0D!J3;D52F6H-8!KFD(;@BADV'P=AR'@Y#K SV(O9- &A1.OD:GC"3!8' MB)_T\$HO>TU5R'-82(R_?
TNWD!B>7CG!B>F(A!#+6_K'1/@10S@R-T7 MB2=67-H730<5J!D.6+J=E%N2>=3A>!?
Q@E0^B)X753.BMH*E8\$/TD\$N0;C(MBR&S93_6Z3540XC0#(D!Y#R0#3IM=!D=JZ>O*(1490RB5PI9M#
!XVP69NA6#4!T/Q0:N2WE>.WN6R'7!NGR>M56MWGZ MP\$C'0^2EN(Y
(NNO\$%T1C@M+1G:@0?P\$XQ&S;\$DZ5!/_G@T5!/=0\$S_ M3D3!Y!UHWA)NM.OYXTJFK.D\$9#H9!1H;
(D=FUWN3&@W7!A!D!034K!^R MPGE!>=UOXIG5.%AJ95RR* 2*I#R= &854G(D)E!LZCF5H!2F)N!#R+U*;!J
M:Z1KWH^3& TY0! B67\$J6PL.%PG)LIBE-!1!Q:Q>>SI W-EAZ*/MA3!/JIS M=-!2Q!GX4VB3W/#XQ!_UK'6!H>
!4"!)F=)RV9!(K?EY1F.1!"!&))O!VDQ! M#XNUB0S70!R3A6R86(+!I(2-I'6PM/K/6>4Y7P;X2Y!"B"X-DW'9B/
G;NC6A&&JLV8HV M\$D"E@P 7.QD65HN@_DB.AZ0.MJMWU>Z!@4US86XF\$4V!29R)/7\$3%HX-K4
MZN#90D0C@:N07-(F>L!J=^SH80GA@LT385X6%4VNOL/LJ19^Z3 L%E;<[N MZ!5W0IF*=M)F85PXJ\$HCC\$;
(7PR6:1L+<>14NW.@%4W.F@!#9)X4<"P1HJFE ML6F"C#++29-Z>-FV6(<0!Q@D!782ZN% C'Z;20+
HA TP7N+2!P>X+XC(D9 M8K\$;DC5JSSU+G>;1V:2*8;XKZX B%E RX+KI+3QN(&IP/K/O99!C.V(4_/\$NE!\$YR%
MZ;7FAE<=&H8!&@ T?T6ACW&5@C;!(LEWNBK;.%JX @RDUW5: EU@_P6R M5#@SMG7%ACXZ*28Z?ZORU@!-
(DRUJ9I5J0(*M52,#8!"_&B-!6GL3A)O O-MZ\$!:@@_YML!!"\$TS\$Y.QET+IN/Y^-Y0Z?7 MB\$?
3_&Z.)^S59GY;G1H@Z&>%!LIEJ9W3\$;=D@TF>=8BUY)%K'8UKB'Y)U M;Q>[X<?9+!_GEZ:&I'R)-
(CG@V=9BM)YLLKR(0=1*)U!BUJWK+N!>L-3 ME'!JPR3QSVR8""F;4'G!E?XWF!H>_?FGYT!X!""%?EY@RW
MM/G!:"X5?>5D)3T@MO6U!U!H09IG<\$+N6+^E>L_!RNLB!7""%>UI#CM
M.F%27QIA4;I(D<\$RGFE>R8VN=8M!*VY8L=&FM<%WFFY SI3V;L!J8SOGMG3
MH7RT)#.CVNO1G:%_!\$AN5OL%CI#P('FSZ\$61#U5OAK3U=6=A:4DT7T+\$-PD:Pl?;*JC* 222A&KHK*K8!T
M^QWID*HGN&2Z);_!HLDZBBN#>K!9N2#0!+*8TD?3.&FU=X=0D@!2V #6UY8FBIQH!HU&Y"BY
MHA&/#IQM,#&%+!Y3.D2\$-Y;P*(M FFF5W<=>WTH34;A5%:2P92:P_*Q5P; M;CG@_DAMC:&)/K01M-&
AI3!@P70(LZ3E ^F;ZA<0)4_4(>>C_*7.Y&(Y M^!TV\$EL)N>|R;Z5\$IX!F8 "X^G;7%.(#?
(R+H)5BEKI7CZ8WD8^\$M8&7 M*&CIU..\$7ML+%D5V>S:"%V><L1!Q!6_L/7#U!|=C?<#E2B7AD0X'L:Z#!!%@7!"
729.&< M(&_4M+Z_3BB!L;M0Y!ULG9294FYJ-5!D\$GV%*COO\$C 9&"A=UP1S!IQ\$
M'8*AO5QLK;AR@W56NIG!;U=(8IYV;2!6CH!#^!L6H!/@M;"H; 0G2;N!" MDX);&2MO(S(9=X?JSL SOA.""-A?
-83?;!&XG79"WTMQ\$^!1*2!(9K#;-% MYY9!J7'MP95ZR5D.4B"(((@=N3"(-1=
(5ADK>2QAS!H<:SOLWL23WW^BNP> ME94H/403R8ID-!\$!&35HC=YE(62,K,EPUE8Q>RE'VEK2-^Y#M)_Y-
C=GG!+U MT X;9.LGLFE3;H\$S@K@T!C+5!LR7!;S98 -MR8^C%N#D^;%N+9WW!U
M:K\$&:6Z^D!7!TR/ZV%JN..&ND\$=R; K;>6 M%;OAUV0*E(S)!J 84STD#O!C;PFDE= G.)TES\$K+UY=I=\$
!A_^V!;YMXB8W%N@^A!1LE_53F VF! !8:X!I91RX M>F@CDR'5GTKB<9_!B0>!B/?-E3B8(!46UW1*/ O;_!XDH
ME6-!C)8!@G1@*6#X=S&8CPDY;K2GIX50NEI41!"!5A-R?8_C0!FTOT)!#;R!Q+J!"!6G7!R;+YKQ&6=CVT31-EX
(WB(O5);Z+ MY?RLYDF!"/YMYK/MBJ!Y%+;4F<&G.M;/H!XV5\$*N687'8N MZS6;?QJ!Y;L L>3H!+=7V\$;-
!&I^&R9OI'=^9HRP!T!DGSGD&@R?(U(M1D3MI/%E!;3L1!/(45\$FK'L3FFOO8FT7>'32!?-+2"NFM39!=
(A7ODH9H MG0<;&*I2JWWBZW&0;7_*1@R#;YM(#4JWSGE#KMG0!;CG\$90@)YIV<@&9&
MH3@66=C:P=A.Z1#BH..&BX;"%PA.N<9!E;45X4/4M9>KA!!H;6A=DM<8 M!+G/A^;T\$@!PZ;QB(!-
NZ!@"UYCZA&P3)Z!>@EUO-LY163.AG)!ZV M@44_!L2V345X"+;=);S.)J6!@>6:SC;THKPD;9+"&YRB-
(FVXW)!TFXP08! MAL"Y!079<[QC=U;VN&U+)OCY6><MOYB=G;[Q.TX7+@W!C+!^G?_MG_#%@"\$!)&?
+!0B@C0K(5-*BN;FY(<0A MA6WZY-MMK=RG))O9 &OK@#*>8OX9I_3-!EW!-
E\$JUQF<@PX;F3OCLHE:M2TOU/*1!9+@>A!#HDK?QDB8
M3VG/7+SK1GDRFW!X.98!WRV/\$_!2/7NPRYVQ48/&0B;#^H9A>T+TCRFIC! M8M5P@!"=ZSA@7&UJ3%*/+
(9ZH4>#8!F!0Q1%<2!Y<1?B:52!\$MFGGW" T7;! MD>1=MO^V4W+!16!2?EMY)V+!AH&L21:NEEF6AZT?
K4SF6&A%YL?K?/:C; MCHT)%M#IEW.S!STB&= QT.\$T%1> M)>XUV6^-W0#V/(8@P!R=N+>J!
!4DC+3AG*!B(3\$!7Q2\$ZS.DKE&1<10T MM@X%W\$4Q!UJ&KL*)\$*#.5?46ROM@:!\$@YD6T-
D!7BK%+*25Z/4H>D MB@!@U5@MM.K9@F8;\$*80;#DD;+Z7W3F\$ZC%?S7/3RYE2!43YBWT+LR0R
MOVOL94#?9!"(6_!UL%2@YZJ?7OFI2!#9BS! M9S?EY(M^C3R?
!+>SDXCSXW^*JW7%HOCL^5B&8U#7*Y(2T^D!DZ1HB7E/ M&UYWCPOK99XHL3G1-H2XD!HG@:W.R!+DVL-
K5CRO7;HJ1!)+SC=H/Q!O% MJ'@19_9" JPE;HHLY%0%!Y@L>J!-5!F=#L_H^EU0#\$G)HTFN&T!^;V+K>JW=
MF9.5#G(9=2QD33+G&A<A++0Y!&25W0!P2!H!Z3K7XHMS8BG MET;W&H'\$ &Z5QW@TGX?
D)UR5/S9&HPJ@/*8R;6!1?J!<=>ATT.L5!1QQV M1SVDZQW!H.2>Y=US=L@'_%0Q52'D4?F5=80G\$K!<96C;EU8;
(-#VSNFNAZ=SK?7Q5TE@_XLA6BZ! MROFDSCG7F1(9@M0/-L&N1*=!ZXYBC! 9Q""AT E!)TC82+S+(N?SQ;C*=:@
MRDD!_!E&C@BW!HCUVZ8LO9@L.MXJ622G.3&KR?QM249"M N6IT:6\$D:_%=:_R81!+KSL1>X-
G;'55\$SFX7SNR.#W M.2&/6H.IKA;NCP&Z\$;Z9KR<^%<"ZV;_!-R>PUB^Y M%O;^WC*TYBE<;Z@/YQ?7F@;V9!Z;L-
;Z:6X7HZOFC RIE09X+\$ZYU&8!^?SG;GX@TC37J>=5QD9*ZMXJH!>%+LWM3.T!JRD.PQK:3DK3?T6Q V MO
C)DP5W%6;HJQ&)U&%2W;M!H6U;SN N\$%*#)E"0-9L0)-+4F;!IPV!FS4 M)9;\$!F/K;/P3D-
+AFOV3;_VN4T" 4T38M4;%G;= U^!V<+!J5^E7W!^;2_ M_9=YF)Z_!<!SD)*R=E*J\$.I^9T>'!DCO)
(H15J6_-WB>P!>138%M@Y=W9_F MY3"(T8;:%SAKGL.%?</p></div>

P\$2)T#XXDI\$(7FJ18P"G:..PJT0N;\$DMG83S01EJ5_KWIO=C
N@\$T8MBI12MZE>AS16B3<7QOH87.P!R&W47;OD7SYU'7-IEDZ+I=J M^=U!5E;+HL!%Q>%PS7R\C%/ZE%5%9;-6)RN&8Z!B#;5T-CM((D@=CA+?.MF#;DZ?I?0!;BZW#N2D\ (UY2&;T<-
'XOH#4S3P7>I5^/=)>"M1D:Q2LL7YA M\$T3A,ACGLJH9W&;3HU/7XMG0YYCK-7*:=AXXO9_'1&TU;KOYTOFLLE=;
I_M:1.8Q<+@RQ* D76!H2@;"LP3&8I8Q\$OK\$6^=9ZV%M24G9V9DGT(F-M,SKOR MV3'RIBS9N)S5%JO;-5=;^%I"
(ZQQ;1=W>;-+>7W^6G9S31Y/Y%FW4"71NV MJED)(R2/P'W(CKM45&X=O;IXIA RY L_KMGC^\$;=/1\$F5?
HCH,IOXHHI-# MXB9Y#D;7(L&2)!UMI0B1ZZDS JN5XZF#9X-IE?QGWS4\$#);:ILZ8M@+8
MEHHW+^H1IY9QC;Q6_-U9V@HIZQ(@1^8E=RO&NYYMM26 (62<#-"QYU08^I^;
M/XT'9=Q(KCGF_<+&N"GV7R,B-CMXOU-KR1O\L3>KB)O/>Q&5Y#ONG;6*16B-M#D#N70'EG818--K*EN5-
%+LV=(>4)FJGLWR109!5(G+7\$B5BDR<=U&"MQ9! M1:>%B#DVR'Q:Q34M0!=OJRIC?ANJ)5MIZU9T.>
<I:LK^%57U020-S3!J9C M3%N13(WEP)P A3F IYF!Y)+KD)A@L74+H2<@#2&8W98)?&|S;..I>
I7GR44J(MO02F@IQ;UYUYK;771KX&<OQYVH@G7Y+;6\$-D:4P M;2&;Y\$ *8M6)EJYID'W/I_A/AJ#^+=?
2HJAROI3M=E7&Z5GIFLD4\$;6D' M=W&;QJ3Q\$7<>X(Z,X:T0PU6;V;?YV6)Y>F\$0;JY;QV;JO5(\$>*N12#(RL0
M49&O\$*K7\$"R0LV_B_2)@<&NNN" T>WZZ7.>A+!+I>!DFM63&Q?"C\$;%6:P\$= MN*Y;@9(WO7 *5R7BK9O"?1Y/
MP_S;:A.)Y+T";Z5#N_!H>(D/(H#E09A4LO6L=3>O!K"\$-X%G3=7>B'
ML#DO7SPWN!";>V.9IX3(I VYR8#;%H/I32;^HN"\$5H7R-9UD%5I M%YK-T5H6%; "D\$%CM""MML!D3I(E%G1I?
7MY+6!#TK+L;Z>AD-84E;E9O&5/ M.9K!|K_B_T:@^Y?N/(XF9/"YT/M;F70D"*2(0Y%6+9"V2!_0XC>7'WMS
M4AIXVM&%(NX"G3)WZ!^OM;10Q3(I^2&C")!+^ (D0JQ6+BV6C,NA?;M"X4W M'<"0-M46W+N_!>DAI-VX\$^Z=
f=QO2M?>V5&FB/60J-M'BO/@N# 02HY2N#27L7TOYHM3K;_CAI-YH M&2_HA5";(U)KA/FNAO%-
'2:X@NUTM413BV7M+15H!24E!002BTFT#ZWN9) M*2Z;=,I+R)(H;CQ0*7BW^\$R=E*3A>E;T=")FFYTA#I?
5Q5VY3!5!#0"^DC M&LIN%ZWI: ^?;/60LHSWN!GV)=?I*+5",9761"S!O!A_/_-=%[S]UR\$&.F M&<,NAYY!2UY!;I-
I\$C)_O< AE2M=QO2!!90""7D GCT2K1UU'2 M Y";GS]?^_B1UNEZ/MG(X1%RES\$Q0(77NI;!!=)D97 IF/*EFT;H=I?
U(AA1.V 9M8MJEUWN1!;Q+I@;I;F)D+QCM0&0 MA" 3AY(%N=?
>9V\NBX;M!%N2I%M%L;FBUE+*5\$1*88TM-.0Y1(H U!D-IN> M>M(0=5!SX;>?ZHW1%+&5JE4P'C-;I:Q@1BY
_82&A!<|KIU#LHZ>V*#|= \$W M%Z^=AT8O.O?5UGXIS<-"I%;LCB\$PE@%3\$;_B#I6&0STKEM)F2POPO3O<;R\$=
MHM+<@4M/6@WMQ=?4KJ1T;18R)!JY*#8";I""8C""S1BE5=HB|NUTW(0U1 MZ?9)GAT\$TA!+
IC)Z90TH;JF#JR6.R3;B)=PL84UT#Z07?;>MXZ#7Y=;\$* M!3F;TME<1;T-M@I-?/!&9MB\$@R85!3FX
R0Q<25M<6^*-S;I/&%+^ M1D;YMYS9_O3\$9=VVT N19C/OY79_&N8Y15("6LIP68I>27^T*;I&F;,%P1 M9#EF9T3?
JN)A>\$/*NMB'MF@DJ+Z+2I^=GDZZ&G1A4FOROYL OKZ9\$M+5/'ZH M\$SK_-BN)?H?
_=3;^\$B;U7G^8YMKV83Y;2!SU=IM4F6X;H5'9Z3XGIM'Y><55 M _JZOGO+Q_>=5B8YILO7'LG63^3LTS!?
#E>G.X684)KX_R4_!D6VE!57L=|MK?2Z--ZC9AZDC;7#1TJT.(F;PF%9M9&?KM+_>Y7C28XOMUJ;*ZP(+@GB=^
MG!&U1MF;D(H\$&O)!7KY);ZOS=ET@2.S J=UMNOMG\$SUOQM UN3ORQ<+!|8Q.HI68@YZYKHK(URY\$M+MA9-
6Z-9DL/Z/ B!<PXT MJDV/=C 4.6;@ "I1U")9LD!0!;D9DGI720>JIZ=00;_SH!G_@_2!/%J V MEIO2K6LS5(X9(E;
(V>B?/(Q-87DW8&83=);_DN^-(I%7H>ZKWXOE;-EY M/C2>OJ/HV*XDZFF'
=3/2Q!"JQX!H&\$!I(*WMP8A!\$M@0=H#DJZH 9D MNV**V97@@(E\$Y"4Z!-
HR2)*QD@M*JL;KS=;>=ME!G3V%8918K-D3\$CPC!T!Q M9;%V4B=Q!9NU0&-!+S\$GL(T&)6^=SK=+?+94'J-
8LGK!S=/HID!AU8 MJ\$WX#C)"C\$LR&;E1NSGI?0\$-1@5/O!R'=0.3-' M'C@\$\$SFD\$AJFLZ#76/-T)!#I
<<23!60X&N;+R/\$&HU>2"49Z)4).16V=^ M-3"GD5\$;B/>;6>4;2+ #AA7*GU 1*\$JRW>T(86@?
TRE#!\$4#"EETY+G>D1B@ M%?(LHD8ID;JY/9N@2QVFSBN@D9?@U<8ZL\$;15Z;>0U.*L7(E4E&^0
M#Q1#XD%PSU6\$8F.&%3&*B!7F->69YR;GYWXKN)(0V3VNU#3IN09'ANBS?)
M!;M(QD2;F-A.C)=+)IV20&6'7JZWS/HMPZ;P;O;G0ZWV32M M?
AA#(SBS9)+XA*H)TQ600(D;D2;^<_W;KK!K98=R!BM;2;7+^W'NG(T3- MI50U5"#)13&Q70.S&=
D&8TEOT6VKO+T)*PA&E!9=K=-D%M1=2.N^S6^#I3 M.C)2R!0@>B'HA'2R.O"3SS4;2J%|K8!K@QO"#GY0?
O4COG8!13)8EO.S M5*?OL250N(A107GZWV!&")\$EA#JY609E'.^2^ZFM"&E(!_G;C(U<)6!Y?E M);HKH%239=?
I_34^-_%2N^2%@FB5I EP%F+("7(I-HCDRSK90"N_!PA9?#Q
ME3AJRJ;O3.WSBEUOWKRYNI00NMDZ.ZE/P/P23^>8;I0LGY5UWGQ!MCRE;VC\$
MOV!>\$^1=TKD!@;-1SO?|HB1XW(C!J+O8WH<4;N&J4?%|L0T3.E.ONHS>OE!CF&!(Q>|2B\$Y\$#YE4#SI>J>@-M-
AC;6@5C&|KN1^!P-M50=IXS&UQ_R&7V_!E221>VB>9J#|SB;?P+(. MP6\$T.2O56ONN#6X(>_I*!A;?<
KFSU9*JLUH!#&D_7" MZ!E71HH'7@0OTLO(6P#Y7*)G715F0M=JM MJL4/O^&A!D54-DH0UPO?>87>+M>-
*CE@UI/YO4HJZ14R5-42\$0-"E4F/S0&0%\$.%H42EJK3!|^YKNH^N!|86 ML+Y/W;T3Q_H6!H>VOGKI9K0_F?
_N_4\$E#!!0 (\$!\$1%I>I*7=J! M+U^\$P 5<&5A;RTR;#(T,3(S,5!D968N>&UL!+U9IAR!^!S^/#G_X@HOE=#
H!VX_!+^S"W"6YGDZ^_2W'W_ M^NX'_WO-W+O_SK_P/PGS^_?_O#JWDZ.<+9ZH>7"PPKS#_!5U!_F'U&7_X
MC_GBG!OX8=WAV%5YHLC@!;_!;7!^OB^FGSZL?!!Z_?;?|KX:XZ8!+<) MK\$T%E%(9O/\$(SBDMN;62?7_?
QHK5CPE9 QT8!E4S!PTQ&\$CS(DS1SIVOI# M#Z>S?_ZU_A#\$G^@Y^_T YJWN??^I_5/O_WJW'DG/HPG2U7
M898N'D"/SZMO_R&OW3Z0_15Y?3OR!7_!M/(756D'W+N&'6W^C_@W?PWJ MMX+D/PO?RISC_V+S_!<
<"JYL\$B+^2&^Q_+ #V9>_OW!S'>ETMOH!3X!^_ON= MG!+A(2%>?I+JZS^!^C;=
ITZ=MC_O99D+&\$D!-50!37/!LIWOE1F+84+6;H!V_4%P MA<1%RVA?O>YEW">@IR*L!D9PRJ!_'&/YES0_^FD-
!;7!Q!_WKYY!>+C MZU_'@U!>_W^_O GX_I XI=7IUIZ!>O_IUQ<I07_IV!OHL?W M!V?
OOGM!V!^_CZ>L'S_G;_!O#42VLF.*YQE/-W>SN\$=SM-WOW18-I?Y-S8?2!IR;)2SCFDUG
MC_BJN;G!%PMS!^S5M!;.;>C.15Z@W5!#/\$0)QAXL\$!2#(X4;);B(8)-D7 M2P3(RGFB+0/_XP7V1< MD 5&/UIO+G!-
A_EYK_IN%JKK MR_G1!7Q&?UV^&^;ZG\$1'(HB!0R%5E1H;3&R %;G)07(10W%#%N M20)W>8 M""P9@-
%W!;9K05^\$X6V9;.53* 6AULG4).K1DLC-MP(I"\$+;C6Z|N#_!HJ; M#R7U!2B!245I%#N"N%RBK=-)H!F!<
(@N6!QQ(=+A>_LV3U@0@!A#!"=V%! M6'Y=6!@3EJ!_J430T@G;^!C(CRX#<U:04ZYU!U-AURW;5K>TKJ/Y!-
JGOYY!HB'(NFI=)BY8FEFF"\$Z9B%;H0WCWHBD&ROX M&HCQM;RY3N8M!3K_V_LBY!7LPN&L_UO9B_#!705#L-
H8R9>UI;S;Z%8BZ! MUY)#"C85BXZ%W_K NQ/O_I9!T%29X'8F@4IG1R=-;X!OI<-7K;+!K%?E%7I
S4D*)*7.C) #VC!3!0&+1#_M9LN@ "KG.(F000>KSIBH)^C/U>3Z0M^!Y0SQ!U% 4'X;@IY UZ0%>2S#I87 MYW!
(YMP-IG\$PIJ\$"KC-%;3?J6SDYG^KJUXW 7GL=@3S;3!P#6!_%R@6&)K_#TOV!3;/AT/Z_M_.6I+X3!%_FBS_-
(D!4G83&;@>153EH3!Y3\$@IX1.;)&?*MHZN!H0X/F;: M!RV'5;D 'LJ\$!2!+M!LER=
(6#C94\$D&D#YEPD*!#EEI2*#J;D3-H;6!+PI'3GO)LOUC)?G1I-2#I<7!S'CG!6-6 M&;\$!E9WEAF<4
X<0!+&#9KH1/X=0ODCYOIXVMW_) JFX'^=KY6\$!Z!RL@PT3PR4!0C!1@TYL40B-MPD4^VR)CN>-
X^&T=%U,NF!R/2/<'B"W^%\$9U4DIQB\$SGAU_*5A;R2L'G MP(0.?!PN7W9_1219MHYWK'+)#ID87(*
SBLA>0&@K02\$GIT;#N8LX!852;ZR M&G\$K>MH;VD(WUPGD;MV\$7LYG9Q47!^5W4@UMFDZV*)#B(E%
<<D06!8#1&LLP58RVV"" MEWG\$3>J968UT=4.X=>?LH>T7!HI'NDS">;&EY\$BM#2!D1LOUT\$IBX>N%(E.O
ME!;6!;D;T-N!_5\$^!0.ZW<0)PV@?L(*ZY/M\$;_S_L !D)H#AZ<IP!_RS MR-\$R#.V+^X!H71ITUAG-
!F^W2D_%|GRU6!TUQ^G-^2.+4F>*U8S#4;AK/E MNA#R/9!ZF_@!%U^F"4!71!13_-!D'7Z+D2ND0ZF5-49-0R UX9
H@L3ID M)GWK6;0;WKS^6)!7EZ(70NB%|H5-IE!_YV M^_GOIZ*Q!
L&9L!4=16KG*FK3PFL YY&9;H F5C"K7"- KAIMQ_-WT#5K0/T M=RWD/68!CZ-
_FIZH!@N&7*19PFJ/DH)SEBFF"TLZM;AC(H0GB!1-M7/#3S;_M;CQ_-!O)571?CB)RVF>AL77LZP0=FO:O)'<

M8W*;>4!;>I/-WC9MM(6KR!@%O'IN^' O/DDGDUC#/#+02A"*I/GOP3+X!)+NG=L%[E*^&UZIT^C_V M<9)F8"?/P)3M0_N7DV^3LPF+1+1F2Q:~U!%B<0C69UV,6AYITNA6I.<=Y+M*Z-PS@.U1C>R4E"/7&A9,K;^G_D\,NO;L7?)NBZ*)VR\ 'XPYHO,Y+EB-M*H&V.%.(-<6#-KYD\ARB9ZYVOHO@>X3E\$HV4,4#6_!5D+!B!95X^>)H?C); M;(<)D\$AUyFDZ;#-)05L1:G+QBM:2LJ24ALO16U7!4^G*M6#/?Y4/3^>)O M>=>36\$SD+!/4* QOI#0_S\$7)NSW3:L,YBLY5=MBM8=+-Z=7=|>E(NMF9P_YV,MPW/1DS/D_OA<(F3M4F\$E^WOUV-^*J?=>V;G_M\$#IL6+O1?34OZ!?.WZ^ZI%M+F"32<I:.\$#0?,"3K,S)H0#)-6BM".C!U1_M/6D>#J&YAA4?W1=R7US/"VZ2Y_YH%V>@6(@0:C|&B=P|D;7@R-M1|P\$S\$7G=&MN9+++E@2=H&G'D3(-19)V@&YE^!E9" T M:LLT\(\VKTGMA&RTCNK#1.5:2G-!>Q+!_9WB_DQ+E9?WQW6MWZ6ZP*/ZP?_M_/4C?<2ZH_4S&B,"9"YVD.4&8AH+3F.\$;-P2!K?176=,NK\$/0;K/7H: M*V6(MLRW0:P_S|K*=8\$X4.?V#O!VT!>N6J|4F+=+O>R(0CHKD>H+Y%&0M1VL_M@^@E;(>85?(>E2^C:3U#4^>>ON_|P)P^ZAB_3^?3^<8KT*H\$K\KQ^_UB4J+-G=#!GF@*ZQVBE!2%G^&F6WL1^TR9=(M07^|C_2UASY**V4|P3:G/T.R!F=NT#18W_TU?4N;(HM%7&3.K>08L/!_B9(-M+J444XR@A:)=!&D#"<L/ILX_P&NIO'6WHIV\A_MIX-W9R>"0Z7J2(P=J_LCR^CTQ#\$)&GD(*5L!&?&MT^_JGCW?G.BWG>3LA_M#=-Y^,XQ0UE8D0)\$-Y).M.#_%_J23HIC#&2ZQ+;9!NXVBVX8,!10Q0"?/MF_O)=P^UU\$>V!5)8S),"SAWM9BEH>@.4_Q1:AE@2IN:~MTQ_*R+;V3.@C|_\$8<.(B"2+JMV&ZMY7C\A3=T(Q86S4?5HLP_?1Y700QGM;Z'A_OZS[4M=>PB\.#^=_U-K,MY01K2YB2)-R/1V0F4-QX\$YE63(QKJ2.UF\$G1^Y@|J*082^K!H1X:UZAQV7M_MB9^&O0BTP-/MK@X^I4T<'1R_-D64I:,@<5J^/J@(!2RF++B4IHDF#&V\$Q?N_M2,SCU"VR:9V_V!%OY<(RO<.D\$;\$_MB48^V/PR\$FXR%1%0R3RF0FMM_YZ6->ME,XWD&SKPHDS#*<|D5Y!"=/#NA/L,E|E,ZN)R^|G(^M6ZX6)VF=R)>2HJ/*_M_LUD0E+X!6I4!|W.,FEO=|7QH!NEQ:_V^Q^R^9:<"(E)Y+9C^4B(N.#+RV\$:.00B\$IPR7/K/B\$W\!9DZ!2,9PG0&S7G-M+K<67_4=DI_Y<;P3_M:3G3@ARL\$H(E74_P6OW9)M\$E9*7H5<71YVJ.CO#!ROG7HPDYJ|Y%."|_MGI-N:MB^_LB7_|<+%^>SDQ:#5Y>L_F8\$2L0M!;5^4\$UCOC^9+_DY\$.92U<MG:A=("G_.15NZ'5X!\$4*+0LWA3PDM\$N!1)"D(49D/^A8B0LHZ:,<=3I28WI=0>TF^M-Z&9&K018PL=MC\$X4'9R+WCBP)9"12F!&>\$YF!#.T^;HHC4RMR^EV0)!:_6^JA|9AH<_!H*);/S6E!|28WTU758#_M>3H|P7QPRG#"?@93<|N300|HR>I7B@#|6K_%C)*N,&FT=YTXTQV9CX88_XFY_M|77X1=CBO7(CY:YJ(DX|5|=G|H(Q<,TY, L_*|0(MG|9-Q_CGD4X6|H|2WZ_MO^LIG|!_2O9L51^QO@NT&YV37HJ?Q<>1V/-=-'W%F)M0?7?_Y%+SKS_9+I\$ _MZVI_/+|XASHPCUWEC"%N_52W(7&W\$A=J?P/M(<0|S07IQ_>%%.L_!U;SX_M4I-|9:P|C8VJ0Z\$10229M;0!4;-E?WJL|8|TYOKY3Y|R^4UF|_E0N(LQ!%M^C#RC|JM/LAX94+N2>>#8'2.O\$S)N8!<\$HQL_2|_OIS8)7#>2Y*VZ;7RA|_\$S_M:."+3^2?_NCW=?N"-_E0ZXBUT878>>?%%^ET%N8IX#-FY.*\$R2X"5YE4Z;6_M4\$|_(-I:/HIG74Y"X|I2Z|GC^N>OE_YV:M,Z%JTP^H/@D@B,CM8?N(=,M|B>" +47KUHEH?3&.=1'6C">W7WT-H)1|N02|86FG-E5D\$75UF(VI->*)MJ: M,4.*|T+9%FUOF.^!ND<^*!KL'O!_M|>8JK(DJ.!C>SWLA#6G3*L,/'EJNWAPH(9GQ(4G01FQIR2K1,W=D24>Z|\$_M=L.3/N)O|=-.^_QU.4W3,%N^K!;EUX^+DV\!I=YKAK5T+%M+JV:T8.=J02GR_MR^U,V?%NSNP=#QG?UVFLC_D_PFS<&^07^6+U*7S"MW-"=C"KV% XO:V3^%2|3_M8KI.LJO|P@|*>7+_FO0>K1/!U#6%U_QD1A\$0+^Q6!V5\$D9TZA9|3Q^>S=-|M:@MD)*4U;M!U^>?PA&>@|S4CZX+U(8-O^K^&|_!UQ@:IT^PAN|HW^FL+V25_MC0TV_VYL_M4!W-AQ+P_W/7HS!S|A:4WS-)E\$5SJM^M80LY0_4I/!WA|!#S&51.=Y=%Y\$MGNW#>O>">M36SS"J&_EVBT+|V^0_.(FY%|QN(C&-E=J_!EMJ9("8S/U_M/5>_R=\$(>HL:9T;!L\$!)L|LT*(E_/CH,PL,9E=,Z;/(EJ;)!|@+M^%?.XX_MO|B+_3G,_KE|_USUJ|1\$17IE|DB3H#1TF*J0BLJNWOYU_M,52Z/WAV\$UC;'2>N\$M=DLXW.#ACXHC0PN_I?;Q;_0_MZF2L^*W^UOE+G+VZ'8WAH2%Z_MD0%5BJ8H+5.X;2+_YB=%GI&4T3JQI=V|_#GSI_FGS#/T+>A,JW0P_X-Y_M2Y+903D/HY|-6ZRC&|7X%P1TMA,UK|+=8*B|H|U38QU74IB0!|)HW8E-+=+M^EJ_K|H6+;S>XJ=P>_.\$#X&XDT|<=7G0N@O5>7-3KD)S0@.R5%OGUE\$WUB;0_MA>26M?-2=+N+ZO2X|160|@)NV.GKQJWQVYGCZ^G|Z=\$;L@_(2%RL2!|!%>KG_M@V_-I9Z2%9"P'961MPH|_0BPQU_33(KJU7MD&Q;_BS&C|_C|_PW|AL^0K_L_MG^MI^K|^5)*4+1Z_3QY2R()\$D+6'@KM<,RF\$.W5%.5;N'+?D_6B0OM5BEW_M|27:VA?Z|:2*Y_NMQ1279T=-V_M9SP6%3>2X@!|LK_/Y_F/Z>'A)\$J5TOH22G;_&*M4_UB77NC^K<+7>I^EB|Z_M%G;^|>@Y:W\$V=";N+K_2WO^L6>39KTV2";LB|;/ETL:B4|E^C^;/_16_MB"029Z6QXKC>T34&\$@E_IRYW("4_JY?YHNC|&96ZGL\$7_IV0E>^#P?IM6Q_MOEC2*UK0B|0B|WL29)VVA0Z_LHHV.<;_18-RS28)&/R:LG^\$!S;A&/FXHC_M*GB^L;=%00Z+&;U5OQ@480;_ZU+1Q9T;_SJ/*^56+2A^T#OI,8K2!73N9_M^7G-B=M_+4^_OP.K^U;_JA^N8N.C=|H^1&+@LNR)AL44+7_2EM:~LV7-T8_M17>1ZV)"88|)U/29B&2LU0<\$QTG|SI%TVG2|4.MNO_IR|1CA"*2!U5.@2AK_MXUDL4D@D>9CGHKN>/-FZZ^Z/40:|Z\$X;%W/(&H11-6_?1PB!95J0Y^KA/+J_MY>F3+|KKI?Z.17=|U+^3&JHN)^+|G|KLG|OTF1_M/5<_*4BG3(PH>?.|TH=5=#|I^YZ*Z'_.=(+C|O8W@ZX.+2F#\$5,47/-M^J9%.C%SJ/|@.3#KHW^H(T?_9>_HBNU)6!V#G92^JTG="._=7;|!>A<|OLO_MJL8H&4;3O>BTI9H&,%8ZXRUV9,/7_ELL\$Y0-1E^@ZME@;Y5IG&26\$K=M8|K|%YOZ.*>U2?>H"VE:85Y;|G/|L\$+5?|2P3F@P.E.05M)#E(GJVTZTFWG.H,K%R2Q_FSI3^I?#L.DK%@|J)5EN_M>&I>H'(%Q"/3?QMA#W!_7.+D^7RNY?L/OY^!L\%*K0T#KPIQ_V#7^00%3,"4_MHC7>*|:8"7<=>J2L.*>\$UBGB-JQYG>Y=^<_XWF^6)ZXR^V*KK;.*.(V76;@_M.#E|DDG4F+C\$Y#L=|MV>MQ=>|G81^*&DVSH3|HXP52<(W^|7J:2_ZZ*JK;_MF0*;%4/;\$S+7>K|TN|_*GTS24Z3GSS^TUP>747|S/7NZ4G.EHKC=.T_M"N|_V5JZF1.=+B"=BSZ@\$E.WVR'!'P:(>J#"K|_(JUO#>T9D)^12|LDI_MJ%&B&ARRX).QT3|2V8:0_"M.TCO!/2XZ;_AX.=)|%|PMA>-&SK^8Y7/23P+S_M+G%AC^U@)79@PL|4&N=*1%13Y"OM6F|!AX|96;NNRIO|K>+|BTS^>K;_NMQ/O^S=|I7\$SG>8*6;\$_&1CR#|D#T|FB4_8TUJ9F+9_SW6(M;7\$|_N+M6ENM_MZZ3:|<_SLINX<|7ALN+^+;+Y7O|C_+|U|>DF+;F:Y^"6EZ2*_11UR,O|H7:S+Q8S,1&X44R)#"?R_UAO\$_.VD+B&*1VB5Z'-G02_MW3B>"HT::N_ZD=RVEO|HZ"=*A3"U7QZM+172QJ*?%BPD1Q5Q|APOO6XDOLP_M/0+F#"^Z_3P(SJ&G^C,M./@EO7M&L1Z%G_ZRYC6NELBR|J=YX??T2T&4PM_M-X1!OX>=5\$T|A|3_-L^C^8WV1Z)Z9E2BX"00FK;Y7689;23D_LIERMOR;G_M|*AUQHE^MM^BAEW^MMLHFT<>L|_M+G(^@A%SBR)\$#UF\$FWR%JGE3ST>IM>ZN|8;|_!#3LIG^@|+G>IK|=1_M;*G1#&^50;|@6^V0_JU=0;|FJ+^N.|T.\$FT_KD>ECU-L/RI(-XQZRWX3')_M8(0&RTN=IM>^NA:;|_F_USD.I\$B_-T_M;CP1GA^J>HP|H^EN1Z;&29>6260E31=WC|HYGZ|NV|CH.V%RT#7_!OH\$X_MHUD7&TG1UUIA|3H384_E7U;2&YAKOQ53@EEVRDK<40LB_Q10.1:>>02@K/M4\$7RFQZ" N|8OM16?WT\$UEA0OY^DCDZ.SM_-E9%:>2=&-5M_L0+>U;-CBM_ME\$G<=6J+<-|HK06>/3=?PYR4@66(07M<(&@)HL/3H7(&H|M(7H4UF0>BN|4;GJ?|BX_|J\$J.V.9M=XQ<3V_JT9=UAN)|KHF_P(Q%*O3FAI_M+)%FRY-4HGLW9)F|H|UOW_LXS=SMA!SP|3%*U^F>OW@VE|EP%L/_#9QMU_MW*S6+60YW^M|H|H+GE!9R^XJHRR_3^H_M1-A8GQ|2SL)B.G^WP" _3^|<^&ES" _E_MEP,W.1:A&ZCW/APCG|+J6@^D^Q:1QXN\$3K_U|GIZ*@\$6#+Z%|!#)3+^"BUGU'_M^J|J.5*3R&KK3/!7HTM;|57(#Q4C;>2ZH"QYDM)"M>OL;L|OU%JHN;+K+/_M?B4N5XN05A-OI-|)

<9"T1B"Q%=-H,8&2)-!"T+P"#4&C5:S%V/MTVN9=-\$ MY2/4.6Z\K(L9PA<#LXG"?
^&JV_KM5Q@8>0^%9D5J"P%Q.0CH.9.Z2PSFBO. M9_/940>16:UM=-+=/OZ.?GC^Y9NCX\7R^F\MPF=BC*R
M\$"%E)#N&200>,'61JZY9EXP_K;<0_H=Z*AT&_H=Z5EMS9YW?D%7I/P_EQ
M7=2;VGRJSMR<<"X9XSY!"M6.Y+EV/B?#CSGE=-11LHYI\$8=&^OPVC/V;V2
M\$;J@+RXMY&Y_@!YJM7W)44Bf8)+H%I/L+M,Z+T((KK8=ZCJB,"0L2Y.3>,L+V;TJL
96V=8%F8S1Q:\$W3>'XOG=&.?=-M;F=\$>-4%X4>B+PX/ MYW_4\$9^S!>GY<1U#LW\$9Y-
D4AIHY1F44QFMW6NHU6R!NN*!-(K.V9I=1M/ 72BW/I;+)=;##+-S/ZC1?Y2UWLQ_F+4N@W:0M:?
CB)RYF>AL7IOYJG17?I M=-/G#CV#_JG)R2M2>19>1\$9:)&1_+@ZIRF2BC5*5_YI\$&GC9FFI7HSBIBW_MJNG%O'TV&
<^FG2!O=-J;CU8810Q@*941(3_30!IF(CFM^NZ" _5=9S/!>>_M<6&_#NOA!HW9*JK=-WWBBY+G(2K\$C&>0-
!)O+L!+WR4:"&8J67Z'Q* M.NT@/G_9XY-G^#YQH&%CK"&D33Y5F'V:POOE@15G7'S!&?YKL7BU8*S<#P
M0A!5NBF5PE0Q5ABH/M#S6R<)0%/OFW9?JHU;HS6-M8?KH^J@_-+X!>4: M!C21DW_#*#08JD'H;AB%#BO?
>&26>W8^\$2\$-9Q/GOCIOH6&2!R" M8-(!>>VNSE;F<"A'DS_5R_*S6&\$SFQ;KN+!HWY/""ICICIX/SEFY+VSFG_M?
37*5'3K/^BTXM;1X>5IG<+EK%MY!MX2<19XX,H2Y3_FH+Z!S.%M.0K;) M).8A:Z5)9_AZ(@U!)(Z.I@HJN17R#H
WZJT9-)25LIGZIIYG0+T!6" _H' MEWIP_6?3>+WV1+3"?VKW^8KL-)ORA;0C@L(L!0:-Y=EC4^,G> MW;
_OPH/A3CIG#-Q?;F_SA>K3^\$3OL)8LI_!DX9Y8+ZD12!O!%(KB_P#%XS1_M;K
/I=ES_OQ:X39;=Y"S>L!NNU".RE95;W70L(24+N10!Q75!B;1@#TV&WNZAVK>XMA^6UA7R=(UEZRJ08.ZGS)!/A-
!KRBPUSD(YWE"/!+7L!XS8B!_!NST_CLI6!R)IS MV1=ZFY&S6K.A(10NP6CM4K0RF;B!++4^*WE^41XFJ?
8!>^RLI@N+A5#IAZ2_M&I2P6%N^U)R.J(1)NH3F WP&6LKSRI)O?-GK_7,B\$?
K!M07JISY*E#B=JLP%T%;C^TD'E=3H!LF M*WE^5QXFJ?8Y5>+F);^925!M_A:S\$)B*\$)EEWHMD61C?-NL\$ _M_?
F=>2D:9AT=-HWQ'5UP/9?B=2_2O!D&Q)Z9H2Z!H\$QOMP8JTI1T2T\$PLM\$24EPT+9FW?EIA4OS(8BTHE+MQGC!
/LV;H!VX6PH2TP2V&_HO#Y;1(@R&3ZHSI=-\$>0!_5=-_PAQQO@O).B_*Z&'W93+-\$^DV\$F?#BJZ-QA-KY4003\$/!3-
ZQ_M"@:BK*5YCOT<_MZ"!5_/AV^N5ZM=1_8"V\$(LOW"/TRG_#W)9:3P!3@A.>_)VC+\$"R(8_*)7/
M48"HC?;I3I8WW!6VP?N(*#>:VAK>^:TMOALS5JY_I3=CL9K^S_I%N@2;%5%, M9&2V:6-
K9XX(SL8(HKX_6MD0;,>_O!TQ/ (&C:F%UC=EOYU481V4IX.H2DM MAVPI(MNDH+*!J44F*
I=6@HCZZ!2ZP:/_ZOJ'QIV36!I3E?ZC_"8NW>?;M) M(H=O!27@CODNEI^GQ^!PD0@ID7'B4=HHM_&#M?
N49(H(F") (27L9;R!9!H? M-9W!/0**#N06ZN_O6G^R^C5?QS_8/UJZM(WF/YH?IW!_ =OOHGOC\$ _^^,OG
M.F#XU!Y^QEIQ0D7YW/AYN7=8EJFBZ_PUI_P+Z9K!>)_8*
M5V%ZN/P>Y7)Z="QXIU3G9?_TTVZ_OE_SV>^ (AF0!0_5SC+F!L/EG!@H?) M%^YJ.PC)D4X*91\$<6@%DV-
*_DU).82B'Y"8!V^Y5_6<-"BSX5BPWST'JB!ASA4.#S?BQO1YV0AACC4;L5X_1MJ1F0#OR4EPP3J!WF/*0W7.&)DH
MMAPBW2U/^HB_=-7SN!/?EU.R(&?+VAY_I?7CXF1Y/EH1N6!8*#O>H0>E(X.0 MN (1T*F2D^=H!>19"!6VT<=|
&\$V'.UWQZJ7Y\$7!4KV&L_@%9R!0)1?W@GLBG_E<G<=>(XTC_#?-7%E6_MO=IT@!M+W")6L_4SFT1MVJZ4?
SEFXMD7Y#0L1L<_T!^VTRATXILG*(3\$&_M\$HM,K=C&V!LNV!>2.2IXV<89!PX52TVVD;)>?H-09_2C5
Y:9J%2Z!L"H2Q M8BW;ZO3JAK_-)'<=0:G#PL^;0:R!"/W,+L:S"!L3U>!P?
H0#>+7/N(0@BX?;Z&+64CCL=+=!SW3VS=#M#MZR1?FH^JDH6-T)^+? MPA&>@ZROSWR&+E#IQ%PVI='!;:-
NHRE12X\$;ZBN3;L.A2&1_)*R.C\$B_! MR(VN78EKXEHTYFHZQ_-EUBUAF@=-K#Y;AW+.3A9'8?5E;175%/4S@!GPR!
M/(M!Y)_L>2"L5IZ161"#AUC67B;3)C@C0NZ6;7?D\;SOP;7T7PH_8_CO*) MIVSQP4L-CC-
9>ZDX"!8SU!%>P6F=4C?;YN%>' +4P9%I*>8_R@_OCFET /M!+ M!59E!WC_)GK8R;U01JZCD1:TYH*
)@_!VUQ;Z6%10L32O&#E8=T+#+01\$T)S85!<+Y_RLGI(HL1NEMCM@=V+!1+'UWOA?H(LZ)%V.MZ)F-
5&QJSO+_)ID%Y9!G**9_I_Y;@+-;T@&9?6W>+TKLIN;GS&^BEN%REH* M!U;=CA2)ESN(Q'=^YJ"1^_U6/F_DWOG-:-
=P%135-6AI"%Z#2*:Q.APH4H MG2;10B1>)JW6U2=-UW%16B2(27HHP4I>=\$ (FQ6"KVGGDOH!_!XO\$!Y'D/D3B
M/U3H!4/^CO-/BW#N;K;_!M)99-340S(6**3%#VY7UJ1D'2@?9;_1&=?@UC6
MK0#VQ0WMI=%Y;ADV#FA<_&7;94AGAE;74_V#X!<="&3!_WDA1Z&D/H%R;:1 MC!<#7M4B%2LBD'\$E@*&UR%R;
fEHSYX>@^COBU+JOH!P6V!>;R8_/BP&C?7_M\$59SZ!6EXI"_)^W?XF(4>=@XIWZ')Z2^?
YE!^JAIWJMOZU26!GCFYFW)AR M(V/-Y=40V=O_?B7+R;D@Y#M@1XLEX8P<\$X'CV'?;JC+U_9!U642!2QJ)Z
M2JKU&_7Q/R>)>6!K%E>.=?IZB?1X\$SAHG/P!3R*6NSR!3HKZ^)\7E\$!)>4P_MZ+Y^_(OW\$Q!5CL5R8*EV/?
7.UFF"#_PPDMED97)W.3>=%/7B_8-75\$!)#="M_MY!MQ?;!F.UOE!O1(-DZPHA3\$8(E%)M!"G*NAFV_5X5-@A^R?
MM)2X)=E9UC.+><_8_Z&L_R&XNP1HJZBH%MI_R=>WX.RPNJHM;LR_17_M7-7_C;EQ#P='E%9?
G7(S\$-0^3W766-IO(1P6U!@O0WQ! (9%>\$=[%0%PMA9O_M&58@E\$(G3!921VM*N!ILNN4JXIM^CG!SL85)S0_M_?
LB@65!>T1GIPB6I<_RK!XV+N-NSUA@!_L_K:5E"MHSo?JH!P#B!JO/MAWQQ=W+!N!A.P5KO*ABSM\$8(ON!_!@
WA=1&3.19(=E?>2-M4E!D!;8'S(C_M5M>H^FEHGU?W5Z!&L8;X;S0Y'R^I=3ZH2AIO1O<@E\$P+H8L9!4&
ME222J^ITS??+T6JN;\$_&H&2Y*^B^AUSIHGXG61N" OWQWWOKLS3_>OCUY=H8J_M!EWPFD!)DI93U-43%VU8;f
!Y^I#=-MDW_0_M2M8#T_#F!>VFOG69,X)A.. M0..Q6@S
M!U0BO5!)U#H%+3R/0'9U'=E=RU5%3);S8I\$Y3PMK;9WL40)U'YW>ET#=-1Y+! MG4"=BA#&KPN-
;RF2XA!J8@H83SZ@%X+^!Q02J'MIM%,"=1_)C!8!VP744TN@_M!JH6H3FFTTTAY_K(DE6*4!R5M;:DYVL!0?+
<!D#N9%9;)WNN3!)U+V\$;=|<4@_D4)_# MHXT(I(GOJF4'\$1!+-:Q"A-T:S<11(^L3JC1754U(#)%#G8+ASB=C!_3W>
M\$E!""@P8\$R;R5*06V>ZIT"/!<_*ZBFI_1*HA1(16.Y!*E?O\$1SMY5IH**84_MCI&Z.YRV1Y8
O7&BNHJ=3J^EDR;@DP5M>1^S&0BSR^2_7O@YA.O; &Z_MMA74+OG74DUTOIH4C@E!^M3?
3:4G@IG8#QACF2;ZO/N_@9C!>K7Q1C#3>E8_M+W1NL_H0@X@SCQ\$%#4YVIF@Q3H!6CEHS83.?CZ4PL
MEQS2QJFUR9>7VQ!_#W(X;9!>+U<_>2MGU?78WURDJ#B6CLSAXI@J8!AHV=-#S5--O11U=IAA_RD/KGH7
M=>.);4ZL8%XS23\$&@G7&KD1P7_F6W?W/=4SN-JQ'NX&_KSASUB#EEK@*(
M4B(HD24X1D>I8S;K&#;+LG1RA6YYP*ZC&KUD?N<8B@T\$UMJE00B.65V0%U5!_M8Z.KDU9-
R\$(SRA1E#!E#H!+!B19NK^C_A+Z_7KY!OUY!XY!VMD\$HQ0_M9"4PHHD>;Y;L12;5RB;=%\$+EX
MF4&\$0AMJ00L^E@#D60AG8C9>MS;+!P6U%QWZVSA>;14P5D?W5!E!2S.(YA?_M*K4*LTP_JN!;='!^8#\$D?
<7A29U'=O+*+ M%P6UDR;S\$#ZNX@!)>D=EYJ5+KH2XC+F_?O7AXJ?>^NK4RYA01D-DZ
M>4P8"\$Q*L@(_\$-3!K&SK>)(2QLK>+>+O!S5PV4?&?4P@H&^!)NRT2#)2"9_
MOG+P@Q=83R/W@7.9>4IX<>#-Q+!O6*(2;1Y;"!Y@GFH;L9>B!HPPH;2+E_MP55?
DE>A9F9)D!B;%T3N6!NMR1A08R_03ZU9+5V&N!CW-%WJ!@;"J!EOG_M_CEP<\$E!\$GQ!@!T!;^QR=/1M!VT
+08;+!A%AZ_#B+_3Q0IQ=B!K(U52_M=;!K"C4%1_C"%WP"C3'D8K5!;#GKD!L/H>1*0#)%*>A4/<1Z3E>(*>E!; M%
(A*UTN@_*!_!W!%!)^++K<4DP-8YIK.!_F_+JH);#0%Q*7UC&5FG!G_M@)!2.DQ+<2-
VM*W_ASU80;869.ZH*LQ=13)R@((5<!(DC;)4K28(P3BK8)_MHT2WV/KIN5K86&T;BN763C;
!_XZK7A0UF5.NTNQF3;1(=K!GQ!9%SXV.. MOO7IQ#@>K>W;Y;W?YIY!
US;10!>H!@#11DVA+R>;0^LEB^!PH;\$+9_M7!Z6)6K;+!BOAH6AD;L6H;PKN0B
R_1Z/L7/Q"1!8N+YT7QK<^RI>M!_M!0PY#S!DQD+2"80TL@X?YO^Y_V^!_*\$+!P;G!2;4!8W!P<13_SUL)MV5=E
MVY!U#LG!08L@A_*W0Z<(08%R484H!4C=[2+O4(IXKLLPDY!M!^G5;2!>GS_MM)
(6NT^@6(3E8PIK23S9+V21%XX_*_8^"L45"84RR4R!/JJO.#(ON+?9!(MH9#9_M9?>^'6> "&6!_83!FZCK%4J\$(*
(EG7!L22AB^JDQIL_?WS+=^3KUHI8X@) M-HMY0LS+7TBH!)B=19@2>I.)N24F!J2M6P-Q"#Y*!>M-
*_0+Y>Z_R\$._!MT^K6A%&_FQ!@EPJHWS>SL/L^5!3#C!LC_4'0NY;?J!S2!SX&#MXEV6Y6+_MT5G%;Z-
N;IF\$!GK*_V=NW(J;_6;_'"<=P;"L_QAP>3"K;X>E_N!EUJF>28_M(FVRLQ*62A!Y@B0LCAR'R4;J;347;*"KR

\$PIVD>Y+)Y)C:K0105?.\$J!TU+009^S*-P&VWQBT9.N<>G%H%XE+GTT.7B=0QB
MIBQXV\$3*(@ZN>.XW(DP=\$12XDRQJ-1*U=A#.JO(-!4OE6)2SN-IQ'N1Q#K2-D)HBD1-
CPIQ^C9>KS>;MQ#;NU1MG07V_9TOO)HE9)IQM08)^R MI96(B\$#\$NCH/J.1+YP YG.F?
2/Z6%JWU=DKYNYM01.B-M#X-G2!OSNC-1MJP)#!JFYHJ^9'5G\$I21LPE,7;5#>R;+2T?7+9T' WJBT4
M667.30+62NYSOLBVQIM\$NI=ZFGN0+R+V)^.D7APIRQ?DZ\$F"BC"XI20^H1L-^?YXNTFW@?X8Y039J8S!&Y
&ELIF59A&AYH3/.*.2FEW MRT780I.)O2113P%I'S&-F4I"\$G5:\$A)RW3THIQAYV18#RTYHCB&T*UX:TI3
M23;67PN!#=#Z-^"VYU^_H_!\$<('8M)&5&W&)DU*!,M>"DMI%"X2Y)QAV8S=5YI
MU.-1!%9""#78:0KS62#UZR:Q3X84-(DB#YX2\$QYHW*RMK#&_!1SMM"N?8<1 MY-8>90MU@?V<+;2?
+&J4=+)\$!28H6(@PG;3*ES) 906M;:W.#K\$,"0FH@BL M=1QGKYBFI"ENRIN^T/GBTDSBPI+L%("DJ"H41H94B
\$1#T%R1?9QYFM MMSWAX60+]=+/G="FPAWI&PA96-1UI1KA1YN!@3."L;+;0-A=JK72X MRVPAIA3+I":?
>U+9>U-G IXW-WF;TCWB#;W=MLH7 "PUSFBJK. M6WJGS*RA/GAVDSVTL<0>8!91BV2H=,O,1-T3%SQAS?
>^M\$F\$25Y9W:51=242N2 M1?3=,E!>AN5R6J9IO:K3.BE=HG5)0)11DE&H)011\$3T.).JC6 YON@?38 M;P-
ZL>BN6-.6VAPZ"/HIO/2K X OPC8WP1N-ZYIBKM3IO/LA'WJ1U&Q'?+ESYJ&(8GM_L6!S/(JTB1<<9>;(A
M*P*2P^U.R#I+2-6.2U-NLMV-(%VHICWJLKJ3IEFFMD@-CF+0IG6C3TG?+S
MUP176%W\$Z(PMD&0@6I2J&BC3&9""J=TKRTHIS5!_!3H% #W0R1,GMGOJC, M0JA,N'2J3HPQ:KPEK)
(78;3RW%S-S7M.RM^5*=U.DP/DPWR?=<%S%-RN^E MJ#M3M#>1N!)^2IP@KQ>&2M6)P(0S;U3
>HX;^)XYBRT+H7;IZ3)=AKO(IS! M.X/4XQ)(3>0VSY@K*FB5+7I&RBV-2.S>5A/ELK,& T:0 MA;N*.T.OV8..GLS
)U;:RFK! UGEUAB5A;*V=3I21VC/G+LM M4#&\$;@<(5ETD-KV=AC@JG-
87A;#/TY2^E_ICNOKI4W!>X1<G!H7T9.XZHF MLLBHD>QI6;#HLN^@-2TC)B/H)\$;EL75F^?HGXEI&W%'9L0 L?
;S<:#IV:X M6?Z>KIC9YG^CLIA)J7@N/DGZ9J<7A#A@/.*9D(#.9DK#@U6%G<+O8VA
MP^BW83S@^S/@RHY MX@FVA:52!+@96UV45P ^F@98S9A.9D@ZUK)S: ^4S. MN|X71^G:9J6YI>VN?IXOY>H1
4V1WC%A)41=4IW;E.G;5I%UMOGIEB? M"7L;84?1_G76ZOVH SH-/M5?7IXO!>9E!5 O4'MIB)H.|DIP+*@8!CC467(
MTH(YD;(&)R*"X(8(GIB-YKDL;"/)4='HM D!MKS 53-' @B(>U)B@I4W*I MI:#=YI*^4=Z9794%I6'40RD+|DHR:
(ISYP&Y7PBFY*GVK(*R16RBCYT0)IC A8T%OLEUV*J=;27 M LZDH/24JA.)"9@#PK""(S.BO M14K/OM":Q?
A41/8G!_ZIZY7IOC5V5TFVGS.OJID;3Q-IVSGTK6(MM M8HUW-FH+IF19)TM&(%D'T)ES&1F3;H@:Q9XH'RBK1E++'?
7+^?+527VZS^/MR6Z!)(908DULU%#7#SHYBXU5V""H9W7.N%MZIKSVI|GV^W:V)VJG:/9U! M.?MTMH9)
FH8&VTN1KH0(CE"%2%I:742(N?6%J!9PQ^=F&YU00G%MI;A MVA)WPOUOQ@J5X4W25Z8Y)0GM;:N&;7)9
XN.64W"V82RM45U(YC3JQ NM3? 87BP^HR+TIW)JEDBIPZ(WI69DWHDDC@#1<0E/79O-BYX/Q
MMOVLH2:"EYQMSH5Y;+=XMYF:YJKI2)T1I|SCAXS\AN6 MM#8J1709M>-IYDALA^9L&HWNAD@K?GF/9:D6C?
7VK?^?)\$'->#_8QEOL#3 M)7T;TY(AMD\$12'SPNMR+\$3:AR'ZG /C620V2J^WS9?P;/CUND8:B2MC49IP
MO2X%T^J6-4RD)G!<"G!D@.7T(*K|@S)JN*2+;Q.0A^!H&G>B<5.1+SK MIW00+*^I9+AI_2<=0<@YIJFTR"Q8M
M0N/=O!GXYS?@IESCL?EQG>AFD+J8-T?8;I8M^"I7-JQ15'+/9-8I""E#^I6-MY23K1V)^.YH>COI@OFBUIGH^ON2?
O*.;C&D*)!+X#&1+8HNU09KM.%Q4;*7 MS#C6^DJV|IRMVUA^!-S T-/SZ QB.O*KOXP TKZN98+
(.8.VF1^9&K018PL=C\$X4QY3E.1DHEEY E4WM4L+!:-43)8INS#)!)@DFI MX4\$MTI,T#;9""3S11'=AJ7;7=2_H8
+@TQE#.*2% M>2/I=3AK<7?&=F>)U.NJD#M/TP@@"A17"EAD?Z#K\$RTDOAL?L>_W2A+1HV M;#.#)I0=+NVLX>G"
IJK-"ID>W&#&VGR8X4V4(-VXMYU--=\$&=0@*6Z/50 M(24(V2G(07-M4W)>MFZON N2W&.*IHHC?;3?
VAAI7IO8'7XKB)GE6XJ?SDY(M'XI0TN>SL6P6&42K-7 M>=2JFNCW1G4W>.|XEDE+E9 MF8?D @/E0:OC:=7
K/DPLD4FL=BIW&0V;@V23N=#)"IOUTF"Y@GNI(LEZ*MNG- U292'GPDF0TB>IXQWM+O0S0Q_?^AC!=-#YW
MZ=-18LVI+FYBCYUTZ3*29IYS-KD>E.(T0C2!7M%4M(B84>?6\$N'AH9P*"Y M2.0IN)3-
Z\$G^V1%;=I#QI42M.B(G)/=EG+0D|\$NJM(=I6.U)^ M6-/MIZ"/9VJ=1G.Q8BN<I%I#
(I<85@=;)7\$'0FLE6LQZ9EX45S|OU@>CR MM>G_F\$W3I /0IL8HS+&<2O+SYJ6N
G^M+L%A!GHLZ5A22\$5V+!/=-LLC9=:(2AK@-O9B!9<QHD.A7M= M"@CTB;9 @R20G\$&D&.C|UCC>N17HC4
>VW:R7V %B/G:TOR: ^ #\$/ZU G M00G(3)0\$1XCZAZ^MNRV\$P\$JR-OC00!??33@>+Q6VEOH X9)UBM%OJID"TEB
M<;F!EG.L6"4LE\$*K548K|.S3N8A*"9;I?ZQU>.TV+ (^7\$4VD/198H;<8EKC| MC0XY
OS'#:8N#25K).U!6"Z^_8QVARE)1L(M=6TY14%D78. MH.70\$14K/+6.E^UEL8SK?*=R^@C_<'OYKN
>;H&T4=>YZ6T4IC280I@*9?SA?J<D;AN6G=+Z CM\$=IX#24R"! MR3;H-X
13VSJ@&I8: ^!6;#LV\$%HHN:#HZU6AK>IL"913#1%\$ TU0\$K\$KQ# M 9BPYJ@+;DKK.-9N6-
/5QM@I:7HH8SBRO#Q-%B"%ID"9X=H"!A! 6\$9;6B MDI66IE*#S2Y&X.PS4.VIX+.F9'22(WDZ21\$@:P9-
XMY@DOKUM@?0@UK7)I M-K^GQ4V_U%Y.?2\$B)HJU48+0NB1 3*_IW27JM2@RV=?+X_.C&YF0P;_&M6AB
)^=7>S4WR S5>XO.W.82/U2P""76(1%3#57G\$).#B-2NN^/= M>EP;2G_0Z;O^_JK7#=#7^_Q)T;9I=;R3.KWAR*
(4KJXPN@XT80H"#^0* M0B8L".XJ20AUG\$&\$&K4Q9\$20)=(ZF+C#"SAN4M*R9(A&97I9C*A%
MN;G&EGAV*=MB<)35|M<%7_|+F ZR/M?;F NIQW|NW4L(^&EOIM-9AVJX
M#DVT&L9.&DQ(FV0>#71=OV"K=@V<I\$EN(?EQR)(N.)Q6AQ'EX32Y_H9I""J\$+F.9%H_<+< MUX5E9\$ITD?@
7%CGD)WFOYW%9V)7-:0>7;13+!LZ0:8Y6E8@Y9=ZLND: MB'TT7&FDH9M2 #
<6IQI'E2M WJO^X4R0:.64KPUE;*20C:2\$%"BTF7)AO")GKD\$;.<38I919K^XZ :&.&8;EU:5QOEUA\$Y
MK _I9I8CM\$S'DK?V2R;1^H1"0_F*F^*2JHXUIEC=R/P!#Y%G&O MAM(?
@HLO4CHY.EEWU+X<Z;O#&_L=:'2(UB"7P\$142I43.N LJ9K;6<@3L:B MKI-
QM<+YU3^7G_&X+&*Q9.>^N9MJBGJSHJ3;0N.H#B'R3I U MX5&2(UUJ^T:NJRI5TI33>1H@CU-#%(\$YQ9
"M.YA5HUJ+30D M;3+!"<8W;V.I9S5TO11R3PU='VGNLH:.(UJ? S#R%.H1IFG)Z"\$9E@+A+@"&M.^8?
7@U=DP_H49V4D/7=IS#=#VVBNU=#K6!5G910Q>L-)D!)UH=.SD"M6 ML-?S-N,26G>.K/T8=?
0#4F;ALK820T=%BZS\$;LY;65KPAU\$)6\$EE@UBBC MI4#FYX.JH>NEQIXU=V4.\$1MU#W%\$JRFVOR20I
Z6T(85)76:FG+PX8TQJ M?8'WX(I?M@EIM93_K?08)(1^.@;UJ^_6^URZICYC9_6.&!^/K1XN3>NB Y M>-
H!0IE)GHM)NIM/?W;W&EUO-A-#CL'SQ5'>A<L99IOE G%:\$.EF=9SQI MQ9Y@I4I?
#O2)D>1HJCY.O%BKSZSDSH43@L5E|_T=XVD6I#L\$;Z'.I@'5 M W2,E>&A7P43@?&KP2*.Z=TF"! YF/KO#GZ?
P"4/8;IUE%G-EN'=8.P0<6M3T70HAI1)RW?I.F/M3KEB;B!#U*_QR?G0TGWTXGBZJFS.X(GE3JAOMBB!7EZ5,%
(I)+T8E%FGE4G MC5L|\$>GSRW%13-QIW7NG3B(")+M?AR7 IIC0@MK;9XA3)81OHZODNFUCZ
MI:4 W*77MU:JIX-YJODNO11U3P?A_E(>/M5)UDYA)=7K%E6WNYKU'3DP)T+D M);DL6W=2VO=EW8:IR;6V B
<_!2)Z"";.*;ZG MH|QIR;S+*!^ ALDKV41H^KVJHGVMTV|I*QCT.@NK"8B&2C.;%OP)3@ M;M?
M6|_3V&2;SOY3QIN Y6\$AYIM>7I%.LG9:FWK0J*K@^FI@)A#_E^L4I6Q M?5&ITIOZ_><^#@5N*
I#66^IW4%X<R'F7S#_E^I_Q "M"Z "40F@Y5;!(0. M2I9K!6D"TI4//D)5 M:=M+G3<I ZM#K>6K #V-O2;2?
UDD\$'W"U^K LO5MW M&S>R/OJ+;BW<+X^D^S)/DFHF MT2V*|COH1-%I?
*BO&J@("ZG)Y_/F8_PW_RI)>9H5@WY4I^?XF:RHZYIPK M>40C+L+1HR0*5HZ8N7S@ZZ41ES"3<.XG&HSQS|3-
I|G/DRT8O^#2&<OT MI(08DFC)@O=)%!)*M%RIYX.S5026FH>1)=R=)IVQ^Z2FQ7O.UH7)QM M%/9XFEU-
\$<4HBP;2NET>A I!66)HMM2H555FV\$J@Z)S8PD0*8A\$.GD=HM32IMZ.IAT(QI%U#_G>HOU=M/> ME/_OXX+5I?
I\$N\$BNQ@Q95|QI"Q\$J>Q;9.&I5\$'4WLOV(W)".2PUZR?V^2OC| MCE^V%>K C?
U5 _IP)7Q(O3.2.E/ZFPTOQI'AEIJ8A%|H!O4M /E8GL|! MTJIE?!=!PQ!1.*IKP"AHP+|0JO..HD?
Z%UI;W^WSGAZ&7M4FRM MJ\$@@"^+IRB8"-9<)BSK;7=1^V@T^/?+1JT5GHIS4D3KA\$ _MQ_OMWN#KJ
M^Y9=VZM=">EHE69(HI4)!BT%I+/\$CQI+TU5E2?08='8"N|HJ64:"AXX9=KO MB/!+T)?%SMZLKY3I77U/2I#9I10

%<(NB=<[7@.CF!08KFB?%9BJM.8+=+) MOB IV3K@T>I%Q\$ _H =RFER
J9f=ZN7R: Z=RL4I+>N=+_9)\$!@Y1)^L@7WF MU2F5X'M>:LXR*!<=&I.3Y= MNK&I(F175%9G+?&.K2^44,4Y VB
J'EIBU< MA>@.0L:BA+%510!QF87G'N!0%>\$O*LC1K^,LR@YQRO3>>#17YM^\$7508%"
M&8I+EK3KIB'MC:NE(7)=>Y>+S4/@<=>YO"(2/FWJG!T" +G"K>92LN5SDSU! MZ,Z@26R?
PE6\$Q!)3!3MU64"SQ.EI@P*M(L*3!+^P.JR!EY.Y9L+1NIRMV/X M\$:HIU<@@I=J4Z\$6(6?B'H!%@T>0WKW-!2*%
IPO_1=?)@)%A*(K)ZIH'IDL\,'KX!^H'LO 3_1 T? MGK'#=1M09N=*\$Y_)IVZ&#\$#E
7C0!)D)KQ@JS>POQ#3W!UM:MX@DBO-ID MW,*%UIM.R1M<+!W/_YN^;WW_C9VVS1J2:(0*VC<5/V/\$&
(1D)2UU6F4 MYDY0+7IGO*,_YR-V@G4IDM\$5R>\$\$P3>7@/X7D>AVT^5I<343*!V_4@-@K>
M%LU@0I&LMH0VKM3@6JH-7M-1O>N"#.2FCSA!V6EHQA8@+MN+:S:I!:=!H& MZ"S)\$PC=&KYG;&4,V53O-
PF3:HFV?N48@IP\JDI_0C9X*0J2^S!(>:T9Q:.(M>C2=!,*!*U7R M7J3\$6^P0!G!WON3.-17"PG%&3OXUIF=#?
7"Q."X!_E*4UU5+!A?0>#92 M-.OS)NPH4@%;3IV8&39\$R.16(JHBG">Z!QO_LJG%V53;3FO+MI!WSFM:W^
M#=-7E:HM5TYH^)#9_64 FM!!EP #ILBR)&D#B9QZ'YQU@GX0AZK3QO.1A!D3 M^"0/3..?
9WC9TY)*JE:Z.7%YDSZW6KQX28)C%WY7U:T<7^Q!<O%>N/G!QNM M3:LA@JHVD:L>(<.@H08L.OI+!N+
D3_04VGGHG&>9?5AXVH+!\$88;=21 MODJV%L_!F6O.=)>\$5;Z=QA@5V.C7J:03\$CO!O<(&(O>%Y?_?LC5HHNO;
MT:EMF"TB3/&?>VJE4%0VOQ_O/M_X!@?YTZ.C7%<^5E.T18'9>&AY?1 M3>0!CYNM8'WBM(Y%
(D&PME="Z41"0?M.):V*F&2Z6QAIBUA8 M:>^,7W+W/KAXZ>+OL5_VP2%"\$=&
S%FOYR58GU.M(&..IDAVZ/KW"1X\$ MH(@U:3J")BC<<(WG.NOK9AE)H^RL-UN@ MO-)Z4"UBH/T^:_.?8I_42K#
f3JEUIWY%3Y_!CKM3_MP7U^UM6_D2PXWR M!:R9-PP+06'A#<3S;QO-
H24J:2"DKU!LPI%UBI!;FCPP>75H8I*Y=Y(2R*
M>=>M#E&:RL&BTZJV3WPH^!09TK0VX2:=J>%3<=>5\$H24K7.'K94O.H8+1"L.95*Q0"1&RO.NEU-MJ.F
5GB4?|ODU> SL^:# M>:*26EH6"=D2!35!"FR"4359NH2'EBFZ/CRX48Q-C ?;HRX>P>./)R00X42
M%0<R548RQK5(632 5+>(D4V-R8A#_QY02M3/S>XNX=S=//MPN0!WTIO@%G% MDP5#K6\$!LA4JA#4^!&'=,+?
TJ6Y_UP_!BM!>PEWQ"K!#;J*YX;Z-D\$!&:H M^<=MIBC!N_3MGDIWM_C
M'3C!C=&8)UY^XDEI?BXQ606I4!);9RUIJWCY9"D%11K;1IYB4F2SNL<3 MS'TOZR-^G85^!S#H:1AL@^<?<?
8'DI2RSR=JYM!W^Q*56=*\$J&1X&RIL:6.D!*T>HW.6S&LN>D7_MCYW?CIWTS'O/N?7V2^!_I=W^0^?<
H2:;GZPO!;'C/RV%#R'1?^9^?^@6I_) WNQ8_YI"@3A18\$!\$ AH\$0
MA1!0\$!_O+6#"06L6V\$5!#U:M+LZ)T!_HZ:N JGM.F(ZOZ&>ZZ@!U(EA) MLU<>5&D='A/+S\$D((&/<
!B!^>.5:C!@9FD7O=\$LIH!HEBRA+!0HE.JSL7.B3K!:@DDTTH M4/RNB*39"1F&:>)UIKC40%6^0 U%ZBL-%5!IR?
22126.TJ5=DTABZ#B4R MZ:F6W=')*)4ZQR8=K!GP20J2'D.AJWUL!#ILPR80:;HJR1AFIBI_-0#;
M:ZU*HJHOVM4!"#ER:G/6NJK&3,DDP\$O_\$Z0H4AA<"%U4EZ+39P-KV*7=IF9G-/&0I4Y@_O'50A
Y0;3)BBH(UMHV@_NAM=D MV>TE PERUF CN5+ (8@FLNCNHWD>LVX_EAZA?+13!P87)> \$RKQ^J9 QW:Z
MJ**"F\$F!DHE:<:8LNI>CG(OT)PR!J3D?(IE)3/=F.N!VAUUIOMWJON!9)A M65?7AH@SO&/GUM6QU=43P4%\$K!
I4BY'%9/O:10/@C:_6:_OB<_/_X4+=<% M'VX!OOWGI_YX:S07I_^B9_:_!O5NOS7Q=:_0!_!M%6.^AR>GL7E3?
OMS^3^\$JVO MECTUY!#%/:Z?8@.6"0%1004)6"-QT:9?17^Q..(!9U^8FD9_U!XA.OM" MK5O_"EIEH/FY E%T
Q6N*ETD/T!N!WR(\$4PLFC_MH'+@!I!\$D_@6_A'0>A_%L+VOX%YETO!^!SKS.SU!4%>?1+PAD_B:1#1-R00H
M!9HD97H7!@VZ5!HK-F5EDX:9:NSY=D/_NU.AIT@:ZVW888:G(>BPK.D_1^ M!H!@?<:D_Z!L!%@!D
D"#.I);IH!7+BDH:Z!70>19C2_H?Q=C I!QXNY! M^G:=YO/+LEFS_F"UK!MOV?>_2<>*04#\$EVRQ6_'NSRL
D\$A@J9B0!!MN.O:..#0Z%U"^-GI*=(2_(PH\$Y7UIRR57!\$9K9_!6;!!*A/K=8*46IAY<8X
M4O9!\$5MRK:B!D+WKJ3X"YCTHC"F_5O_%@H^CY^?(N?%N=X^M?G^BL+YY6_K^8!O
M=YFR<5D+^!S*B2FH8PG+_6W-FHE:WP6=02I5J@W&N^(&43!TO&-4@TFDW:M\$ M^U:0;Y?K!W?UZNNKG+
;R#)CL(D4B%IETV('L?H.1:(!651EH8U"MMM_%>E
M+OV8Z%BT_:%\$@U=EEI&-4G.E9F*!^V^#Z.WR!)3R^0;PW=TRYQ+9U8I0_MFYMD#-&+278F
/%ZFK>D+K!%H1Z9)4Q*SM9+!&9_!+8W0V:0P5?#&L MX;J!4U7VY@-H4:;SOW
F/%!POV9.DPDY_N:X!>=2;ZE=I!#V?A=;\$[NLU M!G9:>VOZ_5W+ET0^)!OOSO@?K8!QTXDNUS>6@)!E-CP4JT
7!S@7""KA-16 M+!TV@/ND:G8W>3>U!VPK!^!D!>S^!C!DP7!)Q T=P7:M3Y@,E0CZ'H9!;BR3+6T.S6Q
M0FB7(ZUGMG&M K8H'6V@_HFH!U6;HO&C*!8:9Z8L2#0\$6NMC2+J!>I\$
M.TAY04JHP350J!IM8H^F.R^VP=DNQMKN\$IZPP=D0&.??X&R4+_(TIV+0-SDJ5_M29D,4B*O):VB5<).O)M@D_*
(.Z>)[_D!F>CQ+ZIP=D(F4W:X\$Q%SZ:8(\$^7 M6!_6JGH75=2B!_@\$>B-SG8F;V>93=7@!YE\$V_EI7K6(AU+"PAO MX
&!)#PEQRH6:A@67_WBKNUV.2SL)"T:V_G M1:";5"?NDG:16^V^=%Z?E)@QZ6+ (6+KX=;*@4#0EK>TL@Z4L,B-
9XKQ82%V28K8BUA"8I-6\$%5!DGO<68J0-ODD*7MING?T>A30 MD2E+?
Q)Z!CIA*O_+9L/^G!V!5Z(XMW!3WAZ7?KILDGK*_D5:107!PP=N! M0V97ATCPK&L6:ECDWU,C'1GU_:7;2?
NTIE=GF5<_YN!0NNS!^!7*!D/YSE MY4>V9E.J3CMB/+8T>*T(H8^@C2DFM8)&_*S#RM-C'2!G27<.3%MIWQP-
F0! M!978G!6M;JIR@:(G=6U5L+H*)XNM^D<.#!YHB<^B7.
<I>QS;H5*10D).VM.MD*H00\$H94H!ZGTH>BQOPV.TJ5?<!\BZ#B5N>.@_MO_G!UFSYV9NKWBHTF_TF@=
E7#9!2U\$7D#\$E8_2DX:ZC!2!TL+9!FE3!MG MXG6"R-00\$5W%=0W!-%%L!D-XGB=\$>3Y6EQ-1,I>ZN"1#9M,3?
H6#(K:_R+! M5S+%4A%:JBY"/9^/!'6?%A:.H):H!/_Y!_3=:N>5%/P*2L(NJVFR@3=@_N MK(S!9E^R&79
=NA!_MY^XMXV4\$^\$P0'_J!UO2_%VS2?/<_BLCP&%*!I& MJ V_*<5 H&0@RJ@QD.HBEMXV!_07!YT(-"5K#/
#KZA48 FR!U*5MH)XI MC:D'=4^KPOYRGR*9:2M_!UKR>E5_U4EHAY6_PAC(H18K)=:@_OLH.RO\$4TE
ML^K#&'%KP=76ULO+C\$PT!X!D&T:QZ "PO/599XLA80XK0X!6VY_Z(>IW!_M*4!@0/3H!"*!8P%4P?AMJZ"A^*U
44%F@!8DEPEH^J_RK9A^Q@G!S/=,09J MU"2>:.(R9!)?VX9-TW1IE)_TG1H_8GV'0!349JWSHE0ZO\$#;_!V@IX6!C5
MU9)\$B\$!2!&VX;=@:_/(TWH=#C_2QJC8H^O"*EF#49H-BR.00"JEM\$66
M_"S^<G:AHUB;&#;L#"BGN+HZ=\$R\$%:5Y\$WPX)QIH4^,)+DETHJMEZ\$!6@_M+++76CMGKV.H:LQTC&:>4G=@@
>C76CMG%&@/5U+90S/>2I<

M272KIS9YYI^>*_OR\$ 39?Z-GN/I=O/U9?Z-TJ>>F7IC>)TKE6L(HJ^9?JU8
M'9+3M0LESCZ7T=@ZJM;V/J9\$V:FN/-HG;M\$#"OM=-V**(>
MK;RBY0GKI5=C*2L%\$(.R;&8P)L\$8I8LRVR>N%4IZC20Z^UW8_Q,<*=@.E_
MX6JQB5IBV5ZUJ\$.%5GHHR17>JU*\$Y+4GA=O5;Q=-,I-I[B+X37M_O)?X*4 MBMMX/K>;?;K11"O_?33/L_SOQI
(GE;AXHD7@RMD65;CZ;R;HAWN(^DXSQ#H3!;\$JF.2!GF MQU7-
NZ(FU8K7MRM0F2UD&876L89H>^O1JTP*W<<8F9_I";**^X3F#YG\$UZ30
M:5+J1BG0)"EUNH!_L\$FAU;\$;V5:\$2+ST&%M).T2R!A4K9XWENY5O@Y8A6=) M"GU^#1Y#^HQ)H>1(5DJJ9FP*8-
8_(D2^"R-4#6C4I)"P(XO*7048P.30L>(< MNW<\$IT.PY;4N'T54-FG(H;8N9HP0M0I^&*JL1G;N3NK@?RJ/WL)?9P;5-)
M*RD;(B1-5,+2%)>+J.%*AUX71G6,X=H!;\$ UD>(\$GN^@A4FLHJ\$;R4A1U8 MHJE)YM^R<4'82M&[WA<(+H
[R#YA=E,0.WFMR>O3E=MY)^TF_JH1&G_SW1G_MP06VN9PD14(ZE;=&L(-10D-(T@+_@JT1HA&^=^OZ/>
>J9I-16#05);IPGBI MY.UYM=Z(M_@>K'^)=_*L+P|NWW@=^*SU5G)EAL3V19<+&!!#=:&D&PL%);
M[2TC7YD"C0!"UOQQR9/>U;S13T;6BBM(21>O:EB)JL.%T:39".3L4HD".4B7*>2E1Y2.XOVI MB)(QIAGJ&
(HM<643**L>C"W813SD&T3%JHP_7YOJE0UHH0SYV.D;I&9_Y98AG?2O_!S0IL_OFUZY_XJ7WS_6*U/OIU==/
MO!?!?GUT'5N?ZK_AOU!'42PR2B""S@:GIV= MB>X4QL[C1P_C21RL:5*WE@QMI3W+IXM%Y<.;A)"C_ =5JV0.87J6.
f01J!VB? TAHR2UDAA1#9=(L%LV);KONYY&M*W-W'IZ-UPF2<1Y, M3AN"Z6OB;C=6AZ1D[D+)]7(FI/JNNE800;
<3=WX3.7K5;GLPVRR2SEL=LZB M)6.8F#)Q-Q\$IP3XC.MNIV_VIE)F+T36(D1HL0=AF!%T>(FIHT2)+7%WC'P. M-
O(ZNR2BIA)T:7V+BBZ0R"K0D;U.7RL5_RQ_(8XMGH?TV1^IB?(>L3_S1D M\$EICKZ>)6QVE0)/\$K>
I" _L%&7F=OLD.R\$&W.O'T(A-3,"\$19;Y8*V;W(V &K M)"R1UP>@P2-(GS'R.HJ4;"V6G5B6"%&2-
4E7EG(=:50AHRX>Y^2/M@K1K'QZ'Y*M);.8P*Y;.%Q;"H)MJCL7:(T+.#VF-KQI;S;WB*>M)
<@:00I>VP24* NM3AF(R1"(G_1YI5NSH&_LME5*'%&<_LK14;KJ9_HD
M.N\$<&M|MLN5Y.^T@!DZC9%7'.I+40=">+Z(X^4V<R;I-IY=N|M/I=6%M:~?3P)PB=ELH9<2FX;DV1?
M)R+D7&1(H9B,PTSZ!QI^"A@>+<.)BA7<@:0H#W+B\$;X#\$&DUM8A,\$IT\$2JH_MM"B*\$%*JSEO[4&Q'IBJ34G-?
A>P<&0EOWIY_~YI6B).T>;K?CD(6QV1=;: ML'G.G6= J(AW_0GR8/1MF7IA;KB(JN%&H)CIF_0I@X.HI\$%BBBN-
2JD;PG;.>*3RC)8&#SWA;VX7_Y%P'/MIBV^J%"L=IR*YZ28H6@:P&5?
+7"A1#.H!R%P;2+1=RSZ@D8^3>^X3LF15R_M^9^"I_33;V_?)WHBVI#42I#*LWCSPPE&?XM:A\$>L>_P)I"FD@H?
#ZW:4(. MEAT%V/L_!'+>/K=NE7QYIV0M)>+CQ>GK8GIM!1.7%YLBA!2^N!6GRZ/+I_M9;7DK?2[XVN"]#6/40!-
JK4TLP;H@)O""5G#_Z9NJR NP!K58'?QV?'. M=BCPIN;= (+YZ;X=@JFMI(9S?N-
E1E48J8#=>.QN!R@;L<8J4"KJAV=A8T M8!&7+8DK52NI#XVT"TWB;F10M3O3'TI3:EVC'=?_K)@ICRAA
*7TA5DS-I78QF?HS.T&L^)=<(:>:W-I481!6BKH5VD/'ES M*559E:M'R.PGMHUQXVY&
(-1"!33*R_ID)0ZIN50_QL< (=Y(ALY^79^_ITW)U MSFO;%2K;:LHHX36&F1+F3"!B2U%D"*_0KOK<(PR/AX?)SY+Z?
W8.1>&EH? M/HKD_? 9:MRKGM!\$1 MUP;9\FY-W/3WNJ7B_!NA#?2D_A*M^H1+CQYPBAF+/F<1=7%&C%TH_3I8V=RE
MVNX;+ "HK5\$*#5+IO\$0<>G"%)Y6IM@Y\$-OR&(Z_1418\$SYI+CLD(TULDOQ)<
M.4;:>@57C*KN8.KN1+:"W/7!"Y%0YJFM4\$+/.D\$.L3CF51>W= _UE< 9 MI4H2^".X76VFB8#.'TM@=-.
U4"%37:@9"YU\$3&SK<39EVXM54QKLO)*52"J_M<(F*2,4Q,H/W7;NWAK.N6^44,B'!#\$*:3:L<#8&<1^=
MUYI_2MW;JIT^YD;HJZ8SB;CF;H&=)D2X^H_5@^5@)*&.8:"WO.OF1%&0V08"#JXT(3V_ZR?Q"JHBS:.0Q\$W1 MY
#>9UDHYRISIRU!+;7Y\$E.PMM/#4_Y;.6E^K;I@XIM0=5
MTY6)&H(X5">2;:5@CJMIG&_Z4%V&8VJ(7500H9\$HUK.#3P>C4&(8FT*4K M6+O,/I!>7^W11A0A*U7PQ?"FKS!
%*WSE026-"GBWWY>\$>7N06EU.>K\$L_!5;KM?_7BW.V0VHUTZ=+KEJ;1B=:!6K MK\$J_GM>H2;9CT9CIR'ZF
IOZ6*M#K)%I^LCN MO%\$R0*IM9A%6T.L_@_1400\$0^_JSVENI76RRQA=RV YIT978?T4+F:VO>+ M=<;3INV)K-
:6R(:*SDA@HBZ_UB:(2CA7L!U\$NK.WT74"!QR\$MT^W7EB>: OK>MOD) 5/TE5P/O#D4&G_8@MX"LEC3M+7
M&4K(IYO05PV?6 FFNT(9.KGOEQ>K6W-K4WUT=BKD6FLB4)YT>WISH&3*[A: M368SCN2@4@03J?
G(6Z7W5;G58)H-8_:"K1>XS?71R666;JJ90876QI*\$ MS;XC>@0;E.)O2-EAR?
03ZOBH"7U5I8F580;LR.F=S.IGW@FO_V.9VVJCTZN M(Z\$OEB(DIUB8RH!!B7
*A5TI4F+VKOBXZ03^JKA\$RO!QZ/7_Y@2_Y:=XZ MEPL4C^Q'^%9-P00/F0QJTSI U(GNZO>%_E5KNO%I7S_=(F)
I6/#2AUK--I_MYA2)A4!@IY0X.*COSXW6(3HT41*376OK!^8!V?YE.*"(3J&N#AP*!28ZA"@20JZ8M4FH4YRN
M;/.^Z.=*0Q0_I8G';Y*!:'D(Z;I)-_4W%B.\$K""JUADBQ0MIT!" KDG&V M9C6#73H>^/'\$L^K=).TQIU#_L%V\$1TRB;+
<:=D)SI*@29D)H+^P>KRMG% ME\$D:4*U@GLL^A-7 MY41)0VA_/(M2D)!TEA!>U:4:WJM;A!^LUK-
(#5:8^30\$;Y.T3!O4PZFW' MFB?:"&MK<8 N&S J2PC;D*2O+IG:TU_08L^!0WZ(!2QNW;LJH!=J'W>*;
MD_G\$9BR_Y7_0:HVG)ZF2+ZVW;3O!";RDH(\$V4Q:*TY#PIJ_7?5MRO54.G M)?AY8Y!^Q=-6DYW_8-
N%K4=23&EORW_0:>%Y=F^Y';%A!TR!86J;.8Q&:(5 M""4-
E2C3DK.X(GN.X6OJCLQI?.\$&8W<*X@-9(U!0LZBI9L)H!0L.E4BI0^ MD!'ZP.V D;I;X-
'>58OVOUB+CI^7&R.S04)!5DH)#8V*.;3B)LI#S*TH
M;LH(H6D_)WJ5V0'_0+VILLGY^CK190YWOY&PFMV_3*F_)F;_Z?G/L/P!
M6RI/%Z4%Q_SWDMGY%_<S"l:UF^*ZW_WOQ>+IY_H_/2E+6'O6P6I>#V59#47DET*T4PLJR/N8K9"+B*R_SBCLI?
V1HJDJ38G:7DZNO:T24O_<\$FV'(YKK^GTA?ME_I=Z/C4*IU_M'^HD029FD4_U5H:F=88"3,..K64E7*.OCN+IEA-
PSJIP^C^@-(6+R)C%#_MP+S6_D'CBJT6!PN4IZ^/U.F6PRX+S6KH_4OE(C_A)E2<77@5=SI_M9SH^Z
QDEIV\$U/OJH0GVA+56*PON76XE/D2&I9@H1A)3IMLAGF;HX5Z== MV>PHONJINBL/^Y8@.FA?
<=7F%2VJ4J:H3*>@7M!;GE2(8&:N+-=8TL*#(ME@%>+I<=!:YX?
135N/I0Q*U)J6;:8706.5JHD*XR;5*MG01R(754D"J3#? MHHF&O_M@/\$)K?%::JO-
EQ7;I809;VIF#^_9OY>Y?QNIR4DLX-R9I_F_Q% MK;T
E0V_0I9HB+YIM+;2K#ZBDRJ461YI+GZ(NC*&B>YQFAN+VH_Q;/O5^UB
M89V7_VOSW7JO<.\$5K;RENSIE%0@A=+;7R:9@W:B.#_('MD^QKR=Q'O2L.PO MPIX>Q*_OI??_SWOZYI&;2V-
2D'3.S&FC:Q&\$L!%)J#457;_SE^<^*Q1T+@_MSI+JWFL#3T_QI/VB?#*;5S>?&F@1G06M/6L3?WOP_GY7-19FUH
0VUM;:1YKFPV@ (IB;:O!<"ASEJMYJZ_M'SN+*?>U5I_Q/091XS\$GH=SP&L!*XY.#H*PK\$?52ZJ9<5-X^O60X^#KEVE
MU+MNZIJ\$Y7?I^>_E5_XJ73Z&94.T_I'."\$7Y8YS*XJ9!2I2R3&; M@M.#R'OX^/(D'B)
M#KXBJI!I\$<%@&N/OSI^>CL)O=E7ZU_M=HOTL4IX=DOJ^4G6ITO_V#2J; MVK@.6A>&IA)?YT/BIWCYX?
)9*74N1!=>^> MF!/'#MKI(C=&8)UY^XDEI?BXW47&F5B_.\$_1<.3R<(QAH2\BIN*PJ:0=(I;
MDRI&G=>>W5GLRQXRZW@ (O@&"?IT"D@VAK&1XQV)ID*R^RJDAJ2=*H4ML M1-53Y-T>I
62M(I;)HA1_/FBH7A7WQ.>?K=NT7HW5M>)+@Z3K(S_ "<86%4I. MF
3>2F>%DIK\$.H3/\$2&+C^%YA@;">8+DNY\$P0<+_PQ_-I^<9K=;+SHPM8D-M?8/Q-
N!H4G#EDUCIM\$RUM0MI"3/I6V0J5WCJKWUL;IX(Y6=::A9X*%9HL4_M6K=V5RBRG\XN:LW_PA9\$FCADO8U)^%
IERC>N65Z<@XT4^0"7I+R@IG;VI= MG"XXY5NSHJ>E_6V-G5OUNMEWOSUS=F7N78GM;#.6D!0A91@BA>
QFIO)5GI M2S2;V OPT6K7?3V0G>WGC;WY2>.(RY"A7!ZY9F+R_(E0T8+Z:4G% MJF%1^4^/=70*;H6.)^@F00^?
7F6M7R360PKVK9;UMO%5HPM7YWY_CO37:8)VI_M0+4C.#KR)\$3-0#)2U-
)C#H/>JR2."QI:~\OU\$;1N^PHYMZ7,O3I8I5_QS6I_M^;"BC3K=A7@5QS\$59.^IMZ'
YK^9VY_#Y5P\$)NV1%=\$&0AY4*M%)N'5\$T\$ MX:2EX-F?P\$&[T6%KR2/7?I^D)&/DWCW/?E'UIP@-AJO6XL_G-
U_#7F+IXNZ_M7)TM!;8B%W519;8H.LW=9#E*/TKYF\$\$_^@FUQ;R5_YA_MM"E%400X&)%#H26D@*G=DS@9?
+3E;FS>U!3Q/G;K;+3-FS@^!-G7Q/\$.K_Y/

M!M!MZ%DGD3QI!%GGZ)\$L!8!6W%MI3120K1!450VF!HCNO28\$LY*WOXD!10+SFKCL!T;GM8?LV20S M-
360L+TDC!V3B3L5!TE.44 PT6)ZOCK"5CR#0LN,8!<0B0\$
M+!%M=2GD.&C;>"4%1W>Q5/L3,4%I_B^+@T!UH+CHXBZM'RD!M(>?J"HXH7 M/N\$45\$.M?N;1ZBP
!JAAJQ5*JO!BC?J!HA!"">"@J/7?H4!<_P6KE MP+1.&RD(7M-"0.\$3E9H"UQD!D""*8^2ZW%LHLP5,?INHE5;-
IOR&SO!D.GN+M!H7?K<7(QW8T!<L /,QS!M2!APDERS.NARIM3""_5D!J90%:7@#(4)H8 M>1<:1<)^T!%
(^!S./PNYSQK5+X7U-9L PIO<7DCBU5(4""7\$&#SY<+>H->H M_HG4%!Z9D!>BMJ21 "%2@C&M_L?S\$UM><-4HG?
0V!@Z;>K!0_MH2S<2)@CR M9R29J*R_9^!;=. _JH*I-&R5DA1;9@-2E^2C3W?O:>/
MLAY!>6@5:5*R)G!UOZ6;\$%*6_W^Q*^M6GNNRWWW!#1>%4!/1-0'M@39XFW) M!9)_BS+YK%5UO3V@)R
=K>KTI&*"(IM8>_4DJW*55#)"%9@J2!L?CB+_L4 M95C&I%GG_6W9<:)?KZ(-Z!<H!H!WB!+<KE-
T_4"!G6+FOV!XZ4<>I=P_M_6:HMO*0M'5*DBTWKK!@O4@!\$59-X/O"BF6-JU1V"JU^<_".C79XM9R&%
MDE:J"W^1=<(J=0"".(1PA9T8KH&>T^AFRM>OKNN;(^4ITK(43+_1M(US-K6;:*@-
@M*TRA2\$G(89"9*73@K2)QO2(>CH(S7HD#K.M%6L,2Y5:M-
Q!K2=8E)F8(PSP&2I361KP0IL(=")J+7+@95>E0+>Y#H><=<M)J5IV4_&\$!Q47&
!;IP!MVEN)BT=B%""8!QBUXY8\$-6M>Y*35Q25.M3AV":WZ??G*CNSL=O6/A!3
CPM,B!/%H0LX9!O.LU5ZF!HF:\$409_61AF
MI"!#T\$!H(89T^!@UW!HPD8Q!ATB!2FS=Z^7IS3Q>DTZ,97MH5Q:7<5V_HQ&ML3):#!&ATZYZ6T*?
%_YZQ&/3@\$DDW:NBTIUY_YL6"WX_L+F#UJO^?3F8^M5_M^W^&X!KJE>G+98IQ.9\$\$/2"-
(I7J@RL4S8C@:0O8A:5(YF&IL/RQ*Y>)-\$P312=<9B.%HJF92-CNUS MKN5R000^H(H
!B#%:K5@H6)!&R!_NTX!NG5O=D;R_WSW&D!X#TBK9N=MOHY=@*ZO_I=R6?Y;
!U9YDAR\$8,OC<<AV4JD);4L7JE?>Y=%O_ZI"-4MB9W\$VK\$KT%T.C)H#.G\$\$52?
A240G(17G>7W*H"VKF>JP2&4BQMZ!2@<65!%%=LGQ_MY!49?IFI&HA>\$'_RKL@5
B)!!"@RK&Z;H>015C""GNH(J;8M6!-M#G)+\$?MVW_0;-ITG_?%4DF&Y90B+^U9_J)60#G&#U;>*YWY/\$C<%Y
N;0H!A7-/P!M\$1/D-&R!=G6U_@3<1_FUCP!G@3;C0.4X!L)A=48*WP1HI@&Q+0Q150^35_M%AIZUJW0G4W-
_E*L@3Z;C/HQ!C1-!YND=K!6_Y>S#YIYD?1=H^<I^H!_M+CZWSA_BA_2\$%1<\$T_&J-&UG%6M;:D5?N4!;W3R/;
!1U96!XE!M!WT!_2_MIO6U9AAMXL2>5?NE%4:_Y8W!O#S!M%J6B!P^7&\$N5;B8@*?+Q-&5;MOQZ@A
M"-F3\$S!G06JR(X"CT98Y")A@LWG\$&OO^HF5CW<_W5^?>(&F-VE!JOL)!?*,M#E78!);A:X1KCB+&
!CI&F0UBJ+K0!2M@=CYA!MEHV^R\$P*L3^<F=V_MYV!HDT!_H)_8A_MJ?;*#GIN&I#%K!H!D;063*JA@
!W7BK9.QMBA0!7Z=MM6.X60:F=MXU0!T.X^<NW/Y8F60E/*E2?;/@U%@JB8#-4*62(*!DI%U7
M8R>@7!6P(Y\$3I+!O_K5B4ZL9Q.%104JB18@TD)_F506=64G*YD!P4M3ZM_M#>I7#>Q*Y@09!_A?
!<16)TP8#*^)>HOY+*V;5NX84_UB*41TXXVW"(TB_M.F!/*B=(K!<?<
_5OZH^J!XZ7;9@!K#%#0>4&D)56B2KC4L'H(#!;J8\$J_M)PBZ&H?Z33VGU6?HA7PQ@(@)D9=BA;Y;(6U;J?<
G!OD)RL_YJUA@EITB%I\$!9;IA*V_(58(&>M9<#L
MC)@FH?!@PFU**OPV60DAM(!90H@:0\$4^_5+UHJ2!J62.YPFS&ZLD>XS1A" M#B7>GR(6!>:J7Z440!6L-
!%RE/3GTH03H*6(@TUKY*\$BF%+RZRBM\$2;W_MQJH!J_KU_1@?(ISN@3\$7YY_8I&

7(6BE=9=SM!S152M;71_MA.A#B.YNQLJV^)>'!WCNBO:C9+!L++#NG8;>OG!HW0S'&YUR%("RW;ZDX"#R
M%@15B1R>&0L@!#6N\$^/LZ+9;&C^";X;ORD"O#+2R*CI6*GQWS^S04_SV!;V\$NO69;7S!
<^WE_Y^YU^HM4!6NUQS//@_M<H!ZV;8_-HDN6SK!)5#3Q;FATA&0E@C*!7TA?1_B!M!LW0-
F_FOGMOUIZ>10.GV!)%1@H@O*0BA"@0!HL!/ZRBVZSF_6XI0?_M!PN3!R?50SE*^7(>ET7_HJHR!EZBL&UT&
D04P)MLDZ8;9;ZJR7J?13=6BR_M-Z^/ZLEH^4!@W^")9Z9WRR&C)CH=V8;I>OY*JN7L41784^!S*H20QD=)9RB
MTHKG&\$3YA_*(F\$U5K3!^US;J0A!^)_J0=CY_RJHAU3\$ZCU<=6_ZZ-&J_M06?9RKSF"H9!@-3!(1G-
L.F3!9@X;H"CZ_J=F!L.N;NMI>O(KG2V6JW^>_MKU2E2K*CI0#RGL<7Q"CI9W0D0HX)1!"2?
==6=E6!IQ<0=:@F936.T2>^!@9^M^J!S!QNI!5VX/BLR!5;%&N@?N_M1+D5G997Z+(H4H7D@?)Z+0!\$-
JHO0#"6M!W>6R!O70QTUVSO)LW>AR>N" MW&W>5W""3\$XHY;\$J!@:;S&A4(;@:++6G)R?
A"JYH!#"SN*;\$0I=7)Y!M_&?C8'_\$O2-QEYUF09^T^(*KN0JB^DG#-0%CRS4HS!W@F)^+EQ9^L?I/95"-*%\$5
MJ@(?_75X_4D@#6*\$S_MVV2ZMMQ/=?!>B!6MZI)PHF.69_!<OW4MB.TT.50"!T!H;8(E@4Q5(S@CC
M>L3QZW/X=VC!)^).7>=>-D!2EI/*=?_1/5UL<:EX9E4QM<2PMW"LV_MJU5#-<)E95RQ?)N>XMZ)FMBW?
JT9L4!3;HC M5?3@!4E5V\$HTQD-1_%H7/4MO6NHQ/2E!""^<_GI>\$ZT1R847K0Q/F QS
MZL(864JRR44)B;J!17&F!7P.GHJE^R"#"#%LH88^";#0+<QJRH1*BJ615?I_U M25C/9BWLR>\$!140_1U-
A!8*CV>?;B!<LVRNK0!;8!NF*GEQJ97!87Q* M;2D&7^Q4VH!^Z8?^+5^Z0;"H#J6H_H_XDJ3AL
8LIT/(-Z_KTKKZ' M!_2MX?D;J!7=^(EZPM4D".18+1PC"<*D_Z2MO1L;+06OR6U;+<CU=5"*TY#2X!A(+
&"83P;)^*41%5;1V8^V+0^?;*O<2^M!"&SSAO@3_C7+2B>;M\$42!1Z1;4B_\$D0&S"EE7^!.PHY*GR+L!Z_LD;V>9
M35%7YM&B*A@%<4*6M_(@P(L:OG(EESQ2#(99;IWM!)>#+#!5^QBDG!2WUECL
M56IH")C76F5J!%&UAS:1+T!<^J!4Z!1B6S9FLPEV)8UDB%DGT!44W+5TJ(=MEH7SU\$C/709G%
N/UIW:1X23!&+A!WEW/WFMA-M_OZN5MN-6ZU23!HS_X6IS.7"B*B;41D%@1YIU/SE(4FO@_M5;%="R1V@J?
=B\$;14;EFHZO2?(2;D;_IM>+!<?5H3EW=GU/H!<^1)L\$C^Q_M9JM#ZWG&N!U;&R")4=1">
!U=U!L#T=WCG%K3C8V.T4!7C8_3^<OE^GS!CI^M MSO^T!7!46FA#8%<0LEM8V)=3EG=9Q5Z=-/Z_J=1,>A\$1VE?
E!G0E^=X/UGL2R+_O^?7N#.D\$3V0T7#C*V^BN("C"U
MNYX062R!AH6!2>Z=56,+L&4D!X4V^A/Q6!7!0!NS)1OB(W=LP_?+_!_M5-W^";Z<4%6*?"R\MGG6!H5Q-
9@K!9N;6B)9/?%9!S"XU"="5EYX*AM!^/8_MVT4E!L&JZXE?+9
N64!J=29J!&L<("2!%!"X7)QE6KOU!IP#P>=9J2GP=T_MJDM=GJVOP\$.G.R>J*(0Q(BFRF98-
A!B!PA>Z5)R!\$;5WD5P1X!GV;C!L' MM*GS8>X_S_"RPRB5;Q?
KW/3!EQ5!7%Q!O&P#*JVOPH#W!78S^J_KO(D%TFZ_MK*JC;N!JPKO.#1H*CX>T!T!66...#L/TT?ZO_MV;ICP);!M-
>18.XN)YVF80BAJ0G<2LBTCS^C03T6=(0;#85V9MJ;N!^G;10MX_M8WA75;IU=(L95';&J"18TZ<JP#^(<AYC;!<
!2SE..5^EG9LN_558(8HC45=C)#4!JH/H!#"D=Q>O=5.S!Y#M%"OX7
MB*Z"M(9@FB@\$J2\$!SQ;NBJ7CU*_AZ#G4H)4@O.F.DB1G7@C7_THKGS_!E) M1VU!G!V-1_X3;ES<#J!OA-P_H^6)
!<P!1E^"NDR2"U7K3*K*V#)?@VET2_M!>U+CE\$*RCT-G@>!32_@!\$_9!NI!_Z!TGN=
!YQ=1O3N!3!%2!!"\$K!UHFPQ_M12\$"6B<@2.%\$3%2&M9L!9%CH_4W>37NY?25R_!F!3HWS:%PI!F0P&4S6
M/&W+6Y26)JO@L0PK.W#CX<^Z^!R:HWUX!6#!IO74ED*@(=>:B?QA-!"&Y_M(9D4_4Z=Z_7YB/=M+8.!Y!2?
#N5IZE2E!QK!^8R!X:M6PKZEDTN-3@0R_M&'L?NAQZ2X!H;N!93Q?2X!AJ%YK2X!1C
UKY!+N=KZ4&2?I50!IMZ!M!5AY"(IZ(#66%5H!^4?>DN"/71@C)2GX^YQ1N^N;C(^9RN25;X&L\$!QEA1B
M;-6);&2=(P5I2=JMDKD_I=0\$RGCU!W*5!/^V;J-W=1U)BI*S5@-MIBA;M%1_26S!2A* A;(#ONT+NLV!)E+!E-
GK.W6;\$"!%)@Q.(Y*#K"UFU-\$ MF-&%8&S_"G2'W.)!MM3_E.GOETJW@\$%ROM<7Y*;Z&MK;>1>"3+P&W!F>
MFFUQ"61)K2IWP%:5NP_I4=%2=@ZGC54^O!;GD^C!&#E/=9SZYL.*Z%853%EU_M8/NB_CG!F^Q*\$V)4
M&6UTN7@JKBKUE@>J=I5_!<N>TCN!X&6CLJBG=,M#162598JZ;L!S!>(\$1#K+!E.9Y;=AC"!97U;L!L/X_IRJSW;
!G-5+2>C2L@_MFIH6PO/+FQ!>M?_H<25!3.#+O>.!@CNS^Z/60W266#QHWY:1DK019",9&_M@=7.)!18HE;1!
!)8+Z4MXGZF=R>93Y)_EA/O@'8OK9%;WBJ+;(U_P_MB6G^";D>&MB0P.PMC2V+U@41.*1L0D_78NW'
"VN+.)5VC)!!"JQI5=?M<#7EVDK\$986,*B,\$*@B9F-&9.N!UYWUX46T11S%UK"VB&-\$5H(5!6TJ^M@O"@T&1(;

(3D-EAE295DWWO2I?#;R^TCP710Z%1'-I07F@,-T/V-74WNJ-/AI M>79IKFU1*R-D
A%;ZVA)&DU!!)M2E3)U#0LPG+K\$"-)N@HP(IEJ:;CNE+G M(G;>M@G&\$P-IHCX=?@P?NS4NQ2#!"A0M
%0'.I^A&T":W54 M=V-L=H7E+;OXJ! M:6(9'%,@M:I8+;)F6S4J4E-&TSV%
HFOC7HLDN0^&2;JC@-I#V9751*OBBP0 MSUI3\$9M4I;59L*V34#%LP;(H*E51M3&AV#QHD7AJI)=
-2JAI MX,JIF=PO< M'0I28BH1D6E%43F"=-2,D2-WK;IBT+H'8B^-I#1;R2*MGOFTO9?R>RD7>
M2/H/7)RVW>SY>K7B-4YRQ#358+M^6JHURSW;ERYU887/QK;FN:#4.I/OI
MR;6<;\$4;LAN(&I!"/<\$\K*U9G8J)BCB?QO^">8H4B\$#D4QH#05BVS\Y<4R9 MO
HYH>H37H_)>M#7M+M&_Y_HUF7COR+0;X?9*B-25& 3HIPTC8-DHIS<@2 M,BI6AD0==FKZO6?-
F5IBFF"LOA;&U_FK+UP3D 4+=^U^E;3-KV;0;1@KKT MM 4I#
I'%;#13<4=)IRQJ_X#'->T*-QM\9\$NCVK>5;I!WIXNUIR+G\AC-\$:5 M0* @6FX JK,VXES5/#)BK^C1GS9K\$IGW"EJT-
^YKJ?5QY,TA9I%.AL M?7-HVQI")B>+0%,U1%VOOZXC^-)EZT GZ4Y1)GY(7IN6KI.2PQ8DXX Q&4"7
M%61MC5#%;>%(I&V9A7IHPQI68OJ3L>-H9 M^1)8MSHN-W8/&"JE_ADR@^\$=BZY.PI<#NK\WF>_X9M@HI8RMLZ
N\2"1%L:M M2H0<;A NBYI,IW9)HP>H_IY;0!#=-KOZ%N_1\$-Z S9F&X% @I9OUFLZ7Y^X MFJN4*" \$7AB-
K@%B% @HH.-XUM=I/A1U DX?&>MGT3R'0;PC?^9#P\$7R_7B:8 M?P'32U&,Y95-
*B'!1(^0T!;\$54RN660UL/I5X" &EOYIQ?N %NOWF/@PS,^% M!BZ!_O.,SO+&E&I!_Y>@4=:4E8#J5
)3&#FVT^Z08E11VUAN.MSOH!-/CA- M#>DK^@?T9>>SS\$=-,RSIMJ_CZD.I?UTL?
V(VVB5(THCY@0"OGD>;UUI_IO_-+U?GOU\#5#EBU(+ 9%6! M+60+P2#O=-C_L->NS6T<2;KP+IKSUOWR42-
-LIZP)86LF8WS"5&7+ EG*4(+ M@+;UO_I- @B*(@&B&ZAN@*!C9V6*I-/93Y=E;?;*Y#(#IS;G=P.CWN8AEP
MC%BW:!)X/LNN9)M?H)LIY?A*!P\$V>?YN>?D6/LGOI09A/L>F?>'B=3EP: M34ZD93Q4GS*3>G,\$AEZD8&4R2% @?
-PI\$ /K>&&229>U!QMIO\$A.CA4&21GN M:S2NF&\$GR9_ %I+H^NXRO*Z/5+<5=9IB>-WOGVE3^ BPELIB@?<
\$Z(IB>CTF MDV0",9GD(T4_.BIM56OV;P5R3K<I>VEWUEK*ISK?@1JFWJ@_ZR!^CWL@'2: M=@_E+;I/D=(? \$1"
<\$E6;D(N@/74MR2):5X_ MBM(HS74KK#D"C\$F% /JX?Q M>-
!T*UO!6TWO3:#UM")J+P;6OW@IB0%NLM9"4TDYB=DMU\B*>>,K\KTS0/
MLR&\$...SMOIT7\$#.SRMIZ2TE64CM:>#0Q@92)6U6B2>807_ \KW@>8@H.)= @! M\@6_6@IE7IWI>%?
>3.FA317>;+<3&+I8CBQ;...L1JH&@N\2"/^3N>+B.;JYQI2<1-36NU@HXS72+8*\$)D)MO,6X_4V0+C
M,G1_K'P;13J\$+1269#*DH9-.U7O((6.B/VK S*=D#6NL7.N?VL8#. @K
MW8'N;X73CHKDYC_LIY^/3A;^1K)5BZ-32')2_I2S&+I^N^E*J@+_FSI MNN^!=#E;,"7WG?2Y*2" HJ!=DW>=A
ZJ#AHN) M;2^04H7085HH#HM-5C8@Q M'ELR05U4P/CKN\$BIN(I5S"1=OG3TH#8NA6CQJ3G
D2;*B!%)R>-9S9F MV?P>[9E/9>VEVRY36?O(> "78&JU%>|L<?C\<5K5-D&#PMB%XB,'Z0"
M;I1H3E95HFOM>>T_%B;FI2\$;S@23;KF1_ZX1.@_RG;0'O21<^O\$|+80BQ;Z M\G#RB<6"="25(.K@:BG !!%84?
&I;C'G#HX>*@J9H/(L75R
M>I LRJ=C=7'A"4YMAAUP)+4T!;S4'HIQU*3@E>+>^\$|^YE(U?)@H"4T!98FW*7#L"&*OC;!>I\$)7\ M5+>?#D?(<
9R=86-^8K(L1 \B'H_KF3P M09(GZP,I4C-7=-L6*2,38E_IWZA\Z"/NX7EP>VR9Q!*2&40'GZH3K;*#X(L! MY
FS"LPXV;H1QE8@)Z@;*.HH5_@)0'C_&#0/YM^G\UHOV" @1 ATAD-Z-6 MKLG;IL4E.@LU9I%=B5K9Q@QX"L^I+
<4A\$)2'QP-MOKY*9Y4I@UV4*6EJG(MGR43EHS970)K\TNE@_A*LF=>_I0=*>O" SP_3;I=U#MV\UAFZ=EJ1**H
MIFZ-E9YVKLQ!*NDY4ZPAI?I!VQGI A#=-)*DF38&B!Q_P* A6P6Y>%B29" \^#ALZ/S7(2O& M0LFQ9!F
Z1K.M*N+48Y!"E;Q)'SR^054C/71<9>*L3Y2/>N*LODI&'6X.(KQGKIMDO%6\9CU2102>,2*^B4*;Z\$V1K0N'SKUB;
@.I)#R\$&%1P5-%JTC M@U5"RK9.+?;./="13GGV?IHL'G*Z6RKQ7HYV\$L\2C1#A Y6OFCI4S\Q\V"
MK*#%XO>U\$;%8CU6VM*B(C"%I5N74B;G"ZICDMBIP=BRJW#B0^">A2COIV4A\@ M)'" +93/O_8H5*-IX&
<*+W83E&(-H)CI3S(SG!?"N(L;T E*9>@8)*G*>O M@DE1N^B4CL2@ZT
MNCK\LFH<2QD_.BRCR6B>1CIVU\$XM.;!)@ (B\I\$66.!M:X!>_WZP^M;&"@S
MYI0BK0L5J*!J+I+E)QX\$5R\$U+QSG=K.OSI\Y^MJ@X4R^ IF=7V(C)GCEE.UIVE
M5=4^1.YH#5IS%HW/RC00W3KQ.OQCC* @CY300?ZM!8I=<+W4.OQ>.NM;?GV(MP,5Q?F7X@=" @CYS'B:1P\O;+
MSD"P:B\$2T(3A)5E#1L+27AA<F\3GSR2TD8_ ^V,I/80I2I7.9EK2H5^F" \^ M>T7OB)&IVD*)%4+ \$%F&D
EES#;)%\$).LO/T-O-UX+L<(: "3SG;U;60#A\>QZ M.0_I?A2Q" \;3(+N\$YE%K32XDYZ-%+!
(\$;"4QA5<\$9F";8H#RJ2<^EE0!! M,"IB\$<;V;U.S-CWV&@LG84KL8BV/HY>FSO34;-4Z M,T/6,7#D4I?
2^JKIR'PYP\$PY&5WZ;&_FKP.B\I0KF9_W@*V/5%EIC(R8=< ML(X,EG5HLL@I%4Q)QZ7V=G>6CI#X
&QXNOKE_*YIP^#U\Z*6Y;V?S\ C@6DZOAGW),^*6 M@4I/X)1 B*/;A4@G/G5?LXZ%-X+H_-S23>NF#Q
4UG5^1X3Q<_9K>K^I^EOY\K\T;I B:<(T)I: XN:002\$%-D,3;@+F?P/T>A2DCUK#NC%)J\$%R"9<I1
M0G@I9W6I"&I:EDD<UH7IYJ9Y0^NNW2&6/C;=KAM\$U4QMC)+8I\Z8APB M\O'(H&54A7L;/E4')E@-
CF<+0==*5.=I8;U;)9Q\9Y0!-I'RD/HGH\#=#7U M' /TDS)Q.BOE2@8365FW\8MD-
>L'=G1C;Q;T;PCSB,49L;I9=^J\K!..\$. MD(%X?ORA4I";.AZ^A(O-7%#"?
^% @>ASOQ0A=5I84%7F\ @%6GO\$YI.8MP*Y M"4?+^!)MOAPO7@?OE5C9H,H>H&)C%X\I3YZ+
(;VLAC(KHFX3HAF+K=.33I& M<1\$;U*X Y0)MHIP\R(B1PT6\$7IC;2SJY;3>9D45IG4XZNQOLY0N(Q"C\6 MO
/\$^AI?4V;..)=3'1Q\$Q%.)D3#^ZT^U<5XTAD^W\+2O>OWA M@<=-3\I<>@TWZ#L0FKF#C#Z_-Q=E-
G^U=SO61A_ (J.T)R#0VKAW" T'D;K M(D'DN" H+H,U;90Z2\@1?"J-SOIG;_*0"=WC%I?771V"-I?8;2>K+S9?-3#OK
M\7#;7ZR3WGW_-H E7>PS;O(O!;W\Y M6L6WKJ)9\2_6<&RF=%LU
OD7@ZZ&G96N<8>;26I+5AU;4#UW^Y<@^0I> MM_00X;U^WP7C* W(MN;
I\AV9DQ^NV%W6.4.SHV\RF69/R.2J\ILS*ZQ%7T68# MLDI#94%8(=W%D*=7 I/3<*> //D;GS+OKS3EL."W6.
XFD=&CM&-T#G,+QACA M M/*#EQ=NO/J;NP6NBU%W\$.4\K@-WT>POSXYVQS(4DP;9#;+8_ 3E*U0X+
M\DRABIN0-;9L/;+=T)\<=PY3"FC\SL?B08;DJ.5T=>N"CQ+
NJ"!5.OH'M>;Z1HWARR=HD@D7!I: ^3/\$D\!1SW)"5\$%M*P M5U9W8WMY\#E;+VOF>S;
(W&.H2SO'B&4TS'4ED"VZ\JZ_FIT#62&+CQ.2OU MT';N='UQWW.OB!U#2WV;RTU*_OO-
BO\O;#_CS9NTNSOUR_Q;^6'_ \$*V+W M\KY>3%189\$.40=;)0LJHZCIA@0Z)IU3#D'FUB;S48!S;5?FY2XCZ>S;RQ
M7N#_+X8Y^0(3DYUGFB?@43+7%J&2)H<@<@<2!;T-JX/@3G"Z37(1H;J%"Z
M^_J(4P8MX&F(&E>B\$-3;T;IMJ+O;0A;&*#VO*M*7RJS>6AK @^N-NGH/
M\$VMJ8;FN4X2\!E5D3<1R\4PXD\$)B8'&(&OW>0%\HLWKK;_#?KCHHBLF+FGM
MF#6U35<\$LE(#A%6I"U#\$"RH\$EO"0X"^E*)U5=' PR#Z 'Z575%ON-VCDYM ME.3J&)\'%F)
5T=\$\N!%)@;)EM?/ST4ZXNCU^&.&L!M?+*7%!.HN8\1D@JK MNU@LZ?G-EI/_Q?53=\$J MP/=S_#*I^?
(6EQ/A(DLI*2BIA0=FYIL4VX?_*I?87GIX_ S*42!;\$VO7?7_ MZ3OUZE(7BYMPG?#GOHBI0(G;?(Z=#X\+
I16VJ7(-@Y"0?12B%*,<;YU^/H M1)2!@ (92?P)W_-P^&\$>3NT" F=_C/\$/PB><"%.<I\BF30U9O;BEG(2IE(5F5 M4\F/
8>=7/D42^N\@RD#;V\+B;U+U\X_?2YMA7^&^>?Z3I>=I@M;L.A*K> MO(DD!FTSF\$R.O=&1&S>?V?
D\$!N42"NY;^%RVZM#V#>>E3?)JH@E\$;\$E; M;O;UAI<I=1VY*3L@I'0G1*;>YXW/6^T\BW;Y,4C#M7K+?H<>
<A.M?Q M; >OG(?G0N/AHN?UAY\ ^?CKKZ^Z;W6\PE-VK =LZI&'=GJ;\$*?OR=9R6;
M('DBGIF;_6'>@M/&@52JZ#I@))O6;4MWHSG>)7GPR>N;9R%+),7X"PQ7D6N
M(2@9:DPO%1E2R*Q\KF@;DK&ZLS72IV/_Y&COGD^/M@=+^<>WMW5OK*UE\KH
M;56@STM&E%*#Y9S7_*@&%ZOEK9(+3/&86/O;E=THI U8(^*IC51B6#I*SO M(IU%>5M\U 7:8-W>=L(Z5EV89LH
M\;\$KYP107XDU,E/V\H4I.5'Z;\$& @OQ"5MZ7ZVF9IM4@GW_>A'F@ @V\3BTJ. M6#*1'(\$B5*B5\A!>-<^XJEB;

<^1H1*=H0M-(>8.&.C>3?->^90>S>*MS-IS0TL;ICV.N.7/I!GNU@1Y.%M^+3H*:(*(%V@DSA:1^1"DL
M!GWFR=M.C-ESB?18C!=@NXRJH8M)LTZR1\$1M!JZRW!-(W?I.MX!/:2GZ64NY#5#TOHE51+XV8QO<.%XO=U
&.Q(F11+BDA\$7Q0"A0/9(+5.MB@2).1N9)*-_-9+GP1T.29%>|\$/TAESA>66!%W.#13S^!/:(<#17UJ\$GF
ML5(>P%/4\$11S(-2,&H1B12M.O5F+!)*NJO"A>H4R7\$52^)^UPQEL;f!"+?Y
M&1B1C!K\$HRRALL1!SPX0JZSHX4RQ*E!M\$Q?X/S25MORC-C#;S%)P/CI6=(,">,WN&\$8'#O-
@LE<,04'B9N07<3N42SJ)M&PAI@*L"6V!MPF\$=@UU'N!=""*SN87JIM/A"+D/<4+O!"BC#|VE.9..HGIK.MRH)CO\$
NT4J'KG"6GS|/:YPO/D^_WJL/YDF!\$KD";^7W&f.K-"&EY\$Zf>Q:OHU5&=9ARS8X"/J"Y"U-RKJ?+?C/-f.MT+ZS-
^TW\$H/F\$!A1IRO'55TV&/R8<MD<63!8\$B"9\$X(\$7HZS6-K.NR=L*9*R"SC;Z?K@C'2;,"
M_B!3/M(V*UMVU&1^S(UA6/0-!&IPR\$M)NWOXTEO*S@Y#S'=601=4.T4.M.MF.Z#3QC^,UMH<"1XA|/f#
(XJX.GK1!B+>12R&H-%QEQ%KW-P02RTEMG<12N&19+A/L+3G?0!E%(#\$R%<2^!G)M-@<0
N%HX447**SG;3fY>OWK;27&(^GA<+FOPY<QSI)9).18*P7A\$D(M""X82,f9!V+V+C:?F;T%Qf-6?3,-
RX^O4NA.YIP.LRGLW5Q?PA6Z9I0Q;f"MX1"BE0(6N5!E.E3L\$S@J+E;0!_F9Z&fV500MCGI|=+fYBF18L;MHT=P'5
ML,IX)Y.3U!28KZ394!)N7"^\&YP+,66M!>A1-K*MZKP50S!Y5%*J9+@(#WK!/?\$GGC(<f=L4R&.E?
M;9Rf)=ZPC,?f+5#?SJYK.M*)f^3).X=-4:/3!(IQNM<fV2,YF4U-?ER^SZf^4L-??TFCA|C:F"^\G.Z
M_\$S"OWGGW!^3%>74?UR2B>3J*-DH/fJEZ^OQ2E!";HO0.MG0)55-'OA814.M#&->JUEZQf7Nf"TKJ;-69);
(U7&=LL1D-LY)T%QO&\$+00K6fB;f.Q.M5N*QB9fW5.%)*>L^7HLZK
M#/MX%7fE%V+U4UfGHIA"YCTL;GT1+D+(-952!/(3(G.Mf60!9>YPA#L.9UB\$/1-?
>HAfM(+L&)0KUEN0TI+W;AFY<.;MNC0:4.N5L.8S.MTL^f^+N7HCH58?>1H!7H?6/MGL7V?7=QEXI.72NLB+
-PK)f5.!O.fJ3P74.M.7@=;/MX"E.FV,I!-fPU3(Cf7=YANJ=1%U\$"VPE9)fY(?;SBMf9>MY#Z.M"?)
\$=G#"IN0%HXU0>0X.W47VWN!fIACCIANJ+Y\$F*PCA'C%.*#CX5@f"#+S(fH?ID;.%;MXXQ.M=<%U#f/-
^V^Sf'S=4N46H'S7!ONN4VBO0/f\$=PSANPRMCI.M5fPL;??JXV.OYf-f.fE"S-G%3;LJZ&.;)HGH;YMW?S;2WCOG/46-
D.M*A%T;4RBN'10.-f!98QHQ-)N77=1&=P1VfH=|T1|SURf?HKYA7+WH#F/M4K.MMAZ"Q'K9MA8W(#>"-P^f-
f8,X9NZM/7!>f7\$#ZN><fG3KE?T>5BNM^fJZ.\$X+MX8RGW3KS6F=;NRMZH<.;AYJ\$57PS?
N7f0)SL@CGO1G2ZUUT"=#fDRC"Y.PQHfISY*(=B.GBS#MR;!Ql@Q-42:PG'3(S6MR;fD3
M*2B1E'8HY)PHf6f3D6S!>)LXEIPQRfTfY-/(\$/UE@5Lf9R;fVI>47:D#N1.MH1%.;f1T@%V-
K=;Z'R#.#6M^fT(N4f+>.UTf^YL+4W\$RBS5.DCf-f)UCNAO*MNfD:ZZ-35f+Qf0*ONXf>_YfA@<)fJ+XC)-?X?
MEfL\$QX#fIS\$?77W&f(XW.8-PEJf1Tf7R.MW\$^MP"=N+!;57Q^f!==;;R2f+S>4YPEYC*"2'Cf5Z9fL)-PZXCBX*
f43P.MMHf?GCHN+<#Q.fK(C;fEJY'R'AKWM.E&>2<<9.8W75=,ET\$.@6FCf>f.;
MIQ9W.7fXZ#-4WfL\$R&R2E>%M-fHJ+!;W->Z@K(G%!7*6\$fWER;Pf;B-\$3"7X
M+*6TK8N;=H*Y9\$NHK28&F.=R^fM@=1%T4#1SL=H3ER0>)RZ'M;?M)'U\$'5H.MCY&f8..9%Q)fJMf!;@24A>&D?
4R&2XVA>2O1L;3?M09Q.;7W\$?2\$H08\$2f2.HH#5=WGYM.J^3D?_"&VJH";+f8+^(CS.M+Y-2C"#"^>Y
220Z"2XB)G%)1E.Af!Zf1ML;fHCWf(LG05+P#Q+fL/f4#5FG6.MCA7&HCf!<(@FU4XTf1M0".PM-
&T+f^0>1'3\$<9>;UY)V00;"MR';7AZSQY\$X.L9J-1_PZfTf20X+O#4'QVF7MN?9(f.Z").(ZfPKfHO;GW<
M=^9J+T.1G!QTK.5(CLRD6f1"JHL-f;TRfV.BG.U=39^&<52fUJT?O4YST"\$=MBTL<+;\$&MP8?@P'4WD:C?+?
fY>P.M;HfKfJU(fUB;2/24%BMUK647"MD.N%f%!>f\$0ZEQ5YH5E(f%=5M.M<+P+Kf;MVY_%"8UB.WH-
C4N0ADK/-DNHf2%L%9*X.C&B=2*+FP.M?89fMT>-W-
fJf4H>EKfWD^<0UQK4D^ALTCQCS"!f""*LK,X5>K#9YSHJ*(.;M0Y?V/Nf2M-U.GfJWWf>fS/fH&
fA*1ZWP#GQ291='(P)620"42@=>L@&=>Nf*-M#fW;5NZ=S=;)SCG0HH&;
f#LfVA:f&.87\$S.f!>Z.Y16V44T34Z"TFQf0'M)22=098KEHC2Q
MAGN390;)@&(546f!924@Q2V)&2M"XFZ8KM0HK32Q@")XAfPKN+f|&f5Y3H.M/.\$VYZA#A"*DJf72M?
AD1TM3>VBHRWSK9M.=;UH6QfH84!LL#;3f6fBH?Q.MQ^/WWfD'3.M)6=N+P;RMV8H.NBSU=f.2V#L!;
fE9H>0.9.VQPJHT9MN.X7fGZGN^0F8%_MLC4.;>8N0"4.G.6\$@%3;=f3
<6MA^=OIER?;5^fC^<K9YRVf6;9QZ*0f1.Y.MfE"=>7FGR(QD4M)R7PAUKWD?T"3ACMV.M.W.
(K.=A00f^>f>FEf^f60/f(=9f3-\$Y5RFRfH.M'W"Z*L^KO^f.%XG-L.Hf1.F@M4F@E\$X0:GOCHDJV00CE'V9YABUHW
7TM'QfM9&..KJ&Q:26fL?JfBf2R&+B=.(JfPV&.T)K/?GZ.7M@%*#5/@L^CMJQ_!""MBR?2<3H9NfWf!Z+Z?)J6F-?G;
fU*f!;7fJfV;S@='E3KZPP7XPH.@)SJHX'MXfEQ.Z.MXV5fZKfQSIZ^f^.;L;fTZ_K((C7R03:C.W6.A3&\$GFS
<\$f^f5WA@KNCfC.M3RW8#PfH53BX@2Yf+>38N.SO#fL@f"MDf2L-R_@>/f^f"PA%./G\$5(<6+'2.M6YE0<=";
<"GM'3A>fRX;56f>&f9;7.0:1.%/5.;/Hf^fPFM=Q&D*!<@YfFZ38QW:S7^f^+/+48Y2LZS=D(.?>HW'1(fYWHs
M).75%;#3F\$#&3fJDH0UJ?5@Uf.<^MWN5&TOfJ^?G8\$Wf6"HEN;f?ZMCOfDSH(^P!&+fING%fBCE5.M?
-1>@_"UY0E7#+'7(0S)4HG0..M'f5#8;2-ZMHfNfO:D0Wf5fM@;)L/f#4#@V@E0)5fP*#PPZT+1(EDe7"?fK^fL3QU=
fVR#<.(f%0?^f;fKfM7'GRZfY.O9=;Z=0%R0Z"^\5.N9)0(f!KZ^fJ'fL.L)*7C5E!NfD+PHSCf1
MOPfGRSfHVK3;55<7)XY*f!YW;R->7VB@/4L3;-R-fA.H9
M2\$;D(+D7PG=K(K'O2<f|=f^W%V;#CY@KO+%&GH2fXSJ7fH^MN=2Yf9'OJ.fI=N86BCN>.*
MTQfJKV*5)*U(fV0A!2YE'=-96E=.%/;7BHfHK@f9fT.f;f!>>@.OE^(Z.MY6T.D?fHE\$@8,+MD0-fCX#R07;NB
N\$Bf1TX00=\$O-8/7G@EJA#UVfL_9\$4fT.M.8+(LLZS%Q*
fLL3+).@VC=;G^<fC@f15)9GPQ>fWfWSMfYf;f25*.;N9KE8.MDF5fIS-
EF5A;fL&\$S.MUXfJ+0f1ERfJ)RDfJ'BO%Q&M<3SLF#f/;f!>^UCH
f5%Vf97YM;3LG"6=fJ.f8fUNN&W3>2DfPW*1\$OY#@fP(B"@3CHZY.Xf!^X/X*U.MfVD7H>OF8FU==
fE)6U(^>NOKQ<3%Z/f1fHB8.;fTR&@&)Wf!6=K.;\$KA0^fD.MYVf?A%Z/f5fL(Z2f?
KE^3fK!^f1QSW6K^8W9%SUE;.%9fF;3!^f!(9.%=AEL\$M;Z-\$ESP=5ZWf)'5#fMR);
>1KOR%^.UA=WB_5WGfLE6@/f_S_!JE^fLRFWf)Mf2_'f!f/fZ5-%f+(U36*fKZZ7DfSf.fE.f?T#?>T.UUA?
OYKWf1U0Q_&AEa.MKDA.N=2^fJ5MC;8(fM\$M\$ZD".38732fG#>
(QW#&K^f^JP%6=\$2#G)UfGfMBL8*YfZ\$NfNfE.WNO+/-M6fHY;+f6Wf!ZP"%SQYfV)-
S;D0R0U^D";R>fED\$ZH6\$S;f8fEWfZQGKC.MDWfVGF09("U=G;f50.S!=f
f4fLZf33AZfA0R>2JG)4Sf.fVfPYQ>M"U9.63+fIO546;.>(65f!T_9\$QYfMT?HHL'4X9A-/N(WRBN28S\$Q"SM5*
MRMJ0&QH92.TBERHfF0^>VO+YXfO;.<5^K9HZ@&2&^fD&DORUfLZ6\$X*;MXY6LW8"(V2DfJ+>f
U=;!&fNZ\$U.3X.2"JYfID?&5WCKZ.fMUFf+5f1@).%NfSf|=+O\$GTO!MDR5X;>O.HTQf4G+fY?(*fR2R.HJZ=HQ5
M2f!+E1M?"_00Q'OfV%.;HfS.CNV+L&f/?"B'H6.MYY5#;.858YDHFR\$fF1M&f8.M-S:OC=?
N_&B(^&7)S2)7fZSfJD9QRf59fQ")K^;SK7+0R**\$*1&9."4f0fJA)QX(O=22^R*;#f2f_S3f_Y&9<"LD28&")EL
ML&Q;DGf1.Uf!(fD2fL92f).8UE(f2+U;fJfP2D8;^f19T.9%7D-%>QN"*=K2fD7X?;2&
M%DT.2ZPEL#\$HH630fJO!NWE^OQXfOUQVCH.DHTfT=*fB'E*NM2&66&DVfDfNK
M+24S>f\$M9"52#BZSH+HUZNfCUV.OCP?2'6L\$;f4FFDQGOU!S?2'Q&\$H@D.M@;O+NDZCO(XfFOf
f.7QX'CI#C%1N^&B.-KZKE^fV8Y.R?fY^f5\$M.M@fLL@fF&54"1D(fOHz.Bf/SB0?7f9C@.M97PfJGMH3f@=2#-'RM-
&ZfL8\$M3f@WWAf4&&U"+R.N8f!"UE>/AN<MY.SJf?S.M>fR;X'N0;=f1'2*;ML\$J6/Z??f1P#)JNYK.fI_&E.H.?
2+#+V;MZ.Xf;0C2.M6f!";fR&R+*Gf>+4+RDf9DZ)!Z0&9fP(M(^\$E/AS40?7F)^J@f+MAM/f5'VJ?
-3=0K#fAJN54#6&UG02.W6"%Y;2C+P@K;Z%#*Rf.;fWNS>P9.M\$G+WP.>?B>JEZfIQ.FHf
(V8%XC90T@5&P;fL_1QXfM'2X7.4'U'2&Y.19fL.MA*fCR&4*#)03"*YVB;4f1=*<%V8f!>fM0*2&f+35GHf!98;f^f1f+
fP3C.XfL+*ZABG7UYM.M2E&fLZf!W0U!X%EFQ'f6fH0@1N\$!^R^>V4^P!>fBUTO"Y.D;79*8CORfC.

M#Q>7=8T4"/\$.LYT1V1PVG2-THIEHX'V-@&65OTVA7'&*"M%>TA9W"2YHW
M%XR)E6Q:MT=I/KS==^/OO&G;1[6##"EY")W^/N-14<9-8(&3G\$Z#TH8PRX M0+2R86@Z?I8;%TGI R2@,TQ8#*
[S1-6BFL=0G6;V^W[AC]21[,GBT_H M0^U9)C^H(F7=M#TM^X7,REM3NG&FP)->.F-.ZZ.AB[#"^I^O^7H?QO)#(-I F
M,F^L7KH77H\$SU@)GEC9#%@U-^+;P8T"-S2>7",G/L+7H5[QA+3RQC/H/ MR&
I30H*7P@/GEBF3A%;BTS\$*KL47VYX#C9#T6"6V)W@=(P9+@)>/G38Y0 MQ#9U'B"QG^X1W/HT6<74P2C?
9W!PQ.\$GSEDL/EAH>86P1S1U^H\$WF48?39 M1WBM+;G_N*N->??^IM!@M*VD9"00+^')%07710G!-
)H5194Z"/^/"C?^ M?I2<9^V\$-\$3E)/S K0T4);B16<"9F6JC7L!HOIGR=I_PB1JV<1Z2^G:X:MSAK<@-L^:Z+J)
<^GJ67XGH-Y3A\$ZN-!/"<.,JHR6ZAPTY"\$1&+;XLVT6YG M:&=JF>-9VC.ACI#""L^B3,F:"P...4/8K:GD(P@P;4*3^ML?
K@A_\$LO536 M9SQ+WF?TQVEU1_IG7<#=-;DDRQU5D7RU3R*&NGV\$^A*P#\$S+2(7B;=N,IX2
M_QF&EP8N\3V5)ENG.^X/I^Y7FEWS^ UKM^1Q-UU^TUY(FW.MB42&"<(2C4 MCARV!^!EQI@3CNS
:F^*QI_8M@VDH:&JAN(^P46^PKL39C_QVN;O#58G&S MGBV!^FOKU@C1Q1Q_H5H0B@.N93
A;TMM0>GHS>@D?<,D0V_1\$%OE(^MY M.50^Y^4^SNG-?LBCIMBJRK#V103X06Q2@R>CC+MM%)T
:*L8P-IKTX6FTVWH.(8UD+OU.W.5^+^B-.PXS^(2CA.P<189.7^FO.U- OP4EEO@I MT&?U^OPT7.3.Y/W-
:/Y^MEC^L?:Q-W4_13M-1B+^9?K=>#LXVP9KKZO.D3/@G6EU@F2PR1-@J@=K9+(*RWQJ=!
M@DVCK_3%O#G/B%"/7R.WP/FO:YWK_E#-5U^_HQ7M(QWI2QP^3^M?K6I^K3 MT?@N7DT_A?
7)6\$PQ7\$%)5D)RN4=4P8H%(BER2U2.>T%&L\$||7P_.PT_IC+M_B@NKXJY?R^3C3S[30J\$WK.W^.?
JFXM)S3E+&204%_1.>E>C7_P*BR(49Z45_MLA.=ISWI93&H=RW))H8B/.*O?
KYE.*GSN@+.)GEK/^71"TS4P8(^RP/2_M/H^5=(P2C)0N6;.=&?^^(S/J^_9B(-^*T!KS?I=.;QVN2@V*ZU^5+I3.Y>-
M.[XU8^EP=-Z^/O4=-^VWTEW3DD92^TL4JV+=FZG@P%D-X;RX26K+2FZX5U_M/^G%=@2>
IG_31Q7^M^E37IW/^G5_073<9H(W&(C^+2XW#S.K0666%JWX_MKT0IQ/(99E10ISG&MQ=<(^A)7+2
M=4IDE\$56/(BZ\$1A4I88.U&F11V%76#.T%)>7-K7X^W9IU5JSZP5.L(FB*Q_IH@B:#!-#IX1W_M4HCHHU.MZW.
I(7MQC/I_8>=4.OXJ);S">5W@_7_Y>K98KN869O2>IMBL0>6(M\$)R-\$#.3SD@?
Q/G,=7MB^2^LB17>O^4EW\$XG7X.EV&J_K=5UJG=;\$^IN=\$_701/(\$I=D+C,^VJ7\$3+Y
M/QQGUSZCU61R1@TZI\$Y.\$K^W.V+^X+^H MB35%OX (I6_!9;2!6+P!@J=Y^A3P=9QH\$6|S2;3T*+
4JX!UO8^B5_YO? M2JO^TD\$E>Y4*BM*!4EN^O#KE_M-I4X*UO:EH;KO.EF&=)R^L=T^:UI/LXA\$;
(1GD@7IMZ+AA^VSH"S">?U^SR9E^M(8"\$@VMHHVD-A!"F\$S_M"TE^9UVG,2!G<<|XVPK/D-
X#;+G2Z\$S^ASLOMK;2C+ELT6G(VA?6S=E(>DL M2I;Z,HXTCG93J?#KEJEW<,WD1F#I^_4_11H5D?/JW^8M.98\$+^
\$_%6&""M^L%1"UX#8@/T3#E>6\$SN;YEIES;WV_22=ZD(PAV3F5U/5M3%QQ2M1FRYHV M!
D)5K0?/L%Y1+Y8\$DA9U/DWG-M?H^OWF1CB#8.25MW:M.TD+!Z?VE"N&R_M1AZ!"U-^=H/I)
<)F+^"L;Z9C:U+^D9I^H=DX=8/L;LSP4E6EY MW-G;Z45YYR^=I18>I.^W%CO_LNC/6FJ;_6)47V MDF<060G
HI&6!"(GV3_041P3/^YI-F&@P^CXKW|^>I^_9)1;JK5L9E^T#_MP0TX:0(4@RDP8^BGSS#\$M^?S^C=,P?
RG^&+W(NYS^KM_3&PL%|00AIBX3_MYT!63!)^OE(I^Q^C(+LDR;YI_HPS\7_1Z?YWL)(>?61<^4#F%0<M28%J)?
4@+8UQ:(JSK2?OWX6*_-I3/UW@P|C|/F\$&^7#H|(^M^Z9B&=MA) 3A.QY9\$E\$9_/_L|K&PH|^G_!KFE8RS|O-?
F&Z64X+7+G?DP18Y@?2_MJS6=SS6!^1R67C(NA3;JY2F^YV8G@T+^*82;)^Y_.C7;[RFYZ)%R^L&7R=;_M2,O^UIY?
+@F))<=>2_JX@5>T^O#T@&OZ?50H^KEXRLKE)PE_WQ(D_VJDHUTWHR|^+LN)^TD^:SXA|LX%7_KPX_9_H:(2Y
M_HM%7P7</_=S^L2V&FNV#538S=Z^*#^T8EB';=D^A1^T7AF!3DI\$)4SSTZ@3L/^C&OV5.1M:\$T-972_(865-1?
H30:X1AXQ3DHEPH\$P+I50FH#^H M6M|U/!#JRS9UQM#O\$FB_K!OW|@NP(=J7G_HZ_.83Z-0XW@Z^J^7(4H1#EZ
MDKI8&PV|MH;.DNQKK;55D\$*)EB\$RW|X^;P(N<=<=>UY|!%.(3J&I5\$|06=M%O6;J\$9A8?YUVF(TRM;
&YN/&_P@9M0-N80#%A(^J8@=^B72E^>M^Z4K<I MNA.DL_91^<N00X1&T%5;2Y&BX
M+L\$W+QI^\$<(S2G(VBJ(>H8*=C&B<9/I^3+I;JH\$=;Z^P:YFL^YXC,4H=/
M;9).ZHN^50YI=^@/^4V7TZO/_UR76;S+^%V!1OF6;9XU_B%\$7T4R@A>O&KX MNWJ8*8S8_&9%UP^T^I^GT;OU?
J^MYX^I9\$K>S.(BDZ=IUG.EY/7L^O%|&J;5VM9B6QE1^J>O.F0EC%_M|^+^+@IM P>LTW9EE^Z,(T><8JEI+?O#-
QH#.(40RC|UE3N3I37\$586CS5%BTR?K9_M?7VYSVESOO@=0!^=W7.L&=K;S6SC;D?;*6
2!HDFEM+02?I6BET;9(C_MFYKIM_WL#|V0!G/RVFGIUEI(0^9X_C^S8+LL5B_V%=)FXSL5&P.00E"=W
MVYE""Y8Z64.FE(-Y^8^!>C2C8^V6ADB_W#K^Z?B2Y@ALHIW=RXCS!8IZ M%.OLW!"KO&HD?6.-I MA-
M0TZN^H.JNEEH2R.POV&>IG|U>U:%Z(S\$%,#QI.O<(P;1^*@F)UW06)\$>MIFEV|&='18_3!#;/E_FLL?
R60%X>IM""L_0IG@=%|MHR)35HFIT<<^G_EL576@6)J_8Q5:Q-Q9I9TA<;N\32=>6I^5Q)FB^QD/ABFB
MD!^0+^K+5F/&1+1/2;>JW9_7F/ QI5_7_MZ0_@/VSI DL_SF|NIHDI7/3^Z@DZ+VDD@0#9>@24='M)C:MT==/I
M^Z+!46+^N=\$/GBA/G?MGB3H"JKJUC^J;N7&VFR:1SSHR0/EH^7PICY2&M#_M;9D^L^RU<=0IG-
8R.ZGD\$U63+DK^U^M^G-WTMN<^AK^M+^S0?Y4O2^_1?>0^5DJH^Z:7E(^L;L;NN:E#|^R6H57;9J0.TTK&7=9JHM
M^8*T2@9=7;8J4G162FI?SZRN<HR^7\$?"0G9U!;3#B8TP1+NMKQ.*X,^I^<
M8BZW|DEUWOG(7GKJF(^L(^31Y%9.ZY#Z299\$=BPFTH^*+^10+GC0_M1AG&?
516=_(+SDOE1^4CVVF|CW#^RD=BM-K4MGXNUFRKUA^XP(8I72B,(= %
M=C18VU6>E\$)@;9+BJ3=1\$*CO;SS.@^"I^F^Z MJ>WN(Y^MH@X32NOWZUY.5&F0_~^WJ>N<D8(,9
RU%*&.&\$|P|MK+/_%1^L MG/_%IR)LW^*X!_X/4-OHJUA4).3K@QN69%(,7(ZPVY0A0J\$KAGBGLIC+
MKX51TG>F2>CXK#^J&8_U^H6SF(BT#"^)/\$F91U/XSE\$@05,<9XE3L(OK>NV_M-L|^*P(?)6^D^<
M^H5.TI;#CMD^D?^MK-9D+4GT5RLI+G&."JI#0942ZITJ2R:WLF_3QC!"ANX
M84DJFTTFRQ7?==HY;3!3YT9P+VC^5K27X;B40_2BET^3W_M!8ZMZU
>@;@XQK01IV/IF^/B@@_1=#EBWR*15DM\$0;Y(7C\$7^J6-^.;O%_MJ6)4Z6CQ^(K@X@@RGCX>D|B.2;
(=VZ#*669T&H32%I0D)Z3W6;2Y4^90GY@_MMR.K^9R_Z=5&4X^YYHZI&S"?AT6GU_E_W>S6*ZR-
03EW<+N^=/\$O+H0U!M|_/_L^O%A_Y3\$HY^X(S+M=C0I^AD&G^!\$;+^708_6;7-8&C<%PFNT;4S6+^M^.;
HM<.;N0=<^9^T!@PKABH(C0XS@TPJTLAH07F8R
MEXH@+0YUALR*S#ORAWH|-9F2Y_G2U6V^LFF_QQ|OK>Y9G^IJSBRR*81RT_MR20X|Q\$B6@U1RI2X-
YAS5Y^M^;#;+LIM>?%B@TZ|H|Y_4<|>B4;6HDD) MHJW=_50_X&6Q4*Q#YIS2)K5VYG9
N3>=>M13%DHM#5\$W_NEA^M5+^%L>%F%/_MYK1R;L;H%+N5Q9;@ESLR;ZR-B\$4@8SR3,6ZX_BT5^NA-0.XI&2-
=GG9Q^!A&MSEN8<3T=||8D0DC2\$QD_YG1^PH-I6;)^\$G7+^Q62I;3^+8^GBR#*\$K90_MY>+10;2ICSVI>Q+G%I?
=C+^GYOINKGY|IRJEO&JL_1\$&DZI00B^UG&04Z|@_M>\$7;G2JZ|P.%ZU+J+JCNU@"#.2@+5PZ+EPY>O83I?
EU@3V:~N9G_6=N10
M9Q/7<|QKW^L#^G#^!VY0#=#D9C|>RM|VN|V0I+;HB^#Q|OKW<\$7_*^L|A^OY;1)O4Z;)^4T;%L_@DBV%
MP8/SU@/^I B2;7)2A^0G5\$=O^T6A0Y6QAT<^!W;MLZVV7HIF/<7-DE#^TX@NEC\$-%;&EYN^X0.ZA9N?_TI7-QES
MC?YM0M^[BQ:W1.5-8O6\$"/+K#;+X25_K#<&DY);=>1U1;8Q9^K MY-K;0L7CZH_?
XBNVNG>3IR^#_EN0>+K26/T8L<4^M@FI\$U5WODACK&Q7^I_MZ>I.D?
%NJ;B#^G^9MH>=UO(O&-23SB|BZ6Z>=^D2VO@QJKK^TT_6T3I;9+I<^VMR_MKCI1FG\$1-STJVO8SI//\$H?
H8^KSJ@?H7OB)=WE7-T_OPI*_TW|3)RK;.R_M^0(*#4K7^8W120@6B62HHW6M9WWT
GC|Y<<9J\$%7DRB/+U5(WH&)4X"U3(E2
M+;@QM^I&I^SZH.XMOHIC&GKH8;1OK1UP/22VB+VTE&G.6T""@LY1NI<_!
M@_32@&K&@OD)NFB69&)"9I^51GI?0#QK2UUGD?N8I8%G&F\$_U7&5CAM8PX_M,G#DOM_Z"-DNP4;1O/R>;=%
I^6GCFI^1PAY|+;((3JTU9PJ7(8Z=4A!034%

MOD96NWJP9IW(3 'MH@GL@W:*VGP+HE=P+S4+HEI%/5DSIQ#I#QXET1Z:I:A MT-
855+VH5,CMPL1\B!M="*,HO%F7=),*?Q/L(=,6L+<4LO@*=8*16,1B(M=69MS#YB+DP@IU:#+=9=\$GO)O-
/4MAX"&ZY+HHZ:1.826)MBM6\$#1"Y<+,KF MQ9/IRE.WM.C9=\$D%6&"67+HF)(42,-,KVO#. TQ:0W.%2&-
CDDWDDW MYL,E6#E"B6UKVO7L^U"C1YL("67QD "V 1.NPZ755C_QS!G,5I(?H&B7
MUE\LR\26+YHN1YT^N14+ #J D%OOG6\$FELPIR5+16"ISH3U" M.U"6+JGN ?E3)6VIBDZ3L>Q1ZL6H15' #V*K?
JRI7N=%5+G1Q.Z^5OA// M/6W_O@ZV8_0HU2:L@O1O,CMAI##^X17C!@F8G7 ND0VMM="^P6&M :IX?B.! M+?
%ZA8C)&)P/#G1BG^QVY^NQ\$T&@S+D83OY\ZO2N_ WX2\1S(V\$V:\$"X6?N_
MEINAG0NFTVX3RDRLLJUK<:%BA&B360)2LVE+,YP/WV\PI1SB9QHJX&&G05W MB6!5E%W7^ ^K+I(9,#Y>+
CY@:3V6:A4VAZ 2 M=>65&J!""\$.\$IB.UL##EZ> MMNE^&:IS2C@#U:3M?Q A6@IUW>2ZK-
"LLM,29#1"CI9B@&7B(!,H_**(/% M#;QUCUIME;\$05S4UE14K.EK8?@/!/*
MLSZ,VJ=AU6Q:9UQ3IJU(6M1YZS844+(@Q)(TOJLN8ZIR/7\$:O(T!OTI.MT3/+JW&L.\$GGC>562I
M1-2QB9R/D\$>O(I,R9!1*5!== AUN&H+/F9P_7E0,3 K3W A_#E5D@UD#I=4R M>-U8%\$ OM6ZLEZ*>K"
(ZLJ#UXTI*TT)-3:4:H-KP15XX04(JR*.R*1NWGCC MW.O&VFF\CW#JAMS6#17=2"Bj8.\$&N3I**C?
4U+'C@MU#Z(SRONK%>,N12 M-19'8,/5C24FM"/J_)J8YC.IO.-.L=+SD076.WM9U-W=C\BCL*/6C669 M:Evy
YE+!%7#XL\$'"=IE+J4A@JAN52GG4S=VL'(.%,L) LZKJZM5INJ!L6Z9 MRSK(!BKYQ=I@1"# &8XJ;BC; :H,
H:U1DEI^Q9H M>R54">SM@I\$Y2S94+ FS&RLP' M:2^0\$1/J&+;4"4D\$RHIP2UA>BYA<1< M\$:*0Z6;-W38JO(?
<&2E=//E9M42JWZG=OKZ"K>T_-14ZKZ "M>UOTSM*/-U M5:^KC9.A%(M2V2XVN+))7/5D&-
&1+'C+IG6_4=;8;_D5^>KCFE3=-;J#KF\BRL5Y)?TQ_-E=G\SS#B/^4B(XE&Y%4ZAFI
MN2X^1""4G^*HO"HG6UMHW2 U2SJH_1ZS@Z+AZZ0#!6D!5<8H M36#X!-I&@*L>M;ZE-2=VYJ0:2/4:2P9IY-?
15.X^OEZ.5U^6P5C#?="&- MC-EPBA<%SK,ZFB8\HRKSNL3%UE@^C^29G_1?_31:1+0%J^YLN6H1H/=7C
MK(T)&UKI%.%O^LH>R&U*6SH93\$!6AK(BBA MZ\I\XE!%F2M4 OA44I-ST.&A-%@*NPCLM:1ZYIF?
UY_ /F7C!=.V10.*O) M6&6>_8I!\$1\$73P3\$3HC(=&@G\^+GCV>C""7?61C*M,SJDM=9I_ N5O>IM
M8G^_B8MIGH;:3: MO(+OI@:OH;Y\MO;+57>X_S4ECD'A<)#SZKW'
MSIXDPZB)2!NFK"J># CU9IX^AP6^C3'E4!\$&^QU JS?H0SL% 6IQ^IP M-
I8"&N.W<\$JP1.KCA%874!E62#6,2;2F<0SM5(3J^IV;)DQ7)R%)\DW MKTT(5U?A^L,T?+IXQ=N#S7E%,1%:C
QN#H5/\$%T*M1R5:UD1A>UJE:N-1C MQJWW'4@OLT&\$DA*M/> I^C&3I3-"E:1FND@F1T F4YG:5TA(4M6VBSMGJ
MUC>LCX I?NQ_ZI#>6+H\#H=#?#ZYS\A@A"D?M\$B=#3Y1+Q@KVC#166H MT_NB1Z><(:U'X<8 M0?U7O9Z?
9COEDO)R)HZ30YERS4^8+M;PAU\FU(AU\>D\JM.#/ _U+Y%G=2#I(N/H%P>45K(?#ZBY^PX'R_&=
1625LE_7<I.WDQ M0:<=\$5*!R8G, HZ&6!HS",^\$SE*47)IO+7LP71XYFFIA@,Y*&WR\$:%U4LEL@ M\$X&9/3"0V
Q0(CD)FFC(HNM2WEZP+M<I\K36S0 IEWI_?TF_C\Z M0#_..+N>V*X8\$F'PL!QG7H>#\$/H!:-L;Z/Q
M\$>W132ROYAFCZZG IM:Q*TM6.^+*JYI#X84L!^TUD?5+V%YI04B5D.KO5, MUQU0+H\T+63^F INF"9T-
U^_KBOAPM7KL/CYFKVY\UYM+ ??D2YMI\FY?IO M'=,
IHC'M6E^UVJHK9K3I<^8;Z\P7=D1)OI.23*;N#DRO.0R7_CU97/LHX> MB\$5)&SF7S6^I=T9W1_7_24I;)\XY\+;:(
<5MI-I2G@4-3&H\X4I^*S>_I MW9"-UGIN&+X!@:G07AVG+M2M&=JRWK\7<2H"LYOC9&8X&.=%(O\$))XQ7M
MYLES PHK60M;HC)Z6.PGJK>90BZ\$SZ@ML8%#IMPW69UNR\K6\;S-)KQ"V&
MT^IL4)6,2QKI12Q:ULO+AL1:13\$Y) 0F_)/%\$&6FK=76_OB*D?L2BF:0+5>.7%\$I MK-
IGINIYOKAE,BW5,&LOPI9%U\$^7!&0K%-"U4(=,N1"9Q"0,&(L(9@B4*#I MI-TSJH,:2L'M)#E\$1L.G'=%7<;&<>"
M94JT:M+^,O&#&\$JG;T#CES\$@-L'/@117*KRCY+V("4U:SJ^GBV6B\AZY167R/\$U9+QKB@9L+!8O.8F)@K92T
M5)1UGPJ@F2%%,BR%86,^,\$=RF6QH(4!ZF?>SJX3+7AM\$16>+!2YS:2.TIOM MH*X6\MWHC;:E,"8KA82&=A1)
>ZL!QYY,DWKYH#.XR&3...@:HGODP_?1Y M^:A.X&KI/>[N"01UIJQG_I*G\U)WPSF_J(U^G(=99?=-F/I+YZES2-4
MQ*E"V@N#!(^!2_/WINUQY7C;,*_#/*0 @GGRU8,/H*EX=O:#,I MP?VJAWMB<_I MA:T/U]=I\$T3A%I.I"V=N>M-
+FL^K?HFFERRBJ4?SB_/PE M^7_CQC(89P,<)2A?HDEC%7+CW\H+@JG4M#C18\1X)15"5;A,S6!07PGG
MU>IU6)U2>?9^G\Z1^L_*V3RTU^>7R\IP/*P^768!;7Y-ZIC^:;\$YQ3;^X>(^9 MGR@G..80@9F;,
<)B1*:#10XELMLR\U\O M32AL%17!\$DN% MDD>@.32E>QJ!CH4UPNHQO#5Q\H? ?WL?_Y#G_#U5MDDKQB
M5VJ<1&1\$&65&-D5T4I5KT>C.%2IV@M WV+RRLW/#O#U8TXR\$3X>)HQOUK\ M<+K^L+SA."S\$J)
R60:*&X=1!4I<.=ML#RA5M/>_CJ^H/4 MH/F)V%L7Y8D)G56BA7YW>ON!2.2%Y/+F>1>LEMWQK+7U-
<^2>T_+Q9%LB6E M""(A:64H#KR3H!&P6+P2)K\$!\L\YS>7%DK_D2)D&H28ZS-?R'23SRR@BY% M(?V_IV(?
H2^/S(O=A8ZGSHN\6=IU?I&N-S,A^!JR*JTKBFVPJY5*.23!P M2%:H,BY""
(D.GL@Q&2Q9AM\$DR9""\S7W=2BFUJ@O>2,U^;O@:(ZT)&\$ _#- MV\I0*[8G\N,XDMAV?
I@QK#R9\A3%K\$6K@3P5YKE3(9RH\$G;\$.-%&ST#223 M;W45H/J32ID#%C1\!6U9/K-
\$YG:) =EY*!@IAH4*QF%#@&8"+HD8R57HXN\$ M38#U9(U
!G&YI70H")FR)2\OIS_..FJ=UTD@L@<I\$B2U9\QCQOVY_\$ XMGRPIU0RIH^"896"@U8.
G%&PW.A@B2Q\SIHRBYC+ZN_"JH M@I>B,73,48SM3F>M>PVU3HQ7"9.MF>F\$3P7%(C)K(5IA#
YS_"ZK3ZE==9B9M2\Z=CNEQ_GM(8\Q*QD4:&Q_ NE6I714 MPM'6
#F0U7)I&L7:W8S^**PNV@ZW(!":5Q(<9Q@K^(5&%G_-H,3J6:U&@/! MT,I=0I%-%%_L4-
*7TSQB\#V%50GEVFFN_R.N5 M;Q1!ES03_8H/"H8JH/0,>LU3+S% QZ"%3?>0\3Q\<'.CS8CI MRM.<@FK@F_?
M2)ZB\<.(KY"?8>8JZ<\$.27:"PL"%+7I"8!@G;JLG,\$3-@8 MW"?3?
YQLC_XOI"/_ 2I2G<&5:1^OR_/7ZLZP7S93DL_K17GZY?XBK-E=, &MT&X 2Z1C5&40!;TI5D=C1C\?VOGD?
E1\$CV)WN4HJ1C^\$O\Z_1?+ER^NX&#- M,I%#H@!:=MQ*1@>BP+,243@N&/2\VVVC/U=\$SQ"7G-TI%OAZ7G-?
5S@:OWN M_-U.%A*QY4-\$FA%@(QE)L_QVO2,"I(TB_ZGRR0:M\ _Q_=Y2'X#\$^8WL%Z>
M%GR33G&1+9>AHK\J(89%U;NR>1(3IO09)^.2V+SVQ:AEYKJ.^?RFZ9CC_/2+SB_7I M?
7E1>7IBERI+PP.CQ433QWN8#3P4!1,D>E MBB\#21!\$=A>O#CF9CA@=3U#>-E9S\$%S+PI/
I\$ODX_45ONT1\OY1FS+*XJ M,17+=*G;5:X\8O&U;6FNF>"12\$PA&3/ZSG(E\$! MIF9!5V\$.J16?QGBU8E4 M.P5G5A)
(IQRHS&NG06M")-JF^-A<1V6!)70_Y9.DNCYKLEH\IW@IL* M7!EFLW%@_JDM'D7M%4K'DF IZEB<,O>-
MR.L6#M/6'YOO UT2;4XIN"/I E M;P>P.KT,Z6,HV6)6BUM@&PS;..IT4_8, 0HY4AR+AK&A7/K&Q@U+0J9PJD;
+94(Q#D,R")I+I\$+JP_MIQL;"LHO&V*ZJ>Z4XD+(=+<28_O5J^>%3.C^NH(0L)M&R*KFEM;W? D
MR%:214CIBQ!A\$IF?CWL8#';(G@G\NKY;SC\=5.WY>;9 #HE,H(M@6&A02@C81 M'->R=JG763J?
@OHE/S;U\2O1,B^>47=A=19*MJ\?TIG#T';DZ?QO>XO.0 M_D);5\H8;4Z3ZV=2+Q,R0\$3%;((4-
0\$D&+XECB\$07PTE%3L>T_BO=T&O"@ MK-T,I\VPY^J!>E2I:I#LWFG1K)@F-6@3:8 M@I,BEOM5-
I;YU5^=ZX\H'BS8T:E4H\&E&_D4GS*ORYY+4J>+I=XI=T" MFZS6R=<33)0\$2NL SDL#.6KFT7NCXK3N\IO.?5
Z..001R=JW0?H.W.%;ZE M\$ZB^@CXQ\DW,4H+=I=F8R\$6LC\<+RI+0_14XE\J-DT!\S\X\4YNM+F?615
M'6MA/ER=+O)H=4:&23AR;86W0.UONOH'T5\$0>A8GK;?W&: R;Z!>*6G>22\$S\ZX68RN/0EGDY
MV5H\$XDIRO:&@#-;SQ\$=Y4MDZG(I5\$3.CQ29+DM,=#@EHL8GKWW-BLU.H(M&=QA*,F\G#0B2VROU6.N;
I7Z6V^>9R@K.WW26>O-/!+M>RI\$TS*VHL\$V3!_ MWPHQ<+YP4M9<7"
I9>3GZ9O(*43C0RQ*%W+23&2UX:HBEYP,<\$YVMS?9:N?G M*_#1712BV44W^EN(9A<6ONE"-
"E")XMRD.K+;"7H)Q>I\$1':TQ1'G;3_P(I
M'T'LO/40C2IR'M_4BFH#JV0C0L36M&ECQ+S'0C2A:/1)0PGH09GHP4>) MP)V@+!HBYQ2C.0;
(_QA6AFX'X7Z8Z^4MVAU\$GUW&_#--<9U0ES%@FIL>1 M,2W\YW !23; MB_OTN\$OS<I5U\$IM3".AY.N+A&_>

(6ZJ^HM%C)W.(NF)9WQ-D0E"N.YIN6#WGN\$AQ>1I4+J.VK/2DM."D8L%0B-M?BU)-+HIO'2681G%IUX;
(1G%Q: ^Z0A/MCJH)#Q(57=U7PKX5!P8)7RP&BW&M20#XWPL3SE C/+O+>HW_ =6Q17AV8FJBE-
(, >11"5Q2,EH;SEC2=5M; M8-G\$ZSL0\BI#=#+, %>S\UB(AQ0M/OR;B%
MQ)DAN23N>C.E;LA_ '9<1EUXG>0@#2%EAD9-5SW4KQMJR)5461A29H9E(H2
M/H'@0Y(EUEB48WN^/4Y/F_ /6>ZQ/#ND.P/7MT&@YQ>G9_FRL_KUCYIU#V/I M)*6K4C)HKKF"0B?@J@JK
M9<+U^B22IN>Z3453")/(0%DR,1!HXL>W66[A>JUH!NP\YK.G04W\W4-896@>5:9P=7
MY^>I73Q_N*L6CAWVIN=6(!<*(RJA&AW\$!G*AMXZ)3-HJD6!@=;WH\$S.I: M->F98;2-U^" #N>G_
DG2>#1S(3M\$N14"#6I-%240+" ,##*1B?7?@72P6K(MKN*>X976536)Q=L_ .IQVHB_ BO=:Q,5I26EU@OC:9GQ7ZI
L.SL^7?I4KA MI^7JQ0KSZ7FI!SJ1WDOIR80";&O1V<#!D4L#T1O:X4 ED8G+XY! EWKUA.0 M+!KSN/AWY="/OEI
(PV2ER_N8CKTTP^=(WLK-?+M/E;J3OWFR3XR:R8_2Q M@\$%+G/1D^@.@B17OF_0WMO1OFP7X.I:X?
9-U0POP^B+J+74ZNI/I>Z_W@O ME%Q: @'2KRP^*Z(*%E&7R/\$6KV>AP61/(=ZT7_!:=^#KL&M2+L'Y'.EC_5=J M?
>QG56^2G\A(JI4GYB_#*EU#P0DS.QKKDD8HT^N M2<"^:WT8+_H9WIOJ05O9ZC21>3X-KB.EJ\$>)WK3-
STK\IP5FV7(>%F!/:^I%+M>#2&U+92IH.SL1->Z*9%9
M,*:"9'3NN>3(R#+62<45BV'T_0IN+YK11DN^(9V=\$=67Y^I^XNU+#+&O) MX_3MN_-7Y_6EY!/:^,UT8=DF"
RJ5>#"4'1GL60FCAKM+7P3T7>O#.%\$W M%*\$[ZOK]!TY7IO5GCC.%;V4_ THU%*AM\$J1D;7!MIG@J!3B!GZA=
(H11D=7CT(AIAO_:W5'0 MEZZ21M9Y#2GR_37N^49#;Z^K&MRLI9@D@DUT\<>3+*6@^>D:F.36;" M(+H
IWE+A'1O,IYN#9_NQ_HAHOU5*:^U5IXOO\$F FM1PL?E:I-0 MGKVSP14.I=/%#3B0P_-#H!.4>NBR?(9S?Q6;
>JIV.A.E^><^YK4L/ITH M;5.1R1M6*2H(V)N_!190!1YZXSUF9X?&=+5.52,&"Z&:/K"X\KPX36?W7?
M>DJ47NA;H9K!A?>Q6;Q SPI?>B8GV^?I^KV^_!6*^581%0U\$32Z NXH0D MVB7)H!VY-NZA-GIPY")U)PKAFR
MB_!%I8X4/82*^MEIN#WJ3=M9RCM-MGN&R7\$X_>MG_ZNNVYM /N'RI'A_>MG:9PMO4_IW\$/%QK"D-?
QLVET+/YSR:MDIU&U9P-1)!L(EI4(8:<#5OW&G&M?#.#H!_I+6I!^8^WSDR]>Z!@.FI!MSW-
?/*5KP&358'9.3S"C)1Z?AM) L MZRG(+X;IU2O>+^%1^JO:L)I!>3N=IEYWZF4(B)-@1S\H_-V^R!Y8U2E\ C
MI!J2HGSEJ>M6_\$ _U!T\$!>2\MY40#+!,^<,F*QI:ZPB@RMKVAJ++ZIH5\$VYIX_Z+SQQWR?SNPAW)/G
M'U8G+YZ=Q)A_!HZL9^ULI3#M((A2XSJ)!IXM.O++U'7F/7V^7' UV^N^2V M_G2'UMHJOOP?)PEX^7U_#Q9OI?
WYI\$15"5:(VIS#VT(MI_ .@>C^?>BOV> MDQ'UY_HHG:45(#[O8WT_VI"28DD5B#AR&BH6!=ZE^C)"1:0OVZ?
I+2JW M)@JW\W_KVU%2,UP,/C#_G\J/P77+BY,EYHCFV_7LTC'Y570;0 M,4,RT5=Q&EZ8_-N+NFSQA+X;=F%AI FT
MY#)I=M.WJZJ(E,Z^/ARGXS.@(-2D@O>00Z454I)2&7HU)/X#8_RM/6Z)_MFA#-<X\$?<7%1WU->@);:T4+56-
W)YS=A%I#-HQ&T8Y@!(JU_.45.2.FE38AX)2C=Y)D(H(-T#C)F>"MQ.M:4HML-
FX!O)DOU:IB>QER=A=@'3ZQF8&6.'>=K.\$0FC%+GFPI; T\$>AO M"@BC46!BS*3A6\V3;U7+-
EO0FEV(6,^9:E9^>+P)XA72Y6%^=GTYYA\IK M*#EF(\$.*@Q.N
+.&T1GM;)%\FW9#FK_ULM8'MM*,HB\$>HUU_*\XOUZ0+7 MUY_ '9<.06E^1*=3:8Z56"N*U"P0+="
(7G;)V3NCA7:F^!.@0#99NP< PA_*MR14'_7.O#)-V&_I/5WAPZI#S2L7&=DZ)REMPPR#8;4*^ZIN4+I%);1E*
MC&)T!=D14#I5>IB9\5V\$.Y#I3>?=[Z-4DC?L%3G0G)QJ:37/ MSG%KS;W
YY:<Q#=#/MD9_ABY+KN%;O14WJX=7^<@X;K/VO<T/N^*DF+((M%8+TG"R%K!)9"AFAE!*SE=D87R81M66"
IY:Y\$0G*%K_6_C_EJOK^7E0F%5 M3MGD"#+VG+8.0A?>BB;X#X2)! "@!SIAS,?@_ \$T0*0#7YU7+^I_BJ?<I
M2HVG@!KX'&= W.O!9;T*+3%..GIZT3/(A2\SR_4\$(2 M1C&B\>R>? ".YR\4+Z+5,2;2:NWN#
I_\$Q=A<9WX\$C4Y\O6B%XB\&O,U)6! MS X+9MK< IHH,3T8?+)Z(-DOAPHL)\$/#.PI6D3W?LETVAE!16^LB71UB
M9+AH15BF0\RO-XF"W%.D8I%;F;AQ-N<4)YWZ!?'W>_#/Q,1RK\A'1U9>+^_M7RI?>#A=G=Z8)DPYK=&#S;+>-
H:UQ,&7,K)THLOC")U8=C'ORCG>+;1T+G M;I*
(Z"_"6^0G41KG.080ERUE"9;W2H"+\$B,Z)1!G3P* @^<;R,MZ,4!9G<<*M?23G_?
M%E<>K/I\$;GGQX73QJH)9CB(N=)Z\$3YLL@JN%8@Y.I*SI6!T+*"N8!;,\$ON MOM-&XF%C;IBZ\7ML;
I&I3SL#Z!#)YZU\$P%B'46N#="@F! M*!;-)5;D512)! *^3BE:T%ZJH#5>178KF/=5,Q@VKY>KC9B/K_!>?/##Z?K
MJK.\$^H*GP)UI@2='6^3?K;A)I7^<5H!K5J_*S!;AWE\K?U\U.C:B)0K(
M(&GKUDZ"LRIETFI(Q*W?1=A2FXGB09;\$I&4I&\$^I#MN8^8?)ONPJ"BC& M4XY\3CX8%)99-
UIOGFC_F>:VC>>W8P;A9PY'M)=;C\ S\O;_R70M@_5ZHL ME.82;(DUVL.HKB\$9BP7E,0(MKA\W%W@IA_?9J-I@EI
M\D->E0ER<3&F)I&^+QH(E-0.8JHE#0F5IQP?GA*^R\X#E>I9F-IAH)E=PIH MFQI_<453?+NTTO\B)>U9IV-2@2?
@2;PIQ>64\$IF(-#!'V(0D:71>I0T9,2@ MMCTB9DIUN1L\$?CWR@"8 G8FIVTGH\$ NOPUC?M2S4:7G(I<)-A2F+3&!
<M-2;)3HM:T-0@U*GTH87J;@&I"MZ:I=MZ%;NI TITKINOAP<;I>2(!?'!UK;5@Zi&_!W)07\$ZN<3-
;"&IAW">T)4;3^0VE>ED80?K@5-7\$+\$ MG&N9/I+S6MK4NLAH\$9_QZ+0J2_YI'M0\$&<"O(8%F;807I
U>G<^I2D;"M MSU<750CUNOJRA%36;+20&=C_84EDG4O(FC#68R_VRQ&6M?P-Q(P\$F8H MTG>+I;I;X-
TJ<1.PS60(?PG7TIB\XUCU?;YBNCZ=NPB^1FTXM>;S8CK\\$.":IY.WRX>5T2 MG+(R
R"C2,@)/(B>!)T>W5N@C63_1L4" Q0978HN%:F&IW;I*JHGM\$;?(GMG,\$TS M*+M=W-
9V/Q\$EZ"3RA))+7'EZ86R"?%CM)GET1@^DNJF_K.E\$1,1Z8D713, M<+C45;VZZF=I(K7PT2H/+GI&)ZC30_Y4K?
818M;_IZU'UU&I_ ^Ij<^C13I# MZ\FEDEPP7+W2I&\$_D9R>A5?)T%IHR=>YPI_E4V<1=-;>R^&M=VGTIM_\$
M*\$S@_MIU;*VSRAN;5A7IZ>TV>OIHMO)HN9"Z^5ZPI:/I<7^ILXA\7Y+%?ON;Y M2?E^91=C_NDLO#VOV2I;G(>
<:Z7H'E=D*V;P4KW&C@TFOEN9=R2*JFVP MN\5DT>175K<+O5G4;5H_7M8K3;-I'AWM>;_0UYB\OJT-
NLNQITUY;Z+ MM)PTS4I"@CWT7UG &H@I#O/=I=3.%VHO^9F<;<;OD=0L&IUL3E);S@#3)DP MJJ
@J<@I>D=BGH-KHP_7=VPS>7=NPB^2W=1_6BJQ2F(&#REU6T!\$A;#3ID-MYPI)6L31SO5W<<_W\$UO3;OAV\$?
4.%S_8'Y+?MT/N#Y\N\AX4)IBX-7+G-! MGENMYL(D\G_ ^T-4U\W)O^":R6;8ANEI MI(41O'U5%3J\$/L-YL!5?-
L)A\$!)0)*XDD:(01E(M&TQ&U@N8OX-XOFM@WWJ MPBZRGL52O_2\$^=GZ"N.M173=";HVG!<TIT="E*
(3B#3"93&2Z)%KY<(O MJH#V;RV;X?!"P3B6@%GS.>Z\$^ZFA;I1D?QUI(=@=NR!HOEN>QNPKOOU3 VKUWR
M\$-2W\$!@8S6SIL!\$RWR62P.@=R(9HQ.P0\NP4JS66%<4DR>924E#LI0W+^ M/'R163JL@L;MW\YTM_IX">-
VX1DF+1CNP/I)?+YB\$\$. Q(U@3'N=M^>CX5Q/(DQDPO40J&?1*^59;!)9X?
OL!%;12#1%;D)064*2D@'C3Z#U\$3=2QMKHR25"QUP.F>(7F;PUG&C7/(A3^IJU!C!>XM1HA!5!FHZN-M_!9KF;...
U^F_#I^N6J^G+T\$S_S-I!+6;2X\^M;,>I^I05R7I> M.Z(BT_IG@>+EN#Q^YG7W\U-IK)3GG-L#5OG@7?
J4KZXEU8;7UKXN;O-D# MUW0ZU&(<@))Z\$7I/ I^+IY2.0\$^5I<<+3?
I48)IO%6@C2T8JO6Z/=#=#/E9,ZU_P+I)4I833M*.AJKWLOF(OE0H@
M\$8VD'S3*T??\$V!/_HS6O:SYB_OJS"#6>71;)/3&9<(E:KMY0*0QUPY09 MLM#
<))>TS?;I=_@O"\$D/\$.RXKWB%??)

LR+5=(D\YE0XG;_<@Q2> M'.G\$HO#CKW&^_B0I*!7WK/4M+L;*_LI)+S"19&E&&LO/A3UY:DB7!PS1!W(
M:S+;RCSZIG;ED-0@0%2WGJQM\<7M;Y F^UQ\9SFED<7X%GR MDKIR^654V+B<7*B;K+&2IER?R;=G"3
ZHU%P^M=13I\I\+O_R%SZIZDW_KA M/X7SXVC\8(S\$X&?@&*IPBQ)*0_I^CT\$+(T2\#ONWGQK-
JQ"X/DW=A9N\U M92=@^?#Y)U9W*FXI",HV/O#9(G*)1. M7;T:416IT(3E&*CB0)#&7XU_ TI M3)Y-.W:1_X>)K-
2BBG.@>L)B:9 JZF*6KA59"U:3DP?KP?3Q,WH6M:0^3
M=Q'UZ,ND^Y"4IZ_#I_JGZS069@A")O>3TRH51DMG9GUH583P"77AR7S-C9LT MT_YY'D"=\$-4:4H92-
L#S.FK@7I#QKAG1R1Y'I+V9 M#I#H'ED.C.\$VP0G#/@.U+%A_@H2CLQT> MT5VR!B2;8;IKX6,Y;"<&"#4*82Q
Iz;.564K)HN+I<5OW_9D.D.@>60Y\ M8I\$)\$_ ^7OCY87BVN I12.1:4 EY;%RBA:>DJ<_#_B\DVGC_5"^(OA:3-

KX7M)O9CMHTA\G MTZUE3,>1;C\2A\2,5FKK@5D7R(Z4#EP6\J3TT01R38J=H3BJU,=) T=TGS(MM1W-
M:WG+ACOBV>U0E7MIS\$Z"#XX#19)I&B%Y ?+2TIGVAX^UOW22,BU&\VU MNX>,15B,A\T/6JR%Q"5M:
J,F>\$CZFDQW+M#I_K#FD^Y-H/YOJ^T\HO=KY M "*"J6+ONRIK44<"3\$2FCRR\<,\\$RF>N#I\#ZI-D(JHP-
GO\$! CFX@*S*,A^ MR*HV?=\$67*)SIB1')POW2MH^29?G>H@R>Z09H/L&JV;>X&,"TTZQM2YM5
M:5JLP4MM@.D<G,,&^N\>I3?<#&JLI3L%US.4>=>)M:HF_QPA\MG^4>G>+J8F?
Y)O:DW,,B01C\50L_ \LPY-[491LM)\I>2N32HHOR=% B;XPY\$Y\$32H,N8N49\!NFN4WLN)DM=\$"BV%DIQM'
M%EV*#F1@4DNGG1W?D?J;+J\$T3\NDFXD9"DEN*?PP!=6QEB_-B;:%H6L>(^H
ME2^J2=@8HP6K+;^%5SQXGFKY)14WK RYKI\T.G5L2005%T%NK1/>K00?AFJN#LQ,ORG%AG#76T7KZ7
MX(GJO)-9PV*3\VC_1E;:K;:9T\ VA2L5HINS64Q\LJS4^G_D\H\IP MI*3BK<19#
(92BZ9RB"+4)SLO%1FBC\5S.IC0/X\RGRO2Q.NNSM^=A?I^V% M^INKO3_"ZK2:T1N(27(T6A\$F6BRH@AFO&-
WBX>=)&T\T(#EHRUS66B%1D'1MN<9;+(7)RL=^7 M<4QJ^L0Z,\$.T_WI%/ _JK WDA^K\77W %!
(=YZ.F\27:B;1=%1FPIUSJA^M<3\=<9A>WL5QC)KU:YFB,AJU97BB_ \$U+T=+HK+<"9>M@;Q;+E16<L.O?I
M&Z4N&-&?H?DH20=0<5\$6\T@40E2(AXRB5Y_5L\F>,I-5R&0\$M/4*65BC
MV6C;_>D4Z"MW:|^_*_NS"R>@B,3>XKC?@Z\219)F27_*.S;.)#_6_DQJFWQJ" M%J:5AMDRP?ZIM?%4+ ?+<8:KDS?
GYIE62^<5G<[A_#.O\VE#;31\2 D"N<4 M;) M%S;^K/H;J/V;-V-Y;"O)(+FL&LN =:C^!(CYH<0A;2Q9_ZR1JQ43:KW/-
% M8P.S/\$G/AD=)L_Z3\$T91L0LN84?YOJKXLONP\+_?EJN_@ZK3")1/"\$G_M3P\J\J1U3)!\$HK(415/PY.C;^D?_7-
_NK2_P/&^6)MA4_HRT.?AK/I5B4S" MH!(.*?@J&?K:1*"5)E\HFN/IWJ_+8DV&P\I-OT\I^TA?DDJB@31@DY
MOIKWYA@Q@.P\$95A/!=E1C!*?CS:H\6\813N?O\I?-%VHCD)"(+F8E_-IZN M'=Y9?5%M2#Q6F&!"!";8X^EW
5&R>WC.RM;B#3#;+6\$6L"HJF3;<6H>0 M-E" MENBY3&A;EBG_!N+V_P_TZ;R3CY-X6Q(FM)><0L%7PJ"0I
(+P%)VPKF-LX M\T924KOP3A77W^4^@9);2L.V-2R%3\BN\)=5N)U_IB893)GK^Z25J^0%7 MYX\N;PGIO\319
U28@%EF85H'8*P3@L;68^_1<9((-T\T:1=#B?OMQ-_)R; MEZ=..YRZQA\PG5:G'S8\0KE>
IN:FB,XQ;71R(.M'5:QEDA.=OU\$JZ5/F4N1) MG4X'..%6D\$IQXS^YNRH16,8'.C\307^>WB/MXBO+ABF8-XE.V"
JK5PIC=3 M8_ ^JL*,"#N/Q61'4\59\6\Z8V?G %?&WTHJSAL7'90-C75K<_W=N2;_ = MJMXN\ W/D332/5ND=IM5>
(O/ O.FXQLSRA8'20D-2NH 4: &IGU#F40\$YNJ M-8??H7>?FA9#F7IZ+Z8SUXRQLSSTI7\T7;=>^JLY?7=^TB\K(I
(C@4*1 MP)H1DAW_4\JS\BBABP^)>R@;_9EH\$)SE!@A3_MSHX+9L.T?DO;9C@&NKLE.
H\Y@:4:.F@S2YQ5&%"JTV"#_GK(6DF6&2\I^M)WNO@Q'07>09\$=WRMQL;.)67'A\JR9*)L68ZN9
GJ"PL>_%L_VZ&HUY\&.@NE.JHSME;B\IGTADGVJP**0U\8TU,Y9657*J\F\$J#;JW9(+M4J^N\SI**CND.?
HNB;W87_4C\JZ>G=J\3.UX6ZQ8+(AVT&HFOZ<6:V2 MIXM4QILXK57>MAE.@>ENR8YNA_E..F&>X^)\N;@J
<<5D)QLRI\$%<,PF_E5\ M^17F06R/NMO\LCQ_ \V%UL/Z%I\UVF*! M.C4^@PI%0BSD\$S*)5GJ-0IMI#?.VS7#P=
(^0L.BFF!MOI@4JZ?;1, M*R\$P&X#^SG'GC2UJXM>J98:CH+M7LJ\I8FY V08H6W.%).
<@@.PO3&J%<9.*C8^0G\IM*TIE8J^#XRI\SI\A8YG^ND%N=-D3\JP2M6M MR%CP=I2!-
#H@BSF7M(\UYCA*&COE6R#\I\6D4E&J@*BN#%N!=C>Y&H<"K M4(L:BABR+*CLM+0^*I8@JL"CHFE;I'LUO
'SW2QI3\LT=I;9A+;B\GS)X6YT@'\$R;:2\$J+BD ME=4GG)RVGJHZ*(I(4Z\#6M/*KH=I@NC/I@5\I2XL\AFN:A^9
M\QPI9#;I\$&FC*9Y\MD^A>4C;I^I9M^'<@/W@6>Z5;I/CSJ@;Y_+G;IRG
M;:X45K6"Y\YU\$16"YYF#H)4EG5Q@4^/EC=%/GN>B38X\REU;Y%A241.. M5"YER^JZ(CCN\$@>@3A9"/JW\IP?
@'SW_5\MY*IU\I(M(K)<DC47/-)3)A3DS7 M=P3!\$B:MZWT"Y?>,L3C>^AHF.Z3:H\TSAB98(KJANMP \?Z6B*R M-
O8E3QX41C(*D0NPO6@=650ZA6DDWQ_ZX/GMDF6#VLYPV/ 4I+?A/C+1D0 M!C &#DJ62'@P0,S96_+KF-
43D\>C'WPY/9)\L%N9_"K;B;Z\LE+D_=0.) M29M\0_89&2W/J=JLAR5@/'E39%&V\
6WQ_&#CNDVF#YLI@5X5DIT*V47G M1(1L=6V66I'4KJXU\T3:N:GNLFMX8^"YBZ9-
FCN#WOO\YK'92;HD8R^6*J0 M2<_I+2Z\YFI=H8B_#W\7DIR0U MN)K)RKCO3&H7_V",%<^<^<'PQT!SGTP;-
'>&O8@_-B8MS\7G_ET0:CBDG\0 M@O4UGY%6&YT%)XO0BG.MY633NC7\P5;J0*X-LCOC7P1*M\$ %1%+9#)9Q1%62
M1Q>R03#%;)1121\$F\I#;:SQP#V;UR;;S=Z0R\I\$2C9_16YED<V G\>'3U?R OP M9\$%8Z:Q3\$9V?>F*W)S@&LGOEVB"
LPI6Z6E*EH(XPU8%PVH7\$19;3QH#%Q S MIU\I_<N7R\<QOD-TKUP;9W8\$PHIN@5#911%2D@5\$J?
14\2FUZRQ+M\; M\$GT;LQP3&0W2O7\MF=H;\$:06^ \IRLO>H2""FKJTF\3D+";CFC%N;@T3
MKR;;QP#V;UR;9#=&2DC4+UW4B-G)L\$S_<G)M\$9B\$C61#2*-B#A14@3@Z'M M"8Z\I%ZY-LCN319CPC5
Z2@4YDOFH\^UOOG\$ 5C(+WDT1-D;521GN"8R" I M5ZX-LCNC9M5;.)TMUI;YPO\$6#6090TQ205<\1B*TA9-
S3H3W#X9/2+M4%V M?^R_08H\AS+%C(15A09=-M/DIPKDC%2N(&=I@-;QP\2/D&R#\X@6@W? ML@8JJQD=
(XQ#\$;\$:6\!; H4-&I2\2GOID\;LQ\WMV0;?2GD?%6=-; MPD.A+=3..Z MIM0.Q@R1">F\$"3KRB4?
WEAF.@N\>R3;JH_1GD_?6&\$!(RWQ" M!"XSK0Y=H%.&4!&F0%;&3L7O\T'8WQEA&0;?'&TSA3_/D*%<^?U:N M7;-
V#<36EB%1%#)0A2\(&>).YTF\;M;XQH_U20;3#=&4KCY \N\$BGB^4- M'92J0%;<#6&JZ(W\$&AIP'ET-
KB;.*FTOQ@L\GN\$^>#8(IPV><2??3"M=W M %G.@XLH0(=;B2E8 RXF
Q@T9Z@2.VQB-.7AX(=/<))\P1WALR;B^7ZY_I MOUG?(-I9!^+H\Z8L7Q0"JGR/-'\$S':Q%B86(ZP.?
K\4PKT0;'G9\$R)?B; ML/CA%_>:IUS\$EVH*#"D F&J_U011UN?IRN1DG4(C)G\%C=\$/GN>B38X\@R0 M;;
(T7\LUW@#J"31#\$(3%:EJP5X @H&6OGLZ\$;ZX?6N*HZ""6_- M2K)JL;-+
F"LR6NG;X4_6((5@:'18)A;8=.F%"9FJ;W\QUBJ_@O%NV#\$/G>I^F39H\HR72<;
M0TPFUA&A.XA%_U"2%8C&"4"C8\I"FC^<PK#94_*N#Q)\;\$6B<03K)0%RHGB<#&-L;+L;JPGS0\G?SRSKVY
M\T@H*67(HHJH6>GOMUYUQ\XG3;RY#9_#*<I/S@>^V49X\@SG@9;+W_#&) MI#J*W>YIC_Z
T\3R8&FB(PZ<\XFOMUY\@Q\$-PCSP\O4\OO=W \$F3M+&# M@XVUS\WCM>2D%D"SW@POQK*I=T?#G\PI!?'
*LT%P9YH8%_%;HSPY.55T>D; M8#PYTC2&0/@T.236@%&C&Q^L7V20Z>\\$R;:3?
ZU+-8@W'B(ZWMDQP\8\DVR"^-W&,>_I#<C\BZ@:0 M0V-3M
I2\$=4'X\!%PRRM/7&+1K&)&8(AS\X(GNE&>#X,Y)_OIC_%L;GB9MY;_B#)JE;I@V;V-ACOF' MD_R760BG_54MHD4
P2&K^XOGBB=IFC>Q7'MK^".@N5.F#9H\8V&.LX>0<@XN MTU\$;B2,Y\=(E".3K@4\$;%9;L^C-QPVX_2@T\JT07-
G\CO_A\2D<5;26A0 M^\$2:OPA2X_B\$;%LX\$ZUP%O#P'G3)MT-P7\$70QJMKZ/ 3E31"H"H.B=:V1 ME@-
\$#I&D+IP;1>DG7@OW9\T'D>(<=<V7W1L0TH>?J=)T^W""*=&040\8@_MF8*6\$)-X'RQX+3)VI8D?>Z\Z7NC'P7-
I)M<P;(#;I_7+Z\MU96;3U^V&1 MWMTJGV*%2MI2L&3;M;H:B=06Y9HMY\$30\W;)SETQD?)MT#9UI9547^
M\MWB_7Y\N_%#2AE#*KI"V45'WWF^<KRI/N^4O/2\ICVOW#+\IHL_0JZ_ MYL61P3)\U;
IK2'D+R2LCI%&O/S\IN7:DD\$#S+Q\OCBJR)J=;9P^\$/G>A^ MF39H\@R_-2X?
0BJ*#A(3:K*+**2K2_VE:Q=TC.@OY=E:KN\UO\0'.G3\LT M=P;(Z'1XN5S@GRO\$VY"="3(9;X&1T0
J8GWB20Y'XC'SS) MO1)M<_P9'3/&\$!\$?CT7CHZ/@+7=2ZHIDYU#<-PGEI26R4TTR\JC'SS'O1)M M<-
Q:B4Q(^0\2+QVDS JWI?GJ6_H.H-B\ 1"RI5SE+4S6&/WB6NV7;H+DS M-") (GP_R0; &IVNQ57(^"I<@*OO#9*20'?
BK\$3:6X_?_T=INT07\OXTK_ M_GRW7"WNV@F1?#EDEGRZD<@<%%&!RR*!";X)BUQE;I'JY5Z(-C@=# MQ-0#3-
SYH(MID&B45Q3Z=(R9_9*SH;J&PBDHV4'5I'ES =#6PL2\$S_1@-2EEU\$G^("0K\$YI?;9GA*/CNE>Q#
MOEWG\$IN^BK\^HZ5\#TIPQM4CO\$2F<02F@J^I\IRZ3J\F0LN\Y\5+ME
MAJ/@NU>R#;X\WU=N=IT&*DFV871\DF^?2.C.L.Z8_?T"\ZTI7-FA_W\2\GN ME6R#H\X8V0\ 5BW\8?D15S_1>
TH2(_U\$9@)5M"&@Q\0=IU;K@D*6T\;R MON""SG^O\IL\$ISZEE.K9^5E8G)^N?WY\I1P8D8W6 (#
(&QXP9(2@&N\;04)\$6N7\16:E,T\78#5& M\WB.>R7:X+@O-;3R\H\IP\$FSB7F4\ _Q:1J55(12TOU%7K;&6Q:1K+I?
\$/MG>*Y2/8AW\XS3YE);W"NC-3B.M2% M9\3)3MO%M\JO#)0\D&Z#I=IT>;_W2\IGW_ F\A*=IULB\;M#_TN-3\Q;ID
MAL183DH4Z\IS\$8\LU_=%SW2_3\LVA>DY>PA)BQ2#R^<30!*G+N#1.D@39#%/%7 MU@%

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

M+I2F<:IUUE+V)OC]=H2!//^7*!3?#-U.N:G7I 3,8E*B!*<25\$P-2C15Z7I0<:,H/D MR:OFA*^3N4OC13;I-
E.O(4:9HPN4\$<IVM]<57^UO=H\W3M9&E%C)<=#8>A85-MDEI(1I(D*:/N_OAGR X>&"ZR=[6OH=
<0VL^I3BR&JXFC1TTETW3@,4NK?K MC0K1H\$EUNM_)MF^@EY';/C9)*=<-
WM:W1#KTS:FR(BTTF1.T;1/%P1H M\$81"/K:.\$0^LYN:|D(W=^|_BGM- G7#1J,
MM2W2)H7H^TO" T8\$T&JK/ADJ K5>3D^1&XM=-.U^G(YZ90:6O^T/SJ%|_KD_W MJ?7A 986DJX8>F=
<3A4./3R0)!T_7X45MG@L:3+.B9JAZB)(I;JRODTEU98 M.^-7T>R(<.Y(4-K(
)4U&G,NKHP=-0.M0:4IO0V45*2%TCOS^R/^"!M=-I M#;T.V+;<_FK!Z2IK/3Y_=-/NINI\UB80\Y-
&FA(FS6M1@&A>2\$^GULOQ;,) MH/F%;;-UNSA^9U9U2^/#9S?ITE>IYO5.H/>:6"OA3-W6/"6(0#>A<6J%+
MT.E.EG8.I*^>.*Y&1R0S@VK/N^WXYT.I08(F*+1R=9^YG0_-2L-134H2!8C
M8B)W4+DP^6*/Q*^=9KY.1SPSRSEF/L\$OF^LC5G0(96*W4:(0_.E1.9# HRF M@8M)IMB:RVZ^T>VYI+6SS-
:HB&1FS\$P*)XAY5YH6/HC\$AMM\$- \$ ANHABR\ M"4X:/5??-9*)Y&AV1S R8I=M%G6/J(ZI,K!:
<082)Q\$@I',8:14Q>V *MY%G7H?BUTIS7Z8AG9IRL8J*+LJ=J32%E'.SOINK7SUJ2(=3 A4=BPY\$BBR"+OY*)Z*8OK
M8:RYB.A8_MJ9OH)61U0STX(E/U^=-/3NX%D#ZBL)@Q0>P3\$**MZ5*8IQGOP
M7I70G\$BTEVFN!PML@6RN7D=L<|_CSKH!*N\LF0I" IF*Y BDW@=UPK69V&J MD;-4.LWV8(\$ML.W5ZX!MOPN/?
74:B? 7VNGQ:O_FHJOIH0@FAN"MM",_O3#&-M%S(6C9,0:16NYD)'<(SAGA0_&K9YJMTQ/O/#8"9,|QY1.WTC3
M8%WODZ^B@Y2\$!/-MR%RTL:3) 4%#|9O@F:73\$<^|I_@D_IR=YOW-I"1
MCZ=#B9!=KS*KV\$>^DI F0HFD2=6MY|M>REXIPTOMCNEQ<:ZD1/JUXAR:*AI
M&R"K|&T4"1OV)A">P*MD5.EC+&9_B_.\$KYU@KCY'#/.B8B=\$YM>(A(O:54%G M+M-),|
(G"0HU"/,\$F/U.O.8M;\$7@K?!,,,28X8YL7#3L^&-C4BDI-L?5R)E;UJ MK"1)CX86H#.=OYJ=;I,9I
|A6V"8H\IP^PPE%/IV07;I7G|_'+0IU.%" M2;
|GKI4,J>@ "I=4HBH^IDNP@/I: ^>8K=\$1R>SHEPGGD\$QTY):K"DKI|J:7 M_M+-DH&L_>B+=E**N4X)(^E;
)FET0')GCUST1/7QWW/ST:CE\$9Y2"9K(E M/TITJR6>N157'X.W6DQ_MSB3O06"&=H1VPS8UU_Z9'69_O;PIY^
MMW|S>WRY>_4 3=-HARA4D*0Q8!&JU'L'FK62=F"R:FYMN^_M;^:AD?D ML|O|2_5L?SCLWH79IU'Y5I0H0H" T?
8<-/:2Y))36:@(AMCLD?AA0763ODU MI#IBFQD&(U1Z@\$KU!#7C+A"1I04#E(CNP)+2BDV6;6;_#0Y7F +;/_U.F*;
M%Q7KJLP_%9D/*MBF((>#%\$JG4&4F0)1IE!;:Y9WRPP!;8YNIUQ#8S00:7 M4|SNIGORV)47I0\$5DI^
IC207K7>DD4*W3\$;BA;:TDY3;Y@V_8(O%U@IV?0 MZXAM90:85_)37K|7Z_K@?H/U-
I0Z\$X)U1.D"2I*J:2C8.ACY11CGI8Y2S M|(G&"ZR=[6OH=<0V,W)FO?P2CW^K+_#XU=_N0P HFR|1@?6JE9H
5"7GK;_MC8^EA9(FIY(7SW/7V:2&9&SNB\$+2"EJRO8'0LO=-<^0=&)N@9T%HUS,7 M)
|LAC*2OGF2N1@ "\$*"NO4I.\$UD+X!DGD:'9'C(JY MN'Q!
M_ ^OUJHX^8'+&BF*R!%7ZEY=8&R1:3GQ5.OA6L34QVU=N('U+ +U.N*9&0;| MSSXXY)/#?O_CS=O;K_ |SWE;
(H964*JC0:&>U"DA6(&31@O(R6IQL5C*6OW:F MKZ#5\$=7.C+_'?#>_W#|HFIN'D#)&%1-I@_Y2OI=
(^C.V8/R*C5%#H.N0&P\$ZCX^>MRW#^>OA)#EDD:R%;;/V#6D)1(>9_QTR:@^V.VO>'28W=8'7-
8\$S WKE;BJN%XDD^U&0N4A& M02(3O!=EF.LL=G&)+=#_U^V|H@LG^RXI+0;^ MU&X|2P.1+&\$C
D#\$2\$20M?;1%OI"_:I:96AU1S-!>TM\$TQ87)X0QC^9N@FJ?5\$=7.OD1XG/LZ1#IVZ_O_UBORD*KTG^K MWUL,I+W-
D)S2)F+_.PH6BU>0WGR^TM=;UNB(9'8%I35>GW VINO_WJ/*I2R M 7**7%_A726"H806DB)(HD9)QLIDPI>E1-53S-
3GB&%FA"Q(_4;|IW#X " MF0-"P?5V=IS4S/9AOVK:4'K>_# 'U.D@Z\$+VZOG E:7-\$+R|PUK/6Q/-79/N-
M;+MZ4H^|CZ(8T.(O9+%;W3O4AD2)%LRB&"EUC)Y-UE&>6F%U5-1#% MQ|YYTH>T/<6?7O5B@V^>W%=Y9F=-
)|/*DL^?I *R'IHX'1,Y @B%G_G68WE MKYWL^VAU1#4O/'8" I9IBX69WO*D/H+3*R5=E06(?
K=K(4BV2:@ZMFBR"O:G M6AR.Y6^".IY61U3S@F0G4&8IJM'_D>E FTS.D5I/=B&6&B\$.*Y/-MI@XIR%K
M+|35/.TNJ2ZU^AQJ9:FT/VN\$9:3TCEO_#C3|S|C:2%&H<&VAB+F8FV=JY9> MRMX"Q0QMCNCE!<-@.C-NIW-7
|F\$S.(<9R:GFEZ7;_) 5)/>A\$VBX11IM3F MI^R^<^\$V0S_+IB&=>).QTM_AWIGQZ?7CQ_MZ#+)D!;D%@B6S|NS-
&6(AUTIX MKV+=IB^ML 6VV9H=\$N'H"S2^-!@8BI12^J%6'^_MK5Z(WP35+)V.;_FD%DOOMSJ5
^|_#)CIC19#_!R7X7E!_F15%I@!\$1-KY% M:2VVV2V_..%KYFOTOQ/S%"94MHW)W0;^S:N7.WRT)&(M4=H?-(C\$(-
M,9!#X&N)O>Q/H9UKAW|QB?7S?0W=CCCGMN.W0@I0HA42P)A+2S8^TN+|^%SJ^AVQ'G_+"95-
7XIVG>+S;WSI:CID);4."BIZ M8B%8(=!O5<86=0LB?T#@;+3"VAF_BF9'A/_.#9U)W6;IVK=%?>< 5JDN5?_Z M3V*K-
>?K^| ^;\$>/R"X3'Z M4UW64A;5#Z \$8XJD?^KMY#&V75 X|3UI9;S"VAF_BF9'A%AKB;_?IO_:7<| M|FX?G<12K
FVVD#&V\$O)\$MTIK3=&#&4TB:YBG^L|N+3"V@F_BF9'A#;K,96+ MAG1 ON+^I0G16!_I0C8H)-C:9^6VIB&H&D#8*
H&.DULMYV)|M5/-U.N*9 MF6=&|XW^|&9_Z_/"S" H 3YAPV:|;\$^E2/0>T*8? XNB&)*G:S&^ (E?A|<
MG8YX9J;:2\$P)2-R";X7F:4.YX&!!LK(1)V|92M*Y,=JT-B="SSR=CGCF MA|/L E/Y%+('1SY?V"B)4S&-
O#"H1C^ZL|P0OP6>>3H=|/J\$H).50?>XT160VY3V+;4H-40DK5Z_OEL.TI7&#17/U.F*;&T@+ M1@U0J=
(S7E%#H3L'R(I(@%'0K9.M3|7D(L.L/39<8 ML<_4Z8IO:TS|8/4#E M1*K&2TLGSY.EJ#4Y@H16X UY^9KQ#
Y76>|P!;8YNIUQ#:WN7|P9H J"E%* MB@UTOEX M8G\$*
|R0:'1#;JH*WIKY=WNPP!;8YNIUQ#:S:1FA1VQS(V?;B@JYC%7X' 4HA3V>I_OG5T2R)JS(9%=H MD6:3&88+;
(IMMEY';/C9)&.;\$?;_AWB+TO.O.=.#J#L1:(6(U1Y#TOVFEV MMVE3L_4Z8IL;10MV9#L.Z91NA7:(D:P)FR,=O|;_*Q-
RPFC;"O*|0;8)NK MUQ';_%A:Z*@.#X"2\$S)"KIAR\$!*.TPBITK532.IKC;)R98*2ID;X)BCS1&J
M_!9_#6@:D71/LI4&F'OKD^+;8(2_1GH705<^FGYW+W@*|&#&V.Z&5'RYQZ
MJO9P=U_!J9A?CKZ*0MI0H\$4Z>FG>;C"J|JCF:W9\$ M.#M@9N5W_!RYWM3#|=MZO^NT&M GD6J%Z+3KW|
(SV0^Z0%"N&LITFF_!LG_ M&R#I&MH=T^I9D3-G/SG4VILW+WWY|HOH(DF^B1ENGR/CQ9*(R.Q MBJA-F,IX&|G?
-U*=%+ #W-62|E|/G_C|/I|PQ2.F'V33 MO59%TBW3*Q\$%H*_|N@273^U%3|Y&G4D?
O5DLW4ZXID90K_+C%9KZV1QH). MO3&N|PK06@N|8FFE)H=UEN>|^/7SS-
7IB&=F+;TZM<2DZ|ZI+4E0&#WTSM<| MI8*0EJ+|H@_I\$>E =,==B)&90+O59 MCEE
:M6#SE7+V^PU=MXP6XA?;|JG8YXYL723IGD7W>W+XZOIH>|OUM&^FID MM8!T8Y"Q6"2@S!%LR:;)X;X;+;:IL
FN&;J=<"VX8703IZ|6J+RKCE7'&%) MVO8N 162\$!9B;5*&6&W-E00DY*3?I8(-\$X)FITQ/I%|96&+"ZE4@P&|(3@F6
2LLH(JO@&RZ)/ MDU;51^ (WP#-3IR>F:;\$Q|424A%2K(^APA.GM!)TC*+ #D\$&;E@C=YIGT>
MB%|_SUR=CGAFOLE.F3D<| M;Q/G-8#FT&Y+(P.X)O5O:X0I%;X|GIDY'/#(SS)PV M@I=|9\$90>Y!|G-
K74"2#%BA6R|SUS.O|I+|IO@F:G3 <^6F5YCL#7*Y96 M)2L \$CHZ>X0 OC.%3\$5"6UBUVE7 D?
@_!W4ZXIE;C|G=P-EKRGKGG* I M|CX>JGH(@IZ55AH9DIT/F*|@&C7R PQY=" @TH+9D^VK: M:0C%0?99A1M+9,#
<.;?RUTU6ZLCJODY9&(0D_58T8;>PJ/TNX8N&*|IT&1 M"7VSPA|H5X9Y88&UDWT-O8I8YL7&3JC"N|EP?5;8
ZRD43:A-/1>|K0I0RY! MJK3M|*1N)8.M<|MD)9FIS1^W1-)|H6M K1:IA#10:"PID2T"MF+H
M.7%"M=;HQIFMX3F7O05Z&=H9K=,1SIQTL^00MDGKXIWNT=(QB1O\$T*^SO6J
M7WHX@N_&H2V2#/PJL2@XYTM;/_UNB(9&-N6(?D/B%SG@0^8 I"5>?(B4J6 MDXU@>|XQ6?W@>H;+R#7K6<-
K)X3+T.N#9;,\$WF\$Z0,7DU>;SQH-OC.6 M3EUF4Q5&VC21EN8(5@U67>W%+X1CG^W/D<.,^LK.R+;_T39H-
>:A>_F"| MI#_GBX\$.BAT0=3P_0SH3.T>=(868UNY7 TC,2G>""EW:OO)X|HC7IT_RZ1R+I.G
MOHIYVAS1RZV=|X.D#1%:Q|J\$%FICZF7 M\$%+RH!6*X&3(>?G>%"I_1RM#FBEQT#"V> 6J;
|1\$L%041+6U(&@I017)*B M8G)-U:(7F8VF/7Q#)_ 52I@*MBJ8V|IV.A\$ONP*A-I)<.P MU.D.L
O9&Z"7HAT10OCTY>'W?%NIOXNX4LU\$C0I&2KY JA MIQBWB?9G8Y\$2)H37%IB_61?
0I<#SCTW(4RL;Y:O^F^T2Z+I*NEA|Y;7 LT M7X4IM9 F9I"/+BRQ>LZOHML1Y|QB27'A+);OXI"UM^WA|
!9=38U008S|T5FL#E)3%GP*11F! M3DX.+1Y)7SW37(V.2&963=J@_H0W_-@ (2.@HJV "2.O!=Z,J1*T*#+UZ85) M,

<IV"5W(7CW!/&V.Z&6P:26Y@O1:LFE&"M4V6\547LKD_)3>^5:OMLG@MR%+XZ@EFZG/\$,#/Z18CL&:)&IB
JPF&KS&0?%O(0Z!!":6B5C&8V3^C2^%:M8)BCSQ^#S8(7)GB"2Y12(&"2)YVO&19:"5-N6MUD\^9..D#IT40@6&.?H<
M,0G1Y@!>I>[4HAF?04Q^H9=J M^3X0,T.C1YB\$3SJK^>2^<^E:(OFET1)S&K'^DF=0=)694&:(F.MF5E-C3D
MTJF>UQ059T^&2U09(Y&ADV1S(MOG2%#:TC9)Z?HI:WHY SIWK9EA^9<-&3 MDH(-
DL-/E(WP3)^(V..2..%N\$Y9P^G.DH@BAY"17=#(K^M'8WM3=UUR8E,M C@Y^*7@D?
0LDLS0Z(ID7Y3I9^>JSE V:>GBV?WWI6-"3=^E%".Q6 T&DX94 MDX(H0S%)NZ!QKMG:Q26V0#=?MR/KU#Y:\$XI
PR6D6XL#=-VMZ>M5@5D-DHZ MB%'4 &)>JZ,E-L\$Y6I<1V9.F WZL_WAIGOZ\HOW+\$=?T: !C:4<+*0>V C1^95
MM+Z1Y3B;IST0OW:N^3H=-&F?@7A1F7/H4I,8'4/W.4^X5:Z^I+^J: HNIG)UC(G
M1IQ@F:G3\$<-J" E9%R"LD^XA,E^M;V3?IT^3JH8VD2(I1#D91I^7SW3 M2^*V.J.971(HEJ(S:U> TJ-
9Z""F",DW4\$F"&F^MLW^R;R-T U5ZLCJKE= MP6)02U Q:F4U^U@C.H !.=OH_VZ10PII
M(2HEAQ+))>U=HPC:9JR#IVLC=3TH28-1^7P+M^/T.6*8R33ZK.I?SOS M%^UZ),#)25YI,WWS/'HP"J: M8^9:%
<I&GC?>.X<:OVD(BJ@SE:8+).WDWEB(%K)YJOTR7/IC#C84:+ MS >OGH^>W&*3,18060R/PTY?9
D.7D)Q2)C2XJP^F6E)7SS%3GR.&F9\$P M8JPY(N5:%K^W3ZB9K^YT!4+SN0?
SIZ68HFR8K+M8"E\ PSQICAAFOL/LB.>(M1.W2J89 MGWJE=<.\$&L 35<0F?HH8YT<2I440GJ&F?H<
(203Z!VQ.A:%04U^AAQ)7SW^7(V.2.:&NZO9G#MO9%0F(&#J0I^). O/ MZ0:6TO^T8(K7L&NI?
35DIS5Z(AD:BM: 0YD)0E\$"&X:>Z^!.)4BHP%?? MDA.2I>STP(T+9#;TNB(9&LBR M+I>(N:\$-
BOST7D%OFR=P2H%LPHG@O2:0 MTR1OIKKF:G1\$.K.6DB^9!:32%+GK029\$D;NN(IT@(!O5X-TD:A4>?+XU+Z
M%DAF:71\$.K<E4P^GA=?ER=F:)GES#C)7HP.2 M3/*19#1.22+
(K:~/2OG0QO,JM>\$6+I<2JK!M=I/Y33)YI^W0#)+HR.2N7.A MK0GGD%*N1 Q(2I>))YI2@*!"A5J^7V:M)>S0Z:6TK=
>DNC(Y^YQ:ZL601G M ATLH:AWY>2HR+!A>Z:VQJ^T9<8M17SAF;BW9Q-3HBF9OL%=WB!0E.R4#^M#70B@Y"!-
4IM#MH(6B0I5.SS9T6TI?AE.C8Y(9D:~!1^I>W:YX=-O! M^X6>;2.T+^I2AI.KIK3^K0^_BG2I3.MSV6OGF">-D?
T.F=7BP F8K!90?J MU"6RNMV/V!8/ 4FM-^JKOB00;JZ>5I7\$OX,42@YJ"(S9-6IGD1Z
M+X+H_>6DR^5Z.G>3.VD&PE=/.%.(X;Y59I2_Q7O'E,5) EIRJ(!KXC.QZ M!^D &-
LE6X:~?<# !2JMKY96IS1^! ETN:7P%246NRIBODVILD!&A5E7Z
M%JR\$ZR6.OURU\$W0^NU..*7&J8^1OR5:LW^_UIM7?E!94!\$(P+08
M(5DR#E3^K&K0NHF/RB.OU^&=9+Y:SPK;CUCF_6-IOCN^GN#IYBU:~)6@34 MI?1BZ@RH>CBFR%IS-:)V=;
(FK9YJOU15S/B6-;+>Y+GW?US2,DF7SN MNU-G9J09%U@04;X+ TF1LDU^H)73S-7HR.2F?M:?
27KJN/TFI+L;7 ME+6\$*I6?REDZ"LKH<982XNJ5AMF^3Z300&".=HV^E#@ =UEZW5N.%=H062LZ MTPE,102?
=Y502_F?HITK=,DNC(Y+YI;Z4/(4^CJLPD(1J0(I^UV;"1C M/I@ML@6JN7D=LTLS4Z(IDIYI"!;22DY"AMZE1K?
^B2^DEJE MM+4I"IS,UL,,I&^9)Y&1R0SHU!2;? 9%)4K18'SDA'^PID,-02(5E"(I- MZ">#(B/QJZ>9K=;!S_H^G>
ICLUVYP?<I">9@2B0XV1=/6TP10FUJH 8J+ZN(CMR&:&OFQT7_7JZ&IW^67'I2GNYN;H4=59SI2 7+! Y5
M@B3HD\$OLRNEB!HFYS# UC1K9_Z^6AX=@2MTPQ??X1%+O<7=R:~*+1.2?0A# MZ-\$ZI@IRTI!-W_1P^M,?
VSOI2=LJOH-41U=STKZ#M-Q4/OJ!C\$^K2W90 M:R)WOZ^*0!%*#YH(2PD:CS63VR\$CIVHGFZW3\$.I?
15!A@4D+VH7\$ E)LAQ% MJP%=\$2DHT:~)3N<3>81R_/HJ29CIR:UGHE?+TN7(VZ9>6#.JU_C102UE9
Y^+IN%0_9>SS M1E..2DHCZV3MS+GHU7I+TN6(6_TQV#."%9>X%LP(BU?STCFXP!&C87Q*5 M19K):
A"INK9Y6ES1"^WO_%9>T^ @&VX>"I5\$.8D>? #*S"Y1DBYI:PT M%PW&(F68+6(=B%IR6R=CGAFMID76BY
I:SU);+V)OD_8^W.W2I5B7SZ M)J^>CY(LY: ^=Z2MH=4"U86:~!6F?X^V3/N!LWC/I-RD!%#;J":Y/*J2= M2I-
_4&:~/L-8RA_51?0:LCJKD-H4:/@N.Z&HJ^8:C%#H#WV:~)3.SJ24
MC^J3R4)#^1N@FJO5\$=7@_0!5(C!)=H> YOB>OSE4-J7<=4T(553I^8JX MX0*K)_L^>AVO?
86)D^/IDJL/H: ^R=20^V!5A\$ &!:@BK+^E%IY.#Z49KKIV MOJ^BV1^A5Y@...IU:HQ)59&_O"5GOW\$ZT.6(&)W
89>2TDDLK(OPKF9^MA^:/ 6K6K^LMWA:IOA>@W9)CTON#7+T&8SR9#6+!\$;2I.0QO=Y-LI7F#M
M="J^KR.VK\$RTCL=7B_M\$^CE!K)0TBEMY.L+4 02D)*+2I&MJ?JC&H1HZ%VI?F3H=H!
M_U0S=3JB&IVAS^KEJ^D\$+I(E IMGI)_@TH.H93SI^LA:9JLE2Z4X6J&9J M=40U/UU,ANI>UB4P755YN8?PG.O3I?
JLC:H:"!FM1!ECFYP9>'F.M5-^)>V. M:&>FCDFK_K;+I# =VCIEL263GI94@3?IVKHN"5+TC"Q+).9!>C-IA@^DKYUJ
MMD9')/SQFO,WI=TO^N^1I^@&F/1.(BU^GI9G(7HJX 8JD@YZ9AF!UX,I^>
M9^Y&1R0S@V2:F#F%"V4O>@3M*1=&NQ9Z%*:D\$YXI\$U^3A" A&T!2%Y@M3+;U)9#Y&:&GV\$^9
^A9(9FET1#^WD9A6 M)BX.7I%!"^@-OC)-KN!_\$3(K/PHA3KW&POL8^XM=^U^F(9V9L3"MIOWH MLWMLF)-
+M3(K!H7V21Q!% A)5I^A.(R^\$>#)IC0+V6MGF^G-\$WJZOS^B&E0>+K A)K(6Y2UBJ^DG)SP.I2>IKY6AU0
M!9@A>GB\$E,N 474"5RADW<:8QA<I-"K;6T9M-DJ=50-/J)YNITQ#,W^B:T
M_=:8/B\$H5TSKL0=>Z^F%AYGH%YV0JR^TH-IH0A^>8J<+IPI54.>/B M7_ 'MNSYV#YA44MH)F4&
(6GLY\$&VPG-)QO^U!W+H9P>^H#L2OGF6Y3D<I,^>MY(EIB6_OIKAW\$K#0;Z7#A#8IMGF^7-\$W<MB)LOH.35
MW^V)/I>X/B_Z11A.4^O!OQ=MR#"PCJX5TXIM&6V9#7.-5I@ T7S-C@AG MIH)I:X:PJFXUU=@@6ZFIA1
AH.DU!3F%:0I(I)(Q=6V #A2.V."?&O:P= MPFK1)U700Q:2#\$\$ZB!"=4V1"Y)(UHIM-
V+^TP@8(YVMV1#@S\$D97Q!6;J4D M;_I.Z9K 6\$\$73Z?G^Y5\$S("8YP<-G=AA=43?@W-#@CWW";
IS@UAR>9=4E" M<IW+G7^YN7_0AB/5PP/Q^>^ Y% M"D_VL2VB3W^I9\H70\$F%\$T;>5E;)+0!"LB MB-"GZ\$FZAX(I
01ZF0P&+RTM7YYF=4?@*OI>_0_+F+F/3Q3=;0(M4NE1 M PG1A@H^9#3)FJ: M^M^>9D+!E'8_X9X;BZ\$TRW!?
CW5I)(#Y&?JO7#4LO M2NACKAVQS8\$#2HW0%60-J6I^M2 M),^BHWDOJH\$U.A1TL0J1VPS@W"2SM-
GN^LT_>_F&IGD M7.\$>343)-U^SR!8\$3^7>XL>I5A!Q:QC:&Y><+!159/^97T.V ^!)P.M2WLB(A)
7H&FEBXW)@10IX8(HA6B.@V^*T!XH_-R.9:Q60%H-10.NR1ULT%:.KH4UZW>,%ML_V5ZCMMEF MF!
(/4#60#!D^GMP%LAM:~)99N^4A9&^"P!;Y>AVQS8RH6: ^ ^ MKS5<I\$3YHA>7@CM^VXD MQL^Z2X WW^:/
I^I^AV=9ZOTP#JO8T^T_>8<(FO03E3M)SO/7EIA!5I?I;C MPGE1M;LI^?>B\ OD/;!U1;I^%0^H^*0/876DDL0G*I
=F)5U9/9V.8":1<6 MV.3=3+V.V.%TTZHU% KI6U10R_ZJBDK!6"T") 4.IDH N^VA^V2RDJ.9# MV%XNL
FVF7H=L!UY(03^MF3;M!LI^4!5&XY6&PIT^EESI+;B62A\$B_J^@\$ MQCIGAH_E;X)KGE9^5/"9AV4%
M0H1A0#2:~*+;QO=IOF@B-)6=T=;(^N:I M7LK? M5,K8ZHVA9XFO!M!>VM^P#9.15;8IH98;?)#^/I
I=W=0^1^XE460P(+VGV3E^N.)Q)T37B^(67I5D MX&0I^/4\$_.4Y8I@9^O-
IG2/"&S+U.8\$NPA,BZ2"%YD&KY@P=O\$87SBS#Y@WM P#I+GR.&F2\$Q^_0YHIA\$L\$J.OQI+S8EF_I=Q9)JJC7G!
(:)+@M+X1M@F^7/ M\$M4U(6ZV3_X^7P#3#.TN>(8?XH MS 6DU\$SF_G \$)!?
>I+S6F\$L"@87^84M90*:DA?/<=OJD,P9IS!6 MONIHDO302I)AM!ZAYQ%;JFX^S\$R?
#0/HF2.9H=\$OR;K5(=DS2#\$594KO ME.=<-Q.L &PU EIC4B! N7W 3I+= (DXIY ME;!5%*
QZIB2266R1IU(^B9(YFAT1#(ORG6"Y)Z>G53>^CMBX?06Q^ZN1Y/ MU8\$Y)OHL9=JL;4KX.%:-
Z258Q?T3SM#JBFA?N>G?Z?J^J=JFV0DI^O/+ MDPH00^5G+I@BDRVI?@C5" _F.H)JGU1^5O+C7N!>DDI-
^_V;U9OR^L):UL5 M_1-)P)4>YMI(SPD\$5Q(CEZ4^?D#D#U;8!_U97BZP":Z9>AVQS2VQ M%^H^C/>IC34I_ S_A-
IB+X^%709LT9-)2K!6I7+I1<4TF.TISKIVIODZ M^?L2W>I^417B^<^N%YU%I2.NDI?W6T!^7%_YVQR?
_O3O^T%3Ts;N>/O3J?C M=#^F %WOD+PD!1WRZU2! FV!9^4WWWI4/GEI?TR^PW13?RB)U.2^!4T_KMV!
M(NO+APK^!ZM!\$K7(?Y^*KL (IL#I/C#_.IAW6^Y89@!P.OA^JOJYI3-X^ MSE-DELCH
MHIW1I3HB\$42IL2LJ1FYSZ!7EC@CWO_KZ#S_945MB2I1^GK%R1?M!+HIZ/
MBP8#6O^R#IB.*4.RN4&UU=^&O:ENCL"II9IKB^NN)/7I^N#S\ PMRZ%D>_23E#P1_I^O@%6!E! MZ;H2U-
KO.14K)#0-?+(FB52#/*^I_1<@_8+I4=R_B^Z_0AFI==TA1&FVQ?W MMN16D6L->GL>K-S0!4A^!ZV_L0D)6+3O:I

WL"U#^V.C.=7C:7U)5J31MIF!7=|M3_BS9V^|>OGMI@!;@C.^2T|I-9)Z.Q9M42>)1)GB9C\$ENU\$*U+
M)AC\$6/V5S!#?@;1F8^!CL#)(7?R(A^:7GY09@|I|+-WP2UC0C57I73^N##X M^ @OS010D;/-=F*/M7.F%:
O|!#GL!5Z3&K'-9Q8/Y.H.R|>U_/PTIO|>;TL:7|@X/!=^6""R>EEC*SY^MA=I!MH?XZXJG+(W-
U|JYHSLP^TDJ^ZJ|OVZ?WM(P|P>YXGK!0:*4MH" MV9>ZT+4_2@-#INUV1LE4%W!K?F|~/|Y/DM^N;NM){OX!
DY)N12?>S>?WC7|D_Y|CPCM|OX|/"?X>|J|GIW M4W:W+X|TH XZ=5A_/J.^61W H2
@JL9HLY|(*.D"RYQ|BUB16="=5\$G|M8:P\$ _O|=T('115S0TX?TF9VT>\$?G^*KW1W>|/Z_6I2_3L?Z7Z|)^W?D_F-
M7N^.)WI_P_!E+J_E|W1> @6Z.GI&:Y*>)5*^!;L;CPI?*"H;V.O|!#2?L(MB4E36|'X2WJX-S;MOVFIH|Z>?
H;?;YE+4|""#)F|_V)ZD5R4\$*T6+23>= MKQV*_XC:6=M)_F<|_5?I&S=V@|_1*%T|S!-)U60_J4\$43+P;N:4JK_"JG
MA/6?|'_0PL_E0|R|!|!#S);SW%?M&4PR%J3*#|T|3T)1T'.TH+33;6D1.C3 M??_Q)=?RW3I5SG-5SD5|7<^A?
SP^N;L'_C>|>5U_P%S1:E)3B|W=A3&\$ M#ION\$)O#2|HGB)YQ3_I0Q3_3N%'.|CONICE?W@O=UG9F;YBR4
MY'R)D8Z^(@FZ|C4|@S)*!|Q;0|@? _|F=X(8^G/SC|>ZZ7;VO|_U_ ^W M7SSH;V; _VDA#>O>PNW+_E_4_?
E+A|_RREMYN MCOLVY>_Q/3+W_UKHZ|GU|=_*SC(V;|ZNI7.OT%WJLXC^3%NM_W|7; M4LO_+A?WQY_
(QK*2IT(%)_2)%2^A|CGK100FL%L_/|HGMp=0'_O:XWF" MD##;"O|LO=|"+4OJO=|
I5>|C=%4TW82|5O^FYAJ7Z8>3# (^NC'+WO+_ _EC+_ _F?>X?7|?%?|F_OZ?*MTYN394^WU|MLP(H
M|OY4C_FP>|7_!&>)1'(AO=D)X**?/;V321.|@H1<+M+DDO(U\$OM9(I5_M4OX^Z.1X"FI#H-
7SA3_W37;YBO6\$;P>W'^64&?^I1^_#>#4>_UG.(G+
MU80BP6/8|)Y=#&B@_2B0>FR3|6M|NS|HK7#O|C1^O#ZKEVA^D2:H#|Y|X)
M;^O3AYE958C6^Y@9+7OSND;7G6DD2QK\$REA2;-|F?B_ _E|73XM^ZOJ|HE MK|V162|J7ILB"\$)* M!;4V"
I'_MD>5U+|;3_Y*3GD?@ML_S3Z14#V0^</_+<+9;|1@>M_YTTQA_B M0;J5VTZ^8?T_2POQ&^!99Y.KUB|HDL?
J^?7;XA#;S+M\$KQWXE0^"0%K^|SA M;H?4MM9ZVLD?O4LLW4ZZ_W&9GGYAOBH5)=#EB3=J3|
I2Q@%75H3I=LLP<6;2EC@M\$F;FRUSF#MZUWFN5S5X+UT+)3Z+6B7^:ZYP_%
MKYYEMDZ7+#+/%FEIO;#J;H(W4>)1_="NI"\$&>DV|*\$5Y5"%:9;7XC?_E.G M2Y;Y0C<1O@66>3I@(@M);*?
EUCD@41>;@TJ|38B0HB)R&;EGG8N?;I(^E;X)BET0"|+B7 MT;.>(.#J9A+\$@JU%@8K&03-
&06O;N>.^KGW:5%|*WP#%+HP..V5\$O80"B%"5/J|@_@V.SZ5O@6.61@<PLXC;ED|E*@A
MQ|YZ\$V@ARA3(A6|EYS(G9|_C|^E;X%CED8"#;C7M*;N+00K+&VGZ?2_G&_MTQV#5Bf0JH|Z+?
V|'_L(L=+Z>OGF^G1)>T5IPCBB|5D^TF"R^T+C^5_M^#M7.F@ZCJFB(H_ _|F/C4OH&..9I=;
Q_H^B|;6OC^H^1T|M%+KYFFZR6L M^V""7HFL5LS9-S@;=2=|QRR-#CCFCNBV=FGI2IMK_1H(2LY|X!HC-@57;Y
MQA|+FPR"#*1O@6.61@<<R=A&AAZ4L4K8HBB+73QY)0(>@H(CM6C\$U)|#\$W M3FXD?20LE+I53P^OPV8P\$CC8.
(V4&-DNQ#^C.4|QQOSW=B M;G20%;*2M|QRR-#CCF MOKFL=>>@;@U-6>F!\$#BR|N@%\$/ _/"Q6^D_!6F?
3NY;2M|_Q2Z;#CMEQ+F6^MQ+_L;V|PT=)7S@A^|KT(O1<1W220;*_ "I_82PA9Z>ETW(7T|7;U.B_8W:<M2IES1"
(*GOK9|HJGB_!LBV\$9J|3@B^A|Z6;8|H6^!8Y9&!QQS XUQ&N7-\$ M^C3AB|@JR"/W07?Q|MJ\$#(X8;-
M34Y_DUA(WP+^+(T...&N8SRBU_G;H M^N0^LJ86B^2I0>^66>D^G16_70""MIS.\$R2PW06AG-
@|D^WU";U.N^8&^|_2+5>0;>*"SZO?*KY?MZN;+JN;Z&9@=|LV>0HQ0|56+Z.WBQ;I M|JC+4HR_1FM_ '2;-IG%
U0.PGF5_7I+|3|_I6F\$+?+U.M.^;G2|F_/"5J;X%RP(UVOQF%\$@F(2^K^23HI^A0\$_WZ;5ML_W6L;#OMFY
M8R(00;23^XF@H@|H;1%9#9BBZE;DE(DN^2.G|T""VR|;H9F|WRS|C\$;_JD
MHG'.6P7)ZM1=10M|Z0|VRF9MRS&VZ=SNX0L;X)NMV0?|B;.\$!DHW6B|Q^ MB20;9|>L#H%MI=H)Z-\$;-
_W^7""#?#_U^R@40D|OB;4;4#6E(C|@K|IT//%QA^WRS-3O@FOU?D\HD/\$^Y)P=-%TZ*AO);|_5
M6Jc5*MIDS/_WQN_K_\$U.^;5^3PRB0+*4;VBD8%-UKD!*"=P&;RE@;^JK<MM#V7&\$+?
+U.^;.&5IS/CS^VS_MZHO|>U5CNHC>4T585|H92\$1\$(@B.E^+ M16DFZW<&TE2|U>C
XZ9;37GXP*1R;6X1!"J^1&.%XGV9WO_0BIB|5EE/_D|M;""|_QSS-#K@F|E'(S-P@7+2VT_MXH14@(^7;Q--|0"
(224WO6P;9TMC|^-(7SW+);T..KJRVXK)Y>TBFK^V="LA M;8)4&J\$)=+ND&)H.=/KL?^OFI?
@MT.S3Z8|F=F70@8P_#HO?>=M4+ @TUJ^9_5_BL;T|FZW3_IEN|
(JT+J6\$4WF(E9HW3ELE3@^163|ALINW^<^PN2;/_S^R^U^TM=;ENC XZ9(3#EY+8V11#G|);IT0IX%X
M\$|H&FOK77&B%FG>21^|2SS=3J|@F1D"(TA+DU"YI^O/+O8NDDE8;A_KT*>S MT
_20BO/DX14/1<5^P;AN^5<^N9(Q6*S583;U;R1^ M_31S=3J|F3|83H=
MT_R=|^"G<|L;H=PZCL|*RV^CSIMS4Z&P\$;BUT|S5Z<#FMFS)>7RPZAS M.MB;H3LP=<2+
2K>DZQ;C|FN^#;9#QVD?@MT.S3Z8|F9@A;2|MI1TJS*!K9_M@@%|9^V0N8_N^LBV)=6JE|5- S00Q6^9J9;|^
^8E@_WHW|DUHVD^;Z_ M8F+>LXW|96-G(F2YW;T->=UA>;HWJ4^5XG1L;*.K)+M^?6;H;JF^O_()\$!6
MB4?|H%);TD>_+X#9;R0M^XLR|?H5P_KMQO*6*S#/=E|9H^S|^8+BSN-C>#1 MFR^5(X_#6H<;H
(^H;R0_3LL5|G3GB;_LU4VYYR0)<7%V^+";)O*!|<MDWQ@3@O-
6WN+SFQSAp8;\$C+%09TIX|HMETV)G3F/"6(F3CS14_4&)/PA^HW?>P34(\$DCG;.*%UQVK*(U_WA*32.NLKJEUYL"
05JN.*|IS@#7_MVV7SN_QOQ.H_'?XSE;|2#8E)DIU+0|34E\$^O_@0&#M%QA0^<*>?;92LY M;EH\$|3Z;*
H(OE^F6C44B=/?>|_GUID#_P9I^3\$3#'=4\$Q9J\$)6(Y=X#)M;9_P;.&;G"@.Z8H)B(5AEIM<|4-R1-T_4|;|17
MJ1_YLV^BDLT1H8EUYL_05JN;*DBBFHE54&RNR+MTV)>Y/#\$HP0Q\$%|W
M(F;1;@E.K#;|!@S2BR>HZ&^W@KG;E#1_M?@IL7V<;#|BDY0H#NF."8B)6P2BQ7E_+"%_1\$OM1-H^_TT12W)P\$)
|F=;..M"(W2=|/7EJG1DP8)26_M^PSHC@G^*4UR\$P=E084(R52>K;J'_FXO.K#61T-9*YJEUYL_05JN.*|M|J@FK-
3L&#N%Q>EW^O&DD)N2KF_S_Q0GAUSC;E_D^O_@&CM%QA0=4\$U8_MJ3HK027ZITEQ^T(JBV(C%
RD;|C|6K7V>9Q<9PX;&3EQPRPW3!_6&E_H26 MR^9U*0E;A;&;GM-
0^8Y<1V<5Z;Y%)A89PX;&3E"@.Z8X)JPD;17.0T.Q_ ^"FF^ U\$W<690;8|S*3*)4L^#69^RZ+2I&-
%E1;V5QT^B^W%M^/*ML|+2D-K^F?9M;8^IM;9_P;&?DQ_RCI#0I; M;Y^&JDWRA\$D^R
I2VXIS;JM5DWQ=&*)";3<&I=>9 @4%;KE&@-RIHS82O_M*^@4G^60.T3B*|Y7FX_QC\$+3S3)5HEF^."\$RM;P<*#
JRC0^I84%K|I05YI7(M^W43#.*9Q2Z^DEDT+<@F|9YD|HY*;&SxK2*_MDL-B@";CB8L9C|C69OA3Z|R|_H.T7*-
9V@0A9MP5R^CLMQ0@+9E\$D?."BR; M^%_L6&M8BDHWFH.3Z|R|_H.T7*-|R0_*2?
*&@K!|@?;B@HJ2^TJ8(*U)_C4.B=|@7%;_MKE&@;Sj(PDWPLPOLX|A1T-'B^65P=|{6|ZD4>Y2GA
N&LW;R77F0(C|6JY1 MH#;ZB;)_%+=HGU6F^H^4U<^W^P8PP;D^0+#@XIHU|A29^*=5;|@D)9K%;B;
M#G\$%;B*;12;BO2@0>|XJF8^@YU8_5|'OF;6;M|>OZ;Z#""W7*_|"(L
M1;^CSE^5E#;#YU4Q5"@8Z@0DHGQ4UFN5FVV!.=|1C--RC0^IT4%-Y\$OWW|I6
M|6WZZ79K"C0HXB7DS>PX@IZJ(=P|H881M%"|JTAH=KS3Q|R?JW6H.Z- FJB M^@M%@Z-
62^S);H6A;|G/4^@6|+>|Q|U;_T_UYX_IZ@|M5J#NC?;IXFN";4<M-9Y*%\$H+W&H8^I48|P3^7(9^LI4C!^M|Z;/_V_#E
W;G5&M2|T3M;_4HZ2D/%;12IU&H M;M/7|K>|_F65^AGG_P4S4+P|F254>EQ_MjXD";Y(>IFMEXU0UY^E^W
I4&=6^NGF45_I4^H^?Q_8P7^E12^IQJ2E&1_MU#Y8(I^K;+V|JSU_#E|W;K4&=6_4C6CQ6^A^O;8RJ=)(I_B^KVL^B>
_M_CN MU_C=&FVK/?_DH>|7;@WJNA;S2W0;.%#>N+=4&CK8B;CLN6_3<|48X>O|^_M7W7U^;KND;HUMZ
T@XT|6>_VF^*=9SX|C5;E&|D|C1|(5SCLY6OU9K4>/_MU;VY|89Q);SQD^*+(&(OX+BDN-5(EUV4GK&;LKJ|^<
=;=6;U|WCI;EK!;M MC?B2-D%"S_YZ_ AMG^A@2L!PX_O&*IG|V<=;|6^U#SSSF@9^L4K(3P=N\$C<=
M0)*A7;CJ>|Z>5%LHS\$1>ZS;H;Z|?G_6G5FM0=T;+4^B^6Q^9IR3^&
(D61N2T51L+^FH/G;4^=JM09U=TX;K5RW^1VM8I&#;LZ7%JUE M;);KXWN(MHYK%T1C8+3Z_#E
W;G5&M3=N6NTX@\$\$\$;TH72BHS|(\$H1R5;@H|_XT%HH18A65|@VI7R6|CQ5J|9;L;|K#|EYY_@R@
M|H5J#>KN;|FKN_79Y^L1%M19?0_&K|LE8^F;EM;E)EYHW;KSYP|UIU9K_M4^='RWCE5^"B^*%!"R?7_KA(AA")?</p></div>

@464X^IZB;- #*1V<=;J6:U\W1\MX M+34&K4.ALX=D%1H0CB8P2B3P.F:D'Y&?0.O/'1.4'=JM09U=[1,T,="40X
MMX\$1.1SYOIT&3IT OI@W7*9.VO/%*1^? =2I6JU+.JC9:(2F!=&V>R# 264 M0+?
BA+7R9#P./Y.A)>|=4GS\J#NU6H.Z.UHF*FX\&I Z*\DIFNL"*T^?PY0=VJU\G5WM\$Q6W0)\$8Y (&J#YIT (5)K4.0+
MG=(N(0?;0^K*1V<
=;J6:U\W1\MDX53)U#/#+%"DQNU2<@>+L:PO6B&YK66\E2H\$HS*XDLPJE*7@.CH'^)*R=IQAI"LVY8%
M3AWL\$7JMH=W;PDUQ\CK\OKAX>[F\N O89F&<40JEL+ITFT? #\|3(%'(*'D*
MV;2V;ZD\J2QJ#5&M2IQ9B*TXI0BDF>60"=!"15HA+P2%\$@F<*MATI39THR HYQ"8;X*!(N:4A8^WY MI7
M:@5JV1LP(JRU8A\$4^K<97BB92I\$*1OT64&@E&'Q0"K8T\1&3")1.C1ED;/7\$K;&ANM/7.4'=JM09U\1.6/X=W\Y
MSKV_NX11W\!61&31GRZ\&4R>Y>TVRT9JV#M&L/T&./=IM_9R9ZC.XOI^M2!=(NU _ITU:>DI*&RVHM*%HT
<(QED-Q'ZP.^7>L1_?CA)PIQISYK""?F MDY6Q\7B\H _^O7&9G">2*\$CH(E8;EZL\9>9Q%.%N1!-M#0UWE)O
M6>'DL1ZAV1K@G4\$RH615+= (TLEKX@K@&" +0=92H&ISED:6=KLM0)>76\$&
M@=KM@9X9ZA,%%47RVO)2DF_YYZ49&ZFS&(N#?;H=-YZ05BC_YEA1D_WJ_9 M&N"J
TZEY56Y=+"2\$))ID>+R)VT\O4(R5M%A4G.F\9 RK8E3A[R\JM8:YW
MY.OJ#6^=^W#VINCA/=H6WU^M%Q=IO7Z3WI8?UR\^7ZS/L.:2D> A&.=!\$!>1 MG&4/XB*3K"U1#
I.&"S\K&X"R6_L-2M>K?5KK@_S3HY\<15V4
M.Q#IS5GUVQF.I@%4>E.Z0E@O\7T">AQ>4PH*W0U1YNHGH1E_NH" ^<'Z'79 MK93'T.OI^U\$.HI?
+B_7R?!\\$W)\XK).(GV@GI4Y#"%@>7XH5JRI' #>@I9\VC MX8^:CM;_1%SBWE>(/IU\@=M7/^4#>9#._I-
@I\OJ7:)\K\>:N3H8YK* @>X?O*J_SNK5XO+M+&+CX3 M*GO+G +B2\Z_D0Z*V/P&_J2Z<("(\$S57Z'A8' YUJ\44]-
:8=ID#G(0IBOUS M?NTNXIGD7DBET"Y@#'^))H\$W5\$+#+12CKVIBI\$J+MT^""O^4/H^-JBW\X;+ M@7C?
7RW_X^+B\I\K _JOW^U+CYM+K\5922KALV= YR5_H.ISO\+T7#R2&8 MB\I-Q^LAR.A^&S\IS6.Q.-
M=G+6\I\Q%^=-\|6E^Y\|=I\OKGRZ_20*Y3\ MU^6+1*^KQ7H#I\UFRV2LK&9A_GZ\I6./L.76(%&2J+G;H/_!N;-
NRT^/?W08JW7W=4EIC X7@RYQOQIDK7&9* 2YTUX^C% MJ:>P'_=|G5-C\G-CP,#+X-
Y7.\M>>|6(IZY):8@52BL5\!&\$T,2XI)-E^IDP M\WD>|D:LLDXS2G1(-6UH (T: "2^DBHX8 MF_/A.%N3Z\L+ #X#
<8<_WNLK.F&).26KQ94\^U%O>%@5\$Z2%DI\G&+!T%J_/TZM6KNQ=P6U7U0HTB_/U;K?Y9>?+I_P<\I/
M\J6Z7*PVW^+;Y?OW5RC\I'=/\^_R=UXOW\Z_V&KG6A?C6OC/6/SU M0\^OTP7.
<5_/@RIWMUG1X#O5@52(HE)\^3!\$!0%@TJ4RX<)>Y\I3&Z..S#=%"P;HX(%H S=L=WX^
M8IO>A2^I\WF^YX%+SGOZM"">_L\POERG^! _?KFZ2G= _B\G?FU_/M\H;CW M?XX\9>206 M;A7R;TDFW(DY.
DT#(*#<|W+HMD7E@.@<*^&_U?99L-4%J") _JN#=#11_&546\7^&871K\@Z.I OUB\ M1SOIG7O_XO5-VP9KA0J&
26R= 40F_ =6\5K9E.R6C\TZ;9WKZHM\VP\Z7YH MEH/U.C"?I+I:OE^Y>*FZ=*/-R+A.P8F;
3..+YC9A1);:\MT\$D9A3CS7TF M*1^? =*J6AW^43-K\H;4(A"/LA(@E6EW BH\IIGXCR MI@WI^@(G#_4 O8\0BD;C?
K2+OQSO;SXN#@_3W=2)1&-H>@?2*Y4%=&I\CO M/A KHI>_Z28MO+K\$R>_I1+
<#H^>W+2%O4UK\H7;N_W&X;J61Y"N=*OVG("A MW(-17.MD"<\I/^8GONU'CSIYI+MU.K#LI58B^.?EZO+E.
IWT\Q\1"D MP+;D&UK\$IMK@5B6:HZVO_>I\VG.T>F<'2A3+O\$EH-"IO;394 MH<& S@>XZ%\$B&0PXYA@0K\I)-
G+OV_%\I/@Y0-VGT\OS)HJRMTHFJF MSUYTUBOOJ0;%2.0M1A.P4A&@4CIA(@LVM(ZMWK;&#/->H=W'H/=-
"9&_HN M_1VM12^*8J;G+X2,KM/H3=1.N\Y/E+081+1.375UA\H#W;_8QW-U#
M6HSXZQ(ENH@_O;H9_*4%8=)8\A,*7NH4H? L*2\3Y\#S%T;K<12 M;J-F;#_0ETM\I?
7&!_S;3MZSC@S6D#2.98(#WH'RA'0'(E(N\$HT^V;SK+;" MR6;10K;5O/LCXN2OFF-
:97S@K4S;4V&C#LA;Y4"D4"Y#2\IR+!+1.13HIN _MZL?/WFL\^5:0;H_=&:>2%@M+M\>3B#(7+*L&
(64B;3\%U^+Y"SIW&66EOG<#>3)< MB*O<+<31G)OK?_MZRO_>INS=-&YAVV\I=6\@E+%;#IT"TX?_'PI(+@DW
M_JORH+'AHGONG;_W20<C\I;W^W"#/7SM\ 379\WH?+1^I\ S=U5/N<&QSBNRAW\%WX%I/I;X<%6D\$-
B6BHL(SG_M8=-%YT#=#-#E&HJ;_I\VS\OL4D:%SPJ;N&\X3)\L_*/4Y/<I\K\BF^;^;O^I)T?
JZ=XBTQSZBF^\$T8M_7W4?^Q>HH+ MXR@KIUK>=-26R8%5/D.2FG--30HD?6@IY3?#CFN^CUB#W%;_4^T%
\$U=Z MM)3M+%\@&ALND\7>+!%YV2/N*;X33HTIO7=I\A/T%#T3O@I>3H3WGB;"C(>
M.041*0'OM(62.T;Y43;X;SW%#\^776\XPH\BLR\9GAN1N>+ \$F@\$I\Z;FJUO MFC)EO1_/EJ^UI_A.H.
I94WP71)Y+3W%+17 L%;HLR627#9H(41N_488= MJP3P;^LI?LB*_&ZLGE%/<;3M"4D9#4V")J\OS*!+*
24A&@AN;+4C=ZH3K"G M^#YL.R9RSZ&U\Z;UG\TR";9PVW41A?8AHJ)*O-HP_&R\$#42-GK5QXCW%=Z+! MD)
I\BNV#X'(BWM0L2(TI+4@EN#8HOL@I@0VVDV*8@I2>3TWA3L;SW%OPJ"#L'Z M.?<4MRX;QM&ITA&_R&EA?
0SXJ\$DL18U-D\X.R\>XKO)O3\RF^\$V%&I13?I>WGWE-<^&^_T<1D8E;45;"I% MS-0
_2\$&I8NE_KZUMA>?"YB&L_'Y/<6*SS\I\$%*);.HZ*H*V@I4Q\BK^Y>O_>K?Y8YA?A8M.AWV\K K;I
<5G(2&#KY6)C47D\I\B1;JHB\68=>M;1>S &2;5D MB2_)\1;2HR>/6M;*PN2DC2I@'\$X\MS5RIWEG-V4R"6\;RZ-
PO@O)PX*7+ M8"BQR?#@E;&'8.O\KX MF_-7FV#;+I\OS\Q^7J\ <*IXQ8I4@T@3I"(A\I\I?"@I\MSK\6*83'S9^1#3
MZ)/Y.8<I\K^GP3+@V8&5L-IFAHM2SQ\XH<'HE2%HI8<1\$JCS8L&P\XW%/JY M\&_B?I\NT==X\I'E=9?
_FSRIO8CR4;7.GZ6D 3\Z0""YP269@SY;_P/D1UO:U _1HZ9\NI\$R=+/70*_R0 M\J;SY8=UR0/KLAHEOX\I@?
HL)H*5.4 NHW>34I3G<%\!&3@CWC9\I_P;@ MUU62\$A+O?GZS\IG7N_75)H5"R5I&6V>P2<9(03%G2-B\I-
41M\KM*U)-.Z M'0">T;_I\O\8POVR\+D;MY.TB@F3#L MR3<_*I@UK^>XW+O?^L5J@BI7\I>+GU2HG58?
TR>56CF16"RU>JE*J^&^" M46^F/N1(7_2=2ATGVHM@M\$X M.V_P4I"4ZZ=;5.N\17XQA>
<^1;51Z8THR\$CC+&SNUJ5WYTA"! (M?CT_OW MEWT8)?_? M>.>"W-3D\$S#&PB>EM-6 M+
<I=D0S4=JEGO;C0WS8(KLM\JOHU\$ DYSSY\#18#H(XM#_*Y(\$8IAD-D3(W MNFOYCB+;B'Z\!&_TI-
_="/Y7/OPM*B<@XLV"TR"R"TI\3=D*B*_Q...?E=O M:0\Y9D"N8Z-U (#DEI?XY.8IEE?7D4&.UH\(+H/(0\$7-@8O\I"&9-
2G=4YI\I'(>+>P; M\I/@QOU;)\2X#S&I+5?!!U\G\+;(.:PHWC'G_%P#;1;"#80KB=FF">36V4 MUI6;*)\$U VN%
"MIH.C;*Q4/NF<=DUD3@R2>.;%V06ETINM665^5P>1H??D3
MLGF\I)O5\IYZ0;AT910#JB82#IYR#P%I*IELXIFVS1K=; WCWH = M%;_E<<\$8F'I_C\Z6F3T+FU;G5%-
I8O20@MKTNO3@#;V@B=8L44ZS;YMJO;<(WUC4 TBN?EW>VUHM)Y;O*" JUI\XJ<"5FPU%(Y-494VI/A2O/I/D&I7Z
I\H M\;3K1GLM<IA#5>;M_4#VN""F;IO8=K(MJ@^OW'5?GIN\I\PT2;BET&IGJ\4\I*\$Y\WJ@Z;
<5R9Q4A\DLHEEUN(M#)H"(G\KZ\U;WC;FKQ3T+_O.C3FNVCV(UJPM4JQ9\IM7%XNV\IQT7%<XB M+ "
I>Q)\I\3Y;1+M^/E_ MO2@^:NXS'H(#M%5Y4TZ;FO*H;U\$;!<I6->RW;RX;I#FL\TGT6_P7Z@ZKW_K\I
MN"YQUT(9;F3BF4-65I>=RH(1B9=8L\$T\9J+5@?H'/H=F@0=&?I?E'@#I%?^G MFP3;FI>I" ?*Z)\$_6^6\?>);#
M=3MXDN\MIJ?^2EF\7IL\I17#G&T('P<5U\7B4;58.&FP">T2J526+C@65=-X
M\ _DDVP5X.0_""*AB;W@CUB8OW1;I>HM0_W/6M@IR_ RT04 M#Z7EP;EF MVX7S*C&9G"1%"1Y\$9\!%;
8"TV7TN\$W9-/522%I03Z2"/1Y790\I?C.BK\I M>AD^:S;_2;#;J@_I*UF&G92;0)W.A&MT88\$HL;R6U9X+BW(-
TOORLN_-) M62I6B_I>7K@7%_7J+N\IDKC MOWH@^Y4V^+Z>_ SI**VANN\$ 5/T8O@!@Q3"1I67GE/-
_8ZNRS_7= MPI_+C\+5Q\W;:\MO\NWUWY;YGC8C=+T+U>+Z/#%5F7;L-9.(_NM2 ME\RXN\$G;I\A
+@E\$1Y%1%(X\XP#0@UW@86 GMTNFV73JE\SPH=5\<#@Y;O MD;MX^>ER)PM\F38>G+;C^FDT
5;#K0C9;B;\$Y;&0;MI8(GZ;7NIR\I"3&W M0EP3JT6_@7J\O;6\YGNJ?R\^5H;K#O>5\<8;T61"C@EIDRF).IY5F#Y"(
M0WC*>D3Q\I\$G/ OQ^*WB)\&EZ>AIMY?O\61*N4;30&RAUEF=8;P3%#(,6 M"?X7X<20LO/BOZY=Z^E^_T-
G@J;I\O=f@N1;)\K\$J@NO7F#>72;^*R M;I^EIA_Z"CN\HH1;I\I\6V>C8S?^Y*B+<%C NTOH?B\MW\RY6Z\N;HH4
M-I;_*BB04=EB>0=9OWW\+;I\GM?_W5\N\$PNAW\Y7XIW;3D ME)QEIY35)\$_*H\$PR9=\$5E;Z\N(IQIRVYSR?6N!
I\PM\$MPXC.I;PQ_0+M/3R4\6OY#;EN*_H\O%7:EOS@3P)R0OYTH\SQD1;7=[6NHS;_YLIAS=I3_BUK9%EI@PT\$4

M/SBZL56^UU(-IW3/TZOZ(F4-J^2WD9GRL,N"P-"AYR4BH12ILZ8.I+D:I4 MIT^6?C &7OS?)*1LE?.,\$:Y8^6M>6F?
H-|S9J^0:&XLLZ@N3LXWV>K,"=| MCK\$J^OO.FIKB+L+B@SN_H>X/^?_JOZ|P>-S|W3/C8PB)X8\$82U\$<08/8*X,
M&L.ULC+;R:N\$0\$0?.I(GP9WOC073802CV^X,U)MYQ&5**ZQ|1V|D#^ZAO?/ M6!#\$J>|^!685GKJ4^|= <@FG69Q4-?
>CF-5D^2OE21#P>6&Y=8;*EL:EUW|< M?O%NG?|S?_Q_4\$L#^H0 (- \$f51%L:K@&:HQL| #ZA-0-4 <&5A:RTR M,#
(T.3(S,5IG,2XJ^<?L00=84|NV+|Z4)HB\$*E6B@+2|5102FR H(B@H-0-M\$9_HG1^HB"#\$54|125(\$9
F76JD^X@HG2^\$T#L)032WO+|H0;-I M_WO//O?NY3?XUDK6F!ESCC) 8|TQEXP|QBC:,"KKPMLV|X-N|^ QA+-=)
M.XV;|H-|H:&\$/:6#|MN_!H_!OQ_3_!LC S,S&SLK"R_H78V"> Q,;* MNF/G#G:|P=XQKF3@_!H0?
=&_C_6|2Q.3^P<,*Q|!+|H_#X/#N8/C"W_6W; M#VSGV<,\$LXW1^\$!H&5G^(MXVX-^,=N9F%E8V4
Q=H(WE^*#XC,Q@4*S@!^*# MWP:|WP:/|R|^Y1.LO(9V|!M|^1700?X|0Z)4X5U_B9?"0=4.MP.9N?8+2@D
M+^Y4\$LYM_1U_!JZL>_GSZCHZMW5M_@TN4KIF97S2UL|>QO.C@Z.=_Q|O;Q_M|?,"+D?
&A;^X&#>|W).G|OF)SYXG|:E9|S).S,1^6U1<4E16_KZBLKZAL:FY MY6-K6U=W3V|?+ @%C|V/C\$Y-3TS.T=
<65U|YV0-|>^|VL_P+3M?Q_!1>_6=-"X|/S2_9|O|!Y4^E:/,H%#3(Z2!
M/^E/^|/^V)2UE) GZF974U.1(V035=UM@+ "SYEP@ "(Q3D;,:)=3=VZC:!(M:3F8T22H\$.JA8+ #JTM&1(T38?
2Q.IZ3/7HK|8&f^B^+A1SFD|!8).+E3=,K4 MOMN.VS="8:-
O<00CE#U7^79,@W96|M+|VIRZZ8M#OY)W>_>MNA_BCHJ*_K MF&@VS^O!U55?
2^6SEBPIC):H2^G4@KBPH?7<1.1@B^EGFEX&6-?@8:"&\$ MH#C:QY6&4QJU6T4S/CFU5I_6!3) 6:F|# "DG*
(HET8R)-04A""% MI AJNN% C+?GY!^JOL7;>H7W:Y^A MN9N|9(\$:8;X|!TQ&8YE7|Z#+(M|_A#1!C%
|4H^R@C|+|\$|L_B|WT@9FO06)>QHK=6ONX-VT|ZPZBZ0^7&X_M%IV9<+|U0#/#|!-2-?|HX;W0+
PSRA^Z^UU2^HS^VR,|88|4M7\$41+1^7K<="M;W53E+^ZN^WBOE7SIT5+UZ(F|,S4) A7Y(N<:,13_"H0Y7
0DL5>5H#>U= M,K.#^J7EK|Q>;HQ8^6H|C^C|HIC@0*|J0WQW| #6: 2_K7|@2-!W22; M+!^*NW9*S,*Q-
PKY)*>N/W5.I(AO^C:44.9_M_H^J2GF7@SYD-0^|35B|SA>WG|A2*&|7U11P00A1PY|G?D0(3>M**|_-
V%W+L=7|Q.G5A.3S^4<#(+MOP6|B?7GUQ_!R7T|!RPA_U)06.G|TR6AH5M_!DO%UX^.-
GO8P>,|+NXOE/L>Z9|@(-= MI8UN8J35YCT^3AV^|H1P4HP|X_O;N-5D&T4L|!^? \$DU|^55LXR?742J^5D, M?2A&?
J8?)HCG59GUEO|O+^:QO=:M;N&EW JO58<=YCH29%A=0^8L<|A#PM_M6)L?
H4F&4W00C@2C|!5|GA#7Z0DYH&B9^,ZB:"HJET_UERH",#|X^A29 M.E&H:XOH?WA\$8IZM|P03S@!-
E5*, \$K+FSB(1"-1^O@?^GK>Z_-/F=(HWY MF\$JE,V^4QTY7AZSB|HSD^F*,\$*"COHWRU|F1+0R
M5HFWEY5,|C6G(KZGK.)9 M^JT7MW_WA|8/GUD=F2^-R^*X11_S=E=5P_&4B21+9B2X?^F13R^<4>U64!
M9^R5ZD3|!C9AYFU?;7J^41>Q<*&|>Y@NJYM\$M3T;D/R0_!< /OH30X_M%9SMPY|W3U/Y^Q3*
(\$+S&PEOTOH3^A_!/%+*|N@PG:#8|JRNLD6Q|L:7.TI M|>:1.1E0@B6^!W61@/FOKC@%|7TNW622Y%XBHNYO?
XK\$8(^>,E+S|^:7|R MX5 I>F&1 G-B +PWR>TV!,6Z+W|U^/;L?<()Y\$Q#E|^C*=|=),MRO&@:|JTRW(H<#8|4 M^1
HWJ^6^&TW?XK3SVWU=:%5=-|/2IZ|(+P305XM|FK.FL^8^3R|S|LM|T*\$_M@ (DMA42.B)#U=\$:32^5KKT(?
=N4H0940 4:H?H>\$F<^L)^ZJ8&|!^0HZB MBF,7A@&@:H(#N99T.S%TJ)WLLS/^&KM)VV?9ZV0MY?V=XU9-!>9S?I
>TU/ M0H+VVE2=4W95^NJX^MHAO_V%# !OAE!A^F^KU&CJ5#ZP7+^%AV4#?^IW?A
MZG9=R7|M;N",SVC+VW|N_X^A2|7,\$U.(J&0-"Z&60Q3L!&_U1K5">AG M0F?;"THL!^K+5-VE+3J2?
YH+|D&@:Q61)(/F@%H^Y8 MN=-ZYQ2.CH|S0<0->^820MOA1_WXJH_|#2(GUP|S<&IH6)H2XR=VN0GKE\$2|
MY1=BDWH6OZ#HLS+X^L:(^! /X5_ZFOZ(WGC^Y:ESS#Q3^ R3|K%X|>^L^K^Q
M3+4DZD^72XC|;RDEB(&^!AD@UZ=2K|Y|ZAT:@3PJT2_DZ7,J|H<^!+C2T#_MT.NO,0L&H<)QS\$3X',@:#
(ML)?>XO39)^C\$|_2GI^!%?Z^+^|)3Y^*ET,_BRQ@ M +8C(,)*FQ_)J4-
OH^OG%Y^4<378VE0Z_43+|S&_SC|Z|^@B^_E_DV_TAI^MPK4_T>@5F! #^%@(100:KFO=F DH&^T3/B&|W?D7C4AI
3/A6^,"J0QST&#_M_,%IRGYM^2_7Q0L*!<#F^IF^E)W_|3#PJT|L+N8&*FWN64?_MBE,N-PI_M\$|37?
>4|:0K2V4^8>P!FQ@^*EZ|R@*_KRU=&,80+!90|MC^TV(6>FQ|0,KV M".E_G JYQC_OB_H^6-
\$#P:~^/2D>G&K\$0%\$B?N9THJA(Y^35P^NY|FN^&_M6X&T^7K/^O4_U%,Q+Z7: ^QY>=?YQ,H4|1\$THIH\$MS3*
+X:N?W_-N^Y^*M8W|H4^N1&K:169|47 7#PP|B_KJO?"=Q,=A|B-T^#2^0QLY^FMC;>_GTP
M_V>^,5:/GZA5P.CGX#;I5RW|HUPG|H?F0%EH(V9%)^L#F%|C #,^R_|F^M(&YK)7(3#!&_2?GKSO*=(^Q_G|
|^))IG_9.C&9:/3|6:0|=W^V(MFK^7D^1+^#1D%+4&6&@H8_JH=_9|W@)#|5V9|!@=@Q^,;@0:POH5:X|AZ|M?
MGUC_&CAX_+ @0D?)+:70*_JGP3TR_44+;MQ<|4>HD82XT4Q^Q_Z.W0H|D MH/H%Z^?N^OQ5&_H=QW&Y|
<|H^H|Q_A1=^=,U?G^R_="00)?UST+Y|S>=?Q\$ MF=GD%KL|&YKU^G|J^0/82X;-1X PX_3?
KUK/HF:;N\$ _#WVR_!XF^!V#S.H MY00B@^R%HD_5(^HNLA:,FCP=D_DC.?^T_*=Z?|XCFX(B)V:A0+Z.BP|^!^ M>?
M9@0&S:%3="91M+>^J@3%#O(6K@/Y&M.&G5_O(NA M-Y^@EIM65)RN2|Q\$|2)SDAVE4=4+SX|2Y
M1&S|HJ^YWR9,K59Y;R|US9|H/8KPB|NNZ^JNHKS.WF5EM!<48.8U\$+<5N^*MP51!"HR|.H9KA/#6>=YY36;?"
WY;+HBRNYO:\$>@M%U5HCLUI%4:12?Z"QA? M"OO:K**
F^WNI/9>>B.L%|H%&WT%)5CEB=1W&Q.SP|W@'^#/HW0OWGC182Q:%
M8:=&F&O1>X7A|M7&WN:;N+^WBZ+VB/-RQ;O6,KY=N%#0%O/MA4&0.4KIG/@"+XD:D#\$16MOMT)(\$='UG9%P
M+I+^&_(@W^O39;WN.5|RI+L,BBCD.W6N>:2-V54)#9|64=B5<<6A.8W.6&M% MV@L&<#^VGLA&DQ\$O5;W;S4-
!O|!^T6%)5_M^G3CAHSXAM|BM:B%,H^O7IN?_MCSMZ-5):6XNBB-A=2%YG_"POR1CPKS2A-
^*X|K|@+H5Y&UL/33/@;D9(|>H:KWWA?7^AQ3(^U16)!95G+G(0E^OH=P@2|4MB+M>.54+<(|O|CU9B^-,
|2:K^5N^O!W|P|J8O^HM#W>|@H=@9%,(UE^K^G^4C1 M09PFLX|M^Z^N)D?F8|UJ><@9^9V.A=
R|Z=0_J3SM|P^Y&F%4^P.TLH^!@LR@<=QG MJ8BUH7W|K|3V^9^FVA@*.62C|0ZVQ(|QM%TE1.TW62=>SV?VU=-
?+!\$./F_8(MOUT0^Q^TJ>.^H_)EMHQ(D?/B+9%#B">;NXWZ| MR>4WKNC|VG9JA>|TYX#N:)*490^U>@6HX-
6XON.EK|)S|Y,B%\$IZ1;>DA%U&XR|LR=&XR@^T?.S6KL,.(B8 M;#^AL^F5-EHZR=\$+O_)|C=L;#|+G<+^8OG|D^L-
&SYEE;E&\$HVG|B?KY_AH M^Q|Z?"XV;WW:ER#)S|=E|^J|S!_ \$?OZ^N?;|%>Y|7D)4"\$Z6KZH),MG^AVW:
M/NAW@.^Q?^H:/3G_&FO7_BKYNH3Z|3Y3ZYHQ^!H2|T^0RX_3!|^!7H^W*;M1N+@):B%)PR_HXHN_M|
(VY@C/\$Y_0#WA: ^N!9H@X^T0-Z(&G3S84>N%|14>_CQ+7J|H(XS;9NF ME=TW6Q=L?V|&T:5DKU%KJ|G82/-
)X2|S,"E_X^O&3#@-(2V8|!)G&,\$# MH5#8:|F^<"EK&6UBA^7@.WMO^P|_!0D&@/6;HU@Q8&-
M5^9:3(|5|HH=F^4QC^M8>_!LS&V%_Q^<(D)^M:KL*>:1=8E.(10?)P514T\$@_M>69M^4S^@!U_#15GV0_9691#;
1%)HXJ|GLH>+O@,Q&>T1?7|!#MO:25H|Q=7 ME(8^F|D9FGXME25+GDV0C%|C^G_Z.U7GXUXX%EQ.O0N3
@=KWL^V!SF&1V%W MDLZ2=2@2?LL7B1Z-0_)U|4.5#DAS?/N2NY-T5_JKGVG-*KW9-)QDR3\$|
M,"TCY.T@>45Y%,2@RO06AD>AX9A"\$S\$(H1QA0TY+XG/D55|@.*YGC);=(^ M.KS#.,|58U>(P&1=
!\$8BP.BTQOWC|N_<@O4SO2P8?95.Q0|A=^_M;9+|H>MGG&7^GLG/5;4_Q|4*!#F
*_5H^R(Y^,|7_1#WA\$TIFH:E^G^+I M->|RHZZN2XLC|XLYLKE+1HIEQ1
Y^QRC=M7^O<6^%\$D\$1+^#2HO?|RSR#)Z MAKQO^"Z\$D"=G\$|^C^N XES6WX:=
!#Y3W^*MXXN|Z+=THZQK6ME9.5^6K(|2LT MV<|^!HXT/@%_PK|A1A^F2Y(?)
@ACP^9E^T41V|9N^Z^4H8@;+5|B\$9;RU6-S M\$(B+^F9J3?R9V,|N1_2|^H^ERJ>.&G.^RT=\$U1B@U|!\$X7|^"JE_L-
1|D-M_\$TC\$/*3,5D0B|(|%|5:Y3C|Y+?7UX|+|JKN(PAHL|>R|O>3; LB4.EQZ|^ M+OQ(DTV|H|U0K1F9K@^4BL_
=E(%;\$E6H@T|JOGQZ9;NG4|!UJ>?B1_M_L5@2BJP^AJ3|700G3VHX^EQ:#&!^9PK1HLC>4_R|U-;)-M>KO5J4R_JC6|
=B01JCZCJ/DD@,@)"N M^8!"83B^C|2PN!_FF4@_"_LG%*EB+431#|H^B|H|UJ&UDWV8+WHI?F:|O|^K
M7;.QSDW3B/9J8K_M_5GH@FW*:HE%_3(E^0_D?5NSZ3;|W/3R6.OY_L7\$ MJ=CV).E4#^*IM)
|OUH6^"CLGEH^DV0#SQNA?C:PW/\$O_S^M<^_6|0N^,FZV#|S,>CF3Q^07Z;^K(EA3WK%Q_)^XJO.^_6^<|^!-R|H%

I M% !SVU="G!U45_+##+*+;CF^0%7C;K*MK?8U1^65BI8=IYZ16%,S#+02IH_&
M69:GGG+3L7IEI[^PI\$9Q0!&%2F\$ILXF9K80L-8CGNE^4V!F=F5VA"?Q@S>C?I+>-94C(5I;-G7%U#Y9G-
@!G!&0NF)1->W_*I2!OFHSHOIRO M\$UAS-OM^IBF7BEMY?T%!*@Q,BTU0!07HTB\$H5K?@8P!-G?M=#J+J+J37
M!JG";KIVB+YI@3EAIZH>#C,M0EUJO?90T\$Z">1L32D9!L6!1&?/W;8/-GHX!&\$F#Q>BQ6 MP,_V QU:1?
2(HNK8!CN9\$2I=T1OW~7C)_C5%P<)_@9>)
M&9T?@<["373S6CQ>A^K;-9;2>)1^A)!2ZDHKQ0H_M3MRJEVKJ9FH0Q@J"6_M&^4(XI9_&(/B0AKT#SH!\$;SS>
((X3-N;ZRM,D!0NG1RK7<K*!9<2M;G M5XWAL MP)/>M1O&WLPICQO!1J)5(RPA".?N(2;?W(BSN;2;YX'9\$7?
LD*4H<&IPN6 MTW1C;_'KK;T_P 1;8G;3JZ"L:Q\$BHJ!ZI1I3+(*)P?7C@_*S.Y6!Q_#11TM
MN,+0Q2)##;7"7IV_+&JW"81IKJ!2M G;T7-1 W!@;8H7 !P;YE !N*B;B2HZ M2;XU+9&8W>_1^N1IU1&6)4:/5IR\$&X*
ZS C-@-%^/KO!++/!=NK0_BSG_M-8LY_6&+6A17^F=TD4(!P,0TKR5_18"/8Z60L6F-Y^;;/VY!:_W!VHN+ MI=OVIA;
XP9@!&(/T.HTT7Y18V&64#1-M!PRI&!GX<)>O'E;JBMHA?N-E M#MNEI%5/X5=IYW45XYTIBOV^L_2-)7?=A3U
M09&_H!ZZT(9Q;M<6;-6B0MB&%L90?>#@DDO&TM4*?U+!R6V6;M!%OY3 M;C?NIR(6V1XQ!H_X?
_6HY\$!H!S!6_0JFKO-H"IEKCF;\$.X,B_RKMAA MX2%%"!FJ+>BQDIJ32_Q_LV+98H3-N;JC:A=SJJVG2A!#=#7_M
+?#MT8.C3ZLW4^!38Y!X^=Q_GSO-6<5_)M;*I-0NV?R#;/LT?EQNVE!4^!^29FA=+)17N&&D7#BT\$(
MWO"V8WSQ;#VE":G9H!S5T@>7MGI!LU!2%;HAB5H_%.6I7!B6Z2MZM(18^L\$ MZ*!P>A.2UXTT?;5U:"1A3IN*
(47_#BW2_6;ZWI%>M3;0EH8;3<_QT-G!MWB.\$R8!Y(43MY@_K9P^IB7_!D0W7
M9RD&7<;P%PL)BZ1S)E+JE!R>%*!OKS;X!2SVI5-ABTA"G_YU@LB1A^!CWL2%UZH;OI+L89?
MFWWL6'6M=8*,"UXHP9X!BN4G(@X<4'K\$.XUSG)IK(7Z8.Y2C)+C=;*S!E M;G_R/Y"TF6O/&AEJ5Z!(;\$:"1Y?
BV;VY4K6Y7GQ:6"EJ7954LDB84_41 MHF+!E">O;@XBT;>(-S#>=1878_9D89*9>1_%!;U>IZW/I)\$+XA9U1D
MJ_KLUS4T9_9G2SPD8@CJH.6!0@OSP0!0!M%!.S;A!>+!+!<5!\$2A;J=DHQ6!4Q_#&#;ZI8)+B9!3T6M"1E@(!Z#GY8
M3NYL%F G0!EBN/5+Y2;6B!^G^5QYM0.0>'<2IE#H2L_55_6!YUV0#K/K_H*+ MDRF>WP&JSDMNQ"5BI&&!LY"
(8DB)!*ZIPNPJL4_KN&^G_RX*)C?<=SCE MKIJA.HB+5 PHM%5(^--1 #15^>|=7GK.DMZDDU5S?3=4L
\$;T;2N3%D M;?CB.@7W,*E!>F&54#;=&;F!5@JTO!Q"7RI5MW;SA!>D3;WMLF!Z*_AE> M%+! "A2?F?(!J.P!I<1O;
(GU!SWIQKW"V>-!C+O9*C5U@_56"12L5^G! MJ*6IR&7A@PK>NA.SC3!LP72Z572LDRBX"J!&Z@^!-!4"-
FOJG!6^O!M8;X_MAU*4C.\$QU"TM1;PT.OF7HS4X.J(P5&PFS52&>Y;+@PZT!50VX
M)10S!A/H;K82J8,PHY9WKK/-K0M-?3#;_5=8?(-ZBK0+_Q5.8-1G TU3J
M80;POI_7^%<B!N@#%<10!/YT,ZWL"DO!0!8?=JV1Y7.&G!+X_^WB!9!)V_>4^!%UG6"IL92ZT^(MCT)!NM%/1!
!SV'R4JTF*_*_9?7/A1<M<=1^""4!LR\$+Z!SFNT=<16!^<2;M+7(KKJA929!&#&=Z&G4N>(P#T8W^)?P
MGC_+H_!^!IC0@TD#^!1@SB!2!1MVED#U\$!QR;-O/V.5FRHH9G!DA;87.7
M!Z;/N7IMX5.WL!B4&_9C)&&V4+*T5"-TOR41@1A?AH9VG;50MG!2.\$!4B! M%=_8!"E/Y?
&LHM#UX8^!9/B/KG!WL6YGN5/JN<;CZ"R!>)G_+4878S!4/" M!/@ =_TWA4N0Q\$8KJH8P
!9F6AQ5D@*GJA+*G!_UB*1").RP M;_>C.QGF/3)V KJHEVL2"\$@G!D?6OW!9'=BBB&I"MY!DC&MADE.O!BYPC
M4*.Y_*E/7JD0080<@-A2S\$DJH4GUD+Z-<IE.1\$%B/WA!CZK)><&2I_M!9'?MR3H@!&U.OG^8L
M>DNP";5/E!5;3M_D+!M;/_MO=FWX^7JTY#="!80!&JIC!1F<_#&G!";_ONG\$=0LI!>5+4"JB^KEIF
M>3RO!HJ2RQ@N!^\$J3^!_M.M>/D*!^!JW74DL!L16=&SUIK2N!^!^8D%SL&I\$S!AJUC_#P_OME
MZ!+!%Q7Z*+!+!M0<3*A6P8FD=DG!U!36938?;#P! M_.CFIPAC;IG.'O(6X?@5Y>I!-(8SE>MIGU^
MO=E3HNW!6HR=8_?F?BI6G\$00Q?/H';5"B%D*#!(3KHT60?9M2.QD54BAXS\$ M;^U*
!OK\$>/_O<2QX!OP_/HA.G6>!UDS_QOED!H4VC!AEUB94!;=_#16_M8LUX@Y%/O#2_)?
N4(4"#!X'S;VH!IEI+4B!155U41JV;,>FF)/+PS5:P S&C M*QH!G3_8.?%L*ZG262E0WZ2!SO%<XN^%?
X#U03_EDQ_Q6J^80%=<OH!_!(M;3;WPT7;RT!T>=D_YAGIX;M!_W_GRFE".7J09>_++RC'G27J15IBI(B*D6!_M%-
H_T<6NYTS?9!8@KR;-2GM2!/BK!)2KS8LNR5;5&*Y"&7U_IG;!\$GA MG!>A_X.8VBIBUCOL.ISQ;
M\$%B=HNA!P!H+U_L'OV!G^L;K3;NAZ%"1.5;^CF;38BF4AP7N!FOU.%3;.""!>OH>PA#9A_MHGVW6H
V\$;HJL:T^H2B!C.E%>YMK@N%_LO2YAFH0T^_0%;;Z+>O+UA M!2AU@FC)QFE36NDU/6;H;+Z;0!E".LC(H?
EOCP;_DI.IZ)6W\$!2_8/4 M>?#35^8=G(*PXJ/HX,>@7IR_5,*77!@_#LOT46;_!%4"10A#@7>=8;_ZUK2Y"">A?5C'C M?
4X^!JMCE(/2RHAI368G!MA@=ZAT9ZC8F!DWV1LW+N3D(M<=5PL;2LFOL_I;K#&! (MAE5 FW
#*Y>)O8OU!"ZQINM#W>I!HG/03G.OV\$; MM;RW^0X8N.KC;S;>=NV_*IVF!;?/H*#"+CX!2<(!
RKW+BD\$K4B9@%EDH M!Q#!8^K2;ARL>TXT>KK%3HNH"W8^XP%@!>UZK3LJ8L7F.DT<7 GN?1-W
MYVG4!>+6Y#Q5P>G1XT67!D_9*R\$!A9X_7?IA!^LU(W5G62E..Y) 91!&2S MJ.O9-G;??SEGS!I!>V9/31P+NZ_;
!313 MTIA@F*M0)JL;JZLH!ZPG8^3T^IA!&_508J;7X<&H*4!%NX3?7K7E_<5U9
M1C&="UC\$%)!+*G'KBKJYL@!FESSA!F.G"YQ"H"KUAELM44 Y_@F#_&LH>*8
M+Y4W?_QA@6^!DV>VT"ISK/EUGE!H!44FN^%J!\$;LXMIZ(^G>UHV<F!8FA MOF'6=/_;^07>*!&(!
("3#YJ%PT83L9D+&#&L!F8VJ3Q1(";%W1M(5^HZD M)NV^9V/CZ;JQ!J4J*V;KF#;\$^DGC!6'=>FIW#D((OX5@PJ-#X1
O M;"B=HY"B\$(VO\$>DWZ)(O=V@M+7IHU_MMR;"QC&8&@%\$;-6W7"YY8M2SD/J^M/-
ZGG9D8KB<>_!1L"J;_6@Y#K5U84Z3RGP;=OV^12!QJ!40!T)WRX=AQ5CQ&^Q/57??
AV8G;7>^*T!70!Q!H!5(OR!ZDS_L"Q_%L#^7UC!4(M0_0(MT9XS@)LT;Z3XG/B^!J)#C#NT_1T9-
>HBD3VWVA!#W<33*(59-M<7N^OR'8'_M0T)P\$A+!A(DX_3"%IK)Z&SBW'H9S79/?
B#1AK95!2&F18)9J.59^%VETIY M25^B!0R'O9WE>I\$+R1GIMJN^!^C_\$(A7K!O%3;_2M!Y1"#F@G MN1-
8JFU=CSRC\$)ZB.WU.BE M+!B/ZL/%F9%R>422@#WT;YS;+NY3)8R6ZBB*;!CD-VD8JZ<)/K)IOGQ#6(!
MKU!HUB.S=I3=T4S;_+!O!HM#_W\$2Q.K(\$6A MBM^AVLF851@;=@-
*WCN!*FQ9/(F/Q9Z"8Q!CSM>*4=R!CA+4!EDZL7*9!OS MDC0(0!8-6L.K9^/H\$AG:S\$J3BS(WU>9%?<%
!C38U(EQ>7XXY=C!*POWZ; M;_<9Y46#1?M"42;;A4NCL!;J4HU)X6!M;S&KQ.U;JS*\$5"W0L_XC!8R
M!TJ2_U;TYFKWDI7&IC7"2@E#QD=I5L5?WRR;8I=H';9S>3C9!_Z.\$^&11.8 M/6R8JD_V P45K"IC_C7"%IZ;>0(!1;SN-
9!83ZS#_"_?L.%Z(S^;_!(LIW M&M0.X_<^PJY6U6VMX#Y=N;17K=4_2;>\$B*^;SIZBFQ&BY7BR"=A>7M7<0
M!9CLCAW"6XAZ(*P\$;5X4)M7#_04M3N+!^_O^!0H)J17L<+!@;4^!<_UW MO+^_<%Z21!>Z!XE)\$60@K8!-
E7S)^Y0TF0(T!H^#E;_7ANFO^N0_Y6U!9FG MA&XM^5L!T.U;P!Z4_#H_553\$PE2-RCK>H9N"
<10!&_K!U^AVZP?ZKZ MN5H!E'@IYCIBBK7W9A>P>L;5!XQH%PQ0KIN4!(!+MC4"00E3Z>!SL!
M6;;ZRQ!V9!_OO_E45D-695QC(#K=4N>EG6+"82Y#EQ_U_>*O*N3^U;_*^3H%? MR\$E"?
O2=,1B_BT^2.J!V&)3I^T"6/>8S!10I3STNS=FL%T!W29^# MA\$X2&UDI^%*W%=_/!@Y.OU22 Z!@#)?
E!D;MA1>ICOFP.%)IV=N">HT>4!1VVOXTJ%NH!9*<*HF"\$2ZC!SCJZ_!+MU
>/7H3A>+L)5UR'8JH=YLWA1!=F!P*N<"D<5)%OAK9DW1X6?XE?^KM/F# M_+_G(Z6&B8=6<4L;
/9^_PK9@29@K.B_!K@CM.73H=_",XE*W3!HL4_9!2IB@);C_L>"YI6*H(C&R)U^
M=YI6J;_T%15*N0@GXM8D!B!1@DEC_061_?H#ARV3#G&^!BE+!0!MZ\$;_M02)8-18-\$S_.WIBO<
S&H5!/JO93Q+4C<^XVXR_*2!_!KT(M_XZK/=V;_!RA+YME M4!9ZPJ7DY3!58L42^H6A
5VDN8+6;PBF3X94B'S\$.HN/_U_952T-NG*O"1 MEQ/A^WDY9YK+LJ7!_YB";#G!O4C1;34KWPI/*_GWSH(!8!@K?
ZG<+17Z MW8T5GO#>VD<1,@3W%_ZO_2);CAX>>=;V0OU;^R&T!M4&_JG*1)*12+KC6.D MI_GEL7+N"1^<-
LAF"W/N&_W6B(BKU;T\$!;(A MHT?>B5!)?SW7."F3;%9/&K\$#<_*V;-YI-BS;4EDQ^US!9;/!\$QO.BW=BXBE MBZ)
(GYC/45!8@+O1P-CRI!18_#(#U5>DY("VWV/RL3E_15^Z"9^=;_RB M/GZMV>06?64#OY'A/2_>Q%;F23_@-
EU)KS'1KDFM!B<%?7!&YO:'S!WS\$ _CR"!0H7(2A@&20IZ!HD_Y1

M.;RE03&8SH=N@>^N#DHGWl\$K@l.T>+l8*Wl@9B>MH#NECM?5UP1B&J.5M3.;;E>007 A%M6CV8-
IX"R1PL"/.KDBES^+3XB7U"VA)@:7% MO+RIZ!(24I.O#90*IR.\$'AU*07-I=K-%MWC+!/?
E.;3H@-04@0&\$!#62TW02JT9%00ORBVO;CJ2,ZI.MAO)0;S'ZY 3UI<-
KLHJ#A_/716;R2P=;AUJW48!T*!_l61/1WE9ZPC.,#X MYXL ?WF>0\$1D>U -PVOMGFZL/=00Ml9Q0\$U"?
NIUEM6IPR=KN)N\$LG*2TLFNCT*^ SF%L6.6%KL1L.DlE6XlZVW=159P_3,BI.)NIECVS(F#SL9UC
MQ=HYI_8.OU.;%&1/AEZB:9!?"!EXJ5+YZ M)Z&J3L0LO.1%M:GL>=I
1K7.G\$!\$DU2%Yl/6@V6S)M7FEQBLClCXXK07M%Wl M44,=F=0LK:A,JAY* 4U HCS;P=_81P@?A=S?
3Q"lIP@7T00S>G!+)_GQS4)V M42'DJ%A:GQD(=\$'\$;X/IT1FJ)_+>I=4Q:JS08F3XS2
MG#7+9SO>E#E!PN,QI^YL# *DX-X _IH"R>U(/\$TlE6C;9C6BIWQVlGE.^;.) M)_.G)K'SG!+D6EHHYWTl8_D'-
MX(F8Vl/CQMH&*?G\$?DNO"?/CVM,O>+l M,L#L.E^ALlY""2+,6!>D3A""*YTI/=,%54Bl.;DJ/HF=
(>*V7"..Ml1D.V#X5_-/*;#(^+J-QNlC*!.'?_XHI=I#&+RClQVT+*T M36ENZ9C%B4_VlU!X6FC&Y%1SU?
*0U"CN7#6-13W\$%635J_MlLX<l7TXl29X MR<+l#E.L *YHl9FE%9;
KGZEEHl50B1L-/34%OYO!6""*R/JD39^K+U/Q#@2_V+YUNWSl.8NP?@&\$D1E?DX#.-l!*HUN8
M.'+?;L@l(C;9;W+T)MD9P HOB@Q@4)!EQ0K0W2;"00(!=)07BTKVTl.Q7 MlN.;?
3l'BL(6Z0S@!AMS@J7B2@4/_R@_ "KO!!KDL;S:4Y> Q!\$8!5K6 ME(A>/2KJ>.;!1).4H::@LN5RV;F-1HC/
@/9HTY4S;R'&^&^/XK(*&CBE6 M.;.=5D7NOC'B_1,%K%G?3H1.IDOS&UH^S?J4\$7&"UI05-ELEX-\$GA MX?
<lO&\$Q6&/DS0lMB..%1U M2%,7596C_+^L.=!#59@VBE?D"X IO#lF.; MlM/R@Z.8XOYl^0%D^(>.*UU_.D.
<6;2lD+G?D0?PUTHT*3YP/YJ/ M'J5Q2 3EC&@M.\$9Zl6M1>E>)T5;69V.;"74_F729_\$X0UH-G/ZYV26BG%*M8)///?);?
FR4)JK&YAl;SB;T+ZlRKYVlM;MU!4D?7PHHT%M.(@=1_9WDVl)80 MCIOQ>BKP\$(-WF!>YD#.;.3;QLX50!&G:X^
M25^?8_Z>?2\$GKl2UG6NG2);!&R7QH#@<lSS=FUJ 4lO>K#&TV7?)-.(= MZ0?
Fl#T7&WNW=KN8!#XC3.@UA*KlV/L.O.6F9>BLMNC7l4S?G\$C3RDGO Ml;O!l"1*+Vl%)F@JlBH099K;W%Nl;
lA)^GAY/QF/%2=+X-%A"M4Nl.&FK9NA M.8,*367S&IClG;HY6C>EZ9N%L0IT# 8QUALONl7V.A+6*\$N-
B%NR=8C\$LVl M+!PBZUP7lQV.T03\$FP0R(8JlU@>@V<_9_AK9MlGV8"DYA^)/O=;GK>_W9l@Z MY+++4Z<l?U?
RW3l.&KSC#=#S!4UP(#)VHCTZKSlO\$S+lA%l00l"?2*!H M*TJDSZ@&LU50Q6P3QKVHT70_-P-PM#) L8
AlBC&H9Tl/% 4RV-l;3@2TlR M""%VX)l8K>;MHl\$#+_DJFF2-l0"J< 8P^MUANSG;>&H-0^5W&/V<3+4V"C;4R
M@Q>\$UY9WSA8,2*;K6(P6&*F?WRUVO#0(GN%TW#3DS<\$lC+2 M9<4Nl@AQ0\$UA;_R&lF7S;WZH\$>/(T\$;IO
%3EHJ9P#EWZlS0500C%T*^WE M53l_Al/lF7VHA982\$H,lJHDS6U>B3FG(JYTK/A?HQXWBT+U!/*;Zl*D(V3Yl
M'7-7#l#L^3_!5lJ2KS(FU6+\$C-"NM@);M2/R#90R0l+UJW-GK&0V YMMO& MW.U790_lV)lAT6R+T-
VJ983/H5(2l5MlFAU>:2DHL.WEU+\$5"JR0lZ0;&@3D M=EL9CGGR?&W>=;N;
7lC8XY=T3K)#FM\$8CIM+l/VW5+TEVYW?GBF-Al1/MPJ&SS MJV->"7KY@JK&U #3RTY-lY+'PN-LQ_#6;
MlLZV%>9G9Z\$?P3Z;=4lCG#(#5FZKE%X <l(2)S'D-A3U*1\$!MB".=lDLC%/MU-
QVGY^\$l?"9RG.0S#2<lC.0ARMF4Hl7E<^FE!PGUF#DlW0M MZD\$;KE%QlV+4\$;^M^>0lHR4G7&BS;l5*#.#.W>-
lZQ:R6X("">-R^RB;l%&l M l/Ol_(W7_7J57G+M*U-^O;'ZROZ*\$>--"l.F'6?l^59@RlKC3l
M@3ZBUE#P0.W6HKK;KK042^UWYJ_84V&VUQ?B.6JY?>@X3&RN*A@>E\$;@.X
M\$TNW&_HJlHUGY\$TIMAVG!>8P!EQ9l>G;=,l@U!l7<)<M%;7EG44lO?+? M'K>NF+48U>#JlM;MTPMEX
MPBAM3F;"JK\$A2ZE<:D;l;1B/F=6F=INV^KG27B MWOZ4*.S<19X-ZM3lL;lVSBN%HB%6!?
JV;Al_D_N_.\$l&NC#V)Xl84Z+ QF M-G?2A:5(=%HB ^C"V.*P\$Wl3)lT>T:74U^C\MA3Z#E7U\$!lO:5_6W<;*JlC
M8D05-.6"OY#)=A_C\$308V8lCl18^P/VFYHZK-QQRK?7+CN7%RW?U!YVN240(
MGl260MTJ>Y+A@G7=.EK0QG)Dl%NS;45)5:A=Q&6M* _W_&O!;88P;TK#2XA M;_&TP4
"Y<44G+00MZ).4@XG3'l(O64_L(KG:\$BM)\$*#7(C/O@0_"T6>@l*
M7L2N'T^(<S&KQ9H(\$@N%A2>lAR/UUJl0!l*IF6/\$V4P_%B;JY_&)T9'l M&C&%A"\$3EW/F'R?D2%
(OJM;8=7JZXl_?W0ZD^9J3+H)GBPL2AM)lJ68^_M4K-MRY-'3';G/8;FV\$^;S%<%_R=825*?
FY*7E;8).&72=0lPQ@FY;OQ\$4= MX;F9AQJEL_67E(Tl4@4M25UD58Jl!250"+YlA/XlS^&80",Wl^VZ3A_GTC8
M_V+00<.;^M;VP5A14 ("E*BT@l\$!l?R4P0\$!_2\$T*,B74 \$l'B<0>D^H@;39OE.^<l
lWG#lO?;5F;GF+ZZ00;+W6GO=SWW? MJSPK07#.0\$KPUYRSQ(+_??
X+Zl8l9W%>@U9(F/L'8@R>VY^7\$RlD(KMBEJ5_M3>%4>DUF6(7S)5>_YlB@Sl;@DPO_NUN?Z3(+@P-
P%2%E@'=lOC2R9lZG=K; MlCM&??B_>=3J?^Ql7>>H6B;SGAD;\$!lVVOD3lJNM=#U-H4O? KS@4MXlLl
M9ZZH%3LP@>@9"BlV/B>-U_&^#WDSA2#EG+M@6/(HF"-P1R28M2UU*#@8?7@
M>Vl)OE"YMO5&188^734%;YD!P7.W(&CCY!_.;l\$+4%;K0(O;C!O M*/6 AJl"\$EHC&A"_4X+*
(CM;.,l2F^2EVR_TlQ>R3^B6V/UT+=)OBlO M2lKlQZST9^6l3(U:00>Yl)HG\$S#0lZNS\$.K;) @Yl^P;;KQOZ\$/'P-
P*>l3 ML;E!&N%Y7LB39@P*!l"D_lQ/'lH^B^2K70lY>#M>F9CUF2JXC/H>lMU M?
S4=NlHlLGRlN+6;@3TElN#1SD@*7.\$lL*F)?VRJT! M"@YM"Z\$=lXCV462>/#C;5JYM?
EOHlCO#0#1KV6W93/%#L033l)C'QlMTl)_MDA1_R'MMT"0W4C3Z>9_ZX0!_Rl_74M"4L22VZ#1\$)+?
=4;AG(=Q&3;(CW#l5;Q5_SlWK5;l5L5FT_lGPlMN%
lWl;MlL_(:83;GVKC==>16l54=\$QWVE@P8lRl\$)7@MZ+9G8V4V8Y;MEF\$) MNJL=1Q.4WA+Q&-(462.
(A9l>Y6F1%HA0Nl2>CY4;2l;KZN73^MJ_DG-P/M MS%#J>+Tl+l IKP.08QAEY\$E!(8DDL9.03l#;S;2l-
>REL4l;RD_Y6B8@/L M0Z*VH;1lX(Vl6PH 3R+BTk TT&M^MlF"KBF=EL8G*S%;JBlCKS7Q653YN>
MlOK=4+;&VR+V0l3X?S^&EDlX>(l@lR)B?="7@""+7DlKH0l)"U<433lB# M5l_W
#UZ86M49!^ASD4H;^M0OT&!502Z^@M MX?;#G?SPD("3HlL5G5@T-
MQl+TD*\$W_!K!T9lR=*P;H;F\$K6H#Vl3E/ T9*S=2E)Y_7)7R=*P;^E:UQ7 M02"NXY&YlK*K^@l;VH?
BMPB8NQ)H(O)!1\$;lHW\$V;M ^+Kl>/EE>BH0 M*C BlU4SH0 M4Y"/MU7@;^\$<%
9"=8N"JEUQVlEX;JBM;lTNN*5A^;@65L;K->#6>;JO#LYZ3K> MG;l3l\$ 6)l)MA"lQ7G
MQTB2Q=5lZl;^<lX!\$6RA6U3=H<:TL\$ADZ9)U5&9; MWA>5lV-0;C_3P4_ZXX"3?2\$10;WZTl3? LCHST-lA-Xl9"5;
l=)%MWS)*Z M?7?#JMXO?R75N5?l+V%ZFARlO.3!*>??Y\$SRGBMl(*lWCQ)@?8N)*EP=
M3DA;WZCYlB520+&YOV*?^&NlH%LD>(<6WMLER%l)V^lJ&B6@lJ)#!2;l# O. MPlU+#+C5l"2-M8)_@8-
#95K)@Y02A_lA O*\$?K+2=0Ql!DR0lO.K/(PJJF MT))R^l(ZHG6@_lV(85%F?T03KYA;70;MTDlKFC-
@*V&^D;lE;YD M&7lC&E14D02X7l9^E XTY998;+49L!2;C'U=IFQRKQlWT/#^/H_>.COS MC32(SY?;".l:L7?
8V'P; APYJ-WH+&HlENTU_8_C3 4<l^?7=F6QlJ0_KV8^;lTAN/>KlQ MO&%lXF-lRMJ+Hl&CIPJGB?(RYlZS?
^OW#"@8DZl<;&#QXlCFPA0JA#)l M0TV;TYF&^O*!@U9K4Y\$<@.% M2N<@H*+l4-
lWSG'lY&E!ED=!"l^0^Z3Y;"3lGIA(NS%.l95URBRYH4;2lTA M)"2S=%#C7HlH(MQTD&&+SB
+M9@08\$0KXSWlD.lR?6B%*l7BB%F_!HRP!R M\$R;"%T8)=6)1R;l2.(#;H@+V7/(8;HF%8AN5PRIJEVl
MDR_"W#l(<lHBFGY9(lG;A\$?JlZ#HB;*@89_4F;5YTH?lM5L&_T2+8\$86l?G M\$TM>":RV;;GZVC;G?HUZP@5_\$ 44M
A"78GA;5S7Y&^H@&W2>_2GB_l M02AU MVY7lW;W GWGUU@E"MM)l_Z=0QlPE4=UJMW90<+?G1;lHl;
l"G/0QH2Ll M..M_&HlVY6;/?42l"0^);FE!P?lKUZ;Jl@T8_%=^<(WG-4Ml-"2K49&27 M%B"WTN;X3l
<6CJAT2EL;I=(\$4H>YR0N\$B^S6l@>@C#2_1l;0Dl.\$2;UVY MAU.;+^*G1#BJTRZ?MO% 62"WCYHECP!K?
O^lJlD?DT5?+=98M+BD20Kl7>Z&&WB M(Z^Q^S;A3lGBASJ="DK=?&(-W*W4UQ<0KY?Y;QROlC?
E;^&YQlO.KN#6(&Ml6.8)_6>;7"GPI&SlZl"Vl8.9;=4+2T9;&<&Y5P?UH-&A(ZU\$4>7Dl6)(Kl;O'3*GRYX2lSA?
O<[Y/lN;P>;802X.AQ*H(C%T2N/ M+H6lV5+;6B6-LA9@/9Z9-UlZNIHXO=^9(CH-XGSU"_(6<l\$;TP9*EC

M5+FA#)SD7TF6I ZJ:T4)0"2YYP^EW=_N\W#2#/8IRHRE@QX@*15IU8JHW54 MO"2@:/;
@^1E.)JEANY72793J8=0POE@|TGR?N0U3)SZWXW4I1"A:VJEYO0E
M=N\$7G>2G0POVPE999B!&Z.K@UC,858 7ME"24^O.C AJFD=3B0YZ V^~/G+Q M"?*% IF(X&Y?
=1VZAF&2G>W^D<I&Q J)<5JYJ,V=0V^AT?%-ZH6;EX6H^@Z
MP0,Z)>L+=A/I 068.TP>H<%0:%A.4LI@T7RC>N8C02L#K|6CZ6)>M92_6C9NJ&T1M<_I4C|D *CVJH6R)
M>2P5SNXL|6GG|ME:N9' 6JL_14D6@Z*=1|6>BUOE'8)&4IWE4B\$,R8|L,D>3*,I|D|(.Q)&\$,YE\$08 MX^@=@=L'\$^/4-
Q|XR3SOI+O=3HJ:H_ OQ+D:(>)AA_X&-D0OPFIQF_M:=J?) MCF@&&-Z\$SLY#"2%T4
OASQ(5&D0O|O3P|8,;:/+4\$.=*G;H:00>4U2+=: M"G |RTVZ:(B 7)2E@|:2\$^_X_#8V:ATBUZ:|&9W4J66REZ3^+
I="3BEY|/M-CS*|~|QK\$%X4'K:%:\$S8T@5*106X#I&VQ(8VQ>1C95KZ:T_@(T1R8"F>@
MV1G2#F&KFG|S|V)&7M4&U-0*,T02KN+6E^~;_D*0 980I4;O|7Y7|VKEW'S@*Z8\$Z;|TFG^"G-W8 M:*G|U_ I-
+5|NT<59U/HJS_*Z)0|Z|O5O.MBJ5E%_<6#K+%/3U?)|8^+C(M3'20/%1|B^%?%|B&+E3)RF<@("I?
_A2FSRKO1%#J.\$|9%Y1%2#2)|<|>IT% MER1UK^U+D^T^~;U+K7Q&9A>U7N4;EGHJ_08JD>U:|IMX
MEW0*K8U3O|SY.)B_V |SH(C&%2|QC<62#B"*E+*7RG|PDLHVN/H*^&1CX;H MMLJD&#|S@LOEK2I+|64J#*87#
1/1BPDFWZ<< M&|A9HAA|>XKL/14|O|3IR/%BLP6BA")98IH8N_@:,%%'EIN5B0_||^"|AX
ME57Q+NQ|(|Q:\$*\$*0@B.3L7% XOY0+PH5I%KWCJPI_R&|F,\$%X|^% 6XM(Z(AU M/+POQID."C_IX|)
(ZX0GWU03)F%5DJ4?PPLX\$N/E+;L00X48D1T+>L"IM 8W<:;I4

MD)@T6ZU^K@R/FU@!>)>@6D5D&SC@LS!O*.D301Z|JW|>EM|OZC-R)=I:O>:2UM_ ^*0MV#6)0%Q0I M^?
I>\$0':FO(Q.3GVP)9Z5\$O7"V45%34*=_/5M|W|U5:~N4-U M9_8V"UKW-) &S;B^|@+U6=-DAQ%8J<(|#.LC?
YI6A'B|<>_&F/?4>_RH<|2 MVV7W1H|FU|E^0|XKL|#\$8(LCH656.%92JB&|EA(*F(7'KUGJ?%5"
(3U8'5:>L7%PK<8T0;&JF|@U7|VP>/-Z8J|RDR+= 'RE|*A8%LF7-J3|,4O M(^+(O-CV-A
AL%|H|_ Q^F^%B*N&1T.9RIS(\$*:>_F7Z_D&1E0PY=W&/'>U
ME"G;)9@U\$U\$MUN<|)7^-6Z4^@'6F2P"W^XEHK;#L2K|TL@C9>*+ZR"04?0Y M57&O?-
VVS|V|QA@/'EB<=P"/:1.8XXB5!|@3R\$=;X""5@07|>>0<0Z3>KP<'<
M|AF>KC="T^06|90D|Q:R1S97WN1)TWT%OM0PZ*V?;Z|@T> A8Q\$0Q , ME/,#0"A4EPZR)>!"9T2K>&R&_JEP?
L7M4|UEKS6#HJB@|X)D|TH3Z@&T|A
M/04A/GD|^/4BPPE*CS0T(N%K"S+^TO^KON^M^YZMKL4D&\$#.7ZDAZNPN\$(I M2PIWM|H%*H<):|9R*?H.>&?
H4@:92ED|,+|(|LBAG X*077+-RT)(&0N+X3T M|:4BR3#Y/>07|*7.IK"00?M^Q|O9-
QX19:F*).BB"CCF"Y|U6.SG1\$27Y|' MSIZ*,:S|UNX<<-K<K'VARJ'B60|'\$7?%I6 M_5+/-H|WCFT.2|KWXX#V;-
DD.N'R2&E9_O)UQ|0DS5M"D\$PZ65V.2,<0U%|X&HYO3XX=KAVI=Q MEV-E&?_OYF>"P+J_.S3&:(*(K4A0#Y%VIK!-
B-!)GE*2K6@==*Z|Q 3I|"? MYE??)|23VZ<K+79*KN:5)Y)WV58UA4OX S+B6Y|T-1=SMW2.A\$HY^@AG7/*
MF%G2H1"1K3I7"1)3)+* Z:95@.N0GA0 4JXTTL2'4K|W>|0EG\$+#+|IV^9 MY%5B96(E%2FN1Q?
_<@LR8.4=@BA/(-^3G5K/4W|EX2,(X' T49V1"NR
M01S|;\$&13<4^Q|X/XB3US2+7|=B<<_/H<4N|B8<-MH.VC#?|Z"# \$|5N'Q:T M#LWG7C"?N1Q|5C-02>2L?17S#?-
HU<5Y_-R6|%"J8999-1|7T/GKLH=?<&|(-M60#@F%R5OQEB32,%\$*^PIEF;^'=X#
|SI(LHBG^E3!!PG\$MI7EBPJLM:S|* MTXFD6?N(EL\$89<|H8V>AG> C"9Q&D#H:U1AWOV0Q|1V|=+<8@A0-X@J9*,:
MD;:J+|P3@VR6|F0.R11)00G=_1U|I425^U|+IP%QN=X+J\$T>@PWW18|C)?# MP^=ES|:SQY\$5U,LG7T|NSK,\$C'C-
@/X3Y|LOO+)-" @8;^A1X>TW0\$T|VE M"Y%SXA0_#G3'P4'PI3>IF+0F'9|M:87Z>SO+;_0QS?);D).#THD?
M5^L\$FFPO\$|9"O#_L2C(NOQ^&^>_9S) 71QLH)PPF6X8@-4J|(Q+XSI6SR^
M^DEWVRS)\$I6255M5B05XF_&FS=5850?GR-9);B|BY|JN%G%LK|)!>+M>X^ MP%|M_|^NI^>
XU\$7228_CZY|(Q\$654B\$SE=SH(O>0>MB|~T%:B\$;:)|H|F) MMFN);40:1U|=\$'D2PRB^;B;+|V@?
JOX""2'F(Q9*-8S|R|D_4(4^=/_FY0 M/>U_>+;P9|'C(0%Z>?QT4\$D<@I6.>7P>YF-C";M6+U)%+5;_C*TI|/T?W
URO+Z\$YH5KP68^|G) &&(+ #EX=;<-H5#8Y^7).0I M^Y<7Y0%)&O(AA5\$\$_|KMQ<:B8^:2>|8==GN^_B73YM#*|?
@2(-#5L<(&HF^U MWT?-IET)@O^8YM<7N3|TH=NG\$?O|O?S3#*7=(%YF<4>D*YO-4>T4'?1=; MG^)-
MP\$|5^&=KUEJ/AZUF^|E*CO2=|HSBC7:>C<#2EMZ=|9WK'>)V2P:L5T|Y|%"S M)|@N;:D?
IU*HF85U16B>@PGDO?S|H|/L>..S4@^N;LYE27U:5;+EX*;C@|: M>L_OL|*L=J>R.+6X9
M)#.I/KOPI.\$|X888L;&K88FTH0.LH! K*Z|!#JU=G>29VPQ/G"/U(RJ\$4H MVA"M;XEZ (4J'& "J51U|=U> L|^!A6=-
<8QTT&A@0|?54<7L7GK0&6L#|CA MIERH+CVH@MSY2+5Y1W00O|GA;/=5M+
A;*+D4W0UH7P|MVL&Y+GKA|A|D M0L2E;
(Q@LB2M/R"#X|NJZB\$<@1^%=|82H%|%|JD%\$YW3,B=_|'Y;D>|FARI M@+4_)IC7G0*PC_@Z>Z;:F=W?
=|Q9<X0|4QLB L-X=-)6=|WCXSU\$|B|I_ MJUA.6T|8350594|5Z|%'FMV=-ZOCY|Y)_C.8Q6&L U7\$8/)-4;*AE|W63^6!
M5|7F0^V@;&_6^XWMN-V?_&%U8I';7M91HCT9'_%967.%3S#<#0=O\(\$S/R MRC/_6)ECPLL&|9N54=N)-G-
"P.J4'V|'3"3VKJ';EQ:H)BJ0:)|^C5@&M MNPY'2'H-B+RR#9DUO.1GTF9IN6;+0CQ5G|ETRXX|47Y@N2D??A8D?
0Q+H'+ M>Z=K#UJ0L:C7>S9&M28S|9V8LVN?M+(-8Q-YCW18#@49?OP4J<*PK=;:Q|^% MY7Y|3|H-
'107HH|G/3=L?Q|M13:UP&V4!'&)F>LBE+|:S|2'-F@22N;SP\$<M' MPPC=UL:|KU)\$6"
_*:45JCP@>TPIDCSX6@'I*|H*|BW&_42S44X1;S21 M-1K4A2QJ3;G?'"
H5M|Q9%P%OAF6|)ZK#|N#5"X17'D.7AC3;3JS=E/@W?H|
MT&FE|Q8&_DOZ\$^(&Z)V&^>W%@ZCM^*AMA=POD4=L7?_M4J5_!\$*|^N/ZD|' M_:=I=VS?
O0|FL>ZJ(33,'X=+5V;:ZBPKPN@LN9S:A|?T\$SDMT5TEZ|6L.K? M7VLZ=,6)3M-AG|R1R1)<2E!!W+R/+_QC.|F"
(E3E|0|5*L|8E;MX|1(UT_ M?GP_Z4FE@YB+:FE;2%8|RS+7?'4V_-M|BC_O/H<"?;2M|2:M;'|NH%=ZW*T
MHH|TM1Q5:|A)E)B'9HT"5B/%7>13F@9IB58&U_9PD-NJ|:|NK)35YP|DAZ M;-
_P3.TZIGEOGODE#W4R|'BG|Z"L5U.Z2|5|7V%520DGF2%=E|H?;+I6#
M?|_LZ6J6*A"CR=7EZM|D4Y|!SDGN!'_8>Q&A&4&52_YT;|IZZ?S\$N+RK!-B3 M;JR0Z0=K|H07X&Z(-
BC"BZ"0S13S_NLJL^HLB|VGBH9N_3JN%?XK8^&K|MH MQT2X+DN.3LQ PI2%_3PLB
PQ:AZ"Y7JC&QL7IH_NFH|=+TNM8*W9RAE(H2K| MG|Q0^&C9?&WAFZE;H7#_6?U&";T:E77>B+Q-7-|CP|/J)|!2|
YH).WF1 M"2C|+W."B2EN8UFL9N5,"MXQ|H9D'V2D&-T6#11JMRMW3.CEQ<|!\$^&^&(C M>@.2<>D62)X_K|8UJM
H|AZ7QYRT;S1W7RO|S&CL VD_X) M51HD|MM F;OLUSPT-00^KCX1FX_LC):%DI8HLEA TD*I;+R.X.H%M57H%0
MZS6MML8-9|0^H6WUO\$K0V_!ZC DERQ|D:2SO_-0799\$PRG|A66FN.4Y:E+FXSE M\$;EQ.VF7&|&L-
NGJ&FUSL*(K8DB@0K*^51+@|L|THZH;XAW>/%G>YHD56(0 MC'E")#U+IH.X=*|4D<0=29(EMHSOX!)|O5/0)4
O&%_C1-R|7Y5)NP =;Z6# M;KJO'ZZ36KJ4P6=-|3KS3'Z7U|!KE)HHI?UG3JU-S".SFU)(GC#^CKB')|0
M'10"H24987|N2*YOC6#I=6#M&=40,BEGOY58^C6 H103 BV"43:8VA@|V/5.@ M"SNK1=&O|03MR(8X7D?FH+
D|H7SE0ADOX.C=3|Z|903<_"G|A';^OC;_33 M6Y&|X|?H("2" |PY6Y0.BBYR_*C|0Y9R%U"VQG3_2EJZFP-
4Y#W|O4^J4-&K&8@5U".6"/R^|LK_*X6Q-W9
M@IA6.YJ0CMY0Y>\$WT+\$ N^%VF1_^V|H)^%O;\$|10B3U@P:\$X)ORHG4K09SI
MB(-ZO2NK_/J'U39K|Z8<17>@/'%"I4-8;:H*W9(|A@P(Y_/A.W4NW\$9 BES MWG F4G*S;|I|
AT4ON5L|#YSRIEE&SK_-84J_+?+. Y+;QD|BG788"=C7TD M)H&+;|J#/'C_47Y1^X1<@2@(|H|;|JEP;):28|GJ6'8|G+?
I7KV611 M%|MC@YFD|*+P27U|EA@%_7_|ZS5AYV*U3Q^N@AS==52IN_|7|^L^|H|209
MD5BK|RVY(B^F2Q+3MQ/Z-|+=03C=01V:I>4VAQ'ER);5-J7XX'=0-6<: M|+|I_ 'U5Z M;:M+"6BZT5T?!

__DGFHYCD/F#4*F"0T0N4IH%E8XNB@*S T7+IC6IF.V.A. M+3WO)?81F13Z5F..UH6RK(01;=-L%Z9LDN-
1LX4PPF&AF_0C'O@Y3;U_8 MTBUW55CN=1.8YN>KNRAIJC@(-.0_ZN#P9IG@?(/N+^)JR
MO.1.TD+1#5VV1=/'0VICH/DG++I'+J9Q7MA;'5*IT MWHH?<)(?;\$.%B#R E#A2V%MXIFUM1IX2(3"?
3^73@_WIT/M0DY1IMV1H/'M)HJ=SKUQ0?3G7(4#C3EZQUUN EN1&(ED)K+CD84E03C;T_>Z36I'ALI>+F
MC94M'Z;LL&MMI2K0&/'N"W"2\$8Y@/9AA#IT%...K#5#&W17_1&V2U:P#MOH)M.02ESKJP5.%_#<
M#6)&@B7)5..W..FU.&>FBP<W.2SYJP'5-U:RO0.#J(7&1PMN/_1D0*P M%';IV'RWI)^JIS?
5Z^:MA^HCFAK#IGHTD&MS<^+!_')-/T;'G77PH6<@XPK M 9NN@A9\$C:G0&/6(N8?
8.FT^*VDP@WDG#=#N\$/D61KPCUG'G'(1\$D+3.L#G;U M^(DEFW/48138HY-
JVM)!@S015X1_159S74#P8V1K99=EP%0D<_L*ZO+^;R='3DP%;47P4DX^IZ+&#QMD-1?;4EO%)?8X4 MKI>+BO?
M1?(C)17M6*Z J<^M:G|OIF206/OE13 MCAN_1LINN:);N&Q>=1#H\$7D"1.N5A6X/_<\$NQH*C-A87J.<.\$KIX..6H
MN@HE>N?001ZV1\$D*48>HDF1UN;18FGL1 HGX(T'F)5;1^J/0PAW>+CK@YY M=PM?
C0Z'GULE(DP1#A5*V&_1=IK1GPL@LA5'_94)C9#EG<=/OLPL8PEX.M?C=JG5M5-
;CBIC3^&U"TT#T.J#.#O105OU#+04HZ<+EZNYG/(?H-C 9;EK1<- M@/IX1P*AK#YM^WBD>^>J
(F(47;*U/G6BG5@YAPIW/AOGBW2M/)X)165)G\AH<#6A=6J2C9Y>E=-/(02N/7 M)\$+G%(XDUTW(K*2M5D)G;
18459.=+SF?EF)&MQ1^4/S08!IS.%+A&UK'/_1 MVXD8*.4XIX A15>|BX@=OL05<==
<4)BKS^_5:9U(OIC1T+E7DGD1/3)L^=8 MM%/@%C/L M4&1G&HYS_H9PQJ:IKSG1%/_Q1O"&W2-C+^T\$ZT:0E1M8-
1E5# M.NAX?#0:H1B%:WN3H+!<@'FN0/RV)B6T(8Z36+IT#P_154H'O0FW.E4S6DB..MLE><426I/'ID%OIG?
+X\$:*E13R48X'0G%(M?TQPS6G6R&M6.O*#O>TY_4OMI MZ-4'NUHPD"?OI')C:M=CSAY)27.I^M@O<\$#"W=S_..
?D_G<1>6L32Y(G?B*^<9/(+R1@=U=155MDK6U@P XF5&MMH)+80'/\$VJ'+38;67(X+CWG?#*M^<%(PI7K%N3I%
(T\$/*8_&*#K1;\$6?2% M_Z9JDO_71.Z&_U&G*67KK4KFCG)?IWIJN(S)UK3B:7X4G>6C_AV5)CK@E.2&J
MTO7KHBG#B=?.C;-ZVRN.9IH^QP;*#07&J_Z91;8\$FLAQY8AC:"G?3\$ M'" \$0V/C>S)#/1@2COUZ+
(1FG|TD@+J\$ TZ9UL%\$78.01(VIWF#;_#AJ/535GN&DL%GM7ZKZIUG=67G L>EC&1/3^*K%I%ET'5?LCQB M2-ER!
<J@MTYI9DH/*%F?N4U;)>#=-O%<3&0_SB/L1|UV9>'S"SGS&E1@> M&Z7\$0&24?OLE0L(2!#L1VLFNQW-
8GPU*KKBJH<#TZ57OT=&V&'N;"IMCYS(M9^6.DI?UO;3GT1CGGDB""*"/Q1O;HEV.
V6G8|EPC9Y%8DD_X*DK16^0=E8O MK:3)_O.7.1+@8&5^:NF1KW-8.&F1)W215DI4G_QPO).*(9KGISZH(ZB
M0"R.=YGF34N(C1N24\$LWA-U>|XQ^9:/>>4+&2X2CG-V1<9EQ2^ALA(1B1%P
M5_0MCFRN:G6C3%J6&K1NEJ>/ZMFX M9JM;YVR51@2"84VPIP;=F/_1?2\$0&\$77I>XKJ"/D;1("V2)Z;1(W,8J)W
MZY|WJHDK|L"ESR8O2SS*AP1ZGTQPAYKKIJA6ERHTI|H4@S1G:S\$!_D23LONQ7H1_6*
MEP\$^CB03;H0FVPX(\$#>C01ZY^1O MY103AKZ02Y\$ \$7;#*:LT2) SR8NHX(-1DE/ 5G6_%U>53)C8CTIU)2YN
MR1;T.9H%P4A1(GTP6VJN/EZTZW?3I>+IGTM'G|@:J)R(VX"K41.:E>2K; 4F M3.#;JS5NV>,<_5IP_U;3O4@U;/'1ZJ4-
S4-FYX'X/5X3A:<^F-VN:%2RR A15PZP=Q2100 M-5!=99NUHN4-#W'16W:#P7>I/M_+IWY_N%\$Y1%42K1L72<;
160/_L1+11&#^#19\$(<1#U5"@1G_&W::2XO M-H73FA1'.&BRX+1'I(E1#N?CVDG-'PU MUU=1^)W01G5M:O-
48+:/7VB9\$S4)SC86179/+V6\$=WC=LZQC9(O?_#).7@^0 MXUB\$SOHLIS%MKVG'2#V Y'YN-7&J*(^=MV/ ECH-
Y71>2/(1>59"1)H.J%0XH/721)8 M06\$FP.7"/8" 5fU%":M7<1%961M==#)=2R-VI B0)H..7%L96.^1H?
Y5\$3(K1K1^1V B^K1V&=@9H=YZF*Z.S.G>Q1GTA1^1Z1+YXB20@_&7DU M*MN'3;??XN1CL1=-
NIN.T>7AF7L%1WFCV(FY5@XS6SG 1:EF&1%1Y15G MNPT7"/F%-
=1%3E^Y>C\$6U25H_BKK4CHK"/M=1H2/P1U73/<7-R+?URA-1> MQ.G9PY\$<(^U1'.MCZ+273EM'DMA1^*&Q7%1;?
8#TLG>&QL:\$@7PQ9(D5:@! MP?!"#GJ"&*X^H"#JL U'C J&ZQ-GB1,MA8_95\$5/P:@XJHMG-SD
MM4Q12S_HP4IWA8<3.J1CM6UR++2M+:T *@4004F^@@?(?#&Y!-H""@6LXK MP@\$.W<25?O!8S(S@_%%O6_+
O2L/OJSN51JVDX1FKG)L%V9.Z;5W:YV+H MZVQ1YQ98>21_"ZINE_!P+K1(W_2-
2;F>OQ&H\$KV@%X1QA7"2KE&3:F_1C\$; M_**G=CH8JNJP.MB2=OIN4F BPVF-
1Jc=1J8BGI^&0@6R7&+T*Y'ZAH1)H M@YD."H")7%1/+1+U@./?DT>Y9K1C>/W%)1:0VS17=
(8PMV1K11OTH"\$PL:S8ZV0E5AV7HYKM7Z201K6>1>_O^ M2ESXN>
(LZ9("T9.G_H(P6P41^3/Q3\$(X#W:D*UQV:A2.CW<MYJOIG1%<0+T4:"0#J0'F"0TF0X/C#W1-
(#6Q%BXJ7LUASF<?*?EIH++17O MB5EW>18Y'H=)1 U4_0 M0;R@'(V,RT!0!1&F.Q>LEC/8-
X<(1X1Q&>1SG>UA)'BG#@2K2)-#07@?E+US D'+;BS*Y6GC9SQ M?/*WSKU_7R3;)&8DC YHQ\$<"V8C1_1>?
8WT%50^1Y19".41+H9D6N4_ M-Q@:DT_1)AEFD-SO;J1*SE*-S>TBK53FL)7IPC&E^J+ XN1X8T'PFA(X+4 MC31-
"NV7N/JM&?CYQ);F/WV"4#F* (KL1@5*53=YFAYJ MNQ1H>DQGPI52.^+QHR@U@U(=)"7) U?L-
VD6|D1N_/A.54JB9@FWS-[#L=) MRS16R1N33YB;J/A7H13ZQ#ABT&GPJC3EC6PNLWN) 1133=K?E+V=^<
M3N;6YFP7KDY>OBFF5#DT)W3QAN/OAR'IR'^+@:0TN6
MR5Y.Q!>=KEI@/_O+G)^HS^HD^E'KN&U5KDRW!OW9GP1\$(AQ0X M.B4!
<#1UC1J%=.R5AT1|R1"AWFNY.HLK1X_>UM9:1TQ8^<>CR(NU133^5W/0 M2.PR'70=MRV U..S)\$2Y>5E1-P0H3AF6-
74SOM>_CS';8=DH(<(2011'K. M@MY7X 5)UP83%CD6E-7J"/S;VU% B%DV&?882G\$1*"N8Y3 M?#HW?
Y0+#"DR@^3611_1D646RZ\$H5P0F.F^8F%1+\$4H4 U*+Z_*N%1-RX1&U1P0)3E^(-FU_07
MFX1L812%N1!OWM\$1!?'\$M01TUD(+MOQYYP9 MJZ=-H*?<
EP1SWKXS=KP=J(O"HRO*^=S.913_(N0ZYAHE)S81JR.K'GL^?H M-1!2R/H&@7'K9XIZ
(1&W97OT@=17IW#8S6C7#HU?P6\$3QZ@17213M^_S M6:K'O0_IKR7QA1XC\$?
R4&1U1131001*3**YH1.2.7Y3O7+U\$Q MV1,ZLU)@IT: 5B?S DKIYHM'833TZ8(5F,IC)S8@WZ_0_Z26?;?
12(Q&5&_JC'1 M26D/Q>H?N0..>11?PPIE1^&5;6^1AWNOR10M;LTN1ZS;.\$E3YCS;<M1"6QVY1%OEN@4/
D"1J6MXS"#K(>Y+ DSE696174S4>_1HQ?>4L1K)S^N M#(4.BAWPIO'75SY>?OY.?V&>
HROE*_8C:211V* 1Z1\$U<BO0?Y CB1_15 MOM;D#;ZG"1D82)NY91J+EG2RL1KN=-2^S?
XT18V=-2N1L7@:15)6GY3M*C&S MQ4BZ38:/)10'7@'DXJC@11LG@N::WD17@G3-
Q^;BB(KX>SM"OHH7>M.AJHK05*.7)X(H:H6.+*/F&L: MY1O(Y*WU=0@QZE;((SK 1C1^1<@7EQ16#^VH1_5
M471+B Z:P-FK_18K?2|WL/+U1.F*1E"16+E_VTGYV10\$_1MO51TU_1Y1=3U MTF*44)V->>Z1J6\$4W.SA1K4#N1T@
&1G-M9@S=VYG'G'MR15-DLR7KA MCCJ3%31=U3E/>1+61R2=6NJSMDX^%ZVQQ.^&)BCL>"?
O1JOM1PK1.@%XD M'WV++1;1D14R-EC.&H3N^E'8Z1^X14"&1&H168@T19IN?X/G?
+*\$QOCD"1T@=FG;WD#;K71@?/>790:1 M1_H2=86V"CE47D)1SQ\$:&O%D_1 MFY%N+A19G@IZ\$6_AUP.S1H!
(>P)VAD1WZ(N@/D&VXCF/B+FKC?2ZT+NL47C5VKO4*(1_6D>.<_UR1H U M_8TB_O1537P&26\$;V9>C1COJ&1YB?
NJSRMUQ6H(9PBN"1B;D>7H^M_F=T#1Z MP+\$1/E2XD;W1;1C 1+=KOW>2P5UHZ\$3Q5M<\$N.G0@#^<&5G M\$;
1N-IC<8>*T.2? U?A:"0V4.M_4B 1^01/:(7B:0)JGZ1?TYMXXQ?<.=6 MTMB\$^L7".3^4J9YB7)"0W11GV_1-
1P5@=S1_G1Z-CLKROC/6CYA(+16SZN M7FS.GFY>+1DKZ0?'X^F6?XOOC)..(2ME%\$S_1 LEV1_Z1-ILN4+"2.F\$
M2.%F=(3KTZ;.*@T2F^K%<^_ENKDN9(81694V1R,R,D3Q777).WC.^>1 M7-W4.PN N-7KZLMT'4Z0X1Y(6?
V1+E1+F3M89R.K4@)1V1J?211Y761TKO M VV1&1MGG1.31+V;B@4H7.R#>X^1H1_Z@1FO1?>V1
P.X;G.E3F%@O\$K MI_W1#WJEMPY<1FNA19EE(R07(4P6?F)-OB*91G#BF9QAA!%OZ..B>T8#=-
MS=0@\$IHN.2.NE1-R)TZ1VW?"Z>M=UZY\$00Z3_G#_1Z<1110)_J\$ P9U(1 MY_8FA0V_K)6:WR311_GX=H?
+ES6Y+X3W?C;5%^ZLSP4J5E 4NR1ST+A_1XQ_OUD"?Z;"_PSMDQP=YQ"Z)
MW.K&L_1W1X1#;1=1X+10)AQYQ>GO@CUH1%4_7S^7Y8L1/_W2" FSLAW PF MFN1'.K2N?DQ^>AU9=74VF2
1_6>H1XYJF)4Y1_J-E.^99V#5JH.K.;3RU?5V M79" M*8=+1033JH4/?^X+>O_77Q->7E-6N(#-M79/D@1T%U-

HKAIWK.4.^)P_X1MLS>5O_JD6G9F5G>MJ9H^T+P:<+GX=B(&3B(Y.\FW;?**)Z-TF6YN\$A3ON5<.,0U:7N.NQT-3
M^D_3<5+18JE4.\$P0I+BBW!1>0 MAU(MZ:CL1:ET53ZRW%K):3*F&-IT"/6\Z>-A@-|<=(G%P?3\I3O6*24P
M+WFE@_P1TK75VJ?.\$R\J:F)7F\@P)D.2HJYK\TXW M'33?PE8"P.1&@>D3\02^2 M..U*Y+4"TFLS\$Y+P)-AE
M/G\$F57LV\W%GFU%PS\LR(4*\$DF%?E/ZOIOG'O7&A1!?*\$RPW1ZU929T_EJ:KNU5T^W?? MJG=6K53L WCI5?
\$SY=R^+PH9^XN^FD;O>:U15551R\\$:S;W&JA0M%9XH M7XP9<V/5.K8=TW*/3HK*.
Z/C @N\ NSI9I^O6Y?FKI3HS-9\Z/(5BN-.MEN:K.P7R\3\I9\B\B-.I.->C-[+Z):EX:YH\ZH\Z1@8DLJV<C_1>
MR^LNBH\Y-7IT_S3U7PU0^B.WD@P/+C!G=17V>QD@OKR1 HI0PF:LT7J+:MXCN/F+:1K?2VYJY-
ZK:1%+_V^LU8:/%\^IRH3N\%A5FYF)B0VM=BWLIUI_BIL-5HK)XZI?3 M%K9(H2>'9F97DM=1\$=#S%*
L6L! #36L8CG5ED*1#P?^:X35VZN\J\ O# M&%02+^IRS(M9=9O1UKTUVU>:H*F
/+AU)AZ662#&O(").B%+8M&> M>5.#TB%PI\TJ/73Q:W\@SO*.E^B7L6<9L>:3=^JY?&GUV:H?
IX^"G\^|>Z)=2(#7TAW&16N:AYOQ; MZ4DMKBCRUDC08?B,.5"SCZ"1\$|^24+0.Q;
I6WJCO7M@_UJ2I^EOX5&SZ:WF M@:(JO>K8N0B97SRH\W7X= _JG\^L_!|=0I8_0SA(9W@LKB3G-78F#5O.T IF
M7.6=I@AX9C7@SP?>C5SQH8-X5RX\^-\^*2FK\4KWP0G)H* X)5RG&O?C\HC M/@NO=OR9L/
I:F:74E)12S7HVC\FV03-G/G0(I _&"Q'2O?09W0\$E*_2<|MH3I'PPU)>5ZI=%"\$*<+J?N\SZ_ZL5ETT+CCOA#U
_IR1>=%#3Y">^V"\$S&QO M&1UDAVQ>W.I=IX.^|=U12VK0U^41%0D29*BTI3J@V0 M&AL@(\$9 B-(B(EU 04D9*F
@)0H**"(41\$1\$"+26R)=140ITDE"E9Y0PH*T M:WGN _=Z\HSE\WIL\HSE ^YH\QI+?
PN8:XTYYYC/>.:8:XY:9%PMC:TT A\$B M&1 (M%/_JB: JEHB<\$X1OK*TA\2V45X-T<4F.DD1?:4F^Z/>^ DMKU\ZI#R
M6.)7+^4 X^~^D'=/3\J^7WA2)IOBMA.NF5J=GE%S:0MS\$+:M%G\|EEKV \$' MX-K&>|LFT.7H H
EL.^!|=C>J8.82.@L-(1+H7Z^Z9+J)DVD//N_>Z\W M/HJ?/IN+9JH^L?#NIV98GLN+7%CE!A?
6X)8'S+N\$JDM<16^XBMTI2W& M7.*#8S)? U-PC=ACF)/K+5)^O3I4\$Q^G7SQVY-5GE&M!OY^LE7F"HJ==D+;
(NOCIDJ3+UG.K9!:=7K1X2 MHKGO5M0UFA4AD+IRD)YOF*CS2CG^1=6I-Z(\$#RL??)UE6M" M'9Z1X
Z_PFAQ\B333B)COUV 4&01%/9^79?W;7;WTMR::O(L0T7F8.NK,>+8 MZI/5K7#|><^J?)WD7NIWZU)A*
(LY=2OS=E.I(\$W%:L2:2 MP?N7W?_JFB"<\$0DZY8LRX_(I*O*?V\$TQ3.S@\$?LP.M#O*X(4Q\I("HTHU5
M2(MLZ(L1\9Z2HDFVS-ZI^X/M<+@V\@#D#@("U>RI01=IX4E@&"!^K5Z6<9 MI-4:&@1"@YTQ-
L"!MP8\YP"1%3XF2PX.ZXITW/<&7=1EL<&\$1J0 K0Z0*U M9&D13?YTEWLVIQ:@P2\3Z.11.6Y&WN\W"<[5-|J
(#,UFN? P*\$S#ST(U?M6 MOT7K+EJ\X+0^HJL/NSS*F*M16*+|^JGQ#%R. 5 S2\$A M9 T.E^2E#.1^J5*&A-
U"F M+M)@HQADRX9VJ)NE^20VG0C:=C*\$RV^=>DR M=%5^+XV?G)K1^AD.PI^Q\06(=##R(P%-CQ5;
I552BF"D_<GY%JWK8=#IL M_/_<MHA4F2#J^VP7D^Z^XL(FD)3G=BY#5O!"2FV\^C^6:2LWS\\$:S;
MT(N^H&6IBVD<213\LLZ\IP% E#IS)!<G\X_G5^L^M0O@0I?/4P-|^KFG4 MOGI@NYQK55\GF8\!RJJ1HDGB476L?
%4L:T%|U=,>^?+:WEZP1,F(FPR),L M: _R"..O)>A:O9/!>O\$NXA.>P2K:&C364R.\$^TM&K/I1TS M4-
^XO5JZ(ZO@4".DDB70#UI:=WV3<#M:1MTVHY#J71.XJ2CN#(I%W4QB MW9&T: _&ICWM5S.H/
MU^ZA:B^V4V3%.36:)R0Z%/D4O-2^THZ@P9\$=_.. M^&V 9D/FHU.A5RB02HZYSOZ10\NV#F^2+_KC.O&KN7@NI-
BJH/H*^JS-8+U ML!:QL@IX^63(PJ14+\$1XFF/5+^_ \$LMW>LG-).I6L8+CP# JQT/LM"+^A\3R
M7.CCE/QGMWSJ^/K^H4G^XR0E^4JU9%*4MLP?^X 5A#@A1\$(F?YRU+.L981
M&2ILLN4:IL^SXB1)DI>JHC+I&=CJV_@=F97NB3)>[58_UOZGMTV^PM,FF MJ +.G4>NZ\5R-FDW4@:I-
SGR\XCM2"@&JGO03BH3P0:WL^:/E=:Q*BL_KC
M1;L:UOU7\2NLE.)=Z9+APC4^*M)C8S>RE8<\$R+U=%/U;^UEGH;7D@/ES2*^
M.1RG=,=X\$DG5I:GX&LJP1\$D72UA(?5M?_6H^B=+7=5C(2V=#N2=E5?C5>X2(
MR8B\RG%JL_LW=^>1\$ZIZSK0N\$ B0F"(HL?PJ#D\$1U01JH8GL<:#8E:HKD/D M3=|TV6_*
<[GJ:@Z#HV=:B\JX\$W^0:"7K9-/L:@K.BVQCI\$UF-FJOA_HTN1\ZM8.Z) M)H*HS^,KR=
(TCD54P\#;0+@+7ZMILEF2ZFOFOW>>INGV7
M:P^/W^F+7N\$C/1L:Q7;&6(4L1RG9ODLM356HVZ/W^C#0V\2IYDO\JOX! M\$P9,SBPD1PT\G24&HI896PS, NP?
&BEDAP^BU-8P M#804>,<[Z89#;JNEH\JM6D^&(^JH=TD#00U&SEB"-8ZO\B+JQ^F(F>(0?- M3%RV2WXRJ;E6;
(X@4=ORV<,D\28.B:6RZ9D39T\?-/6-?1ZJX\EH=#RCZ.3^%J+&#RN#^H5?% M
QM&1XH">2S:~E.T)KI^!)5@P<75H7MJ3Y,|CP^ZV^U!%@X*XP@A^|2#C>IG3O9G=)|ZIO26\$NE\&?8K>HWB\A1-
fKB%PR2HB.C.(+?B1O8#TF7?*/@HAJZ MYS*CIA0Z/"2V?OH1H^9?T TWZBF\,S\5;GIZ7JD*,VX3=5KWWHJ=?
CU&G4HFWMK3RN>,,X^ICU:2R@6\$H JS286:/LF _MTX/3? U3YIS)6XK^LB?CX.MR516\=@,,ZOOA+ M>&IPE##
_OVATT\$L:"3M MP>RAHV\$*)+JQ?3+J_F>_H\T-3NFG0\O\$:8WJ1G?NP0&?4D+>M5PWNJ9P(M* MAWDK,Y8:-
D):7/AD^6#_I\$6=Z?S(M%EH)=&"!K13=P\$& OY8WP2BDRO^C^E1Y^|>KL^P6@3V2R\$"#O MY8VLVP\$5:
I+V+I+A+UMP3^L:DEDA\2?WN8A.^YI8/+^XO2=%Q4)LI#O+< MY:R\Y6P2LWOQB(?)&A6)47C#BO
M^X^5Q_C>[RV ^S8OT^:WTOFH/IC7#KF74=OU5T9NP^S9F.9A\&=DKL^K1 MP2BV+37%?>
9Z(H7N.MD)L_G.RB\JA9O=P3J(G\$EFRG-AF9P/O-\$Z0*1^V?VK?X=H\X>/WE MP^WF\$J^EY\%
I#QAP2+&"1L8>Q/;-18^G#!&OHV#%GMB"P:L@&Y=L)@=YL: MT.71VQ >*32<[OLL%//G8V3&PE>3#1??N!IQ
3^QHY6.UV26#5U8T5ZBC^H<)(ZXM:./I&1YB^PU*1HR>^C.ZKT#)_O M^A?L\YO8\LR2"495-
2D_4P9M^0(TNR4/5ZEWWV"\$:.\$AP20WR^T^H.A MB8^Y1IG228%2V^+;J#&F+@3PU,=4P>G60CVU-F P.-U%B
75F=IS^FOE1< M\$UNP(CFC8\$(RK)?_9EY\;SR4Y>6SRG1PNK%020U\>_G+8#5U\-\$#IP,
M9B.840FC/TIU17Y:_7RW@RAJU/^P@<.^\$1RMMJKC+^QQ_9XZ^JS K06S M6KMVIFM5^I9^EU=|<^<
K2PWO3\GOE1?_2EKL0M:&E!"_="#T:)/S3@<(N18 M32;KEZS312@R\GG^5L=3I8+1W%NH/ALE-HL8:2
B_-UT>MF&UW66FJ4VJJHZ&K,>B* M.1_1.Y.R*#FB&B\$ M(43'5\WM@=|J2\$VEUUX/W(%O>IFANLCB:T#C-1?
I.OE(FICUK\LM^XXOR3 M3\86UES^4Q561%&0M^8JJU^DEU2D,?RY,.\$%JG%=%5<+S@5R>:O^++J^>
MAP85#C-7GM\57DY^LP_ KTHPG%%96-BAVMO&^:8\=#7RKGN=LN^5(UY
M487V#8DV:FN&\#UF#\$=ZXQ5XH_B@X)K)ILZ^TX^0V?>|J#HUNI@0@R)DHB@ MG6Z5.)2\D35=2&4ZHY/IDP5)?
@BM^Q/U5>,CZRI80Q7L@5QAP2CBH:#Y MJ8IM&*U.LY#_VM>|J<211WZ_9_N9\2E>#T: SW.R.(%J:FR>L-R
R&54NG>5 MXU*=?I M:/O:B%5 K^JXZUV-)1:=U=1M@|VD:NJ?*>||QH3.QSF(NIGDBU\<>%HWY M-'4A:"
<D21^HC+^Y&2%851S3Y\B7V+;D;3H^<_0LRC7@R\$ISO)J/1 J M1BB7L^@X-
\$VEO+3\T%N)TJV\DDP^OIZZOQ#W#IW)0>Q"?|)OKN:AO/40)*
M^#:^.5N59U=WXS6JY/%>998\T3FD\V2V3(X&\$B>.4P\$;C=@(T877K& MNT\G\0A1.5CVT&
IBUU.R>AJN^>JL.^Q M.B?#+^3NI=P^O+.CZ\$SJZ>|2YN?Q^S" N(B*\$0VB+ LV8F8: DL87ILEO^D
M#&^R3^KU=RJGYTO4_:%IQ=N4:OR3=%UB\$N:&:4J<"%/<=VD0L_L@QIO:3-
M=%FIE09%&3PVN9.872>^W)=^2PW.Q<:A".XX@V/^G&_!7V:2S5HX.X9S MR@'F'Q\$#>OO/\$,<>#-
BO&Y1\HC\X&^%AU>:,>+:M12+^3\^C=S:S@A@9P<<MS.^P@0697H.V&RK>W^&6B6PKY?
<4RGP:SQ_1#^:8\$C8Q^Y^HJ0\A:PS OF^ M.L.(N6TMM@A?16L^"K\H(JVQW ^+D-7G?
8.0W.W<7TD@T^W(SYS)8Z91 MD^Y\):E^7UN4QR9,*95P8(LG)=OJLY^LJYH+ABSW#5Z.619^U-/G2-M>TY:BQI
I_Z)V\A>&V*^LH/Z5TXS..5?DT&M0_KO*G8&%QC\$&^PE1M^T^P^R M\$EO@#VI3%('19HTW/L@3VSS)5#^7XKON
MV1OHT.5:Y\$8C\JPP&_0M=GBM^XIL1K06I&5 VE^>G^7U97_!5@_AP^M^5 M61&+P^H:L7=W\^V\YN<>?
MP^0Q5,#4+0||>7^*,\$HX=UQR_*U2 M0;"_KD+YGUT<:CQC UU_1RKJ_^L.PX4^4ZG.74X^2E;OV\U(49:O\3^WSO8
MRA<_WP&T2T9L:;7HY\GZ9>@D4^7UKY^ACGB.AL^N%|#(Z@A6\2UM.%#:/ M?%)UU-
2G#INU@S0&C)MH\QP%ZY^#D32P_2Z0+JPJFG+MCSGAZXL.MQZ%>%R>_6_X21N^H^49*T?&OIZ9L25L-)#\$&8

\$UIK<>IYI/Y'9FNM(7Y R3'23DWUPMKIK@:*AOPZ\$Z:5.G:Wl.\$NF^\$/SI/%3 M!C!2Y"@-2?TSM.7APGU!A
4H,TT+1#6=-H.4.R3UXB%/-C=E>^%5(4I|=M1!DT!#41!^PC!1#W!9\$8 %A-)W^0=(TC"G4+H.!D<6IO6HJ:
=<=F!^22S>E^&*MN(INJLM)&YR5Y9?W> M&ZJ!)+R@RXN.&S?>OA327BFJ9?UQM+F/3V7"9C#-W.
I(L!_2HGAE?6_-<I^_5J4THLZ5PO:G'FW#^Y,,"^&3JSA"W>=!'9LX:WAPNQ1*_RP ME)I(N+@%-8S!07!N;,"-&\$-
Z1E.RHTTBM5K)KJHJWV.%K /UCR=G1RV.KU 1 M!5!1 TYN&>6.X,?IE-'X-2
A9H*6#5TA5W5FKY10D7.X)2=GHYOG^5T^Q%Q.2^4._>URJ MOY*,Y@+=C74<6D4H A?
VB,R%\$368BG=ZQOFN#&I)PUR73:HVIO(SGV^XG/- M&P'E!O4:8AM=:_<01!1LHYRA=6Q-Y>
<+I#B&^@FQ^Y!7C'0G(%0!EJ6+ON!E50"^-U^EN+7!AGH(6' @S!R83YP9IO:8*!8S\$NL
MU+VWWHA#R#BS! ^@^(F5T6#SK0564KI0QIE-N!E\$G>Q:D/66XC/726:@TF
ML&YE0.6N9I'OURLL4HFP6:JV+AY&I(\$XEf,@_Q=2!-F*V,0X MO@GI(E_1,9^WP#EE!>U=UFZIL-
NJV^&Y'Z!Z*HT<6%K4A)8@F3!/I,M,+5\$,-A!B6,B!""H0A&MUK'WCO!J6LA0W L X @IK)TR)#X""AC'
MG&P0,U=-N+#+*871GO%0^H.8!R^UGLVIA*9C;G#&9=**!+4F_!T386
M*,QL5+FYRT/IMH>:LTS,*!>1MCALN^/DP&N!U#C#!<:I!0)Q3%,9090 M+N!<,S'Y I<(7AY\$,<=Z!7^,2-VP?
4D:P!+V9ISB?|=OK MG:FH)O1&!(Z)P,2\$<93W^ /X<0EM%X-Z'H?KA<^&\$W>WC!3I':E?- M&ZUHEL1=NW"4(
+^2"CXF7T;J)D#C@Y.%U /)=D_5CMD)_+2M(G9,/W!%+)< M.P_ QVN.OPC _(",DWB63%:<5>K!T.S3'.68B=
(J:>2.Y!7"P8!)UIQ89'6 M0?XUB&IV&N!%B.7!"!#K!H#N#) , \$GQ-2!2.O2X8'07%@\$Q.37>X'K3>I MRXA(0.@9GNU
J\$?R&*2, A4NI8^2\$#,RU=IY'YN5@KR)Z"W MQ.^+N)I?%1!!T3SOD.MI% I^7"ZIPA7^VD@00&+I%Z4=+,@/??
\$L5375H M,:M^-WA_X1,^W#&@RC,,-S.O ?5R*P!7:Al0^Z%YG=-P: ^3RE4;)PU2*!T7
MBSX;M=-P2UZ'TXMYVD#X46Z4P75:QVQSA2,?&FK&E!7?>%K1V.&Q98U<3GN
M!%70B^F+A=I'G%7G>D>*T0!IT9'5+JB37:S7T!^?2"3LFYW /(8!D)I3X9*! MK%/ZZ+=QB2 K%-!@I/C!
<8M@42*2KH!Q4!>(B=3GOYRMRV%^:7(PO!P- MBI+Z7QK^,7=WX'N0:73!8!1H'16LJL!
<7D9*FK!XXG<\$3S1>\$Q MO6MW3FDVSA54*T/H1WF#*!D'4!/1^8 M=HYP3(J!2V2!W6:NADX#.F8=NR MS-
D3U\$@3N9AO)&4\$!4BAX!)#A_6:X&X5^I' M:OT%\$Y+4^AG5!@PGHL\!4;7\$U9=
(X\$Q!?,>K:"Z#J!4KK5QJ8L.S0:X5S M,Q 4ATBC8VTR23>:F7EPT@,+0^P-;S/ELC^C42YN7_#DG!N#/^1\$!#^!M>
MJ34"(J+O"TC@TI79OITTN=E7T6/4%GK^9/>Q4!EAG09LDE+2*.ZWDS.)!-
MVF^!S-.P#JM73P45P(=,7DXC6KSJ@!%,SB>L #'=B6YX/N^OO!2;^!^(S# MH9)(+&%%!I:6FXKK61CJ:O"-2."IV
1W143.WF_9IO=F5\$;OV!)1IG> %< MF\$YM74Z;@SIXT_0!_!LH8R\$;ZYU=F71ZUL+ZN/P'Z6J;Y"%,-A>VJ0X"
MBOV@QP(+&\$1-88@-5UTR79.RE MJ=OE(4812B-W(IWV@D\$7^<0K>3"*K0)N7ORN+23!1I2+P%KO/6?
U="KS M\$^*K!F!3!06SR9!)DIF&?FC6 @-B*(IBG>YL^*N.OVQS?@=I+3T"-?>:5O M2!H&RF3ZL,;73!(T*H#U!>H-
&@&BJ&'&F%7@T,UG&NB0W.TI'S>"V<)+FP\$>J2C!PSEIZA3DS11!F)Q2!U-#E\$)#5@-
_,>836C@P!H\$M5+SGRG!>\$&P MS-&J?GN%!"@^SX&W",5-;\$;K3%4BJK#X2F^+&F>M1U.KM%>0@5H:J!W1=
M!K!1Y*U?0JB<-X4DJ,1#T+CWZX8600(IV "W??X# W1Z#L.L5KTVZRV M_P29U14D1X0.JL!K.7IF-'J0\$' G3-
!BXR>/617CF(32GFV^BX'94*RI 9E MO,-7L)^3+@Q@UMI."3+!D/KOA5!#PVT!H^O!AT7!7(2!R"7@X10*6C)-&
M26!E#Q?V!50%GEGO:ZB<75(<@3&F!J/9%QGF8<\$!B^FE8 -(8U M^U#H"1=6+GD>%U=I=.5+=TH!
LX>IHX'C!Q(>:,==C5-W!0HKX@*30HC J MCL_47\$03.6^T!O'D3@MLEAGULX2IR+
MT==9%8*>:O&Q?7IR+,H0)9Q>Z!8+'5)E45.K:B!W1->VF!>-24%8^E/9ZCT/V@Z9!5MH*9;("L!?
N3W'=8I=-9&+W!YI I^U M!0Y7YYN!V?E6!6@9I;P^%6Z;R/-O"V!+,&%)VW!T."R6J6/M!7M.E23O MK_PVP*5+9>
<6O#-PG'_D#JXIW0:3O6NLV;G\$^E5G?LX")V UM#I_-HY!O^MF*\$D'X>7JS\$%=AAOS1GVR=&S13A-
DT&JHO_\$2U17NW*,HM<@-R.NMJSR2_D MN+CS7GUVAND>_ /5^H1Z&F*SVCM0^FT925;55FL*/@:K
98B(#^G"H-.OM# M^)#UZCQ2!HM^0UO" LHCQ%2.D>9>-H#YO>T:DO!(72!DP&_!B>MLH%R:;
M(FR&XE+\$!N<8.S!K @-M:??0XF:(Z@MZ\$!L"!)^@B&O*!M3S%M_WA5?2
MQ108A!%7#67HN#PX+0GZA:L>A!L!@7 QCHDR0E;Y60'07V!^6ZM.T36Z18< M>4!
(ULLZH%>L.#Y%<*,B0HHT*B+;CDA4U!*"D9!VQ(P4!8G@R-%9R!XXN<18.20!>V%Y=8HXFIR MAZIEQ>;
*>,,O^V8H\$9H2DQC,*4S@H3Q!7"?2"1"?@UXIY1HJ.P2/PL)H4JTI%\$Z!XP3;6SP!/,+?D?/H3_!&T2
M6_D6;8XE+,GAJZ/>SLO"-M!XD7G;-!4DJ03QZLH" T:N2-C>JERD&6GE! 2ZU M1N!3P24Y4_H4!P'O!@^0!Z2>
!IE;B!^9H"#NH!F%<^F<:8F-H!Y5!D3! I* MOX&4QOD;G7?1?ID_ZY%:7GT!6' H8!+
(G#U;3)JW@K0GFIRET9K!#DX!W=JK M;-7:GPI!X2;5>;&@4AS(IK_DD@#%#KH!2SBS*,YS# M7!\$FY+AG,)%
I(VMNA4\$Z.DEB*UP1G*X,;!&0,0%CI7!67YU:L>-L!('\$%NKQ M!^O9B5C1(*)')BR'E!CK)70(^I&R^(-;
,5H!N'T!J1L!D!G+ZGY UG MC:Z:P/#H&ZLO?VC\$!7><;@3M_!6!C(8&+>R1X(&T,6D9M7?*-W#4;.B)OU
M1UN(W)&62U"WG?U(PUAXJCE)D" _!>9;%B^HFY6!BL-F8NS)A05!Z4VY:KEQ
MC<I^AZUB?D6!\$OELM)V7X,+Z9"G*!(T8UUBA/J#4Z@Q3B,,\$A05YI>P!=
MS;R7\$T+=/>I%\$.X>PM3E+5OBT>%W9!),HM MW4/0NI2 NO&I% "O:G?ORIT#02EM/I:G>4(^>M!UVTI&
<9S9)80DP'Y^>* MV/<62>#))22B(7U3S_@Q\$^8#YKU\$. T&6^>)VE0P)>>WBNK4/D@Y<#^*_-# MF5FO 76.L+
!5>QH^EN&>+K< %ZJK:NJ937TSGRFK=-M;T9%ZMT&I_@5J!7:<)E'QX:6.@HW!TOH!4%W%LP3U)<6\$85+LH
M*B.19<%^,8E\$%:72R%RI7%?&YZ#B!W!>C/E!<4^5D (R@#&+C00P3A!BRD0 MV!K:VD2(@#B5I>=?
0TOMU/!2?PPOI&TD5!TN:/.NW#T3.F2WR4(H=7.I M&B:/M#T:'V,^!\$ZM&R?376_1@!(960!6S.
(N&LJX?JV9=^!_IO?S@N(&6Q)OI M09BIAZLN.O:65F!/-+9T3E;E^<K!&@!Y! MSK3^!D9PND2!C57BU>(5-
W_0*WI=J,-.H&7I+MYQ!;XZ042 MA;="2Q375-R\$#Q2#*!M2!P)AAR!JS89#E.06^!AJ@H5%?G(=0(8DK-
C!CW" L(< M42IDWQO@D%>9NT,9I/Y(MIL)802!>/(@DI"!>2.W9!DB //6.BO=/GTC? M2?
^6O;V9(ORG!BN!P!G@X&,DZR'^KM%N<(H7M2 MJ9R4LOG7DYHE*,K!9Y7?2Q! MV!VHS+&ZT_-ZO^Z9M5_V?
3ZI>G1B!_H3_ M4R\$ \$^+XI\$LV("HL_SNH,(+^U4 B:E3_X8KC_G'R4@LU^K^G.V0A!QNK;"
MCH!N59)K2_95/TL(Q CBWP9N+F 2>H(56QKX5?FBK*,Z(NO^XHA_QFM^",; MH #5<7MBY:NO)/-2"YL-V8
LH6G(22\$S-370BYL=/S'U_XWN+#!N8N3BOZ MI,;(-"+423!+>
=,ZVC9)HO9CT.4>HRY<47N9Z.S!3OYJF=*XKI&^TMWQ M:K?R,9V8C.B<!D)JT>)*6Z!OD;B>Q!_T:L!
I+FMG3MO\$R)JS=H9:GH-F9 MQYWIPIXQ.YN_?T99^M.VFE9!>=J M/P+CGY*EP
U7>>M%2V!A)DNOJ6B/IW0D,U2IQMT+!F>B+4J0D6D(2!I!H MG)4E^IV\$*M=69YSZWH?
WSKE74G;W(=5;MV_%6>J(S7"DP(U!L><95?Z!*C? M6@6:"))@2!_#!31A+OJN4U7,/MPZ?S#7.%? M3NXX??0
IX=4E,42%6R"%X5Q((^49B9M1!\$345ZXD%)-SP^9C&2.U!:' M&C^WJ1X^E+MVS (CS2/OU3R0')H
<6T!3:V.JW!N!;BS#A\$ MC1F<>E0.N!7_ Q&BT9)="9WF51P?G:CE4+0C:DW*P,LS@AL XG!-EY?WZ! M0!&)
ILCC\$!M@MWH+)W9Q3R&K4?3D#@Q:>>9BTHA#&HI&O=7IR:03G@J!)Y M(S?LWA">?
OI<3<9KFHPZ2_A6R9312Y*)4_S>RW.QC6:Y?OP-OFN4W=T*MA!LKVME7HGCQ:ZNGX=I^>NT:.*
M3NX'WSK3G@J6%GZ&I_-HMV&T(*>9P8!5B>!V!D)H!^G&OS;: U?FV6^6NM=VFGC6C7OJL/FUOT"*B=*,HU
M%W!+GM9:_I_!1R IQ:2,;_ O5^517KY2Q#C.EQ4H?P3!^!N%J_!Z MHNB:SG!EHL_V_ZRK?
EO64Q_CGQ7L6!ADF^JOW7^ (M,!!(%ICU;\$F.6CL M&"U>BXI=9JSP5Y&Y!N&F?G. 4_KNV:7UI^U%ZO?
\$ _EH=3<3-I LVZ?41L MI?^IR(<I!Q!P_ 'W) #XW!+RKPDJXI>/*=1H!;? 6!1?2JP+W/HHUFWS0;5+ MNC?X89/?
7P_2""QBZ=#5+SI5V_XU?@W^W/AK_?)<.SJH^!2+S!MJNLMH M0!.#L.G+PYLA>Y_6'RZ>?6_VC^F(>
!@"@Q7,@STVO!B=T72T"!CH&4!_C=Q2I!E=Y^!G!W0&.>WS008M^" M*QZ0L*WZBA3C!)*+GV!2I+3P/9Z-
M\$(I:6M>R0=O^>[*XK4MQ24:H*P23 MK2U!H,IVY7C+H;SUGTZ>74PR)@:R=KF?Q)H_S? N(8F;!-BB"ZLK/UY_=

M.L/#10%:W36%R ?WHYSO=-&27Y.2.Y^=Y+#+/-^:DH3T#6IZ=5I&G>W.?)OV MH0VY%ES1 K&""^
/^#.*H^.@OQC/Y-QI@'>ST\$FOI\$".&CW*Y?RYS.-') MOSDI0_B-") H0L^INS>?8WJTLV70UD_KSNX'#H+O?
RJXKS7Q5=-AV1 MG(+?_3IFY?C^MOMVQ0MR&2H.J7DOH2OGSH+VVIC_RN/0?YS(&P3^;)?
YYW^%Q_YX9Y [MSN7/SQU.*>J+;FJ?A5_7B>H=9.6HI C "6*T*NGFG-O>\$I0@.K)<_8>WIZ8"Q^I
MS\$K5&""^J*RB8FI\$YV>G\$#X#H#+\$EE@+IP.IZ\$3U9Y8@NNC=RV*Y>!,JB
M6,+PZA&7U'!6^L: X4MNTT2Z6:7E*JD!WT95+\$KN:EG7VK\HY\X=ZAD8P= MVJ_3I1(^FPPX'F5:8I3-&B874*-0A
3W\MI\$*H\$&\$W"9H@_2@=PUV8"ZY<3 MZX:%KFJ4,DH>AUQNVH^?OR8KX)
<+9EY/C(BHL)XC"V"R%*A;L: ^)L_LI_MX@APVFBV7ER8*.""C^&MPRK2-<,VJ+!,?
9/HIA?12*LK>^KCB29P*RW1YS+ M258B70)JW#CI@EIV7%A8H%X@>#1^K,8P>T8Y2\B1H=Q8=H5.@\80GVO+_B-
M5BWMW-+/>"I8;K)8T4C-R"!D7!'LHW_PRPJA M>?U\I3^K)D_3<:%W:NJ^TI>Z?
LZ6IBZ8&Z38^WNQU=OG.P(5B0M1-!X<M5>>LX)J+9\$QE("S8%?-?Q'1/6AS>*;<SG0.H)KIJ,8"?)\WV
909;FP_HXU#_TQ>BMK M+P"J^K)EG&M:67(.P46G)A-%ORJAXN @^>Y,*6-6"A<8882RZ,'T1@;,,0 M^#ZMD
OC@W/&CBB):V4@Y.ENK&\$4:P6XI_G2W04I#DR9#0WR#..8)1@>X@_MX+"X)_2-1.7UDWD)
I?);!69!M+; &B;5^&+\$^R,N!G6<@U6\XNVH_8 MH?G4WKL@:LJ3%VY3G&.??%EUST+S8*_VJSIB\FH?
TWRIZ4\$N6Q"A"?WT/M1_,R',!;0[ZIXI3BSCL/+H5E+ZEW5NX=.9(H6PICIZR1BD5'P'0;_WJZVY@
MBUV83BSUDIXI%I-%DVL1.W*?7MBB6O!\$ L:TO N_!6TQG_ =IYL&C<^)VK! MJ.50=/^I8.\$K00QOX"/P6_WGF?
94'L_-I>C" W.R8\$R)/7IYXF!6O\$+BD6X M6:0*YP@CYK!"NHC"09QO^"U6-FT!NG93E:6TA!5A0^6M.66E
V7.3VXJE_X/M67_-ROMS!OY5!_3!OM!F6'TB*!UT?2Q&-98M2!0\$81Z'_5?RCTZNN #IX8 MN=Q?/T2T2-03RI6
M2*8WU_8H_9\$INGPIE^+4ZIK*27WVFI(9K@_E->^IM3SW"66K_@X4J_A\$W M&{TK}>+HIB-TVV0)
(3LT&/(LJIZM T**IY>92(VFN(PT\$2.Z ^V MEC.X9L;GDK(TLEOQ9.3C06=12LU+;S,R\$;T!7! W286HFD2:
(%7KINH,1D,O MVIL2453?F.!(>H%#@#2,IAQ!^C*_N'+^O7KNVO\$.MH?,<^*G>IZM"4;H67H@_DDZE+<8#)%
M60!4AVKOWIG%\$/>LZ-6,UZ8ID&4HW;_3'IL!KB>OJUR)FL8624>,HF^O>* MR+##%3M5PYOSHRE:%
HK3ZXAH\V3O\$>X4D M_RU/:Z=85!>M\$B&8&T+6G^0_#_ \$S=>,X')=>O/HUW3UFBI'C,Y.7%Y/3MIQF_@1ISE?
+H13=>I99VD>NP@-R=Z:0K!%EI!;?P8L;_T*8;< MJ6^!6> M=936%(YOH7K<I>J#24\$ _D@<^UX,%')E(^%L!Z)
(V<74-.*+A9OG!%6 M3#Y&4ZQ1WP)J658=96:AJNE80LV?/4T/NA_ OJ6;ICQ4CL<- '93D;)%G M)I.42\$7H>
UUOJ'Z&H.#Q J_ FRNU W#UXS>T'=Q&26E!?)^V^QY4UON788C MI#FW6.?HXQ\$;4&+JF#:
<)R(2@/RB_NRSLN"\$,6!TN+2Z,RDXI.O8@^4)SQ MF0M{&(MP^F0J&B"XL/80U%
<2I0P>+)>1H^E/W)8(#7"16T!*>//PFZWF)G MJ4T MS*ND9=Q+I\$J8I1_*,!2G"*7CH,U)
(B\$6!;H6IQ"W@0^8EUADB MW;C!P?IDA?LUEQ,IXT\$^3#EVUW7_J0*[Z"\X71IU(C#A!;FE1H=FK57EJ65:)
(%\$ED#NF.%NJJZY&S12K M&KV7#I^T_#PT#-CJY\$4!*7,\$9J+ T#_"1(%C^!A!1)IS55=V2 MHQI=W;_IFG X=9-
Q>SM4EIV9+&DIEYAT#1QELCMOZ3/K_7M56^2V9J)IG>, M<O_#+*SCO{MKPIQM{Y4\$TN?K_?NI=53Q)
IZVXX,S^*Z\$;2!2@3OBLG!;" MTT\$T\$B=M)G>&T&LWDK(U_*T\$@^"1-?^B..(K31P4P90;!JTI&=*QFP:T/
M">MN^KI4HLSG M-I>RKB6S2UH2Y&QNK^4E*#XMID MS>#H!OZ"81(@(-@W\$S&\$-?VQ?
1&A\KNR-W^SU\$T>W9_*!XU;?;?4E M(0%GHI=M#LS/KQ#5;
MHQILISPEV\YR?7N>Y60DN".0TDHISBATTIR"D\$-!V9;_HG2WV9>GE=5 MJ^IG>F G3_IP_"RUOWIG:R5%7!;@)
(A(I))_/\$5>@T7IH8+@T:=OW: ^F2*X M!20U.LHGL(7>_R)GC%4>?3IK;W=ZVY+JCM%UZRB?
S<_3IZ*47P%CM8Q(HIA4BAK MIAE0(ZN!Z&MM("J",!4B4'"#WYK;>W;I_!KX.*.X)RS MO8/C*5!I6^
RY;7UE'B=0"-6_PW*7!A3)5T-PI 85">IB MKQ\$DU!;_G MOS(U/I,Z,CZ57!3IU !@VN\$!\$/CKG%+S;?K3=>I?
4YZ57>WBSL;+!#>9" MYTR> \E,"Y8M.XIE3\$T-C=URISHX@BSW.F"=6S=)E1F"B#4/?%RO5FY=(I!
MK<=R7X/#DYPVIG^B/EK5NEEU;L?6> >FTY'=X4)XTK9H;ISR!+!<M!%IO/(H/+WHO;+R1YRH??
*8W&^QK!0/%G/!5LG_&27AAUO0' M2FNXS,X,&Z9=^Z%KR0T2*0\$=&JF17FE& EL9?_SG1-
7)BLAXELFUYAZ07/OR#0;1?S\$#)NT3 MO.4I2N<2YU"AB1;I-
RDSH(KDZ@+Y>>D7!ISA#TO=6L+ZSA<5=BZ1A8I9J_MG:@NQ"RNR_FGL
5@9J*03UZ\$T1>05EDC2^<94I/RAV2#K\$N^L5L93G?R9A M=C;6*G!25E5H^FE>\$I;C(E)I\$E\$D@&A\$!-
E1U=_INKA!;)K_>M (N9:'O:/\$("(0J2V4&93Y8FNNV;UW3JIT.6?PV7=+JLGAA#7SA)DP+FR= M+YA&-Z9HQ2"!\$-)
S5^BP>I T38!E4D2FECMBC38V>I&)0L.U@GT*SQV<IYJ MB\$/B?I-!O)XW7;ZK?;I!R_@HQ3"SC+X48ZGS&-
NP)CXL7+4B_!A&1F(T MKNDG""%S!_LQ>+N-A7Z&_LQG9VI7+3)1W=W5949A*(K14@ZY+!=P\$1^C M#?DQ(?
PIK"OTI#0%K2WPJ7-"C">_RF3J#>:M;R;)>V"YH!BL\3S:FPL<&MVT"?.@Z?%U5W+EQ"/P'T90!@_U4?9?
=E<=K'J/7NN28GPNGGI4?Y7<6U)I M_.YA05'8\$8D?1HBE>2 WZ+8FYZ/C.G:UP6;_3JV_ ^C3!&=>I#3AQWHUC<
M&S&MELPS#NHCDI7Y6JD#*+*^YCG_!WEMOHJ9>=D:A6'7-DRV Y!;J9Y.)\$!Y2SZEK-!?
MEBY6_E!L%Q)U;0_:J7A7I_R*0")*)U&KL\$TOM&5.VK MO9\TWN7CSN/SN_M?V@A*JFID-Q<& VK_
(BZ;X;9@OSH>CJES/AF9)^?2E\7 M8QV_6<:ZM"!ZR'F34/&O=:IG^;4!%B51!;2C*862CD" ES87E5H/#!<6_&E
M+L3BP&98:#3S/&L?V\$ G4_,1&SE;,>HD>I4E! M6PW763KES6":JLF5"C"\$4*F=+TD?5L9PC45?
YLCT#%:1(Z.O%N1\B MKP6UH)^H81 NSYM\$^5_^Q: ^T4K>I2;5J^HF"V.)UT=C'0J_/&.7#OAHL9.) (MAN-&Q
M^A9"TG+&E396Z\$;_W-8K>^=N.3EMA^G#P+T_ZL6LT=+BVPD)YP7?/B! F(+ M!^%J;Y7B_&9IQ>%4P/!"M#D
%XVZ0'IQ^E2XBY;I+(9&3E(Z<IT<+5. MLH>FUDC@ZZX+1^RI.HEO=YI=9\$HS\K!;K<>LYI33<_?@?
&W^X.YEX4Z@H7T M4YTZ_4SO;A>O2M2I @L7D#6!71XWE0!+1XI<)&MSY*80Q!NFURKLOO4R M?
2Q8RGAS=>7^VPOI9K)R?G7;W1\$;SYXQ6W.\$GH(N1:0XL@T.SRH6GJ;=!(M XJ0.SP#K3L6&?
NC*ZB9=7#MWI(15^5^S9!%J3F\$/Z_H5SZI>_O(7>%SHC M=5D7+69/^8'#BH85=-CJ(HSXL.X#2;NG)U?
O7T"6ODG"WJ.9A_W?V7LJX24 MNQJ39)D8V@_1*10?%)J9XZ"C8C ^-5YR985H8NF6PCM-GXG"1 ?H2\XS=
MZ8(TL*PE*2KASEIY_N6#P5TJL39FCRW+!0.HB!L) 7R85JW_&ZQH4YH^!@ M%A<ICL"7G_UH@D8;B-2
L=50NAK0D7=I89S;?Z#_V_B=N:2C1H8IM_15\$T;B3(TMW(LJVF.*38#+(YZH.TY MS>CYR!
68/IX&V+QKA*_U0FI9PI0LXCI1P?<_H^UO>R/ED08W!R_6IGQ)QC8N;LBZ7W)1DG&#G7%-M-
9#!2S;>166>Z^VCIE62PFUJ8ZJN"B99ZFOTF<7/TISU(2(T0 M\$9\$@(4&0W@0\$7E&)"(B(\$H-1+J(B/1.2"*B%);
(QBTIG/CIN"?<HONV)<<
M.Y2INCTJ_@Q^VR5NN5'\$&FU^/I@S1E3QI9)GS_/KM7N@4K3*IRV\8^DR\$'NUY(=YI_+=Y!IC
MI@6X_3IM7_7IT^X/QD?+IC_612^I@*W8)7E!_UK.R.#/I3XMI_H77J>3O!3L_A32W3
MNTY;7^NH^!>>1Z=.L15P^XG:2^.\$R!9RU2VT!#5<:&N&0F" ^G#/'E7+4 M3(X%W%0D1N8!ZU1TE6UE'Z=A-
YCL+_SFVNT;A8ZY*HJ%N5;_5N S^LD<_0\$ M409IAJL^Y2AVK#_O/9>^8058PN3^*T54 M.7Y-R#01FPE9K8!P5= !%
_)B\N+4TMXXQ_5GP60LGD?YEF7-T7")E675 M_JMK\$8EXY7WPTNTA%="#'"=&3LCPC@VIW7^3Q+G?
JW^W"/PR=9^G2'F94>IA M)EUFMF8E!M/1H*+BZ9&N+Y5WH58: ^)(OSF/T7U1?MY#511% "SH\$X>=14CZ2
M@NGA.N>1.\$PX;-U;_Q_UJA?=%Q<0L8IKNP42/Q!U!^=@0I>7%AW'F"?4I M69!PL"27W CC\$?3-P9)#@/++Q?
YAFFAN>6*=-!>Y>N M\$B\$9@/IC9QV9NJH&5;I++?2PE2H2ADE6!(REIG/40%TS=7:4MI5D=1N M.66+&?
#5:MJSO@WX=9VDR9V&LWJRM0&4A<5'F1SR3U\$!A_2"8>1.LLL)SP M4UY>B>
I!*K3")Z0O#M4X!>6E8W"XUWXAZI@-L&\$+2?YYB_ ^\$>HS.&.\$&=7X# MEJBL18=NRS"M-TI
H'R\H>I%LU1EP;=A6RHMK0!#.. "ZH\$.!Z1/+@=)YZ#; MWDM25TBBO_3_ZF7@_?6K7HU2*J+RD7D?
C<:T)7D^3?%Z <24AETLPV)6< MPP"%D4PG9/T/HT#")%O*."D0ZMTHH5T" H_XG:2N\$W=)4+3OD?MH!+OP
M=UQM,S'A.)DYE@5PGTX=7!\$&G"J^DF.7%4B\$U\$5I_MVT6J?A6:/#8;0%15X M@!\$1H8#S\$SIBZZ);B!);

/B/YC/77P-9JL\$MF0!@S4DITM"O"L%M!A::JU MOP07-
_LG66:DKJ.F^5=FFX_ORMX,4U/G+V#4:Z27!^?H!O.5-SK1):\$9B^L M27-KV.^D=4 E=T7U0',X!D !S1NEW
0DKOYA15=,EF%(+2H@UN#SOB%G\N Q MW_0D/K=(7BO-?+,\D3=W0-EC#\$C6)J L SU#H"PQ=UD>
fM_W5J5+X#H! M!Y02,N7;&?4)248UHL%MBT.DY:**) H)_%02*!@P'2M=00Y(R.V_K-5R!Q\$
M7(KUY\$A2R+7&YFOOTT)D(5:;>JVU=CXL!P?C2ZAX3R%\$!\$0Z39Q5+LQ.&DP<(+D^QC:@1=>F#&6B-MHD-(^G+
(B!2^WY8&TYQ)C8(FAMOO !*Y4D?N\HGY5!(^)&8N0.#8GHN6\$!Q MB^@/K82#>)7#D%D1(9!%)S8>?
R;RYESQC.-5J.K&#PBCYB9Z,9:8<:IG&R MZ\NU'"&OZ1)H3F.L!1?9 +S->IYKY(MS,D?0-AG#U6:!\^FJ48\$8* MLORS
:(QH3))\NQ!4W-S^H3*,A(5<%!6:0IH7M4:W2:\$!H!@:W(NYS""(" MF)Z EQOD)
<00)PLCITL_S13&8ZD^5(HZ#221AWW)WW_,D.??1R!(CN<IV7<
MGK!<PDBV.JOCAQY@EW=#0C&".C_W0"F80S!5.&(L1WKHJ\$P"2MIX0/7ZD_-=M29NUCMW8L"
fYD/K!=M5,B!ES"l.8.9! KNA"V#&%2P\$C?XKQ#-Z#K3.B>Z6 MV;Q)473C:,WH!=L.1,FE*B89CHKO!WYC!*JOWV?
>5?U_6TH2R*%3?P!M^5-MT.*VU.IB>BXO)7OZWDQ#1?2>M9Y!PXJH^9N_G*VYTOQWC=SEGY8+C+N.(E&I?
^=%Y@/UX/WZ)8D+L/PGPA>>/J MV4@!CC'OFYLIW@IX9S,32G\$:X@26(GE"IOQQ5\$J0!%I9KJ47IEJ*1?L69L.
MR>.1\$#X;>_!&FZXLIxB_FL&QG\$=YYE?XJ!2_B^W!GU86H0%40K%!5D^+!%# MAY%\$MGDIT'VAW3+CU!K3!:
JFT\$#.:+76?KHB=2EX!+EN1&2I8F\$+!OQ_\$M1 M=%N6(A?IM?X!V'N@ZUTXSM,+=ZOV ?WBG)NL#/Q!M6
M&"8I8 P.2!IE/P9 M7U\$APA,N(CX.2O!#J.Y"42B7S01'="1W.IPAJX!PXI!XKS"\$)AV90^4A*%=-MQ613*&-!<8<0TKY
YS_TOBPC!UB_!^B)O!X1FRLVY5O4@TBNA?Z(XY_%IYU M8>IBANM97O)+V*W!YK0JAZ\$!<(SF%ZI%
_9ELU+R%86F1?B4I2!XE-)<PR MLO#IOX"E,% "G50,TN>XV+NXL^4U540 @>?"D+F_QE94W\$.7 /N)FP+0\$7
M20G-SA\$+Z=:CIUMZV/V<#=:S'^EI^E\$M9W@KAN<6?^CL&=0V0+XQ51\$NO5A M9"PU_5R/(%U#^!1GQT8-
>I9>_1CGL%VYA4Z) PY*AJM#:WY!4IUZT5_5X M6W(MTZIA+J3U;O5SUC5:T'W"#<3!4>B.I8'D"1I?ZQ8\$0!
(MC3WSZVIBS3 M_E"-<&8Q//&W>K>-FH7IY+_4X7S+LSR1%(8YY&A:\$?E9?090A0?D)1#F+ M.#)U?
L2.=C5R9T0H!*75*!P!SDN_@U5_+DAQ&IZ!S.MX:B_GW0\$.0(!&#J&9/97Y?
f5@ "XLXV=\$WC=UT,!B"KK2/3#BT7BMK+MUUQ!MKURJ?Y:H=3OR^4N_G16%-8YB6#
(Y7.%Q&#.F^JKW0\$XTS)=8ZDL6!K"VX4I M4)I>U(V)*\$&(X)5:>\$^_O!O:W_.!P?V)XN6).ZA^NX_Y/R)>?ZAV'T6
M)LRZSJHUF/=SHIH.Y0.P_S>V3EA*P@!TGR,I)RC\$<F^6!%P4NNW8\$1L M1/BKU3+HB!>R8?R0LYP)HH(Q=H
B*-CA!(">ZBJ-&R*WB^MGP!F!N:H>,FO M.3!/PLSA!G7>O DM);@:XPQ@&F&:
M)R^<H DUHB'Y8JHS!6F5VV" !^P+9HJ!<MG^7E!YX!X>G3NS7;R@D+6=K MD9;O#-13!&=4T&7M_NF3Z6S?
OM,164Z!1 MXZM1#WE>UE+NPXNPNX?PU2M8W=8F%"3V3!QD6,CS=QH.64 MR&+V"=S@&*1LBW_O+>I)?
D0%KJI@UC:Y9&P0YN#,KX!&>31%RR_R5H"R=Z? M<-KQ^0^U#WG>Q+V\$K-Q.'#G!GE"?@37<^6^C@=?
2ERU/);4)412(HUV:C MJ_=95K2LFE%L"BMF=?/=ZEK#6V+Z_-VFNG!>C7/"L#02XY)^4A!TLZ:KF:> M1(_L@0YB-C
_Y2E *>R!3<=WULC:H8IVE\$="5L-LK^G!_U!O.8=2(9!M@_MXW+^QL7Y22N\ZF(S@!"I30L17!A 1;#.HG2J!/>)
IH+D)W_E_.(6-GL "\$A!Q8YXI3Z^T=J6:N-FIY1X3/E! MXBA*F9V!EF=I_ZU1S+-RD#)4?
fZOW:6P)V3*#CE"1"NKW.G.?#4ZKI+JT!M\$:.9@Q_O./^W&XX)+N",N0!AQ*V4Y9C2F!H(MS/7K-
F@9S1H!8412QW8P:@&MP9%GO^T=^+L&R!YGF>1">VDU_ZVY(^<>O..K4I?Q ?GEJ
MHQ@!X8A!Q"M.">)L5Q@(#5)A\$M^Z%?F"=I/T4K:=J+UPAT+XMW9C^ZXY^N MG5!S.NX.2E@+65V_9I=C.%%
Y5T"T/T8AK1"Y*,W60IUK<.=^PI2 M\$!7H1&ZO@NB_&1<,-6=6K<4AZ@!N4M>_%N+@W3*+FJ8#/'@#C2Z-G)##!.
MN;(O_FIR5TXXY1;N5X(\$OYPSM@82Z^5'6=)%!H:SZ^&J(5+""(!S'_MS7*70MVDKTB?+AP)%U+-RSWV=
(YA*3=QX\$YH!SIC:G_>@N^1XD!C4U_QYM\$ MDI!_!S!^DDRF_&1V_?>6A;&XR3_(S21X2I!+D)!"L
MSK(D.MI&\$P1!@L:D@2Z6_:9J*1!:"N!H_#DKF<%(HOLY8!8-A!L16!_X93 MBNG@=(L!X%HQ=1^_,XYD@B>6SH
%T_XY\$;"W1">75W2S1N"TSZ;9J>2D_MV&+V/DKKT&RN!MYR*%!'F1X5P_SO?2AJE!NFG_\$8:=31.=ZM!7=&?
Q.%L MR8!M\$<HJ1>+Y;,"OFNVN48W9R/5!T_?^G!H/(O6<*4(C(@\$)QJZ_MJZU M!Z)/+!>G;CS+JOYY<^Y
0!N_4BGQ!7X8/W+D44J6/?_QOB./\$FSN"4OR M<W^&\$5BQ!JEMDH4:3S9W-T41>!ZBKDZ7/Z#W
<::#G5^!\$H\$3+"3;O(X<MFZO0(?C8:=TE6E_UY=9*)1?;WL!D+95#,<+?64\$U7UT!NMX4MELYV*Y?(UA8+
MB.79S=A?SQI9>G-AC6?09)U@)O&"FME%:Y@9J"4<[BQ_MM2W!JGXZRBZ!8ESHAZ_.+LS(FG#4H_C2Q1LNUTQ?
R?%W_7XT:_W:3E!P;#& MH_XG&=MFYVC\$D)J?2LID!CPU=;D)60%;C!ON;K2C(*U'_V*LWXXV(3?NB<
M%G@D)Y97B#UT+H49*C9#C%4?(!>=6UO>/QA_S+G!U&U3J-C)3=I^S59R?
MOB_9DE:_WUSTE!J.D9.DCR!457=CKH#Y54R9* K4+ZJ!(-8!9E@<%)N>.T@730UGF%(IHQJ:(
MP(G4WCPOS4)/0.6:8*7UEW!F_MGTJ2/&1"2!&6)@W'8 !J84P(ZAY7TN?WU!J81!T:(F"%GNGYN+K'Y&SKAJ>K
M6ZT!ZK_57?3G>L02"L@C!JJ&=>F+=X2QRF&_/5PFVA!.#SG=7/N!PRP-K;A MTR*#X!LY;AO!E^GJ/J(BE))@J\$V!H.6:
AP23!&!&4H%R!C!HLS)0:ER M:4NJOHE<IG*M7!8&!)LJM-
@!7YQ<&81X!13S!R)!F\$^LV+1M'3M4ET_E36+IT5?%GKN(4\$;G! MU>(MX,*V_REEB!GJCE9\$:=
Z0NYY1QLM7Y+_X!7V_?O+A!_GI@?Z/_Q86G)0
M.QHVKOUA;J#3/_N0=8V+NS=91X%9ICO@P)BF0P=R4DVI+6G"78W^7I-YW9UJEL_Z>.:)>A/Q77K+%V
MB2DL;2;V<8%IT.?(@)N=OZ^I2H"KZ-R&%1NHWX!NYO_MV@IPG4*A9G%4;V
"R%ZQHZ0!HX)H)K!K<>YSLCAP4_BCV6&GY??<(\$4>+MX&0%EOL;"D0!BYDK8H0!FR3L@D?*H!H02E:*H6YO?
S5E&.*Y.96>W@MV?_!MC"\$&/7UD>/SBFM?K%MG;^<^1MXE,\$\$KA;^E*E!97-D@QSP%E_X!\$S!GHF*? M(Z-
=L!<#Y;>VDOFO5,U4LKD;1XU\$K#H1S^T6!H84@*79LHUUK\$JFQ7": M9:WQ- #2W#R;J!V+H.8+*&
(M\$39F%+5B/2IS!L_YMPT7>\$_.C<"FWO49S.MN.)9FD"5!;/=
O/%+C!OEF7@V\$!L%^FZ=P>S'M_<3%A>RZJ!#YD-F.FB: M1MR:K4#Z,Q"(>PA,B'KB;TC/U.^ST?
^0P1<60JZ5)*X0MOU"VIG93U2#1.B M\$>K!S!BF@UB,"GRZE9QZ_M_I!Z!6!HJOZ6-
DV!\$=Y&\$PA0EZ?"Z.MDMBS#U":?C&HH^DK\$QM?%KY!7!O0 M^Z-763C!JU!1'9;"G>J)?
>X#LL%QJ)!.DGD49F(W.FE!H4/(LZTLW1GM_M.L5#>+I=Z8&A!XLYM!R+>8L!1PBYD!3.#60=G.\$'0=%!
NN43TICH_MBIZ:('C-G\$K0%AD%3CA!3H/+;2=Y.EX:*^W!.43C"%5Q!BR6&A#T/Q8A9_MGEK^B:2;_HDDEYT-
3:F!J#0I2=U5!)=J^<G!D^=&Z_?5QRID!.D0>" M!@DR*^ZYB5+H0E((^I8!5)_%K>)KM(0,&[3!B-QV?JN-
\$OK51"E)4DY_8! M4"5L13(547?KV&66R!L6!J!AGU!)KEDV A!YMPU/4GUAC!%SP!>#G6< MH3QK.\$F%>?
_)PV!QC!<0!H3<"9Z0OD.#Y_LM1%G6T'4B@*@G 1!:>+&Z=\$W
MA1TUS!HLDI>W:5!WB6ME69UX<-4W!X/E!K=R^9+*+0AJNJ?9P%CV^D@4 MK>6U8:DT63)BW4RK!!=!IC?
3HW!J.25=B\$<=JO7!H!M!O)D6 M(G_ZU0\$2"EV;_G9!7^(!?W0(<@JP_!O-TR2++Y;I>VO/F&G)7EV%B!LD!H_0
1NF^OK3BCFFTE*1=9G^M.RR-HIG2\$TT_N.DY)6.Z!F3!7&K.9GYMRGOQ5O&U_Z_!PU!T+U7V2>2@!8#
MG.A0!23!NH/0.86/(V.WM!4H!=\$F9L!H!HVV7>.&IC%NJFNI^!J/T!X
MM"IS#Q0"!8Y@M!\$8KBST#"\$EDZ4X!CHYN!N!Y:XB-"SEH!VHOS%\$H" MNGY?
T(A;3S:O_"N_POZF\$SP!WK!\$JZ+!&8)4!H0TWC+BO!\$&8-SW&UZ_MC5.JE*ZS<2Y(U!8>?6!K_S7KM7S^M!2
!F!EK004!_!H02#!M_MZ12?C!AOX>443(C:*8Q:5SG_I!>7;_6E:M!PN!+KZ_Z!LHM&PZ_M 1+B^>_(0"YZ_5M?U
=:"%DM+&6>1L!T!+0.E\$+!5I^&1#IE#I)=!1W7!O2 M>-0_!JZOZ;%S&K^R&!AGLVF*_Q/
0#H/H\$W8)JU;@WYTV&#H^4O\$IE9?K59_M@2>_P0-#06F"2!9J&F_\$+!IE!V!WC_8-#
(+0P,\$MBW7IB!MPGCCCHKJ!\$A_M!43VQTF*7IFBG6R>E8V*4)X!<1!_8!+^!UH,@PI0)A!YHWD4KRFZ2,M0!B-
MLIEK*5&Y:P081\$189%1M!>*(5.8^\$!_1=)9KVQ9L9&!/@A+ES;_ =+?Q!M*5*7!_%P#EV>SF:V!O.C?D06^A!V!
O):7V41ZZOPP)JL4-RNUU^E+ MB@THAM_C,N!PKX=C7:FSSR,J45F#"RLE4L7\$!P?F_L7X6V%M(*#;S^X)(2

M^(+NBEKEIBLM,OIW = ^CEXDT*#410W.")0W3'1C) = &B&3" X9L*/=20:=YQ2
M9K2;#:=0D6>3^N&BZ<\$K)\$.>XW8'NCZF@W9P>OXL&B)K" #HJ4=5GL<-S!?'L&D(@8EH: O@KKL4= MY
(8T+8'2@S:K):7O *EL?V0L.CIT7V?1YIN<0*F'I9<:I/E#BZ):F6U5W MFY- JWX0 &+!+@895KHZOIM?T4-WL_ 6?
W*J_2R^%(KT.%X%RX.OE+=+<:Q M?I:Q:SB1"&+!+F'&@I#%?F078-2QO"O@RAV:X% 2HJH&TZG4%N:48G.O
M0UJ WAG^- ZX\$SZV.ZT=> \QWU-TTCGZ61'VJW>1I#&Q:=M6*10'A)3 MP# WT2\$KGFV:WHU/W=,2_ODMN_1*
I?4VXO=X#:1<(J MIYI413:IP)?M"1..8>1OWBOHE&I/GK"Q* 6;EC^-^ 3?ZT.%3 /SIZW@9)@8I
MX365US>H+8YIH^D-VW>9#R'? Y9IE_.SP9:K:8 7K'X9T^C_GV/>S1* MP:E2C6YH2?/%ORL&);
IL/RT> #UL5GKCT8JIT=\$" B5_-E8'G:LT6"/F+JL MGS)NS GZ%I?UJI J0+KBY?
+0&3SIS4.H8+*I:&8RWRUKI0W//W#&:7:9.24 M4H:TWZ?EU+>P4J3I)+OFMI!TN<.,<75)0(Y# XGSV_EUP_1>R
K?8D) M\$.F.&>#V"W(86=K;OF)I3LE+D)#14X361<I!APM=>L^P+H'H_16WLB.+ODB= M^/GM8D3&A'WPS#?
VXI<2QS06)8)HBIGEP>)W0.)?"/TYOP_9RI6LTGDQWR* M@K \$%.%:WV.Y3>YP)PI7<
<.:%(G+H>:P8P8^ZGS.LGUQ&QB7?LWSR>M., M.NAZ:VI9\$U8*CH_ ^&QI8&
M4#EB<&NW4E' PE4:1%I8Y=S*Z M0(3&MG>H)*?WALI|H56+O&K:&5.CZ>E M+LL+D3&#%<*L/N_8S5"Y
C.:ACB(XJCH?6:KA."*N4O.(V_4 W)^:000 MY?UOIYB&R\$@RI0\$D:(P?
Z46AIDUZT5NP)&:PA=N;H5X8I#6A8:9Z73TR/IA MA8 *U10"H";>I:R/!"K*.V@.5BSJ+??^~:U;2<%EW<-
NL9GZ+/&B(=-C M-\$*2I3/X X1F:UT=-.AAG.V08ZNTL_&RDK5#>P1F(H5C,5R#5QH/L@W:(T/I;Y:
M.@D!Q+2W95U-CB#D? D>FVB((WUL+R Q9)FD9D!X M-IGEKR@I
INWEN6\$0=E2N<.&+:N/K;K%/^H6RVOA7+0"UW W*0"&ICMI!>H M*!;) =0!&SR&);#C)P2%(_<73H MFD@D#
<2*=4JH_-ZINQ&H5.#TF&C;H@UK@J+IDMWMI^R?/550?XVZ=A=W MGX)+PTAT02--
CF3G!^&E+UR)*U/XITJ)O.TK""H^A^JK7&JW"3HTP+>: M%#>4@1+1F\$1%Q)89L FWQ@%N/G"3+3-LPJ'B7@!;I+
I>^>D+ #I29SI9IS4O MGH=J^I^JZE(TRK5>Y*EXWR/0%2-B<=I/8QH6VW*J/S94&<^1SOHJ6^LC
MBJO/AO6O5/9Y2J%.H8Z5RF4L8ZPZIM/H:#L GV64A52@HSK#?/:MG:818C" MO'R-<I?UI#?M'P?
C@CW2<@I_%GGR32J?ZPL&-8\$S3+>62!ZL8N. N8,I#%\$ M8 I(H@Q@:0_50\$:"8B)CPA#R9I5V+/9 AH-
A7V^E/Q=3\$^A)X9 MD.R2=S:V/Y(62:JQ:2V#NFGI8&4?MI#2" Z. 7-13: CE^>IYX;TW&*I%<0Z&/<>^X
@UVV.E&&DL5- (?A9=X\$R M.EN"G%U1|WR-TIP|(666S6_RCL/F/B8*2I.87)SIO1R1\$=<1W3|L'W8K|2 MSCXY6_=I!
(KF&YADY%?1(9MC|_.H)7B|9%*E>0SM:76#=#TR?@W\$;3/QQ-MOYNDEC.,YIJV+A/GI";5D#L35J-
6WHLX/FU)Q:=E^7_ZH/4TW>4FSAB: M2J#E+XZPJUYJ%='^#V*H1OJB.6#CL-
M@I5..FD..T*JW^LW>=7P&:I4#0%I%:"LA^85 MO+DISYMIT-OR.QU.0@I1-C_3%-BD0+--
H+P^+\$.ES) TC3=9_K1Z?.S M146TCS..@:2NZD=IH&)3B0A.W=^"MHJRF=HT?W//I/#05:CH8FCQO0VSE@_-
MQELU%W3U*IK;Y77-!Z#&KCU0 MN@DFR18=OKOAB4G=WEX5#ID:\$GVWZ&S @7UJF(>X?'3EZWH5.
4JU8>G\$Q8 MS<4(HOSHJN".OO"9XL>\$&>Z#7NI*5 7<=6%>.:Y2TSXI:4&ZT'.AY+2V_%MQO9
/6XW13&O.#U^D%7L78P0WKX|I)ZR09"PI'NUV:>D56NCKPWU_H8(37: M./QHJ4SBJ&RR>?QQ*L.L((9IC?2?
X9@MH!2!"J9N:+=\$ZQ3***XZA*.%\$<(-ME3:TAYIY">WL%5?/#I1)I%GJI/ KXM=-_7^ST:2-IN2ZO//>)&'!L<64LA#
MR7>8:1*ZIZ^U+Y:(TVI&?U>B(:I7_"O%:LDO_7+>*"HPI">:RY7\$8766 M\$=,9^9MR^6_-
(MD)R&IE1 2V+5WM.MI(2F>VWVD8XJE3Q=OKI_8EG?2N:E:M.7EDTN^H D)+I^NCM:"I>2D@!!/GX|OP351
^AORU-"VUQ=.:9@HB^8KT MXV3N8W?7*N=:/ER1B@I/B9:DV:6^1C)IY<I38A|FY|LKI9F|L'O-I9_#I%& MIK1K3?7
O?)WEE:YKDC-P*ZJU#9!0"&JMC.G|CI#|HY2|W.DW#4.A/"CG MR%O&I/"FM:8N+.|E&
|BXE|^%NL%S8..3O>5#IUP>QE_PS6): R.<@6GF=>BXR_P.^!LR';8-ISLSN))URYJL+PI4DO8G%|62/9K&Y\$.B
MO'RL7RT^WA8N||\$?Q7#&E<L:;&/HWY"W |C.N|SDD @RPT:U#.+F'GX MIH44A\$B|I:1VHW%.S2:R=/69GCV
|GSZIKS29OCST'|T8' R""A!=<I:1% M6)*"9-LMM=4IT"%DT>"N3|X|6P1)9^>)NO#D/QBO>H3HQI|XO?I0I1.&
M19+\$L:9F4-P|ICQZA7"(@.#%V.'L?-#ME-)C)1:WV!+%1HF@P9G3+V"9S" M82M7^'8*CTF>5BS-
/1BU7FNQSCC'|>V_J_8K99B1%80<(0IOJE7^6U%8ZKI MV.HTJ+2:TEA42(3Z)5WP2)>5.\$6TJH&==<CP,AS!;
T|I>\$>AD&K(N3I-" M+76.O#W08(DY9KZ(EWI+4_8F8U1JE?^*LO)Y0:Y(BIC#_YG(## MJH#%Q\$\$(S9&0?
@^SU4G_18M5):#LHI>3L!41&8V+WTIO_U4G8-D&J7FKW M*5|D5.EIL 'NRFR4.DYE!O'U\$2_1Y5EXU
13&UD8>R92%CSIRB,P%"-I^WK MKOU?R."ZR|*_C\$|_C%):L)YF&I?N||ZO*|SO(T4F*P>"@1#V*PBW5<_HL
MA9IG|8ZU(9P3DZMU37F!'7L@ZS:2I>I+^#*"8X@W.@==IT*AS|VH:LY2'8MVG*%|Y|K4J.S'2%:++!
HM#Z#)K.5I8RPI.XY3+--N#S3/IT A/:IREO'SL\$>XTMC##@_-2V'AKL M2.HR'T(K+I>43J^X^3PI&#R^_LI+*
I.47O|+X"UZGG+Y%_-&EPI MY"RXK)XOA6M"MS)&99"R\$A7A!1_5B?V0:P9265E^AXH
M(IPD10=7A0GR18\$737G7=|85304)NO6:X,+ @&!/&*PQ74)R^7Q4J51Q_VI?G.4I&G>N3CDK25>X>|AUD
MT>%MO_J_*"V2(1RKW)I?H?F MGM^C>2JkW@I)X*28U1JE?^*LO)Y0:Y(BIC#_YG(## MJH#%Q\$\$(S9&0?
MZL4#I.FW&TF*=1(PVND!>F/RD%W7JOMJ"FI!:=GH(L^NH TZ MC#-?HLSNZN:AI6/0N!QSHR"3KK;
(.:I2I8I%VD|AU#|WW1_1Y07>+ CYI MV_-I%:?\$1:C=#B1N>H>X<*!L2K(ZN=8DJW|OJ|/^VW'/6K2E6W/Y(T!K6
M_UN^8C85H7|SRW?#JN&W%J>E3@6OV+.449J)+>H<8(**.I_@(>293B:'P% MAZ.5N..IP7(*>+44IJM:VM:9%:)?
^Z3(RJH_0O#@H@U!'2FCT((&-O5Q\$1# M: N^>R"ZR4#AULG3IV:225BI/QU'2EX+EH1E)M|ENP?I?0G:7T@AV5:
M1&Y@O_SB<@I4#@7:'8XD|B(>RGK'1<2N5RCGD1A8-@)+%:SF"). 4724_MLH_-?O\$&HZ">6\$5T4;A4:-
M\$Y^?9O|HA|D|SY|M:P.M|E5E.M=/@ M-TXA.-I.Y*7#IVLNUK@4%OI X 7'4PN5S'X!:%AG2XQE@(\$P?
0Q0#/G0)I@2 MS\$CN&IS#&W34G(8I"|"I?VBZQIL1FL'Q0^4_ZD.'S4#V%|HI-2I>P/ MNZ\$ZEZO0.ARV6Q+3XP0)
(F3'Q.IDI)@+T&SL_+>79%_(W5O9UMK38JCP= MULY48A'R^0Z3F'V.OYOLMZ=2-
(^F#7^J4J=V7:OOVE1Q+2ZA2_XT:IN2#E9 M^'42# SL4"@2N-E4N^M5SB9R#6V+>=0!H4)G0_A-
>8.93HR=6T/.99^96_MJA#?(W5QH3I'SXL@JKO#M^I.69VJ?9KQ62I(KMI?1Q6X:J0ME).26 I.\$ MZ&2|L9UOI*
(B7=ZHC*3T""%7T@EYY-E55T#G-7S|17A|071)Y?>H^2>G' M/OB;I%0J>SMA|@EG8PYGVZ.'346:D|FDZ,RC;
+U2ZWNDEIGIL9C@ MW'8-1%I+1*CI8RFQG#@M&@+"F1RPA?IMRV1Y|H)LI&02-DD,D"GB+" MR'L>J_*HI
<4+7W_+3"P:ZCH1TJ+6"IE98H6"9#R@P79%E0WL@A5^8^4Z* M3\$|(2HQROJRG1?
EXPGNPZ+G77MXA1=\$2BT*CH%\$9(S\$^JY!_OY4:CV M>|X'F*%T98I2A>|NI?0HIM8#:'G!*"GH|YG_C7CE-
C4|52H-3A|S:54 M.RZH6HUF51Y:CO7K>X-XGFSRIN5-\$\$(Y0JD+^C%Y+D)7771@O|3PV4JO MGH|^_04?==R3?
UC*WH\$Z-27>4&KVS: @K) ^?Y)B=F)I|337PVW38%N0M.M3#N>I?&D*|Z/7@_J.+ H^_IWR(R9_5\$W= MZ?
G:YUS)VS8H*FV(|I!_Q:S#I^O^>_N6\$S(6-JN7@79T8CTFW4\$#.*E//A9 M=:UNW/C+L_5B+?BU|UKD9U@#YLS*
(D.@)<^ M!:_L^>V95;.S|^HJ0U9X9D@*UZV0L%8I7I|.G91/W2|DW)A)|KO+GL7.A-M<#:OR;>I|H-U@WT?
K<*2G6P*Z.G.IV*>?TMIVFG4?I26IAF:O*T.V#>@6UZE M2._9.CJ:^QAO#5)YI#ZDQM.V\$1.)
(+JHJ07KT82:VH@RUC4:HC"YY\$:% 6 M8R%L|/ZDIG.VG"A3)YL6?X'L&G(B@|I_L_%4+/P&B.&=CL:FV@D90!FR^Z
M0D.IT9<&KXN: ^Z.^RONW%6S|>P*.R46.2_XY/M4YIN.H+HD24D2@:6\$2 MF:V'REA.EF?>4^R@I&S/FH"|-
\$2T6D5I<^DL02|L>6I:(N-D9?8I+&RCS*2I\$U\$Z0-FY2RG*JI*#':1GUX(#EHL7/
MMF^#YZ|PK_Q?I28IAZHCX@)A.0R?2:44K:X%T2_?^O4R:C MG#<1(NQI8H|69*%/= SUJA5FVGI=8P4H2;X<0?
DPP#(0>+&MNC"D.\$+ MF.:J@:AD-"Y\$ _ENIWQ9\$K.2I8HOH7(\$Q9@ZDY":Q*/
MKSVL/:%<4S\$F^W.4KIJD+Q*IN"EWI>3"i8K+!G?#/'^&CC.Q>+;NU|I?J.MIO")?I:N5|DW:YQOI:_.Z15:\$!\$5T
AF/OGI9=MO=K/IEG.Q.KIH(LB.7AJC_NK=) +#H(OT/C* M9:KL@<8A0/4>*GAIOXHK>S_XIP:PG3V\$>I0>K
L9O0PYA/ T|H:AOI=IB@ M!:=Y.Q=:9:6280LCGH?I#I+FOX:U:GADG%G=X# M+25P"Q?"?_CH
RG>'W2N|3J'WH\$_5/+C8Y9|31I9.J)|<+G@0?G(A7:IPZ M\$V&T&X-LAIC&??W0/6F\$+9N"TY:ZD'_*OSTR=23PW?

NG8%Z"63V4EX=GXNI M&OCE62/B 31S:6H95Q)N:5=QEB05-63@9=)JU4HCQKDU=E^X5WQFW\AN. M#
<7CVFZ#UZ*3:#UW+@."FIEV & XYC.Z%&.,+L@":4+51/)Z:H-&^+7.R8-MNOJ#I*.W7=9VOI+@U?E'Y?&/KI*0?QH?
6EJSFU#F(%I7&KO"E3\$U*)B?-(M4OVMX3=G5IZ%T*6AZ&4<E7=WWO=?M?+Y9=7=,2WI?
=ODMY&38,JDA^,QMVZWRU.FG2?NS M03I6:8+<*X)FJ#;ZH MT;PCEP8.5-PHDEFAK?BR:W:\$ZKRW
->ZL0^OA!+D(TKCS;EP%?<9YI=MYC(I8PQ)*+CQ2QI%R:B^((Z*L"3\$^*,C8CL/M-L=7;"K76WW6Y M&W!%L
L.@*R6=HNOJS#^RU!&/Y"U.@ @RH,I&%V5<&G/DH96@K^C'B?67B/&
M/XM'QT^WGO=;G80>+4>N|>V:6M9^IT\$6F5R>8AY#| T>,*F%C/:=UK\$(W5TZ M)L3OD'PL,"FLP->8(?L|V|?
EMNIR+^E76.=CF#C 5,1P:+/U;+5-M89C\$O MPQP"V\$|P*QYEQD1Q_Q;,,2,8)SV9D<,>,-Z6IEO.2JG9!!_T H3O)I9S;)PI
MCG*EM?#9+^V|+^%2:H5>60.F+EUI'35-&S-E;G2'?=ZDD\$U"PF5 AD6MGQ MS'CPBSMN%.R@?
B:V;:87"AP5V=Y>A1|DS| EDO9^V\$9T:8P\$8N-/)^*-M.%.O.\$/2S8^IO&(XVH^EZ3/DJ^IX7^RAPMO8^ Y M%?
YO9Z3^1P*\$%?>UM09C:I3+JV8Y1B<T 2I-1\$R;L.^!*"M(IJO MKKOAG6?J)JBL4P=*\$!
(V&V:03DLJ.JUM.VJR^V.#W6Z",L.PX(31^%S M"NC\$-
J3#*C2A96\$V12DGJ42GZQ/W3I3K@N|HGLN|N3OLLTAN^N:0YWDV/0 M^W/5RFH4JW;*(S#
B2H;=;GD0/= @*J|'K>DVQJ6BARE&-0.2I^'?|P M.VS@H1^7/EHTR1G<|_I7FDMIEM\$7.2N0YJ% ^3#+G))>4Q*7?
A.\$3#^IW5K-M)22(I&AK\$C;M57Z6:6EF;.;>SA+2GKZ((\$1/G\$;I*+65QZIQER9K RY%A M;MNV(I_D_05;;Z
<*8+I8C#L>)\$1U7;K="ZL^ T.G5S+VI2U+O?2AT5#;S MO;C|*<#^MND0Y\$34Q@_H@Q+G|8UM,6N
CZ@/G3N\$2|@5X&SLO+XEY7;Z>-MXF9D=6C_UQ7%YI;N^V3.48#(BM@_MA)"E-9DWA-
+)\$KR.^|_0Y2_:%+KC^6'-U^V-I|TE2BR91-!,GCKJH7> M3.)5K@/NIZW/;>I6)XXR3;X0C?R66T|^/#5P(S+7)?)-?
ET009G|K/Z M)4 M->O>C(=*I+G2I/NV14A?GLI4(O&7X)*8ELZ.@Q-IBGXAB3\$<>.,LI_@W9QOB
MXQ)MT(8H/F";>>EOK?0^OSN7I07A|9G>+*|ZH7_4G&1;YI|\$(H@BRY>J|Y
MD|F@.\$R\$OZI!"7GZ7|NC(8;J""Q@Y2<;I!%9R>@BLD+9IISQC\$|Z#/(G8\$T M,C9C18\$&|@|3%
VH|>0OE4PH^|@'_=K@W(TS9O^R)H|!A<=U2I+;|@OO7/ MKK-
&H:293|C|%,7,|B\$|20:QNMOVGW4'=HG&GB0MY)U&D;RO**OAG&&,=
M4C;'ER6'0_/E|H*#:60G>|KUE;:5+2.97%*0D.29W@.UV08IYI^M\$OL%4R|T
M2&3)'LANYLA\$6'_T;D|3ZT%/_2:8O>2^(T?FHM\$ MCUCV1WV4#;D4Q;|E><|_M F=.^N9P=*J^>_W=6_-
:=#U:MTB\$6*O8H|9"R M4C*T?N7,P)=1|B:\$Z\$.0|H(INA|OD3|:%IN|@,KN5|LDH0%\$T;|@M
MRVZ^#8WR@56O?+R|EE?*\$KSO<5ZSH>V>F_6X1H"A.(\$Q|FF?T4?
JXE5M\$751%ZC(A?^I|8MQBYR>|#99BZ)H<|=@I3.5716)#TH_9);/M-
|I+6|!""^:_B3TX0:%^(22HSC^K1KPX"6E7YXXY'@+&6<,(%YZ=4G06.5 3I^S5CPX,I 0 MZ|I <=(X:3X>|H|6|@-
B48WQF\$|<(C&O(*E0=CN5HX?4)Q^2+0)>FO6,+2B0 M9C->\$D(X=ZZ^?X|6:&|TEJS;HQ4I_R8L@/W^O-
.;|)DH=;/K26XU?YJ|HO M(?&WJGGD/>H3T('XB(977IH;|8>2|KIW_O#;T=TX>ONTRN^;XO;GF>I;N-
M5: ^|K&T.^KX*9|VH7J UYNNGX92|S0F#G"D^26N=+5XU|H FMH_QH6ZS"MQ240E+5H?>4VSS5>
<"IA=1WSQ|H^+;|B|8^X|I|G O;S|_?C|3S.W^UE M*^<2FRFR|TG.6U;2%QTN@VH|VL5I1^G>I%S*<_4T^_..B_N-
S>4K:F|YJBDV MUWA^QTG|;:| %S4IZRR;A*)2G1LR(%S)OTAXH43HX80|\$(H)\$Q\$V&?S9Y M^9|YO7T?
HILZ(PK)@AZUQ7>R70V&5;J&7WK*?P_!\$|,"Y4,(T|BWRRCV M%HER>\$_.9)(D4?H C6W_OHRM#Z
G^1/N;NL%&\$';,HF>_N/L|TQ>;(|"Y M_RIR|W_U<4?T.<|Q|6SHC5M)=B>Z#^@:8(N|X'#_UR<^IN5=)J=K6?R#WH
MH|'B3C131@_E1N11Y;1-=B|_)UK"Z77."XXA53.5|Y|AP&5O0M_0|R86""@
MB6/>|&B;/ZYXY2OUM|K7ZDE'+YKF71H;Z;8M:R/K|N|51 M=3|8+?F|XG5T0ZX|A>C0)3(4>6E(M|,D7*8."|F.=?
_32I-72)*1KX6Z|N|J+D|T-H|T|P>E_Z|T2*&2D-+(>|C:6 ME;^YW@M^V JE|RD:?)@XU@F'B?4KKQV1_Y10-
E@8>I^B7L2K=20I9^CH MDCKR^)^OW|WZ|H|22ONJFI>J4)D6W00G;'UJ23AH:"N>^?6TF)H6T-UBVJ|O
M|I;Z;>|)7+WJ8I_XV=07&CF*;,\$\$&ILEQ_.H%V0E0W7@KE|I2X;E>\$
MQ5+J|YU\$VU4C8)3I.^*7P+7|;&1"O7;5>=W|AMB0RDR7);70N/8UJP?MTQQ*;F_"I7-TZ/(84&K3*E2C>;^R)O?
W/>S^F2?E^T-TKH5.V0;YIEA:M#|A1G.4*--+18-"TT5#
(@*>R%AR6!>^VZ6L0RAM*2M_1HT8GXN1AVJ+8+AJ<5+@2%C>L0A05B|8(C_07LPQ|H|KBDMK>-
FIE:H6S|07.>1R; MU"P3,I'4#_O.62KGD6-I8B(TX6R:FI:EJ&EVZ>L=SW|Z|?>M>VX*0UVFV|AD8|B=?^P-A|
M%9YY)3 MIDQ&|U/01?D|RKMI7S2|@|_U|'X8|;&3=7P=K0,RA8=B(ZFPI<+S MO.+FYQB?4(7FA)H|OIT
BSVD5^4+X|4L7I6|URBDUXX|+|\$R*|=L>|MRQ)WX2HJL=LAO#I|FREL9GLUK=?
HQ,+>0(>9L>H/#=9RZ<|H@4@OA=QR;:6?>P4-D8RRRC*Z*FW&?Z M|W^TZXY9.R^Y:\$|5OPA.UK|T&WDE8-
7T@.RK(70C|P(E;|2^G8)F5Z"DR,K MH|E4|UG-5 3(M^U.@W/*FZ Q^&|2^N|/)-#P4>#;\$9 M7|=QDI
@1VBI*)\$(14Q2A_ZBZ&V|I+^%X)F=W<,%S*="L0S9FM0^NN/B^OO MFXQ>.%+A0=2Q
|2*+Q5@3>Z/Y6N:0N|ALIG03_24K(MQZOBK97HZ\$.K(2_FI M%'F=D;@|RY_PZNOKU"HW6\$\$H|0\$.
I%JZ'"|J=)I:OD6*6"3@+E"=|^ST MT%K|1*"&5^@|;(E4B|'VDP\$|L8)F&HT=RE7|M>7|<7:4^#D6|.B*&U3KRJX?/
M9JX?E>*_ER4I;.+YH|'F"5_\$01\$/43C+@T=C@NOBWZ+E>%KT,P6)FL)K3 M^VYL*8%%^VM1#LD%Z+|_L&30=?
+8^BUEF5R2M=#&C1^&G"ID2=*\$7V,S-! M|5KY;X1 W@X7IE'(/T,H\$|H)|>6Q;(\$#G78%<<<5=GIWZ_Q=^YJUL-
NP1.MPVC966*L1)5"3YXSK2WH(!=,OU^M3LK<93EPW;V>3#3V/Z>DTW*G5&/>M:B?;&-IMMBH5|;)>"3@41-
F\$RG.9G6*"P AA^<(X1^J+*MEE5^G.5|H;V MEIV?LWP|BOC_O.8^AQW!>Z|&8&C.@|;@M&|IR=-RU#H|1JP;.*?7I
MV62#21|_6C5^=?P0IC0HU^%0WJG|;@E^AMWZ_3FU;|H T);B)NB5AN ME\$OCIP?>;*
< SE;"BQQW68MA\$D9EH0>@B3T_OA8| EDCT_3DQ3#=\$I0PZ MS.PD^S+OMON9%ACR-IKJMFXH
@9'QGQD*4CM2ASA; M6|B67@I=SN,0|U6U*U7ZYT|N*MKD|E;+/*0 M+<#VX9H8-
W&7&)+CJ*'=BKH|;ZI=KRMV=|I\$8I U>>QY.7*Y)"54DY_ZRH;/#N92=6HV_C=@|I|AOM MQI^WV-K?D9)AN)VX-
Z?FP;D|5F@C/PNTD10DT=SS0EV>QO(2_YM_><3N&85 MLA?080=J^'_5FY"15|X|Y.IX)?27(I;%
IOLZSN%#Z9L@N@.P>RD.=@F*?IV^ M\$EDGG@WX2UFM;Y)00*QFZ#MD;.*J%I\$|N|ZR?
7Y#H')VI8HVF\$WDV)FOT9. M==%&|SQ\$|3C|HWC|'<@Q7J|H-|HYAU|&?*L.)*G-KDD5N%|I" W;GC%ZKTT' M*714-
C|>1D8?D-NVY1K@^V2X0 H/U'BHF6%2H(Y^<K'E"Z37_ %T5 Y.'E. MBOD=5|5 Z|(*"6|D=)
@>Z7OHF='GA19C=V_8%044R%Q52I_1F@|C=&HH ME%U""1T|?D8EYEE"758HYQ%\$|<9^%D|Y*V_PQ9'D94
H_X%=#R2^GTQ9J M#|46Q#)|0P.%M-@+Y_Z4I8-6H31AO(9_O*&@04G\$+N);Z>JL/R8;JQZ MZP|JZHW;?
E,2+!20YD&ZR0ITS|I+S|Q'@\$ 38"<01.DXBR"(_!27PJ+ M\$TG|_%\$SKPNC6-7BW;@>24FTG3F%|*Q\$U/^<B6Y*
DX8U!==&L(S+EZ#3U MT+7Y31"7PP,QD5:8"0:~8FR^!X1.VZ81|62T?^B);B@JNA-YNE;8+*ZK MW;
I\$H@&IN*A>+TJY_66DXAR@W%,#2AX+UB0B_NZ*LX#XA>%RDOBW/I_D\$4@ M:A-4&/T%<8LI0|
#C(56B@2JH5;""*995L<2#|I'3)VB%BPC|HCO2_0*LL<^7WK_>^BI3W|IH;KGD)7E%1>M^W
R7W\$J6\$@TMHYG#O^1R0K|V>>9
IQ|Z(V^A1|6L|C2WE5D|%;95;K>%(N908F8'!&|SA_"\$%@NA2S1S#RV)E|P+EHNI|ZAT<_4,X-MV4W""#TDJP;.*?
8^U TJHQ^5|X%Q7MY;I'!"|H5E3VKP_-E|H%T_3|YPK M^+RGLB-|>V6PDJHC|TS-
ZHB,X|C<7T<=|^X@|I78I7RIL=B_EC\$5 MUFZQ7+ MSI/%A2U=+*|=BITY;I^CZ;|+)|#*9EV"\$?
/#W<&6J0FVH|!A|U15;M M&L,S+J|N>=>.VG//Q|XV_CY C^F*D*X(#9IG%|E>K0*BR2(-S/A;)-XO
M)6U@CWA1PL\$D.RC|>9A";D?EW|<_0R^I44UST0\$88?>>9K?;U;PI9,=#Z M;C|>NW;GPJMI|/%/"9T=("(@!%#Z?
D3;7V1;\$R7?S=4^0I7O-MA)?9V(GC1T9EC;KGZF.GW1UJC)RQ_/V4|@/\$^<#3>|#Y;C+CB)/L6VSA)*M:9(2I|I@L?
2&D|NIX9S(*G4+S36|%%O&ATN1M-M0C-1*5GQ"U0.*P^<-U/I\$>IYZ>^NYYIFA#.3.GV_-DJ_-Y|_U|5U?S0=^</p></div>

MAK;>6>4! KK DN2:2B3%3> MC://6'D3A@9/XM45 2BK\$'A(6 VZl>EIQ M^5VSO-
'''^67LR94|>>B1YC=09XWAO*H=\$TOW TPVYR^6 C6HKI+AT%WY/MH2A7->2)<4YQF(U^83^NMY RIW
3I?2)F@C>0DI?2(1L 3T)RFU7F_O->85 MZ/3IVUWH MGY2IGU I7+):S)C+D^P53_I?
=CHK8OHZA@Y5I/U1+IZ(A'2E5)R;' ME) MH^N^I(4CI+,%0H='#,LTBGA&?&K/VU+;\$:S?^VPA;AEZF9 (BV\$J
MN^GI_!OG#>+>OE0Y(7=V0 M23T)JW(NMKMI8,KB(N%(<7 JHP-US5FPI-4IMGMM&64^<0TUWAE"%8F\$76
MKI7/ZCX+J>*0^T%@MACM? ZI?BI>7S&.&6PI9BQ?X)4 U8R#M3U M/9XF:TA:9R<)E77XD4" 0!.MQS6KZFY M?
XJ-Z9I9 |>#YU@IXZ)5 \$WPR*ODVPTCF06H(JY;Q;^!L'2L?JB1U@S3^C0 MSG\$CJ#(CQTOS^M;4T',SZ&+^*0T;?2
L8)8!#8&SUGBH+N8H)XR;:/=,AK-M15-G7SF M^V31-&O;f(EK'Q\$!A+G4U.+ZX9N@L+HN(DDJH0P'
RGB>U&,7(Y8@'2A;OP%SDLP M"-DP^KL?<*F)N@Z!=(XF9FLI(+DfE-2*(?>MS3 2B-KTQ/FEWV^9)"-D@8
MfID8MY\$R4IT&:D4.6\$WSQ^UD1S:\$F\$N>8K#=";/%&HCZE# \$?Y U^T/ MGER5F7>HJ/A4J?0?7J>47>
149":YX7HOY;f^*">8;(K5ID4B+ _#|? M+I_-fE5MAG-FS3L?6YO;D.%(97QPI5.OXL4B;J) _#_/7I?7F+G+YS3-,*L^<;
MBI(6!@)O6.XRM-><0@;,"E"040fMJPZL?ZC^4J^>Q8WfE2H?2/4HSI MBHIC5&I^S^9N>9F+76A9%
ZL @SD+/"H@TG@- IOH\$%;_Q=10.%*U;+ZC\$=T ML FRV=%O6K3JCU6MTS/2I5>4J0?I-";6W9L@6>#QG'=V
O,>036<)"KI MNZX+G;fX(HK8VfX _;38&A:U'C-)XJ;fXIZ?P<S*(L?L\$ _%K<#=#GD0 M03TH5 +PG*WG7\$-
>3AQ:E^fG+/?I\$KK(1Z?94. M3:BZ:0OE=XMNVD&P4JB#\$K<-RZ"H">.K!KG-U(MD\$RZ>F&.<K).VfHG@N&W
MDR>>#)K _J9L?S GS>94^3_6VY\$D\$2I/9TWC=D=#I#IONZ^OZ%=#F>*D=JP7
MV9KM\$JZ AQ "KAYM.#:2>4L)OP^f99?7I;BOC4)&?RX%XBBA(A4+(F^&*4VV ML?&HWfDI)*PO)#:0)'?PCMT\$1\$ZM
_2V?V(+@-M _U^/N^18+/X=-B,7JDC6 MCH#*Q0VOL8CIF^3G\$XCHBD_P+<5C^V7;FF^G=)JM+!08!;WZOK_<+O-
Y;S? M<%61C<:";^8Tf>2K8@:J<%_O:0^<WHVY<,MM^WUUIH637^1D3K_L#>M
XZ^IX2^713C L8V>;>7;@R2+VM3^+&_U7-^"fHZ0X14"X1^=5K?>,"POURU;,\$K;S88^ECEUN-*AWF(@-fHRI,T
fE)P8Z9Y&4Q1>#GV;fE-OH+)M+3C075^J8S<:MRIM^7E5IG1WfWBPfH/%??K9^_BYfI-
\$CK3BA5LQ=BVB;fHQUH^P7AZ^YfI& M*:"WDK1J?0^%>;KG _J9GK->_GZ+^4A?#+!N_L(?O?+^<+7<6R%+;7:F
M\$^3%AY>02E@MC# _058FVfL/JI:8\$ M:8(f%>5^M6-4O<#GR3;fX&10>/LZ M^1WD-1RR1EY9PH;C&7?*.6(P-
1.8RAfD%_8.3WN>V)B4;SfNO4O0328F MC _\$0XfNfOVS?K?I+B/@I@=9PI6Y9O;fCHBWB9Z1-
9!AXOEK=D2(^H*\$^fJ MP^D KOZ-LW5S\$#\$5fN8WPN^@BK7>Y^OZfHX&V^<5L/7YJf8#**RI/295#@Y"
MTU86!&,"E60\$Z5C&L=KE+EXM56P+@f2762BQX+47K>VEWCXF.MVXB&^YfJ#
MO\$JW;^<SRE^fWOWIR\$=D^G9#fO;K;f6#P#3^f(@fV&+^YfJZ36+TT(5?3S?3 MDV-BXT)?PUfJ#
fHM9Q<5;U_Yf@&f56H;fHfYY<fN f1.3-#RfL4^2fTf8,*S?@=N-
%=:ZM2BSG/8 !K;O&QOIAFM;M^OG^Pf9MFY9B=#f#OK?1V MZTSOAF;f^S44G0+J(->V&fH&K^fW^fO?
MO_!O_QK_Q_SRD-B? _Uf+P04 M _"!A\$1;LE)X 8^O P#^M2, %0 _!E86LM,C R-#R,S%?;&%B+GAM M;-
Rf>7/<.)80^O;f"KR:B>J(A)57."Mf_3^QJ=)6D?_Y%_D%PP8%0+RVf? _fUNf>R?/f+3SfH_OSYQR;fD
M7_V8Y0f_9;E M0^_5WS^>)CYS^fU=-V%\$4_5; _f%HD70^*9NV?2Q_XX8X^
MAB<,DfOH<4JE@^+Y2U^f1^"fCN^RL?A87-/F\$ _!L^X/R(V@fT+5 _%*PfI_fS
MWP^fHS9%G*_Z)QT^>_NGfR=%1C_)WY^*8/LVUN>)Qf^*W0>?L^"fKP3ZJK7R
MZS/_ZW=%02fXNUGGSfNYM=Y2E>JQ)E)^>fOD3YfZ>f_30 _DAXRV.fL(X^K MU+T>^"V.23;f^@WLO&O)/#WA'S&
(f12?F5S?7SfCf4?^1^B^M\$+NLL@/(6983%1f1*8OVW?%#;5)f%#LXP M
MRfW>LE3^_M="Z&2HX3@N7f7F/YfSUHfJV(A=@(_7
M _3%J^fA95;SZ+L;K^KXHY;Z_X^@,VOOf=2.RK_WOOO345=^(EFPOUZ+N^>UR7.
MLR=Uf&6FWGNUM83PfT^6.YX+UfH#D?WOU\$7Y=/6O=5)^O8EC;.&D#f=YH#C
MfXN^fASBP8NG;)V6%<OR,584H_K7H#G^f\$<9#fHRHS^MN?_fI&4&="=%MA(_N;9^N\$1Xf3@\$HH_&3fA_\$f>
L%\$99^NLW4f>_UQ6=MQ MSf7R/Xf\$QfL;f>5f_5;G8W;CC?>XW;P5_f_Q(M22)^fEWOWB,77LG\$DG-CU
M^";6="f7>8Cf1&f+YfS#R;>fHAfAS^QfLK4WBUC8Of>^@6U5_W.6\$4f6H>KfH>_M_QYf>);
GEf7@T>fJVU&ENf=K\$==_?KTfM;)5^fTQSYE\$fED7f_C M^Y^6=G)4^f62f98^XXUY?>);_fD%f6UI;_M,36CVTK?
%_NA!<_8(Af%\$0 MX1>J2? MfN;ULQXS5MfHL;78NfJ4+L&UXY N&AfU.^_9Y/MNE4AC%(9);8%J;S22/E) MfLf?
%46f2<5(U5L_*064AK/(UW#9BBV84>)%\$4O+PHW^fD_PVOUOSR47PS M>?
\$^W7PBF>f>fGfXPSMAAfVOO7OKfV.5U>%"",X^U0PD7fS/TK9 MSRO^=LWE.8 VS UQ\$DXA)XEW\$QD^X
5K@5X:A fL;SQ^2SfV^fQ%\$)8A;X+ f/(S\$W8^1&_X-03#P^fW#^fHV,f4,f2 M-K.HF@<fN9WT^+V&LP;0^f!^M
_3(MF:~46)fVf!fL^BOM(8..YN(fL,D)3 M:X9A5C=VD)D.^=AC9FOU24N^N5_fI_2
M7\$)JR^N_Q;f7:WELNf+^OU_XHQf%<>LMP<%K6)fPZ\$JOS^<Q^N)@T;fUKfP@PU@JD^"fJ/ZNM MTD8;f?
Y3N22fV7F0#<fAOZSfJKT^WVZOZKfY9=5KfDfPM=MK.WM%12.R&Pf^MW^C5@fJWWPf6KU^6(f"
_J#5#4CE0^W=>%/"Z_3^2fD\$S;fGG81>fV.9Zf7 MOC&fD_Xf1E^M<_fV/R8K?R_E&V^M^Y?8MGT^Q^R,
B\$BRZfY#8#N0QfQBQ M;\$AQ.)J+WHUAZKU ^LC9>E6=Z^FW%<X^f)BDU?F?^AVX(fODH0fE;f2>%R;G1
MCSfA;f&f^&fG;f;_&f/RJ\$0\$(\$%<;3BS7C^O/fIK#FS^fX-OQY?M.f7) MGVE^Cf_83Y;W.98D>??
UB62K)7\$)08^GP8;QX6(fV(4fH;fH\$)P\$O^_Q4KG Mf8Y;GGfUH)8%;F%JS^*L23f?#
)CP44U5\$>R">A=PS@M;2^f7GfO;fH<@4 M^VP^Y%+LPRSDFfT@^?T_V9S?^URf2;O^Z5Gf2)<#QE_WWQ.Q7?
S.7D6+@>5 M^f;f7F\$W",OBf\$3,2)OKO@0NUXHE^&X\$ NV2RVf.fLk2YfX2&UE@ZP5^fXW
MTOf5;W5SfJLW9DQ);XPVQf5K#&+0LS=WE=GC>7fE2LK?H(4f)"ZW%DG7FUS M^ZW^@V8..BAW41XGUYSf0?<
GOB^K^C^EB5f^9N0)fISG6YR7 M\$HfX.>=B.GZ24_Z2^E+AfA;SLH,f1%;f(<81@SZ.N^BST^fNSRZfWfV0(V#
M3FFTfJ5V)f1EYMZMUf1>PCQ@D#>3B_WWT+&#_P6^ZN^<^\$;4fT6V2EAUS_Z? M4@7P4Nf
+M@_UX7f^/KFO1ZAC=2;fFPW8^<84>%f5VRV;f).4R&7)&B/X7fJ+M 50X00,4M\$@78
_K>0YKNU&XM^10.U^M;f;fH^%1Vf=C^+?fP_f M\$LW61WKfJ;f;f+TFQY,fB@4<9C\$G@LB+\$ SCP(fB-
D+\$MfSFV)&_MW=>Y,fN MG@0 M@CD^G^+8;-R_?>fH7CX0;6.N0WKH7TB&fS^XV@3EKJ^f(Y&f1@L;9B4;=M
(S\$ff+SfY?> M^)=J)#_fH^9LF?>N9W(6GN^<.>283(W?K LRfH^#?NRC2^Vf5;.>Jf1?^Z&@E;H fS_H^fW652FF<^*
M;LX6QWf;7^XH;f;Pf6W)f^<3fLDSAf>KGO^fY79Z2Q7NSf;3_J\$G2^MOR M;4E<9)U_O?^f^2Z%&+^*(86E>?
ZD6=^f@BOYMO^f^FfR^Z>^f^1^U,24(D6^ M5N8^W^fNDS^fTR0?#)843fTZ.=+fA\$RZE=7)
#54;3J&2O^4A_Z^C1^G6 _f.MF^fH^_E^fJ3>fTfXP_%0f\$F0f)LW7QE.(HC9@4QY^9P@V)^*(P^fAT\$AVR>(f
MfG;f+^7^Z) P.6-(B;_1J4L87?90X8N!6NKfQ;&^fFSfI;D.60S4^6YH@=fM/U5TO3@C4_3@WB>*O@<->^*
(Z0%C(f;_W37;0FVf5O#ZDVYSfO4C3-fI))O MO _?JN5SRI,7N;OVf5WA>2=H6))0^B%Q%
(7^"Z^fS#AC3BAf3&ES/=ER;? MG5_&1#8U+UE.fI#%f1f6Y H>fEB7UN^fI&6=E/f%;fLG3fI&%3C?E#.%G?;fJDD\$
MfF)W=\$.(R>3^f72ELKP^)<^"WB;PYf;f5VMHfUGW6Y)=L;052^*Z-D.^@9XE
MD<f1UX;\$f1AZTL6O%S^%Q%)E;Of_LR<8QHfF<+f;Y+;R.OF:0GSMCF049 MK6OZ))7.?
>8Y^46H(5;9Z(ZZHY3Y^P;P.=01G;A^=5;D_UJS6<8VYN&fMEf;_SPfEQ3/68%7f^?9^KG8W+X4^S>INCG;fL!
<6;Y+G5#6 MH9(fEED_HXfISZf;fA;fZ+B<4 M.UA/CRN-#*=_Z&Z8Vf.=Q#_\$.>_QO&E-fCJS-f
Y@P61RfM^fVB64^BT&>_M0YMX,41^B^)&85QS-R0>6%@.51Y.6;fHf1D(f@5fQ+Pf^BHL)9AIf3>HfO;R3
MA<f=33fB;S._S^+GWfJf1BW^/8?&fJ#N/SQ=A^f^fH_D8f;f>(#_2fTBKHTM5G;V.@2fJ_fE9^#_C^K8ZN^V?<9+>?
KMQD#f+RZ(B.(PS^%fV7%J.)^&.(S#4)ZP MB)@KPHTP^#D)M.f1G00W,8?42;ZWTD\$C^OSfM^+GPSQfHf
M6;S^fCEF@Nf3PN;fO7U6f<_MWS.A+(D3N=1<02@NZ+_62<f9fHZZ.fLLH^ MfLf(1=HUDRfXL5fJE7V6f;G79?
FE;#0fY2W%I<6f1^?JNf5T>fA!Q.X+\$9D3\$ M&+&+f;fL.%#*f1?2-ZCVCf+ MfWfOM^fH>>fU%=:039&

MLTHLMGCV63"=17.0X9K0%5 MJ>|W".0#C.4C!S5(!W!..C.2@|<'S3< 4\$H! -SF5W/<*3J)2R!><+<3 M+&J
!L\$!B0!<:TRN\$U4-.K-&#.7N7!|LN=23&K.*1W>A\$"S/,%(RD**A#81PF>& M-)"=5(ZT68>92BR9'X+>V-W1?
TD@!P*+SHC@L\$Y)BT+4AMBF!(1FW7Y+ 2(+^M'SA(J*TFJ!%:TP5?04H<>E2!R\$G6-YU!B,7-N&%O+= MV')L!9?
2:3@<U1,IEEOYH\$))00!>@KO-V4Y@11K6&N7W&+!+D%.YBVBPMI:B6,-
CPZ~**KJZJE+H.=;F8!AE37:HT#UM_0XKLC+CN(MG.,<>7.B&T7"
M8X8<.QY\$/F>0<(((@|IV(VRZR7:QTM_"|J(FY;|>|D.'=0053!5/:N:0HS-! MW97'J;I:25&R:&4G0A; VD;'')@)F&;
HJBK9#5^-.PX/ZG>'&3=IP\$*0XJ M>|9NX+J^+!A'Q.(XCB\$V/-<:-L^B4A((T+UCO\$/ #/QT-^KJHYO&Q!@"PV M.
<4X2H>H+;K-96;-3DJTY::G4,"XUUVZV (E'GO)(Q@M*",,"V.T;<:,MUDN MO=F+,-
B;+X=HKK68ZZ>:>4/6M,27@&:/3T)XJK|=:" MP-!\$195K56;523TQ^%
!\$%T/RFW!^6ZQ@C29E(1X0G>9YQORD655/IRXADJ2 M):NU/!/!<9Z*:,J058N;- 0 (IWA=5&)8!HH.?16* EJDWU+/-1P
MM?Q:B(\$6%)N5:R6JOVUC[2/2Y1PG^N<:,!]"\$A9S^M))#4W4FJHT8'KRW M!2-=6|Z,0C)HDA B>|6.=9CC>I;@?
V!%E1=1%(2>PZ.,_B"\$X<"^W(M%KJ33PMQU/H\$G";D@5J@D:(8TLHD-LP_20GEUHU00QSKJ)(8!OKIH\$X
M":T "<3Q:S.F@#B)>3!Q.G'#/C@-BO*G.M(5U^>>5KP"TKY2H>Y^PW7L@S
M_#=Q:I&"&BJHL6H.Y%&Z28>YC:~N2F8->4W8W M8=)1.D"#>^?N"#.VJE#1B+1.6W6.TV.(FB^B65,N^Q-
1;V;%0""OGA7;8N M'^IP^BZ72XP%\$2XOFN%&8QORC!5YJ\$6@;C'AV(8!9,3#@2!<6J4#@(\$KR)IX
MPI&R025B LVISOIBT: M!ZX!P>PY(B@/ @X)HA;..24=+W)B_-8&%XWIOS QIXDO4#!1"%9(S=E3@M.FM MH=U?
95\$;DPRI-BBJ@Z^2ERC578Y8L1:KB,9UO#6ZC:SYO!2@7)3!)O01 MQ'7!%KPMU)+7"#!S2UV(!%+0 MU/.'\$ SV)2-
UKN<(^15'SA<537FQO.:&U6\$0&T^EJ5\$4!#B.W(*O.G)S)\$A>TO_'"YZ_!)>-'KQ)2F6;:9N MA&P.*;9D@.X(\$K)C#
IK4!GP:H9>2K9,X;F*G/GOX=0G; X@+8#00BA9@>VQ! M!JY.PM"" Q(=^\$/BTTQ K&CK?
D*!SH)Z!#:.A;3/L.C98J3C.HI!"9SVHY>(< MPT,ZEF^;9(!#ZAZPM W>|6OV9K%;7_VCF,1Q)R8VA8%/10A-')Q&76.=_A
MMF?I%E2?/*=PM8V(JJ86"5NH"7/1#)Q10MUD4)OARNJ-^@X!31R:\$PKKI#8:
MK+AA.*K1T9H9B'HUZL!MU/WJC%F#>K'OYP/J?JOH@K*CX ZG;Q/^L%T8=CBU MJ>4QB%' H'!0:\$A(@&%H!=0-
F1U9;A!+1:1%31TU"9+6\$7@G5W3_HM(E2J#10 M4T@Z4A)L_BH2UNMR&B@UJ!<\$_6@/Q,-;TY9QS4@_P@
NHFC0?KESLV10 M(&W=AF,*")U!@19#P,(Q#KV8>9/ ZU,1/O-3!P6S5*T:6V4 U.HA2#F
M"AHMLT!1Z:1:A=&2R.XU/G.&V"!%CM._=CYEDHYA+X5L42>\$D-D?J@/1U8>? M^M/UYN!8'OXX@!\$.%
7O!AL;\$6\$T-"\$OJ93WSB*=U>-I(^6#15&1!U(C O MJC!9TXC7V?/1-JG"!#ZEH?0&14%VZ6+1)H_9H%G4OVE-9Y3:0?
M;J9!84)3 M&B9^&-DEDDA#\$W2GR_"MJ\$94T88ZKN?0<*T\$<-LC\$F:E/R#3.K17GS!TH=D
M4!@YUS65!\$15YH!Y &GB!FSPHALIT*+10C'X=1X#M(*R'C&8\$38R/PZ(=,YR7EZLW=5@OZ=#%J"RFUJ,PX!Y MF
MM^11).00&"J>P\$->6AK.?LY@1.3ZYXL)5OE!L.V89J!#RF9?0X=*!1!-! M*6HZ5LJ?
<^+F3>NCJ/Q1ZA!5!XQNZ7A>U'-+A!QF1-!&EMJO:(F'OY2!BBW='KMI;+=-IH5!9ZGP;,"NGT6D+KELY8%GGF
M6SHJ:IRYI=4Q)RW=%1T;.BEH_2*F;.R63&XP_5&?VX;7;H5)5!@HDCBAU7QVG_W"5^Q=ELO?+!0
M(X_!#K1"SQ;_9S&(23=BJW7%>9!&Q6 M55Y+D#2:L&56?5R (ELOF?XJY!X4:RG-E7OC;XP-
UIGS+04)_\$TN^7|B&5_M2).H"S_-B>6K5A9A:D>|U>3Z>"9J/E!%C(HJ8H>W\$CJ;CA M6MPXO6%,S-/6(^.!YIW#&
(U!+T=&J Z;5)U-R,"M0YH+3E48_<&!%US2! M_T)OWOL<H+96EW2!BPCNO!2/Z!_<@+L;WRG\$~!MZ
M)YRX@#?^H"~WT2D5US_UGP!W"CR!8#;D+M)V)\$;~!XN+Q-
L!>\$N&EO/GZ:R%!EO;5;*0:17M2D862UT&@:T^GOE;2;! %N M=ZWV:VNU!KZQ7FK:0=#^@88*>+1\$%QK6*
OD;/8Q: %\$^?S\$M4+K%_S"!UB! M<|MN9+N<\$>+%&+J(^A)GP1&OL<@9=3C5FA;@:U>4!9;Q!0.B!0)-D(7X%;K
MP\$.W55!E,&ZZHWZ8S6-W)1N?74#1/CBGW5S!(0'.FHE7U@B*ZOG'K@%0S>0>. M7ILSZ< IS <9!TX^9A;"M-
FR9(YUT67K:D?ZIGSD^67V)SS1YX6R0NO+P#* M>HP'54A=RXZ)0Z@!SR!CRC \$(>6#P.7!&XPO;:Z <2Y
JZ(<_03E&+@V8TM1!U&5MYTCJQ(YEKI;!J*)I9XZN13^<8 M=(W5K&A=,=VKU:KA&9E>2E+=KJMSZ-
CBW\$BN#R(WDGO8!@&LQ)!#&+<S9 M"#&EFKJ8B;F.2D6M"!%+P 'HJ;T^9!15-VL,K?4HIUMALT/GIS37.F!^
M@&5>^:CY&0W.G#(-!2:K(M!>VZC!B4%VY^MC!XX 0;RES.0@XCQ^<0V9A#'#D(\$KE?93&1FKE:P8CF=HG
M6S!X?RK=18\$#IXG>"5!A*>D.B^@N-@!W-SJO#;K\$?6H;P<6V.);!%XM!BVV M21RLT6S3YUH)(3MNE?
C7UJ4;+G!64AK-3"UOC=>@@0.E1RC/J1BLM_B9Y!>Y M!H#CIV:FM#S+L2/JP(
@A&QA0!5<1?E&+7!DEHNT39A^J3-#S\$U;46#2C9H MA&NX\$!UV40"EOM)>EU.Z%3=QJ'HHM.%3C64);!?"W")Z?
!>*EKVN5V!#WE? M*GKL.6!*+PR!VE?EO?H-"Q=#T&#UGSJV7 8!(I2U7!A9'\$'+!^V<2%A)+8
M9LQ%@LB,+OF=DC@Q<4298%VN;PB.V=G*!^N/V!XP^VD\$=56K48UC1ZK';2R MDY4%&C/5">QJ^1-
<@#NGZMA7X4!*>YU+<>?4WDH!NR+^C'9W2/.^2?>5MUJ M.*;RBY:Q37WD\$ _J2XF.(+N!
(M+RH\$>Y36V.2(B5ZEB?D3-U)"4E@ZWH!4Q5 M25>>3977BG845!L0R_2U/ENDHJ#B;ARB!KC>8&4!65ZE
MH0A!I&>0!7>0!7>NBQ*G.HK64LK"ASDT0#2R;\$@BID%,6<8VI@YH8W!MP^49FXU<1,AW1H J!& "L("U"#
#@JUS:QHP/Z!/+Y9L;S4(LH#VL!13M&
M=|TCP_9RT^BH7IPBQ^VXUJO^5F&MYZJ!2C7?;0.4!_G3!|9CO.O="P2YSG MLK;EQ5.V3DLQH?
W,&^SO"HH5)9Y0M9EM:170NEY6)(MA+M/!1W-(NE%UA! MY#H^!\$,>U?DI!&5@Z\$94./O<1A!
(@+)DXS=E3@QU!S!8!JC*%#N.K#Z0U_M2-)4>L!_85*!&&"!F\$1YIXOXBTFWM#A\$;LPAD4D&H!#
!W&;4CBS<=,15RO!G M=\$X+5H/IV+?4+VK!W.M:6F!JV6 _%=@%.:&"&F^5V;Q)!! !KN89=Z ?=2; M;
<C'NZ>Sj0C19D3)PU+)W.P(=Q!(22#&03R"PEM_AK+>_30!9>#>D>U8%+N6\$VO5ISD2;_/?_SISK!BF9QFF-J">
WU M.*N2!HADG^DN!\$+U9Q49:QB<<"YBU8)!.(Q!BRD-(L.M""G&7Q@BCD&NEONT7_-\$8E;)E
M!0.A6S/KTIDKJ8W(4737&YV5VEO!PJ'8B&YU\$5HEQ6K3E(34&ID;ZI?9)F_9HJ
MJ'SX'55Y1>|+RBE;7CP!E)>P!U_B_0WO?J?RO-5N5RT>2!*)ZLWF7YQ?.* MK/Z1-
WOP"K.,4<,33SH"3U!E!P.7C^)^SN=<);L7SLJR"+#H=|S!#4!YG)0@
MSG)921STVO\$79EJ!L,U"8(;T5+;L\$;T2>XRN^,K*B'G
M!XZ+=,A1!GO7W+&B!UFQR;=%0A!Y#@!IA%L!1%B\$J*# M+!@!IC/J^&W*")V\$Z)\$Q!9"3,L!J
(P<;P;I9U+HMTS_81M)7;IQ5!NZ!7; MN%-?K10'0_5^Y50'??#/W#SN'?7.V!>IV IN(!<^:AP15YN+@6-
H#@&@&9""X@X\$UPBZW!B%(41\$S!B!NNL=7(FIA36LER(1;7 MLD\$NA->2=;,>H\$F?(BPAB&T%Y\$V-
B@&0ND7#5;P-3!8!SVHYWAG!2TMQK M"=4!EA#;/N*"@5MP=W797AFQ?2?_EK!>HFL*QF='V??A2AVP^X-
4;^DVZ M?2?HVSRCCK@G5!417HUUVZ3B>0>.#P.26Q#YXJ20=4)!ZZZAA40!9660B=^M.C6=-
#+K!EY*U5CSIZTFQ0!G6_%^H4)E"#%08"V YTHL4NAX\$>GDBH,4O M5R9;#4"!+Y>ENZ!MP*9#I2+@TI?
6H1JNW+?2L68.X3?3P7H.Z!Q&IW5C)P4P MGS,|AQWW7.I9!!K,XA^O++O!&I5?+QNHKK8!>,@0AQZ(8T@!G@
M0Q)X\$/H#BWD\$!Q3Y2GXDB)Y!+J@%@TKR GR!UJ#;TP92F/Q&45MOYCJA ML4FX?
UIUC6EB%1.8<;QNY^M!15G%>GGT!_QSD>!9#?88!S3^FOTIYBL5SC_
MD!3E0!H%Q87ZDPU,?*LE@NDX(7NM!MHK<|OTX^BL!ZC!HZ27(O.V,%NQ/
MMSK;JOU9Q7?7!L!+;VG=;~Z!6*VRS_+P>#%5!2IX+IR.MA(MH?*"WJ@!MH:&N;QV/R!3FV!;AMR=S7
66QW!082G\$E_I2SRX4!16GMYRG+(5U+!F M!C7*%&N%2W !A;8XFHY 7(%F"#;RE/%UCC+2N!RQVUD4^76,K
M*E'Z17T>M.KG5SIWS1%%00L\$?I@R!8ALH!QW0X MDW8QZDR8N)*FX;1/V"!*
<^W86T!FPO@QW0E/W!J.3B!OG)W>AGOO M! SB#;EMSP6J!ASDE(>G+Q>RR#)I8_W^*!3&CRC-.R6/(
A;01)#0*@+ M@&!HQ3\$D+B'8X82R0+VDB+K36TMC^IG&F;3R7C6TYL7!&W0R_..SO&A;3DJ^2EZJM_AV)\$?
D;B!#%A%B81RAD*(7/\$=JDO(FL+4):MU*83<<2KSZPIG!^J+ MQ.
!F=R!E=N^ZWH2NHFO<"X3KA2W/*^RY30W6Y%/N\$>P!IGO.(B!\$_.0L1T4U,=GL8@3%!B3@#F^0 IETM:C2NWW?

I/5/ MNG59QNDZ>.:04/TJ&VO+LXP-5>7USNIT4+&@B4=1:NO>@7G4>UVT@<.0ZF
M64ET5#>LNRXC1M\$PM=7B9G5KKTU(@YMI^IK%EPJ=ZM>[-BC2V^0V/7>?-%@#^JL*O.-:
B3U\$8WF7K@O.I^JRG-*D MH-EE6WA5D(8;A3;CBV)(^"N".NB&\$8VHS&SJ!U8.A6?^F1-S"%2-JB\$ R\$=
M;.00P*560=Y^>REORWA6T&.9/@.8%8/JM8161:BQ+&+&0.LHULI2D77.P6D
M>IN8LXJ4BBXT:247G&+B!%)N4IS"5FPQ2WY9\$.SF7G:81CRP*O3"0231# M.D,K#*/^;YMAM:L5*U#XA\$U-
7+1*T.L.\$?M53%P=IK^5X;C.>D2EK.YV M'-6GSTAA4:>(6-.9TR-2-FD)6#/WWXQ'E/ M7H#?U7R2)I&<1@Z-
K3#,.+CU2.08SN @4V\$(X((0EBKW(@ACJF7>OHLU0&S M#0:P!5'HE208:G4U'IC!EIHK-K:I T3BWD6/(7\Z! DG
I*/4B8IT(7^VI@(^(*_ \$AI M/:53QM1+*I50T\$H5X?<=%8;NLYBLK R6%G-M95C/8V65/H5UEEA&:RXX2*+
M1D=KKK/T:M2 U-+I ZHRK+;W8IQ=<^AIUQ7WD:1 7/;>?HYRICHG:9SV)\$ MJ'
4@@(*441I/HQ@4I(N45B\$;IXZHLM)X1.3^NU5+ 1NP*O=2X=GK*, K&, MH*!>LW2L:D(MIW36X)81=#-\$
Z5.73YCWYO6.54GC.L^ZXY?Y2Y55^: M8HD?LD(>+!Z)I_&7VZHVH?@|E\44W_+Z|TWRZI@ARK
30N\$!""&I/@Q%XL MJ!A=42?B)I2Z9^OQ@<_B+9I4X7V@-JCGM:P>=1&
MW0/7E%8%WTM/U27*^1Y\$@%RDOXCUUEGKJLPP-6IHU->U78=KV6CG6#D-MVJ?WAP(M DF\$;0='\$. \$'
I2GS(8^P\$*0@|YED|:TUY94^|)\$|FCI 3WVDLA M9!G/"GHDU<-LYW@7DMHI02/99'739>JL.93=>|>)N;I6P-
5)UKR^V/7NH*D=<G'D0\$J0#1&G#B01=V\$0X1@S M+R;1%!=_3C_RJD;-V0H!^";\$=0ZC%3^JZ8W92K;IYH9U0.
I5F#&\$E| MC<I>I^M8L:I27AU/&80\$OUS>_B9|I+7HQ/>??APV3AT&#DVPEX;+<0B&S/
MAI@+8@8P1:R<\$RX>H;\$:AD3#RHA%+12P?O?%D (UG!X3IA%P>4?KJW>&/L%
M7(C54V<-I.Z:SCWPW4W<^K%=%,77RI DL99_E3?V7GF>8F3JN!WF8&N;X1P
MKE*PEL5FBVR5L^I4TS^")W:I2_VD7*^<1.30=5>WW'T>*OKMU!LUG'AUOFBA M'_M>E'F4;.90H<+M<(F-?
=*206_8VHIEA"JH@R#^") TPQ#;A&0X@!9 M3>GOTB 44Q_XV*_.G:IEDS?WF \$NJHP1H9?Z(I?>*<
IG:YB97|TMF=RH>LQZ MHMIV52B)0E3?NS*QS.>IS/(0B.Y1&88906:HGIT+T.UICAR?9UG@NN?>9 M+-1Z)S-
BRWPZXONQNL=?KKI(6H"R02QV2TA+B5.I(QPA_E\$N&D6%:QFR9|< M*|3|B MZTSKY;@!B8E)K(&D>A#X?
IADVVF(9<8ZDF"8=XC^P,=^2D?TA;)F5Q9.3)VQ5FNNON5&REC+E-<8QIM\$V*G:9GWJ(X5NIX@Z+C&<-I%);
I9I5E3V).EUFZ M.3L2IY:%N\$RBSN5AI= 7@|UW/>C;+*16*ZS*V;%UB)AYLM5RP(IC@-D6W M?
11M%&TUAMFW0J:WJGHUESS5L5@"YC?JI#H>OV;%:UZG;U:T?WVO+C4X MNE_1_I0!IWQ(8GY'\$RI
_NVWUL4_9NQP+.AYP>XOA8:V0Q!R|:=R"6^S2-U MVNF2;/5R&E?)?+Z?S0;
P=I^TQAPG>908)FA2NH1C)0&G%"/Z.(K%-3#589 MJQ'\$>Z'DGJE_<I^" 524^>+I%2^XJ0NHT("+_GXA"
IY+YZF _" _QI M>_#6PHA'Q/9A-FNH"YLY0'(6011982NQ8FEZEG_3@B9F)%JH6 C=@^KG-&
M^Y1E%)AI!WUR*E+51."J6S!D>-H+L936EUMQZKG-&IEUA.O3L?MYQ!OTF|809_?9^Z)8BW%II:^UF
*J8IC%,D(6IL(X@LP) M8IENU(\$A0X'D8\$H%_G6\$15I UD3|Q" &7Y&G|U*18!HD 4!7260M(8AK
MG(I7@&\$"!90(-)!S7A71-LI-K&-IM763B2RJQW@-"_B T.Z8040/Z_ M10
M%G5*Y1\$/B1H88*RL|AJ2YTINKV^2H0SS!DV8W54+_3=Y4A"<|FVR4HN'-HUE M3700!|*^#S\$2@9A-
+_WD2L^4^*?UREB8G:1(D\$K4_|Z6H=)%:R=P8KJ#?HC M'0UOG'4HJW?1;)C2KWV_|#3Z<I?
*MZ<I3;9>2'E AZG3A#>R|&G.%@;@N@3W!\$|2A?|X1.S!M2**BE M BEV_YU%FI.64:%(KJT|SR9EGS2*BPI(-
_W"1T.VP2?TNB^:O?B2%N& MJANXYT+|(SYU XACKD(IES;%XZ&8P6>50TJ5<\$3LT-8W/3 4BQX@LOI&LF
M*58VI"03&>33XPL(P^#6BJ.18CJ(Q=EQPTC7'\$S\$IKOFP0'MLUL'X:(RZ/-6"80LSOH>83@P(EQB)7-?
IT2,\$\$%2(&@EK@_O|HK M^-L=QE")X:H#>.#10S"BLZU-0)*8:I^|KAQ&GL_.\$QOWLSAA&G4>^'\$#W/
M&7#*#K=RC"7_I N5S@6.R7-%RGD)%R?/*E9_)W M|U-9HE(\$3V|EMJZT3%+I\$XD@O_H>%)^RU:K9W5E:41Q:|F
)=D-9_L|E&2\$ MPLBAKN'/(4H|7-NXY*F-HDF 60?X(=OQ)J3N46.J@?VZ &N|!%C?X0R(' M#70=KABY0Q6(I?
6Z28^_R_M(8TYX/5ZRFSE&+?1HRIC%BIT0ULLCYIK=I M;+4W*4XDPJ0BT%I.QC?Q#5DE#W7+5U^>DUS(%2-
BZ&*/BBFQNK A.(POBR+_A MC5TKCDD<>
I:Z|XC:))KI8L#_=F6JGRNE9VZ0>.8P;|XD)DQ_-I(G=>POYA0S_LS5A0ZK\5^62&%YAWV*2Z: MA\$|ODC0I^8?
DA;WHN/3AX2L^\$5U+_/O7%YZY>SB1:#C _UX/%Z)8^E+QG#
M#G<#"WIO%\$!D8TMX17\$S'=I#G+J44A8MQ5LD4|V|&)'YON^"TKY"FY%TMQ8 M78#/#1B
:S0RK6Y>)O|=I=\$"K"MP8"70Z>UZ#.H6I'"&&(PIKCL%CF\$4.J* M;J%Q&(E@C'I:N|ES=8K)D?I#^>?
I;FCLML3YZK>WN.0JO#J MW:F/T&R\$ 2E_-82+C^LZ3JL;*P^6<6AW>0_I
MCP_9RT-BU<81H&P|YIL<)81=\$Z==OBIOOI73 M:TA"HO!)!;U(8K\$3Y%%+1CPR ILS_)M7"C7|S4RUBU7"
%@UJR7E*#T_91 M6:P:0VO-I.M.A8W*79_47&?E:@P+&*Y;Z76|YGK5_-WZ5ZM.OCWC6M4Y#?97 MJLX^;<I
IS@O:G\$BKP:F+|PH9I^_P>F?^(^JJZNM|R)V4D"1)=MU@P548*JKQ:QKC5L"H" MA4UC*SU.VYKIOI-
%SME;N\$Y#7MI^I T=C-C0G7IC<2_1LKWTJ5<_/Q|Z_ M>X1J+H|P_Z,DU16#KU)
I_"W122.%Y=%3(I*IR6<^)=TFO'S@TO>OV14 M>ZQO6!
+0J1^<0P|GTJG^_.*2*6Y30>_N4/A7002+C&N!0&A91/2R.T"/ M#0D*?A@X/T Y:TF@4|N>>8""^ 5P":M
ZL@GB35W8E0>KPLDE?!.#T5*8U MJW0NP#1%C%_-
"B0BN7\$H.8\$:%A0@1K63IK>"MC\$UM2@IXFM:L:C4UE7CIP' MF*:7Y4W:G8_N|VBIQ_M#VC%;6H^"JRE+<(J?
LU52;)@O/LAX(QIR*"\$0! MQ'X8P=CB(66>&SIC:W6|6|SD"^Q1_'.E:F9'/6T>M67VX4KKKK1WZ&NXV'IJ
M>Z&UWC|<_*^|Y-ZOP:E5IQ-OS|KPWJ_|X=K|F>:-".P_ \$O1^*9_1C>V.I M|I:%A&MNOB%\$E.G@U'+G0"\$;-R+/C-
@F"X94|+D DV0A?@HU8NGFZK M'^*4%TU2>5(33-&Z=17BTZ&ZOW*7(-PR1=+XZ)XOT83^@D-Y'3>|IX^_R
MTXKIK#F T-9.X17N?5YMI|QQR-R^H|7>+|+%25IM+2#GSJQW\$.74X01-C&
MLF:0+8^L6L&W*_.9>'89F8CUKAX\$E(EX>>1>FPEV4&VN?D_*Q3L\$|B@T>
MG8MGPSI!@=:F.ZT>_6VL>I^!|AG80EN "MP";I3^1ED#KI!|A|60K7:< MS>J&5P8GM|HF<-1I_5_&7&8B|FO+
(YBB_V+C>T:3#>?05_#E(TX?Y2G? MI&_+1N|+HQB"Q;4_ |R|H>|S2#!W&0FP/25TS&|U|=068^Q.
I4U5E/HU|L&H:T:=|VN1X/GM.HEN).OST==Y_#O MD=+9APW.I&4E7E7L|9BMQ"N?
RO3BJ50^E=:Y|I0<4@D%.U+!)UZN|Q1^F1_="^AE';3T>=58IYO:KU)F)I6ZFYSOK%JO2GNGU?J?-K@:G
M|@AC|SJ(RFSS(8;8MCB.L1.(#P>*A>YJ);QL3#3|HT7VSIJMHK*8M-@77?&
MW+&:9IE;-752MPZ5.I7SMO:|_I.VM;5^?;VMJ' 2.H^<C1EGC)SSHH+JL|WZ3W_4KX1V/Y4=?E/O#XQ831)2RJD
M0HP""K^B1:L0#OLQJ.YWJ'10T!O(7& "L@(&5P5U#2*
M!4ZU.5LP<\$:IW6C@W*_.TIG:1=TV=RU.+0PMWQ:3.9/3.6\$VE.7PN!|'\$0:
M259/2)E^_G>'3N>=QE&JK#V='VMK.IUWJJTYG0I5_I6G|SX%SD|GG2/_
M.YWXX3^:SGL?I#CZ3;/9(74A|=WY8HM(TYC\$@A*<0B*(H0@H1%LJ1#'/L> MDR'2N)3>+6-
B5MEF=JSG8!"R#3(71@&_)B(L|FW"J|X(8 A10(8\$XL'
MG\$>6&W*UI#&CF<8H%|S6_|.P2.92(%TARNM|IC;U\$Y;B>|N%&T-LEN9:STT ML96JF8YK;KU4DIG=?
#J_)FLNK%)WK\$Z:AI_BK1H^N50-5Q4SIR_#|>L|Y
M(T<+Y(6_3YGVQ.4IZK<|3E+;WO:4_%#>REIGZ45:OW;.%67.RR2OIHYO1=|7
MUIR|B>_QER4+";02V\$8VC%\$3DP@|2F"7ABYG#D_|^+)-9=^MHDL=)PV+|.MH|=|^OGYWJ77=XF^+INA3_Y8Y(
P=(_I2:OBIZL\$DV0EYEK=G\$O3|FL_MR7Y+?668N6D#"%0HP|YT|T_@?PH3HUTR@_&@VJ'EP' NO
0B<8Z9PFL6@ MHV5YFA;MS(F@9C'I<:ZH><0:G4&OB?/(O!)"#S.EDDQI0B;VW:50L|6Z_'=Z&:6Z#;.R'#!<73VFZ|4
MI%1ZM|E:QI(C|I*YD)A9YF-IHPGTWOI'QO-IW_6A\$LV_|O(CRM)4_IU_M_O?
FRX.9MD.1IT_/QRB#_8V3R"@D:88T<>I4_-K\$=\$B9F\$2\$1M"(7X/YW

MG?49015_ABH11Y?"IHQ!Q=FNK0OD"-7YL#W\$T:7BS.R10_N?>KH>U"/M)XJ7!L!O!C/PB71_@P-
^GV4NIE)HBHNJ%1R_@Y26GRC%+=+ZODLYJX">>1B-MB\$+LP<@-NC:=N!CC'V/8(T<"P80#.)@_0*&W\$@Y|_
T6ZU,6ABU7X>FLI(M1@QU=W4!)N@C9VOIVACEY&BQ=Y%?^M,X3>05B)V,+4D*6A5 I8-,6K'SV@+L
M")7,3>J#">?>KBJM\$LSLOF_C7-EXSD32,@UPPP1?4!2ATOIC&E2?JU/OBXJRXI;KG0=3\$3H1*V(2%0"%T:
M^IBRE,2.TITZ ID3^SZU;\$.!X8 VTO76L72,J8F-9&!)A@:_L%_00F&L#
M!+1(%J_=DAY@(@)'6@W0DSJIV8V"2PW4.DR.T#S! =XR?-HO&-W&<4\$#T#8Y!
MG6UHZLU1*7IG^;M%8'(>ZKQ1^IEA='MH;@Z>-<4\$1Z24J34Z+'6^! =F.32DK MNGN
2QTE,Q>A6I6M\$ _TO&0NCV,4TEECs7 \$W;>XRB.K^PT UI2CE M2\$.C#8@N574V(-J+H;,\$#W@^S<@NEZ<<0.B!_?
^ID3?@V;,>^W;H\$-S."OA MA?R.IK(Y?N)^5C!2A(MCI79;_Y2!E3W+/KY(F4Q'N@P#Z>_.0Q=QX/(
MMGT8VBB"3D@9=F.?VK'2K8GQ(\$W.13NP0.IK@U5EUIZ,2A2H0)SE55YH@U!B-MA!Y1BT#FM;,>&>
IN:NR:>PNO3YE6 P2_M#;?P5B50I HQPMQK/82/"2"(F
M#;/&_<IA=#9BRR9%23Y8(CZJR<5WF&7O/K2WPQWL6912*_*B9 NM& 4.4&,
MA#LIMFF.HTB!_DB7B(F)KI8)&J\$+L.Z#3HE.3ILHN%V#=#6CFE.EC0I'='&JK M4_MCJ-&93!4NUBSG\$>?/OV5.SK?
G+%(1Q_R_7HL_.L&A<7N7\$ MDN;JJSQ77YYY6O#&%29V',>\$!@("F7'=\$6\$1<:T8^BCF)+1=-I+TMX;/'")V8
MG7L.7GB>5FL_#!6J2EA !R3J7YF#QYF54JL,TOONU9*^HAYF;V.9'S!W(K&J%S^UOU7;Q&/'T;@VTREC8I:0,H?
DZ.RRBLKF MU6!:=18;UL9J&.3JH-7+T3E0;S-W1;M-V!BAT+FMGUZNS9NWLP7Z3M;/O M40-&N> TG7-V(R?
IY.%Q6R#O\$R!YW9XR#8T(-&+N.I""#."= M!I 2\$OA>POUAY <58B A5P!L0(4:"-B@QJU!!F-VH)COE*WZ-
L!#UBPM.C MCBU889:27 %,6LBP,376X7C"T;_.E!_=&M=_@%IRE^_ES!C4DEA6Y%G3D_BCR2 0C'/K0LP.+!<
*/40U5A Z1\$R!@!"\$ M@E;F ORLMW!091*EY8.!BFJN'ASJ;+9X?*"6LUMK!0*5?N;Q/#_HSZP1=,ZY M3-
"#&5H.I)TSON.<^M(W;OH!Q*JB@LNC-M,2>Y(8^C""+L,QC%EAC>GH>832ERN;J/B-%@3>P!-#C!-
M7)4^K.P%/SWGVPIM",7625@IKC;8?QRK1.G9!-=T M'4W.C\$5@QI;0?M78T5LWF%-
%7)XW2;N;,%P6VRPNRC)/R+JLX_2WR;!*&'\$5 MOYR6_-!;H4A8WZ!H<,(751R"/?#3%7 M2O@T)JB)Y!6
'G.Q/@N\$^%-6?2(5^L-LCIR07_1F MMY\$-Y#NWC25K0IEM9.OLS6MCMVV4JL"/_@M_+;HTSK_>MW?P2?'>0>S".&!A
M?08&"ZC R&S+#+1RPBP=L M,DTS16D\$5>@GDEEU6L_!17^598;W*7R(PSO+ MQ-8QCFV(+N 4>O@Z!\$2,
L3RW+4L!_U29C8BY\$202-2OR#ML3U4?)B!6NHQ MPJ&^AC5H.WI>J !L(U?N;_L2?#GZLX>OSAKS=F3N
KS9Y^T#"1L X2P6 MKVP2!WHQCFs/I6 0A4S\$.JR!(-=*XWDD8B)F:*6"1JA!BDD MCVVB0!;#=-5CBV,E39-
FNKE3IRD;FB2,5NU@;>1?)1 M'R6;/VD60QT*1*^!"5"Y,4?JZ+>=MYF3SA)ERP. M=%#/*0(T)/09#3@@
M463Y(MIACA5IG?MD34QL^Q)E(TD+!+!5TQ9&G8C.U@&8D2^@QCI\$1M,4 M!25&BD3Z,T;V&(M
MY%&8D(EH(F;_7F>'?J61B!Q0LK\$ UE(E8G!2B#E@LNLJL(C>NN@IZZB\$%2/H MK#=#DN!4U.R!HOF^M,
I+#+17_E8I+!IPY*7OBY3D/R;_C/S@O>^9A VZL,@&T M)_W;-3S"\$2+(F!HRW1#6-;(\$@?N(V#ES,W5 I">Q)"1-
S2IV58G-0 C^S M7*=-H%04^&_JK!T24:FY.R)Y;E5144X.^AJK!AV;NL12H*O632^>)1-* M>X!\$>A!T<4Z%.+7
M!%_K1/#7DE%D\$=^BD!&_"YJQ7!BZQ(>!A8C'0^ZIOE(IC^%0)F:C5@RXS672 MDID06V^!8X"1U59
YC&^KD=%=FUH@78 5;1%5^~1;C K0800MQO)64X68; M;.%E)!9UV&&&^QPF6:\$%DVRNZXE5\$G MN3\$+O-
A9D>H:R<23G#3I42_2J(^%BVJHAR*L1SOL0=;N,J&M3BT,F% MJF)(4JK;H45-CF9MXA!&!! #DB?
DXE65T\$!;_""#W+#+&69259#Z_ZD MLBH-S9A25D.O_52S.B^N8"R9L=-7"62D"5;_<+!*"<%KFI-/LPU/-"RW5<
MZ/B>#Y'C6S#R;_2=R/9"RBV;A\$J;X>HB)^9&_"Z!R@A&&Y<*=A-S7L,UQJ; M7H>(61+=G7=1G*M%
3.ZD*I&^#05=)X4V_@,YXLWS;3P;NDH'A57Z-D)SXX MEK'+!+9?Q /H1DOM;K^TOT(8AC\$.\$/(<I'B-!5XI\$P_05BZH!;
<7A"O1;H!_MWT;IXWHTS?6&L!2R@-:2:F>NN#B_7KXBA^VH!_ U5D&H)B! =A4>JBP8\$T3
MEQF3R!ZRI)QCY%4A^ (K>KC769%62R#R'5=*_*@Q631&L^*Q1B-"8R9IP>4 MX<"E)
(YZXN>>.#N4%RU+/#&\$P>>P!8X()40_-08J%N5!5;_?<13 2 3;"- M&0QE@EHGL.+0020DH;_~8-
!XU7L&M5VW87PA.R:G!0-!"/1+=K#IM@%B M'1B@P0\$N>RVF7RE(6_FQJ@6I'YZW8I"V08ZJ!NFWH,?
G@K.&Z!_X8^JN!Q/J3UBP0Q5-MY7I)M%\$X(IVP!W9R^S1*EJB+<A#S+J MAK+X10!#Y!(8V<)ML9>KK)
7Y)ZE+!FZ!+QJGR4JT6; M%!!5;"J^~^CL^ CL!9?6GBJ/HM6*YPZ;@/G5-
#;_6&FIWUYOG!UC_0,8*=>Z!329H%W%Y);H44" MB")&8>31& 8>Q5:5@1MIE<L;WJIF?KN!NK^3F^T'NBO-CS-
M=*<@^N2XU-D MJ^Y68:0! =!#XK".L6!/#(77B*;>I+9MD6;?XJ!Q H6 7?ICR;&/ M;\$1F-W%P!H\$(QZXT5'O?
%NORA)G?LFC(XI.FI%;+T^H&ZEB+*?<_I(TT)X MJH,I=>!O(GO!9L!IG M.9'SU_E4-
\$JGG4_5=XT_X>^!_%K7JHX&XHXIUE6R'838!3IH!\$;5T.S'-Z.A=YW0V/N!4T4KZO8BC9X/M4?!=Y44JUTD%<5 M-
7D+0&XE-AT;^HF%;_59_8)H#5L 6QPRKV%CO+H(BG \$J3P!AE@8 M0\$(A5Y";.W/+!CU.M&I?10F;>K+>B
:M;_CV;T64V60<>R@2Q@!C @AO.Z MC<8#"/)F'O;GE3X>Y0KOF,7LRAIYSRM,B!OPC,>N-
2AD1C"D1="A&A,1LD/U3L.HA>M#U=6-UHT-855.U76!6' MJOLD7H?_G!>N>H!;I?>@P_3>9PVW9G'Q*/^!^M=:T-
5*5L;Z)+R1/*R M8*X17VU=N>#G2=W!RIOLS*+SKS,1=+*1269?L>M\$A@063S_!\$B@BRDCNUP MV!6!-
(P!#7!7XKQ4H&!@A:OK_M\$E4!_!M!WZKQC1!S!6'WWZO4QI(J"@D'F!ZG4L.JR7%R.B;112\$6O:~S: M?JL!K#
H!;WW_JT5%WVJWZ7EN=8_)A'5;H!MD8/ZD28CR>Z^V_LU:G8
MJ6!10=E=NF+!\$NR^OT1MC';*9\$_J)W5>H5..CON!H;L;CO>YMF!+_"H-8 M_B4_NL*Y=(^*FUQNF!_\$33(8?I>
(MDY;?P6E^*?Y!JOEC'W7>3Q"-HX%#_6 M\$GY&^@8.NH0FV&N*UR^VD!E*72
M9GHD MJN4T>+GH78ZJYX#M'S=Y_97-4P!9C/N!UY9E M6!^L!'/U!WW@C+B8"<6(I^*Q>0?MS_OV*!% M BEQ
3Y>:PR0#E,H\$;P!24HX\$ W\$Q;H4%#*!X8L!8\$JAVJ1PRG>FEAH?7 MYB.'TYCWZ*G,1/'P\$;646&_B-
DX1!\$#1;CG0Q02+(<RX;_!#0.\$@ @_%KKG% MA"X)Y;E\$A!KW04G'G@?U<I+(1-WRZS;5<%&LGYZK\2)8YYS@?
Q=>L^_E&!\$U#15 ML!3HM3KU!DX%9C>?I@8.V.(HGF6E6E6*A!_#!>I/M;S<I&M(U&?A#@@(5
MJ!RP9B9PBA#C*.HV7+&F)E@_XN,80L&ID:5A^(-+F26J*=GGA:5P#=?MY_? MXJ!R5KB0Q%5!6J7G?
>0K=I_="Q"IRWOH!HH6!FEH1NR2AZ;G3<_""X;_J?^+XK=P%!.4C!^FF=\$!Q;#;)
MU^!HG#IG>2G!3;PC9U6U,2MK\$6#Q'DV>L9#UXTC^!2S&I!W6TIT4PG<^BR7W M7!Y)H_L_I>7GR!_!MOH(47!93?
+DA;_0ZX)!H\$GE4V!>& MC-E*99Q!9\$P!W4JAX&^_@:U8#<(!816%B6^XKGHSUK&.)NL_)35F!F&ZVU&
M32N! =Z#_!BM86K+W.I7IC+!5PJ!_YDEPC@O0L(ZYT""Q3=+P MY%GV)V/RR/LZ%;
(8#Z!_="NK"U"GF!O+Z!YX;=83BKCHJOF!4'STO!X M;3?;J5>KCIQGPDPVXHCQW//&IV!9=DB8E_Y"!?
O2AX2L>)TSDJ7 MR!BV(I#AW#R*?1!2&G%(XLCV THS!V=(Y_!XB8^I+!F5"" E<@%2KDAX
MBO;JY!HOK;!"@f5<6 D&_!X:*QQW6_-!9,B;DJ;=-!CC+!93VVH*7YX!D+Q M+;_-\$M>.WN+5"A?WOI?D)ICTSCFD
4^%YY+0"&.(PHMQ^ (68=@)';JO3W(D M8.IM\$B\$0U!(7X/YWK;V#8V,H;9(4E%SCV1?_!MDF,UM79(JG!RALD)H&?
MV1!Y?F_!9&3J IV1TX_9^8!2 BL)*9IY>_V;_'08C@E\$W"BM!2!XR#M(-!2 R@_J&9+^B<"57=PM\$;H^LL#K.)
M@2.H.EHIF6_M)F=3B75CUU1M=?_*#ITS_!D!G%T/9^C)JTB;^2.E<_V&2 MR916U9IRV!57+!+E>P(
HXJ+I@#P9XX_J"9Q"07!09?#O#G_Y^+;_JF784,9!VH!M!GS7KXNE46K^N9P6XOOV;1"=6X/B^X#
@FB5!Y;YG'F#_-MLTQ1R2.G\$Y^X@?^EJR407=*E^!SJOH7;\$!:=;RW;?7A3_3!+JRM8R?M!J6'
M1>?UKJ@/VIM4*_S+L9H?2M;:#P478_0QS.NG^!13.OIUE^8-15W5R8!O
MU\$SI8OD0;15F<9;@G"B;V!UIG.=QBA5A-(XB)G26A54H!WON>4ZFZ5ZC1U M;#UUCF0!3Z/ZP!WJ4@VLHMUN-
#L<7 BX-I"1A\$DC29H5B!10-8%K95QCLD;#^PM8^5@EDM\$!W M!_89H"(-+M7J X@9K3@'1S2;CC/XVZ?G;V:(
BB2S9_5M/K=8W\$2#+),RXQ M8Z&-!0F&ST2 N^T<=80)W MA0X1^@3Q&J%"MFXZ00;7."V2@N;HLV2IAM'W
HT7M_8Z/M0@_JL#G= M'TLV^!\$;37+<I6XG;GU4=
T#*@B(9;I#%#%)4HFY!>^C9DX=-J=WBYF;\$JZT/O")Z@>XA_<IH^+FS4!VH@%S4"JF*B MD\@A-2!3Q9"#;T0

XZAZN=@4I>/2+ G\$.PSSYGKX9C.MTNGI3IIR6:)) M"-6K9=9*."973L%#I,>QYA3)G 6ZE#&7(@H+YI-
J1&M1JG&S59 MHU>>L 'XY5I:~?YI)089Y3&:2.M8V88M^E^D^I[<>JD?IJSI M;CIS)=U3.5-1\$N;SK)TY(20
M@1FDEHHV8B?HYG? G#IE&O<2Z\$OC\$6:H/KPR"G, ^+I;L?DX^&18N9S"U MTLNI>I?CES/:IQ,N6OHLB?
>#ZWF6);="16Z(^U)CUF6IEAIF2F#XHRP43,HW(?9E XWN4WWS^O M^IS;^O1?E^B=5T ?)(2JZACT3&I O>YN:G-
(WI)%%(1YT9I-R).EQ0I19P6BIM.8O"\$&TZNDEI&E1SFC<=>5=P^ME3%"TVFOIO2NC;/O/NBT M^F9(K22#14L?
0T2B."(Z%%@0'6"2&6^1L53@.&&Q3.) \$J+70W2CEC R *W5 M6U7D/Y#S(*VZMU?=&#;IV\H/Q8S-1.&F MG\NZ9_?
&K;Z)(G*%%9QFM@*01^F0A(<1#Q)TDI&C(JI+D^C=@?WJA@6\JL MES;K+5Q\07I
fNO%=WU:"\$5H/I@*3%01Q3VSD)4NH\$8X9;/0?VN6BNP@O M17&I#7I:">^A&W097\$OZ =, >Y#=%L#
fM C\$X^ (PR"i9,YI7IE%16O)=CG(> MIWDLL9;\$? AU9)9*N28X\$9IF2@4I:3I*);F6@C=(^@;ID-UO%)1I7
M&2MLEAI#1(K->.%Q.ZXWf;,%RK^NWQN.9;1XS^M>J^XIKO1SI=#8CV^G
M62HUGOU<8 KF6T&9G18LGI\$YO=5C5%I_>A RVH&+LKZ,. '5LOM(U_U MD.1Y^O.08ZFY2DX"3 / H8--4E!
Y.%B5-SEK<0.3 +UJ^1N '8XKJ1I^ MS(%KLU_I=W+=M_/6 KKNKN<IT&I _RT_.+1" T\$U/KM56".<(NO:I7>0Q;U
MCS\$^2-TDWP:\$N&O3-QVHHI7NVVK&82;EH8VNVHZZSE\$D>FW?)^M=C51U^
MS:H.4R*0(A*I@/13W#X;I+I^I^Z_44M#="4I) ^F=ML:&#+8FB#/1\$1TJG' MM%F
Q(+@W^SC,65QF,=\$T8(K,N4GQ&VDSU9P;' (@7-BGQ6):U1981R3, M/Z>O5&1=&I=FGZAA7\&(Mf8/'C2D<
3H*#1Q?X=D*8",5IZS0A:CH9=790AQJ39GN6^EC13N< MLBB)X^EIM4K&P0./>M0/^VKH?&<-G3ZP81-
DL/T/FV=3V\$ "6SKV@^NFI=U M/:IV::NA >-V\UA-9';5U/7>=U%B?)X@_3QXJX9I
(WBAB8'ZQ(M)8Y0L#N00=3FDSBPA\$%=<@)8X@BC MWRf<)K"@0S@=0;_Q&9P6I<18C-8H%8_F"82J8?2
PC\$S:I=:N9^E.;LN;'7#;5 M9'4BJ\$%61W^EITVK7X(JL%SG8.1-K1: +B'/&^I:=-8JH.+3/5K^MIZT
MJRL#+1OMB/5.9>AS3OFS^+;CHH/ZSJYW^2A(01BE7YI4 %M9RHNHUI1N9Q%; M\$17@((X23&S&V8B##IE
0MU*)%.0%BH^="."#1\$A_KNNW.#FPS&(\$Y5(2?H(U*.*V33=@ ^.WHP M\$4:0MG 7K&^1*WQ*13.;PD>WC;DG?
\$KG@RWADY=U/O=5A_L09E46S5PIJ=FB M^*16/UT?610)275DED*2;K8(8YX:_R5.L0Y9G*4AHTGJM-
WC*7I@/MDH+2G MQCH9HH?S8\$YV=O_?IK0>C*UZ,5R7SHO'8E;?1@?F-1%),4\$Y"3)3Q4JC.(QQ'04;#+(ADY%3_
MU4G:P\$2SEETI^U;FKC<\$0I:(&LQFON3I&8.&& LVZ\$JT7SK8@>?S+^S^I+ M)FN1-79^V7G8#2EG#C?Y5'-
fM1I+K;Y3;I5=<=859HLU.+Z^845\&FJ.X^@EXV;JIB MI0>D\$J)+(1T6-V;IS;Y5Y:YU="(M>8 N/8+ST%NI-
"+8Y.DN5ZPAY084QPD.K:6%\$. O3"=(Q MFG.B0RZH>W;."2\$#I^V^0(P"1?5, IDU<-&@)U{W2<=>/H78!WV^@
O6NG MC?;#I=DXPDIP8;A_>.WUSCA^C35.7>M!+U^N+K^O'R5?IRJ.(KIE;N6 M8S.+8C.VM.^*V:?
ROGRD3TJH2BC.UP7G4,ZKT2QI-9I(78.(F4LARGG&=F M51:FF\$=1AB,F(T5XDO", MJ*#J>ITWO?
4RM2:707@\$7<@./CP)%O9VZ;...K M2I36=X+""\$=TLN<2;=2VOY76BMMCJVO5^W);H^*V>IMD=:H5K1&I^= !N/I-
MAI#O2_'F0PGI_ QJY=:/US"2Q_OT#6JY00_GL)*,NYS0G\Q7_'Y-MT^HWG& M\O0GQ);&RD-;8?\$.12)SJA,<_G(-
W^I/D#^_)6JH\$@A/MCRSA\$F_MA_V M:=F^YI=?X0IE%\$S?I>L9I:24OU.6OWI;6/FU)_2^2"A NIEOM5S#.U8# _I
MXLM\XSWY3,K9K9EKUGAJOBK7\$A;_' USL09X1&+;I!H=.%;C.R\DZ?FJE MXJ5=1%JY\$V0EHSIJV="
(Z0E+49&N^.'NJ85I^LH=(I:*.W>BMBTBQEY^HC MK5"/RX"IT7^IS
<-RY(MBR^54_:=NDB8(34C:=V0D,E_PT#;79C3'84J(#D^A MX@20,74L8. I:@2BE<0)^@U4);_I&"X?16X08;/P
W79P)N0IW@WNYWI(M3^O> B5ON&_ \$3_EIK>_Y2W7>7##9S;."R4_WYIKYI+;55;IUI-V&QYIRHI
MVOI\$;UF5%+HL%1O%^EVBMEI\$RW"B=6Z^I\$SA/\$H(SF42\$I*&.HO=#\QY^C%M=D.M%3)JH:U>YI-
8:8:VJB&CVZK>6*4=8)KZFM^IL48P^HS5O.WIPW->[4I M1XY@8#I>I?
_%A1%PI\TDK3OL\XT =,>+62F);+U_GVC\$6L\DAp%6"5!=1IR.) M4@Z0-/ZIU=JL.W>J@K3K>!UI@IG;:_H,9\$\$8+?
=H. M3I5>NB)0F^R1Z46+L<4HI?0V14)%7Q%\$ILNF5>?KR^15?Q>(A2O*4ICS&
M/I_1K1GF(8QQ9+\$<A(\$TUF;":>ICN!@ M4QR^RWD*MR;HF*+)?)JL?SZ?Q=I=PT?JE.R:9GC3+A6D^LIU/;)5Y9\$FD8
M74RG;K8I7Y60*;JURC&+A5E19PG%.8I)+%*5)BPWSR#N9T".GSITEH21ARJ! MT(*EQY9P";!TP@>;_00_+
(DCC""LB2Z8^WC+(E3JL)DCBZ;DUT*%(1D;I@KG82VJZ^YBMJ>98884LYXP!) MX.2\$D^9P0A%6ZD3=/?
H*63;I@6CN@.%T@4QTCIV*(9;H@R.D- 8JYHU?; M>33?R.#M&I 0"/MUWK60T\;E.S>4IT\$@\$.
IUA8HJ3T8PE;I9"4.I#E(5. MWO@I 0-SB;7H7P-IT!@NW-\$ (HPW#M#YUD, A FLAIX\HIO70S^A^IEZZ(?W
MC5L/_8361_703UW7X33Z^_+I;J^OICQ\O%0QR%+)#VX^G& N-D&\$\CIRPR M-LOC)(F(DE\$/(GV^*V^HK?S-
;?;U4&2EHI^*&);H_I; JF_HM-&@'@?%?0%IGK=1^A9(3>NSIG/U8BZMMBV73PK-3KP*NIRC;T^% M>*JN404>2%?'
HOFI^&0IZKZ?7O/9I;S*.T_G0Q1O^R>P?C^?#&"SVX M.;2ILZWIMIR>3GD(1)F>9;B2;157;2EI^5&6?
S\$CRJ\RYB17;=XR11 MAHI4R&U90%LP/6"49CQ^N7N="H#@H<?U0G3^4.5"2K6.0)SV.R%&-IR@8R
M\$8S;NO<[5AGKQ^"-6JH^TN QD,P\^#&PT;9-5G;ZNV(%;G4?P?0/=R\$%W:"N"/NMSY% MW*+^N9/\$3;>.>JX1??
#15ME_KPIQG_VSQI+683M7EQ0E\$2+56%\$L;XLI M387QR&1B(^KF\$14D0 4/F&2.3I&)%H(Q-
^HTF<>&.KD\AU^&\$T8LY&L%" MB KZ+2EC3;MVVFC\ M>\$MTX06E* 3\$24.9^RT:"F9Z?
ISC&S=EHTAC;:O2@S5^*^=_EJ_+ M#16.S40Q>ISNT:Y>GRR.J\$A\$BJ.P33&AE-G#IRF.A5)QDD>I^O3#5S7GI1.%
MG);>=MVI3J;_"LJJD8QD*26LX9R8)4^P<.(9HUZ(WHG5.)#-6>M 6"=JWB M1T#=-K-
C*5>TK81UIB^C<9S4W3UM6;4VWM?%3/Y-29N1
M=2^KZKT08;CM;G.A50\p.G0.29^AICE.L.2IH^F7.8T2"\$GF3OH.K!GM=5L M;R%EC^FNE\$;I?HXYIOE6-
K9=61CP\AW2#N#ST3W8*>3DAWT634IJ(F.SP MJ30G_2CQ@;*W;9&%F+^JN0Z;/^I8O/XJ5>JRO3\MX.O;
(_7KQ3NIRKRN>Y MC;YI;JRPJWY0RI4HC).6=*8(SB3G^4PT3W.2IG&8. AI#JONT\$H-IA
M#GPZ+BI2(HCUW>:ITWB4\$39/5IO)YB^8H I#I815 MI*69;=IR@+I8=5IE3I0"%W/Z^;KNI^QZWW#08
M(\$<5X.%/@!&.\$O+A:CZW.96+&9M^7Q2+>_77IV\I<+;I3=/S_&+^E3)6O MBX/PY4H-S)HQ=I^I?
N"#IO@9U"C/ZP.J%BAZGM@K&E\$I^Y?35_A=Q.VI:'
MGC)!76"MIZ+3M7Y%0>+I ZBLS^IRIMO0ZUX,F2\,F<2*ILCG=KBFU&&XT@* MD0H6J1S23;E!O."KK3A^YD3I-
OOL-H8#29QB1-VI0J;@T<8/ON!-(%EO^I MIOJMBX^Y6;+H0DWEI=WZM>\$I
M#6*M<983A@DE(68)4UA)GH2Y5HRY%?YLE3(P0>_3*=NXI\$6_ OND&I3889\$2L3'I(-)=_0#HYX4T(
4Y)=T00f\$B^G13YP0%HN^GB M42Q>R@6;_C(O7U^N9ZO=4AL=JRH/ORIY^Z+FAA5@N+MGBR?I?;EQ\95.[67&G
M^LMY(99*VEJ6/LGNMH=V^WVJTOL2I_+W+4&4;5Q0S65/D/6)C3V7QQ MD HF@AU'819B(F-
;K)XI+;+HXPC6B)6XKYD-TRC8_KHTD 7;_9LAK+O+S M4.83%"EPP35IK&?E>YF 3.
(MT'.TT@ (38KDX.A:.\$9M_GJHPC" MQ:Z^A^;BZXMWUQ^OIZ^OOJ"+F_?HZO_ ^I_K>.<0%MJ\$;G0QA&1B=
fA0<<@J MIV2(O&DHV)XXPUGL)P!-<8A9X#OH@QVBLO\HVID(1\9M_MOU9IC3PAJ6(D
MP5G+C.F68)S&L4X9^H@B -I;N;NSGI W.#GNUH!58(+ (OR?D?IF#14/ M 00TLY9SV\$WTOXP3CAO^I =ZK_V
>PU\&D;ORV"#I+;"70^K5U 7IV(>_M MFUWOI^UWG6_RC.M^G^KYO%@LRV^SFI^O7LQJE-GW?ML:IOEW!94
MO=D#1C=3 %>1CEH&GMU^YKU 63\$^S#59+;3?"I^INZ5X0EZ?2*3)UG>I+(MD+6M1.2:>=_VC*%GIE8TVI=??
IR3IYO-4IA.W3L^YZ<<=>E;O@LPK;IUMP;EWIO VTM;=fK>fW-
I;6=+>M0EYWNJW;+I\$&A.E893@17&CIB28<^I MYWD8L""7H62@@W7-8@;>IGM"D96*_JCD
C^L)VSDID7MCAPV/3U>W2U\A/4 M6_OZ1B\$CIZEO Wku>DB\$B%/I.>9) M;:f4@:8933"
2\$Z#KD@6>*4+S^8A@/3PK;fW;)N^Z^R5@.MK)(+5&f5J?KL MU3IVf+
(WW*BYLSQ8_%5R;KOU^)^O.BKMXFMA>X%9CR-(M^0D^9BL?)H;Y:1YAGM\$ 9S%/99QF2A&G+55O#8;.(VT0%8-
7.FOIBQG-.DW M""P>+EQ<^LM%\$ MY&H9J/BY6R (4D>2R9R\$F\$;1E:12%B.*9';J31F4Z#4^GWT/5I.0.3Cf&+
MJ@6#6I;_Y7SYF_G_T^9\$7JR36%+.<*I20S542\$R3C;."\$X4IE* MB7N+Y\$81 I;_8FL3%0)A1I';+2)"

!ET10KCE6.07IS2B!9")UU10RV3M&G? M3B*=-X!(VV:U-'ZY5>W=7Y5W)!7.)6FN 5BJ@3T,9!2MO6-
&:G=P"R@Z:OD#OJ-IRJYC\WY6RN MQ.O@PXLG!(T,".N MI*!RADJK 6Q!Z*1UW"!^L,
(IVZW=BN2+22V=^VSC4/>W>G!0SZB;-," M>S%GK?<%U:/5:2_13#JVB-F:&8!;Z,SK"5-/8NCEQ1D!Y< XR
M!YZ!)TZ& !=X4SGN*G;KT& !DRS+7KL ^,!LZ^6@!)XV!NIO@:#,6<*MO M>LZBZ!JP8I9M,J<6E*>
<:DP123%)\$XGS@# !%>4VBI OT&DYF<\$-RFDX!V- .SG3!/>QV# M"Y==D<+FY#%
(O,036A!1U\ZHG!C@RMVYI\MTYYB'7EHT\SCRTG:E!VO< MJ^>7+DECOF.KD8:8>JZX>CB0TJ.9.+SNM
M7_8CO2'N!58CM"SI;\$!G5*R4@I04&W8@'2CS!V>F+C@:QQ'UH!>&'&40 !^&'&5//C>8W'UO8%VP4<!=^"8?
58+POZBB6 MW/LRCR!1\TBKLC8KID4U?6IU/\V.8?DX* _!YFCH!4!-E"Z6BVT'KN>JG- G M^LB=^<%!>?
47>RYFU>5W:ODZGRWNC*8?RKG-3WU(DC#D(LYPO.U2@V@E,\$ME MAL- !'F6T(CH\$'0J=F""!UZSI*J+C
)HK3#ZPRJ!5EI C!<./8IN.O8 TMC M/O6=AP5^U""J7DPGZ#/AHABUMI M.5>R6#Z(3(5"BP#'(=-
FM99S3!51.&5YDJ4TR!@ "Q71.2AJ8?M^5!J8S1AR M@5YMAB#B;8GFMHRBJ5&HE*AV@
5Y?.SEHN"3=+>X&:T;THU(>S\$&C'7 M(FLOMQ)J35*!f8_VSB+KB:L.RQF5;,"/62!S=TR*!X;Q-J1\$T^%S-IV&6^
M+!ZG7NOE4Z?F-PSU%J2GU"2IF^&7*AS)3ZX;70:RK5 V!YV(>6 "I H9!SOK=C0WZ M-"2.%HTCB.H@KO.9_# 6:?
>1UMXL;/W WYCGX7*?3ICH8Q"\$T.O"UG1X M?&+/%Q_7D;T35A*"18J"3'A.L6YC&(LF91ADO",*QGY=R/3-
^M_I8+A.K;,"&W)4;M;S59O5C%D7OB^GK4L6J9/1# M0M()YE9G>C_) \$1C:F(LQ9(.L2Q3-
4L@2I8.N8Z:CE=L4+%L10IK%(LO MD/EI71T"6!RBRPBX>3.CV17&CI52Z">KUL^C7I&1#?K&V:R!@GIF3;& /"
M MI F*#/UHVJD=1%(ISFWJP9T!>51=-1G6V>C#9H1_6QR!/, .L2?5< MU80P4HI2?C!O .H+!:@L241.C!F
ENA@6"6AC:37G\$=QD6&.*@-BZO@=@G0 MO(8YC..<+>9&:/8 <9>1T>,MDI4U&/40%:/9)TH>!
!HAIGL"R"MO8AR0" MOM^G!^5FL\$^WV897DRGY3=FP'THY_4^DZ6P.I50!Z_*IBDIOQK9RE+7 T-
MVHY8_LARADBF M6A TTWRCT<13-.G=TC!^I>4H5&7Z5COFO+!HVN&.%1MM<&K.%HH;F>
MNUWSWHQD7DB3@C!_!F!8\$AS _L!+=+52>^, #I Z>V!&AJP7V6R5T?IK"!^/= MZ!+&(1.7Y3-2U7;!^DL\V<)D=_9?
#T(G2<"IP*HZ!H\$1AG.64"QML49"XTP* MIYJ-
3M(&=B;7LE#EL@-8YZR5'+B!3^PPBEY+1CNB)VACC+N^C0%@VCZ XD>H MG8P#(TQ7L*V!>/8AXI&?
YXJEG.^R2>D<1<\$0?ZW79IA(ON)8^/C.BV.6Z4_="HQ"(C%ZT\$3!#%61S_YIU M7&C:/6
&QC0:X7H%-4!AA@0U>L#O&=2_#3LPJG&\$5GM4X!3-(T8USNB_!4X M=I%W6M6+FB^?<
S;#MK1^ _JU6KS415WOS1_O_BH6#XE-I CBA5;/%!@. MB@DVJVO>)0RG<7 !*MS.@=FHYTRG_>KJ(FZWB?
ZPTH9KKBZV!MNZYGR!X MRJLH/HE6KC#(2!DZ*W'LY"M7\$52D83G?"B.%J8J!JFR,1^Y=-?)B6;/F0
MB\$0&RE9V#H/9 M=VOJIT&^/EE)^N%E(7!UH-C4ON&FY>+5C/"H^N@I2_S!O5E81Y1YU@WQ^H
M#TH>\$V8^RK:C6Q9ADO (GX,<:/&6 \$\$\$XHGH&8!FHUYR\$P95^@_2%L0:B=-A.D^A00^RRSC
MDBJL=C%;EK.BW-3J#9,H(XFM!"#F^...Z)D#A-\$IW0)#\$ _SIPW>4Y)&9A^ M:I%519"58YI/6<=CDZ0,SC-B:X?
H\IS\$#3GTW@-^S_/JL&\$"BX_ZOI M7/BIFT<TGU_ W3V.(EDUZEGIU:M:@ATO.@MO0S:L; MU#+ #!.*E0G*
C_@UL>-UNW#EB7B"JTUFB"K3Y6!U9!CYVV.GGPRN/Q1W2MO M!QQZ2OX/ZB-!OBXV4DMGTIY/?N!JLM*
_+=9+4.\$TBR@F66K6LSKA.LB
MJ3570=HE3_Z\$U*WH"JH%AE<4^W6=ROMG3&HIP6TA9D00^O+P<^VI4LGYI MEJ3X4^_%K#=-I
J.A1K2W5FG9+YAIOD9!3GF9^! MV2=""E*2BQ?BT75.N+>\$:/?I=KO!H_/7.O!>^R>6!*_U+5M5A@MR^7E>+!YJ
!K>B2C_ M7^O4!S6#K=ZS1'-(HB':49)D*DF.9)BDD4*1&8Y5:.N%>H!C:T-'RCY<I M^TJH=S&C.^5>-KY.6#N=K6!
ZV:_%\$8_!T5VQ:C6!7QC&YHI1S:T0ZM#M!L MS_!E5WM#>#4\$>WNOIUWV!8JK.K.8SSSC6V_%VSX^H
<0X%C9E_=?KJY_-8!&W!)>D>630JH>8UF:7!^!BO MRCQDMSBC+F9L5A7U6==113!92=*8:Z;DSW7-#
IUZ9F47M@G&XXOYZIZH7S_MLGH!^..274?ZFEED6H*766.1_7JR!H7IF^GMG""OYR#GV8%W..^WA7O6OU M=??L+
!7X5.Q*VU!HK?#%3+HM1(CL8"QC"L=Q2LPZ/T!M:VH(LU3%G.N\$1S:E MI%RRJ<Z?U#>0=-.#0+PZK?>)N#UI%
!M'2RMWG73A_W%(9!(*,Y"2.),Y" M26Q?O.N!+D6!*\$IE&T#A^F*GE_SJ?ATWE!67+!./Z^6TUO/U!;5AM
MD>Q69U@X.G=K E;H">K+JU""7J.8?Y"MLV\$U?!,N%&I^T;QP5?#8# MTRRN4F
KG3ZL:SUT9!#819DL<4\$RI#XU70!M5N98BD32(G+!B6F0.O_PV M,M%6Z!1)7^>.K.*RT9@9ZPPVCR&Z;4-
V(P7L@O8&??:@*VJM^!^!A\ZXA; M@*VZ!^! ME JP11?/)=)3^5!^4C>S!O6:+(.4Y)F""I.#'-.#7_9
#MA...CM_O&XR _%'B&Y7_!2C=701 &_U!L/E?/Z!6 M;YH(&5-\$8A9F 28Y(Y@KJC#7-
ES2H)\$36;/BUB8";J9:*54+.TN0+P6; M.+!9Z0PWGD&Z<X)IX=ZHC-J/90!#.#.75CRMS-)YWB"/MT
!MA)XSAP2A^08:32B-!64!"H+!_#1^4VZ#""M.8>JE65.WCP>T9S32X!KSE!M9B:_%>7!GI_%
!17=E\$NU>/^J;KUZAU+(TE2 MGH18YH1@H@+!#0#)<8CH4D81HJZYT<%3?XPLK*1QL%4*4!BH@!QR1!Y
MK;Z=-TK=5J!"EUSF3@!9>9K&=_GEH! 5V&0.^LOLV*E_7!7)JNA M/J@DIV?J?
#X910DF01YB+KG\$">-4&103(1HH&+Q%N9858!+P.\$1JM\$#S MCHU"Q;M_5E/SO9\$F'16_?H&QWLHT7VK36
5V&EO4:730Q2"F 2Q^>S:1 MW_JW!U!EL(0V*VK8:<C;<@AN#:6Q.#:00@Q!H++!H!7WRUYR16R5^7I51?
ME+""PJ9_Q/D1@DD5UJL MTW.U!6Q>7N@4HMR>,4+>F7"NP MRH;=-NN?
R;!B+5_8_E1:V!&@Q\$!#XKQ3H^:CR2A6;HUG@K?#K!_!L\$P_M/Y4S=?>K1ZI-"YGD\$DLJ(GL3B/-QSS
17.M.A!HE39>FAP!G94X5.E# MM4#WPIQ'=FCGMZ!H8\$0&_JRGH*@5=1UJ_!C5:3!H2.W9*L)Z_QB4RN!F!O
M!25!^99L>OW!B^_JKK2C=U2N%=-+>9!>Y!\$+E.&\$.ZD%)BF+<1Z&"NF@=. *F_9GEM^M3CEIV+4H
IXWHBA53C_2"KQ T^1WQLU/!+*)?>A613=??JTUS)*\$ABG' MD;2Y!)F<)>Z+>YC(\$YC/F?L9GV8A-W-
RE1ROE3!L_!25RPC_E-L# M7!B!B-U.NAS C+DI\$JWZ&HU==_S/B?N"?&P3!OV^Z=JSEK5^&@KFEH
MV>FW8OED*NVN5X26:S%>OIU313+!+4""4EO)9819EDK.(IK1!/U5EDE! M#4(GJ0.SS3IGYD!7Q; 4^U4U2)A9!?
=I-?/X-9!\$9(6_%UO9>5 IOSU1/T M_IR)P">M09!L.B/MG/4T!T@,QR>2X;=I-NQ&%(+IDSGQ?R47VZV!X&I#K*
M&Y40#%>HESJ7*<1\$E+!)S+FM!\$H8^#L:V6BC=)^G0!^? V6!7%U>B, M%3:QCV%Z.1K>="^1F?<^MFM*K?
!F4TWSJBD!J^!Z/T7XI/*WKXO%Q>36? M7Y;+S2E!G>U?*, 7VYU;NV2WS'T'V79PU,&D:%N7ID2X6.(N5,E:15E!D7
M-5O4*8RV8)W1#&U5<1^>FF!>T7EH MU7W?>6B_U!L7!Z; PH7XUVLQWQ2"O)Y!>>6+0A9L7JB%
!62E=3\$MS)=G!1#H MA(8LM?>J\$!DX@GF_!Q%/, @%2^A7_8/L^HS)=TV+'S4<'H-V7PMLHXOYX! M1:-
L^G"/90Z!K.ZVT3&8)?T2M5?>V!3KE3!XK7&IKLJ58&7L53!(MO!M8)*^M>@'J#N<^<
_1CKJ!MSE67X!MNDJ<_67!87=&&YXF%!"14X3*CS)L4!3G3+ M_*1(H81F140?N6ZM'@COHZ!N\$6W!(ZF57!CC'-
N'BS")T3A.%6&Q!E/M.O!TXP9103J5FH50H!ZNGV!H!V:Q\$W@NV\$!>6XA7YR""2\$DC)X8!_CY
MHI+927B'7?Z0C!BVH:I3!2?K\$+5#I'(-2#-HHR)1!@72BC.54"P(C=9KNCT%\$I&:(MOUX WNVQ>_AHP\$5_9V)/Q?
EK%K3:4J)H#03/\$@+OV.8^L=>NGY?OMG_8!C; G*XW""&G83'T4<>T)B\$4N*8"WMT*HMP
MS@3!FM/8^"M1G@GWZDG_@:/02=AEQATDU5.0>H?RX&W73KJ#H%MT/8!MEW8ZIF#74&*Y\$6=^54-XZV^
@_Z>RR_MNW2Q6*CEHJK40_!IOX+Q8EHUL3K(3&=9^@=A:)90\$LOD5+@7.<.)UHH%@4Z M#&.G@T8#ZC@P?
^V>\$KA+>(OG:N-Y&P+>A6"OV6J:A35ENJ.IE72^Q433^M< M^0_%5X6^O JAE\$V4_-!>V)-5?7?
EZN9!V^Z+7K4:DA7P@ZGWI8891JX(KMS1V^-=G^Z.<\$!1WH=.*!S)FU@'T?1U&BS5
!G8OM>!"V!>T:XK^CZD_32!UIZ?>T6AU^&ML V!&I2 MO_W1_@T%_*ZV:C' BEN>T/O,764.NZ6*!B
M>>F:VGIPV!#3_2/5+K\$!6=F0DHS-6%MG!@=8<(FJOI"4(KT"2Q>V:2'SQHM
M0)EM3F3L@PP4P&="8!B_!YE\$FG9>_HUI!>Z\$F7= MIK!L ET^66*B9UR=*BHU*@I*%55DQ; 3W9/H^/V11_?YC
.6>N'=A2K"B=VH&I^W%;^K593YY"3TJ-ZDCT:A#Z/GIW?I7?YE M.5P;NUU@Z!>4!9S_*A8/64XDBZ7\$6E""B>
!HB!F.\$!G2D26ZBAQBM!ZR!J M%-FO/3 MDTU@U_#< NC /OGER8-DFCNC_D !>=&=;/%R8SQ=\$)\$K>.>^KQ-
!LD3\$ M9G9K!>=1ADD2\$!PBDN*04T%SE>@ \$4!G!^E#!H%6 I&5+X^D+RN!E,X>""=M-)W5_>Q^21S-8 \$^!?

=P/JY%*X#^0>3B-I=1@:AO/1SBMYY;T*9GR?P M70&H!%&=OKH>R:S*
(H3RK&B48D)Q@5F01CC0.M<2*W"4#HU&&D7.S!=6%*H M*Q7<)NZ.C=P^]=V1PWC\$ S3XJHZ.J:~L;/7.U5ES2E!HF
M^S9C+^6T6%RO.REG.@V-(V|<|D FF%"A,V2^LP2-0,Q*R'^0)9I(28@2>H M%8MVY4I0-2JHFGS.'S<>P\$-FYN-
>/UJE)X^#JH2VH,IWKA.Z1D\$9RJ5GKH MS%JE9Q<5^L]=F5G5.YA15S.XRWA,|Q)D.,@E2G/"4JD%HB(?WK M.#"
1.36V.ZE64URIN0/^TM9RF.%=-J.H@PP7H1E|<=|1C=|@| *W5;1R, M'=HH?9QY;98FERVM-H)I^XH2#:#AN-
&EX4Q%)4:4)2^HDA7^> MERHJ7F7ZEN 4EW(JX@T7*PS@FF>1X.HS2J/IH+@G.9I++XSW/W7B2GY0Q;
MMMOTD)>.+0P<@%>58N1^S)?J#&&Z%^E:CK51T7Z)W^GWI#30 I>S^!GX^ MI:M8^IG>82M/F?+
|>,YG>,L%)J9 MQ6RLE;9IQ@PMH528OPDIE4RBQ*W/V&D10_0)1.MA\$|0S15D\$C%;Q(5|NB(% MTLX12)I%#;#-"
MTI>U)-.Y#.#.26-CSMM-)XYXB,TJ,Y|FT7MFU^E)#CN#B MW?>=2I75@T2L:!"2)/%MK75%MOH(1-
68E.LDT=2JTIZO P|RT>|ZT*^'6 M+&CXHT?="W5Y&AVMR7FD;.\$T5S_ =NQ0UPEFC-XK/|F*?Z-.3S#CG*|Z|'R. M?
|CMNFI:9|JVOQ|9JR2?F5I7| ZSG 9;XS2_ TRBF.%<90G.^C2)M^0R#-H M#,Y|IM|_D&4P_-O+09RC|?U; 6/-
U6@VE.C-IM2MU;#7#F\$0BJQSB>B|31 M WL 4S1%<B"W^1I7N;|<U(812F=8M.KA4URME?
&V.RLPK9EZ.YGVU^ 5U 5 MM^RJM794|X|_1(?!E|S^04_|H"NZ.R.16L>K?A6?GV@&\$&SF\$)^,;# ?2LKB|16ML)"HWG
MG5L>.-.1*X4V2D|VRV86L|V+^FA7=W1ARZA.\$.&*7_RMD/G6?OD2;&J@/_J M|>|AC"IVZNBSNB"X1.NG>?
GZ^%3_8'WZ;|N^|_9JQFIY*2:D/|"O:Z|STQ; M)4I*/6H W%M5E.%&K+TDR@:R1ZR',IS5IHNA#"BG0^SE
Q.K*BNWVY9*000^ MSIW>\$G^WK25^K3M+|^*0BS|TC+4<8H)R37F46; V21/HS@)^*-O/.RAP&C1
M&KW1^956*NB;NNYX1^2@-@=\$.<9R)J^_"M.JC2|IWICO8U0I5*Z=-1#.D1 M-
|K(H^VC2;T9UB_0Y&\$5IP@4Y+GCAZ84#?&K'R>X|D);0^90V,+)^7>KHUS;
MY^:MJKXA|HYO+UGU2KCGXN;R0@|UM>T(IN^+|^+|^YI3Q2^NL8PRBDD<1Y@S M^6 5TE0\$@Q*
<.&5Y#JGDGX(NYC60DC#C@Q^040H^&XC W&M@:NR*PJN-(%K91| M.H.T.XX7+;-
WR>T|!#|4/H2*X^Z5#VCDH WT(67|V%FJXN%JMBR6WR^- MD#F;7L^D^NL?ZOM#3|A-XTIAS6-M
X\$9SD5(<|S)4DB*=%U3I.2AB8%VN9 M:"4455*1\$>O&CZ?
MTDYN0:"",1,8J#;|G0734G?;W%L3A_G+EBL/W&4R7X6
MTJFGK_0M^+G8|TA F*+C|X>Y=|EX=9;WV=X P_0S(>4X*CD\$>8""8PT|;_ M=Q|EG/_|SCFL 5*|O(&G8^4-
+6H=4&'\$ KN1G3.7HZ/1GQ&_/L,*^4;R!-4F M6?^B/E0>5X%(-|>2G.V2QNY5*<3I;2G6ZW>6QN7;
|Y^+1=>#K1BU_FYMY M<^OU8A64352>4^T)3L(P(3S_ A#A|\$FIXDF2NX>+JOI^*KX|S4 M\$GVS"N#2;
#83CEG,H<|H|X_90R:QNLXM1&^ID8RO<^PGPG\$%^T@|&L50 MSZC5.#UM^SF";T^O>+9I^'L;VXWN/GP?
RB9F8|K5=-N5S.2OL&=YE M456M&D6NWDH|UJL&Y^G|LW2|JY;+W;|9ZYTF50+8.""/SHZ;S%=%19#AT?V,T>
|L|O MUT\$01%^>V#J|<8L;P6F-Y(ZV;|_D@|52Z>1|O@F;LG|7TVGYS9;6_5#.+^=%LN/Y6*A%G?E
M=&I^9+=,'VBB0^P9#B2J7%1*9Q^H@TYC*)%1&M^/_@0P+=G;ZV;4G|=-3B5'=- MH6Z&.02;C|IZ)1^L8?
B^5RJH|E|A|V|E4.@|4(##/F8US)W&_6V@=*^?_%5L;H?50';916ZB^K#|AMU#D;M;_S^;!
MT4J_E@&UFW+|_5^ZMRS1VM^Y0ARMSV5ZRT^W ^0L;\$7-GM?L?R0"-B ?0%2?;>@|MVK=|
(UWCN@|M&F^|P&T7NF96O+^%X4L MV/SH;SN^_1)+9|*61_E4.IC;5.VI+UX4%R\$A^*%);%H&@<86;8!6=2IHE
M3^CJ^-(&2QZ88|9ZV)VJYYIM2IHK0OZPVI3)5Y NOJX&IAMJV;0L\$|JS^+ MP9-
4H.C|2E=QECMNX@K4\$#=#XERNV4.I5_ =KV840UN-?JYJ|B/^GFC|E?# M6QS&75MCO|UJEHIM-
JCDFOI^VC6|=Z#H8IK|&=3Y^C-V|KHA&MK;=7D; M?)NERL"-?
W|_6_GMT^REN)PMI/GWICZPXRY+^U&|JA*+HOGJM<5*,"^G3S
M^H=EC/S|5"&=|PW5,Y8X_Q^2G^&@/'&61N@/WHM7^R.U6L;Y\$>G8+%-W%|7H:E|T%*J.ZHXSG5N
RDIM7U;\$DOY)K0**.?J2OE&3GC MA^NKTQYKL5Z=VDZ9R;EG M"
|8@NF3S;.&8;MMRI8K&E.4QUCK/S^*|,NVTXC.MFIK MN^7<=FVG=3|JV=9RJ5|7J^3_6_X9
9+^NX,9SUM(NF4|)"G56F(FTZKM2H1Y MGG;/CM;.&1M5_j4OU;B M=;|D|57VP|V^8KY8WG|K?
U=LOCX|3A)"LI^GV&9ZV(KY M&C-F.\$8F(==O)^JP+^8S27H^9Y|GEECN
M@^N AG^7|_EXB6;9&%ZR9SXOY*/ZM^82F.CC.\$XYIDE(S0I2|9C*.;|SEDB M@XP+JMS=Q\$89 W.VE8DV0B?
H\$|A|+^BZ/8&2N,48|A>GF*S7@AKF)GW&_K M^|JW^XL M|ZHK?8JON^N|A^_1HE>KZ;
(58U9>|GIFY;Q:X#TDHHDQ(6U0| MH38_+Y9|KG6K-I3R2#|0A=Y(Z;,>LQ=@,/"NV2W^E4W9SVY/JW1HP%CKJ
MK;368%W3UK83J948JW2&6^Y:NO5-UNQ+U1QT_*I>>U8"@^|6EV6XDI|FY4|CLODC3SPI
MN+JC4018QC|DH^D^GT8|9LMMMA6P/C_BGGUV/?%0DS+1=6|1XL@R^G"@AM^M)S10F&E#
|4H8=S\$EE&025&7GO;B|R;E2_UWBK|_%!O=#";&|?V:PP8;|9V MV^U^8|6C2C|_*M ?_J#|8G""
2.2D+N|CBD\$<="CM0+R|HNNH,U5|+PT6V
M#_"#GB(>A+^\$+&Y)HF4.\$5QB\$G*|S|2|5U3|H|)VW@Z;IMP*4V(M%/Q^;TC6XKW_|SF_YX>,Z)T-R%4;289&F
M|);XR3_C@<Q^_*0<|Y^ VZG|F_|3YWC\$S0ENUA@|;_6;P%UR19/US,Q M?297%|_
%Z8^5L6^E;QIL=V<+^|M^0S81P4>7&54DEQSG/M%)8L^|P#|_|@+;+&V0.GLLU*|HYV@A&-
^6RI6R#LV7<2*\$C7MCDWV^LEA^| MMTIH0=/33&Z2;J;8%X.#;+O59+;09^6S&LW;-NXAC:00,H^P#EAI%@LR
M-(N%G&*IPTA^A.OI==H1;9\$Q| PT.M%6*^2ET&P5EX5^9ZRPV7<TVN5T(P7 MLDGHC-MOC0
89N^JH150^Z*A^=81UPRMNN|O&=HO|BT.NSVDE#>|3F6;9)C\$HK<^ Q MQ8(D(0D)SVGNY /TJ/
C+5S|@R2C|B*|FV-I09<^>D25<^>J=F2A?>Q8;A |C7&).A?U6:013K0A6@>0D8Q\$7&7^|VBAGX_/
MKE2T9^AOH+7;8V&RD)94+BE^"1T R2)\$EOH?2I9HGB8RHVF;-3=5|L MV7PYFJD.93H;
|Y<&K|Y(64VQ);H|VSY;@O4AOW8;AH?%9QAL<B**)+F#S/U;#YR|AX04>FEEM.4H/44.%G-R0B5U6;OV*5_1E-
;LRM|K M6I9HM|>M|05K=1? ^|_R*S^\$RUL N)|J&65WLNU%WE&"/W(I^5A.RPMQ(Z@A|IMT002D^3C|XTR
M|4ZIOYY|)W|GPH7K|P-OQH36DWB6*J|0IUB_.D3|PJ(E8X%SG#DD4BE"G5-M0D;NL^'^V0-
/B)4TM|;G/B4;7|<5G1_HL8SJ|_4^.\$^EZSX_!9HTV0\$R|V MY|BI2_RJ%\$31|?GT.*9I3+3
A/GDXC^IM)AD60LD13*LR2%*EH\$&P/& MRN02|.#)*@XA@.Y881/H&*9GE8(FO+
J|IUQOW65@A;USU4L+IUU^H%+;H? M5BEHN|2#|VZ73VJ^K@.\$N59HP^6.;ZIV;AS@6S^YY9SK7.D|@M\$?
+PP0.S M124)%EV(3LP@B<0& U40GOF_BX8P^3W|.4WQ^<464M|G+^*@\$30H.7>|&-Z;RKSG7==N5^
M+C^7TT(4:0%Y7HJ;XICD<6YT@2;E|4|(-%\$|KAI;ZIZ^>&BX;|25 MPVFM|Y<+^YG=;DV>54L?
DW9N;A|K0FC6)*^<4ZC|_A^@|(15IFF*A8R MI@&_XJ%#;P15BC;2H4?UFPTC M7=(+&XXL&DYG-
1LAP|YJ=H7^UFQHD|"\$WV00)V>C&TR@MW&(T_?;(*^I+ M,2ORG5|J?A=(#>*)AE#LT685G-D76^|OI+
(D:S>+&\$%W! CGC&*0\$>.^CGCV@|&N|&C M;C%?/M@2IM7P7|SD_WUETT)_+V;/%T*4K|/E8EO;+ZF03|\$84HXCS;
<.DMZ M4;8PUUE|)|#DFN6;|J|J?058|L \$>^2B-Z
3M%&P^H^N541K^7\$|LZX>W5=K.5YB^IRM;/_QI A|D:A^6|SK"G(P%^M|H/6K|^M J(>I>2I3KV4V5UI&*33?
3N^<^J7|P(QO&D01HBB&3<\$%08DH^ M@0,=,LI%3&A&(")>?%5S M|JA^_8I>OF?+;<^NW(Z_5#;|5;?
XHBDB8P)CO(TM&=<|RC(9I^*HX^K(T M%4Z9/#|HOH^Y<*T^6NT^*F7^H^%?^25J6JH4O|STHSH^?V8IG2U
MT|^<6NV^W6WMUGE.S;U|J359;9C0+1^K4Q+^@QJM8\$_0|Q@&\$^|Q>|R MK;H^#5+^&@<=V+|M3H@A^RK|Z6;"
MID|H">.>6%#3|^E^W4RO)WBV;^|6+^6^37^9EZ|OI=TC|H|^70_H0?D2&@8 M8T6I72!%&G.FH-45WD^)
<=O\$=S+44=X;D_S M/YWAYH-CSMERN|XERA4D0WBGYK2REK0FW.> C6)1&N528 M|_
|04B0YYJF6.%&*,93\$81.=0U;|0S,1U8J6HE%EU5^&^R0URGCN(2_>H, MHZ%&M%ZQL%.P(1&Q^N^_5SL#(#VZ-
BIFT>D9W1?S|2=NYBSWC9^U^H?IV; M;G;SZ;D|RYBD7?Q6+AX^&-(|)@@;YY@H;=P=F9BUEF19|^K7D-;BEG-
RAD|K MV4A^E5ADY;C_K&1HULX).SG&+|JC|^YP^0^1RS;8?45.3@A9=P=_;H1SOI M9R|W=

"1LHG0:8CXP8(EMEB\$6F\$J=-)5G%*>"YTQH3IRN24E.'=@*"K&I!H M'\$.1RSMNN 1RIE+O8I,Q.2SC3B)
(YS\$J4X5X&6 M:2)XYI8.=UK\$P)1B1** 3&B2;J-7#R4KD!A=!*\$T: ^X1!-84&V)CJ#?N+1\$
MB_9G*DLTW3EF88D6S0_J2K1=Z;OJYRV50+@Y@T.6\$YH0CG6<1!CDJK(M?&)-GID(HYT'B51#JL>X1?
>HK62TW+7%(Z3T1L@< HZ8H-/NT8(24VVM_8>:/14: @1U-K:K/7Z2-.F#N-29!FA..F8F57,S"1*4X*ELB?;F)E;D5/G
MIE8IPV_TD:X;38W&<=SHZPH90-%WG-9WHZ1-G*GKRO1J_H:P-P=J.O1>9Q M-
_K:1# :Z&NIV"> Z:,*C^XFGYFBVVY/RX(R6B>8RUL+7HN 1RHCG%LF"9,
M9);+Q+W!59.\$@1FE%HFNL@*!=9;+2(Y5TQ0FCD6.(7GE+35@A"4L=,7MF M*KD/+S!J05.>W)2TXTC9B6UZ+V?
CM1VH>=I>[K.<5J/H/F&*?VDV#Z:KY^+&#YZIPN*+ M6BZG2CY0KE02!@)G@4XQ"9(0R11.&-\$A)\$4N0"4A1I
P8&G_4HL6K"t>JV MD6Y+""S1\$ _NJD#0#"UJ;=!/A?E!>IGP)=VB(%S!\$?>>#A@M+2C+*JUK8,(M"
I2KKZVON188U2I,*EMM?*Y\$-S:~T+2M MCN(0TVIZC.J0CPGE&%-.,,GR
M2*H\$D(!:)&+@+YX5Z=ITJ=\$F+DOCKDAA'Y-CD)! =XAO0PIK%=T/M1: (09W MCS^~YUSS^(8!^T=?
UKSP;Q+5=Z;BG:YM!J5,57%*X1^J"CF+31>KXED M(M5IK&5863;Q:4WXY9DDLLRQ5<;
[-*UJVBAJ85YK9:"T5;G= MX14+(%EVL\$C\$!U2*DIA,1LVUJ!2@8YE+1@.HD2RF@@UR3B*~C 4.DO^O3
M:1.GJ\$!~L"XP!%(OIA \$UI0=* CZC>NR=NB_9F80.-=8T8%6C0_B NT7>D7 M&?
A8SAYMJ.&IXLM:/DZK^HDW*F7NIK@XE9_GAXI=>*DP:G2CBY\$.XQ^=G@6C("7DP_U< M7LSG7Y18";IX?
+SXRHKIQ?2A4#./&)@CC"2YNK15B*N!_KM+C2*(>IG15Z M! V:/=S5E5IVRE;=
IUSJ@!GN@BV?;Z<I(3B"JCS"R7^~;^!G_.\$U:3 M7HTT@_@HB)=HJB\$0/Y\$9SDLEWE;B!6U5U^!8"39*
I\$Z1NF2FRNI?/P"7 M7\$DF "JRG9A;+4L\$SP+BP3G 6>LQ!513!O&O&B_7+<=&KV1H!Y@YH4D20I)4YF(>I+ZBZA?
ILM+ M:1*1S19411)TRCRIU7M1_*MEU?_6Q1;71<\$EICEA~M.VOVY?JWR>_H5IWQ
MMFGYH'YYG9>AHZ2+@N\$1_*S.8.(~@C:.608X<'KH>C.\$1W6>7W<+WCKHLT MM3I~N/YH#REK?ILMIR#)"!%
(HI"<)"D&9&NO?R4F>+! /CKLB+USKJF48I5 MBFZ,%2FE*+@F#IH?WU3M,'5OH#I0KG MG-^KQ*Z#I!(^9!\$3\$
5N#&&-(LA#X0@>253_D4G=G*4OUB1%^WNU+H5HN,-C MQ31;S&<26A;-&7>G-
E+DURZ98WFCUC5PT8(YFO=I0P^:(047Z=V5G"FN9NOI MFMS?8>PP'D0>=%4?Q0Y\$B%<@:#_MT7;"C
M*3>7+T9I2I=*M;/D8(;J"G.MIMH"W"&NV@CX5^Y2UT@/L+>VC7R"4WT0'. M3W;1H2A9DQY^?
16119M97=5SUPF_9E MA6!~M5S^&XCZD+=M;+6KA%DDVR/NP3!5^~^YX=I@0=M-C@:ZS:YRJ^/R
M#XTE/U::5#R!8Z9_Q15HV;+!2#N5&F#HJ*JUPI95&R&T:T,XCA=F!>#N-' M27ZT!XQIDV6G%)6B??
7I)(\$OK3ZAKU4T!>KKJ!T:QRU7S8SN>_9_8<,@)H# M!D03=U65U>F>QDVK%#~!O*61"%#~6"=JH^A?I+=M115?
1IXIV@,MBQQ% MYXWDG-OX5Z8:0^QJ MAM6!E6EXV!_I0"SI=XKNVY)IXE&!9+FD09UF63#~!
(PI*%16I6\$NI_PW+ M5E6Z*.E9?;7+(&RLDBHEGI3BK:C IT-V*QZ?H(4+!61I#5?KYODIH(ND'H M41<&-
@@(G\$,2>1@~5^")5\$D0A1JG8/9\$)9T%I6P\$M.W1I#NI7P85XK""# M/^?~0-Q(FMUYPADU2\$!6SD;
IUK)ZYM&B&BCT*W+'2UN#X0W'35N*8T!JR MT<I\$AI\$1Z45M)NEG)I+5N^PL)R^O:O^QAX\$WZ!\$AP!~O@JR?E?
34A<.;D? M;=?~7LKID;:9&?GKJG-T?55MAD.H7"J&("IQ"3B\$-*,2_HCCQ@I->IG5 MM+~#&L601%7-
K#EPG16U&SE-.R J3@TLD9'ZUI#7%E"GG>_VIAJTC)V0HH MWD#-'#C@#ARRMP(G#"ZG:P.S<#F=VIF-
<^O>S,J<1EN#9NA(\$L09J=/HXLB0 MG>B55CT1\$!>)&E)22;V#=#9XHF\$1!G#E*E44)(..?0<9&4!(DA!E\$1761
MF-EJ5212I.X\$T*72G3<IK&'FJ'SF8QV_0^ZA#5?C12Z?N?#~# 86VUTC ME^OX_#Y2<.#H2!J6EP*?P/42.6YL)0
?^XEIGVG!FF+CI;6I* M>LMM;C-HZ6A+G./I=L2;ITE: \$;66 %)LK2MBI"6NU ^DHI"OO+AI2EI+W@4
M4I_ \$D%2U_EW*(XB!@5"C,:>PFIDN%6U&?>\$A594-\$%.(2,SCX?/6;95, M,^7J'2K/IC*S?6^V>XEY.K)\$+Q5Y^/(E
M>5<4U_GCTINT9.MRNW3?7A1Y)O)MN6I2X;5E MH1A2G9,K W#/#&?A#108JYB;~CS?
1@U5FKQ!Q9)13<0ISWAZI7N2.Y)2I42?BZI"X4-(=GT284/VJ MMTT9EZ9DBC84UVI&\$B#LX,>M6@V,\$PF
MVNO 8%BB0=^~9^AR.OHPIT<>IX5'S9-TWV4;U1<;LCZ/I.GZYR+
M.O8X"70)@=01,40((T@)H"X/120)8I+M,Z4AIG,#"TU8=:07H&:I#\$@:*N MG\IH*AAI)E.?#.PL97<*/7WLF!6><
#KUTL*?BR:(<9PAI/VUTKH^!;OMT M?"/9^T)5HRG90O("YHQ%,0HABWPL#?00XQ8"".(M?Q7(>Z10?+
1IFOVA& M-1B(5T4J=N3~YR!~5A\$DRGL;5_J0 RPOH(4V8W4Q/D)7QJ+6\$./27?70 M*Q;JM:.0Y?3V6F>
(=9#W0:~.IG01QF6!&/(FBNIRLIA26D)IOM1O"%E MRJK6:'>Q2!@-70ICY+G2=TFD%X,%AVI
^0IL>N%W#~BVXZ3F?'MD!0IUBI MNG'R?+TF10GD;^O.G(9;?;USN_6\$2G9FAYG"-);70?;7C/6'68+_VE)?2
M^,F3ON=60(J@_BZ?D+!2G(I*CKH'Y*11Y.-T.5U(N24?2)>7GU-7H#YR!:= M6'%_X?C..")N6S^EZ+?
I^CV87=KS0C;DRV%Q*(8H!V./N=+."CPIAGZ< M)KI>GU49D.VFBS8TUV!O_#P%#I58Z&L3:%R&; TRFMC7W6*
I!;93:%^8V MF=FDFOEJEZ0:-~Z!RIGG%WB_@LN_BPG4'V)4D^D>)?8E-%;/R:>OY+U3 MQ9T?
>!'S@Q!2PAY(A'A'D_1MB5OXV%ZM1H8G#U4IH9=CI(3S;13U64TSHE MM\$E97(%&%)NI*M*SSJ:1
%F("1)PIHFJ(BNP_9Z6B5BY)-9(OTFUGAUK@H MJHMD<7F A:UP3V9K%4,PU7&OXIRAZ1L(CZVPU)^55Y0PHHWP2
MQ:U(?2P@(@C'\$65)&!NGIUGRHO7ACIY+43!DZ2N MLD#E%&>"5<\$*5>BB"D"LN3%
A%'ZUI!6YE2G%8XH@BM0*~? IQ607(\$I6_4# MBC%P50+~%OB2-HU*<=@JUD#@V@!#=#O92W-
JVLrz&JFB0>+/IMW+V68CI3R MW<;^RIZR4V^59\$X);ZY)4:A@ZRK8I2YD210FV(.8<@((1F-(TZAQQ.?DT10
M)S0*<-6B.K%5RT-=9K#U IBSX:90:>G0#W;~W*UF-.WI9%S8"\$T#1A!=-.M9Q8:"3V1B:A;2).
(DA(AQ#JGK^Y#\$7(=UXTI%ITIBX+VVFZA-G&3Y7'(@08J MJ3DP=KU=;?D)\$_V (-.UZH6J3~/CTI%_ES'WI^%
M+HMCT M3KV*~>LU@I+"BOPJX'O3P<5\$/%1U/LNHT\$!V+JV?G6QK?U#;EKZJWAT(E;M MC-
2EH/EL&L/EY)J?"VGXVMG!)U\$! M442<@%A2C M<4PW@;AF@-8AJ57\$5X_O)J%>XT5_W1B08?
Z@IMZQBX8U3Z_7\$XUX51+;#D M!U:IX4OR2UX^HINREK;YX;~#P.8!HD*~<^C#FCT.6\$"?^!Z:6G.7C!S M?
M3TU;_IT%(T6\$SGRM! CE\$BFF%&(IV7!PRB70&(#%*2CMX;)'6#~#ZA1G\$ MBO-1RZ%\$+I='^~# E%W3JIN
~R:ZR39ZE^>U_M-7-/')(C#~T">,0^<^!)/\$= MZ=IY2<)I\$)\$ F72MZJ_Q,T9(FE6T=4-U!6I_PZR74Y=;=\$R,T<~;H46'G);-
MJH\$-NM>+5+PUVY?<#^I?Y574,7;6 UP/MI!ZNA1RW;DZ@H2E4!AA_6%K@J M"CE/E2/TYF7_2-/MJH&T/92:7-
IRR^!;U'>J+=!^("JH9_4*6Q3;*Y<@0_Y=3^W"70>_%#3
M.%5CG1I#J&6I!_P8,O<<^OY@W%F=+/JN=TT>~9'R>_&L6SR>1ABEIKOI=R' MB-
(QBX7D,HR/'L7*_HGC\$!L7#APIARYWCC\$^EQX^"C%OA11TY7^+8/F:LZ MI_V:19M=/S..X!_Q3X6C!~ED0N)
<W(@@A3%@3(B;320_5)SHPN3=A^;I! M1!6I?TJ;@R6GYX2=IG9I\$VQ;5'E_JL1NOMU%82GZY>W0B+(8YJH7).=
M,7>3KU/VLH!+(Y2C_*(C)H0PB\$).(*4X@*IP&;>XRAR30XZQ,T,I36ON3. MR6P#/PP#;B;00-Z!P;+Z-
/C1HEIYJL&LD=-. @#A_P=GOO\42.(9HDHG\$YE
M\$SG6\$S"TI%.(G0)/=H)WVS328,4IW*YWU8EZ9MM/ODI/R;J(I+K"(B<,(8\$
MD1A2!WE1X+\$H01SZSL(SIQF#450DS3H-"A"PT+<*2\$90AR+)R:~7,%""9)XD 4)=2-/1H+3Y^~^?
&25J@J"F:)*+>X(#8P8 M)YX91Q)9H,0'2*.9)*.M4R251K_@W3/7OE&ID/!^V8)F+!~^9?ICIDY
M7;^1(E462MMYN2H^~G#2W!3I(RE>WHA.)"E+Y8IM! P6Q"Q!&)&1@YD;~MB@~*.\$&(NW\$2HM#~\$QS+F8&9X:?
G9~&~4ACICMAE:'1Y2>;T?W6*K-5SZ@/9O@.KVX*54APW(COIC-55;= M#3ZI>?74B3;I<H'PO,"3:A'5"N\$UH#DS
M)K4&#(4Q#@M?SU>X"~R6=OE>MI2+OZL,D!=-.F+U*ITB4
M.+ZJAO\0)4FW4<2J8I+>,>21@)\$I866UI&:Q+//<^LBI DWYE,=IAA.F.DX.&ERN09E#N5\$S40357U8"
MNJM(=S7L#"IAM2LMT=-I#RSO>DXQU;^:RUV*CSDO!G'V5.1RT;_0M.A9=
MEJRID7IE!;N6W11Y/619>'S%=6H"V!4K=+&DAHGX*81,1+H#1C(VG:(A_&M-"\$P<<,\$X*3*#9ROJ=D;F8
YTIG_J#0NK_E_.\$@:/DZ*%ZG:##Z6*#30 M6UA@-7FIMCF4OF"-_6W62K@R
Z9*M:DT8\$S#YT:U*CKSYUFWYSK7,\$!1T:N MASN7)91\$002I*U3I~Y:TE&Y@A!"L4 N8:ZT!?(~6608&V"=

<ISF91UDF%IVS*&U4%K-4T-.. M*DCR OSYD+('D%1-T^5&T+9+EVY\$ICIV/=7Q_R4@!L_%KG=Z-505NDW29P%>
MA\$JU20+U.O13I2?J#Y1(^M+Q*!^\$V"N=B,Y3^N#.7QJYS!OLV_~5!W9Z4LU M?E-?SS^2%R#6@FW
)@>\$_=S*^6E+%,YQU*NJ^HJV?1!#W\$L8@GWT\$E<9&C(M%.HS"!OQ'&LFEA0_5HSP!1F-JOWQ,&>.E#D+I>"-
U;:!N)!APPE%14#P9@ M/IT^I^AC%L,L\$1!FD&IN_*Y3!3Y8C7->8L.VYH5!^N2?I2;UD8"Y75S ML2R5%Z.
A3!0)Y3=2C\$<:0P#9\$D0*\$T6_UJ6703F1F%&PHH"GZL-KEZ M%*,14Q.(X9"/9);. UB&R2039>1=-7QOF?SA_K6?
L@>ELPIP?9!!=>.-V M9BT112'X+?DND4HL2OE#^[MWWU5BKZC2\$NY\Q\$3L,Q\F)%*EM*(\$HQBZ"\$ \$
M.6N*RV"!RA\$7L@A):X'D!AQJ!10!^9&;KTR,Z,%I_S#=#Z2C-RK M\$X/"G_!-
E.9(A5U,QS15*0>BDRO'C,_D9H1C2CER+72S2Y8,W C!\$JL1A M!@!\$N^+;7YLJ^HCT4A5A-\$O@N M1('(\$&
(09BVNUB5H+X69(4%1! U)T_)!72K0<5=&2FFVLD!M.OE MWC75)AWH\$180R1BZ4!P0(?
AE&"*/=\$Z%"M;!/!>"G,2;DB"H"%IBA=-^M ZUA@G MI>&9QHF=@<:73-
OB*FZ!;ZD44@%1B^#5+!NU^&;9!8%10K!|3>#17(D MM@8,V ICMOP;.6Q6_9% !JO=5C"!57YIHL6>Q?
Q@XO!;IRBIN+SZ_W2F MS1WME63-?O_-LOS_0)S6X@-8^\$%*!#0C0*FJMU22\$+?@XCX1!R!-"*^9Z M@;,<=
!(54=!278&?3>KQI:A%8IF/%|8,#KDM&#^H%+EE"VYYN6HPT8:7 MJ8,2#5^B=@!^V)TD/?
C2!A1^V.*S^+S8>,Y8_B8UZ65\|D7:00H|N|2;Y6 M5:~:TLWI\$S97> *%+E40#^I+!/@E@"3DB@SUR?C|BTI+0"?
RSI&|S1N8! M@)(&D%;L@)_6DJ&- /+TM\$Y9%8ZUR0&K,_BK8M>&QYFFBM8IUYQ1?88"G%)S M^QK-?PTM^
&*;XM?7# T I4+ \$UWT&FIBXE,/\$V!+WKT;:F:TS-0V! =8-A1H M0O_-)6-WIQBM0\$5/A816-1! J\$AK&@8Z"M.#DXG48
8==AHPK_Q^6::IRK\$4%JV M1OIED<^EVL L7!PWF\$+!-E*9&"IEEE.X5++ /5!ST!RZ-R32!BO45!-7 M=1
RO!KX1-GK=%W5G)_DW:GRI!0.1#E#7F1!C!6;71-G!E7EN+.E|B;_X^JVDH\$#T53V6RL<.)2N"7L!K7Q L@H.V 2-
B^NP M^W9NVH^GD?P!54UQHJ^O&_Y! =CX""_J SN+_G;XELZ.%V7N!@!Q7HW)
MY8Y+7EW4KH.9^X8LS_KH(U,YUERZD3?MEN5B^2C6!HN6F&QSA!USA R' M\$+L!A2CD#B2"!M
AU'JN>-J/E;\$ (WSU8!\$ _E^QN07=0AM ME7/D5J_ OPZA:MR!HPDB!!\$N|X;0B02-C%F\$10BOAX)\$%\$,3E|KE|!Y%R
ME5,.2\$7*#4J0!|CR-\$,&0A!2^BG\$,2(@?Z)!0^DKW;+_3HO-U^2G_< *VOGFRB>
M4R;*;_F:WWDN!W\$HEP"G+);F1YC F#H^C/S("UW7B8BGE<9WF=3,"^3+DT3. MC81(LS4RH!|J|=3-
P&9K2=%4ID!%M3HV;ND"17BZ1799N(D6W@ "A1!2C98%/ M%ZC&_LJFC^K2@32\$H7_-K3ICF1BZDZ:(614-6\HI#
_8HY"Y/k,>|2&*M M UA->G/O;WOJ0)\$WW.DNZ\$IS"YQ. X9!XXGP!S8%TA1SJBWU_K5E!UHT<V M8#Q/FQ8\$(!
M21(SK3!02HS+^J;+^CH@HKP"GSZ8M/L\$!|&C<-4!ALMHR!Q;7JP!@GMTGK
MQ0GD@RV;#;MA@T6+X@UW%;Q;"";100!^<?2PQ:A_ZC?2?_F!BDG?+^ M8_-!3B,4L"&!#,I4!
<1C#FPH4>9202<< #7H!M;|>%F9&F)!EJFBOW_!J! M8NM4B+_C!73#%S.)+3!E4Y1#3!EK,AV>*(N690,B3-
((QT#EP.0H;X/H*/ MP0=MZW<4Z;..F5!UH^3.6. M+!T2XD^7Q1@B)#T7' H.J1N&7D1"%OM&EQS6G.P,17N^P
%CE9?>L_VO(\$# MYNQBU.PG1!H6D3-9E
XGX8M"HJ.U.YD%49L^5BXY,A(=9W7(!G!0ML3UU7G>Z1ZR0*.3US/=,%\$=DI3UPORC:9D6L_<
MI87/7"^^?^IH>GG(V!CY=TDB6(TL^D+_EGS_2C9"Q%(NNZB'@%)?MCQH#Z M7NAC#..\$4XB\$Q
#LR9<4(01XA3%>E!4%,S.# TM;^H:XI@_!9LF<475!&HJ M00&R
=^DW;^5G_+!4,R7*HU%0466(+TEZZXQ12!RHO*.*?0CT\$6FIBS"#J M<\$YV?WJ5;%V.ENU233/2?4:IHA<""E5?
*;!76G2PHAW6N9#RA>3N%+M<4.*32,/*F"O3*O^VT+|C/Q(84+!2Q2.2!2.X=|1R"\$ VA!9\$&E2.A3&*
M7.@DV"=|Y!1&Y6%G);!F4%7Y01F-8!@?7PB;_/4IU.ADS_E^G?(?13\$|S;E^0!BS56)!*!;82(3CX9YFF&
L=U1H(ALF8DX|PWH('KS M9H;)#6MRR0#%*6C_?<#K"JAY/6#W+*#|IXYH|GZKVSS!A87"W_L%Q"1+Y,Y"?MJ54A
|CF/D0M>+\$HB<(((\$T<1U:(FGFX,S_A5H;A,IMJK M!7R:23T&X#6YFNS0!9!M;MJC;.&JCJHW)OYMTW!W+W^JD-
=DF:B<@R4!)&5 MTMOOL|R!961B@8A4N!RV&FD61'(&HVTM+_LJJC^Y(T)='R8!ACR\$/8D^XS
M#7WI0_N\$0AIX'*\$D;X;/(/*_BG,3.J-GF!QKZJ>>:T!OU!EGZ"!6M)3_ MOJ<&_ICE=*Y?
K^EN5#|3|K4\$Z9R)7BO_ \$INHWWV'7M;SV MOGXN!K^XPV^V N!%,%15L@1,<2J!R=S"4L!C^)\$+QY"G^3,J!^B
8CB!^Q6 MK-2=\$V!VMAH4<.&F5PW9BNZ(@!J^J!B_PYV+4_J9B87#LF!8RGU!=""3.% MM@S+(O!L(EP76>M-
"Q9*!LN!*RT4B!DNNA_U&AMM6W>1N=@;.#D^BP2?
M5*BRZQ!RI&U"8^@*A_LN=P(749.RZYU49@9"155^N^+ +T%#V#%#LO5<!.F@W M@TI@C!43>-@ MT3.JZ+E
XZ0==>AS25"+F.T^628+QCPCL"499^ Y^&304!;=>J.%WUC^693 M(!
!N;GDMIMY=TB&^WDHT5_Y8U!DA+^WCWV"6W!4^N M3W;QX6?L\$0P?G=;D^K<35%4FY0&.)R/FAD2&F)
4L_%NHSIZQBUB2^@!.* MD!UL_7>(-=D.W"!Q!X;_O;7^_SY?E!S;+^ZQ!7C5(FNC7X1V10P!862.
MOB=A1M9;16:ES=DK3J!7W!08B-!V3)!0?NRX/B"AOA+54ESET)U80J9 MAU#L;|ZV*%@JBI!AF1>;<@U45%2>5-
=3UZ0H7M076K%6!^>K3MM_R!>IYGD M-
JV"BG=9(6:6LK;2!>SG.5HMHJW*EH!^@(!+D#%|FCYF#4.V%0\$UGCVF07 MM=%_E7%JN1N/-
!^#W_W7YN7JSX*75_R2Y.OO;"TO"7Y!^C!0Z;69/%RG3!^<
ME9OLEJX;ZTYSGS9_||P0!^Z_MNGF!5S!22130*U+>OLDA50!&WY#F_5_&4 M%YOZMEQQ*;*R#KFM5HZ^<
6"AWF_&&_#M?MLBR&Q^C752#S!A=N 6N=\$N>Q51^!%1%N?EVW1!9)!# MDL2#;?(91#&1/T6."T/LQ@D/G8
QD^_Y/CJS7!H%+M@1!HKR"GR!KMIZE.1 MUD'=%((GM5URVQY! =8GO-GEVP1*>_WKMPLB7+J_ZQN^Z!7JR*#
(HPL1%D;=<=YS(IQ#6:|F! M3&9FO#D*JVTI@S!JVIHK!X*>AE%G.NG-0,=2<.U5J!77T.&?_//P8#\UW!3
MO_#R19:HGH#M"M5!VCXY-||VDFOYT/V'3^X#N?H:W!|2D(Q#0'L!ZH"!1M# M'
1.10UCSL!\$9SXS3;7M(S;W67U5_Z8=|MR!H&^0S0=/_J31AMG!|DQ_0 MM3:1;+!TT^Y2BR=|7A*Z^W7SXAA;_!_F*
<_FVLO?CYDFW+LX!2+FN@ (FTD& M!R(D#11494H"-V34!RD39!YR!Y5E7;.&XJK! 2C:X\$NF>08WK"==3WJDI!%8N
MM;G@%@!V@& C_VNMR!L<@!| (=NY!#SULXX2!R'6^Y=O-PS>202_4'57)!NLV M6S;13D@YD=NLXQ"
(\$'9@!(4(HHHVJ(@#21WLR*_ MM4GZ! 5!Z7CEDVG!;*.D.*<#*/1_6A(F+!E&7M=-UQ)CV?04?P!6"[KJ6+;R"%D?4N^<-
_6XWHA;).GF\$O>%\$!S;,,,@8A*(X"X)(28 M,LO9%#JX!M,W"MWY=:@SN\$P6:U;ZX_S3/B^M?D-
77#DH87%*.G%4PAOYU' M7Q.&#>6C\$FP_-0G+#+>C*>=490XO4%NVU*&>Z&?E#C6'3>='1B-P8)0D;
MPTA(8R3P('!& H^NRAR(NKX6L;(077!1N_!S>PK>"\$ _!2/H/84AP2?Q
M%+R!)6S0*7BO!REXIPM4!V+);T.>4BXZH+!F.>?=NH+!/0!7D4N!X,B7!4 M\$77E(C ?
NDZ(L_1%P&^! =KM^MYD;3:DT/SQ4MP%O:AEDL79K1VY.MI;7+ M9&FJ<(EE<05P0E360;\$F2J9I8O\$LNDL
T>);0.6N#W&C_FJA%U6V^X!2X5 MT-S0B)!YS=NAKR3;2"AR@MNI U1#Y=SS!#;"OX-V_=J-NU
ME#>%/!Z!W.KW53D9V!4!<6D\$J9OX\$ 6J8!\$(\$,2)+R+"0AQY6E%EVA3GO!%N
MZ6.C!EOXN&+!J/TLAHUG=|E6/H_H!4BT6-?TU9)ZOT?XG>PO7^<4_K_JO M.1!V+T^4Y!O/^4:776*Z+@-
GU4MHF?M!V^V^MNA7S!P0?7K73R&RV3(2\$!7!HVA,%API+9A4 W/O/*Q8*!AT4Z#_2^!3=7OMK M5@B6WV?
IOP6_)=^;8ZORK6"%JBZC0LZY;16TWNN;XHT+VZ\$_*|ZIB:QIOB7 M=TY.O#CR&/010A!%1+J^V(E@X
CFQDX4.\$E@<>H!16_+!\$TW!4>|VU6=?_F M+8L@R0OP!%@#+X(4Y?_!|ASH_!#-N0!>&IY-O6)YDQO9U_L0FP0IU#
!J# M!9;%6@Y!#L_ZVK!%8^@9K(! X=+!+/*&B(ET.D!O@-27_^! (=R+?%9XP_"O=M0V3NX))%.RIKL#?
_Y%TD!ZMF&_PFD!<_#ID-0N>*!;9*H@=&BOW*XP" M% ^(\$NL)=_"!DI*2FIYE*R#! M0MZ.%!(-
\$8*.P<8AD*.P&UNZI*._P.Y*A^H+ M6!6:N29/E>'S.R!*)Z-L#*<17!22_Y0?H=(X4^7U!
M^AM3G3DH!9R\$00=%%*+8CR!/(("1U%". NY7DH/7(SHYPB#RKZ8;+;#@P MK#XK#8=IVY*99C!TZ>;
(LN#BO\$!|SB9!QJL^7L/A3S*HU:8EZLUSC!EF4K M-VD)=%;#46^4^>7.C?<%M%2!(GM<
ME.BJ.H77QV7KT<#E6!;OPIMATCBYC>|9AD6SNF7K>>5B!VS#(AW>LUUXTL*(M^!L_?!"<=|@OK\$|!(\$T@A'\$+&
0!+&#O3"!%7X_-M%HF#U*9>3G69.U/ M?7N5HV!A3"&RV2+LE-&C.@5V!_F\$)!N^W2;-+</p></div>

MOU+4@WNIKV#EJOD+_% MM+=??-@":KX*LCY7*G2H0_8LZM)^-TW+!;OI^Z*ZFYFKM=.;E4CR0GQX?)>
MEGKZ+N&.P!\$;P.@G J+!\$%1Hf\$)*L4=\$%":8ZYAC^=G!G"=E@G V@JVSU7U M0UKQ435TKQDQ6. 3S((&
BZK6S.L5+R!FCFPYPZT!W 7N_E8!S2/X!IZ M-X@:9?50!J9+S(.9Q\$^GM<'-8 (RRVT:T^GD:(.9)+46H90\G/=Y94
;M HX M&C0WNIJWX) ?N1&4(30.;)RLN-H+; 9_/-+FG7@;YH\$(QC)ZT7 1FEP!'
M@9>=#IA=N_U&BE3=X+4%6A>H4Q?J_ G1AWU558)5!^ Z4EJM"U\$H:5\$51_Q MH.MPK@!(L(QA!-(0X<1 E7
3\$=TSNVJRXF'DI-G3!6H52BH9RU4)@9Y01@Z.= M<0K7NUZ;78UF"
IYE9U_K&9EU53Q5BILTH_E7I"OGT7=N;W5?)5BU3*!FNQ M:1)M372A9L?
#HK=HHH1T>G4VIF56JVS5A\$Z>KE4JP";//K>5:@.?.>I(AQ*" MH01%P+&(4V@D XE=T(_BAV#_DK=1.;^&Y-
\$P9JH"GPV*V!#1XAK> M2IU+;G?GU2VRT4W7;-?%N63Q(A7+JZZQRY737(_LA:* M640"ZL#8P10B1'R(F<25\$
6(_DWAVD%(&G0FAM9).TI:K(-ZTL+;2@B'@ M#^C
LF3ZD";RJ9D)7+IVN(<E;NE#KUBTA+J&+*=EU66"5S.\$T6?Q) MM\7IPX?/I;V>PVDD>
(YX3TUWP.8Y!%\$D\$8>8F@4NUVKWUDY@9D1J)T.)< M@0^?C7C:NE2B@SYC!34#G3.9!1(XNH0U2M!8*20K)VA
<4A=.;KY)*&P.< MGZ1M##UI9=?\$V'LO'?+2Y2!W/Y!V!\$@E(A\$(.10SR(@L2#6"0!=""?1!3 M(6*39B!=-.;V8R1-
H(B"BNH*W/Z'T.;=J18MLV6LL(CFRKF<=E9*P!&ULE8 MP5_9*AEB_X(UTCET22MDB/<3ZV/P4.M3%L^1%IP4-
Z3XU^!+03IU.14>L(D MALAQ\$FEVD2V.R 9:3@KWV^L#^I>.5KJ&+GJX+YZN#+TJ-U55%6!IR%?RQ%E
MW1'T018T_IQ1MP5Y=K79%G=;JH4LIRI(9=G(1NA%T.@X)7?C#HGX2^M\$)11%\$(2;-
%=7D9HUIV3+"J1USVHOW;5&5.R9W4=-I77L(XR% W\$4. GU M*NN\$4 !-F/INSY@7A>K;474+OFU(L?E1=7_*HO8-
+E KZ)!%R5AXB_!E@: MZ0BA &+ ".71BZH:N3Q(>L\$;YIS+8J^OI?J6P?6BA_>R5!E6.;?W3"NRX M @U;X)
0%;31TQ=JNC09;54UT27M1\$PM>FLIK2)/KW\$G?K05.6<0>V 4I7"; M.;> WC:6IH="YN(P@P.O.A 1UX/405T6\$+"
(1F60Q!)8^Z33DD3!(BN MP*^W!J= G5K1.NL<#ZOA8>>9E;GG9WR&AUWGI7E<4AJB<.;#9.73)\$HA MWD^/
@SCA"72(JP=!&0Q MI?3!XYS S.@A"8*&X@K!G11VZ\$.!)!60C)5Y7@^!.\$XC M#2AS\$ICXTF%
H6L:1S&"\$0D0IA('Q0AKK_!0C.O^IHR."*!C^;F-#6M+ MA(ED-T.(/K%M\$&-(?@/AF\$@/=FAB_!F8H8N&;
(-8.S1^>31D.((AW2>M_% M?#=-PKLDC+5)^+SZUGYKGO1PH2<-
#^)"A\$(\$6\$"1@AI#">>1\$!@K8Z:DB28\$=S!6Z-8CXI5:*#6%8...OFMD*36!/@&"OTZ^+&M\$/?#L-\$Y2Q>F+
(R1)"P1A!&\$74!2*01 G& *8XBW_\$#K90Y2_HSHV>&U#NV%FU M/51(S5'=M2-7/(\$GQ91AJT-#C0_CU0)Z-.S
Q5^_U!AS0NX.E1AQ0ZX&52A M>9!\$T5_U301D/JR_13M5/68!R-68 M6^5_#Y=B^*.;1!7KS\$F>LDQ-&R'K>/S/-
)GN4G0T1M"WZLD&%F\$! ML_50)J%#_!..49T*CI^!W(JPSN%.>16WOV87<1\$Y"7M1"W64>Q@3YA"A.
M9#SD"11FCY8!0M"0_U!#="CH<#UPT.J*7H/8B*4!K_!\$G4:JP+O&Y MO3>+(A!Q! N8N*!<<1GE.;4A[Y">;Z.
FX06Q\$%XF9D4*1!W-%?ALH(H4KWO?_81E.EW/=1&\$+L4)41\$.B?7!I#* XIHP'*=+JB=Y8.[3 M1]<#
<45>/_1Z#CN7!E;)X^C1#0!=SR6SN[4!5Q.HS/'4>*^HEC+^!7SAO/ MQRUYYVMC+!;.=7%,"D_- M""R%TUXO/;
(.G;K)(0^2IH&V+!)>=\$=I5T_=GJU_)2^/(M"3A)7 MN95_!9!+TE (^\$1#SH^2E08H@.ICEW(F(L"@CWF8X/MM(_W
\$!DBQHZ3:9 MOG_9G1)WJWP:A 7V2&T4(3**!5PX2N"#!A3B!OM%+A@I< MD. D6N#2TW:7?
UUEN&^+.;EY*W>#*G+3NXM^:IVAVWY56RV1?8EN29/Z8:L M;T3Q:Y9N!L(D\$20...21CR0F.1\$DU&&0\$=>C22A'
J3&(\$IF)H9P3!G4^? M4R!E&DLS*A^*E:S/<f&D14&X M H4
MDH;EJ0BIP)P4MU(7I3!E+GICZJW@B+U5WWB19U4Y*N;?I=\$MRE_\$FK_/MBSV!>QYQ'(RI X,DD?;>\$TH+T
"QDI(\$6_-DA; <5;I?2*N150W,\$D+^">O^D0=RI-382V
MHIE9%&FG4MXIRDIV70.^+E7SBX.>B+^5G!7F0;R1W\$KOF_>2/'I=O>1>== M.ON5QWTSCUIH/I=-!9(?
4#.DWP-&2T/#.#6^W+L=>9F1HJ^ERA0!;HUJF?S*IBUGTPO!1^@DAUD+GX%COH:8E!E;ID6U%(5V.3/DO2
MTHNLCD#&S GFK2C3^TP^P^DCNRE)LKC;Q25I4S>SN6.CZCN!@ M2 +EUPDWDC!A.3H+Q".7!8\$;(Q-
XFH!%F2%.T.G;F9J!U@QSH0=LKZMA_#; M89YB%NRY!0?<_DOV#..2 D:E@^?6H&*.T VH)JOWP9GS!@EYU/J1\$@Z
X.+MHNU"CY%Y!DIV;)V97Z2(Z4)JDT2.13PB:X@0*3V(M0MA7C:(C&.'.6G' MHH :HNB9E1L_%S-HHB>%
(>T\$ R.HF7#.#X8.I>CBX!B937&L\$K GT^GB_?WB>MHH<#%/Z2;M-GNWJ?U.?<.>?&GN M^<
(EYU5)9DHHHC#"8N1Z(+Z)92Z*RI^!1%T) T+@?H8_AJ3;)E&.+!51 MN[CA#DF-PH;22S*4%3'MMV5X.L:M>D*%
ID;YN>IV\$0>!@E.700)G5T(75#N;99
M\$A_X9@F6MD"8YB8>=GO60+9<6N%M&*.'+!%2M%ZL#"W^LP0XT!S/4TI5J#M
M;I'RU%0BF3(0T%XEDP7^6;"P<*"?O9+._M&O;L!S.1&B.+G(M!^5>V5OJF MWKKIQ==
=O6XT8TPN?"F3%&40<5>5!WB3I@H(V7Q; PC!4SC"@3Z!0..90 MAU\$HJ.&!?JIR^8LF* CJRG-
16T1IB@5%OMJ7TKJTTT5YU+=C9973%HVA> JFE;_E.EU74>WR_+3X&^VZ5JUW!)-
M;_!V4Y;15*FJYQX.H20*.8.@.40!)5!B0/X/ZC.T8 11RM-VG&9T;/MEF19A;G!X0\$&!)>=0
XAJT=LQ0014"BA4KM.;<"A('682@E:4<5RDG8 M"P..5.;%):Z80>/#S_@O.ML.S_H_-OM83_>=V"V>;!9
SNQ\$ORLIRV @I: M/K(17H.^C5.4A(\$T8OZ6EV+O"<6.X!ED(8)E89!\$D'B)@%T!6;<"86'A,%I MZSF!F3=P2;
R^Q5)4Y>G0QLZ?LXX&EG^MCSV3@..MP##?&OPM:RF6X#JLB!(!?CZ!05ZHH<-(('\$A'X>(M.2SQ8JJO-
W11F#L<0U(\$4GCL*T.?>@ Q\$@IS1#B5\$"f8(P.28V",<9)_K! M&AW,7PC&Z;BX9#!&HGP1@##JHJG+IR9%THC
L4 19 !F\$)&80D+H/J^ M1SC!@GN18!JJH&S\$BA:(YI5=6E%1V!&"VK&6*M0N%N1HFJ4:3%HEMZIG+
IL/MW!1HYYL4G_ M74WIN^JH5O!0Y#B5BI4W 6.GZ@L#NAI@2.OAKF0>IX);H(CR.'4\HK!>2
MC!EM%L>+S\$(-/4YC\$X+LD.P6J&8.41V+4_!^L@&*\$J:RV0^Y60#\$&*LZF MB_X8J9J)
D!LN5@T!F2DJD!#0.;^SL;PP0Y^EIV0Q9IYSJ^_#N>&U/B.TD(MG:I(DW*32.Q&T'7C;.8TB7T+V-H9?(-;
I2)+V+7!J M#)G@G_.*JNA=KBF^<N(2XA^C2"J^!03!G#H43IRB7!FNUU.-C.S.6 MU/3!C@%0<0 D"T#?JM%4G
.*3*H..2YH D;+FL\$@_LFE0U=KAD^!&8P9.V MH(C=ODMR!&9MD1'T*8_RLZG>ZO"8K)-
FFT%_(DBN!^!FDV<>|K.K#R0>> MI*LOR2=CIX125Z(72;R'<681DI"(1).K\$+_.<0T!B#W*/>PGI"8;=E5_.\$W M.Y
VR>| K25S?P&TH@W2PP(*F!%5+!>^;AZMZC5L5&EWFZY17I3W^F:?? M!CS+!2KGWC"?
8;JDU7.Z7W&ZS(#^D#K8D5!Q2QXZ>.^2EJ&567BOD'-1!+
M'TSGJLZDT(E!:=8H>)#)+=N364OPLQ.;>J/LUO6WC7S'A!4R/%V6!C7 MWX@BS7F5G5&^.?H>?!7IKH;OC?
QR(A_ JNC2NN)K.OP9I9);8.FAT71:I2:3D!LW,LL ML4V! (U?&S'+NYXQ%W.7.PY#11-2@
>/83>0<=>SB*)"K!G!S<3HS CYB7Q!/> /M("NX4Y.C8" M(P:8*"9*Q<4\$ 4P^4(H)QK-C6Q!
>8(T.X501AQ0!XKJN^ M9QK0%W#XZ..XN*JICW>S6S_!;@ZEME*EQ>6853P7=>@Y+K/K.RS#6!N
M>L;GFONIG5)5;6!QR?%6+T!O4^?V^Z=R&.^!F(\$D31N(9+(&V-FKQ>XLO_ M%8D314:8KTMX_NB3V/"
4%=CFB=_.^C!\$A/-O!LZ#RC5HF5HUI"A0?;U2. M-Q5^JN.W7;+GJL9*N/LP.OTO.4%
ISIXI+RBDA1AFIN(DAB+@%\$7> E\$022M M099PB".IA)AZ3NSIA)V\$)CHIF%\$?
S1TC2YJ.S2B<9M!4A)S=;X+\$G.W+^_ M%.;NQM50;+;U@&)JH6N!8M=YDZP/71!>G0LN"7?V^1 5DUD
M;=G<>30.L8MC&(HXE/C!!21A%\$*:Q \$BU UN!%Z MJ^VROH:Q95(MF(&.M0*T5YZV< /%A>0!AM!_K
W#2Z>9%G!JBU@NUKU!UB> M(=7Q\$JVN\$."A(&G;"@2KHYI.(%4);YXPH^SQ@*S4J'KQHI:O-C
M%ID)9GC"TT1201T2R/P8YISUJ4Y.#MZI&N"4AGYQ=CUA>E:LFF%7 U6U!
MN+C*>%5D!>NN2GH6^(<)/ZZ*.2!A!3\$C"(N@=CE/L24JZS:@\$E: M1C?H-ES.2;%=M?
#>LV!XQ6ZE5!WE.KNVS!9VQ&\$J@2ID<)Q12SPU\$2!W?T:E70)SXQ+1M50%YG%\$S5#DT%7GYKVO-Q;
M.C0V+BI(E!U-30+IDJ8"J319?LLO;H3+.C!W3!7:8!HX4F2JW=R.*ZO9&
M54G*6+L.ZIN2IAR-M*)B#B%+!9ZA@5P3B*24B80SEY/IW0A-\$T2!=- B0 MR/51TJUSSX.%2:FQ,KPK#
(Y&&OKI'J>^0P3\$+DOY.VDDI\$5)H\$ET4)P4 M<8H2AJ/M.*+UR@^F^&^D'D!>IPD@)C"6EH\$

9Q)Q%SH>GX2QI@E2J"5*G>1 MTE*+I..3I^*D(I%3)@ZC"(<(BXQ-\$:"0Q(ZG\$E+S D9-CN0F41)5LTO,,Q)?PHC"!-
\$FG>.#ZIV D2&+FAPR+I3<6"F>#8X%IB+!2. @#X8B(-6P
G\$@8IA(81=E#S0EM0P0JHF\$-5M;7+9+ W^P0<+NH"Y.)@NY&)9H..JB M9^AR@1?#O! %7EQXU
J4WHHGLM+IK/BF/NGI,XD".SS%30I4N5\$C MIA/LJ9T;<4:TMN>+E&8 <-B1KNX*I"U!;NVYI9@%0XJ3@-
HE*#00=;N*H MPZ0Y# TJP ".IE*\$21H%4 RKY4.5)V 3;%EU=F+^DSRZDKIX/H(OL/IT2 M!EX*O)H^8KRKQ-
IF8X^!@%M 7+P9J.'\$?@IC7 -I63;*I(^J8G7OIXE&?J MI97IS=Q0NAI^E&L@M@)CR!B0.#A"/YS1.J-#UD%J.T-
=31+L:5JY)VZ MTKR6F4H+AL>H@JPR'4\$&RR7,@A6@OG/&J(29I;J#/(JO:RYT90"@G3>?;^ M8I0K"
(Z"1'B0N,JV).0(QAX1,"2Q%^0(I15JHK:2VFO:LH@H;D"KS_?%2% MN\$;?&F;(6"G-%N>I@';UEKMFJ3;CB)H>P.
I:DUK;W<+R%RLL=Y>LNIS/ MHTG5Y8\$K7##?SK_#G-[C=YIG'7 -6L0^X-&B0+HIDB;..4N@B\$44;BIB
M*#2IV=Y08VILD#3;CN@?#2KV=ZI%2W&^NK(8*6;3;"5.-TS=X0:BYP/0V%QZV)NWGIT'_[MMF2
M8K;S=H5+HQ I&(H 28N%)"@R)AT,H5*%UX?B!UMJ.FB.#/;U"1;3=/0S^E4 MB^C;I73%#K.)+2IE4Y1#2IEK,AV<*<
(N690,B3-(Q?#EP.0H;X/H?P0?M MCGW;IQ5FTR52-8WA3Y^I(0X)"_IBZ J6FW@D<X<)"#P8NEI#"PQ#2&\$N\$
M27P">*&Q=J2FE,>6;HD;1.B@*3IZ=URJH@H DU>^>[G;=4ELS-2?>7JG92-MHC(SV-KU&#I@804D\$Z#B
BAMMO68JWJ^TOVJ&DL T0&K/MU%#UN-U7%ZI&K^ M LO#%3;+M^I3L2%1R\$-1-7&P8.8B ZPD<3;,X-HA'Z;
(P_T\$*LFV4V:4/ MS4.4,5(;'Z&@T8TRNR0U/#X9C(&K'YIT,7_QZ.1LX+()WUUGOV;I#YH6TRL M3::I6E-ISM7\$D?
758H-G>)<(3GL0&@>)DS\$C4%0Z2Z\$&3D*\$H<%RIBQLM M;G;'
TO0"JIA7\$AM3D(9_YJL;:"ZGBFGI(8>Q\$&\$92>9P'B8AI:A;3/IFB MK.+:=ZJZFEQ5>C;79.*;
(?!!CF#3J4I7\$Q9EU#0DG*QVVA"MA0NF:8AI7B5- M9YIEV'M=MK&4IBJ4IYFIH=YN2FK0)>R5-
>95<9014:RS8?IR) KFI-RSN2 M;)'\$E\$>)-3?16 *6G&BMAK>#8?;."^MAAGIDDEN5F;3<0#2 Q963?
>VQ95@6Q&GM*7# "M3;DJ45%"IM9P6XLH=B3 M_C%ETEWYL
)>R@;"82X2+D"ZT3N"7F9%RSA IN,Z*"IPOHV6PG;IFJ(@M; M25_7^CI@JM9SS1@XY&S"J
(QQJIDJD).2BV63/L:IZBP_9.3K+!SW&Q5"OU" MY*HMZ;:XOVEOP_.;8)'X;
<2,8HBX2*3S3J4UIG'79\CO8D\K%*0RLRP59,% M>IHK<&2#-&K' U/?@J1#1&D2UH;E!Y7;.W?
@KQI5QILTDWJ_16\$F1I>"-EC3I0JHIF@;2A7 JYPV*(XL"!<23M*12%81 R MXB\$4WVUR:4WHF5"G!(Q
9D=&^WN\54-JRZAN0-B0;-VSK2B9I;.D=4,7.YW M KZI)*"QQ=\$GQ42FO-GK%I41^H0IW?OIGYOLQJ_ZL1#B;?
Y(TNP.N5\$2A)* M\$T29=%V\$=%V8BR"/!>(&H*8E8ZX2"FW;HSHJE ?Q1,V&8_W!9C7H+=5+E
MF*WC'#A&5F%2HLI>225_VZ;5EV9W=YD,R;UN)NMP@W;-RW8 MIMU,NN-FI89CQYE-
U_DC587Y:=QG6=ERIN&P;<R'9I(2I58RXITE;&@>R MWE9+Y1=IUII'8FI**NJR65-
IGQ0%>,C74IY2C;MY>"E3EM;E MD.4K7L;ML2TWQZ%.*Z D+*F>KJWOIKYIFMS4OI5_F1G4WQ!9C9A@OJZ45
M><"E.ID^X!,<,+H"3?KMCM>VIZF;E9;=Z6W."74XL74Z;6>O8L=J-(^BW=* M\$M-487V;KK<24?9MC(@?
ATF20\$9)*UE%\$L>@T0I>+?2\$!-&8JLGI& MYX8;\$&WET28DJFI5Y7U5(GIM*QJQFRK.*IGJUI6UXI;HD)MCZ
SE;H2;J MM6MIH+I4M+9OFIV6OI=0GC'Y GW%2%455IZ!IBUKOXH@?_#1CR6=IA//YS
M"DFL0OXIY,'80QP2\$0;8M'R RJ\$.4.1H#-VRI@=(0R)+PI'=HHYQ23+ MMYA!5%ELH5H?A;Y?
4&>"N17LZ!*&8D\$A!3E#G1#HJK<.2&,4>A FG#,'\$R(MFV@%'PI2F1EP#LD957P:5LTP7DPFL;DLF,BJO=RU9IE:U?
%&IRM;_FN_FH??MOA&G>%VKAERR;-@-?IASJ(C;H;Y-EI M%J
(XIF'D^%0N31K@1#^O>9C6S.M1T085<2"I@QUYN7L9E649UI?&E<-T6C!;
MHT,*L,HW&M;\$2>;19IYW1PD+3&&LY&&7I%@7I*6+,<92GI#K#*";/Z7IS M4%TL8*@(HJAI_L.1 @C"40A!;?
A'YJ>=Y6MG1?03F1B)-\$-043;O*=2A# M"W5&B6@(-+X#'^;@E\$;.7ZQ.8Z'_AL^?7,D
MIWCI%IEGGWZUGPI"?#Y,8A#\$/'5R<9I&+D\$NC'A/H=+CG; 4^IB\$1/'?)#SZ CTCA#&EE.%0W@;K.AWP&I>#I-
^IU6F=[A MYH2*,-@7>B0I%RG;HVQF+27%MT2;+IAVFMG"^KY;HYQF>L,L;(5W22)8 MW3Q4E5J1%+Z2S4F?
P)^+O"RK@+G*%C|SRGNTTP^*LH|+P@YI7T&/>P0B)7 MKGWJ>Y"YE+HZMI7(SD26MM)*<
WUH<92H&5\$YIO4\$5_08;."M0S?I8I(TT#BEM"HW6ULRUA;L\$FACN+MI,GH"M3Z_GJH;YI#<+NPO@W.J 7U
M;EE5LRH;H+(95)0;3R6_A9I0JC8_"E\$C PHQ0=->3*U*S9)1. G*C*1
MDN I%*+V,4GY9^>JKMV^E+5.'M1IIV85;3FFW*0.)\$C(%V*Q!*479RIWDY?%"0 MA51?J8+RG@JA_GU<-
\$T!KNJ/LDFSK7IO_M2\$ZLCO9;,I4KK=M;75IH>7IU1= M4B;Z 8MU+\$TEK-E)I+&D=4IU3MM;I;DI%I?Q9-
<7@^D%/SM5A48N!%FQ/? M5(CI74@L3R-1NQR%;I@X0/H"8;:NHK4-&?LJN+HJB3=7;Y1&_AIBZ; MXIHW>-\$=;
D\$NP2;UM;ICPEQ&\$FF"-ZIH M LG\$IF(Z0<0)'IA%*AZ*F\$<0^J&"?2I1"2>&9>HH7V4EB9L!I)\$%+TSI
MH5.E.O>'8P4U X,S&:WN\$%#N%-E%"OTZIXC#G\$?)/8.7+!N0ASHIO\$P>? MM.\$;
I#KOL0MUUOIBLHPZ5;*#&6%<,,,QFM,-36!/,^OTZV+&Y?/?#F-\$Y MQP_6"G2?@96844IR/6OJP*IF M;I>
<6IV'KX;IB\$R09Q\$<+&CH-8Y9&=WKRT7;7JU;NJ+2Y"1RMILDM2>TX6 MOD
=K;+SRJ7QK!ISQ+PIR0K27FMW+QV6W50M6,T\$SAHGK0A1@'Q(W;0AXE:A=P11DC116-NK) TP8ZH,5IT;D4+
M+V*H@89V);)I=TR6N67S)2IM=,IE@_U*62=?011--IG@_S349>M0;X+X M--<@1D'B.R*!B@S1+\$K(I9.*;\$/ZAZ
M/L^B(=:'RUW@4@2+XZD.O(G1%7;1Y 0%\$",7I+)"\$N-XJ*N4;O9@OI*4-2 MDP9I>RHPEC(3I)?JH8%Y.?
<^/6BM%ZI 23JO>Y/8%6A)@X;V3'LM>L M&F;.)8Z1&WQ(U(T;O.1'6&V?3T=H(W>9-
^?"V=F);1.>IBUDD?)M!Q+Y M"(HC!FO@^3*!;.% J>'WOZW7TNTIL9;JLS8Y(#4+0-217.F>"9...0Y4+@12;B?
A.)UM#0/B^3.\$%C1@+L.G90-U)BL;CVM;6#>Y+HP@IV; M*SH@ST#X("#5=5=T:3Q@YVR#-IO
\$RC(#02;Y!W%0ITW+0&19\$=H M;#;2 A#?IN537I+UST6^?2J0L?
66HGI6U4EJA091XH8B03A&"R3@R@E;HFIYD4 MNP30M/R+RN0#>3JSS0!&M"IM%H-
=&&.U"Q!W;|@4,&P8Y#<ABF|G<,+FT M|@V0?>DYL />);>84F^#&I7
M=RHQ7:X|PL(XP0)&#%U5IE!\$BE;G;K<"QG"@4_L.M|WD=1>F/2>@I;NU4M
M;@JA>J17M.VZH_L'O!O6B753ITN"3MRIO)?< MJH0IOR17S_RB^/L_.#XQ)"T7A2W+PY<;2UHP=-
X&IT3:FMB#1+7-BAR\$ M\$^H.\$9:9Y/#9&VQ_=\$1RWS'A7I+>IQ@ILMZ6.99UG&PR) M'AIB"RZ9(<%
M/5VH%YXVKY&ONC#EZY17ID;5<+^JA^X 2&>AY4;&\$/DNB&DW(I@%+O(D_XA MC3RJ6R" F13.R_*(TAPKA(?
HJNAM?D";K4<+88VJY_+Z)\$?L^+Z%N/R/MS887"TI;L1^IDJF/E:9IBD/4^?;*D039RYU #G(C)A#JFFT.BAV(
M0Z*7<3"19\$@G 5&;7-TJ,ZI^N^D143X);@Y;H&@8-L+1TH>#CJY3@Q/ ML_?JDIOJH.#!O5Z)DB
OS1_*IUUSUGIBJXT6S64;W9BHX;R C=%@ M2XNZ%>JZ^>#OZRI-9ZMU38-14ET&N^&C_NU;AG
M8'66%>J57IT2IZOP-6)3FI(,038YO:^MD:FLOTO\$US6#I6P)E/H#_2XEI MFIC2O/@E5PU4C.*XPM(H;5';=XONN
M\$%P_P4&+Y,P&2LT#;)@.R| C@V#RPDI'6K<_ \$RN&3/HN*P4FAG/>T8W,U, MKB6IRY>OXDG^51V2E+7>AH
I;I8GEJ>HJ1;B3ZXV)WIN6NR QDN\$H;L1L MI5\$WHI'9&D>*GCF\$Y+20(2G6U45">LI4;H0_P*H5NZ8=DIJROV
W7Z M&;(L(C%G+G+(TCB;W.B;+M!%T"HYF!MACGG;AW&4;U;D!*<\$3*78%E3^)-MXEX4!K@RR;1H@/+2RC;#
I!UW3@O M/0MV>|(RLV+V9TRIN<\$M9I)"R^TX4^KE\$;1.5V/3GC^*O@5=*B9&?"H.H%
M3CSA0NHTHHUJ!&\$78IY%\$5\$+V5HD,K_<XJB"AJR30D-TP.RVV?-&/79"WM^W78'3@4F_-
H&+=M4IRIR)H(I(P0:ET8)B"^-<H M5K>H^8" [XQG/8L 6 D #H4\$;U*JQC_'SS62@JNZX,XNOVHG;1XM9'R@D;@
M%:A%EAJ@KL^#WD)VK M;_SRBDKF"/MS3CTBD7NVP_H@C|RG/A>IUID_Q"ZHI;(S= M=H/E-
OGGC8WP2I73#H;JSH^B6*B^#6|LN1!YD?2%0^# M!;"<1 %E!K&I%MPH;4"QH6H^@?"D"X;N)&O-
BD_I;X.1OC,+1#731A%T MN:N:>58=;X-(?>8I06/1.(+@^Z7RVK=HNGE#Z1Z;B>2Y-6""X0='R0Q_-M=
IRLP%Z#UF;#ME'Z&BP+2A8_%18(2*3K>;_<R#GOX-2L%DQI1_YOOI!EX M07;HYC%;_NYBF-"(0Q2Z\$;2.%T/Y5&\$
I=RD1B&_-206B;84<<5-1!%Q'R-I8.\$0*<#RJO MC#U'IDH"FI/3IO\$;W;Z!+4L8-TMMED1Z!BOW8AZT\$!+A6S

MLAZ!;\$K0?Y/BUH//SRV+6L3UIH=5WV@GU5.L&H2+=%1L:9M42V=-/ MV1= M'5GQM)J@NG4HCJA\$Y%
(@(TE5I8O=1%+5L=7G.%)9W&LEUXV/6LS8IB./;#G M3R/LBA_0_1V'(WMXSIZGC100UY% ^X8G?M,J2D3CUZET-
'E/V-&,05*[V*D4 MVM])=C(*YOFYG_)B<9.67;.%WQ2I9.F)K*!>|ZU*!WXKY"O^:RLY MJ9ZJ|BQ#C/ @P1-AU(!
(XA"0F" J6X"#F"1*=>5MK@*"YFAM,=>5#3J| ^V) ^"
M;52&RIX3L|_+NTVP\$H_#JA^#H;Q7(X2J6@:1*61VMU1\$ZS/>W%TIVJ^
-(VNA2P8= SXIV)*,R")\$@@"TV6|HOR);. MK>Z9COZ@-'&1;J=4I665;&M_0N0Q:KR H"7ZC@;L3V61#
O(IYDA*9!U1G MX/,7%V^O03\$V/FY <=V ID92+P>W0607 |_Z)=U;IQY;=N&|9_Z-
RVD@R@L_T13#E*88XRO+M_@H_LPC%.\$4R M4,RIHL_T|(^,?|H*0)CI.5S:OZYWJSXOXN#T1>9JU7^K.UQ>?I
ZW)>7"?#;MS+|KL?XL*8BUGX"E9_VGG5A'DW'R9,*=7/?KP89C)%90'8_ C"R@JVP0_KV
M%YFEWV.W;S-W S|&R:F.FR.5JY|_L2YJ?Y>9I=1#;.>#I72CO-6NGOY.; ME,MKEN=O^5C;=I?+
<6O2TUC87Y5ON\$A4B\$EA_.0D3B\$6(H09CP(H+; \$YFF M.4&\$N.OO0S\$VINZU9PAD)4>
;UDR23W&ZS7;V.N.JVW_\$K?;K:9LMN&+J%| MMPUFNSN4+!Y\$)6;@8\$*V;
(*SRH,829DS^IVIQEN>QA:>P.;V|L30KI0ROS M%*P?| ^O0|+*_3 M0+IY#61 I" T-)4PQ5A+%D,6)RD46_99^I_
ME7T=FYR(X?GCYX+H(E0U>59VM|(L &|0;C|W8\$&RA)*V^+ _14G1@CS0 M|_5B_/0#;H8YCKJ2
WK+6.MQ7INMR'-.GG MKRHK6)B+9;&\$BB)MU_E\$NV=8>VN)".(HB;_01/:UM6L(C(QCFB#84IR|^W^Y
ML;6*,"L7J*Z(91)I)Y90#7B.F2_=M/W.MF_C;SWHU6S_NPHS?9JZ/LWU; MGO/ AC(C%;=RZ7&G?6#"@EB*
(EAE|HK)XOCTI6\$PS#*LE@.\$J92158Y2WP7\$|58(\$8150X.M7+<*W/>6RP\$">LCGM_SMY73#@P9!6K'@ M=,QT.-#
H\$&_#WCL?Z+FNK%7^VN5|_JY69&S8V^I^I7Z^>_W.O|L/2DF^ MN56W=X7WJ8#".(PB#4"9I
ABC"DD)E"49D)\$5(89LDO;|W)R.A24040*PTM M&I.&D|VQ12WJV85_L+RN|8WZ6R=F0?
4.1%NN%VA1JF#DN8,E%2'.QCL\$&N@0|\$F M*L>";(>GH8V/6XW|HMKM)30A|(H,|@1G\$ "5,8HH2H# L5
MQ2QU6;%G%\$9>J^5MN)*@VX(UX7=4NPEH=LB/|2N.T+DO/H;)1EHW9V_?|(5 MURC>Z5IK?
M#V_!^4\$|NF&)O)^%C&5N\$Z2>O|+ \$ R% C2I1\$D4@-1P%D89^S,@E"X.|\$NQS=&);*_6_B M95FHY+?
D|6.03XEB.W_|T78>REC|AU;EM.2O;"._6 OT= _B|(Z|F1^K MZZ=\$HTN28JC"+_@.HS)
(B4PA23D+\$J)\$FKB<3^60&|OPJ2|9&8K<# #AH? MUO0\$G|H=;2I3NKXZ0|>)>Z9M2E#"|J5,K3L< _VK|XS'^Y
Q/<@OE+7C ME#K+5;>Q5A=+'>8CO* ^|_U81\$S;_O4LCGHM|V+>P_DE39DK3WWZJG,2* M8B1ARDD(L?
C4|LM9%";W_DS0E%8WV2L697RR8 MQM+M;|RA>5Z72 >@ "CLDIA;%E3OP7D^RE0DFV*H%92M@:KRLB^PT_;
|B M6?8R^*;JF|#@;&25EN1V?&5T|&TGZQ'F.WY"K|F1"BN:SC#,QP)"\$8(X0A M#@2%1-
TDPRD7)%PLB|5\$ME9%;V5#MV82H7CD62#R\$R&Z86RNM9Q.B>K'=- MFA#U%O_238A;|>AJ0E0>_>
(F1*WGS8A;G_8;JZDG>+U>I9.|>:U7(7X^4) MB|((YB)F\$;_0A|(&8X)|0CE_04|:E.T'_R7@>@+!U+|>/X9Q_IY2
MNT?>SP7VC?W72^X8 >^M? X0V/4NY M.K5>090/AWK:4X|6"<|_ =J?IK|J MDKH=#\$Q#"B1L?
V5V28JXULU25^KIE8YEE9- M7Y&=K9IS:7VMFEJO':V.ON)?W*H\$Z#3JJD=/*U5T|_F573^K#?&6_# VOI
M|X4LBH40Q=5!1_BJ|_6=GD|3?;4G^TQ^!&D.F(9|KP;^VLW""B7;Q9_H9
MX|E+DDA*W"GM>="C&L|OPV;OXH|D.OREYLSX*0965"&8|YY\$@_-D_HO<% M'|&8%8*EA-UQJ77?|VR.P;|AHL*
M3(2V*4XZ)VAEGIZ.# Y^|ZLYNVX;7|MIX|JUW|JSO5HLY?|N7/S2;1>#_?J RBT;I%"I M.(889RFDA!
(8)0G%F<1!'>E>U;&A_ *66%R8J&FYXWQ7QTJ'=B@X@F;<0.ZH M|J"6 U"PH &L8 +|L?U?PPTHV!GPCH&C H;|I6-
%=>I;0^ZJ+D5Y#3J|DW^1FX>8(JHM%@D5813B-"0
MA7\$;\$:13(|"1AEB;TX;O_LY6#AWE.O^4+/*3FXI845+4G7Y&=@:4L>D>SQ6+U MH^@J7_X?^9=JL+ |ADX3_ F"-
%A5E2IJ6.X)2#+\$(\$YBI3\$ "NO?@TD""0 MW*H;|& Z|(N-U&IP"/U8_|H';V9\$N!OQX(7&:W7.V^&+7*JWSLF|5Z@_H/
M5L(C_YW;6T)C:AVP6L|8A;'G8PS3|;\$YXHN0|;UABUW#YP1A1A:2\$%B>.% M(20<15%#/.9(*8*!?
6%6A(C+I62)M@2=>S|7;|3"ZNMZIN- <2|3JUY;
M|N|JH|1^H7#%+N96*WRM%|6I2.C;ZA;3^RHJ?J|K4#6AR|9JOI@ED<"9B0_YC\$=
(0V1<%K"\$PIE&N)@A*BM|JN74ZS3Q7 MAHW3UD|)\$ _XD<|OT/9<3*?SVE|B7OBHMI'WCE|:W%3'M V2K80JO?
NU&QNFUN/ /W.Y.VYG3OD48%;AP26+M5YXX#; M/OTIYLFEEK|8EY|NS"|=%YLVQ@|=8:FWO|S\$XU0F|@XREL>>
(J_1J3&T(Y2B M&_FSS;2|7\$7^913';I422A9S\$U|CD*9!"M.L"462AH(J;F|KU|8V=PV_-& MJ|;GG\$Y_ZK5B8W3WEM5M
SD7T|OTKI?7Q?KN+?>E#?2|6|MMM|JAS|YKAK;P? M6^+MC J=#;S_V|C _E.4-AB|O5>E|V6*|_|@_"%6;@
MXFP&*M|OPKNP|^&AMUW"RAGH#_*7BTE/*7J MZO0ZZ)1CB-)049Q|(B;4|T2B M0#JA6AV1D2'+D(2&)C!\$9|0|
<*B6@79_4U?L=U0D)*XWDUB|X)/+2(-5=BI MCL2T;9!%GAS+PKU-3VK%=>=&(FB;Y|L;|Y|I#5_'A35;9-
8Z|\$X|G"FEW1EL9 M64|B|T9F44XS02S;Q|2;L;#1_QGS; _WL<_ QONG|*)Z MM?
RNWZYG|U;|8^OY^MM++|FX7?|&|KEYP)1?>D@S14462QAG<0)QEDE(%L@ MDY\$&&+|N&/Z5|^WK(X9;
YR")5#R!&Z7H.+*M0Z?ES8=\$'LK?J|Z3C;=4/B M|H|6FO?T^WWWD/H+V7B_R0/UWK^OY4J|7UZOG3/N8Y?
T&OGI2|U5+1W?8R?A;4D59S;)8YYN' MZC6%07.K&62+ #VL3T+|*UIN<<0TP&.*;2N)R;SU>3
L|@B&"|IDB")I"16 M1=2LJ(U|O;A&GSC3U*|&KL|'&%(#6BP!2C9*Y\$LY6QZCHDVZJ*4YWYLL|
M|I3F>W%1>#_LCX|_RZB0G>;_3|I>EXIG4Y55HCK9.*VJ+@^D4\$7#|TS|Z
M;4=C\$M|S\$K>*"K=|/K=R/ID.3U(AAC@V M'OJ\$1A:L\$A&K-(I(P.OOYC21&=LQ*.B"@C H*6N+X9/+I95&!5E8|C(|;R
M&R3VNJ_3*+K+G9TA5.;Y|_=@H0|O|W0)UGZ;|WTA)=XNB0XOLC3^3?4?D| MMC"W_|H2;G9^I"/H|
MLGRV#J'=IS=JT>Y.20C=.%QH|OZO%^="J2^>#MX;R4QZ^XELD?2?S'K9& M99#>JE|6WV6^+/_2Y;9?
LJ5+N^OOKZX=L5W|P7#>|WM8HRF241#RED49AJ M8X2;"01PV|> M0_L6ELXT.G6\$F\$J=MUWJ-
(P9=8(| "MZL"DD-JF\$'@VH:3?M97.X:"|@8ZZ^4 M5FNMQ^NG,^?ZZ^#
(WAO@=7X&X7NI9)Y+|6G)5|_RGOW|_4#9/OY%*J^>:_M1G%;9;)@E"4\$XC1F,\$L5A311<1(F*M0_40(+;LN)F
77|SLP2'4(CKZB2,"@I TT;.&F#QVRI W4XZ|2SH&P"YJ MD|J"EJ?FH2VPSS=P&T|O@BTESI_7|ZN;J?V;>E,O|C?
K72.57(\$|W@_90I M0Q|CI@U#A3*HE(H2&H7;:0J^>|?)T)+4+1T#_PD@XXNVO|HY"A\$Y'ZM,ZHGZJ_2-
/5_CDSL>)_0S_|=|MN91O|_1D_93J2D/((!"27\$49I"\$J4Q%\$&0A9(&(E+VT?SZ"B_#C*8"(I(S M-O? MQPG@:0|ZX,0_?
G|HS(|?^992HW(L@&.(D=W HU9:P1H;_1|1880 MWPD)W"=;#5ZZI&J\$F;|T|Y%;_J4_X|&=>D9)Y+OMFZ;D<47 %
M5.466|B^_L%66C3.H0R|X^RL|H|H?EO9XR^;MD^?HAX(EV;_&(01AC%&D=,"ZQ\$9)"&VN%|;1H|>SO MJ
W)V|AXH|^_U.76U*!;MS".+J9+UPJV00-) |RF8EIZ|D%6QY|7MFS6TK
M"0R|X=)DFQX!@4+%|L;ERNNEUJCOS,ONU|T|9&8>3(HS6X_7JF9>>7BA MLYA6/2WZ|D;YI+|\$|?;7|Q_"R*W-
7EC&;@1^F MKWVY5HS?R*4Y.GQF;T NS;_V60%6IF(7?W|=-C1&)HZOM.W"@7|AW+S5S;%Z^;^7Y3?
+7O.CY_ "3+UZ% M%*8NGTFO?BV7W;WZP/*E D+7=S+ |L1R>3-?RD|;^Q^0;."7LPCY\$&0EM5E M.R\$S|)
2A91S(E59&|HOD;>4P_9!'L^0<5H;=0?L&K@I&(6;&Y|P2|XPS_ M"HX=T^4&FT\$|C^2|^*V/T|Z)>X_@;6WU
|/89B;|HV(|_K|ZQSR_0|P|H ME;P=K?J_|^O0.JM>>)=SUUHDC
M>|EZ8\$0;"D_."\$M\$@T%)_5\$|@6^5D^EGK|TVX+5W+Q<+<+Z_\$?Z_O|OS;
M=WZ|WFS#Y18+LF7XR*0Q3BZ+|B"|FMVD4|OB/EH?=\$O1;G7;M2NW67YL2 MVA??0/*|K3P|T;M;3J?7|64-
;MQ+?G?E??_T_|WBY\$+O;KK^V=DRP^"Z&J ME6?S|J>PL*PWOK|>O7XF!|=)C&;Z'D@|N(|@X-ID-
Q|0=\$9!\$0F\$;C#67DL8 M2/OV;JVD1EZD6TPWQ&?@1>I^UUNS(U7\$|H|B_5JY3^>KY>5Y^T@XOIG9%
M6L3S|E;|VT+>:N;3@69VE|W@RT(|#G&SP73A%P2SUXE;E,E*S_:P4?L;|@L# M64ER%:Q&^&|;_?L9;
|7|E">OUJPE\$UC9"1TQ&5|O^4&;IU(Z_C"&- M5_Q)"(LCCE#_.+&-
WNZ(V/=EA&PY014K)2|TQV6LX,F+?!M/VX@5V|:IS: MR?=2EP,4CJ,V/UQV|U|S|6R;P+3T;=L%&KT^%+JS?

1HY84FYTO^6N3TSY>F MYN-2\B)T5-3^ZWR>2G94#%I=T6U(JO#ZZ:#67<9CS#78\A_%?3I;17GSVRS
MC01JE=41TJW2OL*2SU-8XLT^C6Q^8-SI-(AP0#2<2@3((08IHA2!A.8\$((
M312A6"6Q:Z5T^T9&ANA<I)5=#EV+Y\N15>I,T4VG(I/3XIPKJEZJWJ\$6TX M
(-#84NRJU""&7;O=B8O+1FV75E7_O13X-O-JEXNQ#2;W+R5UOH^K0.Q.;AJ3/T@E8J(0@U\$L3=(#B"ADL%
9BQC/L+""&I MS+.5+8-Q)G+<CWDSSYU8)=W=ECN^3%Q:J<^ZE1\$--F,FT,<I PQ%@@D"6\$
M0H%9E))8I\$S2AXW\+=+\$+3,3&I OKI911NM\5<0(UN-I^0SZL;WC\$6R9/&CF
MF\5\@AVCAIE3W3#FVGU2T@T")J^=-?VXZ%I^% MZR-?ONTYI\WJS;I4EET(#U.OSZ)4LG@O7I0I-
R_F;J)I>B^>H)M9_ERLG&-\$T",(.W26JZ,Q,NP9FF!" MU+51=KU6+*RM_K*Z0HAUU?N"S>0;V_HWM<I=
I6>U7I2 M-ZIU4; (HI ZTGF5>I*9E+S+?2CMHF+1%4FU724PA5A&+I,SA) \$B&0I9EH56
M52I;J8QI#+VC"0JB:E&I>KW8Q9AZ2^N&(J> "#ICT9B710&<>AJ3;F5:Q3P-ML;0-D>I^FZI-NLK\=I?
#RIA.62@U@P?>9%5;9C;4FSKPWQ;I4JO5IOERK;Y M7YL2VA?>0/*I+3LI<\$?@I;YLI#4.PNUHV39J&V""6:A=KVJ-
J&>I+INWR MMV;,-Y:TYW.O.F>I89"=40D0:0B4 2&;H #%%PO1+99;QF24LSFB&K6(. MKH1'7LE;BD7^C,E-
I>OB6M52MA\J5HL%RI?IWS97P^RG6KOM=0R%.88"GK9E ML\$O.;U
IK\@YWIU)&VI_ =15YH"W9FNDRDN\2K.DXW;N?Q;H BY\SA_ =8=*J% M?Y4QJWSS\$"<1#YB4D"-
OOB%"C+;0IB(\$L<)3&.K0X_F@B;#! 5R6V9I% 2 MM4."IIVTK_@A'5;V8Y"6B_D+DE:-
FTIM%RK^A_D)=KXPDF68I5-K56RWUMI\3A".OIE)J6=#B(.I MYOLD0-7RH I.)&'RA.V?
BKIWIU^JV'@J91#J79>1F\$S L90H2AE4 4%%412 MN\;5S21&1@I-\$NOHZI7TQ64IU;K\$!BOZ"NH&%FI%%K; N<-
%7Z.OB11OW M\8I.W)Q&CC_!@R6I_TP8P)_C;ZG7SI(TM/^8FA6K-5I?5D0HC 14IB2&5
M20@QB0DDG&I3(Q1EC248695PL&"UL@H8FB#@CC0U.&_ Q<.QVUM>O+!ED& MTX@Q+0IP MMVC7A
CN#>2R^&.E1C0M;JB0D2RDN48ENR&>_A0"1-W M+1LL(OQP)%\$!812B;&@D" E.893E&4T"PC;<&IAH"(Z-
121&4)\VGSIM M6;L3QG=L.94/I\J9UU>U#I^?DEA\JONRM.C2"B=UXZ;#D\;NCX"C\3F?
MUI>F#I84MZ;1VOSO;5_TIRO;R&^W\>L/7F@_F+E,O/J^7F;W\N@A/99") M&+(81Q#DD&6,OT?
+..8IK%VE^Q#*MYLC(P\6H CK&# M;.&-?7PIQ?9\#P M;RH&0;_I" M\GLN\SE_SU_7F_7RJR>?9;I'ABOTTG;1?
MUI>YTSE;V7A^#N9_H<;OZP"<1*(.Q4QG46X9VE:E)FLXBKO_ "t\$B=3LD" MX&GDK;2B"<3^US(H5@/YP?
D"1#71N/P1'DQH#ZC"TI/^<5_M87_K^<6RV.X7 M)F%PM2QS1ZXV>VB??J_9HI0>E)-I A*(A82#709IHS7OI1
+L<I@A\@;CFA MQIB8JC*KY3^KL\4DHQ@GF8I?XVCF0;LU0^2F2TBA%6%&'CM;G\QJY6IZ MH"0X
_IT.GL^UX3>7.O^=S6KY%H7J?YS*ZG"3WDO6RH>K+>?)&I/F "4 MN)'GXY\AXL=I3X?>
I98I/7N8%BE"0A3J?%*DAGB5"#(LC2I818+0C0HD.>@ M\$>HH3?>3\$)IT^= ^00AMB?"/<3T;I(^E-#I3/A45-
=#X1XBIS@5MH=P5 EM?+<77;5.2 MKZO%XN;J-SD@V1\$VQD\@U2;UG\$*"T@D0Y!3!LB(OU5D+JX#1XC P_%4>F
M=LN.IWUJO;+S4<66FZ?AHW_I_V-D-3H>_YI6RD%T\HS4"OXPC((MIP->9>^A MIX%&Q\.)O5X>JCHU
_JRH?;TCFSS13%*42H.6 M5Q';J\$CU=QF1_9I_P+IPH-5;YBDP9;D.7I FI6 M-NK\$QC@;0V_%JA'6 MRT9JDMK%3AI
>D\;R67*"KB+4J ML8G*H\74#5S.9/2*S=0*ZQ*>Z2OT92.T;=RW\VEJITX8IVGC_#A4T JDUIUE MA<O;+&Y8?^6U_+
VZ_W0%6Y0)!\$G(20BQ1'6\$)BP",+41PE6,4LL3=0&LF,MC\V&+#!T@2\$.KHM&&.>_UWQ;5*0#8H;(8;DC1(I'>
IN4ETIRO_ZC@PO><M.R3HN.S<^K^H=\$IQ<>^YZNG\I+M=JEWDN4;SGI3_S6GSU4->)0^D-1 ME21A
BJ<<(B34;L.D0&&@K@<4XB6;GVK+B8&1TYE<W\>DP7Q+&^1%@C\;M
U9UY71.TG17MEU09U05NB'=:2>D/3N@4FS%T\$%OBH.G#OC=\$ERTLP(I9'L MZ%^L+Y*3>MH;(KFIR
^VWKVNYTNY7E^OGK\Y\J1FKX>8;.!0H0VEZA4S.2N M,\$A3K*"4*(U4&(9*6%U.\$VXX4I\$!PP<M%48?
M)ZBG\0#88@ET4F;PTT\HVCA_-JL JUZ>JYW'S4+V4+TWSMPU*+XR7 M\$*.B_T,2))D&A#"68
"C0HAID\$2(2FL;D"W\$1EY^6_)@DNV5I04P;OVS9_M>PVU+_^AY'9;I%XB.Q5=ZY+)J_I;XTLG*H6)=9A
+..9SV+L(6GL;B2@21 MD S*6\$00;H5R&*.8I0B)DA".4Z%4Q&V4PICAR\TQ1Y%V.IT816RZ">E8\3B M1\$#?
(FOGDCH68>LC\<6+L#4QWUF\$16S@M\$78FO@^*+6^""?1=I^V\N.+BO;+E_?0?V M9FU)"S\MNK'^7)I';.5*K8I-
VO?3H1&_0DXAG.N(9A+I'#\$6\$(ZNDE6<0) MY2S8ZE-O;Q?59D721Y?&6!A1BW8NT^I?<4\UVF2;S@2;&AZ7KTN!
I'PZZ2& M@5PH.YJ3>EL;CAUH-P&>F&M8.FY;U>2KJ20%&FTH57<3?ET*4ZA*?QA2
M?BIR;+S^2!A)*R&.P9N8;*LDDU\$!8);F3 @F<"3YPU(^FHY7\PY\8AIF MK-82+=?2&4OV\$4I-
IS_I_/GEU31JX+;%CH%A+UU;H='4YU?@+A@9P9V#(&" MHX.K2#-PR\4HV1HR3=)4GM62N.(HE A MB'H?
5)"(^V#T@_2AGF@L.0A6F&%Z00BI3#&F0QF(-;QIYE#Y\XS R(AB"(*2X@QWN)>^%"08V\=U3G/IW94G>1JY/ZO
V\^=? M3Q/S*M\LD=IK5PI M9M90JNE1+;2B7*3F#Z2A4\$6QHH&_/(IQ%09FY40;<)F5&22D)(*I5IW M\#ZT;_<78;
<5;.&5 I%CO_-I^#8I2MICOH4;T3G;WNJ0\="O"*CEFO"J M*-HBF\$W)T+KAD\<\$;9&AKNAGV^,>^Y8I8I?
^M%Z_2O^I;1NW16AIR_R1_' +M\8(4JF<FLSR3C0;K\YBB5\$&.IW&\$;I#;5Y#OHC8R3;LBQ0'2H';_J
MN"GJOQ7_H8>U2A MH>AV2F&K+MSB1'4X89\APR\0E\@NMP#Y\HRVYS=9\UW;U=2Y&9WB%&6
/ZH;LN.=& VI\RO.D(3&/ M8,"UF81QJD\$DX#%.N(BS.(VB2,36!E_7D8&E@.N3(W2+I>?'\$R&GEJVL^*F
MTYT;"FF^@&\$;'KO7NM;/@L2\$ON@&\$/H/D\0*WI=.U@O\$VGY.RT2(CZI
0F\$590!_L W@#&>2I+@O'L67M;I_MV6TT_#;IG_K65J8
M8TQS!*I?<I6VP2;K=Z'3U7MQ.4E_N_#60G#J\95BNR)XGL_OA="D@0IT M2K?M9IUO'KI^H@9IT0C\YWSI@*G(&
HXE\$&&\$ O!8;9;9J8QAP)&@2152O) MFG>/O!UE= GZ^U"N=F>IYUFL ?AKAE*M.)>U8WU-0^SVE=%ZK;=
(TV85-MZF\$%'I^<6-UKUQDJ7;(DJU\H>I7UKH28FR7)%G=L+CH\I?TRW\#%UD\A M-
\$A02@44(57;RPLC\>#%&990+"@E*6(NCAX=1&M\XJVL 0AY^55&0=_Q MVC5FYJD-
I@>WU7BJ@OE.I2X<?8R#N2YM=..U%>S\$0042L;Y\G.T8#IG9G"
M^>^6VH8KC.#U+VR^O%FMU^>-BI%H^F\$)1?EUOPT?RDVD3BB.@MX \$D41!S MS"
SR>^>)B"E+I^ST^GOE\;HX=Z"JK@D*S3\MM3R99QH-%5YP8C/EIS#P'U M\$GJHB) ?\$I&B'HZBQ>U.I M?
A\57;JX55>R&I=?UEMY+HXLKM;BGV\IFE MYLYT^JA=QD=9@ (DIS"UX%\$*<< 5IG&
(8(TQC%;2HDE9UX@;@9>RDB2UGOI8N MS\GW/+BA51HVT'61\$ITPZU#159LS4#IV&RK41.7..CWN>..%?_H-1&
M4-9>->'DTE\;P"5G2+?*\$-TNP>I_ IKX'6;L8ADIY?7#5@*48_ \$I+P0 M7OLE.%T)IRGWI2^%M\I#?>2V\NBD%I-
>#^&M\IVJ>&_-WA\I^6;W.U\ G MBX7@Q_<5 3V)P@A)27*M\;GB4FYJ1QRE3":4I&V+Y_21.5D7&D) OV=&?@
M\H+*M&X5@ R1 BNT%)K;0^<-(HM@>#&^<Z'X3;H;S\I)U0HTG8.G@YHN M_H IO-
A'Y.E0B3XN.HW\^3B^V\> U;UU""D\$549S!_3>IU&C(\$A3"1#"M TTIB\$;///26RB.C+<&*IF6X8I+U'0G8'G+JI-
2G'QFX90&0WN*F5ULMX;1+; MQ7P90/S+&C =K2;.\$V#)S1B.O@_F.Z'O9 EKLKA(+PGW*1^7\IL;93; 5N&D-
I6QRGW0UQNL1J19S&P=,A3A?_1XC3^;G M<^<%6Z\OU;?BO_9KZ4GS;R>?W 59")*&8PH;:
(=QK%D(D\$0ZQ4H"\$'\$1\$Y M'7W74AD9<0J)MI94_5_&+J@<QXO%6O(KM0<&_I'W6#1V;W#LYM.@W5N;F6
MOK0=FI0\$;O4W\PY\I(T)H&T 900\7_ZXKOORR;I3"-_FSROH@I*1!" M\$9@^(&*2%N5%'
A.O;/'63I?;S7N13S#3#<_='D\I;@Y4(>6"^Z_I08;M^_6L720>KEH\I FIV\9;*Z&F>I0I6_<SXR>6RW=L+
<7UOZ^E+M=EU;<I\UQ\ MD23W\FW_R\U\^+F3O%CTS\+&SQ*J_6ZI?GE^<(X^_VVODV;^Y6ZAUW;6H4
M)SHK33\G97(WXCP.OYI 3;_XA"";.)@BA-4VT5\&E&K>+I3_V#I.GBK(M#@ZGDI/*=V^/4 AT P8D8K2F\(<
M"#4#E5A F53?@X_A\W'X'YR?IDI&>IT'6+NISVAO\54G)WJ7X@-S\VL RNP^M_*;+.=R\$)\$&H"&0R2>N1;-BO)\$L>'
M\$+V?4SIPKF2G1\$;15B.=;.&E2IPS\$.@+3+M,M%M8NEVBUJ\TPI#IOM+MO\!%I#L> M\2J9B0E^E\ 7&5O*Z^J<
U%I @.B\;80Q%)Q2#D1\$;4H"#).T7LTWAJ28P_ M*88DJ&C.P+73@7JM2BSPI+>@;G\RIJ)?
^I+;RAO6YLK&N;&=7W-#W;I6\YSGU<I;UDKYLB@WGU5;Z8 M_*O+QPIZP;MP<2V0D8RB\ E\$&.5PBS.M#7#
I\$2P>.89^;U88M\IR.P3AS M0J@=?_9I85D^XB\+S>E?@9E<(ZKWZPU."J&\CK&HZO2;VTP=5YZM4-3\#8.0G

M [M: LH^+53X7I!>IM35G] (G,W=& EGPM)XOM MX2A@C-I@P*-(@VLL@': M2!Q4P!// YFEH5!72B/-
YM69F!+3,SL&50!@J&9L6!JAU!+O:0BWIM,*1 ME,:&@ (I ZC(D713G8E^,I\$
_LW.HK_120700:OQZO+'''6U: #SF/35V?%_A4 MH/LOA%#P>:7,50K=?
Q37DK_!U_ C3DB44B\$TU&H_&6(1^9B92G,)IFE,D32N MM7U!N19*(X-L21J4M\$%%7)M(^52V:Q-
4QX:93!;GC9++H/-+JP*5VVT"Z M!C_ ^C!_!L8":A7CMY=:7CIAI3,+8Y+ FID,+KIJY'H&UM>+3>KY7RUN^"9
M!BPDG,=08-B(\$VG+1PS&_0IBE4L HRQPU726B(C8Y,A"C15L"7K?-W7C,V M!EU->=VPJ\$Y40JN^!J3(I7?M+?N%
[NV\MIQX;=^D)0W?ENY/IGRV_!LD*EO M#T@3RX2V=0)L.A:GIF-QHAAD\$14R8\$R@R.H\$LIW,R(A2'-'"K,@!XH4
!^N"(6 X' ^4/+C>4NG4HMT:'U0W;LNHUA,MSM M1!TNO;V#WM2YI7;BUR2Y6P!TO%I/WAU-7>S')_9!=5,Y"BPT-
UT91%)0B&E M3:EC G&,>)"R(6(X'2IOH;(R,O>\$ 5JHC-P=>XR:Q:,39^0GIQW59RC;2^ MI^KK1!:5M13H(Q?
JF_AO-2?>W8:>_4MW!_ =J6^!5D/+ "DZB*! S#=#=WJ6 MGO0/MT4NY=7!^:5NLO-R?9F+M=?Y,--0^Y^"X:W!
I6C!D2A(2I G,TC#6 M?@:(.I54P_#%"2,1R51FE7+I^8ZS^G.7!"ZG5C M+CRRY?5+>;JHU"DP7!9N"E! [70/LG^G>
IRI5&ROD2K)820\$E60^CS\$&_ M%D5K0_63E!L^Y\$;I#-E4XIM;+!4LIVJKO!>)*YS-Z*%VSDDFDS!9F!;F0 M?
&-2,AC_GI>YF^ _KK4\$+5X^V^",2!*LO5#M?2H/X.M^T:/UT^WM237P=N
M!,#K?"N49YMM>%/2XWB^F/YJK^6(G%?W.G,94RIH7J1'WH8JTD!\$A+!A>EE#%Y*XI9!-CVT:><.CZ,C MMTW!
#V3,S 3E!?"^0J.0%I5H8L1.XJ_F#%QZT)3UQPW%4AYT7&G=_@XT8G
M27C#UK_!1L: ^!M0G:IDFLB(O3"6@2D7GD:0,17!D%IMY@H"UHHH!.PL@X MH2D"31(4-&?
@RV\NOF2=0FO!YYYBNBWU,PF!W.8Z45U!YIXB7!9A;F&^W5NN M&SBAJIS"!!&?W/;@GPWR9:5<'?PPBG,<,B@S
D MT@A3!:7C/A&2D!(X9!A?F^&@)4VS7,PWZ9@; \ /_CH#2!F<2>VH.#NK8A U MN'"'+()!OI=
P8!Q05,+OF3:4&Y M?T)N:19\$="8*!) S+3?D)E^-(8\$441(BJ7T+US.T5H+C'Z&=5D3;,>!--@M:N
M0NL#M,\$4XWQ^UD.G_0M\$-0@Z5G&H4W*7+0S5^QG4;BF<>I-0?<I!\$SICK+4 MQU+!2
R92IDPDJNK!45<\$39!0)"&C:,12!_!HD#IW1XJHE*FIRIU*J,7\$!^
MQLZKJ7K@?/KTGV#?7)\$FOV=OUQW^O@=I^!VW@!J\$^G3#FF?KD'%V QH;Q+1 M&3CL,=2IWO\$JV
VDM!XM5/M0GZS=Z@_J.FS_-L3KO (=?:"/^7H!P?WZ6!F-U M0BPCRH_!FSI!_7 M:CJ:E65F"!#;O^U;BGFA^/7!<00_\$
4QCGD.\$<^! M4!M%7T;&-I5>GI51^E8=FHT3!9!^S_KINS!_%'^60BPY>GL:4=&%D+=,@3U7HW9H!^N<@?P_
M;S8F!00!^NO47^SI/CIX_(WE<_,^:G:O=@A3#HW;##45!G0&B69:"E7D-@TD7<
M+.#HFOYLD!QHWOV4Z!WS>Q!_2_RNLG<^GET_*!5#+7Z!H4)="!Z&:!!H46
MB!4/DI3TP\$,6892\$4(8Q*0MM;#%+:0V=<)"FF"4K0PU(^FL/F>_OUV!SJR^> MEE_!&7_V4=""(3!?
@N_!\$3%0F&B"VK8,-^E8PZU/7J_!57HF:BQ)QCFI=@2V,5 P7SY8L!P2*=DS/P-6SB14,7=YH"\$4.6M>H
M%T,7*&@TA +K*QD-!F?:IFO:Q-&JIQP809FUH,3I6E5\$N@P1B10/(A\$@T MCH4<)DF*G1HN!9(9V2KIR)<(-^B!-
!V^; \$N? VDG^L<9# M'49REOYL@VC-LPN;ER8CJUY^-(0-V3IE.&D)UOVXGQ%XHVV*^C8,F MV_AJ*8K;X\$^KA1Z_ O
_KT6ARHSS*(M2B!360IA(8T@93J!IA!R%*J8_A6J MI"(X27_8L!\$<68D")NEEFGYN\$SLKB^UX09;-R=^*_
"N!&=#R%:R@O,XDFO_M,A8!)M?L.M,!2SJM6*QF?>7U6WUG80I5!^B5EZG^A5!Y:YP^8HV!CN!5!0_ MG;X1100!
!4K6A_UP(!?KK0G3ZXV>E(V!)2PTGB+\$A0\$D\$1FR1^C_7?3R6^ M"JM0ABL,2*JLX:,6Q,CH4=(\$6Z(S!(L+>M3KQ
!>DOJAAWG00I@!HVT#M#1 M6VH_Y""88C!4F=^KW"E!U!)LG
MW6M,W4H!LW3HKR:6%Z^OTPIFU%.=BU)_VE;TW2UCJ^PI/"!^Y"05%V_#LM M.UJU!9E1/9J*4Y^!^MROEE?
F1R%>:M)"!4410)GH4PP22"6#(%269@3V&_ M8Y9Q\$CMELXW)
!BX>'AK9!_4MEN08:LXB+BY_W2W_6G+!&AX3%GTPY5_RQS MYC;"G460S^,3%?M1,Y Q?RH"
<-3Z'FH\$LOCLCIM(><)E'Y6#GH*FAI!V%6 MIN%GM=0+99NNJX(@22)L^<:1>:*!A23F&*PR1,J_9_:%!#IX70R*!IG.,
!MH^V8UMRI+00G>B=N(C!L(!>-!J!<^Y_96AYL^B%CJQ_>-GXZ:IO"BB?<
MW_9Y/POWJV2+ #T5ER"NN!UU84YUWLN77/(R"? (A2K*(!)1"!7J!\$.,@)2+
M\$(8J!1'23CF)>7+;6>H=M^T^EJ/L!3=H.N +C@D!&9/=NM.:P?1-(XACY'6 M'8U32,)\$08G#B"5(B\$R9<IG*
!T9L7PSI?ZVJ_V4NK4.WY4%3->_4 F'^?+ MI?&CM0%OHP.K4@29"QF4D"&L_XR441@9FHAXU_0D4@4HU1L?<
EA>EG>*3& MBK:7\$J6VF4=2GYUS,JA""#V.TUH.(3%>!5N DJ'M!<^Y7)08SG=MPA5.R^QY M^>)#Q+1S7M;_-
C8:VC@;R#;GJ3FOC6X!_Z?8#?2!_U4?QIG6^,)\$>I7_-ST
M_)^00A>^ZOHA4I(&0F"H1*^@Q.142TD3_AX2(AD@E/!.)6RM*8LCE7_GZN,IOJPIZ1=7N*COW M!0\$I^BG##
8RC;&VC;67CT,%1!=#9!>\$V5!\$DVC?C@2=121T,92STXF=;,ZJ^R,P-K@%=Z M!LHBWUYR_=)="!68I\$&8)01&
(345>S/MK(4HA92E8!^&@D?)G_UZ7(%V^/WR1_S37H?/HWBZ?
%P4Z7CW9A0\$!\$0!O#EB.!'%.ARMJC\$F9R0)8@7#,,001V\$"\$!"^K A1Q\$).0J0!F1"3:H,@R;5!P"27_ M&-+V!9?
P.)/1"RUJA76!B!Y" M7Q8OVKAO!XS.D1,B1AOGQY#1^J3GM9W:5!"#&POOWO:/;^!T7!G_!LCFN2GN
M;_Y07L+KMNE_!HOZ!^P^&3&)MBW"8,HTXF#;4 Q3 E.6<CK*?"Z=+;
M:*R.C&\$5+;#;/CO>PQEO>NSB)W!_!OAZ\$=\$G\$.NCPIS9&^@HJY;,\$9!HM;
MM!6I<<7_#.RF!KYM*MWOX(RNY:%NX(S'Z+3W;T97^GMF_\$!>EB-57DB_=#/ M4JX?
(HY0FDH,120T9F=!!\$D6<,A\$Q_3BH;99J;6!>+RD5^V@!I0TC8_!E8+ M%B9B#JGJ9W MI=I;1Z^?
EFMV>*7?7ZLBI+4^MK_ (%2D41(Q3 H^E_R32^EH?Y/RD(E4Q4% MA+L8=I,Z,C
PIAP5>#W+QRC8\$X\$DN1)\$ZIGF5^HVIO;509!M-H5,W,*N8_47 MA!4GZDM5S,!!"#*.4U?
52S/^E=MW8N!097B!EM93G!7N?5Q"=80*+=/Y>-J M%TN5&8HIUB9.J!"6!\$."1(Q5"262-
DC2!/^ERU).8.HVN20_,\$!5^G0J=

M3JPBZ3TE=0REGPGI?TRPD18IFEMY3Z@N^TUNX!XBGUXV<J#>POE!)1+WM21_4 M",
(WJQ>Y^OO!!5" N/W!5<3!31&_ JUDV1.Z5F20,82!#_2<1X+\$VIWP(UZ
M(B,CAR\$*!E1GX!^ _NRRF!L78@\$=-<=W@HT92+_QH\$-D%0?J+?ED,:>>_'44: MQDZ(^W<^R-
J)Q!>H79SI=/_WLU*3_!2ZX?XIO+ (1B&4@0:27AD^*B8F0YP
M.\$!HF"E&K!/+/%M9!G/B+A!7X>DI.M%4GPAR\$*"JJ.GHK=&,9G^XEKV<-
MV4U0!RAPHRQ#16_/"4P;=6T4"Q:VORDOT;^IG6M7!>7Z^>LVWLY!JU7_,%
MUK6XSJER738N.ZQ!>+^6Z2TW!X/NBLH%#YBR3" 60A4BK/?_*(T4!)RR4(4 MH"@_X!2A9>,
(+%)JM@=Z!&V!TO_!9!5!+XY*5@JY^ (Q-P&J_VL33P!\$;Q_M_#NI+6G;56L/<^Y7@905HAPV)T^GF
+^8!"^69@%SR"0YH.A:J:\$X>J^T= M%_ ^!ZP#+SP8#_XN/#D.%M2E)LG/4)MLMP,P"4V6HW#DQR.G-S'%T=6:DC
MD? *KT4!2L6"!>W7). YEP0B0,\$E!/"_HE!X6!:(^!>H:3S<5&_ MTAJY/@FC-3_G@0U?7LT;M57*!1-
@!T7\$ZJJB;^S_GFR3Q39CAH(!/S(M7A M@68D\$V\$4PU"@.((29CQ.(6*J0!C#3)99AJMZ!O-R*A3LF?LZ'S'(%>EU^?
M;UD\$!S2/Q7,ED;0WG+IL(QI3X!%M\$VI=#<ZE/MMN_\$JB?I#_ MVAYDB=
(PI\$+O*1AI"Q4S\$4,2R0BF2;S;G%!"HU1"TB&^9IB2_1/8;"C FL M,AHZU&EJH#(R6&BJP)_%ABXPA&?
@UWL7EZI).S;N!0 RN^%O;A>KFZ3W"!^ MI@#R7!;H1!"@W?M&CRA^!O!_!\$!W/7P,
f=07R5?2IG_R0%)Z^G=:Z^R05% M4;HK_C^O!MR#0_-W MM3DK
<="5Z6&UJX^ZE<"D"^!F14".HI_=GVIF^YU176Z&ASRVFGZF>YIFC-X MUP.N@;FXZ)G7;!KM.@8;B!O73CK8!K@(!9
XCK&((44X@3A3!"*(XABE2K_ M\$AQE!<-FM6&+!BWV5L#0UA_M?
32F4@Q9?;!=_,%J!#F0GK@4G!M2SBOR>;S#PT_!H_6A/V22!G!L5J)3U4I M%5-.*TE# N/\$=%-2F&F0#C/M8F4!9T%
(!:4_AVP@,K9!5%_%.!+;S*!H!D M&0L_9@!YVW=9_G:@^L9!FF1TL_%DIH/+G;;S7CND*G5Y&T;YVAVL!D7G9
MH:Q/E)F0!JU6.5.K;J:X>OKV^UWI8V26^F_0A3&^F!H!H!BBJ!IZB9C)G&_M^X6-1;.&6DT85!HWM;2U!
!;!U+U+5%2S8!YV%D=-,=)K&JHLX M!KL\$GH?1 MPV5CS!TRM(>?6!9/&

(NEN(X"&W00)H+^E|E|Z)K+I=UJ.>=O^H|L<9 M#:0LDB|33B5&63*9%&F\$NN"\$F|5<^:E(C|
IX:+X|M^E>-0J=-^/6A1E MYPP-(IX:"!W0G(&2*OAC^|C=))#O%G(@!Z>%T*3N3+?I|Z+Q8@>N95WN6D.
M9L)557CK@4QW4"V6|<# MWN)?NN|JP!=00_J|T_-Z"5_|>".T/>R#++U<(A>D-^Y%+S6U1E^&7^:@D
M\$B629S# 0D|,8@590@,81%@ADDB<9,@:7%HC(8P0)65P1H&?G&F#8M6:#, M0+*|4V3V#Y8TR: JP,I<-Q"^^#-
R0R\$*V5C|J&S|=EE(<01)-L^H=(Z MWY1%2_*Z@16VU*,7N^V=4P25E 1*PB**S|36*60Q9E J\$K.8\$2)53E=
M"UHC8U-!>S)@RU|CYHO-HIKOZ|U>\$&5 TT8;U6'61LBZ|HUQQ\$501/^ZB* M#85)%K2#J-6:=AG2-
T;Z*21XIOBO/(+\$+E96|H(O=:6EX"^.VY+9D!NPVIA|X/A^V3F0>U M8AP:_4/N+=>O| %59Y?B55Q|?
B|@6G+=NOG(T?^| "M2X+WUKM0@8?L;Z"^^< MVT*XSUE1\$OZP6X^=K\$X=TIM%|NJ*7O.ZR3JA-XMRV/VY2F?
2|7I VXOZ|V MV|2\$JZ|5GB0/64;U%F).&B%. ZQ|W@1#%20|8D%HBK81_H|J(R|M#39&&BR
M^R2>JZ|N(>|FY=A\$^@<0V6W|E11/Q24*|3?)|I+J|T|^O|;O1Z&.@#H\$*O|M*|H(0^!W|Q|
=#WLD^R@F63K|H0|C6N6|J0^5(?QIR5?AD\$HA!*&.(R% M.89;#2DBD.91#602*4M+|VTU0|2U1(:HGOW?
%Z0=3G|H|9|2(:JPDW M;|2Y|).3|N?9WA|1^027%(C|E6.9X|7R4Y9DM8B|B>=^H@F\$)ZQE M.LZBL|V>LF
==#K>=P..6^<K^FGF10%2=-"EN|0(|"6JO|MT&_F1ZLR-D7,%F|M@=&_A#%K#PPR0-6(>C^SY^U^L\$@6NY1F6
8^EX|@)|?5CG+WSYH^INW*_*MK^7|U|?J3N;|*G_7?|M?G7R|\$-*69@\$D^*>JQ::1'6&3NVH<4)?IG\$5G=-M%^G-
R>C|UATOIFW%0=G=7>N+|I*|LUI>|R*A4TPE:X=8|5(5|2FH%#Q9L<M|
(JUI0.FZ|TH*FT|1|>1M^S9?E/KKAV;^VN|H|US#P)3|H+NKX>3QM\$# MO-#GH!"*+B1A?W+|B^|X|A_M8G_?
+O?F-Y81M7T;0/VEK>O-WL;D1QF)(H|!R|J+\$T@_M3D@&=\$H\$B*&
<9@<0BEOR<^KH#@^"KTR|Z@Q^;_D\$Q:@#>3R/R7R6<@Z4T=-% M;=*D/DO13Q|/;(?
Y8:AIT+^C*W|SR3FE|_WE0YXU?^M_0^ZTU=!"\$6\$<@XQY|(+CDEJ0A#AR9|11&7NB:(JA(SL#^&Z>B_C7ZL"!|
M>DKIMIA|12K7U_CJ5/KQX27IAM03\$S2T+;@9.Y;Z@F>^35@4M#|KG|U|_MF19;_?|
V.)J?M^6V^6C^WIDQ\$ GO^X7|V;U<-6".Y^+|XC(5N%YI_T7_TSQDGYCMK?IVU)|^ZV|_H^|I|Q_83JO|+)|
MO8E.EG+>5RV'B>F|W^55J_!0W|K|5BP78%24@0Q#)"|,8951"S@*\$6I)_2 MR932CE^N%5,J9"R"AF*
((!@J:SL5|A1B8P_U%,-LXD| "M(4R.J4S&_M?B)?N!|_,=16AJ|DY9@*9|Y/B,RT/NAM\$Q5|SX6?;|TQU?
5LSYWC4R.O^MPT^9|WE1B<"Z4"-;UFA+|4;JN|H_LQ7+;S>LE^JC3UXUVAHG
M+QE#\$^R(SL|G|ZVR7BLV|FV5O6=T6TKF87OMEPU?@L&/VEONR>V8K^<^V|9OW0 M"??-5MZ/=|V1_W_(:8G&S|?
Y^<M;S=|H|H|HODUS8U"P;2AC3(:41";6A^M),4T30/L=,901V1D|F=J.F2IMMI0ZU6|\$X7^LKJAB#|@.2W P4!
<|@&3 M9Z#^#@EH2DQX,M EY>A#0^JS?&OS&GZ1X7?(R|DBNN3\$SIV_QQ.5=S MSI8;
f<0@9;4LB#U7_0T%+|AR|?LP85_T+L.UHR(HO%;CA@>|V4&^|W
M0Y5#E9^KM|^F<@C/+E8E(8ZZFJ4Z3K^SJOUC|H^;C*_4 M_14=8Q_B|CH602|M0T04"9MD0BED!"5/;
(J&2,H>F.S4D1H8P31(8FJ @_M.@/W_W)J^-.G\$QMO|H^D;J|Q+J|1?6YTZ;9T:ZO24^L*M=%JX|VBB4S=RR08Y
M+9R?_Y|>|*OJCV-ZOK|/P24HB_3"8R"D\$.K<|H@X*L3A &\$-OQ&*>8L_H|@VBNY6W|Z^"2|>W
M;Y>@H|HP^A)*IRW2W!;XK|C:=6H^%Y|TEMA:A 1 \$,HC#1|H@G&D*!T;^MH^\$X_6 MHL3|=%ZM%FF|M;C-
6;C;CW:S|UYZ|&69WVK6|Y+3LFNU6VK\$:#12'51K MD|H%+7<"ML-#/IG<0*^NJ&6G>!
|U+|^EZ5+|JB>M8GHP7L|R|G?^I5|M3;G"(TPSRB|%)\$AQ^HAD,DXAF&0:H2?"EDWTRFB 99UV;_SY M
61Y6USUXGH7L^R3V|6_94_Y>O2PM)|YCP*6+&0;U%|!"L&SQM?H1+>";_AOB8149AQ@6\$HTX0A M0JA,K^IY#1?
2R\$|VS*YH-RQ^\$H>P5|_EW|9L|Q:@|I^G7(ZO:(TO&Z^0 3 MUHZ7EYD&-W"=:@:<3XJ4H_A|8#,#3I^?
%P"CP|2A|PS1Z677E-|H=|W2W M;49V6|2&*WLLKPYZ+^7|S|6Y|2^B\$C-(L"<^>7+|^2\$8&624TA7@I#N(T
MBNPOF_AP,#*0Z|U<,"\$O^1H81R.K1DW;-O>P3?L@/(H?4#(\$JLWN#QJ=SY= M;@6N7@Q|1R_KW(-S+RZ0E8&W
1X;U<+MQF@F5,\$^82K)^DW_11 MW%1<@L7|L|0Y;M5K0G_N-YC|H^190Y_*DF#YS-R 7IDR#WK086?^S^/OK
M4D/XLUL>?F^O7?|K*M^|Q>|JWM|>+L/|^Y)M^;K)5QN9WK|T M|O;JOX_M3J>_L#N9OV/K.2_Z8CZ\$-
).IRD,\$ZZWERA\$D*(O)DEH4<1S^U M.C/T|IVN&%"ZQV#("Z_4JS+VO? WT_-7J|S)U34SVTW/=O;VB-IS)/PL
M&#DRH|TN6=G9FI^@H(C+|T9;WEX&2P9WHSYQGB7;LY3R/U>XW5#C+@_M>J4WW41N;BK;@4H#B7CC
<=|3JJ8QMPFJH MX("L7A1N|H0=&-SB#*Q&H(4>LWVVOJF=|HOUE_|!^!>BX;18P;L_M8^W|G|P;ZWC8
U=^,14IEF;^?LFUL;SMRX1Y^0Q9Q"%60|Q3|C,4A,<3\$A M(AXF^+0_*DE,3*B|&F^1T/4O:57O6(L\$*6WN&YPH
XHTEMB M/PAQE=P-65J%;H65^I^384HKYT> TOZDEY6"PK"P=;|^RC^7/H>@KONUT@R
M\$9E*PB)&IAYY#^EB%,8T2P*LE_#&BX_YTD%N_-|;6%KM8;|
V^+@M)5WJ_&R;+H4X&3D#*L8JOP^%%=3R%+;#INHZR|U3&D>6\$IU82;C MW #.=#_?
=P>Z6HHKKC^%UX4YV7@O7W+)|RT.1|W+|^E+>3Y2M0ZZ^CE?Z|! MQ.(XC&! 0@EQIA)(:9@&&0)I2S<6QE5?
7F9&18_*>Y4%_X_0W|88A;KO_@_M;F|F|DF5YF;CKG|SQH?|9&Z+^#6DB|W\$A_=,^M2?_B2@;YB;*CP;|H5^E^EB
M|?Y9H04L;NOH4|(^H8;=<|QA*\$U,+1^?DF9+|DB_-<"@=HD4Y\$&D%1|\$DZ M%|ZKT8>-7=532C<_!70|Z|3<*FG?
F2+HV6C|G|2F M*8|^0GV%MF|O+ B;C;LL-G|Y|N 95/8D9"/1&0HX|N|U6^9R/3M|C|? M EL5#IPSQ5MW(|LZ-
1/V3_%6@ZLM<_X"#IM%?V751Q;\$(-W3W7U=^V|KOO| MRC>|H%>K-AR;7J_5D_?R7R^\$|6/#=Y!
|JCF_,9019)*@Q>1^822D@PD3 M%;X"A/KUNNCL.B\$DPXFQ3@38F%|75S-?>+16L)CQ3HH M>#=#93@?
#BBP|^0"H)|+CXU#F8DQ>?0CH|)3Z6;W|JKE5L_Y^K36=ZC;N|C M=|^7DOLUJ<^;?^O^<?
UK2HO_X+WEE>66|^P|@&^V>MAWRN5U5|W43;FY^ MV|H;1%\$^R8UG|+<AHK^0?N068GH=-
^);7368KOEPTQORQD|H+|W7|Q| MV.LGMMFYPY6KUR.ZK.B1|3%&.(@Z?1#^\$/L@Q4C!&|!3\$P!"|O#@W8R(Z-
MDBXX(#P#|R|U;9KU8V%+^B*UVS^M%|@GJ^<2X+C^?;337@<*&??V+|^7#ZN=G^C*\$2RYA G 828HP3R-(X
M@900F1&F_R^,4X;DB;?62@20)^Q1\$G0_ZG1B=6K04U+8X;S?T.#NJD
M=3HYZ^GUA8|6KCO.#NH&SGEX4\$+YR>G|VU/>J#&|SH*(KO&5|LW_N|D8 M9R)D%":I^?
2K0@/(HC\$44282&4>O(/-2^HHC(P9)4E0TIR!?!1JU"+|^C
MKYAN@^\$FH0|>U,^|/5ST%=D/+>PGUPT^VJH18_:@=,|10Q?|H|G1^H|O;,"D
MH@B42E(F;8^TS6^J<&F4(^@52!"D^*6**%5=N25BHC0TA)MFHL#KMV%@? M^CLAB?
UXG|7|JN3V|4T6\$_Y>Y0&LY|V(C|@+6)UEP;K&SQQ;_6_L|+@|4| M|^NK9W>&67^
N7_@VVHA^H(TP#%1(ORBO>0R|1F!&8T|H(48XC_*T7PT MKVE^T|K+Y96GZSAWS8^W2PA2Q:@?
S^*@>;G^W72L=^<5_|H+R|>BN_Z_MUD^ZM|MQ|TW8|MHV|PD;M|J>M0H M=<=EV^8SNQ4YD";
<@J>W\$CRK=K2*VB%CGI^M%ZG&T2IR?>6-|B%<B|KH_EEM5Q4E>U*4MLND0|H;(\$*8."Q#")\$*.0|91#
M@90.4Y%&^%D=A|B1&WEI%|2W5^!|7|8_5O|Z TMIF3|A|32|A3V<*MS6=JF% M0|^@JMZSI=U=L).=*|R
VZ2^W\$ _QTG5N;|CKMQ"@XO223(J0WYBR& M#%;<1P)F"D60AFG(\$L_N<7#H>=YQ3&/NO4%+VO1|7HPR;4V%-
*M|5Z^J#? M^6>-|S^Z^G^TDOO 99S/S^4><0.G/;%LYOOD@+^E03^3X_1R99<@_777D_2C/W4;DD>?;24"JEMGV-
Z;157>|J8D^Q M2|P;SZQ<@ZUXD^PE>VK.Q\$7.DBV#FDRP|S 3SHBG|)!9"<%CC3G_-9KHV%+M>?
BBEKOP=1Z&40SRVSU4S_FG6Z=|_M|5@Z&35DT;13RBZK2%_17&%R1|^|* M@_Y7=\$7C
;:"#201*@\$)SK\$21^MD8_P)RP\$^N,1(\$2(HU9|H(C|G^R^N-M|H!O8SY_ZU99H-E3K4)E15QKV/S^HXH3U5;R7=7L
O^IX6_008WXW1WUZ MH|^BSF9G^Y^K 7L|7W\$;9YX202(18 M^2D4)C5Q+4ZR M^|HTBG@F;@JP PH/4D0EQIX-
U#_ZU^~^HUL|H^~^IFXT M+BE@|^AS 2F;|H^?B)S>9D|C(R RGI_|/|MM8F5^+^#-#7-251 SW;K5C
ML)^+0GZ=S>|^#F7^RG>O^BF\$M OUJL3/&|<881@%|K+EUA;8Z#^C""8\$|V<|^Y\$3?|D)P M+|YMPW 6K^3SRB|9?
^P#?QWYU|JHT%>6)80&0X5=O;9")+GWVY M^G_H|^X;1GGZUZGY|IME_H;TGUVB9|_|
|FB_7^A#7|K|U/AF1<4FU/9S1E MF^2IPCD+^*9\$F#|GBN3<;>DMYB1;6BVK|J|C;9(YV SG0QR^P81S2@MAK
MHFHK=,A(U2%;X#E3%?CP@5-5+P^K|JO;NGK^N;J7\$|P/5KUXM<^X/WM3|CULM9JK-

VP^+HMFRIJ009JG811BP6*)0IS^I%6 M&+8A1+,LXS1SSP1I%3,RR1R42T859*OT#M(OXUV
SE0S2"P8633@MB',HJA M OAG\$/X<0/TX<-HYR*P3N)I7ST=I5Q\$<\$0^EZ V/J>M/B-18- M5Z:,I=+
M2KU>R/<&0OV7AR1-0RIB@AF7AH&DTIBF*L''Q%TQ\$7G\$0I G'@>9(Q/3I@OL M,*;)^SVHLV'M
3X=+82G2;2SV'=84UW GL18E3;"ZFF#A_5YJ< Q MZ_VI^DO/G=9J68I.MI-
KCI_7E;EF!:/Q7JQ^JB>V&QA OE!!HJE.HIQ\$B09
M)J\$F.,IMYZ_1#TB8UI1P'F4.EC\$1%6+&*57+3<"H8<:D(MZG*V.Z*=8#1A M-E^T-WJLANMM#=?K0IZ.(7Y(.?%
(YK1LT_6',"3Z-1S=%I.@VIZ80GUYXX MCT^U?
6_BUP_-9I^*)>KQ\$UN16=HDH%+L6V\$QF@K)1(2%/7XB040QBY/8.&8J MB.)8Y4'FWH2Q6I;8WAN,;%0)KJ&I<3#^Z-
UVS HQ6NPS@V3NMRQ*P M)FH#6>2ENZDYP+C45JWK%I/V5W/ (TY H3EN0X#X3Y?T0K3FG*A7J
MOCBQWB/3R58A5&M6D6W-MDV@/E4)IK="E5Y>#5+&?JN!^1_NV<'H(1'IMG
M2Y?)C#AH>YCOM7Z;5C.3/8KFM73B?>)N,@BV15-R A52S>;<100BZC5)\$, M,ZK-
2R\$CQB5.9(1EEJ@T\$\$(DL70^9L.D0GB8I'@/B7+<)A016@8)P\$!)PWB1B9/8Q(M.)'%K4 M;!
(7IN@+%%\$8=9QBIF*1+(OX^H)^6=IHTKZ;AI73L@:79H?DT;GE9X5;>2T M*BF.1)3R1&%
F+ #4(ZYP81)R(L\$7\$F(J>LIU8)8WIA,Q+I5*2=&<3I8UH MF,1/.*<(202SJ
"*)+Z0'IQBK0VY2I6D)TMG+8BK4WOLXJTU@NIF"'+*,HIY ML62RV,P%N+G;EH6\$:2;3-
..IG8MHIL0QC<.0LS!:@4923+Z=JMD0"1J-ZC M;2709TCNGY)N+M*\$YHY+U7K%-GU4H8F4?
MMY*7F8LLSX)B).C&^B.XVYIB&669"B 4DA7@I M9 YE,77RS*U7(MI\$.R3?QNBB<3%IU^YEDD0Z#+!A"85)
M1#7./'0Q M6)NRL!:+!1.E-)58SV%IJBVL5SE97P MO"S^2XE5-8(*+54I)NEKL?S+?J03'FV80/-00LB_X^A201=
I=I=JG_Q+A.6 MI+LB.BI'=UEEF;PKOA2?>QZNAW7+>?V6=5I3N1.QAXI-&AV^I6W9_)P
MH3(194T*9L>EA)S.E.V19;><."*H. MQQ;'@I^M#0I@IP^0#XK+H>OPG *MOY'Q2D\$?C8<*I,*S2#_I^ACGI
M+NIV%P^7;2YV^HJOGIO/"NOZBE\$70I9.3/ EVL;GME5I/V=:/0/E4T(5 MPPFW1UM19E.R).MD)PH@56E>J
MH;G1#>I^9G?P1T=W:@PKFOH_+C5"&U40M='JRU0K=3V1/;@S8YN5SV=QSI MPAS87J;I=&KJ
fCR=HJL+^9'SV^I.G@6&I+U,+KX.LL3IG&-D#%1AVV.OI:1905@!^T.@P@&^188WAE0GP2JL7^L\$?<
V6E17NS;%IYI0)FF!G7B38)\$"NWN=IG07:+3V5A &N/8C.N@ G<)\$X.N.<X&=#@F&-
HL,\$+96*02OZ6.2H\$MGZ"M#D.;I19.*R)/IOWIS<5-%'?'% M7 '&TV9+N".ZR1C + #0SRO^F(3FZLI0?)>6SYD\$2=I
(CA6VK;# MU9IBH7"6L'L'XA,-6&P@X<...?%BYZ(?/1H,?)%@U8H^L&*K8QA)5M;,@>SH5R #B00I0E:5+GR 'RJ2?
D MLL3G,P@LINOX'R+NU^V38>B@.0T95B',1\$) GF<9#<C&0)45\$2;.'4=J3E M.B.I-\$8>J@5>H;M?(<?
ZYY9P^:C1"QIL4QY#I IT<8X1KFB%I:7 43JGKW M9XGS91^BFC5^?CS0 ME/FDQI^ULCY_FI?
%4EZ* W58.AT\$;B%)K#A.-2&)MP(S'(4XUBY(HY\$PPI\$ZV /E&JAT2I1 M&L\$S"Q-
"/E#B/LQ@'@<@)58JK^BN572R RTDPN+ M(HH-XQ9%# (71CTID0<-\$#="APL>+N(*'1HES-IX'
HFG8<'TWT.MNBK; M/V>C2WFWU1=4LM&Z)I/L^A6%PO9'75AZ)<+=5JMJQ;F%TK/5I_-3*, E M?
ZWK&.:16MWI>;M<:99QC(>V9I) 29IGF*>T@B'-(I)PI.0A. SA9\$T?T MXN;1 \$W93/=Z^?G>:62S6 IL1Z95"@CSM-
D=41%7P^~URI\$ZL'GL(B@I. M6_5C:)>D'UZ.YZI#ZH=;Y1V2UOD*OC&(+)=%&Q>I!72&FS80#/#I@Q-VH
M3,I\$ =3VNFQ>H/IY4CVW<@HAU+RTEI>F13GY+V.+I.@D%T7^RHH9,8Y<;
MJ9G(5<8#'(=I\$DEYR+UAS+*)\$4\$HE#2&=A.XDC.RI68EH(Q+>2.C<BFG M2SU1PACM%*!G'Z%SI+
^0KT0OW0?H5;E+ 41.EIX:1^A5KU/^PBU7^CG2HW
MI%HNE7RCS;HVKZG+T_&4=UPU\$.N"40L=.DH588\@HQAGE")\$TVX5(\$,PTQN M/<-HSC03;J'MW-
#C"GS=%I;Cf8@-PZQ*ID8V"J!; ^L(6-'L-& MB_!D!+!K!(JD*?C*12QP5FB%_!+C:QZV(HIC>%NM9^64VGZM?
_K7M D.-M'IY\$3BG-F)^<0/9YDF8XRF2D&I5I+ IM39N%G.Q<6*%H+ 4* ?(OR%NWO3 N M+D9 N+!
WH#4RJ#H@0SQ-?I#?UEWHUO_~H^C9>V\$3D>WIL=^QX5K 5R/-I/% M;*5N3< D3PL0#RL--QU:6/R?RFV?
&6/*0Z-3S#4TS_V#"C5"/LM@&C;TRJ M. TCKIP:L0^@R1C,=& B1E4=2, \DSI6=7-7)K(9C-YJI7"E3JM3IJZW!A1
ME2 -O3HINV M7'47=?>?P9JB)#7C+@F0)DG",.I\$X(BRC@ASL9I?7XNRIN9J:~FJA MOBAY?G.+MGA7H.*I
%ZGf&1^QNP&8C"/<95F(0QX9EX9*9-I,IB(A\$&FJ^ 70BS7/JZ>*&SQ4.4 MTYD<8I#C I.TDQCJM.TT#P+
(+G)D9VB.VE.1V.4796J YP MH);#3*%K5"DWC7TA%163V-FSSF)\$>P,+I;J;LLP_V\$Q9KI+;I!<0E' IN-M4.
I7GVM JE14(RF61(\$6&9A:%X\$ <7.EGQD(N%\$DX3\$B5-;9C8D9W\$JC;& M=C\I:8=0U7>,5&F1-ZF:PSB)H6
LIU)9:12HKYBJH/8.I02%M'NA?YI"VC-# M@ IGSU=H>"GT2LVGI/R_I^;DI>I7E(@TT3&D*R!#;242SS/-0QR75* 94C
M9>3'ORMEWEF:RI*)=9+0SF*KQZH"G2.LQC'.>>8Y"+>2RJ M(Z:0JCL,M@I^'=I^I."3VHQ*Y9H016)%L4*G+I)9
T6.18+QC'7\$=3U#3. MPT#@D'6.9EFF%&P?C'>I0J!S:1=S1(&^4.CQJ:DE1J MWI8IXG\$A-
L&I01G.D@H#\$C3(>@>,5H1LATM-4"V2>15H_*A"U;76P0,ZI: MH"JWZL"VI:MMW3;L"1#;:>5C8IT<&:KN%?_QLI'
&QT(>R*&)4Z*3D-37%* M&J#EONOE%GY%I;A\$&FJ^ 70BS7/JZ>*&SQ4.4 MTYD<8I#C I.TDQCJM.TT#P+
(QX)F4*.Q+QU&1L'VBKE/IX.IW05C6TU>T* M;6S?ZKT0W 6&@C M?D \$IZ+27RTGS8%: L5&7 3PKR/HI
:LQ&I@B+UUMY@#C4MU9 MURTFK4!SP):B^:RO(>CXB"/BFV6LW5IIO?E\K#-.JT8:94Q)A0:N^*(\$FQ
MCKEF2LN4"/<1LDT1N8C*Q%M1\$ZAWT\$/'%OVR"%OIAIN_ %VJ&I%
"146(2.S12T5I<1>H7M(GI0VRSB0Q@IX8;S1 MI-6'.JHP^AC.Q^#
)ZW#!6N8"IDUC:UDI'+1>T/Z*72I=Z..QV#&J=O/. M?3G1KG?&6'K)RL V"NH:WD1V.N MUAI(UB"
_SG.Z4:3\$1X\$UQ'I@19Z;F7AFZ6-178Y;"&B(PCAO,*Q.3L0 S M2CD64;L6"9HPC4H)CL1.Y(%J);
(C3GL;8C@%9#XC@>.P0G6IX=@H3&(WU M@/OBP5B+I A=CL=UTX9B+5J216)MUWEPPVIL;-) 6I79A>J-YT
L0YH\$QC*36P/I.T-08<^ED'QEBN:#OIZ^I-IN.R5SO* MQ.AR"IMR1)K;L7H_%POP8-
NDO>4(COL_&THCF(2A83<6.IP3SK*TUS&8A4T)I#I5*99QLA:TLCL MT9&LV2HN04I0K+I> I3*UIHQ@N)5GKC?
MF I5/HIBE>>F\$84NGIL>12>E M/OSQ1Q \$T?678B'97%W_L?GE<)U*^&@>)9_1+N0)9@J>&99+%F9W' ^"/
M1ADCITC%(V(@_0&I/L<@D<-))5. M1-VDTKQTOE+IU/V85+HOJ>R4FC6ICQ0C<:IRAD489\8KB1-
:N!!AFH="YMVAIC\#00-LIY"W:CZ-AS9F&IYAP?JGNXY7:3;+JN*M==>J MGS::H8W S!GLT7U1KVYWI/A::J53FF
LZP1K8I'W0H;TG-R/B>'25I#QW8 M(("JNX.D&V+)^SO>\$' X^Z-ERIV"=S3+QEY6 J.R02-IY6>5*"V7>LQX MQC
)1&ZH1JHG7#-F=*4J@I:F^0,#+-(G(B\$25S"OT_C=(I-ID\$)=HO2=, M&+6<(20*U)N@0J+TGI!?
D304+X/I;F!&#PWJ'W<63>=;%?;L10;+ZNNP+, MY15V7I.T0%I(CZI4RR^JW'SIC@,1LIQP;+R5\$).
<.\$R5T@%60F4D#I3.G.8N M0H2.S">?7M@<3^I)R;5I>841#0(KM,+I16K&B=05?;.*7 R- M935P6@+&\$#-
E*3B)G#1I 6*\$TOP&T%H)V0_E4"Q4GU0YO=DW@J?U9V^7BS6 M;%
HYI>E8/Z(5#&N@D8R+@&6VY1F)E?),DX3A/I0C#/:I&C@I'*\$#I(Y/- M?H3&W J^0LHC6S7'E;I5A;4GNM
_HL+D=W)QC0BCC8.1)+7HJ@.XUJ M=>I 0Z^GL1 IQK3CGI^UM#VA+EQO;H=-'YW.O?%>^3Z>=,\$J%*DIP-
M8(X+XLP"@PKYQ\$F.HUP'F4!SFE@1I?%898!DDD;)(S.P5;BI^CM!GNXQ(I M4<)
(A2@7X.4J2@MBCI\$+JP.Y1VY2^T0&E8.&7CDW:J3J==%SHU<_2V^*
MQQ:0I/PW18YH2E>1.93DE.LLPY2+&*D@)3;P2JHIOI?S^X_.\$48>J@6"&B? M6<*&WKA@I'#,32 !OYG&\$\$_/M@?
>\$&FVJ7VC@2I9LR@:~3J2-/!00%I07ZIU5DI 22C5KHN=:K"K%:+33?ZW55-MG9X4JT>U/I\$#L.GIR>11B+*M
XPBT..B1-I9CG1=CIZ%L9)F.6OP+^Q=LS/MHJ7*B!NET*V#&<"@7UM_-1H;<:DOX;IC76 MZ5%BI MY)2<I?<?
E=E.M_F"5L>OVZWE &\$M#*;.)5I4AKUSA7 M#7B+@<:9R M'@NG+Q5=0D9^15BAR\$I M=@KI'LDGZ+
_BI^:~^*)H@NJ7GMR;&92>W!OI M"Z>V4Z':9-RLA4HM%>IE7Z/DI*O5. Z,,@1D M&*4THO7AE%;8 %(9 KX?H
>.HQJ+J)Y)K6Q=.1S27ICIGEXL4PNBF7JX<; MZRVY3-KKZ_9T_J^MNL?*)#I)
HB*C&)B0U^>)PRG2LDDEDRPT&DF3)N MD4GF4"2R.M&75JKCAFNU2C?%#

(\$50BY@F,XIZQ*6K@C%K#V(3LS?H%)ZVTG MV6Z70&UWVL7K *8\$A&"E(-D#I(XEU@E:8:)(@K37&H\$X)Z+(\$;\$K
0!9YZ2D!#C N30GHN16D M4P(1 \$GJ3)QAC1A1YZ\$.*=1CA.2 M1CR.RUOP MYK0/6^X\A:<->QI-
N*NT\$)5(P(>=YZMVSV;R71;,%!^O&J97;^3;BZ10A=N,Q=OT\3+;:@^MYP>O=)/R.T0#OI M.M:VF5?_YC"
(VATSJC,5Q(SA1(3:5E-2G&=A=,@SC+K!2?5U872V2>6+E;KD4,Y10H\$=1B FUH!2
MS7\$)3+D29ZFL5,BK8NPD>GA:\$*Y%8XJZ>#FZDYV<10!0UD*MMH&*+/(96 MA//6C1715+CU%MI=TO;U_C,W?
KO?UP^&DUF^_&@G+=JMA:H+S3,14XRP.M(-/V)PFF)CS!*0IH'-(D#*ED)X8V*2-
OZ5HLVLN10N\@P_U:C>,0DPP!&;9O M&1%ZCF0B9*9H9R4NGY#.+OIR/3R47V9E?80
MW;PG/RQG)JSXH,S_2(QO'>&N?SIH!<=&+7X(P5!&A%U..+P?DI)_M4T KG M\!M!^T5^!QJM*LMB>5*'NPL1?E(?
E5 F-) #W)LY53*HL^F LC,N.,YHEI@!M*'+,4Y+C*,UY\$\$.2^/L.Z8/^*HR!4?>"8"Z1ARW=/'MQ+03;V14NAU8MM7V
MM4(V_<*,56Z0I4^Z%^*+=;\$\U^&"P\K3)0B."AP*2!@!^!3L.'G?R"#)N M"
18HZUO:THO7WU9J85@G;Y1ZX#PT+ _HTPB)(2O?< MYOY!(U_).1DM=Z*OD-H*1UHY=EV^:"R'N&,@\$P
Y!\$+_0#13BYZ.QAZ0/@Q MD17(A!2:1B\$0>(G>%U_K1(A(%\$=!BB0.2:FYJ8-FO7<;XO%9VSN!82L
M'FBO2(G^K^0!GG V6F>.,IO M=%WJTZSZ+@@"K8G%SM SVU3.QTETSB-*/<3GVAF-I\$S%3+E"@N2:(3
M1U;5C3)&WK"U4+25>H5N1B#1FIO_XN_W1<+VY4-.+T:5#<#AK2G1@WEIK14@U1^7%\$1MJA^2:."+#XO;
(U6VE^?3=-S3*O MIV4V:33R>G'8&L3F_FARK?FHKX/-M=?&?SQ>X?V>+GHI!9_/Y0Y@PDIOH M\$YS
@D9IQ4^!^2)SOYB*6GC_T^J1,*NW?3RP_M-1461CK<87V2-AE\$WNWS8K4%:9DP=PT
:/%3IXX/6:*U2!0BN#"FUA#1=S MOIC3&"B:GU:W2<1)7N2QG)Y O(P2/DWH/=(H:~650\$!&6%HOX2"/T3A,Y1-F# 8?1
M1!EF1&+9Z= _XM)NXN#JIMC>>8<)>V1.1(#GNQ>ZT MPJO
+0E_9^6C<=U7Q>)>+9=,J%TW,R5RI4B:XYASCHF.DD+)%*J21<92IV M:Q\$S6=3(-&1\$HIULM!.\$17/7:2L'HAK,
C'N?>P051G690508=M UGCANG8' M%12*VKKN,&55FP.2DZ(VFQ4^W2&6Q?1\$H_+T&,\$\$XPT\$D-281#3%G"<\$Z
M9V&6I&&JE7OGG.-ICPI6V&0+G#^V!UHQ1\1C\$>VMR310QF0:87COZQT MM!5?GVL1)K%>-E@W30Q1AAI^%Q
8U1X!7011H>WW7GB*>(7)X/%+^TP,/E M?%;%_H_?R@VMLR2CDIG-
2F3,.05(@HU'8+9M2E4HN61IX/X%M5W.V'E6#5T@ MC&S VZ1#1 !O\V& P19I"V:25WT">.!K?Q@C^+D T!
S".XC*S3.^A8/IVG MHLB^%=K92L".CG*8R&*!^%::Y^_8!UQ1+0JY+ZH6
M01*),"Y\$B9LB52"C31D/^!0F7;8INZGY>V"!F906JL:"26IR^P3(.L!M>&.,T 35N1.^Z=<=
++!OAU^A;WKX_8HL&_ '=+F^OF^MQ.7U!>J?5!>W7.O! M,&1N@R!*/ZW6;+EZ<10!.,4#+7D.
@.LQ!.\$LS#&@&)&DB24)2Q=AJ8WB1A M9&Z11:YA5Z&08*\$A^FA?%4_UAYNWVA:2)4YD8J@GL^6-8TP
MY2K1.%T(&@&0)HF!>1(J9F02!>6B_1%7Z"W\$16FWCP=#(G:QB@-@V(H1FY M@%T&L8?Q0
?/8QG+N+J))OVU=,QSD4\$11S^6J_(8D1M369MK9WZ170G"+9NTC&(5J?CD!LO.T
MT>E)+X#KA:Q2WAYTEN4B4A(53\CFN68\$4_+1GME+2@3Y< MY3K1!O/Z-W@HW?
U5MOBBRE5=K3Y;H/E)RY%[_V)(CH6K41U8:~!#16M9?+1O M67S:C0.9>HBA#'.!E2&<%@#;_CE:T169&1Q&.!
(L.L^= M1D<_H*T^P+Y.CN:~!>(&#F1F// K#X:U^Z#_K^6Q>J!"IKQ.,EQ\$%*&B50Y MSFTUA(-44:YXIFD-P1J(C4^E6
<1J#9%#VSM M;G:=PH8PJCW++1C9BY+?UX6Z^>WB!U4N4K(PJBP5G*CC:U^+6>V1-708FD6<70Y48P
MP+T9P.H.GN&TMH11V58W5"*=MJA0_703C^T,1O5L HN/IV(V0\$>Y13F1_&M)W@.,&JU.*
U>K(#B).G.RQW.D<~!>("W12..WZN54IS85E,7>7WW_M,2M M\$M!,%C:%=_%Y/!KT(634O&-B@BE-""8Z"#"/L@C3*
(DU33.6QN8=4ZS8W.TO M=A<-
>IWL%#>@+;F71BA2<1;51#_CGY8E14HFM&PIP+@W%\$,8"Z!O:N"8ZSU6JNWK#YO-RG:&QR%G_CZHGS^+L0G&?
R=UIM,S*G.B1_.EL1?C A=1 MY:YJA?IFO5HOU;O98O:T7KI>+9L;MO7_60N^&A^!_LOQ._5M1715S7_HMZ9 MZ.^Q?-
1Q3118YS;V5XDRV6^47.UG5CHU%L1JA32/EK:D^M)AKH19AH_X!XB@T(=*
('*6.VWF\$-0<9RE#X!OX5/TNS"W8_)7QNL7JHBBK M1M\$/<4JY#H7\$+_UM^D_.1>&6)2(#8^D-
_B5DQ/3+F)DRMC(1+(2BH25"JEX M;.;2*0P#?&RMLJVIAUO)0)1#:119?Z2RMR1FSZI>.'9@8617K.ZBWL:5\$Q;T
M=FE^7,S;>26,3I20#1?>V5+&0#1O_2OC1;UAL^5O+&YVZHS6L7QDKK!R4"4(ML=*>;E0:(*N"VS;J0M1&0.!A1%&)?
1-H;H/ 6<4#4T415K-Z1B M1HKG)+O*=-1V6IE&3EPQS12V9S<^L'-_9LLW:8 MX?G21+
1PAS(.?1DK1)W75"Z*=-.NNLRG12F/X(@R#X1%FHQ^W;1Q^_W2D4@_MN=0"!X+;7H%Q:.)1&N"
\$2:R@+,L=IHMV"YBY)U=RT0;H5?H^@1(8D^C31P< M1Y(@>_8,Y!>:4R-:"\$Y3^U1>19#NC1B8\$13%YIN?
,&E1,F.W51?1S)U'FE M#X^DE81?9O.YNMU10JD3%/_L&"Y#?&SU 316N%81S#%*.9BMQY1G\$
MR#QB1**=S"MT#TE<:C.)"XWT10JCD3..7BS2"!;"(GU!OVP:9)?VW9S1N")"
MSNC2_)@S.J_TBS<^K0KQU_F.YBJ4V0UJ?N R%DD2.TQH2C%)@QB:2"/!>:IT
M&*HR!^173D^W2O6%5JXGJS!C:@6@PQN&A@75>);JY7 M.AS.711N) &A'B@P<9,Y:7@",L-ID);#!_*1&K#
1V1EBT^KH7KY:(P =2 M'BK:U(TY^_ R01H1E#<9\$)B0E*):?1&??ZK15Z1"/NA/JY'C"101FMV\$;R-8\$POJ'E
XYS<470=^X_62# MG=RA'DYW JSRB#1N;C1>);M*JYV5&U\$4"172H7&2= "DSS(<)1Q \$=2Y;G0
M(@E31UBC1.%NFN)KSN><1=;1! M!LO= T#WBSP:3#10;'(!4F>6L2C5^(&E* MLCB36+(PQ136:C\$>2!R\$B2!!*
F+0&F8KH)1J%/C1S1YK57CBSR5#+U38C M^YU:7G9M:0DV:A8Q==,@XB-82FUW\$W-" 3C2!HM9WXH>-
+1^""N11+3Z2Q N MC*1Q73IEG1+&\$Z&U%^\W(=S0A(9V.M;ZZWOZH1T1'6**=4VDE-0AC>"1GF
M5%*21\$SQU+WM6K>LD;G'RD8- U&OT,TU9=VVIN%@P:S HR'N@S@Q447?CD M/AK,
(B+24XPNGF1^Q837,YIK;10WQ=-SL3/^&AJS M-K^T/W",3Y?&F MC7G17 X4-9P18135@=^H2X8 L!0PQG\$CZ%1?
A@P1G)^V\$E^%VXQ_7FY83DB M+1?6.!^A0JDS*\$M,&LZ*(HYE'(<"24D\$9D((?<?<MDX41J6HCL^K.64F%>Z-
1G%QG2H"A=1&480_ZD1+01Z@Q,V7.^0\$#0:0N M.-W.4>/*^7VB+LV/7:.*SU(Y/Z?P74409D7Z17R7:SVL_WGYH?
\$A2*!RHRW MDPK1)2L),_N4P&D4"\$U2IDCD/@FE5U<1!\$/9>OIBSV.2TG MN)TMU-N5>BH?TE3H**
<)>EE+884PLO\$SE\$X;>5WRY\$ M1:3NV;>/RBH_F1J\$91V34-NS<.;1ZY1Y8,*F H3&6.>90\$FJ8HPS52 PX1E
M7,4TR+G8CJZ1=F0#6CBS^Z<4AK16VR5M?%*K%(2.O/K1AJ(AZ#2)R4G31<.;1O:~QHI%8H;W,1
MMQOIU:Q<+6=177V!>1MX_4VHLKS316J%O>0)G:4XE"FM.R&L:K*DTL5RFV7,P6GX&MB"-6
M=B.IH:WF=ZRS5P(=:6%MIIG,SO^H59E.[RP#1O_T D31H1B8YV1V?6_AQ
MSKZAFIU@_R_*15+=JV^KGPBBOQXBK8FVV7TTT<914CJR54<"R,%\$DD2A3)2\$ M!\$*=TD:..A0Z;
Q1.^<812+>YW"AC"/2.(0_UXP^M.*117L.;A)XP*\$4W MK\$FWOA/LTWNMEB(2K;=>G#(N01S*17-/Z0-S
MMYBQ#S>1JEL1\$NEH@IU:WX9M5\$KFJB496Q^V0L,@M'FZ..1JGKSK9?B1 M6CKD^2=B=VXH+_A8"1P-
@IU*W*16:>GD\$:9:+H31H)S2T^!=D1G/O:K^D MO5Z(Q1+.-1W^97-\$GFK%J(T)=!\$F.AN15S':8JCF@41PR
6DZ<"YBY&UM M1**=3!_T_P*KPV1PB<,"DIY 8=OP#*.GTX\$&L+"F_U OW33@7;M+S4=:;%@Y
M;=:1=LU/FPYT7.G1&>_71@YW^E<3.RS*8CZS0P7D82_E1V&16@6X3BU/0?B M/,*<)>(2:1B3?PR\$G
KDL:V0V16P;_JUD0KH0ZK^X%N10?W1J\$#X0QK
M&1CH&UR+VX9_JP)@'0TK"FI>.HC^K9_&LUIF/A1@M"7*V^*K5_YN_6L:Q: M9R^,%UJ:OU:1NPF_1'N>U3-
E1N6&@XU:N_(6HKF^AE\$%=N1XG,5W^A3X=88KELD5^H1L?BD/ML'MSMK>EVG M>)0/FI HCV1N2(GF+
HP\$PK\$1EQ09.H4)(\$T#&B1/@:7)<=H1A'_9.W+ MP_N/M.%U1&Q:0.H1#_8D3RSW1&.>+Q1C1'P*_1LDPD_XT
QO(LQU-7T.! M>10 0^V&1\$ M18#EO_Z_11A3++#KY F;_MOSXUW7&2S=4!9:N-NB1QB3^>"A-) KMBT3OI
MDYH771^QY5H57V^>FOX=?%YQN?3K.YEG)6^W115%_48JT> LE5K"K_A;? MES.F3*!"55#-11B15^4"UK(67.
1^@QVZ>P#! M1N,VX99;(.BI0G+R6=FYQ-X CHEA)KJ<XX_K\$)5BJ-1_L_KR-#G2KLM_V MVJ&-
>1/9&1*_365OS_*FOUEIYTE7+MDR?U!NLRW8WL".251/G7<+1JM%. MG_8Q9G?
@V40"A!J\$)8X#F4N:"V^F31>Z617WC19?2%;KU4R4:Q=BUPM5-M<9U&\$4Z\$#785B3"-58)9JD,I6&W77=C>7

M X.9 .O>A13M6ZS0"@Y\X4>/C!*&4Z>RDO.XI3\$=Y3DB.*UM!3P" MK;J*?E3/XI\$^VORO9?
%YR9ZNO\W*ARCF(F8YQI2V0R34-D&T?50IET0GC*0\ MV!=BI^.,R%MMSRU**NG=[U<
MFF=4'77H\U R:9HYI"01L^?5V6ZZ?G*K'J=S7\&CXI/J+LIG;0Q6VF-G6 M&JFN 0^24:JT)EBK.#1^1!!@'ANW0AH?
0G.M8A6#JH^F4WUDEM\+0TOGT? O M "HJ?0_5@|@AM<:8@.4: #&(A_1X?7;."@'LL5LFCJL1#H .5VB)"&TCH
MX.E \K'Z\+1DS^ (H093?2XM*.K)G|@9\OIM?JTEB.*+*WQ40#9GN&R0R ME:HXUUC'D;
(9Y\;9#4.%99SJQ'8L\$|PIXIQI0Q.@T7\MS\$Z'@OHA--G%P9GLC MA3'G.4B_5HA-
:.\$%M\$'NB\FV\Z/R(H=T/.!T.>BHS<| M/O|>@ (G.X;S;13AH9SG?'R"[6W|@S?%TF90;"4D1PAC,147L^1S!+8XEI
M'D4IB87*N_.GL);|CW^8_KR)>^F&|5;:U2/G:A M T=F+1@&"H.ISYIC-"{300;:O;U^|FI7/1'928L"(@(:5!\$BH)&N?
90Y>1\^M. M'&R;|C&NVY;>R&2PL\5^E5:58DFM5\H4#&T^SJO&QB;.(8P\$(#D4L2328E MH@%=-DI:0\S2IWF)
_MXN;8K&HQZW/_ELI'M'A_ EP^I4#%+ H8UE0H3R@BF\).X"@G+E\$Y2+=SI(PVAT^%#;9^+|0QJ%
4FS#;LD.V&OLA.)\EAXV\SSB7)\XA M+G>|J)?>?EO;Z% RS+ON;.)|SP;>|CK-^)&M53TY^9_1VFP>QGM0'YNAZ!)
MW=C+@&^|5(<5?COZ\7^09ZOO\J3L3@DD;..T#S\1&9J9TO).29A%N;1#S(<MY"MA.M.44*=2^+CHD7?|VV-OTA9
7LLOS#S*TA8|=C66 Q(#P-IN1#&.#6'\$M4>N.B6.7!%KR6-SC=^M&VZ1@<@%('A2LH\$;Y)1V/
|@ \$1' .:R9VZ(LWQ@\$ M-XIV=^%&T\F9; ^O*EDFAKG@N8D-LY%:@)= \$6F\ MTKO3BQ6.?OALU/(@1K9^
KRXJ+;8=SLS=JVE&@/'IRX0.46E?BWBQAO6?*K|B M?T16,*HEHSN-K(|, @ @+!S(\$'17@^#P (X|Y2=
<5G7^NG"+0<41U&4R_4^ MN?IA\$. WYK\$NBEV\LXR&1+ PPUT05\5P"G;.)%CG*A"\$J5A#,07/!8SL%EF!
MJ)8(H6_78 P^ ND)\$<8D^B\LO;8\$)R\ O!/?=G. '=-N /R&I9-F)?KO5Q
M3G\'=7YAUAL3M"W\$;/'YHQ)JL4.LI^>SXNO-LAX4RQOEDK.5L:65'FIFT2: MZ8"-! X#BC!)).*LS3-#);
(GH1!\$M+&?FICQ)CIS#M54)IG:|03JO\WVM MZM#ZK<?)?^)KUY/P" T(&JNN.&
(Q:3@&R/308'R+Q4F#0TZY.DTR"MU|T\|YWM MZM_9@MSIRK).EN:&"@2LM3X.4&J.4D2C6D89%A'N6).!D2&3H?
K1)&J.= M2#2W.@&^0*,Y'R>OB\AW+#+5VC@|C4\7D\2P'YNSPGP@;R@+BR=;E#C MPNG\H"ZICORAS@L\Q-
./F)>VVG\$59NX322'(|69(0MJ\!8SPR%B\$|1+;GGNB'D7|=F'DL?E-4:|NM"V"?LA8K%B422Q5 M)#
A.L#4YCL1\$F0IR)EK@E,O+48FB-MZNHY\$ LZ?G92%%|9KD"C&N&UN;C(8 MA9P7=U#XHI#BZI?(>#I@_
V'45'&3QV-XBVB,<|>|AU\ S"Q\$AQ<|/MA MIO:QM#XW\XF.7@=|!\$ZT7" *KS/QU|O;I=03GO\$HH
%.4I49YR;C7,3&5\ M)5E*XY 'Q'DQO4Q(V#%2)17MQ%ZA=|>0^*10;BZQ4G^|P" I:7S-2"&1(V MI/
M=|O|XNOB@02*Q#*(L-VI^AD\$69,\$LR%)\$T814-E O!-=,@8F5\JJ6@C|@I9 MP3;UU8IVVW=|NFFF8%0PUC&"
f#S3G.U;4E\$KIQ^?BR\QJVM_POQA|T9T MW7.2#>@ :KO_7"|UF9YX_#K|9CV)Z 41'E(0!5%CE);(-?+@,,AQ'01C0
M);Y(<ZC\$XIO/G8_XI2A2AQDHN)?H?7=PI4L VU\|0U* \$&610HHCJ"OY>S MPZ.#SC1L1M
JT\!DS833#)NU\1YEV'+- \$6I97>Y6&-:9QK*+ B5B5O3@&"2 M<-
^3HC&7!)!PCS1299X5Z9Z*#0RM\3JS>I<U;Y_|>KA,YG:KY8Q7 M\|-Z??A/'&|O1KMES8;V(G:HTG7Y\$)
(P%\$E(<6Y>0)AH33&/) <=;I4E. MA81CHST8>BF F=8B4X3;AY@R;IW;-1 MN.42\$VKO1\$G'53FPI^Y.(OK!<\$-
IU2Y_G*AQL?#=(M; FX/Z*5;-V^J%_P MH J0H7.V0'2:3L|H\WX#Y"=2P_@-F V?Q4MW;-0_!&^V;_1S)8_8>*GB^
MJC:0%N?ZS6QAIGL^V+OOIV->%V6:E7>V\3C_ F*TB(CJUP1\$;NAFE.(1% M.Z\!2/H;
MK0ZNI#DT8JT1^K/2:9SN\$SUL,A2Y>F@P+4GZF^B,|KXJEK,BN6OBU*9 M,\$_)H5'E;_6*KB<#M@-:
<122;154M(+1 YE:1;=PZC.H.8#DFTF)KZ&K"TT&;PZ|&DIAZ\Z M_EB UA=@78/8;UXEPD'L;HB.AI&ZKS*IW?
&=6L=KTRSW?%?M\6(B>9(3*= MAB;0MR?FDH:89G&\$8Z.EXEE&4^9>C=4H8F0ZJV6BC=K|\$.D"+W9)@ZLU1LI
MC*G.0?J04S_-2;^+OJ@|NUVX\V)@=XLN/_U\+1I73MC1HDOSXUX6G5<\$.Y
M5H16#MM#FB<1B62*XYQQ2SH"Y|EFF&2QY#G3*A"P67#>JHS,2^2ZTHI;+67 M_X/P"9';R^#
(>V;+|HT.LH8P2%.\$5>+C;T.EAGB.AW1S_JNU\J5JZ7WS^M M3-19#T83_|V>+>W\7+FF^Y\H\G\SS*."6L-
B1'&>:QTC@V?Z4YEUD:@YIR MN @=-VJTHM%R/ 7IN9Y?H56Q8K-T1>K%8R\G\$SI1E-#&PA&2%OI|) 50|_M-
(RT4>J+A*KM1B.A2'8!^(-)Y&3;@O\$"*<< EKK6\AN1R0;)/:-9?B0415H M\J4X2ZG\$)+2UJIED.(NT\$2\$()9.&>
MJO_IY&@C#0DK#EJ8?FP*1_#R#T M+&B+
f:83FT>A>2."P>K*C^|<1EY(H3SJQ'FRWPF8M@J>CNB3VRJZ^W514A MC62H\0YY;B(*DH:8A?8-
DW#+\$RR.*>Q^X"+F\$Z34(<49U0& MADB2&-.(CB40G-%@Y0R)R+QD#TVQZB5S5<4|53*17K;SK"41D5@'07
H+96 M)>4QQ6FD#\$/|/5IE&EO\!;)HP1\$<,RR88V:9\L(VH|@KJL+5M^>55;%B MS8IF9;G>.TN-
LT^IG;SID;Z1<+>%"%;)@Q2K*W2@|HJ|@G|8J&(L^K| #MHX\$;I*SDA&/6W@W26W+"BNA5;OZVQ)=(H:|
FE:S7;D91" T0\$<%"A34;Z.3C%>WC>8|3M9KHQ/08;>-M|@L| #UK7Q)S)&5M^|3L5Z'J3/?ZVZQ\2E" @R2*
<);G"28AE9BS0.T.WLM M3B@1.;Q5;)NDL0I?69T%6W^ (^=-*A'XL;K61XUGL\$.B\H(OT/"CV4N ACJD
M;94S\7M);AG!|<7%AMUEME7KJHT6T2H*_G3\$^F\J6W|<#XE^MU0.+5\$(3 M13"+MB>V!@O.TG
MXY4K9_0O"H%>-XH@695V7U=8F0K4.M_GF^5A>U9X;I\$<889H3Q0JW\X>3U M2HDKM%/#?I=&7*\$/;#;@-
UXU<(E%VR_Y1S.=L M-W^|B6H4HF>.Q2 M@T\$-" M+Z9(DO_V7=;+G|M0A;
|&Z<#"P2;=R.O'#;2&3^RO(DI'0.\$LD 3'\$N86RF M;+11B28*|KLX404_5 "B>(\$H\|/-"
%|40_Q_"\$^W*7^")AH53\D2|WB<| MT7&A#T_ \$89C^G.G/ZMW.IT@84S0,L&A<2R(80J>|0P+DN6V:9^E7O3
MIF89(W.%E8EV0\O.Q\;%O% A2IZ8X4QQCE;+YHQ@MAC=ZX7Y8W.M7O9HIF M\1-R1Z?NQ^S1?;D/?
R1Y^KY8KAX_SL2C>3+R/V?S>7G_S\TO**4YC1EQME@ M\JA#;.)S^C;)HY3S*)YPIQ;
(3C&|E/C&S\TTEHTKT%;K_)V27=-O*A5T& MLP".92KP5FZ#;SXIML2\$-X9S"
(ORS|;+IY\JL6\$ _1\$Y9C7G);XL%|O_S+M/D|<%NM9<7<4_WRK\UO+
|CE44QQ3K4\$A.6Q9BS+19JGD6)J MD.#.3&U2 M1N:D6BS;RIU"O_P+L U;C>-14-AI%0(UH?IFF%#>")=(>#
f.O|LH<-HZ!| M3@|J73P=|5S2_XAT+E|LXPY% OG>J9)= -|J326*JR2BF&O;?Y|RB6D41C@7 M2F=4|3@.W9NMG-
U^9(*OXI"5=X6N_X"W\X.+<| \$HY(C7%X.S/ES\O@L M?
8"^K)O2IGFW9W*V;D)GI\$WC8_ ^C|2H8|R@A'IXNRIFY\GD;)OOZ^7RUG&V M>O?
B\3;#1B;:"#UL.#GT\0WB\W\0N8&FR^_0NX_+%ZXI22_-C=HVU^=XJ5^ M 7GP=OG%W'\$73BD5L%3&.0YC8S4BE<
|LR5E1(J4)5FDW;HT6^X>N=H% H@ M/_P^M81;B-T#^S2L/H3F&4B?8H0%SSVPOG3-W*+ZI2#Y=-FD@7&+SJ?!<-
ME M/GQ_XDV|G%GY9C>%.0M2G28YSDD@086+3D:A;I*IH%&N;\$"X">#;)&%D3C_2 MT5;D%7H&#<;9;
|77NB)|L8;IP"JN*QRO/8H2?BE^6'#N6|&)|X80C|\$O\$I4W\0#4^X+#+I_6J'AA0_2HMMWA=V.L#*X#
(W/_QV83;Q\$E\$QOIPSB760A%*17L/EU\K;J5&9DCH6BYD5K^/_WB?S M_|=N|6|S?MN'?*|BE;G-D|NWR8Y^9
@). #1ACIG.GM_HAJ^#QV\ITJ".Z M+I#)X\NJ;G|_0\^7/PX_%IG@?L\3"HZ3K?(L-(FNZU,ZAECMY3PH9N\K6 M-
E5C\WU\1P>UU;7RR5;T?S*_|5958XPJGG" T@_3RA+S^DI3G\IL8K"-.\$L MCM+4*946*GCDE|1.C8-"=72@*"HU\2K#
<9M\IRME3(O\7B0#&Q4Y?*@HS14|P+6^_A.=^S;Y;S\^S7>KSKY\T0M%VIT4QM9RH3DK-DY\+' MJ2;VKY\'+
(4QV&6*1HOD0_RZD"B1R;7^X^?_X2S&@;NEHH"OOD;-HVF_M>TW0H2H^L3S;
|O;+N;)V#Z87TR)TN\|Q)9VVJ|>1H|@04Y2;4 MX20+&#;W\|<)BE6@2"&^C;AZ"Z;+ &HV<"1-DX59H|&|HYB*
;|D;ZL+K-M3?52J|T;SC\$#%Q;=>_M^RJO;/+|EG>?JO;2U7/5S=O M^J_-+W3=Y@*OG^UWH2T(R-8?Z-
&YL_T#P3&IMAXTQ2017M\MX@7> X0RH^>?A1_AWCK\1J7EMINO_?9#_ID;2A;+C>W; MQ#|+1;
8O.LV>Y9'FR@H8+O@4W<_18:2-;\$ZUAK7AEAOXWAYOQ10V/%MM MIF1NNUZ\^M%E8?
Y9#L9&36>9BO#Z@|4JBP)8HDIXPDF>29PSL;*U4:X%NOK02X'4QAK7\W@?#6 W&Y%#TG53M?+|N!B*
|XALP8N\SB02 M*AC2/UW6\2Y2T4F.C>FS11.96+;4TF%61\3* @LRP0G:9P\$@;.)AECCGU88 MF<@*1954;
9ZLUF<#BOZ@&6>59SC\#NK;0.JKH" R%3RJZU+IP4^&X=IS MBBF=3XX\B_U8)\Z\5R5JZ9/1_%NO2\$-0'58?
LP\5?0U@H>ZP-MK(^>_U>QP;@-<4/H4|B4W01CW@T"C_9I#|&IG6LL#W"-BHZ;_|NB+7 M*(KHO"WK>+PU+@

MAB.F1\$1G"BN31\$%Z>8YS3"D5(Q3W@84>Y4)>1*8DH".10R9Y@JE>"(YE\$NC5/#A/O\$JB8)(^K M6B2J95ZA=ZJ
5:C01Q"U+XP8=OV#%0/-D(%1FIH7L%ZY/UQ82->)IC-4M:UPX70C6I?>1-5Y(8PZRN7IX3ULOF)-9?Q?F7:Z*)
f5153R9J.Q1(KC M)-4X"/<.EYAG.*991D:4Y(F63DY"TY21*60K#/U9BW/<5IV&Z:1P>#"MJ.0=j?->9-
LYP=MN;/>+O7+ZDBS_L#;T^>-9 MPW9U9U\$64LT(QQ6G,2:QSC"--<5,JRODJ4H2F0"2^AJ^C+SYK%1424656"1
M8K-E7+Z2I<<+VWU_4TR^YHQ@U+I>F_X=R^30TOI)>Q>>HER5#R35(@YC@N1"&VFB8TI00G1\$9I4E.0Z?
(2H?0%"J.3.XO>P4GS>P>\$)GUIOVQ@TJ5I=UC2 MN'+ "H*1+1^_0I-*KSDY47#S:%SQN5KNAGB%2K*TP3PU"V?
3W%/#&4P72J MHSB3 0I E-\$@863&,+15B1T9%N3/5SXHB=*%V< O2;F=-.%#0UIQ_B%YZ; MTZ\AK_YP61!"(4)
(SC*M1(Q)EL28AY+B,%61"J.<QQ"M"+.9J00FBC)^*7Y8P.Y;L)HVGAA&S1H2%&IN>Z<+.WTJ-7W:L1&D(=<*4IQ
MD"6&2#@W1D(H4@WX4T%DXI?^1LN\$1>+)CGZ&.4SVZ'DG#Z?E)ION0)7E3?'\$-R4R
M'W=)XV^EG8J@9S9+ +HLU;A%O^IGBV5O!f(8/LF2K_OYGCWCPW12_?+LP5_MU_*+_ "<8SK\$T@A@D)0T-V)@K3
MN>1,OJD,M'MSJ^EQ-4^_TM.G8U5YI6M72?JI>+H^D)J_-6IG7Q,?^6 MBH_WDMC"10=XX1>,3J\$C&K;:
L&3W16RTP7Y%#GJE,Q?5=1OPMOR#_J M;\$.%:J:X*Y%@M#_EIP?P_/^6_8//?I_17N\$Q4E_ZT?=&.C/36?+E+I
M>^O"Q"E7 WIKZIA3%KIR=BGTW%Y6+3+.\$8*L_>8/HAS&>1,L"C(\$_O200+ M*#JL\$4Z48QJF3D1*<&
<7IX^L*\$^1MG"+W3B\$ZA0I.(>D#ND4+DI_1\$HA: MT%Q.'SI="R4(O>YZE#;1=Z4.?O;X,@2'Y:L5?>J;FIO>WVR-
YGN@DDHF) M)G-JZ.(%F.E88)*E2H>2)8RZ5RBV21F90FJO;"_W"OW^%K"W6HWC0"5#0(1 M22-
+THA0V@E2"@U\$+1*#Z.42JDZ*.5T1?%<\$14HM5O6 MO19J_VH_4:XP/AE;+K_KNN^"I9S^2XG5??ZV_L6?
J4I*H;1C@X-8D*D MPCSA! =YFL8Z)4)HIQ/^8=09F<#>JQ4J=L5YT8A) XULK-.K4KVM\$KME(*5 M3?
1^MU4.+V589RYU;MJ1^K=C3.TEK12+LJ*Z_/_5EDX/K.X:OU\$ 5'#V5
MF;3&8QC#G5;1#17/ZANO%#4S6K09H\$=&M_/.NFUIGEBB2!#>+VHZ5(+&A M08TPUFF12#=#11'H0).Z6-
3^0JZ;17*TCVBIPA7YB1^IX"EH9F9%_X: MS#8P>AK(1&2\$Y)1RO_UJ023ZGNN!;V"Y60#S2%)SAW;W4E
MWRE6KI?*=HPV5VMBT?>6G9!(%M1UO):"-6=EN^ZP==
M91<1=8P;.&LWNT0(-9JO^D.^HBH.UVNGRA5^YO%*;O_C JOJTYAQ)IZI@
M8F,WNB.*F'Q2X2MPNL31DE=W>7W\ LN1% "P!> MU.=AIBV)9&9^)#YD)H!;JO/N'R5 MEU=?2;L2K:N=&O'5?
YEO6)/*V62D#YAI09>Z1)*% "1.O)EO#JO(>\$Z4_-MG*K4F2P/*&4\$A*X+;JV6OSZV*"0"<0?ZP;4.* G+L&H*^:3
MEY=EQJKM).M5U0!WE8/RB=CM-QKC#1DPX,RXV_&ESMSN_9J"||>IX."8*^A MWGE3ZPB.E025EC-#;1^,1^"
->Y578?^^(N'5.\$V/(F6J2&1&5DREHS.>Z MJ=5"-I?
59OWTA>3O=>N%K&2KZZM1-4&)N8PI&B3I2 M1J=N1O C+X^7EV/F+6GEX\$MY_VI3&YQX;C/GN?
@^LJN.U477B:~16@HV)~%~P"/JZD+P#KUS42 MJ=N1O C+X^7EV/F+6GEX\$MY_VI3&YQX;C/GN?
YMJEZO12Z+M'5YUVRF?(H MP\$+ , PBB'0;0!S*52<)3S"/-V5P)R=6J1.S\$NU6%#>+K-8+,"S6;Z10_7;,,,|
(HKMOCN5KMV2B'K.Z.:CMYAG9IT?_4IHNI BI MJ@B.HZM-L2K(1=VN^)#/><1"O=TP56234-UNE\$=08(Q\$&-?
Q.8'VAH\$3,PS M6B'H):H9_VJH.8E&"<.LO\$.UHYL\ZM=LBEEF59U0P:9Z18BIB_5MH1(JRDI
MY4.NIYNS=\$BKUF=E0H0Y#^FC@_"M/X:\$IWW(A93CF0WX8R*CV4NK18):IG17I0C%T.N-6RDY?IV;..NJ?>:>
fZPWG^# MV1^G^796MOF7_5AJK5ZHG^Y-7IC3X:=5R(>=NS)HJ6ZX*PI4,48L.BR(Q MPC%\$?AA G*H?(YRR-)
(TH+Y1f0,928FB^E.GNN/GSR^%B(1_7BQKJ:YVW MFUGMN&'0JS"CCID MF.86BM8J74)X@)1%&L5.QR#055M
=ZK\$)PLP3!\$*^_'MHBS(JH(B6Y5'W.DS(GC4=)@569EN3%.R?^49H\$%#J\$7FV*GY13V_*/^X M6HLR1-
f6CR8^9U<&8A4L20(1BW6MYQC#4,"(14P(#YG7C^14_3/U;+17CBH
MI(P;A)C1=ZM.WEUIH&017HV%#@1T5=YKMU_- "P:IE^4AXN/8D=_@L;%N.&UC8 MTU.ZPES-@TWL.2L*
fC)4..=R3/_4I^YQ5Q^+5J1_>LN1V\Z15^OW0CV; M+/66ZHUZ7=VIRN?YP&EH>>G(8-
)B(1NC1\$@%&.&72#1.\$1QYIR"O B_- MGGX824FCX8#KX7"AJ0&0T&>6:*T/^&\$;#/X(R\K\KE1NS_94:6-
7ALJ/C9.HJEV.68fUE.VJR_I?FQ.GOI%2H*H=AMPH!
MOSDM\$ISJK= =5D6PU_1GLH1W>3M>^8=3WN.C.*HIT&TNT53L.#&OSZ9.Q MA=CO/!29P_7JJRCVL2".
D1#AJ4\$&4" (I8T@YHT^)^(3/S%*RET)>6+?2 MLY)E\$KWUV_-7H.LLF,>8X,.2:5^8ZM1J>>JRK?
QR&-.639AF>K0;LAE;1 M10YIVZ\$XY6?Q5>0:4,Y7EAQ7_OE)BJU0_Q30?+M3J4")C"7GA3*K=\$=?E_-M@C027 VHP"-
"-JH365VE%1'C M7EGPJ+7=>C\$609'K6S\$(&V? VHX"CDK?@IU*0.MT6L_-'0'E5Y;OV,&5"V"
MT!G0=0M/IT+9+H(="fG;OZI\FBWH'6G13#0Y_EM\$ITL//@G1;K?AUMOZ^ MW^<7)L3W*6_9XM-1^YTI-;fIGCT7
M.S#>K2"E^7E?+7BBJF7NJDP1E7% "\$RST^;AY40fG3GV;Z-1!-'7JH08B4;_ *G^FFYX5G^
M^fESCR*B1;K(Z&9=1S4VPM7^5H9D1^1A.J1>f2HA0F".13V 0>P(B(4*(M"?=A0G#")N)>B1#<9f3^1Y%>5GQD?
W#_7MI2;?K=Z1Q;LJTA\MT8f)DP9Z+;6T6"1U3K'.(M?>8VC7?F>f8V& M&^=>B"(+FJ;8
MDY@)+TTLFD^7\$J;/_D>V(FI/4+>A(=1#FJ8E999J#.#W?)00#99:9.*&6?S* MN:AVY7NR40TWSIF;M?
f1^/5<.%S3f17T^MMJ(C7G(N2E)U%)T90_W/JV5/_A
M#QZ*49@@"X94\XO"*8\$4TP#BD*.\$*#=#^O+AJRCHRO1\$@8E8F^_N6+A-3D-7 MLN;f1L@113;?
78_9.H/*HHD17GXX7U*J11;R0.OD>E M JAT4+_=C%JFLS8YO'R7_TBYTYH&8/0D*4RO1?)C801%Y+_7T5L^fU-
5(A4 M(E1<")#B!+IPU20&(-12#T/"YRDYCFG!@%3.W\$QJLK_9&VNJP:T#RX0;9
M;G" G9GGYL)=VFGEP0VRIY4=N%;=>_RWR_OF=-1.M3fSWMJOLJP(3LXOZ.F+;=CF6")JY\$U/B8L=(M28G??
NT.LJUI-71"W*T M.FM9*;2HBW4HO<9LP^.&QF@M>BS%SIR^QPVB5EFGLP/=TM-
EEJEH8=9_1H2;E>1+0#3?;F89NU_LL#>UQ MH6M#8fJ^R!^?BU(6Y*^2YDU_ ^M2%>_"^K=L_?2.%.00
M1Z)XW1_>S7UQ08fE;f(34TQ_U_F9H.O%3f3H0f7ZU=-6T4X*COJ6@1 MJ#ZfLM(\$24*^9T4(K
f8'4"AU;&8V%U1_-fR9L2C6G@N0f\$USL);JV M5@MH04'E&#C2#R>"5<+GVH?>WKfFL5GY62L;DN,K86
MO+KLZALI>'4^fOVID"+3%;C*AYCPU(f#U*?^?#3RFD*8fA\A6(@4f9% MfT?3;&+N^E6f4+7LEJ#8;f-
M#;3)LW59f3FL&W9;C0<_C+;?)M9(8CRDHF MJ'4#M7+;)/VB=H9*G<#?PUY?
7NFX/QYfL=XWM%HD(WD/PW79U8;S3XSGVP M1Xf1Z^CO5T;<FQM9.f1%0"61.8."AQ0BQ@-(<*K/U
@_"%C"16=5-@J4"+!5KNMFKU+_ /C.F.LBB!\$L?*>1>!!&.\$^@KHG_f04.2=+170@;fLONP-4;_>;9EQ.O(SfUMf-
MXEK>B9U.#D:SP3;N06#W9R+!@#&\CKV_HOG='7Z-3fU_/HOM2.503C M#f5"QfWSXfNL9+=9+fF6XKEOf-
fUO@E'CA8fK-G'4HKFEG2X35HO!%A/6<./=)BR;#VTW875;U#EAM=PZWfX35K?O) MA-5Sj>.-(?
8G&f1f6EZG_W7NQW/f-<@&M.O(*B848APK&)(H)5.S?#?#" MAJBPV@UD(G5BXMgf /9*6.fJ.0.+!H>'0Xf;Kf
8fZMR596Cf7fQDCfOMH M;M;"XV"AC;=CfDQf1^f)LI@N#W'fF0P0@3ST?f(B0D)#@*(QR'W)?^Yf8+15 MN?
GQ4WL;ZB>@f3FNfFUA89CL(f7fY7,>%.fE_f1L(-.CPF)C&&U'9\$T M&^RV0-
YfN=4*^0@f(O/(2>8f%/60D;7?/N4C>8f'9*GG?U2.LDY.EN)-5K8;Z
M_)>N5<^,"-1.P1_1#S/8@H8S"5D8f1A!FE1*8fP\KY(fBYUHHKf;#2Z7"
MOB'U=NVCfM@#2_.'88%1f1+>.)f1f7R+3"4??#9_9MA;.>.>Q4RR6-PMfO=7R M3@
ZEfNfHW2LO9>5+RLU.GXJ5fN7_>9>O;Yf;_X5?+_W5Y=/N.fY_L^fVfV4 M^*6N(fJO\$%_fE#_HO#B!""%\$2:~7VfG'
0f8EHG5)MSf&DU,+%6MS%Wf!_T/M<9fK6;fO;/fF3#;KG'9M%;-5+H=GVLX5NfP#&);fT5C7_WCG0'VfK4 Q)fK
MK\$*f!_69MXK@6f!>E!@<f<\$.D=JU7f;f2R+1?+^+H3X8U^fSWR<=>+X*TCP_ MfB&2TH-
8Q6B0\$)X0+T1\$@6@L'X2ERfD0fW3* M(-0 GR*4Qf2N-0\$Bf01NfWfFDO;7GM=+*MF.R'fZ'+-35*fFf65AVPU69BS-
@NfS;_1A MCO4Y&5MME-?U<;46Y>V*Y*62^#f1+2^AY\$<0XT# (f2QfUJ<&CD5(VAS;3L=1
(M\$0UYf1.Rf7K05B;4=I<M"-HQFR5XfH4Yf1fZK#J=0U29MVCG"*=5/ FP%#QE8H_082PB!
(C"TF1fLD3\$PY2f+5CZZ2=MOKPD0Df6X M@6;1<~%A4YK<(WOWf+Y;#)KfIORUf%1fZ;fXTfSKK=UZ'VZU-
9UH90+U&L M=X'.82S^%NL@.f1+%f(%\$^E"(E(fJfG=#+ M0;.\$*#fE@fTfXfY1+fQ=LZ/MUXf;A HZ%@1R5=

+BU^M\$PIKOWUB(O^+0L\$M>IH!=CYBSK:~)K:<-0@TNL6:HWI3N?3XI^SQ9U+05?~IA,C/DZC)-5;#&+U M?Y\$? 09HD,8PICU,DPRB,C3HH=-F9F)5JJ4")1;7^%V1-1C5^?SM-TI^7T:~"-7W7.I#W_A>7YP M*_Y4+M9ZE?_I^SL/**113(^IC^\$/EZ6Y,NZNL^V,>2\$H139\$PR+4(F)IE: M*MB+78" _1BN+4A81 Q(IAKQS%-IKI03)O- %A0S@NUN%&UNNT8IL>F3H9I MNW<^ANG1_H1A^JYU/8I--H7@NDWJKL*#2.(X""(88(2A/M&AZ\$4%6%#;E\$<8 MBR@U.N^1^F%B;OFP*M:VY%\$ +=VB/4Y&:&YF4\$FVM)5EIE7#^~.1R1;K%D MM,/0Y1^?^>ASBWF7QYS;+G28R- JLRBP797F1>J11L."K1YSW1.QABLZS62F M%X:NRE*LRROVKTVFA.N% ^LQ"2%*!H*!B\$8I3#P6>N8!PO_X34T0M\$FOV.D&NA5I, MQJ_P1@U^FI_V> I+CN9TMX,@8W;)E9PXXM@?4/H&=1>1^;R_ZJ_ZV1NGNF959 MQW1<@.WGL#<-?/SK?PX6;M1?^I-PIRC_PI^G? _Z>B^GTS5^1;7FIH?#_3 MA_X5U7 J(Q&MZ3153R2IN.O6_EUR0V*-& MW6L)4SL""B)0(D\$EI5C^BXT(\$HC:K%-6FU/OZ(C&R+~)EOJ(U^E M+L,01XD,_"R2!\$&BA""E/@1% E\$%59A2XS,EWS#I\$R,(?Q8"L?I!6P&&I MFID0RYA(V)%%P@N?~.A@7WC(F*8QW*0NIMJAS-I1-9 U(A\$**JFM68UN:M174_XMM3QIZJBIIE2*7R193KJ9C1>8OP2IJ,B;^Q*F_4R7N1#YE_4WM.MF- #X)@=60/4OSPNVXW1(4OWO98IEBC^H*\$[U>G*8AH)"3%A"0QG21)IW MX6Z2,#I(U2)!+=.RIW8C(8T-I1,VJL- ""SOI-M>"PH2:I9,YR16CFBYK M.NFE<~Y**5+IQ;Z:S0@3IV*OK518(I%222Y,M2Y7.M;1L%FNLY>E>+L1 M^K7H? J7^/ITY6Y1@%H<2,D(#B#@+%;N(\$^9^\$1^X(DYEM2AF@RU1+/4ND& M5CDHE")5-HMP/-6+1 W FC="I*K90%*! FT&@RG:2YPI0APCVNE%KC+@58, MU)KM^W>"G6X+1^1V-L MA#H+;@ECG@MR-@=#/Q)ACX%2)H\$/C\$C?I#& M#B<3Q2@/=-IBI6A5N1?17%IMOTU.\$PHKN\$!RG\$*5> K&.UA1B@~).*/" M?)YH\$# Q_6N!HD:X- =W5KN&+1\$P2>~.1&A.^L<1L:~C;H M5MUHJC?WC?GAN=6K<1V;=2Y1-'S?Z"7?RL^!~.OEAY:~YB3\$8YH#%.. M0XC1-(\$DQBG TAD^%\$8<R?'F!KPS M15)Y9+0%Z4Z~@PI6?~T^@&3!6E_Y49EHXIF1WNVQG=RH?"#YB-(6_M.6-/Z M9L2ME>N"9(I/ZILL^Y_51_0Q^R;~<@E;JQ31^E\$.O#M9+@B\$>2>QZ+W+Q MJ)Q WLY;26;OE52% (HA#\$OE6AXV=(FPG6PK#NP!&8A!S0PAI5VC+1W4(L^GIL M-IQ MVF+~%6!M.SQ1_IW13%N,NMINV7>? >%/~#6#^M^*\$QE,PZ;A1XA%TTB*R%FTV MA+HLIAY%(OEK-Y:I 2_CIKKRL"L07TPSYIY>R?%;J;~>F&V76H_J.X+HL;G-IK?%T1#7=-_6R7"T2*)GJUT)H^5"UVE0K.O&=^0I?GP;K21 M? VP--MN8!E8K::UF&D;=9EGM;:WS@;*.KRYSCH=5YG5.F,HJBG1EW/6+W M1_51XH1%5- ""20828B30(82D91(TB91)4T=?Q M.1UDUB?=\$C.S\$;4)"RSBT-L(X^>PT<*0QMES-K/-IKIGE@VG^#O3-IDY>9 MNG+K2E2M8S-1ZGXRH^GX5.F^TBWPL1.=R)KS9N5IUQ^*~.0A<1&-6@MS79R M0TV>/YM7:F^LL9- JKE+PYPI2_B=-GC4GQ;K?A^+X2,F4_3(8P^HK_04ACF0_20_XD2Z25& M;0;1A\$P;FNI8">6<(IMJ-T"93G5KDM- ALTR!GN.V;17%L7K=E M.YQNFHIXI3<~V?G&I-M3IOB1\$SK%JO^4HHI^~Y<91\$18;H113%(8PIGX- M\$8LH1^G^T(131-D7",G8)D-1??S\$K**\$Z7EP+1XN-CU#PBSL=+2/CD7.3504 MCOQW/OVOZ,NS71;- U*>?;P6;+9L;0VJ6JORFIN/GA<\$~L-/A"B;4BCQ(=QS#W\$)<(^,S18U2YGX1%7"P;DA?@YJ1% M_-8ID<&T/HIAEJ%UL^TNDWN^1;S^S@~N\$WOMA^W2S2;UGG1-IQ^WQS?;~M)1.IP>4NJUA1DEZO(F(EH?I-AZI. (SZ/%A1-ARB%~.09Y(@*1!\$0RBP)<ME1^2F^B4/%+M#S4V8"\$<1L1^7TY- U7Z9P08L_C_WJ^O511O51HXW171/1/IJ JV-3^YVKE;~#?2V_OLLIMFU6",V1ZJXP?-MZ&J0?V3751- M? I+;DE;~@H;V^BN*Y=H?1+4^32+~+1?&IOYQ,H1)=JF2?~8"9UN MV1;Z#24.AXIV#J-^UXFIE<19;#.FE+?ITM(<J- UUFUV3.S3V(XB"1/T? M(A)B00E\$TDJ(CX05A;+~RE#>Q&-UQU4XL&I?*>17WXF.6R1D3%;C@/L2^ M>;*9F6.U2>Z1-F1#9#3+UH?&IYF- BYR1I>Y>ML_?W+UDN=R4F^R)?ICR(M=1_O;J5\$@12GE#H)>KW.&~.1%N8;GG^Q(CIE@JD6 GTVPTMP?2/7I;~N MM-I9;#P1>^SHF&+5G? 5(5AX#,"VY1TRXJ,V0VPOLO<9M=-GJH^Y^M5DC7G MZC?%1AS78E5#FBU7Y;80AT,H? DRI("2"\$4FP&GB)&H*)&H^IGWHR"/S0IT8M M>0?J.75(N=4*~52@62MU6DE9;TIZFH) (KC7IMU%+=1#V;S1OSH6H;R9116 M\$#9@"PY:C7R@:"1H1FXV;JO^J_09=X2JK<6XZ^~<\$MIAE-P5XOF7^VV"DTE& M;H12!\$H8H5&*1^0B#QN<=%*#W?~.(?&1^,3DI_4"+6X1?IFW2O.<8F^2R M1:UAF1PS^1CDEL<^MLTEA# I#R=1/8+8IWIZ_/YHQ>=VB1VGJNNTBQXH%3Z00 M;T@I^"NY^A^IB-3 M3#@.&~*3D^H+~\$#%- 1AU2+AN8^734AQ/K1QJ">HGP>Y1^9X7Y;^T;QO MP8X-V#2?&+Z-ZXOP+ZXP6B8C54.8.A")Q90&W BY(+XSW991N?Q!<\$2E^B2<8JHX%;5^"(D@'L184#^~YZ&YEZ7 MD; M-4SN4IXY5FVZ<5IMT/LT9NVZT(4G M- HI^;G^Y*YK-XZ6ZX(PHX*;~=-F-35\$1L&12/#13JC5\$&DSVF:8C&"VU"Y M&&LL=-C4?? X;MYQC_4H_LJIV&\$LW0H5193?LO73)_7JGM0/=R_ZV>1W M>H+D_791^Y^L1W9*D;%6Y#H_*S8"+ I6A72K\$IKKN2AH^RY1QE^HA56% M&\$80L22&~\$(ID00^L(^S@QGKHG5^1B#Z 6_~YL?>?U5^C^?R+4;E*) M@#7-(N#;\$6^M-!@YW;H-8;U(I#K>;@H/HN452"@_+@4^CZJ+N7\$XM/^1XM M)H^R/MTFM>_IW:S5\$S@- TYS4TI?I@<843R;~>OYK=5ZV^M3\$-TP6^ES M>ZAGP(1\$#/+ 2R^B\$8/\$%PE;"/HJHME"8LHN5^U.NV2B;8"UV1 I=6ZYN-MJ1BMX0ZUU7(EH),M_7<1GNM5G6^YOW^;IM=Z0>L#;~.NZ MGJ+VKDGO+;1H1T#N4AS%D7D@4>R _8XCZ&~(D@~B+~1-G\$B;FCEHD MJ&6ZG)D^112~.::4<~%Q8ZGY ^17V;0 DP>@6_2^/W<=J%3>CIV?M5L2Y- _>ID*#W%3WY@8A/H0(8XACD(*XS! M\$H\$PC2TZ S7+F#1%KV0"+1144JVS1(CVP&7IAQIKF:F M-M6=1HL%6Z? JCA MKYRP(IU*_JV7?>.N<2?LNV<_2HIV7NC#(K;T?4^RXDG%1%?IX"7Q_9!)#++TT M2"\$**((9IO&8)C"?- P.%&K5G&Q_Q2"P4J10MP9161_-BPP#C;5.\$D2PA)F0PBG221NM, AD3R0!1%*(6YW,1(I M-27LE 1R50^R.T%21.5;GK@Q@I^FZ8#R)*N=F@P+8=2^TRN3M:HP# M>&YVCW58QDSHO&=CK("X_IC= I>#0W+~WRI\$E6(I(Q:N1(9PF,N)Q E+ME\$M^E\$NB!~(&4>IH0);MZ4I\$W^Q,O0BP4^N9!32LX;H1)&";C?5&UV< MDU;S+=R3,3TGKS?&Y^G_XGCDKQOYT1X41"Y9BCOY M5K>I\$CDOKW+~ BO7148W^CV758^EPT%6#X;RW4%1?>2LB2B\$E8H1MX1@1KTRW<1/3% I?20"1/7J^7F5@RIK)1;G M.%#WV16WO!#9^A,IUKFBNJ?LI=SZ18C^B^0!AT&\$?<71.(9H/Y%8X^&2>C1 M1!D5?>B1,S\$91P2#8\D6M-!D ^)CF.V^9LV6NSB,7;8;D&-XT#@QH&?Q8OZ M;141BH#_667Y&GQ5/VT*%2IKO3Z_NID_@>EO(W%?O1&=)- =Q^WQLUF_#^6T9 M7.Z617OW+)BVJJS4K;K1#GE/C8#Z#16_"13%-4(@X4\$<(R8BCJR. M;+=*FIBC3IS\$6JYE09EVC,PR6J-8;NGT_9UB/AQ<7>RV/H17H M&5\$S51@#)SO2J#72W+~#5"51*+? 95I+XO+=5D^A2E9^P!_B%(>IRJL4"- (8 MBLE(W.*LOJS4.Q2LWG;=1&H?2DI_CDD(4(P13P0CT8H1+ MSGV> <M&2N;J_-6ZWI&*8NC&K0I^<@3U_-5FRS7)H+~GW_T<+R,+5_O M-5BN^H1^NSKR4P^U%BU9<95;MXZ,Y, >U%9SAH1;M2L13B2>2ETN\$F9ZMG M1?IK.WE/GO(51R(4I1#1A&#R%~DY.Y(I\$0INMECH1_+H 2K1=FE(+<4&W"?U8811L#~^1&8 M1FO2K#1D8(CIYGCZAO=K/2&1/2QPB1;.&~#-K!~*80 Y=L>(Z.OJ(16Z1*5 MV/&&>~IE(PWR=CFS#O%>>11>A;H=&O>AVQ?YX617KF1UVVS1;~<02"H_X MTGN<(@K34/W((DI^FR&.>B,WW%C2^F#A\$TB+!3J;~LRU/C#9 8K12=-A0NV%Y M8;C<=\$&8^U.BPXSVFU9ROP%6Y1>;3>G1_!HPYVSGAUMU_S1Z&C^E81HK5% MS^MU;1421P<"DX""D^DI@HBC1+D\$+(%)R_~H(3;71LH_14V=7JC^P61A3 MMZ13C;SF=&? S++6Q19;VMNLF^LW\$P^I<=D/A=-1ICY;~(YW MCXB-XU^O1_~%1NRWH;G=Y1# I^C+CF71#>T1AYO>Y!)Q^"A.OJPVZZ.C=>)G\$;~A8;=K70 XQ2H17XY^T#(JHVM\$C.ZH1L1 M,X801K;54=ABJ6 DOI^B/Q8D15;HARDS)Q>~RZ.6JZ1M&Z>Z>TY;I:02#1K<3H(\$;HJQEFV&J#+ONLX(MH%TL(SQS.\$K0V1%73107S"2^@GD5+\$2PFD *~,IE(+D PH)1&1H8F8&(R M.UWIX\$J@^~).A8?1FHZME4.6;8B@F6;K^O1JS;%Q78LT)1?9 M#3#~N_&R;*JZ1TKM9K- 9PK^/HDCP^L#1;=#M92(470,1P+\$0"<0>H;%4 MWVT81J9=G-O%3)TING1_&6PE@R/10;LV;^K< 5WZ1O>;MTCY;=5JV>^1UR MZOC<=C9&C_WFW<~JG@~L>~>6JPH1&\$~)AC2-@A"00F*2X01\$7L8R1) M81S9;) (Z>K;5\$3=+%+5T1<~%1#(+93;=HFMT_~DL;1L_5+SL?A^SUYWJWE MER9=[190N,2QM^P?J@ADI9SEC^M5O1QFB;!

(L\$.EV69\3I8NOK#:<@IK-BU\&RSY9:59PA\2KMOAM\IWS5J3MM."B+&WWU6Z3I8\$\\\"V M\$Q6FAFD,TRB4D-&
(ZU/YF'G29L8~%S#~M)TK_%?Y6A>AT:>XLJULRSG\ANS MB7R(Q790<)N(GIAl:API/183 MI- M\38:~\LA:~<,YP
V+T,490G&~C~\R\$OY~QZAL&D~)F7U%(<Y9-0 MG YCR_1Z5+~7OJH^>,O2#T\$.O?
+LIU\IS\IOUSVS%W~#%A~!~?Z,8N5&B~!~2 M(2(8\$9HG.~4QN~.,9Q4F)BB#CKI,~9RD Z>:~\4 K_0Z^=-+I9E%#.
&OD% D M-#FD=GQUA:~\$>~P58C4~L\$H \$R9\ S8.H1<0U.~\$~#BQ5E1U5J=DIDNF# MDHQ7#15WVC/AZTK
&^O//NRP>GC#V\K 3/F^4Z>UEF.FK>/C??MXW,Y)G2 MXK\$@^?KPYQ=2K#.6O:A?CE4F:~Z(P?
W9X\7VPYR/*3N~/8DQPI8?&HO^~\K M%<)D^48)V)9D6.6\ F&\$1S+\$/H-
4ZK54J=~/D9\0R#3\R)957=~\$>D>*N^++61U5_)AH\$7\5T\$.6 \Y:~DE1ZMD5E%J7'ZV/U_?
5:~@U@~\4 *F@W\$%1 *C\FWM3B\8\8\TJ<^ZB\00-1^Z- M;W5M01~\7ZZ^B>+#+L\SO\WY~&98\$~W5E,~IRI0@6.O@
G#B1(O%SJT(FK)-RUX\$0R\$8T(S_XN4\ MM~/H,JR_ 'T'CW3,W).BRX+(C0>?50\U%9E5E49UG1&1E\7K\BHV6K\Y?
KAF M6T>N/AE9U?~2E 4T%~@B\$@F(\$I1^&DL)\2QX&LI2R.C'6NC:S9CDK\NUTJK MG_?~GI<@Y68JK?~ZRO\$A(
H\4AQ\Z+M&~%&(4\$T@&00H:"L"2D^N>E+R5,\(Z51+ 3N0\7 \0Z#JR AT'D M-1\1~NV%Z;J#;R>
<&2ZW..P^S^>5/;~&.4\TM^M\=HZYXT(W/^~C M6.N\I^~*E6Y Q-J_ T4Y&S?Y3?Y5E+KLI05;9U^K;=U7M%P7A*T?
0DE\$2@6' MG 2^<~@Z8A*D7.N4A~^~^~(9PJ.K%Q#NO5F#H'K7<&214CET~_*9#M- %DK\I-
MVGD/#C";N133@F='8+K4:X7=3AL=~ V@%5(0_@CV.HN#WG5HC^B#NF(SD MF#@H,~NWX@I0N0LSX\$DN?
DT0^~\D7DK_ Q..AG\$>2QFE(1#Z%6.C20>1#X) MH @H@DD!(F8N6/3)&)BOM\$B\H(GE5#JB^F)@X-
T.MM2.'2R.=~)M&~VT< MG*%6NWDX+M9;.CI=AG5\XUWSNC^=&E^ZOIT7NE~*%&27* R8B7VJR(ICOU(M\I
"R.\$(0~\L\KJ\0B.O"5F(DA~;KYA=~/G\B*E'R0"W0Q'SF/I>4O"#AHL\CMV4^D"ILJ8\#7#P;.@K@E!~.U MFO
0\$2YA0&4\$?91P&(4\ALR@RC\I_ AY,++W=K>28RVSYR\1VM/4~%4UV9Z\$~&9,>662P5@=\$6.<M~QF95S6V\$CUU
~BD\KU8H.5.\$(<~B:~<~.QDT=HQ:M^B\7&Y?@:~7Q\I_ ^L M^~8R U+I(K>=~<F /#Y @KJ6\$=~/G#H9&"D)\
I^OTZ6GK"OVQ-<2JW<>IX7 MO%FIOS_28K7Z8\ 4P^>,2.0%C")\$(8H(@2GE#/HA0=B3:4R0-"^UTB9F8DZM
MY8(CP9;=7=KQ;.#04:RVH\MF@YU*K;1;E-J90P\$/G.[M5;EEKILZNIU\$KK
MW3.66NFSX+342N_5#MSS9E\JOE2EHCB:Y=7;_2S8ZC/_ E?P&ZYI3F9ZE\5 M68IU><7^ME1G2OU-?
1S\7A3\MRN2EP\^2W5.1%~@2#P&.*MZ(\$BD) MC%~B"12/Z=&IV&F4W%BSM-RP%(+LACMTIP+
XY)=83M^~6G+CC25Y=9WFD, MCE4&M;W"9%F1BG%:2VVZ>MT*0@FY)W_64K=G4O-
'W8WWFA3%=Q7JZ3W\$Y0.- M/(8PI=~/,%>S)?(A@&&~LL0QW&"<4MT~\I?~&A-P(DJXVW/<~\I^TY-DGW9#C,GY
M3AR71\@U94K~T564I+~_08,3W@!#;P8DBA67(*)~%1ZNUH)RG' A&#<8@M. MDXB)*4.~!#N9JGV7&B-Q<(
&~VHWY~\L=&RMU&"L74>E84;=B.E=NWI^BB+F<61CIVNP=0=C?Z;JC?9RDW,=.KW+U\H\FW@O M1'F4>Y-
OE;QDR/H6 _PX(6AAQ&.H>2I5(Y'G,"4!P0&~*5>&E#EEI@?~C*7
M.S\$W~\0!8JL)D,*TZ8(MA@:>RC3(V%~*2@I)8#60GDRM>AJ~\Y\DVG LO\T MI@~M=I\A2.#9N4OV\$3Z4!~\F\^OLK?
QQ-MRN-VQ1>&EN)?&_6@~U_5 _IUF MN:A9B^?R02848\X\&~.2ZD10"%J_A52Z?MIRCS"
I&IGMPB:F#0/8D\$E%_RN M)8~*M&T=C#;HS!(8PI@Z6XYV6Y?~*~L+%J\2)E:<4I(^O%Y4=~JX?~7+~MN=9UL16?
H0 ERNOQ@E"%3C3R(81A3A,@S!~\0FYTJGNQ("XS\G?OT1@9@I.M.%9(UI3Q&G@EX_<W~@Z:
H3*04<>EGP;~M M5OPZ6W\ 9 \$JR9F@M@DTUJ)~(X2F/H(>P+3#~ES^8+W~QEZD2PD@JVB8L@U MU4_&AG<
HY1\GBXR98FX2KN=++~^~369XN\FOG\SN J G\IORYPIXEL MSI++\$1<L@MN^HIPJNF#
(BET,RBZ(4(KA,~*!~4IVEBEASNE#(H\^"AS-(C MCB&S#~79FEDNK75EED:S+9EEJ\FOSBQ=!00R2^~\S)+E_X7S-
)YL5O^XU.A M\X2LO^O=|SJOHML#O>@W^E.O*LL@4,~. \A*(C0AXLBF"94,4I,1)(P'@=F M+7K,Q\$W,-
=>KXF55:++^<5~L\I(~/4B9)4^&L\I^>~9R%J4)ECJON9>I)7T M3(B9E~.E!~I\$39K=L3,V,%=#JH#;S>>YZ\$V?G~V?
PAQ&\WNZIW\,@ M"E.8QYZO=Z9@2)- 0LFIOQ\DA29>PXM0B8>S+54L!>I++=6\$R@;<@8N TC
MV&LW>)M,=7\$~VFRV\!E&L-W-9;ZW79N1(I-G5Y\$V\WS.1\$IVI_X\$W7.A6? M2CQ\39YID?
%~\6'GAHHH33\$*~.0B)1#QB\$,<0I)*\$~.~\GRU*~Z5)~.B?E% MRP1\H0OPP:I\5~.JC')8%OMN.723+
<"5(WV6E6&~FKWZX8BG>KW%)HJ0'7. M2E=NI^5FNJ\U5\EW?Y.6ZJ%I?I7Y9,2*2IV\DP3@4&~*~,\$AY+~,%8%(
M'OJ\$6<4>+7(EYAS\$M1S\$#EA_~\64~J6CQ\WDPN-U/UJ^ZIH2_NZ\IHIRGT_%0-7)\&D-X MAFF04AK*1
2)>5I?YE3#~*ZL~R6~.1X725B\T-D,4; FC@)XP\BIWHWJH M7D\!S?P2-
BR\AB)&%;S\$~5FZ^AAEF(WDD=D9W>BB&CYK/8\&S\<2#L;S5@23_ M_@~59\$6WJTU6?LV62_ 'W?^R. R\$O0CX*8"
(KFBW\X>I/@X4^EY M-5G520T0#A+V(ZO, \$J(H3~. 1~R5%(9\BC&9J7!>5\H:O5 M8JO>N%4_W-
~R\XMG%Z44B_E(12(^A~*8\$TP PF811\$;HQ#IML-K\9D^?IP M\K7XZ\I)%LY.~)EM=X4XOVF>NGUJES?
R>V?XE~U\I\$3I9.S MM5+A@1#~HR#FD\$4B@BCT\!\$A\)*~PPE.D@~E9JOT-W28>NF^E@K\$02L@-H\Q
MQ91B>KRP^J~%~+N>HE5~_V&IGX:HYO@({~_W5Z8.V8:X?ID4+@_0Y3K1.XD^~\Z MA^E6+W~\Z86SO~TV+JYSE-
A;=D#T.GTQ5W?~\1#OHPVT<~X&~L\H\I~.M~*7\W6LOOL6?~WJT*20OB5+~\OR;JG?
<~\8F+* O~QTPW0HI>K4G VE09 MKHK3+L&ZKK9A)8 ^2+HY>\$0T+%E%D" W\4N(ZR/&%K;X
~6@OWMGY\SV\3\VBJE %E0_~CH6#~T5T.%~5ZT+~KKS<2(B~\ITY S/Z~LYU/6+6RG,&
MMIR7H#.YQ;\$0BNZP\1;JCM*?0!A_?TA2E\$4I^K7+@LP1^E,80*~.0L#).4 M\G&BRTB9+VQ)>WP+*(I~\6HX"?
~\40EWK+~R25~9FL5P^RVXZ#Z M^0MPM5X7&=V\J^&~ZQ7X1.8I8-10TUCE3BX%\$%OHI-7 BQ(GI5>Z#
<5COV17 M.V)W1NBC6#_XL4<0Q2\$&~?T18\$(\$B\((.7\$#WQI>H?~N.R1H\@\$U37I3X~M~^W&9\H49@-T1
#L1NMI2+&O~W(XK>DCS=F#4REZ7~*WTV\I>S>R5#?KZT*~\9Q7ARP%(5\$^=VA^T 4>0(2F@90Z~RQ M8#+FQ#-?
W6\3_4~?B47UO\)=DR+I.D~%&G~V^6FT6.S~NVFVRR1CP&\ MXRJXY.E;~\ MA"B.1!+GT@\$(QYAB~*~&~&~(0B:
(0GD4_9Y9%M~4\ MTK4:X?~N^T^O96PU(KHC ID3V>L6 R~%4S~I@~*~SM>J#0 /I0Z5\$AIV2%
MM,ITM/(T'D/8&C\271B+G94\,~\$X)Q+K^QVKMWG_5%U?1IYYN.VT@~\2'(9:KDY=6NI:PZW)9.LB;@~?~
~4J\AWZ\I9Q:\IWWCIN=I?%'+KNM:%2S\K MM/3\J_67%UU:I?
Q5/9@~BJO\NXVN81HQQ#~D\$;\$024%U24@/~H\$#&4:"1,B" M4HJ%355&H-RWT~F
M^~&23^2I_ M65;B; JQ%0%P>XVJR25D7VOX(!E)<~A/ZOM_-R5+56@6,~5C MS%B,A P\$EU9YE\UG)@Y/Y_~L^?~
~\CW13+~FB\JB~M~\75\+D\H#4QWDB/C MOS?#/~\KO@W+D)&6!"M%3H^A^FD+Z~P?~
U68U~\IO+@L=~+0>~2DTU20CI6J M&EV>1~<4%\D1~;3)\3V\LFZ\$V1E93D8K^7)I(2_TD@C+131\$X5ZYJ' K(MDR"
R~H-PBZ&T0,77(JT2~G4S;4U>D~\B%NP-M0QVSVUT~W6;C+4*~<~ M_67^
M.3&CAX@Z\$S\$G(YG8XA-RWJ SQ7A3\NOKH++>D~DZ\$~5G15~\5.6= M_*0~99;ID.5-KC<90%5@=J28\6:
&V~GW2;H#2PL>+Z0;9/E+3IU>74=\\A)BP?.\$HC/ (E M#+\$,(4IX^E,2>2HZPSY%L3Z(CML0TW~5)F:~JHIE6
E\5:BV84=V\F-OQWT~NH%9NG\PZ.T~?S'OH~\LO4\HG>?&CM0> MCS"@W-D^AQ~H5FY=#P SXEUQ">
H>P;~HKYH)KX\~&^U5^2\NC?KIY)EC\ P M3XA I\1&82@59\8,DBB((B@~*69EPW#D~*6J?
SOP.\$F\Z\I~R*~>#D&S\$DJ_ MP>=\$87~"0UJMYO\L_H&OGPC+^?8D\IQC\YQFU\((S)\@H\TAIE6A2>4ID3B. M8(KIU
H\6>SK=VFXB8F@GW=~/2T1: T60.OP\WH~KGYID9C\IQ\X@2S4J(K;_ M2Q\8+NFJ?
E0L.E:CHN.6M\KPR=BEM8QM\Y2Z%CV_MOJ(OY\$Y@4T@3&. M\!\$0(89@&D?~*2.(G.6=4FG4D~J3%I~FNV\JLH
~69K\0Y C9L66M#JST0>% M0~71HJK0SZH^>D>Z;=~2JHIC>YPS+>~3X">8^KN<4;QQ
\$/LR_7F?~XZ4&L~N\WC\$Q~RREORT.%#)7H#WJ\4Z7YEZ5WT0=// MB~;~427X>#W4< 4&=KH5)Z_ZIFSE>QEGA9
M~OT\DO\C0?~QOE~4~\YA^H=~JXPPB\$5GMZFJ2N>EA%3YQ A@41R/D^D+C ME,E1B:D3S4=~:~7-
R;QG\$2ZX0FP06LT G\U\~!~NT~N5+N\;@~\U7*(P5U@M M8K,9X^6+V~.#V2Z>&XA/9Y3G^NSY8K^~\UH\$A\$~?
Y<#~\W6K5?SSAI?FT2MN MN\Z0<101F~"D8D\Q8 4LP02%H~"\$XIC:KY)JTG~Q)Q=BP2U3\7UVW1>~@3\$
M@~(2~FFG~L\<6NG\G\~LW~):A)KNQGOG+M~.Q+FLZ~KQQQD(J\$00\$W;IO~#F M@S_02594C;Q4<+EY?

M%WE;O.PMOL;9%SG4BI!"\$* _J8GT)2JFF(IV29Q1R MGF"\$D2?"\$ _IR\$.A4XXFL9I^X5N9XLFEEH9)N=L;6:9KJ_4RI!
<3!Q^+D@;ML>UF=V3&489M9/E(R?2947_MHT/&^O|<93%O|ICA99"W;:3%J3GT4WTI^M|N_1G_DX"6_2J/E
S0!"8C|&4+>0T12YGE&O5:M4_MMIXOX/FX%6#|UJB|_M")KQ|R2X6/+LNVNP*Q6U_X
IPXZ3"GOV629T(1YU'9G6P'9XW15B>_Z73'_MB&^GXQJ_L:PC424YG)G)3QK;_R_X13N>60#|Z6Y_74?
QROTMQ\$!9O_M_M_IZ\$%"42IB&-(8L4Y?>AB9DP_H7>)F#R9Z>L;= _M.WDB_HMQO_Q4S3U"O4H/PB/R&O(I)/E_9,>A\$-
(YF8Y|@N|4SM:E020252_M38:O;-)B8).B^V6B9'SLSSRD|UF"G379LF+V_R3'3UVJ9&VNWI3LUUG#?
MC)FQ=JU/\$V;=USF>+LQR<2>O"!&S17O"LF6V_JYWO6>5=_I>B\$|_O3_U|P21@F_4+_E5_M|T@AP^D!
2IU,I8GLFQP=FU&F"GQP(<-_%%7#09<3#_MAO8_C'7\$T\$+RO<+|2&Y.\$|H|
BWH@L(L_1S:E.O5H7\$:#D+B14@Q"44(CAHD_MD\$1>)F*9E*!,^(T=Z5(4ZUT)"U\$I6Q^2WFEFN|KC";A9),X|J
MN2)SA.=6*MCK=(SPHEIGWUXQ3V_7)XA&;_IBA4K_81Q@/JH68S:X|SX|DX-
MV^-(F9ZMG<97S|&7|HHJB5L_8|!@ADG\$J'4Q!)"Z4&:>K|ZOSB_5;BE_"_K_MK4G=XB9FKTHXR"KIX
=1"_Q/^T8J@(-+M@<CBV";0(1S;U/+L1W6JW2ZF"E"P"+?M(O+BE7>P_!+M|C(%QG6F9KOOGR|X86'&2L#&Y
MWNE,WG%4=[U;+HD;^V3YLR#++|L,CA=@FE#_17L_B^*ZH6J7WH/'\$|+PB\$;?M(C%_%6S*\$A_@L>0LD;PG?
FK>0<99C;D7EJA>M05XVBNW6W-2V@<V50|U?I9_M'3)S?14&U#@+P_.30P>MP\$M<-!+7;_#|M?
9L+4ZPC<#QFZ;|*V=6VJ_MYJ_WVU/&GH#^92G8IA|DKB4")!7,!?CX|U*61,(@)FN"
|VTH|X+|YT6|9M,M5D4'&CRZRX*_M=BC?02C8=...BX(=>AN"G9=...B8+UND+M&9|IP>_'&N\$D1#&"S\$HWO3
-7"KLLWJ2=<)6H;^X2-@'1/<*8>_=(T2K7T5_1K7^|2VJ+B#U_M\$F)_Q8S&"4AAHAA"5.44|C0F(8)8E&4&K5;-Y0W?
_Q9ZU"YXKH2_JG4<-KG_M:JH0W@Y#*C|<>06H|=;C&H-Q@5E0%PX#|PWM^?^28|EHQ5H9|>*|T_4V
MT?5>K|89)_HPV|_U*UOZ_R?77)7@NRE+CUW|I?2V7+&BES7)77V;_MNR^UG"i@;(?1*C)L>;_SKA8#M-
G7&>AYW_6|'V_12_&NC'O|N|J|KU_O=#U2Y_M7EX4_7WZ1#EE=>KD"R")*8TE8@_R#_BUBXA4V^?
V(L\$E;&)H.M;:Y?GS;...|?KYVIEE>D_M_UFPU6.NV|V|<^4BDQDY%-!D_H|DA>17;_15OHF>ZHC|8)-%HHR,GV@_H4
M3P|L8B"*_G;_@CHC>P55X_8A*K_|RK|J#"M0?QK0\$HWQ_*57ZF="SD|T)VNYX3BYW-9A?PQ-6=09S=K%P6ZX?_1
MS7G|/%%><4Q@R/U-T_CD'@D<1/H|AZA-UF|\$|>O'DJ7?LU++Z/+2|XY_M;I_Q=K|*5LR(9PA:E>|R:=5-
1^ZL^NG@REX^Y;OVFK&;H2U7^#@J=|_M^<%M_NU&_I\$='1)+6;)%G@<3%D4019Z
F\$82^EX8\$2HIY=S|>&"3A(G'2"T2U#(M_MSP;-4WN7
MWB>3%+GVS/GJ>G|P22;Z+|5K=A#L/4UU4+8L4>_4X@%UX4_M".1'@6^>S&|1,C&|U%+!7NP"W'RTZ?
_4@HP|C8Q@KQV3)GJ|U;JQ6;;3E?#_M;7?L_V7SNTI6G7;U-W|JN7>@;M7=6M_VK_JYUJ7C4H^0EYKF_>R/-)Z(<\$
M4HRU"Q|Q2\$B4PIBF\$V3B">|Q9;E3ED3|XV6#2KA0\$D>_+\$+<'UELFG&R|_M^AD|3L6Z@+_.9M3-
Q(V&YY&0^1UMSX9F=&|'_K|\$3_NAS*RY71CE-DM;NMN_M5_DZX|O>UE_T|MPJ??"N3|<=<_?'^5U)=)-
_>+OY#M2Y%G^6'X215U4|WOS_M_Z|^S_H'CB+N><*4NA.>S|U(28D@3&G.\$5"RH_9I?MGT'5BCCP6#_Z2P>|;
MMN5;X)1OS&Q)|2_R'N08VO\$56*|/S@#_2_N<4VHZZYK|)#"?+|K;.(=+)Z0R|_MY*;X|F3MDR(|88('D&L;_"A%.(29F
2G|S^S^)^L-DFBC8|4|N72B"H)=I6_MRVH_P|B_&2BI>|X;IV;NWAHH6|_C<5W8_6W7O|08O|YO3|6S5^LSO;|_;
MA1M"+_#>%|HWW|GB<38QRKL5_X;UPM)0F^P8I#'_4EB%".N3DW7_J8F|NT_M0%|+M.6&|C|_N&&8B7;
<<=<=<=\$S|FQ|;H|N1&J|U|N6&_MCNM9|GOU/O;I5_N-LY#J\$401H&
(8<*7)@*GR3V("1XDARJ2R#K5YDHDJ&4NP(<|E|(|38_8\$.10.^T8X|)"IPH03;..E'X3;+)CS0?C
MEVM9ZZ'F#NXB#TTWSEC=H4|OT|(.71A-0W2|VE3EUVRY%'_?5P,O|CY_M)(U@FH@0(D|*B
;0'T:~X6Q'_N19U&FMU'(Q_2BA8*#U_7XNTW'S39@3-R_MX>;\$4F#I6Y5>YM-
MBK<_1CT5Z|=VZE_3_G>YGOGK;#J?U9\$=_N:QVXY|VM_M|ECP+G|>J|H^U=;?6^-|J4"3_N6UY5
MZGOP(N2)B_80IYZ_*413\$_.09H03CCRO8B85|X;ILO\$?%7)L|BL_X\$UX+Y_MX+*CN|M6CFEK*|VLWI8|(E1-
K|^-|J>#Z>PG'3"X?UI@_S_M*T=;U^|1_N02O)GAYZOKAG>Y^'|BN0OLSO;B|OLJ^#JA:M/(Z+<72"ZWW
M#^1_5L7UDIIE=;ZT'D(XZL(UA@;.(B^)/7C)_I&A/2PP|I%BOH8&DWL_M"YZV@-
A|H'FZ|G|6W|ES>@XG3;#_ZEJHC\$;_U?J|2_3EH_J|NHE_25_MEC9_(29Z_S9^Y,QOPO&_#J*|RD
S|JV7)6;HGHWRX_R#"J33YZH|9KC=C|M2P|3E|O)SL/'E+|EBV7|I_D|H|V\$<"A|X8<1UC8'\$GHD#7QA*5E
MCW;DH0LODX6>TC"09F|U|Z'K\$K\$<2#&PY_M|Y)@_E_MO;FWZ;ZW6EB^SO*_X'BE3?Q9OR%
(G^+X|";&^ROD5YYF^_MC"S?|A_*Y2%|ZF;.>C%AS%)-E;_5"4CU&B3U4^11Z04>_HA_XHV3+WTL'E^
M)L5WG82M34USM0|>W9L1^>|9|V%K|1Y>_97U_ZU>WY5W++^700S^?Z_%SO_U&2
M|DSR\$|K2IR&280QQR"7D<9|D|0@|E=^Z\$+Y|E^+P|;D?99_4L|S'+Y@ZRTMS>"?&NB8M;^TU"Y7ACBU|
|0MRK?EY>_O"6;'RKWN402WV)X+;+9FO7J=NDD;R;#B&S_B#>A|H'_M"#U7.X;H;^4*W)2E;@KE;-0=SZJ>2>K7+?
|KJ|K_)GZ_(A01S+)&0_ML\$|"%@;8DH2H&9|GU_L"%;8Z_'FD_2)!_!7A49KK|EG|>=W(-%J|UW="I/_MZUG|K=0J6P;
5A@;AFY3(62'14;H-8#U|H|NQTNZKY;N|9;_Z5|B_&62XP_MC|4?6-D|Q@>4B)G%ZB%L5F13|K|L|Y_S#S=G#(DON-
XO%(5"-0@819|\$M_A\$?)\$B@*I'9%5&YD+Q'2B)8*MR_7X<&-78>42#Y_H8|'5=D|_W\$#6C*7
MEMH5DQED|6M7DVE5OJ^>|H_UHFN;^>JUE1"1J|(<^ZQZ3YGIYFH|O)8|1|H2)A|TL4AV(|4|73V3+|@_M)
(DED@%D+,(0(11"RBE3|_4X3%(IF&?4_*Q7TN1+PFV|?W0;_MA|'|&A810%NY@_NLWMAVD3=|@R7K7C|H6Y?
6UW+V|PF>C_Z7E>|ED)?+L_MSZM_|A;K;|H|Z<<0>|2'R|AD3".F|K*DDNDRCO_YC-IDXBIG>M*)M@*78"K
M?|L_@8V8E;SV0RVU=*LOC'2;|NMM9GOAUKNM_77_!5;.@%=-|G1|_8UWSN@&_M=&E^Z@=T7NGF".S;F%;5#(K-
BWZ;>@UB;|)3W|5|1|02Z2MO(|_IO^/O'=M_MKAM_V@3'_B(V=KK2|8|D|K|J|H|_MPH<>J(U\$|>V5;-
M^<@'(Y)Z>+=>EDAF|DGB02|0R_Q)"(DDF";_!3PP_L_N)FYB?MFT_M|_Z57F|T.?H%)XQGYAR_9Q(|A|B#6LWP0SD2+
I"6&S;@QFP^H|L_H|G|_M;J|ZRV5_RZSX6)22TVJY=AT"Y|C'AC'0:QK_%P|/#=#L_GKG2;_M4_HN+57W5NDN.><\$|C%
H9)UTN|_CKC6|P\$|9#H3>+@K|_S+MYM=-L9MCN^O|KF.8"6|T;H6|+?02WR#*R\$CC>;GD_UTC3;)676^2,\$U;_)
M|H3E|C|FC5R71#M_*6=DWM1O_AY^9F6RU=|RG;E|F\$B)-&ES;(\$5R_|Q0)_B'_E(4|AD9_I4;_-
*RD3CRO|@JMCVY;_LIV%GPI^4YB%|L1|F_2JXG9&N*_MN=I>=#K<|B5|RS3>_)U/E5337W='04KON_MLEIF_#
I&;2**2_70*_*Z7TH**2\$4"N9A|J|B86SD;X^@R|3D<;GG*.C7#A&
M/5|L#^VP6L&U8|'4*MHY"4>AYDC_9.5|AH;>"KK8&WFNV>BEH9>'5IK9UR
M2U;ZC>>7C&"DD7R7(9K_ZM^_8+)|#_VB_1|H2B1ATM+4@W)"E?|#(8D4W&/_MSQ3=
<0H|L1_1EZ_O=1|5Z)5QLO|TIF0;.._2;A63?8G;6_W(Y|BFT|9\$;UZ;_MG8G;N+V&Z%7_?Z=B/9;9JR*Z_5|?R^B_U*G|*7
CWY|761RTX_P|U8IF\$M<1#|@<|>)PQ+>6|G|HB4%Z86)0;/_K^Q+RAY8%;H'77R2+|F|/#%('QV7+\$|
MS2UCZ0BC5;|2\$*QN_&#X.FUSE|J_G_A<_KIMSKRE+IT/LI8Z+I-2A;G^EJL'_M^)|@IU_WGI2=|@C018\$G_-!
(|_13J(TRQ%Y\$<>91TY6602=/S_@;6;?R9_M?WJ=Q|F5'0|8_D):_6E5?L_JQ_|S9EO);(6QNUK1?H'+U|E|X17|4_Y6E;O'
M30_L3P0\$1Y3_D'/E>8=(0_IP...\$2AQY@4A|B|V|2(F'BY*)_R02W4LA5;_MNTU_YM&A2_V&T#%(I^FT%;W-
C#H4|=LZW7W;|H^DK7?..)GV;X_G_9>Z;..M^4D|ZX\$^R*N"YM5UONVW1H|Q2O;|/?3C_\$R8"(S_ZIV4_M-
/4&|BW+5|T;=OZD%X|U>=6U*I9KC_VVP@'CE*K@)%.|H;(4\$4#JQ0GT!\$EH_MFF!&9:S>H3YI>;NDY7)&BQU*_
;JNX_H\$O_Y\$6Y_62;0I>)35L0&PC;DI MB>>A"2_U3>+|_4GU\$H)?
<#>+H(4^6AEMP^Y84^E\$;VYENEB_YF+L;UEMDX1_M"GZ|&>RXLQWH&QWF7^5U;(N;)'EY\$G;FUID>=>
MZRI\$F;C+3HW"UGUB7E_MDW_/XQ|WV_?L#6_*5Z|9?&D2+N_6OR|B2_?8@E3R'R\$PFI|D&A4%.*3/V0
MIXE15|SVQT|CZQD64=N+88X';X->V_M403|R_M_|YMQK"M4^?|F*W|_@<^V_G|="K%JAWQ7G=4NP?H%-
/2P>8<&4ZD3<|=N@|NRT;/N6=JT5_M4JH"TM*\$%M1;_2|_<#N|&G#%;_R8Z)=0ZU4'_<%;)0_6@N@U
_WM;\$^3V_H'^^*;MPFI_N=#;X>SHS|8_O;|H_+|Y|-(6WQZ|6M_LM@YV;N|J%<|_OE#W;|TVUWV_MG;R17_HN?>
^>?)?JBO|C'&)+5+A_L5#3#8@0I20AD)0|(|@)\$|1;(|%68_MVEGS@L1N|<+|BF;+&M/QD>;UW_P\$;_IL'M&5@H'^+

(@=="R"=@2THL(MJH)>^M<0\$%.*^H@J: M<@WP(\$U.O4#V."KBZ."?_2 SG?" 6GOM PH?B%@G||/^,783QUB^J-
V)V.^7F MBX#>VOYI\$=6.*^/4FR0*=<\$IOP(@G'O83&0)@|C'!(F/IBR% D64^"U(L"&J0* 6A
M;N<'9\$QC#\$G'A/(BX5_G'N')>NG+JE#HD3BCSY0TG^F14.-/17)SCA.P1BIX M239Z6:9_Z+(:34)H!
3#D!E.B88#X0P#1 @81%#X3@DJUER8HY#8+U!OR
M7&RU.AX:66TD6PE9.PQ3P(8^T1H86%\$(<6(0NY\$2=8J/^5FR.O4(B%8 M?1F2^L:==||+'WUG/<>_QS&JVL40_Q
M'DMY@P.ZG5#.#JIV7^XV>RA'NUB00#825H_9I6RI'QYGI(XB@6A4\$:Z1VR.M^!)Y<0P#0B/J42I-
J=5VQ\$F)\$WO"UAM'66Y*#:U'I=-LQNYILYF-XE&-83>>
M=T6OS^_J&%-4QT20R(XCGLIX5#02D+.F4@2Y4I:B:I\$,UB)AXC&N)-O3"W3-L1M,XA)
M8#L0IMWH/4+H=K;G!;K5T9YAD- X9\$^WAB<.,JK3<...>YGFZ1#XJUI%SHYBV MEV7V5;VMK_)ST30+;@Z_W
=I'P'SNQ9 A'\$4)(HP8L4:220XPQZC3):.*#LE
M:;+>V(H%M)9GYQ5TFL?,&1@#M!V+;"7J81&YNHTWC3_BE8(WVG6)FG>1/ M@3V/W2@-
HOMJ\$A"\$F.OI+""*21H!*@F\$2"B33")-(&|ULIQ(P|<#< M|&B5^MA/EBN JYXY+\$/N/(I/8#DOH*X#LMG\FV(4IE,8??
2M'O|&HVX?7/=H.M.|C.O7\$FZO^|5H|@D6|*C3"AE^B1#*A5PIYHEMFZ'-K 272\$P)'GM%I"X! M\$XIR+1
T\$FT+R|08P|1G'@:1;FP=H'-RF%M@VOC+P^"K;O7WJ MGZA#U7KKG+6H^G0_J\$?5>ZD#?I0I*ZY?
EL_JL:E7|TF*C-/0%NY=L(70%|G4) M.^&)F"0:3.,40R1E7)?0@*%
(1FFRK RASM9/KV7:/E%|JE>OOHL'^4I24HGXFV78KTB<*KF B/<)*""(* M!A"E@0^QP FDS*>
((1DPLS.&N(G9L:56)|JN2#:6PGYB5: Z@XH6D7+M Y+ M&YLME4QC.30^U'I K0C0FIR!K2Y@;<|FTVN|X-E-Z-
6B7&SR5CGJ>R\$SWN6 MRLDP1^>HW)|BX);MG|5JMF+/JY7_Z_1&?I7YBZSN4Q\$DO@".A1'NFR7#XD^
MP4F1\$*6"11CHWXM-D(G)J&=P5&DH)(48G\$Q(YNBD MYBJ-XKQ:DPFX3L'=-\$:R1-8F.);QS:2T>S+
TOTO3ZWY**84T\$Y<0/(9R).|V35#OY8 MQ.24>"\$|SWX#(JF69L9>F&TJHUT:N@T.^R7&:Z0<^RZD<-5VZ3V>?
66Y: M'=O.<-MJD\$4L-ZI6L+?"SL""-)5J.WRCE89I?>X M.@\$>[7]U7^G@|P+.;IG.K>|TB:X|^7WY3BG|YST*TI3W
MB1K&L;|&-0LDI#&6NCU+FOB2R8"8-U:P\$CWO.%-KHMV?1ANP5@>L|+&8X.V.M:N+368J.OHPL!+XHU8&:&U
K8I-&I=X2S|H|D.Z.8EC6Q(.V)R1:I/I=- M\$^?SG)R0|OE/|DIP| #1|+PH7J4B|O)KQF4I|@ZJ950I=-U?F5?V)?2J2KA2
MG'^^C|CJ RV|?|HJN7G8ODON=R>SOU2ER7^6)2K7^GK_L9Q0E|00POYP2B M2.&CSJC_U?D5I4.@E+
|=G|F.FNH?>DVIJ?>L.W&Y M5OE00VI=*O#&X%W;MV9^\$Y.U?%Y7N7G;23D)B_FJ# UVVCADAR# M/?(A?
UC(C4A+J17W1Q|GJAQV%)(0ZKWE%(J9I"3I2>1_R0!<1S:15Q.03 M@A)-C(53US;9(JTFL3 |1|U(XNCS
ZI<6T|K7)BAD*^FV38OJTI^);US MQI28/LWW;JZKW0J6.Z%#X2W-Q>LO=ZL|HP107\$2PI S#%\$>9I240"3B"\$:
M4HD0@2P\$EAI^2V\$VTI)+?..G592.IP7+RJS/+DNEQ>T>OOQ2E|S<6|UUA|JO=/:MH(C)H=SOLR^LOERG>@F"
<4!GX:0D0" 3'E#%?^2%&(O9%>+|TKU|A+MJ* M1>RK52A% %>:@.:>5"H"l@H>|JCI/Y" J_Z4
G2CD>4Y=W.CFP6.TYC.CJ" T MU;02X,NNU7Y96VVC"S@_37I0_#6!ACK+RYX'F/Q5L;Y.A|O/T37\$LM-7DD
MJ^/WIS2)D<UAIH<#WK@= MYVW K23MEAG7^|*I-2.&K;3" F^T*CH3Y^Y>D|KM..J/>V7N1'0NL1F73NS
MJI=BKM00+I?R21?;I2\$G\$;=-/##"20Q)X/;#+=&\$L\$F)T!;\$V.345#2K MDTV//H57X\$ _M.:@5L\$PH#
RG=E@'N+R|9;MGBYZ|X6RG|HNZ|H|BRY?@5_77E|V M:NFWH>\$UUB6L10MC5C0R
6)OJC3WN=K15VK'V@GIES.M8UP+|.*?%Z":7 M1R/69XMY97N.'G)JOB0Y59V+^6.L%M!\$,2OE\$|H= M-
TJRF7YIV8G?K4'KRA& TYVR=(.D).EE.G+.;&6T.#S2ZP5HYL-5NMQG! M&=B.CY6&H%\$1;UG.;K-6O&J?-
>)SW(VOQ RO)_I0?/T?ZL:5" |C%UO/K>-PL I0? MRGK G;AJU%!NFX., <*PL|W.ALJ84Y!>.*0\$7I#E;TL5IX O\$?
%U2CDKK>2_7/2BQ4A.,P78#OLM*9N-|..R6<-<6 MMH:H>?
#B!&SKP7P"U\$ACN\$O*K\$W!-3#\$7OJF1.O:Q2"P5KJ2JDO+2(MWCO.8K.,ARLW8ALP>F2JH8|V&
(-8CAPMX4%FO=MMT+OCZ@W|.X=-Y8OE_W MO0#|O*4N%)YUV67|A85M2EG%&(A4>O'BIR" 6;
<12L4K"8N0%49J\$GM\$A MK(JG3TPF2AYH!-H6E#VVA.E.ZB|=-ORO#|TIS?48HW2Y2"L.YOFVJEZ_Y+@
M6TSKO%UZKR.-=JF5/..X|0WTL|AZ_98B#O+I9I20D.-(#&D.\$X@0BG<0I M32"W"):
(2Y|@B_XI4(F9@8M%#H"."ZL;7;#F#<+AV1&"U" TIOAVR M56;A8.AOG|I?
J_)/GV>^=.E_5_B!;00I:IRIY=*NIE>"2E/19%?FGV_77 M\$R-<.(@#8)H"1I2Y 28I8JDL&Q4+QBS"2M(B;FD48F6
DI Y|N+<94NTT_M2&0P4CL*.0;IPB=7X Y?PQ&|<8>%J_8CD|Z|2R2?N=|W%)K^9|3-) IIV/
M5.7R_I+G)99|4M>/4N>I9D4|PN=-W%/91C"D/OQW\$(44I#2".A_AE2&N @ MB3_Q2C|IE3+Y%D8C%_S1B#;
<7OV&Z>>3T>#:48HY4N.Q982D;Q52/6|G|5+1 M;|OZV/_L60:>\$;SUV#;
IV&V#8+|DWI|=OGN&/>QS\$4&|&|O%1<\$/\$\$LHAY M*8I3+S\$|I12TL3#|\$/;\$8OZ8\$(I%W4^I%VIT=-.F.MLG&.4
=@/SJ#YF_9I5 MEE@(|I'1-HCE_U-6_RHMUE042>CCT> 0#YA.(.XA(P)#C|J\$(C_D MZO^_5P.ZI\$Q.)
(U8L)5|BYL'FQT&L=@66_R8TT(K697&@|J%>^L 8|V6
M".Q>NMTJ2E400L%G33/MU9P2O^IY8*3%SOV|XK8CR;.*B1.XP G/\$UL2G68"K8B)?M""76E-/0%..O"B|L".
G6BHS8?42^EB=5TS\$SMMSQ=(8 M|H|U6;.JW|\$. 6QVLOBB>6Y?5.L*U">"F4I"S=%)LT|5W?5!";.5 |QR+4WJ|I\$
M(FZDD/)7_RYT"=.E|I82N|YF!^G*|U|BY7?3COU"-6FRLRB8GP @YOBAA\$W M4&.43&(' PG'
M.):8=1%I\$S.Q>=3M9)?;=K);L.4.U0DS&|B# 9ON69ST\$;7#+=3A|QN6"-V MPFT1.GO^VZ@:9UM>ZZV&Z9"9O?
UT>O7)\$6D M|BHE-- S? 1QH_ J3WQ"\$|26"0F_64H(F'.B.;K&2?@5|ZLA!8RS<;KB?-
MU3I@QS2"W9|UOV|\$.W!|I2*4(IHOJSZ83M43SYXEL%|F|I7(VOM|8^524 MRP?Z(*FE?
7^7:S^N9%>55)O/*OU>.>8S55_HI!=\$"?5)_K#6K%==RP..SY_GQ?U3?
E@|9%|^K^<(VR5L(I^>DJ|K^9U!|@*G/<=" \$ MGS)FWEBI7<.\$A- (I5HJT&+P*?/L<>VNUB\$+T|1VLW_MN
AWT.\$L<|D C M.'+HOXVK|KRL\$. 9GX2A#)"YE2'NJL S"V-V'K;."78|JZ
MIW4.^&4.S'8.TP|7A6.Z<5NPS|CXW7C&K7;.C|%M|G4)T;U!.147*9 M?U1O_E^ZW.^|G\$XHM*#88H"B%(B072A|
(+9|PG&#?;%EC=,TF9C;U:6&+ M3RJ50VX|ZTL;G^66L)OBDU#_NO@T93L%(5;4%6EF@M05;=764IA4&-|I
M0CWJBI|\$@Y|=Z06Z\$OGH9=/L2F'X)97.0I'F5H*;|<* ?AWZGZIVDZHGJY>K2 MX/HXQ?)1JCO5H|D\$U;..42R#JY;.
<+8^A>?UUT7=|P+=64KV6M^ K|O! M@R?Z"N1" |CJQD38|O/??
7W2QRT6=F5|N&YW|=399XKWUCMCC2IPOEEN"COM MS8R3""9SX_#|\$.M'NM*\$G?
K8#".8LDY"R#S40P1|@C\$ODRA1S 2//|D8-| MK%O\$Q/;.\$@DV,I7W9K.DT&X2@UEK;#|Z><(H|V?BM8F^WH.#?<
=CN_3_O^M|?S6.V?M81|M81""OJ<8128\$;1R=FBT8@T|+/P|GO-L/GV|0F1#\$(H|U+!&|SXHACD#8\$
M.OBL8UL,PQ=J21=2/J9XOBV&6EB4=|CJNB^S"W2YZZD>96JH7B>BUM9?LVX MFBOTX^9IGYX1A>7>;4L7YI#
(4I"U?ZG5?H+YBSD3\$C((E1!\$&2<<"A0E MB(2;EYLD R4TIG(34I-&-B1DA<..H|Z;>YMH:T'4ITF0LD P M|ITQ
A%..;1A1&%\$O4 DJ8AUOG?36NUV2O61^YKE.L327Y2RF%/@.G\$|=7B^-^F'B"J^@8"TI")%."B0@Y
M|+O4D"A244W@&6^&= B9>-EQ(Q74Y_NT7(O|WF48 PH<X=XI4@==DCZ8)L M06<9?
@_S:\$Q|>H#8>66V*LV/=0M_^-E)@QB=*SOI%-23C&-' MQ1=.;7/^"4H3FF#E!4RAL@7%
(T2F")/6HC(1.S9/)VB1.3#R-2/!!^>M MG\$Z_%K\$P|B.M..)HXA.I_Z..1J>^>)C_.8|ISW_7J_#28|..*=/>1S>./.)
MCPZ|CTH#%WHMKNIN'E|TN?CTVZU^+5+M/ZTP# AF(91>S"\$*XP12SGH
M1|N|H|D:FL8L=0:RWT\$M.L7M4G2;7TVFDY MR5C6^PHNT\$=.;|<2/>LZO8M1#M23G9|AOBCZF.Y=5R78*
|WM3+I>%.^#|SFS'Y\$8<&%MY*K;..MZ BV2M8%2|=JGNGB.|G*O(W.^@B05KJ^J7V>"0VR&HCL9F;#K/2VB S'?
+;ML(29\$9WDXOI+U^<|?2C(A)|VKY^88;|05_"U E|DF1;E4WUL;LON9KRRAZZ?
M)ER|V8WZ7DS@CUKZ""Y(&YB>BEG|J M4XY&(H_/8>_LMH:E-I|3A;_9R_ "3T M(W1;O"P?;VG^L=1IEA7?
EB(E.1%1K"9LY.6LA(B|.8RAMRG"6.L#;S8_ \$AW MOZR)AX^6#6KA=2V"C?@SR_IT_?8R6(P8SPIV8ZW/ \$X'6?
HM87.H932+N"U: M.'T:EJ==C"#VGWSI?2.IV".L.R?B#&|99H^CVT;#SSV;|^<DR=K|C-IR#S M)8*.8Y_3\$">)"\$/C-

PW(VD3\$UHM#18I?G48-("594^LUE MMG(RFA'L6.BHF=O&(\$IVT!9EJH5'1@GZ5MJ*L-L->U=WP.
!07!UUD_TZQ(>R MU!+!E;R59:O5FL2;?=-/ #Z5R*7Q4NU>&T..QP>DE@K8!Y6T6J!T^L60!%; M;J:8XAYW/./I-
/1NL#9UOGZ(.SN^1>YW#^L>OYWK;J1_TZ7E9Y+^N@U>? MA-@C:0!HJ69+I+NDDC@*
(&I\$+X7\$Q(XV6/5A\$3#I9&E@)/0_VJQM-O\$ M8&E;%#ID7<,TF4=HOVMQ?+%8-1NJQ86K!ANK:(73^121?
N=1ZU;I&J^MR#1 M2Z7+FH4^_0Y5_VI^_TD^_SQD1Q(=)0A.JXEU14P&>1(B)2!A(HMLK581 M\$_.(\$@DV,FU+?
!6:Q&2%="A0.QHYPNBT&MH*UF81="CHMRW!U;=J !DFZYS MKF;V;Z_B-EH0MG7'F>HW+U"/SAT?Z='ZU:23
8DI1-.DTKLN'H:8DP@* M1OR8!EP1AT4!L XI4R=\$U&+!5NX9.+^R&5!=QC\$AD!\$@VW%(*UHG'NF";4,E
M(!W+!5F!=(M*>8\$JGZ6Z;IY1J(YH?^UYRZY+7>35\$N(W;ZG)U_SZHA&1" MA"=@G.A50B(%I
@SJ&V8\$B!)N5EW@5XI4V!W;)G'?0.U9.O^7NTV,EL:(\$< M!\$UC4CT2DL9L>KNZ9;Z; NW--HL;/.T(!E?
@W&OL=A9Z=C6 M&(<./7V_2P#G>Q%Z_Z^*KRUS_O@IRP6G_!^60L%BY4"G'D!#&8!!(DGB1Q^0R M7SIN\$3
Q^6N!H)%X!JY_MNIE?FP,DUAM&\$2!@7V SJUE^S%;JX;M@^"^^<;OV M3MU/-&L_OF_5NV=6A!T;N^N^SC(Q;?
ETP&\$8P27!55*HJ^+D^*MAREO2A;HL!)9DUSYMX%_0198699Y1PR2P%Z@N!V00CB_NOOX??Y MJ9!197-
W*!VDEZ6CUAG@2F?74WR4@^OW9I9\$+*UK!^A!H!^G7 M% "JB^915CYQ@3L2Z44*K@^V!^&4TM9K86"1-
_X\$HB4")!+?..?/!5 MJK-'BT%;9K>!.W&PA%"MR8F+5"M>I@, @_S&+4RZE3_1P:3EQCD;F'3K?="_
ML="Z8(!1>JX!400WQA99_GRI/CH2J9B9^AP&"<\$018&_*!;(B>8)3SB MBB_Z;) +S;2?9%E71UV>Z(@91PACW+
(?"PA M\$ES7^B0I3 A2S\$ "D7^C^H\$G)4W_-6NY^CBDSB!^O*FDK1EU8L0YDMOXT"
MWXYTH#70D<^!6&..R"\$YURYJTN<0KN42F)DS>X^3%%P;LRJQC-Y>9!(&4" M!"SY7\$LC_*0Y2\$_.3(EI
CPF>1ST./656!4R=-K^1B:H MA5JF)I3:Q6QJ^XS6CCT.@4Y05^H7T5BY".TRYLU-Z(-YE)O0>|;.+R1U;+
M^<#*!UHIGN?U?_2.VE>ZT+MHYAL+6L;ZT7;3+89+S+G>I6.416IVCW29RE1G M+*34\$R+TB;1**;*4/_\$(WFH#N-
+%;@#;FM)L;\$!H(+M!OY;K)4H+G^84<9 MY2VIE&42I5D3@2/^D2C^5OJLY.%HFD-
<7V.X!FEFW=I%G_0JY;./J^RKO.QY M!22OBJK2@C!NBF_D.)! IUFN?IE.YD6L;R1?&&K:M.%Y#Q5P_N.?K!^H21Q_M@!
(8>5)!#12^#D)5\$3\$*%9_BCFV.@DIKGX3\$!9GN000>2GI(ONW&IAU;3KP MTT^D;N_Z'+4ZL6H!
!A4,"PSJ!9^3V9LIX;6MV/#IK?7GJ;@417!I/7ZRUE# MCEIA4&M!K3.FI^R6G%PJ/D9H%IWH)0?|=#W-%8=ZYCXR-
K->I!&M;>'46? M2;RUEVU;NA57>9?ZF;IYL7.D82PIB \$ODZ^8M^B^49TB1B^I2C;%=!=(? M!MG\$!T8MT+P)X0->
!+=VJS\$;JG!42<Y&2K>IE_UJ63OECU6?U/!^I^#I_M^!Z8MKC^#VF\$Z?@ZY^N&Z;J@VV2_JBBN!V;?
S^_4Q+^\$4R0D!%(5%A5Y) M+\$(5@N&(>68Y8!U2HX\$M3^NR;IY!\$F!;O2CW70Q!O>D6AD-WV6!U?
KMT&;!^:WOW7!UAOGVW!MTWMOH!7W0J>4SIC\$M!Q8+BM!%;+! MJW7&1A""0!\$!#SJZ=9C.63<0Y#A-
\$8IEWZ\$C(XS!F9F\$^T4+^5>@..2!2^ M;PWC +C #7CDA;D+HE<;9#MDKA' SICLX>_4.D;I9?
N^_U(900U#^#1^P1^K_TZ2KGD^X4C!0J>86>.% M4V/0X;3USMTOI&R 'M9O#Q?5M6+&@D?
!^TW;=H,I_L1\$X!#^+I64HL%*!AGX M6!3+O#!M8G5!;/W#=#2&&-UZZ_0!|=IYV.Z?;!77@;C<<>I
M/FB/YWWQ1+!AWE/QN4PI#DF0.(AXS^!N;PXI4OYX@-0L2HG5_M7NTZ=-=VQD
M5>"/!HQM;.8!0QANR;C^LIP6.49FOP0!AF^LG8^!9!^!&M&ZVA%O/4BUIS%
MTT!9VE+300^Z_2^YN*>QEX048Y5=\$MTY58;0;_%"*PUGC&3)(?90+&%';11 EF'OFM1RZI\$S.76NOX\$7+!
<56<0)U4N>5(=) W6 M;EC@&I;=&C2D)8(<?RT3! @=|/%"M!8V-V6^X>) _4!|=2U MP%-
(>Q<#_V^>;S7PEYIRX\$G+W8@I+I%304M6SY^4; T4?VC25;X7+_\$ (OU2
M%L^R7^JY4!W;4M9)KO=1%&..ZM0!WEZVU) 35!P%GZI?D4H84;^IPUF)C(
MMH(L!JZ3)0V(&K!V)%IVA#3/7U;!^O2)!>7/J^K8^IS^LIUD=E7W85GE9&^
M5)2<9JEZ7Z^2UD_7OV%T47=WKAZE7^A^6#U!A<|;_Y_7;+>2!@_VT+IEK? MOY2YSOIHHJ!+B1?
!A8QU7!_R14!+;3K!^0!R!K1VLLVA_R_GJG!*<'SS==M#;&I-Y4;>I#K-
//+!Z7Z70.'3^V<=2^VZNI457W(DW2((E^79%/US%3!V+ M/4YP)(AY0I+'YEGP?
1)FCH;1LMHQA!>5;QY5H%PP#^M^5;IXL1!#M;_ "7 M9!^5VW1 K%.(E>BQ+&I+!B-
8PHW;W2WB0(4G4)QO^X^S^QMD)W<4JBI&YRR M;.(H!11R)
DON0L<""**RGT@YBRD^G\$#Y4#;)Y^TFR=KZMP!|=NZRHJ MU0PH:SPKV)%6GP^<&7*8HRY&^S%I/N(CC8P_Y-
T%?;:W!W>9ME1 MQV^8NOK?@_FGM^43138*@5JC74!F1Z>I39/S>4UJ0:DSF-;Q1=>.^6BIS!C MI-UO4_I
!L=7T#;CO?/%2KZNG6:YI1078>Q5_ZC6E-)/BW4N5 MY;JFFRVBT+(6!GUTWU^SN_I^\$5)A!5JGMJ_D%
(0A)YB7IC^8!8)!+IFX?J M9C(GIH(W2@^"VTD(C!G56I5YY>WXIGPN!H8^K198Z06T8H;.5!L8W6#B&-^4
M=O;\$UHIK!595-&CYF-?VQ!9&MY MJTL2;I&* (U3=HM9%@"^?+BVR<_MC^")Z9P!VA^*T!I%Z8:O2CDFSQ9RA::OB
M^PFQAWIT<Z^2/42#RH9G\$5VK:OES^I^H^YGY M\$4^A2!4E(13YD^5>_%"F48C!1(O_!N=|
I9\$S;1+L9J7JHH;"6!FCWV;?@(: M";\$=^5B#^9!@>P1G!S9K80W2HLJ@MB=17HJ4LRJV3+;F;IJK=?KA^U)7
MNE-4GRD)B8!3F+^N04!UEFA(*0P2^&!O)0+!H6\$!(F!97.GJ8/EKG0^!J M0+9!;BU!GH)0.EDD^IYPGX&+L
(5K\$;NEKP3O&PLU5Y;#UU;J2; J-Y?Q M3.+F2-SH?8;J3LC2F5"+S;>C_W7!QDM;=;"OWYL2>>.6.;K!F;_6Q9PWM<
M4@2B.+RN^RD5^Z!64;%.<#G?@KIA\$G=/L6#&&\$?>82-^BN!JO@ (D)
M3@D\$^XEGX..5S:YWBS\$;F&L@1#NV.D#GM+G? M-F1W!8W+?=QN_6O7_OON6^ M&3?LN!7>WZ7ON)BC1BG&
(8AFC5_XO2K^=*!^IQ)*DGC^A@!R) M1_YYF?VIR&UZ#^N(0/<07&A7Q^<_GH>>Q&@QQ-
75M,*R>.%^#X;VZ>PV& M=WYMOT9!5XKSLKS.Q6?Z9.23!TT5>J19@O5N_#;U@!8S\$!K!^VFI;H3 M3%2?
2!79UTR!J%"X%Z358G8K(*<?@!TGS;HW0I@=V&I_0(9VY!T3+?^4RSKU=?G<-W72A6WNEC%IOR)";Q;.!A031
M!+^8T@2)"#SDH#X(49B8U=PLG4G^C@K076 =#Y05++>YG^LI0"U)J^BZ+2
MAUC@!C_9)567W=C6QR8!98;9+!HWN!G!N#_!^I^A!H4(-H#1>R5^~ MWD I#FK-
0;ZZBWNQ>25IN"/6G^CHE2SCE!S!_Z^>)=N8<#;OU;I>&_R4_=& M+=-)GR_VF=R">Q^4!-
+&+5;L%&Z!GX9'=8H!4D)NLU@!^343';!W+L;A MM:N6.A#W6Q=+
!5'_5*W4MEMG+97;H_MAI=2^2UW6<6!N8P"\$J<1!)-8<867 M)!;\$CX*8HRC1/*_&=5#73UOZG6W!HLY-
P8+>18;6ZID^-;=FSI6;AS\$+44H9)H%OW@-^@")3QZ1KR1M?5NFF M^QAH!>I%;!^E=I!F!AEP)LPB2!GL;IE-
AJVCLCTH!\$!L!/!S6-KQ_AN M@_W!^MF&VZ<_*!OP_!G#KN%6V^L1GB>XPGXJ/L<RQA>0)<^
M^N!^0GXTS!;GH@O><2!)^!8SDZ_6!PBTMX=G6?Q!^O8OQ"\$L@4HL^G\$#;/
M0>\$!^6.A4(8+>6LGC=U>^9?T2>K;^8KH^C;2G^+Z.SJ_-UYS_J297!VM?^J
M.PIG5W;9U>^G_3AKUVF5H2!WV2U_>\$>V6%0;7F0LY5&.);0HC<**60LUG6_M(!0)G!OF==3;^4Q!<>M1
(M\$!1";/25IN8S)I#D=J^AF.03E-D^UJ;F7\$H MZK>=\$NTIY!^6^<I#K MMI&*ICAD%!*8DBB2?
AB&*IHWXP6"1,SAD8!ZJU3\$O";+."5;1E^%WL MG>FB#;H-6PR\$+_9DT;^VU>TW3@C5?3HO<I4?1A!OM@C
!15.*GD_H20>\$+/THY8-\$GE4^M+^L=IMXEYLE^*3_ESICZK M^\$&B!^&);H^3;U.6&L_A5TAZJH^G>F?IT^;3?;B-I
MJL^3Q_IH!MD^R195J43^J9^YN^V_G\$S;1UMH)"3P_84\$*TY#B^RI^"3& M(?1PZ^4L0+&
YL5\$0.9\$/+5@.P^&ANV8?8Q&9F^QLC6!^..??;1%3;7U; M6;8@;I5ZM<("ITBK\$R829UV-L##!X>J#S:T.WL3=?
WE>0^YE0I<N?NOU8<=<M4)\$R^_0XI2H";07D_2\$PCBF<1!>^H=B_8fY_K>C7?4VJ1T!B M86(641*!%@FTS#-
P85A@O^L@N^)(0)AV%*\$T^V86 M4!VIBPR"<3FO;N5;MU!
KN7!@F+=>A!4%.NYT(4I6/%5HR;/SI:OVT^WZGQ!5YOM!L^92AY^FT M4L!*1^+CQ2WX!2*)!
(I4E&3LK@YMXRBT!1L!+ZOXU?^94FC_\$!J8NZ<;MC MU!;17I\$)V!UN>_M-
FMJD>I5#6CJ@!C;IVGM+N@")8Q.OO=Z!#0W/_BX<6XS-M!\$XLYX%1K=<_E!|=!WEU3 M!
(^!USTE@1*J9O^BI@8L!VHU)"SZ8!1@!N^Y87 MZ7H@4KQ!U90:EOE M^X^.;U>1%
<+>!GC!%8/KZ!HOZ3>=|=!4LCY/U6>M=IFS_-&1AZ62(02YV+ MAUD<8^2+Q4".%,@G-

T^;2IW<=JLKE'ZVJHJ.%8A\$8'YPKS/<8T, &F M,)'=L#TJOZ^5:;)B5H7X:SW-Q71VPVHC_:?P65?E!^O96-MY?
E/X^NITVJPLP.3KEO!^5)F65Y, >2%PIYJFI+H62FZ49W7&L_OLF*Z50
M/LINUJ6J4B)*F^SA<7F=_E(U^W^6R_08\V68^C&PJB#B*N?"\$I#F(1^*7' M TL
(^MI=9V8M6N\L\$CABXHQD)9I03T3OR4#80IQ; &W^6QZB.XH?@:VJH=
FW3>U/E2;U'='7D/O/H;Z0/FYKU/X216Z6ZQ! I%>J<4<L_16K>9ZP=YQ783 MWSQ&
(YTN)U9AODEV'EON3DW4GN#.0FS+Z^);OGX/G MM:=EQ+72="1*Z;8-*I7
KEY@HJ@9J%4#C6I@)ZU==V\XZQ2AX28:*7-H@*"S M)A0--IAAGM\$(3W1COC%I>?O\N\NKRI'_
+SC^_IQ_ ^YR^7=X:;UG.1.3: _8'> MPYSA#>WR?7=_< <:Q8AIG#;/9>R0BGUK;6=E^M,?3@ESB77TF%?
M=NIHJ;^ MKW3QTFSN+L;%UU(I)XB"B82YA\$ 8&OHK!\$QQ \$LM8RI#P1++IO-XQH; M16FIHQ!&N;8E6U,
(N1^*YE6KJ\J8S!&U, H?CML&JX9*2OMGWVWQK_ *1Q MI/U4<IAC:.0&\$N?U;U-<.1B6MSJF,H>!A^7?
_VM*)>AVSU/2\10PIJ/ M4>AA2\$3,81I3%)" (B8'XOKES&Q5I8(4HJJ,4ZI+.WV,5@-7DX6KL!W0;4 M-
6H!;%E3OLPY,Y)!<;OVCZMO102R;SYEEOG36SOUOTH\WG4L>20A\NUE5 M+B\O;R1=?
*B7FWXK,S5I%I_RZ_)&5K+!IL\$Q5T!M@+8@JZB0P@DCY7IC,M*_,!9AAJ7>Y=CSN+,H*6>KAX(KZ(.ITL?
HK_MB5TO^V5Y+D3=ZIC2I2EY(.01IP@%7HE\$M*Z 5#>5.GZEJCK=LG06;74.VA/*RU=J@R86M;,\$9K
M7D4^V+H_ZQ5!7NH#CPB&H 8(U@/!?(TF(C>3ZF4F=U>"Q-<>CGV-INQD0M M-1\$^?
%_M79YS7K14K7NE^D2738U3O6&YZCIUH M-571QCY@D/%129\QQK%>(M\$DBDAZ,68A!&E-\$C5;
(QE1J8@H4A9?LTJODJ8JH!^*M<^I31C 9U@(>LA MEHD807;"IO,;^4-LHK,N\N0U01X8;I#^M%1TQ_6).NXU\$B;H-
M?CFG\$0S(=I=DN9I83^-Q*NEPNY&^;AAT\@(&O M26\$8!0%\$4:I8TXD).JWBQ/BE#ZY@>PCP5,S(!*(%A)/
_6=7>;S&0>PX M\$*(=UQR@Z%_402 MEFV55ZV8!_#9#BHWJ9^K75.ZE\7GQ4LJO7_*DX7^O?WGBJ8XA;!E;TU
MT2^&"9(8>A2G\$8YB;CLO?K2G23;CLO;ZEOSI_0_7)XZ!9=-.2&J3>L#M/HJ M0MT,;0QVW^K_!%BA
V_ ^FIOXLZYFWM^/H!UQ_5 70W^P#/(I0EIV^M:T 9!&<5.=+J(EN^?MH4!4.QOAY/(\$I^ I/;0)(U#0/_#56^B4?/=APXI
M4^_U&)!Q=HP6?@DTUUL\$IKF&Q"C(#9E>TL23GG(N1\NEX8AU02#^*\$H&KD6PS?L9<-%HAK CI^T-
G+!76V#3R/P(^71K.%&SG=Z)&55W#>?DH MUQ_#NM!(I2QYEF,*6I5KNF5I27G!)?UU)#
(SLD4OH_4_83Y;T*ROVUF=IA% MVIR^>IEOCJ5E3!4S0X)2*A@D, +H-X98=Y5G^\$4\ M%\$""4Z,R.O:B)R; BT?
U+UF!+/^;72AL83RSN^8;DIA1X5H^--B\H_=-M(F^ER21G@NP,_%+8;%"XUAC0WB"" 9W#\$YP.3WE!?,N+Y;(2=^/?
U^YX93P MD^OX@M0+M0^4E41^R6_09P%/^4JEF;EE;/0)F7Z)+ 9;J6?@->KCD\$MAC%9
MXH\UV\HMR;U;T+5#MFJ#5=Z&_*+X(42IRB,*4*KIC1#^V(HCDH32LVMA=R!@>Y1 D\$C
M0QO+^LZ^9H#^/N&_31DC^VT;DVKCS:=FV;@#<-V\;UZ^IR99UA_?V\^N M0^NC=G5=USEP@_)FBB=Y1I_?2JY?
EAKZNHJ+3D_X(DO=2Y<^R/LDY1X."(\$ M0Q%\$V%=LX;\$8IC0_ HE"3X;F?2*,1\$I^R010,D^
WSE@M,^6T9>ZG_1KQ1 MQ6+4F5G3@&Y&MY%US*+ZV.I9V#^5* I%/7E@%?IC.0!5&-B@WZAK)8^9\$
M9X6IE_K.GC0?&5HAVZ^NSN=NGM&OGICQ>B\$^IA_&*=>N/U/.)XDC?%Q2B M6"!
(\$H&A(&G*:4PB&EFD6W5(F9@6M52P\$KO/KFPRKSJ,HZ)AS4^9#N6;T7K MUNNS I95M_A!
^XWV<_@!_=/SMNGK/G9I_ ^!UT_3USLMGI^;NJ**^;Y.6* MEJFS?I-U_-IA+W(BU\$?21BB#R40)9\$&"9AR(*
\$(HBJS)9/;(F9IE&EG3 M&N0,I\$@^?I3R#<>=B=7,UHE^LH4=_0PP@_4ZL^D19^R3-NM)K/EP:=?D M%L>&OF6A
HKEZ?U12S<_AOU^RYWKG23W0?2&D7)1P;BLVY2E,80(>)* MG^0(QBEF1(8H2YL=&2S(6,J<>Z\$7^
*^RKW4% H-WV/^/1KIE0#>QHMF^IDV ME@/?W2SVO7W_@8I5V]=XKR!77ZN,9 IT MJSZ?O^P%=^5+M02!>"K2!
<9KA>J3_EU7ZKSJJO/SC97GX\$OMI^H_14WW:B? M@%QC 3IEZT=V^!UT?CD&_#;^R>V(K;WN;,"N"O
_PDV6HQOH&^_08::LPF M&98&&|SBH@>Z;N*MD>I;H6Q%W4K^I+!B?JQD;4QE)+P@@ MT^T=D*)?
B!7Y0A6N>;OB!075B?2GB1,S*^_/_%+M O%CFUA%G@-0FA^9IQ@
M30MHUI%5)Y^1XJCCY_-77".XR1NB1TBH@((E?TG\5B03>KZ!\$&*&OCHA\$ M^!%#^+*\$2(@P3M,4(RF(TV*?U
M1T)2XM%03<\$!KW=A/34C@4J6=-%N M%1!"&(S5CC*,83IQ1CM>+J88C/MM>_7_7FE+!U1N!HU7V/??
HO=>"/SQIT MW<6K+;?%(O_84T?J=IF_0IM)3#KUD\$)-(0!92XBD=*7F2RBM(B9FCT8F M^%G2,M?E.#J_L!A-
I38Q(C_12.VX8P5R)4^#=&_&K06U#\$8M1MS^?B4MZ M2122?N=IS%)K^9I1-) 10.7)QIGA?1A?YBR!M)?
_7K^Q=Y5ZS*"EZG^_*T4^I60_?SIZ4)U5@^=U MIKI%QL M%T=MYKO+HDGL!>=+G
MT7VYO)0\$PJ@.0:>\$B6E"201KD;:_=OL8;8,A"EW: ^!.BT4-*&U&:99"#B MMUTDZ5&^?XFDI<89%TAZ!
Y?^NFI^T^VSSND0S2 M,* 8^I&70A2\$5\$4W<0A#0ACV41 1SI/9^CPA;V(J<HK5K6ZTE29*7D2Y!N
M^DPN=%^PW1;I^0QV!P\$=K%CG=VC;WH;=669MHJ;XVYJ&J(=80UE+19-UP-
MH1INOYK>YG@@)G1O1OM^E,MGS_3#T(I;2J^K90GE4NCQ%F"(?#W^4A1-CZN1GA(O
MBIA1HE>7@F^7),1U^+P*?/-(5)6ZQAX*\$Q&@WU@IA.15>;<%I4W-U&%I^ MM5OK_Y3=*WAD&_NQOY7)2Z#-
FF2I23 M<8JB,^CU@I^\$PDC&(81I@I^\$P13^BAN5I3@E;+V6(D%&IDFI?+L+&4V?X^!
MWXY9C*#;IY4I@6NL_K%=8N;M\$WL^I%\$ V%/7.LD^;IOM!0715X_I3(7)KL4 M=15E5;VH()/FBU?5Q?
=T*6I)TBYV22,89Q(-9AIA^"FH818\B3D2<3IR"BS MR56;Z1?IM210ZJZ\$S)I3F+49S*\$SADKJ^UO#8IG.)O:C VF-
*#UJGIMN!4J M8*6+7OEOM/E_*I#HHWM=-!KE71-FN:PHC+1S_E;"EQQI;@<#3.45<) MU^?8D555+NJO=4I
(S8^W7;TS(KS!UEUW\RS3BD 2)K@C&\$L@P#B&).8H M@5E.C5I4=TJ8VJ=8B5+SJ1)FZ\$9TFZ.2.48!;>DX&
(S^MXG.?2-7W7SSMA5 M_HV^C(GSC(P3);CIS3%(KY^!#Q*(C.200Q)@B^42^!+1Q_RSE3SPL^VU HY.Q^FD&>M
M\$5BKYI(P%V)K2S+/-ACU^*ZCD_,D(ES3D_8+DNTR)J8;+1-L MA-J>LVBWBL^"Y"=FQP#_.MG^ K7JN^PD-
QNZU16KQFV\$+?8L5;INO77. M8L-INA_4&^ZHU.7DQ8M^PG5;-YZ_YR0H/0#"C1V4=<0!Q0JF^PLB3^3;L
M17I2(GYHY&EMIGJNLV!P_V#&#&@Z!5>#\$-DE4H@ M+ARU>IMO<\$CZ%*U>7-P^I^5W_WRL98!BCI-
_KG=;K^F?54IAI9I> MI^AU?2IR^7;I/SP7ZGW^O2Q>GFU7#BR? MT(WE4\$;#6IUPW6NH!&F4D6#AP-
M,=+"@:WT61<.'\$USN^#@^ABG @V>CW_+^&.VI#_?K@)&1%&_8A^I.DBUDQ@ MI9-R!-(P#!;\$*
H83IR.O;1(FG0*U1+ 2>09^OK4J5=IB#Y,%@X\$HJ2C@\$*!; M48861%8E&88A?N."#-W*GRC^T+CG,48NO4^*,703_#
IUF\$1^BB M-\$YF @A(>)Q""&LX@-I^5"IF^L&72Z^C^Q!ROD096J2.YE=7VC6^F0PR
M;\$<01^@F^*W6^F.TPFK!3Y^YK%HKM..B;NV7;.83>I\$M_4H?Y";S-/D3/TX M@B+%/D0>"R"+.8)"IV /,"74XLQ?
FX2)QU@C\$C0R^3**CPQB,!\$A6DWSHXO MNB85^T^US^H> MDJK=CLY=KG%7>A.9E8?3CO)G%77H?
I19W7NB86ZSK.CX6 M^I^)*M^C^08L2BJEU+>R>+TK3/^15<6 LTQ1BGW.(JHHA6 "B2Z+*@(L M\$R^LDHU-)
<^3DE#7BY9^RB=IK I5N1)UJ5BX5>M+G;U9-EM31<-+>WKID7 M,(G-
I^AK9:X M^A0RQHS4=D6WUB9R19RYTUEMC7^46ZSIO&.:0IH6GB(8^ MIBAD@H8084X@#2F%/A?OIQ#2%&E-
AG(G)@YU@IR5K(M/1B8S9_8QC6&'24< M^V+8BI^**;S03G2XX>W)P=P\$IXX!C\$<(C9MRZ7E^>%/P1S5CRO(?
V6)1?&8,= QSI M08_)#4Z)CUX0W?BN:P\$7?^YQ@KB70!H+!H^TA?)8F/HGHT2W@>"<M6VQAM
N9F)NT4+"5>@:_2I?^*16PWC_E>QG^X=E34@M0M_;\$=LE7^XV#H;INO MT;_B7S^IGOG3^CLU?X@X^I_6L?SGC0K?
Z6+%;_GN19.DVI?2K_ (=K^J/D\$4 M^#@^)"\$H@%K\$?P)?,8H,*)0B0@1A^Q-I55;EA+RIO9^M2%#^+M^IG96HSLIAG
M1\$M8^D&V1K_ _VD&;RCE2>DS7N2T@SZT<%)P1NB^ON>AF&*4& WK3@D3#V0E\$2B1H)9Y!CI^_E5S
ML,4)EI^0)AVH_0(H5MY01;H5N45AT^<X_**WTW^AS^2)Z?Q^O^YW6^200*\$DJ#V(-JA-
04ZC&:HY\$&4^X8(SIQ3U.P MD3COL%IKT!3?T\$J<_W&_PV4(O4OSX#2Q6+B,3*CP9P!MG^LAJFA75QF9B,#
M68>^B^93? VF^LG?*,S><V.#: MN-B^F-_%D5?%(M-
GS,2^?)GI0U+U4EHL0RX0Y9#04#>^TPFAS/=A(&5(*C^IW_AP\$ _OVI5(+)(P8M.Q=R.@_I55SCZVB@-
BC4L(>X+9< MYQ=DX(L;FG-MEHM&X750&MTWD)*+^K%K@K0*,84)K-85@+9V<_IY0Y,9 MVLZ9&FJ@7F?
+^>'S.6-#I>Y;X,2YA0FHI#<%B_+QUN:RQU7Y;.%YO ((G3 MF^9,P-3C!*(0Z?*<.%Q(R\$^T)T)ZQ+P!;_LJ4-

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|_&M*IXI*G9^B%O86ZIX2U\$? MWGE|S_?2I:|3T:|!(9Y(3ILJ&*C#%)&8PDIZ7O4UI*|KT;4(FYMS+JGJA MZI4UFTBL*,OBF_*7*IV:K1|WU/2P/@.5S+.B!|Y)?E+*07(BZ6.N_1=3T6Y M?- #12AH6+ <5K_:O:U#C67'N&MI0'+0.L#|_O06H>3?7I&"A%:1J1U'2K3#(5I-W(YW4N4IH9HLCKEA?W2_1I&(GIZ+ @D.+R5=+EHG'M,X3%+,"#.JVH8M8F)^ M4"+!1N89^AE5IL4O_3I9|N:UL^E1-83/"9EBCV?IRZYQ%/> <0DY,SS/(1@LR3\$E*61G'"8Q1ZS*C89;_B0GO MXZ(H,T\$-2TBN(-3F/(B=NST)>KZYQ)I=V!H7@-R7I.-> M"#I5|P|CF^.;1;HU'D_.\$B^S*5_Q6?AY)WBZ)XRO(!=#+SZL/A<8TE9(\$ M,*9)I)&7(\$A8P*P0R^A*6*!.2(151P'&- IN6_H1B_K_#W MU#_ '\$6YI0Z9_= G^U7K5X6X.#5K3QG MC+?OJ811H9T6E6?2NQS3BX>|_J|>GM9WH9XK>7- NY&_6ZZRX;<6IZEZD M2>1CYD-/L@2B@/#(0C4G"IDFWOIF|MN:(I>1=^*7C;.)Z+@PPMXP;YIJ-7= MMG;ZHM.2I?X08\$;).Y+51JR2FWMK\$|_6R;6"PD>-%LQ'HD-8G_.\$A|3"02 MF3P-DRBS.L@!%SVR1W|=Y N1/I|\$Y*M13DQ035.*5=\$ G.P.G'1&. Q*_|@Y3_M_W9:&.&;Z+%7FFS HZUPXT=(%#PC^,W2|^T Z4HJM|S|Z2182KR_XXR#9IN M_|%9Y,5*+ +10.'0GR@F2AABYD4A3F+JT3"+TE@|ZEJWB1B9*(Q(U,BTD6)NOH)- @/8U^XY_@'=J2.0G6=N>4)|\$Z_#|Z M"-9U97|GY&I1KDVU?76C3\$I377;|+>9PZR:M)ZK/E-W0<+30&4*BS@TI6I% MP\$PPO6Z/I\$JRS).BH*Y.B9T*HSLG^Q_?O%)^"?+9U6|N/LGE@C#_93A<>OC MKVRU03MUFN/R50/LK4;C."XP_ \$9P8"P5>#-!@90ET,#;G|L=F7|CZOAC95 M>|N06;_!OUKLS8*|L_041D@<OW\$5_"F48Q9Z_68IS)(?);D_>JW>F? EJR_M6CVHMDX|Z+I+=%* U8R49<77_ZHL\$QM_"1D72D:ZJ3F?IRB#EIM^UE>+ MPRYHP:@0 GRU4:%T|^&AQ3F_SDC TND;PD>=SFITMOC IW0?Q:G|DI?&_1W\$ MG^5R|9SKE?VR3D- TB".I<0>X3\$F1,28\$LP%*F8RBSR5&9/V2?%C\$S-1BS: MEPM-=C)C|V:=0BC82S;J|_Z93AH_Z,T P|NW8#ICP9D>3*?NGK()TQD+ MCKHPG;O;4W|1:UV87|ITWPM3=ZO2S,0WT5WB^45.K1_H8ZV_X|X/@HOJ MM+(\$?)F9C6B|U4U/V6L8>\$Y3+D.H.5L)Y6_4A|I=3|6>SHY9QIM_F9O|M@> M^"8+8I?#F(8AQIL#_8VS3IYHRW;J- NVC;G3>/Q-S7&P&C9;|!RDR()OP'V M>+D^DA0W:KY9/SW580(VOV3EP|? Y|ON'^@_E12_UFE6LIB(54)PCFDA1H0Y"(HPV0D?V#?=50\$8'9)1 C1;HCT8/8"5N*SSM*'-H ME&|\$.!_8&*#6P075F(G)2\$(? <4POH7D?*"V1C_9J98BRW%4^IOU:OYJR MAT^%GXC4QT(O\$C'A68@9IV+,O2|C";_B|_0470(&YL@_J+-#O1-7?CHEVWA MHR^F|!&0&+IPLR2\$@= \$L\$>\$8N^J.2C(QH5,D>D@DL3|QJYG>)FG;&6QC| M;J;W;/:7>A"C:_6,@+^9@O|K)JO_FL/M0MP>XIG^JOOF0X#*F/B9?%F\$5, MX3I)_=#/O\$BD5@40+.6-/AWTJLB9NQ /K1=;C=|S.S)LM#""^?@0^4Q7&_M6"9H'YKB>I#TO_0*W/GFW4R%G1XX#OD4P?MR'X5_TVL@>LL&PE9&#M1?N MEC9Q8;)&E>R*#4PKR(WX(9N2V1DZ6(C_R_^(F:E9F9_SKQF66|E4 M?'GO>9I_&YO+99%|?M_4D M9&J@TPK'G#3UN;(JB7)&SLB_4@E#|T8:S\$TX;8V==\$S" P3|BV0I\$ ME<09^G36;+ G<;H@1R_4U(F->Z?;? 7X4Z);"UV0E)@^MGK|E6W'JS_9)C3MG2GP;3<-V\$*S&FM#U_?JYS M|&-J>B;LSI'18V5>WCP5BLFOBU|9D9L_? F.K=1=X_-I.0: T3C_4|ICWLO_M84DS\$47.8.#*W5;PR.S2B\$*B8\$!06OH|#!^8P_"HZ)*@|WSH3_4*8%J+=IR M@;9H? >M""IX8%6CZ4)U2;<5.VSH5";.K7JK0^QWU3AXK58@_)P8H8%Q|VG^;T/"NKO!& MLBU_Q0ZFU0; (4VI7)E_>%PNA2=|TWE:XOE^5|I^B;Y5S>Q;@%4@8"^Y1ZILPO_YWL RR\$|(@>D,0, M6'.M6^#H61TW;%YO7_|? 95\$?6Z6;TQ8|@6|39P#=#; OE/8Q.WE;0Q_W3S>ZBZG@D T M#M5R^6? Y>&9.AJS0/AZ0>>GOEG0I0FF>HF"?;)'5B4)10RH%"Y"RLC>AY&* M|L1"3UJ>PL8FJ#R_Q3 F;#|6K430";M!58+Z6_-&A8*Z#3A3*^C\$S5.6"^K6_M_ZABT)F+W7R4S0J+S;6Y:I8:UHAZV_T8U4)1#_8=?E^< MS#BXP7AL_,C3@G<^H\$<(#@29T5_"#CHO#""YAE_D)1@M+|+9(8.L-K3_OTORNDJ)V#|5TLQ4X<;8&|3K, KS2;4T41JZ|_M73JE)X_|_*IDAH';@U8A|E'28D?22**_7T(-*4>2D1:0BH/M,J8^SUD);) MMD|GZ|_T+J@%16KM5;? 6X\$KH5=FNJV#6NT#K8+ZVNVV|G*Q'JHZK+LS.*H MJ=8IET9=NA|MC#HO=3V=PU<|QM|H2";F; IPTF01IA\$H<(L|'WMG1#F<1)Q M:D=H|/%_;"R*4Z;+R3.)+|<;LP8|1M\$N9^/I,IZFO M#|UT7^|0WO/SQ9T;.:2G28Q#*A0F,0EPJF*)E>()#Q*E|I:M_?|?#R)/O, MRI*)AW6I5AV'N%H- I9Y5#NK#9L_GBYN;BIN?2IGY<M|U"KSYV^KJT^|OC3_MM?K#_K+;25U|'2#ZK@<;H6+H40|\$(#|_!&A, (I;G:4IU5+;GV:(8 M\$YGC\$.STXOXI(TB"6'_R|\$(^M.L8>=:70E\$C%=CUXP0L%JO9_L;"YG6+G2|+ MV1& Y.S_0U_TRV|O4|UZPG;IUNS=JM^&_:I#Q=|SC2M=NN74E37-VX^8|>|KPM?2 M@;F39DFHA>JOL1.2I QS<=(HSB3G)_9NW8Q(T^|:9U_.EO>LB?|_F|O+S8O'K\$_.VC<(\$!)1,TH!@RL(4,Y%"%;!'-E5HNN0,?+| M-#*1\$8HJJ3- T>0&KTH&BX5KW=18V1LL=;Q_4&P;N!#T=W.M(0;W*6@_MPZ)S+0K;|VT/T&^|L2- ";HN=2"5CY^TNKX>+A_8DYIO\$S_|+P|3F(>8 M^YQAHED& <|)I#;"E9=Y<9(R;V(Y+6=D);9W|TW'|=!Q|TWH8#_K*XW+@%1%O(T^& MB8J8AV-5M;UF MT|BY_-MN:9@7 .TH|*@-SNPYT|7GN=|%RO|QS83U; M;4E#S.39R|3A4DF|=(E|#\$F.\$YFFC\$;4"^QC(JTB1N;%6B;)"VAGR_1D79, M+|BOMZ4PDGMM|OZI-U; (UMMJ-K0"/&9)G?9T\$E#IG=-.Q3:2FH32?4# MC|Q|N&S.M?MID.Z?@_X<_-^=5;I; I|YZ^K!;_&D5.6^8CC5ZQ_-(C_-0%* M|IXO\$R93086|_I9+E9%YI9(F)S|8+6@K_G_@E';0'42IH4;P)F3P?ZF.1R#_M6- G)_N/DT3,?@R|OP.#C.C_|"C>W<|I#|I*W|HXOV1/3)B: MVLH+T8|B2;A/7Y"X&.*A0^*D?L2CVK+JX_62.S- T;L8@WPGMW|46)J9OU_#>V9DFUGV0M(O|X|V| MC#2/H=EHL.WO/4.F=WBMQ9#ENR|6#U;&RTKHQ.6I) (\$"|+NL%N&M&\$K(NL' MTY+|HRE|_|#7INEZ5UT40Q2E)EOC M01&H(S,&+|K5N#ELRJP^!L^_PHAY_OWA" |GBNG|1);&|08!H6'&8PHQ/_OV2,O/_A3VJN|2G|9BN4V|3U)N(BYH)CY+;/S_MXP0S)1F6+);IZ*=)1JPZ1UG(&GF;&- FH\$H7T=+05#ST/T8V7S0=V;|1@TZL+ M_*=/C<2D\$_08(B|2?8RHSN3W'W\$!-^DJUL.? PTV|WBP%&7ZZ*H:XWF2_E_M";(S56SF;44|Y0|(>1TIX^WU-44F*\$|^CJ214|HG5(L<6? 9DOISN=)E3|3U0\$2M.4IW\$; M.X&%I+,%V';=AT<;F%;.FIEF7U9AXV<+EUV<=D%>1NT(IZ0L?3.4;\$P:4 M_/_=8MJ;H5(M3.AOO=">|MIT3%LL5R8UQ|QSVN"Q6|^Q>(0FN=-@*L^U&CR-J MKLVA&J0T.D8>ZJRLZ+)"# <|J\$S=USIX(%=?;_&|/4;_MO:C52EU|7P|O|Q|@FF@;DB' L/L\$-3!%R&2B;|@0093PA9&2OHY;*MF)G MBV.H+X%MI^AD+5V_>V\$|L,U4%_BE.T SV(V|U|M"#CAKD39VSJ="1.W3N= M"W%&^P/GX=RU+W=WXL/" |G9.3G>*;E|+N3OQ?%^"FOKUW7|*79VE78#+/<0 M+XV;IG^L=B|7PVWE.L/237- 3(0^CP7%!"WCGMB|3ANWSD(GV|M"|O^MFWO ML1R;O"RK+ #MA/E|F.WAYK|_9LJHW)?_5Z?|PM1:FE2;?K5=? EJO?U>J;Y?); M"DY41B4.611@D\$F%*3-G 'O.8D()6D*ZOGBIL?8NSI"%&O37'I/_U+"3WW_M|HJRW3H_NR <_!HN*JDDUHEM*3;H"?'>+U"6BYD|^/(*#9@GYA^R S5-L91 MBVFIR2#ZE53F9|N;9WH&+JZKNW8\$*8_7C^NYB;&|_QWF15|YZ_L_-4F MX|G(C;^H.

X*!..*7*PUDB)1JG0.:@;D=TFV()MXIR!3L/MF8+V19|= #9!W='AH!V(-=0.#+^! I 8RH=<&3' @BO.ZY?K=1C
MG4K==,4?A"3S:/F@\$2F'4(8R12#"=Q'!,C+) 1* N"19"1V;&O9799!6, M!M64=6PL:@.B'0T.#0V,Z%Q1@?=">
)@Y5"L\$&Y'3=D(@/!"J\$0+D7I>L17IZ MVJ?>ED0YHEAQ<|F')^*.)AKO%X2\$/&IB&U&E1
M= _H1<ZT3IAUUZGZ8,M1HJ9N_H5>+0BE9?M1JW>,"Y<IKMG)Z?U5QFRR+?>M#F: M!<@2/Z8^EN:@>
0E" @7D2AYC\$,\$BL+T(5AG2/JN!+6!<#)! RDNYK8?V.-MH@ MAY1QJ26I-K +LV10FU7#0@%WI6\$0VIDEH\$&>
(I5#O(PBL,EEM\$%:V7P;ADV MG-/B!.) W@M,HJNCL;LO_Z.VR!..W8H"/^!7)>KY6+7WBCB8>J;O\$;IGM%N MC?>
9M6)0&.#-%D;CR/<&L*K:>E#"R4V,DHHU(8&>G5COL_)F>5L(F_K&!:AV* M6RP%12?N9_';IDYW*!^F>
7'+C5.V'SZMJU'SX8X+X>D"%)_)-I?7:FDB>Q!7 MNS:|EMD)VX?>VTC_V>|B3W>+M'UAZ158%(MRDV8!>->
RN3*9@?;:H=@Z':(M@1+G@LC1^X!;&%K4X|Y*?&G&P# (Q1^_O:YR|MTZ\$U7|SOZCZ8-&(H@MQY>
M=^!>+N>L++|F+5=?)67=UX81E\$@8RR%T\$!L(12),B8IQE\$B1B#B*J!_-.|CV MU&ID'JB\$FX5\$>Y-3HP\$TPCG(LI>
@4Z;,(QG>H'KV#1V(#&2K;5Z19+=; />US6-G1U((P AH:|R6C&K1 M9@=Y|!:=^G_\$9&GF0-1R3MJD1&%I^C\$=V->
|F\$+SX^<^>Y1%|RW5> /N?SN?K! M|TD6:UM'>B?;|H0VAC#?+;P!>^BPE.5P>
M8T=-.ID*&J%&G2EQ'S^6/=3^#)C4*4,??\$JKS4=414)&/P C1!!!=K05E32 M4L9T)21A1A\4C>
3>]>]7!O5XO|HJO5TT5""|P=J!*(FCD/#0:KNY4|K(#%.+1;5<9_3/T"VD9,U) M="P89@B;8033;JX+PYRT&T>
P0|COQB_ QPYCG7-F=9+.R9NGXYQ\$^A!0SMF+ M70ID;?JFG:|PVK%UL|*X&+MR\$ "W=5J+I:>
E6C^+WWAU=EKY.PNSEANG7).=UOMH M.=9Q(3S_%%KNURH37WAE_ =K=:O!-5_JX?W-?>
MY^:@NS9'HXN43^W|QN+*_-M/D/'9DX-NHT%:I2D%PKM%|JBK4HF9&J40ANMD%9K=JZ187|TST>:QP02QDWC>
M8 B**KN"X114!@N;+*:,L" L^-2-EY# =?Y/57L_%9@|!"OM.OE/A|M?DJ9=*+ M"0LIG&6^P,2+*:.F?;SP;IT&BP/%>
(ZNLVDX|U+!+;;89&H\$CQ@GZ! W^N3 MZ%ALQ)T/8#&.! =G=-)23=@->
!E2L_=-7@(!=YL6<Z03DSEY|W3>S#G!#SR:MXQ?#09K;0EX40:TJ'O-%?2A)KZEL7926F|>
<.&>^D59NY|BY'NZGG_8K>5@*# MQ_6K"O%|F:8K;WW,T-9HD(0:9B3(I ^XF1?^TZ#|C_IW1>ZY:|> "%%51+IF>
M+15)FX7S_/5KFV-'S+3|SW?%AC\$^F/./O)X&-?T\$3YF>1!"JH. M:2|ZY.G9*(VFE19%\$WYVSUE8%FM>
&2|9_X>,&FN2U4(^2ZPLT?*.45('G2>
MS%"1%0;A#BFOFU/HPG=%SGZ)XL%_ =F666:M'UFJW51>3H+=RNBWPA|BE%|:6CLO4B_'=&JT6->
GI5S1:U_*Y5>|DX_%|7 Y8A&_2"H=R97KI_MZ|P_ =LK5V>00=VH|VZS!?:U;I X| 3Q M\$QZS5%BY4..K.G:Z:FP^T-C>
9??"YV/GO@3;0!N=T9|2,|13&^WK02GU M@AK-J|4?DAJH_RLN?"/QH !@U3CHSP0IX^HZ*0\$/C|@Q^P^@42'->
>^7M?&# MOV;5NKJ!%U\$2|3RBF(8BP\$3Z0.4" \$S31"NI4&26;6H:QE|9*"MA9E4DWDE M#K"/,+8!K;AF;R#9&?>
KUQ*4#5;7H5B6+ 8WKZAQ!%DNBYF-+S_#+)8BD3+!%PSDL76+ M&YD8MA7<5NPOQ"KQ_!FSKMTA6G9^U'>
8P"BDM:I=)7L41!..S+&|VAT*>|NB M=Jv&GZUIUWZ78V?30AA\$JH8>
MIU(OY%+EDX#31A,HH6|H1N91QIMC801L130/UHN)("-(=^B'9LJ8:/!D9O-M@ST5|!>E,AJTM,|(<|5->
G)@L;M(3D.M*!;2HXDQHW90ZA57?3TD_Y.W 4J>
MS9(THUC(V&PD\$(9IOB).8DY(R'+6""W6H8W(Z7#T8'L>I6AKWSKTP_5R_>
M_3#7XOZ&V&I5Y'RJF;C:HE^5FR^>C^L.F).:2*M:U;8?K/(@1QJ2'H#\$O2P+I MQ=CWDQ@3W_-Q&F8,>SZ->
14MJO0CFD(^9.V@:;UT-VM4&-"/N;WV/L/L@.)L^M7/>
>6X8NCEZ:U8.VGRJU:"|B/5P|!\$E|L=6L8U)K|@|ABO0K*ZK057-R18/F M13--JWQ*9+0%U)|C:(CM+>
(&5%4_OH0(2.E(FY_PO2LN)'G7R,?8|&-QH M_C3G;,(1 V*!&RJC@:|KCZA"R*_*:;@R#@6_GA0R'@(A4)RVTT69S'P->
Y^L|DUZJ4A3Y4W.\$J6'TU<_5DTRV"Y?OJO<6LUSZGY95-XO M?_E|/(-_3KU8<2:<(HE_->
<5@5FN1)L7:|JK\$KD"K+ZK>G(G|DQ8N^8J&R M7.3ZYQGZ(=@,LEBN;_8REYTTJK(42 MJBS->
N/E" H_A8GQ#8B&7/+)L;3\$H|;#XH?4+U!E2|/#_*=%%&:XL_H_V=PW6_MGNC#7Y|L|!\$DK;D17.7X;:06UR_SJ@+O|?>
>E^60Y3NDW0EVN"^^=?-2SC_M2W2MBLH?T4:O=|Z>GKF&EWLCVR^KN; (7M;#&.T%F'/B)EV6N5T3O/U;).= >
MT3QIR/|YS_-7N=2S>WQB>5&M"RYK/E|^=T|JH_+XK)0,E^9I?XW5:KB695W M->
/'C*\$PIH59E7M,>T=>X&\$54D^OV)E) ^KA;J'LSW2W6Y1#95N|K= _3?0VL M7|<J9;JEQWS)%LB\$&%&Q40'0>
QX.K<7B?2?"XW(K@|>?T84YE-GH@K0BJ-4%&M%=3H,A9DD+)X(T'G6"%O_B!%?;<8.@NG@<9<.(Z>@YV'L;4J\$GK>
MW;I8U,VBM@>)*6\$)B&,\$.^ZF2F'!#M**L> "4^YF*0ZZLSL!W"1G9US%"T4XJ M|#39*6 L:'(-_\$.01/6WNO6_K#|>
MWIEK';A\$|J&JR(5V?"Y9^:IR_R/!=_QS.:&R*Z:0+9%"_1MY/WJF(A%8. M;%T'@=N"SJ8&\$<9|>_@902K/N?IA3|>
JWTT3QMI7\$NVTU&M?H^?4|_H=>K' MX;,#\$ST.&L/'5WG)V 00=-I+X;\$Y>#C;NC ;KLT=9|C7YHJSW"W>\$^GTJ?>
MQ:23*.68R#C!C.8<1RKR;I83'U0Q943P&IRC<.;J@?8"3DF9-(I_QM3C^|NYRYW*NT=1|-MR*25SEN7M|H9IS#.?>
M*+W^E.(W=@RACF5@5Y_LHPPPE4:1X_"|VTRQMZ|U*#1R:C8"M8?M7^RI^W M(F.S>
_UM+VQ65J8>F.E6|KW57E#|!HYVOW")|R|USO1|;|UURK+O7;H?%7|O MO+1WZ?>KA?S"JVKI+;?/3(Y&!'U=@:>
HOMO6W#48\$QY75C;H12.@B3 A(H44Q0)"#591D M#>MNR(QD%|/%C^IP^!\$SQ*P'DZ)+X4Y>
M!)YB7RF|LL^B\$'.12.S1-%>3TC(K3(G_3+!A(.E-AFWH&J*MAA9|&H&!X1 M&*V<>
@/I4:M@E=3C#!'D';7@0+FM2G:)757^?5T"V4#W5_-E|OH7AZ_VV?WE>
M4#GI,"RZ:UW8#35A#0R0;8>U,6"WNH15?!"E-|OUZN&&+3X6)FNR%;O+IM&U M'Z5^F*;F4'RD_R->
)@#F1.19)\$CMVC\$O_X17.F6-S)%&-J|\$(RT=-;<7/T"6H>
M&7HW7C9!E!%0@/%B%P!..89AN)"#AF.\$0>=NPC)49W>&9|B\$F#--8V7(8KK&| MQ7'=N7I0A6%#5C|4P>4/?>
SVH1GN\$C_@GA|3E428N+K52:7S,>1GXHT|!% MXJ#)|+P%K#-/'1Z'0_3.V A.%6)-U|=!1^4HJ_KMMG\$;"?>
E3+4N4.V?NJS7-V1NU6"N3 MJ_A-E;FL_%15;_>J.(Y%|L;+!+?>A7GF"4Q(FN_TJK*X,TY|&E-IK*H8 M;,@>V1&E4&->
E5>;,;|@I5?VE4_B6@!|V<%7&PPU&#&#(7)P9(=@)#)RO M;'1-O|GD18,FUKB<""%|C3DE;DR+K8>I<4X#0?2?>
NZ7I4KMJB.Q=W?K\$X4 MQ>7R|0G0|?CD_"3Z)Y.HN?Z M41:K_ ^KY_I+J+U_%.>J3O/CZ;J@!G<M5UMT%P?>
PUJJA3Y/!"SE9-PG,CN?LOH;,>.ZN-TC=I_#93H#P7A'F4RXI%RK'K; M*F_D#|)^O53S>
6:+E_13HCJDF|_U+Y|I:Z\$*O|V;%|H3DX|<|J X(\$8_1|M?&H@^>
NJA\$|4(+;3WL\$+OK9+>Z,"KIVFGR|VGV:4PZU% X07JL'J9D5?ZK5 M=;&|+|AC\$|3P5.KI8825,>
(5#8RXPXU1@XJ<>#?PX"4@.2*7N\$#4AR%1C1Z&% MM7!<2T<A;_LXRZL;YAD(-L|/ &^6:|WYQD!2K@="P|W!..Q>
M(|\$S5&-3U4Z>#1;&_IHY6'N';FD3|>P.OUU@P^|VORG?>MY3_W7IV6L_Y*| M>|EA<|7Y#(6"!9RR!>
(<!)\$S\$)_A_3P*OK;_!\$&O(H\$J2F!#A(Q"/R6'/C3; &MG=>.%%\$ (2_10A"VY8B3<@;0!@.R12P1G\$<@<0AJ(5B.A|>
<8|E%>\$X\$)&S\$A MALP^E.N;ZGYXGXG|EH5|_Y>J7D50.KU|V/PB"2G;_X#C@F220QISS|L6|>
M;TD2@*K.DC.&HS_0SL-T*K_OI!Y'E-J|OKL_Y|30_M2#3|V06.5K>AH*C;_H2|L<@)B_'WTM|R->
M/T"/&L8IW29UDLJ)6Z=CE6|= #VCES*6.%6+CBT+_ _UJN?BYVN_NKSXU+U6< M>\$KY(>:>EV"2Z9|2(A2.9)>
(EOD9"\$JMR6N=%C\$OTW?K;I9M%|@4%>.)C3T28L:'!_*M.DQ|'N.8QCSC04_8S2#1+>
&8T=S:FWR9|5X|EDEL272U0K0WZFI\$/K#!U M&8_LG"D16(YH^('8!_15="!+BC?XK2.T%ZIS^%#S,YP#!3*@->
T12/XA5YN&8!3\$F*HTQ#6-I^M-I@8Q5_MG'KV%4LZ|(U..QO)>_"U;('D,72|9>T!"FPQCCA-4N#E.7^0!W:2_8W)PE>
MZ\$|L_ZL3.OTH+KNGY_LK#BP'NRN=YE14?BZ\$:/^XG|J2|SU22|@ (0|B2(#YA)21R4A+50_*V3D(B-XAGZYA:Q>
M3J%CLWP_P&88"16;Z1|J_V4W9.\$V@/UONU8I8T\$W.NW4S1.NT|H2|@X.W>Q M>
I=|5C(7;XURW*A_OO?YBL61DPF5*^| \$BDS3_S!&\$@<4Q8%(DTIC_F*A= MQLB|LA&*;JE(BP7,K1.H6#!!*?>
UMA?/+3!=9A74ZI8Q+Y58M).+,%=V\$AP;CAG_9"#+M%GK1#2GS(90 MS0#F.Y(->
Z*\$#;:>:5=U\$<^KF":GFC/Z'9/N8K=|+S_ ^G.OYI%\$ \$|P"R;_2*M#_I=0B?TY_-I-"1M_K|F.TDSI#OX*)9X MQF9|U-I>
<&-&T6;JXH5J.FPOJZ_I|V+U;7_N?VKUGLGW;GJTOYXSZKS6K>R>
M'U6%UV|L16Z^LR="Z35L;|M7B26)1FGE.\$P)=J%_8B;J8Q#|+|09GX6BIY MD.(>G=)&9I=&/#>

(2D5%@ALB/E/X'.,@W9S1JA-22ZD;-@G2'O@-/->2AJ+''^7 MCSQ?5&^!Z5)ROIC 5\DK4^%DA<+N5=!0 ^.?HGD M-
17F'TK3;OJ\;SU-> 5=6'.**Q>OJA=GfK(BQB+.<&,>A(3XON8LRC @OA, M:1YER@^MB?, -#1B9BXT62%5J_ "> 8=
1B25H0^.,Y\X%&^OICT)XU\;2S\^T; MA&J+4&254H->6855D2E3)XCA348;)2'W,HMBT!@H#V@4Q*#1
M6YG.T6\!%8+;Z"KEM>F2<+."IS={M@\$(,?J?T7=5L<+^@Y@I.ZM1.TS)!6 M:93T30@6PR=06DE_HJ1-
"#0=B9N@8=R^L>+V- QE,9)YGL^TKSA\ADF 5! MBGD0<,^7<2@BJZ-UM@)7RLVXI!S &CEI^V?)D!#
"&3/>B.S\IVK' :D M#1<5MG8.1 YGQ4W*K;&T\ Z_ O@!2.O% ^7B0OY/>2.L+LO5)HQJ62N [=Z1
MI^JUH3Q3J5W^SHVA,NFM8/^H6 FOBMAG?/U2%LALW-<^8.F*)SSCBGTO>M M TY6!;
I+GAV"JYW7.6V@^V%RR1YYDU^XTWSKO4/I-OWGKKE-OF7;H?I9IW7NI4!" M5L)8XIA M_(W+9:"JM_TL_B-
BI^<5OY,I9N6&Z1+8BQ.LQX\$8MT'@49F;U9_7A2A;W);%AW*5/U;?X\HH:"4
MN_XLEE\$:Ff%&YN:Z/,@YDE\$JA03IO">'Z; M2(65QE_5K>;1#UPM5);O_E;ML)F_BK-7FB2JG8V?
T\X26G^8ESN2K;^!Q.3 M@)G2E,/FR*0K37OO^P/6&C0RGH""?/H019%7;=;M-9!9ZNZ.% "57*?O+JG
MLH#10IZ?;\$.C^R-/%\$!T9A\DZ#>2TVY*%S&RH>ZTIWF^80M;VAH5*; M*NYY."(F98FF 4ICA&9I"3T"/;#A
V/3ISc;WW\$05H)OMMA\$+K'1B9;45 M.A "P\I\1D\;H8OTH0#;(ID(C3?>)I&PXLOV2=
<(4^Z;6%ARM'EBSQP*,998GO0?I!OA(P\@Z*%HAJ MB=#JO"U@6.V?I#(1N'UR;)W;fLEK.T&);fW,?
>.;IDY.ZG\IDZ>7W?E#LG)H4^ MVC@Y?9W;OLFGY>)>LWCIR5;5'U-WK"%GW>^D&%L\$MF3I KK1H9D9HEHE0P
M1L) 4_40+I5RL@L8>2AN18(")>W V(7=NJM)HPI^C'FC&RS.C'B9NB+?N'6
MA5Z/#=A%L=.R@6+FI3(FC8UWFGD<^^^V/LR5Z\^* 9OWS;H&)E<6I2W;J+ MA:PZI;U-,FV;.)9&681C86J0\$"
(Q#83" 00\6! 2,NF##IU8"AYYTNZK8<(+ M4F7;%=+K JS12" 4M4I5Z\$ JOD*RT0S)H!/?WC_GZ\$7PNPA9S.Q(8
TD8+QR# M^f@=%66;f.8I\$O6^&U5&? \$!-#XH8X^VQJ=JLP#\$(Q7AOV@HN>
<9QEH14KPZDARF+.;>T(UD6)!%#8I6>> &^ID;MD_V/I)=#2.5FOEXMY!?
VJ&RWK+O&&'D>&1'V6I&=QG;/H""M\XG*ZFHF\$FN;-SF MCY4;_?G+I57U<=3_L;WZV7X0HN&FLH3IQ
6U\VOCM/7<.;?D6\XVYNUO M-5M=f;.% ^V#RV_J62W6ZHMJSKBP2&9^ZNM5+?=I4++%*<IC;&%%>>))QD
MH.;BK5)&GJ772OHL3*Y5>8P;W6\$V)R)9(L7M%\$%V.FE'2NfCV!O!""?PDH2
M>J<6XN&1%7^T)&ETZ2IOHOM;B;I.G;:>2R-I+I8;8JVE(EH2D%\4T+ES^9K
M7/Y4+;TEBZK.@V;C>A_Z+HY2E;&48X_YW.RM)9A%@8?#E,898Y'V6D"=I;H\VBV-.D8?8)>\$J
()"/2P3DC&2+C+%90%M6Z'0\$;M MJ#CQ1E\@<3ORDS'TY)M\J+2_-T^ZU/3'H?^L;9-NMDYZ;f-#f^~ODUZ4N
M_/%)S_/f&f%;4S1-2S1G1^fGW;6.L=CJB*#9C5;R3D8\BU+ +1\$1);49I@3 M&6%?L4QZA&HW)=+%;E2WJQ8L;
(Q;Q/@+OPQX+L PEL7FVM;Y\H@%"%4273 M+VQ""T\$YD1S#;)<1;2)%9)*\$-;4#YL)30.*(>2-+((CB;"6+;6;D.U MG
'CS'W;#Q5>WAI\ZVJARBU&O@LEMUSCF;JH7!9?ZL\B_M\BI7JFKU4)W-N ME^I4';U1IC-
;K8M\I5+M.Y.RH8QCX0,4NWR) R3T!;8>YJ1/*7_*"(2!Z%5 M5O0PZHSL&IV(R77\VK;Z.-;Z!;\$f+|@!Z6+2&2O_I
MHRT>;*# /MPMA;L%B)7Y;=H;Y6ZK&!"fQ89FD@L,>YAXE(M2;Q5EF\$9!%6>N\^I")8-?DK4R*3WJ=G#V4H&?QC9J!
(.S\K_R2IP;+fI?; M'(+8VOB?H45=I9UMU0'\$1>R1M8@/C8(7<"G30%41@%%B;N\I+I#-4,7XT(% MB"F-
IE;D&DPZ&#Q)S "G0\$I^f&BU""!+3P(6<O=B!8DUZG%F6=%!"03?^9 MSVS;H5YE>f")*#\$;V?
f\$UIADGH44VZX"(f7\$RFM" _I6Z4AVXD8FU'WYU;F1 MIXT&Z'K H 9SJ-G09Z#8@;(CS0,X3 NV1CCZ/ X<
((<+;8W8NP%#XP,K'WM M).SHTQ?2M86'9">_5TN^X.Q1SXLIN?J^W(H=SDI^1PK&1,3>UV\$BF'649C MK%+M-
OHIB2/?OE=QJXB124V+1%N9T)RD5D@L6*NWH3"F>F6CTUY@^_'; 3V M-?IMPJZM. >I6N\<I*MOB\#-?
Y.JITX(R/>IP/=06O.XT))3%+<;.3&);@ MD)@+A8^";*(93Q+J7VKAfV\1^8'(PDP2_8MMB "1SM@T\I(01LICJ8 IKFC
M26Z3V\HTV\$1OT;fS>N?/JVD;M'R8"JW_ ;OK5AHKE3EH?+0+0T44\2H1.94, M\$R5I3 G)
<."D%V4A;f\$%09IES/AYE?=#K#>|H;9.NBKGS*W=MJA\MTZHW M"-
#=#J&KQJ6Z<-.K^4J=A@VT\$>HfI376SW=ESM\=O ^N^=YPM(O MM"R?)_E<?
WWC<<6^3\RK0JQ5&f"B2F6FP.F; *fT4Q61* V8U1;64DCS\Q_ M-#J4/4_ QWPB>L\$RN+S/93YL#EITG(7M\X3 L!G?
R@HW/P^L L GKBYBGKG7;K2U3J;S%?>9Y4)(YN\$X MJ%/-D+AU,15IG'?)-f"569QG.2AJ98?9*_fB6-
#J&QFZ\;HCL'f9LW6&M;JGHC\W CK)6.6OCX\$60CN43FD\$^>+HQTZ@;W\K%>VM(GE*4A3Q*.E8R%
MGK!)B%.;!SCE(@SIC'L>R\UHDS&V.Z\EIFD0VX;*E1_0UU;@%_*#3,<&L;UO M ;A!;\$^fWII;C?
ZYQK\$MMTZ;8/8#MV/&1V70KCCD)8f72Q4)>"/T\$UW/3 M8^>I>BJ4I%L\U'49OF8?%OJ?>5%G'&?&\$-
"GIOICKTY%QS@5282C*!,LC5)/ MD<2&8/HH,3(#I8M"K#2ASMA5*Y;6.YLJ
*XFZNF@U&9CfZ8PGfYGD4F3UST+X\HKG+O4W;.&0+1+@=' MCL_GW.C?=-HY+J&3\00X#1\$-
LA83FFIVM5ZQTHEI_-I-KOU<)>4@.N?U;5^ MFYL&#S*442
2G\$E',8D#=#_LE5P@(%C&2^R;T;fT#TR*QFf**M6&3D@M)2 M(2!;.%NC00-
DKJf'8J4'VE=DAEKP%C.I5S6'fH%^LQ>D_7Z_ 5\$LPJ3\YOY I MRP! =K#T* _8903^fSJ_K%*.38-f+ %_ =X>J?M@2
24YZ%+;+5\$ "DD-&*8 M2Y%A(G+)>XDO21D\$% "FV\$CKV'7JN MCKL\YfW.%9EA;==V&fHE("DW\I@^"ER
M@.5#G2ZW\$3GMJ7, "1.HT/N=8U32Z4>JT.)VAY30' YGU>B\I"\$S4BXH/_ UKG MJQ=SU>.3D?
LKfZ_572P21DC,I8HUE)B\$5?(MS7 4Q!\$GQ\$13#CJ#Z;3%Z/M M1AIZ-N* @06X77&T#X".C!OV. ^J@0WU0HJ
_U2J9!>P6U%IH076(F<9;H MNHL.\$T?>+T;@K29S")@.S^6W\I)9P4>A%;V@H-SX^;9-##K&&)E1M&BT
MD8WVA0.;&W0!T\$T>0H.XX=39@J8'fW6.+<&fET#3I? P_*\@P8&-M<f+C(V M8I63BZH9T-
STQSI^/_55QE0L'0Y(ZF/B!0FF1\$K, MDHB;4)G*5!)&T<fQEZ*!7S7E-PK>MKRJU-LVN*L50H\A9VZ-*=>#ZQ/%1
M6"Y9Q@<8N(K9P_8U=+6@;=,*X)SU!+DNfETEFU(Y51^9ZC^_H=
(;WI=U;#SIU26BH02BH5D!;_8YH^@BT3\$P# MF7(6)59!3&4&YLA34_ \RI S'H^S/T7"N
ZA) _#N7YAGHNELSX1F@#Z=*H M@%fXO?=-.QWK^N*0%6*3JK_P=M%\$;7W4_'K<f@P#_.6;=P*-6FKW_X,*BM
M=1*EN&R\$;Gf\$S*BMR0_7;MN5CEJUR55PLO7TLEKO;W#VI3"?3F0;GCPU%>
MG.G_DRF;/f5@A_.fY@'f!;>>5E(A);)6\$;JH;DONJB7;YS6>4)7)2EVO1E M;3US^>5TN;RQJ\ M< W>+;:M M=
(6XNF_ ^\$16"UO/6=%U>"Y;L1H)L/*#FX^O!_ 2K2JfMTQ/6WT M S/39KXW;?
+FN>6+ZA;Q/7XYB&6QJ\$;fF>'1K9fHW8P;1/NZPZ-T.&>f^"C MPZ.EWfI\W^_1KS_+ %W+Yf% ^VCW-
V;QLH/7'fV+LNA@6-6.P?>*D;#>Q#I>L M/QVE';<J2GOIPL-GK&JVPZ+E+!^JL7#?KfM-7
M>8KNY+8MAWMV7K;f7#X<#L#-"4L(ANMN;F?I<*V6)^QN;F?;V3;+?7J=-P04
MfWM^5HD7%44NRD) 42CTF^&1<<*&R\;V4ZLR8D)36(F/D";N3 MV".GJ0T;NZA73X-A.Q-J*SCXU&-'0#&D-
@F3AH(Z3#R.Z'1=ZC@%fT*)U<=I MH5W;H\!f1_ M^BX?U=&R,0TS(@)fRI3&^!- \Q5PK&O8D\$E8W&06M7FH.T,?
_C+K 1-D-118%>)>:H04W\?6@((AKWEf\+42 O M5&J@KfY-fXf.\$?>fGf"82A&
EFM<8'G%0DZ#P_f4RDID;f UNS>9Zf MF\$R)NGEYN?H=f_E (A/LQX9f_E;4M" DF =)AA.9AH&DOA1V2=-.fL=/3*fI+
M4;-&f M#>7 DNfEF='R D=GC8W@>G;&M?E6D;Z?A%KZIE'J88R#1+ %8R%#Z MPKXNV@DA_Z94THF+Q2;/-8"
P>O#^4J-G#"8DBU@?Z6.VZ);.0E4O.Z5EGL MSJf9'8YM2Q/\$G3J31#&DH<79.L"R>6;Kf+U?OU#)6;
f@EXOM;10P\5F59AYD9#V/8%LI8Y;D(T;.*<VBB"MIJ 2B1;@FE\HF-!&-5
M*WfA>E@A;GAEEHG*UY6I3EK6&Y7=4QfXfXOW^_W4 MP_R4KU9Sf4TO@R^>5f=-"
>I3S!02;U^>@f">.\$CW"8R3@-A5(fL2f'W2EE M;f^Q\$HMIN<@Gf&+Q"/ZA0Z-DfD
#8#OQW(S#@8PU>EC*7;FA\BfQ1.#'5&#?TJf M;%(&F-U+7&OVM8 +I6E30-
M'YR2;NE&P1E3Cf<\$SEWNX\$&fSfNG99F;+U3Y=-,H MA8T"%7E,*D5QJATf,TD)9AZ-
_2&fIT(S6A@E=73*67L'(\$fL6;#T0@&^f!\$G ML;PGX;PS#XSf6AOKXCV=M\K@f0UA09OWU@;0+f3.;Z?;>3-
f_G.YW3 M_!W.GfQ/#OPFKWf6NX5fH)OB\$F;MX17#fLU2+_Z^*?&RX,91*G(?>O&(8"\$QHPS"(1X4!%

M'@F"B.C_VL<7VD2,'5RH9**4+W'"=-D@=V*B4U4H:~EP)#"*R.=P@FMUD)B
M"7VM=@PDV#|B8!"ARY|N"\$+KG1.&#|HT/XP==%|9-Q&W3@//.#@)C11.4V7:MD:,8|H4FTGS'<_8|KI%-L^&>
|U3|6CV+M9KEYNM^|8()&?|CX,594KR0(B1|4S_5\$|)(KR)"\$3SW-(j)-Q.B,9\$16
M4|52"N6A5DQZL">O13#6>6VD\$|>T6@NAF+Y6ORVS=&G?32BM=TH((UV:~|)'MYY7
Q|S54W%W^X^|E|L,5|8|A7WH\$&^HKS\$G"L8@RXE\$DJG8*H|A.H(?!K M_F*V^2C_1OGNX/L,E|~^&?%S<#P*(?
ZMD1BS-7UDZ|^6DOL7PSPC2IXH?J M.L_C_X|3M^G=R_7Q?)%:N7>MT7LX3(-AP*|S|%33-9GEJ6CYED9|HUR0
MR*KZFZAD:?\$%+V+^MJ3((MO5T?V9E)._Z#@\$WR?|=G,'CSJ!-(CMPWZECJ MOU7+J!.00+M%G1K&90U
TO"W7#SD*_|WF^:4"TW2+\$TI#&@281(&&:8B8C@(-M|4?>4TF6\$4|PXK6 DOO|5,B_?MSJRW|?A/ZHMH|?<-Z&W?
UKK0U^_XSKXSOC7U8JS!;F9|Z.ON7%|XJV8\$|+MK2-/~DKBP|X1G33|~&^1\$Z;W=TL,(#),)PMQ:TT=|ADH|&?
MMXDVDW=DQBS MOW"?=9E3C,T+Z=_9HF3E9;YZV?)M%,1,9^&*913%F#_68AHG,MM^QO^MW^KU/Q-U:
|HWRKA;I_9D;?N:UW8|)D%N>?|SN;K|LGE|DCCPJ1(49TF M_,E|@GD8"RDETH_8:F7\$7LN:1,Q,I
HD6@KKFE,"2S*KQ0=(ZLAS?ZL^VE?\$,1,"WJMA_M>1B4U7_-(|@)&!"#?|CT%)3H9WQ|3T?>#4OZ|IV=
"3,@DO:|G>\$|(3;S;Y|MA9M|AMWFFVQ+EO|W)5Y^OM'+Q;|M>-OF1=7K*G2,7E|/0|<:V*7Q;YZHZ&
MTB=*F;W_2)-(4#4+3 AF|4|2Z)()E:KC|J\$4&MNWJ_6B>RVOK|P|N9S/65&: MCEBU4P^T*7H_
3N_8TI<8;2TOX^YM-9*3=#^~^K|H1+|~|4:SE#S*(R2LZJ|MH-%SR\$|PR V6-/BGNLW+|X&|/!>MS(>:%RG9&Y-
;Z_2Y"A/>,"#P*0|<4P4 M(9@+D6"14IG;|S.B.P|+6)D2C,BW1,E6S&QB:OTM11&J^-=O\$*K,6E(O=
MT^HW3L^NT|X,YG7;G5,F7=H?H1GW76E VM|6K)%^4TE3^+;(VA^6R^*,Y MZRYE29)1YF&6F<M<9WD<_+FZ?
CGG/X^?3V8A??Y9/G>?&|O'C,%)Z2,S\$*U6+23.T,7GR"?|5/@V/@Q Y@,XYQ6 M:YVAF5-F0QR_NA
1<=>,5=V^S|F|W1WSNA_Z|K&7_7C71>J|7D|J5,C;782QDF5_?E;S7|>F|L^XX=_11B|PHL5&+M09-
-1N=>JN,;>>QNIQ|M7=>=>,>?R<+Y9%OGHNC_5Z(P;2\$<^M:E6_*D>GZJB;W=4>H0G7_~|)3-K|>L'
32I%|HHC|)2RNX6Z-|MF=G/4 M4K+5.TSKUWA?0O7;?W_F_82PSM-|/;E8Z<'FYK7_-ZK|9K(MI'9S>TB8 MG&
|ET_&CUFJ-\$F=<|>FB7T"TCVISRX|588&H#\$08ME(G|1 @%,>D KW= M86WRVX7G^=XG|J?ZOES*WYHHOO)
(YBM"|5<^2#\$A/L&4*VKHE(%0J5,V3=U M;I_%HH;J3/T&V0GYP0L%DN1_L,"**%#3I?%OPF# :N_ H;|+3<@#QJV
MSNBVJ;|<>+6Z586W;H2+^G.7.KFNU1AVVOV8F^VFW?8UPH%3,<9\$%FCO|K)VD&5JH5?
5|EJG">,MBV>7VN@)M-|A0|VTQO9|=I@AV;|C^P# M4:W|<|?WMJ|N,"X*3<8_5<|G2K=D?
|GPJE%M71FIO+|N871\$*05^+@ MB>EKGP8,V|+OW/5;|K07?2^G=VA|7P.N|UH5+0B^ (W^E' MMZS'W/9R"PB-
|LXIYIGF\$;)(A+F@("BLO|F.E1|@@:G|H\$;D8JVA,+|>|W M"AL;|AG
8ABAM|GKQ|BGK|90R@#60RVGG#&@FU1.W3PAJ\$S1_Y|6SEWLMKY|M2L|H53|FBWRE/N7/2E|H|
|JXS_4;Z|L|JL"||Q5,2^HC|VJFITQ\$|P55Z& M|OV#1\$,"HVD(6>?8BOY|O;.5B2JA,U0KA"N-W K|
W"U6|;,@Q;O7H"||5|< MP&T>.)\$#\$S|8@<.R/&BOV\$S-V^Y+J"1BH|YXXOA%Y5%4K>>3R)\$Q(\$.*3\$ M,S6_%=
<(K&7L2Q(DZBV;|L(6LL;?|L,CA7K;|A|)Z|_7;C9,<5:"H MH1%Z?/2_D3P<*5B8-Q +=\$F;=-
L;F^|SVUN<8MJO.0W5C|DBWOMB=RJHF!" M_7+;|GS-/D4SBA,C7LCEFL9_XID1&H|2GL0(D>?2
*&CW&\$1.T\$XXVF?H MEUO8PK|+KN0QT @0",?)^UWC(|T 0\$+A P\$R%O'ORS..!<6Z1|B|TNB(A2W'
M01*6QP8ZILR*N?SNG3QU^SKDRKTCXO|ZV*8Y:M|R|(*~ZH^ZKLP>WR4"UKY)|@5/)>8D36C@|=BG|O:
M@94.F0.OY^OR|/S>+1;HBI?KP*S2NBG8<&8;Y@QC&(/%35|>K>|JHEI79)1% M|EO4| (MNEVA?8:0UIE5FZ|L;_B
\$S^A@ *C?J_F9KH93T1^A1B4G*FW?YE MIOW_@N7W#YHF3?;PEPR0^|?D),B\$+5)278X|D8Y?L|VO|SR,K_E0K*|IR
M"?/M"JRL=EGKO^HY^Y@OZCLRI3;|BF4-"K2XV4:CZ6^6RP?E9F=8O_5,+NR M|3_|.1:7;Z1^UOF9&UKF=-_D=
Z^").CS_RIVAG\$^V|G|J"Q_6WZU^YL\$^M|O>6N?CS+28^F+^?J6|D;?L7T7
M+=-|+T(|*E;>2E|@|1|**S/=)|6>T^2%~|W|@/Z5+ _G|1>NN4?D>7|D?^ MIN>E;KD|H05?
72W*55\$|OMUQTVM5Y\$MY^WW9|5-TS3S.<>9%YNNL(G 3\$4<MAZ&2F4JS*(E_12\$LY8|,UX0PW(B;|J9|L148
QD%\$|328|1TBK^H+;RV0 M5E;DV) TP?H|'5.FE.11"*X_P*Z.TNCD85EE7RBUIMH|753C?1^0OEP0|MA|7^V^8?
36T^I9(L=(KU2%2V^+;A|=B\$3*21\$R0)|HWJ^6*S6V^>+|1\$%L MM;,">XU"9@|29;ZIS)|(-6|RLV^&3KRP%?
&W=F5-1@+1;#3*WV-A=K=>K-MD|U",*21N"||?2*11P72L|HC_%R8E8J9|O|HXN;E>NGH|FAIRC+%^8Z(3^
MZ;%N|8C6)C%PM43JF; M%|MLK|I(C,OTI|F|>USN&>CPSNLHR)59EYOZE45^8>1|6^DB+W*|Y+|X|R|
M@=EN@^F_O;F*5673_)1V4J_&J*|J8M&_5=VN+_OOO|H|M0|C_4@66Y& MWORCKW|D?
RHDEIS;"&%&UL_HJ>E? M/E?/^EW?>R8_FB@W|<7V%V@MEJ;Z<5_3|?EN7?C%D&|=EN4(R+_1#F+|L
MA%1|H|GBVT9|H|@_RS MV@Y6|I&TE-?ZG&DTN|KW;2E?I5S8KZ6^5^IQ_)^I%=F%ZFL|KN#4S_M1DX;UZD
YL>V4MCT|XR6D,SPMV| MU;S1BBVK-K3?/ES=5K5V|B9(27=O)Y5R+|4H^L|~?
I9UNAZBF48&I7W5AMHO=>^O|@44?~@)U?-A|NO-R'<6JY0-/H|9#1"2/MLYC@..@)\$B\$5F!,N<4B#4/I9((,
GHO=>D>?%E9^Q0=6-EXV?|@*)^H M"P"W5=V=2(|Z~R%R|LW;|QXTP7A|XAIFSG8&/+45|JUL<..|F+81V5|Z9
MAR77|*5RH|ZIR@F|7=ZHXCD7ZK|8/N=ZQ^+S^ODO"L_PDCB@H6FIYWF81T|A M7Q&9ODG86: ?
^6@P,ALMM\$(5RJA1B>T4L|4E*XR#%<:1"XW%FF%+BX|CC:1|S\$|>I@G3|>BUB;\$=3B^S3|L%\$RNO_M|J>E0&?
RP\$CW9E|MQL*:?24S^Jv;?9W6_ERSKY8|)VWV=5KSXV9?^5>ZD;J M|D%|K|)RFHKN"_.X>6U"
(FB<11^V|9|H|A|F\$H9822?/+"M.GXW^RL_B93G|<|*R QR|PXQBG\$M.N.W>%)0+PL30^RL5<;(G&-DHJW0&?H,P?
+HQ"N|JSD)|#6&Z>CCRZ|B|BC|T^GO&OM M5|Q;)DCCR)>\$>"H5?BP
:=>ZS5I0RG5|J|XX|H#^S,)UVUW3IEOW:Y4;IUUY5.K|!%3 MJ1N1*ZWD?
B|O|J7|CCZ;Y|FR6_2LX122<3^D\$@=9R#Q58;Y^VT4>JH>_5XE4RS58WP&1U_1Z"N4:'\$9LCDBZ M)|;|!^!U:-
X<^F6%T6XO4^H|V6WDZ6B|E^4M-YO)2.OZZ:M?W,%LMG M55PWRPN>|)X*2(Q9&@.8"+VVI^P-
<*82^H69%)BOQ?'*F|DVJYEHHW0&J& M+|#;,%@W-Z6PACUM9\$N9-EN+8,>UOM1G;
1PSCL4Y|GFJ<|H>*A3|P.> MZ;|2@4>:EK+?V\$K=?&=X8|1>LU>S^~;X|H0)GBF;Q(|#DEB_1.B9_X|T26
M|8SH%:CH|O.LN)'YI9&/C\$1D_)@AH|_F)2WZH^&7@>.PON&101&^=|L.% ME|ZC
N"H0=%QXZL>KPR.OZQM|>2R|Z-QVO6%AUFG/U=;@4-/CP^S98I&F;J;K;7;SH32-?|L|J33VRGB,S;4FYE4;15=
MD|H8H5W@>U77#V"5%DCL|+55QCK|75S|_10X&1?/T|M*MT<7^|Z@50)<6 MSP-
9#ZF.@5_9^0K&D/DUB/Z0T|I2Z:A,Q|J|D6@KV>BT>|J+>3WT*_1;|M|T|J5|H^Y)ZYT3|YT:7ZX>|)YI5N*;!K=
M|J;=|H97|^&F;(1KX<9#H_2|W4TPH?9CZ>MW+OJG2^DU4H|
_T=FS9?C2)KP7X^9FNU;+|HY0\$>V|VD5|ZM;N5A*776|O^2ZF;4*JH,1 MRM3|^@7(N\$4RX."AW"?7IKH|DZ#
|XP@^<#@<|F@K7|V|R)1M,8L,9?8" M...%1L2DT.PL_S0?J|?S6T7?MSF;\$-(R=-#&W7_#0OM-)MRVD=F94_F0J M@-
S|J%|PM'EBN?R>Q(D%\$;R4Z2>6|A1SGD28AC(F49OZ/(PA^|F(2/SQEXD M^J,6".PDVF@8NYU57|@PIH @|6|H|NJ
_M&=I%#^|AJ,+Y.ENH2_9AV7|XY7G M^?Z:95&67|QQF_IXM4VQ5)S&7D2P^R6A*6;|8|9|3+O|D9_XC\$>26GV\$W6)&
M_@QKN:@2C&K),_01TLJ|W4_6" D@L&&?8PMBER6|3|@61_\$|&Y+;W3R820^M66"=JWHZ.E6_K
(CE;_T^|T,|)%~*&.T6*92HB(L\$J|7U,?)A%G@~2|)4 M|K)4^6?&J1X-R_C44TEUOES69AD;UNF/%|@Y#5"=**
<%,X1N^F-W|O=(.9 MIAM3+^TC)V09;JU^>8;^Z9^6;I5L(L|J@|JX>,BKB|2;7Y87AR|FOH<3
MFL|A7CE|L>CE7@|T|EBO|O/GNS213C%|KDE|UN42IMQ?G B_FJH|9_.,ZIC+G^*K MLIBF7&S8W=9&
YTSGL^U8MNB?6_7ZE^*+=_G3^HN|?Q8Q=S#) Q^3_*8*X\$QRR3TAK^&TUF|WTO*F5F*?S|2(Y0H8;F< M(C;1,BH-
=VCA;HR|;#C3_XB<|H' USNE|B|_|W'(|X|>E&M_8|9Z;\$|OQ*3_1
M(L;|B\$.L_H_P))Q2*W;=+6+&#VW(>Y1|H|A);^:V^D,#YX"=(ONZ\$|+2R| MH1_JU|YN:~?^7'9#P|A)LOO:-3-
_NAXTBF+THO>%|O5|_K_IG>5CPA3C@|I MQ9\$T#4.E9@T693Z_A*;\$U>|X=D43;(&)DUM\$AD9*)**+|N5;--
_/%BC+U(8 M;|P\$Z99^V806E\$?9\$_4KYU%V;|FC|DIY)1YE|V;G^11=CW|HDS|/\$MY("PS3@6#&#(\$9|B)-

)U.A=M@PTY&T ON)&C2@4>C9U!UGXVVM#9|PGH^<>AM&-
\$O+NW:17SQ<EK*6MRLQZ6S^,22;E:W/*Y9K6+ MOSF? VNY^,%9<
OPE2.SS<7W|TOUW=PU,:MMD)OS;^~9_D2?6/S=+4MKPYI MH8L?;"DW|I=,JP|37|2TN%L@
!\$1PI0XZ|;DW|G|_U"C=Q-9%;%T9MXYIV MP")!XLUAA*)?|Z0?CZ7_J-FRB,D/O@("U3,)|3C""Y+J|H#G>KU123|6|SN
M5|6^2"Q/\$DSC(7#&35IX#F.\$@PSSP2)E2&04T0Vf0_9T5DM&Y'025*3 M/6RV23U1PEC@%*!;L;X&I!""??
T00W*=OG;ESY3L:Q@X996^=KU/BO1U/B2 MS56P1;G/@?^?|7I4K|0|EB^|JOV-
QTNKU3&1&.)3X.TSC"Q),I3M,LPU|H^RE) M_%>A*<%30 M=G',Z>IE'V'6ERW<|LRNLV^9,+O+%M%QAI?U*)?
8CY*Y8///69;+,8D?D0:" MA=+#H8IB3 AGF&8JPJE(4R\$|Z?'(OKYH@X#O&>Q1_ZKK/MR5<\$C-I&> M?
BB!09Y.&*JE.45W&E|" COIT#J6GEN;/O.KTU|I= <L7I|J"MER939^8M>D M>|N.OEB8!NT+B7IEC.65GF65ZWL|+
/1H V^H-NP=ENF."S6.FS D MU*|U<32HXSD|MG4V2R_75_ORF7'01(*3C"/ TT|PHLP\$U&^94^|9.XBS+I
MIG(OWS|RVP%HF|SI&4"/L@&4UBP3C^, (YP>";.DWS;4Z<"Z<AF5:" 77Y!>^L.Q23M<#N)I&^8=#S2K0,1C70|
MYL.C=IG*~)JOFWQ.9U&|URM?P"IT>)324D?2^<7>82=C+M,%6!A^,H26042|ZSY&Y5K-
B|FW.&T0;\$4#N=K' 01MH,"?U/I/9"ZY5RN=,I M>@ "6Y=O"KJY;G+ #PIBQM|JGY)WW~.J*JA^Q|CYY
|1PR7#3B(H09*#>RG MRZ1Y@H.8|31|<)B7NL2W?2^./K*E7K"NMK5QPBACB1?|, ZRR/3.5#AE>GN7 MACCE4>
(%2MK?<6X0,+)_902B6N(,78 J(C48PR:VW0|BC\$=.T+DU^X)\$|3> MNQ?<5V|NW:KIF=;>+|= -
V=B|5>N3MM|MSXU82|=3L7C2W*1D=;1.WAJ'X_#O M31W(3|7I7V|UKQ|Y%Z7*B|XQ%F6>9@ \$RM1>2V/XE"FB?
(D8>G@I71=-|V9 MK78J(69TTFZ7U@\$MBA5Z5BOM;6W5V%;5'&2KM|V3ECO|2LP CV;#7= _8Q= MU#-F| -
_6L_8UX.9N^B>L7%J|?:QYI35=IWT_/7J|28QMU/%W5X"G=I'B.)!
M71=E=7NN3HY|J%;WA;RJ%*GNL^B'YFMSV/#6=,&IPJQ?*MX%6> "O/-#G_@X M8&&
(B6|:LGLTPT3 A5HDL8AN5M4B3O2PJD<0B;2R7^G+WVMO+ (MY+LU;T7|5L">_O\$.4|^&_;&PL&=S-R-/2Z,=LBH
M5U_W1B^UA=J*@=YJV2Z%|+M%=S:NN#&F5,.PNNO32FF UHVXWA+>E,|< M@J9LWC&<74|Z>PSX8|?
6:5R)'W\$EL==B5\$|EH@M5\$#90JTOMB9 MTF(1&=Q L%5B9YMMMA8@#VVPU0_ 'L VD7|O0-G(^1.H*V!;-
PCL|C905F^; ML.T;|EQ&SC02<:UVS^KM0_#G6QD!="" U36<^,10C4'FB*O?C17BWR5FQU&
MN;K@956Z|8X3)OQ,I5AEPO2+\$Q%F?A9@&B2<^CX-)8U@9;"=|B933<2Z^W| MJHBN1#%;|L:MIN)
|<(K\$Q@.&#QY=XENQ+V2;Y|UYF=Z+35'7-J*M9H;(^J M|OZVKH"Y="XD#D".T"##N&8<0?
S|L<6TZ"UO7M9=;#RWVY:3%PAO)>I7A81 M|_FD6^<|6QTRWZ^40N5Y:ORXF%E M>^,Y=TC<|H&);35"+/F MI?
KW6L_W;7\$A_KW.R|SCE472\$SX5" M9F&B|PP0SDP)\$C_BF9=X5_36_#.@ M8B-S5J?78<|4M-?#K/\$F@
^|F"\$GQH+7LG<,,ZTW_KJ<G,"(A7EALW4KJD MR6\$S;G9|9FI2%i5=|> T3E2=?K9
YT:SOVIB9J|@_%#F6LW|G+%,?XZ(M|=6?H7QW\$O187^|Y1OF# M>G*N>BK'X68JM">|?<
LF*)U\$ _V|&B6V:7Y#;GZ M-|1B/U4|)%^4ZRI8H<9XNN5?GPKQFB>;P|CQKSO:E" _|@<|)/"-/N>8-
M*6^Z=7(\$*QVMK6.WZU0IY|S.6|6-WG;/%M6Z@Q"J/(8X1<2DP67"(5YK&* ML1>E?
A10+V\$OP+=O% C+R.FF\$HKW4&?H&K-.9;|@:W|X_7_@ZU8#4L61G(V18 MT7_N<*=S:.G;1T9Y?V|4L_YIU
|CYM#80^9QM|Y= _U93V5BWS M)SV:3ZK|FYK+NS)L|2+*,Y|D|7OJP"G<9S@P.>^X)\$BGF=UN@V0.7-J;*6!
M12ZV|3#PTJSWVY9");K72L#;9VPL:7<6,|H8-2T-U6#+RT8\$ "Z&|=Q@\$? MD@#@#@G0@8B-QTL,/ @
E.#SH@0QWWK;Y18+Y6L;D/8%GGU9)8|(W_&U%HKF4|EMM&6UBX%WTING|6YB5P+XX M_3Y%7|QN#@44-
|S/Z,+4Z60T#IS.P^C2^|B|Z'S0|3J@|W;:,8%? MSICR33,NXDE,8L_#|/4|SF*/IEF61#3R0/+FX&M#|T M_?
MD>BZ_7|+%G_J1VT_!PIA|'94;S*H9QKX)F,\$MDWYJ| M6<;(7%\$+15NLW3|="" +P|T|S \$F&M@? MKA-
1=Z>WYJ\$3|FSKU|VX^UKWHTX)\$#%-/O:%GK7J(|J^W,*?9JJP\$MQ\$H4, M\$Y^9RD|>B",NDR0-
;1!"6L.T2|D|!4)+10=B9^@*PBRMMK%Q1@9 #&.7|K|N M:1 MJ\$Y\$|W1OW(B1#>,YD0+8.G3(7HUO|D% ^+,PTZ'+
|HOO>B1|4).DT2F M.&AATD|J0LPH?202IDG(ORFIJ'3|="" +@XBQ#UZTR|Y=THL8D.F?9"F.OE
M2+M)EQCJO|1 \$URS/|4_ MV&J9+I2G?VU^|ZC.B^DIOQ_H/F"\$|W?H41AGX0F,9/Z669U_.5;S-B'*95< M9
2CC>09^0002,"QU4 VT=4A8_#K.V(7?BD3HDX#J\$1RCKL#);T9=SP'K M#KVVCIXP_GH.P7\$0JNS33I%8XH(7D|
(%)M54|6Z|.66_9|5L5_FOUOF=>*A#TVTQJYCM4%8_1F| M#_.6R>Y|T!"BE.Y1?7CFZ:P/C3|RWAQ531GQML)\$S?
JV&P#A*JORN.C3*5|_O M?HH4Q|K\$WM0=W\$|L.1.^TMLJ&6.B|<24AY\$|DM*O(CYPJK-29N_*0Z93;V2 MK4QDA-
H?:TVZ2:?(9#"&<(TOIK.X>DX|'9'EKG@_A_V=^M+YPD@_N')SM M5W;V,*KZX6Y6I9,><;5N;ES>-2,?
EY18TM>B%08I_Q' MK+H@QB1_/19@H1C)1:B'40S*1+(5)/%G: ZS9X@;BLY*B@9XV&B"3^@7+ M|;V:/?W.J:98-
^QT0#M59BA2@ETLS/65H|J&6RXW" |H|H\$2P*S%3H%|C7&
M:2H8>+Q;|3SVEU"FD0RX2K&U)>!"6AXF+&LQ%PJWP^20\$4LA(1".V2-'A/U
MO"\$v\$|WV|@N3#F0%+RTV0#N@=,N0|BJ_9Y+5#J18PSL54NUXQ:7#5 LMI ME-
5FB\$N+L|LOA_P2|3^DNT2D,*013'75\$033|JYCM|9_B-.8ACN*0ADQX_S|L M'L A36_+'5F%=FA|W" ^M|TBENZ@>?
G|123Y|PI9_F/|0^*IKX+83W!" M>80E1ZF7I#B*&IH'YG(H5DL39+&3M6Z@=H*O89N3/T#U@Z:XMOK,*C_2\$#
M Z-;TBHBVP0;'0_O!?:0K;#>|, +E)21SV|H3V*>9QYV8)8/%UKEX.UZ M;_HY/.'71Z)D(QR&N(LB&-
_%|32C:B36EJ&3D/A8EFW|8%NO'HK8FTX/Y;J6.AW/TW#;U7>>9('091IMX8D M(2:1"#"W @|3+Z#\$(V\$8|YE-7)|:M
\$1%;PO825S4_1#^1H(Q:P|2:VMP6O M36E%8;XHQFJ5#M;?Q_5|J^KIF@%T:M7_#B_5ZRF'=-L|;
MR'1+P5#V.%HT|GNI6|V9)+Q6/|7 5;'XN/55.D(S'C(PLS3R|5(1)YCKO;' ^ M3YF0(.4*)@X|L.@8^Q
OY;=D)GZ".PZ\$R35;"^GVQO L/Y+V Z5|OIP@LK M_..3|VO7F^E0_URYF::ADU;Z=#|M-A.UZ-
N:0@79;E65P^+/+%;^;N|9|0O MJKQ5/U=OM(X_WL6I2GS%J+9=(C)4XE9E*38ETH&A;A|\$@M(|L\$9>2/SREYP
M5>#NH#0A+2@G-6ZN68\$6|XIQ*J+1|C3ZPPA'EF20;*X;XAPHC^"M9|_2W|N2%(O6N|WP2Q4""...O);+
M#S#C+6|B(8R:A/PG3;U_ _6G@"LA%O|H(^|HTZ9_/|WP|T|E|_L-9PJUE M?2T>W>P|LU8;5)7L-SJ@WS9;_&7
0000U\$|UG|>2.6V?>8@97023|PUVV%A< MZV|J?B&\$*0:KW0W|;BWF^|I>+;OMR_ X7J@P|B&O="+,?
%3A6F0AMA7;18S_MZ7M1;I4;,"|R9/>@TF&&|EK.S-T;,\$U&=P;+)HL\$% ML653| MO-
|D+|9="P99KXO?*83##ADE_JL@C36/E;Z!\$DL3|R;|OQ.@T:D6@K\$|S_ MH|DD-
K&7OD|AA/8"HUL|BR:PH.H5/4&_OQ/<6I+907QD.CEMHC5#|VI5)6U/ M%'-
N0F9IRVXNFI2,*H"6W#%;,SYODPS1A-0G|G-TNV;(TWM"FI=,="W'E)^9_6OG:8Z\$JUO_&)/8SCW/F MA|KSB36U|
M09::BS;_I?|YS(7N=:@.K|6W0|M0YBJD^1|"9AN+1C"#D+=QB_OA|J?7J_7SV^*|Y8L| M\$OJ^5)\$%"@.^F
MY3Z08"OKBP94CJA)=;19_#?WC.% H'6SW?L2V MD|K|9<(4IP%YNJ|#_6FG|<4RIE@6(THK2F2/G^D3^6J
L;OD|0|?_6EI M- (4%HY+/X"P#^4\$FU?AI<@ (3T;H%U|=@.. 7@VM2+K|+P<F&AE;= MC_LSM#_F>)
=W#PN|H5WR>;JXNOF5Y_\$H=Y;8H&'),@B3_+.8>9EXH/*FD M2B,&.LIN\$#+^87;_IE)GZ.(K|(2WR3
V.9S^<&\$T8#4|5"|3+P6+LG|1%<_MV_|0_ ^S1=M8:0^W_|1<;S=I:QC@K'1TG1M-9/W_2_**6Y@_8=^7?^8E/
M5)))+|+|8>+|+##|L>8|D|X3.E&AE>=A(VQD:CD2C99;-OJ-E8BAQUJ%|K19 MN-FZ&6=H8)"8Y|@_1NP,
|04/F#ML@6ZHE.\$N4=-F"EN ?IS@;#;FOX6A|G.&
MN/=XYZDLE9O<1:"YB|TH|EL4X|+N>V&4R.@J4MM#AY&9H:-HZE"-LF*)
MRFH|7JB5PTBH"MB&%DD|XXOB>|SL16GMRE3J#WPERYJA>;ZR=NE_%+,R>%PI^7L OMNFTYU|T)K/9#W)S/D|
<3RWNM^ (WZ;K;+MX5V?4HM M6U9W DUYY3N1^DDL5(SED284*&ICRB(<1SRB"64Q4EFU4RECQ(C;|6Q2N:8
M>..0F#E%&|70JD""BJ\$ _M4L8P.|H|.#.1QG;L#"6&<>F8\$^ECU\$&|P#O1><O;#
|_Y_4VWH2,0Y(SX6(HC,+2)B&M(EF"M|4F0 MO#&W#|TVRQB9E&JA."O5H?|<@UDL_J|P<*(H@&G;|>Y|L#
EG/|@+OWFL= M:'BON79\$9QO_0R=MLM7//|1=K%?WQ3+_
M;R7O>&3N9@N%@Y"\$F&0BP&F:1C@DP@|5D'I9|@K(=,@:/01K)*2(B)ZALA*. MV\$XZ^BU?;X4'(QM-

YIM+'80HT!#L94!FHU'+170"0L=BSZ 8+Q;9+FC@2 M>Q;RRT#L^2\$. /L.5INC%IUO!K5W8HI
Y/4E(-WG,@&5>5J?/!!<@9#13 M'F.9B,T7'V-&F< L\$&GD^YBS+XF%CVZ(&2K3Z0-
\$RX\$2V/LK@T/8\$.#C&I+QSR5^IQW,@R&!*5L=D#>T9>1RA3\$-EJF_1*!28 MQ&&,J6 2>\H+4QD3X27V/R:)
(SMINTE@6IE-!K\$@HK!P@2>:9EN7741G -Y M'6%*RB/WA.M8!A@&&UC N
-2=U'BIH\$3%AKNT/NX>#7@P!<416W^50LQJK' M8FEJWFO'5MMF%E\$<^#&E6'\$ P"2, QDZN-
\$9I300"6>M&HE:B%K9#ZIA, ^ MKC.&L6"3X>#">*4N%:4%XYWD7?9(FG)GO=FQ50 4VISTH5\$J)OJN\$D8EI<JUO
M)Q354J&7&\$ -TLTM@X"%L084H/UQA8L/>XYGKYQX@N/+8!>WGOL>I#-DIA5 M#IH_T6H!^<^U?
ODGM;L.B.)!WOF>92K-0NS!\$<KE?:"C2#TFR8IZ(%7JWGLUO.A0, ^O9U\$5(N<(6.16NIP2_\$Y7-M
MM:UB)EU.SX\$!72W/WN 4U.CW /:FI%7+>DXIEP0Q3!F"E.9.-Q'DGDLXRE1 M@JZG;)& EZ-;%0)1UHZVHF?
H4M8NZ->UF\$-H.S NP#;C. QN_6!ZG3\$*!^ M2\$;9Y)7!(MG_..?J?;54_9)LL%RTB.):HAC6*(.<>Q"M7!T"YU
MKO.%,O!;WH590OPB;#H@ 3*83V;'B&?2_S%!&P0Q"88N=; M<.,(\$M:IA?&L@!PI+ Q54Z/S44F=*
,CJ@/XPVU;^60X817,PP5/)O: MD(&+65X\$!Q>XM+I6"=4KJ8Y4FY/#NYTHM)(?V6JHK&H"Q_N:"JYX\$3A
MC\$24%,^<>HG#*=)RA@C@<^D_?PA<C"1*^5H@)8!#69<71 #OLED!K Z3) MB(41+3RE@4T#8Y-*/I28);M?+15
-T:Q9(Y5AS>/8=Z6OF8"-5^PQ=[== ML7C/A\$U7!%\$=MUP!C'-SO/ZFY'=S:525^?>Z3OJFT!EC:9SXFOT!H!C8CJN
M.,H3*(HYBSFON=993B>\$S0R!VW\$H@.YP!)P9RUEYT, @1H<=\$!0P4!1.5P# M^3^M8B9U=;37P\$1UM
Y(*P%8H"UL M9^&V#&L1V\$=ISA@ND1X+JP"IEF&MX^T./D8.Z\$=1.7!7B=-,Y*O:8CCP5 MP#
W1^5J86(A!MV3%O%!4^AU499W@G%/T%&(96A<\$QHJG\$!XCCC-1.2\$5>" M!UZ%?0P(I\$R.BM+ #6
7.V^N+UH8Z6^! M5N)FR A\$OUUWGF"-;@N1 /Y<(TB)O7?ND">^FZ=SSHU=-&TWWZ>DH61")@D
M6*HTQ!1PA6DH,ZQ!4*5SSP_B &=7;IDC?
Q9&ME#;1UVIO"3QO."K#/MN3E.#8PS76(7ZS%ENO@;+"=I8ZR&.%8V#TQ_SAH^;.%8
M+^2NX'4.Q%R1T, RBJ2F)R4P%2K\$VEO(DB#STPR0)!J9F1FJN6B6C"J)#O4 M.VVD 4?
#0<1D4MB%VKH#=#!Q9#IVT"JYKHD,F'UT,O!':V1'KSZ&DKI7%\$PO?MIE_Y5%YIGA!^K09^@+QB=H-
9\$\$_@!"&T4!+8A?Z:8<.:>\$T MA D<^S;.)Q_8<.D65?7%@Y!7"1.A M"1*%6>))13!+
<!)H)@.@.9>>%D2)/\$CLO\$KJR.2TJ6GQMVW)YIMFZB!S!NJG/Z(- XYRDPF\$?:"PC9W.2>,X(#!..?
_AA2WUOI2%49"P(CPP53\$S M;))A'D<\$S\$YJ\$DTDCV-0!3")\$YY9.>36UI/7QN#J+SC4(S5&Q5VK9VT#HA
M_FRJNW1=(^YM:CN^&86!J@#;0Q\$ MJ0!XV"24!9Q>87CULF+_F9>K9YWKG<,&D_Z?M4D/.)\$"\$TM:.*
!R2PTU73N0IGQV)<H&J.)%!(MA+FY);H22FW+N6+W%#.#E!^G<84=@D-B.IA<&C5T^Z?#>!.EV?
&Y!Q6(" L65NBX7)A?F9 MEW! =2!8!..G6!3/(CA:N.) MI9)B!^FB^V-;%:KLNH ^9^!M1,1%1X..-8))E\$G,=
N5/_\$0(GZ: ^LC!^ M:9.R=H"R\$HOVWFU!5%7Y /<%QP.W5 M@S0_-/4(Q521F-8!
<*\$K34)F!DDC"\$42UQACZ^!25IO32&#;/T@P@CE1-T M;KEH+V& "\$M!ZP7WEK+-6W<^DFKT<-
V5^6:O6)TEE!<^YE9T)XTOVP!>Y_*X^ M;L-1)E4CE,S\$*HDT/42<84Y%G(7T)0TE!6@80.K-;@8F2&,3+03JC!C8'&9
M)JO8!\$1OK#"?J> G3L89,\$UY8!9B>N%<I9DR'^N=JO30-G;1&3(?NH5ANAYU MCT.N-
I&9@!2I7=-.B^_+=/V6.7BH5@O5G>9#/TD-5VQ0U!O=&@:XS1+/H47'4TR8-Q6*#@&DX=J'4W4%- %U?
96+!Q,7D6A9S-!1R<=H! MQG<>2\$ _DV7YL?N3>>3;M!>Y80O!Y M6KUY?
L!FYKTS;U2JP _+8OVH>;!N!\$R20'E8.,P4T2SB9PE.;4QQ\$%%(JEH MZLNZ=H('9E7C JHTEF%F.KXV;J!*\$
!15Q*V7MI5)!9R8H0T%XZ5A; 1V4R"@ M!) +K\$1.ZHA C'#J>8#&.E!X+MC09E:MBL;^=%Z9,^23!*DX!3"+1#ZK_
M-,D"Y(TC87V1D"WYJDC\$P,M5BTE^MP-;_1!9^OQ"089!X(UK7:WF-L(&W M!OK"=
!^49S_H"MY7:C.WLAK'#SMA;PN_5_7M/=OT*5+RDUK5ETCN9&@.@7B"0_U23&(18)X\$C;>M)'KWDPG-
!J9TY*%K%V;2!U<81K>!9JF!8M6(\$3<*,N3FE-!MGC^ TI3L 4M M-
QJD*AA(/S/76INQB^K1Y4;W320'TLW1>8XL6'\$*R!-8TVB\$;I701J=-AP*D MM4*56NAZ9JNM9E4G@UJW*4P+8-
XI3.S:FE=M?H!&!?UQGXO!YM^YJGJ+N/S;
M\$;M>J\$8\$JN%*HM;U^;=JX+SB^?;MWHB _JH7>G!MBZXH2NRU6;%ZU=I!O
MYGK(U!7B6_E%J67E1^!O"UHL((#7C>W=&BW0@!J;G%;KY0)!*Y%1HMI6Y;\$3 MQ\$C=-#^28"NL)5H%JJ6S.%
*.#E'Z;9O=KI#!32Y\$QB3TX !Z2P8N0UV" MZ83\$?R06Y=%&)LLRY;4!#KD?8N)Q@BEG>G.KF.?6\$H2)/:A!)
<"1O!RM4" T MD0C<40&^:M^O>'3IO&#=#AX+Q=Z^P M>=<=SKD5
GH1S;;;K0%I<9%QD^S!5G4N!NRN;JU.Y'G;H_O5C(OQ?Y805-/VY; M3-
Y17P8BH!KR/3K#AC'C"1%99SQE;8)!Y65MG00;49FG0/=4+ZH"CDP^61" MDJ5IXKPV%I/+8H+JLKH?QG-T-
&-6@5S3Y5(A-WUX!69N'YU>9DH/ !^:\$!HAD.DO#%J0&(U_41C8VWNMI6A'O:TZ
M"6UTG66#G71MW/F=ZBS.H#9!BO(VD>7B2NW#F"VER5>AWBI4Z(%X0-=S)(
M);@0(0=,L)HND>?R4>22=VJDDG0_ZI EGIYZGN?_MG3UH*BM^+ #YM;V7X) @ (21+M!48Q)HF*!+;99UB1E*;%
M(N91\$(?OK7B<(J-IQ7%D\$:" UK<@NU>R8XPAJR51#^TEFBK)JKU1+6B*;I MVJMJCH05,LH>M# T^T*M+ZH4?
J59@;2!?)W9<>/PS4RP_0QP.P.FO!F;HT?V
M7_..HU(JPG5\$U*:7J^R.@S>GBSS3=YC6>4HJ@ (TG;I/_@=/&Y_!7CI@CG MCWNU5/RJ/H6"Z8G_H\$!(S578F4"
\$S!>YUK!..?)H?RX-QZJ&H M\$::MN^/E@/(F!PYO)6..VB.+ZG#3^ET9=BN;J9!NY=O_5^<^N-9Q9XF!Q
MXF/&1.3!:=GA5"0ACL@S;PT!(6PH;Y8R!P&FYR A&_DSI/X:M !N-9'5 M!G!X_0#-FMR! *WA0'&-(IQR*. #?
_GB^NMC^E4&2\$>GZ>>IQ3*+4PUQF"?25(2"X!TX0002\$^;LOA:/TP)NG TDDA3>.F MXXX.K8!
(H^LYM!U^K""^_29"ZK15G-XL5RJ>=*F5E!H!O_Y\$OMR%_!8\$OY
M3GO4IKYQN5I6LU!UL!UTF0!UY!6^4THUD!>+;ZH95!G.^&I_1IBH.H\$*8H M<8R92
4.0RZ9*4!LOF;M+;AZ96W>L..X!"F.X6ASZS>R'C;(#1Y?>PZ! MN?_7G!>W*NO&/5SIAPXQH_0)C_Z!+D-
\$%0AF;\$:"SH @RHT=5!TY^W&=3/U M>N9K3;.=.\$!J'P=3D^FH3GV%_/ONF1!^3RG3;+;11^6"JU>.KGYGG>K0
M;3_YNEBH6_W;RVUUCBSSA\$!#CGF6)MH%34/;59Q@H>*4^\$+04 %2RIM\$C;PC
M1B0R;I\$1.D-7H/(LC3;Q(9&^2&\$4A*D6PVZ)K2@G60!4;IR!;H;I<4H&L; M.67!N0!-3K/=3WTY('\$?
GK#%FIS!7W?!)LD.O&X#&Q!7F%3TQ!S&FK6""@6 M)D*2P>P1L(L:T/+)J25X)A?9C;
!2)E>O1\$RG0!7@!TLWO:\$(+!CIZHG9C M#1?T4>D !@99Z!HY)2N2(F)XY(UY-A!*\$X4LW1#J1P'#21)(O:&A*4I#
M1.)!^!@/B\$J&#&TB;B;+1(MW=D\$B;6!%;6!%3Z1-0GD!THU0FM""4G:C=" M6?PO-AAQ=X0QQ-
(ZU6/(<O!P^7_!^!>IG^SR9\$@MU"UG% M+ASMB5&M!64 5?
=+O4'BK4>O7K2>&@3J-.89>,\$SQIR!4J!793E^J&.>!- MRS_ZZ^!6TO6!/*Y2XFD61SJ-
9W(%!;OCG%*LP@+/U*)^M_EZ!+IJ-K!/?
M;T2B3.O<%;Q&2RUUHG.MZVD;^4!KC;F8_"1K7Y82"<"8H6J*#9)!=">VJ1!@O M<((%?<
MK'UU9Z_O_QID5U/R#';5:!!3MLZ7Z;AC;GR!\$^I6H2.S-FU5&3\$HDKN#U^!=CKM)G& M8FW & 8+S9B==G@M?
X>[+=X X!WV^3!)ARV!3L#JG/CUS9VNJW?&>V/-G_G MGG6)&_B27UDRS_5JLIDU^2EYRWG!22*;
<@)CFD48A,KP!1F%_OJFU(F MCJ!>?39GAZ"1R..2C!XJT?7ECIEQ%;?2(2&6#F/9A)6&0&?FKTM51T7;..
M!APD;PTC!413!H2F+YUT820!7>E-#XW/V M12T?F.ED6T=T;HM;J?8+GRN?
Z#NS@+0Q%3'W/*28L49@1G^ (HC+T@!D_9 ML5WNYZTM=4\$TL/H-'Z=PWCIPVEXE<^ELJ;2JO5#T5&V?
BJSZ_50W8!;.*;R M\$TK+G)N!;M!NCC!V""#1D;E0W>CIPPY.<[1399E7>%FBG"RB,Z& U"(F.
M93U'6AW0BD"J=3%\$-F"WCA;L@/29HIS>XQ4\$OA# EF#7=?"GFN3"%CGBY M6C*QNJ-
F\$Y!DY)R+!;Z1.LO(@CB46(8DPB;T0!S"!L'0>H!1)8F*7VM@F8.SC@HVX_PW!E^8P>ZK M!;JBUN)8WR
;.!&.BS>_Z23^V-G"GGUCK9I2CP%;V!^4/*G922BC<@9^@;*_6NRA!TN

MHB=*V#*=V"M"MOWT#4E"#^WZ(7/G#?:OR9UK<-PRX/G3@B?2?7 MINO2Q4I/OBHO=R4;1;1#2@'D\$1Y)(3*
(HPTPJ31<9S8CR(KWUMX,,LL8F2MJ MH6@K%5C*H4L%#H31'RR,,AIPNK!&'V',0'EB0"3#1,#+I1M1))RU#IR.4
M;MV/*,7,HRZ5.SZ98Z2/>7G/?K_V=6G;2;4;C;NS4ER1-Q,F)]@FH01%ED2 M1_H?6U)?
J1%VGOE/=TS65^ISZ<.,^4:=Y72- MU_ZC2_?E/GKCYN-V,^>K^OQ(6*J"86&\$?R\$N8;E=Y&_&'[O+VQ?
W*EWFU#|SFI=Q MZ)37>;MT/IG/V FH.^?TL/9>_5X44L^+>MQA(O)2K4I)%QFF 2D@Q3Z7< MRXBP,"5>
*B_V2YG9;ZI/2/3M74GVJ6!>K.-+!AE&.0P5FD#I=Q'O1D1M)-Z M;ROTZ*4.^0DXM%/OA'.^H7KS(EJG=B>-E4O?
MQ/RIZ4#RIY<+,[X]S_<[H];(G-FQ0,,VPSC\$)\$TE9@F<.:9BY2>ADGYH==L/*'=DKMHK M@BI-BV]
1KP(06U#6.86!4UF*3^N#^&?VQ^5^>'KBIS 7@NG',YL9IW>8; MB_A@#L9\$?"ZZ1@2CO&61V&.U53(-I?
+0%0!&_M/RXC Y F61)D WILD7(R-RHA:(#J7JG! F0MAG&9D28'RZ,1J0NM55 M;
(8,JIS0&_HK%XC KU/L:87FL5.65^C4_J2!0Q>S(UT*+ION&5;_N-52+Q;R
MBYU\$'^9Z6SRP?"/F)P3_18TB#&Q!;1YE[\$LYE%GFLS2QJNTRH(C;"7\7<,"Z%6'KXV]<13#^5A6L7%7^M.181C
R^5MU' MEE.V4WCFV'IN KJAB_="Y&78EIT-U02RA)8911A4F04,R4BG"8>FG\$0R&1 M!_@IU/6R(1H9*
*>%6B;2<>6HFOVUXVSMY@5H#Q5)J+(OEYT>U9";,OJHN6'0 M^K9XH^K&8DI^TOO@VOH_J0^%HO5?
7G'TRR4DIMB\$9F/2;I=Q33.1'^RR.-^ M%G 1A!! T561L?>W7A#;G\$!GB|HY>E/8"4;2M48SM-I>Q-Z6XYG52"NT%:Q
M6=7'\$GU>#%APIZ|1;G+KG-68U'7K;ZQ3JZSW^IR8ZVZS!:=M/8)>;ZH5B\ M MJ?
B^,T1KZ26GF>YN;1499J5514C32E1@2Q11_GWQE;C69>CO;KV3EO?X+ M15(&?1@GV/%/KE(H4,R16
(M8E"0AS;R,0_AM7'5'9D\$C\$+&% M1,+BIK+A5'CR%-F1Z"-SD3-:K-SI0?C VJH-#W5&M/-HJ7TW>@?YH T" I M;INI?
6;SYRLE| ^T MBC=5DV4E/^H%:IU4^S-%RSQ3R#O^YN>C HD;G9;1"CV5?ZWJ)I+%,IHAS;J MV>>N@NS7S<-
CF@|fJ(Y60W_8G&J#;FA=1&49@L2-%DNK@0PX1=I_&U^??"
ML6UJ4@H05F;XB1(8DRR1.*4Z)TQ91ZE@5(9ESI^H^MQ+&2/S1RVTS_6Y\K-8 MQ/7Z@X51!0TX7;-/-0
&7L KHS|^ISM1..OSI4C.GMIKF^HM-?GVC5_<7VN MXU\$4KFV|?0K/I^%N#<="9>7MYN?
\$V.O89ZBF\$;D\$HOVS,7TD&|C7R+Z>|5|7Z;|STVZ2|8X|TH^/L7/?8P&/&R2 MWKXS507>FG3|M^ ^V<9SFU
M1%2)G*&W/P#I@R9K6.R(>F*\$,=8I)=|4!_..P;H)UZWW8_UM,(V/AU8.O<1
M3>..FV^YT:VTT^EZSJ4D476/YIHHR_=:G|HDC<|O!_+OU?VRO+Y?MM0.KHTH M|7IO_ ^BWN5;W+1A,')(^&J-
BIS*D_ (^Y2T;QQ|PGAL%R?23|<@8&K++#R M1ZZ_Z)&??Z/SY7#24^K5=" @9<1EA\$F@-
MCBAJ:ELD\$1>|5H),PL"=C)Q5&YF7|5TL!_..F10MB=TV,(ZMU4%&'115 M"-4:H5HETX)DKY19OHQ:52HI9'ER,RB
>T_>|5 MO4<.:<%H?>|J162;^60GL3YP00_>B>XV#;D_&OEHH_5^7:F^E0?VC^H3 M?);JH9?7WZX5FH/FS23-
>?JVA^K4IU%1^6CIZ35_ G4N+VYN6E5H(CQ;8 M2FIRB^A^4C;6A8L BX7^5U?#6NN&Y%03^8^3I
T)4F),FV/8Q7A2(HP)=03 M0615<-15@9'7&9-S;1KA'G34_-0%|5%6IKX=13W<.:8=KPSL(F
8=\$#ZU3BTG*MK;7|1-6|>+AT(|3?|=|T%DH|(-#D),ME4@P,5EB3*D0AZ\$*8BE81))TVY?2CC?@2EA|(>M*6%\$;
=X8;7MA8THPZ|A;8R 2XX)VCD#Z,6C0YD(R,<.:3;23-G MC=7|50UI MA7Y8K>^D-SA=:QY>E7U%>_I?|EW?VQ9-
1BK;PMM^FI2..!2!,MR-2LVG=%|RZ,A"KCZ\$9IKH_Q3SS33GB4.(T8@)H;1BKV\$|2 M;??M
N6_"GOZVSL;_C&|HN3I+;HYOR,8!_1N|@%7EP.AG^H>G&64J\$)P&#&|>:8DQ8S1!"OJ1PF7'DU2*|>V
M0!;8Q4;IGL7EF;K="E V&?>=\$08;15W&W\$RjXVQ?W*12;|5+_3+G=QJ%3 M5MOMTOVDV&IGHRY)+
5;E";AN3K1+|H|_OZJ3E)S5B7Q<#QJK.#^Z");D MI|7F46B;J'J&:>8EF_4QEF;2;1"NB")8|>E+@1B>9J<,L+%7
I*#_&J M!2N-92L85U5;U!P! M>>&\$1X..(|3.UO>X.*X1.E 62P?U^7E 3(O5_FNMU'\$4N%Y089| 3^:94->
MW|/S5,+3*,O,6;,>=VL3,S*E;K&HEHLV@H&MK|KM8^/0%#8\$;1H|_@)VD+|AR"8| N|,NC;V6|/\$^7ZDW>7&U\$-
NJ&U| "M(TIC'&6,ZLUAD>4(JHE'F,R|.?/L4Y"8)(W/+5B32,F>FK1"DIU*302P8 MI2|&)F0.C"(XU0(D)V;ME/G
3E\$=:+H0C4-G+|14X?>QWV>NAYT MBRP%_ELVGI JV4@5*FD<801636_"U)L;#AE.P(0%02K?>T(4IONX)|+19-
&CMJT HT M<3ZG;W1(G->S|_4Y5OV*IOFPCCGX6T#4K@6-B<0DH;G6U*!PDE O\%(5 M>R"")8R-
DMHJ@6BRNY_0%GQN,8X58?2'#&2-/5JT0^O&^2VP0032'_XK MLT@W@#-4TC)X2C|HUO^\$5,X|
f%)_M"G/ZZ#;QH=E499W2=AD&5ZAR+##),X
MCC%7YJ#++)X*DD9<02NW&D=J("U+8VX/Y_LDONHV&9KOM8#4IK2RH04;#6X9 MKXM&+1;1##6:HTE%PXT#JG
YM)#<"NW@P=SX05UEAKCD>)\$*:.XOS0Y.I MGV*^EB;.G.4+TVN'S8?F#;/QI GKQ OG.A?Z;LU+U25GB.S |W4S/-I
ML'N)(#MV%UNU>M.\$M5?#S/7I8GFY5#)? MF8OT_UODYEJJ_.'OPY,81FA""0FP#\$/
OXD\$S;4>A546*9R(H(LA3|Q+YU& M)NE;/C+%1)!^3"V?JHN_ZXTRU>&AXX%AIWFP8_/)K LF^EJS@^,PM,-:70
MQO95D8VM?L@HZ'C>P+ 2|5@!CNW2003,ND",H@13M>6 M85|JEN#Z5;YNZJPP<5""ESA>"MP""L;NQ?
+1)74ZAS^L7_G|30(@M##(C2E M2(-(^_JBL6A9%,AY%IK6;|0I@31 M+M|0Y545S<>UQ@!+F.TU+=V+T-3&AJU|
^1NT8VX5W)M4C|^>IRM-5K0R^.'C'9'8?WS@Z5GZ%J+@VLJBD)X=|E|T|A'4'2NGM ML;Y#&.TT^7>0=SJX|#=JD1?
+?RY#=:;PV_5L\$PIR88)Q(;|1+<)0I MAHGG^3B5I@;53U+*XC@;L|S;7^14-3(OUK+13C@RTBN'!. %>MO*PJ<>S)
MLFH%|Q*Y|:8"P-\$=SHN7JS#3P+FEUKAZW0ZNP4G=IA>3(7;0;X5I\$)%+
M|U+VL|I2^TFM|@B/"54BPZ%D(2;"XYC22_5ETH1AY'OZS< RLTW"0%Q%+Q@ M_%8D6K&?F|KO,
f10*Q.1>V+SI>:J_1;KAA8+3":G0?6UQ0PLM19080;7<|_ M5%OAVX*%V>MX% 4H!WF8%5 &D1,7;C>3+;A|=SSK5(-
fZP>75HDP|E M|V|9|%;_9!1C)DBA9%IKO2\$G;2;0 |B^95R7D\$=C0/1QML_O2\$ *H7; M82X+9V,H|
^WTA5PM49|!_1P_JCO_9P+??K9@JHE= S&,4|>UXP925 M?_C.*G=:S' @:OJTHR?L|A7^6+U3;|>>S'E71BE. MN*>
(9_K/9?8DU2AB9';5SW|+R,5/6W\$ C|+9LM8!%00# BVD|JG*%*(HV M%0%0 1?2&W*NVK3UT&-
ETHNIDF>1T|>+1^9^O+H_>M;HT;4|>E(29K\$ M&94)|FDL|Z(HB2D)O>+4+22/E2'H^+R>O'YE(M#A4R0/?
TSDU@P5S|_C M8XTC7&f7<4X|@HAI_#ZRM=06C0<^WF=24UUV_#ZY9M/VE L^/E;2L M2X6ZG\$)A&5)#
YUC%B<3\$YP13/Y6:#'RJ;\$@)|8@1#S2)&)D+C\$BTE3E# MEZ#LUT;3V!"7Z P7GB|T8D;&L%"^\$OZ-?EB"
fMNWFB<>2\$7-E^3?>#H M6-QI_?@XKPYJV?R2E??OY|6|JT56+!^J;S@Y+,UI%QP=P4@P M9CJRC|\$
&170@0HHCZT60Y9|@N\$>JNR3I=1HRS|3/&B|!-PN\$NOR+Q)+\$HY M_I
LUH17BTT^V.GHZ|*B|O%2DFCR|6B^HW_UIG3VQ>9;)%-8|RS+MKF1Z MVT(2@5FFMRTB31G)?
%|*9N^N#*C8R#2T%U^1\$*1EXX#&MW",7LFDP\$.>CQ^H MTA+MU&QIAH8.K%1IG_-U_I<#;5H2B#=-
U|G;AR|=DXY1<#;G\|;L;MCZ(#R M)NPT.KR5CCN4CO!^UUYJWTOXLGEL|_<^/V..FGQ>)F58@_IXNY?E_Y I^; M);
<|f<7<QOQOLOV(Z\$5;,>|E4^>|&F(0_CR(O2,*&0;_&P|F.G\$A@HJB021X M;FO*MMJ9F*BT@^5|PZ,NYN=#N'>E13
H0U"Y7IK2KRG@7A|:K-4*!LW0 M|HDAVR VYF.P/DA0^1.WOG(TS|M;2*XOI\$DK(T2O.<5%?)V4>IHQ53)-
A)QD24(""-J|C(M='EKAJ#%D6ASO;2#>3%B>25CE1_W=F",?(6|SH 8O+NMU#0(99-IAC:HIFA M+9Y975-
Q#PEM,,V0086.8;\$MKN%(_77F8Z 586+E)UU.7F=B3M>B5|+Y4B+ MQ.2&S5?
7|5|UE^>_WFL=7(F\$QBCVF_Y@M-FY#4PRGU*XXZ_Z#|Q*MM|(2'7F?T/S|W.O>P6|FH.*DN*9;A6!8?
M@>FF=ZS^*HEV/E MP\$1F%*>\$|U@&4QE&G^A(-T*H6,S"Q|E,1H+U5|DL"248V&L6&5_G|AI&+D MG2!U+!?
5"!E6+;HOI-RTNZ M2_-8ZSV?;2NB(R#1\$8>#CU/;3Z)>.:11'Q>Z6T#|F.110'F<<2&@.2Y|HDC/OQ
M.HG;MUZ@2B8T1Zf)(#9K?4^8L&_Q|4^G9;X)*F2|PGY=1?X#N6|5>F@1,N M|1UZ_Z_K70_"NY1>K&6NS?
D^7SYO(S+^1A8PP=760N_H_?QN/N@%_L8#MGA G40;=7=J'7KVLEZ MA38"1.P.VOR-FZ?IGN5+>O?>3NBT?
>U!AGC1ROXVVNE>2NA^IW7|MSX'\$289GZ|S MNXO2,;0FRB|X+|R/916W<<0GDY;LH|*U;G|Q>7_..S9WXYF+?
36;?O/O M|6%DM>(%GO(XU;MQG@42\$V;[9A\$;OV/)+92B#BRJN7;+69DGM@ (10=2G;R\$
M%AO9>07|D/'OQC308MAB9+QO1OHZ6)^YFF'Q=LQ5Z Q1Z_Y/^I J M<5(- (5+43_5&(?^E29|4IRRE,,LT|MLF?F)
fPEKUV|R|4?3PKOYI6<)1GZ14LBJ6PV->6.M*6.FYHIS_9%7^+3M|'|S)V:NJ5PMRM6R^FI_ M+^V.
CW0A|%15.IDI1?2.BU")OU<_5&VWV/^X|B*;AA0'C"L,4L4PRXB'@R#Q M T*I'\$*K_..(AE|G9I=BKAM|O.O<: DM|

K#ZG;fE:EL"50X#lOXH%85_=QN MB//H;UJZ ^C*JT&W"#-(21|BM+VD.5BR(2TCZIL47(V(SMTXVINV5/
MRI@).%T:W<8.2LTX)U.0+OISG7@.9VF2*\$*#-\$GIW4)I-IVQI&((#5*L M?F:T ID=RK*/
FPEH4>62|2|UMKQ522@((5LFJQD%XEQ1>|5*5MAIKS3MOP M 9..+/%09HD3|K>Z(CX&K7H>M1A&3HG; M?
_INXTIO22|FEG=Z8T(2P+3 MD27%A.8*<|92G.217N"CS//<_D+W67\$C+_#7)VU99FBQZXR@=DH EL+SJK-P M
0:U"NS;/>+U,D/D)++OQC\$(P%\$8U#|N7D-/1%<"6NAG7P|^;=,YV18(SKR M..Q'.5#>+L3L.VAU00%JMI?
RI6^U9Y@JL^?Q&+526BUS_ZH+S(\$)V.;E MU>X*)ZE'<9C\$&28R-(7DL!)Y\$M%-B+N7W\$=C"U1J:03TK)>=
KLT!RA=M M>FW?OW#..1PIK>@UE>Q*HR"MRKN\$P1J)9'6\$FW41=Z'O85/DTE<-G-
#32UKZBI5'7#YE6|N.&;VR|UN;HO"SFN:R>.>JT-\$_JL|<>8D8 M;IWQW|Y=O?N+>5O|H;I>
(57_C2Q4B1;Z|W'/GH^Q6%B2;8|'Y>_T;L1D) M;<"%DG^I3CJU?I-1H.KZK=^L5Y!"_V#..XV|_J>|5K7|YHIS|1M.
MVG2KY.6.EI-AW^|8S^#3=-TS|E|E|G:U^SJZ+Q7?3)O:MXJO:JO3B+NL@ M%
(3:3FJT\$D)@XK\$;IY1XF&=I0)5'D|:9RZC*C#R2GJS?J@.^?UM5D403|IX MOD)IW:HO=ZNT-&N!_LP?|7?^53UNMH'
%C@O5|A;^I-HQ15|A:NM7\$V3 C|J_ MC#;XZ01<&?F2B.T2H:JSE&Z14 %3JMTPI'XISHGN#Z?TSU)0D'Y9*+9JR
M^5S=7&|G3#E*^AEA-?'\$QX(C|G.L0R4UDF"8LX!=R5:Q8RIEF%HKV4F?H MYA)TH AL&*MSU-
YP@:>H+Y&ZG:\$V0P:=H/;&_LKG|YWZGSD|1X|Y=EH_8G M)Z?=-SSIPR5=5JN63>E|L39#U)O6Y1V-LH:|(<@)2"
(H)40132JALBL2ZINJ M|_VZ;/6DD^:|F6G|1=4^&TKX8"/K-%(%J3BC-F)4;8XM;BJ
MOS.Z'@0G@G\$ZXG6C\$2AN&+MT8>JDEL:IT %*E|Y|+Y((Q1E)IW5PMI#H+6 MK*Y'8>%NO!PULLQ%V;9LJT5_?
7WP|2|+/?RQGL|FRI^AVU;O2@S79 R/TN MH.%5DWP#|1^V/ Z.) HE\$=P6;TTUC.+QJV+S=Z792MZ8S|+(QOB.4HA
MDF11G5RM\$A6F.8MYDGAN*06M.L=/_CE&BUF.*GDX7|6D3X3VT./|+|T.^U.YY=-:6:0J;=TR\$=I-G5%._@M SWHNV-
|D2#ZBD%52|Y|B>)|HBB^A M+TM23#Q?|X%|SK|/_#|C1.8.<+NN1B0%_-
_1.3>+E.S=CFL=,>3FF4 N3^S'=SSHPS# _Y7F^ M?Z^YHOQJY+QCV M+MICYW\$|HC.61)B(3+LX?A+V.-Q1"
(-|3|C.-6(2.S M3^T5|<3.T# _|^?C.VBQCP3 #X(4Q3|4%X9IPPQ@F &PNSS.;+IA#'.&4R?#
MM(V=CF:.'\$_.>=>=2B6J_R JG|G'TJ%MI:ZX4T.^|WB|62:0#OE3+U M4"YX|:3>J'GOXR-
_JE6UXJ5)I=0SW*NGRX J=5=H_*8923"4:|H?ED"4ZE M8I@FRESJ4VGL)?;9,\$ J-G:0YT|7\$ _I=%
N5I=DFU;ZHDQMTQF841G|QHW2 M?Ts/E=IH:00VY;M:Q2\$)*8_-I-6-OMKT_*0ZKY:O;|22MZK7EQ6QBFF1|@
M9M.8)NS.AQI4XH195&-8ZCCW:A0)HQ=;JBN^+SKQ*SUVOWAG9*294E";-2
MKYE"FDX+L8J|*FF:A9'G159M6.945_-MIZYUJHYD8K83S*\$*Y6J'BPF1R5% C'8Q -6'+7 -:06%09; MKT?
U8+BL5VYM<"%L5ZL#FZ3WU&6|4@0CGU&0KU9|4+;8AK@C'&J:54"FE _M;6-<7<=|4;@E?& \$&UW1HZKP=?
C.6=@|&79INK;|DFW&Z=Z7RE/@|H067 M:BHF=|
I7:Q 0:0#)>@4TJ/"K+N"NMARM"T"2)=0<^@3|TR+SE;J%UWYRP_MHD3X&58|_|53_!BGL0BP'R62Z|*F6|_E-
4H8N3%TXA\$6YG0UMZ-)K\$)008%
M"ENC7F|TNC+9"82V>P+^G6Q2W9IWQT<;PY89"O2_/C8%WGDZ<\$:7T;|6Z M7|6+79M*+_
C&K<_>R1BAC&4J03AXXA&BBCA.Q'8|Q|K\$# R7VB!";1V|JT MP1@V7-\$(HPI3M Y|40#3 A+|C|INAS1KGLW0S2,FY
?VK4^9H>.YORXP43Y M:XLZUF|ZX)BDFBA4D&(>|H'4:Q4FLA\$1M*.*Y)
M&YDUC&"3"K|Y*98;#9RN&=E9S|)9AKO)C&;'3'Q:X%HVV@HWU1@;AD-0X M
PUTC&&G9PNUDL+;OF8|_/\$<<9QU(|%3'C)/3|@_H04TB1J8T+1+M9&IG 7+|H=DD-LY0 M7Z
PGGJ|TQOLY*+;R@8?|I8|K"3- M,+9PK4WSJ/^VOH!^K|8 |O2HEGDA4?FH1)|E2J+U0G|U2/+E|^DH0J?6MGB
M7\$V;CC=,6MSF)+3*C<6(^#E;LS-T@NQ6K/Y_/D+R^6W|K98|G-/5NJ^V*N M7_)UM=@7L+0LAP-
|Z|C<9I0Q|>"JG.*M5LBHA9|*OZ)*;W2@FG;M5^OEPKZT M#M"&W0PXXOE@C.AHN8\$|O;I;Q*G:#U#49-6
W\$QP6"W|A0T.7M-FJ^7G"V^ M+ N|5)B3L-OK;67'U_*L(1AH92'B2GPF5(F_/A)(FSS(I2^Z9F'8)&916M M9+07/4-
_..|)Z+*2A9LT\$88)33 1M?Z SL5 _^PR_|&L@003VD_*"RO5&\$ MY0M33WY5H+8?R^Q(S3..58D2#;
M>|2DS(NA14L'TLWJ*^I=Y_1\$J'M(?J@9L>|@"0WLQM?O+G|')4D70
B=X#&D6*9C|L#=#AU>+I+ZK3DE"\$3,5>|C@H>2E@9(== M"W3-%VDPALT123^())X_0>=T/-
(FYX#*#D7YP7=H1%WW|H.LAG\$3'HNT:WU M^+QG_WO|OW6N|J|A3T?
KV0>I_S|8H)WZG4"R+|4YR(4&_O>1#A-#_)F-.M|AOG_K\$FB4Z18W.%QM9FU@WX#OJMH%
<0R&&D8AM=@#1V.&MC;XJP-*PR MF"W<^,7=)C "LH+9247=;YB.E*R0'-&3W0@'HKI<+TV|T_I%'Y9%6?Z^S%?J
MC M?IA5,"%U@'P|9XWG 6+ #6H.X+C%QA*U;%0)1Y5T;2L;\$?G30(@M4%-XT9L M9TPT\$*U9 ^VDMO-
OF8|>K|\$=49S|*+2FX|A-%_*DU D/A-) %DNK-|4|<2/3W(%P)\$WOP7PC|E; M|JSV|QG3=1/+=!;\$=VA+;H^C%O)Z-
T96X|+?M|*BN|Q|EADQ:SM@-^6L'; MT#7QK#)C33#R+L(SU|Y|8E|25.4(?\$7G|?N3MBJ^YG
M.B.^#=#E5|16K4Z(K8_Y)-G|F#9^SjG9(>?%8|)=&1|XOE5_5?2E0_E\$ %
M|N5Q*Q|28+4:8M8H1C(7D|6+J6|F&B93S(28%G10E"1R313 MILSV.8|A_&;+6YX:WD;/\$UD>^4 M-
6W3>|O8+SK\$6PUR^X2WKZR|D)2Y(87RRD)X;|+IOJHGM5BKNR3B 4 B#&>9
M|V'B11)3&BJL4DYCEF4D4E;U/0\$R1_Z@:|@HY&XJ1?A \$IQP &>K&|&_5.G_2GIUH% H M+|MI7>^TF|T%#&4'V+?
O9+P|V^#;: 005/4I)^X#>C3;|MJC.M'S5?|EUZR MY?(Y7WR_>#"7^_5|84|31GV1|3KCYJ-H;>PY2Q1&8|4\$*U)+
M7DQMK\$.AUN;ZLLP7G 4/A|G|^K4HEA4EAO09)+&F&"Z4V?B8Q|+;|;2?2 MCT2F1|3\$4:27#..(3?
SKVHG|97Y=MFO%._+K145=G|CM3KFFM7GU4.N\$N=| M#;9(=
(B:>)\$X#_KE(F\$QOJD^:6WZB74_4KUROKD|L.S7KFD9.6:6N0_.3NG5=3|YR8?NW>OLZ+Q|K.Q5Z3ROT
M>^|8RI.41R&F*E)U;|F|8.\$P318.\$^H?>B|E|9NT'W'NA.)1%&NZOYK MYL:|7@VJ+ZYF/2X+|+|KET"R#4>?
10Q%*"7FQC&"FO=L|9Q|KN+8M2.%92 MJ?29|WIGH;K? V?
Y|0K@=UG|_U+WKL|UQXTBZ|!|Q+YGHR>B..L+>_N)UFV M>SUK6WYM3<_|@<%:I0X4V)IR"IW:WH
BV)9&8^)!XD M@+Q.5@+_I|+_Q;|I-SM#+XO4(=SW|7>9(WQ2^L;O7X4.FY337+=Z9B@I9| MVS7*D)
(&&2\$XCT2*21P+S\$+|U.)HBFC69Y9-50\$RAUY2M(1A0A)7^C'YM M|4;B"VQM-LG& \$AV;3H#
|!|EFJ|_S9\$NIFYXLPZ X.F&WNX4|AL%|>2
M/9;2\$J>F<(**L0TCB0F1\$F<%X7\$DC(2))P'\$;_OXGC|_)%)P.A#K4|P|P1 M\$C;_X/L@PWA0|/<F>|/
3%S0ZQ|97#9L^I?B%J|NBV*8-FS^G|(F.V|&4.
M?/Y|X6#90_7|63Q|J.5^9Y.V|+2FG&JEY.V3JMMWV+Q1Q;+6E"06C^J6 M_Z:=|O:Z9%;<^H?OZP5(-
YX6|YK34-FH|QOQVNI.%S&3 0QR0@F.2.4TV M(HIQ2B6+@C3.15984PD*H_6NO\$VK)5#|TF753-
'Y#Y'GK+84\$6H-.|6 O& M_%>%XR\$-^JC5G^T-0#M6X|V|J#..!M09@5HKT(\$9J+4#1JR=-^N%<F#|^ MN%?M-
@?|.*|<N=-BG|O_#J)M/-S).B>S#93RO9L1L?O6:/O"EO?JT:<0I#L*<9EPI SQ_0>WXCf6;/\$;F6@K=(8^01ORG4#%
M9GTQV%;8|'9LIFM/OA/V IOR#;/|U:ORG5?_8EN^\$|=VY?OO.Y'C?EZ+Q41
M'F>B7.Y"J|DC#0A.4H;+0F&61@)TV="I2D+>"RL6FZ=%S'Z;_)S-J^G+7=M)-!|984>?|^-
|8\$KC40A0)DF22|B6A&B&I0+G|JPE()K|2D(AT2#<% MR2D\$K@U|6A2H8*)M|SX8%;O-V6&6 MF3\$HHM=-
C;758,HAXU61S3M1O3X&.% M?;5FR.B%G&+^&8.)XXQ%&|27EF&%_ON6C@_MT^"-*
|F|P^5++^793PD\$LG.7=X5' PVPIS<+Z;+|Y|A&W|..0NVL#>^)T MFSE.EAIL|_IP8&O|GMH#"I6(=-K<)ME-
F|_T57U?S+|KT=>UDN7R_7J/ MP"SLUJ%X=UDL922*Q&R"*&Q*(^J*_9(WF0)'F8Y_MV8?K;|+3L7AN2E%
MR;JF:8"Q?&W|;I9FA(*G6)(M)IMMU/;7>U;@_Z|O|B+(A|6KAA;+1#=#TN M-F\$*?>O_!|"O@.IT1|LET>UK 0^8'*9|
6XSQB00 C:7^(.M=X+Q(&Z M6<2_8IT1BP6B*B1+F|")<.&R/*1H(OI_7|AS4L8FEE8L6LM%6K#^Y"IO M\$V?
JL6\$7#S8#^>6DN4X4<|YN".EXL-^19F"O^<@T%|S|JY|S-T_(-A?T/^2; M2Q>|F61^54\$5WTWJ2?%FV7-Q(NBE-
6A'&&DRR*J_*YR#&+ HDSE:8RB#*2 M"*N:Z3TR1F;_/8GHUXU.8+7*63L3AP'V@MC&J'IX%/'F_!0&>DC#I^5Z/

MB2/I HN=9CR2UY15W5E/6J:\$.\$^\$(-CO/&VID>D8 X IX M0L+-)3B/B">WP.7M>@IP'3N0FDB-
&=A%9F6ZSE<2<5,"/ M V/I18/A?H(G:6FVL4GCY8".&>PQ6YD I4C?%1SU,]=5O5N7"4CZ6
ME6K3">^2/),TRA/CN1),DB3&N8P)+I0**4D#ED5610Q0?>1YXUUKO+6E!E: M&X::UI->6-"/;LH/QFYB^D\$-
JA\$16^-M>#H/I7>A?I:4K)YWN7N&5O)S^7D,%ATV7ZYL^,(-+1ZJ9KGXK;J^61_I MQ7&4BR@0.
(T3BHEB&::QS@24N0IRR.5V1I+GQSR@33245;L3-T20-I.1& M&8M]P_VPICTF*DNA#G;
LPBPW6T/I02Z81LP%VSJW8(Y=^/TFS 7M# 8 MAKETL;#NBS;S9KF|<(<
M);2ID'\$@&>9IF&*2:17ET6\$8YZ'7:."91F%K"Y/BQEYGFZ%HCVIZ=-,+G"5 M=@8C.S89;CF,-1R,IA-
QTV>!OH9(9,ZY#7P|<"U>|#= "VFK;2S7NMW#=#F M"NAN-I'NF:F)8I2G\$5%CE>YJ\$H&ER&C"3;Z3#QFL?
9:;#UA,0L)%B&W-09O+F('KX6UGD;PWV2)AW(%B: ',TV MMIA6A2I472MYRWIOZB;LEH5_<>%GO:-
UG6QJ'ICM6P^+Y;25MQT4I=O/OI MJ>Q6Z'=%4"22D #3.-6+!;X0S,(@Q%E1*\$DERS-E5736FT8CTI-GI?N-BHA
M4U(6B7VE4+58HJ93"RT72&T5@Y9= &OIF/AE4AQQ+11S 3Z7+<;F:M>LCH MAPX4G"&M(OJV__=9?-=D%Y
LQ;Z:BA^DQ<;%J7PIV&+&FRK7C:6L'EXF'KW;84 :8MJ'8:T-O M=N+LZ;3.S5 &KL?I%OY9%+A|MN:?
3>#U:OP+3)A"0IX2IE%\$<|9H, M.HZ9EIQ^2G6:92G-I'V:P/RIF:43C#:2%YW|_P\$28WMPFZ?CH\$NVW!
0Q:7.W"17NET|IS&?VHW M|=|=|E|8O:RTI*OELBIY:FER>&X7^K?ZSW=*)3'C<81SD>68Q(Q@'N4Q+F@@M>5#
(G%|5!LG%49FL(^J:2X3_)FUT0OM*F:HEG5JCXPE@ MV-%Q=2/?EO6>LG\H6E6)LOG M4Q8T2
6A*0TP2IPB5T82,|S R:,-11Q*FD\$:VYV1.C*G:I&HDXNV@B&-&PI8YW:49RS&M*0PH/U:D0(>N7-
A47C.I05"NY@E:55S0_I!9 MQ:6+!;C&9S @=;B|^-7_I8?9W<99D7\$0,TX)K/S4G^D\$%CF01@Q612\$616/
MGTKAL;U:\$IEC E?NR7RE3NSG7ID%F_Y@+P)&S"/U7|^~VO8?W|<|PN8-WZP M|^PV!?!TXIQLVOTT(?
N|4.84>TVZ\$Z)Z,(%/*=>E@#SCFX5&3O4'DD%.L9,@Q M"8;
(TXIRG"E.OA)%*1&K6DJ'COU|7N60\$N5:8RWE B<38#.2%N&R.MB9 :FB MIF*.8X7TGI<"+'G^4NG^F&EZ|'4L;G
\$ZE|9KL?1MF^9/@YU%F#+AY!'=|Y|>G36>IVW^?U/J&AN^=BM_#G3XMZ><-NMSO7A3:BR-,\$%
|Sf&))QAGE>4.PY MHS2F7(4*5.GBQ?/'=E@VTF"1QB|JZ*<3#Z8!92-(I-WBX8X2DRJ^73)XVS
M/6/:RZC9:ND\$68RX#BA)I_!=|TJN99: M*|2H4&UJ#;IUK<"M49(KI19;Z20W14WR&UVFT8'TLW;0ZU"Z:;@8"/*(4V
M6LW0VS6:3IM6;K|!"=K5&A|=QV\LS9E^;8X-PZ=|@B3!"26&=4Z#?23.A,7|S'4C.%^A?.=UIX_B M.W?A_%|Y|4^C-
WKN|HU|^?A|<.R&'I&M_R",7KG6IV;FHHF6|N;%V7HWMPQI|WVS|_MH=\$@E8*T5&B>VE...?FU#
*PI0(E"*A_8'A4U&9J|=J=K=9_-B|8G^C4=-MM HU93*,HI *FD/?C07O38DXC"/P:O4F|
|M|T*EPZ%'5+A=\$+X^4NA^G@-MOFJG>D^KO|CJ4'"\$35F/UA,=AV59?#W7Q;/_7=S)A;+92/97%WHR;
(+M=?PSYD<7\$1E_&_@9ZZ4#^IX)5_9ION9LG="TOZ'_H^UZZ
MV\$<47+3YM%)3FCIG6\$1\$TTU:,\$RSO,"4%"0WU6"2P'ZGI9R4Z:/@HB'Q8)\$I MV_BP&8V)^*(B|1*9IA(MSK7?I%?
G0:0X87%&:&)/9*|BPL@L:>2CIT8|PY&5Z13419BP_0B3O5@@|_VC? M=J|PW|9XR<(3_>%O\$+*/Z7JFMFB^J_G-5
M+NI4D:11D<T2RV_||JMR4: M|%-9C:GQ9G6#GE3=%=/I_ZBMN@O'"%K|&Z+C|?(7#>YM9^6HQG:UVG6UDWQ
MU)HAK1@RFHT.*B3_B9:/HOM6DOEB15H>*YWDJ.50%Y4IKNFTFL,U:S5ZXSYHEG5ZE;IOGRC ME?W'GU_X?
H^K M^O_8>WGH/'!@C%4+TYHIPKZU2B#6FT|5OAR@1%3P1N@1\$GKV+@|H|AC>-3 M7%R3*,^|SM=B0
P(#S'F6+M'FF*G2*)W\$4:FEES3*|+V47EDC\$XN1|6:/MMHO&T?
&&PHPON@#P.G|Z4<|XNMX0^1UW1XK_ H|H/Y3:_6=ERZ|29W0+C M*"7DW2?%#_U=_5XV-
E3SXL:1.64MZ3_M|LY+< KI8H E,&I8"TS &C\$>O(O\$ MBI^8 ALE GB ^/X?^H|US" D:L) ^9Q)OO|SRF^<^I7-
=IA|I3AY6ZK|I42R M?N;<1:F0:!"9"F-3"/_8A/H_+&%1DH19:E 5XY2\$L>=9+J=8%K|P-GU M)"
(6<^I0.X\$;^AOKC#C7Z?DJ8!)-W,V*?W MP7S8>Z\$+6ZCY7-7OR|K,K-7IEWIA@CSE3;67OG13I.(IVAC=NSP.8W-
8B+,_P MIYAD@F%*PP|G6946|/"X/;C\$XJC^VZV.J\$BHU2Z&FME:G5(7=ZF=R=- (= MZIR?
GOJET.>%_D4."8MU>QDV3#8VQ\$|JZ|#=ZH,V"IFJ\$&VT=V/P&K5&AU/M"%V.C:L;GXZ#+Y")AT#33I5.3YZ0RX=8?
DCV@YX\$FPVD*N>5*WY|F#P_<8Q|\$LNB7EX_L'J^6"|5^X|K1Y|-\$T)H3A+5(!)
M&"K_1*YP.3ZMXJF(K%WRWH\$C3Q:(G(BL9/V3/T_B->ZN^#R<A)AF0|;(2> MM=ME)=@',##|02\$FQ|#_Q|@/HJ%
<Y>2_-IT_D_3%E8<>4VUSL&KX79MZ=>ML|FV-B&J"RK-0E&&280RR2F/FQ"&+*8BEBGEFES)R5,(5=2)1)I,A?
NT(M\$ ON&6HFC'2,+0-83LR%1C#-L1DJR VNY<+CV(I9W%0,+.C&Z>-8SNGIU\$@
MVID+W:5)B|THU3|^%;QY2>V7-5MMO=7|<2>VP/KF^*+EB;*)S;_4/U_;;TJ M^JIN%_-
QE.4)#EEA8MEYC%F:1U@4O(A)\$J=\$6BU*!FDO|IM:W)FM8B(H;EOW_M-!E"/8RZF"C#S(*S=!:I>
<9.K*|S>XQ/&60I9ZB5-QTF#1891I,+V-6ACW_M)70E#>-^7LLM|YRFI&0AS+\$A/#(L9EF.?
Z7R(-OI+G)\$IE8A^MO+Q(I-'M:@K\$&WG |=,Q#|!:>RR#C8/_P'ZG0),C R&Q)4,?=UPDG:IT>0'-TU8=#(
M.8T/XT3.7N66XALGYX.0TIS&-TR'\$1)@4F:!)BIG.#01B1-'_U_ \$M BHU?6 MR.Q@9(M)>W#RX8YO*\$ HY\$^
I032N0@*7X>D+DM5-1+G%:(&70_1%OI@-|+EF3_31;MG:=JK&CON.F:*K;>+*!(N|V
M>?SPYT7LUXYXKH.QWZ|&U.536WAJFI-C&2Y|^4DC.Z16_/I=74%;2)QJW2P-MCRRV*2?\$_UC
:/|/A@)|S+!3'6*7+9X_&0|S?;F|I|> MZ3R)"|H?N V7KG4@F4V5X;|LJ|I|OIZB-/C"GLU/FTB<0-0QB0H<,_1%58@8
M|Y|2S\$20RI2'84@*|:Y)&UDVMFV9C,2D5%@AJ(IL'_05J+|H> X7@1.0LR MHD'C)4N0^%"41ZGLXD.FXS1>PI(S?
HFMV/Y M;^)|R=5?J?WBI+?F+|ME01Q&09KQ'/|R#0) MAAG.22ZPS.*4TH0'/+4*1_2AS,@S/ > M_7-5?
F=S\$XGP59DBY6*H/F#5N'P%WM77G'I|R:6=W\$4Y4\$:%SA+\$H\$)C2+,_M)"\$XBO.1A5326#%0S1T?
6HW.E%W9D9794S55F5O? EJ'QPOX=IPX.OP+KB_071KQ(E<9PR05%!,F M0P(S3|/N0F4'F+|;-K;6.?
8J1:1%RJ@;B:4JJ.ET0=) S#P M_4&A>?E8MJTGE_J'=AHV/IR\$S01Q7|Q+R:/OOK&0J'K;R1K_0).M"+3QL-
0N^VWK25O62BRW^<@?2%604 M5Z6EK=2=IN" <IEPE..U*DEE-(@QH5,PR0DBI#8\$LC\$0M;H^YUB;B0>4-(
MMEKLU8&8&SV_FH?;9>J" M" ND"HW+P?^,<|U9LK.MU4H?|)U/8F/'@1MB=8;YW\$E_H|J&@VIM^K
M7H9^6*K'YG9A.LEJ|IRKSVK93=P?%XW^O5FI,NJEO'G^M9/=|8%02;26\$8XDDSIQ:7C,\$V*,<933-)(VX*YU7-
5_8.C|CJPP9 M*/N*6X^3/0/4J#>J-WVK"|^<FGN5;|#^;|YI?&R%VE+Z;?EHU|=K@#YNI M/NU%L*TEEN4M)_L&
I'RQ'^FIPN:~XU;_M#;|V@G_ZN'G! M|9;AE_V7^<?R|U;@W;FC+*C.17VGMS-
T=6=U&=>"OR7CNID4%C@4U.TO*..%;425EU%:D#%69M4V6E44-K19#1!%I-JQ_&?G(> 1P8M_K Q:'4EI6U
TIN|3|_MXM);5L8>E^"RNW:T<7|G_75B/Q45N7CZO\$N2&))\$R\$PS:(4DR24 MF&7ZQYSE)
Y\$0\$(V|CBG.A;V)X12CPNB%1*M8^I?;9-T+V3PKOPYN)T/M_3R.Z.L@HU4%=J@5ZID96JLS&FZ#3S0X.=^JE&K?
ZY* M|_3B DP.A)QCGGOC:IQ@7+4XR;CTI?NOEDMG_2CM|I2I.'S>=I6%&8LC E-M'0XB3C)>8)9R\$*
<*\$6C-.\$%5|*I<|(&9F=U+16BR+I.A8D&G'JR%\$>>Q MH2Z;FNVHO% MG#5-692: UF#MOKKI(^ MR+^Y
)&5^*C/<*&CWUTE&6O1^"/_LOS*|3S1_#IX_5-P(GA@Z4#_SMH+KMF% MATSIC=G9|(L|S).9_\$/_!FTTHT*><;"
(-"A3#DEJ=3DE24/K\$21-)403 MAATE+9R^RJG_ =QB2;_;
(V|363YMS^#R+I=A1"@N|A.\$DS@G.PTC|MA P_ ^E#OSO436-4MN#L75_V2.K|U|IO#JATK;
M5|+4V^EJ="S>_Y4E;R+1:"23/,*BTUE=YDEF-&4XE@5I!IH-%@_Z0?A1D%W88VA:T-
1F&);KU)KM0QALPTC7NG6_0\$| M&=KJAI:XWRY0I^D6_H|RJ50>GG'TTC|HPG1DP>)<9ASGN4L MB;+O'/'16N?
YH?+UIXKAQ8G^H75I=E.VU1#;@_#N:))\$19
M3@D99#%9I71MV;U_E5/2U|L|SZ4|6+^K%IN^M<|VVV&BE"+C.68"Y5AHE4
M/-8)9IT!),D#V(26+4E@XL>VZ'I%\$%;3=">*MOR TC:_GU).UMO|K)(.QN*
MO*7;PJ>0(=G;"CA_@18%5_NCFW@;T7;"!S@_!|6|D|)Z5=5OWYT/UM%HV M'_7#Y^%ZVE-9HI(%3B-
J<2\$QP)3TVBH\$41)DD6%\$2'L%&(K)'HQ6%0AAI M|S%CIQ>>#(Q@Q'E7(RIS|&
|@RMI;_L\$X"OH6)G@9IGZ1)H>%R2^'L'FM MCD5+C<|5L@L%_UHV_WCS_\$95XN&1U?

^X^KULIC(1!GD>#C*E\1-6I33TOBC>IRV\SE.X9OR45^54.5WX^Z\^WUD)+PNE:S9.3'-
ME&J-6IS4Y:V^::GD^I(1:&Y^49I#T=K^L:F>2LS:O@D2Q@N2F@+\$(. \$FI-M69)D*8YEJ(Q
94&46L4\$3:+MV(<_010#28A1WXVE%_*C(I78I8UZG9ZS!6
MAYV)^(WNZ-;P6OT9VADP0YVNW1JY:P1:6I^X)I>T11P^*11M5U6JH"MB/M_+DA+I-
"YNZ*M5W+=WH4FMNFVQE>W>AT183QE068QDGLQGR"">JQ\3(8-MQB*,JMDF#)HX?Q/#W-
VIA\6J7N>:/:GMN+33?&E+K74)S:4+6J^~^Z=MD>Z/8(99IXEM')68E'J&762AP8^S>&0?Y?
KNMX\;JYK&^T*OE+UKBJE97MRV5=|E5I6*|,\$RYT"OVQ7S>;KYW+MQ=P#B),JYPS+(<\$|9R3'.1X2@7.0V9
M(D\$BIRIU\JRI6\O0-#^J68U(VHW((P5:KL!;MO>:N'-O_!;H79?Z'FP=2?MZ.I4I%H,--
W8@KYWQJHEVW""@7ML*)SWI+H>7J5^JSDGMIJOCQ@89%5&K M(UHKB?;U'D?+UI?IM'TWP\$@GF+Z=^\$6?
C'5.X&%;OA%KS?2PY.HZ0)#-&)S M\$S?B^=%N7OB;55-6JFFN%X<I#CHK_E+O7AOCi/3Y--NIVVRiKZIF=>U?H0
ME..:"MIJ*!%J3W IKZ-JFA\UYFI8(U: M=4^PK1-1@>UYI6Z&W\OJHZWQ=X:3\$;HY6?|UFW1!;A\+JM0?
+W5OEP*N>;L7+J7J= M.YT>D'I?2STK5N.N.FIGI9/O.FV+FO5T*_Z-7<+..?2J;=B>Z2KHAU53X
M&ZOE'54BH)QF6-"08I(SI1P*N(D22.6BB10C:CLUQ\E1N:J\060W,-->%8T M"&XISVXJ\$&\$4^..W=-
=ID\Q0&.\$H/ZC\9YRD)U;U)0&|PXHV=+FLIB\B+MON M->S;@XU5J"U&I/HWR@Z.F5>GNG@?^GO\MT&UB(?
UPO MI(=9+TN\?N_~V1@Q1MB="\$A\$19A@*M,\$DRA@VAN+%98BSD(5IP\$1J;4W9B5R MD)A+HP-JC!*F\$!;6C9-
WBP25&T\$E5V?IS:8 M.A%@;:"W;K^NSQY"Z=%&I&IIGY\$OWIO=:M\8M5*|9;^+1LQ7S2K6NVJ
M\4221*R0"5.1S+7#HKT62E.&A20BC,V>?V25ZFXC.;3\N>YPI&5#RV/T(FOW
M.'W9#1N@.Y\13NY(U:=L+0T9'M%33IT;8Q^..82MIG&JA5\$T3>Q6"X;R>;J
MZG(W=;4*H4B;I#A,LPB3G#;LIACP:A2D4B3"/: NEHGA8P?&1>AG52IOO? M4+FITV\8K\|F L;L2^4E;9ZM7H
M:ZO-6@3C?2QRQFK73BFIGNQYQE/;#@Y MU)~^I#*LC"MEY;Z\I^BBRL*CF^L=*_E_A9HS;JF">I+~JW(^5_S
MM_7W%D91D"18Y62R&P@<SSA.\$DHE1F1*24684?790T,BEUHM&A\GZG\! MQF404!;Y,M\&#&=M=R%FGHA
"3+RC_JP_F_80(WWM'EC+7;2C1PH&"W=<#WNS3P*2MU4US72L;+|R<M<2^?
KZ1L@PC9_.H*^=&V)M%72I^*ZOI;_DKUH^?V* MZV^F6""\$S6">993 MI20E""R(I.OT;Y--FKU0\5;0<2V&B)V?
U^WV4Z(C M\9HBIS\TV*?D&:3P5\U8>&.3X@OCKA;BFP)UJLW01CFTTPYMU4;_=!&0?H
M^*TS\$)QIAWF.%=%P&+08.07K<8.*=C3L8V#V6G9%MO8U\|;>%M-MT4Y5YR*Y?EZ;G2|^~^VXPI+A
ML\$<5;W83?MGRM6J_*=+;J2OVFY%U&E,R8BG%"\$X")C2_4BIP))X8E&<
MA8@J7P;KN6.3YI(81XK)IY;.S.AL6D50H371SE.K"L/M4/3PKGWC&A@TUJ\VB30;&)^~TP\$9)=#7D>
L../>87)SD;W\2+09;W>KJY3YK.QP59=N#)PNYIT M"J3)D^#G6JFW1G^=KD)I&%)2)8P+S 1+,\$FXPC10\28;T;^1;
<8YH-/Z:2%C M\I)HH6@G=8:~78.B2DX#8\%T'LR%<=L)2IT".4Z;# JD&6SZ*P?2I;I (9#F
MI+U3!M+T;O\BD*;_6I>T\I;\$"2_%.FQLOEO5=X_+)M/GH^DD5FE\$XW6LM%:~QI^@Q)6^Y#RH)A?D/
MHYGSICNE;O=A_G?IH2?8Q(W';)G;F>?T=WW@_G3NBWL_SMMKG\;8?N MK2I472MYRWZ;AJU;\$R
|OIW\WY_4I5I+IZH^KMJH**U+6#;YLT=21F5><)Q M'#\$SC,TE9CREN.C3F\4I82?CK'=U\CI4+L3C-
A:~P3S1%9NUVS\?&")>%&M=IMST&DTZ(-G\8;V6RNCN\VNVSJTO0@O?%AB'C:2\48E)=|Z&?5RJVO@
MTQSS\I)3L>XTR(59J<5)ENI%&@Q8Z8%,"=\$1 G+1&H?FWQ&R-C+2UT6-I#
M*6"LEFN#S04NXXM=HK^ZGD\?I2S'LX=>^T>0\VA_E/2I=MZWA4N=U>6C3--
;OKYZ*K#M%|+"05UD* \$RDO"ID0S*0TO3@+BFG.4JP91XJ\$ M1RPAH&J"%C(GVRDW*J_#="O1HNNF#_T-
\$3,OC0\0.6^4.Z(#/I;SMJ?7 MH9V%Q&F/Y.PA.#IP |SJV%SO.)+"I.@+GL0)B1DNH\AB0J3"N5D+94&FET@R M*6*
I>'S(D8F@4I@+I++J6?>2YV WR8M;#Q#~#04W@KOK"V^FM="YBVW=U9 M X\;W)V_TF4I5?WK7ZS20_CC@E5F
=60U@|>5D;?P)0&4Z#@F 2IP?25A@ M%B1%\$5.6DM ^T:E/TMC;J\O12(M%K5S'CF(21#;J)DX;I^ZC;FUNQ>XL=H&
MI8_LHWJ"OK";=1SD/C:1;6PKG\7M>|I\$^ZB6MAQN(MJEGE+#+=8?&!5Y\$J<8;I#I0;Q M2&*;)RHA<\$0%
M4UPDDH8AK*.DK>B1Z;+;H=R)1)T:3ILY#SM-GG&00G&FFX.720A-KJK6ND MM>").T5" 3GN#@E^
HQ(I"KOWND'+9^JOO2Y%U4R\I4=WQ,\$~#3 FL_RLP M"62.N4@SG,4J(\$DDPB"UVELZ)V\$L")96)-
K)1\$;H'1E;I@G%T@;JWXU/OJPI0\NU@W6FW95/-SK?V%Q.0%3*O7_X205FD>B M7/O\0G(<\$Q'K?
Y"\$BORN;3ULOR.7\(+X8RO6>FOJ=6I?"RKMA #:OI\ALJE M;^I%Q6.. "YB9T<8/A&I\$<5&LJE/L9;=L)GJ\7OCQIL#?
7\$"Q?%3+|8+*O%TM)AOXQ_~I#V"@IL/|O%\$S*WMKP'H? M/V,IM(7C+3YYD%L;N\G#IC>X3=Y_KE;-
BLUOZ@I54;M_KO2+~1%9ZR)^ M\4LBQ7F*DX1FF*1Q@3DO(KWHIF\$1%*D=KU+K;2-/~7LMO?*EOI;=3@S/SN
MS6+YX%@3LH#NQG<&S*PX>X%/%L;F6LRF7L;D\>5V2\G;IN;AJ69IP7\$F4F9VXD*IGURU MI?WD+3S?5\$8JW%
NW%PH(GUF&@U<XUM M-LEY/ZVU^8/_#%("X3QZQ%OTJZ&24XI(;%VL WJIKJ;CQO4ZG#
M0HD@U"*S,O1.FA05K?Y@;=N%~X?E/2OK M7IAH\I3Y43ZME\U%I5-
H\$W5%|DR\$<8@CHKCV3_3JC<6AYA45%F\$0I07AH;J4 M\;+&#B_PHE \$A3J*D MWH%R2^=
YML;8..WJ9=WW\2IX=V?U>*~9D\I78X-IT8 I(CD2_X2B*AG0&> M8+W6D%C&
<4SB);LLLH3\Y4R\IC=%PC<1N@TW_L>C.9-FIAUEH/4RMK^@:H M?L#>X_0_109F_LG&9)6YFT&H\W%3M4;I&!
ILH_ON?U8O&/#Q_7LP03A M+(-PE/&NM5L.&UJ&C#<.M?N6I#OP\$7RC;^?;
M:O6&-4KNGQ1=U;5^66T=Y3?NTO61Y)7B\|J(OBG:OS;;0OCO%_7)N+I MJOFJFF5=BJ79KEB(?
YB2S;HN%O4CTI"~^..?JW+9W.DE@'8@.H(SI?I#TBC\$
M5+;S@5A05XPF0EJ364_D&\$CL^>ZUO"J6L7;LVMZGN=*K1VJ\$BUX;JLJZP M7""N4-FU36(-
JK=Z\8HWFX;ANL;KY@I4U\$M/Y756MKY<_?^Z.SF"^(? MFX9:"7%KPN&A\9Z=Z;TSVK\N;2MJC9VAS\I/L#-
KXK^~0L;FVVMC;?;=M^M.WN&U_OVO\Z<&F(Y (+7\IP#Z.O%7I
M=|CK\|U(^D\G= U(5HRI7Y\$>|O9N9QZW8<|V)E4EXLHPN.W'KR&I4GD3T M5ND'F=@8T"ORG?
0S9*:O\O0P\|L^F^WY;O:5T7;#+*1SLU\F"P+K.68_M*OO,K,I\$D6,*Q\$D)A4C"&64_HHD2_M242+).@6.U^<:"!"
(_40C6WP(Y+L 39#Q/29*A;H8)B+...TE#H\HHE\I)BSNDXPYRR(UE0>(@64/XKI*O^!&L\~2GN)8P!G=XKG
M#PK@JN=-?HF'I M\P7LT/ITYG=IV*3?G&OSSYL|P+GM*|3CEZ#B~6RIGZDZD@5"!#*".PA"3 MA
8X3P3'C\9%AH/-PR8?|MD^E<(C/ZI=1\$ MV#B&6@=*XCUGAE;"I\#)DO>?6?&N+NV6M/L>IHW
M2P)%>9&HC)OLW_P3I2+CLZ4X%442""ID+ 95TNB1?+0.I."C&AD)+O50>U!
MS&XJH80#;PY0N"0.70I.&)M>I'DXQ3;R\>X9^>OJG9SI'/OPBP1 MH4HRG\$>)7GE%L<)4*H\$+5@2I)"1(2'+W7=5I
M22>VNP+/W#UZ#+3VXPP0EA;7 M;QVNFVBYUG*J>GS/&88G_P^E3Z4\9=RIE_NIUC@DV92\FBV9=V>W_2I5
MS4URRO6B63;M_BK?VWW=I>WF4<IT_IW@0)(\$RX#S/LQS*+;U*HE :!5=U2
M/^J//=WOX"~\#AP\30M87ZP'= @QP73(0M8\$5S(2&(IT>OAGP4)
MCF64C2;5*LGH1LA(U_7A01;%IVUZQ\$9>W2"YL=(_D"~8W\CB<;&0\$D MTBMJ4HJP.?HE
5C=XQ1(G\$;DF_-Z'IZQZKY>4X1FFL7UU;..W;B;3C&8QCE.2
M8R("B?;XXCAAD(E42R2V+X91+^LD0>WD8U;X4A+1UOQ.W1\0JSI<6K?UAI M1@\$VJOL<
LX\I4^"Y%7#CZV;~""+O(Z8;1+~QY44XLM4M;BY(NYCK M%LMO5W59W7_ISDB\I;93\$*DIS3MO\F)&5)R0
B=4<\$QD9LB""YRJ+%(D*M*4 M6C\$66(44ZMF+I#MB=5+L50_N0^J2I>U?#P6SB=GI+*~1%TUM+%^G^J4
M0)T6LW4Z@SM;^+|P\$;|G\L9<|J;<#AN.EZP_@ \$M+K'5QQ>*>+DK\QU5DI^MM5'=V89.JLSH?MJ8Z?YEC
MR8*R*I?J8_E=2;T TV^FY/5->;^N.W FL;B+D;8NDB8EB\#.19UCEM" A M-WT10\N\~
D)~I%!=SJ@'9*K%O2#^AH:P6HG;_A&R88&?E ""%X\6"RKU((-M-B*GK8D_&H.
+D7M>R;7Y7;A=_6A;L;UJMN0K>1 *WFO?29@KH?_4EF> M; >WNM;60B4R27#&J *%& 737I('6'>\$IR\$LPH.X)A;A?
R.&DJS&&_3+<#N7A\;#DK5I<\$%TF+B#G;CBG(^

M'NK2I/.001#0=-,OK%G<_G7ME"L319Z13/M2J29/DH:89D1@29-\$>U?1>ZN5N?U?*-0I?ZL7W4BKYYOG/
MC?'MM'-G-J+JWJ6L;.%!*I-(M3TJ?39BDF49!@2EF,@U33"Pl(XS2'^^AP%4:F M'Z'.*N:+WQIDWA0J-IH@ME7%,I%Q
QVSM'XX,(3>N'6NPVVB#^C'XR'M^J&R M^@:/ZK30)XT1@^..B2=WR&@;27T@=X!>.CX#GN1RZ!
f2G)X_.DV\$D\$64<1/- M/#1=1B*^1H-8DJ&15%1H41D?^C>^VMD!C*R?1RZ!^EX17Y0P%&)7T_.IVZ
MIR,.73WALCKKL:F=% Z-1_B DAW:UL.3QTM!ME6>+14GQCR7CY;REP3LE MXB".80SDE"l0N,.!9CPT-
7NC/%8%3T1>0'+,^X2!6 J>8;ZMCHDOZ/Y3JO; M^X"3:-GN&/G!+HAM#;?I'8D^@!CI?
&/,^% T^*>I5" WU&GROLWWN/VYA^ MQVI3%*#YHNI-Q9A2W*49EJH2"(>80)E0)S22EF5,D!2:.0Y!(RF\$1*&7D4
M&Z^H!H: #37W^T?.\$"MZF!>B+1.U7""QSFOJXFA,JQOL;DPUJ,l7P*B9 MTUC;#?7I" '&^\$;
<"8!PEJF!7LW3W6N1H6)<6,>EXIC7SY4#NOIAEY9#& MT6>14&GK!-INFBIIDLAE*G.L0DSQD*N)V_6_G18R!3M
B MT5:F#-V"FG^_H,TE4.WRTVJ^+)_FZNU*:>"R327Q5/-(3!66 MA CMX.<\$TYAPG\$9!0A-.XS#+P.%O!U&9IUM5-
5-<X6T;U";(C9J7<3F<:T1 MDBN%CX\$.669 R"U<:WP@8:RVQ;!5"-T<5)"&Z701JL9>KM&=&(A=ESL*
+E8!A^G6F^6P!BTS^@QFC!2LM"M M02?9TFI7G/F280>-F2!>I%SLJ3TH.GU?^;R!V8?5M BDY3AG"3"!&>)<9X4
M!=""1FM HS;@ (K;RJ7BECGRLO'A+MO(?<(OT-"1V&R;#84-Q3UQ;"2!>^6F
M!^XJHETOL;4U9K.FWFB3E//Q0XKG^NK(C"OI!YM5I>UTKI8W?\$RGA"@RS" M*DI-@H!>@2R(%1:\$93\$/HRJ C:?
C%CC!-6+NH\$HU8R!&#U/\$_62Q\$O9@-' MY6F+7=82YTT'+!>10."V(H"?)B_?I&P7I?^_W3>>T7+3APS"!I4_K9?
M50E5?C>.\$%VN8!WDG90R"CB5N(AY;GHEYIA'_.8L90"G.HS2T"!3J?%*R.33 M+43KG=P98FO)@%%X%B(+_0%A.
(Q^_IN_[MMY=Y=F/'XL-V=UPP@')=MZ MJ>?LS=,QSR7I#XCGXL4:_.H^67JFNy^_!:_=;-)_!
=M87535MJRGYIU578;Q!WU3!O12F'ECFL?I+YIH5-5MCR+OK'J M;:GN=I&IQ-0<*=
(JR@UQ=A4H5<_4F!6%PO\$*BF%6+!2_B1B8/(!*_@VZ% M@BNOG<+@\$CX&6PKCCV.CW;JKG;(65%1MH-
607\$NM1_L+)=1.W3EEY;0>S5!4 M3.NTFC&4ZA>EL^?UOA(7<->M26)JNEDLU_>8T+2WXJHOFE81)6!2.8,18
M@8E*4TS3E.(X3V26YF&+!_#BK3#Q(I/-@Q3*4UM@B#;+A5I5GLYB7TE30_M17I?E-42?>?JFI1F8" H#6I
X_QL(3QV9=Z(922!J0ZK5"GUEx/J!G:5)=C M5*D3"KJ"36""IXU#>0+F*\$#5!2G>JRA=2!J9?FO=JYYI
HLLZT^H!^7M!^I M^7?U:5\$M'S19B4(5"0EQFB;K#(68<8IP2S*4T6T1"JMEDY^U!G;50JBQ%M)
M)1MTI4ALLO@)-5;AFF&C#YMA^=)62H;WI&0#?5^8_2GY69/B,7!11D? MI9H3_#A_G2?
(4QU6<"R.MU1:B5+S:TR"6+%) (Z)-(W8!@33_M.(DP%)XCB+@L*Y+^P!V?5!PZL_Z(^Y.CIYT4ILOU:3P*AJ4;
(Y>F)!"MB7 M^=&L69#B&:6S"GX04>MU!)0YCJF(>)AF)*:Q-G2L^3BWJ)D#(SAUVM1HV MG7Q<5/?
X5M6/Z;_!YDZB/I?UE!V>G_"#1T_J4IXRZJ6#>K/Q08%ZP1/TXU!MUZ!HKT_7F^?>)>L.36W!<;
<&WRNX=Z/GP!KY@!54W;9N7YF2HB&7SH>KJGM^% MEMM\$%_0%&D\$K-"@8M"!#2/TY0(4_VJH10?
F39;87J*=V^".4+M..6 M' &UP'AKOV=O@T'S>OX.SK9WAY8.MML-^X7*FVMT6XBJH#:'E.HPEAD^M!W M-
GELYC#Q6_#5"V(JM:=M)3'QRSCJ1#&U?;=.B MSM+'4R.J+IC>I91VJ2EI MQ=YK6+^M>%/DM7!V:9L7T*
f@C_2_23 @<9M1TSXESS\$@28!8Q3C)><_M^ M7!-5&7FY;_.MH=#I=%&="K65FVR@+/@@+:S'P53W179-
HBBH!_R!F-/R)CL2W.D?H-14NK_9+O=#K MP+8\$EZF10D1"L6(TQ(03ACGCYHN.HCC.HTRP!%;NM4?8R.2U%O2L%
IRKRG(7 MT0HC2P;R9#F08UJH9O6IG_J^D^R10BSL!T42?.*FI0\$+HX!&NLT!L*VJP.Z0WJYT792\$6AV4AX.TQ+
'OIPG_?7G:A) MIS79P%#JHOQH#VJT3 M;:92R!1\$ S-X0S7_NURR(HQ3TORE7#YT1_4@_ZA
M6YJ7YE(L\$HE53ZJ^J!L7FY;^4-NIK_HV>7LW-80B9AG" E" E.OF6_6 M!QSGE 1Y3F@6"6YJCCM8G9%>6_
+9!LM!P6ISV3@H:H4P^M!4,l!4UM1H6.BGN9=L."#LE%G!)MY/F=ILIS W_?FO>:LZ+G;
M6MQELZ)B4;='T87ID_2L3)G00JIG^K^9!WY V=SLV)!S8-22V1B2_U_=H MVT^;M!W8;/%^H!70ORYO7^I?J9?IR-
f1FJNQ_*4%TGT+9_7U6:O^;M^?>= M63)29!>WEE_N9@*1_F?I"Y#"ITIM3W5;\$_H;UT.ENF5:2_3%15N_IG>
MHFSN6!8*HHC\$61S%F*1)BGD4_4R2* U4F+ DL>JF!;LLEOI0ORI#1H2P*W
M^T^+C5KK<0L:5MB;:>&JH0:0%K:RD>MP%GW_U"GP^:GC1K^EM8PLSTMLBV% M3KK..BR)\$Y8U^VV6I:M(>_
\$NC1WQW;)VUKM!X4_-\$B7U4;BVX*N31X2+KD1M3FF0 MRX)@B8<\$T8+G!>2F3CFQ*2(L)_K4_P8?
J,T"QOR#V1?)VGYI(-IV8W=" M#(&"J=BZ"/I/Q6#_8,AZ^F3P.UF;8OE!_HCEI>7JL&^5UJ77M+NN6!%E
M>10R\$N\$IM34.lQDM(\$9IGJ4R+0#&L\$C\$6_6BCI^VII#>7UJ?S'KKS MP^_E4#U_H7Z M?>=L=K=[_>*>M
):_I5_Q)Z_!l@5L#U#7>J*?IJ>S_5PR>'W M#J" C'Y JDV=W^|=U!/_OYE.\$240%5N8QUW2_?
M7^UU:""PE89Z3/\$K#Q+H ME@^_1F9=HR(JMSK.MO'WJ&L<=4;11;_KNWC0'NJ+'3EE K(27M!5/S:_R
M#F!W+_80_^4^IKRW!6QW15DFDM42;J)/KP_(%IEZM?@%K RT>N_!8WX MA*XW;L2+H.E"1WSBLHHHHBH5(
BP*IN>F M6.68!CS\$0LHT('H+"FI?Q^".D)&G&R.4!3.T+=K6"7.D!83_>S(4Q^PE+
M'0N2GC095)TJ.FO792T3_!+94E/WCMI8=(^!5^6)NV!UH%+?KX*@BAINYJO ME@_ZNAQSS-AGBH!
D)B!F+&PP%1&7_0J3V)F57_TK(216:03B3J9_0S MD!Q24 L^2HF3#V.+!+0A3M.F@H@CJ\$FN!&_N7N_5LDOF-
H0!>(+,X"==SQ069IK!T5) M4^0H+ *<"Y.A**5%DN1HD=/_FES<=!B9?OY.*!5!/_KJ^!_E49C!5!-5C%'
M%7WEC='2(0IDR*NPH+7Q_881WW!FUT8C9%1"K4YHK13:UPK=+E"GU_B0 NAS M?&C="8DB&%L/
R<7KYV?/1TC#L!l@/_ BHP;NLUX00;4+-GZM&"2U-FC_? M+OYKL&>5!O4-C
(%2==T5'0=>11NR?)"R7FJJP)N!A87XX1OEZW^\$YAAS! MTM:1-
+5)6%FUJ4'M\$N!L!DAWJJ_#D04L#H_^S7VA(%6!^S"PI EF.U6:6? MTN73_% T5R6>=[&("LEYDL6I7E00A8E()69%
(#"A+.%AE,<9C4#%9<+&GFF MZ"2C*!\$>>L5!;D:@!C_9SNV708=7="UUEH#?JU\$XQ&"9&T_-!7I=4>2=,6
M7KUL!E\$=5HM;7!K+!Q'O=+?I;7V-!^J95FKCD0>'U=5>TC212D6.HV9S&4 MY<)4BY;FL#W
\$0D"1J6B>9'MX.W\$SKRR-YI80JFUSWC1YMF>16\$4B!=\$LD M+3RY\$?!"#?I:(P&#<"VNK U%+>\$B-
(@WG_6#FVF!2 S?>O9C_9WH+9!U M85!ZF'6'>JHSH>^9(3QWQID7*>L1C30!#&D_1S2CA60,@+SH4L(BN7IT-(
M^\$>^9-B1!RE@+ C/@!DP@CMAJ>N1!RF3@4>^ TU_!2/?OTO'OF>NG?:(!> M!8^?/NN1!3?
F6JZ)C2.>17=5=X_^B;=I+!N8KJ2_42Y%ZU?8(8-=!L(T M*.BHL4(3S")A<(!"3!/9!@0JH(H"\$%E.P=K-#)+?56-
JKIWL8WSM@Q=#;P MY0_H(D4YRS';>52KW.+%;4YC@D62JUDQO1E=I5;?L>^2.A3SOT!S5SQE_
MHP&7BAD.O2C"_%<8LD3#3T)_2QC&2!(DHVH:H1ZXIEKXMR6KES!2_N/
M_Z5V0U_!#"%U7U:FA:O9_WOJK_0_!AT)FH;*!E56%-2BO.PSW""R)S%619Q M&JW?
R!OJAQH4!VJEH!OP=Z(J^7IOPVZ!5)89!Z328K78MW)U^R"AH.EFN M541K';>1P;FP+CA-5!6"U"?
UTYU>8/(K_%!<_V;WSJMM!G0?C'47S;N"
M)043!_!\$#DFLJ'8FD0\$2&%7BS&61&"BLG9B1W9+>N28=OH&LS;+'NQ7! M=4H87VUQ7YET(V!;L!VT=GS6'S
8J5VH1="UX!4:>\$PI!EGL*_!_83NBTR<<@ M(CXRDf%W#R@KMT0\$;V!>K-Y'A5QG(L_V;W;3_4!%-
H01Q"0R593!E>1> M2AF9(HJ;:"M'T:~M6,LJEWZ!G^8+^A(QUNL5LAN;6^:S!>B1C^G)OY!P!
M6>"M!6.Y!W;^C^VE^&5=C+4^K.3:9C%W&SY2E;('&=Z^!1PJ%4K."AB(4 MU!#JM)BQ3!E_&\$#J6XC!PQ&=D-
SN.6PL>E@/OPN!Z3=;^C1 M:7_U6X#L_VJ*205-%>F2'A3MLE_OY?_8V*0"19;KWQIB\$C.\$R7<9%\$LM
L92!G.WS!@9>8ANI*(IL>A7(Q@X1L_!9#=(1@/Z4N=H.'Z06K/(W3LD8U:X4A+1UOQ.W0-R8.l@%?_N/6_FSL
MG@-V^!TW-H!34U1L@KW0X:F5&_QEL_R.F/(JULN7P1_N%AA*2'OWGZ7_MLKFH2JB?E=7!T7>5.J!^>
R>>JW6C;2E^_WOS52B!E8R@_5!7)N!@#_N+W M6OZM7G^&-%SE2=3(+/_V_%Y\$5N.OZ_U;0J4%26"E-
5Y=UL!*VE6^# MJL6RN_"WLFW24YCV+5TX^X^X'9GL-W!7WOOP!#_IEAM!PB^7E_>H"X(Q
M!-00QV.U0!_8GO#1&B7^>+_X_A!TMH!\$W+GE?F2/PE%>@9K0Z.^!^OD#099
M^%_IKC_9Y;+ZM)G.62JE"\$..BRON,\$EB@ED4"9PDD5ZWY7!*)""RDD98WM_M6B;:"IVA3S"?
IR0J5K!>4%N!M/Z1F6ZNW4E!02!>4+M?V97K4_""W?RUBE= MMSI=7!ALO9.F22QU?
IQ&YO/_^Z^7!2GD=A:AIO!""3*\$HPHT&!19S' MO!!RE(-X)\$2.SAQ&)-C)GZ/OH+!44Y#8<=00V'4<62C6PSNR?

M,(Y=&&D18""&.HS8YYWO:0%8@?>;T\$LC)&Z?CCSZI#^BCIT(1OCT63^/M7C^PZL&4@Z@^?
=ZL63*JC4@5CH,XQX2,SC1,4BRR-&%%(\$ELE_7<*V5D%NG\$
MHU<[=,%_!@RNL^18D(D/DV&T(CEBA=1"CKJMA4|JA;TIHOF6A^G|G.7T>NGJ#SQ@:'66H.N9?-&
MAZZE^D+D=I906WVWP7OLMC7Z))G#<.:9+GKV|V(OZKR|NUZ.GA?H+SO;^M>_V.YDX(28-(H-HU"5),HJ#E(%\$
M*JB_/_K0Z>@Y7I-W=\$._Y(W,M#Y6H3<66MZK|_Q^J=1VA9B|H9+M<=RV8_FZ-EDA:0WB6&%*%<-\$B4Q/
MZC3>G80TI"+6*@EEHZ0|NK#WM(4NE&)_13N=:R#^9\$DJT5W\$OQ;=L<=5W'
MV;H/6Z4LRXGZ>"IV3L+86#N1R\$8H|-&K1;DC69|&78MR-UQ|E;|2V7YP,Z\$M|XP|^1=#-)G4Y?V4LOQ.U=O%
(RNKNRA2&9-"8*G,X0U/MM?"2(P3F25\$R#@0"A12?T|0Z*N6%_4OC63T.R<;&+1|BLL.O*!-!A<3,>
MWF#W@F6^N>>\$S.M2|P+QAIUNKUTO=MY;Q1H|7;4MW08B^SE(=*CTV|C-AR.M\$V.?
XUP/5"P(B5/!"0>:%_YP2,?Y:Q2U0;JM4&B\$|DE,+8|UL*^Y3'1CJ>
MN)ZP%G;B.L0QJM.U.%@O!A!G#;MT&OBSDD/8|K_O(PMN=*T))DO1+5+>@M*B|S*!!),6\$Q@+SHB
XBJ@425XD20%(!^B5.3.%_D^T@Z|)B5|H.FG.M|P.W(NI%L1(OA|YY6O&S.N\$%O(Z9D)|M;7E"3U2TN.2/F7"?
YS)J'MO;_M|>9T+Z9))K(O@QEG"-#G%\$=,K%:EPPI.(Q7\$4.FE/3F>\$C|TVTDI%6|S\$=LYM|SV'C4->;7QC^G3'4*
(#EC.R2&9+CMCF\$DD<-#"3IMZD_EN3.O1.&D_1K.M?QA1&6"5#ZI)2OK4GW19ADJH\$R
M6M1.2ELL|6\$OUTH|B*9")\$0@GEJ.AJK*,0TDSG.\$|+3J,B"/+1J.FHK<&1V.M:2-W3-<^/2::+B++G)V63;-
JZY.N"E0M3*2H98P->HY?H-"LF7P36CGM|MP@6CG(WD#I3/AZ|N.@*F\$%L+25\$!?'
%/3/HN=,L3E=BT1LV;8/(6@|8'1|=F\$W4UH1O++KG3O^ZB2C.(9A0G.C"O.TNT.M+QIR'&0))T%.K^T^\$SE
MGSTK\$|&TNO&U-FFWI>|:L0T&7VAZT-FB&MB;I?|9&^7=)WV/GM8.T^D|MZ6)B|M?Q>L^6>*QZ|RT#P0Z=;
(KK>|H=Z(6_VY|JSJNF@;|OVOTZU17O&G3O.^R).8DX^G.8U/CG.8.%MT_3_|>|>MO&L?#|_J^ON\$ "61\$K4/
|HTRFYO;H4.#S\$|/"F1EO?F1G.MO/OEY|LOXXEFJ0N7NQ++P&HWO^T4?RD#S:8O2&L&K&)|F8;NH\$-5/M;OD
M?)MD|_IGD2-D_2DALL4E+2G.)8B*|_5/5O)K13?MX_RN.M3W"W.B&|>(QX<.8F1ZLI\$;+XM"-
_G.&!B05X^P+|N8!\$Y|7JB|_YK7I>,MEPMS@L=JLR0|*8E\$AFBX|56|WH|<-;+5_|@*\$|9@|3?
0=!,BEOT,Q<)7HSA@?-&\$XQL('GO/&LXQ>PH'&R.M=>"167&GY/U"?2@Z;KBN7OZHI|_%.@TDJH|
(<9RQ3\$"4X@0YS_0NJ%/\$H)MX|@IC|0(R96J*U)YA#CI3.BE.M|PF=S)*7-_.UYCC*\$U6|Q@*D=Z"=V^|HK
M*LR|NC|G"P|J-3>5O<\$DV:B^&L\$W|A|LO|>&^DX|X0UY5E|J*)K0CXX5.M^I=0|D;#))5)G|("HUA@B+-
0*8DA3Q)9*8BRDCF|HOHA)A8@0PDV&|ZU-J.M^I|_9+^124?6L#*#B\$7ZU|8L(-R<=
1MDWG+0S89=-18<#>AF|ES8Q_K_40EY5|0U;J|25^B.KUQ^5^7J5|5BBS=U.M=?KEN>JX)&*(2D*
K&0N5F^8%A03A*<\$L&5|(E|H)9;U.MQ|T|U4#B_MJH#R*Y.=(N@3._/VE|#+@Q@*HO0)O&J^8'2ECA@FE;
T|C27C|4@|J8|4.M\$W%G34.XNF*Y\$W^YA&T/YO|O5JOSY4ZFKZVT"2\$)Y*F4&8Q8)B(E>LO!4
M95#%."E2DB*5\$Y|H6.(R3>\$|H.M_S|5H^E95"-(_S2_3U^9;|;MMME!_.MA4@34<"10.G\$;92:79S"Y'.4BE.%
(^&^7.G&F#|SJC|'#00'O//+D_-I%:<@_MZ5"NGE'2(YIA8=).OEYQ|T&|SQPHM9E_(E+;V77.4*G-|B>Q4FO3_/WXLJR5
M8+_,5IYHYK+^%%.T|M362|N)""I3|-(BTB.\$0*.HU)>_:"!\$A552.(F|
MFEA)H^!AH8;|=@S>Y.V2U6+|Z9=+9M^EL'/_8G'2A@^*.Y|!_V>GWB<\$=MB;R'_(SDA#-"G2>(Y+3*F*W_-?
%KEP.)L\$%:_ZF6;7:|JZ|O*|K_-X_MJ5|5;8L|FT|JZM;EHH48R1A1+E6K2B)|&>(P2+BF=QE.9R|2AZ|4
NJ>VQH&S%CUWH|5=-FH_M|*|_456W|B@K>22)7E(D|_*6Q+%)|L<00.Q|C5.*SYDXUR*TH\$W^FS>UP
MU=X.O|O&|PONZ\$WX?0>YA3<'T_|/NPS);4YQ|H?TNC7XOO@E%&T@)SDD?(M:6|/"@C'U)D0#"K:H%#^%
_Y^U=+=;7&('|EZ;BL<|PP*G03|@D>#"8>-G'W.M>=&>|00K(WL|H;OKC/\$\$J^V|01|TP|1>?
N^>6*MU*Q|D|OMPF4)|4(EA.MD;((XDS/SIG" B(44<8BFNDQWUE5>D.FE|46%>Q@+|;GVQ?:29YQ\$)81^/HH
M2Q?5\$&GIX^RA+2-P#Q.7K|2MIRXG.%GEL_Q?|IRPOH#@3G5-BBM3T+Q1_VJ.MJMT'4STCU)LD0H0!"(U.A.-+?
Q'G6."(\$>_CW/GUA7#|YH+T3^AQY.MPF66.HB?GXX<4@M+Y7|\$T2N1SQ"N9T|CTV?
ZB20^1|WF3_'39_3|'#Z|S<%N.MB)#XYDXMV5)6|.IQDHA@:(D@K%"&*9%CI')
(_"T#R5+\$|A@&GA=D).RWX61H=3/26?90^I2R.=26>|F*S
M_NG%\$6O;T#FE.EV78JWDS;H2/|XLR_7JTV752|2K&8.%P@6EBX9|C2@C9YZ*+1HPT*#|QBUMWG*7X|D
|X9A=|SQ#KYZ?M%I^F*8#S=%BFS.LF6.<#K2/8YTNG0)OO:IK5GZ_6U^72_7)E(F0_|E?K9O.M\$+
<)5@E&E).8YN90=JP7\$FE*H%1%)\$5>H(CZ77|OQYK|XUZN_7N\$|S;_O&1
MVT<|S.G_3WH+|@P|:%SPPL\$%_M2.3Y;ZW.Y|6G>2^2G*1_=%7?H\$|JN4|2*MK=0KU?
H=MG(Q*9"95ORY5.U6%Q5M.D|<|ND7@|8>FZ'P.QWB.M\$X82M_/XX8AD0>JEZA|V&4@Z+;B_7+|@A(V-
_0+1V7&^|(-|H/8@|6A.MGW0H(6|?/RAQ;S(47K^U^E|5?|HX*%'6)5V&E"+>@_W3Z6?K9V71B%|MJ|N",.\$?
QK\$8;_DVPLOPYUWAW8+N3CD-|_Q^F^GL\$ME/_Z88|_+^NJI^ME!;|SY?;K4WSG.9*YQ.B|OY<#*TG%^@
DC%<@15;_4KX/B.(K\$%4|A(8-M3(^|J.L9#F/N0|G18.K"\$7.MYVL208;@>R#1MM?5G|C;D62M8AMZO??".N
MQ>|H=#?6.FAV3%-2MEHV06&+@W_9_P^L&4F54OU5(5Y;K)8?B8N5&A6)%"
MS^(1QN;D.LX@YYS"|AP)EF5LMUN;PW!_4WE0RJH6_H<M8|?DC.EV@QV67_&S?|!@GD_N.*M?|7HIM?
Z+X&RE?Q.MOU!+P04M"!A\$1.LP|+>RDO@|Z)AH%0"E86LM.C.R-#R.S%?<)>E+GAM;R|
M67=;_9(N^MZ_(F>UXM*\$S.O|CY+EN4L|7%;K;SZO|HX<(0L|T2(MTDY;3K.MUY_1@9*HB2*Q.;&JKO2@RP1,7P(1
Q_Q_<X^>D;S!|CV?3??V9_H3_M|_X2^/YVW_?>XCI^7_|Q|_|R|_|X3|UA8OSF&Z_.EX#GX)MZ;
<Q|LO/RV_P\$|_G|W_&S/IV?&6>S<|)^8_NQXG7W_.OY^+^_BE*NK.M;
|OZU_F_|@1I,Q).3\$3*64B3CL@UDK%F7+&OY_?|7?F0"E1GB8B0V+^M414(=T'XJ^C%;^L^=#*>_O&OY9?@%
3LC==="HY^+)=?_677|H|^M2_SR5|F|H|^<\$K%+U?2?|EMW^_|J_U.BNZ|F7/NE^Y?K|H;=|TC?BOD?_
M=O;C_+\$G'LRGBZ6?AK+HOQORZZ+|Z=1;L|XD73|_|!WE;^3|VTCY\$F<M"/7|XOT|W_|RT|_K<0QGTW@^2?
RN^?SB|M>07|)/EEZ_@_A+G)W_4K|E.ME^_90@%)|7YX^>;K_/O/B_'YUPEW+/'*_UQ^"!EDO'5DO_OZ@=_N5GY
MZQP6")>.T|?XA@%4MTI8@Q.M+Y|GWW|!#_ZE""+H9-(XU|RTDLOO=5SOO\$W|OR.0@M9&>2"HED8_6)"9_M"
JDI=(NIR+|75;E.IKM&C>?QI-D|P1-QM9R?QWQ:O0W.R^XY.N?XP>1
M^&4|25<_G>>S|QJZ6LXJ2&ZE%B3WYY^0ZPSS..2W*ZT|R%SV1C_(*G3?64/C.M1|IA9|@*^S^7*4I-911T|JR%|H(G5
(2>>MQQ3B;|JZ|Y|56W0@|O'P\$|_M2|(1+R'^7B63J|_I-9Z|C%|^ID.LB^R"SP2\$S%*U9LD-)P&U05*-Q;=BL|
MB|Q+LL|P|<6|2.K>_|Y|+SZ|XT\$G;9Y(BYL)"Y4H66M(E,YF|=H\$MZO<|ROY8>2M(R'8A446BC9B(3W_78R+
|"-%BG0>N.CK/#R_00)|@L2L.MT|&B7&ZK@*U>|"A6|7514D>C|_#B9+L?+^V_&\$WAW<1Y@/N**77"\$LD-
M)DE2T**O)Q|PDF;-0B^%QKNKK@5"G2|*A+@DUH_P+|ASC#H1|DHJ3VC<(^9|J6Z'_M(Z"/239!!).FW\$V1Q/6"?XC
MRA^_9Q?3Y?S'12QA9.0|RPY.M2B;(*SO%(6B0>J+/4Q&1J_-1(K;"B6T=M)_7DW_1L/OGOIPG%_|
|CU975I244&B0'3XF4J\$YGC)%8&3C*+&06@_8IQ0J.M>6#YK;#B6H=##=DV_9*CE%_%B|O?WHZGP\$;
<>@/>190*H(\$4UI\$RA&*?I*1M^">1HPM0^UQZNRLKVCHZ|A5JHAC@XJA5.SBZX^M!2AW+W(2\$*F*6QP<8;
M;NB&L=#1L.WF76\$VA(RCO&/9_-/LS^GHZ<=W@^HA2,1N?;<1>".(SUT.H.M;"#4<\$|O+;P=*AJ^X.PAT)8PT7E-
9_/W|FW|33""(K\$R(2)"PE,FF&41=%MX8#_4H'FDH2P+BS^G;H;C.LYH6X+(^|EBZ2?_AKYU4+R_XJ_)92I<7
MN|1C|^OYCOFA+G6-Z&73VMO!H^|STIB?2|>O/P|_|B6X;L6+(DYH2B0.);MUSEF9R6B6EJ^Y6%|M.P.T?
_6YL^@&5GG)H9B|_S*;7EW.;8=NCR|W_K|_MDB6"8345AB|H|!)B*CV|Q_NKKB=ZAN^W|Q+A
_K_R/\$BSE"E_P;R6V4WS#_Y6|'"Z^137_R.M/7|QT_|07<4G2QU+7!!A?"1244<"AKS\$."TET*
D=54V_OHVV&@X2O(O479.M1#CP=YA_N<4@|VX|XCI73Q>*B7*2+%\$""4^N|H(B\$(A7G@;3LP0DO/54U
MH@>6'Z|E*GE.R|K"^(<)E/QM-KE|Y:0BG@.ZOMKX\$|S'Q|_23ML-'64&T34#D=(J2AN(8?X/7?NDOV|J%
M(#AS21(7.1H^BX%Q2)P32U7F-F>>V'Z>QF.K;P>1YB|B*XBV"8ATUN_8+^S.M;YC9*B5EMM\$HH=);&

(fN(d@89HUPT/-Y+Z" M; (-)^S\Z|^F.DP"B5H!QZCBG;"D)^F2E)+IO@E3-R MSXN)1Q;?#A<-7T 6\$NS ^#B->7YTD<;X'42+))2Q6.G@S!9!TJNLN(B\$.EJN M7A(E-C)&#/?16AF\!XNYB1/G MXQ>83*!L(3,VT)P489("D0I#|<"H1J.89(XN.JZK.YK:VX'BH:00/<48Q.@ M>^1)N/X9C+SRQ%2%.B&>T0!3X!)S:UXRS6?QCX!/?4&R+LXMEZ3A07GA&C\$<5.##B8Q9X\$J)E.#H02F\$3!|^4K_.8_1CXX MJ76!OBZY;"M0LJ1!@&7.1V&5-75&C!D93L(-7P!VH_OVS_R:<3TZG"-! M3!# 3\$!08L\$.64Q.).4MP(&H R#9HG/A^/0HV+KL=0H_!U'F.CX0CQ MG3H7NSC3+&3A9#E M4\$Q0.@D!.)H5HE'WFT>|Z'WEIN.^TW?!.ZN_.4UN_MRN??X%<6(W23:\$)K170OJ5PC#C&+!L&9/<^HU(OLL=IVL,M65EJ='>%;!@X M3Z/UK@06U!)K2\$N44E\$YC99!96^6V9!7RR/KK#7D;^Z?>TROQYRA-##!L\$,8 M8!AL!+&>9Z(I)*T.TR'MY_+M+39.3DZBKU!N!HPZ&!O179+;S!L.T8BPG M&74FWB<.6D-%=%=>)DQ;Y:6S7L!^MPRWEANF(5FOZM!CFT X.UE(N1\$L:S MD\$IOH4_ Q% A+0GERR2\$*YD%3)* &!*X6"*836:|@V\$F6!9!HOV?O/IZ!|7U! M!GD!NCMT?OCD!_ O7DY-/78IVAS^L5K_1!C=|!"_6)#/WG!|=668Q9TF MRV_4S<8_3!9JMA&4!>P\$!1RRX4!&E\$N\$S!J\$!)1<6TNSM9Y9K=AC96S9+T*G M!M%5_1!)LO%U5=N-MASZ-K5:ERM<_18P!QPR5NDZR=(>8E)9*K'13PL"&M>8Y0CX:JQR+%;B!3<\$PWD!02+@R+!7\$/>_1>C.;KZX^GYUSF& !HW5_<@Z+;)W B/K6(HCA2 M(=\$92F/XD4&'!CU" G'B(Z@4H^U<|T%:YOH&"_4.B2LH9^ PAZZZ<)-T/Y M|=9&0+\$D65*8T(LN\4AR:VU(=J@.T R\$^=B>S"X@>(&68;.V0.*JA@P:@ M!BHC*!_+^8E*?KUX \$HJO:A.N2>J^8Y0#%*E"Ps#8&.).>=9H\$IGGI6 MV_ =Z@.QA^E0?&H)IZ^|Y!^0K>\$!A.FDJ!B M-BY*#>JQ7E\$!H +#M.)N!7C/U?T"\$!3/EVQDZ\$<+GQ+BB)HR8H+3 MA&XH#03ES+E/3JM4^V*C#N7#.GT5(!8!%+DS? +!-/RJA!2+T^E1SN.)6GM8 M?+P(BW\$:_D8%BCF6>R^BD!+?|!&T^7?|_LO4!0C&+ESF420KEL@@2X6R\$3 MW*H:18!QE'NLC=)^8>X.!_K6U:.\$Z^4UH"CB?NOM.5>W&S_<_G!UKSO_G)!8P<+*RIJ3-RHAL@2!"EMHO:IBZ*#%J8VB?N M5H0-ZP%61!-131@B3Z@T9V!(P8HFID;"5_VLIR)B!G?RG0QC(%*+;=-12 MHHFM'E(3M.P@U5Z>52H*/P&P(3^D)!^J.=70D)K>VUR_GK;).^!\$F(X!K M<|4!T<)>BK.5+CP.1#&\$^&#)\$)#Y>E+;A_4T7G%D;JLA: M>+DKS!) M&)Q!Q.WQ;K9|!^? +L_QZO/@Z6_C)K_/9Q=18)1)IGF!L8P)*(>18P:YU\$HG MH55TO)_G!|=)&V:|2Q!^50^J: !A9U^A*#V9?GX+?@\$? RM3FL_S!8K6'1K!T M@O;>\$N!@<+N(2%SY:PPY99U98E !*GR4H&\$FP/2_IGIB:P%#RR!P7PEGE!A MWO) @D\$!N4M&HRNU"XPJ+D(7.C:SP)KRP!T!*@.PHTP;@<\$EU@#)8U2M2 MN"4R632\$ 4_>Z!E/D4A'VU@L?N9--"E! !.G&=)!LH&|!+=C!_:3!7+CJ=PEE>W^".@H/"\$%204G1%0RQWH(CSLF4^46Z4JGT4K!_ M:)/6QJ^/Z.=Q=T"5!9NGCO?Y3;T4^S5W!ZQP@2319T@277D#22^(A)&(R M2!8B!>/E2_O!)A!5 QK>0X#F U\$WPIX2AN2B/UDE81EB.JK-\$).(&29=ZR 8J!(_15 M52RNB>H#=\$F GV;W;S&A5#*&K; RY\$*Q6H7.8!***+Y+PU(5Z."S>:QLN9 2)@(%EZ MXL14IM4E)8BC:(P@P*NG MD :0M2:QD5.IM/PP2!J4Z&)R0:P0@1BP/C*E09CJ!5LWRP_!@G:@:AO=I-W MVTK!1SM>90N7M"G< ^@P(P#065BSZBYXS1SA+BDCE\$HHH970!_)1@:>ROA%Z MD)R!7^\$.9(J!*"!_"0!\$L!YERJ.9W2QK;/A!_187Y9*K*1VE2)Y=%X_ 5'P MI3.Z<"2!_T!2#B3H2#SDEH;2(+*OGAZR"YW:0?%EWZGWKK!&+K6C'N5IQW\$-> M^W\$ZG!HKV!DDE7UN"2RAXO"U>)T>0*!_)XR^!@65J^G\&^52HYD44HC-\$=Q MB:Q+;E;)W6\$!LMK_#/(VPY!+_LNOR!M-5\$7Q!9ME/PH M*? L&:CA^&TIG!ZN)P!BXG\$Y05SQ.8.\$9GHA/PJTM"<C8CDIS=!%F0CI7&TH M/4'2=KAZV=?!_:72@FZS!|*TI^GXZ7? UW);X0: XY2?1\$NYFC):61"OP3 M3=P#>!!W^!|W@+5-E&T'N9=|P=^#CAI\$'M(?..=6\$^Y%&4#)43I<.&*M!@'% MOIR!8+>I6&|E-.7?>>_E!P!_:OBP4=Q55QZ_090-/5*^*D341|Y!\$5=YD>W?=\$J%|.XR^!>\$ 73<+*?\$NU(6&6B M!)0\$&G"G9N D2!;).T8H!U_ \$3Z_ !|&-&V'QI?|HE!5+!5P=KB!!>|57R! MY3CZR6T^!HQ>MH/KU!5:408!RW7WPV(-Z&@#=#VK.RGE%G!TZ.J7MA?@_ S:MSV2.!HJ+1 M!_? 2A=_.9!&5!3%UKL4BSEBK6!OVV(&O8@KO>X59;.6UA:37'_>AB^64V'_!# MTL@!^/GB:2N+Z+0@#(&0*8&L!*)!5F!/?1H?T@X*!%9Q?+Q=)/MBU!YPE ZF0"49&VA=/G TYTZW!"*>*L>-_3S7=KD>HV?8RZW#(V!75;R_8T? M/^&OOYV!^_3Q!W9^Y/!Y!_!5_WO>MXX%|N.38AOY*=QRKM(QK_%ZC+4IO M5+22%*>_2!82<2J4SFW>(UQ\$JZVL7+^4"XXPJ_X!<_0K M3#BFY3-D.!TU)_BZKY!E?6E4H%QM BEFR0>)&CUH!IEG!8?4N=JO6T^0 M-&S!U N<_BJA 4R!NEB;H!8'_!_&G6KB?U^_5!^E TV.T&J(K9:=PC MGEED+U)!&D*QC%:_\$)PFZMGCFLW;#Q6"!ZTDU0S?2/3W_ZL?SJS9/FS-! M/Z#ZYM!OIX2!"@:US!"FDB02 GJ/W@8BLE*<_9_W&G)!4!G MW9U)&/:!OBK*#JB+9CRP=>&-!;5?V.!2 M,&Q_W=Z!K9W%W."ETK09=9UK!ZZ/KGDY:J#3U&+3PGUI6!8) HG>@U 1,P ME#7&!56!3=N31 WKMO=QS517#PTX6K_Z!711!"DLSJ:E8_GB+!LJ!_?G*R M*!(;<_<64U1B%! QC+;UF=A@RE4NMRSF%*K_0*R+6W#WE!5A!1=O!X/_32 MNZXGSH.B&W%(("G",? !4JK2:TOA!8:TE83MPF&IDSO#+;J=HV)NL?C%641<- MG!L!HCQZ 0";.SD.&2728C)DP@!>IDA(&N'.B*!/1K!Q5.=#33@==VTZ;K* ME!E/+Y"IRO2'V73Q"O)!L? !FK!=\$/Q.^1.NRU7!PW\$ _F^W!_!_%3Q_M%7R;_9&93E'C:9)!P!@>3.0S2E-B.0>==3)4N%Y-YC!&KK?KN/Z-70U!_H M/FW!=^K.XW_*F05.&"ON=|_M!7PEA=?C15P) M*_*|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|MI5GG>Y#;EBO7'TC!TV\$#<^U C*.D;.G3E4DN&ZX;_M_QYHO!;G:B&#=#I3YOJH1+DEIRZ6K";.LF_K? L!C#!_*3+YAGOC!R!_!P MAOWFBO?N"4I03:;!\$T5C29AAAEC/T(LUB4NG(\$#U>/6Y_X!HKH/QZ!7-35@ MR;E:Q4Z.88!#" 3K5"(4DE*G\$V9H'RETAEMM;K!|OLL H?U/O%RHI_?+|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

GHH"U".V:IJA#38CM"TR@=MD4^VAB5L1MJI MO%ID4I'S(_W7PI213>\$LF=
(4%33G1RV2AJ:4ZU\T)O4I#.^T.E+-PUD9:RUW5#DA#P-##"I"@=HYZ<.C M!#6"HIT 1!HJA9I QBZPV/KV:D?
3TPFT '4 H)BO#B_Z(9Z M7;>W677*//D>8;,\$XRI?>=1BX93\$&8Y02W" &22,TXL5H(DD_3'!.!2V\A\F MU*)-
+2MY2<1S5QQ\$IXGCZ"6ZI+QAV5KH\$W6;\$S?L M368?.\$NHC 90MOF" Y*7H'62(0I"4XQ7=2C)O@EE:Q*^.?T=ECI
Q<=%G= MJZXF^P9P=IW"OAU/X13_N!@Y*F*61"=42I2*TL<,YEH8 HCVABJCV_3X5 MC3Q75IP_VDW
3>00WTTI.9W>OVHJ@+OAS6S^IY^GD4274IMD*I"RN923" \N M"0M G189-UEM!#V3Q\$;NC7:\$Q/W2H
I4TX*)ZFJ63A>+"T#:&08BN V)<6% MJD)#ZY-4)/(@DZ&4FU"IG)I_6%QTZNBHJM7:6^,V*^=BENN#?FRTI'VUW9
MD)3^HU*)!.0I&GIX"\$2L5Q:8BE@.\$Q!A^H9:G4H_8(2A6#Z_I9E!^JW'J MDVPCE0#GY\VR(IRS:R_@5#E2F>W+
(D/&9:Y9SVF1GF>NTIOC<@P_P/I CJ M\H1\$UH5GG+N)TC2(R_3\$+92I5\$Z53(\$85444<HFFU>)42SCOL'NP5!;
M74LM>*1%6BO7Z/7%O&RZE5'07*.CB/;=+?IBQ*%C7J9H:"C;H\$0:5_+R@R(I
MTH@BAIQ_5AZ2^(&GRAX6/^@NKI!>+?_0";O\$%I%@A14E^?V4(I^+*\$VE(MDM&IY"E7OG:7MFUI&WSTX-
PW\$H!I)PM;Q>P9_ =RU&^\$EO#?;D*510/FAP;#C6T#P3I?%CV^T^>UEY M'R(Q_&I_@23#:(*2),,=Z)V&Z-
G\$3CIX&A@5E!<.W8RP_P16(>OZ<M-VRI\$5=,IX-IF*?>=390K61A4DB@M9IY0+WCM.YNGJH^-.%A15=14UTIWB,
MIVYCC90"3S7U!+0H73? \$2LU(XXY&A@8"KY^+=431_T_AI)T#U?04U@IJ:K
MR^+3H(\$,VVX_A<)PN2.%Z:+3I@=8W0;_1YA_&T=8B>\$#Q-GG:24J_A21#@3Q&H"
(Q#75/BH:G2)YD3^,1#P;+O=70A.WI:3R=MS;M\$@-7SYI7D+H=CW.2=/Y0+>5;\$?I_XW:)
)0FG')5+J_A\$B.M4Z\$Z(*N MW@ZE%NW#3X(Z&&@'47?S0A"QXNP&*>QG_ ^XS-!+?"I_)(6(P>
M:10D>*SNU&Z'U7^*MZ(#J:0I_!3E!+=+93_M6!27*(RGG;Y'/B=+Y15<.0RX "I@)E:YFG_#*(IOHP4Z\$;@?9?
XHIOX5.M.2I:2W>FI9CQ+&8=^ZGU^TG/LT^X0\$RFU_OQU%@1M,R/<1SB9RYZ# =)Q0 MP01N0^
DNG.1>KIAU?2W0YP+ HJ)6==M-ZIU850+2EIRQW*F#OK%0@81L M@1B75'9:@V'5WRZ?
6WO!_SE>@'85^YYIZ2?3BK?M^R?DBI"MU9R179ECTN!_T4+I+FZ*IWXYWDL,IRJ&P'Y?2G?L?GK(D83G44"
(!SZ22L M,PHJ.Z*TR\D#8#6SCYZ#GV-E-N^I:D>L)B&HA5IGIRI.?S^V5TW/GL8KK< M9>>AJ&6(5NE\$A
XE4*.0=6 T"11I&82@R'644>|=10%K)*L/GKN(5LJH\#"1W4I70?3"M M!?:G2&NMZ+()@%?5YTL"17YTM7.+DXL"Y:
IY:E(#0>(PIEHE5U!_JM,^, M"B.XKX?G+&EJK79S,"CWH<47X8P\I:KA.--1,\$OPJ%\$4A^(+RVI!#IG>5*<M_!L'VQIO4
=IXI,KC6UUAAG_<<(FV0EN:XCW-1*_,46?7B2I9"DEP\$<-V M3U/I4-%X>,1.
MR9;HTBU""j%)8!Q_22H#PC@HT=M\$GSZG7JUEHEIGI^/9U;V2ORYCQG&GC:B! M,F@E\$F-
IJ7X,96IRIX(O9V2IL5J/Q900U:1>1-U=,Q=OI@103X_MZ_?WPI^WO5D7W'HJSH7N_@JFZ!@00KR9S/Y<7"
&JDXU3Y?P\$I%+XRSQ MT0F2%*6<1KQU_8MVCIT(SQO*9I^>SLA/2IQ^+R"=3L_PAS>-H2L2EIA'
MEF.XD8#)GEHH'05BMS6B11=,N)*=19_5LG7+G9^/I7-&+I\$+2A@V*?ZFH@_M(D+6ICA9>NV:,P&'=A\$G"W=
3+3L:(E\$943+Y-9(ZL^>)>FI6\$!U+>>@IF MVDWH330-6:L?*\$12JW+Q_DT*16ETSB>P*VVHYIFSQ6LHID_03,,"
(M1GTH&DFLYYQQ9XU4M:<\$:,9D6/O9_!@KJ'X! M+_12KK_!_#/_T WCNMX5NY7K;_4DC1\$>73A)6,"IY'46FP-
MN@9?4YP@12 M,VS^4L PK^/!I"X:LC\IOQU*HYI\7M#.00XO8GDL6(P'I'DFLF4B"2 MAN I4<4S?CSEZX^X@.*?
N03DSER M1XP(4"IV//&F9-FRD" X!R!K1U*QW:1@V!EI&ZEKD'I:P*6V_MHFYV2+Z8
MIO)2>C)UJ81W@'4#7449M_@%4QF?_IFYW_1NWJ?7?HY_'^UEP,,H 0^_M>DLR\RA(%PIQVF+\$F,;&YBVCE-
Z&ZD-R#7)&C8CJ4GT#JSH=,9:L1=DK-6 M+V2_P2++&#71#2ZU=9U?TITE4Y3^:1+193&+XO^ANS-
IE+W/3GJ/WKTIHU+>@/WC&0ALM0Y6P5F*Z_!MP^+MM-O\$J4'T>/PE2A7.GAIN?I*S)_IY\PM^A8NE@;LOG:-
QDQ'68Y.MDE-E8G@FD0IG0P@TA^HM3I^@>:I^TW"MA=I-G"W<+18H#/#O_KQO\$C\^N? M?P:T;Q0-7B7<;
ZW&&ZV3\$S"0T\$X;M&K#R*XVET!_E,R<./HK%807<-(#N M6;#FA8^<\AE<8L1X\8E4R1(78B!<,"%C
D93I0>"1@9N\I_TUBLI<7AH^N M."G1(6ZIZ6?DYGA5'3_QE(1%"794\$TDA4",I*EH(JRX2_V 7O"5IRPR(#
M\I'O\$F55%=_A 1(%^KN2<>QV4 M_73^#?1,7#/^R9A6\$UO\4"PRW>YDG_GSI/O)=,1C;+8^C2)6-159ID>H
M"@B\$XNC)8M1E:OY"8@709-PW&AIL!Y'W"P.O)7%9\$'SFWPM6/GI:D:N+%/TYCM2<<-1#/W.3N*JZP#E#N,OY6G
MM*IZC;MC71+(&?&CQO\GXC\$BV)%*=&,H\Q!;FLH^H@
MZ\$F@HJ_)MZE(F:Y0I0R2E^97Z!ZXU&\$Z@S!)"GGDY61(-HRI5THXIG:6 M1&UIB!%2I5:XNU:6DN^
R_VFA(;,+/ESV_&:EE? D<(#951Q+KL"74L M(K,R_13^!R>NF&S3@I(>SY!) M<:>0URQ=9B!\$K#Y Y-E4-
M(8^D"5G\74U8;I1M_-5HR_O2%> Z=AW+SS#KR M3H.+6J"IGCANYC+QQ'TX;.+>
PFW+MT.DIFIJL\$JY&B;M5HC45U(3W>./1 M_@&DIG7&V8N'>*HJ(Z*66*X+/(JCZ0&'1S#;58:3X^H:G=G?
I^H)JLW^P== M#14UA;HWLWE)\$E*RIH2<:+14EP*L_S/73E**+OHBP!(S86*?YI(7%9Y+;H08-T+I5&
<:N)W/(D#J'K/NYD#1%28IS^;C MZR?4D4>&.&.*%04FOJ++4Y)*,'MZJ-1/M;VUE\H'#%B4=&J.H6I0>N'N
MC76=MJ?3C6I+^U3G34OHT^E_SL;3Y=^0_P/J*XYZP4BC_5'0:\$N/,<I,AD M=#K'I)0VS7I?
Q:2PY8@'0ATH#*TFIS^5NE+V.63T2@1UYB)99&2D1(C M\$HR I+7JH7+H#E@VUC+AGZ:3%^/B&K>NYMN-
5H5:X\D83?MBI"X%:B@0K0WR M&#(GOA0>Q.TS\$E+16HWZH\$SF\$+?X;HVLK# MG:?
QK\8I9I+@00K(N>=3.6SISH A30I*,RFIS\$^B^_O?O(LOEX>'V?3MS/? M72YTQ4:+\$L>IF#E-5^3G_P3G-
G@H78ZW+XT#US' M,R">|=P_Y'Z7<>G8^I^5LK(A=E!O_QUE5+WP:V/U"OFM@O,=R1@X *=0R+O\$^I)R=X>|F:
MN".IDPQHBLC1-I(8%JC3XT#UJH8."SRN?TIM0-7MSX!Y)ZVUF^IS7;&^ M29#*0'E3)SIVZ=(V\$H_6G\0
FFF3>@O:"1?TW+8M9#Y_O44E=CXLP.A."6Q6B\IO(6_M"_\$BFDSDZ0M;=532_M7"+\$*S_IXS6\$Y!
180@#Y+7,DI^BZRFUCD-? MN=0/\$M5DO_MB-!BR1\$8+Z:L*35#69(G.(I."DAHX0-?R;I&\$7\$C%I_HVJO:
N.)H#Y+4G:3Y-59,Y+VW;NTI*.L/>W9CPIE(E&I M8R&BT:8_1I*B:56DJP5A>B5""<I=I8I5Z_(#)QY0_GZ4YJ:
I+GV;_C>S M.9KA;I#Y?23D70TH31L4X:8QKJ)(F\$H(A64I5)GU5X:TB:(F4TWZ1E@% MY;0!MC428"
'W#\$5+""BL@PH+)Y)B*45CU-2,)>))B43_@=I G9"U>|EM3UV;2)H;_GK37P
M&+HA%>%V'L*IQ(2UIWPAW*I4W^W: ^B9:GU;R=;PDU_G
MLXNO5R//ID\OB10U'R(0D,D1&:D@5DA'G.""2@:>&=K2%GHF?V>?;Y@?J\$ MR,
I:YVNWJU%@I^7+VT3:0I KE;^>UY\$IKVMWZFMMSO5WD_M_G-LHN=9.I=#)=#V?_I9=I6GN+7^C^J?N7AL?(I4?
Q_IP^FM_-Z GRR_ME"53QI39^6J15Q>+DF:PN\$WM8GS^=?+D1+/KG_WE9OVI E%U^Q#T;4+2%"_M%IWKG_?
LASS_I^>7\$_.KVNT5G/WZ\I23U?U\$^NL;K6&U5Q#4Q%HA@&0G5Y M>%(&2MXY_B92+2NE6U#%
<+W#DUHJ6JRYM!_6@-0M @D?O2I)252\$<))8 M72ZGK4JUGPON4S%LXMG.A,740^
Q/+I4N;K;I8I7Y^=^E.6\X_3I=Y/UT M>=GOSLWT>YIT+>?<-.UBM+3^YDDW;A8I%N_^,M>0*R/@LC*>,
(F!E"57_T%I M13@+G DIP,3:F3/4I/W0%.7')/L)A?EJ4E\A\$R&.^>+))DJDI9Q>+*4B@-0 M_
_W&J_IZ+0=9D137O"4:\$ME;:8MB;>Y MG.>LW_16"#66/2;_X_\$Q9R)C<"XDF SKYWEI\$P2_MIOZM?.M3U^IF-U"Q:?
ER90->(H63:2SX;@J1U)XLYR\$6U*U2=#I\$OSL*Q M3PS>&I12.VV:UHOQOO>LCV\&-
"/J2F=R*TEIW5ALG^U_C3D1%)?..>%FZ_MGY9G_!
\$0I*.R%YI53U!^GJ)IW3=8IXXQ8\$3RURI*80Q2<*!+_FM74& M@*J#_R(H;JC^V&:N^FBG:-
SJ\UBY6YO(G*QF53714LB&KCIYY7O&4Y2@I M
T2T2D59SE(Y:W6.DY3Y*V<_YM"O:U\$6!D0G7PY16"WZ#2SSP/I4JA@E M8MX%19Q2I7V?
H)SIY*VMIO^3M&P%F(I=^U"!4%WTI\VI T^SG)A;S;?>>6 MDI\$B1F(T4"*I266VH2\$Z>AMY#(E7KI+?
GKIA^T%4A%="/AFT@^ZUBFLS"\$N MKS.A\VZ@G&F.I6&XB63TT5.%66&&&"I\$RH2&N'=:00-
6QSB,KVJZH2&G9K M;K=GW,F_N?1M1R=QRBK=KMJH?WP'/2_Y^3(X (PB@Y;&(3XT1GP9F75'A; M.Q5X
QE\YX\$B07>S)2)VIM_UVIVUE3:9RS+65#%B*EAH_# A\$<\$38J#3/ M)CE:NZ7O3H0.?
1^<^VKNF90>=6N_5E\ORJ&-AVE;Z5GP&(Y>ZQS_BYW/3LM

M5.LF:\N*UF51.&WV#YI12/7%.%F+NUIC6NF3=>R(OH#A&#=#QIE.4\$3465N M4 :&0JYM#9D)XKZ6H'E-
EZ@JE+;+4IOV*3D2VZ\$!(8DD16D=' \$8H=N+H| M=|J2QEHWDTD| C|M)L)OIN-GQ:@:M 8KV-%=-)^>U#|HJ9-"
M|Y8"XL5A((">" E*2D)S4,D(16S>;JC:A@-?JS/XS>>M|H:6=0HW4^0W89+| MG&V6@C!;IH:SP(F+I>NT^"L5&4BV3-
9V7+I84Q\$%9W>;O7=K|S;M0=TIQ= M\$@6NF^U5>|N 1T.MYWS|X|O5K8%\$9L1"(ID51210!
G0T#7+TUII9GCMAS- ME.SI-' K4I>.*(V|K&A@-%05G|BTCZ-VK4HY@HJR=X|@ *0_ I->^O_WLO
MYA5\$WJXUZ\$8 KUP?#"F.NOR SS#=#M.SCL8^K9#NVIKB225E;| ^C.>AN0EJ/|
M&+Q+DC1/I(QR(@XB)5JAGVJ"U9G6|A|X+ +WK@>7>9K&;32+Q\$.);&)>HTD1: MH4BPN32"21ZBE3)5|^Y/
J'-5?I8>M>@6Y>FO7N*UB/%|*CQ/>;D%>S^|RD|UI\$8P)+ &4E#G&SU_ "=EC@\$*0"DBG2RL@B="115T
M#OAH53NK8EKX.ZIH>7.#?WXDO):\$OHA\$IV8SUHH#M5SBA^B9>^KXCN?NU:U M\$'(2+"J2R|I/27,@SD<@
|I+)>2.^9R5:L2@THJUC.L3HMNL;_URM^<@EY&NNZUG?*"WX|Z:HZC6| ME\$P|2DH)RV6>9-
JR2=#%>62%F:I+K2&;1AYA* MC+VY4/<0+7N'=W<^=U,D861*)FM,J(-.Y0\$@CAGI>>9.#H\$!;IV)|MR|K6
M1E7|QKW@KK(RVK4PIUA(WSRWW=|9| Y6K0|I05,F87|^ACM+(9W1T967 M%XF8,9D1|P(0D6DR43BPJ?
9|~^/D|M2-GST6JX-JY|PD+|)8K PQ'A:R(Q M"/LP*D=308/R8 0:TIJ8>*N'.FF@78-R,>+KY@GBK7TDZLNG.?3/N)?
=Q^ ^ MD|_RQ\$=6:|?V#;IK>3C:UCR9W&GRIVADK6302B)(EV.Q EMB&6>"XK0T*IV M7+
<-734:|Y;/75|KS7.|V1B)>|5MF2|N OKNC"<&\$H0HS7-!@UV-INSK:T
M#>SKU\$;|L:XU574KNWZFY^|RI/4U4/4R72Y&DJQ@1%Z|+J6:OM:*V1B-C0 M2M<(|XG;(*-IQ?=:YF|
(5YX1T(&*P/ED?KPE+BV6FFO+6/GSM828HZL' M\$|L#P54>?D#2"V&0NE'&<>
|L7"RUD(5;5YJV4Q+H";M=*; ^F\$3HU65D=CEC M^|X|<=N-18/75BUF^NMJ*U5388?7%(T?
L=^YTL GMZ&EN.9|>3*F%5*9%*) MV(QN;A. "4X-8ZYV&J5""=H_G6A-MF6E36YIR>%5(#GA7::=D1+W\$R|JE;65
MWDCMJ0>ZWH.N>@O|JN'D?JH099VT.XC>^/|WYR;^|+ SMW*QA|P=5.D;L M4%G)^%ROM.;BKLV'B_ L.&)-
>7OE(1\$78B#46<\$HH|K-VF|J|C|&SK^G9|_EK M^ 8>))ZJY;&YM(4WGCCT|G4T?'\$*=|5AZ0^2M"POJ8;+N|FGI*~?
(O;Y M^!M^SC>XGD-P.D797>QL;9|XQ&I%&MO37:UXVK)M97PD/LKL^WAOEMN%5T MB;J8)24F64:DDH
GDK'\$_RG_Y;|56|N#NY^Q>"/OIM7V5H|J68|B0RD+ MT@E%)=|X%*!=SXR5_W5?@|ZARX|OPFH|>='C#
|5K.RHD%B_?^1PF+|; S M"UBOTO.770|6OK2+/-UIG416=G|>*|G>2P(*O#HB_&2MT#J*Z=>?9%*!R0K M
@D|6*)X|1%F1&22K_3U" #E|MWV|C++>%"I^D|_4:C(C&FU|J*AHX.NBA\$
M^N2U=UKRZM,4=B1U6(M9"TGW>D0>0& M&L/7E|1|@&|PO=@I3_SN1U1S%|^A
MK?|J3|>ZSUX9&|V54DYQ\$E_&\$"JT AU\$E\$-|" \$Q4;M+WET:|A|?T'U>&:|> M"K+*1_Y|O/QR?+%8SLYA?@-@;
(8|S"DHC82E.LY>452L6L4V)0NWGNVU| M&|JTAZHN#12H=UM&M/L8OD"XF<T: O#N |5^%|HKKH
M2SI&%16W9BLK|H00|B|Q&&6\$XZNS-LAU?82K-WIK5\$CR/G%^467 ?|<+DX MWCW)ZIE+5+=I.W|6P02N#?
9Y<-\$5R,19&:'3*G2+6@2HG8?D>.D9 MOY7_JH0UV(VZ?4SD|U9<2P 2.F4O-4G.9R(=3|0#9&+EX5/Z|1LE7E?52-
ME.8#X&O=5|Y"?2_3|MM|E|^=E_AJZO:*D2VF=&RC8?26|L<;LM|!1-X:Z6S MZ8919|F #IQZDE4.1|H?
2(B:HI2T3DJEE,16#;B>V-Q/\$K*/87OPPU_1%*: M.(V'Z1L'-6%ROKEJMG 31L MM+;|MW-U)AHE;\$>
<%^DU/6+|\$1R4|P)R96J_4|ZFX)FIY(1^MW M+|CV\$'(\$ \$UQ>^<5X<9;OR.;ZM>UMH A*XGV&@-
S#WB|8H*DB&4H^.(D. MU"YXVXR28>W| 2|I32-2>N(F^ROV^&'7P@D1=N).24X^0.RHT|*HR=ZEV
MWYCG43GL>)>H>@D:(\$8%>|.OL&RG>)"DUSGZ^N:R|T|RV8M@5%&+&." M2.4X"=Q&0BYUPE-
I@| ^N#_7V.VZ%)OE"T-2GO|NP9*O.P55(4AIL=^./F:2 MK+@;&6-8M#02R0"9B|7;D)"<*|H|J<24|7?"M/Y4T@#;H+=
MNQN&>9%P:QB2>"DV|V:)TS(O!=D\$IZ.6>;NGMV<=C@|0LQ6>| O#4QW1-X"A M5Q>+|106B^/9><|TDW OMP-
T3J5I9"\$IX""MW:2V\$@I42PHD;F@3M0&TW1|26LXH8,2+^">2,R#.&DDDB1L"2|A=R MBELY2X|N|O4^| O:1V6I-
F|F5JUM/T^F<^9BR5HF%|TLT8RF|>3:|^5SG\$ MX%|71QSEV/%=#:9Q2)#BAQKA>Y@V2""P'4F8# M|Y-V-
95YVC7=92=0HKZC'\$SZ5EPN3B1/>DX#N8Q312 NUC6:(HAN1882/'PA;\$8=+%;&T)| MG30-M?&6UZ&5
*HUR*QDJPM'6H<I-U(%1D3R.W=,MY&<|D-|OM|VP7MH+ M03T=-
"HAUI&W|TGD9OHR^Y(MLR9B\$0%)|MVJ8YEVVR2JG;CA"U)VPYD+^7A MH\$^JM
WQ_A2|E7A;V4;22.3LG4^X|Z;CV|A<^;_7VXM&P-7 K<6A")|0RQ MU@02T|D0.F3N96TG,=<\$QS&\$<(WO+24C9
M\$B4" Z.ZD KH^@A6K;#T\$M|?Z@B^080=)2^P7PY7|H-KH|@?NDO&\$.B>) M|(BE;5-
\$PZJH=YQ#8K4G(3|TG9X>BGO%7WH8>A'K6/_=;STDP^8^=TL;@H M"00;V=+..^2+J-
A2M5UEL@6=P1R"LE3ECF|U@^|_*U_9K;X>>E|/"ST?& MS-/=:2;+ _64DMQV79) 1")YQGT192)
A0&#&|>:VM<36Q&V70KM2WM|J^<3 MH0W6 T-Q|STVZ;F^WWG;H>2F7^GT) MN@\$C=?
U4>Y8W=3Z|1%&|JU2%&A:P\$5:85*4&|T8Y\$J4P+DK8KJ3O.4F+VQ"V M"VB5|?9TT+2|TGTGOO3F Q4"D&I HE*.
(R'NY|1VJHM4^|QO|J\$G; M@>O%7=17U\$;#LH'7ZX):CZ;XA|CK.V3>WD#RAN|)QJARI44E*2);UX2|ERY
M*2B;7>WZ^22N|WP7MKE?;^>NDM^NY^X^H'W*N:E9KGOY^08N>5;|3-Y^J6|G<XT;K13;W-3P+ X/O|P|O\$H
M+CM9K|VX6&HU!70&-#.X=?N|T|L5>|S '(K #B0 M/MHU99^&P&P PSSW;W5W8^H9)
>I:R2S=F0M5^ZYI|K;XWQ?CQ;C|TDWS M5YFI*.;L@D(^=0Y923X"D+7O/|P;D3:O?NPOI780(AP MPR.;ZADZ+|^
=)H0#^BY7&5B=GPB:5(|;|OX;AMSICC'7.0(U+|E292 MIT LBYI@=)1+?^?@9/4;V|HL#-
L>81X'U|U#2| PY|P.M-F5&|JYV?6-3 MSG.P1+|SRE|R22S%L\$MZ|4;H*L_?
+^3|*|YPO.3V|JYV/9:H348FZ+.)G0I2E\$)"\$|23+W669.I5"N*5P|=|&A M&|_OI?('8MBZDF|7I*R*;U;|^|S?
ZAJN1AB=W.SZU*U1E/4X+36<+."QYU ME'2UE4+..9Q=?
UV89)&I5YIDP5F8):RY|L\$D1#EIS2TSU7^GDEBO2CD|N=?
MUX|MIF>5J>OZ+^L5=^4M)C/GX|=#G0I4B|T<#<|:A%9KYHH7@+|(|DB M(\$E.B3DO I6;H:I'(|S-@4>F|8CTA|_9-
C'4|BFP|B>W;3?^OE*|OIAFBH9 MX=4"U|C3B"TIM2(LX"RBT1"XIXH;2 OX|.(M>|M;E.P?T'I'+R.B5B^KGI
M|.Z7JX3FVW?NR|R-3|'C5"D"XA#=#X(PXC(9G""^=IN|;('9L|8&-^S6E M?;FE@2N4TH)@-K^TI92,O?
<_5O|RI|6LWGX@>;7I2W&CWL/SE@D))4 JE MM1A'1ST+8B!@5;Z|Y9BK|HE|*|V;K
B*@^HN%30*_<@EG^|+@)E^|OYOS+ MLGOV|<;_7T_PX2HI%7*3G+
(\$A0QI(4F0C:F23NCB9Z(H#>;MEA+^XJX^IG M23=AZI'3DGA APTEN.O42)*D*ENAY+9RSDM?
UPS|&|5L|9?;|T@9MAMJ5>.T MOZB;0\$SISW|QEZH?QXR+&Q+O7@L3LRIAHEXD5GI/_LG9,J|=|<&R.Y Y M;#?
4RL=|&GRIJ_.0K35|O4GVB/TV?E" M(|T^JN|"%QG*W=(P<;LK;.*A6(M)|Z(E4X0P825.I@H_%8S;Y|U="|C'17;U>S_=
I-EK"XZO|H^FLB?GFC&99 MA6B0Y83&5L9.B4O|\$J3|5HLO.U'20IR|WZ|6C_!#UG=6OWAHX*3P?<=>"M*59?
NDFK(W01 IKB2?|E|O#++&3*5H2:5|B|TCHL MZ%@;G_216 /(|)L9G^6^<^
WL_F*P;=L|W^#;^M>|O8V1/<9|E*_F(UCBMYE0_T?|R\$KDOP MW;;=|YPHQ2/PED2I09T"@C3G|F TA,OD@Q-
KMUG8@L_2BI ME8>D|_A:2X|_I>_W_W_0|9SXQ5Y&-7/1,%DZO)8|H.P\$|58X0B53GCF;E.=; M|;6U
P3DU8%W\$""0V*DTU;#3V\$5X|!T&|^_@IMW@F?U4@<|DSM|I3#Z+=)!=> M2C28=2L|@-!;-S8=T3@I3-
*4MS.P28B*9XPN*T=@22U*^..B\$GW>.WY=^H9Y MJNT3PX-|KX+|PO72|UGZYGY";S=*?
0UAN4>YQ(">6D41^/\$W=9KUQDZAN03 ML5"F:1B?B4>+@&BQTL7D.5>U1UIO|H|BB<.5(=26YR6E+);(
M#|S/G.T3D MT@L3@BJ7-CU6 M^G9^B@?>V|I\$AMP|T";^JXNK2V_ M3<==M;+42GHAD72G(6N)/G1+?
X|)^|E_@YU<)>5=| MZ|X.DHD?ZU7QIS|VA_2 MKLS?8;78KAU""|L/A A^3=S>*SUZAD)??CK>K+^DWKS:QT26TC
MV4^&TQ;"L3P#07E9X%|OE&OW+;U-03VG|N,2M|K'ZLKZNMMP3/SH(0G_3%^T0V"Z^:F
MEP%Q<_@T|7XVV7Y8?IVY&ULEA+1"8B U623%L<+A_@&^P|HM=|QO.LX|S9!\$I+|\$NDMQ%(\$")D*HDEGEM/
M07N G\$9YCS^3_LW\$N8NNB*2AXIE=7)R%&AC+N|N#3_-D&P%8@484V0(LEA MQK;V'2C|>
<^95H"X)W%Q^O9W%06N-N%Z53L5@8<< M=5\$2L%A9|YTG|A%S=(3W&4GZ=N3:<#1Y;X_6V-

SE/+KRNH_E(*5G DJC?B M7^ (BZK#*59I>.;A;^K_5I+3\$8E44\OI>B#0Z#=&.N"%:HDO=&M;^P/H7?>
M&OOIP3JOI+M^Z\7/-BK|+;|HISREIOE4&K;_G32FK)F\$.M^11Y;7>_!DVMR/P0GG)3;_0 M0IY9\I;."BZC;.*9I1P;.
<+I^Z&.IG;.<%W?0@G51Z_7K|A^D(M;??MPIC)L M/|T26?|Y;OY|XT3%1.E.%SF^O^O;+H;NCP7;
|CYUMN;|I1OFLF UT9^8877_..0(OJ9;.).%" ML.BT4*TK3/8D=>;_7VML/>#S3"; KE1T769-Q*5_.;A;1UW^"/PX;.\$C87%G0!
M/%#D11^E@CZEX*%H*BU9R.T3.L91;.*#?F14-A57OWKXWV&SK.NZ3.7I975Z M;1S0I8 ?>6(CS3N&|A;.
=.YIWQ7R5*J)|S;#P-HI7_%9Q;1\$8;.)R47O)>;^M6#?
H3>U.I7MY>%V?;3"Z)!V@S!%4JMV/Z6O;3H);+ "&\$.EV^U;|DS=A2IRD< M|C^(VDJHGO80|ZWK?()3I8|OX1|>^
|T>Z2)T>=;PDAD)NNL\$@@"UV#4;6P-M4DJ|C@W;;_U(FK^#SB18G%%@_2K+EVM;7JUYJH|E_-NH^6V_H2/+?
PXIL ME@0X@Q)6G=;A37D|@>|>G;_EJO00.F<\$T&;0D93XF3+1%T.(2 *XIE9F7Y0I
MK;_O^B2HE5K=UHN<&|Q^4^IK?_I6|ZB|ZPWU|O"<|84+QD|3QZ44+0Q#3+(M+CETJ_#8J>XT1I Y<|?
U9BBZ|U;);%<S!%78;GY=S@YPI|P5#_ |P/G2#SVN MT?DUF.)&9|?5^VX\$(Z|UJ0FEV%);1<^DU|7Q;.;S
P^H0<|MUCQ|H;_MM56Z7/&-JY^B_ _|Y6YGG^|HT= 'S0.O*"((U/M3NKA^3-B\$5XX\$IS*&U M(7(
N2UO|N|@XL:N2L4(ZSF(Q#4Y3MF#MR&#&\$2YA0&65GZZ"XF".YF|<=|RL M/72WWTOR_9Z'E_.
WH9O|=R@+S=G>#.%(:S.JX9O9S7L=4H>|+9&9V>K|38Z_M42_(J.#>D1);.EPTA%RB#AX2;@7*;
X^R0!&|I0\$9SGSUG>)#Y#3?G38I0@N MWH4);Y\$EF*_.0%GJ|E<^2#;=IKP7;52D;OS^O)3^IG?>D;(6IOX>(323!
M2D_+RW20=_@55V<^|!&X^T^L_!J6PVZ7#WAFMR<*|Y77E.|KR1\$H2Y);8
MPE=13"C\$^G^U|UZW^X*QMH+;D@|T\$|L5-M3>T)H0X)L=|HFM31^FRZGYJ&A0|WS%FJ&VIA&4J9C0^K2.LK|B4M-
S*|I6K+ M-/?"3I>^Q|E|OYHC5#R0.U^"Z%TD&V=K/^@IO3;|6SQRG9>G5M7^IR?OKV
M^|H0XJ_E=B\$%;QK)O\$F;_WR0N8=6ELGQ6*V(IADK?26 +)FSG&<WK:473 M.|KJ|@GY>?
PI+U4G)5+EEL=;ZQ|O/&E^@E|18852(>E6|L^L3N K)FIOM90&_JU M/>72=1^B;_UECB^E|A^N0G+YOUU_.
|OI|P<|3-(DFEBF0>=&65DB6!"Z; M2+\$\$)5SVK07LMT&\$=0JW?>PGEHV.P*N=C)^|>*GO-I^66W\$UF4J+
G=-1G M0SN16W!>>2@IBQACTGK8;.<@C_6_>^G.N=73;"@:O|SGD(*5K);Q\IX:4?G|V|I>1T;H=PSJP/_X3QW>*
M|P|LO&|+L-L\$65B1 D<0WDG2;D\$ Z;\$(3@ICC;2Z_ ^B/DC00(T&CN!&M1-' M;|BZM8;+S4;&ELD|^*#07|E;Q<5
CFM*J<9T+);Y|5QB.AK2T+|UH08BF;0I05W8>DIY3X.O)N3|WIMIAMO;V2H> M?P@GG<;W7S^.;E;?
CHO;@64|;@<7|?_B@(|3;B5EQ62?_6/L(|P|^)K_ M(S@-L_..RYWB)?RU6TEM(BM(=X-M;86&8>8C(>D53|.*I.9.
00YZ_IW^&_ M#B|H<^ENO\$S0_!8WRW5^|34L3^J)^6J|>9/2V9=0EUCH52|QN|TH(CN1;/%R MOC&N^P^NG-MC=E?
5|039>VFL%TNIM/0|I^X8H0I^_!S0KQJDI;2;JA(C^|JZNS*(S=M^?AYFI4=TN<|4#%_#>^|S_ MEC.3EXO"RZDY
I|H6R">ZKEHV.YPMODBU9|?;.. "F\$M?<M)M7QO;2+^F4IU+|+G+U5VYU/U/M>TU86TG&E!CF)H4XHT0%)%|Q"
|I4KK)2^ MF\$6\$U|W^#8*3?Z)PFH;G3|TBX9+IZ_*O-9WK|KH?VW^S5#>|F6H^OC2Z>1% M^ L0<|2ZAH.Y-7WI
VJ^OQ &F*|/;.&7BX\$MMI8P2I;6.(VMIRS)|Z0;+8LW M!;QDM%*7ZBR_0HYT\$HIQH8UMGB3|Q\$?QJ|DS|^*^4+IP"@|
|U^E37PNOY! ME5/_%A_VBERB!&DE@K+9D*^DQ2LHV;_!51;MZY|@)S.KY7VD/YZ&E^TBZK+
MK.G@7/3&@2V|S)C;S-|S.C2.G69B^P;G/630_!V#2M^ M7Z|H3"><#SBL|HOPQ^|R2\$Q1B24K;4LR
LB5SQBT1"=YZKD@JXYKH;0U26| MH^!>F^9S.V9GI_LYZMXO=YN7Q\$S_Z@Y2UNR(W^=4/R_ULO5Z;^)C;4YV>4*
MA3^BA_0FU#U;|Z*^5|1116\$|<^U^W89L^?K>YCGUA)<1Q+&W%#?|FEVUP=.Z M6JQGE-
^<|R9;Z16R!+OGCWR_L7Z3|6_/B2|W_EG&2.6>4 R<00229M;0! M40^>?#XNSI\$RCXR?0PK|S^X_HLO.6%|!+UB\$R
M;N/_*PI^HY^)/0=YI3NW+U7|O|S|PMIP|Q\$W+9J2W?^P10=S ZEM=+_V MTIF6P+|=OEQ_CLO5;17>3?
V|T4BM&V7NV|=2^6FHF4\$F2FZ3QB;D(Y^7+
MD)|VK^86K=O^4=A.^UV^=X;+|G^L.W&5^JSCV9R"+J&ALQIC;84#6IV@0H MUECI72!_IK6==0|IO2C^*>3_0S.?
PX71*;;|HQN|A^DT2F3"@-29W62)K3D M!=\$&+62\$8G;.*|DZY^!1HOHXT@X2_0 X|2^N8WTMY^>9=I&5;;=|7\$^?
9A M_6;XG8.S.#;)^ M6V|X;|^!T^*WFSJFOY950#_S_C-FV6NT3%VG3M3;E.ZM|J.M.(6">?)>+K^<^
M@(|V^8"@HW%ZJB4;.(.8H>Z2.U^W6|;4GU^U^\$EVOX|P|?;+1=UH^BR ML<%&#A@>7?2.O|BU5%.AB
_/4KAJ8SOS?DPP;|1UEBLUK^|VL3=U M^"K<6^EU/Q>P.3/N7N|ONCWA>C+O.%U?>-WKG^I;0.U2 TL;.*@AID)043G
M1>38/GCQ*%&I0.G/X\$*Y%5" B+NQO.3U3^LFXI2\$D;4Z=#3^!2;/_""I=; MCX9|E^AYG87&(|@&L3TE;K|C|B9C7))L2
M>\$<2S-P ?>O>GMZX?|M8I0Q;=2>5FYC_3;V;/_#9_1_B5W?#>R?
+SQ29Z4U|BYI081YMK>3/KGQ/!SD@+R5@.RLC; MJ|9A%ABJ%F=10SK.7\$(%?/V9CJB=IU;_
+U\$^N/Z(%KV^RLK+Q0F3702N;G^O M;P&A)IX+\$4T)&(TVK;L4^Z*GE|Z%|R1H|^>6N8^Y.|*H?ODK?;I&Z;OZU;.*4
MH&A#"N#|6HE04+(VD.A9<|L^M">QM@|HEC;^KN;GU/@;ZGXN|<4/G|K|Z@
M5Y=KM1G&N;68%PE3X/H%|^RK|>9S^!55ZC_G*_R^JS;|&G>|7|9XW#4+?B8&O\$BG
M9^>D\$60=KH<.C+^*%F/P^6#0&PQF^2MX79?ABGP>=@BY@T|^!&1Q3VDT^I M+V&Sj@DG;S;U;|S@/NC(@JZ-
|WGM>2+%(M/M|^<^"G-R^J);_|Z|6N9 M-Q(R_8G%OT3^=|HCGY?
2AJ\$U;MV6SOP>|J_16R^D>E_*0JN>2^WRB*=TCF EYD#LSXJASIR M;_W2?2AM3ZRZ|Q|I_XFXNH?AC8R^4F^5?
>W#Q0*MRQL_0=D NDZ|UL9;95H7 M^0REK8<)>X;V1.OI^>X|;C7YCL;R6;93S+OY*Y=9+FBY^EXB;|S^;DY^;@U
M9;_0V1B=E6&0AKS|^3VC95|KMMRM8-SZ<:HGLO|396+DUF-G6X\$|JO^// M6"@|EF2YX;GO ?
0#\$?JO\$FQTX;Q^2#G|OXO|SUMW|W_XV(Q-EBIM6^@5>%U MZNNKN(KJ "9A2M;9IQ|JCZ\$&"YKWX/PJBV@FD
W0|>""^YVDQH3#)&HM=\$0(MKE99DIO#4^MC>-@@N M;=9F/H|2F\$ MCA!UX|B_+T7ESOWU8I4O-
|@B;_|2|1/4XT(F3VXP!;8Y\$|8D+D1A^VY? MCM;O6Z#UV+NT\$J;|TO3LESCV>GNVC ^E89|EO<+
=Y@;8D&R0#HS#4E)4; M42@#FFMKLY|N6^AVK9T=9P^V=(^/9;DQH/6GX-VA1HW!;Z;M8O.J%|6%|< M^5^R!+?
_VJRWWV2X=7WR=;GZ^)+H6YZ^FEY0CN7WGY97+N023MK8@+|^">^ MCG/PG&
<0@7;MD;.*@=UJ#J=E\$S;MT|+HD24T|V^ZV+?X^GIR;Y^RINRVYXA
MG6_6IP2C|0FE0+&5JHK;T3I19@DX|A^VY<^%9J?P@5@T#HGA<(FTFE=_A=
M_ORWD/5>K.SQ|7O|H|1>);,=@G|O08+Q^CMI X|JE=HJW7YBQ|F(Y;\$3/ M^X(-)=.!L_38;A=*&A3^U;
(M^2F2_L1@LV|BR.<>)%ZW8/C|\$T+*C-G@SL M|I% MA;GX;38SOBG/8-
TXX|^V|7(D6+0+9#WC4^U4IG6WPYP^C^F>^D;AKFG M|8)5KO_*T_KL_C?<^
G73^I9EB6>EWI<|48Q_QZ&6(U>6O^A.WV M|^/K^JX#B9BNP^LE=^!_Q+>|J98;N^D|4)04Y;#^24_U7
M^=9C|@62|0;4MPFBRQ%;8EBT44^T)|@CS|K^PS^#J|_&B;|&FS;^&^L|HFD M;G0\$|D#%80^QV(FRQFSCYQ;9^T3
Y|^;.;U"?=\$ZH&B7Y^=<8;

E7F@3(G^)(1&BPO M=.*|A-><&*S^4D)7TR T.N3I?^Y0LA|9_C6^LS..TWM6&QBWL7^SBST?42V;L&_N04?_KI!
M>)88A>U-Z(FNXG;/(A:2H@>A369AZ(&%?@^)OB;+YU^#S03_!F N(QIV0 MOAJ>WQUXSBNC8S(@\$N-
Q|K6+)>D%Z\$|3/M8AN7/G;?_>U87LK<1<^S M^|)AF^B2^NV&P|R|G M;L+|A^NP6;|?;O#K8+T<^>G\$|M+&U;
(#7AO|AP@)9<# M-S\$6H1O@XC\$ZNH#)|N)=3|3K?>Z0%_G_..SL?3W>Q#|E|^HBD(^VH?0@B?59^ M#-
|K5U|OC;8B#ENP7Z|JX<^Y^<^5=^%|(7OW)Y>: MJ"\$1#|^V=1;)|DXP8D=|DKD@16WP(|16-%I=Y;|1^W>K^C;.*?
^UZ@)|INN M|HY?SY^|/S^_YY>|<=R@8613UQD5J^R^!_3CX";Z6SS&AN11>&EV=;37P? MNV%NT#Y2=
(5@H3#OOIC."Q7^VD^UY^>N0G+YOUU_..1PLR\$&5D(4+*2.X
MDQ;|80^LC5QSS;Q@|N@|ZQ&BY|E13P.Z4^VSECAZ30OK9_R*)^LOE0F_UN;_
M==SU@G)&|<|)4JCN&^UNI%|T.9HYD;_I1^#@!|D80ALT^&UR|O@&WSW\$SG;3|??>1^UP MYSVT2/^6_#
LC0Y@;>|D^U;|PV9|G4\$=&\$V_..5.SG8F<4J;WKB16;_%X7^?7%RLOZS3LA^
MM=Z^V2;77>E*_EJ9V^JHA3Z33KNMN_/XG;9EV%\$S_E?KM/LN_>|_6B|7

MI ^E/STCIBX"S!+R\$"+C.3GUAEMD2"A4:)RZ(->SZZ;>X4 M/J=-I3\$?=>^HS8=WT*+GRTPFAG \$,QH"(B!&X*2,=,\$>
<IX8^^(7^DLXIF><IU M9QV(BV=VM PR;# 1#VJ MZ A9.<7/ M,\$"YX8KZ:~?
7R7J\$53/2>M<I Z03D\$6*Y)QWD"0B3Q?0<=+%"BA6.DE.I^2 M3C/\$4F12V\$??P\$YV1T|X>&::AGS.L/JXO/KE-Z>?
YFYA50)4,9882 GJ>::F6!770 J&2GJ0^Q9Z66EA! G;XI M?VS?|F&9TWDDYAQ
RF&:Q1Z|ZX8|TV9X>::L+!CQ@>X6JXW?ZRVFJHKWY?GR+I4|VC,+7#B|Z MDLP;<\$9?P,2-YIEA4<Q_:X5EOHPE
I+SWV& KS>G"!% QEBSS|V3 MAGE@QJ3=R%WP4BN(#.GA=)TV|>NDGS|FX>4|F.F 0*VI=-=7OOT05;-!
MEAH2D0)32\$F#"SG407"UFU4TX\$W**04T.4^1*+X'J<|GHV;&G3,U1|AGF- M870%B&|+)(LVV3KAW0:L?
5K)R(W,@)9.>?J><58?>YMA3^#S28 IG MM26&Y=V|I#=-IV?W&>B7|SHU;G.?<~WUJ0S>JS+W1^(&>U1DM!*%R"T=JE:&4R M<Z,S3\$K>3Y9-MW::L,#)DE=ZIQD 1/%I6+
(G\$42FQ(6:Z>WFI<4=3!9EI! M6ME\$2WD^23:M-EI^V.E.=7|O,"^~KK|^WJ5UJM3(O2D|KJX**XZGZ'I.FPV
MWVKEU>=Z."V<<<9K6Z^1+7F0B9/V9Z MAI=2#JH(ZNT/99R?)R^E6H4T. ML.=D7M|
HEJ7WQ>=#Y2U5IY"Y#J3AHL!&8B1&9JR)9%HYO3PXB_2DD^W2I MWJH#Z.^PP=Y>+NR/U?
+T/18G!3MPA1M270,=*EM0)'HXB6@RDEHL1D6"C= M|I.J5O"~H2>W"XI&%%/UU&
I3%2_6Y#TO+MYMB#A<8NACI7* I3/;R0%A+C M67&O-5-3#6T|S@HIF2/@ZOY%9::?X>3.WQ3|N\$0|X|18CD\$
M@7142>;J:.*>O&);1(@R&3ZICW<8^7W<C?+ZWLBA.95T52:7L9>(1(9=Z M&"6>8:=Y??
Q)*^\$**T+P\$>5R\$U^4=L|J700UG8 B3QVS2U3|K7R)6BFH6!. MH%0P\$&U YG-9F1)ME.\$(<|WTM?^>\$QP#H-
"+LX+R|7-BK)7FN^KY|<>:V/ \$6G))K@%MD _1|AB.3MYO2RX MX\$D3U2Q LB& "O29SU&J-.70\$Z6-
S|_#Z&WCXNVYG IF@AG/5|W50&=65NW M%0D?|<:Z.^=7&LE!513&1DVFI<|>D".|&"*+N5JULB'98|NS^~/1Q
=76 M3SF21.8.2_1^5J>&O2G?|H5)/L7V6X.*G%_90U.#HP73MP%486K|VB7<^ MOH_|D|9P.9R"/>C.2X2-
S06^NM4D9 STVYL_5_2&3!O:W&3H0^X|CM%0%HM P9K)T)%(K|19"23EUF1%+)-%:0@XGKY+Z@N3J<1CK-8/?
_12^\$WK M^I M^U^40 J'9-J|H|O|M?OWO^>PPGIY J3OH?:?WY_4?N%ON/F(F|O)=^OR M=K.NZ|WG<-~%7-
YSINMH75_V.YZ&Y;J?UVN|O>J+ M%_X K*K6B7^=XBIC_K_~WBK?)U5>PIGZ|HG.C.TP4**2M#Q9A|B\$*3M.KJ@
MK1=6^<:GP#@*%ST0Q|I<%%BX#PJTUZ3ZA=(0%J|O1;K M6*Y>?+>6|JHZIM MA;#;Y^6DPNM
6|^QJ|MPVZIBRL"D9P.C)|V\$|0Z@+8B)8D)2I0P.RWS8U-3! MPIXC@JTG|8.IH872*|7.O"~|F%AMK-&*.J9(QTHYD
KPG"|<%ZP1ZCRD? M82;OIT3U<:0=)/H|<-I?#G.|F6|_?=LNR8Q9;>N@DM-O'S9GV|MYU<@%PV)8
M|8D|^T9A,05B(!.E9P\$'S@C|(&7|(>V2YGH"Q?9X|UVY3|H6|VB92?U*%10|J|MPY*MIV%TZ_\$;2| MOL)M*RKN^L%-
IAP02SOXG8VB:FW7WBB^=OWNJPB;5F|F#XJ|B9:9Q|.#)" MUL&4H&QYE?
(U)QZ\$EW<1SB|P5GAQJKH^=&B3(P2AR A&J1R)\$S*EUEKT M%@GS:LP#Y7S|W#J\$O3|Q.WF="9LV?79-I-
ZGHE/^V:99?>E8J|>=>N9Q7 MN?=>A4#G.@|F:|."Y<09/&0>4+46@J'@W8%D7_#|/35-7#VIZX7.T!A051
M)=K|GX/G_%R476)%VYX="@.C^2&|T:F!48.D1M=&Z_7+QHS.U.BK:@NYNL M>=|V+(0_60#
<|CSAFYCH8.4*VYH 4E#|V: M7|LG8E%"Q_*|LN2)WN..\$OWH>YPO\$H'&27+H?&VUD|,BU7^175_>89BL@ (5 M-
"W#:DEL R;X.3Q\$E#CM&|G|'+^HGK*|*^OX0\$8^00BVG"&"/?B=\$T>PIUOI
M=1%LCX*X%Q44QFNE#=:NHJ#RZ2GT*=B|72G^U01.)FTV14/5VGPVJ1("I
MH00K>=\$)F123+K"/88.3!6P1H#WIFCB|KU76+ 007?S?ARZ<4=@Y|B|; MG(IB0-X F7OH285K9<'H0"=OB)X.M
|QPL|Z>4>XATW9J PH5/M0|6D|)%GP*M:1K%&1+ H.AA:BES\$Z&ZW3=X)/<1_%^|KY%@UZVY/"=43KH
M%K^|6#_.41)MIZKQ:DB\$ _WS4.2LA1YZ#B Z#88OH?|I=? V=|W#DHZF07|Y8D+4=O48/EDM#'-2E77*?
>I3N|U-0_X4^&_M";DYJ'7B80|DFMS" _G#?RTT2H6*%<8R'7+1*Y)G#0/@?Z7R*6APHA|PGY MPW-
\$J82.@CN3:WD%~16_BH"#D#*|MOD,4ZPHA3\$8 FO)A\$CG*N|E6_5K4=Q M9#&WJNP|R&^"KIQV?<
V:~W'D|T300%|K"~ZJB|TANS(NE529Q2EDFO*#??"9VS+Q)8%G0F M%N")42\$^Z)"<).I=S.F*|Q)|D+D-
J(^E"FS1WRN2K#A_~|N>?EKGZXC|MC|_%7:3|O3#F*4U0@!H1O)G@PW@=1&0.1=)"E22#|
(.CT6%#J"QK^O2O:~+ MOY+2S&B|;QT7FU0R+80N|A5&E222:~T_7R.4>KN:(=W|O#U.Q8SSJ:"A8 M3R*2N?7;?
IQ>|G3ZM=OW|N^T5MR|X#6^DN5NGC4#EP2Y>5HC|U|)%AZI M:7W@^?|A|7HUFWYV(&3E:W|
(HY7\$_.D;ONW98A M>=>\$BNL1DQL:&DQ<+|Z-Z-O".1B8=@.TRF>Z:8=I=0LR5X1/M.)NDLSTH
MMX|6\$H4.VH0L56M/41/+|Y9&T@UXWP'*/KA|+U|OVQI=XC"\$EJ0OC|I5)R.MOI
51)MDCBYJPJUOWM|E*6R|FU\$3ZL(5\$.D#;O|@5J78RUFR+>\$~Z)S*E)
(=@E"~L2F54UMSPULIB^AQKG8(6GD<@SX.VCZ@% MOB(FR#FOR)RW&%O;5+WG6(^1V,YUF/8._=RKVIHJD(8?
RN5+N6U"FNP2NF M@/D WHAZ/^3X|U*)\$.RK\$>PI^Y07)OEI(L6:58"B1G9:UUXF2X*0_%)ITM
M#^1G|K|CO4HP0|L1H#Y;F3|GY|LO@^&B_(*M|6#+.R*1WJAC0Y#@&R8O.
MXN#S.#YSK\$<):KT_U^86|LL7"S+=M1^0_*\$;962@^@ (ZE:~+&*4H|I6'=OX3
MSK>6|@CN3:WD#_UR(PYU+A\$3.B5Q+P RJ;L.F.@SBT(>G\$C29X|UWD(> MR:6YA?SBW4(HD8+ F'J1R|6:"D;
I20D.OI7".W\$7W4|MD)YQCO;>01W*M@Y#5 MPREA/)D5)+@+;|#FEAQ'H.4D8O?(YXOZ4*9U<S?=96CN!?
%JPPJL"K+3+ M.&|MSTZ*T&8^J%/K:"5%A.Y*%X<""N9 F@9="HJDF01D% M;A|6N; GF1'31';O.M&?G\$|LM?
KE?;T|U9VO7\$QE6HTV|SF|/N'D9OBQ/ MP|FOG|H|UE|WMCKSB_.I7C|E#?KAW)CN*KT4SETJ|ICU2#8ODE-\$8
+7161> M6B+|=YV19AM.2Y8B^8+D^V4R|Y'S+GD:/U):Y.C|6|HK0*?UF#:_Y%RV/#9 M,0+JP-QZ:/
0%8N2D:H/7BGR5VA949.NX<)FH8QR|EMG=AP>R>MG\$.TH+(P* M|8T13
|H^|X+=E%GGLB2K|(DB|E.OJQA;ZV1&Q\$.9D)UC=&3?76-\$NR#H.XQ M7|I:~|ATL-%B"-B3IEK
**42+YPEN"8H%W\$_.8Q9A9D&62QW_."GL* H^3U MX)B/9@W.P"N0YE6%^1%U8|KZ.K4&5=OT5Q-G_.%&9-=#H-
\$B|I6>Z0-X-Y" MWH|2DALDU^MGSANW:R38 M|5G4@5) <+OGT**E%EM U= <>8AHJC|I|ID)"PGF#;6|
<|HTO.AAF.SL70 ML1^"DFWZUS#5\$ QO7:~Y|4^N7B9001R%1!"SZ6 +0HX4S.QNO6'LJC1'4W
MWF1/^3|6(3Y(&W&|7|>:K^L+~F^D8M8UA^E%:KTZ7|JS;|H@90>VW33: M^|H@!#A)'0TBA9.SZ-&@<.
H7FQ(Y.("2?_VIS/OFR08T5"9J.X|!MW+3RD MAL "0A1H2PS*IV%MOD<~)R)/1/9^~?>V%AI.P2OC^\$^(IO?<
%SCL!A9-* MULEZ6WN<_3M>U+H\$2=G=1#?W:2?ZS|K9.1 MQ@TD.&H|1AVSHV-
5^NSS2GBZM%%>:V2JE/4Z@9(\$+0>H)/H#&&7*PVB_.P M.O2-/05Q|I;*).R=&S/TA-OD\$W7.>|+%KJ'Q42|J'2|Q
HHO.O6Q|Q_~UP M<~28|HXX)|EPT?SR?2\$4*N=E:0=)J5I.\$8)Q0=9T:8;>X(Z|^)NM* MU\$CD>|*H Q|C>J?NO.Y)69:
M>0HN>8<(ZY#?C5K@C4;769:H-2;A/FJ. R'6+0F3|>57&3@I?D FSU)?>| MJO&H6Q|? G;#C|DGO"*#3D/S
&CIP&*.PI%|DID>#M|H^Y.NA8/A<
MF#\$BF5OAWA&0*L9HQT0\$C|&"VDUL2|+F|N3.2C*TA#Q(U>X9PYMC'LPHD3T2
MT|O#OPX|B^G/^==726BHG32997!RUR@I\$IL+%U"B*3(I+U4:=%AUY=:_T5J M.EDTLF=|W3O6YCZ%?ZRX?
K|^R0NAC+>&C@YOHJZ701&"B_98UD7'DH0N:M|) M?;SG|O'O2<6'BZ%RV8#HYXHCXAYNTK\$|I+I<)Z-?
J&S%JDXFY)28'U*U8.T M\$/(DH%VTTH0/+9.\$WF G.<>CT.DJWE.?>Q=Z?P*^KU^NPVK|A.NO.SWC
M6.C%.0Y&=IC.7#P-I%QIG(Q.JOXP^CM>PJ_ AHRW|WL|D=@.R%U=LWY3K|~WH>^/188ITP.Y3IR*7H
OO)"E8|LVLK40.7\$4-J>MNY79YHB<1+~PZ)W%=E*YAB@=.U.NC./13)4K+&H47ORR P'H#VC<8= Q<
M^BRC%*SQ825.*U>ON2*OU;YQ#@^5.GX^AF(X@:6:9Q7K?M3_%YTY+ AIQK|W_3DM|FC=G4:@-
MGDISG|J5|9|:3ERAAY M|@#.H+JN-(:~N1T6N|L.O#1\$O*K^&S*L2~|C\$^EE-KOQGTGE0Y.U|!&0(&ZUTC*3)Y@&?"
F0YD|*BG96^0MF-?|T7^D MQ+N.1D|/A1O? U4\$8AC:7V^0_ TI"<2/4M4HH'@&|N4V.').O\$97K9/IA00
^C.S@7CWG|P4ID MD8=2)WPH4 H5^&0*D*7&92%:E1/SBAY/2H=Z@G?K3X%RV0_K;U|:~3=>~J
M.P6.#AAZ8C7GN<|'":U^4_16&UO=Y:)QWJ<"P.2(<:(Y@.CO@TV>|#S)Z
M|V.HZ60WG+6DC(G<L4L:MC^1_TJ^VA&76?78 S<%|I'JRES\$4VM<4WZ9YH

MD7BG:FY\$45"FI"1O"<[HFJ#RA/5^&I!. (NGGE; B.DE0>92.&1-400%HI@25 M(#.9 =&"")>0#&5CP-4(=4+R-
;U5+)<K62O69JJA81J86-0VA03**0TND5MM M918Y.BJ+-UAH\$E0.1/5MKU1%8Z<#T>?
C>FVD9HS0(M@A2M4U&1%2D2C(1H= M+1.6\$^JLOP3=A;W@-"H")4Q/NP!G-^/_%:6,NUKT8!B?S>B &>,A&P,+I)Y
M!5/S47Q/4)EE& 2?F.U@LMS1ZSN*-..3..(7(T.I.*8!BY05(32BC20\$I
M#TMBZ*6,NH&4JF<L.RN25^7 I%QN*T)K)I..@O&/DKAD/+ #OMN>..8PK"R MI2>0N!*"W!%LPKSL
O"8 -J2W1@Y>K83\$H<I^1*+,&9D15H>K6KP6=7V:M:..P*6.??>><*.OPUH)V^T.TIN
M^@H R66HJ9RYIW>..F>0TAIZYDIWVYME,24I1&JDO,V#:DG/H2H^@T(%:@8P+ M\$!^Y,AGFO2DO0T!B77!.5)SC-
QLEPQIO<1.T#%QQ9I>U^ GF/0T!M%S)3V- MP4H)M%W*WQY\$K;..95FFEA!\$01#1HTTVFJ!..S!%Z MA*3GIDKN
..8L!RKIOB%X\$5E\$Y6D14P U69@5:4#\$:3.\$N>0LB..M(<..MDJ80& ZO/>3I!^#N-
..=HH7@1:1%9"5!>>G"LIAADIVW\$(G_HACZ1 M0?4#:=V"!!-
BWM+I%G3GK*3OE)^^O:J>FXL8G;\$%D@OD^%A5XRPZ!(O M32&-P\$OKAF1CZ)LWD#8"!K(J0..I/Q(*
I.0M,Z=&+UUSP@XRWHTPN/9PPZ^="I L YW=")??JP@KS>="M6^I P3;I03>KH.6).YBRT M#F8!F8SW48)I!..1#)?
GOLB+X4W8>)08ZL5X.RYK<291FXIC4G)S*W8- M0?ISD7+?I EK2/IS&..#8#KEI&!.N%U*"CXF3Z>0_1.?
K@2XS2"LA/%#TY MCV3DOK>0IV/04YZIFITU&#"+"MS5=68(GOOP9,)&'2.?.% @X)^9JC-8.4>5 M?
M!S5;>P>:ESSWV! I4;&>0\$0= MG/@OMEL_ 6X9ZL.W87/ZIGS^U\$5(&)DR%KS@I.A.562"!W+ _K#\$J"V5MZI-Z
M(&G/8A!&%ZGE^!+U.LGN!#"%Y!JR:DM:Z3DOZ7OI/Y>FGIU;^..W!%D-67 M*BH23^7#0A89-
9+FD6+RDL.7M.R8S*"C^Y4'EMGD!I.I7/W^=N_LCHZ&- MW.W=OOES16_XM/SR%>I
N4C+J)V^3A.5ENJSHTW*..@6"Q!"=+0E;7P /M)NZY&IMT#V-K#L+?
F>0*69F;I0MNBDD"O*QM5HH+X"/YW8Q!DH3&9C.M MZROV(^.0L/7?-=A3R!/#B-_01^/6&9CT-
GE:6(JTGX65\$N)=3L.#IS4D8JM MC^U!1T\$=O-W! M1D!..ZHPN(GUEI=G!QUE;_8.#11
M(IWHRB0&2A4\$;Z6!S\$R)/N0D8^O&L^TLB1*A0Z(M1&-!J2D!0">G<..D%) MF9)+K6JU%%U"CB3@MA(KKJ!
M("O_9<=C8+ Z+*C.?+H V"#^EN*JUP:F0!+D77B>@)G0(6<-+DJW+L2XSJE
M1P<#8L^RHS^2Z0!TQW2T@V&..1Y4A2VM!H:C!"=(M@AMR>1.WT3SWG)\$G?)Y
MN\$0*!8ZV(GO!O24IYI#)YI2I\$XD+ZFGO&L(<@0Z.NBHQ7ILMAZKIRFX;E; MN"N^Y8=;R@;D-
W>VTHB(Y3O<+C.)XA5B=8W?X^;K.N%V84EG9JL<I++KRB08 MQ/I9^3M\$;^..ZVE-8?
3.BI@P#P^C^U=CR:5#HZ_42O>L7EAC7G=1/I/M<7 M7&UOL^V46"L(-%0>@5*..!I-%1A02\$-8)IQM7?
A!RW/WY^I..DI#U9Z0VH" _A I.864W"V8/2RM05Y)R7S^Y-07A! MR72@P^<&I69!..LE5Z!%\$#U/TITD# M/D29-
X3JFU+H!^O:I=O-NBO/>?BA=/\$+LXX>..(G.Z20^1I0B1G3DLM#8!S M:O!U.ZKT%MB9G^U?H@-GQ94;!
I4.*23!^9PDN=DL2%A5 LKVZ!4JMA;P! M9/"HANFEE)M1*..A6%G#(?6JKJ2=
MT2VBRZ@=^S.6ZC!JYC4&)D#C/^+JP RI6Q>\$Y:HJ@3HUXY(I;^I.WOP)RWJ#
MYRSX\$Y;\$^S"=I#YH77Y5N(I"@"@IP#XUDD=I0VH LOX>I3\$72(H3LG:OHP-M-^I P2!-?OY2"?22>-2^DIH5P*
Y2*#IVM?X-?OT@K\$V26H#YME.ZZ<IZAT3H MR4YITJ!\$!>DBI*!R4 E0^..%2C.GI^D!WZ^?OX3E M9MJ.KI!AE/8?
+SA(LM@?3))@A@!AN^EZ\$NY/3..SRI<8/SV;_7-4(HG)8J.S ID.U89(^ (M.H)/Q3(AT%D5^I.S^GME_C81XIK^9@Z-
SC>DGNTPQS;FY!^QL_KDYUS!%7 MH8XBWOUT%=JHVE=EDYEVMD6%QB&827.P/I_#DI
I?TO?7%1N(QY\$^V)&#> M^I.10^4.872@WBY^Q>S^/NS+SNWBS:0LSE#^+TPPD^AA=2&0>GHH.L3+22
MIH!OK(9:4#K*S#PD%Q@HKC1X;3QM MAR2^R=3:!!+GC8X63I0:JL-@(.6TRP@E)J0/(L0\$F7ZVON^XP%=%XG
M!6PN_LG,+9PE+R&C^TT6N952U+ZD\$7I08!"FL3<9\$ MY5HW@VC1_6RRR+ICJL6TND;!!?T4B6>PYI
MS\$8!8M^9B.DTP^H'E<\$KZ!2B&)(42^7M%L3KQ=4J0I038!..3%;4Q#IFC2M^NC<@YF;HI!QV)DZ9U
MFM#^E.S#>#Z9IB;YUP/I+MFXD.JDO!6"E5CGU@5I/*=- M.#TR+PLKG@_KH3#D;3.WH9D8.M.P?
6X472_D>MC009*^O?CX<..K;G@9-IMO-MRI7^?X>3.IS(I_0(LHG%!!^R@N!5#16W!2..)8TDA%3FP7)P6F;NG'-
M!!Y98!UHS.L5W!&^%S(4IG4I(-G.JH-\$@-S!%BH;JXWCK;L=W\$C)S#>.1 M!7A.N@_2+^N.H%!!_N4K.?R?
G(IE#1;1\$GD^UW^<JXUD((K^1K@P_-^P7> M1^5<)"*-<0=9;0^SIRH2=M^ML\$S_LI;1V/MHF;EDIDAH:B*)?
H=HO<PQ>WNXWEYT@^S- <^JU^=S3!;U7< MG+ LN@F%UG6R#&@)ID
I9_'MK;/:IONUYO=W &:=HLOYRW=JDW2.EE M1A8!R^EK-DZ#((QN:8LTLX9PXMJ/=R 7(ZLW*&R_VV<2-6-
Z!*GHX<3#; M*7^5!;36Y@41#I1 !:ZU.N<)3ZT2^PW-U)T10(I&/RLH=(X,>/5=J^R
M21DRZH!^A)6P.Q&P62^"00."5D

++FA3I M94*.8UXE9HARX44--CD(5D<0@AE4,7ME6FNI6R3TE+((2I@_C.28GI,=-.J MOUQY?"2F8/+>C=I P:3=SK%;
<%%H:;HVB%(TF&K @>I<H8A>>F=9K10-+F MJKDG5E-Y=(#W.Y)OY-1EIGS600330%\$\$T#I(L\$!%(
)^F5X*:TOHIXC*9. M%%I+(-RMVMI(H1^4O3Q/#:4%7>>7IS2(6#PP1<0EM7Z^MJTOY9?^L^V^RJB^HDV
MGI\$UINZI 3(Y.S^:U5*D.&VCE(3E6/08(I0;">5"=(8.PRA>7-ZGPJOZ)/ M<7NIGH6A!..^E++*
"IMHP5P\$&IS^I6^CSZ.PC)5HX;=I5TM9I M7)%; MJDUR?V!7^UKW+?>+5RFN.10"E>T2831=?@:4Q!X(+
<I.8D!R7)M/L;Q\$9)Z MU(I-H-50%KU?MKTZ.SW:X&^TRLIGGVNCC^W/MV/IW/I+H=M RB>ZAZ.C1+<
M(=9L\$!6U!>3_OUR5\$D6%6+K<1-3W_-IGZMPF?#R8?W3A9;&_#OO!..?>/(5-M?R/Y-.65NYC^DX=U;_2CD
N3)TKEKE;"L((T/KK*1!9W;M-H;_7>;ZA;+ MJP.E.'2='Y<_I!8-MN%SSZ7Q#@YUJ)>BV8#07H+O^112@PQJ?I@-
HG-L" M.SH(IQ+4P(2^OG/5QAE2%)\$;RF)&C;_LGF)I&L3A=?%(>Z;=OH53;..<= M^X#I!^>@)0?#5^FQSOL"@E%3&
(FL9V X10ZTH>6)LUFIYH-ISQIHP-D"++6VA(E" " +ONE+357*151FL^JY9^SNGT4.6VHU! JV
M\$!L3PM^3IC!4.C%"!5SYLEPLFM3G5%5&^@>:<Q)Y0Q@= S%P^OJ9RW/&L6 M%;R7@)X0!!
<%,R/GR@%9\$1F4^L3&4!+8DH-9FEWM8!_#* MWA%@.I ME#Z M^<)USKGSEO-OSS;I\$WWY9A?
7I#PHI^I3F;EAM_36BN..ZSHQ.F.%^G@(' MW@N"GDC228XI=8=>JN\$YG;M^LX?I>?RI-
/W/PNVQEBM3H+I)O_QOS3ID^M M3BBXO/CX(0;DGPI/0=T7D>3K#%;)UT@HQ-69.@&LYTWD(=;
<0LD^9H^..PSOC3U#/_Z^7 B=L8T\$F\$5 IV6Y%L8*>P0_!DM X6&; 4R+;ADFP;YCPA\$&LP0^D9AXV;TE55Q""^0S1 M?
>74!T^V)DWPE5#H7#(LVM&O(N>9V&V/ U0&^7JF1.0FW;YFG@J37446YT/B*(DTBS<> M1WU?
QE=OQ"=V/7#7Y;KSI94(T>1:1;M+0%52F.?5%2%>0:1N55"<6;3PF@O.JLP^9")HFX&+C+M89G)6<3;_5P-
MFZ2T/PWS1#S! M.05#>6YM;I?ZSA9.XB9R#R\$500LT^H(+A)AR2+G5G/> M&#
I+<F<.>SP&H>TKP24^T.M#&A7.9>P1^D*EB@ N>#*#>\$^NO,M%";./ S^ M>6*?
SP2F^TGQ^0^U.MZ&I!*L5POBR(7LKD^^(F,&@E#)UD+9%-H?IC,'0)!^ M3/>381^H_="O)PGI|CH8Y M_3Q1T-
Y1J4_!T#ID^UX<FF57DIV:(A%4;N^:HO2%\$R73;4R\$=-S; MYPE%IH!1^27X="Z4#X&)U""5;7%KB=+.Y;2R-
S.Q#&7%*Y;3#GB8<^!SB.MDE;O*9N!CR_7VP;%TS^JOW\$AOLIG28CDUM9^@L)K^ZY&FX.B!&2J
E9IV2505;=PB!>GE7Z9^C M9/IC6O<^I-S!\$B^FIB>9+;^?^+RXZ=3S^_H%>\$C^1RUVI?E#S_@YC.OB1Y.
MV=J3.9,"99B\$;\$6!+I^2G&X7A0^-.3.6OJY2^_!U:3^Z^ VY<^UI>8YGYZ.MW!49E;A)Q/O!2=Q935N+92=!!8G@A/
C^)-JS22ECF^Z@L;OLO&N!-=WZEYTYLBN!B^M^!ALRO8^IXQH 76;ID;U/L>Y+;7.OA13+\$Y35
MZH!%YRS;.KDAJMJ@Q!@+(4I^7Q)?L12=F!F&\$UD5RI^T= W6CQ/#^_U7G?A MHW>L>
'2I49!\$S>=91XP)G3%>^1NBNX=8VCLRFTX%OI&^">I@6_Y%1=%&83 M4!"SI/4%S8#V%CEB4NAH@V^63=^!8PR-
714F^0U!8X7SA,#WHEI 7BV2C M; MM\$NTR(I&4)(&LC82&"5C!J.C^BFZMXTFM^L^I&/<^!Q/2\$^L+NJT+6(=I;\$8
MD=^E^3AFZH=@4Y;>93I^I(TAM^55^0;O(T2QHPE18/6I<^SZ M DVFP&D^>O?D9Z8EKOG74R#;/_C^X8%G-KUM
M&\$K!%-<AN!D^<05%87.^!_!TPI_06-I4I?U5<-I8/BX24E+PG@4W^4S@)JX3O/R&>OJZ
M7:519T^BL4EPFBCV/4E3I0.RQDP:3&B;IYZPC82;3.C9M&PEY/P/E.\$70Q M7C)9=#RI""76&%+61I@

(I<'Z#D#TY003 M,EZ02W\Z.3PTEL0U\094MK5#N&3@:AX<6E4BYI2Y;IW0^@,1_4%F^'G>S<@I MB-
4=8(4L^_5GO)JA_UN8B*64J_@54C\$&\$F+ "B4AH\$3EK\$WH36NMJ0
Y5&^O^HEH+;_!HN^VD<^UV7IM)UGG2PE"P>2.3 M/B3EILZ0OP6*L@9+Y-XD-O>FN_.,@:'3-7Q-50\$UQ-K* @4+\$C
%)2%81,TH! MT^68&1.FIT&3%,P8,W4W@U.U!^A@ H#;,Z%Q>^"ZPKB,)"3&Q*9@.()AWM=6
MH,)XQUHFP20+L\$"#TFYMY@%8F+6J@T9+(9*5@X31@E)0E3)@T9M MC\$%36A2\$72FXV\,8V8E_H-2M2I^/?
EHO5ZB(Q-MYZWP%D+(M-V%00 "#9BHO"DJN>);YP3NIFB*EP,*Q_->6M-#\$!7#U+Z>KS-MU65J6;E\X40?
7^)&6W0X?UXLU\/_G\)/,7185ZUB.\$&C4KB04\6!*KKB\# M-IG@6A>NM;)IBO% &ZR.HMT)H/HNLQ<*I+Y9?
%DD1S-MWX4I"G6UJ%&U;43U;730D.2)A\YP7C7NF;U_0DCP^1P92I;278"P/BV7HE
M=3Y+ZIG76>VKM1729N=8CFAI#L#(B-,1C!9U_ILA%#P4)2F+<9DI*=?K;/IHF8M!; M-N%QT\9&*I-!V8OK'-)
ZY*);+M*8V%RRR\$!6OIL%BB1!6;.,MH. MY^0J3=0D+&(C##P.L\$8*F0#"IEV=-.6>+*9)\$A"R#RDY\!\$Z"U-
HX)6M3L"%Z-M@ISE2\XQ9K*E'B8-JSVOWA?<B<K%#X\2.9^1<C&E;?NQD@&L.+;DUD\Y>TB: MXO7
>KOEX^02Q=30I3^@I_P7_S2R92Y_BV5XJ^6M,K\!WTG/S-5,V7-6W MK:@#V4"4X&7<%/&#PF)EH_9)
[NYCIXKCC2\O"\$8XJ]"@P.040"YCLXSGK1B-M2!;DSYZ\W-SW4?D(CJGU7)H6)3VIDDI;W_ ^"5\QDW0\$W??IG-
!XV^ICI96\3-F\DB3LT7H.TC&150@\$?%0.*&@V/ MY/U9M]=KV;_,>92*>+000+
E3^101_FJWQ^6QORT#P1\$F4"JRMNDH\A-M(V2;B\;S.*3D.R'DL4?Y_-+Y1,X6IQCX^%XO/GQ?
SIEIERMMZ2+Y(WI4;\$ MK@B*VEC*&2RY&QI&)19IZ\H8_ ^K\N6\$Y\$1.%.4\$IE9VOPR3545&#ALX
M7GN\$.1;!N"/A%*J0\LOH_R>7=C*H8A\FU\4P\4?>D(U.B+D.'5*!SG_0-M-
0LVKM;V.1V=K:T@!8<\$OEBGLVYJ&YC@>I_A3=U>;4?ZSPIJ7W M9U^ ^+!+=?;.;!+:-
_A_1.T*;SY88W\W_W6%J5#=#VU,,"SW.R<_B\ANS^?PJ7&Y^_7*5PN6V^7I6 MI02!(@)LLDZ(@2E%3@34M(EUR?>
W^T2^5N-WWLS^W_56/I3M@M2#?2QV7K3-MR!_...X_NLD7N00M\$GIP,2.Z/\$M#M(F#16FY*J(0PPU.JR<)>Z.:VLH7
M>ID^IH6YZV.1SU;.:C?6VO..O.+^BZ)S3#G2X4R'M0<5^7".D&0YB\$6K53,
MW2XB.R\8#5/G=U\I\A+PG7+JR^//5.TPX^UK?!\^G3YBO+G%1'OSAF'J6GDNT M*G(YAK-&E2^WJHR605B594Q*
@N)W^EEZBE\$EH'&(3W)3O3N@G_(V0<?%M MQ?FVO**3=9YHOJRN\NSR%.X>P+@OIL_7JQJA5^FR?
HG))//&8PUFD2-M0)1UDJ0_\$.C+)FJ4IGE>#^UXS\CHN?IV+\$TVAM C<2C_!WU5\Y9_G7_\$Z M_!^QXO+L%HI+HV;
<^5BTADe.-)G:;C+4-@Q+ESB=F.(CG1NA-Z\$V)'SEXZ-M\$R=4ET\$!+^Q?D(C_M@#L\$!DVU/W8T\H3%2WY9K%/?
1OGDA7GQ@)G:;C3TD)#C@R"\$<%E MYFVRV-YRGE\C#/#65MN+J)O.%3RT(J6%^>O;/5+&.=MG#+!7,Y89(1N+(?
M<5Y3Z8@%7!^HHI8E=2QK>7R\N07%619;1-H?C#J@4;JG\!E\$478P,7.H!6OX? M3.^XYJM(48R.
M<5YSTZ@T5@E\$X#5C4=YY\9K>J@K)1-"B\DCG4T56WQ0_&2H(T)8H2>>O\ MER>)F+Y=1753 ??
Z7#MBPN9XOM\$4L\JX\.<>#1 MD.6WDCA+08^F(EK+8J1CO=M5U?I%IE3)W\$N/BP&%.C9(OJO.?GY%8B2F;HRP
ML+)(^HY)/LJ2\$::@.6RR^V+TF(V2G?,YMBSTLA!6QMX-!7G!&Q,#^O\^EO&
M2V\H50B^_#9NK^J9O%\$!4LB&*0)_T.W+EP^A<IQ2LNF\3;95Z#1!^_+W='F5 M-XW0T_*JWAK2R6#XA@3K\
(U(0Z> N^;(46HZ-M-2)!^IDU\!0Z-M.;>9/H_H'O^/"_NI4^"" D^MI4>(JC RH9GV?^0(UF\!D5I^GZD\PM/G)/M<^<^(!*
IHJ?XWJ.7ZLOY=/_!@.*_3_3Y@QB9B.RA(D3^0?2D4QAA^&@E M MI\$.E!=?-JR\2%VW6+GIFE_C;N+IUFBM
M+HR4O_X#X0CJ1R@("F#I7A5O@>?S8\NN)JX<^JX\!^!)D&!Q6&Q/P\$6ZY MJ=57/W_ ^56J^JN2YX^87+9,
F^J(BY^_JH_3MB.N.^W\JRRH\PD.DZS0+^+OQ4#T+H^E108=C\!M>=I/PTB=2@+;8^TFE C1<0U85.*F@Q)@Z=IKY
ML8O@>FF\8Q%<^I&C;#?2VLP8\1L@==>.\$J9FE@<%3,B;J\AK6^3L'5S)- MO/CM8-0<+>ZQIU*^&XG*<
CBVFC<INAN@^0W,^@*?S;SSY??=X27HI0+OO:T%C2H5ASXZ+(HC:*3+0%\$M?= MFM?O4?
FI14=6^B\$J6f20W\B*#_!_?(=QJJ4R4Y*F^2C@R0KVR=,@%!\MQ5+BQW M>\39I_BIBXXX^K2%X@^6WP2"
f\6L+Y>WK\^OGTK<"2/\$GQ=2)D4-K2=^@5 MQ.B\$*BC(3VH=1W>E;2K55Z>I#QI\$.V-
+I\FQE1F+DRL/22RAX**Q)_I @L>M-TBA@I7\6,VZS2.^H\$3JB=NIK9I^I^TEN^8VG\@B\=7Z\4ZS&OVS0-P65\Q
M+QBR@HSP^V6%(EC\B^X\&.B4K^83/_KGL&R;ZEOPY\A4=)6UA-#SNI9^M^K M&=%PD87R3#(\$I\$!D1W
_!8@1Y^2-FBUZM;#Y:D5QC4\!)2)89*=&#QNA>_MA35N^EWS;3?
SBZ0#RF*17#93F^J3\$=N6X;D9\1912P\Q5W0\RN1.32.39<+Y5=E(V; MGCDH\94T=ED+>TLKWZ/EY>X_!:=D/G?
C_/_N&#<+;\$3-0* &I#5@CE6J_M782D5%!44K0Q0H20D;IC&HL@.QODZ*;">58\6R\4C6PB60Q% ^"N)<.@K0\
M_/_U-"&^Z9@Z*-57?I>@G\JA(HLY% MU+)UO_C.O\!+B>J%R1ZM1_JHY\I@.U>QXPDN:1=R,@'B1R4#PX_
QDRL>\$<MYH!";@VNN^W)1.\$/72Y6)0P8X.E0Y-E8D)14KN03/<7:(M(D)_9AM
M%B%*55+I5@S8JE/5B5H\0Z3QD*=@.GY5UC.AE3=-I>YSLD-\$8J^T4F#H6-M^K-9BN\UU*PPY*6TKG1^2_-
YY@4=X\4G/_!^L8U3L=I=0=\$#A#Q!\$"R3;J^Q67\SJA78GU40@15G> MF%FCR+ZD.M.OMI9DSH/5H
1*\$SRPD?_WN-M1-ITX^0(KYS@JNK8W2O9R=/M;U^I^_7G<^<9?W_6_A2_)JMERMW\I^?
I.8KSJHEWL2\BKR;TSW\A+P\$B-MN7L0N PJ:1+I#;#%NB618S0; R#ED03\DZ003\I.GS/MO5&&A4!<:UXH;B
M82?!(T8H5Y^NB5I9CKQ)H\!C2-!^I\$3*F RF-WLR@^+^?X^P_*&04WQCS&A M9L'6;H
A\$(_L^LB2!9EC<%"V2^H&H_5IT\+^M?\$.?WME = M\$;0XW_30(1<HPS\9(&LN4E"*ZT95U?R\!D00I>VNY82-!^I,X-
#MG)Z*/B0?4D+TA-MOHQ+\$+6U8^"/.8>: ^Y7VW.Q:6^4"88RC,Z^#Z^U6<;WY3U_+IH;K
M#XOG^YQF2HLP.@4HTS^9KJH=+^B\;.
ME.X\$#BWB("FU2N2XOM0M\ZWD3FTK7BD.SU"C#7%.1M#VH%P*31U\$87C+2N
MSKJ#G#_IL3H\$4ZV5;_8\=-LWK^Z>/Y#4139:H D.F\$,*^@VW\+4@0G92E=;M)34Z?C9M@M,1;_!2>-
TQ\GRQ^3*G8-GS+1VF-XV\IG4E75^FKM-MM#(V\X\I<6%"NCEBC\I-CRL9JOW1^7G<^=WHPO'-
>^"SKMI^@SBJD 4=@.M.C\44W^""T(GV\VR^K@HH<^W>:F9CW_F)Q>8EIO6^PH4>0409.6@^E7JYR'^@,=X-IH*
(.K8+.B MW21J^F*1M@Y2H-.9V\5A=T6JX3E-Q90FD@F4_@/L)X_KG^6HO*K\!S;U9-M2+2D_P-
ITLM;\$N:T5\>SND?+C=:O> 4"ENM\$01B)=4U;_9/H\$Q#K5@7&K6 M^A^U^"(IP=.?)3Q/K#=#NM^6H65G#W%OC\$
(3J\$74\HGW_0LIT M@*N8B0\LY""JVE.NHW5X4%_(NXMTP\@90P^T\$O#9=%-I>f7^0H^G_V&SLH4
M+@=KE=9UI6^ZH\W\$YX!_SK2GB,U6<&Y&)S_;C.H\2B6_#=5) M='9+1.%HG<@4(P.GZJ^X/EAIN0;"??"
=I*8W=.%B#BZ\$.38V/ORVV,^/M=U9KR<#FRH^P^5Q4_0IM)Z-*EJ%TNR3OL-C8K0V;(*2U4*
f\X\N%1Z\$2CS#LI_*GYQGVD_-8BK\WCT\X2XX-0P@FU9\$B6D.P+1+M&N\)+E%J-M)SCA&#%RR_"
<28W>""NR31YTH5J\M;O\17IN^RDUZ7 MYCT\I^NOYAL=<T4A\$N5@Z\Z7/MOZB;BT7%8#(D(8.5U=6BMC\I-
G9QDID\02\I(2BX+G>,EE?0S)D+GUM=QCZK\I.P2H%#WX.G MF83^ALH#VF\U6^0^*N+I%
(.BLP(80ZXK^VCG,*&-?D1*(V^+KET.Q=ZDQ* M&S2^+>0JK3V^7 MOX;E>OO#S8G\SPM/E.D\$&VTB#1KW-
EIW;XLQZD4EG%VF,1NXW?VK_6F=2I M^GX=U%;:8X/GH#87%"18=")"KJV^18&0DP&1-8LS0\7^Y\VD\H&RTU;.
M4WN5G\$T&/%&/_C5AR7IM,%;M\$N\I+C1_OLA7_Z8_EZT%-Y;"9EI27&>M)"0EE4^XH\$J4Q8KR_Z>_BQ^"ZZ
#BS7U*8.CGX%%/R6\$+B16;2^"JATM_I M(*=5^GL?24T@>NS^W/_IC*G(W)IRE,4L2B(C"9W?
4PT>AE\NZ3\$LEQ)_B@_M+I@IZ3W/Y/E>@-KUJCRD=B>Y/L<!--#3>0ND1"-CH^*K"-W#C(@BIKS\$SR MUB;_I-
C0D_2@Z)@T5@E8P?&9(6BS1V9@\$.%GWH5_.0GUD%YHY- M276\Z\CSH5.QF8>J9I% 5A.X.MY?Q17^I(Q6)
I.57^O<-RXPED7Q4^KQ^F<%M#J;"SIT.#D5BO05@R=(;<TZE_.5PN=3I^_S4\JE:(9P%8#(=Z\$0_!^07)
ME:PY#\69UL\3D\2;fFU4/5^<^!P@I^D\!^O 9F4B;) U4H453OP!\$2LL&(2-M^0==#&%8!\$S!@#52\FIH""#Q"
<"FS=0M;@T)K#B#B5I?>@V8&-%>%)J6@2 MAM;UIW_BL7\^F.O3Z_M<0+YWU\^GTM;V%
;%H.ROM0>VH2,24G%YESH\RN M_#;_I>L%N\$'&^O71_MCAZ(I9?;=DA5_M\+%^O;3=<;Q?^I%/X-#NED<;2
>K#SN_=?=#)FS@284<_!\$5;_*F.67.62H"=2X4&A:ACI8AOWH M#X;MM#;Z(?=>125.FPFC3P/EI7I
fT50VI98\$A1>NTV5L;"E"&A='E@D-CX9;BOD^"GK^2\G5_2YDXF^15DA0H4EP7H;+;@+4/E-9IHNQ6C-MMB@2&

!>J2C4M)+S%##3M4@I2K0\UO%"NA8IU9FXP6D'D15=D-Q\3-U&D;4N M\$AN_3+75"-1_F/CZM?PQR;?+58/J585LP;+H4&I5@E9 X2#Y!2\$Q;+U(N M272"T=-KG\$F9ZL&H;23=L4R8V^W^Y(T;5BZ8\$11R^@C\9V(4+CI:@)MLD%G M61RQU;V?Y&??B8UIP<#XVB)3B"*ISKKLTB6K25H^"18*6P@D\$)(0)3#@2 M\$FO=)_L^&IAZ_J&5-(YE>2H4Y7D=%EHL)*@4IC1BA3("I|=DPEY?ET*.A2MDM-)6/J72+3+AF(EIAP65=1Y"B(E_62I J^ZEXML&R25I>&93DI%+4R4YM?60U@:/C_NCU#>RE8C(YKR%5= 0218^< \ZFVAJ4PLZ=QL?'-I3<9Z%.,<8 MK",U,3DL_1(^?IM8M8-806\$5W0X1Y\AUMR< M)'5R#D7('4>I=EMO2C@Y5+&+8.4|+>"|7\0'Z8V\ZK?V"U# 2.RVE_0AU%JT0GM6\$VWL|B|@&;QU<;UV@-#9H&\$IX69-ZFI8(XN_X(S\XL9Y>5 MOYML2B#-E<20 M;#|+ET\1>P^!02C0_!&Y>Q=6/2@(|@CH@B;=F7'P\613Q\WXA@9-4>+>VR\0%AL_U;D'E MX<7B\^?9|= "7+3>8)\$55)0,7C-!OK(7_782@O)),*1NY4;|U\UJ7*=N9"2U M5<0\$?+>G6OT(%FM9M@/)-+NX(DDI_70(GI8-42&,T09|F(X/U>LJE)OOXK5/K*>)&YUC%E9ES M/H_M4F>RPEBS!DR=Y;B\$<&<H8^TH&;PJUE9H;B;_L7'U;#&+4U;I2_58 MF>G<#LCHW"8#Y@H4@K-6F/4V;5>6.@.@O%+3H;|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|S ?G>).QBR;\ M8O<8D9@N&J(T\$;AWHA1+>|YY^Y" M"KX. =P@!5HM#_VY=B;JB,TR M&48,V,D\A4*B%&,\$FKI@H*1C1H6GIQR\X MZJ7MC@5?740_103Q+1_6,R\TE'46;ITC1\!P%;1U@<\$447Y"Y-0.TCT0D<M4)U;GRM\D;L_H#G/%-8K";.%^EY1Q3;?TUK1^#6C9GW\A/A#4#;DDB;_O?N- MB6\NJ^YF-?7W^TH(OK+RSGIP^5&M1=1(-&)*AW5J"(G"1;Z\O0AV\HAM M/7A""+D)!7-&(R>2IECFI\$PGNQ((=XN=ILO^=A-5N)\ZI^CN>_U89.6 M2?;E>"K*YS)&TS.G?0D+M,JY)"<#;19GAPC9Q3\$K@X51)XEX4& M2P+OS>62>1\$00BVDH\O0^1U\3Q,71/>F5\^2R,G% MQ5;_%E@X\$Q\$Y-O/OS@H'R3R25KU+|OGR3/EJ8&(JVEY,J!\$'&C8\$M-502 M;_581".D1L@>2(PRM)ZFW-OE\DUY;W9\OTD?2\$8WOUNL;WKYZI^TOX;+?OI MW*7^I=7L^5J_7IV^YO%?/WYVW#UTFY.GH083-M@E,43I(#Z;SVWF;+I5MG MZH9\$30=IAX#CD<>|DVOJ3\Z.GS/=F0IZUPX&8#@;:U%MJC,*Z@R<&.DG1W;" M# G01V@;|Q)O Q@|5D\3L+);%?XKEB0-E(47D=K'Y6;,,_O%J%1.'(UP;IR;TFXZ(@)O*V>WUD-8&CHTVZ7S*1>6DYR%(G/^2O?)# #=(G\$2I8JM MNWPARG\B7MCOF\$ <1_=@(>G2B M@2\GOGA=R JHV@2HMB3+;8".HMD3<38+? GN1QT@<3\JCA;W\QLY0)K;1* M,2KBQDIRLTE>L8J*7!>OK,MU.'^TAT @?44UFU_L^IV0\7'C# MC F_-ND24Y&G".TVD>/_E12X;|>2^1\!M2=20+Q3@;:6%53.9>NMT^6MBAM M\$9(/&53D2\$1G_2QE+X)WWLAN;#Z-U>|W72Y\J.HOPS^UO\N0;10H12\^&+ MD84BA&I^M6B*8S'L;/L3T8)6UE/3'D?;#EYPO';10J24@Y MIVL;9? &""ES%UT6;70+9!_Y;/I-EV*W3TEN<\$G)D'+#R=.)ZX#XJ9!(I% MVF+>\$5_!>BBE8&"9,F*VV=8&.;\$F;#JNEL\OM? O'CWAXVN9ID^??G M=AG\3WIT;#G\W3@9,&N_H)0H2P F;@<_D0NXS4%E4_*NCEUIF*3W(V7MNV"" M5S)#9MG4\$0@9H@P(FDON,0F2^5J9^PV0TRIKOX^1C2FJ^7ZXD5E"Y\$*/4=|QWP1LM<=K\,MSIY;^SRS M\7LI?-%0^B.CYQU^N5JE3V&%SSXN<=,;12%+VIF0Y@ M;16O/E|=UKF"/R%1DV8;+?V\$J2;,,+S\3.8+&K M\20\$QQ28D)%K+DR;4SE8?2>5B>#HJ_7NT'L>VN#7_!>_G;JMG8B<&XS MB@R6\TV^2>00(P8@(V%1AF@UZY;RIOCG3QM*QRMUT5;"\$|AWW3UG03KAE\$\$\$# MR7?2#G(&SFD\AG\N.6JR"1^5+01Y00. MCLY06Q@\$QDSFUG"TH*2N?;J=@Y2\$-SDKA;ZUP? JO%Y>U23KZ\Y\SPK\|/+/R15O-4GCU6+Y@LB=K5\O5JL+)|924.60(MR650WM9IZ;" _;,"ID>.6N;U3;4GTER;"I4\;^Q&5K%9_*?G.4+|IVXU_ MO%W;/I+DZI+_@V'9\GF\YK#O)LR? N0#^H^JOP8\XFVYOO4D7A*&F"JZ(B< MCG#1^DEY0@_J%D6R4A; I2=%>#^3/>)X#6\HY)Q\54IEU+/'#/*CW0\$ZK\;_4^ M^H Q3^J4*=|&4<2I6\38WEO "29(+D? #;"B;3*7I/03PJHEJ\U5^FAW DA^ MM%\$\$\$XE"0"O_U/D@JDYM<+D(8(69B)D9I&8PV_%#M%;IA8(NK57ZJ&0"L+JI M#IYC7VX&QF14+I^A85QM;L9(<&@46&^LM/25R\91SI/\$3;7V\JKGQ1"/Q@_I M7W\$9%X;59V? KHTL"0>FB0"%7@GWF;(WFT);W*F.U433^YN\H0VTAO\UO>| M7.2;E\1<K=0GDZOM_?B?N'76D+U_Y; IQL&F5Z\#;Q#;F5\AJL^T MI>T\W^_!9\T=J9H&I<5TQ+|++\$2)5%N%D0AR3>M+Y\R+;_F>@0\3L&O M'@8=|T#P%5-(1;_FC+|K)WMZ>|8IGQ@@5L5F0V1^#@69WDPFW&5+(S#_L9 M'E->OY^LZ_/PEX6LIZ?B\N%HNK\4T6^2_+1>KU;^7 MLS6YLN4FG)\$Y%.FMKHC5,Z^W8"PM*+? I4\$+G6=.;H@*U3\$JHF(DXNC;I9\$V\K MK8WJ;1V0J5;3DM\;291"?-V;|Z;K5*XX'^|X\$7K\^FXD"D@*"|S!*TC>;& M*4DGO_9M.9HR;\$GY&8H.SPUL;""W#ZIF3^PV^+6^9ON7Z;9.+P>V%0D*3J MQ&L(6&NWG"_@&090J PC;02! I\J#;_0F736/_N&!_09I@|'.-W#@>23?WM MZBEA<06N2E@K"-A!"\$A9)W\HHLV\AM.<&B'8;G4EGT5\NCN\$ <7Z\X\7B M;GE"FE4T.Z4A7"JE1_1A4=;S(D\$P%-8X4X\%#HA\I298KCMT9.C.^FI>L+| M,20DSG"#S+|>.2RJ;'8* (Y\$V8DD4W=<9FLJE0JR_03@OZ"0G?K@C@^_NC% MT)DTE3WEJA@.\$>U.VZ%|(8X_ IS*MH=@HCD^4_-FOPC).P5\$\$\$3C#00CA9 M;2JLM"12&92A.^F%>Z+=;3 @SFMW7\A1;5D;58;DS)D&RC.LK5SBG(6\$JH@ M59W)409*1#J6\Z(MW\6Q#=#3\N'87JS#Y0G+8NN/E3MLV\7Z^||=?OW(P;T20Q8_)3(#R)H\G;4 J(4D5@XQ^N_-0QU(E0*;P_#U="K M2;4Z360^;|HAYRJ\$GOP5H 3L;9" \P7B9NX :A;5T24U+TD_W13E\$U3_GA9U M@PQ6\@;| <|_K&9QL>\$7(&H?954"@F"905L=|4#%>MR\X_FNP\B&&V;P M<@_MGYT%M6;Z;TS6*209HL(Z#%1_1)F"A""91%Y+%ESNW*6P<|_V;LM&"CP50;X7J_7'RG(/H3@'A?;CD9Y^CJ43 M@G;M;HD*@\$PU\$S\YV)Z;Z\Q0C!>8\|\$6"F@LK3\$7.EY*5T5RF70I^@2)2CLH MG\$H9Z/2=R;4.DW(G\AA;MWB\B M+^M5O89DO!%<8E" MA9F&VXH) T;I^D\ MZ8J5K/F5QV&4GH%)|A|^V';6'F;|>G\G00I&;EVP@U"9A2B0.CBP71\$Y. M=|J;E=@Z\IEHHB<XN;(&A3;3=1;*_Z;_H\WJ_#|C@_I("WB;LB^(+S%9TK M7VF7A6)9\Z\16\ISOQ?29)NB?G;|(^|6&5/WXZ+.;@;#_F/6;ENG;A@+^O^E)OG7OUIP;,,D'8 (HHZ;4@F9@&* M=|1>AD%\$MU3\$L3*+=Z*P;PZ\;(RX;FZRY2;DOR %P#(X#BFQ6A;-)(3 MR%?F7/K4#%YGG\T 7)Y^7'1%'SD7L;RWD^_C;M;|?_G)>K^AY?KWU>+ #Y_ MGFUBH=4%.H118J\T- 667*"3I7M>4P\6711V+T9"\$THF9Q#TCIR+V^IML> M_E;FJRJ0_"Q_K1)8K1?_G*?%?+6XG.5J? ZOQ;W7_Z)=D5+WS92?_F_5\U M^VIP_6EQ1SW)-\$.2U"C#)P32JU1^LX32Y*7<8_&ZD744CA=680HG4\$<4;H MKL-PL16;>VR#WON7J2V"[MYXF%KV\08Q\$2(U8KB*;N=0ZQAM=>J\!25\2\;+*QX*81B4JY;B"[I89\$2%W7 KZZ=.;&J>3Q/_=3ZJD4?0?;_M_1L5>BDU Y\$4B4V"=|6\4NR(0UP?&_-Q-Q3@NSFE1L\A\$)6;_P/>+J_6G MIV^;EFO@U=|81_29N_84V(Z0;K)EB@QPS1?2KL_7(DY;96;16<&GUQ@/_M- RU5N&@OSI%A|>I7_^CW=>|I\ZUIT!B%2@*BJ(+S/&0*36;KE5='=@|_I M'SN;=114^0=+;6Q\OPB7EV'^;I8_XMT+S&\CN8(P6B0VA)RA1(0;V;_Y3Y% MD0U'UK%U\;YE00&*A1#;ZF.C8\? WSS\I/^;3Q/DF\$S\$4N=T;95\?_E.%6B MCM8R%KJ%1W<_=-9P<@2&U?I#;QE8V?<(WNKU\|Z- 3\J\$""0&G\;Y;+Y582 M2C(HINL\SI\Z\$A57VHQ;6I"^(^5/X_#K;VZ\;5Y^XX(HKX+*9S-O%X; M%W#%"AGIRB7&Z\|R)@C;2\I\3/X6OL\4WRFWPR#C\;EZ MIV=|

!7!>/*&YN)Q"MN3,=,+,!08|=H_ ,D+H_7&ICZWMI>_>VE%G"VVA%,Y^M M=ORXWK 0/3FNBH\$)G!2K)#HC.RG^|
<_OA !W3@AH(>QH?#W%[>9"[* 7 MKU 3'.E@ B9IN94R%V/,>_ QQ+@&:Z6S15H!C8^#J
M5;Q:QC#_=:GX@LOU#%>W?'">@E0F@939@F+5H'DX7"?!:/%\$XI.0-BQR#BW M H.@H94H1JZ?A?F'Z_O2|E-"
<4E3QI-U;6U&GPT1+30W!_C1&=YJ'ON60^MMN!49GT,IGYQF%BG@:(6;4TTIG6JG\$HU*\$82)HCJ^WAB"\$?
+4N=VAUV0G>HB,K_1"5+5K(&VS%A|_O\$)X4!EY0D0VL,3X8IP"6<0E1&IS^<:F6SNT M28J_N^AXIP--
%!'^P_*.00+G/I+W^5H\$B=|26>4L^46W5@N3(1*\$+LS(9H& MB=|4L6GITB;7<814T @K|%J3;W^:TPJ?9EUJQ
MF:H&/^)%1F\$S^0J2J*^|IH0:0A1(M_WG^K)39Y8S.Z-7|JB:Y5FHLXZ?K5;+M/GMPT*UBY)IAVB+X!GGH+)\$E\$)26
MP+/3W%#H7HFX|>HH@B?NV;7!YNE4VFQ2P:\$/T5OGXNGZX0L3?"I,>+"R-OS@
MGC8D9@G!;1D=OZQ%MR2T_6N_-QYI8'-(>)F--?PQ_7,=7B62*Q+?&I@UTX MX0/*!#E8"RHYVB#<2=")1=HOQD?
TC4^ZKK2-.WCH1(?:(KZP3L_!*62UKI M*YZZD1W"X_9,6*W0%\$;J#&%;I;!&@&1*U!8|W-
")R!"\$X);I5@TIC3N^<INBMLX|U|U'_SQ= *\$#L#Z06LX/LT0_)/(A|9|_OEG6|")>SLEC. M9^%;CI=%
!>K(%DXODRHFTR;\$.= RS"l8K#+;YI(=OOR(C^3#8&Q4H6.#;G=
MA4+29TPF4.3#7*ZY8A9|KKB+%QV|'VX>'4#L!GW/+ JIC MI*QDL-X%\$!_D\$%V(I9G\$<&>|S@-S-
_J6=#2X3J9J;=LB#89%/G_0.EMR MNMT4Y^"U\$^B%3JIT2"/(5L6I\$)!IY8%?50RMK\$|S!WP"15C0@/G0=42+\$UI
M5B0H%&|2,&W9>Y'!;_*OYXIZR/%L;&V6Z?@:(D;ZRTD"PY#JK\$&C/5C8@Q
MG78W5|3#8*CM9=#5&@|R.L%Y#!"R#|J8Z)+O M9,=VL1T|*0WRKINJ8 K;NMVD3M,>8\$5_4UJYJY
\$\$\$3+0;E&HM1|)I_98 M.IZ!-N.NX%)88!2V% 56|B43;_:%@5%;*9Z!-H|+"F0DMLN*_@C0+46K;_Z3O/HTU2 M%-
/ZIF/26=3#G_!%JJ90(H>RJ|'W419@)@H(IVBQ<@-M|,3*8A)SE;HT_ M3E1=-X5D_-^6S|U3#FW?QWF'V?
Q|NYTPSN_?(TUIV6UPB_009>I5G6_G^M'9FBO|G^N|JY')R^W\$P\$|MH.?9RE=?;ZZK&4S9;,I2/G01F7D#RIK-
H70EOE;N4R6 M.DH/66EGE-&*9I=VI_*\$=O|G1R+51T|'ZH6'X'ZXON Y1RU# JDS.82@ (M49(.55\$F9!
<|A.>:431.-<5IX977I&/6.5|P|VVYC/OX.K?/OXJ>Z8K|@_ M'_?&*RQ7ES7=B^AE@=>N^4S&#5|J|C.(F.
<|0PG.X(&T,78J-NWCSJR'-%8\$BD^03R3"REJ.DSA M(\$L0/"K&A U-#K&&.&P^).+T|P VCG;2|_@%|/0IQ=SNJ|ZW
7IT^M=)K+ MTT|Y#G6|ZJ2-23L&SCE5D|X41%?KOFU'ZW5*|72K*&UX@;KY0\$?GBSM2NO8'
M##.F*3J|M76U^&\$#6'F&A)A8&XS|YP.TF X^9.A.W0|MBM=N=B9V^3D8HEK(JCKSP^G
M@5HBD,C=6(Z0TAUZR_9:9^Q@+2Z^!0CEHX="CLL-K\$+SL\$@U%>N8S>RW'E1 M=H>OIV_+K.99&>-CMZ"D?
%A2)G9>3#&3JN3 ML"|Q|'B_+3#9GDD|F^UL5NM5;=)7Y;...U7_S#C>G^>)U/...7MZ.CO=<^
MD(R&NDU>D|VDV)21_!4IM^V\$#4K\$%EB&\$S@H=O546N_ JX+WQZIGZG^QRVG|_KSJ_J@U9D
ME@D\$84P\$Q0-63BTD|432T<_0NN4?^47Q*%(10@/4A=689K;|Y|N^&H M^<0B3>O!
JG(A@?!"AG4JW|^!&8.MR@")TBJ8&2_*|S;|=|6!^77^&&>" M:T"9.TD)HLC_)8.T0?%*.@)A@TW/VL?
=1.S<7U4_G2M;E.5C#VECXI.CQ2K MO%Z\$^>KM_+9\$Y"=7L2U75!_JH(U7M.N4R"D"R;J&MD)+Y=?|+E#0LW
IUY=\$P9 M_Y'GVG*HDPZ6P"5#U8;|T1N,<7VD:4GB*6*E2TD_>T4^Y??RN*0F|*2?0'
M5>IP)18DA.J4.NM95EE;4^8?RZ5|N5\$S0\$&.1V#J;@R8#N|O\$B@NOK;WYA M?)32.
_9&.Q"XR0TCE"2Q!*"XEMFT'KG1A:YQ';V;@4;@U5_UEIYWD.VI
MRX4UJ;3"):"7Q)G#@+/O);'PAV3AO*NEUR=EAOWX|H,OP)>VP\$9W05A-(ME*
(@74.TM;17P9|DQ;J0I\$<Z8B(LA-N=BPR.C>28="22K9C8V1 L.4CJ8T-I3ZG1W0>\$
MNV5'.00790|N!|VH"4F&%|B#E99YR8KJ^DIST/+C_@T9%F3#ZV,ZB'LZ/^0) M-
K.2AA2)P,2;*)UO:0V"IAE*5L360ZQ)^SZTC|N:Y%386|0S4P@)#R|YC)R M(W.&:SS\$53M#5\$5DL
R.XK3_VSSQK"#E|HVKS@Z60AY,E5. +9_6RSR;|/+ MRPMC0TF)W|95#9D*_I8X84.?%"FE3ZY'R-VN/4SAT,C@=).
(0>/GSU_" M:%D3BEYOBH\$KJH6I=R:=OPI MYP2?/BH_(L&GCTHF8#9_GM_.QF|S4%|7_Z|J|J#
|YHT:#TP\$Z&/O2|T7K'G_X^=>XO50|J+|=9V|O\$ M\$;8/#*2Q_4B9W0@GR5IVTGBR!"21.YG*H.TP4P|Z|V|LBB!
MWIP.C^OI/8/\$L5|HZ0|/MJJ<-FP?X?(7_'W|X3>|_(IO%O/U|H6%)=)+8.AY| MDL1MY+IV^"L@G^9D&)"P7_)0J|=3/%GH-
D96CU|7C=5|=J#^'PS+&|M+B1G M\$F,JY\$PG14<&\$^9Q89'&(7*6,%JZY&'IQ\$ZV93+*4'X\$*6>)W(BGBA+?G^<
M0%#H0D6VZB7N#1C&|2*+\$.&1!W:DT9EGL5E(GEP(Z.23V5N9QX0?5XFIY00RB
MLG7VF34DV90,!*\$S_5AR|8XI6\$E!@6RF=; KJU_#;6ZWG"5|ZMW6";K%1
MD(DQ28/BF9RCP"6X(B2+6BH3)P!>^K>336V="C|JO7LP/NLT,K?6.UHLV+H MH,ZW(?>>F'8^1K";R|R,
<>UGUAY|IF2S9*<\$X|,5/&TLUIZ2,8LDD\$%@76)U M"A,#SVEGEH)&9RT?|=#3P;5K4|QLF!0V1?35K_WF:MN-
F+E.K M9N=/??Z0+@&(Q0RQ9<|'^5R\$Z%|H|Q<|9RS+1E M-?
G;JF,4|D^2@;H;=;%K5E.K0==G6W.6|^5'Y\$SUDJ*|@MF8J MF0*^KFF_R23(CAMT#KQ#|1|)#(^&FGV(>0.5C* M8^?
KO+U?;R\$%\$/%O;_J2N-RF@#^G|H_ R@2REWD.F0J>U+E6_(5CG\$^CN-GKA MB05&1L+A^EHT%MI8
'COXMY/++=G*AF39Q|X?3N)SH"GPQ*8,D94|AUW3IU MWG|F.DM;=1H(C&UNRFQ=CM13L GZ%;
AA*EJWV!:=AM;D)M.>\$SI^0E M=R\$9Q8;I8?6#Y.L=XX\$V5|_ \$0/>M%C9B(1*|KXF\$CC8+MQ^L4%|;UE?K|/
M8^9>Y<8C-T#KH|6GRHW|B'BZE:(_85Q_^(10.0- MVHUNZT(-S5;IGV\$(VAHB8;|X<>E!7\$7&8"i
LF9|JNW6_|LG<S+&M/30;Z/WA,7&LJ"=@3.ZS<-U3V8O"O: #+E3?+GB\$&(\$j9;,(>G\$9>M7^>^I
M&AK1REV)U|Z2WER_*DME+>1_/*^CJ?W C,M<=<5@C=D=0-#9%J&\$G3KML|/
MT3(ES/37|4|("CPL0/G9Z0|HP&7GVL3|HO>V+\$XF7CMT9X**+0.8KW<899B M_A)#U%U""7W_X5-"P*\$I6S24W|CZ?
X_SV6+YS_D*\$JG<_MBC;N?KI"XLM^X M0>;2C|(^VUE.UVDN)L+OY5+\$81V M8T+MJ6|S^1IY21^2(6,<+=
H+U+C7O1=DJD^+;R2)%BTWB64N7#1 I^81(4BV8R'E9@)(E=.62;>C84)8*\$ (Z M(I_J.N8P^D9E)(Y1=-
M9.CWGSCUNCGH+|PI00G\$+^17X T.9W5T0TFWYQ| M#_Ia2 DR.)&S4J^U5\$CS6I95K|L03KV\$HIA)
M0IG\$8^OCZ'%I@*A8S7I7;GK%"1+?^L.N|G0OM+>TB;3BD7C|D?_% Q9 M"SWOA&X8P/QLM>7I=H?>=)
2DG(SC#K+.%&Z@KD&P\$9_49N=502W; M.^)|R9H;I|1_W>N=UMEC(BOU7)|2|/U|?
^OM>3^!00^UOUD6>MS8FU4 M0?P((3GK=\$| GWH/?33+7+N+3ANQYI69NIP&4Y|3>EF"9JG3F#Y.ND&LD4
MD5T8<.5MH5-66=|A.BB^C\$/AB.4I5#=#TAN9(6_F#T# MF0.(4)R62F>A6E_GDV/E%Z*W=DCI8^4Q|Z8^!-
Q_KDB%%1ZOMP5F|8\$F3 MIY6RTS6|(-%+@-(K*|I4^0.NZ8|6'+\$@^3|^1@|RJDKV?S M;KZ^D^22&N4+P9|B-
I(Y.SEG_KR46)#AUKGQ|S."UC/P_V4|1.|PH|0F@ MY|Y>K>E2^+7=3-&X?3%=_Q|M|@=8\$A6B|N=I+HE|HX+.
(4%);DG6+3K1.&N| MU11RR-M@JK4N|@^O^V^ZRJC+4C|5OG|6|9;J^X@7M5#8DBL#3-.4;D<^I3
M0*Q4UCIB\$.W30GL0_*4IT2&L9;ZF1SX_A66L^HSW&68RYK|JK(IJ55K6_SLLY M_U>96X_V>0|EZQ00T%|D
M|HK7|T.D<^A2C9KB_7K|V7^66X MFA?YE|SXG06'\$3(&I309\$D(IT\$KXHP/4>6!(V(?^<^D|A|>49674&4JBS'T(0 M\$&
(-CM;|^1=ZQZV,S>&U1.\$#0NLLO.%5PN!=(^RVBK^<=FV\$1 JW/I(0M7:0B!^BZ?^W4;5A|(-+F6FP_"H?A|JPB^B.*
MJI, 7CYUNH?AE9TF-U&@^5|07\$*E'8&-D<&&_S^9N^I?5ZQP/C_!%LTH\$ MC"VI30#XY&U|+
PWHP.4P!@I^UC(3DU*^C)H|IT(CVZV7E.NX|J|UWJWPR_SJRW8U)=*P76UHH29PM=,A\$A
M&H_<)%\$.CCL<^EGRAJ^OC_.|833|H_|G|+B7Y5_R_*Z|I^AL7_*C|Q<_ M^_D-
QKL>XYQ=QQP(X+WY)AFICSA0RIPT40@+&N1E72|>1_AZ87? MF_);D+P)B4H26|2|I5&*23P7.D@LV(<6W="?
D_!|%@Y2K|Y_!XW)W-D5 MY|LC%70/3DZBIE_|3+JM+OPXHO=2MXUZ/T3\$M5HZ5|_0.8#1^8#E/7Y;
M7GPC#^#^8;X;@)R68QRV8O29CTQ;VSDV M(-IC97^8^/CG|KI5U09E(^?6R@#&ID&D:@3V^LX"RZ#80Y5|*U#
(^>O|^>8?_H M3G>(EMU50HXVYL(@VYAJ:9V 4\$@YVNB D^UH45J7_I-SH.D)#QLY\$^|X| M-
!_%OMW%LV_ZC%\$+6QOH(TA).N_JU"P.22;/CFN4#W?Z^0^8|ZCH"RR'R/8A M7(YC|1VRE-K'^+
+26@|N6|+H|+|NZ=HPQ|S^_*A|LHQ\$S%&>V8;XJ_9 M%SM0&H|LW5\$N(PJ0_.;Z"YH(3-5 (QI&"<4|K|_*#|@R?
=/'%3;)D5SN M#B=W|IA9NOLZFP@|QSI.FOSWB^0L%*P\$C2|=|P_LP?JG MYEHWOOF|T0KPS8Y,7Z>BE+

("&T1ELC.!MIN3+!:^+2=G*8=MEG_A 3T@X5'2/MA4B.X>/46*CNO'_P6_H7M=!:80!9:%Q>6",XKI%MB9%+!)!.>&
fYSV/9D;f3P M+!/^FE0I3!LV9!Xf5CTU+LE,2IDL,&OJ7DR7G?#.J&\$A!&/SM-O#3X8!RWX
MV(5!)=Q6J!0%+P4AT9=H2-(J!C &8<^V*4!3VA!N@M;?"=W.<.=J(UVA MZ)'%4-
&05J3W*8*OG3B)6PA9:~+U@J:C1&U#^!Z!JS"MH_4HJG"MH(H#3 M\$^O G"DQF3JN+XE
fT!&8*7M(#S)*VULK&0#Jf+6Qf27K8K9fV-Xf!Y8 M@J&Rf=2=9C"965")?#f,\$GD&f(5BTfV=9+G7%:/+!/*
>fVEYc972?A!7,~M)~!^!U#fT4D (/ &9 M_LGf%5/@F&:0\$SKK>)T#U'YPW:FNEME+ @>LEME'&%.fZW='2;U>?
OFZ7%Q' M-7600C\$>@?FZ;Y6CA*~@~\Zf)4E3BLONG)3_0T0>GPEZHA&fL\$P^f2D)%G MHG<<-
NLEMfP",8FR\$H:1WSQXF\$"8f\X3/D\$Mf13@BY@X@)M=HN*YGL>:(,B M<2@ZFSfTCfS*2,HU,PP2>7\$E!,,fL5fYf
fQ<8@&@7T3'85SMPD9YQf5690RL MQ~&ZQJfMfC)H<fVf)=#S2"9@T:MR!NF_V&AU TK4E!3+~A &f!BfN5-B<f!-%
MLEWEf!RM5K^67M,PE?ZDfN_9X'+PBV38"3256,J@ZOfD(-*DGP!+U",6>7T M\$GU3fVf:.*9 JBfTfGZf17N0K=D-
fHOfETNZGH8'46Qf7H(=M#5N0A\$.L! M*ME:D4BfK~A>^E+!64OCp->fVA9+M+ fAYD%9K,fV0f7f->YfN2@DfLC7
M2fYf:YN&f!#H)f!HJ?2,9G.,?260BfR~fHfO-5fVLCH6YA?U?^U^7fJfPf7Z MDHS&\$?MDf>K>5K/4JR+9WT5Y
_3(>L@Y,T&9!>Z>EB28<@*/#fL DUfH< M;"<04
=&U3&3ZWU04:2Z974S0%/4>*ORCECNBQ."/&'5>A+NV%L'3CfT_1B3
MZU2RZPZFSfRWUSDZf1,G!&6MfE23f7&0X,%:/+O%Y^&3*_W*S/PKM;9E +43_0_V)U9;*_fI_!9_%OJ_&\$S*76f25f MD-
=3(&fVfL%*,V#A!fUZM,ORf9A8L,N^f7WKG8fTTRG;N@*9U4YYEE=MAEQ*#f!HH=S9N
VSB,fZ7,> <\$VX2G%TfGFFX7D6W)U:,5T'9VfHf7H6O5;9>P8R'D64D^T88T3@ MV252fJ@f9&9;\$N?<C.QT?<
f#F.)QG'>Bf)Q>&fB0M,X:f9f6fM=@Z2HSK^DOO M6*WSD^.,MQW3>M9!&=&L'UJ97'_ \$#^OPf?YUfP&
fMf5>@CKR^6:WHJ9TH M&Q(f(fAf'X3M=TA0f!)WDQC,(<7Qf3Nf<5.AZAW"E@UXGf1WVJ?VM,Q2X#fS M)4
E:6N4HCZ49f3QR06A>AYZWS>fUfT.C"IG<~9fFf4=@&7(N+;^f2C",6J MS@=04\$P24"26C&fC62VM27;~B?
TZ2>@P.GUL+H%^WY#^R5@63+SQ&<#8' M4"\$+
<%BG5W)ZEf7#\$QOX/6D'KKDYLOfW&^9W@:/fRP&NUfB_"QOLS#VE MX^5Z9DHJG <&Sf!^5K(Xf
(D)P&C(f)&NH=K+@;Y@f(H:QATSB-fGf@*fW_%3f%ML Mf'YK^&(A)
<(O?88KfXB0#XR5_M\$TQfX<~EZO+Sf8E\$fL%+Af'2*\$#.AP:G M_CWf03@,~X:f'9D>ASPfSKfL'R%CSN>RU?
+8HAMV\$>+MZ%KfAZMUI^6H4O_MfVfD>_Z'ES&MP?UX^fA2U(*,fI)fC9C;>&4MA^A#_%^U%NfRfL;8_+L?;P M
<(DRfJ#C'48f2T<"fL,DC+BENZ;U6O(f5;5KfF2ZEf9RL)TB9%CO_A/P2;f@&^2&f^f/
M_/5N_0B*NfHVSfZf)28DYG+&60G~&G;Y#f!HfFO=(*0V2X'~A:~B4fUP MG;@TVB>PC(>~@,EDH^<(&+U(PNK(f?
X=;fL'QfJf7*3fV8"> MEf2&3KG+RfJHW'=YQ;&(*f!WJD23S'&NfFU^&fEUZ==Z29;fD#=&Of"NGC^M?
QNQO"V_SA=AD>fQENO+12P6+&3PHRfCNfRVH\$WWH\$42=MDL^~9Z8f1Tf/ MBNN:XRIE80/=
\$V^L(\$M/EP@VBA"9R39S,98=?\$M& MG^,fCL'~L;SN "Z/U&"RJ"2308 T9 2f.O\B9\$STCOKVf"E9PT8U<0:7NYZf
Mf/f8fLfS)Z8.Qf@U7<=D0+?_ \$&^?/=PD>_#PZ5f+1TPC.9#%T5NKR RD_ZME MWD6#fU(5U
4=ME8T+Y#49^?fL3A)f8.^LP@?<#%?KfFYRMWfL+W%f9_fANf1_9 M,(PefO)P?~*LO"2Kf/4-
9?))42T;@*AH>5)9fCf)3Y~H MC+;VU@~)E M4"\$*B\$Y;0_2(&f/)<=Qf"~WF#_.1^Y#fP3ZfLfL'F>70?JS0LAFf-
f50W=Tf22 MMA\$C@DY,&fLfLS+YK(f1#<QN?~"NPEW"f#;~>Af,=HF47f?7f<6F)=CfJf2?; M)GfJB3000A&V,f(=
=VR6,fDf3,fOY7\$Y653YHf7D=YO<@9fJ4 M&XfDS&ZYH_14f3T9_#L+^A2VW8?
C4;~?G\$TMf\$Y5^L1B05*0)8BZ4%P* M~P+2fFE4B4)Qf1X,S7@BV_3L9Wf"O:%B7(f"TOf1(f7;G:1XHfKfNC BY7AYf
M"GA+CfJ-1WKH4G!)fVfB;9S_3TSL\$CH.XVD'~CfZfJfC&_fTBUOSRK;f!#UT9^
Mf8=0/M3fZ:(XHB^)^Jf6(f1~E7QfM'K'5YX@fL?~\$T?%F2@M^fPefW;5*f"P+ MT0,/HK9ME0P^2#+V?
2";~&~;CTNY4EB)JZP:BfJE^%S_~fL>9K\$SfH(f1 MfTf8U3UZV4'PQ0#RA%Ff1f^ADZZD6CQ+2'7_.\$?+ST#F XQW
YfF46E12(LL: M~\$;fJYf70H#T HLf\$G;>MYW@S5Z%>2?<SMW,fJSZ,WfWfYfG58K?Z>+SfMfFfH0 MSG6(f(^
J<5BLDX%f0f)*=.8F: M%~X51fTVRO!;5?+7fR0fO)fCTVNMB@;@HVG,fY>>XO&+^NR MUCOf35G0=Jf-
00%&L=H%)3PJSYB"4%<~)R)C#T0_CCL_Y2U//MD8"&fLFF0XP
MHQZ_AK_KH=902SWE+&KMG'fHP.5=T9RKfHW\$9QACfEA6N^H.XA#3T926WP M/4Bf>_67fFM/1_~^~EXSDVf!~
M2C*.DVX(Mf@f15f9f"Yf"R;%D&8#fI&O6VfU9fQR_%fW@2fOGfUfIPM8_@ M^?f!<#9f%ZfBHfDf"RK2L.O0f/Z3P).>?
9^fBP>7fJ+(fMfHfLPQ#Q46SN_2?5_M5fMLA+M:DUF_7G_<
3QNC?~/M"4Ff1\$3PJBfC(%&#TS76;5%df5A4N76@fUf" M>HK3'AXM>~fT#;TKZf4ZP@D>\$%H#2UG3@J<~
f^+9@4M8M.V=@f+767@&G3 M4>T\$>YV^~93+4f25O+VZ_ \$H"V.3f1CR%B^MTfFDf9E1R(&W4K~*Cf5C(8~fE
M'TM\$~S"VfDf1%Sf1_?f!)A~MKV9AY4P@f!>OWKW=DfHR84XK\$!U2@&@fJHf5;6f M%~E-2,4fVPH.W/G/9E;"3F
UG4@?9_LY4f1,~<(Z<^H24NU)E)COQ^T)JS M~Q6fGDfU(\$5VR^CKXf!EA:O W0\$#fIH@?A)f(f
M:#MN\$WfW%<MfJR7AHQ28^#~.fAX6fSfK*(STH%QfJ90_3=)&2K(Z^L'3@DOM M3QD0
MA!~BUB\$~L>UKYfYZf9VHMUSfKJ3f+I2f!%T *=fYf1~_Af_7 IM+(fD?<fM-H2\$S MX)*H~/CAf60R8-
K*~3'~>D%0L=*>MF<f1V Yf\$;MOXOXfLV;Y7KfTf_ P/QfMOOCT'~BfV EM_GG_~OJA,99S"TYX2XPS;f8+~
MfD3#<=H7WH98_RUKU;~4fS MAf9Yf1M+JP_/G*,W7W5V<7BHRf1FU95fFFWF MU~fX2%B_<
{98.fV4ZK#_>Kf!@G>*6R6;B?P9RP;f&5~>DZ#D%,%Q#~3 MfLG5?fLZ.\$3(NKfD)>MN9Xf!f9\$?fSKN>?
%ENfU"~L53+##%@fY MP.CP#%+SUC'fVfCf0N\$<)>>7H7_ TSL_S_4fZF*W9GN3-O>ZEf!T"7"~Sf6
M%~B7>%V3f1Y~E:BXLf!PUN7C~CfJ#5*RAfTfNM,+K U^~5fJUP&DS6+D+,R MH(H~X\$R0D&~4,DA>K8f1fR5OJfK?~<
&2YfHfMfLXWfUfL'CO0DEY~M2D@%9U M0KNCVf6C NTDf2f8Z%5K;^CfVC?W\$O@~f9Of<+^+<
(=9;#; OBW0;5SfLJE M3>f6RZ^XNfQC#?~20fHM X&>U+5f1 B'~;A4@G/G5?L(YG/Tf)0@V9+S;@_ M=?<
W/@TNQO"#O%5?AXA^;UJf1\$~/XUf/GO!fL^Lk3fBXPEGTfL;"ARU+;0FHU M=X)<
(KS6PX(P6BL0L#MLfYB\$GLfHCH/5"47f1W3/X#E?S99ZG=JN^PW>K^2+~<
MOX;+&=>84.H;U;@JN=9f!AZ)D;+~\$R%GB/Kf1N0fE&64_YX3&>QB82Z0YG=fKM MN588+;?DR<
A)+G(A5M5666M)3Y2;8A;C%~L'M.>/@Y)L=VfFf10*Yf_2Q>O^fIO MEfF&QGK&0=;EV(<^<?f2FB?+@~40=T~M8M_QfT%~<
Wf!2V%~5L'P=SK(f5;4U Mf7=3Tf!>)HO4_f!+f12**~f BA3fE64<7&(%DfLD3HMf6M M6fBfZD\$~f)GS%<7N~<
R;6_@f7%ZM_A>~L2MB7OBQ+~?f\$!_"<2<7;f9DX46" ME2&_8SfXVXDFZ#_.f10\$00H\$IOCX(fHf;Q3fA@LEFNN?<
MCW9f)Z?>fDXf8<f1R7@f9W5M1)>RR2\$~ZV+~fLD M(ENfJf1E5X9Z#3f5&#U;~XfJE"~T+4LU'E26.NNXX.97+~7<
MA(=+~MB'W3V ADfRfM^4U?7A^G;S;BOE2@836=L.AHfDV;64_fJEC\$PPT7S4 MQ7=4f660V3fS"~fL;H#fJ+Q>?<
OF"JS0/%^~"5USM#fL\$;HM2'(2Z;~55f2G M!\$V/=7"~!>f6Q^5+~1PF9_A'~MQ9#.C8'>ZICK'f!^MUU0P6A4) M(L=~<
#fV0fJS(28#fUf3fZ#)N)?DK7Y0AA/13W 9R;6_" SQ?S+U=?KE=<62;8 MNDB4fC)f)?~U=XSR"C05CDJA3'N3<
QB#R>Q^<6.B'B&S9@Gf3"~SfH=8=P+Z66_M.Mf+5PCZ9_~f!IGB\$ESKB;+Z=5EKPD^+L'G4;5-QAP?SKP<
f!~fZfIOXQ? MOE&~^M<~GK0&FY.)H.6(fUJ<~*GfY#8f'6.D4=KR?H9~;2R&%4fU;~<='SfIO_M+<
(7N<74fH47Y')7=%+Sdf6;f+;~f6;8@/K' M'4'H^D*AE='7H0Pf2SfJ87=#FN M.)3+FP(#Y70=0J2+J& DP"+W2~<
f09N2_Y*~?0SfK7_O?3=GfHfF&B)K;~ET M?>W+0*(~QfKI=O.TP?G<~FYfJ<
M_KA+5V%MQ=4WG3G_C;X@_fZ+~CGWA!~"GBYN/Q.AQ66^3^#E/f)@LHH;GfXK<
M@8Y)YYf1%D+FU5WH4P3W%2_Z\$S'fEKZ>1WfFf!f2fA6)%fC/9>~9Y AXEH\$6<
MfT*~)A=,>2,3&TfE/V;G;~H\$T#Q\$6F>)R.JTSQBW@:D<@~7;OX>F%KPC MFfH>VA"8-T5,CfE*;4f!EJE0N;?<
\$SA&7U:&?65/KFG5=VN,UJ")KQ0%7P(0S_M*2,&%L?H4=F;T)XLR8E0N;>fSA*4Y.K/7+~.6OJf,4(Y/P%)OY45J&<
(%A0 M);8_1Y\$;~SfHfE_N;^fS@N4KVfTX; M/=+PY*~RCD%9_~X?CfJ3E9;@8_4G_00A?EJO+^2fIAKOW^f4#O5OAE?<
O7E#fR<~M"1=92DEfX2&f1^K>;~%F&*)VTQ,^Hf+AS5fE;Q#~WfGBK)ULfH>=W)fN@9_fJM0;F#^R.Y5QR,<

FLK\$.JF%)D"BR6#6=Q"<=&6_?>7C[-4'0]><G8.YV\`C M=A?HE37K[558)/SEKZ^X6..L1UXWQR?@A7A#^I2|FR
41"~%*.48YUL'EY^G M.%CTF)T3?IJ*H - W>?0Q3U8=89L?H>K5\$7V"6?"%*=|RN0KUSY+Y2Q\$12PD
MJQ(XS'@N*M7GZ-N&.*D|ODF@Z=T_/_JZ\F8BXIY?#0<|9AS-9J3>(>\$5P|)^Z, MGO=)<<,
(3L*1ZQ9,A(#:009&X5*M>Z=V00_H_W|_K>Y_85MEP(K),7H"S M=)54Y|J'DJ\$&A.1(87_YB<|Z-
DVNJ|A#R04JXMPZL\$N^_15?2_11%7,= MWW7SYW|QFMEXR8A2:K"<|UHTH,%ZJNHY)3|"/6/A0_E+JH1Z@=CX67X-
5&M_-U|G>J7=FIRIBCG0_D9\$XEHA93#-@/OJ@E7."MR|U>Y*HHP=83@O|N.WDP*\$P_?E_FWQ3=R>*N) M|?
WO(OX1ONRFT0_0;5_1I ND_+U\$!R=N,1DT&>>O|V\$MA?FP5)9=>6_ZR3+!')
M8WK8G/Q\$%.ROGSX=5EJ*:=F2AQV84IM0:TP/UVMYPM32#>KCY5W&- WM5|_YO MM1_T>A6%|H&QHLD'9)P|
<8_1:F0>3|_*H3=(|Z"U#GB'X"NQPUP M:QSI8'I@=205G&M7#V:(51%|;XESS6MN'R6D.^<(N3GHZ, QSN
S7<:^(GA3FV;KR^VT<2"5*CH%J)IO7#W:6JF'KX_?K|K_,9|/^+*@Z\$KGME>9;@74S@BV7T)RGRTCKM?="*
MN+>7GW%UXXM;6P2+|RIS#LCK #-C D03(O# BU6%Q;M;5RL|2L@YEO%X*71@_3|Q,:=CIE|0?
|6S:2|>&WHYH/*5Y;KB,>?6|6/T3\$MDJ|C MJP7|WK*0%R73UC=?
Y.8BUSD4AJR4N9&Y8|*8\$|@,;9T>>YR2OC"SOX12 M@,P|J|/_ P90^%|NNFT WV(>+;7CRA8Q&8#R0GV)-
|BJZ961U@H|>GF M03|AEV8YW'AMP|VIX;&C^|7ZZ^8YF6. MUU_78@L:RU YH|!9,"EPOI2.9+9M*%7
8YS2_6+#!P(1UH|<+|=F.PYW MY_?E"E-87^M|\$9+/2D?(Q=/#*6MJKZ&YFRBOZ<-BX.V# |\$R/V03UE8W\$2D
MCX#D"YV8)@|U*YVW42_ T7\$KR;5+H<|DB89>X%JZE(Q2D9YFP>_F^R7+CV9 MB=(^>'(8USN
SZ.Q|QGY9<%@R("A4QR8_+=?E(1E;G#T04K0W;1PGIRU<^ M4.C+UAR?
VE6^SO#>DK_ ^Y:_O|H5|6G&96(IDUF>O8CT8M<|28:.Q_24B7# M17@P^NP)1_F9C_1ES|Z'BJ8_|3>+NK/^>5G\$|L?
ON|H\$ M)S@BX7E2^AKE1J?C;.,TZ08_1DOC=&D(AP@VQA>N@_9_P8,J3|QGY)S5>1 MW:>@=(>F7"F3W
M9G(1M=3A<.,62;.SHT|1M+N+2Y4\$R1D4+UR|Y.YRUKRMZXR_)/5Q^XOXX% M^?
LPO\$ <|Q@RZVG"Q4AY)H*8|'9";DU(RGC)W>(*&CAZ2GDU\$/@H?Q^<
M|P>@Z|VF0;EBO04I+;ECRICW;&XS7|Z&_FJ"23'K(C#82|J"B_ "TXW@-L MKH.SVW><#,>OR|5-
10\$2>X@/Y+H:A>2AJ|!>(>E_XH(9VT)A|O MZ\$=K|H_A>@?0N>..N7D|R8NA\$ @Q2J-
O*4G'@0LR04L);.5|M|JZ| XZ'ORJ MHP3|773R&"YW|_.'^OE_E M-2MU_1;E|+S+6|";LZ2;F_0F|H|FD)K'LOG>;
(Q<<#GNC*6C|/-2#SN0#%M MCE,#|YA_OJH9C;H&|V7>W(3UJT1&P'J^R1K-0BZ>+@F;M7%;|Z^E(K<)YK
MPSVW2;3WQ082U|6KUT9C2.8'R&-|KCI^|6RT^K|4D6;GO/W?R)-L+)QXG M9|9RCD;6%6DYU8T?
B6"UY4J|LTH|.6&N|4R\$QCFSEWF1J8+|SRL_GZ|FPR MX-9.5@L3;1%S+);,P90*QA"1|?*>?<1A1-#X_J
MS;\$^A.TAJR|25IUI(9SQQ*K,^%8'17IA0)KZ\$FHI7_!Y^0IQ0Q\$IOU8T+@ M\$2_R>'GT*Q|NLTH?
EXRHLUF%37'\$|B4Y(G91"L|D|60.1@>-D#9BB3&|T M54-N;J|2-
7T+F0#|3|\$55M93.U|OKK|^|E_#ZM_X>7.UKA.**6@1%*:2"=+
M5FE79VMD";Q+DC\$&&9&T|^X6)P=%8C.06)T<("1)^>1)T BF@@Z0B|&U MI-1#Y)E|+2Q4Z\$5*8MC|Z&
<..W\$H84R(-/NY#CY^/OAO6FFQVHUZVZ/CIE M98G@_J QWQS 62\$_.3EA\$|L.AT6=GOK"Q-
|_F.AHP=.)>XW>A|6G;9T.%UH X MJ1V@|H3F\$ V1S0)8|1DOW\$IF|WF4+|07W7QP8JUQ @/W+^9>KZW>-
M)1^8R@DB(AVE3\$X|<^ Z^BBT\$X\$;QN(-Y)Q;Z(2);MN#?U((/?TA7'DF M&6<.,%:'2Y=,2DX6T\$)+S|
@/K7H+WWT6F>@6;'YA_<0KKNN.7E^<?|2JN MYQV4_&X0Y/HCA#61|X= .LN =>E
M2<\$&>C0EU|E4M3Y)00#2_/H8#)<:0_>Y_IZ*3_|SCQ/BR6.(|7|:#EN|HS M'0/7-BOP@5BA2#5#7<|B?
G,R#7SKOG@O|J^XZ5ZHO%??NPN_.,O*1W|QD M|8TU3B;R076=@JZX=% 7R(% QYC122C>NIEP,"3|CR9)J?
34EZ3|!\$NOVP/ M|L0QV05Q58>^K3IQ5^<(NW^ZLOR;G'YZHJ.NIK_ '^99L5PHAP6"H2.J&HX
M1L9EGDFBR\$*K^""H|F1X?L|/Y+4.2K_YNE+TQ<*C@RDJR>
M&C>O/OX^Y%:_|QVI3U#53QJ(P17"HG=EU+*RH57_B).BJ|_E-31'M^>?JJ MP+5\$U)BBZ;
F^W6Y^C.L|O58F|>\$|UYWFRNF#B=+'>B0X; MG|!#0H|6&5|D#>Q738J%,>6UKD 7WM.|FXF8;\$QH(9
_@JHU|;ZVXQ)K.M.).399Q00;@7QJG73/5520/E5L'N'RB2Q_PL45_H%_OYD/2O<{|#J|LD'LS|D|Z1T8_0/+
(Y_WO|>K5*G|_:=P;S M;:>|O2#MD|>5L_+<7L4E361E&*4R@ M8_(F\$6+B.OB0AL_ ^Y;)LAOX^R
M;QO9)/A%L|QVX|>8Y.82|*|6(0%X1^Y5?DFVF"7YB<=AG<&?;IWA|RB#@?
MENFWXVT/2%/GL8FS3/&#" +4=9&V;OIF|K;|'-=GQ3#P*54+WYJNNJ|9#2
MCK==/D2W#JKV.A3)"P2L_2DN.8A%(62OK\$56M,J#(DL'045O|BIZ."&\$QC|A M#N/YU/"|,8CO7^N;?DV/<5G1691-
#)PI9|D.C&>..E*|X;&S\$|HOK MJP;1T|Q;:=#HE^/H8.PY,<5A075ZN_1>X_1JG#FX|H&KUEP)CRH|0D0S#3
M#_D|_*|ZV?(Z4U#^0>IUOSO#4K7AWCU#5?A\$|Y>KB^OAX/K_>9)E| MLJ|_Q53/1164E(4MB1DK0M'A|
(V3;G#24'62C*|6Z3#KH^7#W5-B,PXS;G MJ\$.\$(J2J1ZU+BB1BRM-G>RD+?.M1|C;H6N;H:3(JV%1#I
V)_O_TU|T^T M.#J)YFF&G(L1)Y(>C|S M7F1?>K3L-TNT=NT(K|+E_0|S&^O_0S\$(L<|(RM/%#XX,XH*6
M|U*X8|VG^3Y#3E?IP'WD_LSHN*8WL7C_%2|7HDEF&CH?7"AD"/Z-|S3.#I MMT-
2(20FF|^|QW3'GF).W"B'MP)NP_O.P#1(WU|^?CB7>3@K*E5WMZ 5|& M\$2J|HF3VLO4(N/|A-
U+O^|WPN|ZQ|0EV;)>O_9Y8MN"AMC?DY<)K8XXI M;B5B??4;@Z7|3MBH|IB)^P^+X|(W?
X<>O'2&X"IL4@6^/HS>8>8N0"4-G_M6\$@%36M;|5%NAG|U/OY.HG'0#GV9+3ZST+|W&^J7.MROG=15C;.(Q1B9)!
M;Y_*9T@U\$F195L@Q#*TPUCULE_12A_2BI P&R3X#P\$VGU#LG;U0UORW|O MYI?KF=-)JOPT&_IH=-9""#%
|8"A0U?S|I/YTO|0%W%\$ZK_4X.PN/DTSOZW.M_U6LW3)>:M<5HD|_R|?EU^6JX/SRJO;).5^,*#H"QM2?
N34.V8|TD+J+V;H% D|(87R%);DP5J M5*\$HRF>IFK;)=B3@M9/#P<@B)1R7_07Z7Z5T|>7J@AS|?W-)H(^XV(|X_-
MT7_|=|LUZ>.^NDU80I@&X-TX^(|3M|7E1D)45H%R=4N93'1F58K'5|6:M8Q0M|P&OEF>>?
8ZK#->K^|Q^8/^K+9>J|?|5YHOZQZ|*">-C^&M&9U6* M9S*?LZQCG%.|YS7|D@LOO9 N^|8Y@CU)|"IOL
|^BK3,473P9L|^#(7>IKR M3|B@?|E|5_ ^8)+G8_C?OEL1G0)RO|K=6V|,F9P+;R#|'?=|4N&|TA_ZX
MJO'_MZ7^<^|NPNIRG^=>PN%S/8K9.5|311FM2AJPY MO;|&>E>G|92"FP%'A1?5=) 3Y?+%?
T|ZYNAV7.254R8YL.YD3_4_+;E C M4WH3G)7*>MW:HGR4D*X|G'UD_?|M/9|_S|>+O?US03_G|_SKME##;|Z.3W|
M6/4W8PF<#>@V^<"M.98.00?+S2%W?OHM%AH(|E"V|V H=-.88D.R^AXJ U MT: ^T=^
X1X@VJL", "RVF*7RX+/3=0\$>(;C^Q^| %Z?N3|_|T.Y|@J|J*,- MX(W=|
L68QD*X(UCN>.;1V%|V|*Y|W|V|Y(^1\$;+=@SK(YU4|_W71"K7|A<MT"-7N_45+N5<9WND7|_HTH|36
|GD;HD04F-K85GB5HYMA1NW>B?<|@-*# M_ ^SNELV|G%&5R%D|0IE|L>8
\$U7(Y427."M_ ^F/\$M)7>SQ@EZVYGH'T'G< M|HMI5*>*CHK\$+X.Z>2*0>":@W"F1.F\$=|QUH=|S|/3@MQPE|N5(O_|
1P|U M|N;>@",.C+4&;C/C+2TM!!T?>)#';|@,8K<L7Y)#'31I7;OV)MN#ZU|7L=
MT'PH(C5#9C@L;P2NG0|5H@6'P@.S+A0MDE7"#3*)AWZQ+^_X0.DNOV.UN>#G MG_ /+S_70?-DL)WF|7.1Y_1?
R.)\$TM50"+&>6=&U@X*LFUSPD.G|P.NFN'J* MDKZL|/BK8EH.G@&7SKGUHXB/>EFZ;
(L")6|3@&D5&7;1Q0'EKM.R.SEJE;36>P?BZFS#..URF*L/_^/?|S92F*5LF#9&D|Y^X|I
M(^!>63#;1B8R*FM;3V#9@|QID|KC0'_LZ4S|+FZ&+XO(|A=Q4JFKM1&>9 B MU@&V08)7SD
R(C|7)O1|^V'36E|XT|>7\$=|5JR=&B=W4D?2KN6YU|;D>SO? M9>;X=)P@#D;JZBN)#-
\$S|9EG;U5=#_IPOOP36|GRM6GWM(R E^8LGAHS+UV MU|1 ^IUP>|*92|KU*Q/HGR/9 M_R_4)_V|_ /Q_I??|ZF'>.
|KYV|GNCY|XY3*!1ERLD)!&;(\$%(Z<|ODU"B M"C&|(-H/37F%(5".D7-2JXE@HK3L;0_XLG(R|)\$6R1(HT=,NVO4&@?
60|K M%-J'S1TX<<|GLHSFCBM.U>E62D).HRR\$8(*7\$HM7/MVA>,3QBCR7E3|@=LF
M)\$_X7D=BQI5"|.|H#TH8;P|USN MSK-)2Q.3%=\$\$"""+4"4+"4;8+98F61=-JZ.N7<\$L9|B7N?A/\$^O_|1T|
M):6@T'"@Q,*|(0'1%2NF+I1@V3GC4@J M-PD?ES ^<=G3;|8&ZY|?Q?NQH;

M+_3MU>7ZDAR4NNTIR1B,@@FD'FH\$JO# 90A?S8F)QDJSH9Z>L+L;-Z_7.D2.I-8\$^<2:(*=%_2%J#
ML_1J8Y3"AS0(X_H)ZSIP=CFX@6=FB&_+9X=FU)58G_6%Z06-8SFU54)FDP
MO@0Z52%MR"V"M5&B2YXLNM9C*X91UFL!H!OC2B3C@/*854W&ZS?W0RGKSJU M>@U7VQ^++^!^W!,'FO#
I0*&Q!JE:1XEL*MCFNZS@B"J9KPS@/*FN6RRK" M.%;0F"G.,*75L&VR^T0YXGJ#E:%)
<+VAG"+SZ1KRLS.#Y9W"OAVLOP4UOT MPP**GMYGFA+K-
/H00@7*.;PS!H28YHPM8>UH&D3NS!M#0=TF!/"836P<-Z M>I9?B:JD.U!.%U?S+=?
<41X)K<QL55137>+5<;B5Y>KN:1L.&'4_4I0HC M"JS#HC3\$E2N)GN;;WB/C?6-I=C*-Z M^=0S'^F)5(H!5XR8:F0!
IXV#(&(*1DJFFF<*7J9J6@^!3WSN);D!)U)=G^AF M(A*=Y,'3%>K!8ZO^7HSS"-6L;F6L_?
6WE52YL.#LS7@CC50"92EVL26P-M)3O(I63Q%M>!@WBV.<#A0P!7L!>MCE20QJ\$@BZC'WU17F0^2_)
M!GHUR&LIM:FTD,WD>*0)F<7A_K6/MCI^U2<|WABHJW-/B5L)Q%?;RKY_B-# MMS-
MCXWYIM0WAPH#BJ4NNL@%EOG05DRYT=-,5-"1V!S8:W;3_-A;|K*.E-MA(2Z_9VY.2,XZ&%V-
KA3Q#4(F3+10=&;:HGHC:QQV;#Z;;D1H!VGP>8 M,NQ>?XIO|BJXHOS9N9R!G0&2+DLM.&*7J0C|TGB6G-
9.L18H_)Z*04!S_M/Q+0CI3\$6:FI55DQSV3PRA92X%Z.;@F:(X0L-"C-39TG*Z1L71*Z-Y&#D.A_M)"2.*|<E-
I#Q.M)I)*.CS2_F6!%>|U!KEV0MGBRQ!L:<5'56MH>4181I*.UR MZYKW891-
/E_C+35""+I0"/^\$^>?/M,SMMX!M1>!?65+6R!D>2IQ-5P5=92C0%U'\$2|N M5\$T|2!%L?N^GNAWK7?
B|_N57JU582-K)=^L9U@(|+!%6-U?USB(XL5_1N1>MY!)<Z6UQU/=E|H<_!HZOI"Y|J@3*7HK5NG5K?
D!2)HXLJLHW\$5F'SLT#OY"YH)-6@.EY4#QQ_M"&G3Z^Q)SW/!+;&129K!*_!I@E'<64.%T'^NWE#X=%T;,-8*
(J&4PWITZ/\$A03T2^)_BC@#'WK46ATNJ.R^GR>Z?U#-M4/#D#.A8#UHK3)PS_K@6T3!FA1K#9SE,V+YX90YX!
ML>ZA<_)!D>?K)CO"FI)53O+H0;;MX4!USLTW8&Z0V#C!;EE<+^2>IL"HR;THB@I MH11&I06U_H=^!S
J+804VNO6?>JDN7.3<>2>380=P28*_-U(M+T4)+D.ML/1P4M7H!\$48Z2UH_L\$*7T9=2UAUH+W4R^Q/B@80IM-
^&=8Y?4L>B^3 MM(+,V%#<+9F#@)P!-Z3J118LXP.EUS)C<9>4.6NIFH\$|CFG--F=^/A#)4L M3&IPJ>
I,2\$R"M^1E*2PA5+!-11X/C|3-W=->H!%);YS;XE7>;G_)|M MRG+U9?AYE,LGOW*J*,LAHOI'D6-
CN6F(@@Z^AV95*=JUTFI!+8\$F1H%| M!O)(RP^L^8KR|P;7E%UFK^KM|VE|H?SCFK>-U,TN\$5/X#@K;#|F0J+J;
MX+S'VHP0(+H!W869T1(2(V03K+WU5+)Z&!:S\$PEPSM(+U0LHOG>GA&/_\$X E1NNP3,MW>GC_" M%|S-
UM4VVRH+FF#/(6+6)ID"MS1-B^-NP#,(U=*F|2^6ZZL5&3=WO_D>+^HTJ=?+8&IXC#>
M:1L;W!9@*)5%D!\$BDA95ULLZ\$S-#B4EH(U@HLO44L^H;A<^OFVENTO%W7ZZ MG_|^OMVN7M.M%>AS9DS)
B75%20%(5U-0R^3TC!LX)(W>:9D4P!M&Q#M1<%8! M"O)56GN"1U/=2Y9F2LAQ+
(_9|3?ZUU,V/PU^7JO^C-B_O9Q)Y(%%L!D0!9P MT!@9"M(*XL"LAZXQR!_9L>F%:YF"?8#8V5@AY^JDP2LCRJ("IE
M3B90(*A8'77?ZJ7?P2K^ZQ>J|X#_X#J=:JA+T!EO,IP&47.359"2-B ID"J^_O\$)Q. M 6Q\$PP77A3V<='PX8*,DQAK(?
B/H!S\$POH|_EB_N7JRXYPK5*VR_XG;". MJDW@"R/JA9(BD'O(|*";K!=\$?
N^C\$PO!\$)S\$M6_!O:L&^Q^X2GA0/S%CO6D=0 MF0'K7ZR^VWD7XMRJ!5)2!)_NY'IXG>-!AP?SKORX?=
IH+V!47HJ1D4_L M0#;TH%BT\$*L-2)9IF+|\$N 3I!N<02^%XB70_L_9=WOL17Z0'XY> MN^(8
I2U_CSD\$R7&86?R)E6Q:SSP=XQP3H|<#JM|PIUCR|@#G#16HWQ_MX;^OJU5(RPL9.<3H/2AC#+A W-7)A:#!F?
UAL78SX+\$&=)PY^QMR+.%-G?OX M/:S^A9<;OCUV|V)B|LV9V7H#;#B&C8%'.H\$H1\$!HZ3/@PK,1KTN7;H&AK
M+9N!2;EXV_O!M(>OR#&.3)@K IR\$S^H'9Y:4-HN&#URX!>_3SMO"_,M';8;_JBSZYN"3';U"2HK0@4/6/EMN>
(C#|04.!<^4 M#N*1@GM,-P<=>JWYA|W>?VW|W:JCQ',4S(2Z!B^+KY6\$%UT4)P32%460V; MEOSIS^Y TH?(-
F.81WX|!^(XOMMN!U_4%7EQL1,MC/\$:N'0!I J#)#60:2?G")K82,DB--L8AW |\$9=0?1"&Z8=|4ZK9#N%5%"
MQ.+:!HDUT@0Q=5M!8=H!2,G'(J)V@'RX").KK'4#GC^6BKLF@GTI_XI-O" K) MY/%=1Q_,R9HK XY10V>QY.LH,=
<<*T"TOZ;*ZIGZ)EX-/#QXEZ.Q/L<-2@ MN)9.A3Y)!. J@WEZ2Y*:T\$|H3(LB316E^=J,5LM.T3G;REIY7!;-!X_
MH5M.% X=KN;+S&=9ZJR*Y(ZZ9HEV!|X2L_Q.RTB%XFW+IEM27_G&:'&V&L%
M_6!+632S37MNCBPB73/G8:#W!%&B|<_7ZVYV|K^>T19HJ8%.JZT<8@D+M
MP,OL(&7'N!..J,ZPL M!G^|G30.4D!DK5Z4 M7WXY60^K|2|_?<6!P?
B(JR!%D)QR*4\$+K2FEGU=^H3H3!HF&JQ8ZCH M44I3>9|K| H>I#TO.^9 MT*(816X,9YDX@RY
E#9"H%|Z69PVPV+@H!P|CY=YRF_3NV?<4THUVO:T7S
M|_S:/;B;QBBF,H2BZOF8FTJ!4(#8NUX\$/H3\$X;_7'/M^JO0TWL30! E^EH MR/OH=^C!^VO7U>
(UW&V#4,PHBR6.9"ED(FKBP:GL0_IV,X43(S%UNOK1S_4 MM*LG?Z0!=#1D?K0|M%FJ?;6X_6Y>K=
<7W!QB^N:1JWY@HJYEQB0\$)4(&*M@4%,2=;+!#8QJXLMW0Q).NR(@^Z7<_!CF&P2%RZJW%|(9S;-!%?
MGLFF!>_Q1X4! M=X8^AM2ADT+I8D JK%T)D8-S3(#0&H)(UK?VO+|48;4L5C(4E+40&P9(F3=>|)
M:@!O;%;E';^SN/Y+F#(7|06"9T?2!|.1#N T2G_M<9A9VFS^\$Z|ZA!0_ MSQP4F601/GG!3CXS_@<03A=0#)PYL-
4(+7&W#;2_90TY;M:A902>WH*L M0>6(\$)R-#\$.3SD@Z1#|+!#9YQIEW84QB,+0"1@>7X!;|Q=6W>
<(G6++5" 1O M;|M|3,M/B|JC;IM@W_3@7X>O||MP47_WU9=;FCBSPF8G1_\$TT8-*7)/SS#QH MEQ(SP>+<
!NXA^VZ.D!WBWC)I9DW1,2!"*5A_6D@%F^@Q.@D!YD*M@YCCW:8L^@&@VFC Z1'_FN M;|7*K|O5|K?
JW^_S)"!+7FSA9E!4RA*=<\$S7V:SQ7M9C&C19:AD)S|YOHLM; M=3R8SJE&A>D7I9'YE*1;X>.1S2Y?
S;_+OIG54|WY|IM%JK%KSHHOY+!<^M^10@O)9U<8B'D%,5S+!%Y;DEI/_O!ZK&D1.&MA
V7IKGQ#4I#!TX%_0R M!%*:9|K^4X^U)V;|J?_1_P=F%3WRS1|"DRXR,"HFB@4&B\$;Y4\$X;CT7C*_M
M'7KZ(>N0!@+!L_58^TBD SB-4H!FIO@_D(RW)%;P1Y|F"9E'HC@/OZG M'FNO>JR!8'6*>J0!9-
P!S!_I4=W6^@_S"B?R@6"TT29.^>9CUD;PT!H;3W|
MNZT(VPLO>ZT(VT=X4!="/5SHPA4YDZZN.1;.@|8("B%8&W(AA3W,#E3(@N5!\$7:(O@=L,D;E
AC97=3*QAE@*UR8J'D4WP^/>_&BU M2;>8EB>6_3FC<5>|YO(X/OEQ<6ORU7ICV9.RN2E,1 P(|AH RF5D\$8P4+2
MT5DW:"15%P.,CMAYY9\$8_R>;#!T6#Z|HAJN|DY;_%IR-H7V?F92?)0DL> MC*,G/61TJ|_Q|L>|DPOV D0?OK>#
<#KZ'7S=)HP^78779^6W<3#=:7P!9 MF9\$)S5,Q%IBO.R31(43\$!&B8_8?^DF|^EH MYH!3HNX%T*2.R
>U'CS#;H5#2>>#10%VTV"RY|G.M&KZ1J\$1X!M TOHMY=P M@9HSJ;S:TAR*SB RQPA7;((W!A"BA.NLISF8
)RPKCG-G8NCCUA,<|TYKN M'^DR'@>Y'_P^?F>Z!U!4)H9P9^O(*^7!U;9KY;77V7/N=3?Q\$?Q%|LK'O^1
M|N(Q<#024_QE<39W!<2D>^GX|X5M;\$.P,(86)94+>)A\$D9)P**IEQIP)ID9
M!E^W8<9>IUG\$V(=#8X_M,YG^VSS!:(+9)J,"M*_DR9_9@_,X;^!S# MLR^>^X>|W(YW<3I4 GNA^_
|NZOLR^X0THJ;DP>=IE#" H&E L*Q+>+DKR2 MLU\$">Q|<3%_P2RM;";>?
VA#X'XP|&7&\$=|X,+62+M0!9!\$R"+6ZSF9NO<*\$ MX6QW.K11!<Z/A%<\$N\$E5=P^|R#7ED7/E YA4"&->Z@-QD-J
M5+&HBC.AFY+!B?_X2/F/X_*&W)/_3|W|.74MSPJ&P K60&,%@'(>0\$(7L> M61(1V?DX XTC N<IR3DQIV;K_MJ?
&ZL*P_&8#9,B2)+^4_3_>=\$2Y:M+RJ ME+K235H.ODY7=4E(=%GP6)J_!HNMA3LR,VW>|A_@Z,LM6I+3P
PEY<|@W.MN0%GF|Y<+K,W7F3(5A5Z)C,=);_Z2RL|GB3|2?_MS<^0|_TY;|D.4XTNH7_M>+N62.NX-
3D*",IY:RQ:M%?I6_S!?'S^B!4,VLWSW?7(NMM,IQ5;GV=|N\$G7U*H)-248F=##-M=H@PKH\$V""
6(XHE0Z@=LHM^77^2(LTCQE>%TEB\$8^5YZ!<*A"!_1+);22RJ|K/8SA0%)_F!E(Q!4TCY;+!TPM% MZF)M_-1-
0WHA^UH|O6D4*EB.RW+S_EB)K<=30.EX^IX@UPX 3.37:GLAZ'Z)B';+^@^/U@
R,4=B@#6@:R45DPD" T,0!|3+I2E/2^=1^V M<K.#J!*P.7AA+%Q9-T8|U5+!D)N@G1!QG507I?7JE#0917\$N*"M@)(B1-
U M";YY|?Q!\$LZT!O9!#P\$X!BZ?B|P?|5/ET&R9>_Q%66W?RB 31@)_.*"NT M+_V-4D&
ISH'K!O5Y7SQZ39@7K0119(WISPA3)*=Z8*FU|NQ*),(#\$|S>K@G
M:&F8OGGPA=|69;GZL!\$7W;GM'^XT"O6Q(C@A\$S;L K\$P7:QR(9<2)C|T*@_M_|A>7+Q?KY<4;XZQT>4;7THQY
TW\$<(F4)M= M@L!_H1/PF&W*M@Q+J=(GID"-?G4+LZ>_WDWR9!R!+YMROSO|H RM))U7R6NR

M"J"TU;+0\$80PIA70CLOX%05.&4%K)1%F(.#@#HSNMU_K=C:Z1:N+<^TLM"QIL"0%W'I7UL,\$=9.*&/7L:B^
M'H"V57\$@_1_SOF>0H7.WT:HC,24P#^LZ^!X!A\$6RNYR:&K):HK;_C_V7O3+K=N)\$WX%T4/IN6C+O5IB-;
M&DE5/>|G'BP!B5TI4D-FRJ7^j6^2V8JUTL2EQ?IZ3JGY%PD(I8'B-6!B%JI-MN3.7.W'L.163
PD?I9=R\$0:I@BN7D"QZ"W;C'P4PW;XD^M,?IG1:.W\$V4-
M/L%#:M2MW+=E@8P>0F&"SC"4\$;R(H1K&U4MOA1%T*N:NZWSN**M-37U-MF;IMC?
6V_IK2IFKYI9\+S#J|_LB78>+F/IC.5|<-H.XOUKA#(-C'.LV9=&
M"J"6IM5;0=I=E45O51ET4!VQ>!=N2D/U+|^HBPY.NK\ME_G/<^7%+"F=V8)MRDE1^|DMV|6Y!%NI-MUE-
^TDV000!;N71+DI/EV/8EZF81|&*HA)ECK_F;XJ6_/ZG*7@3F;9O+;W
MHM4)PVFI#BX1"NZTA2;...8+8!"B1*=48LW;2OIE+E_/P4Z+RIH#E-7=9=@F
M7U;.%E&P3J;L>EN_/C_|&7J00I_C+U\$.EWAY|=."Z|MBM&\$7_NJR6W(6M4N6A&D53+HXC+!^0<4O?Y7+U(-
T.NORJ1!:=^M/W:WQW5)MTF:BFSE;_A7\$&_C8I9DE/,Y=9%4B_G,O4@^0^|3#U\$X\$?CYANNXO(LUZE9_M.ZY"
|^C&?S+;+(GL4\$MYGM9AP,3|2YXT\$89QGU45@|R@?Z?UZD*?;)Z11#I#QU?O.Q&T&,5IO;='#%M>KFL=;W:Y
(8|2M1E.BAEVMO8#KU(T>0Z11#A30T^H3IY!C;58ZD1\$E_MZZPRV<10>
(288T87;_@S3.77!E%)O%4)1\GH*G5>NL*6&FQ_*^ODJJ*?8_M(,9I!"NEC%#"^|O>1)M;|C/=D1ZMV"%U(Q1?
S!;BT9LLP"6+ZY^4#SAH!MV?D4LLF*Z?;/J?Z*|Z\$G^9*M=-4W^M|C-UQVO/YV_(KA95/)LFJ-LV1;^2"%^>O_+
MAU*7=4T3!%#26;E=4/+JG(UCU>;N^./RW<;/M;#@51HP+\$MPM\$IKX(=5IEXW/I=>..CHNP>ND?>@|N-?).8_4&
(B"SJ>8;R\$7PCD'B64FK_M+3?|;+>@P1/!&@_"=KIG^T?C|OMC64ON+HF\$BXW4B0Q\LO5)E-
O(40!*Z;0+/G|L75%TCXA!H#;O%1M1#|A+;I^|M.#'SJ_D#;M+EHB"@J"#"%%>X8)"\$S5*^QE"T4M
^SO4W&810|_00AMH;6HGD5AX'=??^7_MNEI?;B|B2V|O!;\$K>"?)TOKNAGNUAN^L9>1\$D3)7
&9=KM5B\$(\$A2Y@)MC)9;=O>IUF/8DZB8Q-R_4M&YAGU_#4DMSQB/H!9"TI!@PKABH(COX\$@TP_MJTLLA(0?FXR
8'K|V|*0Q>|G8&UDAQ^~M>1DN6L3)=(C7UV<;VM^6.QI?K99E_M?OEFN=Z8@7UAT(T2T&J*4*7%O;..>A-7-3
MPH8A|;7>;TRNR@XNT?8>R'9S7C_T|A2-"E|M+7MIXH'O"P6BG7(G%/;I-8A
M|".D#;/@2|T|;F+DJ;|XSLW.%9D;P;I8&Q!M.7N'A&\$>JD7(RWD?FH_WOX/R.MG;;'<&WF_J6*Z|WW|Z;LA0#;.5-
;ADQMD!P'OY_X8C&G4M_7U7HPWA/D#_/42|WL;*V/2<&UK?!.KDA4I%EDKG?">R!Q_MZ9+;#;I4
A\$HW_D4|ABN0\$N%/GH3D/M|+MB0U88AZ\$5?2307^O19NNO6-4/MHHO8H2);"
S^D.AH5.7F03HE"LV)NM%Z_?|+IZAL= MZOPS^028P7LK0=G(ZDB?_D(DS(R)6%(89\$M_M
VD;|L?7>J4PJH8Z2(3M6R4N7?T?|WT'GA+^H_AZRV)C#;.3#|0<"H8F!@J!M1.OAKT|3-*RF^*5>
(HR@E:GO|L|WRKW1QE3?7W/+^LN3Q(N|JDM;8O5A_M.B/W/M28MXR5_K"^3DD;2P+JPN*2Y;|UB";W|
_4^IADYO+6;_*BCQ"R7FKR3%;D?*=MMZU/+#(E2_MKQ#.D8;./3#Q3._+9YEGOX48OX9?2T|?G_P#2.T4"3G7SK;
<04A|ZH(Y_MAJM7_R?;C:4#V|O2|_J)\$#++_>06;SAIS%K|A"1UW/Z|C^%?N/Y|OEBNYI??
MIY*B|/#'3_GE_U|IKW_R|_+?;JKV?1|IN@VTYQ-H'4-@D@=O_M6@^)/2-
|PS;+2|^EZ14QS2ITSM\$I=_YL2_S1(f;+K|X39OZ\$PD)UW"?!M_MAJQ#5ARO_^|I?C(=\$5=;|H0+*HKFN-
HYQ\$X1YDSOQL88>@_UIUQ#VIOFC?M>2)HS;|*S*^&D(KB"48-\$K)XI7K7;|U/=U|OXHY|U_QW65797?O3I>3\$
MR)5'EFNT8\$%#2*^T3(&D;_*8@QK#H#;\$+|HKGU/V_TZ0*Z_Y.NA9-1NI<M?/
@O:2@O@.OGINF469&)"Y&GVU^EF^H|AW23^U=7<OY#_6W#6F\$U7_M&5CAM3X|_G#D-9-
<"KG_P4;10\$WAR^FF>Y".|W;3/43@>#FZ;..>(3JTRB8H_M7(8Z)5%!208(9/-9;5"M!&O>|JW?
7KH36;+VJNH!=S^T(23JL@R%=DE0|=44_MA?;\$!\$P>*CJ6-3F33'F^L+DT6&;M<*Q&_MTRJIZ/VX@_MUCGD;?
N(N3"!7%BAS_MHK7N0O@9_*CU>;#X*9SK(Z:1.826)MB|>|!"Y<MK;+F%_X;Y&G8+5B7K76/5O)Q_H;K;?
ZQO*2%\$JLC9V|KOT9-<2D-3A7A#3;_MY)#X(+WVY5KW;4>*)^C/I_-FBIQLMKKVGO?K>;Z|H7ZUJ52G;=
<9|29|35:UN#|!4C1)LH_M&I2:2UMPNBNRS=..|H77Y97Y)JY7+3Q_6LK_MRE3?^G(*B*P|945Q;G_QJXIN4-
27RU"QX-82|UT+3|S|BC%+S47E4R|@QD_MKU#C;|JOOP'2;|%|26>*^E7-8Y(TX1Z1%?'Z9
MT0H0#^1P|I#SU_VVF7PN42'I:2X|!@|I|ARO+W28;R|N|&K#K?BO95F>S#+_M%FOAB97
E*84M;_*GHT(O@>7R9/43K9.8QY#9Y>|HF|O|UOE87-U=5?M;D0_MUE8D+31'L;_D@4AEJ2!RO"++*#FT=9?
_%:PO8;?|YZ|!#Q=P>@W=V49U&8_M3(*P)I%!(5!;D2@#@#261G@TGN'CQ(IT_J|P|1<\$_.^9UB-C0%#?UU
M<(G78%9SB\$A.HBDY":9E5J;UR.N74SUXD(X'5@|>(O_>K+D)=*WAP6S56=_VKJ'#^ZO#-_MZ&@7;U_"X*8=+3&A';
=DU8;VG_5C0&K_M'2|YT;.(PU3>9;W@T4H^3D|3J_56;5R6J18R.9";5\$%-6P8?)&B7N92&P*B&
M55O162IXM&*/%#%\$1OW5Q<7F5N;..SVR9RSK(|AK-!9|@1"#_&H^2|*+H'9BLR+**^M3".Z*;_<_D*\$'\$UG')?NTN'-
\$Q_MU'LOZ7^\$K+N;17%W6_E'SGQF\$73AM9VI%N"5H_T6H@|&YRS96+^CAD:TTGM_MZ2D8;J&)GHX=8;D-B!*2"?
4=L|80;?>OF"M"%_K9;/M6)P<+>.YT4F38Y=@Z1_MJ80_PUZY=OY2NOEQMFJC?'DU"7U_@_S-
*JL7Y|RI"HK;XJDMOFYJ|+<O;@1'_MA1M_IHQ.HNM^F@;IN?=@92Y%"HN2@_M^CQ=V\$%O\$9_-3
31K;8E&I=CD=^275OIX\$LV|EW;O8-B@|N|ZAIT/ZC/G|_M|P|E|?+|E^7BP^4R_?/G;@^E=H#;_*2C"|B.6;91
=G)'#8J(+NFXZ;4|;H*_M"%G(9#L9<"L9.5XI0\$A"0A;*6<6MX*%UW/0\$.>V>"-WT@?RXNEI?WA8UK5SO_M<;
f6;U=YO@BK|UN"WN'JXOYY'M0ZYV//;I'1?V"/(8A!4Y@5<*9(<_MYH*J1"B;NTNGDKSM-%O^<
f49.O#KGO|2JHM7A;=GSO>2Y%1X4Z@=_ZND<^M'DU'\$5C1B'(C=/'K>@>H@O-\$-I#HU">>AS&YQ"-
")A)Q";%^IB;2_NMDYOCE%&6X+BQSIQIQR|_8S=&GIG4L;\$^:\$A_|*ES,ROSSOIH*!7RXP?
M,%7VN>?O9DX7D60M\$A5@E8X\$A;:#D\$JB%XD\$)P7)HJUQHK#L/D>M;^M#AT7.^T\$35V_KY880I?
ZQ220.=!%;|SIG+KIC(+60F."C#;V|X;_F&7A@_M|FQ;7_MK@;8K/<3V07>V!"\$J;_M@Y@BNEJ#IVA;_YV+=W\$
M2L3K@>MZDXKTUR3;|V6Y^C;L|GL9E=XM(90Y)J|GCMX|IR'CT#5X#4QHL^+9V_P4|CX97\$YO_R^>0-DN!?"&
<"MR>U3O"APGC%P+!KOO*LUQ\$|_!(WIWSXMO_TO^N@M>NB+&|_L."T&FJR&4;
MJ4X,B"W5N|)Q9T,IB00;02;"\$MJ_3RZ!BS)7EHB1IR86/H^&VZM_X63U;5L_M(+NI_-=;?
EWANWO_RV|===>;|W*)S5\$B3SY)+(2!*BZ"#9R)*%YD9UBK_Q|^=M3L""V;91DI3*YAL8#W0'DI;?IB*ZWF>ASJ%
<_<^9\$HX:4-5)F9C!_M?945_MIB!1FJB>=30/7W;..6H|V|A|Q|LW|FJ9<|DQ|OO?X00N#DCG9?"(N=@Z6?
M6Y*0J^\$8K7*PHHTJ|V48@H>>|K|H#)^AB90G1LEI_|JU2I_#&E|H6N'F_ME?
E=E08T@1/K#A&3.D"*LL".6KRO)U)/+C|Q4X?;=_83-&6'D%-UOAO;_M5;KM?AXB(LWL_S)
|P|@WQWBBJG>"Y2@XG!@?(<^U?&BH78IT4F=%K09;J_MR66F|A(EV.(N_..G@>Y\$?W'3#="S1UE+\$\$2/S6Z_8?
<@1BDI9T.FMG6W|M.FH.6=-6X(QAU;220>|YU'CR|3LK_/%|L5!4;|HX^O|A4\$^T^H|WXNO_^_MEY^7^2;865-
LPI5'!D\$H0T8C<3HM;!(7'K"N#1.&UV&63#53O\$+2P'PM#;+_EU(P7;XM#_Y^)^H*63E.8S\$X*W%.M|0%Y|<5A
MO;\$A%X.MM)1A;/J?K0!|BZZ^;1<8L;ZE\$.Y7ND3%OO>YX#|3Y=1%UXN?=PK=>CK9Z;^OZ8=S.K|1_M:4>
f0C)B3P@CH;V1LP@/L_Z2U'R;7ZY/4/3M|7_HQ|C+372@4^ZYX,X&L-?Q\$X/DSTM!72_M2&X@4X|
/F^<'RTV+^WQNF=|YR;4;MN"9;_2E@|L;A%_DQ0|8&34U(D9C&X_MITJ|CH^#_ITQ90CPVX%O)_\$=73-
RU_'HG06C=I>6;9;9NT;+A&;JP*=@E_M;U|KL+SF^4C_X(63P+VW;4?KN&EM9D;LPGY|_M;H;|U>DC1N-
BWU*0H0_N_MXH\$KT5@O8J9|JBN;9-DHG7GLTHP|O#;8|+&(CB&SG|KM0_T|T5;G2-M=6!?'^3Q?
OHIA"B|3PJDD^06*_H(%<%)&N62QM8O(9XA;5JLC8^))T%X_MFH+ZR3;ON'L?
C(I+)=>)D#)26L%;AR!"N4XSJBQM+;F1M\$V+17>5-IL*&R_MN@/B8IEW9WUO@1P5^>IRF;|L|M*NBU4_)F&O6
M(GDTIY*IK)"7GCKP_H00OM;G;+SB^SCIP_M|N|P^=BNDR|Y8BRON7IR;13\$&LE1G(*#|&E1*<QX+&*R)T%H
%#;)|DIP>75+4C&K>MUG2)K6=9P.A"TTU(_S_M^&B=4&;LN0_&9WO2M?
KD1&OD|(\$*5#X|>I#^|_9V;Y@"WDWAI%DIY|_#C1_MZTRW(|O.L&=R_#NSI&G)H|U5;R;R*29Z?
H9"R"\$*@D\$Y;6EF&WTQ!7L;G?_X|;9;9R#8G92Q8F>UVH&RL?1FBSEQ9(Z3592S9

MM&"@WSN50U#WZ#%Z=AWWXSH^(H.G652V&.9P2L-M'3I&C4-L'R@5->|JH(SV+4>6"Q_6IN5\$00KU.8|X-
E5IX+0 MN&VW-W'Y;K7|E-7RC67*5JSF0\$K|U-K<%T5CK@P6IG0B@YFV880+=|QWWH MQT3>:6J8'F_/G/&O/X?
%)^+_7EWEA+<%U5:|%Q2+/\,BX:Q8'ZU)##(N'A1*
M\$C%R|Y*7P*3D1MK6=X2G4IUQS_OV%GLL;4X/X|'=2N"^(HW;7@(
M+|Y|W2W1%>CJHIGFYL>KRAE%4H;K|&EA'7NH8>0%*^3=KS3-J7L6^>@9TCJ MH|*FA?:?<
J8)JN@164|N399Y8#9@D!=78(Z=|U3-BTTHY|V',QPC-K3)LE'@\$Y+67Z,DZNMV>?<
<343*9F%>H9WOH^X6%*ILW&GA-0APM^PDG*CW+QP&U&/A^AI1|37 MH39%>XLMIGE5A:,9ZJG'JY=,DY2)-
A%,FID9"W3&9)J8|^&N3Y#339ZS%9Y;JZ C-%T?U+<8FO&BA8MT+B<>&"C, M|2)GB>(2YJ+|+2L1D1X+30_1TDZ,
<"TG*Z\$Q_VCKX|WBLH&K5+3|>@<|: M(AM?GR9:8"7&.I|1M6ZXO|9DQJm%VSI-Y^@AV:P.D^YS",-
|O+RY^W5X-MM;Z8&|BF\$4S1-)IAKH9SI2*!..M^U&EM8+H4P|'H L:YTTZU;E(|;- %CA M^/8QN?
-RKW1QE>>+3|MJQ_4|7)'T%_2#VITV?)DO-GH6VY^4TLS3AMWR(AH|X%>UJMZPR MQ*U|YUGP)C)4DM=(A?
%>T<^SA<>V=W8J.<=T;M:1><M(&JX&X-C,43IBFK=BOJ4LWFT^XEX08@Y9UX-O^RR&-
&K+EI#ZOBWRW-IX)8=PIRS6*X9IQW"B>XB>7|8 MN)7F8IK8FMFSK,2|+JG#%"T0C4G"U(4#CTV(7:
<>COL@^FUY9#+G=N@S M9UY8&XE|'NGDEZ: 0^' 66&|*=G&YF-MS_G-(E?'Y#Q+GU0IWG&0K%'. "9.*4 !4HI
Y8DU&QA&"*0%W;LCR'AR MF6DR*&."HYU4.T@S/VO>WUP/@M,460LC#?_012UUA"RC*|+|\$: "KIEZRKA MX=1-
FZ@;T4D:65\$|0/#IX/TZZG\$4I&3.(T1-YZU2>D3F+MG21I-Z%>:|%""S:(H2+(&(BLU 'IGH>-\$CN MO&/,B7:-
X3|@83^\$A GJ_E>^YGC9=X%9*XK108<".>-B.0+1A="34@C.&A-H/S13(LA:6^67B8DFE?S)P#20TTF&_E@N\$@EH
MZS6"IE%_G6^J+|F/Q>:-YW@M*^|\$\$\$I(8*Q6L""*GZ-(#G1A.2+(\$YVXC:\$U MF+AHX_/@:9Q|0|-_/WV^?%O^OL9-
A?7:6 L:|A7+_|F|7OR7/VZU M?0WV|QF|M#|..F0#G5_04(ZLX,(\$GVJ?|@0^L^6">0.ZUW/Q*|M9RGDF;
M'0#W|7|)I KM*V_4IU+|3Z3H:;21)I7M..2-8ZGC3="7YQ+R|_-U#-C MG(|E%N">W):69V#6Q.&07%5/K(9.NZY"-
)G3-J_|@SZ'%#L"Z\$^..U:NP MNMQ|RK|WZOYMAR/PBGZX9?E B_#ZOOVJVZ#H|^MN" MMO|"-YO_/^>7GV|?
ZJQGS\$@34"#XE JH7|F61@%#)3|I74@|@|V|)6E S;3PU M+F"G45D^&*W|PF|C+|H8N/V6)Y0JV%>C(8Y:2MKN8V=
W_A*:0|f MR0K9JPK*_6Y^|M&HT|+|I&^XI\$5="D* MZ7^G/KX|;6EKE4HY),|(M#K,R+D((B6Q5Y)@,EBQ#ZQ=I
TGKQ;F"%35Q2^VJ5X=9%+6 MK:Y=GLA5287X096 VX@8)6W8Y@_:GZ-I8JR-82|8&NIE7Y0|O,M3^;MM2>S
MJ|QUAC8D(R<8L|>@6.G@M0C 1-E&4L6HW4_T@%D38RUICAX&&3-E-(#SH;7 M6J)(MJ04020L=29,?
=I>NXZS6+P2)K'F'0_<8N72)UG3<135_03W-2;_+E?U MZIOV|;.*?GERWQ=9^S6^-5'7(3%Y6|?
QJZK_W|+C7WYTI+3V\$A FRT0=+YIQ):.%59IX)D (XQ2>6 M0T@|@J|=#3%;SK%UGC=
|UY_K_7VX3_0S_7@7V^NM'JF1Z.WFXW M8V)%ZB0%>587|PRR<E"A8JHY&96@JEAU5(M*7K|>2I#P'7G2?
(DVFP SQ_M/<_LGY/%K?EM!=^T-
'PZ#+4T:V@>&U"QQ@#G31:C9HW_IZJ0GAT^|Z;R|TX6|)Y'26%LTP1HL/JLX5(IXHf+RMD@Q_QZ|^C-%FU
MGEPQB+|H#^0)/_9-MJKP-(W|A'29FA2FI)<0E,FI#|F|_ ">^(P4|IC8 M&HW/T31M=#|I\$)QJK
..GB3164J|F\$S|N>0HLLQ@4RW6PBC|6Y(N<|Q8 MSK2S238&_E\$3^_4C@*GNZG58?<C.FERIS.B_CHG9257X@J'
|/LV1BLP5\$Y.^"GD30FMP0G2E'#9 MJ*RU1SWLV<>X)IF=4_X1^|+7_-=W|?/R>CW7MF;\$NE% L<+?I'Y0Y
M^|PY;|C*8H9%&D0RH^G81K8|N(XGU:|4^/T.4LTB.%<3|+;<#"YSH 7/M2J M8
V:6^&*=P/PBQ+|B9YKUR5|@JNU(|R5H%<5IN^<3&F&_>%A;V9B:XV MC&&U(XK#|&:M|5Q|1:R|S| S=@?Q-|
|RZERW4|+ZG>?|C|":US+|?;_# M7XC1S<3BL*J;?L3JHX&?W:C#FQ3FBS!QY;^=I7)R^8E9_6|^7IP4-%;UL+/4.D;-
|BY93RL(6#BA" MO36,"H\$S");SQ("P;A|+P6.P;|4 Y+;|89J|PAY@|NG1|<2M_6%Z^6|UK MD?%VP&>:TY?
|\$2WD:"JG#:#=" @10E091\$%KBM71F;-V@|FLB^H'8_Y3G5-M-7?>=|H|IOWKS>D8^UTXY%
|R0G)2C|#P6|9Z5B_+O|HXF&-XH.GFZG4 M&|PM9#>UZG|>_KE8X?RR=|Q;T\$=^GG_=/NZ6TG%E@P220""GD_F*
(>EP-BI(M0C|3Y=|S'A|C6FRPV-IH9\$LIX;\$FWG|;#VF.BX0W@^_4#)87Q2#K9\$ ED2\$Z M;T\$2EIV6Q6?|IC_<
ML>/*VSKD)D5_*53-;7ZP_|35|(|PABZ&/R(&+SD-G%L: RCJ0|<&NON|#| M=+6>+W"|_VR=?
N1H<^%D8%4M<6IRP6<#@*DCDj571Q\$9,T3Q'4RX/HG%U M>WMT
*Y=9Y;=),QBF2YU9^2Z^8I'<+09;|OR(C&%9\$SK%<@_\$(.)NZ73?M(C M_YO#I3RU_)V)V:T6+;K"203CE0F1>
(T1H0PF23:B?ENV.I'O-|A_91<C M8W2R/%E \$Z?63JRS95A-AL'-I|=5B@2B8H.4.%2U+\$X9>XZ*DN
M"N,D=|^F08E1^LS89BUM<@PS,,4=ZR\$*R;#0@LKI+B'|/ MDR"+|HN0TA'KF&8+J%CKH \$H?5V&QH5K>=P'7'V;
MUTD;|L#W*T_TD>N' |5;GLZ*5GRIDY8|@)H T9P7-/&M%QGZ3Q%*JWIAK;D M?|KPK@F@E|UHMP-
DUW:4N\$|L_+Y<77X*G "GD(Z)|=TM=H<_OL^QFB|3.D| M\$VS3*#|4|)B^|8XA)U|UEP0VF%|F3H>?>C,,15-
D|!|N+|ASW<|01R4<M6@DYE+SK8|W)/BGZ5EA=M&W>|OL9DB;>4WP&N|Y2)U-'W|.#>3W.5J|4|85G;
SD.T10\$&'7517'6N|D4,SZ|Uf6'65*_|P3<+<?V;^M?;G^_K|,%^L9G=|,UO?#Q>1*?9#U64#B1?
F04^8T|T\$D>N;GJ;71\$"?2 MJO%PTUMY-TQU&X/PZK\$|*XP7+AFK&|).YVNRX)A5H WEX*RY>ZHG%WS"6K=?
+5\$10E@=(Z M@//20(Z>23>J+NMU1Y|T*\$K3YN8& U|HRJ@-W2|^O1IA9 (RM:Q S-CT,OL M)=A-P67M/1
+A0'_%Y6EH3^5. I*/RPSK>-|MP<+|K>0%(|7X>|.XFJ^S#-# MTC\$R2*(_VSI4U-
>\$R|9=.)TAE1R'E""6AJ@|S(C:|VCJ2%V.\$|CK|UDV-?Z1@\$(| M2|30"9">VGO:IRSJ*Y;WO_SVJ4BRD(4B4*
|H|+|A,W#&\$0*N\$|KH+ZG5;UV'7|_D)H^>B%T B=8H8O.G(|+F2.Y/TMO-M&66T*
E\$|D&4)9Y|)HCE(B>|:R24|>#|26|:'6)0N%-R:R\$ 5I9*N=|VFIHOM+7.(#(|M+7.(9CKL\$+(|DDY.EF4@U2?
CBM|7|GH)21R M#XB|&\$5_0|UE^XMT*F585|B<_94-=5MEN,F0|F9>U%@FR8K5T7&#A? M. 7HN;AK+F^5Z_?
5E>+2YG@67NF; 0419TTF=#;+7T3HG%*TBO3|<|)XAM.^2SH/M.@B(+?7VAK)M/X6+L\$CXX3/B9>T_?;%A?
8P4VS,KC9Q7.X3/LR33HA==89 M;1WCZP26|>LB"-H'F(6S>F_ ODZ2;R(|+ 4R0&W(1+ABP4G|@*42R;VM2;%_M-
H-"R33#H'|LD@R|1"I=XBY_/XKZ_K|;- MAV|BD+O>1\$'=PN|FT'E>92EK8E \$3XY|B|1Q6.+|VQ"5*(SG>|!|O;|Q3\$V
M<R== "Q5^LUW|IR+@M711'ADC8#*%5GWJ)W\$@\$^+K|\$HAK4,NT 1/U(0=^9 MA8.4NVPFZ0YPL4Q*4)HG
M(X41.V9LUQQC:W+YP<3-RVZ3D'|ASJZ_IG/^,WO% A^W=XUO%LM\$Z|7LT@|
M+5>+^0U%P4ID#D\$(|'R9&VG"Z^*0'.><^U2|2IV-XI80/2<+N8L4>VWA-E.E MN,PUV>X@|JB"HEY_U3+;;
(TA9|*7UEVEZ|K3/D|N"(6#A=C|&2%0S_3:V U7 ME|I?I73UY>|BAAD_(Q%(WG_5RLPR#(8+1.Y^|2R-
^'|SBB'B4S:*I%AHG7D|_M@LQ17RDWA-78*CH|8P_H&7,YZD|^090F:"CE45"LI_-5U*
M2EX81GYCZTKY9TB;JDSG4|VJ.@|&\$&|Z^U^0>|\$Z_U3CDEW_MQL#2GEE= M8=|')|_*??
5Q<7RSW|>MR|9K(G5_6F|F9|Y%Y*RFXS;V|0|:
MU|XS++4N7VA#^;2QJ|OB<@)%=F"5;SV6_-&WQJH3Y|9WKN/YP%=?S/*? &M+GH2M4&0P:."07A06R<>3B)XVH?
8HT22 M8ZNM XS2|JOU&NN;C5GMA#?"Z45:(>*0N2H(|@(|669/\$_1:M8Z;?|@=(. ^MLFZ(J=/%W_%6=B|:
|TZ3OWP=5JQO=)|_ (UQ*G|=_0D-MS.OKKDEXK;WM(|F?6W=\$\$OMU= !MM|3D;N;)PI\$AK'G:-(X9S)P1AM&68K2
M/9C H&=(,FM1|TZRW\$@BL_ZVX;58RGFPZ@1YYG6'R;TYFE|F=S-?Z=^6 MR SG_).BIFL?L_@L&%-
Y8F3;77+DA|KKI.*Q="Z%DE9//R:T'\$U^IH;X(YR9XUR18#C0?T/M@\$|"\$1G)QLN@_C.6
M|H|E#;>6'P.0EY#C/U:F'7E|4E|O^W1=BR:89\$*|LV*. M(DQEK0?/*|3O C-A\$%T>|H#^D'O
@J;3UW>WZE)*64;33P:GS9AD6ZW2A>Y7; MQ^5/8?/F4&F#?<2BJV=O:5JB,@MY."X3BBE;G_/?
(^*;%W@%:/MPBW2=E" F<*I\$4D5YTE<,8(2-
P8=\$PZ%ACK'PX\$FCN;MG0D#4#VF#O>R^SY2V*5FC:E="00>H|^BS> C3|SG MK\$SSW-|CI\$Q;J(<^>
#500@=8VE_X|1PWDM>NSN&6\$%|?K:K8Z7= _+|=I^|V, M|H3,DDYADR1%'R0NB-
)26*LOQV*#TIDUY(ZE==KRE+,@|2QJ| "NKY>+C;#^ M|8KY5A\$5#4BOGH"IBD%"0ZS2DFMK;DUJF\$)PF;MM3D
M+;|KIY.T'5+8C.6%+(@R EPR.L_\$>QJW0@|>>:(8L8;6;LW5I^VH*2|^0+ MCA1VL|QF|RXLM|=J\$^?

5YJ.695L0^Z^N=-V|^X2+3*GS/\$_AXM&?2D)I MEM8D-K;JD3FSH9SIQ/\$K
MDAIH=EE:S%/C17|=)>?7>L(R3C/G#-@L@ZJLXHL M?M8&7/10%9VJ+J\$"*X1L,%T-C4;*7:6\H10N?
RZFKU-8LOF>0=-7W:V3H% MW\$50I6915.\$A&C94P_0UYC-|=RV_-J|^<?1?WJ?B"VTRH^C:6AXOM:F5
M_N:650*58D&3*6A2AOBT@D.Z%F).A.Y3JZ5%&+RKV^FZ_@I@H/E-K420IX M?V82HQ>JICVS:5.%363_N
4.1@=-.J2J9K104K^<^<^FN?@:2H04/5 +OPXIKYC=3(RGY0*EUD1L MYL:5+MSI<1P2N1J?&Z1%)H4.@3.K23SXXF?B
9RCA*=HR^:CR=|CJ9I2R<: M!@*C*%0+4.VYV6TPPPM3CK8&J'D/0^0\$4)*#5D(4LC<^OLZW.T=19=GH2
M9^%U@CHZ@->V809CS??NV@?JH&M+ 3JF SIRGR2%5IQ'H)-;E5(2 M\$;T!Z!0=/UBB?S.T#,AW"!Z_?X#1=7I
<7KC@FK=5\$\$.&"NSWADH:YC1 #K M9+#H14^F1IWW@X1T9LH:(N=TP7> G@<.YX_T3S?G.CGM.O/
0+AZ!>H*AQ^4 M!FF\$"EXZF<0(=1*D3-MJ)>|Y/*C1-|CBBHC^TZ|15HE*=XOPD50AK-D1ZK|V:N9X^3?
91N0M9I3.U.6 I>T117FX/7TGRQ M*.H#5I;W8=67MJW0Y_|:=F|W-Q&V. M>*.HE.VB0^3Q@&+D-
T3./"F|>)*07EW307I3ODPTJ:MH1 !N1H#)3T@;40Z M TSM=F4(4C-F*?P(MA|O)+H(
P&@4FODQJ#K%G#X1I.T80+CWQ*>A50H M62V0G2^NBM\$*=9!O%>G=-.4=J^AYB|K#P)UP!9@TC(^HLD7PT.
())^D2G4=EJEH#A=3@+^"W3P%YVB M=D|<'47SDX^1-"T.X+&M(XGB|'|+&UIW|HJPE-PRRU0:4J:|"-DT&=%):
MAA*C.-W3|P<".K%VIROVX2/H""E//1VD@A.3K19-7%%%PBC*D
MU3PIQZTU=U)1CXRV0/H(+FS_.3I9GBR@J=7Z|NKR*TD:Z13Z7 L<=CPHICQR-MA2
JTN852)+F!%*33%;F8WQ99"2UE@XFE3:53>0G@3%^C^OYKN=HG\$K;G MFU4Y99.C"" J#&:G(0CIH6CN TJ3?@-
*G/OKSSM.W&Y=LG"C9B6/P1ON#; M!@./^X2545H4 K.31+RGM6A|18R_402;R(C%I-.R5@NN+=4S6Z;"W>J6W'
MFI#ZA.O+Cl@ (B-W%;=04/PF2")JH)*I X1|@LR.*RTDP(?Z!S<^_#15-I(
M7N&PIM^N15I4I&HKO^J76SV0XL(N12>*^3IT5B0)GIP/P(BV3PODLZ7- MG|W\$>W_M:5I:-
I8=JPMW8G"OZ1ZJ_0YK^5IQV7B-NGR(TNH<^_R1YKDE) ML>8+!\$1.B- M+H|62X^?)VOYM=VE"FG-7JP6=9;"%MS-
<*2SE9^LYF#(0")\$N"BQ(A."<3IBSEOT=-9 MP=2I.G|2L.<:X M&V26[GOP9I5-
IZ'@9,DUTWKS|D" _AOEJ.WCF=PSKJ|5VRO<)O7Z>_+O&C7N&-MT|RH" U@C_/U^EB6=>|;:R2&:>Z!
|8\$N\$@9.)2G4CFO0E&LFQ%;%U9^!0I M)X|W7_V3H|"A=UC.2'SXB7?ULMKH.%Y^V5CEGEIAD|
T!JZ0#C^863I=V4I4A=HFL3UJH@C/\$\$KM MIVR%A""%J\$WIN#59&
<4')6&.0I4#)4"KF88>!OD)RND)WS=;9J_UHV70D MW06EO(ZC4**#+* TDZ"L|R:ETFI(J*WO^7X-82N;H.V.A>
UDKK72 M?+ MU48UE|?;/<#E_@EAK.('3W#7#QO(| MBNH_@_L1DN_Q*S&)>2NTQJF3*@NEN02;
(P5|H1.4#P"J9K#%)\$Y_SEWF\$D M3HO^T;R;QKM>^KK);_K" G7I(E0BT^Y.AB3%\$C|67Z(?!2.XBICM^0F%SQ
MPOGFI<^T#*=M0N-<@!Q-8QV@199C< WEONQ14I| OX&O^&VX;S48G@;Y"M
MJ7O.\$E>2&0CDW(081&2I|=DXC+)|I\$7C. *25>GH"W>U
&@\$=BT*G@N3#G@%7J|@JM7NMMVZMDG3J|5AJ|THLD1Q2\$4\$;SF)DW&1VF%|BIYINQF-|J8U M4T57L-
I/#+K5I2.ZP964#+2PHCZ8\$>"J0Y%*M8^9AN75:0%#W3FL1V6G|4 M3B>JH_XI6=BOZ<^L.?
X>MU!7UPRLH\$+&+Z%?#K|73).#=-6\$+Z|)U4EN|CJ>D@:6H;K(#4?KLD@A.MOYH?9>&3B+.*0|VDCHZ@%.5
MPMO=L+^9U.)J^KP9_ (T74.%ZN_39"S)KYH^7K%ERWU^ELISBG#I6#4=# MZ!NXXK^9821W E=?J?
MKR39G|+BG|@.->%"3.1+1-@D^D>?GLOA@+7>I MJ<^T|C^I>+&3F+|3%=-!\$?7WQ1H36>K|_|+69 AORP0I-ET
J|=XM_@%&N9 M!"8QE1C5/U P+0=M29T^*Z*.4^G+|^*%E4:4@1*.2.7UU.EIQ.CF=!
M=KIY|NO#@1@:K>G*!|@Z5@F3(FCS/N; &T|L>M7|3H; 4N|L#|ZT7X+|/9^IN16|K8 -|2O<:.\$+1 M\$0XDMUT*9)O#|
(0=5J0%"HW(CA1=H |N|: IN1BU361F1N.^@X=9YT+. MX|F/P_7005SQD)V?"5F3%PO&%XJ1@C.0?
>"0341ELXS>BC/LJ.NW<|L".4 M?=#|^@%2|PI|.#USYV9RD-9P|HDR|I* @J<@!;>D=BH6UKK1^\$N|7S|ZX?<
MKQ^B@@|@|@L A%;R IE|4I)9.HXJ6&-16@PI9^6>"%K%UK|KB|M';& F=J QHDTV\$|UUY%K8LSJ9D
MVCNBEA:L@:2|Q.MU=TWA. @)*)*EK:018E &\$NT#9@/+18R/F|YL5@L|PN= M(X3>7CV#&|^M=
IQ=6/7|Y.PBJH#9S7P1(>H(L% J(\$D|E\$IDLB237W?YXE MJS=(^/ >RY06V5T@:|^| (MJ_D:#>+?<
KG|HON^R%|M).I G7I=3(JR(2CD+ M4M;|?H+7093|0@ZZ^B"*D\$AXV)R>J)8.V4ZK#>_>K^|<?0 M?J2DA:-
=F|H*|&; DAY@")&R)">YUYZPS"@X1T83-|5?*\$JS=2G2KCP#V-1; MUO-O-MME.*CB5;
(A@@HS\$@24.5"E@O^F9^TCB:QW""|CX5TU;O|3.%0-O) V+MOVMR<.T3&VX3M/ODY Y4N|3MU%| M1;IS^|Q?
4+2QOKH|65"QVW.F>(7F:PUG&C7/|A#QLSL""|X2_8U6V;"B_ MJ?7_ ^W)U^2E|PBJ9?0@L/.Q9"@&-2B)'F+-@
3C5|0:B|'#2E7N?;4N<6 MVCH>AU8C5HX2|_V|7)0T^R;4U\$2OZPZ6-7%V=,TX2#IOA0&NT0<.;!W
MPR:++E;7Z@X1HG+420Z-38>L)S:>^8M^83K^DC/"46^_ KP/%BTQ |G+|I/O M:(V""\$V77@2VY77A|<|:ZK?
4T8+&E.44#@+H#%\$\$(VOF|ZF^8TW|ST\$ON MT2KVQTC8^R^C#F^R>6EYJU7DZ|A|0G7ORVN?
(>UU<7E|5.G&1Y_6OZ=U=? MME7B_&5|<^<3^4V.DPBMA2=;10GR#P;|^*ZTSJTV@QJ/E\$Z"RGU6,T-T/
M6:E=6%\$TY2@4=5!<=\$QB\$H?D(A&TA<9>M:S.%D31VCMX5> M:SUT^T|Q185K6\$BVYWY9G)C"N.6 M6;
(M@|J/929LA"%G.V)?(>9A-EC5K0-7")G(Q5.KBCW((4G^R2Q*S|&Z4G".KE M(A>BY MO5".428^1&H^#TG_>^!U(
M;"^QY|AH"%3?V%RW7=CN)UYH1>L%9R8">1TD-YXBQ)*0OHU.D%VAIUP2E4LF&KM2\$B1U>1F@E)I-
%*%*,UOF5_HN|F# MM^|0N|D#5-!G|YYP;=**88.>|^:U2(N4|#5)<%Y?V|+U^MR_889(SA1!<9**PFCIQ^XO=
(H0J\$N|GG MXH|*TV+D1;J7(XEU^Y HM6|S 3^G1#5CBO#MP|O(P:N|Y#H8\$@N;02 MM#GVL4%RDER|
|E=Q#.6@S:"@0U"@6(N0?"\$22NSE))%Q?EQYN:N2M.FT4<'<
MR2ER|0TD|M_TWGB^7>P9.@1N%I0^7N<^*%0)5"IS_|XJ+R3;>|=;R!0'EIM MVI3YV&Y6:X=^;CG|L=0UP^7V>7 H
T.J|R0A 1S1|U).AM ^F"N5YNY M6N|@.#E.OAT"QOQX7FH9K=36 L|ND(N^;@L/\$CHPD4,A8H|^G|TM-VV/T M#%
Y;@:XL3>^>_.H6SVA2ICN|C|G|SH U\$CU.X?G+=GG#<6Q|XEIP3@Y M0;(-XL3=X88SQ6(R\$^0U|H+D.B.I.T|Z9|++5-
Q.'&X|2_8)R<(-G^<^(-W MF&D^U|1%5K-9.UW^>#)09?191?N#B 9C)-CHF3.7BY03A%MAT#A/W)3 M7&-6!?
E76=41*=J^2V1+2W)D1;E3T@Y|)?3L4L_|F(SLZ>)MH/+GT>ZM-GZ M<-?Y.OLW|SI=VH.O^8V9SB\$POS@S|D>
7|H|SKJ|3K|S|UN|2S^FL8A5- M<#7E&E9WR X24I%\$;-S4K>^H7Y1^1(TO/0#HF""+T#| QIRL<+J^= ZWK M|
M3*W6I^*C0FIQE2"+^3X2\$X_1_1(?\$0Y31|;Z.ZK:60.04JR3K0.X OQI64T M&'D*3|/|+15F2|C<2_ \$0M72
KX<|^|5@E+&DA!179QX:4>=<DOZA>B@5_OQ4.DW@%L'NS4DA4GOX(\$4@PC=I90P|U2=" #DUHZ|6S|
M@;C'=CPZPY.W<@S1@M66UX8L%|_Q5#O@AJ3J^K\$VC(RJ M^HSUAO|S"%W)H^Y?U/C|A+
L^JP.N4J\$0B|*YVC\$D+U1=^HWG^|^_ MAX2^8^*5I2M1-P10HXYD-I5(>A@LP91D)Q\$)UGMEAR(62=R)D=1-A^@
M?|++!O3S8G3P2^7#7<^YH2?P?B@^B|D 8@C1ZXHQ)P|I2.4M_-Z>|H:6|> M2J^KMV=^N.M@1@6^..EHR+4|U|HPIVH.
|C|%-;S|0>B).2WBW^\$U;P.BPU327(T M6A\$7)|Y0|3.XG048DV(0J20|XAC:1EZ>8G8UO|KH|\$.#-W#S:YNS|E>7CY
M5;^*V|%MOD32S@L-6#+6N8N))&<&&USMDDB<|S\$09MMS|?+2*VT@/C\$>.MH1 MO_SK^R|6^&R
MMJ@|6B<=X&I8>|%2A)9U7)\$G^T9I H="MN5^7 M6F/HM1ZE5(-V=;OPQ?JR-"WJRNBC;R: ^<5&MF&1-
YONUHL.Z^IURG*^FHU MX|A|9ZT='178&UK"Q^JZ5Y\$O+*""&@JOH0FEQ^U|UL<8T&2HRE;GPI/D^2
M%2^&FJ1ZT?_4OM.++|^BKA^?6J)P\$M|L=RD;?S^@IR@4T@@"@L*|L.(L MQ6?
&+N|J&^EO_/7G#;/TPH^/I3VCB3P#NSIZ^7&^*2JGIWH^F0+(UKC26 J M^OH#4VUX&|.8%;+6M|JR=67F0-
^FS>*TAMN8>ND;GLGX^F6G PFV>2!"53 M^|2-HF2>^_*|ZF2C^V+EO:0-
6VV9BR8M=9^!Q#;^!MW^9=V^|P368Q!1\$ M20JY;^6)03O\$@<5_OI2N.JF=-&\$S=MYF0LN(VCFPY-
X2G|S=7TLH\$;1|D M|>0N1 S@1.F052@F">|O=3@Z?5K&D;1.FS89^Y)GT=SQ"%U>AHMQ^T|OJ7F/
MWW|QA1_29|Q7%|@L=WYQ40?GPY9HUO/Y|;X:Q.;D6Z0^EF1/"@)1==B4 H4 MR(SF6|>_>
OK@A4RML_IW:3@H3|KOZ_A6;>_.^\$TZL\$P6_6BM@ M7AD5^79B.%8 M3 HLCM4T^EA|4 KPMB0G.
(>06U<6/4G0M+%;\$^2T%-_S4|B|U3(AYG4=0;X MD9B3E@6| ^%"G>AJ\$@3'(TAF377.M|4M|H|ZZOGQ&ZVOP|

M4\$Q1DJ9-29&WD*(C,+5BGD%&8TMIC*#.L5=2?18CFZCKI'WNY5(C*.4GE>M>XPCN0F90%
F(Z"MKIz\$-9JU+M\90M>T2B\$|R>E"3(YF7/KYA4#29LF1WY>M(SB&EGH WY;T|YC:[4ZEF12RCALN|L:A%
(('XDID:V63EIO6|JB>XZF<^T M48|P%VPM=(/RNHUPGOQ10SM.%LN|FO" MVA|NSQ\$U.)U5S?L5R-M)#UK'D0.
(&O:"9SH*R94B;\$V2.QIOK%TSH0E1TA%)|BHRF%TK\$*QS-6) MY? G|FV;*ZN|=U?
E\$ H_>6C*#L|@J(AFC.S)>)>E)2J7MRU+I7G|JH8N'MCQ_ ORH^Y@V2S3|'^F8/OW M Z0_-R|/OW6(A^?2+
|^=KJY^?QTIPO>?Y=KJ2YE7X^%;O2E'CIJH+ MW;3B>N9_MEOO_OL#W3R^H78'H3F|L^K?^Q_|
*3_/+/%A&|J_ ^QU01RYE&U M)3D"<8@UQTNM*ZB|JIM_1:|J&/|5G_ =CP^RG#|S^K/PP@5PC7|L;+K+N' M|;
L|A_KJK7KQV+DZ2/_XUTSJB|/\$Z&B<"49(GO^_C.XJ6--SL|^G|8?|Y\$ _MHUL%_J=H^|?_2
X_ZOVV_ZH=WIUNA|;^_|Q%|+ _=|%(FLC|_#&?;+|HN#Y M%TV%4|QEY|6D_?2
ZN@^H^*_ GYN/&@ZW^>G|3W_ K_LF|>RYV|N_YC^O_ MOKOFCOY/<<56*A9:*>->F*0_F490IKB@=.MN|T_L?
|RW^XRM|V_VLO_GX<^| ME-|O)YCO_Z>0PJ9_XYG|C|VF:ERE^UC.; (&*_GUK6_ ^D_9MW|WAQRHO_ ^|/M|_-
)S+^1> \$MOQ@U8W_V'5S|5|TZM_ ^B>Y|PBN_ _FWK|JOPU\$KCR&D_K> ^B&J| ME;_#3|_ _9S|VJ>VF|P9;7Y|Y< M7>
|YDPOVO%|^_Z9KM5SJ@8N20_EA|XC=O(Q.2YZ"TE&M7_A9_JX*8&G_+|36'|CJZ,YZ4K5UO%
M.IMKT|8T_9_Z9;W4R6.3N@J=C|1TFY_C_P|?H4_TG.&_ CRC#UQ|=4K#P!
MN01+^3*Z0|IT*5K6|Y3|&ZU+|C8|H1.A)|J?X^|;=(-5|?U|>D.W|5 M7_ ^Q1P&3"B|V|_49#|YZA&+(@RXJYD06#
<9_5=Y>#G|H_D_?2\$^_ZKL|5|J MI<(GUW<_7M^>8L_7GWYCR2L3|4%BV" I#9A08S58&98D@^1""_OM
MLMV|DRU4|@J6BTD87S/6'6&KHAEH4"0(M>WG\$-K29L4|Q:CLM3"?OM|HD% E MM/DT|IA_M0T#B/^>
(OS|UWQ%K@)H&6016H;<^+E_M4|/@4H|UH?2HV7GP?2ZV|!&/%=H>
M@0VMQOB&G^<^OKEY|EP%_XON\$4(+7%L9_PZK_#5>Y|3=NI|D=UZ=*D%\$25Q_M'DI6J|P|*E:9|_EK>
|K|+8F_2_)5F_M12\$D%2LGD<:SXB|J#A%|@S14D|C)4 M+K0@0B5-
@LH6*N^_RM_&J/C%Z>^;G^ZXNK|_3F+X|30^HH;1)4ME#Y\$*B\$|22*#C|L:0/F66)%E|!%|Y|W2:<<8G?2"
M4>5""S*K34W\$REJ9#|V%*7\$@BC|U|5FLPK3#PO?#8;+^|;LZT|3Q_)6\$U>Z\$% M&2NS^+);R'P(5M)"\$KE\$7;
(S4%/E)+1|@)P%(*_86)5L|_MAB'_ \$A_>?WP<\$_-|4?GI+0.OG|JVVC/Z+>_M76A|ALPLENT6_A^"";_01"G16E3?
CV+=W|AP9\$9)3#H|H#77RN.G0A*\$0A_M993.8M^N%GAW1(RYK|Y<0K_1?&TWHAI'18=81:??>,
MJ5@EY&0QO@R36;S_|1+O3HDWZM5;O&TW=/?40*@N8^J=ZZDR'@7*"DJL%BBE
M\$IR+U7OADWGBANHR062S;M?+NSH?6|D|W|+P|1RB|@ZJ3ZA=@19-PV&A:B^M)E32#T+T64|W6:Q=?*NSL?
\$PC4YRE4TAD1BNFN+;LA0(E4P81B?;NF1|D_ML|Q9?|DCL|BSZR4^|7|+4;(F7E_7|5%?
YQ|KSK"1\$;CYLFI"|L_K@87T;)_M+;L>HD|08G|Z_?B5|GBYMI5\$Z=J_(*WH|X3QQ_L59ZG&|AO|CSV)|
M&26SF+K)=Z=\$J.<>DWW^_3|F;+|@*V"SV|L|2U<^Y.V\$'OPOJCB?49("I#_MR|B8Q6U=)>SN6|SWV-
|HN^YGU)'KJP|44.(SO7#W";&TEB,OU57TPEVQ9|E_M8,QBK:Z3|@AD^/_VQ/=70_?IPR4C34C*6BD6(WD_F2O*BA=
<^BYN|@_HO9X_M&5|&ORRFZF|_#X%?(2)E|;ZFD9|!;+P_"YV8|R\$-HL^5O_I2&V0|O_R160S5_MU0(?
1%|!KFV+5.FK|2+V|7_2\$^_&41F6M2E_1N&MZ*P.D8G_U'4""P&1_MJS|(O>XE%.1U5QH|_*OUD_81
:5#5M8GS""O(?LGB|R)R\$ER\$RBYNZ6N#=\$>\$? MJ_ZVGAX>|G^W3\$?C>JHF0<>8QV90%J>D".EVXYW6WEOQ\$F:I
=F9T|E,U0U\$ _M|@|(H9BD'I\$Q=;|"5)A:%%^G8_D'H09\$MSAH4&JO+#{
MJ01P;ARD/F3PA|+XL6:%M8GRPW(0)G%7|U_Y". XA=R<"T4@I8#N/E<S
MIVL*5.4|G\$|SHN4URD(#_E#F.5M7BWP\$4.)"#EES(3Y6:L;X?QPO<5KN_K:_M;Z5C;)BK<^O
<@_R4&8Q7S<0^0B@Q*51T7K2.E10<9Q;+^E_(2ZV2G_3|H ML_H_ ^N4&9*#;XL)N(/(10\$D+?2
AB'+7&%;BS>;RUI*%PXV"SU25SAD9ZO=9R_M_S)090%B-Q|Y?U"XF%J;F/FE7SN4_J_734|5H'VNF"/?
G@I#O3EAN0@3^+M(|N|R+N#_CX|Y(4DE%.I*8S0NHG@NATG0HJ#E+I|JE<=Z"V02^T(\$-E(F=V_MMH+40X#
|ZBK:&J3'B&^T(+L_K99|_DM9#X\$ _M*TLF"3L8W-W@Z*.32;@+U|8|EQH0<_*+|M%C(?@I4E5|C8_M|'(E
FT;BT\$)>2+E)#@%Y"+UYX_8ESYH|Z;F|6DW4+FW5G1RNE/AKCCA.*K_MJP|V2C2?*\$A@:C|L5TR'59
"M:(VJ3CX(3=K^#).90%|HUTN|R4<|K|>GU|M_NJ_\$(G|YNO|3_M_S?W3PE@;RZ7|D%795D
CARW(RZ|J;&-52D4WC_1\$%Y&ORPE|FY=^?#&2TM_MWGYZ36^>;>4ZMA|QPLSJ|KPP:Q6*32UN-
|J3(Z"\$8X>"1%E?SBO:Z5=W<^M?""5XAX_M#O^R_17W;C_QW%\$SW*2&J5_1=#2)ZR:J7%Y+X7@97
;+^|;K2G'WAN/5U3C&_M_#W>W+Y|>'5'|/S^>)2+1H_|&|H|/N(PM."K7M&)2)PNOV+C8A>|!@\$G|U
M&Z\$7/@8M9RL(FE0TB=7"R<E_/QYS=F.6Y2P|).H6.H^/(EB4TFBUOL0H;+)"|K-D(?A>WE_4Q_MUMW|"-
H<3EA8"NF%/_G@E6WF(R;C|29DN\$QBMFXC|"%P|4M9|_J|U|DA_M:17&>J
YO'ZA>W"XO/0NOD8A.R7";Q7K<1>F|G1>)>QU^|NSO=X:NOWYO)CO!Q_MX"M^G\$W+W8R7/ K\$;+G_R?
1.0B_V|+;:CEFOUT\$N|UK;B|PZ%-?6ZX>ZWTS_>:7G*0|?4"L"3L>#_M2S%=J4_DL=;=:!"&_NMR(#)9)G->MQ-
X=F|3,I3P"|366%9|HER|C'A_M>R9?Q-Z#%2\$AX8O_R*#Y4+_ =2NQ=X>&J|'*=W^3'=/_4|48BW10>UF+;UF
MA)R_@F;C^!-!@M+^"=#GP6603.*ZKA5W=SB22I=OKFAQQVZ3U66|YV'Q_+&_M=%Z?|<(3J2(>(G,8M|68D)MP
EH*+P-D\$|HUO<_0"2?9Q" T;_<8D#^3&O:2<_M#R128QC_VNEJ&'+A4TE+X66(S.*OKA9X?T2T.L^@-4R-
9T.HFGBM9E.%Y.4|_M|(K%*:N*|))9BF|)#%9';5_A|_ \$7V>0;<|1|N=)Y_K0ZXX_10|BC\$8'K.3
MKG26PLL0F<5F72WPWHB|^GHDCS|(0K0|%)O|/"#J_MT_9|@V2(1|5Y4%1'_3=7&Y\$1N"/T|/
M&607C/4N0.W|LR1|)%J8P5;=\$B;EN_B25K+CX6603&_K47X(C8|PRZX|DR_MX_A39S|JX&L?
E/_Y|'+\$A_WO;I<^0+X67(3M^+L|LX-T1X0GPR|_M2?=_|P<_M|H0UY_B*;RIPA<;-^+QNZ|HE|Z=3|+S?>?
198#.8KNNE7=W/D(9PEHRMH MGB&1QDN4M2#DE_B2SE5YVU-PN)U(J.CUD|U|7R|LZ';=>95"Z28;/_AN_M;
(HU@^Z|7\$RMY)_M|XUZ6=^"EA_QBN:X6>^=\$+1?;9QESM.OI^>7'W&Z_|MNC:0QM&SZ|SN.F/48C(4G@9(K-
8KJL%WAT1K|5W;T|WMQ^64867YZ0B+L_Q_M'*=OAN&|>MA_=\$|QWSUW?MOV"DG_MEVR;_#83DP|)'0Q^R|
|4H=\$IVF=ZE%D2DI\$FA^_**_G_HNOUJ*QJ@N/_U|H0<;*+;\$K%C(?@A7|S0TK|?US0T|)9&4
M|HARAI*8=8=FW;2\$T^FG9HVVF027DQOH049*Y/XK9O(?_A6S\$(2ELONDM|" MJDV#HU:&0
I4YC_0RD>>2C|B#Q|CK\$QBO&XB|ZL?K9_H3T|T| ^EGL_N/M_M_XPQPP&AX7R0-
VXL\$QD)=\$BKR533|+P66\$3.*|KA5W;SBNG'57#S=X^W|I_M_F7|H=LP;3@/4)X=
(Y;Y9%0Y0BZU3J^95.5W|VV\$%V&QRS&ZUTY#|"/TN_M*O\$XY|C085RQDL+8|M|2U_A+K2H'2L)H|C
O197S.8KNNE7=W/H(R9PGDH|&P_M\$;17;NS4Y;5;=;R;+S%;_WHP7E;P+D67|3&+Y|H6WKWY^/Q+GAI/4|#:4L-Q
MUKU4-R|U#N#NSX_ADB_1HEAEA'S'ESSRB>VZ<^1H;3.L0QZYE+&|?@N.MXN_M\$|L3BP?MK24>!
(L7/DJ^'^0|&R23&ZP82|TW)E34Z?G*_M^UT^Y1_2|@|C5NM_M%-J_2F) MF"QV|/L;WJS2^4?2;DTE+?
9IX85@_0IV.469)Q.8K9N(O/NK_3EGHZ%/&6@_M=%E:0NIC_#S0@_R3"9Q6+
<0^0B@6/7K#_RYW(<)G\$;MU(ZKV)X<\$Q_7Z_O|Z
MOQ_I.0"/@V|+78%/@>2/L;4.C6U0E6K5F1Y3\$|8I2^%EG.SBNZX6>'|S_M#K/_MP)M;+4&K8|UFQ|68'0|+
H0J_|P|&)X&2*S6^*K!=X?D:C/_T#K%37#_M6|@A_UH%6%|H|;KN+01?NW37_\$)X&2+3N*|K!=X;DKFQ^>4Z#>
M4K=8@8P;KH>N_ZM@<%"5JXYVBH|F|4<7P;)1;K2HGWH|G2_LE_D#?G^X>
MW CZ7X+PP<19T;\$9ACTV**X14*8|BY0JTEQ=Y2>|DCDYBOZP7>?Q*M7N/= M&L|J?|_
>>+^C|!7XSMV(@_H>QR(NZ:32DY)W9*SX"(AM)K>EVH|'HL^*O_M|^ ^MFM|W7^NB|G8%J?QF_8FR)DIHEG%3
|LD(PSF(+R9C%8%VG|?YH&/6";-6_MIQ04)"PL14@1>*A3\$MA4_1_2|)M16>QA6A.8J|NU'9W-+0*|7US<_WR\$|
MCD>;K;?QC\$R90NDA_Y2*.ED;|C6%MXD?QY<".GP_@80|^?;NAY_M%P.VQ1#K_\$IQF>3RL_VKJ>+|Y;TBYXZ0?
>L^!";F8Q3E>]>P0ZTLO^|Q08_M2C>@>_C*3ZV|7M&W%|H?_OFDA'=+007TC&+9H2W?WIR.%|_0_127LJ'WX8
M(%VPQ@3=%;ZIF|&0:S#0><'5B8HK*+35EQL04C*+;J|RD<@Q7Q|A|=OZ|N|_M^>^\$|L_4*G443LV_2W5|6|

(H222^W*9TNR@S.7&A^2,HEWNH7*NY/B@_WZ M;EP'>7H>\$QUUEWT#5=VX6B<.*#D11&J11.HM.V\$IF8WP=
M./XL@V*SBM4"-[0S..1<2F+(>1!\$.RA0.?*-S62A983H2;S3I0KOS<@5ETK?
M8'V>.*\$OE*5A*8PMXPMC#50PI/PZV8"!*-JTT%A_\$5E(QBS>Z1H=#P"%^X9N MH<>;O"YA.(1KL?:(-IQ-
*S:"EDGSXID>#UF2FI6^NS50G@A^K.8J^L5WIN1 MQIUPZCP"KVH)'78\$AC*UP#3)5 Y91C+PYSE^I076A
R.DD;NH6*NJ-RE6(MJHMQ)=1G^<IDZ5J70DIF6Q>D74/ZJJSWY+5Z#H&)W3<%^,+.9G%6%VO0\$P
M<0LI^\$;=^M:AC>=&G>T9BJH(U#;D;TO%*+RH=5&^\$)-9'-;U&N^-R6/G;V MW3V>HWW-Z>#I8MJ%;3UJ3+G
(;FSA3Z49..4USW10NMIL_2>-"(&9Q'3=M2NVJ1GF'QTH#O&L>6VLT1<>S7";KI&I\$HXNBPW M(*1E&O-
UQ_//HNSD,^4*WG<6(I0(R 4\$;)NS1UO1 M28H(7&I'2,LT'NP62N_ R^(-;YI> (=W#QHEQIU>3=@VRC//N!/?
=Q#&Q%I M,HA8/F(B>A%=-2,DD)NQI20!2B10%COQE! MO@G^9709(&8F#W;-OD<-1-
F_T^WU!W;AKIVJ31&B'B5YU!5RSERAUZZR&0D M1-E=BD01A8!8L6NUO<(@%CI/=W?T*H!
IFP^V0*2B+2H_X_Z#_JKP_@Q M0V1-V! M\$!*U#B'6'E95I+PMH"%X\$(Z90%B5ZJH-QU_NE)"JY<9.#*I>N1HG&;JT1
M2,@D-NOZA_B'O^L'F9I>B QXN>K.?A159>SG MJLY:6L=C7V)SL(+&9G\$>5VO!"822Z-
5\$QYR#QG&\$*#E!J9J79;KZKUM M10BPWF)X(2.3^*WK%3X"(U9HJHSC^8I 536Y&XS8%%UO/R6>\$AL 4+GOUK=
M/0K?35N*+B1D\$HJUM;Y',2\$3I_ =O'MX^Y1 HQB*Z1H;.IX?8VJ0N_%.@"(3 M.*\$J?
\$%&*,H0D\$GLU=7Z'@ \$0JSIH=SNNQ6#?0^!8F+,42HR^IZ"@I4S@2LV0:1004DBI&Q5+ MEIW@NQQ?
B.DD1NL&A!\$^_ Q%I8W4I/E PIUIX8C4FM0BLAC;^2I8JG/MZ5 M5^5Y99N52;Y)XT(@9G\$;_U*H4-0\$Y2SH!8<4;'
I^F82_E7H'BEP49/KN>H M79/MFOXGC0BIF<1W4KM_ FQOH5O3ASRIBF!.*KORG"/?1WIS@/Q5&"IM"!M0&-
SK^RIWU)T(2>3^+"K! =T;D'\$IOOL62!;6WPNSHLE%VL8!TA&GDI'#IF\$ M.0\$9+KY*!4ZH5&_%%Z(R"1&I'J% =V?
\$^I'"_9K=EJ/=Z=D\$BD6G\$EEKPP/MA#U6P&XR&\$+KFPZJ5?&QJ4&A)Q.8L9NH?
+>I>Q.F_9I+LWO*TIUA^"&2;+>DQ.3%X(0)W'CKPZIO1V!;8T97+7A79N7-1^H_5ISE;GHP.?#\$.E#/QO
PV9+K.B1KA.22%X(+&9G\$ MOEYKIMYTC\$G4?<%3YI-BUSIYQ%;SC10JAE'(-=%3HO_1/PRDYIE5U(1GBG
MQ:4FA*1,XMMNH_01>/%?-.8S^<5N@&&%R"TEL;>_7X M^X27;"V%W(RB5.I7N'=&=\$J^-=XQI
(SYB9LM*10H1^+/K'57C."P1/&*+3 M9(SP2L?SX\$(-)G%HUZJH.QTFZORB_IZ'Z'+O_?WU)C2L7*(+/M;F&U7CA
M%<6%X\$(Z9C%G5ZJH-QV/H93_!FI.IRI7I'\$. \$%FNO@/JHR3HH+3L(*GF0LI M>.&E%I2;\$+(RB4&ID=.:0\$9 RU75+I?
UI?_8Z(N)+B.@)P->1Q7J7N(SMB8 M72JNRW8>+,<7HC*)0!N!OKMCIM4XT?C)S>GTXV^_X9^>N_<C_?I3+@"L+(J
M3#NK\$@DT^IR^1UZN^4FYU(00EDF,V6V4/@00;BF+1KUV510H.UX*\$/;(RB2VIC=*X,409A\$R:U-
ML^H/VOZKWE9;D+ (MRR1.[39*X\$705B%I1 [DI?<(UK'/3V@ \$+I9>X+M>*&S?I\$)(2^3+;+ M*T\$7H1YA7<_TLWS
*F^HX+IM 4+ _#BN%QY+!+L&S.%IARVSI@A"2B;Q M;5?K>P1 C'J10'5-1160A1 2Q(N&E)/#EHL031KQJ\$5.2
OHPLIF<2Z7.WO M(0#1GU_?0^5XSVM^77GT*Q%.'XAC#Y!BYR4=CWW>6>>M/VW0Q?!"1&9Q.%<54DDO-G10@-
"4B9R;=>J? A2S'D. MJ.GW<=# ZD+@QM^E4_!A93Q9;RJ*R?EO \$9*6\$B?W;MRGN3I\$)(2^3N+!/*+TW+X15^G(-
M5>7Q?HP>G185;J14LH>;(4Z)9.ZN8_PW-80.Y\$ _NX'61T#&E.4T7'71MG%0 MLO0^GMIE;892!EG;"4;9^12@);;\$"
(SD5FI@=9'0\$;I+I^CK_3P0\$Y>/ZY M*Y<*&5Y9G6-L_ \$CFOZSCC;FC,+SAL-"&&9R+A=J_ (A2 GG.43;=<.;@ "^&
M5_!F^"B6_!&/2XB412^IG?9_ T)2)O)OUZI^%+B>0YD^&MY@/@Q&2B M3J7.*_IONI" D)29^R5*A^!%5?
7I^_Q5_P!WS.(=E2F&G(VK,H13^ML2;0 MQE7%BE&K?^GE0_"4B9R<->JO#0HMZ^FQK! WH\$U M@U
6>A:)G6^JDP^U0NM2G)4IBX6ZB!<ZP_7C5_3+>"?Q10=E.16="X&Q M/H^RO\$2+H)WXUNH
<4IV6)Y..P0DUG.VI4^!W(XTK?GZ5_N8XWP!&4YZ6^ MZIU"<<% R@VSUE7I_!&.REE\ (2636+8;+PW)N/J(7?
K;R+X;#5YK01'3IE M;0Z# QX&'<3;00JZ*W*RO?H7&A""HE3NX7*^Y.B;XKWMIC_ :OKAU_ ^NWI MK9Y&JQ O@U;
(4E1C(<:GRAIM6YE*O,<I00@)"420S;+53>G12MS=<_TIWI M"V&>DC!%U^3#^"
1695\$57+N"HJJ%A60IZ+T.H0++0A9F<2?W43GW6\$QRMG%
M+P*2B>FG90WX;.:OF1XM6^U2KZ.3^@DO^SG4A-"780;=>1>G=>K K+U*O. M/ZJ@*_XR>CK\$J%0&-
M;07/1^9J%+T5=;\$+(RR16I39^IZ+2_!;Q;V 9_Z MKVM69
/W6HV^W1#7L=9;IIMX\$^JHZG^K2OCP86;3&+2KE5W=SHL#WPO\$XB^
M1N^;1Q7/I_ C8HVU6N&MR*;J0CTFLV=7ZI@X(EIWN2_I QOV M_ M /=W@W97M^D-L18V/\$"S(>)H&>
<&6!UBV>>\$%OHOQ99"D63S9J1KOC"R+5;VH>=" T)0)G%EMU#Y\$*28 M!QQ<=1G#H-
WU!61CX#!+!VC*LO;VD)MLW@@"4B9Q9K=0>6I2KJ+U7YI> M7?_F&7X
>_0N0;>IW%7@_7CP6>\$VL;OLYQ=L)I^HOQA9S.8LRNU_@ F.2% M%&KHWHS;\$/IUO#+GE3R43_%Z0U=X0.S-
"K!;+1878C*+*IM>XP_@DA92"%Q+ M% =I26%I4HT/@E>2.&4;&)" A! M#XB4&Y
V7(O;4(G_72W"AQ66XPLOF<6(7;_QH89-U2#CTI^J2&0(I.LA^? MJ7P'EJ3GI#)ADAX*6VQ
",HL#NP&*N!BLYNJ<3*9#00T6!L&#;/SL R D918?=@.5CT!*6_@A=5M+4VU\$BDU%#S MZ"@F9;\$!(2FS.+ (J+PI*
<8LUN/VYNQ)M#C63R4I?Q2O4XK7UJG9>Y@MG MG14&9*3D66S9#50^
BE+)>7G!4G4J;1PBX)6;IP52YN6;>+LJA#%;Z;O(R MD)I)?_DM5#X"*4M5>0U<@IMJ&_NP6%D42I.FZ;.:C8DU;
<)3ZQ<:;) (RB2^I MA:VQ M&*4#1CV=:XEU_?4+!V3R);N)SH>_97%)5I_/3G>P_+;9VXX#!K8*W(Y)JR
M(IFGH\$LM"&&9Q+?=1!< M:\$4(SB2FIF9ZIPW.E57&OCKI_ NFX2^OWF^W<#7U! =VB/7Y\$ _Q8!M2;0P7F?
M2.EDA%L5%N_+89G\$U=U XITQ^?+JT6M?S;94PI>1%M+M\$#6NG&;0P9TXS*A M4F-3D5=X2;8NM" \$)I)-
TM5#X\$*?HU/>#UW?5S"BG42+XVGCW!>%JBC!FT M:= "EZI#'-78DFX.6XPYF<3.W4#CO3&YXJ6;?
H4_EKOKIH9/>Z7@06O.&_!U M^O2W@\$.:BUIO>XWRDYU"7X@LOF<3&W4#CO3%Y_>GC^_W>-M^>7ZEEY-
M^MY<#;DI;GK1H2E)8LH)N.O9.6U.MK\$YU((OE4E,W\$UTWAN6*;=?G9S M=8\$20JXJ-ENI=:?MA2;\$N\$QBXVZC
M-MJ3;)00L3;M_ CC4P(ZMC3N-82.S8+>(7I5I6C88M)&6LNLN_2I&%E\$SB MWZ16=VJ QI68YK03+>GVZ?
^IV#8DV-IR9R"UEW&QT)P M&1YZ\$=VK;IT_&(M_X>_IKIKCIE0)1_XKH M&YC (PLC"H!2LRZJ=*K=K)K
M,A;#"PF9Q)Y=K_#>C%R9X-4GUZUIYQ_.Z!>+^AS3ZB;@)H"/>2%*_9L!U M593WL;DFO4!R*;Z0DDFV
TTWAN3UYI-T#^Y>W=I_!MU_>UE^ISP%;I1 #& M>\$;I: ^I601.&(QJ\$;N5I6NZT(
0E\$EIV"U4WIV4X_/G)_@KXI5IY_?IYY(MKM7>(M3"HZ'+G\$%&E2_IBDEQH>6*D).E!\$*)C%AURM!\$94^_8S^IR@!?
U M^0DNO^E1L_!K5^!0T">_&ZR*I4SI.GI&#I1:\$I\$QBPVZB!Q%&@6!G^!O MOSE=WSI04Q8^I!H5S;C&E! =
(D+N=IO!X&TJKU(+;9+30AQF<2.W4;I0_!B MOJ&T_T/I^P^!JQ3K9YGSJOY?*PX=I#S_@X-
FLOE5^25O1R6L A"4F9Q8I=K M? A;I_!J2W=<I@OKFI^NFI?OS_-5,08YIG!A+&SIED%26<+M=>\$Y)U52G;I
M_9^U(DIF\$D=V;FI/8HEJ/Q^I Y@J?O^YX? H5X &2C\$E=<=PUKR&X"*GP M;P0%K67FYUQ\$>05SL1DA.K/8M)LI?
@1V5/KN#G!>I7Y?OW=>RBE; (=2Q<4(7 M-;8-%ZAIQC)JFIE0YR&S)JS^3N!49:'P*9J^4LC66*_D\$/+=F5J1R'MP^
M>*O&\$P\$JIRZTO%QQA64^>?7WC!>P7K!_#"LU M;LDE# =VA!Q>P0TG)
Z;8C;_>2Y;MFBXT(&1E\$GIW"Y6/0(I=R*4UZHBKMFILM<
FO_!M#)=0P\$ULXHHAC*9A3""U="%%H2PS.+Q;I'S(6D)KTZGVI_A3I?M_BF)B-5K8S(H
MI^VJ2@="P2^6MVRQU"DNZ NM""\$919W=PN=#P&+?77W*TMWAY1!UJVD3#06
M^<^VW2UA1N32VAP;O=>B!K^X*0WP>7!6%G!6Q7JGL\$.G3I?2?H4;Z8I("3B;I2 M;
IRXMQVBHY7W;\$!>0W!(KB0CEG.Y97JH(J<6I_Z>GIMO<"Z5Q\$K^/?Z@_ M_4#&\$Z4R(5H>IKI^Y?
6DYI&%;QBPZI3IA!HA" Q!_KLYL?G%+JHJ;1^S N M;JA%0RI&>K87^V!>DIV>GTIOA"12=S7#30^!";VR^N^AQOZ;
<.B!<JCIK MC!Z;LRS/DL&IP*"A5I2CS;DKH*!EEL0@C+);_L-DH?@A>WE\$5(N09GONTO MCUNU8H5_%
(6ID1)C1HY;2'3(>0 MDW_!!) U!Q^!\$VY/N=2\$D)>)K-CU2A^"";_?HA7TZGH3#N;.:C6%ZN61P6
M8;+00G168(HW67>*7I\$Z^I>@)"5B9S8M2H?@IHGD-4K866.F 9WZJB;<.% MY-R99QZ?
7UI2_C3Z>;Z>5RLUJF6B9=S M%OO8YXF!TF>X6I&ZVO&W67HD=;\$!(2F3.+%;J+PI*58MYM "RY(P0_U<5SL

M@J.AR:R073H"HGO!OSCI+A)/DM5-Z;E\$=2.3QF7"Z">9/AS/H@^H!U M+=QURZJ\$I,"JI&(Q6&V5W? IVJ04A*Q)YM*MU/@0L<2\$)GYT+8Y^X5V41 M5W*IG O/H(\$U.)TO.-%H2P3&39KM;Y\$+"8."%G?/JH6IOA2KST<<^A MM07RXPLVQD>5"W(O9 JX+\$470C*1::M*WR, HO6W#J)>5;Q-;%MR%#H2D MS&+7;J'S(6#1GfXHI0G!#I3(##@L/\$JCEKEF!J"IL/U39=DC"WRD)T(22S M.+5KJ=T;D"NCK/GS;...B/IR6^EY3(S;H E^&JRBQKQ)XPW&R\$EU8ZON*C>9 MIW*Q"2\$JTUBU6RB)R^/P- N XNTJWC)JWZ?A"O6I-@I8.AC4X6.X Z&"F2; M8L4I6>%KEY=-D-B)I%K-I%Y;UBN#*>ID(- W%FMM83Q\$QAX:P&M:~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j>XIZ;@O^HVM1^H4IY/"&EV9H!C)@>ZI>F<=>B^O_-(? H2/-8K"N5=W.DPT^F7=E%O(5_A" M52R&0@D60I-D9K;8@/?)%I(OBZNZ4MVIZ7C)!!LC6K "\$2)Y"IM ^R>\$^#E% ^D4OZP9XG5IOSU0?0/HR; MJ.VX!2(1ETZNEI;#N#M-GRD8>%OI(H%:K7?#R6MHQURUM MO)+V00H8I MBV%=EZUJEZ(+^9C\$+EVMIO\$ 4?JSFV_P_O3!;5+5740"5TH: M!XTCY\$05.I-25"RQ6OE&YI? 1A8!;8IFNUO<0@)@7"5AOJN*406-@;\$;PN@ (Y7 MZ7Z.C;JIX@LD_"D.&N"#7C'Q6 ME#IB4- 52\$S)>IB3>ZC9*X"7JV7J76-UZT^0RE6Y+I MI%R32I_1+(07X=T92FC#D7%@*B%7W_6XPLI MF<2#W4#C V!BU'D*%5.@%"R8WH>1G ND\$CN8I&OIK(QO,AJ V;X0DTFNE5&NB407Q?A"3";Q8S20>=,+/2H MI

!OK^_IL&_8H(8V=E@DC0 M+ K?6DTMX(LT+B?W3.Q'L#Q5)W/I5@K'!AFXW"@_G!MX?HL2XKY#&6 \$9K M?C:
>4 WCC*U:+=7KYI9KG\46..#61L:I2XITON=(J MZ#=-X6UY=-?K\Y<4L'G<0IHW%OOH@10FB) 6IUR59?HA?M:E\(+
(9G\$UVO M\Z..*N^+V\JWFNF'XN,X\$JG*A\7@9?T7S4KZ\$W'3N0?"Z7D:(>7 A\X
MK"O5W9\%U\YWX1>51ZV+EM1B&JE'U\MBJY9GP2GL<I#RZD8Q9W=-6Z MN\A4W\9?
T55H\1>.55QCTI?A\>6IDA=@\#.)G^TI#RZD8Q9?=-6ZN\1 ME?G_V3NWCAN\J E3W\TM.XZ\I
I9%UEN=VM&/>YCN=N\^(3)2'5,L#8OT M93\I\DJB%> SLW80\+H\IC+5'4<=K.CH871TWA,%E\I\T?9YQ<>V,K
M8#OPA"E4IWWOWOY1V9UHK"5^_D\;V=&02OB#IH>2@RHR0U8M)UOD%3&(EBE8 MBES(,^&=;V<.%-
X)QUIBIR\5G9N.23H#_1IX=7NH2;)K2P:<*H\SI=-2P6;-M'&"E7A.U#W31S'97>RL9*PZ4AM%X&&^4/S5=2:?
2Z"3"V540_6(BGNB,YL M15DM8^H\I'F'Q<=A\;B4\TY:SHW&"Q6,^>W\I=;K^X=;Y\J4%-%Q>,#5& M2)9-
Y4P*VKO\$IC.3?VAXCL\64W="S"LS-BHWQ-OVYVOVS.SV^?8\B5;(6 M 74I+?5)!E0ML%=DH\;R-
2\+W>9"A\CLI6404+=S&LV.BC7F\O7C\RX9^O>V M3#XW+515^Y2P\JQ\03D3;19FHRU_3'0.F=B*PE;CI6WP4
HE\UY\WMT&_M8CREK'5\$T>YWE<+NE\2*8J-2HB&WKQ."B\XZUQ\$S:3LW&GLK*AYT0 B*MQ=8
SE;N0?J*K6LLX%72/E1>5F5_%K#TCOO6\$G\$=+2^2P\B4"/L_2Z)8 M
MW"WVP71FUL\I41\;B@%WVSQU#IG8"L)&HZ6M\%("(.E)'9*P4\$0B8)=" M-K('6B7=CO*+U3?KNU0Z9V
K"1V.EK2)0 BPM_P8E>I2_PW<@0HZ,5E\)%4'E>&X\IHY0B_L@&@EW5\$/3(JI4G'@C'2L M0F!SBDJ%)3AQMN,OC-
@-E1)R)KB;J.5GAN1O8&52S;HSCF_FD3FK6\$F;=3O.YI=GG MPQ%_OOT6NL#;E32*++2I9EVT&+&
I+7E\&EF"K\I\I+K'N..2Z \$Y>5!%XG MT'AN3%ZHH.W?2_.\$\A5:7\I(H3"\$%D)%H+W (>00I3YT-%=)R4K"
MK^,57@CX:@'6G"?1.0*K)-+H7\XH(2OCCS\H#WT/E\!)R.KB<".5WAV M1FST?^?>
6WR;HD\+Y8@2"TH'M<6E:0JTDH.;IBX\)-=I1."/17>RL9+@ZSAE M9^?7">?7UF;*D6\$+EH,"X50'D%\QUS4%
(.29WW.0^+I\N1B)='6<I3)&ZP(OO_*3*4+M9YV=%@+)%&WD00\7W 6+6\$E.=K2#<
MC.PI+WG4A51UEMJR1RX\>UX)VVLXU?*(J'R543='T\$[+K^3DI6\$62?0>&Y.M7@1HW^#%B_4I.9V-
DRAYBJ#AUB5\6-<>ZN>=9\$FF6*"-*%W/V^P_\$Y.5A)I MG4#C\6#B\KK@779">ITV\$YHI3V\$&! "9F=22D91YP"%P?
(I.5E+;'6IQK-C MPEZZ'^A#2"HH\T+I^RG.I*06@Y8)710117LOIT\6\$G*L)JDZ\MRDI\$ _"
M#.V*)%)\#.V0@V"S^H(@.9@#9VLK"2V.HG.BX\!E:&ZD M&).BD<_7PSVAEIM.*P-68&)G3D;?
^3+B735TPK*2(LD.L\I^I.5KUY1Q=X M4;XQ5-*DI?17"ODZ#.8Y=D@+UF
MI87THHVNDY;9;B"3E36\$G.=0.6Y2=D? M^=-O/EQ^>:E=HY0.V6I+I24DIOH@""6AQ\I32=)5U?
_8IY\IG8RL)\XZ6M^Y M 7EA8WAS_1807W^YZ12<\$I\LAFS;Y51\$PRLG%3.XE H.1."E'9&E+7BI^UV?I3NB\2Z'-
N)W5IB>VP5(Z F5=-L;16S_<K'M"<4ZB#DP.NF1M+66^7Z\$WP/E^_) MR5IBL>,U7@FZK+4@A29\$J-E?
VZH4&%)1AGT\$V.Z&MZGRG:++\3DS6\$HL= MK_6@G2M).RNBA(Y\W\YLCNFM32FTYW9Z#T
M3DQ6\$HP=K>_L@"@9PT^4=ES>K;=&QE@T#B*1XK7368B>!,1 (N6D8^H(&^@ M\SY 5A*':WOI(H'M7#D0?
94N5 %JR)@;G:) %J03'E0*>T.Y#Y"ITCL M6408=-R^2P#'\$G:"MO9+B000=NV\<4=-!2AO4ELF\$>LJ?
<8P4#IG8"L).8Z M6M^Y ?GO?VMEXA'B\183O(12N2%&HFUN/"^2,@LO2K'.I>9J'2B^\$Y&5Q\$S'
M*SPW(^UZL_W\I^_2K 7.C*K\RO;>_15\$@)\$D@0W\$8?>7N=6;2.R\ICPZW MEFC&UG1T\;J+I97EI
<=>KU^3I^+RCH,EYA9\2X\90\$D*0B6WN&B61*\$K* MOH,"P^5W(K*64.MXC>?Q.7CN024\$2=P\5F?/^0?
7#10_66J_1J4^25W\B.M.R%92ZIU.M.\$S.Z\$MMJ>(LOQN2TEFFI%IJJ2X^@A8>8^I=MT'LBM/*=Q^<'
M'N_D8S41UG'JSDZ'/&8D IT EI9V0&80@:A=268ZR/V3G/5\$.1I?. M:~%#Q7<2LI*ZGB%YV?&NM?
X^I7VXG/S\$V4M.YM128OFBCD)6/A'Z3"AS2Z0_MZOR6'97=2<=-8JGCM)T=#26..F@_M\I)C0
FJG9@S\6I(E8#3WL615">E^K M.2Z\X\I5Q%"J3LI'=KZIR_I->?&N^B2B=QNJ61MQQ@RUAW MU='BU\I
^4"G6>A.V\I4ZD6DKR\GGQI 3&"IX> _B_)\$N\I;V/D(^ITU M=.*REBCK%#K/#HMU;K 3LGI'4FHKN4K-
MD">AL\9;#I\H;I\I;.^&JZA\$Y.U M1%NGT'EV6-AKDX.IP*JCJ=' L4>0X4@:' ^FS(FFPB\ZX=T<5G;BL)_@Z M@=
(+X\$6SI7Y1\INOT)>0@V;H\I"/M%=U= M32<I;XG83J;X MA1=-=\$%UMV01.I-)B2!'B#00^9#3)FJI=-CE\FHZV5E/
M5"TM^W"O.I_VV_6 M#%30R7;S_WPOA;G:('I8(T)\E MEGS0@4UH,>L8J^E-FG1G)9VXK'6L.Y:~/0JD/'<IIS!
MU)8I664^Y2\$OL.E@I-R6'BR^\$Y651?'*SPW(RITL_Z;Z\4^VFU3=J#2.W\ M0I7WJU
T_YBI9DL\Z=IY=G^H^\$Y&UA+?;WP AB1MCU?N+UZM%;SMD;2I9:
M\>RR\I+ "PA%1<@2DTTUJH1Z;X(-5M#)R5J'NA.HO_12W\$?O*04L13(F9=-. M@U%)S)?.@AC"Z"C4SJC*<
6=I*PF@CM>Y260X@?Z4+TR;\$9Y=N+8JC*E6IX7 ME8>4.3O'RI30>3%LNQ.4E83KQVO\NRD6*I^H-V7IE;J0I:L\$&K
3X\;QF " M>Y8\VDV4KO\JR6'8G'VN)SX\3=FXT?FKF=-RN.6IX A/^ M-)VRM+>.Z M 47M(*CAIK>" (I:"=
(^IY7\$.ZJH1.3E01G)I)%Y\$;"XOVS>_A4OT_R6X@DY25A*>G4+E19 BV\&^ M7I2\KD+N>9@L49_CQ9.S9(-
K20A\B\J*H&1^MR=X?(I.5E).8"C9> B11' M72C%>*LPL22)YT3?
WDA%\$G4;H(RV1\+HQ^2X_\$Y.5A**G4#CN3\$Y84SX@=J# M.+?M^S 25/Y-0R063VYBV\I#G\$X%V.J\+S-
NI1V9UXK"4*.TL;V='P0;XA MO+HZ\I_M=S6)(H\I3UKX01KX6.
IHD(1\15/JC.H=EQX)QOK";V.5'MMY1^RX\XZUA)N':GN NC0A^V/200; MI&)\WS+<4#>R)?;PSJZJHU3F\H3.
ITG'AG72L)<0Z4MT?T&\$VRI".1+M44O; M-B>-::UJZ;UUCHE99\$ZW\X+KR3CK4\$6\$>J.SL=4A\W(%6/N2V-
6ULIWX\Y K%A)\6TOG.#\M.KP47^B)F%N'6I0F9/W\$G0SK+Y M%+GM.5O).Z)%Y2E&K?
MN\0Z5W@G(6L*H8_5='!#FH_!22_=-A^J.EK&P="FHDQI.8^=;T.4%8"5(J U M)@5N?J\WF\$'L@P\92^1TK+Z+_.0?
=-;6;W0&63&I\H42H@J'M 8=4S)I_*9 M\WBH\Y 5A(I'WO@I\Q+SY).*<6 'IU.0'\&8^ND';N'%;!FTE6
X"VI\6F6Q)=I; MCLKQO&EP=0)-%X@O;R^WVYJA\Y\$U586TFS<7VM"FUAVU;I\Y<="Y M7C/G/4
9J\$3E95\$5B2I>1&PF+IMSG.%ZY^)/O=I;DD0:A308CN#>ID@=-MP29MJB/2IU+>15THK*2_.I4B^%"/7F"?Z%0\O//9
^_I_-(6W%UK=AN")-MT\$Z\I&("D1&Q+Q0_6'PG)2L)MHY7>I&R)8FX<7Y^6;WN0_)^E19&#OC*TL
MIPDPJ<)^FZ9;BT86H^2XPKZ.)\$KB;E.H?+KADJOI.2E01>QRL\I(R/7.WB+^_L35/L M/6O\I\$25N#6 MIATW?_
_HBKNT;_FGVOI4/H3G5_M;OI-GJPI55T-Z@)LMK#M-I ?H/4CIG.Z M*XG%9#LJ8?ER5_IK'MGSXXZ8IFD*-NU9
MH4)HHGMOE*HV/Q9NIH?JR 5T033Y/<+ 'B+S8)7G7JN^OHZP/C2;
ME4W&Y\LO8Y8RN\3VF*^L\I^D^@+4.N0K\$L@Y E5=NWC7Q'!3.3\#QVDXLWMP M?&KYI
I5N.MVTWT6#@5U\+V;PDP9DLD5R))CH;PAUS?X X7/LXY;I\I19MQ MT-N^G)IL=N>+I>IE<I)WZ< 6UBLRHZ
6B3I-/>KDIE"@GBBE%T='I\^5 M@:OX8F7\GYV7A;MK\I^BMEV_*>R+B91?'#N?;J2@I
4\$A"UCTE%@H2F@D_6 M))\$HR..+X1/L_Z=L=68GD3D_0(OP+I\GC\7IL/%VOLKZ^XOR1\$KOV\>I
M>DI%"*H\9%52-*JXQO8HVW0.YJR)&0>_L;Z05?_#??G82MCL\I\OE\OK# MRW/<I3.ARGX6#6F%F# #SH
OW&+L;L=% M16-#YS4MGP2A<=@^8#R?(I3?7/-_2I>I\OC0OWK_X7+IRWZ3=G=6R(?@\$/4
MN;U4I".DRV861FTBH\A\K)TX+5^/GW>9Z%G\;NYS;Y_V\+IU=-<2\VRN M\SSWU3>7*
<=-;W;IM3..SD2I"WC9WK<(P0(OC>T K1)> MI5*1.8@W+M.F&CEKTM-I.Z.F'4
G\I_1(O+W_GC_3&I\K\$O_MNH=VYG\$ M.YE+4""#-BR%;6?Q2\$*P4M28=-5YZEV>1^S.LBA3V=3/P4-
S_C#*_LB"J5C MZYB)K\9UEI&\$#4\I\BEI^XB4 M7;IU_22P3?01W&ODGRGA=HK&"I1D@&4 M+KJ=?%
(0I\3@=%4I*=<3SQP.9V_I\EV^JY#9V0MZ'6C2/D2Y\I\XB@I\GT>0>M2R=-F.YPG&GI
MHQ8_HG9\;UO%7\#VO_YTI#KW^_2I^W_I\UW/U#I^V?_CAU1H>,>INGK7 M7.1 RIOW'ZMXDH1N3ZG5ZI>W78:
IY3W6\K"S?EN6WO^_K?IT\I_HQ*IS?L/ MYU^I9OM\$+?O3K7;JGYJX\&_2I&1?KNBBT+E?S\NWF\I4W&^W5U?
TNVA&I**/P9+6&0.53_5SNYQZQY\K_OPP(PV@B;><Q ?F7HEH M;I8F1D>BZBIDUR0I@I@'35OV#O=
(KNZ\I3UFV)I\I'8QO:9Z/M\IG^LZHT'I^LZEZ-KBB5Y'2RT6:7%*>X@I\I\$8NEH1I2-P3TVG&ID>I?U M<4(TI
B3V\$&%%\$ M&@=-DG_2FA@O@P/^RIYJ3"&7SL3M0\4O>QI>D+&Z;L\$0M01#T\I.MN@AN\$.Q0E*>YT.E

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|2^#ARP#>#:"0B"-ON9-O0!@9D M "E3!^?9SjZ!H_CTOOX6\$W!="#2|2^#>?%1E10=NL&,'K+V'9? AWP2+Q M_Q4DZCV!>EQZ'Q^KB9^,E'=#/HPRK '?M^?G>.N^*6>\$8!#A);EC2<|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|L25&*_UW M+@9KZ&-E/7;|3(O@97!@*+Q/N2<'51=6B=L9&?.\$M1_9!5K\$G/_O/+@N*U9 M3IQVO,Q+8&4PH"A+());#MD367D3R667?N;|4'H?VN)T8Z5=W8^ MV, (^ZH#CSDOTL;6*=_RP==_:PV^| S8GMK\$%/KX&"BICX^UQ&7RKL /HXG MP\$ UHQ^L> %>LS?IVT+(H0*%@7+4R"&H^7C@^K^66.O8>1? Q_-\$6\$DF2RE M=IX/X#0!>FR'KU(AS=YI2)UW_@9*!^C+?7L?+.SX<11QU0EH2JV8.4I%K2 MR,#.&_N*D PW N>#?OY."ZH!WF!M<1M4XYI!&C&TO :UO=I0%&6QJS!\$+ M%/U7_QZXSJPFKCI6X"4@ (HJZ(\$NH#J4!S(7 F.O@5JW ^VE3B4(*WYJHX*CX M/D16\$TX=*_ 2\$%?"2V4E(74L(\$K+)>S;C=)V)K*AJOKS>+N#(8;#=#R%JB MJ;,%7@ (B>J 'E6*6FLTG67>3(P!6<\$!"#LX\$3_EGDJ@^1-824/TM/R(ML'<|LR"|^N&%CO6)#/4@Q2U>\$VMABA;+LU |7V(K"6F.EK@)2!R/D/Q M!\$?\$.RB@H;JIV7IJ;FTM|ZC-!&6H'IO^PT4WX?<6L*JHP6>'1\$EXS'DR10T M|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|NRN<@PI21=B6T0Q4GN8E*?E#+\$+3;+|HSC)^KIHVKNKBCCJH9\$4*I GD9-NYU: E3/G8DQ>I?_!LZ>OKH64N4=CK)ET"/O\$A M)+*Y" N"K/C2KL|TK*O"<3)5%3Z=Q /EE/'SUK">!.)_D"Z-\$G\$F* I>W* MK\$#8\$%N.#0!QD^#?E6AM LKU;@R=K*>/GK7\$=J>3?_GTC%J\$8!T:P2E)'>@ MN@Q1B #M#1.MO&WY"+OI&6OWK"7L.YWD2Z#"WMV5Z%#72!9""2+<M@UTE MRX(TFW'6I.X5G*RCGYZU1(2GDWP)I+B|NY)JK#&2@LB-IV.C!D2>58L-AC!1 M\$4CTOF5!JIX^>M82+)Y;B70X^_N2N*)4F\$AE'14D! 2)V!S# 1\$%;DKLACK:!)>|:|<=|?3 M1|:0LS32;X >LPHX"B)6T25!T2FW!M0@VA@ "DX\$H/_E7)Z;7!\$DBSZZ 1%;KRJ\$XVQTM/%%"SWKB35)?D2Z#D5^)^0^M1%- !2PAO>1H5O_@%!:|@2;...4DV_U7RBGCGYZUA-KGDKR)=!C3DRC-FDA083V M3FPI^WL2"- =AP!D5K;+\$W_RG5W/7WTK"76)7D2Z#G1.A*21&3D0)4E;:= MT^*N)/Z=%U;R'&JT|WTC(P6A07\$FJ>2? 'TV'!B\$8Y4K+,2*I\$^@V@!G50! MC6;V*Z7&I'M? 3E53Q!ZXDU3R7Y\$N@Y\$7S(MDK4-H)3HIV%!*R.-PY2J\$YB M#\$7(WFP@I^KIHV<HL>:D%)!/>Z\$ U!1'H6U>8!MN\$HMWT'N_UEJPI25U38 M>53Y9#U=1,3UQ)JGDGP)I)QP 'QU!EL0\$Y',-9%ID4.0"7HK%+UKC=-JEZ M^NA93ZQY*LF70.)!R B&VO!\$Y)D9\$L_G=M3U@8J5M(^8W*A>^4Z44!/?>N) M-4E^1+H.6"">6UJS<&!BBUAJ |24DP!HJ>J'6:I4W>T!\$0!?? 2L)!8E>0+ MH"><.N!O7\$!;..#!OW;K)T482^@F6!5YH0R=)^?%/U%"SWKB35)?G!|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|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|^8Z(60.TL9L MK7;IMLF#9W51&%'.!P 3)0X!@+7\$YVT H0/+>F\$S+Q2@!;5&51H!S'HC-0 M?B=P% M34+KF!6(H)ETG3PDF0PHI5+0EJKHO||S4'XG)NN)PH!5>_F8#&Q+F>!B33F M,|ZPLQ9- BQ!6(C%XP\$X9;F^NNL'R.S%93Q1VK,9+P&3_66/3W%>_&MBS3SPA M9H*8R8'\$DHHF_@BP,S/'8/F=F*PG"CM6XP5@8>>-9(E6QYP8*<,P1AL266T

M@BC1>22F071V&2B_\$YU1&".KP\$3.6S2J3BLD)%CFFJ*UT(^/\$.6.1D MHNL^2#10?B!\$'CVOF""*
ML<5JRC7TIH<.*K^3D[4\$8L=KO-1,Y\$ 7G+*ZJ@R>C&YY%2SPHNG *L-SH_.Q MN-L,YD/E=V*RED#L>
(V7@ (DZID(E*W3F"5'9P&XJ3X" 4DO(*H14#.E<>Q-M M#Y7?
AXE=2R1VO,;S8Z%*Y@0"W7C"JY%+P%22V (#ON@ \$15L#J5F#)KT6N2"!>B<=,@AC MU9V=#N/,&Z;|-?
Y,+S=7Q_ CQON+T.LPOA=<XJOM6<8(6)7EE5-A+J%\$29VG M3.ZHH9,3E<1>J)Y
;#8P4Z@>\$>0I>=IL28%1ANTJVV)O2% ^K#:8E3.Z%9;,"&
M3EC6\$H"=ON<%P.*&.Y&152UY3I)M)1/;%UA;*F2I<44DO&JTI&YHX9.6-82 MAIU"YIEAX>'0@fWP.5HA1-4G6@"(?
3V1PU0BDZ:0)A"9Y#MKBKZ<"%K"<=, MHO2,O%SOX"WBAI,W3;7WK.1WU1O-!>UV;^AM^W"WXK?-fLOZ;97("7)
#49@-MX<^@S93;5%%1%.IP9D9KIXX;OFFTO5W:M_Q3;7H/V)SJIV_-fE3IB>KJX&
M=4\$V6XSNFHO/H1TSF="1YW8?>YD0+R+T5!J%&!C!&1J+J*VP?X;NB:ER6 M-G'MG_ZZ!+%(
Q5J#+S1U>,@520(+0SP=)POA#=#67#>B;J;:Z!\$&A"9 M1ZLHK%)=RD=Y\$VJ9;DR;+<fLORE)1!X@|
)B^_Y<^\$^7+R16490SL\$54UIGL%4 MWYVZ:H0E1UP(^L:IB@DU53VQDW-&4)2'SDR#>3B_XKCY=K/fL-
WA^5)NMJHF_QO6/&F#15"Y_X0VHL?T)IOD%; Y4=PUrt"IK\$Q/QI4E='VV MHSBEIS/EV"P.M4 ?
8Q8F5AMYUC9*M:/#.#@ (BN'"= *F9\$J.H3P?;\$KRD21'H MQ^L!X!\$,P/+V@N?D:RJ?IF>>^?I*YZ5N+IFC=,fN&315-
fY>8f> <8C08A MJE'2)\$%"381931,6"IM#@#C&;?+1F=DZfUD07FfN:&fSGfE74U3H0*2V-QQR2=F=,f
030'NDFUY814DCQ%4BIZ"1.VE22(6A1HWGZ_PB C<\$C1Xf M%;FGGZfN-E<f^fYW5VJ2+NK2fQ79^Q
Y538F"G)4+Nf"1fZ4%5RfY:fIS" MB5?HfS9UV3fLOXTAIRE%?Kf^7U_C13FS.AGKfO?20\$O)1"DC(fT4_AA3<"64
M(N=%f6-#YS4MGP2A<=,@^8#R?(f3?7/-,2f>fOCOOwK_X7+fRWX7;G?6SG#H
MELfJH58M6MFVSYJBPk2XDk.DR"1X3Y+L:AfL_*S@GF3EUZ^fN M)7f87.YYK^fO+E..fO: ^fKCH7^;^N-fM-
^VMG&fMRT2H(553^fVEM2+A; M/26%*%<7K6/M.M4-8J&5ORXVS)f8=P&20PD;7WU2@=AWfSVf@;
fL^P(^fJ9U\$!PS/^,YfLDFI MD4fT?+fY9:UB%\$ON9E4-6&4(D^-(3MG^Y9OJS^5+f(2017T=?fG<fG8OKFXZ^DfI
MOZ:S&D*V,B-4:6ISR"VD6C.@fJZ@+"^6Q^fJ\$7S&.G/A^#1H_AP)K?L,DPI M8PI+?%;
<4LfR.+D^O%9DM@f\$S;QOZ50=9CZK,7&f7LW;S)#><)1N;^fJ,6/MJ%W0VU;Q%f!fKSf=fJ fRRXfI?QYfF?*K;K:7.
fG-M@f2;f^fO+S97OWfJH8fZf3;OYQ_-5?5(MKHUO=#fT2D4_/Vf>8T" 7=%% MH2(f'W27N)W6-_NKB-fI^fI
\$=fLHP5^Q-fJfI*22PGX*f,fY0V=MU7F6#f/M^+AUCfV+?G@4(46OLJ^f78f 2R52-\$PZ-45Df,46E;HB+A.
(=<"T9>=C^3J MOIOH8X;M&9SM^f)9V^7+SH?WVfDfG_f" @fJ64HCP(VTRYB:"HW:C4R-JU_K#
M4QTVNK.1RR9U%#KWQ2;<7P&P f>/K:6;.&@f'&LV_@5\$ #fK56<-RU>0N
M#Vf"5H2;M9Q)fT+GGL".f>Y=Q)?/8YQ%P&R*A*fP-7f;MS70U5L&R8Q@_K=F%*!f)%-f<8MDG9?KNI@NfI
M258F% M! *LR9520A%f1\$@f9D.J.*6fLW_.E+L4V634S)6X=DA43^ZE^>\$E f^R M5f>?^Zf+S=9^XD8GU>
(<%f)O f30E^T&FA") BM4.C.3V9+JRD+*(fB2KE.f?=@:K6:f^fO0+ MSWB=9Z>%B7>OB7:f^fO+Mf;P8N*51%
f#8.fTG+2f!(2-8f3U% H>MAVH_3<fH-MOlf/+fW5U2WHKNfL#;^7-Jf4SYC(fU%f1>Yf<:2+;W' M9+(fMK-
WVfV>f7?1@f1_@'26C2A)fQSI<7DCCfZ6% E6+LYfGO\$ \$2Bf f!_?2?_9\$LRONfSfDBEKE6K+fI;fJ;UM
7;%M6*LYf1,MHF9? BOGK MEGMP4fVZN9%06^fLB&RJQ9:UHf/3RGD7+B-M:C2SfEAZ7V,K"@B.fTK>V?E@_M
fN^W+)^NfUC_?/RAHf57PfLc7fL% f+8Y%. U0R^fT(UE3MPTf5\$,?)VN)
MR4XAf^fL;fSBK_@+758>GLf=4\$E:6^QfWfVfH=RV<%LNRf+8f4B2>&f9Y/C MfOLX64M0=KS\$2Z
DO/EPN;EX^_G)C;fMJDY)(f!5TPM(fGFO>4M-5\$fI77VG M0WQ<>.>KGNOA8XRX2Xf!#?K>fO/fJ&SG_9;Bf f^?<
fI2;U;G2"9*OD>5f;P%Q\$ M6STfRDH4Y?(f1_%.L!&fEDHY#43K+9" MAYCIBR>?_Y5\$?
HKC5f;RQ@(^fT;f8G2fUH56!*L38@.4+37"(4Q1>OHfJ4S^
M.Lf\$S22) KX\$If43^/BK/O69Hf5CYfI4fN fFRK/fJA\$ f1+3 MX?.#=RQAGf14N*0fO<9S^fCB+Bf f^fICTCfI
*fEKNRf5>A93)&@f!78_MUQAWfJ>_C^+X.9K^;^=KRK*1\$#8<@f!) KBBf10&D\$ f0 BG^*SWf(WE54Xf f-MfE&
f>;8H2f(fJ-!%2Sf!)"DCH(fOS/E(f'W/Z5WKZAR-Pf_3fTfQf/90#6E0f!=MM>?%<_.f5,3319(f7B0-
0;T4Kf8fO28K2\$ f;V>^Z^fON;SC.XD/?Z^fRA3fZ>fS;@M8Df1^fN) ==)R&X
MR;P\$ f=MG\$+VYHf=;M3;6.YDQ*fE7Zf6GfWf(f4YBLfUD^9\$F.UY2C%fI@D6
MfF3*A85M@>^@^fL.U.0LWf15M' Q^EHf70fLDF f>#Y'.fL;fJ@>\$ MMR&.3 MW34U98BYf?
fT(K3Cf5*HV4%^OCDO9X=fDG&?>^MURNfSF4M0.A^XPM^XL38f M*L%NfY""fE"J^A@f>_Y6>?HPU;f>L
fL9^f%Yf1;...D>70(8HVSfNf@;fF*EfD MR(\$7+AfYCF= %5fZ>_K%MZfJ>@XfIE_&&?;fLLfKK fE_ %VO3f;f>_Sf@_4f+OM-
=f!_@#5E#2MHR^M5V^EP%\$R"4fWZRY MJ?T_Y6>?HE?PB2\$+KK&\$QfL+fF-M6""&9-
JC<9*UQ>#9/Q>>1&\$7RA_>>?Y7 M>Oif9"1XfBLfB/7U6@4+fT%GR4;/S9ELK?UPQ;)A&"R*K8fPR7f;_fTf;9SA;_
MS<52UW_ fV* >X=6/f-LWN-OLMO4_Z>H+O78fNMJfHMWNQW=XfFE M?/PO=T^7D7ZfRLZ3A/YQEfXOHfQ1JD3-
Z&+KfH>;Y\$ fO7F4Sf1R6>>K)fJ M.WBZO/fX;OB"<_fJUP8_-fV.T(WP;.#^fHSGP5fJ.fIO%PIQ2MA1@C\$
M;Q;%;\$f116Gf1EQ^AH2U8f@fX2(CN" D^XA@MRLPfM416^L>.RG?;RR_M3S3 M5%X(RfFML>,<+05@5%HY-
\$)f?#f)5/XO3=U=YEfXf1.f^3#^QD\$;fMJKRY M?O f>+W_?UA?
Y;O+YfNKWNKVfQ^LO3V"AC&WA(f;fH+K.9XfJHU%7DB)"L\$F"" M31"=\$/POYHfS5fA)PBKM-
S^0="=S0%T@)&fD)fEY06.Q4f65%EFfIOU\$8CSW M=W#NPIfH=W#N.6P+;X^W_ f^?<
*WfTO2RH9fLKW_Of!HA9^fL.9.9f;A^f4MH MJ.R*HfKf+f>97f(BH7335fLVC:/PN"O9PHfCM00\$/S9fH%?<
+A^0;=BB@05 M\$?GS30E"<f(f"A3HV%+KNfS!_fTP;=f9fH(4@1.2@X M#8-'D:5)&*%?29f5R fJT\$3)fD.fEFZ"?<
ZKW_U>Z>2DHH;f?f92Q>#f;XO"YMM890X MfEKF0?W?WYf\$WN32H7;_KW3E+AK_6fM;+<99f(W%*f1+9
SDZC\$2;fW.5E(f6_-PF2EQ)<#&99F502?7E)f)VK0?*(G-4 M^O#Q\$ fOQCL%f1fH_X?>YfN-USfAM>+fRf_8f!(N?<
Z&(W&&AEf1;8fJM.S* MYN_@8(S@fJ@W2%NDf1)X^3WK_-
fSR@N(B9fE&4fJNYfT&94,^9Y0/fY3K;W'fM%6:B#Xf1&9CWB7G5RfO?"FE
MMU'6Y@5ZfJ5fJNEfV"KfJB\$*PEDf7fZ2^6fRfRfZfZ>fQM@<\$<;ST5-G'==fJDI M>%6= f79XC8Q9XCM27%?
E(fDZ.OGKU(="IKf&f160;_8_QfUO9MUGfL&;?fB: M)7WG6=K;W_YMPfTL>-5 YU0&M@LOM35S69fL;R M)N f1
fFH<&O?A_G'fDQSfBBM(@2/&8SW\$B)5f!%&.3fEHQ003?>WfHf1C6<_fMIT?SfJ4?
NV42fN(fNCfQ_&4Y4E+@fJB0\$;8864.X\$VfL>1D;fRf f'+<>U8UD; MDf/ZV"/W");^fLU!-
fJOEN%3G/LTTfC%* _fE1fHPM.DfMNDfCf7SU96fYR_NfMfFO2Z-3C72CfYf^fVEU=O)f2VfWB(O"G_8=AM_&?
3KfI4HD?>_9G@f\$N8?OS^fMRI_>?B(KEDf14N34F)f&6-5QfP%%.0%5Z8@L^W;R?O%?20-f3;R?Lf!fHfM_N;f!
<4HMfO8;NMfS)&U2^KS7S'5J>EHDO3f8_PCC_M2*?CSAYf2fMfN?G0QNM^N?VM>fH;fLJBZf_1*8F7O!-
fOQ)f)W:Nf1#L+JY33 MV3f;f2=;MT#Rf1O#f1@HT@f54^N+ f9fOQW!!G^YfH4AL="fOL.V7FNKY0Xf&
M0+0R2_>fG2NfRN%PLQ8(X(2\$ fYP7#_?<;XSKZfINN_?UM^OSfJPW;8Hf>
M\$VfB/MWG2S\$9H2VV5S=9RB(fT)*D39^;f(ZDfSf1?L^f&U+f1J*9@8?NT_/_MV;?NL@>DA36-
^fKG7*2fJ@)_AT+G(fT(47LC'X.f?P_VfF5_>fJGL/6fGAEf MfJON+fF<fI9=&Ef) LMN_M9\$@ZS@A?
>Mf)85_6@=fJN\$^5Z86"Jf!QR>N2fL MCUI?75fG?32BfUNH;E57F2f1^7A+f4Zf= f=32fBf!\$4DVKfHRVXfJAGS/?3P
M9#_W3 f10R#=#CfLOEH" fH52Z&"@N9>ZL=8fMG?2fHfQfT54M9^XO)f1DOC3* M2f;RX8;U_YGW7f1
^=9% "B5^@f\$#fHS8VWfDX5-'G94R!f009>"/K*5(CT80.(4ZBfH<0? \$Hf!f9BGEN M*"R;PP
&00%\$fS;5^_PM=7FS>OKOZ;G.f!%WESf?;_f6^#
M>GD3Y@E>V*01V^LI/\$6S;Q.RXVX% XU^fFK.VAC3f;fUYVT.&2KAfJBFfYf!%&f(=V" @fI%TJ<f[f1HS MNX2%;
<^f!<fT^0"5%X#(B_/S_OGf&S5N_G399fJUfO-GJ2)VD;fR0#;4fM9.4ZLf/?@Y7AEBPB0^Q#AG8fN MDB-E"5;fQYQ
%f!4A6f1_@;YD4UD@U=&6Z_!HW=S5@OA.3\$PWL=FfJ59XfJPHf

MO6Y [8M4V45DJ;+ +H*NSI>G#EH3(/=D2@P^B!Q\7X;-RJ8D81HOFTIL8AS M@_#B 239*M)9>2V/HP@JP?
M%H@=Y7HN WE3ZVXCPM\$^IT7B\N;Y^*<I>W#)9MJA%?>4HR1^E!H>JZ?
M7NZY7R#B\SH(6%N/^&!@W4XW 10 M;NY\09N+S?OK\Y:IAW56\$*MH,#)MH"J(*JE41_ "<&S11#_H=*9QITAPS9
M=@K\IYAYX_V+AM091LHU+; Y#_U0Z0#1)7-;F^F:1)YD&OMJ2\IYF
M2@0\IP\A+F\J/\^E_IYIN+IKJM+EZHWF-CCJKX00-13VP*OZSUP+>J?2YZ*,\$Y3MX,E91>>B%Q6H1 (3
M*+6SF;HE&L?>N6;NTI_/OZ^K(Q"SQS.(ZKQOF&N2>DO\ E;@/SE@X309\Y MHU&B9U\
<8\N2707P3_RA;_VL3UH)T\?9<7<="SS",\D,Y&F2YUR_GZYV5Z^
MWM#%3IZAT#Z10G"%V)P+A6=/F2J@5K\$FS0M^FF++O;!*_=UPS6V^_S&=;OS*,S\G--EFHK+ICD?G!_J MOI>_?
_VKNVW;9U)2I^_D6_92HDD7\T*HLD;OO MWQ\2OB26=;&H48;%SDO1-L%PN_9P-!P.AWW?Z;DCW\ZDY&
(*R;V8XE_IC+7 M/_\$*1G;^>VD4IM<6"UQWM+I>@MA#*J@!H\1PO2TE2P+3GZQV_ZF2D_-70/3 MYDA\2F?
4H=;C,6VU_ (=L6EQ"%YAY.2B;_4F_-#G7KBN;I2_*#V\8SZ#N!L MWG:M6(H?N0Q3WB3\9\YV>;9E!;&
<I&;W+&8X=V;_Z XOT\1Y+EQB3<^VP_QB2V+ 0TF%IDD7;I MG.YNTG1\000?&M#)
MR!OU!H.O"WU\75DYW%>73+^5G29\6R>VU30L+LLL\$/ZRMX6 @HMS_FUB_M2P)KW+-MROT_AO(5\I
(EC*\$7FA;#_"4\5PGT\RP09;4\4G\;C#N#0@GV?>^2\VM.743^J/G47LT&H^M^LDV8D?<
<D:3D>4\$8FU2QW/UWJ@'4@_W4:5/;%A#F-6W M;9;Z47<9SBL!+U\ZV26RI&*?/_OA^B)TZ\L2:B(51S/=B9C^=8T
M=2QGX_66U\186YX74"16TVB4_ZB7^_DBZ;CO^GV6FVN_JR^V>JNK^G>75-O M-'9ML1?
S_9\$G0A_PG*);UL^AW%O//#IO_E_H?XH\I.2B)HMGMI^;KHQ/+^D\ FE P#^FGI&YQ#&)-V(WH;_M
MN);_J\0GNR&F\$J-%N KCY768^!%+UCRW_2\Z)"F\#BN%ILS*)^_65#Q"PI_0
M; >5;GFN(H7\1IEEE0QS/^K3A^)*H3H^/^OP\?@VET(68\J7XX4O<^EHN1T M;IDXXK%XE!_3"R?ZT?
2%\$6^_S6Q_CEPD6CUO\Z1#_N9EEI%56" M8@!9CR\BLI=N0HE,@6B<I^CLKU(UH;ZN;%F6C? M-
!>6\TY41*UT+#+&?_X#IDOP\!N5\1VU+ZF(H@;9;I\5\KRG6LIWP2A#CQWW%7UT M12
D9PB_B3H(5C&#B7G;J\PN)E#W3TQXM%UF#S2%LN_/=)6VYZU0J\K\^&S M5@6)"93=O"%_SD;?8V\BU(BQX
3R;0)F\#(-_%2*^SY@!A?W^C-O U\3*5 M.#+@^+(<#F2R3E?V\N^?;69*5R_Q\H7PI"
I&C; &+;M7&J#%DMU+!0S3/CE2*! M MK\B\$GX^+M0H69"?J0+,"O^SIM<-
IRNTL\%P>&E^5N#;E\$/I5QR>=1">J\IP=MG^P=G#3BYI\%Y1\D^J">^@L0IK5C-
Q@IXK5(A9OY8^T^_7FD*5<L;@%9)"O"OK(4F>%;(93\%1#;3 MB /I\$!%H%:6Z+%9#8Q9OUVNZ8#=#O\JR?BGG&>-
Q@EFJW=;9-QD\$H_9B6_5\$ MVE_"EF4P3P+_F(K>B6;/_M= =W%IQ7#H9W<YI 2IX&F@&8L;_UFX4\J&_
MUW\AOEW2F_9AVKI80FM_O*Z2-0Q=4LDO\N+^+CO<)WJU?9855_P NC_-W" MQ&YZ(^+5!@_913-
DS=F\089X%6+Q"@@-F%FOGH%"+@OH_-BE4@T^M=5CY%! MIP*)F)?^\$!_K4-^I^LP3KG!_SHD&Y7Z;HZA\55
+TU7%4"GDD&J?RJ4!;C\ MF;O;IV1.N=AMK=S8I"%/RKR6ZQK 4H\6I^C\$+0#UP8L?%R1^=EC^PB\47^=^
MAAMZ)=S\$DO%MZI*18HEX_-7Q9HJ3OTXD1U%>O9_"%9&4"!;KOJHD@C7#!9FZ_M.64
/+U+P;PIJ<=>_54P%MY=Z;DE(#P5;OXF5^:K_K\$K_K\$
M9MR0_RU8MA\ONSQ;)&5456MCL+)&8A.014>U8)9&7AS>9\T0;J8R=VQ2ELLT
MN\44_&3*Q;OXWJUYN6MDC1>>+*Q\20U\J)G#L%9X\!P(I4RQA@_?;0+G46_M4TP>_Y5D@*Q6R@4,I3)+\$*#;S-
#S1\VAQUL\J\T&=J4\C"TIQS<*+R_O'6_MDP97)8\@9^E^I=OLTX2J2(547R\#HL*FI"@A,(?C<*3);_AYO_J;BMC\
M8V*0DXG=O/G14D10#Z\))>=3@%ZA;L/A7=)LR^EC\)&I?^8W;_F5\2YFP7\$2
MWW@L%;_ZX\HAM/0M\6<";_RY.8X/(Z+;1W_0_QXZ/9 YA)\!0@D(8 M\I^&UQPO,DUF7X;A5+8<"0;A;@;+
<I^P7V(%MC899VQ6*27/Q%RC+ 5(I\6(IC\W\!H%L5=<0I(9GZ4O_\$9HF,S)+#I. MYCZ5_]
I>0@B7TYKD482(FP\Y1)08R;=KD5QIX_*ZLBZN\5^F1SEH
M^YVJ@R"B6(G>O?;PM1*GTO#J\9H5WYIVK63*_9(Y60EE.QMJ/6-DV*)>_?
M>GQ5XH)=7B94(<=;K%D0A+Z0>QO#K+5ZZ7@N4(I+9;RP?2:E_!MGZ\>D)%D# M,EHE%RWVU?
6C\1AA>107V;N?^6%8K%*+EKJ?>M=ZS%"7XLL>T\$>XOI>7A9;_MEQ3M-5>(I3Y#4S)=NU&TG;LA
2*J2"1/Q1HOB\JP;ZIDD?N0L-LUPCD&LMD_MHK4YT22N\AOLL\0T#_ =+,%\8ZE00
XENE%F#3P&L9=HL%#0)8)!NOO0@_MEQ5@F>I*^CZJ".I12R7B-0=KXU3J@T.M\UF&ZE4^_I*
4VYM5\H3;=1@;(9:B8 M+12\#8?"ZO.B2;<>E-C;QIR;>4JRCTCV^_L+BP3*#RG43K+94^@M1K1S=SIO M&L?
_4W08I^M@^+H2@/@=1H\X\H<-N;8/DLR=15TQ4*C\N5;I*_\$9GY_OUZZTCEW\ MDQ3PJ+MN;_X\SA";R3K<2D
M2;DL1;_0*3V\3WX,W+^SP^>2^<9^%/92B2;DL^JA<IVLE%WFFV77Z%);L
M2D\5P8+=H58&5^&0(05R5/BRZ2\$404H)J3X05XU^RA(B2"3LCQ%_*_(QU MJ>1!AA(?)N5@_N3D(IYH*
MV1UK#7U0U_?JPMX\HLY7R;\$^Y^ID%?"TZ\$?<%Q5BT=90_MLOBA^ACT2\$%J!?
%RXZDDM\OS36.X@NF;0LDB3^N^UR>BT"!YR@_R^P_K MB-H\;VC+J\G_PUY22VA=MJ*G3";)?=F/-5_@I_<
IX*S^K%HM\J;T58/C\\$. M;_+7H)Q4P@G>".(I4;ICB;L L@9\@C@ISB%I84?1*+=9==WA>>_F.4)@0@K
MEXIVC;V5^S2.ML.&@;_ "W;/P0)XP+Q'OYKJ_-RS\PPBN;MY>OPY)54X@WKUT M^;_*T3""J.OU3C\$ _BHZB\&Z9ZY"31
(6AZIO^9A&M)DNEQ_-VX8M;I?4"\$7 M\YZX#F&5V/P9Q\%S%H6^F;"<_<
I_#X^"383HX#BZ?OAO\>ASFP\$X%RX6^ZK_M0Y.I>I>A<-
-3>NUZZ(4?E;R=GK0HXH5^&%;DYSU+IZK^Y/O51S\$D_ =^2YPK\ MNO?H^Q_ (/SPWH?_IS_!4\$!_A0#%@
2H1\$6L,BBGE*)P "O4 !, M (! &5X,3_Q.C M1T %_7&0_\$0 @_JPP_97@S,C(Q,C,Q.C R-"YH=&U0_M2P\$"%_4"
!*A\$1;JYIY&NHP"T^0\$ \$0 @_%9R0_M97@T,34Q,C,Q.C R-"YH=&U02P\$"%_4 " !*A\$1;TWV7U;D)!@ +^H8 M\$0 @
%R^@< &5A;RTR;#(T,3(S,2YH=&U02P\$"%_4 M" !*A\$1;4,OE8@15_#MSP0_\$0 @_&01 <<&5A;RTR;#(T
M,3(S,2YX&UL4\$!_A0#% @_2H1\$ M6FEZDI=VKP\$ O7X3\4 (!5N<"^IE86LM,C R-#R,S%? M9&5F+GAM;%!+0(4
Q0 (\$J\$1%I;K@&_HQL!_#ZA_0_4 M " ?^6"0:P96%K+3(P,C0Q,C,Q7VU(P_5_"=2R"@!P96%K+3(P,C0Q,C,Q7VQA
M8BYX;6Q02P\$"%_4 " !*A\$1;LPI+>RDO @;Z)AH %0 M@_&68@X <&5A;RTR;#(T,3(S,5IP&UL4\$!%!@_1!\$1_0_#3
\$\$ \$!_end XML 188_peak-20241231_hm.xml IDEA: XBRL DOCUMENT 0000765880 2024-01-012024-12-31
0000765880 2024-06-30 0000765880 2025-01-31 0000765880 2024-12-31 0000765880 2023-12-31 0000765880
2023-01-012023-12-31 0000765880 2022-01-012022-12-31 0000765880 us-gaap:CommonStockMember 2021-12-
31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000765880 us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-12-31 0000765880 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000765880 us-gaap:ParentMember 2021-12-
31 0000765880 us-gaap:NoncontrollingInterestMember 2021-12-31 0000765880 2021-12-31 0000765880 us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-01-012022-12-31 0000765880 us-
gaap:ParentMember 2022-01-012022-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2022-01-
012022-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-012022-12-31
0000765880 us-gaap:CommonStockMember 2022-01-012022-12-31 0000765880 us-
gaap:AdditionalPaidInCapitalMember 2022-01-012022-12-31 0000765880 us-gaap:CommonStockMember 2022-
12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000765880 us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-12-31 0000765880 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000765880 us-gaap:ParentMember 2022-12-
31 0000765880 us-gaap:NoncontrollingInterestMember 2022-12-31 0000765880 2022-12-31 0000765880 us-
gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-01-012023-12-31 0000765880 us-

gaap:ParentMember 2023-01-012023-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2023-01-012023-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-12-31 0000765880 us-gaap:CommonStockMember 2023-01-012023-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-12-31 0000765880 us-gaap:CommonStockMember 2023-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000765880 us-gaap:ParentMember 2023-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2023-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-01-012024-12-31 0000765880 us-gaap:ParentMember 2024-01-012024-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2024-01-012024-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-12-31 0000765880 us-gaap:CommonStockMember 2024-01-012024-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-12-31 0000765880 us-gaap:CommonStockMember 2024-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000765880 us-gaap:ParentMember 2024-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2024-12-31 0000765880 us-gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESActMember 2024-01-012024-12-31 0000765880 us-gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESActMember 2023-01-012023-12-31 0000765880 us-gaap:OtherNonoperatingIncomeExpenseMemberpeak:GovernmentAssistanceCARESActMember 2022-01-012022-12-31 0000765880
peak:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESActMember 2024-01-012024-12-31 0000765880
peak:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESActMember 2023-01-012023-12-31 0000765880
peak:EquityIncomeLossFromUnconsolidatedJointVenturesMemberpeak:GovernmentAssistanceCARESActMember 2022-01-012022-12-31 0000765880
peak:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESActMember 2024-01-012024-12-31 0000765880
peak:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESActMember 2023-01-012023-12-31 0000765880
peak:IncomeLossFromDiscontinuedOperationsMemberpeak:GovernmentAssistanceCARESActMember 2022-01-012022-12-31 0000765880
peak:GovernmentAssistanceCARESActMember 2024-01-012024-12-31 0000765880
peak:GovernmentAssistanceCARESActMember 2023-01-012023-12-31 0000765880
peak:GovernmentAssistanceCARESActMember 2022-01-012022-12-31 0000765880 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000765880 peak:HealthpeakOPMember 2023-02-10 0000765880 peak:HealthpeakOPMember us-gaap:NoncontrollingInterestMember 2023-02-102023-02-10 0000765880 peak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880
peak:OutpatientMedicalBuildingsMemberpeak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880 peak:PhysiciansRealtyTrustMember 2024-03-01 0000765880
peak:PhysiciansRealtyTrustMemberpeak:RestrictedSharesMember 2024-03-012024-03-01 0000765880
peak:PhysiciansRealtyTrustMember us-gaap:CommonStockMember 2024-03-012024-03-01 0000765880
peak:PhysiciansRealtyTrustMember us-gaap:RestrictedStockUnitsRSUMember 2024-03-012024-03-01 0000765880
srt:ScenarioPreviouslyReportedMemberpeak:PhysiciansRealtyTrustMember 2024-03-01 0000765880
srt:RestatementAdjustmentMemberpeak:PhysiciansRealtyTrustMember 2024-03-01 0000765880
srt:ScenarioPreviouslyReportedMemberpeak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880
srt:RestatementAdjustmentMemberpeak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880
srt:MinimumMemberpeak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880
srt:MaximumMemberpeak:PhysiciansRealtyTrustMember 2024-03-012024-03-01 0000765880
peak:PhysiciansRealtyTrustMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:FeesPaidToInvestmentBanksAndAdvisorsMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:SuccessBasedPaymentsRelatedToServiceProvidersMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:SeveranceExpenseDueToDualTriggerSeveranceArrangementsMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:PostCombinationExpenseAcceleratedVestingOfAcquireeEquityAwardsMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:LegalAccountingTaxAndOtherCostsMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:SeveranceExpenseRelatedToEliminationOfCertainPositionsMember 2024-01-012024-12-31 0000765880
peak:PhysiciansRealtyTrustMemberpeak:LegalAccountingTaxAndOtherCostsMember 2023-01-012023-12-31 0000765880
peak:PhysiciansRealtyTrustMember 2023-01-012023-12-31 0000765880 stpr:MApeak:LabMember 2023-01-012023-01-31 0000765880 peak:HCPVenturesIVLLCMember 2023-04-30 0000765880
peak:HCPVenturesIVLLCMember 2023-04-012023-04-30 0000765880 stpr:MApeak:LabMember 2022-01-012022-01-31 0000765880 stpr:CApeak:LabMember 2022-01-012022-01-31 0000765880
stpr:TXpeak:MedicalOfficeMember 2022-03-012022-03-31 0000765880 stpr:ARpeak:MedicalOfficeMember 2022-05-012022-05-31 0000765880 stpr:MApeak:LabMember 2022-12-012022-12-31 0000765880
peak:OutpatientMedicalMember 2024-01-012024-12-31 0000765880 peak:OutpatientMedicalMember 2023-01-012023-12-31 0000765880 peak:OutpatientMedicalMember 2022-01-012022-12-31 0000765880
peak:LabMember 2024-01-012024-12-31 0000765880 peak:LabMember 2023-01-012023-12-31 0000765880
peak:LabMember 2022-01-012022-12-31 0000765880 peak:CCRCMember 2024-01-012024-12-31 0000765880
peak:CCRCMember 2023-01-012023-12-31 0000765880 peak:CCRCMember 2022-01-012022-12-31 0000765880
peak:OutpatientMedicalBuildingsMember 2024-01-012024-12-31 0000765880
peak:FourteenOutpatientMedicalBuildingsMember 2024-01-012024-12-31 0000765880

peak:LabBuildingsMember 2024-01-012024-12-31 0000765880 peak:TwoOutpatientMedicalBuildingsMember 2024-01-012024-12-31 0000765880 peak:DispositionsOf2024Member 2024-01-012024-12-31 0000765880 peak:DispositionsOf2023Member 2023-01-012023-12-31 0000765880 peak:LabBuildingsMember 2022-01-012022-12-31 0000765880 peak:OutpatientMedicalLandParcelMember 2022-01-012022-12-31 0000765880 peak:DispositionsOf2022Member 2022-01-012022-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember peak:OutpatientMedicalMember 2024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember peak:LabMember 2023-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember peak:OutpatientMedicalMember 2023-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-12-31 0000765880 peak:LabMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember peak:LabMember 2024-03-31 0000765880 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember peak:LabMember 2024-03-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2024-01-012024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-01-012023-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2022-01-012022-12-31 0000765880 peak:CasualtyRelatedLossesMember 2024-01-012024-12-31 0000765880 peak:CasualtyRelatedLossesMember 2023-01-012023-12-31 0000765880 peak:CasualtyRelatedLossesMember 2022-01-012022-12-31 0000765880 peak:RentalRevenuesAndResidentFeesAndServicesMember peak:CasualtyRelatedLossesMember 2024-01-012024-12-31 0000765880 peak:RentalRevenuesAndResidentFeesAndServicesMember peak:CasualtyRelatedLossesMember 2023-01-012023-12-31 0000765880 peak:RentalRevenuesAndResidentFeesAndServicesMember peak:CasualtyRelatedLossesMember 2022-01-012022-12-31 0000765880 peak:PlannedMOBDEMOLITIONTenantRelocationAndOtherCostsMember 2022-01-012022-12-31 0000765880 2022-01-012022-03-31 0000765880 us-gaap:OtherAssetsMember 2024-12-31 0000765880 us-gaap:OtherAssetsMember 2023-12-31 0000765880 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-12-31 0000765880 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-12-31 0000765880 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-012022-12-31 0000765880 us-gaap:CorporateMember us-gaap:SegmentContinuingOperationsMember 2022-01-012022-12-31 0000765880 peak:SorrentoTherapeuticsIncMember 2023-01-012023-03-31 0000765880 peak:SorrentoTherapeuticsIncMember 2024-01-012024-12-31 0000765880 peak:GraphiteBioIncMember 2023-10-262023-10-26 0000765880 2024-07-012024-07-31 0000765880 2024-07-31 0000765880 peak:CommonSpiritMember peak:OutpatientMedicalMember 2024-01-012024-12-31 0000765880 peak:CommonSpiritMember 2024-01-012024-12-31 0000765880 peak:SecuredMortgageLoansMember 2024-12-31 0000765880 peak:SecuredMortgageLoansMember 2023-12-31 0000765880 peak:CCRCResidentLoansMember 2024-12-31 0000765880 peak:CCRCResidentLoansMember 2023-12-31 0000765880 peak:MezzanineLoansMember 2024-12-31 0000765880 peak:MezzanineLoansMember 2023-12-31 0000765880 2024-03-01 0000765880 peak:SunriseSeniorHousingPortfolioMember 2023-12-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-02-29 0000765880 peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 us-gaap:MortgageReceivablesMember 2024-01-012024-12-31 0000765880 us-gaap:MortgageReceivablesMember 2023-01-012023-12-31 0000765880 us-gaap:MortgageReceivablesMember 2022-01-012022-12-31 0000765880 peak:SecuredMortgageLoansMember 2024-03-012024-03-01 0000765880 peak:MezzanineLoansMember 2024-03-012024-03-01 0000765880 srt:MinimumMember peak:SecuredMortgageLoansMember 2024-03-01 0000765880 srt:MaximumMember peak:SecuredMortgageLoansMember 2024-03-01 0000765880 srt:MinimumMember peak:MezzanineLoansMember 2024-03-01 0000765880 srt:MaximumMember peak:MezzanineLoansMember 2024-03-01 0000765880 peak:SunriseSeniorHousingPortfolioMember 2021-01-012021-01-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2021-01-31 0000765880 peak:SunriseSeniorHousingPortfolioMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-06-012023-06-30 0000765880 peak:SunriseSeniorHousingPortfolioMember 2021-01-012021-12-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2022-01-012022-12-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2023-01-012023-12-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-02-012024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-02-012024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember peak:SecuredOvernightFinancingRateSOFRFirstTwoYearsMember 2024-02-022024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember peak:SecuredOvernightFinancingRateSOFRFirstTwoYearsMember 2024-02-012024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember peak:SecuredOvernightFinancingRateSOFRLastEighteenMonthsMem 2024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember peak:SecuredOvernightFinancingRateSOFRLastEighteenMonthsMem 2024-02-012024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-05-012024-05-31 0000765880 peak:SeniorHousingOperatingPortfolioMember 2024-12-31 0000765880 peak:SeniorHousingOperatingPortfolioMember 2023-12-31 0000765880 peak:SeniorHousingOperatingPortfolioMember 2021-01-012021-01-31 0000765880 peak:SecuredMortgageLoansMember 2023-02-012023-02-28 0000765880 peak:SecuredMortgageLoansMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-02-28 0000765880 peak:SecuredMortgageLoansMember peak:SecuredOvernightFinancingRateSOFROvernightIndexSwapRateFirstSix 2023-02-28 0000765880 peak:SecuredMortgageLoansMember peak:SecuredOvernightFinancingRateSOFROvernightIndexSwapRateLastSix 2023-02-28 0000765880 peak:SecuredMortgageLoansMember peak:SecuredOvernightFinancingRateSOFROvernightIndexSwapRateLastSix 2023-02-012023-02-28 0000765880 peak:SecuredMortgageLoansMember 2024-01-012024-01-31 0000765880 peak:SecuredMortgageLoansMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-31

0000765880-peak:SecuredMortgageLoansMember 2024-01-31 0000765880
peak:SecuredMortgageLoansMemberpeak:SeniorHousingOperatingPortfolioMember 2023-12-31 0000765880
peak:SecuredMortgageLoansMemberpeak:SeniorHousingOperatingPortfolioMember 2024-12-31 0000765880
peak:OutpatientMedicalBuildingsMember 2024-07-012024-07-31 0000765880
srt:MinimumMemberpeak:OutpatientMedicalBuildingsMember 2024-07-31 0000765880
srt:MaximumMemberpeak:OutpatientMedicalBuildingsMember 2024-07-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMemberpeak:LabMemberus-gaap:SubsequentEventMember
2025-01-012025-01-31 0000765880 peak:OtherMemberpeak:SecuredMortgageLoansMemberus-
gaap:SubsequentEventMember 2025-01-012025-01-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMemberus-gaap:SubsequentEventMember 2025-01-31
0000765880 peak:OtherMemberpeak:SecuredMortgageLoansMember 2024-01-012024-12-31 0000765880
peak:OtherMemberpeak:MezzanineLoansMember 2024-01-012024-12-31 0000765880
peak:OtherMemberpeak:MezzanineLoansMember 2024-12-31 0000765880
peak:OtherMemberpeak:MortgageDuringJune2024ToJune2025Memberpeak:SecuredMortgageLoansMember
2024-01-012024-12-31 0000765880
peak:OtherMemberpeak:MortgageDuringMay2026ToMay2027Memberpeak:MezzanineLoansMember 2024-01-
012024-12-31 0000765880
peak:OtherMemberpeak:MortgageDuringOctober2024ToApril2026Memberpeak:MezzanineLoansMember 2024-
01-012024-12-31 0000765880
peak:OtherMemberpeak:MortgageDuringJune2024ToJune2025Memberpeak:MezzanineLoansMember 2024-01-
012024-12-31 0000765880 peak:OtherMemberpeak:ConstructionLoanCommitmentsMember 2024-01-012024-12-
31 0000765880 peak:OtherMemberpeak:ConstructionLoanCommitmentsMember 2024-12-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2023-02-012023-02-28 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2023-04-012023-04-30 0000765880
peak:OtherMemberpeak:SecuredMortgageLoans1Member 2023-05-012023-05-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2023-05-012023-05-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2023-10-012023-10-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2022-05-012022-05-31 0000765880
peak:OtherMemberpeak:MezzanineLoansMember 2022-11-012022-11-30 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2022-12-012022-12-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMember 2022-12-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMemberpeak:SecuredOvernightFinancingRateSOFROvernightInde
2022-12-31 0000765880
peak:OtherMemberpeak:SecuredMortgageLoansMemberpeak:SecuredOvernightFinancingRateSOFROvernightInde
2022-12-31 0000765880
peak:BrookdaleMTCAMemberpeak:CCRCJVInvestmentMemberpeak:OtherNonReportingSegmentMember 2024-
12-31 0000765880
peak:BrookdaleMTCAMemberpeak:CCRCJVInvestmentMemberpeak:OtherNonReportingSegmentMember 2023-
12-31 0000765880 us-gaap:MortgageReceivablesMemberus-gaap:PerformingFinancingReceivableMember 2024-
12-31 0000765880 us-gaap:MortgageReceivablesMemberpeak:WatchListFinancingReceivableMember 2024-12-31
0000765880 us-gaap:MortgageReceivablesMemberpeak:WorkoutFinancingReceivableMember 2024-12-31
0000765880 us-gaap:MortgageReceivablesMember 2024-12-31 0000765880 us-
gaap:MortgageReceivablesMemberpeak:CurrentPeriodGrossWriteOffsMember 2024-12-31 0000765880 us-
gaap:MortgageReceivablesMemberpeak:CurrentPeriodRecoveriesMember 2024-12-31 0000765880 us-
gaap:MortgageReceivablesMemberpeak:CurrentPeriodNetWriteOffsMember 2024-12-31 0000765880
peak:MezzanineLoansMemberus-gaap:PerformingFinancingReceivableMember 2024-12-31 0000765880
peak:MezzanineLoansMemberpeak:WatchListFinancingReceivableMember 2024-12-31 0000765880
peak:MezzanineLoansMemberpeak:WorkoutFinancingReceivableMember 2024-12-31 0000765880
peak:MezzanineLoansMember 2024-12-31 0000765880
peak:MezzanineLoansMemberpeak:CurrentPeriodGrossWriteOffsMember 2024-12-31 0000765880
peak:MezzanineLoansMemberpeak:CurrentPeriodRecoveriesMember 2024-12-31 0000765880
peak:MezzanineLoansMemberpeak:CurrentPeriodNetWriteOffsMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberus-gaap:PerformingFinancingReceivableMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberpeak:WatchListFinancingReceivableMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberpeak:WorkoutFinancingReceivableMember 2024-12-31 0000765880
peak:CCRCResidentLoansMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberpeak:CurrentPeriodGrossWriteOffsMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberpeak:CurrentPeriodRecoveriesMember 2024-12-31 0000765880
peak:CCRCResidentLoansMemberpeak:CurrentPeriodNetWriteOffsMember 2024-12-31 0000765880
peak:MezzanineLoansAndOtherMember 2023-12-31 0000765880 peak:SecuredMortgageLoansMember 2022-12-
31 0000765880 peak:MezzanineLoansAndOtherMember 2022-12-31 0000765880
peak:SecuredMortgageLoansMember 2024-01-012024-12-31 0000765880
peak:MezzanineLoansAndOtherMember 2024-01-012024-12-31 0000765880
peak:SecuredMortgageLoansMember 2023-01-012023-12-31 0000765880
peak:MezzanineLoansAndOtherMember 2023-01-012023-12-31 0000765880
peak:MezzanineLoansAndOtherMember 2024-12-31 0000765880
peak:SouthSanFranciscoJVsMemberpeak:LabBuildingsMember 2024-12-31 0000765880
peak:SouthSanFranciscoJVsMemberpeak:LabBuildingsMember 2023-12-31 0000765880
peak:SWFSHJVMemberpeak:OtherNonReportingSegmentMember 2024-12-31 0000765880
peak:SWFSHJVMemberpeak:OtherNonReportingSegmentMember 2023-12-31 0000765880
peak:CallanRidgeJointVentureMemberpeak:LabBuildingsMember 2024-12-31 0000765880
peak:CallanRidgeJointVentureMemberpeak:LabBuildingsMember 2023-12-31 0000765880
peak:PMAKJVMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880
peak:PMAKJVMemberpeak:OutpatientMedicalMember 2023-12-31 0000765880
peak:LabJVMemberpeak:LabBuildingsMember 2024-12-31 0000765880
peak:LabJVMemberpeak:LabBuildingsMember 2023-12-31 0000765880
peak:NeedhamLandParcelJVMemberpeak:LabBuildingsMember 2024-12-31 0000765880
peak:NeedhamLandParcelJVMemberpeak:LabBuildingsMember 2023-12-31 0000765880

peak:DavisJVMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880
peak:DavisJVMemberpeak:OutpatientMedicalMember 2023-12-31 0000765880
peak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880
srt:MinimumMemberpeak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880
srt:MaximumMemberpeak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880
peak:MedicalOfficeJVsMemberpeak:OutpatientMedicalMember 2023-12-31 0000765880
peak:MedicalOfficeJVsMember 2024-12-31 0000765880 peak:HCPVenturesIVLLCMember 2024-12-31
0000765880 peak:SuburbanPropertiesLLCMember 2024-12-31 0000765880 peak:HCPVenturesIVLLCMember
2023-04-28 0000765880 peak:MedicalOfficeJVsMember 2023-04-30 0000765880
peak:HCPVenturesIVLLCMember 2023-04-012023-04-28 0000765880
peak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LifeScienceJointVentureInSanFranciscoCalifo
2022-08-01 0000765880 peak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LabMember 2022-
08-01 0000765880
peak:LifeScienceJointVentureInSanFranciscoCaliforniaMemberpeak:LifeScienceJointVentureInSanFranciscoCalifo
2022-08-012022-08-01 0000765880
peak:CallanRidgeJointVentureMemberpeak:CallanRidgeJointVentureMemberpeak:LabMember 2024-01-31
0000765880 peak:CallanRidgeJointVentureMemberpeak:LabMember 2024-01-31 0000765880
peak:CallanRidgeJointVentureMemberpeak:CallanRidgeJointVentureMemberpeak:LabMember 2024-01-012024-
01-31 0000765880 peak:CallanRidgeJointVentureMemberpeak:CallanRidgeJointVentureMember 2024-01-31
0000765880 2024-03-012024-03-01 0000765880 srt:OtherPropertyMember 2023-01-012023-12-31 0000765880
peak:OperatingLeasesIncomeStatementLeaseRevenueMember 2024-12-31 0000765880
peak:DepreciationDepletionandAmortizationNonproductionMember 2024-12-31 0000765880
peak:OutpatientMedicalMember 2024-12-31 0000765880 peak:OutpatientMedicalMember 2023-12-31
0000765880 peak:CCRCMember 2024-12-31 0000765880 peak:CCRCMember 2023-12-31 0000765880
peak:OtherNonReportingSegmentMember 2024-12-31 0000765880 peak:OtherNonReportingSegmentMember
2023-12-31 0000765880 peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember 2024-03-01
0000765880 peak:A2028TermLoanMemberus-gaap:InterestRateSwapMemberus-
gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMemberpeak:SeniorUnsecuredTermLoanMember 2024-03-01 0000765880
peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember 2024-03-012024-03-01 0000765880
srt:MinimumMemberpeak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember 2024-03-012024-03-
01 0000765880 srt:MaximumMemberpeak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember
2024-03-012024-03-01 0000765880 peak:A2028TermLoanMemberpeak:SeniorUnsecuredTermLoanMember 2024-
01-012024-12-31 0000765880 peak:SeniorUnsecuredTermLoanMember 2024-03-01 0000765880
peak:SeniorUnsecuredNotesDue2027Member 2024-03-01 0000765880
peak:SeniorUnsecuredNotesDue2028Member 2024-03-01 0000765880
peak:SeniorUnsecuredNotesDue2031Member 2024-03-01 0000765880 peak:MortgageDebtMember 2024-03-01
0000765880 peak:MortgageDebtMemberpeak:OutpatientMedicalBuildingsMember 2024-03-01 0000765880
peak:MortgageDebtMember 2024-03-012024-03-01 0000765880 peak:MortgageDebtMemberus-
gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-03-01 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2019-05-23 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2019-05-232019-05-23 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2021-09-30 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2021-09-012021-09-30 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2024-12-31 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2024-12-012024-12-31 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-12-31 0000765880 us-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberpeak:VariableRateComponentOneMember
2024-01-012024-12-31 0000765880 us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2023-
12-31 0000765880 peak:TermLoanAgreementMember 2022-08-222022-08-22 0000765880
peak:TermLoanFacilitiesMemberpeak:TermLoanAgreementMemberus-gaap:LineOfCreditMember 2022-08-22
0000765880 peak:TermLoanFacilitiesMemberpeak:TermLoanAgreementMemberus-gaap:LineOfCreditMember
2022-08-222022-08-22 0000765880 peak:TermLoanFacilitiesMemberpeak:TermLoanAgreementMemberus-
gaap:LineOfCreditMember 2022-10-31 0000765880
peak:TermLoanFacilitiesOneMemberpeak:TermLoanAgreementMemberus-gaap:LineOfCreditMember 2022-08-22
0000765880 peak:TermLoanFacilitiesTwoMemberpeak:TermLoanAgreementMemberus-
gaap:LineOfCreditMember 2022-08-22 0000765880
peak:TermLoanFacilitiesTwoMemberpeak:TermLoanAgreementMemberus-gaap:LineOfCreditMember 2022-08-
222022-08-22 0000765880 peak:A2027TermLoanFacilitiesMemberpeak:TermLoanAgreementMemberus-
gaap:LineOfCreditMember 2022-08-222022-08-22 0000765880
peak:A2027TermLoanFacilitiesMemberpeak:TermLoanAgreementMemberus-gaap:LineOfCreditMember 2024-01-
012024-12-31 0000765880 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember
2022-08-31 0000765880 peak:TermLoanAgreementMemberus-gaap:InterestRateSwapMember 2024-12-31
0000765880 peak:TermLoanAgreementMember 2024-02-29 0000765880 peak:TermLoanAgreementMember
2024-03-01 0000765880 peak:UnsecuredTermLoanMember 2024-03-01 0000765880
peak:UnsecuredTermLoanMember 2024-03-012024-03-01 0000765880 peak:UnsecuredTermLoanMember 2024-
12-31 0000765880 peak:A2029TermLoanMemberpeak:UnsecuredTermLoanMember 2022-08-222022-08-22
0000765880 peak:A2029TermLoanMemberpeak:UnsecuredTermLoanMember 2024-01-012024-12-31 0000765880
peak:A2029TermLoanMemberpeak:UnsecuredTermLoanMember 2024-01-31 0000765880
peak:TermLoanAgreementMember 2024-12-31 0000765880 peak:TermLoanAgreementMember 2023-12-31
0000765880 peak:TermLoanFacilitiesMemberpeak:TermLoanAgreementMember 2024-12-31 0000765880
peak:CommercialPaperProgramMember 2023-12-31 0000765880 peak:CommercialPaperProgramMember 2024-
12-31 0000765880 peak:CommercialPaperProgramMember 2024-01-012024-12-31 0000765880
peak:CommercialPaperProgramMember 2022-01-012022-12-31 0000765880
peak:CommercialPaperProgramMember 2023-01-012023-12-31 0000765880 us-gaap:UnsecuredDebtMember
2024-12-31 0000765880 us-gaap:UnsecuredDebtMember 2023-12-31 0000765880 us-
gaap:UnsecuredDebtMember 2024-03-01 0000765880 peak:SeniorUnsecuredNotes525Memberus-

~~gaap:UnsecuredDebtMember 2023-01-17 0000765880 peak:SeniorUnsecuredNotes525Memberus-~~
~~gaap:UnsecuredDebtMember 2023-05-10 0000765880 peak:SeniorUnsecuredNotes340Memberus-~~
~~gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember 2025-02-012025-02-04 0000765880~~
~~peak:SeniorUnsecuredNotes340Memberus-gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember 2025-~~
~~02-04 0000765880 us-gaap:SecuredDebtMember 2024-12-31 0000765880 us-gaap:SecuredDebtMember 2023-12-~~
~~31 0000765880 us-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:CCRCMember 2024-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:OutpatientMedicalMember 2023-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:CCRCMember 2023-12-31 0000765880 us-gaap:SecuredDebtMember 2024-01-~~
~~012024-12-31 0000765880 us-gaap:SecuredDebtMember 2023-01-012023-12-31 0000765880 us-~~
~~gaap:SecuredDebtMember 2022-01-012022-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:OutpatientMedicalMember 2024-01-012024-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:CCRCMember 2023-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberpeak:CCRCMember 2023-12-012023-12-31 0000765880 us-~~
~~gaap:SecuredDebtMemberus-gaap:SecuredDebtMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880~~
~~us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-~~
~~gaap:DesignatedAsHedgingInstrumentMember 2022-04-30 0000765880 us-gaap:LineOfCreditMember 2024-12-~~
~~31 0000765880 us-gaap:CommercialPaperMember 2024-12-31 0000765880 us-gaap:LoansPayableMember 2024-~~
~~12-31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:UnsecuredDebtMember 2024-~~
~~12-31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SecuredDebtMember 2024-12-~~
~~31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:UnsecuredDebtMember 2024-12-~~
~~31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SecuredDebtMember 2024-12-31~~
~~0000765880 us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:UnsecuredDebtMember 2024-12-~~
~~31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SecuredDebtMember 2024-12-~~
~~31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:UnsecuredDebtMember 2024-12-~~
~~31 0000765880 us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SecuredDebtMember 2024-12-31~~
~~0000765880 us-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:UnsecuredDebtMember 2024-12-31~~
~~0000765880 us-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:SecuredDebtMember 2024-12-31~~
~~0000765880 peak:DebtInstrumentRedemptionPeriodThereafterMemberus-gaap:UnsecuredDebtMember 2024-12-~~
~~31 0000765880 peak:DebtInstrumentRedemptionPeriodThereafterMemberus-gaap:SecuredDebtMember 2024-~~
~~12-31 0000765880 srt:MinimumMemberus-gaap:UnsecuredDebtMember 2024-12-31 0000765880~~
~~srt:MaximumMemberus-gaap:UnsecuredDebtMember 2024-12-31 0000765880 us-gaap:UnsecuredDebtMember~~
~~2024-01-012024-12-31 0000765880 srt:MinimumMemberus-gaap:SecuredDebtMember 2024-12-31 0000765880~~
~~srt:MaximumMemberus-gaap:SecuredDebtMember 2024-12-31 0000765880 us-~~
~~gaap:IndemnificationGuaranteeMember 2024-12-31 0000765880 us-gaap:IndemnificationGuaranteeMemberus-~~
~~gaap:SubsequentEventMember 2025-01-31 0000765880 peak:LifeScienceJVsMemberpeak:LabMember 2024-12-~~
~~31 0000765880 peak:DevelopmentCommitmentsMember 2024-12-31 0000765880~~
~~peak:LeaseandothercommitmentMember 2024-12-31 0000765880 us-gaap:LetterOfCreditMember 2024-12-31~~
~~0000765880 srt:ScenarioForecastMemberus-gaap:LetterOfCreditMember 2025-01-012025-12-31 0000765880~~
~~srt:ScenarioForecastMemberus-gaap:LetterOfCreditMember 2026-01-012026-12-31 0000765880 us-~~
~~gaap:SubsequentEventMember 2025-02-032025-02-03 0000765880 us-gaap:SubsequentEventMember 2025-02-~~
~~022025-02-02 0000765880 us-gaap:CommonStockMember 2024-03-012024-03-01 0000765880~~
~~peak:AtTheMarketProgramMember 2024-01-012024-12-31 0000765880~~
~~srt:MinimumMemberpeak:AtTheMarketProgramMember 2024-01-012024-12-31 0000765880~~
~~srt:MaximumMemberpeak:AtTheMarketProgramMember 2024-01-012024-12-31 0000765880~~
~~peak:A2023AtTheMarketProgramMember 2024-01-012024-12-31 0000765880~~
~~peak:AtTheMarketProgramMember 2021-01-012021-12-31 0000765880 peak:AtTheMarketProgramMember~~
~~2022-12-012022-12-31 0000765880 us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember 2024-01-~~
~~012024-12-31 0000765880 us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember 2023-01-012023-12-~~
~~31 0000765880 us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember 2022-01-012022-12-31~~
~~0000765880 2022-08-01 0000765880 peak:A2022ShareRepurchaseProgramMember 2022-01-012022-12-31~~
~~0000765880 peak:A2022ShareRepurchaseProgramMember 2024-01-012024-12-31 0000765880~~
~~peak:A2024ShareRepurchaseProgramMember 2024-07-24 0000765880~~
~~peak:A2024ShareRepurchaseProgramMember 2024-01-012024-12-31 0000765880~~
~~peak:A2024ShareRepurchaseProgramMember 2024-12-31 0000765880 us-gaap:CommonStockMember 2024-01-~~
~~012024-12-31 0000765880 us-gaap:CommonStockMember 2023-01-012023-12-31 0000765880 us-~~
~~gaap:CommonStockMember 2022-01-012022-12-31 0000765880 2024-04-30 0000765880~~
~~peak:HealthpeakOPMemberus-gaap:NoncontrollingInterestMember 2023-01-012023-12-31 0000765880~~
~~peak:HealthpeakOPMemberus-gaap:NoncontrollingInterestMember 2024-01-012024-12-31 0000765880~~
~~peak:DownREITMember 2024-01-012024-12-31 0000765880 peak:DownREITMember 2023-01-012023-12-31~~
~~0000765880 peak:DownREITMember 2022-01-012022-12-31 0000765880~~
~~peak:StockBasedCompensation2006IncentivePlanMember 2023-04-23 0000765880~~
~~peak:StockBasedCompensation2014IncentivePlanMember 2023-04-23 0000765880~~
~~peak:StockBasedCompensation2023IncentivePlanMember 2024-12-31 0000765880 srt:MinimumMemberus-~~
~~gaap:RestrictedStockUnitsRSUMember 2024-01-012024-12-31 0000765880 srt:MaximumMemberus-~~
~~gaap:RestrictedStockUnitsRSUMember 2024-01-012024-12-31 0000765880~~
~~peak:MarketBasedRestrictedStockUnitsMember 2024-01-012024-12-31 0000765880~~
~~srt:MinimumMemberpeak:MarketBasedRestrictedStockUnitsMember 2024-01-012024-12-31 0000765880~~
~~srt:MaximumMemberpeak:MarketBasedRestrictedStockUnitsMember 2024-01-012024-12-31 0000765880~~
~~peak:MarketBasedRestrictedStockUnitsMember 2023-01-012023-12-31 0000765880~~
~~peak:MarketBasedRestrictedStockUnitsMember 2022-01-012022-12-31 0000765880~~
~~peak:TimeBasedRestrictedStockUnitsMember 2024-01-012024-12-31 0000765880~~
~~peak:TimeBasedRestrictedStockUnitsMember 2023-01-012023-12-31 0000765880~~
~~peak:TimeBasedRestrictedStockUnitsMember 2022-01-012022-12-31 0000765880 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2024-01-012024-12-31 0000765880 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2023-01-012023-12-31 0000765880 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2022-01-012022-12-31 0000765880~~

srt:MinimumMemberpeak:LTIPUnitsMember 2024-01-012024-12-31 0000765880
srt:MaximumMemberpeak:LTIPUnitsMember 2024-01-012024-12-31 0000765880 peak:LTIPUnitsMember 2024-
01-012024-12-31 0000765880 peak:LTIPUnitsMember 2023-01-012023-12-31 0000765880 us-
gaap:EmployeeStockOptionMember 2024-12-31 0000765880 us-gaap:EmployeeStockOptionMember 2023-12-31
0000765880 us-gaap:EmployeeStockOptionMember 2024-01-012024-12-31 0000765880 us-
gaap:EmployeeStockOptionMember 2023-01-012023-12-31 0000765880 us-gaap:EmployeeStockOptionMember
2022-01-012022-12-31 0000765880 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000765880
peak:LTIPUnitsMember 2023-12-31 0000765880 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31
0000765880 peak:LTIPUnitsMember 2024-12-31 0000765880 us-gaap:GeneralAndAdministrativeExpenseMember
2022-10-012022-12-31 0000765880 2022-10-012022-12-31 0000765880 us-
gaap:AccountsPayableAndAccruedLiabilitiesMember 2024-01-012024-12-31 0000765880 us-
gaap:AccountsPayableAndAccruedLiabilitiesMember 2023-01-012023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember 2024-01-012024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:LabMember 2024-01-012024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:CCRCMember 2024-01-012024-12-31 0000765880 us-
gaap:OperatingSegmentsMember 2024-01-012024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember 2023-01-012023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:LabMember 2023-01-012023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:CCRCMember 2023-01-012023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember 2022-01-012022-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:LabMember 2022-01-012022-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:CCRCMember 2022-01-012022-12-31 0000765880 us-
gaap:OperatingSegmentsMember 2022-01-012022-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember 2024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:CCRCMember 2024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OtherNonReportingSegmentMember 2024-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OutpatientMedicalMember 2023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:CCRCMember 2023-12-31 0000765880 us-
gaap:OperatingSegmentsMemberpeak:OtherNonReportingSegmentMember 2023-12-31 0000765880
peak:DownREITMember 2024-01-012024-12-31 0000765880 peak:DownREITMember 2023-01-012023-12-31
0000765880 peak:DownREITMember 2022-01-012022-12-31 0000765880
peak:TaxableRealEstateInvestmentSubsidiariesMember 2024-01-012024-12-31

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j38A+730 MCIAP!'#S_KK_80T=QN-Z=AENIVT4+N] M4+O&4%_+OSY\$?EX? Q_./GU2^OT9V38!@) \$TB8!X)IB1CN\$C\$P>0T1"8* M"1-(F >":8D:[1(U,HZ8FZX=Z@I?JPOC)V9AMD),P# MP;0@CW='!AN#_/MJ<2?3_KJX&IQ=J?!YQ:D7A^%V\$^(NOX@6AZ_*B*'SUO \$CR&,LTFX=+ M4@1P5FSQ'UJG^8I8)GX7H'K<3V0A^PEVO>J3]FPGS!I?@<<04\$<9 MJ&-6T-O5W2J]V- 2#>509IT5T(RRGE:A<@FE>2B:GA3EJHY]BBH(M5DH34!I M'HJFITL9K6/TL!?-XE"!A=)\$1:M5A>&H7A:.(;>_LE/'K'A=DLZ?J6QTRV#C!4;*\$T#T73:@/0VFBHNUK1&V.H;G4N6YU"AF+RD99J)MP*\$T M4=6)J);>LR5K%*SK'JVTF#F64<<21,535,5/G2X6X]YTZC9A+\$1;[^= M0I6Z4K.ZUNOOE1]1?'1% 8/Y>V5UGB"1+**)Y(FH#0/1=-SHY29GN(&,(7> M 8;2!)3FH6AZNI2#4L.#6]5=,LZ*U) KYBF;_I1'>JA5F9- S;:>!7U)WH1H- MI8F*5JN[K%\$CN"5/DQ-?NQ?>&%VC&4)BK:~N\$=3D:#23WDP\90&'247*6) MU\$YYR_<=E19JN%":@-(%\$U/B3)<>@K#I5#A=(E\$.A:'JZE.%2H.&:6=99 M@1HN;1JN4Y^!CF&X3!DN@QNNF6CIR""4<%FKX?+ZM(J5 ^Z4EP&5EPSSKD M4,5E3<6EDXDSK(>Q7"=T=I[KI9,"2ZS\$[S?IO5F_J*HNG% ;OSB0HXZJ]9 M;!U4J.=":1Z*IJ=H[SGGDSSHC'W2&? NH_99YV-X+E.>RX">:V999P7JN:SI MN8/ZK'0,SV7*U>^ZX'O1C">"Y3GLO GFOF68</M^3V75>AA6HNE":@- 1%TLA M->)=0G,95'.A- &E>2B:GBZEN0RHN6:6=5:@FLM:-+>A7,?P7*X\E,]UTRT M_HT6U'-YJ^>ZC1]I'<-SN?)

<#O9<,\ZY%#/Y4W/992Z:OT+=XBNHP.)OV MC./*=+G9=#^N\J6?
A^4E /0SN>_DYOKBMXZ:99!Q/JMU":AZ+IB5%^RT A MMQSJMU":@-(\%\$U/U]ZO>8%^:V999P7JM[SIMVZ]
[*]ZU&M!)?#!==,M(XX M5!'YJ^Z]:OGJ\$[UH'O!Y6#!-?.L0PX57-X47\$9=IU%U#I[Z1RY7<F?DMJW@
M"G=9ET5#RHZ4)J TCP43<^,SEU^"M'E4-&%T1@24Y%#H>KJ4Z"*@Z)I9UEF! MBBYO\$=WZ4SRH'O7U,Y3HNG#1-1-
M(PZE"?>P&[JH3O6@*]UP:~)KYEF""JZ M;E-T1[SQL]K;U-R;@NLJPW5?
8+@'+@D#E5TH34!T'HJFYTC)KGI*V76AL@NE M"2C-0!T="G9=8&R:V999P4JNVY3=NO:A>I0# 7>TE5FU[4O
MAUK+ +6;G- M(N!&F6W9:)]WBFOU4"ZYH%IL Z4&X,XW"O6K1&%R]U4)J TCP43<^6TF1W M=(J* '5G*\$U
:1Z*IJ=+N;-K7LOP)8(%64H352T9Q9'026IOUP)I&L68(L) MS?
..%IQA*\$U":AZ+I*Q\JA1Z>8G6K(=2JH30!I7DHFIXN)=I#LWR_8\$(S M\$ZUS I7OBO:&PO=VIR:W-H965T,1-
M\$)=\$E::L!^N-'?42R%(6ULH/ 1BQ47,9)L.>N<.V<\$IY. I(X'SO:J
MX#M*N51B*~)Q64PZ_22%K&0^3I4L.Q8PL6A@G)M.-;NT4=2:AI^?Z21I M>/,PCU2QA0C_YH%>SSJ3#@K8DFY#?
20V?I[+@88)SQ>A2O^B?7YOKX\K=(B MRH--"R(>9Y T>]X1!P%]YY4 G ?@8P/Z>4" %H#Q*P&#/&!P; P#Q@>&S#*
M T9IWW>=E?:T2S6=3Z78(YG<;6C)EU2N--IL(^3D76GI?F5FS@IOXQW3&DS M5+1"W @=I^@V-
'89PII>YC7!1*A#R@F@7HB^"Q1@ FIJTT- R_ J2TF1L MH(NTY2'ZA/ZD("N>1B:D:F76U:F=35]?,6+;
(6X5=;Y!*K\$>NU0EXDO]U/2\$ M=MX7&I^@?L8;,-S[3R7^2IY#1CO> RV8,CQF'XSIJ)"OQBI_93;?X5[9Y]J ML T9\$DOD?
=MR_82NF5Z+ !V.X7^N3!BZU"Q2_S:T_2*K8I!<1Y+&S12&^FS6 M,7E;:,ECG?FOOSBCWN]-D/"7\$B8!PDC0+""ZH-
"I8&-G?Y(1)K4E'2<[FE=AFDI2\=&D ;6FMIJ#PES,I@XA25K@=U\ M@*?=W:&BD/61AOLB_HJ.@T+G896G?
XPBQCT,13*3 !FP1"P M6S4@8>[P1>^,)S4U7M]2=YSJ/02H314Y1H4<(ZL<5WS)T)W/TQ>G,FN;:(GN M:(R(-
)\5IIXC!8TY&-&G.*J K^MBDEK6MFI!PEQ(F <)(T"PR@ 8%P-@ M_ZSY1A2=4B8*PGS(&\$%"91?
5*H/K&^I]6V2.QC)M6;Y!95?JFQ.P3FR.M @I0Q7U3L;55+PUM16.DB8!PDC0+""=>%=*6Z6IY3_RTT7-
#I]M^X")# MC0YGJIBULK:*@8)\R!A! A64=DI; M1 I*: T D6K MCJ#28V:%='T6H#07 ME.:!T@4K2I^Z7
Y=HOK+3,KI%NTR&GU>7I8WUN!^EV@- %)JQZ\$*!TOW:-Q M.MH#LY;/2@E*&'X/#PR#>F"@-!>4YH'2"!2M*GI@6&I
M!_;&C&TGME8:-V7L43UC@U;J@=((%TJ8>F&8;L;I]M/-D#V^M6#IAJW5I"X7 MJ/4\$2B-
0M\$RN[L']S(C)57J&5F66I3=3^6N<^9EIVU+3';X M]YK*%8\5"MG2(LG8I/YEMEYVNO"BTUZ_O-1:"VBI.N:T8#)Y
;S^U((7R1 M5%"<:I] !U!+ P04 " !A\$1:#=LI%W(# 3"P @& 'AL+W=O&'26P")/I<% M%3-K^*7NSK9%MH42BUNV
Zi6UHR76*HAW]ABQP'GOJDL;JQ(KO\$A%KIU,P] M\3**ED0"@6HQE! 9G4\$%CII6\$! M1:&1%(I_&'E"KW5,
[=K^Z/+9\4K,"@M8L.(CR>5V9B46RF&-JT^*9X<_H!\$4 M,KR,%<+HD-CZU@HJX1D9>.I&)2\$UO_X)C?
%6:@C5Q @HN5HERD^E;ZC\$=6!0AT@QY5 MEN15 8BM47?E+:A(H:D0(
5ZN02)22%>*8!1JNAIXQ*K<" 4ISR\$!\;*61%>8=A=UIHXA+R&Z1IY& MGN,% X06UIOI(W3_-
LZ^P?.OB/.G^4I(KA+XIZ% U3C!, (Z^U7=BAS.86>K; M"N!IL-*?W(CYY?
ND&43))P:N^IHOIVL3_QO*0U.Z\$;MG3#4;KS+*OJL 2)3F1_HJOCB/7!5)%0=T)6&T,U) M@-\$.&&Y?E*^
.:#N3*^47C1?L7/IVZO"Z9B=<)RW7R15<8KM0=46_J2ZA_JN_@?K22^;@I#N6_E!AXR64EG1+L?I^2_W]RS8XG">4-
M2.J:Q7U!=J>I*(%O3-ZXS-MRS-,W2Z^PWQ# MJ+XO:P7IW.;JH>1U!U8/-N9)F:EI&J\$S.=6=:W M8%:7S.FCP.J0=L TU/I
M4\$L!!0 (\$F\$1H;\$O 5^ ("4(: >&PO=V]R:W-H965TV%I%_?L16[M7:4^6AC,]I]XKH MLBBH>KD&I=I+ 36"P]L.C-
VP4I]F.K) QES]YXZ.L@XA.RP\$WQJ.M,OF?R+8LMYK+K4/LZ5D-14%01+MT=ZIM7<.:M]XLQI/B4'3)/:SIL\$AA=AM]O:
M\$=L0%B5Q-VC6FM1:DX-:?[H*BTFE"U#8, +GV*[/Q*0KRV0.BLG=^5*_JZ-?:JF6] MTE0-I(ZJ*1:7[P\$*8/S!_^,JII2-
3%R[NKZ6!KL\$FXXPSX.R@:@_D1*LYI8 M^I_!ND_4\$!#!!0 (\$F\$1%JUM8X7]@(!@(: >&PO=V]R:W-H M965TU
MU^_R=D0%/\$0UI(-JS@E@R'/A1YX M2V-6UIZOTR7D5%_*0A4_5G#%QN!EIH;2>F;+T=L(?IE=T ?
=@'E9W"D=^S9*Q'(1F M4A %X\$W"J^3MHUW 3I8;/3..I%*9E(^VL%--O "FQ!P2(UEH/A8PP0XMT28 MQE/%Z=6?
M,#=IRW]Z<=M2#2-R*X59:O)99)#M
M\$ _BHO)8?;>6/HZ.,":27I!5^)%0Q0T)34Z'MQK@R>GPZ(B:5KV9+6VJN]8JF,/"PEFA0:_"&[I^%G>!3DT=O29:|\$=F>
M?W'M7WR,'?<#25-6'G]R.GN?8!GK+4:L-B5I]W(76I+QRO"5P4*SSGJ4XT
MV5^ET75IV,*!D:=5AAW^OYZU]B782\$>E/AJ/RQI"HM]O78=MF=&NS:C?2, M*:&
[FS8*E:P!E'@X3IB@L2\X1P1F>_8[EH-J3]0D(GZEW% M!WZIC(JZ01@=V-\$0%7?BX_-?Z=FYJ 6KO=HDLI'F+)^U+-
U>QNYJGXP!V M5W:I S1ES[RE:L&\$1@?F2!E<=C\$S5?:A@C]TSKTZQY:OU6!-V3-? M
CT(TMS/G060A37KLNG")@POZ(%Y/+C+C, ("WG*YBXO&.!\$@I+4#3PO=#-, MV6A
ER(E.3PRQ)=9AMG++:IT/71I9WOA"YDOA+K@C@8%GL,3B* % M(Y-G:L62D QR3FB.&R&SHU_'?L!=
C_B2PYGO2\$UE0NFS.KE+AHZG,H(4 MID)18/FS@C&DJ6*2>7S?D#I53 7P-HGPKH; !ZZFX=RU#1A=(Z9&2S9UH-
77:*D7 MR=6#I!B28O!LD3HSNN MD \$1\$K)UNR,7"\$W_0 !W%@J.X3R!\$[@RTRK=8)ON;6!D?_#L"GG^!0J\ MH-
V4D!D>P?0*M8[#H]AK09X?#H.(C1JKQK;[6\$;Y)"<"N^E7PG:&8EN M_?IT5_WPM"1*Q M@)G]M?NC]VJ2[M3;+
QEELB:SF4+MRI&UBWSJ4:H?(SB%<.H2GWY>_07XQ2G=*XJXF5JOI:M3K M^YI^&[BK?>F-
*9PK_6'83D/V%+FJB=2M2.4=1ID!^&RV6Q)RAO4K'D"?<5 MJ 2-"AKCG:N@3;+8\$EE-YI#2.33J?
#.A]D,@RX=G6:^D2O2+MR0/#R1O]1L5 M-T8^5W&;9+\$ELIKBW4KOKE'QO34)7A"4B(F)>)
[L'IZL.U7R1[NR]",TKVI;4=#%272O)YS1A4 "-4E4')XU1SJW+GTC[I1/*)W M(V-;ZAIL=?I^<;/E.:K\$F:-
HKK'I9WS55EP!A0UD]@Y%1PTB_YP7=PZK1 MG/AIA0EVP@0G"2/+F*S
A&60R1*&N;T,AUIE,8^AT(.,:0V+CD+HHNQI2 M-S9 HS_ % AAZ9%2^FN'E40FKC:)5ML@J6VR+K6I%KEGTV_I]G/^_::
3'5MDB MJVRO+;Z3IO^TSPNEIM7= _H#=M7U=J2UOOFNYHROWP!SF).>RRYU)2N^J*R? RBWF\D30 M0N^A3J@0-
-.""I)_#5 WJ!*"K8G'D"UT3_Z%U!+ P04 " !A\$1:(<=0 MD>T# %&@ 'AL+W=O&ULO5AK;I]V M%/TKA%8,+=!%(O7;:
-JO&(%6B!PVNTS;5_1"71\$VF[VZ]?*2MZATX,NU]B M4N(I/>2XCWAZ,#SIV(#(-&-G\$V-
I(N;VU;:"80\$K%#=#I"IMZL>)Y2J;KY MVA;.'BR"\$H3FSA.8*>49=9D5#QIR"2W]4.N>G:%LF0I9(+Q#.6P&EMW^/;>%
%B+!8'\$2C MC;24.>??=>?3.\$M2JYM2!S?83^L="O!(S MIP+N>?(W6IK-
V(HLM(05W25RQ@I_0BG(UW@+GHCB+SJ48QT++79"K0.5@Q2 MEAU_Z8R\$8T I#T30.H\|M(
MPQP"Z%"9H6L*95T,LKY>5ZM\$+3C2(W1:12 MPS*IC(I R5V^9BL33YFDV9K-\$Q#H- 2'D\$RE!L;H;KW.8:V:Z"
[EN63_T2+K M?(7J""OG!B!+;+9\$GQF=IX1)IG#>3D2EHAW"O';XQ2]??,O4\$LOUW"?*4
M:#&RI>*N&=B+DN>?T_R#,I+&Z0B]CXAI@O(S^Y>%N.JO6&:021J]TD0+/_M?0:O3A2M\$D5)06I(I7\$;:W@:_0W?
BBU=P-A2'ZF ?_6Y=?<.#V]2#"X&U M,N)6&7%-Z(V-A&BAICW*0)Y/N*\$18X^92:3"(2\$5ZNZ;XKI#W.QA_V@&M:B
MZ54T/2/-&2B>2;%E9Y 4*SB#/60I&%P> (IAKE^="8"W=J7;_SD;UK]D1BX\$ MULI(4&4D..X\$=1+X0P*/44\$SWY\$
1YW=;<0^DWE8,0I/0^&F(<]YB0F+NXP M-V*?R3RJF\$>GF(=#S*,^<I=UNB>"\$?M,YG'/%[!]/IB'O>8XS""XPYS(_ :9
MS+%3EWCG%/=XL(Z??(N#KI:W8Q^+ON&0<%&IE]WH/SI2D(^J_W-'@DPD%7 M@W&.*@
M+B/>:^O&I=#:ZFL/@;V?4TSQ1?W%I=#:6:D=IC:6ZV<+AG6.MW](-#VUOZ M&FX UW8_G_0#@U45]PT!#K%/G"
[I:U@"7'L"?-(4#)96W'<%V D'LG!-7X!K M8X!/.H!^HK]UB_G9!TV5_#&^#;.'3]F"XPO:M@>I&I/L.S.AGLB>U/R!F M?
V"NL&3):@P.UN(I,DYXJH:0(QVX27E]@2J/F?91AYGM,ML>8)7RO(CMS1 MZ NR+S1?
LTR@!%8*WKD)U>F7^&^&PO=V]R M:W-H965TY*\$U.QI+Z9HD)90BC M_-X-
[T=T)1*2P0U#?)6FF/TIAX1NOH9M;& #RVAL6&I&D\$ H% ++ MCS5,(\$D42<[C:PDUJIO*~N'NI5_DQ\$9*(Y7B7BEFZ^
M05E03_%"FO#I+I]H4L8.A@<(5%S0M07(&*4G(? BRP/V)T@YB*EC1UD9N9JV7Y)%/O?2J8?JD3OB7F<#9
M@LP2X.@\$3>6RBE8)(#I'7RF--B1)T!06[D4+CHX\$@)D_..O)L&Z/CH\$SI" M)\$_8KKB.(OXR!1R3HILAF7^IR*_TS^_.
(ZMJ?D6.Y:H-IBZ_QJR#K.?E MP>NS=^MR4QI9N>E4:CHYK_L[X]D1.#)E5S*\$7JT^IUO#M+ WU==
[SV]JZ315)RS0!*N9VJL MJ;^YFPIE?I>;W+WI\$FK?Q#K=A/;OVP&MNND%5XZ"UQLGD=M)47ZOJT!6A

MSQ9H@M7<|BJWO/=L,T^GJ3IA@298S=1A9>KPS6TVW%_SPZ'WL,M:18MMMVY"6SNNE-
:W=CW[2::%>ILMA_DFD^&B*A2OAXYEC89Q&"6#Z67U MV8=L>IENBW64R\9R[=Q'&9?
KN4Z?:P:V(/|/Q^CY:HH/QA,+S?A4M|)XO/F M0Z;>#10*(HIEDD=IPC)Y?S5X:[1HZI M<70D7S,#UZSJ?,TO2O|LV|Q=7
M^ELDUW>E(AO_?<@:1Z79)4_Y:OP=-G67|P]=[NJA^O/HOLS"7-^GZW|&B M6%T|)@.VD/?A=EUL3|/|_D?
4|D0>/%WGU;_LL=16&K#Y-B_2N"ZL6A!R>|_M?G\$>\$0<%O/\$S!9RZ@-_.JX\$Z>*>#6!|=QV@>>:Y-4%Q)
<6\,L" _DL+C.H"HVK? M|W96M:>#L BGEUGZR+)|R:T4K7U1R5:75#HZ2|LBZ*S+U::3*%=- S@KV,_NT
MDNQ69DN9L5>|+,)HG;|F/|(H4=^DVSQ,%OGEL%#UE:6&|Y|LV,|S|!MA|VF M2;*'&4|6AX1Q)\$R
8(98HT:L\$=W|U.OS\$>7S=*M"JY|JQ6E6+-6< M4/6V6=\$E'(GKV|5&QT>|>Z'^60T.62='P@0(9D@W;J0:G^AG^8H)-
:=GO|C% MLIS ?&6!S*EHL+G@H5Y|D>/:L4)6O|JR.@2%B|A' D3()BA^Z31?0*=\$V0 M^B)A 1+&D3
!@AGZ7C3Z7GRW"1%94U_M+XXF1\$XK4".KXTB8_,.06U+GR5; MI*30:B%9)63^&&Z4MOL.G'JCW*~K|'LNE!9
:1Q*\$RB>2P<."8V-'S7).3, M2%HM I7\$H3!|HILR.EMGY:E&9"L*9!;S7|,P MZ90#:G%!:0&4QJ\$T@:*9(FLWS!YC_R_4|X+2
BB-OVD"13-EUN:737THO4Z0 M+(O+O|J|3U6PCL|GJ|^%2 M=N|XH|K.@9#6N>5Y7EM(J+
<\$|7\$H3:~H|I#&AG)H&ZH57|_8|V\$6A:~UBK%| MB3|6\$G_ZL|L#_Y4E.FM!^ R"SLR|9")*PF1>
M&EIEC>S5W7OQ|75G5(9Z4% :A|(\$BF8>-J#PM\$-0|0M%,@:1|Y-#N48|YL?KR M-DJB>|MW2@:UCJ" T \$KC4)|
T4S|M2'EC+ "S8Z@E!~4%4|J'T@2*9|JL+2F' MSM#ZUC@|H|H#D|K':Z.PC+4@H+2.)0F4#135FU!~.0%U3-ZAT_/1F|H:A:4
M%D|I'\$H3*|J|OW:TG ML|(9:6%!: *5Q*\$V@::R\$VUAN732UC=&|YK:CM|V MR&_ %:IKZWHM+H"85E"90-%-
(~5*YM\$G5+UY MP0/NM6|5RI!+30HC4-I D4S MCR9MH:D-./|T.0M*"V TCB4)E T4^:#58>TSX5.|BK.KPHZ:8'
^Q*0^Q2 M0R^Q:PW "W.U-^;2WMA1|AM+63.@JTL%|"..^6#IFA!:0&4QJ\$T@:*92FN3 MS?6Q@1KJ|4%I
93&H32|HIDR:_I9.|3ER^=(_7&9>@1KJZ:T7U|2#T@2* M9NJE33&7-L7,^24K-
5TJUO.E=Z..SDA7V5LJ.4#10D4S1|6SX^?GL_~^ M6|07|1?N-7ACI^WBTOWI+2G4VX'2!(IF2|J|?'|S\$BE#?>^?6O)8-
T)8/ZME M:1Q*\$RB:*9_V:'S:LS'.(-E7|GY::.(B*D|Z:N4BFH=K=ET_&J#|%M:0M" H M+8#2.)0F4#13|H.
|DV/3@GQH6A"4%D|I'\$H3*)HIL_:'?~H?^I'E:C0MOK!= M>|/..:C4^,=ZS!|VA4A1I 4|J'T@2*9@JG#2"?
S@^J^F>8YZIW=B:3UL4/ M|U&GZS23KJ:W8% K|TH3*)HIF+9R?-K*:8^CWVT!|=VNWI\$9:B5|:1Q*\$RB:
M>:QH*G'9A7YT*PB*~V TCB4)E T|DBVGT:~VLHE%~5M'H.(K3E?25"TKC M4)I
T4RYM+DTHLTEY'J7NBKBT4DW=&MZZPKUG: T@:+M=|T>*/LO+I^X5SY5 M,=|-/|6L^;9|<^+9Z7N%0:|Y|L.-MF*E!-
F=K>:~^6N<C-6'/=D|2W+TI MTDWUY+|96A1I7+U9|E|/|02P,\$% @ 281\$ M6DQ?^+/J#P >P !H
|X:~|W:W)K97?Q5VXNX050LOL3483(^7<9(>79R0?O9C M?G&>W9>+)%)4_YJ*X7R|C_.M'M<@>/QP-
CYY^|~F9WY;~U#XXOSN_BN?JBRL O M?LRK|XXWRG6S&F19*G(UB2NU4U|OR@_9X^~J|0|9FV;|8_5<|KB|&N!
MR6C' I-F@W|%6|TH|+N.+|SQ|%E|^+T6ORD M|J6069R*~|8JXV11_/WN*SFUDL?
SYH9SGJ&M6/&4/R0I>5M(9ST6EUW+_M M6=XR_?5%=Y<:~OI6G^TC.(/N*W9I9KZ_G|3
MEK5BK"= &+*H_5X=E|UNEK|(U=3P;\$E*E6A>(_ V5W|D-7UES>CM|J|SZ.M
MZUD|2.7)0UP_~OWG5BVN|TIQS5_~J+MJRF U97CXNGO_EW7WS5-<=57=A&=| M|PF|F0GCM%W9CL7#PZ_KR+
6D9GY-~LWC&5@Y_%WZPV\$|1STOQZ^J|)RC5LOAWQ|I^7&OC:JW>3'E?W,4S|>&HV@XI5/Z@ MCB|^J|?
A=/'/KD23F\$UB#HFY).1F\$|B 8F%)!~.1F(OP+~WC35K')OUBM6FP M:#8-9NVFP2Q;+E4^2^~%N(OO5-Z57*/<-
|DD9L8L9.5EC|N?A8C@9K/^= M\$S|CR4YUCMXK\$^~#4@L?D=3|S.ZQ"18R6\$:8&:: (U,0:JG_?+*Y77:4K2
M4E5^~^5T>EZH*5%KFU:020|RV:/XP/_N V:~?YY+B Q\$(2BTA,0IB6N>DF:>)X9X|F^S_/|/%=J MUQ:O\$>F:/!*S2G1?
=:S&|J?89_~%W=9LC M6=XOQ5665VB|UVD65^M1_~XSTH=UY)S4\$U%|45/|~K%| M|RT6H)-
#5(M035*:GD:K3:/UI|VL:~9|/ZF2FHUJ3J-I=UUKQSN;Z&2OQV0? MG1R@6MAHSU^|I7BTCM#!DM+T?+4-
GZ&QD0|L=T_~AJQ?8-G1BOMHAGJG:61X
M9=Q\$!"WMH)J+:AZJ^:@6H%J(C&J24K3D|BV=X:F^L|J|D6|I7N?:ZBGN0:5Q M|>*Q4+|/ZIE/7-
>7*#,1%Q4J"_\$F+D0LJN>~6770KO:@1_/SWT%>SVHYC1: M_=)A|W@R>#?>?NI#6ST'S?31F0&JA:@6H9JD-#V:~?5G:~
|/|S|C?J=Q_M4 M|/5^~BJE'~H.-%*\$K9J.8TVE90IMOA1)M|!WTT9D|JH6H%J&:I#0|G&U' M:@N">T.XS)|5_MH;I+?
JRS:~N~KE: S>|JBSPNZPSBVA#"~5L5::~3A^_M_H+MW60|BVC|YZ"9/CHS0+40U2)4DY2F|M&M|PR:~01#%E-
5UI_L+&_?/L6R M.WIHW0?5:%1S&DVK4)|T|V-PTC|D^~CE M1#5(E23E*~L&WM#~VUG8Y> M@A#F-
NTG7%\$.SNH9J.:@VHNJGFHYJ-:@&HAJD6H)BE-CW3;|!F>L1T"M/2# M:C:J~CFHJ|:CZJ!:@6HEJ\$:I+2|C6M/4?
RIA1N'!7+S^3Y|^~^78DU*WT3 MBVHVJCF--
K2TW3&#TG%ZV"= &S%:O35VT\$(1J3L|WU38U59'!WN'#_~1P0&JA:@6H9JD M-#UQ:37(E>#~.O8(B3_JXV.>|=E% A#:
4,U&-0?57%3S4,U'M0#50E2+4\$U2 MFA|AME%DL<~+LM &\$:K9J.:@FHMJ'JKYJ!:@6HAJ\$:D2M.CV|:0+~.~2NZ
M:~|40<9|5\$PO5-I\$^QZ5\$~W|Z>J?&K|J097V:B/KW3HEHML>KGIMTA1WM)>Z|& MEV83XM.#RM/Z|!#"3=
(XG=5;|/7ZBS=|?KF?NUYHV^AZ.JCFHJ|:CZJ!:@6 MHEJ\$:I+2|."W'27+?
#BB>G/Z:7UVE:00Z|+B"P5#T^IWUE|0*M*J&:CFH-J M+I|YC:~CAB<~5?ST:\$|JH6H%J&:I#3|Y
UM"VED:B%I|=^W0MWG1?7::W.M MZ>EY|AN|V>>TCO1|-G/7E:SK!U'MW+0R6|Y-~8^IYZ&0?U0)4"U\$M0C5)
M:7H:VW:3R-Q\$~H|'M8|A.T6)6:FO~BO7Y(XN_5YO)>T|I^=\$|K'_HOXZ#4+4"U\$M0C5)*7186GK12-SO4BJ=%
|>UF&YUDN! M:7CJ?3U)UGEV|C>~.QQHWVC/?9|V7A&H.JKFHYNVY^5_MK&KF> :B&J1:@F M*4T/?%M5&ID/?
O3*MS_~N|THXTE5'-0S44UKJ%>O/VY?0I1= &J :B&J1:@F
M*4W9MM%&AW017K^~.9FG/3OB1JD~CL|IYGN'%#T2\$JHYJ:~BFM=H+T.ZW5% MQP:H%J):A&J2TO24M@6BT9X"4??
>5%Q?5|J66V|Q0L3S>:~|F|?~3^L.GFSVS
MG:E'FT6H9J.:@VINHWPZ5T?/>RC6H|J(C:I%J"8I3"~T4H0|CFHYJ*:UV@O|B"=G@Z>_JO>ZXNN1(!J(C:I%J"8I38|J|VQ):F_~
M|5\$?FDWI1-4G->PX/YG8M&^~\$*K9J.:@FHMJ'JKYJ!:@6HAJ\$:D2M.#W:: MQA-V5+O
M5*.J)U1S&FW/21+1F=Y|,WUT9H|J(C:I%J"8I34|AVTT:F|M|.J:~SNWQGLZ3|_TL1TSWCO(YE4=K@X.WIE9M,R\$:BZJ
M>:CFHJ|:B&J1:@F*4W+|*3M.TWVG-\$M-
I|PKQTWU|.7M9@=GQNT:83JCFHYJ*:AVH^J@6H%J):A&J2TO2(MR6HR1C= M-SQ!:T^H9J.:@VHNJGFHYJ-
:@&HAJD6H)BE-CVY;>YKL:~13@AR-T#RE=Z(/ M/FV:C0YV4,U%-0_5?%0+4"U\$M0C5)*7I<6VK3A-SU:ES8_JGQ^R:-
Z:1WA.J Mv:CFH)J+:AZJ^:@6H%J(C&J24K3|
|VJ|~LZ>@F:\$<~M6Q4ES:7M3\$79ZW=M|:UJSQ|UF|G=3ZUHGT5'-1S4,U'J4"5 M1+4(U M26E:5J=M'V|J|D-9
^M\$ _ID2.3#|/9MG5+~1S4\$U%|45/-1+4"U\$~4B5).4 MIF>|6~-A^@KWRE:PT(U&|4<5'-1S4,U'J4"5 M1+4(U26EZ=-
MFUK1G,RO1 MSP5:2G?S^KCJXKX(4X6J|/8W&2Y*.Z+,D|2^&I|%+JE*O-DUK6|^|&~ KW# MOM:&HV>OBNN#M&P?
EL5&QSJHYJ*:AVH^J@6H%J):A&J2TO0>= M4<0|N'=^S5?C|6?&L-'U=%#~134/U7Q4"U
M1+4(U22EZ8%QJUM38|_DM8>: M.ZNITXPVN%#~0347U:Q&>W&HN:/QUB\$UT+\$|JH6H%J&:I+1U.(^+6Z5*.R|C
MB_/JN7*N+M5B48A9_2&_#T?UMO:FI|4&|TT5WN'~|ZVCXQ<=X:OW6'|^~6 MN3B_B^?JASB?
5YOA8J%N*G+P|F1R|/+Z"?#IFS*|J^XP1^~(J*~MLN?KRM@J| MRNL+5+~R:~RZ9MZP&6_|9:|8O_5|+P04_"!A\$1:
(*+~3TL#~_4J M" @ & 'AL+W=O&ULK59;~|HP%/TK5|DT M=+=~0"#0=1|D)9M6:970NH^~0|FN8"UV&:V@7:~?
M~.R-@45>~!Q(|IQS? M<_OU1UNE?YHEHH5:44@S#L6KB|T&1+~%RI_~^@E.R4^ND:5_DX
MZ+B\$~L#..@9&CPU.L"@<\$:7QJ^~(ZB\$=:R M0(YSMB|L)|7|@)6>V%E|C^~^|9E|/!U-G:6"4J_&4@N"R?|+~R80_0'1P!
M1|4@.@3\$1P"~|~M |I/2|/H5H.^~*~5X'U)F63+2:@O:11:>_~%F>C3)Y|)- M^XW5|)43SB8ISBR#^~|UP-|PZ.6~:UZ?
GJ>KISN3|DPJQ8AN.#@F#>H-|N)9=|YT^34_R1+_Q/9/1?|M8O|O:D MFMURL18P4YJ07"X@8S08MW=-
T9<0|_ECLU-0H=H|1N%FWY"A^~MEFX1/UQ MK3|NU7E+1*K|:RE^|@'=~@%LYB#53!~.~|D#DPH;?EOYL|C-:~3DY8>-
V:- M9:(0*6--DUOERC|~UXW6O7(N#1^8.EAW#T+!K4%@U8+I:D|I1L\$%Y8DY+! M@Y&

[IMDK^L321.YIII='UGHI0Q1#SNZ:IGW2 M#NP-CP'35N 3'3FO'3EO3>N;+P.P/V4:U%35 -JM#\$W; 4X8I02@FRVCHI;Q
M.BOINI>S'2..OU!?! FN/BX<J;. WV7/IT(IZH NJ<7OIHRM"7TI;79JU: M%VQO?9URT')A5Q9= VE*:O
:Z877!HH<Z4G;.A:59=5E9EPZJ5KS5FRE+E MXE^75(RB=@T':Z4W37< '5YF_P!4\$M#!10 (\$F\$1!#)BG.9P0 &(B M :
>6PO=VJR;W-H965TWQAZI#O MEJWU@=&. \<|B|2#)URS-Q=A82;F~4TO6T%&18^M(5?/+IC/J%2G?&F* M-0^ Q
M6:ZD2L'9)" +A.6\$PV)I &K?QK:O!<6/(Q+8B;-C MHFIERMAG?27('QN60B)(828U@JH_6IB#--4D=1U2J1U=3'X^-
O)*BX>74S M4RK@CJ5)G.Y&AM#@|QA03>I?&2|WZ"|H> ("9RP5Q6^RVX|=N :9;81D62E6 M5Y E^?
XO_5J^\$<\$<"VSLC<\$J!25FPC:#X7(U.J MJJ LOZ)RI&,&T1RSO#7\$LOV^OWI7+ YCUB&L70;-;E(MIM=[-8#
<2|C\$WTV^|FE>,TW/F;=B364I&&# J97 MU>UD./3|EC<D/+|WSW:*"630|>+K|/44CS*(Q\$JSFI:#R=M#J;.:3
A&9LD|F1UO% M71W%A 6#\$Z=LQS|U*L0L&F""8B18S?9A9?OP/VP3R#_G_L7T>X|_NBD@K66Z M!@0.3%F#"0DQ8A
F+D6"U%-U4*:I|W47<8(8%Q9@PD).6(0)BY%@M:#00UJ&) M9?V?M:9=W34>J+0
E1:BTJ?2=KP4N@TK8=PPSJOO;>J^'C4G|59?|W.U.00A M":<2R|45A)(U)F:\$JX;C6|%=38:DQ:@TD)46E32;.:?
(0:MG^:I6W?ZQP/K M5A|ZD79K|ZKSOL M>=9K_21F^N#1+1B|2X1;.O/I1.Y>HM "5%J+2(E1:C\$6K
M!^S0O|1=U"V% C=K(1*4J+00E1:ATF(L6CTTAYZGW=[T|+P>8WSH^O5Y|&| MJK*=XX#:UT2E1:BT&
(M6C|.AMVFW=L.FC|'F+WKV\$(OMBIY58PC|TVV3-SS9 M-MVU%^L< M1^)^2HMOJ7%6+1|",RC#|_UMRI^4+Y.6P &@
'AL+W=O&UL MO9QO:|LV\$.: "N\$50P>TL27Y7|K\$0&.18H|U"IIU>S\$, V,SME|9|B0Z:8| ^
M^%&R8IF60EOML|Z)+9GW.S)ZK*Q%*X).FG;"FE(I|749Q==I9*K=|ITN|EL
M*5<&^4&Q0M @CE0|:WGN1#N4V23_G|!PRTTMD".Y4SE" MZ)=[.951E)-
T/_XMH9V=S|OP _T3G16#UX.Y%9F<)M&?X5PM+SOC#IG+.|&) MU/OD@?R|!%GX V?;7!+ M_? H#|ZQL
K#;Q#|XS|OW2H'|@X+K/& Q*%|&AA^< &2P-AJ<:C\$J#T:D& MX|)@7% S=[>4HKJ4OE)A6M
M(Q_)NR15"ZU54AR_|#42893|1%Z0." :+Y-.)N)Y=M%5VF5ND)V5^LMWGT& M|VARK)89H?%Z&|#[-.
KUTKTY>R>_XKXO9/9WG/O\$; M_.R.8?+VC+CCELE|PVW !7;92C?Z9J|(7|_H|N1:R57V=|_W94OK-
|/R&/4F6XN9O.SH(03)|%YV)C ^ MX Q|/S?|S0GSD3"*A#\$D+\$\$. AF**^ 4U|?
1|_IT*)QM4EF5B|J98:\$^4@81<(8\$A8@81P\$,Q0YVBER|)W(C9#*0)|\ M)(PB80P)"Y P#H(9RAOOE#?
^:F'7ZJFM*L>UL.L>A%VD.XJ\$,20L0,(X"&9(M|7PGM7.KU*Y+@9%"8-F#6&O-/=WRLJ^_P5:7:36'A/E|&\$7"&!(6(&\$|A6.
|J|:R1-)|*(U" M:0Q*"TJ:92+#40Y-S:F5YMQOB|NHW|OV?K06)))+F0VD42F-06@"E<13-U&Y5 M '&P%1
'6@*|TGPHC4|I#\$H+H#2.HID2K"HACKT4 @W9T#)O.E.9#:11*8R7- M\$F0#J\$-N=6@*J2J
./8*R&|M;=RR&JCI^0|O|G(E|B|98%M\$H&6BQ TKSH30* MI3H+8#2.(|F"K\$JCSA#;% "%D*~-|J*HU :@|(""
(VC:*8\$|WJ|8TUZ3V|2 M9"U3|:BCZ\$8K|(MMI=&5G=5:2.C|5^H0PJE.2|M@-(XBF:*JBIU./9:1W%?
MJW|:OB):8F&B(RU9B|?RS-.ZED:=00L<)6U_)8OK|7J|OZU!RQO0&H/2 BB-
MHVBFUJ|:AV.O=DRG|ZLRFH5T3C|K'T%H-T.OJE.91-%.-5?+>M3_<4\$MRS9(H\$DJF(GI%EE)\$:CD3 MJ7Q*J(8R(_HX?
Z> M8R?T.OZE.9#:11*8U!; *5Q%.W<<*"KGO6S&F|PG3).A)7@X.I4U.;|X- M=P*VOO=5@%06@"E<13-
5\$"5V_!N>WCT?"4NI_2=M:\$Y3F0VD42F-06@"E M<13-%&:54/=<:'3TH.OQH30?2J-0&H/2 BB-HVBF!/?V(DGX-
M%1^QV1%X| M1GJ<12|S|1VGR|L1D|8G8;^CQR|5^78/6L"|5@UV6|=6D?|6K; Z:OUY /4
M*X72&|060D<13.U5"7+/7NR_#VEJ_3:A05=%DJE.9#:11*8U!; *5Q%.V4 M7I69|I#&ZCWHLGHH8?2*)3&H+0
2N.HFBG!*LWO 9?2> 6%|Y|N|H\$ JX M\$VKO=,O+>TWD0YD<1=M> NI>IKLF2Z*#9BS|:7=;D>|I.O:Y/EML:7QP?
FI M|X9NMVJN_-N=H|^)=|'&8GDG4;VSD;Z%IIN-V/>'JAD76SM>YLHE:R*MTLI MYC+&-^C|/Y)\$/1WD#G9;8D_ ^ U!+
P04 ")A\$1:Z:(\$<5D+ #A:0 M&@ 'AL+W=O&ULO9U=;|O(%8; RD!=% D0 M1YPO?
J2V@8W=10,DBV"3|X406"DL4U\$)%V2BI.B|XD16E(SNA_#M37R26 M++X|+WFD|Y V+I*JLOI8,0#?J6|XKZ:O70-
(^OUNMZIR#RM'Y9/HJB_5ITSZL|M?U8R72;:|00EN3(C7>9H5J^O+ _KGWU?5EN6IV62'>5ZC>YWE: M?
7|M=N73U0JOC D _EMT --T3Z^O+Q_1>?!#-I?W5?MH?25+99KDHZ|JPL4"7N MKE8_XU/I?EE^|F^W5*NA"\$CNO:3J-
M|WOJ|@1 MNUTG|UO:R|T%U=5IIM^#XJ|Z/Z+|W|ULWGM|8WY>Z/;-L7*WB%=J*NW2_ :WXX
MG_XA|D>|T|N4N|K_#ST=7AL%|39UTV9#PNW\$>19(NMMW>9>GU9E4^HZE|JG6_-JNF7|UDQ7=?OS05.U?
MLW:YYOI6?&|0|?K0YL=VOQ.HO\$|4^ 29EIE329J|Q6-&FVJY^WK OTX18| M^DY^EE!KX4|KM-
C6E^NF#;437&^&U:X^K):<62TFZ%U9- |U^GNQ%=NI MP+KU<#)"CD9>\$U#Q5FQ>(HI?(!|OI@GHYL<7IT
X|+1=::|'H>WZIJB::M|F M?8/^&:9| 7K3B+S^EVYS'=287JUL|J^J|.N%JU|I9:5% _%ZOJO?|%A|>=
M54=B\$^L9)Q|ZM?M|N.Z@X>EHGZIJL/EZW4<1(R2R_77<>B@N&7H_10Z-X4> MZD(+|6.0D|2EB3)+_10W#+T|1Z:
HITH4>*J%CRH.8S3<|J|X9>W2*/3+% M'NMBC|38"2=1Q&>Q@^J6L<>GV&-3|(DNIEB-G?@_9G%#JL:QIZ<8D_V#|^
MB+&RWS6BTCE(4H M4/S\$.0|/%L_P"NT-30JQQ@T|+X2>::|ZQ?HV3:K-^6^:KG+U|:97N"*OK M?5IL|-J4=.=^JA"-
UBY6|Y@FJ@?6G XMG:)M\$|L6|I#^M\$Z+NN^A=/U.<@&NR M=2+K/O:KZO6G(LW+JLG^&@9|2GQKH:L66G-4_9R(U?
<8O&I:|*B8|BDOTZ+ M+ZCGEY8;.RJQS?1|RE'M'CS|(\$L40|SL RK^57_P|EL 2)K")1K0.AU6<
M4%+5|TE@B1+8R!):A_.J3"B1^&^ (+\$\$&TE"2W|810DE.TE+M2FQJ6I9R\$3CF&.*K?@WD?-\$ D#1 C#6@Y MAIAI
%:VC5S2_#2@)9CB)D&8&7;R"4-\$.-:#F&F&D 5K;.G\$H:H\$8:T'(C_ M=-, K&P;N:0!"M/.8ZA*=@W5DH6-XV? D#%
(8!&&:HF0!@?=>OX1Z?Z80+X M89BAFL-|I?|P4>BI+/04+O2.B(:;:0 .Q:HI \$*TX"9:AZ|E^_QWQ4>2JK
M|(4/V#|V'MZ6::%|ZV'-42\$?S/O BJQ@|JQ0 LTU(P% ML+)|MY|(+J|!\$+M\$!#S5@_*JM>S|I8P(Q8H
4:IF(!UUT@>5MPY=LP(OLH*4: MIK(!TX:O@PV89_&L|\$YM&\$J%42Z#V98WC9|B08,1@.8:9CYF!_6MXU_=#%
MR3\$^@9+?8XU.X0'R6?R9+X)+OB&V8R@47-.1W*P/+& 2"QB,16: ^89H& M@9%"-S)SZJ|I-
5G|%'|A|D945^E348K.OQ|:|6C9"GX.A|TKM:EM6>|9 M|1VF^B/YCW@0Q.(@.S(H_&DTA%AEA;N7QP Y?
8AA% C(|+N P#YC)9A"ON^4D|(>S|WX*%< MEG@.'|+ T3>:B^U%^E54Z;U_6='Z\$G6#|K012%E:HQ0|BFK3UO_G6J,?'
4S& M1Q\$O YHH1GV4:@K4X^B|220=>O(&7M&W#E54_A*N^ M'E31?|J\$YFH'UEB*:*|6I>PD-
(7:*JZC2|C_&T".4)" ""FX50W\$%.?>J MS=D^6"24+!+ " *EM)9P8;W%>|4^RH0294+F-J6==D&Z4IN:EP04P@2T.*6Y
M|J7G| "OUM;6Z&8)&):C:-?1N'T"HHKM:E|R4ZAVRLHH=,S|J|4IN8E;H4P M;BW.Z#-T1>8GR.#UVOJ2=|7"1_2EM/9
&-9:O%=|4%I|34IK/4QI>KZTOR5.1S%-02FM/CL|ZB_>J#^J*)'5%;F|@ MC9Q^ERNUI7D)71%|_FAQ2C-12H?
O8(^>"J2!/7!/'4VI>\$39K#JXGWK |XB M"5^1VX|4R'E|N5.FA_ =Z@J?MUJI":9S7F|^&->+VV MOB19Q3|9G<_JI-
NYK(8EE^Y85VK8Z>1 M"9.LSIV2F"NU*:F)8^'|FOQ5E- MM5D=QO.N\$B|MKXD7,4P7+TKJ^&^P%_>^2";S|XKWH
|EBB5RQVQMYK8Z>L MY4IM:EZRS5FQW(^&PV/CF&86'RQN&|QDI=CN7MY8O7N,LTVEC>-OS19!"I
M&WICM5=7G< <":|O&+FDFMKNE-|9_!5\$'LL#BME-)(TD=G?U)N:|>@&|EVI@E M;R1_Y|I>Q?Q7+ZOO&
|_ \$A<317;V)VH5#=<-8AM>-/Z=(WS"A:Y=(9&U/_B|W M|29J.TX4S- +<"BV.T66^V1)"Z_6|5.VRO="P>9|@*_@_1N/-
IB8-%FMGU<\$ZRS?J5YFGP6CX6>|VP:@HYZS#>"#NG PFH06N&T" M.NHI6:);|AL*UEF^4|V.20M&<|("MTU
1SUG&|#+ MM+5@-&XM<-L(=-13LEI|C.LV=K::":|. (6)JNU9T0.LMWJA?T&D^#Q6|I M@+^K::_#|Q
T/8|/=9M+|!1KPO|I%DEPTJM;8W RC F=|I0|(DR@|KRO>J% MO<:C9;:7B#L:F#L<0-X8:#Q %K#!-KE:JP
7@AL/*G6_*IV>4|K>X&H8H%OL;3<+;:3B#L:@CN<0-X@:#14%ULF*J|+&)|OAWH<% V MZ6?>|68(8ZG1|>@|=')1W?
=?+52C_M+OX>MT3L^>OK_HY_Y+>J;RY8N\$%#@^:K' 1|I/9.4>?_K@TBWHNI>T/|KBR; MXX-N!:=O=;K^'U!+ P04 "
|A\$1:G|DI30| "R"P &@ 'AL+W=O M&ULM99K;IHP&: B|5|TR9UY.E=!'IA4ZC M8E-%M^|#M |F.8#5V\$YM
ZVT'S_:"1E4(1M3|@5|>U_|.3ZQSF#&Q8-< 2CT M1%.FA|Y*|>S"=66| HIEBV?
LR""XJ5|HJE*S_.!+&BKFJ|YW5=B@ESH\$= MNQ71@*|52AC<"B37E&+Q? 4IWPX=W|D-
S,ARI@^U5)P68GT"2EC^CY^*0.P)/8105 (@K15A(4@M*#Y MR2S6&"L<#03?(F%6:S?3L+&Q:DU#F+G&.R7T+-
\$Z%8TXI43I>U\$289:@\$6>* ML"6PF(|\$|I'8:|GL>O^%3:/H:XE+OW*|WKQJQ@:_CL@#DOBT+|' M1XBG7.H7-
_UJIM>@B0|J?U2QATVR-V1VP-XNV=NUMSUA&Y VX9%.:1|R13*D M\$SG6(_K=JF^O-3R5/3?3|YYQ_X_L|O):|?| W51

```

=4JHSA@#$J!"+$B,I>-X MN10 AK$*IJ:J5)R&S ZHNR5UM^DTIC:~)WI#9 7NO9, 5WOCG-9V#0RO>XIW?>+I
/IT00=MA/3C\LDLH.6I/<2JE MNU>0F6KX$Q9+PB1*8:'MO59/YLB+S$SCN*9K='F7.F*SS97NB@'81:H^07G M:M
%!\+ P04 " )A$1:EJG==$$ "D%0 &@ 'AL+W=O M&ULK9A1CYLX$,>_BL55520=+9@$LMDF2$U\
M52NUUU7W>O=PZH,#DV 5<&J:9$^Z#W_&L 16A-VH?DFFI?R8^=I#IBR.7'R7 M*81"JWE6R*63*K6_<5T9IY\3>
<7W4.@\6RYRJG13\%RY%T 38Y1GKNJYH9M3 M5CC1PO3=BFC\2Y6Q FX%DF6>4_ 'O"C)^7#K8>>CXPg:JJCK<:+&G.
I@=175_ M*W3+;2D)RZ&0C!=(P';IO,4W\!(>5@1GQ%X.C\RC*IO-Y\^KQH=DZ7B51Y!!
MK"H$U7\6$.6523MQX\ZK3/K R\UP_ T=R9X'2?+CLU8STQ*O17/&V/M0-T)\T#/'S/C?&C/ M-
9@T\I\!OX9@VEc,#7*U*$8'0A5-%H?(D2B&JUIU841TUCK\%E1S2N=$OHN MTW8J6O,\9TI/I)*
(%@E:IT*Q8@=%$S$ "BW\]=7FA)F0'B6W-/Z(DJ:88^;S*V MHV:J7A%0E&7R-7J\6(' ^3'DI-4HN7*4=K!
ICQHTSJ\H9_XPSV$>?I#-2B7XO M$DCZ %='UH;G/X2WD>)>)\.(K-&_ (M_S01;IP=16S^?%(R3R/-)4_3UCJ\7
M+UZ/Q#I\W)BN).SW,J\I8&Z$ K\1ST$25^0RV\#LU'SIL\ZHUS( _#EG$T8LP7HZ3EL=IV/T:DH,B39J?^EH-
F&DAL.T.K'K? M'R) 'LO?>^$>!\N0(6CF"43D\/'3785_I8=X0 D.3SPNUBCZ4K%LPH@E6$ 2 ML)4TM)RIH4T=;<*
(O5A\OUFKX^QG,G74^%+1,;)(#0L\F8KGSV3JN\6ENEFED8;63=;K:1A,AW,5=S;>^ (EL54JO+KVOCO4GE:E!
M7481%*MBDT9LT\KR^2?Y,NYV0\MB6F31FS1^F*>3@YX=$\I9'I:2A8I9&+ MUMWU8CSWSWQ*!>D0@,=/
8_3$ _VWG$!,97#F6KU6&^51FS1^DJ>S@X\I)VI
M5H-5FG$*JTOYNGD@$*X';*5SF(G2D#2KUE+0M5EWK:WK:4^~84V!\JUK_#-NBX8 MGC\U_?
(3%3NFAU4S/HJA+@G5#;TIDFVX4CPWERG0!$OU0- ? M&M4#VL)L\#J02P,$% @ 281$6@U\ZJH\! (OD \H
\X:"IW:WK M8^N@<@W2\I^+&21K6R^9H\3\506MN 5S$^L7Y@L MV0TES4L@/'<$,5A.K<_N?>QJ\VWQ9PXI?O2,5%
<6E+ZIPE,ZM1P5$120"(7 MFI+CU 4BB3C>*^A5M.FZ
M^P)UAP:*E\""ZU^TJVT="R4;+FA9.\L(RIO4_A\I\!'"M\I@H-7.WC7.OBU M@W_JX%YPZ-<_.1_WJO@,*@=!M>&-
*P=AM#9A=(>8 ML8IT#:#SJJUE1G*BI#@>73+I-I9^8A>^>7/Q F*3H%5*O.E\4@+Y1DE B&"VD
M_OH\0$,_N.#H5Q3DVSP*DG+M\I3Y\!,$$VB1UJ64EQS09,WE!-9)J06W"X7 M&1(9H&=@*V \9W7)Y1-
;R)ZI^_RD\I58\<*IT O7 M0\RWHRCD*20M@&V))F7+S\N#QXG<0(%CWD^!^1YW@#I#_RZT#/\O9X#_?
7Z4>A)0\G_./1\OX?KG<6\J.N.=KG,#4DBL \I8% M: ;+3^J0^>V<0DS" I.PT^0L,@F+<#%::NDW:NEWT6>'22Z%)I 23-
$:&$JJ M&4Z+$GV04U8J)T@LIS/U4M?>G9-29UNW2LDD+>#)"R086,/4#F@I\Q-X>
M^*0*FIC;II7\09\06<^CY>FJY\33":\5.R9A005SW:-YU^D-1 WV\I'R:;#R'8L-P5JJ&#>J&^>J8EZ? M8N1Q2.X5L-
P18">4H>APZ-$AFH_X?>X^O:Q^?NALZ5):F(0%6QXO#(//<=O M3B1RULSSW9.J@,G08D.P5O(- M4"%HJ1\SP"DP92?>
+RD5^X)JH\DN,OL/4$!#!0 ( $F$1%IEE7O3A 4 M^&PO=VJR-W-H965T8M:-
KM8M@%8YW80B31>DX>?>C1TJ*9"4,;G MS44LR3PJ?-*1J1KCC=C*E0 6%T%9V@T\;IC-
6))W)N\BV+68C/E:I4D.UX+((=98Q\70)*=<^ M= _S\X%/R6*IS('N9+QB"[@!\I65U+?1>MZ;$20:Y3'A.!-R==R\,QH$)J\H
M\6<"&[FU3H3FA@>'.>RN( _V51MO0Z9 MKZ7B616L1Y E>?G)JM$; 5HCCT@J **EP#-P)Z54#094#_C8\!%=#?>V\O
M\OSV#1A6<_BIV6RBDR'3+>'6/-;:UIIF-QJXB6B +P3+R M+@3%DE2^U>_W(3DW<_OOUVE1V78W7DU@LMRL$;
(_#)3>UE"3*8X@M\== M\8$#T-7J\,2\?D.G 20Y@?DYX_1 (O"&P#VC^;PD\JP_O6<*C:QL\W3< M=^2R5U\?O8+7>X-
WL\Z529SHHD6X(-75-@.UY+&^K\!T105_OY-1YK\9G\ MQW8\!E5WT\5V8VGLF5VP.YOU=7"6(!^A,?
OG)'WJ_VL3A(68L @31\@+&=I MM@A\WUR)>6:Y7, @ (>9)D\X@N9\I(Y*#L@GLO\TJ< DJ*6FP?HP\;W3
MON=YX^I#MG:6=OW>Z>6\Z'6IGN;Y)Z\4J33:.5\4=>\X.SYA?KP>0D?9DS< MZ_E(5:%MN79B<LTU)BS$A$68,
(H$;PD\K(4=?O)*.L04'1.68L(B3\!A%&K5$ M\ZE%/W'?S8N%@ 530%C&U\DB;*T%F_UAG2I1-
VJ+PGK^OBP^O^7I10S^XC M3\!A%&K7$&7BC9SBS=ACD\JTS(I=,PTEBGH9F5KW6\U-!-O@AHF80'DG2Y;J M-DS+>#?
J%39%W25X%6N?29<_#>+7%_?8LR4^<(#\U,6$1)HSN3D=+P=-P5.G
M@K322)@[\<5%*Q0IM(GU.Q$3LCEJE:G$C\;G#UCSWADG,0AXJ$ "8LP8=22 MC,%Q,+!+Y^O-
FZN\,NL>_V9W.A6V*~NK@^5\I46H=(H%JTMX\;I\!^>27 MD5F2FOIJE=) )//IATH+46D1*HUBT=F*IXW2P?>?
QU9J8F&20M1:1JC6+1 MVMH\I#OM\!L?ZP*SG1$Z\B(GBQ:0\J& TG 4=$07"?K.C>C\ANF3)V# " MJBVJT8-
*HUBTMK:-U^.\S9XW*W@Y"?'BNKWM\)'5%J\Z2J-M+&2CF\I%)46HM(B
M5\K%HK6U;^PLW^UGO;*3\9A5)TF^L(J,ZZY,*II>?C)JSQ$JC6+1VDL2&K-;YL6KJIAV)2@M1:1$JC6+1VFHWMEC@
M?_JB': :9:BT$)46H=(H%JVM?6.4\4XSONUK\ _IJR,T^6//@U>\K+TOV\B;1
M\B84\IAERKM;Z^$R$(MBY:+4R=2\OG(96^VT7AUY4:P)?%|\Z\ 1B;*58SECN*K8M7=+>5>*9\7F$E@,PC30W\IQKIYW
M3 ?U6M+)_U!+ P04 " )A$1:...O+1 $ J%P&@ 'AL+W=OP0:XE_RBCN\ MH81Q"AF+288H;??:M7GEF\9,*"/^CN' 6M=
(=N6\I)D$=YH.S23O( DK/R\#G6LH;&@8)RD=;)H01IGU2_ ^40012C^=,PE6G6")=)MAG
(M$J9PU02"7:=8+I\T858GE*W7J\Z7PGF88W=)R0%1&2UH\J)40\p6>L69?&$V MG(JGLBC;(F\;C;BBWEB#1
^""9J: 'Y'E6'9\@803\=ZTKWA M\^*9((L^VSM_G#Z=;:&(*_W\HX8T\;N:NQDU K112Q^T7L= Z0J$IK S:-6?7\K6\
M\FB9\7>8#/'*JH(UE\TT2BZ&3T>@14+,Y10\A_-=I*Q5+/4*$$.&7'TEYI M*_RB+>U\H,M'2NJ(EA'5-,X\AN,_YLN\5'3Y3\0\I)BLE.8I MI?
FJ;8UG6CLZ\VTFS9JKRB$>_5\T$5=SSZD_1VRWG(E/TP?I9-*VE?3AM?G MM9F*~NZ;<-P)FX_N5>07VIL>UUR.A\,USO:4J4\766TKNK'/:[YVDTN\7FN
M'8">6A\!'W#>@WC)K\I\VING&SBG-5TGK-;6X(IT\TYU,^QF$2'1U>-7- M@>I\U;_I^P&FQ5:~#/@I)_U M7<M$?# KN<2>V\_'DK
*NF.\$PG+J7/H7:6SLK<$W\ENUUR9&R9T0\Z9SDT\= MSS@5\63:,%#\;6 &96F(T\U?+>?3+6F ^T^="SNK';7<404547YGN2ZFSKE#
MR7;M;SR9K;2H6C\Z4#>_E#&X<I@I\ \ @A: M0- 'C\X\A\T@?^I@U_&C*~;N'E&J:3*38$FFLD,\AR:/IT>#L#3I\_.#SVK"+L_AY0L?
X9N55^F3K2;X\S/@+G14^F? M0\#NR$;#9*8(7>@US6\B8)51(?!@).'^?^9'W=BAQ_Y_L 4D\T?<=4$2VS_LL/F9>4D0>XHYN\ 7(HQ,U2D5W^E.5- M,HXG\F8<,
M_'I\H$A\YXRCGJACFSCHBJJ@B8=19VHZ#2H;Y@L4\_-0D2EADF4'.^?+I$2N\LQJTDFTN 6B
```

MJ\$R6U1A"/7KRS"/JUF9G%#E#QV"/PUK,0,10,70V">6L*SR6=11=RU@5=X5?. MLWF??/R7/&H/*N42BGLE/(:.64&I)0H79@:#-BF(>&K)V/P4GG6?79X3/W = M* (CGPUCU18"/C9S"/@80ZL/EU)Y3YPKU/JC6_B9729YYK/H#GJ2:4Y(I)S\$5_ M^5M^1(J,NR7?7&H;-_3\$/NZP-L: TP/LIK TP/JD)M@W/M7R2K MB"HEDD=H=H\I0XJC#XRF:KUA)M#:"(U3"8,&!0ZN3:"P>Z,GGHL|THE%'8Z MON-.,|'HPSR(A'\D\$D\$B=)'BS^8E#.TH\$!EF6R -T1 LN56)K;OZ^#H)\Y M8-)) [I|TIA_RZ1 WH(A_.\$%:0.:=WBA&MALTF2YKX|EN1:6ZYB)=VC(.7%# MK\,1#W.=CWA1A1_F3:VI\$YJ3VONTW.YQXFLZ+-X|(+3WIB<#KE|1-1'D/' M? (L5=AKIXMB|>0&G1GT)RGYV;TUV./->NRF3_F7;QUESVZQ;)=K\$R^>L< MHGZA>B.BE@. \$N\+MP59?<&\$&/L:4_5.NE3|H%|3LT':-|H-ANVBK*)%3Q\$H: ^, G;G>+8*02-2"S=: "X?6EE9.3+;_4_'JWZ R6MF;&3E:9=S9|>Z2WJ)+ M>6M^M5QV"/C|HUZ5==,#/LY^F0I X2^TYO(IW8>'E7OM^MWB.,\$FL#\Y^,/= M0C+9_%L92:/0B\$W?16:1>@9ETA=DW9X^#(FLD#;W1M\$1NZ|Z|2N>P|A\|=2> M9^-J(.I&FEZ-):@0?(7;Y4_6^H6YA)&05DN| ZM93\$Y9 M\$8RH822:; (XFN=&#QX'00QH\$)=&NFK-&S|K|114-H=K<&A(3A^|E|Z MI" L7_->ZWC;IG<7IE9&WQPEI4Q^52<"4H(R#97Y;E._;0^=WQ76+9UGM_A M652>?C9NRL/3,30U)= &4K8^EYU "AKR0^|D;Q3?B|LB5XEEQ6N8T9D(#X|L5AT15- H%|2GM_!02P,\$% @ 281\$6J>GM|8) P U H !H !X M:"|W;W)K=N&6K3)C% QH6- 5S,% +68* M9W|D#K(N@;=,42 M^DF|:3:-CRP;2 MAZY>#N N@<DZONX|OK\$P+&6M\$51YI^4"C,|J-9|PDL4C^R5 MS&V^BM)469+&TLIE<0?GY&83 WD^N>+>5>|/9|8:<2W0U8>8>WBD:U|J| MZ/6K3C_XL\$ A4Y+%)R)KJ=|KU.\=8X_PIME0E1)-.6I.5PH ;S|CBL13X47^4XZ^1X^*H M'+<"/|/?VVR|BCT+>10/<0WUUV?>VE1S^ MSQ<^|5R79/&@SIAJBI|FL|J79F/7D30:GV#5658#S150W=#U8H)33@LD3(X M^V UJ;J^JB9&JZK6\$B#8H;9MAV@K(&^XII=E.[9-(QO) 5!+ P04 M")!A\$1:>UX 3#4# #9#0 &@ 'AL+W=O&ULQ5=M;|HP\$XK5B9-K;22-|I+|Y%;JFF55@D5;? LP|8.3^ UL3:/@?;? MSS9I2D1(44M^|V|I|S\ @N^\$9KQA \$D^BIS2A8FPMI9IB GP# M^5N/+==Z67@BZ74^W8PRO '9B| 9E.N9G;\$S1_4J^"" (0|SL77M7D>3SL8 MBU|HUF|KC#25D\$^';F+QY:C#P0)1%)#8/6S@QDDB492^_A7@%IE3.VX/7Y| M^V:*(S(A^C|AR6|2R^75&E|HAC6.\$G_4M^"A^'2I^2*6"/.- UH6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%#%#X(C-BYQ>*>*M (<|/4>-1^TYCQ&^V8#U#)A^7Z| "9V20:AA?EHP0 MQR&MMW ,32""#NB); *WU|U^ ?!0!<KAZJ6P^I214N2^N|>#(T1CQ6G?V@Q MH\$KQ&S>^P?,'(9&D&_ M 16X31L^XQ^N|B&;4K5\$EA*\$M=Y0K5Y|UX_10KY|EALN|] (VMTA|:OUI|LW=2KIUNBNVWQ1 M/.G\$)4,A(") \$KD3|B#|22353)A+-J8QRH";?DR|:G8-\$|@V M4, GC,F7B>YNRFXV^ |02P,\$% @ 281\$60GV8:?!|P |T |H !X M;|W;W)K09?G M,%,+580|Y^-*|ZJ.HX2?|^9^+\$|[?Z3Y9TCP0|:@B?OFM*8""F8S0I^D5(2 M|J\$9QU,>#P:@?D\$ITC< 4N9MT?;.6|@H3>I,BOHQCDKY|""^? 4^ZHG^N)|2\$%=[3/^ M4GE@|#\$|N |>.X.L1S2B\$Y|&#/GKB5|1*,J09^,+&4|Y|36SANN^7|1%_5|G+ M9|X|IUHS+|1:9G@3%G_U5ZV^V\$%/3992J^|Y|(.CY+ MVQ6M8Z5H^Y^E MA;|=04KHAY<&4|JL.C=|0Y>X>=ZN 7#KXANMF976+|0Y&G^T1U|8^30^, M-L9;L2^4'^-,3YQMVO MNNM^>RF 5PK@;&SN^CR= [|^B.1D|U^AD)ZC@U@NA:NO(9CF!LJ6(2P%=@19\ MN3WG;QW#EL J7/VZKV_0 3U|V_K8+L+=L|WF'-,|J|*5^Q&VM93_&R6K|>8 MQ^C/#P6) [B2DXF^=5^Z;4K4\$5A|67K5;4R>= Q\$TCQ%

MW*FEE+Y\$"&!AGU&=X IM&13+Y695;24GQ\$U||%@ M\FLFX\1P-)W\$TV\T>U\('X+A^/X\D\|M.O8#1|G#V-
|\>3^.'&#Q,9'L, M+KY-X @27('O<00N/EZ"CR C8)[2DB.2+X|Y* 4M;G<#^"N'H|J8@#0|H^4 MB)2#4EP?<>Y)%
[T1VY*K;N,J|>8Q|Y:Z:U?9= MY)3S2YUU-4504:C|^HV7 _B^3HB3R|,RS?W\$^"UO+4 MY+6+F%\^">4@EF&5;I
XJ|497L _L_|IQS?;N5+5W05=BSK%;R=%&.15U/GRM| MHR\XJV^4(K)6Z0'BE\$@6>L,A8O=G,39M7G,TD M5;FF\$QYT-
4&OI;N+@4Y|B6@PT/|UHL-&='A6|)PJC?17RT0C%|3,|L:Z@+ MN@H#OI5'1%V4 ^T0ZJ7U+FF|TCI35|SDCLP
^|5@*.NC#'|GHJ|MZ6K" /< M(+!.)"JT?E8EUF|+NZBU70*E#2 A6+8H|5KD& @*)5?B6 TEUQKZ8/ ^;K&Z4VN|T(VTG-
+A> M8+M^VXDNSG.@/%I;3I@='6V!V;JZ'W"IM"2BK>;WN8.KE MGS3UQ>81L;7:YG.^DI36=2 /(%/?
%>J&H)NJ>EY0(6OQZC65|RO.%\$|^7U\$J M7A0J#YH;V _4\$L#!|0 (\$F\$1%K9/H+20P\ />K 8 > &PO=V|R M:W-
H965T&ULO9W 4|LX&L; %0^|L|>=619 _D65|ES+3Q|;\$ M3\$M|P|->@2 |DF,1L|9?> /SND""V)8L/# =
(2>/5Y)>N);3V6Y./|>O6U MN:VJUOMK,5V;P|NV _NMZ.CYNJV6I3-K _5=M>S^A|I.C13E;|P<;W|W>75R7* _^6Q9?
5YYS7JQ*%=_OZ_F|?>O;@#&@ M^R _9S>W;?^+HY/CN _FNJC;|^X^K|I1X^4Z6Q1+9M9O?16U?7;@W?|;R^A M^8%-
Q+|FU7WSY>>O;|J7NO|?SB=OCWP^Q15^|J|1%|E|I^W:E+YSV|J|>? M6C^8|Z^X^-?
O|/9|O%=8|Z4336IY ^>3=O;MP?I@>3>MKLOUO#VO|T6U;5#< M^Z|J|>;YU|O?QOH'WM6Z:>O%MG|7@|5L^?| _^=?
V0#PI\$0|"H3; J%6(\$QV M%(BV!:*A&33V<7GSZ<
MYN\NB|R|N.S^ ^UB<75YXGYA7 _./T\O _> _M7|B;F;.*D7B^Y+MT%:2A?NTN^FTUG_I>TJ|;F<30|/E|ZDO)O9
MV|VU&216, _+ _KOOY;-OLVG5'5BO Q9 755-XWVZ|HIRM9PM;VRF^ ^IY|75 M
|V;|I _VVKE=>WNSHZW 6FK2WBZO*H7E?SA|I|IWECP8DBWG-4=9=FNZGGW M|YN.V5:=
<=|JMND>=I|U'3|J.MPD(|L2O" _GY?*"JJV"GN@<|OO*"ULNKJU^| M^C/%" _TPL(G02>TO)+U=^55|?;@.Q9-M?I6'9S\|-\$
=|MTD3""@<#W #Z M*"|WDSC*" _PY|OKV5'|G(P)XTB8 _4\$46/VHH&;6N(GAY(R9->2 _PX3;BO M=MO\$C*-Q\$)-
B|O.*L*S+># _WP _S|@:R.S OQ*\$2|D|H@=P2&5\$RRLLU2-1 ME,E6* >J _;A;VC;>\$ M^3XAF?;%=U9HK\$20, #;L
1R94Y@Y@ _YL:C^|T,=>I?;B _N5+N; _V.C5J M\$@5A&FB="/@J=U9O;|C80P)XX.A@"E5)20/"HA<2KAM&G6FTM|?
=WKH; / M; J+S" >LOOF/|F7M"G"B1Y|F4""L0X%|D64>V6 9F1(6\$<"1, @F""O|)%%> MZ?/E99-
4;GYC _P\$VEW79%A8GAHW9Q89F*PPRXC^+67.AH|M8"1, @&|*|V>/ M^9PY.WA2+|IU-Z.|*==U<5|?
+|^+TTMOO9RUC=?62J?O.YTX.XTIG2|A>69* M1|J (/Q)(PC80(\$4|O6^<-
*ZV%|JLOINOM&1^K#4\$I*F^IAT&Y2X|&\$#Q9%V M4G&W=VQ/0VG"TH##IX="|<,G|FO@|/_SZFZ|NKKM|I?;16'?^<\$-
'GN"@-+R M+4TY6"4)4ET4R0,2N-0FD(15)5),S1PNZ&|5695EFDU"M(DC5+|Y# L+M _M)?O48,|%)3ULP34E832!
(JFK,T)|.W,|EQQ |I9WG3S7BV&R6 _=, &R| MEN\$8"4"|DP>%Y>Z*C1W#&DO*H\$DYE"90-%4)TC\$-G#
|8|Z=4T^ _/A:P*O8O M'.F&|S37P, # W%VIT2| _J|H#&A&A:06*|N|&L|V|,9TV|FGU9|V>|S4WA M4GW-
K, <|L^Q+3;#B, 2C-='TB|+X?2"BB-06D<2A|/|>TO5D+1' |< _^F|Z
MWW73+JKEP|B54VKQ=UFYLFWW%+TOZL6Y9=Y-4Y@IB5X&"2^3W6!#8O+ MW0T9+9UA61DT*X?2|(JF2D?
ZJ8'4|WP&#ZT"@-JID)I>6#;J3&AE(3Z _2S4 M4872.)0F4#159-)5#=RVZHI|G|79AF?
YF\$J1AG|F#&S.0TOZ|O|P|C|M5;L< M3&#@1R2C@?Y,WA)Y2\$*:4?W"RRV181I\$&E|8PN(P29 _&E"/O+O| I?^>ZZ
MF2W|&4;>EQ%S(@+30\$R3B|AWG5#3\$DHKH#0&I7\$H3;|H|ZBPNZ7& _G.F?IS+
M^XUAD^>E!!_VA*2CZH9D^B'+G M&:TF)"V TAB4QJ\$T@:*I:GHR;|5MU+YHN|Y:#-3 F&GHKL%HG2%I|93&H#0.
M|O4D3=69-|(#MU\$VZ37U|/K5;T8IS33GPVBS% _TE#&H;0"2F-0&H?2|JF M^DT:T';B^X|R@T#5V;=^2NWV@50AUN*
(U!;1Q*\$RB;JD)I@X=N&|Q83AVC M5*M3\$%KFFOHQ38S|JCY#;454|J#TCB4)E T55 2(@ I:5G84|>M _J'<)MZAV _
^UIJ%T&(LIPF-|X>%)|:SBZLY\$T M|J7O80=\$H)*JDI|F?;@VXU^T>,'-GT%|EKWH?F@*%;P2^@*1F4QJ\$T@:*I
M:U^E(Q^Y9QV/7L00F3-G V),)AP4E4?F5&-3"A94\$FO+|YB|E6-|&\$H3*)K: MPl+2CMR6-G(5@SO5V/*E)9'IBN?
Z\$|MH1D9E;A-(&B|J*3SG?D=KY?NI@A M,LUO8XV|&1*\$>H _GD3E;V52%C>3K\$Y7=+1|V=VU# _V=*"0^5@J-
WX9&L\$M|'\ M_/4;O#H,P74>XY,O|N?P:ZK NHI0VD<2A,HFBHRZ2E';D|YW'*&R#;Q-P|U
MZ2;#PO)MF+Z809>#1;J=RK,W<|1?OQU;%\$TM8^E8QNY'=LQ2QDBBU6;TEAW M:BUA84;U.:3N>HT=U@[*R;
Y.90E; #0M)%4W4@C&ETR\$B4QK,DAT|U=A=\$"DYDAM(8E;A-+&GJ|2- MZ;0;2MQNZ.M;R&FBODG<;B?
G8:%Y>YFC?7-L*0,FI1#;0)%4W4K%Z;B|E@' M+(R*K*J ^JE06DY/S4F23=8T;'T*P,2N-0FD(15)%3Y4,VP1WD+!,OY#V
M^Y3JZY@FML H|@G1|!|+&\$%+M6O.(V\$|2R<4&8Z/X MW348K3.HRPNE,2B-0VD"15-U)DUCL|T?
M%PG=BVH#6\$|IT^"Z454|J#TCB4 M)E T56C2E29N5 _H5Q 46\$|0ZL(=UE!; :4Q*(U#;0)%4V4HC6WB-K;=ZU;L M
SG3""5I;LH+ZFI#;.064QJ T#J4)%\$V5EW2 _2?;<8>K@%VM)PU#;3F45D|I M#\$KC4|I T=3W:T@ _/7;
|ZL&:SR%-OGT _X8DMCD2|;FGE|CJ-U0|4Q@:V M@4.S"FO6G=3KR/U>JF4N>;:/N#&,O0E|;
M'EML;|J&D3Y=\$)J506D<2A,HFJHWZS9(W|W|J|, ^;|ADA#C _6>3H8%Y M;'E#FU49%B _@DQW+9B|X;.
|>IUHVAJITNO.W9|W2|;&=FCSZ|O.WRV|3G MB;|Y7P%-R; T#J4)%\$V5V9-WP|D|_-
\$+XV+;#A/Z&QHG@Z+R;53BEH*|HOK^ M4,S(M+R*K*J ^JEWNYX|S|TG^_|IIC-L89P|U>CS"M2SCDV;|#0>VT-3,BB-
0VD" M15-5)ZWHV&U%OW1E7&P:SOK*.\$M('I+7|91B5L6)HID5)|9YF|RZ.Z&6KZ6
M%APJ1T/M1^GEQFXOI_E+X|S@T><*J;V^;E^G&F+YF\$9F50&H?2|(JFRDQZ MNK%|1O.XO7&Q.2OV.,A):FSF-
S0PWP8F>P5A Z: ^K^ _\$S=SM'=W74+<415/? M6RO=4NIV2\U M@Z5?
2O=MQ;| _D1RUO&PMR>+8V/EU;#&NKM3HWH6;I\$;:P:|I8|FZD#Z|/O5
MIP6FEFFS\$8UB?;3IKL/8&P.HK8#2&)3&H32QO|=4#4GOD|J|SV-;U.OV90|Q1**Z T|J5Q*\$V@ M:*K,L,M*W2|KV0Y-
>>75G@^O9;LQ3'6IO5J.(IL9U\$3KS&\$HKH#0&I7\$H3>SO M+551TM6E;E?W|:9Z4LN&#E%&8UU?@)\R=S-&"V=04@9-
RJ\$T@*|NI&^+^WQ MN^V(5170=|M|:3DUO4^:92359% LS(HC4-I D53129-8 _JL=|O9A65:L9D?
MQI|^@KD)-519EQ(_;:4T\$W=11JL;H%#;0Q*XU";0-%4U4D+/%;X*|G6";F MQVKQ*|W5&RU"J|,I3\$HC4-I
D5312A=\\3MFKM7IEO|J2U1<71H8(Q&H5.9 MH;0"2F-0&H?2!
(KVH*ZCYK;JVKOLRY/CN _F^EBN;F;=G=F^NN|P _J^|EE>S MF|O'#VU|I _;@&ZAJ=NV7FQ^O*W*;;7J
|J _7|=U^ _W#4<> _KU=?-SE. _@=0 M2P,\$% @ 281\$608U^ >R @ WP8 !@ !X;"|W;W)KZIQ27O#^(|
(\$24|I4DF.E8L97YCVR*,.26B MQG+,U,Z"|91(M>1+6^0<261 _6(|I?J5G1*66|;Q*;<;.53&B&4PYBE::;\$
M/_=DR4&* _R*5"V= M;Q)^4=R(G3EH)?>./>C%(I8=5T0)AA*S4#4L,8^HDF4F4EIQ6=:0&|LZW M|+=&N|)R3P3V6?
|C+N6-<61+@>|J|T3.V.8'EGHN-5 (\$F%^&85/FUBT(5T^R MM 2K"E;%2Y^ONP VA<^0 X)=^Y|\$,S5;/_+^P FM^#
MO|O, T'W|,|JWQ_U.T^1A|Q@HSGTV&P^X.PS&K^FH;O>8 OD\$2B>GX2V (" MR<*"F"41=55;=SUC-WMLS159A31-
8TPB|0\$Y,B+ _S"<4;7| MDH1P|1|IW|?;XHOK>?HI|6Q4 \$A6V6R M>IM5M'+IKC&G->5Y66;2J/_+N^<M _|6E|?
5=LF5Z7|6A.|+8|T?GPK|^KA MS1D|>WKCF|I;-^:R^NK37HG;V7SQ^9K#;\N=Z,L52%+K;J2U'+UYNR&ODY
M;@YH%7|J^:#W_B;&RJ*|I@7'Y9OSCQS1C*766.&2.&_>SF7>6Y&@O/XIO_T M;|>=YL#|OY|&?|^!;S.+5.MYE?
^EELWZS5ET1I9RE6|SYEOU)|OL#?EFO*S* M=?LO>>BUWAG)MKJIBOY@.(^"E=W_Z<|^|(O8.H'(^:P _@-D'B)\$#>^ \ ?
^X! MHCI M#|366GG(4F;|J|KAY(=OPFOFCGN6S, @?MPEY|0^K2L|^79|; _M10/O|B4G7*PY\$2#^4RGV\$VGF|K|^C-
D3E5F52')JIS2^AR;NFZ(L'W"Y,G| M:Q:\$W(-HN-^?%&N0C|)% "6N**?!L*\$YCUBQ-|9?2^CXF;Y-R0#2+B-)DT%
M&3>KRDSEI2V0 _Q>3,SD;2IJWL%IQE9/)76PU _J/^4^EGS^H3CE8M>(2D<0%X M08S'9;B;BW|R+FZ;*OLO,RODD
O HIH?E|VYT3^~|I(S&7HNO1|8=|B\$J| MR+J.NBH6"# _48|A|&DPT^ROI/UK)8Y7,XEV52ZE8'3A2H|;|K,P*W";N1
M;R1@S+;KJFRK4XH#F _'.9CQI\;*86 G6= @> 5&(=5 LLC NF|C=RD7#5DJ MG55;DY!>P?U0J|V|I|?8O2I1' K+L|NB-
!;91M1>5%\$<>O4&R#.(Q+%=6H M<68^@-L73%HXSE?/O.4A=99SC\$=%3RREPITO)A&?;3/'M31%UW,LBHA@%?;
ME\$<1?;LH\$(6BG|D6M@P+6QR6M|JLU7-(S+)'G5+9KG'69MX46IJUPM MVYO|PI8O;J1E1&2N>L"TC.E"-
Y&8ZP"2=A*OK1.FF5HNM MB0-M D&F=0FWLOY 77/7-528S|5V93&U.Q@F\$F.1/_>G0;^C^VUQ4M;S(CD
MG\$X^Z|(X'H)B^|2P1K>|&6W-MIQU^)8.IX?ER2(9,98\$(|9'LB03L(X\$B? MJ7L;,-*23RN0N:-+N5(-

FI<0^C< ^>F^83 0VAR28+O"\\L>0T!:=QJT/ MQ295=8>^)E?E55IV\\W"/=G#!#0 ?
ROHX|OS"\\T"\\JUR4@QN(PLNVZLID?.#B% MR\$+/&Z%.N 4G>8D\\ZU@Y1C!EW^F=\$P"F(G+2""! !MSUB
WK"%+JHRP4I)ABSZ4,5S;C7N36P2<+=3G5:(FM2@\\H7*F.;+1=|'=40W;4\$|\\JB%2-S.2GR V|G=\$0&J=JG|KJ% MZ7C
@V*\\TZSP4A)ABSZ4,5S;C7N36P2<+=3G5:(FM2@\\H7*F.;+1=|'=40W;4\$|\\JB%2-S.2GR V|G=\$0&J=JG|KJ% MZ7C
QC""\$>3%CK2:7MAS0NVZF\$2|)\$@XM V|PM@/F/"V843G>2P8X1(V; M;LG9K5I5 HHVIZO&3MI6.^EHR:E&.YS3@?
78-.O=9%"B:;6K5 .P|YU)A-6" MT*ZSYB.^I&PZW%4%T9T-%4,6,>FL2Z|^SNO-@9B+\\#4%N.F#9V-
9UJTPWJC'^34&S5*.5*4- CE(_C)Q90(7|'B,O?F (!<^D5T5-# =U8#5R?":(\\A#S>O!CKD MTW1X:!"&"F|Q6VV9-
;|)%T>V|Z3Z9W2|_ 4Q/3B=)INPDVZ|J|V&?#P%)@D@H M|^-.1LP.^\\NENFVMVGN8Y./VFEE#4 _/|G|TRZ;2\\XO2!@ME-
7YSB=DAR:'\$B/ M3Y/>AW9UZY(20,Z+6T<G\$|'"CL^?>GN?VBS2(UR+'>|83\$7PL9V1,8\$05V%8 _H8'G:;YX?3LM 7/Q(
M=^WPOD:=MW2"FL1Z98SN5>2|2PRL(/,ZEQ|3>:.=?S|P%Y_FKY;5-ZDRM8AI M,97|8T)P M%,:.146\$?
AB\$OMU@PX11&/#1/#U0=(|?5'X-G?QC3\\L.TMF+Y4Y6C)J48| M?
%AFP#8QC6UOJQJ.:9>X|:=DD98 _2+L|EJS4+BH|LT(6544LX149,Y-NL&3 M@W|YBX<"UBB;W1 A|2|7ALX6
Z;THPANPY%P\$@\\\$B6F(^S8L ">PCFOA"DXQ M|^AF9_\\|G|N4&G@^|)\$;K3>FM6^6Z'93&\$ 7A09%UTZ|(C%K'FE
M@A)U6|;+V27LFJ>FEFFS _DNO>M61W167&0+?< _=|L1T@H?V3DV"Z-KA1K*I
M&!!03"/@7BQTU>AF6V=KLSUXVOEP"6|&@M &HCFFBSW/7F433.=|8@01Q-XS M=\$>
(\\&DR5F|U|+D0U""RY4ECMR;="G=B8JRI_F9M?MA|6F+0|:2FA?KV NIF? Q39.|?84(F)NL",C>1\$=#?8! M _4T '|;1?
M'S6\$DIP7Q\$|08JTYG|E_K":&S_30S%)XYTW)3AH*I.^PS M>XS'K&'|L5B\$D?._@*"(_
!C3L;&A"+ROGA6#+PGIGGOL\$AMJ|C94|Z|C697| M3FIN A1*4PG _!D&*%H6N6 M^HOOM7?_OL@WTB2SVQ&
(1KB)%QF(QR-WIC_0F#|8T>@^->|]"%>9 @8C<4890@#=?G3U/4BZ|*T)29.=U^U
M_Q0^C01WGIW&=,CD)CN<|(ZTY=[O0|33O|*)DW9#N|MDR|^|=W:^F;MK? M"EGOOZ6OD^ZW3\\,PW4^Q/J4U7'5-
BJ3;M|WT65=-4 M1?OG6J90TA@!|?+ZJ|@%|'%^8+=K|QN_X?4\$!#0 (\$F\$1%KX-P,7Y@0 M _P* 9 >&PO=V|IR:W-
H965TX+G16#YB7QK8ZK MSJF|J|G1K|/+/\$#V\\YD|J|691Y7YP|/B|,|>N;PK4M).:FPM/4|L9N,*B2(01 MK@;CX?
#K(|=21_-16%O: ^=247DF-2PNNS'-A=Y>HS'86C):FX4%N,L|+@_FT M\$|M+%1+OS"MCX|C"
NG3=Y;4P>Y%)7 ^*UYN%#_:UP3CX M75T4O+P27LRGUFS|\\FE"XT\$(5B32G9|?EHY6G)L/_/*QVB"N
M+2\\KR_%O+\$=CN#/:9PZN=8+)|/L' W&A|&3>^7(X_1+S"N |'HQZ,A^/C# ". MVMB. M|1;_#N|49H^:|@^7NP,-H9)1-
198-.8&G1H?;5@DGA1FJ|A8RD4K&@1 M*?6@|\\OULY;2IY_WJ.HXH,Y=(6*<107?95|PFA|\\>=3CX(|@- _M|_@C| ^E^S-
+N\\AG|ATOJ%0/BM0|/L;J8>I'ZA52L WE(5P""?QY.'JYO'-P-/D<1&3<^F%MA
W M|'L42J8|\$&Q&/44|J8>I'ZA52L WE(5P""?QY.'JYO'-P-/D<1&3<^F%MA
MT&=HJ7I|\\D)TBUNYZ2K"D1P1'%|A|G:P@HK4*FA@B9OB(TLW!|@+BY!(%QO285>C M*!DF4@_ "3%:/+D/*|
|H1S(LY(2N|K|8N|J9G;4F35|RD)L'5Q'J6'14F7B4 R. MV+:FW&1\$8:4RZ0GW&FYP;2F@'8R&H0L>|
<)V34'03R'GOY7A30@63:25P6\$G M=1_VMMK*D9J|3V@H|I6E+Z* _@FC4Q&,F'^ :>TNU9?;D^K JJ1*4E0H12FK
M%._>2?T>G==D9"C&I(S9\\3KP:L;Y7 _;@QX|)%>^/>UKNYP)!96":ARK'?\$W%
M3Y|L&5<594@(\$;3@#7MB\$|LH5/(F(GML1*"G64LFJXYG01:BIZ-95&0JDI4>D MY|XE?:#G03>UI*
|>2N&K4E=Q(|'VO>A17N|'U"U*: _FJAU""%#,(O\$C|GTT MOH14*B(R-
+HV=U88E|9J<1SSI6M,\$6P"\$U|*ZNVP(+R|N?Y|GZ9| MYX61H|V\$=Q3K6FI?/3::U?;I=E&|4-
Z.5^\\^C|J09@X4IF0Z|)^>1&"KMU,U M:8(|Y6U\\23Z'4.N=+1\\@/938WPSX00:|!^SV|U!+ P04 "!)A\$1:A=MK MGD@I
!8A@ &0 'AL+W=O&\\ MV|L6OMET _XO7M)GO_2O7G;CT/C6 M _=(78=SMROI|PVC7= ?9-UUM_C'^_K|DPL\$R#6N&G"%
M\$O|OSKUQ38,+ 1C_E#5/XI;XHOVWKOZ.S@YG69?|O>F:WWP|;+\\>7Y2U&Y3 MCLWP;W?_DY/S?
(/K55T3Z+_ %/3_|L|E)48UAZ';R,D"P\\RW _?_E9|&|>>'YQ MY(4K>>&*X:.-,JWY5""^>MEW|IT6/3|_J^_Z*KT-
P/D6+^7CT.W'MX;7GWD MRRBZ3?'1W|1^XZNR'8KKJNK&=O#M3?%+U_C*N _#R\\0#|X5N/*UG|:-|]=63M
MRZOBKUT|;\$QOUN|E_@.0 :H;U2:%|?/:CB6U>=%T\\N5|75Q=73|!9|D\$ _MA-9|'B@V5;%V4
_MC1X;"M6P=06@:E_V)7\$|+SQ;=E6OFR* M,|KN'X|6G4M'B\$ _(|'AFWQ|_\\X6:-UU?_LT|^+MR^P'V+1/_|^#2OL&
|M|C|IS_\\X?G5U|>+Z^M?Z)^7+QZ=%Y^V<L|0%AN-B ^"\$H LNMI_1TN'Q14 M>-0-_%;CR|5O _!E%7RE|J|JNC#VA#"
'X%"-!U|CW>J_11| ?\\-+P5 _/Y4 M+V-&-UN"KW=WKAT%(O<9)'F /^JQ1^2DEPA5KO==?0XW/HRP 5 OR+4 ^X|_ M#0?
&Z#)ZV _@7IOQWX5C|U4G@K|JQ=@28 M7"(M|J9,KFV&|=^4MK KJJ\$=DK8KW;76^*CP<|_MD_*Z^Q:6#N,Z^_
J7/3WT M>^_Q?| ACA MLOQ E|J#(8/|^FZV19W':&S1VT T/=%!|?IBYTK6T#|>UR|ZG;|LCT4(&7: M4%9':0#\$NFP_*
|_#EMKQSQ=JYMG"-|ZE/!|OW76NP"&|1_19O9+D)|S&YC<0; M|JYL1J|QJ|< QYL:(6P|7O>VUP/7@|RA2+@?@N
>&+NV@_!|OL7;"OYYD MQQIX\$>2&%SD'7WDX/MP7;P6T17O#,_NN^*VN "I0GK54B#+SA ;<#AG\$>?9= M<>H?
T29X,OC2MW=P.21KX)Z'VYQ|^&<8-;X^<&).7XUOB92.QDAT@|X,| MP% IRKKV""*2XCN^EHP;JATW".CK <@ =);
#QZ%GP- W@O:|G?@T""W7 MP-4'690|L4015K@3W.S:;\$Q.L\$6|.R9 _\$CIS:(72P|09LGHS<
M5K@P0+B\$|JX|A.;B|NAT7S1E=5L@U8BP%&"Y-?WW;WKIW0-&P2@ MR*;LE<0|W370G\$A) ^QT.U^A9"+C\$RX4
M|+|FX+IUXV|8N Y3IT_9I7 2E* 7|&R90,'XJ7H' OY68?XVB !? MLR \$R='FZYP7;WH_H,!L|=WENH,5@!*-
/MKO&\\|@CR,BX*6&^#KQ'2"2G@: M3 Z@A!%Y- _+=^D"*(@1\$|/_%D5")>X%& SG>|1P\$K87
NP9>4#22596RX1L\$>2B2Z:M-!\$;CKY%-|DS1_CRT'JA0 MI4ID<6&|JAR#_ZFX*5K\$-JP ^E3,89+8I2= |8S|WLD9) E+
|KA|\\^R\$1 M72F/L6AD7\$9!"FH\$?)8"-21R#BL?P/2J6 -D;3=\$C X=BZ&RJ+8E* _\\^AF
M,A213,J^QZ|8D\$/O<95((+/)S3S=|!^N+65|=GB"ME<9) M,U#*O1_*QO^+WXO4E(-
BY\$-9P;4\$S|H'E;|L'F4_P5F650+\\H(Q|O?W9%L_ MU1Z'1+GF1,)|#81?H;0 _AIU(3>U04V#_L^H(8B%MQJ8?
OHB@H^U^@C62(7V|JXU1+M6L1O!N_9U;4|USL|M&C,J"HO-VCT,T7|B* M+6|Z='Y,;>7NHBC0?3-F#&SE3A8&Y(
=X|0ELE&/CSX^ (KK/BW=(8QDFR#N; M&-|S|'BZD69F8@!:-:TDK=;J_Q|PV'O\\EL5O&X=<,_ZL*3P3H-8Y;OR@"XE
M^Q*9O:QO1M4YP1)S',6F9@_PE2M"MT|H0'+O8.@*H0N%B8|D;LMP4X0MR8 U
MP@\$0HA_1HN|J3(AOYR^(>1ZM^:3*SHM?V<.#_Z|Z8#M;Y_\\#YAMX"GBP^B" M*;
(K^0H=PZ*AI|D"%V.=)J\$ _!6G<=JV;&8DS|2QV.CHT&|BZ>J\$+AN\$V.D5 M.#B3&BZT?%H5HMSDR2V|_ W8@|K|D -
C2)Q7M*"XRM%_TPT/YC.:|<*GVC M=5?&8#;O>Q(MB5KH_G4?,A@%00CRK#&;R*:QA9HJ3G@|^3HXQ9W*I!)&|5(
M|23|9JOK|I?|:]|=0+ O#)7_8UX,"\\ X\$6G@VZE!J+^RX#@|T?0)A^6; _M'D84Y44
^|>C(O\$D#R85PF90&8GLE|WY|O\$YZ14(_)|@T3@:;#4A=G>N|K+G99MR#>K+ M-VC:D:#"R\$)?D|*A,)|O<7T\$_-9E7P?
8MTZLHP& ZX|OHO _G5BADMV_Q MRRZE|BNV&=5G2 Q*H4HG/T_4S-LR,2 _+&24BZ%@T&_EC VD9|PMX"&XXF
M,@\$4M3T\$0LG(P3MA^Y|)@"&5|43/Y\$*;S7|>19?MZ,GC-2+RUI%(CCQI+& M&<=K=-L=N+=W&M-
",9G1,\\9,&C>PLU#.|5+@VP"OL.U\$5S=Q#A&LJ_2F>P M,*0BNN0AD0ZRXGGQF|Z+B<>0/D9|JIA9|(QB00L|;Y|5I|LB _
(M('A!_M(199CTX1"&*V|0|I|C|N@#P->J5#?=/M +(L;:ER-\\FY/4G3X&"JKM/P1@_
M/9;%5C|6WC|J1G9>V/0(W"ZL4ILQ/RS>*B?HS+ "\$RR@.@|MK8EL8=UE@_B(MD|@ZHB_*T@B?/M"0)_C|^
WAV7;W=#K8|YZLH?1B.8-^@Q|^A%7)HO M/OJ49\$;|N@=ZCTDEQO4)GYHHJ!>0@=YR PMB'S'/H+=|L,L|9@/4XW
9Z1 M_GJ|7U-(RQZ)BWOCU(9K3Q30M9|BG\$;5H@:/9^T>OTL>1AYXLHW'#0I1 M:4^Q5|_4D;|ZL0TOZ,26T!_?
(<:>O9<0@_EQ-8""|<C,%0&M8L(M0%!)D M|_D7T<0VB06ZN|(|N0;|!|D&M6|T>U1?L\$0R&=02VP\$H|/?
>&&!E\$G0*:P M|32AK0R@?D2#(X2DHJN6465>2(AIB=F4C1E7Q)SRELK@LVQ:V5 6H)H)4R\$ MQM%F(" _FD%_#?
A8J2HJ|<|RJ+DZC*NW%|DBK\$6++NOA@#6IT%""!7XG-[B;F@DZ*]J>Y M(WY&0-
7;1K3"9<13G_I6\$<\$K,FXU%_70J/HX70>35\$|BJE|0E\\,S>C;%.ZO M1M9M84GC,AL"9C7+A8E87SEEISZS.Z?
PL47)U|5C6|_KRBA|8*>Q_\\9%THT M1PX6O4 \$A^F?N?G)1F-NGL3L\$S^V#H_*OAB _=:0^"7\$4"!0L+M3:.R+7X9
M/1B5M49-6L+%I5.JDCW&8T1L.JF8&U(/3;\$M9;UYZ>RD|AC':U.% X878=

MG>APP&W=C\$:DRDJCF7DP<\$QG&+)>Z*2S< MFP1ZQ1"1+^X4.C*:(
M7TF<5&B(I0J1,86TLE/W;.!W\$)R0%B4O>@ T"\$,V&V\$4R (E!JQZ,=*LQ*,3 M"-_B:P+Z\$N'!)LE\BIC,D=?=BPT+EQ
T6LZ\$ MJJ?IO 48T6*!LHMUPYQK!I!P!\$Z4Y"J< M_O+D\D(_6)&EYBH.A(9\B
Y^QC\$1M=I#I77_#N7GTV4YSP6GC@ (U95A8SF MXAT^H(1?DM2:VSB4!U0!,T"3>J!=@#%DNX'UAD5_.W
\$W/12B#RAJZ!2! M) MPMKUNYBGB;R.0L(6% ^E**@3 F+RC(P+W> (FZ"VU+<@HD58,)(S9L86\$*
MI5=*Y,8Y!^.: \$L0YDX(KXIST:@ MP&PN;WJG 0E (&(GH0(I*6 M8%N6 1'&QV-+4(A(B'=P>+M(
GB'BF=*4C\$#8>],\$/DP'1TR@QA"@G<-R"6 M=LB7X|B)7C*9VO@RAE'8-N6;\$+40S^9?+02GQ-5 P3YYO^Z|BB\$T(47
3@PL M93K_01&Z%(:.06O4#40+I8Q5#8JD7!./@V^ (X>M|^LS-OC)9.A)(GU&_B3N M1-
97|5Y:OWN^G6Y%95ID.A#GON7TXSNN!0*(5?(_ XS5=J#+=.#=N.P@^F
M.),3Q0H#3_.D4\E5A|/;=ARB+V*!ANR*&0'E-+%;'3_ \$^X156|:S?8KV4W!- MG;*BUCL&0^PIKYL=&K&,R%R\$GO)@\ B-
(&IR>KB3\$2BB;%(EFN)/B0?^_ MX C=8DCSP8 F,9=\$44H.P*#:.7A,)!|Q,-(*UL(V:22L\$.W1GWN;*BDWO@<%
M^4^@P(\$#16 3;RZ@ 4YG)36_-&V"U2XP5D9OCRI\$|L2TI-#AAZYLO;HF M4@ 86+T#.|OS%QX#&,NE&R2:S(P)E-
"FSJ&Z/BTH|(# #10BZ.MA2BZGC/3 M_=EA1G\$)2@ (5A"!.A@[HW"]>Q8@&7)D:&RX#PPR;-H?VY,E C>@^=!+'\$M
MQ@H/WSH,8)611N&7KW1JPR_>:7YC&5_ '9+R-#H6B*BS|>\$, _U\BL':U/&E MY(T@!|^DW4ELIW<-L9/E%7HF+~?
1\$8:D(X?=>^3VW|NFH10 ;DWJ\$UTD==4D MD&1JL&H4H*RLBLF3C38';4E%I&JO3U)|DE1%?
G#IGOR\$ZJV2T6%:ZIS,K%DD=S65764D214H)<X^ MMY2XJ)6"LB*\$9'H&>#EL1-Q81PIO"E=%|3Y\$&3_VJ
N\$)WYN@6AZV.SJ&;FQ M%Y+/-<37E*VI2: ^"YV"<:U|347JW8(.5">EC/(B5GOCEP#?H=U2)QH,BT(#"H M5+TD45?3E%
9G ((-8B\ZEPN:Y&1)=Q-7O; I\$?E@PJHDO(Z! MJP K+BR_3P!?(S&BE2\UE70&+P_*J:BNR/%MY2?D7=(Y*7Y-B+Z30
&Z#KRF M9!"1:1@)=C;V*+;(I##@W(4+3Y4Y8T'4AZ<(N@1(ZYV"; &/4;4J,|AGI M#@UF)MGF4S*&0=O!8^'1=\5_V-
PE|I".(N8 QG#RH9I?>19CF\$^!.7B>|31
MIK10PO#RZ@7|Z_+Y4_COMZMGWW|S5>O&;GY>F#4%>2@/:V7=|>KJOXKGSYY_MU5X+FY
=PK12FZ:.N'S73^" _SU;/O|THWK!|IX'+ M;*VNS.L#N3)1ZR|9(+P'NVE+4E&ME:ZJOGU)Q0D,<*=UD.NN|I&T.+ 1|IX
M?B46!/;FJC47P\,I"!IMPWW-'36NIRV'Q@2I-QL*O6CXLADN"l%&EPRAE4Q MAABGVWJL*Q4,8#H,>97QA^I@I-
Q>/8:A/Q@>7L5G8^F: 1(M_:H,@PGA9=|G M+<3F:(ODJWN7=VL(/[*|=XM|2*!(OST:@L,("G%O!XWQWPMA:G\$E5,H
:=|3/ MR->+^DQ)"V#|_./BOW)8|D',?YD.0NIRLI5+F54"4A:5|<)I?KF0353A+7PCJ+ M+#6/A+&_@D4V8|_ZL#4>?
+QV?O0&6_6Z/K'NL89YR&6NOQ6J|LPA29B,DKW M5H+M+EE4XV-UC"S5X|5&6X|Q%>@Q62G@+<2 45X!
M3#X'E5U0P#C@LB1+IN*5*7.7FZ6: 4/Q" T5XN-<:G(IT|JT=0:VCYQ/NNZ&
M90Z1|V/MZ\$TH_K.2^@S'L8*)K8I5RNU3-B;Q5D'M1\$|JLJEC>0-Y,7%S!S MK+01);-DQ!A^_?
|3V^OBU/3|882',+IVR+&F='H/Z|\$6UC*|J&5C.#T^CDB8_@SG%0 M / M5_ST?
\$(J*M8,512'VK/3/;>:BY9"QOWWT(O:E&7# GMRK\$P=\$(J DOFJ9; MS@D#.!K0"l@E_3%E.>HG9HJFVKO?
R@&\$W02W2F')\$<1HC27SM5,VYS|/2'F18*%'W(|O:>_P^ MCUR(\$D0%+8H9CM,IH@M^.#
M^XP&CPV'5QR:\$*!A,UO4Q_ ^L5JGLB:AB@&JYI0M8KFE^*C3M-8E@-1&'FSI\$3015|LKMIS..
<&RZO)0=_>HLRAFF\$>WP2TA^74F"^^7 7R05;A|0OHEQ NSS3FWTG"DD7#KPT0K-2^|YIL| FJ:F BL\$|L8^%5
M6KBD505\$&S(U2#LO?@ (9?Z=ZA,\$V-\$AFCV8|,1-+3%UI*-%COGX7HH2I**^
MFOJEK@W<6^>XLJ|S|QO%290K68@|5PX48#*#;!B? J'+Q*0&2C8F;.RBS4 MQB.,U,7*),X+QIR(|CH " .APEQ*Z=E'
MMKJU=C)Z)4:(SOGGQ>?1|B7:S", _U!10NW.-7!*-90D'4*OM>,ORDJ*(DF&
M&\$,J9'887&!ZG4/(YS:EN!C2L1G#;,I#GB7+RP?8",L>WQ!>IS8_PP\B""ME MX'4-
GE&53|73AU;Y4"N,K.&'Y.2U!ZN.P321O&+#+(0>=/4%N&%@%SUVN)M.
M5^(\+JB70A@*7DKV87:;%7:JWG1=379%QEHK+B*:YYL) DE/ZW@-|57S8Y@& MG#R|Z?/>#%O/-
^&.Z6LS2T|:5L.O';LDTP+H^-TB!QA(L&PYI16\$)F9Q8<\$ M?|.!
(MHB0/#V#ZA,58|YVLP6VU3|=I,TCBL^T1.*@)**50M'=GN6"#'=VSV MQWDB&?WB14;*-
J>1)CC3L?2A10HFE<;X&7\$U>^N,N6O: ?U8/7CVG32.0K. MS6"l5
_5U|11: "+.=J1D\$3XZ;1*T6BO%U6)KTVT+AIJ0DSI=0RDF0(/ 9(\ MZ'E87#)H>1-XV=YXPYELF"I_IF IEC_J49 @L\M^!2
P&-9/!:)5.6T&L|: M\$:J%AC(X+A+%O'^^IQO%HD!;N\$>L.7&?V4Z|JF#/VHX.!X3I0BL'JW:>+8
M|A|NPV*877<7D&=XG")GUKO/Q7ZQ163MAGLTC|7C6?*%j4*?'HM?BZI+N., M!W&D5A_R0!X8M<<\$|I_*#<%SNDJ
MZ\$;MKJD4D,)08OJ# SJ&E)9'N4V(2PZNL+9=&-ZQ=K|F' M6_M9\$@E3FH^DJ%4OL5.'|C)E&&^(9D=,895DFLSD|T.
+R(Z:.'G|+K^|V/LC0 M'FJMSHOJ|\$.@FWM|;+>K_3*X!MLN\$;BE;/BAS:N&SFH|D.1CT3|4TG\$7N>^NM2_>(F#182?
4&S M 4WU&E8G2U|;|LWR814UQ.Q:(H33U*V*)?4":I3*3^M60E:-4P'T'72S@I
MN8T6W*GI)WRBT5K|Q\$6PO,*@EBO*C^+&8JB,K|6?;<,1^:GT,71%*WD!|I#(M&;4193# [9])I*S=[< MU1_/Z!\\
(TZH/RS2%\$5X>3%+1H92>98-E2RNXLB)ED?91'@XM)DS-7'KH3& M5!HM_KT96CP<8:X84=>:^QFWV6D@\$2=^,0.
<0:6(Q'9#+!/N#ID :XKJRC5L MU.'lFM?#XVPU\$;P4.: 9@N4D/CA.MGIQ0\CI \$>831,XCME(J|RON!#_SZV
MYM2|,U.M;-&=1_B-)8DYEIZ#OT0M&085L|ZJ\$%%&5T ? A V|&)JD9
M1=DLQF&;9*Q\$S2"G86.'C|;GSH+F<4|)*9L%V<2UI2N4AJ5EZ8>4,UKI2Z M0-F>TA<)2=:WV9;'#W"1>\\L6\$!-
*+,P.,|YZ8@.WG(&2".NH,V0:;1\$E- M&VY:|IVMZRTQHE'Q_ B)_3/C,D3D|^6|8JKEFFH|7E1N1C:|4?R6"Q,K&NU M#?
AK|^!;TF|Z,D5!*R%?-GSMGZB|P7X6G6&98&S2M52.%!DN>>|QY82Q(D'!UT M<305\$?
>>M:|J9PNR7=P@A:5QE|Z, #TFI1Z8NZFBPVOU=1Y9/TTY_PAD\$*/ MHA+YZG3&0_D+XUZ6J2:(;%I35>XUUB3&
5QJ^9D>)%FI&EOCS*C?N0J+@;GH16_M_PIS-&LJ|'_08X&C:Q_NWL87S+<E|)RBM&3F PR9=.T>K^<|)KNAJPV>|L(
MDP:P5CKO@%KUIB TRF|K|C)|H| V>VUJ-"&!S"K<=CH04Z1%G-&,AC/'%|J|
MMV+_WL\$;:O&@*E)WWQAR,XI_YY#-9(PIXC|H|6R@EU^-.|IGZL1BN* XQ:FY M?^N V2Z?P4,QW64^OWB\$>1M-
@0BEI.^?T=H|@&FMV_3|U176OQ_*9K_'865 M93#/Y-#M_TM^:85\Y_ZP133/_B|VB5A53P9R(*+MQWM.Y-
)#CR=7ERBY+ M(NKRA>PGI7E(-SR68M&L6NH(71@50P(P2;5FF1^HD_JFU0#Q=ZWY1>)%^Q
M"A7#H;7^K\$D_ AO&9YZ*?"^?4L)MB^R'.(MVK6.7Y)R&WE+MI!;+6)"Y:U12 M!9*E;9|"O6FM'6:|U?
60XA"AC^79\$U1OLDADBE|FRIK*(WLC7&2S)GDSMY MW7M:(2T6(L:>|G=|K9'R7'D^':&
(|U"^^CKPR\$YSU4^%M1N*5,ZLY^H-7BF MK;'.6Y0GOVL#8F7H_7KDL-"T @@@22;_%E
9<54|B3>.YHH&;+Z@>)>ETO,| M+;H"54A39Y50@=7G%\$0'RAJDPB|/*\$^**G|31STXK?)2(=OA#Q.YQ8Q"U@!.
MISKK-F=C4&O=CB=D:RX&IK|)'&BU.E|=E6%/(5)2Y==HM\$T MFPXRF,B*D^:OXM3D#)+/E%(A_04QJ|7HV7,-\$A\$#
/8H94<7P8F)UL4R"1VS M0;C/AI5(&:|S1S,UT:J=5?41><^G?75|G,/E\O0"NP4:\$7WB?PXG6@D3I2|
M(C+A8_6<>'TZ5=.|M1=JYDJ\$!"/&'0|SN0LS-X#"F3J\ <|3'@UR4YZ+WRE##TB\$.,9CLYOI!%&@&I MU81<0T*
<6|I5E5H"TTA1@VDGFM)G2D D:)(>|S:9^R9%RJ9JXOUFB>"X_M_2'!\$=)=I88/X@:JWM46MH@^=ZX?^?
%6|'VXQRR+"8T'7K2C"Q^ M9)(81FI76| 2LH3M|V-|\$W,LJ<(U|@=|L4Y>1#JO&Y7G\LK1%!9'+Y;J1+FC M.2LA)3>%//.;
(:1N 9FMH&AE=,4MY\$:AU4S-!&32R.#QX8 M|%,>(GCW2VHN3 8M E%Y,K33:9Y&8TSF(7U
|MFL;?.LIXE2T)ZD@L^O15QD@YE NU MO.>J'_2%_S^+>8IMX,"F=+#UC?^O*DKLM7\VR#V;E>EOI%^;VE,>(OYX
M,|A>+>.DRWD:|F|W+|YA=F1Y@NHFU,EU^QJW=L\$PD|2JQ*.%E0,'?92F>C+N">BZ+^|;:0-90%2_)++;B M5:2YI?
J;V\$4-IUVR\$Z%KY6KS\$JQ/#!0)38%_*F#CDI'8HKJ_#A!4DN'I9A?
MHD5+AFD#_2*'KYC4:'=X>&8C_PA3&MO/(Z8T6>)/XG8RX;+|=7UD4E"J>0B MI-%T^D,&N2=,R-
#OV),Y8SQIQ#B;R43 UD^X)_%?!.0%#?6GU&PP40VV>.T M5/9\$|G<#)E|8^LV0-J7H8&QBEE^<-_S|\=VR'V;&*)&"BD-,-
_RIK;BV>#_F M9+1R|:%CR<;ZB_(F_83E.B762|G|S|A/7;J|N/\$_*9.;+V<@-5|N"P?E/PR
MC+4(=/%W:B?/W3B4?M0)VC/E68"/NG^/^NT|JOI|?WPH0&SJ<#O3_U:"Z?_M_4W"9L'?<>116^361^P+CC-

_JLJZ7HJRGR.TZ(@FOG8!_A/!?!#PP/^&!S?5L.Y:N7.AR%O@!%+COVN3 MRQ/S*;H3WY|<7WYW?77R&-
Y.C|JZN0>1UX90VD2 S.@ &0 'AL+W=O(R51 MBNWQSG;WCQU)X?
&.WSM)OWE4^JM9'5&RIW5>F+|A%>|O#0;+7A&D|;Y91R&X|LUE/7)NS?T|5: >Z.J,I>%N-7.5.LU
MU_01:X>WYY\$'_6'.IEU'^O+G5\;9K+)|M2B,5 7380V MY"IZ|7Z(XVG WZ1X--XSOT|F2GW%EYOL|4F(!E8X+ 1G_
M<6N>-%OB1/^Y7OTXAUXF7,CKE7^=YF5|J7*L(!%)K+N I= 2\$--7%/S/CZXX@>1#E@2|2P.X^&!|9*&NX362_:L M|
|XR\,48=JW6L#| T;|H:' M5O^&|HZ=R|X4|#[7/7Z8HYP: S\$O|XIS|XSA\?9TKD.&2 ;H\$?8I>GP=L4VE3
M<1!7|J1@.OEI|((MGM\$O2V<6-;_)9I=YH_ MTY)\K8 (G &JW/#B.6 ?OERS#W?L1Y5GJ0K8IT_7H\$?VN%)Y_LS48P%|FFIN
M9";!VR YWFOVYC;N+--+N:C?L^B/@N?E:B/X5 ;EMK|L?+FOYNVRMZMG(U) M"/VN<-XS>|!@XQ9_+_X:7
|Z(C)&W++=5D(59R4Z_ BIW)\WU|L#6*; /W M4|YH.P"|ZL|PJW|O.%6"P\$^7>R|MY.EH6@|RT%QZ7EO\$)D\CROIT#8
M,B5(!|<5X|! >B G :9;&GCJ+-\$G%FVAAX8.BVY#<"DM6Z@.(8.T@; [;#H0\ M"!S4KD5A%TC>U(Z<&3)(2BT%
C-9VO7VR|CN;H2XK7L(6A)!>ZC@1R6B*%;(JXY6FJ=(8)?MRV/|OR.Q1S4: .%#;/-M""@YO|Q/D6;:30L"9(VI4T|JT+?
#>.%8(FA')%8%*@M9 MJTSM-7F;WHQ@RI7*41N- I:@>*K^VLV#4?(!?
J|I>E<9Q;="W60'V1(;\$#@/A0IIC1>WO[0W;L|75?D|-GH+4 MCG H2=(V@S% &PY1E0%" 9OB*14;\$#7
P|8|@#6'O+4I/XZ+2;NS93L2XZ:6 M*2+>CH9%|W|VUG/=P1,205X7)!>=LW@8|F/PHUU?|(+0?1-AO"3%#RS KJE@
MI6@@@1:579APDN;L_ Y)+FH2P4&5%VGK41\$ \$OSR M60*)230.XCC97|YHL54Y1=(4H >Q>L%39VY"K^L5SX96B|_
@&\$7L7I1EWB|\ MS|J-?1&RN4WA4H4)?Yp\$LRB|@/Z.;QBPFS|LRO6L \$R|V|GHG\$51D\$0C=LW- MJB<;D<&\$H\$MFF-
KO,2V4^6P#4;CA/W|N\A(SC=%FE<98#8>1FPM|QP7 AVL MJ|L"<|<);!^8%
E!D.6EC7'X=AXPR.WGYIU_+65H'@<|O5?A\$|UL&0\$F| M3L@*+K#?
EW5((LNC7+%)P.%\$VOQ:BPZ_B;8Z|KJLUR|564)GIK=I|-C MI/-_XG\$G1Z9AZ">| XE=ZI>_T2+_1NV..8M7FHE;;;-
+O=|)-\$ "M8TG|8U66W">303< M)WG7Q^&/F#XUV;#+=R-MZ/(V.H0>0!0UH%VJ<9IC;D|Q/>PPH3HC5FOP1-^_O
MAARDB+HX^D*+G BR4:A6'L0*E4O:3+TOX1\;E(#;+QL70J |P@C80^J+|\@M# MDA8;&|;H+;(.F.VW44*7O. ?_U(9
+X98K<@Y:7(@G:?.6..UMD 'V9M!..2!P< MP "/2\W="A2S%MKJ%G"|(T<:L-L*G SX^G9+^ND*V'/ON :?
HUL/H#.M;UK,T<#L6X69 _D\$2(^J|L2U%N\G,&:33H)ZF|&L& M 73/;|/LUL)"%=2:A?
K!%NEUY67ONWSIES|)%G@KX|Z+#+3:1O#^ M"H;
@CE*G45WG#I^*43YHIR7 ;8#D+-4*GN\$#&7@'RPY" 8@N5.;I#COM!&% ML7X|!/%Z%|D"#-
W2FA9HR6OY_ ^VBI4C2Q\$O9+)|JC+QMHL^+>| M|."MF EKRK|L;T\$GC*.XUYE1N5I*T0,EBBX >|5?A3L@
:FHM<^B6BN> MKFA;(|IKU(\$|H#;HG(BV#C04T7V:1,J|C|K9@&P|U?RH!_*|KX77AB7-| M;@VNVW4M?F>M|
H|G7(:ZN9:0)9\$;ZF?V14%&7113839Y7T "VX|&T|9K;V_ MKK)?*MMH,^>NL7>UTU(|IHU1FL7L4Y9\$D2S M63"=#N'Y;
P/LW/W%:J>V8A|P&19;5P+@Z1A03+D4)6-&R_)0#(9,P"8;AM"\$N"<:S<3"*9NR3PCA@
M>|4\$BRB;!C,86B|8O|\T|4OJ#|,QV.ND!\$Y!#\$K|@/X+^3YO|>&S8;IU(?C M9DWW>F6=CK|I0 X**|I9,((A9_%HB,_O-
+:E)PD.'| N *1\$3Q)"?3QIEG>O M=VV*2C.B(S;0?;M|K*P8BG)\$UB.8WDPG87!-&|UN|TQ^-+2X|X|S:;! M9B,@.8*
<&M^2,&9?J(7J5AP.0=H1R'XV/<<7/"Q^4)C|N0&G;|2\$PVDP'8X0 M0)-@%E/=CU|># '=WUR|O ET\W#S|9Y=_ ?2!??
SKSS;|/;O>VD5>"0P1,+-%..A5\$0);-@,@X|J=1?/BM=+OD2_=_X'7;QPV"<_C.ZD#;|DQ, 'LGC:|XC=P M
."MNGVO7:DI2GBGK|?!.&?_QC\$B-QC66R?CT;G|@'XE';2LSR|8\$; (B0 MAK|1&("S"R+&UJ1-*6^+Z320?
Y;^QM70:#9MF#+_TU(KRF8(NR>Q?Q%G_ I|HV M@GSA0|KAK7B&|P?H)A7*\$DI;-@HGR T_|3,X1|Q^Q9<-2V\$0(@
7X|L|IM MJ=|;IZ.0|MLMF>SH2<7(Y 8(<4< >|EY|DKD&=V5L >&+2 T4@|066BU
M9J|O8|/'#!NS&3|L",EUK73P(/K|+P|ZU#_6P>?W8,D9P+?GL;VDM/11BLA M4:(D7FS' _H.FHC^XG#1=#AN0
P+T,"2MX36V'E:;VR <.;F@ M^N(I?;+B64?SD7)<L:9FO=^HR79|;0I%/_-O%67?+_ M2(7&%8|U3_2|VEBA-.FY.>2Q
L=%?99;V#X->A 8ORZ'<(73I'87_;>:;U9 M&?6<%F^K8)C;YM;|3?R?
*.D&9Z.VI;P"NM<(8JF;LU&|JO:OP*1IN7;GNH"P#11J'0A0'^U!PO#|IRR%W<.;M>4H7|HD8JND@F|\$ K2
M.+I=AKK0|>LVBF=^B-G5%ZM/XUO+^N /F;8T2C|X#266/ ^\$^H F0EV-1Q M F |#V5M^Z9T4;\$P=H
KT|TLRC7H%JZ;|DW03CK, <>K+NPD=EK(VV74|K; MU3I-|KX^D|@=B>)/>|JQ|P77TU=72#|5%U 5-ET!%V(I2IE?
7)N.UT.%\$X3 MTH9Q|L=|DOG?L=S4M+IV0.S<+T+M9'H: |W"G|9|*L|XAG\$;|_L|JX4O=B MN,%M7&=)SK_|
|IVSM6*+-XW%FP4;G3';A3X7O'?2WC#++8" _+2^3; X;& MH.P*R;:C5K>Z=|SD,"|A5E-RZ/J|/1 ZC3K,O
3L7H@V=WSV=+>/Z92;%W=^ M.Z#18R+H'KK\VK.B(PZ).L2AC+9H(R-?1/MLO6>PIC88SH^2PWCQ7 HNGC|I
MO**=J&>|O\$XYY<31-M)VG#X@PJ7OJO|_108_%|R"+ @/S|2R
M%^_9#X#R@BY#WGAI<.OBS86<"@4U7RQT^&D@P,-."@J=Q1YVK%"+-RK'= M9SD\$;|H47_3?S_OL|+N652-6
M0!>=QO).CMF<\$?Z)SFU<>^F==&>271N"074L>ZX!;RM*!|K;VR1: @++RK< M)ZI_ M#I9Q|P*+|A<*1,|'E: **Q &
|J|J|F(2Q,DV?2TU8(|W=R6A-|IP:L|B##!#F|G.FWJ;&C M5B6QA2U>:|L!RR20|8MB%W\$NRD>DM*.MKE99:PCV.
9G|8|^FA9=K=EZY: M<>&=^ 5>48;M*2|N,UOX06:|K M;G@2*G&<|OK7|H|)LJ*8NN5Q7GU"@F|U M'VB|L,B:
|!QVPIL;)1N)XU'P7@2NIM*43 <3|E/8*GNQ. ,+?;|H,DFHR1(MAA,&">HX"0F(Q\|S_%FGZS| % Q:6P;4D@P\$I(|O"J+>9-
71M)!|IKZYP) M\$'5:TA/2(?."\$1V&Q=8TU&N>M'-MMN|!ZWA!'N.U MK5TT(>F(*8EU+
(=&0.%H5*O|7@@^*N:U@O,RP+|HX*&P- QV_?|KTOLA'VV" M/U?S|!P08G_3UWQM?A%Y97(V ZW/Z?
\S,\$>P1GD8@%3P|D=&(|OL|8OI=K0 MSP+G|BS5FAY7 D"i<0#|?;' NMT+;M#303= P|02P,\$% @ 281\$6A1 M+ P|I0 ?
0P |D |X;"|W:W)K&ULK5=A;|LV M\$/TK|!> >|=X=Z;.-TEL,CFCAOA#2G'=R;O3;M==4VID:7>J|!#=L-
>+NP7CLC,|N|6>GJF*BNXQ(4&4O4%TP\7*-3FO-/O M;# <|RWID-W>E;R#&_1_E8N-
+UU6Y24R@-5Q(TKLX|L_|I1>36^P5W#=#F M;PPND|J527|S+57K>Z3E"*#Q#H'18XUS%,(!8VO#6;G=>D,|)=;|+
<^=HIE MR0S.E?C.4YN?|=8=2'"%F%OU.8=-O\$,'5ZBA/' 85.O#;..))6QJFB,B4'! M9?
UDIXT.>P;CWA,&86,0>MZU(\ RDEDV=-J |JM)COW\%Z;R+'I=N46ZMI
MEI=G=X@\$_#&6&81KN0:C27%K3GK6@)W2|I) W11 X5/ /5#N%;2Y@;>R|33 MOP!=8M52"|?
4+L*CB)>8G,"@T#8"Z,C>(\VU(''&_O\$J'_EL9J2HD_#T5: MXT2'<5R9G)J2)7C>H3HPJ-?8E;YXUH|KX^PC%|J6T3'T?
|A1X\$.TWP"W4L, MAR=AEGRMN.&NB O\RA&N46>H86: 45T:RG|0*|#M3.#*OG.#\$0;\$E_9%?6=ES"G|5+S=, |AFQK
DKPQ:4HEZ M(#R?4!D*09Y/X|. #X @?S%=S%=S=-#Y\$YK-2|A/2 M?JYD4FGM/&VXS3TRVVG^.)
E9D\$S|6+PLUON8%35V.B,LF_>:|HDJ|\$[B/9U|I|E\ M.CD82RN|I?" 3_Z?@343;|8DE'3408^P*?R|
1W|9.AX6>@O|;H6/U4B.M,FUB|6GVX|0.A,O,NN\$|&Z5WP,%BYP.KBZ^N^N;VF++CEF*B 6@I-R5GM M-
XSV,AJ|+Y)(!W)ZH:1=TOXK1^*.BB4_0&O&AL,IVO4O?C?IA^KY3|KBC'?^& M|ZS1)!KLN|T@P'SCRJ*E)-
@W5M,YI\$=+QM?0T|Z=\PNGLUR3+|JC3;+_R_ZXYW_2US3;|L4I0N-(1|Q4ZTZ#BK
MDKH/X%DT@: ^|C|Z0IFS|DEN^*HMH5ICW?=-*Z<-HFN9+Q>V%-CB.JDL7.2)(4Y"ON-#>OG<+OKF&^ \;YAW&+F-
??GI#^9?/X^U2/8?!, |T8|&X2_ ^H.A M'XV"4=RG%A%D2WB 811.(PG\$PH6_OZ=\$KF>&/
EEDFS.P2E9Z>M8+6?%.63E+""YWSTT)\ |E^++& MT%UG8266&>96ZAP,)F>MB^#DLL_R7N!WB5;/N
.:9\$SU5|IY\$)^UN@P(%4; M+0CZN|WH**GK?7VT|I|E#G-!|-1,T| MHVO"PE\78^L,E=3?FYBH_/0W^&^\$V.
|&B/"|L17UDT=QCZ_SUJV#8?;CBOXB MBOXNZR^9TV.-H?Q@|Y|F&7MO2R'P"+D68H3" 7\$1 |8#9&|VB#-I>XDIG
MA,4H/#)>|&TOV2N|&T @#I44.%|/2D-AXYB4-1X%5 M% RH,M|O#A;&|RTB_*|I>B@37|);!|_L
P|YM>+7U."W>8PY*C|^K|J,5 MU?LU33?53T'0^ \8"OI;"&)/^X\01Y1Q(RW9).R"(F8TPD2HO|B|_%*7EOXC
M0=\$LHR#C\$1|FYED|KU^PN#HC86KJ|ILKB\$16E!;GY(5+|JCR:YS:9O MIQU%DM-6.O\$6*5*AT-?R7G|T/-
&\$A,RE(FL3AX;2 M<24,D9;+=AU.L)K%IZ6^MYN\$=0)&P4K|X00\$VZ(7^>X\$C|NA/*P:_B*XE* M-VO#%R?
2M2+CT!,Z(>R.G:78Q0:A9M%5% V?25\$P6%+T'NM&(|"I9^>5|XP M"K'?@7#
S%18B):R5B223=)?G3*F|KQY(V',C|7NA2JQ2N8R,NH|LY)-5MM

MZNF3.3&Z3CXW:T2HJOQ5%0.1(9!13I4BMHGV.NN@H.I&H1_T>AM)KDYUGIA M1_J6M+#E'^0E"%Z:F=[WF&:J-
 EKM%NCFUQJ:)9FU4FLZJJ/5++ICAW4+^PB
 MC\$D5,!S1+7MR+=UOLC9VUH"EJ^^((\$A/LNW:RPB9=#^)#S17<5,;5(I,IJ M\$R+K "A^-&@D,68QE^0@I5W!4V-
 DH?!G3@U'<_?^TUR=V'6_1\$G9^8%\\G/ MX41&8%.9N,I1*OA1)OXAJY@DI-!+!Q2""QF F7^ 6&,Q;LZ+!@C*C5 *;\$JV,
 (R,D8AI-O4/L<9@W#X7JFJG> @NIOTU#P&LMJKAJ:WAYI (+S?9X&@.- MV?%YE>JM&O'J?
 F2WQS\KN#7PT*=ER?"87X+IO,7=0?R0E#VHVH?SY+QPZ^8A M(-1^,O;IWL#8@,4\FQ,) G;ZG7FZ6KLXG'?
 LNGQG+M"5U9.M=1IR>1%?5 MWI=4%; ' J@4OEFY.FKW1?PV>?'U&86C^?_E="5MG4ZI:&@MWWV5^INQ/AC
 MG6&I/PAKPI&YA:Q3I2187YUAK!?"Q^@?>5MI2%YD;Z8_4,(. 9 >&PO=VIR:W-H965TC\$< M>I53(PW
 5E3BEZ5UA0QX=3=#7SF2650JS' R&AT/'ZG+WOPT?OOHYJ>V#D:7 MI-
 \$)7Q>%=.L+,G9UUAOWV@I7^B8/_&\$X/ZWD#5U3^%1I]='@:=BB9+JCTVI;" MT?
 L=SY^<3%C^2CPAZ:5WWH6L,G"VL_\C8I\ZXV8\$!E2@1\$D_MW2)1G#0#Q MI<'L=299T+5/MBB40:#0I?
 IO_S:Q&%+X62T1V'2*\$PBI[V0HLGPE@YR?.KL2 MCJ6IQ@_1U:@_1M&7(O7I<997 MM/-V&O&F> #.O4>=;WP6E[ET-
 ^3%7^<+^OQ*Y. IW\$Z@L M!N6U>^\$HJ.NNA M+SRY6^K'S:'X!>'J\ZRC/#J\$_. \$\$ BW5?3%I53IRA6
 MU@6HZ6TU#Y1,& LL8SU+Q/AZ8O-W9+3Y) V14FA+I^CB4GIK=&99+!K=JYS M^%\$%30(P8"
 318?*FC5H<(O3+2@3!L\$9E%KDKDZ 2/X:(GL.A)8A<)+0T(Y M^@A #L/2I^*/2:L^&+ _#M\$Y:9?V42B2B3CCZNX"0/QZS-
 IPE)3W#L]>5\$XKVJ1;(0DZ(Y=2L\$LQ#N M)2-0&R1I][6+6, Q#KAO\$#8=<(X)Y>O\$K@EE%XMR=);!;1QN.N-
 &)J.0D M=9\Y157EK%1Y6XIU":F1#&TDPODNA'%E"BI5*F*N#A+NK%!-V7%?&*^HKB
 MND&RUN3I8+>9_)YNFD9/(\$SN5DFF8CZ6C3QT=/ID\W;ZOI[=+QY1]LV 3'K6&I)H6)1MP[3MQ<:' M.
 IW]3>3VT_8U.M=BK%!=W/>MGLF"D2J%C)Q+("^F=&:VJ%")6;I>VT"DT;B MD5<#;:M<NE3;V^0?JQ&&6\0"
 M\D+ _8"%Q#GOMO=5/ID\$^+0QZ=:"YJCQWOF0LRY^HJ'G6Y/(H'PV>:;[7I M;*)I_N:- W";X/IX!M]@)7;R#L.
 [K(FWWSDN8XP+:GYPAL;L]_:\$\$/Q(>8 MM7=(Q@^?10LJG'G.-MI:L"W^ ^50A3SH6,%-_%B4)8IJ8Y5.5PI\$(9E(JQ8I
 MTRH=D>+^"8/R,"L"AN#W&N^:2/QF<2HXB29UF:YGG;4C;IPSW)L3E!1K3M7
 M87'<=U0=;MTK"D)W>V)=W=AG3%Z+YV%I3S=" 9B*?;W7LTI: #""VABI\I
 MUA,NW9C22I!5O*4L;")=)SIFN&228P^OK1PMWEA JVU=?X?4\$!#!!0 (M \$F\$1%JBM+07JPT "IA 9 >&PO=VIR:W-
 H965T;51^DN]J)A-T5>UJ^/UDU3O3@Y MJ=.U*@[4)4H6:I=.\$/K525UIP3.SJE)P61Z=OC+??"GKU3; MY+
 (4'S2KVZ+@^O9C%^936FP4_2K&I>Y\927*EU!=Z>)>I/AH20R(7:4,4.'Y= MBPN1YT0(/SB;!YU1I]+&_F=/_V1')<\5L-
 /7VFU89I6@QI].*:W6!.EF24RT:CK<2^YO0I_9'J5R<-:;\$W)ZG; M=V\WQ??L&7L>U4VZYI]768BVR5P B8Z3F+/R7G\I
 (.4W(AVP9!2Q>I/B/'Z"7 M=)(EAE[RH&3L/V=7=:-A _>\$M*2&I\F00'OHJYX*EX?P>-KH: %T>E7 QA- MAR\?8'#
 <,3A^B/H#JG_/_F9^L7=EJ@K!JT'6ZH<(2;+%60X52YH?W@T>UFSW.R7=OI366*1:FM>906S%^Q?@FMK60:
 [B;_Z,XV MI"]A.S'Q!F^V^PPM#8:E4PH(7F3#316S:/V2B);-.HO\$C.YSB91I-A;#Z/YG\$T
 MGB;L1I]I6'Z0TF0RC6;#A"6+2930I\DB2N""I\&P#K-SNY;L0I6J2EVF/ MB!\$ _MG!A/3.7MC5I _M5CL=&R\$/OV27'
 R_::51.*E?:O#P2\UV&%J:39' M?=6S6N705E,#S0@O>=:U95L>_Y:%LSSMZ\ 0Z6U.P8;!4RSPUTE1FVI&I5
 MPIH9%JVPF^%33S@J&8Q"V.V&8MTS63->DC;S-C(*; A^ZL+6X ZK5X%K\$2 MN*!QV4)!F7&&VRY:/ +X MF0?
 ^JM046#,C5)Q*BXCQYH!W\$+/D;(NBKWG& M2N6MD.:AKN52DC"U"7K@#IEJ VW;M%JPIZ&IHBW81V/-WCZTNXIWI
 [KYI6_MM:(TBET)4J5 *LBLIS0"=L4I:X!2E<I3V%GDAO(=)^1&'W>E/AA 9X5JRX86 M3(R_C^-9-(OXXLI'I-
 D\$<6S"3W.*#+&TV@J(^-Q3GZ9S/%H%B_P.IPF4;(8 M6_7S)?E8\$DWGHVB6C\$!\\$FFT6@(*WC3+:+A
 M;_3FUG+S;#R:L&+SVS2*L7)BS0:#3A(VZOL-F)!QVP!JO-Y%,\$(IAC49T)KD?ECZF<#?!I7T-M!-
 *E9I=6US(B:+7IM_;GB.O-8?5'7&GAQ MX-L0_M)*T*N%O) &UYS3E<*D\$*PO90I(OK87&D 1>;(1*0R9R\K5FIXU< D
 M@F:A M(O=H6WJM,PT1I(I 00)>GX?KREBOG,V&=VEE'D>M'.ASM;Q8+9@3_+GCR MNT+TI)XDL9L:-
 X2;1N[AQS/PR!0MP@(&UY<2=K;>IYTZF!4>MPTYE|B'H M70G3&N6W@S^770I4.?:=*BM0>XPUR|3|B|4,WZ./?
 <'V!9DGXR@>)8B- MNGI!9%&UC5GLRMFGDW@:+1;), _! CZIYGEKZKU|2L<"B!_) 5IJ@("XY#I
 /%FIN(U;EP">+HP(YOR*IR-.NX0U0 M\UJEM&_7B,1.7=%1RZ;E+KWW^5";TCJDW4UUB=OO&VQ0FEF)\$IOR'J:B/*@4
 MSAI@ _&=DW1V\$*I4I4F@VQDL^Z*8KO_EL+NQ2\$WW"F/SWE.+LXNJ?&N7:KI M:=Y#)+\$)GZP|-F2IY0(>1&(I
 _.(CRCI431ZQ5I8?')(3=I7Q9XOTM3Q'B/(.%V7TSIT(EA3=NBM2ER
 MOQ:IO+G/^X#ZYQU&'V.OI3AX0<I[C]IUTG3VSDB;?'_CS;8@UUROKJ*A*2G??1@HU M^S,*7:XO9SE1E4 M^HT^?
 R^*.EK9 H=[X3.W8+6I;^V=;EK139VS@=W;ZEC?PI|2PIITHE(-I=) \$ M1ID4O2O1-C)%@.&K!^PIZ3<>001KS./HY3-
 OY"J J*G.Y:Y4AD7).-E5IQ MTM?7_.%4"*H^4\$F1A(ID6Z2=85I60TG;^/_+BD#J+HNMJ26^A M'U35V5:5\$\$FJC*H.L.
 <&24@\\)Z51M=* _JJ : M3PK?4K61K-.6OI(/#U _>T MV5I52.IN,1FJC+/1M2U)KU :XA3U_C('2X)HYCI:-I'W22+M3<,) \$
 E8.=)@ MN8*E,Q#E4UD-I5WP>)<*&7>;N3< : R+@0 XO(>>6.[>/9NBCISL>U&7SOCNI[U(?)%,U: MBXX?
 XIS|/KO+WD'6#&>>(I|A|BBX0A >C_OA9AEWWF10?-QI|@F<^I\W5_GZN]*=E9IE;OI=#@^6PT9*VJ R2'6I|3D|C26-
 N!;HQNH M2.I-"I9-RYZUO:ZOVEN+DW?4ZW/5-S"-.%05:H2X"BZ^V7/5 R+*+ZYS=H%D7<%NN-
 JW72E7IT)6I\YVBKY\$(W\$@3?""I)A)%?0^&OD\$BMX,%V;E4-I5XWR3_TZP0R/..O>^ ^ M_N'AW/(U/8IUIAB.S.7-
 OJ4MJF(TPVT.T'ND:XC,OMTI4E2TE.EZRMYNH M6-%UH1I[ON012E)/(J!43VEU7ZJ+NS.^DDXEBO=J 811.
 M!CM05XK<-"NPMA'49(O9'*-Y+;^ZXU+U>V|@?7;85=I\$J+K8W-'VR6Q; M0\$|0+6F/
 ('1:\$XZH!L'RYL)3SMWJ.R|[%]*!S=%=\$(K/77?H!JU:[6.WJB MVY M9C*)MJHD_-KS".#A+1FO,-=J9I^W (K,I^VNC V.;?
 %.S1<^~OI^F)K7<-. M|@)(J0:%Q; DST#^AIOXO6 MQ_5QXSVI:C|P-KI\$Z+;!:O;8&Y%4XUWH#4"
 [B!%EU94!B=C7F3MCO'3PP M\$|IT(')QR)/V9?&(F'D7@8B8>1>I)B)AY%X&(F'D7@8B8>1>I)B)AY%X&(F'
 MD7@8B8>1>I)B)AY%X&(F'D7@8B8>1>I)B

JR2@FN!"%N^*8KE(D :81GW0-OI+FMG M-'C0@S'-'(=3S64*DV<;98N) M5*GF%F#T"(XB%H %L20'GHTH@YD,!BR'39
MVD8S [*;-5A.IIBN6OPP*05\U@I"@27/QZJK583;1JFI[0R<5S9)CYG3;%9 M0I-
8"Z5PD3H*XJ(HMPZWD0X;CIJT_YCH@V)XA-;)GV"!L=NN&-25PP&0/ MEK1UB8H",_1:X@J!*Q/KO07.
<%+X/S0\KAKBD;H^3EZ*S"[DJ;_YCH@V)XA-;)Q(=IT^9- R.97.)7065VT2BM.5(HM5#?AUH&Q.5<0<' \$
E"E\9OV-;!T\$%TJL;J\PP8'6:1B2A\N*! MD<98CJ\$@H4*# N#_K 1608[F@-/@\ZV0ZF-8BJ47G+RWZ(*I,0H6_+,6(W0
MKJ!)F4J^MR8H?G!_(SQU/4VNF(MMK2%A. &R;I@GEK<%!CRTY>97RC'M2\ M3LEB9J;.I6 &
HE4D3\8X4F)*I4+X"W;X_?X;.'RL(*I,-LKN_S^@,Y*1QR@ M:%H76S\ILCDFW%L ;12V,13;-JKL\$,7H<,DI-P>HJ/2/K
T'=L>HI*(2<7PJIG\$);!+521K0DL^_#2LFP>+K&>0@PWXD/,
M,IIW.7+7K\NUY.JF&%ZDD8=VTI9V1\HW1\HV0T*W.92HY!DY^8YI\#BI&3#O3 MV6F0NDO5/4)_F5N\XA7XM2-
<#2L,RV(=(BI@^UM'N\Z36N4+>XF\,@CXTQ+CS;[!C*_6.2'7'4S\3HJ%\M@5CR7 2B)YO>I5
MZ;A9*+@('WYL@Z"*A'=(&@QM\;W3XO?)I00ISD"5QG83IX6A:RT,JI, M0>HTEIENM9*)SG<2.Y)41UBB2G-
,)%0Q51,E+OV(FI)(NB<95_8&Y3;"90 M*QXW>'0>9Z4<2@8,EP?MI;_5<6/QE4%1;=XCN/ H*Z3^%I#=#NO
MJFF@L9MD4ZZ;I=WNVZ<^E5ONWM? M9_@ "B%QJK6OIM@;YL3(Z1NKI=\$_ \$FH7\R5;+V#R#+"RF^5Z0\,D_ :F
M0^147-KX<"(O!.CM_=-2^AH@>QJSI<;LFL4\$:&375FY31>Z@+=<#"QD0A*F MA'4/IDIV;/:AKPJS39>895!IT(Z?
=%3KP-#8TE)X J0-VY&6H+TTP>;KJI& MMJ>S'G7\$9% DN)/M.W0CAR@2\S999.!K?+B:1R\$MOC-IQH&^G
)@GMF!QH M0'9YVR=C'JO,H%N7;NW[=I/Z'3&)IG3=N3'EGD@T5WEZU%\$85\DCIW%;I"60 MA^!II2B/34@WH-/ '\$&
22GE<&"\$L/?^&G8VIOIF=.RM5I6>-R\W\$ _QP;"^/B(*TVC8Z "XEN\&@6U!FSQ5*S,?//5 ASQ(OVAY
MRI2.)ARO5GF"EKI92COYG('=HH5E,LF+8 !!&7F@UHZ(8WM;IE092P5VL82" MT!0?IF@*3!?
EPIO#*WINI@JAU9VY1LDJNZN-M.(HY<5L;RV%[:XMV974^ M6V+37KB\GK;*\$EI^IC
WXD.5,+2"JL@:M8%|ORM00GN%VF>U 9= [BG,2+< M/I^4(H22WLJ0X&\D872Z*WY^0X 0F!""EU6'R6AG=FJ4X
M@U\I\SI(KM9XV)>A);.RA!\^LI&X2A M-^G|>#7Q1J.0CY_/O2"D\$ _+JH=>?3."J.;N7HWP!M\!NP/GH&AQ5(7A^>+
M1X\I_\$.E7R#('?'<5(Z,P#W%,J_R-\$4%F:8G6Z2@8I!:"J>_+ICM"7C5F MP485._N53Y6'@V*:-1/SG7S!8E!1N>'WFB(.@
5@&A!*#Y@,\$)A>\.Q48G7 MO\0?0M_/!I?Z?AC^?JI:ZCB=ZSO;R;P77+>SK\#&UXZ84!>KWOC>E5&7\4 M)W00OSS?
VEK;4+XOF7^;7+=5T>I4.6<I*GW/,17L!***KDI2,K3V6'J9ZZ
M'%E6T4HW99\UUAFTJXWX_ :^+=UP+!ADS66\6IC^5!<L\J+*KXT=T MO,D':D
92;V8)"U4@|\+6^FKD5=R80+>J_F#LWV"@R&+(QY#Z7<?3G6(6^WG-JIGE9^>[_J0WONP)"M'+L<I6SL M#@*;
A!TP117 (%S'YEOY)N.VY=ML+>JG14 IO7%70>8(X=?I9<;ZH!!4^LR\K\F#J6;@3IKC M4,NC+,H7\!#
<|LX[6S)DX5PWHVWR'_:9U*='^HJ1%JSE150#GI MLFKKM:*6ET(.?I^OU_8ZI
(7SDOH*^-7\;+%+8(S\ZN7=\NW_ =^8E\RKQU_M%?)I^#J4."*.0P%/0I/6&I>OS=?_K6F5\ZG*LO4BBZ7@D-TP ?@I
ID"W+9? M<(+R_TIX_5I02P,\$% @ 281\$6G">=R\JC" >!< ID !X;"IW;W)K M&ULW5AM;|LX\$OXK V^IB \$UL22_MDF -
&VQI3;; MH+GM?C@<#K1\$6\Q*HI>DI&9_3U#O?@E3FX/>WLX7#^D%D4.9YYYN%0YQMM MOMI,2D??BKRT%
[W,N=7+LS;:9+(0IE2O9(DW"VT*X?HEF=V9:1C_(:B/XL& M@_%9(539NSSW8I?F\EQ7+E>EO#5D)JZ(0YOZUS/7FHA?
VVH'/:IDY'CB\I/%^) MI:R3[N?5K<'366;Z?\\$7)C=WY31S)7.NO_ / ^ MO>@-V" &9R\2Q!8'_UO):YCD:@AN_-
C9\W9:Y3*A:ARJUEQ?I!-/_.VE^C<^K^TJ>>L6-26;>+9C&>"U76_XMO#0X\ M"Z:#1Q9\$S8+ (^UUOY+U\
(YRX/#=Z0X9GPQK_*ZU7!_E9R4.Y?P5F&=NWQ? MKJ5U0-E94@I3.DJ78LRD9:S:TS(-;?CD%1;S0\OA\$7
MVTN\SHF\Z*&:K#1KV;O\ KMP/'CU1!C#+HSA4I; XVG\W:COV22KG6Q\$N4I
MZ4W)%IS\$B\J6P\N%SJ\$=JEP2UBBGV&HF' DC4=6)KDHV"X&B"JPR?HVL\UC4
M>3Q)84*8QJ*N+%RT_9=T+8RY9\7!5LAL\$D6\I).S3G5QR='1K MH(8&@I=^ ^DG4IT^;4AJ;J14I_,0_X3TQTT*,I4=(I
RR4331)^&+D).I3 M1S&G"4T&I(R&PW\$0#D?X%<_B)OX,Z>Z7=W3W ^;2)X1B*)S1:\$AQ% 6C44AQ M' 7C60S?
\$5))GU6ZE#R73484CV@\"R:#&7W_W30*HU=T>W/U(I_&<+9RJTS M
(30A4Q5(G:(S0A5"9NC_.S6L*W&9\$C#&46S8!;.&97).?2I\$PS4> U\$GK M3")SOI&HCJLU\$DI^H-
X.*5P\$@RF0WHCULH^X4HXXKTFP1!!M\$9VIMTTTSR& MXZ,6(B!/+V@,;(-PQK9FPQ#(SN)Q_V'^#691L%T%-
/2?I\ GWTPU,HMJYAV MI7:T1^JY3\$2%66Z'S:G&I&E,SHA\H:IG16CMFG>\$CPQ*(JWVB"RE*&W@; M_!%LFZ*Y-
13JV.?IWRM2+JC'UXEF(Z3M'91P\!BGI'.S5//O_ =EDEJ_99Q@% M-P4,I' 'C0.0#086"43%8!S0KH1QK?D;:99
^,1*23ID)RGN>^I52=,>[R/D:F+QB#74@IVHO_:=O94/UW!\AS@OR_I:F54IH4XV\A2R(/&LEI M*R=E"G*V!P\
[KTO9II?CW\FD/WHVF->@3IM^/D4@GZ)G0W1Q>+BC8>#;_M.D#8CV>7\$//?
DG)VCP\$)\@UR/!"ILJ9.IM";&T_ILTBUB*O.F1* MR05FI\MB)'Y45F!Q42L%&K<0ITYT: \GY\X_T&[44;:%I M3H;D-
AIX6N@T1@6\;KGPI N)WDVMI^K3U/ MTN#TT4\I\$JX6N(21#55H_U2AD\$X0?%;I5J@5/H#%;%ZI/\$5_O^OL LH")M=<
M74NHEQ0YYB\JUARF=S1XQ8T9^AT'?C(XD:N^IU4B;,:)';CEKVG*YK6QW(M0K@HE%;XN^B!(C6,VK%.-JO!I:2?
82\$MUR_:2Z;'+3=!(4V>I?2.WPT8T1 M1J;ZKD1N<I>5\I57I3H9:E^&NPNY%< LC8Q&#LAIPO: ^ (ZG
MN8,2/%X(CH3+**@I5K?W\ \#7==HYT9EVP#VVOV:\5M3\I&QZL+;L>F5?>X5 M@24)=VWSE2MYA2, 34I E5-
YC9!@639HAE\4*SU71X27\$ \$2K,BEEZL\$@=2J M PHP\ I\0%W3<^!.'IFD*;>6SP*PV@4%PC17GRX(" YD^&)U?
TIO*M,&?B^% M06O*%7@HI ?
5TN:6:YB6K&RUUYDHEUZTFBI5\$SG&9:"3X5+*WL!RQ[IWMW.FY\$N'7.ZZ@%4)&0(@8!^%<&&_"8+G
2UDEOE72!*MOE%SN"J%NR1QLW96*!Q(L,>D+ M\ID3OIQ;!Q6,JQ0<2,\$E 6-NHU?2X6LE_+5;:/?
[GM"H>=.JPR3^66+S;VD- M6MI_"ZD9_@&IF4S_@-(^U1VMO,UM."K&7_SM?65I_XPVHUVGY6OZJ^IV^GU M-
^D:8987,JIE DLTY1KR9M^M^#TRGI;G6OG=.%_9E(=YZ IPL-56L> >/(N M8_OE/P%02P,\$% @ 281\$6N\$T)\^!@A,!D
!X;"IW;W)K&ULM5CI;|LV&OY7",J8\$D"-J2VY2P(DZ6W7'WHMTNZ& MPV\$XT!)MR'#FOG;2X)8%"47R_W^JM95LQ ?
-3%Q77-I?BTJIM+T;I!)^XE8NEI8G)Y?F*+I'87I=?="X MFVRUE+(6C9&J85K,+T97P>OKF-:I!?
^68FT&8T:1S)3Z3#=#ORXN13PZ)2A26 M-'#\NQ,WHJI(\$=SXML\$YVIHDP>XU_ZSBOVQS+@1-
ZKZ399V>3*1ZP4<IY6 MIE:M_RDV\22DKU"5<5>VIM:T&T8@5K;&JW@C#@UHVW7_ ^=9.'@4#N'Q (-P*A M\
[LSY+Q\PRV_/-=JS32MAC8:N%"=-)R3#17EH\5X*B%G+I\VEC+;:N\$.9\8 M**3I2;\$1ONZ\$PP/"0J<8N#?
M'4XIR5\\$\$GFS="7MWKL.C&M^(XHQ%@<=" M/XR/Z(NVX45.7_1>_R_5S-C-=K@I\WV1=GKB_7H(&J_-BA?B8H3>-
T+?B='E MCS\$J?_3\$2_CK9?>_W?%>'%PNOAS+@QPAJVTa)@D\4]*Q209'Q3,S=2?
07OHSZ,(M&BXY8Y^6@LU5\23+9L\$)T,=G.624&Q^?>_A#^I<_A#^I<_93V8@OU&X<>RDA!ZN:0'D5&M@WYR^9N@
4<^\$=EWPIH P=0== M(O:0+5N;(D>)"4C5G@Q6GN3?,\$XRR:>F&8LZNB;.NVXE:4_#%J6DC>T02EH5;:
MRC^I[B9/PE)VD2>!E\$;2=Q&'B^1GFGN3:8PVR-F9YD'EASF,4!;\$7)"G\I7\$# M+/\$IH4%U8#/B2\KACJF5T%*5E)%
[0:E)\N_E_VX4*,579V\$ "AG\$3'CPT^*^\$8L\KW2.O")?I@YXSK7!W\3/ M*GNNVRCSWO)2&ON\I/L1?L0)_N(6P-
_AP\$&"_T:S_Y?)YI(S!(?D**6T\$DX- M<#ZC/?=OAO/0I/=A>JCA66_!%P-@&@&7J\AQ@!TU\@)I^"ZR"9>EF0 I.!IWOH
M_M,#*>V!^4P#+\V\$&8>5'N?S>PIRS:GWPB+9RTI')77HLN(JN&&1G2#H4G MCWA_V@D_X\$?W:ZI!URN
+B\$>'8LA>(&KSH9&#-W;:>(#6PW*E45>\$*>42C_T MPGCI1C'2FI!:@:65L\8KUN).-"TDCUBB*/L;>M-H!"%[1D"?Q%?
MPU\$<^>R(IFS)1D,3H\8F>+^L>V-.O6G;HA'B)5S:0K(.0Y@^H8VKH1\$/LUE M#-6+!_!@D?7K>I&?LE^4*MX2U9,
9ZZ5\$?>8<^4>ABY[IMIC4JWK%7R'A9II@E5Y9QPK;
MW#SIMX^;E3NV=V\>^W'F*5@>>S4J#G.XEG.;FYN; !&,)WFF^M\EX1&-;^T M6*%+':JPT;HW14Z68 YP3\RS24I8=
<.<2\WN>-5N&VO M\$@AZ"-#^Z>I<).-M(TD\$5N@S:G+I9)WU7O@1U9PK>I^3Y\POVVKUKG+%6. MU+2515_@T
\$OI;I+Y8<*(IEH&00T&?I7H,G@^2-8&'OKI0";5M;/>)8CNI M_%C>?1UZ!ZNRH1>0.43\LRP9,=UI
<>ENK%)JYKQPS9:VJW7 I>"DT M+<#SN0(-C=D8/O9Z_(O4\$L#!!0 (\$F\$1%KC\$AG&=A0 +), 9 M>&PO=VIR:W-
H965TGQ5+/GY?99_55LA"O9MEZ3JQ=FV*/9/KZ\5M\4[KH)L+U+X9IWE.U\ QWQS MK?:YX\$#-VB77X7 XNIYQF9Z!?

\$[7/N8OGV=EDJ9(+\H21?^S>WUO M.#\C4:F*;&<& P<[F>I7 LW(P1FP&/8,"V D/C6\$Q&7;WC!7SI/LWN6X\U
M#=_04FDT,"=3W)3;(H=O)8PK7KX1J^+Y=0&4\/-U9\$:IUJ/"GE&CD+W/TF*K MV\$|I+.(F@6M@H>
(CM'R\#@|2?"B@('U' Q8.P\DI!>N-J76.B-SZP+O9&JBC) M5)D+|E^O5JK(00?^V|=[:36OBIX5V\53M>21>G('B*Y'?B:?.7?
_W+:#9>=H#3 M2<7IY!#UWATX/HK|+'A2;/>?"V4?/@Y8L17L)MOM>?KPU|\LPM\F6)1EJHL MD3\$O1,S E'->R'O#-
KA2,I9@A\F%8U<93EP+G)6PI;F \;3V*4X8&\^W+ W MG|C/61)'F?
[>7/KPD=V6*!9\SCAB4 *1|@O&4\575C6%P8X\T|DD>0)^B!=?8QSS8YW|%+P;.MXPK-#^02 MLQ4ZERO-DQ*IS'
52D2P\S%+LT(H6*4)\M7LLK.LTU?UPIX;.)S%@Y1|<.O**2HY!A?P\<%GS M/VBM42^|,UN!XD|0"YF\$2 % -
YM<;,!H4'AI)/>XDEU6IB@=@CX9#L\$9)PG. M=XDSH+V%PV?-O:2+HV=7P ,OP&G32B4NXT'O^J42@OT**V7C*
[8O5R(T&R0/((%92'-. \$ >ZR5>1:A3/X+Z?=EX*4 M/1=%|)\U@X"J2W%;4Q.\|V6QI=MH" ?N1C<'MC8\^KV4M.%;\$!J
B(3\H 1] M!D=>L!QW6-WS/5R"%"B6)7>+E@C#HB%DIN41H'L(JZV; U&R;8BWJ#B*O& M#00:5&J(PD+K;:\: 0/0(0V-
7E D3?825@KP'\O Q) MFXI11QH0EB1Z,-Q*!L*ZV*U 7<:5U7I\WI8C8^ >\$P8!JL%M%@%HI-@,KF
MN)5&2:GP#K,%\$B00%>;3<=F29|J|:.4 _&Y|[:@G\$^ITL=P&|!=7ABI6D)WHF(MBI_Q+6C\$!;S2YE)|7L#PX6\$Z/
MD5UH<0)I#T|F>4PF(V/T|Z/ HRL;?_6=+(1W\N") *?./A\5\$T.,T29*A!6 MR-AZJ14@@@RW\$ =C! ;O?2H1QX&=7@O" -
D9M,EFMY^(:!*\@SR;:W|B0|K: M%VW/.,\$'#7 SM*
<[8T(8.57;)@_AC1Z)@)87D.2R2.3Z%69(>1400=,>3DIS]>3A=UKS1YC9D \$J+"Y2JL8H!&\$<|I-X3307<
M\$/HQE<=@3|\$R|.MO|P1G6LG&HV#^?R"+) 0GB00!;YK@RRO\VP',KG301!Y M0RB2E9MM'1KAZHS&G\^:|:-
WQ7)+K_HJ52?RGF1?)V^0|8S10\$?+ILNIDA<. MEAW4D;SVAWE%,3\$S&
[2YKJH)1IA&PQ|8;)_2_GC8<:|AQGS\$EOSW980\$+YBY, MA3&CK (\D'I7O\&V8\BJ)?#T5XGC^P*K45E&*CX-AC9Z 09*)
MQF=-<<+-. _\$!;,>:8OPZTL| !YH?)%!3EK5CE-=(SS\$^(E:;)/OK3#1EEH*? M+,#1&;YCD2J31%ICXJD7SRI07'S|A" 3%@:?
D\,=BZ^-9'Z!3@|\$LZ18>01C'R MMTRF|:RZ6XU3S32|XUDD|ENK.>K\HXN,Z3N;IR8M""#3\EX?4&5 0ZKF/H M)|
FB(X67'WSOAW8|4I4^C3PZS-.*\A.+5\364/2FP/"0FB0)27HI&BM=*P M/OVCM(R;+\$U|J5A |J5C5ZM!-
NZ\E;!MX,E\$|")U0^PGC1"EJ8U>|Y \YL M72E;BRI@@GI**H-TG4F'1=SK)HM.R X#"K\$' M,P 1Q|_!EA%+-NP:
V;#8+&XJ'+-Q@((Q8@Z#T?1""2SE3H7%"0:H6MW&N@G M\$%%50 <;|KO2(6<'
MF/(E<%^UA=;>=:%8;TDSD&+"TTCTE|Y+|I"N1+RJJI#@)%^5&|@@"\T:|@;
MW7U%3*QW6|!|>KO+8KF6&L'4.0^6)*6|I9EHZ&&E66 =Y|F=I'H2%K?0\$|0M M(P9U><#7G-
_M@1L=FW:7PAVSS8L9U5AT/U2EQKY'9>)+9T.F4AV5"KG3 M93Y\C8TVL-%B^"0&)PC
568@KS6L@K4;V#4|6^71+VL?%NW%AGXMZQ?E!> MXVH;JVW4J|K+;4+&,!T;>C"6=@+60R*'69 EL@:1-
*I|/98|>O"KAR8 M\$%"Y?EV6 _S|I&^S@CG9QW^N2N&G,8R>P<,FY:C\$IP8(8&@ZWM1A|VC-KS&3
M)Z;0M^3BWM76U|4\F%R(K0 \$- |S^,G,&E.)S"G%,*QL'D'M|((PZ_EW5 M;TZOY|^M 'U*+M2 _&YITJ.JW^_
@/OL3JMI: JO5"1T)>|!|L2^8..B.^T\$ M;*5|Q|_)7;G3@1COQ;)_2-PI79N8CCZC 1O+89\$LC)SM"ES^JLZ'?!&I3^W57 M;|
[2?L|YL,>:)"|V#.U8I5S|&Y#E5M4/I9J4 ##I\$2;Z?>G'9X| 8|SR|C* MM,2M^JZ==MW49?
LB,CGD9VSE""6|E=J|/E=K;4<,U_KEMN+.1\$K_QO>A#Y M SRQ*XU"'/T. F6.^)4G63H |ELG9%AK=K#< !/VO=VE 3*0'#
&KY'ZDRA_MDT_CN-XPW=|*; CIHK:U3\$\$\$DHI:(#X9:>^!!#1LJV%+=J@8:QOQ=;KGD*A/ M;W!|E&=*/3'-?
#IS4\$0T98K|(.4)*12_IRBC-[NB.|IU9#1^LAT|,FW7 M ZL2\Y)A("AMY_U ;:#G "E|V,|,"P9*OE3FYBW=-,
:ZPCZ^|U:A>9. =QU MJVI9*H)|HG@WC;0.>&_!8Z9_U2F7|C++5O8).Y3-+HF'/0368!|VUI\$KHZ MU3YO)0'>
<7WT5Q|Z/#R7'IAZY9,*BW68?%2% MQ:+0&J^M.598\BYNHR@>966"1|H-5TM|'0|TD\$2,*Q2P|!;!77)TC@'@:C
M3*#P.GC27M9GUY7SM#X2W :=%4(BY5""_E8BD A <1ZK1:(;::!Q1Z1?&U) 7\$Y!^R-
3@, @6^_*#Q;1^F,TJ97\$R>MYTNW M*-\$YY'2JGVMLU_0|P^H<,>A\$'L5".GYBH(^+.*#(V;BA;K'V'T>Q;2(IOW
MZ|YG8V5X#^X-S \6 U@3|\$Y.A6V40Q? W(?F\$+51%N/#4 /P3UW,>|ZXQ4R# M.;9SW>J|L@Z_QO*?CP2//?
TP|FJ|31NUNZNJS|!+9W4L-2C43:9=%|J=K3@U MU"-8\$GN!4E+ \<.G5 |J5?-3NM"#(_0 V*:Q(*1X(C\$M
0X@"CA)KG21X.# MTT"!\2;6B_0|>1)Z%0\S2H;5Q3IRCS:0M(\$'T":V"B@6V@/M'0_8UL(+?'4 MXNM6XOD*^/UQ/4;?
W;BGI;W.\#"&Y\$- 0#|:!,Y2>:..EU0MJBHH'!#TF%W& M,"FZ<+R6:E (I354_8.(X3NJ-
#A&::G#05/>_F|KF_SGM#XU_5S6?M^SQF?:D7CMA4YIG.RY9PZ6?BC399*3E7S!,PP;2,)ZL0'T\.=V*Y
MW:>3_J96^T@#88#WMB>)\$KS'5B?&T|K=B<").WV%2?DB>UC3GC|ARC85= 8 MU>I7""T=BOJ-
;&;FT\WIW8NSN=.R;\$:/!OE: JCV9HNYC5;|QMS;T0*<1 ? M,C'Y,S*7%MODP=69U*GD&42MZ-&R"+UE@10(PZZ0#
S0'2)5T*7Q"C0K?8* MMR5:/-1/.QQF0T^FN&<*BM\$\$+5DDV5Q?;YGJT :/9@S/RKOK A"4-\$O)Q|F
MCB"H1*L+M|@6,(13(H)*#UX*EH YCS96PXZ\$Z)=K9E*'*&><.)|=PI5#P;YJ0
M+FL!7T|&K6%ZLZH.3#%|JT./:TNJBAH@EJU<(9QWW# @C\$SGO,UVE;B::H9) MLBV2% :5P-KU8X-
8S@=9D,RY'\ZX=2TMG7HX);:VUJ6|6 E!HZL,'?_YG8G3 MCL?"ZRHJL2F/U\#FXKG3,:QTJJ0:L?H=\$|L4WRST;)%,[9YM1:
(/J17'PA10 MHZ|9%&2#02NK6E"OT)63ME850X70=I\$^\$@P*3M?3/^X M9- G=|;H=M6-FVD\$=AF"3C#_OK
Q*8".CX<)1PVE/-8XHQPO"M8 M7>*QJLH/ZN:^ZEG.9@H:M<X.N=,LMW>WFK^QC;4=OO"#SH6JQKA16?5+GHR
M0,7Q68|>A6|L)*QY>E&MXCUM \$J3Q_JP#F\$TJ?O6DING|RLY?IL\$Y5| MCG1,>HAVUPF=N6
JIUDU9O8(;GVGC@=W^O_U8Y&!!KSOZ|K-|Z2E17W0YU2! MZ+'O'+@K\$^QK|3DT7\F@-T'MJ09=CJ|:\URFW*M+?
X4S(PM&>>Z=>U>WP|/BE.579B^H'",SAG%|&X;9B\$|^F NV'2L.H MQ,"E76:GY U*!\$F/(6"GY!#9Q<.P_7C79UGA?
HX1?YD|!\L.K.|ZF2Y!1& M*4R.@NGD@DZU@|7\HO=1OH.M?^O91=\A@-OIU3P|,&VS 3GV8^MH1F>' 3\$^
M=8_L+X+I+O8!|Z/>R'EOW/76A@*_ZBU7GC0,##4,(C0L, IX4\$|6GS=T M'P,*(1|O3|0|J,UDKIY)ALZ@?
S\|D86\FHPVLGC|/

'''
==